PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 2692716-0 1989 Elucidation of a protease-sensitive site involved in the binding of calcium to C-reactive protein. Calcium 68-75 C-reactive protein Homo sapiens 79-97 2692716-8 1989 Protease-cleaved CRP loses the ability to bind to the Ca2+-dependent ligand phosphorylcholine but remains the ability to bind to the Ca2+-independent ligand arginine-rich histone. Arginine 157-165 C-reactive protein Homo sapiens 17-20 2553815-2 1989 Maximum association of 125I-labeled CRP with neutrophils and 125I-labeled CRP degradation during association with these cells was achieved by stimulating the neutrophils with PMA at 10 ng/ml; a concentration in which azurophil granule release was not significant. Tetradecanoylphorbol Acetate 175-178 C-reactive protein Homo sapiens 36-39 2553815-0 1989 Generation of biologically active C-reactive protein peptides by a neutral protease on the membrane of phorbol myristate acetate-stimulated neutrophils. Tetradecanoylphorbol Acetate 103-128 C-reactive protein Homo sapiens 34-52 2593200-2 1989 CRP binds to phosphorylcholine (PC) in a calcium-ion dependent manner. Calcium 41-48 C-reactive protein Homo sapiens 0-3 2553815-2 1989 Maximum association of 125I-labeled CRP with neutrophils and 125I-labeled CRP degradation during association with these cells was achieved by stimulating the neutrophils with PMA at 10 ng/ml; a concentration in which azurophil granule release was not significant. Tetradecanoylphorbol Acetate 175-178 C-reactive protein Homo sapiens 74-77 2553815-4 1989 The neutrophil-associated 125I-labeled CRP in the absence and presence of PMA proved on SDS-PAGE analysis to be approximately 50% degraded. Sodium Dodecyl Sulfate 88-91 C-reactive protein Homo sapiens 39-42 2553815-8 1989 125I-labeled CRP degradation mediated by nonstimulated neutrophils, and neutrophil-conditioned medium (from both non-stimulated and PMA-stimulated cells) was inhibitable by alpha 1-antitrypsin and approximately seven times less at 1 h than that occurring during 125I-labeled CRP-association with PMA-stimulated neutrophils. Tetradecanoylphorbol Acetate 132-135 C-reactive protein Homo sapiens 13-16 2553815-8 1989 125I-labeled CRP degradation mediated by nonstimulated neutrophils, and neutrophil-conditioned medium (from both non-stimulated and PMA-stimulated cells) was inhibitable by alpha 1-antitrypsin and approximately seven times less at 1 h than that occurring during 125I-labeled CRP-association with PMA-stimulated neutrophils. Tetradecanoylphorbol Acetate 296-299 C-reactive protein Homo sapiens 13-16 2477447-5 1989 CRP immunoprecipitated the U1 RNA species from [32P]labeled HeLa cells and the protein bands of the Sm/RNP complex from [35S]-methionine-labeled HeLa cells. Sulfur-35 121-124 C-reactive protein Homo sapiens 0-3 2478861-5 1989 Haptoglobin, alpha-1 acid glycoprotein, and C-reactive protein increased markedly in both diabetes and glucose intolerance; ceruloplasmin and alpha-1 antitrypsin increased more marginally. Glucose 103-110 C-reactive protein Homo sapiens 44-62 2477447-5 1989 CRP immunoprecipitated the U1 RNA species from [32P]labeled HeLa cells and the protein bands of the Sm/RNP complex from [35S]-methionine-labeled HeLa cells. Methionine 126-136 C-reactive protein Homo sapiens 0-3 2477447-6 1989 By blotting, CRP bound to several discrete bands in a calcium-dependent, PC-inhibitable manner. Calcium 54-61 C-reactive protein Homo sapiens 13-16 2471736-4 1989 The second group consisted of mAb that reacted with native CRP and also with CRP modified by direct immobilization on polystyrene plates, urea-chelation or SDS treatment in the absence of calcium, thus identifying a fifth native CRP epitope; these mAb displayed significantly greater reactivity with native than with modified CRP. Urea 138-142 C-reactive protein Homo sapiens 77-80 2803750-3 1989 The purified CRP had an apparant molecular weight of 28,000 as determined by migration of the reduced protein during SDS polyacrylamide gel electrophoresis. Sodium Dodecyl Sulfate 117-120 C-reactive protein Homo sapiens 13-16 2471736-4 1989 The second group consisted of mAb that reacted with native CRP and also with CRP modified by direct immobilization on polystyrene plates, urea-chelation or SDS treatment in the absence of calcium, thus identifying a fifth native CRP epitope; these mAb displayed significantly greater reactivity with native than with modified CRP. Urea 138-142 C-reactive protein Homo sapiens 77-80 2471736-4 1989 The second group consisted of mAb that reacted with native CRP and also with CRP modified by direct immobilization on polystyrene plates, urea-chelation or SDS treatment in the absence of calcium, thus identifying a fifth native CRP epitope; these mAb displayed significantly greater reactivity with native than with modified CRP. Urea 138-142 C-reactive protein Homo sapiens 77-80 2454996-3 1988 Conditioned medium (CM) prepared from human blood monocytes activated with LPS in the presence of dexamethasone led to substantial induction of serum amyloid A (SAA) and C-reactive protein (CRP) synthesis whereas the defined cytokines IL-1 beta, TNF alpha, and medium from a human keratinocyte cell line (COLO-16), containing hepatocyte-stimulating factor activity, failed to induce these two major APP. Dexamethasone 98-111 C-reactive protein Homo sapiens 170-188 2522966-6 1989 Binding was saturable at a CRP concentration of approximately 0.2 microM, with an estimated K from Scatchard analysis of 1.1 x 10(-7) M. Specific binding was calcium-dependent, with optimal binding occurring at calcium concentrations of more than 1.0 mM. Calcium 158-165 C-reactive protein Homo sapiens 27-30 2522966-6 1989 Binding was saturable at a CRP concentration of approximately 0.2 microM, with an estimated K from Scatchard analysis of 1.1 x 10(-7) M. Specific binding was calcium-dependent, with optimal binding occurring at calcium concentrations of more than 1.0 mM. Calcium 211-218 C-reactive protein Homo sapiens 27-30 3233765-1 1988 Chylomicrons show calcium-dependent agglutination by C-reactive protein (CRP). Calcium 18-25 C-reactive protein Homo sapiens 53-71 3233765-1 1988 Chylomicrons show calcium-dependent agglutination by C-reactive protein (CRP). Calcium 18-25 C-reactive protein Homo sapiens 73-76 2844586-1 1988 Treatment of human neutrophils with C-reactive protein (CRP) causes a concentration-dependent in the extent of activation of superoxide production and of granule secretion, induced by phorbol-12-myristate-13-acetate (PMA) or N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLF). Superoxides 125-135 C-reactive protein Homo sapiens 36-54 2844586-1 1988 Treatment of human neutrophils with C-reactive protein (CRP) causes a concentration-dependent in the extent of activation of superoxide production and of granule secretion, induced by phorbol-12-myristate-13-acetate (PMA) or N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLF). Superoxides 125-135 C-reactive protein Homo sapiens 56-59 2844586-1 1988 Treatment of human neutrophils with C-reactive protein (CRP) causes a concentration-dependent in the extent of activation of superoxide production and of granule secretion, induced by phorbol-12-myristate-13-acetate (PMA) or N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLF). Tetradecanoylphorbol Acetate 184-215 C-reactive protein Homo sapiens 36-54 2844586-1 1988 Treatment of human neutrophils with C-reactive protein (CRP) causes a concentration-dependent in the extent of activation of superoxide production and of granule secretion, induced by phorbol-12-myristate-13-acetate (PMA) or N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLF). Tetradecanoylphorbol Acetate 184-215 C-reactive protein Homo sapiens 56-59 2844586-1 1988 Treatment of human neutrophils with C-reactive protein (CRP) causes a concentration-dependent in the extent of activation of superoxide production and of granule secretion, induced by phorbol-12-myristate-13-acetate (PMA) or N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLF). Tetradecanoylphorbol Acetate 217-220 C-reactive protein Homo sapiens 36-54 2844586-1 1988 Treatment of human neutrophils with C-reactive protein (CRP) causes a concentration-dependent in the extent of activation of superoxide production and of granule secretion, induced by phorbol-12-myristate-13-acetate (PMA) or N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLF). Tetradecanoylphorbol Acetate 217-220 C-reactive protein Homo sapiens 56-59 2459061-1 1988 C-reactive protein (CRP) can be structurally modified by heat, acid, or urea-chelation to express a neoantigen designated by us as neo-CRP. Urea 72-76 C-reactive protein Homo sapiens 0-18 2459061-1 1988 C-reactive protein (CRP) can be structurally modified by heat, acid, or urea-chelation to express a neoantigen designated by us as neo-CRP. Urea 72-76 C-reactive protein Homo sapiens 20-23 2459061-1 1988 C-reactive protein (CRP) can be structurally modified by heat, acid, or urea-chelation to express a neoantigen designated by us as neo-CRP. Urea 72-76 C-reactive protein Homo sapiens 135-138 2538700-2 1989 CRP at 8-64 micrograms/ml concentrations inhibited degranulation and superoxide production by PMNL in time-, and dose-dependent manner and stabilized PMNL membranes against the lytic effect of lysophosphatidylcholine. Superoxides 69-79 C-reactive protein Homo sapiens 0-3 2538700-4 1989 Furthermore, CRP, 32 micrograms/ml, diminished specific binding of [3H]-fMLP and [3H]-PAF to PMNL. Tritium 68-70 C-reactive protein Homo sapiens 13-16 2538700-4 1989 Furthermore, CRP, 32 micrograms/ml, diminished specific binding of [3H]-fMLP and [3H]-PAF to PMNL. Tritium 82-84 C-reactive protein Homo sapiens 13-16 3198919-1 1988 C-reactive protein (CRP) is an acute phase serum protein in man which binds to phosphocholine (PC) in a calcium-dependent manner. Calcium 104-111 C-reactive protein Homo sapiens 0-18 3198919-1 1988 C-reactive protein (CRP) is an acute phase serum protein in man which binds to phosphocholine (PC) in a calcium-dependent manner. Calcium 104-111 C-reactive protein Homo sapiens 20-23 3198919-16 1988 By blotting and by ELISA all CRP reactions were blocked by PC and EDTA indicating binding through the calcium-dependent PC-binding site on CRP. Calcium 102-109 C-reactive protein Homo sapiens 29-32 3198919-16 1988 By blotting and by ELISA all CRP reactions were blocked by PC and EDTA indicating binding through the calcium-dependent PC-binding site on CRP. Calcium 102-109 C-reactive protein Homo sapiens 139-142 3069247-6 1988 Seventeen of 36 patients treated with Cyclosporine A and prednisone had at least 1 acute rejection; only 8 of these patients experienced a significant rise in the CRP (mean increase 27 micrograms/ml) and in only 5 of these did the increase occur prior to or on the day of rejection diagnosis. Cyclosporine 38-52 C-reactive protein Homo sapiens 163-166 3180854-9 1988 Follow-up of patients during bromocriptine treatment by ESR, C-reactive protein, and chest roentgenogram is recommended. Bromocriptine 29-42 C-reactive protein Homo sapiens 61-79 3385211-0 1988 Modulation of stimulus-dependent human platelet activation by C-reactive protein modified with active oxygen species. Oxygen 102-108 C-reactive protein Homo sapiens 62-80 3385211-6 1988 Each component of the Fe2+-ascorbate system was required for modification of CRP, suggesting that CRP was modified through an oxidative process. fe2+-ascorbate 22-36 C-reactive protein Homo sapiens 77-80 3385211-6 1988 Each component of the Fe2+-ascorbate system was required for modification of CRP, suggesting that CRP was modified through an oxidative process. fe2+-ascorbate 22-36 C-reactive protein Homo sapiens 98-101 2454996-3 1988 Conditioned medium (CM) prepared from human blood monocytes activated with LPS in the presence of dexamethasone led to substantial induction of serum amyloid A (SAA) and C-reactive protein (CRP) synthesis whereas the defined cytokines IL-1 beta, TNF alpha, and medium from a human keratinocyte cell line (COLO-16), containing hepatocyte-stimulating factor activity, failed to induce these two major APP. Dexamethasone 98-111 C-reactive protein Homo sapiens 190-193 2898046-1 1988 Like the liposomes of certain intravenous fat emulsions associated with embolic effects in acutely ill patients, chylomicrons and very low density lipoproteins (VLDL) show calcium-dependent agglutination by C-reactive protein (CRP). Calcium 172-179 C-reactive protein Homo sapiens 207-225 3168329-4 1988 CRP peptides (Mr less than 14,000) also caused a dose-related inhibition of Quin-2 fluorescence indicating interference with intracellular calcium movements during cell activation. Calcium 139-146 C-reactive protein Homo sapiens 0-3 2898046-1 1988 Like the liposomes of certain intravenous fat emulsions associated with embolic effects in acutely ill patients, chylomicrons and very low density lipoproteins (VLDL) show calcium-dependent agglutination by C-reactive protein (CRP). Calcium 172-179 C-reactive protein Homo sapiens 227-230 2837757-1 1988 Four cAMP-independent receptor protein mutants (designated CRP* mutants) isolated previously are able to activate in vivo gene transcription in the absence of cAMP and their activity can be enhanced by cAMP or cGMP. Cyclic AMP 5-9 C-reactive protein Homo sapiens 59-63 2837757-1 1988 Four cAMP-independent receptor protein mutants (designated CRP* mutants) isolated previously are able to activate in vivo gene transcription in the absence of cAMP and their activity can be enhanced by cAMP or cGMP. Cyclic AMP 159-163 C-reactive protein Homo sapiens 59-63 2837757-1 1988 Four cAMP-independent receptor protein mutants (designated CRP* mutants) isolated previously are able to activate in vivo gene transcription in the absence of cAMP and their activity can be enhanced by cAMP or cGMP. Cyclic AMP 159-163 C-reactive protein Homo sapiens 59-63 2837757-1 1988 Four cAMP-independent receptor protein mutants (designated CRP* mutants) isolated previously are able to activate in vivo gene transcription in the absence of cAMP and their activity can be enhanced by cAMP or cGMP. Cyclic GMP 210-214 C-reactive protein Homo sapiens 59-63 2837757-2 1988 One of the four mutant proteins, CRP*598 (Arg-142 to His, Ala-144 to Thr), has been characterized with regard to its conformational properties and ability to bind to and support abortive initiation from the lac promoter. Threonine 69-72 C-reactive protein Homo sapiens 33-36 2837757-4 1988 Binding of wild-type CRP to its site on the lac promoter and activation of abortive initiation by RNA polymerase on this promoter are effected by cAMP but not by cGMP. Cyclic AMP 146-150 C-reactive protein Homo sapiens 21-24 2837757-5 1988 CRP*598 can activate lacP+-directed abortive initiation in the presence of cAMP and less efficiently in the presence of cGMP or in the absence of cyclic nucleotide. Cyclic AMP 75-79 C-reactive protein Homo sapiens 0-3 2837757-5 1988 CRP*598 can activate lacP+-directed abortive initiation in the presence of cAMP and less efficiently in the presence of cGMP or in the absence of cyclic nucleotide. Cyclic GMP 120-124 C-reactive protein Homo sapiens 0-3 2837757-6 1988 DNase I protection ("foot-printing") indicates that cAMP-CRP* binds to its site on the lac promoter whereas unliganded CRP* and cGMP-CRP* form a stable complex with the [32P]lacP+ fragment only in the presence of RNA polymerase, showing cooperative binding of two heterologous proteins. Cyclic AMP 52-56 C-reactive protein Homo sapiens 57-60 2837757-6 1988 DNase I protection ("foot-printing") indicates that cAMP-CRP* binds to its site on the lac promoter whereas unliganded CRP* and cGMP-CRP* form a stable complex with the [32P]lacP+ fragment only in the presence of RNA polymerase, showing cooperative binding of two heterologous proteins. Cyclic AMP 52-56 C-reactive protein Homo sapiens 57-61 2837757-8 1988 Although cGMP binds to CRP, it cannot replace cAMP in effecting the requisite conformational transition necessary for site-specific promoter binding. Cyclic GMP 9-13 C-reactive protein Homo sapiens 23-26 2837757-9 1988 In contrast, the weakly active unliganded CRP*598 can be shifted to a functional state not only by cAMP but also by cGMP and RNA polymerase. Cyclic AMP 99-103 C-reactive protein Homo sapiens 42-45 3348555-1 1988 C reactive protein lactate and LDH isoenzymes were quantified in CSF of 32 children with meningitis (27 bacterial and 5 viral). Lactic Acid 19-26 C-reactive protein Homo sapiens 0-18 3285537-0 1988 Serum C-reactive protein concentrations in cyclosporine-treated renal allograft recipients. Cyclosporine 43-55 C-reactive protein Homo sapiens 6-24 3285537-2 1988 To assess whether changes in serum CRP level might assist in differentiating nephrotoxicity from acute rejection in cyclosporine (CsA)-treated renal transplant recipients, we measured changes occurring in serum CRP concentrations in 74 CsA patients in response to transplant operation, acute rejection, cyclosporine nephrotoxicity, and serious infection, and compared these values with changes in AZA patients. Cyclosporine 236-239 C-reactive protein Homo sapiens 35-38 3285537-2 1988 To assess whether changes in serum CRP level might assist in differentiating nephrotoxicity from acute rejection in cyclosporine (CsA)-treated renal transplant recipients, we measured changes occurring in serum CRP concentrations in 74 CsA patients in response to transplant operation, acute rejection, cyclosporine nephrotoxicity, and serious infection, and compared these values with changes in AZA patients. Cyclosporine 236-239 C-reactive protein Homo sapiens 211-214 3045325-9 1988 When the known recognition sites for CRP are ranked according to predicted binding affinities, we find that the ranking is consistent with the hypothesis that the level of function of these sites parallels their fractional saturation with CRP-cAMP under in-vivo conditions. Cyclic AMP 243-247 C-reactive protein Homo sapiens 37-40 3045325-9 1988 When the known recognition sites for CRP are ranked according to predicted binding affinities, we find that the ranking is consistent with the hypothesis that the level of function of these sites parallels their fractional saturation with CRP-cAMP under in-vivo conditions. Cyclic AMP 243-247 C-reactive protein Homo sapiens 239-242 3285537-3 1988 Serum CRP concentration rose in response to operation in virtually all patients, regardless of immunosuppressive regimen, from mean baselines of 5.9 +/- 2.7 mcg/ml (AZA) and 6.8 +/- 6.5 mcg/ml (CsA) to mean peak levels of 43.8 +/- 33.4 mcg/ml and 65.1 +/- 39.5 mcg/ml, respectively. Cyclosporine 194-197 C-reactive protein Homo sapiens 6-9 3285537-5 1988 In contrast, in 80% of acute rejection episodes of CsA patients, CRP remained undetectable or failed to rise above a stable, minimally elevated baseline. Cyclosporine 51-54 C-reactive protein Homo sapiens 65-68 3285537-7 1988 In 14 CSA patients with serious infections (8 pulmonary, 3 intraabdominal, 3 genitourinary), CRP rose by a mean of 67.7 +/- 50.7 mcg/ml. Cyclosporine 6-9 C-reactive protein Homo sapiens 93-96 3195982-5 1988 In the acute phase there was a tendency to a negative correlation of erythrocyte sedimentation rate and of C-reactive protein with serum cholesterol and/or HDL cholesterol. Cholesterol 137-148 C-reactive protein Homo sapiens 107-125 3195982-5 1988 In the acute phase there was a tendency to a negative correlation of erythrocyte sedimentation rate and of C-reactive protein with serum cholesterol and/or HDL cholesterol. Cholesterol 160-171 C-reactive protein Homo sapiens 107-125 3218913-7 1988 Among all subjects a correlation was found, between C reactive protein and age; patients with abnormal fasting blood glucose levels or increased white blood cell count had higher levels of this protein as compared to the remaining patients. Glucose 117-124 C-reactive protein Homo sapiens 52-70 2946790-6 1986 Although less than half of resting PMNL bound Agg-CRP, up to 93% of PMNL activated with 1.0 micrograms/ml of phorbol myristate acetate (PMA) expressed binding sites for Agg-CRP. Tetradecanoylphorbol Acetate 109-134 C-reactive protein Homo sapiens 173-176 2848181-2 1988 Human C-reactive protein activates peritoneal macrophages of guinea pigs to release superoxide anion in vitro. Superoxides 84-100 C-reactive protein Homo sapiens 6-24 2848181-3 1988 The effect of human C-reactive protein (CRP) on macrophage function was studied in an assay of superoxide anion (O2-) production. Superoxides 95-111 C-reactive protein Homo sapiens 40-43 2848181-6 1988 The O2- production by PEM exposed to CRP for 18 hr when control PEM were still high in O2- production, was decreased by larger doses of CRP, while PEM cultured without CRP for 72 hr, when O2- production by control PEM was very low, followed by incubation with CRP for another 18 hr, produced O2- CRP-dose-dependently as in the case of that observed after 72-hr incubation with CRP. Superoxides 4-6 C-reactive protein Homo sapiens 37-40 2848181-6 1988 The O2- production by PEM exposed to CRP for 18 hr when control PEM were still high in O2- production, was decreased by larger doses of CRP, while PEM cultured without CRP for 72 hr, when O2- production by control PEM was very low, followed by incubation with CRP for another 18 hr, produced O2- CRP-dose-dependently as in the case of that observed after 72-hr incubation with CRP. Superoxides 4-6 C-reactive protein Homo sapiens 136-139 2848181-6 1988 The O2- production by PEM exposed to CRP for 18 hr when control PEM were still high in O2- production, was decreased by larger doses of CRP, while PEM cultured without CRP for 72 hr, when O2- production by control PEM was very low, followed by incubation with CRP for another 18 hr, produced O2- CRP-dose-dependently as in the case of that observed after 72-hr incubation with CRP. Superoxides 4-6 C-reactive protein Homo sapiens 136-139 2848181-6 1988 The O2- production by PEM exposed to CRP for 18 hr when control PEM were still high in O2- production, was decreased by larger doses of CRP, while PEM cultured without CRP for 72 hr, when O2- production by control PEM was very low, followed by incubation with CRP for another 18 hr, produced O2- CRP-dose-dependently as in the case of that observed after 72-hr incubation with CRP. Superoxides 4-6 C-reactive protein Homo sapiens 136-139 2848181-6 1988 The O2- production by PEM exposed to CRP for 18 hr when control PEM were still high in O2- production, was decreased by larger doses of CRP, while PEM cultured without CRP for 72 hr, when O2- production by control PEM was very low, followed by incubation with CRP for another 18 hr, produced O2- CRP-dose-dependently as in the case of that observed after 72-hr incubation with CRP. Superoxides 4-6 C-reactive protein Homo sapiens 136-139 2848181-6 1988 The O2- production by PEM exposed to CRP for 18 hr when control PEM were still high in O2- production, was decreased by larger doses of CRP, while PEM cultured without CRP for 72 hr, when O2- production by control PEM was very low, followed by incubation with CRP for another 18 hr, produced O2- CRP-dose-dependently as in the case of that observed after 72-hr incubation with CRP. Superoxides 4-6 C-reactive protein Homo sapiens 136-139 2848181-6 1988 The O2- production by PEM exposed to CRP for 18 hr when control PEM were still high in O2- production, was decreased by larger doses of CRP, while PEM cultured without CRP for 72 hr, when O2- production by control PEM was very low, followed by incubation with CRP for another 18 hr, produced O2- CRP-dose-dependently as in the case of that observed after 72-hr incubation with CRP. Superoxides 87-89 C-reactive protein Homo sapiens 37-40 2848181-6 1988 The O2- production by PEM exposed to CRP for 18 hr when control PEM were still high in O2- production, was decreased by larger doses of CRP, while PEM cultured without CRP for 72 hr, when O2- production by control PEM was very low, followed by incubation with CRP for another 18 hr, produced O2- CRP-dose-dependently as in the case of that observed after 72-hr incubation with CRP. Superoxides 87-89 C-reactive protein Homo sapiens 37-40 3245050-5 1988 The addition of C-reactive protein restored aggregation and serotonin release of platelets incubated in human neonate plasma. Serotonin 60-69 C-reactive protein Homo sapiens 16-34 3034878-3 1987 Close examination of the primary structure of human C-reactive protein revealed three regions evenly distributed throughout the protein each of which contain peptide sequences closely resembling the amino acid sequence of the immunomodulator peptide tuftsin, Thr-Lys-Pro-Arg. Threonine 259-262 C-reactive protein Homo sapiens 52-70 3034878-3 1987 Close examination of the primary structure of human C-reactive protein revealed three regions evenly distributed throughout the protein each of which contain peptide sequences closely resembling the amino acid sequence of the immunomodulator peptide tuftsin, Thr-Lys-Pro-Arg. Lysine 263-266 C-reactive protein Homo sapiens 52-70 3028793-3 1987 Correlation between modulation of cell function, at least at relatively high CRP concentrations (greater than 50 micrograms/ml) and an increase in the intracellular level of cAMP is suggested. Cyclic AMP 174-178 C-reactive protein Homo sapiens 77-80 2979210-2 1987 Seven of the eight patients responded to treatment with cyclosporin by symptomatic improvement, weight gain and a return of serum C-reactive protein concentration towards normal. Cyclosporine 56-67 C-reactive protein Homo sapiens 130-148 3675091-5 1987 There were significant correlations between the inflammatory activity and certain lipoprotein lipids, ie, between CRP and VLDL triglycerides, VLDL cholesterol, and serum triglycerides. Triglycerides 127-140 C-reactive protein Homo sapiens 114-117 3038302-5 1987 Mo exposed to CRP for 48 h also demonstrated elevated superoxide anion production when challenged with phorbol myristate acetate. Superoxides 54-70 C-reactive protein Homo sapiens 14-17 3038302-5 1987 Mo exposed to CRP for 48 h also demonstrated elevated superoxide anion production when challenged with phorbol myristate acetate. Tetradecanoylphorbol Acetate 103-128 C-reactive protein Homo sapiens 14-17 2443837-3 1987 Soluble native-CRP was found to express neo-CRP antigenicity upon treatment with acid; upon urea-chelation or heating in the absence of calcium; and upon adsorption onto uncoated polystyrene plates. Urea 92-96 C-reactive protein Homo sapiens 15-18 2443837-3 1987 Soluble native-CRP was found to express neo-CRP antigenicity upon treatment with acid; upon urea-chelation or heating in the absence of calcium; and upon adsorption onto uncoated polystyrene plates. Urea 92-96 C-reactive protein Homo sapiens 44-47 2443837-3 1987 Soluble native-CRP was found to express neo-CRP antigenicity upon treatment with acid; upon urea-chelation or heating in the absence of calcium; and upon adsorption onto uncoated polystyrene plates. Calcium 136-143 C-reactive protein Homo sapiens 15-18 2946790-6 1986 Although less than half of resting PMNL bound Agg-CRP, up to 93% of PMNL activated with 1.0 micrograms/ml of phorbol myristate acetate (PMA) expressed binding sites for Agg-CRP. Tetradecanoylphorbol Acetate 136-139 C-reactive protein Homo sapiens 50-53 2946790-6 1986 Although less than half of resting PMNL bound Agg-CRP, up to 93% of PMNL activated with 1.0 micrograms/ml of phorbol myristate acetate (PMA) expressed binding sites for Agg-CRP. Tetradecanoylphorbol Acetate 136-139 C-reactive protein Homo sapiens 173-176 3733149-3 1986 The co-precipitation of human CRP with histones in physiological calcium concentrations suggests that the calcium-independent binding to chromatin is mediated by the CRP-polycation site. Calcium 65-72 C-reactive protein Homo sapiens 30-33 3015932-17 1986 The coding regions of the Limulus and human CRP genes share approximately 25% identity and two stretches of highly conserved regions, one of which falls in the region proposed as the phosphorylcholine binding site, while the other site is very similar to the consensus sequence required for calcium binding in calmodulin and related proteins. Calcium 291-298 C-reactive protein Homo sapiens 44-47 3489756-11 1986 The detectable C-reactive protein in isolated complexes and sera samples increased after treatment with sodium dodecyl sulfate. Sodium Dodecyl Sulfate 104-126 C-reactive protein Homo sapiens 15-33 3733149-3 1986 The co-precipitation of human CRP with histones in physiological calcium concentrations suggests that the calcium-independent binding to chromatin is mediated by the CRP-polycation site. Calcium 106-113 C-reactive protein Homo sapiens 30-33 3083530-3 1986 The presence of CRP stimulated ADP-induced activation, whereas CRP has no effect on collagen-induced activation. Adenosine Diphosphate 31-34 C-reactive protein Homo sapiens 16-19 3723078-1 1986 Biosynthetic labeling with [35S]met and immunoprecipitation with anti-C-reactive protein (CRP) antibodies and Staphylococcus aureus indicate that cell surface CRP is produced by lymphocytes. Sulfur-35 28-31 C-reactive protein Homo sapiens 159-162 2425359-1 1986 Expression of the crp gene is negatively autoregulated by the complex of cyclic AMP and its receptor protein (cAMP-CRP). Cyclic AMP 110-114 C-reactive protein Homo sapiens 18-21 2425359-1 1986 Expression of the crp gene is negatively autoregulated by the complex of cyclic AMP and its receptor protein (cAMP-CRP). Cyclic AMP 110-114 C-reactive protein Homo sapiens 115-118 2425359-2 1986 We find a second promoter in this region that is strongly activated in vitro and in vivo by cAMP-CRP. Cyclic AMP 92-96 C-reactive protein Homo sapiens 97-100 2425359-5 1986 cAMP-CRP does not block crp expression if the new promoter is altered so that divergent RNA cannot be made. Cyclic AMP 0-4 C-reactive protein Homo sapiens 5-8 3084170-3 1986 The concentration of cross-reactive protein (CRP) correlated positively to the concentration of total triglyceride and low-density lipoprotein-triglyceride, and negatively to low-density lipoprotein-cholesterol and high-density lipoprotein-cholesterol. Triglycerides 102-114 C-reactive protein Homo sapiens 21-43 3084170-3 1986 The concentration of cross-reactive protein (CRP) correlated positively to the concentration of total triglyceride and low-density lipoprotein-triglyceride, and negatively to low-density lipoprotein-cholesterol and high-density lipoprotein-cholesterol. Triglycerides 102-114 C-reactive protein Homo sapiens 45-48 3086219-0 1986 The role of phosphate groups in the interaction of human C-reactive protein with galactan polysaccharides. Phosphates 12-21 C-reactive protein Homo sapiens 57-75 3086219-0 1986 The role of phosphate groups in the interaction of human C-reactive protein with galactan polysaccharides. galactan polysaccharides 81-105 C-reactive protein Homo sapiens 57-75 3086219-1 1986 Human C-reactive protein (CRP) shows binding specificities for phosphate monoesters, polycations and for several other biological macromolecules lacking these ligands. Phosphates 63-72 C-reactive protein Homo sapiens 6-24 3086219-1 1986 Human C-reactive protein (CRP) shows binding specificities for phosphate monoesters, polycations and for several other biological macromolecules lacking these ligands. Phosphates 63-72 C-reactive protein Homo sapiens 26-29 3086219-2 1986 We report here that the formerly observed interaction of CRP with snail galactans, as exemplified by Helix pomatia galactan, is not due to a lectin-like carbohydrate-binding reactivity, but, instead that CRP obviously binds to phosphate groups that are minor constituents of these polysaccharides. Carbohydrates 153-165 C-reactive protein Homo sapiens 57-60 3086219-2 1986 We report here that the formerly observed interaction of CRP with snail galactans, as exemplified by Helix pomatia galactan, is not due to a lectin-like carbohydrate-binding reactivity, but, instead that CRP obviously binds to phosphate groups that are minor constituents of these polysaccharides. Phosphates 227-236 C-reactive protein Homo sapiens 57-60 3086219-4 1986 Thus, the anti-galactan reactivity of CRP can be attributed to the protein"s classical anti-phosphate/anti-phosphorylcholine specificity. Phosphates 92-101 C-reactive protein Homo sapiens 38-41 3750270-1 1986 Serum amyloid P component (SAP), and its acute phase homologue C-reactive protein (CRP), prolonged activated partial thromboplastin times (APTT) in cell free plasma when assayed at physiological concentrations in the presence of heparin. Heparin 229-236 C-reactive protein Homo sapiens 63-81 3750270-1 1986 Serum amyloid P component (SAP), and its acute phase homologue C-reactive protein (CRP), prolonged activated partial thromboplastin times (APTT) in cell free plasma when assayed at physiological concentrations in the presence of heparin. Heparin 229-236 C-reactive protein Homo sapiens 83-86 3919399-2 1985 The reaction is calcium dependent and appears to be similar to that reported to occur between C-reactive protein and various galactans. Calcium 16-23 C-reactive protein Homo sapiens 94-112 3471057-3 1986 This appears to occur via the Cr-CrP shuttle whereby the ADP produced as a result of contraction is converted to ATP via the adenylate kinase reaction with the production of AMP. Adenosine Diphosphate 57-60 C-reactive protein Homo sapiens 33-36 3471057-3 1986 This appears to occur via the Cr-CrP shuttle whereby the ADP produced as a result of contraction is converted to ATP via the adenylate kinase reaction with the production of AMP. Adenosine Triphosphate 113-116 C-reactive protein Homo sapiens 33-36 3471057-3 1986 This appears to occur via the Cr-CrP shuttle whereby the ADP produced as a result of contraction is converted to ATP via the adenylate kinase reaction with the production of AMP. Adenosine Monophosphate 174-177 C-reactive protein Homo sapiens 33-36 3471057-5 1986 The increase in the mitochondrial protein concentration of skeletal muscle that occurs with endurance training has a direct effect on improving work capacity by providing a greater potential for the CrP shuttle, produced by a greater surface area, increasing the number of transport sites for the exchange of substrates and products between the cytosol and the mitochondrial matrix, exerting a tighter control over the adenine nucleotides as they turnover during contractile and metabolic activity, and providing for a tighter control over the Embden-Meyerhof pathway to prevent excessive lactate production. Lactic Acid 589-596 C-reactive protein Homo sapiens 199-202 2947442-2 1986 Early activation markers (increase of cell size and formation of thermostable SE rosettes) and the lymphocyte proliferation (3H-thymidine incorporation) were changed by CRP (10-50 micrograms/ml), whereas PWM-induced stimulation was inhibited and PHA-induced activation was enhanced. Tritium 125-127 C-reactive protein Homo sapiens 169-172 2997165-1 1985 The gene for the prototype acute phase reactant, C-reactive protein, has been isolated from two lambda phage libraries containing inserted human DNA fragments using synthetic oligonucleotide probes. Oligonucleotides 175-190 C-reactive protein Homo sapiens 49-67 2998916-8 1985 In Crohn"s disease patients, copper serum concentration was increased and correlated positively to fibrinogen and C-reactive protein concentrations, erythrocyte sedimentation rate and thrombocytosis, and negatively to hematocrit. Copper 29-35 C-reactive protein Homo sapiens 114-132 4026186-0 1985 Immunoturbidimetry of serum C-reactive protein in low concentration of polyethylene glycol. Polyethylene Glycols 71-90 C-reactive protein Homo sapiens 28-46 3156933-1 1985 Stimulation by phorbol myristate acetate enables human neutrophils to phagocytize C-reactive protein-coated cells. Tetradecanoylphorbol Acetate 15-40 C-reactive protein Homo sapiens 82-100 2859021-5 1985 These results indicate that assay of serum CRP provides a precise means of objectively assessing the course of polymyalgia rheumatica during initial therapy with steroids, and suggest that routine measurements of CRP may make a useful contribution to the management of the disease. Steroids 162-170 C-reactive protein Homo sapiens 43-46 3919022-4 1985 Inhibition of platelet aggregation by CRP is accompanied by an inhibition of arachidonic acid release from both phosphatidylcholine and phosphatidylinositol. Arachidonic Acid 77-93 C-reactive protein Homo sapiens 38-41 3944459-9 1986 Cells were also sensitized for CRP binding by using diazophenylphosphocholine. diazophenylphosphocholine 52-77 C-reactive protein Homo sapiens 31-34 3953280-5 1986 Increased cortisol level and immature neutrophil counts preceded the elevation of CRP, alpha 1-acid glycoprotein and haptoglobin in four extremely premature neonates. Hydrocortisone 10-18 C-reactive protein Homo sapiens 82-85 3035044-0 1986 Significant enhanced superoxide anion (O2-) production in vitro by peripheral blood monocytes of lepromatous leprosy patients stimulated with liposome and suppression by C-reactive protein (CRP). Superoxides 21-37 C-reactive protein Homo sapiens 170-188 3035044-0 1986 Significant enhanced superoxide anion (O2-) production in vitro by peripheral blood monocytes of lepromatous leprosy patients stimulated with liposome and suppression by C-reactive protein (CRP). Superoxides 21-37 C-reactive protein Homo sapiens 190-193 3035044-0 1986 Significant enhanced superoxide anion (O2-) production in vitro by peripheral blood monocytes of lepromatous leprosy patients stimulated with liposome and suppression by C-reactive protein (CRP). Superoxides 39-41 C-reactive protein Homo sapiens 170-188 3035044-0 1986 Significant enhanced superoxide anion (O2-) production in vitro by peripheral blood monocytes of lepromatous leprosy patients stimulated with liposome and suppression by C-reactive protein (CRP). Superoxides 39-41 C-reactive protein Homo sapiens 190-193 3035044-6 1986 The most dramatic suppression of O2- shown when purified CRP was added to the mixtures in all groups examined [0.4 +/- 0.1 (500 ng), 0.3 +/- 0.0 (500 ng), 1.5 +/- 0.1 (100 ng), and 1.3 +/- 0.6 (100 ng) nm O2-/1.5 X 10(5) PBM/well for normals, IM, lepromatous, and tuberculoid, respectively]. Superoxides 33-35 C-reactive protein Homo sapiens 57-60 3035044-6 1986 The most dramatic suppression of O2- shown when purified CRP was added to the mixtures in all groups examined [0.4 +/- 0.1 (500 ng), 0.3 +/- 0.0 (500 ng), 1.5 +/- 0.1 (100 ng), and 1.3 +/- 0.6 (100 ng) nm O2-/1.5 X 10(5) PBM/well for normals, IM, lepromatous, and tuberculoid, respectively]. Superoxides 205-207 C-reactive protein Homo sapiens 57-60 3035044-7 1986 Results of O2- formation with incorporation of CRP into liposome as compared with liposome alone had no significant effect on PBM of lepromatous or tuberculoid patients. Superoxides 11-13 C-reactive protein Homo sapiens 47-50 6396081-2 1984 Binding of CRP to a 62-bp fragment containing the major site leads to an increase of the rotation time constant from 0.33 to 0.43 microseconds; addition of cAMP to the complex induces a decrease to 0.25 microseconds. Cyclic AMP 156-160 C-reactive protein Homo sapiens 11-14 3938944-3 1985 According to the CRP calcium dependent structural changes or ligand binding properties two buffer systems, Ca2+ rich and Ca2+ depleted, were used in all methods. Calcium 21-28 C-reactive protein Homo sapiens 17-20 6396081-7 1984 The rotation time constants together with the dichroism amplitudes indicate that binding of CRP to specific sites in the presence of cAMP leads to the formation of compact structures, which are consistent with bending of DNA helices. Cyclic AMP 133-137 C-reactive protein Homo sapiens 92-95 6693419-3 1984 The binding of fibronectin by CRP was relatively sensitive to ionic conditions, being maximal at physiological NaCl concentrations. Sodium Chloride 111-115 C-reactive protein Homo sapiens 30-33 6316274-1 1983 We have determined the stoichiometry of CRP binding to various DNA fragments carrying the lac, malT or gal promoters in the presence of cAMP, using a gel electrophoresis method. Cyclic AMP 136-140 C-reactive protein Homo sapiens 40-43 6358357-5 1983 S-CRP is expressed in the absence of calcium, whereas the binding of complexed CRP is calcium dependent. Calcium 86-93 C-reactive protein Homo sapiens 79-82 6316274-4 1983 Direct binding analysis and competition experiments performed at 200 microM cAMP allow us to measure the affinity of CRP for these different sites and to correlate them with variations in the consensus sequences, already proposed. Cyclic AMP 76-80 C-reactive protein Homo sapiens 117-120 6316274-7 1983 Conversely, we have studied, at constant CRP concentrations, the cAMP levels required to obtain half maximal binding to a particular DNA site : the required cAMP level increases inversely as the affinity for CRP. Cyclic AMP 65-69 C-reactive protein Homo sapiens 208-211 6316274-7 1983 Conversely, we have studied, at constant CRP concentrations, the cAMP levels required to obtain half maximal binding to a particular DNA site : the required cAMP level increases inversely as the affinity for CRP. Cyclic AMP 157-161 C-reactive protein Homo sapiens 208-211 6433926-2 1983 By addition of L-alpha-lecithin to the pleural effusion in the presence of calcium ions, a flocculence of the CRP-lecithin complex formed. Calcium 75-82 C-reactive protein Homo sapiens 110-113 6857266-1 1983 With a synthetic oligonucleotide mixture as probe, complementary DNA clones of C-reactive protein were isolated from an adult human liver complementary DNA library. Oligonucleotides 17-32 C-reactive protein Homo sapiens 79-97 6877243-0 1983 Influence of heparin on interactions between C-reactive protein and polycations. Heparin 13-20 C-reactive protein Homo sapiens 45-63 6877243-2 1983 CRP binds with phosphocholine and phosphate esters; initiates reactions of agglutination, opsonization and complement consumption; and precipitates with protamine and synthetic polymers of lysine and arginine, and these reactivities are modulated by calcium and phosphocholine. Lysine 189-195 C-reactive protein Homo sapiens 0-3 6877243-2 1983 CRP binds with phosphocholine and phosphate esters; initiates reactions of agglutination, opsonization and complement consumption; and precipitates with protamine and synthetic polymers of lysine and arginine, and these reactivities are modulated by calcium and phosphocholine. Arginine 200-208 C-reactive protein Homo sapiens 0-3 6877243-2 1983 CRP binds with phosphocholine and phosphate esters; initiates reactions of agglutination, opsonization and complement consumption; and precipitates with protamine and synthetic polymers of lysine and arginine, and these reactivities are modulated by calcium and phosphocholine. Calcium 250-257 C-reactive protein Homo sapiens 0-3 6877243-7 1983 However, heparin did induce a rapid and efficient dissociation of CRP-polycation precipitates preformed at equivalence, with total release of CRP. Heparin 9-16 C-reactive protein Homo sapiens 66-69 6877243-7 1983 However, heparin did induce a rapid and efficient dissociation of CRP-polycation precipitates preformed at equivalence, with total release of CRP. Heparin 9-16 C-reactive protein Homo sapiens 142-145 6877243-8 1983 Small amounts of heparin augmented precipitation under conditions of polycation excess of CRP, but as heparin levels were increased to amounts needed to reach equivalence with polycation, CRP was resolubilized in favor of the preferred heparin-polycation complexes. Heparin 17-24 C-reactive protein Homo sapiens 90-93 6877243-9 1983 Chondroitin sulfate was similar to heparin in its effects upon the CRP-poly-L-arginine (PLA) interaction, while hyaluronic acid enhanced CRP-PLA precipitation at all concentrations tested and DNA had neither augmenting nor solubilizing effects. pla 88-91 C-reactive protein Homo sapiens 67-70 6877243-10 1983 These data indicate that CRP-polycation interactions are significantly and selectively influenced in the presence of small amounts of heparin and certain other polyanions. Heparin 134-141 C-reactive protein Homo sapiens 25-28 6300060-7 1983 Thus, by Scatchard analysis, the human C-reactive protein bound 1 mol of phosphate spin label per mol of protein with a Ka = 3.91 X 10(3) M-1, whereas the Limulus C-reactive protein bound only 0.5 mol of phosphate spin label per mol of protein with an overall Ka = 1.95 X 10(3) M-1. Phosphates 73-82 C-reactive protein Homo sapiens 39-57 6300060-7 1983 Thus, by Scatchard analysis, the human C-reactive protein bound 1 mol of phosphate spin label per mol of protein with a Ka = 3.91 X 10(3) M-1, whereas the Limulus C-reactive protein bound only 0.5 mol of phosphate spin label per mol of protein with an overall Ka = 1.95 X 10(3) M-1. Phosphates 204-213 C-reactive protein Homo sapiens 39-57 6300060-8 1983 Inhibition studies using purified C-polysaccharide-induced inhibition of the phosphate spin label-human C-reactive protein interaction showed competitive inhibition with a KI of 4.78 X 10(-5) M at 18 degrees C. The phosphate spin label did not bind to dogfish C-reactive protein. Phosphates 77-86 C-reactive protein Homo sapiens 104-122 6300060-8 1983 Inhibition studies using purified C-polysaccharide-induced inhibition of the phosphate spin label-human C-reactive protein interaction showed competitive inhibition with a KI of 4.78 X 10(-5) M at 18 degrees C. The phosphate spin label did not bind to dogfish C-reactive protein. Phosphates 77-86 C-reactive protein Homo sapiens 260-278 6300060-8 1983 Inhibition studies using purified C-polysaccharide-induced inhibition of the phosphate spin label-human C-reactive protein interaction showed competitive inhibition with a KI of 4.78 X 10(-5) M at 18 degrees C. The phosphate spin label did not bind to dogfish C-reactive protein. Phosphates 215-224 C-reactive protein Homo sapiens 104-122 6300060-8 1983 Inhibition studies using purified C-polysaccharide-induced inhibition of the phosphate spin label-human C-reactive protein interaction showed competitive inhibition with a KI of 4.78 X 10(-5) M at 18 degrees C. The phosphate spin label did not bind to dogfish C-reactive protein. Phosphates 215-224 C-reactive protein Homo sapiens 260-278 6656768-4 1983 We report here that in the presence of high concentrations of urea significant antigenic, electrophoretic and binding site modifications of CRP occur selectively in the absence of calcium. Urea 62-66 C-reactive protein Homo sapiens 140-143 6656768-6 1983 F-CRP retained a partial antigenic identity to native CRP, displayed decreased intrinsic tryptophan fluorescence, and expressed a new antigenic reactivity. Tryptophan 89-99 C-reactive protein Homo sapiens 2-5 6656768-9 1983 The formation of F-CRP in urea or by heat was prevented by the presence of 0.7 mM or more calcium. Urea 26-30 C-reactive protein Homo sapiens 19-22 6656768-9 1983 The formation of F-CRP in urea or by heat was prevented by the presence of 0.7 mM or more calcium. Calcium 90-97 C-reactive protein Homo sapiens 19-22 6656768-13 1983 The formation of F-CRP from native CRP resulted in a loss of capacity for calcium-dependent binding to the C-polysaccharide despite the persistence of calcium-independent binding reactivity for polycations. Calcium 74-81 C-reactive protein Homo sapiens 19-22 6656768-13 1983 The formation of F-CRP from native CRP resulted in a loss of capacity for calcium-dependent binding to the C-polysaccharide despite the persistence of calcium-independent binding reactivity for polycations. Calcium 74-81 C-reactive protein Homo sapiens 35-38 6656768-13 1983 The formation of F-CRP from native CRP resulted in a loss of capacity for calcium-dependent binding to the C-polysaccharide despite the persistence of calcium-independent binding reactivity for polycations. Calcium 151-158 C-reactive protein Homo sapiens 19-22 6656768-13 1983 The formation of F-CRP from native CRP resulted in a loss of capacity for calcium-dependent binding to the C-polysaccharide despite the persistence of calcium-independent binding reactivity for polycations. Calcium 151-158 C-reactive protein Homo sapiens 35-38 6656768-14 1983 These data suggest that in the presence of sufficient calcium CRP can resist urea- or heat-induced structural denaturation, maintaining antigenic, electrophoretic and binding identity to the native molecule. Calcium 54-61 C-reactive protein Homo sapiens 62-65 6656768-14 1983 These data suggest that in the presence of sufficient calcium CRP can resist urea- or heat-induced structural denaturation, maintaining antigenic, electrophoretic and binding identity to the native molecule. Urea 77-81 C-reactive protein Homo sapiens 62-65 6656768-15 1983 In the absence of calcium, exposure to urea led to increased electrophoretic mobility and exposure of a new antigenic reactivity, and to alterations in the phosphocholine- but not the polycation-binding sites of the native CRP molecule; this new antigenic reactivity may be of value in further studies on the CRP molecule. Urea 39-43 C-reactive protein Homo sapiens 223-226 6656768-15 1983 In the absence of calcium, exposure to urea led to increased electrophoretic mobility and exposure of a new antigenic reactivity, and to alterations in the phosphocholine- but not the polycation-binding sites of the native CRP molecule; this new antigenic reactivity may be of value in further studies on the CRP molecule. Urea 39-43 C-reactive protein Homo sapiens 309-312 6433926-4 1983 This extracted CRP was further purified by sequential treatment on column chromatography of DEAE cellulose (DE52) and gel filtration using Sephacryl S-300. sephacryl s-300 139-154 C-reactive protein Homo sapiens 15-18 6822675-3 1983 Serum copper in RA correlated significantly with a number of disease activity markers--for example erythrocyte sedimentation rate (ESR), C-reactive protein, haemoglobin concentration, morning stiffness, and grip strength. Copper 6-12 C-reactive protein Homo sapiens 137-155 6885107-9 1983 We propose that Tb3+ (by inference Ca2+) binding takes place near the CRP subunit disulfide bond, where two histidine residues are present. Disulfides 82-91 C-reactive protein Homo sapiens 70-73 6885107-9 1983 We propose that Tb3+ (by inference Ca2+) binding takes place near the CRP subunit disulfide bond, where two histidine residues are present. Histidine 108-117 C-reactive protein Homo sapiens 70-73 6885107-10 1983 The pH dependency of Tb3+ binding is best explained by the deprotonation of a histidine residue(s) in CRP. Histidine 78-87 C-reactive protein Homo sapiens 102-105 7061105-3 1982 Platelet activation induced by H-CRP was sensitive to the presence of EDTA and dibucaine, required metabolic energy and was inhibited by increased levels of cAMP. Cyclic AMP 157-161 C-reactive protein Homo sapiens 31-36 7092339-0 1982 Relationship between urinary sialylated saccharides, serum amyloid A protein, and C-reactive protein in rheumatoid arthritis and systemic lupus erythematosus. Carbohydrates 40-51 C-reactive protein Homo sapiens 82-100 6129507-2 1982 This reaction is probably precipitated by C-reactive protein in the presence of calcium ions. Calcium 80-87 C-reactive protein Homo sapiens 42-60 7129640-6 1982 All strains were found to bind radiolabeled CRP in the presence of calcium and to activate the classical complement pathway in normal human serum. Calcium 67-74 C-reactive protein Homo sapiens 44-47 7086355-1 1982 C-reactive protein (CRP), the classical acute-phase protein, can bind phospholipids by virtue of its specific, calcium-dependent reactivity with phosphorylcholine residues. Phospholipids 70-83 C-reactive protein Homo sapiens 0-18 7086355-1 1982 C-reactive protein (CRP), the classical acute-phase protein, can bind phospholipids by virtue of its specific, calcium-dependent reactivity with phosphorylcholine residues. Phospholipids 70-83 C-reactive protein Homo sapiens 20-23 7086355-1 1982 C-reactive protein (CRP), the classical acute-phase protein, can bind phospholipids by virtue of its specific, calcium-dependent reactivity with phosphorylcholine residues. Calcium 111-118 C-reactive protein Homo sapiens 0-18 7086355-1 1982 C-reactive protein (CRP), the classical acute-phase protein, can bind phospholipids by virtue of its specific, calcium-dependent reactivity with phosphorylcholine residues. Calcium 111-118 C-reactive protein Homo sapiens 20-23 7086355-2 1982 However, analysis of acute-phase serum by gel filtration and by density gradient ultracentrifugation showed that the CRP was in a free, uncomplexed form, despite the coexistent presence of the various classes of serum lipoproteins, all of which contain phospholipids. Phospholipids 253-266 C-reactive protein Homo sapiens 117-120 6804565-6 1982 SDS-PAGE analysis of solubilized precipitates indicated the formation of covalent complexes between fragments of C3 and both C-polysaccharide and C-reactive protein. Sodium Dodecyl Sulfate 0-3 C-reactive protein Homo sapiens 146-164 6799578-3 1982 The inclusion of 4% (w/v) polyethylene glycol (PEG) in the diluent buffers made it possible to quantitate CRP within 4 h at room temperature. Polyethylene Glycols 26-45 C-reactive protein Homo sapiens 106-109 7046573-2 1982 After binding of the divalent cation, CRP binds all phosphate monoesters with a stochiometry of one mole per mole of CRP subunit. Phosphates 52-61 C-reactive protein Homo sapiens 38-41 7046573-2 1982 After binding of the divalent cation, CRP binds all phosphate monoesters with a stochiometry of one mole per mole of CRP subunit. Phosphates 52-61 C-reactive protein Homo sapiens 117-120 7046573-8 1982 In addition CRP has another binding site accounting for its ability to react with depyruvylated type 4 pneumococcal polysaccharide which does not contain phosphate or choline. Phosphates 154-163 C-reactive protein Homo sapiens 12-15 7046574-0 1982 C-reactive protein binding specificities: artificial and natural phospholipid bilayers. Phospholipids 65-77 C-reactive protein Homo sapiens 0-18 7056562-1 1982 We previously reported that C-reactive protein (CRP), an acute phase reactant, inhibits platelet activation through an effect upon a factor(s) critical to ADP-mediated secondary wave platelet aggregation but independent of a direct effect upon platelet contractile elements. Adenosine Diphosphate 155-158 C-reactive protein Homo sapiens 28-46 7056562-1 1982 We previously reported that C-reactive protein (CRP), an acute phase reactant, inhibits platelet activation through an effect upon a factor(s) critical to ADP-mediated secondary wave platelet aggregation but independent of a direct effect upon platelet contractile elements. Adenosine Diphosphate 155-158 C-reactive protein Homo sapiens 48-51 6799578-3 1982 The inclusion of 4% (w/v) polyethylene glycol (PEG) in the diluent buffers made it possible to quantitate CRP within 4 h at room temperature. Polyethylene Glycols 47-50 C-reactive protein Homo sapiens 106-109 7086148-2 1982 CRP was obtained from malignant ascitic and pleural fluids by calcium-dependent affinity chromatography on pneumococcal C-polysaccharide covalently coupled to cyanogen bromide-activated Sepharose. Calcium 62-69 C-reactive protein Homo sapiens 0-3 7028874-7 1981 A markedly enhanced rate of binding was observed after pre-equilibration of CRP with calcium. Calcium 85-92 C-reactive protein Homo sapiens 76-79 7277698-0 1980 [Reaction of Actinomyces polysaccharide with C-reactive protein (author"s transl)]. actinomyces polysaccharide 13-39 C-reactive protein Homo sapiens 45-63 6269081-1 1981 We have demonstrated in vitro the existence on the plasmid pBR322 of a promoter signal that is strictly dependent on cAMP and its receptor protein CRP. Cyclic AMP 117-121 C-reactive protein Homo sapiens 147-150 7462634-3 1981 We have previously presented a model for CRP-membrane interactions using liposomes composed of dimyristoyl phosphatidylcholine (DMPC), cholesterol (CHOL), stearylamine (SA), and galactosyl ceramide. Cholesterol 135-146 C-reactive protein Homo sapiens 41-44 7462634-3 1981 We have previously presented a model for CRP-membrane interactions using liposomes composed of dimyristoyl phosphatidylcholine (DMPC), cholesterol (CHOL), stearylamine (SA), and galactosyl ceramide. Cholesterol 148-152 C-reactive protein Homo sapiens 41-44 7462634-3 1981 We have previously presented a model for CRP-membrane interactions using liposomes composed of dimyristoyl phosphatidylcholine (DMPC), cholesterol (CHOL), stearylamine (SA), and galactosyl ceramide. stearylamine 155-167 C-reactive protein Homo sapiens 41-44 7462634-3 1981 We have previously presented a model for CRP-membrane interactions using liposomes composed of dimyristoyl phosphatidylcholine (DMPC), cholesterol (CHOL), stearylamine (SA), and galactosyl ceramide. stearylamine 169-171 C-reactive protein Homo sapiens 41-44 7462634-7 1981 CRP binding to liposomes was dependent on the presence of SA in the membrane and could occur with dimyristoyl phosphatidylethanolamine in place of DMPC. stearylamine 58-60 C-reactive protein Homo sapiens 0-3 7462634-10 1981 In liposomes with a limiting density of SA, we found increased CRP binding with changes in composition that would increase membrane fluidity. stearylamine 40-42 C-reactive protein Homo sapiens 63-66 7462634-12 1981 However, increasing the amount of CHOL in the membrane was found to increase C activation while decreasing CRP binding. Cholesterol 34-38 C-reactive protein Homo sapiens 107-110 7462634-13 1981 These findings indicate that CRP binding to membranes and subsequent C activation can occur through cationic molecules as well as phospholipids. Phospholipids 130-143 C-reactive protein Homo sapiens 29-32 7190145-2 1980 CRP caused as much agglutination of suspensions composed of egg yolk phosphatidylcholine, cholesterol, and Span 60 as of those composed of cholesterol and Span 60, suggesting that phosphocholine residues of phosphatidylcholine are not important as binding sites for CRP. Cholesterol 90-101 C-reactive protein Homo sapiens 0-3 7190145-2 1980 CRP caused as much agglutination of suspensions composed of egg yolk phosphatidylcholine, cholesterol, and Span 60 as of those composed of cholesterol and Span 60, suggesting that phosphocholine residues of phosphatidylcholine are not important as binding sites for CRP. Cholesterol 139-150 C-reactive protein Homo sapiens 0-3 7338519-2 1981 Liposomes composed of phosphatidylcholine and stearylamine were agglutinated with CRP. stearylamine 46-58 C-reactive protein Homo sapiens 82-85 7338519-5 1981 Agglutination of liposomes caused by CRP was dependent on the fatty acid composition of phosphatidylcholine, cholesterol content and temperature. Fatty Acids 62-72 C-reactive protein Homo sapiens 37-40 7338519-5 1981 Agglutination of liposomes caused by CRP was dependent on the fatty acid composition of phosphatidylcholine, cholesterol content and temperature. Cholesterol 109-120 C-reactive protein Homo sapiens 37-40 7276568-3 1981 C-reactive protein previously was shown to selectively and reversibly precipitate with certain small polymers of arginine and lysine. Arginine 113-121 C-reactive protein Homo sapiens 0-18 7276568-3 1981 C-reactive protein previously was shown to selectively and reversibly precipitate with certain small polymers of arginine and lysine. Lysine 126-132 C-reactive protein Homo sapiens 0-18 7276568-5 1981 However, in the presence of phosphocholine, CRP rapidly precipitated and formed stable complexes with the polycationic polymers in the otherwise inhibitory calcium concentrations. Calcium 156-163 C-reactive protein Homo sapiens 44-47 7276568-7 1981 These results extend the characterization of the binding reactivity of CRP for polycations and suggest a relationship between this binding site and the sites for calcium and phosphocholine. Calcium 162-169 C-reactive protein Homo sapiens 71-74 7015262-3 1981 Ten days of cefadroxil therapy was used to treat 44 children with urinary tract infection and CRP values greater than or equal to 28 microgram/ml (CRP-positive group). Cefadroxil 12-22 C-reactive protein Homo sapiens 94-97 7015262-3 1981 Ten days of cefadroxil therapy was used to treat 44 children with urinary tract infection and CRP values greater than or equal to 28 microgram/ml (CRP-positive group). Cefadroxil 12-22 C-reactive protein Homo sapiens 147-150 7015262-5 1981 Recurrent infections occurred significantly more often at four to five days after completion of therapy in CRP-negative children who received one day (44.4%) compared to ten days (20%) of cefadroxil therapy (P less than .05). Cefadroxil 188-198 C-reactive protein Homo sapiens 107-110 7217669-4 1981 A weak interaction between CRP and agarose was observed, which was also CA++-dependent and could be inhibited by phosphocholine and galactose. Galactose 132-141 C-reactive protein Homo sapiens 27-30 7217669-5 1981 In addition, incorporation of galactocyl cerebroside in phosphatidylcholine:lysophosphatidylcholine liposomes enhanced the binding of CRP. galactocyl cerebroside 30-52 C-reactive protein Homo sapiens 134-137 7217669-7 1981 Furthermore, CRP bound to galactocyl cerebroside-containing liposomes bound approximately twice as much C1q as the same amount of CRP bound to liposomes lacking the glycolipid. galactocyl cerebroside 26-48 C-reactive protein Homo sapiens 13-16 7217669-7 1981 Furthermore, CRP bound to galactocyl cerebroside-containing liposomes bound approximately twice as much C1q as the same amount of CRP bound to liposomes lacking the glycolipid. galactocyl cerebroside 26-48 C-reactive protein Homo sapiens 130-133 448084-11 1979 Complement damage in the presence of CRP was enhanced by certain sphingolipids and also by digalactosyl diglyceride, but not by sphingomyelin. Digalactosyl diglyceride 91-115 C-reactive protein Homo sapiens 37-40 7382134-0 1980 Change in permeability of liposomal membranes mediated by C-reactive protein and its inhibition by cholesterol. Cholesterol 99-110 C-reactive protein Homo sapiens 58-76 118839-6 1979 C-reactive protein, which resembles protein SAP structurally but has calcium-dependent specificity for different ligands, bound significantly to only one of five different amyloid fibril preparations. Calcium 69-76 C-reactive protein Homo sapiens 0-18 471064-4 1979 A number of observations suggest that at least some of the biological activities of CRP depend on its interaction with phospholipids of cell membranes. Phospholipids 119-132 C-reactive protein Homo sapiens 84-87 621279-7 1978 One subject exhibited a second rise in SAA and CRP concentrations after acute over-indulgence with alcohol, suggesting that acute liver damage may have caused an acute phase reaction. Alcohols 99-106 C-reactive protein Homo sapiens 47-50 762075-3 1979 The NH2-terminal residue of CRP is pyrrolidonecarboxylic acid and the COOH terminus is proline. Carbonic Acid 70-74 C-reactive protein Homo sapiens 28-31 70475-9 1977 These data, therefore, raise the possibility that CRP inhibits platelet reactivities by interfering with an aspect of porstaglandin metabolism, and that this occurs subsequent to the hydrolytic accumulation of arachidonic acid and prior to the movement of calcium from the platelet dense tubules. porstaglandin 118-131 C-reactive protein Homo sapiens 50-53 588590-2 1977 The method consists of two chromatographic separations on diethylaminoethyl (DEAE)-cellulose columns and utilized the difference between the binding of C-reactive protein to DEAE in the presence and absence of calcium. Calcium 210-217 C-reactive protein Homo sapiens 152-170 70475-2 1977 The role of cAMP, contractile elements, and prostaglandin metabolism in CRP-induced inhibition of platelet aggregation and secretion. Cyclic AMP 12-16 C-reactive protein Homo sapiens 72-75 70475-2 1977 The role of cAMP, contractile elements, and prostaglandin metabolism in CRP-induced inhibition of platelet aggregation and secretion. Prostaglandins 44-57 C-reactive protein Homo sapiens 72-75 70475-4 1977 Multiple considerations including selective inhibition of secondary wave aggregation suggested that CRP exerted its inhibitory effects by interfering with the release of endogenous ADP. Adenosine Diphosphate 181-184 C-reactive protein Homo sapiens 100-103 70475-5 1977 In the present investigation, CRP was found by direct assay to inhibit the release of endogenous ADP and/or serotonin concomitant with inhibition of platelet aggregation stimulated by ADP, epinephrine, thrombin, and AHGG. Adenosine Diphosphate 97-100 C-reactive protein Homo sapiens 30-33 588590-0 1977 Purification of C-reactive protein on DEAE-cellulose by a simple two-step procedure utilizing the calcium-dependency of the protein. Calcium 98-105 C-reactive protein Homo sapiens 16-34 70475-9 1977 These data, therefore, raise the possibility that CRP inhibits platelet reactivities by interfering with an aspect of porstaglandin metabolism, and that this occurs subsequent to the hydrolytic accumulation of arachidonic acid and prior to the movement of calcium from the platelet dense tubules. Arachidonic Acid 210-226 C-reactive protein Homo sapiens 50-53 70475-5 1977 In the present investigation, CRP was found by direct assay to inhibit the release of endogenous ADP and/or serotonin concomitant with inhibition of platelet aggregation stimulated by ADP, epinephrine, thrombin, and AHGG. Serotonin 108-117 C-reactive protein Homo sapiens 30-33 70475-5 1977 In the present investigation, CRP was found by direct assay to inhibit the release of endogenous ADP and/or serotonin concomitant with inhibition of platelet aggregation stimulated by ADP, epinephrine, thrombin, and AHGG. Adenosine Diphosphate 184-187 C-reactive protein Homo sapiens 30-33 977942-10 1976 These experiments extend the platelet reactivities inhibited by CRP, show that CRP expresses its inhibitory capacity in platelet-rich plasma as well as upon isolated platelets, raise the possibility that CRP exercises its effects by inhibiting or interfering with the release and/or utilization of endogenous platelet ADP, and support the concept that CRP plays an important role in the control of platelet responsiveness to a variety of stimuli during acute inflammatory reactions. Adenosine Diphosphate 319-322 C-reactive protein Homo sapiens 80-83 70475-8 1977 By contrast, CRP did inhibit both thrombin-induced release of malondialdehyde, a prostaglandin endoperoxide nonprostanoate endproduct, and platelet aggregation induced by the prostaglandin endoperoxide precursor arachidonic acid. Malondialdehyde 62-77 C-reactive protein Homo sapiens 13-16 70475-8 1977 By contrast, CRP did inhibit both thrombin-induced release of malondialdehyde, a prostaglandin endoperoxide nonprostanoate endproduct, and platelet aggregation induced by the prostaglandin endoperoxide precursor arachidonic acid. Arachidonic Acid 212-228 C-reactive protein Homo sapiens 13-16 830761-5 1977 CRP also enhanced C consumption during heparin-protamine interactions in whole serum, and in the presence of CRP depletion of C components C1-3 was observed. Heparin 39-46 C-reactive protein Homo sapiens 0-3 830761-6 1977 Similar C1 binding and C consumption in the presence of CRP were seen upon the interaction of multiple additional polyanions including DNA, ENA, hyaluronic acid, chondroitin sulfate, and dextran sulfate with the polycations protamine sulfate and poly-L-lysine. Lysine 246-259 C-reactive protein Homo sapiens 56-59 977942-2 1976 Inhibition by CRP of platelet reactivities stimulated by poly-L-lysine, ADP, epinephrine, and collagen. Lysine 57-70 C-reactive protein Homo sapiens 14-17 977942-2 1976 Inhibition by CRP of platelet reactivities stimulated by poly-L-lysine, ADP, epinephrine, and collagen. Adenosine Diphosphate 72-75 C-reactive protein Homo sapiens 14-17 977942-4 1976 In the present experiments, CRP was found also to inhibit the ability of washed human platelets to aggregate in response to poly-L-lysine (PLL); in these experiments, the magnitude of the inhibitory effect was dependent upon the m.w. Lysine 124-137 C-reactive protein Homo sapiens 28-31 977942-7 1976 CRP similarly inhibited ADP- and epinephrine-stimulated platelet aggregation in platelet-rich plasma (PRP), and this was characterized by relatively minimal suppression of the primary wave of aggregation. Adenosine Diphosphate 24-27 C-reactive protein Homo sapiens 0-3 977942-9 1976 Finally, CRP inhibited the activation of PF3 and the release of serotonin during stimulation of platelets with ADP, and this inhibition was temporally related to the onset of the secondary wave of aggregation. Serotonin 65-74 C-reactive protein Homo sapiens 9-12 977942-9 1976 Finally, CRP inhibited the activation of PF3 and the release of serotonin during stimulation of platelets with ADP, and this inhibition was temporally related to the onset of the secondary wave of aggregation. Adenosine Diphosphate 112-115 C-reactive protein Homo sapiens 9-12 977942-10 1976 These experiments extend the platelet reactivities inhibited by CRP, show that CRP expresses its inhibitory capacity in platelet-rich plasma as well as upon isolated platelets, raise the possibility that CRP exercises its effects by inhibiting or interfering with the release and/or utilization of endogenous platelet ADP, and support the concept that CRP plays an important role in the control of platelet responsiveness to a variety of stimuli during acute inflammatory reactions. Adenosine Diphosphate 319-322 C-reactive protein Homo sapiens 80-83 977942-10 1976 These experiments extend the platelet reactivities inhibited by CRP, show that CRP expresses its inhibitory capacity in platelet-rich plasma as well as upon isolated platelets, raise the possibility that CRP exercises its effects by inhibiting or interfering with the release and/or utilization of endogenous platelet ADP, and support the concept that CRP plays an important role in the control of platelet responsiveness to a variety of stimuli during acute inflammatory reactions. Adenosine Diphosphate 319-322 C-reactive protein Homo sapiens 80-83 13908279-7 1962 Carbonyl iron spherules, Diplococcus pneumoniae types IIs and XXVIIs, and Serratia marcescens were phagocytosed more rapidly and in greater numbers by leukocytes of normal human blood after incubation with C-reactive protein. Iron 9-13 C-reactive protein Homo sapiens 206-224 809531-3 1975 Cationic homopolymers of poly-L-lysine were found to activate complement (C) via C-reactive protein (CRP) and deplete C3 and C5 as well as early-acting C components. Lysine 25-38 C-reactive protein Homo sapiens 81-99 809531-3 1975 Cationic homopolymers of poly-L-lysine were found to activate complement (C) via C-reactive protein (CRP) and deplete C3 and C5 as well as early-acting C components. Lysine 25-38 C-reactive protein Homo sapiens 101-104 13634834-0 1959 [C-reactive protein in typhoid treated with combined chloramphenicol & phenylbutazone]. Adenosine Monophosphate 58-61 C-reactive protein Homo sapiens 1-19 14441688-0 1959 [On the appearance of the C-reactive protein after the administration of dextran]. Dextrans 73-80 C-reactive protein Homo sapiens 26-44 13577562-0 1958 [C-reactive protein in patients with pollinosis in preseasonal & seasonal periods after hyposensitization]. Adenosine Monophosphate 64-67 C-reactive protein Homo sapiens 1-19 13597956-0 1958 [C-reactive protein in the serological diagnosis of silicosis & silicotuberculosis]. Adenosine Monophosphate 63-66 C-reactive protein Homo sapiens 1-19 13454748-0 1957 [The presence of C-reactive protein and its relation to blood sedimentation, the Weltmann test & electrophoresis in various diseases in children]. Adenosine Monophosphate 96-99 C-reactive protein Homo sapiens 17-35 13590811-0 1958 [Behavior of C-reactive protein in premature & newborn infants]. Adenosine Monophosphate 46-49 C-reactive protein Homo sapiens 13-31 33259720-7 2021 There were significant differences in inflammatory markers between the two groups: interleukin-6 (p = 0.0001), procalcitonin (p = 0.0001), and C-reactive protein (p = 0.0001) were lower in the dexamethasone group. Dexamethasone 193-206 C-reactive protein Homo sapiens 143-161 33934788-0 2021 A sensitive and quantitative prognosis of C-reactive protein at picogram level using mesoporous silica encapsulated core-shell up-conversion nanoparticle based lateral flow strip assay. mesoporous silica 85-102 C-reactive protein Homo sapiens 42-60 33934788-3 2021 In this paper, we demonstrated a lateral flow system for CRP quantification by using mesoporous silica (mSiO2) coated up-converting nanoparticles (UCNPs) (denoted as UCNPs@mSiO2) as fluorescent labels. mesoporous silica 85-102 C-reactive protein Homo sapiens 57-60 33940096-10 2021 CONCLUSION: Although interaction terms are not statistically significant, the associations of temporal patterns of NT-proBNP, HsTnT, and CRP appear more outspoken in women than in men with HFrEF, whereas associations seem similar for temporal patterns of creatinine, eGFR, Cystatin C, KIM-1 and NAG. Creatinine 255-265 C-reactive protein Homo sapiens 137-140 32967742-5 2021 We hypothesised that a daily oral CGMP intake would reduce high-sensitive C-reactive protein in healthy adults. Cyclic GMP 34-38 C-reactive protein Homo sapiens 74-92 33740541-0 2021 A sensitive label-free photoelectrochemical aptasensor based on a novel PTB7-Th/H2O2 system with unexpected photoelectric performance for C-reactive protein analysis. Hydrogen Peroxide 80-84 C-reactive protein Homo sapiens 138-156 33740541-6 2021 As a proof of concept, the proposed PTB7-Th/H2O2 system was successfully applied in the construction of a label-free PEC aptasensor for sensitive analysis of CRP, which performed a wide detection range from 1 pM to 1000 nM with a low detection limit of 0.33 pM. Hydrogen Peroxide 44-48 C-reactive protein Homo sapiens 158-161 33929466-0 2021 Metal-enhanced sensing platform for the highly sensitive detection of C-reactive protein antibody and rhodamine B with applications in cardiovascular diseases and food safety. Metals 0-5 C-reactive protein Homo sapiens 70-88 34056870-8 2021 RESULTS: Surgical debridement, antibiotic, and hyperbaric oxygen therapy were used and discontinued over a 6-month period with normalization of C-reactive protein. Oxygen 58-64 C-reactive protein Homo sapiens 144-162 33662886-11 2021 In stratified analyses, the significant negative association between cord blood 25(OH)D with foetal hs-CRP and glucolipid metabolic indexes was observed only at low-medium levels of air pollution exposure. 25(oh)d 80-87 C-reactive protein Homo sapiens 103-106 33512567-8 2021 The unsuccessful CD rate was found to be 28.76%; this is likely a function of more neuropsychiatric disease, more accompanying sigmoid diverticulum, previous abdominal surgery, abdominal tenderness, onset of symptoms for more than 48 h, higher mean intra-abdominal pressure (IAP), IAP over 15 mmHg, larger mean diameter of the cecum, the cecum diameter over 10 cm, and higher mean C-reactive protein (CRP) values as statistically significant. Cadmium 17-19 C-reactive protein Homo sapiens 381-399 33512567-8 2021 The unsuccessful CD rate was found to be 28.76%; this is likely a function of more neuropsychiatric disease, more accompanying sigmoid diverticulum, previous abdominal surgery, abdominal tenderness, onset of symptoms for more than 48 h, higher mean intra-abdominal pressure (IAP), IAP over 15 mmHg, larger mean diameter of the cecum, the cecum diameter over 10 cm, and higher mean C-reactive protein (CRP) values as statistically significant. Cadmium 17-19 C-reactive protein Homo sapiens 401-404 34019244-3 2021 Immunohistochemical staining showed that CRP expression was upregulated in TSCC tissues from cisplatin-resistant patients compared with that in cisplatin-sensitive TSCC samples. Cisplatin 93-102 C-reactive protein Homo sapiens 41-44 34021415-5 2021 The optimal CRP cutoff value of Clavien-Dindo (CD) grade >= 3 for predicting severe complications for each group was determined. Cadmium 47-49 C-reactive protein Homo sapiens 12-15 34023513-7 2021 CRP level was lower in the TOF group than in the CON group (7[3-22] vs. 20[5-52] mg/L; p=0.048) 7-10 days after the start of the administration of tofacitinib. tofacitinib 147-158 C-reactive protein Homo sapiens 0-3 34033278-0 2021 Moderator role of vitamin D concentrations on the association between metabolic syndrome and C-reactive protein among adults. Vitamin D 18-27 C-reactive protein Homo sapiens 93-111 34020922-0 2021 Comment on "Role of Serum High-Sensitivity C-Reactive Protein as a Predictor of Therapeutic Response to Tadalafil in Patients With Erectile Dysfunction: A Prospective Observational Study". Tadalafil 104-113 C-reactive protein Homo sapiens 43-61 34049969-6 2021 Importantly, plasma IL-6 and C-reactive protein (CRP) levels positively correlated with mitochondrial mass and negatively correlated with fatty acid uptake in T cells from COVID-19 patients. Fatty Acids 138-148 C-reactive protein Homo sapiens 29-47 34049969-6 2021 Importantly, plasma IL-6 and C-reactive protein (CRP) levels positively correlated with mitochondrial mass and negatively correlated with fatty acid uptake in T cells from COVID-19 patients. Fatty Acids 138-148 C-reactive protein Homo sapiens 49-52 34030097-2 2021 Inspired by this, poly (diallyldimethylammonium chloride)-capped curcumin nanoparticles (PDDA@CUR NPs) with high loading capacity were synthesized as signal labels and further applied to dual-model colorimetric and fluorescence ELISA for the detection of C-reactive protein (CRP). Curcumin 65-73 C-reactive protein Homo sapiens 255-273 34030097-2 2021 Inspired by this, poly (diallyldimethylammonium chloride)-capped curcumin nanoparticles (PDDA@CUR NPs) with high loading capacity were synthesized as signal labels and further applied to dual-model colorimetric and fluorescence ELISA for the detection of C-reactive protein (CRP). Curcumin 65-73 C-reactive protein Homo sapiens 275-278 33991227-6 2021 Associations between DII and CRP were assessed using multivariate linear regression adjusting for confounders (age education, physical activity, sex and smoking). dilC18(3) dye 21-24 C-reactive protein Homo sapiens 29-32 34019244-5 2021 Moreover, functional experiments showed that CRP increased cell viability and decreased cisplatin-induced apoptosis. Cisplatin 88-97 C-reactive protein Homo sapiens 45-48 34023221-9 2021 Age, hemodialysis, and C-reactive protein (CRP) levels were candidate predictors of the need for oxygen supply in patients with COVID-19. Oxygen 97-103 C-reactive protein Homo sapiens 23-41 33992676-7 2021 Additionally, serum iron, ferritin, and CRP levels affected intracellular ROS levels in specific blood cell types and T cell subsets. Reactive Oxygen Species 74-77 C-reactive protein Homo sapiens 40-43 33992676-9 2021 Finally, when divided into three groups according to serum CRP levels, dose-dependent increases in the intracellular O2 - levels in blood cells and central memory and effector memory CD8+ T cells were most prominently observed in the high-CRP group. Oxygen 117-121 C-reactive protein Homo sapiens 59-62 33992676-9 2021 Finally, when divided into three groups according to serum CRP levels, dose-dependent increases in the intracellular O2 - levels in blood cells and central memory and effector memory CD8+ T cells were most prominently observed in the high-CRP group. Oxygen 117-121 C-reactive protein Homo sapiens 239-242 33992676-10 2021 These results suggest that an increase in the levels of certain intracellular ROS, particularly after radiation exposure, might be linked to enhanced inflammatory status, including elevated serum CRP levels and reduced serum iron levels. Reactive Oxygen Species 78-81 C-reactive protein Homo sapiens 196-199 33994437-9 2021 Canagliflozin also significantly reduced the body weight, glycated hemoglobin, homeostasis model assessment of insulin resistance (HOMA-IR), high sensitivity C-reactive protein (hs-CRP), and volumes of adipose tissue and skeletal muscle (all p<0.05). Canagliflozin 0-13 C-reactive protein Homo sapiens 158-176 33994437-9 2021 Canagliflozin also significantly reduced the body weight, glycated hemoglobin, homeostasis model assessment of insulin resistance (HOMA-IR), high sensitivity C-reactive protein (hs-CRP), and volumes of adipose tissue and skeletal muscle (all p<0.05). Canagliflozin 0-13 C-reactive protein Homo sapiens 181-184 33974699-0 2021 Retraction of Vitamin D Supplementation Affects Serum High-Sensitivity C-Reactive Protein, Insulin Resistance, and Biomarkers of Oxidative Stress in Pregnant Women. Vitamin D 14-23 C-reactive protein Homo sapiens 71-89 33988174-7 2021 Hs-CRP, LDL-C, and GDF-15 levels were significantly higher in the CAD patients (P=0.091, P=0.008, and P<0.001, respectively). Hydrogen 0-2 C-reactive protein Homo sapiens 3-6 34023221-9 2021 Age, hemodialysis, and C-reactive protein (CRP) levels were candidate predictors of the need for oxygen supply in patients with COVID-19. Oxygen 97-103 C-reactive protein Homo sapiens 43-46 33326704-9 2021 A significant correlation between hs-CRP and testosterone levels is observed in males after adjusting by BMI, but the correlation disappears after adjusting by leptin. Testosterone 45-57 C-reactive protein Homo sapiens 37-40 33326704-12 2021 CONCLUSION: The negative association between hs-CRP and testosterone concentrations observed in 12- to 16-year-old males seems to be related to leptin levels which are closely negatively related to testosterone levels in males independently of BMI. Testosterone 56-68 C-reactive protein Homo sapiens 48-51 33326704-3 2021 OBJECTIVES: To analyze the association between high sensitivity CRP (hs-CRP) and testosterone, estradiol and sex hormone binding globulin (SHBG) levels in a population-based sample of adolescents, and to evaluate the influence of leptin levels on this association. Testosterone 81-93 C-reactive protein Homo sapiens 64-67 33326704-12 2021 CONCLUSION: The negative association between hs-CRP and testosterone concentrations observed in 12- to 16-year-old males seems to be related to leptin levels which are closely negatively related to testosterone levels in males independently of BMI. Testosterone 198-210 C-reactive protein Homo sapiens 48-51 33326704-3 2021 OBJECTIVES: To analyze the association between high sensitivity CRP (hs-CRP) and testosterone, estradiol and sex hormone binding globulin (SHBG) levels in a population-based sample of adolescents, and to evaluate the influence of leptin levels on this association. Testosterone 81-93 C-reactive protein Homo sapiens 72-75 33326704-3 2021 OBJECTIVES: To analyze the association between high sensitivity CRP (hs-CRP) and testosterone, estradiol and sex hormone binding globulin (SHBG) levels in a population-based sample of adolescents, and to evaluate the influence of leptin levels on this association. Estradiol 95-104 C-reactive protein Homo sapiens 64-67 33952812-9 2022 RESULTS: Atorvastatin, but not the diet-only treatment, significantly reduced LDL-cholesterol (LDL-C, -43%), serum CRP (-37%) and S100A12 levels (-28%) and improved FMD (+38%). Atorvastatin 9-21 C-reactive protein Homo sapiens 115-118 33326704-3 2021 OBJECTIVES: To analyze the association between high sensitivity CRP (hs-CRP) and testosterone, estradiol and sex hormone binding globulin (SHBG) levels in a population-based sample of adolescents, and to evaluate the influence of leptin levels on this association. Estradiol 95-104 C-reactive protein Homo sapiens 72-75 33952812-12 2022 CONCLUSIONS: Atorvastatin treatment reduced S100A12/CRP levels, and the changes in these circulating markers mirrored the improvement in arterial inflammation. Atorvastatin 13-25 C-reactive protein Homo sapiens 52-55 33601275-6 2021 Singlet oxygen (1O2)-mediated oxidation of multiple proteins (alpha-lactalbumin, lysozyme, beta-2-microglobulin, C-reactive protein), and subsequent incubation with the Cys-containing protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH), generates inter-protein cross-links as detected by SDS-PAGE, immunoblotting and mass spectrometry (MS). Cysteine 169-172 C-reactive protein Homo sapiens 113-131 33512007-5 2021 CONCLUSION: Elevated vitamin D levels could decrease COVID-19 PCR positivity,D-dimer and CRP levels and the number of affected lung segments in COVID-19 positive patients,thereby shortening duration of hospital stays and alleviating the intensity of COVID-19. Vitamin D 21-30 C-reactive protein Homo sapiens 89-92 33847390-13 2021 Moreover, histological and ultrastructural improvements were seen in the rat population treated with BPA and Se, whereas ALT and AST levels were lowered and malondialdehyde (MDA), glutathione peroxidase (GPx), human C reactive protein (hCRP), and the serum levels of interleukin-6 (IL-6) were significantly modulated. bisphenol A 101-104 C-reactive protein Homo sapiens 216-234 33847390-13 2021 Moreover, histological and ultrastructural improvements were seen in the rat population treated with BPA and Se, whereas ALT and AST levels were lowered and malondialdehyde (MDA), glutathione peroxidase (GPx), human C reactive protein (hCRP), and the serum levels of interleukin-6 (IL-6) were significantly modulated. bisphenol A 101-104 C-reactive protein Homo sapiens 236-240 33714740-0 2021 Crosslinking of human plasma C-reactive protein to human serum albumin via disulfide bond oxidation. Disulfides 75-84 C-reactive protein Homo sapiens 29-47 33926518-9 2021 Although erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) had a weak correlation with PGA, they were not statistically correlated with GS, PD, or GSPD. Folic Acid 103-106 C-reactive protein Homo sapiens 50-68 33714740-6 2021 Here we demonstrate that photooxidation, or reaction with the biological oxidants HOCl and ONOOH, of the single disulfide present in the major human plasma inflammatory protein, C-reactive protein (CRP) can give rise to reversible disulfide bond formation with human serum albumin (HSA). Hypochlorous Acid 82-86 C-reactive protein Homo sapiens 178-196 33714740-6 2021 Here we demonstrate that photooxidation, or reaction with the biological oxidants HOCl and ONOOH, of the single disulfide present in the major human plasma inflammatory protein, C-reactive protein (CRP) can give rise to reversible disulfide bond formation with human serum albumin (HSA). Hypochlorous Acid 82-86 C-reactive protein Homo sapiens 198-201 33714740-6 2021 Here we demonstrate that photooxidation, or reaction with the biological oxidants HOCl and ONOOH, of the single disulfide present in the major human plasma inflammatory protein, C-reactive protein (CRP) can give rise to reversible disulfide bond formation with human serum albumin (HSA). Disulfides 112-121 C-reactive protein Homo sapiens 178-196 33714740-6 2021 Here we demonstrate that photooxidation, or reaction with the biological oxidants HOCl and ONOOH, of the single disulfide present in the major human plasma inflammatory protein, C-reactive protein (CRP) can give rise to reversible disulfide bond formation with human serum albumin (HSA). Disulfides 112-121 C-reactive protein Homo sapiens 198-201 33714740-6 2021 Here we demonstrate that photooxidation, or reaction with the biological oxidants HOCl and ONOOH, of the single disulfide present in the major human plasma inflammatory protein, C-reactive protein (CRP) can give rise to reversible disulfide bond formation with human serum albumin (HSA). Disulfides 231-240 C-reactive protein Homo sapiens 178-196 33714740-6 2021 Here we demonstrate that photooxidation, or reaction with the biological oxidants HOCl and ONOOH, of the single disulfide present in the major human plasma inflammatory protein, C-reactive protein (CRP) can give rise to reversible disulfide bond formation with human serum albumin (HSA). Disulfides 231-240 C-reactive protein Homo sapiens 198-201 33591234-10 2021 Nine variables were independent predictors for in-hospital mortality, including creatinine (Hazard ratio [HR]:1.327; 95% Confidence Interval [CI]: 1.040-1.695, p = .023), troponin (HR: 2.150; 95% CI: 1.155-4.001; p = .016), platelet count (HR: 0.994; 95% CI: 0.989-0.998; p = .004) and C-reactive protein (HR: 1.037; 95% CI: 1.006-1.068; p = .019). Creatinine 80-90 C-reactive protein Homo sapiens 286-304 33995051-10 2021 The 16 postoperative interventions revealed that the effect of DHI at 14 days was better than that at 7 and 10 days for hs-CRP (p = 0.013), the 10-days treatment produced better results for CK-MB than for the other treatments (p < 0.001) and a dosage of 30 ml proved most effective for IL-6 (p < 0.001). dehydrosoyasaponin I 63-66 C-reactive protein Homo sapiens 123-126 33856185-5 2021 Combining the two CRPs, with the Qz-CRP as a cathode, the NQ-CRP as an anode, and a protic ionic liquid electrolyte, yields a 0.8 V proton rocking-chair battery. protic ionic liquid 84-103 C-reactive protein Homo sapiens 18-21 33926518-9 2021 Although erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) had a weak correlation with PGA, they were not statistically correlated with GS, PD, or GSPD. Folic Acid 103-106 C-reactive protein Homo sapiens 70-73 33920813-8 2021 Serum Ca, Fe, Se, Zn correlated positively with SpO2, being inversely associated with fever, lung damage, and C-reactive protein concentrations. Zinc 18-20 C-reactive protein Homo sapiens 110-128 33930706-10 2021 C-reactive protein decreased significantly after treatment in the favipiravir group (p = 0.016). favipiravir 66-77 C-reactive protein Homo sapiens 0-18 33917391-10 2021 Furthermore, we related TFR1 expression with the clinical profile of patients and showed that greater iron demand in sera-treated cells was associated with higher inflammation score (interleukin 6 (IL-6), C-reactive protein (CRP)) and advanced neurohormonal activation (NT-proBNP) in patients. Iron 102-106 C-reactive protein Homo sapiens 205-223 33852740-7 2021 RESULTS: We found that high CRP is associated with a lack of response to iron supplementation after 1 month of treatment and that BMI z-score may moderate this association. Iron 73-77 C-reactive protein Homo sapiens 28-31 33852740-10 2021 CONCLUSIONS: Our finding suggesting that adiposity and CRP influence response to iron supplementation, furthers our understanding of the relationship between inflammation and anemia treatment in children and has both theoretical and public health implications. Iron 81-85 C-reactive protein Homo sapiens 55-58 33838041-8 2021 Low total testosterone levels were correlated with lower high-density lipoprotein cholesterol and higher triglycerides, high-sensitivity C-reactive protein, high-sensitivity troponin T, N-terminal-pro B-type natriuretic peptide and glucose levels (all p < 0.01). Testosterone 10-22 C-reactive protein Homo sapiens 137-155 33898494-3 2021 Objective: This study aimed to examine the validity of the energy-adjusted DII (E-DIITM) using high-sensitivity C-reactive protein (hs-CRP) concentration in Japanese men and women. dilC18(3) dye 75-78 C-reactive protein Homo sapiens 112-130 33917391-10 2021 Furthermore, we related TFR1 expression with the clinical profile of patients and showed that greater iron demand in sera-treated cells was associated with higher inflammation score (interleukin 6 (IL-6), C-reactive protein (CRP)) and advanced neurohormonal activation (NT-proBNP) in patients. Iron 102-106 C-reactive protein Homo sapiens 225-228 33869637-0 2021 The Association of Hemoglobin A1c and Fasting Glucose Levels with hs-CRP in Adults Not Diagnosed with Diabetes from the KNHANES, 2017. Glucose 46-53 C-reactive protein Homo sapiens 69-72 33916342-12 2021 In the 2009-2010 subset, the association of mean CAL with serum CRP was mediated by DII (52.0%, p < 0.01). dilC18(3) dye 84-87 C-reactive protein Homo sapiens 64-67 33121835-10 2021 25(OH)D significantly directly related with white blood cells count and the different components of leukocytes formula, Neutrophils-to-Lymphocytes Ratio, Monocytes-to-Lymphocytes Ratio and C-reactive protein, but not with lymphocytes levels. 25(oh)d 0-7 C-reactive protein Homo sapiens 189-207 33112413-9 2021 The levels of white blood cells, leukocytes subfamilies, and inflammatory parameters significantly correlated with vitamin D levels in both patients with and without diabetes (diabetic: p=0.012 for WBC, p=0.004 for NLR and p<0.001 for MLR and C-reactive protein, non-diabetic: p<0.001 for WBC; NLR, MLR and C reactive protein, respectively). Vitamin D 115-124 C-reactive protein Homo sapiens 243-261 33112413-9 2021 The levels of white blood cells, leukocytes subfamilies, and inflammatory parameters significantly correlated with vitamin D levels in both patients with and without diabetes (diabetic: p=0.012 for WBC, p=0.004 for NLR and p<0.001 for MLR and C-reactive protein, non-diabetic: p<0.001 for WBC; NLR, MLR and C reactive protein, respectively). Vitamin D 115-124 C-reactive protein Homo sapiens 307-325 33787283-6 2021 In those with a Fontan, high-density lipoprotein cholesterol was inversely correlated with body mass index (r=-0.30, P<0.0001), high-sensitivity C-reactive protein (r=-0.27, P=0.0006), and alanine aminotransferase (r=-0.18, P=0.02) but not with other liver disease markers. Cholesterol 49-60 C-reactive protein Homo sapiens 145-163 33291002-3 2021 The peptide with two alanines (n = 2) yielded the immunosensor with the highest performance in detecting C-reactive protein (CRP), a biomarker of inflammation. Alanine 21-29 C-reactive protein Homo sapiens 105-123 33291002-3 2021 The peptide with two alanines (n = 2) yielded the immunosensor with the highest performance in detecting C-reactive protein (CRP), a biomarker of inflammation. Alanine 21-29 C-reactive protein Homo sapiens 125-128 33024987-7 2021 In patients receiving ivosidenib (n = 60) or enasidenib (n = 91), end-of-induction complete remission (CR) rates were 55% and 47%, respectively, and CR/CR with incomplete neutrophil or platelet recovery (CR/CRi/CRp) rates were 72% and 63%, respectively. enasidenib 45-55 C-reactive protein Homo sapiens 103-105 33024987-7 2021 In patients receiving ivosidenib (n = 60) or enasidenib (n = 91), end-of-induction complete remission (CR) rates were 55% and 47%, respectively, and CR/CR with incomplete neutrophil or platelet recovery (CR/CRi/CRp) rates were 72% and 63%, respectively. enasidenib 45-55 C-reactive protein Homo sapiens 149-151 33024987-7 2021 In patients receiving ivosidenib (n = 60) or enasidenib (n = 91), end-of-induction complete remission (CR) rates were 55% and 47%, respectively, and CR/CR with incomplete neutrophil or platelet recovery (CR/CRi/CRp) rates were 72% and 63%, respectively. enasidenib 45-55 C-reactive protein Homo sapiens 149-151 33024987-7 2021 In patients receiving ivosidenib (n = 60) or enasidenib (n = 91), end-of-induction complete remission (CR) rates were 55% and 47%, respectively, and CR/CR with incomplete neutrophil or platelet recovery (CR/CRi/CRp) rates were 72% and 63%, respectively. enasidenib 45-55 C-reactive protein Homo sapiens 149-151 33869637-9 2021 Changes in the fasting glucose levels were also associated with the hs-CRP levels (B coefficient (95%CI) = 0.005, p = 0.006, and R 2 = 0.086). Glucose 23-30 C-reactive protein Homo sapiens 71-74 33869248-9 2021 Additionally, serum 8-iso-PGF2alpha levels were positively correlated with circulating inflammatory cytokines (CRP and TNFalpha). 8-epi-prostaglandin F2alpha 20-35 C-reactive protein Homo sapiens 111-114 33788001-8 2021 The 25 OH vitamin D level was correlated positively with the lymphocyte count (r = 0.375, p = <0.001), and negatively with age (r = -0.496, p = <0.001), CRP (r = -0.309, p = 0.002) and fibrinogen levels (r = -0.381, p = <0.001). Vitamin D 10-19 C-reactive protein Homo sapiens 153-156 33737300-6 2021 Non-statistically significant associations were found for glucose and CRP. Glucose 58-65 C-reactive protein Homo sapiens 70-73 33782413-10 2021 SPIOMET treatment was accompanied by a 3.4-fold rise of circulating GDF15 (on average, from 308 to 1045 pg/mL) and by a concomitant lowering of CRP and insulin concentrations towards normal, so that the relative GDF15 levels became markedly abundant. spiomet 0-7 C-reactive protein Homo sapiens 144-147 33782413-16 2021 In contrast, SPIOMET treatment was accompanied by an absolute and a relative abundance of GDF15, and followed by normal GDF15, CRP and insulin concentrations. spiomet 13-20 C-reactive protein Homo sapiens 127-130 33790636-10 2021 Oxygen saturation at presentation had a negative correlation with D-Dimer, age, and C reactive protein. Oxygen 0-6 C-reactive protein Homo sapiens 84-102 33740951-11 2021 The only independent variables for CRP/alb changes were CCI and heavy alcohol use. Alcohols 70-77 C-reactive protein Homo sapiens 35-38 33740951-12 2021 The CRP/alb ratio was significantly lower in non-heavy alcohol users (odds ratio [OR] 0.114, 95% confidence interval [CI] 0.024-0.541; adjusted p = 0.006) than in other patients. Alcohols 55-62 C-reactive protein Homo sapiens 4-11 33740951-15 2021 CONCLUSIONS: The CRP/alb ratio was high in OSCC patients with combined comorbities of age and disease history and in patients with heavy alcohol use. Alcohols 137-144 C-reactive protein Homo sapiens 17-24 33782820-6 2022 Regarding oxidative stress and inflammation, pooled analysis showed that CoQ10 supplementation significantly reduced malonaldehyde (WMD: - 1.15 95% CI - 1.48 to - 0.81) and high-sensitivity C reactive protein levels (WMD: - 1.18 95% CI - 2.21 to - 0.15). coenzyme Q10 73-78 C-reactive protein Homo sapiens 190-208 33692633-0 2021 C-Reactive Protein Mediates the Effect of Serum Progesterone on Obesity for Men and Postmenopausal Women in Henan Rural Cohort Study. Progesterone 48-60 C-reactive protein Homo sapiens 0-18 33726658-14 2021 A significant negative correlation found between vitamin D and ALT (P= 0.02, -0.21) as well as vitamin D and CRP (P= 0.05, -0.17). Vitamin D 95-104 C-reactive protein Homo sapiens 109-112 33687883-9 2021 Serum 25(OH)D was positively correlated with BMD (lumbar and femoral; p=0.002 and p=0.01 respectively) and Z scores (lumbar and femoral; p<0.001and p=0.01 respectively), whereas, negatively correlated with ASDAS-CRP (p<0.001), BASFI (p<0.001), mSASSS (p=0.003). 25(oh)d 6-13 C-reactive protein Homo sapiens 212-215 33692633-5 2021 Mediation analysis was carried out to assess the intermediary role of C-reactive protein played in the association between progesterone and obesity. Progesterone 123-135 C-reactive protein Homo sapiens 70-88 33692633-8 2021 Also, C-reactive protein increased with the elevation of progesterone, and C-reactive protein was associated with obesity no matter how obesity was defined (P trend <0.001). Progesterone 57-69 C-reactive protein Homo sapiens 6-24 33692633-11 2021 We firstly found C-reactive protein partly mediates the effect of progesterone on obesity, indicating that systemic inflammation played a critical role in the association. Progesterone 66-78 C-reactive protein Homo sapiens 17-35 33647767-8 2021 In agreement with the known anti-inflammatory action of testosterone, patients with long-polyQ and age >=60 years had increased levels of CRP (p = 0.018, not accounting for multiple testing). Testosterone 56-68 C-reactive protein Homo sapiens 138-141 33655432-7 2022 Zn sulfate supplementation appears to have favorable effects on serum copeptin and hs-CRP, FBG, and renal function in Zn-deficient DHPs. Zinc Sulfate 0-10 C-reactive protein Homo sapiens 86-89 32474847-7 2021 The plasma Cu concentration was positively correlated with blood pressure, body mass index (BMI), and the C-reactive protein (CRP) level, whereas the plasma Mg and Ca concentrations were negatively correlated with SBP. Copper 11-13 C-reactive protein Homo sapiens 106-124 32474847-7 2021 The plasma Cu concentration was positively correlated with blood pressure, body mass index (BMI), and the C-reactive protein (CRP) level, whereas the plasma Mg and Ca concentrations were negatively correlated with SBP. Copper 11-13 C-reactive protein Homo sapiens 126-129 32474847-10 2021 Path analysis showed that the CRP levels and BMI mediated the associations between the Cu concentration and ABP. Copper 87-89 C-reactive protein Homo sapiens 30-33 32474847-12 2021 In contrast, a higher plasma Cu concentration was positively correlated with the risk of ABP, and the association was mediated by CRP and BMI. Copper 29-31 C-reactive protein Homo sapiens 130-133 33333044-8 2021 The concentration of CRP was significantly higher in UC and CD than that in the healthy group, but there were no significant differences when compared to the intestinal polyp group. Cadmium 60-62 C-reactive protein Homo sapiens 21-24 33605405-7 2021 180 patients initiated GC compared with 294 who did not.At baseline, the increased CRP is the main factor that favors the initiation of GC followed by smoking, absence of ACPA, prescription of methotrexate as a monotherapy and age.5 years follow-up of DAS28-CRP, HAQ or VAS pain values did not differ between the two groups.We also analysed a subgroup of 139 patients who received >1 g of prednisolone during the 5 years period. acetyl 4-aminosalicylic acid 171-175 C-reactive protein Homo sapiens 83-86 33068293-7 2021 After 72 hours, L and CRP had improved in the HFNC oxygen therapy group compared with the COT group, but the differences in WBC and PCT were not statistically significant. Oxygen 51-57 C-reactive protein Homo sapiens 22-25 33296854-8 2021 In bivariate analysis, plasma copper levels were positively associated with serum LDL-cholesterol (r=0.22; p = 0.004) and chiefly with C-reactive protein (r=0.40; p < 0.001). Copper 30-36 C-reactive protein Homo sapiens 135-153 33625709-10 2021 These results indicated that exposure to BPA is potentially associated with expression of pro-inflammatory genes related to CRP secretion, which may promote the risk of CVD development symptoms in young adults. bisphenol A 41-44 C-reactive protein Homo sapiens 124-127 33672176-5 2021 In all subjects, vitamin D was negatively associated with c-reactive protein (CRP) (p < 0.001) and with probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), and plaque score (PI) (p < 0.001 for all parameters) and positively related to the number of teeth (p < 0.001). Vitamin D 17-26 C-reactive protein Homo sapiens 58-76 33672176-5 2021 In all subjects, vitamin D was negatively associated with c-reactive protein (CRP) (p < 0.001) and with probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), and plaque score (PI) (p < 0.001 for all parameters) and positively related to the number of teeth (p < 0.001). Vitamin D 17-26 C-reactive protein Homo sapiens 78-81 33672176-7 2021 The multivariate regression analysis showed that PT (p = 0.011) and CRP (p = 0.031) were both predictors of vitamin D levels. Vitamin D 108-117 C-reactive protein Homo sapiens 68-71 30959530-0 2021 Elevated C-reactive Protein Levels Independently Predict the Development of Prediabetes Markers in Subjects with Normal Glucose Regulation. Glucose 120-127 C-reactive protein Homo sapiens 9-27 33718411-6 2021 CRP, LDH, and D-dimer serum levels were also lowered in metformin-treated patients compared to non-metformin treated patients (p = 0.0001). Metformin 56-65 C-reactive protein Homo sapiens 0-3 33728195-15 2021 Logistic regression analysis in the control group showed that the odds ratio for increasing remnant cholesterol above the cut-off value was determined as 2.01 for low bioavailable vitamin D and 1.1 for elevated CRP. Cholesterol 100-111 C-reactive protein Homo sapiens 211-214 33603528-10 2021 Furthermore, levels of CRP showed a decrease in patients treated with enoxaparin and fondaparinux, although the decrease in the fondaparinux group seems to be more relevant. Fondaparinux 85-97 C-reactive protein Homo sapiens 23-26 33603528-10 2021 Furthermore, levels of CRP showed a decrease in patients treated with enoxaparin and fondaparinux, although the decrease in the fondaparinux group seems to be more relevant. Fondaparinux 128-140 C-reactive protein Homo sapiens 23-26 32790827-12 2021 In the pairwise meta-analysis, DHA and EPA had similar effects on plasma CRP [MDDHA versus EPA = 0.14 mg/L (95% CI: -0.57, 0.85); I2 = 61%], IL-6 [MDDHA versus EPA = 0.10 pg/mL (-0.15, 0.34); I2 = 40%], and TNF-alpha [MDDHA versus EPA = -0.10 pg/mL (-0.37, 0.18); I2 = 40%]. dehydroacetic acid 31-34 C-reactive protein Homo sapiens 73-76 33559714-11 2021 Tofacitinib was clinically effective by suppressing DAS28, CRP, and HAQ. tofacitinib 0-11 C-reactive protein Homo sapiens 59-62 33559714-16 2021 Age, CRP, anti-CCP, and DKK-1 influenced the effects of tofacitinib therapy on BMD changes. tofacitinib 56-67 C-reactive protein Homo sapiens 5-8 33168652-7 2021 Higher serum 25(OH)D levels were significantly associated with lower levels of glucose, insulin, HOMA of insulin resistance, HbA1c, blood lipids, and C-reactive protein at baseline (all P trend < 0.05). 25(oh)d 13-20 C-reactive protein Homo sapiens 150-168 33616345-9 2021 CRP was positively correlated with HOMA-IR, TC, and AHSG (r = 0.485, 0.331, 0.226, p < 0.05), negatively associated with 25-OH-VD (r = -0.443, p < 0.05), and had no correlation to TG and Hcy (r = 0.019, 0.058, p > 0.05). Triglycerides 180-182 C-reactive protein Homo sapiens 0-3 32812381-3 2021 We aimed to evaluate CRP effect on aPTT and anti-Xa assays in the presence of heparin and to determine whether elevated CRP affects laboratory monitoring in pediatric ECMO patients. Heparin 78-85 C-reactive protein Homo sapiens 21-24 33551315-6 2021 Non-DM patients with EHG also featured higher levels of median C-reactive protein (306.3 mg/L, P = .036), procalcitonin (1.26 ng/mL, P = .028), and lactate (2.2 mmol/L, P = .023). ehg 21-24 C-reactive protein Homo sapiens 63-81 33341448-5 2021 RESULTS: Across all tumour stages, vitamin D-deficient patients had the highest median levels of IL-6 (8.3 pg/mL, range 0.7-91), YKL-40 (177 ng/ml, range 25-5279) and CRP (15.5 mg/L, range 0.8-384). Vitamin D 35-44 C-reactive protein Homo sapiens 167-170 32812381-6 2021 RESULTS: Elevated CRP prolonged aPTT in normal specimens with or without heparin, but did not affect anti-Xa assay. Heparin 73-80 C-reactive protein Homo sapiens 18-21 33333394-11 2021 CONCLUSION: This meta-analysis suggests that Zn supplements reduce serum concentrations of markers of inflammation and oxidation: CRP, TNF-alpha and MDA. Zinc 45-47 C-reactive protein Homo sapiens 130-133 32812381-11 2021 Discordant changes of CRP and FVIII in plasma could contribute to aPTT/anti-Xa discrepancies observed during heparin therapy in the pediatric population. Heparin 109-116 C-reactive protein Homo sapiens 22-25 33449065-0 2021 First-principles investigation of the hydrogen evolution reaction of transition metal phosphides CrP, MnP, FeP, CoP, and NiP. Hydrogen 38-46 C-reactive protein Homo sapiens 97-100 33065582-10 2021 Among HIV participants, FC concentrations were positively associated with high-sensitivity C-reactive protein, soluble tumor necrosis factor-II, and soluble vascular cellular adhesion molecule and inversely associated with CD4 counts. Fc(alpha) receptor 24-26 C-reactive protein Homo sapiens 91-109 33350058-13 2021 Serum bile acid levels were increased in cachectic vs. non-cachectic cancer patients (e.g. total bile acids, +5.409 +- 1.834 muM, P = 0.026) and were strongly correlated to systemic inflammation (taurochenodeoxycholic acid and C-reactive protein: rho = 0.36, Padj = 0.017). Bile Acids and Salts 6-15 C-reactive protein Homo sapiens 227-245 33300083-12 2021 The levels of interleukin-8, matrix metalloproteinase 9 and C-reactive protein were increased in the conditioned media (CM) of rGal-10-treated gingival fibroblasts. rgal-10 127-134 C-reactive protein Homo sapiens 60-78 33508990-6 2021 Moreover, vitamin D intake led to a significant reduction in high-sensitivity C-reactive protein (hs-CRP) (beta - 0.64 mg/L; 95% CI, -0.97, -0.30; p<.001) and a significant increase in total antioxidant capacity (TAC) (beta 47.54 mmol/L; 95% CI, 19.98, 75.11; p=.001) compared with the placebo. Vitamin D 10-19 C-reactive protein Homo sapiens 78-96 33508990-7 2021 CONCLUSIONS: Overall, our study demonstrated that vitamin D intake in patients with endometriosis resulted in a significant improvement of pelvic pain, total-/HDL-cholesterol ratio, hs-CRP and TAC levels, but did not affect other clinical symptoms and metabolic profiles. Vitamin D 50-59 C-reactive protein Homo sapiens 185-188 33523023-8 2021 In addition, there were statistically significant correlations between pentraxin and serum CRP concentrations (p < 0.05) in diseased group. pentraxin 71-80 C-reactive protein Homo sapiens 91-94 33402303-8 2021 Comorbid cardiovascular disease, lymphocytopenia, elevated CRP, liver enzyme and D-dimer levels, and higher chest CT score were significantly associated with an increase in oxygen requirement CONCLUSIONS: The expanded CURB-65 score can be a better predictor of an increase in oxygen requirement in patients with SARS-CoV-2 pneumonia. Oxygen 173-179 C-reactive protein Homo sapiens 59-62 32311700-12 2021 IMPACT: In this vitamin D supplementation clinical trial, baseline (first trimester) but not increasing plasma 25(OH)D concentration impacted select plasma immune-mediator profiles in pregnant women.Baseline 25(OH)D was associated with baseline TGF-beta and with IFN-gamma and IL-2 at second and third trimesters.Baseline IFN-gamma, CRP, TGF-beta, TNF-alpha, VEGF, IL-2, and IL-4 were associated with concentrations at second and third trimesters for respective immune-mediators; however, 25(OH)D concentration at second and third trimesters were not.Some racial differences existed in immune-mediator concentrations at baseline and at second and third trimesters.This study assesses the impact of vitamin D supplementation on multiple immune-mediators in pregnant women of different racial/ethnic groups using longitudinal data from a relatively large randomized controlled trial.This study found that race was associated with baseline TGF-beta, VEGF, and IL-10 and with IL-10 at second and third trimesters, a novel finding that sheds light where relationships were less well defined.The results of this study suggest that vitamin D supplementation before conception or early in pregnancy, rather than during pregnancy, may be necessary to significantly impact immune-mediator response.This study sets premise for future clinical trials to evaluate the effect of vitamin D supplementation before conception or prior to pregnancy. 25(oh)d 208-215 C-reactive protein Homo sapiens 333-336 32311700-12 2021 IMPACT: In this vitamin D supplementation clinical trial, baseline (first trimester) but not increasing plasma 25(OH)D concentration impacted select plasma immune-mediator profiles in pregnant women.Baseline 25(OH)D was associated with baseline TGF-beta and with IFN-gamma and IL-2 at second and third trimesters.Baseline IFN-gamma, CRP, TGF-beta, TNF-alpha, VEGF, IL-2, and IL-4 were associated with concentrations at second and third trimesters for respective immune-mediators; however, 25(OH)D concentration at second and third trimesters were not.Some racial differences existed in immune-mediator concentrations at baseline and at second and third trimesters.This study assesses the impact of vitamin D supplementation on multiple immune-mediators in pregnant women of different racial/ethnic groups using longitudinal data from a relatively large randomized controlled trial.This study found that race was associated with baseline TGF-beta, VEGF, and IL-10 and with IL-10 at second and third trimesters, a novel finding that sheds light where relationships were less well defined.The results of this study suggest that vitamin D supplementation before conception or early in pregnancy, rather than during pregnancy, may be necessary to significantly impact immune-mediator response.This study sets premise for future clinical trials to evaluate the effect of vitamin D supplementation before conception or prior to pregnancy. 25(oh)d 208-215 C-reactive protein Homo sapiens 333-336 33454206-8 2021 There was a negative correlation between vitamin D status and CRP levels (=-.364, p=.007). Vitamin D 41-50 C-reactive protein Homo sapiens 62-65 33552948-11 2020 Meanwhile, serum sodium was inversely correlated with cell counts of leukocytes, neutrophils, monocytes and C-reactive protein levels. Sodium 17-23 C-reactive protein Homo sapiens 108-126 33468272-9 2021 Body mass index (BMI) was found to have significant mediation effects (to varied extent) on the associations between serum 25(OH)D and CRP, apo-B, fasting glucose, insulin, HOMA-IR, HOMA-B and HbA1c (all p<0.05). 25(oh)d 123-130 C-reactive protein Homo sapiens 135-138 33468272-10 2021 Both waist circumference and apVAT were also found to partly mediate the associations between serum 25(OH)D with CRP, FBG, HbA1c, triglycerides and HDL-cholesterol (all P < 0.05). 25(oh)d 100-107 C-reactive protein Homo sapiens 113-116 33677945-9 2021 25-OH-vitamin D deficiency was associated with increased CRP and dyspnea. Vitamin D 6-15 C-reactive protein Homo sapiens 57-60 33585533-6 2020 The between-group ESs were high for body weight (ES = 1.2, p < 0.001), small for body composition and physical function [handgrip strength (HGS)] measures (ES < 0.25), moderate to high for n-3 PUFAs and 25-hydroxyvitamin D (25-OH vitamin D) (ES range 0.64-1.37, p < 0.05 for all), and moderate for serum C-reactive protein (ES = 0.53, p = 0.12). Nitrogen 10-12 C-reactive protein Homo sapiens 304-322 33389237-0 2021 Handheld pH meter-assisted immunoassay for C-reactive protein using glucose oxidase-conjugated dendrimer loaded with platinum nanozymes. Glucose 68-75 C-reactive protein Homo sapiens 43-61 33397249-8 2021 Curcumin and nano-curcumin supplementation also improved significant changes in plasma levels of total antioxidant capacity (TAC), malondialdehyde (MDA), Superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), high-sensitivity C-reactive protein (hs-CRP), Interleukin 1 beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) in comparison to the placebo (p<0.05). Curcumin 0-8 C-reactive protein Homo sapiens 232-250 33397249-8 2021 Curcumin and nano-curcumin supplementation also improved significant changes in plasma levels of total antioxidant capacity (TAC), malondialdehyde (MDA), Superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), high-sensitivity C-reactive protein (hs-CRP), Interleukin 1 beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) in comparison to the placebo (p<0.05). Curcumin 0-8 C-reactive protein Homo sapiens 255-258 33412927-9 2021 RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: Based on available evidence from RCTs in this meta-analysis, metformin decreased CRP level. Metformin 110-119 C-reactive protein Homo sapiens 130-133 33412927-11 2021 CONCLUSION: The present study evidences that therapy with metformin can reduces CRP level significantly in T2D patients compared to other inflammatory markers. Metformin 58-67 C-reactive protein Homo sapiens 80-83 33389237-0 2021 Handheld pH meter-assisted immunoassay for C-reactive protein using glucose oxidase-conjugated dendrimer loaded with platinum nanozymes. Platinum 117-125 C-reactive protein Homo sapiens 43-61 33389237-1 2021 A simple and feasible pH meter-based immunoassay is reported for detection of C-reactive protein (CRP) using glucose oxidase (GOD)-conjugated dendrimer loaded with platinum nanozyme. Glucose 109-116 C-reactive protein Homo sapiens 78-96 33389237-1 2021 A simple and feasible pH meter-based immunoassay is reported for detection of C-reactive protein (CRP) using glucose oxidase (GOD)-conjugated dendrimer loaded with platinum nanozyme. Glucose 109-116 C-reactive protein Homo sapiens 98-101 33389237-1 2021 A simple and feasible pH meter-based immunoassay is reported for detection of C-reactive protein (CRP) using glucose oxidase (GOD)-conjugated dendrimer loaded with platinum nanozyme. Platinum 164-172 C-reactive protein Homo sapiens 78-96 33389237-1 2021 A simple and feasible pH meter-based immunoassay is reported for detection of C-reactive protein (CRP) using glucose oxidase (GOD)-conjugated dendrimer loaded with platinum nanozyme. Platinum 164-172 C-reactive protein Homo sapiens 98-101 33545754-8 2021 The pooled results demonstrated that vitamin D supplementation in patients with PCOS resulted in a significant improvement in serum total testosterone (TT), high sensitivity C-reactive protein (hs-CRP), total antioxidant capacity (TAC), and malondialdehyde (MDA). Vitamin D 37-46 C-reactive protein Homo sapiens 174-192 33404397-8 2021 The AH-CSU group was characterized by a higher plasma high-sensitivity C-reactive protein level (6.4 +- 3.7 mg/L) than the CSU group (4.3 +- 1.4 mg/L; p < 0.001) and the control group (3.1 +- 1.8 mg/L; p < 0.001). ah-csu 4-10 C-reactive protein Homo sapiens 71-89 33545754-8 2021 The pooled results demonstrated that vitamin D supplementation in patients with PCOS resulted in a significant improvement in serum total testosterone (TT), high sensitivity C-reactive protein (hs-CRP), total antioxidant capacity (TAC), and malondialdehyde (MDA). Vitamin D 37-46 C-reactive protein Homo sapiens 197-200 33545754-10 2021 Subgroup analysis showed that vitamin D supplementation reduced hs-CRP and MDA irrespective of the treatment course, type of vitamin D intervention, supplementation frequency, and dosage. Vitamin D 30-39 C-reactive protein Homo sapiens 67-70 33545754-12 2021 CONCLUSIONS: The current meta-analysis demonstrates that vitamin D supplementation in patients with PCOS resulted in an improvement in the levels of TT, hs-CRP, TAC, and MDA, but did not affect FT, DHEA-S, SHBG, FAI, NO, and GSH levels. Vitamin D 57-66 C-reactive protein Homo sapiens 156-159 32976826-10 2021 Higher PUCAI score and C-reactive protein on day 3 and 5 of hospital admission predict failure of intravenous steroids. Steroids 110-118 C-reactive protein Homo sapiens 23-41 32888161-10 2021 Bioinformatics analysis and the rescue experiments confirmed that TTTY15 positively regulated H2O2-induced myocardial cell injury via regulating CRP by sponging miR-98-5p. Hydrogen Peroxide 94-98 C-reactive protein Homo sapiens 145-148 33902044-14 2021 A CRP level higher than 15 mg/L may suggest initiation of low-dose aspirin in low-risk pregnancies. Aspirin 67-74 C-reactive protein Homo sapiens 2-5 32415383-8 2021 Longer survival with CDS was more prominent in females, patients with renal dysfunction, and individuals with low C-reactive protein (CRP) or ferritin, compared with their counterpart subgroup. Cadmium 21-24 C-reactive protein Homo sapiens 114-132 32888161-0 2021 LncRNA TTTY15 knockdown alleviates H2O2-stimulated myocardial cell injury by regulating the miR-98-5p/CRP pathway. Hydrogen Peroxide 35-39 C-reactive protein Homo sapiens 102-105 33184983-7 2021 Finally, resveratrol significantly reduced the serum levels of IL-1beta, CRP and PGE2 , as well as NF-kB synovial tissue expression, which showed a significant correlation with p62 expression. Resveratrol 9-20 C-reactive protein Homo sapiens 73-76 32415383-8 2021 Longer survival with CDS was more prominent in females, patients with renal dysfunction, and individuals with low C-reactive protein (CRP) or ferritin, compared with their counterpart subgroup. Cadmium 21-24 C-reactive protein Homo sapiens 134-137 33369762-7 2022 To achieve the lowest detection limit of CRP, H2 O2 (200 muM), gold seed (0.2 muM), and streptavidin-catalase (1:500) were found optimal. Hydrogen Peroxide 46-51 C-reactive protein Homo sapiens 41-44 33355850-0 2021 Can High-Sensitivity C-Reactive Protein Levels Predict Functional Outcome Following Epidural Steroid Injection in Patients with Lumbar Disc Disease? Steroids 93-100 C-reactive protein Homo sapiens 21-39 33373378-9 2020 Potential risk factors identified in the aspirin group were concomitant insulin medication (p = 0.0006) and elevated C-reactive protein (CRP) (p = 0.0021). Aspirin 41-48 C-reactive protein Homo sapiens 117-135 33373378-9 2020 Potential risk factors identified in the aspirin group were concomitant insulin medication (p = 0.0006) and elevated C-reactive protein (CRP) (p = 0.0021). Aspirin 41-48 C-reactive protein Homo sapiens 137-140 33370481-3 2022 This research work introduces a modified interdigitated electrode (IDE) sensing surface constructed with single walled carbon nanotube (SWCN) to detect the cardiac biomarker, C-reactive protein (CRP). Carbon 119-125 C-reactive protein Homo sapiens 175-193 33370481-3 2022 This research work introduces a modified interdigitated electrode (IDE) sensing surface constructed with single walled carbon nanotube (SWCN) to detect the cardiac biomarker, C-reactive protein (CRP). Carbon 119-125 C-reactive protein Homo sapiens 195-198 33340057-9 2022 A negative correlation was observed between 25(OH)D and 25(OH)D3 serum levels and Birmingham vasculitis activity score (BVAS), C-reactive protein (CRP), and white blood cell count. 25(oh)d 44-51 C-reactive protein Homo sapiens 127-145 33340057-9 2022 A negative correlation was observed between 25(OH)D and 25(OH)D3 serum levels and Birmingham vasculitis activity score (BVAS), C-reactive protein (CRP), and white blood cell count. 25(oh)d 44-51 C-reactive protein Homo sapiens 147-150 33340057-10 2022 Linear regression analysis indicated haemoglobin and 25(OH)D levels to be independently associated with BVAS and CRP and 25(OH)D levels with SF-36 MCS score. 25(oh)d 53-60 C-reactive protein Homo sapiens 113-116 33331351-8 2020 In CD, previous resective surgery, perianal disease and elevated C-reactive protein (CRP) at assessment, while in UC steroid therapy, an elevated CRP and fecal calprotectin at assessment were associated with anemia in a multivariate analysis. Steroids 117-124 C-reactive protein Homo sapiens 85-88 33334321-7 2020 Among Kitavans, there were small negative associations between lnCRP for CRP values < 10 and total, low-density lipoprotein (LDL) and non-high-density lipoprotein (non-HDL) cholesterol. Cholesterol 173-184 C-reactive protein Homo sapiens 65-68 33414641-7 2020 [Kyn]:[Trp] was also positively associated with CRP (P = .044), however no significant relationship between [Kyn]:[Trp] and TNF-alpha was found. Tryptophan 7-10 C-reactive protein Homo sapiens 48-51 33334321-8 2020 Among Swedish controls, associations of lnCRP for CRP values < 10 were medium positive with weight, body mass index, waist circumference, hip circumference and waist-hip ratio and low positive with triglyceride, total cholesterol-HDL cholesterol ratio, triglyceride-HDL cholesterol ratio and serum insulin. Triglycerides 198-210 C-reactive protein Homo sapiens 42-45 33334321-8 2020 Among Swedish controls, associations of lnCRP for CRP values < 10 were medium positive with weight, body mass index, waist circumference, hip circumference and waist-hip ratio and low positive with triglyceride, total cholesterol-HDL cholesterol ratio, triglyceride-HDL cholesterol ratio and serum insulin. Cholesterol 218-229 C-reactive protein Homo sapiens 42-45 33334321-8 2020 Among Swedish controls, associations of lnCRP for CRP values < 10 were medium positive with weight, body mass index, waist circumference, hip circumference and waist-hip ratio and low positive with triglyceride, total cholesterol-HDL cholesterol ratio, triglyceride-HDL cholesterol ratio and serum insulin. Cholesterol 234-245 C-reactive protein Homo sapiens 42-45 33334321-8 2020 Among Swedish controls, associations of lnCRP for CRP values < 10 were medium positive with weight, body mass index, waist circumference, hip circumference and waist-hip ratio and low positive with triglyceride, total cholesterol-HDL cholesterol ratio, triglyceride-HDL cholesterol ratio and serum insulin. Triglycerides 253-265 C-reactive protein Homo sapiens 42-45 33334321-8 2020 Among Swedish controls, associations of lnCRP for CRP values < 10 were medium positive with weight, body mass index, waist circumference, hip circumference and waist-hip ratio and low positive with triglyceride, total cholesterol-HDL cholesterol ratio, triglyceride-HDL cholesterol ratio and serum insulin. Cholesterol 234-245 C-reactive protein Homo sapiens 42-45 33367210-3 2020 Steroid use was "biomarker concordant" if given when C-reactive protein (CRP) was >=150 mg/L or withheld when CRP was <150 mg/L, and vice versa for biomarker discordant. Steroids 0-7 C-reactive protein Homo sapiens 53-71 33367210-3 2020 Steroid use was "biomarker concordant" if given when C-reactive protein (CRP) was >=150 mg/L or withheld when CRP was <150 mg/L, and vice versa for biomarker discordant. Steroids 0-7 C-reactive protein Homo sapiens 73-76 33367210-3 2020 Steroid use was "biomarker concordant" if given when C-reactive protein (CRP) was >=150 mg/L or withheld when CRP was <150 mg/L, and vice versa for biomarker discordant. Steroids 0-7 C-reactive protein Homo sapiens 110-113 33203750-7 2020 The loss of nqrA or nqrF led to the decrease of membrane potential, ATPase activity, and then ATP and cyclic AMP (cAMP), which reduced the cAMP/CRP (cAMP receptor protein) complex. Adenosine Triphosphate 68-71 C-reactive protein Homo sapiens 144-147 32157634-8 2020 Mediating analysis suggested that CRP significantly mediated 22.0-30.6% (P < 0.001) of the estimated association of copper with FM% and FM/LM at whole body and limbs. Copper 116-122 C-reactive protein Homo sapiens 34-37 32859615-8 2020 Compared with control, exercise and metformin reduced sTNF-alphaR2: -13.1% (95% CI: -22.9, -1.0) and IL-6: -38.7% (95% CI: -52.3, -18.9); but did not change hs-CRP: -20.5% (95% CI: -44.0, 12.7). Metformin 36-45 C-reactive protein Homo sapiens 160-163 32204978-6 2020 After three months of supplementation, the curcumin group showed a significant decrease in NF-kB mRNA expression (AU) [from 1.08 (0.77-1.38) to 0.52 (0.32-0.95),p = 0.02] and in plasma high sensitivity C-reactive protein (hsCRP) levels [from 3.8 (2.5-6.8) to 2.0 (1.1-3.8) mg/L, p = 0.04]. Curcumin 43-51 C-reactive protein Homo sapiens 202-220 32843285-1 2020 PURPOSE: The purpose of this study was to investigate the effect of preoperative oral carbohydrate on postoperative serum C-reactive protein (CRP) and albumin levels in patients laparoscopic surgery. Carbohydrates 86-98 C-reactive protein Homo sapiens 122-140 32843285-1 2020 PURPOSE: The purpose of this study was to investigate the effect of preoperative oral carbohydrate on postoperative serum C-reactive protein (CRP) and albumin levels in patients laparoscopic surgery. Carbohydrates 86-98 C-reactive protein Homo sapiens 142-145 32818758-0 2020 CRP-binding bacteriophage as a new element of layer-by-layer assembly carbon nanofiber modified electrodes. Carbon 70-76 C-reactive protein Homo sapiens 0-3 33153974-4 2020 From analysis of 203 samples, CRP, IL-6, IL-10 and LDH were most strongly correlated with the WHO ordinal scale of illness severity, the fraction of inspired oxygen delivery, radiological evidence of ARDS and level of respiratory support (p <= 0.001). Oxygen 158-164 C-reactive protein Homo sapiens 30-33 33254652-6 2020 In addition, we used mediation analysis to investigate the mediated effects of CRP in the relationships between copper exposure and blood lipid profiles. Copper 112-118 C-reactive protein Homo sapiens 79-82 33254652-9 2020 In addition, urinary copper increased monotonically with plasma CRP elevation, which in turn, was positively associated with TC, TG, and LDL-C and negatively related to HDL-C (all P < 0.05). Copper 21-27 C-reactive protein Homo sapiens 64-67 33254652-9 2020 In addition, urinary copper increased monotonically with plasma CRP elevation, which in turn, was positively associated with TC, TG, and LDL-C and negatively related to HDL-C (all P < 0.05). Triglycerides 129-131 C-reactive protein Homo sapiens 64-67 33254652-10 2020 Results from 3D mesh graphs demonstrated that increased levels of plasma CRP with higher urinary copper corresponded to higher TC, TG, LDL-C, and lower HDL-C concentrations. Copper 97-103 C-reactive protein Homo sapiens 73-76 33254652-10 2020 Results from 3D mesh graphs demonstrated that increased levels of plasma CRP with higher urinary copper corresponded to higher TC, TG, LDL-C, and lower HDL-C concentrations. Triglycerides 131-133 C-reactive protein Homo sapiens 73-76 33254652-11 2020 Mediation analysis observed that CRP mediated 6.27% in the relationships of urinary copper and TG. Copper 84-90 C-reactive protein Homo sapiens 33-36 33254652-11 2020 Mediation analysis observed that CRP mediated 6.27% in the relationships of urinary copper and TG. Triglycerides 95-97 C-reactive protein Homo sapiens 33-36 33097953-0 2020 An Expression of Concern from The Journal of Nutrition"s Editorial Office about: Vitamin D Supplementation Affects Serum High-Sensitivity C-Reactive Protein, Insulin Resistance, and Biomarkers of Oxidative Stress in Pregnant Women. Vitamin D 81-90 C-reactive protein Homo sapiens 138-156 33200848-8 2021 Living with paternal grandparents was protective against anemia and elevated C-reactive protein at the time of the final interview was associated with a lack of response to iron supplementation. Iron 173-177 C-reactive protein Homo sapiens 77-95 33205245-9 2021 Patients who were prescribed steroids had significantly higher white cell count (12.4 vs 11.5), CRP (79.5 vs 57) and heart rate (94 vs 88) on admission. Steroids 29-37 C-reactive protein Homo sapiens 96-99 33203750-7 2020 The loss of nqrA or nqrF led to the decrease of membrane potential, ATPase activity, and then ATP and cyclic AMP (cAMP), which reduced the cAMP/CRP (cAMP receptor protein) complex. Cyclic AMP 102-112 C-reactive protein Homo sapiens 144-147 33203750-7 2020 The loss of nqrA or nqrF led to the decrease of membrane potential, ATPase activity, and then ATP and cyclic AMP (cAMP), which reduced the cAMP/CRP (cAMP receptor protein) complex. Cyclic AMP 114-118 C-reactive protein Homo sapiens 144-147 33203750-7 2020 The loss of nqrA or nqrF led to the decrease of membrane potential, ATPase activity, and then ATP and cyclic AMP (cAMP), which reduced the cAMP/CRP (cAMP receptor protein) complex. Cyclic AMP 139-143 C-reactive protein Homo sapiens 144-147 33203750-7 2020 The loss of nqrA or nqrF led to the decrease of membrane potential, ATPase activity, and then ATP and cyclic AMP (cAMP), which reduced the cAMP/CRP (cAMP receptor protein) complex. Cyclic AMP 139-143 C-reactive protein Homo sapiens 144-147 33203750-8 2020 The reduced cAMP/CRP complex promoted l-alanine catabolism and inhibited l-alanine anabolism, causing reduced levels of alanine. Cyclic AMP 12-16 C-reactive protein Homo sapiens 17-20 33203750-8 2020 The reduced cAMP/CRP complex promoted l-alanine catabolism and inhibited l-alanine anabolism, causing reduced levels of alanine. Alanine 38-47 C-reactive protein Homo sapiens 17-20 33203750-8 2020 The reduced cAMP/CRP complex promoted l-alanine catabolism and inhibited l-alanine anabolism, causing reduced levels of alanine. Alanine 73-82 C-reactive protein Homo sapiens 17-20 33203750-8 2020 The reduced cAMP/CRP complex promoted l-alanine catabolism and inhibited l-alanine anabolism, causing reduced levels of alanine. Alanine 40-47 C-reactive protein Homo sapiens 17-20 33203750-10 2020 Our results suggest a novel mechanism by which the Na+-NQR system regulates antibiotic resistance via l-alanine metabolism in a cAMP/CRP complex-dependent manner.IMPORTANCE The Na+-NQR complex functions as a unique redox-driven sodium pump, generating membrane potential directly. Alanine 102-111 C-reactive protein Homo sapiens 133-136 33203750-10 2020 Our results suggest a novel mechanism by which the Na+-NQR system regulates antibiotic resistance via l-alanine metabolism in a cAMP/CRP complex-dependent manner.IMPORTANCE The Na+-NQR complex functions as a unique redox-driven sodium pump, generating membrane potential directly. Cyclic AMP 128-132 C-reactive protein Homo sapiens 133-136 33203750-10 2020 Our results suggest a novel mechanism by which the Na+-NQR system regulates antibiotic resistance via l-alanine metabolism in a cAMP/CRP complex-dependent manner.IMPORTANCE The Na+-NQR complex functions as a unique redox-driven sodium pump, generating membrane potential directly. Sodium 228-234 C-reactive protein Homo sapiens 133-136 33203750-13 2020 It proceeds by ATP and then cAMP/CRP regulon, which inhibits l-alanine catabolism and promotes l-alanine anabolism. Cyclic AMP 28-32 C-reactive protein Homo sapiens 33-36 33203750-13 2020 It proceeds by ATP and then cAMP/CRP regulon, which inhibits l-alanine catabolism and promotes l-alanine anabolism. Alanine 61-70 C-reactive protein Homo sapiens 33-36 33203750-13 2020 It proceeds by ATP and then cAMP/CRP regulon, which inhibits l-alanine catabolism and promotes l-alanine anabolism. Alanine 95-104 C-reactive protein Homo sapiens 33-36 33203750-16 2020 These findings suggest a novel mechanism by which the Na+-NQR system regulates antibiotic resistance via l-alanine metabolism in a cAMP/CRP complex-dependent manner. Alanine 105-114 C-reactive protein Homo sapiens 136-139 33203750-16 2020 These findings suggest a novel mechanism by which the Na+-NQR system regulates antibiotic resistance via l-alanine metabolism in a cAMP/CRP complex-dependent manner. Cyclic AMP 131-135 C-reactive protein Homo sapiens 136-139 33237691-2 2000 LDL-C and HDL-C levels were inversely correlated with C-reactive protein (CRP) levels i.e. the lower the LDL-C or HDL-C level the higher the CRP levels. Carbon 3-5 C-reactive protein Homo sapiens 54-72 33237691-2 2000 LDL-C and HDL-C levels were inversely correlated with C-reactive protein (CRP) levels i.e. the lower the LDL-C or HDL-C level the higher the CRP levels. Carbon 3-5 C-reactive protein Homo sapiens 74-77 33237691-2 2000 LDL-C and HDL-C levels were inversely correlated with C-reactive protein (CRP) levels i.e. the lower the LDL-C or HDL-C level the higher the CRP levels. Carbon 3-5 C-reactive protein Homo sapiens 141-144 33181831-8 2020 The BRINDA method-adjusted iron deficiency prevalence was linearly associated with the proportion of left-censored CRP data, whereas these were not associated in the probability method. brinda 4-10 C-reactive protein Homo sapiens 115-118 33224249-5 2020 Results: Vitamin D supplementation after the intervention led to a significant decrease in triglycerides (TG) (P = 0.02), very-low-density lipoprotein-cholesterol (VLDL-C) (P = 0.02), and hs-CRP (P = 0.03) concentrations and a significant increase in the serum vitamin D level (P < 0.001). Vitamin D 9-18 C-reactive protein Homo sapiens 191-194 33525211-11 2020 CRP was correlated significantly with the duration of stay in the ICU and the duration for oxygen supplementation (r=0.56 and 0.61, respectively; p<0.01). Oxygen 91-97 C-reactive protein Homo sapiens 0-3 33525287-9 2020 Moreover, there was a significant inverse correlation between serum folate levels and C-reactive protein in IBD patients (r = -0.563 p =0.001). Folic Acid 68-74 C-reactive protein Homo sapiens 86-104 33205000-8 2020 When stratifying inpatients in a low- and high oxygen demand group serum iron levels differed significantly between these two groups and showed a high negative correlation with the inflammatory parameters IL-6, procalcitonin, and CRP. Oxygen 47-53 C-reactive protein Homo sapiens 230-233 33205000-8 2020 When stratifying inpatients in a low- and high oxygen demand group serum iron levels differed significantly between these two groups and showed a high negative correlation with the inflammatory parameters IL-6, procalcitonin, and CRP. Iron 73-77 C-reactive protein Homo sapiens 230-233 33171659-12 2020 The combination of FDG-PET and CRP is expected to increase DA for detecting residual PVO. da 59-61 C-reactive protein Homo sapiens 31-34 32653486-9 2020 In correlation analysis, HDL-cholesterol concentration was negatively correlated with C-reactive protein (CRP, r = -0.396, P < 0.001) and positively correlated with lymphocytes (r = 0.336, P < 0.001). Cholesterol 29-40 C-reactive protein Homo sapiens 86-104 32016825-7 2020 Further, C-reactive protein (CRP) as an inflammatory marker was also alleviated, in addition to the apparent chromosomal aberration and liver pathologies including necrotic and fibrotic hepatocytes after exposure to 250 and 500 mg/kg of TiO2 NPs for 14 and 45 days that were deduced. Titanium 237-241 C-reactive protein Homo sapiens 9-27 32016825-7 2020 Further, C-reactive protein (CRP) as an inflammatory marker was also alleviated, in addition to the apparent chromosomal aberration and liver pathologies including necrotic and fibrotic hepatocytes after exposure to 250 and 500 mg/kg of TiO2 NPs for 14 and 45 days that were deduced. Titanium 237-241 C-reactive protein Homo sapiens 29-32 33157907-7 2020 RESULTS: This study will summarize the present evidence to investigate the effects of XNJ on serum hs-CRP and NSE in patients with ACH. Acetylcholine 131-134 C-reactive protein Homo sapiens 102-105 33157907-8 2020 CONCLUSION: This study may provide an impressive understanding of perspective from scientific basis for effects of XNJ on serum hs-CRP and NSE in patients with ACH. Acetylcholine 160-163 C-reactive protein Homo sapiens 131-134 33224343-5 2020 Among statins, rosuvastatin had the strongest interaction with CRP (pKi = 16.14), followed by fluvastatin (pKi = 15.58), pitavastatin (pKi = 15.26), atorvastatin (pKi = 14.68), pravastatin (pKi = 13.95), simvastatin (pKi = 7.98) and lovastatin (pKi = 7.10). Atorvastatin 149-161 C-reactive protein Homo sapiens 63-66 33224343-6 2020 According to the above-mentioned results, rosuvastatin, fluvastatin, pitavastatin and atorvastatin were found to have stronger binding to CRP compared with the standard ligand phosphocholine (pKi = 14.55). Atorvastatin 86-98 C-reactive protein Homo sapiens 138-141 33224343-7 2020 Conclusions: This finding suggests a new mechanism of interaction between statins and CRP that could be independent of the putative cholesterol-lowering activity of statins. Cholesterol 132-143 C-reactive protein Homo sapiens 86-89 32016825-0 2020 C-reactive Protein Signaling and Chromosomal Abnormalities in Nanotoxicity Induced via Different Doses of TiO2 (80 nm) Boost Liver Function. Titanium 106-110 C-reactive protein Homo sapiens 0-18 33187976-15 2020 Steroid-sparing treatment strategies may be considered for those IBD patients with higher admission CRP and greater disease duration, who appear to be at the greatest risk of hyperglycaemia. Steroids 0-7 C-reactive protein Homo sapiens 100-103 32730761-14 2020 Multiple linear regression revealed that IL-20, in addition to IL-6, glucose, CRP and D-dimer, was independently associated with the presence of AAD. L-2-Aminoadipic acid 145-148 C-reactive protein Homo sapiens 78-81 32653486-9 2020 In correlation analysis, HDL-cholesterol concentration was negatively correlated with C-reactive protein (CRP, r = -0.396, P < 0.001) and positively correlated with lymphocytes (r = 0.336, P < 0.001). Cholesterol 29-40 C-reactive protein Homo sapiens 106-109 32946851-8 2020 Besides, patients with higher fasting plasma glucose (FPG) had higher IL-6, IL-8, CRP, and mortality. Glucose 45-52 C-reactive protein Homo sapiens 82-85 32799012-9 2020 Oral supplementation of NAC reduced serum level of C-reactive protein (CRP) [WMD: -0.61 mg/L, 95% CI: -1.18 to -0.03, P = 0.039, I2 = 79.6%], and interleukin-6 (IL-6) [WMD: -0.43 pg/mL, 95% CI: -0.69 to -0.17, P = 0.001, I2 = 89.3%]. Acetylcysteine 24-27 C-reactive protein Homo sapiens 51-69 32799012-9 2020 Oral supplementation of NAC reduced serum level of C-reactive protein (CRP) [WMD: -0.61 mg/L, 95% CI: -1.18 to -0.03, P = 0.039, I2 = 79.6%], and interleukin-6 (IL-6) [WMD: -0.43 pg/mL, 95% CI: -0.69 to -0.17, P = 0.001, I2 = 89.3%]. Acetylcysteine 24-27 C-reactive protein Homo sapiens 71-74 32799012-11 2020 Dose-response investigation showed a non-linear association between oral NAC supplementation with CRP. Acetylcysteine 73-76 C-reactive protein Homo sapiens 98-101 32799012-12 2020 CONCLUSION: Oral NAC supplementation reduced serum level of CRP and IL-6, but did not affect other inflammatory biomarkers. Acetylcysteine 17-20 C-reactive protein Homo sapiens 60-63 32919309-3 2020 Patients with complications showed higher levels of CRP and C4 positively correlated with Triglycerides and Cholesterol concentrations. Triglycerides 90-103 C-reactive protein Homo sapiens 52-55 32557963-6 2020 A lower-than-median level of serum creatinine (Hazard Ratio [HR] =1.67; 95% confidence interval [CI] =1.31-2.12) or albumin (1.49, 1.13-1.96), whereas a higher-than-median level of log-transformed CRP (1.33, 1.04-1.71) or glucose (1.34, 1.01-1.78), at baseline was associated with a higher mortality risk. Creatinine 35-45 C-reactive protein Homo sapiens 197-200 32557963-7 2020 Taking all available measurements after ALS diagnosis into account, we found an association between per SD decrease in serum creatinine (2.23, 1.81-2.75) or albumin (1.83, 1.43-2.36) as well as per SD increase of log(CRP) (1.96, 1.58-2.43) or glucose (1.61, 1.21-2.12) and a higher mortality risk. Creatinine 125-135 C-reactive protein Homo sapiens 217-220 32649272-11 2020 Mechanisms include its "calcium-channel blocking" effects that lead to downstream suppression of nuclear factor-Kbeta, interleukin-6, c-reactive protein, and other related endocrine disrupters; its role in regulating renal potassium loss; and its ability to activate and enhance the functionality of vitamin D, among others. Calcium 24-31 C-reactive protein Homo sapiens 134-152 32919309-3 2020 Patients with complications showed higher levels of CRP and C4 positively correlated with Triglycerides and Cholesterol concentrations. Cholesterol 108-119 C-reactive protein Homo sapiens 52-55 33080990-3 2020 We recently demonstrated that C-reactive protein (CRP) inhibits the ATP-induced release of monocytic interleukin-1beta, although high CRP levels are deemed to be a poor prognostic marker. Adenosine Triphosphate 68-71 C-reactive protein Homo sapiens 30-48 33154657-5 2020 Results: There was a negative correlation between serum retinol and hs-CRP in alcohol drinking men. Alcohols 78-85 C-reactive protein Homo sapiens 71-74 33154657-6 2020 There was a negative correlation between serum retinol and hs-CRP in the alcohol-nonsmoking female group. Alcohols 73-80 C-reactive protein Homo sapiens 62-65 33154657-7 2020 There was a positive correlation between alpha-tocopherol and hs-CRP in the nonsmoking and alcohol-drinking group. Alcohols 91-98 C-reactive protein Homo sapiens 65-68 33154657-8 2020 There was a positive correlation between alpha-tocopherol and hs-CRP in the nonsmoking and alcohol-drinking female group. Alcohols 91-98 C-reactive protein Homo sapiens 65-68 33063668-4 2020 Lifelong increased free testosterone had beneficial effects on increased bone mineral density, and decreased body fat; adverse effects on decreased HDL, and increased risks of prostate cancer, androgenic alopecia, spinal stenosis, and hypertension; and context-dependent effects on increased haematocrit and decreased C-reactive protein. Testosterone 24-36 C-reactive protein Homo sapiens 318-336 32976314-6 2020 [ZERO WIDTH SPACE] RESULTS: Cox regression analyses revealed that parental alcohol problems (HR 3.09, 95% CI: 1.38-6.88) were associated with an increased risk of type II diabetes during the follow-up, even after adjustment for age, marital status, education, Human Population Laboratory (HPL) Depression Scale scores, smoking, alcohol consumption, body mass index, and serum high-sensitivity C-reactive protein. Alcohols 75-82 C-reactive protein Homo sapiens 393-411 33080990-3 2020 We recently demonstrated that C-reactive protein (CRP) inhibits the ATP-induced release of monocytic interleukin-1beta, although high CRP levels are deemed to be a poor prognostic marker. Adenosine Triphosphate 68-71 C-reactive protein Homo sapiens 50-53 33080990-8 2020 Accordingly, the inhibitory effect of CRP on the ATP-induced interleukin-1beta release was blunted in monocytes from coronary heart disease patients treated with atorvastatin compared to monocytes obtained before medication. Adenosine Triphosphate 49-52 C-reactive protein Homo sapiens 38-41 33080990-8 2020 Accordingly, the inhibitory effect of CRP on the ATP-induced interleukin-1beta release was blunted in monocytes from coronary heart disease patients treated with atorvastatin compared to monocytes obtained before medication. Atorvastatin 162-174 C-reactive protein Homo sapiens 38-41 33053824-8 2020 In addition, the abundance of Terrisporobacter showed a positive correlation with C-reactive protein, triglyceride. Triglycerides 102-114 C-reactive protein Homo sapiens 82-100 33067169-12 2021 At the end of the intervention period (16 weeks) and 6 weeks post-intervention, the mean fecal calprotectin, serum erythrocyte sedimentation rate, and hs-CRP levels were significantly lower in the NAC group compared with the placebo group (p < 0.05). Acetylcysteine 197-200 C-reactive protein Homo sapiens 154-157 32707089-5 2020 NAC blocked hemolysis and elevation of liver enzymes, C-reactive protein (CRP), and ferritin and allowed removal from respirator and veno-venous extracorporeal membrane oxygenator and full recovery of the G6PD-deficient patient. Acetylcysteine 0-3 C-reactive protein Homo sapiens 54-72 33026590-9 2021 In a multiple logistic regression model, increased CRP levels were significantly associated with deficiencies of vitamin B12 (OR = 5.84; 95% CI 1.25-27.2; p = 0.024), folate (OR = 4.02; 1.87-8.66; p < 0.001), and with the presence of >= 2 micronutrient deficiencies (OR = 2.31; 1.21-4.42; p = 0.01). Folic Acid 167-173 C-reactive protein Homo sapiens 51-54 33089038-5 2020 Among the 72 patients receiving supplemental oxygen without mechanical ventilation, severity of condition on the NEWS2 scale scores fell from 5 to 2 (P<0.001), C reactive protein levels fell from 95 to 14 mg/L (P<0.001), and lymphocyte counts rose from 900 to 1000/uL (P=0.036). Oxygen 45-51 C-reactive protein Homo sapiens 160-178 32012468-6 2020 Once the C-reactive protein value returned to within the normal range after surgery, we reduced the steroid dose. Steroids 100-107 C-reactive protein Homo sapiens 9-27 33035182-0 2021 Exogenous triglycerides interfere with a point of care CRP assay: a pre-analytical caveat. Triglycerides 10-23 C-reactive protein Homo sapiens 55-58 32447974-9 2020 Maladaptive coping behaviours were apparent, notably hazardous alcohol consumption, which was associated with a clinically significant elevation in C-reactive protein levels (> 3 mg/L). Alcohols 63-70 C-reactive protein Homo sapiens 148-166 32707089-5 2020 NAC blocked hemolysis and elevation of liver enzymes, C-reactive protein (CRP), and ferritin and allowed removal from respirator and veno-venous extracorporeal membrane oxygenator and full recovery of the G6PD-deficient patient. Acetylcysteine 0-3 C-reactive protein Homo sapiens 74-77 32707089-7 2020 NAC elicited clinical improvement and markedly reduced CRP in all patients and ferritin in 9/10 patients. Acetylcysteine 0-3 C-reactive protein Homo sapiens 55-58 33044103-0 2020 Serum oestradiol levels are inversely associated with C-reactive protein levels in premenopausal women, but not postmenopausal women. Estradiol 6-16 C-reactive protein Homo sapiens 54-72 32737139-10 2020 Among supplement users, folate intake was inversely associated with serum C-reactive protein levels (P trend < 0.01). Folic Acid 24-30 C-reactive protein Homo sapiens 74-92 32552387-7 2020 The erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were lower in the aspirin group than in the control group after treatment (Both p = .000). Aspirin 95-102 C-reactive protein Homo sapiens 45-63 32552387-7 2020 The erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were lower in the aspirin group than in the control group after treatment (Both p = .000). Aspirin 95-102 C-reactive protein Homo sapiens 65-68 33044103-2 2020 Therefore, we investigated the association between serum oestradiol and high-sensitivity C-reactive protein (CRP) levels in women on the basis of their menopausal status. Estradiol 57-67 C-reactive protein Homo sapiens 89-107 33044103-2 2020 Therefore, we investigated the association between serum oestradiol and high-sensitivity C-reactive protein (CRP) levels in women on the basis of their menopausal status. Estradiol 57-67 C-reactive protein Homo sapiens 109-112 33044103-3 2020 METHODS: This cross-sectional study examined the association between serum oestradiol and CRP levels on the basis of menopausal status in 151 premenopausal women aged 42.7 +- 6.7 years and 394 postmenopausal women aged 58.1 +- 6.7 years who participated in a health examination program. Estradiol 75-85 C-reactive protein Homo sapiens 90-93 33044103-5 2020 RESULTS: Multiple linear regression analysis showed that serum oestradiol levels were inversely associated with CRP levels in premenopausal women (beta coefficient = -0.298) after adjusting for age, body mass index, smoking, mean arterial pressure, and levels of fasting plasma glucose, triglycerides, high-density lipoprotein cholesterol, aspartate aminotransferase, and alanine aminotransferase. Estradiol 63-73 C-reactive protein Homo sapiens 112-115 33044103-5 2020 RESULTS: Multiple linear regression analysis showed that serum oestradiol levels were inversely associated with CRP levels in premenopausal women (beta coefficient = -0.298) after adjusting for age, body mass index, smoking, mean arterial pressure, and levels of fasting plasma glucose, triglycerides, high-density lipoprotein cholesterol, aspartate aminotransferase, and alanine aminotransferase. Glucose 278-285 C-reactive protein Homo sapiens 112-115 33044103-5 2020 RESULTS: Multiple linear regression analysis showed that serum oestradiol levels were inversely associated with CRP levels in premenopausal women (beta coefficient = -0.298) after adjusting for age, body mass index, smoking, mean arterial pressure, and levels of fasting plasma glucose, triglycerides, high-density lipoprotein cholesterol, aspartate aminotransferase, and alanine aminotransferase. Triglycerides 287-300 C-reactive protein Homo sapiens 112-115 33044103-5 2020 RESULTS: Multiple linear regression analysis showed that serum oestradiol levels were inversely associated with CRP levels in premenopausal women (beta coefficient = -0.298) after adjusting for age, body mass index, smoking, mean arterial pressure, and levels of fasting plasma glucose, triglycerides, high-density lipoprotein cholesterol, aspartate aminotransferase, and alanine aminotransferase. Cholesterol 327-338 C-reactive protein Homo sapiens 112-115 33044103-7 2020 CONCLUSIONS: Serum oestradiol levels are inversely associated with CRP levels in premenopausal women, but not in postmenopausal women. Estradiol 19-29 C-reactive protein Homo sapiens 67-70 32992442-3 2020 We review the CRP-specific detection platforms with high sensitivity, which feature the thin metal films for surface plasmon resonance, nano-enhancers of zero dimensional nanostructures, and metal nanoparticles for localized surface plasmon resonance. Metals 93-98 C-reactive protein Homo sapiens 14-17 33380704-6 2020 Results: : Both candesartan and atorvastatin treated groups showed significant decrease in serum levels IL-1beta and TNF-alpha, acute-phase reactants (CRP and ESR), number of swollen joint and patient global assessment. Atorvastatin 32-44 C-reactive protein Homo sapiens 151-154 32648790-3 2020 AIMS: We are evaluating the blood inflammatory biomarkers: C-reactive protein and interleukin 6, as a potential consequence of ayahuasca intake and their correlation with serum cortisol and brain-derived neurotrophic factor levels. Hydrocortisone 177-185 C-reactive protein Homo sapiens 59-77 32648790-5 2020 RESULTS: At pre-treatment, patients showed higher C-reactive protein levels than healthy controls and a significant negative correlation between C-reactive protein and serum cortisol levels was revealed (rho = -0.40, n = 14). Hydrocortisone 174-182 C-reactive protein Homo sapiens 145-163 32992442-3 2020 We review the CRP-specific detection platforms with high sensitivity, which feature the thin metal films for surface plasmon resonance, nano-enhancers of zero dimensional nanostructures, and metal nanoparticles for localized surface plasmon resonance. Metals 191-196 C-reactive protein Homo sapiens 14-17 32976513-4 2020 After adjusting for confounding factors, there was a significant association between vitamin D sufficiency and reduction in clinical severity, inpatient mortality serum levels of C-reactive protein (CRP) and an increase in lymphocyte percentage. Vitamin D 85-94 C-reactive protein Homo sapiens 179-197 32976513-4 2020 After adjusting for confounding factors, there was a significant association between vitamin D sufficiency and reduction in clinical severity, inpatient mortality serum levels of C-reactive protein (CRP) and an increase in lymphocyte percentage. Vitamin D 85-94 C-reactive protein Homo sapiens 199-202 32976513-6 2020 The significant reduction in serum CRP, an inflammatory marker, along with increased lymphocytes percentage suggest that vitamin D sufficiency also may help modulate the immune response possibly by reducing risk for cytokine storm in response to this viral infection. Vitamin D 121-130 C-reactive protein Homo sapiens 35-38 33088461-10 2020 The association between DII and hs-CRP was not significant (P-value >0.05). dilC18(3) dye 24-27 C-reactive protein Homo sapiens 35-38 32959547-11 2020 Sputum production, chest discomfort, a large number of symptoms, abnormal procalcitonin and C-reactive protein levels, and abnormal chest X-ray or chest computed tomography findings were more common in patients requiring supplemental oxygen than in those not requiring supplemental oxygen. Oxygen 234-240 C-reactive protein Homo sapiens 92-110 32982379-7 2020 Ideal body mass index (BMI), physical activity, smoking status and total cholesterol all had significant impacts on hs-CRP levels, with ideal BMI having the largest impact. Cholesterol 73-84 C-reactive protein Homo sapiens 119-122 32921708-11 2020 CRP was correlated significantly with the duration of stay in the ICU and the duration for oxygen supplementation (r = 0.37 and 0.42 respectively; p: <0.01). Oxygen 91-97 C-reactive protein Homo sapiens 0-3 32496664-6 2020 The prescription of ART was paralleled by significant decreases in plasma PCSK9 and hs-CRP levels, and increases in total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides and lipoprotein(a), independent of regimen. art 20-23 C-reactive protein Homo sapiens 87-90 32360116-0 2020 Aspirin to Reduce Risk for Sudden Cardiac Death in Athletes With Elevated C-Reactive Protein Levels. Aspirin 0-7 C-reactive protein Homo sapiens 74-92 32782515-8 2020 In the treatment of pediatric epilepsy, sodium valproate combined with LEV produces better efficacy, fewer adverse reactions, significantly improves patients" QOL and notably lowers the content of NSE, IL-6 and hs-CRP with notable EEG improvement, so it is a safe and reliable treatment that is worth popularization. Levetiracetam 71-74 C-reactive protein Homo sapiens 214-217 33042627-11 2020 The comparison between the means of the biomarkers in after-before DOX-based chemotherapy of the two groups of patients showed significant differences for MPO, TAT complex and CRP. Doxorubicin 67-70 C-reactive protein Homo sapiens 176-179 32394604-6 2020 Total-C, non-HDL-C, triglycerides, BMI, and waist-hip ratio were associated with hs-CRP, with an increased magnitude in at-target patients. Triglycerides 20-33 C-reactive protein Homo sapiens 84-87 32394604-7 2020 Conversely, glucose-related parameters were strongly associated with hs-CRP only in at-target patients, overall suggesting glycaemic control, insulin resistance, non-LDL-C lipid parameters, and especially central obesity as possible contributors to RIR in patients with T2DM and LDL-C < 70 mg/dL. Glucose 12-19 C-reactive protein Homo sapiens 72-75 32677046-9 2020 The three challenges with elevated iron absorption also had elevated STFR/log ferritin as well as elevated ESR and CRP, but these inflammatory markers were, in general, less elevated than those in non-absorbers. Iron 35-39 C-reactive protein Homo sapiens 115-118 32622796-9 2020 Serum calcium levels were negatively correlated with leukocytes, CRP, PCT, IL-6 and D-dimer, while positively correlated with lymphocytes and ALB. Calcium 6-13 C-reactive protein Homo sapiens 65-68 32968400-8 2020 The mechanism may be associated with the impact of vitamin D deficiency on hs-CRP and other body inflammation indicators, as well as on thyroid autoantibodies and other immune indicators, but has no effect on IL-1 levels. Vitamin D 51-60 C-reactive protein Homo sapiens 78-81 32015430-6 2020 Mono-n-butyl phthalate (MBP) was correlated with higher IL-1beta, IL-6, and CRP expression in placentae of male fetuses and with higher IL-6, CRP, MCP-1, IL-8, IL-10, and CD68 expression in placentae of female fetuses. monobutyl phthalate 0-22 C-reactive protein Homo sapiens 76-79 32015430-6 2020 Mono-n-butyl phthalate (MBP) was correlated with higher IL-1beta, IL-6, and CRP expression in placentae of male fetuses and with higher IL-6, CRP, MCP-1, IL-8, IL-10, and CD68 expression in placentae of female fetuses. monobutyl phthalate 0-22 C-reactive protein Homo sapiens 142-145 32015430-6 2020 Mono-n-butyl phthalate (MBP) was correlated with higher IL-1beta, IL-6, and CRP expression in placentae of male fetuses and with higher IL-6, CRP, MCP-1, IL-8, IL-10, and CD68 expression in placentae of female fetuses. monobutyl phthalate 24-27 C-reactive protein Homo sapiens 76-79 32015430-6 2020 Mono-n-butyl phthalate (MBP) was correlated with higher IL-1beta, IL-6, and CRP expression in placentae of male fetuses and with higher IL-6, CRP, MCP-1, IL-8, IL-10, and CD68 expression in placentae of female fetuses. monobutyl phthalate 24-27 C-reactive protein Homo sapiens 142-145 32015430-8 2020 Mono (2-ethyl-5-oxohexyl) phthalate (MEOHP) was negatively correlated with CRP, MCP-1, and CD68 in placentae of female fetuses. mono(2-ethyl-5-oxohexyl)phthalate 0-35 C-reactive protein Homo sapiens 75-78 32871878-4 2020 Serum 25(OH)D levels were negatively correlated with hs-CRP, while not with TNF-alpha. 25(oh)d 6-13 C-reactive protein Homo sapiens 56-59 32908083-5 2020 Multivariable regression demonstrated rising odds of in-hospital death related with age (odds ratio (OR) = 1.055, p = 0.002), levels of C-reactive protein (CRP) (OR = 2.915, p < 0.001), creatinine (OR = 1.740, p = 0.023), lymphocyte count (OR = 0.999, p = 0.008), and magnesium level (OR = 0.032, p < 0.001) on admission. Creatinine 186-196 C-reactive protein Homo sapiens 136-154 32908083-5 2020 Multivariable regression demonstrated rising odds of in-hospital death related with age (odds ratio (OR) = 1.055, p = 0.002), levels of C-reactive protein (CRP) (OR = 2.915, p < 0.001), creatinine (OR = 1.740, p = 0.023), lymphocyte count (OR = 0.999, p = 0.008), and magnesium level (OR = 0.032, p < 0.001) on admission. Creatinine 186-196 C-reactive protein Homo sapiens 156-159 32757858-7 2020 In CD, significant correlations between DCE-MRI parameters and biomarkers (CRP, faecal calprotectin) were more frequent in unaffected segments than in affected segments. Cadmium 3-5 C-reactive protein Homo sapiens 75-78 32823680-5 2020 hs-CRP exhibited significantly positive correlations with body mass index, waist circumference, systolic blood pressure, triglyceride, and fasting plasma glucose, and a negative correlation with high-density lipoprotein. Glucose 154-161 C-reactive protein Homo sapiens 3-6 32408752-6 2020 Furthermore, the significant negative correlation between vitamin D level and CD8+ cell percentage, PLT, CRP and D-dimers was seen. Vitamin D 58-67 C-reactive protein Homo sapiens 105-108 32823680-5 2020 hs-CRP exhibited significantly positive correlations with body mass index, waist circumference, systolic blood pressure, triglyceride, and fasting plasma glucose, and a negative correlation with high-density lipoprotein. Triglycerides 121-133 C-reactive protein Homo sapiens 3-6 32408752-9 2020 In multivariate analysis, only AIDS status and CRP level were correlated with vitamin D level (slope estimate = 11.6 and p = 0.032 and slope estimate = -0.83 and p = 0.002; respectively). Vitamin D 78-87 C-reactive protein Homo sapiens 47-50 32408752-10 2020 In summary, we report that low vitamin D level may be associated with high CRP level in HIV-infected patients on suppressive antiretroviral therapy, especially in AIDS phase. Vitamin D 31-40 C-reactive protein Homo sapiens 75-78 32821362-8 2020 The baseline hs-CRP level and PASI-90 non-response correlated with elevated triglyceride levels. Triglycerides 76-88 C-reactive protein Homo sapiens 16-19 32821362-10 2020 Higher baseline hs-CRP level and PASI-90 non-response were predictors for elevated triglyceride levels after treatment. Triglycerides 83-95 C-reactive protein Homo sapiens 19-22 31972338-16 2020 CONCLUSION: A combination of depressive symptoms and CRP was implicated in the onset of CHD, stroke, diabetes/high blood glucose, and pulmonary disease up to 12 years later, reflecting the role of psychobiological processes across multiple disease states. Glucose 121-128 C-reactive protein Homo sapiens 53-56 32198016-0 2020 Gene signatures in peripheral blood immune cells related to insulin resistance and low tyrosine metabolism define a sub-type of depression with high CRP and anhedonia. Tyrosine 87-95 C-reactive protein Homo sapiens 149-152 32198016-8 2020 Within patients with High CRP in GSEA, the insulin signaling pathway was the top enriched pathway in patients with High versus Low Anhedonia (n=10 and 9 respectively), which was driven by genes expressed predominantly in monocytes (z=2.95, p<0.01). gsea 33-37 C-reactive protein Homo sapiens 26-29 32563168-13 2020 hs-CRP increase was associated with PGES. pges 36-40 C-reactive protein Homo sapiens 3-6 32198016-9 2020 Conversely, within patients with High Anhedonia, in addition to enrichment of immunometabolic pathways, the tyrosine metabolism pathway was also reduced in patients with High versus Low CRP (n=20 and 10 respectively). Tyrosine 108-116 C-reactive protein Homo sapiens 186-189 32198016-13 2020 Together these data suggest that anhedonia in MDD with high CRP involves both immunometabolic shifts and reduced dopamine precursor availability. Dopamine 113-121 C-reactive protein Homo sapiens 60-63 32951715-9 2020 CONCLUSIONS: Administration of 6 mg/day melatonin had improvement effect on many factors related to NAFLD such as liver enzymes, hs-CRP, anthropometric measurements, blood pressure, leptin serum levels and the grade of fatty liver. Melatonin 40-49 C-reactive protein Homo sapiens 132-135 32951729-8 2020 The BG decreased us-CRP concentration compared to PG (-1.2 +- 0.2 vs. + 0.8 +- 0.2 mg / L,d = 0.88; p = 0.01). O(6)-benzylguanine 4-6 C-reactive protein Homo sapiens 20-23 32404823-1 2020 OBJECTIVE: Recent studies have shown an increase of C-reactive-protein (CRP) after exposure to zinc- and copper-containing welding fumes. Copper 105-111 C-reactive protein Homo sapiens 52-70 32404823-1 2020 OBJECTIVE: Recent studies have shown an increase of C-reactive-protein (CRP) after exposure to zinc- and copper-containing welding fumes. Copper 105-111 C-reactive protein Homo sapiens 72-75 32387344-9 2020 Moreover, an interaction between the glucose-related composite score and CRP was observed for these relationships (F[2,33]=4.3, p<0.05) whereby significant correlations between the glucose-related metabolic markers and FC was found only in patients with high plasma CRP (>3 mg/L; r=-0.61 to -0.81, p<0.05). Glucose 37-44 C-reactive protein Homo sapiens 73-76 32387344-9 2020 Moreover, an interaction between the glucose-related composite score and CRP was observed for these relationships (F[2,33]=4.3, p<0.05) whereby significant correlations between the glucose-related metabolic markers and FC was found only in patients with high plasma CRP (>3 mg/L; r=-0.61 to -0.81, p<0.05). Glucose 181-188 C-reactive protein Homo sapiens 73-76 32690176-2 2020 This systematic review and meta-analysis were done based upon randomized controlled trials (RCTs) to analyze the effects of berberine on anthropometric parameters, CRP and liver enzymes. Berberine 124-133 C-reactive protein Homo sapiens 164-167 32690176-9 2020 CONCLUSION: This meta-analysis found a significant reduction of body weight, BMI, WC and CRP levels associated with berberine intake which may have played an indirect role in improved clinical symptoms in diseases with metabolic disorders. Berberine 116-125 C-reactive protein Homo sapiens 89-92 31679041-9 2020 The effect of melatonin on CRP levels was marginal (WMD = - 0.45 mg/L; 95% CI - 0.94, 0.03; P = 0.06; I2 = 96.6%, Pheterogeneity < 0.001). Melatonin 14-23 C-reactive protein Homo sapiens 27-30 32722447-5 2020 The association between the serum folate level and lung function in patients with COPD was evaluated using multivariable linear regression analysis after adjustment for age, sex, height, high sensitivity C-reactive protein, total calorie intake, residence, smoking status and smoking pack-years, education, and household income. Folic Acid 34-40 C-reactive protein Homo sapiens 204-222 32723264-3 2021 This study assessed the efficacy of sublingual consumption of melatonin in reducing necrosis and inflammation, in patients undergoing CABG with respect to C-reactive protein (hs-CRP), Creatine KinaseMuscle-Brain subunits (CK-MB) and cardiac Troponin T (cTnT) levels. Melatonin 62-71 C-reactive protein Homo sapiens 155-173 32723264-12 2021 CONCLUSION: Our findings suggest that the administration of melatonin may help modulate oxidative stress, based on the reduction of the levels of hs-CRP, CK-MB, and the duration of AF following CABG surgery. Melatonin 60-69 C-reactive protein Homo sapiens 149-152 32646381-14 2020 E2 and E4 were significantly associated with high and low CRP, respectively, but no associations were seen between CRP and comorbidity. Estradiol 0-2 C-reactive protein Homo sapiens 58-61 32559180-5 2020 Interestingly, metabolite levels in these pathways correlated with clinical laboratory markers of inflammation (i.e., IL-6 and C-reactive protein) and renal function (i.e., blood urea nitrogen).CONCLUSIONIn conclusion, this initial observational study identified amino acid and fatty acid metabolism as correlates of COVID-19, providing mechanistic insights, potential markers of clinical severity, and potential therapeutic targets.FUNDINGBoettcher Foundation Webb-Waring Biomedical Research Award; National Institute of General and Medical Sciences, NIH; and National Heart, Lung, and Blood Institute, NIH. Urea 179-183 C-reactive protein Homo sapiens 127-145 32559180-5 2020 Interestingly, metabolite levels in these pathways correlated with clinical laboratory markers of inflammation (i.e., IL-6 and C-reactive protein) and renal function (i.e., blood urea nitrogen).CONCLUSIONIn conclusion, this initial observational study identified amino acid and fatty acid metabolism as correlates of COVID-19, providing mechanistic insights, potential markers of clinical severity, and potential therapeutic targets.FUNDINGBoettcher Foundation Webb-Waring Biomedical Research Award; National Institute of General and Medical Sciences, NIH; and National Heart, Lung, and Blood Institute, NIH. Nitrogen 184-192 C-reactive protein Homo sapiens 127-145 32559180-5 2020 Interestingly, metabolite levels in these pathways correlated with clinical laboratory markers of inflammation (i.e., IL-6 and C-reactive protein) and renal function (i.e., blood urea nitrogen).CONCLUSIONIn conclusion, this initial observational study identified amino acid and fatty acid metabolism as correlates of COVID-19, providing mechanistic insights, potential markers of clinical severity, and potential therapeutic targets.FUNDINGBoettcher Foundation Webb-Waring Biomedical Research Award; National Institute of General and Medical Sciences, NIH; and National Heart, Lung, and Blood Institute, NIH. Fatty Acids 278-288 C-reactive protein Homo sapiens 127-145 32708997-10 2020 Elevated hs-C reactive protein (CRP) was associated with new-onset CKD (OR: 1.045, 95% CI: 1.005-1.086); however, this association disappeared following adjustment with the kynurenine:tryptophan ratio. Tryptophan 184-194 C-reactive protein Homo sapiens 9-30 32708997-10 2020 Elevated hs-C reactive protein (CRP) was associated with new-onset CKD (OR: 1.045, 95% CI: 1.005-1.086); however, this association disappeared following adjustment with the kynurenine:tryptophan ratio. Tryptophan 184-194 C-reactive protein Homo sapiens 32-35 32684941-0 2020 Vitamin D status affects the relationship between lipid profile and high-sensitivity C-reactive protein. Vitamin D 0-9 C-reactive protein Homo sapiens 85-103 32684941-2 2020 Objective: The objective of this study was to evaluate the role of vitamin D status on the relationship between lipid profile and high-sensitivity C-reactive protein (hs-CRP) in pregnant women. Vitamin D 67-76 C-reactive protein Homo sapiens 147-165 32684941-2 2020 Objective: The objective of this study was to evaluate the role of vitamin D status on the relationship between lipid profile and high-sensitivity C-reactive protein (hs-CRP) in pregnant women. Vitamin D 67-76 C-reactive protein Homo sapiens 170-173 32684941-6 2020 Results: There was a significant non-linear relationship between lipid profile (TC, TG, HDL-C, LDL-C) and hs-CRP (P < 0.05). Thioguanine 84-86 C-reactive protein Homo sapiens 109-112 32684941-7 2020 Increased serum 25(OH)D was significantly associated with decreasing TC, TG, HDL-C, LDL-C, and hs-CRP levels. 25(oh)d 16-23 C-reactive protein Homo sapiens 98-101 32684941-8 2020 Compared with medium levels of lipids group, pregnant women with higher levels of TC or TG have higher levels of hs-CRP, and pregnant women with lower levels of TC, HDL-C or LDL-C also have higher levels of hs-CRP in the vitamin D deficient group, and there was a significant correlation between low levels of TG and decreased hs-CRP (adjusted beta for TG: -0.063, 95%CI: - 0.120,-0.007) in the non-vitamin D deficient group. Thioguanine 88-90 C-reactive protein Homo sapiens 116-119 32684941-9 2020 Mediators that had appreciable shares of the associations between 25(OH)D and hs-CRP was TG (10.2% of the association; beta = - 0.011; total indirect effect: 95% CI: - 0.019, - 0.002). 25(oh)d 66-73 C-reactive protein Homo sapiens 81-84 32684941-10 2020 The cubic model suggested that a steep increase in the adjusted regression coefficient of lipid with hs-CRP up to 50 nmol/L of 25(OH)D, and the highest adjusted regression coefficients were observed in pregnant women with 25(OH)D above 50 nmol/L. 25(oh)d 127-134 C-reactive protein Homo sapiens 104-107 32684941-10 2020 The cubic model suggested that a steep increase in the adjusted regression coefficient of lipid with hs-CRP up to 50 nmol/L of 25(OH)D, and the highest adjusted regression coefficients were observed in pregnant women with 25(OH)D above 50 nmol/L. 25(oh)d 222-229 C-reactive protein Homo sapiens 104-107 32684941-11 2020 Conclusion: Our findings suggest that high levels of vitamin D during pregnancy may improve lipid profile levels and inhibit elevated hs-CRP induced by high lipid metabolism. Vitamin D 53-62 C-reactive protein Homo sapiens 137-140 32696635-8 2020 Univariate analysis at 1 year of follow-up showed that the levels of hs-CRP, CCCK-18, MMP-9 and DD were relevant risk factors affecting the neurologic outcomes of ACH patients. Acetylcholine 163-166 C-reactive protein Homo sapiens 72-75 32696635-9 2020 Increased hs-CRP, CCCK-18, MMP-9 and DD levels were independent risk factors for poor neurologic outcomes of ACH patients. Acetylcholine 109-112 C-reactive protein Homo sapiens 13-16 32696635-12 2020 In addition, raised levels of hs-CRP, CCCK-18, MMP-9 and DD are considered as independent risk factors for poor neurologic outcomes of ACH patients. Acetylcholine 135-138 C-reactive protein Homo sapiens 33-36 32602547-4 2020 MATERIALS AND METHODS: Human CRP transgenic (hCRP-Tg) rats were employed for streptozotocin (STZ)-induced diabetic and oxygen-induced retinopathy (OIR) models. Streptozocin 77-91 C-reactive protein Homo sapiens 29-32 32602547-9 2020 In STZ-induced diabetic condition, overexpression of hCRP deteriorated retinal neurodegeneration as shown by ERG and apoptosis assays. Streptozocin 3-6 C-reactive protein Homo sapiens 53-57 32602547-12 2020 In retinal cell lines, hCRP treatment induced cell death and over-production of ROS. Reactive Oxygen Species 80-83 C-reactive protein Homo sapiens 23-27 32639009-9 2020 Treatment with metformin or a synthetic AMPK activator may be a potential strategy for vaso-dysfunction and hypertension in patients with high hCRP levels. Metformin 15-24 C-reactive protein Homo sapiens 143-147 32661220-15 2020 When CRP apheresis was restarted, CRP levels and creatinine kinases (CK/CK-MB) declined again. Creatinine 49-59 C-reactive protein Homo sapiens 5-8 32660440-0 2020 IMMUNEPOTENT CRP induces DAMPS release and ROS-dependent autophagosome formation in HeLa and MCF-7 cells. ros 43-46 C-reactive protein Homo sapiens 13-16 32659891-6 2020 RESULTS: The vitamin D group showed higher blood levels of (25(OH) D) (p < 0.0001), and a significant reduction in hs-CRP and TNF-alpha concentrations (p < 0.0001) compared to placebo. Vitamin D 13-22 C-reactive protein Homo sapiens 118-121 32645080-10 2020 Disease activity measures, including ASDAS-ESR, ASDAS-CRP and BASDAI, had positive correlations with ASAS HI. Aspirin 101-105 C-reactive protein Homo sapiens 54-57 32646381-16 2020 The positive and negative associations between CRP and E2 and E4, respectively, could indicate effects on inflammation and immunological reactions. Estradiol 55-57 C-reactive protein Homo sapiens 47-50 32458487-10 2020 In addition, decreasing lowest oxygen saturation (beta = -.159, P = .004) was also independently correlated with increasing hs-CRP concentrations in multivariate linear analysis after adjusting for confounders. Oxygen 31-37 C-reactive protein Homo sapiens 127-130 32884931-3 2020 Objectives: This study aims at investigating the relationship between vitamin D, fasting plasma glucose (FPG), insulin, zinc, ferritin, and high-sensitivity C-reactive protein (CRP) in GDM. Vitamin D 70-79 C-reactive protein Homo sapiens 157-175 32884931-3 2020 Objectives: This study aims at investigating the relationship between vitamin D, fasting plasma glucose (FPG), insulin, zinc, ferritin, and high-sensitivity C-reactive protein (CRP) in GDM. Vitamin D 70-79 C-reactive protein Homo sapiens 177-180 32884931-8 2020 In the GDM group, a positive weak relationship was observed between vitamin D and zinc (r = 0.18, p < 0.05), while vitamin D was inversely correlated with FPG, serum insulin, ferritin, and CRP (r = -0.23, -0.21, -0.20, -0.46, respectively, p < 0.05). Vitamin D 115-124 C-reactive protein Homo sapiens 189-192 32057092-8 2020 Overall, 70 (9.0%) fulfilled the Cr AKI definition by CrP measurement. Creatinine 33-35 C-reactive protein Homo sapiens 54-57 32057092-10 2020 AUC (95% CI) for delta-Cr-% to predict AKI on day 2 was 0.82 (95% CI 0.78-0.86), and 0.74 (95% CI 0.69-0.80) when patients with AKI based on the CrP were excluded. Creatinine 23-25 C-reactive protein Homo sapiens 145-148 32720617-10 2020 The LV function completely recovered in 66.6% of patients in group 1 and in 27% of patients in group 2.Conclusion The bromocriptine treatment of periportal cardiomyopathy in combination with an optimal drug therapy was associated with an additional beneficial effect on the clinical functional status, intracardiac hemodynamics, blood concentration of CRP, and a potentiality for complete recovery of the LV function. Bromocriptine 123-136 C-reactive protein Homo sapiens 357-360 32325367-0 2020 Adiposity is a confounding factor which largely explains the association of serum vitamin D concentrations with C-reactive protein, leptin and adiponectin. Vitamin D 82-91 C-reactive protein Homo sapiens 112-130 32325367-2 2020 Our aim was therefore to assess the association of serum 25-hydroxyvitamin D (25(OH)D) with C-reactive protein (CRP), leptin and adiponectin and the role of adiposity in this relationship. 25(oh)d 78-85 C-reactive protein Homo sapiens 92-110 31744333-11 2020 CONCLUSIONS: In statin-treated patients with atherosclerotic cardiovascular disease, remnant cholesterol was associated with coronary atheroma progression regardless of conventional lipid parameters, C-reactive protein or clinical risk factors. Cholesterol 93-104 C-reactive protein Homo sapiens 200-218 32325367-2 2020 Our aim was therefore to assess the association of serum 25-hydroxyvitamin D (25(OH)D) with C-reactive protein (CRP), leptin and adiponectin and the role of adiposity in this relationship. 25(oh)d 78-85 C-reactive protein Homo sapiens 112-115 32325367-8 2020 Although after adjustment for most examined potential confounders, each 10 nmol/L increase in serum 25(OH)D was associated with 2.3% (95%CI: -4.0 to -0.5) lower CRP, 3.5% (-4.7 to -2.2) lower leptin, and 0.13 ng/mL (0.04-0.21) higher adiponectin, most of these associations seemed to largely stem from an additional potential confounder - adiposity - as they either disappeared (leptin and CRP) or were largely diminished (adiponectin) upon further adjustment for adiposity indices (total body fat and waist circumference). 25(oh)d 100-107 C-reactive protein Homo sapiens 161-164 32325367-8 2020 Although after adjustment for most examined potential confounders, each 10 nmol/L increase in serum 25(OH)D was associated with 2.3% (95%CI: -4.0 to -0.5) lower CRP, 3.5% (-4.7 to -2.2) lower leptin, and 0.13 ng/mL (0.04-0.21) higher adiponectin, most of these associations seemed to largely stem from an additional potential confounder - adiposity - as they either disappeared (leptin and CRP) or were largely diminished (adiponectin) upon further adjustment for adiposity indices (total body fat and waist circumference). 25(oh)d 100-107 C-reactive protein Homo sapiens 390-393 32325367-9 2020 CONCLUSION: We found that measures of adiposity largely explained the negative association of serum 25(OH)D with the pro-inflammatory CRP and leptin, and the positive association with the anti-inflammatory adiponectin. 25(oh)d 100-107 C-reactive protein Homo sapiens 134-137 32474217-12 2020 In addition, urinary copper and zinc increased monotonically with plasma CRP elevation, and plasma CRP was positively associated with the MetS prevalence. Copper 21-27 C-reactive protein Homo sapiens 73-76 32474217-13 2020 Mediation analysis indicated that plasma CRP mediated 5.2% and 3.2% in the associations of urinary copper and zinc with MetS prevalence, respectively. Copper 99-105 C-reactive protein Homo sapiens 41-44 32342619-7 2020 The significant improvements found only in the metformin group were body mass index, fasting blood glucose, high-sensitivity C-reactive protein and 10-year risk of coronary heart disease (Framingham heart study) (P = 0.0004, P = 0.049, P = 0.035 and P = 0.029); whereas that only in the placebo group was high density lipoprotein cholesterol. Metformin 47-56 C-reactive protein Homo sapiens 125-143 32422661-6 2020 We found that vitamin D supplementation had a significant effect on insulin metabolism, total serum testosterone, hirsutism, C-reactive protein, and total antioxidant capacity in women with polycystic ovary syndrome. Vitamin D 14-23 C-reactive protein Homo sapiens 125-143 31912618-7 2020 Our findings imply that CRP levels could be a useful clinical biomarker when blood glucose levels are controlled in acute phase patients. Glucose 83-90 C-reactive protein Homo sapiens 24-27 32695177-0 2020 Correlation between C-reactive Protein with Malondialdehyde in Systemic Lupus Erythematosus Patients. Malondialdehyde 44-59 C-reactive protein Homo sapiens 20-38 32579049-4 2020 Results: In the COVID-19 patients hemoglobin is decreasing and protoporphyrin is increasing, generating an extremely harmful accumulation of iron ions in the bloodstream, which are able to induce an intense inflammatory process in the body with a consequent increase in C-reactive protein and albumin. Iron 141-145 C-reactive protein Homo sapiens 270-288 33178875-5 2020 In addition, the levels of IMA, hs-CRP and FIB levels showed a strong link to BMI, WHR, TC, TG, LDL and glycated hemoglobin. Triglycerides 92-94 C-reactive protein Homo sapiens 35-38 32726040-5 2020 The results showed that the lower the concentration of chlorogenic acid, the higher the inhibition rate of Jun N-terminal kinase(JNK) at downstream of IL-1 by the combination of chlorogenic acid and linalool; the higher the concentration of luteolin in IL-6 pathway, the higher the inhibition rate of C-reactive protein(CRP) at downstream of IL-6 by the combination of chlorogenic acid and luteolin. Chlorogenic Acid 55-71 C-reactive protein Homo sapiens 301-319 32726040-5 2020 The results showed that the lower the concentration of chlorogenic acid, the higher the inhibition rate of Jun N-terminal kinase(JNK) at downstream of IL-1 by the combination of chlorogenic acid and linalool; the higher the concentration of luteolin in IL-6 pathway, the higher the inhibition rate of C-reactive protein(CRP) at downstream of IL-6 by the combination of chlorogenic acid and luteolin. Chlorogenic Acid 55-71 C-reactive protein Homo sapiens 320-323 32726040-5 2020 The results showed that the lower the concentration of chlorogenic acid, the higher the inhibition rate of Jun N-terminal kinase(JNK) at downstream of IL-1 by the combination of chlorogenic acid and linalool; the higher the concentration of luteolin in IL-6 pathway, the higher the inhibition rate of C-reactive protein(CRP) at downstream of IL-6 by the combination of chlorogenic acid and luteolin. Chlorogenic Acid 178-194 C-reactive protein Homo sapiens 301-319 32726040-5 2020 The results showed that the lower the concentration of chlorogenic acid, the higher the inhibition rate of Jun N-terminal kinase(JNK) at downstream of IL-1 by the combination of chlorogenic acid and linalool; the higher the concentration of luteolin in IL-6 pathway, the higher the inhibition rate of C-reactive protein(CRP) at downstream of IL-6 by the combination of chlorogenic acid and luteolin. Chlorogenic Acid 178-194 C-reactive protein Homo sapiens 320-323 32726040-5 2020 The results showed that the lower the concentration of chlorogenic acid, the higher the inhibition rate of Jun N-terminal kinase(JNK) at downstream of IL-1 by the combination of chlorogenic acid and linalool; the higher the concentration of luteolin in IL-6 pathway, the higher the inhibition rate of C-reactive protein(CRP) at downstream of IL-6 by the combination of chlorogenic acid and luteolin. linalool 199-207 C-reactive protein Homo sapiens 301-319 32726040-5 2020 The results showed that the lower the concentration of chlorogenic acid, the higher the inhibition rate of Jun N-terminal kinase(JNK) at downstream of IL-1 by the combination of chlorogenic acid and linalool; the higher the concentration of luteolin in IL-6 pathway, the higher the inhibition rate of C-reactive protein(CRP) at downstream of IL-6 by the combination of chlorogenic acid and luteolin. linalool 199-207 C-reactive protein Homo sapiens 320-323 32726040-5 2020 The results showed that the lower the concentration of chlorogenic acid, the higher the inhibition rate of Jun N-terminal kinase(JNK) at downstream of IL-1 by the combination of chlorogenic acid and linalool; the higher the concentration of luteolin in IL-6 pathway, the higher the inhibition rate of C-reactive protein(CRP) at downstream of IL-6 by the combination of chlorogenic acid and luteolin. Chlorogenic Acid 178-194 C-reactive protein Homo sapiens 301-319 32726040-5 2020 The results showed that the lower the concentration of chlorogenic acid, the higher the inhibition rate of Jun N-terminal kinase(JNK) at downstream of IL-1 by the combination of chlorogenic acid and linalool; the higher the concentration of luteolin in IL-6 pathway, the higher the inhibition rate of C-reactive protein(CRP) at downstream of IL-6 by the combination of chlorogenic acid and luteolin. Chlorogenic Acid 178-194 C-reactive protein Homo sapiens 320-323 32496940-0 2022 Ibuprofen use is associated with reduced C-reactive protein and interleukin-6 levels in chronic spinal cord injury. Ibuprofen 0-9 C-reactive protein Homo sapiens 41-59 32655691-12 2020 Oral TU was not associated with liver toxicity nor did it cause an elevation in high-sensitivity C-reactive protein or lipoprotein-associated phospholipase A2 (cardiovascular safety biomarkers) after 365 days of therapy. testosterone undecanoate 5-7 C-reactive protein Homo sapiens 97-115 32599804-3 2020 Here, we report the fabrication of an interdigitated sensing device integrated with polyvinyl alcohol (PVA) nanofibers and carbon nanotubes (CNT) for the detection of an inflammatory biomarker, C-reactive protein (CRP). Carbon 123-129 C-reactive protein Homo sapiens 194-212 32496940-3 2022 After adjusting for clinical and demographic factors, ibuprofen users had significantly lower CRP levels (2.3 mg/L versus 3.5 mg/L, P = 0.04) and IL-6 levels (3.2 pg/ml versus 4.0 pg/ml, P = 0.04) compared to nonusers.Conclusions: Our study suggests that self-reported ibuprofen use may be negatively associated with CRP and IL-6 levels in chronic SCI after adjusting for known confounding factors, and suggests ibuprofen use may be an important, potential variable to consider in future studies focused on systemic inflammation in SCI. Ibuprofen 54-63 C-reactive protein Homo sapiens 94-97 32496940-3 2022 After adjusting for clinical and demographic factors, ibuprofen users had significantly lower CRP levels (2.3 mg/L versus 3.5 mg/L, P = 0.04) and IL-6 levels (3.2 pg/ml versus 4.0 pg/ml, P = 0.04) compared to nonusers.Conclusions: Our study suggests that self-reported ibuprofen use may be negatively associated with CRP and IL-6 levels in chronic SCI after adjusting for known confounding factors, and suggests ibuprofen use may be an important, potential variable to consider in future studies focused on systemic inflammation in SCI. Ibuprofen 54-63 C-reactive protein Homo sapiens 317-320 32570995-6 2020 RESULTS: CRP levels decreased significantly following the start of dexamethasone from mean initial levels of 129.52 to 40.73 mg/L at time of discharge. Dexamethasone 67-80 C-reactive protein Homo sapiens 9-12 32632417-11 2020 Severe cases of pneumonia requiring supplemental oxygen were more likely to exhibit bilateral alveolar or interstitial infiltrates on chest X-ray (55 6% vs. 0 0%; P-value = 0 003) and serum C-reactive protein (CRP) levels >10 mg/dL (33 0% vs. 0 0%; P-value = 0 05) at admission than those with no oxygen requirements. Oxygen 49-55 C-reactive protein Homo sapiens 190-208 32632417-11 2020 Severe cases of pneumonia requiring supplemental oxygen were more likely to exhibit bilateral alveolar or interstitial infiltrates on chest X-ray (55 6% vs. 0 0%; P-value = 0 003) and serum C-reactive protein (CRP) levels >10 mg/dL (33 0% vs. 0 0%; P-value = 0 05) at admission than those with no oxygen requirements. Oxygen 49-55 C-reactive protein Homo sapiens 210-213 32566743-9 2020 Similar results were obtained for correlation with markers of obesity (insulin, CRP, and leptin) with estradiol and estrone (-0.15 to 0.12; p = 0.11-0.82). Estradiol 102-111 C-reactive protein Homo sapiens 80-83 32496940-1 2022 Objective: To assess the association between ibuprofen use and the systemic inflammatory biomarkers C-reactive protein (CRP) and interleukin-6 (IL-6) in chronic Spinal Cord Injury (SCI).Study design: Prospective cohort study.Setting: Community dwelling individuals with SCI.Participants: 338 (278 male, 60 female) community dwelling individuals with chronic SCI (>=1-year post-injury).Interventions: None.Main outcome measures: CRP and IL-6 levels were quantified by ultra-sensitive ELISA assay. Ibuprofen 45-54 C-reactive protein Homo sapiens 100-118 32496940-1 2022 Objective: To assess the association between ibuprofen use and the systemic inflammatory biomarkers C-reactive protein (CRP) and interleukin-6 (IL-6) in chronic Spinal Cord Injury (SCI).Study design: Prospective cohort study.Setting: Community dwelling individuals with SCI.Participants: 338 (278 male, 60 female) community dwelling individuals with chronic SCI (>=1-year post-injury).Interventions: None.Main outcome measures: CRP and IL-6 levels were quantified by ultra-sensitive ELISA assay. Ibuprofen 45-54 C-reactive protein Homo sapiens 120-123 32498466-7 2020 The data show that selection of acetic acid as the solvent in the silanization step generally yields a higher protein binding capacity for C-reactive protein (CRP) onto anti-CRP functionalized ring resonator sensors than using ethanol as the solvent. Ethanol 227-234 C-reactive protein Homo sapiens 139-157 32503322-6 2020 Overall, hs-CRP levels had a correlation with total cholesterol (p < 0.05) and a trend of correlation with HbA1c (p = 0.054) levels. Cholesterol 52-63 C-reactive protein Homo sapiens 12-15 32538061-7 2020 Further study showed that peripheral blood miR-148 level in the UC group was positively correlated with CRP and ESR. mir-148 43-50 C-reactive protein Homo sapiens 104-107 32401056-2 2020 Serum CRP levels recovery (after one week) was associated to -SH groups and GSH recovery, but not to anion exchange capability restoration. Glutathione 76-79 C-reactive protein Homo sapiens 6-9 29895893-2 2020 Furthermore, increased peripheral blood CRP in MDD has been associated with altered reward circuitry and increased brain glutamate in relation with symptoms of anhedonia. Glutamic Acid 121-130 C-reactive protein Homo sapiens 40-43 32528415-8 2020 CRP, ANC and classical monocytes showed positive correlations with waist circumference, insulin, HOMA-IR and triglycerides. Triglycerides 109-122 C-reactive protein Homo sapiens 0-3 32443740-8 2020 RESULTS: After adjusting for age, gender, C-reactive protein (CRP), and body mass index (BMI), a negative association was found between whole blood iron, ferritin, and TBI and incidence of reduced HDL-C (odds ratio (OR) = 0.63, 0.49, and 0.57, respectively). Iron 148-152 C-reactive protein Homo sapiens 42-60 32443740-8 2020 RESULTS: After adjusting for age, gender, C-reactive protein (CRP), and body mass index (BMI), a negative association was found between whole blood iron, ferritin, and TBI and incidence of reduced HDL-C (odds ratio (OR) = 0.63, 0.49, and 0.57, respectively). Iron 148-152 C-reactive protein Homo sapiens 62-65 32528421-0 2020 The Regulation of Bacterial Biofilm Formation by cAMP-CRP: A Mini-Review. Cyclic AMP 49-53 C-reactive protein Homo sapiens 54-57 32528421-5 2020 Although the underlying mechanisms of biofilm formation mediated by cAMP-CRP have been well-investigated in several bacteria, the regulatory pathways of cAMP-CRP are still poorly understood compared to those of c-di-GMP. Cyclic AMP 68-72 C-reactive protein Homo sapiens 73-76 32528421-8 2020 This mini-review provides an overview of the cAMP-CRP-regulated pathways involved in biofilm formation in some bacteria. Cyclic AMP 45-49 C-reactive protein Homo sapiens 50-53 32129408-1 2020 We present multiple-bent multi-walled carbon nanotubes (MWCNTs) that enable the picomolar detection of C-reactive protein (CRP), which is considered to be a promising biomarker for various diseases. Carbon 38-44 C-reactive protein Homo sapiens 103-121 32129408-1 2020 We present multiple-bent multi-walled carbon nanotubes (MWCNTs) that enable the picomolar detection of C-reactive protein (CRP), which is considered to be a promising biomarker for various diseases. Carbon 38-44 C-reactive protein Homo sapiens 123-126 32113022-6 2020 Pooling 9 effect sizes from 8 RCTs on C-reactive protein (CRP) levels revealed a significant reducing effect of vitamin d-calcium co-supplementation on serum CRP concentrations compared to placebo intake (WMD: -0.82, 95% CI: -1.56, -0.07 mg/L, P = 0.03). Vitamin D 112-121 C-reactive protein Homo sapiens 38-56 32394193-3 2020 Au nanoparticles were loaded on COF-LZUl to immobilise the CRP antibody (anti-CRP) on the surface of a glassy carbon electrode. Carbon 110-116 C-reactive protein Homo sapiens 59-62 32394193-3 2020 Au nanoparticles were loaded on COF-LZUl to immobilise the CRP antibody (anti-CRP) on the surface of a glassy carbon electrode. Carbon 110-116 C-reactive protein Homo sapiens 78-81 32394193-5 2020 The as-synthesised activated carbon-supported bimetallic Pt/Ru/C nanoparticle composite was used to label secondary CRP antibody because it exhibited excellent catalytic behaviour toward hydrogen peroxide. Carbon 29-35 C-reactive protein Homo sapiens 116-119 32394193-5 2020 The as-synthesised activated carbon-supported bimetallic Pt/Ru/C nanoparticle composite was used to label secondary CRP antibody because it exhibited excellent catalytic behaviour toward hydrogen peroxide. Hydrogen Peroxide 187-204 C-reactive protein Homo sapiens 116-119 32379116-8 2020 RESULTS: Serum high-sensitivity CRP >1.0 mg/L was significantly associated with IAC (OR, 2.47 [95% CI, 1.65 to 3.70]) after adjusting for diabetes, fasting glucose level, HbA1c, dyslipidemia, TG/HDL >3.5, and thyroid-stimulating hormone (p <= 0.031). Glucose 156-163 C-reactive protein Homo sapiens 32-35 32379116-8 2020 RESULTS: Serum high-sensitivity CRP >1.0 mg/L was significantly associated with IAC (OR, 2.47 [95% CI, 1.65 to 3.70]) after adjusting for diabetes, fasting glucose level, HbA1c, dyslipidemia, TG/HDL >3.5, and thyroid-stimulating hormone (p <= 0.031). Thioguanine 192-194 C-reactive protein Homo sapiens 32-35 31858957-10 2020 Higher CRP values at 6 months appear to be associated with a higher risk of longer steroid therapy. Steroids 83-90 C-reactive protein Homo sapiens 7-10 32232398-11 2020 25(OH)D was inversely associated with sICAM-1, hs-CRP, and AGP, which were positively associated with BMI. 25(oh)d 0-7 C-reactive protein Homo sapiens 50-53 31255351-11 2020 Four of the ten were associated [glycine (inversely), caffeine, 1,7-dimethyluric acid, C52:3 triacylglycerol, (positively)], with C-reactive protein levels. Glycine 33-40 C-reactive protein Homo sapiens 130-148 31255351-11 2020 Four of the ten were associated [glycine (inversely), caffeine, 1,7-dimethyluric acid, C52:3 triacylglycerol, (positively)], with C-reactive protein levels. Triglycerides 93-108 C-reactive protein Homo sapiens 130-148 32113022-6 2020 Pooling 9 effect sizes from 8 RCTs on C-reactive protein (CRP) levels revealed a significant reducing effect of vitamin d-calcium co-supplementation on serum CRP concentrations compared to placebo intake (WMD: -0.82, 95% CI: -1.56, -0.07 mg/L, P = 0.03). Vitamin D 112-121 C-reactive protein Homo sapiens 58-61 32113022-6 2020 Pooling 9 effect sizes from 8 RCTs on C-reactive protein (CRP) levels revealed a significant reducing effect of vitamin d-calcium co-supplementation on serum CRP concentrations compared to placebo intake (WMD: -0.82, 95% CI: -1.56, -0.07 mg/L, P = 0.03). Vitamin D 112-121 C-reactive protein Homo sapiens 158-161 32113022-6 2020 Pooling 9 effect sizes from 8 RCTs on C-reactive protein (CRP) levels revealed a significant reducing effect of vitamin d-calcium co-supplementation on serum CRP concentrations compared to placebo intake (WMD: -0.82, 95% CI: -1.56, -0.07 mg/L, P = 0.03). Calcium 122-129 C-reactive protein Homo sapiens 38-56 32113022-6 2020 Pooling 9 effect sizes from 8 RCTs on C-reactive protein (CRP) levels revealed a significant reducing effect of vitamin d-calcium co-supplementation on serum CRP concentrations compared to placebo intake (WMD: -0.82, 95% CI: -1.56, -0.07 mg/L, P = 0.03). Calcium 122-129 C-reactive protein Homo sapiens 58-61 32113022-6 2020 Pooling 9 effect sizes from 8 RCTs on C-reactive protein (CRP) levels revealed a significant reducing effect of vitamin d-calcium co-supplementation on serum CRP concentrations compared to placebo intake (WMD: -0.82, 95% CI: -1.56, -0.07 mg/L, P = 0.03). Calcium 122-129 C-reactive protein Homo sapiens 158-161 32113022-8 2020 Also, we found that the associations of vitamin d-calcium dosages and duration of intervention with the reduction in CRP concentrations were in a non-linear fashion. Vitamin D 40-49 C-reactive protein Homo sapiens 117-120 32113022-8 2020 Also, we found that the associations of vitamin d-calcium dosages and duration of intervention with the reduction in CRP concentrations were in a non-linear fashion. Calcium 50-57 C-reactive protein Homo sapiens 117-120 32113022-10 2020 We found a beneficial effect of vitamin d-calcium co-supplementation on serum CRP concentrations. Vitamin D 32-41 C-reactive protein Homo sapiens 78-81 32113022-10 2020 We found a beneficial effect of vitamin d-calcium co-supplementation on serum CRP concentrations. Calcium 42-49 C-reactive protein Homo sapiens 78-81 31597622-7 2020 In addition, melatonin administration resulted in a significant reduction in serum high sensitivity C-reactive protein (beta = -1.92 mg/L, 95% CI -3.02 to -0.83, P = .001) and plasma malondialdehyde (beta = -0.21 mumol/L, 95% CI -0.36 to -0.06, P = .005); also, significant rises in plasma total antioxidant capacity (beta = 253.87 mmol/L, 95% CI 189.18-318.56, P < .001) and nitric oxide levels (beta = 2.99 mumol/L, 95% CI 0.71-5.28, P = .01) were observed compared with the placebo. Melatonin 13-22 C-reactive protein Homo sapiens 100-118 32126476-13 2020 Postictal lactate levels correlated with MMP9 at 6 h (r = 0.48; p = 0.01) and CRP at 24 h (r = 0.39; p = 0.04). Lactic Acid 10-17 C-reactive protein Homo sapiens 78-81 32425567-7 2020 Results: CRP administration significantly and dose-dependently increased the intracellular-free calcium concentration ([Ca2+]i) in cultured adipocytes and in the VSMCs. Calcium 96-103 C-reactive protein Homo sapiens 9-12 32577185-7 2020 Results: Serum iron were negatively correlated with BMI (P = 0.045, r = -0.154) and hs-CRP (P = 0.032, r = -0.165). Iron 15-19 C-reactive protein Homo sapiens 87-90 32304240-6 2020 CO2 e emissions for biochemical tests were 0.5 g/test CO2 e (95% CI, 0.4-0.6 g/test) for C-reactive protein (low because typically ordered with urea and electrolyte assessment), 49 g/test (95% CI, 45-53 g/test) for arterial blood gas assessment, and 99 g/test (95% CI, 84-113 g/test) for urea and electrolyte assessment. Urea 144-148 C-reactive protein Homo sapiens 89-107 32304240-6 2020 CO2 e emissions for biochemical tests were 0.5 g/test CO2 e (95% CI, 0.4-0.6 g/test) for C-reactive protein (low because typically ordered with urea and electrolyte assessment), 49 g/test (95% CI, 45-53 g/test) for arterial blood gas assessment, and 99 g/test (95% CI, 84-113 g/test) for urea and electrolyte assessment. Urea 288-292 C-reactive protein Homo sapiens 89-107 31802559-7 2020 Furthermore, the curcumin supplementation reduced the serum hs-CRP concentration (-6.3 +- 13.6 vs. 3.7 +- 11.6 mug/ml; p = .01) and ESR levels significantly (-1.6 +- 2.7 vs. -0.09 +- 2.4 mm/hr; p = .02) in comparison with the control group. Curcumin 17-25 C-reactive protein Homo sapiens 63-66 31802559-9 2020 CONCLUSIONS: Consumption of the curcumin supplement, along with drug therapy, is associated with significant improvement of the clinical outcomes, quality of life, hs-CRP, and ESR in patients with mild-to-moderate UC. Curcumin 32-40 C-reactive protein Homo sapiens 167-170 32286421-6 2020 Further, methionine, isoleucine, tryptophan, xanthurenic acid, and indole-3-carboxaldehyde were negatively associated with C-reactive protein (CRP), but 5-hydroxyindole-3-acetic acid was positively associated with CRP. Methionine 9-19 C-reactive protein Homo sapiens 123-141 32373171-3 2020 The main purpose of our study was the assessment of the effect of spa treatment on changes in concentration of TAS, CRP, and PRL in patients with osteoarthritis. spa 66-69 C-reactive protein Homo sapiens 116-119 32286421-6 2020 Further, methionine, isoleucine, tryptophan, xanthurenic acid, and indole-3-carboxaldehyde were negatively associated with C-reactive protein (CRP), but 5-hydroxyindole-3-acetic acid was positively associated with CRP. Methionine 9-19 C-reactive protein Homo sapiens 143-146 32286421-6 2020 Further, methionine, isoleucine, tryptophan, xanthurenic acid, and indole-3-carboxaldehyde were negatively associated with C-reactive protein (CRP), but 5-hydroxyindole-3-acetic acid was positively associated with CRP. Methionine 9-19 C-reactive protein Homo sapiens 214-217 32286421-6 2020 Further, methionine, isoleucine, tryptophan, xanthurenic acid, and indole-3-carboxaldehyde were negatively associated with C-reactive protein (CRP), but 5-hydroxyindole-3-acetic acid was positively associated with CRP. Tryptophan 33-43 C-reactive protein Homo sapiens 123-141 32286421-6 2020 Further, methionine, isoleucine, tryptophan, xanthurenic acid, and indole-3-carboxaldehyde were negatively associated with C-reactive protein (CRP), but 5-hydroxyindole-3-acetic acid was positively associated with CRP. Tryptophan 33-43 C-reactive protein Homo sapiens 143-146 31828772-5 2020 RESULTS: Forty-five patients had SPH, who had a significantly higher increase in CRP levels the morning after surgery (median 50 mg L-1 vs 41 mg L-1 , SPH vs non-SPH, respectively, P = .028), and a significantly more positive fluid balance at discharge (median 1457 ml vs 1031 ml, respectively, P = .027) vs patients without SPH. sph 33-36 C-reactive protein Homo sapiens 81-84 32399331-6 2020 We postulate that elevated CRP may warrant steroid therapy over conservative management and could lead to a possible decreased hospital stay. Steroids 43-50 C-reactive protein Homo sapiens 27-30 32154703-4 2020 Anti-CRP functionalized micromotors (anti-CRP-rGO(reduced graphene oxide)/Ni/PtNPs (platinum nanoparticles))-based immunoassay coupled to thin layer Au-based electrochemical microfluidics operating at -0.20 V under controlled fluidic detection operations (30 muL min-1) allowed the sensitive (LOD = 0.54 mug/mL) and accurate CRP determination using very low volume preterm neonatal clinical samples (<10 muL) in just 8 min of total assay time. Platinum 84-92 C-reactive protein Homo sapiens 5-8 31383995-0 2020 Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Sertraline 0-10 C-reactive protein Homo sapiens 86-104 32266401-8 2020 Similarly, correlations between CRP and serum folate ranged from -0.13 to 0.08, and correlations between AGP and serum folate between -0.21 and 0.02. Folic Acid 46-52 C-reactive protein Homo sapiens 32-35 32347005-6 2020 RESULTS: The CRP and IL-6 levels were lower in the TXA + DEX group than in the TXA group (all P < 0.001) at 24 h, 48 h, and 72 h postoperatively. Dexamethasone 57-60 C-reactive protein Homo sapiens 13-16 32100190-6 2020 RESULTS: Associations of estradiol with 7 inflammation biomarkers met p < 0.05 statistical significance in linear and ordinal models: C-reactive protein (CRP), adiponectin, chemokine (C-X-C motif) ligand-6, thymus activation-regulated chemokine, eosinophil chemotactic protein, plasminogen activator inhibitor-1, and serum amyloid A. Estradiol 25-34 C-reactive protein Homo sapiens 134-152 32100190-6 2020 RESULTS: Associations of estradiol with 7 inflammation biomarkers met p < 0.05 statistical significance in linear and ordinal models: C-reactive protein (CRP), adiponectin, chemokine (C-X-C motif) ligand-6, thymus activation-regulated chemokine, eosinophil chemotactic protein, plasminogen activator inhibitor-1, and serum amyloid A. Estradiol 25-34 C-reactive protein Homo sapiens 154-157 32100190-7 2020 The positive association between estradiol and CRP was robust to model changes. Estradiol 33-42 C-reactive protein Homo sapiens 47-50 32100190-11 2020 CONCLUSIONS: Endogenous estradiol appears to be associated with CRP and adiponectin; the evidence is limited for other inflammation biomarkers. Estradiol 24-33 C-reactive protein Homo sapiens 64-67 31892506-7 2020 Serum markers of iron metabolism increased significantly compared to baseline, as disease activity measured by C-reactive protein (CRP) was reduced. Iron 17-21 C-reactive protein Homo sapiens 131-134 31760526-0 2020 Intra-subunit Disulfide Determines the Conversion and Structural Stability of CRP Isoforms. Disulfides 14-23 C-reactive protein Homo sapiens 78-81 31760526-2 2020 CRP dissociates into subunits at inflammatory loci forming monomeric CRP (mCRP) with substantially enhanced activities, which can be further activated by reducing the intra-subunit disulfide bond. Disulfides 181-190 C-reactive protein Homo sapiens 0-3 31760526-2 2020 CRP dissociates into subunits at inflammatory loci forming monomeric CRP (mCRP) with substantially enhanced activities, which can be further activated by reducing the intra-subunit disulfide bond. Disulfides 181-190 C-reactive protein Homo sapiens 69-72 31161628-3 2020 RESULTS: We found positive associations between unprocessed red meat and serum C-reactive protein and triglycerides and an inverse association between unprocessed red meat and high-density lipoprotein (HDL) cholesterol in past smokers, but no associations in never smokers and current smokers. Triglycerides 102-115 C-reactive protein Homo sapiens 79-97 32296446-4 2020 The initial folding of CRP subunits depends on a leading sequence with a conserved dipeptide that licenses the formation of the hydrophobic core. Dipeptides 83-92 C-reactive protein Homo sapiens 23-26 32292750-0 2020 Effect of Vitamins C and E Co-Supplementation on Serum C-Reactive Protein Level: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Carbon 19-20 C-reactive protein Homo sapiens 55-73 32296394-9 2020 Serum 25(OH)D concentration was significantly negatively correlated with body mass index (BMI), waist-to-hip ratio (WHR), fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), total cholesterol, low-density lipoprotein cholesterol (LDL-C), and high-sensitivity C-reactive protein (hs-CRP) (P < 0.05). 25(oh)d 6-13 C-reactive protein Homo sapiens 286-304 32219132-7 2020 CRP positively correlated with insulin concentration in 0, 60, and 120 min during the oral glucose tolerance test (INS0: r = 0,343, p < 0,001; INS1: r = 0,276, p = 0,001; INS2: r = 0,320, p < 001) and negatively correlated with progesterone (r = -0,194, p = 0,030) and SHBG (-0,244, p = 0,005). Progesterone 228-240 C-reactive protein Homo sapiens 0-3 31255367-1 2020 INTRODUCTION AND OBJECTIVES: Previous observational studies have suggested that low vitamin D status is associated with high circulating C-reactive protein levels, as well as other plasma inflammatory cytokines. Vitamin D 84-93 C-reactive protein Homo sapiens 137-155 32219132-7 2020 CRP positively correlated with insulin concentration in 0, 60, and 120 min during the oral glucose tolerance test (INS0: r = 0,343, p < 0,001; INS1: r = 0,276, p = 0,001; INS2: r = 0,320, p < 001) and negatively correlated with progesterone (r = -0,194, p = 0,030) and SHBG (-0,244, p = 0,005). Glucose 91-98 C-reactive protein Homo sapiens 0-3 32256716-12 2020 Besides, the results of the present study suggested that nano-curcumin supplementation significantly decreases serum concentrations of malondialdehyde (MDA), and hs-CRP in subjects with metabolic syndrome. Curcumin 62-70 C-reactive protein Homo sapiens 165-168 32308675-1 2020 Results: We found significantly lower concentrations of total cholesterol, lipoprotein LDL-C, apolipoproteins A1 and B, as well as hCRP in all children with CD. Cadmium 157-159 C-reactive protein Homo sapiens 131-135 32188088-12 2020 In patients with serum vitamin D below 25 ng/mL, vitamin D seasonal change correlated with CRP and prealbumin change. Vitamin D 23-32 C-reactive protein Homo sapiens 91-94 32188088-12 2020 In patients with serum vitamin D below 25 ng/mL, vitamin D seasonal change correlated with CRP and prealbumin change. Vitamin D 49-58 C-reactive protein Homo sapiens 91-94 31125398-6 2020 Individuals in the CNS-IMP cluster were the oldest, with the worst function and more likely to live in a nursing home; those in the HEART cluster had the highest number of co-occurring diseases and drugs, and they exhibited the highest mean values of serum creatinine and C-reactive protein. Creatinine 257-267 C-reactive protein Homo sapiens 272-290 32219132-9 2020 Multiple linear regression analysis showed that CRP values are positively associated with BMI (beta = 0,374, p < 0,001) and insulin level (INS1) (beta = 0,282, p = 0,004); and WBC results are negatively associated with SHGB (beta = -0,284, p < 0,001) but positively associated with testosterone (beta = 0,163, p = 0,024) and BMI (beta = 0,157, p = 0,047). Testosterone 282-294 C-reactive protein Homo sapiens 48-51 32147032-0 2020 The effect of intramuscular megadose of vitamin D injections on E-selectin, CRP and biochemical parameters in vitamin D-deficient patients with type-2 diabetes mellitus: A randomized controlled trial. Vitamin D 40-49 C-reactive protein Homo sapiens 76-79 32207583-9 2020 In patients untreated with aspirin, AGE-1 positivity was associated with higher C-reactive protein (CRP) level. Aspirin 27-34 C-reactive protein Homo sapiens 80-98 32207583-9 2020 In patients untreated with aspirin, AGE-1 positivity was associated with higher C-reactive protein (CRP) level. Aspirin 27-34 C-reactive protein Homo sapiens 100-103 31319037-9 2020 Mean concentrations of CRP placed CU at higher risk for cardiovascular disease compared with NU. Copper 34-36 C-reactive protein Homo sapiens 23-26 32147032-6 2020 RESULTS: Vitamin D resulted in significant reductions in CRP(P = 0.01) and gamma glutamyl transferase (GGT) levels(P = 0.03) and significant increases in 25(OH)D concentrations(P = 0.01) in the intervention group compared with the control. Vitamin D 9-18 C-reactive protein Homo sapiens 57-60 32147032-9 2020 CONCLUSION: Vitamin D had beneficial effects on the levels of CRP, serum 25(OH)D and GGT among vitamin D deficient patients with T2DM. Vitamin D 12-21 C-reactive protein Homo sapiens 62-65 32147058-0 2020 The effect of resveratrol supplementation on C-reactive protein (CRP) in type 2 diabetic patients: Results from a systematic review and meta-analysis of randomized controlled trials. Resveratrol 14-25 C-reactive protein Homo sapiens 45-63 32147058-0 2020 The effect of resveratrol supplementation on C-reactive protein (CRP) in type 2 diabetic patients: Results from a systematic review and meta-analysis of randomized controlled trials. Resveratrol 14-25 C-reactive protein Homo sapiens 65-68 32147058-3 2020 This study aimed to evaluate the effect of resveratrol supplementation on CRP level in patients with T2D using a systematic review and meta-analysis of randomized controlled trials. Resveratrol 43-54 C-reactive protein Homo sapiens 74-77 32147058-10 2020 The results showed significant reduction in the level of CRP [SMD (-0.34 mg/l) (95 % CI, -0.52, to -0.16) p < 0.05] in participants with T2D following supplementation with resveratrol. Resveratrol 172-183 C-reactive protein Homo sapiens 57-60 32147058-12 2020 Subgroup and sensitivity analyses indicated that the pooled effects of resveratrol supplementation on CRP level in T2D patients were affected by resveratrol dose and duration of resveratrol. Resveratrol 71-82 C-reactive protein Homo sapiens 102-105 32147058-12 2020 Subgroup and sensitivity analyses indicated that the pooled effects of resveratrol supplementation on CRP level in T2D patients were affected by resveratrol dose and duration of resveratrol. Resveratrol 145-156 C-reactive protein Homo sapiens 102-105 32147058-12 2020 Subgroup and sensitivity analyses indicated that the pooled effects of resveratrol supplementation on CRP level in T2D patients were affected by resveratrol dose and duration of resveratrol. Resveratrol 145-156 C-reactive protein Homo sapiens 102-105 32147058-14 2020 CONCLUSION: We found a significant reduction in CRP level in patients with type 2 diabetes, who received resveratrol supplementation. Resveratrol 105-116 C-reactive protein Homo sapiens 48-51 31985315-2 2020 Patients with high serum CRP levels had lower therapeutic responses to EGFR-tyrosine kinase inhibitors (43.8%), and shorter time to treatment failure (TTF; 5.8 months) and overall survival (OS; 14.2 months) than those with low CRP levels. Tyrosine 76-84 C-reactive protein Homo sapiens 25-28 32728357-14 2020 A significant correlation was found between the level of CRP and haemoglobin (r = -0.3; p < 0.0001), red cell distribution width (r = 0.22; p < 0.0001), ejection fraction (r = -0.24, p = 0.007), troponin T (r = 0.3; p < 0.0001), creatinine (r = 0.26; p = 0.001) and body mass index (r = -0.29; p = 0.005). Creatinine 229-239 C-reactive protein Homo sapiens 57-60 32117266-0 2020 Monomeric C-Reactive Protein in Serum With Markedly Elevated CRP Levels Shares Common Calcium-Dependent Ligand Binding Properties With an in vitro Dissociated Form of C-Reactive Protein. Calcium 86-93 C-reactive protein Homo sapiens 10-28 32117266-1 2020 A monomeric form of C-reactive protein (CRP) which precipitates with cell wall pneumococcal C polysaccharide (CWPS) and retains the ability to reversibly bind to its ligand phosphocholine has been produced through urea-induced dissociation at an optimized concentration of 3 M urea over a 10 weeks period. Urea 214-218 C-reactive protein Homo sapiens 20-38 32117266-1 2020 A monomeric form of C-reactive protein (CRP) which precipitates with cell wall pneumococcal C polysaccharide (CWPS) and retains the ability to reversibly bind to its ligand phosphocholine has been produced through urea-induced dissociation at an optimized concentration of 3 M urea over a 10 weeks period. Urea 214-218 C-reactive protein Homo sapiens 40-43 32117266-1 2020 A monomeric form of C-reactive protein (CRP) which precipitates with cell wall pneumococcal C polysaccharide (CWPS) and retains the ability to reversibly bind to its ligand phosphocholine has been produced through urea-induced dissociation at an optimized concentration of 3 M urea over a 10 weeks period. Urea 277-281 C-reactive protein Homo sapiens 20-38 32117266-1 2020 A monomeric form of C-reactive protein (CRP) which precipitates with cell wall pneumococcal C polysaccharide (CWPS) and retains the ability to reversibly bind to its ligand phosphocholine has been produced through urea-induced dissociation at an optimized concentration of 3 M urea over a 10 weeks period. Urea 277-281 C-reactive protein Homo sapiens 40-43 32117266-6 2020 Both the in vitro monomeric C-reactive protein and the human serum monomeric protein displayed a molecular weight of approximately 23 kDa, both were recognized by the same anti-CRP monoclonal antibody and both reversibly bound to phosphocholine in a calcium-dependent manner. Calcium 250-257 C-reactive protein Homo sapiens 28-46 31806506-7 2020 RESULTS: The steroid group showed significantly lower CRP levels on POD 2 (P < .05) and POD 4 (P < .05) but a higher CRP level on POD 6 (P < .05). Steroids 13-20 C-reactive protein Homo sapiens 54-57 31806506-7 2020 RESULTS: The steroid group showed significantly lower CRP levels on POD 2 (P < .05) and POD 4 (P < .05) but a higher CRP level on POD 6 (P < .05). Steroids 13-20 C-reactive protein Homo sapiens 123-126 31806506-9 2020 Peak values in CRP and ESR in the steroid group (POD 4 and 6) appeared two days later compared with the non-steroid group (POD 2 and 4). Steroids 34-41 C-reactive protein Homo sapiens 15-18 32117266-0 2020 Monomeric C-Reactive Protein in Serum With Markedly Elevated CRP Levels Shares Common Calcium-Dependent Ligand Binding Properties With an in vitro Dissociated Form of C-Reactive Protein. Calcium 86-93 C-reactive protein Homo sapiens 61-64 31587982-10 2020 The DEX group also had lower rates of nausea and vomiting: 29/50 (58%) vs 42/50 (84%) (P = .008) and lower mean C-reactive protein level: 89 vs 167, Delta = -78 mg/L (95% CI, -100 to -58 mg/L, P < .0001). Dexamethasone 4-7 C-reactive protein Homo sapiens 112-130 31790604-6 2020 Furthermore, MEL ingestion attenuated the hematologic parameters before and after exercise (White Blood Cells (WBC: p < .001 and p < .001, respectively); Neutrophiles (NE: p < .001 and p < .001, respectively); Lymphocytes (LY: p < .001 and p < .001, respectively)) and the ultra-sensitive C-reactive protein (us-CRP: p < .001 and p < .001; respectively) compared to PLA. Melatonin 13-16 C-reactive protein Homo sapiens 307-325 31545524-11 2020 C-reactive protein levels reduced with weekly nab-paclitaxel (P = .043). Paclitaxel 50-60 C-reactive protein Homo sapiens 0-18 31006835-9 2020 CONCLUSIONS: Breast cancer patients receiving metformin as treatment for diabetes showed significant reduction in levels of insulin, fasting glucose, CRP, HOMA, leptin, BMI, and Ki-67. Metformin 46-55 C-reactive protein Homo sapiens 150-153 31770074-8 2020 hs-CRP was positively associated with body mass index (BMI) z-score (P < 0.001) and HbA1c (P = 0.012), and negatively with HDL cholesterol (P = 0.029), after adjusting confounding variables, including age, sex, BMI, white blood cell count, PA, and nutritional factors. Cholesterol 127-138 C-reactive protein Homo sapiens 3-6 31770074-10 2020 Conclusions: Elevated hs-CRP is associated with high BMI z-score and HbA1c, and low HDL cholesterol in Korean children and adolescents. Cholesterol 88-99 C-reactive protein Homo sapiens 25-28 31992279-7 2020 Multiple logistic regression was performed for significant oxygen requirements using two different models using age, C-reactive protein (CRP), smoking duration, and BBE score (model 1) and age, CRP, BEP, and PEC (model 2). Oxygen 59-65 C-reactive protein Homo sapiens 117-135 31992279-7 2020 Multiple logistic regression was performed for significant oxygen requirements using two different models using age, C-reactive protein (CRP), smoking duration, and BBE score (model 1) and age, CRP, BEP, and PEC (model 2). Oxygen 59-65 C-reactive protein Homo sapiens 137-140 31963691-10 2020 During severe pancreatitis, calcium supplementation in saline pH 7.4, unlike lactate, prevented hypocalcemia, increased NEFA saponification, reduced circulating NEFA and C-reactive protein , reduced pancreatic necrosis adjacent to fat necrosis, and normalized shock (carotid pulse distension) and blood urea nitrogen elevation on day 1. Calcium 28-35 C-reactive protein Homo sapiens 170-188 32002126-0 2020 Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer. Paclitaxel 115-125 C-reactive protein Homo sapiens 44-62 32002126-9 2020 Low levels of NLR and CRP at baseline were significantly associated with improved prognosis in patients treated with bevacizumab plus paclitaxel. Paclitaxel 134-144 C-reactive protein Homo sapiens 22-25 32674229-7 2020 CHP administration improved postoperative thirst and hunger and resulted in increased albumin levels and decreased CRP concentrations and blood glucose fluctuations. chp 0-3 C-reactive protein Homo sapiens 115-118 31746314-8 2020 NOx significantly predicted cIMT (P=0.014) in simple and multiple analysis (P=0.036) adjusted for Framingham score, C-reactive protein, serum creatinine and parathormone. Nitric Oxide 0-3 C-reactive protein Homo sapiens 116-134 31923274-6 2020 Markers of tryptophan degradation by the kynurenine pathway (kynurenine/tryptophan ratio) and activation of vitamin B6 catabolism (pyridoxic acid/(pyridoxal + pyridoxal 5"-phosphate), PAr index) differed in survivors with or without CF and correlated with known markers of immune activation and inflammation, such as neopterin, C-reactive protein and Interleukin-6. Tryptophan 11-21 C-reactive protein Homo sapiens 328-346 31483910-8 2020 RESULTS: After treatment with resveratrol, it was found that serum levels of IL-6, IL-1beta, TNF-alpha, IL-18, NF-kappaB, and CRP decreased in treatment group. Resveratrol 30-41 C-reactive protein Homo sapiens 126-129 32280080-0 2020 Effects of nimodipine combined with betahistine on CRP and other inflammatory cytokines and vascular endothelial function in patients with hypertensive cerebral vasospasm. Nimodipine 11-21 C-reactive protein Homo sapiens 51-54 32280080-1 2020 OBJECTIVE: This study aims to investigate the effect of nimodipine combined with betahistine on the levels of CRP and other inflammatory cytokines, as well as vascular endothelial function in patients with hypertensive cerebral vasospasm. Nimodipine 56-66 C-reactive protein Homo sapiens 110-113 32551440-7 2020 Anemia, hypoalbuminemia, increased FC, and elevated CRP were more frequently present in Zn-insufficient patients with IBD. Zinc 88-90 C-reactive protein Homo sapiens 52-55 32551440-8 2020 In contrast, lower serum CRP values and a trend to lower FC were observed in Cu-insufficient patients. Copper 77-79 C-reactive protein Homo sapiens 25-28 32551440-9 2020 In multiple linear regression models adjusted for age, gender, and serum albumin, CRP positively correlated with serum Cu (P < 0.001) and the Cu/Zn ratio in both CD and UC (P < 0.001) but not with serum Zn concentrations. Copper 119-121 C-reactive protein Homo sapiens 82-85 32551440-9 2020 In multiple linear regression models adjusted for age, gender, and serum albumin, CRP positively correlated with serum Cu (P < 0.001) and the Cu/Zn ratio in both CD and UC (P < 0.001) but not with serum Zn concentrations. Copper 142-144 C-reactive protein Homo sapiens 82-85 32551440-9 2020 In multiple linear regression models adjusted for age, gender, and serum albumin, CRP positively correlated with serum Cu (P < 0.001) and the Cu/Zn ratio in both CD and UC (P < 0.001) but not with serum Zn concentrations. Zinc 145-147 C-reactive protein Homo sapiens 82-85 32551440-9 2020 In multiple linear regression models adjusted for age, gender, and serum albumin, CRP positively correlated with serum Cu (P < 0.001) and the Cu/Zn ratio in both CD and UC (P < 0.001) but not with serum Zn concentrations. Zinc 203-205 C-reactive protein Homo sapiens 82-85 31982934-1 2020 OBJECTIVES: This study aims to (1) assess the associations between sugar-sweetened beverages (SSB) consumption and C-reactive protein (CRP) levels, and (2) evaluate the modifying effect of body mass index (BMI) on the association between SSB consumption and CRP levels. Carbohydrates 67-72 C-reactive protein Homo sapiens 115-133 33877102-7 2020 Vitamin D had a significant negative correlation with US-CRP (p = 0.026), NLR (p = 0.013) and PLR (p = 0.022). Vitamin D 0-9 C-reactive protein Homo sapiens 57-60 33877102-9 2020 The values of US-CRP, NLR and PLR were significantly higher in the presence of vitamin D deficiency. Vitamin D 79-88 C-reactive protein Homo sapiens 17-20 33877102-10 2020 A significant inverse correlation was found between vitamin D levels and US-CRP, NLR and PLR. Vitamin D 52-61 C-reactive protein Homo sapiens 76-79 31982934-1 2020 OBJECTIVES: This study aims to (1) assess the associations between sugar-sweetened beverages (SSB) consumption and C-reactive protein (CRP) levels, and (2) evaluate the modifying effect of body mass index (BMI) on the association between SSB consumption and CRP levels. Carbohydrates 67-72 C-reactive protein Homo sapiens 135-138 33356789-14 2020 Hs-CRP has statistically significant associations between alcohol use, dementia, white blood cell count, and HDL levels. Alcohols 58-65 C-reactive protein Homo sapiens 3-6 32156842-0 2020 The Effects of Nano-curcumin Supplementation on Serum Level of hs-CRP, Adhesion Molecules, and Lipid Profiles in Hemodialysis Patients, A Randomized Controlled Clinical Trial. Curcumin 20-28 C-reactive protein Homo sapiens 66-69 32156842-4 2020 RESULTS: The results revealed that the mean serum hs-CRP level in the nano-curcumin group exhibited a decrease by the end of the study, when compared to mean serum hs-CRP level in the placebo group. Curcumin 75-83 C-reactive protein Homo sapiens 53-56 32156842-4 2020 RESULTS: The results revealed that the mean serum hs-CRP level in the nano-curcumin group exhibited a decrease by the end of the study, when compared to mean serum hs-CRP level in the placebo group. Curcumin 75-83 C-reactive protein Homo sapiens 167-170 32149559-6 2020 In binary logistic regression models, young and middle-aged adults chronically exposed to cadmium were significantly more likely to have elevated CRP mg/dL levels. Cadmium 90-97 C-reactive protein Homo sapiens 146-149 33086971-5 2020 Initially, steroid administration achieved remission, but her symptoms and high CRP levels relapsed every time the steroid dosage was tapered down. Steroids 115-122 C-reactive protein Homo sapiens 80-83 32962582-6 2020 In addition, serum disulfide level was positively correlated with CRP (r=0.736, p<0.001) and disulfide/native thiol ratio (r=0.779, p<0.001). Disulfides 19-28 C-reactive protein Homo sapiens 66-69 32962582-7 2020 Furthermore, in multiple regression analyses, the disulfide level was independently associated with CRP (beta=0.226, p=0.005). Disulfides 50-59 C-reactive protein Homo sapiens 100-103 30606276-6 2020 In a sub-sample of cases and controls with available CRP values, patients with high CRP (&gt;3 mg/L) had 1.9 times the odds of suicide attempt compared with patients with low CRP (&lt;1 mg/L). Adenosine Monophosphate 10-13 C-reactive protein Homo sapiens 84-87 33242860-7 2020 After the steroid pulse therapy, the C-reactive protein (CRP) decreased from 6.47 mg/dL to 0.76 mg/dL, but there was little improvement in the symptoms, and the CRP then increased to 4.44 mg/dL. Steroids 10-17 C-reactive protein Homo sapiens 37-55 30606276-6 2020 In a sub-sample of cases and controls with available CRP values, patients with high CRP (&gt;3 mg/L) had 1.9 times the odds of suicide attempt compared with patients with low CRP (&lt;1 mg/L). Adenosine Monophosphate 10-13 C-reactive protein Homo sapiens 84-87 30606276-6 2020 In a sub-sample of cases and controls with available CRP values, patients with high CRP (&gt;3 mg/L) had 1.9 times the odds of suicide attempt compared with patients with low CRP (&lt;1 mg/L). Adenosine Monophosphate 90-93 C-reactive protein Homo sapiens 84-87 30606276-6 2020 In a sub-sample of cases and controls with available CRP values, patients with high CRP (&gt;3 mg/L) had 1.9 times the odds of suicide attempt compared with patients with low CRP (&lt;1 mg/L). Adenosine Monophosphate 90-93 C-reactive protein Homo sapiens 84-87 31780028-0 2019 Effect of l-arginine supplementation on C-reactive protein and other inflammatory biomarkers: A systematic review and meta-analysis of randomized controlled trials. Arginine 10-20 C-reactive protein Homo sapiens 40-58 31888286-6 2019 The application of phosphate-buffered saline (PBS) and human serum (HS) samples containing different concentrations of CRP in the electrode array caused changes in the electrode interfacial capacitance upon CRP binding. Phosphates 19-28 C-reactive protein Homo sapiens 119-122 31888286-6 2019 The application of phosphate-buffered saline (PBS) and human serum (HS) samples containing different concentrations of CRP in the electrode array caused changes in the electrode interfacial capacitance upon CRP binding. Phosphates 19-28 C-reactive protein Homo sapiens 207-210 31288869-6 2019 After adjustments, we found that individuals consuming more choline had worse lipid profile and glucose homeostasis, but lower CRP levels (p &lt; 0 001 for all comparisons) with no significant differences in anthropometric parameters and blood pressure. Adenosine Monophosphate 142-145 C-reactive protein Homo sapiens 127-130 32099860-8 2020 Vitamin D was positively correlated with CRP, ESR level, the BASFI, and the BASMI. Vitamin D 0-9 C-reactive protein Homo sapiens 41-44 31504095-11 2019 In mixed models, CRP was associated with ferritin (positive) and serum iron and retinol (negative, P < 0.05). Iron 71-75 C-reactive protein Homo sapiens 17-20 31926627-9 2020 After multivariable adjustment, plasma copper was positively associated with serum CRP (FDR < 0.001), whereas selenium was negatively associated with serum CRP (FDR = 0.01). Copper 39-45 C-reactive protein Homo sapiens 83-86 31926627-10 2020 Moreover, selenium and zinc attenuated the positive association between high plasma copper and CRP (P for interaction < 0.001). Copper 84-90 C-reactive protein Homo sapiens 95-98 31926627-12 2020 Furthermore, the genetic association with CRP was modified by copper concentration (P for interaction < 0.001). Copper 62-68 C-reactive protein Homo sapiens 42-45 31926627-13 2020 CONCLUSIONS: Our results suggest that serum CRP is positively associated with plasma concentration of copper, and inversely associated with selenium. Copper 102-108 C-reactive protein Homo sapiens 44-47 31926627-14 2020 Plasma zinc, selenium and CRP genetic predisposition would modify the associations between plasma copper and serum CRP. Copper 98-104 C-reactive protein Homo sapiens 26-29 31926627-14 2020 Plasma zinc, selenium and CRP genetic predisposition would modify the associations between plasma copper and serum CRP. Copper 98-104 C-reactive protein Homo sapiens 115-118 32114587-12 2020 Multivariant analysis showed CRP and Hb levels to be independent prognostic parameters for CSS and OS. Osmium 99-101 C-reactive protein Homo sapiens 29-32 31780025-1 2019 OBJECTIVE: The aim of the current study was to assess the effects of curcumin supplementation on glycemic status, lipid profile and high sensitivity C-reactive protein (hs-CRP) serum levels in women with polycystic ovary syndrome (PCOS). Curcumin 69-77 C-reactive protein Homo sapiens 149-167 31780028-1 2019 OBJECTIVES: We carried out a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the effect of L-arginine on inflammatory biomarkers including C-reactive protein (CRP), interleukin-6 (IL-6) and TNFalpha. Arginine 128-138 C-reactive protein Homo sapiens 176-194 31780028-7 2019 However, when subgroup analysis was performed, we found that L-arginine supplementation increased CRP levels in subjects with ages >60 years old, participants with baseline circulating CRP levels >3 mg/dl, patients with cancer and when used in enteral formula. Arginine 61-71 C-reactive protein Homo sapiens 98-101 31780028-7 2019 However, when subgroup analysis was performed, we found that L-arginine supplementation increased CRP levels in subjects with ages >60 years old, participants with baseline circulating CRP levels >3 mg/dl, patients with cancer and when used in enteral formula. Arginine 61-71 C-reactive protein Homo sapiens 185-188 31780028-8 2019 CONCLUSION: Results of the present meta-analysis indicated that L-arginine supplementation increased the circulating concentrations of CRP in subjects with ages >60 years old, subjects with higher levels of CRP, patients with cancer and when used in enteral formula. Arginine 64-74 C-reactive protein Homo sapiens 135-138 31780028-8 2019 CONCLUSION: Results of the present meta-analysis indicated that L-arginine supplementation increased the circulating concentrations of CRP in subjects with ages >60 years old, subjects with higher levels of CRP, patients with cancer and when used in enteral formula. Arginine 64-74 C-reactive protein Homo sapiens 207-210 31668733-0 2019 Role of Serum High-Sensitivity C-Reactive Protein as a Predictor of Therapeutic Response to Tadalafil in Patients With Erectile Dysfunction: A Prospective Observational Study. Tadalafil 92-101 C-reactive protein Homo sapiens 31-49 31610512-0 2019 Roles of C-reactive protein on the association between urinary cadmium and type 2 diabetes. Cadmium 63-70 C-reactive protein Homo sapiens 9-27 31610512-3 2019 In this study, we aim to investigate the roles of C-reactive protein (CRP) on the association between urinary Cd and type 2 diabetes risk. Cadmium 110-112 C-reactive protein Homo sapiens 50-68 31610512-3 2019 In this study, we aim to investigate the roles of C-reactive protein (CRP) on the association between urinary Cd and type 2 diabetes risk. Cadmium 110-112 C-reactive protein Homo sapiens 70-73 31610512-9 2019 Compared to those when both Cd and CRP levels were low, the adjusted ORs (95%CI) of type 2 diabetes was the highest [2.053(1.395-3.020)] in individuals with high levels of urinary Cd and plasma CRP. Cadmium 180-182 C-reactive protein Homo sapiens 35-38 31610512-9 2019 Compared to those when both Cd and CRP levels were low, the adjusted ORs (95%CI) of type 2 diabetes was the highest [2.053(1.395-3.020)] in individuals with high levels of urinary Cd and plasma CRP. Cadmium 180-182 C-reactive protein Homo sapiens 194-197 31610512-12 2019 Plasma CRP may serve as a mediator in the association between urinary Cd and type 2 diabetes risk, providing clues for further study on the biological pathway for type 2 diabetes related to Cd exposure. Cadmium 70-72 C-reactive protein Homo sapiens 7-10 31610512-12 2019 Plasma CRP may serve as a mediator in the association between urinary Cd and type 2 diabetes risk, providing clues for further study on the biological pathway for type 2 diabetes related to Cd exposure. Cadmium 190-192 C-reactive protein Homo sapiens 7-10 31668733-3 2019 AIM: The aim of this study was to understand the relationship among hs-CRP, mechanism of ED, and therapeutic response of ED to tadalafil, a phosphodiesterase-5 inhibitor. Tadalafil 127-136 C-reactive protein Homo sapiens 71-74 31668733-8 2019 MAIN OUTCOME MEASURE: The main outcome measure was the therapeutic response to tadalafil, in relation to the mechanism of ED and hs-CRP levels. Tadalafil 79-88 C-reactive protein Homo sapiens 132-135 31668733-11 2019 Those showing improvement with tadalafil had lower hs-CRP at baseline (median 1.5 mg/L [interquartile range 0.9-2.3] vs 2.0 mg/L [interquartile range 1.1-3.1; P = .034]) and had proportionately greater reduction in its level. Tadalafil 31-40 C-reactive protein Homo sapiens 54-57 31668733-14 2019 STRENGTHS & LIMITATIONS: This is the largest study to evaluate the relationship among the mechanism of ED, serum hs-CRP level, and therapeutic response of ED to tadalafil. Tadalafil 161-170 C-reactive protein Homo sapiens 116-119 31668733-17 2019 CONCLUSION: Serum hs-CRP level is higher in vasculogenic ED compared with non-vasculogenic ED, and is associated with poorer response to tadalafil therapy. Tadalafil 137-146 C-reactive protein Homo sapiens 21-24 31668733-20 2019 Role of Serum High-Sensitivity C-Reactive Protein as a Predictor of Therapeutic Response to Tadalafil in Patients With Erectile Dysfunction: A Prospective Observational Study. Tadalafil 92-101 C-reactive protein Homo sapiens 31-49 31723229-0 2019 The Vitamin D status is associated with serum C-reactive protein and adhesion molecules in patients with renal cell carcinoma. Vitamin D 4-13 C-reactive protein Homo sapiens 46-64 31546116-11 2019 The C-reactive protein (CRP) levels were greater in the prediabetes group than the normal glucose group (0.37 +- 0.07 vs. 0.18 +- 0.06 mg/L). Glucose 90-97 C-reactive protein Homo sapiens 24-27 31450416-0 2019 A C-reactive protein immunosensor based on platinum nanowire / titania nanotube composite sensitized electrochemiluminescence. Platinum 43-51 C-reactive protein Homo sapiens 2-20 31771607-8 2019 The malaria pathway upregulates C-reactive protein and serum hepcidin, thereby reducing iron absorption. Iron 88-92 C-reactive protein Homo sapiens 32-50 31752150-11 2019 The five components of MetS indicated that abdominal obesity and a high serum triglyceride (TG) concentration were tightly linked with ALT, SUA, LDL, and CRP; while a low HDL concentration and elevated blood pressure were related to enhanced ALT, UA, and CRP. Triglycerides 78-90 C-reactive protein Homo sapiens 154-157 31752150-11 2019 The five components of MetS indicated that abdominal obesity and a high serum triglyceride (TG) concentration were tightly linked with ALT, SUA, LDL, and CRP; while a low HDL concentration and elevated blood pressure were related to enhanced ALT, UA, and CRP. Triglycerides 92-94 C-reactive protein Homo sapiens 154-157 31752150-11 2019 The five components of MetS indicated that abdominal obesity and a high serum triglyceride (TG) concentration were tightly linked with ALT, SUA, LDL, and CRP; while a low HDL concentration and elevated blood pressure were related to enhanced ALT, UA, and CRP. Triglycerides 92-94 C-reactive protein Homo sapiens 255-258 31731651-7 2019 Vitamin D supplementation was associated with a decreasing trend of iPTH and C-reactive protein (CRP) (p < 0.001). Vitamin D 0-9 C-reactive protein Homo sapiens 77-95 31731651-7 2019 Vitamin D supplementation was associated with a decreasing trend of iPTH and C-reactive protein (CRP) (p < 0.001). Vitamin D 0-9 C-reactive protein Homo sapiens 97-100 31723229-2 2019 This study investigated the association of vitamin D status with serum C-reactive protein (CRP) and adhesion molecules among RCC patients. Vitamin D 43-52 C-reactive protein Homo sapiens 71-89 31723229-2 2019 This study investigated the association of vitamin D status with serum C-reactive protein (CRP) and adhesion molecules among RCC patients. Vitamin D 43-52 C-reactive protein Homo sapiens 91-94 31699008-2 2021 Recently, scientists studied L-arginine effect on inflammatory mediators such as C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6). Arginine 29-39 C-reactive protein Homo sapiens 81-99 31781024-8 2019 The multivariate binary regression analysis revealed that the CRP/albumin ratio was independently associated with unfavorable outcomes after adjustment for age, WFNS grade, serum glucose, albumin, Fisher score, symptomatic cerebral vasospasm, intraventricular hemorrhage, and delayed cerebral ischemia. Glucose 179-186 C-reactive protein Homo sapiens 62-65 31699008-2 2021 Recently, scientists studied L-arginine effect on inflammatory mediators such as C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6). Arginine 29-39 C-reactive protein Homo sapiens 101-104 31483873-8 2019 Multivariate linear regression was performed to test the relationships between alcohol consumption and systemic oxidative stress (4-hydroxynonenal; 4-HNE) and inflammation (c-reactive protein; CRP). Alcohols 79-86 C-reactive protein Homo sapiens 173-191 31228727-8 2019 Combining 12 effect sizes from 11 studies, a significant reduction was found in serum CRP concentrations following administration of Atorvastatin (WMD: -0.57; 95% CI: -0.78, -0.35). Atorvastatin 133-145 C-reactive protein Homo sapiens 86-89 31646893-8 2021 Partial correlation analysis showed that the mean least oxygen saturation was significantly correlated with CRP after adjustment for BMI Pearson"s correlation coefficients examining the relationship between BMI and total cholesterol; TG and CRP were found to be 0.531, 0.401, and 0.321. Oxygen 56-62 C-reactive protein Homo sapiens 108-111 30885444-0 2019 Vitamin D deficiency in a psychiatric population and correlation between vitamin D and CRP. Vitamin D 73-82 C-reactive protein Homo sapiens 87-90 30885444-2 2019 The secondary objective was to investigate a correlation between 25(OH)D and CRP. 25(oh)d 65-72 C-reactive protein Homo sapiens 77-80 30885444-8 2019 25(OH)D varied with age, ethnic origin, BMI, season, CRP and medical history. 25(oh)d 0-7 C-reactive protein Homo sapiens 53-56 30885444-11 2019 25(OH)D was inversely correlated with CRP. 25(oh)d 0-7 C-reactive protein Homo sapiens 38-41 30885444-13 2019 25(OH)D was inversely correlated with CRP as observed in the general population. 25(oh)d 0-7 C-reactive protein Homo sapiens 38-41 31356558-8 2019 Increase in vitamin D levels correlated with reduction in UCDAI score (P<=0.001; rho=-0.713), C-reactive protein (P<=0.001; rho=-0.603), and calprotectin (P=0.004; rho=-0.368). Vitamin D 12-21 C-reactive protein Homo sapiens 94-112 31651331-10 2019 CONCLUSIONS: Although the effectiveness of LZD and DAP was equivalent in terms of infection control rates for refractory PJIs with gram-positive pathogens, DAP therapy significantly decreased CRP levels and caused fewer adverse events than LZD treatment. Daptomycin 156-159 C-reactive protein Homo sapiens 192-195 31646893-8 2021 Partial correlation analysis showed that the mean least oxygen saturation was significantly correlated with CRP after adjustment for BMI Pearson"s correlation coefficients examining the relationship between BMI and total cholesterol; TG and CRP were found to be 0.531, 0.401, and 0.321. Oxygen 56-62 C-reactive protein Homo sapiens 241-244 31646893-8 2021 Partial correlation analysis showed that the mean least oxygen saturation was significantly correlated with CRP after adjustment for BMI Pearson"s correlation coefficients examining the relationship between BMI and total cholesterol; TG and CRP were found to be 0.531, 0.401, and 0.321. Cholesterol 221-232 C-reactive protein Homo sapiens 108-111 31646893-9 2021 The correlation of CRP levels with disease severity as assessed by RDI, ESS, and least oxygen saturation was significant after adjustment for BMI. Oxygen 87-93 C-reactive protein Homo sapiens 19-22 30459099-7 2019 Vitamin D and probiotic co-supplementation significantly decreased triglycerides (P = 0.02), VLDL-cholesterol (P = 0.02) and hs-CRP (P = 0.01), and significantly increased TAC (P = 0.006) and total glutathione levels (P = 0.04) compared with only probiotic group. Vitamin D 0-9 C-reactive protein Homo sapiens 128-131 31432072-8 2019 Analyses using KEGG-defined pathways revealed statistically significant differences in tryptophan metabolism between diets, with kynurenine and melatonin positively associated with serum C-reactive protein concentrations. Melatonin 144-153 C-reactive protein Homo sapiens 187-205 32598808-0 2019 [Preprocedural high - sensitivity C-reactive protein (hsCRP) decrease during intensive atorvastatin therapy: the presumable impact on atherosclerosis progression after coronary stenting]. Atorvastatin 87-99 C-reactive protein Homo sapiens 34-52 31547562-15 2019 Additionally, after adjusting for BMI and total energy intake, testosterone levels showed significant negative correlations with PREDIMED score (p < 0.001) and consumption of protein (p = 0.005), complex carbohydrate (p < 0.001), fiber (p < 0.001), MUFA (p < 0.001), n-3 PUFA (p = 0.001), and positive associations with CRP levels, simple carbohydrate, SFA, n-6 PUFA (p < 0.001, respectively), and PUFA (p = 0.002). Testosterone 63-75 C-reactive protein Homo sapiens 332-335 31519292-0 2019 Effect of Berberine on C-reactive protein: A systematic review and meta-analysis of randomized controlled trials. Berberine 10-19 C-reactive protein Homo sapiens 23-41 31364019-8 2019 High positive correlations were found between Cd levels of participants and IL-6, IL-10, TNF-alpha and CRP levels (r = 0.568, r = 0.615, r = 0.614 and r = 0.296, respectively, p < 0.01). Cadmium 46-48 C-reactive protein Homo sapiens 103-106 31444965-9 2019 In pre-obese and obese children, a positive correlation was found between CRP and copper (r = 0.305, p = 0.011 and r = 0.440, p = 0.013, respectively), and TAS and RBP (r = 0.528, p < 0.001 and r = 0.434, p = 0.015, respectively). Copper 82-88 C-reactive protein Homo sapiens 74-77 30983166-12 2019 C-reactive protein level was also significantly lower in the atorvastatin group than the placebo group (median 2.59 mg/liter [IQR 0.94, 6.08] versus 3.60 mg/liter [IQR 1.47, 7.49]; P < 0.0001). Atorvastatin 61-73 C-reactive protein Homo sapiens 0-18 31474368-4 2019 We show that microbes integrate cues from metformin and the diet through the phosphotransferase signaling pathway that converges on the transcriptional regulator Crp. Metformin 42-51 C-reactive protein Homo sapiens 162-165 31326727-0 2019 Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. Metformin 32-41 C-reactive protein Homo sapiens 97-115 30606506-1 2019 BACKGROUND & OBJECTIVES: Recent studies have shown that the C-reactive protein-to-albumin ratio (CAR) can predict the mortality in patients with hepatocellular carcinoma (HCC). Adenosine Monophosphate 12-15 C-reactive protein Homo sapiens 64-82 31432820-0 2019 A zirconium-based metal-organic framework sensitized by thioflavin-T for sensitive photoelectrochemical detection of C-reactive protein. Zirconium 2-11 C-reactive protein Homo sapiens 117-135 31432820-0 2019 A zirconium-based metal-organic framework sensitized by thioflavin-T for sensitive photoelectrochemical detection of C-reactive protein. Metals 18-23 C-reactive protein Homo sapiens 117-135 31432820-1 2019 Herein, a novel photoelectrochemical (PEC) assay was developed for the sensitive detection of C-reactive protein (CRP) based on a zirconium-based metal-organic framework (PCN-777) as the photoelectric material and thioflavin-T (Th-T) as the effective signal sensitizer coupled with rolling circle amplification (RCA). Zirconium 130-139 C-reactive protein Homo sapiens 94-112 31432820-1 2019 Herein, a novel photoelectrochemical (PEC) assay was developed for the sensitive detection of C-reactive protein (CRP) based on a zirconium-based metal-organic framework (PCN-777) as the photoelectric material and thioflavin-T (Th-T) as the effective signal sensitizer coupled with rolling circle amplification (RCA). Zirconium 130-139 C-reactive protein Homo sapiens 114-117 31432820-1 2019 Herein, a novel photoelectrochemical (PEC) assay was developed for the sensitive detection of C-reactive protein (CRP) based on a zirconium-based metal-organic framework (PCN-777) as the photoelectric material and thioflavin-T (Th-T) as the effective signal sensitizer coupled with rolling circle amplification (RCA). Metals 146-151 C-reactive protein Homo sapiens 94-112 31432820-1 2019 Herein, a novel photoelectrochemical (PEC) assay was developed for the sensitive detection of C-reactive protein (CRP) based on a zirconium-based metal-organic framework (PCN-777) as the photoelectric material and thioflavin-T (Th-T) as the effective signal sensitizer coupled with rolling circle amplification (RCA). Metals 146-151 C-reactive protein Homo sapiens 114-117 30199916-4 2019 RESULTS: The serum high-sensitivity C-reactive protein (hs-CRP) and homeostatic model assessment of insulin resistance (HOMA-IR) levels and odds ratios (ORs) for MS increased across the blood lactate or UA level tertiles (all P for trend<0.05). Lactic Acid 192-199 C-reactive protein Homo sapiens 36-54 30954352-8 2019 In patients without postoperative complications, a secondary peak of inflammatory parameters, CRP (p = 0.015) and PSP (p = 0.004) was observed after HIPEC for 90 min with mitomycinC/doxorubicin or cisplatin but not after 30 min oxaliplatin. Doxorubicin 182-193 C-reactive protein Homo sapiens 94-97 30954352-8 2019 In patients without postoperative complications, a secondary peak of inflammatory parameters, CRP (p = 0.015) and PSP (p = 0.004) was observed after HIPEC for 90 min with mitomycinC/doxorubicin or cisplatin but not after 30 min oxaliplatin. Cisplatin 197-206 C-reactive protein Homo sapiens 94-97 30199916-4 2019 RESULTS: The serum high-sensitivity C-reactive protein (hs-CRP) and homeostatic model assessment of insulin resistance (HOMA-IR) levels and odds ratios (ORs) for MS increased across the blood lactate or UA level tertiles (all P for trend<0.05). Lactic Acid 192-199 C-reactive protein Homo sapiens 59-62 30199916-5 2019 Interactions between lactate and UA with hs-CRP level, HOMA-IR level, and ORs for MS (P<0.05 for all interactions) were also observed. Lactic Acid 21-28 C-reactive protein Homo sapiens 44-47 31338797-0 2019 The effects of vitamin D treatment on glycemic control, serum lipid profiles, and C-reactive protein in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Vitamin D 15-24 C-reactive protein Homo sapiens 82-100 30349011-11 2019 PGE2 contents were positively correlated with some anthropometric parameters and plasmatic CRP in both genders, while the correlation with the plasmatic MMP-1 density was significant only in women. Dinoprostone 0-4 C-reactive protein Homo sapiens 91-94 30349011-14 2019 The positive association between PGE2 and MMP-1 or CRP has been observed in plasma of women. Dinoprostone 33-37 C-reactive protein Homo sapiens 51-54 31338797-10 2019 CONCLUSIONS: This meta-analysis demonstrated the beneficial effects of vitamin D supplementation or treatment on improving fasting glucose, HOMA-IR, triglycerides and cholesterol levels among patients with CKD, though it did not influence insulin, HbA1c, LDL and HDL cholesterol, and CRP levels. Vitamin D 71-80 C-reactive protein Homo sapiens 284-287 31385179-9 2019 Serum 25(OH)D levels showed significant but weak inverse correlations with CRP (r = - 0.205, p = 0.020) and with NLR (r = - 0.219, p = 0.013). 25(oh)d 6-13 C-reactive protein Homo sapiens 75-78 31309655-1 2019 Catechin in green tea might be able to reduce inflammatory mediators; therefore, in this study, we aimed to indicate green tea effects on inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP), and interleukin-6 (IL-6). Catechin 0-8 C-reactive protein Homo sapiens 210-228 31385179-13 2019 CONCLUSION: CRP levels and NLR values were significantly higher in the vitamin D deficiency group. Vitamin D 71-80 C-reactive protein Homo sapiens 12-15 31385179-14 2019 A significant inverse correlation was found between serum vitamin D levels and CRP levels, and NLR and PLR values. Vitamin D 58-67 C-reactive protein Homo sapiens 79-82 31574853-7 2019 MiR-21 levels significantly correlated with clinical systolic and diastolic blood pressure, MAU, C-reactive protein, and CIMT. mir-21 0-6 C-reactive protein Homo sapiens 97-115 30824647-0 2019 Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. tofacitinib 132-143 C-reactive protein Homo sapiens 47-65 29687969-9 2019 CONCLUSIONS: Levels of serum hs-CRP, TNF-alpha and IL-6 are significantly elevated in patients with type 2 DM combined with essential hypertension, which are important factors affecting changes in blood glucose. Glucose 203-210 C-reactive protein Homo sapiens 32-35 31309655-1 2019 Catechin in green tea might be able to reduce inflammatory mediators; therefore, in this study, we aimed to indicate green tea effects on inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP), and interleukin-6 (IL-6). Catechin 0-8 C-reactive protein Homo sapiens 230-233 31095994-9 2019 Combining data from five studies, we found a significant reduction in C-reactive protein (CRP) concentrations after vitamin D supplementation (WMD: -1.74; 95% CI: -2.82, -0.66). Vitamin D 116-125 C-reactive protein Homo sapiens 70-88 31041591-10 2019 Iron status improved in both groups (ferritin to c-reactive protein ratios). Iron 0-4 C-reactive protein Homo sapiens 49-67 31095994-9 2019 Combining data from five studies, we found a significant reduction in C-reactive protein (CRP) concentrations after vitamin D supplementation (WMD: -1.74; 95% CI: -2.82, -0.66). Vitamin D 116-125 C-reactive protein Homo sapiens 90-93 31095994-10 2019 CONCLUSIONS: Overall, the current meta-analysis demonstrated that taking vitamin D supplements among patients with psychiatric disorders had beneficial effects on BDI, PSQI, GSH, TAC and CRP levels, but did not affect other biomarkers of inflammation and oxidative stress. Vitamin D 73-82 C-reactive protein Homo sapiens 187-190 31695383-0 2019 The association between cortisol:C-reactive protein ratio and depressive fatigue is a function of CRP rather than cortisol. Hydrocortisone 24-32 C-reactive protein Homo sapiens 98-101 31695383-4 2019 Results: There was a significant correlation between cortisol:CRP ratio and depression-related fatigue, and this resolved to the effects of CRP rather than cortisol. Hydrocortisone 53-61 C-reactive protein Homo sapiens 62-65 31695383-4 2019 Results: There was a significant correlation between cortisol:CRP ratio and depression-related fatigue, and this resolved to the effects of CRP rather than cortisol. Hydrocortisone 53-61 C-reactive protein Homo sapiens 140-143 30569733-6 2019 Higher baseline SA was linked to higher inflammatory response assessed by higher C-reactive protein values at day 1 and day 3. Superoxides 16-18 C-reactive protein Homo sapiens 81-99 31443557-12 2019 Significant associations between SNAQ-appetite (p = 0.003) and ESAS-appetite (p = 0.013) scores and CRP levels were observed. snaq 33-37 C-reactive protein Homo sapiens 100-103 31411090-0 2019 Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis. Cholesterol 99-110 C-reactive protein Homo sapiens 57-60 31443226-5 2019 Using a cross-sectional design, we found positive associations between dietary acid load and plasma CRP and HbA1c. dietary acid 71-83 C-reactive protein Homo sapiens 100-103 31443226-6 2019 In the multivariable-adjusted models, compared to women with the lowest quartile, the intakes of dietary acid load among women with the highest quartile showed 30-33% increases of CRP and 6-9% increases of HbA1c. dietary acid 97-109 C-reactive protein Homo sapiens 180-183 31443226-7 2019 Our study is the first to demonstrate positive associations between dietary acid load and CRP and HbA1c in breast cancer survivors. dietary acid 68-80 C-reactive protein Homo sapiens 90-93 31039432-17 2019 In a multiple regression analysis, serum CRP levels were independently associated with serum cortisol (B = 4.5 x 10-4, p < 0.001), urine norepinephrine (B = 9.6 x 10-2, p = 0.044) and high-frequency power of heart rate variability (B = -3.7 x 10-2, p = 0.024). Hydrocortisone 93-101 C-reactive protein Homo sapiens 41-44 31377747-6 2019 We found that CRP promoted osteo-/chondrogenic transdifferentiation and aggravated phosphate-induced osteo-/chondrogenic transdifferentiation and calcification of primary human aortic smooth muscle cells (HAoSMCs). Phosphates 83-92 C-reactive protein Homo sapiens 14-17 30853478-8 2019 Moreover, serum levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and C-reactive protein (CRP) were markedly decreased in patients with iron repletion compared with placebo treatment (WMD: -332.48 pg/mL; 95% CI, -497.48 to -167.47; WMD: -4.64 mg/L; 95% CI, -6.12 to -3.17, respectively). Iron 150-154 C-reactive protein Homo sapiens 84-102 30853478-8 2019 Moreover, serum levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and C-reactive protein (CRP) were markedly decreased in patients with iron repletion compared with placebo treatment (WMD: -332.48 pg/mL; 95% CI, -497.48 to -167.47; WMD: -4.64 mg/L; 95% CI, -6.12 to -3.17, respectively). Iron 150-154 C-reactive protein Homo sapiens 104-107 30853478-9 2019 CONCLUSIONS: Our meta-analysis suggests that iron therapy can reduce heart failure hospitalization, increase cardiac function, improve quality of life, and decrease serum levels of NT-proBNP and CRP in patients with heart failure. Iron 45-49 C-reactive protein Homo sapiens 195-198 30503868-9 2019 Strong correlations between V/S ratio and C-reactive protein (r=0.521, p=0.015) and high-density lipoprotein cholesterol (r=-0.576, p<0.001) were observed. Vanadium 28-29 C-reactive protein Homo sapiens 42-60 31039432-17 2019 In a multiple regression analysis, serum CRP levels were independently associated with serum cortisol (B = 4.5 x 10-4, p < 0.001), urine norepinephrine (B = 9.6 x 10-2, p = 0.044) and high-frequency power of heart rate variability (B = -3.7 x 10-2, p = 0.024). Norepinephrine 137-151 C-reactive protein Homo sapiens 41-44 31311491-1 2019 BACKGROUND: This study aimed to evaluate the association between serum vitamin D levels and nonalcoholic fatty liver disease (NAFLD) parameters, such as metabolic syndrome (MS), inflammatory cytokines (tumor necrosis factor, high sensitive C-reactive protein) and adipokines (adiponectin, leptin). Vitamin D 71-80 C-reactive protein Homo sapiens 240-258 31221293-10 2019 In the models adjusted to DMV, the values for reduced albumin and increased CRP were significant. (2R,3R)-2,3-dihydroxy-3-methylpentanoic acid 26-29 C-reactive protein Homo sapiens 76-79 31221293-11 2019 CONCLUSION: A significant association was found between serum albumin and CRP at admission and the outcomes under investigation, LOS and DMV. (2R,3R)-2,3-dihydroxy-3-methylpentanoic acid 137-140 C-reactive protein Homo sapiens 74-77 30633345-0 2019 Fibrinopeptide A induces C-reactive protein expression through the ROS-ERK1/2/p38-NF-kappaB signal pathway in the human umbilical vascular endothelial cells. ros 67-70 C-reactive protein Homo sapiens 25-43 30633345-8 2019 NAC, TTFA, DPI, inhibitors of ERK1/2, p38, and NF-kappaB all downregulated FPA-induced CRP expression. Acetylcysteine 0-3 C-reactive protein Homo sapiens 87-90 30633345-8 2019 NAC, TTFA, DPI, inhibitors of ERK1/2, p38, and NF-kappaB all downregulated FPA-induced CRP expression. Thenoyltrifluoroacetone 5-9 C-reactive protein Homo sapiens 87-90 30633345-9 2019 These results indicate that FPA induces CRP expression in HUVECs via the ROS-ERK1/2/p38-NF-kappaB signal pathway. ros 73-76 C-reactive protein Homo sapiens 40-43 31441836-9 2019 CONCLUSION: The combined administration of TXA + Dexa significantly reduced the level of postoperative CRP and IL-6, relieve postoperative pain, ameliorate the incidence of POVN, provide additional analgesic and antiemetic effects, reduce postoperative fatigue, and improve ROM, without increasing the risk of complications in primary TKA. Dexamethasone 49-53 C-reactive protein Homo sapiens 103-106 29949232-6 2019 Additionally, melatonin intake resulted in a significant reduction in serum high sensitivity C-reactive protein (beta -0.15; 95% CI, -0.27, -0.02; P = 0.02), malondialdehyde (beta -0.31; 95% CI, -0.57, -0.05; P = 0.02) and protein carbonyl (beta -0.06; 95% CI, -0.09, -0.04; P < 0.001). Melatonin 14-23 C-reactive protein Homo sapiens 93-111 31020672-8 2019 In stratified analysis, a significant positive association between vitamin D level and CVD was observed only in the high CRP group. Vitamin D 67-76 C-reactive protein Homo sapiens 121-124 31043057-0 2019 Association between 25-OH-vitamin D and C-reactive protein as a marker of inflammation and cardiovascular risk in clinical practice. 25-oh-vitamin d 20-35 C-reactive protein Homo sapiens 40-58 31020672-10 2019 CONCLUSION: Within a cross-sectional, nationally representative sample, these findings suggest that vitamin D status evaluation, or vitamin D supplement may be especially important for individuals with high CRP levels. Vitamin D 100-109 C-reactive protein Homo sapiens 207-210 31020672-10 2019 CONCLUSION: Within a cross-sectional, nationally representative sample, these findings suggest that vitamin D status evaluation, or vitamin D supplement may be especially important for individuals with high CRP levels. Vitamin D 132-141 C-reactive protein Homo sapiens 207-210 31234146-6 2019 In parallel, the expression of CRP and growth signaling pathway proteins was assessed on cell lines and paraffin-embedded primary pNEN. Paraffin 104-112 C-reactive protein Homo sapiens 31-34 31222137-5 2019 The evaluation of the benefits of drugs may lead to individualized therapy for CKD patients: Cholesterol-lowering treatment for CKD patients with high levels of both LDLc and CRP is suggested. Cholesterol 93-104 C-reactive protein Homo sapiens 175-178 31243577-0 2019 Disposable paper-based electrochemical sensor using thiol-terminated poly(2-methacryloyloxyethyl phosphorylcholine) for the label-free detection of C-reactive protein. Sulfhydryl Compounds 52-57 C-reactive protein Homo sapiens 148-166 31243577-11 2019 Graphical abstract Schematic presentation of highly sensitive and disposable paper-based electrochemical sensor using thiol-terminated poly(2-methacryloyloxyethyl phosphorylcholine) in the presence of Ca2+ for the label-free C-reactive protein detection. Sulfhydryl Compounds 118-123 C-reactive protein Homo sapiens 225-243 31220128-10 2019 The most striking increases in ORs in the group with the highest numbers of risk factors were observed among men in serum GGT: 26.6 (12.4-57.0), ALT: 40.3 (5.3-307.8), CRP: 16.2 (7.8-33.7) and serum triglycerides: 14.4 (8.6-24.0). Triglycerides 199-212 C-reactive protein Homo sapiens 168-171 31153358-5 2019 RESULTS: The SNB with 0.75% ropivacaine not only decreased IL-6 levels in plasma 6 h after craniotomy but also decreased plasma CRP levels and increased plasma IL-10 levels 12 and 24 h after surgery compared to LA and routine analgesia. 1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline 13-16 C-reactive protein Homo sapiens 128-131 31196200-4 2019 RESULTS: Platelet count inversely correlated with blood hemoglobin levels (p < 0.001) and positively correlated with serum levels of CRP and multiple cytokines including IL-1RA, IL-4, IL-6, IL-7, IL-8, IL-12, IFNgamma, and PDGF-BB (p < 0.001 for all), while aspirin use was not associated with the levels of systemic inflammatory markers. Aspirin 258-265 C-reactive protein Homo sapiens 133-136 31176378-8 2019 Skin fold thickness, fasting and post-glucose insulin, HOMA-IR, PTH, LDL, Serum cholesterol and hs-CRP showed statistically significant negative correlations with Vitamin D levels. Vitamin D 163-172 C-reactive protein Homo sapiens 99-102 31153358-5 2019 RESULTS: The SNB with 0.75% ropivacaine not only decreased IL-6 levels in plasma 6 h after craniotomy but also decreased plasma CRP levels and increased plasma IL-10 levels 12 and 24 h after surgery compared to LA and routine analgesia. Ropivacaine 28-39 C-reactive protein Homo sapiens 128-131 30935429-7 2019 However, there were statistically significant interactions on both multiplicative and additive scale between serum folate and C-reactive protein (CRP) levels or smoking status and the associations of lower serum folate with worse LCSS and OS were only evident among patients with CRP &gt; 3 0 mg/l or current smokers. Folic Acid 212-218 C-reactive protein Homo sapiens 146-149 30935429-7 2019 However, there were statistically significant interactions on both multiplicative and additive scale between serum folate and C-reactive protein (CRP) levels or smoking status and the associations of lower serum folate with worse LCSS and OS were only evident among patients with CRP &gt; 3 0 mg/l or current smokers. Folic Acid 212-218 C-reactive protein Homo sapiens 280-283 31032644-6 2019 Vitamin D supplementation in patients with CHF improved health-related quality of life and C-reactive protein levels [weighted mean difference (WMD): 6.75, 95% confidence interval (CI): 2.87 to 10.64, p < .001; standardised mean difference (SMD): -0.41, 95% CI: -0.71 to -0.11, p = .007]. Vitamin D 0-9 C-reactive protein Homo sapiens 91-109 30878797-4 2019 At baseline, median levels of serum CRP significantly differed by demographics (sex, age category, marital status, and education levels) and health behaviors (cigarette smoking status, alcohol drinking status, BMI category, and physical activity levels). Alcohols 185-192 C-reactive protein Homo sapiens 36-39 30878797-5 2019 In the multivariable analysis, the study participants who were women, older, never drinking alcohol, overweight or obese, and physically inactive had increased likelihood of having high CRP levels (>= median levels among all study participants) compared to their counterparts. Alcohols 92-99 C-reactive protein Homo sapiens 186-189 30097651-10 2019 After adjustment for lipid markers, age, and gender, vitamin D deficiency was associated with increased odds of CRP, eGFR, gammaGT, FPG, HbA1c, and the surrogate for CVD. Vitamin D 53-62 C-reactive protein Homo sapiens 112-115 31064976-6 2019 CASE REPORT We describe a case of 38-year-old female with diffuse musculoskeletal pain and elevated ESR and CRP who was initially misdiagnosed with PMR and responded partially to steroids. Steroids 179-187 C-reactive protein Homo sapiens 108-111 31094477-10 2019 And CRP level (r=0.59, p&lt;0.05). Adenosine Monophosphate 25-28 C-reactive protein Homo sapiens 4-7 31131767-7 2019 WSR &lt;300 s-1 was associated with relative risk (RR) of ASCVD presence 11.2 (95 % CI 1.26-99.3, p=0.03), adjusted for factors such as sex, age, smoking, obesity, hypertension, estimated glomerular filtration rate (eGFR), low density lipoprotein cholesterol, and high sensitivity C-reactive protein, carotid intima-media thickness. Adenosine Monophosphate 5-8 C-reactive protein Homo sapiens 285-303 30940490-0 2019 Effects of folic acid supplementation on C-reactive protein: A systematic review and meta-analysis of randomized controlled trials. Folic Acid 11-21 C-reactive protein Homo sapiens 41-59 31065018-5 2019 Compared with placebo groups, steroids application could effectively relieve pain on postoperative day (POD)1; decrease C-Reactive protein (CRP) level on POD3; improve range of motion (ROM) in postoperative 5 days; reduce morphine consumption, achieve earlier straight leg raising (SLR), and shorten the length of stay (LOS) in hospital. Steroids 30-38 C-reactive protein Homo sapiens 120-138 31065018-5 2019 Compared with placebo groups, steroids application could effectively relieve pain on postoperative day (POD)1; decrease C-Reactive protein (CRP) level on POD3; improve range of motion (ROM) in postoperative 5 days; reduce morphine consumption, achieve earlier straight leg raising (SLR), and shorten the length of stay (LOS) in hospital. Steroids 30-38 C-reactive protein Homo sapiens 140-143 30794428-8 2019 We thus present convincing evidence demonstrating CRP as a therapeutic target for DKD treatment.-Zhang, L., Shen, Z.-Y., Wang, K., Li, W., Shi, J.-M., Osoro, E. K., Ullah, N., Zhou, Y., Ji, S.-R. C-reactive protein exacerbates epithelial-mesenchymal transition through Wnt/beta-catenin and ERK signaling in streptozocin-induced diabetic nephropathy. Streptozocin 307-319 C-reactive protein Homo sapiens 50-53 30940490-1 2019 BACKGROUND AND AIM: Given the contradictory results of previous randomized controlled trials (RCTs), we performed a systematic review and meta-analysis to quantify and summarize the effects of folic acid supplementation on C-reactive protein (CRP). Folic Acid 193-203 C-reactive protein Homo sapiens 223-241 30940490-1 2019 BACKGROUND AND AIM: Given the contradictory results of previous randomized controlled trials (RCTs), we performed a systematic review and meta-analysis to quantify and summarize the effects of folic acid supplementation on C-reactive protein (CRP). Folic Acid 193-203 C-reactive protein Homo sapiens 243-246 30940490-3 2019 RCTs that investigated the effect of folate on CRP were included in the present study. Folic Acid 37-43 C-reactive protein Homo sapiens 47-50 30940490-7 2019 Pooled analysis results showed that folate supplementation significantly lowered the serum CRP level (weighted mean difference (WMD): -0.685 mg/l, 95% CI: -1.053, -0.318, p < 0.001). Folic Acid 36-42 C-reactive protein Homo sapiens 91-94 30940490-11 2019 CONCLUSION: This meta-analysis suggested that folic acid supplementation could significantly lower the serum CRP level. Folic Acid 46-56 C-reactive protein Homo sapiens 109-112 30940490-12 2019 Folic acid leads to greater CRP lowering effect in women, patients with T2DM, and those with less than 12-week intervention. Folic Acid 0-10 C-reactive protein Homo sapiens 28-31 31080419-8 2019 Patients with CD with above-average free thiols had significantly lower CRP levels (median 1.4 [interquartile range] [0.4; 2.6] vs. 3.6 [0.6; 7.0] mg/L; P < 0.05) and BMI (23.6 +- 4.8 vs. 27.1 +- 5.2 kg/m2; P < 0.05). Sulfhydryl Compounds 41-47 C-reactive protein Homo sapiens 72-75 30864188-0 2019 The effects of curcumin supplementation on high-sensitivity C-reactive protein, serum adiponectin, and lipid profile in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Curcumin 15-23 C-reactive protein Homo sapiens 60-78 30864188-8 2019 At the end of study, the mean concentration of high-sensitivity C-reactive protein decreased in the curcumin group compared to the control (2.9 +- 2.9 vs. 3.4 +- 4.2; p < 0.05). Curcumin 100-108 C-reactive protein Homo sapiens 64-82 31114584-12 2019 During evolution, changes in the intrachain disulfide and interchain disulfide bonds and changes in the glycosylation status of CRP may be responsible for different structure-function relationships of CRP in various species. Disulfides 44-53 C-reactive protein Homo sapiens 201-204 31114584-12 2019 During evolution, changes in the intrachain disulfide and interchain disulfide bonds and changes in the glycosylation status of CRP may be responsible for different structure-function relationships of CRP in various species. Disulfides 69-78 C-reactive protein Homo sapiens 201-204 31280277-12 2019 Higher protein intake was accompanied with higher CRP and ESR and higher carbohydrate intake was related to higher CRP and lower nesfatin-1. Carbohydrates 73-85 C-reactive protein Homo sapiens 115-118 31012350-8 2021 For the entire cohort, a positive correlation was found between basal oestradiol (E2) and basal CRP (r = 0.71, p < 0.05). Estradiol 70-80 C-reactive protein Homo sapiens 96-99 30946764-7 2019 RESULTS: Cortisol showed the best predictive ability, with AUCs of 0.758, 0.759 and 0.705 for in-hospital mortality, and 28-day and 90-day mortality, respectively; whereas AUCs for 28 days mortality for SOFA and APACHE II scores, and other biomarkers studied, such as Lactate or CRP, were 0.644, 0.618, 0.643 and 0.647, respectively. Hydrocortisone 9-17 C-reactive protein Homo sapiens 279-282 30293230-3 2019 We evaluated whether the olive-derived polyphenol hydroxytyrosol combined with omega-3 fatty acids and curcumin would reduce CRP and musculoskeletal symptoms in breast cancer patients receiving adjuvant hormonal therapies. Curcumin 103-111 C-reactive protein Homo sapiens 125-128 29752008-13 2019 Interestingly, the Hs-CRP was reduced in AA carries while was elevated in individuals with GG and AG genotypes, after high-dose vitamin D supplementation. Vitamin D 128-137 C-reactive protein Homo sapiens 22-25 30268669-3 2019 The results demonstrated in a step-wise manner that the phosphocholine-modified screen-printed carbon electrodes were highly responsive to the clinically required range of C-reactive protein (CRP) (0.005 - 500 mg L-1; r2 = 0.993) levels with a detection limit (3sigma/slope) of 0.001 mg L-1. Carbon 95-101 C-reactive protein Homo sapiens 172-190 30268669-3 2019 The results demonstrated in a step-wise manner that the phosphocholine-modified screen-printed carbon electrodes were highly responsive to the clinically required range of C-reactive protein (CRP) (0.005 - 500 mg L-1; r2 = 0.993) levels with a detection limit (3sigma/slope) of 0.001 mg L-1. Carbon 95-101 C-reactive protein Homo sapiens 192-195 30293230-10 2019 CONCLUSIONS: The combination of hydroxytyrosol, omega-3 fatty acids, and curcumin reduced inflammation as indicated by a reduction in CRP and reduced pain in patients with aromatase-induced musculoskeletal symptoms. Curcumin 73-81 C-reactive protein Homo sapiens 134-137 30790162-12 2019 Multiple regression analysis revealed that high-sensitive C-reactive protein (p = 0.014) was independent predictor of absolute increase PA. Our study showed that aspirin has limited effect in inhibiting exercise-induced PA, even in the absence of documented CAD. Aspirin 162-169 C-reactive protein Homo sapiens 58-76 30477283-5 2019 RESULTS: In 88 patients with Crohn"s disease (CD), a negative correlation was found between serum vitamin D and CRP. Vitamin D 98-107 C-reactive protein Homo sapiens 112-115 31109413-12 2019 There was a negative correlation between serum calcium level and PCT, APACHE II scores in patients with sepsis (r1 = -2.10, P1 = 0.04; r2 = -3.91, P2 < 0.01), but no correlation with CRP and SOFA score (r1 = 0.75, P1 = 0.46; r2 = -1.21, P2 = 0.23). Calcium 47-54 C-reactive protein Homo sapiens 186-189 30682545-9 2019 CONCLUSION: We found a strong association between 25(OH)D concentrations and the prognostic indicator CCI and clinical complications (acute respiratory insufficiency, acute liver failure, and infections), but no associations with the prognostic indicators APACHE II and SOFA score, CRP, mechanical ventilation duration, or mortality. 25(oh)d 50-57 C-reactive protein Homo sapiens 282-285 30632900-5 2019 In pulmonary arterial hypertension patients, the urinary albumin to creatinine ratio was associated with older age, lower six-minute walking distance, elevated levels of C-reactive protein and hemoglobin A1c, but there was no correlation between the urinary albumin to creatinine ratio and hemodynamic variables. Creatinine 68-78 C-reactive protein Homo sapiens 170-188 31114292-5 2019 Results: An increase of 1 mg dL-1 of postoperative CRP level was significantly associated with 1.4% increase morphine equivalent consumption [exponentiated regression (Exp) coefficient: 0.014, 95% CI (0.011, 0.016), P<0.001], whereas preoperative CRP levels were not significantly associated with morphine equivalent consumption on POD 0-3 (P=0.450). Morphine 109-117 C-reactive protein Homo sapiens 51-54 31114292-5 2019 Results: An increase of 1 mg dL-1 of postoperative CRP level was significantly associated with 1.4% increase morphine equivalent consumption [exponentiated regression (Exp) coefficient: 0.014, 95% CI (0.011, 0.016), P<0.001], whereas preoperative CRP levels were not significantly associated with morphine equivalent consumption on POD 0-3 (P=0.450). Morphine 109-117 C-reactive protein Homo sapiens 250-253 31114292-5 2019 Results: An increase of 1 mg dL-1 of postoperative CRP level was significantly associated with 1.4% increase morphine equivalent consumption [exponentiated regression (Exp) coefficient: 0.014, 95% CI (0.011, 0.016), P<0.001], whereas preoperative CRP levels were not significantly associated with morphine equivalent consumption on POD 0-3 (P=0.450). Morphine 300-308 C-reactive protein Homo sapiens 51-54 31114292-6 2019 A 1 mg dL-1 of increase in CRP level was significantly associated with 1% increase of morphine equivalent consumption [Exp coefficient: 0.010, 95% CI (0.008, 0.012), P<0.001]. Morphine 86-94 C-reactive protein Homo sapiens 27-30 30885233-15 2019 Decreasing HDL-cholesterol levels were associated with increasing triglyceride levels (p < 0.001), increasing high-sensitive C-reactive protein (hs-CRP) levels (p = 0.021), younger age (p < 0.001), male sex (p < 0.001), and depression (p = 0.045). Cholesterol 15-26 C-reactive protein Homo sapiens 129-147 30944864-7 2019 In multivariate analysis, C-reactive protein was the dominant predictor of hepcidin and contributed to iron blockade even at very low levels. Iron 103-107 C-reactive protein Homo sapiens 26-44 30562044-6 2019 When stratified by tertile of C-reactive protein (CRP), a biomarker of inflammation, treatment with aspirin restored a decrement in the live birth rate in women in the highest CRP tertile (relative risk 1.35, 95% confidence interval 1.08-1.67), increasing to similar rates as women of the lower and mid-CRP tertiles. Aspirin 100-107 C-reactive protein Homo sapiens 30-48 30853012-3 2019 In group 1, systemic ABT was administered only when serum CRP was &gt;28.5 mg / l (threshold level of the biomarker calculated at the previous stage of the study); group 2 received a standard treatment. abt 21-24 C-reactive protein Homo sapiens 58-61 30853012-11 2019 CONCLUSION: additional measurement of serum CRP in patients with CHF and suspected non-severe CAP was able to reduce rate of systemic ABT administration without outcomes and prognosis worsening. abt 134-137 C-reactive protein Homo sapiens 44-47 30562044-6 2019 When stratified by tertile of C-reactive protein (CRP), a biomarker of inflammation, treatment with aspirin restored a decrement in the live birth rate in women in the highest CRP tertile (relative risk 1.35, 95% confidence interval 1.08-1.67), increasing to similar rates as women of the lower and mid-CRP tertiles. Aspirin 100-107 C-reactive protein Homo sapiens 50-53 30562044-6 2019 When stratified by tertile of C-reactive protein (CRP), a biomarker of inflammation, treatment with aspirin restored a decrement in the live birth rate in women in the highest CRP tertile (relative risk 1.35, 95% confidence interval 1.08-1.67), increasing to similar rates as women of the lower and mid-CRP tertiles. Aspirin 100-107 C-reactive protein Homo sapiens 176-179 30562044-6 2019 When stratified by tertile of C-reactive protein (CRP), a biomarker of inflammation, treatment with aspirin restored a decrement in the live birth rate in women in the highest CRP tertile (relative risk 1.35, 95% confidence interval 1.08-1.67), increasing to similar rates as women of the lower and mid-CRP tertiles. Aspirin 100-107 C-reactive protein Homo sapiens 176-179 30657241-8 2019 The OR (95% CI) of the highest TG/HDL ratio quartile as compared to the lowest TG/HDL ratio quartile for high PWV was 2.77 (1.16-6.63) after adjusting for age, BMI, smoking status, regular exercise, mean arterial pressure, fasting plasma glucose, total cholesterol level, hypertension, log-transformed C-reactive protein, and the use of antihypertensive and lipid-lowering drugs. Thioguanine 31-33 C-reactive protein Homo sapiens 302-320 30013206-13 2019 CONCLUSION: The analysis indicated possible decreasing effect of resveratrol on CRP, but it might not be able to change IL-6 and TNF-alpha concentrations. Resveratrol 65-76 C-reactive protein Homo sapiens 80-83 30804146-0 2019 Postoperative Level of C-Reactive Protein Is a Prognosticator After Esophageal Cancer Surgery With Perioperative Steroid Therapy and Enhanced Recovery After Surgery Care. Steroids 113-120 C-reactive protein Homo sapiens 23-41 30804146-7 2019 CONCLUSION: The present results suggest that the postoperative CRP level can be a prognosticator in patients with esophageal cancer who have received perioperative steroid therapy and ERAS care. Steroids 164-171 C-reactive protein Homo sapiens 63-66 30006830-10 2019 The stepwise logistic regression analysis revealed that CRP on POD3 >= 12 mg/dl [odds ratio (OR) 2.08, 95% confidence interval (CI) 1.09-3.95, p = 0.025], laparoscopic surgery (OR 2.25, 95% CI 1.17-4.31, p = 0.015), and TG (OR 2.23, 95% CI 1.17-4.78, p = 0.023) were found to be independent risk factors for readmission. Thioguanine 223-225 C-reactive protein Homo sapiens 56-59 30427060-8 2019 Finally, KDM individuals on metformin treatment exhibited significantly lower levels of sCD14, sCD163 and CRP compared with those on non-metformin-containing regimens. Metformin 28-37 C-reactive protein Homo sapiens 106-109 30761568-7 2019 In a post hoc subgroup analysis in patients with baseline CRP <3 mg/L, a significant increase in CRP was observed in CG (1.44 +- 0.82 mg/L to 4.35 +- 7.85 mg/L, p = 0.01), whereas CRP remained unchanged in TG (1.40 +- 0.96 mg/L to 1.33 +- 1.26 mg/L, p = 0.85), resulting in a significant difference between groups at 3 months. Thioguanine 209-211 C-reactive protein Homo sapiens 100-103 30761568-7 2019 In a post hoc subgroup analysis in patients with baseline CRP <3 mg/L, a significant increase in CRP was observed in CG (1.44 +- 0.82 mg/L to 4.35 +- 7.85 mg/L, p = 0.01), whereas CRP remained unchanged in TG (1.40 +- 0.96 mg/L to 1.33 +- 1.26 mg/L, p = 0.85), resulting in a significant difference between groups at 3 months. Thioguanine 209-211 C-reactive protein Homo sapiens 100-103 30761568-8 2019 In patients with CRP >=3 mg/L, a significant reduction in CRP was observed only in TG (11.3 +- 12.8 mg/L to 5.7 +- 4.1 mg/L, p = 0.04). Thioguanine 86-88 C-reactive protein Homo sapiens 17-20 30761568-8 2019 In patients with CRP >=3 mg/L, a significant reduction in CRP was observed only in TG (11.3 +- 12.8 mg/L to 5.7 +- 4.1 mg/L, p = 0.04). Thioguanine 86-88 C-reactive protein Homo sapiens 61-64 30890498-9 2019 Our results showed that metformin treatment decreased MAIBD and relapse frequency in the patients, and significantly lowered the clinical inflammatory indexes including CRP and ESR. Metformin 24-33 C-reactive protein Homo sapiens 169-172 30333073-9 2019 Among single foods, only fruit intake was negatively associated with CRP levels (standardized regression score=-0 043, P&lt;0 01). Adenosine Monophosphate 121-124 C-reactive protein Homo sapiens 69-72 30333073-10 2019 The "Fruits &amp; vegetables" pattern, the Mediterranean and the AHEI scores were negatively associated with CRP levels (standardized regression score=-0 079, -0 043 and -0 067, respectively, all P&lt;0 01). Adenosine Monophosphate 13-16 C-reactive protein Homo sapiens 113-116 30333073-10 2019 The "Fruits &amp; vegetables" pattern, the Mediterranean and the AHEI scores were negatively associated with CRP levels (standardized regression score=-0 079, -0 043 and -0 067, respectively, all P&lt;0 01). Adenosine Monophosphate 17-20 C-reactive protein Homo sapiens 113-116 30823404-4 2019 For instance, higher levels of oxidized phospholipids on apo B-100 lipoproteins (OxPL/apoB) predicted cardiovascular events independent of traditional risk factors, C-reactive protein (hsCRP), and the Framingham Risk Score (FRS). Phospholipids 40-53 C-reactive protein Homo sapiens 165-183 29728047-11 2019 CRP-containing aqueous solutions were treated with poly(MPC)-protected Fe3O4. poly(mpc) 51-60 C-reactive protein Homo sapiens 0-3 30781529-5 2019 As proposed by the BRINDA group, we adjusted individual ferritin concentration by internal regression for circulating concentrations of C-reactive protein (CRP) and alpha1-acid glycoprotein (AGP). brinda 19-25 C-reactive protein Homo sapiens 136-154 29728047-12 2019 After poly(MPC)-protected Fe3O4 nanoparticles were separated using a neodymium magnet and centrifugation, the concentration of CRP in the media dramatically decreased. poly(mpc) 6-15 C-reactive protein Homo sapiens 127-130 29728047-15 2019 Although inhibition tests in the presence of 1,2-dioleoyl- sn-glycero-3-phosphocholine liposomes or free poly(MPC) were also carried out, the binding of poly(MPC)-protected Fe3O4 to CRP was not affected by these inhibitors. poly(mpc) 153-162 C-reactive protein Homo sapiens 182-185 29728047-16 2019 In conclusion, poly(MPC)-brush-bearing magnetic nanoparticles can serve not only as reliable materials for detecting and controlling the levels of CRP in simulated body fluids but also as diagnostic and therapeutic materials. poly(mpc) 15-24 C-reactive protein Homo sapiens 147-150 30651805-8 2019 Analysis showed that there is positive correlation between Cr and CRP (r=0.6961, P<0.001), as well as between Cr and TNF-alpha (r=0.8969, P<0.001); and negative correlation between Cr and BMD (r=0.5472, P<0.001), and between Cr and 25(OH)D (r=0.4733, P<0.001). Creatinine 59-61 C-reactive protein Homo sapiens 66-69 30712159-0 2019 An origami paper-based electrochemical immunoassay for the C-reactive protein using a screen-printed carbon electrode modified with graphene and gold nanoparticles. Carbon 101-107 C-reactive protein Homo sapiens 59-77 30026044-2 2019 A high C-reactive protein (CRP) level is a risk factor for diabetes, and individuals with prediabetes have higher CRP levels than those with normal glucose tolerance. Glucose 148-155 C-reactive protein Homo sapiens 7-25 30026044-2 2019 A high C-reactive protein (CRP) level is a risk factor for diabetes, and individuals with prediabetes have higher CRP levels than those with normal glucose tolerance. Glucose 148-155 C-reactive protein Homo sapiens 27-30 30638307-3 2019 OBJECTIVES: We aimed to evaluate if COPD patients who meet the Medicare guidelines for nocturnal oxygen therapy (iNOT+) had higher serum hs-CRP and IL-6 than those who did not meet the guidelines for iNOT (iNOT-). Oxygen 97-103 C-reactive protein Homo sapiens 140-143 30638307-9 2019 CONCLUSION: COPD patients who have more than 5 minutes and 5% of their sleep time spent at oxygen saturation less than 88% have increased hs-CRP, which is associated with increased risk of future CVD. Oxygen 91-97 C-reactive protein Homo sapiens 141-144 30119141-8 2019 In the multivariate analyses, the N-stage, and CRP/Alb ratio >= 0.1 were identified as independent predictive factors for OS in patients with AEG and UGC (P = 0.0061 and P = 0.0439, respectively). Osmium 125-127 C-reactive protein Homo sapiens 47-50 31485188-5 2019 Moreover, we found that the level of glucose in serum was positively correlated with the APACHE II scores, TNF-alpha and CRP. Glucose 37-44 C-reactive protein Homo sapiens 121-124 30761006-12 2019 CRP not only increased the expression of pro-IL-1beta and NLRP3 via the FcgammaRs/NF-kappaB pathway, but also promoted NLRP3 inflammasome activation and IL-1beta maturation by upregulation of reactive oxygen species (ROS) levels, purinergic receptor signaling, and activation of cysteine proteases. Reactive Oxygen Species 192-215 C-reactive protein Homo sapiens 0-3 30761006-12 2019 CRP not only increased the expression of pro-IL-1beta and NLRP3 via the FcgammaRs/NF-kappaB pathway, but also promoted NLRP3 inflammasome activation and IL-1beta maturation by upregulation of reactive oxygen species (ROS) levels, purinergic receptor signaling, and activation of cysteine proteases. Reactive Oxygen Species 217-220 C-reactive protein Homo sapiens 0-3 30787261-8 2019 After operation, breath acetone correlated significantly with CRP (Spearman"s rho = 0.559, P = 0.03), but not with albumin. Acetone 24-31 C-reactive protein Homo sapiens 62-65 31023051-9 2019 CONCLUSION: Our results showed that vitamin D deficiency predisposed to the development of sepsis, negatively correlated with CRP, presepsin, sTREM-1 and SOFA score and their levels associates with both 7th and 28th days survival of patients (Tab. Vitamin D 36-45 C-reactive protein Homo sapiens 126-129 30255760-6 2019 RESULTS: Results showed that in the NAC group, the serum levels of MDA, NO, IL-6, TNF-alpha, ESR and CRP were significantly lower than the baseline. Acetylcysteine 36-39 C-reactive protein Homo sapiens 101-104 30658193-9 2019 Moreover, we showed that CRP-activated platelets present higher levels of tyrosine phosphorylated PLCgamma2 in obese patients, confirming alterations in GPVI signalling. Tyrosine 74-82 C-reactive protein Homo sapiens 25-28 30518661-4 2019 RESULTS: After multivariable adjustment, a 1 mmol/L (89 mg/dL) higher nonfasting triglyceride concentration was associated with 17% (95% CI, 16%-18%, P = 3 x 10-17) higher plasma C-reactive protein (CRP) and a 4.2% (4.0%-4.4%, P = 6 x 10-17) higher blood leukocyte count. Triglycerides 81-93 C-reactive protein Homo sapiens 179-197 30518661-4 2019 RESULTS: After multivariable adjustment, a 1 mmol/L (89 mg/dL) higher nonfasting triglyceride concentration was associated with 17% (95% CI, 16%-18%, P = 3 x 10-17) higher plasma C-reactive protein (CRP) and a 4.2% (4.0%-4.4%, P = 6 x 10-17) higher blood leukocyte count. Triglycerides 81-93 C-reactive protein Homo sapiens 199-202 30674312-6 2019 Network meta-analysis showed that Fluvastatin (97.7%), Atorvastatin (68.0%) and Rosuvastatin (49.3%) had higher cumulative probability than other statins in reducing CRP in COPD patients. Atorvastatin 55-67 C-reactive protein Homo sapiens 166-169 30674312-9 2019 In addition, Fluvastatin and Atorvastatin are more effective in reducing CRP and PH in COPD patients. Atorvastatin 29-41 C-reactive protein Homo sapiens 73-76 30854952-0 2019 The Effects of Vitamin D Supplementation on Glycemic Control, Lipid Profiles and C-Reactive Protein Among Patients with Cardiovascular Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trials. Vitamin D 15-24 C-reactive protein Homo sapiens 81-99 30854952-3 2019 This systematic review and meta-analysis aimed to determine the effects of vitamin D supplementation on glycemic control, lipid profiles, and C-reactive protein among patients with coronary artery disease. Vitamin D 75-84 C-reactive protein Homo sapiens 142-160 30854952-10 2019 Additionally, vitamin D supplementation significantly reduced C-reactive protein (CRP) levels (WMD: -0.75; 95% CI: -1.28, -0.23). Vitamin D 14-23 C-reactive protein Homo sapiens 62-80 30854952-10 2019 Additionally, vitamin D supplementation significantly reduced C-reactive protein (CRP) levels (WMD: -0.75; 95% CI: -1.28, -0.23). Vitamin D 14-23 C-reactive protein Homo sapiens 82-85 30854952-11 2019 CONCLUSION: This meta-analysis demonstrated the beneficial effects of vitamin D supplementation on improving glycemic control, HDL-cholesterol and CRP levels among patients with CVD, though it did not affect triglycerides, total- and LDL-cholesterol levels. Vitamin D 70-79 C-reactive protein Homo sapiens 147-150 30328360-8 2019 Total cholesterol, low-density lipoprotein cholesterol, triglycerides and C-reactive protein were reduced only in the atorvastatin-treated participants. Atorvastatin 118-130 C-reactive protein Homo sapiens 74-92 30651805-4 2019 The correlation of in vivo creatinine (Cr) with C-reactive protein (CRP), TNF-alpha, BMD and vitamin D deficiency were analyzed. Creatinine 39-41 C-reactive protein Homo sapiens 48-66 30570241-7 2018 Moreover, C-reactive protein (CRP) levels were associated with plasma glucose and insulin levels measured 120 min after the glucose load (beta=0.91, p=0.0003 and beta=0.77, p=0.0006, respectively); ISI and EISI were predicted by CRP (beta=-0.79, p=0.0006; beta=-0.80, p=0.0001, respectively). Glucose 70-77 C-reactive protein Homo sapiens 10-28 30609650-6 2019 The association between SRH and progression to metabolically unhealthy status was much stronger in individuals with obesity than those without, especially in relation to any metabolic abnormality, fatty liver, and high C-reactive protein (all p for interaction by obesity <0.05). 4-(Indolin-1-yl)-4-oxobutanoic acid 24-27 C-reactive protein Homo sapiens 219-237 30273860-6 2019 A low ratio of ROS to mtDNA damage in serum was associated with poor local tumor response to the neoadjuvant treatment and, of note, elevated systemic inflammation factors (C-reactive protein, the interleukin-1 receptor antagonist, and factors involved in tumor necrosis factor signaling), indicating that deficient treatment response locally and detrimental inflammation systemically link to a hypoxic mitochondrial metabolism. Reactive Oxygen Species 15-18 C-reactive protein Homo sapiens 173-191 30268443-3 2019 Here, we observed the effects of peri-operative dexamethasone on the APR following TKA by trending C-reactive protein (CRP, mg/L) and fibrinogen (mg/dL). Dexamethasone 48-61 C-reactive protein Homo sapiens 99-117 30268443-3 2019 Here, we observed the effects of peri-operative dexamethasone on the APR following TKA by trending C-reactive protein (CRP, mg/L) and fibrinogen (mg/dL). Dexamethasone 48-61 C-reactive protein Homo sapiens 119-122 30268443-8 2019 RESULTS: Compared to the non-steroid group, patients receiving dexamethasone yielded a significantly decreased CRP on POD0 (5.5 vs 8.3), POD1 (11.8 vs 22.0), and POD2 (85.5 vs 148.9). Steroids 29-36 C-reactive protein Homo sapiens 111-114 30268443-8 2019 RESULTS: Compared to the non-steroid group, patients receiving dexamethasone yielded a significantly decreased CRP on POD0 (5.5 vs 8.3), POD1 (11.8 vs 22.0), and POD2 (85.5 vs 148.9). Dexamethasone 63-76 C-reactive protein Homo sapiens 111-114 29926959-9 2019 RESULTS: Uric acid to creatinine ratio was significantly correlated with Crohn"s disease activity index (rho = 0.184, P = 0.002) and Harvey Bradshaw index (rho = 0.154, P = 0.010) and C-reactive protein (rho = 0.591, P < 0.001) in CD group. Creatinine 22-32 C-reactive protein Homo sapiens 184-202 30721633-7 2019 Alcohol risk category was roughly linearly related with the occurrence of elevated values for GGT, ALT and CRP. Alcohols 0-7 C-reactive protein Homo sapiens 107-110 30570241-7 2018 Moreover, C-reactive protein (CRP) levels were associated with plasma glucose and insulin levels measured 120 min after the glucose load (beta=0.91, p=0.0003 and beta=0.77, p=0.0006, respectively); ISI and EISI were predicted by CRP (beta=-0.79, p=0.0006; beta=-0.80, p=0.0001, respectively). Glucose 70-77 C-reactive protein Homo sapiens 30-33 30570241-7 2018 Moreover, C-reactive protein (CRP) levels were associated with plasma glucose and insulin levels measured 120 min after the glucose load (beta=0.91, p=0.0003 and beta=0.77, p=0.0006, respectively); ISI and EISI were predicted by CRP (beta=-0.79, p=0.0006; beta=-0.80, p=0.0001, respectively). Glucose 124-131 C-reactive protein Homo sapiens 10-28 30570241-7 2018 Moreover, C-reactive protein (CRP) levels were associated with plasma glucose and insulin levels measured 120 min after the glucose load (beta=0.91, p=0.0003 and beta=0.77, p=0.0006, respectively); ISI and EISI were predicted by CRP (beta=-0.79, p=0.0006; beta=-0.80, p=0.0001, respectively). Glucose 124-131 C-reactive protein Homo sapiens 30-33 30412376-3 2018 In this study, inspired by the highly specific interaction between CRP and the cell membrane, an excellent anti-biofouling compound 2-(methacryloyloxy)ethyl phosphorylcholine and a highly hydrophilic crosslinker N, N"-methylenebisacrylamide were employed to fabricate a novel cell membrane biomimetic polymer for selective capture of CRP in the presence of calcium ions. Calcium 357-364 C-reactive protein Homo sapiens 67-70 30426122-8 2018 The pooled results obtained by using the random-effects model showed that resveratrol supplementation significantly decreased C-reactive protein (CRP) (SMD = -0.55; 95% CI, -0.84, -0.26; P < 0.001; I2: 84.0) and tumor necrosis factor-alpha (TNF-alpha) (SMD = -0.68; 95% CI, -1.08, -0.28; P = 0.001; I2: 81.3) concentrations among patients with MetS and related disorders. Resveratrol 74-85 C-reactive protein Homo sapiens 126-144 30426122-8 2018 The pooled results obtained by using the random-effects model showed that resveratrol supplementation significantly decreased C-reactive protein (CRP) (SMD = -0.55; 95% CI, -0.84, -0.26; P < 0.001; I2: 84.0) and tumor necrosis factor-alpha (TNF-alpha) (SMD = -0.68; 95% CI, -1.08, -0.28; P = 0.001; I2: 81.3) concentrations among patients with MetS and related disorders. Resveratrol 74-85 C-reactive protein Homo sapiens 146-149 30390888-1 2018 BACKGROUND & AIMS: Albumin and C reactive protein (CRP) concentrations are associated with the loss of lean body mass in the elderly. Adenosine Monophosphate 12-15 C-reactive protein Homo sapiens 35-53 30390888-1 2018 BACKGROUND & AIMS: Albumin and C reactive protein (CRP) concentrations are associated with the loss of lean body mass in the elderly. Adenosine Monophosphate 12-15 C-reactive protein Homo sapiens 55-58 30086086-5 2018 To evaluate the effect of CRP on the CD ratio, multiple regression analysis was performed with the following covariates: CRP-positive status, body weight, and use of phenytoin, carbamazepine, or phenobarbital, and combinations of these drugs. Cadmium 37-39 C-reactive protein Homo sapiens 26-29 30238410-9 2018 Plasma levels of C reactive protein and fibrinogen showed positive correlation with myeloperoxidase, malondialdehyde, carbonyl groups and PHASES score and negative correlation with catalase. Malondialdehyde 101-116 C-reactive protein Homo sapiens 17-35 30257125-1 2018 Exposures to occupationally relevant ultrafine, zinc- and copper-containing welding fumes cause inflammatory responses involving systemic IL-6, C-reactive protein (CRP) and serum amyloid A (SAA), all associated with elevated risk of cardiovascular events. Copper 58-64 C-reactive protein Homo sapiens 144-162 30257125-1 2018 Exposures to occupationally relevant ultrafine, zinc- and copper-containing welding fumes cause inflammatory responses involving systemic IL-6, C-reactive protein (CRP) and serum amyloid A (SAA), all associated with elevated risk of cardiovascular events. Copper 58-64 C-reactive protein Homo sapiens 164-167 30592706-8 2018 Low concentrations of total testosterone at baseline were significantly associated with high logHOMA-Ir at follow-up in a multivariable model including age, waist-hip ratio, physical activity, alcohol intake, smoking, LDL, CRP, hypertension, diabetes and logHOMA-Ir at baseline as covariates (beta = -0.096, P = 0.006). Testosterone 28-40 C-reactive protein Homo sapiens 223-226 30408622-5 2018 RESULTS: Reactive oxygen species (ROS) generated by the copper-hydrogen peroxide system could rapidly induce the dissociation of CRP at mild acidic pH within four hours, but not at physiological pH of 7.4. Reactive Oxygen Species 9-32 C-reactive protein Homo sapiens 129-132 30408622-5 2018 RESULTS: Reactive oxygen species (ROS) generated by the copper-hydrogen peroxide system could rapidly induce the dissociation of CRP at mild acidic pH within four hours, but not at physiological pH of 7.4. Reactive Oxygen Species 34-37 C-reactive protein Homo sapiens 129-132 30408622-5 2018 RESULTS: Reactive oxygen species (ROS) generated by the copper-hydrogen peroxide system could rapidly induce the dissociation of CRP at mild acidic pH within four hours, but not at physiological pH of 7.4. Copper 56-62 C-reactive protein Homo sapiens 129-132 30408622-5 2018 RESULTS: Reactive oxygen species (ROS) generated by the copper-hydrogen peroxide system could rapidly induce the dissociation of CRP at mild acidic pH within four hours, but not at physiological pH of 7.4. Hydrogen Peroxide 63-80 C-reactive protein Homo sapiens 129-132 30249443-8 2018 Concentrations of cholesterol (total, LDL, HDL, non-HDL) were also lower at 2 weeks in patients treated with infliximab compared to placebo, but only in those patients with CRP >5 mg/L at baseline (all p < 0.05). Cholesterol 18-29 C-reactive protein Homo sapiens 173-176 30249443-10 2018 Additionally, our findings suggest a causal relationship between increased inflammation and high cholesterol in depression, as a single infusion of infliximab reduced cholesterol in TRD patients with high CRP compared to placebo. Cholesterol 97-108 C-reactive protein Homo sapiens 205-208 30086086-6 2018 RESULTS: In 10 patients using enzyme-inducing antiepileptic drugs (AEDs), the mean CD ratio increased by 53.5% [from 1389 to 2132 (ng/mL)/(mg/kg)] when they were CRP-positive. Cadmium 83-85 C-reactive protein Homo sapiens 162-165 30086086-7 2018 In 13 patients without enzyme-inducing AEDs, the mean CD ratio increased by 100.8% [from 3826 ng/mL to 7683 (ng/mL)/(mg/kg)] when they were CRP-positive. Cadmium 54-56 C-reactive protein Homo sapiens 140-143 30086086-8 2018 By multiple regression analysis, the CRP level was a significant independent determinant of the CD ratio of perampanel. Cadmium 96-98 C-reactive protein Homo sapiens 37-40 30400262-6 2018 Significant associations were distinguished between TG and CRP, FBG, high-density lipoprotein (HDL), C-SBP, P-SBP, P-DBP, CR-PWV, heart rate (HR), and body weight in the pooled sample (p < 0.05). Triglycerides 52-54 C-reactive protein Homo sapiens 59-62 30555261-10 2018 In multivariate analysis, OS was significantly affected by PCI (HR 0.64; 95% CI 0.43-0.94; P=0.026), LDH >400 U/L (HR 1.91 U/L; 95% CI 1.21-3.05 U/L; P=0.006), and CRP >50 mg/L (HR 1.43 mg/L; 95% CI 1.01-2.04 mg/L; P=0.045). Osmium 26-28 C-reactive protein Homo sapiens 167-170 30568518-0 2018 Relationship between oxygen cost and C-reactive protein response to marathon running in college recreational runners. Oxygen 21-27 C-reactive protein Homo sapiens 37-55 30568518-10 2018 Spearman correlation analysis showed that the change in CRP level was significantly positively correlated with oxygen cost (r=0.619, P=0.011) but not maximal oxygen uptake. Oxygen 111-117 C-reactive protein Homo sapiens 56-59 30568518-10 2018 Spearman correlation analysis showed that the change in CRP level was significantly positively correlated with oxygen cost (r=0.619, P=0.011) but not maximal oxygen uptake. Oxygen 158-164 C-reactive protein Homo sapiens 56-59 30405154-8 2018 Sodium levels correlated negatively with WBC (P = 0.037), CRP (P < 0.0001), and number of hospital days (P = 0.020). Sodium 0-6 C-reactive protein Homo sapiens 58-61 29143304-0 2018 Inter-individual variability in phospholipid-dependent interference of C-reactive protein on activated partial thromboplastin time. Phospholipids 32-44 C-reactive protein Homo sapiens 71-89 30499693-5 2018 RESULTS & CONCLUSION: Mean CRP rose on day -5 and reached its peak on day 1. Adenosine Monophosphate 9-12 C-reactive protein Homo sapiens 31-34 30415553-7 2018 Additionally, folic acid intake resulted in a significant reduction in serum high sensitivity C-reactive protein (hs-CRP) (beta -0.36 mg/L; 95% CI, -0.52, -0.21; P < 0.001) compared with the placebo. Folic Acid 14-24 C-reactive protein Homo sapiens 94-112 30498759-7 2018 Higher CRP, ESR level, RF positivity, and the presence of fever or vasculitic skin lesions at the time of diagnosis indicated a higher steroid demand and the administration of higher number of immunosuppressants during the follow-up within anti-Jo-1 positive patients. Steroids 135-142 C-reactive protein Homo sapiens 7-10 30374221-14 2018 We found a significant inverse linear correlation between serum sodium and C-reactive protein, as well as serum sodium and procalcitonin. Sodium 64-70 C-reactive protein Homo sapiens 75-93 30178473-7 2018 After accounting for the effects of steroids, CRP was higher in carbamazepine patients than in other patients. Steroids 36-44 C-reactive protein Homo sapiens 46-49 30007118-9 2018 Platelets from Rac1-/- mice or human platelets treated with NSC23766, a specific Rac inhibitor, produced significantly less ROS in response to CRP. NSC 23766 60-68 C-reactive protein Homo sapiens 143-146 29756266-4 2018 In addition, the self-made platelet lysate (phospholipid) was added to correct the APTT prolonged by C-reactive protein (150 mg/L) on STA-R Evolution (activator: silica) system. Phospholipids 44-56 C-reactive protein Homo sapiens 101-119 29756266-10 2018 The increasing in C-reactive protein results in a false prolongation of the APTT (activator: silica), and it is most likely that C-reactive protein interferes the coagulable factor binding of phospholipid. Phospholipids 192-204 C-reactive protein Homo sapiens 18-36 29756266-10 2018 The increasing in C-reactive protein results in a false prolongation of the APTT (activator: silica), and it is most likely that C-reactive protein interferes the coagulable factor binding of phospholipid. Phospholipids 192-204 C-reactive protein Homo sapiens 129-147 30020457-8 2018 In youth with T1D, glucose rate of disappearance correlated with free fatty acid at the 80-mU/m2/min phase (P = 0.005), markers of inflammation (IL-6; P = 0.012), high-sensitivity C-reactive protein (P = 0.001), and leptin (P = 0.008)], but not hemoglobin A1c. Glucose 19-26 C-reactive protein Homo sapiens 180-198 30007118-9 2018 Platelets from Rac1-/- mice or human platelets treated with NSC23766, a specific Rac inhibitor, produced significantly less ROS in response to CRP. Reactive Oxygen Species 124-127 C-reactive protein Homo sapiens 143-146 30007118-10 2018 Treatment of platelets with Phox-I inhibited diverse CRP-induced responses, including: (i) ROS generation; (ii) release of P-selectin; (iii) secretion of ATP; (iv) platelet aggregation; and (v) phosphorylation of Akt. Reactive Oxygen Species 91-94 C-reactive protein Homo sapiens 53-56 30007118-10 2018 Treatment of platelets with Phox-I inhibited diverse CRP-induced responses, including: (i) ROS generation; (ii) release of P-selectin; (iii) secretion of ATP; (iv) platelet aggregation; and (v) phosphorylation of Akt. Adenosine Triphosphate 154-157 C-reactive protein Homo sapiens 53-56 30256816-3 2018 We first consider the allosteric transition resulting from cyclic-AMP binding to CRP, then analyze how CRP binds to its operator, and finally investigate the ability of CRP to activate gene expression. Cyclic AMP 59-69 C-reactive protein Homo sapiens 81-84 30355032-8 2018 In multivariate analyses, low serum bioavailable 25(OH)D level was significantly associated with increased risks of mortality, independent of established cardiovascular risk factors, features and treatments of CAD, factors associated with vitamin D and mineral metabolism, and CRP (C-reactive protein). 25(oh)d 49-56 C-reactive protein Homo sapiens 277-280 30355032-8 2018 In multivariate analyses, low serum bioavailable 25(OH)D level was significantly associated with increased risks of mortality, independent of established cardiovascular risk factors, features and treatments of CAD, factors associated with vitamin D and mineral metabolism, and CRP (C-reactive protein). 25(oh)d 49-56 C-reactive protein Homo sapiens 282-300 30319609-0 2018 Acetylcholine Inhibits Monomeric C-Reactive Protein Induced Inflammation, Endothelial Cell Adhesion, and Platelet Aggregation; A Potential Therapeutic? Acetylcholine 0-13 C-reactive protein Homo sapiens 33-51 30319609-1 2018 Objectives: In this study, we examined the possibility of using targeted antibodies and the potential of small molecular therapeutics (acetylcholine, nicotine and tacrine) to block the pro-inflammatory and adhesion-related properties of monomeric C-reactive protein (mCRP). Acetylcholine 135-148 C-reactive protein Homo sapiens 247-265 29572131-8 2018 Participants in the highest quartile of DBR had higher nitrotyrosine, 8-isoPGF2a, interleukin-6, C-reactive protein and lower Montreal Cognitive Assessment score compared with those in the lowest quartile. dbr 40-43 C-reactive protein Homo sapiens 97-115 30202011-6 2018 Using brain-wide, CRP-Glu ReHo contrast maps, a covariance network of 41 regions-of-interest (ROIs) with similar ReHo decreases was identified in the High CRP-Glu group and was located to brain structures previously implicated in depression. Glutamic Acid 22-25 C-reactive protein Homo sapiens 18-21 30202011-6 2018 Using brain-wide, CRP-Glu ReHo contrast maps, a covariance network of 41 regions-of-interest (ROIs) with similar ReHo decreases was identified in the High CRP-Glu group and was located to brain structures previously implicated in depression. Glutamic Acid 22-25 C-reactive protein Homo sapiens 155-158 30202011-3 2018 High CRP-Glu group status was associated with greater severity of anhedonia and cognitive and motor slowing. Glutamic Acid 9-12 C-reactive protein Homo sapiens 5-8 30114262-8 2018 High CRP levels were associated with younger age, higher body mass index (BMI), chronic obstructive pulmonary disease (COPD), lower peak oxygen consumption and higher endothelin-1 and aldosterone levels. Oxygen 137-143 C-reactive protein Homo sapiens 5-8 30202011-5 2018 Greater decreases in concordance of oscillatory activity between neighboring voxels (Regional Homogeneity "ReHo", p < 0.01) within the MRS volume-of-interest was associated with the High CRP-Glu subgroup. Glutamic Acid 194-197 C-reactive protein Homo sapiens 190-193 30021340-12 2018 in vivo, berberine significantly reduced the levels of CRP, TNF-alpha and IL-6 in the patients" plasma. Berberine 9-18 C-reactive protein Homo sapiens 55-58 30334413-9 2018 The negative correlation for the hs-CRP and fasting glucose and DIA were found in low hs-CRP (r= -0.619; p less than 0.05 and r= -0.580; p less than 0.05 respectively) and for the hs-CRP and uric acid (r=-0.850; p less than 0.05) in the moderate hs-CRP risk group. Glucose 52-59 C-reactive protein Homo sapiens 36-39 30334413-9 2018 The negative correlation for the hs-CRP and fasting glucose and DIA were found in low hs-CRP (r= -0.619; p less than 0.05 and r= -0.580; p less than 0.05 respectively) and for the hs-CRP and uric acid (r=-0.850; p less than 0.05) in the moderate hs-CRP risk group. Glucose 52-59 C-reactive protein Homo sapiens 89-92 30334413-9 2018 The negative correlation for the hs-CRP and fasting glucose and DIA were found in low hs-CRP (r= -0.619; p less than 0.05 and r= -0.580; p less than 0.05 respectively) and for the hs-CRP and uric acid (r=-0.850; p less than 0.05) in the moderate hs-CRP risk group. Glucose 52-59 C-reactive protein Homo sapiens 89-92 30334413-9 2018 The negative correlation for the hs-CRP and fasting glucose and DIA were found in low hs-CRP (r= -0.619; p less than 0.05 and r= -0.580; p less than 0.05 respectively) and for the hs-CRP and uric acid (r=-0.850; p less than 0.05) in the moderate hs-CRP risk group. Glucose 52-59 C-reactive protein Homo sapiens 89-92 29803716-11 2018 For CRP, a significant small to medium effect was observed with probiotics (-0.43 mg/L), ARBs (-0.2 mg/L), omega-3 (-0.17 mg/L) and metformin (-0.16 mg/L). Metformin 132-141 C-reactive protein Homo sapiens 4-7 29976096-2 2018 Among the multiple mechanisms of inflammation, the arterial deposition of lipids and particularly of cholesterol crystals is the one responsible for the activation of inflammasome NLRP3, followed by the rise of circulating markers, mainly C-reactive protein (CRP). Cholesterol 101-112 C-reactive protein Homo sapiens 239-257 29976096-2 2018 Among the multiple mechanisms of inflammation, the arterial deposition of lipids and particularly of cholesterol crystals is the one responsible for the activation of inflammasome NLRP3, followed by the rise of circulating markers, mainly C-reactive protein (CRP). Cholesterol 101-112 C-reactive protein Homo sapiens 259-262 29976096-6 2018 Other drugs, mainly active on the triglyceride/HDL axis, for example, PPAR agonists, may improve CRP and the lipid pattern, especially in patients with metabolic syndrome. Triglycerides 34-46 C-reactive protein Homo sapiens 97-100 29302924-1 2018 PURPOSE: We aim to evaluate reactive oxygen species modulator 1 (Romo1) levels in obstructive sleep apnea syndrome (OSAS) and analyze its possible relationships to OSAS severity, reactive oxygen species (ROS), and C-reactive protein (CRP). Reactive Oxygen Species 28-51 C-reactive protein Homo sapiens 214-232 29302924-1 2018 PURPOSE: We aim to evaluate reactive oxygen species modulator 1 (Romo1) levels in obstructive sleep apnea syndrome (OSAS) and analyze its possible relationships to OSAS severity, reactive oxygen species (ROS), and C-reactive protein (CRP). Reactive Oxygen Species 28-51 C-reactive protein Homo sapiens 234-237 30190688-10 2018 Increased CRP has also been associated with high nicotine dependence in SZ smokers and one study has suggested that increased CRP was associated with sedentary behavior. Nicotine 49-57 C-reactive protein Homo sapiens 10-13 30190688-11 2018 Conclusion: In the light of the above-mentioned studies, increased hs-CRP may be reasonably suggested as a marker for SZ onset risk, as well as a risk factor for increased positive symptoms, cognitive impairment, hypovitaminosis D, microbiota disturbances, cardiovascular and metabolic syndrome risk in SZ subjects, and increased nicotine dependence in SZ smokers. Nicotine 330-338 C-reactive protein Homo sapiens 70-73 29775873-8 2018 RESULTS: In both cohorts, inflammation as measured by higher levels of CRP, sVCAM1 and sICAM1 was associated with kynurenine/tryptophan ratio and thus enhanced tryptophan breakdown (beta: 0.145-0.429). Tryptophan 125-135 C-reactive protein Homo sapiens 71-74 30086150-11 2018 Furthermore, changes in serum phosphate correlated with changes in C-reactive protein (hs-CRP). Phosphates 30-39 C-reactive protein Homo sapiens 67-85 30070873-10 2018 Individuals with inadequacy of vitamin D showed higher values of CRP in both groups (p = 0.000). Vitamin D 31-40 C-reactive protein Homo sapiens 65-68 29655951-8 2018 Replacement of cross-sectional renal assessment by DeltaeGRF and addition of 3 clinical parameters (diabetes, anterior infarct location and C-reactive protein), forming the new ACEF-STEMI score, led to a significant improvement in MACE prediction (AUC:0.75 [95%CI:0.66-0.84]) as compared to original ACEF or ACEF-MDRD (both p = 0.03). Cefazolin 177-181 C-reactive protein Homo sapiens 140-158 30012383-8 2018 Pooled analysis revealed statistically significant mean differences in CRP serum levels (mg/L) between groups at 24 h post-adjunctive therapy with melatonin (-1.739 mg/L; 95% CI: -3.205 to -0.273; P = 0.020). Melatonin 147-156 C-reactive protein Homo sapiens 71-74 29907916-8 2018 CONCLUSIONS: In summary, the current meta-analysis showed the promising effect of melatonin administration on reducing CRP and IL-6, but not TNF-alpha levels among patients with MetS and related disorders. Melatonin 82-91 C-reactive protein Homo sapiens 119-122 29775873-8 2018 RESULTS: In both cohorts, inflammation as measured by higher levels of CRP, sVCAM1 and sICAM1 was associated with kynurenine/tryptophan ratio and thus enhanced tryptophan breakdown (beta: 0.145-0.429). Tryptophan 160-170 C-reactive protein Homo sapiens 71-74 28882065-9 2018 The dietary intake of zinc + 6.4% and calcium -3.4% and body mass index +3.9% explained approximately 13.7% of the variation in serum high-sensitive C-reactive protein among diabetic hypertensive patients. Calcium 38-45 C-reactive protein Homo sapiens 149-167 30105015-7 2018 CRP elicits metabotropic functions at nicotinic acetylcholine (ACh) receptors (nAChRs) containing subunits alpha7, alpha9, and alpha10 and suppresses the function of ATP-sensitive P2X7 receptors in monocytic cells. Adenosine Triphosphate 166-169 C-reactive protein Homo sapiens 0-3 30105015-10 2018 In conclusion, PC-laden CRP is an unconventional nicotinic agonist that potently inhibits ATP-induced inflammasome activation and might protect against trauma-associated sterile inflammation. Adenosine Triphosphate 90-93 C-reactive protein Homo sapiens 24-27 30105015-0 2018 C-Reactive Protein Stimulates Nicotinic Acetylcholine Receptors to Control ATP-Mediated Monocytic Inflammasome Activation. Adenosine Triphosphate 75-78 C-reactive protein Homo sapiens 0-18 30105015-5 2018 Here, we demonstrate that CRP, in association with PC, efficiently reduces ATP-induced inflammasome activation and IL-1beta release from human peripheral blood mononuclear leukocytes and monocytic U937 cells. Adenosine Triphosphate 75-78 C-reactive protein Homo sapiens 26-29 30013561-0 2018 The Effect of C-Reactive Protein Isoforms on Nitric Oxide Production by U937 Monocytes/Macrophages. Nitric Oxide 45-57 C-reactive protein Homo sapiens 14-32 30013561-3 2018 It is unclear how each CRP isoform mediates nitric oxide (NO), a signaling molecule generated by NO synthase (NOS). Nitric Oxide 44-56 C-reactive protein Homo sapiens 23-26 28882065-10 2018 Approximately 9.7% of the variation in serum high-sensitive C-reactive protein in diabetic non-hypertensive patients could be explained by body mass index, and intake of sodium, iron and cholesterol. Sodium 170-176 C-reactive protein Homo sapiens 60-78 28882065-10 2018 Approximately 9.7% of the variation in serum high-sensitive C-reactive protein in diabetic non-hypertensive patients could be explained by body mass index, and intake of sodium, iron and cholesterol. Iron 178-182 C-reactive protein Homo sapiens 60-78 28882065-10 2018 Approximately 9.7% of the variation in serum high-sensitive C-reactive protein in diabetic non-hypertensive patients could be explained by body mass index, and intake of sodium, iron and cholesterol. Cholesterol 187-198 C-reactive protein Homo sapiens 60-78 28882065-11 2018 In the healthy subjects, approximately 4.4% of the total variation in serum high-sensitive C-reactive protein concentration could be explained by cholesterol consumption and waist circumference. Cholesterol 146-157 C-reactive protein Homo sapiens 91-109 28882065-13 2018 There was a significant association between dietary factors include zinc, iron, sodium and cholesterol and serum high-sensitive C-reactive protein, while there was an inverse association between dietary calcium and serum high-sensitive C-reactive protein in diabetic hypertensive individuals. Sodium 80-86 C-reactive protein Homo sapiens 128-146 28882065-13 2018 There was a significant association between dietary factors include zinc, iron, sodium and cholesterol and serum high-sensitive C-reactive protein, while there was an inverse association between dietary calcium and serum high-sensitive C-reactive protein in diabetic hypertensive individuals. Cholesterol 91-102 C-reactive protein Homo sapiens 128-146 28882065-13 2018 There was a significant association between dietary factors include zinc, iron, sodium and cholesterol and serum high-sensitive C-reactive protein, while there was an inverse association between dietary calcium and serum high-sensitive C-reactive protein in diabetic hypertensive individuals. Calcium 203-210 C-reactive protein Homo sapiens 236-254 29730525-6 2018 Since IL-1beta production leads to increased levels of IL-6 and C-reactive protein, this could be a mechanistic link between early deposition of cholesterol crystals within the vessel wall to the macrophage-monocyte interactions that initiate fatty streaks and promote local atherosclerotic progression. Cholesterol 145-156 C-reactive protein Homo sapiens 64-82 29683202-4 2018 We confirmed that serum total cholesterol and uric acid were elevated in pre-eclamptic compared to healthy pregnancies and correlated positively to high sensitivity C-reactive protein (hsCRP) and the pre-eclampsia marker soluble fms-like tyrosine kinase-1 (sFlt-1). Cholesterol 30-41 C-reactive protein Homo sapiens 165-183 29164398-2 2018 MATERIALS AND METHODS: We have prospectively followed up a 42-patient cohort for surgical treatment by osteosynthesis or hip arthroplasty, and CRP was dosed at admission, on day 1, day 3, day 5 and then twice weekly for 30 days at the same time as a platelet count control of low molecular weight heparins. Heparin 297-305 C-reactive protein Homo sapiens 143-146 29941884-8 2018 Total soy isoflavone consumption was also inversely associated with baPWV even after adjusting for multivariable covariates including serum hs-CRP (P value for trend was 0.043, in Model 4); however total soy protein consumption was not. Isoflavones 6-20 C-reactive protein Homo sapiens 143-146 30221147-8 2018 In a linear regression model adjusted for age, gender, and BMI, a significant inverse association of C-reactive protein (CRP) (p = 0.031) and faecal calprotectin (FC) (p = 0.025) with 25-OH-D3 levels was observed for CD patients. Fc(alpha) receptor 163-165 C-reactive protein Homo sapiens 121-124 30221147-10 2018 Conclusion: Vitamin D deficiency was common in all IBD patients, but more pronounced in CD patients, in whom it also showed a significant inverse association with inflammatory markers such as CRP and FC. Vitamin D 12-21 C-reactive protein Homo sapiens 192-195 29628291-13 2018 CRP can be consumed with tea, food, alcohol, and medicine. Alcohols 36-43 C-reactive protein Homo sapiens 0-3 28737646-9 2018 Receiver operating characteristic statistics were used to determine the optimal stool frequency, CRP, albumin, and CRP/albumin ratio (CAR) to predict steroid response. Steroids 150-157 C-reactive protein Homo sapiens 115-118 29506595-0 2018 Inverse association of calcium intake with abdominal adiposity and C-reactive protein in Brazilian children. Calcium 23-30 C-reactive protein Homo sapiens 67-85 29458053-7 2018 Linear mixed models were used to test the effects of diet on bile acid concentrations, and determine the association between plasma bile acid concentrations and HOMA-IR and CRP. Bile Acids and Salts 132-141 C-reactive protein Homo sapiens 161-176 29877315-7 2018 Procalcitonin (PCT), interleukin 6 (IL-6), and C-reactive protein concentrations were higher in patients with AdP than in those with URI. Adenosine Diphosphate 110-113 C-reactive protein Homo sapiens 47-65 29843881-1 2018 In this work, a nano-mimetic enzyme Co3O4 nanoparticles with catalytic effect on the reduction of H2O2, was synthesized and used to label C-reactive protein antibody. Hydrogen Peroxide 98-102 C-reactive protein Homo sapiens 138-156 29335791-1 2018 PURPOSE: To clarify pre- and postoperative C-reactive protein (CRP) levels in patients with facial fractures and to investigate the influence of perioperatively administered dexamethasone on postoperative CRP levels. Dexamethasone 174-187 C-reactive protein Homo sapiens 205-208 29335791-6 2018 However, postoperative CRP rise was significantly impeded by dexamethasone (p < 0.001), regardless of gender, age, treatment delay, site of fracture, surgical approach, and duration of surgery. Dexamethasone 61-74 C-reactive protein Homo sapiens 23-26 29335791-7 2018 CRP rise halved on the 1st postoperative day when dexamethasone was used. Dexamethasone 50-63 C-reactive protein Homo sapiens 0-3 29335791-8 2018 In addition, dexamethasone resulted in a CRP decrease on the 2nd postoperative day, whereas the CRP rise continued in the control group. Dexamethasone 13-26 C-reactive protein Homo sapiens 41-44 29335791-9 2018 CONCLUSIONS: CRP rise is a normal body response after facial fracture and surgery that can be markedly reduced with dexamethasone. Dexamethasone 116-129 C-reactive protein Homo sapiens 13-16 29335791-10 2018 CRP changes should be considered with caution if perioperative dexamethasone is used. Dexamethasone 63-76 C-reactive protein Homo sapiens 0-3 29567181-0 2018 Electrochemical detection of c-reactive protein based on anthraquinone-labeled antibody using a screen-printed graphene electrode. Anthraquinones 57-70 C-reactive protein Homo sapiens 29-47 29567181-3 2018 The Anti-1 Ab was first covalently anchored onto an L-cysteine/gold-modified disposable SPGE (L-Cys/Au/SPGE) to create the anti-CRP surface. Cysteine 52-62 C-reactive protein Homo sapiens 128-131 29880175-4 2018 High sensitive C-reactive protein levels (hsCRP) changed with OC, combination and metformin therapies by 102.32%, 3.2% and -7.14%, respectively. Metformin 82-91 C-reactive protein Homo sapiens 15-33 29567181-3 2018 The Anti-1 Ab was first covalently anchored onto an L-cysteine/gold-modified disposable SPGE (L-Cys/Au/SPGE) to create the anti-CRP surface. Cysteine 94-99 C-reactive protein Homo sapiens 128-131 30015322-6 2018 Recorded CRP was higher in AL patients when compared with non-AL cases on both the 3rd postoperative day (152.4 mg/L vs. 93 mg/L, respectively; P &lt; 0.0001) and the 6th postoperative day (130.5 mg/L vs. 68.2 mg/L; P &lt; 0.0001). Adenosine Monophosphate 147-150 C-reactive protein Homo sapiens 9-12 29793637-0 2018 Impact of C-Reactive Protein and Coronary Artery Calcium on Benefit Observed With Atorvastatin. Atorvastatin 82-94 C-reactive protein Homo sapiens 10-28 30015322-6 2018 Recorded CRP was higher in AL patients when compared with non-AL cases on both the 3rd postoperative day (152.4 mg/L vs. 93 mg/L, respectively; P &lt; 0.0001) and the 6th postoperative day (130.5 mg/L vs. 68.2 mg/L; P &lt; 0.0001). Adenosine Monophosphate 223-226 C-reactive protein Homo sapiens 9-12 29343081-9 2018 Use of high and moderate atorvastatin therapy significantly reduced low-density lipoprotein and total cholesterol levels, as well as plasma levels of CRP, MPO, nitrite, and TBARS, and increased plasma SOD activity in patients with moderate to very high risk of ASCVD, independent of lipid-lowering effects. Atorvastatin 25-37 C-reactive protein Homo sapiens 150-153 28756540-8 2018 In the group treated with cyclosporine A, patients with C-reactive protein >3 mg/L had a response rate significantly higher than those with C-reactive protein <3 mg/L (P = 0.03); those with negative C-reactive protein and moderate Mayo score did not responded to therapy, while in the ones with elevated C-reactive protein and/or severe Mayo score, 15 versus 4 responded (P = 0.008). Cyclosporine 26-40 C-reactive protein Homo sapiens 56-74 28756540-8 2018 In the group treated with cyclosporine A, patients with C-reactive protein >3 mg/L had a response rate significantly higher than those with C-reactive protein <3 mg/L (P = 0.03); those with negative C-reactive protein and moderate Mayo score did not responded to therapy, while in the ones with elevated C-reactive protein and/or severe Mayo score, 15 versus 4 responded (P = 0.008). Cyclosporine 26-40 C-reactive protein Homo sapiens 143-161 28756540-8 2018 In the group treated with cyclosporine A, patients with C-reactive protein >3 mg/L had a response rate significantly higher than those with C-reactive protein <3 mg/L (P = 0.03); those with negative C-reactive protein and moderate Mayo score did not responded to therapy, while in the ones with elevated C-reactive protein and/or severe Mayo score, 15 versus 4 responded (P = 0.008). Cyclosporine 26-40 C-reactive protein Homo sapiens 143-161 28756540-8 2018 In the group treated with cyclosporine A, patients with C-reactive protein >3 mg/L had a response rate significantly higher than those with C-reactive protein <3 mg/L (P = 0.03); those with negative C-reactive protein and moderate Mayo score did not responded to therapy, while in the ones with elevated C-reactive protein and/or severe Mayo score, 15 versus 4 responded (P = 0.008). Cyclosporine 26-40 C-reactive protein Homo sapiens 143-161 29723366-8 2018 HDL-cholesterol level was higher in normal C-reactive protein patients (t=1.98; P=0.05). Cholesterol 4-15 C-reactive protein Homo sapiens 43-61 29915443-8 2018 DES-CD revealed a correlation with FC (gamma = 0.691, P = 0.001) and C-reactive protein (CRP) (gamma = 0.631, P = 0.003) levels. des-cd 0-6 C-reactive protein Homo sapiens 69-87 29915443-8 2018 DES-CD revealed a correlation with FC (gamma = 0.691, P = 0.001) and C-reactive protein (CRP) (gamma = 0.631, P = 0.003) levels. des-cd 0-6 C-reactive protein Homo sapiens 89-92 29713320-0 2018 A Conformational Change in C-Reactive Protein Enhances Leukocyte Recruitment and Reactive Oxygen Species Generation in Ischemia/Reperfusion Injury. Reactive Oxygen Species 81-104 C-reactive protein Homo sapiens 27-45 29938421-15 2018 CRP had got significant correlation with total cholesterol and LDL and non-significant correlation with triglycerides. Cholesterol 47-58 C-reactive protein Homo sapiens 0-3 29938421-15 2018 CRP had got significant correlation with total cholesterol and LDL and non-significant correlation with triglycerides. Triglycerides 104-117 C-reactive protein Homo sapiens 0-3 29601504-3 2018 Hence, we have developed a simple, cost effective, and label-free electrochemical immunoassay for the measurement of CRP in a drop of serum sample using an immunosensor strip made up of a screen printed carbon electrode (SPE) modified with anti-CRP functionalized gold nanoparticles (AuNPs). Carbon 203-209 C-reactive protein Homo sapiens 117-120 29796304-5 2018 Results & conclusion: Limit of detection of 1 pg/ml was achieved for CRP and IL-6 in human urine and synthetic urine buffers. Adenosine Monophosphate 9-12 C-reactive protein Homo sapiens 73-76 29558888-10 2018 Thrombospondin-2, C-reactive protein, TNF-receptor I, and placental growth factor were the analytes most highly associated with OS, all with Cox PH p-values <=0.0001. Osmium 128-130 C-reactive protein Homo sapiens 18-52 29713320-10 2018 Leukocyte activation was assessed by quantification of reactive oxygen species (ROS) induction by CRP isoforms ex vivo and in vitro through electron spin resonance spectroscopy. Reactive Oxygen Species 55-78 C-reactive protein Homo sapiens 98-101 29713320-10 2018 Leukocyte activation was assessed by quantification of reactive oxygen species (ROS) induction by CRP isoforms ex vivo and in vitro through electron spin resonance spectroscopy. Reactive Oxygen Species 80-83 C-reactive protein Homo sapiens 98-101 29713320-15 2018 Structurally altered CRP induces leukocyte-endothelial interaction and induces ROS formation in leukocytes, the latter can be abrogated by blocking lipid raft-dependent signaling pathways with Nystatin. Reactive Oxygen Species 79-82 C-reactive protein Homo sapiens 21-24 29662032-8 2018 Regarding Agriculture, Forestry &amp; Fishing, the duration of exposure altered SBP, CRP, and LDL cholesterol. Adenosine Monophosphate 33-36 C-reactive protein Homo sapiens 89-92 29426615-9 2018 In univariate analyses, significant correlations were observed between childhood HDL-cholesterol (risk ratio (95% CI) for 1-SD change (0.58 (0.42-0.79)) and CRP concentrations (1.20 (1.01-1.43)) with IBD. Cholesterol 85-96 C-reactive protein Homo sapiens 157-160 29426615-10 2018 The inverse association between HDL-cholesterol and IBD remained significant (0.57 (0.39-0.82)) in a multivariable model including data on age, sex and CRP. Cholesterol 36-47 C-reactive protein Homo sapiens 152-155 28275869-1 2018 PURPOSE: The aim of the current meta-analysis was to investigate the effect of increasing dietary ALA intake on the blood concentration of inflammatory markers including tumor necrosis factor (TNF), interleukin 6 (IL-6), C-reactive protein (CRP), soluble intercellular adhesion molecule-1 (sICAM-1), and soluble vascular cell adhesion molecule-1 (sVCAM-1) in adults. Alanine 98-101 C-reactive protein Homo sapiens 241-244 28275869-4 2018 Subgroup analysis revealed that increasing dietary ALA tends to elevate CRP concentration in healthy subjects. Alanine 51-54 C-reactive protein Homo sapiens 72-75 28275869-9 2018 However, in healthy subjects, ALA supplementation might increase CRP concentration. Alanine 30-33 C-reactive protein Homo sapiens 65-68 29248753-0 2018 The study of vitamin D administration effect on CRP and Interleukin-6 as prognostic biomarkers of ventilator associated pneumonia. Vitamin D 13-22 C-reactive protein Homo sapiens 48-51 29248753-6 2018 Although C-Reactive protein (CRP) levels showed an improving trend in the vitamin D group, no significant difference between groups (P=0.12) was found. Vitamin D 74-83 C-reactive protein Homo sapiens 9-27 29248753-6 2018 Although C-Reactive protein (CRP) levels showed an improving trend in the vitamin D group, no significant difference between groups (P=0.12) was found. Vitamin D 74-83 C-reactive protein Homo sapiens 29-32 29664424-8 2018 The level of CRP was negatively correlated with HDL cholesterol (r=-0.275; p=0.032) and total cholesterol level (r=-0.313; p=0.014) in FMF patients. Cholesterol 52-63 C-reactive protein Homo sapiens 13-16 29664424-8 2018 The level of CRP was negatively correlated with HDL cholesterol (r=-0.275; p=0.032) and total cholesterol level (r=-0.313; p=0.014) in FMF patients. Cholesterol 94-105 C-reactive protein Homo sapiens 13-16 29552019-5 2018 CRP inhibits endothelial nitric oxide production and contributes to plaque instability by increasing endothelial cell adhesion molecules expression, by promoting monocyte recruitment into the atheromatous plaque and by enzymatically binding to modified low-density lipoprotein. Nitric Oxide 25-37 C-reactive protein Homo sapiens 0-3 29353098-11 2018 Nine studies reported a change in C-Reactive Protein (CRP) after atorvastatin treatment, and the pooled analysis showed that atorvastatin decreased CRP in RA patients by x +- SD95% [SMD = -3.033, 95%CI = (-4.460, -1.606), p = .000]. Atorvastatin 125-137 C-reactive protein Homo sapiens 34-52 29353098-11 2018 Nine studies reported a change in C-Reactive Protein (CRP) after atorvastatin treatment, and the pooled analysis showed that atorvastatin decreased CRP in RA patients by x +- SD95% [SMD = -3.033, 95%CI = (-4.460, -1.606), p = .000]. Atorvastatin 125-137 C-reactive protein Homo sapiens 54-57 29353098-11 2018 Nine studies reported a change in C-Reactive Protein (CRP) after atorvastatin treatment, and the pooled analysis showed that atorvastatin decreased CRP in RA patients by x +- SD95% [SMD = -3.033, 95%CI = (-4.460, -1.606), p = .000]. Atorvastatin 125-137 C-reactive protein Homo sapiens 148-151 27913877-11 2018 However, 8-iso-PGF2alpha was associated with smoking, endocrine stress axis activation, C-reactive protein levels and low plasma concentrations of brain-derived neurotrophic factor. 8-epi-prostaglandin F2alpha 9-24 C-reactive protein Homo sapiens 88-106 29074374-0 2018 C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation. Steroids 82-89 C-reactive protein Homo sapiens 0-18 29074374-4 2018 Because C-reactive protein (CRP) is a systemic inflammatory marker, we aimed to investigate whether plasma CRP concentrations at the diagnosis of aGVHD can predict the risk of failing first-line therapy and developing steroid-refractory disease. Steroids 218-225 C-reactive protein Homo sapiens 107-110 29074374-10 2018 CRP levels were significantly higher in patients who developed steroid-refractory disease compared with those who responded to high-dose corticosteroid therapy (odds ratio, 1.50; 95% confidence interval, 1.18-1.93; P = .001). Steroids 63-70 C-reactive protein Homo sapiens 0-3 29074374-13 2018 These results suggest that CRP level at diagnosis is a valid predictor of the development of steroid-refractory disease in patients who develop grade II-IV aGVHD after HSCT. Steroids 93-100 C-reactive protein Homo sapiens 27-30 29183404-2 2018 These cases highlight an association between prolonged prostaglandin-E2 therapy with periosteal reactions and elevated C-reactive protein levels. Dinoprostone 55-71 C-reactive protein Homo sapiens 119-137 29515239-0 2018 The associations of serum n-6 polyunsaturated fatty acids with serum C-reactive protein in men: the Kuopio Ischaemic Heart Disease Risk Factor Study. n-6 polyunsaturated fatty acids 26-57 C-reactive protein Homo sapiens 69-87 29515239-5 2018 RESULTS: In the multivariable-adjusted analyses, both serum total n-6 PUFA and linoleic acid, the predominant n-6 PUFA, were associated with lower CRP. Linoleic Acid 79-92 C-reactive protein Homo sapiens 147-150 29515239-6 2018 The mean CRP concentrations in quartiles of linoleic acid were 1.86, 1.51, 1.53, and 1.37 mg/L (P-trend = 0.001). Linoleic Acid 44-57 C-reactive protein Homo sapiens 9-12 29515239-11 2018 In contrast, the main n-6 PUFA linoleic acid had a strong inverse association with the key inflammation marker, CRP. n-6 pufa 22-30 C-reactive protein Homo sapiens 112-115 29515239-11 2018 In contrast, the main n-6 PUFA linoleic acid had a strong inverse association with the key inflammation marker, CRP. Linoleic Acid 31-44 C-reactive protein Homo sapiens 112-115 29527997-11 2018 Serum testosterone levels were positively correlated with hand-grip strength (r = 0.445; P = .033) and serum albumin (r = 0.399; P = .05) and negatively correlated with serum C-reactive protein (r = -0.454; P = .05) and age. Testosterone 6-18 C-reactive protein Homo sapiens 175-193 29527997-14 2018 CONCLUSIONS: Serum testosterone level is correlated with hand-grip strength and C-reactive protein and albumin levels, which may indicate that testosterone affects nutritional status and inflammation in male renal transplant recipients. Testosterone 19-31 C-reactive protein Homo sapiens 80-98 29527997-14 2018 CONCLUSIONS: Serum testosterone level is correlated with hand-grip strength and C-reactive protein and albumin levels, which may indicate that testosterone affects nutritional status and inflammation in male renal transplant recipients. Testosterone 143-155 C-reactive protein Homo sapiens 80-98 28612359-0 2018 The relationship between moderate alcohol consumption, depressive symptomatology, and C-reactive protein: the Health and Retirement Study. Alcohols 34-41 C-reactive protein Homo sapiens 86-104 28685957-9 2018 Atorvastatin significantly reduced homocysteine and C-reactive protein, and delayed and reversed the progress of carotid atherosclerosis in very elderly patients with type 2 diabetes. Atorvastatin 0-12 C-reactive protein Homo sapiens 52-70 29193350-9 2018 Curcumin nanomicelle supplementation also resulted in a statistically significant improvement in plasma levels of total antioxidant capacity, malondialdehyde, C-reactive protein, and tumor necrosis factor a in comparison to the placebo. Curcumin 0-8 C-reactive protein Homo sapiens 159-177 29464415-5 2018 RECENT FINDINGS: We included C-reactive protein, erythrocyte sedimentation rate, white blood cell counts, procalcitonin, and nasal nitric oxide in this review and found that especially elevated C-reactive protein and erythrocyte sedimentation rate are related to a higher probability of a bacterial cause of acute rhinosinusitis. Nitric Oxide 131-143 C-reactive protein Homo sapiens 194-212 29415048-9 2018 Finally, c-statistics significantly increased when phosphate was added to a model that included age, sex, CCI, body mass index, eGFR, MAP, hemoglobin, serum albumin, C-reactive protein, and APACHE II score. Phosphates 51-60 C-reactive protein Homo sapiens 166-184 29107850-6 2018 Regression models found several significant fatty acids at which the strength of the parameter beta for each fatty acid on selected markers of C-reactive protein, malondialdehyde, interleukin-6 and serum amyloid A was estimated. Fatty Acids 44-54 C-reactive protein Homo sapiens 143-161 32153865-0 2018 Impact of vitamin D supplementation on C-reactive protein; a systematic review and meta-analysis of randomized controlled trials. Vitamin D 10-19 C-reactive protein Homo sapiens 39-57 32153865-1 2018 Background: To evaluate the effect of vitamin D supplementation on C-reactive protein (CRP) through a systematic review and meta-analysis of randomized control trials (RCTs). Vitamin D 38-47 C-reactive protein Homo sapiens 67-85 32153865-1 2018 Background: To evaluate the effect of vitamin D supplementation on C-reactive protein (CRP) through a systematic review and meta-analysis of randomized control trials (RCTs). Vitamin D 38-47 C-reactive protein Homo sapiens 87-90 32153865-2 2018 Methods: PubMed-Medline, SCOPUS, Google Scholar and Web of Science databases were searched (up until April 2016) to identify RCTs evaluating the impact of vitamin D supplementation on CRP. Vitamin D 155-164 C-reactive protein Homo sapiens 184-187 32153865-8 2018 Pooling the data together indicated a non-significant decrease in CRP level following administration of vitamin D (weighted mean difference [WMD] -0.26(mg/l), (95% CI -0.75 to 0.22, N = 26 arms, heterogeneity p = 0.042; I2 54.2%). Vitamin D 104-113 C-reactive protein Homo sapiens 66-69 29078256-1 2018 BACKGROUND: To evaluate whether maternal serum adiponectin and high-sensitivity C-reactive protein (hsCRP) levels at the time of gestational diabetes mellitus (GDM) diagnosis are associated with persistent glucose intolerance in GDM women at 6 to 12 weeks postpartum. Glucose 206-213 C-reactive protein Homo sapiens 80-98 29078256-13 2018 CONCLUSIONS: Midpregnancy high sensitivity CRP is a potential predictor of persistent impaired glucose tolerance diagnosed on the postpartum 2-hour 75-g oral glucose tolerance test in GDM women in the immediate postpartum period. Glucose 95-102 C-reactive protein Homo sapiens 43-46 28647788-11 2018 CONCLUSIONS: The administration of two low-dose peri-operative dexamethasone can effectively reduce the post-operative level of CRP and IL-6, provide additional pain and nausea control, ameliorate post-operative fatigue, enhance mobility, and shorten post-operative LOS following THA, without increasing the risk of infection and gastrointestinal hemorrhage. Dexamethasone 63-76 C-reactive protein Homo sapiens 128-131 29319392-9 2018 CRP levels correlated well with both the adipokines (r = -0.236, P = 0.04 for omentin-1 and r = 0.296, P = 0.008 for vaspin), although these adipokines did not show statistically significant correlations with fasting glucose-insulin levels, homeostasis model assessment of insulin resistance, and 2 hr postload glucose level. Glucose 217-224 C-reactive protein Homo sapiens 0-3 29439678-5 2018 RESULTS: With adjustment for lifestyle-related factors, including folate intake, the global DNA methylation level of peripheral blood leukocytes was significantly but weakly increased by 0.43% per quartile category for CRP (P for trend = 0.010). Folic Acid 66-72 C-reactive protein Homo sapiens 219-222 29111269-0 2018 Oxidation of C-reactive protein by hypochlorous acid leads to the formation of potent platelet activator. Hypochlorous Acid 35-52 C-reactive protein Homo sapiens 13-31 29111269-1 2018 We examined the structural and functional consequences of oxidative modification of C-reactive protein (CRP) by hypochlorous acid (HOCl), which can be generated in vivo via the myeloperoxidase/H2O2/Cl- system. Hypochlorous Acid 112-129 C-reactive protein Homo sapiens 84-102 29111269-1 2018 We examined the structural and functional consequences of oxidative modification of C-reactive protein (CRP) by hypochlorous acid (HOCl), which can be generated in vivo via the myeloperoxidase/H2O2/Cl- system. Hypochlorous Acid 112-129 C-reactive protein Homo sapiens 104-107 29111269-1 2018 We examined the structural and functional consequences of oxidative modification of C-reactive protein (CRP) by hypochlorous acid (HOCl), which can be generated in vivo via the myeloperoxidase/H2O2/Cl- system. Hypochlorous Acid 131-135 C-reactive protein Homo sapiens 84-102 29111269-1 2018 We examined the structural and functional consequences of oxidative modification of C-reactive protein (CRP) by hypochlorous acid (HOCl), which can be generated in vivo via the myeloperoxidase/H2O2/Cl- system. Hypochlorous Acid 131-135 C-reactive protein Homo sapiens 104-107 29111269-1 2018 We examined the structural and functional consequences of oxidative modification of C-reactive protein (CRP) by hypochlorous acid (HOCl), which can be generated in vivo via the myeloperoxidase/H2O2/Cl- system. Hydrogen Peroxide 193-197 C-reactive protein Homo sapiens 84-102 29111269-1 2018 We examined the structural and functional consequences of oxidative modification of C-reactive protein (CRP) by hypochlorous acid (HOCl), which can be generated in vivo via the myeloperoxidase/H2O2/Cl- system. Hydrogen Peroxide 193-197 C-reactive protein Homo sapiens 104-107 29111269-2 2018 HOCl exposure resulted in the oxidation and chlorination of CRP amino acid residues, leading to protein unfolding, greater surface hydrophobicity and the formation of aggregates. Hypochlorous Acid 0-4 C-reactive protein Homo sapiens 60-63 29111269-4 2018 The ability of HOCl-CRP to interact with several platelet receptors (TLR-4, GPIIbIIIa) and plasma proteins (C1q, IgG) strongly indicates that HOCl-modification leads to structural changes of CRP resulting in the formation of new ligand binding sites, which is characteristic of the monomeric form of CRP exerting pro-inflammatory effects on a variety of cells. Hypochlorous Acid 15-19 C-reactive protein Homo sapiens 20-23 29111269-4 2018 The ability of HOCl-CRP to interact with several platelet receptors (TLR-4, GPIIbIIIa) and plasma proteins (C1q, IgG) strongly indicates that HOCl-modification leads to structural changes of CRP resulting in the formation of new ligand binding sites, which is characteristic of the monomeric form of CRP exerting pro-inflammatory effects on a variety of cells. Hypochlorous Acid 15-19 C-reactive protein Homo sapiens 191-194 29111269-4 2018 The ability of HOCl-CRP to interact with several platelet receptors (TLR-4, GPIIbIIIa) and plasma proteins (C1q, IgG) strongly indicates that HOCl-modification leads to structural changes of CRP resulting in the formation of new ligand binding sites, which is characteristic of the monomeric form of CRP exerting pro-inflammatory effects on a variety of cells. Hypochlorous Acid 15-19 C-reactive protein Homo sapiens 191-194 29111269-4 2018 The ability of HOCl-CRP to interact with several platelet receptors (TLR-4, GPIIbIIIa) and plasma proteins (C1q, IgG) strongly indicates that HOCl-modification leads to structural changes of CRP resulting in the formation of new ligand binding sites, which is characteristic of the monomeric form of CRP exerting pro-inflammatory effects on a variety of cells. Hypochlorous Acid 142-146 C-reactive protein Homo sapiens 20-23 29111269-4 2018 The ability of HOCl-CRP to interact with several platelet receptors (TLR-4, GPIIbIIIa) and plasma proteins (C1q, IgG) strongly indicates that HOCl-modification leads to structural changes of CRP resulting in the formation of new ligand binding sites, which is characteristic of the monomeric form of CRP exerting pro-inflammatory effects on a variety of cells. Hypochlorous Acid 142-146 C-reactive protein Homo sapiens 191-194 29111269-4 2018 The ability of HOCl-CRP to interact with several platelet receptors (TLR-4, GPIIbIIIa) and plasma proteins (C1q, IgG) strongly indicates that HOCl-modification leads to structural changes of CRP resulting in the formation of new ligand binding sites, which is characteristic of the monomeric form of CRP exerting pro-inflammatory effects on a variety of cells. Hypochlorous Acid 142-146 C-reactive protein Homo sapiens 191-194 29111269-5 2018 Overall, the oxidation of native CRP by HOCl seems to represent an alternative mechanism of CRP modification, by which CRP reveals its pro-inflammatory and pro-thrombotic properties, and as such, it might be of causal relevance in the pathogenesis of atherosclerosis. Hypochlorous Acid 40-44 C-reactive protein Homo sapiens 33-36 29111269-5 2018 Overall, the oxidation of native CRP by HOCl seems to represent an alternative mechanism of CRP modification, by which CRP reveals its pro-inflammatory and pro-thrombotic properties, and as such, it might be of causal relevance in the pathogenesis of atherosclerosis. Hypochlorous Acid 40-44 C-reactive protein Homo sapiens 92-95 29111269-5 2018 Overall, the oxidation of native CRP by HOCl seems to represent an alternative mechanism of CRP modification, by which CRP reveals its pro-inflammatory and pro-thrombotic properties, and as such, it might be of causal relevance in the pathogenesis of atherosclerosis. Hypochlorous Acid 40-44 C-reactive protein Homo sapiens 92-95 28612359-10 2018 Further, moderate drinkers had lower CRP levels suggesting that inflammation partially mediates the relationship between moderate alcohol use and depressive symptomatology. Alcohols 130-137 C-reactive protein Homo sapiens 37-40 29168915-5 2018 Interestingly, "high-risk" T2DM patients characterized by severe chemotaxis impairment reveal significantly higher C-reactive protein levels and poor lipid metabolism characteristics as compared to "low-risk" subjects, and their neutrophil chemotaxis responses can be mitigated after in vitro metformin treatment. Metformin 293-302 C-reactive protein Homo sapiens 115-133 29122443-7 2018 Correlation analyses revealed significant and positive relationships of saturated LPC, BCAA, AAA, and Glu with blood pressure, glucose, triglycerides, apolipoprotein B, and high-sensitivity C-reactive protein, while unsaturated LPC, Gln, Gln/Glu, and 25-hydroxyvitamin D exhibited an opposite trend. Glutamic Acid 102-105 C-reactive protein Homo sapiens 190-208 28841229-13 2018 The mean difference in hs-CRP was significantly lower in the vitamin D group (P = .045). Vitamin D 61-70 C-reactive protein Homo sapiens 26-29 29340241-7 2018 Binary logistic regression analysis for factors including age, BMI, creatinine, hs-CRP, smoking, steroid use, and forced expiratory volume in one second (FEV1) revealed that an hs-CRP level >=5 and decreased creatinine level were independent risk factors for osteoporosis in COPD patients. Creatinine 68-78 C-reactive protein Homo sapiens 180-183 29120646-1 2018 C-reactive protein (CRP), a biomarker for cardiovascular disease, has been reported to have a strong affinity to zwitterionic phosphorylcholine (PC) groups in the presence of calcium ions. Calcium 175-182 C-reactive protein Homo sapiens 0-18 29120646-1 2018 C-reactive protein (CRP), a biomarker for cardiovascular disease, has been reported to have a strong affinity to zwitterionic phosphorylcholine (PC) groups in the presence of calcium ions. Calcium 175-182 C-reactive protein Homo sapiens 20-23 29120646-10 2018 Notably, the dissipation energy also dropped during the binding process between CRP and PC, indicating the release of water molecules from the PC groups during CRP adsorption. Water 118-123 C-reactive protein Homo sapiens 80-83 29120646-10 2018 Notably, the dissipation energy also dropped during the binding process between CRP and PC, indicating the release of water molecules from the PC groups during CRP adsorption. Water 118-123 C-reactive protein Homo sapiens 160-163 29756982-5 2018 On the other hand, inflammation in HD, as assessed by C-reactive protein, is not only related to cardiometabolic alterations, but it is also one of the key-points in the development of malnutrition, exacerbated by the state of oxidative stress, which has been identified in this group by the increase of the serum levels of gamma-glutamyl transferase and malondialdehyde. Malondialdehyde 355-370 C-reactive protein Homo sapiens 54-72 29340241-7 2018 Binary logistic regression analysis for factors including age, BMI, creatinine, hs-CRP, smoking, steroid use, and forced expiratory volume in one second (FEV1) revealed that an hs-CRP level >=5 and decreased creatinine level were independent risk factors for osteoporosis in COPD patients. Steroids 97-104 C-reactive protein Homo sapiens 180-183 29340241-7 2018 Binary logistic regression analysis for factors including age, BMI, creatinine, hs-CRP, smoking, steroid use, and forced expiratory volume in one second (FEV1) revealed that an hs-CRP level >=5 and decreased creatinine level were independent risk factors for osteoporosis in COPD patients. Creatinine 211-221 C-reactive protein Homo sapiens 180-183 29340241-8 2018 Lower BMI tended to be associated with osteoporosis development, although it did not reach statistical significance, and hs-CRP was associated with COPD severity and steroid use history. Steroids 166-173 C-reactive protein Homo sapiens 124-127 29172154-9 2018 The complement 1q (C1q) protein recognized the active form of CRP on the supported phospholipid monolayers. Phospholipids 83-95 C-reactive protein Homo sapiens 62-65 29479472-0 2018 Moderate use of alcohol is associated with lower levels of C reactive protein but not with less severe joint inflammation: a cross-sectional study in early RA and healthy volunteers. Alcohols 16-23 C-reactive protein Homo sapiens 59-77 29479472-7 2018 Association between C reactive protein (CRP) level and alcohol was studied in 1070 newly presenting patients with RA. Alcohols 55-62 C-reactive protein Homo sapiens 20-38 29479472-7 2018 Association between C reactive protein (CRP) level and alcohol was studied in 1070 newly presenting patients with RA. Alcohols 55-62 C-reactive protein Homo sapiens 40-43 29479472-9 2018 A J-shaped curve was observed in the association between alcohol consumption and CRP level, with the lowest levels in patients consuming 1-7 drinks/week (P=0.037). Alcohols 57-64 C-reactive protein Homo sapiens 81-84 29479472-10 2018 Conclusion: Despite the fact that moderate alcohol consumption has been shown protective against RA, and our data confirm a J-shaped association of alcohol consumption with CRP levels in RA, alcohol was not associated with the severity of joint inflammation. Alcohols 148-155 C-reactive protein Homo sapiens 173-176 29479472-10 2018 Conclusion: Despite the fact that moderate alcohol consumption has been shown protective against RA, and our data confirm a J-shaped association of alcohol consumption with CRP levels in RA, alcohol was not associated with the severity of joint inflammation. Alcohols 148-155 C-reactive protein Homo sapiens 173-176 29945132-3 2018 METHODS: We searched randomized controlled trials from PubMed and the Cochrane Library in October 2017 and conducted a meta-analysis to evaluate the effectiveness of vitamin D supplementation on high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6). Vitamin D 166-175 C-reactive protein Homo sapiens 212-230 29945132-6 2018 The results indicated that the vitamin D supplementation significant decreased the hs-CRP level by 0.45 mug/mL, whereas the vitamin D supplementation did not influence the TNF-alpha and IL-6. Vitamin D 31-40 C-reactive protein Homo sapiens 86-89 29945132-7 2018 Subgroup analysis showed that vitamin D significantly lowered hs-CRP by 0.34 mug/mL among trials with a daily vitamin D dose <=4,000 IU and by 0.31 mug/mL among trials with time of vitamin D supplementation > 12 weeks. Vitamin D 30-39 C-reactive protein Homo sapiens 65-68 29945132-8 2018 CONCLUSIONS: Vitamin D supplementation is beneficial for the reduction of hs-CRP inT2DM subjects but does not have a significant influence on TNF-alpha and IL-6 in T2DM subjects. Vitamin D 13-22 C-reactive protein Homo sapiens 77-80 29938621-2 2018 Curcumin and omega-3 fatty acids can exert neuroprotective effects through modulation of IL-6 gene expression and CRP levels. Curcumin 0-8 C-reactive protein Homo sapiens 114-117 29938621-7 2018 hs-CRP serum levels significantly decrease in combination and nano-curcumin within groups (P<0.05). Curcumin 67-75 C-reactive protein Homo sapiens 3-6 29320465-0 2018 CRP Genotypes Predict Increased Risk to Co-Present with Low Vitamin D and Elevated CRP in a Group of Healthy Black South African Women. Vitamin D 60-69 C-reactive protein Homo sapiens 0-3 29320465-6 2018 CRP concentrations were higher in individuals with lower 25(OH)D concentrations. 25(oh)d 57-64 C-reactive protein Homo sapiens 0-3 30134223-7 2018 RESULTS: ABMSC infusion led to a significant decrease in FBG and CRP levels (P < 0.05). abmsc 9-14 C-reactive protein Homo sapiens 65-68 29768263-0 2018 Fibrinopeptide A Induces Expression of C-Reactive Protein via the ROS-ERK1/2/ P38-NF-kappaB Signal Pathway in Vascular Smooth Muscle Cells. Reactive Oxygen Species 66-69 C-reactive protein Homo sapiens 39-57 29768263-12 2018 FPA activated ERK1/2 and p38 phosphorylation, and PD98059 and SB203580 reduced FPA-induced CRP expression. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 50-57 C-reactive protein Homo sapiens 91-94 29768263-15 2018 CONCLUSIONS: FPA induces CRP expression in VSMCs via ROS-ERK1/2/p38-NF-kappaB signal pathway. Reactive Oxygen Species 53-56 C-reactive protein Homo sapiens 25-28 29172154-0 2018 Specific binding of human C-reactive protein towards supported monolayers of binary and engineered phospholipids. Phospholipids 99-112 C-reactive protein Homo sapiens 26-44 29172154-2 2018 We have shown previously the calcium-independent adsorption of CRP toward 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and lysophosphatidylcholine (LPC) on supported phospholipid monolayers. Calcium 29-36 C-reactive protein Homo sapiens 63-66 29172154-2 2018 We have shown previously the calcium-independent adsorption of CRP toward 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and lysophosphatidylcholine (LPC) on supported phospholipid monolayers. Phospholipids 177-189 C-reactive protein Homo sapiens 63-66 29172154-3 2018 Here, we extended our study to other phospholipids and additives to elucidate the pattern recognition of CRP using a surface plasmon resonance biosensor. Phospholipids 37-50 C-reactive protein Homo sapiens 105-108 29172154-5 2018 CRP recognized 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-l-serine (POPS) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1"-rac-glycerol) (POPG) in the supported POPC monolayers without calcium at pH 7.4 and 5.5. Calcium 185-192 C-reactive protein Homo sapiens 0-3 29172154-8 2018 Calcium-dependent CRP binding was observed only at pH 5.5 on supported monolayers of engineered phospholipids with inverted headgroups relative to POPC. Calcium 0-7 C-reactive protein Homo sapiens 18-21 28081696-12 2018 After Metformin therapy, FBS, PPB and HbA1c%, Hs- CRP and fetuin decreased (rho<=0.001) while eGDR and insulin dose in units/kg increased (rho <0.001). Metformin 6-15 C-reactive protein Homo sapiens 50-53 29172154-8 2018 Calcium-dependent CRP binding was observed only at pH 5.5 on supported monolayers of engineered phospholipids with inverted headgroups relative to POPC. Phospholipids 96-109 C-reactive protein Homo sapiens 18-21 29172154-10 2018 The discovery of CRP recognition with these phospholipids aids our understanding of the activation dynamics of CRP with phospholipid-based biomaterials when used during the acute phase. Phospholipids 44-57 C-reactive protein Homo sapiens 17-20 29172154-10 2018 The discovery of CRP recognition with these phospholipids aids our understanding of the activation dynamics of CRP with phospholipid-based biomaterials when used during the acute phase. Phospholipids 44-57 C-reactive protein Homo sapiens 111-114 29172154-10 2018 The discovery of CRP recognition with these phospholipids aids our understanding of the activation dynamics of CRP with phospholipid-based biomaterials when used during the acute phase. Phospholipids 44-56 C-reactive protein Homo sapiens 17-20 29172154-10 2018 The discovery of CRP recognition with these phospholipids aids our understanding of the activation dynamics of CRP with phospholipid-based biomaterials when used during the acute phase. Phospholipids 44-56 C-reactive protein Homo sapiens 111-114 29378052-0 2018 Soda Intake Is Directly Associated with Serum C-Reactive Protein Concentration in Mexican Women. Carbonic Acid 0-4 C-reactive protein Homo sapiens 46-64 30417782-9 2018 CONCLUSION: Overall, the current meta-analysis demonstrated that CoQ10 supplementation significantly improved metabolic profile in patients with CKD by reducing total cholesterol, LDL-cholesterol, MDA and creatinine levels, yet it did not affect fasting glucose, insulin, HOMA-IR, and CRP concentrations. coenzyme Q10 65-70 C-reactive protein Homo sapiens 285-288 29371759-0 2018 Dietary calcium intake is associated with serum high-sensitivity C-reactive protein level in the general Japanese population. Calcium 8-15 C-reactive protein Homo sapiens 65-83 29371759-1 2018 The beneficial effects of dietary calcium intake on high-sensitivity C-reactive protein levels, a risk factor of cardiovascular disease, have not been fully elucidated. Calcium 34-41 C-reactive protein Homo sapiens 69-87 29371759-2 2018 This study investigated the associations between dietary calcium intake and serum high-sensitivity C-reactive protein levels in the general Japanese population. Calcium 57-64 C-reactive protein Homo sapiens 99-117 29371759-5 2018 Analysis using a general linear model revealed that dietary calcium intake was inversely associated with serum high-sensitivity C-reactive protein levels (p for trend <0.001) after adjustment for age, sex, research group, leisure-time physical activity, smoking habit, drinking habit, dietary intakes (energy, dietary fiber, saturated fatty acids and vitamin D) and menopausal status. Calcium 60-67 C-reactive protein Homo sapiens 128-146 29371759-8 2018 This study have demonstrated that dietary calcium intake was inversely associated with serum high-sensitivity C-reactive protein levels in the general population. Calcium 42-49 C-reactive protein Homo sapiens 110-128 28176762-1 2018 Zinc- and copper-containing welding fumes increase systemic C-reactive protein (CRP). Copper 10-16 C-reactive protein Homo sapiens 60-78 28176762-1 2018 Zinc- and copper-containing welding fumes increase systemic C-reactive protein (CRP). Copper 10-16 C-reactive protein Homo sapiens 80-83 29378052-7 2018 Results: In the entire study sample we observed a 50% higher serum CRP concentration in women in the highest soda intake quartile (median intake: 202.9 mL/d, IQR: 101.4, 304.3 mL/d) compared to those in the lowest (median intake: 11.8 mL/d, IQR: 0.0, 152.1 mL/d). Carbonic Acid 109-113 C-reactive protein Homo sapiens 67-70 29378052-9 2018 Premenopausal women in the highest quartile of soda intake had 56% higher CRP concentration relative to women in the lowest quartile. Carbonic Acid 47-51 C-reactive protein Homo sapiens 74-77 29284229-10 2017 CONCLUSIONS: Obese women exhibit an increased level of CRP which may affect iron homeostasis. Iron 76-80 C-reactive protein Homo sapiens 55-58 30394135-11 2018 Age, vomiting, generalized abdominal pain, change in bowel habit, abdominal guarding, C-reactive protein and leucocytosis were univariably related to CD. Cadmium 150-152 C-reactive protein Homo sapiens 86-104 28539201-10 2017 Plasma ghrelin concentrations were negatively associated with age, smoking, FPG, HbA1c, CRP, TNF-alpha, baPWV, and Lt Carotid IMT. Ghrelin 7-14 C-reactive protein Homo sapiens 88-91 29202716-0 2017 Prediction of postoperative inflammatory complications after esophageal cancer surgery based on early changes in the C-reactive protein level in patients who received perioperative steroid therapy and enhanced recovery after surgery care: a retrospective analysis. Steroids 181-188 C-reactive protein Homo sapiens 117-135 29202716-11 2017 CONCLUSIONS: CRP value on POD 4 may be useful for predicting SICs in esophageal cancer patients who receive radical esophagectomy with perioperative steroid therapy and ERAS care. Steroids 149-156 C-reactive protein Homo sapiens 13-16 29502530-10 2017 Trends were seen for improved grip strength and a reduction in C-Reactive Protein (CRP), Angiotensin II to Angiotensin 1-7 ratio and Interleukin-10, with no change in DNA n-methylation. Nitrogen 3-4 C-reactive protein Homo sapiens 63-81 29502530-10 2017 Trends were seen for improved grip strength and a reduction in C-Reactive Protein (CRP), Angiotensin II to Angiotensin 1-7 ratio and Interleukin-10, with no change in DNA n-methylation. Nitrogen 3-4 C-reactive protein Homo sapiens 83-86 28965840-0 2017 Electrochemical detection of C-reactive protein using Copper nanoparticles and hybridization chain reaction amplifying signal. Copper 54-60 C-reactive protein Homo sapiens 29-47 28965840-5 2017 Under optimal conditions, the anodic peak currents of Cu NPs at the peak potential of about 0.08V(VS.SCE) were linear with the logarithm of CRP concentration in the range of 1.0 fg mL-1 to 100 ng mL-1 with a detection limit of 0.33 fg mL-1 (at signal/noise [S/N] = 3). Copper 54-56 C-reactive protein Homo sapiens 140-143 29203814-2 2017 We take dopamine as a cross-linking agent to immobilize the anti-CRP monoclonal antibody, which is an efficient and simple method for specific modification of the fiber optic SPR sensor. Dopamine 8-16 C-reactive protein Homo sapiens 65-68 28556504-0 2017 Effects of conjugated linoleic acid supplementation on serum C-reactive protein: A systematic review and meta-analysis of randomized controlled trials. Linoleic Acid 22-35 C-reactive protein Homo sapiens 61-79 28827067-12 2017 We found a negative correlation between serum levels of tryptophan and disease activity or levels of C-reactive protein. Tryptophan 56-66 C-reactive protein Homo sapiens 101-119 28369752-3 2017 Accumulation of excess cholesterol due to the presence of increased circulating LDL promotes endothelium dysfunction and activation, which is associated with increased production of pro-inflammatory cytokines, overexpression of adhesion molecules, chemokines and C-reactive protein (CRP), increased generation of reactive oxygen species and reduction of nitric oxide levels and bioavailability. Cholesterol 23-34 C-reactive protein Homo sapiens 263-281 28582961-4 2017 The ZnSe/CdS/ZnS QDs are used as fluorescent labels to exploit their application in fluorescence-linked immunosorbent assay (FLISA) for the first time in the detection of C-reactive protein (CRP) with a limit of detection (LOD) of 0.85 ng/mL, which is more sensitive than that of CdSe/ZnS type-I QDs based FLISA (1.00 ng/mL). Cadmium 9-12 C-reactive protein Homo sapiens 171-189 28582961-4 2017 The ZnSe/CdS/ZnS QDs are used as fluorescent labels to exploit their application in fluorescence-linked immunosorbent assay (FLISA) for the first time in the detection of C-reactive protein (CRP) with a limit of detection (LOD) of 0.85 ng/mL, which is more sensitive than that of CdSe/ZnS type-I QDs based FLISA (1.00 ng/mL). Cadmium 9-12 C-reactive protein Homo sapiens 191-194 28582961-4 2017 The ZnSe/CdS/ZnS QDs are used as fluorescent labels to exploit their application in fluorescence-linked immunosorbent assay (FLISA) for the first time in the detection of C-reactive protein (CRP) with a limit of detection (LOD) of 0.85 ng/mL, which is more sensitive than that of CdSe/ZnS type-I QDs based FLISA (1.00 ng/mL). Zinc 4-7 C-reactive protein Homo sapiens 171-189 28582961-4 2017 The ZnSe/CdS/ZnS QDs are used as fluorescent labels to exploit their application in fluorescence-linked immunosorbent assay (FLISA) for the first time in the detection of C-reactive protein (CRP) with a limit of detection (LOD) of 0.85 ng/mL, which is more sensitive than that of CdSe/ZnS type-I QDs based FLISA (1.00 ng/mL). Zinc 4-7 C-reactive protein Homo sapiens 191-194 28582961-4 2017 The ZnSe/CdS/ZnS QDs are used as fluorescent labels to exploit their application in fluorescence-linked immunosorbent assay (FLISA) for the first time in the detection of C-reactive protein (CRP) with a limit of detection (LOD) of 0.85 ng/mL, which is more sensitive than that of CdSe/ZnS type-I QDs based FLISA (1.00 ng/mL). Zinc 13-16 C-reactive protein Homo sapiens 171-189 28582961-4 2017 The ZnSe/CdS/ZnS QDs are used as fluorescent labels to exploit their application in fluorescence-linked immunosorbent assay (FLISA) for the first time in the detection of C-reactive protein (CRP) with a limit of detection (LOD) of 0.85 ng/mL, which is more sensitive than that of CdSe/ZnS type-I QDs based FLISA (1.00 ng/mL). Zinc 13-16 C-reactive protein Homo sapiens 191-194 28425575-0 2017 High Dose Supplementation of Vitamin D Affects Measures of Systemic Inflammation: Reductions in High Sensitivity C-Reactive Protein Level and Neutrophil to Lymphocyte Ratio (NLR) Distribution. Vitamin D 29-38 C-reactive protein Homo sapiens 113-131 28425575-3 2017 The aim of the current study was to evaluate the effect of vitamin D supplementation on serum C-Reactive Protein (CRP) level and Neutrophil-to-lymphocyte ratio (NLR) distribution in a large cohort of adolescent girls. Vitamin D 59-68 C-reactive protein Homo sapiens 94-112 28425575-3 2017 The aim of the current study was to evaluate the effect of vitamin D supplementation on serum C-Reactive Protein (CRP) level and Neutrophil-to-lymphocyte ratio (NLR) distribution in a large cohort of adolescent girls. Vitamin D 59-68 C-reactive protein Homo sapiens 114-117 28425575-7 2017 Moreover, we found an association between hs-CRP and BMI, triglyceride, white blood cell count, and lymphocytes. Triglycerides 58-70 C-reactive protein Homo sapiens 45-48 28425575-8 2017 Interestingly we observed a significant reduction in neutrophil count and CRP level after high dose vitamin D supplementation. Vitamin D 100-109 C-reactive protein Homo sapiens 74-77 28425575-9 2017 Our findings showed that the high dose supplementation of vitamin D affects measures of systemic inflammation: reductions in High Sensitivity C-Reactive Protein level and Neutrophil-to-lymphocyte ratio (NLR) distribution. Vitamin D 58-67 C-reactive protein Homo sapiens 142-160 29403332-3 2017 The second describes the use of c-reactive protein as a marker for starting treatment with steroids in children with orbital cellulitis. Steroids 91-99 C-reactive protein Homo sapiens 32-50 28369752-3 2017 Accumulation of excess cholesterol due to the presence of increased circulating LDL promotes endothelium dysfunction and activation, which is associated with increased production of pro-inflammatory cytokines, overexpression of adhesion molecules, chemokines and C-reactive protein (CRP), increased generation of reactive oxygen species and reduction of nitric oxide levels and bioavailability. Cholesterol 23-34 C-reactive protein Homo sapiens 283-286 28770703-10 2017 The levels of AEA were correlated with the number of oral ulcer, ESR, and CRP. aea 14-17 C-reactive protein Homo sapiens 74-77 28770703-12 2017 CONCLUSIONS: Serum AEA was increased in BD patients and correlated with oral ulcer, ESR and CRP. aea 19-22 C-reactive protein Homo sapiens 92-95 28968774-5 2017 Among these, associations with the levels of CRP (beta= -0.53; P = 0.01) and CCL15/MIP-1D (beta = 0.20; P = 0.02) were observed in workers exposed to DEE and with increasing elemental carbon exposure levels (Ptrends <0.05) in multivariable linear regression models. Carbon 184-190 C-reactive protein Homo sapiens 45-48 28985195-10 2017 RESULTS: Compared to the placebo group, the dexamethasone group showed statistically significant reductions in the incidence of POCD (relative risk, 0.43; 95% confidence interval, 0.21 to 0.89; P = 0.02), the incidence of systemic inflammatory response syndrome (30.0 versus 58.0%, P < 0.001) and postoperative C-reactive protein levels (P < 0.001). Dexamethasone 44-57 C-reactive protein Homo sapiens 314-332 29118583-1 2017 Objective: To determine if vitamin D deficiency was associated with higher odds of left ventricular dysfunction among patients with acute coronary syndrome (ACS) and, if so, to determine whether this association was mediated by increased inflammation as measured by C-reactive protein (CRP) and white blood cell count (WBC). Vitamin D 27-36 C-reactive protein Homo sapiens 286-289 28646711-8 2017 In the high CRP (> 2322ng/mL) group, patients in the VPA + memantine arm had a significantly decreased in their CRP (p= 0.009), total cholesterol (p= 0.002), LDL (p= 0.002) levels, BMI (p= 0.001), and waist circumference (p< 0.001), compared to those in the VPA + placebo arm. Cholesterol 137-148 C-reactive protein Homo sapiens 12-15 28764912-8 2017 CRP was inconsistently associated with elevated fasting glucose, insulin levels, serum triglycerides, total cholesterol levels, and low high density lipoprotein (HDL) levels. Glucose 56-63 C-reactive protein Homo sapiens 0-3 29736227-4 2017 The intake of these fatty acids is related to decrease concentration of C-reactive protein (CRP), proinflammatory eicosanoids, cytokines, chemokines and other inflammation biomarkers. Fatty Acids 20-31 C-reactive protein Homo sapiens 72-90 29736227-4 2017 The intake of these fatty acids is related to decrease concentration of C-reactive protein (CRP), proinflammatory eicosanoids, cytokines, chemokines and other inflammation biomarkers. Fatty Acids 20-31 C-reactive protein Homo sapiens 92-95 28981082-4 2017 RESULTS: Multivariate analyses identified that two preoperative factors (serum C-reactive protein (CRP) levels >4.1 mg/l (hazard ratio (HR): 2.75, 95% CI: 1.65-4.73, P<0.001) and carbohydrate antigen 19-9 (CA19-9) levels >300 mg/ml (HR: 3.76, 95% CI: 2.18-6.49)) were independent prognostic factors for postoperative survival in the training cohort. Carbohydrates 185-197 C-reactive protein Homo sapiens 79-97 28981082-4 2017 RESULTS: Multivariate analyses identified that two preoperative factors (serum C-reactive protein (CRP) levels >4.1 mg/l (hazard ratio (HR): 2.75, 95% CI: 1.65-4.73, P<0.001) and carbohydrate antigen 19-9 (CA19-9) levels >300 mg/ml (HR: 3.76, 95% CI: 2.18-6.49)) were independent prognostic factors for postoperative survival in the training cohort. Carbohydrates 185-197 C-reactive protein Homo sapiens 99-102 28764912-8 2017 CRP was inconsistently associated with elevated fasting glucose, insulin levels, serum triglycerides, total cholesterol levels, and low high density lipoprotein (HDL) levels. Triglycerides 87-100 C-reactive protein Homo sapiens 0-3 28764912-8 2017 CRP was inconsistently associated with elevated fasting glucose, insulin levels, serum triglycerides, total cholesterol levels, and low high density lipoprotein (HDL) levels. Cholesterol 108-119 C-reactive protein Homo sapiens 0-3 28709031-5 2017 In two epidemiologic studies, we detected associations of BPA with six inflammation-related markers (WBC, CRP, IL-10, ALT, AST, and gamma-GTP levels). bisphenol A 58-61 C-reactive protein Homo sapiens 106-109 28534297-1 2017 A biofunctionalized reduced graphene oxide (rGO)-modified screen-printed carbon electrode (SPCE) was constructed as an immunosensor for C-reactive protein (CRP) detection, a biomarker released in early stage acute myocardial infarction. Carbon 73-79 C-reactive protein Homo sapiens 136-154 28534297-1 2017 A biofunctionalized reduced graphene oxide (rGO)-modified screen-printed carbon electrode (SPCE) was constructed as an immunosensor for C-reactive protein (CRP) detection, a biomarker released in early stage acute myocardial infarction. Carbon 73-79 C-reactive protein Homo sapiens 156-159 27771020-7 2017 Six trials (two with galacto-oligosaccharide, one with inulin and three with different synbiotics) showed a reduction on high-sensitivity C-reactive protein. galacto-oligosaccharide 21-44 C-reactive protein Homo sapiens 138-156 28537577-9 2017 Of the metabolic syndrome components, elevated waist circumference, low high-density lipoprotein-cholesterol and high triglycerides were significantly related to CRP in a graded (dose-response) manner. Cholesterol 97-108 C-reactive protein Homo sapiens 162-165 28537577-9 2017 Of the metabolic syndrome components, elevated waist circumference, low high-density lipoprotein-cholesterol and high triglycerides were significantly related to CRP in a graded (dose-response) manner. Triglycerides 118-131 C-reactive protein Homo sapiens 162-165 28868218-3 2017 This study aims to improve the secretion of recombinant CRP by Pichia pastoris via optimizing signal peptides, promoters and carbon sources. Carbon 125-131 C-reactive protein Homo sapiens 56-59 28868218-8 2017 Subsequently, different carbon sources and at different concentrations were used to further improve the secretion of CRP. Carbon 24-30 C-reactive protein Homo sapiens 117-120 28711174-5 2017 RESULTS: Hair nicotine levels were correlated directly with blood pressure and serum C-reactive protein, and inversely correlated with serum high-density lipoprotein cholesterol and endothelial cell progenitor cell prevalence. Nicotine 14-22 C-reactive protein Homo sapiens 85-103 29416235-10 2017 Lower serum CRP and ICAM 1 with NAC versus C on day 3 (44.2 +- 13.4 vs. 68.7 +- 48.2 mg/l, P = 0.003), (308.8 +- 38.2 vs. 352.8 +- 59.4 ng/ml, P = 0.002), respectively. Acetylcysteine 32-35 C-reactive protein Homo sapiens 12-15 29416235-13 2017 Conclusion: Prophylactic NAC in hepatic patients undergoing liver surgery attenuated postoperative increase in transaminases, ICAM 1, and CRP blood levels. Acetylcysteine 25-28 C-reactive protein Homo sapiens 138-141 28850308-10 2017 The results indicate that this novel curcumin in a turmeric matrix acts as an analgesic and anti-inflammatory agent for the management of RA at a dose as low as 250 mg twice daily as evidenced by significant improvement in the ESR, CRP, VAS, RF, DAS28, and ACR responses compared to placebo. Curcumin 37-45 C-reactive protein Homo sapiens 232-235 28886725-1 2017 OBJECTIVE: The aim of this study was to investigate an independent correlation between high sensitivity C-reactive protein (hs-CRP) and glycated haemoglobin (HbA1c) on one side and between hs-CRP and arterial pressure in well glucose controlled type 2 diabetics on the other side. Glucose 226-233 C-reactive protein Homo sapiens 104-122 28654562-10 2017 In the ibuprofen group, immunization significantly increased CRP levels but was not associated with change in CRE (6.7 +- 7.7 before versus 6.8 +- 9.7 after) and PgE2 levels. Ibuprofen 7-16 C-reactive protein Homo sapiens 61-64 28336391-8 2017 RESULTS: Unadjusted and adjusted multivariate analyses indicate that there was a significant positive association between dietary protein and sodium intake and serum hs-CRP concentrations. Sodium 142-148 C-reactive protein Homo sapiens 169-172 28751572-5 2017 The 3- to 7-day moving averages of fine particulate matter (diameter<2.5 microm) and sulfate were positively associated with C-reactive protein concentrations. Sulfates 88-95 C-reactive protein Homo sapiens 128-146 28692940-6 2017 Treatment with betulinic acid and fluvastatin showed significant (p<0.05) reduction in Arthritic index, Rheumatoid factor, C-reactive protein (CRP), total lipids and anti-CCP (cyclic citrullinated peptide) antibody. betulinic acid 15-29 C-reactive protein Homo sapiens 126-144 28692940-6 2017 Treatment with betulinic acid and fluvastatin showed significant (p<0.05) reduction in Arthritic index, Rheumatoid factor, C-reactive protein (CRP), total lipids and anti-CCP (cyclic citrullinated peptide) antibody. betulinic acid 15-29 C-reactive protein Homo sapiens 146-149 28689298-10 2017 Furthermore, augmented C-reactive protein and creatine kinase fraction MB were found to be significantly higher in paclitaxel-treated patients in comparison with healthy controls. Paclitaxel 115-125 C-reactive protein Homo sapiens 23-41 28336391-10 2017 There was a significant inverse association between dietary carbohydrate and fiber consumption and serum hs-CRP in both crude and adjusted models. Carbohydrates 60-72 C-reactive protein Homo sapiens 108-111 28336391-11 2017 CONCLUSION: We have found a significant positive association between the dietary intake of fat, protein, cholesterol and sodium and hs-CRP level, and an inverse correlation between dietary carbohydrate and fiber and serum hs-CRP in a large representative Iranian population. Cholesterol 105-116 C-reactive protein Homo sapiens 135-138 28336391-11 2017 CONCLUSION: We have found a significant positive association between the dietary intake of fat, protein, cholesterol and sodium and hs-CRP level, and an inverse correlation between dietary carbohydrate and fiber and serum hs-CRP in a large representative Iranian population. Sodium 121-127 C-reactive protein Homo sapiens 135-138 28336391-11 2017 CONCLUSION: We have found a significant positive association between the dietary intake of fat, protein, cholesterol and sodium and hs-CRP level, and an inverse correlation between dietary carbohydrate and fiber and serum hs-CRP in a large representative Iranian population. Carbohydrates 189-201 C-reactive protein Homo sapiens 225-228 28824243-1 2017 Objective of the study was to assess effect of iron therapy on serum hepcidin levels in iron deficient pregnant women and its correlation with hemoglobin, serum iron profile and C-reactive protein (CRP). Iron 47-51 C-reactive protein Homo sapiens 178-196 29177259-8 2017 On regression analysis, adipose tissue volume was determined to be a common independent predictor for SUL of liver, blood pool and muscle (P<0.001) and furthermore was serum C-reactive protein level for SUL of the liver and also age and serum insulin level for SUL of blood pool. Sulfisoxazole 206-209 C-reactive protein Homo sapiens 177-195 28824243-1 2017 Objective of the study was to assess effect of iron therapy on serum hepcidin levels in iron deficient pregnant women and its correlation with hemoglobin, serum iron profile and C-reactive protein (CRP). Iron 47-51 C-reactive protein Homo sapiens 198-201 28251379-5 2017 RESULTS: In the propensity score-matched cohort, preoperative dexamethasone was associated with fewer patients exceeding the established CRP threshold of 150 mg/L on POD 3 (odds ratio [OR] 0.42, 95% confidence interval [CI] 0.26-0.70, p < 0.001) and fewer postoperative complications (OR 0.53, 95% CI 0.33-0.86, p = 0.009). Dexamethasone 62-75 C-reactive protein Homo sapiens 137-140 32313849-8 2017 Serum albumin and serum-cholesterol levels correlated negatively significantly with s-CRP levels (R2=0.247, p<0.001 and R2=0.06, p<0.001, respectively) in the hip fracture group. Cholesterol 24-35 C-reactive protein Homo sapiens 86-89 28953677-0 2017 Effects of metformin treatment on serum levels of C-reactive protein and interleukin-6 in women with polycystic ovary syndrome: a meta-analysis: A PRISMA-compliant article. Metformin 11-20 C-reactive protein Homo sapiens 50-68 28953677-1 2017 BACKGROUND: Metformin is effective for the treatment of polycystic ovary syndrome (PCOS), but conflicting results regarding its impact on serum levels of C-reactive protein (CRP) and interleukin-6 (IL-6) in women with PCOS have been reported. Metformin 12-21 C-reactive protein Homo sapiens 154-172 28953677-1 2017 BACKGROUND: Metformin is effective for the treatment of polycystic ovary syndrome (PCOS), but conflicting results regarding its impact on serum levels of C-reactive protein (CRP) and interleukin-6 (IL-6) in women with PCOS have been reported. Metformin 12-21 C-reactive protein Homo sapiens 174-177 28953677-2 2017 To provide high-quality evidence about the effect of treatment with metformin on CRP and IL-6 in PCOS, relevant studies that assessed the serum levels of CRP and IL-6 in women with PCOS receiving metformin treatment were reviewed and analyzed. Metformin 68-77 C-reactive protein Homo sapiens 81-84 28953677-7 2017 Data suggest that serum levels of CRP were decreased after metformin treatment in PCOS patients with an SMD (95% CI) of -0.86 [-1.24 to -0.48] and P = .000 (random-effects). Metformin 59-68 C-reactive protein Homo sapiens 34-37 28953677-13 2017 In addition, we noticed that metformin treatment could decrease BMI in the CRP and IL-6 related studies (SMD = -0.45, 95% CI: -0.68 to -0.23; SMD = -0.44, 95% CI: -0.73 to -0.16). Metformin 29-38 C-reactive protein Homo sapiens 75-78 28900428-0 2017 C-Reactive Protein Binds to Cholesterol Crystals and Co-Localizes with the Terminal Complement Complex in Human Atherosclerotic Plaques. Cholesterol 28-39 C-reactive protein Homo sapiens 0-18 28900428-10 2017 CRP, PTX3, and SAP were all found in atherosclerotic plaques and were located mainly in the cholesterol-rich necrotic core, but co-localization with the terminal C5b-9 complement complex was only found for CRP. Cholesterol 92-103 C-reactive protein Homo sapiens 0-3 28640164-5 2017 RESULTS: Without adiposity adjustment, estrone, total estradiol, and free estradiol were significantly positively associated with CRP, whereas SHBG was significantly inversely associated with CRP. Estradiol 74-83 C-reactive protein Homo sapiens 130-133 28640164-7 2017 Inverse associations between CRP-total testosterone became stronger with BMI adjustment (beta = -0.20, 95% CI -0.40, -0.01). Testosterone 39-51 C-reactive protein Homo sapiens 29-32 28640164-9 2017 CONCLUSIONS: Prospective and systems epidemiological studies are needed to understand whether or not the cross-sectional associations we observed, independent of adiposity, between CRP-SHBG, CRP-total testosterone, and CRP-free estradiol, are causal. Testosterone 201-213 C-reactive protein Homo sapiens 191-194 28640164-9 2017 CONCLUSIONS: Prospective and systems epidemiological studies are needed to understand whether or not the cross-sectional associations we observed, independent of adiposity, between CRP-SHBG, CRP-total testosterone, and CRP-free estradiol, are causal. Testosterone 201-213 C-reactive protein Homo sapiens 191-194 28851320-7 2017 In the multiple regression analysis performed in cilostazol group, serum L-arginine levels were inversely correlated with FMD at T1 (ss = -0.050, SE: 0.012, p < 0.001) with age, total cholesterol levels, and C-reactive protein as confounders. Arginine 73-83 C-reactive protein Homo sapiens 211-229 28801571-0 2017 CRP-level-associated polymorphism rs1205 within the CRP gene is associated with 2-hour glucose level: The SAPPHIRe study. Glucose 87-94 C-reactive protein Homo sapiens 0-3 28801571-0 2017 CRP-level-associated polymorphism rs1205 within the CRP gene is associated with 2-hour glucose level: The SAPPHIRe study. Glucose 87-94 C-reactive protein Homo sapiens 52-55 28801571-6 2017 CRP level was positively correlated with diabetes prevalence and levels of fasting and 2-hour glucose (each P < 0.008). Glucose 94-101 C-reactive protein Homo sapiens 0-3 28801571-10 2017 Since 2-hour glucose is an indicator of glucose tolerance, this study indicated CRP gene is associated with glucose intolerance. Glucose 13-20 C-reactive protein Homo sapiens 80-83 28801571-10 2017 Since 2-hour glucose is an indicator of glucose tolerance, this study indicated CRP gene is associated with glucose intolerance. Glucose 40-47 C-reactive protein Homo sapiens 80-83 28801571-10 2017 Since 2-hour glucose is an indicator of glucose tolerance, this study indicated CRP gene is associated with glucose intolerance. Glucose 40-47 C-reactive protein Homo sapiens 80-83 28789684-1 2017 BACKGROUND: To examine the relationship between cadmium, lead, and mercury concentrations with high-sensitivity C-reactive protein (hs-CRP) and homocysteine in women. Cadmium 48-55 C-reactive protein Homo sapiens 112-130 28846009-6 2017 RESULTS: After 12 weeks of intervention, changes in serum high-sensitivity C-reactive protein (-2171.4 +- 3189.1 vs. +696.9 +- 2774.8 ng/mL, P = 0.001) and plasma nitric oxide (+1.8 +- 4.0 vs. -0.1 +- 2.4 micromol/L, P = 0.04) in supplemented women were significantly different from those in the placebo group. Nitric Oxide 163-175 C-reactive protein Homo sapiens 75-93 28058664-0 2017 Elemental Zinc Is Inversely Associated with C-Reactive Protein and Oxidative Stress in Chronic Liver Disease. elemental zinc 0-14 C-reactive protein Homo sapiens 44-62 28728065-8 2017 In cross-sectional analyses, multivariable-adjusted CRP was associated with plaque prevalence and total plaque area (TPA) in men and women. Tetradecanoylphorbol Acetate 117-120 C-reactive protein Homo sapiens 52-55 28728065-9 2017 Age-adjusted baseline CRP >3 mg/L compared to CRP <1 mg/L predicted novel plaque formation (OR 1.44, CI 1.08-1.92) and TPA progression (beta = 0.0.029 (CI, 0.003-0.056)) in men, but not in women. Tetradecanoylphorbol Acetate 125-128 C-reactive protein Homo sapiens 22-25 28058664-12 2017 Elemental Zn showed an inverse relationship with MDA, NO, and CRP but positively correlated with antioxidant capacity, whereas MDA showed a positive correlation with CRP level. Zinc 10-12 C-reactive protein Homo sapiens 62-65 28728065-10 2017 In neither men nor women was baseline CRP a predictor of TPA-progression or novel plaque formation when adjusted for traditional risk factors. Tetradecanoylphorbol Acetate 57-60 C-reactive protein Homo sapiens 38-41 28728065-11 2017 CONCLUSIONS: CRP was associated with plaque presence and TPA in cross-sectional analyses, but was not an independent predictor of novel plaque formation or plaque progression. Tetradecanoylphorbol Acetate 57-60 C-reactive protein Homo sapiens 13-16 28058664-13 2017 Thus, we conclude that attenuated level of Zn and antioxidant in serum play an important role in the inflammatory status of CLD patients by elevating the concentration of MDA, NO, and CRP. Zinc 43-45 C-reactive protein Homo sapiens 184-187 27395328-9 2017 An animal-sourced pattern (animal protein, cobalamin, cholesterol and omega-6) was positively associated with CRP (p for trend across quartiles 0.057). Cholesterol 54-65 C-reactive protein Homo sapiens 110-113 29095019-6 2017 Serum copper was positively associated with CRP and also, this protein with the proportion of Lentisphaerae, ProteobacteriaandVerrucomicrobiain feces. Copper 6-12 C-reactive protein Homo sapiens 44-47 27395328-11 2017 The association between plant-sourced pattern and CRP was stronger in participants with severe sleep apnoea, smoking (p for interaction 0.019), and participants without diabetes (p for interaction 0.238) and/or with normal triglycerides (p for interaction 0.005) and high density lipoprotein (p for interaction 0.120) compared with their counterparts. Triglycerides 223-236 C-reactive protein Homo sapiens 50-53 27702411-0 2017 Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practice. agomelatine 10-21 C-reactive protein Homo sapiens 35-53 27702411-2 2017 The present study aimed (i) to investigate the effects of agomelatine treatment on CRP levels in a sample of patients with MDD and (ii) to investigate if CRP variations were correlated with clinical improvement in such patients. agomelatine 58-69 C-reactive protein Homo sapiens 83-86 27702411-7 2017 CRP levels were reduced in the whole sample, with remitters showing a significant difference in CRP levels after 12 weeks of agomelatine. agomelatine 125-136 C-reactive protein Homo sapiens 0-3 27702411-7 2017 CRP levels were reduced in the whole sample, with remitters showing a significant difference in CRP levels after 12 weeks of agomelatine. agomelatine 125-136 C-reactive protein Homo sapiens 96-99 27702411-8 2017 A multivariate stepwise linear regression analysis showed that higher CRP level variation was associated with higher baseline HAM-D scores, controlling for age, gender, smoking, BMI, and agomelatine dose. agomelatine 187-198 C-reactive protein Homo sapiens 70-73 27702411-9 2017 CONCLUSIONS: Agomelatine"s antidepressant properties were associated with a reduction in circulating CRP levels in MDD patients who achieved remission after 12 weeks of treatment. agomelatine 13-24 C-reactive protein Homo sapiens 101-104 28628373-5 2017 The largest reductions in serum CRP (mg/L) per interquartile range increase in urinary phytoestrogens (ng/mL) were observed for total phytoestrogens (beta = -0.18; 95% confidence interval [CI], -0.22, -0.15), total lignan (beta = -0.15; 95% CI, -0.18, -0.12), and enterolactone (beta = -0.15; 95% CI, -0.19, -0.12). Lignans 215-221 C-reactive protein Homo sapiens 32-35 28628373-6 2017 A decreased risk of having high CRP concentrations (>=3.0 mg/L) for quartile 4 vs quartile 1 was also found for total phytoestrogens (OR = 0.63; 95% CI, 0.53, 0.73), total lignan (OR = 0.64; 95% CI, 0.54, 0.75), and enterolactone (OR = 0.59; 95% CI, 0.51, 0.69). Lignans 175-181 C-reactive protein Homo sapiens 32-35 28498159-11 2017 CRP only significantly correlated with FC (P = 0.0007) and PGA in the second trimester (P = 0.0003). Folic Acid 59-62 C-reactive protein Homo sapiens 0-3 27638106-5 2017 Fabricated devices show high selectivity to CRP when compared with other target molecules, such as urea or creatinine, while maintaining a low detection limit (0.0625mg/L) and fast response time (61s). Creatinine 107-117 C-reactive protein Homo sapiens 44-47 28615259-4 2017 Depending on the approach used to adjust for inflammation (CRP plus AGP), the estimated prevalence of depleted iron stores increased by 7-25 and 2-8 absolute median percentage points for PSC and WRA, respectively, compared with unadjusted values. Iron 111-115 C-reactive protein Homo sapiens 59-62 28603799-4 2017 Ag NPs were conjugated to antibodies with specific recognition for the corresponding target antigenic molecule, CRP, and the Ag NPs were used to catalyse the oxidation of TMB by H2O2. Hydrogen Peroxide 178-182 C-reactive protein Homo sapiens 112-115 28746193-1 2017 High-dose atorvastatin pretreatment was proved reducing the risk of contrast-induced acute kidney injury (CI-AKI), especially in patients with high C-reactive protein (CRP) levels. Atorvastatin 10-22 C-reactive protein Homo sapiens 148-166 28746193-1 2017 High-dose atorvastatin pretreatment was proved reducing the risk of contrast-induced acute kidney injury (CI-AKI), especially in patients with high C-reactive protein (CRP) levels. Atorvastatin 10-22 C-reactive protein Homo sapiens 168-171 28489774-7 2017 Subgroup analysis of adenocarcinoma showed that CRP/Alb ratio was significantly (P < .001) associated with OS. Osmium 110-112 C-reactive protein Homo sapiens 48-51 28721055-9 2017 The combined treatment of COS and sitagliptin presented better therapeutic results by improving insulin sensitivity, lipid profile, adiponectin levels, and glucagon-like peptide 1 and reducing side effects, insulin resistance, HbA1c, body mass index, resistin, tumor necrosis factor (TNF)-alpha, and C-reactive protein (CRP) (P<0.05). carbonyl sulfide 26-29 C-reactive protein Homo sapiens 300-318 28721055-9 2017 The combined treatment of COS and sitagliptin presented better therapeutic results by improving insulin sensitivity, lipid profile, adiponectin levels, and glucagon-like peptide 1 and reducing side effects, insulin resistance, HbA1c, body mass index, resistin, tumor necrosis factor (TNF)-alpha, and C-reactive protein (CRP) (P<0.05). carbonyl sulfide 26-29 C-reactive protein Homo sapiens 320-323 28592042-12 2017 Membrane intensity of CD(55) on neutrophils was positively correlated with patient age (r=0.514, P=0.001), C reactive protein (r=0.376, P=0.018), peripheral neutrophils count (r=0.485, P=0.001) and BVAS-V3 (r=0.484, P=0.002), whereas negative correlation between membrane CD(55) and disease duration was seen (r=-0.403, P=0.01). Cadmium 22-24 C-reactive protein Homo sapiens 107-125 28649659-7 2017 Finally, the presence of crown-like structures was positively associated with systemic markers such as the Triglyceride/High-density lipoprotein-cholesterol ratio serum C-reactive protein and glucose/(HbA1c) glycated Haemoglobin. Cholesterol 145-156 C-reactive protein Homo sapiens 169-187 28502329-8 2017 Serum ghrelin levels negatively correlated with patient age (P = 0.041) and age at diagnosis (P = 0.017), and positively correlated with C-reactive protein (CRP) levels (P = 0.017). Ghrelin 6-13 C-reactive protein Homo sapiens 137-155 28502329-8 2017 Serum ghrelin levels negatively correlated with patient age (P = 0.041) and age at diagnosis (P = 0.017), and positively correlated with C-reactive protein (CRP) levels (P = 0.017). Ghrelin 6-13 C-reactive protein Homo sapiens 157-160 28502329-9 2017 Multiple regression analysis showed that serum ghrelin levels were related only to CRP levels (P = 0.032). Ghrelin 47-54 C-reactive protein Homo sapiens 83-86 28721055-10 2017 qRT-PCR and Western blot analysis also showed that COS treatment reduced the levels of resistin, TNF-alpha, and CRP, and increased the level of adiponectin. carbonyl sulfide 51-54 C-reactive protein Homo sapiens 112-115 28592572-9 2017 In the No-iron group, age above 24 months and weight-for-length z-score at baseline were associated with high CRP at endline. Iron 10-14 C-reactive protein Homo sapiens 110-113 29113390-4 2017 Studying the correlation of serum bilirubin levels with iron, zinc, copper and high-sensitivity C-reactive protein, we found positive correlations for iron and zinc, and negative correlations for high-sensitivity C-reactive protein and copper in whole participants. Iron 151-155 C-reactive protein Homo sapiens 96-114 27932449-8 2017 The inverse relation between baseline CRP and hepcidin levels and the haemoglobin response suggests that CRP or hepcidin measurements could influence decisions on whether iron should be given orally or intravenously. Iron 171-175 C-reactive protein Homo sapiens 38-41 27932449-8 2017 The inverse relation between baseline CRP and hepcidin levels and the haemoglobin response suggests that CRP or hepcidin measurements could influence decisions on whether iron should be given orally or intravenously. Iron 171-175 C-reactive protein Homo sapiens 105-108 28424258-3 2017 Iron absorption is governed by the iron-regulatory hormone hepcidin.Objective: We sought to characterize changes in hepcidin and its associations with indexes of iron stores, erythropoiesis, and inflammation at weeks 14, 20, and 30 of gestation and to assess hepcidin"s diagnostic potential as an index of iron deficiency.Methods: We measured hemoglobin and serum hepcidin, ferritin, soluble transferrin receptor (sTfR), and C-reactive protein (CRP) at 14, 20, and 30 wk of gestation in a cohort of 395 Gambian women recruited to a randomized controlled trial. Iron 0-4 C-reactive protein Homo sapiens 425-443 28424258-3 2017 Iron absorption is governed by the iron-regulatory hormone hepcidin.Objective: We sought to characterize changes in hepcidin and its associations with indexes of iron stores, erythropoiesis, and inflammation at weeks 14, 20, and 30 of gestation and to assess hepcidin"s diagnostic potential as an index of iron deficiency.Methods: We measured hemoglobin and serum hepcidin, ferritin, soluble transferrin receptor (sTfR), and C-reactive protein (CRP) at 14, 20, and 30 wk of gestation in a cohort of 395 Gambian women recruited to a randomized controlled trial. Iron 0-4 C-reactive protein Homo sapiens 445-448 28570595-14 2017 In cancer patients, only the CRP correlated with the BNP independent of the age, creatinine level, hypertension, and body mass index. Creatinine 81-91 C-reactive protein Homo sapiens 29-32 28603593-7 2017 Folic acid concentration [5.4 (4.4-7.9) ng/mL vs 12.2 (8.0-14.2) ng/mL, P < 0.01] resulted to be lower and High-sensitivity C reactive protein levels higher (4.21 +- 6.47 mg/L vs 0.98 +- 1.13 mg/L, P < 0.01) in the patient group. Folic Acid 0-10 C-reactive protein Homo sapiens 127-145 28404960-0 2017 Impact of metformin on C-reactive protein levels in women with polycystic ovary syndrome: a meta-analysis. Metformin 10-19 C-reactive protein Homo sapiens 23-41 28404960-1 2017 The impact of the recommended first-line treatment with metformin on C-reactive protein (CRP) levels in patients with polycystic ovary syndrome (PCOS) is still controversial. Metformin 56-65 C-reactive protein Homo sapiens 69-87 28404960-1 2017 The impact of the recommended first-line treatment with metformin on C-reactive protein (CRP) levels in patients with polycystic ovary syndrome (PCOS) is still controversial. Metformin 56-65 C-reactive protein Homo sapiens 89-92 28404960-2 2017 We conducted a meta-analysis of studies reporting the impact of metformin on serum CRP levels in women with PCOS. Metformin 64-73 C-reactive protein Homo sapiens 83-86 28404960-6 2017 CRP levels significantly decreased after metformin treatment (WMD = -1.23mg/L, 95%CI: -1.65 to -0.81, I2 = 93% and P < 0.001 for heterogeneity). Metformin 41-50 C-reactive protein Homo sapiens 0-3 28404960-8 2017 Interestingly, the degree of decreased CRP levels was not depended on metformin dosage, but more significantly in patients treated beyond 6 months (WMD>=6months = -1.47mg/L vs. WMD<6months = -0.94 mg/L). Metformin 70-79 C-reactive protein Homo sapiens 39-42 28404960-11 2017 Therefore, metformin shows the potential effects on CRP levels in women with PCOS. Metformin 11-20 C-reactive protein Homo sapiens 52-55 28404960-12 2017 However, considering the very low quality of evidence for the analysis, the effect of metformin on CRP levels are still very uncertain, and large-scale randomized-controlled study is needed to ascertain the long-term effects of metformin in PCOS. Metformin 86-95 C-reactive protein Homo sapiens 99-102 28577105-5 2017 Atorvastatin therapy significantly reduced the levels of VEGF (by 11%), C-reactive protein (by 26%), total cholesterol (by 30%), LDL cholesterol (by 35%), and triglycerides (by 18%); the levels of endostatin, MCP-1, and HDL cholesterol remained unchanged. Atorvastatin 0-12 C-reactive protein Homo sapiens 72-90 28063246-11 2017 Besides the challenge test, elevation of CRP and positive DLST appeared to support the diagnosis of 5-ASA intolerance. Mesalamine 100-105 C-reactive protein Homo sapiens 41-44 27797973-5 2017 Patients with low glycerophospholipids presented with more systemic inflammation (C-reactive protein and fibrinogen negatively and albumin positively correlated) but less adaptive immune cell tumor infiltration (lower tumor and immune cell PD-L1 expression), less oxygenic respiration and increased triglyceride biosynthesis in tumor cells, and lower histone expressions, correlating with higher numbers of expressed genes and more transcriptional noise, a putative neo-pluripotent tumor cell phenotype.Conclusions: Low serum phospholipids and essential amino acids are correlated with worse outcome in ovarian cancer, accompanied by a specific tumor cell phenotype. Phospholipids 25-38 C-reactive protein Homo sapiens 82-100 28422153-9 2017 Pemetrexed/cisplatin model was based on 57 patients and included CRP, MTHFD1 rs2236225, and ABCC2 rs2273697. Cisplatin 11-20 C-reactive protein Homo sapiens 65-68 28422153-5 2017 Gemcitabine/cisplatin model was based on training group of 71 patients and included CRP, histological type, performance status, RRM1 rs1042927, ERCC2 rs13181, ERCC1 rs3212986, and XRCC1 rs25487. Cisplatin 12-21 C-reactive protein Homo sapiens 84-87 27907269-9 2017 At month 3, remission rates with tofacitinib 5 mg twice daily were 18-22% using the DAS28-4(CRP), 5-10% using the DAS28-4(ESR), 4-7% using the SDAI, 5-6% using the CDAI, and 2-7% using the Boolean-based method. tofacitinib 33-44 C-reactive protein Homo sapiens 92-95 28245055-4 2017 Therefore, our findings suggest that dissociation of the CDD may be critically involved in cAMP-induced allosteric activation of CRP. Cyclic AMP 91-95 C-reactive protein Homo sapiens 129-132 27965017-1 2017 Because of the recent discovery of multiple c-reactive protein (crp)-like genes in zebrafish (Danio rerio) with predicted heterogeneous phospholipid-binding amino acid sequences and heterogeneous transcript expression levels in viral survivors and adaptive-deficient mutants, zebrafish constitute an attractive new model for exploring the evolution of these protein"s functions, including their possible participation in fish trained immunity. Phospholipids 136-148 C-reactive protein Homo sapiens 44-62 28167447-9 2017 Interquartile range (IQR) increases in PM2.5, BC, UFP, and AMP concentrations were generally associated with increased CRP and fibrinogen, but not PF4, D-dimer, vWF, or P-selectin. Adenosine Monophosphate 59-62 C-reactive protein Homo sapiens 119-122 28031420-6 2017 In a linear regression model with both GlycA and CRP as independent variables, GlycA (beta x 1 SD, -0.04 +- 0.02; P < 0.01) and CRP (-0.06 +- 0.02; P < 0.001) were independently associated with SI even after adjusting for demographics, smoking, physical activity, plasma glucose, and BMI. Glucose 277-284 C-reactive protein Homo sapiens 131-134 28167277-8 2017 While the methods to purify wild-type CRP are well established, different purification strategies are needed to purify various mutant forms of CRP if the mutant does not bind to either calcium or phosphocholine. Calcium 185-192 C-reactive protein Homo sapiens 143-146 27878970-9 2017 In this same sample the DII also was associated with CRP >=3 mg/L (ORDIIcontinuous = 1.10; 95% CI = 1.06, 1.16). dilC18(3) dye 24-27 C-reactive protein Homo sapiens 53-56 28286655-8 2017 Serum testosterone levels were significantly negatively correlated with inflammation (CRP r = -0.471, p = 0.001; IL-6 r = -0.516, p < 0.001) and endotoxaemia (LBP) after adjusting for serum LH levels (p = -0.317, p = 0.03). Testosterone 6-18 C-reactive protein Homo sapiens 86-89 27975188-0 2017 Vitamin D deficiency is associated with acute ischemic stroke, C-reactive protein, and short-term outcome. Vitamin D 0-9 C-reactive protein Homo sapiens 63-81 28237892-0 2017 Increased C-reactive protein levels at diagnosis negatively predict platelet count recovery after steroid-treatment in newly diagnosed adult immune thrombocytopenia patients. Steroids 98-105 C-reactive protein Homo sapiens 10-28 28348498-8 2017 Subgroup and stratified analyses revealed a potential influence of smoking status and aspirin use on the association between CRP levels and colorectal adenoma. Aspirin 86-93 C-reactive protein Homo sapiens 125-128 27380125-8 2017 Serum phosphate concentrations were associated with C-reactive protein (coefficient: -0.63; 95% confidence interval [CI]: -0.96 to -0.30; P = .001). Phosphates 6-15 C-reactive protein Homo sapiens 52-70 28382079-0 2017 The Relationship between Vitamin D and Coronary Artery Ectasia in Subjects with a Normal C-Reactive Protein Level. Vitamin D 25-34 C-reactive protein Homo sapiens 89-107 28096464-0 2017 Functional Transformation of C-reactive Protein by Hydrogen Peroxide. Hydrogen Peroxide 51-68 C-reactive protein Homo sapiens 29-47 28096464-4 2017 In this study, we investigated the effects of H2O2, a prototypical reactive oxygen species that is also present at sites of inflammation, on the ligand recognition function of CRP. Hydrogen Peroxide 46-50 C-reactive protein Homo sapiens 176-179 28096464-4 2017 In this study, we investigated the effects of H2O2, a prototypical reactive oxygen species that is also present at sites of inflammation, on the ligand recognition function of CRP. Reactive Oxygen Species 67-90 C-reactive protein Homo sapiens 176-179 28096464-5 2017 Controlled H2O2 treatment of native CRP did not monomerize CRP and did not affect the PCh binding activity of CRP. Hydrogen Peroxide 11-15 C-reactive protein Homo sapiens 36-39 28096464-6 2017 In solid phase ELISA-based ligand binding assays, purified pentameric H2O2-treated CRP bound to a number of immobilized proteins including oxidized LDL, IgG, amyloid beta peptide 1-42, C4b-binding protein, and factor H, in a CRP concentration- and ligand concentration-dependent manner. Hydrogen Peroxide 70-74 C-reactive protein Homo sapiens 83-86 28096464-6 2017 In solid phase ELISA-based ligand binding assays, purified pentameric H2O2-treated CRP bound to a number of immobilized proteins including oxidized LDL, IgG, amyloid beta peptide 1-42, C4b-binding protein, and factor H, in a CRP concentration- and ligand concentration-dependent manner. Hydrogen Peroxide 70-74 C-reactive protein Homo sapiens 225-228 28096464-7 2017 Using oxidized LDL as a representative protein ligand for H2O2-treated CRP, we found that the binding occurred in a Ca2+-independent manner and did not involve the PCh-binding site of CRP. Hydrogen Peroxide 58-62 C-reactive protein Homo sapiens 71-74 28096464-8 2017 We conclude that H2O2 is a biological modifier of the structure and ligand recognition function of CRP. Hydrogen Peroxide 17-21 C-reactive protein Homo sapiens 99-102 28111407-5 2017 High plasma levels of brain natriuretic peptide (BNP) and glucose were independently associated with aAO SI (P < 0.05-0.01) and the SI ratio of aAO to dAO SI, whereas body mass index, plasma levels of highsensitivity C-reactive protein, and dAO size were independently associated with dAO SI (P < 0.05-0.01). Glucose 58-65 C-reactive protein Homo sapiens 220-238 28178951-8 2017 After multivariate adjustment for T2D risk factors such as lifestyle, body mass index, plasma triglycerides and HDL cholesterol, the OR comparing the extreme quartiles of hs-CRP was 1.74 [95% CI 1.12-2.70; P for trend = 0.016]. Triglycerides 94-107 C-reactive protein Homo sapiens 174-177 28178951-8 2017 After multivariate adjustment for T2D risk factors such as lifestyle, body mass index, plasma triglycerides and HDL cholesterol, the OR comparing the extreme quartiles of hs-CRP was 1.74 [95% CI 1.12-2.70; P for trend = 0.016]. Cholesterol 116-127 C-reactive protein Homo sapiens 174-177 27858176-1 2017 We have shown that serum levels of reactive oxygen metabolites (ROM) were associated with C-reactive protein (CRP) and disease activity score based on the examination of 28 joints (DAS28) in patients with rheumatoid arthritis (RA); however, their clinical significance as biomarkers has not been elucidated. Oxygen 44-50 C-reactive protein Homo sapiens 90-108 27858176-1 2017 We have shown that serum levels of reactive oxygen metabolites (ROM) were associated with C-reactive protein (CRP) and disease activity score based on the examination of 28 joints (DAS28) in patients with rheumatoid arthritis (RA); however, their clinical significance as biomarkers has not been elucidated. Oxygen 44-50 C-reactive protein Homo sapiens 110-113 26566148-0 2017 Effects of Atorvastatin on Serum High-Sensitive C-Reactive Protein and Total Cholesterol Levels in Asian Patients With Atrial Fibrillation. Atorvastatin 11-23 C-reactive protein Homo sapiens 48-66 28207502-0 2017 Impact of the dietary fatty acid intake on C-reactive protein levels in US adults. Fatty Acids 22-32 C-reactive protein Homo sapiens 43-61 28207502-2 2017 We assessed whether reported dietary fatty acid intake correlates with a serum high-sensitivity C-reactive protein (hs-CRP) concentration in a population-based sample of US men and women.In this cross-sectional analysis, participants were selected from the US National Health and Nutrition Examination Survey (NHANES) and restricted to those with available data on dietary intake, biochemical and anthropometric measurements from 2001 to 2010. Fatty Acids 37-47 C-reactive protein Homo sapiens 96-114 27815167-0 2017 Calcium-independent binding of human C-reactive protein to lysophosphatidylcholine in supported planar phospholipid monolayers. Calcium 0-7 C-reactive protein Homo sapiens 37-55 27815167-0 2017 Calcium-independent binding of human C-reactive protein to lysophosphatidylcholine in supported planar phospholipid monolayers. Phospholipids 103-115 C-reactive protein Homo sapiens 37-55 27815167-2 2017 Here, we measured the binding kinetics of CRP to supported phospholipid monolayers deposited on an alkanethiol self-assembled monolayer on a planar gold substrate using surface plasmon resonance. Phospholipids 59-71 C-reactive protein Homo sapiens 42-45 27815167-2 2017 Here, we measured the binding kinetics of CRP to supported phospholipid monolayers deposited on an alkanethiol self-assembled monolayer on a planar gold substrate using surface plasmon resonance. alkanethiol 99-110 C-reactive protein Homo sapiens 42-45 27815167-3 2017 Surprisingly, CRP binding to supported 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)/LPC monolayers was calcium-independent although CRP binding to supported POPC monolayers was calcium-dependent. Calcium 114-121 C-reactive protein Homo sapiens 14-17 27815167-3 2017 Surprisingly, CRP binding to supported 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)/LPC monolayers was calcium-independent although CRP binding to supported POPC monolayers was calcium-dependent. Calcium 188-195 C-reactive protein Homo sapiens 14-17 27815167-4 2017 Binding inhibition assays indicate a specific interaction between CRP and the glycerophosphate group in LPC in the absence of calcium ions. Glycerophosphates 78-94 C-reactive protein Homo sapiens 66-69 27815167-5 2017 Binding experiments on supported POPC/1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1"-rac-glycerol) monolayers further validated calcium-independent binding of CRP through the glycerophosphate moiety. Calcium 127-134 C-reactive protein Homo sapiens 158-161 27815167-5 2017 Binding experiments on supported POPC/1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1"-rac-glycerol) monolayers further validated calcium-independent binding of CRP through the glycerophosphate moiety. Glycerophosphates 174-190 C-reactive protein Homo sapiens 158-161 27815167-10 2017 This paper reports the novel calcium-independent interaction of CRP to bioactive phospholipid lysophosphatidylcholine (LPC) in supported phospholipids monolayers as determined using SPR. Calcium 29-36 C-reactive protein Homo sapiens 64-67 27815167-10 2017 This paper reports the novel calcium-independent interaction of CRP to bioactive phospholipid lysophosphatidylcholine (LPC) in supported phospholipids monolayers as determined using SPR. Phospholipids 81-93 C-reactive protein Homo sapiens 64-67 27815167-10 2017 This paper reports the novel calcium-independent interaction of CRP to bioactive phospholipid lysophosphatidylcholine (LPC) in supported phospholipids monolayers as determined using SPR. Phospholipids 137-150 C-reactive protein Homo sapiens 64-67 27815167-12 2017 Our study may explode the established concept that CRP requires calcium for binding to LPC on damaged cell membranes or biomaterials. Calcium 64-71 C-reactive protein Homo sapiens 51-54 28086966-6 2017 The remnant cholesterol associated with high sensitivity C-reactive protein, neutrophil count and fibrinogen (R 2 = 0.20, 0.12 and 0.14; P = 0.000, 0.036 and 0.010 respectively). Cholesterol 12-23 C-reactive protein Homo sapiens 57-75 28676731-0 2017 The Ratio of C-Reactive Protein/Albumin is a Novel Inflammatory Predictor of Overall Survival in Cisplatin-Based Treated Patients with Metastatic Nasopharyngeal Carcinoma. Cisplatin 97-106 C-reactive protein Homo sapiens 13-31 28166841-10 2017 The overall associations between DII and ADII and long-term CRP were not statistically significant (P trend across tertiles=0 16 for DII and 0 10 for ADII). dilC18(3) dye 42-45 C-reactive protein Homo sapiens 60-63 28487744-7 2017 Considering this, his confusion and his neutrophilia and high C-reactive protein levels, empirical antibiotics with dexamethasone were started and the patient responded to that. Dexamethasone 116-129 C-reactive protein Homo sapiens 62-80 27749321-8 2017 The increments of serum omentin-1 levels with atorvastatin administration inversely correlated with changes in LDL cholesterol (r=-0.145, P=0.041), interleukin-6 (r=-0.162, P=0.023), and high-sensitivity C-reactive protein (r=-0.185, P=0.009) in patients with CAD. Atorvastatin 46-58 C-reactive protein Homo sapiens 204-222 28693022-10 2017 Exposure of platelets to CRP was followed by significant increase of [Ca2+]i, P-selectin abundance, alphaIIbbeta3 integrin activity, annexin-V-binding, ROS, caspase activity and aggregation, effects significantly blunted in the presence of temsirolimus. ros 152-155 C-reactive protein Homo sapiens 25-28 29358969-6 2017 In particular, the addition of CIF further decreased serum levels of tumor necrosis factor-alpha and hypersensitivity C-reactive protein but in contrast increased interleukin-4. cif 31-34 C-reactive protein Homo sapiens 118-136 27714659-3 2017 This study evaluated whether BPA and different phthalate metabolites are associated with the inflammation marker high-sensitivity C-reactive protein (hs-CRP) in healthy Korean adults. bisphenol A 29-32 C-reactive protein Homo sapiens 130-148 27601292-11 2017 This analysis showed that inflammation, reflected by CRP concentrations, significantly influenced the metabolic ratio, voriconazole trough concentration and voriconazole-N-oxide concentration (all P < 0.001), when corrected for other factors that could influence voriconazole metabolism. Voriconazole N-Oxide 157-177 C-reactive protein Homo sapiens 53-56 28174353-8 2017 The mean high-sensitivity C-reactive protein in the montelukast group decreased from 5.48 +- 3.86 microg/mL to 3.86 +- 3.58 microg/mL, while it increased in the placebo group from 6.69 +- 4.49 microg/mL to 8.14 +- 5.20 microg/mL. montelukast 52-63 C-reactive protein Homo sapiens 26-44 28751001-12 2017 Markers of systemic inflammation, serum amyloid A and C-reactive protein, decreased with tofacitinib. tofacitinib 89-100 C-reactive protein Homo sapiens 54-72 27783183-11 2017 Sudoscan scores were found to be inversely correlated with CRP and HbA1c, and directly correlated with ABI (p < 0.05) in the patients. sudoscan 0-8 C-reactive protein Homo sapiens 59-62 27653088-12 2017 As D9D expression increases with higher intake of saturated FA and carbohydrates, dietary changes may influence D9D activity and thus CRP. Carbohydrates 67-80 C-reactive protein Homo sapiens 134-137 28535535-10 2017 At baseline, serum cortisol levels were negatively correlated to sleep efficiency; this may depend on inflammation, because controlling for CRP eliminated this negative correlation. Hydrocortisone 19-27 C-reactive protein Homo sapiens 140-143 29168363-1 2017 Agirbasli M, Tanrikulu A, Azizy M. Free estradiol index levels associated with high sensitivitiy CRP levels in male children. Estradiol 40-49 C-reactive protein Homo sapiens 97-100 29877557-10 2017 The rate of hs CRP were significantly correlated with HA1c, total cholesterol, the LDL-C, index atherogenicity microalbuminuria and duration of diabetes for the two patient groups. Cholesterol 66-77 C-reactive protein Homo sapiens 15-18 28193012-1 2016 A novel and simple electrochemical immunoassay for C-reactive protein was developed using metal-organic frameworks (Au-MOFs) as signal unit. Metals 90-95 C-reactive protein Homo sapiens 51-69 28004756-7 2016 Immunoblot analyses showed these four proteins had higher tyrosine phosphorylation levels in response to CRP in platelets from STEMI patients, being these levels more pronounced at the culprit site of coronary artery occlusion. Tyrosine 58-66 C-reactive protein Homo sapiens 105-108 27938961-11 2016 The initiation of steroids decreased the diagnostic utility of the ESR, CRP, and platelets values (AUC = 0.58, 0.61, and 0.63, respectively). Steroids 18-26 C-reactive protein Homo sapiens 72-75 27581604-7 2016 However, further adjustments for fasting glucose at baseline resulted in significant association only for CRP. Glucose 41-48 C-reactive protein Homo sapiens 106-109 27581604-10 2016 However, after additional adjustment for fasting glucose levels at baseline, the association stayed significant only for CRP. Glucose 49-56 C-reactive protein Homo sapiens 121-124 27387048-6 2016 After multivariable adjustment, elevated CRP and sICAM-1 levels were associated with deterioration of fasting glucometabolic status from normal fasting glucose to IFG and type 2 diabetes (odds ratio [OR] 1.73 [95% CI 1.18 to 2.54] for elevated CRP levels, OR 1.86 [95% CI 1.30 to 2.66] for elevated sICAM-1 levels). Glucose 152-159 C-reactive protein Homo sapiens 41-44 27816692-1 2016 AIMS: Systemic C-reactive protein (CRP) increases 1day after short-term inhalation of welding fumes containing zinc and/or copper. Copper 123-129 C-reactive protein Homo sapiens 15-33 27816692-1 2016 AIMS: Systemic C-reactive protein (CRP) increases 1day after short-term inhalation of welding fumes containing zinc and/or copper. Copper 123-129 C-reactive protein Homo sapiens 35-38 27816692-11 2016 The median increases of CRP and IL-6 were most pronounced for the welding fume which contained besides zinc also copper (AluBronze). Copper 113-119 C-reactive protein Homo sapiens 24-27 27370977-9 2016 In women, the mean serum CRP concentrations in the highest quartiles of riboflavin (P for trend = .084) and pyridoxine (P for trend = .093) were 37% and 47%, respectively, lower than that in the lowest quartile. Riboflavin 72-82 C-reactive protein Homo sapiens 25-28 27798347-0 2016 Associations between Vitamin D and Cardiovascular Disease Risk Factors in African Americans Are Partly Explained by Circulating Adipokines and C-Reactive Protein: The Jackson Heart Study. Vitamin D 21-30 C-reactive protein Homo sapiens 143-161 27075896-5 2016 There were significant indirect negative mediation effects from BMI to cognition mediated through CRP, that is, increased BMI was associated with increased CRP which was associated with decreased cognition (natural indirect effect -0.20 unit; 95% confidence interval [CI] -0.39, -0.02), and through fasting plasma glucose, that is, increased BMI was associated with increased fasting plasma glucose which was associated with decreased cognition (natural indirect effect -0.12 unit; 95% CI -0.24, -0.01], but not through serum triglycerides. Glucose 314-321 C-reactive protein Homo sapiens 98-101 27075896-5 2016 There were significant indirect negative mediation effects from BMI to cognition mediated through CRP, that is, increased BMI was associated with increased CRP which was associated with decreased cognition (natural indirect effect -0.20 unit; 95% confidence interval [CI] -0.39, -0.02), and through fasting plasma glucose, that is, increased BMI was associated with increased fasting plasma glucose which was associated with decreased cognition (natural indirect effect -0.12 unit; 95% CI -0.24, -0.01], but not through serum triglycerides. Glucose 314-321 C-reactive protein Homo sapiens 156-159 27075896-5 2016 There were significant indirect negative mediation effects from BMI to cognition mediated through CRP, that is, increased BMI was associated with increased CRP which was associated with decreased cognition (natural indirect effect -0.20 unit; 95% confidence interval [CI] -0.39, -0.02), and through fasting plasma glucose, that is, increased BMI was associated with increased fasting plasma glucose which was associated with decreased cognition (natural indirect effect -0.12 unit; 95% CI -0.24, -0.01], but not through serum triglycerides. Glucose 391-398 C-reactive protein Homo sapiens 98-101 27075896-5 2016 There were significant indirect negative mediation effects from BMI to cognition mediated through CRP, that is, increased BMI was associated with increased CRP which was associated with decreased cognition (natural indirect effect -0.20 unit; 95% confidence interval [CI] -0.39, -0.02), and through fasting plasma glucose, that is, increased BMI was associated with increased fasting plasma glucose which was associated with decreased cognition (natural indirect effect -0.12 unit; 95% CI -0.24, -0.01], but not through serum triglycerides. Glucose 391-398 C-reactive protein Homo sapiens 156-159 27075896-5 2016 There were significant indirect negative mediation effects from BMI to cognition mediated through CRP, that is, increased BMI was associated with increased CRP which was associated with decreased cognition (natural indirect effect -0.20 unit; 95% confidence interval [CI] -0.39, -0.02), and through fasting plasma glucose, that is, increased BMI was associated with increased fasting plasma glucose which was associated with decreased cognition (natural indirect effect -0.12 unit; 95% CI -0.24, -0.01], but not through serum triglycerides. Triglycerides 526-539 C-reactive protein Homo sapiens 98-101 27075896-5 2016 There were significant indirect negative mediation effects from BMI to cognition mediated through CRP, that is, increased BMI was associated with increased CRP which was associated with decreased cognition (natural indirect effect -0.20 unit; 95% confidence interval [CI] -0.39, -0.02), and through fasting plasma glucose, that is, increased BMI was associated with increased fasting plasma glucose which was associated with decreased cognition (natural indirect effect -0.12 unit; 95% CI -0.24, -0.01], but not through serum triglycerides. Triglycerides 526-539 C-reactive protein Homo sapiens 156-159 26925610-10 2016 After adjustment for the cumulative duration of steroid therapy, these 2 correlations remained significant (CRP: P = 0.0008; orosomucoid: P < 0.0001). Steroids 48-55 C-reactive protein Homo sapiens 108-111 27798347-11 2016 CONCLUSIONS: Our findings suggest that the associations between vitamin D status and CVD risk factors in AAs are partially mediated through circulating adipokines and CRP. Vitamin D 64-73 C-reactive protein Homo sapiens 167-170 27203463-8 2016 Furthermore, by employing C-reactive protein as a model, we successfully demonstrated that the new water-swellable polymer-based ICA sensor can be utilized to detect biologically relevant analytes in human serum. Water 99-104 C-reactive protein Homo sapiens 26-44 27555076-0 2016 Vitamin D Treatment Effect on Serum Endocan and High-Sensitivity C-Reactive Protein Levels in Renal Transplant Patients. Vitamin D 0-9 C-reactive protein Homo sapiens 65-83 27555076-3 2016 OBJECTIVE: Our aim was to investigate the relationship between vitamin D treatment and serum endocan and high-sensitivity C-reactive protein (hs-CRP) levels as inflammatory markers in transplant patients. Vitamin D 63-72 C-reactive protein Homo sapiens 122-140 28028514-6 2016 RESULTS: After 1 month of melatonin treatment, the mean level of ICAM, VCAM, and CRP showed a statistically significant decrease in the case group. Melatonin 26-35 C-reactive protein Homo sapiens 81-84 27496931-0 2016 C-reactive protein level partially mediates the relationship between moderate alcohol use and frailty: the Health and Retirement Study. Alcohols 78-85 C-reactive protein Homo sapiens 0-18 27933186-0 2016 Effect of type and amount of dietary carbohydrate on biomarkers of glucose homeostasis and C reactive protein in overweight or obese adults: results from the OmniCarb trial. Carbohydrates 37-49 C-reactive protein Homo sapiens 91-109 27827910-1 2016 The hypothesized effect of vitamin D on C-reactive protein (CRP) has received substantial attention as a potential means to alleviate the risk for cardiovascular disease. Vitamin D 27-36 C-reactive protein Homo sapiens 40-58 27827910-1 2016 The hypothesized effect of vitamin D on C-reactive protein (CRP) has received substantial attention as a potential means to alleviate the risk for cardiovascular disease. Vitamin D 27-36 C-reactive protein Homo sapiens 60-63 27819306-7 2016 Furthermore, serum 25(OH)D levels inversely correlated with several systemic inflammatory markers, e.g. serum C reactive protein, but did not associate with prognosis. 25(oh)d 19-26 C-reactive protein Homo sapiens 110-128 27496931-4 2016 OBJECTIVE: this study aims to elucidate a possible mechanism - CRP modulation - by which moderate alcohol consumption may protect against frailty. Alcohols 98-105 C-reactive protein Homo sapiens 63-66 27496931-11 2016 RESULTS: results from structural equation modelling support the hypothesised model that moderate alcohol use is associated with less frailty and lower CRP levels. Alcohols 97-104 C-reactive protein Homo sapiens 151-154 25237981-14 2016 C-reactive protein in the ibuprofen group increased by 60.1%, decreased by 47.1% in the AAB group, and decreased by 36% in the combination group. Ibuprofen 26-35 C-reactive protein Homo sapiens 0-18 27496931-12 2016 Furthermore, the indirect relationship from moderate alcohol use to frailty through CRP was statistically significant. Alcohols 53-60 C-reactive protein Homo sapiens 84-87 27496931-13 2016 CONCLUSIONS: overall findings suggest that inflammation measured by CRP is one mechanism by which moderate alcohol use may confer protective effects for frailty. Alcohols 107-114 C-reactive protein Homo sapiens 68-71 27522390-6 2016 RESULTS: Clinical and experimental parts showed that groups with RIPC combined with atorvastatin pre-treatment showed a synergistic protective effect against I/R injury as evidenced by significant reduction (P<0.001) in the levels of TNF-alpha, cTnI (in patients) and IL-6, CK-MB and CRP (in rabbits) while the level of NO was significantly (P<0.001) increased compared with other groups. Atorvastatin 84-96 C-reactive protein Homo sapiens 277-290 27591289-1 2016 BACKGROUND: Users of point-of-care testing (POCT) in Norway participate in a quality improvement system that includes education and guidance in safe laboratory management along with participation in external quality assurance schemes (EQAS).The aim of this study was to identify the effect on the analytical performance of POCT C-reactive protein (CRP), glucose, and hemoglobin (Hb) with the use of a quality improvement system over time and to identify which factors are associated with good performance. Glucose 354-361 C-reactive protein Homo sapiens 328-346 27591289-1 2016 BACKGROUND: Users of point-of-care testing (POCT) in Norway participate in a quality improvement system that includes education and guidance in safe laboratory management along with participation in external quality assurance schemes (EQAS).The aim of this study was to identify the effect on the analytical performance of POCT C-reactive protein (CRP), glucose, and hemoglobin (Hb) with the use of a quality improvement system over time and to identify which factors are associated with good performance. Glucose 354-361 C-reactive protein Homo sapiens 348-351 27580687-7 2016 Rescue treatment with ciclosporin or infliximab is indicated in patients who do not sufficiently respond to corticosteroids after 3-5 days, with close monitoring of the patients" symptoms, serum C-reactive protein and albumin levels. Cyclosporine 22-33 C-reactive protein Homo sapiens 195-213 26865084-7 2016 CRP levels in plasma were positively correlated with the body mass index (BMI), insulin and glucose levels, HOMA-IR, HOMA-beta, WBC and neutrophil counts, and the NLR, and were negatively correlated with TAS and total thiol levels in the overall studied population. Glucose 92-99 C-reactive protein Homo sapiens 0-3 27726926-10 2016 Steroid treatment should be reserved for patients who present with major pain, nerve lesions, associated autoimmune disease, or elevated C reactive protein or CK. Steroids 0-7 C-reactive protein Homo sapiens 137-155 26865084-7 2016 CRP levels in plasma were positively correlated with the body mass index (BMI), insulin and glucose levels, HOMA-IR, HOMA-beta, WBC and neutrophil counts, and the NLR, and were negatively correlated with TAS and total thiol levels in the overall studied population. Sulfhydryl Compounds 218-223 C-reactive protein Homo sapiens 0-3 27084958-8 2016 Three-month atorvastatin 40 mg daily significantly lowered low-density lipoprotein cholesterol (baseline 3.55+-1.15 mmol/L, -53%) and CRP (baseline 5.0 (1.5-9.3) mg/L, -58%) with a concomitant decrease of carotid arterial wall inflammation (maximum target-to-background ratio from 1.90+-0.30 to 1.67+-0.27; p=0.009). Atorvastatin 12-24 C-reactive protein Homo sapiens 134-137 27327576-7 2016 Binary logistic regression analysis showed a strong association between the presence of vitamin D deficiency and benign prostatic hyperplasia (BPH) after adjusting for age, International Prostate Symptom Score, urination time, urinary volume, abdominal obesity, aldosterone, glucose, insulin, parathyroid hormone, and C-reactive protein (odds ratio 5.22, 95% confidence interval 1.96-12.76, P = .001). Vitamin D 88-97 C-reactive protein Homo sapiens 318-336 27292573-6 2016 RESULTS: In overall analysis, elevated pretreatment CRP values were significantly associated with poor overall survival (HR 1.60, 95% CI 1.30-1.97, p&lt;0.001, I2 = 71.9%). Adenosine Monophosphate 150-153 C-reactive protein Homo sapiens 52-55 27018756-15 2016 Metformin significantly (P < .05) reduced insulin, BP, CRP, and PAI-1 levels. Metformin 0-9 C-reactive protein Homo sapiens 58-61 27446307-7 2016 After treatment, the carvedilol and trimetazidine groups showed higher LVEF and CRP, longer walking distance in 6 min, as well as lower heart rate and blood pressure (both systolic and diastolic) compared to the control group. Carvedilol 21-31 C-reactive protein Homo sapiens 80-83 27658133-7 2016 CRP and sICAM were not related to CGM average glucose but log CRP increased as 3 day glucose standard deviation increased (r=0.66, p=0.006). Glucose 85-92 C-reactive protein Homo sapiens 62-65 26754953-7 2016 Increased log plasma C-reactive protein (CRP) was significantly associated with increased log left basal ganglia glutamate controlling for age, sex, race, body mass index, smoking status and depression severity. Glutamic Acid 113-122 C-reactive protein Homo sapiens 21-39 26754953-7 2016 Increased log plasma C-reactive protein (CRP) was significantly associated with increased log left basal ganglia glutamate controlling for age, sex, race, body mass index, smoking status and depression severity. Glutamic Acid 113-122 C-reactive protein Homo sapiens 41-44 26754953-10 2016 Plasma and CSF CRP were also associated with CSI measures of basal ganglia glutamate and the glial marker myoinositol. Glutamic Acid 75-84 C-reactive protein Homo sapiens 15-18 26754953-11 2016 These data indicate that increased inflammation in major depression may lead to increased glutamate in the basal ganglia in association with glial dysfunction and suggest that therapeutic strategies targeting glutamate may be preferentially effective in depressed patients with increased inflammation as measured by CRP. Glutamic Acid 209-218 C-reactive protein Homo sapiens 316-319 27725801-9 2016 The treatment with atorvastatin was associated with a decrease in C-reactive protein and interleukin-6 by 23.1 and 49.2%, respectively, compared with baseline values. Atorvastatin 19-31 C-reactive protein Homo sapiens 66-84 27627703-10 2016 Furthermore, camellia oil consumption significantly decreased high-sensitivity C-reactive protein (12.3%; P < .001) whereas tumor necrosis factor-alpha and interleukin-6 were not different (P = .079; P = .660, respectively) compared with the control group. camellia oil 13-25 C-reactive protein Homo sapiens 79-97 28487875-0 2017 Impact of sertraline on serum concentration of CRP in hemodialysis patients with depression. Sertraline 10-20 C-reactive protein Homo sapiens 47-50 28487875-5 2017 Objectives: This study was designed to assess the effect of sertraline on serum concentration of C-reactive protein (CRP), hemoglobin and albumin of depressed hemodialysis (HD) patients. Sertraline 60-70 C-reactive protein Homo sapiens 97-115 28487875-5 2017 Objectives: This study was designed to assess the effect of sertraline on serum concentration of C-reactive protein (CRP), hemoglobin and albumin of depressed hemodialysis (HD) patients. Sertraline 60-70 C-reactive protein Homo sapiens 117-120 28487875-12 2017 Conclusion: Sertraline significantly decreases CRP levels and can be a promising strategy to reduce the systemic inflammation and to treat depression in HD patients. Sertraline 12-22 C-reactive protein Homo sapiens 47-50 26873242-0 2016 The effect of a single dose of vitamin D on glycemic status and C-reactive protein levels in type 2 diabetic patients with ischemic heart disease: a randomized clinical trial. Vitamin D 31-40 C-reactive protein Homo sapiens 64-82 26873368-2 2016 Previously, the use of a zwitterionic phosphorylcholine group, a biomimetic ligand for CRP in the presence of calcium ions, for binding experiments has revealed that the adsorption dynamics changed by ionic microenvironments. Calcium 110-117 C-reactive protein Homo sapiens 87-90 28531394-17 2016 CRP, an indicator of acute illness, is a useful parameter at identifying patients with increased probability of dying after PEG insertion. Polyethylene Glycols 124-127 C-reactive protein Homo sapiens 0-3 26857805-6 2016 The subjects with a serum hs-CRP >3 mg/dl had higher TC (P < 0.001), low-density lipoprotein cholesterol (LDL-C, P < 0.001), TG (P < 0.001), fat percentage (P < 0.001), and systolic and diastolic blood pressure (P < 0.001) compared with subjects with a serum hs-CRP <3 mg/dl. Triglycerides 134-136 C-reactive protein Homo sapiens 29-32 27570748-1 2015 BACKGROUND: To investigate the effect of supplementation of standard treatment (inhaled long-acting beta2 agonists, anticholinergics and corticosteroids) with vitamin D on C reactive protein and pulmonary function tests in patients with COPD exacerbation. Vitamin D 159-168 C-reactive protein Homo sapiens 172-190 27087567-7 2016 Linear regression analysis, however, it became clear that for each increase of 1 mg/L in the values of CRP expected an average reduction of 0.072 mg/dL of HDL, the 0.083 mg/dL of LDL, the 0.002 g/dL albumin and an average increase of 0.564 mg/dL of TG. Triglycerides 249-251 C-reactive protein Homo sapiens 103-106 27381673-5 2016 Higher rolling speed was observed in T2DM patients (P < 0.01) which strongly correlated with neutrophil activation, rolling ligand P-selectin glycoprotein ligand 1 (PSGL-1) expression, as well as established cardiovascular risk factors (cholesterol, high-sensitive C-reactive protein (CRP) and HbA1c). Cholesterol 240-251 C-reactive protein Homo sapiens 268-286 27168055-7 2016 Patient pre-treatment baseline, unstimulated neutrophil superoxide release showed a significant, positive correlation with plasma CRP concentration (p = 0.01). Superoxides 56-66 C-reactive protein Homo sapiens 130-133 27168055-9 2016 The positive, pre-therapy relationship between unstimulated neutrophil superoxide release and plasma CRP is consistent with a protective role for CRP in reducing oxidative stress and systemic inflammation in vivo. Superoxides 71-81 C-reactive protein Homo sapiens 101-104 27174235-11 2016 A CRP declining rate &gt;22% was found to predict longer overall survival (410 days versus 299 days; p = 0.001). Adenosine Monophosphate 22-25 C-reactive protein Homo sapiens 2-5 27282272-8 2016 Multivariate analysis confirmed that younger age (p=0.016), diarrhea (p=0.042), and high levels of CRP (p=0.029) were independent predictors of QFTnegative results in patients with ITB. ITB 301 181-184 C-reactive protein Homo sapiens 99-102 27021506-7 2016 RESULTS: A high CRP was associated with younger age, steroid use, colonic or ileocolonic location, high CD activity index, and active inflammation at colonoscopy (p<0.001). Steroids 53-60 C-reactive protein Homo sapiens 16-19 27381673-5 2016 Higher rolling speed was observed in T2DM patients (P < 0.01) which strongly correlated with neutrophil activation, rolling ligand P-selectin glycoprotein ligand 1 (PSGL-1) expression, as well as established cardiovascular risk factors (cholesterol, high-sensitive C-reactive protein (CRP) and HbA1c). Cholesterol 240-251 C-reactive protein Homo sapiens 288-291 26271127-1 2016 We conducted a meta-analysis of 13 randomized trials comparing the efficacy of rosuvastatin versus atorvastatin in reducing concentrations of C-reactive protein (CRP). Atorvastatin 99-111 C-reactive protein Homo sapiens 142-160 27053688-6 2016 Remarkably, treatment of CRPtg mice with an antisense oligonucleotide that specifically blocks the human CRP acute-phase response also led to a reduction in renal g-MDSC numbers and improved albuminuria after renal IRI. Oligonucleotides 54-69 C-reactive protein Homo sapiens 25-28 26271127-0 2016 Meta-Analysis Comparing Rosuvastatin and Atorvastatin in Reducing Concentration of C-Reactive Protein in Patients With Hyperlipidemia. Atorvastatin 41-53 C-reactive protein Homo sapiens 83-101 26271127-1 2016 We conducted a meta-analysis of 13 randomized trials comparing the efficacy of rosuvastatin versus atorvastatin in reducing concentrations of C-reactive protein (CRP). Atorvastatin 99-111 C-reactive protein Homo sapiens 162-165 26705388-7 2016 Cholesterol crystals initiate inflammation via NLRP3 inflammasome leading to interleukin-1beta (IL-1beta) production inducing C-reactive protein. Cholesterol 0-11 C-reactive protein Homo sapiens 126-144 27287781-13 2016 This study shows that atorvastatin and its metabolites are detectable in breast samples and may lower serum CRP among women without hyperlipidemia. Atorvastatin 22-34 C-reactive protein Homo sapiens 108-111 26778547-0 2016 The association between vitamin D and C-reactive protein levels in patients with inflammatory and non-inflammatory diseases. Vitamin D 24-33 C-reactive protein Homo sapiens 38-56 26865349-7 2016 Similarly, significant reductions were noted in steroid doses within groups at 3 months (P < 0.05) and 12 months (P < 0.05), with notable reductions in C-reactive protein (CRP) at 3 months within groups (P < 0.05). Steroids 48-55 C-reactive protein Homo sapiens 178-181 27093965-9 2016 In addition, there was a positive correlation between Imp-R and age, ratio of extracellular water to total body water and high-sensitive C-reactive protein. Water 92-97 C-reactive protein Homo sapiens 137-155 26656902-6 2016 Compared with those of Group 2, patients with aspirin resistance exhibited significantly higher white blood cell counts, neutrophil counts, neutrophil-to-lymphocyte ratios, SUA levels, high-sensitivity C-reactive protein levels, and fasting blood glucose levels. Aspirin 46-53 C-reactive protein Homo sapiens 202-220 27040804-10 2016 CRP led to a correct diagnosis in 19 of 22 patients with discordant esterase and glucose results. Glucose 81-88 C-reactive protein Homo sapiens 0-3 26928883-11 2016 The reduction of thiols was correlated negatively with CRP and NLR (P<0.001). Sulfhydryl Compounds 17-23 C-reactive protein Homo sapiens 55-58 26303195-7 2016 Increasing carbohydrates intake from <45 to >=60 % is associated with significantly lower triglycerides, HbA1c and CRP (p < 0.05). Carbohydrates 11-24 C-reactive protein Homo sapiens 111-124 27125438-6 2016 CONCLUSIONS: A significant relationship between plasmatic sodium levels and C-reactive protein was found, apart from of the underlying disease. Sodium 58-64 C-reactive protein Homo sapiens 76-94 27075863-1 2016 BACKGROUND: This randomized controlled trial aimed to evaluate the effects of seven-day preoperative treatment with two different dosages of atorvastatin on the incidence of postoperative atrial fibrillation (POAF) and release of inflammatory markers such as high-sensitive C-reactive protein (hsCRP) and interleukin-6 in patients undergoing elective first-time on-pump coronary artery bypass grafting (CABG). Atorvastatin 141-153 C-reactive protein Homo sapiens 274-292 27270110-9 2016 The results showed that plasma chlorogenic acid exhibited negative associations with fasting blood glucose, glycated hemoglobin and C-reactive protein, whereas plasma total coffee polyphenol and plasma caffeic acid were weakly associated with these biomarkers. Chlorogenic Acid 31-47 C-reactive protein Homo sapiens 132-150 27272805-6 2016 C-reactive protein (CRP) and interleukin-6 (IL-6) correlated with each other and exhibited positive correlation with age, body-mass index (BMI), leukocyte count, platelet count, kynurenine, kynurenine/tryptophan ratio and urinary neopterin and a negative correlation with vitamin D and retinol. Tryptophan 201-211 C-reactive protein Homo sapiens 0-18 27272805-6 2016 C-reactive protein (CRP) and interleukin-6 (IL-6) correlated with each other and exhibited positive correlation with age, body-mass index (BMI), leukocyte count, platelet count, kynurenine, kynurenine/tryptophan ratio and urinary neopterin and a negative correlation with vitamin D and retinol. Vitamin D 272-281 C-reactive protein Homo sapiens 0-18 27247730-0 2016 Effects of vitamin D supplementation on metabolic indices and hs-CRP levels in gestational diabetes mellitus patients: a randomized, double-blinded, placebo-controlled clinical trial. Vitamin D 11-20 C-reactive protein Homo sapiens 65-68 27247730-2 2016 This study evaluated the effect of vitamin D supplementation on metabolic indices and hs-C-reactive protein (CRP) levels in GDM patients. Vitamin D 35-44 C-reactive protein Homo sapiens 86-107 27230043-0 2016 Beyond Coronary Calcification, Family History, and C-Reactive Protein: Cholesterol Efflux Capacity and Cardiovascular Risk Prediction. Cholesterol 71-82 C-reactive protein Homo sapiens 51-69 27001565-0 2016 Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. Vitamin D 15-24 C-reactive protein Homo sapiens 92-110 27001565-8 2016 A lower vitamin D was associated with the blood draw during fall/winter months (P < .001), older age (P = .001), increased CRP (P < .001), increased tumor thickness (P < .001), ulcerated tumor (P = .0105), and advanced melanoma stage (P = .0024). Vitamin D 8-17 C-reactive protein Homo sapiens 126-129 27001565-10 2016 The effect of vitamin D on these outcome measures persisted after adjustment for CRP and other covariates. Vitamin D 14-23 C-reactive protein Homo sapiens 81-84 27001565-13 2016 Although lower vitamin D was strongly associated with higher CRP, the associations of lower vitamin D with poorer OS, MSS, and DFS were independent of this association. Vitamin D 15-24 C-reactive protein Homo sapiens 61-64 27177774-0 2016 Interactive effects of C-reactive protein levels on the association between APOE variants and triglyceride levels in a Taiwanese population. Triglycerides 94-106 C-reactive protein Homo sapiens 23-41 27177774-6 2016 Using subgroup and interaction analyses, we observed significantly lower triglyceride levels in subjects carrying the rs429358-TT genotype and non-epsilon4 alleles in the low CRP group (P = 2.71 x 10(-4) and P = 4.32 x 10(-4), respectively), but not in those in the high CRP group (interaction P = 0.013 and 0.045, respectively). Triglycerides 73-85 C-reactive protein Homo sapiens 175-178 27177774-6 2016 Using subgroup and interaction analyses, we observed significantly lower triglyceride levels in subjects carrying the rs429358-TT genotype and non-epsilon4 alleles in the low CRP group (P = 2.71 x 10(-4) and P = 4.32 x 10(-4), respectively), but not in those in the high CRP group (interaction P = 0.013 and 0.045, respectively). Triglycerides 73-85 C-reactive protein Homo sapiens 271-274 27177774-7 2016 In addition, multivariate stepwise linear regression analysis showed that subjects carrying the rs429358-TT genotype and non-epsilon4 alleles with low CRP levels had significantly lower triglyceride levels (P < 0.001 and P < 0.001, respectively). Triglycerides 186-198 C-reactive protein Homo sapiens 151-154 27177774-10 2016 APOE polymorphisms interact with CRP to regulate triglyceride levels, thus triglyceride concentration is influenced by both the genetic background of the APOE locus and the inflammatory status of a subject. Triglycerides 49-61 C-reactive protein Homo sapiens 33-36 27177774-10 2016 APOE polymorphisms interact with CRP to regulate triglyceride levels, thus triglyceride concentration is influenced by both the genetic background of the APOE locus and the inflammatory status of a subject. Triglycerides 75-87 C-reactive protein Homo sapiens 33-36 26778547-7 2016 RESULTS: The correlation between (log) ln-25(OH) vitamin D and ln-CRP was highly significant (p<0.001) with a regression coefficient of -0.879. Vitamin D 49-58 C-reactive protein Homo sapiens 66-69 26762571-9 2016 For patients discharged from the ED with CAP, diagnostic utilization rates for blood culture, CBC, CRP, and CXR were higher after guideline publication compared with expected utilization rates without guidelines. cap 41-44 C-reactive protein Homo sapiens 99-102 27074299-1 2016 BACKGROUND: Prior studies have shown that switching patients from inducing antiepileptic drugs (AEDs) to lamotrigine, levetiracetam, or topiramate reduces serum lipids and C-reactive protein (CRP). Lamotrigine 105-116 C-reactive protein Homo sapiens 172-190 27074299-1 2016 BACKGROUND: Prior studies have shown that switching patients from inducing antiepileptic drugs (AEDs) to lamotrigine, levetiracetam, or topiramate reduces serum lipids and C-reactive protein (CRP). Lamotrigine 105-116 C-reactive protein Homo sapiens 192-195 27074299-1 2016 BACKGROUND: Prior studies have shown that switching patients from inducing antiepileptic drugs (AEDs) to lamotrigine, levetiracetam, or topiramate reduces serum lipids and C-reactive protein (CRP). Levetiracetam 118-131 C-reactive protein Homo sapiens 172-190 27074299-1 2016 BACKGROUND: Prior studies have shown that switching patients from inducing antiepileptic drugs (AEDs) to lamotrigine, levetiracetam, or topiramate reduces serum lipids and C-reactive protein (CRP). Levetiracetam 118-131 C-reactive protein Homo sapiens 192-195 27074299-1 2016 BACKGROUND: Prior studies have shown that switching patients from inducing antiepileptic drugs (AEDs) to lamotrigine, levetiracetam, or topiramate reduces serum lipids and C-reactive protein (CRP). Topiramate 136-146 C-reactive protein Homo sapiens 172-190 27074299-1 2016 BACKGROUND: Prior studies have shown that switching patients from inducing antiepileptic drugs (AEDs) to lamotrigine, levetiracetam, or topiramate reduces serum lipids and C-reactive protein (CRP). Topiramate 136-146 C-reactive protein Homo sapiens 192-195 26733407-8 2016 Patients with iron malabsorption [IM] showed higher values of ESR, CRP, and hepcidin [p = 0.02, p = 0.001, and p = 0.06, respectively]. Iron 14-18 C-reactive protein Homo sapiens 67-70 27437268-8 2016 SJC, TJC, CRP and ESR also were significantly dropped in the atorvastatin group in comparison with placebo. Atorvastatin 61-73 C-reactive protein Homo sapiens 10-13 26341668-8 2016 Of these significant factors, only the MSKCC classification, CRP level, liver metastasis, and early tumor shrinkage were shown to be independently associated with OS on multivariate analysis. Osmium 163-165 C-reactive protein Homo sapiens 61-64 27234858-10 2016 There is a statistically significant negative correlation between serum total testosterone levels and CRP serum levels were found (R - 0.75; p<0.000002 Spearman"s correlation). Testosterone 78-90 C-reactive protein Homo sapiens 102-105 27175089-7 2016 However, subjects with deficient levels of vitamin D and high CRP produced significantly higher levels of the proinflammatory cytokines (TNF-alpha and IL-8) as compared to subjects with low CRP levels with nondeficient and deficient levels of vitamin D. Vitamin D 243-252 C-reactive protein Homo sapiens 62-65 27175089-8 2016 Further, the anti-inflammatory/proinflammatory ratios suggest a role of vitamin D in maintaining an anti-inflammatory environment at low levels of CRP, an association that is weaker at high CRP levels in subjects with subclinical inflammatory situations. Vitamin D 72-81 C-reactive protein Homo sapiens 147-150 27073847-6 2016 CRP concentrations during pregnancy were positively correlated with a measure of insulin resistance, namely, the estimated glucose disposal rate, assessed in the first trimester (I, P = 0.01; II, P = 0.0165; III, P = 0.0062). Glucose 123-130 C-reactive protein Homo sapiens 0-3 27073847-7 2016 There was a positive correlation between the levels of hs-CRP and total cholesterol (P = 0.001), low-density lipoprotein cholesterol (P = 0.013), and triglycerides (P = 0.0014) in the first trimester. Cholesterol 72-83 C-reactive protein Homo sapiens 58-61 27073847-7 2016 There was a positive correlation between the levels of hs-CRP and total cholesterol (P = 0.001), low-density lipoprotein cholesterol (P = 0.013), and triglycerides (P = 0.0014) in the first trimester. Triglycerides 150-163 C-reactive protein Homo sapiens 58-61 26747436-8 2016 The effect size on plasma CRP concentrations was significant with lipophilic (atorvastatin) but not hydrophilic (pravastatin and rosuvastatin) statins. Atorvastatin 78-90 C-reactive protein Homo sapiens 26-29 25753552-1 2016 BACKGROUND & AIM: The magnitude of systemic inflammatory response, as evidenced by C-reactive protein (CRP), is a major factor associated with lower zinc and selenium. Adenosine Monophosphate 12-15 C-reactive protein Homo sapiens 87-105 26863424-6 2016 Serum RA levels were inversely associated with 8-iso-prostaglandin F2alpha (P < .001), high-sensitivity C-reactive protein (P = .015), and IL-6 (P = .020) and positively correlated with high-density lipoprotein cholesterol (P = .038). Tretinoin 6-8 C-reactive protein Homo sapiens 107-125 26936137-6 2016 We examined associations of DII with maternal plasma C-reactive protein and white blood cell count in the second trimester and the following perinatal outcomes: gestational diabetes, preeclampsia, length of gestation, fetal growth, mode of delivery, and duration of breastfeeding. dilC18(3) dye 28-31 C-reactive protein Homo sapiens 53-71 26883707-10 2016 Covariates such as age and interacting comedication ([es]omeprazole), also showed a significant correlation between VCZ and CRP concentrations (P < 0.05). Omeprazole 57-67 C-reactive protein Homo sapiens 124-127 26184426-7 2016 Upon testosterone treatment, C-reactive protein declined significantly. Testosterone 5-17 C-reactive protein Homo sapiens 29-47 26905640-3 2016 OBJECTIVES: To estimate C-reactive protein (CRP), interleukin (IL)-18, and cortisol levels in patients with CU and to explore their association with disease severity and stress. Copper 108-110 C-reactive protein Homo sapiens 24-42 26905640-9 2016 We further observed that patients with CU with hypocortisolism had higher levels of hs-CRP and IL-18 and higher PSLE and DHUS-R scores compared with those without hypocortisolism. Copper 39-41 C-reactive protein Homo sapiens 87-90 26772984-6 2016 Testosterone associated inversely with weight, the degree of inflammation (i.e. C-reactive protein concentration) and signs of a chronic infection. Testosterone 0-12 C-reactive protein Homo sapiens 80-98 26606398-5 2016 Decreases in the 28-joint Disease Activity Score, the C-reactive protein level, or the erythrocyte sedimentation rate were associated with increases in levels of HDL cholesterol, LDL cholesterol, and total cholesterol in all treatment groups (P < 0.001-0.035). Cholesterol 166-177 C-reactive protein Homo sapiens 54-72 26918445-5 2016 By translating molecular recognition signal into a large amount of glucose with the encapsulated enzyme, disease biomarkers such as thrombin or C-reactive protein (CRP) can be quantitatively detected by a PGM with a high detection limit of 1.8 or 0.30 nM, respectively. Glucose 67-74 C-reactive protein Homo sapiens 144-162 26918445-5 2016 By translating molecular recognition signal into a large amount of glucose with the encapsulated enzyme, disease biomarkers such as thrombin or C-reactive protein (CRP) can be quantitatively detected by a PGM with a high detection limit of 1.8 or 0.30 nM, respectively. Glucose 67-74 C-reactive protein Homo sapiens 164-167 26938991-10 2016 Correlational analysis showed that although oxLDL alone was not associated with HbA1c, oxLDL/HDL, oxLDL/LDL and CRP were significantly associated with HbA1c and glucose. Glucose 161-168 C-reactive protein Homo sapiens 112-115 27053615-8 2016 CONCLUSION: NaHS can inhibit A549 cell injury induced by LPS via increasing cell viability, TER and the expression of ZO-1 as well as decreasing CRP level. sodium bisulfide 12-16 C-reactive protein Homo sapiens 145-148 26861200-8 2016 Antiparkinson drugs did not affect O&NS biomarkers, but levodopa+carbidopa significantly increased CRP. Carbidopa 65-74 C-reactive protein Homo sapiens 99-102 26969644-0 2016 Associations of cigarette smoking, betel quid chewing and alcohol consumption with high-sensitivity C-reactive protein in early radiographic knee osteoarthritis: a cross-sectional study. Alcohols 58-65 C-reactive protein Homo sapiens 100-118 26606398-5 2016 Decreases in the 28-joint Disease Activity Score, the C-reactive protein level, or the erythrocyte sedimentation rate were associated with increases in levels of HDL cholesterol, LDL cholesterol, and total cholesterol in all treatment groups (P < 0.001-0.035). Cholesterol 183-194 C-reactive protein Homo sapiens 54-72 26606398-5 2016 Decreases in the 28-joint Disease Activity Score, the C-reactive protein level, or the erythrocyte sedimentation rate were associated with increases in levels of HDL cholesterol, LDL cholesterol, and total cholesterol in all treatment groups (P < 0.001-0.035). Cholesterol 183-194 C-reactive protein Homo sapiens 54-72 26134428-10 2016 CRP, apolipoprotein B, and triglycerides were higher in overweight patients versus overweight controls (all p < .05) and in overweight versus normal-weight patients (CRP p < .01; apolipoprotein B, triglycerides p < .05). Triglycerides 203-216 C-reactive protein Homo sapiens 0-3 26752690-14 2016 High sensitivity C-reactive protein (CRP) had a small indirect effect through blood glucose control (all p = 0.05). Glucose 84-91 C-reactive protein Homo sapiens 17-35 26752690-14 2016 High sensitivity C-reactive protein (CRP) had a small indirect effect through blood glucose control (all p = 0.05). Glucose 84-91 C-reactive protein Homo sapiens 37-40 26706026-11 2016 Low-fat diets (29 +- 2% energy from fats) decreased C-reactive protein compared with control diets (SMD: -0.98; 95% CI: -1.6 to -0.35; P = 0.002). Fats 36-40 C-reactive protein Homo sapiens 52-70 26931369-6 2016 There was a positive correlation between post-chemotherapy CRP and IL-6 levels (r=0.45, P=0.005) and between CRP with carbohydrate antigen-19-9 (CA19-9) levels at baseline (r=0.45, P=0.015) and post treatment (r=0.40, P=0.015). Carbohydrates 118-130 C-reactive protein Homo sapiens 109-112 26333596-8 2016 The beneficial effects on AF and CRP were more marked in patients receiving atorvastatin compared to other statins. Atorvastatin 76-88 C-reactive protein Homo sapiens 33-36 26667403-10 2016 CRP, IL-6, and cortisol were significantly lower in the dexamethasone group compared with the control group during the 24 hours after UAE. Dexamethasone 56-69 C-reactive protein Homo sapiens 0-3 26950284-7 2016 The fasting plasma hs-CRP and FGF-21 levels were significantly decreased in the T2DM group after metformin treatment compared with pretreatment (respectively, 2.56 +- 1.75 mg/L vs. 3.28 +- 1.89 mg/L [P < 0.05] and 232.6 pg/mL [range, 154.3-307.8 pg/mL] vs. 313.9 pg/mL [range, 227.7-474.2 pg/mL] [P < 0.01]). Metformin 97-106 C-reactive protein Homo sapiens 22-25 26997996-0 2016 Severity and prognosis of acute organophosphorus pesticide poisoning are indicated by C-reactive protein and copeptin levels and APACHE II score. organophosphorus 32-48 C-reactive protein Homo sapiens 86-104 26997996-1 2016 The aim of the present study was to investigate the plasma levels of C-reactive protein (CRP) and copeptin, in addition to the acute physiology and chronic health evaluation II (APACHE II) scores, in patients with acute organophosphorus pesticide poisoning (AOPP). organophosphorus 220-236 C-reactive protein Homo sapiens 69-87 26997996-1 2016 The aim of the present study was to investigate the plasma levels of C-reactive protein (CRP) and copeptin, in addition to the acute physiology and chronic health evaluation II (APACHE II) scores, in patients with acute organophosphorus pesticide poisoning (AOPP). organophosphorus 220-236 C-reactive protein Homo sapiens 89-92 27605722-14 2016 Serum creatinine, BMI, triglyceride and atherogenic index of plasma correlated positively with CRP. Creatinine 6-16 C-reactive protein Homo sapiens 95-98 27605722-14 2016 Serum creatinine, BMI, triglyceride and atherogenic index of plasma correlated positively with CRP. Triglycerides 23-35 C-reactive protein Homo sapiens 95-98 27076887-7 2016 RESULTS: Consumption of calcium-Vitamin D co-supplements resulted in a significant reduction of serum high-sensitivity C-reactive protein levels compared with placebo (-1856.8 +- 2657.7 vs. 707.1 +- 3139.4 mug/mL, P = 0.006). Calcium 24-31 C-reactive protein Homo sapiens 119-137 27076887-7 2016 RESULTS: Consumption of calcium-Vitamin D co-supplements resulted in a significant reduction of serum high-sensitivity C-reactive protein levels compared with placebo (-1856.8 +- 2657.7 vs. 707.1 +- 3139.4 mug/mL, P = 0.006). Vitamin D 32-41 C-reactive protein Homo sapiens 119-137 26923508-10 2016 Plasma total and individual catechins were weakly to moderately associated with C-reactive protein, but not the case for urinary catechins. Catechin 28-37 C-reactive protein Homo sapiens 80-98 26923510-2 2016 We hypothesized that inflammatory markers interleukin (IL)-6 and C-reactive protein (CRP) mediate the associations between antioxidant and fatty acid intakes, and depression. Fatty Acids 139-149 C-reactive protein Homo sapiens 65-83 26923510-2 2016 We hypothesized that inflammatory markers interleukin (IL)-6 and C-reactive protein (CRP) mediate the associations between antioxidant and fatty acid intakes, and depression. Fatty Acids 139-149 C-reactive protein Homo sapiens 85-88 26923510-12 2016 CRP significantly mediated the relationship between total fat, saturated fat, and monounsaturated fat intakes and depression in women, and saturated fat intake and depression in men. Fatty Acids 63-76 C-reactive protein Homo sapiens 0-3 26923510-12 2016 CRP significantly mediated the relationship between total fat, saturated fat, and monounsaturated fat intakes and depression in women, and saturated fat intake and depression in men. Fatty Acids 88-101 C-reactive protein Homo sapiens 0-3 26622051-14 2016 Testosterone treatment also caused a significant fall in circulating concentrations of free fatty acids, C-reactive protein, interleukin-1beta, tumor necrosis factor-alpha, and leptin (P < 0.05 for all). Testosterone 0-12 C-reactive protein Homo sapiens 105-123 26865526-8 2016 The combination of LAM and AFB was significantly better than AFB alone among patients with Karnofsky Performance score <=90, hemoglobin <=10 g/dL, albumin <=25 g/L, C-reactive protein >=25 mg/L, or CD4 <200/mm(3). afb 27-30 C-reactive protein Homo sapiens 174-192 26739034-8 2016 P-phosphate was lowest in children with edema and with elevated C-reactive protein, and a lower increase was seen with increasing caretaker-reported severity of illness. Phosphates 2-11 C-reactive protein Homo sapiens 64-82 25882339-14 2016 CONCLUSIONS: Soy protein containing isoflavones intake significantly decreased serum creatinine, serum phosphorus, CRP and proteinura in predialysis patients, while no significant change was found in creatinine clearance and glomerular filtration rate. Isoflavones 36-47 C-reactive protein Homo sapiens 115-118 26314869-4 2016 ASA usage promoted a decrease in high-sensitivity C-reactive protein (p = 0.01). Aspirin 0-3 C-reactive protein Homo sapiens 50-68 27121518-0 2016 Impaired systemic vascular reactivity & raised high-sensitivity C reactive protein levels in chronic obstructive pulmonary disease. Adenosine Monophosphate 39-42 C-reactive protein Homo sapiens 68-86 27121518-11 2016 INTERPRETATION & CONCLUSIONS: Our findings showed raised hs CRP levels and impaired systemic vascular reactivity in COPD patients. Adenosine Monophosphate 16-19 C-reactive protein Homo sapiens 64-67 26697531-9 2016 However, the serum lipids and CRP concentrations were significantly lower after one month of atorvastatin therapy in both groups of patients - with decreased and increased MPO gene expression. Atorvastatin 93-105 C-reactive protein Homo sapiens 30-33 26546248-6 2016 CRP levels predicted shorter exercise times (R = -0.65, p = 0.006), lower oxygen consumption (VO2) at the anaerobic threshold (R = -0.66, p = 0.005), and lower peak VO2 (R = -0.70, p = 0.002), reflecting worse cardiovascular performance. Oxygen 74-80 C-reactive protein Homo sapiens 0-3 26546248-7 2016 CRP levels also significantly correlated with an elevated ventilation/carbon dioxide production slope (R = +0.64, p = 0.008), a reduced oxygen uptake efficiency slope (R = -0.55, p = 0.026), and reduced end-tidal CO2 level at rest and with exercise (R = -0.759, p = 0.001 and R = -0.739, p = 0.001, respectively), reflecting impaired gas exchange. Oxygen 136-142 C-reactive protein Homo sapiens 0-3 27382488-2 2016 Iron depletion was defined as follows: (1) SF < 15 mug/L regardless of the C-reactive protein (CRP) level and (2) SF < 15 or <50 mug/L with CRP <= 5 or >5 mg/L, respectively. Iron 0-4 C-reactive protein Homo sapiens 149-152 28078290-3 2016 Elevated NO x level was observed in patients who received the first-line disease-modifying therapy (interferons beta-1a and beta-1b) in comparison with the subjects treated with the second-line disease-modifying therapy (natalizumab; fingolimod) and healthy controls without significant differences in C-reactive protein and interleukin-1 beta. nicotine 1-N-oxide 9-13 C-reactive protein Homo sapiens 302-320 26849256-1 2016 OBJECTIVE: Recently, it has been shown that exposure to welding fumes containing both zinc and copper leads to asymptomatic systemic inflammation in humans as shown by an increase of blood C-reactive protein. Copper 95-101 C-reactive protein Homo sapiens 189-207 26734075-10 2016 Only rosiglitazone decreased Homa beta, PAI-1 activity, CRP, fibrinogen, TGFbeta, FFA and triglyceride levels. Rosiglitazone 5-18 C-reactive protein Homo sapiens 56-59 26800186-12 2016 Compared to patients with sufficient vitamin D, patients with deficient vitamin D more frequently exhibited diabetes, elevated C-reactive protein levels, and hospital-acquired infections upon ICU admission, and they more frequently developed acute kidney injury. Vitamin D 72-81 C-reactive protein Homo sapiens 127-145 26547218-6 2016 In the patient group, a positive correlation was determined between c-reactive protein (r = 325, p = 0.007; r = 316, p = 0.010, respectively), fasting blood glucose (r = 279, p = 0.018; r = 251, p = 0.035, respectively), and glycosylated hemoglobin (r = 341, p = 0.004; r = 332, p = 0.005, respectively) and rates of disulfide/native thiol and disulfide/total thiol. Disulfides 317-326 C-reactive protein Homo sapiens 68-86 25993991-4 2016 There were significant positive correlation between high sensitive C reactive protein and waist circumference, systolic and diastolic blood pressure, triglyceride and fasting blood glucose. Triglycerides 150-162 C-reactive protein Homo sapiens 67-85 26547218-6 2016 In the patient group, a positive correlation was determined between c-reactive protein (r = 325, p = 0.007; r = 316, p = 0.010, respectively), fasting blood glucose (r = 279, p = 0.018; r = 251, p = 0.035, respectively), and glycosylated hemoglobin (r = 341, p = 0.004; r = 332, p = 0.005, respectively) and rates of disulfide/native thiol and disulfide/total thiol. Sulfhydryl Compounds 334-339 C-reactive protein Homo sapiens 68-86 25993991-4 2016 There were significant positive correlation between high sensitive C reactive protein and waist circumference, systolic and diastolic blood pressure, triglyceride and fasting blood glucose. Glucose 181-188 C-reactive protein Homo sapiens 67-85 26547218-6 2016 In the patient group, a positive correlation was determined between c-reactive protein (r = 325, p = 0.007; r = 316, p = 0.010, respectively), fasting blood glucose (r = 279, p = 0.018; r = 251, p = 0.035, respectively), and glycosylated hemoglobin (r = 341, p = 0.004; r = 332, p = 0.005, respectively) and rates of disulfide/native thiol and disulfide/total thiol. Disulfides 344-353 C-reactive protein Homo sapiens 68-86 26547218-6 2016 In the patient group, a positive correlation was determined between c-reactive protein (r = 325, p = 0.007; r = 316, p = 0.010, respectively), fasting blood glucose (r = 279, p = 0.018; r = 251, p = 0.035, respectively), and glycosylated hemoglobin (r = 341, p = 0.004; r = 332, p = 0.005, respectively) and rates of disulfide/native thiol and disulfide/total thiol. Sulfhydryl Compounds 360-365 C-reactive protein Homo sapiens 68-86 26043647-9 2016 There was statistically significant and positive correlation between C-reactive protein (CRP) and glucose with NLR (p = 0.001, p = 0.043). Glucose 98-105 C-reactive protein Homo sapiens 69-87 26610293-6 2016 Each 100% increase in 4-hydroxyphenanthrene was associated with a 6.18% increase in GGT (95% CI: 4.064-8.301; p<0.001) and a 13.66% increase in CRP (95% CI: 2.764-24.564; p=0.017). 4-hydroxyphenanthrene 22-43 C-reactive protein Homo sapiens 147-150 25073857-6 2016 C-reactive protein decreased, but the effect was significantly greater in the IS group (-32%, p < 0.0001) than in the IP group (-5%, p = 0.0005). ip 121-123 C-reactive protein Homo sapiens 0-18 26408073-8 2016 BPV declined in the high-variability group in association with lowering of PWV, C-reactive protein, glycated hemoglobin, alanine aminotransferase, asymmetric dimethylarginine, and increased high-density lipoprotein cholesterol. bromopyruvate 0-3 C-reactive protein Homo sapiens 80-145 26043647-9 2016 There was statistically significant and positive correlation between C-reactive protein (CRP) and glucose with NLR (p = 0.001, p = 0.043). Glucose 98-105 C-reactive protein Homo sapiens 89-92 27713770-7 2016 Generally, Vit D levels were associated indirectly with leukocytes/ neutrophils number or with ESR, CRP, and Fibrinogen levels. Vitamin D 11-16 C-reactive protein Homo sapiens 100-103 27047809-4 2016 OBJECTIVES: Due to increasing oxidative stress in dialysis patients, and the effect of CO-Q10 in decrease oxidative stress, in this work, we assessed the effect of CO-Q10 on C-reactive protein (CRP) level as an inflammatory marker and homocysteine in dialysis patients. coenzyme Q10 87-93 C-reactive protein Homo sapiens 174-192 27047809-4 2016 OBJECTIVES: Due to increasing oxidative stress in dialysis patients, and the effect of CO-Q10 in decrease oxidative stress, in this work, we assessed the effect of CO-Q10 on C-reactive protein (CRP) level as an inflammatory marker and homocysteine in dialysis patients. coenzyme Q10 164-170 C-reactive protein Homo sapiens 174-192 27047809-4 2016 OBJECTIVES: Due to increasing oxidative stress in dialysis patients, and the effect of CO-Q10 in decrease oxidative stress, in this work, we assessed the effect of CO-Q10 on C-reactive protein (CRP) level as an inflammatory marker and homocysteine in dialysis patients. coenzyme Q10 164-170 C-reactive protein Homo sapiens 194-197 27047809-10 2016 The treatment effect of CO-Q10 on CRP level is significant (P < 0.001) (95% CI = -20.1 to -10.5) and it was also significant for the increasing albumin level. coenzyme Q10 24-30 C-reactive protein Homo sapiens 34-37 27047809-13 2016 CONCLUSIONS: CO-Q10 could significantly decrease CRP level as an inflammatory marker and can protect cardiovascular events. coenzyme Q10 13-19 C-reactive protein Homo sapiens 49-52 26728928-2 2016 Associations of serum CRP with FAs in different populations have not been established. Fatty Acids 31-34 C-reactive protein Homo sapiens 22-25 26728928-9 2016 Japanese Americans had CRP associations with n-3 FAs, n-6 FAs, and TFAs similar to but weaker than Whites. Fatty Acids 49-52 C-reactive protein Homo sapiens 23-26 26728928-9 2016 Japanese Americans had CRP associations with n-3 FAs, n-6 FAs, and TFAs similar to but weaker than Whites. Fatty Acids 58-61 C-reactive protein Homo sapiens 23-26 26728928-10 2016 CONCLUSIONS: With the exception of consistent inverse association of CRP with total n-6 FAs, there are considerable variations across the three populations in the associations of CRP with different FAs. Fatty Acids 88-91 C-reactive protein Homo sapiens 69-72 27642237-10 2016 There was a negative correlation of CRP with native thiol, total thiol, and native thiol/total thiol ratio while there was a positive correlation of CRP with disulphide/native thiol and disulphide/total thiol in the AA group. Sulfhydryl Compounds 52-57 C-reactive protein Homo sapiens 36-39 26630041-3 2016 While on steroid treatment, the patients maintained clinical and laboratory remission, but with the initiation of mesalamine treatment, they had abdominal pain and bloody mucoid diarrhoea and/or elevation of white blood cell count, C-reactive protein level and erythrocyte sedimentation rate. Mesalamine 114-124 C-reactive protein Homo sapiens 232-250 25277876-0 2016 Relationship of the Serum CRP Level With the Efficacy of Metformin in the Treatment of Type 2 Diabetes Mellitus: A Meta-Analysis. Metformin 57-66 C-reactive protein Homo sapiens 26-29 25277876-2 2016 This meta-analysis was conducted to investigate whether CRP was sensitive in predicting the efficacy of metformin in the treatment of T2DM. Metformin 104-113 C-reactive protein Homo sapiens 56-59 25277876-7 2016 Pooled SMD of those studies revealed that serum levels of CRP and hs-CRP significantly decreased in patients with T2DM after receiving the metformin treatment. Metformin 139-148 C-reactive protein Homo sapiens 58-61 25277876-7 2016 Pooled SMD of those studies revealed that serum levels of CRP and hs-CRP significantly decreased in patients with T2DM after receiving the metformin treatment. Metformin 139-148 C-reactive protein Homo sapiens 69-72 25277876-8 2016 Subgroup analysis by country yielded significant different estimates in the serum levels of CRP between the baseline and after metformin treatment in the China, Israel and India subgroups; but only detected only in the China subgroup considering serum levels of hs-CRP. Metformin 127-136 C-reactive protein Homo sapiens 92-95 25277876-9 2016 Follow-up time-stratified analyses indicated that serum levels of CRP were markedly reduced in the metformin-treated group in all subgroups. Metformin 99-108 C-reactive protein Homo sapiens 66-69 25277876-11 2016 CONCLUSION: Decreased serum levels of CRP and hs-CRP may contribute to a more sensitive prediction in providing a more accurate efficacy reference in the metformin drug in T2DM patients. Metformin 154-163 C-reactive protein Homo sapiens 38-41 25277876-11 2016 CONCLUSION: Decreased serum levels of CRP and hs-CRP may contribute to a more sensitive prediction in providing a more accurate efficacy reference in the metformin drug in T2DM patients. Metformin 154-163 C-reactive protein Homo sapiens 49-52 26515873-8 2016 CONCLUSIONS: The primary finding of this study is that GI bleeding in CF-LVAD recipients is associated with significantly elevated cGMP levels, despite high levels of CRP, which interfere with cGMP production. Cyclic GMP 193-197 C-reactive protein Homo sapiens 167-170 26630041-5 2016 Within 3-7 days after the mesalamine treatment had been stopped, the patients showed improvement of colitis symptoms and normalisation of white blood cell count, C-reactive protein level and erythrocyte sedimentation rate. Mesalamine 26-36 C-reactive protein Homo sapiens 162-180 26456189-0 2016 Interaction of SNP in the CRP gene and plasma fatty acid profile in inflammatory pattern: A cross-sectional population-based study. Fatty Acids 46-56 C-reactive protein Homo sapiens 26-29 26987842-3 2016 Iron status was determined by a combination of several indicators: ferritin, transferrin, blood count, total iron binding capacity, transferrin saturation, and C-reactive protein. Iron 0-4 C-reactive protein Homo sapiens 160-178 26456189-10 2016 CONCLUSIONS: The INF group exhibited changes in metabolic parameters that predispose this group to chronic disease, where polymorphisms in the CRP gene modulated the risk of being in the INF group depending on individual plasma fatty acid and lipid profile. Fatty Acids 228-238 C-reactive protein Homo sapiens 143-146 27508369-5 2016 KMnO4 released from CRP can effectively degrade phenol-contaminated water with different concentrations. Water 68-73 C-reactive protein Homo sapiens 20-23 26627016-3 2016 In CKD, interleukin-6 and hypersensitive C-reactive protein are known to be used for the evaluation of inflammation and serum levels increase with decreased creatinine clearance. Creatinine 157-167 C-reactive protein Homo sapiens 41-59 26627016-9 2016 In patient groups, while hepcidin, NGAL, interleukin-6, hypersensitive C-reactive protein levels were correlated with creatinine and glomerular filtration rate, iron metabolism parameters were not correlated with the inflammation biomarkers. Creatinine 118-128 C-reactive protein Homo sapiens 71-89 26516642-0 2015 Retraction notice to "A novel modified electrode as GC/PPy-AuNPs- rGO/L-Cys/Ag@MUA nanostructure configuration for determination of CCP and C RP antibodies in human blood serum samples" [Biosens. Cysteine 72-75 C-reactive protein Homo sapiens 140-144 26730169-6 2015 fC levels in UC patients correlated with UCEIS (r = 0.696, P < 0.0001) and CRP (r = 0.529, P = 0.0005). Fc(alpha) receptor 0-2 C-reactive protein Homo sapiens 78-81 26588324-0 2015 Poly(3,4-ethylenedioxythiophene) Bearing Phosphorylcholine Groups for Metal-Free, Antibody-Free, and Low-Impedance Biosensors Specific for C-Reactive Protein. Metals 70-75 C-reactive protein Homo sapiens 139-157 26588324-6 2015 The specific interaction of CRP with phosphorylcholine in a calcium-containing buffer solution was determined by differential pulse voltammetry, which measures the altered redox reaction between the indicators ferricyanide/ferrocyanide as a result of the binding event. Calcium 60-67 C-reactive protein Homo sapiens 28-31 26318589-7 2015 Only within the highest 8-isoprostane quartile was periodontitis (pocket depth) associated with increased serum CRP levels (P = 0.0003). 8-epi-prostaglandin F2alpha 24-37 C-reactive protein Homo sapiens 112-115 26141306-12 2015 Mean high-sensitivity C-reactive protein level was 11.6+-5.3 (SE) mg/L lower for patients in the heparin group (P=0.03). Heparin 97-104 C-reactive protein Homo sapiens 22-40 25986867-6 2015 RESULTS: Intraoperative blood loss and C-reactive protein levels at 3 and 7 days after surgery were significantly lower in LPG than in LTG (p = 0.018, 0.036, and 0.042, respectively). Lamotrigine 135-138 C-reactive protein Homo sapiens 39-57 26840464-12 2015 The total iron dose ranged from 1,000 to 2,000 mg, with an average of 1,650 mg. Crohn"s disease activity measured using CDAI and C-reactive protein correlated with the intensity of anemia. Iron 10-14 C-reactive protein Homo sapiens 129-147 26644840-0 2015 Effect of topical application of melatonin on serum levels of C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in patients with type 1 or type 2 diabetes and periodontal disease. Melatonin 33-42 C-reactive protein Homo sapiens 62-80 26644840-1 2015 BACKGROUND: The present clinical trial study was designed to assess the effect of topical application of melatonin on serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and C-reactive protein (CRP) in patients with diabetes and periodontal disease in comparison with healthy controls. Melatonin 105-114 C-reactive protein Homo sapiens 200-218 26644840-1 2015 BACKGROUND: The present clinical trial study was designed to assess the effect of topical application of melatonin on serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and C-reactive protein (CRP) in patients with diabetes and periodontal disease in comparison with healthy controls. Melatonin 105-114 C-reactive protein Homo sapiens 220-223 26644840-7 2015 Following topical melatonin application, there was a statistically significant decrease in the gingival index and pocket depth (P < 0.001) as well as a significant decrease in IL-6 and CRP serum levels (P < 0.001). Melatonin 18-27 C-reactive protein Homo sapiens 188-191 26644840-8 2015 Local melatonin application in patients with diabetes and periodontal disease resulted in a significant decrease in CRP and IL-6 serum levels as well as an improvement in the gingival index and pocket depth. Melatonin 6-15 C-reactive protein Homo sapiens 116-119 25618800-8 2015 Regarding the importance of CRP as a risk marker and risk factor of cardiovascular disease, a random-effects meta-analysis of clinical trials was performed to estimate the overall impact of curcuminoid therapy on circulating concentrations of CRP. curcuminoid 190-201 C-reactive protein Homo sapiens 243-246 26220267-10 2015 In patients with AAS, a pathological glucose uptake in aortic wall lesions by PET-CT was associated with high CRP levels and increased mortality and MAE at 3-year follow-up. Glucose 37-44 C-reactive protein Homo sapiens 110-113 26436683-11 2015 CONCLUSIONS: The 6-week camp intervention resulted in reductions in CRP and leptin. Cyclic AMP 24-28 C-reactive protein Homo sapiens 68-71 26525102-6 2015 In conclusion, total n-6 FA levels in plasma PL and plasma CRP levels are modulated by SNPs within PLA2G4A and PLA2G6 genes alone or in combination with fish oil supplementation. Nitrogen 1-2 C-reactive protein Homo sapiens 59-62 26304464-4 2015 To follow-up these promising preliminary findings, we tested the efficacy of two doses of supplemental calcium (1.0 or 2.0 g/day) relative to placebo on modulating circulating biomarkers of inflammation [C-reactive protein (CRP) and 10 cytokines] and oxidative stress (F2-isoprostanes) over a 4-month treatment period among 193 patients with previous sporadic, colorectal adenoma in a randomized, double-blinded, placebo-controlled clinical trial. Calcium 103-110 C-reactive protein Homo sapiens 204-222 26569292-0 2015 Inverse Correlation between Vitamin D and C-Reactive Protein in Newborns. Vitamin D 28-37 C-reactive protein Homo sapiens 42-60 26633088-5 2015 With the HUVECs, we found an appropriate E2/T ratio of 5:1 (5x10(-8) mol/L estradiol and 10(-8) mol/L testosterone), which has a significant anti-apoptotic effect on HUVECs by inducing a C-reactive protein. Estradiol 75-84 C-reactive protein Homo sapiens 187-205 26633088-5 2015 With the HUVECs, we found an appropriate E2/T ratio of 5:1 (5x10(-8) mol/L estradiol and 10(-8) mol/L testosterone), which has a significant anti-apoptotic effect on HUVECs by inducing a C-reactive protein. Testosterone 102-114 C-reactive protein Homo sapiens 187-205 26823819-4 2015 An elevated CRP/Alb ratio was associated with older age at surgery (P=0.007), more advanced TNM stage (P<0.001), more presence of tumor necrosis (P<0.001) and lymphovascular invasion (P<0.001), lower concentration of hemoglobin (P<0.001) and calcium (P=0.005), and shorter OS (P<0.001). Calcium 254-261 C-reactive protein Homo sapiens 12-15 26028060-9 2015 Higher C-reactive protein was associated with only wider retinal venular caliber (difference 0.10 SDS (95% CI 0.06, 0.14) per SDS increase in C-reactive protein). Sodium Dodecyl Sulfate 98-101 C-reactive protein Homo sapiens 7-25 26371408-6 2015 In the whole group protein N-linked Hcy correlated only with C-reactive protein (CRP; r = 0.44, p < 0.0001). Nitrogen 27-28 C-reactive protein Homo sapiens 61-79 26371408-6 2015 In the whole group protein N-linked Hcy correlated only with C-reactive protein (CRP; r = 0.44, p < 0.0001). Nitrogen 27-28 C-reactive protein Homo sapiens 81-84 25985199-0 2015 A simultaneous electrochemical multianalyte immunoassay of high sensitivity C-reactive protein and soluble CD40 ligand based on reduced graphene oxide-tetraethylene pentamine that directly adsorb metal ions as labels. Metals 196-201 C-reactive protein Homo sapiens 76-94 25985199-1 2015 A simplified electrochemical multianalyte immunosensor for the simultaneous detection of high sensitivity C-reactive protein (hsCRP) and soluble CD40 ligand (sCD40L) that uses reduced graphene oxide-tetraethylene pentamine (rGO-TEPA) that directly adsorbs metal ions as labels is reported. rgo-tepa 224-232 C-reactive protein Homo sapiens 106-124 26028060-9 2015 Higher C-reactive protein was associated with only wider retinal venular caliber (difference 0.10 SDS (95% CI 0.06, 0.14) per SDS increase in C-reactive protein). Sodium Dodecyl Sulfate 126-129 C-reactive protein Homo sapiens 7-25 26587192-6 2015 The mean CRP levels at post-lead implantation day 2 were further elevated at post-IPG implantation day 2 (3.41+-2.56 mg/dL, n=46, respectively, p<0.01). 2-Isopropoxyethanol 82-85 C-reactive protein Homo sapiens 9-12 26587192-8 2015 Mean CRP levels after IPG implantation were significantly higher in patients whose IPGs were implanted at post-lead day 3 than those at post-lead day 5-6 (3.99+-2.80 mg/dL, n=30, and 2.31+-1.56 mg/dL, n=16, respectively, p<0.05). 2-Isopropoxyethanol 22-25 C-reactive protein Homo sapiens 5-8 26587192-10 2015 CONCLUSION: The mean postoperative CRP levels were highest on post-IPG insertion day 2 and decreased rapidly, returning to the normal range on post-IPG implantation day 6. 2-Isopropoxyethanol 67-70 C-reactive protein Homo sapiens 35-38 26587192-10 2015 CONCLUSION: The mean postoperative CRP levels were highest on post-IPG insertion day 2 and decreased rapidly, returning to the normal range on post-IPG implantation day 6. 2-Isopropoxyethanol 148-151 C-reactive protein Homo sapiens 35-38 26587192-11 2015 The duration of post-lead implantation period influenced the magnitude of CRP elevation at post-IPG insertion day 2. 2-Isopropoxyethanol 96-99 C-reactive protein Homo sapiens 74-77 26288392-6 2015 In addition, GJG exhibited significant increases in total antioxidant capacity (38.7%; p = 0.009), vitamin A (11.8%; p = 0.016), and uric acid (28.2%; p = 0.005), whereas alpha-1-acid glycoprotein significantly decreased (20.2%; p = 0.006) and high-sensitivity C-reactive protein levels remained unchanged. 6-(cyclohexylamino)pyridine-3-carboxamide 13-16 C-reactive protein Homo sapiens 261-279 26324506-3 2015 The maximal response to acetylcholine was inversely related to alkaline phosphatase (r=-0.55; P<0.001), and this association was independent (r=-0.61; P<0.001) of demographic and classical risk factors, body mass index, estimated glomerular filtration rate, serum phosphorus and calcium, C-reactive protein, and albuminuria. Acetylcholine 24-37 C-reactive protein Homo sapiens 294-312 26233863-0 2015 Effects of supplementation with green tea catechins on plasma C-reactive protein concentrations: A systematic review and meta-analysis of randomized controlled trials. Catechin 42-51 C-reactive protein Homo sapiens 62-80 25393908-0 2015 C-Reactive Protein As a Marker for Initiating Steroid Treatment in Children With Orbital Cellulitis. Steroids 46-53 C-reactive protein Homo sapiens 0-18 25393908-12 2015 The average CRP at the onset of steroid treatment was 2.8 mg/dl (range: 0.5-4). Steroids 32-39 C-reactive protein Homo sapiens 12-15 25393908-23 2015 Patients who received systemic steroids after CRP dropped below 4 mg/dl were discharged from the hospital earlier than patients who did not receive systemic steroids. Steroids 31-39 C-reactive protein Homo sapiens 46-49 25361222-7 2015 RESULTS: The ghrelin group had a shorter SIRS duration and lower CRP and IL-6 levels than did the placebo group. Ghrelin 13-20 C-reactive protein Homo sapiens 65-68 26106052-0 2015 High levels of vitamin D in relation to reduced risk of schizophrenia with elevated C-reactive protein. Vitamin D 15-24 C-reactive protein Homo sapiens 84-102 26106052-2 2015 This study aimed to examine the hypothesis that vitamin D is inversely associated with C-reactive protein (CRP) in patients with schizophrenia, and high levels of vitamin D may be linked to reduced risk of schizophrenia with elevated CRP. Vitamin D 48-57 C-reactive protein Homo sapiens 87-105 26106052-2 2015 This study aimed to examine the hypothesis that vitamin D is inversely associated with C-reactive protein (CRP) in patients with schizophrenia, and high levels of vitamin D may be linked to reduced risk of schizophrenia with elevated CRP. Vitamin D 48-57 C-reactive protein Homo sapiens 107-110 26187318-4 2015 IL-6 and CRP also influenced the extent of the arithmetic bias when calculating the GFR using the chronic kidney disease epidemiology (CKD-EPI) formula with just serum creatinine. Creatinine 168-178 C-reactive protein Homo sapiens 9-12 26106052-2 2015 This study aimed to examine the hypothesis that vitamin D is inversely associated with C-reactive protein (CRP) in patients with schizophrenia, and high levels of vitamin D may be linked to reduced risk of schizophrenia with elevated CRP. Vitamin D 163-172 C-reactive protein Homo sapiens 234-237 26106052-8 2015 The proportions of patients significantly increased with increasing quartiles of CRP, while significantly decreased with increasing quartiles of 25(OH)D. Among individuals with high CRP, participants with high 25(OH)D have significantly lower proportion (adjusted OR =0.217, 95% CI 0.063, 0.751) of schizophrenia compared to those with low 25(OH)D. The evidence suggested that high levels of vitamin D may be linked to reduced risk of schizophrenia with elevated CRP. Vitamin D 392-401 C-reactive protein Homo sapiens 182-185 26106052-8 2015 The proportions of patients significantly increased with increasing quartiles of CRP, while significantly decreased with increasing quartiles of 25(OH)D. Among individuals with high CRP, participants with high 25(OH)D have significantly lower proportion (adjusted OR =0.217, 95% CI 0.063, 0.751) of schizophrenia compared to those with low 25(OH)D. The evidence suggested that high levels of vitamin D may be linked to reduced risk of schizophrenia with elevated CRP. Vitamin D 392-401 C-reactive protein Homo sapiens 182-185 25895642-8 2015 CRP directly inhibits endothelial cell nitric oxide (NO) production via destabilizing endothelial NO synthase (eNOS). Nitric Oxide 39-51 C-reactive protein Homo sapiens 0-3 25916185-4 2015 In covariate-adjusted models, a 10% increase in water As, urinary As adjusted for specific gravity (uAs), or blood As (bAs) was associated with a 0.74% (p = 0.01), 0.90% (p = 0.16), and 1.39% (p = 0.07) increase in CRP, respectively; there was no association with AGP. Water 48-53 C-reactive protein Homo sapiens 215-218 25411996-9 2015 Instead, plasma IL-6 and serum CRP concentrations are more effective in predicting the severity of the clinical course in the early phase of LVAD therapy. lvad 141-145 C-reactive protein Homo sapiens 31-34 26094490-8 2015 In folic acid supplement users compared to nonusers, we established a lower abundance of C-reactive protein (-2.03; P = < 0.01) and higher abundances of apolipoproteins from high-density lipoprotein (HDL), most notably A-I (+1.28; P = < 0.01) and C-I (+1.11; P = 0.016). Folic Acid 3-13 C-reactive protein Homo sapiens 89-107 25916185-7 2015 This was primarily driven by stronger effects of As exposure on CRP in participants with lower plasma GSH. Glutathione 102-105 C-reactive protein Homo sapiens 64-67 26247637-1 2015 OBJECTIVE: Emissions from a particular welding process, metal inert gas brazing of zinc-coated steel, induce an increase in C-reactive protein. Metals 56-61 C-reactive protein Homo sapiens 124-142 25893544-1 2015 BACKGROUND: The aim of this analysis was to examine the effects of icosapent ethyl (eicosapentaenoic acid ethyl ester, IPE) on high-sensitivity C-reactive protein (hsCRP) and lipid parameters in patients with metabolic syndrome, with and without stable statin therapy. ipe 119-122 C-reactive protein Homo sapiens 144-162 26266357-6 2015 Participation in CRP was related to the lower probability of having high total cholesterol (23% vs 32%, P < 0.05), fasting glucose (11% vs 18%, P = 0.05), HbA1c (8% vs 16%, P = 0.05), and body mass index (27% vs 37%, P < 0.05). Cholesterol 79-90 C-reactive protein Homo sapiens 17-20 26266357-6 2015 Participation in CRP was related to the lower probability of having high total cholesterol (23% vs 32%, P < 0.05), fasting glucose (11% vs 18%, P = 0.05), HbA1c (8% vs 16%, P = 0.05), and body mass index (27% vs 37%, P < 0.05). Glucose 126-133 C-reactive protein Homo sapiens 17-20 26209440-6 2015 RESULTS: Hemoglobin, hematocrit, and serum C-reactive protein level measured after admission for 24 h were significantly higher in the alcohol group than in the biliary group. Alcohols 135-142 C-reactive protein Homo sapiens 43-61 25377269-6 2015 RESULTS: Patients treated with ghrelin showed shorter SIRS durations than controls (1.6 +- 2.7 vs. 4.1 +- 3.7 days, respectively; p = 0.0065) and also showed lower C-reactive protein concentrations than controls (11.0 +- 4.6 mg/dL vs. 15.3 +- 7.3 mg/mL, respectively, on postoperative day 3, p = 0.030). Ghrelin 31-38 C-reactive protein Homo sapiens 164-182 26193292-7 2015 Age, physical inactivity, abdominal obesity, a low LDL level, an elevated fasting glucose level, uric acid and urinary albumin to creatinine ratio (ACR) were correlated with log-CRP. Glucose 82-89 C-reactive protein Homo sapiens 178-181 26193292-7 2015 Age, physical inactivity, abdominal obesity, a low LDL level, an elevated fasting glucose level, uric acid and urinary albumin to creatinine ratio (ACR) were correlated with log-CRP. Creatinine 130-140 C-reactive protein Homo sapiens 178-181 26193292-10 2015 CONCLUSION: Age, physical inactivity, abdominal obesity, a low LDL level, an elevated fasting glucose level, uric acid and ACR are correlated with log-CRP. Glucose 94-101 C-reactive protein Homo sapiens 151-154 26159541-6 2015 METHODS: We applied an extended multilevel approach to a large cross-sectional study aimed to elucidate the hypothesized link between drinking water pollution from perfluoroctanoic acid (PFOA) and plasma levels of C-reactive protein (CRP) or lymphocyte counts. Water 143-148 C-reactive protein Homo sapiens 214-232 26159541-6 2015 METHODS: We applied an extended multilevel approach to a large cross-sectional study aimed to elucidate the hypothesized link between drinking water pollution from perfluoroctanoic acid (PFOA) and plasma levels of C-reactive protein (CRP) or lymphocyte counts. Water 143-148 C-reactive protein Homo sapiens 234-237 25904444-5 2015 METHODS: CRP concentrations in Dried Blood Spot (DBS) specimens were measured, using the validated enzyme-linked immunosorbent assay (ELISA) method. dbs 49-52 C-reactive protein Homo sapiens 9-12 26147588-3 2015 The aim of our study was to investigate whether vitamin D has an inhibitory effect on systemic inflammation by assessing the association between serum levels of vitamin D and C-reactive protein. Vitamin D 48-57 C-reactive protein Homo sapiens 175-193 26147588-3 2015 The aim of our study was to investigate whether vitamin D has an inhibitory effect on systemic inflammation by assessing the association between serum levels of vitamin D and C-reactive protein. Vitamin D 161-170 C-reactive protein Homo sapiens 175-193 26147588-7 2015 In conclusion, higher levels of Vitamin D are associated with lower levels of C-reactive protein. Vitamin D 32-41 C-reactive protein Homo sapiens 78-96 26150144-10 2015 In the COPD cohort, CRP was higher in patients with iron deficiency (median 10.5 vs 4.0 mg/L, p<0.001), who were also more hypoxaemic than their iron-replete counterparts (median resting SpO2 92% vs 95%, p<0.001), but haemoglobin concentration did not differ. Iron 52-56 C-reactive protein Homo sapiens 20-23 25958099-10 2015 C-reactive protein increased with increments in 2-h plasma glucose. Glucose 59-66 C-reactive protein Homo sapiens 0-18 26275690-6 2015 CRP was used to assess the correlation between the aforementioned markers of iron and inflammation. Iron 77-81 C-reactive protein Homo sapiens 0-3 25899452-2 2015 METHODS: CRP levels were measured at baseline and 1 year after randomisation to atorvastatin in 2,322 patients with type 2 diabetes (40-75 years, 69% males) in a secondary analysis of the Collaborative Atorvastatin Diabetes Study, a randomised placebo-controlled trial. Atorvastatin 80-92 C-reactive protein Homo sapiens 9-12 25899452-4 2015 RESULTS: After 1 year, the atorvastatin arm showed a net CRP lowering of 32% (95% CI -40%, -22%) compared with placebo. Atorvastatin 27-39 C-reactive protein Homo sapiens 57-60 25958099-11 2015 In linear regression, TGF-beta1 was independently associated with fasting plasma glucose, and C-reactive protein with 2-h plasma glucose after adjustments. Glucose 129-136 C-reactive protein Homo sapiens 94-112 26311995-6 2015 CRP levels significantly decreased from beginning to the end of 4 weeks in both atorvastatin and rosuvastatin groups (from 35.48 to 23.07 mg/l and from 35.88 to 19.91 mg/l respectively, both P < 0.001). Atorvastatin 80-92 C-reactive protein Homo sapiens 0-3 25293433-7 2015 RESULTS: Sixty percent of participants who had estimated sodium intake above recommendation (>100 mmol/day or 6 g salt/day) also had higher diastolic blood pressure, mean arterial pressure (MAP), urinary albumin-to-creatinine ratio, high-sensitive C-reactive protein and uric acid and used a greater number of anti-hypertensive drugs. Sodium 57-63 C-reactive protein Homo sapiens 251-269 26311995-9 2015 CONCLUSION: Both atorvastatin (40 mg) and rosuvastatin (20 mg) are effective in decreasing CRP and LDL cholesterol levels even in a short duration of 4 weeks. Atorvastatin 17-29 C-reactive protein Homo sapiens 91-94 25711952-0 2015 The effect of C-reactive protein reduction with a highly specific antisense oligonucleotide on atrial fibrillation assessed using beat-to-beat pacemaker Holter follow-up. Oligonucleotides 76-91 C-reactive protein Homo sapiens 14-32 26310644-14 2015 Steroid treatment, small intestine involved disease and high C reactive protein (more than 8 mg/L) are risk factors of vitamin D deficiency in CD children. Vitamin D 119-128 C-reactive protein Homo sapiens 61-79 25895432-1 2015 The aim of the present study was to examine the association between intake of five common antioxidative nutrients from supplements and medications (vitamin E, vitamin C, carotenoids, Se, and Zn) and levels of high-sensitivity C-reactive protein (hs-CRP) in the general population. Zinc 191-193 C-reactive protein Homo sapiens 226-244 26262697-6 2015 Dairy products content saturated fats, however recentlystudies have found an inverse correlation between its consumption and CVD, possibly due to their content of trans fatty acid palmitoleic, which allows to increase the levels of HDL cholesterol, decrease C reactive protein and triglicerides. trans fatty acid palmitoleic 163-191 C-reactive protein Homo sapiens 258-276 26902038-5 2015 first demonstrated that the preoperative serum CRP level is an independent and significant factor predictive of a poor prognosis in patients undergoing surgical resection, several investigators have identified an elevated serum CRP level to be an indicator of poor outcomes in HCC patients undergoing transplantation, transarterial chemoembolization, radiofrequency ablation, percutaneous ethanol injection and best supportive care. Ethanol 389-396 C-reactive protein Homo sapiens 228-231 25312097-10 2015 CONCLUSION: Different effects of oral cyclosporine therapy and oral antihistamine therapy to serum high-sensitivity CRP level, TARC level, and peripheral blood basophils in adult patients with AD were shown. Cyclosporine 38-50 C-reactive protein Homo sapiens 116-119 26261626-7 2015 The factors of stages (P = 0.002), HLA-B27 (P = 0.002), ESR (P = 0.001) and C-reactive protein (P = 0.000) were considered to be related to the expression of SP selectin, which indicated that SP-selectin might be involved in the development of AS. TFF2 protein, human 158-160 C-reactive protein Homo sapiens 76-94 25711952-3 2015 ISIS-CRPRx is a novel antisense oligonucleotide that reduces CRP production by specifically inhibiting mRNA translation. Oligonucleotides 32-47 C-reactive protein Homo sapiens 5-8 25987110-7 2015 Notably, we detected a significant association between increased total cholesterol and high CRP levels (p=0.002). Cholesterol 71-82 C-reactive protein Homo sapiens 92-95 25459491-13 2015 Clinicians should keep a high index of suspicion regarding ALN, particularly for those with ultrasonographic nephromegaly, initial higher CRP, nausea/vomiting, and fever for > 5 days after antimicrobial treatment. aln 59-62 C-reactive protein Homo sapiens 138-141 25501922-0 2015 Clinical significance of C-reactive protein levels in predicting responsiveness to iron therapy in patients with inflammatory bowel disease and iron deficiency anemia. Iron 83-87 C-reactive protein Homo sapiens 25-43 25832339-13 2015 The associations between cholesterol intake and risk of T2D, plasma glucose, serum insulin, and C-reactive protein were mainly nonsignificant, especially after accounting for egg consumption. Cholesterol 25-36 C-reactive protein Homo sapiens 96-114 25733507-4 2015 Observational data showed an association between CRP level and the ratio of voriconazole N-oxide to voriconazole. Voriconazole N-Oxide 76-96 C-reactive protein Homo sapiens 49-52 25501922-11 2015 Among iron tablet-treated patients, Hb increase was significantly smaller in the high- versus low-CRP subgroup (1.1 vs. 2.0, 2.3 vs. 3.1, and 3.0 vs. 4.0 g/dL at weeks 2, 4, and 8, respectively; all p < 0.05). Iron 6-10 C-reactive protein Homo sapiens 98-101 25501922-15 2015 CONCLUSIONS: Patients with high baseline CRP achieved a lower Hb response with oral iron therapy. Iron 84-88 C-reactive protein Homo sapiens 41-44 26131181-9 2015 Compared to patients with OH < 1.5 L, patients with SCOH >= 1.5 L had higher levels of blood pressure, peritoneal glucose load, plasma brain natriuretic peptide, high sensitive C-reactive protein, interleukin-6 and LVMI; and lower levels of serum albumin (P < 0.001). scoh 55-59 C-reactive protein Homo sapiens 183-201 25607338-3 2015 In this study, the authors aimed to compare the anti-inflammatory properties of pioglitazone and metformin, with respect to their effect on serum concentrations of highly sensitive C-reactive protein (hsCRP), osteoprotegerin (OPG), intercellular adhesion molecule-1 (ICAM-1) and adiponectin. Metformin 97-106 C-reactive protein Homo sapiens 181-199 25620670-8 2015 Combined 6- and 18-month levels of FC correlated with the presence (r = 0.42; P < .001) and severity (r = 0.44; P < .001) of CD recurrence, but the CRP level and CDAI score did not. Fc(alpha) receptor 35-37 C-reactive protein Homo sapiens 154-157 26487877-0 2015 Effect of Vitamin D supplementation on symptoms and C-reactive protein in migraine patients. Vitamin D 10-19 C-reactive protein Homo sapiens 52-70 26487877-4 2015 So, in this study, we investigated the effect of Vitamin D supplementation on symptoms and C-reactive protein (CRP) among patients with migraine. Vitamin D 49-58 C-reactive protein Homo sapiens 91-109 26487877-4 2015 So, in this study, we investigated the effect of Vitamin D supplementation on symptoms and C-reactive protein (CRP) among patients with migraine. Vitamin D 49-58 C-reactive protein Homo sapiens 111-114 26137274-6 2015 Of these factors, only the MSKCC classification, CRP level and liver metastasis were found to be independently associated with OS in the multivariate analysis. Osmium 127-129 C-reactive protein Homo sapiens 49-52 25797037-1 2015 Herein, we report simple flow reactor designs that enable photo-controlled living radical polymerization (photo-CRP) from trithiocarbonates (TTCs) with significant enhancements in scalability and reaction rates compared to the analogous batch reactions. trithiocarbonic acid 122-139 C-reactive protein Homo sapiens 112-115 25740979-1 2015 BACKGROUND: Metformin may improve metabolic factors (insulin, glucose, leptin, highly sensitive C-reactive protein [hs-CRP]) associated with poor breast cancer outcomes. Metformin 12-21 C-reactive protein Homo sapiens 96-114 25832424-0 2015 C-reactive protein stimulates RAGE expression in human coronary artery endothelial cells in vitro via ROS generation and ERK/NF-kappaB activation. ros 102-105 C-reactive protein Homo sapiens 0-18 25832424-6 2015 RESULTS: CRP stimulated the expression of RAGE in the cells, accompanied by markedly increased ROS generation, phosphorylation of ERK1/2 and NF-kappaB p65, as well as translocation of NF-kappaB p65 to the nuclei. ros 95-98 C-reactive protein Homo sapiens 9-12 25832424-8 2015 Pretreatment of the cells with the ROS scavenger N-acetyl-L-cysteine, ERK inhibitor PD98059 or NF-kappaB inhibitor PDTC blocked CRP-stimulated RAGE expression, but pretreatment with the NADPH oxidase inhibitor DPI, JNK inhibitor SP600125 or p38 MAPK inhibitor SB203580 did not significantly alter CRP-stimulated RAGE expression. ros 35-38 C-reactive protein Homo sapiens 128-131 25832424-8 2015 Pretreatment of the cells with the ROS scavenger N-acetyl-L-cysteine, ERK inhibitor PD98059 or NF-kappaB inhibitor PDTC blocked CRP-stimulated RAGE expression, but pretreatment with the NADPH oxidase inhibitor DPI, JNK inhibitor SP600125 or p38 MAPK inhibitor SB203580 did not significantly alter CRP-stimulated RAGE expression. ros 35-38 C-reactive protein Homo sapiens 297-300 25832424-8 2015 Pretreatment of the cells with the ROS scavenger N-acetyl-L-cysteine, ERK inhibitor PD98059 or NF-kappaB inhibitor PDTC blocked CRP-stimulated RAGE expression, but pretreatment with the NADPH oxidase inhibitor DPI, JNK inhibitor SP600125 or p38 MAPK inhibitor SB203580 did not significantly alter CRP-stimulated RAGE expression. Acetylcysteine 49-68 C-reactive protein Homo sapiens 128-131 25832424-8 2015 Pretreatment of the cells with the ROS scavenger N-acetyl-L-cysteine, ERK inhibitor PD98059 or NF-kappaB inhibitor PDTC blocked CRP-stimulated RAGE expression, but pretreatment with the NADPH oxidase inhibitor DPI, JNK inhibitor SP600125 or p38 MAPK inhibitor SB203580 did not significantly alter CRP-stimulated RAGE expression. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 84-91 C-reactive protein Homo sapiens 128-131 25832424-9 2015 CONCLUSION: CRP stimulates RAGE expression in HCAECs in vitro via ROS generation and activation of the ERK/NF-kappaB signaling pathway. ros 66-69 C-reactive protein Homo sapiens 12-15 25661410-8 2015 RESULTS: In the adjusted model, high-sensitivity C-reactive protein was significantly related to high-density lipoprotein-cholesterol (beta = -5.797 [-11.500 to -0.093]), femoral IMT (beta = 0.062 [0.008-0.116]), and the sum of femoral and carotid IMT (beta = 1.107 [0.223-1.919]), but only in the group without sports participation. Cholesterol 122-133 C-reactive protein Homo sapiens 49-67 26419097-1 2015 BACKGROUND: The present study was designed to evaluate the postoperative values such as body temperature (BT), white blood cells (WBC), P/F ratio and C-reactive protein (CRP) associated with propofol or sevoflurane in patients undergoing thoracic surgery with one-lung ventilation. Sevoflurane 203-214 C-reactive protein Homo sapiens 150-168 26419097-1 2015 BACKGROUND: The present study was designed to evaluate the postoperative values such as body temperature (BT), white blood cells (WBC), P/F ratio and C-reactive protein (CRP) associated with propofol or sevoflurane in patients undergoing thoracic surgery with one-lung ventilation. Sevoflurane 203-214 C-reactive protein Homo sapiens 170-173 26419097-7 2015 CONCLUSIONS: Propofol and sevoflurane had similar effect on BT, WBC, P/F ratio and CRP in patients undergoing thoracic surgery with one-lung ventilation. Sevoflurane 26-37 C-reactive protein Homo sapiens 83-86 25521923-8 2015 Total cholesterol values above 200 mg/dL and higher ultrasensitive C-reactive protein levels were significantly more frequent in the morphine groups than in the controls. Morphine 133-141 C-reactive protein Homo sapiens 67-85 25461166-6 2015 The eFBG sensors show high specificity to CRP even in the presence of other interfering factors such as urea, creatinine and glucose. Urea 104-108 C-reactive protein Homo sapiens 42-45 25461166-6 2015 The eFBG sensors show high specificity to CRP even in the presence of other interfering factors such as urea, creatinine and glucose. Creatinine 110-120 C-reactive protein Homo sapiens 42-45 25461166-6 2015 The eFBG sensors show high specificity to CRP even in the presence of other interfering factors such as urea, creatinine and glucose. Glucose 125-132 C-reactive protein Homo sapiens 42-45 25880559-15 2015 CONCLUSIONS: Risk of metabolic syndrome, hyperglycaemia and diabetes, and elevated high-sensitivity CRP may be affected by childhood BMI and skinfold thickness, while risk of hypertension, raised triglycerides and reduced HDL cholesterol is associated more strongly with BMI gain from childhood to adulthood. Triglycerides 196-209 C-reactive protein Homo sapiens 100-103 25880559-15 2015 CONCLUSIONS: Risk of metabolic syndrome, hyperglycaemia and diabetes, and elevated high-sensitivity CRP may be affected by childhood BMI and skinfold thickness, while risk of hypertension, raised triglycerides and reduced HDL cholesterol is associated more strongly with BMI gain from childhood to adulthood. Cholesterol 226-237 C-reactive protein Homo sapiens 100-103 25746024-8 2015 Monocyte chemoattractant protein-1, interferon gamma-induced protein, and C-reactive protein levels were higher in the CF-LVAD recipients at each of the time points (baseline before CF-LVAD implantation and 3, 6, and 9 months after implantation) compared with levels in healthy controls. lvad 122-126 C-reactive protein Homo sapiens 36-92 24797104-9 2015 Female gender and high C-reactive protein (CRP) were associated with vitamin D deficiency in anemic group. Vitamin D 69-78 C-reactive protein Homo sapiens 23-41 24797104-9 2015 Female gender and high C-reactive protein (CRP) were associated with vitamin D deficiency in anemic group. Vitamin D 69-78 C-reactive protein Homo sapiens 43-46 24797104-11 2015 Therefore, the measurement of serum 25(OH)D levels and appropriate vitamin D supplementation should be considered in anemic patients, particularly in females and patients with high CRP level. 25(oh)d 36-43 C-reactive protein Homo sapiens 181-184 25904961-7 2015 Before adjusting for age and BMI, CRP was correlated with LDL (r= 0.16, p= 0.03), total cholesterol (TC) (r= 0.17, p= 0. Cholesterol 88-99 C-reactive protein Homo sapiens 34-37 25911075-0 2015 Total cholesterol-to-high-density lipoprotein cholesterol ratio predicts high-sensitivity C-reactive protein levels in Turkish children. Cholesterol 6-17 C-reactive protein Homo sapiens 90-108 25911075-0 2015 Total cholesterol-to-high-density lipoprotein cholesterol ratio predicts high-sensitivity C-reactive protein levels in Turkish children. Cholesterol 46-57 C-reactive protein Homo sapiens 90-108 25683977-8 2015 Maximum body temperature and C-reactive protein were significantly decreased in the moderate-dose steroid group compared to the other groups (p<0.01). Steroids 98-105 C-reactive protein Homo sapiens 29-47 25399887-13 2015 Furthermore, the ERK inhibitor pd98059 (30 mumol/L) and the JNK inhibitor sp600125 (10 mumol/L) blocked CRP-induced COX-1 and COX-2 expression for 12 h. Together, the findings of the present study suggest that CRP can promote the development of the no-reflow phenomenon by increasing COX-1 and COX-2 expression, which is regulated, in part, via ERK and JNK activity. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 31-38 C-reactive protein Homo sapiens 104-107 25881225-7 2015 Patient age, neutrophil to lymphocyte ratio, and CRP were found to be independently correlated with peak pulmonary pressure (P &lt; .001, P &lt; .001, and P = .004) and mean pulmonary artery pressure (P &lt; .001, P &lt; .001, and P = .001), whereas preoperative mean pulmonary artery pressure was found to be independently correlated with intensive care unit stay (P &lt; .001). Adenosine Monophosphate 128-131 C-reactive protein Homo sapiens 49-52 25881225-7 2015 Patient age, neutrophil to lymphocyte ratio, and CRP were found to be independently correlated with peak pulmonary pressure (P &lt; .001, P &lt; .001, and P = .004) and mean pulmonary artery pressure (P &lt; .001, P &lt; .001, and P = .001), whereas preoperative mean pulmonary artery pressure was found to be independently correlated with intensive care unit stay (P &lt; .001). Adenosine Monophosphate 145-148 C-reactive protein Homo sapiens 49-52 25881225-7 2015 Patient age, neutrophil to lymphocyte ratio, and CRP were found to be independently correlated with peak pulmonary pressure (P &lt; .001, P &lt; .001, and P = .004) and mean pulmonary artery pressure (P &lt; .001, P &lt; .001, and P = .001), whereas preoperative mean pulmonary artery pressure was found to be independently correlated with intensive care unit stay (P &lt; .001). Adenosine Monophosphate 145-148 C-reactive protein Homo sapiens 49-52 25881225-7 2015 Patient age, neutrophil to lymphocyte ratio, and CRP were found to be independently correlated with peak pulmonary pressure (P &lt; .001, P &lt; .001, and P = .004) and mean pulmonary artery pressure (P &lt; .001, P &lt; .001, and P = .001), whereas preoperative mean pulmonary artery pressure was found to be independently correlated with intensive care unit stay (P &lt; .001). Adenosine Monophosphate 145-148 C-reactive protein Homo sapiens 49-52 25881225-7 2015 Patient age, neutrophil to lymphocyte ratio, and CRP were found to be independently correlated with peak pulmonary pressure (P &lt; .001, P &lt; .001, and P = .004) and mean pulmonary artery pressure (P &lt; .001, P &lt; .001, and P = .001), whereas preoperative mean pulmonary artery pressure was found to be independently correlated with intensive care unit stay (P &lt; .001). Adenosine Monophosphate 145-148 C-reactive protein Homo sapiens 49-52 25712819-9 2015 RESULTS: In men, CRP levels had significant associations with depressive symptoms before (beta=0.420, p=0.010) and after (beta=0.336, p=0.025) adjusting for age, body mass index, systolic blood pressure, number of comorbidities, smoking status, alcohol intake, marital status, education and sleep duration. Alcohols 245-252 C-reactive protein Homo sapiens 17-20 25637150-4 2015 It is likely that the vegetable and high fiber content of a vegan diet reduces CRP in the presences of obesity. Dietary Fiber 41-46 C-reactive protein Homo sapiens 79-82 25336462-9 2015 Adding biomarkers to the models to test for mediation, the vitamin D effect on respiratory health was not a consequence of any single marker but was partially attenuated as a combined result of leukocytes, AP, and CRP. Vitamin D 59-68 C-reactive protein Homo sapiens 214-217 25399887-13 2015 Furthermore, the ERK inhibitor pd98059 (30 mumol/L) and the JNK inhibitor sp600125 (10 mumol/L) blocked CRP-induced COX-1 and COX-2 expression for 12 h. Together, the findings of the present study suggest that CRP can promote the development of the no-reflow phenomenon by increasing COX-1 and COX-2 expression, which is regulated, in part, via ERK and JNK activity. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 31-38 C-reactive protein Homo sapiens 210-213 25378535-6 2015 Further linking intracellular iron and inflammation, 14 SCD patients with a ferroportin Q248H variant that causes intracellular iron accumulation had significantly higher levels of interleukin-6 and C-reactive protein compared with 14 matched SCD patients with the wild-type allele (P<0.05). Iron 128-132 C-reactive protein Homo sapiens 199-217 24934222-11 2015 Copper levels correlated with CRP for CRP >4 mg/dL (P = .03). Copper 0-6 C-reactive protein Homo sapiens 30-33 24934222-11 2015 Copper levels correlated with CRP for CRP >4 mg/dL (P = .03). Copper 0-6 C-reactive protein Homo sapiens 38-41 24934222-15 2015 Serum copper levels may be elevated in patients with acute inflammation and may be falsely elevated when CRP is >4 mg/dL. Copper 6-12 C-reactive protein Homo sapiens 105-108 24607247-11 2015 hs-CRP was negatively correlated to serum Fe levels (r = -0 319, P < 0 001). Iron 42-44 C-reactive protein Homo sapiens 3-6 24607247-15 2015 The negative relationship between hs-CRP and serum Fe indicated that lower serum Fe levels were related to the inflammation linked with higher BMI. Iron 51-53 C-reactive protein Homo sapiens 37-40 24607247-15 2015 The negative relationship between hs-CRP and serum Fe indicated that lower serum Fe levels were related to the inflammation linked with higher BMI. Iron 81-83 C-reactive protein Homo sapiens 37-40 25574099-7 2015 Factors considered to be possibly predictive of long-term efficacy of cyclosporine were sex, age, disease duration, clinical activity index score, C-reactive protein level, hemoglobin level, disease extent, endoscopic findings, and clinical course. Cyclosporine 70-82 C-reactive protein Homo sapiens 147-165 25592634-8 2015 Also, CRP levels strongly correlated with the value of PaO2/FiO2 ratio (r = -0.69, p < 0.001) and creatinine (r = 0.60, p < 0.001). Creatinine 101-111 C-reactive protein Homo sapiens 6-9 25672297-9 2015 Additionally, a significantly positive correlation was found between the levels of high-sensitivity C-reactive protein and low-density lipoprotein-cholesterol (p= 0.014, r = +0.320) in patient group. Cholesterol 146-158 C-reactive protein Homo sapiens 100-118 26339617-5 2015 Additionally CRP and Alb levels were found significantly associated with overall survival in univariate analysis (log-rank test, P < 0.001 and P = 0.002, resp.) and CRP remained significant after controlling for age, alcohol, performance status, and TNM stage, whereas albumin showed a borderline effect on the hazard rate (P = 0.052). Alcohols 220-227 C-reactive protein Homo sapiens 13-16 26229958-0 2015 Atorvastatin Treatment for Atrial Fibrillation Reduces Serum High-Sensitivity C-Reactive Protein Levels. Atorvastatin 0-12 C-reactive protein Homo sapiens 78-96 26652682-7 2015 Levels of CRP in DBS were correlated with plasma CRP levels, even when pre-processed blood was stored for up to 48 hours. dbs 17-20 C-reactive protein Homo sapiens 10-13 26652682-7 2015 Levels of CRP in DBS were correlated with plasma CRP levels, even when pre-processed blood was stored for up to 48 hours. dbs 17-20 C-reactive protein Homo sapiens 49-52 26339617-5 2015 Additionally CRP and Alb levels were found significantly associated with overall survival in univariate analysis (log-rank test, P < 0.001 and P = 0.002, resp.) and CRP remained significant after controlling for age, alcohol, performance status, and TNM stage, whereas albumin showed a borderline effect on the hazard rate (P = 0.052). Alcohols 220-227 C-reactive protein Homo sapiens 168-171 26229958-1 2015 We investigated whether serum hs-CRP levels predict the efficacy of atrial fibrillation (AF) treated with atorvastatin. Atorvastatin 106-118 C-reactive protein Homo sapiens 33-36 26229958-4 2015 Our meta-analysis identified seven cohort studies (2006~2013), providing information on the change in serum hs-CRP levels in AF patients receiving atorvastatin therapy. Atorvastatin 147-159 C-reactive protein Homo sapiens 111-114 25791278-9 2015 Regarding inflammatory parameters, both CRP and B2MG were lower using CD. Cadmium 70-72 C-reactive protein Homo sapiens 40-43 26229958-5 2015 After atorvastatin treatment, hs-CRP level in AF patients decreased significantly (SMD = 1.02, 95% CI: 0.58-1.47, P < 0.001). Atorvastatin 6-18 C-reactive protein Homo sapiens 33-36 26229958-6 2015 Subgroup analysis by country and hs-CRP detection methods suggested a negative relationship between atorvastatin treatment and hs-CRP levels among Chinese AF patients (SMD = 1.34, 95% CI: 1.00-1.69, P < 0.001) and by using ELISA method (SMD = 1.11, 95% CI: 0.51-1.71, P < 0.001), but not among Turkish population and using INA method (all P > 0.05). Atorvastatin 100-112 C-reactive protein Homo sapiens 36-39 26229958-6 2015 Subgroup analysis by country and hs-CRP detection methods suggested a negative relationship between atorvastatin treatment and hs-CRP levels among Chinese AF patients (SMD = 1.34, 95% CI: 1.00-1.69, P < 0.001) and by using ELISA method (SMD = 1.11, 95% CI: 0.51-1.71, P < 0.001), but not among Turkish population and using INA method (all P > 0.05). Atorvastatin 100-112 C-reactive protein Homo sapiens 130-133 26229958-8 2015 hs-CRP was clearly lowered in AF patients treated with atorvastatin, which may be helpful in the choice of statin agents for AF treatment. Atorvastatin 55-67 C-reactive protein Homo sapiens 3-6 24655315-8 2015 Serum total bilirubin, interleukin-6 and C-reactive protein were significantly lower in the steroid than in the control group on postoperative day 1 (P = 0.02, 0.004 and 0.02, respectively). Steroids 92-99 C-reactive protein Homo sapiens 41-59 25807640-10 2015 Multiple linear regression analyses adjusting CAF for inflammatory parameters (i.e., WBC, CRP, interleukin 6, PCT), age, and gender showed a strong correlation between CAF and creatinine (r = 0.643, p < 0.001). Creatinine 176-186 C-reactive protein Homo sapiens 90-93 25807652-7 2015 DAS-28 and CRP were also correlated with the percentage of oxidized albumin-thiol (r = 0.46, r = 0.44). Sulfhydryl Compounds 76-81 C-reactive protein Homo sapiens 11-14 25470633-5 2015 RESULT: Significant difference in CRP was observed between groups A & B (p=0.000) and A & C (p=0.007). Adenosine Monophosphate 69-72 C-reactive protein Homo sapiens 34-37 25599732-1 2015 INTRODUCTION: Leukocyte count, erythrocyte sediment rate and C-reactive protein are available laboratory markers which may be helpful in prediction of technetium Tc 99m dimercaptosuccinic acid (DMSA) renal scintigraphy results. Technetium Tc 99m Dimercaptosuccinic Acid 151-192 C-reactive protein Homo sapiens 61-79 25885871-2 2015 Therefore, we performed a meta-analysis to evaluate the efficacy of resveratrol supplementation on plasma CRP concentrations and selected predictors of CV risk. Resveratrol 68-79 C-reactive protein Homo sapiens 106-109 25613456-5 2015 However, serum C-reactive protein (CRP) concentrations were 31% lower in the UAT-negative patients than in the UAT-positive patients (p = 0.02). 4-methyl-~{N}-(phenylmethyl)piperidine-1-carboxamide 77-80 C-reactive protein Homo sapiens 15-33 28255396-12 2015 Conclusion:Our findings indicated hs-CRP levels of hemodialysis patients to have significant inverse relationships with serum albumin and vitamin E and C intakes but was not significant. Carbon 0-1 C-reactive protein Homo sapiens 37-40 26161268-7 2015 While there were no significant associations (p > 0.05) between total plasma PUFA and C-reactive protein (CRP) or lipid levels, plasma arachidonic acid was inversely associated with CRP and triglycerides and positively associated with HDL-C, CD4+ T-cell count, and plasma albumin (p < 0.05). Arachidonic Acid 138-154 C-reactive protein Homo sapiens 185-188 26161268-8 2015 Plasma saturated fatty acids (SFA) were positively associated with CRP (beta = 0.24; 95% CI: 0.08 to 0.40, p = 0.003) and triglycerides (beta = 0.08; 95% CI: 0.03 to 0.12, p < 0.01). Fatty Acids 7-28 C-reactive protein Homo sapiens 67-70 26161268-8 2015 Plasma saturated fatty acids (SFA) were positively associated with CRP (beta = 0.24; 95% CI: 0.08 to 0.40, p = 0.003) and triglycerides (beta = 0.08; 95% CI: 0.03 to 0.12, p < 0.01). Fatty Acids 30-33 C-reactive protein Homo sapiens 67-70 25613456-5 2015 However, serum C-reactive protein (CRP) concentrations were 31% lower in the UAT-negative patients than in the UAT-positive patients (p = 0.02). 4-methyl-~{N}-(phenylmethyl)piperidine-1-carboxamide 77-80 C-reactive protein Homo sapiens 35-38 26114153-8 2015 The eCB 2-arachidonoylglycerol (2-AG) was significantly, positively associated with both interleukin (IL)-6 and C-reactive protein (CRP) and negatively associated with depressive symptoms. glyceryl 2-arachidonate 8-30 C-reactive protein Homo sapiens 112-130 26114153-8 2015 The eCB 2-arachidonoylglycerol (2-AG) was significantly, positively associated with both interleukin (IL)-6 and C-reactive protein (CRP) and negatively associated with depressive symptoms. glyceryl 2-arachidonate 8-30 C-reactive protein Homo sapiens 132-135 26114153-8 2015 The eCB 2-arachidonoylglycerol (2-AG) was significantly, positively associated with both interleukin (IL)-6 and C-reactive protein (CRP) and negatively associated with depressive symptoms. glyceryl 2-arachidonate 32-36 C-reactive protein Homo sapiens 112-130 26114153-8 2015 The eCB 2-arachidonoylglycerol (2-AG) was significantly, positively associated with both interleukin (IL)-6 and C-reactive protein (CRP) and negatively associated with depressive symptoms. glyceryl 2-arachidonate 32-36 C-reactive protein Homo sapiens 132-135 25449712-12 2015 DISCUSSION: Our results suggest that the IL-6 and CRP contribute to impaired anisotropy of water diffusion in selected pathways that have been previously associated with schizophrenia suggesting differential susceptibility of selected neural pathways to immune mediators. Water 91-96 C-reactive protein Homo sapiens 50-53 26237587-9 2015 Serum CRP levels were significantly higher in cancer patients at initial presentation and seemed to be correlated with copper levels. Copper 119-125 C-reactive protein Homo sapiens 6-9 26336722-7 2014 The CRP level was influenced by % fat and % water in the low body fat group and in females. Water 44-49 C-reactive protein Homo sapiens 4-7 25734013-11 2015 Arginine treated patients had significantly increased BMI at the end of the first and second months of treatment (P = 0.032 and P = 0.04) and a reduced CRP at the end of the first month of treatment (P = 0.03) versus placebo group. Arginine 0-8 C-reactive protein Homo sapiens 152-155 25017001-2 2014 The authors tested the hypothesis that C-reactive protein (CRP), a commonly available marker of systemic inflammation, predicts differential response to escitalopram (a serotonin reuptake inhibitor) and nortriptyline (a norepinephrine reuptake inhibitor). Norepinephrine 220-234 C-reactive protein Homo sapiens 39-57 25017001-2 2014 The authors tested the hypothesis that C-reactive protein (CRP), a commonly available marker of systemic inflammation, predicts differential response to escitalopram (a serotonin reuptake inhibitor) and nortriptyline (a norepinephrine reuptake inhibitor). Norepinephrine 220-234 C-reactive protein Homo sapiens 59-62 25277829-7 2014 Compared with the other groups, the dexamethasone group had significantly higher CRP levels before and after surgery, a significantly higher N/L ratio before surgery, a significantly lower rise in the N/L ratio after surgery, and a significantly lower HLA-DR expression at baseline, which remained stable after surgery. Dexamethasone 36-49 C-reactive protein Homo sapiens 81-84 24422992-6 2014 Clinical response [Physician Global Assessment (PGA) "clear" or "minimal"] was associated with greater CRP reductions vs. no response (PGA "mild" or worse) overall (-0.4 vs. -0.3 mg/L) and in substudies E (-0.4 vs. -0.1 mg/L) and M (-0.5 vs. -0.2 mg/L), but not P (-0.1 vs. -0.4 mg/L). Folic Acid 48-51 C-reactive protein Homo sapiens 103-106 25369444-9 2014 The median decrease in the high-sensitivity C-reactive protein and interleukin-6 levels was significantly greater in the atorvastatin reload group (P<0.001). Atorvastatin 121-133 C-reactive protein Homo sapiens 44-62 25215557-9 2014 Individuals who received joint calcium-vitamin D supplements tended to have a decrease in serum high-sensitivity C-reactive protein levels compared with placebo after controlling for baseline levels (-1.14 +- 0.25 vs 0.02 +- 0.24 ng/mL, P = .09). Calcium 31-38 C-reactive protein Homo sapiens 113-131 25215557-9 2014 Individuals who received joint calcium-vitamin D supplements tended to have a decrease in serum high-sensitivity C-reactive protein levels compared with placebo after controlling for baseline levels (-1.14 +- 0.25 vs 0.02 +- 0.24 ng/mL, P = .09). Vitamin D 39-48 C-reactive protein Homo sapiens 113-131 25190219-3 2014 We hypothesized that the DII could predict levels of high-sensitivity C-reactive protein (CRP), which is an important inflammatory marker, as well as metabolic measures that include the metabolic syndrome and its components in European adults. dilC18(3) dye 25-28 C-reactive protein Homo sapiens 70-88 25190219-3 2014 We hypothesized that the DII could predict levels of high-sensitivity C-reactive protein (CRP), which is an important inflammatory marker, as well as metabolic measures that include the metabolic syndrome and its components in European adults. dilC18(3) dye 25-28 C-reactive protein Homo sapiens 90-93 25397920-2 2014 The biomarkers are the human C-reactive protein (CRP) while the BMNs are the anti-CRP bound onto dextran-coated Fe3O4 particles labeled as Fe3O4-antiCRP. Dextrans 97-104 C-reactive protein Homo sapiens 82-85 25411946-5 2014 A significant trend towards lower levels of plasmatic sodium, paralleling the increase of C--reactive protein, was showed. Sodium 54-60 C-reactive protein Homo sapiens 90-109 25411946-6 2014 CONCLUSION: A significant relationship between plasmatic sodium levels and C--reactive protein was found, apart from the underlying disease. Sodium 57-63 C-reactive protein Homo sapiens 75-94 25168126-5 2014 Baseline serum hs-CRP levels were significantly associated with the urinary albumin-to-creatinine ratio at baseline (P < 0.001). Creatinine 87-97 C-reactive protein Homo sapiens 18-21 25393688-6 2014 Lipid intake modulated the pro-inflammatory effects of some SNPs, i.e., an increase in both saturated fatty acid and monounsaturated fatty acid intake in those homozygous for the polymorphic allele at rs2808630 was associated with a larger increase in CRP. Fatty Acids 92-112 C-reactive protein Homo sapiens 252-255 25393688-7 2014 Those harboring the minor alleles at rs3093058 and rs3093062 presented with significantly higher CRP in the presence of increased triglyceride or cholesterol intake. Triglycerides 130-142 C-reactive protein Homo sapiens 97-100 25393688-7 2014 Those harboring the minor alleles at rs3093058 and rs3093062 presented with significantly higher CRP in the presence of increased triglyceride or cholesterol intake. Cholesterol 146-157 C-reactive protein Homo sapiens 97-100 25393688-9 2014 Carbohydrate intake also modulated CRP SNPs, as HbA1C and fasting glucose levels interacted with some SNPs to influence the CRP. Carbohydrates 0-12 C-reactive protein Homo sapiens 35-38 25393688-9 2014 Carbohydrate intake also modulated CRP SNPs, as HbA1C and fasting glucose levels interacted with some SNPs to influence the CRP. Carbohydrates 0-12 C-reactive protein Homo sapiens 124-127 25393688-9 2014 Carbohydrate intake also modulated CRP SNPs, as HbA1C and fasting glucose levels interacted with some SNPs to influence the CRP. Glucose 66-73 C-reactive protein Homo sapiens 35-38 25393688-9 2014 Carbohydrate intake also modulated CRP SNPs, as HbA1C and fasting glucose levels interacted with some SNPs to influence the CRP. Glucose 66-73 C-reactive protein Homo sapiens 124-127 24521195-1 2014 OBJECTIVES: This study aimed to compare the levels of plasma B-type natriuretic peptide (BNP) and C-reactive protein (CRP) in relation to oxygen transport between patients with restrictive right ventricle (rRV) and those without (non-rRV) early after tetralogy of Fallot (TOF) repair. Oxygen 138-144 C-reactive protein Homo sapiens 118-121 25259849-6 2014 Biochemical data support that CRP molecules are secreted into the spinning dope and assembled into macromolecular complexes via disulfide bond linkages. Disulfides 128-137 C-reactive protein Homo sapiens 30-33 25538368-0 2014 Effects of high versus low-dose atorvastatin on high sensitive C-reactive protein in acute coronary syndrome. Atorvastatin 32-44 C-reactive protein Homo sapiens 63-81 25499944-8 2014 CONCLUSIONS: Purified palmitoleic acid may be useful in the treatment of hypertriglyceridemia with the beneficial added effects of decreasing LDL and hs-CRP and raising HDL. palmitoleic acid 22-38 C-reactive protein Homo sapiens 153-156 25538368-2 2014 The previous findings which suggest the reduction in C-reactive protein (CRP) levels by statin encouraged us to conduct the present study in which we tested the effects of atorvastatin, on levels of hs-CRP in a prospective randomised clinical trial study on patients with acute coronary syndrome. Atorvastatin 172-184 C-reactive protein Homo sapiens 202-205 25538368-8 2014 In this study atorvastatin in high doses decreased hs-CRP levels about 40% and in low doses it only caused decrease of 13.3%, and significant correlation was observed between two groups (Paired Sample T-test) (P = 0.001). Atorvastatin 14-26 C-reactive protein Homo sapiens 54-57 25538368-11 2014 CONCLUSION: The present study confirms the novel observation that atorvastatin therapy results in a significant reduction in hs-CRP levels. Atorvastatin 66-78 C-reactive protein Homo sapiens 128-131 25087591-0 2014 Associations of erythrocyte membrane fatty acids with the concentrations of C-reactive protein, interleukin 1 receptor antagonist and adiponectin in 1373 men. Fatty Acids 37-48 C-reactive protein Homo sapiens 76-118 25445628-9 2014 Nitric oxide in Group I showed a significant positive correlation with morning stiffness (r=0.45), arthritis (r=0.43), platelet count (r=0.46), erythrocyte sedimentation rate (r=0.83), C-reactive protein (r=0.76) and Disease Activity Score (r=0.85). Nitric Oxide 0-12 C-reactive protein Homo sapiens 185-203 24879591-1 2014 We report a protein antibody, Ab-CRP, functionalized Pt nanoparticle-decorated chemical vapor deposition (CVD)-grown graphene on glassy carbon electrode, as a bioelectrode, for the quantitative analysis of human C-reactive protein (CRP). Carbon 136-142 C-reactive protein Homo sapiens 33-36 24879591-3 2014 Ab-CRP was covalently immobilized on mercaptopropionic acid (MPA)-capped Pt nanoparticles that were covalently anchored over the graphene to form a bioelectrode. Platinum 73-75 C-reactive protein Homo sapiens 3-6 24865622-4 2014 We performed a multicenter longitudinal study to assess the effect of the switching from bicarbonate HD to HFR in patients with serum C-reactive Protein (CRP) > 5 mg/L coupled with albumin <4.0 g/dL in the last 6 months. Bicarbonates 89-100 C-reactive protein Homo sapiens 134-152 24865622-4 2014 We performed a multicenter longitudinal study to assess the effect of the switching from bicarbonate HD to HFR in patients with serum C-reactive Protein (CRP) > 5 mg/L coupled with albumin <4.0 g/dL in the last 6 months. Bicarbonates 89-100 C-reactive protein Homo sapiens 154-157 25555182-7 2014 CRP was decreased with metformin (P<0.001), but was increased with OCPs (P<0.001). Metformin 23-32 C-reactive protein Homo sapiens 0-3 25555182-9 2014 OCPs and metformin appear to have differential effects on atherogenic molecules in lean PCOS patients, but metformin was superior in reducing serum AGEs and CRP. Metformin 107-116 C-reactive protein Homo sapiens 157-160 25140577-8 2014 The plasma concentrations of isoniazid correlated inversely with the C-reactive protein level at the time of sampling (P = 0.001). Isoniazid 29-38 C-reactive protein Homo sapiens 69-87 25140577-12 2014 The inverse correlation between the plasma concentrations of isoniazid and C-reactive protein indicate a suboptimal treatment effect at standard dosing regimens. Isoniazid 61-70 C-reactive protein Homo sapiens 75-93 24865175-4 2014 In lithium-heparin tubes, statistically significant differences were observed in S-BIM values of all parameters, except urea nitrogen, CRP, and sodium, compared with S-NO-BIM. Heparin 11-18 C-reactive protein Homo sapiens 135-138 24198051-6 2014 On the other hand, serum oxidized LDL and high-sensitivity C-reactive protein were lower in the atorvastatin treatment period than in the ezetimibe treatment period (109 +- 38 vs 146 +- 67 U/L, p = 0.002; 1.02 +- 1.46 vs 1.47 +- 1.77 microg/mL, p = 0.003). Atorvastatin 96-108 C-reactive protein Homo sapiens 59-77 25216457-4 2014 RESULTS: Cortisol levels were negatively correlated with plasma sodium (Rho = -0.26. p < 0.025) and positively correlated with C-reactive protein (CRP; Rho = 0.26, p = 0.027). Hydrocortisone 9-17 C-reactive protein Homo sapiens 130-148 25216457-4 2014 RESULTS: Cortisol levels were negatively correlated with plasma sodium (Rho = -0.26. p < 0.025) and positively correlated with C-reactive protein (CRP; Rho = 0.26, p = 0.027). Hydrocortisone 9-17 C-reactive protein Homo sapiens 150-153 25087591-6 2014 Palmitoleic acid (16:1n-7) correlated positively with CRP (r partial=0.096, P<0.001). palmitoleic acid 0-16 C-reactive protein Homo sapiens 54-57 25087591-9 2014 Palmitoleic acid was associated with CRP, whereas, interestingly, its elongation product, cis-vaccenic acid, associated with anti-inflammatory adiponectin. palmitoleic acid 0-16 C-reactive protein Homo sapiens 37-40 24827394-0 2014 Acute alcohol exposure has an independent impact on C-reactive protein levels, neutrophil CD64 expression, and subsets of circulating white blood cells differentiated by flow cytometry in nontrauma patients. Alcohols 6-13 C-reactive protein Homo sapiens 52-70 25266928-7 2014 Over the first 12 weeks of ART, there were significant decreases in serum levels of LBP (median change -8.7 mug/ml, p = 0.01), TNF-alpha receptor 1 (-0.31 ng/ml, p < 0.01), and CRP (-3.5 mg/l, p = 0.02). art 27-30 C-reactive protein Homo sapiens 180-183 24480677-8 2014 The 15-mg dose of tofacitinib reduced levels of C-reactive protein and fecal calprotectin from baseline. tofacitinib 18-29 C-reactive protein Homo sapiens 48-66 24480677-13 2014 Reductions in C-reactive protein and fecal calprotectin levels among patients given the 15-mg dose of tofacitinib indicate its biologic activity. tofacitinib 102-113 C-reactive protein Homo sapiens 14-32 25046320-4 2014 RESULTS: Officers in DII quartiles 2 to 4 were more likely to exceed a threshold of 3.0 mg/L for C-reactive protein (odds ratio [OR] = 1.88; 95% confidence interval [95% CI] = 1.02 to 3.45; OR = 2.17; 95% CI = 1.19 to 3.95; OR = 1.57; 95% CI = 0.85 to 2.88, respectively) compared with quartile 1. dilC18(3) dye 21-24 C-reactive protein Homo sapiens 97-115 24709327-0 2014 Label-free detection of C-reactive protein using a carbon nanofiber based biosensor. Carbon 51-57 C-reactive protein Homo sapiens 24-42 24709327-1 2014 We report the sensitive detection of C-reactive protein (CRP), a biomarker for cardiac disease, using a carbon nanofiber based biosensor platform. Carbon 104-110 C-reactive protein Homo sapiens 37-55 24709327-1 2014 We report the sensitive detection of C-reactive protein (CRP), a biomarker for cardiac disease, using a carbon nanofiber based biosensor platform. Carbon 104-110 C-reactive protein Homo sapiens 57-60 25337473-9 2014 There was a significant association between the history of high blood pressure, C-reactive protein and preoperative creatinine levels in both cognitive disorder and control groups. Creatinine 116-126 C-reactive protein Homo sapiens 80-98 25366207-10 2014 INTERPRETATION & CONCLUSIONS: The findings indicated that in patients with CAD, CRP was a better predictor of mortality than fibrinogen and offered prognostic information beyond that provided by the conventional cardiovascular risk factors. Adenosine Monophosphate 16-19 C-reactive protein Homo sapiens 84-87 25034026-0 2014 Synthesis of water-soluble CdSe quantum dots with various fluorescent properties and their application in immunoassay for determination of C-reactive protein. Water 13-18 C-reactive protein Homo sapiens 139-157 24965144-5 2014 AA genotype of -717A>G and TT genotype of +1444C>T were significantly associated (P = 0.02 & 0.03 respectively) with the risk of CHD whereas, +1059G and +1444T were found to be strongly related (P = 0.023 & P = 0.008 respectively) with multivariable adjusted CRP levels. Adenosine Monophosphate 98-101 C-reactive protein Homo sapiens 273-276 24827394-4 2014 After multiple regression analysis, alcohol exposure remained independently associated with values of CRP, neutrophils CD4 indexes, cytotoxic and noncytotoxic T lymphocytes, and CD16-negative and -positive monocytes. Alcohols 36-43 C-reactive protein Homo sapiens 102-105 25111123-7 2014 In the glucose beverage group there was significantly improved adipose insulin sensitivity, high sensitivity C-reactive protein (hs-CRP), and low-density lipoprotein (LDL) oxidation. Glucose 7-14 C-reactive protein Homo sapiens 109-127 25048483-6 2014 After completion of the initial IVIG, C-reactive protein levels in the combined IVIG plus dexamethasone group were significantly lower than those in the IVIG only group (2.7+-4.0 mg/dL vs. 4.6+-8.7 mg/dL, p=0.03). Dexamethasone 90-103 C-reactive protein Homo sapiens 38-56 25163828-12 2014 The linear regression analysis conveyed an association between high CRP and increased fasting blood glucose. Glucose 100-107 C-reactive protein Homo sapiens 68-71 25221751-3 2014 This study was conducted to examine the association between dietary fatty acid intakes and inflammatory markers, interleukin 6 (IL-6) and high sensitivity C-reactive protein (hs-CRP), in CAD patients among Iranian population. Fatty Acids 68-78 C-reactive protein Homo sapiens 155-173 24447269-8 2014 The high-sensitivity C-reactive protein was decreased (tacrolimus group, 1 mo) and increased (cyclosporine group, 6 and 12 mo) after the kidney transplant. Cyclosporine 94-106 C-reactive protein Homo sapiens 21-39 24378766-1 2014 OBJECTIVE: Isoflavones and exercise have been shown to affect C-reactive protein (CRP) and body composition and to act synergistically on trunk and total fat mass (FM), glucose metabolism, and lean body mass in postmenopausal women with a body mass index higher than 25 kg/m. Isoflavones 11-22 C-reactive protein Homo sapiens 62-80 24378766-1 2014 OBJECTIVE: Isoflavones and exercise have been shown to affect C-reactive protein (CRP) and body composition and to act synergistically on trunk and total fat mass (FM), glucose metabolism, and lean body mass in postmenopausal women with a body mass index higher than 25 kg/m. Isoflavones 11-22 C-reactive protein Homo sapiens 82-85 24378766-10 2014 CONCLUSIONS: Despite an increase in TNF-alpha, the use of isoflavones-when body weight remains stable-seems to enhance the beneficial effects of mixed-exercise training on body composition and CRP in overweight or obese postmenopausal women. Isoflavones 58-69 C-reactive protein Homo sapiens 193-196 24107546-0 2014 A population-based dietary inflammatory index predicts levels of C-reactive protein in the Seasonal Variation of Blood Cholesterol Study (SEASONS). Cholesterol 119-130 C-reactive protein Homo sapiens 65-83 25452862-6 2014 As compared with NGT 1h-low, NGT 1h-high and IGT subjects exhibited significantly higher body mass index (BMI), triglycerides, high sensitivity C reactive protein, ALT, GGT, and hepatic insulin resistance (IR), assessed by the liver IR index, as well as lower high density lipoprotein, and insulin-like growth factor-1 (IGF-1) levels. Hydrogen 33-35 C-reactive protein Homo sapiens 144-162 23716069-0 2014 Analysis and modelling of cholesterol and high-density lipoprotein cholesterol changes across the range of C-reactive protein levels in clinical practice as an aid to better understanding of inflammation-lipid interactions. Cholesterol 26-37 C-reactive protein Homo sapiens 107-125 23716069-4 2014 Our hypothesis was that there would be an inverse association between raised CRP levels and both TC and HDL-cholesterol levels. Cholesterol 108-119 C-reactive protein Homo sapiens 77-80 23716069-10 2014 There was an inverse relationship between HDL-cholesterol and CRP. Cholesterol 46-57 C-reactive protein Homo sapiens 62-65 25489444-0 2014 Effect of Vitamin D Supplementation on C-reactive Protein in Patients with Nonalcoholic Fatty Liver. Vitamin D 10-19 C-reactive protein Homo sapiens 39-57 25012289-0 2014 Effects of an antisense oligonucleotide inhibitor of C-reactive protein synthesis on the endotoxin challenge response in healthy human male volunteers. Oligonucleotides 24-39 C-reactive protein Homo sapiens 53-71 25063045-9 2014 Phase 3 data confirmed that patients with higher baseline CRP or greater CRP decreases following tofacitinib treatment had the largest increases in SCr. tofacitinib 97-108 C-reactive protein Homo sapiens 73-76 25012289-12 2014 These data demonstrate the specificity of antisense oligonucleotides and provide an investigative tool to further define the role of CRP in human pathological conditions. Oligonucleotides 52-68 C-reactive protein Homo sapiens 133-136 24763850-8 2014 Calcium concentration (OR 1.37 [95% CI 1.09, 1.72]) and calcium-phosphate product (OR 1.39 [95% CI 1.09, 1.77]) remained associated with incident diabetes after additional adjustment for BMI, plasma glucose, SI, AIR, C-reactive protein, estimated GFR, diuretic drugs and total calcium intake. Calcium 0-7 C-reactive protein Homo sapiens 217-235 24824230-0 2014 Increased C-reactive protein is associated with airway wall thickness in steroid-naive asthma. Steroids 73-80 C-reactive protein Homo sapiens 10-28 23955082-8 2014 Coupling of S1P3 to heterotrimeric Galphaq triggered the expression of CRP, utilizing signaling pathways involving reactive oxygen species (ROS), Ca(2+) and extracellular signal-related kinases (ERKs). Reactive Oxygen Species 115-138 C-reactive protein Homo sapiens 71-74 23955082-8 2014 Coupling of S1P3 to heterotrimeric Galphaq triggered the expression of CRP, utilizing signaling pathways involving reactive oxygen species (ROS), Ca(2+) and extracellular signal-related kinases (ERKs). Reactive Oxygen Species 140-143 C-reactive protein Homo sapiens 71-74 23955082-9 2014 S1P-induced CRP expression was crucial for the transcriptional activation of matrix metalloproteinase-9 through ERKs, ROS and c-fos, leading to breast cell invasion. Reactive Oxygen Species 118-121 C-reactive protein Homo sapiens 12-15 25317609-7 2014 Positive association was observed between the levels of NGAL, creatinine and C-reactive protein. Creatinine 62-72 C-reactive protein Homo sapiens 77-95 25436282-9 2014 DISCUSSION: Serum ghrelin level can be used with CRP as an important marker in establishing the mucosal damage in inflammatory bowel diseases. Ghrelin 18-25 C-reactive protein Homo sapiens 49-52 25137264-10 2014 RESULTS: Among obese children, C-reactive protein levels were associated with triacylglycerol levels and body fat percentage estimated by skinfold thickness (R2 adjusted = 27.6%, p < 0.001). Triglycerides 78-93 C-reactive protein Homo sapiens 31-49 25627231-6 2014 Four of 7 studies found a significant negative correlation between vitamin D levels and Bath Ankylosing Spondylitis Index (BASDAI), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Vitamin D 67-76 C-reactive protein Homo sapiens 173-191 25078741-10 2014 The US-CRP median was of 0.3 mg/L (range: 0.3 mg/L-6.8 mg/L), and it was positively and significantly correlated with BMI (ss = 0.226, p = 0.032) and LDL-C (ss = -0.267, p = 0.007) and negatively associated with cholesterol (ss = -0.267, p = 0.007). Cholesterol 212-223 C-reactive protein Homo sapiens 7-10 25627231-6 2014 Four of 7 studies found a significant negative correlation between vitamin D levels and Bath Ankylosing Spondylitis Index (BASDAI), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Vitamin D 67-76 C-reactive protein Homo sapiens 193-196 24813814-4 2014 Herein, we present the use of thermally cross-linked poly(ethylene glycol) (PEG) polymer sensory array interfaces in the ultrasensitive quantification of two protein markers, insulin and C-reactive protein (CRP). Polyethylene Glycols 53-74 C-reactive protein Homo sapiens 187-205 24918698-1 2014 Vitamin D might elicit protective effects against cardiovascular disease by decreasing the level of circulating high-sensitivity C-reactive protein (hs-CRP), an inflammatory marker. Vitamin D 0-9 C-reactive protein Homo sapiens 152-155 24918698-2 2014 Thus, we conducted a meta-analysis of randomized controlled trials to evaluate the association of vitamin D supplementation with circulating hs-CRP level. Vitamin D 98-107 C-reactive protein Homo sapiens 144-147 24918698-5 2014 The results of the meta-analysis of 10 trials involving a total of 924 participants showed that vitamin D supplementation significantly decreased the circulating hs-CRP level by 1.08 mg/L (95% CI, -2.13, -0.03), with the evidence of heterogeneity. Vitamin D 96-105 C-reactive protein Homo sapiens 165-168 24918698-8 2014 In summary, vitamin D supplementation is beneficial for the reduction of circulating hs-CRP. Vitamin D 12-21 C-reactive protein Homo sapiens 88-91 24813814-4 2014 Herein, we present the use of thermally cross-linked poly(ethylene glycol) (PEG) polymer sensory array interfaces in the ultrasensitive quantification of two protein markers, insulin and C-reactive protein (CRP). Polyethylene Glycols 53-74 C-reactive protein Homo sapiens 207-210 24813814-4 2014 Herein, we present the use of thermally cross-linked poly(ethylene glycol) (PEG) polymer sensory array interfaces in the ultrasensitive quantification of two protein markers, insulin and C-reactive protein (CRP). Polyethylene Glycols 76-79 C-reactive protein Homo sapiens 187-205 24813814-4 2014 Herein, we present the use of thermally cross-linked poly(ethylene glycol) (PEG) polymer sensory array interfaces in the ultrasensitive quantification of two protein markers, insulin and C-reactive protein (CRP). Polyethylene Glycols 76-79 C-reactive protein Homo sapiens 207-210 24595228-12 2014 Myocardial and systemic sevoflurane delivery effectively suppressed surgery-related inflammatory responses including postoperative C-reactive protein levels when compared with controls [63 (47-99) (P=0.01) and 58 (56-81) (P=0.04) compared with 107 (79-144) mg litre(-1)]. Sevoflurane 24-35 C-reactive protein Homo sapiens 131-149 24914983-1 2014 The prokaryotic global transcription factor CRP has been considered to be an ideal model for in-depth study of both the allostery of the protein and the differential utilization of the homologous cyclic nucleotide second messengers cAMP and cGMP. Cyclic AMP 232-236 C-reactive protein Homo sapiens 44-47 24914983-1 2014 The prokaryotic global transcription factor CRP has been considered to be an ideal model for in-depth study of both the allostery of the protein and the differential utilization of the homologous cyclic nucleotide second messengers cAMP and cGMP. Cyclic GMP 241-245 C-reactive protein Homo sapiens 44-47 24914983-2 2014 Here, atomic details from the crystal structures of two inactive CRP species, an apo form and a cGMP-bound form, in comparison with a known active conformation, the cAMP-CRP complex, provide macroscopic and microscopic insights into CRP allostery, which is coupled to specific discrimination between the two effectors. Cyclic GMP 96-100 C-reactive protein Homo sapiens 65-68 24914983-2 2014 Here, atomic details from the crystal structures of two inactive CRP species, an apo form and a cGMP-bound form, in comparison with a known active conformation, the cAMP-CRP complex, provide macroscopic and microscopic insights into CRP allostery, which is coupled to specific discrimination between the two effectors. Cyclic GMP 96-100 C-reactive protein Homo sapiens 170-173 24914983-2 2014 Here, atomic details from the crystal structures of two inactive CRP species, an apo form and a cGMP-bound form, in comparison with a known active conformation, the cAMP-CRP complex, provide macroscopic and microscopic insights into CRP allostery, which is coupled to specific discrimination between the two effectors. Cyclic GMP 96-100 C-reactive protein Homo sapiens 170-173 24914983-2 2014 Here, atomic details from the crystal structures of two inactive CRP species, an apo form and a cGMP-bound form, in comparison with a known active conformation, the cAMP-CRP complex, provide macroscopic and microscopic insights into CRP allostery, which is coupled to specific discrimination between the two effectors. Cyclic AMP 165-169 C-reactive protein Homo sapiens 65-68 24914983-2 2014 Here, atomic details from the crystal structures of two inactive CRP species, an apo form and a cGMP-bound form, in comparison with a known active conformation, the cAMP-CRP complex, provide macroscopic and microscopic insights into CRP allostery, which is coupled to specific discrimination between the two effectors. Cyclic AMP 165-169 C-reactive protein Homo sapiens 170-173 24914983-2 2014 Here, atomic details from the crystal structures of two inactive CRP species, an apo form and a cGMP-bound form, in comparison with a known active conformation, the cAMP-CRP complex, provide macroscopic and microscopic insights into CRP allostery, which is coupled to specific discrimination between the two effectors. Cyclic AMP 165-169 C-reactive protein Homo sapiens 170-173 24914983-5 2014 Additionally, the finding that cGMP, which is specifically recognized in a syn conformation, induces an inhibitory conformational change, rather than a null effect, on CRP supports the intriguing possibility that cGMP signalling could be widely utilized in prokaryotes, including in aggressive inhibition of CRP-like proteins. Cyclic GMP 31-35 C-reactive protein Homo sapiens 168-171 24914983-5 2014 Additionally, the finding that cGMP, which is specifically recognized in a syn conformation, induces an inhibitory conformational change, rather than a null effect, on CRP supports the intriguing possibility that cGMP signalling could be widely utilized in prokaryotes, including in aggressive inhibition of CRP-like proteins. Cyclic GMP 31-35 C-reactive protein Homo sapiens 308-311 24914983-5 2014 Additionally, the finding that cGMP, which is specifically recognized in a syn conformation, induces an inhibitory conformational change, rather than a null effect, on CRP supports the intriguing possibility that cGMP signalling could be widely utilized in prokaryotes, including in aggressive inhibition of CRP-like proteins. Cyclic GMP 213-217 C-reactive protein Homo sapiens 168-171 24914983-5 2014 Additionally, the finding that cGMP, which is specifically recognized in a syn conformation, induces an inhibitory conformational change, rather than a null effect, on CRP supports the intriguing possibility that cGMP signalling could be widely utilized in prokaryotes, including in aggressive inhibition of CRP-like proteins. Cyclic GMP 213-217 C-reactive protein Homo sapiens 308-311 24134216-7 2014 Mifamurtide-induced increases in serum C-reactive protein were attenuated in the moderate hepatic impairment group, consistent with the liver being the major organ of C-reactive protein synthesis. mifamurtide 0-11 C-reactive protein Homo sapiens 39-57 24134216-7 2014 Mifamurtide-induced increases in serum C-reactive protein were attenuated in the moderate hepatic impairment group, consistent with the liver being the major organ of C-reactive protein synthesis. mifamurtide 0-11 C-reactive protein Homo sapiens 167-185 24399680-2 2014 Since CRP is able to bind phospholipids (mainly phosphocholine) in the presence of calcium ions, we explored the possibilities of developing a high-sensitive affordable nephelometric CRP assay based on diluted soy oil emulsions. Phospholipids 26-39 C-reactive protein Homo sapiens 6-9 24399680-2 2014 Since CRP is able to bind phospholipids (mainly phosphocholine) in the presence of calcium ions, we explored the possibilities of developing a high-sensitive affordable nephelometric CRP assay based on diluted soy oil emulsions. Calcium 83-90 C-reactive protein Homo sapiens 6-9 24399680-4 2014 After 12 min of incubation at 37 C, the CRP-phospholipid complexes were measured by nephelometry (840 nm) using a BN II nephelometer (Siemens). Phospholipids 44-56 C-reactive protein Homo sapiens 40-43 24731651-7 2014 In conclusion, patients with non-STEMI and those with increased C-reactive protein levels show a lower reduction in MR after intracoronary adenosine-induced hyperemia, leading to FFR underestimation. Adenosine 139-148 C-reactive protein Homo sapiens 64-82 24511127-8 2014 Sulfate beneficially associated with eGFR, net acid excretion, systolic BP, high-sensitivity C-reactive protein, N-terminal probrain natriuretic peptide, and proteinuria (all P<=0.01). Sulfates 0-7 C-reactive protein Homo sapiens 93-111 24576416-8 2014 In response to glucose ingestion, plasma IL-6 and sVCAM-1 increased and CRP suppression was attenuated in both PCOS groups and obese controls compared with lean controls. Glucose 15-22 C-reactive protein Homo sapiens 72-75 25164229-12 2014 Aging, higher systolic pressure, higher sensitivity C-reactive protein and excessive salt intake are risk factors for IDH subjects to suffer from ISH and SDH. sdh 154-157 C-reactive protein Homo sapiens 52-70 24622804-10 2014 Among women with complete pill counts (97% adherence), the mean decrease in CRP was 1.18 mg/mL (46%) in the vitamin D arm compared with 0.46 mg/mL (25%) in the placebo arm (P = 0.03). Vitamin D 108-117 C-reactive protein Homo sapiens 76-79 24607659-6 2014 An interquartile range increase in urinary cadmium was associated with a 47.5%, 8.8%, and 3.7% increase in C-reactive protein (CRP), gamma glutamyl transferase (GGT), and alkaline phosphatase (ALP), respectively. Cadmium 43-50 C-reactive protein Homo sapiens 107-125 24206243-3 2014 Clinically, elevated serum CRP levels were found to associate closely with increased serum creatinine and urea levels (P<0.01) in patients with AKI, which then fell after recovery from AKI. Creatinine 91-101 C-reactive protein Homo sapiens 27-30 24206243-3 2014 Clinically, elevated serum CRP levels were found to associate closely with increased serum creatinine and urea levels (P<0.01) in patients with AKI, which then fell after recovery from AKI. Urea 106-110 C-reactive protein Homo sapiens 27-30 24344735-5 2014 RESULTS: Multivariate linear regression revealed that higher levels of depressive symptoms were associated with higher levels of 1-h plasma glucose concentrations after adjusting for age, gender, ethnicity, BMI, antidepressant use and high-sensitivity C-reactive protein. Glucose 140-147 C-reactive protein Homo sapiens 252-270 24607659-6 2014 An interquartile range increase in urinary cadmium was associated with a 47.5%, 8.8%, and 3.7% increase in C-reactive protein (CRP), gamma glutamyl transferase (GGT), and alkaline phosphatase (ALP), respectively. Cadmium 43-50 C-reactive protein Homo sapiens 127-130 24607659-8 2014 ADS significantly attenuated the association between cadmium exposure, CRP and ALP. Cadmium 53-60 C-reactive protein Homo sapiens 71-74 24848386-1 2014 OBJECTIVE: To determine the correlation of C-reactive protein (CRP) with fasting triglycerides (TG) among pre-obese and obese patients without established diagnosis of coronary artery disease (CAD). Triglycerides 81-94 C-reactive protein Homo sapiens 43-61 24803317-8 2014 In addition to attenuation of lipopolysaccharide-induced expression of TNF-alpha, IL-1beta, IL-6 in macrophages, and human C-reactive protein in hepatocytes, respectively, at the transcriptional level in vitro, DHI also reduced TNF-alpha protein expression in aortic root of both Apoe-/- and Ldlr-/- mice, suggesting the importance of the anti-inflammatory properties of DHI in the inhibition of lesion development. dehydrosoyasaponin I 211-214 C-reactive protein Homo sapiens 123-141 24803317-8 2014 In addition to attenuation of lipopolysaccharide-induced expression of TNF-alpha, IL-1beta, IL-6 in macrophages, and human C-reactive protein in hepatocytes, respectively, at the transcriptional level in vitro, DHI also reduced TNF-alpha protein expression in aortic root of both Apoe-/- and Ldlr-/- mice, suggesting the importance of the anti-inflammatory properties of DHI in the inhibition of lesion development. dehydrosoyasaponin I 371-374 C-reactive protein Homo sapiens 123-141 23607539-1 2014 We describe a case of serum amyloid A (SAA) and C-reactive protein (CRP) positive nodule detected by immunohistochemical analysis in a 37-year-old woman with alcohol-related cirrhosis. Alcohols 158-165 C-reactive protein Homo sapiens 48-66 23607539-1 2014 We describe a case of serum amyloid A (SAA) and C-reactive protein (CRP) positive nodule detected by immunohistochemical analysis in a 37-year-old woman with alcohol-related cirrhosis. Alcohols 158-165 C-reactive protein Homo sapiens 68-71 23979817-6 2014 Serum total testosterone was inversely correlated with age (r = -0.32, p < 0.05), CRP (r = -0.31, p < 0.05), and IL-6 (r = -0.24, p < 0.05). Testosterone 12-24 C-reactive protein Homo sapiens 85-88 24848386-1 2014 OBJECTIVE: To determine the correlation of C-reactive protein (CRP) with fasting triglycerides (TG) among pre-obese and obese patients without established diagnosis of coronary artery disease (CAD). Triglycerides 81-94 C-reactive protein Homo sapiens 63-66 24848386-1 2014 OBJECTIVE: To determine the correlation of C-reactive protein (CRP) with fasting triglycerides (TG) among pre-obese and obese patients without established diagnosis of coronary artery disease (CAD). Triglycerides 96-98 C-reactive protein Homo sapiens 43-61 24848386-1 2014 OBJECTIVE: To determine the correlation of C-reactive protein (CRP) with fasting triglycerides (TG) among pre-obese and obese patients without established diagnosis of coronary artery disease (CAD). Triglycerides 96-98 C-reactive protein Homo sapiens 63-66 24848386-18 2014 Whereas 1 unit rise increase in triglycerides on the average cause CRP to decrease -0.006 times but this value was insignificant. Triglycerides 32-45 C-reactive protein Homo sapiens 67-70 24884656-6 2014 VO2 peak was correlated with body mass index, C-reactive protein, FEV1, FVC, RV, DLCO, VE/VCO2 peak, VD/VT, PaO2, PaCO2, P(A-a)O2, and breathing reserve. Oxygen 1-3 C-reactive protein Homo sapiens 46-64 25396060-0 2014 Vitamin D deficiency is common and associated with increased C-reactive protein in children and young adults with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus substudy. Vitamin D 0-9 C-reactive protein Homo sapiens 61-79 24594292-0 2014 Cytokines and hs-CRP levels in individuals treated with low-dose aspirin for cardiovascular prevention: a population-based study (CoLaus Study). Aspirin 65-72 C-reactive protein Homo sapiens 17-20 24847348-10 2014 Though the true relationship between MG and TA was not revealed in present case, considering the fact that complete remission of nephrotic syndrome occurred following the improvement of C-reactive protein level in response to steroid therapy, TA might be the secondary cause of MG. To our best knowledge, only two case reports described the association of MG and TA previously. Steroids 226-233 C-reactive protein Homo sapiens 186-204 24766776-8 2014 In Cox regression models, after adjusted age, gender, body mass index, other lipid parameters, fasting blood glucose, high sensitivity C-reactive protein, neutrophil count and HbA1C, TG remained as an independent predictor of adverse prognosis. Triglycerides 183-185 C-reactive protein Homo sapiens 135-153 24346636-0 2014 Point-of-care C-reactive protein testing to facilitate implementation of isoniazid preventive therapy for people living with HIV. Isoniazid 73-82 C-reactive protein Homo sapiens 14-32 24594292-3 2014 The aim of this study was to determine the association between pro-inflammatory cytokines and hs-CRP levels and low-dose aspirin use for cardiovascular prevention in a population-based cohort (CoLaus Study). Aspirin 121-128 C-reactive protein Homo sapiens 97-100 24959437-4 2014 This study aims at establishing the reason for glycemic variation in menstruating Type-2 diabetic women by estimation of C-reactive protein, an inflammatory marker that exhibits significant association with changes in blood glucose levels. Glucose 224-231 C-reactive protein Homo sapiens 121-139 25237354-5 2014 SERUM CONCENTRATIONS OF SAA (P: 0.02), CRP (P: 0.02) and ferritin (P: 0.01) significantly reduced in heparin group during measurements compared to baseline, circulating levels of IL-6 (P: 0.002), SAA (P: 0.009), CRP (P: 0.01) were significantly decreased in enoxaparin group. Heparin 101-108 C-reactive protein Homo sapiens 39-42 25237354-5 2014 SERUM CONCENTRATIONS OF SAA (P: 0.02), CRP (P: 0.02) and ferritin (P: 0.01) significantly reduced in heparin group during measurements compared to baseline, circulating levels of IL-6 (P: 0.002), SAA (P: 0.009), CRP (P: 0.01) were significantly decreased in enoxaparin group. Heparin 101-108 C-reactive protein Homo sapiens 212-215 24959437-9 2014 Observation and Result: The result showed that hs-CRP level significantly correlates with increasing levels of fasting blood glucose level in both the phases of menstrual cycle in Type-2 diabetic women. Glucose 125-132 C-reactive protein Homo sapiens 50-53 23434617-13 2014 At 10 days, a further significant increase of D-dimer (P = 0.04) and CRP (P = 0.018) concentrations in HL&S but not RFA and EVLA patients was observed. Adenosine Monophosphate 106-109 C-reactive protein Homo sapiens 69-72 24529136-0 2014 Epicatechin attenuates atherosclerosis and exerts anti-inflammatory effects on diet-induced human-CRP and NFkappaB in vivo. Catechin 0-11 C-reactive protein Homo sapiens 98-101 24495103-12 2014 CONCLUSIONS: FC, CRP, and SCCAI seem to be reliable markers of treatment response during steroid treatment. Steroids 89-96 C-reactive protein Homo sapiens 17-20 24767374-6 2014 Additionally, an in vitro study demonstrated that the down-regulation of brain-derived neurotrophic factor (BDNF) gene expression by CRP treatment in retinoic acid (RA) differentiated SH-SY5Y neuroblastoma cells. Tretinoin 150-163 C-reactive protein Homo sapiens 133-136 24767374-6 2014 Additionally, an in vitro study demonstrated that the down-regulation of brain-derived neurotrophic factor (BDNF) gene expression by CRP treatment in retinoic acid (RA) differentiated SH-SY5Y neuroblastoma cells. Tretinoin 165-167 C-reactive protein Homo sapiens 133-136 23436914-0 2014 Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. Atorvastatin 43-55 C-reactive protein Homo sapiens 134-152 23434617-11 2014 The highest CRP increase was observed in HL&S group (P = 0.003). Adenosine Monophosphate 44-47 C-reactive protein Homo sapiens 12-15 24452238-6 2014 RESULTS: In men, the HF F&V diet increased endothelium-dependent microvascular reactivity (P = 0.017) with +2 portions/d (at 6 wk) and reduced C-reactive protein (P = 0.001), E-selectin (P = 0.0005), and vascular cell adhesion molecule (P = 0.0468) with +4 portions/d (at 12 wk). Adenosine Monophosphate 26-29 C-reactive protein Homo sapiens 147-165 24529136-7 2014 Epicatechin mitigated diet-induced increases in plasma SAA (in ApoE*3-Leiden mice) and plasma human-CRP (in human-CRP transgenic mice). Catechin 0-11 C-reactive protein Homo sapiens 100-103 24529136-7 2014 Epicatechin mitigated diet-induced increases in plasma SAA (in ApoE*3-Leiden mice) and plasma human-CRP (in human-CRP transgenic mice). Catechin 0-11 C-reactive protein Homo sapiens 114-117 24529136-11 2014 The observed reduction of circulating inflammatory risk factors by epicatechin (e.g. SAA, human-CRP), as well as its local anti-inflammatory activity in the vessel wall, provide a rationale for epicatechin"s anti-atherogenic effects. Catechin 194-205 C-reactive protein Homo sapiens 96-99 24484740-3 2014 AIM: To assess relationship between vitamin D status and C-reactive protein (CRP), a nonspecific inflammatory marker of CSU activity. Vitamin D 36-45 C-reactive protein Homo sapiens 57-75 24463788-3 2014 In the present study, we examined the associations of serum C-reactive protein (CRP) and white blood cell (WBC) count with lignans, which are more frequent in the Western diet than isoflavones. Lignans 123-130 C-reactive protein Homo sapiens 60-78 24463788-8 2014 RESULTS: Statistically significant inverse associations of urinary lignan, enterodiol, and enterolactone concentrations with circulating CRP and WBC counts were observed in the multivariate-adjusted models: In NHANES 2005-2008, per one-percent increase in lignan concentrations in the urine, CRP concentrations and WBC counts decreased by 8.1 % (95 % CI -11.5, -4.5) and 1.9 % (95 % CI -2.7; -1.2), respectively. Lignans 67-73 C-reactive protein Homo sapiens 137-140 24586854-10 2014 High sensitivity C-reactive protein (hsCRP) was positively correlated with traditional cardio-metabolic risk factors including waist circumference (r = 0.127, p = 0.05), triglycerides (r = 0.19, p = 0.003) and Total Cholesterol: High Density Lipoprotein ratio (TC:LDL) (r = 0.225, p<0.001). Triglycerides 170-183 C-reactive protein Homo sapiens 17-35 24586854-10 2014 High sensitivity C-reactive protein (hsCRP) was positively correlated with traditional cardio-metabolic risk factors including waist circumference (r = 0.127, p = 0.05), triglycerides (r = 0.19, p = 0.003) and Total Cholesterol: High Density Lipoprotein ratio (TC:LDL) (r = 0.225, p<0.001). Cholesterol 216-227 C-reactive protein Homo sapiens 17-35 24484740-3 2014 AIM: To assess relationship between vitamin D status and C-reactive protein (CRP), a nonspecific inflammatory marker of CSU activity. Vitamin D 36-45 C-reactive protein Homo sapiens 77-80 24022862-10 2014 CONCLUSION: The pharmacologic effect of aspirin is suboptimal in 15% of patients with SLE but in none of the control subjects, and the suboptimal response was associated with metabolic syndrome, obesity, and higher CRP concentrations. Aspirin 40-47 C-reactive protein Homo sapiens 215-218 24342929-6 2014 In linear regression analyses comprising age, smoking, triglyceride, HDL-cholesterol, C-reactive protein and waist circumference as well, creatinine was significantly and independently associated with ADMA, further in women glucose (inversely). Creatinine 138-148 C-reactive protein Homo sapiens 86-104 24508289-0 2014 High-sensitivity C-reactive protein is associated with the presence of coronary artery calcium in subjects with normal blood pressure but not in subjects with hypertension. Calcium 87-94 C-reactive protein Homo sapiens 17-35 24315778-11 2014 Percentage of energy from carbohydrate was inversely associated with CRP. Carbohydrates 26-38 C-reactive protein Homo sapiens 69-72 24390062-7 2014 Clinical remission at week 12 was achieved in 155 (73%) patients; both exclusive enteral nutrition and steroids were associated with normal CRP remission at week 12, although in a post hoc subgroup analysis exclusive enteral nutrition was superior in mild-to-moderate disease for this outcome. Steroids 103-111 C-reactive protein Homo sapiens 140-143 24390062-8 2014 Among those in steroid-free remission in week 12, normal CRP predicted 1-year sustained remission (86% for normal CRP versus 61% for elevated CRP; P = 0.02). Steroids 15-22 C-reactive protein Homo sapiens 57-60 24390062-10 2014 CONCLUSIONS: Normal CRP steroid-free remission at week 12 was impacted by type of induction therapy, but not by early immunomodulation. Steroids 24-31 C-reactive protein Homo sapiens 20-23 24622715-15 2014 Patients taking metformin had lower HbA1c, insulin, HOMA-IR, and tissue plasminogen activator compared with those taking placebo, but there were no significant differences for total cholesterol, HDL-cholesterol, non-HDL-cholesterol, triglycerides, high sensitivity C-reactive protein, or fasting glucose. Metformin 16-25 C-reactive protein Homo sapiens 265-283 24327720-7 2014 An interaction between baseline 25(OH)D and vitamin D supplementation was observed for outcome change in log CRP (month 3-month 0; P for interaction = 0.04). Vitamin D 44-53 C-reactive protein Homo sapiens 109-112 24024499-7 2014 GFR(cys) was weakly to moderately correlated with HIV RNA, CD4 cell count, high-sensitivity C-reactive protein, interleukin-6, and D-dimer, while GFR(cr) had little or no correlation with these factors. Cysteine 4-7 C-reactive protein Homo sapiens 92-110 24778661-2 2014 This study designed to evaluate the effects of atorvastatin on serum highly sensitive C-reactive protein (hs-CRP) and pulmonary function in sulfur mustard exposed patients with COPD. Atorvastatin 47-59 C-reactive protein Homo sapiens 86-104 24141169-5 2014 Intraluminal treatment of pressurized arterioles with a pathophysiological level of CRP (7 microg/mL; 60 minutes) attenuated endothelium-dependent nitric oxide-mediated and prostacyclin-mediated dilations to serotonin and arachidonic acid, respectively. Nitric Oxide 147-159 C-reactive protein Homo sapiens 84-87 24466039-8 2014 Moreover, chronic alcoholic hepatosteatosis, as well as the diabetic obese condition significantly increased CRP gene expression, and this increase was significantly attenuated by GSK5182 treatment. GSK5182 180-187 C-reactive protein Homo sapiens 109-112 23807310-3 2014 Aspirin and corticosteroids are known to down-regulate CRP production. Aspirin 0-7 C-reactive protein Homo sapiens 55-58 23807310-4 2014 In this study, we evaluated the usefulness of CRP as a biomarker for complicated diverticulitis and specifically in patients on anti-inflammatory medications: aspirin and corticosteroids. Aspirin 159-166 C-reactive protein Homo sapiens 46-49 23807310-9 2014 Mean CRP levels were 133.5 and 63.5 mg/ml for those with complicated and uncomplicated disease, respectively (p < 0.001), and 139 and 60 mg/ml, respectively (p < 0.001) in the subgroup of patients taking aspirin (n = 61). Aspirin 210-217 C-reactive protein Homo sapiens 5-8 23807310-12 2014 CONCLUSIONS: The CRP level distinguished between complicated and uncomplicated disease among left-sided diverticulitis patients including those taking aspirin, but not among those on corticosteroid treatment. Aspirin 151-158 C-reactive protein Homo sapiens 17-20 24262762-9 2014 The reduction in CRP levels correlated with the improvement in peak oxygen consumption (R = -0.60, p = 0.002). Oxygen 68-74 C-reactive protein Homo sapiens 17-20 24141169-5 2014 Intraluminal treatment of pressurized arterioles with a pathophysiological level of CRP (7 microg/mL; 60 minutes) attenuated endothelium-dependent nitric oxide-mediated and prostacyclin-mediated dilations to serotonin and arachidonic acid, respectively. Serotonin 208-217 C-reactive protein Homo sapiens 84-87 24141169-5 2014 Intraluminal treatment of pressurized arterioles with a pathophysiological level of CRP (7 microg/mL; 60 minutes) attenuated endothelium-dependent nitric oxide-mediated and prostacyclin-mediated dilations to serotonin and arachidonic acid, respectively. Arachidonic Acid 222-238 C-reactive protein Homo sapiens 84-87 24141169-8 2014 Denudation of endothelium and blockade of LOX-1 but not CD32 prevented CRP-induced elevation of superoxide in the vessel wall. Superoxides 96-106 C-reactive protein Homo sapiens 71-74 24141169-11 2014 CONCLUSIONS: CRP elicits endothelium-dependent oxidative stress and compromises nitric oxide-mediated and prostacyclin-mediated vasomotor function via LOX-1 activation. Nitric Oxide 80-92 C-reactive protein Homo sapiens 13-16 25605194-11 2014 CONCLUSIONS: The glucose fluctuation of patients undergoing intracranial excision is related to postoperative IL-6, TNF-alpha and CRP levels and those with small range of glucose fluctuation have better prognosis. Glucose 17-24 C-reactive protein Homo sapiens 130-133 24561973-9 2014 On the other hand, dietary intake of saturated fatty acids showed a negative correlation with serum C-reactive protein levels (p=0.001) in males. Fatty Acids 37-58 C-reactive protein Homo sapiens 100-118 24136895-7 2014 Weak to moderate positive associations were apparent for WC with CRP and triglycerides (r = 0.240 and 0.254, P < 0.05), whilst moderate to large associations were evident for WC with clustered cardiometabolic risk (r = 0.317, P < 0.05). Triglycerides 73-86 C-reactive protein Homo sapiens 65-68 25267223-4 2014 It was shown that measuring cytokines and CRP in blood serum may be used as an additional method for diagnosis of unstable nature of ASP in the CAs in order to determine the indications for carotid endarterectomy. Calcium 144-147 C-reactive protein Homo sapiens 42-45 24326321-0 2014 Association of C-reactive protein levels with fasting and postload glucose levels according to glucose tolerance status. Glucose 67-74 C-reactive protein Homo sapiens 15-33 24326321-0 2014 Association of C-reactive protein levels with fasting and postload glucose levels according to glucose tolerance status. Glucose 95-102 C-reactive protein Homo sapiens 15-33 24326321-2 2014 The aim of this study was to determine whether elevated CRP levels are associated with fasting plasma glucose (FPG) and/or postload glucose levels according to the glucose tolerance status. Glucose 102-109 C-reactive protein Homo sapiens 56-59 24326321-2 2014 The aim of this study was to determine whether elevated CRP levels are associated with fasting plasma glucose (FPG) and/or postload glucose levels according to the glucose tolerance status. Glucose 132-139 C-reactive protein Homo sapiens 56-59 24326321-2 2014 The aim of this study was to determine whether elevated CRP levels are associated with fasting plasma glucose (FPG) and/or postload glucose levels according to the glucose tolerance status. Glucose 132-139 C-reactive protein Homo sapiens 56-59 24326321-5 2014 Elevated CRP was defined by CRP levels >3.0 and <10.0 mg/L, IFG by FPG >=100 and <126 mg/dL, and IGT by plasma glucose concentration 2 h postload >=140 and <200 mg/dL. Glucose 123-130 C-reactive protein Homo sapiens 9-12 24326321-6 2014 A multiple regression linear analysis adjusted by body mass index, waist circumference, and lipid profile was performed to evaluate the association between CRP levels (independent variable) with FPG and 2 h postload glucose levels (dependent variables). Glucose 216-223 C-reactive protein Homo sapiens 156-159 24326321-8 2014 CONCLUSIONS: Elevated CRP levels are associated with FPG and 2 h postload glucose in the individuals with IGT, but not in subjects with IFG or NGT. Glucose 74-81 C-reactive protein Homo sapiens 22-25 25605194-11 2014 CONCLUSIONS: The glucose fluctuation of patients undergoing intracranial excision is related to postoperative IL-6, TNF-alpha and CRP levels and those with small range of glucose fluctuation have better prognosis. Glucose 171-178 C-reactive protein Homo sapiens 130-133 24784986-3 2014 The DBS approach generates values that are strongly related to whole blood levels of HbA1c, cystatin C, and C-reactive protein. dbs 4-7 C-reactive protein Homo sapiens 108-126 25535128-8 2014 And blood glucose fluctuation was correlated with FMD, CRP and HOMA-IR. Glucose 10-17 C-reactive protein Homo sapiens 55-58 25228402-0 2014 The relationship between specific Fatty acids of serum lipids and serum high sensitivity C- reactive protein levels in morbidly obese women. Fatty Acids 34-45 C-reactive protein Homo sapiens 89-108 25228402-1 2014 BACKGROUND/AIMS: The fatty acid profile in plasma lipids contributes to the increase of plasma high sensitivity C-reactive protein (hsCRP), a marker of inflammation and predictor of cardiovascular risk. Fatty Acids 21-31 C-reactive protein Homo sapiens 112-130 25651710-3 2014 Release of the cytokines such as prostaglandin-E2 (PGE2), and interleukin-1-beta (IL-1beta) from the periodontal lesion, stimulate hepatocytes and circulating leukocytes to produce CRP. Dinoprostone 33-49 C-reactive protein Homo sapiens 181-184 24161452-3 2014 This study was designed to examine whether and to what extent CRP is related to baseline cortisol concentrations in a well defined cohort of short-illness-duration first-episode, treatment-naive MDD patients. Hydrocortisone 89-97 C-reactive protein Homo sapiens 62-65 24327055-1 2014 OBJECTIVES: It has been shown that exposure of subjects to emissions from a metal inert gas (MIG) brazing process of zinc-coated material led to an increase of high-sensitivity C-reactive protein (hsCRP) in the blood. Metals 76-81 C-reactive protein Homo sapiens 177-195 23981104-6 2014 RESULTS: Metformin significantly reduced levels of vWF, sVCAM-1, t-PA, PAI-1, CRP and sICAM-1, which, except for CRP, remained significant after adjustment for baseline differences in age, sex, smoking and severity of previous cardiovascular (CV) disease. Metformin 9-18 C-reactive protein Homo sapiens 78-81 23981104-6 2014 RESULTS: Metformin significantly reduced levels of vWF, sVCAM-1, t-PA, PAI-1, CRP and sICAM-1, which, except for CRP, remained significant after adjustment for baseline differences in age, sex, smoking and severity of previous cardiovascular (CV) disease. Metformin 9-18 C-reactive protein Homo sapiens 113-116 24803739-4 2014 Blood CRP is synthesized primarily in the liver and the liver is an organ where antisense oligonucleotide (ASO) drugs accumulate. Oligonucleotides 90-105 C-reactive protein Homo sapiens 6-9 24312441-12 2013 IV iron was associated with a higher rate of achieving Hb response in comparison to oral iron; RR 1.25 (95% CI 1.04-1.51, I(2) = 2%, 4 trials), CRP levels and disease activity indexes were not significantly affected by IV iron. Iron 3-7 C-reactive protein Homo sapiens 144-147 25472577-6 2014 RESULTS: At baseline, the independent predictors of lower plasma sodium were C-reactive protein (CRP; OR 0.96; 95% CI 0.91-0.99) and body mass index (OR 0.89; 95% CI 0.78-0.99). Sodium 65-71 C-reactive protein Homo sapiens 77-95 25472577-6 2014 RESULTS: At baseline, the independent predictors of lower plasma sodium were C-reactive protein (CRP; OR 0.96; 95% CI 0.91-0.99) and body mass index (OR 0.89; 95% CI 0.78-0.99). Sodium 65-71 C-reactive protein Homo sapiens 97-100 25472577-7 2014 An inverse correlation between plasma sodium and CRP was observed (r = -0.32; p = 0.01). Sodium 38-44 C-reactive protein Homo sapiens 49-52 25472577-9 2014 During follow-up, patients with lower sodium at baseline showed persistently lower sodium values (p = 0.04), higher CRP (p = 0.05), lower serum albumin (p < 0.01) and higher erythropoietin-stimulating agent resistance index (p = 0.05). Sodium 38-44 C-reactive protein Homo sapiens 116-119 24434384-0 2014 The effect of treatment with N-acetylcysteine on the serum levels of C-reactive protein and interleukin-6 in patients on hemodialysis. Acetylcysteine 29-45 C-reactive protein Homo sapiens 69-87 24434384-3 2014 We aimed to assess the effect of three months treatment with oral NAC on the plasma levels of inflammatory mediators like interleukin-6 (IL-6) and C-reactive protein (hs-CRP) in patients on hemodialysis (HD). Acetylcysteine 66-69 C-reactive protein Homo sapiens 147-165 24548450-8 2013 And serum level of Ghrelin was positively correlated with APACHEII and CRP. Ghrelin 19-26 C-reactive protein Homo sapiens 71-74 24349396-5 2013 RESULTS: Among the baseline parameters, serum bicarbonate level was positively associated with hemoglobin level and residual glomerular filtration rate (GFR), while it was negatively associated with albumin, C-reactive protein (CRP) levels, peritoneal Kt/V urea, and normalized protein catabolic rate (nPCR) in a multivariable linear regression analysis. Bicarbonates 46-57 C-reactive protein Homo sapiens 228-231 24474658-11 2014 Our findings suggest that CRP genetic polymorphisms independently had positive association with the risk of HDL, LDL and TG elevating and further replication in other large population and biological function research would be warranted. Thioguanine 121-123 C-reactive protein Homo sapiens 26-29 23554365-9 2014 Baseline CRP levels negatively linked to HDL and TNF-RII positively to triglyceride. Triglycerides 71-83 C-reactive protein Homo sapiens 9-12 24335710-7 2013 Vitamins A, C and E and iron were negatively associated with CRP (p < 0.05). Iron 24-28 C-reactive protein Homo sapiens 61-64 24132976-2 2013 OBJECTIVE: This study was designed to assess the effects of vitamin D supplementation on metabolic profiles, high-sensitivity C-reactive protein, and biomarkers of oxidative stress in pregnant women with GDM. Vitamin D 60-69 C-reactive protein Homo sapiens 126-144 24145678-18 2013 Significant predictors of Hb response to IV iron treatment were baseline Hb and C-reactive protein (CRP). Iron 44-48 C-reactive protein Homo sapiens 80-98 24145678-18 2013 Significant predictors of Hb response to IV iron treatment were baseline Hb and C-reactive protein (CRP). Iron 44-48 C-reactive protein Homo sapiens 100-103 23963688-8 2013 Association between "poor" platelet response with lower ASA dose was confirmed by conditional maximum likelihood logistic regression, which showed the independency between erythrocyte-derived parameters, as the risk factors for suboptimal platelet response to ASA, and other risk factors, like CRP or LDL-cholesterol. Aspirin 56-59 C-reactive protein Homo sapiens 294-297 24131677-10 2013 CRP was significantly positively associated with serum phosphorus, calcium, alkaline phosphatase, and PTH, and significantly inversely associated with HDL and albumin. Calcium 67-74 C-reactive protein Homo sapiens 0-3 24099969-2 2013 OBJECTIVE: To test the concurrent and predictive relations between C-reactive protein (CRP) and use and abuse of alcohol, nicotine and cannabis in a longitudinal, population sample of adolescents and young adults, at the period of highest increase in drug use. Alcohols 113-120 C-reactive protein Homo sapiens 67-85 24099969-2 2013 OBJECTIVE: To test the concurrent and predictive relations between C-reactive protein (CRP) and use and abuse of alcohol, nicotine and cannabis in a longitudinal, population sample of adolescents and young adults, at the period of highest increase in drug use. Alcohols 113-120 C-reactive protein Homo sapiens 87-90 24099969-2 2013 OBJECTIVE: To test the concurrent and predictive relations between C-reactive protein (CRP) and use and abuse of alcohol, nicotine and cannabis in a longitudinal, population sample of adolescents and young adults, at the period of highest increase in drug use. Nicotine 122-130 C-reactive protein Homo sapiens 67-85 24099969-2 2013 OBJECTIVE: To test the concurrent and predictive relations between C-reactive protein (CRP) and use and abuse of alcohol, nicotine and cannabis in a longitudinal, population sample of adolescents and young adults, at the period of highest increase in drug use. Nicotine 122-130 C-reactive protein Homo sapiens 87-90 24099969-6 2013 RESULTS: CRP levels were higher in the presence of nicotine, alcohol, and cannabis use and nicotine dependence. Nicotine 51-59 C-reactive protein Homo sapiens 9-12 24099969-6 2013 RESULTS: CRP levels were higher in the presence of nicotine, alcohol, and cannabis use and nicotine dependence. Alcohols 61-68 C-reactive protein Homo sapiens 9-12 24099969-6 2013 RESULTS: CRP levels were higher in the presence of nicotine, alcohol, and cannabis use and nicotine dependence. Nicotine 91-99 C-reactive protein Homo sapiens 9-12 24099969-7 2013 In prospective analyses, higher CRP levels predicted cannabis use and nicotine dependence, and nicotine use predicted higher CRP levels, once covariates were included in the models. Nicotine 95-103 C-reactive protein Homo sapiens 125-128 24099969-9 2013 CONCLUSIONS: The inter-relationship of CRP and substance abuse has implications for the later health risks associated with early drug and alcohol use and abuse. Alcohols 138-145 C-reactive protein Homo sapiens 39-42 24148377-3 2013 The two developed immunosensors were tested against CRP antigen in phosphate buffer saline solution and in human plasma. Sodium Chloride 84-90 C-reactive protein Homo sapiens 52-55 24363868-0 2013 Serum High-Sensitivity C-Reactive Protein Levels and Response to 5 mg Tadalafil Once Daily in Patients With Erectile Dysfunction and Diabetes. Tadalafil 70-79 C-reactive protein Homo sapiens 23-41 24363868-12 2013 A significant correlation was observed between serum hs-CRP levels, the degree of ED, and responsiveness to tadalafil. Tadalafil 108-117 C-reactive protein Homo sapiens 56-59 24416046-4 2013 Serum sodium levels in hyponatremia are inversely correlated with the percentage of neutrophils, C-reactive protein, and N-terminal-pro brain type natriuretic peptide. Sodium 6-12 C-reactive protein Homo sapiens 97-115 24148377-3 2013 The two developed immunosensors were tested against CRP antigen in phosphate buffer saline solution and in human plasma. Phosphates 67-76 C-reactive protein Homo sapiens 52-55 24303898-7 2013 We found significantly positive correlations between CRP and creatinine titers in serum in all 101 CA patients. Creatinine 61-71 C-reactive protein Homo sapiens 53-56 24075505-0 2013 Consuming a hypocaloric high fat low carbohydrate diet for 12 weeks lowers C-reactive protein, and raises serum adiponectin and high density lipoprotein-cholesterol in obese subjects. Carbohydrates 37-49 C-reactive protein Homo sapiens 75-93 24124163-5 2013 Higher concentrations of total (slope per one quintile in concentration, -0.18; p-trend, 0.001) and calculated free (slope, -0.13; p-trend, 0.03) testosterone were statistically significantly associated with lower concentrations of CRP, but not with WBC count. Testosterone 146-158 C-reactive protein Homo sapiens 232-235 24124163-6 2013 Men in the bottom quintile of total testosterone (<=3.3 ng/mL), who might be considered to have clinically low testosterone, were more likely to have elevated CRP (>=3 mg/L) compared with men in the top four quintiles (OR, 1.61; 95% CI, 1.00-2.61). Testosterone 36-48 C-reactive protein Homo sapiens 162-165 24124163-6 2013 Men in the bottom quintile of total testosterone (<=3.3 ng/mL), who might be considered to have clinically low testosterone, were more likely to have elevated CRP (>=3 mg/L) compared with men in the top four quintiles (OR, 1.61; 95% CI, 1.00-2.61). Testosterone 114-126 C-reactive protein Homo sapiens 162-165 24124163-7 2013 Total and calculated free estradiol (E2) were positively associated with both CRP (Total E2: slope, 0.14; p-trend, <0.001; Free E2: slope, 0.15; p-trend, <0.001) and WBC (Total E2: slope, 0.02; p-trend, 0.08; Free E2: slope, 0.02; p-trend, 0.02) concentrations. Estradiol 26-35 C-reactive protein Homo sapiens 78-81 23982521-5 2013 RESULTS: The length of psoriasis remission correlated negatively and significantly with cholesterol levels, which correlated significantly and positively with C-reactive protein (CRP). Cholesterol 88-99 C-reactive protein Homo sapiens 159-177 23982521-5 2013 RESULTS: The length of psoriasis remission correlated negatively and significantly with cholesterol levels, which correlated significantly and positively with C-reactive protein (CRP). Cholesterol 88-99 C-reactive protein Homo sapiens 179-182 23982521-7 2013 Patients with cholesterol levels <200 mg/dL (n = 13) presented a significantly longer remission, lower BMI and triglycerides values, and a trend towards lower PASI and CRP values than those with high cholesterol (n = 30). Cholesterol 14-25 C-reactive protein Homo sapiens 171-174 23403039-6 2013 Patients who took oral vitamin D supplementation had lower Crohn"s disease activity index (p<0.05) and C-reactive protein (p=0.07) than non-users. Vitamin D 23-32 C-reactive protein Homo sapiens 106-124 23672831-7 2013 The area under the receiver operating characteristic curve values for association with steroid-free sustained remission were 0.70 for the PUCAI (95% confidence interval [CI], 0.53-0.88), 0.56 for mucosal healing (95% CI, 0.36-0.76), and 0.44 for level of CRP (95% CI, 0.24-0.65). Steroids 87-94 C-reactive protein Homo sapiens 255-258 24229668-6 2013 RESULTS: In the multiple linear regression model, natural log-transformed CRP (lnCRP) and uric acid were independent predictors of natural log-transformed urinary albumin to creatinine ratio (lnACR) (beta = 0.18, 95% CI 0.10-0.27, P < 0.001 and beta = 0.18, 95% CI 0.09-0.27, P < 0.001). Creatinine 174-184 C-reactive protein Homo sapiens 74-77 24335124-9 2013 Glucose uptake was positively correlated with the Acute Tubular Necrosis Individual Severity Score [ATNISS (r = 0.21, p = 0.0036)], C-reactive protein (r = 0.26, p = 0.0167), protein loss (r = 0.36, p < 0.0001), and sodium removal (r = 0.24, p = 0.002). Glucose 0-7 C-reactive protein Homo sapiens 132-150 23868086-11 2013 In a multivariate analysis, CRP and MMP-9 were associated with intima-media thickness, LTB4 and PGE2 with arterial stiffness, and lysozyme with hypertension. Dinoprostone 96-100 C-reactive protein Homo sapiens 28-31 23990339-3 2013 The aim of this study was thus to characterize the catabolism of tryptophan and tyrosine in acute ischemic stroke (AIS) patients, and its association with cytokines, C-reactive protein, and glucose. Tryptophan 65-75 C-reactive protein Homo sapiens 166-184 24142631-0 2013 The impact of high sensitivity C-reactive protein level on coronary artery spasm as assessed by intracoronary acetylcholine provocation test. Acetylcholine 110-123 C-reactive protein Homo sapiens 31-49 24142631-2 2013 The aim of this study is to evaluate the impact of elevated hs CRP on coronary artery spasm (CAS) as assessed by intracoronary acetylcholine (ACh) provocation test. Acetylcholine 127-140 C-reactive protein Homo sapiens 63-66 24142631-2 2013 The aim of this study is to evaluate the impact of elevated hs CRP on coronary artery spasm (CAS) as assessed by intracoronary acetylcholine (ACh) provocation test. Acetylcholine 142-145 C-reactive protein Homo sapiens 63-66 24142631-6 2013 During ACh test, the incidences of significant CAS, ischemic electrocardiography (EKG) change, multivessel, and diffuse CAS were higher in patients with higher hs CRP. Acetylcholine 7-10 C-reactive protein Homo sapiens 163-166 23757435-9 2013 CRP concentration was significantly and directly associated with change in systolic blood pressure (SBP) and waist circumference but inversely associated with HDL cholesterol. Cholesterol 163-174 C-reactive protein Homo sapiens 0-3 24168271-5 2013 Plasma leukotriene B4 also correlated with serum high-sensitivity C-reactive protein in dengue patients (febrile, r = 0.91, p < 0.001; defervescence, r = 0.87, p < 0.001; convalescence, r = 0.87, p < 0.001). Leukotrienes 7-18 C-reactive protein Homo sapiens 66-84 23871616-6 2013 Pre-treatment with the inhibitor, CRP-i2, resulted in a significant reduction in CRP induced superoxide anion, NFkappab activity and biomarkers of inflammation. Superoxides 93-109 C-reactive protein Homo sapiens 81-84 23778008-9 2013 PRINCIPAL CONCLUSIONS: Aspirin therapy may reduce cerebrovascular events in diabetic patients with higher CRP. Aspirin 23-30 C-reactive protein Homo sapiens 106-109 23972896-9 2013 Urinary 1-hydroxypyrene, the biomarker of the higher molecular weight pyrene, was positively associated with total WBC count, and to lesser extent with serum CRP. pyrene 17-23 C-reactive protein Homo sapiens 158-161 22577128-6 2013 Significant (p < 0.001) elevation of ceruloplasmin (Cp) and C-reactive protein was associated with marked decreases in superoxide dismutase (p < 0.01), catalase (p < 0.001), and glutathione (p < 0.05) and significant (p < 0.001) increases in malondialdehyde (MDA) and uric acid when compared with control. Malondialdehyde 257-272 C-reactive protein Homo sapiens 63-81 24378001-4 2013 RESULTS: After adjusting for sex, age, blood pressure, cigarette smoking, alcohol drinking and so on, data showed that both rs1800206 and rs9794 were associated with the changes along with the levels of CRP (P < 0.05). Alcohols 74-81 C-reactive protein Homo sapiens 203-206 23927858-9 2013 A significant positive association between vitamin D level and gait speed was found only in those with high CRP in stratified analyses. Vitamin D 43-52 C-reactive protein Homo sapiens 108-111 23927858-11 2013 CONCLUSION: These findings provide evidence of a potential joint effect of vitamin D and CRP on gait speed, suggesting that evaluation and correction of vitamin D levels may be especially important in individuals with high CRP levels. Vitamin D 153-162 C-reactive protein Homo sapiens 89-92 23778008-0 2013 Aspirin possibly reduces cerebrovascular events in type 2 diabetic patients with higher C-reactive protein level: subanalysis from the JPAD trial. Aspirin 0-7 C-reactive protein Homo sapiens 88-106 24290083-11 2013 Triglycerides were significantly (p<0.01) correlated with glucose, cholesterol, insulin, CRP, systolic, diastolic blood pressure, WC, BMI, age and components of MS. Glucose, cholesterol, insulin and total energy intake predicted TAG, to varying extents, in all participants (R(2)=45.1%), males (R(2)=40.3%), females (R(2)=56.0%), Africans (R(2)=35.0%), TSA (R(2)=31.5%) and mix (R(2)=51.0%). Triglycerides 0-13 C-reactive protein Homo sapiens 92-95 23926208-5 2013 A 1-mmol/L(39 mg/dL) higher level of nonfasting remnant cholesterol was associated observationally with a 37% (95% confidence interval, 35-39) higher C-reactive protein level and causally with a 28% (95% confidence interval, 10-48) higher level. Cholesterol 56-67 C-reactive protein Homo sapiens 150-168 23926208-6 2013 For LDL cholesterol, a 1-mmol/L (39-mg/dL) higher level was associated observationally with a 7% (95% confidence interval, 6-7) higher C-reactive protein level, but we found no causal association. Cholesterol 8-19 C-reactive protein Homo sapiens 135-153 24044608-6 2013 RESULTS: Observed results indicated that the CRP and SAA levels in HIV-positive subjects who are METH, cocaine and alcohol users were significantly higher when compared with either drugs of abuse or HIV-positive alone. Methamphetamine 97-101 C-reactive protein Homo sapiens 45-48 24044608-6 2013 RESULTS: Observed results indicated that the CRP and SAA levels in HIV-positive subjects who are METH, cocaine and alcohol users were significantly higher when compared with either drugs of abuse or HIV-positive alone. Alcohols 115-122 C-reactive protein Homo sapiens 45-48 24023762-5 2013 Furthermore homoarginine was also independently related to L-arginine, serum albumin and body mass index, and inversely related to proteinuria, C-reactive protein and age. Homoarginine 12-24 C-reactive protein Homo sapiens 144-162 23778008-10 2013 Aspirin therapy could be an additional strategy as primary prevention for diabetic patients with higher CRP. Aspirin 0-7 C-reactive protein Homo sapiens 104-107 25340139-5 2013 Also a significant positive correlation between serum CRP and serum iron (r=0.44, p=0.008) (adjusted for age too) was observed. Iron 68-72 C-reactive protein Homo sapiens 54-57 23894199-8 2013 CRP is able to compete with phospholipid-containing liposomes for the binding to histones. Phospholipids 28-40 C-reactive protein Homo sapiens 0-3 23894199-9 2013 This explains how CRP prevents histones from integrating into cell membranes, which would otherwise induce calcium influx as the major mechanism of cytotoxicity caused by extracellular histones. Calcium 107-114 C-reactive protein Homo sapiens 18-21 23046736-6 2013 RESULTS: Across decreasing thirds of testosterone distribution, patients were incrementally older and CRP levels rose significantly. Testosterone 37-49 C-reactive protein Homo sapiens 102-105 23793744-7 2013 A higher degree of systemic inflammation, reflected by the ESR and CRP level, was associated with a smaller proportion of patients consuming alcohol. Alcohols 141-148 C-reactive protein Homo sapiens 67-70 24325097-5 2013 The effects of N-acetyl cysteine (NAC) on UA-induced levels of ROS, mRNA and protein of CRP in HUVECs were also observed. Acetylcysteine 15-32 C-reactive protein Homo sapiens 88-91 24325097-5 2013 The effects of N-acetyl cysteine (NAC) on UA-induced levels of ROS, mRNA and protein of CRP in HUVECs were also observed. Acetylcysteine 34-37 C-reactive protein Homo sapiens 88-91 24325097-9 2013 NAC reduced UA-induced levels of ROS, mRNA and protein of CRP in HUVECs compared with those of 12 mg/dL UA induced group(P<0. Acetylcysteine 0-3 C-reactive protein Homo sapiens 58-61 22503569-8 2013 Significant multivariate independent predictors of decreased creatinine included higher baseline serum creatinine levels (adjusted OR per quartile increment, 2.5 [1.3 to 4.7], p=0.004) and lower C-reactive protein levels (adjusted OR per quartile increment 0.39 [0.19 to 0.82], p=0.013). Creatinine 61-71 C-reactive protein Homo sapiens 195-213 22831953-6 2013 Multiple linear regression models were used to predict CRP change based on other risk factor changes, controlling for age, race, alcohol intake, and hormone replacement therapy. Alcohols 129-136 C-reactive protein Homo sapiens 55-58 23948514-0 2013 Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm. Atorvastatin 86-98 C-reactive protein Homo sapiens 14-32 23948514-7 2013 After 6 months of atorvastatin therapy, the median LDL-C and CRP were reduced by 38.7% and 25.8%, respectively. Atorvastatin 18-30 C-reactive protein Homo sapiens 61-64 23983602-8 2013 Compared to SAO subgroup, the plasma levels of CRP was higher in LAA subgroup (p<0.05). sao 12-15 C-reactive protein Homo sapiens 47-50 23983602-11 2013 CONCLUSION: LAA had a stronger activation of inflammation than SAO in the pathogenesis, which was associated with the changes of CRP. sao 63-66 C-reactive protein Homo sapiens 129-132 21769500-6 2013 Participants with IGT tended to differ from adults in normal postprandial glucose categories in regard to high levels of triglycerides, apoA-I, and CRP. Glucose 74-81 C-reactive protein Homo sapiens 148-151 23950953-12 2013 Both L5-induced ROS and CRP production were attenuated by ROS inhibitor N-acetyl cysteine. Reactive Oxygen Species 58-61 C-reactive protein Homo sapiens 24-27 23950953-12 2013 Both L5-induced ROS and CRP production were attenuated by ROS inhibitor N-acetyl cysteine. Acetylcysteine 72-89 C-reactive protein Homo sapiens 24-27 24416568-13 2013 CONCLUSIONS: Results of our study showed that elevated levels of IL-6 and CRP in peripheral blood before surgery of RCC were correlated with worse OS and CSS. Osmium 147-149 C-reactive protein Homo sapiens 74-77 23644895-12 2013 The CRP levels in steroids groups were also lower than in control group on the third day. Steroids 18-26 C-reactive protein Homo sapiens 4-7 23302662-9 2013 Of the four extracted DP, a DP with high loading values of vegetables and vegetable oils, leading to high intakes of antioxidant micronutrients and essential fatty acids, was significantly and negatively associated with risk of elevated CRP (OR 0 88; 95% CI 0 78, 0 98). Fatty Acids, Essential 148-169 C-reactive protein Homo sapiens 237-240 23988170-16 2013 The most important predictors for duration of metformin treatment in PCOS women were testosterone, progesterone, FSH, CRP and presence of anovulation. Metformin 46-55 C-reactive protein Homo sapiens 118-121 23541381-1 2013 Light to moderate alcohol consumption and leisure time physical activity (LTPA) are independently associated with lower levels of high sensitivity C-reactive protein (CRP), a predictor of cardiometabolic risk. Alcohols 18-25 C-reactive protein Homo sapiens 147-165 23541381-1 2013 Light to moderate alcohol consumption and leisure time physical activity (LTPA) are independently associated with lower levels of high sensitivity C-reactive protein (CRP), a predictor of cardiometabolic risk. Alcohols 18-25 C-reactive protein Homo sapiens 167-170 23541381-10 2013 Similarly, depression interacted with alcohol consumption in predicting CRP in men but not women (F=5.03, p<.008) such that for men light to moderate alcohol consumption was associated with lower CRP but only among those with decreased depressive symptoms. Alcohols 38-45 C-reactive protein Homo sapiens 72-75 23541381-10 2013 Similarly, depression interacted with alcohol consumption in predicting CRP in men but not women (F=5.03, p<.008) such that for men light to moderate alcohol consumption was associated with lower CRP but only among those with decreased depressive symptoms. Alcohols 153-160 C-reactive protein Homo sapiens 72-75 23541381-10 2013 Similarly, depression interacted with alcohol consumption in predicting CRP in men but not women (F=5.03, p<.008) such that for men light to moderate alcohol consumption was associated with lower CRP but only among those with decreased depressive symptoms. Alcohols 153-160 C-reactive protein Homo sapiens 199-202 23381198-4 2013 We hypothesized that preoperative steroid administration, routinely used only in conventional CABG, may alleviate high postoperative PAF and CRP levels. Steroids 34-41 C-reactive protein Homo sapiens 141-144 23381198-11 2013 CONCLUSIONS: Preoperative steroid administration in OPCABG patients significantly suppresses CRP elevation and prevents postoperative PAF without increasing in-hospital mortality or infectious complications. Steroids 26-33 C-reactive protein Homo sapiens 93-96 23799341-11 2013 Vitamin D level was also independently associated with high-sensitivity C reactive protein (beta = -0.143, P = 0.047). Vitamin D 0-9 C-reactive protein Homo sapiens 72-90 23922673-8 2013 When patients were divided into three groups according to time-integrated lipid levels, as expected, patients with LDL cholesterol and/or triglyceride levels in the third tertile had persistently higher ESR and CRP levels. Cholesterol 119-130 C-reactive protein Homo sapiens 211-214 23922673-8 2013 When patients were divided into three groups according to time-integrated lipid levels, as expected, patients with LDL cholesterol and/or triglyceride levels in the third tertile had persistently higher ESR and CRP levels. Triglycerides 138-150 C-reactive protein Homo sapiens 211-214 23460074-8 2013 After multivariable adjustment, change in C-reactive protein, but not the Disease Activity Score in 28 joints, was associated with change in LDL cholesterol (P = 0.03) and total cholesterol (P = 0.01). Cholesterol 145-156 C-reactive protein Homo sapiens 42-60 24198887-2 2013 CRP& TNF-alpha, are acute phase proteins monitored as a marker of inflammatory status, which have been identified as a major risk factor for atherosclerotic complications. Adenosine Monophosphate 4-7 C-reactive protein Homo sapiens 0-3 24198887-3 2013 Elevated CRP & TNF-alpha level in periodontitis patients have been reported by several groups. Adenosine Monophosphate 14-17 C-reactive protein Homo sapiens 9-12 24198887-4 2013 The present study was performed to determine whether presence of periodontitis and periodontal therapy could influence the serum levels of CRP & TNF-alpha in cardiovascular disease patients. Adenosine Monophosphate 144-147 C-reactive protein Homo sapiens 139-142 23557696-9 2013 Positive correlations were detected between TG levels and CRP (r=0.697, p=0.001), DAS (r=0.610, p=0.001), MYOACT (r=0.661, p=0.001), MYTAX (r=0.511, p=0.008), and negative correlations with CMAS (r=-0.506, p=0.009) and MMT (r=-0.535, p=0.005). Triglycerides 44-46 C-reactive protein Homo sapiens 58-61 23324897-5 2013 Only atorvastatin showed a statistically significant increase in NO (15.19%, P<0.05), eNOS (20.58%, P<0.01), IIEF-5 score (53.1%, P<0.001) and Rigiscan rigidity parameters (P<0.01), in addition to a statistically significant decrease in CRP (57.9%, P<0.01). Atorvastatin 5-17 C-reactive protein Homo sapiens 249-252 24306158-3 2013 Persons with 3 or more abnormalities in BMI, blood pressure, serum lipid and glucose were found in 20.0% of those with hs-CRP >1.0 mg/l, while 4.3% in hs-CRP <= 1.0 mg/l. Glucose 77-84 C-reactive protein Homo sapiens 122-125 23826157-8 2013 Changes in plasma CRP were significantly associated with changes in BMI (P = 1.7E-7) and triglyceride (P = 0.005) levels. Triglycerides 89-101 C-reactive protein Homo sapiens 18-21 23669654-4 2013 After adjustment for age, sex, race/ethnicity, body mass index (weight (kg)/height (m)(2)), and medications for lowering blood pressure, glucose, and lipids, the prevalence of elevated CRP decreased significantly from 36.7% in 1999-2002 to 32.0% in 2007-2010, corresponding to a decrease in mean CRP level from 1.92 to 1.66 mg/L (both P < 0.001). Glucose 137-144 C-reactive protein Homo sapiens 185-188 23744403-8 2013 Higher hs-CRP levels were associated with significantly higher prevalence of overweight/obesity, body mass index (BMI) z-score and central adiposity indices (P values all <0.0001), and with higher blood pressure and lower HDL-cholesterol levels. Cholesterol 229-240 C-reactive protein Homo sapiens 10-13 22816656-11 2013 Urinary 8-epi-PGF2alpha positively correlated with CRP (r = 0 235, P < 0 001), whereas no correlation was found between ox-LDL and CRP. 8-epi-prostaglandin F2alpha 8-23 C-reactive protein Homo sapiens 51-54 22816656-12 2013 Multiple linear regression analyses of BMI and HOMA-IR showed that the association between urinary 8-epi-PGF2alpha and CRP levels remained significant (P < 0 001). 8-epi-prostaglandin F2alpha 99-114 C-reactive protein Homo sapiens 119-122 22816656-13 2013 CONCLUSIONS: Oxidative stress measured by increased concentration of urine 8-epi-PGF2alpha is strongly associated with CRP levels. 8-epi-prostaglandin F2alpha 75-90 C-reactive protein Homo sapiens 119-122 23456822-6 2013 In analyses adjusted for age, race/ethnicity, diabetes, menopause transition stage, body mass index, smoking, alcohol use, physical activity, medications, prior fracture, and study site, CRP was associated inversely with each composite strength index (0.035-0.041 SD decrement per doubling of CRP, all p < 0.001), but not associated with femoral neck or lumbar spine BMD. Alcohols 110-117 C-reactive protein Homo sapiens 187-190 23807650-11 2013 CONCLUSIONS: One-year treatment with a non-calcium-containing phosphate binder may hamper the progression of cardiac valve calcification and slow the decline of renal function, as well as reduce serum concentration of FGF-23 and CRP and urinary phosphorus excretion. Calcium 43-50 C-reactive protein Homo sapiens 229-232 23807650-11 2013 CONCLUSIONS: One-year treatment with a non-calcium-containing phosphate binder may hamper the progression of cardiac valve calcification and slow the decline of renal function, as well as reduce serum concentration of FGF-23 and CRP and urinary phosphorus excretion. Phosphates 62-71 C-reactive protein Homo sapiens 229-232 23791132-7 2013 In VTE patients atorvastatin decreased IL-6 (p=0.0003), IL-8 (p=0.003) and P-selectin (p<0.0001), but increased IL-10 (p=0.001), with no association with C-reactive protein or cholesterol-lowering effects. Atorvastatin 16-28 C-reactive protein Homo sapiens 157-175 23566929-10 2013 CONCLUSIONS: The hemoglobin A1c, glucose and CRP correlated well between DBS and venous methods (r(2)>0.80), but there was a poor correlation for total and HDL cholesterol (r(2)<0.34). dbs 73-76 C-reactive protein Homo sapiens 45-48 23460074-8 2013 After multivariable adjustment, change in C-reactive protein, but not the Disease Activity Score in 28 joints, was associated with change in LDL cholesterol (P = 0.03) and total cholesterol (P = 0.01). Cholesterol 178-189 C-reactive protein Homo sapiens 42-60 23918883-8 2013 The initial results showed an activation of both l-arginine influx and via system y (+ )L associated with reduced intraplatelet cGMP levels in periodontitis patients and increased systemic levels of CRP. Arginine 49-59 C-reactive protein Homo sapiens 199-202 24250693-10 2013 However, the higher serum CRP levels were only observed in those with the low serum HDL-cholesterol levels. Cholesterol 88-99 C-reactive protein Homo sapiens 26-29 23484918-6 2013 CONCLUSIONS: An elevated maternal serum CRP concentration in the context of IAI is an indicator that the development of amnionitis, an intense fetal and AF inflammatory response are likely in patients with PTL. parthenolide 206-209 C-reactive protein Homo sapiens 40-43 23445482-9 2013 In human aortic endothelial cells (HAECs) incubated with CRP, inhibitors CRPi-2, CRPi-3, and CRPi-6 significantly inhibited CRP-induced superoxide, cytokine release, and nuclear factor-kappaB (NFkappaB) activity. Superoxides 136-146 C-reactive protein Homo sapiens 57-60 23445482-9 2013 In human aortic endothelial cells (HAECs) incubated with CRP, inhibitors CRPi-2, CRPi-3, and CRPi-6 significantly inhibited CRP-induced superoxide, cytokine release, and nuclear factor-kappaB (NFkappaB) activity. Superoxides 136-146 C-reactive protein Homo sapiens 73-76 23495824-11 2013 CONCLUSIONS & INFERENCES: Alterations of small bowel motility during CD flares significantly correlate with the level of calprotectin and CRP indicating that they represent inflammatory activity. Cadmium 73-75 C-reactive protein Homo sapiens 142-145 23643286-8 2013 Patients with CRP >3 mg/l had more severe impairment of CFR (2.14 +- 0.33 vs. 3.16 +- 0.76; p = 0.001) and more ischemic electrocardiographic changes during adenosine administration than patients with lower CRP, and a negative correlation between CRP levels and CFR (r = -0.49, p = 0.02) was found in CSX patients. Adenosine 160-169 C-reactive protein Homo sapiens 14-17 24278066-6 2013 RESULTS: Serum levels of IL-6 and CRP were significantly higher in patients with CU compared to healthy controls (p < 0.001, p = 0.026 respectively). Copper 81-83 C-reactive protein Homo sapiens 34-37 23594583-0 2013 Saturated fatty acids intake in relation to C-reactive protein, adiponectin, and leptin: a population-based study. Fatty Acids 0-21 C-reactive protein Homo sapiens 44-62 23551080-12 2013 In conclusion, calcium signalling instigated by CRP in human PMN is FcgammaRIIa allele specific, as R/R131 responded to CRP, whereas R/H131 did not. Calcium 15-22 C-reactive protein Homo sapiens 48-51 23551080-12 2013 In conclusion, calcium signalling instigated by CRP in human PMN is FcgammaRIIa allele specific, as R/R131 responded to CRP, whereas R/H131 did not. Calcium 15-22 C-reactive protein Homo sapiens 120-123 23551080-13 2013 However, increased expression of FcgammaRIa (CD64), stimulated by IFN-gamma, can augment calcium signalling by CRP in low-responders. Calcium 89-96 C-reactive protein Homo sapiens 111-114 23616515-0 2013 Habitual dietary isoflavone intake is associated with decreased C-reactive protein concentrations among healthy premenopausal women. Isoflavones 17-27 C-reactive protein Homo sapiens 64-82 23616515-2 2013 We investigated whether habitual low isoflavone intake among premenopausal women was associated with serum C-reactive protein (CRP) concentration, a commonly used biomarker associated with prediction of cardiovascular disease risk in healthy women. Isoflavones 37-47 C-reactive protein Homo sapiens 107-125 23616515-2 2013 We investigated whether habitual low isoflavone intake among premenopausal women was associated with serum C-reactive protein (CRP) concentration, a commonly used biomarker associated with prediction of cardiovascular disease risk in healthy women. Isoflavones 37-47 C-reactive protein Homo sapiens 127-130 23616515-6 2013 Marginal structural models with inverse probability of exposure weights estimated the association between CRP and quartiles of isoflavone intake adjusted for age, race, BMI, cycle phase, total energy intake, total fiber, total whole grains, and phase-specific hormone concentrations including estradiol, progesterone, luteinizing hormone, and follicle-stimulating hormone. Isoflavones 127-137 C-reactive protein Homo sapiens 106-109 23616515-7 2013 Compared with the lowest quartile of total isoflavone intake, women in the highest quartile had, on average, 27% lower serum CRP concentrations (95% CI: -35, -21%). Isoflavones 43-53 C-reactive protein Homo sapiens 125-128 23616515-8 2013 Our results suggest that dietary isoflavone intakes at levels characteristic of the U.S. population are associated with decreased serum CRP concentrations, a factor associated with beneficial effects on inflammation, and subsequently may have the potential to improve health status among young women. Isoflavones 33-43 C-reactive protein Homo sapiens 136-139 23551080-0 2013 C-reactive protein triggers calcium signalling in human neutrophilic granulocytes via FcgammaRIIa in an allele-specific way. Calcium 28-35 C-reactive protein Homo sapiens 0-18 23551080-7 2013 C-reactive protein induced cytosolic calcium signals in PMNs from homozygote R/R131 donors, but not in PMNs from heterozygote R/H131 donors. Calcium 37-44 C-reactive protein Homo sapiens 0-18 23551080-8 2013 However, after the heterozygote PMNs had been incubated with IFN-gamma (100 U/ml) for 2 h, both the proportion of cells responding and the size of the CRP-induced calcium signals increased. Calcium 163-170 C-reactive protein Homo sapiens 151-154 23551080-10 2013 The calcium signal elicited by CRP was augmented by PMN adhesion to fibronectin, but almost totally abrogated by sphingosine kinase inhibitors. Calcium 4-11 C-reactive protein Homo sapiens 31-34 23507424-0 2013 Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein. Cholesterol 63-74 C-reactive protein Homo sapiens 111-129 23507424-7 2013 Atorvastatin alone or combined with ezetimibe reduced both LDL-cholesterol and CRP (P<0.002 vs. baseline; Wilcoxon); ezetimibe did not modify CRP. Atorvastatin 0-12 C-reactive protein Homo sapiens 59-82 23507424-7 2013 Atorvastatin alone or combined with ezetimibe reduced both LDL-cholesterol and CRP (P<0.002 vs. baseline; Wilcoxon); ezetimibe did not modify CRP. Atorvastatin 0-12 C-reactive protein Homo sapiens 79-82 23606228-6 2013 RESULTS: Comparisons of individuals in high and low CRP tertiles revealed that those with high CRP had significantly lower progesterone (luteal P = 0.03, mid luteal P = 0.007) but not estradiol (follicular P = 0.21, luteal P = 0.15) concentrations through the menstrual cycle. Progesterone 123-135 C-reactive protein Homo sapiens 52-55 23606228-6 2013 RESULTS: Comparisons of individuals in high and low CRP tertiles revealed that those with high CRP had significantly lower progesterone (luteal P = 0.03, mid luteal P = 0.007) but not estradiol (follicular P = 0.21, luteal P = 0.15) concentrations through the menstrual cycle. Progesterone 123-135 C-reactive protein Homo sapiens 95-98 23416122-5 2013 Children with Hp 2-2 phenotype showed significantly higher iron storage compared to those with Hp 1-1 and Hp 2-1 phenotypes when children with malaria parasites and high C-reactive protein (>9mg/L) were excluded from the analysis. Iron 59-63 C-reactive protein Homo sapiens 170-188 22995323-8 2013 In subjects receiving SB-656933 50mg, sputum neutrophils and elastase were reduced compared to baseline (probability of a true reduction, 0.889 and 0.882 respectively), and free DNA reduced compared to placebo (probability of a true reduction, 0.967), while blood levels of fibrinogen, CRP and CXCL8 were increased. SB 656933 22-31 C-reactive protein Homo sapiens 286-289 23606228-7 2013 However, when the age at menarche was included in the analysis, both age at menarche and urinary CRP were negatively associated with estradiol (R(2) = 0.44, P = 0.0007). Estradiol 133-142 C-reactive protein Homo sapiens 97-100 23659482-16 2013 HC use confounds the association between 25(OH)D and CRP. Hydrocortisone 0-2 C-reactive protein Homo sapiens 53-56 23681030-16 2013 Dexamethasone use significantly reduced postoperative levels of C-reactive protein (P = .01) and interleukin 6 and interleukin 1beta (P = .02), fatigue (P = .01), and overall pain during the first 24 postoperative hours (P = .04), as well as the total analgesic (ketorolac tromethamine) requirement (P = .04). Dexamethasone 0-13 C-reactive protein Homo sapiens 64-82 23837221-4 2013 C-reactive protein was correlated with fibrinogen, HbA1c, LDL-cholesterol, BMI, WC, WHR and C index. Cholesterol 62-73 C-reactive protein Homo sapiens 0-18 23782463-4 2013 Statins are cholesterol-lowering agents that have been found to be anti-inflammatory agents and are also known to decrease C-reactive protein (CRP). Cholesterol 12-23 C-reactive protein Homo sapiens 123-141 23782463-4 2013 Statins are cholesterol-lowering agents that have been found to be anti-inflammatory agents and are also known to decrease C-reactive protein (CRP). Cholesterol 12-23 C-reactive protein Homo sapiens 143-146 22970699-9 2013 Free testosterone concentrations were positively related to age and negatively to BMI, HOMA-IR and CRP concentrations. Testosterone 5-17 C-reactive protein Homo sapiens 87-102 23601885-0 2013 Disposable immunosensors for C-reactive protein based on carbon nanotubes field effect transistors. Carbon 57-63 C-reactive protein Homo sapiens 29-47 23601885-1 2013 Label-free immunosensors based on single-walled carbon nanotubes field effect transistor (NTFET) devices were developed for the detection of C-reactive protein (CRP) which is currently the best validated inflammatory biomarker associated with cardiovascular diseases. Carbon 48-54 C-reactive protein Homo sapiens 141-159 23601885-1 2013 Label-free immunosensors based on single-walled carbon nanotubes field effect transistor (NTFET) devices were developed for the detection of C-reactive protein (CRP) which is currently the best validated inflammatory biomarker associated with cardiovascular diseases. Carbon 48-54 C-reactive protein Homo sapiens 161-164 23601885-2 2013 The immunoreaction principle consists in the direct adsorption of CRP specific antibodies (anti-CRP) to single-walled carbon nanotubes (SWCNTs) networks. Carbon 118-124 C-reactive protein Homo sapiens 66-69 23601885-2 2013 The immunoreaction principle consists in the direct adsorption of CRP specific antibodies (anti-CRP) to single-walled carbon nanotubes (SWCNTs) networks. Carbon 118-124 C-reactive protein Homo sapiens 96-99 23339056-9 2013 In addition, steroids significantly reduced postoperative blood levels of bilirubin, and of inflammatory markers such as IL-6 and C-reactive protein. Steroids 13-21 C-reactive protein Homo sapiens 130-148 23940437-8 2013 Body mass index (P<0.001) and total cholesterol levels (P=0.005) were positively associated with CRP levels. Cholesterol 39-50 C-reactive protein Homo sapiens 100-103 23223343-4 2013 RESULTS: BMI, prevalence of central obesity, homeostatic model assessment index of insulin resistance, plasma triglycerides, fibrinogen, and CRP increased progressively across categories of glucose intolerance (P < 0.0001), with the IFG+IGT group having higher values than those with isolated IFG (0.05 < P < 0.0001). Glucose 190-197 C-reactive protein Homo sapiens 141-144 23279603-5 2013 Serum concentration of hs-CRP significantly decreased in both the Metformin (5.29 +- 2.50 vs 3.81 +- 1.99, P = 0.008) and diet groups (6.08 +- 2.14 vs 4.27 +- 1.60, P = 0.004). Metformin 66-75 C-reactive protein Homo sapiens 26-29 23448790-13 2013 C-reactive protein drop to normal after infliximab induction was predictive of steroid-free remission at 6 (HR, 5.9) and 12 months (HR, 4.6) and steroid-free remission and MH at 12 months (odds ratio, 6.0). Steroids 79-86 C-reactive protein Homo sapiens 0-18 23448790-13 2013 C-reactive protein drop to normal after infliximab induction was predictive of steroid-free remission at 6 (HR, 5.9) and 12 months (HR, 4.6) and steroid-free remission and MH at 12 months (odds ratio, 6.0). Steroids 145-152 C-reactive protein Homo sapiens 0-18 22528584-7 2013 Serum estradiol was inversely correlated with age and urea reduction rate and positively correlated with postdialysis body weight, BMI and hs-CRP levels. Estradiol 6-15 C-reactive protein Homo sapiens 142-145 23279603-0 2013 Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome. Metformin 10-19 C-reactive protein Homo sapiens 60-78 23279603-9 2013 CONCLUSIONS: Although weight reduction has equal efficacy with Metformin in decreasing serum hs-CRP levels, it was significantly more effective in improving insulin resistance in obese and overweight PCOS women. Metformin 63-72 C-reactive protein Homo sapiens 96-99 23279603-1 2013 AIM: The aim of the present study was to investigate the efficacy of Metformin compared with a hypocaloric diet on C-reactive protein (CRP) level and markers of insulin resistance in obese and overweight women with polycystic ovary syndrome (PCOS). Metformin 69-78 C-reactive protein Homo sapiens 115-133 23279603-1 2013 AIM: The aim of the present study was to investigate the efficacy of Metformin compared with a hypocaloric diet on C-reactive protein (CRP) level and markers of insulin resistance in obese and overweight women with polycystic ovary syndrome (PCOS). Metformin 69-78 C-reactive protein Homo sapiens 135-138 23040261-5 2013 Stepwise regression analysis showed significant associations (R(2)=.264) of circulating log(e)CRP with body mass index, fibrinogen, apoB, age, gender, smoking habits, physical inactivity, creatinine levels, and systolic blood pressure. Creatinine 188-198 C-reactive protein Homo sapiens 94-97 24319627-17 2013 CONCLUSIONS: The consumption of NS-5 mixture decreased significantly serum NO, CRP and gamma-GT levels, improved TAS and lipid profiles at risk cardiovascular and hold promise for delaying onset of age-associated diseases. 8-dehydroxythienamycin 32-36 C-reactive protein Homo sapiens 79-82 22946586-12 2013 Homeostasis model assessment and high-sensitivity C-reactive protein are useful to identify subjects with isolated post-load hyperglycaemia, with improved performance over fasting plasma glucose or HbA(1c) alone. Glucose 187-194 C-reactive protein Homo sapiens 50-68 23674518-4 2013 We also studied the effect of metformin therapy on the CRP-leptin correlation in patients with newly diagnosed diabetes. Metformin 30-39 C-reactive protein Homo sapiens 55-58 23674518-11 2013 This is the first report demonstrating the restorative role of metformin on the leptin-CRP correlation in patients with newly diagnosed diabetes. Metformin 63-72 C-reactive protein Homo sapiens 87-90 23104565-5 2013 There was a significant inverse correlation between zinc and C-reactive protein and significant positive correlation between copper and C-reactive protein. Copper 125-131 C-reactive protein Homo sapiens 136-154 23172977-5 2013 For 1 SD increase in SO(2) and oxides of nitrogen (NO(x)) concentrations in ambient air, a day before blood collection (lag(1)), we observed a significant increase in CRP (9.34 and 7.77%, respectively). Nitrogen 41-49 C-reactive protein Homo sapiens 167-170 23224322-4 2013 NO donor S-nitrosoglutathione antagonized CRP-mediated reduction of protein S-nitrosylation. S-Nitrosoglutathione 9-29 C-reactive protein Homo sapiens 42-45 23408783-10 2013 The levels of CRP and MCP-1 were reduced in patients in the RSG, BEZ and combination groups. Rosiglitazone 60-63 C-reactive protein Homo sapiens 14-17 23914632-7 2013 Pearson correlation analysis found a negative correlation between plasma sodium level and C-reactive protein, white blood cells and pulmonary artery pressure (r = -0.238, p<0.001; r = -0.222, p<0.001; r = -0.444, p<0.018 respectively). Sodium 73-79 C-reactive protein Homo sapiens 90-108 23372170-9 2013 Stepwise multivariate models demonstrated depot differential associations: fasting glucose with SC FCs (beta = 0.667, P < .001) and fasting insulin (beta = 0.413, P = .006) and total ATM count (beta = 0.310, P = .034) with Om FCs in models including age, body mass index, high-density lipoprotein cholesterol, and high-sensitivity C-reactive protein. Glucose 83-90 C-reactive protein Homo sapiens 334-352 23371041-11 2013 Our results suggest that, in patients with solid tumors and CT-induced anemia, high CRP levels at treatment initiation predict a poor response to treatment with ESA and iron, independently from anemia severity at therapy initiation and from other patient and disease characteristics. Iron 169-173 C-reactive protein Homo sapiens 84-87 23359066-3 2013 METHODS AND RESULTS: The primary objective of this study was to evaluate the effect on C-reactive protein (CRP) after a 16-week treatment period with either pioglitazone or metformin. Metformin 173-182 C-reactive protein Homo sapiens 87-105 23359066-3 2013 METHODS AND RESULTS: The primary objective of this study was to evaluate the effect on C-reactive protein (CRP) after a 16-week treatment period with either pioglitazone or metformin. Metformin 173-182 C-reactive protein Homo sapiens 107-110 23218801-0 2013 Effects of atorvastatin on human C-reactive protein metabolism. Atorvastatin 11-23 C-reactive protein Homo sapiens 33-51 23218801-2 2013 Our goal was to define the mechanisms by which CRP was reduced by maximal dose atorvastatin. Atorvastatin 79-91 C-reactive protein Homo sapiens 47-50 23218801-10 2013 CONCLUSION: Our data indicate that maximal doses of atorvastatin lower plasma CRP levels by substantially decreasing the median CRP plasma residence time from 2.94 days to 2.0 days, with no significant effect on the median CRP production rate. Atorvastatin 52-64 C-reactive protein Homo sapiens 78-81 23218801-10 2013 CONCLUSION: Our data indicate that maximal doses of atorvastatin lower plasma CRP levels by substantially decreasing the median CRP plasma residence time from 2.94 days to 2.0 days, with no significant effect on the median CRP production rate. Atorvastatin 52-64 C-reactive protein Homo sapiens 128-131 23218801-10 2013 CONCLUSION: Our data indicate that maximal doses of atorvastatin lower plasma CRP levels by substantially decreasing the median CRP plasma residence time from 2.94 days to 2.0 days, with no significant effect on the median CRP production rate. Atorvastatin 52-64 C-reactive protein Homo sapiens 128-131 23042290-8 2013 After SDS-PAGE and electrotransfer, we observe ~80% capture of protein band mass on the blotting region for a model protein, C-reactive protein. Sodium Dodecyl Sulfate 6-9 C-reactive protein Homo sapiens 125-143 22865000-8 2013 The higher CRP group was discriminated by the above variables in addition to lower VO(2max), serum metabolic syndrome components (triglycerides, glucose, and HDL cholesterol), higher insulin, homeostasis assessment of insulin resistance, uric acid, gamma-GT, and homocysteine. Triglycerides 130-143 C-reactive protein Homo sapiens 11-14 22865000-8 2013 The higher CRP group was discriminated by the above variables in addition to lower VO(2max), serum metabolic syndrome components (triglycerides, glucose, and HDL cholesterol), higher insulin, homeostasis assessment of insulin resistance, uric acid, gamma-GT, and homocysteine. Glucose 145-152 C-reactive protein Homo sapiens 11-14 22865000-8 2013 The higher CRP group was discriminated by the above variables in addition to lower VO(2max), serum metabolic syndrome components (triglycerides, glucose, and HDL cholesterol), higher insulin, homeostasis assessment of insulin resistance, uric acid, gamma-GT, and homocysteine. Cholesterol 162-173 C-reactive protein Homo sapiens 11-14 22777489-6 2013 RESULTS: Comparing the PA and N-PA group, the first presented lower: total body mass (-13%), body mass index (-16%), fat mass (kg -39%, FM% -30%), CRP (-23%), serum insulin (-61%), homeostasis model assessment (HOMA, -35%) and serum leptin (-62%; P<0.05). n-pa 30-34 C-reactive protein Homo sapiens 147-150 24021937-0 2013 Angiotensin II induces C-reactive protein expression via AT1-ROS-MAPK-NF-kappaB signal pathway in hepatocytes. Reactive Oxygen Species 61-64 C-reactive protein Homo sapiens 23-41 23143785-6 2013 Curcumin"s pleiotropic activities emanate from its ability to modulate numerous signaling molecules such as pro-inflammatory cytokines, apoptotic proteins, NF-kappaB, cyclooxygenase-2, 5-LOX, STAT3, C-reactive protein, prostaglandin E(2), prostate-specific antigen, adhesion molecules, phosphorylase kinase, transforming growth factor-beta, triglyceride, ET-1, creatinine, HO-1, AST, and ALT in human participants. Curcumin 0-8 C-reactive protein Homo sapiens 199-217 24021937-11 2013 N-acetylcysteine antagonized Ang II-induced CRP expression. Acetylcysteine 0-16 C-reactive protein Homo sapiens 44-47 24021937-15 2013 CONCLUSION: Ang II has ability to induce CRP expression in hepatocytes in vitro and in vivo through AT1 receptor followed by ROS, MAPK and NF-kappaB signal pathway. Reactive Oxygen Species 125-128 C-reactive protein Homo sapiens 41-44 24167354-3 2013 OBJECTIVE: To investigate the relationship between acute phase proteins (C-Reactive Protein, Orosomucoid, and Albumin) and serum fatty acids in morbidly obese patients. serum fatty acids 123-140 C-reactive protein Homo sapiens 73-91 23298135-5 2013 Resveratrol significantly reduced C-reactive protein (CRP) and triglyceride concentrations, and increased Total Antioxidant Status (TAS) values. Resveratrol 0-11 C-reactive protein Homo sapiens 34-52 23298135-5 2013 Resveratrol significantly reduced C-reactive protein (CRP) and triglyceride concentrations, and increased Total Antioxidant Status (TAS) values. Resveratrol 0-11 C-reactive protein Homo sapiens 54-57 23298135-6 2013 After analyzing data with general linear models to assess period and carry-over effects, the ratios of the values after resveratrol to those after placebo were respectively: 0.47 (95%CI 0.38-0.59) -CRP- and 0.71 (95%CI 0.65-0.78) -triglycerides-, while TAS increased by 74.2 mumol/L (95%CI 60.8-87.6). Resveratrol 120-131 C-reactive protein Homo sapiens 198-201 23378779-13 2013 Similarly, a fall in C-reactive protein and adenosine deaminase levels was greater in patients taking metformin with garlic than in patients taking only metformin. Metformin 102-111 C-reactive protein Homo sapiens 21-39 23378779-13 2013 Similarly, a fall in C-reactive protein and adenosine deaminase levels was greater in patients taking metformin with garlic than in patients taking only metformin. Metformin 153-162 C-reactive protein Homo sapiens 21-39 24167365-2 2013 This study aimed to test two hypotheses: (1) serum 25-hydroxyvitamin D [25(OH)D] is inversely associated with type 2 diabetes mellitus (T2DM) and elevated hemoglobin A1c; (2) these associations are mediated by serum C-reactive protein (CRP). 25(oh)d 72-79 C-reactive protein Homo sapiens 216-234 24167365-2 2013 This study aimed to test two hypotheses: (1) serum 25-hydroxyvitamin D [25(OH)D] is inversely associated with type 2 diabetes mellitus (T2DM) and elevated hemoglobin A1c; (2) these associations are mediated by serum C-reactive protein (CRP). 25(oh)d 72-79 C-reactive protein Homo sapiens 236-239 22829554-5 2013 Meta-analysis showed that: 1) steroid group had lower serum IL-6 level on POD 1 and POD 3 (p<0.05), and 2) steroid group had lower serum CRP level on POD 3 (p<0.05) with no significant difference on POD 1 and POD 7. Steroids 30-37 C-reactive protein Homo sapiens 140-143 22829554-5 2013 Meta-analysis showed that: 1) steroid group had lower serum IL-6 level on POD 1 and POD 3 (p<0.05), and 2) steroid group had lower serum CRP level on POD 3 (p<0.05) with no significant difference on POD 1 and POD 7. Steroids 110-117 C-reactive protein Homo sapiens 140-143 23604041-1 2013 AIM: We aimed to study the relationship of elevated C reactive protein (CRP) levels (1.0-2.9 or >=3.0 mg/L) with carotid intima-media thickness (IMT) in Chinese adults with normal low-density lipoprotein (LDL) cholesterol (<100 mg/dL). Cholesterol 213-224 C-reactive protein Homo sapiens 72-75 23115037-8 2013 We conclude that balanced input from many cAMP-CRP-responsive elements, including RpoS, is critical to the ability of UPEC to handle the nutrient limitations and severe environmental stresses present within the mammalian urinary tract. Cyclic AMP 42-46 C-reactive protein Homo sapiens 47-50 25702427-3 2013 RESULTS: Disorders of carbohydrate metabolism in MS patients are associated with the high levels of systemic inflammation markers (CRP, TNF-alpha, IL-6) and a two-fold rise in the PAI-1 level. Carbohydrates 22-34 C-reactive protein Homo sapiens 131-134 23727640-6 2013 In non-overweight men, BMI, high-density lipoprotein cholesterol, triacylglycerols, fasting blood glucose, aspartate aminotransferase, gamma-GTP, and smoking habit were positively associated with serum CRP levels. Triglycerides 66-82 C-reactive protein Homo sapiens 202-205 23727640-7 2013 In overweight men, BMI, diastolic blood pressure, triacylglycerols, and gamma-GTP were positively associated with serum CRP levels. Triglycerides 50-66 C-reactive protein Homo sapiens 120-123 23727640-8 2013 After adjustment for age, BMI, smoking status, and alcohol intake, dose-response relationships were observed between gamma-GTP and CRP levels in both overweight and non-overweight men. Alcohols 51-58 C-reactive protein Homo sapiens 131-134 23111890-0 2013 Estradiol inhibits vascular endothelial cells pro-inflammatory activation induced by C-reactive protein. Estradiol 0-9 C-reactive protein Homo sapiens 85-103 22841520-5 2013 RESULTS: Compared to placebo, metformin reduced monocyte release of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, monocyte chemoattractant protein-1 and interleukin-8, as well as decreased plasma C-reactive protein levels, which were accompanied by an improvement in insulin sensitivity. Metformin 30-39 C-reactive protein Homo sapiens 213-231 24399727-6 2013 RESULTS: Metformin treatment reduced plasma C-reactive protein levels and monocyte release of tumor necrosis factor-alpha and interleukin-6, as well as tended to reduce monocyte release of interleukin-1beta and monocyte chemoattractant protein-1, which was accompanied by an improvement in insulin sensitivity. Metformin 9-18 C-reactive protein Homo sapiens 44-62 22998065-5 2012 Additionally, as ROS generated in both peripheral blood and synovial infiltrate correlated positively with both DAS 28 and CRP/anti-CCP levels, its measurement can serve as an indirect measure of the degree of inflammation in patients with RA. Reactive Oxygen Species 17-20 C-reactive protein Homo sapiens 123-126 23134888-7 2012 A significant genotype x diet interaction (P = 0.009) was also observed for C-reactive protein (CRP), with only significant increases in concentrations after the HSF and HSF-DHA diets relative to the low-fat diet in the APOE3/E4 group (P < 0.015). dehydroacetic acid 174-177 C-reactive protein Homo sapiens 76-94 23107042-5 2012 Metformin, but not placebo, administered to simvastatin-treated IFG subjects reduced plasma levels of C-reactive protein, soluble intercellular adhesion molecule-1, as well as lymphocyte release of interleukin-2, interferon-gamma and tumor necrosis factor-alpha, which was accompanied by the improvement in insulin sensitivity and a reduction in free fatty acid levels. Metformin 0-9 C-reactive protein Homo sapiens 102-120 22564353-10 2012 Change in CIMT also had univariate associations with baseline LDL-C, triglycerides (TG), high-sensitive C-reactive protein, and systolic blood pressure and was directly associated with the change in TG and inversely associated with the change in high-sensitive C-reactive protein. Triglycerides 199-201 C-reactive protein Homo sapiens 104-122 23234408-5 2013 The switch from SAFA diet to PUFA diet produced a significant change of CRP (C-reactive protein) concentration (p<0.01) whereas similar trend of IL-18 did not reach statistical significance. Fatty Acids 16-20 C-reactive protein Homo sapiens 72-75 23234408-5 2013 The switch from SAFA diet to PUFA diet produced a significant change of CRP (C-reactive protein) concentration (p<0.01) whereas similar trend of IL-18 did not reach statistical significance. Fatty Acids 16-20 C-reactive protein Homo sapiens 77-95 23484049-10 2013 CONCLUSIONS: As the inflammatory responses in ALN patients are more severe than those in APN patients (higher CRP levels, longer duration of fever after antibiotic treatment), these findings suggest that the genetic variant in TLR-2 (rs3804100, T1350C) may protect the host from severe urinary tract infections as ALN. aln 46-49 C-reactive protein Homo sapiens 110-113 22968297-5 2012 RESULTS: Beyond atherogenic dyslipidemia, high-Trg/normal HDL-cholesterol category was associated with elevated CRP and diabetes risk in women. Cholesterol 62-73 C-reactive protein Homo sapiens 112-115 23046186-4 2012 We identified an optimal buffer for the elution of CRP, which contained 0.05 M sodium phosphate and 2.0 M NaCl (pH 4.5). Sodium Chloride 106-110 C-reactive protein Homo sapiens 51-54 23155348-4 2012 The patient received antibiotics and other supportive therapy, and the postoperative course was uneventful, however, elevated levels of serum IgG, IgG4 and C-reactive protein were noted, which normalized after the introduction of steroid therapy. Steroids 230-237 C-reactive protein Homo sapiens 156-174 22847386-8 2012 Serum sodium concentration was negatively correlated with WBC count (r = -0.156, P = 0.011) and CRP levels (r = -0.160, P= 0.028). Sodium 6-12 C-reactive protein Homo sapiens 96-99 22902499-7 2012 The FcgammaR-mediated HMC-1 cell response to CRP was the least sensitive to attenuation by ACh signaling. Acetylcholine 91-94 C-reactive protein Homo sapiens 45-48 23162475-4 2012 The present review focuses on distinct sources of CRP-mediated ROS generation as well as the pivotal role of ROS in CRP-induced tissue factor expression. Reactive Oxygen Species 63-66 C-reactive protein Homo sapiens 50-53 23162475-4 2012 The present review focuses on distinct sources of CRP-mediated ROS generation as well as the pivotal role of ROS in CRP-induced tissue factor expression. Reactive Oxygen Species 109-112 C-reactive protein Homo sapiens 116-119 23162475-6 2012 Collectively, the available data provide strong support for ROS playing an important intermediary role in the relationship between CRP and atherothrombosis. Reactive Oxygen Species 60-63 C-reactive protein Homo sapiens 131-134 23283045-8 2012 Moreover, there was a significant correlation between plasma glucose level and Hp (r = 0.577, p = 0.000), IL-6 (r = 0.448, p = 0.000), and hs-CRP (r = 0.380, p = 0.001). Glucose 61-68 C-reactive protein Homo sapiens 142-145 23046186-5 2012 Purified CRP was digested with trypsin and subjected to high-performance LC with an optimal mobile phase of acetonitrile-water containing 0.1% formic acid (50:50, v/v) and an optimal mobile phase flow rate of 0.2 mL/min. Water 121-126 C-reactive protein Homo sapiens 9-12 22520732-0 2012 Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin. Cisplatin 165-174 C-reactive protein Homo sapiens 10-28 22241543-6 2012 Estradiol was highly associated with TG (r = .783, P < .01) and HDL-C (r = .515, P < .01) but was negatively related with low-density lipoprotein cholesterol (LDL-C; P < .05), total cholesterol/HDL-C (P < .05), CRP (P < .01), and d-dimer (P < .01). Estradiol 0-9 C-reactive protein Homo sapiens 223-226 22909578-6 2012 CRP and urinary albumin levels were significantly higher in high-salt-intake group compared with medium- and low-salt-intake groups (P = 0.0003 and P = 0.001, respectively). Salts 65-69 C-reactive protein Homo sapiens 0-3 22909578-6 2012 CRP and urinary albumin levels were significantly higher in high-salt-intake group compared with medium- and low-salt-intake groups (P = 0.0003 and P = 0.001, respectively). Salts 113-117 C-reactive protein Homo sapiens 0-3 22909578-7 2012 CRP was positively correlated with 24-h urinary sodium excretion (r = 0.28, P = 0.0008) and albuminuria, whereas albuminuria was positively correlated with 24-h urinary sodium excretion (r = 0.21, P = 0.0002). Sodium 48-54 C-reactive protein Homo sapiens 0-3 22909578-8 2012 Multiple regression analysis revealed that urinary sodium excretion was an independent predictor of both CRP and albuminuria. Sodium 51-57 C-reactive protein Homo sapiens 105-108 22879630-12 2012 CONCLUSIONS: Twelve weeks of atorvastatin led to a significant reduction in oxidative stress as determined by MDA concentrations among patients with polycystic ovary syndrome that was independently predicted by changes in testosterone, 25OHD, and high-sensitivity C-reactive protein. Atorvastatin 29-41 C-reactive protein Homo sapiens 264-282 22885531-6 2012 RESULTS: In the control group, CRP levels were found to be increased on the first postoperative day (P < 0.001) and CRP levels were correlated with triglyceride levels on the day of operation (P = 0.009) and the first postoperative day (P = 0.021). Triglycerides 151-163 C-reactive protein Homo sapiens 119-122 22885531-8 2012 In the study group, CRP levels were found to be inversely correlated with serum high-density lipoprotein (HDL) (P = 0.049) on the first postoperative day and directly correlated with triglyceride levels on the second postoperative day (P = 0.017). Triglycerides 183-195 C-reactive protein Homo sapiens 20-23 22690830-8 2012 Peripheral neutrophils isolated from smokers showed greater expressions of myeloperoxidase and 5-lipoxygenase activities compared with non-smokers, while plasma leukotriene B(4) and 3-chlorotyrosine were correlated significantly with high-sensitivity C-reactive protein and plasma nicotine concentrations. 3-chlorotyrosine 182-198 C-reactive protein Homo sapiens 251-269 23236325-10 2012 In patients with a high density lipoprotein-cholesterol level <40 mg/dL, CRP levels were reduced only in the fenofibrate group (p=0.006). Cholesterol 44-55 C-reactive protein Homo sapiens 76-79 23236325-11 2012 CONCLUSION: Fenofibrate reduced CRP levels in hypertriglyceridemic patients with high CRP and/or low high density lipoprotein-cholesterol levels and without severe overweight. Cholesterol 126-137 C-reactive protein Homo sapiens 32-35 23175323-0 2012 Is there an effect of folic acid supplementation on the coagulation factors and C-reactive protein concentrations in subjects with atherosclerosis risk factors? Folic Acid 22-32 C-reactive protein Homo sapiens 80-98 23156066-7 2012 Furthermore, in the 7 patients observed during CU exacerbation and during remission, CRP levels decreased significantly during remission (median concentration dropped from 4.1 microg/ml to 0.7 microg/ml, p = 0.015). Copper 47-49 C-reactive protein Homo sapiens 85-88 23149874-0 2012 Nicotine induces the expression of C-reactive protein via MAPK-dependent signal pathway in U937 macrophages. Nicotine 0-8 C-reactive protein Homo sapiens 35-53 23149874-5 2012 The present study was to observe effect of nicotine on CRP production and the related signal pathway in U937 macrophages. Nicotine 43-51 C-reactive protein Homo sapiens 55-58 23149874-6 2012 The results showed that nicotine significantly increased mRNA and protein expression of CRP in U937 macrophages in time- and concentration-dependent ways. Nicotine 24-32 C-reactive protein Homo sapiens 88-91 23149874-9 2012 These demonstrate that nicotine has ability to induce CRP expression in macrophages through nAChR-ERK1/2/p38 MAPK-NF-kappaB signal pathway, which contributes to better understanding of the pro-inflammatory and pro-atherosclerotic effects of nicotine in cigarette smokers. Nicotine 23-31 C-reactive protein Homo sapiens 54-57 23149874-9 2012 These demonstrate that nicotine has ability to induce CRP expression in macrophages through nAChR-ERK1/2/p38 MAPK-NF-kappaB signal pathway, which contributes to better understanding of the pro-inflammatory and pro-atherosclerotic effects of nicotine in cigarette smokers. Nicotine 241-249 C-reactive protein Homo sapiens 54-57 23677182-0 2012 [Effect of metformin on the expression of tumor necrosis factor-alpha, Toll like receptors 2/4 and C reactive protein in obese type-2 diabetic patients]. Metformin 11-20 C-reactive protein Homo sapiens 99-117 23114023-1 2012 UNLABELLED: RATIONALE: C-reactive protein (CRP) and lysophosphatidylcholine (LPC) are phosphorylcholine-(PC)-containing oxidized phospholipids (oxPLs) found in oxidized LDL (oxLDL), which trigger pro-atherogenic activities of macrophages during the process of atherosclerosis. Phospholipids 130-143 C-reactive protein Homo sapiens 24-42 23114023-1 2012 UNLABELLED: RATIONALE: C-reactive protein (CRP) and lysophosphatidylcholine (LPC) are phosphorylcholine-(PC)-containing oxidized phospholipids (oxPLs) found in oxidized LDL (oxLDL), which trigger pro-atherogenic activities of macrophages during the process of atherosclerosis. Phospholipids 130-143 C-reactive protein Homo sapiens 44-47 23114023-2 2012 It has been previously reported that CRP binds to the PC head group of oxLDL in a calcium-dependent manner. Calcium 82-89 C-reactive protein Homo sapiens 37-40 23114023-4 2012 OBJECTIVES AND FINDINGS: A chemiluminescent immunoassay and HPLC showed that human recombinant CRP formed a stable complex with LPC in the presence of calcium. Calcium 151-158 C-reactive protein Homo sapiens 95-98 23114023-6 2012 The CRP-LPC complex triggered less potent generation of reactive oxygen species and less activation of the transcription factors AP-1 and NF-kB by human monocyte-derived macrophages in comparison to CRP or LPC alone. Reactive Oxygen Species 56-79 C-reactive protein Homo sapiens 4-7 22998881-5 2012 In the cross-sectional study, infused iron, hepcidin, and C-reactive protein values correlated with hepatic iron stores in both univariate analysis (P<.05, Spearman test) and binary logistic regression (P <.05). Iron 108-112 C-reactive protein Homo sapiens 58-76 22745302-11 2012 The C-reactive protein level on POD 2 was lower in the steroid group (P < 0.005). Steroids 55-62 C-reactive protein Homo sapiens 4-22 22710793-5 2012 Elevated CRP was defined by high-sensitivity C-reactive protein (hsCRP) levels between 3.0 and 10.0 mg/L and new diagnosis of IFG by the presence of fasting plasma glucose levels of 100 to 126 mg/dL. Glucose 164-171 C-reactive protein Homo sapiens 9-12 22659808-0 2012 Rosiglitazone inhibits angiotensin II-induced C-reactive protein production in human aortic endothelial cells through regulating AT(1)-ROS-MAPK signal pathway. Rosiglitazone 0-13 C-reactive protein Homo sapiens 46-64 23013352-7 2012 RESULTS: Curcumin, but not placebo, produced the following statistically significant changes: lowering of plasma triglyceride values, lowering of salivary amylase levels, raising of salivary radical scavenging capacities, raising of plasma catalase activities, lowering of plasma beta amyloid protein concentrations, lowering of plasma sICAM readings, increased plasma myeloperoxidase without increased c-reactive protein levels, increased plasma nitric oxide, and decreased plasma alanine amino transferase activities. Curcumin 9-17 C-reactive protein Homo sapiens 403-421 22556030-10 2012 Total lung capacity <80% predicted, MRSS, and serum creatinine were predictors of elevated CRP levels in SSc (odds ratio [OR] 2.76 [95% confidence interval (95% CI) 1.73-4.40], P = 0.0001; OR 1.03 [95% CI 1.01-1.05], P = 0.005; and OR 1.005 [95% CI 1.001-1.010], P = 0.02, respectively). Creatinine 55-65 C-reactive protein Homo sapiens 94-97 22659808-4 2012 The present study observed the effect of rosiglitazone on Ang II-induced CRP expression in HAECs and molecular mechanisms. Rosiglitazone 41-54 C-reactive protein Homo sapiens 73-76 22967596-0 2012 Thiolated DAB dendrimer/ZnSe nanoparticles for C-reactive protein recognition in human serum. diazobenzenesulfonic acid 10-13 C-reactive protein Homo sapiens 47-65 22967596-1 2012 A nanocomposite obtained by a thiol DAB-dendrimer (generation 5), coated with fluorescent ZnSe quantum dots, was successfully synthesized for the selective recognition of C-reactive protein. Sulfhydryl Compounds 30-35 C-reactive protein Homo sapiens 171-189 22967596-9 2012 This water soluble fluorescent nanocomposite showed a set of favorable properties to be used as a sensor for the C-reactive protein in serum samples, at concentrations of risk levels. Water 5-10 C-reactive protein Homo sapiens 113-131 22614460-2 2012 We evaluated the effect of four SNPs in the CRP gene on serum levels of protein and body mass index (BMI) in 150 unrelated Mexican subjects from 18 to 25 years old, without hypertension, non-overweight, and without inflammatory diseases, non-smoking and non-consumers of alcohol. Alcohols 271-278 C-reactive protein Homo sapiens 44-47 22617505-10 2012 CRP positively correlated with the doses of the epinephrine and norepinephrine and the monocyte counts, and negatively correlated with the lymphocyte count. Norepinephrine 64-78 C-reactive protein Homo sapiens 0-3 22329434-9 2012 CRP significantly increased the inward L-type calcium current in atrial myocytes with no changes in other ionic currents. Calcium 46-53 C-reactive protein Homo sapiens 0-3 22329434-12 2012 The mechanism of this may be via augmention of calcium influx by CRP in atrial myocytes, but not because of atrial fibrosis. Calcium 47-54 C-reactive protein Homo sapiens 65-68 22659808-11 2012 CONCLUSIONS: Rosiglitazone at the concentrations used in the present experiment is able to inhibit Ang II-induced CRP generation in HAECs by regulating AT(1)-ROS-MAPK signal pathway. Rosiglitazone 13-26 C-reactive protein Homo sapiens 114-117 22328310-0 2012 C-reactive protein, waist circumference, and family history of heart attack are independent predictors of body iron stores in apparently healthy premenopausal women. Iron 111-115 C-reactive protein Homo sapiens 0-18 21833742-10 2012 Both glucose and HbA1c were positively associated with circulating levels of CRP. Glucose 5-12 C-reactive protein Homo sapiens 77-80 22354676-0 2012 Associations between serum C-reactive protein and serum zinc, ferritin, and copper in Guatemalan school children. Copper 76-82 C-reactive protein Homo sapiens 27-45 22354676-8 2012 Regardless of CRP cutoffs, high (> cutoff) vs. low (<= cutoff) CRP levels had higher ferritin and copper concentrations and lower prevalence of copper deficiency of <90 mug/dL (P < 0.05). Copper 150-156 C-reactive protein Homo sapiens 69-72 22354676-11 2012 In conclusion, CRP was positively associated with ferritin and copper but not with zinc concentrations. Copper 63-69 C-reactive protein Homo sapiens 15-18 22354676-7 2012 CRP concentration was positively associated with ferritin and copper concentrations (r = 0.23 and 0.29, respectively; P < 0.0001) but not with zinc and other biomarkers (P > 0.05). Copper 62-68 C-reactive protein Homo sapiens 0-3 22354676-13 2012 High-sensitive CRP methods and the use of very low CRP cutoffs may be more accurate than traditional CRP methods in the adjustment of serum copper concentrations for inflammation in healthy school children. Copper 140-146 C-reactive protein Homo sapiens 51-54 22354676-13 2012 High-sensitive CRP methods and the use of very low CRP cutoffs may be more accurate than traditional CRP methods in the adjustment of serum copper concentrations for inflammation in healthy school children. Copper 140-146 C-reactive protein Homo sapiens 51-54 22354676-8 2012 Regardless of CRP cutoffs, high (> cutoff) vs. low (<= cutoff) CRP levels had higher ferritin and copper concentrations and lower prevalence of copper deficiency of <90 mug/dL (P < 0.05). Copper 104-110 C-reactive protein Homo sapiens 69-72 22012468-13 2012 CLINICAL RELEVANCE: periodontitis may impair blood glucose control through exerting an inflammatory and infectious burden evidenced by increased levels of CRP. Glucose 51-58 C-reactive protein Homo sapiens 155-158 22593589-8 2012 In both genders, dietary fiber intake was negatively associated with visceral adipose tissue, plasma C-reactive protein, and plasma fibrinogen and positively associated with plasma adiponectin (all P < 0.05). Dietary Fiber 25-30 C-reactive protein Homo sapiens 101-142 22704299-0 2012 Findings of a relation between vitamin D and C-reactive protein: concerns about methods used and conclusions drawn. Vitamin D 31-40 C-reactive protein Homo sapiens 45-63 22481014-12 2012 Postoperative C-reactive protein, malondialdehyde, and N-terminal pro-B-type natriuretic peptide levels were also lower in the curcuminoid than in the placebo group. curcuminoid 127-138 C-reactive protein Homo sapiens 14-32 22824238-11 2012 Alcohol consumption was associated with lower CRP (P = 0.05) and ESR (P = 0.003) but did not influence IR or Ig levels. Alcohols 0-7 C-reactive protein Homo sapiens 46-49 22525206-11 2012 CONCLUSIONS: Metformin has no effect on blood pressure and blood glucose levels, but it does reduce total cholesterol, abdominal obesity and C-reactive protein levels in obese hypertensive patients without diabetes. Metformin 13-22 C-reactive protein Homo sapiens 141-159 22891522-6 2012 C-reactive protein level had a significant association with body mass index (r = 0.18), adiposity (r = 0.23), smoking (r = 0.20), carbohydrate intake (r = 0.19) and saturated fatty acid (r = 0.20). Carbohydrates 130-142 C-reactive protein Homo sapiens 0-18 22891522-6 2012 C-reactive protein level had a significant association with body mass index (r = 0.18), adiposity (r = 0.23), smoking (r = 0.20), carbohydrate intake (r = 0.19) and saturated fatty acid (r = 0.20). Fatty Acids 165-185 C-reactive protein Homo sapiens 0-18 22713099-1 2012 BACKGROUND: We are hereby investigating for the first time the effect of the association ethinylestradiol30mug-drospirenone 3mg (DRP/EE30mug) plus metformin and weight loss on endothelial status and C-reactive protein (hsCRP) levels in polycystic ovary syndrome (PCOS). Metformin 147-156 C-reactive protein Homo sapiens 199-217 22754038-8 2012 Oxygen desaturation index, hypoxia time, and minimum oxygen saturation (SaO2) significantly correlated with IL-6 and CRP levels, but apnea-hypopnea index did not. Oxygen 0-6 C-reactive protein Homo sapiens 117-120 22555281-3 2012 With Gly-Pro-Cys triplets appended to both of its termini, designated CRP(cys), chemical cross-linking using heterobifunctional reagents generates CRP(cys)-XL, a potent, widely used, polymeric agonist for platelet Glycoprotein VI, whereas non-cross-linked, monomeric CRP(cys) antagonizes Glycoprotein VI. Cysteine 74-77 C-reactive protein Homo sapiens 70-73 22555281-3 2012 With Gly-Pro-Cys triplets appended to both of its termini, designated CRP(cys), chemical cross-linking using heterobifunctional reagents generates CRP(cys)-XL, a potent, widely used, polymeric agonist for platelet Glycoprotein VI, whereas non-cross-linked, monomeric CRP(cys) antagonizes Glycoprotein VI. Cysteine 74-77 C-reactive protein Homo sapiens 147-150 22555281-3 2012 With Gly-Pro-Cys triplets appended to both of its termini, designated CRP(cys), chemical cross-linking using heterobifunctional reagents generates CRP(cys)-XL, a potent, widely used, polymeric agonist for platelet Glycoprotein VI, whereas non-cross-linked, monomeric CRP(cys) antagonizes Glycoprotein VI. Cysteine 74-77 C-reactive protein Homo sapiens 147-150 22555281-3 2012 With Gly-Pro-Cys triplets appended to both of its termini, designated CRP(cys), chemical cross-linking using heterobifunctional reagents generates CRP(cys)-XL, a potent, widely used, polymeric agonist for platelet Glycoprotein VI, whereas non-cross-linked, monomeric CRP(cys) antagonizes Glycoprotein VI. Cysteine 151-154 C-reactive protein Homo sapiens 70-73 22555281-3 2012 With Gly-Pro-Cys triplets appended to both of its termini, designated CRP(cys), chemical cross-linking using heterobifunctional reagents generates CRP(cys)-XL, a potent, widely used, polymeric agonist for platelet Glycoprotein VI, whereas non-cross-linked, monomeric CRP(cys) antagonizes Glycoprotein VI. Cysteine 151-154 C-reactive protein Homo sapiens 147-150 22555281-3 2012 With Gly-Pro-Cys triplets appended to both of its termini, designated CRP(cys), chemical cross-linking using heterobifunctional reagents generates CRP(cys)-XL, a potent, widely used, polymeric agonist for platelet Glycoprotein VI, whereas non-cross-linked, monomeric CRP(cys) antagonizes Glycoprotein VI. Cysteine 151-154 C-reactive protein Homo sapiens 147-150 22555281-3 2012 With Gly-Pro-Cys triplets appended to both of its termini, designated CRP(cys), chemical cross-linking using heterobifunctional reagents generates CRP(cys)-XL, a potent, widely used, polymeric agonist for platelet Glycoprotein VI, whereas non-cross-linked, monomeric CRP(cys) antagonizes Glycoprotein VI. Cysteine 151-154 C-reactive protein Homo sapiens 70-73 22555281-3 2012 With Gly-Pro-Cys triplets appended to both of its termini, designated CRP(cys), chemical cross-linking using heterobifunctional reagents generates CRP(cys)-XL, a potent, widely used, polymeric agonist for platelet Glycoprotein VI, whereas non-cross-linked, monomeric CRP(cys) antagonizes Glycoprotein VI. Cysteine 151-154 C-reactive protein Homo sapiens 147-150 22555281-3 2012 With Gly-Pro-Cys triplets appended to both of its termini, designated CRP(cys), chemical cross-linking using heterobifunctional reagents generates CRP(cys)-XL, a potent, widely used, polymeric agonist for platelet Glycoprotein VI, whereas non-cross-linked, monomeric CRP(cys) antagonizes Glycoprotein VI. Cysteine 151-154 C-reactive protein Homo sapiens 147-150 22528165-2 2012 In this trial, we evaluated the perioperative effects on C-reactive protein (CRP) that resulted from starting atorvastatin within seven days of noncardiac surgery. Atorvastatin 110-122 C-reactive protein Homo sapiens 57-75 22528165-2 2012 In this trial, we evaluated the perioperative effects on C-reactive protein (CRP) that resulted from starting atorvastatin within seven days of noncardiac surgery. Atorvastatin 110-122 C-reactive protein Homo sapiens 77-80 22185752-7 2012 For most functional variables, calibrated cIB in the basal septum was the strongest determinant of impaired LV performance, independent of higher procollagen levels, LV mass index, age, body mass index, creatinine level, and C-reactive protein. cib 42-45 C-reactive protein Homo sapiens 225-243 24187901-3 2012 To our knowledge, no reports are available indicating the effects of consumed calcium supplement plus aspirin on high sensitivity C-reactive protein (hs-CRP), oxidative stress parameters and insulin resistance in pregnant women at risk for pre-eclampsia. Calcium 78-85 C-reactive protein Homo sapiens 130-148 21610204-0 2012 Low-density lipoprotein cholesterol and high-sensitivity C-reactive protein lowering with atorvastatin in patients of South Asian compared with European origin: insights from the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. Atorvastatin 90-102 C-reactive protein Homo sapiens 57-75 21610204-6 2012 However, after propensity matching, atorvastatin lowered LDL-C and high-sensitivity C-reactive protein (hs-CRP) to a similar degree in both groups, with no differences in safety profile. Atorvastatin 36-48 C-reactive protein Homo sapiens 84-102 22157880-10 2012 However, exercise-related improvements in HbA1c, fasting glucose, and fat mass were associated with reductions in CRP. Glucose 57-64 C-reactive protein Homo sapiens 114-117 22657586-10 2012 There was a significant negative correlation between lipophilic serum vitamin concentrations and body fat, as well as between iron and C-reactive protein. Iron 126-130 C-reactive protein Homo sapiens 135-153 21688163-8 2012 The MQ group also reported significantly improved QOL (MD = 12.66, t (45) = -5.715, p < 0.001) and had reduced CRP levels (MD = -0.72, t (45) = 2.092, p = 0.042) compared to controls. memoquin 4-6 C-reactive protein Homo sapiens 114-117 22365749-4 2012 Here, we exploited this property using C-reactive protein (CRP) specific RNA aptamers as probes that were immobilized by physical adsorption on carbon nanotubes (CNTs) activated gold interdigitated electrodes of capacitors. Carbon 144-150 C-reactive protein Homo sapiens 39-57 22661996-11 2012 RESULTS: Positive correlation between ESR, CRP and ROS in the preoperative period was confirmed. Reactive Oxygen Species 51-54 C-reactive protein Homo sapiens 43-46 22336660-11 2012 CONCLUSION: The levels of pre-PCI CRP were strongly associated with ISR, whereas diabetes, serum levels of TC, LDL-C, and non-HDL-C were significantly correlated with coronary lesion progression. Carbon 0-1 C-reactive protein Homo sapiens 34-37 22533665-8 2012 Both high-CRP and high-leptin were associated with high blood glucose, waist circumference and serum triglyceride. Triglycerides 101-113 C-reactive protein Homo sapiens 10-13 22417160-3 2012 We designed a graphene-based CRET platform for homogeneous immunoassay of C-reactive protein (CRP), a key marker for human inflammation and cardiovascular diseases, using a luminol/hydrogen peroxide chemiluminescence (CL) reaction catalyzed by horseradish peroxidase. Luminol 173-180 C-reactive protein Homo sapiens 94-97 22417160-3 2012 We designed a graphene-based CRET platform for homogeneous immunoassay of C-reactive protein (CRP), a key marker for human inflammation and cardiovascular diseases, using a luminol/hydrogen peroxide chemiluminescence (CL) reaction catalyzed by horseradish peroxidase. Hydrogen Peroxide 181-198 C-reactive protein Homo sapiens 94-97 22365749-4 2012 Here, we exploited this property using C-reactive protein (CRP) specific RNA aptamers as probes that were immobilized by physical adsorption on carbon nanotubes (CNTs) activated gold interdigitated electrodes of capacitors. Carbon 144-150 C-reactive protein Homo sapiens 59-62 22348897-13 2012 Iron reduced the number of hospitalizations and C-reactive protein levels, and increased the 6MWD and mean ejection fraction. Iron 0-4 C-reactive protein Homo sapiens 48-66 22093677-4 2012 Multivariate regression analysis showed that high-sensitivity C-reactive protein, plasma epinephrine, triglycerides and lean body mass index were independent predictors of glucose disposal. Glucose 172-179 C-reactive protein Homo sapiens 62-80 21849239-1 2012 AIM: To examine the effects of ibuprofen used for patent ductus arteriosus (PDA) treatment on the production of the proinflammatory cytokines C-reactive protein (CRP) and interleukin 6 (IL-6) in preterm septic newborns. Ibuprofen 31-40 C-reactive protein Homo sapiens 142-160 21849239-1 2012 AIM: To examine the effects of ibuprofen used for patent ductus arteriosus (PDA) treatment on the production of the proinflammatory cytokines C-reactive protein (CRP) and interleukin 6 (IL-6) in preterm septic newborns. Ibuprofen 31-40 C-reactive protein Homo sapiens 162-165 21849239-7 2012 CONCLUSIONS: IL-6 and CRP may decrease in infants receiving ibuprofen treatment more than infants who do not receive it. Ibuprofen 60-69 C-reactive protein Homo sapiens 22-25 21769439-8 2012 CRP level was significantly higher in subjects with T2D than those without (p = 0.023), and this result persisted even after adjustment for age, gender, BMI, smoking, and alcohol consumption. Alcohols 171-178 C-reactive protein Homo sapiens 0-3 21970575-0 2012 High sensitivity C-reactive protein and its relationship with impaired glucose regulation in lean patients with polycystic ovary syndrome. Glucose 71-78 C-reactive protein Homo sapiens 17-35 22628929-17 2012 CONCLUSIONS: It was found that serum concentrations of hs-CRP significantly increased in asthmatic patients, and in the steroid-native group it partly correlated with FEV(1) and numbers of sputum eosinophils. Steroids 120-127 C-reactive protein Homo sapiens 58-61 21779799-1 2012 Lac operon transcription activation through CRP dimer depends on cAMP second messenger. Cyclic AMP 65-69 C-reactive protein Homo sapiens 44-47 21779799-3 2012 Cyclic AMP ligand binding brings CRP dimer to an active state via conformational changes. Cyclic AMP 0-10 C-reactive protein Homo sapiens 33-36 21779799-7 2012 CRP monomer exchange accelerates in the presence of non specific DNA whereas the exchange is inhibited in the presence of specific DNA and cAMP ligand. Cyclic AMP 139-143 C-reactive protein Homo sapiens 0-3 21779799-9 2012 Cyclic AMP forms a single molecule from two monomers and addition of specific DNA further stabilizes CRP dimer and decreases monomer exchange. Cyclic AMP 0-10 C-reactive protein Homo sapiens 101-104 21779799-10 2012 On the other hand, addition of non specific DNA increases CRP monomer exchange and may explain the mechanism of CRP monomer removal and dissociation of CRP dimer:cAMP:DNA complex. Cyclic AMP 162-166 C-reactive protein Homo sapiens 58-61 21779799-10 2012 On the other hand, addition of non specific DNA increases CRP monomer exchange and may explain the mechanism of CRP monomer removal and dissociation of CRP dimer:cAMP:DNA complex. Cyclic AMP 162-166 C-reactive protein Homo sapiens 112-115 21779799-10 2012 On the other hand, addition of non specific DNA increases CRP monomer exchange and may explain the mechanism of CRP monomer removal and dissociation of CRP dimer:cAMP:DNA complex. Cyclic AMP 162-166 C-reactive protein Homo sapiens 112-115 21737151-3 2012 The total anti-oxidation capacity and SOD activity were decreased while the serum H(2)O(2) level and XO activity were elevated in groups with higher CRP or IL-6 level. Hydrogen Peroxide 82-90 C-reactive protein Homo sapiens 149-152 21738237-0 2012 C-reactive protein modifies the association of plasma leptin with coronary calcium in asymptomatic overweight individuals. Calcium 75-82 C-reactive protein Homo sapiens 0-18 22306563-7 2012 A 10-fold increase in estradiol was associated with a 24.3% decrease in CRP (95% confidence interval: 19.3, 29.0). Estradiol 22-31 C-reactive protein Homo sapiens 72-75 22497530-5 2012 In this study, we explore the possible association between CRP and key factors pertaining to the vitamin D axis--in particular, VDR gene polymorphisms--in cancer patients with cachexia. Vitamin D 97-106 C-reactive protein Homo sapiens 59-62 22413940-7 2012 CONCLUSIONS: These results suggest that, in class II and III obese patients with an isolated low HDL-c phenotype, unacylated ghrelin is positively associated with HDL-c level independently of insulin resistance and CRP levels, and may contribute to the highly prevalent low HDL-c level seen in obesity. Ghrelin 125-132 C-reactive protein Homo sapiens 215-218 23449275-7 2012 C-reactive protein showed positive correlations with phosphatidylcholine, phosphatidylserine, phosphatidylinositol and total phospholipids in membranes from control subjects. Phosphatidylserines 74-92 C-reactive protein Homo sapiens 0-18 23449275-7 2012 C-reactive protein showed positive correlations with phosphatidylcholine, phosphatidylserine, phosphatidylinositol and total phospholipids in membranes from control subjects. Phospholipids 125-138 C-reactive protein Homo sapiens 0-18 23449275-9 2012 Furthermore, the changed relationship between membrane phospholipids and C-reactive protein, which has been shown to correlate with infectious episodes and clinical relapse, could be an indication of immune cell dysfunction in patients with multiple sclerosis. Phospholipids 55-68 C-reactive protein Homo sapiens 73-91 22241816-9 2012 CONCLUSIONS: CRP gene -717AG or GG genotypes is associated with cardiovascular benefit to Chinese PD patients with cholesterol levels of 200 mg/dl or greater. Cholesterol 115-126 C-reactive protein Homo sapiens 13-16 21894159-5 2012 RESULTS: Patients with the Gly482Ser polymorphism had significantly improved reductions in the waist/hip ratio, fasting blood glucose, C-reactive protein, blood leukocyte count, serum interleukin-6 and intima-media thickness of the carotid artery, as compared with Gly/Gly patients. Glycine 27-30 C-reactive protein Homo sapiens 135-153 21804135-7 2012 Compared with patients in lower quartiles, patients in the highest CRP quartile had lower intakes (p < 0.05) of sodium (241 mg vs 404 mg), calcium (453 mg vs 702 mg), vitamin B2 (0.88 mg vs 1.20 mg), and particularly vitamin A (207 mug vs 522 mug). Sodium 115-121 C-reactive protein Homo sapiens 67-70 21804135-7 2012 Compared with patients in lower quartiles, patients in the highest CRP quartile had lower intakes (p < 0.05) of sodium (241 mg vs 404 mg), calcium (453 mg vs 702 mg), vitamin B2 (0.88 mg vs 1.20 mg), and particularly vitamin A (207 mug vs 522 mug). Calcium 142-149 C-reactive protein Homo sapiens 67-70 21804135-7 2012 Compared with patients in lower quartiles, patients in the highest CRP quartile had lower intakes (p < 0.05) of sodium (241 mg vs 404 mg), calcium (453 mg vs 702 mg), vitamin B2 (0.88 mg vs 1.20 mg), and particularly vitamin A (207 mug vs 522 mug). Riboflavin 170-180 C-reactive protein Homo sapiens 67-70 22832816-8 2012 Furthermore, inflammation was increased in men using serotonin-norepinephrine reuptake inhibitors (CRP, IL-6) and in men and women using tri- or tetracyclic antidepressants (CRP), but decreased among men using selective serotonin reuptake inhibitors (IL-6). Serotonin 53-62 C-reactive protein Homo sapiens 99-102 21710244-6 2012 RESULTS: The analysis showed that chemotherapy increased the excretion of 8-oxoGuo and 8-oxodG around 15% (P < 0.0001 and P = 0.02, respectively) though there was a significant interaction with CRP levels. 8-hydroxyguanosine 74-82 C-reactive protein Homo sapiens 197-200 21710244-7 2012 Additionally, we found that sex, smoking status, age, and c-reactive protein were related to urinary excretion of 8-oxoGuo and 8-oxodG in colorectal cancer patients. 8-hydroxyguanosine 114-122 C-reactive protein Homo sapiens 58-76 22020763-12 2012 Importantly, NFkappa B and p38 MAPK signaling pathways, which were activated by NOX-derived ROS, were involved in CRP-induced monocyte-endothelial cell adhesion and up-regulation of MCP-1 expression. Reactive Oxygen Species 92-95 C-reactive protein Homo sapiens 114-117 21111583-7 2012 Obesity, weight gain, cigarette smoking and alcohol intake were positively associated with high CRP levels, while physical activity and a dietary pattern with high consumption of fruit were inversely related to high CRP levels. Alcohols 44-51 C-reactive protein Homo sapiens 96-99 21111583-11 2012 Obesity, smoking and alcohol intake were associated with high CRP, a biomarker of low-grade inflammation in middle-aged men, while a dietary pattern rich in fruit and high physical activity were inversely associated with the prevalence of high CRP. Alcohols 21-28 C-reactive protein Homo sapiens 62-65 22868815-7 2012 High-sensitivity C-reactive protein concentrations were lowest in men with a moderate intake of alcohol (<30 mL/day). Alcohols 96-103 C-reactive protein Homo sapiens 17-35 21954994-9 2012 Baseline triglycerides >0.83 mmol/l were associated with a higher prevalence of impaired glucose tolerance, higher high-sensitivity C-reactive protein and triglyceride/high-density lipoprotein-cholesterol ratio. Triglycerides 9-22 C-reactive protein Homo sapiens 135-153 21954994-9 2012 Baseline triglycerides >0.83 mmol/l were associated with a higher prevalence of impaired glucose tolerance, higher high-sensitivity C-reactive protein and triglyceride/high-density lipoprotein-cholesterol ratio. Triglycerides 9-21 C-reactive protein Homo sapiens 135-153 22153152-0 2012 Relationship of serum fatty acid composition and desaturase activity to C-reactive protein in Japanese men and women. Fatty Acids 22-32 C-reactive protein Homo sapiens 72-90 22153152-1 2012 BACKGROUND: Although fatty acid composition in serum and desaturase activity, which alters serum fatty acid composition, has been associated with C-reactive protein (CRP) concentration in Western populations, no study has been carried out in non-Western populations. Fatty Acids 21-31 C-reactive protein Homo sapiens 146-164 22153152-1 2012 BACKGROUND: Although fatty acid composition in serum and desaturase activity, which alters serum fatty acid composition, has been associated with C-reactive protein (CRP) concentration in Western populations, no study has been carried out in non-Western populations. Fatty Acids 21-31 C-reactive protein Homo sapiens 166-169 22153152-1 2012 BACKGROUND: Although fatty acid composition in serum and desaturase activity, which alters serum fatty acid composition, has been associated with C-reactive protein (CRP) concentration in Western populations, no study has been carried out in non-Western populations. Fatty Acids 97-107 C-reactive protein Homo sapiens 146-164 22153152-1 2012 BACKGROUND: Although fatty acid composition in serum and desaturase activity, which alters serum fatty acid composition, has been associated with C-reactive protein (CRP) concentration in Western populations, no study has been carried out in non-Western populations. Fatty Acids 97-107 C-reactive protein Homo sapiens 166-169 22153152-2 2012 We examined the association of serum fatty acids and estimated desaturase activity with CRP concentrations in Japanese men and women. Fatty Acids 37-48 C-reactive protein Homo sapiens 88-91 21798891-0 2012 Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Atorvastatin 90-102 C-reactive protein Homo sapiens 14-32 21948178-0 2012 A hypertriglyceridemic state increases high sensitivity C-reactive protein of Japanese men with normal glucose tolerance. Glucose 103-110 C-reactive protein Homo sapiens 56-74 22428468-10 2012 Fasting plasma glucose (FPG) level and HbA1c showed a significant positive correlation (p < 0.001) with Hs-CRP (r = 0.531) (r = 0.750), and IL-6 (r = 0. Glucose 15-22 C-reactive protein Homo sapiens 110-113 21920481-8 2012 Mean CRP levels decreased in the atorvastatin group (mean change -0.75 +- 3, P = .02) and increased in the placebo group (mean change 2.1 +- 19.9, P = .48). Atorvastatin 33-45 C-reactive protein Homo sapiens 5-8 21617198-11 2012 The inverse association between testosterone levels and ESA doses persisted after multivariate adjustment for age, sex hormone-binding globulin, comorbidities, C-reactive protein and s-albumin but was lost after further adjustment for iron medication and hypochromic RBC. Testosterone 32-44 C-reactive protein Homo sapiens 160-178 21457289-8 2012 The patient"s QTc, amylase and C-reactive protein also fell following initiation of steroid treatment. Steroids 84-91 C-reactive protein Homo sapiens 31-49 21864865-12 2012 Baseline fasting glucose (r = -0.36, P = .03) and adiponectin (r = 0.45, P = .005) levels were associated with changes in CRP concentrations. Glucose 17-24 C-reactive protein Homo sapiens 122-125 21995428-9 2012 Patients with CPPE (n = 23) had significantly higher levels of both CRP(pf) and CRP(ser) than those with uncomplicated PPE. Serine 84-87 C-reactive protein Homo sapiens 80-83 21820871-7 2012 In the entire group, multivariate models adjusted for age, sex, intervention group, and 6-mo weight loss identified decreased high-sensitive C-reactive protein at 6 mo as an exclusive predictor of a greater decrease in triacylglycerols (beta = 0.154, P = 0.008) and a greater increase in high-density lipoprotein cholesterol (beta = -0.452, P = 0.005) during the subsequent 18 mo. Triglycerides 219-235 C-reactive protein Homo sapiens 141-159 21995428-15 2012 CONCLUSIONS: This study demonstrated the value of CRP(ser) for prediction of RPT in patients with PPE. Serine 54-57 C-reactive protein Homo sapiens 50-53 21995428-13 2012 CRP(ser) was an independent predictor for development of RPT (adjusted OR 1.18). Serine 4-7 C-reactive protein Homo sapiens 0-3 21995428-14 2012 A CRP(ser) level >150 mg/L had 91% specificity and 61% sensitivity for prediction of RPT. Serine 6-9 C-reactive protein Homo sapiens 2-5 21035882-5 2012 RESULTS: Subjects (n=28) with pretreatment TXB(2) concentrations in the highest quartile ("aspirin-resistant patients") were more frequently current smokers and had elevated C-reactive protein (CRP), interleukin-6, 8-isoprostane, shorter bleeding time, and increased F1.2 production in a model of microvascular injury, when compared with the 3 remaining quartiles (all, p<0.001). Aspirin 91-98 C-reactive protein Homo sapiens 174-192 22280539-7 2012 Stronger correlations were identified between serum C-reactive protein and copeptin (rs = -0.36, p < 0.0001) and between serum C-reactive protein and sodium (rs = 0.33, p < 0.0001). Sodium 153-159 C-reactive protein Homo sapiens 130-148 22375259-0 2012 Comparative Effects of Glibenclamide and Metformin on C-Reactive Protein and Oxidant/Antioxidant Status in Patients with Type II Diabetes Mellitus. Metformin 41-50 C-reactive protein Homo sapiens 54-72 22375259-1 2012 OBJECTIVES: This study aimed to compare the effects of metformin and glibenclamide on high sensitivity serum C-reactive protein (hs-CRP) and oxidative stress, represented by serum malondialdehyde (MDA) and total antioxidant status (TAS) in newly-diagnosed patients with Type 2 diabetes mellitus (DM) at baseline and after 2 months of therapy in comparison to controls. Metformin 55-64 C-reactive protein Homo sapiens 109-127 21035882-5 2012 RESULTS: Subjects (n=28) with pretreatment TXB(2) concentrations in the highest quartile ("aspirin-resistant patients") were more frequently current smokers and had elevated C-reactive protein (CRP), interleukin-6, 8-isoprostane, shorter bleeding time, and increased F1.2 production in a model of microvascular injury, when compared with the 3 remaining quartiles (all, p<0.001). Aspirin 91-98 C-reactive protein Homo sapiens 194-197 22384518-5 2012 There is a large body of evidence indicating the association of CRP with endothelial dysfunction, oxidative stress and production of reactive oxygen species (ROS), as well as with lipid status disorder in AMD patients. Reactive Oxygen Species 133-156 C-reactive protein Homo sapiens 64-67 22384518-5 2012 There is a large body of evidence indicating the association of CRP with endothelial dysfunction, oxidative stress and production of reactive oxygen species (ROS), as well as with lipid status disorder in AMD patients. Reactive Oxygen Species 158-161 C-reactive protein Homo sapiens 64-67 21399668-8 2012 The prognostic impact of iron parameters was independent of other factors such as stage, conditioning regimen and CRP level, and operated similarly across diseases. Iron 25-29 C-reactive protein Homo sapiens 114-117 21933279-9 2012 All patients with PES had high serum levels of C-reactive protein (CRP), which were significantly reduced after effective steroid treatment. Steroids 122-129 C-reactive protein Homo sapiens 47-65 22681482-0 2012 What is the relationship between effects of aspirin, statins, and C-reactive protein? Aspirin 44-51 C-reactive protein Homo sapiens 66-84 22119637-0 2012 Conversion from enzyme-inducing antiepileptic drugs to topiramate: effects on lipids and C-reactive protein. Topiramate 55-65 C-reactive protein Homo sapiens 89-107 21947022-3 2012 The aim of the study was to evaluate whether (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT can be used to detect inflammatory foci in neutropenic patients with elevated CRP and whether it helps to direct treatment. f-fluorodeoxyglucose 49-69 C-reactive protein Homo sapiens 192-195 24578930-0 2012 Serum C-reactive protein level is a significant prognostic indicator in patients with advanced urothelial cancer treated with gemcitabine-cisplatin or carboplatin - preliminary results. Cisplatin 138-147 C-reactive protein Homo sapiens 6-24 22119637-1 2012 PURPOSE: We previously demonstrated that converting patients from the enzyme-inducers phenytoin or carbamazepine to the non-inducers levetiracetam or lamotrigine reduces serum lipids and C-reactive protein (CRP). Levetiracetam 133-146 C-reactive protein Homo sapiens 187-205 22119637-1 2012 PURPOSE: We previously demonstrated that converting patients from the enzyme-inducers phenytoin or carbamazepine to the non-inducers levetiracetam or lamotrigine reduces serum lipids and C-reactive protein (CRP). Levetiracetam 133-146 C-reactive protein Homo sapiens 207-210 22119637-1 2012 PURPOSE: We previously demonstrated that converting patients from the enzyme-inducers phenytoin or carbamazepine to the non-inducers levetiracetam or lamotrigine reduces serum lipids and C-reactive protein (CRP). Lamotrigine 150-161 C-reactive protein Homo sapiens 187-205 22119637-1 2012 PURPOSE: We previously demonstrated that converting patients from the enzyme-inducers phenytoin or carbamazepine to the non-inducers levetiracetam or lamotrigine reduces serum lipids and C-reactive protein (CRP). Lamotrigine 150-161 C-reactive protein Homo sapiens 207-210 22119637-7 2012 RESULTS: Conversion from inducers to topiramate resulted in a -35 mg/dL decline in total cholesterol (p=0.033), with significant decreases in all cholesterol fractions, triglycerides, and LDL particle concentration (p<=0.03 for all), as well as a decrease of over 50% in serum CRP (p<0.001). Topiramate 37-47 C-reactive protein Homo sapiens 280-283 21933279-9 2012 All patients with PES had high serum levels of C-reactive protein (CRP), which were significantly reduced after effective steroid treatment. Steroids 122-129 C-reactive protein Homo sapiens 67-70 22906280-1 2012 OBJECTIVE: This cross-sectional study investigated the correlation between diacron reactive oxygen metabolites (d-ROMs) and high-sensitivity C-reactive protein (hs-CRP) in subjects with or without metabolic syndrome. Oxygen 92-98 C-reactive protein Homo sapiens 141-159 22153549-6 2012 For both sexes, CRP increased as the number of MS components increased (p=0.015 for men and p<0.001) after adjustment for age, smoking, alcohol intake and, for women, menopause. Alcohols 139-146 C-reactive protein Homo sapiens 16-19 21934326-7 2012 RESULTS: Lower serum vitamin D levels were found to be associated with prehypertension independent of potential confounders including body mass index (BMI), serum cholesterol, C-reactive protein and estimated glomerular filtration rate. Vitamin D 21-30 C-reactive protein Homo sapiens 176-194 23204851-15 2012 Interestingly, compared with baseline inflammatory cytokine levels in those with the Val/Val genotype, higher baseline tumor necrosis factor alpha, interleukin-6, and C-reactive protein levels were observed for the Ala/Ala genotype in both patients with carotid atherosclerosis and healthy controls. Alanine 215-218 C-reactive protein Homo sapiens 167-185 23204851-15 2012 Interestingly, compared with baseline inflammatory cytokine levels in those with the Val/Val genotype, higher baseline tumor necrosis factor alpha, interleukin-6, and C-reactive protein levels were observed for the Ala/Ala genotype in both patients with carotid atherosclerosis and healthy controls. Alanine 219-222 C-reactive protein Homo sapiens 167-185 23087143-11 2012 CONCLUSION: EGCG is able to inhibit Ang II- and IL-6-stimulated CRP expression in macrophages to produce an anti-inflammation by interfering with ROS generation. ros 146-149 C-reactive protein Homo sapiens 64-67 22088801-7 2012 RESULTS: Age- and hysterectomy-adjusted regression models suggest that CRP level is positively associated with LH/FSH ratio and LH/FSH>1, high glucose level and LH/FSH>2 are inversely related and HDL<50mg/dL is positively associated with both LH/FSH>1 and LH/FSH>2. Glucose 146-153 C-reactive protein Homo sapiens 71-74 23350124-2 2012 Combined treatment with meksykoru to correct the atherogenic lipid profile and CRP helped reduce content CRP, total cholesterol, low-density lipoprotein cholesterol, triglycerides, factor aterohenosti and raise HDL cholesterol. Cholesterol 116-127 C-reactive protein Homo sapiens 79-82 23350124-2 2012 Combined treatment with meksykoru to correct the atherogenic lipid profile and CRP helped reduce content CRP, total cholesterol, low-density lipoprotein cholesterol, triglycerides, factor aterohenosti and raise HDL cholesterol. Triglycerides 166-179 C-reactive protein Homo sapiens 79-82 23350124-2 2012 Combined treatment with meksykoru to correct the atherogenic lipid profile and CRP helped reduce content CRP, total cholesterol, low-density lipoprotein cholesterol, triglycerides, factor aterohenosti and raise HDL cholesterol. Cholesterol 153-164 C-reactive protein Homo sapiens 79-82 22491005-5 2012 RESULTS: We found increases in the plasma concentration of CRP in the chemotherapy alone and chemotherapy plus tamoxifen groups after 3 and 6 months of treatment (before the introduction of tamoxifen). Tamoxifen 111-120 C-reactive protein Homo sapiens 59-62 22491005-5 2012 RESULTS: We found increases in the plasma concentration of CRP in the chemotherapy alone and chemotherapy plus tamoxifen groups after 3 and 6 months of treatment (before the introduction of tamoxifen). Tamoxifen 190-199 C-reactive protein Homo sapiens 59-62 22491005-6 2012 However, after 12 months of treatment, women who used tamoxifen (the chemotherapy plus tamoxifen and tamoxifen alone groups) showed a significant reduction in CRP and Apo-B levels and a decrease in the Apo-B/Apo-A ratio. Tamoxifen 54-63 C-reactive protein Homo sapiens 159-162 22491005-6 2012 However, after 12 months of treatment, women who used tamoxifen (the chemotherapy plus tamoxifen and tamoxifen alone groups) showed a significant reduction in CRP and Apo-B levels and a decrease in the Apo-B/Apo-A ratio. Tamoxifen 87-96 C-reactive protein Homo sapiens 159-162 22491005-6 2012 However, after 12 months of treatment, women who used tamoxifen (the chemotherapy plus tamoxifen and tamoxifen alone groups) showed a significant reduction in CRP and Apo-B levels and a decrease in the Apo-B/Apo-A ratio. Tamoxifen 87-96 C-reactive protein Homo sapiens 159-162 22491005-8 2012 CONCLUSION: The use of tamoxifen after chemotherapy for the treatment of breast cancer significantly reduces the levels of cardiovascular disease risk markers (CRP, Apo-B, and the Apo-B/Apo-A ratio). Tamoxifen 23-32 C-reactive protein Homo sapiens 160-163 22723940-1 2012 BACKGROUND: In a previous report by our group, high levels of apolipoprotein E (apoE) were demonstrated to be associated with risk of incident cardiovascular disease in women with high levels of C-reactive protein (CRP) in the setting of both low (designated as HR1 subjects) and high (designated as HR2 subjects) levels of high-density lipoprotein cholesterol (HDL-C). Cholesterol 349-360 C-reactive protein Homo sapiens 215-218 23654149-3 2012 Additional use of atorvastatin to a conventional therapy leads to significant reduction of C-reactive protein and fibrinogen and improves effect of long-term sinus rhythm maintenance. Atorvastatin 18-30 C-reactive protein Homo sapiens 91-109 22830205-8 2012 LDLP cholesterol decreased Blood lipids composition shifts were associated with marked reduction in the disease activity: decreased concentration of C-reactive protein, IgM rheumatoid factor, DAS28 index, improvement of the patient functional status. Cholesterol 5-16 C-reactive protein Homo sapiens 149-167 22448235-11 2012 CONCLUSIONS/SIGNIFICANCE: Atorvastatin treatment may be effective in slowing the decline of beta cell function in a patient subgroup defined by above median levels of CRP and other inflammation associated immune mediators. Atorvastatin 26-38 C-reactive protein Homo sapiens 167-170 22105444-6 2011 CRP levels (p < 0.001) were higher in patients with AMC. 7-amino-4-methylcoumarin 55-58 C-reactive protein Homo sapiens 0-3 21246407-4 2011 However, among controls higher levels of C-reactive protein were related to higher glucose levels, whereas among offspring levels of C-reactive protein were unrelated to glucose levels. Glucose 83-90 C-reactive protein Homo sapiens 41-59 21980169-10 2011 Pretreatment of HAECs with sepiapterin or diethylenetriamine NONOate, both of which preserve nitric oxide (NO), resulted in attenuation of CRP"s effects on CECs and EMPs. Nitric Oxide 93-105 C-reactive protein Homo sapiens 139-142 22104550-4 2011 Weight loss (-11.23 kg; 95% confidence interval, -11.54 to -10.92; P<0.001) reduced high-sensitivity C-reactive protein (-1.15 mg/L; 95% confidence interval, -1.30 to -0.41; P<0.001), low- and high-density lipoprotein cholesterol, triglycerides, and blood pressure. Triglycerides 237-250 C-reactive protein Homo sapiens 104-122 21437589-8 2011 Level of serum cortisol correlated positively with maximal CRP level during days 0 to 4 in neutropenic fever periods without severe sepsis, but no correlation was observed in fever periods with severe sepsis. Hydrocortisone 15-23 C-reactive protein Homo sapiens 59-62 22105444-7 2011 Using multivariate logistic analysis of regression, older age (> 50 years) and higher CRP levels (> 5 mg/l) were associated with AIC and AMC, respectively (p = 0.007 and p = 0.003). 7-amino-4-methylcoumarin 143-146 C-reactive protein Homo sapiens 89-92 22105444-8 2011 Logistic regression analysis showed that patients with CRP > 5 mg/l had a greater relative risk of having AMC (odds ratio 30, 95% confidence interval 27.041 - 32.959; p = 0.003). 7-amino-4-methylcoumarin 109-112 C-reactive protein Homo sapiens 55-58 21934067-3 2011 Proteolysis of CRP yields the C-terminal peptide Lys(201)-Pro-Gln-Leu-Trp-Pro(206). Lysine 49-52 C-reactive protein Homo sapiens 15-18 22105444-10 2011 In nondiabetic patients who had been on hemodialysis for at least 5 years, older age was associated with AIC, and elevated CRP levels with AMC. 7-amino-4-methylcoumarin 139-142 C-reactive protein Homo sapiens 123-126 21917349-7 2011 C-reactive protein and CIMT were positively correlated with insulin, HOMA-IR, glucose value at the time of the OGTT 50, prepregnancy body mass index, TG and FBG. Glucose 78-85 C-reactive protein Homo sapiens 0-18 21301856-0 2011 Erythrocyte membrane phospholipid polyunsaturated fatty acids are related to plasma C-reactive protein and adiponectin in middle-aged German women and men. Phospholipids 21-33 C-reactive protein Homo sapiens 84-102 21934067-8 2011 Substitution of Lys(201), Gln(203), or Trp(205) with Ala in CRP peptide 201-206 resulted in loss of the biological activities, whereas peptides in which Pro(202), Leu(204), or Pro(206) was substituted with Ala retained biological activity. Lysine 16-19 C-reactive protein Homo sapiens 60-63 21939649-4 2011 The combination of hs-CRP and apoB/apoA-1 ratio had greater correlation with abnormal glucose metabolism than its individual components in patients with normal fasting glucose, and was an independent predictor for coronary artery disease. Glucose 86-93 C-reactive protein Homo sapiens 22-25 21859817-10 2011 Additionally, monomeric C-reactive protein significantly induced VASP dephosphorylation at serine 239. Serine 91-97 C-reactive protein Homo sapiens 24-42 21975508-1 2011 The complexes of C-reactive protein (CRP) with its polymerizable phosphocholine ligands adsorbed at the styrene-water interface were polymerized. Styrene 104-111 C-reactive protein Homo sapiens 17-35 21975508-1 2011 The complexes of C-reactive protein (CRP) with its polymerizable phosphocholine ligands adsorbed at the styrene-water interface were polymerized. Styrene 104-111 C-reactive protein Homo sapiens 37-40 21975508-1 2011 The complexes of C-reactive protein (CRP) with its polymerizable phosphocholine ligands adsorbed at the styrene-water interface were polymerized. Water 112-117 C-reactive protein Homo sapiens 17-35 21975508-1 2011 The complexes of C-reactive protein (CRP) with its polymerizable phosphocholine ligands adsorbed at the styrene-water interface were polymerized. Water 112-117 C-reactive protein Homo sapiens 37-40 21726166-5 2011 Negative relations of CRP with both total and direct bilirubin were found after adjustment of age, body mass index, hypertension, diabetes, hypercholesterolemia, cardiovascular disease, taking aspirin, smoking, alcohol drinking and regular exercise and total bilirubin or direct bilirubin. Aspirin 193-200 C-reactive protein Homo sapiens 22-25 21726166-5 2011 Negative relations of CRP with both total and direct bilirubin were found after adjustment of age, body mass index, hypertension, diabetes, hypercholesterolemia, cardiovascular disease, taking aspirin, smoking, alcohol drinking and regular exercise and total bilirubin or direct bilirubin. Alcohols 211-218 C-reactive protein Homo sapiens 22-25 21865358-9 2011 Both simvastatin and metformin improved menstrual cyclicity and decreased hirsutism, acne, ovarian volume, body mass index, C-reactive protein, and soluble vascular cell adhesion molecule-1. Metformin 21-30 C-reactive protein Homo sapiens 124-142 21712733-2 2011 We aimed to examine the effect of soy isoflavones on circulating CRP concentrations in postmenopausal women by conducting a meta-analysis of randomized controlled trials. Isoflavones 38-49 C-reactive protein Homo sapiens 65-68 22086789-1 2011 AIM: To determine risk parameters associated with high values of high sensitive C-reactive protein (hsCRP) in subjects with different glucose fasting levels. Glucose 134-141 C-reactive protein Homo sapiens 80-98 21712733-8 2011 Subgroup analyses showed that soy isoflavones significantly lowered CRP by 0.70 mg/L (95% CI, -1.17 to -0.23; P = 0.003) among women with baseline CRP concentrations greater than 2.2 mg/L. Isoflavones 34-45 C-reactive protein Homo sapiens 68-71 21712733-8 2011 Subgroup analyses showed that soy isoflavones significantly lowered CRP by 0.70 mg/L (95% CI, -1.17 to -0.23; P = 0.003) among women with baseline CRP concentrations greater than 2.2 mg/L. Isoflavones 34-45 C-reactive protein Homo sapiens 147-150 21712733-10 2011 Metaregression analysis further revealed that baseline CRP was a potential effect modifier of isoflavone treatment in lowering CRP. Isoflavones 94-104 C-reactive protein Homo sapiens 55-58 21712733-10 2011 Metaregression analysis further revealed that baseline CRP was a potential effect modifier of isoflavone treatment in lowering CRP. Isoflavones 94-104 C-reactive protein Homo sapiens 127-130 21712733-11 2011 The present meta-analysis found insufficient evidence that soy isoflavones significantly reduce CRP concentrations in postmenopausal women. Isoflavones 63-74 C-reactive protein Homo sapiens 96-99 21712733-12 2011 However, soy isoflavones may produce a significant reduction in CRP among postmenopausal women with elevated CRP. Isoflavones 13-24 C-reactive protein Homo sapiens 64-67 21712733-12 2011 However, soy isoflavones may produce a significant reduction in CRP among postmenopausal women with elevated CRP. Isoflavones 13-24 C-reactive protein Homo sapiens 109-112 21724580-5 2011 After 6 months of treatment, in the vitamin D(3) supplementation group, CRP decreased 32% overall (P = 0.11), 37% in men (P = 0.05), and 41% among non-nonsteroidal anti-inflammatory drug (NSAID) users (P = 0.05) relative to placebo. Vitamin D 36-45 C-reactive protein Homo sapiens 72-75 21948794-5 2011 In practical applications, we show that the proposed approach can be used to find sites of such diverse DNA-binding molecules as the cAMP receptor protein (CRP) and Din-family site-specific serine recombinases. Serine 190-196 C-reactive protein Homo sapiens 133-160 21930971-3 2011 In this study, we show that the Tyr(402) His sequence variation affects Factor H surface recruitment by monomeric C-reactive protein (mCRP) to specific patches on the surface of necrotic retinal pigment epithelial cells. Tyrosine 32-35 C-reactive protein Homo sapiens 114-132 21689722-5 2011 Biochemical and biophysical assays showed that under defined pathophysiological condition (pH 6.5, 2.0 mM calcium), the FBG:CRP interaction occurred more strongly compared to that under physiological condition (pH 7.4, 2.5 mM calcium). Calcium 106-113 C-reactive protein Homo sapiens 124-127 21689722-5 2011 Biochemical and biophysical assays showed that under defined pathophysiological condition (pH 6.5, 2.0 mM calcium), the FBG:CRP interaction occurred more strongly compared to that under physiological condition (pH 7.4, 2.5 mM calcium). Calcium 226-233 C-reactive protein Homo sapiens 124-127 21689722-6 2011 We identified the binding interface between CRP and FBG, locating it to the pH- and calcium-sensitive C-terminal region of FBG. Calcium 84-91 C-reactive protein Homo sapiens 44-47 21821723-1 2011 BACKGROUND: C-reactive protein (CRP) is purported to be a risk factor that acts independently of LDL cholesterol in predicting all-cause mortality in patients with ischemic heart disease. Cholesterol 101-112 C-reactive protein Homo sapiens 12-30 21821723-1 2011 BACKGROUND: C-reactive protein (CRP) is purported to be a risk factor that acts independently of LDL cholesterol in predicting all-cause mortality in patients with ischemic heart disease. Cholesterol 101-112 C-reactive protein Homo sapiens 32-35 21813592-5 2011 C-reactive protein (CRP) was associated with CL-LOOH and with AOPP. cl-looh 45-52 C-reactive protein Homo sapiens 0-18 21744073-3 2011 METHODS: Diabetes was induced by streptozotocin in human CRP transgenic and wild-type mice for assessment of kidney injury at 24 weeks by real-time PCR, immunohistochemistry and western blot analysis. Streptozocin 33-47 C-reactive protein Homo sapiens 57-60 21744073-4 2011 In vitro, the pathogenic effect of CRP was investigated using human kidney tubular epithelial cells cultured with high glucose and/or CRP. Glucose 119-126 C-reactive protein Homo sapiens 35-38 22165675-12 2011 An inverse correlation between testosterone and CRP was demonstrated for the 3A/4A COPD subgroup. Testosterone 31-43 C-reactive protein Homo sapiens 48-51 22165675-13 2011 CONCLUSIONS: Levels of testosterone correlated to FEV1, hypoxemia and weakly to CRP. Testosterone 23-35 C-reactive protein Homo sapiens 80-83 21974758-6 2011 Elevated serum total calcium levels were positively associated with hypertension, independent of potential confounders including C-reactive protein, estimated glomerular filtration rate, serum albumin, 25(OH)D, and phosphorous. Calcium 21-28 C-reactive protein Homo sapiens 129-147 21813592-5 2011 C-reactive protein (CRP) was associated with CL-LOOH and with AOPP. cl-looh 45-52 C-reactive protein Homo sapiens 20-23 21784820-11 2011 CONCLUSIONS: Administration of the noncalcium phosphate binder sevelamer to maintenance HD patients is associated with a significant decrease in hs-CRP, IL-6, serum endotoxin levels and sCD14 concentrations. Phosphates 46-55 C-reactive protein Homo sapiens 148-151 21550088-8 2011 We also demonstrate correlations of vitamin D status with insulin sensitivity, HDL-C, and C-reactive protein in PCOS patients, which support the increasing evidence that vitamin D deficiency is associated with multiple metabolic risk factors in PCOS women. Vitamin D 36-45 C-reactive protein Homo sapiens 90-108 21550088-8 2011 We also demonstrate correlations of vitamin D status with insulin sensitivity, HDL-C, and C-reactive protein in PCOS patients, which support the increasing evidence that vitamin D deficiency is associated with multiple metabolic risk factors in PCOS women. Vitamin D 170-179 C-reactive protein Homo sapiens 90-108 21943158-7 2011 These are located on chromosome 8 (LPL gene affecting HDL and triglycerides) and chromosome 19 (TOMM40/APOE-C1-C2-C4 gene cluster affecting LDL and CRP). Triglycerides 62-75 C-reactive protein Homo sapiens 148-151 21587094-6 2011 Among a total of 28 patients of refractory KD treated with CyA, 18 (64.3%) responded promptly to be afebrile within 3 days and had decreased C-reactive protein levels, the other 4 became afebrile within 4 to 5 days. Cyclosporine 59-62 C-reactive protein Homo sapiens 141-159 21929771-11 2011 The parameters of infection including, fibrinogen (p = 0.03), white blood cell count (p = 0.001) and C-reactive protein (p = 0.0001) were significantly reduced after daptomycin application. Daptomycin 166-176 C-reactive protein Homo sapiens 101-119 21896895-4 2011 The subnormal testosterone concentrations are not related to glycosylated hemoglobin or duration of diabetes, but are associated with obesity, very high C-reactive protein concentrations, and mild anemia. Testosterone 14-26 C-reactive protein Homo sapiens 153-171 21670067-2 2011 Here, we have identified the intrasubunit disulfide bond as a conserved switch that controls the structure and functions of CRP. Disulfides 42-51 C-reactive protein Homo sapiens 124-127 21670067-8 2011 Therefore, expression of proinflammatory properties of CRP on endothelial cells requires sequential conformational changes, i.e., loss of pentameric symmetry followed by reduction of the intrasubunit disulfide bond. Disulfides 200-209 C-reactive protein Homo sapiens 55-58 21255134-10 2011 Ximelagatran increased IL-10 levels (P = 0.002) and reduced the decrease in CRP levels after 6 months compared to treatment with aspirin alone (P = 0.002). ximelagatran 0-12 C-reactive protein Homo sapiens 76-79 21640381-5 2011 In HepG2 cells, ER stress triggered by tunicamycin, thapsigargin and homocysteine markedly induced CRP expression and the activation of protein kinase R-like endoplasmic reticulum kinase (PERK), inositol-requiring transmembrane kinase/endonuclease 1alpha (IRE1alpha), activating transcription factor 6 (ATF6), and hepatocyte-specific cyclic AMP response element binding protein H (CREBH). Thapsigargin 52-64 C-reactive protein Homo sapiens 99-102 21923250-9 2011 The AUC for serum lactate (0.922), IL-6 (0.912), and CRP (0.719) in differentiating between patients with severe sepsis and those with sepsis also proves the superiority of serum lactate and IL-6. Lactic Acid 179-186 C-reactive protein Homo sapiens 53-56 20592101-8 2011 In addition, CRP was positively associated with TBARS and carbonyl levels, but was significantly inversely associated with Zn and Se levels. Zinc 123-125 C-reactive protein Homo sapiens 13-16 21798129-13 2011 CONCLUSION: Glycosylated haemoglobin and fasting plasma glucose but not fructosamine are significantly associated with microalbuminuria, fibrinogen SUA and CRP in type 2 DM. Glucose 56-63 C-reactive protein Homo sapiens 156-159 22046880-7 2011 There was a positive correlation between CRP with postprandial glycemia (p = 0.004); the multivariate regression analysis revealed a statistically significant correlation between CRP and age (p = 0.001), smoking (p = 0.055), fasting glucose (p = 0.021) and triglycerides (p = 0.048) as well as between IL-6 and LDL-cholesterol (p = 0.009). Glucose 233-240 C-reactive protein Homo sapiens 179-182 22046880-7 2011 There was a positive correlation between CRP with postprandial glycemia (p = 0.004); the multivariate regression analysis revealed a statistically significant correlation between CRP and age (p = 0.001), smoking (p = 0.055), fasting glucose (p = 0.021) and triglycerides (p = 0.048) as well as between IL-6 and LDL-cholesterol (p = 0.009). Triglycerides 257-270 C-reactive protein Homo sapiens 179-182 22046880-7 2011 There was a positive correlation between CRP with postprandial glycemia (p = 0.004); the multivariate regression analysis revealed a statistically significant correlation between CRP and age (p = 0.001), smoking (p = 0.055), fasting glucose (p = 0.021) and triglycerides (p = 0.048) as well as between IL-6 and LDL-cholesterol (p = 0.009). Cholesterol 315-326 C-reactive protein Homo sapiens 179-182 21871057-11 2011 When categorized by baseline C-reactive protein (CRP; cut point of 2 mg/L), subjects in the lower CRP sub-group benefited more from dietary intervention, including a more increase in cholesterol efflux, a greater reduction in SCD1, and a blunted postprandial lipemia. Cholesterol 183-194 C-reactive protein Homo sapiens 98-101 21806828-11 2011 The abnormally elevated CRP induced by ethanol can be used as a biomarker to distinguish AFL from normal or otherwise diseased livers. Ethanol 39-46 C-reactive protein Homo sapiens 24-27 22321227-1 2011 OBJECTIVE: To observe the association between preprocedural high sensitivity C-reactive protein (hs-CRP) level and incidence of contrast induced acute kidney injury (CI-AKI) in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) and the impact of atorvastatin pretreatment on CI-AKI. Atorvastatin 286-298 C-reactive protein Homo sapiens 77-95 21945876-0 2011 C-reactive protein is directly associated with urinary albumin-to-creatinine ratio. Creatinine 66-76 C-reactive protein Homo sapiens 0-18 21945876-2 2011 We undertook this study to evaluate whether elevated C-reactive protein (CRP) levels are independently associated with urinary albumin-to-creatinine ratio (UACR) in the offspring of subjects with diabetic nephropathy. Creatinine 138-148 C-reactive protein Homo sapiens 53-71 21945876-2 2011 We undertook this study to evaluate whether elevated C-reactive protein (CRP) levels are independently associated with urinary albumin-to-creatinine ratio (UACR) in the offspring of subjects with diabetic nephropathy. Creatinine 138-148 C-reactive protein Homo sapiens 73-76 21852972-12 2011 Increased C-reactive protein and gamma-glutamyl transferase levels were associated with decreased protein expression of both enzymes, and increased bilirubin levels, cholestasis, and presurgical exposure to omeprazole or pantoprazole were related to decreased PON3 protein. Omeprazole 207-217 C-reactive protein Homo sapiens 10-28 21653577-6 2011 However, dietary Zn and heme iron were positively associated with CRP [mean: 1.73, 1.75, 1.78, 1.88, and 1.96 mg/L across increasing quintiles of Zn and 1.72, 1.76, 1.83, 1.86, and 1.94 mg/L across increasing quintiles of heme iron (P-trend = 0.002 and 0.01, respectively). Zinc 17-19 C-reactive protein Homo sapiens 66-69 21653577-6 2011 However, dietary Zn and heme iron were positively associated with CRP [mean: 1.73, 1.75, 1.78, 1.88, and 1.96 mg/L across increasing quintiles of Zn and 1.72, 1.76, 1.83, 1.86, and 1.94 mg/L across increasing quintiles of heme iron (P-trend = 0.002 and 0.01, respectively). Iron 29-33 C-reactive protein Homo sapiens 66-69 21648471-2 2011 Although bulk microstructures and the nanostructure of metallic copper exhibit distinct applications, the amino sugar surface-functionalized copper is almost biocompatible and exhibits advanced features such as more crystallinity, high thermal stability, and electrochemical feasibility toward biomolecule (C-reactive protein, CRP) detection. Copper 141-147 C-reactive protein Homo sapiens 307-325 21774822-11 2011 CONCLUSIONS: In SLE patients 40 mg of atorvastatin daily for 1 year led to a decrease in serum lipids and CRP levels. Atorvastatin 38-50 C-reactive protein Homo sapiens 106-109 21648471-2 2011 Although bulk microstructures and the nanostructure of metallic copper exhibit distinct applications, the amino sugar surface-functionalized copper is almost biocompatible and exhibits advanced features such as more crystallinity, high thermal stability, and electrochemical feasibility toward biomolecule (C-reactive protein, CRP) detection. Copper 141-147 C-reactive protein Homo sapiens 327-330 21648471-4 2011 The combination of a biointerface membrane, from glucosamine functionalization, and electroactive sites of metallic copper provides a very efficient electrochemical response against various concentration of CRP. Copper 116-122 C-reactive protein Homo sapiens 207-210 21423006-4 2011 Simple clinical and laboratory measures predict steroid refractoriness (such as stool frequency 3-8/day and C-reactive protein > 45 mg/l on day 3) and salvage therapy is appropriate at this stage. Steroids 48-55 C-reactive protein Homo sapiens 108-126 21306304-4 2011 The arginine/ADMA ratio decreased significantly across increasing tertiles of CRP and MPO. Arginine 4-12 C-reactive protein Homo sapiens 78-81 21306304-8 2011 Conversely, in a fully adjusted model, CRP was negatively associated with arginine [-2.8 (95% CI, -4.0 to -1.6) mumol/l arginine per S.D. Arginine 74-82 C-reactive protein Homo sapiens 39-42 21306304-8 2011 Conversely, in a fully adjusted model, CRP was negatively associated with arginine [-2.8 (95% CI, -4.0 to -1.6) mumol/l arginine per S.D. Arginine 120-128 C-reactive protein Homo sapiens 39-42 21306304-12 2011 In contrast, the relationship between CRP and arginine was not modified by levels of oxLDL. Arginine 46-54 C-reactive protein Homo sapiens 38-41 21737012-5 2011 RESULTS: Inflamed CLS+ obese individuals displayed higher plasma insulin, homeostasis model assessment, triglycerides, glucose, blood pressure, high-sensitivity C-reactive protein, low-density lipoprotein cholesterol, lower high-density lipoprotein cholesterol, and brachial artery flow-mediated dilation compared with lean subjects (p < 0.05). calusterone 18-21 C-reactive protein Homo sapiens 161-179 21146883-7 2011 Significant restoration of C reactive protein (p<0.05) was noticed after metformin therapy. Metformin 76-85 C-reactive protein Homo sapiens 27-45 21440634-1 2011 With its homo-pentameric structure and calcium-dependent specificity for phosphocholine (PCh), human c-reactive protein (CRP) is produced by the liver and secreted in elevated quantities in response to inflammation. Calcium 39-46 C-reactive protein Homo sapiens 101-119 21765609-5 2011 Plasma C-reactive protein levels significantly correlated with dietary intakes of vitamin C (r = -0.30, p<0.005), beta-carotene (r = -0.23, p<0.05), and folate (r = -0.31, p<0.005). Folic Acid 159-165 C-reactive protein Homo sapiens 7-25 21870702-2 2011 MATERIAL AND METHODS: C-reactive protein measurement clinical value was examined by high sensitivity CRP method (hsCRP) and compared to clinical value of other heart attack risk factors: total cholesterol (TC) and cholesterol in HDL fraction (HDL-C), triglycerides (TG) and fibrinogen (FBG). Cholesterol 193-204 C-reactive protein Homo sapiens 22-40 21870702-2 2011 MATERIAL AND METHODS: C-reactive protein measurement clinical value was examined by high sensitivity CRP method (hsCRP) and compared to clinical value of other heart attack risk factors: total cholesterol (TC) and cholesterol in HDL fraction (HDL-C), triglycerides (TG) and fibrinogen (FBG). Cholesterol 214-225 C-reactive protein Homo sapiens 22-40 21870702-2 2011 MATERIAL AND METHODS: C-reactive protein measurement clinical value was examined by high sensitivity CRP method (hsCRP) and compared to clinical value of other heart attack risk factors: total cholesterol (TC) and cholesterol in HDL fraction (HDL-C), triglycerides (TG) and fibrinogen (FBG). Triglycerides 251-264 C-reactive protein Homo sapiens 22-40 21870702-2 2011 MATERIAL AND METHODS: C-reactive protein measurement clinical value was examined by high sensitivity CRP method (hsCRP) and compared to clinical value of other heart attack risk factors: total cholesterol (TC) and cholesterol in HDL fraction (HDL-C), triglycerides (TG) and fibrinogen (FBG). Triglycerides 266-268 C-reactive protein Homo sapiens 22-40 21427737-0 2011 Associations of obesity with triglycerides and C-reactive protein are attenuated in adults with high red blood cell eicosapentaenoic and docosahexaenoic acids. eicosapentaenoic 116-132 C-reactive protein Homo sapiens 47-65 21584495-0 2011 Atorvastatin reduces lipopolysaccharide-induced expression of C-reactive protein in human lung epithelial cells. Atorvastatin 0-12 C-reactive protein Homo sapiens 62-80 21584495-3 2011 In this study, we determined whether atorvastatin modulates the lipopolysaccharide (LPS)-induced expression of CRP in A549 cells. Atorvastatin 37-49 C-reactive protein Homo sapiens 111-114 21584495-8 2011 The present study revealed that A549 cells are capable of LPS-induced CRP expression, and that atorvastatin down-regulates the LPS-induced expression of CRP in cultured A549 cells. Atorvastatin 95-107 C-reactive protein Homo sapiens 153-156 21440634-1 2011 With its homo-pentameric structure and calcium-dependent specificity for phosphocholine (PCh), human c-reactive protein (CRP) is produced by the liver and secreted in elevated quantities in response to inflammation. Calcium 39-46 C-reactive protein Homo sapiens 121-124 22088250-0 2011 [The effects of atorvastatin on C-reactive protein induced Toll-like receptor 4 expression on CD14+ monocyte]. Atorvastatin 16-28 C-reactive protein Homo sapiens 32-50 20300755-11 2011 Serum 25-OH vitamin D levels were significantly negatively correlated with DAS28, CRP, and HAQ (respectively, r = -0.431, P = 0.000, r = -0.276, P = 0.026, and r = -0.267, P = 0.031). Vitamin D 12-21 C-reactive protein Homo sapiens 82-85 22088250-1 2011 OBJECTIVE: To investigate the effects of atorvastatin on C-reactive protein (CRP) induced Toll-Like receptor 4 (TLR4)expression on CD14+ monocyte, and the production of proinflammatory cytokines tumor necrosis factor alpha (TNFalpha), interleukin-6 (IL-6), matrix metalloproteinases-9 (MMP-9), and to study the anti-inflammatory mechanisms of statins. Atorvastatin 41-53 C-reactive protein Homo sapiens 57-75 22088250-1 2011 OBJECTIVE: To investigate the effects of atorvastatin on C-reactive protein (CRP) induced Toll-Like receptor 4 (TLR4)expression on CD14+ monocyte, and the production of proinflammatory cytokines tumor necrosis factor alpha (TNFalpha), interleukin-6 (IL-6), matrix metalloproteinases-9 (MMP-9), and to study the anti-inflammatory mechanisms of statins. Atorvastatin 41-53 C-reactive protein Homo sapiens 77-80 22088250-7 2011 (2) TLR4 protein expression on 50 microg/ml CRP stimulated cells also increased in a time-dependent manner (29.80 +/- 2.70)%, (47.44 +/- 4.41)%, (81.71 +/- 2.92)% and (50.57 +/- 3.34)% after 6 h, 12 h, 24 h, 48 h. (3) When monocytes were incubated with CRP 50 microg/ml and atorvastatin (1.0, 2.5, 5.0, 7.5, 10.0 micromol/L), protein expression [(68.17 +/- 1.71)%, (52.43 +/- 1.38)%, (27.72 +/- 4.55)%, (17.46 +/- 3.20)%, (9.99 +/- 2.81)%] and mRNA expression (82.72%, 67.34%, 48.16%, 30.88%, 13.85%) of TLR4 as well as mRNA expression of MD2 (81.78%, 71.04%, 47.85%, 27.06%, 18.30%) were reduced in a dose-dependent manner. Atorvastatin 274-286 C-reactive protein Homo sapiens 44-47 22088250-9 2011 When monocyte incubated with CRP 50 microg/ml and atorvastatin 10.0 micromol/L, the level of TNFalpha, IL-6, MMP-9 decreased to (25.8 +/- 2.5) microg/ml, (128.2 +/- 14.7) pg/ml, (65.2 +/- 12.3) ng/ml, respectively. Atorvastatin 50-62 C-reactive protein Homo sapiens 29-32 22088250-11 2011 Atorvastatin can inhibit the signal transduction of TLR4 and reduce proinflammatory cytokines release induced by CRP on CD14 monocyte, and this might be one of the anti-inflammatory mechanisms of atorvastatin. Atorvastatin 0-12 C-reactive protein Homo sapiens 113-116 22088250-11 2011 Atorvastatin can inhibit the signal transduction of TLR4 and reduce proinflammatory cytokines release induced by CRP on CD14 monocyte, and this might be one of the anti-inflammatory mechanisms of atorvastatin. Atorvastatin 196-208 C-reactive protein Homo sapiens 113-116 21527524-8 2011 Additional significant, though less strong, associations were observed for C-reactive protein and total iron binding capacity in men and for total iron binding capacity, alanine aminotransferase, and glomerular filtration rate in women. Iron 104-108 C-reactive protein Homo sapiens 75-93 21714897-10 2011 Multivariate analysis (Cox regression) revealed that CRP/prealbumin was independently associated with mortality after adjustment for age, gender, sepsis and sequential organ failure assessment (SOFA, p = 0.027) while the others (CRP, albumin, prealbumin, cholesterol, CRP/albumin and CRP/cholesterol) became non-significantly associated. Cholesterol 255-266 C-reactive protein Homo sapiens 53-56 21714897-10 2011 Multivariate analysis (Cox regression) revealed that CRP/prealbumin was independently associated with mortality after adjustment for age, gender, sepsis and sequential organ failure assessment (SOFA, p = 0.027) while the others (CRP, albumin, prealbumin, cholesterol, CRP/albumin and CRP/cholesterol) became non-significantly associated. Cholesterol 288-299 C-reactive protein Homo sapiens 53-56 21440886-4 2011 On multivariate analysis, higher CRP levels were associated with older age, female gender, hypertension, current smoking, greater body mass index, larger waist circumference, LDL cholesterol level, and triglyceride/high-density lipoprotein cholesterol ratio. Triglycerides 202-214 C-reactive protein Homo sapiens 33-36 21663637-0 2011 Association between fasting plasma glucose and high-sensitivity C-reactive protein: gender differences in a Japanese community-dwelling population. Glucose 35-42 C-reactive protein Homo sapiens 64-82 21718488-0 2011 The relationship among adiponectin, high sensitive C reactive protein and triacylglycerol level in healthy young persons. Triglycerides 74-89 C-reactive protein Homo sapiens 51-69 21784308-0 2011 The relationships between erythrocyte membrane n-6 to n-3 polyunsaturated fatty acids ratio and blood lipids and C-reactive protein in Chinese adults: an observational study. Nitrogen 11-12 C-reactive protein Homo sapiens 113-131 21414625-9 2011 Increased CRP levels were an independent predictor of both abnormal FMD and IMT after adjusting for age, systolic and diastolic BP and total cholesterol. Cholesterol 141-152 C-reactive protein Homo sapiens 10-13 21736395-7 2011 There was a statistically significant difference(p < 0.01) in CRP serum levels from 21 to 8 mg/dl at week 48.Nine out of fifteen patients (60%) treated with corticosteroids were able to discontinue steroids. Steroids 167-175 C-reactive protein Homo sapiens 65-68 20817211-4 2011 On the other hand, we previously demonstrated that serum triglyceride (TG) per se is independently associated with CRP or insulin resistance in Japanese populations with a body mass index (BMI) of 21.5 to 27.0 (midrange BMI). Triglycerides 57-69 C-reactive protein Homo sapiens 115-118 20817211-4 2011 On the other hand, we previously demonstrated that serum triglyceride (TG) per se is independently associated with CRP or insulin resistance in Japanese populations with a body mass index (BMI) of 21.5 to 27.0 (midrange BMI). Triglycerides 71-73 C-reactive protein Homo sapiens 115-118 23154530-10 2011 Compared with participants with low CRP, those with elevated CRP were shown to have higher levels of obesity, blood pressure, triglyceride and insulin resistance (IR), but lower high-density lipoprotein cholesterol levels (all Ps<0.001). Triglycerides 126-138 C-reactive protein Homo sapiens 61-64 21575917-6 2011 To this aim, we developed a method to measure CRP in a DBS with a good correlation with CRP measurement in serum (r2=0.9927). dbs 55-58 C-reactive protein Homo sapiens 46-49 21575917-6 2011 To this aim, we developed a method to measure CRP in a DBS with a good correlation with CRP measurement in serum (r2=0.9927). dbs 55-58 C-reactive protein Homo sapiens 88-91 21411619-8 2011 CRP but not iron intake was a strong negative predictor of iron status, independently of BMI (P < 0.05). Iron 59-63 C-reactive protein Homo sapiens 0-3 21482278-1 2011 A novel, quantitative analytical method for measuring C-reactive protein (CRP) levels in human serum has been developed based on the catalytic activity of gold nanoparticles (GNPs) and luminol-H(2)O(2) chemiluminescence (CL). Luminol 185-192 C-reactive protein Homo sapiens 54-72 21482278-1 2011 A novel, quantitative analytical method for measuring C-reactive protein (CRP) levels in human serum has been developed based on the catalytic activity of gold nanoparticles (GNPs) and luminol-H(2)O(2) chemiluminescence (CL). Luminol 185-192 C-reactive protein Homo sapiens 74-77 21482278-2 2011 The CL intensity in the presence of CRP and its ligand, O-phosphorylethanolamine (PEA), was greatly enhanced due to the aggregation of GNPs after the addition of 0.5M NaCl. Sodium Chloride 167-171 C-reactive protein Homo sapiens 36-39 21740798-9 2011 C-reactive protein (CRP) was significantly lower in the HES group compared with the other groups. Hydroxyethyl Starch Derivatives 56-59 C-reactive protein Homo sapiens 0-18 21437516-9 2011 Using a backward conditional logistic regression model, age (p<0.001), diabetes (p= 0.001), and C-reactive protein levels >6 mg/L (p= 0.006) were associated with the presence of low AAI, whereas male gender (p<0.001), diabetes (p= 0.001) and elevated calcium x phosphorus product (p= 0.026) were associated with high AAI. Calcium 260-267 C-reactive protein Homo sapiens 99-117 21740798-9 2011 C-reactive protein (CRP) was significantly lower in the HES group compared with the other groups. Hydroxyethyl Starch Derivatives 56-59 C-reactive protein Homo sapiens 20-23 21045713-1 2011 OBJECTIVES: Short-term high-dose atorvastatin administered before percutaneous coronary intervention (PCI) reduces the rate of periprocedural myocardial infarction (pMI) in high-risk patients, such as those with acute coronary syndromes and those with elevated high-sensitivity C-reactive protein. Atorvastatin 33-45 C-reactive protein Homo sapiens 278-296 21406573-6 2011 Patients with high plasma concentrations of C-reactive protein and mice with acute inflammation induced by lipopolysaccharide had significant reductions of arginine metabolites in plasma compared with controls. Arginine 156-164 C-reactive protein Homo sapiens 44-62 21713097-11 2011 There was decrease in C-reactive protein (CRP) from 1.03+-0.72 mg/dL to 0.52+-0.22 mg/dL and that of malondialdehyde (MDA) from 11.20+-4.07 nmol/mL to 8.81+-2.79 nmol/mL with N-acetylcysteine treatment (P < 0.05). Acetylcysteine 175-191 C-reactive protein Homo sapiens 22-40 21713097-16 2011 There was decrease in CRP (a marker of inflammation) and MDA after treatment with N-acetylcysteine suggesting improvement in endothelial dysfunction. Acetylcysteine 82-98 C-reactive protein Homo sapiens 22-25 21713097-17 2011 There was reduction in CRP after treatment with atorvastatin, suggesting improvement in endothelial function. Atorvastatin 48-60 C-reactive protein Homo sapiens 23-26 21839006-3 2011 The results shown high levels of lipid in serum in 100 % of the patients, the highest levels of C-reactive protein corresponded with the highest levels of total cholesterol and LDL oxidized, it was suggested as a atherosclerotic disease risk. Cholesterol 161-172 C-reactive protein Homo sapiens 96-114 21364202-4 2011 Our results showed that CRP increased sLOX-1 release from activated macrophages in a dose-dependent manner and that these effects were regulated by Fc gamma receptor II (FcgammaRII)-mediated p47(phox) phosphorylation, reactive oxygen species (ROS) production, and TACE activation. Reactive Oxygen Species 218-241 C-reactive protein Homo sapiens 24-27 21364202-4 2011 Our results showed that CRP increased sLOX-1 release from activated macrophages in a dose-dependent manner and that these effects were regulated by Fc gamma receptor II (FcgammaRII)-mediated p47(phox) phosphorylation, reactive oxygen species (ROS) production, and TACE activation. Reactive Oxygen Species 243-246 C-reactive protein Homo sapiens 24-27 21364202-8 2011 Thus, CRP might stimulate sLOX-1 release, and the underlying mechanisms possibly involved FcgammaRII-mediated p47(phox) phosphorylation, ROS production, and TACE activation. Reactive Oxygen Species 137-140 C-reactive protein Homo sapiens 6-9 21176092-10 2011 Furthermore, Sirt1 and HNF-1alpha co-localize on two HNF-1alpha binding sites on the Crp promoter, leading to decreased acetylation of lysine 16 of histone H4 at these sites only in response to nutrient restriction. Lysine 135-141 C-reactive protein Homo sapiens 85-88 25961255-10 2011 (vi) In the multivariate model, age, BMI and CRP were independent predictors of the strongest benefit of testosterone treatment on the metabolic syndrome. Testosterone 105-117 C-reactive protein Homo sapiens 45-48 21267537-6 2011 RESULTS: Elevated high sensitivity CRP (hsCRP) levels were found to be associated with prediabetes after adjusting for age, sex, race-ethnicity, education, smoking, alcohol consumption, hypertension, BMI and total cholesterol. Alcohols 165-172 C-reactive protein Homo sapiens 35-38 21267537-6 2011 RESULTS: Elevated high sensitivity CRP (hsCRP) levels were found to be associated with prediabetes after adjusting for age, sex, race-ethnicity, education, smoking, alcohol consumption, hypertension, BMI and total cholesterol. Cholesterol 214-225 C-reactive protein Homo sapiens 35-38 21239514-6 2011 In addition, testosterone was positively associated with CRP (P = 0.006), IL-6 (P = 0.001), and TNF-alpha (P = 0.0002). Testosterone 13-25 C-reactive protein Homo sapiens 57-60 25961255-9 2011 (v) Higher baseline CRP predicted larger declines in levels of triglycerides, glucose and CRP. Triglycerides 63-76 C-reactive protein Homo sapiens 20-23 25961255-9 2011 (v) Higher baseline CRP predicted larger declines in levels of triglycerides, glucose and CRP. Glucose 78-85 C-reactive protein Homo sapiens 20-23 21412424-11 2011 Median levels of total cholesterol and C-reactive protein decreased in the atorvastatin group only (p<0.001 and p = 0.04). Atorvastatin 75-87 C-reactive protein Homo sapiens 39-57 21600162-17 2011 complicated with coronary artery disease & severe pulmonary hypertension, age, BMI and serum level of CRP are the independent risk factors of affecting the survival time from first hospitalization due to AECOPD. Adenosine Monophosphate 42-45 C-reactive protein Homo sapiens 106-109 21178976-7 2011 Patients with PEW and low ghrelin values had abnormally high C-reactive protein and leptin by multivariate analysis of variance, and the highest mortality risk compared to non-PEW with high ghrelin from all-cause and cardiovascular-related mortality (adjusted hazard ratios of 3.34 and 3.54, respectively). Ghrelin 26-33 C-reactive protein Homo sapiens 61-79 21327631-8 2011 Treatment with IVIG and aspirin significantly decreased TNF-alpha and hs-CRP concentrations. Aspirin 24-31 C-reactive protein Homo sapiens 73-76 21327631-10 2011 The results of our study indicate that the functions of circulating EPCs improved after treatment with IVIG and aspirin, which may be related to decreased concentrations of TNF-alpha and hs-CRP. Aspirin 112-119 C-reactive protein Homo sapiens 190-193 21179048-3 2011 We examined whether folate nutrition modifies the relationship between serum CRP concentration and gestational age at delivery. Folic Acid 20-26 C-reactive protein Homo sapiens 77-80 21350098-7 2011 There was a significant negative correlation between vitamin D levels and high-sensitivity C-reactive protein, NFkappaB activity, and TLR4 expression (P < .05). Vitamin D 53-62 C-reactive protein Homo sapiens 91-109 21169815-7 2011 Markers of the two groups were elevated after PCI; however, the higher values of creatine kinase-MB, cardiac troponin I, and high-sensitivity C-reactive protein in the atorvastatin treatment group were significantly lower than those in the placebo group (P<0.01). Atorvastatin 168-180 C-reactive protein Homo sapiens 142-160 21111512-0 2011 Serum lactate is a better predictor of short-term mortality when stratified by C-reactive protein in adult emergency department patients hospitalized for a suspected infection. Lactic Acid 6-13 C-reactive protein Homo sapiens 79-97 21179048-8 2011 Serum folate concentration was negatively correlated (P < 0.01) with serum CRP concentration, and total dietary folate intake was positively correlated (P < 0.001) with serum folate concentration. Folic Acid 6-12 C-reactive protein Homo sapiens 78-81 21179048-9 2011 Multiple regression analysis after adjustment for covariates revealed that maternal CRP concentrations were negatively associated with gestational age at delivery; these negative associations existed only when folate intake during pregnancy was below the Korean estimated average requirements (520 mug dietary folate equivalent per day), and serum folate concentrations were above the normal (6 ng/ml). Folic Acid 210-216 C-reactive protein Homo sapiens 84-87 21179048-9 2011 Multiple regression analysis after adjustment for covariates revealed that maternal CRP concentrations were negatively associated with gestational age at delivery; these negative associations existed only when folate intake during pregnancy was below the Korean estimated average requirements (520 mug dietary folate equivalent per day), and serum folate concentrations were above the normal (6 ng/ml). Folic Acid 310-316 C-reactive protein Homo sapiens 84-87 21179048-9 2011 Multiple regression analysis after adjustment for covariates revealed that maternal CRP concentrations were negatively associated with gestational age at delivery; these negative associations existed only when folate intake during pregnancy was below the Korean estimated average requirements (520 mug dietary folate equivalent per day), and serum folate concentrations were above the normal (6 ng/ml). Folic Acid 310-316 C-reactive protein Homo sapiens 84-87 21179048-10 2011 CONCLUSIONS: We found that adequate maternal folate intake during pregnancy may have a beneficial role against shorter gestational age at delivery, which is associated with higher serum CRP concentrations in pregnant women. Folic Acid 45-51 C-reactive protein Homo sapiens 186-189 21383592-5 2011 The further investigations indicated that rosiglitazone inhibited CRP-induced TLR4 expression and p38 MAPK phosphorylation in VSMCs, and TLR4 knockdown potentiated the inhibitory effects of rosiglitazone on vascular endothelial growth factor-A and inducible nitric oxide synthase expressions. Rosiglitazone 190-203 C-reactive protein Homo sapiens 66-69 21661448-4 2011 RESULTS: The serum CRP level was significantly higher in the ODG group than in the LADG group (p=0.007) on postoperative day (POD) 1. ladg 83-87 C-reactive protein Homo sapiens 19-22 21383592-6 2011 In addition, GR antagonist RU486 but not PPARgamma inhibitor GW9662 remarkably weakened the inhibitory effects of rosiglitazone on CRP-induced TLR4 expression and p38 phosphorylation in VSMCs. Rosiglitazone 114-127 C-reactive protein Homo sapiens 131-134 21383592-0 2011 Rosiglitazone regulates c-reactive protein-induced inflammatory responses via glucocorticoid receptor-mediated inhibition of p38 mitogen-activated protein kinase-toll-like receptor 4 signal pathway in vascular smooth muscle cells. Rosiglitazone 0-13 C-reactive protein Homo sapiens 24-42 21383592-3 2011 The present study was to explore the effect of rosiglitazone on the CRP-induced inflammatory responses and the related signal pathway in vascular smooth muscle cells (VSMCs). Rosiglitazone 47-60 C-reactive protein Homo sapiens 68-71 21383592-8 2011 These suggest that rosiglitazone exerts its anti-inflammatory effect through activating GR and subsequently inhibiting p38 MAPK-TLR4 signaling pathway in CRP-stimulated VSMCs. Rosiglitazone 19-32 C-reactive protein Homo sapiens 154-157 21383592-4 2011 The results showed that rosiglitazone reduced the expressions of proinflammatory cytokines, such as vascular endothelial growth factor-A and inducible nitric oxide synthase, and enhanced the expression or activation of anti-inflammatory transcription factors including PPARgamma and glucocorticoid receptor (GR) in VSMCs in response to CRP. Rosiglitazone 24-37 C-reactive protein Homo sapiens 336-339 21383592-5 2011 The further investigations indicated that rosiglitazone inhibited CRP-induced TLR4 expression and p38 MAPK phosphorylation in VSMCs, and TLR4 knockdown potentiated the inhibitory effects of rosiglitazone on vascular endothelial growth factor-A and inducible nitric oxide synthase expressions. Rosiglitazone 42-55 C-reactive protein Homo sapiens 66-69 20696680-7 2011 Five days after the IV administration of 200 mg iron sucrose, a significant increase of RTC was observed, only in those patients with elevated baseline CRP levels who also showed an increase in CHr levels from <= 31.2 pg at baseline to >= 31.2 pg post-administration, supporting the presence of an independent positive correlation between CRP and RTC when iron is adequate. Iron 48-52 C-reactive protein Homo sapiens 152-155 20696680-7 2011 Five days after the IV administration of 200 mg iron sucrose, a significant increase of RTC was observed, only in those patients with elevated baseline CRP levels who also showed an increase in CHr levels from <= 31.2 pg at baseline to >= 31.2 pg post-administration, supporting the presence of an independent positive correlation between CRP and RTC when iron is adequate. Iron 48-52 C-reactive protein Homo sapiens 345-348 21971662-10 2011 L-Ala-Gln pretreatment did not suppress the increase of IL-6, but reduced the increase of postoperative CRP levels (T5, p <0.01). l-ala-gln 0-9 C-reactive protein Homo sapiens 104-107 21034294-2 2011 In the present study, associations were explored between CRP haplotypes with plasma CRP concentrations and basal salivary cortisol level. Hydrocortisone 122-130 C-reactive protein Homo sapiens 57-60 21034294-6 2011 rs2808628, rs1205, rs1417938, and rs3091244 showed expected associations not only with CRP concentrations, but also with salivary cortisol levels during the CAR. Hydrocortisone 130-138 C-reactive protein Homo sapiens 87-90 21034294-8 2011 There was an inverse linear association between CRP haplotypes and cortisol levels during the CAR, but no association with the diurnal cortisol decline. Hydrocortisone 67-75 C-reactive protein Homo sapiens 48-51 21034294-9 2011 Hence, genetic variants in the CRP gene that are associated with lifetime plasma CRP levels were also associated with salivary cortisol levels after awakening, in basal, non-inflammatory conditions. Hydrocortisone 127-135 C-reactive protein Homo sapiens 31-34 21034294-9 2011 Hence, genetic variants in the CRP gene that are associated with lifetime plasma CRP levels were also associated with salivary cortisol levels after awakening, in basal, non-inflammatory conditions. Hydrocortisone 127-135 C-reactive protein Homo sapiens 81-84 21257003-2 2011 Our purpose was to compare the effects of maximum doses of rosuvastatin and atorvastatin on the plasma levels of the insulin, glycated albumin, adiponectin, and C-reactive protein compared to baseline in hyperlipidemic patients. Atorvastatin 76-88 C-reactive protein Homo sapiens 161-179 21257003-7 2011 Both atorvastatin and rosuvastatin caused significant (p <0.001) and similar median reductions in the C-reactive protein level of -40% and -26% compared to the baseline values. Atorvastatin 5-17 C-reactive protein Homo sapiens 105-123 21257003-9 2011 In conclusion, our data have indicated that the maximum dosage of atorvastatin or rosuvastatin therapy significantly lower C-reactive protein levels but also moderately increase insulin levels. Atorvastatin 66-78 C-reactive protein Homo sapiens 123-141 21223500-0 2011 Prognostic usefulness of high sensitivity C-reactive protein for transforaminal epidural steroid injection in patients with radicular pain. Steroids 89-96 C-reactive protein Homo sapiens 42-60 21223500-6 2011 The purpose of this study was to evaluate the usefulness of high sensitivity C-reactive protein (hsCRP) as a marker for predicting the efficacy of lumbar transforaminal epidural steroid injection. Steroids 178-185 C-reactive protein Homo sapiens 77-95 21076043-4 2011 Moreover, we observed a strong reduction of serum hepcidin in 5 patients treated with heparin to prevent deep vein thrombosis, which was accompanied by an increase of serum iron and a reduction of C-reactive protein levels. Heparin 86-93 C-reactive protein Homo sapiens 197-215 20221887-12 2011 CRP (p < 0.001) was an independent determinant of oestradiol. Estradiol 53-63 C-reactive protein Homo sapiens 0-3 20682616-5 2011 Cross-sectionally, higher C-reactive protein (CRP) levels correlated with lower levels of total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), and high-density lipoprotein-cholesterol ([HDL-C] P <= .015), whereas lipid ratios did not correlate with CRP. Cholesterol 96-107 C-reactive protein Homo sapiens 26-44 20682616-5 2011 Cross-sectionally, higher C-reactive protein (CRP) levels correlated with lower levels of total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), and high-density lipoprotein-cholesterol ([HDL-C] P <= .015), whereas lipid ratios did not correlate with CRP. Cholesterol 96-107 C-reactive protein Homo sapiens 46-49 21208678-7 2011 The risk profile in the low-glucose group could not be accounted for by age, smoking status, systolic blood pressure or fasting insulin levels but tended to show higher levels of circulating C-reactive protein. Glucose 28-35 C-reactive protein Homo sapiens 191-209 21283780-7 2011 Our combined computational and experimental study showed that the antimicrobial response is sensitive to changes in pH and calcium levels, which determines the strength of the crosstalk between CRP and L-ficolin. Calcium 123-130 C-reactive protein Homo sapiens 194-197 21226927-19 2011 The following factors correlated with the risk of ASA low response: patients with elevated hemoglobin, serum creatinine and C-reactive protein values. Aspirin 50-53 C-reactive protein Homo sapiens 124-142 21298210-0 2011 ASCOT analysis with atorvastatin shows limits of CRP as indicator of cardiovascular risk. Atorvastatin 20-32 C-reactive protein Homo sapiens 49-52 21091174-2 2011 Iron metabolism can be described by a combination of biochemical soluble transferrin receptor, ferritin, C-reactive protein (CRP), and hematological parameters. Iron 0-4 C-reactive protein Homo sapiens 105-123 21091174-2 2011 Iron metabolism can be described by a combination of biochemical soluble transferrin receptor, ferritin, C-reactive protein (CRP), and hematological parameters. Iron 0-4 C-reactive protein Homo sapiens 125-128 21519150-4 2011 METHODS AND RESULTS: DM was induced in male wild-type mice (Wt/DM) and CRP-Tg (CRP/DM) by an injection of streptozotocin. Streptozocin 106-120 C-reactive protein Homo sapiens 71-74 21325823-9 2011 These demonstrate that Ang II is capable of inducing CRP generation in macrophages via AT(1)-ROS-ERK1/2/p38MAPK-NF-kappaB signal pathway, which contributes to better understanding of the proinflammatory and proatherosclerotic actions of Ang II. Reactive Oxygen Species 93-96 C-reactive protein Homo sapiens 53-56 21044014-4 2011 Cholesterol lowering by HMG-CoA reductase (statin) is beneficial for treating atherosclerotic coronary artery disease and stroke, together with reducing a surrogate-marker of inflammation, C-reactive protein (CRP). Cholesterol 0-11 C-reactive protein Homo sapiens 189-207 21166598-0 2011 The effect of aspirin on C-reactive protein in hypertensive patients. Aspirin 14-21 C-reactive protein Homo sapiens 25-43 21166598-2 2011 Aspirin, which has both anti-inflammatory and anti-thrombotic effects, has the potential to influence CRP release. Aspirin 0-7 C-reactive protein Homo sapiens 102-105 21166598-3 2011 Several studies have been reported investigating clinical effects of aspirin on CRP levels. Aspirin 69-76 C-reactive protein Homo sapiens 80-83 21166598-4 2011 Some studies have reported aspirin reduced CRP levels, but other studies did not. Aspirin 27-34 C-reactive protein Homo sapiens 43-46 21166598-5 2011 This study was designed to assess the effect of low-dose aspirin on CRP levels in controlled hypertensive patients who had low inflammatory burden. Aspirin 57-64 C-reactive protein Homo sapiens 68-71 20874770-0 2011 Gender differences in the association of C-reactive protein with coronary artery calcium in type-2 diabetes. Calcium 81-88 C-reactive protein Homo sapiens 41-59 20874770-3 2011 We examined whether CRP has gender differences in association with coronary artery calcium (CAC) in diabetic and nondiabetic samples without clinical CVD. Calcium 83-90 C-reactive protein Homo sapiens 20-23 21044014-4 2011 Cholesterol lowering by HMG-CoA reductase (statin) is beneficial for treating atherosclerotic coronary artery disease and stroke, together with reducing a surrogate-marker of inflammation, C-reactive protein (CRP). Cholesterol 0-11 C-reactive protein Homo sapiens 209-212 21074760-16 2011 CONCLUSION: The combination of low albumin and high CRP levels indicates a substantially increased short-term mortality risk after PEG, which should be considered in decision making. Polyethylene Glycols 131-134 C-reactive protein Homo sapiens 52-55 21262869-7 2011 While insulin secretion is strictly related to BMI, apart from glucose levels, increased glucose values can be mainly related to the acute inflammatory response (as indicated to leukocyte count and C-RP), to age and to the degree of myocardial damage (as inferred by CK-MB). Glucose 89-96 C-reactive protein Homo sapiens 198-202 20967757-5 2011 hCRP was associated with impaired insulin suppression of endogenous glucose production with no reduction in peripheral tissue glucose uptake, suggesting that hCRP mediated insulin resistance in the liver but not extrahepatic tissues. Glucose 68-75 C-reactive protein Homo sapiens 0-4 20664179-10 2011 C-reactive protein during testosterone therapy had a significant association with HV at T6 (r = -0.786; p = 0.021). Testosterone 26-38 C-reactive protein Homo sapiens 0-18 20967757-7 2011 Liver tissues derived from hCRP-treated rats showed reduced insulin-stimulated insulin receptor substrate (IRS) tyrosine phosphorylation, IRS/phosphatidylinositol 3-kinase (PI3K) association, and Akt phosphorylation, consistent with hCRP-induced impairment of hepatic insulin signaling. Tyrosine 112-120 C-reactive protein Homo sapiens 27-31 20967757-8 2011 Furthermore, hCRP enhanced phosphorylation of extracellular signal-regulated kinase (ERK)1/2 and p38 MAPK as well as IRS-1 Ser(612) . Serine 123-126 C-reactive protein Homo sapiens 13-17 22247668-4 2011 The detection principle is demonstrated with a time-resolved fluorescence immunoassay for the detection of C-reactive protein (CRP) using CdSe-ZnS nanoparticles and green light excitation. Zinc 143-146 C-reactive protein Homo sapiens 107-125 21321461-6 2011 Atorvastatin significantly reduced the incidence of postoperative AF and postoperative peak CRP level versus placebo (18% versus 41%, P = 0.017; 129.3 +- 24.3 mg/L versus 149.3 +- 32.5 mg/L, P < 0.0001). Atorvastatin 0-12 C-reactive protein Homo sapiens 92-95 21142464-10 2011 On POD 3, the mean serum creatine phosphokinase level was significantly lower in the LSPSL group (126 +- 93 U/L) than in the other group (207 +- 150 U/L) (p = 0.02); on POD 7, the mean serum C-reactive protein level was significantly lower in the LSPSL group (1.1 +- 0.6 mg/dl) than in the conventional laminectomy group (1.9 +- 1.5 mg/dl) (p = 0.04). lspsl 85-90 C-reactive protein Homo sapiens 191-209 21602602-4 2011 Furthermore, m(r)CRP (100 mug/ml) strongly augmented spontaneous and ADP-induced fibrinogen binding to platelets (p < 0.05), platelet adhesion to fibrinogen and platelet aggregation. Adenosine Diphosphate 69-72 C-reactive protein Homo sapiens 17-20 21943003-7 2011 Therapy with 10 mg/day atorvastatin was more effective in carriers of polymorphic marker Trp719Arg of KIF6 gene by action on dynamics of changes of high sensitivity C-reactive protein and dispersion of high density lipoprotein response. Atorvastatin 23-35 C-reactive protein Homo sapiens 165-183 22247668-4 2011 The detection principle is demonstrated with a time-resolved fluorescence immunoassay for the detection of C-reactive protein (CRP) using CdSe-ZnS nanoparticles and green light excitation. Zinc 143-146 C-reactive protein Homo sapiens 127-130 21094359-6 2010 WC and the CRP rs1205 polymorphism showed the strongest relations with hsCRP, and in multiple regression analysis, gender, WC, diabetes, triglycerides, HDL cholesterol, and the 3 genetic variants explained 35.5% of the variance in hsCRP levels. Cholesterol 156-167 C-reactive protein Homo sapiens 11-14 21197412-1 2010 We hypothesized that soy isoflavones would attenuate the anticipated increase in androidal fat mass in postmenopausal women during the 36-month treatment, and thereby favorably modify the circulating cardiometabolic risk factors: triacylglycerol, LDL-C, HDL-C, glucose, insulin, uric acid, C-reactive protein, fibrinogen, and homocysteine. Isoflavones 25-36 C-reactive protein Homo sapiens 290-308 21094359-7 2010 The 2 CRP polymorphisms, female gender, higher WC, and lower HDL cholesterol were associated with risk for having CRP concentrations >= 1 mg/L. Cholesterol 65-76 C-reactive protein Homo sapiens 114-117 20388917-8 2010 In the NAC group, the levels of ALP, GGT, WBC, CRP, and NE% decreased significantly (P < .001), whereas a significant decrease did not occur in the placebo group. Acetylcysteine 7-10 C-reactive protein Homo sapiens 47-50 20926154-2 2010 Here we present an updated meta-analysis of the respective effects of rosiglitazone and pioglitazone on the levels of C-reactive protein (CRP), a biomarker and predictor of CAD risks. Rosiglitazone 70-83 C-reactive protein Homo sapiens 118-136 20926154-2 2010 Here we present an updated meta-analysis of the respective effects of rosiglitazone and pioglitazone on the levels of C-reactive protein (CRP), a biomarker and predictor of CAD risks. Rosiglitazone 70-83 C-reactive protein Homo sapiens 138-141 20926154-10 2010 CONCLUSIONS: Our meta-analysis suggested that both rosiglitazone and pioglitazone significantly decrease serum CRP levels. Rosiglitazone 51-64 C-reactive protein Homo sapiens 111-114 21125208-10 2010 After adjusting for potentially confounding variables by multiple regression, significant positive relationship between SCu and CRP was found, indicating that elevated levels of Cu could have influence on inflammatory mechanisms. Copper 121-123 C-reactive protein Homo sapiens 128-131 20843942-8 2010 Associations with 1- and 2-h plasma glucose remained significant for adiponectin (P<0.001), PAI-1 (P<0.05), and CRP (P<0.01) after adjustment for BMI and C-peptide. Glucose 36-43 C-reactive protein Homo sapiens 118-121 20838744-6 2010 The primary outcome measure of this retrospective study was the ADP-induced platelet aggregation in patients with versus those without elevated CRP levels. Adenosine Diphosphate 64-67 C-reactive protein Homo sapiens 144-147 21078191-7 2010 Lower HDL cholesterol, impaired glucose tolerance (IGT), and higher diastolic blood pressure were associated with having a high CRP in both men and women, while current smoking was associated with high CRP in men but not women. Cholesterol 10-21 C-reactive protein Homo sapiens 128-131 20843812-2 2010 At physiological pH, native pentameric CRP exhibits calcium-dependent binding specificity for phosphocholine. Calcium 52-59 C-reactive protein Homo sapiens 39-42 20728084-8 2010 Levels of IL-6, RANTES, and CRP correlated well with ADP and arachidonic acid (AA)-induced MEA. Adenosine Diphosphate 53-56 C-reactive protein Homo sapiens 28-31 19411120-0 2010 Total cholesterol content of erythrocyte membranes levels are associated with the presence of acute coronary syndrome and high sensitivity C-reactive protein. Cholesterol 6-17 C-reactive protein Homo sapiens 139-157 19411120-1 2010 In this study we assessed whether total cholesterol content of erythrocyte membranes (CEM) was associated with the presence of acute coronary syndrome (ACS) and high sensitivity C-reactive protein (hs-CRP). Cholesterol 40-51 C-reactive protein Homo sapiens 178-196 20728084-8 2010 Levels of IL-6, RANTES, and CRP correlated well with ADP and arachidonic acid (AA)-induced MEA. Arachidonic Acid 61-77 C-reactive protein Homo sapiens 28-31 20494902-6 2010 High-sensitivity C-reactive protein fell by 40% in patients receiving atorvastatin but there was no change with amlodipine. Atorvastatin 70-82 C-reactive protein Homo sapiens 17-35 21273686-6 2010 All three biomarkers of inflammation significantly decreased after atorvastatin: CRP from 4.08 +- 3.72 to 2.97 +- 3.26 mug/ml (p < 0.05), IL-6 from 20.66 +- 20.05 to 13.36 +- 11.21 pg/ml (p < 0.05) and MCP-1 from 271.08 +- 85.72 to 213.24 +- 115.09 pg/ml (p < 0.05). Atorvastatin 67-79 C-reactive protein Homo sapiens 81-84 20720257-10 2010 Serum ferritin (P = 0.045) and C-reactive protein (P = 0.018) decreased in lysine-supplemented women but increased in placebo-supplemented women. Lysine 75-81 C-reactive protein Homo sapiens 31-49 20842713-5 2010 Biochemical experiments confirmed the predicted binding site for UO(2) (2+) and it was demonstrated by surface plasmon resonance assays that UO(2) (2+) binding to CRP prevents the calcium-mediated binding of phosphorylcholine. Calcium 180-187 C-reactive protein Homo sapiens 163-166 20842713-7 2010 This result exemplifies in the case of CRP the capability of our computational tool to predict effective binding sites for UO(2) (2+) in proteins and is a first evidence of calcium substitution by the uranyl cation in a native protein. Calcium 173-180 C-reactive protein Homo sapiens 39-42 20850446-4 2010 The ELISA uses readily available monoclonal antibodies to measure CRP in serum, plasma, or dried blood spots (DBS) made from venous or capillary blood. dbs 110-113 C-reactive protein Homo sapiens 66-69 20850446-11 2010 Our results indicate that DBS CRP is less stable than previously reported. dbs 26-29 C-reactive protein Homo sapiens 30-33 20920644-2 2010 Conflicting evidence is available regarding whether aspirin can reduce CRP after ACS. Aspirin 52-59 C-reactive protein Homo sapiens 71-74 20920644-3 2010 We investigated whether the dosage and adherence to aspirin was associated with the CRP level 3 months after ACS. Aspirin 52-59 C-reactive protein Homo sapiens 84-87 20920644-6 2010 Logistic regression analysis was used to test whether poor adherence to aspirin and a lower aspirin dosage were associated with increased CRP levels, controlling for age, ACS type, disease co-morbidity, baseline CRP level, use of clopidogrel and statins, depressive symptoms, smoking, and adherence to other medications. Aspirin 72-79 C-reactive protein Homo sapiens 138-141 20920644-6 2010 Logistic regression analysis was used to test whether poor adherence to aspirin and a lower aspirin dosage were associated with increased CRP levels, controlling for age, ACS type, disease co-morbidity, baseline CRP level, use of clopidogrel and statins, depressive symptoms, smoking, and adherence to other medications. Aspirin 92-99 C-reactive protein Homo sapiens 138-141 20920644-7 2010 Aspirin adherence was inversely correlated with the CRP level at 3 months (Spearman"s r = -0.36, p < 0.001). Aspirin 0-7 C-reactive protein Homo sapiens 52-55 20920644-8 2010 In the adjusted model, every 10% decrease in aspirin adherence was associated with a 1.7 increased risk (95% confidence interval 1.2 to 2.4) of a CRP level of >= 3.0 mg/L at 3 months. Aspirin 45-52 C-reactive protein Homo sapiens 146-149 20920644-9 2010 Low-dose aspirin was associated with a 7.1 increased risk (95% confidence interval 1.5 to 33.3) of a CRP level of >= 3.0 mg/L. Aspirin 9-16 C-reactive protein Homo sapiens 101-104 20920644-11 2010 The association between aspirin adherence and CRP level was not attenuated by controlling for other risk-reducing behaviors. Aspirin 24-31 C-reactive protein Homo sapiens 46-49 20920644-12 2010 In conclusion, a strong association was found between aspirin adherence and the CRP level after an ACS. Aspirin 54-61 C-reactive protein Homo sapiens 80-83 22577421-8 2010 RESULTS: CRP significantly reduced the susceptibility of Cu(++) -induced LDL oxidation through increasing the lag timeand there was positive relationship between these findings and CRP concentration (P < 0.05). Copper 57-63 C-reactive protein Homo sapiens 9-12 22577421-8 2010 RESULTS: CRP significantly reduced the susceptibility of Cu(++) -induced LDL oxidation through increasing the lag timeand there was positive relationship between these findings and CRP concentration (P < 0.05). Copper 57-63 C-reactive protein Homo sapiens 181-184 21088754-8 2010 Serum sodium inversely correlated with % neutrophils, CRP, and NT-proBNP, and positively correlated with T3 and albumin. Sodium 6-12 C-reactive protein Homo sapiens 54-57 21244768-5 2010 CRP and homocysteine levels were higher in patients with psoriasis than in controls (5.9 +- 7.1 vs 3.1 +- 2.4 mg/L, p=0.0003 and 16.3 +- 12.8 vs 10.4 +- 4.6 umol/L, p=0.0001; mean +- SD) whereas folic acid was lower in psoriatic patients compared to controls (4.3 +- 7.2 vs 12.6 +- 7.9 p=0.006). Folic Acid 195-205 C-reactive protein Homo sapiens 0-3 20883417-2 2010 Five intervention studies using flaxseed lignan supplements indicated beneficial associations with C-reactive protein, and a meta-analysis that included these studies also suggested lignans have a lowering effect on plasma total and low-density lipoprotein cholesterol. Lignans 41-47 C-reactive protein Homo sapiens 99-117 20683528-0 2010 Electrogenerated chemiluminescence determination of C-reactive protein with carboxyl CdSe/ZnS core/shell quantum dots. Zinc 90-93 C-reactive protein Homo sapiens 52-70 20837300-8 2010 A significant correlation was observed between total hydroperoxides and C-reactive protein in all patients, indicating an association between inflammation and oxidative stress during asphyxia. Hydrogen Peroxide 53-67 C-reactive protein Homo sapiens 72-90 20683528-9 2010 Much stronger ECL responses were observed from the Au/CD electrode, at which a dynamic range of 1.0-10.0 microg mL(-1) CRP and a limit of detection of 1.0 microg mL(-1) CRP were obtained, respectively. Cadmium 54-56 C-reactive protein Homo sapiens 119-122 20683528-9 2010 Much stronger ECL responses were observed from the Au/CD electrode, at which a dynamic range of 1.0-10.0 microg mL(-1) CRP and a limit of detection of 1.0 microg mL(-1) CRP were obtained, respectively. Cadmium 54-56 C-reactive protein Homo sapiens 169-172 20538278-11 2010 The further study indicated that losartan, NAC, PD98059, SP600125 significantly inhibited ERK1/2 and JNK phosphorylation, and PD98059, SP600125, PDTC completely antagonized AngII-induced CRP expression in HAECs. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 48-55 C-reactive protein Homo sapiens 187-190 20737615-9 2010 In neither cohort was CRP significantly related to glucose or blood lipids. Glucose 51-58 C-reactive protein Homo sapiens 22-25 20826253-8 2010 In multivariable models, waist circumference (P < .001) and triglycerides (P < .05), but no markers of smoking intensity, were associated with log(CRP). Triglycerides 63-76 C-reactive protein Homo sapiens 153-156 20809989-0 2010 Increased levels of CRP and MCP-1 are associated with previously unknown abnormal glucose regulation in patients with acute STEMI: a cohort study. Glucose 82-89 C-reactive protein Homo sapiens 20-23 20809989-8 2010 High levels of CRP (>= 75 percentiles (33.13 mg/L)) and MCP-1 (>= 25 percentiles (190 ug/mL)) were associated with abnormal glucose regulation with an adjusted OR of 3.2 (95% CI 1.5, 6.8) and 7.6 (95% CI 1.7, 34.2), respectively. Glucose 130-137 C-reactive protein Homo sapiens 15-18 20809989-9 2010 CONCLUSION: Elevated levels of CRP and MCP-1 measured in patients early after an acute STEMI were associated with abnormal glucose regulation classified by an OGTT at three-month follow-up. Glucose 123-130 C-reactive protein Homo sapiens 31-34 20538278-11 2010 The further study indicated that losartan, NAC, PD98059, SP600125 significantly inhibited ERK1/2 and JNK phosphorylation, and PD98059, SP600125, PDTC completely antagonized AngII-induced CRP expression in HAECs. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 126-133 C-reactive protein Homo sapiens 187-190 20538278-12 2010 CONCLUSIONS: The present study demonstrates that AngII has ability to induce CRP expression in HAECs through AT(1)-ROS-ERK1/2 and JNK-NF-kappaB signal pathway, which strengthens understanding of the proinflammatory and proathroscerotic actions of AngII. Reactive Oxygen Species 115-118 C-reactive protein Homo sapiens 77-80 20805273-0 2010 Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with type 2 diabetes. Atorvastatin 21-33 C-reactive protein Homo sapiens 63-81 19937362-9 2010 There was also significant reductions in serum C reactive protein levels in both sibutramine (P = 0.045, P = 0.02) and sibutramine plus metformin groups (P = 0.007, P = 0.001) after 3 and 12 months, respectively. Metformin 136-145 C-reactive protein Homo sapiens 47-65 20805273-7 2010 CRP of individuals taking atorvastatin was significantly lower than when they were taking simvastatin (median 1.08 vs. 1.47 mg/l, P = 0.0002) and was less variable (median SD of logCRP 0.0036 vs. 0.178, P = 0.0001). Atorvastatin 26-38 C-reactive protein Homo sapiens 0-3 20180088-7 2010 RESULTS: For each unit increase in the depression score, the odds ratio for elevated hs-CRP (i.e., > or =90th percentile value of the age- and sex-specific CRP distribution) was 1.06 (95% confidence interval 0.79, 1.42) after adjustment for age, sex, ever smoked, language, body mass index, physical inactivity, use of medication, total cholesterol concentration, triglycerides concentration, and systolic blood pressure. Cholesterol 340-351 C-reactive protein Homo sapiens 88-91 20545993-9 2010 RESULTS: The baseline characteristics of patients were similar among three groups; however, high-sensitive C-reactive protein (hs-CRP) levels were lower in atorvastatin group than placebo group. Atorvastatin 156-168 C-reactive protein Homo sapiens 107-125 20180088-7 2010 RESULTS: For each unit increase in the depression score, the odds ratio for elevated hs-CRP (i.e., > or =90th percentile value of the age- and sex-specific CRP distribution) was 1.06 (95% confidence interval 0.79, 1.42) after adjustment for age, sex, ever smoked, language, body mass index, physical inactivity, use of medication, total cholesterol concentration, triglycerides concentration, and systolic blood pressure. Triglycerides 367-380 C-reactive protein Homo sapiens 88-91 20490917-7 2010 The KYN/TRP ratio at admission correlated with CRP levels, ESR and NLR. Tryptophan 8-11 C-reactive protein Homo sapiens 47-50 20550971-17 2010 Elevated POD#5 uTxB2 and pre-operative CRP were correlated with thrombosis in aspirin treated subjects. Aspirin 78-85 C-reactive protein Homo sapiens 39-42 20814119-7 2010 There was an increase of MDA (21.97 + 3.65% vs 7.06 + 3.65%) and highly sensitive C-reactive protein (HsCRP) (11.19 + 24.63% vs 13.19 + 7.7%) after iron administration both in the placebo and the NAC groups. Iron 148-152 C-reactive protein Homo sapiens 82-100 20111016-4 2010 Levels of CRP correlated positively with body weight, BMI, waist circumference (WC), fasting plasma glucose and interleukin (IL)-6, and negatively with high-density lipoprotein cholesterol and adiponectin in healthy males. Glucose 100-107 C-reactive protein Homo sapiens 10-13 22371803-7 2010 A correlation was found between sodium admission values and: a) C-reactive protein (p = 0.000), and b) leukocyte count (p = 0.006). Sodium 32-38 C-reactive protein Homo sapiens 64-82 20457869-5 2010 Phosphatidylserine (PS) exposure was similarly decreased in response to thrombin, CRP, or CRP + PAR4 peptide despite a normal platelet phospholipid composition. Phosphatidylserines 0-18 C-reactive protein Homo sapiens 82-85 20457869-5 2010 Phosphatidylserine (PS) exposure was similarly decreased in response to thrombin, CRP, or CRP + PAR4 peptide despite a normal platelet phospholipid composition. Phosphatidylserines 0-18 C-reactive protein Homo sapiens 90-93 20457869-5 2010 Phosphatidylserine (PS) exposure was similarly decreased in response to thrombin, CRP, or CRP + PAR4 peptide despite a normal platelet phospholipid composition. Phosphatidylserines 20-22 C-reactive protein Homo sapiens 82-85 20457869-5 2010 Phosphatidylserine (PS) exposure was similarly decreased in response to thrombin, CRP, or CRP + PAR4 peptide despite a normal platelet phospholipid composition. Phosphatidylserines 20-22 C-reactive protein Homo sapiens 90-93 20734449-8 2010 RESULTS: At survival analysis, both CRP and ACR were associated with increased risk of 10-year all-cause mortality, also after adjusting for age, hypertension, diabetes mellitus, prehospital time delay, creatine kinase-MB isoenzyme peak, heart failure, and creatinine clearance. Creatinine 257-267 C-reactive protein Homo sapiens 36-39 21063486-10 2010 CONCLUSION: CHC patients had a higher hs-CRP level than healthy controls which could be ameliorated after peginterferon/ribavirin combination therapy. peginterferon 106-119 C-reactive protein Homo sapiens 41-44 20346059-0 2010 Puerarin inhibits C-reactive protein expression via suppression of nuclear factor kappaB activation in lipopolysaccharide-induced peripheral blood mononuclear cells of patients with stable angina pectoris. puerarin 0-8 C-reactive protein Homo sapiens 18-36 20346059-2 2010 In this report, we examined the ability of puerarin to modulate C-reactive protein (CRP) expression and key molecules in the nuclear factor kappa B (NF-kappaB) pathway to determine its molecular target. puerarin 43-51 C-reactive protein Homo sapiens 64-82 20346059-2 2010 In this report, we examined the ability of puerarin to modulate C-reactive protein (CRP) expression and key molecules in the nuclear factor kappa B (NF-kappaB) pathway to determine its molecular target. puerarin 43-51 C-reactive protein Homo sapiens 84-87 20346059-5 2010 The results indicated that puerarin inhibited the expression of the protein and mRNA levels of CRP in LPS-induced peripheral blood mononuclear cells. puerarin 27-35 C-reactive protein Homo sapiens 95-98 20484148-8 2010 Estrogen caused a variable response in CRP expression that was positively associated with the plasma small dense LDL-cholesterol concentration of the donors. Cholesterol 117-128 C-reactive protein Homo sapiens 39-42 20484132-7 2010 When all MetS traits were considered simultaneously, only low HDL cholesterol proved independently associated with CRP (F = 44.19; P < 0.001). Cholesterol 66-77 C-reactive protein Homo sapiens 115-118 20891039-1 2010 Laser correlation spectroscopy has indicated that plasma C-reactive protein (CRP) is present as a monomer and a pentamer (pentraxin); the latter is similar in physicochemical properties to apolipoproteins, the proteins that transfer fatty acids as nonpolar triglycerides to the cells in the intercellular medium. Fatty Acids 233-244 C-reactive protein Homo sapiens 57-75 20206981-13 2010 CONCLUSIONS: Determination of CRP in patients with renal colic due to urolithiasis provides an objective and useful parameter for deciding placement of urinary stent, which is even more valuable than leukocytosis or seric creatinine level. Creatinine 222-232 C-reactive protein Homo sapiens 30-33 20845101-11 2010 Dexamethasone significantly reduced postoperative levels of CRP (p = 0.01), IL-6 and IL-1 (p < 0.05), fatigue (p = 0.01) and overall pain during the first 24 postoperative hours (p < 0.05) and the total requirement of analgesic (ketorolac) (p < 0.05). Dexamethasone 0-13 C-reactive protein Homo sapiens 60-63 20891039-1 2010 Laser correlation spectroscopy has indicated that plasma C-reactive protein (CRP) is present as a monomer and a pentamer (pentraxin); the latter is similar in physicochemical properties to apolipoproteins, the proteins that transfer fatty acids as nonpolar triglycerides to the cells in the intercellular medium. Fatty Acids 233-244 C-reactive protein Homo sapiens 77-80 20891039-1 2010 Laser correlation spectroscopy has indicated that plasma C-reactive protein (CRP) is present as a monomer and a pentamer (pentraxin); the latter is similar in physicochemical properties to apolipoproteins, the proteins that transfer fatty acids as nonpolar triglycerides to the cells in the intercellular medium. Triglycerides 257-270 C-reactive protein Homo sapiens 57-75 20891039-1 2010 Laser correlation spectroscopy has indicated that plasma C-reactive protein (CRP) is present as a monomer and a pentamer (pentraxin); the latter is similar in physicochemical properties to apolipoproteins, the proteins that transfer fatty acids as nonpolar triglycerides to the cells in the intercellular medium. Triglycerides 257-270 C-reactive protein Homo sapiens 77-80 20891039-4 2010 Two different immunochemical assays for CRP suggest that the CRP-monomere and the CRP-pentamere show different functional activity: the CRP-monomere is a humoral immunomodulator while the CRP-pentamere also activates interstitial tissue cells, but differently, by enhancing their energy provision with substrates, namely with saturated and unsaturated fatty acids as triglycerides as components of very low-density lipoproteins via CRP/apoB-100-receptor endocytosis. Triglycerides 367-380 C-reactive protein Homo sapiens 40-43 20891039-4 2010 Two different immunochemical assays for CRP suggest that the CRP-monomere and the CRP-pentamere show different functional activity: the CRP-monomere is a humoral immunomodulator while the CRP-pentamere also activates interstitial tissue cells, but differently, by enhancing their energy provision with substrates, namely with saturated and unsaturated fatty acids as triglycerides as components of very low-density lipoproteins via CRP/apoB-100-receptor endocytosis. Triglycerides 367-380 C-reactive protein Homo sapiens 61-64 20891039-4 2010 Two different immunochemical assays for CRP suggest that the CRP-monomere and the CRP-pentamere show different functional activity: the CRP-monomere is a humoral immunomodulator while the CRP-pentamere also activates interstitial tissue cells, but differently, by enhancing their energy provision with substrates, namely with saturated and unsaturated fatty acids as triglycerides as components of very low-density lipoproteins via CRP/apoB-100-receptor endocytosis. Triglycerides 367-380 C-reactive protein Homo sapiens 61-64 20891039-4 2010 Two different immunochemical assays for CRP suggest that the CRP-monomere and the CRP-pentamere show different functional activity: the CRP-monomere is a humoral immunomodulator while the CRP-pentamere also activates interstitial tissue cells, but differently, by enhancing their energy provision with substrates, namely with saturated and unsaturated fatty acids as triglycerides as components of very low-density lipoproteins via CRP/apoB-100-receptor endocytosis. Triglycerides 367-380 C-reactive protein Homo sapiens 61-64 20891039-4 2010 Two different immunochemical assays for CRP suggest that the CRP-monomere and the CRP-pentamere show different functional activity: the CRP-monomere is a humoral immunomodulator while the CRP-pentamere also activates interstitial tissue cells, but differently, by enhancing their energy provision with substrates, namely with saturated and unsaturated fatty acids as triglycerides as components of very low-density lipoproteins via CRP/apoB-100-receptor endocytosis. Triglycerides 367-380 C-reactive protein Homo sapiens 61-64 20891039-4 2010 Two different immunochemical assays for CRP suggest that the CRP-monomere and the CRP-pentamere show different functional activity: the CRP-monomere is a humoral immunomodulator while the CRP-pentamere also activates interstitial tissue cells, but differently, by enhancing their energy provision with substrates, namely with saturated and unsaturated fatty acids as triglycerides as components of very low-density lipoproteins via CRP/apoB-100-receptor endocytosis. Triglycerides 367-380 C-reactive protein Homo sapiens 61-64 20891039-7 2010 In the arterial intima, the functionally triglyceride-overloaded resident macrophages form lipid spots that form in each systemic inflammatory response or with the elevated plasma levels of a CRP-pentamere and phospholipase A, and are directly unrelated to atheromatosis. Triglycerides 41-53 C-reactive protein Homo sapiens 192-195 19201044-0 2010 C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. Atorvastatin 178-190 C-reactive protein Homo sapiens 0-18 19201044-0 2010 C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. Atorvastatin 178-190 C-reactive protein Homo sapiens 20-23 19201044-6 2010 Further, atorvastatin was used as a therapeutic modality for modulation of these genes in the presence of CRP. Atorvastatin 9-21 C-reactive protein Homo sapiens 106-109 19201044-9 2010 Effect of atorvastatin was also determined in the presence of CRP on the expression of these genes. Atorvastatin 10-22 C-reactive protein Homo sapiens 62-65 19201044-12 2010 Atorvastatin in a dose of 20 muM, was able to attenuate up-regulation of CRP-induced genes (p<0.01) and effects were both dose and time-dependent. Atorvastatin 0-12 C-reactive protein Homo sapiens 73-76 19217176-3 2010 We investigated the effect of atorvastatin, across its dose range, on high sensitivity (hs)CRP in subjects at high cardiovascular risk. Atorvastatin 30-42 C-reactive protein Homo sapiens 91-94 20618287-7 2010 After adjusting for age, sex, total cholesterol, systolic blood pressure, smoking status, diabetes, BMI and waist circumference, the association between CRP and CVD remained significant, with a hazard ratio of 2.40 (95% CI: 1.25, 4.62) for the higher CRP group relative to the lower CRP group. Cholesterol 36-47 C-reactive protein Homo sapiens 153-156 19965803-5 2010 The presence of an arginine instead of a histidine residue at amino acid position 131 (H131R) in the extracellular domain of FcgammaRIIa reduces the affinity of the receptor for IgG(2) and IgG(3) isotypes but increases the binding activity for C reactive protein (CRP). Arginine 19-27 C-reactive protein Homo sapiens 244-262 20421792-5 2010 RECENT FINDINGS: Inflammation, as measured by C-reactive protein (CRP), has been established as an independent cardiovascular risk factor, even in persons with low-density lipoprotein (LDL)-cholesterol. Cholesterol 190-201 C-reactive protein Homo sapiens 66-69 19965803-5 2010 The presence of an arginine instead of a histidine residue at amino acid position 131 (H131R) in the extracellular domain of FcgammaRIIa reduces the affinity of the receptor for IgG(2) and IgG(3) isotypes but increases the binding activity for C reactive protein (CRP). Arginine 19-27 C-reactive protein Homo sapiens 264-267 20929499-9 2010 The magnitude of decrease in CRP correlated with that of BMI, WC, fat mass, TG, TC and LDL-C. Triglycerides 76-78 C-reactive protein Homo sapiens 29-32 20632462-2 2010 C-reactive protein (CRP), a marker of generalized inflammation, is raised by oral estradiol therapy (ET). Estradiol 82-91 C-reactive protein Homo sapiens 0-18 20632462-2 2010 C-reactive protein (CRP), a marker of generalized inflammation, is raised by oral estradiol therapy (ET). Estradiol 82-91 C-reactive protein Homo sapiens 20-23 20001470-0 2010 Elevated high sensitivity C-reactive protein levels in aging men with low testosterone. Testosterone 74-86 C-reactive protein Homo sapiens 26-44 20001470-1 2010 OBJECTIVE: We examined baseline data from a lipid treatment study to assess the relationship between testosterone (T) and the cardiovascular inflammatory marker, high sensitivity C-reactive protein (hsCRP). Testosterone 101-113 C-reactive protein Homo sapiens 179-197 20623980-2 2010 While HES application the average arterial pressure after induction into anesthesia was less pronounced and concentration of C-reactive protein on the third postoperative day was lesser. Hydroxyethyl Starch Derivatives 6-9 C-reactive protein Homo sapiens 125-143 20138585-2 2010 When CRP binds to membrane phospholipids or Fc receptors, it activates the complement system. Phospholipids 27-40 C-reactive protein Homo sapiens 5-8 20412290-1 2010 BACKGROUND: We recently reported high high-density lipoprotein (HDL) cholesterol as a predictor of recurrent risk in a subgroup of postinfarction patients defined by hypercholesterolemia and high C-reactive protein (CRP) levels. Cholesterol 69-80 C-reactive protein Homo sapiens 196-214 20412290-1 2010 BACKGROUND: We recently reported high high-density lipoprotein (HDL) cholesterol as a predictor of recurrent risk in a subgroup of postinfarction patients defined by hypercholesterolemia and high C-reactive protein (CRP) levels. Cholesterol 69-80 C-reactive protein Homo sapiens 216-219 20457506-10 2010 There was an inverse correlation between testosterone and CRP levels (P<0.01). Testosterone 41-53 C-reactive protein Homo sapiens 58-61 20457506-17 2010 Low testosterone was associated with decreased survival and correlated inversely with CRP levels, dyspnea, and insomnia. Testosterone 4-16 C-reactive protein Homo sapiens 86-89 20561444-4 2010 The results showed that the mean levels of plasma CRP, Fg, FVIII:C and FIX:C were significantly higher in deep vein thrombosis group than that in controls [CRP (2.67 +/- 0.91) vs (0.14 +/- 0.08) mg/dl; Fg (4.73 +/- 1.36) vs (2.79 +/- 0.66)g/L; FVIII:C (126.71 +/- 28.10) vs (81.35 +/- 20.77)%; FIX:C (81.01 +/- 23.60) vs (70.71 +/- 11.3)%] (p < 0.01), and the level of plasma CRP was strongly correlated with Fg, FVIII:C and FIX:C (r(s) = 0.432, 0.571 and 0.544, p < 0.01). Carbon 50-51 C-reactive protein Homo sapiens 156-159 20561444-4 2010 The results showed that the mean levels of plasma CRP, Fg, FVIII:C and FIX:C were significantly higher in deep vein thrombosis group than that in controls [CRP (2.67 +/- 0.91) vs (0.14 +/- 0.08) mg/dl; Fg (4.73 +/- 1.36) vs (2.79 +/- 0.66)g/L; FVIII:C (126.71 +/- 28.10) vs (81.35 +/- 20.77)%; FIX:C (81.01 +/- 23.60) vs (70.71 +/- 11.3)%] (p < 0.01), and the level of plasma CRP was strongly correlated with Fg, FVIII:C and FIX:C (r(s) = 0.432, 0.571 and 0.544, p < 0.01). Carbon 50-51 C-reactive protein Homo sapiens 156-159 20081092-7 2010 Adjusting for confounders, IL-6 and CRP remained significantly associated with serum iron, with no evidence that such a relationship was accounted for by variability in urinary hepcidin. Iron 85-89 C-reactive protein Homo sapiens 36-39 20734839-3 2010 There was a negative correlation between the level of Zn++ and that of C-reactive protein (CRP) and a positive correlation between the former and the magnitude of a reduction in transferrin (TF) as a marker of protein-energy malnutrition. Zinc 54-58 C-reactive protein Homo sapiens 71-89 20734839-3 2010 There was a negative correlation between the level of Zn++ and that of C-reactive protein (CRP) and a positive correlation between the former and the magnitude of a reduction in transferrin (TF) as a marker of protein-energy malnutrition. Zinc 54-58 C-reactive protein Homo sapiens 91-94 20512448-5 2010 Patients having glucose levels at hospital admission in the highest tertile (>155 mg/dl) had lower left ventricular ejection fraction (40% vs 45%, P = 0.003), were older (66 +/- 11 vs 61 +/- 13, P = 0.004) and less physically active (49% vs 63%, P = 0.02), had higher troponin (14.7 +/- 39.7 vs 5.6 +/- 13.5, P = 0.03), higher brain natriuretic peptide (510.39 +/- 932.33 vs 213.4 +/- 301.14, P = 0.008), higher C-RP (42.26 +/- 55.26 vs 26.46 +/- 38.18, P = 0.04), lower creatinine clearance levels (68 +/- 33 vs.81 +/- 31, P = 0.009), higher white blood cell count (13 416 +/- 16 420 vs 9310 +/- 3020, P = 0.001), and lower body mass index (26.8 +/- 4 vs 27.2 +/- 4.4, P = 0.07), compared to those in the lowest tertile (<114 mg/dl). Glucose 16-23 C-reactive protein Homo sapiens 415-419 20214724-13 2010 CONCLUSIONS: We have verified the prevalence of low testosterone levels in male patients with type 2 diabetes and have related them to variations in BMI, waist circumference, neuropathy, triglycerides, CRP, glucose, insulin and HOMA-IR, but not with an increase of SMI or PAD. Testosterone 52-64 C-reactive protein Homo sapiens 202-205 20091096-4 2010 Effect of atorvastatin was determined in the presence of CRP on the expression of genes. Atorvastatin 10-22 C-reactive protein Homo sapiens 57-60 20091096-8 2010 Atorvastatin was able to significantly attenuate CRP-induced MMPs expression and augmented TIMP-1 gene expression significantly. Atorvastatin 0-12 C-reactive protein Homo sapiens 49-52 20400886-9 2010 Higher levels of C-reactive protein (5.31 +/- 2.74 mg/L) were measured in the ASST-positive CU group compared with the ASST-negative CU group (2.53 +/- 1.27; P = 0.029) and the control group (2.34 +/- 1.38; P = 0.003). Copper 92-94 C-reactive protein Homo sapiens 17-35 20400886-9 2010 Higher levels of C-reactive protein (5.31 +/- 2.74 mg/L) were measured in the ASST-positive CU group compared with the ASST-negative CU group (2.53 +/- 1.27; P = 0.029) and the control group (2.34 +/- 1.38; P = 0.003). Copper 133-135 C-reactive protein Homo sapiens 17-35 20339115-6 2010 Decreasing human CRP blood levels through administration of a selective antisense oligonucleotide eliminated the depletion of serum C3 associated with vascular injury and reduced immunoreactive C3 in the resultant lesions. Oligonucleotides 82-97 C-reactive protein Homo sapiens 17-20 20412290-7 2010 However, in the high HDL-cholesterol subgroup, CRP levels were higher than the low HDL-cholesterol subgroup; and within the high HDL-cholesterol subgroup, CRP predicted risk. Cholesterol 25-36 C-reactive protein Homo sapiens 47-50 20081092-6 2010 Lower iron was significantly correlated with higher IL-6 and CRP. Iron 6-10 C-reactive protein Homo sapiens 61-64 20216206-2 2010 It works mainly in the hypothalamus at thirst signal, but given its closed connections with inflammatory and endothelial systems, also has been postulated that it may exert a regulatory control over blood pressure (BP), interacting with nitric oxide (NO) and C reactive protein (CRP). Nitric Oxide 237-249 C-reactive protein Homo sapiens 279-282 20534097-10 2010 CONCLUSION: Chronic idiopathic urticaria patients with elevated high sensitivity-CRP showed good response to oral cyclosporine therapy. Cyclosporine 114-126 C-reactive protein Homo sapiens 81-84 21122648-11 2010 Also, because recent studies have demonstrated that high-sensitivity C-reactive protein may be a reliable marker in selecting patients for statin therapy, it could reflect the presence of intimal injury by cholesterol crystals. Cholesterol 206-217 C-reactive protein Homo sapiens 69-87 20091096-0 2010 Inhibition of C-reactive protein induced expression of matrix metalloproteinases by atorvastatin in THP-1 cells. Atorvastatin 84-96 C-reactive protein Homo sapiens 14-32 20364851-1 2010 Lipid-coated metal nanoparticles are developed here as a mimic of low-density lipoprotein (LDL) particles and used to study C-reactive protein (CRP) binding to highly curved lipid membranes. Metals 13-18 C-reactive protein Homo sapiens 124-142 20364851-1 2010 Lipid-coated metal nanoparticles are developed here as a mimic of low-density lipoprotein (LDL) particles and used to study C-reactive protein (CRP) binding to highly curved lipid membranes. Metals 13-18 C-reactive protein Homo sapiens 144-147 20364851-9 2010 This indicates that CRP binds to the PC membrane on the nanoparticle surface reversibly through a calcium bridging mechanism while changing the underlying membrane structure irreversibly as a result of binding. Calcium 98-105 C-reactive protein Homo sapiens 20-23 20682172-8 2010 Atorvastatin (10-20 microM) was able to significantly accelerate the CRP-induced expression of PPAR-gamma and LXR-alpha and attenuate MMP-9 expression. Atorvastatin 0-12 C-reactive protein Homo sapiens 69-72 19686040-3 2010 Apart from impairment of their structural function, oxidation makes oxidized phospholipids (OxPLs) markers of "modified-self" type that are recognized by soluble and cell-associated receptors of innate immunity, including scavenger receptors, natural (germ line-encoded) antibodies, and C-reactive protein, thus directing removal of senescent and apoptotic cells or oxidized lipoproteins. Phospholipids 77-90 C-reactive protein Homo sapiens 287-305 20362753-0 2010 Does vitamin D modulate asymmetric dimethylarginine and C-reactive protein concentrations? Vitamin D 5-14 C-reactive protein Homo sapiens 56-74 20436910-3 2010 A role of CRP to protect endothelium-derived nitric oxide (EDNO) has been suggested. Nitric Oxide 45-57 C-reactive protein Homo sapiens 10-13 20436910-3 2010 A role of CRP to protect endothelium-derived nitric oxide (EDNO) has been suggested. Nitric Oxide 59-63 C-reactive protein Homo sapiens 10-13 20436910-4 2010 We examined the association of CRP with EDNO-dependent vasomotor function and subclinical measures of atherosclerosis and arteriosclerosis in patients with raised CRP resulting from rheumatoid arthritis (RA). Nitric Oxide 40-44 C-reactive protein Homo sapiens 31-34 20436910-8 2010 CONCLUSIONS/SIGNIFICANCE: These findings argue against a causal role of CRP in atherogenesis and are consistent with a protective effect of CRP on EDNO bioavailability. Nitric Oxide 147-151 C-reactive protein Homo sapiens 140-143 20682172-9 2010 CONCLUSIONS: For the first time we demonstrate that CRP modulates PPAR-gamma and its effector genes and reinforces the mechanistic link of CRP as a possible mediator in atherosclerosis and also advocate atorvastatin as a therapeutic modality. Atorvastatin 203-215 C-reactive protein Homo sapiens 52-55 19818961-10 2010 Adjusting for other risk factors plus serum creatinine the varepsilon4 allele was associated with lower serum CRP under a dominant model, coefficient 0.089, p=0.002. Creatinine 44-54 C-reactive protein Homo sapiens 110-113 19930761-9 2010 However, systemic inflammation (CRP and IL-6) was correlated with the faecal concentrations of phenolics and lactic acid (P < 0.05 and 0.05, and P < 0.01 and 0.05, respectively). Lactic Acid 109-120 C-reactive protein Homo sapiens 32-35 19769617-9 2010 RESULTS: An inverse association was observed, in both bivariate and multivariate analyses, between CRP and total testosterone, free testosterone and SHBG levels. Testosterone 113-125 C-reactive protein Homo sapiens 99-102 20074254-0 2010 Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway. Atorvastatin 0-12 C-reactive protein Homo sapiens 23-41 20074254-3 2010 The aims of this study was to examined the effects of CRP on expressions of interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1), and the possible mechanisms of atorvastatin on CRP-induced IL-6 and MCP-1 production in cultured human pulmonary artery smooth muscle cells (PASMCs). Atorvastatin 176-188 C-reactive protein Homo sapiens 192-195 20074254-5 2010 Then, the cells were pre-incubated for 2 h with atorvastatin (0.1-10 micromol/L) in the presence of CRP. Atorvastatin 48-60 C-reactive protein Homo sapiens 100-103 20074254-10 2010 Preincubation with 0.1-10 micromol/L of atorvastatin significantly decreased the secretions of IL-6 and MCP-1 induced by CRP. Atorvastatin 40-52 C-reactive protein Homo sapiens 121-124 20074254-11 2010 Moreover, 10 micromol/L of atorvastatin completely abrogated CRP-induced increase in IL-6 and MCP-1 by attenuating the activation of NF-kappaB. Atorvastatin 27-39 C-reactive protein Homo sapiens 61-64 20074254-12 2010 The present study demonstrated that inhibiting effect of atorvastatin on CRP-induced inflammatory response in cultured PASMCs was associated with NF-kappaB pathway. Atorvastatin 57-69 C-reactive protein Homo sapiens 73-76 20026100-4 2010 The main determinant of CRP in OC users was triglycerides. Triglycerides 44-57 C-reactive protein Homo sapiens 24-27 19769617-9 2010 RESULTS: An inverse association was observed, in both bivariate and multivariate analyses, between CRP and total testosterone, free testosterone and SHBG levels. Testosterone 132-144 C-reactive protein Homo sapiens 99-102 19769617-12 2010 CONCLUSIONS: A robust, inverse dose-response correlation between testosterone and SHBG levels with CRP levels provides further evidence of a potential role of androgens in inflammatory processes. Testosterone 65-77 C-reactive protein Homo sapiens 99-102 20075180-4 2010 METHODS: We analyzed the uptake of fluorescently labeled CRP in COS-7 cells expressing a series of scavenger receptors and in a monocytic cell line, THP-1, differentiated into macrophage with phorbol 12-myristate 13-acetate (PMA). carbonyl sulfide 64-67 C-reactive protein Homo sapiens 57-60 19880433-6 2010 RESULTS: Regression analysis indicated that the MQ group significantly improved overall QOL (t(144) = -5.761, P < 0.001), fatigue (t(153) = -5.621, P < 0.001), mood disturbance (t(122) =2.346, P = 0.021) and inflammation (CRP) (t(99) = 2.042, P < 0.044) compared with usual care after controlling for baseline variables. memoquin 48-50 C-reactive protein Homo sapiens 228-231 20395923-9 2010 Sensitivity and specificity of CRP were 78.6%and 62.5% respectively in suspected neonatal sepsis & 92.86% and 36.11% respectively in culture proven sepsis. Adenosine Monophosphate 98-101 C-reactive protein Homo sapiens 31-34 20118243-8 2010 Hydrogen-deuterium exchange mass spectrometry mapped distinct sites of GBP that interact with LPS and with CRP, consistent with in silico predictions. Hydrogen 0-8 C-reactive protein Homo sapiens 107-110 20075180-9 2010 THP-1 cells differentiated into macrophage-like cells by treatment with PMA-internalized fluorescently labeled CRP. Tetradecanoylphorbol Acetate 72-75 C-reactive protein Homo sapiens 111-114 19472103-6 2010 Levels of ALT (GPT) AST (GOT) and CRP had decreased significantly after one year of testosterone treatment. Testosterone 84-96 C-reactive protein Homo sapiens 34-37 20349300-6 2010 C-reactive protein levels were lower in the pravastatin group 72 h after surgery (nonstatin vs. pravastatin, P = 0.0180; atorvastatin vs. pravastatin, P = 0.0383). Atorvastatin 121-133 C-reactive protein Homo sapiens 0-18 19850925-6 2010 Physiological FH and CRP concentrations were used in 137 mM NaCl and 2 mM Ca(2+), in which the occurrence of denatured CRP was avoided. Sodium Chloride 60-64 C-reactive protein Homo sapiens 21-24 19850309-4 2010 The association of hepatic steatosis with both C-reactive protein and adiponectin remained significant after adjustment for age, ethnicity, body mass index (or waist circumference), triglycerides, high-density lipoprotein, and total cholesterol. Cholesterol 233-244 C-reactive protein Homo sapiens 47-65 20008503-6 2010 After adjustment for age, sex, ethnic background, body mass index, serum albumin level and other factors, we found that a higher anion gap and lower bicarbonate level were associated with a higher leukocyte count and higher C-reactive protein level. Bicarbonates 149-160 C-reactive protein Homo sapiens 224-242 20308976-10 2010 Waist circumference, fasting glucose, % body fat, and BMI are associated with CRP in college age men and women. Glucose 29-36 C-reactive protein Homo sapiens 78-81 21053472-9 2010 The septic score clearly discriminated patients with different severity of sepsis, development of multiple organ dysfunction syndrome and survival and positively correlated with the concentrations of lactate, C-reactive protein and creatinine (the best correlation ranks were with lactate levels, p < 0.001). Lactic Acid 281-288 C-reactive protein Homo sapiens 209-227 20078870-5 2010 In a secondary analysis we assessed the association of CRP with albuminuria (defined as albumin-to-creatinine ratio > 30 mg/g). Creatinine 99-109 C-reactive protein Homo sapiens 55-58 19850925-9 2010 SPR confirmed the FH-CRP interaction and its NaCl concentration dependence upon using either immobilized FH or CRP. Sodium Chloride 45-49 C-reactive protein Homo sapiens 111-114 19903811-0 2010 C-reactive protein exists in an NaCl concentration-dependent pentamer-decamer equilibrium in physiological buffer. Sodium Chloride 32-36 C-reactive protein Homo sapiens 0-18 19850925-11 2010 In order of increasing affinity, SCR-16/20, SCR-6/8 (His-402), and SCR-6/8 (Tyr-402) fragments bound to CRP. Histidine 53-56 C-reactive protein Homo sapiens 104-107 19903811-6 2010 In the absence of Ca(2+), CRP partially dissociates into its protomers and the NaCl concentration dependence of the pentamer-decamer equilibrium is much reduced. Sodium Chloride 79-83 C-reactive protein Homo sapiens 26-29 19850925-11 2010 In order of increasing affinity, SCR-16/20, SCR-6/8 (His-402), and SCR-6/8 (Tyr-402) fragments bound to CRP. Tyrosine 76-79 C-reactive protein Homo sapiens 104-107 19903811-9 2010 Surface plasmon resonance showed that CRP self-associates on a surface with immobilized CRP with a similar K(D) value of 23 microM (140 mM NaCl, 2 mM Ca(2+)), whereas CRP aggregates in low salt. Sodium Chloride 139-143 C-reactive protein Homo sapiens 38-41 20441243-7 2010 RESULTS: In the atorvastatin-treated patients significantly lower plasma levels of thrombin-antithrombin complexes (p < 0.05), plasminogen activator inhibitor-1 activity (PAI-1) [p < 0.05], soluble vascular cell adhesion molecule-1 (p < 0.05), soluble platelet selectin (p < 0.05) and high-sensitivity C-reactive protein (p < 0.05) were measured compared with patients not on atorvastatin therapy. Atorvastatin 16-28 C-reactive protein Homo sapiens 314-332 19903811-9 2010 Surface plasmon resonance showed that CRP self-associates on a surface with immobilized CRP with a similar K(D) value of 23 microM (140 mM NaCl, 2 mM Ca(2+)), whereas CRP aggregates in low salt. Sodium Chloride 139-143 C-reactive protein Homo sapiens 88-91 19903811-9 2010 Surface plasmon resonance showed that CRP self-associates on a surface with immobilized CRP with a similar K(D) value of 23 microM (140 mM NaCl, 2 mM Ca(2+)), whereas CRP aggregates in low salt. Sodium Chloride 139-143 C-reactive protein Homo sapiens 88-91 19903811-11 2010 Both 2 mM Ca(2+) and 140 mM NaCl are essential for the integrity of CRP in functional studies and understanding the role of CRP in the acute phase response. Sodium Chloride 28-32 C-reactive protein Homo sapiens 68-71 19903811-11 2010 Both 2 mM Ca(2+) and 140 mM NaCl are essential for the integrity of CRP in functional studies and understanding the role of CRP in the acute phase response. Sodium Chloride 28-32 C-reactive protein Homo sapiens 124-127 20068292-10 2010 CONCLUSION: CLS with heparin/gentamicin tended to decrease CRI compared to citrate 46% and heparin and frankly improved the CRP course after catheter insertion. calusterone 12-15 C-reactive protein Homo sapiens 124-127 20068292-10 2010 CONCLUSION: CLS with heparin/gentamicin tended to decrease CRI compared to citrate 46% and heparin and frankly improved the CRP course after catheter insertion. Heparin 21-28 C-reactive protein Homo sapiens 124-127 19800416-0 2010 Plasma lecithin: cholesterol acyltransferase activity modifies the inverse relationship of C-reactive protein with HDL cholesterol in nondiabetic men. Cholesterol 17-28 C-reactive protein Homo sapiens 91-109 20034371-11 2010 Current evidence suggests that inflammatory and metabolic factors associated with diabetes, such as high glucose, adipokines, modified lipoproteins and free fatty acids may trigger CRP production by endothelial cells, smooth muscle cells and monocytes/macrophages. Glucose 105-112 C-reactive protein Homo sapiens 181-184 20683147-8 2010 Multivariate logistic regression analyses indicated that elevated CRP (being in the top 15 percentile of CRP; CRP > or =2.09 mg/L) was significantly associated with obesity, hypertension, diabetes, low high-density lipoprotein cholesterol, high low-density lipoprotein cholesterol, high triglycerides and cardiovascular disease history. Triglycerides 290-303 C-reactive protein Homo sapiens 66-69 19808911-0 2010 Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). Rosiglitazone 0-13 C-reactive protein Homo sapiens 24-42 19808911-3 2010 RESEARCH DESIGN AND METHODS: In A Diabetes Outcome Progression Trial (ADOPT), we examined the long-term effects of rosiglitazone, glyburide, and metformin on CRP and the relationship among CRP, weight, and glycemic variables in 904 subjects over 4 years. Rosiglitazone 115-128 C-reactive protein Homo sapiens 158-161 19808911-3 2010 RESEARCH DESIGN AND METHODS: In A Diabetes Outcome Progression Trial (ADOPT), we examined the long-term effects of rosiglitazone, glyburide, and metformin on CRP and the relationship among CRP, weight, and glycemic variables in 904 subjects over 4 years. Metformin 145-154 C-reactive protein Homo sapiens 158-161 19808911-5 2010 CRP reduction was greater in the rosiglitazone group by -47.6% relative to glyburide and by -30.5% relative to metformin at 48 months. Rosiglitazone 33-46 C-reactive protein Homo sapiens 0-3 19808911-5 2010 CRP reduction was greater in the rosiglitazone group by -47.6% relative to glyburide and by -30.5% relative to metformin at 48 months. Metformin 111-120 C-reactive protein Homo sapiens 0-3 20683147-8 2010 Multivariate logistic regression analyses indicated that elevated CRP (being in the top 15 percentile of CRP; CRP > or =2.09 mg/L) was significantly associated with obesity, hypertension, diabetes, low high-density lipoprotein cholesterol, high low-density lipoprotein cholesterol, high triglycerides and cardiovascular disease history. Triglycerides 290-303 C-reactive protein Homo sapiens 105-108 19808911-7 2010 The change in CRP from baseline to 12 months was correlated positively with change in BMI in glyburide (r = 0.18) and metformin (r = 0.20) groups but not in the rosiglitazone (r = -0.05, NS) group. Metformin 118-127 C-reactive protein Homo sapiens 14-17 20683147-8 2010 Multivariate logistic regression analyses indicated that elevated CRP (being in the top 15 percentile of CRP; CRP > or =2.09 mg/L) was significantly associated with obesity, hypertension, diabetes, low high-density lipoprotein cholesterol, high low-density lipoprotein cholesterol, high triglycerides and cardiovascular disease history. Triglycerides 290-303 C-reactive protein Homo sapiens 105-108 19808911-9 2010 CONCLUSIONS: Rosiglitazone treatment was associated with durable reductions in CRP independent of changes in insulin sensitivity, A1C, and weight gain. Rosiglitazone 13-26 C-reactive protein Homo sapiens 79-82 19808911-10 2010 CRP in the glyburide and metformin groups was positively associated with changes in weight, but this was not the case with rosiglitazone. Metformin 25-34 C-reactive protein Homo sapiens 0-3 25961969-0 2010 Beneficial effects of 2 years of administration of parenteral testosterone undecanoate on the metabolic syndrome and on non-alcoholic liver steatosis and C-reactive protein. testosterone undecanoate 62-86 C-reactive protein Homo sapiens 154-172 19836015-1 2010 The association of 9 urinary monohydroxy polycyclic aromatic hydrocarbons (OH-PAHs) with serum C-reactive protein (CRP) was investigated using the National Health and Nutrition Examination Survey (NHANES) 2003-2004. monohydroxy polycyclic aromatic hydrocarbons 29-73 C-reactive protein Homo sapiens 95-113 19836015-1 2010 The association of 9 urinary monohydroxy polycyclic aromatic hydrocarbons (OH-PAHs) with serum C-reactive protein (CRP) was investigated using the National Health and Nutrition Examination Survey (NHANES) 2003-2004. monohydroxy polycyclic aromatic hydrocarbons 29-73 C-reactive protein Homo sapiens 115-118 19836015-6 2010 Intermediate levels of 2-hydroxyphenanthrene (49-148ng/g creatinine), and 9-hydroxyfluorene (161-749ng/g creatinine) were also significantly associated with elevated CRP compared to the respective reference categories. Creatinine 57-67 C-reactive protein Homo sapiens 166-169 19836015-6 2010 Intermediate levels of 2-hydroxyphenanthrene (49-148ng/g creatinine), and 9-hydroxyfluorene (161-749ng/g creatinine) were also significantly associated with elevated CRP compared to the respective reference categories. Creatinine 105-115 C-reactive protein Homo sapiens 166-169 21076541-0 2010 C-reactive protein and gamma-glutamyltransferase concentrations in relation to the prevalence of type 2 diabetes diagnosed by glucose or HbA1c criteria in Chinese adults in Qingdao, China. Glucose 126-133 C-reactive protein Homo sapiens 0-18 21076541-1 2010 AIMS: To investigate the association of C-reactive protein (CRP) and gamma glutamyltransferase (GGT) concentrations with newly diagnosed diabetes defined by either glucose or HbA1c criteria in Chinese adults. Glucose 164-171 C-reactive protein Homo sapiens 40-58 21076541-7 2010 CONCLUSIONS: The effect of elevated CRP on diabetes defined by the glucose criterion was mediated through obesity, but elevated GGT was an independent risk factor for diabetes in this Chinese population. Glucose 67-74 C-reactive protein Homo sapiens 36-39 21430404-0 2010 Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinib. Gefitinib 136-145 C-reactive protein Homo sapiens 38-56 19933721-5 2010 ROS values, higher both in active and in inactive LN, correlated with age (p = 0.02), C-reactive protein (CRP) (p = 0.0005) and inversely with prednisone dosage (p = 0.05). Reactive Oxygen Species 0-3 C-reactive protein Homo sapiens 86-104 19933721-5 2010 ROS values, higher both in active and in inactive LN, correlated with age (p = 0.02), C-reactive protein (CRP) (p = 0.0005) and inversely with prednisone dosage (p = 0.05). Reactive Oxygen Species 0-3 C-reactive protein Homo sapiens 106-109 19933721-6 2010 At multivariate analysis, CRP (p = 0.04) and age (p = 0.005) were independent ROS predictors. Reactive Oxygen Species 78-81 C-reactive protein Homo sapiens 26-29 20204259-0 2010 [Effect of a high saturated fatty acids load on serum concentrations of C-reactive protein, alpha1-antitrypsin, fibrinogen and alpha1-acid glycoprotein in obese women]. Fatty Acids 18-39 C-reactive protein Homo sapiens 72-90 21430404-5 2010 RESULTS: Having CRP-positive serum and having wild-type EGFR were both independent negative predictive factors for the response to gefitinib treatment by multivariate logistic regression model analysis. Gefitinib 131-140 C-reactive protein Homo sapiens 16-19 21430404-7 2010 CONCLUSIONS: Having CRP-positive serum predicted a lack of response to gefitinib therapy independent of EGFR mutational status. Gefitinib 71-80 C-reactive protein Homo sapiens 20-23 20233517-4 2010 After 12 weeks of rosiglitazone treatment, plasma levels of C-reactive protein were significantly decreased and the median CFVR was significantly increased compared with baseline levels and compared with the control group. Rosiglitazone 18-31 C-reactive protein Homo sapiens 60-78 19818001-6 2010 RESULTS: ADP-inducible platelet reactivity increased linearly with age after adjustment for cardiovascular risk factors, type of intervention, medication, C-reactive protein (CRP) and renal function [using LTA 0.36% of maximal aggregation per year, 95% CI 0.08-0.64%, P = 0.013; using the VerifyNow P2Y12 assay 3.2 P2Y12 reaction units (PRU) per year, 95% CI 1.98-4.41 PRU, P < 0.001]. Adenosine Diphosphate 9-12 C-reactive protein Homo sapiens 155-173 19818001-6 2010 RESULTS: ADP-inducible platelet reactivity increased linearly with age after adjustment for cardiovascular risk factors, type of intervention, medication, C-reactive protein (CRP) and renal function [using LTA 0.36% of maximal aggregation per year, 95% CI 0.08-0.64%, P = 0.013; using the VerifyNow P2Y12 assay 3.2 P2Y12 reaction units (PRU) per year, 95% CI 1.98-4.41 PRU, P < 0.001]. Adenosine Diphosphate 9-12 C-reactive protein Homo sapiens 175-178 21430404-8 2010 Both CRP-positive serum and wild-type EGFR were independent poor prognostic factors in patients with nonsquamous NSCLC who received gefitinib therapy. Gefitinib 132-141 C-reactive protein Homo sapiens 5-8 21430404-1 2010 PURPOSE: We examined patients with advanced nonsquamous, non-small cell lung cancer (NSCLC) to evaluate epidermal growth factor receptor (EGFR) mutation status and serum C-reactive protein (CRP) for their associations with response to gefitinib therapy and for prognostic impacts. Gefitinib 235-244 C-reactive protein Homo sapiens 170-188 19822838-5 2009 Among individuals not receiving folic acid, there was a 4% decrease (mean ratio of year 3 to baseline levels = 0.96, 95% confidence interval [CI] = 0.82 to 1.14) in CRP for a period of 3 years in the 325 mg of aspirin group vs a 20% increase (mean ratio = 1.20, 95% CI = 1.03 to 1.41) in the placebo group (P = .027). Folic Acid 32-42 C-reactive protein Homo sapiens 165-168 20011043-5 2009 To do this we evaluated: 1) the oxidation products of phospholipids (oxPAPC) in peripheral blood mononuclear cells (PBMC); 2) their role in causing PBMC reactive oxygen species (ROS) generation and changes in GSH; 3) the expression of the transcription factor NF-E2-related factor 2 (Nrf2) and of related antioxidant genes (ARE); 4) the activation of NF-kB and C-reactive protein (CRP) values. Phospholipids 54-67 C-reactive protein Homo sapiens 361-379 20011043-5 2009 To do this we evaluated: 1) the oxidation products of phospholipids (oxPAPC) in peripheral blood mononuclear cells (PBMC); 2) their role in causing PBMC reactive oxygen species (ROS) generation and changes in GSH; 3) the expression of the transcription factor NF-E2-related factor 2 (Nrf2) and of related antioxidant genes (ARE); 4) the activation of NF-kB and C-reactive protein (CRP) values. Phospholipids 54-67 C-reactive protein Homo sapiens 381-384 20092788-0 2009 Testosterone replacement therapy improves insulin sensitivity and decreases high sensitivity C-reactive protein levels in hypogonadotropic hypogonadal young male patients. Testosterone 0-12 C-reactive protein Homo sapiens 93-111 19822838-8 2009 Low-dose aspirin (325 mg/d) is beneficial in stabilizing CRP levels, which may be abrogated by folate. Aspirin 9-16 C-reactive protein Homo sapiens 57-60 19822838-8 2009 Low-dose aspirin (325 mg/d) is beneficial in stabilizing CRP levels, which may be abrogated by folate. Folic Acid 95-101 C-reactive protein Homo sapiens 57-60 20031768-0 2009 Prognostic values of C-reactive protein levels on clinical outcome after implantation of sirolimus-eluting stents in patients on hemodialysis. Sirolimus 89-98 C-reactive protein Homo sapiens 21-39 19680263-3 2009 By using recombinant proteins, calcium-independent binding of Factor H to monomeric CRP (mCRP), but not to pentameric CRP (pCRP), was shown. Calcium 31-38 C-reactive protein Homo sapiens 84-87 19680263-3 2009 By using recombinant proteins, calcium-independent binding of Factor H to monomeric CRP (mCRP), but not to pentameric CRP (pCRP), was shown. Calcium 31-38 C-reactive protein Homo sapiens 90-93 19375269-2 2009 In this study, we evaluated the levels of IMA in myocardial infarction and prostate diseases, as well as the influence of HDL cholesterol levels on C-reactive protein (CRP) and IMA levels. Cholesterol 126-137 C-reactive protein Homo sapiens 148-166 19822977-6 2009 Atorvastatin significantly reduced the incidence of postoperative AF and the postoperative peak C-reactive protein (CRP) level vs placebo (14% vs 34%, P=0.009; 126.5 +/-22.3 vs 145.2 +/-31.6 mg/L, P<0.0001). Atorvastatin 0-12 C-reactive protein Homo sapiens 96-114 19822977-6 2009 Atorvastatin significantly reduced the incidence of postoperative AF and the postoperative peak C-reactive protein (CRP) level vs placebo (14% vs 34%, P=0.009; 126.5 +/-22.3 vs 145.2 +/-31.6 mg/L, P<0.0001). Atorvastatin 0-12 C-reactive protein Homo sapiens 116-119 20031768-10 2009 There was a progressive increase in neointimal growth after sirolimus-eluting stent implantation during follow-up because preprocedural CRP levels were higher, despite similar angiographic data just after PCI. Sirolimus 60-69 C-reactive protein Homo sapiens 136-139 20031768-12 2009 CONCLUSIONS: Increased preprocedural serum CRP levels would predict higher major adverse cardiac events and restenosis rates after sirolimus-eluting stents implantation in patients on hemodialysis. Sirolimus 131-140 C-reactive protein Homo sapiens 43-46 20027097-11 2009 The dexamethasone group showed significantly less elevation of C-reactive protein levels at 24 hours (7.17 microg/mL vs. 17.53 microg/mL; P=0.003) and 48 hours (10.65 microg/mL vs. 23.18 microg/mL; P=0.02) postoperatively. Dexamethasone 4-17 C-reactive protein Homo sapiens 63-81 20956150-12 2009 Finally, there is emerging data that prostanoid therapy results in a tendency to normalise C-reactive protein levels, a factor associated with improved long-term outcomes. Prostaglandins 37-47 C-reactive protein Homo sapiens 91-109 19575357-9 2009 The PGA outcome was predicted only by CRP, stenosis, and fistula. Prostaglandins A 4-7 C-reactive protein Homo sapiens 38-41 19836939-9 2009 RESULTS: There was an increase of high sensitivity C-reactive protein in asthmatic patients among both steroid inhaled and steroid naive patients compared to the healthy controls. Steroids 103-110 C-reactive protein Homo sapiens 51-69 19836939-9 2009 RESULTS: There was an increase of high sensitivity C-reactive protein in asthmatic patients among both steroid inhaled and steroid naive patients compared to the healthy controls. Steroids 123-130 C-reactive protein Homo sapiens 51-69 19836939-10 2009 Serum high sensitivity C-reactive protein correlated negatively with pulmonary function tests and positively with sputum eosinophil % in both inhaled steroid and steroid naive groups. Steroids 150-157 C-reactive protein Homo sapiens 23-41 19836939-10 2009 Serum high sensitivity C-reactive protein correlated negatively with pulmonary function tests and positively with sputum eosinophil % in both inhaled steroid and steroid naive groups. Steroids 162-169 C-reactive protein Homo sapiens 23-41 19454128-5 2009 Also an inverse correlation was observed between the C-reactive protein and membrane phosphatidylcholine and phosphatidylserine 20 : 4n-6. Phosphatidylserines 109-127 C-reactive protein Homo sapiens 53-71 19781835-12 2009 In patients with inflammation (CRP level > 5 mg/L), the adjusted relative risk of combined vascular events was 29% greater compared with those without inflammation and a low LDL cholesterol level (LDL cholesterol < or = 123 mg/dL). Cholesterol 181-192 C-reactive protein Homo sapiens 31-34 19781835-12 2009 In patients with inflammation (CRP level > 5 mg/L), the adjusted relative risk of combined vascular events was 29% greater compared with those without inflammation and a low LDL cholesterol level (LDL cholesterol < or = 123 mg/dL). Cholesterol 204-215 C-reactive protein Homo sapiens 31-34 19852688-13 2009 C-reactive protein (CRP) level in PsA patients correlated with sCD40L (r = 0.69, p = 0.012), basal CD62P expression (r = 0.89, p < 0.001) and ADP-stimulated CD62P expression (r = 0.73, p = 0.001). Adenosine Diphosphate 145-148 C-reactive protein Homo sapiens 0-18 19641491-5 2009 Levels of CRP and IL-6 also decreased after 20 weeks of sertraline treatment, whereas they did not significantly change in the placebo group. Sertraline 56-66 C-reactive protein Homo sapiens 10-13 19852688-13 2009 C-reactive protein (CRP) level in PsA patients correlated with sCD40L (r = 0.69, p = 0.012), basal CD62P expression (r = 0.89, p < 0.001) and ADP-stimulated CD62P expression (r = 0.73, p = 0.001). Adenosine Diphosphate 145-148 C-reactive protein Homo sapiens 20-23 19804653-10 2009 The links between the cliques showed biologically relevant interactions: an inverse relationship between HDL cholesterol and the triglyceride clique (r < -0.3, P < 10(-16)), a connection between triglycerides and body mass via C-reactive protein (r > 0.3, P < 10(-16)) and intermediate-density cholesterol as the connector between lipoprotein metabolism and albuminuria (r > 0.3, P < 10(-16)). Cholesterol 109-120 C-reactive protein Homo sapiens 233-251 19804653-10 2009 The links between the cliques showed biologically relevant interactions: an inverse relationship between HDL cholesterol and the triglyceride clique (r < -0.3, P < 10(-16)), a connection between triglycerides and body mass via C-reactive protein (r > 0.3, P < 10(-16)) and intermediate-density cholesterol as the connector between lipoprotein metabolism and albuminuria (r > 0.3, P < 10(-16)). Triglycerides 129-141 C-reactive protein Homo sapiens 233-251 19804653-10 2009 The links between the cliques showed biologically relevant interactions: an inverse relationship between HDL cholesterol and the triglyceride clique (r < -0.3, P < 10(-16)), a connection between triglycerides and body mass via C-reactive protein (r > 0.3, P < 10(-16)) and intermediate-density cholesterol as the connector between lipoprotein metabolism and albuminuria (r > 0.3, P < 10(-16)). Triglycerides 201-214 C-reactive protein Homo sapiens 233-251 19636689-9 2009 sICAM-1, CRP and vWF levels decreased and FMD increased significantly in the atorvastatin group, but not in the control group. Atorvastatin 77-89 C-reactive protein Homo sapiens 9-12 19339014-6 2009 After adjustments for age, sex, acute infection and chronic inflammatory conditions, very high CRP was associated with lower social position, depressive symptoms, physical inactivity, smoking, and alcohol abstinence. Alcohols 197-204 C-reactive protein Homo sapiens 95-98 19636689-11 2009 CONCLUSIONS: Twelve weeks of treatment with atorvastatin significantly decreased serum sICAM-1, CRP and vWF levels, and improved the FMD, LVEF and 6MWT outcomes. Atorvastatin 44-56 C-reactive protein Homo sapiens 96-99 19687343-5 2009 After the 12-week treatment period, the ATOR group experienced a 47% reduction in low-density lipoprotein cholesterol (149+/-6 to 80+/-8 mg/dL) and a 42% reduction in high-sensitivity C-reactive protein (3.6+/-0.8 to 2.1+/-0.5 mg/L; both P<0.05). Atorvastatin 40-44 C-reactive protein Homo sapiens 184-202 19138871-4 2009 METHODS: In cross-sectional analysis, multivariable linear regression with adjustment for age, BMI, smoking status, alcohol intake, and nutritional factors was used to relate log CRP, the independent variable, to IGF-I and IGFBP-3 in a sample of black (n=364) and white men (n=486) separately by race. Alcohols 116-123 C-reactive protein Homo sapiens 179-182 19263143-9 2009 Furthermore, the C-reactive protein level on postoperative day 7 was lower in the TLDG group than in the LADG group (p < 0.05). ladg 105-109 C-reactive protein Homo sapiens 17-35 19636315-12 2009 BMI-SDS significantly correlated with sTfR (P=0.009), serum hepcidin (P=0.005) and the three measures of subclinical inflammation, namely CRP (P<0.001), IL-6 (P<0.001) and leptin (P<0.001). bmi-sds 0-7 C-reactive protein Homo sapiens 138-141 19749491-9 2009 In smokers, hs-CRP significantly correlated with BMI and HDL-cholesterol (r=0.386, p<0.01 and r=-0.307, p<0.05). Cholesterol 61-72 C-reactive protein Homo sapiens 15-18 19695857-4 2009 However, a reduction in CRP levels after statin treatment could be secondary to the reduced LDL cholesterol levels, and thereby less inflammation in atherosclerotic plaques. Cholesterol 96-107 C-reactive protein Homo sapiens 24-27 20011938-10 2009 Moderate alcohol consumption appeared as a protective factor for CRP elevation (p =0.029). Alcohols 9-16 C-reactive protein Homo sapiens 65-68 19691834-6 2009 Resting levels of CRP and TNF-alpha were lower with EPA/DHA compared to placebo (p < 0.05). dehydroacetic acid 56-59 C-reactive protein Homo sapiens 18-21 19268941-8 2009 CRP treatment also resulted in increased dihydroethidium staining for superoxide in aortic endothelium and membrane translocation of p47phox, a regulatory subunit of NADPH oxidase. Superoxides 70-80 C-reactive protein Homo sapiens 0-3 19501581-12 2009 CRP can also accelerate atherosclerosis by increasing the expression of PAI-1 and adhesion molecules in endothelial cells, inhibition of nitric oxide formation and increasing LDL uptake into macrophages. Nitric Oxide 137-149 C-reactive protein Homo sapiens 0-3 20379412-1 2009 BACKGROUND AND OBJECTIVES: Circulating C-reactive protein (CRP) levels are a marker of systemic inflammation and are associated with periodontal disease, a chronic bacterial infection associated with elevation of proinflammatory cytokines and prostaglandins. Prostaglandins 243-257 C-reactive protein Homo sapiens 39-57 20379412-1 2009 BACKGROUND AND OBJECTIVES: Circulating C-reactive protein (CRP) levels are a marker of systemic inflammation and are associated with periodontal disease, a chronic bacterial infection associated with elevation of proinflammatory cytokines and prostaglandins. Prostaglandins 243-257 C-reactive protein Homo sapiens 59-62 19268941-2 2009 We have previously shown that CRP decreases endothelial nitric oxide synthase (eNOS) activity in endothelial cells and inhibits endothelium-dependent nitric oxide (NO)-mediated vasodilation in vitro. Nitric Oxide 56-68 C-reactive protein Homo sapiens 30-33 19268941-6 2009 RESULTS: Dilation of mesenteric arterioles to acetylcholine but not to sodium nitroprusside was significantly reduced following CRP treatment. Acetylcholine 46-59 C-reactive protein Homo sapiens 128-131 19542241-12 2009 CONCLUSIONS: Morbid obesity and glucose intolerance were associated with lower adiponectin levels and higher CRP levels, thus supporting a relationship between obesity, glucose homeostasis, and inflammation. Glucose 32-39 C-reactive protein Homo sapiens 109-112 19686927-7 2009 There was a significant positive correlation between plasma level of glutamate and extension of radiographic erosions that was strongest in the patients with low levels of C-reactive protein, estradiol, or testosterone. Glutamic Acid 69-78 C-reactive protein Homo sapiens 172-190 19686927-8 2009 By contrast, erosions were correlated with C-reactive protein in patients with high levels of estradiol. Estradiol 94-103 C-reactive protein Homo sapiens 43-61 19686927-9 2009 The highest levels of glutamate were found in patients with low levels of C-reactive protein and estradiol. Glutamic Acid 22-31 C-reactive protein Homo sapiens 74-92 19691834-10 2009 However, a condition effect was noted for CRP and TNF-alpha, with lower values with the EPA/DHA condition. dehydroacetic acid 92-95 C-reactive protein Homo sapiens 42-45 19406663-0 2009 Cadmium exposure is associated with elevated blood C-reactive protein and fibrinogen in the U. S. population: the third national health and nutrition examination survey (NHANES III, 1988-1994). Cadmium 0-7 C-reactive protein Homo sapiens 51-69 19406663-2 2009 This study explored the hypothesis that cadmium exposure is associated with elevated C-reactive protein (CRP) and fibrinogen, two risk factors for developing cardiovascular disease. Cadmium 40-47 C-reactive protein Homo sapiens 85-103 19406663-2 2009 This study explored the hypothesis that cadmium exposure is associated with elevated C-reactive protein (CRP) and fibrinogen, two risk factors for developing cardiovascular disease. Cadmium 40-47 C-reactive protein Homo sapiens 105-108 19406663-3 2009 METHODS: The current study investigated associations between urinary cadmium and the prevalence of elevated blood CRP (> or = 2.2 mg/L) and fibrinogen (> or = 10.35 micromol/L) using data from a sample of 6497 participants aged 40-79 in the Third National Health and Nutrition Examination Survey. Cadmium 69-76 C-reactive protein Homo sapiens 114-117 19406663-5 2009 RESULTS: Both simple and covariate-adjusted models indicated that urinary cadmium was associated with elevated CRP and fibrinogen in a dose-dependent fashion (p(trend)<0.05 for both). Cadmium 74-81 C-reactive protein Homo sapiens 111-114 19406663-6 2009 Adjusted odds ratios for increased CRP and fibrinogen comparing highest with lowest quartiles of urinary cadmium were 1.62 (95% confidence interval [CI], 1.24-2.12) and 2.12 (1.43-3.14), respectively. Cadmium 105-112 C-reactive protein Homo sapiens 35-38 19661353-5 2009 CONCLUSION: An increase of serum cholesterol, lipoprotein (a), C-reactive protein and fibrinogen in patients treated with aromatase inhibitors is the result of tamoxifen withdrawal rather than a direct effect of therapy. Tamoxifen 160-169 C-reactive protein Homo sapiens 63-81 19406663-7 2009 CONCLUSIONS: This analysis shows that cadmium exposure is associated with high prevalence of elevated CRP and fibrinogen. Cadmium 38-45 C-reactive protein Homo sapiens 102-105 19232413-6 2009 All patients were genotyped for a frequent functional variant at position 131 of the mature FcgammaRIIa, where the arginine (R) allele results in an increased signal transduction upon CRP binding. Arginine 115-123 C-reactive protein Homo sapiens 184-187 19545552-2 2009 Many bioactivities of mCRP generated by urea-treatment of CRP and of mCRP generated by mutating the primary structure of CRP have been reported. Urea 40-44 C-reactive protein Homo sapiens 23-26 19545552-2 2009 Many bioactivities of mCRP generated by urea-treatment of CRP and of mCRP generated by mutating the primary structure of CRP have been reported. Urea 40-44 C-reactive protein Homo sapiens 58-61 19359389-8 2009 Preincubation of leptin with human recombinant CRP impaired leptin-induced AMPK activation, eNOS-Ser(1177) phosphorylation, eNOS activity, and intracellular cGMP accumulation. Serine 97-100 C-reactive protein Homo sapiens 47-50 19359389-8 2009 Preincubation of leptin with human recombinant CRP impaired leptin-induced AMPK activation, eNOS-Ser(1177) phosphorylation, eNOS activity, and intracellular cGMP accumulation. Cyclic GMP 157-161 C-reactive protein Homo sapiens 47-50 19621193-1 2009 OBJECTIVES: Aims of the study were 1) to investigate the association of C-reactive protein (CRP) with lipid (i.e. total, LDL, and HDL cholesterol, triglycerides) concentrations, and to evaluate their predictive value for mortality in very old subjects. Cholesterol 134-145 C-reactive protein Homo sapiens 72-90 19410579-3 2009 The goal of this study was to determine whether CRP also affects endothelial arachidonic acid (AA)-prostanoid pathways for vasomotor regulation. Arachidonic Acid 77-98 C-reactive protein Homo sapiens 48-51 19410579-3 2009 The goal of this study was to determine whether CRP also affects endothelial arachidonic acid (AA)-prostanoid pathways for vasomotor regulation. Prostaglandins 99-109 C-reactive protein Homo sapiens 48-51 19410579-7 2009 Intraluminal administration of a pathophysiological level of CRP (7 microg/mL, 60 min) attenuated vasodilations to serotonin and AA but not to nitroprusside, exogenous PGI(2), or hydrogen peroxide (endothelium-dependent PGE(2) activator). Serotonin 115-124 C-reactive protein Homo sapiens 61-64 19410579-7 2009 Intraluminal administration of a pathophysiological level of CRP (7 microg/mL, 60 min) attenuated vasodilations to serotonin and AA but not to nitroprusside, exogenous PGI(2), or hydrogen peroxide (endothelium-dependent PGE(2) activator). Hydrogen Peroxide 179-196 C-reactive protein Homo sapiens 61-64 19410579-8 2009 CRP also reduced basal NO production, caused tyrosine nitration of endothelial PGI(2)-S, and inhibited AA-stimulated PGI(2) release from arterioles. Tyrosine 45-53 C-reactive protein Homo sapiens 0-3 19410579-11 2009 Collectively, our results suggest that CRP stimulates superoxide production and the subsequent formation of peroxynitrite from basal released NO compromises PGI(2) synthesis, and thus endothelium-dependent PGI(2)-mediated dilation, by inhibiting PGI(2)-S activity through tyrosine nitration. Superoxides 54-64 C-reactive protein Homo sapiens 39-42 19410579-11 2009 Collectively, our results suggest that CRP stimulates superoxide production and the subsequent formation of peroxynitrite from basal released NO compromises PGI(2) synthesis, and thus endothelium-dependent PGI(2)-mediated dilation, by inhibiting PGI(2)-S activity through tyrosine nitration. Tyrosine 272-280 C-reactive protein Homo sapiens 39-42 19477472-6 2009 After 9 months of treatment, obese children with lowered BMI SD score (SDS-BMI) displayed a significant decrease in insulin (P = .011), homeostasis model assessment of insulin resistance (P = .012), CRP (P = .006), and interleukin-6 (IL-6) (P = .045) levels compared with obese children with stable SDS-BMI; they also displayed a nonsignificant drop in sICAM levels. Sodium Dodecyl Sulfate 71-74 C-reactive protein Homo sapiens 199-202 19477472-7 2009 Similarly, obese children with lowered SDS-BMI displayed a decrease in CRP (P = .005) and IL-6 (P = .065) compared with baseline levels before treatment. Sodium Dodecyl Sulfate 39-42 C-reactive protein Homo sapiens 71-74 19477472-8 2009 In the total obese group, changes in SDS-BMI correlated positively with changes in CRP (P = .035), IL-6 (P = .027), and sICAM-1 (P = .038) levels. Sodium Dodecyl Sulfate 37-40 C-reactive protein Homo sapiens 83-86 19477472-9 2009 Only SDS-BMI was an independent predictive factor for CRP (P = .031), IL-6 (P = .027), and sICAM-1 (P = .033). Sodium Dodecyl Sulfate 5-8 C-reactive protein Homo sapiens 54-57 19464675-9 2009 The urinary BPA concentrations were positively associated with MDA, 8-OHdG, and CRP levels in the postmenopausal women; however, such associations did not exist in men and premenopausal women. bisphenol A 12-15 C-reactive protein Homo sapiens 80-83 19621193-1 2009 OBJECTIVES: Aims of the study were 1) to investigate the association of C-reactive protein (CRP) with lipid (i.e. total, LDL, and HDL cholesterol, triglycerides) concentrations, and to evaluate their predictive value for mortality in very old subjects. Triglycerides 147-160 C-reactive protein Homo sapiens 72-90 19621193-11 2009 In the older age group, significant inverse associations of CRP with total (p=0.002), LDL (p=0.007), and HDL cholesterol (p=0.002) were found, even after adjustment for potential confounders. Cholesterol 109-120 C-reactive protein Homo sapiens 60-63 19621193-13 2009 CONCLUSION: An inverse relationship of total, LDL, and HDL cholesterol with CRP is present in very old persons. Cholesterol 59-70 C-reactive protein Homo sapiens 76-79 19415724-5 2009 Subjects with vitamin D deficiency [25(OH)D level less than 50 nmol/L (20 ng/mL)] had higher mean values of serum C-reactive protein (CRP) (2.40 mg/L vs. 0.84 mg/L, P = 0.02) and creatinine (1.75 mg/dL vs. 1.24 mg/dL, P = 0.03) and lower serum albumin values (3.12 g/dL vs. 3.39 g/dL, P = 0.003) compared to subjects without vitamin D deficiency. Vitamin D 14-23 C-reactive protein Homo sapiens 114-132 19520972-9 2009 The functional consequence is the unmasking of proinflammatory effects of CRP as demonstrated in experimental settings that are pathophysiologically relevant for atherogenesis: compared to pCRP, mCRP induces enhanced monocyte chemotaxis; monocyte activation, as determined by conformational change of integrin Mac-1; generation of reactive oxygen species; and monocyte adhesion under static and physiological flow conditions. Reactive Oxygen Species 331-354 C-reactive protein Homo sapiens 74-77 19520972-10 2009 In conclusion, we demonstrate mCRP generation via pCRP dissociation on activated platelets and H(2)O(2)-treated apoptotic THP-1 and Jurkat T cells, thereby identifying a mechanism of localized unmasking of the proinflammatory properties of CRP. Hydrogen Peroxide 95-103 C-reactive protein Homo sapiens 31-34 19398195-8 2009 RESULTS: Independent clinical predictors for steroid response vs. non-steroid response in biopsy proven AR were "days after transplantation" (p=0.01, adjusted hazard ratio (HR) 1.2), "decline in home spirometry slope" (p=0.03, HR 0.97), "adherence to home spirometry" (p=0.05, HR 0.98) and "serum CRP" (p=0.02, HR 0.87). Steroids 45-52 C-reactive protein Homo sapiens 297-301 19415724-5 2009 Subjects with vitamin D deficiency [25(OH)D level less than 50 nmol/L (20 ng/mL)] had higher mean values of serum C-reactive protein (CRP) (2.40 mg/L vs. 0.84 mg/L, P = 0.02) and creatinine (1.75 mg/dL vs. 1.24 mg/dL, P = 0.03) and lower serum albumin values (3.12 g/dL vs. 3.39 g/dL, P = 0.003) compared to subjects without vitamin D deficiency. Vitamin D 14-23 C-reactive protein Homo sapiens 134-137 19415724-8 2009 Association of vitamin D deficiency with higher serum CRP, serum creatinine and ISS stage at time of diagnosis suggests that vitamin D deficiency may portend poorer outcomes in subjects with MM. Vitamin D 15-24 C-reactive protein Homo sapiens 54-57 19516153-6 2009 Immediately after the third exercise bout, significant decreases for C-reactive protein (CRP), and plasma interleukin 6 (IL-6) and interleukin 10 (IL-10) were measured in Q-EGCG compared with P. Granulocyte colony-stimulating factor and CRP were reduced in Q-EGCG 14 h after exercise. q-egcg 171-177 C-reactive protein Homo sapiens 237-240 19486653-6 2009 The relationship of parental education with CRP in women persisted on multivariable adjustment for both lifestyle risk factors (smoking, alcohol consumption, sleep, exercise, body mass index) and individual SES. Alcohols 137-144 C-reactive protein Homo sapiens 44-47 19447426-5 2009 RESULTS: Calculated free testosterone and bioavailable testosterone were negatively related to International Prostate Symptom Score total scores and subscores (voiding symptoms) after adjusting for age, prostate volume, high sensitivity C-reactive protein and homeostasis model assessment of insulin resistance (p <0.05). Testosterone 25-37 C-reactive protein Homo sapiens 237-255 19447426-5 2009 RESULTS: Calculated free testosterone and bioavailable testosterone were negatively related to International Prostate Symptom Score total scores and subscores (voiding symptoms) after adjusting for age, prostate volume, high sensitivity C-reactive protein and homeostasis model assessment of insulin resistance (p <0.05). Testosterone 55-67 C-reactive protein Homo sapiens 237-255 19447426-7 2009 High sensitivity C-reactive protein was negatively correlated with serum total testosterone (r = -0.128, p = 0.038) and bioavailable testosterone (r = -0.126, p = 0.041), and homeostasis model assessment of insulin resistance was negatively correlated with serum total testosterone (r = -0.236, p <0.001), calculated free testosterone (r = -0.179, p = 0.003) and bioavailable testosterone (r = -0.162, r = 0.007). Testosterone 79-91 C-reactive protein Homo sapiens 17-35 19447426-7 2009 High sensitivity C-reactive protein was negatively correlated with serum total testosterone (r = -0.128, p = 0.038) and bioavailable testosterone (r = -0.126, p = 0.041), and homeostasis model assessment of insulin resistance was negatively correlated with serum total testosterone (r = -0.236, p <0.001), calculated free testosterone (r = -0.179, p = 0.003) and bioavailable testosterone (r = -0.162, r = 0.007). Testosterone 133-145 C-reactive protein Homo sapiens 17-35 19447426-7 2009 High sensitivity C-reactive protein was negatively correlated with serum total testosterone (r = -0.128, p = 0.038) and bioavailable testosterone (r = -0.126, p = 0.041), and homeostasis model assessment of insulin resistance was negatively correlated with serum total testosterone (r = -0.236, p <0.001), calculated free testosterone (r = -0.179, p = 0.003) and bioavailable testosterone (r = -0.162, r = 0.007). Testosterone 133-145 C-reactive protein Homo sapiens 17-35 19447426-7 2009 High sensitivity C-reactive protein was negatively correlated with serum total testosterone (r = -0.128, p = 0.038) and bioavailable testosterone (r = -0.126, p = 0.041), and homeostasis model assessment of insulin resistance was negatively correlated with serum total testosterone (r = -0.236, p <0.001), calculated free testosterone (r = -0.179, p = 0.003) and bioavailable testosterone (r = -0.162, r = 0.007). Testosterone 133-145 C-reactive protein Homo sapiens 17-35 19447426-7 2009 High sensitivity C-reactive protein was negatively correlated with serum total testosterone (r = -0.128, p = 0.038) and bioavailable testosterone (r = -0.126, p = 0.041), and homeostasis model assessment of insulin resistance was negatively correlated with serum total testosterone (r = -0.236, p <0.001), calculated free testosterone (r = -0.179, p = 0.003) and bioavailable testosterone (r = -0.162, r = 0.007). Testosterone 133-145 C-reactive protein Homo sapiens 17-35 19394661-8 2009 Rosiglitazone significantly reduced plasma nitrotyrosine, high-sensitivity C-reactive protein, and von Willebrand antigen (P < .03 for all) and significantly increased plasma adiponectin (P < .05). Rosiglitazone 0-13 C-reactive protein Homo sapiens 75-93 19386745-6 2009 In the basic model adjusted for age, sex, and smoking, higher levels of 24-h sodium excretion were directly associated with serum CRP, with an increase in serum CRP of 1.20 mg/L per 100-mmol increment in sodium excretion (95% CI: 1.11, 1.30). Sodium 77-83 C-reactive protein Homo sapiens 130-133 21977284-10 2009 However, median CRP decreased from 2.35 to 2.14 mg/L during NAC therapy (p=0.04), while it increased from 2.24 to 2.65 mg/L with placebo. Acetylcysteine 60-63 C-reactive protein Homo sapiens 16-19 21977284-13 2009 However, NAC therapy decreased CRP levels, suggesting that this compound may have some efficacy in reducing systemic inflammation. Acetylcysteine 9-12 C-reactive protein Homo sapiens 31-34 19708997-6 2009 So far, no specific pharmacologic treatment, including atorvastatin, has been identified that can substantially reduce CRP and accompanying inflammation. Atorvastatin 55-67 C-reactive protein Homo sapiens 119-122 19386745-6 2009 In the basic model adjusted for age, sex, and smoking, higher levels of 24-h sodium excretion were directly associated with serum CRP, with an increase in serum CRP of 1.20 mg/L per 100-mmol increment in sodium excretion (95% CI: 1.11, 1.30). Sodium 77-83 C-reactive protein Homo sapiens 161-164 19386745-6 2009 In the basic model adjusted for age, sex, and smoking, higher levels of 24-h sodium excretion were directly associated with serum CRP, with an increase in serum CRP of 1.20 mg/L per 100-mmol increment in sodium excretion (95% CI: 1.11, 1.30). Sodium 204-210 C-reactive protein Homo sapiens 130-133 19386745-6 2009 In the basic model adjusted for age, sex, and smoking, higher levels of 24-h sodium excretion were directly associated with serum CRP, with an increase in serum CRP of 1.20 mg/L per 100-mmol increment in sodium excretion (95% CI: 1.11, 1.30). Sodium 204-210 C-reactive protein Homo sapiens 161-164 19386745-7 2009 However, this association was reduced after adjustment for body mass index, with an increase in serum CRP of 1.06 mg/L per 100-mmol increment in sodium excretion (95% CI: -1.02, 1.15). Sodium 145-151 C-reactive protein Homo sapiens 102-105 19386745-8 2009 CONCLUSIONS: We observed a linear association between an objective measure of sodium intake and serum CRP that may be influenced by confounding by body mass index. Sodium 78-84 C-reactive protein Homo sapiens 102-105 19259830-3 2009 We wanted to evaluate and compare the effects of treating with a one-year course of atorvastatin or simvastatin on inflammatory markers such as high sensitive C-reactive protein (hsCRP), fibrinogen, and ferritin in uncontrolled type 2 diabetic patients. Atorvastatin 84-96 C-reactive protein Homo sapiens 159-177 19136614-5 2009 mCRP binding depends on membrane cholesterol content and is synergistically mediated by the putative cholesterol binding consensus sequence of CRP (aa 35-47) and the C-terminal octapeptide (aa 199-206). Cholesterol 33-44 C-reactive protein Homo sapiens 1-4 19136614-5 2009 mCRP binding depends on membrane cholesterol content and is synergistically mediated by the putative cholesterol binding consensus sequence of CRP (aa 35-47) and the C-terminal octapeptide (aa 199-206). Cholesterol 101-112 C-reactive protein Homo sapiens 1-4 19318443-7 2009 This positive association between CRP and diabetes risk did not change when participants were stratified by age group, smoking status, level of obesity, alcohol drinking habit, or family history of diabetes. Alcohols 153-160 C-reactive protein Homo sapiens 34-37 19628101-8 2009 In men, there were statistically significant inverse relationships between dietary intake of n-3 or n-6 PUFA and serum CRP concentrations (P for trend = .03 and .008, respectively). n-6 pufa 100-108 C-reactive protein Homo sapiens 119-122 19398238-5 2009 There was an inverse correlation between intestinal iron absorption and plasma hepcidin (r = -0.61, p < 0.001), HOMA (r = -0.35, p = 0.01) and C reactive protein (r = -0.52, p < 0.001). Iron 52-56 C-reactive protein Homo sapiens 146-164 19583145-11 2009 The association between CRP and common carotid artery intima-media thickness remained highly significant after controlling for body mass index, blood pressure, total cholesterol, low density lipoprotein cholesterol, triglycerides, glycosylated hemoglobin and smoking (p < 0.01). Cholesterol 166-177 C-reactive protein Homo sapiens 24-27 19583145-11 2009 The association between CRP and common carotid artery intima-media thickness remained highly significant after controlling for body mass index, blood pressure, total cholesterol, low density lipoprotein cholesterol, triglycerides, glycosylated hemoglobin and smoking (p < 0.01). Triglycerides 216-229 C-reactive protein Homo sapiens 24-27 19488607-1 2009 OBJECTIVE: To study if metformin, when administered to first-degree relatives of type 2 diabetes mellitus subjects who have metabolic syndrome and normal glucose tolerance, could improve the cardiovascular risk profile and reduce the levels of both C-reactive protein and fibrinogen. Metformin 23-32 C-reactive protein Homo sapiens 249-267 19357218-8 2009 C-reactive protein was elevated in 28.8 +/- 3.1% of females with ID by the ferritin model but not by the body iron model and in 0% of persons with ID by the body iron model but not by the ferritin model. Iron 110-114 C-reactive protein Homo sapiens 0-18 19357218-8 2009 C-reactive protein was elevated in 28.8 +/- 3.1% of females with ID by the ferritin model but not by the body iron model and in 0% of persons with ID by the body iron model but not by the ferritin model. Iron 162-166 C-reactive protein Homo sapiens 0-18 18691271-0 2009 Serum C-reactive protein (CRP) and microalbuminuria in relation to fasting and 2-h postload plasma glucose in a Chinese population. Glucose 99-106 C-reactive protein Homo sapiens 6-24 18691271-0 2009 Serum C-reactive protein (CRP) and microalbuminuria in relation to fasting and 2-h postload plasma glucose in a Chinese population. Glucose 99-106 C-reactive protein Homo sapiens 26-29 18691271-5 2009 RESULTS: Serum CRP concentration significantly increased from 1.62 mg/l in normoglycaemic subjects to 2.63 mg/l in subjects with impaired glucose regulation, and to 3.09 mg/l in newly diagnosed diabetic patients (P < 0.0001). Glucose 138-145 C-reactive protein Homo sapiens 15-18 18691271-7 2009 Both before and after adjustment for confounders, fasting and 2-h postload plasma glucose levels were significantly associated with serum CRP concentration and the risk of microalbuminuria (P < 0.003). Glucose 82-89 C-reactive protein Homo sapiens 138-141 18691271-8 2009 However, the association for CRP tended to be more prominent with 2-h postload plasma glucose than with fasting plasma glucose. Glucose 86-93 C-reactive protein Homo sapiens 29-32 18691271-8 2009 However, the association for CRP tended to be more prominent with 2-h postload plasma glucose than with fasting plasma glucose. Glucose 119-126 C-reactive protein Homo sapiens 29-32 18691271-9 2009 Indeed, with adjustments applied, for 1 SD change in fasting and 2-h postload plasma glucose concentration, serum CRP concentration increased by 14% and 18% (between the two regression coefficients, P = 0.01), respectively. Glucose 85-92 C-reactive protein Homo sapiens 114-117 18691271-11 2009 CONCLUSIONS: Our finding suggests that in Chinese plasma glucose, especially 2-h postload, is associated with biological markers of cardiovascular disease, such as serum CRP concentration and microalbuminuria. Glucose 57-64 C-reactive protein Homo sapiens 170-173 19478633-8 2009 RESULTS: Among the laboratory findings that showed significant correlation with the extent of TAE, the white blood cell count and C-reactive protein concentration were found to have a relatively high correlation (r = 0.540 and 0.514, respectively). tae 94-97 C-reactive protein Homo sapiens 130-148 19554531-0 2009 [C-reactive protein in the assessment of iron status in patients on hemodialysis]. Iron 41-45 C-reactive protein Homo sapiens 1-19 19554531-7 2009 On the other hand, measurement of CRP, which is both sensitive and easily measurable with automated techniques, might possibly be used as a surrogate measure of iron status in hemodialysis patients. Iron 161-165 C-reactive protein Homo sapiens 34-37 19276989-12 2009 Coculturing with CRP caused a significant upregulate expression of RAGE in EPCs, increased ROS production, altered antioxidant defenses, and induced EPC apoptosis. Reactive Oxygen Species 91-94 C-reactive protein Homo sapiens 17-20 19425005-5 2009 PC bound to CRP in the presence of metal ions Ca(2+) and Mg(2+). Metals 35-40 C-reactive protein Homo sapiens 12-15 19390750-1 2009 OBJECTIVE: To elucidate the association between vitamin D status, C-reactive protein (CRP) and fibrinogen. Vitamin D 48-57 C-reactive protein Homo sapiens 86-89 19390751-2 2009 OBJECTIVE: To investigated the effects of oral riboflavin supplementation on plasma total homocysteine, ferritin, uric acid and C-reactive protein concentration in elderly people with a low riboflavin status. Riboflavin 47-57 C-reactive protein Homo sapiens 128-146 19352125-8 2009 In multivariate Cox regression analysis, serum phosphate concentration remained a statistically significant predictor of all-cause mortality after adjustment for traditional cardiovascular risk factors, estimated glomerular filtration rate, and high sensitivity C reactive protein (P=0.036) and after adjustment for renal graft failure (P=0.001). Phosphates 47-56 C-reactive protein Homo sapiens 262-280 19721908-8 2009 Two patients presented a bad evolution; they received 4.2 and 5.2 md/d of Zn and showed an increase of IL6 levels, maintained high levels of IL6sR but C-RP levels decreased. Zinc 74-76 C-reactive protein Homo sapiens 151-155 19359484-1 2009 The cAMP-mediated allosteric transition in the catabolite activator protein (CAP; also known as the cAMP receptor protein, CRP) is a textbook example of modulation of DNA-binding activity by small-molecule binding. Cyclic AMP 4-8 C-reactive protein Homo sapiens 123-126 19491539-4 2009 Low testosterone concentrations in men with type 2 diabetes have also been related to a higher C-reactive protein concentrations, lower hematocrit, increased total and regional adiposity, lower bone mineral density, and erectile dysfunction. Testosterone 4-16 C-reactive protein Homo sapiens 95-113 19565136-8 2009 There was a positive correlation between CRP and total cholesterol (rs = 0.21,p = 0.05), CRP and LDL-cholesterol (rs=0.22,p=0.04) and between CRP and leukocyte count (rs = 0.32, p = 0.02) in both groups. Cholesterol 55-66 C-reactive protein Homo sapiens 41-44 19565136-8 2009 There was a positive correlation between CRP and total cholesterol (rs = 0.21,p = 0.05), CRP and LDL-cholesterol (rs=0.22,p=0.04) and between CRP and leukocyte count (rs = 0.32, p = 0.02) in both groups. Cholesterol 101-112 C-reactive protein Homo sapiens 89-92 19565136-8 2009 There was a positive correlation between CRP and total cholesterol (rs = 0.21,p = 0.05), CRP and LDL-cholesterol (rs=0.22,p=0.04) and between CRP and leukocyte count (rs = 0.32, p = 0.02) in both groups. Cholesterol 101-112 C-reactive protein Homo sapiens 89-92 19225064-11 2009 In the regression model, significant predictors of CRP included AHI, waist circumference, and triglycerides (adjusted R(2), 0.33, p = 0.001, p = 0.002, p = 0.018, respectively). Triglycerides 94-107 C-reactive protein Homo sapiens 51-54 18775100-9 2009 The study suggests that lignan might modulate CRP levels in type 2 diabetics. Lignans 24-30 C-reactive protein Homo sapiens 46-49 19225199-0 2009 Short-term amiodarone treatment attenuates the production of monocyte cytokines and chemokines by C-reactive protein and improves cardiac function in patients with idiopathic dilated cardiomyopathy and ventricular tachycardia. Amiodarone 11-21 C-reactive protein Homo sapiens 98-116 19225199-2 2009 Amiodarone reduces circulating cytokine levels, so it may attenuate the production of monocyte cytokines and chemokines by C-reactive protein (CRP) and thus improve the left ventricular ejection fraction (LVEF) in dilated cardiomyopathy (DCM) patients with ventricular tachycardia (VT). Amiodarone 0-10 C-reactive protein Homo sapiens 123-141 19225199-2 2009 Amiodarone reduces circulating cytokine levels, so it may attenuate the production of monocyte cytokines and chemokines by C-reactive protein (CRP) and thus improve the left ventricular ejection fraction (LVEF) in dilated cardiomyopathy (DCM) patients with ventricular tachycardia (VT). Amiodarone 0-10 C-reactive protein Homo sapiens 143-146 19225199-5 2009 The LVEF and the CRP-induced monocyte cytokine and chemokine production were unchanged in the No amiodarone group after 4 weeks; however, LVEF in the Amiodarone group was increased (32.7+/-6.9 to 39.2+/-6.9%; P=0.005), and TNF-alpha and MCP-1 production in the Amiodarone group were decreased (P=0.012, respectively). Amiodarone 150-160 C-reactive protein Homo sapiens 17-20 19225199-5 2009 The LVEF and the CRP-induced monocyte cytokine and chemokine production were unchanged in the No amiodarone group after 4 weeks; however, LVEF in the Amiodarone group was increased (32.7+/-6.9 to 39.2+/-6.9%; P=0.005), and TNF-alpha and MCP-1 production in the Amiodarone group were decreased (P=0.012, respectively). Amiodarone 261-271 C-reactive protein Homo sapiens 17-20 19225199-6 2009 CONCLUSIONS: Amiodarone attenuates the production of monocyte cytokines and chemokines by CRP, and improves LVEF in CHF patients with VT. Amiodarone 13-23 C-reactive protein Homo sapiens 90-93 18242731-0 2009 C-reactive protein in risk prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. Glucose 83-90 C-reactive protein Homo sapiens 0-18 19280766-3 2009 We here review recent findings that have linked plasma CRP levels to single nucleotide polymorphisms in hepatic nuclear factor (HNF) 1-alpha, a transcription factor with a wide range of functions, including many involved in cholesterol, bile acid, and lipoprotein metabolism. Cholesterol 224-235 C-reactive protein Homo sapiens 55-58 19280766-3 2009 We here review recent findings that have linked plasma CRP levels to single nucleotide polymorphisms in hepatic nuclear factor (HNF) 1-alpha, a transcription factor with a wide range of functions, including many involved in cholesterol, bile acid, and lipoprotein metabolism. Bile Acids and Salts 237-246 C-reactive protein Homo sapiens 55-58 19213794-6 2009 A significant correlation was found between CRP levels, time spent at night with arterial oxygen saturation <90% and ODI. Oxygen 90-96 C-reactive protein Homo sapiens 44-47 19297430-6 2009 When we used previously established categories to define CRP concentrations (low, <1 mg/L; intermediate, 1-3 mg/L; or high, >3 mg/L), we found a CRP x diet interaction on change in triglyceride concentrations (P = 0.03) and trends for CRP x diet interaction on change in LDL (P = 0.06) and total cholesterol (P = 0.07). Triglycerides 187-199 C-reactive protein Homo sapiens 57-60 19297430-6 2009 When we used previously established categories to define CRP concentrations (low, <1 mg/L; intermediate, 1-3 mg/L; or high, >3 mg/L), we found a CRP x diet interaction on change in triglyceride concentrations (P = 0.03) and trends for CRP x diet interaction on change in LDL (P = 0.06) and total cholesterol (P = 0.07). Triglycerides 187-199 C-reactive protein Homo sapiens 151-154 19297430-6 2009 When we used previously established categories to define CRP concentrations (low, <1 mg/L; intermediate, 1-3 mg/L; or high, >3 mg/L), we found a CRP x diet interaction on change in triglyceride concentrations (P = 0.03) and trends for CRP x diet interaction on change in LDL (P = 0.06) and total cholesterol (P = 0.07). Triglycerides 187-199 C-reactive protein Homo sapiens 151-154 19297430-6 2009 When we used previously established categories to define CRP concentrations (low, <1 mg/L; intermediate, 1-3 mg/L; or high, >3 mg/L), we found a CRP x diet interaction on change in triglyceride concentrations (P = 0.03) and trends for CRP x diet interaction on change in LDL (P = 0.06) and total cholesterol (P = 0.07). Cholesterol 302-313 C-reactive protein Homo sapiens 57-60 19297430-6 2009 When we used previously established categories to define CRP concentrations (low, <1 mg/L; intermediate, 1-3 mg/L; or high, >3 mg/L), we found a CRP x diet interaction on change in triglyceride concentrations (P = 0.03) and trends for CRP x diet interaction on change in LDL (P = 0.06) and total cholesterol (P = 0.07). Cholesterol 302-313 C-reactive protein Homo sapiens 151-154 19297430-6 2009 When we used previously established categories to define CRP concentrations (low, <1 mg/L; intermediate, 1-3 mg/L; or high, >3 mg/L), we found a CRP x diet interaction on change in triglyceride concentrations (P = 0.03) and trends for CRP x diet interaction on change in LDL (P = 0.06) and total cholesterol (P = 0.07). Cholesterol 302-313 C-reactive protein Homo sapiens 151-154 19028751-12 2009 Multivariate regression analysis also demonstrated a positive correlation between inflammatory risk (high-sensitivity C-reactive protein >3 mg/L) and blood Cd levels. Cadmium 159-161 C-reactive protein Homo sapiens 118-136 18758684-3 2009 There was significant reduction of CRP level in pioglitazone and rosiglitazone group. Rosiglitazone 65-78 C-reactive protein Homo sapiens 35-38 19164341-7 2009 RESULTS: The initial data (January-June 2005) showed that the average number of requests for CRP was 918 per month from A&E and 545 per month for MAU. Adenosine Monophosphate 122-125 C-reactive protein Homo sapiens 93-96 19222932-12 2009 Children with RSV and raised CRP (>5 mg/L) had higher copper and lower zinc/copper ratios than those with low CRP (< or =5 mg/L). Copper 57-63 C-reactive protein Homo sapiens 29-32 19222932-12 2009 Children with RSV and raised CRP (>5 mg/L) had higher copper and lower zinc/copper ratios than those with low CRP (< or =5 mg/L). Copper 79-85 C-reactive protein Homo sapiens 29-32 19222932-13 2009 Children with HMPV and raised CRP had higher copper and lower zinc concentrations than children with low CRP. Copper 45-51 C-reactive protein Homo sapiens 30-33 19222932-14 2009 Children with RSV/HMPV and raised CRP had higher copper concentrations. Copper 49-55 C-reactive protein Homo sapiens 34-37 19067673-9 2009 Reductions in high-sensitivity C-reactive protein were observed in atorvastatin-treated patients with alleles >10/>10 and 10/10. Atorvastatin 67-79 C-reactive protein Homo sapiens 31-49 19067673-11 2009 In conclusion, the changes induced by atorvastatin treatment on low-density lipoprotein cholesterol, total cholesterol, triglycerides, high-sensitivity C-reactive protein and free F(2)-isoprostane concentrations were not related to the presence of 3-hydroxy-3-methylglutaryl-coenzyme A reductase polymorphism (TTA)n. Atorvastatin 38-50 C-reactive protein Homo sapiens 152-170 18651197-8 2009 CRP is also increased with increasing waist, glucose level, hemoglobin, albumin, Ca, insulin, C-peptide, and metabolic syndrome while WBC is increased with metabolic syndrome but decreased with increasing age. Glucose 45-52 C-reactive protein Homo sapiens 0-3 18651197-9 2009 Multivariate analysis confirmed fasting glucose level and hemoglobin are independent predictors of the elevation of CRP while age is the only independent predictor for elevated WBC. Glucose 40-47 C-reactive protein Homo sapiens 116-119 19370277-13 2009 Patients with vitamin D deficiency had significant differences in body mass index (p=0.003), metabolic syndrome (p=0.05), high sensitive C-reactive protein (p=0.009), microalbuminuria (p=0.04), and glumerular filtration rate (p=0.02), compared to patients with sufficient vitamin D. Vitamin D 14-23 C-reactive protein Homo sapiens 137-155 18687433-1 2009 BACKGROUND: Fatty acid (FA) composition in serum has been associated with C-reactive protein (CRP), but associations with other markers of inflammation and endothelial function, e.g. adhesion molecules are unknown. Fatty Acids 12-22 C-reactive protein Homo sapiens 74-92 18687433-1 2009 BACKGROUND: Fatty acid (FA) composition in serum has been associated with C-reactive protein (CRP), but associations with other markers of inflammation and endothelial function, e.g. adhesion molecules are unknown. Fatty Acids 12-22 C-reactive protein Homo sapiens 94-97 18687433-8 2009 After adjusting for BMI, smoking, physical activity, alcohol consumption and lipid-lowering therapy, the proportion of palmitoleic acid and SCD-1 index were positively correlated with CRP concentrations (P=0.003 and P=0.001, respectively). palmitoleic acid 119-135 C-reactive protein Homo sapiens 184-187 19421644-0 2009 Association between C-reactive protein and coronary calcium score in coronary artery disease. Calcium 52-59 C-reactive protein Homo sapiens 20-38 19092166-9 2009 Elevated fasting glucose (>6.2 mmol/l) markedly increased the predictive power of inflammatory markers (IL-18: 5.5 [1.4-21.1], IL-6: 3.5 [1.0-11.8], and CRP: 3.5 [1.0-11.9]). Glucose 17-24 C-reactive protein Homo sapiens 156-159 19151033-7 2009 RESULTS: Treatment with simvastatin or atorvastatin decreased CRP-induced release of CCL2, CCL3 and CCL4. Atorvastatin 39-51 C-reactive protein Homo sapiens 62-65 19058981-9 2009 CRP was lower with HES200/0.62 (178 mg/mL) than gelatine (221 mg/mL) and HES130/0.4 (223 mg/mL) at 48 h (p=0.049 and p=0.009 respectively). hes130 73-79 C-reactive protein Homo sapiens 0-3 19248856-8 2009 Serum C-reactive protein was significantly inversely associated with intakes of fruit (r=-0.19; P=0.004), vitamin C (r=-0.13, P=0.03), and folate (r=-0.18; P=0.004). Folic Acid 139-145 C-reactive protein Homo sapiens 6-24 19119287-8 2009 Higher C-reactive protein and white blood cell count and lower serum albumin were associated with higher levels of cystatin C and lower levels of creatinine. Creatinine 146-156 C-reactive protein Homo sapiens 7-25 19116941-6 2009 After adjustment for sex, age, BMI, education, alcohol consumption, smoking, hypertension status, recreational physical activity and occupational physical activity, the ORs across quartiles of CRP were 1.00, 1.43, 2.14 and 2.29 for IFG (P for trend: 0.025) and 1.00, 1.85, 2.32 and 2.79 for IGT (P for trend: 0.012). Alcohols 47-54 C-reactive protein Homo sapiens 193-196 19019628-8 2009 RESULTS: When we compared CRP and serum lipids, we found a statistically significant negative correlation between levels of CRP and total cholesterol (P < 0.05), HDL (P < 0.01), and LDL (P < 0.05). Cholesterol 138-149 C-reactive protein Homo sapiens 26-29 19019628-8 2009 RESULTS: When we compared CRP and serum lipids, we found a statistically significant negative correlation between levels of CRP and total cholesterol (P < 0.05), HDL (P < 0.01), and LDL (P < 0.05). Cholesterol 138-149 C-reactive protein Homo sapiens 124-127 19019628-11 2009 CONCLUSION: A significant negative correlation between levels of inflammation markers (neopterin in urine, CRP) and total cholesterol and HDL was found. Cholesterol 122-133 C-reactive protein Homo sapiens 107-110 19151033-9 2009 Treatments with 1 microM simvastatin or atorvastatin significantly inhibited monocyte migration in response to CRP. Atorvastatin 40-52 C-reactive protein Homo sapiens 111-114 18777130-7 2009 From the results of stepwise multiple linear regression analysis, the lowest oxygen saturation was a significant determinant of FMD (beta = 0.25, p < 0.01, adjusted R (2) = 6%), and BMI (beta = 0.22, p < 0.05) and waist-to-hip ratio (beta = 0.21, p < 0.05) were significant variables to explain CRP (adjusted R (2) = 11%, p < 0.01) in the middle aged patients. Oxygen 77-83 C-reactive protein Homo sapiens 304-307 19118524-3 2009 In this study, we report that two synthetic FXR agonists, WAY-362450 and GW4064, suppressed interleukin-6-induced CRP expression in human Hep3B hepatoma cells. GW 4064 73-79 C-reactive protein Homo sapiens 114-117 19143723-7 2009 Along with the improvement of the metabolic syndrome upon testosterone administration, there was also an improvement of the IPSS and of RBV of urine and CRP. Testosterone 58-70 C-reactive protein Homo sapiens 153-156 19035968-6 2009 Arachidonic acid correlated inversely with HBAI in UC and total and HDL cholesterol were inversely related to C-reactive protein (CRP) in CD while HDL correlated with CRP in UC. Arachidonic Acid 0-16 C-reactive protein Homo sapiens 110-128 19035968-6 2009 Arachidonic acid correlated inversely with HBAI in UC and total and HDL cholesterol were inversely related to C-reactive protein (CRP) in CD while HDL correlated with CRP in UC. Arachidonic Acid 0-16 C-reactive protein Homo sapiens 130-133 19035968-6 2009 Arachidonic acid correlated inversely with HBAI in UC and total and HDL cholesterol were inversely related to C-reactive protein (CRP) in CD while HDL correlated with CRP in UC. Arachidonic Acid 0-16 C-reactive protein Homo sapiens 167-170 19035968-6 2009 Arachidonic acid correlated inversely with HBAI in UC and total and HDL cholesterol were inversely related to C-reactive protein (CRP) in CD while HDL correlated with CRP in UC. Cholesterol 72-83 C-reactive protein Homo sapiens 110-128 19035968-6 2009 Arachidonic acid correlated inversely with HBAI in UC and total and HDL cholesterol were inversely related to C-reactive protein (CRP) in CD while HDL correlated with CRP in UC. Cholesterol 72-83 C-reactive protein Homo sapiens 130-133 19166691-4 2009 Effects within subgroups (age, gender, race, body mass index, diabetes mellitus, metabolic syndrome, CAD, baseline CRP or lipids, and statin potency) and correlations between CRP and LDL cholesterol were also examined. Cholesterol 187-198 C-reactive protein Homo sapiens 175-178 19166691-11 2009 Correlations between changes in CRP and changes in LDL cholesterol were weakly positive and significant only when ezetimibe was added to statin treatment. Cholesterol 55-66 C-reactive protein Homo sapiens 32-35 19167957-8 2009 The best-fit linear model to predict serum iron levels included both serum transferrin receptor and C-reactive protein following log-transformation for normalization of these variables. Iron 43-47 C-reactive protein Homo sapiens 100-118 18492490-8 2009 Even after adjustment for age, sex, diabetes mellitus, hypertension, smoking, eGFR and CRP, the positive association of CA-IMT with SdLDL-C remained significant, and again stronger than the associations with others lipid parameters. sdldl-c 132-139 C-reactive protein Homo sapiens 87-90 19075028-3 2009 The expression of soluble heat-labile toxin is subject to catabolite (glucose) activation, and three binding sites for cAMP receptor protein (CRP or CAP) were identified upstream and within the toxin promoter by DNase I footprinting. Glucose 70-77 C-reactive protein Homo sapiens 119-152 19075028-9 2009 Since glucose inhibits the activity of CRP by suppressing the pathogen"s synthesis of cyclic AMP (cAMP), the concentration of glucose in the lumen of the small intestine may determine which enterotoxin is maximally expressed. Glucose 6-13 C-reactive protein Homo sapiens 39-42 19075028-9 2009 Since glucose inhibits the activity of CRP by suppressing the pathogen"s synthesis of cyclic AMP (cAMP), the concentration of glucose in the lumen of the small intestine may determine which enterotoxin is maximally expressed. Cyclic AMP 86-96 C-reactive protein Homo sapiens 39-42 19075028-9 2009 Since glucose inhibits the activity of CRP by suppressing the pathogen"s synthesis of cyclic AMP (cAMP), the concentration of glucose in the lumen of the small intestine may determine which enterotoxin is maximally expressed. Cyclic AMP 98-102 C-reactive protein Homo sapiens 39-42 19075028-9 2009 Since glucose inhibits the activity of CRP by suppressing the pathogen"s synthesis of cyclic AMP (cAMP), the concentration of glucose in the lumen of the small intestine may determine which enterotoxin is maximally expressed. Glucose 126-133 C-reactive protein Homo sapiens 39-42 19073345-9 2009 CONCLUSION: This study shows that CRP and neopterin have a role in differentiating bacterial from viral causes of ARTI, and the C/N ratio yields optimal differentiation in the ED setting. Carbon 0-1 C-reactive protein Homo sapiens 34-37 19073345-9 2009 CONCLUSION: This study shows that CRP and neopterin have a role in differentiating bacterial from viral causes of ARTI, and the C/N ratio yields optimal differentiation in the ED setting. Nitrogen 2-3 C-reactive protein Homo sapiens 34-37 19270348-0 2009 [Effect of atorvastatin on lipopolysaccharide-induced expression of C-reactive protein in human pulmonary epithelial cells]. Atorvastatin 11-23 C-reactive protein Homo sapiens 68-86 19270348-1 2009 OBJECTIVE: To determine the effect of atorvastatin on lipopolysaccharide-induced expression of C-reactive protein in cultured A549 cells. Atorvastatin 38-50 C-reactive protein Homo sapiens 95-113 19270348-6 2009 Atorvastatin significantly decreased the lipopolysaccharide induced the mRNA expression and the production of C-reactive protein in a dose dependent manner in A549 cells (P<0.05). Atorvastatin 0-12 C-reactive protein Homo sapiens 110-128 19270348-7 2009 CONCLUSION: Atorvastatin downregulates lipopolysaccharide-induced expression of C-reactive protein in cultured A549 cells, which may be its mechanism of anti-inflammation. Atorvastatin 12-24 C-reactive protein Homo sapiens 80-98 19174069-2 2009 The aim of our study was to evaluate the effect of enteral nutrition supplemented with a high dose of arginine on c-reactive protein (CRP), interleukin 6 (IL6) and tumoral necrosis factor (TNF alpha) in surgical head and neck cancer patients. Arginine 102-110 C-reactive protein Homo sapiens 114-132 19573460-13 2009 ESR and C reactive protein values were significantly higher in patients with CD compared with patients with UC (chi(2) = 15.938, P < 0.01; chi(2) = 11.184, P < 0.01). Cadmium 77-79 C-reactive protein Homo sapiens 8-26 19812444-7 2009 When combined, d4T+CRP also led to reduced triacylglycerol accumulation, an effect not explained by CRP-induced apoptosis or cell death, but instead confirmed by reduced PPARgamma and C/EBPalpha expression and decreased expression of factors involved in lipogenesis, such as fatty acid synthase and acetyl-coenzyme A carboxylase. Triglycerides 43-58 C-reactive protein Homo sapiens 19-22 19114172-8 2009 Although logistic regression models demonstrated that CRP over the intermediate term did not predict new-onset metabolic syndrome at the final examination, CRP did predict an increase in glucose and new-onset diabetes. Glucose 187-194 C-reactive protein Homo sapiens 156-159 19803417-3 2009 Epidemiological studies have revealed demographic and socioeconomic factors that associate with CRP concentration; these include age, sex, birth weight, ethnicity, socioeconomic status, body mass index (BMI), fiber consumption, alcohol intake, and dietary fatty acids. Alcohols 228-235 C-reactive protein Homo sapiens 96-99 19803417-3 2009 Epidemiological studies have revealed demographic and socioeconomic factors that associate with CRP concentration; these include age, sex, birth weight, ethnicity, socioeconomic status, body mass index (BMI), fiber consumption, alcohol intake, and dietary fatty acids. Fatty Acids 256-267 C-reactive protein Homo sapiens 96-99 19812444-9 2009 Addition of rosiglitazone (1 microM) had no effect on reduced adipogenesis, but partially rescued the effects of d4T and d4T+CRP on adiponectin production. Rosiglitazone 12-25 C-reactive protein Homo sapiens 125-128 19778286-1 2009 BACKGROUND: C-reactive protein (CRP) is able to bind phospholipids (mainly phosphocholine) in the presence of calcium ions. Phospholipids 53-66 C-reactive protein Homo sapiens 12-30 19929286-11 2009 Serotonin level was negatively correlated with microalbuminuria (p<0.001, r = -0.3), uric acid (p<0.01, r = -0.3), and CRP (p<0.01, r = -0.35). Serotonin 0-9 C-reactive protein Homo sapiens 125-128 19130414-8 2009 A significant positive correlation between CRP and body mass index, waist circumference, glucose at admission, resistin, and leptin and a negative relation of CRP to HDL-cholesterol and adiponectin were observed. Cholesterol 170-181 C-reactive protein Homo sapiens 159-162 19130414-9 2009 In univariate logistic regression analysis, variables associated with a level of CRP above the fourth quartile were history of angina, obesity, diabetes, glucose at admission, resistin, leptin, and adiponectin, and independent predictors were glucose at admission and resistin. Glucose 154-161 C-reactive protein Homo sapiens 81-84 19130414-9 2009 In univariate logistic regression analysis, variables associated with a level of CRP above the fourth quartile were history of angina, obesity, diabetes, glucose at admission, resistin, leptin, and adiponectin, and independent predictors were glucose at admission and resistin. Glucose 243-250 C-reactive protein Homo sapiens 81-84 19130414-10 2009 To predict the elevated CRP level the optimal cut-off for glucose at admission was 144 mg/dL (sensitivity 84%, specificity 86%) and for resistin was 21.5 ng/mL (sensitivity 79%, specificity 71%). Glucose 58-65 C-reactive protein Homo sapiens 24-27 19130414-11 2009 CONCLUSIONS: Glucose at admission and resistin are independently associated with elevated levels of CRP in men during the early stage of STEMI. Glucose 13-20 C-reactive protein Homo sapiens 100-103 18974641-7 2009 C-reactive protein expression was less in the GGA + CDDP group compared with the CDDP group. Cisplatin 52-56 C-reactive protein Homo sapiens 0-18 18974641-7 2009 C-reactive protein expression was less in the GGA + CDDP group compared with the CDDP group. Cisplatin 81-85 C-reactive protein Homo sapiens 0-18 19575548-7 2009 Age, male gender, cigarette smoking, physical activity, body mass index, total cholesterol, high density lipoprotein cholesterol, gamma-glutamyltransferase, and uric acid were independently associated with CRP concentrations. Cholesterol 79-90 C-reactive protein Homo sapiens 206-209 19778286-1 2009 BACKGROUND: C-reactive protein (CRP) is able to bind phospholipids (mainly phosphocholine) in the presence of calcium ions. Phospholipids 53-66 C-reactive protein Homo sapiens 32-35 19778286-1 2009 BACKGROUND: C-reactive protein (CRP) is able to bind phospholipids (mainly phosphocholine) in the presence of calcium ions. Calcium 110-117 C-reactive protein Homo sapiens 12-30 19778286-1 2009 BACKGROUND: C-reactive protein (CRP) is able to bind phospholipids (mainly phosphocholine) in the presence of calcium ions. Calcium 110-117 C-reactive protein Homo sapiens 32-35 19778286-2 2009 We investigated the use of this property for developing an affordable turbidimetrical CRP assay based on diluted soy oil. diluted soy oil 105-120 C-reactive protein Homo sapiens 86-89 19778286-4 2009 After 30 min of incubation at 37 degrees C, the CRP-phospholipids complexes were measured by turbidimetry (660 nm/700 nm) with a Cobas 6000 analyzer (Roche). Phospholipids 52-65 C-reactive protein Homo sapiens 48-51 19851514-9 2009 A small reduction of CRP levels after NSAIDs use and promptly ameliorated CRP and symptoms by a low-dose steroid therapy, which was commonly observed in patients with PMR, were also found in a patient with RS3PE syndrome. Steroids 105-112 C-reactive protein Homo sapiens 21-24 19851514-9 2009 A small reduction of CRP levels after NSAIDs use and promptly ameliorated CRP and symptoms by a low-dose steroid therapy, which was commonly observed in patients with PMR, were also found in a patient with RS3PE syndrome. Steroids 105-112 C-reactive protein Homo sapiens 74-77 19204430-8 2009 The serum CRP level of PCOS patients was positively correlated with BMI (R = 0.57, p < 0.001) and triglycerides (R = 0.47, p < 0.001) and negatively correlated with the insulin sensitivity index (R = -0.60, p < 0.001). Triglycerides 101-114 C-reactive protein Homo sapiens 10-13 19188739-4 2009 After 6 weeks of metformin therapy (n = 37) there was a significant reduction in BMI (p < 0.001), waist (p < 0.001) and CRP (p < 0.01), while at 6 months there was not only a significant reduction in BMI and waist but also in HOMA-R (p = 0.01) and IL-6 levels (p < 0.01) with no further reduction of CRP. Metformin 17-26 C-reactive protein Homo sapiens 126-129 19188739-4 2009 After 6 weeks of metformin therapy (n = 37) there was a significant reduction in BMI (p < 0.001), waist (p < 0.001) and CRP (p < 0.01), while at 6 months there was not only a significant reduction in BMI and waist but also in HOMA-R (p = 0.01) and IL-6 levels (p < 0.01) with no further reduction of CRP. Metformin 17-26 C-reactive protein Homo sapiens 312-315 19188739-6 2009 While short-term metformin therapy facilitates weight loss with a concomitant reduction in CRP, long-term therapy results in a reduction of IL-6 and insulin resistance. Metformin 17-26 C-reactive protein Homo sapiens 91-94 19188739-7 2009 Metformin-associated reduction of CRP levels prior to any significant changes in insulin resistance or IL-6 perhaps involves different mechanisms of action. Metformin 0-9 C-reactive protein Homo sapiens 34-37 19145586-10 2009 The optimal cut-off point of baseline CRP values was 2.1 mg/L, with 86% (95% CI 81-90) sensitivity and 75% (69-81) specificity in predicting the MS. Baseline CRP resulted associated with after-study glucose values in a multiple regression model (beta = 0.14; 0.08-0.20; p < 0.001). Glucose 199-206 C-reactive protein Homo sapiens 38-41 19145586-10 2009 The optimal cut-off point of baseline CRP values was 2.1 mg/L, with 86% (95% CI 81-90) sensitivity and 75% (69-81) specificity in predicting the MS. Baseline CRP resulted associated with after-study glucose values in a multiple regression model (beta = 0.14; 0.08-0.20; p < 0.001). Glucose 199-206 C-reactive protein Homo sapiens 158-161 18206145-9 2009 In control subjects, CRP and C3 correlated with glucose and triglyceride, only CRP correlated with nonesterified fatty acids and cholesterol, and ASP correlated with triglyceride (again, all correlations were significant), whereas in subjects with PCOS, several of these correlations were lost, as a result of consistently higher levels of CRP and ASP regardless of BMI. Glucose 48-55 C-reactive protein Homo sapiens 21-24 18206145-9 2009 In control subjects, CRP and C3 correlated with glucose and triglyceride, only CRP correlated with nonesterified fatty acids and cholesterol, and ASP correlated with triglyceride (again, all correlations were significant), whereas in subjects with PCOS, several of these correlations were lost, as a result of consistently higher levels of CRP and ASP regardless of BMI. Triglycerides 60-72 C-reactive protein Homo sapiens 21-24 18206145-9 2009 In control subjects, CRP and C3 correlated with glucose and triglyceride, only CRP correlated with nonesterified fatty acids and cholesterol, and ASP correlated with triglyceride (again, all correlations were significant), whereas in subjects with PCOS, several of these correlations were lost, as a result of consistently higher levels of CRP and ASP regardless of BMI. Cholesterol 129-140 C-reactive protein Homo sapiens 79-82 18206145-9 2009 In control subjects, CRP and C3 correlated with glucose and triglyceride, only CRP correlated with nonesterified fatty acids and cholesterol, and ASP correlated with triglyceride (again, all correlations were significant), whereas in subjects with PCOS, several of these correlations were lost, as a result of consistently higher levels of CRP and ASP regardless of BMI. Cholesterol 129-140 C-reactive protein Homo sapiens 79-82 18940877-9 2009 RESULTS: After 12 wk atorvastatin, there was a significant reduction (mean +/- sem) in total cholesterol (4.6 +/- 0.2 vs. 3.4 +/- 0.2 mmol/liter, P < 0.01), low-density lipoprotein cholesterol (2.9 +/- 0.2 vs. 1.8 +/- 0.2 mmol/liter, P < 0.01), triglycerides (1.34 +/- 0.08 vs. 1.08 +/- 0.13 mmol/liter, P <0.01), high-sensitivity C-reactive protein (4.9 +/- 1.4 vs. 3.4 +/- 1.1 mg/liter, P = 0.04), free androgen index (13.4 +/- 0.6 vs. 8.7 +/- 0.4, P < 0.01), testosterone (4.1 +/- 0.2 vs. 2.9 +/- 0.1 nmol/liter, P < 0.01) and insulin resistance as measured by homeostasis model assessment for insulin resistance (HOMA-IR) (3.3 +/- 0.4 vs. 2.7 +/- 0.4). Atorvastatin 21-33 C-reactive protein Homo sapiens 340-358 19145387-8 2009 CRP value in this population had a statistically significant relation with admission to Intensive Care Unit (ICU) (p=0.008), length of hospital stay (p=0.025) and need for supplementary oxygen during hospital stay (p=0.022). Oxygen 186-192 C-reactive protein Homo sapiens 0-3 19084272-5 2009 Here, we show that both CFHR4 isoforms bind in the presence of calcium to native pentameric CRP, but not to modified CRP. Calcium 63-70 C-reactive protein Homo sapiens 92-95 19008869-8 2009 In treated HIV, subjects with higher CRP had significantly higher total cholesterol, VAT, and IMCL. Cholesterol 72-83 C-reactive protein Homo sapiens 37-40 18806816-6 2008 KEY RESULTS: In 8 of 10 patients, atorvastatin treatment reduced CRP (P=0.008) and sTNFRII (P=0.064). Atorvastatin 34-46 C-reactive protein Homo sapiens 65-68 19032692-0 2008 C-reactive protein levels and ageing male symptoms in hypogonadal men treated with testosterone supplementation. Testosterone 83-95 C-reactive protein Homo sapiens 0-18 19032692-5 2008 Testosterone administration resulted in a profound decline in CRP levels and AMS scores (both P < 0.001). Testosterone 0-12 C-reactive protein Homo sapiens 62-65 19032692-6 2008 There was a positive association between CRP levels and AMS scores over time (r = 0.22; P < 0.001), while adjusting for smoking, alcohol use, age, and body mass index. Alcohols 132-139 C-reactive protein Homo sapiens 41-44 18806816-9 2008 At the follow-up visit, 8 weeks after the atorvastatin treatment was terminated, CRP levels had returned to those seen before the treatment. Atorvastatin 42-54 C-reactive protein Homo sapiens 81-84 18946171-5 2008 When compared with patients with low CRP (<0.1 mg/dl), those with a high CRP (> or =0.1 mg/dl) had a significantly higher prevalence of visceral obesity, elevated triglyceride, lower high-density lipoprotein-cholesterol (HDL-C), hypertension, impaired fasting glucose, and a higher prevalence of MetS. Triglycerides 169-181 C-reactive protein Homo sapiens 76-79 18765457-8 2008 Serum CRP levels were correlated with rIL-8 levels (r = 0.294, P < 0.001); no association was found between CRP and pIL-8 levels (r = 0.025, P = 0.706). ril-8 38-43 C-reactive protein Homo sapiens 6-9 19027603-0 2008 Associations of monocytes, neutrophil count, and C-reactive protein with maximal oxygen uptake in overweight women. Oxygen 81-87 C-reactive protein Homo sapiens 49-67 19027603-6 2008 RESULTS: Univariate regression analyses showed that monocyte, neutrophil counts, and high sensitivity C-reactive protein (hs-CRP) levels were correlated with fasting triglycerides, fasting insulin, BMI, and waist circumference, while VO(2) max was negatively associated with monocyte and neutrophil counts, but not with hs-CRP. Triglycerides 166-179 C-reactive protein Homo sapiens 102-120 18848489-8 2008 ASAS outcome was met in 45%/60%/69%/88% of patients with 0/1/2/>/=3 parameters to guide physician"s opinion from SFR: raised ESR or CRP was present in 66%, active enthesitis or arthritis in 49%, coxitis in 13%, active or relapsing uveitis in 11%, inflammation of sacro-iliac or spine on MRI in 12%, and worsening of articular damage in 5%. Aspirin 0-4 C-reactive protein Homo sapiens 135-138 19060504-0 2008 Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Platinum 88-96 C-reactive protein Homo sapiens 15-33 19060504-1 2008 OBJECTIVE: This study was conducted to assess the prognostic role of regular measurements of C-reactive protein (CRP) in patients with advanced-stage non-small cell lung cancer (NSCLC) during platinum-based first-line therapy. Platinum 192-200 C-reactive protein Homo sapiens 93-111 19060504-1 2008 OBJECTIVE: This study was conducted to assess the prognostic role of regular measurements of C-reactive protein (CRP) in patients with advanced-stage non-small cell lung cancer (NSCLC) during platinum-based first-line therapy. Platinum 192-200 C-reactive protein Homo sapiens 113-116 19060504-8 2008 CONCLUSIONS: Measurement of CRP before initiation and during a platinum-based chemotherapy can provide prognostic information for the individual patient with advanced NSCLC and is able to support or even replace assessment of response by radiographic imaging in defined situations. Platinum 63-71 C-reactive protein Homo sapiens 28-31 18695981-5 2008 In RA patients, SF cAMP level showed negative correlation with Disease Activity Score including a 28-joint count and S CRP, ESR and SF IL-18 level. Cyclic AMP 19-23 C-reactive protein Homo sapiens 119-122 19100419-11 2008 Compared with patients in the ASA-sensitive group, patients in the ASA-resistant group showed significantly higher total cholesterol, low-density lipoprotein cholesterol, triglyceride, C-reactive protein, and fibrinogen levels and lower GFRs (44 +/- 21 mL/min vs 63 +/- 26 mL/min, P = .03). Aspirin 67-70 C-reactive protein Homo sapiens 185-203 18678614-8 2008 CONCLUSIONS: These findings point to a molecular mechanism in humans by which higher triglycerides and CRP can be coupled with lower plasma glucose concentrations and position GCKR in central pathways regulating both hepatic triglyceride and glucose metabolism. Glucose 140-147 C-reactive protein Homo sapiens 103-106 18820652-8 2008 Higher levels of CRP were independently associated with higher BMI, a greater waist-to-hip ratio, female gender, and higher triglycerides (P < 0.001). Triglycerides 124-137 C-reactive protein Homo sapiens 17-20 18925316-3 2008 OBJECTIVES: To evaluate vasomotor function, lipids and C-reactive protein in mildly hypertensive and hypercholesterolemic elderly patients treated with atorvastatin. Atorvastatin 152-164 C-reactive protein Homo sapiens 55-73 18925316-10 2008 Atorvastatin produced a reduction of 20% of the C-reactive protein and 42% in the LDL-c; however, there were no changes in the flow-mediated dilation. Atorvastatin 0-12 C-reactive protein Homo sapiens 48-66 18521928-5 2008 Serum CRP levels were higher in active CD (14.8 +/- 2.1 mg/L) compared with inactive CD (5.6 +/- 0.8 mg/L; P < 0.001). Cadmium 39-41 C-reactive protein Homo sapiens 6-9 18854284-0 2008 Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy. Anthracyclines 155-168 C-reactive protein Homo sapiens 6-24 18854284-9 2008 CONCLUSION: Serum C-reactive protein before therapy and response after therapy are the only factors useful in identifying patients benefiting from anthracycline/thalidomide-based therapy. Anthracyclines 147-160 C-reactive protein Homo sapiens 18-36 18925316-11 2008 CONCLUSIONS: Atorvastatin produced a significant change of lipids and C-reactive protein; however, there were no changes in vasomotor function, suggesting the existence of intrinsic age-related vessel alterations. Atorvastatin 13-25 C-reactive protein Homo sapiens 70-88 18725428-5 2008 RESULTS: Past-year MDD was associated with increased CRP concentration levels (4.31 mg/L for participants who reported episodes of MDD in the past year versus 3.65 mg/L for those who did not; p = .003), and the odds ratio for incident IHD associated with higher CRP concentration was 2.02 (comparing the top versus bottom quartile of CRP; 95% Confidence Interval (CI) = 1.52-2.68), adjusted for cigarette smoking, diabetes, systolic blood pressure, body mass index, and cholesterol. Cholesterol 470-481 C-reactive protein Homo sapiens 53-56 18637893-0 2008 Effect of atorvastatin on hs-CRP in acute coronary syndrome. Atorvastatin 10-22 C-reactive protein Homo sapiens 29-32 18178356-6 2008 The antibody binding of CRP was evaluated in two physiological buffers, phosphate buffered saline (PBS) and Dulbecco"s PBS (DPBS). dulbecco"s 108-118 C-reactive protein Homo sapiens 24-27 18178356-6 2008 The antibody binding of CRP was evaluated in two physiological buffers, phosphate buffered saline (PBS) and Dulbecco"s PBS (DPBS). Genite 124-128 C-reactive protein Homo sapiens 24-27 19080648-1 2008 OBJECTIVE: To evaluate the effect of testosterone replacement therapy in patients with hypogonadotrophic hypogonadism (HH) on insulin sensitivity and high sensitivity C reactive protein (hsCRP). Testosterone 37-49 C-reactive protein Homo sapiens 167-185 18821286-5 2008 C-reactive protein concentrations have been shown to be elevated in patients with HH and are inversely related to plasma testosterone concentrations. Testosterone 121-133 C-reactive protein Homo sapiens 0-18 18821286-6 2008 This inverse relationship between plasma free testosterone and C- reactive protein concentrations in patients with type 2 diabetes suggests that inflammation may play an important role in the pathogenesis of this syndrome. Testosterone 46-58 C-reactive protein Homo sapiens 63-82 18637893-1 2008 AIMS: To evaluate the effect of a lower dose (20 mg) of atorvastatin on hs-CRP concentrations in patients with ACS. Atorvastatin 56-68 C-reactive protein Homo sapiens 75-78 18637893-5 2008 The decrease in hs-CRP was also significantly greater in the subgroups of smoking, hypertension and past history of cardiovascular disease with atorvastatin. Atorvastatin 144-156 C-reactive protein Homo sapiens 19-22 18326562-7 2008 There were significant, graded, increases in high sensitivity C-reactive protein (hs-CRP) and haemoglobin concentrations across eGFR categories independent of age, gender, plasma glucose and lipids (P < 0.0001 for trends). Glucose 179-186 C-reactive protein Homo sapiens 62-80 18708524-7 2008 Exposure of human macrophages to CRP further increased intracellular reactive oxygen species generation, classic PKC isozymes expression, and extracellular signal-regulated protein kinase 1/2 phosphorylation. Reactive Oxygen Species 69-92 C-reactive protein Homo sapiens 33-36 18508833-9 2008 In conclusion, consecutive C-reactive protein measurements are useful in the first week in follow-up of antibiotic treatment for severe community-acquired pneumonia when taking the causative microorganism and use of steroids into account. Steroids 216-224 C-reactive protein Homo sapiens 27-45 18341528-14 2008 CONCLUSIONS: Our findings show that in postmenopausal women high levels of endogenous oestrogenic and androgenic sex steroids coincide with high CRP levels. Steroids 117-125 C-reactive protein Homo sapiens 145-148 17655947-7 2008 CONCLUSIONS: High dose atorvastatin significantly decreased CRP during the early days of acute coronary syndromes. Atorvastatin 23-35 C-reactive protein Homo sapiens 60-63 18562112-4 2008 Bis(N-succinimido)-11,11"-dithiobis (undecyl succinate) (DSNHS) was synthesized for use as a linker for immobilizing anti-CRP antibody (anti-CRP) onto the gold surface of a surface plasmon resonance (SPR) sensor chip. dsnhs 57-62 C-reactive protein Homo sapiens 122-125 18562112-4 2008 Bis(N-succinimido)-11,11"-dithiobis (undecyl succinate) (DSNHS) was synthesized for use as a linker for immobilizing anti-CRP antibody (anti-CRP) onto the gold surface of a surface plasmon resonance (SPR) sensor chip. dsnhs 57-62 C-reactive protein Homo sapiens 141-144 18502107-5 2008 A significant difference of approximately 15% (P=0.028) was observed for C-reactive protein (CRP) concentration between the lignan complex intervention period and placebo period. Lignans 124-130 C-reactive protein Homo sapiens 73-91 18502107-5 2008 A significant difference of approximately 15% (P=0.028) was observed for C-reactive protein (CRP) concentration between the lignan complex intervention period and placebo period. Lignans 124-130 C-reactive protein Homo sapiens 93-96 18502107-6 2008 CRP concentrations (median; 25th, 75th percentiles) were 0.88 (0.63, 2.05) mg/L at baseline and 0.92 (0.59, 1.49) mg/L after the lignan complex intervention period compared with 0.80 (0.62, 1.62) mg/L at baseline and 1.10 (0.72, 1.62) mg/L after placebo. Lignans 129-135 C-reactive protein Homo sapiens 0-3 18502107-8 2008 CONCLUSION: Daily consumption for 6 week of a low-fat muffin enriched with a lignan complex may reduce CRP concentrations compared to a low-fat muffin with no lignans added. Lignans 77-83 C-reactive protein Homo sapiens 103-106 18346173-17 2008 In addition, in patients given metformin, CRP levels decreased. Metformin 31-40 C-reactive protein Homo sapiens 42-45 18638594-8 2008 Hs-CRP, matrix metalloproteinase-9, and NF-kB significantly decreased in the 80-mg atorvastatin group compared with baseline. Atorvastatin 83-95 C-reactive protein Homo sapiens 3-6 18638594-9 2008 In conclusion, this randomized trial of subjects with MS showed the superiority of atorvastatin 80 mg compared with its 10-mg dose in decreasing oxidized LDL, hs-CRP, matrix metalloproteinase-9, and NF-kB activity. Atorvastatin 83-95 C-reactive protein Homo sapiens 162-165 18541328-8 2008 Plasma IL-6 (-25%), CRP (-55%) and GGT (-25%) concentrations declined significantly in the rosiglitazone group. Rosiglitazone 91-104 C-reactive protein Homo sapiens 20-23 18486609-10 2008 CONCLUSIONS: The pharmacologic intervention of endogenous CRP by PEt-based compounds, or the use of exogenously prepared CRP-PEt complexes, may turn out to be an effective approach to capture native LDL cholesterol in vivo to prevent the development of atherosclerosis. Cholesterol 203-214 C-reactive protein Homo sapiens 121-124 18034847-6 2008 RESULTS: Use of aspirin resulted in a CRP reduction of 1.23 +/- 1.02 mg/l (mean +/- s.e.m. Aspirin 16-23 C-reactive protein Homo sapiens 38-41 18080768-9 2008 Circulating ghrelin levels in UC and CD patients were positively correlated with sedimentation, fibrinogen and CRP and was negatively correlated with IGF-1, BMI, TSFT, MAC, fat mass (%), and fat free mass (%). Ghrelin 12-19 C-reactive protein Homo sapiens 111-114 18667998-7 2008 RESULTS: High-sensitivity C-reactive protein correlated (Spearman"s correlation) significantly positively with body mass index and waist size, fasting plasma triglyceride levels, apolipoprotein-B, gamma glutamyl transferase, homeostasis model assessment of insulin resistance, and fibrinogen, and negatively with high-density lipoprotein cholesterol. Triglycerides 158-170 C-reactive protein Homo sapiens 26-44 18493107-11 2008 In multiple logistic regression analysis, diabetes showed a significant age-adjusted association with elevated CRP levels [Odds Ratio = 2.03, Confidence Interval (1.38-2.98); p<0.0001] after adjusting for sex, LDL-cholesterol, HDL-cholesterol blood pressure, smoking and body mass index. Cholesterol 217-228 C-reactive protein Homo sapiens 111-114 18493107-11 2008 In multiple logistic regression analysis, diabetes showed a significant age-adjusted association with elevated CRP levels [Odds Ratio = 2.03, Confidence Interval (1.38-2.98); p<0.0001] after adjusting for sex, LDL-cholesterol, HDL-cholesterol blood pressure, smoking and body mass index. Cholesterol 234-245 C-reactive protein Homo sapiens 111-114 18810827-0 2008 [Apo-E, C-reactive protein, and apolipoprotein (A) are vector proteins for transfer of fatty acids to loose connective tissue cells at the stages of inflammation syndrome and in mutations]. Fatty Acids 87-98 C-reactive protein Homo sapiens 8-26 18667998-8 2008 However, only waist, fibrinogen, apolipoprotein-B, plasma glucose, and gamma glutamyl transferase levels appeared to be associated with high-sensitivity C-reactive protein on multiple logistic regression model analyses. Glucose 58-65 C-reactive protein Homo sapiens 153-171 18573823-4 2008 In contrast, when atorvastatin is added to interferon-beta, hs-CRP serum levels decrease to the normal range (P<0.05), indicating an anti-inflammatory action of atorvastatin in MS. Atorvastatin 164-176 C-reactive protein Homo sapiens 63-66 18521842-5 2008 The serum levels of plasma CRP and SAA gradually increased significantly with time in both groups, but these temporal increases were lower in the LADG group (CRP; P = 0.03, SAA; P = 0.01). ladg 146-150 C-reactive protein Homo sapiens 158-161 18652668-27 2008 Significant differences in CRP levels are reported between each TG compared to the corresponding CG, but not significantly different between each TG and between each CG. Thioguanine 64-66 C-reactive protein Homo sapiens 27-30 18585504-0 2008 An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration. Aspirin 43-50 C-reactive protein Homo sapiens 71-89 18585504-1 2008 BACKGROUND: The use of aspirin alone and statins alone has been shown to reduce markers of inflammation, including C-reactive protein (CRP); however, their combination has been poorly studied. Aspirin 23-30 C-reactive protein Homo sapiens 115-133 18585504-1 2008 BACKGROUND: The use of aspirin alone and statins alone has been shown to reduce markers of inflammation, including C-reactive protein (CRP); however, their combination has been poorly studied. Aspirin 23-30 C-reactive protein Homo sapiens 135-138 18585504-2 2008 METHODS: In a cross-sectional analysis of black and white adults > or =45 years old from the REGARDS cohort, the associations of aspirin and statin use with CRP were examined. Aspirin 132-139 C-reactive protein Homo sapiens 160-163 18585504-5 2008 RESULTS: Estimated mean CRP was 2.78 mg/L for subjects taking neither drug, 2.73 mg/L with aspirin only, 2.29 mg/L with statins only, and 2.03 mg/L for subjects taking both agents. Aspirin 91-98 C-reactive protein Homo sapiens 24-27 18585504-8 2008 In addition, among statin users, the use of aspirin for >5 years compared with < or =5 years was associated with apparent significantly lower CRP concentrations (P = .01). Aspirin 44-51 C-reactive protein Homo sapiens 148-151 18585504-9 2008 CONCLUSIONS: The combined use of aspirin and statins was associated with a synergistically lower CRP concentration, especially among participants taking aspirin for >5 years. Aspirin 33-40 C-reactive protein Homo sapiens 97-100 18585504-9 2008 CONCLUSIONS: The combined use of aspirin and statins was associated with a synergistically lower CRP concentration, especially among participants taking aspirin for >5 years. Aspirin 153-160 C-reactive protein Homo sapiens 97-100 17991470-8 2008 CONCLUSION: Acetylcholine-induced vasodilation in the forearm, but not FMD, was inversely related to CRP and e-selectin levels independently of traditional risk factors in elderly subjects. Acetylcholine 12-25 C-reactive protein Homo sapiens 101-104 18328070-7 2008 The time-course analysis showed that ferritin and highly sensitive CRP seemed to decrease first, followed by a decrease of 8-OHdG and 8-IsoPs. 8-epi-prostaglandin F2alpha 134-141 C-reactive protein Homo sapiens 67-70 18573823-0 2008 Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis. Atorvastatin 0-12 C-reactive protein Homo sapiens 40-58 18573823-2 2008 We evaluated serum levels of high-sensitivity (hs)-CRP in relapsing-remitting MS patients receiving interferon-beta 1b and atorvastatin as add-on therapy. Atorvastatin 123-135 C-reactive protein Homo sapiens 51-54 18573823-4 2008 In contrast, when atorvastatin is added to interferon-beta, hs-CRP serum levels decrease to the normal range (P<0.05), indicating an anti-inflammatory action of atorvastatin in MS. Atorvastatin 18-30 C-reactive protein Homo sapiens 63-66 18475156-6 2008 In multiple linear regression analysis controlling for confounding factors related with sleep apnea syndrome, high-sensitivity C-reactive protein was significantly correlated with 3% oxygen desaturation index (P = 0.047). Oxygen 183-189 C-reactive protein Homo sapiens 127-145 18257023-2 2008 Studies conducted among users of exogenous hormones suggest that estrogen increases CRP, whereas progesterone decreases CRP. Progesterone 97-109 C-reactive protein Homo sapiens 120-123 18257023-3 2008 Examinations of CRP in normally cycling women suggest the opposite: CRP is negatively associated with endogenous estrogen and positively associated with endogenous progesterone. Progesterone 164-176 C-reactive protein Homo sapiens 68-71 18763328-0 2008 [C-reactive protein: effect of hormones, physical activity, and dietary fatty acids. Fatty Acids 72-83 C-reactive protein Homo sapiens 1-19 18555838-9 2008 Median CRP levels were greater in the group with higher testosterone levels (1.17 [0.17-2.36] vs 0.17 [0.17-0.61] mg/L, P = .039). Testosterone 56-68 C-reactive protein Homo sapiens 7-10 18555838-11 2008 An association of testosterone with CRP (r = 0.416, P = .004) and ET-1 (r = 0.323, P = .031) was observed. Testosterone 18-30 C-reactive protein Homo sapiens 36-39 18604320-0 2008 [Effect of a high glucose load on serum concentrations of C-reactive protein and alpha1-antitrypsin in obese women]. Glucose 18-25 C-reactive protein Homo sapiens 58-76 18501785-11 2008 RESULTS: CRP levels increased 10-fold on day 3 after MRI in 87% of MRI studies with Gd-DTPA (+59.3 +/- 57.9 mg/L [P < 0.001] versus -0.9 +/- 3.7 mg/L with gadobutrol versus -0.9 +/- 8.5 mg/L with 0.9% saline). Sodium Chloride 204-210 C-reactive protein Homo sapiens 9-12 18697608-8 2008 Interestingly, ibuprofen decreased total leukocyte count, monocyte count, erythrocyte sedimentation rate and C-reactive protein levels. Ibuprofen 15-24 C-reactive protein Homo sapiens 109-127 18330662-7 2008 Iron depletion was significantly correlated with raised levels of indices of inflammation, C-reactive protein (CRP), orosomucoid and haptoglobin), and with the white blood cell count. Iron 0-4 C-reactive protein Homo sapiens 91-109 18724426-0 2008 [C-reactive protein is a vector of fatty acid transfer to the cells that directly realize the systemic inflammatory response syndrome]. Fatty Acids 35-45 C-reactive protein Homo sapiens 1-19 18330662-7 2008 Iron depletion was significantly correlated with raised levels of indices of inflammation, C-reactive protein (CRP), orosomucoid and haptoglobin), and with the white blood cell count. Iron 0-4 C-reactive protein Homo sapiens 111-114 18545810-9 2008 Significant associations between C-reactive protein levels were observed with age, socioeconomic indicators, obesity status, smoking, fat and alcohol intake, and minor psychiatric disorder. Alcohols 142-149 C-reactive protein Homo sapiens 33-51 18330662-8 2008 In multivariate analysis, orosomucoid and CRP were independently associated with iron depletion. Iron 81-85 C-reactive protein Homo sapiens 42-45 18285417-10 2008 Finally, change in the PYR/Cr ratio was positively associated baseline IL-6, hs-CRP, and their changes (all P < 0.05) in women, but not men. Creatinine 27-29 C-reactive protein Homo sapiens 80-83 18436840-0 2008 C-reactive protein inhibits endothelium-dependent nitric oxide-mediated dilation of retinal arterioles via enhanced superoxide production. Nitric Oxide 50-62 C-reactive protein Homo sapiens 0-18 18436840-0 2008 C-reactive protein inhibits endothelium-dependent nitric oxide-mediated dilation of retinal arterioles via enhanced superoxide production. Superoxides 116-126 C-reactive protein Homo sapiens 0-18 18436840-10 2008 DHE staining showed that CRP produced TEMPOL-sensitive superoxide production in the arteriolar endothelium. Superoxides 55-65 C-reactive protein Homo sapiens 25-28 18436840-11 2008 CONCLUSIONS: CRP inhibits endothelium-dependent NO-mediated dilation in retinal arterioles by producing superoxide from NAD(P)H oxidase, which appears to be linked with p38 kinase and RhoA/Rho-kinase activation. Superoxides 104-114 C-reactive protein Homo sapiens 13-16 18387435-7 2008 Superoxide levels were positively correlated with New York Heart Association functional class (r = 0.684; p < 0.05) and CRP (r = 0.501; p < 0.005; n = 32). Superoxides 0-10 C-reactive protein Homo sapiens 123-126 18453363-3 2008 Decreases in inflammatory cytokines, C-reactive protein, and inflammatory cells have been observed with corticosteroid use, suggesting a possible mechanism for a therapeutic benefit of steroids. Steroids 185-193 C-reactive protein Homo sapiens 37-55 18245817-8 2008 The increased uptake of OxLDL by CRP was inhibited by pretreatment with antibodies to CD32, CD64, CD36, and fucoidin, suggesting uptake by both scavenger receptors and Fc-gamma receptors. fucoidan 108-116 C-reactive protein Homo sapiens 33-36 18442620-8 2008 Triglycerides were higher (P=.054) and Si lower (P=.057) with increasing C-reactive protein tertile. Triglycerides 0-13 C-reactive protein Homo sapiens 73-91 18317874-6 2008 Serum CRP levels were measured in 21 patients with a malignancy and 28 patients with a non-malignancy whose creatinine clearance (Ccr) was > or =70 ml/min. Creatinine 108-118 C-reactive protein Homo sapiens 6-9 18349202-10 2008 C-reactive protein levels at 48 h were markedly reduced by dexamethasone (52.4 mg/mL, 28.2-76.6 vs 194.2, 168.9-219.4; P < 0.0001). Dexamethasone 59-72 C-reactive protein Homo sapiens 0-18 23105739-13 2008 CRP levels in stroke patients showed significant correlation with total cholesterol and LDL (p<0.001), Lp (a) (p=0.002) and atherogenic indices (p<0.05). Cholesterol 72-83 C-reactive protein Homo sapiens 0-3 17971101-15 2008 High-dose testosterone administration appeared to increase weight, visceral fat, and hematocrit, decrease high-density lipoprotein cholesterol, increase endothelin-1, increase C-reactive protein, and increase total homocysteine. Testosterone 10-22 C-reactive protein Homo sapiens 176-194 18356331-9 2008 Total flavonoid and also individual flavonol, anthocyanidin, and isoflavone intakes were inversely associated with serum CRP concentration after adjusting for the covariates (P < 0.05). Isoflavones 65-75 C-reactive protein Homo sapiens 121-124 18669307-1 2008 Serum C-Reactive Protein was measured serially in 45 patients treated with uncomplicated primary total hip and knee arthroplasty (24 THR y 21 TKR). Threonine 133-136 C-reactive protein Homo sapiens 6-24 18308505-13 2008 Adjusting for diabetes, hyperlipidemia, hypertension, coronary artery disease, aspirin or other anti-inflammatory uses, and statin therapy, 4(th) quartile CRP was independently associated with disease progression (OR 1.8, 95% CI; 1.03-2.99, P < .05). Aspirin 79-86 C-reactive protein Homo sapiens 155-158 17562129-6 2008 RESULTS: Higher serum cortisol levels predicted higher fibrinogen (beta = .17, P = .001) and higher von Willebrand factor (beta = .16, P = .008), all independently of covariates, including C-reactive protein, which was also an independent predictor of fibrinogen (beta = .20, P = .001) and von Willebrand factor (beta = .16, P = .004). Hydrocortisone 22-30 C-reactive protein Homo sapiens 189-207 18299144-5 2008 CONCLUSION: In elderly AMI patients the concomitant elevation of CRP and tHcy, associated with folate and vitamin B12 low levels, could be considered a significant predictive heart mortality risk factor. Folic Acid 95-101 C-reactive protein Homo sapiens 65-68 18328837-7 2008 Increased norepinephrine responses were related to larger CRP and IL-6 increases to mental challenge tasks (p values <0.05). Norepinephrine 10-24 C-reactive protein Homo sapiens 58-61 18313449-4 2008 Maternal CRP level was correlated with maternal cholesterol and aortic atherosclerosis of children. Cholesterol 48-59 C-reactive protein Homo sapiens 9-12 18313449-8 2008 CONCLUSION: CRP level during pregnancy is a predictor of increased atherogenesis in children of hypercholesterolemic mothers, albeit a weaker one than maternal cholesterol. Cholesterol 101-112 C-reactive protein Homo sapiens 12-15 18330505-0 2008 Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia. Steroids 13-21 C-reactive protein Homo sapiens 43-61 18096828-0 2008 C-reactive protein inhibits cholesterol efflux from human macrophage-derived foam cells. Cholesterol 28-39 C-reactive protein Homo sapiens 0-18 18096828-1 2008 OBJECTIVE: The objective of this study was to determine the effects and potential mechanisms of C-reactive protein (CRP) on cholesterol efflux from human macrophage foam cells, which may play a critical role in atherogenesis. Cholesterol 124-135 C-reactive protein Homo sapiens 96-114 18096828-1 2008 OBJECTIVE: The objective of this study was to determine the effects and potential mechanisms of C-reactive protein (CRP) on cholesterol efflux from human macrophage foam cells, which may play a critical role in atherogenesis. Cholesterol 124-135 C-reactive protein Homo sapiens 116-119 18389332-0 2008 Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Atorvastatin 37-49 C-reactive protein Homo sapiens 102-120 18096828-3 2008 Clinically relevant concentrations of CRP significantly reduced cholesterol efflux from THP-1 and PBMCs to apoA-I or HDL. Cholesterol 64-75 C-reactive protein Homo sapiens 38-41 18096828-4 2008 CRP significantly decreased the expression of ATP-binding membrane cassette transporter A-1 (ABCA1) and ABCG1, whereas it increased superoxide anion production. Superoxides 132-148 C-reactive protein Homo sapiens 0-3 18096828-6 2008 Reducing superoxide anion by antioxidant seleno-L-methionine or SOD mimetic (MnTBAP) effectively abolished the CRP-induced decrease in cholesterol efflux and the expression of ABCA1 and ABCG1. Superoxides 9-25 C-reactive protein Homo sapiens 111-114 18096828-6 2008 Reducing superoxide anion by antioxidant seleno-L-methionine or SOD mimetic (MnTBAP) effectively abolished the CRP-induced decrease in cholesterol efflux and the expression of ABCA1 and ABCG1. Cholesterol 135-146 C-reactive protein Homo sapiens 111-114 18096828-8 2008 CONCLUSIONS: CRP inhibits cholesterol efflux from human foam cells derived from THP-1 and PBMCs in vitro though oxidative stress, ERK1/2 activation, and downregulation of intracellular cholesterol transport molecules ABCA1 and ABCG1. Cholesterol 26-37 C-reactive protein Homo sapiens 13-16 18096828-8 2008 CONCLUSIONS: CRP inhibits cholesterol efflux from human foam cells derived from THP-1 and PBMCs in vitro though oxidative stress, ERK1/2 activation, and downregulation of intracellular cholesterol transport molecules ABCA1 and ABCG1. Cholesterol 185-196 C-reactive protein Homo sapiens 13-16 17548076-11 2008 After hCG injection, CRP increased in both the metformin and the placebo groups with no significant difference between the groups. Metformin 47-56 C-reactive protein Homo sapiens 21-24 18372583-4 2008 METHODS AND RESULTS: The association between alcohol consumption and concentrations of high sensitivity C-reactive protein (hs-CRP) and fibrinogen were investigated. Alcohols 45-52 C-reactive protein Homo sapiens 104-122 18279736-8 2008 Lower CHD risk was also observed with TG <150 mg/dl and LDL-C <70 mg/dl (HR 0.72, 95% CI 0.54 to 0.94; p = 0.017) or low on-treatment TG, LDL-C, and C-reactive protein (<2 mg/l) (HR 0.59, 95% CI 0.41 to 0.83; p = 0.002) compared with higher levels of each variable in adjusted analysis. Triglycerides 38-40 C-reactive protein Homo sapiens 155-173 18245530-6 2008 Patients with platinum-resistant EOC had significantly higher CRP serum levels compared with patients with platinum-sensitive EOC [6.0 (6.6) mg/dL versus 2.8 (3.8) mg/dL; P < 0.001]. Platinum 14-22 C-reactive protein Homo sapiens 62-65 17852073-8 2008 As only urinary F2-IsoP levels have been validated against known oxidative assaults, their positive association with CRP levels is interpreted as evidence of an interconnection between low-level inflammation and oxidative status. 2,3-dinor-5,6-dihydro-15-F-isoprostane 16-23 C-reactive protein Homo sapiens 117-120 18084042-4 2008 The results indicated that apo-CRP possesses characteristic modules of interdomain interaction that are properly organized to suppress activity and to sense and transfer the cAMP binding signals. Cyclic AMP 174-178 C-reactive protein Homo sapiens 31-34 17964679-10 2008 In multiple linear regression analysis, the independent variable that most strongly explained the CRP level was WC, which was followed by HDL-cholesterol. Cholesterol 142-153 C-reactive protein Homo sapiens 98-101 18573197-8 2008 Duration of RA and CRP levels were independently associated with NT-proBNP in the final model that was adjusted for gender, age, and creatinine levels (r2 adjusted = 0.38; P < 0.001). Creatinine 133-143 C-reactive protein Homo sapiens 19-22 18191050-11 2008 Sex- and age-adjusted CRP level identified also those that progressed to diabetes independent of a fasting glucose >100 mg/dL (HR, 1.39; 95% confidence interval, 1.21-1.59), although not in men. Glucose 107-114 C-reactive protein Homo sapiens 22-25 18608041-0 2008 The antiplatelet effect of atorvastatin in patients with acute coronary syndrome depends on the hs-CRP level. Atorvastatin 27-39 C-reactive protein Homo sapiens 99-102 18608041-8 2008 In atorvastatin/high-CRP subgroup, the level of aggregation was about three times lower after eight days than it was on the first day. Atorvastatin 3-15 C-reactive protein Homo sapiens 21-24 18000162-3 2008 OBJECTIVE: To evaluate the efficacy of atorvastatin compared with a control group in inducing changes in lipoprotein(a) [Lp(a)], apolipoprotein (Apo) A-1, Apo-B, and fibrinogen levels, as well as the conventional lipoprotein profile, in hemodialysis patients over 36 weeks; secondary objectives were to assess changes in C-reactive protein, albumin, and safety measures. Atorvastatin 39-51 C-reactive protein Homo sapiens 321-339 18776721-10 2008 High glucose exposure and long PD duration were associated with MS existence, along with old age, high BMI, triglyceride and CRP. Glucose 5-12 C-reactive protein Homo sapiens 125-128 18724811-10 2008 CONCLUSIONS: The results of our investigation show that plasma layer stratification might occur in primary lithium-heparin tubes for a limited number of routine clinical chemistry tests, introducing a statistically significant bias in the measurement of GGT, LDH, triglycerides and CRP in the upper vs. the bottom section. Heparin 115-122 C-reactive protein Homo sapiens 282-285 17311055-6 2008 Especially vitamin E in combination with other vitamins like vitamin C, vitamin B(1), B(2), B(6), B(12), niacin, folic acid, pantothenic acid and selenium, was significantly associated with lower CRP levels. Folic Acid 113-123 C-reactive protein Homo sapiens 196-199 18312743-9 2008 Plasma CRP levels in CKD and HD patients were positively correlated with plasma urea levels (r:0,437, P < 0,001) and duration of dialysis (r:0,370, P < 0.01), respectively. Urea 80-84 C-reactive protein Homo sapiens 7-10 19343161-0 2008 Targeting C-reactive protein levels using high-dose atorvastatin before coronary artery bypass graft surgery. Atorvastatin 52-64 C-reactive protein Homo sapiens 10-28 19343161-2 2008 AIM: To determine whether a high loading dose of atorvastatin prescribed before and after coronary artery bypass graft (CABG) surgery will attenuate the inflammatory response reflected in kinetic concentrations of C-reactive protein (CRP). Atorvastatin 49-61 C-reactive protein Homo sapiens 214-232 19343161-2 2008 AIM: To determine whether a high loading dose of atorvastatin prescribed before and after coronary artery bypass graft (CABG) surgery will attenuate the inflammatory response reflected in kinetic concentrations of C-reactive protein (CRP). Atorvastatin 49-61 C-reactive protein Homo sapiens 234-237 19343161-7 2008 CONCLUSIONS: High loading doses of atorvastatin before CABG surgery reduced CRP concentration, expressed as AUC-CRP. Atorvastatin 35-47 C-reactive protein Homo sapiens 76-79 19343161-7 2008 CONCLUSIONS: High loading doses of atorvastatin before CABG surgery reduced CRP concentration, expressed as AUC-CRP. Atorvastatin 35-47 C-reactive protein Homo sapiens 112-115 19281089-0 2008 C-reactive protein correlates with tissue oxygen availability in patients with stable COPD. Oxygen 42-48 C-reactive protein Homo sapiens 0-18 18360022-8 2008 Furthermore, CRP was positively correlated with BMI, VFA, SFA, TG, high-density lipoprotein (HDL)-cholesterol, atherosclerosis index (AI), immunoreactive insulin (IRI) and HOMA-IR in simple regression analysis. Cholesterol 98-109 C-reactive protein Homo sapiens 13-16 18360022-9 2008 In multiple stepwise regression analysis, VFA and HDL-cholesterol were predominant determinants of CRP in HD patients. Cholesterol 54-65 C-reactive protein Homo sapiens 99-102 19281089-9 2008 RESULTS: Multiple linear regression analysis indicated that ceHb, PaO2, and P50, were significant and independent predictors of CRP (R2 = 0.52, p < 0.0001). cehb 60-64 C-reactive protein Homo sapiens 128-131 19281089-11 2008 CONCLUSIONS: These findings indicate that physiological determinants of tissue oxygen availability are independently associated with CRP blood levels. Oxygen 79-85 C-reactive protein Homo sapiens 133-136 18504236-3 2008 The results demonstrate that Augmentation Index measured with arteriography and C reactive protein (CRP) levels were significantly ameliorated after 2 x 2 months Flavon Max therapy. flavone 162-168 C-reactive protein Homo sapiens 80-98 17911176-8 2008 The low testosterone-mortality association was also independent of the metabolic syndrome, diabetes, and prevalent cardiovascular disease but was attenuated by adjustment for IL-6 and C-reactive protein. Testosterone 8-20 C-reactive protein Homo sapiens 184-202 18491455-4 2008 We evaluated the association between four Vitamin D Receptor polymorphisms (i.e. those identified by the restriction enzymes BsmI, ApaI, TaqI and FokI) and serum level of C-reactive protein in 88 hemodialysis patients routinely treated with active Vitamin D (calcitriol). Vitamin D 42-51 C-reactive protein Homo sapiens 171-189 18991814-3 2008 Measures of efficacy of therapy with atorvastatin were percent changes of CRP, total (T) cholesterol (CH), and low density lipoprotein (LDL) CH compared with initial values. Atorvastatin 37-49 C-reactive protein Homo sapiens 74-77 18991814-6 2008 Most pronounced lowering of CRP took place in a subgroups of IHD patients with initially high CRP level (-20%) and patients with RA (-65%) to whom atorvastatin was prescribed in a dose of 40 mg/day. Atorvastatin 147-159 C-reactive protein Homo sapiens 28-31 18991814-8 2008 CONCLUSION: HMG-CoA-reductase inhibitor atorvastatin more effectively lowers concentration of CRP in blood plasma of patients with PA than with IHD what possibly is explained by higher initial level of this marker of inflammatory processes. Atorvastatin 40-52 C-reactive protein Homo sapiens 94-97 18504236-3 2008 The results demonstrate that Augmentation Index measured with arteriography and C reactive protein (CRP) levels were significantly ameliorated after 2 x 2 months Flavon Max therapy. flavone 162-168 C-reactive protein Homo sapiens 100-103 19378424-0 2008 C-reactive protein and tumor necrosis factor-alpha in relation to insulin-mediated glucose uptake, smoking and atherosclerosis. Glucose 83-90 C-reactive protein Homo sapiens 0-18 18609082-9 2008 CONCLUSION: The weaker association observed between CRP and creatinine-based measures, as compared to cystatin C, reflects the misclassification of elderly frail subjects as having normal kidney function rather than suggests cystatin C itself to be a marker of inflammation. Creatinine 60-70 C-reactive protein Homo sapiens 52-55 19378424-8 2008 Serum CRP, TNFalpha, sTNFAR2, but not IL-6, were associated with low insulin sensitivity, total body fat, abdominal obesity, hyperinsulinemia, hypertriglyceridemia, low HDL cholesterol and small LDL particles, i.e. the metabolic syndrome. Cholesterol 173-184 C-reactive protein Homo sapiens 6-9 18163969-4 2007 Recently, the National Cholesterol Education Program, through the Adult Treatment Panel III guidelines, identified CRP and another marker of inflammation, the fibrinogen, as "emerging risk factors," suggesting that their measurement may improve the estimations of absolute risk obtained using the traditional cardiovascular risk factors. Cholesterol 23-34 C-reactive protein Homo sapiens 115-118 18035098-1 2007 BACKGROUND: To determine the effect of oral testosterone supplementation on systemic low-grade inflammation measured by high-sensitive C-reactive protein (hs-CRP) in aging men with low testosterone levels. Testosterone 44-56 C-reactive protein Homo sapiens 135-153 17951292-5 2007 RESULTS: After adjustment for age, sex, race/ethnicity, smoking status, systolic blood pressure, and serum concentrations of HDL cholesterol, LDL cholesterol, and triglyceride, CRP was significantly associated with 10 IR measures (all P values <0.01). Triglycerides 163-175 C-reactive protein Homo sapiens 177-180 18042053-10 2007 Both statins significantly reduced plasmatic levels of CRP (3.18 +/- 2.43 mg/dL [T0] vs. 1.31 +/- 1.67 mg/dL [T2] with rosuvastatin [P < 0.01], 7.53 +/- 7.46 mg/dL [T0] vs. 2.92 +/- 2.06 mg/dL [T2] with atorvastatin [P < 0.01]). Atorvastatin 206-218 C-reactive protein Homo sapiens 55-58 18042053-11 2007 Relative reduction of CRP levels was -50.57% with rosuvastatin versus -36.28% with atorvastatin (P N.S.). Atorvastatin 83-95 C-reactive protein Homo sapiens 22-25 17949793-12 2008 Furthermore, antioxidant curcumin dramatically inhibited CRP-induced PAI-1 mRNA expression. Curcumin 25-33 C-reactive protein Homo sapiens 57-60 19227901-0 2008 [Comparison of the effects of carbohydrate metabolism compensation and atorvastatin treatment on lipid metabolism and C-reactive protein in type 2 diabetes mellitus]. Atorvastatin 71-83 C-reactive protein Homo sapiens 118-136 19227901-12 2008 Atorvastatin produces an antiatherogenic effect due to both improvement of the lipid metabolism and CRP level reduction irrespective of the degree of compensation of carbohydrate metabolism in type 2 DM Atorvastatin 0-12 C-reactive protein Homo sapiens 100-103 18629373-4 2008 In the fasting state, LYs compared with LYr not only evoked a >2-fold increase in plasma lycopene but also increased plasma beta-carotene and alpha-tocopherol (p < 0.01), though LYs did not affect plasma nitrate/nitrite (biomarker of nitric oxide), malondialdehyde (biomarker of lipid oxidative stress), vascular- and intercellular-adhesion molecules or C-reactive protein (biomarkers of inflammation). Lysine 22-25 C-reactive protein Homo sapiens 360-378 18254451-9 2007 CRP induces tissue factor secretion from monocytes, enhances the expression of adhesion molecules and inhibits production of nitric oxide and prostacycline by human endothelial cells. Nitric Oxide 125-137 C-reactive protein Homo sapiens 0-3 18254451-9 2007 CRP induces tissue factor secretion from monocytes, enhances the expression of adhesion molecules and inhibits production of nitric oxide and prostacycline by human endothelial cells. Epoprostenol (TN) 142-155 C-reactive protein Homo sapiens 0-3 17942113-6 2007 Pretreatment with sepiapterin, a BH4 precursor, prevented CRP-mediated effects on BH(4) levels, superoxide production as well as eNOS activity. Superoxides 96-106 C-reactive protein Homo sapiens 58-61 17942113-9 2007 In the present study, CRP-mediated inhibition of GTPCH1 activity was reversed by pretreatment with cAMP analogues. Cyclic AMP 99-103 C-reactive protein Homo sapiens 22-25 17942113-10 2007 Furthermore, CRP-induced O(2)(-) production was reversed by pharmacologic inhibition and siRNAs to p47 phox and p22 phox. Superoxides 25-32 C-reactive protein Homo sapiens 13-16 17942113-12 2007 The pretreatment of cells with NO synthase inhibitor (N-nitro-l-arginine methyl ester [l-NAME]) also prevented CRP-mediated O(2)(-) production further strengthening CRP-mediated eNOS uncoupling. Superoxides 124-128 C-reactive protein Homo sapiens 111-114 17942113-12 2007 The pretreatment of cells with NO synthase inhibitor (N-nitro-l-arginine methyl ester [l-NAME]) also prevented CRP-mediated O(2)(-) production further strengthening CRP-mediated eNOS uncoupling. Superoxides 124-128 C-reactive protein Homo sapiens 165-168 17942113-15 2007 To conclude, CRP uncouples eNOS resulting in increased superoxide production, decreased NO production and altered eNOS phosphorylation. Superoxides 55-65 C-reactive protein Homo sapiens 13-16 17991670-11 2007 In the 7-mo interventional study, the 14 patients who received daily supplementation of catechins for 3 mo had less predialysis plasma hydrogen peroxide activity, lower hypochlorous acid activity, and lower phosphatidylcholine hydroperoxide, C-reactive protein, and proinflammatory cytokine concentrations than did the 30 hemodialysis patients who received placebo. Catechin 88-97 C-reactive protein Homo sapiens 242-260 17512573-3 2007 RESULTS: CRP was higher in ASV than RSV and HS, and negatively correlated with HDL-cholesterol and Apo-AI. Cholesterol 83-94 C-reactive protein Homo sapiens 9-12 17996517-10 2007 The difference between the pravastatin and placebo groups in terms of change in CRP by withdrawal was consistent and persisted in analysis corrected for body mass index, smoking status, blood pressure, and baseline levels of total cholesterol, LDL cholesterol, high-density lipoprotein cholesterol, or triglycerides. Triglycerides 302-315 C-reactive protein Homo sapiens 80-83 17980786-6 2007 Alcohol-induced endothelial damage or protection may be related to the synthesis or action of several markers, such as nitric oxide, cortisol, endothelin-1, adhesion molecules, tumor necrosis factor alpha, interleukin-6, C-reactive protein, and haemostatic factors. Alcohols 0-7 C-reactive protein Homo sapiens 221-239 18075240-8 2007 Patients with high CRP levels (> or = 5 mg/dl) during the first week after admission showed a significantly greater elevation of serum creatinine levels as compared to the levels before admission than those with low CRP levels (< 5 mg/dl). Creatinine 138-148 C-reactive protein Homo sapiens 19-22 18024309-0 2007 [Reducing plasma homocysteic acid lowers serum C-reactive protein level in children with Kawasaki disease]. homocysteic acid 17-33 C-reactive protein Homo sapiens 47-65 17049532-6 2007 In univariate analysis, CRP levels correlated positively with total cholesterol (p=0.01), LDL cholesterol (p=0.001), triglycerides (p=0.04) and Framingham risk score (p=0.006), and negatively with HDL cholesterol (p=0.004). Cholesterol 68-79 C-reactive protein Homo sapiens 24-27 17049532-6 2007 In univariate analysis, CRP levels correlated positively with total cholesterol (p=0.01), LDL cholesterol (p=0.001), triglycerides (p=0.04) and Framingham risk score (p=0.006), and negatively with HDL cholesterol (p=0.004). Cholesterol 94-105 C-reactive protein Homo sapiens 24-27 17049532-6 2007 In univariate analysis, CRP levels correlated positively with total cholesterol (p=0.01), LDL cholesterol (p=0.001), triglycerides (p=0.04) and Framingham risk score (p=0.006), and negatively with HDL cholesterol (p=0.004). Triglycerides 117-130 C-reactive protein Homo sapiens 24-27 17049532-6 2007 In univariate analysis, CRP levels correlated positively with total cholesterol (p=0.01), LDL cholesterol (p=0.001), triglycerides (p=0.04) and Framingham risk score (p=0.006), and negatively with HDL cholesterol (p=0.004). Cholesterol 94-105 C-reactive protein Homo sapiens 24-27 17049532-9 2007 In multivariate analysis, independent factors associated with the highest quartile of serum CRP concentrations (0.49 mg/dl) were LDL-cholesterol (p<0.001), HDL-cholesterol (p=0.001), cigarette smoking (p=0.019) and current ART (p=0.021). Cholesterol 133-144 C-reactive protein Homo sapiens 92-95 17049532-9 2007 In multivariate analysis, independent factors associated with the highest quartile of serum CRP concentrations (0.49 mg/dl) were LDL-cholesterol (p<0.001), HDL-cholesterol (p=0.001), cigarette smoking (p=0.019) and current ART (p=0.021). Cholesterol 163-174 C-reactive protein Homo sapiens 92-95 17704300-10 2007 Inflammatory measures demonstrated positive relationships with triglycerides in OT1DM (CRP, IL-6, and ICAM-1 P < 0.05) and control subjects (ICAM-1 P = 0.001). Triglycerides 63-76 C-reactive protein Homo sapiens 87-90 18050145-5 2007 In this analysis, serum CRP and microalbuminuria maintained a significant association with serum creatinine, while the hemodynamic response to ACh lost substantial predictive value for serum creatinine. Creatinine 97-107 C-reactive protein Homo sapiens 24-27 17950110-0 2007 A single bolus infusion of C-reactive protein increases gluconeogenesis and plasma glucose concentration in humans. Glucose 83-90 C-reactive protein Homo sapiens 27-45 17950110-5 2007 C-reactive protein infusion induced an inflammatory response, which was followed by increased plasma concentrations of norepinephrine (3 hours) and cortisol (4 hours). Norepinephrine 119-133 C-reactive protein Homo sapiens 0-18 17950110-5 2007 C-reactive protein infusion induced an inflammatory response, which was followed by increased plasma concentrations of norepinephrine (3 hours) and cortisol (4 hours). Hydrocortisone 148-156 C-reactive protein Homo sapiens 0-18 17950110-7 2007 These metabolic changes increased plasma glucose concentrations from 8 hours after CRP infusion, which was preceded by an increased rate of glucose appearance that was a direct consequence of increased gluconeogenesis. Glucose 41-48 C-reactive protein Homo sapiens 83-86 17950110-8 2007 In conclusion, CRP infusion induces an inflammatory response followed by increased norepinephrine and cortisol levels, which results in increased gluconeogenesis. Norepinephrine 83-97 C-reactive protein Homo sapiens 15-18 17950110-8 2007 In conclusion, CRP infusion induces an inflammatory response followed by increased norepinephrine and cortisol levels, which results in increased gluconeogenesis. Hydrocortisone 102-110 C-reactive protein Homo sapiens 15-18 18024309-1 2007 OBJECTIVE: To investigate the effect of plasma homocysteic acid (HCA) reduction on serum C-reactive protein (CRP) level in children with Kawasaki disease (KD). homocysteic acid 47-63 C-reactive protein Homo sapiens 89-107 18024309-1 2007 OBJECTIVE: To investigate the effect of plasma homocysteic acid (HCA) reduction on serum C-reactive protein (CRP) level in children with Kawasaki disease (KD). homocysteic acid 47-63 C-reactive protein Homo sapiens 109-112 18024309-1 2007 OBJECTIVE: To investigate the effect of plasma homocysteic acid (HCA) reduction on serum C-reactive protein (CRP) level in children with Kawasaki disease (KD). homocysteic acid 65-68 C-reactive protein Homo sapiens 89-107 18024309-1 2007 OBJECTIVE: To investigate the effect of plasma homocysteic acid (HCA) reduction on serum C-reactive protein (CRP) level in children with Kawasaki disease (KD). homocysteic acid 65-68 C-reactive protein Homo sapiens 109-112 18024309-4 2007 RESULTS: Serum CRP level was comparable between the two groups before the treatment, but significantly reduced after vitamin B6 and folic acid treatment (7.56-/+2.94 mg/L vs 12.23-/+4.16 mg/L, P<0.05). Folic Acid 132-142 C-reactive protein Homo sapiens 15-18 18024309-5 2007 Additional vitamin B6 and folic acid treatment significantly lowered plasma HCA level (4.56-/+1.14 micromol/L vs 7.79-/+1.79 micromol/L, P<0.05), and correlation analysis demonstrated a positive correlation between plasma HCA and serum CRP levels (r=0.697, P<0.01). Folic Acid 26-36 C-reactive protein Homo sapiens 239-242 18048467-6 2007 Rosiglitazone reduced CRP compared with glyburide (p = 0.001), but no differences were observed between groups for ADMA or the markers of oxidative stress. Rosiglitazone 0-13 C-reactive protein Homo sapiens 22-25 18048467-8 2007 In conclusion, compared with glyburide, rosiglitazone improves endothelial function and CRP in patients with T2DM. Rosiglitazone 40-53 C-reactive protein Homo sapiens 88-91 17311284-9 2007 Both CRP and WBCC were correlated with 2-h plasma glucose but not with fasting plasma glucose (FPG). Glucose 50-57 C-reactive protein Homo sapiens 5-8 17884374-0 2007 Relation of coronary artery calcium to flow-mediated dilation and C-reactive protein levels in asymptomatic patients with heterozygous familial hypercholesterolemia. Calcium 28-35 C-reactive protein Homo sapiens 66-84 17010351-5 2007 Compared to those without MS components, adjusted odds ratios for having elevated CRP increased in those with the MS or its components compared those without MS or components (all p<0.001), except for the low HDL-cholesterol in both genders and raised fasting glucose in men. Glucose 263-270 C-reactive protein Homo sapiens 82-85 17920365-0 2007 Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Atorvastatin 51-63 C-reactive protein Homo sapiens 95-113 17920365-5 2007 In conclusion, CRP was effectively decreased in patients with type 2 diabetes receiving rosuvastatin or atorvastatin, whereas rosuvastatin decreased LDL cholesterol significantly more than atorvastatin. Atorvastatin 104-116 C-reactive protein Homo sapiens 15-18 17137657-1 2007 The association between alcohol consumption and CRP was evaluated in a longitudinal study among 72 middle aged adults for whom 572 repeated measurements of CRP were obtained. Alcohols 24-31 C-reactive protein Homo sapiens 48-51 17137657-4 2007 Average alcohol consumption during the last 12 months showed a clear U-shaped relationship with CRP-levels, with lowest levels found for moderate alcohol consumption of less than 16 g/day. Alcohols 8-15 C-reactive protein Homo sapiens 96-99 17137657-4 2007 Average alcohol consumption during the last 12 months showed a clear U-shaped relationship with CRP-levels, with lowest levels found for moderate alcohol consumption of less than 16 g/day. Alcohols 146-153 C-reactive protein Homo sapiens 96-99 17652082-8 2007 IL-17 stimulated p38 MAPK and ERK1/2 activation, and SB203580 and PD98059 blunted IL-17-mediated NF-kappaB and C/EBP activation and CRP transcription. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 66-73 C-reactive protein Homo sapiens 132-135 17709798-7 2007 Tamoxifen increased IGFBP-3 and lowered antithrombin-III, C reactive protein, and mammographic density, with greater effects of 5 mg/day. Tamoxifen 0-9 C-reactive protein Homo sapiens 58-76 17884451-9 2007 In addition, plasma C-reactive protein level was decreased significantly in the rosiglitazone-treated group compared with values at baseline and for the untreated group after 12 weeks (0.73 +/- 0.09, 1.71 +/- 0.24, and 1.33 +/- 0.29 mg/L, respectively). Rosiglitazone 80-93 C-reactive protein Homo sapiens 20-38 17953926-8 2007 In males, there were significant direct correlations between the C-reactive protein concentration and body mass index, total fat mass, central adiposity, waist circumference, and low-density lipoprotein (LDL) cholesterol level. Cholesterol 209-220 C-reactive protein Homo sapiens 65-83 17953926-10 2007 Boys in the highest C-reactive protein tertile had a significantly higher body mass index, total fat mass, LDL cholesterol level, and waist circumference. Cholesterol 111-122 C-reactive protein Homo sapiens 20-38 17719297-7 2007 RESULTS: Higher CRP levels were positively associated with PAD, independent of smoking, waist circumference, body mass index, blood pressure, glycosylated hemoglobin, serum total cholesterol, and other confounders. Cholesterol 179-190 C-reactive protein Homo sapiens 16-19 17700214-1 2007 Aspirin has the potential to influence C-reactive protein (CRP) levels, an inflammatory marker, by its anti-inflammatory activity. Aspirin 0-7 C-reactive protein Homo sapiens 39-57 17877828-13 2007 Exhaled acetone concentrations exhibited positive correlation to serum C-reactive protein concentrations and to serum troponine-T concentrations. Acetone 8-15 C-reactive protein Homo sapiens 71-89 17615382-7 2007 This increased CRP expression was attenuated in the presence of anti-leptin receptor antibodies and also by inhibition of ERK1/2 by PD98059 (20 to 40 micromol/L). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 132-139 C-reactive protein Homo sapiens 15-18 17615382-10 2007 Inhibition of ROS by catalase (200 microg/mL) prevented ERK1/2 phosphorylation and CRP mRNA transcription. ros 14-17 C-reactive protein Homo sapiens 83-86 17615382-11 2007 CONCLUSION: Leptin induces CRP expression in HCAECs via activation of the leptin receptor, increased ROS production, and phosphorylation of ERK1/2. ros 101-104 C-reactive protein Homo sapiens 27-30 17532086-9 2007 High sensitive CRP was positively correlated to BMI, triglyceride, and leptin, but was negatively correlated to adiponectin. Triglycerides 53-65 C-reactive protein Homo sapiens 15-18 17646220-6 2007 RESULTS: Patients with moderate-to-severe asthma receiving montelukast (n = 60) had significantly lower serum CRP compared to placebo (n = 73) after 1 month (1.7 mg/L vs 3.2 mg/L, respectively; p < 0.006) and 6 months of treatment (2.3 mg/L vs 3.5 mg/L, respectively; p < 0.04). montelukast 59-70 C-reactive protein Homo sapiens 110-113 17700214-1 2007 Aspirin has the potential to influence C-reactive protein (CRP) levels, an inflammatory marker, by its anti-inflammatory activity. Aspirin 0-7 C-reactive protein Homo sapiens 59-62 17929239-6 2007 Our experimental results demonstrate that betulin disulphate (B2S) and 9,9-bis(4"-hydroxyphenyl)fluorene disulphate (F2S) inhibit the interaction of C1q and its recombinant globular modules with target molecules IgG1, C-reactive protein (CRP) and long pentraxin 3 (PTX3). 2,5-dichloro-4-bromophenol 62-65 C-reactive protein Homo sapiens 218-242 17438557-10 2007 Transferrin receptor, ferritin and C-reactive protein contributed independently as predictors of serum iron. Iron 103-107 C-reactive protein Homo sapiens 35-53 17929239-6 2007 Our experimental results demonstrate that betulin disulphate (B2S) and 9,9-bis(4"-hydroxyphenyl)fluorene disulphate (F2S) inhibit the interaction of C1q and its recombinant globular modules with target molecules IgG1, C-reactive protein (CRP) and long pentraxin 3 (PTX3). 9,9-bis(4"-hydroxyphenyl)fluorene disulphate 71-115 C-reactive protein Homo sapiens 218-242 17884796-6 2007 Use of ultrapure water for 6 months significantly improved serum AOPP, MDA, GSH-Px, MPO, Alb, CRP, neopterin, and TNF-alpha levels (P<0.05), and the level of IL-6 was further reduced after 12 months (P<0.05). Water 17-22 C-reactive protein Homo sapiens 94-97 17659756-8 2007 Triglyceride concentrations were associated with higher CRP concentrations (p = 0.02) and SLICC score (p = 0.04). Triglycerides 0-12 C-reactive protein Homo sapiens 56-59 17605895-0 2007 Effects of folic acid and vitamin B complex on serum C-reactive protein and albumin levels in stable hemodialysis patients. Folic Acid 11-21 C-reactive protein Homo sapiens 53-71 17655623-6 2007 Hs-CRP levels correlated to body mass index (r = 0.411, p = 0.003), diastolic blood pressure (r = 0.323, p = 0.021), fibrinogen (r = 0.447 and p = 0.004) and HDL cholesterol levels (r =-0.461 and p = 0.001). Cholesterol 162-173 C-reactive protein Homo sapiens 3-6 17531211-4 2007 Confocal microscopic image analysis of H(2)DCFDA-labeled cells showed that CRP induced intracellular reactive oxygen species (ROS) generation by FcgammaRIIa(+) HEK293T cells. Reactive Oxygen Species 101-124 C-reactive protein Homo sapiens 75-78 17531211-4 2007 Confocal microscopic image analysis of H(2)DCFDA-labeled cells showed that CRP induced intracellular reactive oxygen species (ROS) generation by FcgammaRIIa(+) HEK293T cells. Reactive Oxygen Species 126-129 C-reactive protein Homo sapiens 75-78 17531211-5 2007 Moreover, CRP time- and dose-dependently generated ROS in VSMCs through FcgammaRIIa activation. Reactive Oxygen Species 51-54 C-reactive protein Homo sapiens 10-13 17531211-6 2007 VSMCs mainly express NADPH oxidase 4 isoform (Nox4), the suppression of which using a specific siRNA completely abolished CRP-induced ROS generation by VSMCs. Reactive Oxygen Species 134-137 C-reactive protein Homo sapiens 122-125 17531211-7 2007 The downregulation of p22(phox), a component of the active Nox4 complex, by transfecting with specific decoy oligomers and functional blocking of FcgammaRIIa not only inhibited the CRP-induced ROS generation but also reduced the degree of AP-1 and NF-kappaB activation, the production of MCP-1, IL-6, and ET-1, and the apoptotic changes of VSMCs in response to CRP. Reactive Oxygen Species 193-196 C-reactive protein Homo sapiens 181-184 17531211-8 2007 CONCLUSIONS: CRP-induced ROS generation by VSMCs, which requires functional activation of FcgammaRIIa and NADPH oxidase 4, orchestrates pro-inflammatory activities of VSMCs and may eventually promote atherogenesis and plaque rupture. Reactive Oxygen Species 25-28 C-reactive protein Homo sapiens 13-16 17504892-9 2007 Only subjects with baseline CRP levels below the median (4.52 mg/liter) showed increases in adiponectin (0.98 +/- 1.3 microg/liter) (P = 0.015) and greater reductions in triglycerides (P = 0.001) with weight loss. Triglycerides 170-183 C-reactive protein Homo sapiens 28-31 17234298-0 2007 Serum C-reactive protein levels correlates better to metabolic syndrome defined by International Diabetes Federation than by NCEP ATP III in men. atp iii 130-137 C-reactive protein Homo sapiens 6-24 17344325-12 2007 CONCLUSIONS: In patients with CHD, intensive atorvastatin therapy results in regression of carotid atherosclerotic disease, which is associated with reduction in CRP levels. Atorvastatin 45-57 C-reactive protein Homo sapiens 162-165 17662770-8 2007 There was a negative linear correlation between acetylcholine-induced venous relaxation and C-reactive protein (r = -.30, P = .02) and waist circumference (r = -0.21, P = .03). Acetylcholine 48-61 C-reactive protein Homo sapiens 92-110 17641277-4 2007 Co-incubation of adipocytes with rosiglitazone and CRP decreased induction of adiponectin gene expression by rosiglitazone. Rosiglitazone 109-122 C-reactive protein Homo sapiens 51-54 17662770-9 2007 In a multivariate regression model, C-reactive protein (P = .02) was the only independent predictor of acetylcholine-induced venous relaxation. Acetylcholine 103-116 C-reactive protein Homo sapiens 36-54 17702268-10 2007 CRP showed a significant positive association with current smoking, waist-hip ratio (WHR), LDL-cholesterol, triglycerides, leptin, and insulin, independent of age, sex, and BMI. Cholesterol 95-106 C-reactive protein Homo sapiens 0-3 17693973-8 2007 In univariate regression analysis CRP was related to obesity, HDL-cholesterol, fasting glucose, glucose at admission and adipokines but only glucose at admission and resistin were the independent positive factors and adiponectin an independent negative factor associated with CRP levels (R2= 51.1%). Cholesterol 66-77 C-reactive protein Homo sapiens 34-37 17693973-8 2007 In univariate regression analysis CRP was related to obesity, HDL-cholesterol, fasting glucose, glucose at admission and adipokines but only glucose at admission and resistin were the independent positive factors and adiponectin an independent negative factor associated with CRP levels (R2= 51.1%). Glucose 87-94 C-reactive protein Homo sapiens 34-37 17693973-8 2007 In univariate regression analysis CRP was related to obesity, HDL-cholesterol, fasting glucose, glucose at admission and adipokines but only glucose at admission and resistin were the independent positive factors and adiponectin an independent negative factor associated with CRP levels (R2= 51.1%). Glucose 96-103 C-reactive protein Homo sapiens 34-37 17693973-8 2007 In univariate regression analysis CRP was related to obesity, HDL-cholesterol, fasting glucose, glucose at admission and adipokines but only glucose at admission and resistin were the independent positive factors and adiponectin an independent negative factor associated with CRP levels (R2= 51.1%). Glucose 96-103 C-reactive protein Homo sapiens 34-37 17702268-10 2007 CRP showed a significant positive association with current smoking, waist-hip ratio (WHR), LDL-cholesterol, triglycerides, leptin, and insulin, independent of age, sex, and BMI. Triglycerides 108-121 C-reactive protein Homo sapiens 0-3 17702268-11 2007 Significant independent negative associations for CRP were observed with HDL-cholesterol (HDL), insulin sensitivity (quantitative insulin sensitivity check index [QUICKI]), and hours of exercise. Cholesterol 77-88 C-reactive protein Homo sapiens 50-53 17702269-6 2007 In addition, CRP was correlated with body mass index, waist-to-hip ratio, neck circumference, diastolic pressure, average O2 saturation and percentage of time below 90% O2 saturation but not with AHI. Oxygen 122-124 C-reactive protein Homo sapiens 13-16 17702269-6 2007 In addition, CRP was correlated with body mass index, waist-to-hip ratio, neck circumference, diastolic pressure, average O2 saturation and percentage of time below 90% O2 saturation but not with AHI. Oxygen 169-171 C-reactive protein Homo sapiens 13-16 19357443-8 2007 Plasma level of glutathione significantly correlated with CRP (r = 0.48; P = .01) and serum albumin (r = 0.42; P = .04). Glutathione 16-27 C-reactive protein Homo sapiens 58-61 17785926-6 2007 The mean values of CRP were significantly higher in current smokers than in nonsmokers after adjustment for age, body mass index (BMI), systolic blood pressure, total cholesterol, log triglycerides, high-density lipoprotein cholesterol (HDL-C), fasting glucose, and drinking habit (p=0.011). Cholesterol 167-178 C-reactive protein Homo sapiens 19-22 17785926-6 2007 The mean values of CRP were significantly higher in current smokers than in nonsmokers after adjustment for age, body mass index (BMI), systolic blood pressure, total cholesterol, log triglycerides, high-density lipoprotein cholesterol (HDL-C), fasting glucose, and drinking habit (p=0.011). Triglycerides 184-197 C-reactive protein Homo sapiens 19-22 17785926-6 2007 The mean values of CRP were significantly higher in current smokers than in nonsmokers after adjustment for age, body mass index (BMI), systolic blood pressure, total cholesterol, log triglycerides, high-density lipoprotein cholesterol (HDL-C), fasting glucose, and drinking habit (p=0.011). Glucose 253-260 C-reactive protein Homo sapiens 19-22 17584566-12 2007 Rosiglitazone for 12 months did not appear to affect CIMT in this population, although it did have beneficial effects on high-sensitivity C-reactive protein, high-density lipoprotein, and triglycerides. Rosiglitazone 0-13 C-reactive protein Homo sapiens 138-156 17372148-0 2007 C-reactive protein is independently associated with glucose but not with insulin resistance in healthy men. Glucose 52-59 C-reactive protein Homo sapiens 0-18 17560879-0 2007 Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Atorvastatin 73-85 C-reactive protein Homo sapiens 98-116 17560879-6 2007 Reductions in CRP of similar magnitude were observed with ezetimibe/simvastatin and atorvastatin when averaged across doses and at each milligram-equivalent statin dose comparison. Atorvastatin 84-96 C-reactive protein Homo sapiens 14-17 17653654-6 2007 Furthermore, among patients with NASH, hs-CRP was significantly elevated in those with advanced fibrosis compared with that in those with mild fibrosis (P = 0.0384), even after adjustment for age, sex, presence of diabetes, body mass index, visceral fat area, subcutaneous fat area, homeostasis model assessment for insulin resistance, high-density lipoprotein cholesterol, triglyceride, and low-density lipoprotein cholesterol. Triglycerides 374-386 C-reactive protein Homo sapiens 42-45 17360715-10 2007 According to surface plasmon resonance measurements, Tyr(402) CCP6-8 binds significantly more tightly than His(402) CCP6-8 to immobilized C-reactive protein. Tyrosine 53-56 C-reactive protein Homo sapiens 138-156 17451439-9 2007 Highly sensitive C-reactive protein was elevated in the group with cholesterol levels higher than 251 mg.dL(-1). Cholesterol 67-78 C-reactive protein Homo sapiens 17-35 17517066-9 2007 Increased homeostasis model assessment insulin sensitivity and reduced C-reactive protein were greater with rosiglitazone than metformin or sulphonylurea (all P < or = 0.001). Rosiglitazone 108-121 C-reactive protein Homo sapiens 71-89 17517066-11 2007 CONCLUSIONS: In people with diabetes, rosiglitazone in combination with metformin or sulphonylurea was demonstrated to be non-inferior to the standard combination of metformin + sulphonylurea in lowering HbA(1c) over 18 months, and produces greater improvements in C-reactive protein and basal insulin sensitivity but is also associated with greater weight gain. Rosiglitazone 38-51 C-reactive protein Homo sapiens 265-283 17382928-6 2007 The presence of the TCCG haplotype was associated with greater CRP concentrations in Caucasian women (p=0.0004) and this relationship was maintained after adjustment for age, BMI, smoking, diabetes, and cholesterol-lowering therapy (p=0.003). Cholesterol 203-214 C-reactive protein Homo sapiens 63-66 17382928-8 2007 CONCLUSION: Variation in the IRAK1 gene is associated with CRP concentration in Caucasian women in DHS. dhs 99-102 C-reactive protein Homo sapiens 59-62 17537152-6 2007 RESULTS: Atorvastatin therapy significantly improved exercise VO(2) tau and FMD, and reduced CRP levels. Atorvastatin 9-21 C-reactive protein Homo sapiens 93-96 17388968-3 2007 OBJECTIVES: In the present study, we evaluated the effect of various wine polyphenolic compounds and several active synthetic derivatives of resveratrol on the inflammatory cytokines (IL-1beta + IL-6)-induced CRP expression in Hep3B cells. Resveratrol 141-152 C-reactive protein Homo sapiens 209-212 17633905-5 2007 The relationship between a patient"s baseline plasma level of CRP and future vascular risk has been consistent in several studies, and in most cases has proven independent of major "traditional" risk factors such as age, smoking, cholesterol levels, blood pressure and diabetes. Cholesterol 230-241 C-reactive protein Homo sapiens 62-65 17633905-8 2007 Aspirin also has an intriguing interaction with CRP in that the magnitude of relative risk reduction attributable to aspirin in primary prevention appears to be greatest among those with elevated CRP and declines proportionately in direct relation to CRP levels. Aspirin 0-7 C-reactive protein Homo sapiens 48-51 17633905-8 2007 Aspirin also has an intriguing interaction with CRP in that the magnitude of relative risk reduction attributable to aspirin in primary prevention appears to be greatest among those with elevated CRP and declines proportionately in direct relation to CRP levels. Aspirin 0-7 C-reactive protein Homo sapiens 196-199 17633905-8 2007 Aspirin also has an intriguing interaction with CRP in that the magnitude of relative risk reduction attributable to aspirin in primary prevention appears to be greatest among those with elevated CRP and declines proportionately in direct relation to CRP levels. Aspirin 0-7 C-reactive protein Homo sapiens 196-199 17633905-8 2007 Aspirin also has an intriguing interaction with CRP in that the magnitude of relative risk reduction attributable to aspirin in primary prevention appears to be greatest among those with elevated CRP and declines proportionately in direct relation to CRP levels. Aspirin 117-124 C-reactive protein Homo sapiens 48-51 17633905-8 2007 Aspirin also has an intriguing interaction with CRP in that the magnitude of relative risk reduction attributable to aspirin in primary prevention appears to be greatest among those with elevated CRP and declines proportionately in direct relation to CRP levels. Aspirin 117-124 C-reactive protein Homo sapiens 196-199 17633905-8 2007 Aspirin also has an intriguing interaction with CRP in that the magnitude of relative risk reduction attributable to aspirin in primary prevention appears to be greatest among those with elevated CRP and declines proportionately in direct relation to CRP levels. Aspirin 117-124 C-reactive protein Homo sapiens 196-199 17602983-7 2007 In patients with higher baseline concentrations, CRP decreased in patients who received carvedilol, but not in those who received metoprolol. Carvedilol 88-98 C-reactive protein Homo sapiens 49-52 17388968-4 2007 RESULTS: Among the wine phenolics tested, quercetin and resveratrol, in a dose-dependent manner, suppressed cytokine-induced CRP expression. Resveratrol 56-67 C-reactive protein Homo sapiens 125-128 17388968-6 2007 The inhibitory effects of resveratrol and its derivatives on CRP expression were at the level of mRNA production. Resveratrol 26-37 C-reactive protein Homo sapiens 61-64 17577433-7 2007 CONCLUSION: The high level hs-CRP is in close relation with acute stroke, and blood pressure, serum fasting blood glucose and cholesterol are significant and independent risk factors that might influence the level of hs-CRP. Glucose 114-121 C-reactive protein Homo sapiens 30-33 17577433-7 2007 CONCLUSION: The high level hs-CRP is in close relation with acute stroke, and blood pressure, serum fasting blood glucose and cholesterol are significant and independent risk factors that might influence the level of hs-CRP. Glucose 114-121 C-reactive protein Homo sapiens 220-223 17577433-7 2007 CONCLUSION: The high level hs-CRP is in close relation with acute stroke, and blood pressure, serum fasting blood glucose and cholesterol are significant and independent risk factors that might influence the level of hs-CRP. Cholesterol 126-137 C-reactive protein Homo sapiens 220-223 17456992-8 2007 Furthermore, patients with higher dopamine levels had lower left ventricular (LV) ejection fraction and higher levels of brain natriuretic peptide, C-reactive protein, and fibrinogen than those with lower dopamine levels. Dopamine 34-42 C-reactive protein Homo sapiens 148-166 17499069-1 2007 Fluorescence intensity of N-isopropylacrylamide-glycidyl methacrylate (NIPAAm-GMA) copolymer conjugated with fluoreseinamine isomer1 was found to decrease considerably in the presence of NIPAAm-GMA copolymer containing O-phosphorylethanolamine (PEA), the specific ligand of C-reactive protein (CRP). nipaam-gma) copolymer 71-92 C-reactive protein Homo sapiens 274-292 17499069-1 2007 Fluorescence intensity of N-isopropylacrylamide-glycidyl methacrylate (NIPAAm-GMA) copolymer conjugated with fluoreseinamine isomer1 was found to decrease considerably in the presence of NIPAAm-GMA copolymer containing O-phosphorylethanolamine (PEA), the specific ligand of C-reactive protein (CRP). nipaam-gma) copolymer 71-92 C-reactive protein Homo sapiens 294-297 17512355-0 2007 Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. Cholesterol 62-73 C-reactive protein Homo sapiens 96-114 17467420-4 2007 We have previously demonstrated that C-reactive protein impairs endothelial cell nitric oxide production. Nitric Oxide 81-93 C-reactive protein Homo sapiens 37-55 17468196-0 2007 The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Testosterone 14-26 C-reactive protein Homo sapiens 69-87 17468196-4 2007 We examined the effects of testosterone replacement treatment on various adipocytokines and C-reactive protein (CRP) in type 2 diabetic men. Testosterone 27-39 C-reactive protein Homo sapiens 92-110 17468196-11 2007 CRP levels also correlated significantly with total testosterone levels (r=-0.59; P=0.01). Testosterone 52-64 C-reactive protein Homo sapiens 0-3 17244159-7 2007 After disruption of the pentameric structure of CRP, as achieved by urea-treatment or by site-directed mutagenesis, C1q binding and C1 activation further increased and the ability of CRP to bind complement regulatory proteins was revealed. Urea 68-72 C-reactive protein Homo sapiens 48-51 17545695-7 2007 A multiple regression analysis showed that, especially in the middle tertile of long-chain n-3 PUFAs (eicosapentaenoic acid and docosahexaenoic acid) intake, CRP was inversely related to the intake of oleic acid and linoleic acid in both sexes and to the intake of alpha-linolenic acid in women. Linoleic Acid 216-229 C-reactive protein Homo sapiens 158-161 17545695-8 2007 CONCLUSION: Intakes of oleic acid, linoleic acid, and alpha-linolenic acid would reduce serum CRP, especially when the intake of long-chain n-3 PUFAs is at a moderate level in Japanese. Linoleic Acid 35-48 C-reactive protein Homo sapiens 94-97 17467420-6 2007 We therefore sought to determine whether endothelin-1 exposure modulates C-reactive protein"s effects on nitric oxide production via protein kinase C. METHODS: Endothelial cells were incubated with C-reactive protein (200 microg), endothelin-1 (100 nM), C-reactive protein + endothelin-1, or phosphate-buffered saline solution (control) for 24 hours. Nitric Oxide 105-117 C-reactive protein Homo sapiens 73-91 17467420-9 2007 C-reactive protein produced a 47% decrease in nitric oxide production compared with control. Nitric Oxide 46-58 C-reactive protein Homo sapiens 0-18 17467420-14 2007 CONCLUSIONS: Our results indicate that endothelin-1 exposure accentuated C-reactive protein"s impairment of endothelial nitric oxide production via synergistic inhibition of protein kinase C lambda translocation and activity. Nitric Oxide 120-132 C-reactive protein Homo sapiens 73-91 17386320-11 2007 Fasting plasma glucose levels significantly correlated with patient age (Pearson r = 0.278; P < 0.001), Charlson comorbidity score (r = 0.484; P < 0.001), baseline serum C-reactive protein level (r = 0.390; P < 0.001), and serum albumin level (r = -0.182; P < 0.001). Glucose 15-22 C-reactive protein Homo sapiens 176-194 17615799-4 2007 Acetylsalicylic acid (ASA) has been attributed with reducing levels of the transcription factor nuclear factor kappaB (NF-kappaB), C-reactive protein, and soluble CD40 ligand, although the evidence relating to the latter two markers is conflicting. Aspirin 0-20 C-reactive protein Homo sapiens 131-149 17615799-4 2007 Acetylsalicylic acid (ASA) has been attributed with reducing levels of the transcription factor nuclear factor kappaB (NF-kappaB), C-reactive protein, and soluble CD40 ligand, although the evidence relating to the latter two markers is conflicting. Aspirin 22-25 C-reactive protein Homo sapiens 131-149 17293598-4 2007 We show now that His-384, corresponding to the risk allele, binds C-reactive protein (CRP) poorly compared with the Tyr-384 form. Histidine 17-20 C-reactive protein Homo sapiens 66-84 17293598-4 2007 We show now that His-384, corresponding to the risk allele, binds C-reactive protein (CRP) poorly compared with the Tyr-384 form. Histidine 17-20 C-reactive protein Homo sapiens 86-89 17293598-4 2007 We show now that His-384, corresponding to the risk allele, binds C-reactive protein (CRP) poorly compared with the Tyr-384 form. Tyrosine 116-119 C-reactive protein Homo sapiens 66-84 17293598-4 2007 We show now that His-384, corresponding to the risk allele, binds C-reactive protein (CRP) poorly compared with the Tyr-384 form. Tyrosine 116-119 C-reactive protein Homo sapiens 86-89 17222316-6 2007 Statistical analysis was performed using the Kaplan-Meier method and multivariable Cox proportional hazard regression model taking into consideration gender, age at diagnosis, disease location and behavior, smoking habits, CDAI score before steroid treatment, and C reactive protein values at steroid weaning, as covariates. Steroids 293-300 C-reactive protein Homo sapiens 264-282 17222316-11 2007 At multivariate analysis, increased C reactive protein at steroid weaning and penetrating complications were independent risk factors for further steroid requirement (OR 5.57, 95% CI 1.20-25.91, P= 0.001 and OR 4.20, 95% CI 1.76-10.04, P= 0.005, respectively). Steroids 58-65 C-reactive protein Homo sapiens 36-54 17222316-11 2007 At multivariate analysis, increased C reactive protein at steroid weaning and penetrating complications were independent risk factors for further steroid requirement (OR 5.57, 95% CI 1.20-25.91, P= 0.001 and OR 4.20, 95% CI 1.76-10.04, P= 0.005, respectively). Steroids 146-153 C-reactive protein Homo sapiens 36-54 17495273-6 2007 Compared with those with low CRP levels, subjects with high CRP levels (ie, >3.0 mg/L) were physically inactive (P = .01), were less likely to adopt the Mediterranean diet (P = .008), had higher glucose levels, had a higher prevalence of hypertension, had a lower high-density lipoprotein cholesterol, and had increased smoking habits and higher anthropometric indices (all P < .05). Glucose 198-205 C-reactive protein Homo sapiens 60-63 17222316-12 2007 CONCLUSION: Despite an initial clinical response and successful steroid tapering, 35% of patients required further steroid treatment within 1 yr. An increased C reactive protein value, at steroid weaning, despite clinical remission, and penetrating complications may predict further steroid requirement in already steroid responsive patients. Steroids 64-71 C-reactive protein Homo sapiens 159-177 17222316-12 2007 CONCLUSION: Despite an initial clinical response and successful steroid tapering, 35% of patients required further steroid treatment within 1 yr. An increased C reactive protein value, at steroid weaning, despite clinical remission, and penetrating complications may predict further steroid requirement in already steroid responsive patients. Steroids 115-122 C-reactive protein Homo sapiens 159-177 17222316-12 2007 CONCLUSION: Despite an initial clinical response and successful steroid tapering, 35% of patients required further steroid treatment within 1 yr. An increased C reactive protein value, at steroid weaning, despite clinical remission, and penetrating complications may predict further steroid requirement in already steroid responsive patients. Steroids 115-122 C-reactive protein Homo sapiens 159-177 17222316-12 2007 CONCLUSION: Despite an initial clinical response and successful steroid tapering, 35% of patients required further steroid treatment within 1 yr. An increased C reactive protein value, at steroid weaning, despite clinical remission, and penetrating complications may predict further steroid requirement in already steroid responsive patients. Steroids 115-122 C-reactive protein Homo sapiens 159-177 17222316-12 2007 CONCLUSION: Despite an initial clinical response and successful steroid tapering, 35% of patients required further steroid treatment within 1 yr. An increased C reactive protein value, at steroid weaning, despite clinical remission, and penetrating complications may predict further steroid requirement in already steroid responsive patients. Steroids 115-122 C-reactive protein Homo sapiens 159-177 17158147-7 2007 RESULTS: CRP values were higher in the study group than in controls (logCRP mean difference: -0.69; 95% confidence interval: -1.05 to -0.33), even when differences were adjusted for age, gender, body mass index (BMI) and triglyceride levels (p = 0.01). Triglycerides 221-233 C-reactive protein Homo sapiens 9-12 17403721-7 2007 After adjustment for diabetes, the risk associated with a 1 mmol/L increase in glucose was greater among those with a C-reactive protein greater than or equal to the median (HR 1.07, 95% CI 1.03-1.11) vs. those with a C-reactive protein less than the median (HR 1.02, 95% CI 0.97-1.06). Glucose 79-86 C-reactive protein Homo sapiens 118-136 16952410-7 2007 After adjusting for age, sex, BMI, baseline glucose regulation status, total cholesterol, urine albumin to creatinine ratio, systolic blood pressure, smoking and alcohol drinking, the association between diabetes and CRP remained significant, with a hazard ratio of 1.23 (95% confidence interval (CI) 1.05, 1.45) corresponding to a doubling in CRP values. Alcohols 162-169 C-reactive protein Homo sapiens 217-220 17392546-5 2007 RESULTS: After adjustment for age and survey and lifestyle factors including smoking, alcohol intake, and physical activity, elevated concentrations of CRP showed a considerably stronger association with risk of type 2 diabetes in women (hazard ratio comparing tertile extremes 7.60 [95% CI 4.43-13.04]) than in men (1.84 [1.27-2.67]). Alcohols 86-93 C-reactive protein Homo sapiens 152-155 17696726-4 2007 Moderate alcohol consumption and high physical activity have been associated with low levels of hs-CRP, but the evidence in these cases is not conclusive. Alcohols 9-16 C-reactive protein Homo sapiens 99-102 17207978-7 2007 Also, through antigen-antibody binding evaluation, the anti-C-reactive protein antibody immobilized on the PMBN surface worked well and it was confirmed that denaturation of the antibody on the PMBN layers was hardly occurred in spite of 60 days storage at 4 degrees C. The antibody conjugated phospholipid polymer layer with well-ordered phosphorylcholine group could be outstanding functional membrane for biomedical diagnostic devices without non-specific binding and reduction of immunologic activity of immobilized antibody. Phospholipids 294-306 C-reactive protein Homo sapiens 60-78 17279354-0 2007 C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser 612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Serine 78-81 C-reactive protein Homo sapiens 0-18 17279354-0 2007 C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser 612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Glucose 176-183 C-reactive protein Homo sapiens 0-18 17279354-3 2007 To this aim, we determined the effects of human recombinant CRP (hrCRP) on insulin signalling involved in glucose transport in L6 myotubes. Glucose 106-113 C-reactive protein Homo sapiens 60-63 17403721-7 2007 After adjustment for diabetes, the risk associated with a 1 mmol/L increase in glucose was greater among those with a C-reactive protein greater than or equal to the median (HR 1.07, 95% CI 1.03-1.11) vs. those with a C-reactive protein less than the median (HR 1.02, 95% CI 0.97-1.06). Glucose 79-86 C-reactive protein Homo sapiens 218-236 17403721-8 2007 After multivariable adjustment, the synergistic relationship between glucose and C-reactive protein and clinical outcomes remained statistically significant (P = 0.01). Glucose 69-76 C-reactive protein Homo sapiens 81-99 17430734-0 2007 Effects of a supplement containing isoflavones and Actaea racemosa L. on asymmetric dimethylarginine, lipids, and C-reactive protein in menopausal women. Isoflavones 35-46 C-reactive protein Homo sapiens 114-132 17307426-7 2007 High-sensitivity C-reactive protein levels decreased by an average of 68% in the rosiglitazone group (5.99 +/- 0.88 to 1.91 +/- 0.28 mg/L, P < .001), compared with a nonsignificant 4% reduction in hsCRP with metformin (5.69 +/- 0.83 to 5.46 +/- 0.92 mg/L; P = nonsignificant). Rosiglitazone 81-94 C-reactive protein Homo sapiens 17-35 17536128-0 2007 Low carbohydrate, high fat diet increases C-reactive protein during weight loss. Carbohydrates 4-16 C-reactive protein Homo sapiens 42-60 17350919-8 2007 The hs-CRP was correlated with total cholesterol (p = 0.039) and EPO-dose (p = 0.03) in diabetics, while with serum fibrinogen (p = 0.025) in non-diabetics. Cholesterol 37-48 C-reactive protein Homo sapiens 7-10 17353499-0 2007 Effect of a high-fiber diet vs a fiber-supplemented diet on C-reactive protein level. Dietary Fiber 17-22 C-reactive protein Homo sapiens 60-78 17307426-7 2007 High-sensitivity C-reactive protein levels decreased by an average of 68% in the rosiglitazone group (5.99 +/- 0.88 to 1.91 +/- 0.28 mg/L, P < .001), compared with a nonsignificant 4% reduction in hsCRP with metformin (5.69 +/- 0.83 to 5.46 +/- 0.92 mg/L; P = nonsignificant). Metformin 211-220 C-reactive protein Homo sapiens 17-35 17258426-3 2007 This abnormality is related to calcium-dependent formation of complexes between C reactive protein and very low density lipoprotein. Calcium 31-38 C-reactive protein Homo sapiens 80-98 17359487-0 2007 Vascular stiffness in familial hypercholesterolaemia is associated with C-reactive protein and cholesterol burden. Cholesterol 36-47 C-reactive protein Homo sapiens 72-90 17064252-7 2007 Only CRP and TNFalpha were significantly associated with UBMA scores in an ordinal logistic regression analysis in which age and BMI (body mass index) were covariates. ubma 57-61 C-reactive protein Homo sapiens 5-8 17359487-3 2007 The aims of this study were to quantify atherosclerosis and arterial stiffness and to evaluate their relationship with high sensitive C-reactive protein (hs-CRP) and the level of exposure to high serum cholesterol in FH patients. Cholesterol 202-213 C-reactive protein Homo sapiens 134-152 17242302-6 2007 Three (of 9) biomarkers were significantly related to incident hypertension on backward elimination (multivariable-adjusted odds ratios, per SD increment in biomarker): C-reactive protein (1.26; 95% CI: 1.05 to 1.51), plasminogen activator inhibitor-1 (1.28; 95% CI: 1.05 to 1.57), and urinary albumin/creatinine ratio (1.21; 95% CI: 1.02 to 1.43). Creatinine 302-312 C-reactive protein Homo sapiens 169-187 17115196-1 2007 The aim of this study was to assess the serum concentration of high-sensitivity C-reactive protein (hs-CRP) in children with nephrotic syndrome (NS) treated with prednisone and cyclosporine A (CyA). Cyclosporine 177-191 C-reactive protein Homo sapiens 80-98 17319905-10 2007 The CRP levels were independently associated with platelet aggregation and aspirin non-responsiveness (P < 0.001, P < 0.001, respectively). Aspirin 75-82 C-reactive protein Homo sapiens 4-7 17319905-13 2007 CRP is an independent predictor of platelet aggregation and aspirin non-responsiveness in the setting of an acute coronary syndrome. Aspirin 60-67 C-reactive protein Homo sapiens 0-3 17115196-1 2007 The aim of this study was to assess the serum concentration of high-sensitivity C-reactive protein (hs-CRP) in children with nephrotic syndrome (NS) treated with prednisone and cyclosporine A (CyA). Cyclosporine 193-196 C-reactive protein Homo sapiens 80-98 17489777-13 2007 Metformin therapy in PCOS women reduces CRP level, hyperinsulinaemia and cardiovascular risk. Metformin 0-9 C-reactive protein Homo sapiens 40-43 17255341-2 2007 By using ultrasensitive confocal imaging analysis, we have studied CRP binding to transfected COS-7 cells expressing the high-affinity IgG receptor FcgammaRI. carbonyl sulfide 94-97 C-reactive protein Homo sapiens 67-70 17489777-8 2007 Mean serum C-RP levels significantly decreased after metformin treatment ((6,37+/-1,72 vs. 1,67+/-0,73 mg/l; p<0,05). Metformin 53-62 C-reactive protein Homo sapiens 11-15 17218028-10 2007 CONCLUSIONS: We concluded that the frequency of aspirin resistance confirmed in this cohort of patients with metabolic syndrome was higher in patients with a lower diastolic blood pressure, higher hs-CRP levels and atherosclerotic changes in their carotid arteries. Aspirin 48-55 C-reactive protein Homo sapiens 200-203 17289483-10 2007 DEX significantly reduced at least 1 postoperative level of IL-6, IL-8, IL-10, CRP, and exhaled NO. Dexamethasone 0-3 C-reactive protein Homo sapiens 79-82 17211240-9 2007 In established hypertension, elevated CRP was associated with increased BP, BMI, insulin, HOMA (index of insulin resistance), leptin, triglycerides and norepinephrine. Triglycerides 134-147 C-reactive protein Homo sapiens 38-41 17211240-9 2007 In established hypertension, elevated CRP was associated with increased BP, BMI, insulin, HOMA (index of insulin resistance), leptin, triglycerides and norepinephrine. Norepinephrine 152-166 C-reactive protein Homo sapiens 38-41 17211240-10 2007 Twin correlations indicated pleiotropy (shared genetic determination) for CRP with BMI (P = 0.0002), leptin (P < 0.001), triglycerides (P = 0.002) and systolic blood pressure (SBP) (P = 0.042). Triglycerides 124-137 C-reactive protein Homo sapiens 74-77 17211240-18 2007 CONCLUSIONS: CRP secretion is substantially heritable in humans, demonstrating pleiotropy (shared genetic determination) with other features of the metabolic syndrome, such as BMI, triglycerides or BP. Triglycerides 181-194 C-reactive protein Homo sapiens 13-16 17211250-6 2007 In control individuals, 8-iso-PGF2alpha correlated only with high-sensitivity CRP (P < 0.001). 8-epi-prostaglandin F2alpha 24-39 C-reactive protein Homo sapiens 78-81 17211250-7 2007 In essential hypertensive patients, 8-iso-PGF2alpha correlated with high-sensitivity CRP (P < 0.000001), TNFalpha (P < 0.0001), ICAM-1 (P < 0.000001), VCAM-1 (P < 0.0001) and blood pressure. 8-epi-prostaglandin F2alpha 36-51 C-reactive protein Homo sapiens 85-88 17211250-8 2007 The multiple regression analysis considering 8-iso-PGF2alpha as the dependent variable showed that in essential hypertensive patients the independent predictors of 8-iso-PGF2alpha were ICAM-1, high-sensitivity CRP (P < 0.00001, respectively), and TNFalpha (P = 0.028). 8-epi-prostaglandin F2alpha 164-179 C-reactive protein Homo sapiens 210-213 16678922-7 2007 RESULTS: In both genders, we observed inverse associations between estimated VO2max and levels of CRP after controlling for age, race, body mass index category, hypertension, diabetes, smoking status, alcohol consumption, and use of medications including aspirin, non-steroidal anti-inflammatory drugs, steroid, lipid-lowering agents, antimicrobials, or estrogen/progesterone (in women). Alcohols 201-208 C-reactive protein Homo sapiens 98-101 17308218-7 2007 ESR, CRP and haemoglobin improved in the steroid group only (p<0.05). Steroids 41-48 C-reactive protein Homo sapiens 5-8 16759717-5 2007 RESULTS: In unadjusted analyses, CRP was positively correlated with age, male gender, body mass index, blood pressure, smoking habit, creatinine, uric acid, triglycerides, an index of insulin resistance, and 8-isoprostane, and inversely correlated with high-density lipoprotein-cholesterol. Creatinine 134-144 C-reactive protein Homo sapiens 33-36 16759717-5 2007 RESULTS: In unadjusted analyses, CRP was positively correlated with age, male gender, body mass index, blood pressure, smoking habit, creatinine, uric acid, triglycerides, an index of insulin resistance, and 8-isoprostane, and inversely correlated with high-density lipoprotein-cholesterol. Triglycerides 157-170 C-reactive protein Homo sapiens 33-36 16759717-5 2007 RESULTS: In unadjusted analyses, CRP was positively correlated with age, male gender, body mass index, blood pressure, smoking habit, creatinine, uric acid, triglycerides, an index of insulin resistance, and 8-isoprostane, and inversely correlated with high-density lipoprotein-cholesterol. 8-epi-prostaglandin F2alpha 208-221 C-reactive protein Homo sapiens 33-36 16759717-6 2007 8-Isoprostane was positively correlated with age, pulse pressure, smoking habit, brain natriuretic peptide, and CRP. 8-epi-prostaglandin F2alpha 0-13 C-reactive protein Homo sapiens 112-115 16678922-7 2007 RESULTS: In both genders, we observed inverse associations between estimated VO2max and levels of CRP after controlling for age, race, body mass index category, hypertension, diabetes, smoking status, alcohol consumption, and use of medications including aspirin, non-steroidal anti-inflammatory drugs, steroid, lipid-lowering agents, antimicrobials, or estrogen/progesterone (in women). Aspirin 255-262 C-reactive protein Homo sapiens 98-101 17237316-0 2007 Intake of fish oil, oleic acid, folic acid, and vitamins B-6 and E for 1 year decreases plasma C-reactive protein and reduces coronary heart disease risk factors in male patients in a cardiac rehabilitation program. Folic Acid 32-42 C-reactive protein Homo sapiens 95-113 16678922-7 2007 RESULTS: In both genders, we observed inverse associations between estimated VO2max and levels of CRP after controlling for age, race, body mass index category, hypertension, diabetes, smoking status, alcohol consumption, and use of medications including aspirin, non-steroidal anti-inflammatory drugs, steroid, lipid-lowering agents, antimicrobials, or estrogen/progesterone (in women). Steroids 268-275 C-reactive protein Homo sapiens 98-101 16678922-7 2007 RESULTS: In both genders, we observed inverse associations between estimated VO2max and levels of CRP after controlling for age, race, body mass index category, hypertension, diabetes, smoking status, alcohol consumption, and use of medications including aspirin, non-steroidal anti-inflammatory drugs, steroid, lipid-lowering agents, antimicrobials, or estrogen/progesterone (in women). Progesterone 363-375 C-reactive protein Homo sapiens 98-101 17215574-2 2007 This study intends to evaluate the relationship between C-reactive protein (CRP) and the newly established marker of lipid peroxidation, d-ROMs (reactive oxygen metabolites), in comparison with different indicators of oxidative stress. Oxygen 154-160 C-reactive protein Homo sapiens 56-74 17664864-5 2007 CRP and serum calcium were synergistically associated with carotid plaque in that those with CRP > median and serum calcium > median showed the highest prevalence of carotid plaque than either factor alone (p = 0.003). Calcium 14-21 C-reactive protein Homo sapiens 93-96 17664864-5 2007 CRP and serum calcium were synergistically associated with carotid plaque in that those with CRP > median and serum calcium > median showed the highest prevalence of carotid plaque than either factor alone (p = 0.003). Calcium 119-126 C-reactive protein Homo sapiens 0-3 17215574-2 2007 This study intends to evaluate the relationship between C-reactive protein (CRP) and the newly established marker of lipid peroxidation, d-ROMs (reactive oxygen metabolites), in comparison with different indicators of oxidative stress. Oxygen 154-160 C-reactive protein Homo sapiens 76-79 17283424-8 2007 The correlation between CRP and body mass index (BMI), insulin and glucose was stronger among women. Glucose 67-74 C-reactive protein Homo sapiens 24-27 17468081-10 2007 Hence the present study shows that serum CRP concentrations are increased in patients with classical coronary risk factors, and that they may be modulated by dietary cholesterol. Cholesterol 166-177 C-reactive protein Homo sapiens 41-44 17468081-8 2007 In the dyslipidaemic patients, approximately 4% of the variation in serum CRP could be explained by dietary cholesterol intake (p = 0.015, 2.8%), and weakly by dietary vitamin C intake (p = 0.06, 1.2%). Cholesterol 108-119 C-reactive protein Homo sapiens 74-77 17477779-3 2007 Thus we conducted a population-based cross-sectional study to examine the associations of CRP levels with CRP C1444T polymorphism and two cytokine polymorphisms (IL-1B C-31T and TNF-A T-1031C), according to sex, age, smoking, alcohol, and BMI, in a total of 489 Japanese health checkup examinees (156 males and 333 females). Alcohols 226-233 C-reactive protein Homo sapiens 90-93 16764962-6 2007 Multiple regression analyses showed that serum CRP was independently predicted by the level of IL-6 (P<0.001, F=4.04), leptin (P<0.001, F=7.09), and triglycerides (P<0.001, F=15.13), which explained 17.6% of the variability of serum CRP concentration in these patients. Triglycerides 155-168 C-reactive protein Homo sapiens 47-50 17110470-10 2007 These associations were also apparent in participants who consumed < or = 20 g/day of alcohol and those with normal weight, with values of alanine aminotransferase within reference intervals, or with C-reactive protein < 3.0 mg/L, and participants without metabolic syndrome. Alcohols 89-96 C-reactive protein Homo sapiens 203-221 17584094-6 2007 Subjects manifesting with identical low density cholesterol and/or blood pressure levels have different rates of cardiovascular accidents on the basis of different circulating CRP concentrations. Cholesterol 48-59 C-reactive protein Homo sapiens 176-179 16764962-0 2007 Leptin, triglycerides, and interleukin 6 are independently associated with C-reactive protein in Japanese type 2 diabetic patients. Triglycerides 8-21 C-reactive protein Homo sapiens 75-93 17910519-11 2007 In addition, it has been reported that C-reactive protein levels and the combined incidence of cardiovascular events (death, MI and target segment revascularisation during the 6-month follow-up) were significantly higher in coronaropathic patients undergoing non-surgical revascularisation procedures (stent implantation) not receiving statin therapy compared with those treated with atorvastatin (80mg). Atorvastatin 384-396 C-reactive protein Homo sapiens 39-57 17135283-0 2007 Increased risk of acute myocardial infarction and elevated levels of C-reactive protein in carriers of the Thr-87 variant of the ATP receptor P2Y11. Threonine 107-110 C-reactive protein Homo sapiens 69-87 17135283-7 2007 C-reactive protein was elevated in Thr-87 carriers: 1.6 mg/L vs. 1.3 mg/L (P = 0.001). Threonine 35-38 C-reactive protein Homo sapiens 0-18 17116742-4 2007 Herein, by probing conformational alteration, neoepitope expression, and direct visualization using electron-microscopy, we have shown that calcium-dependent binding of pCRP to membranes, including liposomes and cell membranes, led to a rapid but partial structural change, producing molecules that express CRP subunit antigenicity but with retained native pentameric conformation. Calcium 140-147 C-reactive protein Homo sapiens 170-173 17074328-2 2007 Rosiglitazone significantly decreased serum C-reactive protein levels, white blood cell count, and alanine aminotransferase enzyme activity but did not affect lipid or blood pressure levels. Rosiglitazone 0-13 C-reactive protein Homo sapiens 44-62 17329914-9 2007 Furthermore, the HbA(1c) adjusted by sex, body mass index, systolic blood pressure, serum triglyceride and current smoking status was significantly higher in the high CRP group than in the average and the low CRP groups. Triglycerides 90-102 C-reactive protein Homo sapiens 167-170 16682979-3 2007 RESULTS: Mean (95% CI) CRP in women and men was 4.06 cholesterol (3.53, 4.66) mg/l and 3.42 (2.94, 3.97) mg/l, respectively (P=NS). Cholesterol 53-64 C-reactive protein Homo sapiens 23-26 17284923-12 2007 The decrease in leptin and CRP levels were higher with a low-carbohydrate diet than a low-fat diet. Carbohydrates 61-73 C-reactive protein Homo sapiens 27-30 17379997-11 2007 Steroid therapy including methylprednisolone pulse therapy (500 mg/day, 3 days) and 2 courses of plasma exchange were effective in reducing the fever, anti-GBM antibody titer and C-reactive protein level. Steroids 0-7 C-reactive protein Homo sapiens 179-197 17146106-10 2007 In 27 patients achieving target troxacitabine plasma concentrations (ie, approximately 80 ng/mL) the CR + CRp rate was 26%. troxacitabine 32-45 C-reactive protein Homo sapiens 101-103 17873309-9 2007 According to our results the inflammatory activity represented by high levels of IL-6 and CRP are involved in the pathogenesis of ACD, probably due to the action of inflammation on iron metabolism, but not in ARC. Iron 181-185 C-reactive protein Homo sapiens 90-93 17118943-4 2007 PE and steroid pulse therapy reduced his plasma CRP level. Steroids 7-14 C-reactive protein Homo sapiens 48-51 17329034-12 2007 Does the blockade by atorvastain of the AGE signaling pathway, in other words, the suppression of 8-hydroxydeoxyguanosine and CRP levels by atorvastatin treatment, contribute to its cardioprotective properties? Atorvastatin 140-152 C-reactive protein Homo sapiens 126-129 17245762-8 2007 Our data indicate that Randox full-range CRP measurements using an immunoturbidimetry assay on Olympus systems perform as well for routine diagnostics as other high-sensitivity applications using serum or heparin plasma. Heparin 205-212 C-reactive protein Homo sapiens 41-44 17909718-8 2007 RESULTS: Postoperative plasma concentrations of IL-6 (days 1 and 2), IL-8 (days 2 and 3), and CRP (days 1-4) were significantly lower in the steroid than in the control group. Steroids 141-148 C-reactive protein Homo sapiens 94-97 17378768-7 2006 The expression of vascular CRP was closely associated with NAD(P)H oxidase, an important enzymatic origin of reactive oxygen species (ROS) in vessel walls. Reactive Oxygen Species 109-132 C-reactive protein Homo sapiens 27-30 17161243-4 2006 Platelet aggregation (5 and 20 muM adenosine diphosphate [ADP]), ADP-stimulated expression of active glycoprotein (GP) IIb/IIIa, and platelet-bound P-selectin, tumor necrosis factor (TNF)-alpha, C-reactive protein (CRP), and cardiac markers were measured. Adenosine Diphosphate 65-68 C-reactive protein Homo sapiens 215-218 17130328-7 2006 The peak white cell counts and C-reactive protein levels after the 7(th) postoperative day were significantly higher in the steroid group. Steroids 124-131 C-reactive protein Homo sapiens 31-49 16473396-0 2007 Acetylsalicylic acid is compounding to antiplatelet effect of C-reactive protein. Aspirin 0-20 C-reactive protein Homo sapiens 62-80 16473396-2 2007 In our study, we examined the in vitro effect of C-reactive protein (CRP) on the ASA-mediated inhibition of collagen-stimulated platelet reactivity. Aspirin 81-84 C-reactive protein Homo sapiens 49-67 16473396-2 2007 In our study, we examined the in vitro effect of C-reactive protein (CRP) on the ASA-mediated inhibition of collagen-stimulated platelet reactivity. Aspirin 81-84 C-reactive protein Homo sapiens 69-72 16473396-3 2007 Influence of CRP on platelet responsiveness to ASA was analysed using classical turbidimetric aggregation and flow cytometry. Aspirin 47-50 C-reactive protein Homo sapiens 13-16 16473396-6 2007 In general, our findings showed for the first time the augmenting effect of native C-reactive protein in the antiplatelet action of acetylsalicylic acid. Aspirin 132-152 C-reactive protein Homo sapiens 83-101 16473396-7 2007 Thus, we conclude that the effectiveness of aspirin therapy may strongly depend upon the presence of native CRP in circulation. Aspirin 44-51 C-reactive protein Homo sapiens 108-111 17161243-4 2006 Platelet aggregation (5 and 20 muM adenosine diphosphate [ADP]), ADP-stimulated expression of active glycoprotein (GP) IIb/IIIa, and platelet-bound P-selectin, tumor necrosis factor (TNF)-alpha, C-reactive protein (CRP), and cardiac markers were measured. Adenosine Diphosphate 65-68 C-reactive protein Homo sapiens 195-213 17378768-7 2006 The expression of vascular CRP was closely associated with NAD(P)H oxidase, an important enzymatic origin of reactive oxygen species (ROS) in vessel walls. Reactive Oxygen Species 134-137 C-reactive protein Homo sapiens 27-30 17378768-8 2006 Furthermore, CRP directly up-regulated NAD(P)H oxidase p22(phox) and enhanced ROS generation in cultured coronary artery smooth muscle cells. Reactive Oxygen Species 78-81 C-reactive protein Homo sapiens 13-16 17287555-1 2006 BACKGROUND & OBJECTIVES: Elevated levels of c-reactive protein (CRP) are known to be associated with insulin resistance and metabolic syndrome in adults. Adenosine Monophosphate 12-15 C-reactive protein Homo sapiens 48-66 17160915-0 2006 Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy. Rosiglitazone 0-13 C-reactive protein Homo sapiens 69-87 17160915-6 2006 Addition of RSG to statin therapy may further reduce cardiovascular risk by improving the LDL phenotype, as well as reducing insulin resistance and CRP levels. Rosiglitazone 12-15 C-reactive protein Homo sapiens 148-151 17087777-8 2006 Compared with the placebo, IgA, IgG subtypes and CRP levels were reduced after aspirin treatment (P = 0.001, P = 0.02, P = 0.04, respectively). Aspirin 79-86 C-reactive protein Homo sapiens 49-52 17087777-9 2006 The percentage reduction of IgA- and IgG-aCL was related to the percentage reduction of CRP after aspirin (P < 0.05). Aspirin 98-105 C-reactive protein Homo sapiens 88-91 17116715-6 2006 Men who consumed >or=15.2 g of alcohol/d (4th quartile of the distribution) were younger (P < 0.001), had elevated plasma HDL-C concentrations (P < 0.001), and lower plasma concentrations of insulin (P = 0.01), CRP (P = 0.01), and fibrinogen (P < 0.001) than men in the 1st quartile (<1.3 g of alcohol/d). Alcohols 34-41 C-reactive protein Homo sapiens 220-223 18156767-0 2006 [The Relationship between High Sensitivity C-Reactive Protein and Metabolic Syndrome according to the Fasting Glucose Level at Medical Checkups.]. Glucose 110-117 C-reactive protein Homo sapiens 43-61 18156767-1 2006 BACKGROUND: This study was performed to investigate the difference in high sensitivity C-reactive protein (hsCRP) and metabolic syndrome according to the fasting glucose level, especially between the groups of less than 100 mg/dL and 100-109 mg/dL, which were conventionally categorized into normal levels. Glucose 162-169 C-reactive protein Homo sapiens 87-105 17119383-9 2006 Similarly, the difference between baseline and 2-hour serum iron level (Delta[Fe]2hr) correlated with IL-6 (P = 0.008) and CRP (P = 0.045). Iron 60-64 C-reactive protein Homo sapiens 123-126 17130267-10 2006 In addition to the hypolipidemic effect, atorvastatin treatment significantly reduced inflammatory parameters: CRP (median 4.1 to 2.9; P = 0.015), TNF-alpha (6.0 +/- 2.7 to 4.7 +/- 2.4; P = 0.046), and IL-1 beta levels (1.9 +/- 0.7 to 1.2 +/- 0.7; P = 0.001). Atorvastatin 41-53 C-reactive protein Homo sapiens 111-114 17214052-14 2006 c-reactive protein was also higher in patients with extracranial carotid stenosis but their cholesterol and low-density lipoprotein were significantly lower than those with intracranial disease. Cholesterol 92-103 C-reactive protein Homo sapiens 0-18 17287555-1 2006 BACKGROUND & OBJECTIVES: Elevated levels of c-reactive protein (CRP) are known to be associated with insulin resistance and metabolic syndrome in adults. Adenosine Monophosphate 12-15 C-reactive protein Homo sapiens 68-71 17027571-6 2006 On multivariate analysis, changes in ADMA, endothelin-1, and CRP were independent predictors of improved endothelial reactivity with rosiglitazone. Rosiglitazone 133-146 C-reactive protein Homo sapiens 61-64 16945967-8 2006 Increasing [ADP] to 0.4 mm or removal of CrP ([ATP] was kept constant) caused a slowly developing decrease of Ca(2+) spark frequency by 29 and 42%, respectively. Adenosine Triphosphate 47-50 C-reactive protein Homo sapiens 41-44 16917108-0 2006 C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production. Cyclic AMP 120-130 C-reactive protein Homo sapiens 0-18 16917108-8 2006 CRP significantly decreased intracellular cAMP, phospho-cAMP response element binding protein (pCREB), and adenyl cyclase activity. Cyclic AMP 42-46 C-reactive protein Homo sapiens 0-3 16917108-8 2006 CRP significantly decreased intracellular cAMP, phospho-cAMP response element binding protein (pCREB), and adenyl cyclase activity. Cyclic AMP 56-60 C-reactive protein Homo sapiens 0-3 16917108-9 2006 cAMP agonists reversed CRP-mediated IL-10 inhibition. Cyclic AMP 0-4 C-reactive protein Homo sapiens 23-26 16931792-7 2006 Incubation of EPCs with CRP caused a concentration dependent increase in reactive oxygen species (ROS) production and apoptosis, with an effect quantitatively similar to H2O2. Reactive Oxygen Species 73-96 C-reactive protein Homo sapiens 24-27 16931792-7 2006 Incubation of EPCs with CRP caused a concentration dependent increase in reactive oxygen species (ROS) production and apoptosis, with an effect quantitatively similar to H2O2. Reactive Oxygen Species 98-101 C-reactive protein Homo sapiens 24-27 16931792-7 2006 Incubation of EPCs with CRP caused a concentration dependent increase in reactive oxygen species (ROS) production and apoptosis, with an effect quantitatively similar to H2O2. Hydrogen Peroxide 170-174 C-reactive protein Homo sapiens 24-27 16931792-10 2006 Transfection of EPCs with MnSOD-RNAi resulted in a reduction in CRP-induced ROS production, apoptosis, and telomerase inactivation. Reactive Oxygen Species 76-79 C-reactive protein Homo sapiens 64-67 17016627-7 2006 Dexamethasone attenuated the effects of MIF upon CRP production but increased the MIF stimulated release of ACT. Dexamethasone 0-13 C-reactive protein Homo sapiens 49-52 17027571-0 2006 Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Rosiglitazone 82-95 C-reactive protein Homo sapiens 157-175 17027571-7 2006 In conclusion, we have, for the first time, demonstrated the independent associations between the improvement in flow-mediated dilation and reductions in ADMA, endothelin-1, and CRP after 8 weeks of treatment with rosiglitazone in nondiabetic patients with the metabolic syndrome. Rosiglitazone 214-227 C-reactive protein Homo sapiens 178-181 17027571-8 2006 These findings suggest that decreases in ADMA, endothelin-1, and CRP may serve as possible mechanisms for the improvement in endothelial function conferred by rosiglitazone treatment. Rosiglitazone 159-172 C-reactive protein Homo sapiens 65-68 17014552-5 2006 The aim of this study is to evaluate the role of CRP and CHr in iron administration and anaemia management in dialysis patients. Iron 64-68 C-reactive protein Homo sapiens 49-52 16962105-3 2006 At physiological concentrations of 1-7mug/ml, CRP strongly inhibited copper-mediated oxidation of LDL and phospholipid liposomes in a concentration-dependent manner. Copper 69-75 C-reactive protein Homo sapiens 46-49 16962105-3 2006 At physiological concentrations of 1-7mug/ml, CRP strongly inhibited copper-mediated oxidation of LDL and phospholipid liposomes in a concentration-dependent manner. Phospholipids 106-118 C-reactive protein Homo sapiens 46-49 17023703-7 2006 At baseline, BMI was highly correlated with tHcy (r = 0.39, P = 0.003) and CRP (r = 0.55, P < 0.0001), whereas HDL cholesterol was correlated with CRP (r = -0.30, P = 0.02). Cholesterol 118-129 C-reactive protein Homo sapiens 150-153 17175820-0 2006 Attenuation of C-reactive protein increases after exodontia by tramadol and ibuprofen. Ibuprofen 76-85 C-reactive protein Homo sapiens 15-33 17175820-6 2006 At 72 hours, C-reactive protein had increased over postsurgery baseline by 123% in the tramadol group (P < .001), 84% in the ibuprofen group (P < .001), and only 37% in the combined analgesic group (P = .078). Ibuprofen 128-137 C-reactive protein Homo sapiens 13-31 16957566-6 2006 Addition of rosiglitazone to metformin also reduced levels of plasminogen activator inhibitor-1 antigen and activity, C-reactive protein, von Willebrand factor and fibrinogen compared with addition of glyburide. Rosiglitazone 12-25 C-reactive protein Homo sapiens 118-159 16957566-6 2006 Addition of rosiglitazone to metformin also reduced levels of plasminogen activator inhibitor-1 antigen and activity, C-reactive protein, von Willebrand factor and fibrinogen compared with addition of glyburide. Metformin 29-38 C-reactive protein Homo sapiens 118-159 16386256-0 2006 C-reactive protein and alcohol consumption: Is there a U-shaped association? Alcohols 23-30 C-reactive protein Homo sapiens 0-18 17014552-14 2006 High CRP association with low CHr and low TSAT levels can explain the lack of response to further IV iron therapy. Iron 101-105 C-reactive protein Homo sapiens 5-8 16936150-7 2006 CRP values were (median +/- SD) 2.8 +/- 4.4 versus 3.7 +/- 5.4 for those with normal glucose and diabetes, respectively (P < 0.001). Glucose 85-92 C-reactive protein Homo sapiens 0-3 16941570-2 2006 We have combined proteomics and traditional biochemistry approaches to study the proteome of CRP-activated platelets, focusing in detail on tyrosine phosphorylation. Tyrosine 140-148 C-reactive protein Homo sapiens 93-96 16941570-5 2006 Interestingly, the type I transmembrane protein G6f was found to be specifically phosphorylated on Tyr-281 in response to platelet activation by CRP, providing a docking site for the adapter Grb2. Tyrosine 99-102 C-reactive protein Homo sapiens 145-148 16941570-7 2006 Further, we also demonstrate for the first time that Grb2 and its homolog Gads are tyrosine-phosphorylated in CRP-stimulated platelets. Tyrosine 83-91 C-reactive protein Homo sapiens 110-113 16923447-0 2006 Relation of C-reactive protein level and long-term risk of death or myocardial infarction following percutaneous coronary intervention with a sirolimus-eluting stent. Sirolimus 142-151 C-reactive protein Homo sapiens 12-30 16923447-2 2006 We hypothesized that PCI with sirolimus-eluting stents (SESs) would result in a smaller increase in CRP compared with BMSs and that a high CRP level before PCI would be associated with a higher incidence of death or myocardial infarction at 12 months, regardless of the type of stent implanted. Sirolimus 30-39 C-reactive protein Homo sapiens 100-103 16923454-6 2006 In linear regression models that were adjusted for mean BP and other factors, CRP quartiles were positively associated with daytime systolic BP variability; for subjects in the lowest to highest CRP quartiles, the mean within-subject SDs of daytime systolic BP were 9.31, 9.62, 10.55, and 11.17, respectively (p for linear trend = 0.001). Sodium Dodecyl Sulfate 234-237 C-reactive protein Homo sapiens 78-81 16850006-12 2006 CONCLUSIONS: Low-dose hydrocortisone seems to reduce MACR and serum C-reactive protein but not procalcitonin in patients with severe sepsis. Hydrocortisone 22-36 C-reactive protein Homo sapiens 68-86 16918582-8 2006 Moreover, increasing CRP concentration in this paediatric population was associated with an enhanced CV risk profile, consisting of increased adiposity, higher insulin resistance, worsening lipid profile (higher total cholesterol, triglycerides, low-density lipoprotein cholesterol, apolipoprotein B and total cholesterol : high-density-lipoprotein cholesterol ratio), increased leptin and decreased adiponectin. Cholesterol 218-229 C-reactive protein Homo sapiens 21-24 16918582-8 2006 Moreover, increasing CRP concentration in this paediatric population was associated with an enhanced CV risk profile, consisting of increased adiposity, higher insulin resistance, worsening lipid profile (higher total cholesterol, triglycerides, low-density lipoprotein cholesterol, apolipoprotein B and total cholesterol : high-density-lipoprotein cholesterol ratio), increased leptin and decreased adiponectin. Triglycerides 231-244 C-reactive protein Homo sapiens 21-24 16918582-8 2006 Moreover, increasing CRP concentration in this paediatric population was associated with an enhanced CV risk profile, consisting of increased adiposity, higher insulin resistance, worsening lipid profile (higher total cholesterol, triglycerides, low-density lipoprotein cholesterol, apolipoprotein B and total cholesterol : high-density-lipoprotein cholesterol ratio), increased leptin and decreased adiponectin. Cholesterol 270-281 C-reactive protein Homo sapiens 21-24 17003600-8 2006 In the female group, however, log hs-CRP was significantly correlated (P < .05) with total cholesterol (r = 0.30), low-density lipoprotein (r = 0.27), tryglycerides (r = 0.51), and body mass index (r = 0.36). Cholesterol 94-105 C-reactive protein Homo sapiens 37-40 16449511-6 2006 Atorvastatin reduced serum low density lipoprotein cholesterol (-53%, p < 0.001) and C reactive protein (-49%, p < 0.001) concentrations whereas there was no change with placebo (-7% and 17%, p > 0.95 for both). Atorvastatin 0-12 C-reactive protein Homo sapiens 88-106 17003600-9 2006 Linear regression analysis determined that triglycerides and body mass index explained 30% of the variability in log hs-CRP. Triglycerides 43-56 C-reactive protein Homo sapiens 120-123 16894332-0 2006 Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women. Estradiol 22-38 C-reactive protein Homo sapiens 91-109 16894332-2 2006 The aim of our study was to investigate the effects of intranasal 17beta-estradiol (E2) on serum CRP and its most potent stimulant, interleukin-6 in healthy postmenopausal women. Estradiol 66-82 C-reactive protein Homo sapiens 97-100 16894332-2 2006 The aim of our study was to investigate the effects of intranasal 17beta-estradiol (E2) on serum CRP and its most potent stimulant, interleukin-6 in healthy postmenopausal women. Estradiol 84-86 C-reactive protein Homo sapiens 97-100 17175466-5 2006 RESULTS: CRP was found to have significantly positive correlation with body weight, waist circumference, hip circumference, body mass index, log of fasting glucose levels, fasting insulin levels and HOMA. Glucose 156-163 C-reactive protein Homo sapiens 9-12 16919544-10 2006 In conclusion, this study shows that in Asian Indians, inflammatory markers (CRP, IL-6, and VCAM-1) increase with increasing degrees of glucose intolerance. Glucose 136-143 C-reactive protein Homo sapiens 77-80 16973513-10 2006 Patients with positive CRP had higher ECFv/total body water (TBW) ratio (women 47.69 +/- 0.69 vs 47.36 +/- 0.65, men 43.15 +/- 1.14 vs 42.84 +/- 0.65; p < 0.05), higher serum glucose (125.09 +/- 81.90 vs 103.28 +/- 43.30 mg/dL, p < 0.03), and lower serum albumin (2.86 +/- 0.54 vs 3.17 +/- 0.38 g/dL, p < 0.001) levels. Water 54-59 C-reactive protein Homo sapiens 23-26 16973513-10 2006 Patients with positive CRP had higher ECFv/total body water (TBW) ratio (women 47.69 +/- 0.69 vs 47.36 +/- 0.65, men 43.15 +/- 1.14 vs 42.84 +/- 0.65; p < 0.05), higher serum glucose (125.09 +/- 81.90 vs 103.28 +/- 43.30 mg/dL, p < 0.03), and lower serum albumin (2.86 +/- 0.54 vs 3.17 +/- 0.38 g/dL, p < 0.001) levels. Glucose 178-185 C-reactive protein Homo sapiens 23-26 16863620-8 2006 In multiple regression analysis abdominal obesity (p=0.001), TG (p=0.001) and glucose (p=0.02) were associated with CRP levels after correcting for other factors. Thioguanine 61-63 C-reactive protein Homo sapiens 116-119 16863620-8 2006 In multiple regression analysis abdominal obesity (p=0.001), TG (p=0.001) and glucose (p=0.02) were associated with CRP levels after correcting for other factors. Glucose 78-85 C-reactive protein Homo sapiens 116-119 16740374-0 2006 Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: a pilot study. Atorvastatin 113-125 C-reactive protein Homo sapiens 36-54 17166451-9 2006 The expression of CD(146) on the three groups of cells correlated with each other (r was 0.66 and 0.853 respectively, P = 0.000), but they did not correlate with the course of the disease, age, ESR, C reactive protein (CRP), antineutrophil cytoplasmic antibody (ANCA), birmingham vasculitis activity score (BVAS) and SLE disease activity index (SLEDAI) (P > 0.5). Cadmium 18-20 C-reactive protein Homo sapiens 199-217 17166451-9 2006 The expression of CD(146) on the three groups of cells correlated with each other (r was 0.66 and 0.853 respectively, P = 0.000), but they did not correlate with the course of the disease, age, ESR, C reactive protein (CRP), antineutrophil cytoplasmic antibody (ANCA), birmingham vasculitis activity score (BVAS) and SLE disease activity index (SLEDAI) (P > 0.5). Cadmium 18-20 C-reactive protein Homo sapiens 219-222 16839838-5 2006 Tertiles of fasting glucose levels showed a clear positive relationship with cardiovascular risk factors including age, obesity, blood pressure, lipid levels, and CRP (P < .001 for all). Glucose 20-27 C-reactive protein Homo sapiens 163-166 16784936-5 2006 An original analysis of available data shows that the ability of a lipid-lowering therapy to reduce the C-reactive protein level is closely correlated with its efficacy in LDL cholesterol reduction. Cholesterol 176-187 C-reactive protein Homo sapiens 104-122 16897175-0 2006 Carbohydrate ligands of human C-reactive protein: binding of neoglycoproteins containing galactose-6-phosphate and galactose-terminated disaccharide. Galactose 89-98 C-reactive protein Homo sapiens 30-48 16897175-1 2006 Binding of carbohydrate ligand by human C-reactive protein (CRP), in both native form and structurally deviated form (neoCRP or mCRP), was investigated using galactose-6-phosphate (Gal6P)- and Galbeta3GalNAc-containing bovine serum albumin (BSA) derivatives. Carbohydrates 11-23 C-reactive protein Homo sapiens 40-58 16897175-1 2006 Binding of carbohydrate ligand by human C-reactive protein (CRP), in both native form and structurally deviated form (neoCRP or mCRP), was investigated using galactose-6-phosphate (Gal6P)- and Galbeta3GalNAc-containing bovine serum albumin (BSA) derivatives. Carbohydrates 11-23 C-reactive protein Homo sapiens 60-63 16901043-9 2006 Furthermore, serum calcium was inversely and significantly associated with serum C-reactive protein in male patients (r = - 0.34; p < 0.001). Calcium 19-26 C-reactive protein Homo sapiens 81-99 16554319-7 2006 The annualized change of the square root-transformed CAC score positively correlated with the time-integrated levels of C-reactive protein (R = 0.521, P = 0.001), phosphorus (R = 0.433, P = 0.005) and calcium x phosphorus product (R = 0.394, P = 0.012), but did not correlate with the levels of fetuin-A or lipid parameters. Calcium 201-208 C-reactive protein Homo sapiens 120-138 16721360-2 2006 The present study evaluated the relationship between C-reactive protein concentrations and survival in a cohort of patients receiving adjuvant 5-fluorouracil (5-FU) chemotherapy following potentially curative resection for colorectal cancer. Fluorouracil 143-157 C-reactive protein Homo sapiens 53-71 16721360-2 2006 The present study evaluated the relationship between C-reactive protein concentrations and survival in a cohort of patients receiving adjuvant 5-fluorouracil (5-FU) chemotherapy following potentially curative resection for colorectal cancer. Fluorouracil 159-163 C-reactive protein Homo sapiens 53-71 16822291-6 2006 Anti-intercellular adhesion molecule-1 neutralising monoclonal antibody and nitric oxide donor, sodium nitroprusside, blocked the effect of CRP, reducing adhesion from 202% to 128% (P < 0.05) and 114% (P = 0.02) respectively. Nitric Oxide 76-88 C-reactive protein Homo sapiens 140-143 16491109-8 2006 RESULTS: Subjects receiving folic acid supplementation showed a decrement of homocysteine and an amelioration of insulin sensitivity; this treatment was also associated with a significant drop in the circulating concentration of monocyte chemoattractant protein-1, interleukin-8 and C-reactive protein, in the absence of any significant variation of BMI or fat mass. Folic Acid 28-38 C-reactive protein Homo sapiens 283-301 16908949-7 2006 It was shown that age, smoking status, systolic blood pressure (SBP) and LDL cholesterol were significantly associated with IMT in subjects in the lower CRP groups (CRP-1 approximately CRP-3), and age, SBP and presence of diabetes mellitus in the highest CRP group (CRP-4). Cholesterol 77-88 C-reactive protein Homo sapiens 153-156 16908949-7 2006 It was shown that age, smoking status, systolic blood pressure (SBP) and LDL cholesterol were significantly associated with IMT in subjects in the lower CRP groups (CRP-1 approximately CRP-3), and age, SBP and presence of diabetes mellitus in the highest CRP group (CRP-4). Cholesterol 77-88 C-reactive protein Homo sapiens 165-168 16908949-7 2006 It was shown that age, smoking status, systolic blood pressure (SBP) and LDL cholesterol were significantly associated with IMT in subjects in the lower CRP groups (CRP-1 approximately CRP-3), and age, SBP and presence of diabetes mellitus in the highest CRP group (CRP-4). Cholesterol 77-88 C-reactive protein Homo sapiens 165-168 16908949-8 2006 To further investigate whether the interaction between CRP and conventional risk factors could influence IMT, a general linear model demonstrated that interaction between CRP and the presence of diabetes mellitus (F = 4.754 p = 0.030) was significantly associated with IMT, in addition to sex, age, SBP, antihypertensive drug use, LDL cholesterol and HDL cholesterol. Cholesterol 335-346 C-reactive protein Homo sapiens 171-174 16908949-8 2006 To further investigate whether the interaction between CRP and conventional risk factors could influence IMT, a general linear model demonstrated that interaction between CRP and the presence of diabetes mellitus (F = 4.754 p = 0.030) was significantly associated with IMT, in addition to sex, age, SBP, antihypertensive drug use, LDL cholesterol and HDL cholesterol. Cholesterol 355-366 C-reactive protein Homo sapiens 171-174 16766544-3 2006 We hypothesized that dietary soy isoflavones correct laboratory evidence of systemic inflammation in haemodialysis (HD) patients with underlying high blood levels of C-reactive protein (CRP). Isoflavones 33-44 C-reactive protein Homo sapiens 166-184 16766544-3 2006 We hypothesized that dietary soy isoflavones correct laboratory evidence of systemic inflammation in haemodialysis (HD) patients with underlying high blood levels of C-reactive protein (CRP). Isoflavones 33-44 C-reactive protein Homo sapiens 186-189 16799235-12 2006 Moreover, the circulating level of hs-CRP was strongly associated with ICA localization of CRP. ica 71-74 C-reactive protein Homo sapiens 38-41 16799235-12 2006 Moreover, the circulating level of hs-CRP was strongly associated with ICA localization of CRP. ica 71-74 C-reactive protein Homo sapiens 91-94 16983925-3 2006 RESULTS: Spearman rank correlation analysis showed that hs-CRP level was significantly positively correlated with SBSS, triglyceride (TG), FPG, BMI, LVMI, Fg, and UA, while negatively correlated with high density lipoprotein cholesterol (HDL-C). Triglycerides 120-132 C-reactive protein Homo sapiens 59-62 16983925-3 2006 RESULTS: Spearman rank correlation analysis showed that hs-CRP level was significantly positively correlated with SBSS, triglyceride (TG), FPG, BMI, LVMI, Fg, and UA, while negatively correlated with high density lipoprotein cholesterol (HDL-C). Triglycerides 134-136 C-reactive protein Homo sapiens 59-62 16493453-7 2006 RESULTS: CRP levels were higher among patients with central obesity than in those without (5.8 vs 3.9 mg/l; P=0.003), and higher among those with fasting plasma glucose concentrations >or=110 mg/dl than in those with lower concentrations (7.4 vs 4.1 mg/l; P=0.01). Glucose 161-168 C-reactive protein Homo sapiens 9-12 16480969-0 2006 The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Atorvastatin 14-26 C-reactive protein Homo sapiens 56-59 16480969-10 2006 Compared with conventional therapy alone, atorvastatin significantly further reduced serum MPO [P=0.014] and CRP concentrations [P=0.032]. Atorvastatin 42-54 C-reactive protein Homo sapiens 109-112 16480969-12 2006 CONCLUSIONS: Atorvastatin reduced serum MPO and CRP concentrations in patients with ACS. Atorvastatin 13-25 C-reactive protein Homo sapiens 48-51 16684119-1 2006 BACKGROUND: In vitro studies have shown that C-reactive protein (CRP) attenuates nitric oxide production and inhibits angiogenesis, which may result in impaired collateral development. Nitric Oxide 81-93 C-reactive protein Homo sapiens 45-63 16684119-1 2006 BACKGROUND: In vitro studies have shown that C-reactive protein (CRP) attenuates nitric oxide production and inhibits angiogenesis, which may result in impaired collateral development. Nitric Oxide 81-93 C-reactive protein Homo sapiens 65-68 16703189-7 2006 In partial correlation, plasma CRP positively correlated with body mass index (p<0.001), waist circumference (p<0.001), waist-to-hip ratio (p<0.01), total cholesterol (p<0.001), LDL-cholesterol (p=0.033), triglyceride (p=0.023), and fasting blood glucose (p=0.043) in patients with metabolic syndrome. Cholesterol 164-175 C-reactive protein Homo sapiens 31-34 16741040-1 2006 We investigated the effects of three different daily doses (10 mg, 20 mg, and 40 mg) of atorvastatin, a relatively new and potent statin, on plasma endothelin (ET)-1 and highly sensitive C-reactive protein (CRP) levels in type 2 diabetic subjects. Atorvastatin 88-100 C-reactive protein Homo sapiens 187-205 16741040-8 2006 Similarly, although insignificantly, plasma concentrations of CRP also tended to decrease by 12% and 48%, and paradoxically increased by 18% in diabetic patients treated with 10 mg, 20 mg, and 40 mg atorvastatin, respectively. Atorvastatin 199-211 C-reactive protein Homo sapiens 62-65 16713426-6 2006 Furthermore, CRP levels increased with increasing number of metabolic syndrome risk factors, as defined by the National Cholesterol Education Program Adult Treatment Panel III, regardless of race and sex (P for trend<0001). Cholesterol 120-131 C-reactive protein Homo sapiens 13-16 16586530-1 2006 The ab initio fragment molecular orbital (FMO) calculations were performed for the cAMP receptor protein (CRP) complexed with a cAMP and DNA duplex to elucidate their sequence-specific binding and the stability of the DNA duplex, as determined by analysis of their inter- and intramolecular interactions. Cyclic AMP 83-87 C-reactive protein Homo sapiens 106-109 16040142-15 2006 Statistical analysis revealed that testosterone treatment prior to stent implantation attenuated IL-6 and hs-CRP levels significantly (P=0.042 and P=0.043; respectively). Testosterone 35-47 C-reactive protein Homo sapiens 109-112 16040142-16 2006 CONCLUSIONS: The present study shows that 3 weeks testosterone treatment prior to intracoronary stenting results in a significant suppression in hs-CRP and IL-6 levels after the stent implantation. Testosterone 50-62 C-reactive protein Homo sapiens 148-151 16703189-7 2006 In partial correlation, plasma CRP positively correlated with body mass index (p<0.001), waist circumference (p<0.001), waist-to-hip ratio (p<0.01), total cholesterol (p<0.001), LDL-cholesterol (p=0.033), triglyceride (p=0.023), and fasting blood glucose (p=0.043) in patients with metabolic syndrome. Cholesterol 194-205 C-reactive protein Homo sapiens 31-34 16703189-7 2006 In partial correlation, plasma CRP positively correlated with body mass index (p<0.001), waist circumference (p<0.001), waist-to-hip ratio (p<0.01), total cholesterol (p<0.001), LDL-cholesterol (p=0.033), triglyceride (p=0.023), and fasting blood glucose (p=0.043) in patients with metabolic syndrome. Triglycerides 217-229 C-reactive protein Homo sapiens 31-34 16703189-7 2006 In partial correlation, plasma CRP positively correlated with body mass index (p<0.001), waist circumference (p<0.001), waist-to-hip ratio (p<0.01), total cholesterol (p<0.001), LDL-cholesterol (p=0.033), triglyceride (p=0.023), and fasting blood glucose (p=0.043) in patients with metabolic syndrome. Glucose 259-266 C-reactive protein Homo sapiens 31-34 16703189-9 2006 In multiple regression analysis, body mass index (p<0.01), waist circumference (p<0.01), and fasting blood glucose (p<0.01) showed independent correlations with plasma CRP. Glucose 113-120 C-reactive protein Homo sapiens 177-180 16635110-9 2006 In coronary artery disease patients, the acetylsalicylic acid-mediated platelet inhibition positively correlated with increased triglycerides (in arachidonic acid-stimulated platelets, r=0.30, P=0.0018), total cholesterol (r=0.33, P<0.0001 in coll and arachidonic acid-activated platelets) and elevated serum C-reactive protein (CRP) (r=0.27, P=0.0024). Aspirin 41-61 C-reactive protein Homo sapiens 312-330 16751941-10 2006 CONCLUSION: Rosiglitazone treatment reduced insulin resistance, fibrinogen, and CRP levels and improved endothelial function in non-diabetic subjects with metabolic syndrome. Rosiglitazone 12-25 C-reactive protein Homo sapiens 80-83 16635110-9 2006 In coronary artery disease patients, the acetylsalicylic acid-mediated platelet inhibition positively correlated with increased triglycerides (in arachidonic acid-stimulated platelets, r=0.30, P=0.0018), total cholesterol (r=0.33, P<0.0001 in coll and arachidonic acid-activated platelets) and elevated serum C-reactive protein (CRP) (r=0.27, P=0.0024). Aspirin 41-61 C-reactive protein Homo sapiens 332-335 16644678-8 2006 Consistent with the above, we found that pretreatment of nondiabetic VSMCs with high glucose abolished the degradation of Bcl-2 induced by CRP. Glucose 85-92 C-reactive protein Homo sapiens 139-142 16707391-5 2006 Serum hs-CRP levels were significantly increased in steroid-naive patients (mean+/-sd 1.33+/-1.48 mg.L(-1)) compared with controls (0.21+/-0.30 mg.L(-1)), but not in patients on inhaled corticosteroid. Steroids 52-59 C-reactive protein Homo sapiens 9-12 16455829-8 2006 C-reactive protein levels in stable chronic obstructive pulmonary disease patients are best correlated with arterial oxygen tension and 6-min walk distance. Oxygen 117-123 C-reactive protein Homo sapiens 0-18 16707391-6 2006 Among steroid-naive patients, serum hs-CRP levels significantly negatively correlated with indices of pulmonary function (forced expiratory volume in one second/forced vital capacity and forced mid-expiratory flow) and positively with sputum eosinophil count. Steroids 6-13 C-reactive protein Homo sapiens 39-42 16774156-3 2006 We thus examined the relationship between serum C-reactive protein levels and nocturnal arterial oxygen desaturation, stratified by category of body mass index (BMI). Oxygen 97-103 C-reactive protein Homo sapiens 48-66 16671874-5 2006 RESULTS: The mean (+/- SE) CRP level was 65% higher (95% confidence interval: -2%, 180%; P = 0.06) in women with periodontitis (2.46 +/- 0.52 mg/l) than in controls (1.49 +/- 0.22 mg/l), adjusting for factors related to CRP levels, including age, race/ethnicity, pre-pregnancy body mass index, alcohol intake, education, income, and gestational age at blood collection. Alcohols 294-301 C-reactive protein Homo sapiens 27-30 18473965-6 2006 At present, the evidence from clinical trials is favouring the intensity of the effect on LDL-cholesterol and/or C-reactive protein (CRP) with atorvastatin 80 mg, rather than the use of atorvastatin per se, when greater benefits are observed with the 80 mg dose of atorvastatin compared to other statins. Atorvastatin 143-155 C-reactive protein Homo sapiens 113-131 18473965-6 2006 At present, the evidence from clinical trials is favouring the intensity of the effect on LDL-cholesterol and/or C-reactive protein (CRP) with atorvastatin 80 mg, rather than the use of atorvastatin per se, when greater benefits are observed with the 80 mg dose of atorvastatin compared to other statins. Atorvastatin 143-155 C-reactive protein Homo sapiens 133-136 16540158-3 2006 RESULTS: High-carbohydrate nutrition is shown to have the ability to induce vascular inflammation and plaque formation through an insulin-mediated activation of the RAS, growth factors, cytokines, the SNS, and C-reactive protein and to cause an atherogenic lipid profile in normal humans. Carbohydrates 14-26 C-reactive protein Homo sapiens 210-228 16553865-5 2006 Moreover, the crp mutant could not utilize transferrin-bound iron, and its growth was severely suppressed both on transferrin-bound iron and in cirrhotic ascites. Iron 132-136 C-reactive protein Homo sapiens 14-17 16563907-6 2006 Multivariate adjusted analyses indicated that social integration was significantly inversely associated with CRP concentration in men after adjusting for age, race/ethnicity, smoking, alcohol consumption, physical activity, body mass index, cardiovascular disease, other major or chronic conditions, physical functioning, socioeconomic status, and depression (odds ratio 2.23, 95% confidence interval 1.05 to 4.76, for elevated CRP [>3.19 mg/L] in the least socially integrated quartile vs the most socially integrated quartile). Alcohols 184-191 C-reactive protein Homo sapiens 109-112 16614110-6 2006 The odds ratio of colorectal cancer for plasma C-reactive protein was estimated using a conditional logistic regression model adjusted for pack-years of smoking, body mass index, alcohol consumption, physical exercise, and family history of colorectal cancer. Alcohols 179-186 C-reactive protein Homo sapiens 47-65 16553865-0 2006 Effect of the crp mutation on the utilization of transferrin-bound iron by Vibrio vulnificus. Iron 67-71 C-reactive protein Homo sapiens 14-17 16410460-8 2006 In addition, rosiglitazone reduced serum levels of 2 inflammatory arteriosclerosis markers: C-reactive protein and serum amyloid A. Rosiglitazone 13-26 C-reactive protein Homo sapiens 92-110 16939632-3 2006 CRP possesses numerous cardiovascular effects (clotting, generation of oxygen radicals, increase in the expression of adhesion molecules and plasminogen activator inhibitor-1, plaque destabilization) that could result in cardiovascular disease. Reactive Oxygen Species 71-86 C-reactive protein Homo sapiens 0-3 16939632-8 2006 Antidiabetic agents (rosiglitazone and pioglitazone) reduce CRP levels, while insulin is ineffective. Rosiglitazone 21-34 C-reactive protein Homo sapiens 60-63 16939632-12 2006 The effect of atorvastatin on CRP seems to be dose-dependent. Atorvastatin 14-26 C-reactive protein Homo sapiens 30-33 16253380-5 2006 The treatment regimen consisting of rosiglitazone and glimepiride significantly lowered hs-CRP by -2.6 (3.9) mg/L (p<0.05) at week 12 in spite of no improvement in blood glucose. Rosiglitazone 36-49 C-reactive protein Homo sapiens 91-94 16553865-5 2006 Moreover, the crp mutant could not utilize transferrin-bound iron, and its growth was severely suppressed both on transferrin-bound iron and in cirrhotic ascites. Iron 61-65 C-reactive protein Homo sapiens 14-17 16553865-2 2006 We found that growth retardation of V. vulnificus caused by mutation of the crp gene encoding CRP was exacerbated under iron-limited conditions. Iron 120-124 C-reactive protein Homo sapiens 76-79 16553865-2 2006 We found that growth retardation of V. vulnificus caused by mutation of the crp gene encoding CRP was exacerbated under iron-limited conditions. Iron 120-124 C-reactive protein Homo sapiens 94-97 16553865-8 2006 These results indicate that crp mutation attenuates the ability to grow on transferrin-bound iron and in a human body fluid by down-regulating the vulnibactin-mediated iron-uptake system. Iron 93-97 C-reactive protein Homo sapiens 28-31 16553865-3 2006 Accordingly, we investigated the effect of crp mutation on the expression of the vulnibactin-mediated iron-uptake system and the ability of V. vulnificus to utilize transferrin-bound iron, and thus to grow in cirrhotic ascites, a human ex vivo system. Iron 102-106 C-reactive protein Homo sapiens 43-46 16553865-8 2006 These results indicate that crp mutation attenuates the ability to grow on transferrin-bound iron and in a human body fluid by down-regulating the vulnibactin-mediated iron-uptake system. Iron 168-172 C-reactive protein Homo sapiens 28-31 16546473-5 2006 Compared with healthy controls, the ROS-treated subjects had significantly higher glycemic indices, HOMA-IR, CRP, and glucose and insulin concentrations in response to OGTT, and lower HOMA-beta level. Rosiglitazone 36-39 C-reactive protein Homo sapiens 109-112 16565249-6 2006 Furthermore, in this study, C-reactive protein was inversely related to the GFR and with the vasodilatory response to acetyl choline, pointing to inflammation as a likely mechanism to explain the association between endothelial dysfunction and impaired renal function in essential hypertension. Acetylcholine 118-132 C-reactive protein Homo sapiens 28-46 16565250-4 2006 Of note, in an alternative model that included CRP (instead of endothelial function), the creatinine variance explained by this factor was two times higher (+10%) than that associated with endothelial function in the first model. Creatinine 90-100 C-reactive protein Homo sapiens 47-50 16549465-6 2006 After intake of the low-fat diet, plasma total and VLDL-triglyceride (TG) concentrations were increased in the subgroup with high CRP concentrations (P < 0.05 and P < 0.01, respectively) whereas they were reduced in the subgroup with low CRP concentrations at baseline (P < 0.01 for both). Triglycerides 56-68 C-reactive protein Homo sapiens 130-133 16546475-5 2006 In bivariate analyses, CRP -732A/G G allele carriers had significantly lower baseline postprandial plasma glucose and after-training CRP levels. Glucose 106-113 C-reactive protein Homo sapiens 23-26 16546473-7 2006 In addition, elevation of serum adiponectin and decrease in CRP levels were significantly found after ROS treatment. Rosiglitazone 102-105 C-reactive protein Homo sapiens 60-63 16546475-10 2006 In conclusion, the CRP -732A/G variant modulates exercise training-related improvements in ISI and glucose AUC, and the haplotype of the CRP -732A/G and +219G/A variants significantly affected training-induced changes in ISI and insulin AUC. Glucose 99-106 C-reactive protein Homo sapiens 19-22 16546473-10 2006 We conclude that ROS effectively enhanced insulin sensitivity and beta-cell function to improve adiponectin and CRP levels in nonobese patients with IGT. Rosiglitazone 17-20 C-reactive protein Homo sapiens 112-115 16520949-9 2006 Positive correlations were found between cytokine concentrations, CRP and urea/creatinine levels. Urea 74-78 C-reactive protein Homo sapiens 66-69 28094672-6 2006 However, patients with a high-risk baseline level (>3 mg/dL, n = 48) experienced a greater decrease in C-reactive protein levels on a low-carbohydrate diet (adjusted difference = -2 mg/dL, p = .005), independent of weight loss. Carbohydrates 141-153 C-reactive protein Homo sapiens 106-124 16520949-9 2006 Positive correlations were found between cytokine concentrations, CRP and urea/creatinine levels. Creatinine 79-89 C-reactive protein Homo sapiens 66-69 16636979-10 2006 CRP was correlated positively with plasma levels of triglycerides (r=0.19, p=0.002), C-peptide (r=0.21, p=0.004), postprandial glucose (r=0.17, p=0.009), albuminuria (r=0.16, p=0.020), and inversely with HDL cholesterol (r=-0.20, p=0.002) in type 2 diabetic patients. Triglycerides 52-65 C-reactive protein Homo sapiens 0-3 27265228-6 2006 We found a negative correlation between TGF and C-reactive protein and blood urea nitrogen and a positive correlation between TGF and hemoglobin level in newly diagnosed patients. Urea 77-81 C-reactive protein Homo sapiens 48-66 27265228-6 2006 We found a negative correlation between TGF and C-reactive protein and blood urea nitrogen and a positive correlation between TGF and hemoglobin level in newly diagnosed patients. Nitrogen 82-90 C-reactive protein Homo sapiens 48-66 16176811-10 2006 The decrease in CRP levels to 30 week inversely correlated with the increase in HDL-cholesterol (r=-0.47, p=0.005). Cholesterol 84-95 C-reactive protein Homo sapiens 16-19 16527696-7 2006 A significant, dose-dependent decrease of C-reactive protein level was observed transiently after BIRB 796 after 1 week with a return to baseline level over time. birb 98-102 C-reactive protein Homo sapiens 42-60 16636979-10 2006 CRP was correlated positively with plasma levels of triglycerides (r=0.19, p=0.002), C-peptide (r=0.21, p=0.004), postprandial glucose (r=0.17, p=0.009), albuminuria (r=0.16, p=0.020), and inversely with HDL cholesterol (r=-0.20, p=0.002) in type 2 diabetic patients. Glucose 127-134 C-reactive protein Homo sapiens 0-3 16636979-10 2006 CRP was correlated positively with plasma levels of triglycerides (r=0.19, p=0.002), C-peptide (r=0.21, p=0.004), postprandial glucose (r=0.17, p=0.009), albuminuria (r=0.16, p=0.020), and inversely with HDL cholesterol (r=-0.20, p=0.002) in type 2 diabetic patients. Cholesterol 208-219 C-reactive protein Homo sapiens 0-3 16520718-0 2006 Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: reversal by low molecular weight heparin. Heparin 153-160 C-reactive protein Homo sapiens 21-39 16054696-0 2006 Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist. Nitric Oxide 12-24 C-reactive protein Homo sapiens 32-50 16054696-3 2006 Cholesterol-lowering drugs statins also lower CRP. Cholesterol 0-11 C-reactive protein Homo sapiens 46-49 16054696-5 2006 Here, we show that pravastatin and simvastatin prevent the induction of CRP expression in human hepatoma Hep3B cells exposed to proinflammatory cytokines IL-6 and IL-1beta The nitric oxide (NO) donor, sodium nitroprusside, also prevented the induction of CRP expression while the CRP inducers IL-6 and IL-1beta were present with the cells. Nitric Oxide 176-188 C-reactive protein Homo sapiens 72-75 16314875-8 2006 In a multiple regression analysis, BMI, triglycerides and fasting glucose were independent predictors of CRP in women and together explained 42% of its variance. Triglycerides 40-53 C-reactive protein Homo sapiens 105-108 16314875-8 2006 In a multiple regression analysis, BMI, triglycerides and fasting glucose were independent predictors of CRP in women and together explained 42% of its variance. Glucose 66-73 C-reactive protein Homo sapiens 105-108 16314875-9 2006 In men, CRP was independently and positively associated to waist circumference, smoking, diastolic blood pressure, uric acid and triglycerides, and negatively associated to HDL-cholesterol. Triglycerides 129-142 C-reactive protein Homo sapiens 8-11 16314875-9 2006 In men, CRP was independently and positively associated to waist circumference, smoking, diastolic blood pressure, uric acid and triglycerides, and negatively associated to HDL-cholesterol. Cholesterol 177-188 C-reactive protein Homo sapiens 8-11 16472047-6 2006 Metformin is known to reduce the risk of developing diabetes, and more recent evidence suggests it also lowers C-reactive protein, in part because of its modest weight-reducing effect. Metformin 0-9 C-reactive protein Homo sapiens 111-129 16216530-0 2006 Sex hormone-binding globulin and serum testosterone are inversely associated with C-reactive protein levels in postmenopausal women at high risk for cardiovascular disease. Testosterone 39-51 C-reactive protein Homo sapiens 82-100 16216530-9 2006 CONCLUSIONS: SHBG and total testosterone were inversely associated with CRP among HT nonusers in this study. Testosterone 28-40 C-reactive protein Homo sapiens 72-75 16405429-11 2006 CRP (6.1 mg/dL vs. 3.1 mg/dL; P < 0.001) and IL-6 (295 ng/mL vs. 122 ng/mL; P = 0.001) were decreased during steroid therapy, but not PCT (2.3 ng/dL vs. 2.0 ng/dL; n.s.). Steroids 112-119 C-reactive protein Homo sapiens 0-3 16443901-0 2006 Association between elevated serum C-reactive protein and triglyceride levels in young subjects with type 1 diabetes. Triglycerides 58-70 C-reactive protein Homo sapiens 35-53 16442368-7 2006 The median high-sensitivity C-reactive protein levels were significantly reduced statistically from baseline with rosuvastatin 20 mg and atorvastatin 20 mg among all patients and with rosuvastatin 10 and 20 mg and atorvastatin 20 mg in those patients with a baseline C-reactive protein level > 2.0 mg/L. Atorvastatin 137-149 C-reactive protein Homo sapiens 28-46 16423559-6 2006 Plasma ghrelin levels showed a negative correlation (r=-0.432, p<0.01) with plasma leptin levels and positive correlations with blood urea nitrogen (BUN), creatinine, white blood cell count and C-reactive protein. Ghrelin 7-14 C-reactive protein Homo sapiens 197-215 16442368-7 2006 The median high-sensitivity C-reactive protein levels were significantly reduced statistically from baseline with rosuvastatin 20 mg and atorvastatin 20 mg among all patients and with rosuvastatin 10 and 20 mg and atorvastatin 20 mg in those patients with a baseline C-reactive protein level > 2.0 mg/L. Atorvastatin 214-226 C-reactive protein Homo sapiens 28-46 16441950-8 2006 Isoflavones improve C-reactive protein concentrations but do not affect other plasma inflammatory markers. Isoflavones 0-11 C-reactive protein Homo sapiens 20-38 16441950-11 2006 In conclusion, isoflavones have beneficial effects on C-reactive protein, but not other cardiovascular risk markers. Isoflavones 15-26 C-reactive protein Homo sapiens 54-72 16401068-6 2006 The Forster resonance energy transfer method has been used to study the distance changes, induced by binding of cAMP, between Trp85 (fluorescence donor) and Cys178-AEDANS (fluorescence acceptor) in the CRP structure. Cyclic AMP 112-116 C-reactive protein Homo sapiens 202-205 15894319-13 2006 The most pronounced difference was observed with regard to inhibition of eNOS activity as assessed by cGMP which was observed at 10 microg/ml of native CRP but only at 50 microg/mL for m-CRP (native CRP versus mCRP: p < 0.001). Cyclic GMP 102-106 C-reactive protein Homo sapiens 152-155 15905085-8 2006 CRP could be detected in a concentration range of 1 ng/ml to 50 microg/ml from a standard solution in phosphate buffer and in a range of 4 ng/ml to 50 microg/ml from serum/PBS. Phosphates 102-111 C-reactive protein Homo sapiens 0-3 16377274-0 2006 Relation of nocturnal melatonin levels to C-reactive protein concentration in patients with ST-segment elevation myocardial infarction. Melatonin 22-31 C-reactive protein Homo sapiens 42-60 16377274-3 2006 However, little is known about the association between melatonin and C-reactive protein in patients with ischemic heart disease. Melatonin 55-64 C-reactive protein Homo sapiens 69-87 16581701-10 2006 Elevated serum C-reactive protein (CRP) or orosomucoid grouped the subjects with high and low serum HDL-cholesterol concentrations better than history of infection alone. Cholesterol 104-115 C-reactive protein Homo sapiens 15-33 16581701-10 2006 Elevated serum C-reactive protein (CRP) or orosomucoid grouped the subjects with high and low serum HDL-cholesterol concentrations better than history of infection alone. Cholesterol 104-115 C-reactive protein Homo sapiens 35-38 17047615-2 2006 Effect of 10 and 20 mg/day atorvastatin on levels of lipids, C-reactive protein, and fibrinogen in patients with ischemic heart disease and hyperlipidemia]. Atorvastatin 27-39 C-reactive protein Homo sapiens 61-79 16607074-3 2006 The possibility was suggested that one of the mechanisms of action of aspirin in thrombotic prevention is through its anti-inflammatory properties in terms of reducing the concentration of CRP. Aspirin 70-77 C-reactive protein Homo sapiens 189-192 16607074-5 2006 The significant determinants of CRP concentrations included body mass index, oral contraceptives, hormonal replacement therapy, gender, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, physical activity, age, smoking status and the presence of diabetes mellitus but not the use of low dose of aspirin. Aspirin 334-341 C-reactive protein Homo sapiens 32-35 16643876-5 2006 Competition experiments with different phosphatemonoesters revealed that CRP and SAP as well as part of the IgM bound to the phospholipids head groups, SAP mainly to phosphorylethanolamine, CRP to phosphorylcholine and phosphorylethanolamine and to a lesser extent to phosphorylserine, and IgM to phosphorylcholine and phosphorylserine. Phospholipids 125-138 C-reactive protein Homo sapiens 73-76 16643876-8 2006 We conclude that CRP, SAP, and part of the IgM bind to the phospholipid head groups exposed on apoptotic cells. Phospholipids 59-71 C-reactive protein Homo sapiens 17-20 17060099-8 2006 Serum levels above the median of all normal ranged biomarkers sCD40L, TNF-alpha, IL-6, sICAM-1 and CRP were associated with an impaired MPRI for stimulation with adenosine as well as acetylcholine. Adenosine 162-171 C-reactive protein Homo sapiens 99-102 16244112-0 2006 Synergistic enhancement of cytokine-induced human monocyte matrix metalloproteinase-1 by C-reactive protein and oxidized LDL through differential regulation of monocyte chemotactic protein-1 and prostaglandin E2. Dinoprostone 195-211 C-reactive protein Homo sapiens 89-107 16244112-5 2006 Enhancement of MMP-1 by CRP and ox-LDL was attributable to a differential increase in MCP-1 and prostaglandin E2(PGE2). Dinoprostone 96-112 C-reactive protein Homo sapiens 24-27 16244112-5 2006 Enhancement of MMP-1 by CRP and ox-LDL was attributable to a differential increase in MCP-1 and prostaglandin E2(PGE2). Dinoprostone 113-117 C-reactive protein Homo sapiens 24-27 16244112-6 2006 CRP, at physiological concentrations, induced high levels of MCP-1 and relatively low levels of PGE2, whereas ox-LDL caused a significant enhancement of PGE2 with little affect on MCP-1. Dinoprostone 96-100 C-reactive protein Homo sapiens 0-3 16244112-9 2006 These results show that the combination of CRP and ox-LDL can cause a synergistic enhancement of the role of monocytes in inflammation, first, by increasing MCP-1, which attracts more monocytes and directly enhances MMP-1 production by activated monocytes, and second, by elevating PGE2 production, which also leads to higher levels of MMP-1. Dinoprostone 282-286 C-reactive protein Homo sapiens 43-46 16417414-9 2006 The increment in CRP level between the highest and lowest quartile of bioavailable testosterone was 1.28 microg/mL. Testosterone 83-95 C-reactive protein Homo sapiens 17-20 17201275-6 2006 There was a positive correlation between hs-CRP level and the activity of the disease according to ECLAM score, ES value, IgG and IgM levels, hematological disturbances (anemia, leucopenia, and/or thrombocytopenia) , and a negative correlation with total cholesterol level, HDLC there was a moderate correlation between hs-CRP and a maximal IMC value. Cholesterol 255-266 C-reactive protein Homo sapiens 44-47 16002176-6 2006 CRP correlated with waist circumference (r=0.28, p<0.001) and body mass index (r=0.38, p<0.001) in both men and women; however the relationship of CRP with HOMA(IR) was only evident in men (r=0.37, p<0.01) while the association with free fatty acids (FFA) was only significant in women (r=0.20, p<0.05), even after adjusting for age, hispanic ethnicity and glucose tolerance status. Glucose 369-376 C-reactive protein Homo sapiens 0-3 16002176-6 2006 CRP correlated with waist circumference (r=0.28, p<0.001) and body mass index (r=0.38, p<0.001) in both men and women; however the relationship of CRP with HOMA(IR) was only evident in men (r=0.37, p<0.01) while the association with free fatty acids (FFA) was only significant in women (r=0.20, p<0.05), even after adjusting for age, hispanic ethnicity and glucose tolerance status. Glucose 369-376 C-reactive protein Homo sapiens 153-156 16002176-9 2006 These results confirm that CRP levels are elevated in MS subjects at risk for glucose intolerance. Glucose 78-85 C-reactive protein Homo sapiens 27-30 16313251-1 2005 OBJECTIVE: Serum C-reactive protein (CRP) concentrations were measured longitudinally throughout pregnancy to test the hypothesis that CRP could relate more closely to glucose tolerance than to adiposity. Glucose 168-175 C-reactive protein Homo sapiens 135-138 16733624-4 2006 There were consistent associations between levels of CRP and markers of the metabolic syndrome (fat mass, plasma triglycerides, fasting glucose). Triglycerides 113-126 C-reactive protein Homo sapiens 53-56 16733624-4 2006 There were consistent associations between levels of CRP and markers of the metabolic syndrome (fat mass, plasma triglycerides, fasting glucose). Glucose 136-143 C-reactive protein Homo sapiens 53-56 16378798-3 2005 METHODS: This study is a cross-sectional analysis to evaluate cystatin-C, creatinine, and eGFR as predictors of the inflammatory markers C-reactive protein and fibrinogen. Creatinine 74-84 C-reactive protein Homo sapiens 137-155 16378798-9 2005 In contrast, both C-reactive protein and fibrinogen had U-shaped associations with quintiles of creatinine and eGFR, because the inflammatory markers were equivalently elevated in quintiles 1 and 5. Creatinine 96-106 C-reactive protein Homo sapiens 18-36 16324921-0 2006 Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients. Atorvastatin 0-12 C-reactive protein Homo sapiens 67-85 16437656-3 2005 RESULTS: In all patients metabolic parameters and hs-CRP levels linearly increase from the lowest to the highest ALT and GGT tertiles, while in subjects without metabolic abnormalities, there is a significant association between fasting glucose, uric acid, waist circumference, hs-CRP, triglyceride values, and GGT levels. Glucose 237-244 C-reactive protein Homo sapiens 53-56 16332659-8 2005 RESULTS: Isoflavones improved CRP concentrations [odds ratio (95% CI) for CRP values >1 mg/L for isoflavone compared with placebo: 0.43 (0.27, 0.69)]; no significant effects of isoflavone treatment on other plasma inflammatory markers were observed. Isoflavones 9-20 C-reactive protein Homo sapiens 30-33 16332659-8 2005 RESULTS: Isoflavones improved CRP concentrations [odds ratio (95% CI) for CRP values >1 mg/L for isoflavone compared with placebo: 0.43 (0.27, 0.69)]; no significant effects of isoflavone treatment on other plasma inflammatory markers were observed. Isoflavones 9-20 C-reactive protein Homo sapiens 74-77 16332659-8 2005 RESULTS: Isoflavones improved CRP concentrations [odds ratio (95% CI) for CRP values >1 mg/L for isoflavone compared with placebo: 0.43 (0.27, 0.69)]; no significant effects of isoflavone treatment on other plasma inflammatory markers were observed. Isoflavones 100-110 C-reactive protein Homo sapiens 30-33 16332659-8 2005 RESULTS: Isoflavones improved CRP concentrations [odds ratio (95% CI) for CRP values >1 mg/L for isoflavone compared with placebo: 0.43 (0.27, 0.69)]; no significant effects of isoflavone treatment on other plasma inflammatory markers were observed. Isoflavones 100-110 C-reactive protein Homo sapiens 74-77 16332659-8 2005 RESULTS: Isoflavones improved CRP concentrations [odds ratio (95% CI) for CRP values >1 mg/L for isoflavone compared with placebo: 0.43 (0.27, 0.69)]; no significant effects of isoflavone treatment on other plasma inflammatory markers were observed. Isoflavones 180-190 C-reactive protein Homo sapiens 30-33 16332659-11 2005 CONCLUSION: Isoflavones have beneficial effects on CRP concentrations, but not on other inflammatory biomarkers of cardiovascular disease risk in postmenopausal women, and may improve VCAM-1 in an ERbeta gene polymorphic subgroup. Isoflavones 12-23 C-reactive protein Homo sapiens 51-54 16357807-5 2005 C-reactive protein was positively correlated with HOMA-IR (r=0.45, P=0.001), fasting plasma glucose (r=0.43, P=0.002) and waist (r=0.45, P=0.0006), but not with postprandial lipids. Glucose 92-99 C-reactive protein Homo sapiens 0-18 16319543-10 2005 The association between C-reactive protein and disease was U-shaped and a graded association existed between homocysteine, cysteine, von Willebrand factor and disease. Cysteine 113-121 C-reactive protein Homo sapiens 24-42 16313251-2 2005 METHODS: The CRP concentrations in pregnant women with normal glucose tolerance (NGT) and those with gestational diabetes mellitus (GDM) were measured at the same time as the oral glucose tolerance test (OGTT), at the 24th and 28th weeks of gestation and between the 37th and 38th weeks of gestation. Glucose 62-69 C-reactive protein Homo sapiens 13-16 16077717-12 2005 Also, mean CRP levels were significantly higher in the presence of central obesity (2.45 vs 1.24, P < 0.001), high blood pressure (1.76 vs 1.12, P < 0.001), hypertriglyceridemia (2.17 vs 1.32, P < 0.001) and high fasting glucose (1.96 vs 1.46, P = 0.032). Glucose 230-237 C-reactive protein Homo sapiens 11-14 16389569-0 2005 C-reactive protein mediates CD11b expression in monocytes through the non-receptor tyrosine kinase, Syk, and calcium mobilization but not through cytosolic peroxides. Calcium 109-116 C-reactive protein Homo sapiens 0-18 16389569-7 2005 In addition, pre-treatment of primary monoytes with the Ca(2+) mobiliser, thapsigargin, increased CD11b expression; this effect was accentuated in the presence of CRP but was abolished in the presence of the [Ca(2+)](i) chelator, BAPTA. Thapsigargin 74-86 C-reactive protein Homo sapiens 163-166 16708805-5 2005 RESULTS: Before the treatment, there was a significant positive correlation between CRP and AHI in all subjects (r = 0.615, P < 0.001), a significant negative correlation between CRP and the mean nocturnal oxygen saturation (r = -0.682, P < 0.001), and a significant negative correlation between CRP and the lowest nocturnal SaO2 (r = -0.61, P < 0.001). Oxygen 209-215 C-reactive protein Homo sapiens 182-185 16251237-0 2005 Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. Nitric Oxide 87-99 C-reactive protein Homo sapiens 18-36 16708805-5 2005 RESULTS: Before the treatment, there was a significant positive correlation between CRP and AHI in all subjects (r = 0.615, P < 0.001), a significant negative correlation between CRP and the mean nocturnal oxygen saturation (r = -0.682, P < 0.001), and a significant negative correlation between CRP and the lowest nocturnal SaO2 (r = -0.61, P < 0.001). Oxygen 209-215 C-reactive protein Homo sapiens 182-185 16314788-5 2005 Fibrinogen and CRP levels increased in these patients after sirolimus introduction. Sirolimus 60-69 C-reactive protein Homo sapiens 15-18 16277783-0 2005 Conjugated linoleic acid increased C-reactive protein in human subjects. Linoleic Acid 11-24 C-reactive protein Homo sapiens 35-53 16290998-11 2005 CONCLUSIONS: C-reactive protein lowering with atorvastatin appears to be effective in eliminating PAF during daily life in a significant proportion of patients. Atorvastatin 46-58 C-reactive protein Homo sapiens 13-31 16263508-5 2005 Exposure to OE-UDP, OE-DEP, UDP, DEP, and 2,3,7,8-tetrachlorodibenzo-p-dioxin led to a greater increase of interleukin (IL)-8, tumor necrosis factor-alpha, and cyclooxygenase-2 mRNA expression than did the stripped particles, whereas sUDP, sDEP, UDP, and DEP led to a greater production of C-reactive protein and IL-6 mRNA. Uridine Diphosphate 15-18 C-reactive protein Homo sapiens 290-308 15883967-8 2005 Higher CRP levels, correlated to smoking and, inversely, to alcohol intake, identify a further 12% of the cohort at higher cardiovascular risk. Alcohols 60-67 C-reactive protein Homo sapiens 7-10 15950309-6 2005 CRP levels were significantly but marginally correlated with waist circumference (r=0.18), triglyceride (r=0.14), blood pressure (r=0.11), HDL-cholesterol (r=-0.10), and fasting glucose (r=0.09) (all P values<0.01). Triglycerides 91-103 C-reactive protein Homo sapiens 0-3 15950309-6 2005 CRP levels were significantly but marginally correlated with waist circumference (r=0.18), triglyceride (r=0.14), blood pressure (r=0.11), HDL-cholesterol (r=-0.10), and fasting glucose (r=0.09) (all P values<0.01). Cholesterol 143-154 C-reactive protein Homo sapiens 0-3 15950309-6 2005 CRP levels were significantly but marginally correlated with waist circumference (r=0.18), triglyceride (r=0.14), blood pressure (r=0.11), HDL-cholesterol (r=-0.10), and fasting glucose (r=0.09) (all P values<0.01). Glucose 178-185 C-reactive protein Homo sapiens 0-3 15950309-7 2005 Odds ratios of the highest quartile of CRP for each component of MS; i.e., waist circumference, triglyceride, glucose metabolism, blood pressure, and HDL-cholesterol were 2.36, 1.79, 1.70, 1.32 and 1.28, respectively. Triglycerides 96-108 C-reactive protein Homo sapiens 39-42 15950309-7 2005 Odds ratios of the highest quartile of CRP for each component of MS; i.e., waist circumference, triglyceride, glucose metabolism, blood pressure, and HDL-cholesterol were 2.36, 1.79, 1.70, 1.32 and 1.28, respectively. Cholesterol 154-165 C-reactive protein Homo sapiens 39-42 16263508-5 2005 Exposure to OE-UDP, OE-DEP, UDP, DEP, and 2,3,7,8-tetrachlorodibenzo-p-dioxin led to a greater increase of interleukin (IL)-8, tumor necrosis factor-alpha, and cyclooxygenase-2 mRNA expression than did the stripped particles, whereas sUDP, sDEP, UDP, and DEP led to a greater production of C-reactive protein and IL-6 mRNA. dep 23-26 C-reactive protein Homo sapiens 290-308 16263508-5 2005 Exposure to OE-UDP, OE-DEP, UDP, DEP, and 2,3,7,8-tetrachlorodibenzo-p-dioxin led to a greater increase of interleukin (IL)-8, tumor necrosis factor-alpha, and cyclooxygenase-2 mRNA expression than did the stripped particles, whereas sUDP, sDEP, UDP, and DEP led to a greater production of C-reactive protein and IL-6 mRNA. Polychlorinated Dibenzodioxins 42-77 C-reactive protein Homo sapiens 290-308 16263508-5 2005 Exposure to OE-UDP, OE-DEP, UDP, DEP, and 2,3,7,8-tetrachlorodibenzo-p-dioxin led to a greater increase of interleukin (IL)-8, tumor necrosis factor-alpha, and cyclooxygenase-2 mRNA expression than did the stripped particles, whereas sUDP, sDEP, UDP, and DEP led to a greater production of C-reactive protein and IL-6 mRNA. Uridine Diphosphate 28-31 C-reactive protein Homo sapiens 290-308 16369062-1 2005 The aim of the study was to find out whether early use of atorvastatin in patients with acute coronary syndrome is associated with rapid changes of plasma levels of the marker of inflammation -- C-reactive protein. Atorvastatin 58-70 C-reactive protein Homo sapiens 195-213 19758923-6 2005 CONCLUSION: After PCI in UA, cyclooxygenase-2 inhibitor rofecoxib added to atorvastatin reduced CRP and IL-6 levels more profoundly than atorvastatin alone at 3- and 6-month after intervention. Atorvastatin 75-87 C-reactive protein Homo sapiens 96-99 16369062-9 2005 In patients with acute coronary syndrome early use of atorvastatin was associated with rapid decrease of C-reactive protein level. Atorvastatin 54-66 C-reactive protein Homo sapiens 105-123 16220077-5 2005 C-reactive protein could augment the production of reactive oxygen species (ROS) as measured by chemiluminescence and inhibitors of NAD(P)H oxidase (DPI and PAO) and ROS scavengers (superoxide dismutase, catalase, and 1% dimethyl sulphoxide) abolished C-reactive protein-induced IL-8 secretion. Reactive Oxygen Species 51-74 C-reactive protein Homo sapiens 0-18 16220077-5 2005 C-reactive protein could augment the production of reactive oxygen species (ROS) as measured by chemiluminescence and inhibitors of NAD(P)H oxidase (DPI and PAO) and ROS scavengers (superoxide dismutase, catalase, and 1% dimethyl sulphoxide) abolished C-reactive protein-induced IL-8 secretion. Reactive Oxygen Species 51-74 C-reactive protein Homo sapiens 252-270 16220077-5 2005 C-reactive protein could augment the production of reactive oxygen species (ROS) as measured by chemiluminescence and inhibitors of NAD(P)H oxidase (DPI and PAO) and ROS scavengers (superoxide dismutase, catalase, and 1% dimethyl sulphoxide) abolished C-reactive protein-induced IL-8 secretion. Reactive Oxygen Species 76-79 C-reactive protein Homo sapiens 0-18 16220077-7 2005 The inhibitors of ERK 1/2 (PD98059), p38 (SB203580) MAPK, and NF-kappaB (PDTC and MG132) significantly decreased C-reactive protein-induced IL-8 secretion in human monocytes. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 27-34 C-reactive protein Homo sapiens 113-131 16220077-5 2005 C-reactive protein could augment the production of reactive oxygen species (ROS) as measured by chemiluminescence and inhibitors of NAD(P)H oxidase (DPI and PAO) and ROS scavengers (superoxide dismutase, catalase, and 1% dimethyl sulphoxide) abolished C-reactive protein-induced IL-8 secretion. Reactive Oxygen Species 76-79 C-reactive protein Homo sapiens 252-270 16220077-5 2005 C-reactive protein could augment the production of reactive oxygen species (ROS) as measured by chemiluminescence and inhibitors of NAD(P)H oxidase (DPI and PAO) and ROS scavengers (superoxide dismutase, catalase, and 1% dimethyl sulphoxide) abolished C-reactive protein-induced IL-8 secretion. Reactive Oxygen Species 166-169 C-reactive protein Homo sapiens 0-18 16220077-9 2005 Thus, our data indicate that C-reactive protein at pathologic levels increases IL-8 secretion and mRNA via enhancing ROS derived mainly from NAD(P)H oxidase and the subsequent activation of ERK1/2, p38 MAPK, and NF-kappaB. Reactive Oxygen Species 117-120 C-reactive protein Homo sapiens 29-47 16115856-11 2005 In multiple regression analysis, waist circumference, log sICAM-1 concentration, gender, creatinine clearance and current smoking were independently associated with CRP. Creatinine 89-99 C-reactive protein Homo sapiens 165-168 16238678-10 2005 In men, the multivariate correlates of CRP included waist circumference (P<0.0001), smoking (<0.0001) and HDL cholesterol (P=0.024) (inverse association). Cholesterol 116-127 C-reactive protein Homo sapiens 39-42 16358230-6 2005 RESULTS: Patients with high CRP had significantly lower glomerular filtration rates and albumin, but increased LOOH and CD. Cadmium 120-122 C-reactive protein Homo sapiens 28-31 16324343-0 2005 [Effects of atorvastatin on plasma hypersensitive C-reactive protein and interleukin-6 in patients with acute cerebral infarction]. Atorvastatin 12-24 C-reactive protein Homo sapiens 50-68 16324343-1 2005 OBJECTIVE: To observe the effects of different doses of atorvastatin on the plasma hypersensitive C-reactive protein (hsCRP) and interleukin-6 (IL-6) in patients with acute cerebral infarction. Atorvastatin 56-68 C-reactive protein Homo sapiens 98-116 16226164-5 2005 RESULTS: In a multivariate model, several risk factors were weakly but independently associated with higher CRP levels: age, gender (with or without hormone replacement therapy), body mass index >25 kg/m2, smoking, low-density lipoprotein > or =70 mg/dl, glucose >110 mg/dl, high-density lipoprotein <50 mg/dl, triglycerides >150 mg/dl, and the intensity of statin therapy. Glucose 261-268 C-reactive protein Homo sapiens 108-111 16186073-12 2005 CONCLUSIONS: Our findings substantiate that oral HRT containing estradiol is associated with a marked and rapid increase in CRP, whereas transdermal treatment is not. Estradiol 64-73 C-reactive protein Homo sapiens 124-127 16226164-5 2005 RESULTS: In a multivariate model, several risk factors were weakly but independently associated with higher CRP levels: age, gender (with or without hormone replacement therapy), body mass index >25 kg/m2, smoking, low-density lipoprotein > or =70 mg/dl, glucose >110 mg/dl, high-density lipoprotein <50 mg/dl, triglycerides >150 mg/dl, and the intensity of statin therapy. Triglycerides 323-336 C-reactive protein Homo sapiens 108-111 16216995-2 2005 However, the extent to which high CRP levels (>3 mg/L) may be attributable to high cholesterol levels and other CHD risk factors has not been well defined. Cholesterol 86-97 C-reactive protein Homo sapiens 34-37 16014566-6 2005 These findings indicate that N-linked glycosylation at N92 in human GPVI is not required for surface expression, but contributes to maximal adhesion to type I collagen, CRP and, to a lesser extent, CVX. Nitrogen 29-30 C-reactive protein Homo sapiens 169-172 15987707-7 2005 The difference among the C-reactive protein groups was significant adjusting for all correlates of baseline C-reactive protein (P<0.001) and additionally for changes in body weight, glucose, insulin, LDL cholesterol, HDL cholesterol, triglycerides, systolic and diastolic blood pressure, and maximal oxygen uptake (P<0.001). Glucose 185-192 C-reactive protein Homo sapiens 25-43 16183427-0 2005 Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Rosiglitazone 0-13 C-reactive protein Homo sapiens 46-64 16183427-12 2005 At the end of the study, the RSG group also had significantly lower CRP levels than the control group (2.21 versus 8.59 mg/L; P = 0.03). Rosiglitazone 29-32 C-reactive protein Homo sapiens 68-71 16183427-15 2005 Multivariate regression analysis (using decrease in HbA1c and lipid levels, change in insulin dosage, and treatment with RSG, with lipid-lowering agents) showed that only treatment with RSG was an independent predictor for posttreatment CRP level (P = 0.016). Rosiglitazone 186-189 C-reactive protein Homo sapiens 237-240 16123329-12 2005 Parthenolide, SN50, and BAY 11-7082 (NF-kappaB inhibitors) significantly blocked CRP-mediated PAI-1 expression. parthenolide 0-12 C-reactive protein Homo sapiens 81-84 16123329-12 2005 Parthenolide, SN50, and BAY 11-7082 (NF-kappaB inhibitors) significantly blocked CRP-mediated PAI-1 expression. SN50 14-18 C-reactive protein Homo sapiens 81-84 15987707-7 2005 The difference among the C-reactive protein groups was significant adjusting for all correlates of baseline C-reactive protein (P<0.001) and additionally for changes in body weight, glucose, insulin, LDL cholesterol, HDL cholesterol, triglycerides, systolic and diastolic blood pressure, and maximal oxygen uptake (P<0.001). Cholesterol 207-218 C-reactive protein Homo sapiens 25-43 15987707-7 2005 The difference among the C-reactive protein groups was significant adjusting for all correlates of baseline C-reactive protein (P<0.001) and additionally for changes in body weight, glucose, insulin, LDL cholesterol, HDL cholesterol, triglycerides, systolic and diastolic blood pressure, and maximal oxygen uptake (P<0.001). Cholesterol 224-235 C-reactive protein Homo sapiens 25-43 15987707-7 2005 The difference among the C-reactive protein groups was significant adjusting for all correlates of baseline C-reactive protein (P<0.001) and additionally for changes in body weight, glucose, insulin, LDL cholesterol, HDL cholesterol, triglycerides, systolic and diastolic blood pressure, and maximal oxygen uptake (P<0.001). Triglycerides 237-250 C-reactive protein Homo sapiens 25-43 15987707-7 2005 The difference among the C-reactive protein groups was significant adjusting for all correlates of baseline C-reactive protein (P<0.001) and additionally for changes in body weight, glucose, insulin, LDL cholesterol, HDL cholesterol, triglycerides, systolic and diastolic blood pressure, and maximal oxygen uptake (P<0.001). Oxygen 303-309 C-reactive protein Homo sapiens 25-43 16235156-7 2005 In addition, fasting plasma glucose was a significant determinant of adiponectin, CRP, and IL-6 plasma concentrations, whereas body fat content was only a significant predictor of CRP plasma concentration. Glucose 28-35 C-reactive protein Homo sapiens 82-85 16190914-7 2005 Peak serum IL-6 and CRP concentrations were significantly lower in the steroid treatment group than in the non-steroid treatment group. Steroids 71-78 C-reactive protein Homo sapiens 20-23 16315884-6 2005 Post operative maximal CRP level was 3.2 mg/dl, 4.9 mg/dl and 10.5 mg/dl in HALS, LS, and OS, respectively, with a statistical significance between HALS and OS. Osmium 90-92 C-reactive protein Homo sapiens 23-26 16315884-6 2005 Post operative maximal CRP level was 3.2 mg/dl, 4.9 mg/dl and 10.5 mg/dl in HALS, LS, and OS, respectively, with a statistical significance between HALS and OS. Osmium 157-159 C-reactive protein Homo sapiens 23-26 16198934-15 2005 A Pearson correlation analysis showed that there was a positive correlation between D/P creatinine levels and 36-month mean CRP levels (r = 0.608, P < .0001), and a negative correlation between D/P creatinine levels and 36-month mean albumin levels (r = -0.299, P < .005). Creatinine 88-98 C-reactive protein Homo sapiens 124-127 16286529-8 2005 In multiple step-wise regression analysis, BMI, hemoglobin A(1c), right IMT, duration of diabetes, and triglyceride were selected as explanatory variables for log HS-CRP (R2 = 0.412). Triglycerides 103-115 C-reactive protein Homo sapiens 166-169 16285590-10 2005 C-reactive protein and MPO-ANCA decreased to normal levels after the initial steroid therapy, but serum amyloid A protein (SAA) gradually elevated. Steroids 77-84 C-reactive protein Homo sapiens 0-18 16126024-4 2005 In PROVE IT-TIMI 22, atorvastatin 80 mg lowered both low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP) at 30 days and 4 months to a greater extent than pravastatin 40 mg. Those who achieved the lowest LDL and the lowest CRP levels at 30 days after ACS had the lowest risk of acute cardiac events. Atorvastatin 21-33 C-reactive protein Homo sapiens 99-117 16536309-5 2005 In diabetic patients with macrovascular complications, person correlation analysis indicated that there existed positive correlations between CRP and FINS, HOMA-IR, triglyceride (TG) while stepwise linear regression showed that usCRP and HOMA-IR, TG having linear correlation. Triglycerides 165-177 C-reactive protein Homo sapiens 142-145 16536309-5 2005 In diabetic patients with macrovascular complications, person correlation analysis indicated that there existed positive correlations between CRP and FINS, HOMA-IR, triglyceride (TG) while stepwise linear regression showed that usCRP and HOMA-IR, TG having linear correlation. Triglycerides 179-181 C-reactive protein Homo sapiens 142-145 16126024-4 2005 In PROVE IT-TIMI 22, atorvastatin 80 mg lowered both low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP) at 30 days and 4 months to a greater extent than pravastatin 40 mg. Those who achieved the lowest LDL and the lowest CRP levels at 30 days after ACS had the lowest risk of acute cardiac events. Atorvastatin 21-33 C-reactive protein Homo sapiens 119-122 16126024-4 2005 In PROVE IT-TIMI 22, atorvastatin 80 mg lowered both low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP) at 30 days and 4 months to a greater extent than pravastatin 40 mg. Those who achieved the lowest LDL and the lowest CRP levels at 30 days after ACS had the lowest risk of acute cardiac events. Atorvastatin 21-33 C-reactive protein Homo sapiens 241-244 16126025-8 2005 CRP decreased 5.2% with pravastatin and 36.4% with atorvastatin (p <0.0001). Atorvastatin 51-63 C-reactive protein Homo sapiens 0-3 15985490-10 2005 CONCLUSIONS: We conclude that rosiglitazone: 1) causes a significant increase in GIR; 2) induces a decrease in inflammatory mediators, C-reactive protein, and serum amyloid A; 3) decreases the rise in FFAs and triglycerides after TG-Hep infusion; and 4) does not prevent FFA-induced IR. Rosiglitazone 30-43 C-reactive protein Homo sapiens 135-177 16108864-0 2005 Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with Type 2 diabetes mellitus. Metformin 0-9 C-reactive protein Homo sapiens 18-36 16108864-1 2005 AIMS: To determine the influence of metformin treatment on plasma C-reactive protein (CRP) and complement factor C3. Metformin 36-45 C-reactive protein Homo sapiens 66-84 16108864-1 2005 AIMS: To determine the influence of metformin treatment on plasma C-reactive protein (CRP) and complement factor C3. Metformin 36-45 C-reactive protein Homo sapiens 86-89 16108864-8 2005 The difference in ratios of CRP levels at each visit to baseline between placebo- (n = 16) and metformin-treated (n = 26) subjects was significantly different at the 12-week (P = 0.002) and 24-week (P = 0.03) visits. Metformin 95-104 C-reactive protein Homo sapiens 28-31 16108864-13 2005 CONCLUSION: Metformin may have a specific interaction with mechanisms involved in CRP synthesis or secretion, not directly related to improved insulin sensitivity and dampening of chronic inflammation. Metformin 12-21 C-reactive protein Homo sapiens 82-85 16142873-9 2005 CONCLUSIONS: Higher CRP values and back pain scores and lower BASFI scores at baseline were significant predictors of a higher ASAS 20 response in patients with AS receiving etanercept but predictive value was of insufficient magnitude to determine treatment in individual patients. Aspirin 127-131 C-reactive protein Homo sapiens 20-23 16130198-14 2005 Correlation analysis showed that FT (free testosterone) had negative correlation with CRP, IL-6 and sICAM-1. Testosterone 42-54 C-reactive protein Homo sapiens 86-89 16125536-12 2005 In conclusion, rosiglitazone treatment had a beneficial impact on Lp(a), CRP, and LDL particles" lipid content in type 2 diabetic hypertensive patients but not on homocysteine and fibrinogen. Rosiglitazone 15-28 C-reactive protein Homo sapiens 73-76 16168192-10 2005 The corresponding predictors for serum copper were C-reactive protein (CRP) (P<0.001), serum HDL-C (P<0.001), gender (P=0.01), physical activity levels (P<0.05) and dietary copper (P<0.05). Copper 39-45 C-reactive protein Homo sapiens 51-69 16168192-10 2005 The corresponding predictors for serum copper were C-reactive protein (CRP) (P<0.001), serum HDL-C (P<0.001), gender (P=0.01), physical activity levels (P<0.05) and dietary copper (P<0.05). Copper 39-45 C-reactive protein Homo sapiens 71-74 16137286-9 2005 CONCLUSION: The relationship between IL-6 and plasma CRP and cholesterol levels in nonagenarians with enhanced systemic inflammation differs from that of middle-aged subjects. Cholesterol 61-72 C-reactive protein Homo sapiens 53-56 16125534-4 2005 High-sensitivity C-reactive protein decreased significantly with atorvastatin treatment, from 0.801 (0.243, 1.865) to 0.308 (0.200, 0.804) mg/L (P=.0191). Atorvastatin 65-77 C-reactive protein Homo sapiens 17-35 15985490-10 2005 CONCLUSIONS: We conclude that rosiglitazone: 1) causes a significant increase in GIR; 2) induces a decrease in inflammatory mediators, C-reactive protein, and serum amyloid A; 3) decreases the rise in FFAs and triglycerides after TG-Hep infusion; and 4) does not prevent FFA-induced IR. Triglycerides 210-223 C-reactive protein Homo sapiens 135-177 15985490-10 2005 CONCLUSIONS: We conclude that rosiglitazone: 1) causes a significant increase in GIR; 2) induces a decrease in inflammatory mediators, C-reactive protein, and serum amyloid A; 3) decreases the rise in FFAs and triglycerides after TG-Hep infusion; and 4) does not prevent FFA-induced IR. Thioguanine 230-232 C-reactive protein Homo sapiens 135-177 16087988-1 2005 BACKGROUND: Observational studies have found that dietary glycemic load is positively associated with C-reactive protein (CRP) concentrations in healthy humans, which suggests that the type of carbohydrate ingested influences inflammatory activity. Carbohydrates 193-205 C-reactive protein Homo sapiens 102-120 16165720-8 2005 Urinary 8-isoprostane correlated positively with PIIINP, CRP and markers of cholestasis (alkaline phosphatase and bilirubin) and negatively with glutathione (whole blood), vitamins A and E and albumin. 8-epi-prostaglandin F2alpha 8-21 C-reactive protein Homo sapiens 57-60 16026400-12 2005 Administration of low-molecular-weight heparin may affect CRP production, however, further studies are still needed in order to clarify the exact immunosuppressive action of heparins. Heparin 39-46 C-reactive protein Homo sapiens 58-61 15975559-6 2005 HCAECs pretreated with CRP significantly decreased VEGF165-induced [3H]thymidine incorporation by 73%, MTS absorbance by 44%, and capillary-like tube formation by 54% as compared to CRP-untreated cells (p < 0.05). Tritium 68-70 C-reactive protein Homo sapiens 23-26 16087988-1 2005 BACKGROUND: Observational studies have found that dietary glycemic load is positively associated with C-reactive protein (CRP) concentrations in healthy humans, which suggests that the type of carbohydrate ingested influences inflammatory activity. Carbohydrates 193-205 C-reactive protein Homo sapiens 122-125 16109328-8 2005 In separate backward elimination multiple regression analyses, log CRP was significantly associated with AIX (P = .038) and pulse pressure (P = .036), and marginally significantly associated with PWV (P = .054), after adjustment for heart rate, height, and coronary heart disease (CHD) risk factors (age, sex, body mass index, mean arterial pressure, total cholesterol, HDL cholesterol, diabetes, hypertension, and history of smoking). Cholesterol 357-368 C-reactive protein Homo sapiens 67-70 16109328-8 2005 In separate backward elimination multiple regression analyses, log CRP was significantly associated with AIX (P = .038) and pulse pressure (P = .036), and marginally significantly associated with PWV (P = .054), after adjustment for heart rate, height, and coronary heart disease (CHD) risk factors (age, sex, body mass index, mean arterial pressure, total cholesterol, HDL cholesterol, diabetes, hypertension, and history of smoking). Cholesterol 374-385 C-reactive protein Homo sapiens 67-70 16086647-3 2005 At 18 months follow-up, the CRP levels were reduced from a baseline level of 2.8 mg/l to 1.8 mg/l by atorvastatin, whereas pravastatin had little effect, and there was a good correlation between both the ultrasonographic progression of disease and the reduction in CRP levels. Atorvastatin 101-113 C-reactive protein Homo sapiens 28-31 16114786-9 2005 Patients on CD also showed a significant correlation between urea and CRP. Cadmium 12-14 C-reactive protein Homo sapiens 70-73 16114786-9 2005 Patients on CD also showed a significant correlation between urea and CRP. Urea 61-65 C-reactive protein Homo sapiens 70-73 16114786-10 2005 After a multivariate analysis, only urea (p < 0.001) and OxLDL (p < 0.006) were associated to a risk of CRP > 0.3 mg/dl. Urea 36-40 C-reactive protein Homo sapiens 110-113 16086647-3 2005 At 18 months follow-up, the CRP levels were reduced from a baseline level of 2.8 mg/l to 1.8 mg/l by atorvastatin, whereas pravastatin had little effect, and there was a good correlation between both the ultrasonographic progression of disease and the reduction in CRP levels. Atorvastatin 101-113 C-reactive protein Homo sapiens 265-268 16053827-7 2005 After the atorvastatin dose was increased, significant reductions in CRP, F1+2, and PAI-1 levels were observed (P<.05). Atorvastatin 10-22 C-reactive protein Homo sapiens 69-72 15899961-11 2005 High CRP subjects were older and had significantly higher body mass indexes, triglycerides, insulin, homeostasis model assessment, and leptin levels compared with low CRP subjects. Triglycerides 77-90 C-reactive protein Homo sapiens 5-8 16127895-8 2005 Furthermore, high frequency of angina pectoris ( > or = 3 times/week), low dose of acetylcholine required to induce vasospasm, provocation of total occlusion and provocation of multivessel spasm were associated with significantly higher serum CRP levels in the positive group. Acetylcholine 86-99 C-reactive protein Homo sapiens 246-249 16127895-9 2005 Multivariate logistic regression analysis showed low dose of acetylcholine required to induce vasospasm as the strongest predictor of elevated levels of serum CRP (p < 0.001, odds ratio 4.52, 95% confidence interval 2.00-10.44). Acetylcholine 61-74 C-reactive protein Homo sapiens 159-162 16092057-14 2005 C-reactive protein was significantly reduced in all treatment groups, with the atorvastatin and combination groups having the greatest reduction (65% and 68%, respectively, P < .01 vs the fenofibrate group, 44%). Atorvastatin 79-91 C-reactive protein Homo sapiens 0-18 16092057-18 2005 Atorvastatin and combination treatment were more effective than fenofibrate alone in reducing CRP levels. Atorvastatin 0-12 C-reactive protein Homo sapiens 94-97 16054551-7 2005 CONCLUSIONS: In normal-weight women, ln-CRP was significantly associated with BMI, PAI-1, serum insulin, and HDL-cholesterol. Cholesterol 113-124 C-reactive protein Homo sapiens 40-43 16130007-10 2005 The CRP level showed a strong correlation only with the serum concentration of cholesterol (r=0.49, p < 0.000), and did not correlate with the serum albumin of the MHD patients. Cholesterol 79-90 C-reactive protein Homo sapiens 4-7 15970291-1 2005 OBJECTIVE: To compare the effects of raloxifene, estradiol valerate plus dienogest, and soy isoflavones (genistein) on serum concentrations of high-sensitive C-reactive protein in healthy postmenopausal women. Estradiol 49-67 C-reactive protein Homo sapiens 158-176 15970291-5 2005 RESULTS: Only the group receiving estradiol valerate plus dienogest showed an increase in serum levels of high-sensitive C-reactive protein compared with baseline values and values in the control and other groups. Estradiol 34-52 C-reactive protein Homo sapiens 121-139 15057566-5 2005 C-reactive protein levels also correlated significantly in a negative manner with vitamin B12 and folate but positively with tHcy. Folic Acid 98-104 C-reactive protein Homo sapiens 0-18 15997206-9 2005 A model consisting of glucose intolerance, age, parity, and weight gain during pregnancy accounted for 61% of the variance in log C-reactive protein. Glucose 22-29 C-reactive protein Homo sapiens 130-148 15992651-7 2005 The coronary calcium score predicted CAD events independently of standard risk factors and CRP (p = 0.004), was superior to the Framingham risk index in the prediction of events (area under the receiver-operating characteristic curve of 0.79 +/- 0.03 vs. 0.69 +/- 0.03, p = 0.0006), and enhanced stratification of those falling into the Framingham categories of low, intermediate, and high risk (p < 0.0001). Calcium 13-20 C-reactive protein Homo sapiens 91-94 16153429-11 2005 Furthermore, curcumin (5 and 10 microM) in combination with CRP (10 microg/mL) significantly increased TM mRNA levels by 45 and 100%, respectively, and increased EPCR mRNA levels by 24 and 45%, respectively, compared with those in CRP-treated cells (P < .05). Curcumin 13-21 C-reactive protein Homo sapiens 231-234 16153429-14 2005 Curcumin completely blocks CRP-induced downregulation of TM and EPCR in HCAECs. Curcumin 0-8 C-reactive protein Homo sapiens 27-30 15998471-0 2005 Serum resistin is associated with C-reactive protein & LDL cholesterol in type 2 diabetes and coronary artery disease in a Saudi population. Cholesterol 63-74 C-reactive protein Homo sapiens 34-52 15979442-4 2005 Women with greater hs-CRP concentrations showed deterioration in their metabolic risk profiles, including abdominal obesity, greater triglyceride and lower HDL cholesterol concentrations, and lower insulin sensitivity compared with women with lower hs-CRP levels. Triglycerides 133-145 C-reactive protein Homo sapiens 22-25 15979442-4 2005 Women with greater hs-CRP concentrations showed deterioration in their metabolic risk profiles, including abdominal obesity, greater triglyceride and lower HDL cholesterol concentrations, and lower insulin sensitivity compared with women with lower hs-CRP levels. Cholesterol 160-171 C-reactive protein Homo sapiens 22-25 15979442-5 2005 Fifty-nine percent of women with high hs-CRP concentrations had the metabolic syndrome as recently defined by the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Cholesterol 143-154 C-reactive protein Homo sapiens 41-44 15979442-5 2005 Fifty-nine percent of women with high hs-CRP concentrations had the metabolic syndrome as recently defined by the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Cholesterol 240-251 C-reactive protein Homo sapiens 41-44 15878871-10 2005 This study newly identifies residues Thr(173) and Asn(186) as important for the binding of CRP to FcgammaRIIa and FcgammaRI. Threonine 37-40 C-reactive protein Homo sapiens 91-94 15955391-0 2005 Association between fasting glucose and C-reactive protein in a Japanese population: the Minoh study. Glucose 28-35 C-reactive protein Homo sapiens 40-58 15955391-1 2005 To investigate the association between fasting glucose and C-reactive protein (CRP), we examined 1715 Japanese individuals (723 men and 992 women) aged 40-69 years who did not have medication for hypertension, diabetes, or dyslipidemia, a history of cardiovascular disease or CRP levels>10mg/l. Glucose 47-54 C-reactive protein Homo sapiens 79-82 15955391-2 2005 There was a statistically significant unadjusted correlation between CRP and each component of the metabolic syndrome, including fasting glucose, fasting insulin, body mass index, systolic blood pressure, diastolic blood pressure, high-density lipoprotein cholesterol (negative), and triglycerides in both men and women. Glucose 137-144 C-reactive protein Homo sapiens 69-72 15955391-2 2005 There was a statistically significant unadjusted correlation between CRP and each component of the metabolic syndrome, including fasting glucose, fasting insulin, body mass index, systolic blood pressure, diastolic blood pressure, high-density lipoprotein cholesterol (negative), and triglycerides in both men and women. Triglycerides 284-297 C-reactive protein Homo sapiens 69-72 15955391-3 2005 With adjustment for age, cigarette smoking, alcohol intake, and other components of the metabolic syndrome, the CRP increments (as back-transformed) compared with the lowest tertile of normal fasting glucose were 0.99, 1.05, 1.21, and 1.34mg/l (P for trend=0.008) with the second lowest and highest tertiles of normal fasting glucose, impaired fasting glucose, and type-2 diabetes, respectively in men. Glucose 326-333 C-reactive protein Homo sapiens 112-115 15955391-5 2005 In the stratified analyses of CRP levels by sex, obesity status, and fasting glucose category or the number of components of the metabolic syndrome, an increase in CRP levels was greater in women than men with obesity and higher fasting glucose category (gender interaction: P<0.001) or an increased number of components of the metabolic syndrome (gender interaction: P=0.003). Glucose 77-84 C-reactive protein Homo sapiens 164-167 15955391-5 2005 In the stratified analyses of CRP levels by sex, obesity status, and fasting glucose category or the number of components of the metabolic syndrome, an increase in CRP levels was greater in women than men with obesity and higher fasting glucose category (gender interaction: P<0.001) or an increased number of components of the metabolic syndrome (gender interaction: P=0.003). Glucose 237-244 C-reactive protein Homo sapiens 30-33 15955391-5 2005 In the stratified analyses of CRP levels by sex, obesity status, and fasting glucose category or the number of components of the metabolic syndrome, an increase in CRP levels was greater in women than men with obesity and higher fasting glucose category (gender interaction: P<0.001) or an increased number of components of the metabolic syndrome (gender interaction: P=0.003). Glucose 237-244 C-reactive protein Homo sapiens 164-167 15955391-6 2005 These results indicate that CRP levels increase continuously across the spectrum of fasting glucose in both sexes. Glucose 92-99 C-reactive protein Homo sapiens 28-31 15994753-2 2005 Because rosiglitazone improves insulin sensitivity, we tested whether rosiglitazone treatment ameliorates high-sensitivity (hs)CRP levels and endothelial dysfunction in these patients. Rosiglitazone 70-83 C-reactive protein Homo sapiens 127-130 15855252-7 2005 Stepwise regression analysis showed that CRP, fasting triglycerides, and the lean body mass index explained 19.5, 8.5, and 4.0%, respectively, of the variance observed in glucose disposal (total r(2) = 0.320; P < 0.001). Glucose 171-178 C-reactive protein Homo sapiens 41-44 15878871-12 2005 Single mutations at amino acid positions Lys(114), Asp(169), Thr(173), Tyr(175), and Leu(176) affected C1q binding to CRP. Lysine 41-44 C-reactive protein Homo sapiens 118-121 15878871-12 2005 Single mutations at amino acid positions Lys(114), Asp(169), Thr(173), Tyr(175), and Leu(176) affected C1q binding to CRP. Threonine 61-64 C-reactive protein Homo sapiens 118-121 15878871-12 2005 Single mutations at amino acid positions Lys(114), Asp(169), Thr(173), Tyr(175), and Leu(176) affected C1q binding to CRP. Tyrosine 71-74 C-reactive protein Homo sapiens 118-121 16037290-7 2005 The relationship with serum creatinine decreased but remained significant after adjusting for age, sex, diabetes duration, hemoglobin A1c (HbA1c), AER, systolic and diastolic blood pressure (BP), and CRP in multiple linear-regression analysis. Creatinine 28-38 C-reactive protein Homo sapiens 200-203 15975486-9 2005 Plasma ghrelin was negatively correlated with tumor necrosis factor-alpha and C-reactive protein in COPD. Ghrelin 7-14 C-reactive protein Homo sapiens 78-96 15939816-0 2005 Cholesterol feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive subjects. Cholesterol 0-11 C-reactive protein Homo sapiens 30-48 15701058-9 2005 Furthermore, specific MAPK inhibitors (PD98059, SB203580 and SP600125) inhibited the expression of IL-8 mRNA induced by CRP (50 microg/ml). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 39-46 C-reactive protein Homo sapiens 120-123 15769980-11 2005 Dexamethasone decreased resting heart rate, high-sensitivity C-reactive protein, and aldosterone and tended to attenuate nitroglycerin-mediated vasodilatation. Dexamethasone 0-13 C-reactive protein Homo sapiens 61-79 16020877-6 2005 Although the adjustment for body mass index in addition to age, cigarette smoking, and alcohol consumption attenuated the associations between CRP and fasting insulin, fasting glucose, and HOMA-IR, elevated CRP levels were associated with increased insulin levels and HOMA-IR in both sexes. Alcohols 87-94 C-reactive protein Homo sapiens 143-146 16020877-5 2005 RESULTS: Elevated CRP levels were associated with increased fasting insulin levels, fasting glucose levels, and HOMA-IR in both men and women. Glucose 92-99 C-reactive protein Homo sapiens 18-21 15927062-7 2005 In contrast, membrane-permeable late apoptotic neutrophils exhibited strong CRP binding, which comprised both Ca2+-dependent and heparin-inhibitable Ca2+-independent components. Heparin 129-136 C-reactive protein Homo sapiens 76-79 16257350-11 2005 Alcohol intake-related reduced risk for restriction was associated with lower risk of CHF, diabetes, obesity, and lower markers of inflammation (white blood cell, fibrinogen, and C-reactive protein) consistent with less lung congestion, external restriction, and/or lung inflammation. Alcohols 0-7 C-reactive protein Homo sapiens 179-197 15877999-2 2005 Long-term treatment with nifedipine (nifedipine CR, 20 mg/day for 4 months) decreased levels of C-reactive protein in the coronary sinus (from 0.35 +/- 0.09 mg/dl to 0.07 +/- 0.01 mg/dl, mean +/- SEM, p <0.05) and enhanced acetylcholine-induced increases in coronary blood flow. Acetylcholine 226-239 C-reactive protein Homo sapiens 96-114 15878000-0 2005 Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents. Sirolimus 118-127 C-reactive protein Homo sapiens 14-32 15842965-0 2005 Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Atorvastatin 11-23 C-reactive protein Homo sapiens 73-91 15893181-3 2005 METHODS: We addressed the relative efficacy of pravastatin 40 mg and atorvastatin 80 mg daily to reduce LDL-C and CRP among 3,745 acute coronary syndrome patients. Atorvastatin 69-81 C-reactive protein Homo sapiens 114-117 15718491-7 2005 Dihydroethidium staining showed that CRP produced SB203850- and TEMPOL-sensitive superoxide production in the arteriolar endothelium. Superoxides 81-91 C-reactive protein Homo sapiens 37-40 15718491-9 2005 CONCLUSIONS: CRP inhibits endothelium-dependent NO-mediated dilation in coronary arterioles by producing superoxide from NAD(P)H oxidase via p38 kinase activation. Superoxides 105-115 C-reactive protein Homo sapiens 13-16 15917962-0 2005 Dialysis water treated by reverse osmosis decreases the levels of C-reactive protein in uremic patients. Water 9-14 C-reactive protein Homo sapiens 66-84 15718491-4 2005 Intraluminal treatment with a clinically relevant concentration of CRP (7 microg/mL; 1 hour) significantly attenuated the NO release and vasodilation to serotonin. Serotonin 153-162 C-reactive protein Homo sapiens 67-70 15718491-6 2005 In the presence of superoxide scavenger 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPOL), NAD(P)H oxidase inhibitor apocynin, or p38 kinase (an upstream activator of NAD(P)H oxidase) inhibitor SB203850, but not xanthine oxidase inhibitor allopurinol or JNK inhibitor SP600125, the detrimental effect of CRP on serotonin-induced dilation was prevented. Superoxides 19-29 C-reactive protein Homo sapiens 310-313 15917962-10 2005 From the 23 remaining patients (mean age +/- SD: 51.3 +/- 13.9 years), 18 had a decrease in CRP after the water treatment system was changed. Water 106-111 C-reactive protein Homo sapiens 92-95 15917962-13 2005 In conclusion, uremic patients presented a clinically significant reduction in CRP levels when dialysate water purification system switched from deionization to reverse osmosis. Water 105-110 C-reactive protein Homo sapiens 79-82 15855593-0 2005 Relationship between C-reactive protein and glucose levels in community-dwelling subjects without diabetes: the Hisayama Study. Glucose 44-51 C-reactive protein Homo sapiens 21-39 15811138-2 2005 The aim of the present study was to investigate the effect of diets high in either carbohydrate or protein on the inflammatory markers C-reactive protein (CRP), haptoglobin and transferrin in plasma after weight loss. Carbohydrates 83-95 C-reactive protein Homo sapiens 135-153 15811138-2 2005 The aim of the present study was to investigate the effect of diets high in either carbohydrate or protein on the inflammatory markers C-reactive protein (CRP), haptoglobin and transferrin in plasma after weight loss. Carbohydrates 83-95 C-reactive protein Homo sapiens 155-158 15855347-5 2005 Metformin reduced CRP in women compared with the placebo group. Metformin 0-9 C-reactive protein Homo sapiens 18-21 15855347-7 2005 In women, the changes in CRP from baseline to follow-up were -29% in the lifestyle group, -14% in the metformin group, and 0% in the placebo group. Metformin 102-111 C-reactive protein Homo sapiens 25-28 15692104-0 2005 C-reactive protein and annexin A5 bind to distinct sites of negatively charged phospholipids present in oxidized low-density lipoprotein. Phospholipids 79-92 C-reactive protein Homo sapiens 0-18 15867284-1 2005 Recent evidence suggests that individuals with high concentrations of C-reactive protein (CRP), a marker of inflammation, are less responsive to cholesterol-lowering diets. Cholesterol 145-156 C-reactive protein Homo sapiens 70-88 15867284-1 2005 Recent evidence suggests that individuals with high concentrations of C-reactive protein (CRP), a marker of inflammation, are less responsive to cholesterol-lowering diets. Cholesterol 145-156 C-reactive protein Homo sapiens 90-93 15867284-7 2005 Regardless of protein source, those with low CRP exhibited significant decreases in LDL cholesterol (-3.5%) and the LDL:HDL cholesterol ratio (-4.8%), whereas those with high CRP had significant increases in LDL cholesterol (+4.8%), the LDL:HDL cholesterol ratio (+5.2%), apolipoprotein B (+3.8%), and lipoprotein(a) (+13.5%) compared with the run-in diet. Cholesterol 88-99 C-reactive protein Homo sapiens 45-48 15867284-7 2005 Regardless of protein source, those with low CRP exhibited significant decreases in LDL cholesterol (-3.5%) and the LDL:HDL cholesterol ratio (-4.8%), whereas those with high CRP had significant increases in LDL cholesterol (+4.8%), the LDL:HDL cholesterol ratio (+5.2%), apolipoprotein B (+3.8%), and lipoprotein(a) (+13.5%) compared with the run-in diet. Cholesterol 124-135 C-reactive protein Homo sapiens 45-48 15867284-7 2005 Regardless of protein source, those with low CRP exhibited significant decreases in LDL cholesterol (-3.5%) and the LDL:HDL cholesterol ratio (-4.8%), whereas those with high CRP had significant increases in LDL cholesterol (+4.8%), the LDL:HDL cholesterol ratio (+5.2%), apolipoprotein B (+3.8%), and lipoprotein(a) (+13.5%) compared with the run-in diet. Cholesterol 124-135 C-reactive protein Homo sapiens 45-48 15832099-0 2005 High prevalence of C-reactive protein elevation with normal triglycerides (100-149 mg/dL): are triglyceride levels below 100 mg/dL more optimal in coronary heart disease risk assessment? Triglycerides 60-73 C-reactive protein Homo sapiens 19-37 15832099-0 2005 High prevalence of C-reactive protein elevation with normal triglycerides (100-149 mg/dL): are triglyceride levels below 100 mg/dL more optimal in coronary heart disease risk assessment? Triglycerides 60-72 C-reactive protein Homo sapiens 19-37 15832099-5 2005 RESULTS: High CRP level was equally prevalent whether the designated triglyceride cutpoint was greater than or equal to 100 (unadjusted OR, 2.0; 95% CI, 1.7-2.3) or greater than or equal to 150 (unadjusted OR, 1.9; 95% CI, 1.6-2.2). Triglycerides 69-81 C-reactive protein Homo sapiens 14-17 15832099-6 2005 After adjustment for other covariates, the triglyceride range of 100 to 149 mg/dL remained independently associated with elevated CRP level (OR, 1.3; 95% CI, 1.02-1.67). Triglycerides 43-55 C-reactive protein Homo sapiens 130-133 15832099-7 2005 In addition, an approximately fivefold higher likelihood of elevated CRP level was observed with triglyceride levels between 100 and 149 mg/dL and normal body mass index (BMI; 24-24.9) compared with lower triglyceride level (<65 mg/dL) and BMI (<22) (P < 0.0001). Triglycerides 97-109 C-reactive protein Homo sapiens 69-72 15832099-7 2005 In addition, an approximately fivefold higher likelihood of elevated CRP level was observed with triglyceride levels between 100 and 149 mg/dL and normal body mass index (BMI; 24-24.9) compared with lower triglyceride level (<65 mg/dL) and BMI (<22) (P < 0.0001). Triglycerides 205-217 C-reactive protein Homo sapiens 69-72 15829266-2 2005 These altered phospholipids include lysophosphotidylcholine (LPC) that is a ligand for CRP and is also antigenic for natural IgM antibodies. Phospholipids 14-27 C-reactive protein Homo sapiens 87-90 15829284-5 2005 CRP is currently serving as an indicator of cardiovascular diseases, but to pinpoint the role of CRP in atherosclerosis, a drug that can lower cholesterol levels, but not the CRP levels, is needed for experimentation. Cholesterol 143-154 C-reactive protein Homo sapiens 0-3 15829284-5 2005 CRP is currently serving as an indicator of cardiovascular diseases, but to pinpoint the role of CRP in atherosclerosis, a drug that can lower cholesterol levels, but not the CRP levels, is needed for experimentation. Cholesterol 143-154 C-reactive protein Homo sapiens 97-100 15829284-5 2005 CRP is currently serving as an indicator of cardiovascular diseases, but to pinpoint the role of CRP in atherosclerosis, a drug that can lower cholesterol levels, but not the CRP levels, is needed for experimentation. Cholesterol 143-154 C-reactive protein Homo sapiens 97-100 15981774-13 2005 Age, comorbidityindex, instilled dialysate glucose concentration, and Kt/V urea were independently associated with the type of time course of serum CRP. Glucose 43-50 C-reactive protein Homo sapiens 148-151 15981774-13 2005 Age, comorbidityindex, instilled dialysate glucose concentration, and Kt/V urea were independently associated with the type of time course of serum CRP. Urea 75-79 C-reactive protein Homo sapiens 148-151 15766555-0 2005 C-reactive protein binds to the 3beta-OH group of cholesterol in LDL particles. Cholesterol 50-61 C-reactive protein Homo sapiens 0-18 15766555-2 2005 We previously found binding of CRP to cholesterol in modified low density lipoprotein (LDL) particles. Cholesterol 38-49 C-reactive protein Homo sapiens 31-34 15766555-3 2005 Here, we characterize the interaction between CRP and cholesterol in more detail. Cholesterol 54-65 C-reactive protein Homo sapiens 46-49 15766555-4 2005 When lipids of native LDL were separated by thin-layer chromatography, CRP bound only to cholesterol. Cholesterol 89-100 C-reactive protein Homo sapiens 71-74 15766555-5 2005 When various cholesterol analogues were compared for their ability to bind CRP, we found that any modification of the 3beta-OH group blocked binding of CRP to cholesterol. Cholesterol 13-24 C-reactive protein Homo sapiens 75-78 15766555-5 2005 When various cholesterol analogues were compared for their ability to bind CRP, we found that any modification of the 3beta-OH group blocked binding of CRP to cholesterol. Cholesterol 13-24 C-reactive protein Homo sapiens 152-155 15766555-5 2005 When various cholesterol analogues were compared for their ability to bind CRP, we found that any modification of the 3beta-OH group blocked binding of CRP to cholesterol. Cholesterol 159-170 C-reactive protein Homo sapiens 75-78 15766555-5 2005 When various cholesterol analogues were compared for their ability to bind CRP, we found that any modification of the 3beta-OH group blocked binding of CRP to cholesterol. Cholesterol 159-170 C-reactive protein Homo sapiens 152-155 15766555-6 2005 Similarly, enrichment of LDL with cholesterol but not with its analogues triggered the binding of CRP to LDL. Cholesterol 34-45 C-reactive protein Homo sapiens 98-101 15766555-7 2005 Finally, with the aid of anti-CRP monoclonal antibodies and by molecular modeling, we obtained evidence for involvement of the phosphorylcholine-binding site of CRP in cholesterol binding. Cholesterol 168-179 C-reactive protein Homo sapiens 30-33 15766555-7 2005 Finally, with the aid of anti-CRP monoclonal antibodies and by molecular modeling, we obtained evidence for involvement of the phosphorylcholine-binding site of CRP in cholesterol binding. Cholesterol 168-179 C-reactive protein Homo sapiens 161-164 15766555-8 2005 Thus, CRP can bind to cholesterol, and the interaction is mediated by the phosphorylcholine-binding site of CRP and the 3beta-hydroxyl group of cholesterol. Cholesterol 22-33 C-reactive protein Homo sapiens 6-9 15766555-8 2005 Thus, CRP can bind to cholesterol, and the interaction is mediated by the phosphorylcholine-binding site of CRP and the 3beta-hydroxyl group of cholesterol. Cholesterol 22-33 C-reactive protein Homo sapiens 108-111 15766555-8 2005 Thus, CRP can bind to cholesterol, and the interaction is mediated by the phosphorylcholine-binding site of CRP and the 3beta-hydroxyl group of cholesterol. Cholesterol 144-155 C-reactive protein Homo sapiens 6-9 15692104-1 2005 OBJECTIVE: To investigate binding of C-reactive protein (CRP) and annexin A5, 2 proteins with high affinity for negatively charged phospholipids, to oxidized low-density lipoprotein (LDL) and the consequences of these interactions for subsequent binding of oxidized LDL to monocyte/macrophage-like U937 cells. Phospholipids 131-144 C-reactive protein Homo sapiens 37-55 15692104-7 2005 CONCLUSIONS: These findings suggest that: (1) CRP and annexin A5 at physiological concentrations bind to distinct sites of negatively charged phospholipids present in oxidized LDL; (2) CRP enhances binding of oxidized LDL to monocytic/macrophage-like cells via Fcgamma receptors; and (3) annexin A5 does not antagonize the CRP-induced enhanced binding of oxidized LDL to U937 cells. Phospholipids 142-155 C-reactive protein Homo sapiens 46-49 15692104-7 2005 CONCLUSIONS: These findings suggest that: (1) CRP and annexin A5 at physiological concentrations bind to distinct sites of negatively charged phospholipids present in oxidized LDL; (2) CRP enhances binding of oxidized LDL to monocytic/macrophage-like cells via Fcgamma receptors; and (3) annexin A5 does not antagonize the CRP-induced enhanced binding of oxidized LDL to U937 cells. Phospholipids 142-155 C-reactive protein Homo sapiens 185-188 15692104-7 2005 CONCLUSIONS: These findings suggest that: (1) CRP and annexin A5 at physiological concentrations bind to distinct sites of negatively charged phospholipids present in oxidized LDL; (2) CRP enhances binding of oxidized LDL to monocytic/macrophage-like cells via Fcgamma receptors; and (3) annexin A5 does not antagonize the CRP-induced enhanced binding of oxidized LDL to U937 cells. Phospholipids 142-155 C-reactive protein Homo sapiens 185-188 15864233-2 2005 We assessed the hypothesis that atorvastatin might have anti-inflammatory effects in acute coronary syndromes (ACS) as shown by CRP reduction. Atorvastatin 32-44 C-reactive protein Homo sapiens 128-131 15787682-0 2005 Association between fasting glucose and C-reactive protein in middle-aged subjects. Glucose 28-35 C-reactive protein Homo sapiens 40-58 15780114-11 2005 There was a correlation of borderline significance between calcium score and C-reactive protein (CRP) (r= 0.18, P= 0.062). Calcium 59-66 C-reactive protein Homo sapiens 77-95 15780114-11 2005 There was a correlation of borderline significance between calcium score and C-reactive protein (CRP) (r= 0.18, P= 0.062). Calcium 59-66 C-reactive protein Homo sapiens 97-100 15791030-4 2005 With adjustment for age, smoking status, and drinking status, the differences in CRP concentrations between those with the MS components of BMI, triglycerides, and uric acid and those without were greater in women than in men. Triglycerides 145-158 C-reactive protein Homo sapiens 81-84 15795363-0 2005 Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Nitric Oxide 94-106 C-reactive protein Homo sapiens 72-90 15795363-5 2005 In contrast to some previous reports, highly purified and well-characterized human CRP specifically induced hyporeactivity to phenylephrine in rings of human internal mammary artery and rat aorta that was mediated through physiological antagonism by nitric oxide (NO). Nitric Oxide 250-262 C-reactive protein Homo sapiens 83-86 15760600-4 2005 RESULTS: CRP serum levels were associated with: gender (men: 1.4 mg/L [0.03-12.8] vs. women: 3.4 [0.07-80.7]; p = 0.02), age (r = 0.34, p = 0.001), BMI (r = 0.45, p < 0.001), triglycerides (r = 0.24, p = 0.03) and E-selectin (r = 0.21, p = 0.02). Triglycerides 178-191 C-reactive protein Homo sapiens 9-12 15864233-8 2005 C-reactive protein levels were lower in the atorvastatin group versus control group at discharge (1.68 +/- 1.65 vs 4.12 +/- 4.18 mg/dL) and at 30 days (0.50 +/- 0.71 vs 2.91 +/- 2.68 mg/dL, both P < .0001). Atorvastatin 44-56 C-reactive protein Homo sapiens 0-18 15864233-9 2005 C-reactive protein levels significantly decreased from baseline to discharge and 1 month later in placebo and atorvastatin groups (both P < .0001); however, the reduction was greater in the atorvastatin group (62% vs 11% at discharge [P < .0001]; 84% vs 30% at 1 month [P < .0001]). Atorvastatin 110-122 C-reactive protein Homo sapiens 0-18 15864233-9 2005 C-reactive protein levels significantly decreased from baseline to discharge and 1 month later in placebo and atorvastatin groups (both P < .0001); however, the reduction was greater in the atorvastatin group (62% vs 11% at discharge [P < .0001]; 84% vs 30% at 1 month [P < .0001]). Atorvastatin 193-205 C-reactive protein Homo sapiens 0-18 15864233-12 2005 CONCLUSIONS: C-reactive protein levels in ACS were rapidly reduced with atorvastatin. Atorvastatin 72-84 C-reactive protein Homo sapiens 13-31 15843280-9 2005 Atorvastatin therapy was associated with no change in mean LDL particle size (p=0.23) and with a 90% decrease in mean CRP level (p=0.52). Atorvastatin 0-12 C-reactive protein Homo sapiens 118-121 15877874-6 2005 C-reactive protein levels in plasma, oleic acid C18 : 1n-9 and linoleic acid C18 : 2n-6 concentrations in triacylglycerols were determined. Triglycerides 106-122 C-reactive protein Homo sapiens 0-18 15613416-6 2005 In multivariate analysis, the association between DC and visceral fat disappeared after adjustment for CRP and IL-6. Deoxycytidine 50-52 C-reactive protein Homo sapiens 103-106 15843280-12 2005 CONCLUSION: Treatment with atorvastatin did not affect LDL particle size but was associated with a sizable, yet nonsignificant, reduction in CRP concentrations. Atorvastatin 27-39 C-reactive protein Homo sapiens 141-144 15695139-2 2005 Compared with controls, dexamethasone-eluting stents significantly reduced C-reactive protein peak levels 48 hours after the procedure; this effect persisted for 7 days and was particularly evident in patients with elevated (>/=3 mg/L) preprocedural C-reactive protein values. Dexamethasone 24-37 C-reactive protein Homo sapiens 75-93 15695139-2 2005 Compared with controls, dexamethasone-eluting stents significantly reduced C-reactive protein peak levels 48 hours after the procedure; this effect persisted for 7 days and was particularly evident in patients with elevated (>/=3 mg/L) preprocedural C-reactive protein values. Dexamethasone 24-37 C-reactive protein Homo sapiens 253-271 15803114-9 2005 CRP showed a positive correlation with BMI, insulin, homeostasis model assessment (HOMA), triglycerides, alanine aminotransferase (ALT), uric acid, PAI-1, fibrinogen and interleukin 6 (IL-6), and correlated negatively with apolipoprotein A-I and high-density lipoprotein cholesterol (HDL-C). Triglycerides 90-103 C-reactive protein Homo sapiens 0-3 15686768-3 2005 The addition of CRP to standard lipid screening may improve global risk prediction among those with high as well as low cholesterol. Cholesterol 120-131 C-reactive protein Homo sapiens 16-19 15708106-7 2005 Rosiglitazone, a peroxisome-proliferator-activator receptor gamma agonist, inhibits the negative effects of CRP on endothelial progenitor cells. Rosiglitazone 0-13 C-reactive protein Homo sapiens 108-111 15557131-6 2005 At study entry, the hydrocortisone group had lower Pa(O(2)):FI(O(2)), and higher chest radiograph score and C-reactive protein level. Hydrocortisone 20-34 C-reactive protein Homo sapiens 108-126 15801991-17 2005 Limitations include no serum levels prior to statin use and small sample size; thus, future studies are needed to address the relationship between cholesterol and CRP and the mechanism of action of statins on CRP. Cholesterol 147-158 C-reactive protein Homo sapiens 163-166 15803114-9 2005 CRP showed a positive correlation with BMI, insulin, homeostasis model assessment (HOMA), triglycerides, alanine aminotransferase (ALT), uric acid, PAI-1, fibrinogen and interleukin 6 (IL-6), and correlated negatively with apolipoprotein A-I and high-density lipoprotein cholesterol (HDL-C). Cholesterol 271-282 C-reactive protein Homo sapiens 0-3 15618238-12 2005 In univariate analysis, DeltaCCA-IMT correlated positively with age (R = 0.32, P = 0.03), BMI (R = 0.29, P = 0.05) and mean concentrations of CRP (R = 0.37, P = 0.01), TNFalpha (0.52, P = 0.0002), but inversely with HDL-cholesterol (R = -0.37, P = 0.01). Cholesterol 220-231 C-reactive protein Homo sapiens 142-145 15750272-6 2005 After steroid therapy was restarted, there were improvements in her audibility, radial arterial pulsation, and levels of inflammatory markers (erythrocyte sedimentation rate, C-reactive protein, and gamma-globulin), fibrinogen, interleukin-6, and RANTES (regulated on activation, normal T cell expressed and secreted). Steroids 6-13 C-reactive protein Homo sapiens 175-193 15788980-6 2005 The availability of high sensibility assays for CRP should provide a valuable tool for identifying patients at risk of cardiovascular events in primary prevention in conjunction with lowering LDL cholesterol and may also have utility in the treatment of acute coronary syndromes with percutaneous coronary intervention (PCI) therapy. Cholesterol 196-207 C-reactive protein Homo sapiens 48-51 15687975-8 2005 The hs CRP concentrations were significantly correlated with total cholesterol, total cholesterol/HDL-cholesterol ratio, and LDL cholesterol for the 2 groups of patients. Cholesterol 67-78 C-reactive protein Homo sapiens 7-10 15687975-8 2005 The hs CRP concentrations were significantly correlated with total cholesterol, total cholesterol/HDL-cholesterol ratio, and LDL cholesterol for the 2 groups of patients. Cholesterol 86-97 C-reactive protein Homo sapiens 7-10 15687975-8 2005 The hs CRP concentrations were significantly correlated with total cholesterol, total cholesterol/HDL-cholesterol ratio, and LDL cholesterol for the 2 groups of patients. Cholesterol 86-97 C-reactive protein Homo sapiens 7-10 15687975-8 2005 The hs CRP concentrations were significantly correlated with total cholesterol, total cholesterol/HDL-cholesterol ratio, and LDL cholesterol for the 2 groups of patients. Cholesterol 86-97 C-reactive protein Homo sapiens 7-10 16642663-6 2005 An inverse correlation of serum CRP with serum cholesterol and triglyceride levels and a near significant positive correlations of CRP with serum ALP and with serum intact parathormone (iPTH) were found too. Cholesterol 47-58 C-reactive protein Homo sapiens 32-35 15635109-3 2005 METHODS: We evaluated relationships between the LDL cholesterol and CRP levels achieved after treatment with 80 mg of atorvastatin or 40 mg of pravastatin per day and the risk of recurrent myocardial infarction or death from coronary causes among 3745 patients with acute coronary syndromes. Cholesterol 52-63 C-reactive protein Homo sapiens 68-71 15635109-3 2005 METHODS: We evaluated relationships between the LDL cholesterol and CRP levels achieved after treatment with 80 mg of atorvastatin or 40 mg of pravastatin per day and the risk of recurrent myocardial infarction or death from coronary causes among 3745 patients with acute coronary syndromes. Atorvastatin 118-130 C-reactive protein Homo sapiens 68-71 15635109-6 2005 For patients with post-treatment LDL cholesterol levels of more than 70 mg per deciliter, the rates of recurrent events were 4.6 per 100 person-years among those with CRP levels of more than 2 mg per liter and 3.2 events per 100 person-years among those with CRP levels of less than 2 mg per liter; the respective rates among those with LDL cholesterol levels of less than 70 mg per deciliter were 3.1 and 2.4 events per 100 person-years (P<0.001). Cholesterol 37-48 C-reactive protein Homo sapiens 167-170 15635109-6 2005 For patients with post-treatment LDL cholesterol levels of more than 70 mg per deciliter, the rates of recurrent events were 4.6 per 100 person-years among those with CRP levels of more than 2 mg per liter and 3.2 events per 100 person-years among those with CRP levels of less than 2 mg per liter; the respective rates among those with LDL cholesterol levels of less than 70 mg per deciliter were 3.1 and 2.4 events per 100 person-years (P<0.001). Cholesterol 37-48 C-reactive protein Homo sapiens 259-262 15635109-6 2005 For patients with post-treatment LDL cholesterol levels of more than 70 mg per deciliter, the rates of recurrent events were 4.6 per 100 person-years among those with CRP levels of more than 2 mg per liter and 3.2 events per 100 person-years among those with CRP levels of less than 2 mg per liter; the respective rates among those with LDL cholesterol levels of less than 70 mg per deciliter were 3.1 and 2.4 events per 100 person-years (P<0.001). Cholesterol 341-352 C-reactive protein Homo sapiens 167-170 15635109-7 2005 Although atorvastatin was more likely than pravastatin to result in low levels of LDL cholesterol and CRP, meeting these targets was more important in determining the outcomes than was the specific choice of therapy. Atorvastatin 9-21 C-reactive protein Homo sapiens 102-105 15635110-8 2005 The correlation between the reduction in LDL cholesterol levels and that in CRP levels was weak but significant in the group as a whole (r=0.13, P=0.005), but not in either treatment group alone. Cholesterol 45-56 C-reactive protein Homo sapiens 76-79 15901207-7 2005 Metformin improves dyslipidemia and altered hemostasis and decreases plasma C-reactive protein levels with little or no effect on blood pressure. Metformin 0-9 C-reactive protein Homo sapiens 76-94 16642663-6 2005 An inverse correlation of serum CRP with serum cholesterol and triglyceride levels and a near significant positive correlations of CRP with serum ALP and with serum intact parathormone (iPTH) were found too. Triglycerides 63-75 C-reactive protein Homo sapiens 32-35 16642663-10 2005 The positive correlation of high serum iPTH with inflammation implies further need to control hyperphosphatemia and secondary hyperparathyroidism in HD patients, also inverse correlation of serum CRP with cholesterol and triglyceride further support the malnutrition-inflammation complex syndrome (MICS) which frequently seen in hemodialysis patients (Tab. Cholesterol 205-216 C-reactive protein Homo sapiens 196-199 15785026-7 2005 Women, obese individuals, subjects with increasing heart rate and higher levels of serum triglycerides were more likely to have elevated concentrations of CRP than the corresponding comparison groups. Triglycerides 89-102 C-reactive protein Homo sapiens 155-158 15785026-8 2005 Subjects who reported regularly exercising, individuals with a history of heart disease and those with lower total cholesterol levels were less likely to have elevated CRP levels. Cholesterol 115-126 C-reactive protein Homo sapiens 168-171 15586013-10 2005 Also CRP is shown to attenuate endothelial progenitor cell survival, differentiation, and function via inhibiting nitric oxide. Nitric Oxide 114-126 C-reactive protein Homo sapiens 5-8 17532680-6 2005 RESULTS: Both NAC 600 and 1200 mg/day were associated with a significantly higher proportion of patients achieving normalised CRP levels compared with placebo (52% and 90% vs 19% of patients; p </= 0.01); however, NAC 1200 mg/day was superior to NAC 600 mg/day (p = 0.002). Acetylcysteine 14-17 C-reactive protein Homo sapiens 126-129 15647646-7 2005 CsA was started on the basis of their C-reactive protein (CRP) and/or stool frequency after 3 days or after 5-7 days of i.v. Cyclosporine 0-3 C-reactive protein Homo sapiens 38-56 15644674-6 2005 Both procalcitonin and lactate reliably discriminated between those children with septic shock (area under the curve [AUC] = 0.85 and 0.84, respectively) and durations of hospital stay exceeding 10 days (AUC = 0.87 and 0.79, respectively) and those without, but C-reactive protein did not. Lactic Acid 23-30 C-reactive protein Homo sapiens 262-280 15647646-7 2005 CsA was started on the basis of their C-reactive protein (CRP) and/or stool frequency after 3 days or after 5-7 days of i.v. Cyclosporine 0-3 C-reactive protein Homo sapiens 58-61 15678964-11 2005 The serum CRP on the 3rd postoperative day was significantly lower in the steroid group than in control (8.5 mg/dl versus 13.3 mg/dl, p=0.011) while it was not different between those 2 groups on the 7th postoperative day. Steroids 74-81 C-reactive protein Homo sapiens 10-13 16201293-9 2005 The hospital stay (days), defervescence time, total fever duration, platelet count, erythrocyte sedimentation rate and C reactive protein were significantly reduced in IVIG+ ASA group as compared with those in the ASA group (P<0.05). Aspirin 174-177 C-reactive protein Homo sapiens 119-137 15668660-5 2005 We noted significant and independent direct associations between CRP and age, body-mass index, female sex, and serum triglyceride concentration. Triglycerides 117-129 C-reactive protein Homo sapiens 65-68 15668660-6 2005 Bivariate analysis showed a significant inverse association between CRP and many nutrients (e.g., carbohydrates, proteins, lipids, thiamine, pyridoxine, tocopherol, and folate), but multiple-regression analysis indicated that only the effect of dietary folate intake was not dependent on other factors. Carbohydrates 98-111 C-reactive protein Homo sapiens 68-71 15668660-6 2005 Bivariate analysis showed a significant inverse association between CRP and many nutrients (e.g., carbohydrates, proteins, lipids, thiamine, pyridoxine, tocopherol, and folate), but multiple-regression analysis indicated that only the effect of dietary folate intake was not dependent on other factors. Folic Acid 169-175 C-reactive protein Homo sapiens 68-71 15668660-9 2005 This population-based study shows that a higher folate intake, in addition to other known constitutive and lifestyle factors, is significantly associated with a lower serum CRP concentration. Folic Acid 48-54 C-reactive protein Homo sapiens 173-176 15783053-9 2005 The leukocyte count on day 1 and day 3, and serum C-reactive protein levels on day 1 were significantly lower after LADG than after ODG. ladg 116-120 C-reactive protein Homo sapiens 50-68 15780504-5 2005 In a recent clinical trial targeting elderly chronically ill patients, administration of vitamin D reduced serum levels of both CRP and IL-6; further such studies should assess the impact of physiologically meaningful doses of vitamin D on acute phase reactants in elderly subjects likely to have poor vitamin D status. Vitamin D 89-98 C-reactive protein Homo sapiens 128-131 16272835-8 2005 Concentration of high-sensitivity C-reactive protein directly correlated with the waist and hips circumference, body mass index, concentration of Tg, glucose and BP. Triglycerides 146-148 C-reactive protein Homo sapiens 34-52 15780504-7 2005 Moderate alcohol intake is associated with reduced serum PTH as well as decreased levels of CRP and fibrinogen; conceivably, modulation of PTH mediates, at least in part, the favorable impact of moderate drinking on the acute phase reactants. Alcohols 9-16 C-reactive protein Homo sapiens 92-95 16272835-8 2005 Concentration of high-sensitivity C-reactive protein directly correlated with the waist and hips circumference, body mass index, concentration of Tg, glucose and BP. Glucose 150-157 C-reactive protein Homo sapiens 34-52 15576654-0 2005 Concurrent treatment with renin-angiotensin system blockers and acetylsalicylic acid reduces nuclear factor kappaB activation and C-reactive protein expression in human carotid artery plaques. Aspirin 64-84 C-reactive protein Homo sapiens 130-148 16739870-9 2005 At two hours postprandial, we found a significant nonparametric correlation between CRP level and total cholesterol (p=0.01), which remained significant even after adjusting for age, BMI, HbA1c and blood pressure values (adjusted p=0.018). Cholesterol 104-115 C-reactive protein Homo sapiens 84-87 16739870-10 2005 Patients in the lowest quartile for CRP level compared to those in the highest quartile had lower fasting apolipoprotein B levels (146 vs 197 mg/dl, p=0.042), lower postprandial blood glucose levels (188 vs 241 mg/dl, p=0.035) and lower nonHDL-cholesterol levels (148 vs 192 mg/dl, p=0.005). Glucose 184-191 C-reactive protein Homo sapiens 36-39 16739870-10 2005 Patients in the lowest quartile for CRP level compared to those in the highest quartile had lower fasting apolipoprotein B levels (146 vs 197 mg/dl, p=0.042), lower postprandial blood glucose levels (188 vs 241 mg/dl, p=0.035) and lower nonHDL-cholesterol levels (148 vs 192 mg/dl, p=0.005). Cholesterol 244-255 C-reactive protein Homo sapiens 36-39 16131811-0 2005 C-reactive protein induces NF-kappaB activation through intracellular calcium and ROS in human mesangial cells. Calcium 70-77 C-reactive protein Homo sapiens 0-18 16131811-0 2005 C-reactive protein induces NF-kappaB activation through intracellular calcium and ROS in human mesangial cells. Reactive Oxygen Species 82-85 C-reactive protein Homo sapiens 0-18 16131811-7 2005 Both intracellular calcium and ROS was induced by CRP. Calcium 19-26 C-reactive protein Homo sapiens 50-53 16131811-7 2005 Both intracellular calcium and ROS was induced by CRP. Reactive Oxygen Species 31-34 C-reactive protein Homo sapiens 50-53 16131811-8 2005 Calcium chelator, BAPTA-AM and anti-oxidants such as N-acetylcysteine and tiron suppressed CRP-induced NF-kappaB activation. Calcium 0-7 C-reactive protein Homo sapiens 91-94 16131811-8 2005 Calcium chelator, BAPTA-AM and anti-oxidants such as N-acetylcysteine and tiron suppressed CRP-induced NF-kappaB activation. Acetylcysteine 53-69 C-reactive protein Homo sapiens 91-94 16131811-9 2005 CONCLUSION: CRP exerted a proinflammatory effect in human mesangial cells by inducing MCP-1 gene expression via NF-kappaB activation, which was mediated, at least in part, through intracellular calcium and ROS. Calcium 194-201 C-reactive protein Homo sapiens 12-15 16131811-9 2005 CONCLUSION: CRP exerted a proinflammatory effect in human mesangial cells by inducing MCP-1 gene expression via NF-kappaB activation, which was mediated, at least in part, through intracellular calcium and ROS. Reactive Oxygen Species 206-209 C-reactive protein Homo sapiens 12-15 16358989-20 2005 Significant negative correlations were found in G IgG (+) between IgG antibodies and transferrin saturation (r=-0.645719, p<0.001) and between CRP and calcium (r=-0.4526, p<0.05). Calcium 154-161 C-reactive protein Homo sapiens 146-149 15576654-2 2005 We hypothesized that the combination of RAS blockers (RASb) and ASA reduces NFkappaB and CRP within atherosclerotic plaques. Aspirin 64-67 C-reactive protein Homo sapiens 89-92 15556359-6 2004 In addition, when it was treated with 2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate, so-called MPC polymer, highly affinitive and selective immunosensing for CRP was achieved without non-specific binding from plasma proteins in human serum. mpc polymer 114-125 C-reactive protein Homo sapiens 177-180 15792679-12 2005 CRP was negatively correlated with HDL-C (r=-0.24, p=0.0002) and positively correlated with glucose intolerance (r=0.15, p=0.01). Glucose 92-99 C-reactive protein Homo sapiens 0-3 15456743-0 2004 Interaction of calcium-bound C-reactive protein with fibronectin is controlled by pH: in vivo implications. Calcium 15-22 C-reactive protein Homo sapiens 29-47 15456743-1 2004 C-reactive protein (CRP) binds with high affinity to fibronectin (Fn), a major component of the extracellular matrix (ECM), but at physiological pH the binding is inhibited by calcium ions (Ca2+). Calcium 176-183 C-reactive protein Homo sapiens 0-18 15456743-1 2004 C-reactive protein (CRP) binds with high affinity to fibronectin (Fn), a major component of the extracellular matrix (ECM), but at physiological pH the binding is inhibited by calcium ions (Ca2+). Calcium 176-183 C-reactive protein Homo sapiens 20-23 15571824-6 2004 Self-reported moderate daily alcohol intake up to 40 g was associated with lower concentrations of CRP, fibrinogen, PV and WBC count, compared to non-drinking and heavy drinking, even after adjustment for various potential confounders. Alcohols 29-36 C-reactive protein Homo sapiens 99-102 15571826-1 2004 BACKGROUND: Statins and cholesterol absorption inhibitors lower the concentration of C-reactive protein (CRP). Cholesterol 24-35 C-reactive protein Homo sapiens 85-103 15571826-1 2004 BACKGROUND: Statins and cholesterol absorption inhibitors lower the concentration of C-reactive protein (CRP). Cholesterol 24-35 C-reactive protein Homo sapiens 105-108 15488879-9 2004 The percentage of patients with CRP levels >3 mg/dL in the atorvastatin group fell from 25.0 to 6.7% (P <0.0001) while in the diet group the reduction was not significant. Atorvastatin 62-74 C-reactive protein Homo sapiens 32-35 15580061-3 2004 DESIGN: We investigated whether variations in blood lipids and plasma C-reactive protein induced by low-cholesterol/low-saturated fat diet are associated with variations in large-artery stiffness in hypercholesterolaemia. Cholesterol 104-115 C-reactive protein Homo sapiens 70-88 15804800-5 2004 Simultaneous elevation of hs-CRP and leucocyte count increased the risk substantially in those with low iron, OR 9.8 (95% CI 3.9-24.4). Iron 104-108 C-reactive protein Homo sapiens 29-32 15488879-10 2004 CONCLUSION: In hypercholesterolemic patients, atorvastatin, compared to diet alone resulted in significant reductions in levels of proinflammatory cytokines (TNF, IL-1 and IL-6) as well as in sICAM-1 and CRP. Atorvastatin 46-58 C-reactive protein Homo sapiens 192-207 15505001-8 2004 The high-sensitivity C-reactive protein concentration was significantly reduced in the rosiglitazone group compared with that in the control group (from 2.92 +/- 1.98 to 0.62 +/- 0.44 mg/l, P < 0.001 vs. from 2.01 +/- 1.33 to 1.79 +/- 1.22 mg/l, P = NS). Rosiglitazone 87-100 C-reactive protein Homo sapiens 21-39 15380455-6 2004 We also observed a significant correlation between plasma glucose and serum CRP (r = 0.53, P = 0.01) as well as platelet-monocyte aggregates (r = 0.69, P = 0.03). Glucose 58-65 C-reactive protein Homo sapiens 76-79 15550024-7 2004 Aspirin and clopidogrel were thus found to have similar effects on thrombotic variables and CRP in this patient population. Aspirin 0-7 C-reactive protein Homo sapiens 92-95 15535926-0 2004 [Atorvastatin lowers C-reactive protein in dislipemic patients with type 2 diabetes mellitus]. Atorvastatin 1-13 C-reactive protein Homo sapiens 21-39 15535926-4 2004 Thus, we tested the effects of atorvastatin on levels of CRP on patients with type 2 diabetes. Atorvastatin 31-43 C-reactive protein Homo sapiens 57-60 15535926-5 2004 PATIENTS AND METHOD: We evaluated CRP in baseline and 6 months after onset of 20 mg daily atorvastatin therapy of 30 patients with type 2 diabetes with hyperlipidemia. Atorvastatin 90-102 C-reactive protein Homo sapiens 34-37 15535926-7 2004 RESULTS: CRP-levels were significantly decreased after treatment with atorvastatin compared with baseline (median change: -4,99 mg/l; p < 0.001). Atorvastatin 70-82 C-reactive protein Homo sapiens 9-12 15535926-10 2004 The CRP reduction was significantly correlated with fasting glucose (r = -0.457; p = 0.019) and glycosylated hemoglobin at 6 months (r = -0.421; p = 0.03). Glucose 60-67 C-reactive protein Homo sapiens 4-7 15535926-11 2004 CONCLUSIONS: These results confirm findings from previous studies that atorvastatin reduce CRP levels in a largely LDL cholesterol independent manner. Atorvastatin 71-83 C-reactive protein Homo sapiens 91-94 15535926-11 2004 CONCLUSIONS: These results confirm findings from previous studies that atorvastatin reduce CRP levels in a largely LDL cholesterol independent manner. Cholesterol 119-130 C-reactive protein Homo sapiens 91-94 15514286-3 2004 The inclusion of CRP as marker of infection allows for more accurate interpretation of VA and iron status. Iron 94-98 C-reactive protein Homo sapiens 17-20 15536598-3 2004 Plasma CRP levels were determined by a highly sensitive enzyme-linked immunosorbent assay (ELISA) in 760 participants in the beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). bcaps 186-191 C-reactive protein Homo sapiens 7-10 15536598-4 2004 In accordance with previous findings, increased levels of CRP were associated with high body mass index (BMI) (P = .012), triglycerides (P = .001), systolic blood pressure (P = .019), cholesterol/high-density lipoprotein (HDL) ratio (P = .009), and low HDL cholesterol (P = .001). Cholesterol 184-195 C-reactive protein Homo sapiens 58-61 15336815-0 2004 C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. Adenosine Triphosphate 109-112 C-reactive protein Homo sapiens 0-18 15451915-10 2004 In the interventional study, atorvastatin decreased lipid and CRP levels, but adiponectin and resistin were not specifically altered. Atorvastatin 29-41 C-reactive protein Homo sapiens 62-65 15379752-6 2004 Among the potential confounding factors analysed, smoking, body mass index, total cholesterol (P < 0.05 for all) and diabetes (P = 0.056) were positively correlated with CRP level. Cholesterol 82-93 C-reactive protein Homo sapiens 173-176 15336815-3 2004 We observed the association between CRP, insulin resistance and metabolic syndrome as defined by the ATP III report, and thus identified the role of CRP in the relation to insulin resistance. Adenosine Triphosphate 101-104 C-reactive protein Homo sapiens 36-39 15336815-6 2004 RESULTS: The mean concentrations of CRP in subjects according to the presence of 0, 1, 2, 3, 4, or 5 components of metabolic syndrome as defined by ATP III were 0.64, 0.95, 1.14, 1.19, 2.40, and 2.53 mg/l, respectively. atp iii 148-155 C-reactive protein Homo sapiens 36-39 15336815-8 2004 Significant positive correlations were identified between CRP and BMI, waist circumference, triglyceride, blood pressure, glucose and HOMA index. Triglycerides 92-104 C-reactive protein Homo sapiens 58-61 15336815-8 2004 Significant positive correlations were identified between CRP and BMI, waist circumference, triglyceride, blood pressure, glucose and HOMA index. Glucose 122-129 C-reactive protein Homo sapiens 58-61 15336815-9 2004 A significant negative correlation was found between CRP and HDL cholesterol or QUICKI. Cholesterol 65-76 C-reactive protein Homo sapiens 53-56 15378141-0 2004 C-reactive protein increases oxygen radical generation by neutrophils. Reactive Oxygen Species 29-43 C-reactive protein Homo sapiens 0-18 15380496-6 2004 However, patients with a high-risk baseline level (>3 mg/dL, n = 48) experienced a greater decrease in C-reactive protein levels on a low-carbohydrate diet (adjusted difference = -2.0 mg/dL, P = 0.005), independent of weight loss. Carbohydrates 141-153 C-reactive protein Homo sapiens 106-124 17670296-5 2004 We conclude that steroids may reduce Troponin I release, CRP and reduce Interleukin-6. Steroids 17-25 C-reactive protein Homo sapiens 57-60 15378141-4 2004 The direct effect of CRP on the release of oxygen radicals by neutrophils is not known. Reactive Oxygen Species 43-58 C-reactive protein Homo sapiens 21-24 15378141-5 2004 This investigation was made to determine if CRP affects the generation of oxygen radicals by neutrophils and if this effect is blocked by antioxidants. Reactive Oxygen Species 74-89 C-reactive protein Homo sapiens 44-47 15378141-6 2004 The effect of various concentrations (1 to 200 microg/mL blood) of CRP on the generation of oxygen radicals by neutrophils was measured as luminol-dependent chemiluminescence (chemiluminescent activity) on a luminometer (Auto Lumat LB953, EG & G Berthold, Gaithersburg, MD). Reactive Oxygen Species 92-107 C-reactive protein Homo sapiens 67-70 15378141-6 2004 The effect of various concentrations (1 to 200 microg/mL blood) of CRP on the generation of oxygen radicals by neutrophils was measured as luminol-dependent chemiluminescence (chemiluminescent activity) on a luminometer (Auto Lumat LB953, EG & G Berthold, Gaithersburg, MD). Luminol 139-146 C-reactive protein Homo sapiens 67-70 15378141-6 2004 The effect of various concentrations (1 to 200 microg/mL blood) of CRP on the generation of oxygen radicals by neutrophils was measured as luminol-dependent chemiluminescence (chemiluminescent activity) on a luminometer (Auto Lumat LB953, EG & G Berthold, Gaithersburg, MD). Adenosine Monophosphate 243-246 C-reactive protein Homo sapiens 67-70 15356091-6 2004 Statistically significant differences were seen at all CRP cutoffs in the levels of TG, HDL, and non-HDL cholesterol and the CRF, but no differences were seen in total cholesterol and LDL cholesterol levels. Triglycerides 84-86 C-reactive protein Homo sapiens 55-58 15378141-13 2004 Antioxidants (superoxide dismutase, catalase, and dimethylthiourea) blocked CRP-induced oxygen radicals by WBCs. Reactive Oxygen Species 88-103 C-reactive protein Homo sapiens 76-79 15356091-6 2004 Statistically significant differences were seen at all CRP cutoffs in the levels of TG, HDL, and non-HDL cholesterol and the CRF, but no differences were seen in total cholesterol and LDL cholesterol levels. Cholesterol 105-116 C-reactive protein Homo sapiens 55-58 15356091-7 2004 CRP levels correlated with non-HDL cholesterol levels (r = 0.16, P = 0.0236) and the CRF (r = 0.18, P = 0.14), but not with levels of HDL or TG. Cholesterol 35-46 C-reactive protein Homo sapiens 0-3 15378141-14 2004 These results suggest that CRP increases the generation of oxygen radicals from the WBCs. Reactive Oxygen Species 59-74 C-reactive protein Homo sapiens 27-30 15378141-15 2004 CRP-induced atherosclerosis may be mediated through generation of oxygen radicals by neutrophils. Reactive Oxygen Species 66-81 C-reactive protein Homo sapiens 0-3 15334369-12 2004 High sensitive C-reactive protein (HS-CRP) was halved by atorvastatin decreasing from 0.08 +/- 0.05 to 0.04 +/- 0.03 mg/dL. Atorvastatin 57-69 C-reactive protein Homo sapiens 15-33 15593040-3 2004 We investigated the correlation between Cp and copper concentration (Cu) with major acute phase reactants such as C-reactive protein (CRP) and interleukin-6 (IL-6) in a population of chronic dialytic patients. Copper 47-53 C-reactive protein Homo sapiens 114-132 15593040-3 2004 We investigated the correlation between Cp and copper concentration (Cu) with major acute phase reactants such as C-reactive protein (CRP) and interleukin-6 (IL-6) in a population of chronic dialytic patients. Copper 69-71 C-reactive protein Homo sapiens 114-132 15540478-8 2004 The MIRACL study showed that atorvastatin reduced CRP levels by 83% (p < 0.001). Atorvastatin 29-41 C-reactive protein Homo sapiens 50-53 15490400-4 2004 Patients with a mean CRP level greater than 1.0 mg/L (n = 254) were older than those with a CRP level less than or equal to 1.0 mg/L (n = 258) and had a longer duration of dialysis, lower serum albumin level, and higher phosphate level ( P < .01, P < .05, P < .001, and P < .01, respectively). Phosphates 220-229 C-reactive protein Homo sapiens 21-24 15490400-6 2004 In a multivariate logistic regression analysis adjusted for age, hemodialysis duration, sex, levels of calcium and phosphate, and presence of diabetes, CRP level was a significant predictor for the presence of aortic calcification (odds ratio for highest versus lowest quartile, 2.669; 95% confidence interval, 1.539-5.421, P = .0010) and of calcification of hand arteries (odds ratio, 2.243; 95% confidence interval, 1.039-4.841; P = .0395). Calcium 103-110 C-reactive protein Homo sapiens 152-155 15490400-6 2004 In a multivariate logistic regression analysis adjusted for age, hemodialysis duration, sex, levels of calcium and phosphate, and presence of diabetes, CRP level was a significant predictor for the presence of aortic calcification (odds ratio for highest versus lowest quartile, 2.669; 95% confidence interval, 1.539-5.421, P = .0010) and of calcification of hand arteries (odds ratio, 2.243; 95% confidence interval, 1.039-4.841; P = .0395). Phosphates 115-124 C-reactive protein Homo sapiens 152-155 15289371-6 2004 C-reactive protein was related directly to serum creatinine and inversely to GFR and vasodilatory response to ACh, which suggests that endothelial dysfunction is a possible mechanism linking inflammation and impaired renal function in essential hypertension. Creatinine 49-59 C-reactive protein Homo sapiens 0-18 15289371-6 2004 C-reactive protein was related directly to serum creatinine and inversely to GFR and vasodilatory response to ACh, which suggests that endothelial dysfunction is a possible mechanism linking inflammation and impaired renal function in essential hypertension. Acetylcholine 110-113 C-reactive protein Homo sapiens 0-18 15540478-9 2004 Researchers in the CURVES study found a significant reduction in CRP levels with pravastatin, simvastatin, and atorvastatin compared with baseline (p < 0.025). Atorvastatin 111-123 C-reactive protein Homo sapiens 65-68 15540478-10 2004 Results of the REVERSAL study linked atorvastatin with a 36.4% decrease in CRP levels, while pravastatin was associated with a 5.2% decrease (p < 0.0001). Atorvastatin 37-49 C-reactive protein Homo sapiens 75-78 15358216-4 2004 Incubation of EPCs with human recombinant CRP significantly inhibited EPC migration in response to vascular endothelial growth factor, possibly by decreasing the expression of endothelial nitric oxide synthase and subsequent nitric oxide production. Nitric Oxide 188-200 C-reactive protein Homo sapiens 42-45 16036753-0 2004 Expression of C-reactive protein in human lung epithelial cells and upregulation by cytokines and carbon particles. Carbon 98-104 C-reactive protein Homo sapiens 14-32 15309577-5 2004 Along the clinical course, changes in cholesterol were clearly paralleled by opposite changes in C-reactive protein, which was the best correlate of cholesterol (r2=0.70, p<0.0001). Cholesterol 38-49 C-reactive protein Homo sapiens 97-115 15309577-5 2004 Along the clinical course, changes in cholesterol were clearly paralleled by opposite changes in C-reactive protein, which was the best correlate of cholesterol (r2=0.70, p<0.0001). Cholesterol 149-160 C-reactive protein Homo sapiens 97-115 15309577-9 2004 C-reactive protein (CRP, mg/dl) and alkaline phosphatase (ALKPH, U/L) together in the same regression explained 79% of the variability of cholesterol (CHOL, mmol/L): CHOL=5.90-0.74[Log(e)CRP]+0.004[ALKPH]; multiple r2=0.79, p<0.0001. Cholesterol 138-149 C-reactive protein Homo sapiens 0-18 15309577-9 2004 C-reactive protein (CRP, mg/dl) and alkaline phosphatase (ALKPH, U/L) together in the same regression explained 79% of the variability of cholesterol (CHOL, mmol/L): CHOL=5.90-0.74[Log(e)CRP]+0.004[ALKPH]; multiple r2=0.79, p<0.0001. Cholesterol 151-155 C-reactive protein Homo sapiens 0-18 15309577-9 2004 C-reactive protein (CRP, mg/dl) and alkaline phosphatase (ALKPH, U/L) together in the same regression explained 79% of the variability of cholesterol (CHOL, mmol/L): CHOL=5.90-0.74[Log(e)CRP]+0.004[ALKPH]; multiple r2=0.79, p<0.0001. Cholesterol 166-170 C-reactive protein Homo sapiens 0-18 15309202-3 2004 The present review outlines some of the emerging data that suggest that CRP may directly promote the development of endothelial dysfunction, by affecting endothelium-derived contracting and relaxing factors such as nitric oxide, endothelin, angiotensin and interleukin-6. Nitric Oxide 215-227 C-reactive protein Homo sapiens 72-75 15321699-0 2004 C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. Nitric Oxide 45-57 C-reactive protein Homo sapiens 0-18 15321699-2 2004 Because inflammatory cytokines experimentally reduce basal and stimulated endothelial nitric oxide (NO) release, we hypothesised that patients with elevated CRP-levels are characterised by a systemic impairment in NO bioavailability. Nitric Oxide 86-98 C-reactive protein Homo sapiens 157-160 15321699-5 2004 CRP serum levels were inversely correlated with L-NMMA-induced decreases in baseline as well as acetylcholine-stimulated FBF responses. omega-N-Methylarginine 48-54 C-reactive protein Homo sapiens 0-3 15321699-5 2004 CRP serum levels were inversely correlated with L-NMMA-induced decreases in baseline as well as acetylcholine-stimulated FBF responses. Acetylcholine 96-109 C-reactive protein Homo sapiens 0-3 15321699-6 2004 Co-infusion of the oxygen-derived free radical scavenger vitamin C significantly increased baseline FBF from 2.0 +/- 0.5 to 2.5 +/- 0.7 (mL/min/100 mL forearm tissue (P < 0.001)) and acetylcholine-stimulated FBF responses in patients with elevated CRP, but not in patients with low CRP serum levels. Oxygen 19-25 C-reactive protein Homo sapiens 251-254 15321699-6 2004 Co-infusion of the oxygen-derived free radical scavenger vitamin C significantly increased baseline FBF from 2.0 +/- 0.5 to 2.5 +/- 0.7 (mL/min/100 mL forearm tissue (P < 0.001)) and acetylcholine-stimulated FBF responses in patients with elevated CRP, but not in patients with low CRP serum levels. Oxygen 19-25 C-reactive protein Homo sapiens 285-288 15321699-7 2004 Vitamin C-induced increases in baseline FBF and in acetylcholine-stimulated FBF responses were significantly correlated with CRP serum levels. Acetylcholine 51-64 C-reactive protein Homo sapiens 125-128 15262834-2 2004 METHODS AND RESULTS: We assessed the cross-sectional relations of CRP to the MetS (National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Adult Treatment Panel III definition) in 3037 subjects (1681 women; mean age, 54 years) and the utility of CRP and the MetS to predict new CVD events (n=189) over 7 years. Cholesterol 92-103 C-reactive protein Homo sapiens 66-69 15286264-14 2004 When inflammatory markers were correlated with the severity of the renal lesions, as assessed with DMSA scintigraphy, a highly significant correlation with both PCT and CRP levels was found. Technetium Tc 99m Dimercaptosuccinic Acid 99-103 C-reactive protein Homo sapiens 169-172 15345733-1 2004 BACKGROUND: The authors evaluated the effect of 3 doses (0.25 mg/day, 0.5 mg/day, and 1 mg/day) of micronized 17beta-estradiol (E2) on C-reactive protein (CRP), interleukin-6 (IL-6), and lipids, compared with placebo, in healthy older women participating in an osteoporosis study. Estradiol 110-126 C-reactive protein Homo sapiens 135-153 15345733-1 2004 BACKGROUND: The authors evaluated the effect of 3 doses (0.25 mg/day, 0.5 mg/day, and 1 mg/day) of micronized 17beta-estradiol (E2) on C-reactive protein (CRP), interleukin-6 (IL-6), and lipids, compared with placebo, in healthy older women participating in an osteoporosis study. Estradiol 110-126 C-reactive protein Homo sapiens 155-158 15262834-2 2004 METHODS AND RESULTS: We assessed the cross-sectional relations of CRP to the MetS (National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Adult Treatment Panel III definition) in 3037 subjects (1681 women; mean age, 54 years) and the utility of CRP and the MetS to predict new CVD events (n=189) over 7 years. Cholesterol 189-200 C-reactive protein Homo sapiens 66-69 15148294-7 2004 The proinflammatory, proatherogenic effects of CRP that have been documented in endothelial cells include the following: decreased nitric oxide and prostacyclin and increased endothelin-1, cell adhesion molecules, monocyte chemoattractant protein-1 and interleukin-8, and increased plasminogen activator inhibitor-1. Nitric Oxide 131-143 C-reactive protein Homo sapiens 47-50 15246889-6 2004 Rosiglitazone treatment significantly reduced C-reactive protein (median 0.56 mg/L [interquartile range 0.33 to 1.02] to 0.33 mg/L [interquartile range 0.26 to 0.40], p <0.01), von Willebrand factor (139 +/- 47 to 132 +/- 44 IU/dl, p = 0.02), insulin resistance index (p = 0.05), and mean low-density lipoprotein (LDL) density (p <0.001) compared with placebo. Rosiglitazone 0-13 C-reactive protein Homo sapiens 46-64 15208162-0 2004 Alcohol misuse increases serum antibodies to oxidized LDL and C-reactive protein. Alcohols 0-7 C-reactive protein Homo sapiens 62-80 15208162-1 2004 AIMS: To clarify the relationship of alcohol consumption with serum antibodies to oxidized low-density lipoprotein (oxLDL) and the inflammation marker C-reactive protein (CRP). Alcohols 37-44 C-reactive protein Homo sapiens 171-174 15220249-6 2004 RESULTS: At baseline, CRP concentration was a predictor of both glucose utilization and insulin sensitivity, independent of adiposity, race, and aerobic fitness (M: partial r = -0.30, P = 0.03, and M/I: partial r = -0.32, P = 0.02). Glucose 64-71 C-reactive protein Homo sapiens 22-25 15201242-8 2004 The change in coronary artery diameter induced by acetylcholine infusion was similar between the groups but the increase in CBF induced by acetylcholine was smaller in patients with increased CRP concentrations (54.9% v 139.4% with acetylcholine 30 microg/min, p = 0.0030). Acetylcholine 139-152 C-reactive protein Homo sapiens 192-195 15201242-8 2004 The change in coronary artery diameter induced by acetylcholine infusion was similar between the groups but the increase in CBF induced by acetylcholine was smaller in patients with increased CRP concentrations (54.9% v 139.4% with acetylcholine 30 microg/min, p = 0.0030). Acetylcholine 139-152 C-reactive protein Homo sapiens 192-195 15201242-9 2004 Multivariate analysis identified increased CRP concentration as independently associated with attenuated CBF response to acetylcholine at 30 microg/min (p = 0.0078, R2 = 0.434). Acetylcholine 121-134 C-reactive protein Homo sapiens 43-46 15148294-8 2004 In monocyte-macrophages, CRP induces tissue factor secretion, increases reactive oxygen species and proinflammatory cytokine release, promotes monocyte chemotaxis and adhesion, and increases oxidized low-density lipoprotein uptake. Reactive Oxygen Species 72-95 C-reactive protein Homo sapiens 25-28 15148294-9 2004 Also, CRP has been shown in vascular smooth muscle cells to increase inducible nitric oxide production, increase NFkappa(b) and mitogen-activated protein kinase activities, and, most importantly, upregulate angiotensin type-1 receptor resulting in increased reactive oxygen species and vascular smooth muscle cell proliferation. Nitric Oxide 79-91 C-reactive protein Homo sapiens 6-9 15148294-9 2004 Also, CRP has been shown in vascular smooth muscle cells to increase inducible nitric oxide production, increase NFkappa(b) and mitogen-activated protein kinase activities, and, most importantly, upregulate angiotensin type-1 receptor resulting in increased reactive oxygen species and vascular smooth muscle cell proliferation. Reactive Oxygen Species 258-281 C-reactive protein Homo sapiens 6-9 15250234-8 2004 Correlation (P<0.05) was found between H2O2 levels and CRP and WBC count (r = 0.31) at 1st day and between TBARs and CRP at 5th (r = 0.34) and 10th day (r = 0.46). Hydrogen Peroxide 42-46 C-reactive protein Homo sapiens 58-61 15250234-9 2004 The mean H2O2 exhalation estimated over ten days of treatment correlated with pneumonic chest X-ray score (r = 0.42), CRP levels (r = 0.46) and WBC count (r = 0.33) at admission (P<0.05). Hydrogen Peroxide 9-13 C-reactive protein Homo sapiens 118-121 15159225-6 2004 C-reactive protein concentrations were higher after consumption of the TFA diet than after consumption of the carbohydrate diet, but were not significantly different after consumption of the TFA and TFA+STE diets than after consumption of the LMP diet. Carbohydrates 110-122 C-reactive protein Homo sapiens 0-18 15615187-8 2004 Standard immunosuppressive therapy with cyclosporine A and prednisolone significantly suppresses the acute phase CRP reaction both in operation itself and acute rejection, but not in infection. Cyclosporine 40-54 C-reactive protein Homo sapiens 113-116 15615187-10 2004 Different reaction of SAA and CRP in transplant patients to cyclosporine A therapy helps in differentiation between the infection and rejection. Cyclosporine 60-74 C-reactive protein Homo sapiens 30-33 15142951-7 2004 Collagen or CRP-stimulated 12-H(P)ETE generation was inhibited by staurosporine, PP2, wortmannin, BAPTA/AM, EGTA, and L-655238, implicating src-tyrosine kinases, PI3-kinase, Ca2+ mobilization, and p12-LOX translocation. Egtazic Acid 108-112 C-reactive protein Homo sapiens 12-15 15184288-8 2004 Light-to-moderate alcohol consumers and nonusers of hormone replacement therapy (HRT) had lower CRP levels than abstainers and HRT users, respectively. Alcohols 18-25 C-reactive protein Homo sapiens 96-99 15184288-9 2004 In stepwise multiple regression analysis, CAF, triglycerides, apolipoprotein B, and HRT use explained 46% of the variance in circulating CRP. Triglycerides 47-60 C-reactive protein Homo sapiens 137-140 15181049-10 2004 Rosiglitazone treatment resulted in a reduction in plasma MCP-1 and CRP in both groups (P < 0.05). Rosiglitazone 0-13 C-reactive protein Homo sapiens 68-71 15154943-0 2004 Strong association of C-reactive protein with body mass index and 2-h post-challenge glucose in non-diabetic, non-smoker subjects without hypertension. Glucose 85-92 C-reactive protein Homo sapiens 22-40 15154943-7 2004 RESULTS: Plasma CRP levels were significantly higher in the 28 subjects with impaired glucose tolerance (IGT) than that in the 97 subjects with normal glucose tolerance (NGT) (median 0.53, range 0.18-1.10 mg/l vs. median 0.32, range 0.17-0.49 mg/l; P = 0.032). Glucose 86-93 C-reactive protein Homo sapiens 16-19 15154943-8 2004 There was a positive correlation of CRP with body mass index (BMI), triglycerides, uric acid, fasting glucose, oral glucose tolerance test (OGTT) 1-h glucose, OGTT 2-h glucose, and a negative correlation with HDL cholesterol. Triglycerides 68-81 C-reactive protein Homo sapiens 36-39 15154943-8 2004 There was a positive correlation of CRP with body mass index (BMI), triglycerides, uric acid, fasting glucose, oral glucose tolerance test (OGTT) 1-h glucose, OGTT 2-h glucose, and a negative correlation with HDL cholesterol. Glucose 102-109 C-reactive protein Homo sapiens 36-39 15154943-8 2004 There was a positive correlation of CRP with body mass index (BMI), triglycerides, uric acid, fasting glucose, oral glucose tolerance test (OGTT) 1-h glucose, OGTT 2-h glucose, and a negative correlation with HDL cholesterol. Glucose 116-123 C-reactive protein Homo sapiens 36-39 15154943-8 2004 There was a positive correlation of CRP with body mass index (BMI), triglycerides, uric acid, fasting glucose, oral glucose tolerance test (OGTT) 1-h glucose, OGTT 2-h glucose, and a negative correlation with HDL cholesterol. Glucose 116-123 C-reactive protein Homo sapiens 36-39 15154943-8 2004 There was a positive correlation of CRP with body mass index (BMI), triglycerides, uric acid, fasting glucose, oral glucose tolerance test (OGTT) 1-h glucose, OGTT 2-h glucose, and a negative correlation with HDL cholesterol. Cholesterol 213-224 C-reactive protein Homo sapiens 36-39 15154943-9 2004 Multivariate regression analysis identified BMI (F = 8.57, P = 0.004) and OGTT 2-h glucose (F = 5.96, P = 0.016) as independent predictors for CRP. Glucose 83-90 C-reactive protein Homo sapiens 143-146 15154943-10 2004 CONCLUSIONS: BMI and OGTT 2-h glucose are the most important predictors for plasma CRP in non-diabetic, non-smoker subjects without hypertension. Glucose 30-37 C-reactive protein Homo sapiens 83-86 15075346-1 2004 C-reactive protein (CRP) is a pattern-recognition molecule, which can bind to phosphorylcholine and certain phosphorylated carbohydrates found on the surface of a number of microorganisms. Carbohydrates 123-136 C-reactive protein Homo sapiens 20-23 15206152-4 2004 Hs CRP is increased in the subjects with low HDL-cholesterol and high triglyceride. Cholesterol 49-60 C-reactive protein Homo sapiens 3-6 15206152-4 2004 Hs CRP is increased in the subjects with low HDL-cholesterol and high triglyceride. Triglycerides 70-82 C-reactive protein Homo sapiens 3-6 15117839-9 2004 The association between leptin and CRP was significant even after adjustment for age, BMI, waist-to-hip ratio, smoking, and alcohol consumption in women (F=7.13, P=0.01) and men (F=5.69, P=0.02). Alcohols 124-131 C-reactive protein Homo sapiens 35-38 15173538-7 2004 Significant positive correlations were found between log CRP levels and AHI (r =.53) and arousal index (r =.28), whereas an inverse correlation was found between the lowest nocturnal arterial oxygen saturation and log CRP levels (r = -.47). Oxygen 192-198 C-reactive protein Homo sapiens 218-221 15312437-10 2004 Atorvastatin inhibited the function of DC and lowered blood level of CRP and CD86, the levels of which were significantly positively correlated. Atorvastatin 0-12 C-reactive protein Homo sapiens 69-72 15078800-8 2004 CONCLUSIONS: The CRP-induced upregulation of inflammatory adhesion molecules in HUVECs was completely prevented by HDL via their oxidized phospholipid components. Phospholipids 138-150 C-reactive protein Homo sapiens 17-20 15078802-9 2004 However, all of these detrimental CRP-mediated effects on EPCs were attenuated by pretreatment with rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist. Rosiglitazone 100-113 C-reactive protein Homo sapiens 34-37 15078802-12 2004 The PPARgamma agonist rosiglitazone inhibits the negative effects of CRP on EPC biology. Rosiglitazone 22-35 C-reactive protein Homo sapiens 69-72 15047035-10 2004 CONCLUSION: These findings suggest that carvedilol inhibits oxidative stress in polymorphonuclear and mononuclear cells, as well as lowers C-reactive protein levels, to a greater extent than does propranolol in hypertensive patients. Carvedilol 40-50 C-reactive protein Homo sapiens 139-157 15136366-8 2004 CONCLUSION: Patients recovering from ACS had lower levels of CRP and IL-6 at 1 month and lower CRP levels at 3 months when treated with rofecoxib plus aspirin. Aspirin 151-158 C-reactive protein Homo sapiens 95-98 14993913-9 2004 Stepwise multivariate linear regression analysis identified BMI, triglyceride levels, HDL cholesterol levels (inversely), and fasting glucose as independently related to CRP levels. Triglycerides 65-77 C-reactive protein Homo sapiens 170-173 14993913-9 2004 Stepwise multivariate linear regression analysis identified BMI, triglyceride levels, HDL cholesterol levels (inversely), and fasting glucose as independently related to CRP levels. Cholesterol 90-101 C-reactive protein Homo sapiens 170-173 14993913-9 2004 Stepwise multivariate linear regression analysis identified BMI, triglyceride levels, HDL cholesterol levels (inversely), and fasting glucose as independently related to CRP levels. Glucose 134-141 C-reactive protein Homo sapiens 170-173 15113967-7 2004 Our findings indicate that fiber intake is independently associated with serum CRP concentration and support the recommendation of a diet with a high fiber content. Dietary Fiber 27-32 C-reactive protein Homo sapiens 79-82 15518420-13 2004 On the basis of the conducted research and statistic calculations it is justified to point the correlation between the concentration of C-reactive protein and HDL cholesterol in the group of patients with the detected Chlamydia bacteria in comparison to the group of patients with no infection. Cholesterol 163-174 C-reactive protein Homo sapiens 136-154 14686876-9 2004 This analysis demonstrated that both sPLA(2) ( P <0.05) and CRP serum levels ( P <0.05) were the only significant independent predictors of an impaired acetylcholine-induced FBF response. Acetylcholine 158-171 C-reactive protein Homo sapiens 63-66 15853546-6 2004 C-reactive protein is readily amenable to treatment with anti-inflammatory drugs, such as aspirin and statins. Aspirin 90-97 C-reactive protein Homo sapiens 0-18 15042565-6 2004 Serum creatinine level decreased, and C-reactive protein turned negative after steroid therapy. Steroids 79-86 C-reactive protein Homo sapiens 38-56 15050501-1 2004 This study shows that elevated high-sensitivity C-reactive protein and plasma total homocysteine contribute independently to the likelihood of an increased urinary albumin:creatinine ratio. Creatinine 172-182 C-reactive protein Homo sapiens 48-66 15047035-9 2004 Carvedilol decreased C-reactive protein levels significantly by a median of 0.073 mg/dL (interquartile range, 0.034 to 0.112 mg/dL; P <0.001), whereas propranolol decreased levels by 0.012 mg/dL (interquartile range, 0.009 to 0.032 mg/dL; P = 0.26; P = 0.003 for difference between treatments). Carvedilol 0-10 C-reactive protein Homo sapiens 21-39 14996776-10 2004 C-reactive protein decreased 5.2% with pravastatin and 36.4% with atorvastatin (P<.001). Atorvastatin 66-78 C-reactive protein Homo sapiens 0-18 15640880-5 2004 The CRP and AGP levels were higher in DM1 patients as compared to controls, respectively [0.23 (0.01-2.90) vs. 0.14 (0.01-2.41) mg/dl, p= 0.0172& and [53.5 (37-115) vs. 40 (19-78) mg/dl, p< 0.0001]. Adenosine Monophosphate 145-148 C-reactive protein Homo sapiens 4-7 14963702-8 2004 Post-treatment C-reactive protein in the DEX group (median 0.9 mg/dl, range 0.0 to 24.7 mg/dl) was lower than that (1.2 mg/dl, range 0.2 to 19.5 mg/dl) in the CONTROL group ( P=0.033 by Mann-Whitney U test). Dexamethasone 41-44 C-reactive protein Homo sapiens 15-33 15242238-6 2004 CRP levels were associated with total and regional body fat, the anthropometric index of weight, age, and with some metabolic alterations (HDL-cholesterol and triglyceride levels, systolic blood pressure, and fasting insulin and LDL-cholesterol levels). Cholesterol 143-154 C-reactive protein Homo sapiens 0-3 15242238-6 2004 CRP levels were associated with total and regional body fat, the anthropometric index of weight, age, and with some metabolic alterations (HDL-cholesterol and triglyceride levels, systolic blood pressure, and fasting insulin and LDL-cholesterol levels). Triglycerides 159-171 C-reactive protein Homo sapiens 0-3 15242238-6 2004 CRP levels were associated with total and regional body fat, the anthropometric index of weight, age, and with some metabolic alterations (HDL-cholesterol and triglyceride levels, systolic blood pressure, and fasting insulin and LDL-cholesterol levels). Cholesterol 233-244 C-reactive protein Homo sapiens 0-3 15019895-0 2004 Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. Aspirin 80-87 C-reactive protein Homo sapiens 91-109 14981605-0 2004 Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Atorvastatin 5-17 C-reactive protein Homo sapiens 34-52 15177126-6 2004 The relation of alcohol use and CRP levels was significantly modified by apoE genotype (P interaction 0.03), with a positive association among participants with an apoE4 allele (P = 0.05), but a trend toward an inverse association among those without an apoE4 allele (P = 0.15). Alcohols 16-23 C-reactive protein Homo sapiens 32-35 14981605-3 2004 METHODS: We designed a 6-month, prospective, randomized, controlled study to assess the safety and efficacy of atorvastatin in reducing serum CRP levels in long-term HD patients. Atorvastatin 111-123 C-reactive protein Homo sapiens 142-145 14981605-14 2004 CONCLUSION: Administration of atorvastatin is safe in patients on long-term HD therapy and, in addition to its beneficial effects on lipid levels, induces a significant decrease in serum CRP levels, with a consequential increase in serum albumin levels. Atorvastatin 30-42 C-reactive protein Homo sapiens 187-190 14996579-2 2004 Oxidative stress of lipids induced by iron may play a role in vascular inflammation, as indicated by CRP. Iron 38-42 C-reactive protein Homo sapiens 101-104 14983228-1 2004 The biphasic waveform that can predict for disseminated intravascular coagulation (DIC) is due to the formation of a calcium-dependent complex between C reactive protein (CRP) and very low density lipoprotein (VLDL). Calcium 117-124 C-reactive protein Homo sapiens 151-169 14709450-9 2004 In addition, significant and independent associations existed between CRP and waist circumference, total cholesterol and triglyceride concentrations, and systolic blood pressure but not age, smoking status, alcohol use, insulin concentration, glycated hemoglobin, and c-peptide concentration. Triglycerides 121-133 C-reactive protein Homo sapiens 70-73 14983228-1 2004 The biphasic waveform that can predict for disseminated intravascular coagulation (DIC) is due to the formation of a calcium-dependent complex between C reactive protein (CRP) and very low density lipoprotein (VLDL). Calcium 117-124 C-reactive protein Homo sapiens 171-174 15019545-11 2004 Both responses to acetylcholine and C-RP levels demonstrated a significant association with participant status with the r value increasing from 0.405 for responses to acetylcholine to 0.491 for the combination of responses to acetylcholine and C-RP. Acetylcholine 18-31 C-reactive protein Homo sapiens 244-248 14769682-6 2004 After adjustment for age, race, smoking status, history of diabetes, history of cardiovascular disease, physical activity, high-density lipoprotein cholesterol, antiinflammatory medications, statins, and total fat mass, alcohol intake showed a J-shaped relationship with mean IL-6 (P for quadratic term <0.001) and CRP (P=0.014) levels. Alcohols 220-227 C-reactive protein Homo sapiens 318-321 14769682-10 2004 CONCLUSIONS: In well-functioning older persons, light alcohol consumption is associated with lower levels of IL-6 and CRP. Alcohols 54-61 C-reactive protein Homo sapiens 118-121 14759393-2 2004 Compared with those receiving placebo, patients in the rosiglitazone group achieved significant reductions in fasting plasma insulin levels (-40%), homeostasis model assessment indexes (-45%), systolic and diastolic blood pressures, and high-sensitivity C-reactive protein levels (-31%). Rosiglitazone 55-68 C-reactive protein Homo sapiens 254-272 15019545-11 2004 Both responses to acetylcholine and C-RP levels demonstrated a significant association with participant status with the r value increasing from 0.405 for responses to acetylcholine to 0.491 for the combination of responses to acetylcholine and C-RP. Acetylcholine 167-180 C-reactive protein Homo sapiens 36-40 15019545-11 2004 Both responses to acetylcholine and C-RP levels demonstrated a significant association with participant status with the r value increasing from 0.405 for responses to acetylcholine to 0.491 for the combination of responses to acetylcholine and C-RP. Acetylcholine 167-180 C-reactive protein Homo sapiens 36-40 15019545-12 2004 We conclude that there is an inverse correlation between C-reactive protein, but not protein S, VCAM-1, P-selectin nor von Willebrand factor, levels and abnormal endothelium-dependent vasodilation and further that responses to acetylcholine together with C-RP protein have a strong association with cardiovascular risk and disease. Acetylcholine 227-240 C-reactive protein Homo sapiens 57-75 14709365-6 2004 A stepwise multiple regression model found CRP directly correlated with BMI (P<0.01) and serum creatinine (P<0.01), and inversely correlated with PLP (P<0.01). Creatinine 98-108 C-reactive protein Homo sapiens 43-46 14751958-0 2004 Raised concentrations of C reactive protein in anabolic steroid using bodybuilders. Steroids 56-63 C-reactive protein Homo sapiens 25-43 14751958-1 2004 OBJECTIVE: To examine levels of C reactive protein in users of anabolic androgenic steroids (AAS) compared with age matched control groups consisting of AAS using (but abstinent)/resistance trained and non-drug using/sedentary controls. Steroids 83-91 C-reactive protein Homo sapiens 32-50 14742654-4 2004 In multivariate regression models controlling for age, cigarette smoking, alcohol intake, physical activity, and aspirin intake, self-reported periodontal disease was associated with significantly higher levels of CRP (30% higher among periodontal cases compared with non-cases), t-PA (11% higher), and LDL-C (11% higher). Aspirin 113-120 C-reactive protein Homo sapiens 214-217 15648796-16 2004 The normalization of CRP was seen during the first 3 to 4 weeks of etidronate therapy, indicating a resolution of acute-phase inflammatory reaction. Etidronic Acid 67-77 C-reactive protein Homo sapiens 21-24 14592848-9 2004 Furthermore, results showed that the stimulation of MMP-1 secretion by CRP was inhibited by anti-CD32, but not by anti-CD64 antibody, and by mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK) inhibitor PD98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 228-235 C-reactive protein Homo sapiens 71-74 15334028-8 2004 The level of C-reactive protein increased on the second day after withdrawal of statin therapy (2,590.14 +/- 1,045.05 vs. 1,257.95 +/- 207.99 ng/ml); however, the total cholesterol and LDL-chol did not increase during the 3-day period after withdrawal of statin therapy. Cholesterol 169-180 C-reactive protein Homo sapiens 13-31 14706052-0 2004 Association between fasting glucose and C-reactive protein in middle-aged subjects. Glucose 28-35 C-reactive protein Homo sapiens 40-58 14706052-4 2004 METHODS: We studied the relation of high-sensitivity CRP to fasting glucose and other components of the metabolic syndrome in a population-based cross-sectional study (n = 1000; age 50 +/- 9 years). Glucose 68-75 C-reactive protein Homo sapiens 53-56 14706052-5 2004 RESULTS: Plasma CRP levels increased continuously from the lowest quartile of normal fasting glucose level to impaired fasting glucose and to diabetes (ln CRP 0.47 +/- 0.09, 0.95 +/- 0.12, and 1.11 +/- 0.13, respectively; Ptrend < 0.0001). Glucose 93-100 C-reactive protein Homo sapiens 16-19 14706052-6 2004 Increasing CRP with higher fasting glucose levels was apparent even among subjects with fasting glucose in the normal range (Ptrend = 0.039), and subjects with fasting glucose level in the upper quartile of normal fasting glucose had higher CRP levels compared with subjects in the lower quartile (P = 0.035). Glucose 35-42 C-reactive protein Homo sapiens 11-14 14706052-6 2004 Increasing CRP with higher fasting glucose levels was apparent even among subjects with fasting glucose in the normal range (Ptrend = 0.039), and subjects with fasting glucose level in the upper quartile of normal fasting glucose had higher CRP levels compared with subjects in the lower quartile (P = 0.035). Glucose 96-103 C-reactive protein Homo sapiens 11-14 14706052-6 2004 Increasing CRP with higher fasting glucose levels was apparent even among subjects with fasting glucose in the normal range (Ptrend = 0.039), and subjects with fasting glucose level in the upper quartile of normal fasting glucose had higher CRP levels compared with subjects in the lower quartile (P = 0.035). Glucose 96-103 C-reactive protein Homo sapiens 11-14 14706052-6 2004 Increasing CRP with higher fasting glucose levels was apparent even among subjects with fasting glucose in the normal range (Ptrend = 0.039), and subjects with fasting glucose level in the upper quartile of normal fasting glucose had higher CRP levels compared with subjects in the lower quartile (P = 0.035). Glucose 96-103 C-reactive protein Homo sapiens 11-14 14706052-7 2004 There was a positive crude correlation between CRP and smoking, post-menopausal hormone use, body mass index, fasting glucose, triglycerides, hypertension, and uric acid (r = 0.11-0.36, P = 0.002-0.0001). Glucose 118-125 C-reactive protein Homo sapiens 47-50 14706052-7 2004 There was a positive crude correlation between CRP and smoking, post-menopausal hormone use, body mass index, fasting glucose, triglycerides, hypertension, and uric acid (r = 0.11-0.36, P = 0.002-0.0001). Triglycerides 127-140 C-reactive protein Homo sapiens 47-50 14706052-8 2004 A negative correlation was found between CRP and HDL-cholesterol (r = 0.12, P < 0.0001) and physical activity (r = 0.11, P = 0.002). Cholesterol 53-64 C-reactive protein Homo sapiens 41-44 14706052-9 2004 After adjustment for potential confounders in a stepwise multivariate linear regression model, fasting glucose remained significantly and independently related to CRP levels (correlation coefficient 0.06; 95% confidence interval 0.014-0.11, P = 0.011). Glucose 103-110 C-reactive protein Homo sapiens 163-166 14706052-10 2004 CONCLUSIONS: Fasting glucose is significantly and positively associated with plasma CRP in middle-aged subjects. Glucose 21-28 C-reactive protein Homo sapiens 84-87 14706052-11 2004 CRP levels increase continuously across the spectrum of fasting glucose, beginning in the lowest quartile of normal fasting glucose. Glucose 64-71 C-reactive protein Homo sapiens 0-3 14706052-11 2004 CRP levels increase continuously across the spectrum of fasting glucose, beginning in the lowest quartile of normal fasting glucose. Glucose 124-131 C-reactive protein Homo sapiens 0-3 15151266-13 2004 In patients with elevated CRP levels, it is very difficult to reach target iron status levels without exceeding the upper limits for serum ferritin. Iron 75-79 C-reactive protein Homo sapiens 26-29 15340345-8 2004 Platelet aggregation decreased only in atorvastatin 40 mg/day group (p<0.05) and CRP decreased in combined atorvastatin group (p<0.05). Atorvastatin 110-122 C-reactive protein Homo sapiens 84-87 15521602-5 2004 In the above mentioned groups, alcohol and CNS acting agents increased CRP values in over 33% of the patients, whereas in the case of patients under the influence of cardiac drugs or carbon monoxide, the same effect was observed in more than 16% of the cases. Alcohols 31-38 C-reactive protein Homo sapiens 71-74 15236798-3 2004 Strategies for decreasing elevated CRP include administration of statins, thiazolidinediones, and metformin; moderate alcohol consumption and appropriate weight loss are also helpful in this regard. Metformin 98-107 C-reactive protein Homo sapiens 35-38 15236798-5 2004 A recent study shows that nitric oxide suppresses the activation of Stat3 by interleukin-6 in hepatocytes; Stat3 is crucial for the IL-6-mediated induction of CRP and various other acute phase reactants. Nitric Oxide 26-38 C-reactive protein Homo sapiens 159-162 15236798-6 2004 Thus, it is proposed that metformin--or AMPK---inhibits hepatic CRP production by boosting hepatic nitric oxide synthesis, which in turn impedes Stat3 activation and CRP transcription. Metformin 26-35 C-reactive protein Homo sapiens 64-67 15236798-6 2004 Thus, it is proposed that metformin--or AMPK---inhibits hepatic CRP production by boosting hepatic nitric oxide synthesis, which in turn impedes Stat3 activation and CRP transcription. Metformin 26-35 C-reactive protein Homo sapiens 166-169 15236798-6 2004 Thus, it is proposed that metformin--or AMPK---inhibits hepatic CRP production by boosting hepatic nitric oxide synthesis, which in turn impedes Stat3 activation and CRP transcription. Nitric Oxide 99-111 C-reactive protein Homo sapiens 64-67 14671049-8 2004 Both unadjusted and multivariate adjusted correlation coefficients (r) for serum ferritin and CRP vs pertinent values were statistically significant for DMS and MIS and some other measures of nutritional status and iron indices. Iron 215-219 C-reactive protein Homo sapiens 94-97 14638413-7 2003 The Crp-Fnr regulators stand out in responding to a broad spectrum of intracellular and exogenous signals such as cAMP, anoxia, the redox state, oxidative and nitrosative stress, nitric oxide, carbon monoxide, 2-oxoglutarate, or temperature. Cyclic AMP 114-118 C-reactive protein Homo sapiens 4-7 14636905-8 2003 High-sensitivity C-reactive protein median values were reduced by 33% to 34% in both the 80-mg rosuvastatin- and atorvastatin-treated groups. Atorvastatin 113-125 C-reactive protein Homo sapiens 17-35 14641004-4 2003 After categorisation by tertiles and adjusting for age and body mass index, total and free testosterone and SHBG were inversely associated with concentrations of insulin, glucose, triglycerides, C-reactive protein (CRP) and CRP-adjusted ferritin and positively associated with high-density lipoprotein cholesterol. Testosterone 91-103 C-reactive protein Homo sapiens 195-213 14641004-4 2003 After categorisation by tertiles and adjusting for age and body mass index, total and free testosterone and SHBG were inversely associated with concentrations of insulin, glucose, triglycerides, C-reactive protein (CRP) and CRP-adjusted ferritin and positively associated with high-density lipoprotein cholesterol. Testosterone 91-103 C-reactive protein Homo sapiens 215-218 14641004-4 2003 After categorisation by tertiles and adjusting for age and body mass index, total and free testosterone and SHBG were inversely associated with concentrations of insulin, glucose, triglycerides, C-reactive protein (CRP) and CRP-adjusted ferritin and positively associated with high-density lipoprotein cholesterol. Testosterone 91-103 C-reactive protein Homo sapiens 224-227 14655192-8 2003 Similarly, creatinine level correlated with both enPCR and CRP level. Creatinine 11-21 C-reactive protein Homo sapiens 59-62 14655192-12 2003 CONCLUSION: Albumin and creatinine levels are independently associated with nutrition (enPCR) and inflammation (CRP level). Creatinine 24-34 C-reactive protein Homo sapiens 112-115 14655192-14 2003 CRP level is associated with reduced albumin and creatinine values when increased to values greater than 5.6 mg/dL. Creatinine 49-59 C-reactive protein Homo sapiens 0-3 14638413-7 2003 The Crp-Fnr regulators stand out in responding to a broad spectrum of intracellular and exogenous signals such as cAMP, anoxia, the redox state, oxidative and nitrosative stress, nitric oxide, carbon monoxide, 2-oxoglutarate, or temperature. Nitric Oxide 179-191 C-reactive protein Homo sapiens 4-7 14642684-8 2003 RESULTS: Rosiglitazone treatment resulted in a significant reduction in E-selectin (p = 0.03), von Willebrand factor (p = 0.007), C-reactive protein (p < 0.001), fibrinogen (p = 0.003) and the homeostasis model of insulin resistance index (p = 0.02), compared with placebo. Rosiglitazone 9-22 C-reactive protein Homo sapiens 130-148 14974819-8 2003 RESULTS: CPI scores of 3 and 4 were related to the test values of high-density-lipoprotein cholesterol, serum iron, white blood cell count, fasting blood sugar, glycosylated hemoglobin A1, glycosylated hemoglobin A1c, and C-reactive protein. methyl 2-isocyano-2-methylpropanoate 9-12 C-reactive protein Homo sapiens 222-240 14669152-8 2003 Gender significantly interacted with WC to predict CRP after adjusting for age, smoking status, alcohol, and BMI (P <.05). Alcohols 96-103 C-reactive protein Homo sapiens 51-54 12842985-5 2003 Tyrosine phosphorylation of PLC gamma 2 by collagen and CRP is not altered in Tec-/- platelets. Tyrosine 0-8 C-reactive protein Homo sapiens 56-59 14642684-10 2003 Within the rosiglitazone-treated group, reductions in C-reactive protein and von Willebrand factor were significantly correlated with a reduction in insulin resistance. Rosiglitazone 11-24 C-reactive protein Homo sapiens 54-72 14578725-12 2003 Dexamethasone significantly reduced postoperative levels of CRP (P = 0.01), fatigue (P = 0.01), overall pain, and incisional pain during the first 24 postoperative hours (P < 0.05) and total requirements of opioids (P < 0.05). Dexamethasone 0-13 C-reactive protein Homo sapiens 60-63 14609606-1 2003 C-reactive protein levels may identify patients likely to benefit from lowering low-density lipoprotein (LDL) cholesterol to ultra-low levels. Cholesterol 110-121 C-reactive protein Homo sapiens 0-18 14609606-2 2003 We find that above-average C-reactive protein with statin therapy predicts failure of carotid intima-media thickness regression in those with currently defined optimal LDL cholesterol (<100 mg/dl) but not if LDL cholesterol is <70 mg/dl. Cholesterol 172-183 C-reactive protein Homo sapiens 27-45 14609606-2 2003 We find that above-average C-reactive protein with statin therapy predicts failure of carotid intima-media thickness regression in those with currently defined optimal LDL cholesterol (<100 mg/dl) but not if LDL cholesterol is <70 mg/dl. Cholesterol 215-226 C-reactive protein Homo sapiens 27-45 14525675-4 2003 Interventions that alter insulin resistance, such as weight loss, exercise, and conjugated linoleic acid, also alter CRP. Linoleic Acid 91-104 C-reactive protein Homo sapiens 117-120 14525675-7 2003 Alcohol lowers CRP, but the mechanism is unknown. Alcohols 0-7 C-reactive protein Homo sapiens 15-18 14743546-7 2003 Using a limit of 0.6 mg/L (75th percentile), significantly lower levels were observed for transthyretin, iron, retinol, and beta-carotene in the group with the higher CRP levels. Iron 105-109 C-reactive protein Homo sapiens 167-170 14714503-6 2003 As shown by intermolecular crosslinking, the solution also contained the 241-kDa decamer of C-reactive protein (9.5S) as a separate macroscopic form, whose share hardly reached 10% in the presence of 2 mM Ca2+ and increased after removal of calcium ions. Calcium 241-248 C-reactive protein Homo sapiens 92-110 14531779-7 2003 Enrollment level of CRP was inversely correlated with nutritional markers prealbumin (r = -0.5, P < 0.0001) and creatinine (r =-0.35, P < 0.01). Creatinine 115-125 C-reactive protein Homo sapiens 20-23 14579939-7 2003 In Group B patients, the annual change of creatinine clearance correlated inversely with the mean CRP concentration (r = -0.682, p < 0.01). Creatinine 42-52 C-reactive protein Homo sapiens 98-101 14520627-6 2003 The MIS and serum concentrations of high-sensitivity C-reactive protein, interleukin 6 (IL-6), tumor necrosis factor-alpha, and lactate dehydrogenase had positive correlation with required EPO dose and EPO responsiveness index (EPO divided by hemoglobin), whereas serum total iron binding capacity (TIBC), prealbumin and total cholesterol, as well as blood lymphocyte count had statistically significant but negative correlations with indices of refractory anemia. Iron 276-280 C-reactive protein Homo sapiens 53-71 14520627-6 2003 The MIS and serum concentrations of high-sensitivity C-reactive protein, interleukin 6 (IL-6), tumor necrosis factor-alpha, and lactate dehydrogenase had positive correlation with required EPO dose and EPO responsiveness index (EPO divided by hemoglobin), whereas serum total iron binding capacity (TIBC), prealbumin and total cholesterol, as well as blood lymphocyte count had statistically significant but negative correlations with indices of refractory anemia. Cholesterol 327-338 C-reactive protein Homo sapiens 53-71 14504187-10 2003 By increasing both superoxide and inducible NO synthase, CRP resulted in increased nitration of PGIS by peroxynitrite. Superoxides 19-29 C-reactive protein Homo sapiens 57-60 14663297-6 2003 RESULTS: Multivariate analysis, after controlling for several potential confounders, revealed a J-shaped association between alcohol intake (none, 1-2, 3-4, 5+ wine glasses/day) and uric acid, C-reactive protein, homocysteine, fibrinogen, triglycerides, apolipoproteins A1 and B, HDL and total cholesterols, blood glucose levels, leucocyte count and arterial blood pressure levels (only in males). Alcohols 125-132 C-reactive protein Homo sapiens 193-278 14508189-7 2003 CRP was also directly associated with body mass index (r = 0.25, P < 0.01), serum low-density lipoprotein cholesterol (r = 0.21, P = 0.03) and serum triglycerides (r = 0.21, P = 0.03). Triglycerides 152-165 C-reactive protein Homo sapiens 0-3 14557432-13 2003 The fall in CRP and IL-6 was more pronounced with the high- than low-dose vitamin D (P < 0.05). Vitamin D 74-83 C-reactive protein Homo sapiens 12-15 14557435-0 2003 Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. Metformin 0-9 C-reactive protein Homo sapiens 24-42 14557435-2 2003 Because the insulin sensitizer metformin has been shown to improve metabolic disturbances in PCOS, it was of particular interest to examine serum CRP levels during metformin therapy. Metformin 164-173 C-reactive protein Homo sapiens 146-149 14557435-5 2003 During metformin treatment, serum CRP levels decreased significantly from 3.08 +/- 0.7 mg/liter to 1.52 +/- 0.26 mg/liter at 6 months in the whole study population (P = 0.006) and especially in obese subjects. Metformin 7-16 C-reactive protein Homo sapiens 34-37 14557435-8 2003 The decrease of serum CRP levels during metformin therapy is in accordance with the known beneficial metabolic effects of this drug and suggests that CRP or other inflammation parameters could be used as markers of treatment efficiency in women with PCOS. Metformin 40-49 C-reactive protein Homo sapiens 22-25 14557435-8 2003 The decrease of serum CRP levels during metformin therapy is in accordance with the known beneficial metabolic effects of this drug and suggests that CRP or other inflammation parameters could be used as markers of treatment efficiency in women with PCOS. Metformin 40-49 C-reactive protein Homo sapiens 150-153 14669391-1 2003 UNLABELLED: The main markers of intrauterine infection: C-reactive protein and white blood cell count are dependent on medical management as steroids or antibiotics therapy. Steroids 141-149 C-reactive protein Homo sapiens 56-74 14502100-5 2003 Metformin has a weight neutral/weight lowering effect and reduces hypertriglyceridaemia, elevated levels of PAI-1, factor VII and C-reactive protein. Metformin 0-9 C-reactive protein Homo sapiens 130-148 12925465-4 2003 In univariate analyses, significant associations were observed between C-reactive protein concentration--measured with a high-sensitivity assay--and age, body mass index, systolic blood pressure, and triglyceride concentrations in both sexes. Triglycerides 200-212 C-reactive protein Homo sapiens 71-89 12943889-0 2003 Relation of albumin/creatinine ratio to C-reactive protein and to the metabolic syndrome. Creatinine 20-30 C-reactive protein Homo sapiens 40-58 12925055-7 2003 RESULTS: CRP decreased significantly in the atorvastatin-treated group compared with the placebo group (percent change respect initial values; -42.3 %[-21.5 to - 63.1] and -9.6%[15.0 to -34.0], respectively, p<0.01). Atorvastatin 44-56 C-reactive protein Homo sapiens 9-12 14521597-0 2003 Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women. Tamoxifen 10-19 C-reactive protein Homo sapiens 51-69 14521597-4 2003 To provide further insight into the effect of tamoxifen at low doses on the cardiovascular system, we compared the effect of three different doses on circulating levels of C-reactive protein (CRP), an independent risk marker for cardiovascular disease (CVD), which was lowered by tamoxifen at the standard dose of 20 mg day-1 in previous studies. Tamoxifen 280-289 C-reactive protein Homo sapiens 172-190 14521597-4 2003 To provide further insight into the effect of tamoxifen at low doses on the cardiovascular system, we compared the effect of three different doses on circulating levels of C-reactive protein (CRP), an independent risk marker for cardiovascular disease (CVD), which was lowered by tamoxifen at the standard dose of 20 mg day-1 in previous studies. Tamoxifen 280-289 C-reactive protein Homo sapiens 192-195 14521597-8 2003 We conclude that tamoxifen at low doses is able to lower ultrasensitive CRP and that this might be associated with a beneficial effect on CVD. Tamoxifen 17-26 C-reactive protein Homo sapiens 72-75 14522018-7 2003 Depletion of Rel proteins from Hep3B nuclei led to decreased formation of C/EBPbeta-complexes on a CRP promoter-derived oligonucleotide that contained only the intact C/EBP binding site but not the nonconsensus kappaB site. Oligonucleotides 120-135 C-reactive protein Homo sapiens 99-102 12975259-8 2003 Reductions in CRP and SAA were observed in patients with unstable angina and non-Q-wave myocardial infarction, with initial LDL cholesterol <3.2 or > or =3.2 mmol/L (125 mg/dL), age > or =65 or <65 years, and in men and women. Cholesterol 128-139 C-reactive protein Homo sapiens 14-17 12975259-9 2003 By 16 weeks, CRP was 34% lower with atorvastatin than with placebo. Atorvastatin 36-48 C-reactive protein Homo sapiens 13-16 12955709-9 2003 Intravenous steroid pulse therapy followed by oral prednisolone (PSL) was effective for reducing the fever, eosinophilia, anti-GBM antibody titer, and C-reactive protein level, but did not improve renal function because renal tissue already was irreversibly damaged. Steroids 12-19 C-reactive protein Homo sapiens 151-169 12947436-5 2003 RESULTS: C-reactive protein concentration (dichotomized at the sex-specific 85th percentile) was inversely and significantly associated with concentrations of retinol, retinyl esters, vitamin C, alpha-carotene, beta-carotene, cryptoxanthin, lutein/zeaxanthin, lycopene, and selenium after adjustment for age, sex, race or ethnicity, education, cotinine concentration, body mass index, leisure-time physical activity, and aspirin use. Aspirin 421-428 C-reactive protein Homo sapiens 9-27 12915501-6 2003 Based on the authors" estimates, three serial determinations of C-reactive protein should be done to achieve a reliability of 0.75, the value they found for total cholesterol. Cholesterol 163-174 C-reactive protein Homo sapiens 64-82 14506615-5 2003 CRP showed a strong and negative association with high-density lipoprotein (HDL)-cholesterol (r = -0.26, P =.0005) and a marginal and positive association with triglyceride (r = 0.14, P =.05). Cholesterol 81-92 C-reactive protein Homo sapiens 0-3 14506615-5 2003 CRP showed a strong and negative association with high-density lipoprotein (HDL)-cholesterol (r = -0.26, P =.0005) and a marginal and positive association with triglyceride (r = 0.14, P =.05). Triglycerides 160-172 C-reactive protein Homo sapiens 0-3 14506615-7 2003 Multiple regression analysis indicated that serum CRP was positively related to serum leptin (P =.003) and QTc interval (P =.01), and negatively correlated with HDL-cholesterol (P =.01, R(2) = 0.15). Cholesterol 165-176 C-reactive protein Homo sapiens 50-53 12957323-6 2003 The Insulin Resistance Atherosclerosis Study found that insulin resistance, as determined by a frequently sampled glucose tolerance test, is significantly related to higher CRP levels, higher fibrinogen, and higher plasminogen activator inhibitor-1 (PAI-1) levels. Glucose 114-121 C-reactive protein Homo sapiens 173-176 12957323-10 2003 Rosiglitazone, an agent with insulin-sensitizing properties, decreases PAI-1 and CRP levels. Rosiglitazone 0-13 C-reactive protein Homo sapiens 81-84 12953165-0 2003 Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia. Atorvastatin 116-128 C-reactive protein Homo sapiens 67-85 12948037-12 2003 So, not in patients with simply AVS but in patients under higher cardiovascular risks, investigation of CRP plus lipid levels might provide benefit with respect to preventive treatment and benefit from cholesterol-lowering drugs can be expected in such kind of patients. Cholesterol 202-213 C-reactive protein Homo sapiens 104-107 12921979-6 2003 CRP correlated significantly to other CHD risk factors like body mass index (BMI), systolic blood pressure, diastolic blood pressure, plasma fibrinogen, serum high-density lipoprotein cholesterol, plasma homocysteine, and serum triglycerides. Triglycerides 228-241 C-reactive protein Homo sapiens 0-3 12805076-7 2003 In addition, CRP was frequently colocalized with p22phox, an essential component of NADH/NADPH oxidase, which is an important source of ROS in vasculature. Reactive Oxygen Species 136-139 C-reactive protein Homo sapiens 13-16 12805076-8 2003 Moreover, the incubation of cultured CASMCs with CRP resulted in the enhanced p22phox protein expression and in the generation of intracellular ROS. casmcs 37-43 C-reactive protein Homo sapiens 49-52 12805076-8 2003 Moreover, the incubation of cultured CASMCs with CRP resulted in the enhanced p22phox protein expression and in the generation of intracellular ROS. Reactive Oxygen Species 144-147 C-reactive protein Homo sapiens 49-52 12805076-9 2003 CONCLUSIONS: The expression of CRP in coronary arteries was associated with histological and clinical features of vulnerable plaque, and it had a prooxidative effect on cultured CASMCs, suggesting that it might play a crucial role in plaque instability and in the pathogenesis of acute coronary syndrome via its prooxidative effect. casmcs 178-184 C-reactive protein Homo sapiens 31-34 12831831-4 2003 CRP concentration was greater in lower compared with higher SES participants (1.18+/-0.75 vs. 0.75+/-0.8 mg/l,p=.002) independently of sex, age, body mass, waist/hip ratio, smoking, alcohol, and season of the year. Alcohols 182-189 C-reactive protein Homo sapiens 0-3 12953165-2 2003 The aim of this study was to investigate the effects of three months of treatment with low dose atorvastatin on serum levels of adhesion molecules, interleukin-6 (IL-6) and highly sensitive C-reactive protein (hs-CRP) in patients with non-familial hypercholesterolemia. Atorvastatin 96-108 C-reactive protein Homo sapiens 190-208 12915627-7 2003 CRP was significantly correlated with prepregnancy BMI (r = 0.38, P < 0.0001), followed by fasting insulin (r = 0.27, P = 0.0002) and fasting blood glucose (r = 0.18, P = 0.016). Glucose 151-158 C-reactive protein Homo sapiens 0-3 12835213-3 2003 Among men and women not using hormone replacement therapy (HRT), CRP levels were significantly related to 10-year Framingham Coronary Heart Disease Risk categories [total cholesterol (TC) score for men and women: r=0.29 and r=0.22, respectively; LDL cholesterol score for men and women: r=0.29 and r=0.22, respectively, all probability values <0.01]. Cholesterol 171-182 C-reactive protein Homo sapiens 65-68 14651593-7 2003 There was a significant inverse correlation between DHEA-S and IL-6, TNF-alpha, and CRP concentrations. Dehydroepiandrosterone Sulfate 52-58 C-reactive protein Homo sapiens 84-87 12876093-0 2003 Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. Cholesterol 34-45 C-reactive protein Homo sapiens 95-113 12887727-1 2003 C-reactive protein (CRP) is one of the important risk factors for atherosclerosis, and its serum level is lowered by popular cholesterol-lowering drugs, statins. Cholesterol 125-136 C-reactive protein Homo sapiens 0-18 12887727-1 2003 C-reactive protein (CRP) is one of the important risk factors for atherosclerosis, and its serum level is lowered by popular cholesterol-lowering drugs, statins. Cholesterol 125-136 C-reactive protein Homo sapiens 20-23 12847067-8 2003 Total and LDL cholesterol were reduced to a greater degree in those with a "low" (below median) compared with a "high" (above median) baseline CRP (total, -9.8% versus -3%; P for interaction=0.006; LDL cholesterol, -11.8% versus -3%; P for interaction=0.009). Cholesterol 14-25 C-reactive protein Homo sapiens 143-146 12835213-3 2003 Among men and women not using hormone replacement therapy (HRT), CRP levels were significantly related to 10-year Framingham Coronary Heart Disease Risk categories [total cholesterol (TC) score for men and women: r=0.29 and r=0.22, respectively; LDL cholesterol score for men and women: r=0.29 and r=0.22, respectively, all probability values <0.01]. Cholesterol 250-261 C-reactive protein Homo sapiens 65-68 12847067-10 2003 Triglycerides were increased in those with a high CRP but not in those with a low CRP (19.8% versus +0%; P for interaction=0.019). Triglycerides 0-13 C-reactive protein Homo sapiens 50-53 12847067-11 2003 CONCLUSIONS: In this study, the presence of increased CRP was associated with less total and LDL cholesterol reduction and a greater increase in triglycerides from a reduced-fat/low-cholesterol diet. Cholesterol 97-108 C-reactive protein Homo sapiens 54-57 12847067-11 2003 CONCLUSIONS: In this study, the presence of increased CRP was associated with less total and LDL cholesterol reduction and a greater increase in triglycerides from a reduced-fat/low-cholesterol diet. Triglycerides 145-158 C-reactive protein Homo sapiens 54-57 12847067-11 2003 CONCLUSIONS: In this study, the presence of increased CRP was associated with less total and LDL cholesterol reduction and a greater increase in triglycerides from a reduced-fat/low-cholesterol diet. Cholesterol 182-193 C-reactive protein Homo sapiens 54-57 12842247-0 2003 Relation of C-reactive protein and fibrinogen to coronary artery calcium in subjects with systemic hypertension. Calcium 65-72 C-reactive protein Homo sapiens 12-30 12867250-6 2003 Benefits from aspirin are more likely in patients whose hs-CRP levels are very high. Aspirin 14-21 C-reactive protein Homo sapiens 59-62 12858318-0 2003 C-reactive protein and depressed mood in a sub-group of smokers during nicotine abstinence. Nicotine 71-79 C-reactive protein Homo sapiens 0-18 12911252-10 2003 CRP was significantly associated with HDL cholesterol but not triglyceride, or systolic blood pressure, concentration after controlling for BMI. Cholesterol 42-53 C-reactive protein Homo sapiens 0-3 12860262-0 2003 Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Aspirin 41-48 C-reactive protein Homo sapiens 97-115 12860262-1 2003 Statins, aspirin and angiotensin II modulators (A II-M: angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type I receptor blockades) may have an anti-inflammatory effect, but the relationship between the effects of statins, aspirin and A II-M on high-sensitive C-reactive protein (hs-CRP) levels remains to be determined. Aspirin 9-16 C-reactive protein Homo sapiens 277-295 12860262-1 2003 Statins, aspirin and angiotensin II modulators (A II-M: angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type I receptor blockades) may have an anti-inflammatory effect, but the relationship between the effects of statins, aspirin and A II-M on high-sensitive C-reactive protein (hs-CRP) levels remains to be determined. Aspirin 9-16 C-reactive protein Homo sapiens 300-303 12852794-8 2003 CRP levels may also prove useful in targeting therapy for primary and secondary prevention, by identifying patients who would most benefit from medications such as statins and aspirin. Aspirin 176-183 C-reactive protein Homo sapiens 0-3 12858458-3 2003 METHODS: In an open study, mesalazine (3-4 g/day) was prescribed for 24 weeks to 20 patients (aged 18-70 yrs) with active AS, defined as the presence of at least one clinical criterion (morning stiffness > 30 min, peripheral synovitis, enthesopathy, or pain score > 2 on a visual analog scale of 10 cm) and one laboratory criterion [erythrocyte sedimentation rate (ESR) > 20 mm/h or C-reactive protein (CRP) > 20 mg/l]. Mesalamine 27-37 C-reactive protein Homo sapiens 392-410 12858458-3 2003 METHODS: In an open study, mesalazine (3-4 g/day) was prescribed for 24 weeks to 20 patients (aged 18-70 yrs) with active AS, defined as the presence of at least one clinical criterion (morning stiffness > 30 min, peripheral synovitis, enthesopathy, or pain score > 2 on a visual analog scale of 10 cm) and one laboratory criterion [erythrocyte sedimentation rate (ESR) > 20 mm/h or C-reactive protein (CRP) > 20 mg/l]. Mesalamine 27-37 C-reactive protein Homo sapiens 412-415 12858318-8 2003 An increase in symptoms of depressed mood and a fall in heart rate occurred only in those who displayed increased CRP with nicotine abstinence ( p < 0.05), while systolic blood pressure fell only in those whose CRP levels decreased with abstinence ( p < 0.05). Nicotine 123-131 C-reactive protein Homo sapiens 114-117 12964969-2 2003 This study was intended to determine whether CRP levels could differentiate between inflammatory and noninflammatory thyroid conditions, especially between type II inflammatory amiodarone-induced thyrotoxicosis (AIT) and type I iodine-induced AIT. Amiodarone 177-187 C-reactive protein Homo sapiens 45-48 12792130-9 2003 We found that the most reliable and sensitive parameters to regulate and taper down steroid therapy were the levels of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) and NOT systemic symptoms. Steroids 84-91 C-reactive protein Homo sapiens 160-178 12792130-9 2003 We found that the most reliable and sensitive parameters to regulate and taper down steroid therapy were the levels of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) and NOT systemic symptoms. Steroids 84-91 C-reactive protein Homo sapiens 180-183 12783932-10 2003 Several blood biomarkers showed dose-response relationships with tamoxifen, including decreased insulin-like growth factor-I, increased sex hormone-binding globulin, and decreased low-density lipoprotein-cholesterol, ultrasensitive C-reactive protein, fibrinogen, and antithrombin-III levels. Tamoxifen 65-74 C-reactive protein Homo sapiens 232-250 14592562-9 2003 Moreover, in human studies, aspirin seems to be most effective in those with elevated C-reactive protein levels. Aspirin 28-35 C-reactive protein Homo sapiens 86-104 12765886-6 2003 RESULTS: Dexamethasone decreased C-reactive protein concentration on the first postoperative day (P<0.05), but did not affect the release of vWf:Ag or S100B. Dexamethasone 9-22 C-reactive protein Homo sapiens 33-51 12838187-5 2003 RESULTS: Patients in the IVMP plus ASA/IVIG group, compared with those in the ASA/IVIG alone group, had a shorter mean duration of fever >/=38.3 degrees C after initiation of therapy (1.0 +/- 1.3 vs 2.4 +/- 1.9 days, mean +/- SD, P =.012), shorter hospital stays (1.9 +/- 0.7 vs 3.3 +/- 2.1 days, P =.010), and at six weeks, lower mean erythrocyte sedimentation rate (11.1 +/- 5.7 vs 19.4 +/- 12.4, P =.027) and median c-reactive protein (0.03 vs 0.08, P =.011, Wilcoxon). Aspirin 35-38 C-reactive protein Homo sapiens 422-440 12808486-11 2003 Furthermore, atenolol and nebivolol decreased serum high-sensitivity C-reactive protein levels by 14% (P=.05) and 15% (P=.05), respectively. Nebivolol 26-35 C-reactive protein Homo sapiens 69-87 12799248-10 2003 Then the steroid therapy was gradually tapered, guided primarily by the levels of ESR and CRP. Steroids 9-16 C-reactive protein Homo sapiens 90-93 12748357-14 2003 Thus, the nature of the correlation between CRP and serum creatinine changes with increasing CRP values: from being a direct one, it shows a trend towards a transformation into an indirect one with beta=0 at a CRP value of approximately 9 mg/l. Creatinine 58-68 C-reactive protein Homo sapiens 93-96 12748357-14 2003 Thus, the nature of the correlation between CRP and serum creatinine changes with increasing CRP values: from being a direct one, it shows a trend towards a transformation into an indirect one with beta=0 at a CRP value of approximately 9 mg/l. Creatinine 58-68 C-reactive protein Homo sapiens 93-96 12748357-12 2003 Stratifying the patients for the effects of CRP, only CRP values </=4 mg/l were directly predictive of serum creatinine (P<0.00001), whereas CRP values >4 mg/l were not. Creatinine 112-122 C-reactive protein Homo sapiens 54-57 12748357-12 2003 Stratifying the patients for the effects of CRP, only CRP values </=4 mg/l were directly predictive of serum creatinine (P<0.00001), whereas CRP values >4 mg/l were not. Creatinine 112-122 C-reactive protein Homo sapiens 54-57 12748357-14 2003 Thus, the nature of the correlation between CRP and serum creatinine changes with increasing CRP values: from being a direct one, it shows a trend towards a transformation into an indirect one with beta=0 at a CRP value of approximately 9 mg/l. Creatinine 58-68 C-reactive protein Homo sapiens 44-47 12667067-8 2003 The binding constants that drive the formation of the WT and L124I CRP-cAMP complexes deviated by not more than a factor of 1.5. Cyclic AMP 71-75 C-reactive protein Homo sapiens 67-70 12751402-4 2003 It is important to recognize that lipid-lowering therapy decreases plaque inflammation and slows the progression of calcium buildup in the coronary arteries, which is readily verified by reduction in hs-CRP levels. Calcium 116-123 C-reactive protein Homo sapiens 203-206 12812265-6 2003 CRP showed the best contribution to generation of UR, followed by sialic acid, protein fractionation, WBC, and ESR. Urea 50-52 C-reactive protein Homo sapiens 0-3 12778774-2 2003 Oxidative stress and carbonyl stress of uremia, dialysis procedure and/or intravenous iron therapy result in AGE (advanced glycation end-product), ALE (advanced lipoxidation end-product) and AOPP (advanced oxidation protein product) formation, favouring together with elevated CRP (C-reactive protein) levels the development of cardiovascular and cerebrovascular complications. Iron 86-90 C-reactive protein Homo sapiens 277-280 12778774-2 2003 Oxidative stress and carbonyl stress of uremia, dialysis procedure and/or intravenous iron therapy result in AGE (advanced glycation end-product), ALE (advanced lipoxidation end-product) and AOPP (advanced oxidation protein product) formation, favouring together with elevated CRP (C-reactive protein) levels the development of cardiovascular and cerebrovascular complications. Iron 86-90 C-reactive protein Homo sapiens 282-300 12716789-10 2003 Serum C-reactive protein was significantly associated with percent linoleic acid and eicosapentaenoic acid in nonsmoking men (P = 0.03 and P = 0.04, respectively) and with docosahexaenoic acid in nonsmoking women (r = -0.46, P < 0.0001). Linoleic Acid 67-80 C-reactive protein Homo sapiens 6-24 12682719-0 2003 Prophylactic N-acetylcysteine decreases serum CRP but not PCT levels and microalbuminuria following major abdominal surgery. Acetylcysteine 13-29 C-reactive protein Homo sapiens 46-49 12682719-12 2003 Significantly lower CRP levels were found in the NAC group on days 1 and 2 (t(24): median: 84.5 interquartile range: [62-120] vs. 118 [86-137] mg/l; p=0.020; t(48): 136 [103-232] vs. 195 [154-252] mg/l; p=0.013, NAC vs. placebo respectively). Acetylcysteine 49-52 C-reactive protein Homo sapiens 20-23 12682719-12 2003 Significantly lower CRP levels were found in the NAC group on days 1 and 2 (t(24): median: 84.5 interquartile range: [62-120] vs. 118 [86-137] mg/l; p=0.020; t(48): 136 [103-232] vs. 195 [154-252] mg/l; p=0.013, NAC vs. placebo respectively). Acetylcysteine 212-215 C-reactive protein Homo sapiens 20-23 12682719-13 2003 CONCLUSION: In this study, short-term NAC treatment decreased CRP levels, but failed to attenuate any other inflammatory response, as monitored by serum PCT and microalbuminuria. Acetylcysteine 38-41 C-reactive protein Homo sapiens 62-65 12738395-13 2003 CRP was positively associated with body mass index (BMI), serum triglycerides, and sulfonylurea therapy and negatively associated with metformin therapy. Triglycerides 64-77 C-reactive protein Homo sapiens 0-3 12738395-13 2003 CRP was positively associated with body mass index (BMI), serum triglycerides, and sulfonylurea therapy and negatively associated with metformin therapy. Metformin 135-144 C-reactive protein Homo sapiens 0-3 12710894-4 2003 The ability of IL-6 to promote transcription of CRP is mediated, in large part, by activation of the transcription factor STAT3; this activation requires both a tyrosine phosphorylation (mediated by the IL-6 receptor complex) and a serine phosphorylation (Ser-727), the origin of which has been more obscure. Tyrosine 161-169 C-reactive protein Homo sapiens 48-51 12710894-4 2003 The ability of IL-6 to promote transcription of CRP is mediated, in large part, by activation of the transcription factor STAT3; this activation requires both a tyrosine phosphorylation (mediated by the IL-6 receptor complex) and a serine phosphorylation (Ser-727), the origin of which has been more obscure. Serine 232-238 C-reactive protein Homo sapiens 48-51 12710894-4 2003 The ability of IL-6 to promote transcription of CRP is mediated, in large part, by activation of the transcription factor STAT3; this activation requires both a tyrosine phosphorylation (mediated by the IL-6 receptor complex) and a serine phosphorylation (Ser-727), the origin of which has been more obscure. Serine 256-259 C-reactive protein Homo sapiens 48-51 12667067-0 2003 Interaction of CRP L124 with cAMP affects CRP cAMP binding constants, cAMP binding cooperativity, and CRP allostery. Cyclic AMP 29-33 C-reactive protein Homo sapiens 15-18 12667067-0 2003 Interaction of CRP L124 with cAMP affects CRP cAMP binding constants, cAMP binding cooperativity, and CRP allostery. Cyclic AMP 29-33 C-reactive protein Homo sapiens 42-45 12667067-0 2003 Interaction of CRP L124 with cAMP affects CRP cAMP binding constants, cAMP binding cooperativity, and CRP allostery. Cyclic AMP 29-33 C-reactive protein Homo sapiens 42-45 12667067-0 2003 Interaction of CRP L124 with cAMP affects CRP cAMP binding constants, cAMP binding cooperativity, and CRP allostery. Cyclic AMP 46-50 C-reactive protein Homo sapiens 15-18 12667067-0 2003 Interaction of CRP L124 with cAMP affects CRP cAMP binding constants, cAMP binding cooperativity, and CRP allostery. Cyclic AMP 46-50 C-reactive protein Homo sapiens 42-45 12667067-0 2003 Interaction of CRP L124 with cAMP affects CRP cAMP binding constants, cAMP binding cooperativity, and CRP allostery. Cyclic AMP 46-50 C-reactive protein Homo sapiens 42-45 12667067-0 2003 Interaction of CRP L124 with cAMP affects CRP cAMP binding constants, cAMP binding cooperativity, and CRP allostery. Cyclic AMP 46-50 C-reactive protein Homo sapiens 15-18 12667067-0 2003 Interaction of CRP L124 with cAMP affects CRP cAMP binding constants, cAMP binding cooperativity, and CRP allostery. Cyclic AMP 46-50 C-reactive protein Homo sapiens 42-45 12667067-0 2003 Interaction of CRP L124 with cAMP affects CRP cAMP binding constants, cAMP binding cooperativity, and CRP allostery. Cyclic AMP 46-50 C-reactive protein Homo sapiens 42-45 12667067-9 2003 In contrast, the L124V, L124A, and L124C forms of CRP exhibited both a decreased K(cAMP1)(app) and an increased K(cAMP2)(app) to produce 2.4-, 55-, and 204-fold reductions, respectively, in the difference between these two parameters compared to that observed for WT CRP. camp1 83-88 C-reactive protein Homo sapiens 50-53 12667067-4 2003 Wild-type (WT) apo-CRP is a 47 kDa protease-resistant dimer composed of identical subunits that exhibits a biphasic isotherm in cAMP titration studies. Cyclic AMP 128-132 C-reactive protein Homo sapiens 19-22 12667067-5 2003 The WT CRP-cAMP complex is a protease-sensitive dimer degraded by protease to a dimer core that ranges between 26.5 and 30.5 kDa. Cyclic AMP 11-15 C-reactive protein Homo sapiens 7-10 12667067-10 2003 The data indicate that the van der Waals volume and/or the hyrophobicity of the L124 side chain are important determinants of CRP cAMP binding properties and affect, either directly or indirectly, cAMP-mediated conformation changes in CRP. Cyclic AMP 130-134 C-reactive protein Homo sapiens 126-129 12667067-6 2003 Substitution of L124 with isoleucine (I), valine (V), cysteine (C), or alanine (A) generated a series of CRP variants that exhibited unique differences in apo-CRP resistance to protease, the mass of the core fragments generated in protease digestion reactions, cAMP-mediated allostery, and CRP-cAMP complex functionality. Cysteine 54-62 C-reactive protein Homo sapiens 105-108 12667067-6 2003 Substitution of L124 with isoleucine (I), valine (V), cysteine (C), or alanine (A) generated a series of CRP variants that exhibited unique differences in apo-CRP resistance to protease, the mass of the core fragments generated in protease digestion reactions, cAMP-mediated allostery, and CRP-cAMP complex functionality. Alanine 71-78 C-reactive protein Homo sapiens 105-108 12667067-7 2003 Differences in the affinity of the position 124 CRP variants for cAMP were observed. Cyclic AMP 65-69 C-reactive protein Homo sapiens 48-51 12667067-10 2003 The data indicate that the van der Waals volume and/or the hyrophobicity of the L124 side chain are important determinants of CRP cAMP binding properties and affect, either directly or indirectly, cAMP-mediated conformation changes in CRP. Cyclic AMP 130-134 C-reactive protein Homo sapiens 235-238 12667067-10 2003 The data indicate that the van der Waals volume and/or the hyrophobicity of the L124 side chain are important determinants of CRP cAMP binding properties and affect, either directly or indirectly, cAMP-mediated conformation changes in CRP. Cyclic AMP 197-201 C-reactive protein Homo sapiens 126-129 12667067-10 2003 The data indicate that the van der Waals volume and/or the hyrophobicity of the L124 side chain are important determinants of CRP cAMP binding properties and affect, either directly or indirectly, cAMP-mediated conformation changes in CRP. Cyclic AMP 197-201 C-reactive protein Homo sapiens 235-238 12714198-6 2003 The CRP abnormal group had more coronary artery calcification (calcium scores >5, 16.7 vs. 0%; P=0.036) and more cardiac diastolic dysfunction expressed as deceleration time >240 ms (16.7 vs. 0%; P=0.036). Calcium 63-70 C-reactive protein Homo sapiens 4-7 12667961-6 2003 When VSMC were incubated with CRP, the inducible nitric oxide synthase (iNOS) promoter was activated. vsmc 5-9 C-reactive protein Homo sapiens 30-33 12667961-9 2003 The NF-kappaB activation caused by CRP was inhibited by 15-deoxy-12,14-prostaglandin J2 and the PPARgamma activators, rosiglitazone and pioglitazone. Rosiglitazone 118-131 C-reactive protein Homo sapiens 35-38 12721499-0 2003 Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. Metformin 10-19 C-reactive protein Homo sapiens 40-58 12721499-1 2003 The objective of this study was to examine the effect of the antihyperglycemic agents metformin (insulin sensitizer) and glibenclamide (insulin secretory agent) on the serum level of C-reactive protein (CRP) in well-controlled type 2 diabetics with metabolic syndrome. Metformin 86-95 C-reactive protein Homo sapiens 183-201 12721499-1 2003 The objective of this study was to examine the effect of the antihyperglycemic agents metformin (insulin sensitizer) and glibenclamide (insulin secretory agent) on the serum level of C-reactive protein (CRP) in well-controlled type 2 diabetics with metabolic syndrome. Metformin 86-95 C-reactive protein Homo sapiens 203-206 12721499-8 2003 CRP level was significantly lower in patients using metformin for blood glucose control compared with those using glibenclamide, 5.56 and 8.3 mg/L, respectively (p = 0.01). Metformin 52-61 C-reactive protein Homo sapiens 0-3 12721499-8 2003 CRP level was significantly lower in patients using metformin for blood glucose control compared with those using glibenclamide, 5.56 and 8.3 mg/L, respectively (p = 0.01). Glucose 72-79 C-reactive protein Homo sapiens 0-3 12721499-11 2003 The data showed that metformin decreases the level of circulating CRP, a marker of inflammation, more than glibenclamide. Metformin 21-30 C-reactive protein Homo sapiens 66-69 12714206-9 2003 Plasma norepinephrine and interleukin-6 levels were increased in patients with higher CRP levels, suggesting a possible role of sympathetic activation and enhanced immune response in the development of LV remodeling after AMI. Norepinephrine 7-21 C-reactive protein Homo sapiens 86-89 12600430-1 2003 OBJECTIVES: To evaluate the value of plasma C-reactive protein (CRP) levels in early detection of bacteriuria and bacteriemia after extracorporeal shock wave lithotripsy (ESWL) of calcium and infection stones. Calcium 180-187 C-reactive protein Homo sapiens 44-62 12689821-0 2003 Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosiglitazone. Rosiglitazone 90-103 C-reactive protein Homo sapiens 56-74 12689821-10 2003 CRP also decreased endothelial nitric oxide release, and this effect remained unchanged by hyperglycemia. Nitric Oxide 31-43 C-reactive protein Homo sapiens 0-3 12689821-11 2003 Importantly, the PPARgamma agonist, rosiglitazone, attenuated the proatherogenic effects of CRP under both basal and hyperglycemic conditions. Rosiglitazone 36-49 C-reactive protein Homo sapiens 92-95 12689821-12 2003 The direct proatherogenic actions of CRP are exaggerated in the hyperglycemic milieu, and attenuated by rosiglitazone. Rosiglitazone 104-117 C-reactive protein Homo sapiens 37-40 12600430-1 2003 OBJECTIVES: To evaluate the value of plasma C-reactive protein (CRP) levels in early detection of bacteriuria and bacteriemia after extracorporeal shock wave lithotripsy (ESWL) of calcium and infection stones. Calcium 180-187 C-reactive protein Homo sapiens 64-67 12768071-0 2003 Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. Atorvastatin 0-12 C-reactive protein Homo sapiens 83-101 12654581-1 2003 A simple blood test for C-reactive protein is joining cholesterol screening as an early warning for heart disease. Cholesterol 54-65 C-reactive protein Homo sapiens 24-42 12661797-4 2003 As reviewed below, rosiglitazone has a beneficial impact on a number of factors associated with insulin resistance and CVD, including microalbuminuria, hypertension, dyslipidaemia, visceral fat, elevated plasminogen activator inhibitor-1 levels and increased concentrations of C-reactive protein. Rosiglitazone 19-32 C-reactive protein Homo sapiens 277-295 12644339-10 2003 Furthermore, the benefits of lifestyle modification and drug therapy with aspirin or statins may be most marked among those with elevated CRP levels. Aspirin 74-81 C-reactive protein Homo sapiens 138-141 12590582-1 2003 The interaction between CRP, T127L, S128A, and CRP and RNA polymerase bound to a 104 bp synthetic promoter were determined by ITC at 298 K and ranges from a deltaG(b) degrees = 1.4 +/- 0.8 kJ mol(-)(1) (cAMP-ligated S128A) to 4.5 +/- 0.3 kJ mol(-)(1) (cAMP-ligated double mutant CRP) with endothermicities that range from 4 +/- 3 kJ mol(-)(1) (cAMP-ligated CRP) to 47 +/- 8 kJ mol(-)(1) (cGMP-ligated T127L). Cyclic AMP 203-207 C-reactive protein Homo sapiens 24-27 12590582-1 2003 The interaction between CRP, T127L, S128A, and CRP and RNA polymerase bound to a 104 bp synthetic promoter were determined by ITC at 298 K and ranges from a deltaG(b) degrees = 1.4 +/- 0.8 kJ mol(-)(1) (cAMP-ligated S128A) to 4.5 +/- 0.3 kJ mol(-)(1) (cAMP-ligated double mutant CRP) with endothermicities that range from 4 +/- 3 kJ mol(-)(1) (cAMP-ligated CRP) to 47 +/- 8 kJ mol(-)(1) (cGMP-ligated T127L). Cyclic AMP 203-207 C-reactive protein Homo sapiens 47-50 12590582-1 2003 The interaction between CRP, T127L, S128A, and CRP and RNA polymerase bound to a 104 bp synthetic promoter were determined by ITC at 298 K and ranges from a deltaG(b) degrees = 1.4 +/- 0.8 kJ mol(-)(1) (cAMP-ligated S128A) to 4.5 +/- 0.3 kJ mol(-)(1) (cAMP-ligated double mutant CRP) with endothermicities that range from 4 +/- 3 kJ mol(-)(1) (cAMP-ligated CRP) to 47 +/- 8 kJ mol(-)(1) (cGMP-ligated T127L). Cyclic AMP 203-207 C-reactive protein Homo sapiens 47-50 12590582-1 2003 The interaction between CRP, T127L, S128A, and CRP and RNA polymerase bound to a 104 bp synthetic promoter were determined by ITC at 298 K and ranges from a deltaG(b) degrees = 1.4 +/- 0.8 kJ mol(-)(1) (cAMP-ligated S128A) to 4.5 +/- 0.3 kJ mol(-)(1) (cAMP-ligated double mutant CRP) with endothermicities that range from 4 +/- 3 kJ mol(-)(1) (cAMP-ligated CRP) to 47 +/- 8 kJ mol(-)(1) (cGMP-ligated T127L). Cyclic AMP 203-207 C-reactive protein Homo sapiens 47-50 12590582-1 2003 The interaction between CRP, T127L, S128A, and CRP and RNA polymerase bound to a 104 bp synthetic promoter were determined by ITC at 298 K and ranges from a deltaG(b) degrees = 1.4 +/- 0.8 kJ mol(-)(1) (cAMP-ligated S128A) to 4.5 +/- 0.3 kJ mol(-)(1) (cAMP-ligated double mutant CRP) with endothermicities that range from 4 +/- 3 kJ mol(-)(1) (cAMP-ligated CRP) to 47 +/- 8 kJ mol(-)(1) (cGMP-ligated T127L). Cyclic AMP 252-256 C-reactive protein Homo sapiens 24-27 12590582-1 2003 The interaction between CRP, T127L, S128A, and CRP and RNA polymerase bound to a 104 bp synthetic promoter were determined by ITC at 298 K and ranges from a deltaG(b) degrees = 1.4 +/- 0.8 kJ mol(-)(1) (cAMP-ligated S128A) to 4.5 +/- 0.3 kJ mol(-)(1) (cAMP-ligated double mutant CRP) with endothermicities that range from 4 +/- 3 kJ mol(-)(1) (cAMP-ligated CRP) to 47 +/- 8 kJ mol(-)(1) (cGMP-ligated T127L). Cyclic AMP 252-256 C-reactive protein Homo sapiens 47-50 12590582-1 2003 The interaction between CRP, T127L, S128A, and CRP and RNA polymerase bound to a 104 bp synthetic promoter were determined by ITC at 298 K and ranges from a deltaG(b) degrees = 1.4 +/- 0.8 kJ mol(-)(1) (cAMP-ligated S128A) to 4.5 +/- 0.3 kJ mol(-)(1) (cAMP-ligated double mutant CRP) with endothermicities that range from 4 +/- 3 kJ mol(-)(1) (cAMP-ligated CRP) to 47 +/- 8 kJ mol(-)(1) (cGMP-ligated T127L). Cyclic AMP 252-256 C-reactive protein Homo sapiens 47-50 12590582-1 2003 The interaction between CRP, T127L, S128A, and CRP and RNA polymerase bound to a 104 bp synthetic promoter were determined by ITC at 298 K and ranges from a deltaG(b) degrees = 1.4 +/- 0.8 kJ mol(-)(1) (cAMP-ligated S128A) to 4.5 +/- 0.3 kJ mol(-)(1) (cAMP-ligated double mutant CRP) with endothermicities that range from 4 +/- 3 kJ mol(-)(1) (cAMP-ligated CRP) to 47 +/- 8 kJ mol(-)(1) (cGMP-ligated T127L). Cyclic AMP 252-256 C-reactive protein Homo sapiens 47-50 12590582-1 2003 The interaction between CRP, T127L, S128A, and CRP and RNA polymerase bound to a 104 bp synthetic promoter were determined by ITC at 298 K and ranges from a deltaG(b) degrees = 1.4 +/- 0.8 kJ mol(-)(1) (cAMP-ligated S128A) to 4.5 +/- 0.3 kJ mol(-)(1) (cAMP-ligated double mutant CRP) with endothermicities that range from 4 +/- 3 kJ mol(-)(1) (cAMP-ligated CRP) to 47 +/- 8 kJ mol(-)(1) (cGMP-ligated T127L). Cyclic AMP 252-256 C-reactive protein Homo sapiens 24-27 12590582-1 2003 The interaction between CRP, T127L, S128A, and CRP and RNA polymerase bound to a 104 bp synthetic promoter were determined by ITC at 298 K and ranges from a deltaG(b) degrees = 1.4 +/- 0.8 kJ mol(-)(1) (cAMP-ligated S128A) to 4.5 +/- 0.3 kJ mol(-)(1) (cAMP-ligated double mutant CRP) with endothermicities that range from 4 +/- 3 kJ mol(-)(1) (cAMP-ligated CRP) to 47 +/- 8 kJ mol(-)(1) (cGMP-ligated T127L). Cyclic AMP 252-256 C-reactive protein Homo sapiens 47-50 12590582-1 2003 The interaction between CRP, T127L, S128A, and CRP and RNA polymerase bound to a 104 bp synthetic promoter were determined by ITC at 298 K and ranges from a deltaG(b) degrees = 1.4 +/- 0.8 kJ mol(-)(1) (cAMP-ligated S128A) to 4.5 +/- 0.3 kJ mol(-)(1) (cAMP-ligated double mutant CRP) with endothermicities that range from 4 +/- 3 kJ mol(-)(1) (cAMP-ligated CRP) to 47 +/- 8 kJ mol(-)(1) (cGMP-ligated T127L). Cyclic AMP 252-256 C-reactive protein Homo sapiens 47-50 12590582-1 2003 The interaction between CRP, T127L, S128A, and CRP and RNA polymerase bound to a 104 bp synthetic promoter were determined by ITC at 298 K and ranges from a deltaG(b) degrees = 1.4 +/- 0.8 kJ mol(-)(1) (cAMP-ligated S128A) to 4.5 +/- 0.3 kJ mol(-)(1) (cAMP-ligated double mutant CRP) with endothermicities that range from 4 +/- 3 kJ mol(-)(1) (cAMP-ligated CRP) to 47 +/- 8 kJ mol(-)(1) (cGMP-ligated T127L). Cyclic AMP 252-256 C-reactive protein Homo sapiens 47-50 12590582-1 2003 The interaction between CRP, T127L, S128A, and CRP and RNA polymerase bound to a 104 bp synthetic promoter were determined by ITC at 298 K and ranges from a deltaG(b) degrees = 1.4 +/- 0.8 kJ mol(-)(1) (cAMP-ligated S128A) to 4.5 +/- 0.3 kJ mol(-)(1) (cAMP-ligated double mutant CRP) with endothermicities that range from 4 +/- 3 kJ mol(-)(1) (cAMP-ligated CRP) to 47 +/- 8 kJ mol(-)(1) (cGMP-ligated T127L). Cyclic GMP 388-392 C-reactive protein Homo sapiens 24-27 12590582-1 2003 The interaction between CRP, T127L, S128A, and CRP and RNA polymerase bound to a 104 bp synthetic promoter were determined by ITC at 298 K and ranges from a deltaG(b) degrees = 1.4 +/- 0.8 kJ mol(-)(1) (cAMP-ligated S128A) to 4.5 +/- 0.3 kJ mol(-)(1) (cAMP-ligated double mutant CRP) with endothermicities that range from 4 +/- 3 kJ mol(-)(1) (cAMP-ligated CRP) to 47 +/- 8 kJ mol(-)(1) (cGMP-ligated T127L). Cyclic GMP 388-392 C-reactive protein Homo sapiens 47-50 12590582-1 2003 The interaction between CRP, T127L, S128A, and CRP and RNA polymerase bound to a 104 bp synthetic promoter were determined by ITC at 298 K and ranges from a deltaG(b) degrees = 1.4 +/- 0.8 kJ mol(-)(1) (cAMP-ligated S128A) to 4.5 +/- 0.3 kJ mol(-)(1) (cAMP-ligated double mutant CRP) with endothermicities that range from 4 +/- 3 kJ mol(-)(1) (cAMP-ligated CRP) to 47 +/- 8 kJ mol(-)(1) (cGMP-ligated T127L). Cyclic GMP 388-392 C-reactive protein Homo sapiens 47-50 12590582-1 2003 The interaction between CRP, T127L, S128A, and CRP and RNA polymerase bound to a 104 bp synthetic promoter were determined by ITC at 298 K and ranges from a deltaG(b) degrees = 1.4 +/- 0.8 kJ mol(-)(1) (cAMP-ligated S128A) to 4.5 +/- 0.3 kJ mol(-)(1) (cAMP-ligated double mutant CRP) with endothermicities that range from 4 +/- 3 kJ mol(-)(1) (cAMP-ligated CRP) to 47 +/- 8 kJ mol(-)(1) (cGMP-ligated T127L). Cyclic GMP 388-392 C-reactive protein Homo sapiens 47-50 12590582-2 2003 The interaction is, thus, entropically driven, exhibits enthalpy-entropy compensation, and increases the binding affinity of the RNA polymerase to the promoter by factors ranging from 1.7 +/- 0.1 (cAMP-ligated S128A) to 6.1 +/- 0.1 (cAMP-ligated CRP). Cyclic AMP 197-201 C-reactive protein Homo sapiens 246-249 12590582-2 2003 The interaction is, thus, entropically driven, exhibits enthalpy-entropy compensation, and increases the binding affinity of the RNA polymerase to the promoter by factors ranging from 1.7 +/- 0.1 (cAMP-ligated S128A) to 6.1 +/- 0.1 (cAMP-ligated CRP). Cyclic AMP 233-237 C-reactive protein Homo sapiens 246-249 12539241-1 2003 In vertebrates, members of the cysteine-rich protein (CRP) family are characterized by the presence of two LIM domains linked to short glycine-rich repeats. Glycine 135-142 C-reactive protein Homo sapiens 31-52 12595863-0 2003 Effect of atorvastatin and pravastatin on serum C-reactive protein. Atorvastatin 10-22 C-reactive protein Homo sapiens 48-66 12595863-4 2003 RESULTS: Mean C-reactive protein (CRP) levels were significantly reduced in both groups, with a 36% reduction in the atorvastatin group (0.39 +/- 0.36 to 0.25 +/- 0.27, P =.001) and a 22% reduction observed in the pravastatin group (0.40 +/- 0.33 to 0.31 +/- 0.32, P =.003). Atorvastatin 117-129 C-reactive protein Homo sapiens 14-32 12595863-4 2003 RESULTS: Mean C-reactive protein (CRP) levels were significantly reduced in both groups, with a 36% reduction in the atorvastatin group (0.39 +/- 0.36 to 0.25 +/- 0.27, P =.001) and a 22% reduction observed in the pravastatin group (0.40 +/- 0.33 to 0.31 +/- 0.32, P =.003). Atorvastatin 117-129 C-reactive protein Homo sapiens 34-37 12595863-5 2003 A reduced or unchanged CRP level was seen in 67.2% of pravastatin-treated patients (45/67) and 73% of atorvastatin- treated patients (46/63) (P =.47). Atorvastatin 102-114 C-reactive protein Homo sapiens 23-26 12595863-7 2003 However, whereas the reduction of CRP with pravastatin was unrelated to the degree of low-density lipoprotein reduction (r = -.05, P =.69), atorvastatin-induced CRP reductions correlated directly to the change in low-density lipoprotein-C (r =.33, P =.009). Atorvastatin 140-152 C-reactive protein Homo sapiens 161-164 12595863-8 2003 CONCLUSIONS: High-dose atorvastatin and pravastatin both reduce CRP levels. Atorvastatin 23-35 C-reactive protein Homo sapiens 64-67 12539241-1 2003 In vertebrates, members of the cysteine-rich protein (CRP) family are characterized by the presence of two LIM domains linked to short glycine-rich repeats. Glycine 135-142 C-reactive protein Homo sapiens 54-57 12607808-2 2003 This study investigated among smokers the relationship between CRP and use of the anti-inflammatories aspirin and ibuprofen. Aspirin 102-109 C-reactive protein Homo sapiens 63-66 12607808-2 2003 This study investigated among smokers the relationship between CRP and use of the anti-inflammatories aspirin and ibuprofen. Ibuprofen 114-123 C-reactive protein Homo sapiens 63-66 12607808-4 2003 Regression models were used to determine the independent relationship between aspirin and ibuprofen use and elevated CRP, controlling for demographics, body mass index, history of CVD, and health status. Aspirin 78-85 C-reactive protein Homo sapiens 117-120 12631127-14 2003 In the AP, but not control, group there was an inverse correlation between CRP and microvascular function as determined by acetylcholine iontophoresis (r = -0.509; P = 0.018). Acetylcholine 123-136 C-reactive protein Homo sapiens 75-78 12631131-3 2003 METHODS: To test this hypothesis, we studied the relationship between CRP levels and renal function loss measured as diminished creatinine clearance in a large non-diabetic population (7317 subjects). Creatinine 128-138 C-reactive protein Homo sapiens 70-73 12631131-9 2003 RESULTS: Elevated CRP levels were positively associated with cardiovascular and renal risk factors: age, body mass index, blood pressure, serum cholesterol level, smoking, plasma glucose level and elevated urinary albumin excretion. Cholesterol 144-155 C-reactive protein Homo sapiens 18-21 12631131-9 2003 RESULTS: Elevated CRP levels were positively associated with cardiovascular and renal risk factors: age, body mass index, blood pressure, serum cholesterol level, smoking, plasma glucose level and elevated urinary albumin excretion. Glucose 179-186 C-reactive protein Homo sapiens 18-21 12631131-16 2003 However, the association between CRP, body weight, and a relatively elevated creatinine clearance is a hypothesis-generating finding, suggesting that early inflammatory processes related to high body fat may predispose the kidney to glomerular hyperfiltration-related renal function loss. Creatinine 77-87 C-reactive protein Homo sapiens 33-36 12607808-4 2003 Regression models were used to determine the independent relationship between aspirin and ibuprofen use and elevated CRP, controlling for demographics, body mass index, history of CVD, and health status. Ibuprofen 90-99 C-reactive protein Homo sapiens 117-120 12607808-5 2003 RESULTS: Frequency of use of aspirin and ibuprofen among "ever smokers," a population that includes current smokers and quitters, was associated with a decreased likelihood of having elevated CRP. Aspirin 29-36 C-reactive protein Homo sapiens 192-195 12607808-5 2003 RESULTS: Frequency of use of aspirin and ibuprofen among "ever smokers," a population that includes current smokers and quitters, was associated with a decreased likelihood of having elevated CRP. Ibuprofen 41-50 C-reactive protein Homo sapiens 192-195 12607808-6 2003 Ever smokers with low frequency of use of either aspirin or ibuprofen had a lower likelihood of having elevated CRP similar to that for "never smokers." Aspirin 49-56 C-reactive protein Homo sapiens 112-115 12607808-6 2003 Ever smokers with low frequency of use of either aspirin or ibuprofen had a lower likelihood of having elevated CRP similar to that for "never smokers." Ibuprofen 60-69 C-reactive protein Homo sapiens 112-115 12607808-7 2003 In adjusted relationships, aspirin use was not significantly related to elevated CRP, while low use of ibuprofen had decreased odds of having elevated CRP compared to no use. Ibuprofen 103-112 C-reactive protein Homo sapiens 151-154 12482559-3 2003 RESULTS: Median CRP levels increased with 6.6% in the placebo group and were reduced by 15 and 47%, respectively, with atorvastatin 10 and 80 mg (P<0.001; significantly different from 10 mg atorvastatin and from placebo (P<0.001). Atorvastatin 119-131 C-reactive protein Homo sapiens 16-19 12551869-2 2003 However, data evaluating the relationship between C-reactive protein (CRP), a predictor of cardiovascular risk, and alcohol consumption are sparse. Alcohols 116-123 C-reactive protein Homo sapiens 50-68 12551869-2 2003 However, data evaluating the relationship between C-reactive protein (CRP), a predictor of cardiovascular risk, and alcohol consumption are sparse. Alcohols 116-123 C-reactive protein Homo sapiens 70-73 12551869-3 2003 METHODS AND RESULTS: The relationship between alcohol consumption and CRP was evaluated in a cross-sectional survey and over time among 1732 men and 1101 women participating in the Pravastatin Inflammation/CRP Evaluation Study. Alcohols 46-53 C-reactive protein Homo sapiens 70-73 12551869-6 2003 In multivariate analysis, the relationship between alcohol consumption and CRP remained significant after controlling for multiple traditional cardiovascular risk factors. Alcohols 51-58 C-reactive protein Homo sapiens 75-78 12551869-8 2003 CONCLUSION: Moderate alcohol consumption was associated with lower CRP concentrations than no or occasional alcohol intake, an effect that was independent of alcohol-related effects on lipids. Alcohols 21-28 C-reactive protein Homo sapiens 67-70 12564455-1 2003 Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atorvastatin 10-22 C-reactive protein Homo sapiens 59-77 12482559-6 2003 CONCLUSIONS: In DM2 patients high dose atorvastatin induced a strong reduction in CRP levels. Atorvastatin 39-51 C-reactive protein Homo sapiens 82-85 12549983-7 2003 The change in the log-transformed CRP concentration correlated with the change in the log-transformed LDL cholesterol concentration. Cholesterol 106-117 C-reactive protein Homo sapiens 34-37 12803732-0 2003 Atorvastatin affects C-reactive protein levels in patients with coronary artery disease. Atorvastatin 0-12 C-reactive protein Homo sapiens 21-39 12803732-2 2003 The aim of this study was to evaluate anti-inflammatory effects of atorvastatin in patients with CAD by measuring serum CRP levels. Atorvastatin 67-79 C-reactive protein Homo sapiens 120-123 12803732-10 2003 CONCLUSIONS: In patients with CAD, atorvastatin exerted an anti-inflammatory effect represented by decreasing CRP levels. Atorvastatin 35-47 C-reactive protein Homo sapiens 110-113 12647284-13 2003 Iron therapy in patients with normal CRP and tSAT < 20% significantly improved the response to erythropoietin, but was completely ineffective in patients with increased CRP. Iron 0-4 C-reactive protein Homo sapiens 37-40 12647284-14 2003 These results suggest that functional iron deficiency plays a marginal role in resistance to erythropoietin observed in patients with elevated CRP concentrations. Iron 38-42 C-reactive protein Homo sapiens 143-146 12548303-0 2003 Effect of c-reactive protein and interleukins blood levels in postsurgery arginine-enhanced enteral nutrition in head and neck cancer patients. Arginine 74-82 C-reactive protein Homo sapiens 10-28 12548303-3 2003 The aim of our study was to evaluate the effect of enteral nutrition supplemented with arginine on c-reactive protein (CRP), interleukin 6 (IL-6) and tumour necrosis factor (TNFalpha) in surgical head and neck cancer patients. Arginine 87-95 C-reactive protein Homo sapiens 99-117 12634320-0 2003 Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site. Carbohydrates 0-12 C-reactive protein Homo sapiens 45-48 12634320-11 2003 For instance, galactose-alpha1-phosphate was not inhibitory at all in the native CRP binding assay, whereas it was a good inhibitor in the neo-CRP assay. galactose-alpha1-phosphate 14-40 C-reactive protein Homo sapiens 81-84 12634320-11 2003 For instance, galactose-alpha1-phosphate was not inhibitory at all in the native CRP binding assay, whereas it was a good inhibitor in the neo-CRP assay. galactose-alpha1-phosphate 14-40 C-reactive protein Homo sapiens 143-146 12549983-10 2003 The correlation between the reductions in CRP and LDL cholesterol differs from the findings of other published studies, and should prompt further investigation of the mechanism by which statins reduce CRP. Cholesterol 54-65 C-reactive protein Homo sapiens 42-45 12918783-11 2002 Thus, the Ca2+-dependent formation of a complex between CRP and VLDL accounts for the BTW. BTW 86-89 C-reactive protein Homo sapiens 56-59 12589876-8 2003 After adjusting for age, cigarette smoking, alcohol consumption, heart rate, and puberty development, children in the fourth quartile CRP subgroups were heavier and had significantly higher body mass index (BMI) and lower HDL-C levels than children with nondetected CRP. Alcohols 44-51 C-reactive protein Homo sapiens 134-137 12891281-8 2003 However combination of 2 atorvastatin groups (n=59) revealed decrease of CRP by 18% from baseline on day 14 (from 6.94+/-0.97 to 4.76+/-0.76 mg/l, p=0.028). Atorvastatin 25-37 C-reactive protein Homo sapiens 73-76 12891281-10 2003 CONCLUSION: In otherwise conventionally treated patients with non-ST elevation acute coronary syndrome early use of atorvastatin was associated with rapid (in 14 days) decrease of CRP level. Atorvastatin 116-128 C-reactive protein Homo sapiens 180-183 12945719-5 2003 On the other hand, five patients with rheumatoid arthritis (RA) who received atorvastatin for eight days (20mg/day) showed reduction in C-reactive protein levels and a clinical improvement that was classified as an ACR20 response. Atorvastatin 77-89 C-reactive protein Homo sapiens 136-154 14650743-7 2003 Interactions of CRP with Fc receptors lead to the generation of proinflammatory cytokines and reactive oxygen species by monocyte/macrophage while inhibit neutrophiles functions. Reactive Oxygen Species 94-117 C-reactive protein Homo sapiens 16-19 12616822-8 2002 Significantly lower CRP levels were found in the NAC group on day one and two [t24: median: 84.5 interquartile range: (62.48-120.25) vs. 118 (86-137) mg/l; p = 0.020; t48: 136 (103-232) vs. 195 (154.5-252) mg/l p = 0.013, NAC vs. placebo]. Acetylcysteine 49-52 C-reactive protein Homo sapiens 20-23 12616822-8 2002 Significantly lower CRP levels were found in the NAC group on day one and two [t24: median: 84.5 interquartile range: (62.48-120.25) vs. 118 (86-137) mg/l; p = 0.020; t48: 136 (103-232) vs. 195 (154.5-252) mg/l p = 0.013, NAC vs. placebo]. Acetylcysteine 222-225 C-reactive protein Homo sapiens 20-23 12454321-9 2002 RESULTS: Vitamin D status was the sole determinant of circulating MMP9 (inversely) and an independent determinant of CRP (inversely). Vitamin D 9-18 C-reactive protein Homo sapiens 117-120 12454321-12 2002 DISCUSSION: Vitamin-D insufficiency is associated with increased circulating MMP2,9 and CRP, correctable by supplementation. Vitamin D 12-21 C-reactive protein Homo sapiens 77-91 12407643-7 2002 Univariate comparisons between subjects with or without elevated CRP levels (>10 mg/L) showed that CRP level elevation was associated significantly (P < 0.05) with greater doses of human recombinant erythropoietin and lower levels of hemoglobin, serum iron, transferrin saturation (TSat), albumin averaged over the 3 preceding months, total cholesterol, and triglycerides. Iron 258-262 C-reactive protein Homo sapiens 102-105 12468765-9 2002 In addition, ORs for progression of atherosclerosis associated with high CRP levels were as high as those associated with the traditional cardiovascular risk factors high cholesterol, hypertension, and smoking. Cholesterol 171-182 C-reactive protein Homo sapiens 73-76 12411320-1 2002 The glycoprotein VI (GPVI)-specific agonist collagen-related peptide (CRP) and thrombin stimulated tyrosine phosphorylation of Vav1 but not Vav2 in human platelets. Tyrosine 99-107 C-reactive protein Homo sapiens 44-68 12411320-1 2002 The glycoprotein VI (GPVI)-specific agonist collagen-related peptide (CRP) and thrombin stimulated tyrosine phosphorylation of Vav1 but not Vav2 in human platelets. Tyrosine 99-107 C-reactive protein Homo sapiens 70-73 12398959-5 2002 Significant but weak correlations were observed between baseline CRP values and baseline levels of LDL cholesterol and high-density lipoprotein (HDL) cholesterol, but not with TGs. Cholesterol 103-114 C-reactive protein Homo sapiens 65-68 12398959-5 2002 Significant but weak correlations were observed between baseline CRP values and baseline levels of LDL cholesterol and high-density lipoprotein (HDL) cholesterol, but not with TGs. Cholesterol 150-161 C-reactive protein Homo sapiens 65-68 12398959-6 2002 CRP was also correlated with body mass index and fasting levels of glucose and insulin. Glucose 67-74 C-reactive protein Homo sapiens 0-3 12407643-7 2002 Univariate comparisons between subjects with or without elevated CRP levels (>10 mg/L) showed that CRP level elevation was associated significantly (P < 0.05) with greater doses of human recombinant erythropoietin and lower levels of hemoglobin, serum iron, transferrin saturation (TSat), albumin averaged over the 3 preceding months, total cholesterol, and triglycerides. Cholesterol 347-358 C-reactive protein Homo sapiens 102-105 12398959-8 2002 Although CRP change was weakly correlated with changes in LDL cholesterol, TGs, and HDL cholesterol, results of regression analyses showed that only baseline CRP and treatment allocation were significant predictors of CRP response after 6 weeks of study drug administration. Cholesterol 88-99 C-reactive protein Homo sapiens 9-12 12407643-7 2002 Univariate comparisons between subjects with or without elevated CRP levels (>10 mg/L) showed that CRP level elevation was associated significantly (P < 0.05) with greater doses of human recombinant erythropoietin and lower levels of hemoglobin, serum iron, transferrin saturation (TSat), albumin averaged over the 3 preceding months, total cholesterol, and triglycerides. Triglycerides 364-377 C-reactive protein Homo sapiens 102-105 12208482-2 2002 In this setting, C-reactive protein (CRP) was shown to add predictive value to cholesterol levels. Cholesterol 79-90 C-reactive protein Homo sapiens 17-35 12208482-2 2002 In this setting, C-reactive protein (CRP) was shown to add predictive value to cholesterol levels. Cholesterol 79-90 C-reactive protein Homo sapiens 37-40 12428180-0 2002 Moderate alcohol consumption reduces plasma C-reactive protein and fibrinogen levels; a randomized, diet-controlled intervention study. Alcohols 9-16 C-reactive protein Homo sapiens 44-62 12421431-0 2002 C-reactive protein is more strongly related to post-glucose load glucose than to fasting glucose in non-diabetic subjects; the Insulin Resistance Atherosclerosis Study. Glucose 52-59 C-reactive protein Homo sapiens 0-18 12421431-0 2002 C-reactive protein is more strongly related to post-glucose load glucose than to fasting glucose in non-diabetic subjects; the Insulin Resistance Atherosclerosis Study. Glucose 65-72 C-reactive protein Homo sapiens 0-18 12421431-0 2002 C-reactive protein is more strongly related to post-glucose load glucose than to fasting glucose in non-diabetic subjects; the Insulin Resistance Atherosclerosis Study. Glucose 65-72 C-reactive protein Homo sapiens 0-18 12421431-3 2002 METHODS: We studied the relationship of CRP (measured with a highly sensitive immunoassay) with fasting glucose and 2-h glucose concentrations during an oral glucose tolerance test in non-diabetic subjects from the Insulin Resistance Atherosclerosis Study. Glucose 104-111 C-reactive protein Homo sapiens 40-43 12421431-3 2002 METHODS: We studied the relationship of CRP (measured with a highly sensitive immunoassay) with fasting glucose and 2-h glucose concentrations during an oral glucose tolerance test in non-diabetic subjects from the Insulin Resistance Atherosclerosis Study. Glucose 120-127 C-reactive protein Homo sapiens 40-43 12421431-3 2002 METHODS: We studied the relationship of CRP (measured with a highly sensitive immunoassay) with fasting glucose and 2-h glucose concentrations during an oral glucose tolerance test in non-diabetic subjects from the Insulin Resistance Atherosclerosis Study. Glucose 120-127 C-reactive protein Homo sapiens 40-43 12421431-4 2002 RESULTS: Spearman correlation analyses and multiple linear regression analyses showed a significant association of both fasting glucose and 2-h glucose concentrations with CRP levels, after adjusting for demographic covariates (age, sex, ethnicity, clinical centre; Spearman correlation coefficients: r = 0.18 for fasting glucose, r = 0.27 for 2-h glucose, both P < 0.0001). Glucose 128-135 C-reactive protein Homo sapiens 172-175 12426218-3 2002 CRP values were adjusted for age, body mass index, vitamin use, statin medication use, aspirin use, the presence of inflammatory disease, cardiovascular disease, and diabetes, and smoking habit. Aspirin 87-94 C-reactive protein Homo sapiens 0-3 12421431-4 2002 RESULTS: Spearman correlation analyses and multiple linear regression analyses showed a significant association of both fasting glucose and 2-h glucose concentrations with CRP levels, after adjusting for demographic covariates (age, sex, ethnicity, clinical centre; Spearman correlation coefficients: r = 0.18 for fasting glucose, r = 0.27 for 2-h glucose, both P < 0.0001). Glucose 144-151 C-reactive protein Homo sapiens 172-175 12421431-5 2002 However, after additional adjustment for body mass index and waist-hip ratio only 2-h glucose (and not fasting glucose) was significantly related to CRP (r = 0.03 for fasting glucose, P = NS; r = 0.14 for 2-h glucose, P < 0.0001). Glucose 86-93 C-reactive protein Homo sapiens 149-152 12421431-6 2002 Adding insulin sensitivity to the multivariate models further weakened the relationship of CRP to 2-h glucose (r = 0.07, P < 0.05). Glucose 102-109 C-reactive protein Homo sapiens 91-94 12421431-7 2002 CRP mean values increased by 2-h glucose category (normal vs. impaired glucose tolerance vs. isolated post-challenge hyperglycaemia). Glucose 33-40 C-reactive protein Homo sapiens 0-3 12421431-8 2002 CONCLUSIONS: Chronic, subclinical inflammation, as indicated by elevated circulating CRP levels, is more strongly associated with post-challenge glycaemia than with fasting glucose levels in non-diabetic subjects. Glucose 173-180 C-reactive protein Homo sapiens 85-88 12428180-1 2002 OBJECTIVE: To evaluate the effect of moderate alcohol consumption on the acute phase proteins C-reactive protein and fibrinogen. Alcohols 46-53 C-reactive protein Homo sapiens 94-112 12428180-11 2002 CONCLUSIONS: Moderate alcohol consumption significantly decreased plasma C-reactive protein and fibrinogen levels. Alcohols 22-29 C-reactive protein Homo sapiens 73-91 12422112-8 2002 An inverse linear correlation was found between total cholesterol/low density lipoprotein cholesterol and C-reactive protein (P <.001 and P <.04, respectively). Cholesterol 54-65 C-reactive protein Homo sapiens 106-124 12463288-0 2002 Relation between alcohol consumption and C-reactive protein levels in the adult US population. Alcohols 17-24 C-reactive protein Homo sapiens 41-59 12463288-3 2002 METHODS: To evaluate the association of alcohol consumption with C-reactive protein, we analyzed the findings of the Third National Health and Nutrition Examination, a population-based survey representing the noninstitutionalized US population. Alcohols 40-47 C-reactive protein Homo sapiens 65-83 12463288-9 2002 CONCLUSIONS: Alcohol consumption is associated with a decreased probability of elevated C-reactive protein levels. Alcohols 13-20 C-reactive protein Homo sapiens 88-106 12102655-0 2002 Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein. Cholesterol 95-106 C-reactive protein Homo sapiens 11-29 12387653-10 2002 Based on multiple regression analysis, C-reactive protein levels and WHRs of 0.86 or higher predicted the rate of 8-iso PGF(2alpha) excretion independently of insulin and leptin levels. 8-iso pgf 114-123 C-reactive protein Homo sapiens 39-57 12102655-0 2002 Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein. Cholesterol 95-106 C-reactive protein Homo sapiens 129-147 12102655-6 2002 Consistent with this hypothesis were the following findings: (i) increasing the amount of non-esterified cholesterol in LDL with cyclodextrin increased, and decreasing its amount decreased, the binding of CRP to LDL; (ii) modification of non-esterified cholesterol in LDL by cholesterol oxidase decreased the binding of CRP to LDL; and (iii) CRP bound to purified non-esterified cholesterol. Cholesterol 105-116 C-reactive protein Homo sapiens 205-208 12102655-6 2002 Consistent with this hypothesis were the following findings: (i) increasing the amount of non-esterified cholesterol in LDL with cyclodextrin increased, and decreasing its amount decreased, the binding of CRP to LDL; (ii) modification of non-esterified cholesterol in LDL by cholesterol oxidase decreased the binding of CRP to LDL; and (iii) CRP bound to purified non-esterified cholesterol. Cholesterol 105-116 C-reactive protein Homo sapiens 320-323 12102655-5 2002 In these two forms of modified LDL, non-esterified cholesterol was susceptible to cholesterol oxidase, indicating exposure of non-esterified cholesterol on particle surfaces and suggesting a role for non-esterified cholesterol in mediating CRP binding. Cholesterol 51-62 C-reactive protein Homo sapiens 240-243 12102655-6 2002 Consistent with this hypothesis were the following findings: (i) increasing the amount of non-esterified cholesterol in LDL with cyclodextrin increased, and decreasing its amount decreased, the binding of CRP to LDL; (ii) modification of non-esterified cholesterol in LDL by cholesterol oxidase decreased the binding of CRP to LDL; and (iii) CRP bound to purified non-esterified cholesterol. Cholesterol 105-116 C-reactive protein Homo sapiens 320-323 12370214-0 2002 Supplementation with conjugated linoleic acid causes isomer-dependent oxidative stress and elevated C-reactive protein: a potential link to fatty acid-induced insulin resistance. Linoleic Acid 32-45 C-reactive protein Homo sapiens 100-118 12102655-6 2002 Consistent with this hypothesis were the following findings: (i) increasing the amount of non-esterified cholesterol in LDL with cyclodextrin increased, and decreasing its amount decreased, the binding of CRP to LDL; (ii) modification of non-esterified cholesterol in LDL by cholesterol oxidase decreased the binding of CRP to LDL; and (iii) CRP bound to purified non-esterified cholesterol. Cyclodextrins 129-141 C-reactive protein Homo sapiens 205-208 12102655-6 2002 Consistent with this hypothesis were the following findings: (i) increasing the amount of non-esterified cholesterol in LDL with cyclodextrin increased, and decreasing its amount decreased, the binding of CRP to LDL; (ii) modification of non-esterified cholesterol in LDL by cholesterol oxidase decreased the binding of CRP to LDL; and (iii) CRP bound to purified non-esterified cholesterol. Cholesterol 253-264 C-reactive protein Homo sapiens 205-208 12102655-6 2002 Consistent with this hypothesis were the following findings: (i) increasing the amount of non-esterified cholesterol in LDL with cyclodextrin increased, and decreasing its amount decreased, the binding of CRP to LDL; (ii) modification of non-esterified cholesterol in LDL by cholesterol oxidase decreased the binding of CRP to LDL; and (iii) CRP bound to purified non-esterified cholesterol. Cholesterol 253-264 C-reactive protein Homo sapiens 205-208 12102655-8 2002 Taken together, these findings suggest that CRP can bind to modified lipoproteins, notably to the non-esterified cholesterol on their surface. Cholesterol 113-124 C-reactive protein Homo sapiens 44-47 12370214-0 2002 Supplementation with conjugated linoleic acid causes isomer-dependent oxidative stress and elevated C-reactive protein: a potential link to fatty acid-induced insulin resistance. Fatty Acids 140-150 C-reactive protein Homo sapiens 100-118 12714834-2 2002 In this study, we showed that the combination regimen of clopidogrel with aspirin could downregulate the P-selectin expression on platelets and the plasma concentration of C-reactive protein (CRP) in acute stage of atherosclerotic ischemic stroke. Aspirin 74-81 C-reactive protein Homo sapiens 172-190 12356402-0 2002 Effect of atorvastatin (80 mg) initiated at the time of coronary artery stent implantation on C-reactive protein and six-month clinical events. Atorvastatin 10-22 C-reactive protein Homo sapiens 94-112 12204808-1 2002 The aim of this study was to investigate the possible association of plasma C-reactive protein (CRP) levels with the presence of angiographically multiple complex lesions (CLs) in patients with primary unstable angina (PUA). calusterone 172-175 C-reactive protein Homo sapiens 76-94 12204808-1 2002 The aim of this study was to investigate the possible association of plasma C-reactive protein (CRP) levels with the presence of angiographically multiple complex lesions (CLs) in patients with primary unstable angina (PUA). calusterone 172-175 C-reactive protein Homo sapiens 96-99 12204808-6 2002 Tertiles of plasma CRP levels upon admission were significantly associated with the number of CLs on angiographic studies. calusterone 94-97 C-reactive protein Homo sapiens 19-22 12204808-7 2002 In particular there was a significant gradual increase in either the number of CLs, or the presence of apparently thrombus-containing CLs with increasing of CRP tertiles. calusterone 79-82 C-reactive protein Homo sapiens 157-160 12204808-7 2002 In particular there was a significant gradual increase in either the number of CLs, or the presence of apparently thrombus-containing CLs with increasing of CRP tertiles. calusterone 134-137 C-reactive protein Homo sapiens 157-160 12204808-8 2002 By multivariate analysis CRP was independently associated with the presence of either multiple CLs (R.R.=1.8, 95%CI=1.5-2.2, P<0.001), or angiographically apparent thrombus-containing CLs (R.R.=1.4, 95%CI=1.2-1.7, P=0.03).High plasma levels of CRP may reflect a multifocal activation of the coronary tree in patients with PUA. calusterone 95-98 C-reactive protein Homo sapiens 25-28 12204808-8 2002 By multivariate analysis CRP was independently associated with the presence of either multiple CLs (R.R.=1.8, 95%CI=1.5-2.2, P<0.001), or angiographically apparent thrombus-containing CLs (R.R.=1.4, 95%CI=1.2-1.7, P=0.03).High plasma levels of CRP may reflect a multifocal activation of the coronary tree in patients with PUA. calusterone 187-190 C-reactive protein Homo sapiens 25-28 12351557-0 2002 Effects of tibolone and combined 17beta-estradiol and norethisterone acetate on serum C-reactive protein in healthy post-menopausal women: a randomized trial. Estradiol 33-49 C-reactive protein Homo sapiens 86-104 12351557-2 2002 Oral unopposed and progestin-combined 17beta-estradiol (E(2)) increase serum CRP in post-menopausal women. Estradiol 38-54 C-reactive protein Homo sapiens 77-80 12368396-3 2002 The acute phase response, defined by raised CRP (plasma concentration >10 mg/L), raised AGP (>1.2 g/L), or both raised CRP and AGP, significantly affected indicators of iron, vitamin A and zinc status, independently of the effects of supplementation. Iron 175-179 C-reactive protein Homo sapiens 44-47 12368396-3 2002 The acute phase response, defined by raised CRP (plasma concentration >10 mg/L), raised AGP (>1.2 g/L), or both raised CRP and AGP, significantly affected indicators of iron, vitamin A and zinc status, independently of the effects of supplementation. Iron 175-179 C-reactive protein Homo sapiens 125-128 12714834-2 2002 In this study, we showed that the combination regimen of clopidogrel with aspirin could downregulate the P-selectin expression on platelets and the plasma concentration of C-reactive protein (CRP) in acute stage of atherosclerotic ischemic stroke. Aspirin 74-81 C-reactive protein Homo sapiens 192-195 12714834-5 2002 RESULTS: The combined regimen of clopidogrel and aspirin significantly reduced platelet P-selectin expression (93.6 +/- 16.6, p < 0.01) and plasma concentration of CRP (1.2 +/- 1.5 mg/dl, p < 0.01) after 7 days of stroke onset compared with the values (P-selectin; 115.5 +/- 20.7, CRP; 2.5 +/- 2.8 mg/dl) of initial 24 hr. Aspirin 49-56 C-reactive protein Homo sapiens 167-170 12714834-5 2002 RESULTS: The combined regimen of clopidogrel and aspirin significantly reduced platelet P-selectin expression (93.6 +/- 16.6, p < 0.01) and plasma concentration of CRP (1.2 +/- 1.5 mg/dl, p < 0.01) after 7 days of stroke onset compared with the values (P-selectin; 115.5 +/- 20.7, CRP; 2.5 +/- 2.8 mg/dl) of initial 24 hr. Aspirin 49-56 C-reactive protein Homo sapiens 287-290 12244213-0 2002 C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Phospholipids 136-149 C-reactive protein Homo sapiens 0-18 12244213-7 2002 Reciprocally, CRP binds to PC, which can be competed for by OxLDL and OxPtC but not by native LDL, nonoxidized PtC, or by oxidized phospholipids without the PC headgroup. Phospholipids 131-144 C-reactive protein Homo sapiens 14-17 12244213-10 2002 We propose that, analogous to EO6 and scavenger receptors, CRP is a part of the innate immune response to oxidized PC-bearing phospholipids within OxLDL and on the plasma membranes of apoptotic cells. Phospholipids 126-139 C-reactive protein Homo sapiens 59-62 12183336-14 2002 Simultaneous blockade of the P2Y(1) and P2Y(12) receptors, and inhibition of cyclo-oxygenase demonstrated that CRP can activate platelets independently of ADP and TxA(2); however, responses to the collagens were dependent on these mediators. Adenosine Diphosphate 155-158 C-reactive protein Homo sapiens 111-114 12218140-3 2002 Crystallographic data on CRP-PCh complexes indicate that Phe(66) and Glu(81) contribute to the formation of the PCh binding site of CRP. Glutamic Acid 69-72 C-reactive protein Homo sapiens 25-28 12218140-3 2002 Crystallographic data on CRP-PCh complexes indicate that Phe(66) and Glu(81) contribute to the formation of the PCh binding site of CRP. Glutamic Acid 69-72 C-reactive protein Homo sapiens 132-135 12218140-4 2002 We used site-directed mutagenesis to analyze the contribution of Phe(66) and Glu(81) to the binding of CRP to PCh, and to generate a CRP mutant that does not bind to PCh-containing ligands. Glutamic Acid 77-80 C-reactive protein Homo sapiens 103-106 12186793-0 2002 A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Nitric Oxide 58-70 C-reactive protein Homo sapiens 28-46 12186793-5 2002 Incubation of ECs with CRP resulted in a significant inhibition of basal and stimulated NO release, with concomitant reductions in cGMP production. Cyclic GMP 131-135 C-reactive protein Homo sapiens 23-26 12163427-9 2002 CONCLUSIONS: Rosiglitazone reduces serum levels of MMP-9 and the proinflammatory marker CRP in patients with type 2 diabetes, which indicates potentially beneficial effects on overall cardiovascular risk. Rosiglitazone 13-26 C-reactive protein Homo sapiens 88-91 12033985-2 2002 C-reactive protein (CRP) is an acute-phase protein found in atherosclerotic lesions, which when immobilized on a solid phase, can bind and cluster LDL particles in a calcium-dependent manner. Calcium 166-173 C-reactive protein Homo sapiens 0-18 12033985-2 2002 C-reactive protein (CRP) is an acute-phase protein found in atherosclerotic lesions, which when immobilized on a solid phase, can bind and cluster LDL particles in a calcium-dependent manner. Calcium 166-173 C-reactive protein Homo sapiens 20-23 12033985-4 2002 CRP molecules were aggregated in the presence of calcium and immobilized on the surface of polystyrene microtitre wells. Calcium 49-56 C-reactive protein Homo sapiens 0-3 12033985-5 2002 Human LDL added to the wells bound to and aggregated on the immobilized CRP, also in a calcium-dependent manner. Calcium 87-94 C-reactive protein Homo sapiens 72-75 12033985-6 2002 On incubation with macrophages, the immobilized CRP-bound LDL aggregates were readily taken up by the cells, as demonstrated by immunofluorescence microscopy, by the cellular accumulation of cholesterol and by the overexpression of adipophilin. Cholesterol 191-202 C-reactive protein Homo sapiens 48-51 12163427-4 2002 The purpose of this analysis was to determine whether rosiglitazone alters serum concentrations of CRP, IL-6, MMP-9, and white blood cell count (WBC) and to examine the relationship of these effects with demographic and disease variables. Rosiglitazone 54-67 C-reactive protein Homo sapiens 99-102 12163427-6 2002 After 26 weeks of rosiglitazone treatment, the percentage reductions in mean CRP, MMP-9, and WBC levels were statistically significant compared with baseline and placebo (P<0.01). Rosiglitazone 18-31 C-reactive protein Homo sapiens 77-80 12103255-9 2002 CONCLUSIONS: Our results suggest that individuals with elevated CRP levels, many of whom do not meet current National Cholesterol Education Program guidelines for drug treatment, may receive a substantial benefit from statin therapy. Cholesterol 118-129 C-reactive protein Homo sapiens 64-67 12151853-8 2002 Because drugs such as aspirin and statins reduce inflammatory risk, C-reactive protein has the potential to guide the use of these therapies in high-risk individuals for primary prevention. Aspirin 22-29 C-reactive protein Homo sapiens 68-86 12185432-10 2002 Urinary NOx concentrations were positively correlated with serum C-reactive protein concentrations (P<0.01), but inversely correlated with the cardiopulmonary bypass time (P<0.01). nicotine 1-N-oxide 8-11 C-reactive protein Homo sapiens 65-83 12138260-16 2002 CONCLUSIONS: IL-6 and CRP were increased and were inversely related to creatinine clearance in our population of 103 chronic predialytic patients. Creatinine 71-81 C-reactive protein Homo sapiens 22-25 12616983-4 2002 The already elevated CRP in postmenopausal diabetic women showed a moderate increase after 6 weeks of treatment with 17 beta-oestradiol. Estradiol 117-135 C-reactive protein Homo sapiens 21-24 12093777-9 2002 Coronary calcium scores were strongly correlated with C-reactive protein and Chlamydia pneumoniae seropositivity, time-averaged mean serum parathyroid hormone, and plasma homocysteine. Calcium 9-16 C-reactive protein Homo sapiens 54-72 12093777-10 2002 C-reactive protein and parathyroid hormone independently predicted coronary calcium accumulation. Calcium 76-83 C-reactive protein Homo sapiens 0-18 12008177-0 2002 Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Atorvastatin 54-66 C-reactive protein Homo sapiens 113-131 12127125-9 2002 However, on postoperative day 1 the median C-reactive protein level was significantly higher in the GLC group than that in the CLC group (P < 0.05). Glucose 100-103 C-reactive protein Homo sapiens 43-61 12362497-14 2002 There was statistically significant negative correlation between CRP level and HDL-cholesterol and Apo-A levels. Cholesterol 83-94 C-reactive protein Homo sapiens 65-68 12362497-16 2002 CONCLUSIONS: Our study confirmed findings by other authors that there is a relationship between CRP level and other coronary heart disease factors such as W/H ratio and HDL-cholesterol. Cholesterol 173-184 C-reactive protein Homo sapiens 96-99 12037301-0 2002 The three-dimensional structure of calcium-depleted human C-reactive protein from perfectly twinned crystals. Calcium 35-42 C-reactive protein Homo sapiens 58-76 12037301-3 2002 The role of hCRP in host defence and the calcium-dependent ligand-binding specificity of hCRP for phosphocholine moieties have long been recognized. Calcium 41-48 C-reactive protein Homo sapiens 89-93 12037301-4 2002 In order to clarify the structural rearrangements associated with calcium binding, the reported affinity of calcium-depleted hCRP for polycations and other ligands, and the role of calcium in protection against denaturation and proteolysis, the structure of calcium-depleted hCRP has been determined by X-ray crystallography. Calcium 108-115 C-reactive protein Homo sapiens 125-129 12037301-4 2002 In order to clarify the structural rearrangements associated with calcium binding, the reported affinity of calcium-depleted hCRP for polycations and other ligands, and the role of calcium in protection against denaturation and proteolysis, the structure of calcium-depleted hCRP has been determined by X-ray crystallography. Calcium 108-115 C-reactive protein Homo sapiens 125-129 12037301-4 2002 In order to clarify the structural rearrangements associated with calcium binding, the reported affinity of calcium-depleted hCRP for polycations and other ligands, and the role of calcium in protection against denaturation and proteolysis, the structure of calcium-depleted hCRP has been determined by X-ray crystallography. Calcium 108-115 C-reactive protein Homo sapiens 125-129 12037301-5 2002 Crystals of calcium-depleted hCRP are invariably twinned and those suitable for analysis are merohedral type II twins of point group 4 single crystals. Calcium 12-19 C-reactive protein Homo sapiens 29-33 12037301-6 2002 The structure has been solved by molecular replacement using the calcium-bound hCRP structure [Shrive et al. Calcium 65-72 C-reactive protein Homo sapiens 79-83 12011986-2 2002 Here we show that CRP exists in different structural forms in solution and on phospholipid membranes. Phospholipids 78-90 C-reactive protein Homo sapiens 18-21 12371641-11 2002 Although the mean CRP level at 90 min for FMF cases with cortisol levels under 12 microg/dl at 30 min was found to be higher than those with cortisol levels over 12 microg/dl at 30 min, no significant difference was observed. Hydrocortisone 57-65 C-reactive protein Homo sapiens 18-21 12371641-13 2002 Furthermore, the fact that the CRP level was relatively higher in FMF patients with lower cortisol levels might also highlight the importance of endogen cortisol in the inflammatory feature of this disease. Hydrocortisone 90-98 C-reactive protein Homo sapiens 31-34 12371641-13 2002 Furthermore, the fact that the CRP level was relatively higher in FMF patients with lower cortisol levels might also highlight the importance of endogen cortisol in the inflammatory feature of this disease. Hydrocortisone 153-161 C-reactive protein Homo sapiens 31-34 12197410-10 2002 Some papers deal with antiinflammatory effects of statins, because these lower CRP levels so they also lower atherosclerotic risk through not only lowering of cholesterol levels. Cholesterol 159-170 C-reactive protein Homo sapiens 79-82 11996943-0 2002 Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atorvastatin 10-22 C-reactive protein Homo sapiens 59-77 11996943-3 2002 The present study evaluated the effects of atorvastatin (10-40 mg) and bezafibrate (400 mg) on CRP concentrations after 6 and 12 months of treatment in 103 patients with combined (mixed) hyperlipidemia. Atorvastatin 43-55 C-reactive protein Homo sapiens 95-98 11996943-5 2002 After 6 months and 1 year, atorvastatin treatment was associated with significant (P<0.001) decreases from baseline of CRP concentrations by 29 and 43%, respectively, while bezafibrate-treated patients showed non-significant reductions of 2.3 and 14.6%, respectively (P=0.056 and 0.005 for the respective differences between the two treatment arms at 6 months and 1 year). Atorvastatin 27-39 C-reactive protein Homo sapiens 122-125 11996943-7 2002 Covariance analysis showed that CRP decreases in the atorvastatin group were unrelated to total cholesterol and LDL cholesterol reductions; however, they were directly related to triglyceride changes (r=0.28, P=0.047) and inversely related to HDL cholesterol changes (r=-0.28, P=0.045). Atorvastatin 53-65 C-reactive protein Homo sapiens 32-35 11996943-7 2002 Covariance analysis showed that CRP decreases in the atorvastatin group were unrelated to total cholesterol and LDL cholesterol reductions; however, they were directly related to triglyceride changes (r=0.28, P=0.047) and inversely related to HDL cholesterol changes (r=-0.28, P=0.045). Triglycerides 179-191 C-reactive protein Homo sapiens 32-35 11996943-8 2002 A model including baseline CRP values and treatment effect showed that atorvastatin use was a significant predictor of change in CRP levels over time (beta=0.82, P=0.023). Atorvastatin 71-83 C-reactive protein Homo sapiens 27-30 11996943-8 2002 A model including baseline CRP values and treatment effect showed that atorvastatin use was a significant predictor of change in CRP levels over time (beta=0.82, P=0.023). Atorvastatin 71-83 C-reactive protein Homo sapiens 129-132 12009719-6 2002 The decrease in CRP lowering was thus fully established by 1 month and this response was independent of lipid and lipoprotein changes as well as atorvastatin doses. Atorvastatin 145-157 C-reactive protein Homo sapiens 16-19 11978661-5 2002 In multivariate analysis, CRP remained a predictor of diabetes development (HR 1.30; 95% CI 1.07-1.58; P = 0.0075) independent of other clinically employed predictors, including baseline BMI and fasting triglyceride and glucose concentrations. Triglycerides 203-215 C-reactive protein Homo sapiens 26-29 11978661-5 2002 In multivariate analysis, CRP remained a predictor of diabetes development (HR 1.30; 95% CI 1.07-1.58; P = 0.0075) independent of other clinically employed predictors, including baseline BMI and fasting triglyceride and glucose concentrations. Glucose 220-227 C-reactive protein Homo sapiens 26-29 12009719-0 2002 Short-term effects of atorvastatin on C-reactive protein. Atorvastatin 22-34 C-reactive protein Homo sapiens 38-56 12009719-7 2002 CONCLUSION: Atorvastatin significantly decreases CRP concentrations after 4 weeks of therapy. Atorvastatin 12-24 C-reactive protein Homo sapiens 49-52 12009719-1 2002 AIM: To study the short-term effect of atorvastatin on C-reactive protein (CRP) in patients with or at risk for coronary heart disease. Atorvastatin 39-51 C-reactive protein Homo sapiens 55-73 12009719-1 2002 AIM: To study the short-term effect of atorvastatin on C-reactive protein (CRP) in patients with or at risk for coronary heart disease. Atorvastatin 39-51 C-reactive protein Homo sapiens 75-78 11950696-6 2002 Age-, sex-, and glucose tolerance- adjusted logistic regression analyses showed the development of elevated UAER to be significantly associated with levels of sVCAM-1 and CRP (odds ratio 1.14 [95% CI 1.02 to 1.27] per 10% increase of sVCAM-1 and odds ratio 1.17 [95% CI 1.04 to 1.32] per 50% increase of CRP). Glucose 16-23 C-reactive protein Homo sapiens 159-174 12021247-5 2002 High-dose aspirin treatment resulted in a approximately 25% reduction in fasting plasma glucose, associated with a approximately 15% reduction in total cholesterol and C-reactive protein, a approximately 50% reduction in triglycerides, and a approximately 30% reduction in insulin clearance, despite no change in body weight. Aspirin 10-17 C-reactive protein Homo sapiens 168-186 11950696-6 2002 Age-, sex-, and glucose tolerance- adjusted logistic regression analyses showed the development of elevated UAER to be significantly associated with levels of sVCAM-1 and CRP (odds ratio 1.14 [95% CI 1.02 to 1.27] per 10% increase of sVCAM-1 and odds ratio 1.17 [95% CI 1.04 to 1.32] per 50% increase of CRP). Glucose 16-23 C-reactive protein Homo sapiens 171-174 11959386-7 2002 Moreover, C-reactive protein was independently associated with triglycerides (P<0.0001), age (P=0.0130), body mass index (P=0.0179), and acute (P=0.0280) and chronic (P=0.0582) inflammations (R2=0.17). Triglycerides 63-76 C-reactive protein Homo sapiens 10-28 11916936-6 2002 In contrast to PAI-1, the association of CRP and fibrinogen with incident diabetes was significantly attenuated after adjustment for body fat (BMI or waist circumference) or insulin sensitivity (S(I)), as assessed by a frequently sampled intravenous glucose tolerance test. Glucose 250-257 C-reactive protein Homo sapiens 41-44 11781328-1 2002 Cyclic AMP receptor protein (CRP) is a homodimeric protein, which is activated by cAMP binding to function as a transcriptional regulator of many genes in prokaryotes. Cyclic AMP 82-86 C-reactive protein Homo sapiens 0-27 11952885-8 2002 CRP and SAA was significantly reduced by atorvastatin, whilst no reduction was seen for simvastatin. Atorvastatin 41-53 C-reactive protein Homo sapiens 0-3 11952885-12 2002 CONCLUSION: Atorvastatin reduced the liver-derived acute-phase reactants, CRP and SAA, whilst the effect of simvastatin was small or absent. Atorvastatin 12-24 C-reactive protein Homo sapiens 74-77 11932303-13 2002 In the placebo-controlled study, CRP increased in patients treated with 20 mg pegvisomant, compared with placebo (mean +/- SEM, 13.7 +/- 3.6 vs. 0.5 +/- 3.3 mg/liter; P = 0.010). pegvisomant 78-89 C-reactive protein Homo sapiens 33-36 11932303-19 2002 Administration of pegvisomant increases CRP levels. pegvisomant 18-29 C-reactive protein Homo sapiens 40-43 11781328-1 2002 Cyclic AMP receptor protein (CRP) is a homodimeric protein, which is activated by cAMP binding to function as a transcriptional regulator of many genes in prokaryotes. Cyclic AMP 82-86 C-reactive protein Homo sapiens 29-32 11781328-2 2002 Until now, the actual number of cAMP molecules that can be bound by CRP in solution has been ambiguous. Cyclic AMP 32-36 C-reactive protein Homo sapiens 68-71 11781328-6 2002 Altogether, the results not only established for the first time that CRP possesses two cyclic AMP-binding sites in each monomer, even in a solution without DNA, but also suggest that the syn-cAMP binding sites of the CRP dimer can be formed by an allosteric conformational change of the protein upon the binding of two anti-cAMPs at the N-terminal domain. Cyclic AMP 87-97 C-reactive protein Homo sapiens 69-72 11781328-6 2002 Altogether, the results not only established for the first time that CRP possesses two cyclic AMP-binding sites in each monomer, even in a solution without DNA, but also suggest that the syn-cAMP binding sites of the CRP dimer can be formed by an allosteric conformational change of the protein upon the binding of two anti-cAMPs at the N-terminal domain. Cyclic AMP 87-97 C-reactive protein Homo sapiens 217-220 11781328-6 2002 Altogether, the results not only established for the first time that CRP possesses two cyclic AMP-binding sites in each monomer, even in a solution without DNA, but also suggest that the syn-cAMP binding sites of the CRP dimer can be formed by an allosteric conformational change of the protein upon the binding of two anti-cAMPs at the N-terminal domain. Cyclic AMP 191-195 C-reactive protein Homo sapiens 69-72 11781328-6 2002 Altogether, the results not only established for the first time that CRP possesses two cyclic AMP-binding sites in each monomer, even in a solution without DNA, but also suggest that the syn-cAMP binding sites of the CRP dimer can be formed by an allosteric conformational change of the protein upon the binding of two anti-cAMPs at the N-terminal domain. Cyclic AMP 191-195 C-reactive protein Homo sapiens 217-220 11781328-7 2002 In addition, a residue-specific inspection of the spectral changes provides some new structural information about the cAMP-induced allosteric activation of CRP. Cyclic AMP 118-122 C-reactive protein Homo sapiens 156-159 11772786-0 2002 Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin: the Third National Health and Nutrition Examination Survey, 1988-1994. Glucose 63-70 C-reactive protein Homo sapiens 22-40 11801683-5 2002 The results are consistent with signaling through the intrinsic immunoreceptor tyrosine-based activation motif of the cytoplasmic domain of FcgammaRIIa, the major CRP-receptor on monocytes and neutrophils that is responsible for CRP-mediated phagocytosis. Tyrosine 79-87 C-reactive protein Homo sapiens 163-166 11801683-5 2002 The results are consistent with signaling through the intrinsic immunoreceptor tyrosine-based activation motif of the cytoplasmic domain of FcgammaRIIa, the major CRP-receptor on monocytes and neutrophils that is responsible for CRP-mediated phagocytosis. Tyrosine 79-87 C-reactive protein Homo sapiens 229-232 11878797-1 2002 Microparticles in the circulation activate the coagulation system and may activate the complement system via C-reactive protein upon conversion of membrane phospholipids by phospholipases. Phospholipids 156-169 C-reactive protein Homo sapiens 109-127 11893365-1 2002 PURPOSE: C-reactive protein is an important risk factor for coronary artery disease, and plasma concentrations are lowered by treatment with pravastatin and aspirin. Aspirin 157-164 C-reactive protein Homo sapiens 9-27 11974664-7 2002 A significant inverse correlation coefficient between a CRP level > 1 mg/dl and hemoglobin, transferrin levels and percent transferrin saturation was observed: the strongest correlation was with serum iron levels. Iron 204-208 C-reactive protein Homo sapiens 56-59 11910871-5 2002 The C-reactive protein is predictive for late complications such as restenosis, reinfarction and death due to cardiac events; these patients benefit from close controls and from an anti-inflammatory therapy with acetylsalicyclic acid and statins. Aspirin 212-233 C-reactive protein Homo sapiens 4-22 11827920-4 2002 Significant correlations were also found between plasma CRP and triglyceride levels (r=0.33, P<0.009) and glucose disposal measured by the hyperinsulinemic-euglycemic clamp technique (r=-0.29, P<0.03). Triglycerides 64-76 C-reactive protein Homo sapiens 56-59 11827920-4 2002 Significant correlations were also found between plasma CRP and triglyceride levels (r=0.33, P<0.009) and glucose disposal measured by the hyperinsulinemic-euglycemic clamp technique (r=-0.29, P<0.03). Glucose 109-116 C-reactive protein Homo sapiens 56-59 11836286-0 2002 Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. Atorvastatin 0-12 C-reactive protein Homo sapiens 20-38 11836286-7 2002 At 6 months, plasma CRP decreased in the atorvastatin group compared with baseline (P < 0.05). Atorvastatin 41-53 C-reactive protein Homo sapiens 20-23 11772786-1 2002 This study investigated the associations between serum C-reactive protein and fasting blood levels of insulin, glucose, and hemoglobin A1c (HbA1c). Glucose 111-118 C-reactive protein Homo sapiens 55-73 11772786-8 2002 In conclusion, elevated C-reactive protein was associated with higher insulin and HbA1c among men and women and with higher glucose levels among women only. Glucose 124-131 C-reactive protein Homo sapiens 24-42 11979597-1 2002 Cyclic AMP (cAMP) receptor protein (CRP) forms 1:1 and 1:2 complexes with cAMP, and the former complex is considered to be the most active form of CRP in binding to specific DNA sequences and in modulating gene transcription by RNA polymerases. Cyclic AMP 12-16 C-reactive protein Homo sapiens 36-39 11979597-1 2002 Cyclic AMP (cAMP) receptor protein (CRP) forms 1:1 and 1:2 complexes with cAMP, and the former complex is considered to be the most active form of CRP in binding to specific DNA sequences and in modulating gene transcription by RNA polymerases. Cyclic AMP 12-16 C-reactive protein Homo sapiens 147-150 11979597-2 2002 We examine the cAMP binding modes and structural changes of CRP upon cAMP binding by UV resonance Raman spectroscopy. Cyclic AMP 69-73 C-reactive protein Homo sapiens 60-63 11979597-3 2002 The Raman spectra of CRP-(cAMP)(1) and CRP-(cAMP)(2) extracted from those of CRP-cAMP mixtures at varied mixing ratios clearly show that the hydrogen bonding state and the conformation of cAMP in both complexes in solution are very similar to those found in the X-ray crystal structure of CRP-(cAMP)(2), which is evidence that the cAMP binding mode does not differ between the two complexes. Cyclic AMP 26-30 C-reactive protein Homo sapiens 21-24 11979597-3 2002 The Raman spectra of CRP-(cAMP)(1) and CRP-(cAMP)(2) extracted from those of CRP-cAMP mixtures at varied mixing ratios clearly show that the hydrogen bonding state and the conformation of cAMP in both complexes in solution are very similar to those found in the X-ray crystal structure of CRP-(cAMP)(2), which is evidence that the cAMP binding mode does not differ between the two complexes. Cyclic AMP 44-48 C-reactive protein Homo sapiens 39-42 11979597-3 2002 The Raman spectra of CRP-(cAMP)(1) and CRP-(cAMP)(2) extracted from those of CRP-cAMP mixtures at varied mixing ratios clearly show that the hydrogen bonding state and the conformation of cAMP in both complexes in solution are very similar to those found in the X-ray crystal structure of CRP-(cAMP)(2), which is evidence that the cAMP binding mode does not differ between the two complexes. Cyclic AMP 44-48 C-reactive protein Homo sapiens 39-42 11979597-3 2002 The Raman spectra of CRP-(cAMP)(1) and CRP-(cAMP)(2) extracted from those of CRP-cAMP mixtures at varied mixing ratios clearly show that the hydrogen bonding state and the conformation of cAMP in both complexes in solution are very similar to those found in the X-ray crystal structure of CRP-(cAMP)(2), which is evidence that the cAMP binding mode does not differ between the two complexes. Cyclic AMP 44-48 C-reactive protein Homo sapiens 39-42 11979597-3 2002 The Raman spectra of CRP-(cAMP)(1) and CRP-(cAMP)(2) extracted from those of CRP-cAMP mixtures at varied mixing ratios clearly show that the hydrogen bonding state and the conformation of cAMP in both complexes in solution are very similar to those found in the X-ray crystal structure of CRP-(cAMP)(2), which is evidence that the cAMP binding mode does not differ between the two complexes. Cyclic AMP 44-48 C-reactive protein Homo sapiens 39-42 11979597-3 2002 The Raman spectra of CRP-(cAMP)(1) and CRP-(cAMP)(2) extracted from those of CRP-cAMP mixtures at varied mixing ratios clearly show that the hydrogen bonding state and the conformation of cAMP in both complexes in solution are very similar to those found in the X-ray crystal structure of CRP-(cAMP)(2), which is evidence that the cAMP binding mode does not differ between the two complexes. Cyclic AMP 44-48 C-reactive protein Homo sapiens 39-42 11979597-3 2002 The Raman spectra of CRP-(cAMP)(1) and CRP-(cAMP)(2) extracted from those of CRP-cAMP mixtures at varied mixing ratios clearly show that the hydrogen bonding state and the conformation of cAMP in both complexes in solution are very similar to those found in the X-ray crystal structure of CRP-(cAMP)(2), which is evidence that the cAMP binding mode does not differ between the two complexes. Cyclic AMP 44-48 C-reactive protein Homo sapiens 39-42 11979597-3 2002 The Raman spectra of CRP-(cAMP)(1) and CRP-(cAMP)(2) extracted from those of CRP-cAMP mixtures at varied mixing ratios clearly show that the hydrogen bonding state and the conformation of cAMP in both complexes in solution are very similar to those found in the X-ray crystal structure of CRP-(cAMP)(2), which is evidence that the cAMP binding mode does not differ between the two complexes. Hydrogen 141-149 C-reactive protein Homo sapiens 21-24 11979597-3 2002 The Raman spectra of CRP-(cAMP)(1) and CRP-(cAMP)(2) extracted from those of CRP-cAMP mixtures at varied mixing ratios clearly show that the hydrogen bonding state and the conformation of cAMP in both complexes in solution are very similar to those found in the X-ray crystal structure of CRP-(cAMP)(2), which is evidence that the cAMP binding mode does not differ between the two complexes. Hydrogen 141-149 C-reactive protein Homo sapiens 39-42 11979597-3 2002 The Raman spectra of CRP-(cAMP)(1) and CRP-(cAMP)(2) extracted from those of CRP-cAMP mixtures at varied mixing ratios clearly show that the hydrogen bonding state and the conformation of cAMP in both complexes in solution are very similar to those found in the X-ray crystal structure of CRP-(cAMP)(2), which is evidence that the cAMP binding mode does not differ between the two complexes. Hydrogen 141-149 C-reactive protein Homo sapiens 39-42 11979597-3 2002 The Raman spectra of CRP-(cAMP)(1) and CRP-(cAMP)(2) extracted from those of CRP-cAMP mixtures at varied mixing ratios clearly show that the hydrogen bonding state and the conformation of cAMP in both complexes in solution are very similar to those found in the X-ray crystal structure of CRP-(cAMP)(2), which is evidence that the cAMP binding mode does not differ between the two complexes. Hydrogen 141-149 C-reactive protein Homo sapiens 39-42 11979597-3 2002 The Raman spectra of CRP-(cAMP)(1) and CRP-(cAMP)(2) extracted from those of CRP-cAMP mixtures at varied mixing ratios clearly show that the hydrogen bonding state and the conformation of cAMP in both complexes in solution are very similar to those found in the X-ray crystal structure of CRP-(cAMP)(2), which is evidence that the cAMP binding mode does not differ between the two complexes. Cyclic AMP 44-48 C-reactive protein Homo sapiens 39-42 11979597-3 2002 The Raman spectra of CRP-(cAMP)(1) and CRP-(cAMP)(2) extracted from those of CRP-cAMP mixtures at varied mixing ratios clearly show that the hydrogen bonding state and the conformation of cAMP in both complexes in solution are very similar to those found in the X-ray crystal structure of CRP-(cAMP)(2), which is evidence that the cAMP binding mode does not differ between the two complexes. Cyclic AMP 44-48 C-reactive protein Homo sapiens 39-42 11979597-3 2002 The Raman spectra of CRP-(cAMP)(1) and CRP-(cAMP)(2) extracted from those of CRP-cAMP mixtures at varied mixing ratios clearly show that the hydrogen bonding state and the conformation of cAMP in both complexes in solution are very similar to those found in the X-ray crystal structure of CRP-(cAMP)(2), which is evidence that the cAMP binding mode does not differ between the two complexes. Cyclic AMP 44-48 C-reactive protein Homo sapiens 39-42 11979597-3 2002 The Raman spectra of CRP-(cAMP)(1) and CRP-(cAMP)(2) extracted from those of CRP-cAMP mixtures at varied mixing ratios clearly show that the hydrogen bonding state and the conformation of cAMP in both complexes in solution are very similar to those found in the X-ray crystal structure of CRP-(cAMP)(2), which is evidence that the cAMP binding mode does not differ between the two complexes. Cyclic AMP 44-48 C-reactive protein Homo sapiens 39-42 11979597-3 2002 The Raman spectra of CRP-(cAMP)(1) and CRP-(cAMP)(2) extracted from those of CRP-cAMP mixtures at varied mixing ratios clearly show that the hydrogen bonding state and the conformation of cAMP in both complexes in solution are very similar to those found in the X-ray crystal structure of CRP-(cAMP)(2), which is evidence that the cAMP binding mode does not differ between the two complexes. Cyclic AMP 44-48 C-reactive protein Homo sapiens 39-42 11979597-3 2002 The Raman spectra of CRP-(cAMP)(1) and CRP-(cAMP)(2) extracted from those of CRP-cAMP mixtures at varied mixing ratios clearly show that the hydrogen bonding state and the conformation of cAMP in both complexes in solution are very similar to those found in the X-ray crystal structure of CRP-(cAMP)(2), which is evidence that the cAMP binding mode does not differ between the two complexes. Cyclic AMP 44-48 C-reactive protein Homo sapiens 39-42 11979597-3 2002 The Raman spectra of CRP-(cAMP)(1) and CRP-(cAMP)(2) extracted from those of CRP-cAMP mixtures at varied mixing ratios clearly show that the hydrogen bonding state and the conformation of cAMP in both complexes in solution are very similar to those found in the X-ray crystal structure of CRP-(cAMP)(2), which is evidence that the cAMP binding mode does not differ between the two complexes. Cyclic AMP 44-48 C-reactive protein Homo sapiens 39-42 11979597-3 2002 The Raman spectra of CRP-(cAMP)(1) and CRP-(cAMP)(2) extracted from those of CRP-cAMP mixtures at varied mixing ratios clearly show that the hydrogen bonding state and the conformation of cAMP in both complexes in solution are very similar to those found in the X-ray crystal structure of CRP-(cAMP)(2), which is evidence that the cAMP binding mode does not differ between the two complexes. Cyclic AMP 44-48 C-reactive protein Homo sapiens 39-42 11979597-3 2002 The Raman spectra of CRP-(cAMP)(1) and CRP-(cAMP)(2) extracted from those of CRP-cAMP mixtures at varied mixing ratios clearly show that the hydrogen bonding state and the conformation of cAMP in both complexes in solution are very similar to those found in the X-ray crystal structure of CRP-(cAMP)(2), which is evidence that the cAMP binding mode does not differ between the two complexes. Cyclic AMP 44-48 C-reactive protein Homo sapiens 39-42 11979597-5 2002 The environmental change of Trp85 suggests an opening of the cleft between the N-terminal cAMP and C-terminal DNA binding domains in the process of CRP activation by binding of a single cAMP molecule. Cyclic AMP 90-94 C-reactive protein Homo sapiens 148-151 11979597-5 2002 The environmental change of Trp85 suggests an opening of the cleft between the N-terminal cAMP and C-terminal DNA binding domains in the process of CRP activation by binding of a single cAMP molecule. Cyclic AMP 186-190 C-reactive protein Homo sapiens 148-151 11796431-10 2002 Serum iron levels and transferrin saturation were negatively related to CRP (r = -0.8 and r = -0.7, respectively; p < 0.01) and erythrocyte sedimentation rate (r = -0.5 and r = -0.4, respectively; p < 0.05). Iron 6-10 C-reactive protein Homo sapiens 72-75 11779602-12 2002 The CRP was related to intraabdominal fat only in postmenopausal women and was negatively related to insulin-stimulated glucose disposal in both premenopausal and postmenopausal women. Glucose 120-127 C-reactive protein Homo sapiens 4-7 11779602-15 2002 Higher CRP is associated with lower insulin-stimulated glucose disposal in both premenopausal and postmenopausal women. Glucose 55-62 C-reactive protein Homo sapiens 7-10 11781754-7 2001 RESULTS: CRP was positively correlated with BMI (P<0.05), waist circumference (WC, P<0.05), triglyceride (P<0.05) and negatively correlated with apoE (P<0.01) and E LpnonB (P<0.05). Triglycerides 98-110 C-reactive protein Homo sapiens 9-12 11803230-5 2002 It was concluded that the reduction in plasma homocysteine levels with both regimens might contribute to the cardiovascular benefit of HRT and the CRP raising effect of estrogen might be partially prevented by the addition of progesterone. Progesterone 226-238 C-reactive protein Homo sapiens 147-150 12324714-6 2002 RESULTS: In the heterogeneous study population, increased CRP concentrations significantly correlated with an increased cortisol:cortisone ratio (p < 0.001; r = 0.65, Spearman correlation coefficient). Hydrocortisone 120-128 C-reactive protein Homo sapiens 58-61 12578155-1 2002 The aim of this study was to investigate the prevalence of hypophosphataemia in children with acute infection and the relationship between serum phosphate and C-reactive protein (CRP) concentration. Phosphates 145-154 C-reactive protein Homo sapiens 159-177 12578155-1 2002 The aim of this study was to investigate the prevalence of hypophosphataemia in children with acute infection and the relationship between serum phosphate and C-reactive protein (CRP) concentration. Phosphates 145-154 C-reactive protein Homo sapiens 179-182 12578155-6 2002 A significant negative correlation between serum phosphate and CRP levels was found (r = -0.41, p < 0.0001). Phosphates 49-58 C-reactive protein Homo sapiens 63-66 12578155-7 2002 Patients with CRP > or = 151 mg/l on admission had a lower mean serum phosphate value than those with CRP < or = 50 mg/l (1.17 vs 1.50 mmol/l, p < 0.0001). Phosphates 73-82 C-reactive protein Homo sapiens 14-17 11742871-12 2001 Body mass index and other markers of the metabolic syndrome (HDL cholesterol, triglycerides, diabetes, and high blood pressure) are significant determinants of CRP levels in this population. Cholesterol 65-76 C-reactive protein Homo sapiens 160-163 11742871-12 2001 Body mass index and other markers of the metabolic syndrome (HDL cholesterol, triglycerides, diabetes, and high blood pressure) are significant determinants of CRP levels in this population. Triglycerides 78-91 C-reactive protein Homo sapiens 160-163 12147770-14 2002 Steroid-treated patients showed less favourable nutritional conditions, with lower serum albumin and body mass index vs non-steroid-treated patients; moreover, C-reactive protein values were persistently higher in the steroid-treated group. Steroids 0-7 C-reactive protein Homo sapiens 160-178 12147770-14 2002 Steroid-treated patients showed less favourable nutritional conditions, with lower serum albumin and body mass index vs non-steroid-treated patients; moreover, C-reactive protein values were persistently higher in the steroid-treated group. Steroids 218-225 C-reactive protein Homo sapiens 160-178 15526541-7 2002 In coronary heart disease patients, Atorvastatin reduced homocystein concentrations with 19.41% (baseline 17.7 +/- 11.16 microM/l) (p < 0.01), and CRP with 21.9% (baseline 4.8 +/- 4.19 mg/l) p < 0.01 and TBARS with 52% (baseline 0.87 +/- 0.89 nM/ml) p < 0.001, but did not influence sICAM and Ab oxLDL. Atorvastatin 36-48 C-reactive protein Homo sapiens 150-153 11679405-7 2001 Furthermore, aspirin and statin therapy appear to be particularly effective among individuals with high CRP levels. Aspirin 13-20 C-reactive protein Homo sapiens 104-107 11730184-11 2001 Histamine levels were negatively correlated with CRP levels (Spearman p = -0.32, P = 0.003). Histamine 0-9 C-reactive protein Homo sapiens 49-52 11730184-20 2001 In this perspective, the inverse relationship between CRP and histamine levels could be explained. Histamine 62-71 C-reactive protein Homo sapiens 54-57 11672458-3 2001 The aim of the present study was to explore the association between the immune response, as measured by antibody titres to malondialdehyde-treated LDL (MDA-LDL) and levels of C-reactive protein (CRP; a marker of inflammation), and diabetes mellitus and MI in women. Malondialdehyde 123-138 C-reactive protein Homo sapiens 175-193 11672458-3 2001 The aim of the present study was to explore the association between the immune response, as measured by antibody titres to malondialdehyde-treated LDL (MDA-LDL) and levels of C-reactive protein (CRP; a marker of inflammation), and diabetes mellitus and MI in women. Malondialdehyde 123-138 C-reactive protein Homo sapiens 195-198 11692019-11 2001 After adjustment for smoking, total/HDL cholesterol, systolic blood pressure, and diabetes, the increase in risk across CRP quartiles remained statistically significant for both men (P=0.0365) and women (P=0.0084). Cholesterol 40-51 C-reactive protein Homo sapiens 120-123 11557252-5 2001 This increased risk is independent of other biochemical and clinical risk factors, and the association between high CRP and an abnormal cholesterol ratio significantly increases the risk in the individual patient. Cholesterol 136-147 C-reactive protein Homo sapiens 116-119 11583732-2 2001 A prospective trial of familial hypercholesterolemic patients treated with Heparin-induced Extra-corporeal Low-Density Lipoprotein Precipitation (HELP, B. Braun Melsungen) therapy was undertaken to evaluate the short- and long-term effects on CRP. Heparin 75-82 C-reactive protein Homo sapiens 243-246 11673760-4 2001 RESULTS: CRP was positively correlated with age, body mass index (BMI), waist, fasting glucose and insulin, HOMA(IR), fat-free mass (FFM) and fat mass (FM). Glucose 87-94 C-reactive protein Homo sapiens 9-12 11591152-2 2001 Analysis of amino acid residue proximity to cAMP in molecular dynamics (MD) simulations of the CRP:(cAMP)(2) complex [Garcia, A. E., and Harman, J. G. (1996) Protein Sci. Cyclic AMP 44-48 C-reactive protein Homo sapiens 95-98 11591152-2 2001 Analysis of amino acid residue proximity to cAMP in molecular dynamics (MD) simulations of the CRP:(cAMP)(2) complex [Garcia, A. E., and Harman, J. G. (1996) Protein Sci. Cyclic AMP 100-104 C-reactive protein Homo sapiens 95-98 11591152-4 2001 To test the role of Y99 in cAMP-mediated CRP activation, Y99 was substituted with alanine (A) or phenylalanine (F). Cyclic AMP 27-31 C-reactive protein Homo sapiens 41-44 11591152-5 2001 Cells that contained the WT or mutant forms of CRP induced beta-galactosidase in the presence of cAMP. Cyclic AMP 97-101 C-reactive protein Homo sapiens 47-50 11591152-6 2001 Purified WT, Y99A, and Y99F CRP showed only a 3- to 4-fold difference in cAMP affinity. Cyclic AMP 73-77 C-reactive protein Homo sapiens 28-31 11591152-9 2001 Whereas the WT or Y99F CRP:(cAMP)(1) complexes were cleaved by protease at hinge-region peptide bonds, the Y99A CRP:(cAMP)(1) complex was cleaved at peptide bonds located at the subunit interface. Cyclic AMP 28-32 C-reactive protein Homo sapiens 23-26 11591152-9 2001 Whereas the WT or Y99F CRP:(cAMP)(1) complexes were cleaved by protease at hinge-region peptide bonds, the Y99A CRP:(cAMP)(1) complex was cleaved at peptide bonds located at the subunit interface. Cyclic AMP 117-121 C-reactive protein Homo sapiens 112-115 11591152-10 2001 The rates of subunit exchange for Y99A CRP, both in the apo-form and in a 1:1 complex with cAMP, were significantly greater than that measured for WT CRP. Cyclic AMP 91-95 C-reactive protein Homo sapiens 39-42 11591152-11 2001 The results of this study show that tyrosine 99 contributes significant structural stability to the CRP dimer, specifically in stabilizing subunit association. Tyrosine 36-44 C-reactive protein Homo sapiens 100-103 11434828-10 2001 This effect was seen as early as 12 weeks (median reduction in CRP with pravastatin, 14.7%; P<.001) and was present among all prespecified subgroups according to sex, age, smoking status, body mass index, baseline lipid levels, presence of diabetes, and use of aspirin or hormone replacement therapy. Aspirin 264-271 C-reactive protein Homo sapiens 63-66 11577954-19 2001 CONCLUSIONS: The extent of increase in CRP levels in periodontitis patients depends on the severity of the disease after adjusting for age, smoking, body mass index, triglycerides, and cholesterol. Triglycerides 166-179 C-reactive protein Homo sapiens 39-42 11577954-19 2001 CONCLUSIONS: The extent of increase in CRP levels in periodontitis patients depends on the severity of the disease after adjusting for age, smoking, body mass index, triglycerides, and cholesterol. Cholesterol 185-196 C-reactive protein Homo sapiens 39-42 11472751-7 2001 CRP levels were associated with smoking, body mass index, age, levels of triglycerides (TG), and the use of NSAIDs or anticoagulation drugs. Triglycerides 73-86 C-reactive protein Homo sapiens 0-3 11472751-7 2001 CRP levels were associated with smoking, body mass index, age, levels of triglycerides (TG), and the use of NSAIDs or anticoagulation drugs. Triglycerides 88-90 C-reactive protein Homo sapiens 0-3 11564380-7 2001 In multiple regression models, blood fibrinogen, waist circumference, total cholesterol, and physical activity grade were independently associated with log CRP concentrations. Cholesterol 76-87 C-reactive protein Homo sapiens 156-159 11564380-12 2001 Thus, CRP values serve as a marker of prevalent CHD risk in populations with low cholesterol levels. Cholesterol 81-92 C-reactive protein Homo sapiens 6-9 11520795-4 2001 Stimulation of platelets by collagen-, (GP)VI-selective agonist, collagen-related peptide (CRP)-, and PECAM-1-immunoglobulin chimera induced tyrosine phosphorylation of PECAM-1 in a time- and dose-dependent manner. Tyrosine 141-149 C-reactive protein Homo sapiens 91-94 11422769-9 2001 With increasing CRP, creatinine declined significantly [-0.142 mg/dL/month per unit increase in log CRP, adjusted for age, gender, race, diabetes (time since initiation of dialysis; vintage), Kt/V, and nPCR, P = 0.002]. Creatinine 21-31 C-reactive protein Homo sapiens 16-19 11432780-2 2001 Upon the binding of cyclic AMP, CRP is allosterically activated, binds to target DNA sites, and interacts with RNA polymerase. Cyclic AMP 20-30 C-reactive protein Homo sapiens 32-35 11432780-4 2001 We assigned all of the (13)C-carbonyl resonances of methionine residues in CRP by using the double labeling and the enzyme digestion techniques. Methionine 52-62 C-reactive protein Homo sapiens 75-78 11432780-5 2001 The result of (13)C-carbonyl NMR experiment on [(13)C"-Met]-CRP in the presence of both cyclic AMP and RNA polymerase alpha subunit showed that the two proteins interact with each other in solution in the absence of DNA via the region around the residues from Met 157 to Met 163 in CRP. Cyclic AMP 88-98 C-reactive protein Homo sapiens 60-63 11432780-5 2001 The result of (13)C-carbonyl NMR experiment on [(13)C"-Met]-CRP in the presence of both cyclic AMP and RNA polymerase alpha subunit showed that the two proteins interact with each other in solution in the absence of DNA via the region around the residues from Met 157 to Met 163 in CRP. Cyclic AMP 88-98 C-reactive protein Homo sapiens 282-285 11422769-9 2001 With increasing CRP, creatinine declined significantly [-0.142 mg/dL/month per unit increase in log CRP, adjusted for age, gender, race, diabetes (time since initiation of dialysis; vintage), Kt/V, and nPCR, P = 0.002]. Creatinine 21-31 C-reactive protein Homo sapiens 100-103 11377237-9 2001 However, about 2 weeks after the start of steroid administration, a fever and a further elevation of CRP were observed with an increase of beta-D-glucan in serum. Steroids 42-49 C-reactive protein Homo sapiens 101-104 11467225-3 2001 In clinical studies serum CRP- und creatinine level declined in healthy subjects and patients with osteoarthritis under rose-hip treatment. Creatinine 35-45 C-reactive protein Homo sapiens 26-29 11419884-0 2001 Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. Aspirin 20-27 C-reactive protein Homo sapiens 37-55 11419884-1 2001 OBJECTIVES: We performed a placebo-controlled study to evaluate the effect of low-dose aspirin on serum C-reactive protein (CRP) levels. Aspirin 87-94 C-reactive protein Homo sapiens 104-122 11419884-1 2001 OBJECTIVES: We performed a placebo-controlled study to evaluate the effect of low-dose aspirin on serum C-reactive protein (CRP) levels. Aspirin 87-94 C-reactive protein Homo sapiens 124-127 11419884-3 2001 Moreover, low-dose aspirin therapy has been reported to be more effective in preventing MI in men with higher CRP levels than it is in those with lower levels, raising the possibility that aspirin prevents thrombosis by reducing vascular inflammation. Aspirin 19-26 C-reactive protein Homo sapiens 110-113 11419884-3 2001 Moreover, low-dose aspirin therapy has been reported to be more effective in preventing MI in men with higher CRP levels than it is in those with lower levels, raising the possibility that aspirin prevents thrombosis by reducing vascular inflammation. Aspirin 189-196 C-reactive protein Homo sapiens 110-113 11419884-4 2001 The effect of low-dose aspirin therapy on serum CRP levels in men has been addressed recently, but the results of the two studies conflict. Aspirin 23-30 C-reactive protein Homo sapiens 48-51 11419884-5 2001 METHODS: Effects of aspirin (81 mg every day or 325, 81 or 40 mg every-third-day given for 31 days) on serum CRP, using a highly-sensitive assay, and on serum platelet-cyclo-oxygenase (COX)-1-derived thromboxane (Tx) B2 concentrations were studied simultaneously in 57 healthy volunteers (30 men and 27 women). Aspirin 20-27 C-reactive protein Homo sapiens 109-112 11397704-4 2001 Although CRP levels were associated with plasma insulin levels measured in the fasting state and after a 75-g oral glucose load, no significant correlations were found with plasma lipoprotein levels. Glucose 115-122 C-reactive protein Homo sapiens 9-12 11395043-7 2001 CRP, SAA and fibrinogen levels were markedly lower among CHD patients using cholesterol-lowering medication as compared to non-users. Cholesterol 76-87 C-reactive protein Homo sapiens 0-3 11590897-12 2001 High CRP group has more increased level of ERI (p < 0.05), age (p < 0.05) and serum creatinine level (p < 0.05) than normal control, but more decreased level of serum albumin (p < 0.01) and serum iron levels (p < 0.05). Creatinine 90-100 C-reactive protein Homo sapiens 5-8 11590897-12 2001 High CRP group has more increased level of ERI (p < 0.05), age (p < 0.05) and serum creatinine level (p < 0.05) than normal control, but more decreased level of serum albumin (p < 0.01) and serum iron levels (p < 0.05). Iron 208-212 C-reactive protein Homo sapiens 5-8 11231856-6 2001 RESULTS: Postoperative levels of serum and peritoneal IL-6 and levels of C-reactive protein were significantly lower in the steroid group than in controls. Steroids 124-131 C-reactive protein Homo sapiens 73-91 11446515-5 2001 The cyclic AMP-CRP complex was shown to stimulate transcription from Pmcc: the absence of CRP or cAMP in crp or cya mutant cells strongly decreased the level of P(mcc)-lac expression. Cyclic AMP 4-14 C-reactive protein Homo sapiens 15-18 11446515-5 2001 The cyclic AMP-CRP complex was shown to stimulate transcription from Pmcc: the absence of CRP or cAMP in crp or cya mutant cells strongly decreased the level of P(mcc)-lac expression. Cyclic AMP 4-14 C-reactive protein Homo sapiens 90-93 11446515-5 2001 The cyclic AMP-CRP complex was shown to stimulate transcription from Pmcc: the absence of CRP or cAMP in crp or cya mutant cells strongly decreased the level of P(mcc)-lac expression. Cyclic AMP 4-14 C-reactive protein Homo sapiens 105-108 11446515-5 2001 The cyclic AMP-CRP complex was shown to stimulate transcription from Pmcc: the absence of CRP or cAMP in crp or cya mutant cells strongly decreased the level of P(mcc)-lac expression. Cyclic AMP 97-101 C-reactive protein Homo sapiens 15-18 11446515-5 2001 The cyclic AMP-CRP complex was shown to stimulate transcription from Pmcc: the absence of CRP or cAMP in crp or cya mutant cells strongly decreased the level of P(mcc)-lac expression. Cyclic AMP 97-101 C-reactive protein Homo sapiens 105-108 11368701-7 2001 In multivariable analyses, the total cholesterol-HDL-C ratio was the strongest lipid predictor of risk (relative risk [RR] for those in the highest vs lowest quartile, 3.9; 95% confidence interval [CI], 1.7-8.6), while CRP was the strongest nonlipid predictor (RR for the highest vs lowest quartile, 2.8; 95% CI, 1.3-5.9). Cholesterol 37-48 C-reactive protein Homo sapiens 219-222 11393381-12 2001 The two MCNS specimens showing positive CRP immunoreactivity were both from patients who had undergone cyclosporin therapy. Cyclosporine 103-114 C-reactive protein Homo sapiens 40-43 11306519-5 2001 hs-CRP levels were significantly decreased after treatment with all 3 statins compared with baseline (median values: baseline, 2.6 mg/L; atorvastatin, 1.7 mg/L; simvastatin, 1.7 mg/L; and pravastatin, 1.9 mg/L; P<0.025). Atorvastatin 137-149 C-reactive protein Homo sapiens 3-6 11306519-9 2001 CONCLUSIONS: Pravastatin, simvastatin, and atorvastatin significantly decreased levels of hs-CRP. Atorvastatin 43-55 C-reactive protein Homo sapiens 93-96 11124966-1 2001 The x-ray crystal structure of the cAMP-ligated T127L/S128A double mutant of cAMP receptor protein (CRP) was determined to a resolution of 2.2 A. Cyclic AMP 35-39 C-reactive protein Homo sapiens 100-103 11124966-1 2001 The x-ray crystal structure of the cAMP-ligated T127L/S128A double mutant of cAMP receptor protein (CRP) was determined to a resolution of 2.2 A. Cyclic AMP 77-81 C-reactive protein Homo sapiens 100-103 11124966-2 2001 Although this structure is close to that of the x-ray crystal structure of cAMP-ligated CRP with one subunit in the open form and one subunit in the closed form, a bound syn-cAMP is clearly observed in the closed subunit in a third binding site in the C-terminal domain. Cyclic AMP 75-79 C-reactive protein Homo sapiens 88-91 11124966-2 2001 Although this structure is close to that of the x-ray crystal structure of cAMP-ligated CRP with one subunit in the open form and one subunit in the closed form, a bound syn-cAMP is clearly observed in the closed subunit in a third binding site in the C-terminal domain. Cyclic AMP 174-178 C-reactive protein Homo sapiens 88-91 11124966-3 2001 In addition, water-mediated interactions replace the hydrogen bonding interactions between the N(6) of anti-cAMP bound in the N-terminal domains of each subunit and the OH groups of the Thr(127) and Ser(128) residues in the C alpha-helix of wild type CRP. Water 13-18 C-reactive protein Homo sapiens 251-254 11124966-3 2001 In addition, water-mediated interactions replace the hydrogen bonding interactions between the N(6) of anti-cAMP bound in the N-terminal domains of each subunit and the OH groups of the Thr(127) and Ser(128) residues in the C alpha-helix of wild type CRP. Hydrogen 53-61 C-reactive protein Homo sapiens 251-254 11124966-3 2001 In addition, water-mediated interactions replace the hydrogen bonding interactions between the N(6) of anti-cAMP bound in the N-terminal domains of each subunit and the OH groups of the Thr(127) and Ser(128) residues in the C alpha-helix of wild type CRP. Cyclic AMP 108-112 C-reactive protein Homo sapiens 251-254 11124966-3 2001 In addition, water-mediated interactions replace the hydrogen bonding interactions between the N(6) of anti-cAMP bound in the N-terminal domains of each subunit and the OH groups of the Thr(127) and Ser(128) residues in the C alpha-helix of wild type CRP. Threonine 186-189 C-reactive protein Homo sapiens 251-254 11124966-4 2001 This replacement induces flexibility in the C alpha-helix at Ala(128), which swings the C-terminal domain of the open subunit more toward the N-terminal domain in the T127L/S128A double mutant of CRP (CRP*) than is observed in the open subunit of cAMP-ligated CRP. Alanine 61-64 C-reactive protein Homo sapiens 196-199 11124966-4 2001 This replacement induces flexibility in the C alpha-helix at Ala(128), which swings the C-terminal domain of the open subunit more toward the N-terminal domain in the T127L/S128A double mutant of CRP (CRP*) than is observed in the open subunit of cAMP-ligated CRP. Alanine 61-64 C-reactive protein Homo sapiens 201-205 11124966-4 2001 This replacement induces flexibility in the C alpha-helix at Ala(128), which swings the C-terminal domain of the open subunit more toward the N-terminal domain in the T127L/S128A double mutant of CRP (CRP*) than is observed in the open subunit of cAMP-ligated CRP. Alanine 61-64 C-reactive protein Homo sapiens 201-204 11124966-4 2001 This replacement induces flexibility in the C alpha-helix at Ala(128), which swings the C-terminal domain of the open subunit more toward the N-terminal domain in the T127L/S128A double mutant of CRP (CRP*) than is observed in the open subunit of cAMP-ligated CRP. Cyclic AMP 247-251 C-reactive protein Homo sapiens 196-199 11124966-4 2001 This replacement induces flexibility in the C alpha-helix at Ala(128), which swings the C-terminal domain of the open subunit more toward the N-terminal domain in the T127L/S128A double mutant of CRP (CRP*) than is observed in the open subunit of cAMP-ligated CRP. Cyclic AMP 247-251 C-reactive protein Homo sapiens 201-205 11124966-4 2001 This replacement induces flexibility in the C alpha-helix at Ala(128), which swings the C-terminal domain of the open subunit more toward the N-terminal domain in the T127L/S128A double mutant of CRP (CRP*) than is observed in the open subunit of cAMP-ligated CRP. Cyclic AMP 247-251 C-reactive protein Homo sapiens 201-204 11124966-5 2001 Isothermal titration calorimetry measurements on the binding of cAMP to CRP* show that the binding mechanism changes from an exothermic independent two-site binding mechanism at pH 7.0 to an endothermic interacting two-site mechanism at pH 5.2, similar to that observed for CRP at both pH levels. Cyclic AMP 64-68 C-reactive protein Homo sapiens 72-76 11124966-5 2001 Isothermal titration calorimetry measurements on the binding of cAMP to CRP* show that the binding mechanism changes from an exothermic independent two-site binding mechanism at pH 7.0 to an endothermic interacting two-site mechanism at pH 5.2, similar to that observed for CRP at both pH levels. Cyclic AMP 64-68 C-reactive protein Homo sapiens 72-75 11124966-7 2001 These properties and the bound syn-cAMP ligand, which has only been previously observed in the DNA bound x-ray crystal structure of cAMP-ligated CRP by Passner and Steitz (Passner, J. M., and Steitz, T. A. Cyclic AMP 35-39 C-reactive protein Homo sapiens 145-148 11124966-7 2001 These properties and the bound syn-cAMP ligand, which has only been previously observed in the DNA bound x-ray crystal structure of cAMP-ligated CRP by Passner and Steitz (Passner, J. M., and Steitz, T. A. Cyclic AMP 132-136 C-reactive protein Homo sapiens 145-148 11300433-0 2001 The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. Aspirin 14-21 C-reactive protein Homo sapiens 25-43 11300433-1 2001 OBJECTIVES: This study was designed to assess the interaction between aspirin and C-reactive protein (CRP) release in unstable angina. Aspirin 70-77 C-reactive protein Homo sapiens 82-100 11300433-1 2001 OBJECTIVES: This study was designed to assess the interaction between aspirin and C-reactive protein (CRP) release in unstable angina. Aspirin 70-77 C-reactive protein Homo sapiens 102-105 11300433-3 2001 Aspirin has the potential to influence CRP release, either by its anti-inflammatory activity or by reducing myocardial necrosis. Aspirin 0-7 C-reactive protein Homo sapiens 39-42 11300433-10 2001 Maximum CRP concentrations were also lower in patients taking aspirin (8.16 mg/l [3.24 to 24.5]) than in patients not taking aspirin (11.3 mg/l [4.15 to 26.1]), although the difference was not significant. Aspirin 62-69 C-reactive protein Homo sapiens 8-11 11300433-11 2001 However, there was significant interaction (p = 0.04) between prior aspirin therapy and the predictive value of CRP concentrations for death and myocardial infarction at 12 months. Aspirin 68-75 C-reactive protein Homo sapiens 112-115 11300433-12 2001 Thus, odds ratios (95% confidence intervals) for events associated with an increase of 1 standard deviation in maximum CRP concentration were 2.64 (1.22-5.72) in patients not pretreated with aspirin compared with 0.98 (0.60-1.62) in patients pretreated with aspirin. Aspirin 191-198 C-reactive protein Homo sapiens 119-122 11300433-12 2001 Thus, odds ratios (95% confidence intervals) for events associated with an increase of 1 standard deviation in maximum CRP concentration were 2.64 (1.22-5.72) in patients not pretreated with aspirin compared with 0.98 (0.60-1.62) in patients pretreated with aspirin. Aspirin 258-265 C-reactive protein Homo sapiens 119-122 11300433-13 2001 CONCLUSIONS: The association between CRP and cardiac events in patients with unstable angina is influenced by pretreatment with aspirin. Aspirin 128-135 C-reactive protein Homo sapiens 37-40 11253971-3 2001 METHODS: We investigated the association between alcohol consumption (assessed by a 7-day food record) and concentrations of C-reactive protein (CRP), alpha1-globulins, alpha2-globulins, albumin, and transferrin, and leucocyte count in a sample of 2006 men and women aged 18-88 years participating in a national health survey carried out in former West Germany in 1987-88. Alcohols 49-56 C-reactive protein Homo sapiens 125-143 11253971-5 2001 FINDINGS: Among men, alcohol consumption showed a U-shaped association with mean values of CRP (p for linear term 0.65, for quadratic term 0.048), alpha1-globulins (p=0.20, 0.0006), alpha2-globulins (p=0.82, 0.31), and leucocyte count (p=0.51, 0.26) even after adjustment for age, smoking, body-mass index, HDL and LDL cholesterol, history of hypertension, education, and income. Alcohols 21-28 C-reactive protein Homo sapiens 91-94 11253971-10 2001 In view of the robust association between markers of inflammation, especially CRP, and risk of coronary heart disease, an anti-inflammatory action of alcohol could contribute to the link between moderate consumption and lower cardiovascular mortality. Alcohols 150-157 C-reactive protein Homo sapiens 78-81 11302876-6 2001 CSA treatment significantly reduced the tender joints score, swollen joints score, visual analogue pain scale, patient"s or doctor"s global assessment, patient"s self assessed disability, and C reactive protein. Cyclosporine 0-3 C-reactive protein Homo sapiens 192-210 11124966-13 2001 94, 2843-2847), imply that the cAMP-ligated CRP* structure is closer to the conformation of the allosterically activated structure than cAMP-ligated CRP. Cyclic AMP 31-35 C-reactive protein Homo sapiens 44-48 11124966-13 2001 94, 2843-2847), imply that the cAMP-ligated CRP* structure is closer to the conformation of the allosterically activated structure than cAMP-ligated CRP. Cyclic AMP 31-35 C-reactive protein Homo sapiens 44-47 11124966-14 2001 This may be induced by the unique flexibility at Ala(128) and/or by the bound syn-cAMP in the hinge region of CRP*. Cyclic AMP 82-86 C-reactive protein Homo sapiens 110-114 11274243-4 2001 Patients with an elevated CRP (>6 mg/L; n = 29) had significantly reduced plasma prealbumin (0.36 +/- 0.02 versus 0.44 +/- 0.03 g/L; P: < 0.05), decreased total weekly creatinine clearance (C(Cr); 52.5 +/- 2.3 versus 63.1 +/- 3.2 L/1.73 m(2); P: < 0.01), and increased left ventricular thickness (1.24 +/- 0.05 versus 1.08 +/- 0.06 cm; P: < 0.05) at baseline compared with those who had a normal CRP (< or =6 mg/L; n = 21). Creatinine 174-184 C-reactive protein Homo sapiens 26-29 11231856-11 2001 CONCLUSIONS: Preoperative steroid administration significantly elevated anti-inflammatory cytokine IL-10 levels, suppressed the levels of inflammatory cytokines IL-6 and C-reactive protein, and prevented postoperative elevation of total bilirubin values. Steroids 26-33 C-reactive protein Homo sapiens 170-188 11367528-8 2001 By alanine replacement mutagenesis, we demonstrated that these residues are involved in heparin, CRP and M protein binding, which indicates that there is a common site within fH SCR 7 responsible for multiple ligand recognition. Alanine 3-10 C-reactive protein Homo sapiens 97-100 11238289-11 2001 Preventive therapies to attenuate coronary risk in individuals with increased hs-CRP concentrations include aspirin and statin-type drugs. Aspirin 108-115 C-reactive protein Homo sapiens 81-84 12213988-8 2001 Statin class drugs and aspirin appear to modulate CHD risk in those with increased hs-CRP concentration. Aspirin 23-30 C-reactive protein Homo sapiens 86-89 11305526-7 2001 Among several markers of systemic inflammation, CRP shows the strongest associations with vascular events, and the addition of CRP to total cholesterol dramatically improves risk prediction. Cholesterol 140-151 C-reactive protein Homo sapiens 127-130 11156862-4 2001 Tamoxifen was associated with reductions of 26% in median C-reactive protein, 22% in median fibrinogen, and 9% in cholesterol (all P:<0.01 compared with placebo). Tamoxifen 0-9 C-reactive protein Homo sapiens 58-76 11156862-6 2001 In secondary analyses, the effect of tamoxifen on C-reactive protein was larger in postmenopausal women and in women with higher waist-to-hip ratios. Tamoxifen 37-46 C-reactive protein Homo sapiens 50-68 11182189-2 2001 The aim of the study was to assess the influence of simvastatin and aspirin on serum levels of C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in hypercholesterolemic subjects. Aspirin 68-75 C-reactive protein Homo sapiens 95-113 28452446-12 2001 Patients with CRP levels higher than 1 mg/dL showed lower serum albumin, iron, hemoglobin, and transferrin levels, and higher ferritin values and leukocyte counts. Iron 73-77 C-reactive protein Homo sapiens 14-17 28452446-13 2001 Under logistic regression analysis, CRP levels higher and lower than 1 mg/dL were significantly associated with serum albumin [p = 0.01; odds ratio (OR): 0.15], iron (p = 0.006; OR: 0.96), transferrin (p = 0.004; OR: 0.97), and hemoglobin (p = 0.02; OR: 0.67). Iron 161-165 C-reactive protein Homo sapiens 36-39 11150578-4 2000 Platelet aggregation induced by 1 and 10 microM ADP was significantly higher in patients with elevated CRP levels than those with normal CRP levels (P<0.05). Adenosine Diphosphate 48-51 C-reactive protein Homo sapiens 103-106 11594454-2 2001 The three-dimensional structure of human CRP has revealed the molecular basis for complement activation and binding of phosphate monoesters. Phosphates 119-128 C-reactive protein Homo sapiens 41-44 11496741-2 2001 An increase in CRP concentration was associated with lowering of apoA1 and HDL FL, triglycerides. Triglycerides 83-96 C-reactive protein Homo sapiens 15-18 11128362-3 2000 RESULTS: There was a statistically significant positive crude correlation between C-reactive protein and TC (R = 0.19), TG (R = 0.29), BMI (R = 0.32), glucose (R = 0.11), and uric acid (R = 0.14) (all P < 0.0001). Glucose 151-158 C-reactive protein Homo sapiens 82-100 11128362-4 2000 A negative correlation was found between C-reactive protein and HDL cholesterol (R = 0.13, P < 0.0001). Cholesterol 68-79 C-reactive protein Homo sapiens 41-59 11150578-4 2000 Platelet aggregation induced by 1 and 10 microM ADP was significantly higher in patients with elevated CRP levels than those with normal CRP levels (P<0.05). Adenosine Diphosphate 48-51 C-reactive protein Homo sapiens 137-140 11076538-2 2000 CRP is allosterically activated by cyclic AMP and binds to specific DNA sites. Cyclic AMP 35-45 C-reactive protein Homo sapiens 0-3 11076538-7 2000 This secondary structure of apo-CRP was compared with the known structure of cyclic AMP-bound CRP. Cyclic AMP 77-87 C-reactive protein Homo sapiens 32-35 11076538-7 2000 This secondary structure of apo-CRP was compared with the known structure of cyclic AMP-bound CRP. Cyclic AMP 77-87 C-reactive protein Homo sapiens 94-97 11076538-8 2000 The results suggest that the allosteric conformational change of CRP caused by cyclic AMP binding involves subunit realignment and domain rearrangement, resulting in the exposure of helix F onto the surface of the protein. Cyclic AMP 79-89 C-reactive protein Homo sapiens 65-68 11076538-9 2000 Additionally, the results of the one-dimensional [(13)C]carbonyl NMR experiments show that the conformational change of CRP caused by the binding of cyclic GMP, an analogue of cyclic AMP, is different from that caused by cyclic AMP binding. Cyclic GMP 149-159 C-reactive protein Homo sapiens 120-123 11076538-9 2000 Additionally, the results of the one-dimensional [(13)C]carbonyl NMR experiments show that the conformational change of CRP caused by the binding of cyclic GMP, an analogue of cyclic AMP, is different from that caused by cyclic AMP binding. Cyclic AMP 176-186 C-reactive protein Homo sapiens 120-123 11076538-9 2000 Additionally, the results of the one-dimensional [(13)C]carbonyl NMR experiments show that the conformational change of CRP caused by the binding of cyclic GMP, an analogue of cyclic AMP, is different from that caused by cyclic AMP binding. Cyclic AMP 221-231 C-reactive protein Homo sapiens 120-123 11127936-6 2000 CRP decreased significantly (sign test P = 0.03) during treatment, and the changes of CRP were significantly associated with changes in HDL cholesterol (r = -0.45; P < 0.001) and apolipoprotein A1 (r = -0.40; P < 0.001) but not with changes in LDL cholesterol or triglycerides. Cholesterol 140-151 C-reactive protein Homo sapiens 86-89 11123505-5 2000 C-reactive protein was, in addition to smoking, associated with several cardiovascular risk factors: age, obesity, diabetes, blood pressure, triglycerides and inversely associated to HDL cholesterol. Triglycerides 141-154 C-reactive protein Homo sapiens 0-18 11123505-5 2000 C-reactive protein was, in addition to smoking, associated with several cardiovascular risk factors: age, obesity, diabetes, blood pressure, triglycerides and inversely associated to HDL cholesterol. Cholesterol 187-198 C-reactive protein Homo sapiens 0-18 11123505-6 2000 Adjustment for these variables, especially for total cholesterol, HDL cholesterol and triglycerides, substantially decreased the risk of myocardial infarction for persons in the highest quintile of C-reactive protein, compared to those in the lowest quintile, to 1.3 (95% CI: 0.9-1.9). Cholesterol 53-64 C-reactive protein Homo sapiens 198-216 11123505-6 2000 Adjustment for these variables, especially for total cholesterol, HDL cholesterol and triglycerides, substantially decreased the risk of myocardial infarction for persons in the highest quintile of C-reactive protein, compared to those in the lowest quintile, to 1.3 (95% CI: 0.9-1.9). Cholesterol 70-81 C-reactive protein Homo sapiens 198-216 11123505-6 2000 Adjustment for these variables, especially for total cholesterol, HDL cholesterol and triglycerides, substantially decreased the risk of myocardial infarction for persons in the highest quintile of C-reactive protein, compared to those in the lowest quintile, to 1.3 (95% CI: 0.9-1.9). Triglycerides 86-99 C-reactive protein Homo sapiens 198-216 11127936-6 2000 CRP decreased significantly (sign test P = 0.03) during treatment, and the changes of CRP were significantly associated with changes in HDL cholesterol (r = -0.45; P < 0.001) and apolipoprotein A1 (r = -0.40; P < 0.001) but not with changes in LDL cholesterol or triglycerides. Cholesterol 254-265 C-reactive protein Homo sapiens 86-89 11127936-6 2000 CRP decreased significantly (sign test P = 0.03) during treatment, and the changes of CRP were significantly associated with changes in HDL cholesterol (r = -0.45; P < 0.001) and apolipoprotein A1 (r = -0.40; P < 0.001) but not with changes in LDL cholesterol or triglycerides. Triglycerides 269-282 C-reactive protein Homo sapiens 86-89 11127936-7 2000 The change in HDL cholesterol explained 20% of the change in CRP during statin treatment. Cholesterol 18-29 C-reactive protein Homo sapiens 61-64 11030213-6 2000 Treatment with a steroid improved the deep sensory disturbance, unsteady gait, and CRP level. Steroids 17-24 C-reactive protein Homo sapiens 83-86 10934201-2 2000 The cNMP-ligated CRP and mutants were cAMP, cGMP, and cIMP ligated with CRP, T127L CRP, S128A CRP, and T127L/S128A CRP. Cyclic AMP 38-42 C-reactive protein Homo sapiens 17-20 10934201-2 2000 The cNMP-ligated CRP and mutants were cAMP, cGMP, and cIMP ligated with CRP, T127L CRP, S128A CRP, and T127L/S128A CRP. Cyclic GMP 44-48 C-reactive protein Homo sapiens 17-20 10934201-3 2000 The transcriptional activation of a 152-base pair lacUV5 promoter (synlac promoter) with a CRP consensus binding site sequence (syncon promoter) was enhanced by an average factor of 12.3 +/- 0.5 with the cAMP-ligated complexes of CRP/mutants and cGMP-ligated T127L, although their promoter binding site affinities varied by a factor of 5. Cyclic AMP 204-208 C-reactive protein Homo sapiens 91-94 10934201-3 2000 The transcriptional activation of a 152-base pair lacUV5 promoter (synlac promoter) with a CRP consensus binding site sequence (syncon promoter) was enhanced by an average factor of 12.3 +/- 0.5 with the cAMP-ligated complexes of CRP/mutants and cGMP-ligated T127L, although their promoter binding site affinities varied by a factor of 5. Cyclic AMP 204-208 C-reactive protein Homo sapiens 230-233 10934201-3 2000 The transcriptional activation of a 152-base pair lacUV5 promoter (synlac promoter) with a CRP consensus binding site sequence (syncon promoter) was enhanced by an average factor of 12.3 +/- 0.5 with the cAMP-ligated complexes of CRP/mutants and cGMP-ligated T127L, although their promoter binding site affinities varied by a factor of 5. Cyclic GMP 246-250 C-reactive protein Homo sapiens 91-94 10934201-4 2000 However, in the presence of bound RNA polymerase, the binding affinities only ranged from 0.8 +/- 0.2 x 10(7) m(-)(1) for cAMP-ligated CRP* to 1.8 +/- 0. Cyclic AMP 122-126 C-reactive protein Homo sapiens 135-138 10934201-5 2000 3 x 10(7) m(-)(1) for cAMP-ligated CRP, indicating that the CRP/mutant interacts with the bound RNA polymerase, which would account for the near constancy of the enhancement factors. Cyclic AMP 22-26 C-reactive protein Homo sapiens 35-38 10934201-5 2000 3 x 10(7) m(-)(1) for cAMP-ligated CRP, indicating that the CRP/mutant interacts with the bound RNA polymerase, which would account for the near constancy of the enhancement factors. Cyclic AMP 22-26 C-reactive protein Homo sapiens 60-63 10852144-5 2000 CRP binds to damaged tissue, to nuclear antigens and to certain pathogenic organisms in a calcium-dependent manner. Calcium 90-97 C-reactive protein Homo sapiens 0-3 10961964-4 2000 Forearm blood flow responses to acetylcholine were inversely correlated with CRP serum levels (r=-0.46, P:=0.001). Acetylcholine 32-45 C-reactive protein Homo sapiens 77-80 10959695-8 2000 Incubation of plasma with heparin and protamine in vitro generated complement-CRP complexes, which was blocked by phosphorylcholine and stimulated by exogenous CRP. Heparin 26-33 C-reactive protein Homo sapiens 78-81 10959695-8 2000 Incubation of plasma with heparin and protamine in vitro generated complement-CRP complexes, which was blocked by phosphorylcholine and stimulated by exogenous CRP. Heparin 26-33 C-reactive protein Homo sapiens 160-163 10871590-8 2000 CRP concentrations were notably high in 54% of the anemic women with no nutritional deficiencies and in 73.5% of the anemic women who were iron replete by bone marrow assessment. Iron 139-143 C-reactive protein Homo sapiens 0-3 10898410-1 2000 OBJECTIVES: We sought to test the hypothesis that C-reactive protein, a marker of inflammation, would correlate positively with coronary calcium, a marker of atherosclerosis, in postmenopausal women. Calcium 137-144 C-reactive protein Homo sapiens 50-68 10781383-4 2000 In univariate analysis, CRP concentration was correlated with (i) the percentage decrease in forearm blood flow (FBF) during L-NMMA infusion (r=0.85, P=0.004); and (ii) the serum leptin concentration (r=0.65, P=0.05). omega-N-Methylarginine 125-131 C-reactive protein Homo sapiens 24-27 10781383-5 2000 In multivariate analysis, the relationship between CRP concentration and the FBF response to L-NMMA remained significant when age and leptin (t=2.65, P=0.045), age and BMI (t=3.69, P=0.014), or age and low-density-lipoprotein-cholesterol plus high-density-lipoprotein-cholesterol (t=3.37, P=0.044), were included in regression models. omega-N-Methylarginine 93-99 C-reactive protein Homo sapiens 51-54 10590187-0 2000 Effect of short-term aspirin use on C-reactive protein. Aspirin 21-28 C-reactive protein Homo sapiens 36-54 10729391-6 2000 Concentration of C-reactive protein was an independent determinant of endothelium-dependent vascular function (P<0.001 for low dose acetylcholine, P=0.01 for high dose acetylcholine). Acetylcholine 135-148 C-reactive protein Homo sapiens 17-35 10729391-6 2000 Concentration of C-reactive protein was an independent determinant of endothelium-dependent vascular function (P<0.001 for low dose acetylcholine, P=0.01 for high dose acetylcholine). Acetylcholine 171-184 C-reactive protein Homo sapiens 17-35 10770281-4 2000 CRP inhibited phorbol myristate acetate-induced superoxide (O2-) production more efficiently than the fMLP-triggered response. Tetradecanoylphorbol Acetate 14-39 C-reactive protein Homo sapiens 0-3 10770281-4 2000 CRP inhibited phorbol myristate acetate-induced superoxide (O2-) production more efficiently than the fMLP-triggered response. Superoxides 48-58 C-reactive protein Homo sapiens 0-3 10770281-4 2000 CRP inhibited phorbol myristate acetate-induced superoxide (O2-) production more efficiently than the fMLP-triggered response. Superoxides 60-63 C-reactive protein Homo sapiens 0-3 10770281-6 2000 Translocation to the membrane and serine-phosphorylation of the major cytosolic p47-phox component of the NADPH oxidase complex was inhibited by CRP. Serine 34-40 C-reactive protein Homo sapiens 145-148 10770281-8 2000 CRP-mediated regulation occurs via the CRP-R because an IgM mouse mAb to the human CRP-R mimicked CRP-induced inhibition of O2- production and chemotaxis. Superoxides 124-126 C-reactive protein Homo sapiens 39-42 10770281-8 2000 CRP-mediated regulation occurs via the CRP-R because an IgM mouse mAb to the human CRP-R mimicked CRP-induced inhibition of O2- production and chemotaxis. Superoxides 124-126 C-reactive protein Homo sapiens 39-42 10770281-8 2000 CRP-mediated regulation occurs via the CRP-R because an IgM mouse mAb to the human CRP-R mimicked CRP-induced inhibition of O2- production and chemotaxis. Superoxides 124-126 C-reactive protein Homo sapiens 39-42 10692524-9 2000 Following HD with CU and CUf, a significant increase in CRP was observed at t(1440), compared with postdialysis values (P</=0.05). Copper 18-20 C-reactive protein Homo sapiens 56-59 10720170-6 2000 Seasonal differences were evident for most of the indicators of micronutrient status, and elevated C-reactive protein levels (indicative of recent infection) were related to lower hemoglobin, retinol and zinc concentrations but higher ferritin and erythrocyte riboflavin concentrations. Riboflavin 260-270 C-reactive protein Homo sapiens 99-117 10570224-0 2000 C-reactive protein binds to phosphorylated carbohydrates. Carbohydrates 43-56 C-reactive protein Homo sapiens 0-18 10570224-5 2000 Both the carbohydrate and the position of phosphorylation influenced the avidity for CRP. Carbohydrates 9-21 C-reactive protein Homo sapiens 85-88 10570224-8 2000 This stresses the importance of the interaction of the CRP binding site with both the carbohydrate and the phosphate group. Carbohydrates 86-98 C-reactive protein Homo sapiens 55-58 10570224-8 2000 This stresses the importance of the interaction of the CRP binding site with both the carbohydrate and the phosphate group. Phosphates 107-116 C-reactive protein Homo sapiens 55-58 10570224-9 2000 CRP function may be mediated via the recognition of large arrays of phosphorylated carbohydrates as are characteristic of the surface of microorganisms. Carbohydrates 83-96 C-reactive protein Homo sapiens 0-3 10783054-7 2000 The correlation coefficient of CRP was lower than that of other classical risk factors, such as body-mass index (BMI), blood pressure, and total and high-density lipoprotein (HDL) cholesterol. Cholesterol 180-191 C-reactive protein Homo sapiens 31-34 10783054-8 2000 A subgroup of individuals with higher levels of CRP at both baseline and follow-up measurements had higher BMI, hemoglobin Alc, and plasma fibrinogen, and lower levels of HDL-cholesterol than others, even after adjusting for age, sex, and smoking status in a multiple logistic model. Cholesterol 175-186 C-reactive protein Homo sapiens 48-51 10675363-4 2000 Because the single nucleotide polymorphism in FcgammaRIIA - which encodes histidine or arginine at position 131 - strongly influences IgG2 binding, we determined this polymorphism"s effect on CRP binding. Histidine 74-83 C-reactive protein Homo sapiens 192-195 10675363-4 2000 Because the single nucleotide polymorphism in FcgammaRIIA - which encodes histidine or arginine at position 131 - strongly influences IgG2 binding, we determined this polymorphism"s effect on CRP binding. Arginine 87-95 C-reactive protein Homo sapiens 192-195 10675363-5 2000 CRP bound with high avidity to monocytes and neutrophils from FcgammaRIIA R-131 homozygotes, and binding was inhibited by the R-specific mAb 41H16. 41h16 141-146 C-reactive protein Homo sapiens 0-3 10685792-4 2000 RESULTS: At 16 weeks, the cyclosporine group (n = 17), compared with the placebo group (n = 17), had greater decreases in tender joints, swollen joints, patient global assessment, patient self-assessed disability, and C-reactive protein, as well as having more patients with > 20% improvement. Cyclosporine 26-38 C-reactive protein Homo sapiens 218-236 10590187-2 2000 In the Physicians Health Study, the magnitude of reduction in the risk of myocardial infarction with aspirin therapy was related to baseline CRP levels, raising the possibility that the protective effect of aspirin may be due to antiinflammatory properties in addition to its antiplatelet effect. Aspirin 101-108 C-reactive protein Homo sapiens 141-144 10590187-2 2000 In the Physicians Health Study, the magnitude of reduction in the risk of myocardial infarction with aspirin therapy was related to baseline CRP levels, raising the possibility that the protective effect of aspirin may be due to antiinflammatory properties in addition to its antiplatelet effect. Aspirin 207-214 C-reactive protein Homo sapiens 141-144 10590187-3 2000 We therefore investigated whether aspirin therapy lowers CRP levels. Aspirin 34-41 C-reactive protein Homo sapiens 57-60 10590187-4 2000 Because heavy physical exertion is a well-known trigger of myocardial infarction, we also investigated the effect of aspirin on CRP levels before and after strenuous exercise. Aspirin 117-124 C-reactive protein Homo sapiens 128-131 10569656-4 1999 There were significant positive associations between CRP levels and age, number of cigarettes smoked per day, body mass index, systolic and diastolic blood pressure, total cholesterol, triglycerides, lipoprotein(a), apolipoprotein B, tissue-type plasminogen activator antigen, D-dimers, total homocysteine, and fibrinogen (all p values <0.05). Cholesterol 172-183 C-reactive protein Homo sapiens 53-56 10567557-2 1999 LAT is tyrosine phosphorylated in human platelets heavily in response to collagen, collagen-related peptide (CRP), and FcgammaRIIA cross-linking but only weakly in response to the G-protein-receptor-coupled agonist thrombin. Tyrosine 7-15 C-reactive protein Homo sapiens 83-107 10567557-2 1999 LAT is tyrosine phosphorylated in human platelets heavily in response to collagen, collagen-related peptide (CRP), and FcgammaRIIA cross-linking but only weakly in response to the G-protein-receptor-coupled agonist thrombin. Tyrosine 7-15 C-reactive protein Homo sapiens 109-112 10569656-4 1999 There were significant positive associations between CRP levels and age, number of cigarettes smoked per day, body mass index, systolic and diastolic blood pressure, total cholesterol, triglycerides, lipoprotein(a), apolipoprotein B, tissue-type plasminogen activator antigen, D-dimers, total homocysteine, and fibrinogen (all p values <0.05). Triglycerides 185-198 C-reactive protein Homo sapiens 53-56 10449692-6 1999 Compared with nonusers of HRT, median CRP levels were higher among women using estrogen alone (P=0.003) and women using estrogen plus progesterone (P=0.03); however, there was no significant difference in CRP levels between users of different HRT preparations. Progesterone 134-146 C-reactive protein Homo sapiens 38-41 10458713-9 1999 MCSF, IL-6, and CRP were all reduced after 6 weeks of aspirin treatment (P<0.05). Aspirin 54-61 C-reactive protein Homo sapiens 16-19 10458713-11 1999 Reduced cytokine and CRP levels by aspirin may explain part of aspirin"s therapeutic action. Aspirin 35-42 C-reactive protein Homo sapiens 21-24 10458713-11 1999 Reduced cytokine and CRP levels by aspirin may explain part of aspirin"s therapeutic action. Aspirin 63-70 C-reactive protein Homo sapiens 21-24 10688417-6 1999 C-reactive protein values at one postoperative day in the steroid group were also significantly lower than those in the control group. Steroids 58-65 C-reactive protein Homo sapiens 0-18 10449692-7 1999 In multivariate analysis, the relationship between HRT use and CRP remained significant after control for body mass index, age, diabetes, hypertension, hyperlipidemia, alcohol use, and cigarette consumption (P=0.001). Alcohols 168-175 C-reactive protein Homo sapiens 63-66 10449529-10 1999 On monocytic cell lines, treatment with Bt(2)cAMP increased FcgammaRII expression and enhanced CRP binding. Cyclic AMP 45-49 C-reactive protein Homo sapiens 95-98 10465182-2 1999 In a 6-month double-blind placebo controlled trial, a combination of transdermal oestradiol 80 microg with continuous oral norethisterone 1 mg significantly reduced C-reactive protein concentrations in postmenopausal women with type-2 diabetes. Estradiol 81-91 C-reactive protein Homo sapiens 165-183 10446082-5 1999 CRP was also associated with other variables of the insulin resistance syndrome, including blood pressure, insulin, high density lipoprotein cholesterol, triglycerides, apolipoprotein A1 (inversely), plasminogen activator inhibitor-1 antigen, and tissue-type plasminogen activator antigen. Triglycerides 154-167 C-reactive protein Homo sapiens 0-3 10451065-8 1999 CRP showed a significant correlation with apo A1 (r = -0.44, p<0.01) and HDL-cholesterol (r = -0.35, p<0.05). Cholesterol 80-91 C-reactive protein Homo sapiens 0-3 10410263-9 1999 The decrease in ESR, CRP and the Thompson joint score was also significantly greater (all p < 0.05) for the high plasma dexamethasone group. Dexamethasone 123-136 C-reactive protein Homo sapiens 21-24 10980827-7 1999 Furthermore, preliminary data suggest that the relative efficacy of secondary preventive therapies such as statin drugs and aspirin may depend on the individual patient"s baseline CRP level. Aspirin 124-131 C-reactive protein Homo sapiens 180-183 10616861-2 1999 The purpose of this study was to identify the relationship between serum C-reactive protein and glucose levels in noncontrolled type II diabetic subjects. Glucose 96-103 C-reactive protein Homo sapiens 73-91 10459204-4 1999 NicoCard CRP kit manufactured by the Nicomed Firm allows a rapid (2 min) and accurate (quantitative using NicoCard Readers) detection of inflammation and evaluation of its severity, helps differentiate between bacterial and viral infections, choose adequate therapy (antibiotics, steroids, antiinflammatory agents), and monitor the treatment efficacy. Steroids 280-288 C-reactive protein Homo sapiens 9-12 10404769-1 1999 OBJECTIVE: To study the short-term effect of unopposed oestradiol (E2) and sequentially combined hormone replacement therapy (E2 + P) on C-reactive protein (CRP) in healthy postmenopausal women. Estradiol 55-65 C-reactive protein Homo sapiens 137-155 10404769-1 1999 OBJECTIVE: To study the short-term effect of unopposed oestradiol (E2) and sequentially combined hormone replacement therapy (E2 + P) on C-reactive protein (CRP) in healthy postmenopausal women. Estradiol 55-65 C-reactive protein Homo sapiens 157-160 10026222-1 1999 Collagen-related peptide (CRP), a collagen homologue, induces platelet activation through a tyrosine kinase-dependent pathway, leading to sequential tyrosine phosphorylation of Fc receptor (FcR) gamma-chain, Syk, and phospholipase C-gamma2. Tyrosine 92-100 C-reactive protein Homo sapiens 0-24 10066748-3 1999 The binding reactions of the DNA duplexes to the fully cNMP-ligated CRP-mutant complexes were endothermic with binding constants as high as 6.6 +/- 1.1 x 10(6) M-1 (conDNA.CRP(cAMP)2). Cyclic AMP 176-180 C-reactive protein Homo sapiens 68-71 10066748-3 1999 The binding reactions of the DNA duplexes to the fully cNMP-ligated CRP-mutant complexes were endothermic with binding constants as high as 6.6 +/- 1.1 x 10(6) M-1 (conDNA.CRP(cAMP)2). Cyclic AMP 176-180 C-reactive protein Homo sapiens 172-175 10066748-4 1999 ConDNA binding to the unligated T127L and CRP* mutants was observed as well as conDNA and lacDNA binding to CRP with cAMP bound to only one monomer. Cyclic AMP 117-121 C-reactive protein Homo sapiens 108-111 10066748-5 1999 The reduction of the binding constants with increase in KCl concentration indicated the formation of two ion pairs for the cAMP-ligated CRP and S128A complexes and four ion pairs for the cAMP-ligated T127L and CRP* complexes. Cyclic AMP 123-127 C-reactive protein Homo sapiens 136-139 10066748-5 1999 The reduction of the binding constants with increase in KCl concentration indicated the formation of two ion pairs for the cAMP-ligated CRP and S128A complexes and four ion pairs for the cAMP-ligated T127L and CRP* complexes. Cyclic AMP 187-191 C-reactive protein Homo sapiens 210-213 10066748-7 1999 Small angle neutron scattering measurements on the lacDNA.CRP(cAMP)2 complex in D2O/H2O mixtures show that the DNA is bent around the cAMP-ligated protein in solution. Water 84-87 C-reactive protein Homo sapiens 58-61 10066748-7 1999 Small angle neutron scattering measurements on the lacDNA.CRP(cAMP)2 complex in D2O/H2O mixtures show that the DNA is bent around the cAMP-ligated protein in solution. Cyclic AMP 62-66 C-reactive protein Homo sapiens 58-61 10026222-1 1999 Collagen-related peptide (CRP), a collagen homologue, induces platelet activation through a tyrosine kinase-dependent pathway, leading to sequential tyrosine phosphorylation of Fc receptor (FcR) gamma-chain, Syk, and phospholipase C-gamma2. Tyrosine 92-100 C-reactive protein Homo sapiens 26-29 10026222-2 1999 Here we report that CRP and the platelet low affinity immune receptor FcgammaRIIA stimulate tyrosine phosphorylation of the T cell adapter SLP-76, whereas the G protein-coupled receptor agonist thrombin induces only minor tyrosine phosphorylation. Tyrosine 92-100 C-reactive protein Homo sapiens 20-23 10026222-2 1999 Here we report that CRP and the platelet low affinity immune receptor FcgammaRIIA stimulate tyrosine phosphorylation of the T cell adapter SLP-76, whereas the G protein-coupled receptor agonist thrombin induces only minor tyrosine phosphorylation. Tyrosine 222-230 C-reactive protein Homo sapiens 20-23 10026222-8 1999 CRP stimulation of Syk-deficient platelets demonstrated that in vivo tyrosine phosphorylation of SLP-76 is downstream of Syk. Tyrosine 69-77 C-reactive protein Homo sapiens 0-3 10026222-11 1999 Tyrosine phosphorylation of PLC-gamma2 and Ca2+ mobilization is markedly attenuated in SLP-76-deficient platelets following CRP stimulation, suggesting that the adapter plays a critical role in the regulation of the phospholipase. Tyrosine 0-8 C-reactive protein Homo sapiens 124-127 10026222-12 1999 The increase in tyrosine phosphorylation of SLAP-130 in response to CRP is also inhibited in SLP-76-deficient platelets, placing it downstream of SLP-76. Tyrosine 16-24 C-reactive protein Homo sapiens 68-71 9813941-2 1998 The effect of intravenous dexamethasone on the results of C-reactive protein, white blood cell count and erythrocyte sedimentation rate during the expectant management of premature rupture of membranes]. Dexamethasone 26-39 C-reactive protein Homo sapiens 58-76 9927522-8 1999 The metalloprotease inhibitor TAPI had only a marginal effect on CRP-mediated sIL-6R release, suggesting that shedding occurs via a mechanism distinct from that previously reported. tapi 30-34 C-reactive protein Homo sapiens 65-68 9851286-0 1998 Serum dehydroepiandrosterone sulphate levels in patients with early rheumatoid arthritis: positive association with C-reactive protein, but not with HLA-DR genotype. Dehydroepiandrosterone Sulfate 6-37 C-reactive protein Homo sapiens 116-134 9778529-7 1998 Here we show that collagen and a collagen-related peptide (CRP), which binds to GPVI but does not bind to the integrin alpha2beta1, induced Btk tyrosine phosphorylation in platelets. Tyrosine 144-152 C-reactive protein Homo sapiens 59-62 9685337-4 1998 Thus, it appears that CRP undergoes a conformational change from the open form to the closed form in solution upon ligation with cAMP. Cyclic AMP 129-133 C-reactive protein Homo sapiens 22-25 9685337-5 1998 The SANS data from the CRP* and cAMP-ligated CRP* are coincidental, which implies that there is very little structural difference between the two species of CRP*. Cyclic AMP 32-36 C-reactive protein Homo sapiens 45-49 9685337-5 1998 The SANS data from the CRP* and cAMP-ligated CRP* are coincidental, which implies that there is very little structural difference between the two species of CRP*. Cyclic AMP 32-36 C-reactive protein Homo sapiens 45-49 9685337-6 1998 This is in agreement with in vivo results, which show that whereas CRP activates transcription in the cell only in the presence of cAMP, CRP* activates transcription in the absence of cAMP, implying that CRP* is already in the correct conformation for the activation of transcription. Cyclic AMP 131-135 C-reactive protein Homo sapiens 67-70 9931317-6 1999 After stimulation by CRP or collagen, the Src-family kinases p59fyn and p53/56lyn became associated with several tyrosine-phosphorylated proteins including the FcR gamma chain. Tyrosine 113-121 C-reactive protein Homo sapiens 21-24 10368284-3 1999 However, CRP is likely to have important host defence, scavenging and metabolic functions through its capacity for calcium-dependent binding to exogenous and autologous molecules containing phosphocholine (PC) and then activating the classical complement pathway. Calcium 115-122 C-reactive protein Homo sapiens 9-12 10368284-8 1999 CONCLUSIONS: The structure shows how large ligands containing PC may be bound by CRP via a phosphate oxygen that projects away from the surface of the protein. Phosphates 91-100 C-reactive protein Homo sapiens 81-84 10368284-8 1999 CONCLUSIONS: The structure shows how large ligands containing PC may be bound by CRP via a phosphate oxygen that projects away from the surface of the protein. Oxygen 101-107 C-reactive protein Homo sapiens 81-84 9924810-1 1998 C-reactive protein (CRP) is a pentameric oligoprotein composed of identical 23 kD subunits which can be modified by urea-chelation treatment to a form resembling the free subunit termed modified CRP (mCRP). Urea 116-120 C-reactive protein Homo sapiens 0-18 9924810-1 1998 C-reactive protein (CRP) is a pentameric oligoprotein composed of identical 23 kD subunits which can be modified by urea-chelation treatment to a form resembling the free subunit termed modified CRP (mCRP). Urea 116-120 C-reactive protein Homo sapiens 20-23 9924810-1 1998 C-reactive protein (CRP) is a pentameric oligoprotein composed of identical 23 kD subunits which can be modified by urea-chelation treatment to a form resembling the free subunit termed modified CRP (mCRP). Urea 116-120 C-reactive protein Homo sapiens 195-198 9924810-5 1998 The rate of dissociation of CRP protomers into individual subunits by treatment in 8 M urea-10 mM EDTA solution was rapid and complete in 2 min as assayed by an enzyme-linked immunofiltration assay using monoclonal antibodies specific to the mCRP. Urea 87-91 C-reactive protein Homo sapiens 28-31 9924810-9 1998 Using the same urea gradient electrophoresis conditions mCRP migrated as a single molecular form at all urea concentrations showing no evidence for reassociation to pentameric CRP or other aggregate form. Urea 104-108 C-reactive protein Homo sapiens 57-60 9924810-10 1998 The results of this study show a molecular conversion for an oligomeric protein (CRP) to monomeric subunits (mCRP) having rapid forward transition kinetics in 8 M urea plus chelator with negligible reversibility. Urea 163-167 C-reactive protein Homo sapiens 81-84 9690231-9 1998 Using multiple regression analysis to further explore these relationships, the serum creatinine concentration was inversely associated with CRP (r = -0.140; P < 0.001). Creatinine 85-95 C-reactive protein Homo sapiens 140-143 9690231-14 1998 Also, the dose of erythropoietin was directly associated with the CRP concentration, before (r = 0.081, P = 0.009) and after (t = 2.03, P = 0.042) adjustment for the serum albumin and iron concentrations. Iron 184-188 C-reactive protein Homo sapiens 66-69 9501097-4 1998 CRP can be removed from the malT ternary complex by a moderate concentration of heparin. Heparin 80-87 C-reactive protein Homo sapiens 0-3 9676757-9 1998 Mean urinary pyridinoline and deoxypyridinoline levels correlated strongly with BMD change at all sites, were increased in patients with active disease (p < 0.005), and correlated closely with mean C-reactive protein (CRP) (p < 0.005, r > 0.41 for both). deoxypyridinoline 30-47 C-reactive protein Homo sapiens 201-219 9676757-9 1998 Mean urinary pyridinoline and deoxypyridinoline levels correlated strongly with BMD change at all sites, were increased in patients with active disease (p < 0.005), and correlated closely with mean C-reactive protein (CRP) (p < 0.005, r > 0.41 for both). deoxypyridinoline 30-47 C-reactive protein Homo sapiens 221-224 9605127-0 1998 Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice. Testosterone 0-12 C-reactive protein Homo sapiens 45-63 9605127-1 1998 In vitro, IL-6 is the main inducer of the human C-reactive protein (CRP) gene, and IL-1 and steroids can enhance this effect. Steroids 92-100 C-reactive protein Homo sapiens 48-66 9605127-1 1998 In vitro, IL-6 is the main inducer of the human C-reactive protein (CRP) gene, and IL-1 and steroids can enhance this effect. Steroids 92-100 C-reactive protein Homo sapiens 68-71 9610529-0 1998 C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Cholesterol 65-76 C-reactive protein Homo sapiens 0-18 9560003-1 1998 Ten overlapping 15-mer peptides, spanning the entire inner disulfide loop of human C-reactive protein (residues 36-97), were used to isolate a potent inhibitor of the enzymes human leukocyte elastase and human leukocyte cathepsin G, which are associated with chronic inflammatory tissue damage. Disulfides 59-68 C-reactive protein Homo sapiens 83-101 9501097-7 1998 A very high concentration of heparin is able to dissociate CRP from the galP1 ternary complex without changing the properties of the complex. Heparin 29-36 C-reactive protein Homo sapiens 59-62 9613434-4 1998 The purity of monkey CRP prepared by chromatography procedures was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Sodium Dodecyl Sulfate 80-102 C-reactive protein Homo sapiens 21-24 9509230-5 1998 The beneficial effects of aspirin in reducing the risks of a first MI and stroke are directly related to high plasma concentrations of CRP, whereas small, nonsignificant reductions in risk occurred among patients with low or normal CRP levels. Aspirin 26-33 C-reactive protein Homo sapiens 135-138 9775136-6 1998 The authors are researching a correlation between the intensity of the acute phase response represented by CRP levels, and a reduced cholesterol level, or a hypertriglyceridemia, or lymphocytopenia. Cholesterol 133-144 C-reactive protein Homo sapiens 107-110 9775136-12 1998 Moreover a significant response exists with reduced cholesterol levels between group 4 (mean CRP level 250 (73) mg/L) and group 1. Cholesterol 52-63 C-reactive protein Homo sapiens 93-96 9775136-15 1998 CONCLUSIONS: The authors report a negative correlation of total cholesterol to CRP levels at the early stage of infections diseases. Cholesterol 64-75 C-reactive protein Homo sapiens 79-82 9613434-4 1998 The purity of monkey CRP prepared by chromatography procedures was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Sodium Dodecyl Sulfate 139-142 C-reactive protein Homo sapiens 21-24 9481720-9 1998 Dialysis patients with high C-reactive protein (CRP) values showed lower iron absorption. Iron 73-77 C-reactive protein Homo sapiens 28-46 9451003-5 1998 When the CRP-binding sites are deleted, CRP still interacts in a cAMP-dependent manner with the stable Esigma54 closed complex via protein-protein contacts. Cyclic AMP 65-69 C-reactive protein Homo sapiens 9-12 9451003-5 1998 When the CRP-binding sites are deleted, CRP still interacts in a cAMP-dependent manner with the stable Esigma54 closed complex via protein-protein contacts. Cyclic AMP 65-69 C-reactive protein Homo sapiens 40-43 9451003-11 1998 Thus, Esigma54 promoters are responsive to CRP, a protein unrelated to sigma54 activators, and the repression exerted is the direct result of an interaction between Esigma54 and the CRP-cAMP complex. Cyclic AMP 186-190 C-reactive protein Homo sapiens 43-46 9451003-11 1998 Thus, Esigma54 promoters are responsive to CRP, a protein unrelated to sigma54 activators, and the repression exerted is the direct result of an interaction between Esigma54 and the CRP-cAMP complex. Cyclic AMP 186-190 C-reactive protein Homo sapiens 182-185 9481720-9 1998 Dialysis patients with high C-reactive protein (CRP) values showed lower iron absorption. Iron 73-77 C-reactive protein Homo sapiens 48-51 9481720-10 1998 Iron absorption data correlated significantly with transferrin saturation and CRP in the iron-deficient group, and with serum ferritin in the iron-replete group. Iron 0-4 C-reactive protein Homo sapiens 78-81 9437833-1 1997 C-reactive protein (C-RP) was purified from harbor seal (Phoca vitulina) serum by calcium dependant phosphoryl-choline and protein A affinity chromatography. Calcium 82-89 C-reactive protein Homo sapiens 20-24 9787412-11 1998 We did, however, find a prognostic significance with regard to the effect of rejection treatment: in all acute rejections with a CRP < or = 3 (n = 11), steroids were effective. Steroids 155-163 C-reactive protein Homo sapiens 129-132 9403745-11 1997 There was a direct correlation between triglyceride and C-reactive protein concentrations, and an inverse correlation between cholesterol and C-reactive protein. Triglycerides 39-51 C-reactive protein Homo sapiens 56-74 9403745-11 1997 There was a direct correlation between triglyceride and C-reactive protein concentrations, and an inverse correlation between cholesterol and C-reactive protein. Cholesterol 126-137 C-reactive protein Homo sapiens 142-160 9403745-15 1997 There was a significant direct correlation between triglyceride and C-reactive protein and an inverse correlation between cholesterol and C-reactive protein, suggesting that the changes in lipids in critically ill patients may be partly attributable to the acute-phase response. Triglycerides 51-63 C-reactive protein Homo sapiens 68-86 9403745-15 1997 There was a significant direct correlation between triglyceride and C-reactive protein and an inverse correlation between cholesterol and C-reactive protein, suggesting that the changes in lipids in critically ill patients may be partly attributable to the acute-phase response. Cholesterol 122-133 C-reactive protein Homo sapiens 138-156 9283073-8 1997 The F alpha-helix, which provides all base-specific contacts in the CRP-DNA complex, became hypersensitive to Fe-EDTA-mediated cleavage, whereas the solvent exposure of D and E alpha-helices was decreased upon binding of cAMP. Cyclic AMP 221-225 C-reactive protein Homo sapiens 68-71 9283073-0 1997 Mapping conformational changes in a protein: application of a protein footprinting technique to cAMP-induced conformational changes in cAMP receptor protein. Cyclic AMP 96-100 C-reactive protein Homo sapiens 135-156 9283073-2 1997 The binding of cAMP to CRP dramatically increases the specific DNA binding activity of the protein and, as has been previously shown, induces conformational changes in the protein. Cyclic AMP 15-19 C-reactive protein Homo sapiens 23-26 9351386-6 1997 CRP levels were also associated with coagulation factors VIIc, IXc, and Xc; HDL cholesterol (negative) and triglyceride; diabetes status; diuretic use; ECG abnormalities; and level of exercise. Cholesterol 80-91 C-reactive protein Homo sapiens 0-3 9351386-6 1997 CRP levels were also associated with coagulation factors VIIc, IXc, and Xc; HDL cholesterol (negative) and triglyceride; diabetes status; diuretic use; ECG abnormalities; and level of exercise. Triglycerides 107-119 C-reactive protein Homo sapiens 0-3 9283073-4 1997 Binding of cAMP produced measurable differences in the susceptibility of CRP to the cleavage by Fe-EDTA. Cyclic AMP 11-15 C-reactive protein Homo sapiens 73-76 9283073-9 1997 These results suggest that a significant part of cAMP-induced conformational change in CRP involves a movement of secondary structure elements in the C-terminal domain of the protein so that the recognition F alpha-helix becomes exposed to the solvent. Cyclic AMP 49-53 C-reactive protein Homo sapiens 87-90 9242368-9 1997 Median CRP levels increased by 44% (CI: 27% to 59%; p < 0.001) at midcycle and by 31% (CI: 17% to 68%; p = 0.002) in the luteal phase, and there was a significant correlation between the relative increase in CRP at midcycle and the relative increase in progesterone levels during midcycle (r = 0.60; p = 0.01) and the luteal phase (r = 0.71; p = 0.001). Progesterone 256-268 C-reactive protein Homo sapiens 7-10 9341289-6 1997 After treatment with on oral steroid drug the serum KL-6 level decreased gradually, symptoms were relieved the previously high level of c-reactive protein in serum decreased, the previously high white blood cell count decreased, and radiographic findings returned to normal. Steroids 29-36 C-reactive protein Homo sapiens 136-154 9077376-10 1997 Moreover, the reduction associated with the use of aspirin in the risk of a first myocardial infarction appears to be directly related to the level of C-reactive protein, raising the possibility that antiinflammatory agents may have clinical benefits in preventing cardiovascular disease. Aspirin 51-58 C-reactive protein Homo sapiens 151-169 9264036-0 1997 CRP:cAMP complex binding to the lac operator region induces a structural change in lac DNA. Cyclic AMP 4-8 C-reactive protein Homo sapiens 0-3 9264036-3 1997 At CRP:cAMP complex concentrations greater than 200 nM, decreases in jM correlated with CRP binding to both the promoter-proximal and the operator-proximal CRP binding sites. Cyclic AMP 7-11 C-reactive protein Homo sapiens 3-6 9264036-3 1997 At CRP:cAMP complex concentrations greater than 200 nM, decreases in jM correlated with CRP binding to both the promoter-proximal and the operator-proximal CRP binding sites. Cyclic AMP 7-11 C-reactive protein Homo sapiens 88-91 9264036-3 1997 At CRP:cAMP complex concentrations greater than 200 nM, decreases in jM correlated with CRP binding to both the promoter-proximal and the operator-proximal CRP binding sites. Cyclic AMP 7-11 C-reactive protein Homo sapiens 88-91 9264036-4 1997 These results show that binding of the CRP:cAMP complex to the operator-proximal CRP binding site induces a structural change in lac DNA. Cyclic AMP 43-47 C-reactive protein Homo sapiens 39-42 9264036-4 1997 These results show that binding of the CRP:cAMP complex to the operator-proximal CRP binding site induces a structural change in lac DNA. Cyclic AMP 43-47 C-reactive protein Homo sapiens 81-84 9256019-4 1997 Effect of dexamethasone administration on SAA and CRP values was studied in 10 subjects who received a dexamethasone suppression test. Dexamethasone 10-23 C-reactive protein Homo sapiens 50-53 9200269-12 1997 CRP also showed, together with iron, the earliest response to recovery in the patients. Iron 31-35 C-reactive protein Homo sapiens 0-3 9200269-15 1997 CRP showed the greatest amplitude of changes and together with iron and percentage saturation of transferrin it also showed the earliest response to recovery in patients with CAP. Iron 63-67 C-reactive protein Homo sapiens 0-3 9192065-9 1997 Cyclosporin therapy should be reserved for patients who have a poor response to the first 3-4 days of corticosteroid therapy, particularly those with serum C reactive protein > 45 mg/l and who do not yet have absolute indications for colectomy. Cyclosporine 0-11 C-reactive protein Homo sapiens 156-174 9212359-4 1997 Studies using the same mice revealed a previously unknown testosterone-dependence of constitutive expression of human CRP. Testosterone 58-70 C-reactive protein Homo sapiens 118-121 9040576-11 1997 CRP concentrations were positively correlated with age, smoking, body-mass index, triglycerides, extent of coronary stenosis, history of myocardial infarction, and lower ejection fraction. Triglycerides 82-95 C-reactive protein Homo sapiens 0-3 9028946-5 1997 In the present study, we show that CRP stimulates tyrosine phosphorylation of the same pattern of proteins in platelets as collagen, including syk and PLC gamma2. Tyrosine 50-58 C-reactive protein Homo sapiens 35-38 9028946-6 1997 Protein tyrosine phosphorylation induced by CRP is not altered in the absence of Mg2+ or the presence of monoclonal antibodies (MoAbs) to the integrin alpha2beta1 (MoAb 6F1 and MoAb 13), conditions that prevent the interaction of collagen with the integrin. Tyrosine 8-16 C-reactive protein Homo sapiens 44-47 8702903-0 1996 Effect of cAMP binding site mutations on the interaction of cAMP receptor protein with cyclic nucleoside monophosphate ligands and DNA. Cyclic AMP 10-14 C-reactive protein Homo sapiens 60-81 9027793-14 1997 It is not specific, but the differential behaviour of CRP in patients receiving cyclosporin helps to distinguish infection from rejection. Cyclosporine 80-91 C-reactive protein Homo sapiens 54-57 9343841-8 1997 In the NSCLC patients there were significant negative correlations between concentrations of C-reactive protein and iron, transferrin, zinc, albumin, and selenium (p < 0.05). Iron 116-120 C-reactive protein Homo sapiens 93-111 9343841-9 1997 Furthermore, there were also significant positive correlations between C-reactive protein and copper (r = 0.788, p < 0.001) and ceruloplasmin (r = 0.831, p < 0.001) concentrations. Copper 94-100 C-reactive protein Homo sapiens 71-89 8879835-2 1996 A novel assay for serum cortisol binding capacity was therefore devised and applied to assess whether such degradation was evident in patients showing a recent inflammatory response as indicated by a raised serum C-reactive protein. Hydrocortisone 24-32 C-reactive protein Homo sapiens 213-231 8906746-1 1996 C-reactive protein (CRP) is an acute phase serum protein that binds to phosphocholine (PC) on phospholipids and polysaccharides and to protein components of chromatin and small nuclear ribonucleoproteins. Phospholipids 94-107 C-reactive protein Homo sapiens 0-18 8906746-1 1996 C-reactive protein (CRP) is an acute phase serum protein that binds to phosphocholine (PC) on phospholipids and polysaccharides and to protein components of chromatin and small nuclear ribonucleoproteins. Phospholipids 94-107 C-reactive protein Homo sapiens 20-23 8859218-9 1996 In contrast to native CRP, urea-modified CRP (mCRP) did not bind to HEp-2 cell nuclei, but was detected in association with distinct filamentous cytoplasmic structures. Urea 27-31 C-reactive protein Homo sapiens 41-44 8702903-1 1996 Although cAMP binding to wild type cAMP receptor protein (CRP) induces specific DNA binding and activates transcription, cyclic nucleoside monophosphate (cNMP) binding to the CRP mutant Ser128 --> Ala does not, whereas the double CRP mutant Thr127 --> Leu/Ser128 --> Ala activates transcription even in the absence of cNMP. Cyclic AMP 9-13 C-reactive protein Homo sapiens 35-56 8702903-1 1996 Although cAMP binding to wild type cAMP receptor protein (CRP) induces specific DNA binding and activates transcription, cyclic nucleoside monophosphate (cNMP) binding to the CRP mutant Ser128 --> Ala does not, whereas the double CRP mutant Thr127 --> Leu/Ser128 --> Ala activates transcription even in the absence of cNMP. Cyclic AMP 9-13 C-reactive protein Homo sapiens 58-61 8702903-1 1996 Although cAMP binding to wild type cAMP receptor protein (CRP) induces specific DNA binding and activates transcription, cyclic nucleoside monophosphate (cNMP) binding to the CRP mutant Ser128 --> Ala does not, whereas the double CRP mutant Thr127 --> Leu/Ser128 --> Ala activates transcription even in the absence of cNMP. Alanine 200-203 C-reactive protein Homo sapiens 58-61 8702903-1 1996 Although cAMP binding to wild type cAMP receptor protein (CRP) induces specific DNA binding and activates transcription, cyclic nucleoside monophosphate (cNMP) binding to the CRP mutant Ser128 --> Ala does not, whereas the double CRP mutant Thr127 --> Leu/Ser128 --> Ala activates transcription even in the absence of cNMP. Alanine 200-203 C-reactive protein Homo sapiens 175-178 8702903-1 1996 Although cAMP binding to wild type cAMP receptor protein (CRP) induces specific DNA binding and activates transcription, cyclic nucleoside monophosphate (cNMP) binding to the CRP mutant Ser128 --> Ala does not, whereas the double CRP mutant Thr127 --> Leu/Ser128 --> Ala activates transcription even in the absence of cNMP. Alanine 200-203 C-reactive protein Homo sapiens 175-178 8702903-1 1996 Although cAMP binding to wild type cAMP receptor protein (CRP) induces specific DNA binding and activates transcription, cyclic nucleoside monophosphate (cNMP) binding to the CRP mutant Ser128 --> Ala does not, whereas the double CRP mutant Thr127 --> Leu/Ser128 --> Ala activates transcription even in the absence of cNMP. Alanine 276-279 C-reactive protein Homo sapiens 175-178 8702903-1 1996 Although cAMP binding to wild type cAMP receptor protein (CRP) induces specific DNA binding and activates transcription, cyclic nucleoside monophosphate (cNMP) binding to the CRP mutant Ser128 --> Ala does not, whereas the double CRP mutant Thr127 --> Leu/Ser128 --> Ala activates transcription even in the absence of cNMP. Alanine 276-279 C-reactive protein Homo sapiens 175-178 8702903-2 1996 Isothermal titration calorimetry measurements on the cNMP binding reactions to the S128A and T127L/S128A mutants show that the reactions are mainly entropically driven as is cAMP binding to CRP. Cyclic AMP 174-178 C-reactive protein Homo sapiens 190-193 8702903-3 1996 In contrast to cAMP binding to CRP, the binding reactions are noncooperative and exothermic with binding enthalpies (DeltaHb) ranging from -23.4 +/- 0.9 kJ mol-1 for cAMP binding to S128A at 39 degrees C to -4.1 +/- 0.6 kJ mol-1 for cAMP binding to T127L/S128A at 24 degrees C and exhibit enthalpy-entropy compensation. Cyclic AMP 15-19 C-reactive protein Homo sapiens 31-34 8702903-5 1996 The cAMP-ligated S128A mutant binds to the consensus DNA binding site with approximately the same affinity as that of cAMP-ligated CRP but forms a different type of complex, which may account for loss of transcriptional activity by the mutant. Cyclic AMP 4-8 C-reactive protein Homo sapiens 131-134 8702903-5 1996 The cAMP-ligated S128A mutant binds to the consensus DNA binding site with approximately the same affinity as that of cAMP-ligated CRP but forms a different type of complex, which may account for loss of transcriptional activity by the mutant. Cyclic AMP 118-122 C-reactive protein Homo sapiens 131-134 8702903-6 1996 Energy minimization computations on the cAMP-ligated S128A mutant show that amino acid conformational differences between S128A and CRP occur at Ser179, Glu181, and Thr182 in the center of the DNA binding site, implying that these conformational changes may account for the difference in DNA binding. Cyclic AMP 40-44 C-reactive protein Homo sapiens 132-135 9035817-1 1996 The effect of C-reactive protein on oxygen metabolism and lysosomal activity of the human blood neutrophils was found to depend on its ability to conform and to render both the pro- and anti-inflammatory results. Oxygen 36-42 C-reactive protein Homo sapiens 14-32 8872505-3 1996 Production rates of reactive oxygen species [ROS] of neutrophils and monocytes from rheumatic patients are compared to those of healthy controls and non rheumatic disease controls and correlated with the plasma levels of tumor necrosis factor alpha, C-reactive protein and the sedimentation rates of erythrocytes. Reactive Oxygen Species 20-43 C-reactive protein Homo sapiens 250-268 8872505-3 1996 Production rates of reactive oxygen species [ROS] of neutrophils and monocytes from rheumatic patients are compared to those of healthy controls and non rheumatic disease controls and correlated with the plasma levels of tumor necrosis factor alpha, C-reactive protein and the sedimentation rates of erythrocytes. Reactive Oxygen Species 45-48 C-reactive protein Homo sapiens 250-268 8599761-1 1996 The structure of the classical acute phase reactant human C-reactive protein provides evidence that phosphocholine binding is mediated through calcium and a hydrophobic pocket centred on Phe 66. Calcium 143-150 C-reactive protein Homo sapiens 58-76 8616412-11 1996 C Reactive protein concentration was associated with raised serum fibrinogen, sialic acid, total cholesterol, triglyceride, glucose, and apolipoprotein B values. Cholesterol 97-108 C-reactive protein Homo sapiens 0-18 8616412-11 1996 C Reactive protein concentration was associated with raised serum fibrinogen, sialic acid, total cholesterol, triglyceride, glucose, and apolipoprotein B values. Triglycerides 110-122 C-reactive protein Homo sapiens 0-18 8616412-11 1996 C Reactive protein concentration was associated with raised serum fibrinogen, sialic acid, total cholesterol, triglyceride, glucose, and apolipoprotein B values. Glucose 124-131 C-reactive protein Homo sapiens 0-18 9575343-4 1996 In contrast, the corresponding S1 pocket of hCG is large and accepts the positively charged "aromatic" side chain of histidine, which increases most significantly the capability of CRP derived inhibitors. Histidine 117-126 C-reactive protein Homo sapiens 181-184 9575343-6 1996 This long range subsite was utilized to increase the hLE inhibitory activity of CRP derived peptide using the natural sequence of CRP, which contains a unique glutamic acid moiety in the P7 position. Glutamic Acid 159-172 C-reactive protein Homo sapiens 80-83 9575343-6 1996 This long range subsite was utilized to increase the hLE inhibitory activity of CRP derived peptide using the natural sequence of CRP, which contains a unique glutamic acid moiety in the P7 position. Glutamic Acid 159-172 C-reactive protein Homo sapiens 130-133 8803706-7 1996 The value of the C-reactive protein at postoperative day 3 in the steroid pulse group was significantly lower than that in the control group, and the postoperative peak value of bilirubin as well as the incidence of postoperative complications in the control group tended to be higher than those in the steroid pulse group. Steroids 66-73 C-reactive protein Homo sapiens 17-35 8803706-7 1996 The value of the C-reactive protein at postoperative day 3 in the steroid pulse group was significantly lower than that in the control group, and the postoperative peak value of bilirubin as well as the incidence of postoperative complications in the control group tended to be higher than those in the steroid pulse group. Steroids 303-310 C-reactive protein Homo sapiens 17-35 7589600-3 1995 Following ibuprofen administration there were reductions in circulating concentrations of C-reactive protein (P = 0.01), interleukin-6 (P = 0.06), cortisol (P = 0.04) and also in the platelet count (P = 0.01). Ibuprofen 10-19 C-reactive protein Homo sapiens 90-108 8771197-10 1996 Simulation of CRP:(cAMP)2 in solution showed that a transition from the open to the closed state also occurs when water is explicitly included in the calculations. Water 114-119 C-reactive protein Homo sapiens 14-25 7485521-2 1995 CRP was shown to detract from the ability of surfactant to rapidly adsorb to the air-water interface at a molar ratio of 0.03:1 (protein:phospholipid) (weight ratio, 0.5:1). Water 85-90 C-reactive protein Homo sapiens 0-3 7485521-2 1995 CRP was shown to detract from the ability of surfactant to rapidly adsorb to the air-water interface at a molar ratio of 0.03:1 (protein:phospholipid) (weight ratio, 0.5:1). Phospholipids 137-149 C-reactive protein Homo sapiens 0-3 7485521-4 1995 The effect of CRP required the presence of calcium and was reversed by the addition of phosphocholine in a concentration-dependent manner. Calcium 43-50 C-reactive protein Homo sapiens 14-17 7485521-6 1995 These data suggest that the potent inhibition of surfactant adsorption by CRP is primarily a result of a specific interaction between CRP and the phosphocholine headgroup of surfactant lipids in the subphase and that it can be reversed by the water-soluble CRP ligand, phosphocholine. Water 243-248 C-reactive protein Homo sapiens 74-77 7485521-6 1995 These data suggest that the potent inhibition of surfactant adsorption by CRP is primarily a result of a specific interaction between CRP and the phosphocholine headgroup of surfactant lipids in the subphase and that it can be reversed by the water-soluble CRP ligand, phosphocholine. Water 243-248 C-reactive protein Homo sapiens 134-137 7485521-6 1995 These data suggest that the potent inhibition of surfactant adsorption by CRP is primarily a result of a specific interaction between CRP and the phosphocholine headgroup of surfactant lipids in the subphase and that it can be reversed by the water-soluble CRP ligand, phosphocholine. Water 243-248 C-reactive protein Homo sapiens 134-137 7654697-12 1995 An important observation was that lactic acid was capable of dissociating rat CRP from lipoproteins in rat serum. Lactic Acid 34-45 C-reactive protein Homo sapiens 78-81 7665583-2 1995 In contrast, the overall binding of cGMP to CRP is exothermic and non-cooperative with delta Hb, delta Cp, and delta Sb values close to the those values for binding of the first cAMP molecule to CRP. Cyclic GMP 36-40 C-reactive protein Homo sapiens 44-47 7665583-2 1995 In contrast, the overall binding of cGMP to CRP is exothermic and non-cooperative with delta Hb, delta Cp, and delta Sb values close to the those values for binding of the first cAMP molecule to CRP. Cyclic GMP 36-40 C-reactive protein Homo sapiens 195-198 7665583-2 1995 In contrast, the overall binding of cGMP to CRP is exothermic and non-cooperative with delta Hb, delta Cp, and delta Sb values close to the those values for binding of the first cAMP molecule to CRP. Cyclic AMP 178-182 C-reactive protein Homo sapiens 44-47 7665583-2 1995 In contrast, the overall binding of cGMP to CRP is exothermic and non-cooperative with delta Hb, delta Cp, and delta Sb values close to the those values for binding of the first cAMP molecule to CRP. Cyclic AMP 178-182 C-reactive protein Homo sapiens 195-198 8751208-10 1995 CONCLUSIONS: These results suggest that the expression of c-reactive protein but not haptoglobin is upregulated in alcohol-induced acute liver injury. Alcohols 115-122 C-reactive protein Homo sapiens 58-76 7654697-13 1995 Human CRP bound very weakly to lactate, so that lactate probably is not a significant regulator of this pentraxin. Lactic Acid 31-38 C-reactive protein Homo sapiens 6-9 7635968-5 1995 An oligonucleotide probe constructed by the cDNA of the hcrp gene that encodes this aa sequence depicted the expression of 1.9-kb LDGF mRNA in leiomyomas and myometrium. Oligonucleotides 3-18 C-reactive protein Homo sapiens 56-60 7677440-10 1995 Erythrocyte sedimentation rate, C reactive protein, and sIL-2R values were significantly less after six months of steroid treatment compared with before treatment. Steroids 114-121 C-reactive protein Homo sapiens 32-50 8527929-10 1995 An additional advantage is the ability to metabolically label CRP through feeding the larvae on an [35S]methionine-containing diet. Sulfur-35 100-103 C-reactive protein Homo sapiens 62-65 8527929-10 1995 An additional advantage is the ability to metabolically label CRP through feeding the larvae on an [35S]methionine-containing diet. Methionine 104-114 C-reactive protein Homo sapiens 62-65 7541236-7 1995 Serum CRP concentration was also reduced in the ibuprofen-treated group (pre-ibuprofen, 51 mg l-1; post-ibuprofen, 29 mg l-1; P < 0.05). Ibuprofen 48-57 C-reactive protein Homo sapiens 6-9 7541236-7 1995 Serum CRP concentration was also reduced in the ibuprofen-treated group (pre-ibuprofen, 51 mg l-1; post-ibuprofen, 29 mg l-1; P < 0.05). Ibuprofen 77-86 C-reactive protein Homo sapiens 6-9 7541236-7 1995 Serum CRP concentration was also reduced in the ibuprofen-treated group (pre-ibuprofen, 51 mg l-1; post-ibuprofen, 29 mg l-1; P < 0.05). Ibuprofen 77-86 C-reactive protein Homo sapiens 6-9 7616354-5 1995 Chylomicrons and Intralipid liposomes are known to undergo calcium-dependent agglutination by C-reactive protein (CRP), and this may play a role in vivo in this type of fat embolism. Calcium 59-66 C-reactive protein Homo sapiens 94-112 7602028-8 1995 MAIN RESULTS: In the whole series, CRP correlated significantly with all iron status variables except erythrocyte MCV (directly with SF, inversely with the others) and correlated inversely with Alb and pre-Alb. Iron 73-77 C-reactive protein Homo sapiens 35-38 7616354-5 1995 Chylomicrons and Intralipid liposomes are known to undergo calcium-dependent agglutination by C-reactive protein (CRP), and this may play a role in vivo in this type of fat embolism. Calcium 59-66 C-reactive protein Homo sapiens 114-117 7845427-8 1995 In patients with high serum cholesterol levels, the risk of coronary events rose with increasing levels of fibrinogen and C-reactive protein, but the risk remained low even given high serum cholesterol levels in the presence of low fibrinogen concentrations. Cholesterol 28-39 C-reactive protein Homo sapiens 122-140 7881902-6 1994 CONCLUSIONS: Calcium-mediated ligand binding by CRP, HSAP and LIM is similar to that defined by the crystal structure of SAP, but sequence differences in the hydrophobic pocket explain the differential ligand specificities exhibited by the homologous proteins. Calcium 13-20 C-reactive protein Homo sapiens 48-51 7628659-0 1995 [Regulation of oxygen metabolism in human blood leukocytes by C-reactive protein]. Oxygen 15-21 C-reactive protein Homo sapiens 62-80 7748016-11 1995 A significant relation was noted between urinary albumin to creatinine ratio and CRP, and the duration of disease. Creatinine 60-70 C-reactive protein Homo sapiens 81-84 7579005-7 1995 In five patients with CD in acute phase, investigated before and during the pharmacological treatment (5-aminosalycilic acid and steroids), CRP values fell into the normal range after the second week of therapy, whereas TSA values reached the higher limit of the normal range after the third week, except for two CD patients with a larger location (ileocolonic) of the disease. Steroids 129-137 C-reactive protein Homo sapiens 140-143 8196250-9 1994 The steroid therapy has been continued and adjusted by the values of CRP as well as the cutaneous and mucous manifestations. Steroids 4-11 C-reactive protein Homo sapiens 69-72 7523502-5 1994 CRP protein, identified by immunoprecipitation of a 25-kDa band with Abs to CRP, was induced in Hep3B cells by IL-1, IL-6, or dexamethasone. Dexamethasone 126-139 C-reactive protein Homo sapiens 0-3 7523502-5 1994 CRP protein, identified by immunoprecipitation of a 25-kDa band with Abs to CRP, was induced in Hep3B cells by IL-1, IL-6, or dexamethasone. Dexamethasone 126-139 C-reactive protein Homo sapiens 76-79 8189060-1 1994 We have used oligonucleotide-directed site-specific mutagenesis to investigate structural determinants of the C1q-binding site of C-reactive protein (CRP). Oligonucleotides 13-28 C-reactive protein Homo sapiens 130-148 8189060-1 1994 We have used oligonucleotide-directed site-specific mutagenesis to investigate structural determinants of the C1q-binding site of C-reactive protein (CRP). Oligonucleotides 13-28 C-reactive protein Homo sapiens 150-153 8196672-0 1994 Calcium ion binding regions in C-reactive protein: location and regulation of conformational changes. Calcium 0-7 C-reactive protein Homo sapiens 31-49 8181076-11 1994 Based on previous observations that anti-CRP inhibited target cell-stimulated release of lytic factors, the effect of anti-CRP on release of lytic factors stimulated by PMA and calcium ionophore was evaluated. Calcium 177-184 C-reactive protein Homo sapiens 123-126 8144898-8 1994 Treatment of Raji cells with human serum led to calcium-dependent phosphocholine-inhibitable CRP binding. Calcium 48-55 C-reactive protein Homo sapiens 93-96 8043897-4 1994 A positive correlation was found between C-reactive protein (CRP), an APR glycoprotein, and non-specific TBA reactivity as determined after borohydride reduction (BH4-resistant TBA, BR-TBA), both in non-diabetics (r = 0.61; P < 0.01) and diabetics (r = 0.68; P < 0.01). thiobarbituric acid 105-108 C-reactive protein Homo sapiens 41-59 8043897-4 1994 A positive correlation was found between C-reactive protein (CRP), an APR glycoprotein, and non-specific TBA reactivity as determined after borohydride reduction (BH4-resistant TBA, BR-TBA), both in non-diabetics (r = 0.61; P < 0.01) and diabetics (r = 0.68; P < 0.01). thiobarbituric acid 105-108 C-reactive protein Homo sapiens 61-64 8144898-11 1994 CRP binding to complement-treated liposomes required phosphatidylcholine in addition to the MAC indicating that membrane phospholipids rather than the MAC proteins provide the binding sites for CRP. Phospholipids 121-134 C-reactive protein Homo sapiens 0-3 8144898-13 1994 These results support the hypothesis that CRP binding at sites of inflammation may be mediated by exposed phospholipids on damaged cell membranes. Phospholipids 106-119 C-reactive protein Homo sapiens 42-45 7679345-3 1993 Site 1 was composed of approximately 25 amino acids and calcium ion was required for the binding of CRP. Calcium 56-63 C-reactive protein Homo sapiens 100-103 8119992-0 1994 Effects of calcium, magnesium, and phosphorylcholine on secondary structures of human C-reactive protein and serum amyloid P component observed by infrared spectroscopy. Calcium 11-18 C-reactive protein Homo sapiens 86-104 8119992-6 1994 Phosphorylcholine in the presence of calcium also affected the spectrum of CRP but not the spectrum of SAP. Calcium 37-44 C-reactive protein Homo sapiens 75-78 8284758-8 1994 In the same 40 patients the 1-week alcohol consumption correlated with the number of positive Ranson criteria (r = 0.40, p < 0.05) and serum CRP concentration (r = 0.37, p < 0.05). Alcohols 35-42 C-reactive protein Homo sapiens 144-147 8315675-9 1993 A negative nitrogen balance was associated with the urinary excretion of epinephrine and norepinephrine, with caloric balance, and with plasma C-reactive protein during days 1 and 2 after injury. Nitrogen 11-19 C-reactive protein Homo sapiens 143-161 8236991-1 1993 In a group of 18 patients with essential hyperlipidaemia the influence was studied of multivitamin CRP preparation given for 12 weeks, on lipid peroxides, cholesterol and triglycerides in the serum. Triglycerides 171-184 C-reactive protein Homo sapiens 99-102 8203284-17 1994 Three other Cys-rich proteins, papilloma viral E7 and LIM motif-containing CRP and CRIP, isolated as Zn2+ proteins exhibit facile metal exchange in vitro with Cu1+. Cysteine 12-15 C-reactive protein Homo sapiens 75-78 8203284-17 1994 Three other Cys-rich proteins, papilloma viral E7 and LIM motif-containing CRP and CRIP, isolated as Zn2+ proteins exhibit facile metal exchange in vitro with Cu1+. Metals 130-135 C-reactive protein Homo sapiens 75-78 7802339-2 1994 This prompted us to assay CRP by a sensitive Elisa in a sample of 30 patients with ovarian stimulation for in vitro fertilization, thus with high levels of estradiol. Estradiol 156-165 C-reactive protein Homo sapiens 26-29 8262633-4 1994 The CRP purified from parasites treated with an inhibitor of N-linked glycosylation exhibited a decreased binding affinity for C3b compared with that of the fully glycosylated protein. Nitrogen 61-62 C-reactive protein Homo sapiens 4-7 8263640-11 1994 C-reactive protein was significantly reduced on postoperative days 1, 2, and 3 (P < .05) in both dexamethasone groups. Dexamethasone 100-113 C-reactive protein Homo sapiens 0-18 8263640-13 1994 Measurement of C-reactive protein seems to be the most sensitive method for comparing the effect of dexamethasone on postoperative inflammation. Dexamethasone 100-113 C-reactive protein Homo sapiens 15-33 8361751-5 1993 Both the quail and human CRP proteins contain two copies of a cysteine-rich amino acid sequence motif (LIM) with putative zinc-binding activity that was previously identified in several proteins with presumed regulatory functions essential for cell growth or differentiation. Cysteine 62-70 C-reactive protein Homo sapiens 25-28 8367755-5 1993 We suggest using the C-reactive protein level as a monitor of subclinical disease activity; it is therefore beneficial in the adjustment of steroid therapy. Steroids 140-147 C-reactive protein Homo sapiens 21-39 8367755-14 1993 After rheumatologic consultation, steroid dosage was titrated to the CRP level and ESR, and vasculitic symptoms resolved. Steroids 34-41 C-reactive protein Homo sapiens 69-72 7685225-7 1993 Many studies have shown that serum CRP concentrations are not reduced by NSAIDs; however, one recent study has demonstrated that CRP concentration was reduced by the NSAIDs flurbiprofen and sustained-release ibuprofen in a subgroup of patients. Ibuprofen 208-217 C-reactive protein Homo sapiens 35-38 7685225-7 1993 Many studies have shown that serum CRP concentrations are not reduced by NSAIDs; however, one recent study has demonstrated that CRP concentration was reduced by the NSAIDs flurbiprofen and sustained-release ibuprofen in a subgroup of patients. Ibuprofen 208-217 C-reactive protein Homo sapiens 129-132 1332180-6 1992 These concentrations reflected a need for more heparin if, for example, inflammation, indicated by increasing C-reactive protein levels (CRP), occurred. Heparin 47-54 C-reactive protein Homo sapiens 110-128 8453797-5 1993 At day 3 and day 5, a significant (p < 0.001) fall in CRP was seen only in the intra-articular steroid group. Steroids 98-105 C-reactive protein Homo sapiens 57-60 8515183-4 1993 It is proposed that distinct species of CRP are formed which have unique activities at an inflammatory site; conformationally altered and proteolytic forms of CRP are created in succession from bound native CRP at the inflammatory site due to local conditions (e.g. lowered pH, oxygen radicals, or possibly enzymes). Reactive Oxygen Species 278-293 C-reactive protein Homo sapiens 40-43 8515183-4 1993 It is proposed that distinct species of CRP are formed which have unique activities at an inflammatory site; conformationally altered and proteolytic forms of CRP are created in succession from bound native CRP at the inflammatory site due to local conditions (e.g. lowered pH, oxygen radicals, or possibly enzymes). Reactive Oxygen Species 278-293 C-reactive protein Homo sapiens 159-162 8515183-4 1993 It is proposed that distinct species of CRP are formed which have unique activities at an inflammatory site; conformationally altered and proteolytic forms of CRP are created in succession from bound native CRP at the inflammatory site due to local conditions (e.g. lowered pH, oxygen radicals, or possibly enzymes). Reactive Oxygen Species 278-293 C-reactive protein Homo sapiens 159-162 1385304-5 1992 In situ hybridization of 3H-labeled CRP cDNA to human metaphase chromosomes confirms this assignment and permits regional localization to bands 1q24-1q32. Tritium 25-27 C-reactive protein Homo sapiens 36-39 1624792-7 1992 Comparing various mono-, di-, and trisaccharides as competitive inhibitors of the lectin binding activity of CRP, only beta-D-Gal-(1-3)-D-GalNAc, beta-D-Gal-(1-4)-D-GalNAc, and beta-D-Gal-(1-4)-beta-D-Gal-(1-4)-D-GlcNAc had significant inhibitory power at a concentration of 8 mmol/liter. beta-d-gal-(1-4)-d-galnac 146-171 C-reactive protein Homo sapiens 109-112 8343015-8 1993 The blood CRP level of the dexamethasone plus antibiotics group decreased significantly within 48 hours. Dexamethasone 27-40 C-reactive protein Homo sapiens 10-13 8343015-11 1993 The relatively frequent transient recurrences of fever and increased CRP when dexamethasone was interrupted suggest that the dose and/or duration of dexamethasone treatment should be modified. Dexamethasone 78-91 C-reactive protein Homo sapiens 69-72 8343015-11 1993 The relatively frequent transient recurrences of fever and increased CRP when dexamethasone was interrupted suggest that the dose and/or duration of dexamethasone treatment should be modified. Dexamethasone 149-162 C-reactive protein Homo sapiens 69-72 8054580-0 1993 [Stimulation of oxygen metabolism in human blood phagocytes as affected by tuftsin-like peptides derived from the C-reactive protein molecule]. Oxygen 16-22 C-reactive protein Homo sapiens 114-132 8054580-1 1993 Effects of synthetic peptides analogous to those cleaved by proteolysis from human C-reactive protein (CRP) molecule on the level of oxygen metabolism of blood neutrophils and monocytes were studied. Oxygen 133-139 C-reactive protein Homo sapiens 83-101 8054580-1 1993 Effects of synthetic peptides analogous to those cleaved by proteolysis from human C-reactive protein (CRP) molecule on the level of oxygen metabolism of blood neutrophils and monocytes were studied. Oxygen 133-139 C-reactive protein Homo sapiens 103-106 8054580-3 1993 CRP-derived peptides stimulated phagocyte oxygen metabolism as effectively as tuftsin. Oxygen 42-48 C-reactive protein Homo sapiens 0-3 8312976-7 1993 The CRP derivative is shown to retain 100% of the native protein cAMP binding and specific DNA binding activity. Cyclic AMP 65-69 C-reactive protein Homo sapiens 4-7 8339522-3 1993 Statistical analysis reveals a significant inverse relationship between changes in C-reactive protein and changes in the plasma ratio of esterified to total cholesterol (r = -0.78; p < 0.001) as well as in plasma apoA-I concentration (r = -0.64; p < 0.01). Cholesterol 157-168 C-reactive protein Homo sapiens 83-101 1460031-3 1992 In the present study, we used oligonucleotide-directed site-specific mutagenesis to investigate structural determinants of the PCh-binding site of CRP. Oligonucleotides 30-45 C-reactive protein Homo sapiens 147-150 1460031-10 1992 We conclude that the residues Lys-57, Arg-58, and Trp-67 contribute to the structure of the PCh-binding site of human CRP. Lysine 30-33 C-reactive protein Homo sapiens 118-121 1460031-10 1992 We conclude that the residues Lys-57, Arg-58, and Trp-67 contribute to the structure of the PCh-binding site of human CRP. Arginine 38-41 C-reactive protein Homo sapiens 118-121 1460031-10 1992 We conclude that the residues Lys-57, Arg-58, and Trp-67 contribute to the structure of the PCh-binding site of human CRP. Tryptophan 50-53 C-reactive protein Homo sapiens 118-121 1403115-11 1992 Also, C-reactive protein determination should be performed and is useful even when steroids are given. Steroids 83-91 C-reactive protein Homo sapiens 6-24 1328445-1 1992 The acute phase protein, C-reactive protein (CRP), when heat-aggregated (Agg-CRP), potentiates immunoglobulin G (IgG) Fc receptor-mediated luminol-enhanced chemiluminescence (CL) in human monocytes and neutrophils. Luminol 139-146 C-reactive protein Homo sapiens 25-43 1328445-1 1992 The acute phase protein, C-reactive protein (CRP), when heat-aggregated (Agg-CRP), potentiates immunoglobulin G (IgG) Fc receptor-mediated luminol-enhanced chemiluminescence (CL) in human monocytes and neutrophils. Luminol 139-146 C-reactive protein Homo sapiens 45-48 1328445-1 1992 The acute phase protein, C-reactive protein (CRP), when heat-aggregated (Agg-CRP), potentiates immunoglobulin G (IgG) Fc receptor-mediated luminol-enhanced chemiluminescence (CL) in human monocytes and neutrophils. Luminol 139-146 C-reactive protein Homo sapiens 77-80 1328445-6 1992 Although Agg-CRP alone did not stimulate hydrogen peroxide generation by either monocytes or neutrophils, it significantly enhanced hydrogen peroxide generation in response to heat-aggregated IgG (Agg-IgG). Hydrogen Peroxide 132-149 C-reactive protein Homo sapiens 13-16 1375509-3 1992 CRP proteins are identified by their calcium-dependent interaction with phosphorylcholine. Calcium 37-44 C-reactive protein Homo sapiens 0-3 1321093-0 1992 C-reactive protein (CRP) peptides inactivate enolase in human neutrophils leading to depletion of intracellular ATP and inhibition of superoxide generation. Adenosine Triphosphate 112-115 C-reactive protein Homo sapiens 0-18 1321093-0 1992 C-reactive protein (CRP) peptides inactivate enolase in human neutrophils leading to depletion of intracellular ATP and inhibition of superoxide generation. Adenosine Triphosphate 112-115 C-reactive protein Homo sapiens 20-23 1321093-0 1992 C-reactive protein (CRP) peptides inactivate enolase in human neutrophils leading to depletion of intracellular ATP and inhibition of superoxide generation. Superoxides 134-144 C-reactive protein Homo sapiens 0-18 1321093-0 1992 C-reactive protein (CRP) peptides inactivate enolase in human neutrophils leading to depletion of intracellular ATP and inhibition of superoxide generation. Superoxides 134-144 C-reactive protein Homo sapiens 20-23 1626915-5 1992 Correlation between nitrogen balance and IGF-1 is preserved during the acute phase response to tissue injury when C-reactive protein (CRP) varies in the range 40-248 mg/L. Nitrogen 20-28 C-reactive protein Homo sapiens 114-132 1569403-11 1992 DNA and heparin inhibited binding of CRP trimers to intact C1q, as well as to each peptide 14-26 and 76-92, suggesting involvement of these regions in C1q-CLR binding reactions generally. Heparin 8-15 C-reactive protein Homo sapiens 37-40 1626915-5 1992 Correlation between nitrogen balance and IGF-1 is preserved during the acute phase response to tissue injury when C-reactive protein (CRP) varies in the range 40-248 mg/L. Nitrogen 20-28 C-reactive protein Homo sapiens 134-137 1544236-2 1992 This egress of proteolytic activity, which was upregulated by phorbol 12-myristate 13-acetate (PMA), was found to occur from both the cytoskeleton and membrane fractions of neutrophils and was dependent on the time of incubation of CRP with the cells and the concentration of CRP. Tetradecanoylphorbol Acetate 62-93 C-reactive protein Homo sapiens 232-235 1544236-2 1992 This egress of proteolytic activity, which was upregulated by phorbol 12-myristate 13-acetate (PMA), was found to occur from both the cytoskeleton and membrane fractions of neutrophils and was dependent on the time of incubation of CRP with the cells and the concentration of CRP. Tetradecanoylphorbol Acetate 62-93 C-reactive protein Homo sapiens 276-279 1544236-2 1992 This egress of proteolytic activity, which was upregulated by phorbol 12-myristate 13-acetate (PMA), was found to occur from both the cytoskeleton and membrane fractions of neutrophils and was dependent on the time of incubation of CRP with the cells and the concentration of CRP. Tetradecanoylphorbol Acetate 95-98 C-reactive protein Homo sapiens 232-235 1544236-2 1992 This egress of proteolytic activity, which was upregulated by phorbol 12-myristate 13-acetate (PMA), was found to occur from both the cytoskeleton and membrane fractions of neutrophils and was dependent on the time of incubation of CRP with the cells and the concentration of CRP. Tetradecanoylphorbol Acetate 95-98 C-reactive protein Homo sapiens 276-279 1544236-3 1992 Neutrophil kinases activated by PMA are found to be involved in upregulating the activity of the CRP-degrading protease. Tetradecanoylphorbol Acetate 32-35 C-reactive protein Homo sapiens 97-100 1544236-4 1992 The apparent molecular weight of the CRP-degrading protease associated with the conditioned medium from PMA-stimulated neutrophils and neutrophil membrane and cytoskeleton preparations, was found by size exclusion chromatography to be 600 kD and migrated on 3-13% SDS-PAGE as four discrete bands to positions corresponding to apparent molecular weights of 209 kD, 316 kD, 398 kD and 501 kD. Tetradecanoylphorbol Acetate 104-107 C-reactive protein Homo sapiens 37-40 1544236-4 1992 The apparent molecular weight of the CRP-degrading protease associated with the conditioned medium from PMA-stimulated neutrophils and neutrophil membrane and cytoskeleton preparations, was found by size exclusion chromatography to be 600 kD and migrated on 3-13% SDS-PAGE as four discrete bands to positions corresponding to apparent molecular weights of 209 kD, 316 kD, 398 kD and 501 kD. Sodium Dodecyl Sulfate 264-267 C-reactive protein Homo sapiens 37-40 1556702-6 1992 The rate of the correlation between synovial IL-6 level and concentration of serum C-reactive protein in RA was inversely proportional to the dose of steroid treatment in patients with RA. Steroids 150-157 C-reactive protein Homo sapiens 83-101 1568518-2 1992 Total weekly doses of 525 mg rifamycin or 560 mg pefloxacin were given for 10 weeks, and 12 months after treatment all clinical indices, erythrocyte sedimentation rate and C-reactive protein improved significantly in the rifamycin group. rifamycin SV 221-230 C-reactive protein Homo sapiens 172-190 1360960-5 1992 The C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) improved significantly from 2.55 +/- 0.28(+) and 57.0 +/- 5.69 mm/hr to 0.53 +/- 0.12(+) and 31.2 +/- 3.45 mm/hr, respectively after treatment including steroid and antiplatelet therapy (P < 0.01). Steroids 223-230 C-reactive protein Homo sapiens 4-22 1958695-0 1991 Internalization and degradation of receptor bound C-reactive protein by U-937 cells: induction of H2O2 production and tumoricidal activity. Hydrogen Peroxide 98-102 C-reactive protein Homo sapiens 50-68 1958695-6 1991 The lysosomotrophic agents (chloroquine, NH4Cl) greatly decreased the extent of CRP degradation without altering binding or internalization. Ammonium Chloride 41-46 C-reactive protein Homo sapiens 80-83 1958695-10 1991 CRP initiated the differentiation of the U-937 cells so that they acquired the ability to produce H2O2 and also display in vitro tumoricidal activity. Hydrogen Peroxide 98-102 C-reactive protein Homo sapiens 0-3 1651357-1 1991 We have previously shown that induction of synthesis of the two major human acute phase proteins, serum amyloid A (SAA) and C-reactive protein (CRP), can be accomplished in the human hepatoma cell line Hep 3B, in the presence of dexamethasone, either by conditioned medium from LPS-stimulated monocytes or by the combination of IL-6 and IL-1. Dexamethasone 229-242 C-reactive protein Homo sapiens 124-142 1717553-0 1991 Monoclonal antibodies to the calcium-binding region peptide of human C-reactive protein alter its conformation. Calcium 29-36 C-reactive protein Homo sapiens 69-87 1667244-5 1991 Incubation of HepG2 cells simultaneously with IL-6 and dexamethasone increases the magnitude of CRP release significantly above that seen with IL-6 alone. Dexamethasone 55-68 C-reactive protein Homo sapiens 96-99 1667244-6 1991 After preincubation with dexamethasone, the kinetics of CRP release, induced by IL-6, are increased and approach that observed in the case of alpha 1-acid glycoprotein (alpha 1-AGP) without dexamethasone pretreatment. Dexamethasone 25-38 C-reactive protein Homo sapiens 56-59 1667244-6 1991 After preincubation with dexamethasone, the kinetics of CRP release, induced by IL-6, are increased and approach that observed in the case of alpha 1-acid glycoprotein (alpha 1-AGP) without dexamethasone pretreatment. Dexamethasone 190-203 C-reactive protein Homo sapiens 56-59 1651357-12 1991 These data indicate that IL-6, IL-1 alpha, TNF-alpha, and dexamethasone in various combinations are all capable of influencing synthesis of SAA in Hep 3B cells, whereas only IL-6, IL-1 alpha, and dexamethasone can influence CRP synthesis. Dexamethasone 58-71 C-reactive protein Homo sapiens 224-227 1651357-1 1991 We have previously shown that induction of synthesis of the two major human acute phase proteins, serum amyloid A (SAA) and C-reactive protein (CRP), can be accomplished in the human hepatoma cell line Hep 3B, in the presence of dexamethasone, either by conditioned medium from LPS-stimulated monocytes or by the combination of IL-6 and IL-1. Dexamethasone 229-242 C-reactive protein Homo sapiens 144-147 1650222-9 1991 CRP at concentrations of 50 micrograms/ml inhibited the neutrophil superoxide production induced by phorbol ester. Superoxides 67-77 C-reactive protein Homo sapiens 0-3 1650222-10 1991 At concentrations of 100 micrograms/ml or greater, CRP also inhibited superoxide production in a cell-free xanthine oxidase-acetaldehyde system. Superoxides 70-80 C-reactive protein Homo sapiens 51-54 1724512-3 1991 Excessive heparin-dependent activity of monocytes in this case reflects the activity of the rheumatoid process, the NBT test with heparin being more sensitive in the diagnosis of disease activity than measurement of red cell sedimentation rate or of blood C-reactive protein, gamma- and alpha 2-globulin levels. Heparin 10-17 C-reactive protein Homo sapiens 256-274 1645189-0 1991 Comparison of cAMP receptor protein (CRP) and a cAMP-independent form of CRP by Raman spectroscopy and DNA binding. Cyclic AMP 14-18 C-reactive protein Homo sapiens 37-40 2025959-4 1991 It was observed that 67% of monocytes bound biotinylated CRP in a dose-dependent manner, that the binding was calcium dependent, and that it could be inhibited by 60% in the presence of a greater than 20-fold excess of competing native CRP. Calcium 110-117 C-reactive protein Homo sapiens 57-60 2025959-6 1991 These studies confirm the ability of human CRP to bind to a majority of human monocytes in a calcium-dependent and specific manner, and provide further support for a biologically important interaction of this acute-phase protein with phagocytic cells. Calcium 93-100 C-reactive protein Homo sapiens 43-46 1707669-8 1991 Sequence analysis has revealed a region of homology to metal-responsive elements in the alpha 1-acid glycoprotein and C-reactive protein promoters. Metals 55-60 C-reactive protein Homo sapiens 118-136 2005402-6 1991 Reactivity with CRP-trimers as well as with Agg-IgG was retained after reduction/alkylation and SDS treatment of C1q. Sodium Dodecyl Sulfate 96-99 C-reactive protein Homo sapiens 16-19 1900197-2 1991 On SDS-PAGE, eel C-reactive protein (eCRP) migrated as a single band with a molecular weight of 24,000 under reducing and 23,500 under non-reducing conditions. Sodium Dodecyl Sulfate 3-6 C-reactive protein Homo sapiens 17-35 1810225-2 1991 CRP on the lymphocyte surface (sd-CRP) belongs to two different categories: i) CRP produced by lymphocytes and inserted into cell membrane (s-CRP), ii) CRP produced primarily by the liver and bound by the lymphocytes (sb-CRP) in calcium-dependent manner. Calcium 229-236 C-reactive protein Homo sapiens 0-3 1810225-2 1991 CRP on the lymphocyte surface (sd-CRP) belongs to two different categories: i) CRP produced by lymphocytes and inserted into cell membrane (s-CRP), ii) CRP produced primarily by the liver and bound by the lymphocytes (sb-CRP) in calcium-dependent manner. Calcium 229-236 C-reactive protein Homo sapiens 34-37 1810225-2 1991 CRP on the lymphocyte surface (sd-CRP) belongs to two different categories: i) CRP produced by lymphocytes and inserted into cell membrane (s-CRP), ii) CRP produced primarily by the liver and bound by the lymphocytes (sb-CRP) in calcium-dependent manner. Calcium 229-236 C-reactive protein Homo sapiens 34-37 1810225-2 1991 CRP on the lymphocyte surface (sd-CRP) belongs to two different categories: i) CRP produced by lymphocytes and inserted into cell membrane (s-CRP), ii) CRP produced primarily by the liver and bound by the lymphocytes (sb-CRP) in calcium-dependent manner. Calcium 229-236 C-reactive protein Homo sapiens 34-37 1810225-2 1991 CRP on the lymphocyte surface (sd-CRP) belongs to two different categories: i) CRP produced by lymphocytes and inserted into cell membrane (s-CRP), ii) CRP produced primarily by the liver and bound by the lymphocytes (sb-CRP) in calcium-dependent manner. Calcium 229-236 C-reactive protein Homo sapiens 34-37 1810225-2 1991 CRP on the lymphocyte surface (sd-CRP) belongs to two different categories: i) CRP produced by lymphocytes and inserted into cell membrane (s-CRP), ii) CRP produced primarily by the liver and bound by the lymphocytes (sb-CRP) in calcium-dependent manner. Calcium 229-236 C-reactive protein Homo sapiens 34-37 1645189-4 1991 Raman analysis indicates that CRP structural changes induced by one bound cAMP or by the Gly to Gln mutation at residue 141 are small. Cyclic AMP 74-78 C-reactive protein Homo sapiens 30-33 1645189-9 1991 These studies indicate that CRP and CRP.cAMP1 in solution are similar in structure and differ from CRP.cAMP2 cocrystals. camp1 40-45 C-reactive protein Homo sapiens 36-39 1645189-9 1991 These studies indicate that CRP and CRP.cAMP1 in solution are similar in structure and differ from CRP.cAMP2 cocrystals. camp1 40-45 C-reactive protein Homo sapiens 36-39 1645189-11 1991 CRP*141 gln exhibited the same conformational characteristics of previously reported cAMP-independent mutant proteins. Cyclic AMP 85-89 C-reactive protein Homo sapiens 0-3 2016530-0 1991 Anti-C-reactive protein inhibits the calcium-dependent stage of natural killer cell activation. Calcium 37-44 C-reactive protein Homo sapiens 5-23 2016530-5 1991 When conjugates were formed in the absence of calcium, and anti-CRP and calcium were then added to cultures at the same time, anti-CRP inhibited maximally. Calcium 72-79 C-reactive protein Homo sapiens 131-134 2016530-6 1991 Anti-CRP continued to inhibit somewhat throughout the calcium-dependent stage but did not block lysis when added after the completion of calcium requiring events. Calcium 54-61 C-reactive protein Homo sapiens 5-8 2016530-9 1991 This evidence indicates that anti-CRP blocks NK-mediated lysis at the calcium dependent stage of lysis. Calcium 70-77 C-reactive protein Homo sapiens 34-37 2065506-1 1991 The effect of intra-articular (i-a) steroid injection on ESR and C-reactive protein (CRP) in rheumatoid arthritis (RA) was investigated. Steroids 36-43 C-reactive protein Homo sapiens 65-83 2065506-1 1991 The effect of intra-articular (i-a) steroid injection on ESR and C-reactive protein (CRP) in rheumatoid arthritis (RA) was investigated. Steroids 36-43 C-reactive protein Homo sapiens 85-88 2063349-5 1991 Furthermore, CRP (10 micrograms/ml) diminished specific [3H]PAF binding to platelets and displaced previously bound labeled PAF from platelets. Tritium 57-59 C-reactive protein Homo sapiens 13-16 1989977-1 1991 C-reactive protein (CRP) is an acute phase inflammatory protein in man which binds to phosphocholine, chromatin, histones, and the 70-kDa protein of the U1 small nuclear ribonucleoprotein particle in a calcium-dependent, phosphocholine-inhibitable manner. Calcium 202-209 C-reactive protein Homo sapiens 0-18 1989977-1 1991 C-reactive protein (CRP) is an acute phase inflammatory protein in man which binds to phosphocholine, chromatin, histones, and the 70-kDa protein of the U1 small nuclear ribonucleoprotein particle in a calcium-dependent, phosphocholine-inhibitable manner. Calcium 202-209 C-reactive protein Homo sapiens 20-23 2242421-5 1990 The concurrent administration of dexamethasone also prevented the IL-2-induced increase in serum levels of C-reactive protein, a hepatic acute phase reactant whose synthesis is regulated by proinflammatory cytokines such as TNF. Dexamethasone 33-46 C-reactive protein Homo sapiens 107-125 2127535-4 1990 The acute phase concentration of very low density lipoprotein triglyceride correlated inversely to C-reactive protein level (r = -0.31, P less than 0.05) but not to serum amyloid-A protein level. Triglycerides 62-74 C-reactive protein Homo sapiens 99-117 2127535-5 1990 Regression analysis showed that the concentration of C-reactive protein was a significant predictor of very low density lipoprotein triglyceride level in the acute phase of infection but not during convalescence. Triglycerides 132-144 C-reactive protein Homo sapiens 53-71 2280109-12 1990 The adrenal steroids have been continuously administrated and adjusted according to the values of CRP and ESR as well as the cutaneous and mucous manifestations of this disease. Steroids 12-20 C-reactive protein Homo sapiens 98-101 2243293-8 1990 RDW and CRP are two of several indicators of iron status in the third National Health and Examination Survey (NHANES III). Iron 45-49 C-reactive protein Homo sapiens 8-11 2170518-9 1990 TGF-beta added along with IL-6 inhibited the metabolic labeling of CRP with [35S]methionine; however, enhanced incorporation of [35S]methionine into CRP was observed when the cells were exposed to TGF-beta before IL-6 addition. Sulfur-35 77-80 C-reactive protein Homo sapiens 67-70 2170518-9 1990 TGF-beta added along with IL-6 inhibited the metabolic labeling of CRP with [35S]methionine; however, enhanced incorporation of [35S]methionine into CRP was observed when the cells were exposed to TGF-beta before IL-6 addition. Methionine 81-91 C-reactive protein Homo sapiens 67-70 2170518-9 1990 TGF-beta added along with IL-6 inhibited the metabolic labeling of CRP with [35S]methionine; however, enhanced incorporation of [35S]methionine into CRP was observed when the cells were exposed to TGF-beta before IL-6 addition. Methionine 133-143 C-reactive protein Homo sapiens 149-152 2170518-9 1990 TGF-beta added along with IL-6 inhibited the metabolic labeling of CRP with [35S]methionine; however, enhanced incorporation of [35S]methionine into CRP was observed when the cells were exposed to TGF-beta before IL-6 addition. Sulfur-35 129-132 C-reactive protein Homo sapiens 149-152 2240943-7 1990 The CRP level returned to normal within the first week of steroid therapy for 76% of the patients, before ESR, F and O. Steroids 58-65 C-reactive protein Homo sapiens 4-7 2120317-3 1990 CRP bound to the immunoaffinity column was eluted by 0.5 M acetate buffer, pH 5.0 containing 1.5 M NaCl. Sodium Chloride 99-103 C-reactive protein Homo sapiens 0-3 2298410-1 1990 C-reactive protein (CRP) is an acute phase reactant that appears to have a variety of biologic effects, including stimulation of prostaglandin production by peripheral blood monocytes. Prostaglandins 129-142 C-reactive protein Homo sapiens 0-18 2298410-1 1990 C-reactive protein (CRP) is an acute phase reactant that appears to have a variety of biologic effects, including stimulation of prostaglandin production by peripheral blood monocytes. Prostaglandins 129-142 C-reactive protein Homo sapiens 20-23 2163402-0 1990 A nuclear magnetic resonance study of the cyclic AMP receptor protein (CRP): assignments of the NH protons of histidine and tryptophan residues and the effect of binding of cAMP to CRP. Histidine 110-119 C-reactive protein Homo sapiens 42-69 2163402-0 1990 A nuclear magnetic resonance study of the cyclic AMP receptor protein (CRP): assignments of the NH protons of histidine and tryptophan residues and the effect of binding of cAMP to CRP. Histidine 110-119 C-reactive protein Homo sapiens 71-74 2163402-0 1990 A nuclear magnetic resonance study of the cyclic AMP receptor protein (CRP): assignments of the NH protons of histidine and tryptophan residues and the effect of binding of cAMP to CRP. Tryptophan 124-134 C-reactive protein Homo sapiens 42-69 2163402-0 1990 A nuclear magnetic resonance study of the cyclic AMP receptor protein (CRP): assignments of the NH protons of histidine and tryptophan residues and the effect of binding of cAMP to CRP. Tryptophan 124-134 C-reactive protein Homo sapiens 71-74 2163402-0 1990 A nuclear magnetic resonance study of the cyclic AMP receptor protein (CRP): assignments of the NH protons of histidine and tryptophan residues and the effect of binding of cAMP to CRP. Cyclic AMP 173-177 C-reactive protein Homo sapiens 42-69 2163402-0 1990 A nuclear magnetic resonance study of the cyclic AMP receptor protein (CRP): assignments of the NH protons of histidine and tryptophan residues and the effect of binding of cAMP to CRP. Cyclic AMP 173-177 C-reactive protein Homo sapiens 71-74 2163402-0 1990 A nuclear magnetic resonance study of the cyclic AMP receptor protein (CRP): assignments of the NH protons of histidine and tryptophan residues and the effect of binding of cAMP to CRP. Cyclic AMP 173-177 C-reactive protein Homo sapiens 181-184 2163402-1 1990 Seven well-resolved signals could be observed in the field lower than 9.5 ppm in the 1H-NMR spectrum of the H2O solution of cyclic AMP receptor protein (CRP). Hydrogen 85-87 C-reactive protein Homo sapiens 124-151 2163402-1 1990 Seven well-resolved signals could be observed in the field lower than 9.5 ppm in the 1H-NMR spectrum of the H2O solution of cyclic AMP receptor protein (CRP). Hydrogen 85-87 C-reactive protein Homo sapiens 153-156 2163402-1 1990 Seven well-resolved signals could be observed in the field lower than 9.5 ppm in the 1H-NMR spectrum of the H2O solution of cyclic AMP receptor protein (CRP). Water 108-111 C-reactive protein Homo sapiens 124-151 2163402-1 1990 Seven well-resolved signals could be observed in the field lower than 9.5 ppm in the 1H-NMR spectrum of the H2O solution of cyclic AMP receptor protein (CRP). Water 108-111 C-reactive protein Homo sapiens 153-156 2163402-5 1990 On the addition of cAMP and cGMP, signals F and G shifted up- and downfield respectively and conformational changes in the structure of CRP could be detected. Cyclic AMP 19-23 C-reactive protein Homo sapiens 136-139 2163402-5 1990 On the addition of cAMP and cGMP, signals F and G shifted up- and downfield respectively and conformational changes in the structure of CRP could be detected. Cyclic GMP 28-32 C-reactive protein Homo sapiens 136-139 2166760-6 1990 Three of the synthetic peptides corresponding to residues 201-206 (CRP-III), 83-90 (CRP-IV), and 77-82 (CRP-V) of the intact protein were identified to significantly inhibit superoxide production from activated neutrophils at 50 microM whereas CRP-III and CRP-V in addition inhibited neutrophil chemotaxis at this concentration. Superoxides 174-184 C-reactive protein Homo sapiens 67-70 2166760-6 1990 Three of the synthetic peptides corresponding to residues 201-206 (CRP-III), 83-90 (CRP-IV), and 77-82 (CRP-V) of the intact protein were identified to significantly inhibit superoxide production from activated neutrophils at 50 microM whereas CRP-III and CRP-V in addition inhibited neutrophil chemotaxis at this concentration. Superoxides 174-184 C-reactive protein Homo sapiens 84-87 2166760-6 1990 Three of the synthetic peptides corresponding to residues 201-206 (CRP-III), 83-90 (CRP-IV), and 77-82 (CRP-V) of the intact protein were identified to significantly inhibit superoxide production from activated neutrophils at 50 microM whereas CRP-III and CRP-V in addition inhibited neutrophil chemotaxis at this concentration. Superoxides 174-184 C-reactive protein Homo sapiens 84-87 2166760-6 1990 Three of the synthetic peptides corresponding to residues 201-206 (CRP-III), 83-90 (CRP-IV), and 77-82 (CRP-V) of the intact protein were identified to significantly inhibit superoxide production from activated neutrophils at 50 microM whereas CRP-III and CRP-V in addition inhibited neutrophil chemotaxis at this concentration. Superoxides 174-184 C-reactive protein Homo sapiens 84-87 2166760-6 1990 Three of the synthetic peptides corresponding to residues 201-206 (CRP-III), 83-90 (CRP-IV), and 77-82 (CRP-V) of the intact protein were identified to significantly inhibit superoxide production from activated neutrophils at 50 microM whereas CRP-III and CRP-V in addition inhibited neutrophil chemotaxis at this concentration. Superoxides 174-184 C-reactive protein Homo sapiens 84-87 2162197-2 1990 Spectra were obtained over the range 400-1900 cm-1 from solutions of CRP and from CRP-cAMP cocrystals. Cyclic AMP 86-90 C-reactive protein Homo sapiens 82-85 2162197-7 1990 Raman spectra of CRP-cAMP cocrystals differed from the spectra of CRP in solution. Cyclic AMP 21-25 C-reactive protein Homo sapiens 17-20 2162197-10 1990 Analysis of the amide I region of the CRP-cAMP cocrystal spectrum indicated a secondary structure distribution of 37% alpha-helix, 33% beta-strand, 17% turn, and 12% undefined. Cyclic AMP 42-46 C-reactive protein Homo sapiens 38-41 2162197-11 1990 This result is in agreement with a published secondary structure distribution derived from X-ray analysis of CRP-cAMP cocrystals (37% alpha-helix and 36% beta-strand). Cyclic AMP 113-117 C-reactive protein Homo sapiens 109-112 2107267-6 1990 However, a radiolabeled commercial preparation of CRP did result in some PEG-precipitable radioactivity after incubation with aggregated IgG. Polyethylene Glycols 73-76 C-reactive protein Homo sapiens 50-53 2094538-7 1990 Patients with end-stage CRF (CRp greater than 4 mg/dl) and those on hemodialysis had elevated mean serum phosphorus levels and decreased mean serum total calcium concentrations compared with those with mild and moderate CRF, and more pronounced increases in both mean plasma PTH-COOH and PTH-NH2. Calcium 154-161 C-reactive protein Homo sapiens 29-32 2338157-2 1990 The isolation was based on its calcium-dependent binding affinity for pneumococcal C-polysaccharide (CPS) according to the isolation procedure of human C-reactive protein. Calcium 31-38 C-reactive protein Homo sapiens 152-170 33798839-6 2021 Meta-analysis of 2 studies including 323 pregnant women showed significantly reduced CRP levels following treatment with metformin compared to placebo [mean difference = -1.72, 95% CI (-2.97; -0.48); p = 0.007]. Metformin 121-130 C-reactive protein Homo sapiens 85-88 2210970-0 1990 New ligands for human C-reactive protein: calcium-dependent binding with epsilon-aminocaproic acid-agarose and calcium-independent binding with omega-aminohexyl-agarose. Calcium 42-49 C-reactive protein Homo sapiens 22-40 2210970-0 1990 New ligands for human C-reactive protein: calcium-dependent binding with epsilon-aminocaproic acid-agarose and calcium-independent binding with omega-aminohexyl-agarose. aminohexyl-sepharose 73-106 C-reactive protein Homo sapiens 22-40 2210970-0 1990 New ligands for human C-reactive protein: calcium-dependent binding with epsilon-aminocaproic acid-agarose and calcium-independent binding with omega-aminohexyl-agarose. Calcium 111-118 C-reactive protein Homo sapiens 22-40 2210970-0 1990 New ligands for human C-reactive protein: calcium-dependent binding with epsilon-aminocaproic acid-agarose and calcium-independent binding with omega-aminohexyl-agarose. omega-aminohexyl-agarose 144-168 C-reactive protein Homo sapiens 22-40 2210970-2 1990 CRP has been known to bind with phosphorylcholine in a calcium-dependent manner. Calcium 55-62 C-reactive protein Homo sapiens 0-3 2210970-3 1990 In this study, CRP is found to bind to affinity chromatography of negatively-charged epsilon-aminocaproic acid-agarose when calcium ions are present, and to the affinity chromatography of positively-charged omega-aminohexyl-agarose if a normal ionic strength of NaCl exists but calcium ion is not present. aminohexyl-sepharose 85-118 C-reactive protein Homo sapiens 15-18 2210970-3 1990 In this study, CRP is found to bind to affinity chromatography of negatively-charged epsilon-aminocaproic acid-agarose when calcium ions are present, and to the affinity chromatography of positively-charged omega-aminohexyl-agarose if a normal ionic strength of NaCl exists but calcium ion is not present. Calcium 124-131 C-reactive protein Homo sapiens 15-18 33940646-10 2021 A positive correlation was found between hepcidin and ferritin (R2 = 0.247, p = 0.02) and a negative correlation was found between 25(OH)D and CRP (R2 = 0.1, p = 0.04). 25(oh)d 131-138 C-reactive protein Homo sapiens 143-146 33940646-15 2021 Negative correlation was found between 25(OH)D and CRP.. 25(oh)d 39-46 C-reactive protein Homo sapiens 51-54 33818731-7 2021 Higher C-reactive protein (CRP) levels were seen in the vitamin D-deficient group (p = 0.013). Vitamin D 56-65 C-reactive protein Homo sapiens 7-25 33818731-7 2021 Higher C-reactive protein (CRP) levels were seen in the vitamin D-deficient group (p = 0.013). Vitamin D 56-65 C-reactive protein Homo sapiens 27-30 2210970-3 1990 In this study, CRP is found to bind to affinity chromatography of negatively-charged epsilon-aminocaproic acid-agarose when calcium ions are present, and to the affinity chromatography of positively-charged omega-aminohexyl-agarose if a normal ionic strength of NaCl exists but calcium ion is not present. omega-aminohexyl-agarose 207-231 C-reactive protein Homo sapiens 15-18 2210970-3 1990 In this study, CRP is found to bind to affinity chromatography of negatively-charged epsilon-aminocaproic acid-agarose when calcium ions are present, and to the affinity chromatography of positively-charged omega-aminohexyl-agarose if a normal ionic strength of NaCl exists but calcium ion is not present. Sodium Chloride 262-266 C-reactive protein Homo sapiens 15-18 2210970-3 1990 In this study, CRP is found to bind to affinity chromatography of negatively-charged epsilon-aminocaproic acid-agarose when calcium ions are present, and to the affinity chromatography of positively-charged omega-aminohexyl-agarose if a normal ionic strength of NaCl exists but calcium ion is not present. Calcium 278-285 C-reactive protein Homo sapiens 15-18 33807159-2 2021 We examined the cross-sectional association between biomarkers of vitamin D status and C-reactive protein (CRP) among postmenopausal women aged 53-81 years. Vitamin D 66-75 C-reactive protein Homo sapiens 87-105 33807159-2 2021 We examined the cross-sectional association between biomarkers of vitamin D status and C-reactive protein (CRP) among postmenopausal women aged 53-81 years. Vitamin D 66-75 C-reactive protein Homo sapiens 107-110 33807159-6 2021 An inverse association was observed between 25(OH)D and salivary CRP in a model adjusted for age, smoking status, frequency of tooth brushing and flossing, and hormone therapy use (-7.56% difference in salivary CRP concentrations per 10 nmol/L increase in 25(OH)D, 95% CI: -12.78 to -2.03). 25(oh)d 44-51 C-reactive protein Homo sapiens 65-68 33807159-6 2021 An inverse association was observed between 25(OH)D and salivary CRP in a model adjusted for age, smoking status, frequency of tooth brushing and flossing, and hormone therapy use (-7.56% difference in salivary CRP concentrations per 10 nmol/L increase in 25(OH)D, 95% CI: -12.78 to -2.03). 25(oh)d 44-51 C-reactive protein Homo sapiens 211-214 33785457-0 2021 The effect of soy isoflavones and soy isoflavones plus soy protein on serum concentration of C-reactive protein among postmenopausal women: A systematic review and meta-analysis of randomized controlled trials. Isoflavones 38-49 C-reactive protein Homo sapiens 93-111 33785457-2 2021 Thus, the present study aims at conducting a systematic review and meta-analysis on randomized controlled trials (RCTs) in which the effect of soy isoflavones and the combination of soy isoflavones and soy protein on serum concentration of C-reactive protein (CRP) among postmenopausal women is assessed. Isoflavones 147-158 C-reactive protein Homo sapiens 240-258 33785457-2 2021 Thus, the present study aims at conducting a systematic review and meta-analysis on randomized controlled trials (RCTs) in which the effect of soy isoflavones and the combination of soy isoflavones and soy protein on serum concentration of C-reactive protein (CRP) among postmenopausal women is assessed. Isoflavones 143-158 C-reactive protein Homo sapiens 240-258 33785457-2 2021 Thus, the present study aims at conducting a systematic review and meta-analysis on randomized controlled trials (RCTs) in which the effect of soy isoflavones and the combination of soy isoflavones and soy protein on serum concentration of C-reactive protein (CRP) among postmenopausal women is assessed. Isoflavones 143-158 C-reactive protein Homo sapiens 260-263 33776569-2 2021 The aim of this study was to evaluate the effects of Zn supplementation on serum copper (Cu) to Zn and C-reactive protein (CRP) to albumin ratios (CAR) in HD patients. Zinc 53-55 C-reactive protein Homo sapiens 123-126 33816149-6 2021 The same study has concluded that NAC"s ability to mitigate the impact of the cytokine storm and prevent elevation of liver enzymes, C-reactive protein, and ferritin is associated with higher success rates weaning from the ventilator and return to normal function in COVID-19 patients. Acetylcysteine 34-37 C-reactive protein Homo sapiens 133-151 33809705-5 2021 Both HIV and low iron stores were associated with lower height-for-age Z-scores (HAZ, p < 0.001 and p = 0.02, respectively), while both HIV and sufficient iron stores were associated with significantly higher CRP and AGP concentrations. Iron 155-159 C-reactive protein Homo sapiens 209-212 33809705-6 2021 HIV+ children with low iron stores had significantly lower HAZ, significantly higher sTfR concentrations, and significantly higher prevalence of subclinical inflammation (CRP 0.05 to 4.99 mg/L) (54%) than both HIV-ve groups. Iron 23-27 C-reactive protein Homo sapiens 171-174 33776569-10 2021 Conclusions: Zn supplementation reduces Cu to Zn and CRP to albumin ratios in HD patients. Zinc 13-15 C-reactive protein Homo sapiens 53-56 33767162-5 2021 Tamoxifen and metabolites significantly decreased C-reactive protein (CRP, p < 0.05), and a CRP increase after 3 years was associated with higher risk of recurrence (HR = 4.37, 95% CI, 1.14-16.73, P = 0.03). Tamoxifen 0-9 C-reactive protein Homo sapiens 50-68 33767162-5 2021 Tamoxifen and metabolites significantly decreased C-reactive protein (CRP, p < 0.05), and a CRP increase after 3 years was associated with higher risk of recurrence (HR = 4.37, 95% CI, 1.14-16.73, P = 0.03). Tamoxifen 0-9 C-reactive protein Homo sapiens 70-73 33801995-8 2021 A positive relationship between cholesterol intake and CRP concentration (p = 0.038; r = 0.342) was also found in the N group. Cholesterol 32-43 C-reactive protein Homo sapiens 55-58 33236293-7 2021 Serum zinc and Zn/Cu ratio levels had a negative relationship with acute phase markers such as IL-6, Erythrocyte Sedimentation Rate, procalcitonin and C-reactive Protein. Zinc 15-17 C-reactive protein Homo sapiens 151-169 33774421-9 2021 DII scores ranged from -4.45 to 3.15 and were positively associated with C-reactive protein (adjusted beta : 1.28, 95% confidence interval [CI]: 0.16, 2.40; P trend = 0.023) when comparing DII tertile 3 (most pro-inflammatory) to tertile 1 (most anti-inflammatory). dilC18(3) dye 0-3 C-reactive protein Homo sapiens 73-91 33236293-7 2021 Serum zinc and Zn/Cu ratio levels had a negative relationship with acute phase markers such as IL-6, Erythrocyte Sedimentation Rate, procalcitonin and C-reactive Protein. Copper 18-20 C-reactive protein Homo sapiens 151-169 32797473-6 2020 Serum leptin and high-selective C-reactive protein (hsCRP) levels in testosterone group decreased from 6.2+-1.4 to 4.0+-1.2 mug/L, P< 0.05, and from 1.4+-1.2 to 1.0+-1.0 mg/L, P< 0.05 after 12 months, respectively. Testosterone 69-81 C-reactive protein Homo sapiens 32-50 32797473-9 2020 CONCLUSIONS: Testosterone replacement in men with age-related hypogonadism causes a decrease in body mass index, fat mass, serum leptin and C-reactive protein levels, and increases serum adiponectin levels. Testosterone 13-25 C-reactive protein Homo sapiens 140-158 34673211-3 2022 RESULTS: After adjustment for age, sex, total cholesterol, LDL and HDL cholesterol, triglycerides, hypertension, smoking, body mass index and previous therapy with antihypertensive and/or statins, PPAR-gamma had statistically significant moderating effect on association of serum CRP level and IS in patients younger than 60. Cholesterol 46-57 C-reactive protein Homo sapiens 280-283 22549098-7 2012 8-iso-PGF2alpha correlated positively with ADMA (r = 0.82), SDMA (r = 0.72), CRP (r = 0.76), fibrinogen (r = 0.57) (all, P <0.0001) and DAS28 (r = 0.44, P = 0.003). 8-epi-prostaglandin F2alpha 0-15 C-reactive protein Homo sapiens 77-80 22549098-8 2012 Regression analysis models showed that CRP was the only independent predictor of 8-iso-PGF2alpha and ADMA levels in RA. 8-epi-prostaglandin F2alpha 81-96 C-reactive protein Homo sapiens 39-42 22549098-9 2012 CONCLUSIONS: Our study is the first to show positive associations between plasma ADMA levels and the production of 8-isoprostanes and CRP in RA. 8-epi-prostaglandin F2alpha 116-130 C-reactive protein Homo sapiens 135-138 34687739-11 2022 Lack of SCFA and L-isoleucine biosynthesis significantly correlated with disease severity and increased plasma concentrations of CXCL-10, NT-proBNP, C-reactive protein (CRP) (all P < .05). Fatty Acids, Volatile 8-12 C-reactive protein Homo sapiens 149-167 34687739-11 2022 Lack of SCFA and L-isoleucine biosynthesis significantly correlated with disease severity and increased plasma concentrations of CXCL-10, NT-proBNP, C-reactive protein (CRP) (all P < .05). Fatty Acids, Volatile 8-12 C-reactive protein Homo sapiens 169-172 34673211-3 2022 RESULTS: After adjustment for age, sex, total cholesterol, LDL and HDL cholesterol, triglycerides, hypertension, smoking, body mass index and previous therapy with antihypertensive and/or statins, PPAR-gamma had statistically significant moderating effect on association of serum CRP level and IS in patients younger than 60. Cholesterol 71-82 C-reactive protein Homo sapiens 280-283 34673211-3 2022 RESULTS: After adjustment for age, sex, total cholesterol, LDL and HDL cholesterol, triglycerides, hypertension, smoking, body mass index and previous therapy with antihypertensive and/or statins, PPAR-gamma had statistically significant moderating effect on association of serum CRP level and IS in patients younger than 60. Triglycerides 84-97 C-reactive protein Homo sapiens 280-283 34586711-0 2022 Effect of curcumin on C-reactive protein as a biomarker of systemic inflammation: An updated meta-analysis of randomized controlled trials. Curcumin 10-18 C-reactive protein Homo sapiens 22-40 34371361-10 2022 In addition, hs-CRP significantly mediated the associations of urinary acrolein with serum TG and HDL-C, with mediated proportions of 22.12% and 41.41%, respectively. Triglycerides 92-94 C-reactive protein Homo sapiens 16-19 34634403-8 2022 For a 10 mug/m3 increase in short-term exposure to O3, NO2, and SO2, there were significant increases of 1.05% (95%CI: 0.09%, 2.02%), 1.60% (95%CI: 0.49%, 2.72%), and 10.44% (95%CI: 4.20%, 17.05%) in CRP, respectively. Ozone 51-53 C-reactive protein Homo sapiens 200-203 34664527-3 2022 RESULTS: The supplementation of CoQ10 decreased significantly the scores of Beck Depression Inventory (BDI) (p = .03) and Beck Anxiety Inventory (BAI) (p = .01) and high-sensitivity C-reactive protein (hs-CRP) level (p = .005) when comparing with the placebo group. coenzyme Q10 32-37 C-reactive protein Homo sapiens 182-200 34363163-4 2022 Elevated cadmium levels were associated with increased levels of lipids and inflammatory factors, including blood triglycerides, total cholesterol, white blood cells (WBCs), and C-reactive protein (CRP). Cadmium 9-16 C-reactive protein Homo sapiens 178-196 34363163-4 2022 Elevated cadmium levels were associated with increased levels of lipids and inflammatory factors, including blood triglycerides, total cholesterol, white blood cells (WBCs), and C-reactive protein (CRP). Cadmium 9-16 C-reactive protein Homo sapiens 198-201 34922121-12 2022 CRP mediated 3.6% of the association between DII and depression in the total population in the fully adjusted model, which was statistically significant (P-trend <.001) but not clinically significant. dilC18(3) dye 45-48 C-reactive protein Homo sapiens 0-3 34586711-1 2022 It has been suggested that curcumin is a potential agent for lowering the levels of C-reactive protein (CRP) and high-sensitivity CRP (hs-CRP), as markers of inflammation. Curcumin 27-35 C-reactive protein Homo sapiens 84-102 34586711-1 2022 It has been suggested that curcumin is a potential agent for lowering the levels of C-reactive protein (CRP) and high-sensitivity CRP (hs-CRP), as markers of inflammation. Curcumin 27-35 C-reactive protein Homo sapiens 104-107 34586711-1 2022 It has been suggested that curcumin is a potential agent for lowering the levels of C-reactive protein (CRP) and high-sensitivity CRP (hs-CRP), as markers of inflammation. Curcumin 27-35 C-reactive protein Homo sapiens 130-133 34586711-1 2022 It has been suggested that curcumin is a potential agent for lowering the levels of C-reactive protein (CRP) and high-sensitivity CRP (hs-CRP), as markers of inflammation. Curcumin 27-35 C-reactive protein Homo sapiens 138-141 34586711-2 2022 In the current meta-analysis, we attempted to clarify the efficacy of curcumin supplementation in lowering the concentrations of CRP and hs-CRP in patients with autoinflammatory conditions. Curcumin 70-78 C-reactive protein Homo sapiens 129-132 34586711-2 2022 In the current meta-analysis, we attempted to clarify the efficacy of curcumin supplementation in lowering the concentrations of CRP and hs-CRP in patients with autoinflammatory conditions. Curcumin 70-78 C-reactive protein Homo sapiens 140-143 34586711-3 2022 Nine studies were found evaluating the effect of curcumin on CRP levels, while 23 studies were identified for hs-CRP. Curcumin 49-57 C-reactive protein Homo sapiens 61-64 34586711-5 2022 There was a significant effect of curcumin at dose <=1,000 mg/day on the CRP concentration. Curcumin 34-42 C-reactive protein Homo sapiens 73-76 34586711-8 2022 Curcumin consumption resulted in a reduction of hs-CRP in a non-linear fashion with stronger effects with less than 2000 mg curcumin per day. Curcumin 0-8 C-reactive protein Homo sapiens 51-54 34586711-8 2022 Curcumin consumption resulted in a reduction of hs-CRP in a non-linear fashion with stronger effects with less than 2000 mg curcumin per day. Curcumin 124-132 C-reactive protein Homo sapiens 51-54 34586711-9 2022 Curcumin seems to be beneficial in decreasing the hs-CRP and CRP levels in proinflammatory settings. Curcumin 0-8 C-reactive protein Homo sapiens 53-56 34586711-9 2022 Curcumin seems to be beneficial in decreasing the hs-CRP and CRP levels in proinflammatory settings. Curcumin 0-8 C-reactive protein Homo sapiens 61-64 34944509-11 2021 High doses of vitamin D supplementation led to a significant decrease in pro-inflammatory cytokines (IFN- , TNF-alpha, IL-1beta, IL-6, IL-8, and IL-17) and high-sensitivity C-reactive protein (hsCRP), whereas the production of anti-inflammatory cytokines (IL-10, IL-5) was up-regulated. Vitamin D 14-23 C-reactive protein Homo sapiens 173-191 34987740-8 2021 In the CTPA cohort, patients with PE had significantly higher D-dimer, prothrombin time, C-reactive protein, troponin, total bilirubin, neutrophils, white cell count and lower albumin compared with non-PE patients. 4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid 7-11 C-reactive protein Homo sapiens 89-107 34839601-13 2021 Urea nitrogen level, creatinine level, and CRP value of patients in citrate group were significantly lower than those in heparin group (P<0.05). Heparin 121-128 C-reactive protein Homo sapiens 43-46 34960024-6 2021 In addition, triglyceride levels increased in the presence of LPS >= 1.35 EU/mL and hs-CRP >= 4.3 mg/L (beta = 3.9, p = 0.01). Triglycerides 13-25 C-reactive protein Homo sapiens 87-90 34773692-8 2021 The group using the combination of synthetic disease-modifying anti-rheumatic drugs (sDMARD) and steroid therapy had significantly higher HAD-depression, HAD-anxiety, mHCL, DAS28-CRP, HAQ, and MDQ scores than the group using sDMARD alone. Steroids 97-104 C-reactive protein Homo sapiens 179-182 34960089-10 2021 Multiple regression analysis, which included serum creatinine, albumin, and log CRP, simultaneously, in addition to sex, age, diabetic kidney disease or not, log HD duration, body mass index, systolic blood pressure, and Kt/V, as independent variables, revealed an independent and significant positive association of serum creatinine, but not serum albumin or CRP, with the serum FT3/FT4 ratio. Creatinine 323-333 C-reactive protein Homo sapiens 80-83 34960089-12 2021 The lack of association of the serum FT3/FT4 ratio with serum albumin and CRP suggested the presence of a creatinine-specific mechanism to associate with serum FT3/FT4 ratio. Creatinine 106-116 C-reactive protein Homo sapiens 74-77 34925916-9 2021 Spearman"s correlation analyses showed that there was significant positive correlation between hs-CRP levels and waist circumference, total triglycerides, total cholesterol, age, body mass index, and homeostasis model assessment of insulin resistance index. Triglycerides 140-153 C-reactive protein Homo sapiens 98-101 34890370-6 2021 In women with a normal BMI, the levels of IL-1beta significantly positively correlated with Ca and Sr, and CRP positively correlated with Zn. Zinc 138-140 C-reactive protein Homo sapiens 107-110 34890370-8 2021 In obese women, the levels of CRP positively correlated with Zn, TNFalpha with Mg, IFNgamma with Cu and P. Zinc 61-63 C-reactive protein Homo sapiens 30-33 34890370-8 2021 In obese women, the levels of CRP positively correlated with Zn, TNFalpha with Mg, IFNgamma with Cu and P. Copper 97-99 C-reactive protein Homo sapiens 30-33 34925916-9 2021 Spearman"s correlation analyses showed that there was significant positive correlation between hs-CRP levels and waist circumference, total triglycerides, total cholesterol, age, body mass index, and homeostasis model assessment of insulin resistance index. Cholesterol 161-172 C-reactive protein Homo sapiens 98-101 34899053-2 2021 More than just a pure bystander, CRP directly interacts with endothelial cells to decrease endothelial nitric oxide synthase (eNOS) expression and bioactivity, decrease nitric oxide (NO) production, and increase the release of vasoconstrictors and adhesion molecules. Nitric Oxide 169-181 C-reactive protein Homo sapiens 33-36 34898992-4 2021 We hypothesized that CRP may be involved in the JHR in syphilitic patients at initial syphilis infection and also through interactions with benzathine penicillin-induced phagocytosis. Penicillin G Benzathine 140-161 C-reactive protein Homo sapiens 21-24 34898992-15 2021 Conclusion: A high baseline CRP level can predict the occurrence of the JHR in syphilitic patients treated with benzathine penicillin. Penicillin G Benzathine 112-133 C-reactive protein Homo sapiens 28-31 34273116-9 2021 The "no dexamethasone" cohort 25-OH-D deplete subgroup recorded significantly higher peak D-Dimer levels (1874ugFEU/L vs 1233ugFEU/L) (p value = 0.0309), CRP (177 vs 107.5) (p=0.0055) and ventilatory support requirement (25.5% vs 6.67%) (p value = 0.007) compared to the replete subgroup. Dexamethasone 4-17 C-reactive protein Homo sapiens 150-153 34857394-4 2021 All randomized controlled trials that examined the influence of folic acid supplementation on C-reactive protein, interleukin 6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) were included. Folic Acid 64-74 C-reactive protein Homo sapiens 94-112 34857394-7 2021 Folic acid supplementation significantly reduced serum levels of C-reactive protein (mean difference (MD), -0.21 mg/L; 95% CI, -0.41 to -0.01; n = 16), TNF-alpha (MD, -14.88 pg/mL; 95% CI, -23.68 to -6.09; n = 10), and IL-6 (MD, -0.93 pg/mL; 95% CI, -1.72 to -0.14; n = 11). Folic Acid 0-10 C-reactive protein Homo sapiens 65-83 34857202-7 2021 RESULTS: There was a noticeable regular trend regarding hypercholesterolemia (p = 0.008), high LDL-C (p = 0.024), hypertension (p = 0.021), and high hs-CRP (p < 0.0001) across various categories of vitamin D status. Vitamin D 198-207 C-reactive protein Homo sapiens 152-155 34857202-8 2021 In adjusted model, vitamin D-deficient subjects were at higher risk for having hypercholesterolemia (OR: 3.22, p = 0.031), high LDL-C (OR: 2.37, p = 0.047), hypertension (OR: 2.32, p = 0.042), and high hs-CRP (OR: 5.49, p = 0.001) than ones with sufficient vitamin D status. Vitamin D 19-28 C-reactive protein Homo sapiens 205-208 34857202-9 2021 CONCLUSIONS: Vitamin D deficiency in obese subjects was found to be strongly related to higher risk of unfavorable lipid profile, hypertension, and high hs-CRP. Vitamin D 13-22 C-reactive protein Homo sapiens 156-159 34717078-8 2021 Additionally, the meta-analysis revealed that circulating tumor necrosis factor-alpha(TNF-alpha) and C-reactive protein (CRP) concentrations were significantly decreased after metformin treatment, with corresponding SMDs of 1.01 (95% CI: 0.74-1.28, P<0.00001) and 0.48(95% CI: 0.35-0.60, P<0.00001). Metformin 176-185 C-reactive protein Homo sapiens 101-119 34717078-8 2021 Additionally, the meta-analysis revealed that circulating tumor necrosis factor-alpha(TNF-alpha) and C-reactive protein (CRP) concentrations were significantly decreased after metformin treatment, with corresponding SMDs of 1.01 (95% CI: 0.74-1.28, P<0.00001) and 0.48(95% CI: 0.35-0.60, P<0.00001). Metformin 176-185 C-reactive protein Homo sapiens 121-124 34302440-10 2021 Changes in creatinine-to-cystatin C ratio showed inverse correlation with blood pressure, HbA1c, lipids, and C-reactive protein at the 4-year follow-up. Creatinine 11-21 C-reactive protein Homo sapiens 109-127 34559375-17 2021 Higher saliva cortisol levels, serum cortisol, glucose, C-reactive protein and interleukin-6 were detected after PEG placement, confirming considerable stress response. Polyethylene Glycols 113-116 C-reactive protein Homo sapiens 56-74 34872404-6 2021 RESULTS: Compared to placebo, 7-day atorvastatin increased the recognition (p = 0.006), discriminability (p = 0.03) and misclassifications (p = 0.04) of fearful facial expression, independently from subjective states of mood and anxiety, and C-reactive protein levels. Atorvastatin 36-48 C-reactive protein Homo sapiens 242-260 34370931-6 2021 Serum nucleosome levels, as well as the white blood cell counts, neutrophil counts, and high-sensitivity C-reactive protein levels, were significantly higher in anti-heparin/PF4 antibody-positive patients compared to the control. Heparin 166-173 C-reactive protein Homo sapiens 105-123 34391864-6 2021 We observed higher levels of serum CRP in the PTSD group compared to the non-PTSD group but after controlling for BMI and triglycerides the association did not remain significant. Triglycerides 122-135 C-reactive protein Homo sapiens 35-38 34472150-0 2021 Effect of resveratrol on C-reactive protein: An updated meta-analysis of randomized controlled trials. Resveratrol 10-21 C-reactive protein Homo sapiens 25-43 34472150-1 2021 We conducted a meta-analysis on the available randomized clinical trials (RCTs) to assess the role of resveratrol in lowering C-reactive protein (CRP) and high-sensitivity CRP (hs-CRP) levels, as markers of inflammation, in various inflammatory disorders. Resveratrol 102-113 C-reactive protein Homo sapiens 126-144 34472150-1 2021 We conducted a meta-analysis on the available randomized clinical trials (RCTs) to assess the role of resveratrol in lowering C-reactive protein (CRP) and high-sensitivity CRP (hs-CRP) levels, as markers of inflammation, in various inflammatory disorders. Resveratrol 102-113 C-reactive protein Homo sapiens 146-149 34472150-1 2021 We conducted a meta-analysis on the available randomized clinical trials (RCTs) to assess the role of resveratrol in lowering C-reactive protein (CRP) and high-sensitivity CRP (hs-CRP) levels, as markers of inflammation, in various inflammatory disorders. Resveratrol 102-113 C-reactive protein Homo sapiens 180-183 34472150-3 2021 Pooled results revealed that resveratrol supplementation significantly reduced the hs-CRP (MWD = -0.40 mg/L; 95% CI: -0.70 to -0.09 mg/L; p = .01) and CRP (MWD = -0.31 mg/L; 95% CI: -0.47 to -0.15 mg/L; p < .001) levels in serum. Resveratrol 29-40 C-reactive protein Homo sapiens 86-89 34472150-3 2021 Pooled results revealed that resveratrol supplementation significantly reduced the hs-CRP (MWD = -0.40 mg/L; 95% CI: -0.70 to -0.09 mg/L; p = .01) and CRP (MWD = -0.31 mg/L; 95% CI: -0.47 to -0.15 mg/L; p < .001) levels in serum. Resveratrol 29-40 C-reactive protein Homo sapiens 151-154 34472150-4 2021 Subgroup analysis revealed that resveratrol in group with >=10 weeks significantly reduces hs-CRP levels (MWD = -0.48 mg/L; 95% CI: -0.92 to -0.04 mg/L; p = .03) and CRP (WMD = -0.47 mg/L, 95% CI = -0.69 to -0.25, p < .001). Resveratrol 32-43 C-reactive protein Homo sapiens 94-97 34472150-4 2021 Subgroup analysis revealed that resveratrol in group with >=10 weeks significantly reduces hs-CRP levels (MWD = -0.48 mg/L; 95% CI: -0.92 to -0.04 mg/L; p = .03) and CRP (WMD = -0.47 mg/L, 95% CI = -0.69 to -0.25, p < .001). Resveratrol 32-43 C-reactive protein Homo sapiens 166-169 34472150-6 2021 This meta-analysis demonstrates that resveratrol consumption is effective in lowering the levels of CRP and hs-CRP in inflammatory conditions, especially if supplementation takes place for >=10 weeks with >=500 mg/day. Resveratrol 37-48 C-reactive protein Homo sapiens 100-103 34472150-6 2021 This meta-analysis demonstrates that resveratrol consumption is effective in lowering the levels of CRP and hs-CRP in inflammatory conditions, especially if supplementation takes place for >=10 weeks with >=500 mg/day. Resveratrol 37-48 C-reactive protein Homo sapiens 111-114 34744148-3 2021 Our work was conducted to discuss and compare the predictive ability of the high-sensitivity C-reactive protein to high-density lipoprotein cholesterol ratio (CHR) with other existing indices, for example, neutrophil high-density lipoprotein ratio (NHR) and neutrophil lymphocyte ratio (NLR), in the severity of CAD patients.Based on the results of coronary angiography, patients were divided into the CAD+ group, CAD- group, and control group. Cholesterol 140-151 C-reactive protein Homo sapiens 93-111 34839468-6 2021 In the study group, the neonatal 25-OH vitamin D was negatively correlated with C-reactive protein and length of hospital stay (r = -0.616 and -0.596, respectively) p <0.001 for both. Vitamin D 39-48 C-reactive protein Homo sapiens 80-98 34841880-9 2022 Both fetuin-A and hs-CRP had a significant full mediator role on the association between DII and HOMA-IR (respectively; beta = 0.371 (95 % CI: -0.029-0.770), beta = 0.424 (95 % CI: -0.007-0.856)). dilC18(3) dye 89-92 C-reactive protein Homo sapiens 21-24 34782065-7 2022 In multivariate analyses: age, body mass index, female sex, neck circumference, AHI, and desaturation markers (nadir and mean oxygen saturation) were independently associated with higher CRP. Oxygen 126-132 C-reactive protein Homo sapiens 187-190 34840966-7 2021 Vitamin D showed a significant negative correlation with LDH, CRP, ESR, ferritin, and D-dimer, which was the most reliable predictor of COVID-19 severity in T1DM patients. Vitamin D 0-9 C-reactive protein Homo sapiens 62-65 34899724-10 2021 Potential risk factors for progression were investigated in the supportive care group and SpO2 < 97% and CRP elevation >1.5 mg/dL were common risk factors for O2 support and progression to severe disease. Oxygen 159-161 C-reactive protein Homo sapiens 105-108 34792741-7 2021 However, individuals who experienced lower oxygen saturation were more likely to exhibit higher total leukocyte and neutrophil counts, a higher neutrophil-lymphocyte ratio (NLR), and an increased concentration of C-reactive protein. Oxygen 43-49 C-reactive protein Homo sapiens 213-231 34901602-0 2021 Fabrication of GQD-Electrodeposited Screen-Printed Carbon Electrodes for the Detection of the CRP Biomarker. Carbon 51-57 C-reactive protein Homo sapiens 94-97 34901602-6 2021 The SPCE/GQDs/anti-CRP electrode was used to detect CRP concentrations in a ringer lactate solution. Lactic Acid 83-90 C-reactive protein Homo sapiens 19-22 34901602-6 2021 The SPCE/GQDs/anti-CRP electrode was used to detect CRP concentrations in a ringer lactate solution. Lactic Acid 83-90 C-reactive protein Homo sapiens 52-55 34779003-0 2022 Population pharmacokinetics of ciclosporin in allogeneic hematopoietic stem cell transplant recipients: C-reactive protein as a novel covariate for clearance. Cyclosporine 31-42 C-reactive protein Homo sapiens 104-122 34779013-11 2022 Significant reductions in C-reactive protein (CRP) were seen for atorvastatin versus placebo (MD: -1.51 mmol/L; 95% CI: -3.26 to 0.24, I2 = 75%, very low-grade evidence). Atorvastatin 65-77 C-reactive protein Homo sapiens 26-44 34779013-11 2022 Significant reductions in C-reactive protein (CRP) were seen for atorvastatin versus placebo (MD: -1.51 mmol/L; 95% CI: -3.26 to 0.24, I2 = 75%, very low-grade evidence). Atorvastatin 65-77 C-reactive protein Homo sapiens 46-49 34779013-13 2022 There was also a significant reduction of CRP with atorvastatin. Atorvastatin 51-63 C-reactive protein Homo sapiens 42-45 34779003-7 2022 RESULTS AND DISCUSSION: The results showed that the daily CsA dose, haematocrit, total bile acid, C-reactive protein (CRP) and co-administration of triazole antifungal agent were identified as significant covariates for clearance (CL) of CsA. Cyclosporine 238-241 C-reactive protein Homo sapiens 98-116 34779003-7 2022 RESULTS AND DISCUSSION: The results showed that the daily CsA dose, haematocrit, total bile acid, C-reactive protein (CRP) and co-administration of triazole antifungal agent were identified as significant covariates for clearance (CL) of CsA. Cyclosporine 238-241 C-reactive protein Homo sapiens 118-121 34779003-12 2022 WHAT IS NEW AND CONCLUSION: CRP concentration was identified as a novel marker associated with CsA pharmacokinetics, which should be considered when determining the appropriate dosage of CsA in allo-HSCT recipients. Cyclosporine 95-98 C-reactive protein Homo sapiens 28-31 34779003-12 2022 WHAT IS NEW AND CONCLUSION: CRP concentration was identified as a novel marker associated with CsA pharmacokinetics, which should be considered when determining the appropriate dosage of CsA in allo-HSCT recipients. Cyclosporine 187-190 C-reactive protein Homo sapiens 28-31 34812265-12 2021 The levels of Hcy, MIF, and hs-CRP all shared positive correlations with the TG level and negative correlations with the HDL-C level (all p < 0.001). Thioguanine 77-79 C-reactive protein Homo sapiens 31-34 34868746-8 2021 High sensitivity CRP was significantly and positively correlated to age, body mass index (BMI), total cholesterol, low-density lipoprotein, cholesterol, and waist-hip ratio. Cholesterol 102-113 C-reactive protein Homo sapiens 17-20 34781136-9 2021 PRACTICAL APPLICATION: The findings of the present study indicated that a low-fat yogurt fortified with 1500 IU nano-encapsulated vitamin D for ten weeks, leads to a significant reduction in serum hs-CRP and PAB concentrations highlighted the anti-inflammatory/anti-oxidative effect of vitamin D. Vitamin D 130-139 C-reactive protein Homo sapiens 200-203 34781136-9 2021 PRACTICAL APPLICATION: The findings of the present study indicated that a low-fat yogurt fortified with 1500 IU nano-encapsulated vitamin D for ten weeks, leads to a significant reduction in serum hs-CRP and PAB concentrations highlighted the anti-inflammatory/anti-oxidative effect of vitamin D. Vitamin D 286-295 C-reactive protein Homo sapiens 200-203 34342052-5 2021 Time-course studies with complete blood counts, biochemical markers, cytokines, and cortisol showed transient increases in neutrophils, monocytes, myoglobin, high-sensitivity C-reactive protein (hsCRP), G-CSF, IL-6, and cortisol. Hydrocortisone 84-92 C-reactive protein Homo sapiens 175-193 34182881-10 2021 NAC improved over time the PO2/FiO2 ratio and decreased the white blood cell, CRP, D-dimers and LDH levels. Acetylcysteine 0-3 C-reactive protein Homo sapiens 78-81 34080928-0 2021 The Ratios of Triglycerides and C-reactive protein to High density-lipoprotein -cholesterol as valid biochemical markers of the Nascent Metabolic Syndrome. Cholesterol 80-91 C-reactive protein Homo sapiens 32-50 34080928-2 2021 The ratio of triglycerides (TG) to high-density lipoprotein cholesterol (HDL-C) is a good biomarker of MetS in certain populations C-reactive protein (CRP) has also been also shown to be a biomarker of MetS. Triglycerides 13-26 C-reactive protein Homo sapiens 132-150 34080928-2 2021 The ratio of triglycerides (TG) to high-density lipoprotein cholesterol (HDL-C) is a good biomarker of MetS in certain populations C-reactive protein (CRP) has also been also shown to be a biomarker of MetS. Triglycerides 13-26 C-reactive protein Homo sapiens 152-155 34080928-2 2021 The ratio of triglycerides (TG) to high-density lipoprotein cholesterol (HDL-C) is a good biomarker of MetS in certain populations C-reactive protein (CRP) has also been also shown to be a biomarker of MetS. Triglycerides 28-30 C-reactive protein Homo sapiens 132-150 34080928-2 2021 The ratio of triglycerides (TG) to high-density lipoprotein cholesterol (HDL-C) is a good biomarker of MetS in certain populations C-reactive protein (CRP) has also been also shown to be a biomarker of MetS. Cholesterol 60-71 C-reactive protein Homo sapiens 132-150 34080928-2 2021 The ratio of triglycerides (TG) to high-density lipoprotein cholesterol (HDL-C) is a good biomarker of MetS in certain populations C-reactive protein (CRP) has also been also shown to be a biomarker of MetS. Cholesterol 60-71 C-reactive protein Homo sapiens 152-155 34525247-0 2021 The effects of pre-emptive intravenous ibuprofen on the thiol/disulfide homeostasis and C-reactive protein level as the markers of oxidative stress and inflammation during gynecologic laparoscopy: A randomized clinical trial. Ibuprofen 39-48 C-reactive protein Homo sapiens 88-106 34525247-1 2021 AIMS: In this study, we aimed to investigate the anti-inflammatory and antioxidant effects of intravenous ibuprofen by using the C-reactive protein level and thiol/disulfide homeostasis as the oxidative stress marker. Ibuprofen 106-115 C-reactive protein Homo sapiens 129-147 34247541-3 2021 First, we conducted a cross-sectional study using the recently released 2015-2016 National Health and Nutrition Examination Survey (NHANES) data to examine the association between testosterone deficiency and inflammation biomarkers including high sensitivity C-reactive protein (hsCRP), liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the US general population. Testosterone 180-192 C-reactive protein Homo sapiens 259-277 34857984-8 2021 The positive effects of vitamin D supplementation on body mass index, waist, HDL-C, LDL-C, and CRP were also demonstrated. Vitamin D 24-33 C-reactive protein Homo sapiens 95-98 34563836-9 2021 Furthermore, cortisol interacted with HSV-1 and IL-6, and CRP for both cross-sectional cognitive function and rate of decline. Hydrocortisone 13-21 C-reactive protein Homo sapiens 58-61 34868746-8 2021 High sensitivity CRP was significantly and positively correlated to age, body mass index (BMI), total cholesterol, low-density lipoprotein, cholesterol, and waist-hip ratio. Cholesterol 140-151 C-reactive protein Homo sapiens 17-20 34661247-7 2021 Spearman"s correlation analysis revealed that total testosterone levels were significantly and inversely correlated with NLR, high-sensitivity C-reactive protein (hsCRP), interleukin-6, D-dimer and PCT. Testosterone 52-64 C-reactive protein Homo sapiens 143-161 34533476-7 2021 Lower sodium levels at admission were correlated with higher CRP (p=0.039) and serum lactate levels (p= 0.019), but not IL-6. Sodium 6-12 C-reactive protein Homo sapiens 61-64 34323735-7 2021 Plasma CRP concentrations were not only positively associated with urinary Cu and Cd, but also positively related with ALT. Copper 75-77 C-reactive protein Homo sapiens 7-10 34323735-7 2021 Plasma CRP concentrations were not only positively associated with urinary Cu and Cd, but also positively related with ALT. Cadmium 82-84 C-reactive protein Homo sapiens 7-10 34323735-8 2021 Furthermore, mediation analyses showed that CRP mediated 4.70% and 7.03% of urinary Cu- and Cd-associated ALT elevations. Copper 84-86 C-reactive protein Homo sapiens 44-47 34323735-8 2021 Furthermore, mediation analyses showed that CRP mediated 4.70% and 7.03% of urinary Cu- and Cd-associated ALT elevations. Cadmium 92-94 C-reactive protein Homo sapiens 44-47 34174792-8 2021 CRP,TNF-?, IL-6 and IL-10 levels were also correlated with serum vitamin D levels (p <0.05). Vitamin D 65-74 C-reactive protein Homo sapiens 0-9 34339804-7 2021 We found that rMDD predicted levels of CRP and IL-6 and physical abuse predicted levels of CRP when considering both predictors simultaneously, while other types of ELM did not. rmdd 14-18 C-reactive protein Homo sapiens 39-42 34185366-14 2021 Moreover, higher serum hs-CRP levels may be related to body fat and water alteration concomitant to a higher ED intake. Water 68-73 C-reactive protein Homo sapiens 26-29 34455200-9 2021 Dexamethasone (8 mg) resulted in increased levels of LTB4 (P = 0.012) and 20-HETE (P = 0.009) and reduced hs-CRP levels (P<0.001). Dexamethasone 0-13 C-reactive protein Homo sapiens 109-112 34541293-9 2021 CRP level was significantly decreased in the lopinavir/ritonavir + atorvastatin group (P < 0.0001, Cohen"s d = 0.865) so that there was a significant difference in CRP level on the 6th day between the two groups (P = 0.01). Atorvastatin 67-79 C-reactive protein Homo sapiens 0-3 34541293-9 2021 CRP level was significantly decreased in the lopinavir/ritonavir + atorvastatin group (P < 0.0001, Cohen"s d = 0.865) so that there was a significant difference in CRP level on the 6th day between the two groups (P = 0.01). Atorvastatin 67-79 C-reactive protein Homo sapiens 164-167 34331825-8 2021 Furthermore, an inverse association was observed between high dietary intake of vitamin B6 (OR vitaminB6 : 0.28; 95% CI: 0.08, 1.00; P=0.05) and vitamin B9 (OR vitaminB9 : 0.20; 95% CI: 0.06, 0.70; P=0.01) with hs-CRP level. Folic Acid 145-155 C-reactive protein Homo sapiens 214-217 34293127-3 2021 OBJECTIVES: We hypothesized that a low-sodium DASH diet improves (lowers) biomarkers of inflammation (C-reactive protein (CRP) and soluble urokinase plasminogen activator receptor (suPAR)) and mineral metabolism (phosphorus and fibroblast growth factor-23 (FGF23)). Sodium 39-45 C-reactive protein Homo sapiens 102-120 34293127-3 2021 OBJECTIVES: We hypothesized that a low-sodium DASH diet improves (lowers) biomarkers of inflammation (C-reactive protein (CRP) and soluble urokinase plasminogen activator receptor (suPAR)) and mineral metabolism (phosphorus and fibroblast growth factor-23 (FGF23)). Sodium 39-45 C-reactive protein Homo sapiens 122-125 34455200-11 2021 CONCLUSION: Antiemetic doses of dexamethasone given during surgery increased plasma LTB4 and 20-HETE at a time when hs-CRP was significantly reduced. Dexamethasone 32-45 C-reactive protein Homo sapiens 119-122 34556343-10 2021 Among clinical symptoms, dyspnea and anosmia were frequent, and in laboratory parameters, neutrophil lymphocyte ratio, high-sensitivity C-reactive protein, and D-dimer were higher in patients requiring oxygen. Oxygen 202-208 C-reactive protein Homo sapiens 136-154 34659176-8 2021 The cAMP receptor protein (CRP) is a major transcriptional regulator in bacteria that plays a key role in metabolic regulation. Cyclic AMP 4-8 C-reactive protein Homo sapiens 27-30 34089603-5 2021 Elevated serum 25(OH)D concentrations were significantly associated with lower levels of insulin, HOMA-IR, triglyceride, and C-reactive protein, and higher levels of high-density lipoprotein at baseline (all Ptrend<0.05). 25(oh)d 15-22 C-reactive protein Homo sapiens 125-143 34591347-7 2021 In addition, the mean serum 25(OH)D concentration was significantly lower in the patient group than that in control group (p < 0.05), and serum CRP was significantly increased (p < 0.05). 25(oh)d 28-35 C-reactive protein Homo sapiens 144-147 34650548-8 2021 These findings suggest increased glycolysis, perturbation in the citrate cycle, oxidative stress, protein catabolism and increased urea cycle activity are key characteristics of newly presenting RA patients with elevated CRP. Urea 131-135 C-reactive protein Homo sapiens 221-224 34631763-13 2021 Serum Cu/Zn ratio was high, (2.76 +- 0.68), directly and significantly associated with HD period, CRP, BMI, VFA, and inversely with Kt/V, albumin, iron, and iPTH. Copper 6-8 C-reactive protein Homo sapiens 98-101 34559143-3 2021 We also wanted to analyze the patient factors that may influence CRP normalization.We conducted a retrospective study of 135 patients who had undergone THA (32 cases) or BH (103 cases) for femoral neck fracture by single surgeon from January 2015 to December 2019. Bh 170-172 C-reactive protein Homo sapiens 65-68 34579742-10 2021 Serum 25(OH)D exhibited positive correlation with hemoglobin (r = 0.4509, p = 0.0002), RBC (r = 0.3712, p = 0.0030), TIBC (r = 0.4700, p = 0.0001), SOD (r = 0.4992, p < 0.0001) and GSH-Px (r = 0.4312, p = 0.0005), and negative correlation with hs-CRP (r = - 0.4040, p = 0.0011), TNF-alpha (r = - 0.4721, p = 0.0001), IL-6 (r = - 0.5378, p < 0.0001) and MDA (r = - 0.3056, p = 0.0157). 25(oh)d 6-13 C-reactive protein Homo sapiens 247-250 34631763-13 2021 Serum Cu/Zn ratio was high, (2.76 +- 0.68), directly and significantly associated with HD period, CRP, BMI, VFA, and inversely with Kt/V, albumin, iron, and iPTH. Zinc 9-11 C-reactive protein Homo sapiens 98-101 34630103-8 2021 Metformin significantly decreased CRP levels and DAS-28-CRP after 6 months compared to the control group (p-value <0.001). Metformin 0-9 C-reactive protein Homo sapiens 34-37 34630103-8 2021 Metformin significantly decreased CRP levels and DAS-28-CRP after 6 months compared to the control group (p-value <0.001). Metformin 0-9 C-reactive protein Homo sapiens 56-59 34302321-0 2021 Effects of Atorvastatin on T-Cell Activation and Apoptosis in Systemic Lupus Erythematosus and Novel Simulated Interactions With C-Reactive Protein and Interleukin 6. Atorvastatin 11-23 C-reactive protein Homo sapiens 129-147 34562971-10 2021 Recently, a randomized controlled study reported that low doses of melatonin significantly improved symptoms in hospitalized COVID-19 patients, leading to more rapid discharge with no side effects, while significantly decreasing levels of CRP, proinflammatory cytokines, and modulating dysregulated genes governing cellular and humoral immunity. Melatonin 67-76 C-reactive protein Homo sapiens 239-242 34486670-5 2021 The proarrhythmic phenotype in SHR-CRP was associated with altered heart and plasma eicosanoids, myocardial composition of fatty acids in phospholipids, and autonomic nervous system imbalance before ischemia. Eicosanoids 84-95 C-reactive protein Homo sapiens 35-38 34236368-5 2021 The meta-analysis showed that dietary soy isoflavones significantly decreased 24-hour urine protein, C-reactive protein (CRP), blood urea nitrogen (BUN), total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and fasting blood glucose (FBG) in DN patients. Isoflavones 38-53 C-reactive protein Homo sapiens 101-119 34236368-5 2021 The meta-analysis showed that dietary soy isoflavones significantly decreased 24-hour urine protein, C-reactive protein (CRP), blood urea nitrogen (BUN), total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and fasting blood glucose (FBG) in DN patients. Isoflavones 38-53 C-reactive protein Homo sapiens 121-124 34236368-7 2021 Therefore, soy isoflavones may ameliorate DN by significantly decreasing 24-hour urine protein, BUN, CRP, TC, TG, LDL-C, and FBG. Isoflavones 15-26 C-reactive protein Homo sapiens 101-104 34371487-5 2021 By using QD microspheres (SiO2@QDs@SiO2-COOH, contains approximately 200-300 hydrophobic QDs on per SiO2 sphere) as fluorescent labels, the LOD for CRP and SAA of 3D microarray reached as high as 15 pg/mL and 86 pg/mL, and the sensitivity was further improved by 28-fold and 425-fold, respectively. Carbonic Acid 40-44 C-reactive protein Homo sapiens 148-151 34479494-13 2021 Spearman correlation analysis showed a significant negative association between serum Zn, Se and CRP level (r = - 0.35, P-value = 0.001 for Se; r = - 0.41, P-value < 0.001 for Zn). Zinc 86-88 C-reactive protein Homo sapiens 97-100 34479494-13 2021 Spearman correlation analysis showed a significant negative association between serum Zn, Se and CRP level (r = - 0.35, P-value = 0.001 for Se; r = - 0.41, P-value < 0.001 for Zn). Zinc 176-178 C-reactive protein Homo sapiens 97-100 34479494-14 2021 CONCLUSION: Results suggest that increasing levels of Se and Zn were accompanied by a decrease in serum CRP level. Zinc 61-63 C-reactive protein Homo sapiens 104-107 34744508-10 2021 Vitamin D level had negative correlations with ferritin (R=-0.316, p=0.044) and CRP (R=-0.530, p=0.000). Vitamin D 0-9 C-reactive protein Homo sapiens 80-83 34302321-12 2021 Atorvastatin interacted strongly with C-reactive protein (CRP) and also significantly with IL-6. Atorvastatin 0-12 C-reactive protein Homo sapiens 38-56 34302321-12 2021 Atorvastatin interacted strongly with C-reactive protein (CRP) and also significantly with IL-6. Atorvastatin 0-12 C-reactive protein Homo sapiens 58-61 34302321-17 2021 We determine for the first time simulated interaction between atorvastatin, CRP, and IL-6, implying a novel role of atorvastatin. Atorvastatin 116-128 C-reactive protein Homo sapiens 76-79 34464543-11 2021 COVID-19 patients with low vitamin D levels had a greater prevalence of hypertension and cardiovascular diseases, abnormally high serum troponin and peak D-dimer levels, as well as elevated interleukin-6 and C-reactive protein than those with serum 25(OH)D levels >=30 ng/ml. Vitamin D 27-36 C-reactive protein Homo sapiens 208-226 34478838-8 2021 Curcumin supplementation in doses of 250-1500 mg/day over 8-12 weeks was observed to be associated with decreases in CRP and ESR in adult patients with rheumatoid arthritis and ulcerative colitis in comparison with the control group (WMD: -0.42; 95% CI: -0.59, -0.26, I2 = 94.3%; WMD: -55.96; 95% CI: -93.74, -18.17, I2 = 99.7%, respectively). Curcumin 0-8 C-reactive protein Homo sapiens 117-120 34478838-10 2021 CONCLUSIONS: Curcumin supplementation was associated with significant reductions in levels of CRP and ESR in patients with rheumatoid arthritis and ulcerative colitis. Curcumin 13-21 C-reactive protein Homo sapiens 94-97 34761635-5 2021 Serum neutrophil, NLR and CRP levels were significantly decreased from baseline in RCC patients who had DCR with pazopanib treatment. pazopanib 113-122 C-reactive protein Homo sapiens 26-29 34761635-6 2021 Also, serum CRP levels after pazopanib treatment was significantly lower in RCC patients who had DCR (+) rather than those who progressed. pazopanib 29-38 C-reactive protein Homo sapiens 12-15 34236141-9 2021 Pearson correlation analysis showed that TG was positively correlated with fasting blood glucose, leukocyte, serum ferritin, LDH, CRP, and IL-10 levels. Triglycerides 41-43 C-reactive protein Homo sapiens 130-133 34453188-0 2021 Peroxidase-mimicking nanozyme with surface-dispersed Pt atoms for the colorimetric lateral flow immunoassay of C-reactive protein. Platinum 53-55 C-reactive protein Homo sapiens 111-129 34485407-14 2021 Within-group comparisons showed that the 2-h glucose of OGTT and C-reactive protein decreased in the EP group (p = 0.013 and 0.008, respectively) but not in the E and C groups; insulin sensitivity improved in the EP group (p = 0.016) and had a trend to improve in the E group (p = 0.052); and abdominal fat mass and total body fat mass decreased in both intervention groups (p < 0.05). Glucose 45-52 C-reactive protein Homo sapiens 65-83 34420546-9 2022 Also, a positive association between E-DII and C-reactive protein (CRP) was observed (BE-DII = 1.37, 95% CI: 0.72, 2.02), such that with each unit increase in E-E-DII, the CRP levels were increased by 1.37 units. Beryllium 86-88 C-reactive protein Homo sapiens 47-65 34420546-9 2022 Also, a positive association between E-DII and C-reactive protein (CRP) was observed (BE-DII = 1.37, 95% CI: 0.72, 2.02), such that with each unit increase in E-E-DII, the CRP levels were increased by 1.37 units. Beryllium 86-88 C-reactive protein Homo sapiens 67-70 34420546-9 2022 Also, a positive association between E-DII and C-reactive protein (CRP) was observed (BE-DII = 1.37, 95% CI: 0.72, 2.02), such that with each unit increase in E-E-DII, the CRP levels were increased by 1.37 units. Beryllium 86-88 C-reactive protein Homo sapiens 172-175 34420546-9 2022 Also, a positive association between E-DII and C-reactive protein (CRP) was observed (BE-DII = 1.37, 95% CI: 0.72, 2.02), such that with each unit increase in E-E-DII, the CRP levels were increased by 1.37 units. dilC18(3) dye 89-92 C-reactive protein Homo sapiens 47-65 34420546-9 2022 Also, a positive association between E-DII and C-reactive protein (CRP) was observed (BE-DII = 1.37, 95% CI: 0.72, 2.02), such that with each unit increase in E-E-DII, the CRP levels were increased by 1.37 units. dilC18(3) dye 89-92 C-reactive protein Homo sapiens 67-70 34420546-9 2022 Also, a positive association between E-DII and C-reactive protein (CRP) was observed (BE-DII = 1.37, 95% CI: 0.72, 2.02), such that with each unit increase in E-E-DII, the CRP levels were increased by 1.37 units. dilC18(3) dye 89-92 C-reactive protein Homo sapiens 172-175 34429160-8 2021 With tofacitinib + MTX, numerically higher baseline CRP levels and numerically larger post-baseline CRP reductions were seen in patients achieving CDAI remission at months 6 and 12 vs those who did not. tofacitinib 5-16 C-reactive protein Homo sapiens 52-55 34429160-8 2021 With tofacitinib + MTX, numerically higher baseline CRP levels and numerically larger post-baseline CRP reductions were seen in patients achieving CDAI remission at months 6 and 12 vs those who did not. tofacitinib 5-16 C-reactive protein Homo sapiens 100-103 34429160-11 2021 High pre-treatment CRP levels may be associated with better response to tofacitinib + MTX. tofacitinib 72-83 C-reactive protein Homo sapiens 19-22 34372961-8 2021 Both dietary and serum omega-3 PUFAs, mainly EPA and DPA, were negatively correlated with PCOS-related parameters, such as BMI, fasting insulin, total testosterone and high-sensitivity C-reactive protein (hs-CRP), but positively correlated with follicle-stimulating hormone (FSH) and sex hormone-binding globulin (SHBG). Phospholipids 23-36 C-reactive protein Homo sapiens 185-203 34382123-9 2022 Operative time (p = 0.003), intraoperative blood loss (p = 0.0006), and CRP levels on postoperative day 1 (p = 0.002) and on postoperative day 3 (p = 0.004) were significantly higher in the high-VFA group than in the low-VFA group. Fatty Acids, Volatile 195-198 C-reactive protein Homo sapiens 72-75 34372961-8 2021 Both dietary and serum omega-3 PUFAs, mainly EPA and DPA, were negatively correlated with PCOS-related parameters, such as BMI, fasting insulin, total testosterone and high-sensitivity C-reactive protein (hs-CRP), but positively correlated with follicle-stimulating hormone (FSH) and sex hormone-binding globulin (SHBG). Phospholipids 23-36 C-reactive protein Homo sapiens 208-211 34375576-9 2021 C-reactive protein level was higher in the low vitamin D group, although the difference did not reach statistical significance (9.6 +- 2.2 vs. 4.5 +- 1.6 mg/l, P = 0.074). Vitamin D 47-56 C-reactive protein Homo sapiens 0-18 34447388-0 2021 CRP Enhances the Innate Killing Mechanisms Phagocytosis and ROS Formation in a Conformation and Complement-Dependent Manner. Reactive Oxygen Species 60-63 C-reactive protein Homo sapiens 0-3 34447388-5 2021 We demonstrate that CRP-induced ROS generation is a conformation-specific and complement-dependent process in leukocyte subsets with classical monocytes as the primary source of ROS amongst human monocyte subsets. Reactive Oxygen Species 32-35 C-reactive protein Homo sapiens 20-23 34464302-7 2021 DHS and PFN both increased hs-IL-6 (143.81 +- 89.12 and 94.13 +- 67.14, respectively), CRP (98.84 +- 31.81 and 104.4 +- 31.80, respectively), and CK (400.8 +- 31.81 and 250.7 +- 31.80, respectively) 24 hours postoperatively. dhs 0-3 C-reactive protein Homo sapiens 87-90 34447388-5 2021 We demonstrate that CRP-induced ROS generation is a conformation-specific and complement-dependent process in leukocyte subsets with classical monocytes as the primary source of ROS amongst human monocyte subsets. Reactive Oxygen Species 178-181 C-reactive protein Homo sapiens 20-23 34350496-4 2022 To generate the SERS signal, the Au-Te nanostructure was immobilized on an indium-tin oxide substrate, and the thiol-modified CRP aptamer was then self-assembled onto the modified substrate for CRP recognition. Sulfhydryl Compounds 111-116 C-reactive protein Homo sapiens 126-129 34350496-4 2022 To generate the SERS signal, the Au-Te nanostructure was immobilized on an indium-tin oxide substrate, and the thiol-modified CRP aptamer was then self-assembled onto the modified substrate for CRP recognition. Sulfhydryl Compounds 111-116 C-reactive protein Homo sapiens 194-197 34418903-6 2021 Clinical symptoms and C-reactive protein (CRP) were measured before and after treatment in the melatonin received and control (regular medications) groups. Melatonin 95-104 C-reactive protein Homo sapiens 22-40 34353339-0 2021 Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients. Dexamethasone 0-13 C-reactive protein Homo sapiens 74-92 34353339-3 2021 We investigated PCT and CRP kinetics in critically ill COVID-19 patients treated with dexamethasone with or without tocilizumab, and assessed the value of these biomarkers to detect secondary bacterial infections. Dexamethasone 86-99 C-reactive protein Homo sapiens 24-27 34353339-7 2021 RESULTS: Following cessation of dexamethasone, there was a rebound in PCT and CRP levels, most pronounced in the D+T- group. Dexamethasone 32-45 C-reactive protein Homo sapiens 78-81 34353339-12 2021 CONCLUSIONS: Cessation of dexamethasone in critically ill COVID-19 patients results in a rebound increase in PCT and CRP levels unrelated to the occurrence of secondary bacterial infections. Dexamethasone 26-39 C-reactive protein Homo sapiens 117-120 34353339-13 2021 Furthermore, immunomodulatory treatment with dexamethasone and tocilizumab considerably reduces the value of PCT and CRP for detection of secondary infections in COVID-19 patients. Dexamethasone 45-58 C-reactive protein Homo sapiens 117-120 34325501-13 2021 The higher initial CRP level in COVID-19 patients might explain the greater steroid responsiveness in this population. Steroids 76-83 C-reactive protein Homo sapiens 19-22 34126229-2 2021 Therefore, the present study was conducted on AGH patients to assess the impact of vitamin D on inflammatory cytokines such as CRP, TNF-alpha and IL-6. Vitamin D 83-92 C-reactive protein Homo sapiens 127-130 34146758-9 2021 CoQ10 levels were significantly and positively correlated with both ferritin and CRP levels. coenzyme Q10 0-5 C-reactive protein Homo sapiens 81-84 34358963-6 2021 Laboratory data showed gradual reduction in the WBC (7700 cells/mm3), as well as in the serum LDH (355 IU/L) and CRP (0.76 mg/dL) levels, 7 days after heparin initiation. Heparin 151-158 C-reactive protein Homo sapiens 113-116 34126229-10 2021 Summarizing earlier studies, we demonstrated that circulating concentrations of inflammatory cytokines such as CRP, TNF-alpha, and IL-6 might be decreased following vitamin D supplementation among individuals with AGH. Vitamin D 165-174 C-reactive protein Homo sapiens 111-114 34584659-9 2021 Within analysis indicated a significant decrease in CRP, LDH, MDA levels, and a significant increase in VO2 max in the curcumin group after an intervention (P < 0.05). Curcumin 119-127 C-reactive protein Homo sapiens 52-55 34590566-13 2021 After adjusting for age, gender, atrial fibrillation, nutritional risk, hs-CRP and other confounding factors, serum 25(OH)D was an independent protective factor for the infarct volume of AIS in anterior circulation (odds ratio (OR) = 0.962, P = 0.040), For every 10 mug/L decrease of 25(OH)D, the risk of one grade increase in infarction volume was increased by 47.7% respectively (goodness of fit: chi2 = 5.357, P = 0.719). 25(oh)d 116-123 C-reactive protein Homo sapiens 75-78 34590566-13 2021 After adjusting for age, gender, atrial fibrillation, nutritional risk, hs-CRP and other confounding factors, serum 25(OH)D was an independent protective factor for the infarct volume of AIS in anterior circulation (odds ratio (OR) = 0.962, P = 0.040), For every 10 mug/L decrease of 25(OH)D, the risk of one grade increase in infarction volume was increased by 47.7% respectively (goodness of fit: chi2 = 5.357, P = 0.719). 25(oh)d 284-291 C-reactive protein Homo sapiens 75-78 34584659-10 2021 There were significant decreases in CRP (P = 0.002), LDH (P = 0.041), and MDA (P = 0.005), no significant increase in TAC, and significant increase in VO2 max (P = 0.0001) levels in the curcumin group compared with placebo group. Curcumin 186-194 C-reactive protein Homo sapiens 36-39 34584659-12 2021 Conclusions: Our findings indicated that 8-week curcumin administration could significantly improve CRP, LDH, MDA, and VO2 max. Curcumin 48-56 C-reactive protein Homo sapiens 100-103 34371837-3 2021 To bridge this knowledge gap, this systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the effects of folic acid supplementation on serum concentrations of the inflammatory markers C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha). Folic Acid 143-153 C-reactive protein Homo sapiens 222-240 34273987-10 2021 Finally, we report an association between the kynurenine/tryptophan ratio and CRP. Tryptophan 57-67 C-reactive protein Homo sapiens 78-81 34366869-9 2021 Furthermore, in platelets stimulated with CRP or thrombin, matrine significantly reduced Reactive oxygen species generation, inhibited the phosphorylation level of ERK1/2 (Thr202/Tyr204), p38 (Thr180/Tyr182) and AKT (Thr308/Ser473) as well as increased VASP phosphorylation (Ser239) and intracellular cGMP level. matrine 59-66 C-reactive protein Homo sapiens 42-45 34366869-9 2021 Furthermore, in platelets stimulated with CRP or thrombin, matrine significantly reduced Reactive oxygen species generation, inhibited the phosphorylation level of ERK1/2 (Thr202/Tyr204), p38 (Thr180/Tyr182) and AKT (Thr308/Ser473) as well as increased VASP phosphorylation (Ser239) and intracellular cGMP level. Reactive Oxygen Species 89-112 C-reactive protein Homo sapiens 42-45 34366869-9 2021 Furthermore, in platelets stimulated with CRP or thrombin, matrine significantly reduced Reactive oxygen species generation, inhibited the phosphorylation level of ERK1/2 (Thr202/Tyr204), p38 (Thr180/Tyr182) and AKT (Thr308/Ser473) as well as increased VASP phosphorylation (Ser239) and intracellular cGMP level. Cyclic GMP 301-305 C-reactive protein Homo sapiens 42-45 34371837-3 2021 To bridge this knowledge gap, this systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the effects of folic acid supplementation on serum concentrations of the inflammatory markers C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha). Folic Acid 143-153 C-reactive protein Homo sapiens 242-245 34371837-8 2021 The dose-response analysis demonstrated a significant relationship between an elevated dosage of folic acid supplementation and lower CRP concentrations (p = 0.002). Folic Acid 97-107 C-reactive protein Homo sapiens 134-137 34371837-9 2021 Conclusions: We found that folic acid supplementation may improve inflammation by attenuating serum concentrations of CRP but without significant effects on IL-6 and TNF-alpha. Folic Acid 27-37 C-reactive protein Homo sapiens 118-121 34214123-9 2021 However, dexamethasone was associated marginally with increased SpO2/FiO2 and significantly with decreases in C-reactive protein and radiologic score after adjusting for baseline imbalances. Dexamethasone 9-22 C-reactive protein Homo sapiens 110-128 34371818-7 2021 MetS components, including plasma glucose and triglyceride concentrations, and SBP were elevated in H-WBC+L-CRP and H-WBC+H-CRP compared with L-WBC+L-CR+P. Triglycerides 46-58 C-reactive protein Homo sapiens 124-127 34213761-10 2022 Patients with a higher OH-R showed lower hemoglobin levels along with higher CRP and ISI levels before dialysis initiation. oh-r 23-27 C-reactive protein Homo sapiens 77-80 34238598-13 2021 In the multivariate logistic regression, the "high" levels of CRP were directly correlated with the Log neutrophil-lymphocyte ratio (P<.001) and inversely proportional with serum albumin values (P=.014), Kt/V (P=.037) and serum iron (P<.001). Iron 228-232 C-reactive protein Homo sapiens 62-65 34347528-8 2021 Lower vitamin D levels were significantly associated with more severe COVID-19 cases (p-value < 0.001), higher blood levels of inflammatory markers including (D-dimer, CRP, and ferritin), a higher CT SS and longer disease duration. Vitamin D 6-15 C-reactive protein Homo sapiens 168-171 34611067-0 2021 The Relationship between Folic Acid and Vitamin B12 Serum Levels with High Sensitivity C-reactive Protein and Homocysteine in Chronic Hemodialysis Patients: A Cross-sectional Study. Folic Acid 25-35 C-reactive protein Homo sapiens 87-105 34429835-1 2021 Introduction: To evaluate the trends of C-reactive protein (CRP) and Erythrocyte sedimentation rate (ESR) in the first three weeks after uncomplicated total hip (THR) and total knee (TKR) arthroplasty/replacement in the Indian population and to compare it with available literature. Threonine 162-165 C-reactive protein Homo sapiens 40-58 34429835-1 2021 Introduction: To evaluate the trends of C-reactive protein (CRP) and Erythrocyte sedimentation rate (ESR) in the first three weeks after uncomplicated total hip (THR) and total knee (TKR) arthroplasty/replacement in the Indian population and to compare it with available literature. Threonine 162-165 C-reactive protein Homo sapiens 60-63 34429835-6 2021 Both mean CRP and ESR values were higher in THR patients followed by in B/L TKR and then in U/L TKR patients. Threonine 44-47 C-reactive protein Homo sapiens 10-13 34235458-4 2021 His C-reactive protein levels started to decrease with tocilizumab and dexamethasone treatments. Dexamethasone 71-84 C-reactive protein Homo sapiens 4-22 34212994-11 2021 In addition, a significant corre-lation was observed between the cholesterol, triglycerides and the CRP level at the time of hospitalisa-tion and mortality. Cholesterol 65-76 C-reactive protein Homo sapiens 100-103 34212994-11 2021 In addition, a significant corre-lation was observed between the cholesterol, triglycerides and the CRP level at the time of hospitalisa-tion and mortality. Triglycerides 78-91 C-reactive protein Homo sapiens 100-103 34234508-10 2021 Conclusion: We found that metabolites in phospholipid groups had strong associations with multiple inflammatory biomarkers, especially CRP, SAA and IL-8. Phospholipids 41-53 C-reactive protein Homo sapiens 135-138 34212039-6 2021 After adjustment for gender, age, smoking history, drinking history, history of hyperlipidemia, history of diabetes, lipid levels, and blood glucose levels, logistic regression showed that the incidence of LAA-type AIS poor outcome was positively associated with CRP level at admission, whether it was 3 months, 6 months, or 12 months after discharge, respectively (OR: 2.574, 95% CI: 1.213-5.463; OR: 2.806, 95% CI: 1.298-6.065; OR: 2.492, 95% CI: 1.167-5.321. Glucose 141-148 C-reactive protein Homo sapiens 263-266 34202657-9 2021 Nano-curcumin supplementation also showed favorable anti-inflammatory effects by decreasing C-reactive protein (CRP) (WMD: -1.29 mg/L; 95% CI: -2.15 to -0.44; p = 0.003) and interleukin-6 (IL-6) (WMD: -2.78 mg/dL; 95% CI: -3.76 to -1.79; p< 0.001). Curcumin 5-13 C-reactive protein Homo sapiens 92-110 34202657-9 2021 Nano-curcumin supplementation also showed favorable anti-inflammatory effects by decreasing C-reactive protein (CRP) (WMD: -1.29 mg/L; 95% CI: -2.15 to -0.44; p = 0.003) and interleukin-6 (IL-6) (WMD: -2.78 mg/dL; 95% CI: -3.76 to -1.79; p< 0.001). Curcumin 5-13 C-reactive protein Homo sapiens 112-115 34158545-1 2021 The objective of the study was to develop and validate a prediction model that identifies COVID-19 patients at risk of requiring oxygen support based on five parameters: C-reactive protein (CRP), hypertension, age, and neutrophil and lymphocyte counts (CHANeL). Oxygen 129-135 C-reactive protein Homo sapiens 170-188 34158545-1 2021 The objective of the study was to develop and validate a prediction model that identifies COVID-19 patients at risk of requiring oxygen support based on five parameters: C-reactive protein (CRP), hypertension, age, and neutrophil and lymphocyte counts (CHANeL). Oxygen 129-135 C-reactive protein Homo sapiens 190-193 34158545-8 2021 "CHANeL" prediction models based on serial CRP, neutrophil, and lymphocyte counts during the first 3 days of hospitalization, along with age and hypertension status, provide a reliable estimate of the risk of supplement oxygen requirement among patients hospitalized with COVID-19. Oxygen 220-226 C-reactive protein Homo sapiens 43-46 34117263-9 2021 In post-hoc evaluations, we found that DMPs in PC, BTG4 and PADI1 showed trends of associations with estimated CVD risk, we identified a separate DMP in MORC2 that was associated with CRP levels <=10 mg/L, and we successfully replicated 65 (24%) of previously reported DMPs. dmp 146-149 C-reactive protein Homo sapiens 184-187 34108550-7 2021 Significant positive correlations between triglyceride levels and hs-CRP, IL-1beta, and IFN-gamma concentrations, and between Apo B and IFN-gamma levels were observed 6 months after bariatric and metabolic surgery. Triglycerides 42-54 C-reactive protein Homo sapiens 69-72 34114445-0 2021 Effect of interferon combined with entecavir on serum IL-8, CRP and INF-gamma levels in patients with chronic hepatitis B. entecavir 35-44 C-reactive protein Homo sapiens 60-63 34150714-3 2021 The gold electrode modified with boronic acid-terminated self-assembled monolayers afforded oriented immobilization of capture glycosylated antibody (antihuman CRP monoclonal antibody, mAb). Boronic Acids 33-45 C-reactive protein Homo sapiens 160-163 34198765-3 2021 Herein, we proposed a lateral flow assay (LFA) strip based on surface-enhanced Raman scattering (SERS) nanotags (SERS-LFA strips) for the simultaneous and quantitative detection of dual infection biomarkers, serum amyloid A (SAA) and C-reactive protein (CRP), respectively. lfa 118-121 C-reactive protein Homo sapiens 254-257 34467691-5 2021 The results revealed that the main compounds of Euodiae Fructus, such as berberine and rutaecarpine, participated in the biological processes(such as neurotransmitter receptor activity) by regulating C-reactive protein(CRP), estrogen receptor 1(ESR1), 5-hydroxytryptamine(5-HT) receptor, and interleukin-6(IL-6) to exert sedative, anxiolytic, and antidepressant effects. Berberine 73-82 C-reactive protein Homo sapiens 219-222 34543566-1 2021 OBJECTIVE: This study"s objective was to evaluate interleukin-6 (IL-6) and C-reactive protein (CRP) responses and performance changes in obese women after 8 weeks of aerobic training with an intensity of 50 to 60% of their individual maximum oxygen uptake (VO2). Oxygen 242-248 C-reactive protein Homo sapiens 75-93 34543566-1 2021 OBJECTIVE: This study"s objective was to evaluate interleukin-6 (IL-6) and C-reactive protein (CRP) responses and performance changes in obese women after 8 weeks of aerobic training with an intensity of 50 to 60% of their individual maximum oxygen uptake (VO2). Oxygen 242-248 C-reactive protein Homo sapiens 95-98 34105470-4 2021 RESULTS: Compared with non-BMI group, the red blood cell distribution width, C-reactive protein, erythrocyte sedimentation rate, D-dimer, lactate dehydrogenase, alkaline phosphatase, beta2-microglobulin, transferrin, CA153, CA125, and soluble interleukin-2 receptor (sIL-2R) levels were increased while platelet (PLT) count was decreased in BMI group, and the difference was statistically significant (P<0.05). bmi 341-344 C-reactive protein Homo sapiens 77-95 34033431-3 2021 A pediatric case treated with cyclosporine and corticosteroids elevated C-reactive protein, and abnormal liver tests. Cyclosporine 30-42 C-reactive protein Homo sapiens 72-90 34045018-12 2021 In contrast, lowering sodium from high to low levels reduced NT-proBNP independently of diet (19%; 95% CI: -24% to -14%), but did not alter hs-cTnI and mildly increased hs-CRP (9%; 95% CI: 0.4% to 18%). Sodium 22-28 C-reactive protein Homo sapiens 172-175 34045018-13 2021 Combining DASH with sodium reduction lowered hs-cTnI by 20% (95% CI: -31% to -7%) and NT-proBNP by 23% (95% CI: -32% to -12%), whereas hs-CRP was not significantly changed (-7%; 95% CI: -22% to 9%) compared with the high sodium-control diet. Sodium 20-26 C-reactive protein Homo sapiens 138-141 34084773-7 2021 Accordingly, the intraperitoneal PGE2 levels were also positively related to the PD duration, serum C-reactive protein levels, and serum creatinine levels in incident PD patients. Dinoprostone 33-37 C-reactive protein Homo sapiens 100-118 34068466-5 2021 RESULTS: Multiple linear regression analyses revealed that CRP moderated the relationship between cortisol levels and productivity despite presenteeism. Hydrocortisone 98-106 C-reactive protein Homo sapiens 59-62 34376935-10 2021 Conclusions: Intravenous AA as an adjuvant therapy with iron exerts a favorable and significant effect on the Hb, serum ferritin, and CRP levels in patients with ESKD having anemia. Iron 56-60 C-reactive protein Homo sapiens 134-137 34267439-6 2021 A significant inverse correlation was found between vitamin D level and 24 h protein in urine, ANA, anti-dsDNA, CRP, with a significant positive correlation with renal biopsy indices, eGFR. Vitamin D 52-61 C-reactive protein Homo sapiens 112-115 34144766-0 2021 Retraction notice to ``Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled study"" (Journal of Clinical Lipidology Volume 8, Issue 6, NovemberDecember 2014, Pages 612-617). palmitoleic acid 32-48 C-reactive protein Homo sapiens 87-105 34217176-9 2021 The independent predictive factors for 30-day mortality after PEG placement included higher urea levels and higher CRP to albumin ratios (OR : 3.78 ; 95% CI : 1.41-10.17 ; p = 0.008) (OR : 6.67 ; 95% CI : 1.87- 23.75 ; p = 0.003). Polyethylene Glycols 62-65 C-reactive protein Homo sapiens 115-118 34217176-12 2021 The CRP to albumin ratio can be used to predict complications and early mortality after PEG insertion. Polyethylene Glycols 88-91 C-reactive protein Homo sapiens 4-7 34331695-9 2021 Erythrocyte sedimentation rate (ESR) and circulating C-reactive protein (CRP) were assessed in six and five studies, respectively, out of which four studies reported significant reductions in these parameters in response to curcumin treatment. Curcumin 224-232 C-reactive protein Homo sapiens 53-71 34406246-4 2021 RESULTS: Highly sensitive C-reactive protein levels differed significantly among the groups (p<0.001) and found to be highest in the low-density lipoprotein cholesterol tertile 1 and lowest in the low-density lipoprotein cholesterol tertile 3 (post-hoc p-values: tertile 1 vs. 2 <0.001; tertile 1 vs. 3 <0.001; tertile 2 vs. 3=0.019). Cholesterol 157-168 C-reactive protein Homo sapiens 26-44 34406246-5 2021 There was a negative correlation between hs-CRP and both low-density lipoprotein cholesterol (r=-0.332, p<0.001) and total cholesterol (r=-0.326, p<0.001). Cholesterol 123-134 C-reactive protein Homo sapiens 44-47 34331695-9 2021 Erythrocyte sedimentation rate (ESR) and circulating C-reactive protein (CRP) were assessed in six and five studies, respectively, out of which four studies reported significant reductions in these parameters in response to curcumin treatment. Curcumin 224-232 C-reactive protein Homo sapiens 73-76 35597099-9 2022 Plasma copper and copper/zinc ratio were positively associated with fasting glucose and hs-CRP (beta 0.38, p < 0.01; beta 36.02, p = 0.01, beta 0.004, p < 0.01, beta 0.68, p < 0.001, respectively). Copper 7-13 C-reactive protein Homo sapiens 91-94 34104331-0 2021 The chronotype conjecture in the association between dietary carbohydrate intake and high-sensitivity C-reactive protein (hs-CRP): a cross-sectional study from NHANES 2015 data. Carbohydrates 61-73 C-reactive protein Homo sapiens 102-120 34104331-0 2021 The chronotype conjecture in the association between dietary carbohydrate intake and high-sensitivity C-reactive protein (hs-CRP): a cross-sectional study from NHANES 2015 data. Carbohydrates 61-73 C-reactive protein Homo sapiens 125-128 34104331-2 2021 The present study aims to assess the association between the dietary carbohydrate intake (DCI) and the high-sensitivity C-reactive protein (hs-CRP) combined with the implication of the chronotype. Carbohydrates 69-81 C-reactive protein Homo sapiens 120-138 34104331-2 2021 The present study aims to assess the association between the dietary carbohydrate intake (DCI) and the high-sensitivity C-reactive protein (hs-CRP) combined with the implication of the chronotype. Carbohydrates 69-81 C-reactive protein Homo sapiens 143-146 35398417-4 2022 Here, we evaluated the associations between PM10, NO2 and O3 exposure (on the day of the blood sample collection and on the day before, and the mean annual residential level) and levels of the inflammatory biomarkers high-sensitivity C-reactive protein (hsCRP), interleukin (IL)-1beta, IL-6, IL-8, IL-10, IL-17A, IL-22, and tumor necrosis factor alpha. Ozone 58-60 C-reactive protein Homo sapiens 234-252 35379042-6 2022 Higher carbohydrate consumption at breakfast was associated with a significantly lower CRP vs. higher carbohydrate consumption at dinner (6.99, vs. 9.56 mg/L, respectively, p = .03). Carbohydrates 7-19 C-reactive protein Homo sapiens 87-90 34819702-12 2021 There was a strong negative correlation between CRP levels and HDL cholesterol levels in patients with PsA, rho = 0.42, p = 0.0132. Cholesterol 67-78 C-reactive protein Homo sapiens 48-51 35597099-9 2022 Plasma copper and copper/zinc ratio were positively associated with fasting glucose and hs-CRP (beta 0.38, p < 0.01; beta 36.02, p = 0.01, beta 0.004, p < 0.01, beta 0.68, p < 0.001, respectively). Copper 18-24 C-reactive protein Homo sapiens 91-94 35339652-6 2022 MAIN OUTCOME MEASURES: The primary outcome was the change in serum cortisol levels in the morning (8 a.m.) and afternoon (1 p.m.), and the secondary outcomes included changes in levels of dehydroepiandrosterone-sulfate (DHEA-S), serotonin, insulin-like growth factor, erythrocyte sedimentation rate, high sensitivity C-reactive protein, and natural killer cell activity, and results from a questionnaire on mood, cognition, and quality of life. Hydrocortisone 67-75 C-reactive protein Homo sapiens 317-335 34988737-8 2022 ROC curve analyses showed that DFA on POD2 had the largest AUC (0.753, p < 0.001), followed by serum amylase on POD 1 (0.651, p < 0.001), serum CRP on POD3 (0.644, p < 0.001), and CRP change between POD 2 and POD 3 (0.644, p < 0.001). Diphenylamine 31-34 C-reactive protein Homo sapiens 144-147 34988737-8 2022 ROC curve analyses showed that DFA on POD2 had the largest AUC (0.753, p < 0.001), followed by serum amylase on POD 1 (0.651, p < 0.001), serum CRP on POD3 (0.644, p < 0.001), and CRP change between POD 2 and POD 3 (0.644, p < 0.001). Diphenylamine 31-34 C-reactive protein Homo sapiens 180-183 35629033-8 2022 In these studies, curcumin was able to reduce the expression of proinflammatory cytokines, lower the level of the C-reactive protein and improve clinical parameters. Curcumin 18-26 C-reactive protein Homo sapiens 114-132 35133602-11 2022 From among lactate, WBC, and C reactive protein, lactate showed the highest value regarding the area under the curve, which is an index for predicting grade III upon ROC analysis. Lactic Acid 49-56 C-reactive protein Homo sapiens 29-47 35113370-7 2022 In addition, one augmented urinary Cd concentration unit (Log10) was associated with a 0.04-mg/dL increase in C-reactive protein and a 0.53-mg/dL decrease in HDL cholesterol in the fully adjusted model. Cadmium 35-37 C-reactive protein Homo sapiens 110-128 35581997-11 2022 Conclusion: High-dose melatonin in intubated patients with COVID-19 was associated with a decrease in CRP levels. Melatonin 22-31 C-reactive protein Homo sapiens 102-105 35436679-2 2022 We hypothesized that SRH would have an independent effect on MetS and high hs-CRP incidence in healthy adults after adjusting for sociodemographic and health-related behavioral confounding factors. 4-(Indolin-1-yl)-4-oxobutanoic acid 21-24 C-reactive protein Homo sapiens 78-81 35620570-3 2022 Results: The empagliflozin-metformin combination increased levels of the antioxidants (TAS, SOD, and GPx up to 1.1-fold; P < 0.01), decreased the levels of prooxidants (AOPP and isoprostanes up to 1.2-fold, P < 0.01; AGE up to 1.5-fold, P < 0.01), and decreased inflammatory parameters (up to 1.5-fold, CRP P < 0.01; IL-6 P < 0.001). Metformin 27-36 C-reactive protein Homo sapiens 303-306 35590447-10 2022 Changes in clinical scores were inversely correlated with total cholesterol changes (R -186, P = .014), as was CRP with total cholesterol and LDL-c (R -0.292 and R -0.259, P < .001). Cholesterol 126-137 C-reactive protein Homo sapiens 111-114 35579027-1 2022 BACKGROUND: Low vitamin D status is often associated with systemic low-grade inflammation as reflected by elevated C-reactive protein (CRP) levels. Vitamin D 16-25 C-reactive protein Homo sapiens 115-133 35579027-1 2022 BACKGROUND: Low vitamin D status is often associated with systemic low-grade inflammation as reflected by elevated C-reactive protein (CRP) levels. Vitamin D 16-25 C-reactive protein Homo sapiens 135-138 35579027-2 2022 We investigated the causality and direction of the association between vitamin D status and CRP using linear and non-linear Mendelian randomization (MR) analyses. Vitamin D 71-80 C-reactive protein Homo sapiens 92-95 35579027-5 2022 RESULTS: In non-linear MR analysis, genetically predicted serum 25(OH)D had an L-shaped association with serum CRP, where CRP levels decreased sharply with increasing 25(OH)D concentration for participants within the deficiency range (<25 nmol/L) and levelled off at ~50 nmol/L of 25(OH)D (Pnon-linear = 1.49E-4). 25(oh)d 64-71 C-reactive protein Homo sapiens 111-114 35579027-5 2022 RESULTS: In non-linear MR analysis, genetically predicted serum 25(OH)D had an L-shaped association with serum CRP, where CRP levels decreased sharply with increasing 25(OH)D concentration for participants within the deficiency range (<25 nmol/L) and levelled off at ~50 nmol/L of 25(OH)D (Pnon-linear = 1.49E-4). 25(oh)d 64-71 C-reactive protein Homo sapiens 122-125 35579027-5 2022 RESULTS: In non-linear MR analysis, genetically predicted serum 25(OH)D had an L-shaped association with serum CRP, where CRP levels decreased sharply with increasing 25(OH)D concentration for participants within the deficiency range (<25 nmol/L) and levelled off at ~50 nmol/L of 25(OH)D (Pnon-linear = 1.49E-4). 25(oh)d 167-174 C-reactive protein Homo sapiens 111-114 35579027-5 2022 RESULTS: In non-linear MR analysis, genetically predicted serum 25(OH)D had an L-shaped association with serum CRP, where CRP levels decreased sharply with increasing 25(OH)D concentration for participants within the deficiency range (<25 nmol/L) and levelled off at ~50 nmol/L of 25(OH)D (Pnon-linear = 1.49E-4). 25(oh)d 167-174 C-reactive protein Homo sapiens 122-125 35579027-5 2022 RESULTS: In non-linear MR analysis, genetically predicted serum 25(OH)D had an L-shaped association with serum CRP, where CRP levels decreased sharply with increasing 25(OH)D concentration for participants within the deficiency range (<25 nmol/L) and levelled off at ~50 nmol/L of 25(OH)D (Pnon-linear = 1.49E-4). 25(oh)d 281-288 C-reactive protein Homo sapiens 111-114 35579027-6 2022 Analyses using several pleiotropy-robust methods provided consistent results in stratified MR analyses, confirming the inverse association between 25(OH)D and CRP in the deficiency range (P = 1.10E-05) but not with higher concentrations. 25(oh)d 147-154 C-reactive protein Homo sapiens 159-162 35579027-8 2022 CONCLUSION: The observed association between 25(OH)D and CRP is likely to be caused by vitamin D deficiency. 25(oh)d 45-52 C-reactive protein Homo sapiens 57-60 35579027-8 2022 CONCLUSION: The observed association between 25(OH)D and CRP is likely to be caused by vitamin D deficiency. Vitamin D 87-96 C-reactive protein Homo sapiens 57-60 35389096-0 2022 Epitope mapping of antibodies in C-reactive protein assay kits by hydrogen-deuterium exchange mass spectrometry explains differential results across kits. Hydrogen 66-74 C-reactive protein Homo sapiens 33-51 35535979-10 2022 In participants with high-carbohydrate/low-fat diets and low vitamin D intakes, those with High-PRS had a higher risk of serum CRP concentrations than those with Low-PRS. Carbohydrates 26-38 C-reactive protein Homo sapiens 127-130 35535979-10 2022 In participants with high-carbohydrate/low-fat diets and low vitamin D intakes, those with High-PRS had a higher risk of serum CRP concentrations than those with Low-PRS. Vitamin D 61-70 C-reactive protein Homo sapiens 127-130 35631138-1 2022 The aim of the study was to evaluate the vitamin D status in hospitalized COVID-19 patients and the correlation with C reactive protein (CRP), ferritin, fibrinogen, and peripheral blood leukocytes, as well as inflammatory derived indices. Vitamin D 41-50 C-reactive protein Homo sapiens 137-140 35532037-6 2022 CRP correlated positively with AEA, and AEA showed positive associations with 2-AG and NAE levels. aea 31-34 C-reactive protein Homo sapiens 0-3 35581050-12 2022 Meanwhile, the meta-regression results of the random effect model showed that HbA1c (P = 0.021), BMI (P = 0.029), and creatinine levels (P = 0.003) had significant effects on the heterogeneity of the relationship between IDFU, and serum CRP levels. Creatinine 118-128 C-reactive protein Homo sapiens 237-240 35584442-0 2022 C-reactive protein levels and prevalence of leukopenia in patients with inflammatory bowel disease treated with azathioprine and/or mesalazine: a real-life study. Mesalamine 132-142 C-reactive protein Homo sapiens 0-18 35584442-1 2022 OBJECTIVE: To examine serum C-reactive protein levels and the prevalence of leukopenia in patients with Crohn"s disease or ulcerative colitis undergoing treatment with azathioprine and/or mesalazine. Mesalamine 188-198 C-reactive protein Homo sapiens 28-46 35625746-5 2022 Markers of inflammation, such as C-reactive protein, tumor-necrosis-factor alpha, and interleukin 6, provide insight into the disease and markers that negatively influence nitric-oxide bioavailability and promote oxidative stress. Nitric Oxide 172-184 C-reactive protein Homo sapiens 33-51 35584822-7 2022 After dexamethasone became standard treatment for COVID-19 pneumonia, mean maximal CRP decreased by 17 mg/dL (95% CI -22 to -11). Dexamethasone 6-19 C-reactive protein Homo sapiens 83-86 35383339-8 2022 Also, folate supplementation resulted in a significant improvement in the quantitative insulin sensitivity check index (P = 0.002) and total antioxidant capacity (P = 0.04) and a significant reduction in high-sensitivity C-reactive protein (P = 0.015) in comparison with the placebo group. Folic Acid 6-12 C-reactive protein Homo sapiens 221-239 35475714-13 2022 Conclusions: Our study showed some significant beneficial effects of curcumin supplementation on improving BW, BMI, and the levels of FPG, Hb1Ac, HOMA-IR, HDL-C and Hs-CRP in patients with MRDs. Curcumin 69-77 C-reactive protein Homo sapiens 168-171 35517802-0 2022 Effects of Levetiracetam on the Serum C-Reactive Protein in Children With Epilepsy: A Meta-Analysis. Levetiracetam 11-24 C-reactive protein Homo sapiens 38-56 35571939-3 2022 Cox regression was used to analyze the relationship between Serum 25(OH)D, cadmium, CRP, and all-cause, cause-specific mortality. 25(oh)d 66-73 C-reactive protein Homo sapiens 84-87 35571939-4 2022 We used restricted cubic splines to explore the dose-response relationship between serum 25(OH)D, cadmium, CRP, and all-cause mortality. 25(oh)d 89-96 C-reactive protein Homo sapiens 107-110 35571939-9 2022 Restricted cubic splines analysis showed a significant nonlinear association between serum 25(OH)D (P-nonlinearity P < 0.001), cadmium (P-nonlinearity = 0.002), CRP (P-nonlinearity = 0.003), and HR for all-cause mortality risk in diabetic patients. 25(oh)d 91-98 C-reactive protein Homo sapiens 161-164 35467748-8 2022 Switching treatment to intensive anti-inflammatory therapy with high-dose steroids and Etanercept finally improved symptom and CRP level associated with the reduction of low absorption areas and disappearance of gas images at bilateral shoulder joints. Steroids 74-82 C-reactive protein Homo sapiens 127-130 35566558-7 2022 The concentration of GA did not differ significantly between patients and controls and before and after the treatment but we found its negative correlation with CRP (p < 0.05). Glutamic Acid 21-23 C-reactive protein Homo sapiens 161-164 35445688-4 2022 RESULTS: Compared to continuing-gens, first-gens had greater systemic inflammation (composite of averaged z-scores for C-reactive protein and interleukin-6; B = 0.515, SE = 0.171, p = .003) during the fall but not spring semester (p > .05). gens 44-48 C-reactive protein Homo sapiens 119-137 35517802-1 2022 This meta-analysis aims to evaluate the effect of levetiracetam on serum C-reactive protein (CRP) in children with epilepsy. Levetiracetam 50-63 C-reactive protein Homo sapiens 73-91 35517802-1 2022 This meta-analysis aims to evaluate the effect of levetiracetam on serum C-reactive protein (CRP) in children with epilepsy. Levetiracetam 50-63 C-reactive protein Homo sapiens 93-96 35517802-7 2022 Besides, serum CRP level was significantly decreased by the treatment of levetiracetam in childhood epilepsy (pooled SMD: 3.505, 95% CI: 1.638-5.373, z = 3.68, p < 0.01). Levetiracetam 73-86 C-reactive protein Homo sapiens 15-18 35517802-10 2022 Serum CRP levels are upregulated in childhood epilepsy and reduced by levetiracetam in children with epilepsy. Levetiracetam 70-83 C-reactive protein Homo sapiens 6-9 35428212-10 2022 The receiver operating characteristic (ROC) curves for irAEs indicated that the area under the curve (AUC) of carbohydrate antigen 19-9 (CA19-9) was highest (0.692; P = 0.022), followed by that for the platelet count x serum C-reactive protein (P-CRP) value (0.680; P = 0.032). Carbohydrates 110-122 C-reactive protein Homo sapiens 225-243 35291882-0 2022 Effect of soy isoflavones on C-reactive protein in chronic inflammatory disorders. Isoflavones 14-25 C-reactive protein Homo sapiens 29-47 35291882-2 2022 Therefore, we aimed to summarize the effect of soy isoflavones on serum concentration of C-reactive protein (CRP) among participants with chronic inflammatory disorders by conducting this study. Isoflavones 51-62 C-reactive protein Homo sapiens 89-107 35291882-2 2022 Therefore, we aimed to summarize the effect of soy isoflavones on serum concentration of C-reactive protein (CRP) among participants with chronic inflammatory disorders by conducting this study. Isoflavones 51-62 C-reactive protein Homo sapiens 109-112 35291882-8 2022 Overall effect size indicated a non-significant effect on serum concentration of CRP following soy isoflavones intake (weighted mean differences (WMD)=-0.15 mg/L, 95% confidence interval (CI): -0.54, 0.23; p=0.430). Isoflavones 99-110 C-reactive protein Homo sapiens 81-84 35291882-9 2022 Subgroup analysis revealed that soy isoflavones significantly reduced serum concentration of CRP in studies among participants with age >57 years and baseline CRP levels >3.75 mg/L. Isoflavones 32-47 C-reactive protein Homo sapiens 93-96 35291882-9 2022 Subgroup analysis revealed that soy isoflavones significantly reduced serum concentration of CRP in studies among participants with age >57 years and baseline CRP levels >3.75 mg/L. Isoflavones 32-47 C-reactive protein Homo sapiens 159-162 35444419-5 2022 The area under the ROC curve for CRP was 0.665 (95% CI: 0.564-0.767, P = 0.003), and the best predictive value was 9.7 mg/L; (2) comparison between the high HCY group and the normal HCY group showed statistical differences (P < 0.05) in HCY, CRP, and the NIHSS score at admission, the NIHSS score after treatment, gender, history of diabetes, and history of atrial fibrillation; (3) both HCY and CRP were proven to be correlated with the NIHSS score after treatment (0.188, P = 0.050) and (0.194, P = 0.042), respectively, using Pearson correlation analysis; (4) HCY, low-density lipoprotein, CRP, cystatin C, glucose, history of atrial fibrillation, history of diabetes, and the NIHSS score at admission as the risk factors. Glucose 610-617 C-reactive protein Homo sapiens 33-36 35458206-5 2022 Vitamin D deficiency was found in 67.2% and was independent of sex, disease manifestation, and CRP, ESR, ALP, or PO4 levels. Vitamin D 0-9 C-reactive protein Homo sapiens 95-98 35498027-7 2022 Results: Tanshinone IIA reduced the serum levels of C-reactive protein (CRP), interleukin (IL)-1beta, IL-6, and P-selectin in KD patients; such inhibitory effect was more significant compared to aspirin and IVIG. tanshinone 9-23 C-reactive protein Homo sapiens 52-70 35498027-7 2022 Results: Tanshinone IIA reduced the serum levels of C-reactive protein (CRP), interleukin (IL)-1beta, IL-6, and P-selectin in KD patients; such inhibitory effect was more significant compared to aspirin and IVIG. tanshinone 9-23 C-reactive protein Homo sapiens 72-75 35380664-0 2022 Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program. tofacitinib 74-85 C-reactive protein Homo sapiens 15-33 35415272-11 2022 Serum concentrations of vitamin D were positively correlated with levels of serum calcium, lymphocytes, and neutrophils but negatively correlated with CRP, fibrinogen, and d-dimer values. Vitamin D 24-33 C-reactive protein Homo sapiens 151-154 35443576-9 2022 Moreover, vitamin D levels showed significant negative correlation with the inflammatory markers: TNF-alpha, CRP, and HIF-1alpha levels. Vitamin D 10-19 C-reactive protein Homo sapiens 109-112 35366783-7 2022 In COVID-19 patients, aspirin can reduce CRP, IL-6 levels, and platelet aggregation by inhibiting thromboxane A2. Aspirin 22-29 C-reactive protein Homo sapiens 41-44 35351535-8 2022 After 24-weeks, metformin therapy for the intervention group resulted in a significant decrease of HbA1c, CRP, UACR, total cholesterol and CIMT while Nrg-4 levels were increased compared with baseline levels (p<0.001) and with placebo group(p<0.001). Metformin 16-25 C-reactive protein Homo sapiens 106-109 35178859-0 2022 Radiation-induced C-reactive protein triggers apoptosis of vascular smooth muscle cells through ROS interfering with the STAT3/Ref-1 complex. ros 96-99 C-reactive protein Homo sapiens 18-36 35480632-10 2022 C-reactive protein showed an inverse association with progesterone (beta = -0.028, P = .037). Progesterone 54-66 C-reactive protein Homo sapiens 0-18 34677149-9 2022 The rectal ozone protocol is rectal ozone insufflation, resulting in clinical improvement in oxygen saturation and biochemical improvement (fibrinogen, D-dimer, urea, ferritin, LDH, interleukin-6, and C-reactive protein). Ozone 11-16 C-reactive protein Homo sapiens 201-219 34990079-8 2022 Stratified analysis showed that the inverse association was only observed in women (OR=0.67, 95%CI: 0.48-0.94), and participants with overweight/obesity (OR=0.79, 95%CI: 0.66-0.94), fasting blood glucose <6.1mmol/L (OR=0.80, 95%CI: 0.67-0.96), low density lipoprotein >=3.4mmol/L (OR=0.71, 95%CI: 0.53-0.96), high density lipoprotein >=1.0mmol/L (OR=0.81, 95%CI: 0.69-0.96), ALT<40U/L (OR=0.79, 95%CI:0.67-0.93), and C-reactive protein >=2.0mg/L (OR=0.56, 95%CI: 0.40-0.78). Glucose 196-203 C-reactive protein Homo sapiens 417-435 34989171-10 2022 In addition, the serum inflammation factors (CRP, IL6, and TNF-alpha) were significantly reduced by vitamin D supplementation. Vitamin D 100-109 C-reactive protein Homo sapiens 45-48 35178811-6 2022 Curcumin supplementation significantly decreased homeostatic model assessment for insulin resistance (HOMA-IR), erythrocyte sedimentation rate, serum levels of high-sensitivity C-reactive protein and triglycerides, weight, body mass index, and waist circumference of patients compared with the placebo at the end of the study (p < .05 for all). Curcumin 0-8 C-reactive protein Homo sapiens 177-195 35129312-0 2022 Interfacial Electron Transfer Strategy to Improve the Hydrogen Evolution Catalysis of CrP Heterostructure. Hydrogen 54-62 C-reactive protein Homo sapiens 86-89 35129312-2 2022 Here, a facile pyrolysis method to obtain phase-pure CrP nanoparticles supported on N, P dual-doped carbon (CrP/NPC) is reported to be tuned toward industrial HER. Neptunium 84-88 C-reactive protein Homo sapiens 53-56 35129312-2 2022 Here, a facile pyrolysis method to obtain phase-pure CrP nanoparticles supported on N, P dual-doped carbon (CrP/NPC) is reported to be tuned toward industrial HER. Neptunium 84-88 C-reactive protein Homo sapiens 108-111 35129312-2 2022 Here, a facile pyrolysis method to obtain phase-pure CrP nanoparticles supported on N, P dual-doped carbon (CrP/NPC) is reported to be tuned toward industrial HER. Carbon 100-106 C-reactive protein Homo sapiens 53-56 35129312-2 2022 Here, a facile pyrolysis method to obtain phase-pure CrP nanoparticles supported on N, P dual-doped carbon (CrP/NPC) is reported to be tuned toward industrial HER. Carbon 100-106 C-reactive protein Homo sapiens 108-111 35129312-5 2022 Density functional theory (DFT) calculations suggest that electronic modulation at the interface (CrP/NPC) optimizes the hydrogen adsorption energy. Hydrogen 121-129 C-reactive protein Homo sapiens 98-101 35443454-14 2022 Pre and post treatment CRP was also compared for Tocilizumab, Fevipiravir, Hydroxychloroquine, Doxycyline, but none of them were able to decrease CRP significantly (p > 0.05) in the severe or critical group but these drugs were effective in reducing CRP significantly (p<0.05) when given in mild-moderate group or if the treatment was started early. fevipiravir 62-73 C-reactive protein Homo sapiens 23-26 35450844-8 2022 25(OH)D level was positively correlated with eGFR, calcium, albumin, hemoglobin, transferrin saturation, serum iron, while a negative correlation was found with heart rate, parathormon, NT-proBNP, and CRP. 25(oh)d 0-7 C-reactive protein Homo sapiens 201-204 35357665-16 2022 The quantification of NO levels and analysis of mRNA expressions of eNOS was to determine the nitric oxide demand caused due to OxLDL + CRP complex. Nitric Oxide 94-106 C-reactive protein Homo sapiens 136-139 35348493-4 2022 RESULTS: The results showed that the ADC mean value of the plaques in the VP group was significantly lower than that in the N group, and the levels of hypersensitive C-reactive protein and myeloperoxidase were correlated with the ADC mean value of the plaques. vp 74-76 C-reactive protein Homo sapiens 166-184 35347166-0 2022 C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19. Dexamethasone 53-66 C-reactive protein Homo sapiens 0-18 35347166-11 2022 The crude analysis showed a mortality reduction in patients receiving dexamethasone when CRP was > 13.75 mg/dL and > 3.5 mg/dL for those receiving tocilizumab. Dexamethasone 70-83 C-reactive protein Homo sapiens 89-92 35347166-12 2022 Multivariate analysis identified the interaction of CRP > 13.75 mg/dL with dexamethasone (OR 0.57; CI 95% 0.37-0.89, P = 0014) and CRP > 3.5 mg/dL with tocilizumab (0.65; CI95%:0.44-0.95, P = 0.029) as independent predictors of mortality. Dexamethasone 75-88 C-reactive protein Homo sapiens 52-55 35338526-12 2022 A higher CRP levels at the time of stopping 5-ASA (aHR 1.15; 95% CI: 1.01 - 1.30; p=0.037) was associated with increased risk of flare. 5-Aminosalicylic acid 44-49 C-reactive protein Homo sapiens 9-12 35347166-13 2022 Our results suggest that dexamethasone and tocilizumab are associated with a reduction in mortality when prescribed to patients with a certain inflammatory activity assessed by C-reactive protein. Dexamethasone 25-38 C-reactive protein Homo sapiens 177-195 35338162-11 2022 The high alcohol pattern was associated with high concentrations of circulating concentrations of pro-inflammatory markers (CRP, IL-6, VEGF). Alcohols 9-16 C-reactive protein Homo sapiens 124-127 35368750-9 2022 TG adjuvant MTX also reduced the expression rate of the swollen joint count, tender joint count, erythrocyte sedimentation rate, rheumatoid factor, and C-reactive protein in subgroup analyses with different courses and doses. Thioguanine 0-2 C-reactive protein Homo sapiens 152-170 35258919-3 2022 Here, we developed a novel Lys-AuNPs@MoS2 nanocomposite self-assembled microfluidic immunoassay biochip with digital signal output and applied it to the simultaneous detection of multiple serum biomarkers including inflammatory factors and cardiovascular biomarkers, PCT, CRP, IL6, cTnI, cTnT, and NT-BNP, with high throughput and sensitivity. Lysine 27-30 C-reactive protein Homo sapiens 272-275 35407370-4 2022 In the present paper, we report on the final results of our single-center C-reactive protein-Digoxin Observational Study (C-DOS). Digoxin 93-100 C-reactive protein Homo sapiens 74-92 35407370-5 2022 Methods and Results: Based on the experimental finding that cardiac glycosides potently inhibit hepatic CRP synthesis on the transcriptional level in vitro, 60 patients with decompensated heart failure, NYHA III-IV, severely reduced Left Ventricular Ejection Fraction (LVEF < 40%), and elevated CRP plasma levels were treated by either digoxin + conventional heart failure therapy (30 patients) or by conventional heart failure therapy alone (30 patients). Digoxin 336-343 C-reactive protein Homo sapiens 104-107 35407370-8 2022 Notably, comparative CRP reduction d21-d3 in digoxin versus the control group also revealed borderline significance (p = 0.051). Digoxin 45-52 C-reactive protein Homo sapiens 21-24 35244034-5 2022 The physiological and biochemical indexes, including immune inflammation indicators, electrolytes, myocardial enzyme profile, and functions of liver and kidney, were examined and investigated before and after hydrogen-oxygen therapy.The results showed significant decreases in the neutrophil percentage and the concentration and abnormal proportion of C-reactive protein in COVID-19 patients received additional hydrogen-oxygen therapy.This novel therapeutic may alleviate clinical symptoms of COVID-19 patients by suppressing inflammation responses. Hydrogen 209-217 C-reactive protein Homo sapiens 352-370 35312849-9 2022 The significant increase in area value of alpha-linoleic and eicosadienoic acids were positively correlated with the elevated level of C-reactive protein at postoperative day 2 (Spearman"s rho = 0.843, P < 0.001; Spearman"s rho = 0.785, P = 0.001). alpha-linoleic 42-56 C-reactive protein Homo sapiens 135-153 35345571-11 2022 CRP was used by 61% (47/77) of physicians to help identify a secondary infection or determine steroid dose or duration. Steroids 94-101 C-reactive protein Homo sapiens 0-3 35244034-5 2022 The physiological and biochemical indexes, including immune inflammation indicators, electrolytes, myocardial enzyme profile, and functions of liver and kidney, were examined and investigated before and after hydrogen-oxygen therapy.The results showed significant decreases in the neutrophil percentage and the concentration and abnormal proportion of C-reactive protein in COVID-19 patients received additional hydrogen-oxygen therapy.This novel therapeutic may alleviate clinical symptoms of COVID-19 patients by suppressing inflammation responses. Oxygen 218-224 C-reactive protein Homo sapiens 352-370 35220312-6 2022 RESULTS: After the intervention, the combination of propolis and melatonin significantly reduced interleukin-6 (-55.282 pg/ml ) and C-reactive protein (-21.656 mg/l ) levels, while increasing gavage intake (326.680 ml/day ) and improving some clinical outcomes (APACHE II, SOFA and NUTRIC scores) compared to control group. Melatonin 65-74 C-reactive protein Homo sapiens 132-150 35281463-9 2022 As proven by our meta-analysis, TG as adjuvant therapy or monotherapy decreased the BASDAI, BASFI, SP-VAS, serum CRP, and ESR than control in patients suffering from AS. Thioguanine 32-34 C-reactive protein Homo sapiens 113-116 35293346-7 2022 NLR positively correlated with C-reactive protein (CRP), complement 3(C3), C4, and serum creatinine (SCr) (CRP: r=0.337, p=0.007; C3: r=0.222, p=0.042; C4: r=0.230, p=0.035; SCr: r=0.408, p<0.0001) but negatively correlated with total serum IgG (r=-0.226, p=0.041). Creatinine 89-99 C-reactive protein Homo sapiens 107-110 35277211-8 2022 There was a negative correlation between vitamin D status and CRP levels (=-.364, p=.007). Vitamin D 41-50 C-reactive protein Homo sapiens 62-65 35272602-5 2022 In patients from the main group, were revealed significant positive correlations of average strength between indicators of systemic inflammation, the lipid spectrum and intracardiac hemodynamics: between the levels of CRP and triglycerides (r=0,415, p<0,05); between the values of CRP and LDL (r=0,345, p=0,09); CRP and LA volume (r=0,434, p<0,05); CRP and final diastolic volume (r=0,30, p<0,05). Triglycerides 226-239 C-reactive protein Homo sapiens 281-284 35272602-5 2022 In patients from the main group, were revealed significant positive correlations of average strength between indicators of systemic inflammation, the lipid spectrum and intracardiac hemodynamics: between the levels of CRP and triglycerides (r=0,415, p<0,05); between the values of CRP and LDL (r=0,345, p=0,09); CRP and LA volume (r=0,434, p<0,05); CRP and final diastolic volume (r=0,30, p<0,05). Triglycerides 226-239 C-reactive protein Homo sapiens 312-315 35272602-5 2022 In patients from the main group, were revealed significant positive correlations of average strength between indicators of systemic inflammation, the lipid spectrum and intracardiac hemodynamics: between the levels of CRP and triglycerides (r=0,415, p<0,05); between the values of CRP and LDL (r=0,345, p=0,09); CRP and LA volume (r=0,434, p<0,05); CRP and final diastolic volume (r=0,30, p<0,05). Triglycerides 226-239 C-reactive protein Homo sapiens 349-352 35217714-9 2022 In summary, high hs-CRP levels were associated with lower plasma HDL-cholesterol and HDL-phospholipid concentrations in male adolescents irrespective of adipokines, while in females, HDL-related parameters are not associated with hs-CRP concentrations. Cholesterol 69-80 C-reactive protein Homo sapiens 20-23 35217714-9 2022 In summary, high hs-CRP levels were associated with lower plasma HDL-cholesterol and HDL-phospholipid concentrations in male adolescents irrespective of adipokines, while in females, HDL-related parameters are not associated with hs-CRP concentrations. Phospholipids 89-101 C-reactive protein Homo sapiens 20-23 35217714-0 2022 Sex-dependent relationship of C-reactive protein levels with HDL-cholesterol and HDL-phospholipid concentrations in children. Cholesterol 65-76 C-reactive protein Homo sapiens 30-48 35217714-0 2022 Sex-dependent relationship of C-reactive protein levels with HDL-cholesterol and HDL-phospholipid concentrations in children. Phospholipids 85-97 C-reactive protein Homo sapiens 30-48 35268272-9 2022 PWVcf and CRP were negatively correlated (r = 0.571) in the T2DM subjects treated with metformin in the AAA group. Metformin 87-96 C-reactive protein Homo sapiens 10-13 35217714-2 2022 Our study analyzes the influence of obesity-related parameters in the relationship of high-sensitivity C-reactive protein (hs-CRP) with HDL-cholesterol and HDL-phospholipid in male and female adolescents. Cholesterol 140-151 C-reactive protein Homo sapiens 103-121 35217714-2 2022 Our study analyzes the influence of obesity-related parameters in the relationship of high-sensitivity C-reactive protein (hs-CRP) with HDL-cholesterol and HDL-phospholipid in male and female adolescents. Cholesterol 140-151 C-reactive protein Homo sapiens 126-129 35217714-5 2022 hs-CRP levels were inversely related to HDL-cholesterol and HDL-phospholipid in males but not in females, and were positively related to leptin concentrations in both sexes but were not related to adiponectin levels. Cholesterol 44-55 C-reactive protein Homo sapiens 3-6 35217714-8 2022 After adjusting by leptin and adiponectin, males in the highest hs-CRP tertile showed significantly lower levels of HDL-cholesterol and HDL-phospholipid than those in tertiles 1 and 2, while no significant differences in HDL-cholesterol and HDL-phospholipid concentrations by hs-CRP tertile were observed in females. Cholesterol 120-131 C-reactive protein Homo sapiens 67-70 35402137-5 2022 Although steroid treatment administered once improved the general condition, her symptoms and C-reactive protein worsened again. Steroids 9-16 C-reactive protein Homo sapiens 94-112 35268272-13 2022 The negative correlation between CRP and PWVcf in males with T2DM treated with metformin may indicate that metformin influences the arterial wall to decrease stiffness in subjects with AAA. Metformin 79-88 C-reactive protein Homo sapiens 33-36 35268272-13 2022 The negative correlation between CRP and PWVcf in males with T2DM treated with metformin may indicate that metformin influences the arterial wall to decrease stiffness in subjects with AAA. Metformin 107-116 C-reactive protein Homo sapiens 33-36 35144596-7 2022 Compared to metformin group (n = 73), FBG, HbA1c and HOMA-IR were lower in canagliflozin group, accompanying with less visceral adipose tissue and lower serum CRP level and higher NO level. Canagliflozin 75-88 C-reactive protein Homo sapiens 159-162 35177703-7 2022 Within the tertile of patients with the highest CRP measurements, amiodarone treated patients presented with a higher decrease in heart rate than digoxin treated patients. Amiodarone 66-76 C-reactive protein Homo sapiens 48-51 35152373-7 2022 Patients with a higher blood Cu/Zn ratio had lower levels of hemoglobin, blood zinc, serum prealbumin, albumin, and creatinine as well as low SGA and GNRI scores, but higher modified Charlson comorbidity index score, serum C-reactive protein level, interleukin-6 level, blood copper level, and NRS2002 score (all p < 0.05). Copper 29-31 C-reactive protein Homo sapiens 223-241 35183882-8 2022 Furthermore, boron citrate in combination with oleoylethanolamide resulted in a significant reduction in the high-sensitivity C-reactive protein and interleukin-1beta concentrations (p = 0.031 and p = 0.027, respectively). BORON CITRATE 13-26 C-reactive protein Homo sapiens 126-144 35277041-9 2022 Evidence of inflammation (C-reactive protein, >5 mg/L) was associated with a lower Se concentration and higher Cu concentration. Copper 111-113 C-reactive protein Homo sapiens 26-44 35168023-6 2022 The Cu:Zn ratio (log scale) positively correlated with CRP (log scale; r = 0.581, p < 0.001) and NLR (r = 0.436, p = 0.003). Copper 4-6 C-reactive protein Homo sapiens 55-58 35168023-6 2022 The Cu:Zn ratio (log scale) positively correlated with CRP (log scale; r = 0.581, p < 0.001) and NLR (r = 0.436, p = 0.003). Zinc 7-9 C-reactive protein Homo sapiens 55-58 34993712-9 2022 In contrast, a 50% increase in Cu levels was associated with disease severity only after adjusting for C-reactive protein, reflecting its possible inflammatory and pro-oxidant role in COVID-19 pathogenesis. Copper 31-33 C-reactive protein Homo sapiens 103-121 35092043-12 2022 Inflammatory markers also showed an association with the levels of the measured gut hormones, with C-reactive Protein (CRP) being positively associated with ghrelin levels and TNF-alpha showing a positive association with PYY levels. Ghrelin 157-164 C-reactive protein Homo sapiens 99-117 35099054-7 2022 Patients requiring oxygen supplementation and/or the use of HFNOT/CPAP/BPAP had lower lymphocyte counts and higher levels of urea, C-reactive protein, D-dimer, troponin, glucose, lactate dehydrogenase (LDH) as well as higher white blood cell and neutrophil counts, The parameter that obtained the highest area under curve value in the receiver operator curve analysis for the necessary use of HFNOT/CPAP/BPAP or CPAP/BPAP was LDH activity. Oxygen 19-25 C-reactive protein Homo sapiens 131-149 35199049-6 2022 The current literature bears strong evidence for the benefits of yoga on the levels of circulating cortisol and classical inflammatory markers, such as C-reactive protein (CRP) and cytokines such as interleukin-1 beta (IL-1beta), interleukin 6 (IL-6), tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma (INF-gamma). Hydrocortisone 99-107 C-reactive protein Homo sapiens 152-170 35199049-6 2022 The current literature bears strong evidence for the benefits of yoga on the levels of circulating cortisol and classical inflammatory markers, such as C-reactive protein (CRP) and cytokines such as interleukin-1 beta (IL-1beta), interleukin 6 (IL-6), tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma (INF-gamma). Hydrocortisone 99-107 C-reactive protein Homo sapiens 172-175 35089248-2 2022 The patients were divided into myocardial injury group (n = 25) and nonmyocardial injury group (n = 47) according to whether the myocardial injury occurred during their ICU stay, and the predictive value of Lac/Alb on myocardial injury in elderly patients with SCAP was assessed using receiver operating characteristic curve and area under the curve.There were no statistically significant differences in age and gender between the 2 groups (both P > .05), and there were no statistical differences in oxygenation index, procalcitonin, C-reactive protein, lymphocyte count, and Alb levels between the 2 groups (all P > .05). Lactic Acid 207-210 C-reactive protein Homo sapiens 536-554 35092043-12 2022 Inflammatory markers also showed an association with the levels of the measured gut hormones, with C-reactive Protein (CRP) being positively associated with ghrelin levels and TNF-alpha showing a positive association with PYY levels. Ghrelin 157-164 C-reactive protein Homo sapiens 119-122 35198792-11 2022 The activity of atorvastatin will include assessment of C-reactive protein or high sensitivity C-reactive protein and white blood cell levels. Atorvastatin 16-28 C-reactive protein Homo sapiens 56-74 35159761-0 2022 Highly Sensitive RNA-Based Electrochemical Aptasensor for the Determination of C-Reactive Protein Using Carbon Nanofiber-Chitosan Modified Screen-Printed Electrode. Carbon 104-110 C-reactive protein Homo sapiens 79-97 34676406-8 2022 Furthermore, in diabetic patients, Metformin treatment was associated with lower high-sensitivity C-reactive protein levels. Metformin 35-44 C-reactive protein Homo sapiens 98-116 35198792-11 2022 The activity of atorvastatin will include assessment of C-reactive protein or high sensitivity C-reactive protein and white blood cell levels. Atorvastatin 16-28 C-reactive protein Homo sapiens 95-113 34994082-10 2022 A longer length of hospitalization and increased inflammatory markers (d-dimer, high-sensitive C-reactive protein, and procalcitonin) were detected in the low-free testosterone group. Testosterone 164-176 C-reactive protein Homo sapiens 95-113 35057447-11 2022 In individuals with chronic pain, based on clinical categories, significant associations between vitamin D, omega 6:3 ratio, and CRP were observed. Vitamin D 97-106 C-reactive protein Homo sapiens 129-132 35308655-9 2022 An inverse correlation was found between creatinine clearance and highly sensitive C-reactive protein (p 0.0174). Creatinine 41-51 C-reactive protein Homo sapiens 83-101 35576543-1 2022 OBJECTIVES: This study is aimed to determine the relationship between 25-OH vitamin D levels, inflammatory parameters of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), c-reactive protein (CRP) levels and the disease severity of COVID-19 infection. Vitamin D 76-85 C-reactive protein Homo sapiens 195-213 35576543-1 2022 OBJECTIVES: This study is aimed to determine the relationship between 25-OH vitamin D levels, inflammatory parameters of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), c-reactive protein (CRP) levels and the disease severity of COVID-19 infection. Vitamin D 76-85 C-reactive protein Homo sapiens 215-218 3598196-3 1987 The immunoprecipitates formed when measuring CRP in serum were stained by Coomasie brilliant blue R250 with a detection limit of about 300 micrograms/l. coomasie brilliant blue r250 74-102 C-reactive protein Homo sapiens 45-48 35379386-10 2022 Meta-analysis showed that patients that were vitamin D sufficient (levels >30ng/mL) had statistically significant lower levels of IL-6, CRP, ferritin, LDH, fibrinogen, and D-dimer compared to vitamin D deficient group. Vitamin D 45-54 C-reactive protein Homo sapiens 136-139 2530919-4 1989 The incorporation of these crown ether-phosphate ester ionophores into poly(vinyl chloride) membrane electrodes yields a CRP-sensitive electrode with sensitivity in the microgram per milliliter range. Polyvinyl Chloride 71-91 C-reactive protein Homo sapiens 121-124 3057546-6 1988 Most probably, some of these sequences are located inside or around the internal bisulphide bridge of each monomer of the pentameric CRP. bisulphide 81-91 C-reactive protein Homo sapiens 133-136 3035044-6 1986 The most dramatic suppression of O2- shown when purified CRP was added to the mixtures in all groups examined [0.4 +/- 0.1 (500 ng), 0.3 +/- 0.0 (500 ng), 1.5 +/- 0.1 (100 ng), and 1.3 +/- 0.6 (100 ng) nm O2-/1.5 X 10(5) PBM/well for normals, IM, lepromatous, and tuberculoid, respectively]. pbm 221-224 C-reactive protein Homo sapiens 57-60 6886420-3 1983 Recently, we demonstrated that heat-aggregated CRP (H-CRP), like heat-aggregated IgG, activates platelets to reactions of aggregation, secretion, and generation of thromboxane A2. Thromboxane A2 164-178 C-reactive protein Homo sapiens 54-57 35010714-13 2022 The most common correct scores for homocysteine, triglycerides, and CRP were SDA, cholesterol by Jews, glucose by Muslims, and HDL by Catholics. Cholesterol 82-93 C-reactive protein Homo sapiens 68-71 35010714-13 2022 The most common correct scores for homocysteine, triglycerides, and CRP were SDA, cholesterol by Jews, glucose by Muslims, and HDL by Catholics. Glucose 103-110 C-reactive protein Homo sapiens 68-71 35228490-12 2022 The serum C-reactive protein showed significant reduction (p=0.028*) after intervention with vitamin D. Vitamin D 93-102 C-reactive protein Homo sapiens 10-28 35228490-14 2022 It was concluded that a single large dose of vitamin D was able to reduce the C-reactive protein in non-ST-elevation acute coronary syndrome patients while non-significant reductions in interleukin-6 and tumor necrosis factor-alpha were observed. Vitamin D 45-54 C-reactive protein Homo sapiens 78-96 3183685-4 1988 CRP, in concentrations comparable with those found in blood during acute inflammation, induced dose-dependent cytotoxicity in nonsmoker alveolar macrophages against tritiated thymidine-labeled human tumor cells. Thymidine 175-184 C-reactive protein Homo sapiens 0-3 3038302-7 1987 Further, when Mo medium (which contained 5% human AB serum) was preincubated with immobilized CRP, exposure of Mo to CRP in such medium did not result in CTX. mo medium 14-23 C-reactive protein Homo sapiens 94-97 3038302-7 1987 Further, when Mo medium (which contained 5% human AB serum) was preincubated with immobilized CRP, exposure of Mo to CRP in such medium did not result in CTX. mo medium 14-23 C-reactive protein Homo sapiens 117-120 3029076-6 1987 In addition, the human promyelocyte-like cell line HL-60 in the presence of phorbol ester and certain T-cell lines containing human retroviruses also produce this CRP-inducing factor(s). Phorbol Esters 76-89 C-reactive protein Homo sapiens 163-166 2947442-2 1986 Early activation markers (increase of cell size and formation of thermostable SE rosettes) and the lymphocyte proliferation (3H-thymidine incorporation) were changed by CRP (10-50 micrograms/ml), whereas PWM-induced stimulation was inhibited and PHA-induced activation was enhanced. Thymidine 128-137 C-reactive protein Homo sapiens 169-172 3895542-3 1985 Etiocholanolone injection resulted in inflammation, fever, leukocytosis, increased serum C-reactive protein, hypoferremia, and increased plasma activity of interleukin-1/lymphocyte-activating factor. Etiocholanolone 0-15 C-reactive protein Homo sapiens 89-107 3919022-4 1985 Inhibition of platelet aggregation by CRP is accompanied by an inhibition of arachidonic acid release from both phosphatidylcholine and phosphatidylinositol. Phosphatidylcholines 112-131 C-reactive protein Homo sapiens 38-41 3919022-4 1985 Inhibition of platelet aggregation by CRP is accompanied by an inhibition of arachidonic acid release from both phosphatidylcholine and phosphatidylinositol. Phosphatidylinositols 136-156 C-reactive protein Homo sapiens 38-41 7190145-0 1980 C-Reactive protein induced agglutination of lipid suspensions prepared in the presence and absence of phosphatidylcholine. Phosphatidylcholines 102-121 C-reactive protein Homo sapiens 0-18 7190145-1 1980 CRP-induced agglutination of lipid suspensions prepared in the presence and absence of phosphatidylcholine was studied by a newly devised quantitative method. Phosphatidylcholines 87-106 C-reactive protein Homo sapiens 0-3 7190145-2 1980 CRP caused as much agglutination of suspensions composed of egg yolk phosphatidylcholine, cholesterol, and Span 60 as of those composed of cholesterol and Span 60, suggesting that phosphocholine residues of phosphatidylcholine are not important as binding sites for CRP. Phosphatidylcholines 69-88 C-reactive protein Homo sapiens 0-3 7190145-2 1980 CRP caused as much agglutination of suspensions composed of egg yolk phosphatidylcholine, cholesterol, and Span 60 as of those composed of cholesterol and Span 60, suggesting that phosphocholine residues of phosphatidylcholine are not important as binding sites for CRP. Phosphatidylcholines 207-226 C-reactive protein Homo sapiens 0-3 7190145-4 1980 Although phosphatidylcholine is not an essential component for agglutination of suspensions, it may modify the mode of interaction of CRP with its binding site on lipid suspensions, since the sensitivity of the agglutination to phosphocholine and the Ca2+ requirement were influenced by the presence of phosphatidylcholine in the suspensions. Phosphatidylcholines 9-28 C-reactive protein Homo sapiens 134-137 3083530-0 1986 Augmentation of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF)-induced human platelet activation by C-reactive protein. Platelet Activating Factor 66-69 C-reactive protein Homo sapiens 108-126 7190145-4 1980 Although phosphatidylcholine is not an essential component for agglutination of suspensions, it may modify the mode of interaction of CRP with its binding site on lipid suspensions, since the sensitivity of the agglutination to phosphocholine and the Ca2+ requirement were influenced by the presence of phosphatidylcholine in the suspensions. Phosphatidylcholines 303-322 C-reactive protein Homo sapiens 134-137 6801137-1 1982 Rabbit CRP is similar to human CRP in structure, kinetics of appearance, and binding reactivities to phosphate esters and cationic polymers. Polymers 131-139 C-reactive protein Homo sapiens 7-10 6801137-1 1982 Rabbit CRP is similar to human CRP in structure, kinetics of appearance, and binding reactivities to phosphate esters and cationic polymers. Polymers 131-139 C-reactive protein Homo sapiens 31-34 3083530-1 1986 Activation of human platelets by PAF was augmented by C-reactive protein, an acute phase plasma protein. Platelet Activating Factor 33-36 C-reactive protein Homo sapiens 54-72 3083530-2 1986 The concentration of PAF required for irreversible activation (secondary aggregation of platelet and release of serotonin) was decreased to 1/10 in the presence of C-reactive protein (CRP). Platelet Activating Factor 21-24 C-reactive protein Homo sapiens 164-182 7028874-8 1981 A small percentage (mean 3.0%; range 0.5 to 8.0%) of PBL bound complexed CRP, and saturation was reached with 200 microgram CRP/ml. Pentane-2,2,4,4-Tetrol 53-56 C-reactive protein Homo sapiens 73-76 7028874-8 1981 A small percentage (mean 3.0%; range 0.5 to 8.0%) of PBL bound complexed CRP, and saturation was reached with 200 microgram CRP/ml. Pentane-2,2,4,4-Tetrol 53-56 C-reactive protein Homo sapiens 124-127 34030393-10 2021 AAMA (beta = 0.10), GAMA (beta = 0.16) and SigmaUAAM (beta = 0.12) were significantly (P < 0.05) related to increased CRP, which was significantly (P < 0.05) related to reduced FVC (beta = -55.3) and FEV1 (beta = -40.6). aama 0-4 C-reactive protein Homo sapiens 118-121 33915511-4 2021 Then, the high-sensitivity C-reactive protein and matrix metalloproteinase-1 released by the atherosclerotic segment was detected with enzyme linked immunosorbent assay (ELISA) detection, which also revealed that CP 1 could obviously decrease the inflammatory mediator released by the atherosclerotic segment, but not CP 2. imidacloprid 213-217 C-reactive protein Homo sapiens 27-45 34032406-5 2021 Ru(bpy)32+-labeled gold nanoparticles (AuNPs) are used as a CRP-targeting probe and a signal generator; they form sandwich immunocomplexes at the test line of the strip and generate strong ECL emission via a Ru(bpy)32+/tripropylamine system. ru(bpy)32+ 0-10 C-reactive protein Homo sapiens 60-63 33991364-2 2021 A recent randomized clinical trial demonstrated that daily supplementation with high-dose marine omega-3 FAs lowered plasma triglyceride and C-reactive protein levels (1). Fatty Acids, Omega-3 97-108 C-reactive protein Homo sapiens 141-159 33895477-8 2021 Besides, there was a positive correlation between MDA-serum CRP levels but a negative correlation between MDA levels-Cu/ZnSOD activities. 3,4-Methylenedioxyamphetamine 50-53 C-reactive protein Homo sapiens 60-63 7338519-2 1981 Liposomes composed of phosphatidylcholine and stearylamine were agglutinated with CRP. Phosphatidylcholines 22-41 C-reactive protein Homo sapiens 82-85 7338519-5 1981 Agglutination of liposomes caused by CRP was dependent on the fatty acid composition of phosphatidylcholine, cholesterol content and temperature. Phosphatidylcholines 88-107 C-reactive protein Homo sapiens 37-40 7276568-5 1981 However, in the presence of phosphocholine, CRP rapidly precipitated and formed stable complexes with the polycationic polymers in the otherwise inhibitory calcium concentrations. Polymers 119-127 C-reactive protein Homo sapiens 44-47 7217669-0 1981 Interaction of C-reactive protein with artificial phosphatidylcholine bilayers and complement. Phosphatidylcholines 50-69 C-reactive protein Homo sapiens 15-33 7217669-2 1981 Binding of CRP to multilamellar liposomes or unilamellar vesicles of egg-phosphatidylcholine required the presence of lysophosphatide in the bilayer. Phosphatidylcholines 73-92 C-reactive protein Homo sapiens 11-14 7217669-5 1981 In addition, incorporation of galactocyl cerebroside in phosphatidylcholine:lysophosphatidylcholine liposomes enhanced the binding of CRP. Phosphatidylcholines 56-75 C-reactive protein Homo sapiens 134-137 471064-0 1979 Interaction of C-reactive protein with artificial phosphatidylcholine bilayers. Phosphatidylcholines 50-69 C-reactive protein Homo sapiens 15-33 471064-3 1979 CRP has a Ca2+-dependent binding specificity for phosphorylcholine, the polar head group of two widely distributed lipids, lecithin (phosphatidylcholine, PC) and sphingomyelin (SM). Phosphatidylcholines 133-152 C-reactive protein Homo sapiens 0-3 271994-9 1977 We conclude that (i) CRP can sensitize appropriate liposomes for complement-dependent damage via the primary complement pathway starting at the level of C1q; (ii) of those studied, liposomes that are most susceptible to membrane damage contain phosphatidylcholine, have a positive charge, and contain a ceramide glycolipid; and (iii) such liposomes also are sensitive, although to a much lesser degree, to complement-dependent lysis initiated in the absence of CRP and involving consumption of terminal in excess of early acting complement components. Phosphatidylcholines 244-263 C-reactive protein Homo sapiens 21-24 3083530-2 1986 The concentration of PAF required for irreversible activation (secondary aggregation of platelet and release of serotonin) was decreased to 1/10 in the presence of C-reactive protein (CRP). Platelet Activating Factor 21-24 C-reactive protein Homo sapiens 184-187 6886420-3 1983 Recently, we demonstrated that heat-aggregated CRP (H-CRP), like heat-aggregated IgG, activates platelets to reactions of aggregation, secretion, and generation of thromboxane A2. Thromboxane A2 164-178 C-reactive protein Homo sapiens 47-50 33865313-11 2021 Meta-analysis showed that glutamine supplementation significantly decreased significantly serum levels of FPG [SMD: - 0.73, 95% CI - 1.35, - 0.11, I2: 84.1%] and CRP [SMD: - 0.58, 95% CI - 0.1, - 0.17, I2: 0%]. Glutamine 26-35 C-reactive protein Homo sapiens 162-165 33865313-13 2021 CONCLUSION: Our findings showed that glutamine supplementation might have a positive effect on FPG and CRP; both of which are crucial as cardio-metabolic risk factors. Glutamine 37-46 C-reactive protein Homo sapiens 103-106 33860751-7 2021 Thus, according to the Naranjo adverse drug reaction probability scale, terconazole was the probable cause of the symptoms and the elevated WBC, neutrophil, CRP, and PCT. terconazole 72-83 C-reactive protein Homo sapiens 157-160 33860751-8 2021 To date, this is the first report that chest distress, and at the same time, elevation of WBC, neutrophil, CRP, and PCT were caused by terconazole. terconazole 135-146 C-reactive protein Homo sapiens 107-110 89234-0 1979 [Anti-phenothiazine antibodies and C-reactive protein as possible indicators of developing therapeutic resistance to phenothiazines]. Phenothiazines 117-131 C-reactive protein Homo sapiens 35-53 33560182-9 2021 After the first TCZ-SC injection, the patients became afebrile within one day and inflammatory parameters (i.e., C-reactive protein and erythrocyte sedimentation rate) returned to normal within 2 weeks. tcz-sc 16-22 C-reactive protein Homo sapiens 113-131 33853291-11 2021 After PMX-DHP, the mean P/F ratio improved (86 [range, 63-106] vs. 145 [86-260], P=0.030) and interleukin-6 and c-reactive protein decreased (79 [35-640] vs. 10 [5-25], P=0.018 and 14 [4-21] vs. 5 [2-6], P=0.019, respectively). pmx-dhp 6-13 C-reactive protein Homo sapiens 112-130 621279-0 1978 Changes in human serum amyloid A and C-reactive protein after etiocholanolone-induced inflammation. Etiocholanolone 62-77 C-reactive protein Homo sapiens 37-55 33483588-7 2021 The serum BAFF level was positively correlated with C-reactive protein, rheumatoid factor, disease activity score (in 28 joints), swollen joint counts, tender joint counts, and X-ray scores. baff 10-14 C-reactive protein Homo sapiens 52-70 621279-6 1978 CRP, but not SAA, showed a quantitative correlation with the amount of fever induced by etiocholanolone. Etiocholanolone 88-103 C-reactive protein Homo sapiens 0-3 4454850-2 1974 C-reactive protein purified by electrophoresis in a starch block]. Starch 52-58 C-reactive protein Homo sapiens 0-18 33450081-13 2021 Omega-3 FAs also suppressed C-reactive protein levels and neutrophil-to-lymphocyte ratio in Gr. Fatty Acids, Omega-3 0-11 C-reactive protein Homo sapiens 28-46 4267515-0 1973 Effect of C-reactive protein and blood-group substances on 3 H-thymidine incorporation into DNA of leukocyte. Thymidine 64-73 C-reactive protein Homo sapiens 10-28 32416181-8 2020 After adjustment, significant associations between baseline sUA levels and cystatin C, N-terminal pro B-type natriuretic peptide, high-sensitivity troponin I, and high-sensitivity C-reactive protein were identified. sua 60-63 C-reactive protein Homo sapiens 180-198 13634834-0 1959 [C-reactive protein in typhoid treated with combined chloramphenicol & phenylbutazone]. Chloramphenicol 53-68 C-reactive protein Homo sapiens 1-19 33860751-0 2021 Chills, fatigue, chest distress, and an abnormal increase in WBC, neutrophil, CRP, and PCT induced by terconazole: A case report. terconazole 102-113 C-reactive protein Homo sapiens 78-81 33254150-3 2021 Furthermore, we characterized the effect of the complexes of UA with ACBs on the expression of inflammatory biomarkers in human hepatoma HepG2 cell lines through C-reactive protein (CRP) western blot. acbs 69-73 C-reactive protein Homo sapiens 162-180 33254150-3 2021 Furthermore, we characterized the effect of the complexes of UA with ACBs on the expression of inflammatory biomarkers in human hepatoma HepG2 cell lines through C-reactive protein (CRP) western blot. acbs 69-73 C-reactive protein Homo sapiens 182-185 33860751-4 2021 In addition, white blood cell (WBC), neutrophil, C-reactive protein (CRP), and procalcitonin (PCT) were tested and showed marked increase when the patient visited our hospital again on the next day after the treatment with terconazole. terconazole 223-234 C-reactive protein Homo sapiens 49-67 33254150-4 2021 The results showed UA molecules can be recognized by three ACBs with different binding constants, and ACBs successfully blocked the inflammatory stimulation of uric acid on HepG2 cell lines and inhibited the expression of the major inflammatory factor CRP by formations of complexes between UA and ACBs. acbs 59-63 C-reactive protein Homo sapiens 252-255 33254150-4 2021 The results showed UA molecules can be recognized by three ACBs with different binding constants, and ACBs successfully blocked the inflammatory stimulation of uric acid on HepG2 cell lines and inhibited the expression of the major inflammatory factor CRP by formations of complexes between UA and ACBs. acbs 102-106 C-reactive protein Homo sapiens 252-255 33254150-4 2021 The results showed UA molecules can be recognized by three ACBs with different binding constants, and ACBs successfully blocked the inflammatory stimulation of uric acid on HepG2 cell lines and inhibited the expression of the major inflammatory factor CRP by formations of complexes between UA and ACBs. acbs 102-106 C-reactive protein Homo sapiens 252-255 33188660-10 2020 Conjointly, our data indicate that the overexpression of miR-136-5p has the potential to bind to the 3"-UTR in the mRNAs for IL-6 and CRP and mitigate acute LEDVT, which provides a basis for new therapeutic targets in acute LEDVT treatment. mir-136-5p 57-67 C-reactive protein Homo sapiens 134-137 33826956-11 2021 CRP could be an useful biomarker in defining PIS. Phosphatidylinositols 45-48 C-reactive protein Homo sapiens 0-3 32710594-10 2020 Plasma C-reactive protein and serum amyloid alpha were associated with signs of increased kynurenine pathway activity in the CSF of PD patients, but not in controls. Kynurenine 90-100 C-reactive protein Homo sapiens 7-25 33204538-11 2020 Using a linear regression model, the change in hs-CRP level (Deltahs-CRP) following a 6-month-nCPAP therapy was found to positively correlate with the baseline hs-CRP level for both hypertensive (p = 0.02; r = 0.68), and even more normotensive OSAHS patients (p < 0.0001; r = 0.89). ncpap 94-99 C-reactive protein Homo sapiens 50-53 33204538-11 2020 Using a linear regression model, the change in hs-CRP level (Deltahs-CRP) following a 6-month-nCPAP therapy was found to positively correlate with the baseline hs-CRP level for both hypertensive (p = 0.02; r = 0.68), and even more normotensive OSAHS patients (p < 0.0001; r = 0.89). ncpap 94-99 C-reactive protein Homo sapiens 69-72 33204538-11 2020 Using a linear regression model, the change in hs-CRP level (Deltahs-CRP) following a 6-month-nCPAP therapy was found to positively correlate with the baseline hs-CRP level for both hypertensive (p = 0.02; r = 0.68), and even more normotensive OSAHS patients (p < 0.0001; r = 0.89). ncpap 94-99 C-reactive protein Homo sapiens 69-72 32441568-0 2021 Differential effects of C-reactive protein levels on voriconazole metabolism at three age groups in allogeneic hematopoietic cell transplant recipients. Voriconazole 53-65 C-reactive protein Homo sapiens 24-42 33154657-5 2020 Results: There was a negative correlation between serum retinol and hs-CRP in alcohol drinking men. Vitamin A 56-63 C-reactive protein Homo sapiens 71-74 33154657-6 2020 There was a negative correlation between serum retinol and hs-CRP in the alcohol-nonsmoking female group. Vitamin A 47-54 C-reactive protein Homo sapiens 62-65 33154657-11 2020 Conclusion: There was a negative correlation between serum retinol and hs-CRP and positive correlation between alpha-tocopherol and hs-CRP. Vitamin A 59-66 C-reactive protein Homo sapiens 74-77 32441568-6 2021 For adults, VRCZ concentrations were increased slightly by 0.006 mg/L when every 1 mg/L increased in CRP levels. Voriconazole 12-16 C-reactive protein Homo sapiens 101-104 32799935-11 2021 The data suggest that supplementation of omega-3 fatty acids could reduce the inflammatory state in women with PCOS, through a decrease in hs-CRP and an increase in adiponectin levels. Fatty Acids, Omega-3 41-60 C-reactive protein Homo sapiens 142-145 32939582-1 2020 An on-site detection strategy is reported based on dual-color SiO2@quantum dot (QD)-integrated lateral flow immunoassay (LFA) strip to realize the quantitative and simultaneous detection of C-reactive protein (CRP) and procalcitonin (PCT) in serum. Silicon Dioxide 62-66 C-reactive protein Homo sapiens 190-208 32939582-1 2020 An on-site detection strategy is reported based on dual-color SiO2@quantum dot (QD)-integrated lateral flow immunoassay (LFA) strip to realize the quantitative and simultaneous detection of C-reactive protein (CRP) and procalcitonin (PCT) in serum. Silicon Dioxide 62-66 C-reactive protein Homo sapiens 210-213 32939582-6 2020 The SiO2@QD-based LFA showed great potential as rapid detection tool for the simultaneous monitoring of CRP and PCT in serum sample. Silicon Dioxide 4-8 C-reactive protein Homo sapiens 104-107 32281016-4 2020 RESULTS: Metronidazole concentration correlated with lactoferrin (rho = 0.17, p = 0.015), CRP (rho = 0.23, p < 0.001) and number of diarrhoeal stools per day (rho = 0.29, p < 0.001). Metronidazole 9-22 C-reactive protein Homo sapiens 90-93 32996333-9 2021 There was a weak negative correlation between BMI, waist/hip ratio, CRP, and 25(OH) Vitamin D. 25(oh) vitamin d 77-93 C-reactive protein Homo sapiens 68-71 32871836-6 2020 The level of serum C-reactive protein (CRP) was negatively correlated with has-miR-1915-3p level in serum exosomes. mir-1915-3p 79-90 C-reactive protein Homo sapiens 19-37 32871836-6 2020 The level of serum C-reactive protein (CRP) was negatively correlated with has-miR-1915-3p level in serum exosomes. mir-1915-3p 79-90 C-reactive protein Homo sapiens 39-42 33618966-4 2021 APPROACH AND RESULTS: In this cross-sectional study using data from 435 participants in NHANES and linear regression models with CRP as the outcome, we observed significant negative interactions between VO2max and omega-3 polyunsaturated fatty acids (PUFAs) but not saturated, monounsaturated, or omega-6 PUFAs. omega-3 polyunsaturated fatty acids 214-249 C-reactive protein Homo sapiens 129-132 32400228-8 2020 The adjusted OR for 1SD increase in log-CRP and log-IL-6 was 0.96 (95%CI 0.85, 1.08) and 1.09 (95%CI 0.97, 1.22), respectively. CHEMBL569412 20-23 C-reactive protein Homo sapiens 40-43 33403775-9 2021 In parallel with CRP, PO2/FiO2 ratio increased progressively during the three steps from 183+-95 to 361+-144 mmHg (p < 0.001). fio2 26-30 C-reactive protein Homo sapiens 17-20 32921963-9 2020 Furthermore, a significant positive correlation of plasma dp-ucMGP levels was found with both FC levels (r = 0.396, P < 0.001) and high sensitivity C-reactive protein (hsCRP) levels (r = 0.477, P < 0.001). Dipyridamole 58-60 C-reactive protein Homo sapiens 148-166 33040843-7 2021 There was a significant correlation between IC50 values of vitamin K2 and patient-related factors of RA patients (p < 0.05), such as C-reactive protein (CRP), rheumatoid factor, anti-cyclic citrullinated peptide antibody (ACPA), matrix metalloproteinase-3, Pre-DAS-28 (CRP), and DAS-28 (CRP). Vitamin K 2 59-69 C-reactive protein Homo sapiens 133-151 32702869-11 2020 RESULTS: This review evaluates the effects of CRP testing on the antibiotic use, CCQ, EQ-5D utility scores and adverse events in patients with COPD exacerbations. C20750 81-84 C-reactive protein Homo sapiens 46-49 33520859-8 2020 However, omega-3 PUFA significantly increased serum concentrations of HDL-cholesterol (WMD: 3.10; 95% CI: 0.18, 6.03) and reduced C-reactive protein (WMD: -1.85; 95% CI: -2.61, -1.09). Fatty Acids, Omega-3 9-21 C-reactive protein Homo sapiens 130-148 33040843-7 2021 There was a significant correlation between IC50 values of vitamin K2 and patient-related factors of RA patients (p < 0.05), such as C-reactive protein (CRP), rheumatoid factor, anti-cyclic citrullinated peptide antibody (ACPA), matrix metalloproteinase-3, Pre-DAS-28 (CRP), and DAS-28 (CRP). Vitamin K 2 59-69 C-reactive protein Homo sapiens 153-156 33040843-7 2021 There was a significant correlation between IC50 values of vitamin K2 and patient-related factors of RA patients (p < 0.05), such as C-reactive protein (CRP), rheumatoid factor, anti-cyclic citrullinated peptide antibody (ACPA), matrix metalloproteinase-3, Pre-DAS-28 (CRP), and DAS-28 (CRP). Vitamin K 2 59-69 C-reactive protein Homo sapiens 269-272 32277430-8 2020 Furthermore, reduction in the levels of high-mobility group box 1 protein, inhibitor of kappa B protein-alpha, matrix metalloproteinase-9 and C-reactive protein are some other important hesperidin-derived hepatoprotective mechanisms. Hesperidin 186-196 C-reactive protein Homo sapiens 142-160 31255351-11 2020 Four of the ten were associated [glycine (inversely), caffeine, 1,7-dimethyluric acid, C52:3 triacylglycerol, (positively)], with C-reactive protein levels. 1,7-dimethyluric acid 64-85 C-reactive protein Homo sapiens 130-148 31902378-7 2020 Omega-3 fatty acids administration was also associated with a significant reduction in high sensitivity C-reactive protein (P=0.006) and malondialdehyde (P<0.001), and an increase in total nitrite (P<0.001) and total glutathione levels (P=0.006) when compared with the placebo. Fatty Acids, Omega-3 0-19 C-reactive protein Homo sapiens 104-122 33040843-7 2021 There was a significant correlation between IC50 values of vitamin K2 and patient-related factors of RA patients (p < 0.05), such as C-reactive protein (CRP), rheumatoid factor, anti-cyclic citrullinated peptide antibody (ACPA), matrix metalloproteinase-3, Pre-DAS-28 (CRP), and DAS-28 (CRP). Vitamin K 2 59-69 C-reactive protein Homo sapiens 269-272 32154703-4 2020 Anti-CRP functionalized micromotors (anti-CRP-rGO(reduced graphene oxide)/Ni/PtNPs (platinum nanoparticles))-based immunoassay coupled to thin layer Au-based electrochemical microfluidics operating at -0.20 V under controlled fluidic detection operations (30 muL min-1) allowed the sensitive (LOD = 0.54 mug/mL) and accurate CRP determination using very low volume preterm neonatal clinical samples (<10 muL) in just 8 min of total assay time. (4-toluoyl-3-nitro)piperazine 77-82 C-reactive protein Homo sapiens 5-8 32977239-7 2020 Supplementation of omega-3 FAs showed a significant reduction of CRP (SMD: -0.27, 95% CI: -0.48 to -0.07, P = 0.007). omega-3 fas 19-30 C-reactive protein Homo sapiens 65-68 32028696-9 2020 Admission low plasma glutamine was associated with higher APACHE II scores (p = 0.003), SOFA scores (p = 0.003), C-reactive protein (CRP) values (p < 0.001), serum urea (p = 0.008), and serum creatinine (p = 0.023) and lower serum albumin (p < 0.001). Glutamine 21-30 C-reactive protein Homo sapiens 113-131 33237691-2 2000 LDL-C and HDL-C levels were inversely correlated with C-reactive protein (CRP) levels i.e. the lower the LDL-C or HDL-C level the higher the CRP levels. ldl-c 0-5 C-reactive protein Homo sapiens 54-72 33237691-2 2000 LDL-C and HDL-C levels were inversely correlated with C-reactive protein (CRP) levels i.e. the lower the LDL-C or HDL-C level the higher the CRP levels. ldl-c 0-5 C-reactive protein Homo sapiens 74-77 31816288-8 2020 Moderate positive correlation between CRP and white blood cells count (r=0.269), neutrophils count (r=0.275), triglycerides (r=0.275), alkaline phosphatase (r=0.221) and gamma glutamyl transpeptidase (r=0.220) was evaluated. N-Me-pAB-Glu-gamma-Glu-gamma-Tyr(3-NO(2)) 170-184 C-reactive protein Homo sapiens 38-41 33237691-2 2000 LDL-C and HDL-C levels were inversely correlated with C-reactive protein (CRP) levels i.e. the lower the LDL-C or HDL-C level the higher the CRP levels. ldl-c 0-5 C-reactive protein Homo sapiens 141-144 33191257-12 2020 In addition, inflammatory factors (C reactive protein, white blood cells and albumin) were associated with vitamin B12 level. Vitamin B 12 107-118 C-reactive protein Homo sapiens 35-53 31106659-4 2020 After 8 weeks of intervention, patients who received combined vitamin D3 and omega-3 fatty acids supplements compared with omega-3, vitamin D3, and placebo groups had significantly decreased CRP and TNF-alpha. Fatty Acids, Omega-3 77-96 C-reactive protein Homo sapiens 191-194 31106659-4 2020 After 8 weeks of intervention, patients who received combined vitamin D3 and omega-3 fatty acids supplements compared with omega-3, vitamin D3, and placebo groups had significantly decreased CRP and TNF-alpha. Fatty Acids, Omega-3 77-84 C-reactive protein Homo sapiens 191-194 33292329-16 2020 CONCLUSIONS: The external application of CQBG combined with Western-medicine-basic treatment in patients with AGA improved arthralgia and swelling, shortened the period of taking NSAIDs, and reduced the levels of CRP and serum UA. cqbg 41-45 C-reactive protein Homo sapiens 213-216 31829277-15 2019 In human studies, dexmedetomidine reduced CRP (4 studies), TNFalpha (5 studies), IL-6 (6 studies), IL-1beta (3 studies), and altered several other mediators. Dexmedetomidine 18-33 C-reactive protein Homo sapiens 42-45 31724337-1 2019 OBJECTIVE: This study aims to explore the curative effect of dl-3-n-butylphthalide (NBP) on patients with acute cerebral infarction (ACI) and its effects on serum lipoprotein-associated phospholipase A2 (Lp-PLA2) and hypersensitive C-reactive protein (hs-CRP) levels. 3-n-butylphthalide 61-82 C-reactive protein Homo sapiens 232-250 31724337-1 2019 OBJECTIVE: This study aims to explore the curative effect of dl-3-n-butylphthalide (NBP) on patients with acute cerebral infarction (ACI) and its effects on serum lipoprotein-associated phospholipase A2 (Lp-PLA2) and hypersensitive C-reactive protein (hs-CRP) levels. 3-n-butylphthalide 84-87 C-reactive protein Homo sapiens 232-250 33829245-5 2021 RESULTS: A high enterolactone and low TMAO profile was associated with better diet quality, especially higher intake of whole grains and fiber and lower intake of red meats, as well as lower concentrations of plasma triglycerides and C-reactive protein. 2,3-bis(3'-hydroxybenzyl)butyrolactone 16-29 C-reactive protein Homo sapiens 234-252 33686560-4 2021 METHODS: The relationships between CRP concentration and both CYPs activities were estimated and validated using clinical data first on midazolam then on voriconazole. Voriconazole 154-166 C-reactive protein Homo sapiens 35-38 32738021-8 2020 Moreover, campesterol and beta-sitosterol were negatively correlated with body mass index, fasting insulin, and C-reactive protein and were positively correlated with HDL-cholesterol. campesterol 10-21 C-reactive protein Homo sapiens 112-130 33358717-10 2021 eSUA patients presented higher values in on admission CRP (p < 0.001) and in neutrophil count and NLR at 24 h (respectively, p = 0.020 and p < 0.001) and at 48 h (p = 0.018 and p < 0.001) compared to patients with normal SUA levels. sua 1-4 C-reactive protein Homo sapiens 54-57 31727165-5 2019 The DemTect scores were associated with oxygen content, 6-min-walking distance (6-MWD), C-reactive protein (CRP), modified Medical Research Council dyspnoea scale (mMRC) and the SGRQ impact score. demtect 4-11 C-reactive protein Homo sapiens 88-106 31727165-5 2019 The DemTect scores were associated with oxygen content, 6-min-walking distance (6-MWD), C-reactive protein (CRP), modified Medical Research Council dyspnoea scale (mMRC) and the SGRQ impact score. demtect 4-11 C-reactive protein Homo sapiens 108-111 31727165-8 2019 The DemTect score had a small, but independent impact on QoL, irrespective of the inclusion of COPD-specific influencing factors or a diagnosis of cognitive impairment.We conclude that in patients with stable COPD lower oxygen content of blood as a measure of peripheral oxygen supply, lower exercise capacity in terms of 6-MWD, and higher CRP levels were associated with reduced cognitive capacity. demtect 4-11 C-reactive protein Homo sapiens 340-343 33061586-10 2020 Conclusion: The retrospective cohort study revealed a lower PPC rate and the shorter postoperative length of stay in the patients receiving CPR, demonstrating the clinical value of CRP as an effective strategy for surgical lung cancer patients with risk factors. cpr 140-143 C-reactive protein Homo sapiens 181-184 31432072-8 2019 Analyses using KEGG-defined pathways revealed statistically significant differences in tryptophan metabolism between diets, with kynurenine and melatonin positively associated with serum C-reactive protein concentrations. Kynurenine 129-139 C-reactive protein Homo sapiens 187-205 33040555-10 2021 The serum levels of ALP, which were adjusted by Ca and P, were associated with Hb and CRP, but not with D-D. Phosphorus 22-23 C-reactive protein Homo sapiens 86-89 33351844-0 2020 C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib. lenvatinib 114-124 C-reactive protein Homo sapiens 0-18 33351844-10 2020 CONCLUSIONS: CRP level was associated with OS in HCC patients treated with lenvatinib. lenvatinib 75-85 C-reactive protein Homo sapiens 13-16 33351844-11 2020 CRP could be a useful marker to identify patients most likely to benefit from lenvatinib treatment. lenvatinib 78-88 C-reactive protein Homo sapiens 0-3 31572549-0 2019 Nicorandil effects on platelet function, Hs-CRP, MMP-9 and myocardial antioxidation in patients with unstable angina. Nicorandil 0-10 C-reactive protein Homo sapiens 44-47 31131461-7 2019 Compared with patients treated with pioglitazone plus sulfonylureas, the combination of sitagliptin and sulfonylureas was more effective in reducing LDL-C and in increasing HDL-C. High-sensitivity C-reactive protein was decreased by all pharmacological combinations. Sitagliptin Phosphate 88-99 C-reactive protein Homo sapiens 197-215 33317455-9 2020 The group with high DeltaCRP/Alb ratio after NACRT (n = 13) not only had higher post-NACRT CRP levels (p < 0.001) but also had lower post-NACRT Alb levels (p = 0.002). nacrt 45-50 C-reactive protein Homo sapiens 25-28 32778146-2 2020 We explored the effects of administering dexmedetomidine on the levels of C-reactive protein (CRP) and procalcitonin, and thus on inflammation, in patients with sepsis enrolled in a randomized clinical trial. Dexmedetomidine 41-56 C-reactive protein Homo sapiens 74-92 33331570-7 2020 Compared with the control group, in the Dex group at T1, T2, and T3, the serum creatine kinase-MB, cardiac troponin-I, C-reactive protein, and tumor necrosis factor-alpha levels were decreased, and the interleukin-10 level, the serum total superoxide dismutase, and total anti-oxidant capability increased, while the myeloperoxidase and malondialdehyde levels decreased (all P < 0.05). Dexmedetomidine 40-43 C-reactive protein Homo sapiens 119-137 31248116-4 2019 The applicability of these electrode chips in bioaffinity assays was demonstrated by an immunoassay of human C-reactive protein (i) using Tb(III) chelate label displaying long-lived hot electron-induced electrochemiluminescence (HECL) and (ii) now for the first time fluorescein isothiocyanate (FITC) was utilized as an a low-cost organic label displaying a short-lived HECL in a real-world bioaffinity assay. hecl 229-233 C-reactive protein Homo sapiens 109-127 31248116-4 2019 The applicability of these electrode chips in bioaffinity assays was demonstrated by an immunoassay of human C-reactive protein (i) using Tb(III) chelate label displaying long-lived hot electron-induced electrochemiluminescence (HECL) and (ii) now for the first time fluorescein isothiocyanate (FITC) was utilized as an a low-cost organic label displaying a short-lived HECL in a real-world bioaffinity assay. hecl 370-374 C-reactive protein Homo sapiens 109-127 32778146-2 2020 We explored the effects of administering dexmedetomidine on the levels of C-reactive protein (CRP) and procalcitonin, and thus on inflammation, in patients with sepsis enrolled in a randomized clinical trial. Dexmedetomidine 41-56 C-reactive protein Homo sapiens 94-97 32862376-8 2020 Additionally, serum Gal-9 levels were negatively correlated with high-sensitivity C-reactive protein (hs-CRP), estimated GFR (eGFR), and lipoprotein(a), but positively with creatinine, age, osmotic pressure, and blood urea nitrogen (BUN). gal-9 20-25 C-reactive protein Homo sapiens 82-100 30171597-9 2019 In the low-CRP group, the high-RF subgroup showed an elevation of ACPA, Cs, and ESR in comparison with the low-RF patients. Cesium 72-74 C-reactive protein Homo sapiens 11-14 30171597-10 2019 In the high-CRP group, the patients with high RF showed an increase in the levels of Cs, Rb, ESR, and ACPA. Cesium 85-87 C-reactive protein Homo sapiens 12-15 31035488-6 2019 The association between calcidiol/paricalcitol treatment and elevated mortality remained significant after adjusting for age, sex, diabetes, C-reactive protein, and hemodialysis vintage. paricalcitol 34-46 C-reactive protein Homo sapiens 141-159 32868633-7 2020 Oral administration of a maintenance dose of voriconazole and C-reactive protein (CRP) level were significantly and independently associated with a low initial trough concentration of voriconazole (< 1.0 microg/mL). Voriconazole 184-196 C-reactive protein Homo sapiens 62-80 32868633-7 2020 Oral administration of a maintenance dose of voriconazole and C-reactive protein (CRP) level were significantly and independently associated with a low initial trough concentration of voriconazole (< 1.0 microg/mL). Voriconazole 184-196 C-reactive protein Homo sapiens 82-85 33423442-9 2020 PMX-DHP subsequently improved oxygenation (PaO2/FiO2 ratio) and decreased the levels of inflammatory markers (interleukin-6, C-reactive protein, and white blood cells). pmx-dhp 0-7 C-reactive protein Homo sapiens 125-143 32862376-8 2020 Additionally, serum Gal-9 levels were negatively correlated with high-sensitivity C-reactive protein (hs-CRP), estimated GFR (eGFR), and lipoprotein(a), but positively with creatinine, age, osmotic pressure, and blood urea nitrogen (BUN). gal-9 20-25 C-reactive protein Homo sapiens 105-108 32862376-9 2020 Notably, serum Gal-9 was independently associated with hs-CRP, osmotic pressure, and lipoprotein(a). gal-9 15-20 C-reactive protein Homo sapiens 58-61 32862376-11 2020 It was suggested that the levels of Gal-9 in serum and PBMCs were decreased in patients with simple ACS and those with ACS plus CKD, and hs-CRP, eGFR, osmotic pressure and T2DM may have an influence on serum Gal-9 levels. gal-9 36-41 C-reactive protein Homo sapiens 140-143 32862376-11 2020 It was suggested that the levels of Gal-9 in serum and PBMCs were decreased in patients with simple ACS and those with ACS plus CKD, and hs-CRP, eGFR, osmotic pressure and T2DM may have an influence on serum Gal-9 levels. gal-9 208-213 C-reactive protein Homo sapiens 140-143 33352101-10 2020 CONCLUSION: It should be kept in mind that, in silicosis cases with arthralgia, joint tenderness or sclerosis at the fingertips may be indicative of rheumatological diseases related to silica exposure, and in these cases, the unexplained elevations of sedimentation and CRP levels may also be a result of silica-induced rheumatological diseases. Silicon Dioxide 185-191 C-reactive protein Homo sapiens 270-273 31010101-6 2019 Low glutamine levels were associated with older age, advanced stage, decreased albumin levels, elevated carcinoembryonic antigen levels, higher C-reactive protein levels, higher modified Glasgow prognostic scores, and higher proinflammatory cytokine levels. Glutamine 4-13 C-reactive protein Homo sapiens 144-162 32639203-5 2021 Patients with vitamin B12 deficiency had significantly higher systolic blood pressure (SBP), diastolic blood pressure (DBP), MHR, C-reactive protein (CRP) and uric acid levels compared with the controls (median 139 vs 115 mmHg, p < 0.001; 80 vs 70 mmHg, p < 0.001; 14.2 vs 9.5, p < 0.001; 10.2 vs 4 mg/dl p < 0.001; 6.68 vs 4.8 mg/dl, p < 0.001 respectively). Vitamin B 12 14-25 C-reactive protein Homo sapiens 130-148 30306637-5 2019 VRC overdoses were significantly associated with high CRP and bilirubin levels, intravenous administration, and age in univariable analysis. Voriconazole 0-3 C-reactive protein Homo sapiens 54-57 33081175-10 2020 Supplementing n-3 fatty acids, probiotics, synbiotics, and trace elements increased antioxidant enzymes and reduced hs-CRP and MDA. Fatty Acids, Omega-3 14-29 C-reactive protein Homo sapiens 119-122 33026590-9 2021 In a multiple logistic regression model, increased CRP levels were significantly associated with deficiencies of vitamin B12 (OR = 5.84; 95% CI 1.25-27.2; p = 0.024), folate (OR = 4.02; 1.87-8.66; p < 0.001), and with the presence of >= 2 micronutrient deficiencies (OR = 2.31; 1.21-4.42; p = 0.01). Vitamin B 12 113-124 C-reactive protein Homo sapiens 51-54 32639203-5 2021 Patients with vitamin B12 deficiency had significantly higher systolic blood pressure (SBP), diastolic blood pressure (DBP), MHR, C-reactive protein (CRP) and uric acid levels compared with the controls (median 139 vs 115 mmHg, p < 0.001; 80 vs 70 mmHg, p < 0.001; 14.2 vs 9.5, p < 0.001; 10.2 vs 4 mg/dl p < 0.001; 6.68 vs 4.8 mg/dl, p < 0.001 respectively). Vitamin B 12 14-25 C-reactive protein Homo sapiens 150-153 32519552-4 2020 C-reactive protein-to-albumin ratio was significantly higher in patients with isolated CAE than in those with obstructive CAD and NCA (10.5 [5.9-30.9], 5.7 [1.8-13.2] and 3.0 [0.9-8.9], respectively). nca 130-133 C-reactive protein Homo sapiens 0-18 31086519-10 2019 Conclusion: Sitagliptin has strong anti inflammatory effect marked by reduction in CRP level in comparison to glimepiride in overweight type-2 diabetic patients. Sitagliptin Phosphate 12-23 C-reactive protein Homo sapiens 83-86 32303765-14 2020 CONCLUSIONS: EV+DNG and DNG only had a neutral effect on inflammation and lipids, while EE+DNG increased both hs-CRP and PTX-3 levels as well as triglycerides and HDL. ee+dng 88-94 C-reactive protein Homo sapiens 113-116 30558634-6 2018 We found that the concentrations of soluble IgA and IgG in feces of active IBD patients were significantly higher than those in healthy controls and that the levels of soluble IgA and IgG in feces from IBD patients were positively correlated with CRP, ESR, Mayo score, UCEIS, SES-CD, and CDAI, respectively. cdai 288-292 C-reactive protein Homo sapiens 247-250 33456597-9 2020 Addition of synbiotic to allopurinol leads to a blood uric acid lowering (18.7% vs. 13.3%, p <0.01), CRP reduction (75% vs. 26.3%, p <0.01) as well as decrease of cytokines level: IL-1beta, IL-6, IL-8, IL-10 and TNFalpha (all p <0.001). Allopurinol 25-36 C-reactive protein Homo sapiens 101-104 30231792-7 2020 However, notably decreased high sensitivity C-reactive protein (hs-CRP) is revealed after omega-3 fatty acids supplementation (std. Fatty Acids, Omega-3 90-109 C-reactive protein Homo sapiens 44-62 32898346-9 2020 At the sixth week, a significant increase in PERMA, gratitude, resilience, and Posttraumatic Growth Inventory scores and a significant decrease in homocysteine and C-reactive protein levels in the RFPP group, but not the TF-CBT group, were noted (P < .05). rfpp 197-201 C-reactive protein Homo sapiens 164-182 30051214-9 2018 The serum IL-6 and CRP levels were inversely correlated with the plasma concentration ratios of N-desmethyltramadol to tramadol and of N,O-didesmethyltramadol to O-desmethyltramadol. Tramadol 107-115 C-reactive protein Homo sapiens 19-22 32921364-2 2020 We tested the hypothesis that parenteral omega-3 FA from a lipid emulsion that includes fish oil could be beneficial in patients with predicted SAP by reducing C-reactive protein (CRP) concentration (primary outcome), and modulating the inflammatory response and improving clinical outcome (secondary outcomes). Fatty Acids, Omega-3 41-51 C-reactive protein Homo sapiens 160-178 32053942-11 2020 In the clinical study, melon concentrate was able to decrease oxidative stress and C-Reactive protein (CRP) plasma level. melon concentrate 23-40 C-reactive protein Homo sapiens 83-101 32921364-2 2020 We tested the hypothesis that parenteral omega-3 FA from a lipid emulsion that includes fish oil could be beneficial in patients with predicted SAP by reducing C-reactive protein (CRP) concentration (primary outcome), and modulating the inflammatory response and improving clinical outcome (secondary outcomes). Fatty Acids, Omega-3 41-51 C-reactive protein Homo sapiens 180-183 32731898-6 2020 RESULTS: Vitamin A concentrations in RMPP group were significantly lower than those in GMPP patients (P < 0.05), vitamin A (OR = 0.795, 95% C. I 0.669-0.946) and CRP (OR = 1.050, 95% C. I 1.014-1.087) were independently associated with RMPP incidence. Vitamin A 9-18 C-reactive protein Homo sapiens 162-165 30307307-8 2018 CRP was found to be associated with retinol (x2 = 3.95/p = 0.04). Vitamin A 36-43 C-reactive protein Homo sapiens 0-3 30202420-6 2018 Correlation analysis also revealed that serum levels of hs-CRP positively correlated with age and SUA, but inversely correlated with serum levels of HDL-c and SOD (all P < 0.05). sua 98-101 C-reactive protein Homo sapiens 59-62 30202420-8 2018 In addition, elevated serum levels of hs-CRP are also associated with increased SUA but decreased HDL-c and SOD. sua 80-83 C-reactive protein Homo sapiens 41-44 32053942-11 2020 In the clinical study, melon concentrate was able to decrease oxidative stress and C-Reactive protein (CRP) plasma level. melon concentrate 23-40 C-reactive protein Homo sapiens 103-106 32708997-10 2020 Elevated hs-C reactive protein (CRP) was associated with new-onset CKD (OR: 1.045, 95% CI: 1.005-1.086); however, this association disappeared following adjustment with the kynurenine:tryptophan ratio. Kynurenine 173-183 C-reactive protein Homo sapiens 9-30 32708997-10 2020 Elevated hs-C reactive protein (CRP) was associated with new-onset CKD (OR: 1.045, 95% CI: 1.005-1.086); however, this association disappeared following adjustment with the kynurenine:tryptophan ratio. Kynurenine 173-183 C-reactive protein Homo sapiens 32-35 31692333-9 2019 Our results differ from the previously reported ones since the highest concentration of anti-hCRP was immobilized using 11-mercaptoundecanoic acid (MUA) chemistry. 11-mercaptoundecanoic acid 120-146 C-reactive protein Homo sapiens 93-97 32251802-6 2020 At D4, the CRP-ratio was lower in survivors on D365 in comparison with D4-D30 non-survivors and D30-D365 non-survivors (p<0.001). Verapamil 47-51 C-reactive protein Homo sapiens 11-14 30189611-11 2018 A significant negative correlation was found between plasma all-trans retinol and CRP level at the end of treatment (p = 0.03). Vitamin A 70-77 C-reactive protein Homo sapiens 82-85 29744898-0 2018 Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole. Voriconazole 91-103 C-reactive protein Homo sapiens 57-60 31692333-9 2019 Our results differ from the previously reported ones since the highest concentration of anti-hCRP was immobilized using 11-mercaptoundecanoic acid (MUA) chemistry. 11-mercaptoundecanoic acid 148-151 C-reactive protein Homo sapiens 93-97 31668347-5 2019 DEX infusion during the perioperative period inhibited release of epinephrine, norepinephrine, and cortisol; decreased blood glucose, interleukin (IL)-6, tumour necrosis factor-alpha, and C-reactive protein; and increased interleukin-10 in surgical patients. Dexmedetomidine 0-3 C-reactive protein Homo sapiens 188-206 31363829-7 2019 Among the entire patient population, SUA levels significantly increased 3 months after starting treatment with TNFis (279.5 [84.0] vs. 299.0 [102.0] mumol/l, p < 0.0001), while the levels of CRP, IL-6, IL-8, and MCP-1 significantly decreased. sua 37-40 C-reactive protein Homo sapiens 194-197 29784344-0 2018 Determination of C-reactive protein by PAMAM decorated ITO based disposable biosensing system: A new immunosensor design from an old molecule. pamam 39-44 C-reactive protein Homo sapiens 17-35 32574262-7 2020 Treatment with IFN-alpha2b with or without arbidol significantly reduced the duration of detectable virus in the upper respiratory tract and in parallel reduced duration of elevated blood levels for the inflammatory markers IL-6 and CRP. umifenovir 43-50 C-reactive protein Homo sapiens 233-236 31634026-5 2020 The numbers of CD4+ T cells were increased (P < .05), and the serum C-reactive protein levels decreased (P < .01) after the administration of effervescent glutamine formulation. Glutamine 155-164 C-reactive protein Homo sapiens 68-86 30097364-13 2019 CONCLUSIONS: The use of a nutritional supplement enriched with O3FA is associated with a greater preoperative weight loss, reduced postoperative pain and decreased postoperative levels of C reactive protein. Fatty Acids, Omega-3 63-67 C-reactive protein Homo sapiens 188-206 32234180-5 2020 The relationship between hs-CRP and LASEC in patients with nonvalvular atrial fibrillation was investigated by univariate and multivariate logistic analysis. lasec 36-41 C-reactive protein Homo sapiens 28-31 32234180-8 2020 Compared with the group without LASEC, the serum hs-CRP level was significantly higher in the group with LASEC (3.16 (1.30, 5.23) mg/L vs. 0.67 (0.37, 1.48) mg/L, P<0.001). lasec 32-37 C-reactive protein Homo sapiens 52-55 30053824-6 2018 RESULTS: Cross-sectional assessment demonstrated significant correlations between the levels of BAFF and anti-Jo-1 antibodies which were associated with levels of CK, myoglobin, AST, and CRP, as well as multivariate associations between BAFF, anti-Jo-1 antibodies, and CK levels. baff 96-100 C-reactive protein Homo sapiens 187-190 29428236-10 2018 ROC analysis demonstrated that a P4NP 7S concentration of 4.75ng/ml predicted mortality (AUC 0.85, 95% CI 0.75-0.94; P<0.001), and that the prognostic value of P4NP 7S was comparable or superior to that of other biomarkers (total bilirubin, creatinine, uric acid, C-reactive protein, B-type natriuretic peptide, and troponin I). ethyl-2-methylthio-4-methyl-5-pyrimidine carboxylate 38-40 C-reactive protein Homo sapiens 267-285 32254459-0 2018 NH2-Ni-MOF electrocatalysts with tunable size/morphology for ultrasensitive C-reactive protein detection via an aptamer binding induced DNA walker-antibody sandwich assay. nh2-ni-mof 0-10 C-reactive protein Homo sapiens 76-94 32234180-8 2020 Compared with the group without LASEC, the serum hs-CRP level was significantly higher in the group with LASEC (3.16 (1.30, 5.23) mg/L vs. 0.67 (0.37, 1.48) mg/L, P<0.001). lasec 105-110 C-reactive protein Homo sapiens 52-55 32234180-10 2020 Conclusions: hs-CRP is an independent determinant for LASEC in patients with nonvalvular atrial fibrillation. lasec 54-59 C-reactive protein Homo sapiens 16-19 32046485-3 2020 Herein, we expand this scope by utilizing phytic acid-doped polyaniline as a novel redox-charging polymer support enabling the reagentless assaying of C-reactive protein in serum with good sensitivity. Polymers 98-105 C-reactive protein Homo sapiens 151-169 32254459-3 2018 Subsequently, this work exhibits an example of a high-performance NH2-Ni-MOF(c) electrocatalyst for application in constructing an electrochemical aptasensor to achieve sensitive C-reactive protein (CRP) detection based on an aptamer binding induced DNA walker-antibody sandwich assay. nh2-ni-mof 66-76 C-reactive protein Homo sapiens 179-197 30293230-3 2019 We evaluated whether the olive-derived polyphenol hydroxytyrosol combined with omega-3 fatty acids and curcumin would reduce CRP and musculoskeletal symptoms in breast cancer patients receiving adjuvant hormonal therapies. Fatty Acids, Omega-3 79-98 C-reactive protein Homo sapiens 125-128 32254459-3 2018 Subsequently, this work exhibits an example of a high-performance NH2-Ni-MOF(c) electrocatalyst for application in constructing an electrochemical aptasensor to achieve sensitive C-reactive protein (CRP) detection based on an aptamer binding induced DNA walker-antibody sandwich assay. nh2-ni-mof 66-76 C-reactive protein Homo sapiens 199-202 30293230-10 2019 CONCLUSIONS: The combination of hydroxytyrosol, omega-3 fatty acids, and curcumin reduced inflammation as indicated by a reduction in CRP and reduced pain in patients with aromatase-induced musculoskeletal symptoms. 3,4-dihydroxyphenylethanol 32-46 C-reactive protein Homo sapiens 134-137 31955966-9 2020 Combining 13 effect sizes from 10 studies, a significant reduction in serum CRP concentration following the administration of atorvastatin was found (WMD, -0.35; 95% CI, -0.54 to -0.17; I2 = 90.6%). atorvastatin 126-138 C-reactive protein Homo sapiens 76-79 30893301-10 2019 For CRP, we found significant increases in NO2 at lag1-3 days after-Asian game period and significant increases in PM10 at lag1-2 days. pm10 115-119 C-reactive protein Homo sapiens 4-7 31955966-12 2020 IMPLICATIONS: The administration of atorvastatin or simvastatin in patients with abnormal glucose hemostasis was associated with a reduced serum CRP concentration. atorvastatin 36-48 C-reactive protein Homo sapiens 145-148 31533605-0 2020 Synergism effects of ursolic acid supplementation on the levels of irisin, C-reactive protein, IL-6, and TNF-alpha during high-intensity resistance training in low activity men. ursolic acid 21-33 C-reactive protein Homo sapiens 75-93 29327150-9 2018 The risk of death increased with high SUA levels both in the univariate and the multivariate models including estimated glomerular filtration rate, C-reactive protein, type of diabetes, and age-adjusted Charlson comorbidity index. sua 38-41 C-reactive protein Homo sapiens 148-166 29508692-7 2018 ASB intake was marginally associated with increased concentrations of CRP (P trend=0 04) and adiponectin (P trend=0 01). asb 0-3 C-reactive protein Homo sapiens 70-73 31533605-9 2020 UA treatment also dramatically decreased the plasma levels of CRP, IL-6, and TNF-alpha in the HIRT+UA group versus the HIRT+P group (p<0.05). ursolic acid 0-2 C-reactive protein Homo sapiens 62-65 30125457-6 2019 Significant beneficial effects from marine n-3 FA supplementation were, however, seen in secondary endpoints plasma triglycerides, plasma high-sensitivity C-reactive protein, and brachial artery flow-mediated dilation. Fatty Acids, Omega-3 43-49 C-reactive protein Homo sapiens 155-173 31533605-10 2020 CONCLUSION: The current data showed that UA-induced an increase in serum irisin and reduction of CRP, IL-6, and TNF-alpha may have beneficial effects as a chemical for increasing of the effects of HIRT in low activity men. ursolic acid 41-43 C-reactive protein Homo sapiens 97-100 32981268-10 2020 RESULTS: UDE had an intermediate effect on IPSS, a small effect on serum high-sensitivity C-reactive protein (hs-CRP), intermediate to large effect on malondialdehyde (MDA) levels and intermediate effect on superoxide dismutase (SOD) activity. CHEMBL4643353 9-12 C-reactive protein Homo sapiens 90-108 28462631-11 2018 KEY MESSAGES Serum high-sensitivity C-reactive protein (hsCRP) concentration is positively associated with sugar intake, and negatively with the consumption of minerals, vitamins and polyunsaturated fatty-acids (fruit and vegetables). Fatty Acids, Unsaturated 183-210 C-reactive protein Homo sapiens 36-54 32981268-10 2020 RESULTS: UDE had an intermediate effect on IPSS, a small effect on serum high-sensitivity C-reactive protein (hs-CRP), intermediate to large effect on malondialdehyde (MDA) levels and intermediate effect on superoxide dismutase (SOD) activity. CHEMBL4643353 9-12 C-reactive protein Homo sapiens 113-116 29728047-0 2019 Label-Free Specific Detection and Collection of C-Reactive Protein Using Zwitterionic Phosphorylcholine-Polymer-Protected Magnetic Nanoparticles. Polymers 104-111 C-reactive protein Homo sapiens 48-66 32981268-13 2020 CONCLUSION: UDE consumption for 12 weeks among BPH patients had clinically significant effects on IPSS, serum hs-CRP, MDA and SOD activity. CHEMBL4643353 12-15 C-reactive protein Homo sapiens 113-116 30732197-5 2019 In addition, the serum levels of pork-specific IgG were significantly and positively correlated with CRP.These results suggest that alpha-Gal, the predominant natural antigen in mammalian red meat, might play a potential role in the pathogenesis of AS, and therefore, AS patients should exclude such allergenic foods, including beef, crab and pork, from their daily diet. methylphenyl carbinol 132-138 C-reactive protein Homo sapiens 101-104 31827125-1 2019 The purpose of this systematic review and meta-analysis was to investigate omega-3 fatty acids" influence on 12 inflammatory biomarkers-LDL, HDL, total cholesterol, TG, HbA1c, Apo AI, Apo AII, Apo B, CRP, TNF-alpha, glucose, and fasting blood glucose among diabetic and cardiovascular disease (CVD) patients. Fatty Acids, Omega-3 75-94 C-reactive protein Homo sapiens 200-203 31504095-11 2019 In mixed models, CRP was associated with ferritin (positive) and serum iron and retinol (negative, P < 0.05). Vitamin A 80-87 C-reactive protein Homo sapiens 17-20 29165226-0 2018 Comparability of Inflammation-Adjusted Vitamin A Deficiency Estimates and Variance in Retinol Explained by C-Reactive Protein and alpha1-Acid Glycoprotein during Low and High Malaria Transmission Seasons in Rural Zambian Children. Vitamin A 86-93 C-reactive protein Homo sapiens 107-125 29172154-7 2018 While, the addition of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE) or sphingomyelin to supported POPC monolayers blocked CRP adsorption. 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine 23-76 C-reactive protein Homo sapiens 138-141 30391689-11 2019 Changes in serum glutamine levels were negatively related to C-reactive protein levels in S3. Glutamine 17-26 C-reactive protein Homo sapiens 61-79 30559614-7 2018 Children with vitamin A deficiency had slightly lower height (P = 0.09) and weight mean percentiles, lymphocyte proliferative responses, and IL-2 activity (P > 0.1), but higher means of C-reactive protein (P = 0.05), pain crisis episodes and inflammation (P = 0.1), and health scores (P > 0.1) than children who were not vitamin A-deficient. Vitamin A 14-23 C-reactive protein Homo sapiens 189-207 28584972-9 2017 A significant CRP adjusted linear association between the TBRmax in DA and the number of lipid-rich plaques was observed (CRP-adjusted beta = 3.58; 95%CI -0.91-6.25; p = 0.01). tbrmax 58-64 C-reactive protein Homo sapiens 14-17 28584972-9 2017 A significant CRP adjusted linear association between the TBRmax in DA and the number of lipid-rich plaques was observed (CRP-adjusted beta = 3.58; 95%CI -0.91-6.25; p = 0.01). tbrmax 58-64 C-reactive protein Homo sapiens 122-125 28584972-10 2017 TBRmax in DA showed a trend towards significant CRP-adjusted association with number of lipid-rich plaques with macrophages (CRP-adjusted beta = 2.30; 95%CI -0.11-4.71; p = 0.06). tbrmax 0-6 C-reactive protein Homo sapiens 48-51 28584972-10 2017 TBRmax in DA showed a trend towards significant CRP-adjusted association with number of lipid-rich plaques with macrophages (CRP-adjusted beta = 2.30; 95%CI -0.11-4.71; p = 0.06). tbrmax 0-6 C-reactive protein Homo sapiens 125-128 28834922-9 2017 The predictive performance of the VRCZ/N-oxide ratio was improved by including the route of administration, C-reactive protein level, and patient age in addition to the CYP2C19 genotype as predictive factors. Voriconazole 34-38 C-reactive protein Homo sapiens 108-126 31434637-4 2019 RESULTS: In the larger study (N=207), a greater number of prior DMARDs (>2 vs 0-1) was associated with smaller improvements in DAS28(CRP) (-1.8 vs -2.2), SDAI (-22.1 vs -26.9) and HAQ-DI (-0.43 vs -0.64) from baseline to week 24. haq-di 183-189 C-reactive protein Homo sapiens 136-139 31691767-4 2019 OBJECTIVES: To investigate the relationship between PCT and both fever etiologies and C-reactive protein (CRP) levels among critically ill patients with suspected intracerebral hemorrhage. pct 52-55 C-reactive protein Homo sapiens 86-104 31691767-12 2019 A statistically significant positive correlation was detected between PCT and CRP levels in patients with infectious fever (rho: 0.461; P = 0.003), but not in patients with central fever. pct 70-73 C-reactive protein Homo sapiens 78-81 30954352-8 2019 In patients without postoperative complications, a secondary peak of inflammatory parameters, CRP (p = 0.015) and PSP (p = 0.004) was observed after HIPEC for 90 min with mitomycinC/doxorubicin or cisplatin but not after 30 min oxaliplatin. Mitomycin 171-181 C-reactive protein Homo sapiens 94-97 29932029-6 2019 Indeed, clinical studies that evaluate the association between phytosterols consumption and inflammatory variables (CRP and cytokines) are inconsistent and have not yet provided a solid answer. Phytosterols 63-75 C-reactive protein Homo sapiens 116-119 31366975-10 2019 Moreover, defibrotide reduced C-reactive protein levels by 13% (0-17%, p = 0.002). defibrotide 10-21 C-reactive protein Homo sapiens 30-48 31366975-12 2019 In conclusion, defibrotide infusion enhanced fibrinolysis and reduced C-reactive protein levels during experimental endotoxemia. defibrotide 15-26 C-reactive protein Homo sapiens 70-88 31349671-4 2019 The result showed that with placebo as the reference, PUFAs was the only treatment showing significantly lower CRP (weighted mean difference (WMD): -0.37, 95% confidence interval (CI): -0.07 to -0.68), but the CRP in PUFAs group was not significantly lower than vitamin E, PUFAs plus vitamin E, or medium-chain triglyceride. Fatty Acids, Unsaturated 54-59 C-reactive protein Homo sapiens 111-114 28811499-7 2017 Stress-induction at the onset/progression of this disease is noticed as the high-level of lipid peroxides/low-level of free-thiols in association with increase of inflammatory-markers c-reactive protein and TNF-alpha. free-thiols 119-130 C-reactive protein Homo sapiens 184-202 31349671-4 2019 The result showed that with placebo as the reference, PUFAs was the only treatment showing significantly lower CRP (weighted mean difference (WMD): -0.37, 95% confidence interval (CI): -0.07 to -0.68), but the CRP in PUFAs group was not significantly lower than vitamin E, PUFAs plus vitamin E, or medium-chain triglyceride. Fatty Acids, Unsaturated 54-59 C-reactive protein Homo sapiens 210-213 30412376-0 2018 Biomimetic Polymer-Based Method for Selective Capture of C-Reactive Protein in Biological Fluids. Polymers 11-18 C-reactive protein Homo sapiens 57-75 30293230-10 2019 CONCLUSIONS: The combination of hydroxytyrosol, omega-3 fatty acids, and curcumin reduced inflammation as indicated by a reduction in CRP and reduced pain in patients with aromatase-induced musculoskeletal symptoms. Fatty Acids, Omega-3 48-67 C-reactive protein Homo sapiens 134-137 28126828-8 2017 Strikingly concordant and significant genotype-dependent effects of dalcetrapib were also obtained for changes in high-sensitivity C-reactive protein and cholesterol efflux capacity. dalcetrapib 68-79 C-reactive protein Homo sapiens 131-149 30412376-3 2018 In this study, inspired by the highly specific interaction between CRP and the cell membrane, an excellent anti-biofouling compound 2-(methacryloyloxy)ethyl phosphorylcholine and a highly hydrophilic crosslinker N, N"-methylenebisacrylamide were employed to fabricate a novel cell membrane biomimetic polymer for selective capture of CRP in the presence of calcium ions. Polymers 301-308 C-reactive protein Homo sapiens 67-70 30412376-5 2018 With its favorable properties, such as good porosity, weak electrostatic interaction, high hydrophilicity, and biocompatibility, the novel biomimetic polymer exhibits good specificity, selectivity, recovery (near 100%), purity (95%), and a lower nonspecific protein adsorption for CRP in comparison with commercial immobilized p-aminophenyl phosphoryl choline gel and other purification materials. Polymers 150-157 C-reactive protein Homo sapiens 281-284 30412376-7 2018 Finally, the biomimetic polymer was successfully applied to the selective enrichment of CRP from sera of patients with inflammation and rats. Polymers 24-31 C-reactive protein Homo sapiens 88-91 30412376-8 2018 The proposed novel enrichment approach based on the versatile biomimetic polymer can be used for effective CRP purification, which will benefit the in-depth study of its biological roles. Polymers 73-80 C-reactive protein Homo sapiens 107-110 28004376-11 2017 Data exploration indicated potential drug effects of dilmapimod on inhibiting the production of CRP levels; however, the current small dataset did not show a statistically significant improvement in the PK/PD modelling. dilmapimod 53-63 C-reactive protein Homo sapiens 96-99 29868945-8 2018 A multivariate regression analysis revealed that younger age, male sex, and the peak CRP level were significant predictors of the minimum PaO2/FiO2 ratio (P = 0.01, 0.035 and 0.005, respectively). fio2 143-147 C-reactive protein Homo sapiens 85-88 28093243-17 2017 The protective mechanism of allopurinol might be achieved by suppressing the secretion and release of inflammatory mediators such as TNF-alpha, hs-CRP, OX-LDL and MDA while increasing levels of NO. Allopurinol 28-39 C-reactive protein Homo sapiens 147-150 26564246-5 2017 Raised CRP was found in 59.9% of mothers, with a significant negative correlation between serum retinol and CRP (r = -0.273; p < 0.0001). Vitamin A 96-103 C-reactive protein Homo sapiens 7-10 26564246-5 2017 Raised CRP was found in 59.9% of mothers, with a significant negative correlation between serum retinol and CRP (r = -0.273; p < 0.0001). Vitamin A 96-103 C-reactive protein Homo sapiens 108-111 26564246-9 2017 Serum retinol may be influenced by factors other than vitamin A status, e.g. the haemodilution of pregnancy, as well as the acute phase response induced by the birth process, as suggested by raised CRP in 60% of mothers. Vitamin A 6-13 C-reactive protein Homo sapiens 198-201 28105083-7 2016 The meta-analysis revealed that the levels of CRP, TNF-alpha, and IL-6 in patients supplemented with Gln were significantly lower than those in control patients, whereas the levels of IL-2 receptor were increased by Gln supplementation. Glutamine 101-104 C-reactive protein Homo sapiens 46-49 27155167-9 2016 It was determined that the PSAQoL score had a positive and statistically significant correlation with the DGD, swollen JC, CRP, HGD, tender JC, VAS-pain, HAQ-S, MASES and BASDAI values in PsA patients. psaqol 27-33 C-reactive protein Homo sapiens 123-126 27485319-8 2016 A non-parametric ROC curve was computed to determine the CRP concentration cut-off point above which glutamine becomes deficient. Glutamine 101-110 C-reactive protein Homo sapiens 57-60 27485319-12 2016 Glutamine showed inverse associations with CRP levels (r = -0.44, p < 0.05) and IL-6 concentrations (r = -0.23, p = 0.08). Glutamine 0-9 C-reactive protein Homo sapiens 43-46 27485319-13 2016 A CRP cut-off value of 95.5 mg/L was determined above which glutamine levels became deficient. Glutamine 60-69 C-reactive protein Homo sapiens 2-5 26613172-11 2016 In the delayed phase (Days 6-14 after SAH), the serum C-reactive protein level and the global end-diastolic volume index were significantly higher in the PE group than in the non-PE group, whereas the PVPI tended to be higher in the PE group. pe 154-156 C-reactive protein Homo sapiens 54-72 27272805-6 2016 C-reactive protein (CRP) and interleukin-6 (IL-6) correlated with each other and exhibited positive correlation with age, body-mass index (BMI), leukocyte count, platelet count, kynurenine, kynurenine/tryptophan ratio and urinary neopterin and a negative correlation with vitamin D and retinol. Kynurenine 178-188 C-reactive protein Homo sapiens 0-18 27272805-6 2016 C-reactive protein (CRP) and interleukin-6 (IL-6) correlated with each other and exhibited positive correlation with age, body-mass index (BMI), leukocyte count, platelet count, kynurenine, kynurenine/tryptophan ratio and urinary neopterin and a negative correlation with vitamin D and retinol. Kynurenine 190-200 C-reactive protein Homo sapiens 0-18 27272805-6 2016 C-reactive protein (CRP) and interleukin-6 (IL-6) correlated with each other and exhibited positive correlation with age, body-mass index (BMI), leukocyte count, platelet count, kynurenine, kynurenine/tryptophan ratio and urinary neopterin and a negative correlation with vitamin D and retinol. Vitamin A 286-293 C-reactive protein Homo sapiens 0-18 26987068-4 2016 This study assessed the anti-inflammatory effect of PS consumption, according to inflammatory biomarkers, mainly C-reactive protein (CRP). Phytosterols 52-54 C-reactive protein Homo sapiens 113-131 26987068-4 2016 This study assessed the anti-inflammatory effect of PS consumption, according to inflammatory biomarkers, mainly C-reactive protein (CRP). Phytosterols 52-54 C-reactive protein Homo sapiens 133-136 26987068-9 2016 The absolute change of plasma CRP levels with PS consumption was -0.10 mg/L (95%CI -0.26; 0.05), a non-significant change, and heterogeneity had borderline significance (I(2) = 29.1; p-value = 0.073). Phytosterols 46-48 C-reactive protein Homo sapiens 30-33 27242125-6 2016 There were statistically significant differences in PAI-1, TNF-alpha, and CRP levels between the DPN group and DM and N groups (both P<0.05). dpn 97-100 C-reactive protein Homo sapiens 74-77 27242125-8 2016 CONCLUSION: Anti-GS-ab and inflammatory markers such as PAI-1, TNF-alpha, and CRP were associated with DPN and can be used as important indicators for the prediction and early diagnosis of DPN. dpn 103-106 C-reactive protein Homo sapiens 78-81 26660887-1 2016 A synthetic polymer ligand-grafted plasmonic chip was fabricated and demonstrated a highly sensitive detection of C-reactive protein (CRP) by grating-coupled surface plasmon field-enhanced fluorescence. Polymers 12-19 C-reactive protein Homo sapiens 114-132 26660887-1 2016 A synthetic polymer ligand-grafted plasmonic chip was fabricated and demonstrated a highly sensitive detection of C-reactive protein (CRP) by grating-coupled surface plasmon field-enhanced fluorescence. Polymers 12-19 C-reactive protein Homo sapiens 134-137 26660887-2 2016 Poly(2-methacryloyloxyethyl-phosphorylcholine) was used as a CRP-specific polymer ligand layer and was grafted onto the plasmonic chip using surface-initiated controlled/living radical polymerization (limit of detection: ca. Polymers 74-81 C-reactive protein Homo sapiens 61-64 30090398-6 2016 Interestingly, treatment with benzo[a]pyrene and naphthalene significantly up regulated the phosphorylation of the p65 subunit of NF-kappaB and increased the secretion of TNF-alpha and CRP compared to control. naphthalene 49-60 C-reactive protein Homo sapiens 185-188 26773109-7 2016 Pyeloureterectasis, hypocomplementemia, and elevated C-reactive protein levels in serum were independent risk factors for IPO in SLE disease. PARA-IODO-D-PHENYLALANINE HYDROXAMIC ACID 122-125 C-reactive protein Homo sapiens 53-71 26552040-7 2016 In DM group, C-reactive protein (CRP) decreased significantly at 3months postoperatively and inflammatory markers interleukin-6 (IL-6) and TRACP 5a improved at 6months postoperatively; in non-DM group, serum TRACP 5a decreased obviously at 12months postoperatively without significant changes in CRP and IL-6. dm 3-5 C-reactive protein Homo sapiens 13-31 26552040-7 2016 In DM group, C-reactive protein (CRP) decreased significantly at 3months postoperatively and inflammatory markers interleukin-6 (IL-6) and TRACP 5a improved at 6months postoperatively; in non-DM group, serum TRACP 5a decreased obviously at 12months postoperatively without significant changes in CRP and IL-6. dm 3-5 C-reactive protein Homo sapiens 33-36 26552040-7 2016 In DM group, C-reactive protein (CRP) decreased significantly at 3months postoperatively and inflammatory markers interleukin-6 (IL-6) and TRACP 5a improved at 6months postoperatively; in non-DM group, serum TRACP 5a decreased obviously at 12months postoperatively without significant changes in CRP and IL-6. dm 3-5 C-reactive protein Homo sapiens 296-299 26164112-10 2016 HOMA-IR, CRP, and triglycerides were significantly lower 2 years after surgery in the MHMO group, whereas fasting blood sugar and HDL-C were unchanged. mhmo 86-90 C-reactive protein Homo sapiens 9-12 26588324-7 2015 The conducting polymer-based protein sensor achieved a limit of detection of 37 nM with a dynamic range of 10-160 nM, covering the dynamically changing CRP levels in circulation during the acute phase. Polymers 15-22 C-reactive protein Homo sapiens 152-155 26631004-8 2015 Multivariable analysis showed that an elevation in hs-CRP, measured at 12 h, was an independent predictor of 30-day infarct size (beta coefficient, 6.80; P = 0.04) using sestamibi SPECT imaging. Technetium Tc 99m Sestamibi 170-179 C-reactive protein Homo sapiens 54-57 26329338-10 2015 Kynurenine concentration correlated inversely with CRP concentration in RA SF but not in OA SF (r -0.65, p < 0.05). Kynurenine 0-10 C-reactive protein Homo sapiens 51-54 26341987-6 2015 Sputum interleukin (IL)-6 and growth-regulated oncogene (GRO)-alpha and serum GRO-alpha, IL-1ss and IL-8 levels increased with AZD5069 versus placebo (all p<0.001), while serum high-sensitivity C-reactive protein levels did not change. N-(2-(2,3-difluoro-6-benzylthio)-6-(3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide 127-134 C-reactive protein Homo sapiens 197-215 30680541-1 2019 A portion of this article was previously published as part of an article titled "Human C-reactive protein and the metabolic syndrome" in the following journal: Curr Opin Lipidol. lipidol 170-177 C-reactive protein Homo sapiens 87-105 30662999-1 2019 A portion of this article was previously published as part of an article titled "Human C-reactive protein and the metabolic syndrome" in the following journal: Curr Opin Lipidol. lipidol 170-177 C-reactive protein Homo sapiens 87-105 30173151-7 2018 Baseline QTc was significantly and independently higher among those with anticyclic citrullinated peptide antibodies seropositivity, higher swollen joint counts, and higher levels of C-reactive protein (CRP) and matrix metalloproteinase 3. qtc 9-12 C-reactive protein Homo sapiens 203-206 30173151-8 2018 Each log unit decrease in CRP with treatment was associated with an average reduction in QTc of 2.9 ms (p = 0.002) after adjusting for age and baseline QTc. qtc 89-92 C-reactive protein Homo sapiens 26-29 30173151-8 2018 Each log unit decrease in CRP with treatment was associated with an average reduction in QTc of 2.9 ms (p = 0.002) after adjusting for age and baseline QTc. qtc 152-155 C-reactive protein Homo sapiens 26-29 30409131-10 2018 The CRP levels were lower in the dexmedetomidine-treated groups in a dose-dependent manner. Dexmedetomidine 33-48 C-reactive protein Homo sapiens 4-7 29756266-5 2018 RESULTS: The good correlation between C-reactive protein and APTT was found on the STA-R Evolution (activator: silica) system. Silicon Dioxide 111-117 C-reactive protein Homo sapiens 38-56 29756266-6 2018 The APTT on the STA-R Evolution (activator: silica) system was prolonged by 24.6 second, along with increasing C-reactive protein concentration. Silicon Dioxide 44-50 C-reactive protein Homo sapiens 111-129 29756266-9 2018 CONCLUSION: C-reactive protein interferes with the detection of APTT, especially in STA-R Evolution (activator: silica) system. Silicon Dioxide 112-118 C-reactive protein Homo sapiens 12-30 29756266-10 2018 The increasing in C-reactive protein results in a false prolongation of the APTT (activator: silica), and it is most likely that C-reactive protein interferes the coagulable factor binding of phospholipid. Silicon Dioxide 93-99 C-reactive protein Homo sapiens 18-36 30212928-0 2018 Effect of omega 3 fatty acids on C-reactive protein and interleukin-6 in patients with advanced nonsmall cell lung cancer. Fatty Acids, Omega-3 10-29 C-reactive protein Homo sapiens 33-51 29896269-13 2018 Furthermore, DEX treatment markedly decreased the serum levels of CRP, NSE cortisol and melatonin, which are associated with the occurrence of postoperative cognitive dysfunction in pediatric patients following tonsillectomy. Dexmedetomidine 13-16 C-reactive protein Homo sapiens 66-69 29843881-0 2018 The Preparation of C-Reactive Protein Immunosensor Based on Nano-Mimetic Enzyme Co3O4. co3o4 80-85 C-reactive protein Homo sapiens 19-37 29843881-1 2018 In this work, a nano-mimetic enzyme Co3O4 nanoparticles with catalytic effect on the reduction of H2O2, was synthesized and used to label C-reactive protein antibody. co3o4 36-41 C-reactive protein Homo sapiens 138-156 29713320-15 2018 Structurally altered CRP induces leukocyte-endothelial interaction and induces ROS formation in leukocytes, the latter can be abrogated by blocking lipid raft-dependent signaling pathways with Nystatin. Nystatin 193-201 C-reactive protein Homo sapiens 21-24 29271576-11 2018 This suggested that there is insufficient evidence to conclude the benefit of omega-3 fatty acids oral supplementation in reducing serum levels of CRP, IL-6 and TNF-alpha in patients with CKD. Fatty Acids, Omega-3 78-97 C-reactive protein Homo sapiens 147-150 29938621-2 2018 Curcumin and omega-3 fatty acids can exert neuroprotective effects through modulation of IL-6 gene expression and CRP levels. Fatty Acids, Omega-3 13-32 C-reactive protein Homo sapiens 114-117 29796036-4 2018 In this study, we assessed the effect of memantine on the pro-inflammatory cytokines such as IL6, TNFalpha and CRP. Memantine 41-50 C-reactive protein Homo sapiens 111-114 29202548-2 2017 We hypothesized that the elevation in the level of TSA along with other prototype acute phase reactants such as CRP is expected more in the coexistence of diabetes and smoking than in diabetes mellitus alone. trichostatin A 51-54 C-reactive protein Homo sapiens 112-115 28739188-0 2017 The long-term relationship between dietary pantothenic acid (vitamin B5) intake and C-reactive protein concentration in adults aged 40 years and older. Pantothenic Acid 43-59 C-reactive protein Homo sapiens 84-102 28739188-0 2017 The long-term relationship between dietary pantothenic acid (vitamin B5) intake and C-reactive protein concentration in adults aged 40 years and older. Pantothenic Acid 61-71 C-reactive protein Homo sapiens 84-102 28739188-2 2017 However, the long-term relationship between PA intake and CRP has not yet been studied. Pantothenic Acid 44-46 C-reactive protein Homo sapiens 58-61 28739188-3 2017 The objective of the present study was to evaluate the long-term relationship of PA intake to CRP concentration in healthy adults aged 40 years or older living in a rural area of South Korea. Pantothenic Acid 81-83 C-reactive protein Homo sapiens 94-97 28739188-6 2017 After adjustment for potential confounders, a significant inverse relationship between PA intake and CRP concentration at the third visit was observed (P for trend = 0.001, beta = -0.07 (P-value = 0.001) for PA baseline; P for trend = <0.0001, beta = -0.11 (P-value = 0.0004) for PA average (baseline, 2nd, 3rd)). Pantothenic Acid 87-89 C-reactive protein Homo sapiens 101-104 28739188-6 2017 After adjustment for potential confounders, a significant inverse relationship between PA intake and CRP concentration at the third visit was observed (P for trend = 0.001, beta = -0.07 (P-value = 0.001) for PA baseline; P for trend = <0.0001, beta = -0.11 (P-value = 0.0004) for PA average (baseline, 2nd, 3rd)). Pantothenic Acid 208-210 C-reactive protein Homo sapiens 101-104 28739188-6 2017 After adjustment for potential confounders, a significant inverse relationship between PA intake and CRP concentration at the third visit was observed (P for trend = 0.001, beta = -0.07 (P-value = 0.001) for PA baseline; P for trend = <0.0001, beta = -0.11 (P-value = 0.0004) for PA average (baseline, 2nd, 3rd)). Pantothenic Acid 208-210 C-reactive protein Homo sapiens 101-104 28739188-7 2017 Higher PA intake was significantly related to lower or attenuated increase in CRP concentration (P for trend = 0.002, beta = -0.24 (P-value = 0.002) for PA baseline; P for trend = 0.001, beta = -0.35 (P-value = 0.001) for PA average (baseline, 2nd, 3rd)). Pantothenic Acid 7-9 C-reactive protein Homo sapiens 78-81 28739188-8 2017 CONCLUSIONS: In conclusion, dietary PA intake was inversely related to subsequent CRP concentration in both men and women aged 40 years or older in South Korea. Pantothenic Acid 36-38 C-reactive protein Homo sapiens 82-85 28628373-5 2017 The largest reductions in serum CRP (mg/L) per interquartile range increase in urinary phytoestrogens (ng/mL) were observed for total phytoestrogens (beta = -0.18; 95% confidence interval [CI], -0.22, -0.15), total lignan (beta = -0.15; 95% CI, -0.18, -0.12), and enterolactone (beta = -0.15; 95% CI, -0.19, -0.12). 2,3-bis(3'-hydroxybenzyl)butyrolactone 264-277 C-reactive protein Homo sapiens 32-35 28628373-6 2017 A decreased risk of having high CRP concentrations (>=3.0 mg/L) for quartile 4 vs quartile 1 was also found for total phytoestrogens (OR = 0.63; 95% CI, 0.53, 0.73), total lignan (OR = 0.64; 95% CI, 0.54, 0.75), and enterolactone (OR = 0.59; 95% CI, 0.51, 0.69). 2,3-bis(3'-hydroxybenzyl)butyrolactone 219-232 C-reactive protein Homo sapiens 32-35 28721055-9 2017 The combined treatment of COS and sitagliptin presented better therapeutic results by improving insulin sensitivity, lipid profile, adiponectin levels, and glucagon-like peptide 1 and reducing side effects, insulin resistance, HbA1c, body mass index, resistin, tumor necrosis factor (TNF)-alpha, and C-reactive protein (CRP) (P<0.05). Sitagliptin Phosphate 34-45 C-reactive protein Homo sapiens 300-318 28721055-9 2017 The combined treatment of COS and sitagliptin presented better therapeutic results by improving insulin sensitivity, lipid profile, adiponectin levels, and glucagon-like peptide 1 and reducing side effects, insulin resistance, HbA1c, body mass index, resistin, tumor necrosis factor (TNF)-alpha, and C-reactive protein (CRP) (P<0.05). Sitagliptin Phosphate 34-45 C-reactive protein Homo sapiens 320-323 28027123-4 2017 RESULTS: Significantly higher concentration of neutrophil elastase, IL-1, IL-6 and C-reactive protein was detected postoperatively in the 30% FiO2 group patients in comparison with the 80% FiO2 group (P<0.05). fio2 142-146 C-reactive protein Homo sapiens 83-101 28225631-1 2017 C-reactive protein (CRP) is a serum protein that binds to damaged membranes through a phosphatidylcholine binding site. Phosphatidylcholines 86-105 C-reactive protein Homo sapiens 0-18 28225631-1 2017 C-reactive protein (CRP) is a serum protein that binds to damaged membranes through a phosphatidylcholine binding site. Phosphatidylcholines 86-105 C-reactive protein Homo sapiens 20-23 27993955-10 2017 SUA levels were significantly associated with increased neutrophil count (P=0.02) and high-sensitivity C-reactive protein levels (P=0.006) among patients with CED, but not among those without CED. sua 0-3 C-reactive protein Homo sapiens 103-121 28079193-7 2016 The QTc was 26 ms longer in SLE compared with RA (p=0.002) in the setting of a higher percentage of women, blacks, Hispanics and higher C reactive protein levels in the SLE group. qtc 4-7 C-reactive protein Homo sapiens 136-154 28031832-7 2016 She received afatinib (20 mg once daily) as 11th-line treatment, with resolution of peritoneal carcinomatosis and CRP normalization, confirmed by follow-up computed tomography. Afatinib 13-21 C-reactive protein Homo sapiens 114-117 27242125-8 2016 CONCLUSION: Anti-GS-ab and inflammatory markers such as PAI-1, TNF-alpha, and CRP were associated with DPN and can be used as important indicators for the prediction and early diagnosis of DPN. dpn 189-192 C-reactive protein Homo sapiens 78-81 27096102-6 2016 In multiple linear regression analysis, increased C-reactive protein (CRP) level (p < 0.05) and decreased albumin (Alb) level (p < 0.05) were associated with significantly increased C/D-ratio of voriconazole, and coadministration with a glucocorticoid was associated with significantly (p < 0.05) decreased C/D-ratio of voriconazole (adjusted r (2) = 0.31). Voriconazole 201-213 C-reactive protein Homo sapiens 50-68 27096102-6 2016 In multiple linear regression analysis, increased C-reactive protein (CRP) level (p < 0.05) and decreased albumin (Alb) level (p < 0.05) were associated with significantly increased C/D-ratio of voriconazole, and coadministration with a glucocorticoid was associated with significantly (p < 0.05) decreased C/D-ratio of voriconazole (adjusted r (2) = 0.31). Voriconazole 201-213 C-reactive protein Homo sapiens 70-73 27096102-7 2016 Regarding CRP and Alb, receiver operating characteristic curve analysis indicated that increased CRP level and decreased Alb level were significant predictors of toxic trough concentration of voriconazole. Voriconazole 192-204 C-reactive protein Homo sapiens 10-13 27096102-7 2016 Regarding CRP and Alb, receiver operating characteristic curve analysis indicated that increased CRP level and decreased Alb level were significant predictors of toxic trough concentration of voriconazole. Voriconazole 192-204 C-reactive protein Homo sapiens 97-100 27096102-11 2016 CONCLUSION: Coadministration of glucocorticoid and inflammation, reflected by elevated CRP level and hypoalbuminemia, are associated with voriconazole clearance. Voriconazole 138-150 C-reactive protein Homo sapiens 87-90 27096102-12 2016 We propose that early measurement of voriconazole concentration before the plateau phase will lead to avoidance of a toxic voriconazole level in patients with elevated CRP level and hypoalbuminemia, although further studies are needed to confirm our findings. Voriconazole 37-49 C-reactive protein Homo sapiens 168-171 27096102-12 2016 We propose that early measurement of voriconazole concentration before the plateau phase will lead to avoidance of a toxic voriconazole level in patients with elevated CRP level and hypoalbuminemia, although further studies are needed to confirm our findings. Voriconazole 123-135 C-reactive protein Homo sapiens 168-171 26997996-1 2016 The aim of the present study was to investigate the plasma levels of C-reactive protein (CRP) and copeptin, in addition to the acute physiology and chronic health evaluation II (APACHE II) scores, in patients with acute organophosphorus pesticide poisoning (AOPP). 3-(2-aminooxyphenyl)propanoic acid 258-262 C-reactive protein Homo sapiens 69-87 26997996-6 2016 On days 1, 3 and 7 after AOPP, the levels of CRP and copeptin were increased in correlation with the increase in AOPP severity, and were significantly higher compared with the control groups. 3-(2-aminooxyphenyl)propanoic acid 25-29 C-reactive protein Homo sapiens 45-48 26997996-6 2016 On days 1, 3 and 7 after AOPP, the levels of CRP and copeptin were increased in correlation with the increase in AOPP severity, and were significantly higher compared with the control groups. 3-(2-aminooxyphenyl)propanoic acid 113-117 C-reactive protein Homo sapiens 45-48 26997996-7 2016 Furthermore, elevated CRP and copeptin plasma levels were detected in patients with severe AOPP on day 7, whereas these levels were reduced in patients with mild or moderate AOPP. 3-(2-aminooxyphenyl)propanoic acid 91-95 C-reactive protein Homo sapiens 22-25 26610293-5 2016 Each 100% increase in 2-hydroxyphenanthrene was related to a 3.36% increase in uric acid (95% CI: 0.338-6.372; p=0.032), a 3.86% increase in GGT (95% CI: 1.361-6.362; p=0.005) and a 16.78% increase in CRP (95% CI: 1.848-31.689; p=0.029). Phenanthren-2-ol 22-43 C-reactive protein Homo sapiens 201-204 25074688-1 2015 OBJECTIVES: OSKIRA-4 evaluated the efficacy of fostamatinib monotherapy versus placebo on the signs and symptoms of rheumatoid arthritis over 6 weeks by Disease Activity Score C reactive protein (DAS-28(CRP)) and assessed non-inferiority to adalimumab monotherapy at Week 24 by DAS-28(CRP). fostamatinib 47-59 C-reactive protein Homo sapiens 176-194 25614125-9 2015 Plasma glutamine was linked to the ratio extracellular to body cell mass (p < 0.044), CRP (p < 0.001), physical (p = 0.014), affective (p = 0.041), and global fatigue (p = 0.030). Glutamine 7-16 C-reactive protein Homo sapiens 89-92 25618800-10 2015 RESULTS: Supplementation with curcuminoid-piperine combination significantly improved serum SOD activities (p < 0.001) and reduced MDA (p < 0.001) and CRP (p < 0.001) concentrations compared with placebo. curcuminoid-piperine 30-50 C-reactive protein Homo sapiens 157-160 26561012-9 2015 The levels of anandamide were independent and positively associated with the genotype AA position 385 of FAAH, C-reactive protein levels and body mass index. anandamide 14-24 C-reactive protein Homo sapiens 111-129 25862253-7 2015 CONCLUSIONS: The risk of rebleeding after BAE in active or inactive PTB was high, particularly in patients with tuberculous-destroyed lung, chronic liver disease, the use of anticoagulant agents and/or antiplatelet agents, elevated pre-BAE CRP, and the existence of fungal ball. N-Methyltrimethylacetamide 42-45 C-reactive protein Homo sapiens 240-243 25899092-1 2015 We aimed to investigate whether dietary intake of total or individual (n-3, n-6, and n-3:n-6 ratio) polyunsaturated fatty acids (PUFAs) was prospectively associated with serum levels of C-reactive protein (CRP), a marker of inflammation. Fatty Acids, Unsaturated 100-127 C-reactive protein Homo sapiens 186-204 25899092-1 2015 We aimed to investigate whether dietary intake of total or individual (n-3, n-6, and n-3:n-6 ratio) polyunsaturated fatty acids (PUFAs) was prospectively associated with serum levels of C-reactive protein (CRP), a marker of inflammation. Fatty Acids, Unsaturated 100-127 C-reactive protein Homo sapiens 206-209 25733507-3 2015 Here, we evaluated the influence of inflammation, marked by C-reactive protein (CRP) levels in blood, on the metabolism of voriconazole. Voriconazole 123-135 C-reactive protein Homo sapiens 60-78 25733507-3 2015 Here, we evaluated the influence of inflammation, marked by C-reactive protein (CRP) levels in blood, on the metabolism of voriconazole. Voriconazole 123-135 C-reactive protein Homo sapiens 80-83 25733507-4 2015 Observational data showed an association between CRP level and the ratio of voriconazole N-oxide to voriconazole. Voriconazole 76-88 C-reactive protein Homo sapiens 49-52 25461166-2 2015 The CRP detection has been carried out by monitoring the shift in Bragg wavelength (DeltalambdaB) of an etched FBG (eFBG) coated with an anti-CRP antibody (aCRP)-graphene oxide (GO) complex. efbg 116-120 C-reactive protein Homo sapiens 4-7 25461166-2 2015 The CRP detection has been carried out by monitoring the shift in Bragg wavelength (DeltalambdaB) of an etched FBG (eFBG) coated with an anti-CRP antibody (aCRP)-graphene oxide (GO) complex. efbg 116-120 C-reactive protein Homo sapiens 142-145 25461166-6 2015 The eFBG sensors show high specificity to CRP even in the presence of other interfering factors such as urea, creatinine and glucose. efbg 4-8 C-reactive protein Homo sapiens 42-45 25055995-0 2014 The in vitro effects of sodium salicylate on von Willebrand factor and C-reactive protein production by endothelial cells. Sodium Salicylate 24-41 C-reactive protein Homo sapiens 71-89 24981072-7 2014 In comparison with that of pSS patients without ILD, significantly higher levels of ESR, CRP, FIB, IgG, C3 and lower ALB were detected in pSS patients with ILD. pss 138-141 C-reactive protein Homo sapiens 89-92 25078741-10 2014 The US-CRP median was of 0.3 mg/L (range: 0.3 mg/L-6.8 mg/L), and it was positively and significantly correlated with BMI (ss = 0.226, p = 0.032) and LDL-C (ss = -0.267, p = 0.007) and negatively associated with cholesterol (ss = -0.267, p = 0.007). ldl-c 150-155 C-reactive protein Homo sapiens 7-10 24463788-8 2014 RESULTS: Statistically significant inverse associations of urinary lignan, enterodiol, and enterolactone concentrations with circulating CRP and WBC counts were observed in the multivariate-adjusted models: In NHANES 2005-2008, per one-percent increase in lignan concentrations in the urine, CRP concentrations and WBC counts decreased by 8.1 % (95 % CI -11.5, -4.5) and 1.9 % (95 % CI -2.7; -1.2), respectively. 2,3-bis(3'-hydroxybenzyl)butyrolactone 91-104 C-reactive protein Homo sapiens 137-140 24625997-4 2014 Serum uric acid (UA) and C-reactive protein levels decreased after allopurinol therapy (P = 0.00 and P = 0.04, respectively), but no change was observed in the control group during the study period. Allopurinol 67-78 C-reactive protein Homo sapiens 25-43 25816055-9 2015 Annual NOx concentration was also positively associated with levels of CRP (3.2%; 95% CI: 0.3, 6.1 per 20 mug/m3), but the effect estimate was more sensitive to model adjustments. Nitrogen Oxides 7-10 C-reactive protein Homo sapiens 71-74 25735646-8 2015 C-reactive protein (CRP) had a borderline influence and CL/F increased by more than 20% across the range of CRP measurements in the data set. Fluorine 59-60 C-reactive protein Homo sapiens 108-111 26150144-10 2015 In the COPD cohort, CRP was higher in patients with iron deficiency (median 10.5 vs 4.0 mg/L, p<0.001), who were also more hypoxaemic than their iron-replete counterparts (median resting SpO2 92% vs 95%, p<0.001), but haemoglobin concentration did not differ. spo2 190-194 C-reactive protein Homo sapiens 20-23 24578449-0 2014 Effect of perioperative glutamine administration on C-reactive protein and liver function tests in patients undergoing hepatic resection. Glutamine 24-33 C-reactive protein Homo sapiens 52-70 30086086-2 2018 This study evaluated the relationship between C-reactive protein (CRP; an inflammation marker) and the pharmacokinetics of perampanel. perampanel 123-133 C-reactive protein Homo sapiens 46-64 24578449-7 2014 RESULTS: Glutamine decreased the CRP response in liver resection in a statistically significant manner (p=0.028) on the fifth post operative day. Glutamine 9-18 C-reactive protein Homo sapiens 33-36 24578449-11 2014 CONCLUSION: Glutamine successfully blunted the CRP response in patients who received glutamine postoperatively. Glutamine 12-21 C-reactive protein Homo sapiens 47-50 24578449-11 2014 CONCLUSION: Glutamine successfully blunted the CRP response in patients who received glutamine postoperatively. Glutamine 85-94 C-reactive protein Homo sapiens 47-50 30086086-2 2018 This study evaluated the relationship between C-reactive protein (CRP; an inflammation marker) and the pharmacokinetics of perampanel. perampanel 123-133 C-reactive protein Homo sapiens 66-69 24973862-7 2015 Furthermore, a significant reduction in serum high sensitivity C-reactive protein (hs-CRP) levels was seen after omega-3 fatty acid supplementation compared with placebo (-236.3 +- 1541.9 vs. 898.6 +- 2292.7 ng/mL, P = 0.03). Fatty Acids, Omega-3 113-131 C-reactive protein Homo sapiens 63-81 24335710-8 2013 Interaction analysis showed that children who were overweight and obese who also had low concentrations of vitamin A had higher CRP and lower triglycerides (p < 0.1), children with low vitamin E had significantly lower glucose and triglycerides (p < 0.1) and higher low-density lipoprotein (LDL) concentrations (p < 0.05), and children with low zinc concentrations had higher insulin resistance compared with children with adequate weight (p < 0.05). Vitamin A 107-116 C-reactive protein Homo sapiens 128-131 30086086-3 2018 METHODS: Among 111 patients who underwent measurement of both CRP and perampanel, 23 patients had a serum CRP level exceeding 1.5 mg/dL (CRP-positive). perampanel 70-80 C-reactive protein Homo sapiens 106-109 30086086-3 2018 METHODS: Among 111 patients who underwent measurement of both CRP and perampanel, 23 patients had a serum CRP level exceeding 1.5 mg/dL (CRP-positive). perampanel 70-80 C-reactive protein Homo sapiens 106-109 30086086-8 2018 By multiple regression analysis, the CRP level was a significant independent determinant of the CD ratio of perampanel. perampanel 108-118 C-reactive protein Homo sapiens 37-40 30178473-7 2018 After accounting for the effects of steroids, CRP was higher in carbamazepine patients than in other patients. Carbamazepine 64-77 C-reactive protein Homo sapiens 46-49 25542532-7 2015 A higher CRP was correlated with a higher dose-normalized plasma concentration of voriconazole and a lower plasma concentration ratio of N-oxide to voriconazole. Voriconazole 82-94 C-reactive protein Homo sapiens 9-12 25542532-7 2015 A higher CRP was correlated with a higher dose-normalized plasma concentration of voriconazole and a lower plasma concentration ratio of N-oxide to voriconazole. Voriconazole 148-160 C-reactive protein Homo sapiens 9-12 30205424-6 2018 Pearson correlation analysis showed significant correlations between plasma hs-CRP and alpha-carotene and retinol concentrations. Vitamin A 106-113 C-reactive protein Homo sapiens 79-82 24595550-8 2015 Serum CRP levels did not differ significantly during the study period, although serum CRP levels in the TU-100 group tended to be lower than those in the placebo group in patients with grade B liver damage. Thiourea 104-106 C-reactive protein Homo sapiens 86-89 23786857-6 2015 In Cox regression models, urinary 15-keto-dihydro-PGF(2alpha) was significantly associated with cardiovascular mortality [multivariate hazard ratio (HR) for 1 SD increase of urinary 15-keto-dihydro-PGF(2alpha): 1.18; 95% CI:1.04-1.34; P = 0.01) independent of established cardiovascular risk factors including C-reactive protein. 15-keto-dihydro-pgf 34-53 C-reactive protein Homo sapiens 310-328 23897106-7 2013 CS-BCG was always lower than CS-mBCP (lower CS indicates superior nutritional status) in treated patients with persistently high CRP levels. Cesium 0-2 C-reactive protein Homo sapiens 129-132 23972896-9 2013 Urinary 1-hydroxypyrene, the biomarker of the higher molecular weight pyrene, was positively associated with total WBC count, and to lesser extent with serum CRP. 1-hydroxypyrene 8-23 C-reactive protein Homo sapiens 158-161 23302662-10 2013 Conversely, a DP reflecting a high n-6:n-3 fatty acid intake ratio was positively and significantly associated with elevated CRP (adjusted OR 1 15; 95% CI 1 00, 1 32). n-6 35-38 C-reactive protein Homo sapiens 125-128 23302662-10 2013 Conversely, a DP reflecting a high n-6:n-3 fatty acid intake ratio was positively and significantly associated with elevated CRP (adjusted OR 1 15; 95% CI 1 00, 1 32). Fatty Acids, Omega-3 39-53 C-reactive protein Homo sapiens 125-128 25592634-8 2015 Also, CRP levels strongly correlated with the value of PaO2/FiO2 ratio (r = -0.69, p < 0.001) and creatinine (r = 0.60, p < 0.001). fio2 60-64 C-reactive protein Homo sapiens 6-9 30205424-7 2018 After adjusting by sex, body mass index (BMI) and lipid levels, only the association with retinol remains significant, with children in the highest hs-CRP tertile group (hs-CRP >= 0.60 mg/dL) showing significantly lower levels of retinol than those from the tertiles 1 and 2. Vitamin A 90-97 C-reactive protein Homo sapiens 151-154 30205424-8 2018 A stepwise linear regression selected retinol, BMI, apo A-I and sex as predictors of hs-CRP levels, in a model explaining 19.2% of the variability of hs-CRP. Vitamin A 38-45 C-reactive protein Homo sapiens 88-91 24063213-9 2013 The serum CRP and MCP-1 levels were significantly higher in Group OBT, NOBT, and OBNT than in Group P (P < 0.05, P < 0.01). nobt 71-75 C-reactive protein Homo sapiens 10-13 23558443-8 2013 RESULTS: The highest quartile of genistein (OR = 0.62; 95 % CI 0.39-0.99) was associated with significantly decreased odds of high CRP compared with the lowest quartile. Genistein 33-42 C-reactive protein Homo sapiens 131-134 25130535-6 2014 RESULTS: Models showed that energy intake (Kcal) and age were positive predictors of CRP elevation while folate intake, total vitamin A intake, and serum retinol concentration were protective against CRP elevation. Vitamin A 154-161 C-reactive protein Homo sapiens 200-203 30205424-9 2018 In conclusion, in healthy prepubertal children, after adjusting by sex, BMI and lipid levels, hs-CRP concentrations were highly associated with plasma retinol, which is transported in blood bound to retinol-binding protein but were not associated with the lipoprotein-bound antioxidants. Vitamin A 151-158 C-reactive protein Homo sapiens 97-100 30205424-9 2018 In conclusion, in healthy prepubertal children, after adjusting by sex, BMI and lipid levels, hs-CRP concentrations were highly associated with plasma retinol, which is transported in blood bound to retinol-binding protein but were not associated with the lipoprotein-bound antioxidants. Vitamin A 199-206 C-reactive protein Homo sapiens 97-100 30140055-0 2018 Facile and inexpensive fabrication of zinc oxide based bio-surfaces for C-reactive protein detection. Zinc Oxide 38-48 C-reactive protein Homo sapiens 72-90 24498865-9 2014 After the treatment with allopurinol, colchicine and predonisolone, his symptoms were improved, and serum CRP and UA levels were normalized. Allopurinol 25-36 C-reactive protein Homo sapiens 106-109 25445629-1 2014 Various studies have demonstrated the impact of omega-3 fatty acids on the concentration of C reactive protein (CRP), pro-inflammatory eicosanoids, cytokines, chemokines and other inflammatory mediators. Fatty Acids, Omega-3 48-67 C-reactive protein Homo sapiens 92-110 25445629-1 2014 Various studies have demonstrated the impact of omega-3 fatty acids on the concentration of C reactive protein (CRP), pro-inflammatory eicosanoids, cytokines, chemokines and other inflammatory mediators. Fatty Acids, Omega-3 48-67 C-reactive protein Homo sapiens 112-115 23062489-6 2013 RESULTS: Treatment with sitagliptin significantly decreased fasting plasma glucose, hemoglobin A1c (HbA1c), serum levels of inflammatory markers, such as SAA-LDL, CRP, and TNF-alpha. Sitagliptin Phosphate 24-35 C-reactive protein Homo sapiens 163-166 29775873-8 2018 RESULTS: In both cohorts, inflammation as measured by higher levels of CRP, sVCAM1 and sICAM1 was associated with kynurenine/tryptophan ratio and thus enhanced tryptophan breakdown (beta: 0.145-0.429). Kynurenine 114-124 C-reactive protein Homo sapiens 71-74 23435396-10 2013 RESULTS: Two months of lercanidipine treatment showed significant decrease in BP, in WBC and PMNL counts, in PMNL apoptosis, in CRP and serum insulin levels and significant increase in serum albumin levels. lercanidipine 23-36 C-reactive protein Homo sapiens 128-131 30028484-4 2018 The present study aimed to evaluate the effects of an enteral diet containing ss-glucan on serum levels of IL-12 and highly-sensitive C-reactive protein (hs-CRP), occurrence of infection, and clinical outcomes in critically ill multiple-trauma patients. ss-glucan 78-87 C-reactive protein Homo sapiens 134-152 23148279-10 2013 CONCLUSIONS: Treatment with 25,000 IU/d vitamin A induced a mild elevation in serum lipids, CRP and liver enzymes in obese and non-obese women. Vitamin A 40-49 C-reactive protein Homo sapiens 92-95 24894662-0 2014 Biofunctionalized gold nanoparticle-conducting polymer nanocomposite based bioelectrode for CRP detection. Polymers 47-54 C-reactive protein Homo sapiens 92-95 25034387-8 2014 A significant inverse correlation was found between changes in glucagon-like peptide-1 (GLP-1) and changes in CRP levels (r=0.41, P=0.01) following sitagliptin therapy. Sitagliptin Phosphate 148-159 C-reactive protein Homo sapiens 110-113 29983927-8 2018 A progressive reduction in VO2 at peak exercise was significantly associated with both increasing American Society of Anesthesiology (ASA) grade (median, ml/kg/min: ASA 1 = 22, ASA 2 = 19, ASA 3 = 15, ASA 4 = 12, p = 0.014) and increasing mGPS (median, ml/kg/min: mGPS 0 = 18, mGPS 1 = 16, mGPS 2 = 14, p = 0.039) There was no significant association between either VO2 at the AT or peak exercise and postoperative CRP. vo2 27-30 C-reactive protein Homo sapiens 415-418 25099132-11 2014 Levels of C-reactive protein were associated with 3-HPMA levels in nonsmokers only. 3-hpma 50-56 C-reactive protein Homo sapiens 10-28 29567181-4 2018 After binding of the CRP and the AQ-2 Ab, the electrochemical signal response was measured using differential pulse voltammetry (DPV). diperoxovanadate 129-132 C-reactive protein Homo sapiens 21-24 29567181-5 2018 In the presence of CRP, the sensor exhibited a significant increase in the AQ current at AQ-2 Ab compared to the negative control. aq 75-77 C-reactive protein Homo sapiens 19-22 25935986-2 2014 In the assay, a CRP capture antibody was immobilized on magnetic beads and a CRP detection antibody was conjugated with single-stranded DNA (ssDNA) using N-[epsilon-maleimidocaproyloxy] sulfosuccinimide ester. n-[epsilon-maleimidocaproyloxy] sulfosuccinimide ester 154-208 C-reactive protein Homo sapiens 77-80 29570616-8 2018 Meta-analyses indicated significant reduction in CRP levels by omega-3 fatty acids (Random model effect: -0.667 mg/L, p < 0.001) and vitamin E (fixed model effect: -0.257 mg/L, p = 0.005). Fatty Acids, Omega-3 63-82 C-reactive protein Homo sapiens 49-52 24511127-9 2014 Thiosulfate beneficially associated with eGFR, serum acidity, high-sensitivity C-reactive protein, and N-terminal probrain natriuretic peptide (all P<=0.001). Thiosulfates 0-11 C-reactive protein Homo sapiens 79-97 24868216-0 2014 Predictive value of C-reactive protein in response to macrolides in children with macrolide-resistant Mycoplasma pneumoniae pneumonia. Macrolides 54-64 C-reactive protein Homo sapiens 20-38 24868216-0 2014 Predictive value of C-reactive protein in response to macrolides in children with macrolide-resistant Mycoplasma pneumoniae pneumonia. Macrolides 54-63 C-reactive protein Homo sapiens 20-38 28306482-0 2017 Serum C-reactive protein levels affect the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients. Voriconazole 50-62 C-reactive protein Homo sapiens 6-24 24868216-8 2014 The levels of serum C-reactive protein (CRP) and interleukin-18 in nasopharyngeal aspirate were significantly higher in patients who did not respond to macrolide treatment. Macrolides 152-161 C-reactive protein Homo sapiens 20-38 24868216-9 2014 CRP was the only significant factor in predicting the efficacy of macrolides in patients with MRMP pneumonia. Macrolides 66-76 C-reactive protein Homo sapiens 0-3 24505395-0 2014 Effect of marine-derived n-3 polyunsaturated fatty acids on C-reactive protein, interleukin 6 and tumor necrosis factor alpha: a meta-analysis. Fatty Acids, Omega-3 25-56 C-reactive protein Homo sapiens 60-78 29042430-7 2017 In the controls, the mean concentrations of high-sensitivity C-reactive protein, IL-6, and fibrinogen decreased with higher CVH status. cvh 124-127 C-reactive protein Homo sapiens 61-79 24505395-4 2014 Marine-derived n-3 PUFAs supplementation showed a lowering effect on Marine-derived n-3 PUFAs supplementation had a significant lowering effect on TNF-alpha, IL-6 and CRP in three groups of subjects (subjects with chronic non-autoimmune disease, subjects with chronic autoimmune disease and healthy subjects). Fatty Acids, Omega-3 15-24 C-reactive protein Homo sapiens 167-170 24505395-4 2014 Marine-derived n-3 PUFAs supplementation showed a lowering effect on Marine-derived n-3 PUFAs supplementation had a significant lowering effect on TNF-alpha, IL-6 and CRP in three groups of subjects (subjects with chronic non-autoimmune disease, subjects with chronic autoimmune disease and healthy subjects). Fatty Acids, Omega-3 84-93 C-reactive protein Homo sapiens 167-170 24505395-9 2014 CONCLUSIONS: Marine-derived n-3 PUFAs supplementation had a significant lowering effect on CRP, IL-6 and TNF-alpha level. Fatty Acids, Omega-3 28-37 C-reactive protein Homo sapiens 91-94 24561973-10 2014 Dietary unsaturated fatty acids is possibly associated with the production of a pro-coagulation factor without enhancing the secretion of pro-inflammatory molecules, while saturated fatty acids have no effect on activated plasminogen activator inhibitor 1, but their level is negatively associated with the inflammatory factor C-reactive protein. Fatty Acids, Unsaturated 8-31 C-reactive protein Homo sapiens 327-345 25159306-8 2014 RESULTS: The yields of DHT from 14C-testosterone showed 2-fold and 1.8-fold- inhibition in response to IL-6 and CRP respectively and 28% stimulation in response to Dox, via the 5-alpha reductase pathway. 14c-testosterone 32-48 C-reactive protein Homo sapiens 112-115 28646711-0 2017 Effect of memantine on C-reactive protein and lipid profiles in bipolar disorder. Memantine 10-19 C-reactive protein Homo sapiens 23-41 23701956-9 2013 HbA1c, fasting glucose and CRP levels show negative correlation with minimum SpO2 levels (by order of r=-.302, P=.018; r=-.368, P=.004; r=-.365, P=.004). spo2 77-81 C-reactive protein Homo sapiens 27-30 28646711-8 2017 In the high CRP (> 2322ng/mL) group, patients in the VPA + memantine arm had a significantly decreased in their CRP (p= 0.009), total cholesterol (p= 0.002), LDL (p= 0.002) levels, BMI (p= 0.001), and waist circumference (p< 0.001), compared to those in the VPA + placebo arm. Memantine 62-71 C-reactive protein Homo sapiens 12-15 28646711-8 2017 In the high CRP (> 2322ng/mL) group, patients in the VPA + memantine arm had a significantly decreased in their CRP (p= 0.009), total cholesterol (p= 0.002), LDL (p= 0.002) levels, BMI (p= 0.001), and waist circumference (p< 0.001), compared to those in the VPA + placebo arm. Memantine 62-71 C-reactive protein Homo sapiens 115-118 28646711-12 2017 CONCLUSIONS: BD patients with high initial CRP levels receiving memantine adjunct treatment have a reduced risk of inflammation and metabolic imbalance. Memantine 64-73 C-reactive protein Homo sapiens 43-46 28431362-0 2017 RNA aptamer-based electrochemical aptasensor for C-reactive protein detection using functionalized silica microspheres as immunoprobes. Silicon Dioxide 99-105 C-reactive protein Homo sapiens 49-67 23677577-6 2013 HRs for retinol and carotenoids were attenuated somewhat after adjustment for CRP. Vitamin A 8-15 C-reactive protein Homo sapiens 78-81 28431362-2 2017 In this study, a RNA aptamer-based electrochemical sandwich type aptasensor for CRP detection was described using the functionalized silica microspheres as immunoprobes. Silicon Dioxide 133-139 C-reactive protein Homo sapiens 80-83 23930336-7 2013 Advanced gestational age and elevated C-reactive protein (CRP > or = 5 mg/dL) were negatively associated with retinol concentration (p < 0.05). Vitamin A 113-120 C-reactive protein Homo sapiens 38-56 23930336-7 2013 Advanced gestational age and elevated C-reactive protein (CRP > or = 5 mg/dL) were negatively associated with retinol concentration (p < 0.05). Vitamin A 113-120 C-reactive protein Homo sapiens 58-61 28808571-3 2017 In addition, CRP may form a complex with oxidized low-density lipoprotein (oxLDL) via phosphatidylcholine, thus decreasing its pro-inflammatory effects within macrophages. Phosphatidylcholines 86-105 C-reactive protein Homo sapiens 13-16 23361365-2 2013 Several epidemiological studies have reported that dietary intake of n-3 polyunsaturated fatty acids (n-3 PUFAs) is inversely associated with serum CRP concentration. Fatty Acids, Omega-3 69-100 C-reactive protein Homo sapiens 148-151 23361365-2 2013 Several epidemiological studies have reported that dietary intake of n-3 polyunsaturated fatty acids (n-3 PUFAs) is inversely associated with serum CRP concentration. Fatty Acids, Omega-3 102-111 C-reactive protein Homo sapiens 148-151 27395328-10 2017 A plant-sourced pattern (beta-carotene, vitamin A, lutein and zeaxanthin) was inversely associated with CRP (p for trend across quartiles 0.005). Vitamin A 40-49 C-reactive protein Homo sapiens 104-107 23361365-4 2013 The aims of this study were to examine the effect of the n-3 PUFAs, docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA), on the modulation of IL-6-induced CRP expression and to explore its possible mechanisms. Fatty Acids, Omega-3 57-66 C-reactive protein Homo sapiens 163-166 28763896-1 2017 Objective: To investigate the relationship between serum uric acid (SUA) levels and high sensitive C-reactive protein (hs-CRP) in patients with type 2 diabetes mellitus (T2DM). sua 68-71 C-reactive protein Homo sapiens 99-117 23143351-5 2013 The GUCHD patients with serum TSH exceeding 5.6 mIU/L had a significantly higher level of serum NT-pro-BNP (195.1 [0.28; 5,280.3] vs 57.6 [0.00; 929.8]; p = 0.001) and CRP (0.30 [0.06; 1.87] vs 0.16 [0.00; 1.40]; p = 0.011] than those with a TSH level of 5.6 mIU/L or lower. nt-pro-bnp 96-106 C-reactive protein Homo sapiens 168-171 28076309-7 2017 IDO and kynurenine showed a strong positive correlation with markers of infection (procalcitonin) and inflammation (C-reactive protein) as well as sepsis and CAP severity scores. Kynurenine 8-18 C-reactive protein Homo sapiens 116-134 23432014-2 2013 CRP consisting of five identical, noncovalently linked subunits and having five phosphocholine-binding sites on the same face was complexed with 12-mercaptododecylphosphocholine. 12-mercaptododecylphosphocholine 145-177 C-reactive protein Homo sapiens 0-3 28107228-8 2017 Adjusted levels of F2-isoprostanes, and also of highly sensitive C-reactive protein, sCD14, and D-dimer were higher in individuals who developed serious NAEs, including or not non-AIDS deaths. naes 153-157 C-reactive protein Homo sapiens 65-83 31667003-0 2013 Relationship of Omega-3 Fatty Acids on C-Reactive Protein and Homocysteine in Haitian and African Americans with and without Type 2 Diabetes. Fatty Acids, Omega-3 16-35 C-reactive protein Homo sapiens 39-57 23234408-5 2013 The switch from SAFA diet to PUFA diet produced a significant change of CRP (C-reactive protein) concentration (p<0.01) whereas similar trend of IL-18 did not reach statistical significance. Fatty Acids, Unsaturated 29-33 C-reactive protein Homo sapiens 72-75 23234408-5 2013 The switch from SAFA diet to PUFA diet produced a significant change of CRP (C-reactive protein) concentration (p<0.01) whereas similar trend of IL-18 did not reach statistical significance. Fatty Acids, Unsaturated 29-33 C-reactive protein Homo sapiens 77-95 28209200-8 2017 CONCLUSIONS: Preoperative serum CRP level was a prognosticator in oral squamous cell carcinoma, and its effect was more prominent in buccal cancer that occurs more frequently in areca-quid (AQ) endemic regions. aq 190-192 C-reactive protein Homo sapiens 32-35 23599704-8 2012 Stepwise multiple regression analysis revealed that the percent change of the calcium-phosphorus product in the nondiabetic group and that of phosphorus in the diabetic group were predictive variables for the percent change of MDA-LDL/LDL, whereas the percent change of log high-sensitive C-reactive protein and that of systolic blood pressure in the nondiabetic group and that of diastolic blood pressure in the diabetic group were predictive variables for the percent change of plasma pentosidine. Phosphorus 142-152 C-reactive protein Homo sapiens 289-307 28166278-10 2017 Meanwhile, changes in acetic acid concentrations were negatively correlated with the levels of glycated hemoglobin and low-density lipoprotein cholesterol, whereas changes in valeric acid concentrations were positively correlated with the level of high sensitivity C-reactive protein and with white blood cell counts. n-pentanoic acid 175-187 C-reactive protein Homo sapiens 265-283 22810988-10 2012 Retinol+retinyl esters exhibited an inverse relationship with CRP and a positive relationship with uric acid and HOMA-IR as well as MetS binary outcome. Vitamin A 0-7 C-reactive protein Homo sapiens 62-65 22810988-13 2012 Vitamin E had no consistent association with MetS, whereas retinol+retinyl esters had a positive relationship with HOMA-IR, uric acid, and MetS, while being inversely related to CRP. Vitamin A 59-66 C-reactive protein Homo sapiens 178-181 24133911-8 2013 The PAB levels were positively correlated with the levels of CRP in patients (r = -0.606, p = 0.001). 4-Aminobenzoic Acid 4-7 C-reactive protein Homo sapiens 61-64 23338919-0 2013 Comment on: efficacy of omega-3 fatty acid supplementation on serum levels of tumour necrosis factor-alpha, C-reactive protein and interleukin-2 in type 2 diabetes mellitus patients. Fatty Acids, Omega-3 24-42 C-reactive protein Homo sapiens 108-126 24027600-1 2012 It has been reported that the oxidation of phosphatidylcholine (PC) is necessary for C-reactive protein (CRP) to bind to lipid membranes, but it remains elusive why CRP only binds oxidized membranes. Phosphatidylcholines 43-62 C-reactive protein Homo sapiens 85-103 24027600-1 2012 It has been reported that the oxidation of phosphatidylcholine (PC) is necessary for C-reactive protein (CRP) to bind to lipid membranes, but it remains elusive why CRP only binds oxidized membranes. Phosphatidylcholines 43-62 C-reactive protein Homo sapiens 105-108 24027600-1 2012 It has been reported that the oxidation of phosphatidylcholine (PC) is necessary for C-reactive protein (CRP) to bind to lipid membranes, but it remains elusive why CRP only binds oxidized membranes. Phosphatidylcholines 64-66 C-reactive protein Homo sapiens 85-103 24027600-1 2012 It has been reported that the oxidation of phosphatidylcholine (PC) is necessary for C-reactive protein (CRP) to bind to lipid membranes, but it remains elusive why CRP only binds oxidized membranes. Phosphatidylcholines 64-66 C-reactive protein Homo sapiens 105-108 26365744-8 2017 NIMC was characterized by longer duration of complaints, a higher rate of non-articular complaints, a lower rate of joint involvement and limping and lower levels of leukocytes, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). nimc 0-4 C-reactive protein Homo sapiens 219-237 22771801-6 2012 Pharmacological inhibition of phosphatidylinositol (PI)-3 kinase by wortmannin partially reversed the effects of CRP on adiponectin, TNF-alpha and leptin genes expression. Phosphatidylinositols 30-50 C-reactive protein Homo sapiens 113-116 22754038-11 2012 An independent association of OSA severity with CRP levels was found for minimum SaO2 only. sao2 81-85 C-reactive protein Homo sapiens 48-51 22119637-1 2012 PURPOSE: We previously demonstrated that converting patients from the enzyme-inducers phenytoin or carbamazepine to the non-inducers levetiracetam or lamotrigine reduces serum lipids and C-reactive protein (CRP). Carbamazepine 99-112 C-reactive protein Homo sapiens 187-205 22119637-1 2012 PURPOSE: We previously demonstrated that converting patients from the enzyme-inducers phenytoin or carbamazepine to the non-inducers levetiracetam or lamotrigine reduces serum lipids and C-reactive protein (CRP). Carbamazepine 99-112 C-reactive protein Homo sapiens 207-210 22982353-5 2012 CONCLUSION: The difference in CRP rise in CVR and OC users does not correspond with the effects on other markers of inflammation and is most likely due to a specific difference in the effect of ethinyl-estradiol combined with nestorone in cases with low CRP. Ethinyl Estradiol 194-211 C-reactive protein Homo sapiens 30-33 22982353-5 2012 CONCLUSION: The difference in CRP rise in CVR and OC users does not correspond with the effects on other markers of inflammation and is most likely due to a specific difference in the effect of ethinyl-estradiol combined with nestorone in cases with low CRP. Ethinyl Estradiol 194-211 C-reactive protein Homo sapiens 254-257 23114023-1 2012 UNLABELLED: RATIONALE: C-reactive protein (CRP) and lysophosphatidylcholine (LPC) are phosphorylcholine-(PC)-containing oxidized phospholipids (oxPLs) found in oxidized LDL (oxLDL), which trigger pro-atherogenic activities of macrophages during the process of atherosclerosis. oxpls 145-150 C-reactive protein Homo sapiens 24-42 23114023-1 2012 UNLABELLED: RATIONALE: C-reactive protein (CRP) and lysophosphatidylcholine (LPC) are phosphorylcholine-(PC)-containing oxidized phospholipids (oxPLs) found in oxidized LDL (oxLDL), which trigger pro-atherogenic activities of macrophages during the process of atherosclerosis. oxpls 145-150 C-reactive protein Homo sapiens 44-47 23114023-9 2012 CONCLUSIONS: The formation of complexes between CRP and PC-containing oxPLs, such as LPC, suppresses the pro-atherogenic effects of CRP and LPC on macrophages. oxpls 70-75 C-reactive protein Homo sapiens 48-51 23114023-9 2012 CONCLUSIONS: The formation of complexes between CRP and PC-containing oxPLs, such as LPC, suppresses the pro-atherogenic effects of CRP and LPC on macrophages. oxpls 70-75 C-reactive protein Homo sapiens 132-135 26365744-8 2017 NIMC was characterized by longer duration of complaints, a higher rate of non-articular complaints, a lower rate of joint involvement and limping and lower levels of leukocytes, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). nimc 0-4 C-reactive protein Homo sapiens 239-242 23023905-0 2012 Efficacy of omega-3 fatty acid supplementation on serum levels of tumour necrosis factor-alpha, C-reactive protein and interleukin-2 in type 2 diabetes mellitus patients. Fatty Acids, Omega-3 12-30 C-reactive protein Homo sapiens 96-114 23023905-2 2012 This study aimed to determine the effects of omega-3 fatty acid supplementation on the serum levels of C-reactive protein (CRP), interleukin (IL)-2 and tumour necrosis factor-alpha (TNF-alpha) in type 2 diabetes mellitus patients. Fatty Acids, Omega-3 45-63 C-reactive protein Homo sapiens 103-121 27601292-11 2017 This analysis showed that inflammation, reflected by CRP concentrations, significantly influenced the metabolic ratio, voriconazole trough concentration and voriconazole-N-oxide concentration (all P < 0.001), when corrected for other factors that could influence voriconazole metabolism. Voriconazole 119-131 C-reactive protein Homo sapiens 53-56 23023905-2 2012 This study aimed to determine the effects of omega-3 fatty acid supplementation on the serum levels of C-reactive protein (CRP), interleukin (IL)-2 and tumour necrosis factor-alpha (TNF-alpha) in type 2 diabetes mellitus patients. Fatty Acids, Omega-3 45-63 C-reactive protein Homo sapiens 123-126 27601292-11 2017 This analysis showed that inflammation, reflected by CRP concentrations, significantly influenced the metabolic ratio, voriconazole trough concentration and voriconazole-N-oxide concentration (all P < 0.001), when corrected for other factors that could influence voriconazole metabolism. Voriconazole 157-169 C-reactive protein Homo sapiens 53-56 28781892-2 2017 We investigated the association of serum TFAs with high sensitivity C-reactive protein (hs-CRP) and fibrinogen in adult Americans. Trans Fatty Acids 41-45 C-reactive protein Homo sapiens 68-86 22007031-8 2012 High-sensitivity C-reactive protein was positively correlated with SUA (r = .125, P < .001). sua 67-70 C-reactive protein Homo sapiens 17-35 29173690-1 2017 BACKGROUND: Studies have shown that omega-3 fatty acids reduce the concentrations of eicosanoids, cytokines, chemokines, C-reactive protein (CRP) and other inflammatory mediators. Fatty Acids, Omega-3 36-55 C-reactive protein Homo sapiens 121-139 22113248-0 2012 Association of serum n-3 polyunsaturated fatty acids with C-reactive protein in men. Fatty Acids, Omega-3 21-52 C-reactive protein Homo sapiens 58-76 29173690-1 2017 BACKGROUND: Studies have shown that omega-3 fatty acids reduce the concentrations of eicosanoids, cytokines, chemokines, C-reactive protein (CRP) and other inflammatory mediators. Fatty Acids, Omega-3 36-55 C-reactive protein Homo sapiens 141-144 27908356-0 2016 Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. dalcetrapib 15-26 C-reactive protein Homo sapiens 102-120 22643151-11 2012 CONCLUSION: CRP is extensively used in OOH services, especially by young and inexperienced doctors, and in central areas. OOH 39-42 C-reactive protein Homo sapiens 12-15 27370977-7 2016 RESULTS: The multivariate-adjusted geometric mean of serum CRP concentrations was significantly decreased with an increasing B vitamins intake across quartiles of niacin (P for trend = .007), pyridoxine (P for trend = .042), and cobalamin (P for trend = .037) in men. Vitamin B 12 229-238 C-reactive protein Homo sapiens 59-62 21804135-7 2012 Compared with patients in lower quartiles, patients in the highest CRP quartile had lower intakes (p < 0.05) of sodium (241 mg vs 404 mg), calcium (453 mg vs 702 mg), vitamin B2 (0.88 mg vs 1.20 mg), and particularly vitamin A (207 mug vs 522 mug). Vitamin A 220-229 C-reactive protein Homo sapiens 67-70 22375259-0 2012 Comparative Effects of Glibenclamide and Metformin on C-Reactive Protein and Oxidant/Antioxidant Status in Patients with Type II Diabetes Mellitus. Glyburide 23-36 C-reactive protein Homo sapiens 54-72 22375259-1 2012 OBJECTIVES: This study aimed to compare the effects of metformin and glibenclamide on high sensitivity serum C-reactive protein (hs-CRP) and oxidative stress, represented by serum malondialdehyde (MDA) and total antioxidant status (TAS) in newly-diagnosed patients with Type 2 diabetes mellitus (DM) at baseline and after 2 months of therapy in comparison to controls. Glyburide 69-82 C-reactive protein Homo sapiens 109-127 22108347-0 2012 Ursolic acid suppresses IL-6 induced C-reactive protein expression in HepG2 and protects HUVECs from injury induced by CRP. ursolic acid 0-12 C-reactive protein Homo sapiens 37-55 27370977-8 2016 In men, the mean serum CRP concentrations in the highest quartiles of niacin, pyridoxine, and cobalamin were 63%, 38%, and 58%, respectively, lower than that in the lowest quartile. Vitamin B 12 94-103 C-reactive protein Homo sapiens 23-26 22108347-0 2012 Ursolic acid suppresses IL-6 induced C-reactive protein expression in HepG2 and protects HUVECs from injury induced by CRP. ursolic acid 0-12 C-reactive protein Homo sapiens 119-122 27370977-10 2016 CONCLUSION: High intake of niacin, pyridoxine, or cobalamin was independently associated with decreased serum CRP concentrations among HIV-infected men. Vitamin B 12 50-59 C-reactive protein Homo sapiens 110-113 22108347-1 2012 OBJECTIVE: To investigate the inhibitory effects of ursolic acid (UA) on the expression of C-reactive protein (CRP) induced by IL-6 in HepG2 cells and the protective effects on the CRP-induced injury to human umbilical vein endothelial cells (HUVECs). ursolic acid 52-64 C-reactive protein Homo sapiens 91-109 27203463-8 2016 Furthermore, by employing C-reactive protein as a model, we successfully demonstrated that the new water-swellable polymer-based ICA sensor can be utilized to detect biologically relevant analytes in human serum. Polymers 115-122 C-reactive protein Homo sapiens 26-44 22108347-1 2012 OBJECTIVE: To investigate the inhibitory effects of ursolic acid (UA) on the expression of C-reactive protein (CRP) induced by IL-6 in HepG2 cells and the protective effects on the CRP-induced injury to human umbilical vein endothelial cells (HUVECs). ursolic acid 52-64 C-reactive protein Homo sapiens 111-114 22108347-1 2012 OBJECTIVE: To investigate the inhibitory effects of ursolic acid (UA) on the expression of C-reactive protein (CRP) induced by IL-6 in HepG2 cells and the protective effects on the CRP-induced injury to human umbilical vein endothelial cells (HUVECs). ursolic acid 66-68 C-reactive protein Homo sapiens 91-109 22108347-1 2012 OBJECTIVE: To investigate the inhibitory effects of ursolic acid (UA) on the expression of C-reactive protein (CRP) induced by IL-6 in HepG2 cells and the protective effects on the CRP-induced injury to human umbilical vein endothelial cells (HUVECs). ursolic acid 66-68 C-reactive protein Homo sapiens 111-114 27669975-7 2016 Plasma 3-hydroxykynurenine concentrations correlated with contemporaneous APACHE II scores (R2 = 0.273; Spearman rho = 0.581; P < 0.001) and CRP (R2 = 0.132; Spearman rho = 0.455, P < 0.001). 3-hydroxykynurenine 7-26 C-reactive protein Homo sapiens 144-147 22108347-7 2012 RESULT: IL-6 can significantly increase CRP protein and mRNA expression in HepG2 cells, and this effect of IL-6 can be decreased by UA (6.25, 12.5, 25 mumol/L) markedly in a dose-dependent manner. ursolic acid 132-134 C-reactive protein Homo sapiens 40-43 22235107-9 2012 The C-reactive protein/albumin ratio was higher (P < .05) in controls than in CHO and GLN groups. Glutamine 89-92 C-reactive protein Homo sapiens 4-22 27418594-6 2016 Treatment with dalcetrapib resulted in placebo-adjusted geometric mean percent increases in high-sensitivity C-reactive protein from baseline to end of trial of 18.1% (P=0.0009) and 18.7% (P=0.00001) in participants with the GG and AG genotypes, respectively, but the change was -1.0% (P=0.89) in those with the protective AA genotype. dalcetrapib 15-26 C-reactive protein Homo sapiens 109-127 22088801-7 2012 RESULTS: Age- and hysterectomy-adjusted regression models suggest that CRP level is positively associated with LH/FSH ratio and LH/FSH>1, high glucose level and LH/FSH>2 are inversely related and HDL<50mg/dL is positively associated with both LH/FSH>1 and LH/FSH>2. Luteinizing Hormone 111-113 C-reactive protein Homo sapiens 71-74 22088801-7 2012 RESULTS: Age- and hysterectomy-adjusted regression models suggest that CRP level is positively associated with LH/FSH ratio and LH/FSH>1, high glucose level and LH/FSH>2 are inversely related and HDL<50mg/dL is positively associated with both LH/FSH>1 and LH/FSH>2. Luteinizing Hormone 128-130 C-reactive protein Homo sapiens 71-74 27418594-10 2016 CONCLUSIONS: Genotype-dependent effects on C-reactive protein and cholesterol efflux are supportive of dalcetrapib benefits on atherosclerotic cardiovascular outcomes in patients with the AA genotype at polymorphism rs1967309. dalcetrapib 103-114 C-reactive protein Homo sapiens 43-61 21871820-7 2011 Receiver operating characteristic curve analysis for detecting BOS showed the largest area under the curve for KL-6 compared with lactate dehydrogenase, C-reactive protein, or neutrophils percentage in BALF. N-[4-(Aminosulfonyl)phenyl]-2-Mercaptobenzamide 63-66 C-reactive protein Homo sapiens 153-171 27150702-3 2016 In this study, a label-free optical biosensor, polymer-based two-dimensional photonic crystal (2D-PhC) film fabricated using nanoimprint lithography (NIL), was developed for detection of C-reactive protein (CRP) in human serum. Polymers 47-54 C-reactive protein Homo sapiens 187-205 21640381-5 2011 In HepG2 cells, ER stress triggered by tunicamycin, thapsigargin and homocysteine markedly induced CRP expression and the activation of protein kinase R-like endoplasmic reticulum kinase (PERK), inositol-requiring transmembrane kinase/endonuclease 1alpha (IRE1alpha), activating transcription factor 6 (ATF6), and hepatocyte-specific cyclic AMP response element binding protein H (CREBH). Tunicamycin 39-50 C-reactive protein Homo sapiens 99-102 21349512-5 2011 In multivariable linear regression models, we observed significant positive associations between CRP and mono-benzyl phthalate (MBzP) and mono-isobutyl phthalate (MiBP). mono-isobutyl phthalate 163-167 C-reactive protein Homo sapiens 97-100 21349512-6 2011 There were CRP elevations of 6.0% (95% confidence interval (CI) 1.7-10.8%) and 8.3% (95% CI 2.9-14.0%) in relation to interquartile range (IQR) increases in urinary MBzP and MiBP, respectively. mono-isobutyl phthalate 174-178 C-reactive protein Homo sapiens 11-14 27150702-3 2016 In this study, a label-free optical biosensor, polymer-based two-dimensional photonic crystal (2D-PhC) film fabricated using nanoimprint lithography (NIL), was developed for detection of C-reactive protein (CRP) in human serum. Polymers 47-54 C-reactive protein Homo sapiens 207-210 26778547-1 2016 OBJECTIVE: A direct, inverse correlation between 25-hydroxy vitamin D (25(OH) vitamin D) levels and C-reactive protein (CRP), a sensitive biomarker for inflammation, was found in some, but not all, studies. 25(oh) vitamin d 71-87 C-reactive protein Homo sapiens 100-118 26778547-1 2016 OBJECTIVE: A direct, inverse correlation between 25-hydroxy vitamin D (25(OH) vitamin D) levels and C-reactive protein (CRP), a sensitive biomarker for inflammation, was found in some, but not all, studies. 25(oh) vitamin d 71-87 C-reactive protein Homo sapiens 120-123 21479867-6 2011 At time 1, significant inverse correlations with the CS were found for glycaemia (P = 0.007), triglycerides (P = 0.05), ESR (P = 0.017) and CRP (P = 0.013). Cesium 53-55 C-reactive protein Homo sapiens 140-143 26778547-9 2016 It was shown that increasing 25(OH) vitamin D levels are associated with decreasing CRP levels, with a stronger effect in the inflammatory disease group compared to the non-inflammatory disease group. 25(oh) vitamin d 29-45 C-reactive protein Homo sapiens 84-87 21543294-6 2011 Effect of n-3 polyunsaturated fatty acids on inflammation was evaluated with high sensitivity C-reactive protein level measurements. Fatty Acids, Omega-3 10-41 C-reactive protein Homo sapiens 94-112 26778547-10 2016 CONCLUSIONS: Our study shows an inverse correlation between 25(OH) vitamin D and CRP in a large patient cohort but more importantly shows that this effect is more pronounced in patients with inflammatory diseases compared to patients with non-inflammatory diseases. 25(oh) vitamin d 60-76 C-reactive protein Homo sapiens 81-84 20727556-0 2011 Palmitate induces C-reactive protein expression in human aortic endothelial cells. Palmitates 0-9 C-reactive protein Homo sapiens 18-36 26908433-6 2016 Saturated fat intake was associated with increased CRP, sTNFRII, TNFalpha, and IL1beta, whereas eicosapentaenoic acid + docosahexaenoic acid (EPA+DHA) intake (diet or total) was associated with decreased CRP, TNFalpha, and IL1beta. Fatty Acids, Omega-3 0-13 C-reactive protein Homo sapiens 51-54 20727556-3 2011 In this study, we examined the effect of palmitate (PA) on endothelial C-reactive protein (CRP) expression and the role of CRP in PA-induced nitric oxide (NO) inhibition. Palmitates 52-54 C-reactive protein Homo sapiens 71-89 20727556-4 2011 Palmitate increased, in a dose-dependent manner, CRP protein expression and production in human aortic endothelial cells (HAECs). Palmitates 0-9 C-reactive protein Homo sapiens 49-52 20727556-7 2011 Palmitate-treated HAECs showed increased CRP messenger RNA expression and nuclear factor (NF)-kappaB activation. Palmitates 0-9 C-reactive protein Homo sapiens 41-44 20727556-8 2011 Induction of CRP expression by PA was prevented by antioxidants and normalized by PKC and mitogen-activated protein kinase inhibitors. Palmitates 31-33 C-reactive protein Homo sapiens 13-16 20727556-9 2011 Disrupting NF-kappaB and Janus kinase/signal transducers and activators of transcription pathways or inducing AMPK activation also suppressed the stimulatory effect of PA on CRP messenger RNA expression. Palmitates 168-170 C-reactive protein Homo sapiens 174-177 20727556-10 2011 Finally, in HAECs, PA reduced NO release, an effect reversed by anti-CRP antibody. Palmitates 19-21 C-reactive protein Homo sapiens 69-72 20727556-11 2011 These data demonstrate that PA-induced endothelial CRP expression involves PKC-driven oxidative stress, possibly through AMPK inhibition, and activation of downstream redox-sensitive signaling pathways, including NF-kappaB. Palmitates 28-30 C-reactive protein Homo sapiens 51-54 20727556-12 2011 They further support a role for endothelial cell-derived CRP as mediator of the suppressive effect of PA on NO production. Palmitates 102-104 C-reactive protein Homo sapiens 57-60 26728928-0 2016 The Associations of C-Reactive Protein with Serum Levels of Polyunsaturated Fatty Acids and Trans Fatty Acids Among Middle-Aged Men from Three Populations. Fatty Acids, Unsaturated 60-87 C-reactive protein Homo sapiens 20-38 21661448-4 2011 RESULTS: The serum CRP level was significantly higher in the ODG group than in the LADG group (p=0.007) on postoperative day (POD) 1. BMP15 protein, human 61-64 C-reactive protein Homo sapiens 19-22 26728928-0 2016 The Associations of C-Reactive Protein with Serum Levels of Polyunsaturated Fatty Acids and Trans Fatty Acids Among Middle-Aged Men from Three Populations. Trans Fatty Acids 92-109 C-reactive protein Homo sapiens 20-38 26728928-7 2016 Whites had significant inverse trends between CRP and tertiles of total n-6 FAs (GM 1.20, 0.91 and 0.80; p=0.002) and marine-derived n-3 FAs (GM 1.22, 1.00 and 0.72; p<0.001) but a significant positive trend with TFAs (GM 0.80, 0.95 and 1.15; p=0.007). Trans Fatty Acids 216-220 C-reactive protein Homo sapiens 46-49 26728928-9 2016 Japanese Americans had CRP associations with n-3 FAs, n-6 FAs, and TFAs similar to but weaker than Whites. Trans Fatty Acids 67-71 C-reactive protein Homo sapiens 23-26 26613035-7 2015 The lowest quintile of sMg was positively associated with lower serum potassium and albumin levels, higher C-reactive protein (CRP) levels and prevalence of atrial fibrillation and cerebrovascular disease than the other quintiles. N-SUCCINYL METHIONINE 23-26 C-reactive protein Homo sapiens 107-125 19702697-5 2010 Also ESR and CRP and neopterin concentrations were increased in the patients (all P < 0.001), and there was a weak correlation between kynurenine to tryptophan ratio and ESR, CRP and neopterin concentrations. Kynurenine 138-148 C-reactive protein Homo sapiens 178-181 26613035-7 2015 The lowest quintile of sMg was positively associated with lower serum potassium and albumin levels, higher C-reactive protein (CRP) levels and prevalence of atrial fibrillation and cerebrovascular disease than the other quintiles. N-SUCCINYL METHIONINE 23-26 C-reactive protein Homo sapiens 127-130 26571421-6 2015 RESULTS: Allopurinol-treated subjects showed a reduction in serum uric acid in association with improvement in fasting blood glucose, fasting insulin, and HOMA-IR index, as well as a reduction in serum high-sensitivity C-reactive protein. Allopurinol 9-20 C-reactive protein Homo sapiens 219-237 20709978-9 2010 The percentage of the C-reactive protein-positive birds was higher (P < 0.05) in the HS group compared with the TN group. tn 115-117 C-reactive protein Homo sapiens 22-40 26585447-10 2015 The predictors for frequent CRP use in OOH services were being a young doctor, having many consultations with children during OOH and a frequent use of CRP in daytime services. OOH 39-42 C-reactive protein Homo sapiens 28-31 20538833-7 2010 RESULTS: Serum uric acid and C-reactive protein levels were significantly decreased in subjects treated with allopurinol. Allopurinol 109-120 C-reactive protein Homo sapiens 29-47 20538833-9 2010 Allopurinol treatment slowed down renal disease progression independently of age, gender, diabetes, C-reactive protein, albuminuria, and renin-angiotensin system blockers use. Allopurinol 0-11 C-reactive protein Homo sapiens 100-118 20538833-13 2010 CONCLUSIONS: Allopurinol decreases C-reactive protein and slows down the progression of renal disease in patients with chronic kidney disease. Allopurinol 13-24 C-reactive protein Homo sapiens 35-53 26585447-10 2015 The predictors for frequent CRP use in OOH services were being a young doctor, having many consultations with children during OOH and a frequent use of CRP in daytime services. OOH 39-42 C-reactive protein Homo sapiens 152-155 26585447-10 2015 The predictors for frequent CRP use in OOH services were being a young doctor, having many consultations with children during OOH and a frequent use of CRP in daytime services. OOH 126-129 C-reactive protein Homo sapiens 28-31 26585447-11 2015 CONCLUSIONS: The increase in the frequency of CRP test use from daytime to OOH occurs in general for RGPs and for all most used diagnoses. OOH 75-78 C-reactive protein Homo sapiens 46-49 26585447-12 2015 The RGPs who use the CRP test most frequently in their daytime practice have the highest rate of CRP in OOH services. OOH 104-107 C-reactive protein Homo sapiens 21-24 20414684-10 2010 We demonstrated that, in HT children and adolescents, increased SUA with a parallel increase in hs-CRP and PLTs with MPV is observed. sua 64-67 C-reactive protein Homo sapiens 99-102 26585447-12 2015 The RGPs who use the CRP test most frequently in their daytime practice have the highest rate of CRP in OOH services. OOH 104-107 C-reactive protein Homo sapiens 97-100 26376895-6 2015 RESULTS: The pooled HRs of elevated preoperative CRP for earlier stage patients were 2.04 (95% CI 1.45-2.86) for OS, 4.37 (95% CI 2.63-7.27) for CSS, and 1.88 (95% CI 0.97-3.67) for DFS. aspartyl-phenylalanine 182-185 C-reactive protein Homo sapiens 49-52 20415446-6 2010 A significant shift in CRP binding affinity was observed when substrates were assembled in the presence of Cs(+) rather than K(+). Cesium 107-112 C-reactive protein Homo sapiens 23-26 22536073-13 2012 CONCLUSION: "Directly observed treatment" with an omega-3 based supplement (as opposed to a pure protein supplement) showed beneficial effects on the lipid profile, and C-reactive protein levels. Fatty Acids, Omega-3 50-57 C-reactive protein Homo sapiens 169-187 21301856-0 2011 Erythrocyte membrane phospholipid polyunsaturated fatty acids are related to plasma C-reactive protein and adiponectin in middle-aged German women and men. Fatty Acids, Unsaturated 34-61 C-reactive protein Homo sapiens 84-102 21303966-12 2011 In the presence of the PI-3 kinase inhibitor LY294002, the ability of CRP to suppress caspase-3 activity was significantly reduced. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 C-reactive protein Homo sapiens 70-73 19814835-9 2010 The results of the present pilot study suggest that enteral nutrition enriched with glutamine and antioxidants possibly moderates the immuno-inflammatory response (CRP, TNF-R75) after surgery. Glutamine 84-93 C-reactive protein Homo sapiens 164-167 19836015-3 2010 In adjusted logistic regressions, two OH-PAHs, 2-hydroxyphenanthrene and 9-hydroxyfluorene, were associated with elevated CRP (>3mg/l). Phenanthren-2-ol 47-68 C-reactive protein Homo sapiens 122-125 19836015-6 2010 Intermediate levels of 2-hydroxyphenanthrene (49-148ng/g creatinine), and 9-hydroxyfluorene (161-749ng/g creatinine) were also significantly associated with elevated CRP compared to the respective reference categories. Phenanthren-2-ol 23-44 C-reactive protein Homo sapiens 166-169 26081056-9 2015 BISAP scores were positively correlated with CRP, D-dimer and serum glucose (r = 0.451, 0.329, 0.241, P < 0.01) and negatively correlated with serum calcium ((r = -0.315, P < 0.01). bisap 0-5 C-reactive protein Homo sapiens 45-48 20032440-10 2009 A significant correlation was observed between CRP and high-density lipoprotein cholesterol, retinol, ferritin, and CEA. Vitamin A 93-100 C-reactive protein Homo sapiens 47-50 22097096-8 2011 The CRP levels greater than 6.2, had a direct statistically significant correlation with duration of hemodialysis and phosphorus level (p = 0.01). Phosphorus 118-128 C-reactive protein Homo sapiens 4-7 22097096-9 2011 Also, CRP levels above 10 mg L(-1) had a direct statistically significant correlation with age and phosphorus levels (p = 0.02). Phosphorus 99-109 C-reactive protein Homo sapiens 6-9 22097096-10 2011 According to the prevalence of high CRP level and it"s correlation with age, duration ofhemodialysis and phosphorus level in hemodialysis patients, CRP level should be screened in this group of patients routinely because of its prognostic importance. Phosphorus 105-115 C-reactive protein Homo sapiens 36-39 22097096-10 2011 According to the prevalence of high CRP level and it"s correlation with age, duration ofhemodialysis and phosphorus level in hemodialysis patients, CRP level should be screened in this group of patients routinely because of its prognostic importance. Phosphorus 105-115 C-reactive protein Homo sapiens 148-151 19471295-9 2009 In a multiple regression analysis, after adjustment for CRP, low vitamin A (beta=3.2, 95%CI (confidence interval) 1.6-4.9, P=0.000) but not zinc, correlated with the severity of TB. Vitamin A 65-74 C-reactive protein Homo sapiens 56-59 26247306-4 2015 RESULTS: In low SUA group, SUA levels directly correlated with creatinine, body mass index, waist circumference, blood pressure, glucose and insulin levels, triglyceride and C-reactive protein levels. sua 16-19 C-reactive protein Homo sapiens 174-192 26247306-4 2015 RESULTS: In low SUA group, SUA levels directly correlated with creatinine, body mass index, waist circumference, blood pressure, glucose and insulin levels, triglyceride and C-reactive protein levels. sua 27-30 C-reactive protein Homo sapiens 174-192 19185299-5 2009 RESULTS: After multivariable adjustment, n-3 fatty acid levels (DHA+EPA) were inversely associated with CRP and IL-6. Fatty Acids, Omega-3 41-55 C-reactive protein Homo sapiens 104-107 21306998-5 2011 C-reactive protein (CRP) was also significantly higher in group A (P < .001) and correlated significantly with SUA in both groups (group A: r(s) = .93, P < .001; group B: r(s) = .87, P < .001). sua 114-117 C-reactive protein Homo sapiens 0-18 21306998-5 2011 C-reactive protein (CRP) was also significantly higher in group A (P < .001) and correlated significantly with SUA in both groups (group A: r(s) = .93, P < .001; group B: r(s) = .87, P < .001). sua 114-117 C-reactive protein Homo sapiens 20-23 26247306-5 2015 In high SUA group, SUA levels directly correlated with body weight, triglyceride, C-reactive protein, and inversely correlated with HDL-cholesterol concentrations. sua 8-11 C-reactive protein Homo sapiens 82-100 21437516-9 2011 Using a backward conditional logistic regression model, age (p<0.001), diabetes (p= 0.001), and C-reactive protein levels >6 mg/L (p= 0.006) were associated with the presence of low AAI, whereas male gender (p<0.001), diabetes (p= 0.001) and elevated calcium x phosphorus product (p= 0.026) were associated with high AAI. Phosphorus 270-280 C-reactive protein Homo sapiens 99-117 19185299-6 2009 The inverse association of n-3 fatty acids with CRP and IL-6 was not modified by demographics, body-mass index, smoking, LDL-cholesterol, or statin use (p values for interaction>0.1). Fatty Acids, Omega-3 27-42 C-reactive protein Homo sapiens 48-51 19425005-0 2009 Investigation of C-reactive protein binding to phosphatidyl choline by CZE and ESI-mass analysis. Phosphatidylcholines 47-67 C-reactive protein Homo sapiens 17-35 26247306-5 2015 In high SUA group, SUA levels directly correlated with body weight, triglyceride, C-reactive protein, and inversely correlated with HDL-cholesterol concentrations. sua 19-22 C-reactive protein Homo sapiens 82-100 25170056-6 2015 Multivariate analysis revealed that an elevated erythrocyte sedimentation rate, reduced serum albumin, CD activity index (CDAI) >220, and ileocolonic/colonic location were associated with an elevated CRP level and that the CRP level was significantly correlated with the CDAI in all CD patients (gamma=0.466, p<0.01). cdai 122-126 C-reactive protein Homo sapiens 203-206 19347930-4 2009 PDMP in the active PM/DM patients correlated significantly with serum C-reactive protein levels (r(s) = 0.67, P = 0.01). RV 538 0-4 C-reactive protein Homo sapiens 70-88 21346065-9 2011 In the clinical study, when compared with placebo, hesperidin treatment increased flow-mediated dilation (10.26 +- 1.19 vs. 7.78 +- 0.76%; P = 0.02) and reduced concentrations of circulating inflammatory biomarkers (high-sensitivity C-reactive protein, serum amyloid A protein, soluble E-selectin). Hesperidin 51-61 C-reactive protein Homo sapiens 233-251 25223994-8 2014 Linear regression analyses, both unadjusted and adjusted for covariates of gender, age, dose, route of administration, liver enzymes, and interacting coadministered medications, showed a significant association between voriconazole and CRP concentration (P < 0.001). Voriconazole 219-231 C-reactive protein Homo sapiens 236-239 21329621-7 2011 In the third experiment, the effects of benzbromarone on IL1beta-induced CRP expression were determined in HuH7 cells. Benzbromarone 40-53 C-reactive protein Homo sapiens 73-76 21329621-8 2011 RESULTS: Log serum CRP levels were not significantly different between the patients with gout and healthy subjects, while log serum CRP levels were decreased by 11% after benzbromarone treatment, as compared to the values before treatment (p < 0.01). Benzbromarone 171-184 C-reactive protein Homo sapiens 132-135 21329621-10 2011 Furthermore, our in vitro findings demonstrated that benzbromarone down-regulated IL1beta-stimulated CRP gene expression. Benzbromarone 53-66 C-reactive protein Homo sapiens 101-104 21329621-11 2011 CONCLUSIONS: These results suggest that hyperuricemia may not contribute to an increase in serum CRP level, while benzbromarone may have a favorable effect on CRP. Benzbromarone 114-127 C-reactive protein Homo sapiens 159-162 19215278-7 2009 RBP-to-retinol ratio correlated positively with glucose 2 h after an oral glucose tolerance test (p < 0.0001) and with C-reactive protein (p < 0.001). Vitamin A 7-14 C-reactive protein Homo sapiens 122-140 19075028-3 2009 The expression of soluble heat-labile toxin is subject to catabolite (glucose) activation, and three binding sites for cAMP receptor protein (CRP or CAP) were identified upstream and within the toxin promoter by DNase I footprinting. catabolite 58-68 C-reactive protein Homo sapiens 119-152 18343384-0 2008 Dietary intake of n-3 polyunsaturated fatty acids is inversely associated with CRP levels, especially among male smokers. Fatty Acids, Omega-3 18-49 C-reactive protein Homo sapiens 79-82 18343384-1 2008 OBJECTIVE: To examine whether dietary intake of n-3 polyunsaturated fatty acid (n-3PUFA) is associated with serum C-reactive protein (CRP) levels with regard to smoking status in the Japanese general population in a cross-sectional study. Fatty Acids, Omega-3 48-78 C-reactive protein Homo sapiens 114-132 18343384-1 2008 OBJECTIVE: To examine whether dietary intake of n-3 polyunsaturated fatty acid (n-3PUFA) is associated with serum C-reactive protein (CRP) levels with regard to smoking status in the Japanese general population in a cross-sectional study. Fatty Acids, Omega-3 48-78 C-reactive protein Homo sapiens 134-137 18854284-0 2008 Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy. Thalidomide 142-153 C-reactive protein Homo sapiens 6-24 18854284-9 2008 CONCLUSION: Serum C-reactive protein before therapy and response after therapy are the only factors useful in identifying patients benefiting from anthracycline/thalidomide-based therapy. Thalidomide 161-172 C-reactive protein Homo sapiens 18-36 21396307-10 2011 Moreover, a significant lower serum C-reactive protein level was detected in glutamine-enriched TPN compared with standard TPN (P = 0.013). Glutamine 77-86 C-reactive protein Homo sapiens 36-54 21941527-5 2011 There was also a significant positive correlation between SUA and CRP in both groups (group A: r(s) = 0.947, P < 0.001; group B: r(s) = 0.848, P < 0.001). sua 58-61 C-reactive protein Homo sapiens 66-69 25223994-9 2014 For every 1-mg/liter increase in the CRP concentration, the voriconazole trough concentration increased by 0.015 mg/liter (unadjusted 95% confidence interval [CI], 0.011 to 0.020 mg/liter; adjusted 95% CI, 0.011 to 0.019 mg/liter). Voriconazole 60-72 C-reactive protein Homo sapiens 37-40 18413218-5 2008 Diabetic subjects formerly in the DCCT intensive treatment group had higher CRP levels than those who were randomized to the conventional treatment group [1.8 (1.6-1.9), n=479 vs. 1.5 (1.3-1.6), n=456, P=.010], attributable to greater BMI in the prior intensive group. dcct 34-38 C-reactive protein Homo sapiens 76-79 25223994-10 2014 Inflammation, reflected by the C-reactive protein concentration, is associated with voriconazole trough concentrations. Voriconazole 84-96 C-reactive protein Homo sapiens 31-49 18299144-5 2008 CONCLUSION: In elderly AMI patients the concomitant elevation of CRP and tHcy, associated with folate and vitamin B12 low levels, could be considered a significant predictive heart mortality risk factor. Vitamin B 12 106-117 C-reactive protein Homo sapiens 65-68 25364242-8 2014 Male sex, age, former smoking with a history of >= 10 pack-years, body mass index >= 30 kg/m(2), and C-reactive protein >= 5 mg/L were also significantly associated with an SpO2 decrease. spo2 182-186 C-reactive protein Homo sapiens 107-125 18379184-10 2008 Aztreonam and ciprofloxacin were then intravenously administered at doses of 4 g/day and 600 mg/day, respectively, resulting in the alleviation of fever in the patient as well as a decrease in CRP and disappearance of MDRP isolates from urine on day 67; that is, MDRP infection was consequently well controlled. Aztreonam 0-9 C-reactive protein Homo sapiens 193-196 21370577-4 2011 Intravenous methylprednisolone sodium succinate (500 mg/day for three days)therapy and oral prednisolone (40 mg/day) improved her fever, hematuria, serum CRP and MPO-ANCA titer. Methylprednisolone Hemisuccinate 12-47 C-reactive protein Homo sapiens 154-157 25101989-8 2014 Metronidazole seemed to decrease CRP but was ineffective in ameliorating diarrhea. Metronidazole 0-13 C-reactive protein Homo sapiens 33-36 20808669-5 2010 A notable rise in serum C-reactive protein (CRP) was observed over 3 days after pamidronate infusion (P=0.026). Pamidronate 80-91 C-reactive protein Homo sapiens 24-42 20808669-5 2010 A notable rise in serum C-reactive protein (CRP) was observed over 3 days after pamidronate infusion (P=0.026). Pamidronate 80-91 C-reactive protein Homo sapiens 44-47 18789006-3 2008 Initial level of markers of inflammation (Il-6, CRP) in STEACS was lower than in NSTEACS. steacs 56-62 C-reactive protein Homo sapiens 48-51 17641277-6 2007 Pharmacological inhibition of phosphatidylinositol (PI)-3 kinase by LY294002 partially reversed inhibition of adiponectin gene expression by CRP. Phosphatidylinositols 30-50 C-reactive protein Homo sapiens 141-144 17641277-6 2007 Pharmacological inhibition of phosphatidylinositol (PI)-3 kinase by LY294002 partially reversed inhibition of adiponectin gene expression by CRP. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 68-76 C-reactive protein Homo sapiens 141-144 25010431-0 2014 Fumaric acid esters can block pro-inflammatory actions of human CRP and ameliorate metabolic disturbances in transgenic spontaneously hypertensive rats. Fumarates 0-19 C-reactive protein Homo sapiens 64-67 17451425-5 2007 EZE/SIMVA 10/20 mg and 10/40 mg produced greater (p < or = 0.001) reductions in total cholesterol, non-high-density lipoprotein cholesterol (HDL-C) and apolipoprotein B relative to ATV 20 mg. A reduction (p < or = 0.050) in C-reactive protein was observed with EZE/SIMVA 10/40 mg vs. ATV 20 mg. simva 4-9 C-reactive protein Homo sapiens 230-248 17499069-1 2007 Fluorescence intensity of N-isopropylacrylamide-glycidyl methacrylate (NIPAAm-GMA) copolymer conjugated with fluoreseinamine isomer1 was found to decrease considerably in the presence of NIPAAm-GMA copolymer containing O-phosphorylethanolamine (PEA), the specific ligand of C-reactive protein (CRP). fluoreseinamine 109-124 C-reactive protein Homo sapiens 274-292 17499069-1 2007 Fluorescence intensity of N-isopropylacrylamide-glycidyl methacrylate (NIPAAm-GMA) copolymer conjugated with fluoreseinamine isomer1 was found to decrease considerably in the presence of NIPAAm-GMA copolymer containing O-phosphorylethanolamine (PEA), the specific ligand of C-reactive protein (CRP). fluoreseinamine 109-124 C-reactive protein Homo sapiens 294-297 17499069-3 2007 The emission intensity was, however, found to increase rapidly when CRP was added in to the solution containing the polymers. Polymers 116-124 C-reactive protein Homo sapiens 68-71 20691317-8 2010 There was a strong, positive association between the highest quartile of serum phosphorus (3.7 to 5.0 mg/dl) and high ABPI compared to the reference group (3.1 to 3.4 mg/dl) after adjustment for demographics, traditional CVD risk factors, kidney function, C-reactive protein, serum calcium, and 25-hydroxyvitamin D levels (adjusted odds ratio 4.78, 95% confidence interval 1.73 to 13.2, p = 0.003). Phosphorus 79-89 C-reactive protein Homo sapiens 256-274 20414684-7 2010 An increase in SUA above 5.5 mg/dl was associated with an increase in hs-CRP [odds ratio (OR) 4.8; confidence interval (CI) 1.3-17.4; P < 0.01]. sua 15-18 C-reactive protein Homo sapiens 73-76 20125012-3 2010 Specifically, phenytoin causes loss of bone mass in women, and both phenytoin and carbamazepine produce increases in serum lipids and C-reactive protein, as well as decreases in bioactive testosterone in men. Carbamazepine 82-95 C-reactive protein Homo sapiens 134-152 19808911-5 2010 CRP reduction was greater in the rosiglitazone group by -47.6% relative to glyburide and by -30.5% relative to metformin at 48 months. Glyburide 75-84 C-reactive protein Homo sapiens 0-3 19808911-7 2010 The change in CRP from baseline to 12 months was correlated positively with change in BMI in glyburide (r = 0.18) and metformin (r = 0.20) groups but not in the rosiglitazone (r = -0.05, NS) group. Glyburide 93-102 C-reactive protein Homo sapiens 14-17 19808911-10 2010 CRP in the glyburide and metformin groups was positively associated with changes in weight, but this was not the case with rosiglitazone. Glyburide 11-20 C-reactive protein Homo sapiens 0-3 25010431-3 2014 In the current study, we tested the hypothesis that fumaric acid ester (FAE) treatment of an animal model of inflammation and metabolic syndrome, the spontaneously hypertensive rat transgenically expressing human C-reactive protein (SHR-CRP), will ameliorate inflammation, oxidative stress, and metabolic disturbances. Fumarates 52-70 C-reactive protein Homo sapiens 213-231 19915887-7 2009 The phosphatidylethanolamine saturated to polyunsaturated fatty acid ratio showed highly significant positive correlations with the EDSS and CRP < 5 microg/ml. Fatty Acids, Unsaturated 42-68 C-reactive protein Homo sapiens 141-144 19625064-2 2009 Fasting concentrations of interleukin-6 (IL-6) and C-reactive protein (CRP), key inflammatory mediators, decrease after sustained n-3 polyunsaturated fatty acid (PUFA) intake; however, the ability of n-3 PUFA to attenuate postprandial inflammatory responses is not well studied. Fatty Acids, Omega-3 130-160 C-reactive protein Homo sapiens 71-74 19625064-2 2009 Fasting concentrations of interleukin-6 (IL-6) and C-reactive protein (CRP), key inflammatory mediators, decrease after sustained n-3 polyunsaturated fatty acid (PUFA) intake; however, the ability of n-3 PUFA to attenuate postprandial inflammatory responses is not well studied. Fatty Acids, Unsaturated 162-166 C-reactive protein Homo sapiens 71-74 17701281-8 2007 In the allopurinol group, serum uric acid levels, GFR, systolic and diastolic blood pressure, and C-reactive protein (CRP) levels significantly improved (P < 0.05). Allopurinol 7-18 C-reactive protein Homo sapiens 98-116 17701281-8 2007 In the allopurinol group, serum uric acid levels, GFR, systolic and diastolic blood pressure, and C-reactive protein (CRP) levels significantly improved (P < 0.05). Allopurinol 7-18 C-reactive protein Homo sapiens 118-121 17351328-5 2007 In the presence of CRP, pretreatment with BH(4) decreased EMP counts and restored NO production to baseline levels (p < 0.05) while pretreatment with 2,4-diamino-6-hydroxypyrimidine (DAHP), a BH(4) synthesis inhibitor, further prompted EMP formation and decreased NO production (p < 0.05). 2,4-diaminohypoxanthine 153-184 C-reactive protein Homo sapiens 19-22 17351328-5 2007 In the presence of CRP, pretreatment with BH(4) decreased EMP counts and restored NO production to baseline levels (p < 0.05) while pretreatment with 2,4-diamino-6-hydroxypyrimidine (DAHP), a BH(4) synthesis inhibitor, further prompted EMP formation and decreased NO production (p < 0.05). 2,4-diaminohypoxanthine 186-190 C-reactive protein Homo sapiens 19-22 25010431-3 2014 In the current study, we tested the hypothesis that fumaric acid ester (FAE) treatment of an animal model of inflammation and metabolic syndrome, the spontaneously hypertensive rat transgenically expressing human C-reactive protein (SHR-CRP), will ameliorate inflammation, oxidative stress, and metabolic disturbances. Fumarates 72-75 C-reactive protein Homo sapiens 213-231 17454839-4 2007 MATERIAL AND METHODS: A case-control study was performed in which CRP measurements in women receiving levonorgestrel intrauterine system combined with transdermal estradiol (LNG/TDE, n=27) were followed for 9 months or longer. Levonorgestrel 102-116 C-reactive protein Homo sapiens 66-69 24813814-4 2014 Herein, we present the use of thermally cross-linked poly(ethylene glycol) (PEG) polymer sensory array interfaces in the ultrasensitive quantification of two protein markers, insulin and C-reactive protein (CRP). Polymers 81-88 C-reactive protein Homo sapiens 187-205 19833744-5 2009 In patients with pSS SAA concentrations correlated significantly with age, leukocyte count, CRP, interleukin 6, and C4. pss 17-20 C-reactive protein Homo sapiens 92-95 24813814-4 2014 Herein, we present the use of thermally cross-linked poly(ethylene glycol) (PEG) polymer sensory array interfaces in the ultrasensitive quantification of two protein markers, insulin and C-reactive protein (CRP). Polymers 81-88 C-reactive protein Homo sapiens 207-210 24799162-7 2014 C-reactive protein and tumor necrosis factor (TNF) serum levels were increased in the 300 mg DEHP in utero-exposed offspring. Diethylhexyl Phthalate 93-97 C-reactive protein Homo sapiens 0-18 19994591-8 2009 In 4 patients who survived for 60 days or longer, serum levels of LDH, CRP, and SP-D were significantly decreased after PMX-DHP, whereas KL-6 level was unchanged. pmx-dhp 120-127 C-reactive protein Homo sapiens 71-74 19994591-10 2009 These data suggest that serum levels of LDH, CRP, and SP-D might be predictive of successful PMX-DHP treatment in cases of IP-AE. pmx-dhp 93-100 C-reactive protein Homo sapiens 45-48 16330117-6 2006 RESULTS: Malondialdehyde, C-reactive protein and interleukin-6 levels were reduced in the rofecoxib group (p=0.04, p=0.003 and p=0.02 respectively) while they remained unchanged in the placebo group after 1 week of treatment. rofecoxib 90-99 C-reactive protein Homo sapiens 26-44 16554319-7 2006 The annualized change of the square root-transformed CAC score positively correlated with the time-integrated levels of C-reactive protein (R = 0.521, P = 0.001), phosphorus (R = 0.433, P = 0.005) and calcium x phosphorus product (R = 0.394, P = 0.012), but did not correlate with the levels of fetuin-A or lipid parameters. Phosphorus 211-221 C-reactive protein Homo sapiens 120-138 24097136-10 2014 Age (beta = 0.231, P < 0.001), gender (beta = 0.137, P = 0.008) and CRP (beta = 0.144, P = 0.006) associated independently with QTc in RA patients. qtc 131-134 C-reactive protein Homo sapiens 71-74 16722027-13 2006 Median serum CRP decreased (p = 0.03), from 3.8 (1.6 - 8.5) mg/L on CAPD to 1.0 (0.4 - 4.4) mg/L on NIPD, but increased on CCPD [1.8 (1.3 - 21) mg/L] and at the end of the study [3.2 (0.3 - 8.2) mg/L]. ccpd 123-127 C-reactive protein Homo sapiens 13-16 16722027-14 2006 Dialysate CRP decreased nonsignificantly, from 0.10 (0 - 0.5) mg/L on CAPD to 0 (0 - 0.03) mg/L on NIPD, to 0.01 (0 - 0.08) mg/L on CCPD, and to 0 (0 - 0) mg/L at final evaluation. ccpd 132-136 C-reactive protein Homo sapiens 10-13 19689088-9 2009 Both vitamin A and iron deficiencies were independently associated with lower z-scores for body-mass-index-for-age, after adjustment for sociodemographic factors and C-reactive protein concentrations. Vitamin A 5-14 C-reactive protein Homo sapiens 166-184 19721904-10 2009 Among the patients who presented lower concentrations of CRP it was found higher beta-carotene inadequacy (64.8%) and 50% of retinol inadequacy. Vitamin A 125-132 C-reactive protein Homo sapiens 57-60 16637303-1 2006 BACKGROUND: We present the influence of monophasic combined oral contraceptive with 20 mmicrog ethinylestradiol /150 microg desogestrel upon some acute phase proteins: C- reactive protein, fibrinogen, haptoglobin and the connection between the proinflammatory effect of oestrogens METHODS: Forty clinically healthy young women between 18 and 35 years, using oral contraceptives in the duration of 12 months, are included in this study. Ethinyl Estradiol 95-111 C-reactive protein Homo sapiens 168-187 24131677-10 2013 CRP was significantly positively associated with serum phosphorus, calcium, alkaline phosphatase, and PTH, and significantly inversely associated with HDL and albumin. Phosphorus 55-65 C-reactive protein Homo sapiens 0-3 23984806-9 2013 Canrenone also decreased plasma aldosterone, Hs-CRP and TNF-alpha compared to baseline and to placebo. Canrenone 0-9 C-reactive protein Homo sapiens 48-51 15963746-6 2005 RESULTS: The peak C-reactive protein was significantly lower in the patients treated with HES than those treated with gelofusine [142 mg/L (113,196 mg/L) vs 246 mg/L (189,291 mg/L) mg/L, P < 0.01, Mann-Whitney test]. Polygeline 118-128 C-reactive protein Homo sapiens 18-36 19758923-1 2005 AIMS: We evaluated the effect of cyclooxygenase-2 inhibitor rofecoxib added to atorvastatin, initiated immediately after percutaneous coronary angioplasty (PCI), on C-reactive protein (CRP) and interleukin-6 (IL-6) in patients with unstable angina (UA). rofecoxib 60-69 C-reactive protein Homo sapiens 165-183 19758923-1 2005 AIMS: We evaluated the effect of cyclooxygenase-2 inhibitor rofecoxib added to atorvastatin, initiated immediately after percutaneous coronary angioplasty (PCI), on C-reactive protein (CRP) and interleukin-6 (IL-6) in patients with unstable angina (UA). rofecoxib 60-69 C-reactive protein Homo sapiens 185-188 19296463-6 2009 RESULTS: In the epilepsy patients, switch from either phenytoin or carbamazepine produced significant declines in total cholesterol (-24.8 mg/dl), atherogenic (non-high-density lipoprotein) cholesterol (-19.9 mg/dl), triglycerides (-47.1mg/dl) (all p < 0.0001), and C-reactive protein (-31.4%; p = 0.027). Carbamazepine 67-80 C-reactive protein Homo sapiens 269-287 19161294-7 2009 For the CRP assay, neutravidin-coated PQQ-doped PMMA nanospheres are used to bind with a biotinylated reporter antibody directed toward CRP. doped 42-47 C-reactive protein Homo sapiens 8-11 19161294-7 2009 For the CRP assay, neutravidin-coated PQQ-doped PMMA nanospheres are used to bind with a biotinylated reporter antibody directed toward CRP. doped 42-47 C-reactive protein Homo sapiens 136-139 19018239-13 2009 Meanwhile, the plasma levels of C-reactive protein were also significant higher in CS group compared with DS group at both 24 and 72 h after stenting (P<0.05, respectively). Cesium 83-85 C-reactive protein Homo sapiens 32-50 19758923-6 2005 CONCLUSION: After PCI in UA, cyclooxygenase-2 inhibitor rofecoxib added to atorvastatin reduced CRP and IL-6 levels more profoundly than atorvastatin alone at 3- and 6-month after intervention. rofecoxib 56-65 C-reactive protein Homo sapiens 96-99 16315884-6 2005 Post operative maximal CRP level was 3.2 mg/dl, 4.9 mg/dl and 10.5 mg/dl in HALS, LS, and OS, respectively, with a statistical significance between HALS and OS. Fluoxymesterone 76-80 C-reactive protein Homo sapiens 23-26 16315884-6 2005 Post operative maximal CRP level was 3.2 mg/dl, 4.9 mg/dl and 10.5 mg/dl in HALS, LS, and OS, respectively, with a statistical significance between HALS and OS. Fluoxymesterone 148-152 C-reactive protein Homo sapiens 23-26 15970291-1 2005 OBJECTIVE: To compare the effects of raloxifene, estradiol valerate plus dienogest, and soy isoflavones (genistein) on serum concentrations of high-sensitive C-reactive protein in healthy postmenopausal women. Genistein 105-114 C-reactive protein Homo sapiens 158-176 15057566-5 2005 C-reactive protein levels also correlated significantly in a negative manner with vitamin B12 and folate but positively with tHcy. Vitamin B 12 82-93 C-reactive protein Homo sapiens 0-18 19164258-12 2009 Retinol concentrations decreased with PD therapy and were inversely related to interleukin-6 and CRP concentrations. Vitamin A 0-7 C-reactive protein Homo sapiens 97-100 23800565-10 2013 Cr supplementation reversed the increase in TNF-alpha and CRP as well as LDH induced by acute exercise. Creatine 0-2 C-reactive protein Homo sapiens 58-61 18178356-3 2008 Monoclonal anti-CRP was biotinylated and attached to 5.0mum streptavidin-coated silica beads to make the solid support for separation columns. Silicon Dioxide 80-86 C-reactive protein Homo sapiens 16-19 18709001-0 2008 C-reactive protein in patients with normal perfusion and mild to moderate perfusion defects who have undergone myocardial perfusion imaging with 99m-Tc sestamibi gated spect. Technetium Tc 99m Sestamibi 145-161 C-reactive protein Homo sapiens 0-18 15939097-8 2005 Peak CRP level was inversely correlated with the lowest PaO2/FIO2 (P < 0.001). fio2 61-65 C-reactive protein Homo sapiens 5-8 23800565-13 2013 CONCLUSION: Cr supplementation inhibited the increase of inflammation markers TNF-alpha and CRP, but not oxidative stress markers, due to acute exercise. Creatine 12-14 C-reactive protein Homo sapiens 92-95 23240685-11 2013 CONCLUSIONS: Dexmedetomidine administration during surgery reduced intraoperative and post-operative secretion of cytokines, as well as post-operative leukocyte count and CRP level. Dexmedetomidine 13-28 C-reactive protein Homo sapiens 171-174 16175781-10 2005 Retinol levels were significantly lower among children with high C-reactive protein (P < 0.001). Vitamin A 0-7 C-reactive protein Homo sapiens 65-83 15792679-11 2005 CRP, glucose intolerance, and HDL-C that correlated with adiponectin were inversely correlated with IMTmax and CAD. imtmax 100-106 C-reactive protein Homo sapiens 0-3 18330493-1 2008 OBJECTIVE: In this study, we tested in patients with metabolic syndrome whether allopurinol through decreasing oxidative stress improves endothelial function, and ameliorates inflammatory state represented by markers of myeloperoxidase, C-reactive protein (CRP) and fibrinogen. Allopurinol 80-91 C-reactive protein Homo sapiens 257-260 18356331-10 2008 Among the flavonoid compounds investigated, quercetin, kaempferol, malvidin, peonidin, daidzein, and genistein had inverse associations with serum CRP concentration (P < 0.05). Genistein 101-110 C-reactive protein Homo sapiens 147-150 19281089-10 2008 PaO2x alone was an even stronger predictor of CRP (R2 = 0.62, p < 0.0001). pao2x 0-5 C-reactive protein Homo sapiens 46-49 23054305-1 2013 An optimization experiment for an indirect-competitive (IC) fluoroimmunoassay (FIA) against C-reactive protein (CRP) was conducted exploiting an immobilized-antigen glass slide and an anti-CRP antibody tagged with fluorescent silica nanoparticles (FSNPs). Silicon Dioxide 226-232 C-reactive protein Homo sapiens 112-115 17717133-8 2007 In multivariate Cox regression analysis, decreased retinol concentration remained a statistically significant predictor of all-cause mortality after adjustment for traditional cardiovascular risk factors, high-sensitivity C-reactive protein, and estimated glomerular filtration rate. Vitamin A 51-58 C-reactive protein Homo sapiens 222-240 17586424-0 2007 The effect of n-3 fatty acids on C-reactive protein levels in patients with chronic renal failure. Fatty Acids, Omega-3 14-29 C-reactive protein Homo sapiens 33-51 17520506-5 2007 After changing the antibiotics to ceftriaxon and metronidazole, acute cholangitis being suspected, the fever subsided immediately and the CRP level decreased. Metronidazole 49-62 C-reactive protein Homo sapiens 138-141 17502528-6 2007 In multivariable analyses and adjusting for established risk factors and additionally for glomerular filtration rate and for hemoglobin, serum albumin, proteinuria, and C-reactive protein levels, a higher level of serum phosphorus was associated with an increased CVD risk in a continuous fashion (adjusted hazard ratio per increment of milligrams per deciliter, 1.31; 95% confidence interval, 1.05-1.63; P=.02; P value for trend across quartiles = .004). Phosphorus 220-230 C-reactive protein Homo sapiens 169-187 17389717-14 2007 Peritoneal amphotericin B level was inversely correlated with C-reactive protein level on the same day (r(2)=0.30). Amphotericin B 11-25 C-reactive protein Homo sapiens 62-80 17545695-7 2007 A multiple regression analysis showed that, especially in the middle tertile of long-chain n-3 PUFAs (eicosapentaenoic acid and docosahexaenoic acid) intake, CRP was inversely related to the intake of oleic acid and linoleic acid in both sexes and to the intake of alpha-linolenic acid in women. Fatty Acids, Omega-3 91-100 C-reactive protein Homo sapiens 158-161 17598653-5 2007 Fluvastatin XL caused a significant decrease in serum TC (by 18%), LDL-C (by 24%), TG (by 16%), CRP (by 23%) and TBARS (by 31%), membrane cholesterol (by 30%) in comparison to the initial values before active therapy. fluvastatin xl 0-14 C-reactive protein Homo sapiens 96-99 18084700-7 2007 Compared to the CS-100 group, the patients of the CS-180S group exhibited a tendency toward improvement with respect to the CRP level and ESR (P = 0.057 and 0.041, respectively). Cesium 50-52 C-reactive protein Homo sapiens 124-127 18332612-7 2007 The levels of C-reactive protein and IL-6 increased significantly after 1 or 2 weeks on fosfluconazole in both groups. fosfluconazole 88-102 C-reactive protein Homo sapiens 14-32 16962105-1 2006 C-reactive protein (CRP) is elevated in cardiovascular disease and binds to oxidized phosphatidylcholine (oxPtC) in the low-density lipoprotein (LDL) surface. Phosphatidylcholines 85-104 C-reactive protein Homo sapiens 0-18 16962105-1 2006 C-reactive protein (CRP) is elevated in cardiovascular disease and binds to oxidized phosphatidylcholine (oxPtC) in the low-density lipoprotein (LDL) surface. Phosphatidylcholines 85-104 C-reactive protein Homo sapiens 20-23 17175820-0 2006 Attenuation of C-reactive protein increases after exodontia by tramadol and ibuprofen. Tramadol 63-71 C-reactive protein Homo sapiens 15-33 17175820-6 2006 At 72 hours, C-reactive protein had increased over postsurgery baseline by 123% in the tramadol group (P < .001), 84% in the ibuprofen group (P < .001), and only 37% in the combined analgesic group (P = .078). Tramadol 87-95 C-reactive protein Homo sapiens 13-31 16825699-1 2006 BACKGROUND: Several studies have reported that the intake of n-3 polyunsaturated fatty acids (PUFAs) or fish is inversely associated with serum C-reactive protein (CRP) concentrations, but few studies have evaluated the relations between serum CRP concentrations and consumption of n-3 PUFAs derived from marine products in populations with a diet rich in marine products. Fatty Acids, Omega-3 61-92 C-reactive protein Homo sapiens 144-162 16825699-1 2006 BACKGROUND: Several studies have reported that the intake of n-3 polyunsaturated fatty acids (PUFAs) or fish is inversely associated with serum C-reactive protein (CRP) concentrations, but few studies have evaluated the relations between serum CRP concentrations and consumption of n-3 PUFAs derived from marine products in populations with a diet rich in marine products. Fatty Acids, Omega-3 61-92 C-reactive protein Homo sapiens 164-167 16825699-1 2006 BACKGROUND: Several studies have reported that the intake of n-3 polyunsaturated fatty acids (PUFAs) or fish is inversely associated with serum C-reactive protein (CRP) concentrations, but few studies have evaluated the relations between serum CRP concentrations and consumption of n-3 PUFAs derived from marine products in populations with a diet rich in marine products. Fatty Acids, Unsaturated 94-99 C-reactive protein Homo sapiens 144-162 16825699-1 2006 BACKGROUND: Several studies have reported that the intake of n-3 polyunsaturated fatty acids (PUFAs) or fish is inversely associated with serum C-reactive protein (CRP) concentrations, but few studies have evaluated the relations between serum CRP concentrations and consumption of n-3 PUFAs derived from marine products in populations with a diet rich in marine products. Fatty Acids, Unsaturated 94-99 C-reactive protein Homo sapiens 164-167 16825699-1 2006 BACKGROUND: Several studies have reported that the intake of n-3 polyunsaturated fatty acids (PUFAs) or fish is inversely associated with serum C-reactive protein (CRP) concentrations, but few studies have evaluated the relations between serum CRP concentrations and consumption of n-3 PUFAs derived from marine products in populations with a diet rich in marine products. Fatty Acids, Unsaturated 94-99 C-reactive protein Homo sapiens 244-247 16825699-8 2006 CONCLUSIONS: Greater intake of n-3 PUFAs derived from marine products, as measured with a self-administered questionnaire, was independently related to a lower prevalence of high CRP concentrations in this older Japanese population with a diet rich in marine products. Fatty Acids, Omega-3 31-40 C-reactive protein Homo sapiens 179-182 16825699-9 2006 Our findings suggest that even very high intakes of n-3 PUFAs may lower serum CRP concentrations. Fatty Acids, Omega-3 52-61 C-reactive protein Homo sapiens 78-81 16403905-10 2006 Clofarabine plus cytarabine has activity in adult AML, achieving a good CR rate. Clofarabine 0-11 C-reactive protein Homo sapiens 72-74 16807987-5 2006 The pericardial CRP and LDH levels in the PMI group were higher than in the SAP (p=0.015 and p=0.000, respectively) and USAP (p=0.011, p=0.047) groups. pmi 42-45 C-reactive protein Homo sapiens 16-19 15308231-1 2004 In this paper, we report the novel electrical measurement for the label-free detection of C-reactive protein (CRP) using resonant frequency shift in the monolithic thin film cantilever of micromachined Pb(Zr0.52Ti0.48)O3 (PZT) which was fabricated with the composition of SiO2/Ta/Pt/PZT/Pt/SiO2 on silicon nitride (SiNx) supporting layer for the dual purpose of electrical self-excitation and sensing. Silicon Dioxide 272-276 C-reactive protein Homo sapiens 90-108 15308231-1 2004 In this paper, we report the novel electrical measurement for the label-free detection of C-reactive protein (CRP) using resonant frequency shift in the monolithic thin film cantilever of micromachined Pb(Zr0.52Ti0.48)O3 (PZT) which was fabricated with the composition of SiO2/Ta/Pt/PZT/Pt/SiO2 on silicon nitride (SiNx) supporting layer for the dual purpose of electrical self-excitation and sensing. Silicon Dioxide 272-276 C-reactive protein Homo sapiens 110-113 15308231-1 2004 In this paper, we report the novel electrical measurement for the label-free detection of C-reactive protein (CRP) using resonant frequency shift in the monolithic thin film cantilever of micromachined Pb(Zr0.52Ti0.48)O3 (PZT) which was fabricated with the composition of SiO2/Ta/Pt/PZT/Pt/SiO2 on silicon nitride (SiNx) supporting layer for the dual purpose of electrical self-excitation and sensing. Silicon Dioxide 290-294 C-reactive protein Homo sapiens 90-108 15308231-1 2004 In this paper, we report the novel electrical measurement for the label-free detection of C-reactive protein (CRP) using resonant frequency shift in the monolithic thin film cantilever of micromachined Pb(Zr0.52Ti0.48)O3 (PZT) which was fabricated with the composition of SiO2/Ta/Pt/PZT/Pt/SiO2 on silicon nitride (SiNx) supporting layer for the dual purpose of electrical self-excitation and sensing. Silicon Dioxide 290-294 C-reactive protein Homo sapiens 110-113 15308231-2 2004 The specific binding characteristics of CRP antigen to its antibody, which is immobilized with Calixcrown SAMs on Au surface deposited on microcantilever, is determined in high sensitivity to the nanogram level per milliliter by measuring the resonant frequency shift. calixcrown sams 95-110 C-reactive protein Homo sapiens 40-43 15458276-7 2004 Supplementation with n-3 FA and a low n-6 FA intake decreased serum sTNF-R p55 and CRP levels in patients with RA. Fatty Acids, Omega-3 21-27 C-reactive protein Homo sapiens 83-86 15463900-6 2004 RESULTS: Serum vitamin A level was lower in CF subjects than in controls (mean, 95% CI: 1.29, 1.0-1.37 vs. 1.80, 1.7-1.87 micromol/l, p < 0.0001), and inversely correlated with CRP (r(s) = -0.37, p < 0.0001). Vitamin A 15-24 C-reactive protein Homo sapiens 180-183 15463900-7 2004 CF subjects with low vitamin A (45%) level had poorer FEV(1), weight z-score, LSBMD z-score, and higher CRP compared with those with normal levels. Vitamin A 21-30 C-reactive protein Homo sapiens 104-107 15463900-8 2004 In the CF group CRP, vitamin E, 1,25(OH)(2)D, presence of CFLD, admissions, and age were associated with vitamin A level. Vitamin A 105-114 C-reactive protein Homo sapiens 16-19 15463900-9 2004 CONCLUSIONS: Serum vitamin A is negatively associated with CRP in subjects with CF, consistent with normal population studies. Vitamin A 19-28 C-reactive protein Homo sapiens 59-62 14572579-9 2003 Serum C-reactive protein levels correlated positively with biliary levels of 7-alpha-hydroxycholesterol (R = 0.948), 7-beta-hydroxycholesterol (R = 0.976), cholestan-3-beta,5-alpha,6-beta-triol (R = 0.823), 7-alpha-hydroxy-4-cholesten-3-one (R = 0.846,) and 7-ketocholesterol (R = 0.973). cholest-5-en-3 beta,7 alpha-diol 77-103 C-reactive protein Homo sapiens 6-24 14572579-9 2003 Serum C-reactive protein levels correlated positively with biliary levels of 7-alpha-hydroxycholesterol (R = 0.948), 7-beta-hydroxycholesterol (R = 0.976), cholestan-3-beta,5-alpha,6-beta-triol (R = 0.823), 7-alpha-hydroxy-4-cholesten-3-one (R = 0.846,) and 7-ketocholesterol (R = 0.973). cholest-5-en-3 beta,7 alpha-diol 117-142 C-reactive protein Homo sapiens 6-24 12947436-1 2003 OBJECTIVE: To examine the relationships between circulating concentrations of C-reactive protein and concentrations of retinol, retinyl esters, vitamin C, vitamin E, carotenoids, and selenium. Vitamin A 119-126 C-reactive protein Homo sapiens 78-96 12947436-5 2003 RESULTS: C-reactive protein concentration (dichotomized at the sex-specific 85th percentile) was inversely and significantly associated with concentrations of retinol, retinyl esters, vitamin C, alpha-carotene, beta-carotene, cryptoxanthin, lutein/zeaxanthin, lycopene, and selenium after adjustment for age, sex, race or ethnicity, education, cotinine concentration, body mass index, leisure-time physical activity, and aspirin use. Vitamin A 159-166 C-reactive protein Homo sapiens 9-27 12741936-7 2003 There were significant inverse linear relationships between concentrations of CRP and plasma concentrations of the antioxidants lycopene, beta-carotene, cryptoxanthin and retinol. Vitamin A 171-178 C-reactive protein Homo sapiens 78-81 12716789-6 2003 Saturated-to-omega-3 and saturated-to-omega-6 FA ratios were significantly and positively associated with C-reactive protein (P < 0.0001) and IL-6 (P < 0.001), respectively. Fatty Acids, Omega-3 13-20 C-reactive protein Homo sapiens 106-124 12681455-6 2003 RESULTS: Plasma pyridoxal 5"-phosphate levels were inversely correlated with the erythrocyte sedimentation rate (r = -0.37, P = 0.02), C-reactive protein level (r = -0.52, P = 0.002), disability score (r = -0.37, P = 0.02), morning stiffness (r = -0.38, P = 0.02), and degree of pain (r = -0.33, P = 0.04). Pyridoxal Phosphate 16-38 C-reactive protein Homo sapiens 135-153 12381339-6 2002 Glutamine was associated with a significant increase of cholinesterase, albumin and lymphocyte count in AP as well a decrease of C-reactive protein compared to standard TPN at day 14. Glutamine 0-9 C-reactive protein Homo sapiens 129-147 12368396-5 2002 In contrast, plasma concentrations of retinol were lower by 0.07 (P < 0.05, raised AGP) to 0.12 (P < 0.01, raised CRP) micro mol/L, and of zinc lower by 1.49 (P < 0.01, raised AGP) to 1.89 (P < 0.05, raised CRP and AGP) micro mol/L. Vitamin A 38-45 C-reactive protein Homo sapiens 120-123 12105349-8 2002 The use of ticlopidine was associated with a significant risk reduction among patients with lower (86%, P=0.0159) and middle (69%, P<0.0001) levels of CRP, whereas a nonsignificant excess risk (27%, P=0.3896) was evident among those with the highest levels. Ticlopidine 11-22 C-reactive protein Homo sapiens 154-157 11545558-5 2001 With amphotericin B treatment, the patient is well with normalization of erythrocyte sedimentation rate and C-reactive protein. Amphotericin B 5-19 C-reactive protein Homo sapiens 108-126 15348325-2 2001 Monodisperse polymer colloids with dimethyl and diethyl acetal functionalities synthesized by a two-step emulsion polymerization process were chosen as the polymeric support to carry out covalent coupling with the antibody IgG anti C-reactive protein, and to test the utility of the latex-protein complexes formed in immunoassays with the specific CRP antigen. Polymers 13-20 C-reactive protein Homo sapiens 232-250 11136199-10 2001 After initiation of antibiotic therapy with levofloxacine on day 14 ultrafiltration, clinical symptoms and serum CRP normalized within 3 days. Levofloxacin 44-57 C-reactive protein Homo sapiens 113-116 11196517-14 2001 Acute lymphopenia accompanied by elevated CRP levels was noted in 8 patients in the 48 h after first pamidronate infusion. Pamidronate 101-112 C-reactive protein Homo sapiens 42-45 11063445-8 2000 An elevated CRP concentration was 2.4-fold greater in females than in males aged 20-59 y. Serum retinol was lower in subjects with elevated CRP concentrations. Vitamin A 96-103 C-reactive protein Homo sapiens 12-15 11063445-8 2000 An elevated CRP concentration was 2.4-fold greater in females than in males aged 20-59 y. Serum retinol was lower in subjects with elevated CRP concentrations. Vitamin A 96-103 C-reactive protein Homo sapiens 140-143 11092464-5 2000 RESULTS: The addition of pamidronate to chemotherapy resulted in a significant reduction of NTx, IL-6 and paraprotein from the 3rd month and of beta2-microglobulin, CRP and pain from the 6th month of treatment. Pamidronate 25-36 C-reactive protein Homo sapiens 165-168 10989247-0 2000 Elevated serum vitamin B12 levels associated with CRP as a predictive factor of mortality in palliative care cancer patients: a prospective study over five years. Vitamin B 12 15-26 C-reactive protein Homo sapiens 50-53 10971057-0 2000 Adamantiades-Behcet"s disease: serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. adamantiades 0-12 C-reactive protein Homo sapiens 94-112 9805849-10 1998 All patients with ACB in urine had raised serum CRP levels except one, where as all the rest of the patients had CRP level within normal limit. acb 18-21 C-reactive protein Homo sapiens 48-51 9857266-6 1998 Serum retinol was negatively correlated with malaria parasite count and to serum levels of CRP and AGP. Vitamin A 6-13 C-reactive protein Homo sapiens 91-94 9857266-7 1998 Increased malaria parasite density resulted in raised CRP and AGP levels, which were negatively associated with serum retinol. Vitamin A 118-125 C-reactive protein Homo sapiens 54-57 7485521-5 1995 The inhibition of surfactant adsorption by CRP was effectively eliminated by the addition of phosphocholine at a molar ratio of 300:1 (phosphocholine:CRP), but it was not diminished by the addition of identical molar ratios of o-phosphoethanolamine or DL-alpha-glycerophosphate at the same molar ratios. alpha-glycerophosphoric acid 252-277 C-reactive protein Homo sapiens 43-46 7519416-5 1994 Furthermore, a significant correlation was found between some of these plasma acute-phase proteins (ACT, AMG, and FIB) and plasma TSA in the MI patients and also in normal subjects (ACT, AMG, CRP, and FIB). trichostatin A 130-133 C-reactive protein Homo sapiens 192-195 8262633-4 1994 The CRP purified from parasites treated with an inhibitor of N-linked glycosylation exhibited a decreased binding affinity for C3b compared with that of the fully glycosylated protein. 1-D-glucopyranosyl cytosine 127-130 C-reactive protein Homo sapiens 4-7 1624792-7 1992 Comparing various mono-, di-, and trisaccharides as competitive inhibitors of the lectin binding activity of CRP, only beta-D-Gal-(1-3)-D-GalNAc, beta-D-Gal-(1-4)-D-GalNAc, and beta-D-Gal-(1-4)-beta-D-Gal-(1-4)-D-GlcNAc had significant inhibitory power at a concentration of 8 mmol/liter. beta-d-gal-(1-4)-beta-d-gal-(1-4)-d-glcnac 177-219 C-reactive protein Homo sapiens 109-112 1916494-4 1991 Changes in C reactive protein concentrations did not achieve significance when all three groups were considered but were significant when all metronidazole treated patients were grouped and compared with the placebo treated patients (0.8 v -0.9, p less than 0.05). Metronidazole 142-155 C-reactive protein Homo sapiens 11-29 1645189-11 1991 CRP*141 gln exhibited the same conformational characteristics of previously reported cAMP-independent mutant proteins. Glutamine 8-11 C-reactive protein Homo sapiens 0-3 2063349-4 1991 At higher concentrations (20-100 micrograms/ml), CRP stabilized platelet membrane against the detergent-like effect of beta-deoxy-lysolecithin. beta-deoxy-lysolecithin 119-142 C-reactive protein Homo sapiens 49-52 2063349-5 1991 Furthermore, CRP (10 micrograms/ml) diminished specific [3H]PAF binding to platelets and displaced previously bound labeled PAF from platelets. Platelet Activating Factor 60-63 C-reactive protein Homo sapiens 13-16 2063349-5 1991 Furthermore, CRP (10 micrograms/ml) diminished specific [3H]PAF binding to platelets and displaced previously bound labeled PAF from platelets. Platelet Activating Factor 124-127 C-reactive protein Homo sapiens 13-16 1701623-3 1990 The proportion of 18:2 in serum phosphatidylcholine correlated inversely with such acute phase proteins as orosomucoid and C reactive protein. Phosphatidylcholines 32-51 C-reactive protein Homo sapiens 123-141 2281095-2 1990 The duration of infection and the C-reactive protein levels showed a significant positive correlation with 111In-labeled leukocytes scintigraphy. Indium-111 107-112 C-reactive protein Homo sapiens 34-52 33385878-6 2021 The anti-inflammatory effect of tramadol may help to suppress the COVID-19 related cytokine storm through decreasing interleukin (IL)-6, tumor necrosis factor-alpha (TNF-alpha), and C-reactive protein (CRP). Tramadol 32-40 C-reactive protein Homo sapiens 182-200 33385878-6 2021 The anti-inflammatory effect of tramadol may help to suppress the COVID-19 related cytokine storm through decreasing interleukin (IL)-6, tumor necrosis factor-alpha (TNF-alpha), and C-reactive protein (CRP). Tramadol 32-40 C-reactive protein Homo sapiens 202-205 24021937-14 2013 Furthermore, pyrrolidine dithiocarbamate abolished Ang II-induced CRP expression. pyrrolidine dithiocarbamic acid 13-40 C-reactive protein Homo sapiens 66-69 34455435-3 2021 Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridaemia (STRENGTH), can be explained by differences in the effect of active and comparator oils on lipid traits and C-reactive protein. Fatty Acids, Omega-3 61-68 C-reactive protein Homo sapiens 241-259 34890370-8 2021 In obese women, the levels of CRP positively correlated with Zn, TNFalpha with Mg, IFNgamma with Cu and P. Phosphorus 104-105 C-reactive protein Homo sapiens 30-33 34516692-9 2021 Reducing effects of omega-3 supplementation compared to control group were also observed in the levels of ESR and CRP after treatment (p<0.001 for CRP and p=0.02 for ESR). Fatty Acids, Omega-3 20-27 C-reactive protein Homo sapiens 114-117 34516692-9 2021 Reducing effects of omega-3 supplementation compared to control group were also observed in the levels of ESR and CRP after treatment (p<0.001 for CRP and p=0.02 for ESR). Fatty Acids, Omega-3 20-27 C-reactive protein Homo sapiens 147-150 16421011-5 2006 Dipyridamole also lowered CRP (mg/l) in patients, -0.96 (0.47), but not volunteers. Dipyridamole 0-12 C-reactive protein Homo sapiens 26-29 16263508-5 2005 Exposure to OE-UDP, OE-DEP, UDP, DEP, and 2,3,7,8-tetrachlorodibenzo-p-dioxin led to a greater increase of interleukin (IL)-8, tumor necrosis factor-alpha, and cyclooxygenase-2 mRNA expression than did the stripped particles, whereas sUDP, sDEP, UDP, and DEP led to a greater production of C-reactive protein and IL-6 mRNA. oe-dep 20-26 C-reactive protein Homo sapiens 290-308 16014566-2 2005 In COS-7 cells transiently transfected with GPVI, deglycosylation with peptide-N-glycosidase F (PNGase F; specific for complex N-linked glycans) or tunicamycin decreases the molecular weight of GPVI and reduces transfected COS-7 cell binding to both CRP and CVX. Tunicamycin 148-159 C-reactive protein Homo sapiens 250-253 24261230-6 2013 RESULTS: The entire patient group showed a positive correlation between C-reactive protein (CRP) and serum uric acid (SUA) (r = 0.27; p < 0.01), suggesting that the nonspecific inflammatory processes were associated with uric acid levels in patients with HD. sua 118-121 C-reactive protein Homo sapiens 72-90 16203907-10 2005 CONCLUSIONS: Elevated preprocedural levels of CRP indicate an increased risk of death and death/MI after ULMCA stenting. ulmca 105-110 C-reactive protein Homo sapiens 46-49 34888169-7 2021 Interestingly, a common factor of UDD is the production and overall effects of inflammatory cytokines, such as interleukin-6, tumor necrosis factor-alpha, and C-reactive protein. MMV689243 34-37 C-reactive protein Homo sapiens 159-177 24261230-7 2013 An intragroup analysis also revealed a relationship between CRP and SUA levels in the hypertensive patients at high risk for CVEs (r = 0.43; p = 0.01); this relationship was not found in those at their low risk. sua 68-71 C-reactive protein Homo sapiens 60-63 25135158-10 2012 RESULTS: Two months of lercanidipine treatment showed a significant decrease in BP, WBC, and PMNL counts, PMNL apoptosis, CRP, and serum insulin levels, and a significant increase in serum albumin levels. lercanidipine 23-36 C-reactive protein Homo sapiens 122-125 34608242-7 2021 Correlation analyses revealed sphingomyelin (SM) and phosphatidylcholine (PC) positively correlate to tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP), and interleukin-6 (IL-6), while phosphatidylglycerol (PG), and phosphatidylinositol (PI) negatively correlate with them. Phosphatidylcholines 53-72 C-reactive protein Homo sapiens 143-161 34608242-7 2021 Correlation analyses revealed sphingomyelin (SM) and phosphatidylcholine (PC) positively correlate to tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP), and interleukin-6 (IL-6), while phosphatidylglycerol (PG), and phosphatidylinositol (PI) negatively correlate with them. Phosphatidylcholines 53-72 C-reactive protein Homo sapiens 163-166 34608242-7 2021 Correlation analyses revealed sphingomyelin (SM) and phosphatidylcholine (PC) positively correlate to tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP), and interleukin-6 (IL-6), while phosphatidylglycerol (PG), and phosphatidylinositol (PI) negatively correlate with them. Phosphatidylcholines 74-76 C-reactive protein Homo sapiens 143-161 34608242-7 2021 Correlation analyses revealed sphingomyelin (SM) and phosphatidylcholine (PC) positively correlate to tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP), and interleukin-6 (IL-6), while phosphatidylglycerol (PG), and phosphatidylinositol (PI) negatively correlate with them. Phosphatidylcholines 74-76 C-reactive protein Homo sapiens 163-166 16198619-5 2005 Further tangible evidence of a reduction by TZDs of systemic inflammation in patients with the classical metabolic syndrome stems from falls in the white blood cell count, P-selectin-positive platelets and in the acute-phase inflammatory proteins, C-reactive protein, serum amyloid A and fibrinogen. tzds 44-48 C-reactive protein Homo sapiens 248-266 15975559-6 2005 HCAECs pretreated with CRP significantly decreased VEGF165-induced [3H]thymidine incorporation by 73%, MTS absorbance by 44%, and capillary-like tube formation by 54% as compared to CRP-untreated cells (p < 0.05). Thymidine 71-80 C-reactive protein Homo sapiens 23-26 16054558-0 2005 The effects of consumption of omega3 fatty acid-enriched eggs on insulin and CRP. Fatty Acids, Omega-3 30-47 C-reactive protein Homo sapiens 77-80 23186077-7 2012 After paricalcitol treatment, levels of the inflammatory markers CRP, TNF-alpha, IL-6 and IL-18 were significantly reduced in serum and the level of anti-inflammatory cytokine IL-10 was increased. paricalcitol 6-18 C-reactive protein Homo sapiens 65-68 34263280-2 2021 This study is aimed to evaluate the effect of isolated daidzein and genistein on lipid profiles, high sensitive C-reactive protein (hs-CRP), and uric acid (UA) among Chinese women with IGR. Genistein 68-77 C-reactive protein Homo sapiens 135-138 34371487-5 2021 By using QD microspheres (SiO2@QDs@SiO2-COOH, contains approximately 200-300 hydrophobic QDs on per SiO2 sphere) as fluorescent labels, the LOD for CRP and SAA of 3D microarray reached as high as 15 pg/mL and 86 pg/mL, and the sensitivity was further improved by 28-fold and 425-fold, respectively. Silicon Dioxide 26-30 C-reactive protein Homo sapiens 148-151 34371487-5 2021 By using QD microspheres (SiO2@QDs@SiO2-COOH, contains approximately 200-300 hydrophobic QDs on per SiO2 sphere) as fluorescent labels, the LOD for CRP and SAA of 3D microarray reached as high as 15 pg/mL and 86 pg/mL, and the sensitivity was further improved by 28-fold and 425-fold, respectively. Silicon Dioxide 35-39 C-reactive protein Homo sapiens 148-151 34371487-5 2021 By using QD microspheres (SiO2@QDs@SiO2-COOH, contains approximately 200-300 hydrophobic QDs on per SiO2 sphere) as fluorescent labels, the LOD for CRP and SAA of 3D microarray reached as high as 15 pg/mL and 86 pg/mL, and the sensitivity was further improved by 28-fold and 425-fold, respectively. Silicon Dioxide 100-104 C-reactive protein Homo sapiens 148-151 23046186-5 2012 Purified CRP was digested with trypsin and subjected to high-performance LC with an optimal mobile phase of acetonitrile-water containing 0.1% formic acid (50:50, v/v) and an optimal mobile phase flow rate of 0.2 mL/min. formic acid 143-154 C-reactive protein Homo sapiens 9-12 22833186-10 2012 However, the nonselective NSAID naproxen was associated with a significant decrease in the CRP level, whereas the cyclooxygenase 2-selective NSAID lumiracoxib was associated with a significant increase in the CRP level. lumiracoxib 147-158 C-reactive protein Homo sapiens 209-212 34467402-10 2021 There were trends towards more rapid reductions in C-reactive protein, D-dimer, fibrinogen and ferritin levels in the fostamatinib group. fostamatinib 118-130 C-reactive protein Homo sapiens 51-69 34429160-8 2021 With tofacitinib + MTX, numerically higher baseline CRP levels and numerically larger post-baseline CRP reductions were seen in patients achieving CDAI remission at months 6 and 12 vs those who did not. cdai 147-151 C-reactive protein Homo sapiens 52-55 34429160-8 2021 With tofacitinib + MTX, numerically higher baseline CRP levels and numerically larger post-baseline CRP reductions were seen in patients achieving CDAI remission at months 6 and 12 vs those who did not. cdai 147-151 C-reactive protein Homo sapiens 100-103 34341450-9 2021 Mendelian randomization showed increased waist-circumference, a marker of central obesity, associated with increased kynurenine, and increased kynurenine associated with C-reactive protein (CRP). Kynurenine 143-153 C-reactive protein Homo sapiens 170-188 34341450-9 2021 Mendelian randomization showed increased waist-circumference, a marker of central obesity, associated with increased kynurenine, and increased kynurenine associated with C-reactive protein (CRP). Kynurenine 143-153 C-reactive protein Homo sapiens 190-193 34914243-0 2021 (Effects of low-dose dexmedetomidine combined with hydromorphone in postoperative analgesia and on the serum IL-6 and CRP levels of prostate cancer patients). Dexmedetomidine 21-36 C-reactive protein Homo sapiens 118-121 34914243-1 2021 Objective: To explore the effects of low-dose dexmedetomidine (DM) combined with hydromorphone (HM) in postoperative analgesia and on levels of serum interleukin-6 (IL-6) and C-reactive protein (CRP) in PCa patients. Dexmedetomidine 46-61 C-reactive protein Homo sapiens 175-193 22713099-1 2012 BACKGROUND: We are hereby investigating for the first time the effect of the association ethinylestradiol30mug-drospirenone 3mg (DRP/EE30mug) plus metformin and weight loss on endothelial status and C-reactive protein (hsCRP) levels in polycystic ovary syndrome (PCOS). ethinylestradiol30mug-drospirenone 89-123 C-reactive protein Homo sapiens 199-217 34273987-10 2021 Finally, we report an association between the kynurenine/tryptophan ratio and CRP. Kynurenine 46-56 C-reactive protein Homo sapiens 78-81 21887727-10 2012 Improvements in CDAI from baseline to Weeks 4, 26, and 56 were significantly correlated with changes from baseline for albumin, hemoglobin, and C-reactive protein (all P < 0.001). cdai 16-20 C-reactive protein Homo sapiens 144-162 34306612-12 2021 The results of secondary outcomes showed that CRP value and lymphocytes counts were significantly decreased while neutrophils, LCR, and NLR were slightly increased after aaPRP administration. aaprp 170-175 C-reactive protein Homo sapiens 46-49 22217366-8 2012 SMI had a poor prognosis in the group with an elevated CRP >= 3.0 mug/mL (hazard ratio, 3.46; 95% confidence interval, 1.67-7.16; P = .001) compared with the group of subjects with SMI and a low CRP <3.0 mug/mL (hazard ratio, 1.37; 95% confidence interval, 0.63-2.98; P = .54). SMI496 0-3 C-reactive protein Homo sapiens 55-58 34202697-7 2021 Reduced vitamin A plasma levels correlated significantly with increased levels of inflammatory markers (CRP, ferritin) and with markers of acute SARS-CoV-2 infection (reduced lymphocyte count, LDH). Vitamin A 8-17 C-reactive protein Homo sapiens 104-107 34744277-13 2021 A negative correlation was observed between the preoperative values of CRP and PCT and the analgesic effect of tramadol assessed at the second measurement point (r=-0.358, p=0.03, and r=-0.364, p=0.02, respectively). Tramadol 111-119 C-reactive protein Homo sapiens 71-74 22217366-8 2012 SMI had a poor prognosis in the group with an elevated CRP >= 3.0 mug/mL (hazard ratio, 3.46; 95% confidence interval, 1.67-7.16; P = .001) compared with the group of subjects with SMI and a low CRP <3.0 mug/mL (hazard ratio, 1.37; 95% confidence interval, 0.63-2.98; P = .54). SMI496 0-3 C-reactive protein Homo sapiens 198-201 22569435-0 2012 Effect of treatment with omega-3 fatty acids on C-reactive protein and tumor necrosis factor-alfa in hemodialysis patients. Fatty Acids, Omega-3 25-44 C-reactive protein Homo sapiens 48-66 34060403-0 2022 Omega-3 Polyunsaturated Fatty Acids Can Reduce C-Reactive Protein in Patients with Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. omega-3 polyunsaturated fatty acids 0-35 C-reactive protein Homo sapiens 47-65 34060403-3 2022 Herein, a meta-analysis of randomized controlled trials was conducted to evaluate the effects of omega-3 PUFAs on CRP levels in patients with cancer. omega-3 pufas 97-110 C-reactive protein Homo sapiens 114-117 22569435-3 2012 The aim of this study is to review the alterations in serum levels of TNF-alpha, CRP and other parameters caused by omega-3 supplementation in dialysis patients. Fatty Acids, Omega-3 116-123 C-reactive protein Homo sapiens 81-84 34068031-3 2021 A systematic literature review was conducted using PubMed to identify studies focusing on voriconazole therapeutic drug monitoring with data of both inflammation (assessed by C-reactive protein level) and the pharmacogenomics of cytochromes P450. Voriconazole 90-102 C-reactive protein Homo sapiens 175-193 23449275-7 2012 C-reactive protein showed positive correlations with phosphatidylcholine, phosphatidylserine, phosphatidylinositol and total phospholipids in membranes from control subjects. Phosphatidylcholines 53-72 C-reactive protein Homo sapiens 0-18 34068031-6 2021 Voriconazole trough concentrations were independently influenced by age, dose, C-reactive protein level, and both cytochrome P450 2C19 and 3A4 genotype, considered individually or through a combined genetic score. Voriconazole 0-12 C-reactive protein Homo sapiens 79-97 34068031-7 2021 An increase in the C-reactive protein of 10, 50, or 100 mg/L was associated with an increased voriconazole trough concentration of 6, 35, or 82%, respectively. Voriconazole 94-106 C-reactive protein Homo sapiens 19-37 23449275-7 2012 C-reactive protein showed positive correlations with phosphatidylcholine, phosphatidylserine, phosphatidylinositol and total phospholipids in membranes from control subjects. Phosphatidylinositols 94-114 C-reactive protein Homo sapiens 0-18 34406246-4 2021 RESULTS: Highly sensitive C-reactive protein levels differed significantly among the groups (p<0.001) and found to be highest in the low-density lipoprotein cholesterol tertile 1 and lowest in the low-density lipoprotein cholesterol tertile 3 (post-hoc p-values: tertile 1 vs. 2 <0.001; tertile 1 vs. 3 <0.001; tertile 2 vs. 3=0.019). -density 136-144 C-reactive protein Homo sapiens 26-44 22108347-8 2012 UA can inhibit CRP-induced proliferation of HUVECs. ursolic acid 0-2 C-reactive protein Homo sapiens 15-18 35398417-4 2022 Here, we evaluated the associations between PM10, NO2 and O3 exposure (on the day of the blood sample collection and on the day before, and the mean annual residential level) and levels of the inflammatory biomarkers high-sensitivity C-reactive protein (hsCRP), interleukin (IL)-1beta, IL-6, IL-8, IL-10, IL-17A, IL-22, and tumor necrosis factor alpha. pm10 44-48 C-reactive protein Homo sapiens 234-252 22108347-9 2012 CRP can obviously increase LOX-1/VCAM-1 expression in HUVECs, both on mRNA and protein levels and the effect of CRP can be inhibited by UA (5, 10, 20 mumol/L) in a dose-dependent manner. ursolic acid 136-138 C-reactive protein Homo sapiens 0-3 22108347-9 2012 CRP can obviously increase LOX-1/VCAM-1 expression in HUVECs, both on mRNA and protein levels and the effect of CRP can be inhibited by UA (5, 10, 20 mumol/L) in a dose-dependent manner. ursolic acid 136-138 C-reactive protein Homo sapiens 112-115 22108347-10 2012 CONCLUSION: UA can reduce the over expression of CRP in HepG2 cells induced by IL-6 and inhibit the increased expression of VCAM-1 and LOX-1 in HUVECs caused by CRP. ursolic acid 12-14 C-reactive protein Homo sapiens 49-52 22108347-10 2012 CONCLUSION: UA can reduce the over expression of CRP in HepG2 cells induced by IL-6 and inhibit the increased expression of VCAM-1 and LOX-1 in HUVECs caused by CRP. ursolic acid 12-14 C-reactive protein Homo sapiens 161-164 22108347-11 2012 Our research suggests that UA can reduce CRP levels in plasma and prevent inflammatory cytokines from injuring endothelial cells by inhibiting the hepatic synthesis of CRP. ursolic acid 27-29 C-reactive protein Homo sapiens 41-44 35120026-8 2022 Patients receiving allopurinol had significant reductions in office systolic and diastolic BP, central systolic BP, pulse pressure, IMT (0.773 +- 0.121 vs. 0.752 +- 0.13 mm, P = 0.044) and hs-CRP (3.36 +- 2.73 vs. 2.74 +- 1.91 mg/L, P = 0.028) compared to controls. Allopurinol 19-30 C-reactive protein Homo sapiens 192-195 22108347-11 2012 Our research suggests that UA can reduce CRP levels in plasma and prevent inflammatory cytokines from injuring endothelial cells by inhibiting the hepatic synthesis of CRP. ursolic acid 27-29 C-reactive protein Homo sapiens 168-171 35611526-10 2022 Seventy-point reduction in CDAI + decreased fecal CRP / calprotectin, calprotectin <250 mcg/gm or >50% decrease from baseline and hsCRP < 5 mg/L or >50% from baseline. cdai 27-31 C-reactive protein Homo sapiens 50-53 22461977-5 2012 Independent of age, sex and education, serum CRP was significantly related to higher cerebral myo-inositol/creatine ratio (F(4,31) = 4.74, P = 0.004), a relationship which remained unchanged after adjustment for cardiovascular risk (F(5,30) = 4.356, CRP beta = 0.322, P = 0.045). Creatine 107-115 C-reactive protein Homo sapiens 45-48 35083561-9 2022 The results of multivariate logistic regression analysis showed that higher CRP was a risk factor for failure of clinical remission in axSpA (OR = 2.034, 95% CI:1.595 ~ 2.617, P < 0.001), while higher ASDAScrp was a risk factor for failure of imaging remission (OR = 1.306, 95% CI:1.026 ~ 1.688, P < 0.05). axspa 135-140 C-reactive protein Homo sapiens 76-79 23087143-0 2012 Epigallocatechin-3-gallate inhibits angiotensin II and interleukin-6-induced C-reactive protein production in macrophages. epigallocatechin gallate 0-26 C-reactive protein Homo sapiens 77-95 35097067-9 2022 During the treatment, the lymphocyte count, ESR, IL-6, serum ferritin, LDH, CK-MB, hs-CRP and D-dimer levels all improved gradually, indicating that both Arbidol and methylprednisolone therapy were contributed to improving the condition of COVID-19 patients. umifenovir 154-161 C-reactive protein Homo sapiens 86-89 23087143-4 2012 Therefore, the effect of EGCG on angiotensin II (Ang II)- and interleukin-6 (IL-6)-induced CRP production in U937 macrophages and the possible mechanisms were observed. epigallocatechin gallate 25-29 C-reactive protein Homo sapiens 91-94 23087143-9 2012 RESULTS: Pretreatment of macrophages with EGCG prior to the stimulation concentration-dependently inhibited Ang II- and IL-6-induced expression of CRP both in protein and mRNA levels. epigallocatechin gallate 42-46 C-reactive protein Homo sapiens 147-150 15735094-8 2005 Trans fatty acid intake was positively related to plasma concentration of CRP (P = 0.009), sTNFR-2 (P = 0.002), E-selectin (P = 0.003), sICAM-1 (P = 0.007), and sVCAM-1 (P = 0.001) in linear regression models after controlling for age, BMI, physical activity, smoking status, alcohol consumption, intake of monounsaturated, polyunsaturated, and saturated fatty acids, and postmenopausal hormone therapy. Trans Fatty Acids 0-16 C-reactive protein Homo sapiens 74-77 23087143-11 2012 CONCLUSION: EGCG is able to inhibit Ang II- and IL-6-stimulated CRP expression in macrophages to produce an anti-inflammation by interfering with ROS generation. epigallocatechin gallate 12-16 C-reactive protein Homo sapiens 64-67 21349512-5 2011 In multivariable linear regression models, we observed significant positive associations between CRP and mono-benzyl phthalate (MBzP) and mono-isobutyl phthalate (MiBP). mono-isobutyl phthalate 138-161 C-reactive protein Homo sapiens 97-100 21784308-0 2011 The relationships between erythrocyte membrane n-6 to n-3 polyunsaturated fatty acids ratio and blood lipids and C-reactive protein in Chinese adults: an observational study. Fatty Acids, Unsaturated 58-85 C-reactive protein Homo sapiens 113-131 21383592-6 2011 In addition, GR antagonist RU486 but not PPARgamma inhibitor GW9662 remarkably weakened the inhibitory effects of rosiglitazone on CRP-induced TLR4 expression and p38 phosphorylation in VSMCs. Mifepristone 27-32 C-reactive protein Homo sapiens 131-134 23763034-11 2011 The median plasma retinol concentration of the children with normal plasma CRP was 1.19 micromol/l and the interquartile range 0.93-1.50 micromol/l. Vitamin A 18-25 C-reactive protein Homo sapiens 75-78 15671217-5 2005 In multiple linear regression models adjusting for age, parity, education, BMI, and days postpartum, plasma retinol concentrations were associated with plasma AGP and CRP concentrations (P < 0.0001 and P = 0.01, respectively), whereas breast milk retinol concentrations were unaffected by plasma AGP and CRP concentrations (P = 0.22 and P = 0.86, respectively). Vitamin A 108-115 C-reactive protein Homo sapiens 167-170 15671217-5 2005 In multiple linear regression models adjusting for age, parity, education, BMI, and days postpartum, plasma retinol concentrations were associated with plasma AGP and CRP concentrations (P < 0.0001 and P = 0.01, respectively), whereas breast milk retinol concentrations were unaffected by plasma AGP and CRP concentrations (P = 0.22 and P = 0.86, respectively). Vitamin A 108-115 C-reactive protein Homo sapiens 307-310 15783053-9 2005 The leukocyte count on day 1 and day 3, and serum C-reactive protein levels on day 1 were significantly lower after LADG than after ODG. BMP15 protein, human 132-135 C-reactive protein Homo sapiens 50-68 21210202-0 2011 Phosphatidylcholine-rich nanoliposomes: potential tools for serum C-reactive protein reduction? Phosphatidylcholines 0-19 C-reactive protein Homo sapiens 66-84 16514905-13 2005 The relationship between SUA and CRP levels remained statistically significant after adjustment for age, sex, comorbid index, obesity, residual renal function, diuretic and allopurinol treatment, in the multivariate logistic and linear regression models (OR: 1.296, p = 0.0003; and beta: 0.204, p = 0.0002). Allopurinol 173-184 C-reactive protein Homo sapiens 33-36 21136015-6 2011 Carriers of the H2H2 genotype of the G-455>A polymorphism had increased fibrinogen levels, particularly in association with increased CRP levels. h2h2 16-20 C-reactive protein Homo sapiens 137-140 15472532-4 2004 In CD, serum levels of CRP correlate well with disease activity and with other markers of inflammation as the CDAI, serum amyloid, IL-6 and faecal calprotectin. cdai 110-114 C-reactive protein Homo sapiens 23-26 21625475-7 2011 SUA correlated positively with IL-6, TNF-alpha and CRP and negatively with IL-1beta (Spearman r: 0.04, 0.07, 0.20 and 0.05 in men, and 0.09, 0.13, 0.30 and 0.07 in women, respectively, P<0.05). sua 0-3 C-reactive protein Homo sapiens 51-54 15302800-7 2004 There was a significant off-drug effect on CRP and IL-6 levels in the rofecoxib group 3 months after treatment (P=0.005 and P=0.009, respectively). rofecoxib 70-79 C-reactive protein Homo sapiens 43-46 21625475-8 2011 In multivariable analyses, SUA was associated positively with CRP (beta coefficient +- SE = 0.35+-0.02, P<0.001), TNF-alpha (0.08+-0.02, P<0.001) and IL-6 (0.10+-0.03, P<0.001), and negatively with IL-1beta (-0.07+-0.03, P = 0.027). sua 27-30 C-reactive protein Homo sapiens 62-65 21625475-10 2011 CONCLUSIONS: SUA was associated positively with IL-6, CRP and TNF-alpha and negatively with IL-1beta, particularly in women. sua 13-16 C-reactive protein Homo sapiens 54-57 20490917-7 2010 The KYN/TRP ratio at admission correlated with CRP levels, ESR and NLR. Kynurenine 4-7 C-reactive protein Homo sapiens 47-50 15226473-4 2004 C-reactive protein (CRP) levels were 29% lower among those in the highest quintile of total (n-3) fatty acids, compared with the lowest quintile; interleukin-6 (IL-6) levels were 23% lower, E-selectin levels 10% lower, soluble intracellular adhesion molecule (sICAM-1) levels 7% lower, and soluble vascular adhesion molecule (sVCAM-1) levels 8% lower. Fatty Acids, Omega-3 92-109 C-reactive protein Homo sapiens 0-18 20891039-3 2010 In parallel with CRP, the content of secretory phospholipase A, as a component of lipoproteins is on the rise; the enzyme hydrolyzes phosphatidylcholine in the surface monolayer of lipoproteins to form lysophosphatidylcholine that the CRP-pentamere displays a high affinity binding to. Phosphatidylcholines 133-152 C-reactive protein Homo sapiens 17-20 15226473-4 2004 C-reactive protein (CRP) levels were 29% lower among those in the highest quintile of total (n-3) fatty acids, compared with the lowest quintile; interleukin-6 (IL-6) levels were 23% lower, E-selectin levels 10% lower, soluble intracellular adhesion molecule (sICAM-1) levels 7% lower, and soluble vascular adhesion molecule (sVCAM-1) levels 8% lower. Fatty Acids, Omega-3 92-109 C-reactive protein Homo sapiens 20-23 15226473-7 2004 Total (n-3) fatty acids had an inverse relation with CRP (beta = -0.44, P = 0.007), IL-6 (beta = -0.26, P = 0.009), E-selectin (beta = -0.17, P = 0.004), sICAM-1 (beta = -0.07, P = 0.02), and sVCAM-1 (beta = -0.10, P = 0.004). Fatty Acids, Omega-3 6-23 C-reactive protein Homo sapiens 53-56 15142951-7 2004 Collagen or CRP-stimulated 12-H(P)ETE generation was inhibited by staurosporine, PP2, wortmannin, BAPTA/AM, EGTA, and L-655238, implicating src-tyrosine kinases, PI3-kinase, Ca2+ mobilization, and p12-LOX translocation. Staurosporine 66-79 C-reactive protein Homo sapiens 12-15 15069691-0 2004 Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy. Thalidomide 0-11 C-reactive protein Homo sapiens 26-44 15069691-3 2004 We used thalidomide to treat patients with cancer-induced cachexia and noted that the drug significantly reduced serum levels of CRP and IL-6 to normal or near normal levels in a substantial fraction of patients. Thalidomide 8-19 C-reactive protein Homo sapiens 129-132 15069691-9 2004 Reduction of serum CRP or IL-6 levels with thalidomide may enhance the responsiveness of renal cell carcinoma to IL-2. Thalidomide 43-54 C-reactive protein Homo sapiens 19-22 20891039-3 2010 In parallel with CRP, the content of secretory phospholipase A, as a component of lipoproteins is on the rise; the enzyme hydrolyzes phosphatidylcholine in the surface monolayer of lipoproteins to form lysophosphatidylcholine that the CRP-pentamere displays a high affinity binding to. Phosphatidylcholines 133-152 C-reactive protein Homo sapiens 235-238 20891039-4 2010 Two different immunochemical assays for CRP suggest that the CRP-monomere and the CRP-pentamere show different functional activity: the CRP-monomere is a humoral immunomodulator while the CRP-pentamere also activates interstitial tissue cells, but differently, by enhancing their energy provision with substrates, namely with saturated and unsaturated fatty acids as triglycerides as components of very low-density lipoproteins via CRP/apoB-100-receptor endocytosis. saturated and unsaturated fatty acids 326-363 C-reactive protein Homo sapiens 40-43 20891039-4 2010 Two different immunochemical assays for CRP suggest that the CRP-monomere and the CRP-pentamere show different functional activity: the CRP-monomere is a humoral immunomodulator while the CRP-pentamere also activates interstitial tissue cells, but differently, by enhancing their energy provision with substrates, namely with saturated and unsaturated fatty acids as triglycerides as components of very low-density lipoproteins via CRP/apoB-100-receptor endocytosis. saturated and unsaturated fatty acids 326-363 C-reactive protein Homo sapiens 61-64 15228720-5 2004 The PTB cases who had >50 mg CRP/ litre (a concentration indicative of an APR) had lower serum concentrations of retinol and zinc than the cases with lower CRP concentrations. Vitamin A 116-123 C-reactive protein Homo sapiens 32-35 20891039-4 2010 Two different immunochemical assays for CRP suggest that the CRP-monomere and the CRP-pentamere show different functional activity: the CRP-monomere is a humoral immunomodulator while the CRP-pentamere also activates interstitial tissue cells, but differently, by enhancing their energy provision with substrates, namely with saturated and unsaturated fatty acids as triglycerides as components of very low-density lipoproteins via CRP/apoB-100-receptor endocytosis. saturated and unsaturated fatty acids 326-363 C-reactive protein Homo sapiens 61-64 15136366-0 2004 Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. rofecoxib 0-9 C-reactive protein Homo sapiens 37-55 15136366-2 2004 AIM: To evaluate whether patients with ACS treated with rofecoxib, a COX-2 inhibitor, will have reduced CRP, IL-6, and soluble tumor necrotic factor receptor-1 (sTNF-R1) levels and improved endothelial function. rofecoxib 56-65 C-reactive protein Homo sapiens 104-107 20891039-4 2010 Two different immunochemical assays for CRP suggest that the CRP-monomere and the CRP-pentamere show different functional activity: the CRP-monomere is a humoral immunomodulator while the CRP-pentamere also activates interstitial tissue cells, but differently, by enhancing their energy provision with substrates, namely with saturated and unsaturated fatty acids as triglycerides as components of very low-density lipoproteins via CRP/apoB-100-receptor endocytosis. saturated and unsaturated fatty acids 326-363 C-reactive protein Homo sapiens 61-64 15136366-5 2004 CRP levels in the rofecoxib group (n = 18) were significantly lower both at 1 month and 3 months compared to the baseline levels (p < 0.02). rofecoxib 18-27 C-reactive protein Homo sapiens 0-3 20891039-4 2010 Two different immunochemical assays for CRP suggest that the CRP-monomere and the CRP-pentamere show different functional activity: the CRP-monomere is a humoral immunomodulator while the CRP-pentamere also activates interstitial tissue cells, but differently, by enhancing their energy provision with substrates, namely with saturated and unsaturated fatty acids as triglycerides as components of very low-density lipoproteins via CRP/apoB-100-receptor endocytosis. saturated and unsaturated fatty acids 326-363 C-reactive protein Homo sapiens 61-64 15136366-8 2004 CONCLUSION: Patients recovering from ACS had lower levels of CRP and IL-6 at 1 month and lower CRP levels at 3 months when treated with rofecoxib plus aspirin. rofecoxib 136-145 C-reactive protein Homo sapiens 61-64 15136366-8 2004 CONCLUSION: Patients recovering from ACS had lower levels of CRP and IL-6 at 1 month and lower CRP levels at 3 months when treated with rofecoxib plus aspirin. rofecoxib 136-145 C-reactive protein Homo sapiens 95-98 20891039-4 2010 Two different immunochemical assays for CRP suggest that the CRP-monomere and the CRP-pentamere show different functional activity: the CRP-monomere is a humoral immunomodulator while the CRP-pentamere also activates interstitial tissue cells, but differently, by enhancing their energy provision with substrates, namely with saturated and unsaturated fatty acids as triglycerides as components of very low-density lipoproteins via CRP/apoB-100-receptor endocytosis. saturated and unsaturated fatty acids 326-363 C-reactive protein Homo sapiens 61-64 14743546-7 2003 Using a limit of 0.6 mg/L (75th percentile), significantly lower levels were observed for transthyretin, iron, retinol, and beta-carotene in the group with the higher CRP levels. Vitamin A 111-118 C-reactive protein Homo sapiens 167-170 20891039-6 2010 For this, lipoprotein-associated phospholipase A, hydrolyzes phosphatidylcholine to produce lysophosphatidylcholine that the CRP-pentamere binds to; it superimposes a physiological apoE/B-100-ligand, becomes itself a pathophysiological CRP/B-100-ligand, and directs a flow of the energy substrates towards the interstitial cells that exhibit pathophysiological CRB/B-100-receptors on the membrane. Phosphatidylcholines 61-80 C-reactive protein Homo sapiens 125-128 20891039-6 2010 For this, lipoprotein-associated phospholipase A, hydrolyzes phosphatidylcholine to produce lysophosphatidylcholine that the CRP-pentamere binds to; it superimposes a physiological apoE/B-100-ligand, becomes itself a pathophysiological CRP/B-100-ligand, and directs a flow of the energy substrates towards the interstitial cells that exhibit pathophysiological CRB/B-100-receptors on the membrane. Phosphatidylcholines 61-80 C-reactive protein Homo sapiens 236-239 14506615-0 2003 C-reactive protein in young, apparently healthy men: associations with serum leptin, QTc interval, and high-density lipoprotein-cholesterol. qtc 85-88 C-reactive protein Homo sapiens 0-18 20364851-0 2010 C-reactive protein induced rearrangement of phosphatidylcholine on nanoparticle mimics of lipoprotein particles. Phosphatidylcholines 44-63 C-reactive protein Homo sapiens 0-18 12860264-1 2003 Limited evidence has suggested that low levels of circulating pyridoxal-5"-phosphate (PLP) may be associated with elevation of the inflammatory marker, C-reactive protein (CRP). Pyridoxal Phosphate 62-84 C-reactive protein Homo sapiens 152-170 12860264-1 2003 Limited evidence has suggested that low levels of circulating pyridoxal-5"-phosphate (PLP) may be associated with elevation of the inflammatory marker, C-reactive protein (CRP). Pyridoxal Phosphate 62-84 C-reactive protein Homo sapiens 172-175 12860264-1 2003 Limited evidence has suggested that low levels of circulating pyridoxal-5"-phosphate (PLP) may be associated with elevation of the inflammatory marker, C-reactive protein (CRP). Pyridoxal Phosphate 86-89 C-reactive protein Homo sapiens 152-170 12860264-1 2003 Limited evidence has suggested that low levels of circulating pyridoxal-5"-phosphate (PLP) may be associated with elevation of the inflammatory marker, C-reactive protein (CRP). Pyridoxal Phosphate 86-89 C-reactive protein Homo sapiens 172-175 20179170-10 2010 In the unadjusted analysis, SUA levels correlated with PWV, CRP, fibrinogen and homocysteine. sua 28-31 C-reactive protein Homo sapiens 60-63 12654170-0 2003 The effect of dietary n-3 fatty acids on serum concentrations of C-reactive protein: a dose-response study. Fatty Acids, Omega-3 22-37 C-reactive protein Homo sapiens 65-83 12721499-1 2003 The objective of this study was to examine the effect of the antihyperglycemic agents metformin (insulin sensitizer) and glibenclamide (insulin secretory agent) on the serum level of C-reactive protein (CRP) in well-controlled type 2 diabetics with metabolic syndrome. Glyburide 121-134 C-reactive protein Homo sapiens 183-201 12721499-1 2003 The objective of this study was to examine the effect of the antihyperglycemic agents metformin (insulin sensitizer) and glibenclamide (insulin secretory agent) on the serum level of C-reactive protein (CRP) in well-controlled type 2 diabetics with metabolic syndrome. Glyburide 121-134 C-reactive protein Homo sapiens 203-206 19996731-6 2010 Increased SUA was significantly correlated with age, gender, comorbidities (coronary heart disease, heart failure, hypertension, diabetes, renal failure, and gout), use of diuretics, and current admission for cardiovascular diseases but not with current diagnosis of infection, malignancy, or inflammatory diseases, nor with C-reactive protein. sua 10-13 C-reactive protein Homo sapiens 325-343 12729319-5 2003 RESULTS: Metronidazole plus ciprofloxacin decreased the CRP in seven patients and the IOIBD score in six patients. Metronidazole 9-22 C-reactive protein Homo sapiens 56-59 12426217-8 2002 Maximum relaxation response to CRP (79.5+/-10%) was attenuated by KCl (2.5+/-11.5%, P<0.001), BaCl (24.5+/-7.5%, P<0.001), and tetraethylammonium chloride (34.9+/-8.25%, P<0.01) but not by glibenclamide. Glyburide 198-211 C-reactive protein Homo sapiens 31-34 20924143-6 2010 Significant correlation was observed between baseline concentrations of retinol and C-reactive protein (r(s)=-0.54, p<0.01). Vitamin A 72-79 C-reactive protein Homo sapiens 84-102 12421431-4 2002 RESULTS: Spearman correlation analyses and multiple linear regression analyses showed a significant association of both fasting glucose and 2-h glucose concentrations with CRP levels, after adjusting for demographic covariates (age, sex, ethnicity, clinical centre; Spearman correlation coefficients: r = 0.18 for fasting glucose, r = 0.27 for 2-h glucose, both P < 0.0001). 2-h glucose 344-355 C-reactive protein Homo sapiens 172-175 12421431-5 2002 However, after additional adjustment for body mass index and waist-hip ratio only 2-h glucose (and not fasting glucose) was significantly related to CRP (r = 0.03 for fasting glucose, P = NS; r = 0.14 for 2-h glucose, P < 0.0001). 2-h glucose 82-93 C-reactive protein Homo sapiens 149-152 20924143-10 2010 In conclusion, a significant correlation was observed between serum retinol and C-reactive protein. Vitamin A 68-75 C-reactive protein Homo sapiens 80-98 19919970-2 2009 This study was designed to determine serum highly sensitive C-reactive protein (hs-CRP) and evaluate its correlation with lung function parameters in patients with chronic obstructive pulmonary disease (COPD) due to SM poisoning. Mustard Gas 216-218 C-reactive protein Homo sapiens 60-78 12392824-12 2002 CONCLUSIONS: High plasma levels of either CRP or Lp(a) but not tHCY may be associated with a higher incidence of late adverse events after successful CS. Cesium 150-152 C-reactive protein Homo sapiens 42-45 19454128-5 2009 Also an inverse correlation was observed between the C-reactive protein and membrane phosphatidylcholine and phosphatidylserine 20 : 4n-6. Phosphatidylcholines 85-104 C-reactive protein Homo sapiens 53-71 19713292-5 2009 Patients with no RRF showed higher calcium-phosphorus product (Ca x P) and C-reactive protein (CRP). Phosphorus 0-1 C-reactive protein Homo sapiens 75-93 19713292-5 2009 Patients with no RRF showed higher calcium-phosphorus product (Ca x P) and C-reactive protein (CRP). Phosphorus 0-1 C-reactive protein Homo sapiens 95-98 19737803-6 2009 Patients with elevated SUA had significantly higher levels of high-sensitivity C-reactive protein (P = 0.008) and N-terminal probrain natriuretic peptide (P = 0.022), but there was no significant difference in oxidative stress parameters. sua 23-26 C-reactive protein Homo sapiens 79-97 19775037-9 2009 Vitamin A concentration was weakly associated with the C-reactive protein concentrations on days one and five (Spearman"s r = -0.5 [P = 0.001], -0.4 [P = 0.03], respectively). Vitamin A 0-9 C-reactive protein Homo sapiens 55-73 19352379-0 2009 An inverse relationship between plasma n-3 fatty acids and C-reactive protein in healthy individuals. Fatty Acids, Omega-3 39-54 C-reactive protein Homo sapiens 59-77 19557004-11 2009 In NT, CA16 carriers revealed significantly higher sTNFR2 and CRP levels than did the CA16 non-carriers. ca16 7-11 C-reactive protein Homo sapiens 62-65 19288149-3 2009 Also investigated was whether changes in the circulating flavonol concentrations correlate with the SBB induced changes in C-reactive protein (CRP) concentration observed previously. sbb 100-103 C-reactive protein Homo sapiens 143-146 23964162-5 2009 Female patients receiving Daflon( ) either alone or with oral hypoglycemic showed significant decrease in serum glucose; fructosamine; total cholesterol; LDL-cholesterol; triglycerides; malondialdehydes (as index of lipid peroxidation) and C-reactive protein (CRB) levels along with increase in the levels of nitric oxide and blood glutathione. Diosmin 26-32 C-reactive protein Homo sapiens 240-258 19628101-3 2009 This study aimed to assess the association between PUFA intake and serum C-reactive protein (CRP) concentrations in a group of Japanese employees. Fatty Acids, Unsaturated 51-55 C-reactive protein Homo sapiens 73-91 19628101-3 2009 This study aimed to assess the association between PUFA intake and serum C-reactive protein (CRP) concentrations in a group of Japanese employees. Fatty Acids, Unsaturated 51-55 C-reactive protein Homo sapiens 93-96 19294859-1 2008 OBJECTIVE: To discussion the effects of Huoxue components of effective drug in treating unstable angina in patients with blood stasis WBC (WBC), C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha). huoxue 40-46 C-reactive protein Homo sapiens 145-163 18343384-1 2008 OBJECTIVE: To examine whether dietary intake of n-3 polyunsaturated fatty acid (n-3PUFA) is associated with serum C-reactive protein (CRP) levels with regard to smoking status in the Japanese general population in a cross-sectional study. Fatty Acids, Omega-3 80-87 C-reactive protein Homo sapiens 114-132 18343384-1 2008 OBJECTIVE: To examine whether dietary intake of n-3 polyunsaturated fatty acid (n-3PUFA) is associated with serum C-reactive protein (CRP) levels with regard to smoking status in the Japanese general population in a cross-sectional study. Fatty Acids, Omega-3 80-87 C-reactive protein Homo sapiens 134-137 19083425-0 2008 Total n-3 polyunsaturated fatty acid intake is inversely associated with serum C-reactive protein in young Japanese women. Fatty Acids, Omega-3 6-36 C-reactive protein Homo sapiens 79-97 19083425-7 2008 After adjustment for possible confounding factors including body mass index, a significant inverse association was seen between total n-3 polyunsaturated fatty acid intake and elevated CRP. Fatty Acids, Omega-3 134-164 C-reactive protein Homo sapiens 185-188 19083425-12 2008 In conclusion, total n-3 polyunsaturated fatty acid intake showed an independent inverse association with elevated serum CRP concentration in a group of young Japanese women. Fatty Acids, Omega-3 21-51 C-reactive protein Homo sapiens 121-124 19281089-4 2008 As the integrated changes of those indices are summarized by oxygen extraction tension (PaO2x), the objective of this study was to explore the association between C-reactive protein (CRP) blood levels and either PaO2x or each of its determinants, in stable COPD. pao2x 212-217 C-reactive protein Homo sapiens 163-181 19281089-4 2008 As the integrated changes of those indices are summarized by oxygen extraction tension (PaO2x), the objective of this study was to explore the association between C-reactive protein (CRP) blood levels and either PaO2x or each of its determinants, in stable COPD. pao2x 212-217 C-reactive protein Homo sapiens 183-186 17957146-6 2007 Healthy children with CRP levels above 0.6 mg/L had significant lower levels of retinol (p = 0.03). Vitamin A 80-87 C-reactive protein Homo sapiens 22-25 17929239-6 2007 Our experimental results demonstrate that betulin disulphate (B2S) and 9,9-bis(4"-hydroxyphenyl)fluorene disulphate (F2S) inhibit the interaction of C1q and its recombinant globular modules with target molecules IgG1, C-reactive protein (CRP) and long pentraxin 3 (PTX3). betulin disulphate 42-60 C-reactive protein Homo sapiens 218-242 17643584-8 2007 Moreover, the C-reactive protein (CRP) plasma levels increased with the number of CLs. Chlorine 82-85 C-reactive protein Homo sapiens 14-32 17643584-8 2007 Moreover, the C-reactive protein (CRP) plasma levels increased with the number of CLs. Chlorine 82-85 C-reactive protein Homo sapiens 34-37 17614367-10 2007 The immunoassay with the LFDA for 10 min (total assay time of approximately 23 min) with a CRP sample volume of 0.5 microL yielded an LOD of 0.15 pM, which is equivalent to 75 zmol. zmol 176-180 C-reactive protein Homo sapiens 91-94 17786078-5 2007 Logistic regression analysis using a cutoff value of the SUA of 7.0 mg/dL showed that some components of MS and the logarithmic value of the serum C-reactive protein were associated with a significant odds ratio for predicting elevated SUA. sua 57-60 C-reactive protein Homo sapiens 147-165 17786078-5 2007 Logistic regression analysis using a cutoff value of the SUA of 7.0 mg/dL showed that some components of MS and the logarithmic value of the serum C-reactive protein were associated with a significant odds ratio for predicting elevated SUA. sua 236-239 C-reactive protein Homo sapiens 147-165 12091125-6 2002 Plasma TSA correlated with CRP (r=0.31, p<0.05). trichostatin A 7-10 C-reactive protein Homo sapiens 27-30 17786078-6 2007 The odds ratios and 95% confidence intervals (CIs) of a high logarithmic value of the serum C-reactive protein, large waist girth, elevated blood pressure, and dyslipidemia for elevated SUA were 1.76 (CI, 1.21-2.55), 1.72 (CI, 1.21-2.45), 1.42 (CI, 1.01-2.00), and 1.87 (CI, 1.30-2.69), respectively. sua 186-189 C-reactive protein Homo sapiens 92-110 17546842-13 2007 No change during the control period regarding baseline occurred when placebo was randomized to be given first; however, when it followed omega-3 supplementation, CRP and SAA recovered, whereas WBC and fibronection remained depressed during those 2 weeks (7500 +/- 2100/mm3 and 393.2 +/- 75.8 mg/dL, P<0.05). Fatty Acids, Omega-3 137-144 C-reactive protein Homo sapiens 162-165 11840366-7 2002 The behavior of CRP plasma levels resembled that of IL-6 PBMC release (23.3 +/- 4.7 in CU, 11.0 +/- 2.1 after 3 months in SMC, and 7.9 +/- 1.5 after 6 months in SMC, respectively). cuprammonium cellulose 87-89 C-reactive protein Homo sapiens 16-19 17145556-7 2006 In multivariable analyses with simultaneous adjustment for Framingham risk score and C-reactive protein, 9-HETE (4th quartile OR = 4.8, 95% CI=1.3 to 17.1; P = 0.016) and F(2)-isoprostanes (4th quartile OR=9.7, 95% CI=2.56 to 36.9; P < 0.001) remained strong and independent predictors of CAD risk. 9-hydroxy-5Z,7E,11Z,14Z-eicosatetraenoic acid 105-111 C-reactive protein Homo sapiens 85-103 11684681-7 2002 In addition to PC-related structures, certain sugar phosphates (e.g. galactose 6-phosphate) are bound near the PC-binding site, and one of the sugar hydroxyl groups appears to interact with CRP. sugar hydroxyl 143-157 C-reactive protein Homo sapiens 190-193 17220028-11 2006 Two months of Lercanidipine treatment showed a significant decrease in BP, PMNL counts and apoptosis, CRP and serum insulin levels and a significant increase in serum albumin levels. lercanidipine 14-27 C-reactive protein Homo sapiens 102-105 16234304-12 2006 CONCLUSIONS: In this community-based sample, PUFAs, and especially total n-3 fatty acids, were independently associated with lower levels of proinflammatory markers (IL-6, IL-1ra, TNFalpha, C-reactive protein) and higher levels of antiinflammatory markers (soluble IL-6r, IL-10, TGFbeta) independent of confounders. Fatty Acids, Unsaturated 45-50 C-reactive protein Homo sapiens 190-208 12614487-8 2002 In patients with overt diabetes or insulin resistance, TZD treatment can lower blood levels of C-reactive protein and interleukin-6, markers of inflammation and cardiovascular risk. 2,4-thiazolidinedione 55-58 C-reactive protein Homo sapiens 95-113 12147774-5 2002 In addition, exogenous factors (dialysate endotoxin, vascular access, cuprophane dialyser material) have been identified in clinical studies which are also responsible, at least in part, for high serum CRP levels. cuprammonium cellulose 70-80 C-reactive protein Homo sapiens 202-205 16234304-12 2006 CONCLUSIONS: In this community-based sample, PUFAs, and especially total n-3 fatty acids, were independently associated with lower levels of proinflammatory markers (IL-6, IL-1ra, TNFalpha, C-reactive protein) and higher levels of antiinflammatory markers (soluble IL-6r, IL-10, TGFbeta) independent of confounders. Fatty Acids, Omega-3 73-88 C-reactive protein Homo sapiens 190-208 16383313-2 2006 The suitability of silicon electrodes coated with thermally grown silicon dioxide film as disposable working electrodes in sensitive time-resolved ECL measurements is demonstrated, and a rapid electrochemiluminoimmunoassay (ECLIA) of human C-reactive protein (hCRP) is described. Silicon Dioxide 66-81 C-reactive protein Homo sapiens 260-264 11401933-5 2001 We hypothesized a relationship between pyridoxal 5"-phosphate (PLP), the active form of vitamin B(6), and the marker of inflammation C-reactive protein (CRP). Pyridoxal Phosphate 39-61 C-reactive protein Homo sapiens 133-151 11401933-5 2001 We hypothesized a relationship between pyridoxal 5"-phosphate (PLP), the active form of vitamin B(6), and the marker of inflammation C-reactive protein (CRP). Pyridoxal Phosphate 39-61 C-reactive protein Homo sapiens 153-156 11401933-5 2001 We hypothesized a relationship between pyridoxal 5"-phosphate (PLP), the active form of vitamin B(6), and the marker of inflammation C-reactive protein (CRP). Pyridoxal Phosphate 63-66 C-reactive protein Homo sapiens 133-151 11401933-5 2001 We hypothesized a relationship between pyridoxal 5"-phosphate (PLP), the active form of vitamin B(6), and the marker of inflammation C-reactive protein (CRP). Pyridoxal Phosphate 63-66 C-reactive protein Homo sapiens 153-156 11446515-6 2001 The production of C51 microcin decreased or was absent in rpoS, crp and cya mutant cells. c51 microcin 18-30 C-reactive protein Homo sapiens 64-67 11214351-6 2000 Women with elevated acute phase protein (AGP > 1 gm/L and/or CRP > 5 mg/L) at baseline who received vitamin A had significantly higher plasma and breast milk vitamin A at follow-up compared with placebo. Vitamin A 106-115 C-reactive protein Homo sapiens 64-67 11214351-6 2000 Women with elevated acute phase protein (AGP > 1 gm/L and/or CRP > 5 mg/L) at baseline who received vitamin A had significantly higher plasma and breast milk vitamin A at follow-up compared with placebo. Vitamin A 164-173 C-reactive protein Homo sapiens 64-67 10844622-10 2000 There was a significant correlation (r = 0.83, P = 0.001) within the hemodialysis EAA group between the baseline C-reactive protein level and improvement in serum albumin. Amino Acids, Essential 82-85 C-reactive protein Homo sapiens 113-131 10720170-6 2000 Seasonal differences were evident for most of the indicators of micronutrient status, and elevated C-reactive protein levels (indicative of recent infection) were related to lower hemoglobin, retinol and zinc concentrations but higher ferritin and erythrocyte riboflavin concentrations. Vitamin A 192-199 C-reactive protein Homo sapiens 99-117 10432314-5 1999 The formation of inositol phosphates and phosphatidic acid (PA), two markers of phospholipase C (PLC) activation, by CRP are inhibited by between 50 and 85% in the presence of wortmannin and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 191-199 C-reactive protein Homo sapiens 117-120 9808227-8 1998 Low serum retinol was independently associated with S. dysenteriae type 1, high serum C-reactive protein concentrations, and low weight-forage in multiple regression analysis. Vitamin A 10-17 C-reactive protein Homo sapiens 86-104 9625099-2 1998 Serum alpha1-acid glycoprotein (AGP) and C-reactive protein (CRP) were inversely associated with serum retinol concentrations. Vitamin A 103-110 C-reactive protein Homo sapiens 41-59 9625099-2 1998 Serum alpha1-acid glycoprotein (AGP) and C-reactive protein (CRP) were inversely associated with serum retinol concentrations. Vitamin A 103-110 C-reactive protein Homo sapiens 61-64 9625099-3 1998 Elevations in the concentration of CRP in both cases and controls and of AGP in cases were associated with significant reductions (approximately 0.2-0.3 micromol/L) in serum retinol. Vitamin A 174-181 C-reactive protein Homo sapiens 35-38 9625099-4 1998 The risk of a low serum retinol concentration (< 0.7 micromol/L) with elevated AGP (> or = 1 g/L) and CRP (> or = 5 mg/L) concentrations was significantly higher in cases (odds ratios = 8.6 and 4.3, respectively) than in controls (odd ratios = 1.9 and 2.4, respectively). Vitamin A 24-31 C-reactive protein Homo sapiens 108-111 9625099-7 1998 Illness in the previous week and elevated CRP or AGP concentrations were synergistically associated with lower serum retinol. Vitamin A 117-124 C-reactive protein Homo sapiens 42-45 9280190-5 1997 Among preschool children, sex, elevated serum concentrations of C-reactive protein, and malarial parasitemia were significant predictors of serum retinol. Vitamin A 146-153 C-reactive protein Homo sapiens 64-82 9070642-3 1997 In this study, the presence of CRP-like immunoreactivity in AD neurofibrillary tangles (NFT) was demonstrated following pre-treatment of tissue sections with formic acid. formic acid 158-169 C-reactive protein Homo sapiens 31-34 9380601-3 1997 CRP serum levels during haemodialysis with the use of cuprophane membranes increased from 4743.3 +/- 3251.6 ng/ml to 5231.8 +/- 3458.4 ng/ml just after haemodialysis and 5865.4 +/- 3684.8 ng/ml 22 hours after haemodialysis (p < 0.001). cuprammonium cellulose 54-64 C-reactive protein Homo sapiens 0-3 9380601-5 1997 Re-counted CRP values, according to changes in total blood protein, increased significantly (p < 0.02) 22 hours after haemodialysis with the use of cuprophane membranes. cuprammonium cellulose 151-161 C-reactive protein Homo sapiens 11-14 8859218-5 1996 By incubating purified native CRP supplemented with normal human serum as a source of C we detected the C components Clq, Clr, Cls, C4 and C3 in the same speckled immunofluorescent pattern on HEp-2 cell nuclei as described characteristically for CRP binding. Chlorine 127-130 C-reactive protein Homo sapiens 30-33 8859218-7 1996 However, certain C3-IFT-negative acute-phase sera showed an arrest between Cls and C4 of the CRP-mediated C activation cascade. Chlorine 75-78 C-reactive protein Homo sapiens 93-96 8702903-1 1996 Although cAMP binding to wild type cAMP receptor protein (CRP) induces specific DNA binding and activates transcription, cyclic nucleoside monophosphate (cNMP) binding to the CRP mutant Ser128 --> Ala does not, whereas the double CRP mutant Thr127 --> Leu/Ser128 --> Ala activates transcription even in the absence of cNMP. cnmp 154-158 C-reactive protein Homo sapiens 175-178 8727946-5 1996 Significant differences in maximum body temperature, leukocyte count, and plasma C-reactive protein concentration were observed between the GDP and UDP groups on POD 14:37.2 +/- 0.5 degrees C vs 36.9 +/- 0.3 degrees C (P = 0.019), 8,151 +/- 1,788/microliters vs 6,914 +/- 1,501/microliters (P = 0.015), and 32.6 +/- 27.5 mg/l vs 19.0 +/- 15.8 mg/l (P = 0.048), respectively. Guanosine Diphosphate 140-143 C-reactive protein Homo sapiens 81-99 7869303-7 1994 The erythrocyte sedimentation rate and serum C-reactive protein levels improved significantly in patients treated with 40 mg pamidronate. Pamidronate 125-136 C-reactive protein Homo sapiens 45-63 7691040-4 1993 We also measured five serum acute phase proteins and found a good correlation between these and serum TSA: C-reactive protein, r = 0.52, P < 0.001, alpha-1-antichymotrypsin, r = 0.79, P < 0.0001, alpha-2-macroglobulin, r = 0.38, P < 0.01 and alpha-1-acid glycoprotein, r = 0.32, P < 0.05. trichostatin A 102-105 C-reactive protein Homo sapiens 107-125 8336521-3 1993 In Lineweaver- Burk analysis with phosphatidylcholine dispersed with Triton X-100, the apparent Km value of phospholipase D for phosphatidylcholine increased from 2.27 mg/ml to 3.72 mg/ml by addition of 7.5 micrograms/ml CRP whereas the Vmax value was not altered. Phosphatidylcholines 128-147 C-reactive protein Homo sapiens 221-224 1328445-8 1992 The capacity of Agg-CRP to enhance selectively intracellular oxidative product generation was confirmed when measuring DCFH oxidation in Agg-IgG-stimulated cells. DCFH 119-123 C-reactive protein Homo sapiens 20-23 1900197-1 1991 C-reactive protein was highly purified from Japanese eel (Anguilla japonica) serum by precipitation with phosphatidyl-choline and Ca2+. Phosphatidylcholines 105-125 C-reactive protein Homo sapiens 0-18 1657391-6 1991 On the other hand, CRP could aggregate liposome consisted of lyso-PC and phosphatidylcholine (PC), but not that consisted of PC alone. Phosphatidylcholines 73-92 C-reactive protein Homo sapiens 19-22 1657391-6 1991 On the other hand, CRP could aggregate liposome consisted of lyso-PC and phosphatidylcholine (PC), but not that consisted of PC alone. Phosphatidylcholines 66-68 C-reactive protein Homo sapiens 19-22 1657391-6 1991 On the other hand, CRP could aggregate liposome consisted of lyso-PC and phosphatidylcholine (PC), but not that consisted of PC alone. Phosphatidylcholines 94-96 C-reactive protein Homo sapiens 19-22 34342722-8 2022 The application of dexmedetomidine in cardiac surgery with CPB can reduce CK-MB and cTn-I concentration and interleukin-6, tumor necrosis factor-alpha levels to a certain extent and shorten the length of Intensive Care Unit stay, but it has no significant effect on IL-10 level, C reactive protein level, the time on ventilator and length of hospital stay. Dexmedetomidine 19-34 C-reactive protein Homo sapiens 279-297 34970774-0 2021 Predictive Value of C-Reactive Protein and Albumin for Temporal Within-Individual Pharmacokinetic Variability of Voriconazole in Pediatric Hematopoietic Cell Transplant Patients. Voriconazole 113-125 C-reactive protein Homo sapiens 20-38 16330177-12 2006 Concerning the membranes, the highest levels of CRP were observed in patients dialyzed with Cuprophane with a significant increase from 15.1 +/- 3.6 to 21.2 +/- 3.1 mg/l after 6 months (P < 0.05); a significant reduction of CRP levels was observed in patients dialyzed with polysulfone in the same follow-up period (from 13.5 +/- 2.9 to 8.1 +/- 2.4 mg/l; P < 0.05). cuprammonium cellulose 92-102 C-reactive protein Homo sapiens 48-51 34709541-7 2021 RESULTS: Serum levels of beta-1 interleukin, tumor necrosis factor-alpha and hs-CRP were significantly reduced with five days of glutamine supplementation (p < 0.05), and patients" appetite during 5 days of glutamine supplementation compared with the control group had a significant increase (p < 0.05). Glutamine 129-138 C-reactive protein Homo sapiens 80-83 34709541-8 2021 CONCLUSION: Glutamine supplementation in COVID-19 patients with respiratory infection significantly reduces serum levels of interleukin-1 beta, hs-CRP, and tumor necrosis factor-alpha and significantly increases appetite, so glutamine supplementation may be useful for COVID-19 patients in the hospital. Glutamine 12-21 C-reactive protein Homo sapiens 147-150 16330177-12 2006 Concerning the membranes, the highest levels of CRP were observed in patients dialyzed with Cuprophane with a significant increase from 15.1 +/- 3.6 to 21.2 +/- 3.1 mg/l after 6 months (P < 0.05); a significant reduction of CRP levels was observed in patients dialyzed with polysulfone in the same follow-up period (from 13.5 +/- 2.9 to 8.1 +/- 2.4 mg/l; P < 0.05). cuprammonium cellulose 92-102 C-reactive protein Homo sapiens 227-230 34744722-11 2021 Conclusion: Taken together, our study indicates that combination of DXM and TMD effectively lowers blood pressure and reduces inflammation through increasing the level of IL-10, reducing CRP and inhibiting p-p38/MAPK in patients with PIH. Dexmedetomidine 68-71 C-reactive protein Homo sapiens 187-190 34712729-10 2021 The results showed that SAP and CRP levels were significantly higher in amphetamine addicts compared to healthy controls (p = 0.0001 and p = 0.0001, respectively). Amphetamine 72-83 C-reactive protein Homo sapiens 32-35 34712729-13 2021 Moreover, albumin levels were significantly decreased and CRP/Albumin ratio levels were significantly increased in amphetamine addicts (p = 0.01 and p = 0.041, respectively) in contrast with controls. Amphetamine 115-126 C-reactive protein Homo sapiens 58-61 16615014-7 2006 The severity of pneumonia according to TTS criteria was correlated with the levels of CRP, leukocyte count and ESR (p= 0.000, p= 0.014, p= 0.015, respectively). Disulfiram 39-42 C-reactive protein Homo sapiens 86-89 34712729-14 2021 These findings indicate that the increased level of these inflammatory biomarkers (SAP and CRP) in the amphetamine addicts may give a potential possibility of their serum level to be used as screening markers to detect PD development in the amphetamine addict. Amphetamine 103-114 C-reactive protein Homo sapiens 91-94 34712729-14 2021 These findings indicate that the increased level of these inflammatory biomarkers (SAP and CRP) in the amphetamine addicts may give a potential possibility of their serum level to be used as screening markers to detect PD development in the amphetamine addict. Amphetamine 241-252 C-reactive protein Homo sapiens 91-94 34126092-10 2021 A good quality cohort showed lower CRP levels in Arbidol (ARB) + IFN group vs. IFN only group. umifenovir 49-56 C-reactive protein Homo sapiens 35-38 34126092-10 2021 A good quality cohort showed lower CRP levels in Arbidol (ARB) + IFN group vs. IFN only group. umifenovir 58-61 C-reactive protein Homo sapiens 35-38 16615014-8 2006 Among TTS pneumonia groups, there were statistically significant differences between groups 1 and 3; groups 1 and 4; groups 2 and 3 (p= 0.006, p= 0.041, p= 0.05, respectively) for mean CRP levels. Disulfiram 6-9 C-reactive protein Homo sapiens 185-188 34420546-9 2022 Also, a positive association between E-DII and C-reactive protein (CRP) was observed (BE-DII = 1.37, 95% CI: 0.72, 2.02), such that with each unit increase in E-E-DII, the CRP levels were increased by 1.37 units. e-e-dii 159-166 C-reactive protein Homo sapiens 47-65 34420546-9 2022 Also, a positive association between E-DII and C-reactive protein (CRP) was observed (BE-DII = 1.37, 95% CI: 0.72, 2.02), such that with each unit increase in E-E-DII, the CRP levels were increased by 1.37 units. e-e-dii 159-166 C-reactive protein Homo sapiens 67-70 16220077-5 2005 C-reactive protein could augment the production of reactive oxygen species (ROS) as measured by chemiluminescence and inhibitors of NAD(P)H oxidase (DPI and PAO) and ROS scavengers (superoxide dismutase, catalase, and 1% dimethyl sulphoxide) abolished C-reactive protein-induced IL-8 secretion. oxophenylarsine 157-160 C-reactive protein Homo sapiens 0-18 34420546-9 2022 Also, a positive association between E-DII and C-reactive protein (CRP) was observed (BE-DII = 1.37, 95% CI: 0.72, 2.02), such that with each unit increase in E-E-DII, the CRP levels were increased by 1.37 units. e-e-dii 159-166 C-reactive protein Homo sapiens 172-175 16141529-8 2005 Preincubation of HUVECs with pyrrolidinethiocarbamate (PDTC, NF-kappaB inhibitor) diminished CD40 expression induced by CRP with flow cytometry. pyrrolidinethiocarbamate 29-53 C-reactive protein Homo sapiens 120-123 34395509-6 2021 The levels of CRP and TNF-alpha in the two groups increased after the operation, with a lower outcome in the LPN group (P < 0.05). CHEMBL1269671 109-112 C-reactive protein Homo sapiens 14-17 16087986-8 2005 Vitamin A reduced CRP (by 9.6 mg/L; P = 0.011), serum ferritin (by 18.1 microg/L; P = 0.042), and erythropoietin (by 194.7 mIU/mL; P = 0.011) concentrations and increased the reticulocyte production index (by 0.40; P = 0.041). Vitamin A 0-9 C-reactive protein Homo sapiens 18-21 15690201-1 2005 BACKGROUND: The purpose of this study was to assess the modifications of interleukin (IL)-6, C-reactive protein (CRP), leukocytes and fibrinogen after implantation of polypropylene mesh. Polypropylenes 167-180 C-reactive protein Homo sapiens 113-116 34405148-5 2021 Results: Based on post-hoc analyses, hs-CRP levels were significantly lower in the collagen (p=0.026) and collagen+omega-3 (p=0.044) groups compared to the control group, at week three. Fatty Acids, Omega-3 115-122 C-reactive protein Homo sapiens 40-43 34213769-8 2022 CONCLUSIONS: This study identified that the glutamine supplementation might have an important effect on CRP in acute condition and have no significant effect on IL-6 and TNF-alpha in acute condition. Glutamine 44-53 C-reactive protein Homo sapiens 104-107 15878871-10 2005 This study newly identifies residues Thr(173) and Asn(186) as important for the binding of CRP to FcgammaRIIa and FcgammaRI. Asparagine 50-53 C-reactive protein Homo sapiens 91-94 34183020-4 2021 The use of omega-3 fatty acid supplements was reported in 856 out of 1002 recreational athletes, and the association between supplement use and the exercise-induced CRP response was assessed. Fatty Acids, Omega-3 11-29 C-reactive protein Homo sapiens 165-168 16194025-3 2005 The aim of the study was: 1) to investigate the ability of the major tea polyphenols: (-)-epigallocatechin gallate (EGCG), theaflavins (TF) and gallic acid (GA) to protect in vitro human neutrophils from oxidative damage induced by phorbol myristate acetate (PMA), 2) estimation the level of reactive oxygen species (ROS) production in obese patient depending on the red tea Pu-Erh drinking, 3) estimation inflammatory marker: CRP. epigallocatechin gallate 116-120 C-reactive protein Homo sapiens 427-430 34183020-7 2021 Regular users of omega-3 fatty acid supplements had significantly lower basal and exercise-induced CRP levels as compared to non-users (n = 348, p < 0.001). Fatty Acids, Omega-3 17-35 C-reactive protein Homo sapiens 99-102 34183020-11 2021 CONCLUSION: Basal CRP levels were reduced, and the exercise-induced CRP response was attenuated in healthy recreational cyclists who used omega-3 fatty acid supplements regularly. Fatty Acids, Omega-3 138-156 C-reactive protein Homo sapiens 18-21 34183020-11 2021 CONCLUSION: Basal CRP levels were reduced, and the exercise-induced CRP response was attenuated in healthy recreational cyclists who used omega-3 fatty acid supplements regularly. Fatty Acids, Omega-3 138-156 C-reactive protein Homo sapiens 68-71 34387512-0 2021 Essential amino acid supplementation is associated with reduced serum C-reactive protein levels and improved circulating lymphocytes in post-acute inflamed elderly patients. Amino Acids, Essential 0-20 C-reactive protein Homo sapiens 70-88 35199285-10 2022 Allopurinol plus standard treatment reduced LDH, ferritin, CRP, procalcitonin, and ET-1 serum level significantly (P < 0.05) compared with Covid-19 patients on standard treatment. Allopurinol 0-11 C-reactive protein Homo sapiens 59-62 35589772-0 2022 C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. lenvatinib 122-132 C-reactive protein Homo sapiens 0-18 35470676-8 2022 Although SUA level at V4 was highly associated with diabetes, prediabetes, higher body mass index, CRP (C-reactive protein) levels, estimated glomerular filtration rate variation (visit 1-V4), carotid intima-media thickness, and pulse wave velocity, rs16890979 was only associated with higher carotid intima-media thickness. sua 9-12 C-reactive protein Homo sapiens 99-102 35470676-8 2022 Although SUA level at V4 was highly associated with diabetes, prediabetes, higher body mass index, CRP (C-reactive protein) levels, estimated glomerular filtration rate variation (visit 1-V4), carotid intima-media thickness, and pulse wave velocity, rs16890979 was only associated with higher carotid intima-media thickness. sua 9-12 C-reactive protein Homo sapiens 104-122 35460903-10 2022 Failure to respond to pamidronate was associated with female sex (p = 0.027), more lesions on MRI (p = 0.01) and higher CRP levels (p = 0.03). Pamidronate 22-33 C-reactive protein Homo sapiens 120-123 35566611-8 2022 Also, white blood cells (WBCs) and C-reactive protein (CRP) were decreased after PMX-DHP treatment. pmx-dhp 81-88 C-reactive protein Homo sapiens 35-53 35566611-8 2022 Also, white blood cells (WBCs) and C-reactive protein (CRP) were decreased after PMX-DHP treatment. pmx-dhp 81-88 C-reactive protein Homo sapiens 55-58 35386257-0 2022 Combined Effect of CYP2C19 Genetic Polymorphisms and C-Reactive Protein on Voriconazole Exposure and Dosing in Immunocompromised Children. Voriconazole 75-87 C-reactive protein Homo sapiens 53-71 35386257-8 2022 The extent of impact of C-reactive protein (CRP) levels on voriconazole trough concentrations and dose requirements varied between CYP2C19 phenotypes. Voriconazole 59-71 C-reactive protein Homo sapiens 24-42 35386257-8 2022 The extent of impact of C-reactive protein (CRP) levels on voriconazole trough concentrations and dose requirements varied between CYP2C19 phenotypes. Voriconazole 59-71 C-reactive protein Homo sapiens 44-47 35386257-9 2022 Increases of 20, 120, 245, and 395 mg/L from 5 mg/L in CRP levels were associated with increases in voriconazole trough concentration by 22.22, 50, 64.81, and 75% respectively, in the NM group; by 39.26, 94.48, 123.93, and 146.63%, respectively, in the IM group; and by 17.17, 37.34, 46.78, and 53.65%, respectively, in the PM group. Voriconazole 100-112 C-reactive protein Homo sapiens 55-58 35386257-10 2022 Meanwhile, increases of 20, 120, 245, and 395 mg/L from 5 mg/L in CRP levels were associated with increases in voriconazole dose requirements by 7.15, 14.23, 17.35, and 19.43%, respectively, in the PM group; with decreases in voriconazole dose requirements by 3.71, 7.38, 8.97, and 10.03%, respectively, in the NM group; and with decreases by 4, 9.10, 11.05, and 12.35%, respectively, in the IM group. Voriconazole 111-123 C-reactive protein Homo sapiens 66-69 35386257-10 2022 Meanwhile, increases of 20, 120, 245, and 395 mg/L from 5 mg/L in CRP levels were associated with increases in voriconazole dose requirements by 7.15, 14.23, 17.35, and 19.43%, respectively, in the PM group; with decreases in voriconazole dose requirements by 3.71, 7.38, 8.97, and 10.03%, respectively, in the NM group; and with decreases by 4, 9.10, 11.05, and 12.35%, respectively, in the IM group. Voriconazole 226-238 C-reactive protein Homo sapiens 66-69 35386257-12 2022 Conclusions: Our study suggests that CYP2C19 phenotypes, CRP concentrations, age, and the presence of immunosuppressants were factors associated with the pharmacokinetic changes in voriconazole. Voriconazole 181-193 C-reactive protein Homo sapiens 57-60 35386257-13 2022 There was heterogeneity in the effect of CRP on voriconazole plasma concentrations across different CYP2C19 genotypes. Voriconazole 48-60 C-reactive protein Homo sapiens 41-44 35241186-7 2022 In addition, omega-3 PUFAs supplementation decreased the levels of pro-inflammatory mediators including tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and hypersensitive-c-reactive protein (Hs-CRP). omega-3 pufas 13-26 C-reactive protein Homo sapiens 185-203 35183882-8 2022 Furthermore, boron citrate in combination with oleoylethanolamide resulted in a significant reduction in the high-sensitivity C-reactive protein and interleukin-1beta concentrations (p = 0.031 and p = 0.027, respectively). oleoylethanolamide 47-65 C-reactive protein Homo sapiens 126-144 35140620-9 2022 The results of BCA indicated that Gastrodin, Liquiritin, Hesperidin, Isoliquiritin, Hesperetin, and Isoliquiritigenin might be the active constituents to activate ROS and suppress hs-CRP as determined by spectrum-effect relationships. Hesperidin 57-67 C-reactive protein Homo sapiens 183-186 35100643-7 2022 THERAPY AND COURSE: After initiation of liposomal amphotericin B haematopoiesis recovered and CRP decreased. Amphotericin B 51-65 C-reactive protein Homo sapiens 95-98 35242650-0 2022 Efficacy of phentolamine combined with ambroxol aerosol inhalation in the treatment of pediatric severe pneumonia and its effect on serum IL-10 and CRP levels. Ambroxol 39-47 C-reactive protein Homo sapiens 148-151 35242650-1 2022 Background: The aim of the present study was to determine the therapeutic effect of phentolamine combined with Ambroxol aerosol inhalation on pediatric severe pneumonia and its effect on serum interleukin-10 (IL-10) and C-reactive protein (CRP) levels. Ambroxol 111-119 C-reactive protein Homo sapiens 220-238 35242650-1 2022 Background: The aim of the present study was to determine the therapeutic effect of phentolamine combined with Ambroxol aerosol inhalation on pediatric severe pneumonia and its effect on serum interleukin-10 (IL-10) and C-reactive protein (CRP) levels. Ambroxol 111-119 C-reactive protein Homo sapiens 240-243 15692104-2 2005 METHODS AND RESULTS: We found that CRP and annexin A5 at physiological concentrations bind Ca++ dependently to oxidized phosphatidylcholine present in oxidized LDL but not to native LDL. Phosphatidylcholines 120-139 C-reactive protein Homo sapiens 35-38 17532716-8 2005 RESULTS: Rice policosanol significantly reduced plasma total cholesterol from 7.37 +/- 1.42 mmol/L to 6.99 +/- 1.33 mmol/L (p = 0.007) and increased Apo AI from 1.49 +/- 0.39 mmol/L to 1.58 +/- 0.38 mmol/L (p = 0.037) but did not change plasma triglycerides, HDL, HDL2, HDL3 and LDL cholesterol, ox-LDL, Lp(a), Apo B, fibrinogen, homocysteine or CRP levels. policosanol 14-25 C-reactive protein Homo sapiens 346-349 15370101-7 2004 The alphaIIbbeta3 antagonist lotrafiban potentiated CRP-induced dense granule release, suggesting that alphaIIbbeta3 outside-in signalling may attenuate GPVI signals. lotrafiban 29-39 C-reactive protein Homo sapiens 52-55 15159225-6 2004 C-reactive protein concentrations were higher after consumption of the TFA diet than after consumption of the carbohydrate diet, but were not significantly different after consumption of the TFA and TFA+STE diets than after consumption of the LMP diet. Trans Fatty Acids 71-74 C-reactive protein Homo sapiens 0-18 15159228-1 2004 BACKGROUND: Low concentrations of pyridoxal-5"-phosphate (PLP), the active metabolite of vitamin B-6, are associated with high C-reactive protein (CRP) concentrations. Pyridoxal Phosphate 34-56 C-reactive protein Homo sapiens 127-145 15159228-1 2004 BACKGROUND: Low concentrations of pyridoxal-5"-phosphate (PLP), the active metabolite of vitamin B-6, are associated with high C-reactive protein (CRP) concentrations. Pyridoxal Phosphate 34-56 C-reactive protein Homo sapiens 147-150 15037536-7 2004 Patients had a mean BVAS of 11+/-1, and CRP and IL-6 were higher in the AASV group than in control subjects (34.8+/-10.5 versus 1.6+/-0.2 pg/mL, P<0.001; 9.0+/-0.7 versus 6.7+/-0.6 pg/mL, P=0.02). aasv 72-76 C-reactive protein Homo sapiens 40-43 15051604-9 2004 TFA intake was not associated with IL-6 or CRP concentrations overall but was positively associated with IL-6 and CRP in women with higher body mass index (P for interaction = 0.03 for each). Trans Fatty Acids 0-3 C-reactive protein Homo sapiens 114-117 15028349-8 2004 After balloon angioplasty, carriers of the short length (<25 GT) dinucleotide repeats had a lower postintervention CRP at 24 h (p = 0.009) and 48 h (p < 0.001) and a reduced risk for restenosis (adjusted relative risk 0.43, 95% confidence interval: 0.24 to 0.71, p < 0.001) compared with patients with longer alleles. Dinucleoside Phosphates 68-80 C-reactive protein Homo sapiens 118-121 15133321-8 2004 There were significant negative correlations between CRP levels and serum beta-carotene and retinol concentrations. Vitamin A 92-99 C-reactive protein Homo sapiens 53-56 15133321-11 2004 The inverse correlations between CRP and beta-carotene or retinol indicate either decreased synthesis or increased utilization of these antioxidants. Vitamin A 58-65 C-reactive protein Homo sapiens 33-36 12821543-3 2003 After adjustment for other predictors of inflammation, intake of the n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) was inversely associated with plasma levels of sTNF-R1 and sTNF-R2 (P=0.03 and P<0.001, respectively) and somewhat less so for C-reactive protein (P=0.08). Fatty Acids, Omega-3 69-84 C-reactive protein Homo sapiens 274-292 12631257-6 2003 RESULTS: In both groups, the combination of chemotherapy with either pamidronate or ibandronate produced a reduction in bone resorption and tumour burden as measured by NTX, IL-6, paraprotein, CRP, and beta 2-microglobulin from the second month of treatment, having no effect on bone formation. Pamidronate 69-80 C-reactive protein Homo sapiens 193-196 12450903-5 2002 Serum CRP had a significant, inverse association with retinol at both admission and discharge. Vitamin A 54-61 C-reactive protein Homo sapiens 6-9 12450903-7 2002 Among subjects with CRP > or =10 mg/L, 21% in the vitamin A group and 20% in the placebo groups (P = 0.83) had a positive RDR test result. Vitamin A 53-62 C-reactive protein Homo sapiens 20-23 12450903-9 2002 CONCLUSION: The RDR test was useful in assessing the vitamin A status of children recovering from pneumonia when CRP concentrations were <10 mg/L but not when CRP concentrations were higher. Vitamin A 53-62 C-reactive protein Homo sapiens 113-116 12421431-4 2002 RESULTS: Spearman correlation analyses and multiple linear regression analyses showed a significant association of both fasting glucose and 2-h glucose concentrations with CRP levels, after adjusting for demographic covariates (age, sex, ethnicity, clinical centre; Spearman correlation coefficients: r = 0.18 for fasting glucose, r = 0.27 for 2-h glucose, both P < 0.0001). 2-h glucose 140-151 C-reactive protein Homo sapiens 172-175 12244213-9 2002 These data suggest that CRP binds OxLDL and apoptotic cells by recognition of a PC moiety that becomes accessible as a result of oxidation of PtC molecule. Phosphatidylcholines 142-145 C-reactive protein Homo sapiens 24-27 12233891-7 2002 Percentage change in SUA at onset of attack correlated with CRP and IL-6 (r = 0.762, p < 0.0001; r = 0.630, p < 0.005), as well as with increased urinary excretion of uric acid, estimated by percentage change in fractional excretion of uric acid (FEua) during attack (r = 0.447, p < 0.05). sua 21-24 C-reactive protein Homo sapiens 60-63 12195834-7 2002 CRP and LDH were significantly higher in the LCRT group in comparison with the other two patient groups (P < 0.01 and 0.001, respectively), while ferritin was higher in both lung cancer groups in comparison with the BILD group (P < 0.001). lcrt 45-49 C-reactive protein Homo sapiens 0-3 12015523-5 2002 HRT resulted in a significant increase in CRP concentrations in the women receiving the continuous combination of E2V plus norethindrone acetate and the continuous regimen of E2V plus local delivery of levonorgestrel. Levonorgestrel 202-216 C-reactive protein Homo sapiens 42-45 12849009-4 2002 Soluble proteins such as C1q, mannose-binding lectin, surfactant proteins A and D, C-reactive protein, C3bi, beta2-glycoprotein I and growth arrest specific gene-6 bind to apoptotic cells and act as "opsonins" thus favouring their clearance. Mannose 30-37 C-reactive protein Homo sapiens 83-101 12056790-7 2002 In normal subjects and cancer patients, C-reactive protein concentrations were inversely correlated with circulating concentrations of retinol (r(2)=0.162), alpha-tocopherol (r(2)=0.297), lutein (r(2)=0.256), lycopene (r(2)=-0.171), alpha-(r(2)=0.140) and beta-carotene (r(2)=0.254): (all P<0.001). Vitamin A 135-142 C-reactive protein Homo sapiens 40-58 11711274-3 2001 We tested the hypothesis that serum TSA and other acute phase proteins, namely C-reactive protein (CRP) and fibrinogen, may be related to the postprandial state. trichostatin A 36-39 C-reactive protein Homo sapiens 99-102 11700398-13 2001 C-reactive protein was also significantly reduced at 14 days after burn injury in the glutamine group (p <.01). Glutamine 86-95 C-reactive protein Homo sapiens 0-18 11504824-8 2001 Thalidomide resulted in a nonsignificant decrease of CRP and SAA, but the concentrations of other inflammatory mediators, including urine neopterin, remained unchanged. Thalidomide 0-11 C-reactive protein Homo sapiens 53-56 11683535-6 2001 The addition of pamidronate to maintenance treatment resulted in a significant reduction of NTx, IL-6, beta2-microglobulin, CRP from the 3rd month and paraprotein from the 6th month of treatment, whereas BAP and OSC were significantly increased from the 6th month. Pamidronate 16-27 C-reactive protein Homo sapiens 124-127 11023761-9 2000 The mean CRP was significantly higher in those with BGE (113.9mg/l) and Others (116.9mg/l) as compared to the NSGE patients (38.9mg/l) (P=0.001). n-butyl glycidyl ether 52-55 C-reactive protein Homo sapiens 9-12 10959719-0 2000 Oral ethinyl estradiol, but not transdermal 17beta-estradiol, increases plasma C-reactive protein levels in men. Ethinyl Estradiol 5-22 C-reactive protein Homo sapiens 79-97 10696629-7 2000 Treatment with omega-3 fatty acids resulted in greater disease activity as detected by a significant increase in platelet count, erythrocyte sedimentation rate, C-reactive protein, and total fecal nitrogen excretion. Fatty Acids, Omega-3 15-34 C-reactive protein Homo sapiens 161-179 9990573-7 1999 Plasma retinol and C-reactive protein levels are inversely correlated (r = -0.15, P < 0.001), indicating that vitamin A status and inflammatory response may be related but the causal direction is unknown. Vitamin A 113-122 C-reactive protein Homo sapiens 19-37 9356549-7 1997 In the cancer group there were significant negative correlations between concentrations of C-reactive protein and retinol (r = -0.682, P < 0.01), alpha-tocopherol (r = -0.464, P < 0.05), and lutein (r = -0.599, P < 0.01). Vitamin A 114-121 C-reactive protein Homo sapiens 91-109 9045965-3 1996 Only DT of CRP and ALP (CRP-DT, ALP-DT) were found to be correlated with disease outcome in patients with primary bone and soft tissue tumors. Thymidine 5-7 C-reactive protein Homo sapiens 11-14 9045965-3 1996 Only DT of CRP and ALP (CRP-DT, ALP-DT) were found to be correlated with disease outcome in patients with primary bone and soft tissue tumors. Thymidine 5-7 C-reactive protein Homo sapiens 24-27 8839511-12 1996 At admission, plasma retinol concentrations were negatively correlated with maximum body temperature and CRP concentrations, which indicated that the body"s acute-phase response was associated with the depression in retinol concentrations. Vitamin A 21-28 C-reactive protein Homo sapiens 105-108 8702903-0 1996 Effect of cAMP binding site mutations on the interaction of cAMP receptor protein with cyclic nucleoside monophosphate ligands and DNA. cyclic nucleoside monophosphate 87-118 C-reactive protein Homo sapiens 60-81 8702903-1 1996 Although cAMP binding to wild type cAMP receptor protein (CRP) induces specific DNA binding and activates transcription, cyclic nucleoside monophosphate (cNMP) binding to the CRP mutant Ser128 --> Ala does not, whereas the double CRP mutant Thr127 --> Leu/Ser128 --> Ala activates transcription even in the absence of cNMP. cyclic nucleoside monophosphate 121-152 C-reactive protein Homo sapiens 175-178 8702903-1 1996 Although cAMP binding to wild type cAMP receptor protein (CRP) induces specific DNA binding and activates transcription, cyclic nucleoside monophosphate (cNMP) binding to the CRP mutant Ser128 --> Ala does not, whereas the double CRP mutant Thr127 --> Leu/Ser128 --> Ala activates transcription even in the absence of cNMP. cyclic nucleoside monophosphate 121-152 C-reactive protein Homo sapiens 175-178 8702903-1 1996 Although cAMP binding to wild type cAMP receptor protein (CRP) induces specific DNA binding and activates transcription, cyclic nucleoside monophosphate (cNMP) binding to the CRP mutant Ser128 --> Ala does not, whereas the double CRP mutant Thr127 --> Leu/Ser128 --> Ala activates transcription even in the absence of cNMP. cnmp 154-158 C-reactive protein Homo sapiens 58-61 8702903-1 1996 Although cAMP binding to wild type cAMP receptor protein (CRP) induces specific DNA binding and activates transcription, cyclic nucleoside monophosphate (cNMP) binding to the CRP mutant Ser128 --> Ala does not, whereas the double CRP mutant Thr127 --> Leu/Ser128 --> Ala activates transcription even in the absence of cNMP. cnmp 154-158 C-reactive protein Homo sapiens 175-178 8833207-13 1996 Patients treated with pamidronate, whose body temperatures were increased at 24 h, had a greater increases of circulating IL-6, TNFalpha, and CRP at 24 h and 48 h than patients without temperature increase. Pamidronate 22-33 C-reactive protein Homo sapiens 142-145 7824175-0 1994 Demonstration of CRP immunoreactivity in brains of Alzheimer"s disease: immunohistochemical study using formic acid pretreatment of tissue sections. formic acid 104-115 C-reactive protein Homo sapiens 17-20 2593200-2 1989 CRP binds to phosphorylcholine (PC) in a calcium-ion dependent manner. Phosphorylcholine 13-30 C-reactive protein Homo sapiens 0-3 2593200-2 1989 CRP binds to phosphorylcholine (PC) in a calcium-ion dependent manner. Phosphorylcholine 32-34 C-reactive protein Homo sapiens 0-3 2593200-3 1989 The structural homology between PC and the major phospholipid component of surfactant, dipalmitoyl phosphatidylcholine (DPPC), led to the present study in which we examined if CRP levels might be increased in patients with adult respiratory distress syndrome (ARDS), and subsequently interfere with surfactant function. Phosphorylcholine 32-34 C-reactive protein Homo sapiens 176-179 2844586-1 1988 Treatment of human neutrophils with C-reactive protein (CRP) causes a concentration-dependent in the extent of activation of superoxide production and of granule secretion, induced by phorbol-12-myristate-13-acetate (PMA) or N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLF). N-Formylmethionine Leucyl-Phenylalanine 225-270 C-reactive protein Homo sapiens 36-54 2844586-1 1988 Treatment of human neutrophils with C-reactive protein (CRP) causes a concentration-dependent in the extent of activation of superoxide production and of granule secretion, induced by phorbol-12-myristate-13-acetate (PMA) or N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLF). N-Formylmethionine Leucyl-Phenylalanine 225-270 C-reactive protein Homo sapiens 56-59 7824175-2 1994 To establish whether CRP appears in brain of Alzheimer"s disease (AD), we immunohistochemically investigated tissue sections which were pretreated with formic acid. formic acid 152-163 C-reactive protein Homo sapiens 21-24 2844586-1 1988 Treatment of human neutrophils with C-reactive protein (CRP) causes a concentration-dependent in the extent of activation of superoxide production and of granule secretion, induced by phorbol-12-myristate-13-acetate (PMA) or N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLF). N-Formylmethionine Leucyl-Phenylalanine 272-276 C-reactive protein Homo sapiens 36-54 2844586-1 1988 Treatment of human neutrophils with C-reactive protein (CRP) causes a concentration-dependent in the extent of activation of superoxide production and of granule secretion, induced by phorbol-12-myristate-13-acetate (PMA) or N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLF). N-Formylmethionine Leucyl-Phenylalanine 272-276 C-reactive protein Homo sapiens 56-59 8144898-11 1994 CRP binding to complement-treated liposomes required phosphatidylcholine in addition to the MAC indicating that membrane phospholipids rather than the MAC proteins provide the binding sites for CRP. Phosphatidylcholines 53-72 C-reactive protein Homo sapiens 0-3 8336521-2 1993 Addition of 15 micrograms/ml CRP resulted in about 60% decrease in phospholipase D activity using phosphatidylcholine dispersed with Triton X-100 as substrate, and more using lipid suspension consisting of only phosphatidylcholine. Phosphatidylcholines 98-117 C-reactive protein Homo sapiens 29-32 8336521-2 1993 Addition of 15 micrograms/ml CRP resulted in about 60% decrease in phospholipase D activity using phosphatidylcholine dispersed with Triton X-100 as substrate, and more using lipid suspension consisting of only phosphatidylcholine. Phosphatidylcholines 211-230 C-reactive protein Homo sapiens 29-32 2460085-2 1988 Following turpentine injection, increased serum levels of C-reactive protein, serum amyloid A protein, haptoglobin, ceruloplasmin, and decreased concentrations of albumin were observed. Turpentine 10-20 C-reactive protein Homo sapiens 58-76 8336521-3 1993 In Lineweaver- Burk analysis with phosphatidylcholine dispersed with Triton X-100, the apparent Km value of phospholipase D for phosphatidylcholine increased from 2.27 mg/ml to 3.72 mg/ml by addition of 7.5 micrograms/ml CRP whereas the Vmax value was not altered. Phosphatidylcholines 34-53 C-reactive protein Homo sapiens 221-224 1377908-1 1992 Okadaic acid (OA), a specific inhibitor of protein phosphatases 1 and 2A, inhibited in a dose-dependent manner (5-20 nM) the induction of C-reactive protein (CRP), serum amyloid A (SAA) and fibrinogen by interleukin-6 (IL-6) plus interleukin-1 (IL-1), and of fibrinogen by IL-6 alone, in Hep 3B cells. Okadaic Acid 0-12 C-reactive protein Homo sapiens 138-156 2460754-5 1988 The binding involves the phosphorylcholine (PC)-binding site of CRP since the addition of PC inhibits binding to Fn and those mAbs to CRP that bind at or near the PC-binding site selectively inhibit the CRP to Fn binding. Phosphorylcholine 25-42 C-reactive protein Homo sapiens 64-67 2460754-5 1988 The binding involves the phosphorylcholine (PC)-binding site of CRP since the addition of PC inhibits binding to Fn and those mAbs to CRP that bind at or near the PC-binding site selectively inhibit the CRP to Fn binding. Phosphorylcholine 25-42 C-reactive protein Homo sapiens 134-137 2460754-5 1988 The binding involves the phosphorylcholine (PC)-binding site of CRP since the addition of PC inhibits binding to Fn and those mAbs to CRP that bind at or near the PC-binding site selectively inhibit the CRP to Fn binding. Phosphorylcholine 25-42 C-reactive protein Homo sapiens 134-137 2460754-5 1988 The binding involves the phosphorylcholine (PC)-binding site of CRP since the addition of PC inhibits binding to Fn and those mAbs to CRP that bind at or near the PC-binding site selectively inhibit the CRP to Fn binding. Phosphorylcholine 44-46 C-reactive protein Homo sapiens 64-67 2460754-5 1988 The binding involves the phosphorylcholine (PC)-binding site of CRP since the addition of PC inhibits binding to Fn and those mAbs to CRP that bind at or near the PC-binding site selectively inhibit the CRP to Fn binding. Phosphorylcholine 44-46 C-reactive protein Homo sapiens 134-137 2460754-5 1988 The binding involves the phosphorylcholine (PC)-binding site of CRP since the addition of PC inhibits binding to Fn and those mAbs to CRP that bind at or near the PC-binding site selectively inhibit the CRP to Fn binding. Phosphorylcholine 44-46 C-reactive protein Homo sapiens 134-137 2460754-5 1988 The binding involves the phosphorylcholine (PC)-binding site of CRP since the addition of PC inhibits binding to Fn and those mAbs to CRP that bind at or near the PC-binding site selectively inhibit the CRP to Fn binding. Phosphorylcholine 90-92 C-reactive protein Homo sapiens 64-67 2460754-5 1988 The binding involves the phosphorylcholine (PC)-binding site of CRP since the addition of PC inhibits binding to Fn and those mAbs to CRP that bind at or near the PC-binding site selectively inhibit the CRP to Fn binding. Phosphorylcholine 90-92 C-reactive protein Homo sapiens 134-137 1377908-1 1992 Okadaic acid (OA), a specific inhibitor of protein phosphatases 1 and 2A, inhibited in a dose-dependent manner (5-20 nM) the induction of C-reactive protein (CRP), serum amyloid A (SAA) and fibrinogen by interleukin-6 (IL-6) plus interleukin-1 (IL-1), and of fibrinogen by IL-6 alone, in Hep 3B cells. Okadaic Acid 0-12 C-reactive protein Homo sapiens 158-161 2460754-5 1988 The binding involves the phosphorylcholine (PC)-binding site of CRP since the addition of PC inhibits binding to Fn and those mAbs to CRP that bind at or near the PC-binding site selectively inhibit the CRP to Fn binding. Phosphorylcholine 90-92 C-reactive protein Homo sapiens 134-137 2460754-5 1988 The binding involves the phosphorylcholine (PC)-binding site of CRP since the addition of PC inhibits binding to Fn and those mAbs to CRP that bind at or near the PC-binding site selectively inhibit the CRP to Fn binding. Phosphorylcholine 90-92 C-reactive protein Homo sapiens 64-67 2460754-5 1988 The binding involves the phosphorylcholine (PC)-binding site of CRP since the addition of PC inhibits binding to Fn and those mAbs to CRP that bind at or near the PC-binding site selectively inhibit the CRP to Fn binding. Phosphorylcholine 90-92 C-reactive protein Homo sapiens 134-137 2460754-5 1988 The binding involves the phosphorylcholine (PC)-binding site of CRP since the addition of PC inhibits binding to Fn and those mAbs to CRP that bind at or near the PC-binding site selectively inhibit the CRP to Fn binding. Phosphorylcholine 90-92 C-reactive protein Homo sapiens 134-137 3028793-4 1987 CRP was also found to enhance neutrophil phagocytosis of particles not containing phosphorylcholine, the native CRP ligand. Phosphorylcholine 82-99 C-reactive protein Homo sapiens 0-3 3086219-4 1986 Thus, the anti-galactan reactivity of CRP can be attributed to the protein"s classical anti-phosphate/anti-phosphorylcholine specificity. Phosphorylcholine 107-124 C-reactive protein Homo sapiens 38-41 1377908-1 1992 Okadaic acid (OA), a specific inhibitor of protein phosphatases 1 and 2A, inhibited in a dose-dependent manner (5-20 nM) the induction of C-reactive protein (CRP), serum amyloid A (SAA) and fibrinogen by interleukin-6 (IL-6) plus interleukin-1 (IL-1), and of fibrinogen by IL-6 alone, in Hep 3B cells. Okadaic Acid 14-16 C-reactive protein Homo sapiens 138-156 1377908-1 1992 Okadaic acid (OA), a specific inhibitor of protein phosphatases 1 and 2A, inhibited in a dose-dependent manner (5-20 nM) the induction of C-reactive protein (CRP), serum amyloid A (SAA) and fibrinogen by interleukin-6 (IL-6) plus interleukin-1 (IL-1), and of fibrinogen by IL-6 alone, in Hep 3B cells. Okadaic Acid 14-16 C-reactive protein Homo sapiens 158-161 6747291-2 1984 CRP reacts with the phosphocholine moiety of pneumococcal cell wall C-polysaccharide, and this reaction can lead to complement activation in vitro and protection against pneumococcal infection in vivo. Phosphorylcholine 20-34 C-reactive protein Homo sapiens 0-3 1650222-9 1991 CRP at concentrations of 50 micrograms/ml inhibited the neutrophil superoxide production induced by phorbol ester. Phorbol Esters 100-113 C-reactive protein Homo sapiens 0-3 2388856-0 1990 Dinucleotide repeat polymorphism at the CRP locus. Dinucleoside Phosphates 0-12 C-reactive protein Homo sapiens 40-43 6331829-5 1984 No sustained correlation was found between the C1q level and the other 2 acute phase reactants, but patients with C1q levels of at least 250 micrograms/ml showed a positive CRP over a period of years, in contrast to those with C1q levels below 250 micrograms/ml. C10Ph 114-117 C-reactive protein Homo sapiens 173-176 6331829-5 1984 No sustained correlation was found between the C1q level and the other 2 acute phase reactants, but patients with C1q levels of at least 250 micrograms/ml showed a positive CRP over a period of years, in contrast to those with C1q levels below 250 micrograms/ml. C10Ph 114-117 C-reactive protein Homo sapiens 173-176 6656768-15 1983 In the absence of calcium, exposure to urea led to increased electrophoretic mobility and exposure of a new antigenic reactivity, and to alterations in the phosphocholine- but not the polycation-binding sites of the native CRP molecule; this new antigenic reactivity may be of value in further studies on the CRP molecule. Phosphorylcholine 156-170 C-reactive protein Homo sapiens 223-226 2094538-7 1990 Patients with end-stage CRF (CRp greater than 4 mg/dl) and those on hemodialysis had elevated mean serum phosphorus levels and decreased mean serum total calcium concentrations compared with those with mild and moderate CRF, and more pronounced increases in both mean plasma PTH-COOH and PTH-NH2. Phosphorus 105-115 C-reactive protein Homo sapiens 29-32 7086355-1 1982 C-reactive protein (CRP), the classical acute-phase protein, can bind phospholipids by virtue of its specific, calcium-dependent reactivity with phosphorylcholine residues. Phosphorylcholine 145-162 C-reactive protein Homo sapiens 0-18 7086355-1 1982 C-reactive protein (CRP), the classical acute-phase protein, can bind phospholipids by virtue of its specific, calcium-dependent reactivity with phosphorylcholine residues. Phosphorylcholine 145-162 C-reactive protein Homo sapiens 20-23 2130295-3 1990 Predialysis C-reactive protein serum values in 17 patients on regular haemodialysis with cuprophan dialysers were greater than those of 18 normal controls (P less than 0.001). cuprammonium cellulose 89-98 C-reactive protein Homo sapiens 12-30 7046573-4 1982 Phosphorylcholine is bound by CRP with much higher affinity than other phosphate monoesters speaking for a second binding site with specificity for the positively charged trimethylammonium group. Phosphorylcholine 0-17 C-reactive protein Homo sapiens 30-33 7046573-6 1982 Protein that has been coupled with phosphorylcholine or phosphorylethanolamine is able to precipitate with CRP. Phosphorylcholine 35-52 C-reactive protein Homo sapiens 107-110 7046573-7 1982 Several natural substances including pneumococcal-C polysaccharide which react with CRP have been found to contain phosphorylcholine. Phosphorylcholine 115-132 C-reactive protein Homo sapiens 84-87 7462634-6 1981 We have found that this binding is more characteristic of CRP interactions with polycations than CRP interactions with phosphocholine- (PC) containing molecules. Phosphorylcholine 119-133 C-reactive protein Homo sapiens 97-100 7462634-6 1981 We have found that this binding is more characteristic of CRP interactions with polycations than CRP interactions with phosphocholine- (PC) containing molecules. Phosphorylcholine 136-138 C-reactive protein Homo sapiens 97-100 34979348-0 2022 Doping of MXenes enhances the electrochemical response of peptide-imprinted conductive polymers for the recognition of C-Reactive protein. Polymers 87-95 C-reactive protein Homo sapiens 119-137 7190145-2 1980 CRP caused as much agglutination of suspensions composed of egg yolk phosphatidylcholine, cholesterol, and Span 60 as of those composed of cholesterol and Span 60, suggesting that phosphocholine residues of phosphatidylcholine are not important as binding sites for CRP. Phosphorylcholine 180-194 C-reactive protein Homo sapiens 0-3 7190145-4 1980 Although phosphatidylcholine is not an essential component for agglutination of suspensions, it may modify the mode of interaction of CRP with its binding site on lipid suspensions, since the sensitivity of the agglutination to phosphocholine and the Ca2+ requirement were influenced by the presence of phosphatidylcholine in the suspensions. Phosphorylcholine 228-242 C-reactive protein Homo sapiens 134-137 34380588-11 2021 The incidence of a low VA level increases significantly with a raised CRP. Vitamin A 23-25 C-reactive protein Homo sapiens 70-73 14211-6 1977 Since C-reactive protein binds specifically to the phosphorylcholine residue of pneumococcal C-polysaccharide, it is unlikely that pneumococcal cell walls must combine with C-reactive protein in order to activate the alternative pathway. Phosphorylcholine 51-68 C-reactive protein Homo sapiens 6-24 830761-6 1977 Similar C1 binding and C consumption in the presence of CRP were seen upon the interaction of multiple additional polyanions including DNA, ENA, hyaluronic acid, chondroitin sulfate, and dextran sulfate with the polycations protamine sulfate and poly-L-lysine. Dextran Sulfate 187-202 C-reactive protein Homo sapiens 56-59 809531-8 1975 The relative inhibitory capacity of phosphorylcholine and polycations in CPS- and polycations-CRP systems was consistent with the concept that phosphate esters and polycations react at the same or an overlapping combining site. Phosphorylcholine 36-53 C-reactive protein Homo sapiens 94-97 34628277-8 2021 Accordingly, serum retinol levels were inversely associated with CRP levels (beta = -0.025 and P < 0.001). Vitamin A 19-26 C-reactive protein Homo sapiens 65-68 4395924-0 1971 Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Phosphorylcholine 38-55 C-reactive protein Homo sapiens 15-33 34609168-6 2021 Our results showed that PAHs bind specifically to a diguanylate cyclase PdgC, leading to the generation of cyclic dimeric GMP (c-di-GMP), which subsequently binds to two CRP/FNR family regulators, DPR-1 and DPR-2. bis(3',5')-cyclic diguanylic acid 127-135 C-reactive protein Homo sapiens 170-173 14325266-4 1965 By use of this method, which is performed in agar-gel plates, from 2 to 654 mug of C-reactive protein per ml of titrated human serum can be detected. Agar 45-49 C-reactive protein Homo sapiens 83-101 14325266-5 1965 The method is based on the inhibition of a specific C-reactive protein antigen-antibody precipitate formed in agar-gel by the minimal reactive dilutions of each reagent in 48 hr. Agar 110-114 C-reactive protein Homo sapiens 52-70 33913752-0 2021 The Effect of Rosuvastatin on plasma/serum levels of high sensitivity C-reactive protein, Interleukin-6 and D-dimer in people living with Human Immunodeficiency Virus: a systematic review and meta-analysis. Rosuvastatin Calcium 14-26 C-reactive protein Homo sapiens 70-88 34656488-12 2022 Interestingly, PM2.5, PM10, and Co levels were positively and significantly correlated with serum levels of C-reactive protein. Cobalt 32-34 C-reactive protein Homo sapiens 108-126 33903806-8 2021 In the case of serum, l-phenylalanine and p-hydroxyphenylacetic acid levels were positively correlated with CRP levels in both groups (all P < 0.05). 4-hydroxyphenylacetic acid 42-68 C-reactive protein Homo sapiens 108-111 34537026-10 2021 Peripheral blood CRP levels of AECOPD patients exposed to PM2.5 >= 25 mg/L and PM10 >= 50 mg/L on the day before hospitalization were higher than those of patients exposed to PM2.5 < 25 mg/L and PM10 < 50 mg/L (t = 2.008, p = 0.046; t = 2.637, p = 0.009). pm10 79-83 C-reactive protein Homo sapiens 17-20 33504955-2 2021 We conducted a 4-week, placebo-controlled, randomised clinical trial of minocycline (200 mg/day) added to antidepressant treatment in 39 patients selected for elevated levels of serum C-reactive protein (CRP >= 1 mg/L), n = 18 randomised to minocycline (M) and n = 21 to placebo (P). Minocycline 72-83 C-reactive protein Homo sapiens 184-202 34495261-11 2021 Vitamin A levels were highly associated with the level of hemoglobin and C-reactive protein (CRP) in multivariate analysis. Vitamin A 0-9 C-reactive protein Homo sapiens 73-91 33504955-7 2021 The threshold point for baseline CRP to distinguish responders from non-responders to minocycline was 2.8 mg/L. Minocycline 86-97 C-reactive protein Homo sapiens 33-36 34495261-11 2021 Vitamin A levels were highly associated with the level of hemoglobin and C-reactive protein (CRP) in multivariate analysis. Vitamin A 0-9 C-reactive protein Homo sapiens 93-96 34440605-7 2021 The C-reactive protein (CRP) negatively correlated with LDL-C (p = 0.013) and HDL-C (p = 0.05). ldl-c 56-61 C-reactive protein Homo sapiens 4-22 33452004-7 2021 Significantly higher proportions receiving FIL200+MTX (54%) and FIL100+MTX (43%) achieved DAS28(CRP) <2.6 versus MTX (29%) (p<0.001 for both) at week 24. Methotrexate 71-74 C-reactive protein Homo sapiens 96-99 33452004-7 2021 Significantly higher proportions receiving FIL200+MTX (54%) and FIL100+MTX (43%) achieved DAS28(CRP) <2.6 versus MTX (29%) (p<0.001 for both) at week 24. Methotrexate 71-74 C-reactive protein Homo sapiens 96-99 34440605-7 2021 The C-reactive protein (CRP) negatively correlated with LDL-C (p = 0.013) and HDL-C (p = 0.05). ldl-c 56-61 C-reactive protein Homo sapiens 24-27 35247857-1 2022 The innovation of this work lies in the trace detection of inflammatory biomarkers (IL-6, hs-CRP) in human exhaled breath condensate on the developed EBC-SURE platform as a point-of-care aid for respiratory disorder diagnosis. NSC638702 150-153 C-reactive protein Homo sapiens 93-96 33645073-9 2021 SIN+MTX remarkably alleviated the erythrocyte sedimentation rate(MD=-9.87, 95%CI[-14.52,-5.22], P<0.000 1), C-reactive protein(SMD=-0.30, 95%CI[-0.51,-0.09], P=0.005), and rheumatoid factor(MD=-11.23,95%CI[-13.81,-8.65],P<0.000 01). Methotrexate 4-7 C-reactive protein Homo sapiens 108-126 33269114-8 2020 After consuming agraz, there was a tendency to increase the levels of antioxidants and to reduce the levels of hs-CRP in both genders. agraz 16-21 C-reactive protein Homo sapiens 114-117 35247857-4 2022 The lowest detection limits for IL-6 and hs-CRP detection in EBC were found to be 3.2 pg/mL and 4 pg/mL respectively. NSC638702 61-64 C-reactive protein Homo sapiens 44-47 35247857-7 2022 EBC-SURE generated highly selective IL-6 and hs-CRP responses in the presence of other non-specific cytokines. NSC638702 0-3 C-reactive protein Homo sapiens 48-51 35576800-11 2022 Mediation analysis showed that only miR-26a-5p significantly mediated air pollutant (PM2.5 and NO2)-induced effects on blood CRP and total cholesterol levels. [4-(3-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-(5-PHENETHYL- PYRIDIN-3-YL)-METHANONE 85-88 C-reactive protein Homo sapiens 125-128 33010093-10 2020 PWH had higher levels of the inflammatory markers CRP and IL-6. PWH 0-3 C-reactive protein Homo sapiens 50-53 35236646-0 2022 Effects of butylphthalide on the levels of serum C-reactive protein, Parkinson disease protein 7 and neurotrophin-3 and neurological function in patients with acute cerebral infarction. 3-n-butylphthalide 11-25 C-reactive protein Homo sapiens 49-67 32433216-6 2020 H2S was measured in sera by monobromobimane derivation (MBB) followed by high performance liquid chromatography and correlated to other markers like procalcitonin (PCT) and C- reactive protein (CRP). Deuterium 0-3 C-reactive protein Homo sapiens 173-192 35236646-1 2022 To explore the effects of butylphthalide on the levels of serum CRP, PAPK7, NT-3 and neurological function in patients with acute cerebral infarction (ACI). 3-n-butylphthalide 26-40 C-reactive protein Homo sapiens 64-67 32433216-6 2020 H2S was measured in sera by monobromobimane derivation (MBB) followed by high performance liquid chromatography and correlated to other markers like procalcitonin (PCT) and C- reactive protein (CRP). Deuterium 0-3 C-reactive protein Homo sapiens 194-197 32433216-12 2020 Serum H2S on day 1 was negatively correlated with IL- 6 and CRP and positively correlated with the absolute lymphocyte count in peripheral blood. Deuterium 6-9 C-reactive protein Homo sapiens 60-63 2553815-2 1989 Maximum association of 125I-labeled CRP with neutrophils and 125I-labeled CRP degradation during association with these cells was achieved by stimulating the neutrophils with PMA at 10 ng/ml; a concentration in which azurophil granule release was not significant. Iodine-125 61-65 C-reactive protein Homo sapiens 74-77 32599111-9 2020 Furthermore, TMAO levels was associated with disease severity in AAD, and correlated positively with CRP levels (r=0.537, P=0.018), IL-6 levels (r=0.546, P=0.016), D-dimer levels (r=0.694, P=0.001) and maximum aortic diameter on admission (r=0.748, P=0.002). trimethyloxamine 13-17 C-reactive protein Homo sapiens 101-104 32903624-4 2020 Phosphocholine-complexed human CRP activates the complement system in both human and murine sera. Phosphorylcholine 0-14 C-reactive protein Homo sapiens 31-34 32689936-5 2020 Our study aimed to investigate whether a leucine enriched BCAA dietary supplement (LEBDs) could quickly increase serum levels of albumin (Alb) or transthyretin (TTR) and decrease high-sensitivity C-reactive protein (CRP) in the development of severe malnutrition within a few days after stroke onset compared to standard BCAA dietary supplement (SBDs). Leucine 41-48 C-reactive protein Homo sapiens 196-214 32689936-5 2020 Our study aimed to investigate whether a leucine enriched BCAA dietary supplement (LEBDs) could quickly increase serum levels of albumin (Alb) or transthyretin (TTR) and decrease high-sensitivity C-reactive protein (CRP) in the development of severe malnutrition within a few days after stroke onset compared to standard BCAA dietary supplement (SBDs). Leucine 41-48 C-reactive protein Homo sapiens 216-219 32689936-17 2020 CONCLUSION: In acute stroke patients receiving leucine enriched BCAA dietary supplement, quick improvements in transthyretin and CRP were observed. Leucine 47-54 C-reactive protein Homo sapiens 129-132 32662405-8 2021 Furthermore, circulating Treg levels were negatively correlated with erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and Behcet"s disease current activity form (BDCAF), respectively. treg 25-29 C-reactive protein Homo sapiens 107-125 32662405-8 2021 Furthermore, circulating Treg levels were negatively correlated with erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and Behcet"s disease current activity form (BDCAF), respectively. treg 25-29 C-reactive protein Homo sapiens 127-130 32508991-8 2020 After treatment with methotrexate 7.5 mg/week, 12 out of 46 patients had elevated blood levels of ESR and 18 out of 46 patients of CRP and fibrinogen. Methotrexate 21-33 C-reactive protein Homo sapiens 131-134 32508991-12 2020 It was concluded that the systemic treatment with both methotrexate and biological therapy showed a marked decline in the patients with abnormal values of CRP, ESR and fibrinogen, indirectly showing a decline in the inflammatory activity of psoriasis. Methotrexate 55-67 C-reactive protein Homo sapiens 155-158 32278414-4 2020 In the presence of the CRP, the ssDNA releases from the AuNPs surface to interact preferentially with the protein to form guanine-quadruplexes. Guanine 122-129 C-reactive protein Homo sapiens 23-26 32596235-10 2020 In multivariable Cox regression analysis adjusting for age, sex, eGFR, CRP, cardiovascular disease, hypertension, and diabetes, each doubling in suPAR at hospital admission was associated with a hazard ratio of 1.57 (95% CI: 1.38-1.78, P < 0.001) for developing a chronic kidney condition and 2.51 (95% CI: 2.09-3.01, P < 0.001) for developing an acute kidney condition. supar 145-150 C-reactive protein Homo sapiens 71-74 32566743-9 2020 Similar results were obtained for correlation with markers of obesity (insulin, CRP, and leptin) with estradiol and estrone (-0.15 to 0.12; p = 0.11-0.82). Estrone 116-123 C-reactive protein Homo sapiens 80-83 32295807-8 2020 Specifically, 19% and 12% of type 2 diabetes risk due to manganese were mediated through interleukin 6 and hs-CRP, respectively. Manganese 57-66 C-reactive protein Homo sapiens 110-113 32374279-5 2021 CRP was assayed using a functional turbidimetric assay based on the interaction of CRP with phosphocholine containing particles (Intralipid ). Phosphorylcholine 92-106 C-reactive protein Homo sapiens 0-3 32374279-5 2021 CRP was assayed using a functional turbidimetric assay based on the interaction of CRP with phosphocholine containing particles (Intralipid ). Phosphorylcholine 92-106 C-reactive protein Homo sapiens 83-86 32117266-1 2020 A monomeric form of C-reactive protein (CRP) which precipitates with cell wall pneumococcal C polysaccharide (CWPS) and retains the ability to reversibly bind to its ligand phosphocholine has been produced through urea-induced dissociation at an optimized concentration of 3 M urea over a 10 weeks period. Phosphorylcholine 173-187 C-reactive protein Homo sapiens 20-38 32117266-1 2020 A monomeric form of C-reactive protein (CRP) which precipitates with cell wall pneumococcal C polysaccharide (CWPS) and retains the ability to reversibly bind to its ligand phosphocholine has been produced through urea-induced dissociation at an optimized concentration of 3 M urea over a 10 weeks period. Phosphorylcholine 173-187 C-reactive protein Homo sapiens 40-43 32117266-6 2020 Both the in vitro monomeric C-reactive protein and the human serum monomeric protein displayed a molecular weight of approximately 23 kDa, both were recognized by the same anti-CRP monoclonal antibody and both reversibly bound to phosphocholine in a calcium-dependent manner. Phosphorylcholine 230-244 C-reactive protein Homo sapiens 28-46 32117266-6 2020 Both the in vitro monomeric C-reactive protein and the human serum monomeric protein displayed a molecular weight of approximately 23 kDa, both were recognized by the same anti-CRP monoclonal antibody and both reversibly bound to phosphocholine in a calcium-dependent manner. Phosphorylcholine 230-244 C-reactive protein Homo sapiens 177-180 32082998-10 2020 Moreover, pooled analysis illustrated that elevated NLR and CRP represents poor DSS, with HRs of 1.46 and 2.06, respectively. dss 80-83 C-reactive protein Homo sapiens 60-63 32810863-6 2020 A worse DSS was found in patients who had preoperative CRP >0.5 mg/dL (p = 0.002) and in those with NLR >3.5 (p < 0.001). dss 8-11 C-reactive protein Homo sapiens 55-58 32810863-7 2020 In multivariate analysis, tumor size and grade as well as preoperative CRP values and NLR were confirmed to be prognostic factors in terms of DSS. dss 142-145 C-reactive protein Homo sapiens 71-74 31866771-5 2019 Results: (1) The levels of hs-CRP, IL-6, and IL-8 were significantly increased in the UAP and AMI groups compared with the CPS group (P < 0.01). 4-Deoxy-2-O-Sulfo-Alpha-L-Threo-Hex-4-Enopyranuronic Acid 86-89 C-reactive protein Homo sapiens 30-33 30790446-13 2019 C-reactive protein (CRP) was comparable between the groups at baseline, while at follow-up CRP was significantly lower in the rosuvastatin group compared to placebo [0.6 (+-0.5) mg/L vs. 2.6 (+-3.0) mg/L; p = 0.002]. Rosuvastatin Calcium 126-138 C-reactive protein Homo sapiens 91-94 30790446-14 2019 Whereas rosuvastatin treatment for 6 months attenuated CRP levels, it did not improve microvascular function as assessed by IMR (Clinical Trials.gov NCT01582165, EUDRACT 2011-002630-39.3tcAZ). Rosuvastatin Calcium 8-20 C-reactive protein Homo sapiens 55-58 30745185-12 2019 Multivariate analysis showed a significant association between mortality and preoperative lactate>3mmol/L, C-reactive protein>100mg/L and ICU stay at the time of AMI diagnosis. amicoumacin A 168-171 C-reactive protein Homo sapiens 110-128 31432820-0 2019 A zirconium-based metal-organic framework sensitized by thioflavin-T for sensitive photoelectrochemical detection of C-reactive protein. thioflavin T 56-68 C-reactive protein Homo sapiens 117-135 31432820-1 2019 Herein, a novel photoelectrochemical (PEC) assay was developed for the sensitive detection of C-reactive protein (CRP) based on a zirconium-based metal-organic framework (PCN-777) as the photoelectric material and thioflavin-T (Th-T) as the effective signal sensitizer coupled with rolling circle amplification (RCA). Pregnenolone Carbonitrile 171-174 C-reactive protein Homo sapiens 94-112 31432820-1 2019 Herein, a novel photoelectrochemical (PEC) assay was developed for the sensitive detection of C-reactive protein (CRP) based on a zirconium-based metal-organic framework (PCN-777) as the photoelectric material and thioflavin-T (Th-T) as the effective signal sensitizer coupled with rolling circle amplification (RCA). Pregnenolone Carbonitrile 171-174 C-reactive protein Homo sapiens 114-117 31432820-1 2019 Herein, a novel photoelectrochemical (PEC) assay was developed for the sensitive detection of C-reactive protein (CRP) based on a zirconium-based metal-organic framework (PCN-777) as the photoelectric material and thioflavin-T (Th-T) as the effective signal sensitizer coupled with rolling circle amplification (RCA). thioflavin T 214-226 C-reactive protein Homo sapiens 94-112 31432820-1 2019 Herein, a novel photoelectrochemical (PEC) assay was developed for the sensitive detection of C-reactive protein (CRP) based on a zirconium-based metal-organic framework (PCN-777) as the photoelectric material and thioflavin-T (Th-T) as the effective signal sensitizer coupled with rolling circle amplification (RCA). thioflavin T 214-226 C-reactive protein Homo sapiens 114-117 31432820-1 2019 Herein, a novel photoelectrochemical (PEC) assay was developed for the sensitive detection of C-reactive protein (CRP) based on a zirconium-based metal-organic framework (PCN-777) as the photoelectric material and thioflavin-T (Th-T) as the effective signal sensitizer coupled with rolling circle amplification (RCA). thioflavin T 228-232 C-reactive protein Homo sapiens 94-112 31432820-1 2019 Herein, a novel photoelectrochemical (PEC) assay was developed for the sensitive detection of C-reactive protein (CRP) based on a zirconium-based metal-organic framework (PCN-777) as the photoelectric material and thioflavin-T (Th-T) as the effective signal sensitizer coupled with rolling circle amplification (RCA). thioflavin T 228-232 C-reactive protein Homo sapiens 114-117 31602920-6 2019 In addition,TGT combined with MTX were more effective in decreasing CRP,ESR,RF than MTX alone. Methotrexate 30-33 C-reactive protein Homo sapiens 68-71 30785999-10 2019 EEAA was associated with increases of 23% (3% to 33%) in high-sensitivity C-reactive protein, 10% (4% to 17%) in interferon-gamma-inducible protein of 10 kDa, and 4% (2% to 6%) in soluble TNF receptor 2, adjusted for BMI and HOMA-IR. eeaa 0-4 C-reactive protein Homo sapiens 74-92 31092031-2 2019 METHODS: The relationship between serum PC-specific IgM level and C-reactive protein level or white blood cell counts was examined in patients with severe upper respiratory tract infections (ie, acute epiglottitis and peritonsillar abscess). Phosphorylcholine 40-42 C-reactive protein Homo sapiens 66-84 31110465-10 2019 Despite availability reported at nearly all centres, C-reactive protein and respiratory virus testing were recommended in 3/9 and 5/9 CDTs, respectively. cdts 134-138 C-reactive protein Homo sapiens 53-71 30674312-6 2019 Network meta-analysis showed that Fluvastatin (97.7%), Atorvastatin (68.0%) and Rosuvastatin (49.3%) had higher cumulative probability than other statins in reducing CRP in COPD patients. Fluvastatin 34-45 C-reactive protein Homo sapiens 166-169 30674312-6 2019 Network meta-analysis showed that Fluvastatin (97.7%), Atorvastatin (68.0%) and Rosuvastatin (49.3%) had higher cumulative probability than other statins in reducing CRP in COPD patients. Rosuvastatin Calcium 80-92 C-reactive protein Homo sapiens 166-169 30674312-9 2019 In addition, Fluvastatin and Atorvastatin are more effective in reducing CRP and PH in COPD patients. Fluvastatin 13-24 C-reactive protein Homo sapiens 73-76 30358903-6 2019 (THF+5alphaTHF)/THE correlated negatively with eGFR (Spearman"s rho = -0.116, P = 0.032) and positively with C-reactive protein (rho = 0.208, P < 0.001). tetrahydrofuran 1-4 C-reactive protein Homo sapiens 109-127 30358903-7 2019 In multivariable analysis, C-reactive protein remained a significant independent predictor of (THF+5alphaTHF)/THE, but eGFR did not. tetrahydrofuran 95-98 C-reactive protein Homo sapiens 27-45 30030926-3 2018 As C-reactive protein (CRP) can act as an innate receptor with ability to bind the phosphocholine moiety of PC in lipoproteins, we investigated whether EgAgB and CRP could interact during cystic echinococcosis infection (CE), and how CRP binding could affect the modulation activities exerted by EgAgB on macrophages. Phosphorylcholine 83-97 C-reactive protein Homo sapiens 3-21 30030926-3 2018 As C-reactive protein (CRP) can act as an innate receptor with ability to bind the phosphocholine moiety of PC in lipoproteins, we investigated whether EgAgB and CRP could interact during cystic echinococcosis infection (CE), and how CRP binding could affect the modulation activities exerted by EgAgB on macrophages. Phosphorylcholine 83-97 C-reactive protein Homo sapiens 23-26 30030926-6 2018 Furthermore, human CRP was capable of binding specifically to EgAgB with high affinity (0.6 +- 0.1 nM); this binding was Ca2+ -dependent and involved the phosphocholine moiety of PC, but not EgAgB8/1, EgAgB8/2 or EgAgB8/3 apolipoproteins. Phosphorylcholine 154-168 C-reactive protein Homo sapiens 19-22 29784344-2 2018 Indium Tin Oxide (ITO) disposable sheets were modified by using 11-cyanoundecyltrimethoxysilane (CUTMS) and PAMAM dendrimers (G:1 amino surfaces) for the first time to immobilize the anti-CRP antibody via covalent interactions. indium tin oxide 0-16 C-reactive protein Homo sapiens 188-191 29784344-2 2018 Indium Tin Oxide (ITO) disposable sheets were modified by using 11-cyanoundecyltrimethoxysilane (CUTMS) and PAMAM dendrimers (G:1 amino surfaces) for the first time to immobilize the anti-CRP antibody via covalent interactions. indium tin oxide 18-21 C-reactive protein Homo sapiens 188-191 30105015-2 2018 CRP is a phosphocholine (PC)-binding pentraxin, mainly produced in the liver in response to elevated levels of interleukin-1beta (IL-1beta) and of the IL-1beta-dependent cytokine IL-6. Phosphorylcholine 9-23 C-reactive protein Homo sapiens 0-3 30105015-2 2018 CRP is a phosphocholine (PC)-binding pentraxin, mainly produced in the liver in response to elevated levels of interleukin-1beta (IL-1beta) and of the IL-1beta-dependent cytokine IL-6. Phosphorylcholine 25-27 C-reactive protein Homo sapiens 0-3 30105015-5 2018 Here, we demonstrate that CRP, in association with PC, efficiently reduces ATP-induced inflammasome activation and IL-1beta release from human peripheral blood mononuclear leukocytes and monocytic U937 cells. Phosphorylcholine 51-53 C-reactive protein Homo sapiens 26-29 29946323-7 2018 The dissociation of pCRP into its pro-inflammatory structural isoforms and thus activation of the CRP system occur on necrotic, apoptotic, and ischemic cells, regular beta-sheet structures such as beta-amyloid, the membranes of activated cells (e.g., platelets, monocytes, and endothelial cells), and/or the surface of microparticles, the latter by binding to phosphocholine. Phosphorylcholine 360-374 C-reactive protein Homo sapiens 21-24 29558723-2 2018 Indium Tin Oxide (ITO) disposable sheets were modified by using 3-cyanopropyltrimethoxysilane (CPTMS) self-assembled monolayers (SAMs) for the first time for immobilizing the anti-CRP antibody via covalent interactions without the need for any cross-linking agent. indium tin oxide 0-16 C-reactive protein Homo sapiens 180-183 29558723-2 2018 Indium Tin Oxide (ITO) disposable sheets were modified by using 3-cyanopropyltrimethoxysilane (CPTMS) self-assembled monolayers (SAMs) for the first time for immobilizing the anti-CRP antibody via covalent interactions without the need for any cross-linking agent. indium tin oxide 18-21 C-reactive protein Homo sapiens 180-183 29915443-9 2018 Furthermore, pDES-CD showed a correlation with the FC level (gamma = 0.747, P < 0.001), erythrocyte sedimentation rate (gamma = 0.492, P = 0.028), and the CRP level (gamma = 0.605, P = 0.005). pdes-cd 13-20 C-reactive protein Homo sapiens 158-161 29713620-7 2018 Pooled effect size showed significant effect of Pycnogenol supplementation on CRP (-1.22 mg/dL, 95% confidence interval, -2.43, -0.003; I2 = 99%, pheterogeneity < 0.001). pycnogenols 48-58 C-reactive protein Homo sapiens 78-81 29601504-4 2018 The measurement relies on the decrease of the oxidation current of the redox indicator Fe3+/Fe2+, resulting from the immunoreaction between CRP and anti-CRP. ammonium ferrous sulfate 92-96 C-reactive protein Homo sapiens 140-143 29601504-4 2018 The measurement relies on the decrease of the oxidation current of the redox indicator Fe3+/Fe2+, resulting from the immunoreaction between CRP and anti-CRP. ammonium ferrous sulfate 92-96 C-reactive protein Homo sapiens 153-156 29580351-6 2018 During the postoperative course, the white blood cell counts and C-reactive protein levels were significantly lower in the LPSH group. lpsh 123-127 C-reactive protein Homo sapiens 65-83 29030923-9 2018 Falls in SDMA predicted reduction in high-sensitivity C-reactive protein (P = 0.04) and increases in peak oxygen consumption (P = 0.04). symmetric dimethylarginine 9-13 C-reactive protein Homo sapiens 54-72 29120646-1 2018 C-reactive protein (CRP), a biomarker for cardiovascular disease, has been reported to have a strong affinity to zwitterionic phosphorylcholine (PC) groups in the presence of calcium ions. zwitterionic phosphorylcholine 113-143 C-reactive protein Homo sapiens 0-18 29120646-1 2018 C-reactive protein (CRP), a biomarker for cardiovascular disease, has been reported to have a strong affinity to zwitterionic phosphorylcholine (PC) groups in the presence of calcium ions. zwitterionic phosphorylcholine 113-143 C-reactive protein Homo sapiens 20-23 29120646-1 2018 C-reactive protein (CRP), a biomarker for cardiovascular disease, has been reported to have a strong affinity to zwitterionic phosphorylcholine (PC) groups in the presence of calcium ions. Phosphorylcholine 145-147 C-reactive protein Homo sapiens 0-18 29120646-1 2018 C-reactive protein (CRP), a biomarker for cardiovascular disease, has been reported to have a strong affinity to zwitterionic phosphorylcholine (PC) groups in the presence of calcium ions. Phosphorylcholine 145-147 C-reactive protein Homo sapiens 20-23 29120646-3 2018 By appropriately using the features of PC-immobilized surfaces, including specific recognition to CRP and nonfouling surface, it is reasonable to create an antibody-free biosensor for the specific capture of CRP. Phosphorylcholine 39-41 C-reactive protein Homo sapiens 98-101 29120646-3 2018 By appropriately using the features of PC-immobilized surfaces, including specific recognition to CRP and nonfouling surface, it is reasonable to create an antibody-free biosensor for the specific capture of CRP. Phosphorylcholine 39-41 C-reactive protein Homo sapiens 208-211 29120646-7 2018 The specific interaction of CRP with PC groups was monitored by using a quartz crystal microbalance with dissipation (QCM-D). Phosphorylcholine 37-39 C-reactive protein Homo sapiens 28-31 29120646-10 2018 Notably, the dissipation energy also dropped during the binding process between CRP and PC, indicating the release of water molecules from the PC groups during CRP adsorption. Phosphorylcholine 88-90 C-reactive protein Homo sapiens 80-83 29120646-10 2018 Notably, the dissipation energy also dropped during the binding process between CRP and PC, indicating the release of water molecules from the PC groups during CRP adsorption. Phosphorylcholine 88-90 C-reactive protein Homo sapiens 160-163 29172154-2 2018 We have shown previously the calcium-independent adsorption of CRP toward 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and lysophosphatidylcholine (LPC) on supported phospholipid monolayers. Lysophosphatidylcholines 134-157 C-reactive protein Homo sapiens 63-66 29172154-2 2018 We have shown previously the calcium-independent adsorption of CRP toward 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and lysophosphatidylcholine (LPC) on supported phospholipid monolayers. Lysophosphatidylcholines 159-162 C-reactive protein Homo sapiens 63-66 29172154-5 2018 CRP recognized 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-l-serine (POPS) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1"-rac-glycerol) (POPG) in the supported POPC monolayers without calcium at pH 7.4 and 5.5. POPG 138-142 C-reactive protein Homo sapiens 0-3 29214785-7 2018 The patients" C-reactive protein levels were significantly lower 1 week after administering the first dose of MTX than those before treatment. Methotrexate 110-113 C-reactive protein Homo sapiens 14-32 28778482-9 2017 In addition, wild-type mice treated with purified human CRP showed significant decreases in the insulin secretion index (HOMA-beta cells) and the insulin stimulation index in isolated islets that were reversed by the addition of L-NAME, aminoguanidine or NAC. pimagedine 237-251 C-reactive protein Homo sapiens 56-59 28834922-9 2017 The predictive performance of the VRCZ/N-oxide ratio was improved by including the route of administration, C-reactive protein level, and patient age in addition to the CYP2C19 genotype as predictive factors. n-oxide 39-46 C-reactive protein Homo sapiens 108-126 28692940-6 2017 Treatment with betulinic acid and fluvastatin showed significant (p<0.05) reduction in Arthritic index, Rheumatoid factor, C-reactive protein (CRP), total lipids and anti-CCP (cyclic citrullinated peptide) antibody. Fluvastatin 34-45 C-reactive protein Homo sapiens 126-144 28692940-6 2017 Treatment with betulinic acid and fluvastatin showed significant (p<0.05) reduction in Arthritic index, Rheumatoid factor, C-reactive protein (CRP), total lipids and anti-CCP (cyclic citrullinated peptide) antibody. Fluvastatin 34-45 C-reactive protein Homo sapiens 146-149 28537580-0 2017 Effects of supplementation with quercetin on plasma C-reactive protein concentrations: a systematic review and meta-analysis of randomized controlled trials. Quercetin 32-41 C-reactive protein Homo sapiens 52-70 28537580-2 2017 However, the results of current clinical trials on quercetin"s effects on the C-reactive protein (CRP), a sensitive inflammatory biomarker, are ambiguous. Quercetin 51-60 C-reactive protein Homo sapiens 78-96 28537580-2 2017 However, the results of current clinical trials on quercetin"s effects on the C-reactive protein (CRP), a sensitive inflammatory biomarker, are ambiguous. Quercetin 51-60 C-reactive protein Homo sapiens 98-101 28537580-3 2017 We conducted a meta-analysis of available randomized controlled trials (RCTs) to resolve this inconsistency and quantify the net effect of quercetin on circulating CRP concentrations. Quercetin 139-148 C-reactive protein Homo sapiens 164-167 28537580-7 2017 The meta-analysis of seven RCTs (10 treatment arms) showed a significant reduction of circulating CRP levels (WMD: -0.33 mg/l; 95% CI: -0.50 to -0.15; P<0.001) following quercetin supplementation. Quercetin 173-182 C-reactive protein Homo sapiens 98-101 28537580-10 2017 Our findings showed a significant effect of quercetin supplementation on the C-reactive protein-especially at doses above 500 mg/day and in patients with CRP <3 mg/l. Quercetin 44-53 C-reactive protein Homo sapiens 77-95 28537580-10 2017 Our findings showed a significant effect of quercetin supplementation on the C-reactive protein-especially at doses above 500 mg/day and in patients with CRP <3 mg/l. Quercetin 44-53 C-reactive protein Homo sapiens 154-157 29217959-10 2017 Results: A statistically significant reduction in C-Reactive Protein, Probing Pocket Depth, Clinical Attachment Loss, Total Cholesterol and Low Density Lipid level in 0.25% lemongrass oil mouthwash group was found. lemongrass oil 173-187 C-reactive protein Homo sapiens 50-68 28859672-8 2017 Laquinimod-treated patients showed more abnormal laboratory levels in liver enzymes, P-amylase, C-reactive protein (CRP), and fibrinogen, but most shifts were clinically non-significant. laquinimod 0-10 C-reactive protein Homo sapiens 96-114 28859672-8 2017 Laquinimod-treated patients showed more abnormal laboratory levels in liver enzymes, P-amylase, C-reactive protein (CRP), and fibrinogen, but most shifts were clinically non-significant. laquinimod 0-10 C-reactive protein Homo sapiens 116-119 28430117-12 2017 After 1 week of fluvastatin therapy, C-reactive protein (CRP) and homocysteine (HCY) levels were lower in the fluvastatin group than in the control group. Fluvastatin 110-121 C-reactive protein Homo sapiens 37-55 28430117-12 2017 After 1 week of fluvastatin therapy, C-reactive protein (CRP) and homocysteine (HCY) levels were lower in the fluvastatin group than in the control group. Fluvastatin 110-121 C-reactive protein Homo sapiens 57-60 28430117-13 2017 At 24 months of follow-up, CRP and HCY levels remained lower in the fluvastatin group than in the control group. Fluvastatin 68-79 C-reactive protein Homo sapiens 27-30 28261955-9 2017 Beloranib treatment was associated with improvements in high-sensitivity CRP. CKD732 0-9 C-reactive protein Homo sapiens 73-76 28486313-7 2017 RA with sSS had significantly shorter TBUT, higher corneal staining score, and ESR CRP levels (P < 0.05). sss 8-11 C-reactive protein Homo sapiens 83-86 28504712-0 2017 Flavonoid intake is inversely associated with obesity and C-reactive protein, a marker for inflammation, in US adults. Flavonoids 0-9 C-reactive protein Homo sapiens 58-76 28504712-5 2017 Adults in the highest quartile of flavonoid intake had significantly lower body mass index and waist circumference than those in the lowest quartile of flavonoid intake (P<0.03 and P<0.04, respectively), and flavonoid intake was inversely related to C-reactive protein levels in women (p-trend, 0.01). Flavonoids 34-43 C-reactive protein Homo sapiens 256-274 28752145-9 2017 LAS (+) group, values for RDW (14.85+-1.48 vs. 13.77+-1.30; p<0.01), NLR (2.38 [1.58], vs. 2.10 [1.35]; p<0.01) and C-reactive protein (0.95 [0.61] vs. 0.88 [0.60] mg/L; p<0.01) were significantly higher than seen in LAS (-) group. las 0-3 C-reactive protein Homo sapiens 122-140 28422153-9 2017 Pemetrexed/cisplatin model was based on 57 patients and included CRP, MTHFD1 rs2236225, and ABCC2 rs2273697. Pemetrexed 0-10 C-reactive protein Homo sapiens 65-68 28171699-2 2017 CRP, an acute-phase reactant binds to the phosphocholine expressed on the surface of dead or dying cells and some bacteria, thereby activating complement and promoting phagocytosis by macrophages. Phosphorylcholine 42-56 C-reactive protein Homo sapiens 0-3 27444965-3 2017 Specifically, we predicted that PA would moderate the relationship between PPS and CRP. pps 75-78 C-reactive protein Homo sapiens 83-86 27444965-6 2017 Using a moderated hierarchical regression analysis, PPS and PA significantly interacted to predict levels of CRP (p<0.05). pps 52-55 C-reactive protein Homo sapiens 109-112 27444965-7 2017 Examination of the simple slopes revealed a disordinal interaction between PPS and PA, such that higher PA was protective against elevated CRP levels, but only when individuals also reported greater levels of PPS. pps 75-78 C-reactive protein Homo sapiens 139-142 27444965-9 2017 Findings also provide caution of future assumptions that relationships among PA, PPS, and physical health markers, such as CRP, are always positive (e.g., PA) or negative (e.g., PPS) in nature. pps 178-181 C-reactive protein Homo sapiens 123-126 27753120-7 2017 High-sensitive CRP and nNO reflected responses best (52% had increased CRP levels at 2-3 days; 66% had decreased nNO levels). Nitrous Oxide 23-26 C-reactive protein Homo sapiens 71-74 27815167-0 2017 Calcium-independent binding of human C-reactive protein to lysophosphatidylcholine in supported planar phospholipid monolayers. Lysophosphatidylcholines 59-82 C-reactive protein Homo sapiens 37-55 27815167-1 2017 Details describing the molecular dynamics of inflammation biomarker human C-reactive protein (CRP) on plasma membranes containing bioactive lipid lysophosphatidylcholine (LPC) remain elusive. Lysophosphatidylcholines 146-169 C-reactive protein Homo sapiens 74-92 27815167-1 2017 Details describing the molecular dynamics of inflammation biomarker human C-reactive protein (CRP) on plasma membranes containing bioactive lipid lysophosphatidylcholine (LPC) remain elusive. Lysophosphatidylcholines 146-169 C-reactive protein Homo sapiens 94-97 27815167-1 2017 Details describing the molecular dynamics of inflammation biomarker human C-reactive protein (CRP) on plasma membranes containing bioactive lipid lysophosphatidylcholine (LPC) remain elusive. Lysophosphatidylcholines 171-174 C-reactive protein Homo sapiens 74-92 27815167-1 2017 Details describing the molecular dynamics of inflammation biomarker human C-reactive protein (CRP) on plasma membranes containing bioactive lipid lysophosphatidylcholine (LPC) remain elusive. Lysophosphatidylcholines 171-174 C-reactive protein Homo sapiens 94-97 27815167-3 2017 Surprisingly, CRP binding to supported 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)/LPC monolayers was calcium-independent although CRP binding to supported POPC monolayers was calcium-dependent. Lysophosphatidylcholines 95-98 C-reactive protein Homo sapiens 14-17 27815167-5 2017 Binding experiments on supported POPC/1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1"-rac-glycerol) monolayers further validated calcium-independent binding of CRP through the glycerophosphate moiety. 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1"-rac-glycerol 38-96 C-reactive protein Homo sapiens 158-161 27815167-8 2017 STATEMENT OF SIGNIFICANCE: C-reactive protein (CRP), a major acute-phase pentraxin, binds to plasma membranes through the multivalent contacts with zwitterionic phosphorylcholine groups for activating classical complement systems. zwitterionic phosphorylcholine 148-178 C-reactive protein Homo sapiens 27-45 27815167-8 2017 STATEMENT OF SIGNIFICANCE: C-reactive protein (CRP), a major acute-phase pentraxin, binds to plasma membranes through the multivalent contacts with zwitterionic phosphorylcholine groups for activating classical complement systems. zwitterionic phosphorylcholine 148-178 C-reactive protein Homo sapiens 47-50 27815167-10 2017 This paper reports the novel calcium-independent interaction of CRP to bioactive phospholipid lysophosphatidylcholine (LPC) in supported phospholipids monolayers as determined using SPR. Lysophosphatidylcholines 94-117 C-reactive protein Homo sapiens 64-67 27815167-10 2017 This paper reports the novel calcium-independent interaction of CRP to bioactive phospholipid lysophosphatidylcholine (LPC) in supported phospholipids monolayers as determined using SPR. Lysophosphatidylcholines 119-122 C-reactive protein Homo sapiens 64-67 27756037-9 2016 Changes in SAA-LDL level were significantly and positively correlated with those in CRP in both the RSV (r=0.549, p=0.003) and PTV (r=0.576, p=0.004) groups. Rosuvastatin Calcium 100-103 C-reactive protein Homo sapiens 84-87 27304050-2 2016 The purpose of this study was to explore the relationships of high-sensitivity C-reactive protein (hsCRP) with IPH. iph 111-114 C-reactive protein Homo sapiens 79-97 27597810-2 2016 In the present study, we compared the effects of clopidogrel and prasugrel on high-sensitivity C-reactive protein (hs-CRP) in patients undergoing percutaneous coronary intervention (PCI). Clopidogrel 49-60 C-reactive protein Homo sapiens 95-113 27597810-8 2016 Patients taking clopidogrel showed a significant reduction in hs-CRP level compared with the baseline values (P < 0.001). Clopidogrel 16-27 C-reactive protein Homo sapiens 65-68 26873368-0 2016 Engineered zwitterionic phosphorylcholine monolayers for elucidating multivalent binding kinetics of C-reactive protein. Phosphorylcholine 24-41 C-reactive protein Homo sapiens 101-119 26873368-2 2016 Previously, the use of a zwitterionic phosphorylcholine group, a biomimetic ligand for CRP in the presence of calcium ions, for binding experiments has revealed that the adsorption dynamics changed by ionic microenvironments. Phosphorylcholine 38-55 C-reactive protein Homo sapiens 87-90 26873368-10 2016 STATEMENT OF SIGNIFICANCE: C-reactive protein (CRP), a major acute-phase pentraxin, binds to plasma membranes through the multivalent contacts with zwitterionic phosphorylcholine groups. Phosphorylcholine 161-178 C-reactive protein Homo sapiens 27-45 26873368-10 2016 STATEMENT OF SIGNIFICANCE: C-reactive protein (CRP), a major acute-phase pentraxin, binds to plasma membranes through the multivalent contacts with zwitterionic phosphorylcholine groups. Phosphorylcholine 161-178 C-reactive protein Homo sapiens 47-50 26573952-6 2016 Moreover, the influence of CRP and SCC-Ag levels on DSS (P = 0.033, hazard ratio 3.390, 95% confidence interval 1.104-10.411) remained after adjusting for smoking history, phimosis, tumour status, tumour cell differentiation and nodal status. dss 52-55 C-reactive protein Homo sapiens 27-30 26573952-7 2016 CONCLUSIONS: The present study shows that the combined measurement of preoperative CRP and SCC-Ag levels may serve as an independent biomarker for LNM, advanced tumour stage and DSS in patients with penile SCC. dss 178-181 C-reactive protein Homo sapiens 83-86 27328699-0 2016 High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial. Clopidogrel 108-119 C-reactive protein Homo sapiens 15-33 27256833-9 2016 Adjusting for traditional risk factors, body mass index, medications, lesion characteristic, renal function, and high-sensitivity C-reactive protein, elevated TMAO levels remained independently associated with a higher SYNTAX score (odds ratio [OR]: 4.82; p < 0.0001), SYNTAX score II (OR: 1.88; p = 0.0001), but were not associated with subclinical myonecrosis (OR: 1.14; p = 0.3147). trimethyloxamine 159-163 C-reactive protein Homo sapiens 130-148 27032409-2 2016 The recognition layer of the biosensor is fabricated by physical adsorption of the anti-CRP monoclonal antibody onto a poly-3-hexyl thiophene (P3HT) organic semiconductor surface. poly(3-hexylthiophene) 119-141 C-reactive protein Homo sapiens 88-91 27032409-2 2016 The recognition layer of the biosensor is fabricated by physical adsorption of the anti-CRP monoclonal antibody onto a poly-3-hexyl thiophene (P3HT) organic semiconductor surface. poly(3-hexylthiophene) 143-147 C-reactive protein Homo sapiens 88-91 27032409-11 2016 The anti-CRP monoclonal antibody layer is physisorbed on the P3HT organic semiconductor and the CRP is directly measured by a label-free electronic EGOFET transducer. poly(3-hexylthiophene) 61-65 C-reactive protein Homo sapiens 9-12 26678511-4 2016 VAS compared with placebo was associated with an increased frequency of CRP >= 5 mg/l (28 v. 12%; P=0 005). vas 0-3 C-reactive protein Homo sapiens 72-75 26610293-9 2016 CONCLUSIONS: Urinary PAH metabolites were associated with serum uric acid, GGT and CRP, suggesting possible impacts on cardiometabolic and kidney function in adolescents. Polycyclic Aromatic Hydrocarbons 21-24 C-reactive protein Homo sapiens 83-86 27174032-2 2016 The aim of this study was to investigate the association between CRP and progression-free survival (PFS), overall survival (OS) and radiological response in CRPC patients treated with docetaxel. Docetaxel 184-193 C-reactive protein Homo sapiens 65-68 27174032-8 2016 CONCLUSIONS: CRP may be an important biomarker of PFS and OS in CRPC patients treated with docetaxel. Docetaxel 91-100 C-reactive protein Homo sapiens 13-16 26588324-0 2015 Poly(3,4-ethylenedioxythiophene) Bearing Phosphorylcholine Groups for Metal-Free, Antibody-Free, and Low-Impedance Biosensors Specific for C-Reactive Protein. Phosphorylcholine 41-58 C-reactive protein Homo sapiens 139-157 26588324-6 2015 The specific interaction of CRP with phosphorylcholine in a calcium-containing buffer solution was determined by differential pulse voltammetry, which measures the altered redox reaction between the indicators ferricyanide/ferrocyanide as a result of the binding event. Phosphorylcholine 37-54 C-reactive protein Homo sapiens 28-31 26588324-6 2015 The specific interaction of CRP with phosphorylcholine in a calcium-containing buffer solution was determined by differential pulse voltammetry, which measures the altered redox reaction between the indicators ferricyanide/ferrocyanide as a result of the binding event. hexacyanoferrate III 210-222 C-reactive protein Homo sapiens 28-31 26889454-0 2016 Changes of High Sensitivity C-Reactive Protein During Clopidogrel Therapy in Patients Undergoing Percutaneous Coronary Intervention. Clopidogrel 54-65 C-reactive protein Homo sapiens 28-46 26889454-2 2016 However, there is insufficient data available to demonstrate the changes in high sensitivity C-reactive protein (hs-CRP) during clopidogrel therapy. Clopidogrel 128-139 C-reactive protein Homo sapiens 93-111 26713054-6 2015 On univariate analysis, CRP, ESR, and NLR were significantly associated with DFS and DSS. dss 85-88 C-reactive protein Homo sapiens 24-27 26713054-7 2015 On multivariate analysis, CRP and NLR were independently significant prognostic variables for DSS and DFS respectively (P=0.013, P=0.021). dss 94-97 C-reactive protein Homo sapiens 26-29 26713054-8 2015 When PIS was constructed with combination of CRP and NLR, it was independently and significantly associated with both DFS and DSS (P=0.006, P=0.010). dss 126-129 C-reactive protein Homo sapiens 45-48 25904733-7 2015 Serum C-reactive protein (CRP) was lower for individuals consuming LCCJ than for individuals consuming the placebo beverage [ln transformed values of 0.522 +- 0.115 ln(mg/L) vs. 0.997 +- 0.120 ln(mg/L), P = 0.0054, respectively, and equivalent to 1.69 mg/L vs. 2.71 mg/L back-transformed]. lccj 67-71 C-reactive protein Homo sapiens 6-24 25904733-7 2015 Serum C-reactive protein (CRP) was lower for individuals consuming LCCJ than for individuals consuming the placebo beverage [ln transformed values of 0.522 +- 0.115 ln(mg/L) vs. 0.997 +- 0.120 ln(mg/L), P = 0.0054, respectively, and equivalent to 1.69 mg/L vs. 2.71 mg/L back-transformed]. lccj 67-71 C-reactive protein Homo sapiens 26-29 25636208-7 2015 High levels of a marker of inflammation (C-reactive protein [CRP]) and an inflammatory mediator (TNF super-family member 13 [TNFSF13]) were found in the serum of patients with PDAC-DM. pdac-dm 176-183 C-reactive protein Homo sapiens 41-59 25636208-7 2015 High levels of a marker of inflammation (C-reactive protein [CRP]) and an inflammatory mediator (TNF super-family member 13 [TNFSF13]) were found in the serum of patients with PDAC-DM. pdac-dm 176-183 C-reactive protein Homo sapiens 61-64 25636208-9 2015 Furthermore, we found that the levels of TNFSF13 in PDAC lesions and TNFSF13 and CRP in serum were significantly correlated with the diabetic status of patients with PDAC-DM (p < 0.01). pdac-dm 166-173 C-reactive protein Homo sapiens 81-84 25455727-7 2015 RESULTS: Hs-CRP levels were significantly higher in the DS group (0.149 +- 0.161 mg/dL) than in either the IS or control group (0.0156 +- 0.0136 and 0.0253 +- 0.0288 mg/dL, p<0.005 and p<0.05, respectively), while there was no significant difference between the IS and control groups. Deuterium 56-58 C-reactive protein Homo sapiens 12-15 25613713-9 2015 The area under the curve (AUC) of the receiver operating characteristic (ROC) curves in relation to the dichotomized status of the infection (infection versus no infection) was 0.74 (95% confidence interval: 0.59 to 0.88) for CRP at 6 hours, 0.76 (0.61 to 0.9) for IL-10 at 6 hours, 0.83 (0.71 to 0.94) for NIHSS on admission and 0.94 (0.88 to 1) for the combination of CRP, IL-10 and NIHSS. nihss 307-312 C-reactive protein Homo sapiens 226-229 25613713-9 2015 The area under the curve (AUC) of the receiver operating characteristic (ROC) curves in relation to the dichotomized status of the infection (infection versus no infection) was 0.74 (95% confidence interval: 0.59 to 0.88) for CRP at 6 hours, 0.76 (0.61 to 0.9) for IL-10 at 6 hours, 0.83 (0.71 to 0.94) for NIHSS on admission and 0.94 (0.88 to 1) for the combination of CRP, IL-10 and NIHSS. nihss 385-390 C-reactive protein Homo sapiens 226-229 25536316-0 2015 Rosuvastatin ameliorates inflammation, renal fat accumulation, and kidney injury in transgenic spontaneously hypertensive rats expressing human C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 144-162 25536316-2 2015 In addition, we found that rosuvastatin treatment of SHR-CRP transgenic rats can protect against pro-inflammatory effects of human CRP and also reduce cardiac inflammation and oxidative damage. Rosuvastatin Calcium 27-39 C-reactive protein Homo sapiens 131-134 25502724-6 2014 Lysophosphatidylcholines were negatively associated with body mass index, C-reactive protein and with less evidence of subclinical cardiovascular disease in additional 970 participants; a reverse pattern was observed for MG 18:2. Lysophosphatidylcholines 0-24 C-reactive protein Homo sapiens 74-92 25017001-2 2014 The authors tested the hypothesis that C-reactive protein (CRP), a commonly available marker of systemic inflammation, predicts differential response to escitalopram (a serotonin reuptake inhibitor) and nortriptyline (a norepinephrine reuptake inhibitor). Nortriptyline 203-216 C-reactive protein Homo sapiens 59-62 25017001-4 2014 CRP was measured with a high-sensitivity method in serum samples from 241 adult men and women with major depressive disorder randomly allocated to 12-week treatment with escitalopram (N=115) or nortriptyline (N=126). Nortriptyline 194-207 C-reactive protein Homo sapiens 0-3 25204405-10 2014 The developed MTX pharmacokinetic-pharmacodynamic model provided an acceptable description of the observed DAS28-3v (CRP) across all patients. Methotrexate 14-17 C-reactive protein Homo sapiens 117-120 25204405-11 2014 CONCLUSIONS: The developed model describes a longitudinal relationship between RBC MTXGlu(3-5) concentrations and DAS28-3v (CRP) in patients with RA commencing MTX. Methotrexate 83-86 C-reactive protein Homo sapiens 124-127 24422992-0 2014 Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy. Methotrexate 148-160 C-reactive protein Homo sapiens 11-29 25412755-6 2014 Piperacillin/tazobactam was initiated but after 2 days he developed hypoxemia, vascular shock, severe anemia, lymphopenia, and high C-reactive protein. Piperacillin, Tazobactam Drug Combination 0-23 C-reactive protein Homo sapiens 132-150 23922235-0 2014 Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? curcuminoids 4-16 C-reactive protein Homo sapiens 27-45 23922235-5 2014 Curcuminoids have been suggested to lower circulating levels of CRP, but clinical findings have not been consistent. curcuminoids 0-12 C-reactive protein Homo sapiens 64-67 23922235-6 2014 OBJECTIVES: To pool the published results of clinical trials on the impact of supplementation with curcuminoids on circulating levels of CRP. curcuminoids 99-111 C-reactive protein Homo sapiens 137-140 23922235-7 2014 METHODS: PubMed/MEDLINE and SCOPUS databases were searched for clinical trials reporting circulating CRP changes in individuals receiving curcuminoids. curcuminoids 138-150 C-reactive protein Homo sapiens 101-104 23922235-12 2014 Compared with placebo, supplementation with curcuminoids was associated with a significant reduction in circulating CRP levels (weighed mean difference: -6.44 mg/L; 95% CI: -10.77 - -2.11; p = 0.004). curcuminoids 44-56 C-reactive protein Homo sapiens 116-119 23922235-14 2014 CONCLUSIONS: Supplementation with curcuminoids may reduce circulating CRP levels. curcuminoids 34-46 C-reactive protein Homo sapiens 70-73 24948846-2 2014 First, in its native pentameric conformation, CRP recognizes molecules and cells with exposed phosphocholine (PCh) groups, such as microbial pathogens and damaged cells. Phosphorylcholine 94-108 C-reactive protein Homo sapiens 46-49 24948846-2 2014 First, in its native pentameric conformation, CRP recognizes molecules and cells with exposed phosphocholine (PCh) groups, such as microbial pathogens and damaged cells. Phosphorylcholine 110-113 C-reactive protein Homo sapiens 46-49 24948846-3 2014 PCh-containing ligand-bound CRP activates the complement system to destroy the ligand. Phosphorylcholine 0-3 C-reactive protein Homo sapiens 28-31 24948846-4 2014 Thus, the PCh-binding function of CRP is defensive if it occurs on foreign pathogens because it results in the killing of the pathogen via complement activation. Phosphorylcholine 10-13 C-reactive protein Homo sapiens 34-37 24948846-5 2014 On the other hand, the PCh-binding function of CRP is detrimental if it occurs on injured host cells because it causes more damage to the tissue via complement activation; this is how CRP worsens acute myocardial infarction and ischemia/reperfusion injury. Phosphorylcholine 23-26 C-reactive protein Homo sapiens 47-50 24948846-5 2014 On the other hand, the PCh-binding function of CRP is detrimental if it occurs on injured host cells because it causes more damage to the tissue via complement activation; this is how CRP worsens acute myocardial infarction and ischemia/reperfusion injury. Phosphorylcholine 23-26 C-reactive protein Homo sapiens 184-187 24948846-8 2014 In conclusion, temporarily inhibiting the PCh-binding function of CRP along with facilitating localized presence of nonnative pentameric CRP could be a promising approach to treat atherosclerosis and myocardial infarction. Phosphorylcholine 42-45 C-reactive protein Homo sapiens 66-69 24948846-8 2014 In conclusion, temporarily inhibiting the PCh-binding function of CRP along with facilitating localized presence of nonnative pentameric CRP could be a promising approach to treat atherosclerosis and myocardial infarction. Phosphorylcholine 42-45 C-reactive protein Homo sapiens 137-140 24095850-8 2013 In women, oxHDLlipids were additionally inversely associated with waist circumference (partial R(2)=1.8%) and daily smoking (partial R(2)=0.7%) and directly with C-reactive protein (CRP; partial R(2)=0.5%) and alcohol use (partial R(2)=0.5%). oxhdllipids 10-21 C-reactive protein Homo sapiens 162-180 24095850-8 2013 In women, oxHDLlipids were additionally inversely associated with waist circumference (partial R(2)=1.8%) and daily smoking (partial R(2)=0.7%) and directly with C-reactive protein (CRP; partial R(2)=0.5%) and alcohol use (partial R(2)=0.5%). oxhdllipids 10-21 C-reactive protein Homo sapiens 182-185 23897106-6 2013 RESULTS: C-reactive protein (CRP) concentrations were positively correlated with the difference between ALBBCG and ALBmBCP in malnourished inpatients (r = 0.59, p < 0.001). albbcg 104-110 C-reactive protein Homo sapiens 9-27 23897106-6 2013 RESULTS: C-reactive protein (CRP) concentrations were positively correlated with the difference between ALBBCG and ALBmBCP in malnourished inpatients (r = 0.59, p < 0.001). albbcg 104-110 C-reactive protein Homo sapiens 29-32 23972896-12 2013 CONCLUSIONS: Urinary PAH biomarkers were found to be positively associated with serum CRP and total WBC count independent of smoking and other potential confounders. Polycyclic Aromatic Hydrocarbons 21-24 C-reactive protein Homo sapiens 86-89 24364085-10 2013 Our research showed that C-reactive protein was higher postoperatively in the control group than in the levosimendan group (P < 0.05). Simendan 104-116 C-reactive protein Homo sapiens 25-43 24174961-9 2013 Independent predictors of TCFA by multivariate analysis were ACS {odds ratio (OR): 2.204, 95% CI: 1.321-3.434, p=0.021} and high-sensitivity C-reactive protein (OR: 1.101; 95% CI 1.058-1.204, p=0.035). tcfa 26-30 C-reactive protein Homo sapiens 141-159 24174961-10 2013 CONCLUSION: Although the plaque burden was significantly smaller, ACL-NCL had more vulnerable plaque components compared with SA-TL, and ACS and high-sensitivity C-reactive protein were the independent predictors of TCFA. tcfa 216-220 C-reactive protein Homo sapiens 162-180 23600368-8 2013 Rosuvastatin monotherapy and add-on ER-NA/LRPT groups were associated with 56% and 24% reduction in high-sensitivity C-reactive protein levels (hsCRP), respectively (P < 0.01 compared with baseline), while add-on fenofibrate was not associated with changes in hsCRP concentration. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 117-135 24049596-9 2013 Quercetin supplementation significantly reduced the serum concentration of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) (P = 0.01 and P < 0.0001, respectively); however, the mean changes in serum levels of IL-6, TNF-alpha, and high-sensitivity C-reactive protein were not significant between the groups. Quercetin 0-9 C-reactive protein Homo sapiens 267-285 24293976-3 2012 We tested the hypothesis that some of the beneficial effect of clopidogrel may be due to the variable activity of this drug on the vascular system (assessed by plasma markers von Willebrand factor and soluble E-selectin, and functional arterial pulse wave velocity) and inflammation (C-reactive protein and interleukin-6) while 32 patients with coronary artery disease taking 75 mg clopidogrel daily, and again 2 weeks after cessation of clopidogrel therapy. Clopidogrel 63-74 C-reactive protein Homo sapiens 284-302 22984272-6 2012 RESULTS: At 6 months, there was a significantly greater reduction in PWV in the MTX-alone group (0.18 +- 1.59 m/s) compared with the MTX plus IFX group (-0.78 +- 1.13 m/s; p = 0.044), accompanied by significantly greater reduction in patient"s global assessment, number of swollen joints, C-reactive protein, and DAS28 in the MTX plus IFX group compared to the MTX-alone group. Methotrexate 80-83 C-reactive protein Homo sapiens 289-307 21782402-1 2012 BACKGROUND AND AIMS: The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) reported reduced cardiovascular and all-cause mortality in patients with elevated C-reactive protein (CRP) and low LDL-cholesterol (LDL-C) levels treated with statins. Rosuvastatin Calcium 118-130 C-reactive protein Homo sapiens 223-241 21782402-1 2012 BACKGROUND AND AIMS: The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) reported reduced cardiovascular and all-cause mortality in patients with elevated C-reactive protein (CRP) and low LDL-cholesterol (LDL-C) levels treated with statins. Rosuvastatin Calcium 118-130 C-reactive protein Homo sapiens 243-246 23114023-0 2012 The pro-atherogenic effects of macrophages are reduced upon formation of a complex between C-reactive protein and lysophosphatidylcholine. Lysophosphatidylcholines 114-137 C-reactive protein Homo sapiens 91-109 23114023-9 2012 CONCLUSIONS: The formation of complexes between CRP and PC-containing oxPLs, such as LPC, suppresses the pro-atherogenic effects of CRP and LPC on macrophages. Lysophosphatidylcholines 85-88 C-reactive protein Homo sapiens 48-51 23114023-9 2012 CONCLUSIONS: The formation of complexes between CRP and PC-containing oxPLs, such as LPC, suppresses the pro-atherogenic effects of CRP and LPC on macrophages. Lysophosphatidylcholines 85-88 C-reactive protein Homo sapiens 132-135 22656421-1 2012 Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel (Urology 2011;78:1131-1135). Docetaxel 140-149 C-reactive protein Homo sapiens 21-39 22119508-9 2012 suPAR was significantly positively correlated with markers of systemic inflammation (i.e., high sensitive C-reactive protein (hsCRP) and white blood cells (WBC), but not to lipoprotein-associated phospholipase A2 (Lp-PLA(2)), a specific vascular inflammatory biomarker.87 subjects had a CVD event during follow-up (mean 14.1 years). supar 0-5 C-reactive protein Homo sapiens 106-124 22158621-1 2012 C-reactive protein (CRP) is a cyclic pentameric protein whose major binding specificity, at physiological pH, is for substances bearing exposed phosphocholine moieties. Phosphorylcholine 144-158 C-reactive protein Homo sapiens 0-18 22158621-1 2012 C-reactive protein (CRP) is a cyclic pentameric protein whose major binding specificity, at physiological pH, is for substances bearing exposed phosphocholine moieties. Phosphorylcholine 144-158 C-reactive protein Homo sapiens 20-23 22687786-11 2012 Correlation was found between changes in ROCK inhibition and changes in CRP in rosuvastatin 40 mg/day group (r=0.47, p<0.05). Rosuvastatin Calcium 79-91 C-reactive protein Homo sapiens 72-75 21792541-2 2011 Lately, findings from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial opened a new frontier: that of prescribing statins for vascular events risk reduction based upon the baseline CRP levels in otherwise healthy adults. Rosuvastatin Calcium 111-123 C-reactive protein Homo sapiens 250-253 21975508-0 2011 C-Reactive protein-directed immobilization of phosphocholine ligands on a solid surface. Phosphorylcholine 46-60 C-reactive protein Homo sapiens 0-18 21975508-1 2011 The complexes of C-reactive protein (CRP) with its polymerizable phosphocholine ligands adsorbed at the styrene-water interface were polymerized. Phosphorylcholine 65-79 C-reactive protein Homo sapiens 17-35 21975508-1 2011 The complexes of C-reactive protein (CRP) with its polymerizable phosphocholine ligands adsorbed at the styrene-water interface were polymerized. Phosphorylcholine 65-79 C-reactive protein Homo sapiens 37-40 21479972-7 2011 suPAR was found to be prognostic for mortality in receiver operator characteristic (ROC) curve analysis, which was not observed for serum C-reactive protein (CRP); the area under the curve (AUC) for suPAR was 0.754 (95% confidence interval [CI], 0.615-0.894, p = 0.003) and for CRP, it was 0.596 (95% CI, 0.442-0.750, p = 0.253). supar 0-5 C-reactive protein Homo sapiens 278-281 21601209-3 2011 METHODS: After evaluating its anti-oxidative and anti-inflammatory effects in cultured human cells, quercetin (0.1%, w/w in diet) was given to human CRP transgenic mice, a humanized inflammation model, and ApoE*3Leiden transgenic mice, a humanized atherosclerosis model. Quercetin 100-109 C-reactive protein Homo sapiens 149-152 21601209-7 2011 In human CRP transgenic mice (quercetin plasma concentration: 12.9 +- 1.3 muM), quercetin quenched IL1beta-induced CRP expression, as did sodium salicylate. Quercetin 80-89 C-reactive protein Homo sapiens 9-12 21601209-12 2011 CONCLUSION: Quercetin reduces the expression of human CRP and cardiovascular risk factors (SAA, fibrinogen) in mice in vivo. Quercetin 12-21 C-reactive protein Homo sapiens 54-57 21940313-9 2011 CONCLUSIONS: Decreases in serum high sensitive CRP levels following calcium polycarbophil treatment may be involved in the relief of abdominal symptoms in IBS patients; diarrhea type IBS is characterized by increased MCP-1 expression. calcium polycarbophil 68-89 C-reactive protein Homo sapiens 47-50 22166738-11 2011 The inflammatory response estimated with CRP, IL-6 concentration in blood serum was considerably higher in patients operated with Stoppa method. stoppa 130-136 C-reactive protein Homo sapiens 41-44 21860701-1 2011 THE JUSTIFICATION FOR THE USE OF STATINS IN PREVENTION: an intervention trial evaluating rosuvastatin (JUPITER) study was a real breakthrough in primary cardiovascular disease prevention with statins, since it was conducted in apparently healthy individuals with normal levels of low-density lipoprotein cholesterol (LDL-C < 130 mg/dL) and increased inflammatory state, reflected by a high concentration of high-sensitivity C-reactive protein (hs-CRP >= 2 mg/L). Rosuvastatin Calcium 89-101 C-reactive protein Homo sapiens 427-445 21742096-8 2011 CONCLUSIONS: When used in primary prevention among individuals with low-density lipoprotein <130 mg/dL and high-sensitivity C-reactive protein >=2 mg/L, rosuvastatin significantly reduced first MI, stroke, arterial revascularization, hospitalization for unstable angina, and cardiovascular death among whites and nonwhites. Rosuvastatin Calcium 159-171 C-reactive protein Homo sapiens 127-145 21562509-0 2011 Rosuvastatin attenuates the elevation in blood pressure induced by overexpression of human C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 91-109 21641360-0 2011 Effect of rosuvastatin on C-reactive protein and progression of aortic stenosis. Rosuvastatin Calcium 10-22 C-reactive protein Homo sapiens 26-44 21641360-6 2011 Treatment with rosuvastatin led to a persistent decrease in CRP at 1 year and end of follow-up. Rosuvastatin Calcium 15-27 C-reactive protein Homo sapiens 60-63 21641360-11 2011 Treatment with rosuvastatin reduces CRP levels but has no effect on the progression and clinical events of AS. Rosuvastatin Calcium 15-27 C-reactive protein Homo sapiens 36-39 23199130-5 2011 Our studies showed that among middle-aged Japanese, 3% ODI levels were associated with hypertension, elevated serum CRP levels, accumulation of metabolic risk factors, and increased risk of developing type 2 diabetes. 1,8-Octanediol 55-58 C-reactive protein Homo sapiens 116-119 21310311-6 2011 Higher clopidogrel dose was associated with decreased proportion of patients with P2Y(12) reaction units >= 240 (12% vs. 32%; p = 0.001), flow-mediated vasodilation <7% (16% vs. 58%; p = 0.0003), and high-sensitivity C-reactive protein levels >3 mg/l (46% vs. 64%; p = 0.07). Clopidogrel 7-18 C-reactive protein Homo sapiens 223-241 21310313-2 2011 BACKGROUND: The JUPITER trial found that rosuvastatin reduces vascular events in apparently healthy subjects with elevated high-sensitivity C-reactive protein (hs-CRP) but normal low-density lipoprotein (LDL) cholesterol levels. Rosuvastatin Calcium 41-53 C-reactive protein Homo sapiens 140-158 21149827-7 2011 In the present study, the hypothesis was tested that the acute application of CRP (25 mg/L), in presence of aldosterone (0.5 nmol/L; 24 hour incubation), modifies the mechanical stiffness and permeability of the endothelium. Aldosterone 108-119 C-reactive protein Homo sapiens 78-81 21149827-12 2011 The data indicate that CRP enhances the effects of aldosterone on the mechanical properties of the endothelium. Aldosterone 51-62 C-reactive protein Homo sapiens 23-26 21263416-6 2011 At subjects with RA treated by MTX, correlation between values of ADA catalytic activities and values of CRP concentrations in serums was not statistically significant (r = 0.33, p > 0.01). Methotrexate 31-34 C-reactive protein Homo sapiens 105-108 20926154-0 2010 The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: a meta-analysis. Thiazolidinediones 15-33 C-reactive protein Homo sapiens 49-67 20926154-6 2010 Standard mean difference (SMD) of CRP and 95% CI were calculated to evaluate the effect of TZDs on CRP. Thiazolidinediones 91-95 C-reactive protein Homo sapiens 99-102 20926154-9 2010 Moreover, TZDs were found to significantly reduce CRP levels in both diabetes mellitus (DM) and non-DM patients. Thiazolidinediones 10-14 C-reactive protein Homo sapiens 50-53 21491734-5 2010 The use of CRP as a guide in primary prevention was tested for the first time in the JUPITER study, a large randomized trial comparing rosuvastatin 20 mg and placebo. Rosuvastatin Calcium 135-147 C-reactive protein Homo sapiens 11-14 20946880-7 2010 A recent clinical study has shown that rosuvastatin reduces risk of ischemic stroke in patients with high plasma levels of the inflammatory marker C-reactive protein by 50%. Rosuvastatin Calcium 39-51 C-reactive protein Homo sapiens 147-165 20842713-5 2010 Biochemical experiments confirmed the predicted binding site for UO(2) (2+) and it was demonstrated by surface plasmon resonance assays that UO(2) (2+) binding to CRP prevents the calcium-mediated binding of phosphorylcholine. Phosphorylcholine 208-225 C-reactive protein Homo sapiens 163-166 19351576-1 2010 BACKGROUND: The JUPITER trial has recently demonstrated an outstanding reduction of cardiovascular events by 20 mg rosuvastatin/day in subjects with high CRP who were apparently healthy at baseline. Rosuvastatin Calcium 115-127 C-reactive protein Homo sapiens 154-157 20552244-5 2010 We found that the rare minor A-allele of triallelic SNP rs30912449 (C > T > A) and presence of a deep infection focus were strongly associated to the higher maximal CRP during the first week of SAB. sab 200-203 C-reactive protein Homo sapiens 171-174 20552244-8 2010 The maximal CRP during the first week in SAB was partly determined by variation in the CRP gene and partly by presence of deep infection focus. sab 41-44 C-reactive protein Homo sapiens 12-15 20552244-8 2010 The maximal CRP during the first week in SAB was partly determined by variation in the CRP gene and partly by presence of deep infection focus. sab 41-44 C-reactive protein Homo sapiens 87-90 21063486-0 2010 Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients. Ribavirin 80-89 C-reactive protein Homo sapiens 9-12 21063486-9 2010 Hs-CRP level was significantly decreased in 83 patients after peginterferon/ribavirin combination therapy (0.24 vs. 0.62 mg/L, P < 0.001), particularly in 68 patients achieving a sustained virological response (0.25 vs. 0.64 mg/L, P < 0.001). Ribavirin 76-85 C-reactive protein Homo sapiens 3-6 21063486-10 2010 CONCLUSION: CHC patients had a higher hs-CRP level than healthy controls which could be ameliorated after peginterferon/ribavirin combination therapy. Ribavirin 120-129 C-reactive protein Homo sapiens 41-44 20569521-4 2010 The anti-inflammatory actions of flavonoids in vitro or in cellular models involve the inhibition of the synthesis and activities of different pro-inflammatory mediators such as eicosanoids, cytokines, adhesion molecules and C-reactive protein. Flavonoids 33-43 C-reactive protein Homo sapiens 225-243 20707047-8 2010 In the SAP patients Fas/APO1 showed a significant positive correlation with high sensitivity C-reactive protein (hsCRP) (p < 0.05) and a negative correlation with high-density lipoprotein cholesterol (HDL-C) (p < 0.05), while FasL showed a significant positive correlation with low-density lipoprotein cholesterol (LDL-C) (p < 0.05). ammonium ferrous sulfate 20-23 C-reactive protein Homo sapiens 93-111 20415446-4 2010 Herein we describe how changing properties of substrate (phosphocholine, PC) self-assembly can affect both binding behavior and substrate affinity to a pentameric recognition protein (C-reactive protein, CRP). Phosphorylcholine 57-71 C-reactive protein Homo sapiens 184-202 20415446-4 2010 Herein we describe how changing properties of substrate (phosphocholine, PC) self-assembly can affect both binding behavior and substrate affinity to a pentameric recognition protein (C-reactive protein, CRP). Phosphorylcholine 57-71 C-reactive protein Homo sapiens 204-207 2692716-8 1989 Protease-cleaved CRP loses the ability to bind to the Ca2+-dependent ligand phosphorylcholine but remains the ability to bind to the Ca2+-independent ligand arginine-rich histone. Phosphorylcholine 76-93 C-reactive protein Homo sapiens 17-20 2553815-2 1989 Maximum association of 125I-labeled CRP with neutrophils and 125I-labeled CRP degradation during association with these cells was achieved by stimulating the neutrophils with PMA at 10 ng/ml; a concentration in which azurophil granule release was not significant. Iodine-125 23-27 C-reactive protein Homo sapiens 36-39 2504917-5 1989 Patients receiving their first dose of MTX (n = 9) exhibited a more prominent reduction of CRP levels in comparison to veteran MTX users (n = 9). Methotrexate 39-42 C-reactive protein Homo sapiens 91-94 2521604-3 1989 The inhibition of cell attachment was dependent on the concentration of the CRP and involved the phosphorylcholine (PC) binding site of CRP since inhibition was prevented by allowing the CRP to react with either PC (or closely related monophosphate compounds) or a mAb specific for the PC-binding site of CRP. Phosphorylcholine 97-114 C-reactive protein Homo sapiens 76-79 2521604-3 1989 The inhibition of cell attachment was dependent on the concentration of the CRP and involved the phosphorylcholine (PC) binding site of CRP since inhibition was prevented by allowing the CRP to react with either PC (or closely related monophosphate compounds) or a mAb specific for the PC-binding site of CRP. Phosphorylcholine 97-114 C-reactive protein Homo sapiens 136-139 2521604-3 1989 The inhibition of cell attachment was dependent on the concentration of the CRP and involved the phosphorylcholine (PC) binding site of CRP since inhibition was prevented by allowing the CRP to react with either PC (or closely related monophosphate compounds) or a mAb specific for the PC-binding site of CRP. Phosphorylcholine 97-114 C-reactive protein Homo sapiens 136-139 2521604-3 1989 The inhibition of cell attachment was dependent on the concentration of the CRP and involved the phosphorylcholine (PC) binding site of CRP since inhibition was prevented by allowing the CRP to react with either PC (or closely related monophosphate compounds) or a mAb specific for the PC-binding site of CRP. Phosphorylcholine 97-114 C-reactive protein Homo sapiens 136-139 2521604-3 1989 The inhibition of cell attachment was dependent on the concentration of the CRP and involved the phosphorylcholine (PC) binding site of CRP since inhibition was prevented by allowing the CRP to react with either PC (or closely related monophosphate compounds) or a mAb specific for the PC-binding site of CRP. Phosphorylcholine 116-118 C-reactive protein Homo sapiens 76-79 2521604-3 1989 The inhibition of cell attachment was dependent on the concentration of the CRP and involved the phosphorylcholine (PC) binding site of CRP since inhibition was prevented by allowing the CRP to react with either PC (or closely related monophosphate compounds) or a mAb specific for the PC-binding site of CRP. Phosphorylcholine 116-118 C-reactive protein Homo sapiens 136-139 2521604-3 1989 The inhibition of cell attachment was dependent on the concentration of the CRP and involved the phosphorylcholine (PC) binding site of CRP since inhibition was prevented by allowing the CRP to react with either PC (or closely related monophosphate compounds) or a mAb specific for the PC-binding site of CRP. Phosphorylcholine 116-118 C-reactive protein Homo sapiens 136-139 2521604-3 1989 The inhibition of cell attachment was dependent on the concentration of the CRP and involved the phosphorylcholine (PC) binding site of CRP since inhibition was prevented by allowing the CRP to react with either PC (or closely related monophosphate compounds) or a mAb specific for the PC-binding site of CRP. Phosphorylcholine 116-118 C-reactive protein Homo sapiens 136-139 2521604-3 1989 The inhibition of cell attachment was dependent on the concentration of the CRP and involved the phosphorylcholine (PC) binding site of CRP since inhibition was prevented by allowing the CRP to react with either PC (or closely related monophosphate compounds) or a mAb specific for the PC-binding site of CRP. Phosphorylcholine 212-214 C-reactive protein Homo sapiens 76-79 2521604-3 1989 The inhibition of cell attachment was dependent on the concentration of the CRP and involved the phosphorylcholine (PC) binding site of CRP since inhibition was prevented by allowing the CRP to react with either PC (or closely related monophosphate compounds) or a mAb specific for the PC-binding site of CRP. Phosphorylcholine 212-214 C-reactive protein Homo sapiens 136-139 2521604-3 1989 The inhibition of cell attachment was dependent on the concentration of the CRP and involved the phosphorylcholine (PC) binding site of CRP since inhibition was prevented by allowing the CRP to react with either PC (or closely related monophosphate compounds) or a mAb specific for the PC-binding site of CRP. Phosphorylcholine 212-214 C-reactive protein Homo sapiens 136-139 2521604-3 1989 The inhibition of cell attachment was dependent on the concentration of the CRP and involved the phosphorylcholine (PC) binding site of CRP since inhibition was prevented by allowing the CRP to react with either PC (or closely related monophosphate compounds) or a mAb specific for the PC-binding site of CRP. Phosphorylcholine 212-214 C-reactive protein Homo sapiens 136-139 2521604-3 1989 The inhibition of cell attachment was dependent on the concentration of the CRP and involved the phosphorylcholine (PC) binding site of CRP since inhibition was prevented by allowing the CRP to react with either PC (or closely related monophosphate compounds) or a mAb specific for the PC-binding site of CRP. Phosphorylcholine 212-214 C-reactive protein Homo sapiens 76-79 2521604-3 1989 The inhibition of cell attachment was dependent on the concentration of the CRP and involved the phosphorylcholine (PC) binding site of CRP since inhibition was prevented by allowing the CRP to react with either PC (or closely related monophosphate compounds) or a mAb specific for the PC-binding site of CRP. Phosphorylcholine 212-214 C-reactive protein Homo sapiens 136-139 2521604-3 1989 The inhibition of cell attachment was dependent on the concentration of the CRP and involved the phosphorylcholine (PC) binding site of CRP since inhibition was prevented by allowing the CRP to react with either PC (or closely related monophosphate compounds) or a mAb specific for the PC-binding site of CRP. Phosphorylcholine 212-214 C-reactive protein Homo sapiens 136-139 2521604-3 1989 The inhibition of cell attachment was dependent on the concentration of the CRP and involved the phosphorylcholine (PC) binding site of CRP since inhibition was prevented by allowing the CRP to react with either PC (or closely related monophosphate compounds) or a mAb specific for the PC-binding site of CRP. Phosphorylcholine 212-214 C-reactive protein Homo sapiens 136-139 2538700-2 1989 CRP at 8-64 micrograms/ml concentrations inhibited degranulation and superoxide production by PMNL in time-, and dose-dependent manner and stabilized PMNL membranes against the lytic effect of lysophosphatidylcholine. Lysophosphatidylcholines 193-216 C-reactive protein Homo sapiens 0-3 3198919-1 1988 C-reactive protein (CRP) is an acute phase serum protein in man which binds to phosphocholine (PC) in a calcium-dependent manner. Phosphorylcholine 79-93 C-reactive protein Homo sapiens 0-18 3198919-1 1988 C-reactive protein (CRP) is an acute phase serum protein in man which binds to phosphocholine (PC) in a calcium-dependent manner. Phosphorylcholine 79-93 C-reactive protein Homo sapiens 20-23 3198919-1 1988 C-reactive protein (CRP) is an acute phase serum protein in man which binds to phosphocholine (PC) in a calcium-dependent manner. Phosphorylcholine 95-97 C-reactive protein Homo sapiens 0-18 3198919-1 1988 C-reactive protein (CRP) is an acute phase serum protein in man which binds to phosphocholine (PC) in a calcium-dependent manner. Phosphorylcholine 95-97 C-reactive protein Homo sapiens 20-23 3198919-16 1988 By blotting and by ELISA all CRP reactions were blocked by PC and EDTA indicating binding through the calcium-dependent PC-binding site on CRP. Phosphorylcholine 59-61 C-reactive protein Homo sapiens 29-32 3198919-16 1988 By blotting and by ELISA all CRP reactions were blocked by PC and EDTA indicating binding through the calcium-dependent PC-binding site on CRP. Phosphorylcholine 59-61 C-reactive protein Homo sapiens 139-142 3198919-16 1988 By blotting and by ELISA all CRP reactions were blocked by PC and EDTA indicating binding through the calcium-dependent PC-binding site on CRP. Phosphorylcholine 120-122 C-reactive protein Homo sapiens 29-32 3198919-16 1988 By blotting and by ELISA all CRP reactions were blocked by PC and EDTA indicating binding through the calcium-dependent PC-binding site on CRP. Phosphorylcholine 120-122 C-reactive protein Homo sapiens 139-142 3168329-4 1988 CRP peptides (Mr less than 14,000) also caused a dose-related inhibition of Quin-2 fluorescence indicating interference with intracellular calcium movements during cell activation. Quin2 76-82 C-reactive protein Homo sapiens 0-3 2453452-5 1988 Group I MAbs recognized the Ca++-dependent phosphorylcholine (PC)-binding site of CRP since their reactivity was inhibited by PC. Phosphorylcholine 43-60 C-reactive protein Homo sapiens 82-85 2453452-5 1988 Group I MAbs recognized the Ca++-dependent phosphorylcholine (PC)-binding site of CRP since their reactivity was inhibited by PC. Phosphorylcholine 62-64 C-reactive protein Homo sapiens 82-85 2453452-5 1988 Group I MAbs recognized the Ca++-dependent phosphorylcholine (PC)-binding site of CRP since their reactivity was inhibited by PC. Phosphorylcholine 126-128 C-reactive protein Homo sapiens 82-85 3038302-6 1987 Unlike CTX induced by lipopolysaccharide, CRP-induced CTX was completely inhibited by preincubation of CRP with phosphorylcholine, a CRP ligand, at a concentration of 5.5 molecules phosphorylcholine per molecule CRP. Phosphorylcholine 112-129 C-reactive protein Homo sapiens 42-45 3038302-6 1987 Unlike CTX induced by lipopolysaccharide, CRP-induced CTX was completely inhibited by preincubation of CRP with phosphorylcholine, a CRP ligand, at a concentration of 5.5 molecules phosphorylcholine per molecule CRP. Phosphorylcholine 112-129 C-reactive protein Homo sapiens 103-106 3038302-6 1987 Unlike CTX induced by lipopolysaccharide, CRP-induced CTX was completely inhibited by preincubation of CRP with phosphorylcholine, a CRP ligand, at a concentration of 5.5 molecules phosphorylcholine per molecule CRP. Phosphorylcholine 112-129 C-reactive protein Homo sapiens 103-106 3038302-6 1987 Unlike CTX induced by lipopolysaccharide, CRP-induced CTX was completely inhibited by preincubation of CRP with phosphorylcholine, a CRP ligand, at a concentration of 5.5 molecules phosphorylcholine per molecule CRP. Phosphorylcholine 112-129 C-reactive protein Homo sapiens 103-106 3038302-6 1987 Unlike CTX induced by lipopolysaccharide, CRP-induced CTX was completely inhibited by preincubation of CRP with phosphorylcholine, a CRP ligand, at a concentration of 5.5 molecules phosphorylcholine per molecule CRP. Phosphorylcholine 181-198 C-reactive protein Homo sapiens 42-45 3038302-6 1987 Unlike CTX induced by lipopolysaccharide, CRP-induced CTX was completely inhibited by preincubation of CRP with phosphorylcholine, a CRP ligand, at a concentration of 5.5 molecules phosphorylcholine per molecule CRP. Phosphorylcholine 181-198 C-reactive protein Homo sapiens 103-106 3038302-6 1987 Unlike CTX induced by lipopolysaccharide, CRP-induced CTX was completely inhibited by preincubation of CRP with phosphorylcholine, a CRP ligand, at a concentration of 5.5 molecules phosphorylcholine per molecule CRP. Phosphorylcholine 181-198 C-reactive protein Homo sapiens 103-106 3038302-6 1987 Unlike CTX induced by lipopolysaccharide, CRP-induced CTX was completely inhibited by preincubation of CRP with phosphorylcholine, a CRP ligand, at a concentration of 5.5 molecules phosphorylcholine per molecule CRP. Phosphorylcholine 181-198 C-reactive protein Homo sapiens 103-106 3038302-9 1987 CRP-induced Mo CTX was observed, however, when Mo were exposed to CRP in medium preincubated with phosphorylcholine-treated immobilized CRP, suggesting that an active serum component which complexed with CRP was not removed. Phosphorylcholine 98-115 C-reactive protein Homo sapiens 0-3 3038302-9 1987 CRP-induced Mo CTX was observed, however, when Mo were exposed to CRP in medium preincubated with phosphorylcholine-treated immobilized CRP, suggesting that an active serum component which complexed with CRP was not removed. Phosphorylcholine 98-115 C-reactive protein Homo sapiens 66-69 3038302-9 1987 CRP-induced Mo CTX was observed, however, when Mo were exposed to CRP in medium preincubated with phosphorylcholine-treated immobilized CRP, suggesting that an active serum component which complexed with CRP was not removed. Phosphorylcholine 98-115 C-reactive protein Homo sapiens 66-69 3038302-9 1987 CRP-induced Mo CTX was observed, however, when Mo were exposed to CRP in medium preincubated with phosphorylcholine-treated immobilized CRP, suggesting that an active serum component which complexed with CRP was not removed. Phosphorylcholine 98-115 C-reactive protein Homo sapiens 66-69 2443837-4 1987 Native-CRP bound by capture ELISA to phosphorylcholine-containing ligand or anti-native-CRP did not express neo-CRP antigenicity, suggesting that PC ligand- or antibody binding is not sufficient to induce expression of the neoantigen. Phosphorylcholine 37-54 C-reactive protein Homo sapiens 7-10 3015932-17 1986 The coding regions of the Limulus and human CRP genes share approximately 25% identity and two stretches of highly conserved regions, one of which falls in the region proposed as the phosphorylcholine binding site, while the other site is very similar to the consensus sequence required for calcium binding in calmodulin and related proteins. Phosphorylcholine 183-200 C-reactive protein Homo sapiens 44-47 3919022-2 1985 CRP of all species binds to phosphorylcholine residues. Phosphorylcholine 28-45 C-reactive protein Homo sapiens 0-3 3919022-3 1985 In the present studies CRP was found to inhibit platelet-activating factor-induced platelet aggregation, and to stabilize platelet membranes against the lytic effect of lysophosphatidylcholine. Lysophosphatidylcholines 169-192 C-reactive protein Homo sapiens 23-26 6363539-1 1984 C-reactive protein (CRP) is an acute phase serum protein in man that binds to the cell wall C-polysaccharide (PnC) of Streptococcus pneumoniae via phosphocholine (PC) determinants. Phosphorylcholine 147-161 C-reactive protein Homo sapiens 0-18 6363539-1 1984 C-reactive protein (CRP) is an acute phase serum protein in man that binds to the cell wall C-polysaccharide (PnC) of Streptococcus pneumoniae via phosphocholine (PC) determinants. Phosphorylcholine 147-161 C-reactive protein Homo sapiens 20-23 6363539-1 1984 C-reactive protein (CRP) is an acute phase serum protein in man that binds to the cell wall C-polysaccharide (PnC) of Streptococcus pneumoniae via phosphocholine (PC) determinants. Phosphorylcholine 163-165 C-reactive protein Homo sapiens 0-18 6363539-1 1984 C-reactive protein (CRP) is an acute phase serum protein in man that binds to the cell wall C-polysaccharide (PnC) of Streptococcus pneumoniae via phosphocholine (PC) determinants. Phosphorylcholine 163-165 C-reactive protein Homo sapiens 20-23 6231426-3 1984 Treatment with Depo-Provera produced increased serum levels of albumin, alpha 1-acid glycoprotein, alpha 2-macroglobulin, haptoglobin IgG; reduced levels of alpha 1-antitrypsin, transferrin, C3c, C4 but no change in serum IgA, IgM, C-reactive protein and ceruloplasmin. Medroxyprogesterone Acetate 15-27 C-reactive protein Homo sapiens 232-250 6195262-0 1983 Localization of the phosphocholine-binding sites on C-reactive protein by immunoelectron microscopy. Phosphorylcholine 20-34 C-reactive protein Homo sapiens 52-70 6195262-1 1983 C-reactive protein (CRP) was reacted with monoclonal IgG antibody or Fab antibody fragments directed against the phosphocholine- (PC) binding site or a second unrelated site. Phosphorylcholine 113-127 C-reactive protein Homo sapiens 0-18 6195262-1 1983 C-reactive protein (CRP) was reacted with monoclonal IgG antibody or Fab antibody fragments directed against the phosphocholine- (PC) binding site or a second unrelated site. Phosphorylcholine 113-127 C-reactive protein Homo sapiens 20-23 6195262-1 1983 C-reactive protein (CRP) was reacted with monoclonal IgG antibody or Fab antibody fragments directed against the phosphocholine- (PC) binding site or a second unrelated site. Phosphorylcholine 130-132 C-reactive protein Homo sapiens 0-18 6195262-1 1983 C-reactive protein (CRP) was reacted with monoclonal IgG antibody or Fab antibody fragments directed against the phosphocholine- (PC) binding site or a second unrelated site. Phosphorylcholine 130-132 C-reactive protein Homo sapiens 20-23 6195262-6 1983 Thus, the PC-binding site and the non-PC-binding site are oriented nearly perpendicular but on opposite sides with respect to the plane of the CRP molecule. Phosphorylcholine 10-12 C-reactive protein Homo sapiens 143-146 6195262-6 1983 Thus, the PC-binding site and the non-PC-binding site are oriented nearly perpendicular but on opposite sides with respect to the plane of the CRP molecule. Phosphorylcholine 38-40 C-reactive protein Homo sapiens 143-146 6877243-2 1983 CRP binds with phosphocholine and phosphate esters; initiates reactions of agglutination, opsonization and complement consumption; and precipitates with protamine and synthetic polymers of lysine and arginine, and these reactivities are modulated by calcium and phosphocholine. Phosphorylcholine 15-29 C-reactive protein Homo sapiens 0-3 6877243-2 1983 CRP binds with phosphocholine and phosphate esters; initiates reactions of agglutination, opsonization and complement consumption; and precipitates with protamine and synthetic polymers of lysine and arginine, and these reactivities are modulated by calcium and phosphocholine. Phosphorylcholine 262-276 C-reactive protein Homo sapiens 0-3 6300060-10 1983 The dogfish C-reactive protein, which exists as a Mr = 50,000 dimer, bound 2 mol of the phosphorylcholine spin label per mol of protein, and this binding exhibited negative cooperativity as indicated by a Hill coefficient of 0.75. Phosphorylcholine 88-105 C-reactive protein Homo sapiens 12-30 6885107-3 1983 C-reactive protein (CRP) is known to bind to molecules containing phosphocholine-substituents following reaction with Ca2+ ions. Phosphorylcholine 66-80 C-reactive protein Homo sapiens 0-18 6885107-3 1983 C-reactive protein (CRP) is known to bind to molecules containing phosphocholine-substituents following reaction with Ca2+ ions. Phosphorylcholine 66-80 C-reactive protein Homo sapiens 20-23 7028874-9 1981 Reactivity of CRP with a multimeric form of phosphocholine (PC) (KLH-PC44) led to binding comparable to that observed with CPS, whereas monomeric PC inhibited the binding. Phosphorylcholine 44-58 C-reactive protein Homo sapiens 14-17 7028874-9 1981 Reactivity of CRP with a multimeric form of phosphocholine (PC) (KLH-PC44) led to binding comparable to that observed with CPS, whereas monomeric PC inhibited the binding. Phosphorylcholine 60-62 C-reactive protein Homo sapiens 14-17 7276568-5 1981 However, in the presence of phosphocholine, CRP rapidly precipitated and formed stable complexes with the polycationic polymers in the otherwise inhibitory calcium concentrations. Phosphorylcholine 28-42 C-reactive protein Homo sapiens 44-47 7276568-7 1981 These results extend the characterization of the binding reactivity of CRP for polycations and suggest a relationship between this binding site and the sites for calcium and phosphocholine. Phosphorylcholine 174-188 C-reactive protein Homo sapiens 71-74 7276568-8 1981 We propose that CRP-polycation interactions in the presence of phosphocholine may have physiologic significance during the acute inflammatory process. Phosphorylcholine 63-77 C-reactive protein Homo sapiens 16-19 7217669-4 1981 A weak interaction between CRP and agarose was observed, which was also CA++-dependent and could be inhibited by phosphocholine and galactose. Phosphorylcholine 113-127 C-reactive protein Homo sapiens 27-30 7217669-5 1981 In addition, incorporation of galactocyl cerebroside in phosphatidylcholine:lysophosphatidylcholine liposomes enhanced the binding of CRP. Lysophosphatidylcholines 76-99 C-reactive protein Homo sapiens 134-137 471064-3 1979 CRP has a Ca2+-dependent binding specificity for phosphorylcholine, the polar head group of two widely distributed lipids, lecithin (phosphatidylcholine, PC) and sphingomyelin (SM). Phosphorylcholine 49-66 C-reactive protein Homo sapiens 0-3 471064-6 1979 We report here that binding of CRP to model membranes of PC requires the incorporation into the bilayer of lysophosphatidylcholine (LPC). Lysophosphatidylcholines 107-130 C-reactive protein Homo sapiens 31-34 471064-6 1979 We report here that binding of CRP to model membranes of PC requires the incorporation into the bilayer of lysophosphatidylcholine (LPC). Lysophosphatidylcholines 132-135 C-reactive protein Homo sapiens 31-34 4379352-8 1966 The formation of CxRP or CRP by the liver was always accompanied by enhanced C(14)-amino acid incorporation into other serum proteins, but the reverse was not always found. c(14) 77-82 C-reactive protein Homo sapiens 25-28 33898494-3 2021 Objective: This study aimed to examine the validity of the energy-adjusted DII (E-DIITM) using high-sensitivity C-reactive protein (hs-CRP) concentration in Japanese men and women. e-diitm 80-87 C-reactive protein Homo sapiens 112-130 33829245-5 2021 RESULTS: A high enterolactone and low TMAO profile was associated with better diet quality, especially higher intake of whole grains and fiber and lower intake of red meats, as well as lower concentrations of plasma triglycerides and C-reactive protein. trimethyloxamine 38-42 C-reactive protein Homo sapiens 234-252 33185785-5 2021 The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006). Enoxaparin 48-58 C-reactive protein Homo sapiens 159-177 33185785-5 2021 The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006). Enoxaparin 48-58 C-reactive protein Homo sapiens 179-182 33735520-13 2021 CONCLUSION: In this retrospective study, theophylline and pentoxifylline was associated with an increase in ROX score and nominal decreases in CRP and mortality. Theophylline 41-53 C-reactive protein Homo sapiens 143-146 33889398-0 2021 Association between dietary flavonoid intakes and C-reactive protein levels: a cross-sectional study in Taiwan. Flavonoids 28-37 C-reactive protein Homo sapiens 50-68 33889398-1 2021 Although the intake of specific flavonoid-rich foods may reduce C-reactive protein (CRP) levels, the association between dietary flavonoid intakes and CRP is inconsistent. Flavonoids 32-41 C-reactive protein Homo sapiens 64-82 33889398-1 2021 Although the intake of specific flavonoid-rich foods may reduce C-reactive protein (CRP) levels, the association between dietary flavonoid intakes and CRP is inconsistent. Flavonoids 32-41 C-reactive protein Homo sapiens 84-87 33889398-2 2021 We aim to describe dietary flavonoid intakes in a Taiwanese nationally representative sample and to investigate the association between flavonoid intakes and CRP. Flavonoids 136-145 C-reactive protein Homo sapiens 158-161 33889398-5 2021 Adjusted estimates of the flavonoid intakes for the continuous and binary (elevated CRP: >0 3 mg/dl) variables were performed by using general linear and logistic regression. Flavonoids 26-35 C-reactive protein Homo sapiens 84-87 33889398-8 2021 Compared with the lowest total flavonoid intake quartile, participants in higher quartiles were associated with a lower CRP status (adjusted odds ratio (OR): 0 61, 95 % confidence interval (CI): 0 44-0 86 for the highest quartiles). Flavonoids 31-40 C-reactive protein Homo sapiens 120-123 33889398-11 2021 In brief, a higher total flavonoid intake and tea consumption were inversely associated with CRP levels, indicating that a high-flavonoid diet may contribute to anti-inflammatory effects. Flavonoids 25-34 C-reactive protein Homo sapiens 93-96 33889398-11 2021 In brief, a higher total flavonoid intake and tea consumption were inversely associated with CRP levels, indicating that a high-flavonoid diet may contribute to anti-inflammatory effects. Flavonoids 128-137 C-reactive protein Homo sapiens 93-96 32474847-10 2021 Path analysis showed that the CRP levels and BMI mediated the associations between the Cu concentration and ABP. abp 108-111 C-reactive protein Homo sapiens 30-33 33686560-4 2021 METHODS: The relationships between CRP concentration and both CYPs activities were estimated and validated using clinical data first on midazolam then on voriconazole. Midazolam 136-145 C-reactive protein Homo sapiens 35-38 33652637-11 2021 In this study, rosuvastatin reduced the level of C-reactive protein (CRP) but did not reduce the rate of POAF. Rosuvastatin Calcium 15-27 C-reactive protein Homo sapiens 49-67 33652637-11 2021 In this study, rosuvastatin reduced the level of C-reactive protein (CRP) but did not reduce the rate of POAF. Rosuvastatin Calcium 15-27 C-reactive protein Homo sapiens 69-72 33603528-10 2021 Furthermore, levels of CRP showed a decrease in patients treated with enoxaparin and fondaparinux, although the decrease in the fondaparinux group seems to be more relevant. Enoxaparin 70-80 C-reactive protein Homo sapiens 23-26 33529638-16 2021 The C-reactive protein level, erythrocyte sedimentation rate, serum ferritin, and myoglobin decreased significantly in the CM group (P<0.05). Cm 123-125 C-reactive protein Homo sapiens 4-22 33185166-7 2021 Patients treated with MTX and doxycycline showed lower levels of DAS28, ESR, CRP, MMP-3 and MMP-9 and this was statistically significant. Methotrexate 22-25 C-reactive protein Homo sapiens 77-80 33269654-1 2021 An 84-year-old Japanese woman suffering from rheumatoid arthritis (RA), who had been treated with methotrexate (MTX) for 15 years, was admitted to our hospital for generalised lymphadenopathy, thrombocytopenia, anaemia, elevated aminotransferases, and elevated CRP levels. Methotrexate 98-110 C-reactive protein Homo sapiens 261-264 33269654-1 2021 An 84-year-old Japanese woman suffering from rheumatoid arthritis (RA), who had been treated with methotrexate (MTX) for 15 years, was admitted to our hospital for generalised lymphadenopathy, thrombocytopenia, anaemia, elevated aminotransferases, and elevated CRP levels. Methotrexate 112-115 C-reactive protein Homo sapiens 261-264 32912735-9 2020 CONCLUSION: Cytosorb courses achieved significant decreases in endocan, copeptin, interleukin-6, procalcitonin and C-reactive protein levels. cytosorb 12-20 C-reactive protein Homo sapiens 115-133 33224343-3 2020 Methods: In order to test the possibility of direct interaction, we performed an in silico study by testing the orientation of the respective ligands (statins) and phosphorylcholine (the standard ligand of CRP) in the CRP active site using Molecular Operating Environment (MOE) software. Phosphorylcholine 164-181 C-reactive protein Homo sapiens 206-209 33224343-3 2020 Methods: In order to test the possibility of direct interaction, we performed an in silico study by testing the orientation of the respective ligands (statins) and phosphorylcholine (the standard ligand of CRP) in the CRP active site using Molecular Operating Environment (MOE) software. Phosphorylcholine 164-181 C-reactive protein Homo sapiens 218-221 33224343-5 2020 Among statins, rosuvastatin had the strongest interaction with CRP (pKi = 16.14), followed by fluvastatin (pKi = 15.58), pitavastatin (pKi = 15.26), atorvastatin (pKi = 14.68), pravastatin (pKi = 13.95), simvastatin (pKi = 7.98) and lovastatin (pKi = 7.10). Rosuvastatin Calcium 15-27 C-reactive protein Homo sapiens 63-66 33224343-6 2020 According to the above-mentioned results, rosuvastatin, fluvastatin, pitavastatin and atorvastatin were found to have stronger binding to CRP compared with the standard ligand phosphocholine (pKi = 14.55). Rosuvastatin Calcium 42-54 C-reactive protein Homo sapiens 138-141 33224343-6 2020 According to the above-mentioned results, rosuvastatin, fluvastatin, pitavastatin and atorvastatin were found to have stronger binding to CRP compared with the standard ligand phosphocholine (pKi = 14.55). Fluvastatin 56-67 C-reactive protein Homo sapiens 138-141 33224343-6 2020 According to the above-mentioned results, rosuvastatin, fluvastatin, pitavastatin and atorvastatin were found to have stronger binding to CRP compared with the standard ligand phosphocholine (pKi = 14.55). Phosphorylcholine 176-190 C-reactive protein Homo sapiens 138-141 33091149-6 2021 Moreover, univariate regression analysis demonstrated that high hs-CRP (p<0.001) and periodontitis (p<0.001) had a significant negative direct effect on both plasma and salivary suPAR levels. supar 178-183 C-reactive protein Homo sapiens 67-70 33091149-9 2021 Moreover, periodontitis and hs-CRP were the only significant predictors of the augmented suPAR levels in plasma and saliva, respectively. supar 89-94 C-reactive protein Homo sapiens 31-34 33165442-5 2020 RESULTS: The PCT, CRP, and SAA in the MDRO group were significantly higher than those of the non-MDRO group (all P<0.001). mdro 38-42 C-reactive protein Homo sapiens 18-21 33065791-4 2020 The goal of this study was to investigate the clinical effect of xipayi mouth rinse combined with minocycline in the treatment of localized aggressive periodontitis and its effect on the levels of CRP, TNF-alpha, and IL-6. Minocycline 98-109 C-reactive protein Homo sapiens 197-200 32043726-11 2020 Six months after MTX initiation, there was significant reduction in ESR (p = 0.012), CRP (p = 0.0003) and prednisolone dose (p < 0.0001). Methotrexate 17-20 C-reactive protein Homo sapiens 85-88 32787053-7 2020 We demonstrate the fluorescence enhancement in detecting C-Reactive protein (CPR) antibody conjugated with fluorescein isothiocyanate (FITC) by means of near-field coupling between surface plasmons and fluorophores at spectral channels of emission. fluorescein isothiocyanate 107-133 C-reactive protein Homo sapiens 57-75 32787053-7 2020 We demonstrate the fluorescence enhancement in detecting C-Reactive protein (CPR) antibody conjugated with fluorescein isothiocyanate (FITC) by means of near-field coupling between surface plasmons and fluorophores at spectral channels of emission. fluorescein isothiocyanate 107-133 C-reactive protein Homo sapiens 77-80 32708205-11 2020 We also observed a positive significant correlation between aldosterone and CRP levels among patients with an aldosterone level greater than 102.5 pmol/L. Aldosterone 60-71 C-reactive protein Homo sapiens 76-79 32708205-11 2020 We also observed a positive significant correlation between aldosterone and CRP levels among patients with an aldosterone level greater than 102.5 pmol/L. Aldosterone 110-121 C-reactive protein Homo sapiens 76-79 32652935-14 2020 Follow-up after 6 months of rosuvastatin therapy showed a significantly greater reduction in hs-CRP and IL-6 levels in the CAE-A group than in the CAE-B group, which again were greater in the CAE-B group than in the CAE-C group. Rosuvastatin Calcium 28-40 C-reactive protein Homo sapiens 96-99 32371387-11 2020 CONCLUSION: Baseline CRP appears to have a positive association with reaching the therapeutic target on TCZ treatment, but is a negative predictor for RTX and MTX. Methotrexate 159-162 C-reactive protein Homo sapiens 21-24 32428019-10 2020 Multiple logistic regression did show that compared to Atorvastatin-80mg, Rosuvastatin-40mg regime had poorer control of hs-CRP (A3OR = 1.45,p = 0.0202), higher (A3OR = 2.07) adverse effects, poorer safety profile (A3OR = 1.23), higher GERD/Gastritis (A3OR = 1.50) and poorer overall tolerability (A3OR = 1.50). Rosuvastatin Calcium 74-86 C-reactive protein Homo sapiens 124-127 32322165-7 2020 Correlation analyses demonstrated that suPAR levels positively correlated with initial serum creatinine, BVAS, CRP, and procalcitonin concentration, and negatively correlated with eGFR and C3 circulating levels. supar 39-44 C-reactive protein Homo sapiens 111-114 32046485-0 2020 Reagentless Redox Capacitive Assaying of C-Reactive Protein at a Polyaniline Interface. polyaniline 65-76 C-reactive protein Homo sapiens 41-59 32046485-3 2020 Herein, we expand this scope by utilizing phytic acid-doped polyaniline as a novel redox-charging polymer support enabling the reagentless assaying of C-reactive protein in serum with good sensitivity. polyaniline 60-71 C-reactive protein Homo sapiens 151-169 31840602-6 2020 At sites of local inflammation and tissue injury it may bind to phosphocholine-rich membranes of activated and apoptotic cells and their microparticles, undergoing irreversible dissociation to five monomeric subunits, termed monomeric CRP (mCRP). Phosphorylcholine 64-78 C-reactive protein Homo sapiens 235-238 30913567-0 2020 Pathological Concentration of C-reactive Protein is Correlated to Increased Concentrations of Quetiapine, But Not of Risperidone, Olanzapine and Aripiprazole in a Naturalistic Setting. Quetiapine Fumarate 94-104 C-reactive protein Homo sapiens 30-48 30913567-6 2020 RESULTS: Pathological concentrations of CRP were significantly associated with elevated values of C/D of quetiapine (n=166, Spearman"s Rho: r=0.269, p<0.001; linear regression: p<0.001). Quetiapine Fumarate 105-115 C-reactive protein Homo sapiens 40-43 30913567-7 2020 Among patients with quetiapine serum concentrations below 500 ng/mL, CRP concentrations were significantly (p=0.006) lower compared to patients with quetiapine concentrations above 500 ng/mL. Quetiapine Fumarate 20-30 C-reactive protein Homo sapiens 69-72 31590321-0 2019 Consumption of Korean Foods with High Flavonoid Contents Reduces the Likelihood of Having Elevated C-Reactive Protein Levels: Data from the 2015-2017 Korea National Health and Nutrition Examination Survey. Flavonoids 38-47 C-reactive protein Homo sapiens 99-117 31590321-1 2019 This study was conducted to investigate associations between C-reactive protein (CRP) levels and Korean food (KF) consumption and flavonoid intake from the 2015-2017 Korea National Health and Nutrition Examination Survey. Flavonoids 130-139 C-reactive protein Homo sapiens 61-79 31590321-1 2019 This study was conducted to investigate associations between C-reactive protein (CRP) levels and Korean food (KF) consumption and flavonoid intake from the 2015-2017 Korea National Health and Nutrition Examination Survey. Flavonoids 130-139 C-reactive protein Homo sapiens 81-84 31590321-4 2019 Odds ratios (ORs) for elevated CRP levels (>3.0 mg/L) according to KF consumption rate and flavonoid intake/dietary total antioxidant capacity (TAC) (=median) were obtained by multiple logistic regression. Flavonoids 91-100 C-reactive protein Homo sapiens 31-34 31590321-7 2019 Thus, consuming KFs rich in flavonoid is effective for regulating CRP levels. Flavonoids 28-37 C-reactive protein Homo sapiens 66-69 31474368-5 2019 A detailed experimental characterization of metformin effects downstream of Crp in combination with metabolic modeling of the microbiota in metformin-treated type 2 diabetic patients predicts the production of microbial agmatine, a regulator of metformin effects on host lipid metabolism and lifespan. Agmatine 220-228 C-reactive protein Homo sapiens 76-79 31331399-3 2019 RESULTS: Response rate to guadecitabine was 17% (2 complete remission (CR), 3 CR with incomplete blood count recovery (CRi), or CR with incomplete platelets recovery (CRp)) in the phase I component and 23% (14 CR, 9 CRi/CRp) in phase II. guadecitabine 26-39 C-reactive protein Homo sapiens 71-73 31331399-3 2019 RESULTS: Response rate to guadecitabine was 17% (2 complete remission (CR), 3 CR with incomplete blood count recovery (CRi), or CR with incomplete platelets recovery (CRp)) in the phase I component and 23% (14 CR, 9 CRi/CRp) in phase II. guadecitabine 26-39 C-reactive protein Homo sapiens 78-80 31331399-3 2019 RESULTS: Response rate to guadecitabine was 17% (2 complete remission (CR), 3 CR with incomplete blood count recovery (CRi), or CR with incomplete platelets recovery (CRp)) in the phase I component and 23% (14 CR, 9 CRi/CRp) in phase II. guadecitabine 26-39 C-reactive protein Homo sapiens 78-80 31331399-3 2019 RESULTS: Response rate to guadecitabine was 17% (2 complete remission (CR), 3 CR with incomplete blood count recovery (CRi), or CR with incomplete platelets recovery (CRp)) in the phase I component and 23% (14 CR, 9 CRi/CRp) in phase II. guadecitabine 26-39 C-reactive protein Homo sapiens 78-80 31180646-1 2019 Polydopamine (PDA)-coated or encapsulating Cu3(PO4)2 (Cu3(PO4)2@PDA) nanosheets were synthesized, allowing the C-reaction protein (CRP) antibody to be attached electrostatically for immunosensing of CRP with simple photothermal detection. polydopamine 0-12 C-reactive protein Homo sapiens 111-129 31180646-1 2019 Polydopamine (PDA)-coated or encapsulating Cu3(PO4)2 (Cu3(PO4)2@PDA) nanosheets were synthesized, allowing the C-reaction protein (CRP) antibody to be attached electrostatically for immunosensing of CRP with simple photothermal detection. polydopamine 0-12 C-reactive protein Homo sapiens 131-134 31118224-3 2019 This study shows that complexed CRP (phosphocholine [PC]:CRP) (formed by binding of CRP to PC moieties), but not soluble CRP, synergized with specific TLRs to posttranscriptionally amplify TNF, IL-1beta, and IL-23 production by human inflammatory macrophages. Phosphorylcholine 37-51 C-reactive protein Homo sapiens 32-35 31118224-3 2019 This study shows that complexed CRP (phosphocholine [PC]:CRP) (formed by binding of CRP to PC moieties), but not soluble CRP, synergized with specific TLRs to posttranscriptionally amplify TNF, IL-1beta, and IL-23 production by human inflammatory macrophages. Phosphorylcholine 37-51 C-reactive protein Homo sapiens 57-60 31118224-3 2019 This study shows that complexed CRP (phosphocholine [PC]:CRP) (formed by binding of CRP to PC moieties), but not soluble CRP, synergized with specific TLRs to posttranscriptionally amplify TNF, IL-1beta, and IL-23 production by human inflammatory macrophages. Phosphorylcholine 37-51 C-reactive protein Homo sapiens 57-60 31118224-3 2019 This study shows that complexed CRP (phosphocholine [PC]:CRP) (formed by binding of CRP to PC moieties), but not soluble CRP, synergized with specific TLRs to posttranscriptionally amplify TNF, IL-1beta, and IL-23 production by human inflammatory macrophages. Phosphorylcholine 37-51 C-reactive protein Homo sapiens 57-60 31006357-9 2019 CONCLUSION: The presence of PBE was significantly associated with lower NLR and CRP regardless of the presence or absence of an infectious condition. pycnogenols 28-31 C-reactive protein Homo sapiens 80-83 31114584-3 2019 Human CRP is a pentamer made up of five identical subunits which binds to phosphocholine (PCh) in a Ca2+-dependent manner. Phosphorylcholine 74-88 C-reactive protein Homo sapiens 6-9 31114584-3 2019 Human CRP is a pentamer made up of five identical subunits which binds to phosphocholine (PCh) in a Ca2+-dependent manner. Phosphorylcholine 90-93 C-reactive protein Homo sapiens 6-9 31114584-10 2019 Literature indicates that the binding ability of CRP to PCh is less relevant than its binding to other ligands. Phosphorylcholine 56-59 C-reactive protein Homo sapiens 49-52 31110572-0 2019 Values and Correlations between C-Reactive Protein and Apolipoprotein B after Treatment with Methotrexate at Patients with Rheumatoid Arthritis. Methotrexate 93-105 C-reactive protein Homo sapiens 32-50 31110572-3 2019 Methotrexate (MTX) treatment is effective in controlling inflammation and decreasing the CRP (C-reactive protein) values. Methotrexate 0-12 C-reactive protein Homo sapiens 89-92 31110572-3 2019 Methotrexate (MTX) treatment is effective in controlling inflammation and decreasing the CRP (C-reactive protein) values. Methotrexate 0-12 C-reactive protein Homo sapiens 94-112 31110572-3 2019 Methotrexate (MTX) treatment is effective in controlling inflammation and decreasing the CRP (C-reactive protein) values. Methotrexate 14-17 C-reactive protein Homo sapiens 89-92 31110572-3 2019 Methotrexate (MTX) treatment is effective in controlling inflammation and decreasing the CRP (C-reactive protein) values. Methotrexate 14-17 C-reactive protein Homo sapiens 94-112 30938763-14 2019 The serum concentration of CRP was significantly and negatively associated with FEV1% (beta = -7.7, R2 = 0.05) and forced vital capacity % (beta = -8.5, R2 = 0.08), and the serum concentration of ICAM-1 with the estimated exposure to H2S (beta = -19.9, R2 = 0.07). Deuterium 234-237 C-reactive protein Homo sapiens 27-30 30268669-3 2019 The results demonstrated in a step-wise manner that the phosphocholine-modified screen-printed carbon electrodes were highly responsive to the clinically required range of C-reactive protein (CRP) (0.005 - 500 mg L-1; r2 = 0.993) levels with a detection limit (3sigma/slope) of 0.001 mg L-1. Phosphorylcholine 56-70 C-reactive protein Homo sapiens 172-190 30268669-3 2019 The results demonstrated in a step-wise manner that the phosphocholine-modified screen-printed carbon electrodes were highly responsive to the clinically required range of C-reactive protein (CRP) (0.005 - 500 mg L-1; r2 = 0.993) levels with a detection limit (3sigma/slope) of 0.001 mg L-1. Phosphorylcholine 56-70 C-reactive protein Homo sapiens 192-195 30268669-4 2019 The optimal binding frequency of CRP-phosphocholine interaction was determined to be 100 Hz. Phosphorylcholine 37-51 C-reactive protein Homo sapiens 33-36 30623852-8 2019 Moderation analysis revealed that C-reactive protein (CRP) strongly modulated the impact of flavonoid intake on FLI; participants with higher CRP levels benefited less from flavonoid intake compared with those with lower CRP concentrations. Flavonoids 92-101 C-reactive protein Homo sapiens 34-52 30623852-8 2019 Moderation analysis revealed that C-reactive protein (CRP) strongly modulated the impact of flavonoid intake on FLI; participants with higher CRP levels benefited less from flavonoid intake compared with those with lower CRP concentrations. Flavonoids 92-101 C-reactive protein Homo sapiens 54-57 30623852-8 2019 Moderation analysis revealed that C-reactive protein (CRP) strongly modulated the impact of flavonoid intake on FLI; participants with higher CRP levels benefited less from flavonoid intake compared with those with lower CRP concentrations. Flavonoids 173-182 C-reactive protein Homo sapiens 34-52 30623852-8 2019 Moderation analysis revealed that C-reactive protein (CRP) strongly modulated the impact of flavonoid intake on FLI; participants with higher CRP levels benefited less from flavonoid intake compared with those with lower CRP concentrations. Flavonoids 173-182 C-reactive protein Homo sapiens 54-57 30702995-4 2019 By contrast, in the recent CIRT (Cardiovascular Inflammation Reduction Trial), low-dose methotrexate neither reduced IL-1beta, IL-6, or high-sensitivity CRP nor lowered cardiovascular event rates. Methotrexate 88-100 C-reactive protein Homo sapiens 153-156 30761006-6 2019 We found that CRP upregulated NF-kappaB activity, the NF-kappaB inhibitor (BAY-11-7082) and Fcgamma receptors (FcgammaRs) inhibitor (CD32/64Ab) blocked CRP-induced NF-kappaB activation. 3-(4-methylphenylsulfonyl)-2-propenenitrile 75-86 C-reactive protein Homo sapiens 14-17 30761006-6 2019 We found that CRP upregulated NF-kappaB activity, the NF-kappaB inhibitor (BAY-11-7082) and Fcgamma receptors (FcgammaRs) inhibitor (CD32/64Ab) blocked CRP-induced NF-kappaB activation. 3-(4-methylphenylsulfonyl)-2-propenenitrile 75-86 C-reactive protein Homo sapiens 152-155 30086945-6 2018 The square-wave voltammetry experiments performed in the presence of methylene blue redox indicator revealed a linear response of aptasensor towards CRP in the range from 1 to 100 pM. Methylene Blue 69-83 C-reactive protein Homo sapiens 149-152 30522429-18 2018 Treatment of piperacillin/tazobactam and teicoplanin was started by discontinuing the current antibiotherapy of the patient who had no clinical response and elevated CRP level, 18 mg/dl. Piperacillin, Tazobactam Drug Combination 13-36 C-reactive protein Homo sapiens 166-169 29155150-8 2018 We inhibited systemic inflammation in old subjects by means of pretreatment with an oral small-molecule p38 mitogen-activated protein kinase inhibitor (Losmapimod; GlaxoSmithKline, Brentford, United Kingdom), which reduced both serum C-reactive protein levels and peripheral blood monocyte secretion of IL-6 and TNF-alpha. 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-N-(2,2-dimethylprpyl)-3-pyridinecarboxamide 152-162 C-reactive protein Homo sapiens 234-252 29714643-7 2018 RESULTS: Most well-designed studies that evaluated associations between DTAC and CVD risk factors showed inverse associations for fasting blood glucose, CRP, BP, and WC and positive associations for HDL-C. dodecyltrimethylammonium 72-76 C-reactive protein Homo sapiens 153-156 27126059-6 2018 Multivariate analyses identified higher baseline Disease Activity Score of 28 joints - C-reactive protein and early use of MTX (within 1 year of RA onset) and of biologic agents (within 2 years) as significantly associated with improved mHAQ; odds ratios of the early treatment were 1.83 (P = 0.01) for MTX and 2.23 (P = 0.04) for biologic agents, respectively. 1-hydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione 237-241 C-reactive protein Homo sapiens 87-105 29657830-7 2018 More patients converting to ACPA seronegative status receiving abatacept plus MTX achieved remission according to Disease Activity Score in 28 joints (C-reactive protein) or Clinical Disease Activity Index than patients who remained ACPA seropositive. Methotrexate 78-81 C-reactive protein Homo sapiens 151-169 30938259-5 2018 Here, we report a severe case of LVPA, who was successfully treated with IFX but was refractory to TCZ and presented a discrepancy between serum C-reactive protein levels and fluorodeoxyglucose vascular positivity. LVPA 33-37 C-reactive protein Homo sapiens 145-163 29330618-9 2018 It was found to be a better prognostic marker than BISAP score, hematocrit at 48 h, SIRS at admission, persistent SIRS or C-reactive protein at 48 h. CONCLUSIONS: Oleic acid chlorohydrin concentration in plasma is elevated in patients with acute pancreatitis on admission and correlates with a high degree with the final severity of the disease, indicating that it has potential to serve as an early prognostic marker for acute pancreatitis severity. oleic acid chlorohydrin 163-186 C-reactive protein Homo sapiens 122-140 28430117-12 2017 After 1 week of fluvastatin therapy, C-reactive protein (CRP) and homocysteine (HCY) levels were lower in the fluvastatin group than in the control group. Fluvastatin 16-27 C-reactive protein Homo sapiens 37-55 28430117-12 2017 After 1 week of fluvastatin therapy, C-reactive protein (CRP) and homocysteine (HCY) levels were lower in the fluvastatin group than in the control group. Fluvastatin 16-27 C-reactive protein Homo sapiens 57-60 28177137-12 2017 The correlation between low albumin levels and decreased midazolam clearance is probably a result of inflammatory response as high CRP levels were correlated in a similar way. Midazolam 57-66 C-reactive protein Homo sapiens 131-134 28586387-0 2017 Salsalate ameliorates metabolic disturbances by reducing inflammation in spontaneously hypertensive rats expressing human C-reactive protein and by activating brown adipose tissue in nontransgenic controls. salicylsalicylic acid 0-9 C-reactive protein Homo sapiens 122-140 28319849-9 2017 F2-isoprostanes were associated with higher C-reactive protein (beta=0.072, p<0.001), high ANS stress reflected in heart rate (beta=0.064, p<0.001) and RSA (beta=-0.076, p=0.001), but not with cortisol. F2-Isoprostanes 0-15 C-reactive protein Homo sapiens 44-62 28306249-5 2017 Some PAH metabolites showed consistent positive associations with the plasma inflammation marker C-reactive protein (CRP) and the urinary oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and 8-isoprostane. Polycyclic Aromatic Hydrocarbons 5-8 C-reactive protein Homo sapiens 97-115 28306249-5 2017 Some PAH metabolites showed consistent positive associations with the plasma inflammation marker C-reactive protein (CRP) and the urinary oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and 8-isoprostane. Polycyclic Aromatic Hydrocarbons 5-8 C-reactive protein Homo sapiens 117-120 28306249-6 2017 For example, an interquartile range increase in 2-hydroxynapthalene was associated with a 35% increase in CRP (95% confidence interval = -0.13, 83.2), a 14% increase in 8-OHdG (95% confidence interval =0.59, 30.1), and a 48% increase in 8-isoprostane (95% confidence interval =16.7, 87.0). 2-hydroxynapthalene 48-67 C-reactive protein Homo sapiens 106-109 28458650-10 2017 suPAR levels were associated with generally accepted inflammatory biomarkers (C-reactive protein, leukocyte count). supar 0-5 C-reactive protein Homo sapiens 78-96 28167277-6 2017 For example, CRP mutants incapable of binding to phosphocholine are generated to investigate the importance of the phosphocholine-binding property of CRP in mediating host defense. Phosphorylcholine 49-63 C-reactive protein Homo sapiens 13-16 28167277-6 2017 For example, CRP mutants incapable of binding to phosphocholine are generated to investigate the importance of the phosphocholine-binding property of CRP in mediating host defense. Phosphorylcholine 115-129 C-reactive protein Homo sapiens 13-16 28167277-6 2017 For example, CRP mutants incapable of binding to phosphocholine are generated to investigate the importance of the phosphocholine-binding property of CRP in mediating host defense. Phosphorylcholine 115-129 C-reactive protein Homo sapiens 150-153 28225631-12 2017 The presence of lysophosphatidylcholine, a component of apoptotic membranes, increased CRP binding to all types of membranes. Lysophosphatidylcholines 16-39 C-reactive protein Homo sapiens 87-90 27444965-9 2017 Findings also provide caution of future assumptions that relationships among PA, PPS, and physical health markers, such as CRP, are always positive (e.g., PA) or negative (e.g., PPS) in nature. pps 81-84 C-reactive protein Homo sapiens 123-126 28280039-7 2017 A high suPAR level >=3.5 ng/mL was associated with all-cause death and myocardial infarction (hazard ratio, 1.83; 95% confidence interval, 1.43-2.35) after adjustment for risk factors, C-reactive protein, fibrin degradation product, and heat shock protein-70. supar 7-12 C-reactive protein Homo sapiens 188-206 20404379-0 2010 Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 67-85 20404379-14 2010 CONCLUSION: In apparently healthy older persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin reduces the incidence of major cardiovascular events. Rosuvastatin Calcium 133-145 C-reactive protein Homo sapiens 106-124 20152247-5 2010 Rosuvastatin treatment significantly lowered total (-36%, p <0.01) and low-density lipoprotein (-47%, p <0.001) cholesterol and C-reactive protein levels (-36%, p <0.05). Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 134-152 20039931-9 2010 Prothrombin fragment 1+2, D-dimer, von Willebrand factor and high sensitive C-reactive protein levels were significantly less post PCI in the enoxaparin group compared with those patients receiving UFH. Enoxaparin 142-152 C-reactive protein Homo sapiens 76-94 20157432-5 2010 C-reactive protein levels, physical pain, symptoms of arthritis and depression decreased significantly during the past 12 months of treatment with quetiapine, while treatment with selective serotonin reuptake inhibitors and mirtazapine remained the same. Quetiapine Fumarate 147-157 C-reactive protein Homo sapiens 0-18 20102894-1 2010 Justification for the Use of Statins in Primary Prevention: An Intervention Trial Using Rosuvastatin (JUPITER) reported reduced cardiovascular and all-cause mortality with statin treatment in patients with elevated C-reactive protein (CRP) and average cholesterol levels who were not eligible for lipid-lowering treatment on the basis of existing guidelines. Rosuvastatin Calcium 88-100 C-reactive protein Homo sapiens 215-233 20102894-1 2010 Justification for the Use of Statins in Primary Prevention: An Intervention Trial Using Rosuvastatin (JUPITER) reported reduced cardiovascular and all-cause mortality with statin treatment in patients with elevated C-reactive protein (CRP) and average cholesterol levels who were not eligible for lipid-lowering treatment on the basis of existing guidelines. Rosuvastatin Calcium 88-100 C-reactive protein Homo sapiens 235-238 19836015-0 2010 Association of urinary polycyclic aromatic hydrocarbons and serum C-reactive protein. Polycyclic Aromatic Hydrocarbons 23-55 C-reactive protein Homo sapiens 66-84 19680627-5 2009 The gradient of HOMA-IR across CRP was attenuated but remained statistically significant after controlling for body fat measurements (0.06 in the highest vs lowest CRP in both cross-sectional [p value for trend = 0.001] and longitudinal analyses [p value for trend = 0.01]), and was little changed by further adjustment for oxidative stress markers (F(2)-isoprostanes and oxidised LDL). F2-Isoprostanes 350-367 C-reactive protein Homo sapiens 31-34 19843321-13 2009 CONCLUSION: In this pilot, dose-finding study, a proprietary mangosteen juice blend (XanGo Juice) reduced CRP levels (increased change from baseline) compared to placebo for those taking the highest dose of 18 oz per day. xango juice 85-96 C-reactive protein Homo sapiens 106-109 19435596-0 2009 Characterization of Ca2+ and phosphocholine interactions with C-reactive protein using a surface plasmon resonance biosensor. Phosphorylcholine 29-43 C-reactive protein Homo sapiens 62-80 19460829-4 2009 Rosuvastatin lowered CRP (37%), LDL (50%), nonfatal myocardial infarction (55%), nonfatal stroke (48%), hospitalization and revascularization (47%), all-cause mortality (20%), and benefited women and minority subgroups. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 21-24 19500485-0 2009 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 71-89 19487269-3 2009 RESULTS: Golimumab + MTX treatment significantly decreased serum CRP, SAA, IL-18, E-selectin, TIMP-1, and MMP-9 levels (median percent changes of -4.1% to -74.3% across treatment groups) versus MTX alone (-5.8% to 9.7%) when first measured at Week 4; decreases were sustained through Week 16. Methotrexate 21-24 C-reactive protein Homo sapiens 65-68 19827168-4 2009 METHOD: We evaluated the association of possible factors, including genetic polymorphisms of folate metabolic pathway enzymes, with the cumulative value of C-reactive protein, an index of MTX anti-inflammatory efficacy, in 87 Japanese patients with RA. Methotrexate 188-191 C-reactive protein Homo sapiens 156-174 2553815-5 1989 There was a positive correlation between the extent of CRP degradation and the association of 125I-labeled CRP with neutrophils. Iodine-125 94-98 C-reactive protein Homo sapiens 55-58 19400931-10 2009 High CRP was associated with high NIHSS (p = 0.01) and high long-term mortality (p < 0.0001). nihss 34-39 C-reactive protein Homo sapiens 5-8 2553815-5 1989 There was a positive correlation between the extent of CRP degradation and the association of 125I-labeled CRP with neutrophils. Iodine-125 94-98 C-reactive protein Homo sapiens 107-110 19400931-11 2009 After adjusting for confounding variables, high CRP remained to be associated with high NIHSS (p = 0.02) and high long-term mortality (p = 0.002). nihss 88-93 C-reactive protein Homo sapiens 48-51 2553815-8 1989 125I-labeled CRP degradation mediated by nonstimulated neutrophils, and neutrophil-conditioned medium (from both non-stimulated and PMA-stimulated cells) was inhibitable by alpha 1-antitrypsin and approximately seven times less at 1 h than that occurring during 125I-labeled CRP-association with PMA-stimulated neutrophils. Iodine-125 0-4 C-reactive protein Homo sapiens 13-16 2553815-8 1989 125I-labeled CRP degradation mediated by nonstimulated neutrophils, and neutrophil-conditioned medium (from both non-stimulated and PMA-stimulated cells) was inhibitable by alpha 1-antitrypsin and approximately seven times less at 1 h than that occurring during 125I-labeled CRP-association with PMA-stimulated neutrophils. Iodine-125 0-4 C-reactive protein Homo sapiens 275-278 2745572-1 1989 Human CRP binds to the basement membrane protein laminin in vitro in a Ca2+-dependent manner via the phosphorylcholine (PC) binding site of C-reactive protein (CRP). Phosphorylcholine 101-118 C-reactive protein Homo sapiens 6-9 19329177-0 2009 Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Rosuvastatin Calcium 103-115 C-reactive protein Homo sapiens 13-31 2745572-1 1989 Human CRP binds to the basement membrane protein laminin in vitro in a Ca2+-dependent manner via the phosphorylcholine (PC) binding site of C-reactive protein (CRP). Phosphorylcholine 101-118 C-reactive protein Homo sapiens 140-158 2745572-1 1989 Human CRP binds to the basement membrane protein laminin in vitro in a Ca2+-dependent manner via the phosphorylcholine (PC) binding site of C-reactive protein (CRP). Phosphorylcholine 101-118 C-reactive protein Homo sapiens 160-163 2745572-1 1989 Human CRP binds to the basement membrane protein laminin in vitro in a Ca2+-dependent manner via the phosphorylcholine (PC) binding site of C-reactive protein (CRP). Phosphorylcholine 120-122 C-reactive protein Homo sapiens 6-9 2745572-1 1989 Human CRP binds to the basement membrane protein laminin in vitro in a Ca2+-dependent manner via the phosphorylcholine (PC) binding site of C-reactive protein (CRP). Phosphorylcholine 120-122 C-reactive protein Homo sapiens 140-158 19332604-0 2009 Rosuvastatin prevented major cardiovascular events in people with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 75-93 2745572-1 1989 Human CRP binds to the basement membrane protein laminin in vitro in a Ca2+-dependent manner via the phosphorylcholine (PC) binding site of C-reactive protein (CRP). Phosphorylcholine 120-122 C-reactive protein Homo sapiens 160-163 2745572-5 1989 The binding of Ca2+ to CRP causes a conformational change in the molecule, which is required for binding to PC and to laminin. Phosphorylcholine 108-110 C-reactive protein Homo sapiens 23-26 3681976-1 1987 Two different crystal forms of human C-reactive protein have been grown from solutions of 2-methyl-2,4-pentanediol. hexylene glycol 90-114 C-reactive protein Homo sapiens 37-55 19264695-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 3152937-0 1987 Lactoferrin and C-reactive protein in response to cytostatic drugs with emphasis on methotrexate. Methotrexate 84-96 C-reactive protein Homo sapiens 16-34 19172709-1 2009 Rosuvastatin prevented major cardiovascular events in persons with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 76-94 20000881-5 2009 The reduction of CRP levels itself or as a statin-related pleiotropic effect has been assessed in different scenarios, including the acute phase of myocardial infarction; secondary prevention of cardiovascular diseases; special patient populations, such as diabetic patients; and finally in a primary prevention study (JUPITER [Justification for the Use of statins in primary Prevention: an Intervention Trial Evaluating Rosuvastatin]). Rosuvastatin Calcium 421-433 C-reactive protein Homo sapiens 17-20 18206145-9 2009 In control subjects, CRP and C3 correlated with glucose and triglyceride, only CRP correlated with nonesterified fatty acids and cholesterol, and ASP correlated with triglyceride (again, all correlations were significant), whereas in subjects with PCOS, several of these correlations were lost, as a result of consistently higher levels of CRP and ASP regardless of BMI. Fatty Acids, Nonesterified 99-124 C-reactive protein Homo sapiens 79-82 18206145-9 2009 In control subjects, CRP and C3 correlated with glucose and triglyceride, only CRP correlated with nonesterified fatty acids and cholesterol, and ASP correlated with triglyceride (again, all correlations were significant), whereas in subjects with PCOS, several of these correlations were lost, as a result of consistently higher levels of CRP and ASP regardless of BMI. Fatty Acids, Nonesterified 99-124 C-reactive protein Homo sapiens 79-82 3152937-5 1987 During the infusion of methotrexate 33.6 g/m2 the concentrations of LF are increased, only a small increase of CRP is observed, and for the other groups there is no changes of both parameters. Methotrexate 23-35 C-reactive protein Homo sapiens 111-114 19463128-4 2009 Besides lipid lowering effect therapy with rosuvastatin was associated with lowering of C-reactive protein level and increase of number of circulating CD34+, CD133+ cells. Rosuvastatin Calcium 43-55 C-reactive protein Homo sapiens 88-106 3083530-0 1986 Augmentation of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF)-induced human platelet activation by C-reactive protein. 1-o-alkyl-2-o-acetyl-sn-glycero-3-phosphocholine 16-64 C-reactive protein Homo sapiens 108-126 28485168-0 2017 Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed. Pemetrexed 95-105 C-reactive protein Homo sapiens 25-43 3455709-3 1986 CRP causes minimal enhancement of proliferation in a mixed lymphocyte culture and a slight increase in 3H-thymidine uptake by unstimulated cells. 3h-thymidine 103-115 C-reactive protein Homo sapiens 0-3 28485168-4 2017 The aim of our retrospective study was to evaluate the association of baseline serum levels of C-reactive protein (CRP) with outcomes in a large cohort of patients with non-squamous NSCLC treated with pemetrexed. Pemetrexed 201-211 C-reactive protein Homo sapiens 95-113 28485168-4 2017 The aim of our retrospective study was to evaluate the association of baseline serum levels of C-reactive protein (CRP) with outcomes in a large cohort of patients with non-squamous NSCLC treated with pemetrexed. Pemetrexed 201-211 C-reactive protein Homo sapiens 115-118 28485168-9 2017 In conclusion, the study results suggest that pretreatment serum CRP is associated with poor outcome of non-squamous NSCLC patients treated with pemetrexed. Pemetrexed 145-155 C-reactive protein Homo sapiens 65-68 19212905-11 2009 The inflammatory marker high sensitivity C-reactive protein (hsCRP) decreased significantly only in the icodextrin group (p = 0.0048). Icodextrin 104-114 C-reactive protein Homo sapiens 41-59 19004040-10 2008 It also correlated with the constitutional, eye, pulmonary, gastrointestinal, neuromotor, and laboratory domains of the SLAM-R. hs-CRP was associated with the SDI (r = 0.12, p = 0.004) in the univariable analysis but not in the multivariable analysis. sdi 159-162 C-reactive protein Homo sapiens 131-134 18562112-6 2008 By use of an AFM tip, a pattern of ditch was engraved within the SAM of DSNHS, and anti-CRP was immobilized on the engraved SAM through replacement of N-hydroxysuccinimide group on the outside surface of DSNHS by the amine group of anti-CRP. Amines 217-222 C-reactive protein Homo sapiens 88-91 18486609-2 2008 An important binding specificity of CRP is for the modified forms of low-density lipoprotein (LDL) in which the phosphocholine-binding sites of CRP participate. Phosphorylcholine 112-126 C-reactive protein Homo sapiens 36-39 18486609-2 2008 An important binding specificity of CRP is for the modified forms of low-density lipoprotein (LDL) in which the phosphocholine-binding sites of CRP participate. Phosphorylcholine 112-126 C-reactive protein Homo sapiens 144-147 18486609-5 2008 RESULTS: We found that the blocking of the phosphocholine-binding sites of CRP with phosphoethanolamine (PEt) converted CRP into a potent molecule for binding to native LDL. Phosphorylcholine 43-57 C-reactive protein Homo sapiens 75-78 18486609-5 2008 RESULTS: We found that the blocking of the phosphocholine-binding sites of CRP with phosphoethanolamine (PEt) converted CRP into a potent molecule for binding to native LDL. Phosphorylcholine 43-57 C-reactive protein Homo sapiens 120-123 28033292-7 2016 After the 4 courses of Bortezomib-based chemotherapy, the C-reactive protein was <0.5 mg/dL and the disease activity score 28-erythrocyte sedimentation rate was 2.0. Bortezomib 23-33 C-reactive protein Homo sapiens 58-76 27852377-6 2016 Results: In 33 patients with UA, the correlation between WASHIN and CRP was positive, r=0.767, P<0.01; as for the WASHIN, there was significant difference between CRP positive group(49.51+-19.79)/s and CRP negative group(19.90+-14.51)/s (P<0.01). ulmoside A 29-31 C-reactive protein Homo sapiens 68-71 4084018-2 1985 CRP was purified using 4-step procedure including absorption on Sepharose 4B, phosphocholine-Sepharose, DE-52 ion exchange chromatography and gel filtration on Sephacryl S-200. Phosphorylcholine 78-92 C-reactive protein Homo sapiens 0-3 27852377-6 2016 Results: In 33 patients with UA, the correlation between WASHIN and CRP was positive, r=0.767, P<0.01; as for the WASHIN, there was significant difference between CRP positive group(49.51+-19.79)/s and CRP negative group(19.90+-14.51)/s (P<0.01). ulmoside A 29-31 C-reactive protein Homo sapiens 166-169 27852377-6 2016 Results: In 33 patients with UA, the correlation between WASHIN and CRP was positive, r=0.767, P<0.01; as for the WASHIN, there was significant difference between CRP positive group(49.51+-19.79)/s and CRP negative group(19.90+-14.51)/s (P<0.01). ulmoside A 29-31 C-reactive protein Homo sapiens 166-169 18602526-0 2008 Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria. Fosinopril 10-20 C-reactive protein Homo sapiens 40-58 18602526-4 2008 CRP was determined using a high-sensitivity assay at baseline and after 3 months of fosinopril treatment. Fosinopril 84-94 C-reactive protein Homo sapiens 0-3 18602526-8 2008 Exploratory analysis suggested an interaction between gender and fosinopril treatment on CRP reduction (p = 0.07). Fosinopril 65-75 C-reactive protein Homo sapiens 89-92 28164672-7 2016 Mean levels of CRP were 0.38 +- 0.21 mg/L in the TCFA group and 0.23 +- 0.17 mg/L (p < 0.01). tcfa 49-53 C-reactive protein Homo sapiens 15-18 6427351-1 1984 Two simple rapid and precise fluorescence assays for determining serum levels of C-reactive protein (CRP) are described which employ sheep antibodies to CRP covalently linked to magnetisable cellulose/iron oxide particles. ferric oxide 201-211 C-reactive protein Homo sapiens 81-99 27376840-2 2016 Although bisphosphonates are safety drugs, they have numerous side-effects such as arthralgia, elevated erythrocyte sedimentation rate and C-reactive protein, gastrointestinal disturbances, and flu-like illness with symptoms of fatigue, fever, chills, malaise, and myalgia. Diphosphonates 9-24 C-reactive protein Homo sapiens 139-157 18191862-8 2008 Participants with DTAC had significantly higher levels of both CRP and IL-6. dodecyltrimethylammonium 18-22 C-reactive protein Homo sapiens 63-66 18436840-8 2008 RESULTS: Intraluminal treatment with a clinically relevant concentration of CRP (7 microg/mL, 60 minutes) significantly attenuated arteriolar dilation to endothelium-dependent NO-mediated agonists bradykinin and A23187 but not to endothelium-independent NO donor sodium nitroprusside. Nitroprusside 263-283 C-reactive protein Homo sapiens 76-79 6427351-1 1984 Two simple rapid and precise fluorescence assays for determining serum levels of C-reactive protein (CRP) are described which employ sheep antibodies to CRP covalently linked to magnetisable cellulose/iron oxide particles. ferric oxide 201-211 C-reactive protein Homo sapiens 101-104 18178405-5 2008 Logistic regression analysis identified independent predictors of increased CRP in men as obesity (odds ratio [OR] 3.5, 95% confidence interval [CI] 2.4 to 5.0), smoking (OR 3.1, 95% CI 2.1 to 4.5), hypertension (OR 1.6, 95% CI 1.1 to 2.3), and low high-density lipoprotein cholesterol (OR 1.4, 95% CI 1.0 to 1.8). low high-density lipoprotein cholesterol 245-285 C-reactive protein Homo sapiens 76-79 6427351-1 1984 Two simple rapid and precise fluorescence assays for determining serum levels of C-reactive protein (CRP) are described which employ sheep antibodies to CRP covalently linked to magnetisable cellulose/iron oxide particles. ferric oxide 201-211 C-reactive protein Homo sapiens 153-156 6433926-2 1983 By addition of L-alpha-lecithin to the pleural effusion in the presence of calcium ions, a flocculence of the CRP-lecithin complex formed. colfosceril palmitate 15-31 C-reactive protein Homo sapiens 110-113 27781198-0 2016 Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment. Sorafenib 130-139 C-reactive protein Homo sapiens 41-59 27781198-9 2016 CONCLUSIONS: A novel prognostic scoring system, which includes the CRP level, has the ability to stratify the prognosis of patients with advanced stage HCC after treatment with sorafenib. Sorafenib 177-186 C-reactive protein Homo sapiens 67-70 17531242-4 2008 In human endothelial cells, CRP significantly inhibited cell proliferation and increased endothelial cell apoptosis evaluated by terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling and caspase-3 activity assay, which is reversed by a function-blocking antibody to Fc gamma RIIIB by 78%. deoxyuridine triphosphate 175-179 C-reactive protein Homo sapiens 28-31 7041546-4 1982 Studies of its binding specificities have indicated that CRP has reactivity with (a) phosphocholine and phosphate esters, and hence with lipids widely distributed in mammalian and microbial cells; and (b) with multiple widely distributed polycations, including those derived from leukocyte granules. Phosphorylcholine 85-99 C-reactive protein Homo sapiens 57-60 18789009-6 2008 Treatment with rosuvastatin in moderate doses significantly suppressed activity of endogenous inflammation and oxidative stress by way of activation of antioxidant system of plasma, decrease of oxidation of fractions of lipoproteins, suppression of " nitrotirosine " stress, as well as partial inhibition of efficacy of action of secretory phospholipase A2, lowering of content of C-reactive protein and interleukin-6. Rosuvastatin Calcium 15-27 C-reactive protein Homo sapiens 381-399 26271127-0 2016 Meta-Analysis Comparing Rosuvastatin and Atorvastatin in Reducing Concentration of C-Reactive Protein in Patients With Hyperlipidemia. Rosuvastatin Calcium 24-36 C-reactive protein Homo sapiens 83-101 26909743-2 2016 We hypothesized that curcuminoids, when administered as a micellar formulation with hundredfold enhanced bioavailability, decrease blood lipids and inflammation in subjects with moderately elevated cholesterol and C-reactive protein concentrations. curcuminoids 21-33 C-reactive protein Homo sapiens 214-232 26909743-7 2016 CONCLUSION: Consumption of 98 mg of highly bioavailable curcuminoids with each principal meal sufficed to achieve curcuminoid accumulation in the blood, was safe, and did not alter blood lipids, inflammation, glucose, or iron homeostasis in healthy subjects with slightly elevated blood cholesterol and C-reactive protein. curcuminoids 56-68 C-reactive protein Homo sapiens 303-321 18155052-8 2008 C-reactive protein and leukocyte count were lower in the CPNB group (P < .05). cpnb 57-61 C-reactive protein Homo sapiens 0-18 6166719-1 1981 Binding of human 125I-C-reactive protein (CRP) to sheep erythrocytes sensitized with pneumococcal C polysaccharide (E-PnC) was found to be Ca++ dependent and inhibitable by phosphocholine, CRP, and HOPC 8. Phosphorylcholine 173-187 C-reactive protein Homo sapiens 17-40 6166719-1 1981 Binding of human 125I-C-reactive protein (CRP) to sheep erythrocytes sensitized with pneumococcal C polysaccharide (E-PnC) was found to be Ca++ dependent and inhibitable by phosphocholine, CRP, and HOPC 8. Phosphorylcholine 173-187 C-reactive protein Homo sapiens 42-45 425611-1 1979 The human serum proteins C-reactive protein (CRP), the 9.5 Salpha1-glycoprotein and C1q show, when tested in the agar gel diffusion under certain buffer conditions, strong precipitin reactions with polysaccharides of the galactan type, indicating that they may have lectin-like recognition sites. Agar 113-117 C-reactive protein Homo sapiens 25-43 425611-1 1979 The human serum proteins C-reactive protein (CRP), the 9.5 Salpha1-glycoprotein and C1q show, when tested in the agar gel diffusion under certain buffer conditions, strong precipitin reactions with polysaccharides of the galactan type, indicating that they may have lectin-like recognition sites. Agar 113-117 C-reactive protein Homo sapiens 45-48 118213-8 1979 C-reactive protein was increased almost in two thirds of patients on admission, but normalized in all cases about the end of the first week of penicillin therapy. Penicillins 143-153 C-reactive protein Homo sapiens 0-18 696428-1 1978 The occurrence of plasma CRP during the febrile response after the first injection of penicillin was followed in 10 patients with early syphilis. Penicillins 86-96 C-reactive protein Homo sapiens 25-28 885587-2 1977 Using immobilized Con A, a peptidopolysaccharide (PPS) has been isolated from Epidermophyton floccosum culture filtrate by affinity chromatography and shown to precipitate with Con A, human CRP sera and a mouse myeloma serum with specificity for phosphorylcholine (PC). pps 50-53 C-reactive protein Homo sapiens 190-193 885587-7 1977 Inhibition studies demonstrated that PC is a potent inhibitor of the serum CRP-PPS and myeloma protein-PPS precipitation reactions. Phosphorylcholine 37-39 C-reactive protein Homo sapiens 75-78 885587-7 1977 Inhibition studies demonstrated that PC is a potent inhibitor of the serum CRP-PPS and myeloma protein-PPS precipitation reactions. pps 79-82 C-reactive protein Homo sapiens 75-78 33203242-12 2021 Besides, male gender, C-reactive protein, non-dipper hypertension, and diastolic blood pressure were independent risk factors associated with MAU in the multivariate analysis (p < .05). aurodox 142-145 C-reactive protein Homo sapiens 22-40 32577988-7 2021 In patients with ischemic heart disease, low plasma levels of PCSK9 and elevated levels of HS-CRP are independent predictors of ASP. Aspartic Acid 128-131 C-reactive protein Homo sapiens 94-97 32252114-9 2021 After CytoSorb therapy, we instantly observed a significant reduction in procalcitonin (PCT) and C-reactive protein (CRP) levels compared with the control group. cytosorb 6-14 C-reactive protein Homo sapiens 97-115 32252114-9 2021 After CytoSorb therapy, we instantly observed a significant reduction in procalcitonin (PCT) and C-reactive protein (CRP) levels compared with the control group. cytosorb 6-14 C-reactive protein Homo sapiens 117-120 32252114-11 2021 CONCLUSIONS: Our results indicate that CytoSorb in combination with ECMO is an effective therapy to prevent escalation of sepsis with rapid weaning off high-dose catecholamine infusions and quick reduction in PCT and CRP levels. cytosorb 40-48 C-reactive protein Homo sapiens 218-221 33751231-0 2021 Functionalized ultra-fine bimetallic PtRu alloy nanoparticle with high peroxidase-mimicking activity for rapid and sensitive colorimetric quantification of C-reactive protein. ptru alloy 37-47 C-reactive protein Homo sapiens 156-174 33506752-5 2021 The erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, and NIH disease activity score were found to significantly decrease with bDMARD treatments. bdmard 147-153 C-reactive protein Homo sapiens 42-60 33506752-5 2021 The erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, and NIH disease activity score were found to significantly decrease with bDMARD treatments. bdmard 147-153 C-reactive protein Homo sapiens 62-65 33605405-7 2021 180 patients initiated GC compared with 294 who did not.At baseline, the increased CRP is the main factor that favors the initiation of GC followed by smoking, absence of ACPA, prescription of methotrexate as a monotherapy and age.5 years follow-up of DAS28-CRP, HAQ or VAS pain values did not differ between the two groups.We also analysed a subgroup of 139 patients who received >1 g of prednisolone during the 5 years period. Methotrexate 193-205 C-reactive protein Homo sapiens 83-86 33413588-13 2021 Change to week 8 in levels of C3M, C4M, CRP and CRPM in MTX patients correlated significantly (rho = 0.41 to 0.18, P < 0.0001 to 0.039) with change in disease activity (DAS28) at weeks 8, 16 and 24, whereas only CRP in TCZ patients (rho = 0.32 to 0.21, P < 0.0001 to 0.01). Methotrexate 56-59 C-reactive protein Homo sapiens 40-43 33413588-13 2021 Change to week 8 in levels of C3M, C4M, CRP and CRPM in MTX patients correlated significantly (rho = 0.41 to 0.18, P < 0.0001 to 0.039) with change in disease activity (DAS28) at weeks 8, 16 and 24, whereas only CRP in TCZ patients (rho = 0.32 to 0.21, P < 0.0001 to 0.01). Methotrexate 56-59 C-reactive protein Homo sapiens 48-51 31965179-11 2021 This was accompanied by a 59.1% reduction in CRP (P = 0.045) and improved perceptions of wellbeing (P = 0.006) in the leucine group. Leucine 118-125 C-reactive protein Homo sapiens 45-48 32969158-8 2020 Children with the ADORA3 rs3393 polymorphic variants (CT/CC) after 6 months of MTX treatment had significantly lower number of joints with active arthritis (median: 0.00 vs 1.00, P = 0.0400) and value of C-reactive protein (0.60 vs 2.40, P = 0.0242) in comparison to TT variant. Methotrexate 79-82 C-reactive protein Homo sapiens 204-222 32738021-6 2020 Lathosterol and lanosterol were positively correlated with body mass index, fasting insulin and glucose, serum triglycerides, and C-reactive protein, and negatively correlated with HDL-cholesterol. Lanosterol 16-26 C-reactive protein Homo sapiens 130-148 33138014-4 2020 The primary endpoint was the clinical response of the Disease Activity Score assessing 28 joints with C-reactive protein (DAS28-CRP) differences in the changes from baseline to 54 weeks between MTX+IGU and IGU groups. Methotrexate 194-197 C-reactive protein Homo sapiens 102-120 27621811-0 2016 Phosphocholine-containing ligands direct CRP induction of M2 macrophage polarization independent of T cell polarization: Implication for chronic inflammatory states. Phosphorylcholine 0-14 C-reactive protein Homo sapiens 41-44 33138014-4 2020 The primary endpoint was the clinical response of the Disease Activity Score assessing 28 joints with C-reactive protein (DAS28-CRP) differences in the changes from baseline to 54 weeks between MTX+IGU and IGU groups. Methotrexate 194-197 C-reactive protein Homo sapiens 128-131 18569918-9 2008 Similarly, the serum marker of osteoclastic activity beta-CTx was related inversely to patients" age (r = -0.383, p = -0.028), CRP (rho = -0.466, p = 0.006), and IL-6 (r = -0.460, p = 0.007) but positively to iPTH (r = 0.657, p < 0.001). beta-ctx 53-61 C-reactive protein Homo sapiens 127-130 33138014-7 2020 DAS28-CRP were significantly reduced from the baseline in the MTX+IGU and IGU groups (-1.43 and -1.20 from baseline, respectively). Methotrexate 62-65 C-reactive protein Homo sapiens 6-9 18042053-10 2007 Both statins significantly reduced plasmatic levels of CRP (3.18 +/- 2.43 mg/dL [T0] vs. 1.31 +/- 1.67 mg/dL [T2] with rosuvastatin [P < 0.01], 7.53 +/- 7.46 mg/dL [T0] vs. 2.92 +/- 2.06 mg/dL [T2] with atorvastatin [P < 0.01]). Rosuvastatin Calcium 119-131 C-reactive protein Homo sapiens 55-58 18042053-11 2007 Relative reduction of CRP levels was -50.57% with rosuvastatin versus -36.28% with atorvastatin (P N.S.). Rosuvastatin Calcium 50-62 C-reactive protein Homo sapiens 22-25 17984166-6 2007 RESULTS: As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-density lipoprotein cholesterol (difference between groups, 45.0%; P<0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P<0.001). Rosuvastatin Calcium 61-73 C-reactive protein Homo sapiens 211-229 17920365-0 2007 Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Rosuvastatin Calcium 31-43 C-reactive protein Homo sapiens 95-113 27084911-9 2016 Older age, >= 8 ACR classification criteria, immunosuppressive drugs, cigarette smoking, and higher mean serum C-reactive protein levels were associated with an earlier increase in SDI scores in multivariable analysis. sdi 184-187 C-reactive protein Homo sapiens 114-132 27182730-10 2016 CONCLUSIONS: CRP levels have potential for the early identification of SAB patients with a greater risk for death and deep infections. sab 71-74 C-reactive protein Homo sapiens 13-16 26032842-2 2016 OBJECTIVES: The aim of this study was to find out whether elevated serum levels (>=5 mg/l) of C-reactive protein (CRP), an established laboratory marker of infection and inflammation, are associated with increased serum concentrations of the atypical antipsychotic drugs clozapine, quetiapine, and risperidone. Quetiapine Fumarate 285-295 C-reactive protein Homo sapiens 97-115 26032842-2 2016 OBJECTIVES: The aim of this study was to find out whether elevated serum levels (>=5 mg/l) of C-reactive protein (CRP), an established laboratory marker of infection and inflammation, are associated with increased serum concentrations of the atypical antipsychotic drugs clozapine, quetiapine, and risperidone. Quetiapine Fumarate 285-295 C-reactive protein Homo sapiens 117-120 17920365-4 2007 Significantly more patients treated with rosuvastatin achieved the combined end point of LDL cholesterol <70 mg/dl and CRP <2 mg/L compared with atorvastatin by the end of the study period (58% vs 37%; p <0.001 vs atorvastatin). Rosuvastatin Calcium 41-53 C-reactive protein Homo sapiens 122-125 17920365-5 2007 In conclusion, CRP was effectively decreased in patients with type 2 diabetes receiving rosuvastatin or atorvastatin, whereas rosuvastatin decreased LDL cholesterol significantly more than atorvastatin. Rosuvastatin Calcium 88-100 C-reactive protein Homo sapiens 15-18 26747436-8 2016 The effect size on plasma CRP concentrations was significant with lipophilic (atorvastatin) but not hydrophilic (pravastatin and rosuvastatin) statins. Rosuvastatin Calcium 129-141 C-reactive protein Homo sapiens 26-29 32388479-4 2020 Quercetin and enzymatically-modified isoquercitrin (EMIQ - a food additive/nutraceutical that upon oral administration achieves far higher plasma concentrations of quercetin than quercetin per se) also have exerted a range of vascular-protective effects clinically and in rodents - improving endothelial function, warding off atherosclerosis, lowering blood pressure, decreasing C-reactive protein, aiding glycemic control, stabilizing platelets - that might also, at least in part, reflect CK2 inhibition. Quercetin 0-9 C-reactive protein Homo sapiens 379-397 26194374-6 2016 In the TSU-68 plus docetaxel group, PFS showed significant association with fold changes in CRP (p=0.001), IL-6 (p < .001), PDGF-BB (p=0.02), and VEGF (p=0.047) following the first treatment cycle. Docetaxel 19-28 C-reactive protein Homo sapiens 92-95 21291692-9 2007 CONCLUSIONS: The combination of rosuvastatin 40 mg and ezetimibe 10 mg offers the most effective LDL-C-lowering therapy yet reported, and is helpful in achieving lipid goals and reducing C-reactive protein levels in high-risk patients with severe hypercholesterolemia, including familial hypercholesterolemia. Rosuvastatin Calcium 32-44 C-reactive protein Homo sapiens 187-205 17244159-5 2007 After binding to phosphocholine, native CRP bound C1q and significantly activated C1. Phosphorylcholine 17-31 C-reactive protein Homo sapiens 40-43 17244159-6 2007 Native CRP complexed to phosphocholine did not bind the complement regulatory proteins FH and C4BP. Phosphorylcholine 24-38 C-reactive protein Homo sapiens 7-10 32269097-9 2020 Interaction of phosphocholine groups on VLDL with CRP is the major driver for complex formation and phosphocholine can disrupt the complexes to reverse their inhibitory effects on phagocytosis and bacterial clearance. Phosphorylcholine 15-29 C-reactive protein Homo sapiens 50-53 17615799-5 2007 There is also substantial evidence that therapy with clopidogrel, a specific antagonist of the platelet P2Y12 ADP-receptor, also leads to reductions in serum levels of CD40 ligand, C-reactive protein, P-selectin, and platelet-leukocyte aggregate formation. Clopidogrel 53-64 C-reactive protein Homo sapiens 181-199 26608972-5 2016 MBDA scores correlated with CRP (r = 0.755, P < 0.001), but were often discordant, being moderate or high for 19%, 55% and 87% of patients with CRP <=0.1, 0.1 to <=0.3, or 0.3 to <=1.0 mg/dl, respectively. 3-benzoyl dopamine 0-4 C-reactive protein Homo sapiens 28-31 26608972-5 2016 MBDA scores correlated with CRP (r = 0.755, P < 0.001), but were often discordant, being moderate or high for 19%, 55% and 87% of patients with CRP <=0.1, 0.1 to <=0.3, or 0.3 to <=1.0 mg/dl, respectively. 3-benzoyl dopamine 0-4 C-reactive protein Homo sapiens 147-150 32269097-9 2020 Interaction of phosphocholine groups on VLDL with CRP is the major driver for complex formation and phosphocholine can disrupt the complexes to reverse their inhibitory effects on phagocytosis and bacterial clearance. Phosphorylcholine 100-114 C-reactive protein Homo sapiens 50-53 26258672-11 2016 CRP levels on admission were higher in patients with AMI in comparison with control individuals. amicoumacin A 53-56 C-reactive protein Homo sapiens 0-3 17338662-4 2007 Also results from the Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study could provide further evidence for the use of rosuvastatin in individuals with traditional and emerging CHD risk factors, such as an elevated high sensitivity C-reactive protein level. Rosuvastatin Calcium 190-202 C-reactive protein Homo sapiens 303-321 32214401-5 2020 The results demonstrated that elevated preoperative NLR, PLR, and CRP was associated with poor OS in HCC patients treated by TACE (HR = 1.81, P<0.00001; HR = 1.56, P = 0.007; HR = 1.45, P<0.00001, respectively). Chlorotrianisene 125-129 C-reactive protein Homo sapiens 66-69 17161243-6 2006 A marked reduction in platelet aggregation and active GP IIb/IIIa expression (p < or = 0.001) with clopidogrel + eptifibatide was associated with a decrease in CRP and TNF-alpha release (p < or = 0.001). Clopidogrel 102-113 C-reactive protein Homo sapiens 163-166 17087780-6 2006 RESULTS: The free fatty acid (FFA) concentration at the 120-min time-point was associated with baseline alpha-1-acid glycoprotein (A1GP) (r = 0.57, P < 0.01), C-reactive protein (CRP) (r = 0.54, P < 0.02) and serum amyloid A (r = 0.53, P < 0.02); in total they accounted for 54% of the variation in FFA concentration at the 120-min time-point. Fatty Acids, Nonesterified 30-33 C-reactive protein Homo sapiens 182-185 16945967-13 2006 These data suggest that at physiological ATP, ADP and CrP levels accumulation of sugar phosphates from glycolysis can stimulate SR Ca(2+) release. Sugar Phosphates 81-97 C-reactive protein Homo sapiens 54-57 17023717-7 2006 In women with type 2 diabetes, higher caffeinated coffee consumption was associated with lower plasma concentrations of E-selectin (adjusted percentage change per 1 cup/d increment = -3.2%; P = 0.05) and C-reactive protein (adjusted percentage change = -10.2%; P < 0.001). caffeinated 38-49 C-reactive protein Homo sapiens 204-222 16829027-8 2006 The odds of having a raised CRP level in subjects consuming more than 10% energy as saturated dietary fat were twice as compared to subjects having a normal saturated fat intake [Adjusted odds ratio (OR) (95% CI) = 2.0 (0.94-4.1)]. saturated fat 157-170 C-reactive protein Homo sapiens 28-31 16829027-9 2006 For every one percent decrease in energy intake by saturated fat, CRP level was calculated to decrease by 0.14 mg/L. saturated fat 51-64 C-reactive protein Homo sapiens 66-69 26523504-1 2016 For label-free and direct detection of C-reactive protein (CRP), an impedimetric sensor based on an indium tin oxide (ITO) electrode array functionalized with reduced graphene oxide-nanoparticle (rGO-NP) hybrid was fabricated and evaluated. indium tin oxide 118-121 C-reactive protein Homo sapiens 59-62 26610293-4 2016 RESULTS: We observed statistically significant associations between PAH metabolites and levels of serum GGT, CRP, uric acid and eGFR. Polycyclic Aromatic Hydrocarbons 68-71 C-reactive protein Homo sapiens 109-112 27058799-11 2016 CONCLUSIONS: Adjuvant rosuvastatin treatment in patients diagnosed of DVT improve CRP levels and diminish PTS incidence. Rosuvastatin Calcium 22-34 C-reactive protein Homo sapiens 82-85 25618800-4 2015 Our secondary aim was to perform a meta-analysis of data from all randomized controlled trials in order to estimate the effect size of curcuminoids on plasma C-reactive protein (CRP) concentrations. curcuminoids 135-147 C-reactive protein Homo sapiens 158-176 25618800-4 2015 Our secondary aim was to perform a meta-analysis of data from all randomized controlled trials in order to estimate the effect size of curcuminoids on plasma C-reactive protein (CRP) concentrations. curcuminoids 135-147 C-reactive protein Homo sapiens 178-181 25618800-11 2015 Quantitative data synthesis revealed a significant effect of curcuminoids vs. placebo in reducing circulating CRP concentrations (weighed mean difference: -2.20 mg/L; 95% confidence interval [CI]: -3.96, -0.44; p = 0.01). curcuminoids 61-73 C-reactive protein Homo sapiens 110-113 25618800-14 2015 Curcuminoids could be regarded as natural, safe and effective CRP-lowering agents. curcuminoids 0-12 C-reactive protein Homo sapiens 62-65 16679086-7 2006 The increase in C-reactive protein and troponin was lower among patients undergoing DES implantation (median 2.1 vs 3.5 mg/L for C-reactive protein, median 0.11 vs 0.41 ng/ml for troponin), even after adjustment for randomized treatment, clopidogrel before treatment, diabetes mellitus status, epicardial patency, left anterior descending artery location, and myocardial perfusion (p = 0.036 and p = 0.039, respectively). Clopidogrel 238-249 C-reactive protein Homo sapiens 16-34 32214401-8 2020 CONCLUSIONS: Elevated preoperative NLR, PLR, and CRP are associated with poor prognosis in HCC patients treated with TACE. Chlorotrianisene 117-121 C-reactive protein Homo sapiens 49-52 16939632-14 2006 The data suggest that lipid lowering agents, ACE inhibitors, ARBs, antidiabetic agents, antiinflammatory and antiplatelet agents, vitamin E, and beta-adrenoreceptor antagonists lower serum or plasma levels of CRP, while vitamin C, oral estrogen and hydrochlorothiazide do not affect CRP levels. Hydrochlorothiazide 249-268 C-reactive protein Homo sapiens 209-212 31820534-8 2020 From the meta-regression analyses, across all study subsets, greater mean falls in all four parameters, (HOMA-IR, Glucose, ALT and CRP) were observed with greater mean loss of BMI-SDS, but the trends were only statistically significant for HOMA-IR and CRP (P=0.003; P=0.021). 4,4'- bis(4-anilino-6-amino)-2,2'-stilbenedisulfonic acid 180-183 C-reactive protein Homo sapiens 131-134 16490432-0 2006 Meta-analysis of the effect of thiazolidinediones on serum C-reactive protein levels. Thiazolidinediones 31-49 C-reactive protein Homo sapiens 59-77 16490432-1 2006 We conducted a meta-analysis of randomized clinical trials to evaluate the effect of thiazolidinediones on serum C-reactive protein levels. Thiazolidinediones 85-103 C-reactive protein Homo sapiens 113-131 16490432-2 2006 Compared with placebo, treatment with thiazolidinediones significantly decreased the serum C-reactive protein levels (mean -0.82 mg/L, 95% confidence interval -1.15 to -0.49 mg/L, p <0.0001). Thiazolidinediones 38-56 C-reactive protein Homo sapiens 91-109 16490432-3 2006 In a subgroup analysis, the effect of thiazolidinediones on the serum C-reactive protein levels was more pronounced in diabetic patients (mean -1.24 mg/L, 95% confidence interval -2.15 to -0.32 mg/L, p = 0.008) compared with nondiabetic patients (mean -0.27 mg/L, 95% confidence interval -0.41 to -0.14 mg/L, p <0.0001). Thiazolidinediones 38-56 C-reactive protein Homo sapiens 70-88 26549279-0 2015 Java project on periodontal diseases: effect of vitamin C/calcium threonate/citrus flavonoids supplementation on periodontal pathogens, CRP and HbA1c. Flavonoids 83-93 C-reactive protein Homo sapiens 136-139 26222701-13 2015 In the BM-CTP group, a significant increase of IL-6 but also of CRP and D-dimer was observed. bm-ctp 7-13 C-reactive protein Homo sapiens 64-67 32462890-9 2020 Moreover, the dose-response meta-analysis revealed a non-linear association between increased TMAO concentrations and increased CRP concentrations (p for nonlinearity = 0.015). trimethyloxamine 94-98 C-reactive protein Homo sapiens 128-131 25908766-2 2015 We hypothesized that a novel biomarker (GlycA) of N-acetyl methyl groups originating mainly from N-acetylglucosamine moieties of acute-phase glycoproteins is related to incident type 2 diabetes mellitus and compared it with high-sensitivity C-reactive protein. Acetylglucosamine 97-116 C-reactive protein Homo sapiens 241-259 16636386-2 2006 It was established that the patients with traumas of peripheral nervous trunks showed the presence of inflammatory process and sensitization of the body which was exposed in the reaction of precipitation at C-reactive protein with the increase of the content of serum glycoides and total nonspecific immunuglobulin E in blood serum. glycoides 268-277 C-reactive protein Homo sapiens 207-225 31141297-7 2019 Increased DCA and GDCA concentrations were significantly associated with decreased HbA1c or fasting blood glucose and CRP levels, whereas increased GDCA and GUDCA concentrations were associated with decreased waist circumference in the OW/OB group during treatment. Glycodeoxycholic Acid 18-22 C-reactive protein Homo sapiens 118-121 16054696-5 2006 Here, we show that pravastatin and simvastatin prevent the induction of CRP expression in human hepatoma Hep3B cells exposed to proinflammatory cytokines IL-6 and IL-1beta The nitric oxide (NO) donor, sodium nitroprusside, also prevented the induction of CRP expression while the CRP inducers IL-6 and IL-1beta were present with the cells. Nitroprusside 201-221 C-reactive protein Homo sapiens 72-75 16239318-0 2006 Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: normalizing effects on CRP, TNF-alpha and the neutrophil/lymphocyte ratio. Flutamide 23-32 C-reactive protein Homo sapiens 163-166 25771851-12 2015 Significant negative correlation was observed between FMD and IL-6, ICAM-1, CRP after treatment with rosuvastatin. Rosuvastatin Calcium 101-113 C-reactive protein Homo sapiens 76-79 25771851-14 2015 Rosuvastatin lowers the proinflammatory cytokines, especially IL-6 and TNF-alpha, which downregulates adhesion molecules and CRP production which in turns improves ED. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 125-128 25732625-5 2015 Weight loss with beloranib was associated with corresponding reductions in waist circumference and body fat mass, as well as improvements in lipids, high-sensitivity C-reactive protein and blood pressure. CKD732 17-26 C-reactive protein Homo sapiens 166-184 31353421-10 2019 Methotrexate use at baseline predicted decreased DAS28-CRP, mHAQ, and RAPID3 scores during follow-up. Methotrexate 0-12 C-reactive protein Homo sapiens 55-58 26056457-11 2015 The factors that were found to possibly affect the dose-adjusted concentration of fentanyl included aspartate aminotransferase, C-reactive protein, and estimated glomerular filtration rate, when analyzed as six independent variables (multiple regression analysis, P<0.05). Fentanyl 82-90 C-reactive protein Homo sapiens 128-146 25832424-8 2015 Pretreatment of the cells with the ROS scavenger N-acetyl-L-cysteine, ERK inhibitor PD98059 or NF-kappaB inhibitor PDTC blocked CRP-stimulated RAGE expression, but pretreatment with the NADPH oxidase inhibitor DPI, JNK inhibitor SP600125 or p38 MAPK inhibitor SB203580 did not significantly alter CRP-stimulated RAGE expression. pyrazolanthrone 229-237 C-reactive protein Homo sapiens 128-131 25542532-7 2015 A higher CRP was correlated with a higher dose-normalized plasma concentration of voriconazole and a lower plasma concentration ratio of N-oxide to voriconazole. n-oxide 137-144 C-reactive protein Homo sapiens 9-12 24595550-11 2015 CONCLUSIONS: TU-100 appears to improve gastrointestinal dysmotility and reduce serum CRP levels in patients with grade B liver damage after hepatectomy. 12,13-dihydro-N-methyl-6,11,13-trioxo-5H-benzo(4,5)cyclohepta(1,2-b)naphthalen-5,12-imine 13-19 C-reactive protein Homo sapiens 85-88 25592634-8 2015 Also, CRP levels strongly correlated with the value of PaO2/FiO2 ratio (r = -0.69, p < 0.001) and creatinine (r = 0.60, p < 0.001). pao2 55-59 C-reactive protein Homo sapiens 6-9 16182316-0 2006 C-reactive protein-induced upregulation of extracellular matrix metalloproteinase inducer in macrophages: inhibitory effect of fluvastatin. Fluvastatin 127-138 C-reactive protein Homo sapiens 0-18 16182316-8 2006 Fluvastatin blocked the CRP-induced increases in EMMPRIN and MMP-9 expression and activity. Fluvastatin 0-11 C-reactive protein Homo sapiens 24-27 17208662-9 2006 Weight loss drugs, such as orlistat, a lipase inhibitor, and sibutramine, a serotonin and norepinephrine reuptake inhibitor, have both been shown to produce a decrease in C-reactive protein levels and an increase in serum adiponectin. Orlistat 27-35 C-reactive protein Homo sapiens 171-189 16002176-6 2006 CRP correlated with waist circumference (r=0.28, p<0.001) and body mass index (r=0.38, p<0.001) in both men and women; however the relationship of CRP with HOMA(IR) was only evident in men (r=0.37, p<0.01) while the association with free fatty acids (FFA) was only significant in women (r=0.20, p<0.05), even after adjusting for age, hispanic ethnicity and glucose tolerance status. Fatty Acids, Nonesterified 242-258 C-reactive protein Homo sapiens 0-3 16002176-6 2006 CRP correlated with waist circumference (r=0.28, p<0.001) and body mass index (r=0.38, p<0.001) in both men and women; however the relationship of CRP with HOMA(IR) was only evident in men (r=0.37, p<0.01) while the association with free fatty acids (FFA) was only significant in women (r=0.20, p<0.05), even after adjusting for age, hispanic ethnicity and glucose tolerance status. Fatty Acids, Nonesterified 242-258 C-reactive protein Homo sapiens 153-156 31737618-4 2019 The optimized plasmonically active strip was subsequently prepared by dipping the amine-functionalized substrate into AuNPs for 8 h. The optimized plasmonic strip functionalized with anti-CRP was transformed into a portable LSPR sensor chip by placing it inside a cuvette cell system, and its detection performance was evaluated using CRP as a model sample. Amines 82-87 C-reactive protein Homo sapiens 188-191 16290959-5 2005 Estrogen plus medroxyprogesterone acetate increased CRP by 44.7% P = .001) at 1 year and 54.7% P = .0001) at closeout as compared with baseline levels. Medroxyprogesterone Acetate 14-41 C-reactive protein Homo sapiens 52-55 16220077-8 2005 Also, agonists of peroxisome proliferator-activated receptor (PPAR) alpha (WY14643) and PPARgamma (troglitazone) could largely inhibit C-reactive protein responses. pirinixic acid 75-82 C-reactive protein Homo sapiens 135-153 16220077-8 2005 Also, agonists of peroxisome proliferator-activated receptor (PPAR) alpha (WY14643) and PPARgamma (troglitazone) could largely inhibit C-reactive protein responses. Troglitazone 99-111 C-reactive protein Homo sapiens 135-153 16123329-10 2005 Pretreatment with TAT-C3 (a membrane-permeable RhoA inhibitor) and Y-27632 (Rho-kinase inhibitor) significantly inhibited CRP-induced PAI-1 expression. tat-c3 18-24 C-reactive protein Homo sapiens 122-125 15939097-8 2005 Peak CRP level was inversely correlated with the lowest PaO2/FIO2 (P < 0.001). pao2 56-60 C-reactive protein Homo sapiens 5-8 25222550-9 2014 A significant increase in MPV, PDW, C-reactive protein, and white blood cell levels was observed in the AFI group compared with the other group (P<0.001, P=0.002, P<0.001, and P=0.001, respectively). AOQ 104-107 C-reactive protein Homo sapiens 36-54 25374024-5 2014 The change in serum A-FABP levels showed positive correlations with changes in levels of glucose, free fatty acids (FFAs), and CRP in subjects supplemented with curcuminoids. curcuminoids 161-173 C-reactive protein Homo sapiens 127-130 31737618-4 2019 The optimized plasmonically active strip was subsequently prepared by dipping the amine-functionalized substrate into AuNPs for 8 h. The optimized plasmonic strip functionalized with anti-CRP was transformed into a portable LSPR sensor chip by placing it inside a cuvette cell system, and its detection performance was evaluated using CRP as a model sample. Amines 82-87 C-reactive protein Homo sapiens 335-338 15877999-2 2005 Long-term treatment with nifedipine (nifedipine CR, 20 mg/day for 4 months) decreased levels of C-reactive protein in the coronary sinus (from 0.35 +/- 0.09 mg/dl to 0.07 +/- 0.01 mg/dl, mean +/- SEM, p <0.05) and enhanced acetylcholine-induced increases in coronary blood flow. nifedipine cr 37-50 C-reactive protein Homo sapiens 96-114 31253226-7 2019 Compared with pantoprazole alone, somatostatin combined with pantoprazole has a better therapeutic effect on SAP, and its mechanism may be related to reduction of serum CRP and ICAM-1. BENSULIDE 109-112 C-reactive protein Homo sapiens 169-172 15818697-3 2005 RESULTS: At week 54, patients who did not show 20% improvement by American College of Rheumatology criteria (ACR20 nonresponders) while receiving infliximab plus MTX exhibited mild but statistically significant improvement in clinical variables, including the 28-joint Disease Activity Score (DAS28) (P < 0.001), tender joint count (P = 0.014), swollen joint count (P < 0.001), and C-reactive protein (CRP) level (P < 0.001). Methotrexate 162-165 C-reactive protein Homo sapiens 388-406 15818697-3 2005 RESULTS: At week 54, patients who did not show 20% improvement by American College of Rheumatology criteria (ACR20 nonresponders) while receiving infliximab plus MTX exhibited mild but statistically significant improvement in clinical variables, including the 28-joint Disease Activity Score (DAS28) (P < 0.001), tender joint count (P = 0.014), swollen joint count (P < 0.001), and C-reactive protein (CRP) level (P < 0.001). Methotrexate 162-165 C-reactive protein Homo sapiens 408-411 25278982-8 2014 The effect of rosuvastatin on preventing CIN was greater in the subgroups of patients with diabetes, high-dose contrast medium, multivessel stents, high baseline C-reactive protein, and myocardial infarction. Rosuvastatin Calcium 14-26 C-reactive protein Homo sapiens 162-180 24846719-9 2014 In multivariate logistic regression models, PGE-MUM was a significant independent predictor of histologic remission (sensitivity/specificity, 0.82/0.82) when the cutoff value was set to 17.0 mug/g creatinine, but CRP was not (0.69/0.69) (P < 0.01). Prostaglandins E 44-47 C-reactive protein Homo sapiens 213-216 31260491-9 2019 The random effects model showed that elevated CRP level was significantly correlated with poor DSS (HR = 2.08; 95% CI: 1.33-3.24; p < 0.001). dss 95-98 C-reactive protein Homo sapiens 46-49 24614628-5 2014 Although not statistically significant, C-reactive protein was lower in the rosuvastatin than in the pravastatin group at the chronic stage (1.14+-1.21 vs. 7.67+-13.67 mg/l, P=0.051). Rosuvastatin Calcium 76-88 C-reactive protein Homo sapiens 40-58 24602049-2 2014 This study aimed to evaluate the effect of gene polymorphisms of CYP2C9, VKORC1, thrombomodulin (THBD) and C-reactive protein (CRP) on the risk of bleeding complications of warfarin at therapeutic INR in Korean patients with mechanical cardiac valves. Warfarin 173-181 C-reactive protein Homo sapiens 107-125 24602049-2 2014 This study aimed to evaluate the effect of gene polymorphisms of CYP2C9, VKORC1, thrombomodulin (THBD) and C-reactive protein (CRP) on the risk of bleeding complications of warfarin at therapeutic INR in Korean patients with mechanical cardiac valves. Warfarin 173-181 C-reactive protein Homo sapiens 127-130 15932660-1 2005 OBJECTIVE: To investigate the effect of fluvastatin on blood levels of c-reactive protein (CRP), tumor necrosis factor alpha (TNFalpha) and cardiac troponin I (cTnI) in patients with unstable angina undergoing percutaneous coronary intervention (PCI). Fluvastatin 40-51 C-reactive protein Homo sapiens 71-89 15932660-1 2005 OBJECTIVE: To investigate the effect of fluvastatin on blood levels of c-reactive protein (CRP), tumor necrosis factor alpha (TNFalpha) and cardiac troponin I (cTnI) in patients with unstable angina undergoing percutaneous coronary intervention (PCI). Fluvastatin 40-51 C-reactive protein Homo sapiens 91-94 15932660-4 2005 RESULTS: The serum levels of CRP, TNFalpha and cTnI in fluvastatin group were distinctly lower than those in control group before (P < 0.01) and after the procedure (P < 0.01), respectively. Fluvastatin 55-66 C-reactive protein Homo sapiens 29-32 15932660-5 2005 CONCLUSION: The result suggested that PCI could lead to a detectable increase in serum levels of CRP, TNFalpha and cTnI in patients with coronary heart disease; Fluvastatin could significantly decrease the serum levels of CRP, TNFalpha and cTnI in patients with coronary heart disease; Fluvastatin could also decrease the serum levels of CRP, TNFalpha and cTnI in patients with PCI. Fluvastatin 161-172 C-reactive protein Homo sapiens 97-100 15932660-5 2005 CONCLUSION: The result suggested that PCI could lead to a detectable increase in serum levels of CRP, TNFalpha and cTnI in patients with coronary heart disease; Fluvastatin could significantly decrease the serum levels of CRP, TNFalpha and cTnI in patients with coronary heart disease; Fluvastatin could also decrease the serum levels of CRP, TNFalpha and cTnI in patients with PCI. Fluvastatin 161-172 C-reactive protein Homo sapiens 222-225 15932660-5 2005 CONCLUSION: The result suggested that PCI could lead to a detectable increase in serum levels of CRP, TNFalpha and cTnI in patients with coronary heart disease; Fluvastatin could significantly decrease the serum levels of CRP, TNFalpha and cTnI in patients with coronary heart disease; Fluvastatin could also decrease the serum levels of CRP, TNFalpha and cTnI in patients with PCI. Fluvastatin 161-172 C-reactive protein Homo sapiens 222-225 15932660-5 2005 CONCLUSION: The result suggested that PCI could lead to a detectable increase in serum levels of CRP, TNFalpha and cTnI in patients with coronary heart disease; Fluvastatin could significantly decrease the serum levels of CRP, TNFalpha and cTnI in patients with coronary heart disease; Fluvastatin could also decrease the serum levels of CRP, TNFalpha and cTnI in patients with PCI. Fluvastatin 286-297 C-reactive protein Homo sapiens 222-225 15932660-5 2005 CONCLUSION: The result suggested that PCI could lead to a detectable increase in serum levels of CRP, TNFalpha and cTnI in patients with coronary heart disease; Fluvastatin could significantly decrease the serum levels of CRP, TNFalpha and cTnI in patients with coronary heart disease; Fluvastatin could also decrease the serum levels of CRP, TNFalpha and cTnI in patients with PCI. Fluvastatin 286-297 C-reactive protein Homo sapiens 222-225 15795363-5 2005 In contrast to some previous reports, highly purified and well-characterized human CRP specifically induced hyporeactivity to phenylephrine in rings of human internal mammary artery and rat aorta that was mediated through physiological antagonism by nitric oxide (NO). Phenylephrine 126-139 C-reactive protein Homo sapiens 83-86 24602049-13 2014 In contrast, our results suggest that two genetic markers (THBD rs1042580 and CRP rs1205) could be predictors of bleeding complications of warfarin at normal INR. Warfarin 139-147 C-reactive protein Homo sapiens 78-81 31260491-10 2019 After excluding the heterogeneous study, the fixed effects model showed that elevated CRP level was firmly correlated with poor DSS (HR = 2.36; 95% CI: 1.84-3.03; p < 0.001). dss 128-131 C-reactive protein Homo sapiens 86-89 15735578-6 2005 Since a decrease in elevated markers of subclinical inflammation--nowadays regarded as the main culprit of cardiovascular complications and atherosclerosis--such as Interleukin-6 and C-reactive protein has been reported during CPAP therapy, and since an improvement in left ventricular function and a decrease in blood pressure were also reported under CPAP treatment, there are several good reasons to assume an improvement in metabolical function in OSAS patients due to CPAP treatment. cpap 227-231 C-reactive protein Homo sapiens 183-201 23780506-1 2014 This study was designed to show the effect of propylthiouracil treatment on sCD40L, high-sensitivity C-reactive protein, and fetuin-A levels on subjects with subclinical hyperthyroidism. Propylthiouracil 46-62 C-reactive protein Homo sapiens 101-119 31260491-12 2019 CONCLUSION: The results of this meta-analysis suggest that elevated pretreatment serum CRP level could serve as an independent risk factor for poor DSS and DFS/RFS in STS patents. dss 148-151 C-reactive protein Homo sapiens 87-90 31130260-12 2019 DAS28(CRP) 3 2 or lower was met by 42 (19%) of 216 (95% CI 14-25) in the continued methotrexate group, 97 (45%) of 217 (38-51) receiving upadacitinib 15 mg, and 114 (53%) of 215 (46-60) receiving upadacitinib 30 mg (p<0 0001 for both doses vs continued methotrexate). Methotrexate 83-95 C-reactive protein Homo sapiens 6-9 24304551-7 2014 Patients with C-reactive protein >=2.0 mg/L had a decreased release of post-PCI TnI in the rosuvastatin group (0.032 [0.010 to 0.143] mug/L vs 0.056 [0.018 to 0.241] mug/L; p = 0.04). Rosuvastatin Calcium 94-106 C-reactive protein Homo sapiens 14-32 16331433-5 2005 Adjusted for age, race, and case-control status, mean CRP was 2-fold greater in the highest vs. lowest quartiles of estrone and androstenedione, and CRP was 2-fold less across quartiles of sex hormone binding globulin. Estrone 116-123 C-reactive protein Homo sapiens 54-57 15668660-6 2005 Bivariate analysis showed a significant inverse association between CRP and many nutrients (e.g., carbohydrates, proteins, lipids, thiamine, pyridoxine, tocopherol, and folate), but multiple-regression analysis indicated that only the effect of dietary folate intake was not dependent on other factors. Tocopherols 153-163 C-reactive protein Homo sapiens 68-71 31164826-13 2019 DNJ significantly reduced the levels of hs-CRP, IL-6, TNF-a, MDA, SAS, HAMD, AP, and BSS scores and increased SOD level (p < 0.05). 1-Deoxynojirimycin 0-3 C-reactive protein Homo sapiens 43-46 15541272-1 2004 Natural IgM antibodies against phosphorylcholine (anti-Pc IgM) resemble C-reactive protein (CRP) regarding specificity and have gained increasing attention because of their supposed role in clearance of damaged cells and in cardiovascular disease. Phosphorylcholine 31-48 C-reactive protein Homo sapiens 72-90 15541272-1 2004 Natural IgM antibodies against phosphorylcholine (anti-Pc IgM) resemble C-reactive protein (CRP) regarding specificity and have gained increasing attention because of their supposed role in clearance of damaged cells and in cardiovascular disease. Phosphorylcholine 31-48 C-reactive protein Homo sapiens 92-95 23932312-6 2014 RESULTS: At week 52, CRP was inhibited to 4% and 40% of baseline by TCZ8 and TCZ4, respectively. tcz8 68-72 C-reactive protein Homo sapiens 21-24 30988752-0 2019 Effect of the drug combination of magnesium sulfate and phentolamine on homocysteine and C-reactive protein in the serum of patients with pregnancy-induced hypertension syndrome. Phentolamine 56-68 C-reactive protein Homo sapiens 89-107 24882949-5 2014 RESULTS: Plasma suPAR levels were significantly increased in infected neonates upon admission, whereas they were highest in septic neonates, in comparison with controls (P < 0.001) and correlated positively with serum CRP levels (P = 0.001). supar 16-21 C-reactive protein Homo sapiens 221-224 24102179-10 2013 CRP levels were found to be a strong prognostic factor for DSS in CC. dss 59-62 C-reactive protein Homo sapiens 0-3 23662928-7 2013 Two patients with an elevated C-reactive protein at the time of thiopurine addition demonstrated a fall in C-reactive protein. 2-mercaptopyrazine 64-74 C-reactive protein Homo sapiens 30-48 23662928-7 2013 Two patients with an elevated C-reactive protein at the time of thiopurine addition demonstrated a fall in C-reactive protein. 2-mercaptopyrazine 64-74 C-reactive protein Homo sapiens 107-125 15791376-6 2004 Serum peak levels of postoperative inflammatory markers (white blood cell count, C-reactive protein, creatine phosphokinase) were lower with C-VATS and an earlier return to normalization than with A-VATS. c-vats 141-147 C-reactive protein Homo sapiens 81-123 15340661-5 2004 RESULTS: The addition of etanercept to MTX resulted in a greater reduction in the number of tender (7.00 vs 2.45, p = 0.012) and swollen joints (8.55 vs 3.86, p = 0.017), and in serum levels of C-reactive protein (1.26 mg/dL vs 0.45 mg/dL, p = 0.014) compared to MTX alone after 12 weeks of therapy. Methotrexate 39-42 C-reactive protein Homo sapiens 194-212 14691439-10 2004 In group 1, CRP elevation was attenuated after tirofiban infusion compared with group 2. Tirofiban 47-56 C-reactive protein Homo sapiens 12-15 29956021-7 2019 The TBS was negatively correlated with age, alkaline phosphatase and C-reactive protein levels, and dialysis vintage, and positively correlated with BMD at the lumbar spine, femoral neck, and hip. tribromsalan 4-7 C-reactive protein Homo sapiens 69-87 14693409-0 2004 Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects. Troglitazone 47-59 C-reactive protein Homo sapiens 18-36 14693409-1 2004 Insulin-sensitizing thiazolidinediones (TZDs) decrease inflammatory markers such as high-sensitive C-reactive protein (hsCRP) in sera in addition to their hypoglycemic effects. Thiazolidinediones 20-38 C-reactive protein Homo sapiens 99-117 14693409-1 2004 Insulin-sensitizing thiazolidinediones (TZDs) decrease inflammatory markers such as high-sensitive C-reactive protein (hsCRP) in sera in addition to their hypoglycemic effects. Thiazolidinediones 40-44 C-reactive protein Homo sapiens 99-117 23512440-9 2013 Beloranib (0.9 mg/m2) was associated with a significant 42 and 18% reduction in triglycerides and LDL-cholesterol, as well as improvement in C-reactive protein and reduced sense of hunger. CKD732 0-9 C-reactive protein Homo sapiens 141-159 23512440-12 2013 CONCLUSIONS: Beloranib treatment was well tolerated and associated with rapid weight loss and improvements in lipids, C-reactive protein, and adiponectin. CKD732 13-22 C-reactive protein Homo sapiens 118-136 29956021-8 2019 Multivariate analysis identified lower estimated glomerular filtration rate and increased C-reactive protein levels as being significantly associated with a low TBS. tribromsalan 161-164 C-reactive protein Homo sapiens 90-108 30293230-3 2019 We evaluated whether the olive-derived polyphenol hydroxytyrosol combined with omega-3 fatty acids and curcumin would reduce CRP and musculoskeletal symptoms in breast cancer patients receiving adjuvant hormonal therapies. polyphenol hydroxytyrosol 39-64 C-reactive protein Homo sapiens 125-128 14609996-0 2003 Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 165-183 23407995-3 2013 When human PBMCs were stimulated in vitro with penicillin-treated Streptococcus pyogenes, bacterial DNA motifs and lipopolysaccharide with or without synthetic CRP, CRP suppressed the production of TNF-alpha and IL-12, but not that of IFN-gamma. Penicillins 47-57 C-reactive protein Homo sapiens 160-163 31406922-3 2019 Aim: To study the effects of PCD on serum levels of C-reactive protein (CRP), IL-6, and IL-10 and its correlation with the outcome. pcd 29-32 C-reactive protein Homo sapiens 52-70 23407995-3 2013 When human PBMCs were stimulated in vitro with penicillin-treated Streptococcus pyogenes, bacterial DNA motifs and lipopolysaccharide with or without synthetic CRP, CRP suppressed the production of TNF-alpha and IL-12, but not that of IFN-gamma. Penicillins 47-57 C-reactive protein Homo sapiens 165-168 12749911-1 2003 C-reactive protein (CRP) is an acute phase protein in humans and rabbits that has the ability to bind a number of biologically important ligands including phosphocholine (PCh), histones, and polycations. Phosphorylcholine 155-169 C-reactive protein Homo sapiens 0-18 12749911-1 2003 C-reactive protein (CRP) is an acute phase protein in humans and rabbits that has the ability to bind a number of biologically important ligands including phosphocholine (PCh), histones, and polycations. Phosphorylcholine 155-169 C-reactive protein Homo sapiens 20-23 12749911-1 2003 C-reactive protein (CRP) is an acute phase protein in humans and rabbits that has the ability to bind a number of biologically important ligands including phosphocholine (PCh), histones, and polycations. Phosphorylcholine 171-174 C-reactive protein Homo sapiens 0-18 12749911-1 2003 C-reactive protein (CRP) is an acute phase protein in humans and rabbits that has the ability to bind a number of biologically important ligands including phosphocholine (PCh), histones, and polycations. Phosphorylcholine 171-174 C-reactive protein Homo sapiens 20-23 12634320-0 2003 Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site. Phosphorylcholine 73-90 C-reactive protein Homo sapiens 45-48 12634320-10 2003 Chem., 277, 225-232], whereas binding of sugar phosphates by neo-CRP shows considerably less stringent requirements compared to native CRP. Sugar Phosphates 41-57 C-reactive protein Homo sapiens 65-68 23874811-6 2013 Anti-CRP antibody was patterned on PMMA foil by the developed method and bonded permanently with R2R hot embossed PMMA microchannels by solvent bonding lamination. Polymethyl Methacrylate 35-39 C-reactive protein Homo sapiens 5-8 23874811-6 2013 Anti-CRP antibody was patterned on PMMA foil by the developed method and bonded permanently with R2R hot embossed PMMA microchannels by solvent bonding lamination. Polymethyl Methacrylate 114-118 C-reactive protein Homo sapiens 5-8 12218140-2 2002 CRP also binds, in a PCh-inhibitable manner, to ligands that do not contain PCh, such as fibronectin (Fn). Phosphorylcholine 76-79 C-reactive protein Homo sapiens 0-3 31406922-3 2019 Aim: To study the effects of PCD on serum levels of C-reactive protein (CRP), IL-6, and IL-10 and its correlation with the outcome. pcd 29-32 C-reactive protein Homo sapiens 72-75 12218140-3 2002 Crystallographic data on CRP-PCh complexes indicate that Phe(66) and Glu(81) contribute to the formation of the PCh binding site of CRP. Phosphorylcholine 29-32 C-reactive protein Homo sapiens 25-28 12218140-3 2002 Crystallographic data on CRP-PCh complexes indicate that Phe(66) and Glu(81) contribute to the formation of the PCh binding site of CRP. Phosphorylcholine 29-32 C-reactive protein Homo sapiens 132-135 31406922-13 2019 Percentage decrease in IL-6 on day 3 and CRP on day 7 correlated with the outcome of patients managed with PCD. pcd 107-110 C-reactive protein Homo sapiens 41-44 12218140-3 2002 Crystallographic data on CRP-PCh complexes indicate that Phe(66) and Glu(81) contribute to the formation of the PCh binding site of CRP. Phosphorylcholine 112-115 C-reactive protein Homo sapiens 25-28 30610443-10 2019 Effect size increase in serum creatine kinase (CK) activity, CK-MB and C-reactive protein concentrations was less in PRO than CHO (Cohen"s d mean +- SD, PRO: 2.91 +- 2.07; CHO: 7.56 +- 4.81, p = 0.046). cho 126-129 C-reactive protein Homo sapiens 71-89 12218140-3 2002 Crystallographic data on CRP-PCh complexes indicate that Phe(66) and Glu(81) contribute to the formation of the PCh binding site of CRP. Phosphorylcholine 112-115 C-reactive protein Homo sapiens 132-135 12218140-4 2002 We used site-directed mutagenesis to analyze the contribution of Phe(66) and Glu(81) to the binding of CRP to PCh, and to generate a CRP mutant that does not bind to PCh-containing ligands. Phosphorylcholine 110-113 C-reactive protein Homo sapiens 103-106 12218140-10 2002 We conclude that Phe(66) is the major determinant of CRP-PCh interaction and is critical for binding of CRP to PnC. Phosphorylcholine 57-60 C-reactive protein Homo sapiens 53-56 12218140-11 2002 The data also suggest that the binding sites for PCh and Fn on CRP are distinct. Phosphorylcholine 49-52 C-reactive protein Homo sapiens 63-66 12218140-12 2002 A CRP mutant incapable of binding to PCh provides a tool to assess PCh-inhibitable interactions of CRP with its other biologically significant ligands, and to further investigate the functions of CRP in host defense and inflammation. Phosphorylcholine 37-40 C-reactive protein Homo sapiens 2-5 12218140-12 2002 A CRP mutant incapable of binding to PCh provides a tool to assess PCh-inhibitable interactions of CRP with its other biologically significant ligands, and to further investigate the functions of CRP in host defense and inflammation. Phosphorylcholine 67-70 C-reactive protein Homo sapiens 2-5 12218140-12 2002 A CRP mutant incapable of binding to PCh provides a tool to assess PCh-inhibitable interactions of CRP with its other biologically significant ligands, and to further investigate the functions of CRP in host defense and inflammation. Phosphorylcholine 67-70 C-reactive protein Homo sapiens 99-102 12218140-12 2002 A CRP mutant incapable of binding to PCh provides a tool to assess PCh-inhibitable interactions of CRP with its other biologically significant ligands, and to further investigate the functions of CRP in host defense and inflammation. Phosphorylcholine 67-70 C-reactive protein Homo sapiens 99-102 12654086-6 2002 Whereas CRP increased macrophage responses to phosphorylcholine coated erythrocytes, no significant alteration in tumour necrosis factor-alpha, interleukin (IL)-10 or IL-12 production from PBMs was observed between CRP opsonized or unopsonized L. donovani promastigotes. Phosphorylcholine 46-63 C-reactive protein Homo sapiens 8-11 23971370-0 2013 [Complete remission by sorafenib for local reccurence of renal cell carcinoma with a tempraly elevation of C-reactive protein: a case report]. Sorafenib 23-32 C-reactive protein Homo sapiens 107-125 23971370-2 2013 A tempraly elevation of serum C-reactive protein (CRP) appeared on administration of sorafenib and decrease of vascularity of the tumor was found on CT. After 13 months of sorafenib administration the recurrent tumor disappeared completely and serum CRP was normalized concomitantly. Sorafenib 85-94 C-reactive protein Homo sapiens 30-48 23971370-2 2013 A tempraly elevation of serum C-reactive protein (CRP) appeared on administration of sorafenib and decrease of vascularity of the tumor was found on CT. After 13 months of sorafenib administration the recurrent tumor disappeared completely and serum CRP was normalized concomitantly. Sorafenib 85-94 C-reactive protein Homo sapiens 50-53 23971370-2 2013 A tempraly elevation of serum C-reactive protein (CRP) appeared on administration of sorafenib and decrease of vascularity of the tumor was found on CT. After 13 months of sorafenib administration the recurrent tumor disappeared completely and serum CRP was normalized concomitantly. Sorafenib 172-181 C-reactive protein Homo sapiens 30-48 23971370-2 2013 A tempraly elevation of serum C-reactive protein (CRP) appeared on administration of sorafenib and decrease of vascularity of the tumor was found on CT. After 13 months of sorafenib administration the recurrent tumor disappeared completely and serum CRP was normalized concomitantly. Sorafenib 172-181 C-reactive protein Homo sapiens 50-53 23971370-2 2013 A tempraly elevation of serum C-reactive protein (CRP) appeared on administration of sorafenib and decrease of vascularity of the tumor was found on CT. After 13 months of sorafenib administration the recurrent tumor disappeared completely and serum CRP was normalized concomitantly. Sorafenib 172-181 C-reactive protein Homo sapiens 250-253 23280928-10 2013 A statistical study revealed close correlation between ASP, body mass index, and highly sensitive C-reactive protein. Aspartic Acid 55-58 C-reactive protein Homo sapiens 98-116 24008003-0 2013 Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immuncomplex production in patients with systemic sclerosis--a prospective case-series study. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 77-80 12417066-6 2002 CRP was higher in the CAD patients with CPB than in the control group after operation [(12.89 +/- 0.29) pg/ml vs. (12.00 +/- 0.31) pg/ml, P < 0.05]. cpb 40-43 C-reactive protein Homo sapiens 0-3 24008003-11 2013 CONCLUSIONS: Six-month rosuvastatin therapy improves endothelial function and lowers CRP, C3, C4 and IC levels indicating possible favourable effects of this statin on the cardiovascular and immune system in SSc. Rosuvastatin Calcium 23-35 C-reactive protein Homo sapiens 85-88 29728047-0 2019 Label-Free Specific Detection and Collection of C-Reactive Protein Using Zwitterionic Phosphorylcholine-Polymer-Protected Magnetic Nanoparticles. Phosphorylcholine 86-103 C-reactive protein Homo sapiens 48-66 23432014-0 2013 Protein-directed immobilization of phosphocholine ligands on a gold surface for multivalent C-reactive protein binding. Phosphorylcholine 35-49 C-reactive protein Homo sapiens 92-110 29728047-1 2019 In this study, poly[2-methacryloyloxyethyl phosphorylcholine (MPC)]-protected Fe3O4 nanoparticles were prepared and used for the label-free specific detection and collection of an acute inflammation marker, C-reactive protein (CRP), in a simulated body fluid. ferryl iron 78-83 C-reactive protein Homo sapiens 207-225 23432014-2 2013 CRP consisting of five identical, noncovalently linked subunits and having five phosphocholine-binding sites on the same face was complexed with 12-mercaptododecylphosphocholine. Phosphorylcholine 80-94 C-reactive protein Homo sapiens 0-3 29728047-1 2019 In this study, poly[2-methacryloyloxyethyl phosphorylcholine (MPC)]-protected Fe3O4 nanoparticles were prepared and used for the label-free specific detection and collection of an acute inflammation marker, C-reactive protein (CRP), in a simulated body fluid. ferryl iron 78-83 C-reactive protein Homo sapiens 227-230 12083784-0 2002 Secretory production of recombinant human C-reactive protein in Escherichia coli, capable of binding with phosphorylcholine, and its characterization. Phosphorylcholine 106-123 C-reactive protein Homo sapiens 42-60 29728047-5 2019 After coming into contact with CRP, the nanoparticles aggregated as CRP comprises five subunits, and each subunit can bind to a phosphorylcholine group with two free Ca2+ ions. Phosphorylcholine 128-145 C-reactive protein Homo sapiens 31-34 29728047-5 2019 After coming into contact with CRP, the nanoparticles aggregated as CRP comprises five subunits, and each subunit can bind to a phosphorylcholine group with two free Ca2+ ions. Phosphorylcholine 128-145 C-reactive protein Homo sapiens 68-71 29728047-11 2019 CRP-containing aqueous solutions were treated with poly(MPC)-protected Fe3O4. ferryl iron 71-76 C-reactive protein Homo sapiens 0-3 23244537-0 2012 Flaxseed oil supplementation decreases C-reactive protein levels in chronic hemodialysis patients. Linseed Oil 0-12 C-reactive protein Homo sapiens 39-57 29728047-12 2019 After poly(MPC)-protected Fe3O4 nanoparticles were separated using a neodymium magnet and centrifugation, the concentration of CRP in the media dramatically decreased. ferryl iron 26-31 C-reactive protein Homo sapiens 127-130 11874944-12 2002 Troglitazone therapy was associated with increases in LDL size (26.21 +/- 0.22 to 26.56 +/- 0.25 nm; P=0.04) and HDL cholesterol (33 +/- 3 to 36 +/- 3 mg/dl; P=0.05) and decreases in triglycerides (197 +/- 19 to 155 +/- 23 mg/dl; P=0.07) and C-reactive protein by 60% (8 +/- 3 to 3 +/- 1 mg/l, P < 0.01) [corrected]. Troglitazone 0-12 C-reactive protein Homo sapiens 242-260 24383779-7 2001 We treated the patient with prednisolone and warfarin, which resulted in an improvement in CRP levels and no thrombosis-related complications. Warfarin 45-53 C-reactive protein Homo sapiens 91-94 30678193-8 2019 Within group analysis showed that the plasma levels of CRP, MDA, and OxLDL decreased numerically by 25%, 3%, and 11%, respectively after 12 weeks of tart cherry juice consumption compared with corresponding baseline values. tart cherry juice 149-166 C-reactive protein Homo sapiens 55-58 11532280-1 2001 C-reactive protein (CRP) is an acute-phase protein featuring a homopentameric structure and Ca-binding specificity for phosphocholine (PCh). Phosphorylcholine 119-133 C-reactive protein Homo sapiens 0-18 11532280-1 2001 C-reactive protein (CRP) is an acute-phase protein featuring a homopentameric structure and Ca-binding specificity for phosphocholine (PCh). Phosphorylcholine 119-133 C-reactive protein Homo sapiens 20-23 11532280-1 2001 C-reactive protein (CRP) is an acute-phase protein featuring a homopentameric structure and Ca-binding specificity for phosphocholine (PCh). Phosphorylcholine 135-138 C-reactive protein Homo sapiens 0-18 11532280-1 2001 C-reactive protein (CRP) is an acute-phase protein featuring a homopentameric structure and Ca-binding specificity for phosphocholine (PCh). Phosphorylcholine 135-138 C-reactive protein Homo sapiens 20-23 11532280-4 2001 The wide distribution of PCh in polysaccharides of pathogens and in cellular membranes allows CRP to recognize a range of pathogenic targets as well as membranes of damaged and necrotic host cells. Phosphorylcholine 25-28 C-reactive protein Homo sapiens 94-97 30642376-5 2019 RESULTS: DAS-28 and CRP decreased significantly after initiation of MTX therapy. Methotrexate 68-71 C-reactive protein Homo sapiens 20-23 11260477-1 2001 Streptococcus pneumoniae is a major human pathogen and many interactions of this bacterium with its host appear to be mediated, directly or indirectly, by components of the bacterial cell wall, specifically by the phosphorylcholine residues which serve as anchors for surface-located choline-binding proteins and are also recognized by components of the host response, such as the human C-reactive protein, a class of myeloma proteins and PAF receptors. Phosphorylcholine 214-231 C-reactive protein Homo sapiens 387-405 29868945-8 2018 A multivariate regression analysis revealed that younger age, male sex, and the peak CRP level were significant predictors of the minimum PaO2/FiO2 ratio (P = 0.01, 0.035 and 0.005, respectively). pao2 138-142 C-reactive protein Homo sapiens 85-88 30516330-11 2018 Elderly patients with CD and patients with normal pretreatment CRP level may have a reduced response to MTX. Methotrexate 104-107 C-reactive protein Homo sapiens 63-66 11036451-11 2000 Significantly more patients treated with penicillin achieved normal CRP values than those receiving placebo, respectively 88% and 75%. Penicillins 41-51 C-reactive protein Homo sapiens 68-71 10959695-8 2000 Incubation of plasma with heparin and protamine in vitro generated complement-CRP complexes, which was blocked by phosphorylcholine and stimulated by exogenous CRP. Phosphorylcholine 114-131 C-reactive protein Homo sapiens 78-81 30130674-2 2018 A previous study found that increased C-reactive protein (CRP), a marker of systemic inflammation, is associated with worse response to the serotonergic antidepressant escitalopram and better response to the noradrenergic antidepressant nortriptyline. Nortriptyline 237-250 C-reactive protein Homo sapiens 38-56 10709157-0 2000 Higher incidence of elevated body temperature or increased C-reactive protein level in asthmatic children showing transient reduction of theophylline metabolism. Theophylline 137-149 C-reactive protein Homo sapiens 59-77 10709157-8 2000 Acute febrile illness accompanied by increased CRP level may affect theophylline metabolism. Theophylline 68-80 C-reactive protein Homo sapiens 47-50 30130674-2 2018 A previous study found that increased C-reactive protein (CRP), a marker of systemic inflammation, is associated with worse response to the serotonergic antidepressant escitalopram and better response to the noradrenergic antidepressant nortriptyline. Nortriptyline 237-250 C-reactive protein Homo sapiens 58-61 10788542-6 2000 Significant differences between the drugs in favour of MTX were found only in patient"s pain score, CRP and ESR. Methotrexate 55-58 C-reactive protein Homo sapiens 100-103 30130674-6 2018 RESULTS: A higher polygenic risk score for CRP was associated with slightly better response to escitalopram and slightly worse response to nortriptyline, reflected in a statistically significant interaction between polygenic risk score and drug (beta = 1.07, 95% CI = 0.26-1.87, p = 0.0093). Nortriptyline 139-152 C-reactive protein Homo sapiens 43-46 30180459-2 2018 Methods: A cohort of 182 AML (non-APL) patients undergoing MSDT in HCR was retrospectively studied [including complete remission with ANC and PLT recovery (CR), CR with incomplete PLT recovery (CRp), CR with inconplete ANC and PLT recovery (CRi)]; ICR was determined as undetective minimal resudial disease (MRD) by multi-parameter flow cytometer. msdt 59-63 C-reactive protein Homo sapiens 68-70 10791621-6 2000 We obtained a good and relatively prompt clinical response except for peripheral arthritis and iridocyclitis; in fact, after 3 months of methotrexate treatment a significant amelioration of the following parameters was observed: visual analogue scale for the evaluation of both night pain and general well-being, Shober"s test, occiput-wall distance, fingertip to floor, erythrocyte sedimentation rate, C-reactive protein level and daily dose of indomethacin. Methotrexate 137-149 C-reactive protein Homo sapiens 403-421 29850124-11 2018 Regarding perioperative administration of sivelestat sodium hydrate, the postoperative arterial oxygen partial pressure-to-fractional inspired oxygen ratio (P/F) and C-reactive protein (CRP) levels in the administration group were significantly better than those in the non-administration group on postoperative days 4 (P=0.035) and 5 (P=0.037), respectively. Sivelestat sodium 42-59 C-reactive protein Homo sapiens 166-184 10521363-8 1999 Binding was Ca(2+)-dependent and inhibitable by phosphorylcholine, and the complement-activating property of E-LDL was destroyed by treatment with phospholipase C. These results indicated that CRP binds to phosphorylcholine groups that become exposed in enzymatically degraded LDL particles. Phosphorylcholine 48-65 C-reactive protein Homo sapiens 193-196 10521363-8 1999 Binding was Ca(2+)-dependent and inhibitable by phosphorylcholine, and the complement-activating property of E-LDL was destroyed by treatment with phospholipase C. These results indicated that CRP binds to phosphorylcholine groups that become exposed in enzymatically degraded LDL particles. Phosphorylcholine 206-223 C-reactive protein Homo sapiens 193-196 29850124-11 2018 Regarding perioperative administration of sivelestat sodium hydrate, the postoperative arterial oxygen partial pressure-to-fractional inspired oxygen ratio (P/F) and C-reactive protein (CRP) levels in the administration group were significantly better than those in the non-administration group on postoperative days 4 (P=0.035) and 5 (P=0.037), respectively. Sivelestat sodium 42-59 C-reactive protein Homo sapiens 186-189 29471485-10 2018 In the multivariate analyses, ESR, CRP and spinal radiographic progression were significantly associated with TBS. tribromsalan 110-113 C-reactive protein Homo sapiens 35-38 10225812-9 1999 A significant 40% to 70% improvement of all parameters (erythrocyte sedimentation rate, C reactive protein, swollen and tender joints, radiological progression) compared with baseline was observed in patients completing their randomised treatment with gold or methotrexate. Methotrexate 260-272 C-reactive protein Homo sapiens 88-106 29330312-1 2018 OBJECTIVE: To determine the relationship of high-sensitive C-reactive protein (hsCRP) and the efficacy and safety of dual antiplatelet therapy in patients with and without intracranial arterial stenosis (ICAS) in the Clopidogrel in High-Risk Patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial. Clopidogrel 217-228 C-reactive protein Homo sapiens 59-77 9851262-12 1998 CONCLUSION: Early "aggressive" drug treatment, using sulphasalazine and/or methotrexate, aimed at reduction of the CRP level, significantly reduces the (rate of) radiographic progression in RA. Methotrexate 75-87 C-reactive protein Homo sapiens 115-118 8977209-0 1997 Site-directed mutagenesis of the phosphocholine-binding site of human C-reactive protein: role of Thr76 and Trp67. Phosphorylcholine 33-47 C-reactive protein Homo sapiens 70-88 8977209-1 1997 We have reported previously that residues Lys57, Arg58, and Trp67 of human C-reactive protein (CRP) contribute to the structure of the phosphocholine (PCh)-binding site. Phosphorylcholine 135-149 C-reactive protein Homo sapiens 75-93 8977209-1 1997 We have reported previously that residues Lys57, Arg58, and Trp67 of human C-reactive protein (CRP) contribute to the structure of the phosphocholine (PCh)-binding site. Phosphorylcholine 135-149 C-reactive protein Homo sapiens 95-98 8977209-1 1997 We have reported previously that residues Lys57, Arg58, and Trp67 of human C-reactive protein (CRP) contribute to the structure of the phosphocholine (PCh)-binding site. Phosphorylcholine 151-154 C-reactive protein Homo sapiens 75-93 8977209-1 1997 We have reported previously that residues Lys57, Arg58, and Trp67 of human C-reactive protein (CRP) contribute to the structure of the phosphocholine (PCh)-binding site. Phosphorylcholine 151-154 C-reactive protein Homo sapiens 95-98 8977209-2 1997 In this study, based on the three-dimensional structures of human CRP and serum amyloid P, we constructed an additional mutant, T76Y, to probe the structural determinants of the PCh-binding site of CRP. Phosphorylcholine 178-181 C-reactive protein Homo sapiens 198-201 29599672-13 2018 Conclusions: Methotrexate in low doses in short-term treatment decreases CRP (anti-inflammatory effect) and increases endocan and IL-10 (potential protective role). Methotrexate 13-25 C-reactive protein Homo sapiens 73-76 18475716-6 1996 Phosphorylcholine abolished the inhibitory activity of CRP but not of SAP or lactoferrin. Phosphorylcholine 0-17 C-reactive protein Homo sapiens 55-58 29972824-8 2018 Only patients without additional tinzaparin had a reduction of -C-reactive protein (CRP) at 2 months of cHD (p < 0.05) but not later. Tinzaparin 33-43 C-reactive protein Homo sapiens 64-82 7485521-0 1995 Phosphocholine reverses inhibition of pulmonary surfactant adsorption caused by C-reactive protein. Phosphorylcholine 0-14 C-reactive protein Homo sapiens 80-98 7485521-4 1995 The effect of CRP required the presence of calcium and was reversed by the addition of phosphocholine in a concentration-dependent manner. Phosphorylcholine 87-101 C-reactive protein Homo sapiens 14-17 7485521-5 1995 The inhibition of surfactant adsorption by CRP was effectively eliminated by the addition of phosphocholine at a molar ratio of 300:1 (phosphocholine:CRP), but it was not diminished by the addition of identical molar ratios of o-phosphoethanolamine or DL-alpha-glycerophosphate at the same molar ratios. Phosphorylcholine 93-107 C-reactive protein Homo sapiens 43-46 7485521-5 1995 The inhibition of surfactant adsorption by CRP was effectively eliminated by the addition of phosphocholine at a molar ratio of 300:1 (phosphocholine:CRP), but it was not diminished by the addition of identical molar ratios of o-phosphoethanolamine or DL-alpha-glycerophosphate at the same molar ratios. Phosphorylcholine 93-107 C-reactive protein Homo sapiens 150-153 7485521-5 1995 The inhibition of surfactant adsorption by CRP was effectively eliminated by the addition of phosphocholine at a molar ratio of 300:1 (phosphocholine:CRP), but it was not diminished by the addition of identical molar ratios of o-phosphoethanolamine or DL-alpha-glycerophosphate at the same molar ratios. Phosphorylcholine 135-149 C-reactive protein Homo sapiens 43-46 7485521-6 1995 These data suggest that the potent inhibition of surfactant adsorption by CRP is primarily a result of a specific interaction between CRP and the phosphocholine headgroup of surfactant lipids in the subphase and that it can be reversed by the water-soluble CRP ligand, phosphocholine. Phosphorylcholine 146-160 C-reactive protein Homo sapiens 74-77 7485521-6 1995 These data suggest that the potent inhibition of surfactant adsorption by CRP is primarily a result of a specific interaction between CRP and the phosphocholine headgroup of surfactant lipids in the subphase and that it can be reversed by the water-soluble CRP ligand, phosphocholine. Phosphorylcholine 146-160 C-reactive protein Homo sapiens 134-137 7485521-6 1995 These data suggest that the potent inhibition of surfactant adsorption by CRP is primarily a result of a specific interaction between CRP and the phosphocholine headgroup of surfactant lipids in the subphase and that it can be reversed by the water-soluble CRP ligand, phosphocholine. Phosphorylcholine 146-160 C-reactive protein Homo sapiens 134-137 7485521-6 1995 These data suggest that the potent inhibition of surfactant adsorption by CRP is primarily a result of a specific interaction between CRP and the phosphocholine headgroup of surfactant lipids in the subphase and that it can be reversed by the water-soluble CRP ligand, phosphocholine. Phosphorylcholine 269-283 C-reactive protein Homo sapiens 74-77 25340109-2 2012 In this study we sought to examine the association of the levels of serum C-reactive protein (CRP) with value of CaxPO4 product, in stable hemodialysis patients. caxpo4 113-119 C-reactive protein Homo sapiens 94-97 25340109-10 2012 A significant positive correlation of logarithm of serum CRP with CaxPO4 product was found. caxpo4 66-72 C-reactive protein Homo sapiens 57-60 29972824-8 2018 Only patients without additional tinzaparin had a reduction of -C-reactive protein (CRP) at 2 months of cHD (p < 0.05) but not later. Tinzaparin 33-43 C-reactive protein Homo sapiens 84-87 29273276-6 2018 In 221 individuals aged 42.0 +- 12.3 years, classification in the highest aldosterone tertile was associated with the highest levels of blood pressure (BP), PWV, and high-sensitivity C-reactive protein (P < .05 for all). Aldosterone 74-85 C-reactive protein Homo sapiens 183-201 22874505-7 2012 In contrast, alkaline phosphatase, lactate dehydrogenase and C-reactive protein levels were significantly higher in the short-term DOC group. Docetaxel 131-134 C-reactive protein Homo sapiens 61-79 7620766-1 1995 The developed enzyme immunoassay of C-reactive protein is based on the use of a plane modified by a phosphorylcholine derivative lisolecithin. Phosphorylcholine 100-117 C-reactive protein Homo sapiens 36-54 29021852-5 2017 Logistic regression analysis showed that, as compared with the lowest suPAR quartile, the highest suPAR quartile was associated with NPAF with an odds ratio of 6.48 (95% confidence interval, 1.71-24.5) after adjustment for sex, age, log(eGFR), C-reactive protein, and systolic blood pressure. supar 98-103 C-reactive protein Homo sapiens 244-262 22278047-2 2012 The 2009 JUPITER trial showed a significant decrease in DVT in non-hyperlipidemic patients, with elevated C-reactive protein (CRP) levels, treated with rosuvastatin. Rosuvastatin Calcium 152-164 C-reactive protein Homo sapiens 106-124 22278047-2 2012 The 2009 JUPITER trial showed a significant decrease in DVT in non-hyperlipidemic patients, with elevated C-reactive protein (CRP) levels, treated with rosuvastatin. Rosuvastatin Calcium 152-164 C-reactive protein Homo sapiens 126-129 22555227-0 2012 Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 37-55 28952295-8 2017 The improvement of white blood cells and CRP levels of the amoxicillin and clavulanate potassium group was more obvious than that of the ceftezole sodium group (P<0.05). Amoxicillin 59-70 C-reactive protein Homo sapiens 41-44 22555227-1 2012 The aim of this study was to study the effects of rosuvastatin in patients with rheumatoid arthritis (RA) looking at the C-reactive protein (CRP), interleukin-6 (IL-6) and joint disease activity. Rosuvastatin Calcium 50-62 C-reactive protein Homo sapiens 121-139 22555227-1 2012 The aim of this study was to study the effects of rosuvastatin in patients with rheumatoid arthritis (RA) looking at the C-reactive protein (CRP), interleukin-6 (IL-6) and joint disease activity. Rosuvastatin Calcium 50-62 C-reactive protein Homo sapiens 141-144 21983163-8 2012 And also, both dosing regimens significantly decreased serum concentrations of CRP, which had an 18.3% reduction in once-daily dosing and a 16.7% reduction in alternate-day dosing of rosuvastatin (p>0.05). Rosuvastatin Calcium 183-195 C-reactive protein Homo sapiens 79-82 21602258-3 2012 The plasma levels of CRP, P-selectin, sCD40L, IL-6 was higher in 65 (18.5%) patients with clopidogrel resistance than in those with normal responsiveness at 6 months after PCI. Clopidogrel 90-101 C-reactive protein Homo sapiens 21-24 8808186-6 1995 After MTX and CTX therapy CRP level significantly decreased. Methotrexate 6-9 C-reactive protein Homo sapiens 26-29 7979374-6 1994 Both SAP and CRP displayed a similar binding preference for PC vs phosphoethanolamine (PE). Phosphorylcholine 60-62 C-reactive protein Homo sapiens 13-16 8348281-4 1993 MTX (5 mg) induced a significant effect on the Ritchie joint index, morning stiffness, pain, ESR and C-reactive protein. Methotrexate 0-3 C-reactive protein Homo sapiens 101-119 28513744-0 2017 High-affinity recognition of the human C-reactive protein independent of phosphocholine. Phosphorylcholine 73-87 C-reactive protein Homo sapiens 39-57 7685226-1 1993 Four independent studies have investigated and compared the effects of tenidap sodium, naproxen and placebo on CRP in patients with active RA. tenidap 71-85 C-reactive protein Homo sapiens 111-114 1624792-7 1992 Comparing various mono-, di-, and trisaccharides as competitive inhibitors of the lectin binding activity of CRP, only beta-D-Gal-(1-3)-D-GalNAc, beta-D-Gal-(1-4)-D-GalNAc, and beta-D-Gal-(1-4)-beta-D-Gal-(1-4)-D-GlcNAc had significant inhibitory power at a concentration of 8 mmol/liter. beta-d-gal-(1-3)-d-galnac 119-144 C-reactive protein Homo sapiens 109-112 22848795-10 2012 For instance, greater use of SSS was associated with elevated VCAM-1 (P < 0.001) and CRP (P = 0.001) levels in subjects with low levels of perceived social support and positive affect, respectively. sss 29-32 C-reactive protein Homo sapiens 88-91 28513744-3 2017 With the exception of antibodies, most molecular constructs take advantage of the known affinity for CRP of phosphocholine that depends on Ca2+ for its ability to bind. Phosphorylcholine 108-122 C-reactive protein Homo sapiens 101-104 21627458-3 2012 The aim of the present study is to assess over a period of 6 months the effect of non-surgical periodontal therapy on serum levels of high-sensitivity C-reactive protein (hsCRP), d-8-iso prostaglandin F2a (d-8-iso) as a marker of oxidative stress, and matrix metalloproteinase (MMP)-2 and MMP-9 on patients with type 2 DM. Deuterium 26-27 C-reactive protein Homo sapiens 151-169 28096464-2 2017 CRP, in its native pentameric structural conformation, binds to cells and molecules that have exposed phosphocholine (PCh) groups. Phosphorylcholine 102-116 C-reactive protein Homo sapiens 0-3 21689722-7 2011 By site-directed mutagenesis, we determined H284 in the N-acetylglucosamine (GlcNAc)-binding pocket of the FBG, to be the critical CRP-binding residue. Acetylglucosamine 56-75 C-reactive protein Homo sapiens 131-134 21689722-7 2011 By site-directed mutagenesis, we determined H284 in the N-acetylglucosamine (GlcNAc)-binding pocket of the FBG, to be the critical CRP-binding residue. Acetylglucosamine 77-83 C-reactive protein Homo sapiens 131-134 1327798-6 1992 Although fever, leucocytosis and elevated CRP and ESR were significantly correlated with abnormal 99mTc DMSA scan, they were also observed in children without renal parenchymal involvement. Succimer 104-108 C-reactive protein Homo sapiens 42-45 28096464-2 2017 CRP, in its native pentameric structural conformation, binds to cells and molecules that have exposed phosphocholine (PCh) groups. Phosphorylcholine 118-121 C-reactive protein Homo sapiens 0-3 21689722-8 2011 This conformational switch involving H284, explains how the pathophysiologically-driven FBG:CRP interaction diverts the M-ficolin away from GlcNAc/pathogen-recognition to host protein-protein interaction, thus enabling the host to regain homeostatic control. Acetylglucosamine 140-146 C-reactive protein Homo sapiens 92-95 28096464-3 2017 CRP, in its non-native pentameric structural conformation, binds to a variety of deposited, denatured, and aggregated proteins, in addition to binding to PCh-containing substances. Phosphorylcholine 154-157 C-reactive protein Homo sapiens 0-3 28096464-7 2017 Using oxidized LDL as a representative protein ligand for H2O2-treated CRP, we found that the binding occurred in a Ca2+-independent manner and did not involve the PCh-binding site of CRP. Phosphorylcholine 164-167 C-reactive protein Homo sapiens 71-74 28208713-6 2017 In subjects with high systemic inflammation at baseline (serum C-reactive protein (CRP) >=3.0 mg/mL) who were supplemented with the F&amp;V juice concentrate (n = 16), these effects were greater, with decreased total cholesterol, LDL cholesterol and plasma TNFalpha and increased total lean mass; plasma CRP was unchanged by the F&amp;V juice concentrate following both analyses. f& 135-140 C-reactive protein Homo sapiens 311-314 21708910-8 2011 In methotrexate-experienced trials, no significant change was observed over the years included in this study in any inclusion criteria (including swollen joint counts and C-reactive protein (CRP)), but a significant decrease over time was observed in the baseline swollen joint count, CRP and total Sharp or van der Heijde modified Sharp score, but not in baseline tender joint counts. Methotrexate 3-15 C-reactive protein Homo sapiens 171-189 21708910-8 2011 In methotrexate-experienced trials, no significant change was observed over the years included in this study in any inclusion criteria (including swollen joint counts and C-reactive protein (CRP)), but a significant decrease over time was observed in the baseline swollen joint count, CRP and total Sharp or van der Heijde modified Sharp score, but not in baseline tender joint counts. Methotrexate 3-15 C-reactive protein Homo sapiens 191-194 21708910-8 2011 In methotrexate-experienced trials, no significant change was observed over the years included in this study in any inclusion criteria (including swollen joint counts and C-reactive protein (CRP)), but a significant decrease over time was observed in the baseline swollen joint count, CRP and total Sharp or van der Heijde modified Sharp score, but not in baseline tender joint counts. Methotrexate 3-15 C-reactive protein Homo sapiens 285-288 1343562-8 1992 During infection the size of the defect on the DMSA scan correlated with renal volume and C-reactive protein and inversely with the glomerular filtration rate, and at follow-up it correlated inversely with the renal concentration capacity. Succimer 47-51 C-reactive protein Homo sapiens 90-108 1717553-4 1991 Three of the 5 mAb inhibited the Ca(2+)-dependent phosphorylcholine-(PC) binding activity of CRP, but did not bind to the PC-binding region itself. Phosphorylcholine 50-67 C-reactive protein Homo sapiens 93-96 1645189-6 1991 This result differs from the Raman spectroscopy study of CRP and CRP.cAMP2 cocrystals [DeGrazia et al. camp2 69-74 C-reactive protein Homo sapiens 57-60 1645189-6 1991 This result differs from the Raman spectroscopy study of CRP and CRP.cAMP2 cocrystals [DeGrazia et al. camp2 69-74 C-reactive protein Homo sapiens 65-68 1645189-8 1991 The latter work showed spectral differences between CRP and CRP.cAMP2 consistent with alterations in the protein conformation. camp2 64-69 C-reactive protein Homo sapiens 52-55 1645189-8 1991 The latter work showed spectral differences between CRP and CRP.cAMP2 consistent with alterations in the protein conformation. camp2 64-69 C-reactive protein Homo sapiens 60-63 27706798-7 2017 NI-0101 prevented cytokine release following ex vivo and in vivo LPS administration and prevented the C-reactive protein (CRP) increase and the occurrence of flu-like symptoms expected following the in vivo administration of LPS. NI-0101 0-7 C-reactive protein Homo sapiens 102-120 1645189-9 1991 These studies indicate that CRP and CRP.cAMP1 in solution are similar in structure and differ from CRP.cAMP2 cocrystals. camp2 103-108 C-reactive protein Homo sapiens 36-39 1645189-9 1991 These studies indicate that CRP and CRP.cAMP1 in solution are similar in structure and differ from CRP.cAMP2 cocrystals. camp2 103-108 C-reactive protein Homo sapiens 36-39 1989977-1 1991 C-reactive protein (CRP) is an acute phase inflammatory protein in man which binds to phosphocholine, chromatin, histones, and the 70-kDa protein of the U1 small nuclear ribonucleoprotein particle in a calcium-dependent, phosphocholine-inhibitable manner. Phosphorylcholine 86-100 C-reactive protein Homo sapiens 0-18 1989977-1 1991 C-reactive protein (CRP) is an acute phase inflammatory protein in man which binds to phosphocholine, chromatin, histones, and the 70-kDa protein of the U1 small nuclear ribonucleoprotein particle in a calcium-dependent, phosphocholine-inhibitable manner. Phosphorylcholine 86-100 C-reactive protein Homo sapiens 20-23 1989977-1 1991 C-reactive protein (CRP) is an acute phase inflammatory protein in man which binds to phosphocholine, chromatin, histones, and the 70-kDa protein of the U1 small nuclear ribonucleoprotein particle in a calcium-dependent, phosphocholine-inhibitable manner. Phosphorylcholine 221-235 C-reactive protein Homo sapiens 0-18 1989977-1 1991 C-reactive protein (CRP) is an acute phase inflammatory protein in man which binds to phosphocholine, chromatin, histones, and the 70-kDa protein of the U1 small nuclear ribonucleoprotein particle in a calcium-dependent, phosphocholine-inhibitable manner. Phosphorylcholine 221-235 C-reactive protein Homo sapiens 20-23 1989977-10 1991 The N-terminal (15 amino acid) fragment of H2A blocked CRP-induced precipitation of phosphocholine-coupled bovine serum albumin and histone H2A, whereas the C-terminal fragment showed no inhibition. Phosphorylcholine 84-98 C-reactive protein Homo sapiens 55-58 21856482-1 2011 BACKGROUND: The JUPITER trial showed that some patients with LDL-cholesterol concentrations less than 3 37 mmol/L (<130 mg/dL) and high-sensitivity C-reactive protein (hsCRP) concentrations of 2 mg/L or more benefit from treatment with rosuvastatin, although absolute rates of cardiovascular events were low. Rosuvastatin Calcium 239-251 C-reactive protein Homo sapiens 151-169 21422984-3 2011 We examined the effect of pravastatin and rosuvastatin on CRP levels in 58 dyslipidemic HIV-infected patients. Rosuvastatin Calcium 42-54 C-reactive protein Homo sapiens 58-61 21239684-8 2011 CONCLUSION: Elevated suPAR levels were associated with increased risk of incident respiratory cancer and other types of cancer, but not gastrointestinal cancers, independently of established risk factors, CRP, and leukocyte numbers. supar 21-26 C-reactive protein Homo sapiens 205-208 2022721-3 1991 Serum levels of CRP showed an inverse correlation (rs = -0.37; P less than 0.05) with phosphocholine (PC)-containing filarial antigen that was present in the circulation of patients with bancroftian filariasis. Phosphorylcholine 86-100 C-reactive protein Homo sapiens 16-19 27706798-7 2017 NI-0101 prevented cytokine release following ex vivo and in vivo LPS administration and prevented the C-reactive protein (CRP) increase and the occurrence of flu-like symptoms expected following the in vivo administration of LPS. NI-0101 0-7 C-reactive protein Homo sapiens 122-125 2022721-3 1991 Serum levels of CRP showed an inverse correlation (rs = -0.37; P less than 0.05) with phosphocholine (PC)-containing filarial antigen that was present in the circulation of patients with bancroftian filariasis. Phosphorylcholine 102-104 C-reactive protein Homo sapiens 16-19 21352592-8 2011 In the MTX group patients with a mean CRP of >= 10 mg/l lost significantly more DXR-MCI than patients with low CRP (-3.1% vs. -1.9%, p <0.01) whereas in the combination group no significant differences between the two CRP groups was seen (-2.4% vs. -2.0%, p = 0.48). Methotrexate 7-10 C-reactive protein Homo sapiens 38-41 27537400-0 2016 Overall prognostic impact of C-reactive protein level in patients with metastatic renal cell carcinoma treated with sorafenib. Sorafenib 116-125 C-reactive protein Homo sapiens 29-47 21262998-9 2011 C-reactive protein was reduced by 57% (95% confidence interval, -81 to -6%; P<0.05) in patients treated with losmapimod compared with placebo. 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-N-(2,2-dimethylprpyl)-3-pyridinecarboxamide 112-122 C-reactive protein Homo sapiens 0-18 21257003-2 2011 Our purpose was to compare the effects of maximum doses of rosuvastatin and atorvastatin on the plasma levels of the insulin, glycated albumin, adiponectin, and C-reactive protein compared to baseline in hyperlipidemic patients. Rosuvastatin Calcium 59-71 C-reactive protein Homo sapiens 161-179 21257003-7 2011 Both atorvastatin and rosuvastatin caused significant (p <0.001) and similar median reductions in the C-reactive protein level of -40% and -26% compared to the baseline values. Rosuvastatin Calcium 22-34 C-reactive protein Homo sapiens 105-123 21257003-9 2011 In conclusion, our data have indicated that the maximum dosage of atorvastatin or rosuvastatin therapy significantly lower C-reactive protein levels but also moderately increase insulin levels. Rosuvastatin Calcium 82-94 C-reactive protein Homo sapiens 123-141 2227796-0 1990 Binding of low density lipoprotein (LDL) to C-reactive protein (CRP): a possible binding through apolipoprotein B in LDL at phosphorylcholine-binding site of CRP. Phosphorylcholine 124-141 C-reactive protein Homo sapiens 44-62 2227796-0 1990 Binding of low density lipoprotein (LDL) to C-reactive protein (CRP): a possible binding through apolipoprotein B in LDL at phosphorylcholine-binding site of CRP. Phosphorylcholine 124-141 C-reactive protein Homo sapiens 64-67 2227796-0 1990 Binding of low density lipoprotein (LDL) to C-reactive protein (CRP): a possible binding through apolipoprotein B in LDL at phosphorylcholine-binding site of CRP. Phosphorylcholine 124-141 C-reactive protein Homo sapiens 158-161 27537400-2 2016 The aim of the present study was to investigate the overall prognostic impact of CRP in patients with metastatic RCC treated with sorafenib. Sorafenib 130-139 C-reactive protein Homo sapiens 81-84 27537400-10 2016 Pretreatment normal CRP predicted better overall survival in patients with metastatic RCC treated with sorafenib and CRP level may be a useful biomarker for predicting overall survival of patients treated with sorafenib. Sorafenib 103-112 C-reactive protein Homo sapiens 20-23 27537400-10 2016 Pretreatment normal CRP predicted better overall survival in patients with metastatic RCC treated with sorafenib and CRP level may be a useful biomarker for predicting overall survival of patients treated with sorafenib. Sorafenib 210-219 C-reactive protein Homo sapiens 117-120 2395439-0 1990 Binding and immunological properties of a synthetic peptide corresponding to the phosphorylcholine-binding region of C-reactive protein. Phosphorylcholine 81-98 C-reactive protein Homo sapiens 117-135 2395439-1 1990 A synthetic peptide corresponding to amino acid residues 47-63 of human C-reactive protein (CRP) was synthesized and evaluated for its ability to bind phosphorylcholine (PC) and to react with mAb specific for the PC-binding region of CRP. Phosphorylcholine 151-168 C-reactive protein Homo sapiens 72-90 21046291-5 2011 In this review, we focus on the results from the primary prevention statin trial, Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), which showed reductions in LDL, CRP, and cardiovascular events. Rosuvastatin Calcium 175-187 C-reactive protein Homo sapiens 231-234 27522380-10 2016 Hs-CRP and fibrinogen concentration decreased significantly after STTP only in patients with longer MWT at baseline-fourth quartile. sttp 66-70 C-reactive protein Homo sapiens 3-6 20471117-7 2011 High-sensitivity C-reactive protein levels were less elevated in the rosuvastatin group than in the control group at 24 h after PCI. Rosuvastatin Calcium 69-81 C-reactive protein Homo sapiens 17-35 2395439-1 1990 A synthetic peptide corresponding to amino acid residues 47-63 of human C-reactive protein (CRP) was synthesized and evaluated for its ability to bind phosphorylcholine (PC) and to react with mAb specific for the PC-binding region of CRP. Phosphorylcholine 151-168 C-reactive protein Homo sapiens 92-95 2395439-1 1990 A synthetic peptide corresponding to amino acid residues 47-63 of human C-reactive protein (CRP) was synthesized and evaluated for its ability to bind phosphorylcholine (PC) and to react with mAb specific for the PC-binding region of CRP. Phosphorylcholine 170-172 C-reactive protein Homo sapiens 72-90 2395439-1 1990 A synthetic peptide corresponding to amino acid residues 47-63 of human C-reactive protein (CRP) was synthesized and evaluated for its ability to bind phosphorylcholine (PC) and to react with mAb specific for the PC-binding region of CRP. Phosphorylcholine 170-172 C-reactive protein Homo sapiens 92-95 2210970-2 1990 CRP has been known to bind with phosphorylcholine in a calcium-dependent manner. Phosphorylcholine 32-49 C-reactive protein Homo sapiens 0-3 26333108-8 2016 Our results suggest that elevated CRP, particularly in the context of concurrent elevated PGE-M, may be a biomarker of multiple or advanced adenoma risk in a screening age population. Prostaglandins E 90-93 C-reactive protein Homo sapiens 34-37 21324198-10 2011 suPAR serum concentrations measured upon admission were closely and independently correlated to various laboratory parameters, specifically biomarkers of inflammation (tumor necrosis factor (TNF), C-reactive protein (CRP)), hepatic and renal dysfunction. supar 0-5 C-reactive protein Homo sapiens 197-222 20971747-7 2011 CONCLUSION: In primary prevention patients with elevated hs C-reactive protein who have high global cardiovascular risk (10-year Framingham risk score >20% or SCORE risk >=5%), but LDL-C levels not requiring pharmacologic treatment, rosuvastatin 20 mg significantly reduced major cardiovascular events. Rosuvastatin Calcium 239-251 C-reactive protein Homo sapiens 60-78 27597810-10 2016 A significant 73% overall reduction in the hs-CRP level was seen with prasugrel compared with 39% overall reduction in hs-CRP level with clopidogrel (P = 0.002). Clopidogrel 137-148 C-reactive protein Homo sapiens 122-125 34508693-4 2022 RESULTS: In patients with STEMI, inflammation, measured by hs-CRP, was significantly attenuated with losmapimod at 48 hours (p<0.001) and week 12 (p=0.01). 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-N-(2,2-dimethylprpyl)-3-pyridinecarboxamide 101-111 C-reactive protein Homo sapiens 62-65 21921413-4 2011 We determined the efficacy of rosuvastatin by monitoring serum lipid profiles, high sensitivity C-reactive protein (hs-CRP), malondialdehyde-modified LDL (MDA-LDL), and cystatin C levels. Rosuvastatin Calcium 30-42 C-reactive protein Homo sapiens 96-114 26271127-1 2016 We conducted a meta-analysis of 13 randomized trials comparing the efficacy of rosuvastatin versus atorvastatin in reducing concentrations of C-reactive protein (CRP). Rosuvastatin Calcium 79-91 C-reactive protein Homo sapiens 142-160 26271127-1 2016 We conducted a meta-analysis of 13 randomized trials comparing the efficacy of rosuvastatin versus atorvastatin in reducing concentrations of C-reactive protein (CRP). Rosuvastatin Calcium 79-91 C-reactive protein Homo sapiens 162-165 34956579-1 2021 Objective: To investigate the correlation between changes in serum RBP4, hs-CRP, and IL-27 levels and rosuvastatin in the treatment of coronary heart disease (CHD). Rosuvastatin Calcium 102-114 C-reactive protein Homo sapiens 76-79 21267417-9 2010 Rosuvastatin lowers CRP levels significantly. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 20-23 34956579-11 2021 Meanwhile, rosuvastatin can remarkably reduce serum RBP4, hs-CRP, and IL-27 levels, which is of significance for prognosis. Rosuvastatin Calcium 11-23 C-reactive protein Homo sapiens 61-64 26271127-8 2016 Our meta-analysis shows that rosuvastatin produces better reduction in CRP concentrations than atorvastatin at a dose ratio of 1/1 and 1/2 (rosuvastatin/atorvastatin), respectively. Rosuvastatin Calcium 29-41 C-reactive protein Homo sapiens 71-74 27279401-6 2016 The levels of CRP were higher in the Stoppa group (P < 0.05) but the number of leucocytes, haematocrit, and haemoglobin were similar between the groups (P > 0.05). stoppa 37-43 C-reactive protein Homo sapiens 14-17 20506360-5 2010 In patients with RA, F2-isoprostanes were positively correlated with body mass index (P < 0.001), but not with disease activity or mediators of inflammation such as the Disease Activity Score in 28 joints or serum tumor necrosis factor alpha, interleukin-6, and C-reactive protein concentrations in adjusted multivariable models (P > 0.05 for all). F2-Isoprostanes 21-36 C-reactive protein Homo sapiens 265-283 34706549-5 2021 RESULTS: In Cox models adjusted for traditional CVD risk factors, estimated glomerular filtration rate, and CRP (C-reactive protein), each 1-SD higher suPAR was associated with a 21% to 31% increased risk of incident coronary heart disease, heart failure, stroke, and mortality. supar 151-156 C-reactive protein Homo sapiens 108-111 27076371-7 2016 Changes in serum biochemical markers, including C-reactive protein and ferritin, were associated with CRS but failed to predict development of severe CRS. 3-cresol 102-105 C-reactive protein Homo sapiens 48-66 34706549-5 2021 RESULTS: In Cox models adjusted for traditional CVD risk factors, estimated glomerular filtration rate, and CRP (C-reactive protein), each 1-SD higher suPAR was associated with a 21% to 31% increased risk of incident coronary heart disease, heart failure, stroke, and mortality. supar 151-156 C-reactive protein Homo sapiens 113-131 20876875-1 2010 BACKGROUND: Eligibility for rosuvastatin treatment for cardiovascular disease prevention includes a C-reactive protein (CRP) concentration >2 mg/L. Rosuvastatin Calcium 28-40 C-reactive protein Homo sapiens 100-118 20876875-1 2010 BACKGROUND: Eligibility for rosuvastatin treatment for cardiovascular disease prevention includes a C-reactive protein (CRP) concentration >2 mg/L. Rosuvastatin Calcium 28-40 C-reactive protein Homo sapiens 120-123 27144849-6 2016 RESULTS: The concentrations of low-density lipoprotein cholesterol and C-reactive protein after surgery were lower in patients assigned to rosuvastatin than in those assigned to placebo (P<0.001). Rosuvastatin Calcium 139-151 C-reactive protein Homo sapiens 71-89 20876499-4 2010 A recent randomized, clinical trial suggests that the use of rosuvastatin therapy in otherwise healthy patients with high-sensitivity C-reactive protein >2 mg/dL can reduce the risk of a first stroke by 50%. Rosuvastatin Calcium 61-73 C-reactive protein Homo sapiens 134-152 20412373-0 2010 C-reactive protein lowering with rosuvastatin in the METEOR study. Rosuvastatin Calcium 33-45 C-reactive protein Homo sapiens 0-18 34731780-4 2021 RESULTS: The case group, who were on methotrexate therapy, had significantly less severe COVID-19 based on their symptoms, including fever (p = 0.000) and cough and dyspnea (p = 0.01) as well as in terms of COVID-19 severity indicators such as pulmonary involvement (p = 0.001), ferritin level (p = 0.001), white blood cell count (p = 0.008) and CRP level (p = 0.006), compared to the control group. Methotrexate 37-49 C-reactive protein Homo sapiens 346-349 34429160-8 2021 With tofacitinib + MTX, numerically higher baseline CRP levels and numerically larger post-baseline CRP reductions were seen in patients achieving CDAI remission at months 6 and 12 vs those who did not. Methotrexate 19-22 C-reactive protein Homo sapiens 52-55 34429160-8 2021 With tofacitinib + MTX, numerically higher baseline CRP levels and numerically larger post-baseline CRP reductions were seen in patients achieving CDAI remission at months 6 and 12 vs those who did not. Methotrexate 19-22 C-reactive protein Homo sapiens 100-103 20412373-7 2010 Rosuvastatin lowered CRP significantly compared with placebo: -36% in the rosuvastatin group versus no change in the placebo group. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 21-24 20412373-7 2010 Rosuvastatin lowered CRP significantly compared with placebo: -36% in the rosuvastatin group versus no change in the placebo group. Rosuvastatin Calcium 74-86 C-reactive protein Homo sapiens 21-24 34429160-11 2021 High pre-treatment CRP levels may be associated with better response to tofacitinib + MTX. Methotrexate 86-89 C-reactive protein Homo sapiens 19-22 34120186-5 2021 Soluble CD14 (-11%, P < 0.001) and adiponectin (-11%, P < 0.001) significantly declined and high-sensitive C-reactive protein (-13%, P = 0.069) and oxidized LDL (-13%, P = 0.084) tended to decrease with dolutegravir. dolutegravir 203-215 C-reactive protein Homo sapiens 107-125 20412373-11 2010 CONCLUSIONS: Rosuvastatin (40 mg) lowers CRP independently from its effects on LDL-C in low-risk subjects with normal baseline CRP levels and modest CIMT. Rosuvastatin Calcium 13-25 C-reactive protein Homo sapiens 41-44 20819623-0 2010 Salmeterol/fluticasone treatment reduces circulating C-reactive protein level in patients with stable chronic obstructive pulmonary disease. Salmeterol Xinafoate 0-10 C-reactive protein Homo sapiens 53-71 20819623-3 2010 We evaluated the effect of salmeterol/fluticasone propionate on circulating C-reactive protein level in stable chronic obstructive pulmonary disease patients. Salmeterol Xinafoate 27-37 C-reactive protein Homo sapiens 76-94 20819623-9 2010 Compared with ipratropium/albuterol, the combination of salmeterol/fluticasone significantly reduced circulating level of C-reactive protein (-1.73 vs. 0.08 mg/L, respectively, P < 0.05) after 6-month treatment. Salmeterol Xinafoate 56-66 C-reactive protein Homo sapiens 122-140 20819623-11 2010 Salmeterol/fluticasone treatment subjects who had a decrease of circulating C-reactive protein level had a significant improvement in FEV(1) and St George"s Respiratory Questionnaire total scores compared with those who did not (185 vs. 83 ml and -5.71 vs. -1.79 units, respectively, both P < 0.01). Salmeterol Xinafoate 0-10 C-reactive protein Homo sapiens 76-94 26523504-1 2016 For label-free and direct detection of C-reactive protein (CRP), an impedimetric sensor based on an indium tin oxide (ITO) electrode array functionalized with reduced graphene oxide-nanoparticle (rGO-NP) hybrid was fabricated and evaluated. indium tin oxide 100-116 C-reactive protein Homo sapiens 59-62 34385832-12 2021 Multivariate analysis clearly revealed that a high baseline CRP value was an independent favorable predictive factor for longer DCT (hazard ratio, 0.608, 95% CI: 0.378-0.981, P = 0.0416). dct 128-131 C-reactive protein Homo sapiens 60-63 34385832-13 2021 Conclusion: These data clearly demonstrate that the baseline value of CRP was closely associated with long time DCT in patients of RA treated with TCZ. dct 112-115 C-reactive protein Homo sapiens 70-73 27642237-10 2016 There was a negative correlation of CRP with native thiol, total thiol, and native thiol/total thiol ratio while there was a positive correlation of CRP with disulphide/native thiol and disulphide/total thiol in the AA group. disulphide 158-168 C-reactive protein Homo sapiens 149-152 20547900-1 2010 Rosuvastatin prevented ischemic stroke in healthy older adults with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 77-95 27642237-10 2016 There was a negative correlation of CRP with native thiol, total thiol, and native thiol/total thiol ratio while there was a positive correlation of CRP with disulphide/native thiol and disulphide/total thiol in the AA group. disulphide 186-196 C-reactive protein Homo sapiens 149-152 26525102-5 2015 Changes in CRP levels correlated positively with changes in total n-6 FAs in men (r=0.25 p=0.01), but not in women. ammonium ferrous sulfate 70-73 C-reactive protein Homo sapiens 11-14 20206126-0 2010 Cardiac glycosides potently inhibit C-reactive protein synthesis in human hepatocytes. Glycosides 8-18 C-reactive protein Homo sapiens 36-54 20206126-10 2010 The inhibitory activity of cardiac glycosides on CRP expression may have important implications for the treatment of cardiovascular disease. Glycosides 35-45 C-reactive protein Homo sapiens 49-52 20206126-11 2010 Cardiac glycosides may be used for CRP synthesis inhibition in the future. Glycosides 8-18 C-reactive protein Homo sapiens 35-38 20118243-8 2010 Hydrogen-deuterium exchange mass spectrometry mapped distinct sites of GBP that interact with LPS and with CRP, consistent with in silico predictions. Deuterium 9-18 C-reactive protein Homo sapiens 107-110 34297765-6 2021 A significant reduction in C-reactive protein levels (WMD: -0.52 mg/L, 95% CI: -0.73, -0.32, p < 0.001) following tocotrienols supplementation was observed, but this finding was attributed to a single study using delta-tocotrienols, not mixed tocotrienols. tocotrienol, delta 213-231 C-reactive protein Homo sapiens 27-45 34278894-8 2022 Serum inflammatory markers (CRP and NLR) were found to have an inverse relationship with dTAC. dodecyltrimethylammonium 89-93 C-reactive protein Homo sapiens 28-31 26771969-0 2015 Prolonged CRP Increase After Percutaneous Coronary Intervention Is Associated with High Thrombin Concentrations and Low Platelet" Response to Clopidogrel in Patients with Stable Angina. Clopidogrel 142-153 C-reactive protein Homo sapiens 10-13 34221091-11 2021 Additionally, the patients in the PCI + tirofiban group had lower levels of CRP, TNF-alpha, IL-6, and PCT compared with those in the PCI group at days 7 and 30 post-PCI (P < 0.05). Tirofiban 40-49 C-reactive protein Homo sapiens 76-79 19857478-7 2010 Correlation was also found between ThT fluorescence tertiles and LDL-cholesterol, total-cholesterol, and C-reactive protein. thioflavin T 35-38 C-reactive protein Homo sapiens 105-123 26771969-11 2015 It may be advisable to assay post-procedural CRP in each patient with SCAD, who underwent PCI to predict those, with potentially low response to clopidogrel. Clopidogrel 145-156 C-reactive protein Homo sapiens 45-48 35578571-11 2022 In PDAC patients, the high-N-inv group showed poor prognosis (p =0.059) and elevated serum levels of IL-6 and C-reactive protein, synthesis of which is promoted by IL-6, compared to those in the low-N-inv group (p = 0.006 and p = 0.075, respectively). n-inv 27-32 C-reactive protein Homo sapiens 110-128 35578571-11 2022 In PDAC patients, the high-N-inv group showed poor prognosis (p =0.059) and elevated serum levels of IL-6 and C-reactive protein, synthesis of which is promoted by IL-6, compared to those in the low-N-inv group (p = 0.006 and p = 0.075, respectively). n-inv 199-204 C-reactive protein Homo sapiens 110-128 26378955-7 2015 This study provides new insight into the molecular mechanism by which the DMSA-coated nanoparticles resulted in the transcriptional changes of many CRP-coding genes in cells. Succimer 74-78 C-reactive protein Homo sapiens 148-151 35445431-6 2022 Serum levels of APPs, soluble CD14, lipopolysaccharide binding protein, and C-reactive protein, were stabilized during Treg administrations, but rose during the washout period and again after therapy was discontinued. treg 119-123 C-reactive protein Homo sapiens 76-94 20026779-0 2010 Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 85-103 20026779-6 2010 CONCLUSIONS: Rosuvastatin reduces by more than half the incidence of ischemic stroke among men and women with low levels of low-density lipoprotein cholesterol levels who are at risk because of elevated levels of high-sensitivity C-reactive protein. Rosuvastatin Calcium 13-25 C-reactive protein Homo sapiens 230-248 26622860-8 2015 suPAR levels were positively correlated with disease stage (P<0.01), renal function (P<0.05), C-reactive protein (P<0.005), beta2-microglobulin (P<0.001), extramedullary involvement (P<0.001), chromosome 13 deletion (P<0.01) and survival >2 years (P<0.01). supar 0-5 C-reactive protein Homo sapiens 100-118 35466929-6 2022 MTX significantly decreased the levels of PV, ESR, hCRP, and blood pressure (BP) in male patients, and the level of WBV in female patients. Methotrexate 0-3 C-reactive protein Homo sapiens 51-55 35466929-7 2022 CONCLUSION: Sex-specific downregulation of MTX on WBV, PV, hCRP, and BP, indicating that the effect of MTX on the risk of cardiovascular disease was related with sex. Methotrexate 43-46 C-reactive protein Homo sapiens 59-63 35466929-7 2022 CONCLUSION: Sex-specific downregulation of MTX on WBV, PV, hCRP, and BP, indicating that the effect of MTX on the risk of cardiovascular disease was related with sex. Methotrexate 103-106 C-reactive protein Homo sapiens 59-63 35001040-6 2022 Active heroin use was associated with higher lipopolysaccharide binding protein (LBP), beta-D-glucan (BDG), high sensitivity C-reactive protein (hsCRP), soluble tumor necrosis factor-alpha receptors-I and -II, soluble CD163, inflammatory monocytes, and activated CD4+ lymphocytes in adjusted models. Heroin 7-13 C-reactive protein Homo sapiens 125-143 35399851-0 2022 Clinical Study of Clopidogrel Combined with Huoxue Tongluo Prescription in Improving Transient Ischemic Attack and the Effect on MMP-9, Hcy, and CRP. Clopidogrel 18-29 C-reactive protein Homo sapiens 145-148 35399851-1 2022 Background: This study aimed to explore the clinical study of clopidogrel combined with Huoxue Tongluo prescription in improving transient ischemic attack (TIA) and the effect on MMP-9, Hcy, and CRP. Clopidogrel 62-73 C-reactive protein Homo sapiens 195-198 26060322-8 2015 SF levels of both cathepsins correlated with DAS28 and CRP in ACPA- and RF-positive but not in seronegative patients. sulforaphane 0-2 C-reactive protein Homo sapiens 55-58 35399851-12 2022 Conclusion: Clopidogrel combined with Huoxue Tongluo prescription can significantly improve the therapeutic effect and reduce the levels of MMP-9, Hcy, and CRP in patients with TIA. Clopidogrel 12-23 C-reactive protein Homo sapiens 156-159 35368750-9 2022 TG adjuvant MTX also reduced the expression rate of the swollen joint count, tender joint count, erythrocyte sedimentation rate, rheumatoid factor, and C-reactive protein in subgroup analyses with different courses and doses. Methotrexate 12-15 C-reactive protein Homo sapiens 152-170 35407370-0 2022 Cardiac Glycosides Lower C-Reactive Protein Plasma Levels in Patients with Decompensated Heart Failure: Results from the Single-Center C-Reactive Protein-Digoxin Observational Study (C-DOS). Glycosides 8-18 C-reactive protein Homo sapiens 25-43 35131596-11 2022 CONCLUSION: Treatment with amisulpride, aripiprazole and olanzapine showed different effects on CRP levels in patients with schizophrenia spectrum disorders, modified by previous antipsychotics exposure status. Amisulpride 27-38 C-reactive protein Homo sapiens 96-99 26270967-2 2015 We measure the dynamic effective relaxation time taueff(t) and use scanning electron microscopy (SEM) and transmission electron microscopy (TEM) to investigate the C-reactive protein (CRP) as it associates with the BMN Fe3O4-antiCRP to form the magnetic cluster Fe3O4-antiCRP-CRP. ferryl iron 219-224 C-reactive protein Homo sapiens 164-182 26270967-2 2015 We measure the dynamic effective relaxation time taueff(t) and use scanning electron microscopy (SEM) and transmission electron microscopy (TEM) to investigate the C-reactive protein (CRP) as it associates with the BMN Fe3O4-antiCRP to form the magnetic cluster Fe3O4-antiCRP-CRP. ferryl iron 219-224 C-reactive protein Homo sapiens 184-187 35142908-4 2022 The filgotinib 200 mg + MTX and upadacitinib 15 mg + MTX groups showed a significantly higher DAS28-CRP < 2.6 than adalimumab 40 mg + MTX. Methotrexate 24-27 C-reactive protein Homo sapiens 100-103 35142908-4 2022 The filgotinib 200 mg + MTX and upadacitinib 15 mg + MTX groups showed a significantly higher DAS28-CRP < 2.6 than adalimumab 40 mg + MTX. Methotrexate 53-56 C-reactive protein Homo sapiens 100-103 26270967-5 2015 After the association, SEM and TEM images show that CRP and Fe3O4-antiCRP conjugate to form Fe3O4-antiCRP-CRP clusters hundreds of nanometers in size. ferryl iron 60-65 C-reactive protein Homo sapiens 70-73 26270967-5 2015 After the association, SEM and TEM images show that CRP and Fe3O4-antiCRP conjugate to form Fe3O4-antiCRP-CRP clusters hundreds of nanometers in size. ferryl iron 92-97 C-reactive protein Homo sapiens 52-55 26270967-5 2015 After the association, SEM and TEM images show that CRP and Fe3O4-antiCRP conjugate to form Fe3O4-antiCRP-CRP clusters hundreds of nanometers in size. ferryl iron 92-97 C-reactive protein Homo sapiens 70-73 25669317-4 2015 The aim of this study was to systematically review randomized controlled trials (RCTs) that report on the effects of vitamin E supplementation (alpha- and gamma-tocopherols) on CRP levels. alpha- and gamma-tocopherols 144-172 C-reactive protein Homo sapiens 177-180 34996820-4 2022 The study was continued to gather clinical follow up information up to four months.Results: Serum level of hs-CRP was significantly lower in the ketorolac group compared with the control group on days 3, 4, and 5. Ketorolac 145-154 C-reactive protein Homo sapiens 110-113 26051510-8 2015 In an analysis by BMI, overweight and obese women had higher biomarker levels than normal weight women; the trend was significant for CRP (P trend< 0.001) and gamma-tocopherol (P trend= 0.003) but not for F2-isoprostane (P trend= 0.14). F2-Isoprostanes 208-222 C-reactive protein Homo sapiens 134-137 26311995-6 2015 CRP levels significantly decreased from beginning to the end of 4 weeks in both atorvastatin and rosuvastatin groups (from 35.48 to 23.07 mg/l and from 35.88 to 19.91 mg/l respectively, both P < 0.001). Rosuvastatin Calcium 97-109 C-reactive protein Homo sapiens 0-3 26311995-7 2015 However, there was significant difference between the levels of CRP in patients of the rosuvastatin group as compared to the atorvastatin group (19.91 +- 6.32 vs 23.07 +- 7.47, P < 0.05). Rosuvastatin Calcium 87-99 C-reactive protein Homo sapiens 64-67 26311995-9 2015 CONCLUSION: Both atorvastatin (40 mg) and rosuvastatin (20 mg) are effective in decreasing CRP and LDL cholesterol levels even in a short duration of 4 weeks. Rosuvastatin Calcium 42-54 C-reactive protein Homo sapiens 91-94 26311995-10 2015 Rosuvastatin was found to be more effective in decreasing CRP levels. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 58-61 25896330-11 2015 CONCLUSIONS: Evidence of an association between C reactive protein and indoor PM2.5 among healthy adults in traffic-impacted areas is consistent with the hypothesis that traffic-related particles, even at relatively low concentrations, play an important role in the cardiovascular effects of the urban PM mixture. Promethium 78-80 C-reactive protein Homo sapiens 48-66 25922102-13 2015 However, while incorporating CRP into CURB-65 yielded a significant category-free net reclassification improvement of 0.387 (95% CI 0.193 to 0.582) and integrated discrimination improvement of 0.015 (95% CI 0.004 to 0.027), DCA showed that CURB-65 and the modified CURB-65 score had comparable net benefits for prediction of mortality. dichloroacetylene 224-227 C-reactive protein Homo sapiens 29-32 25548320-4 2015 Without antiplatelet antibodies, CRP was found to be inert toward platelets, but it bound to phosphorylcholine exposed after oxidation triggered by antiplatelet antibodies, thereby enhancing platelet phagocytosis. Phosphorylcholine 93-110 C-reactive protein Homo sapiens 33-36 25399887-13 2015 Furthermore, the ERK inhibitor pd98059 (30 mumol/L) and the JNK inhibitor sp600125 (10 mumol/L) blocked CRP-induced COX-1 and COX-2 expression for 12 h. Together, the findings of the present study suggest that CRP can promote the development of the no-reflow phenomenon by increasing COX-1 and COX-2 expression, which is regulated, in part, via ERK and JNK activity. pyrazolanthrone 74-82 C-reactive protein Homo sapiens 104-107 25399887-13 2015 Furthermore, the ERK inhibitor pd98059 (30 mumol/L) and the JNK inhibitor sp600125 (10 mumol/L) blocked CRP-induced COX-1 and COX-2 expression for 12 h. Together, the findings of the present study suggest that CRP can promote the development of the no-reflow phenomenon by increasing COX-1 and COX-2 expression, which is regulated, in part, via ERK and JNK activity. pyrazolanthrone 74-82 C-reactive protein Homo sapiens 210-213 25367713-6 2015 For abatacept plus MTX versus MTX, DAS28 (CRP) <2.6 was achieved in 60.9% versus 45.2% (p=0.010) at 12 months, and following treatment withdrawal, in 14.8% versus 7.8% (p=0.045) at both 12 and 18 months. Methotrexate 19-22 C-reactive protein Homo sapiens 42-45 25599732-1 2015 INTRODUCTION: Leukocyte count, erythrocyte sediment rate and C-reactive protein are available laboratory markers which may be helpful in prediction of technetium Tc 99m dimercaptosuccinic acid (DMSA) renal scintigraphy results. Succimer 194-198 C-reactive protein Homo sapiens 61-79 25017001-7 2014 For patients with low levels of CRP (<1 mg/L), improvement on the MADRS score was 3 points higher with escitalopram than with nortriptyline. Nortriptyline 129-142 C-reactive protein Homo sapiens 32-35 20533245-6 2010 There was no significant effect on performance, energy metabolism, or any other measured parameter, except for CRP, which was significantly reduced (p = 0.045) after GTE supplementation compared to placebo. gte 166-169 C-reactive protein Homo sapiens 111-114 25017001-8 2014 For patients with higher CRP levels, improvement on the MADRS score was 3 points higher with nortriptyline than with escitalopram. Nortriptyline 93-106 C-reactive protein Homo sapiens 25-28 25397920-2 2014 The biomarkers are the human C-reactive protein (CRP) while the BMNs are the anti-CRP bound onto dextran-coated Fe3O4 particles labeled as Fe3O4-antiCRP. ferryl iron 112-117 C-reactive protein Homo sapiens 82-85 20132066-8 2010 Patients with a C-reactive protein (CRP) level>300 nmol/L had an earlier MTX treatment start compared with patients with a moderate CRP level (adjusted IRR 1.36, 95% CI 1.16-1.73). Methotrexate 76-79 C-reactive protein Homo sapiens 16-34 20132066-8 2010 Patients with a C-reactive protein (CRP) level>300 nmol/L had an earlier MTX treatment start compared with patients with a moderate CRP level (adjusted IRR 1.36, 95% CI 1.16-1.73). Methotrexate 76-79 C-reactive protein Homo sapiens 36-39 25397920-2 2014 The biomarkers are the human C-reactive protein (CRP) while the BMNs are the anti-CRP bound onto dextran-coated Fe3O4 particles labeled as Fe3O4-antiCRP. ferryl iron 139-144 C-reactive protein Homo sapiens 82-85 25374024-3 2014 Curcuminoids supplementation led to significant decreases in serum A-FABP, C-reactive protein (CRP), tumor necrosis factor-alpha, and interleukin-6 levels. curcuminoids 0-12 C-reactive protein Homo sapiens 95-98 24692836-18 2009 CONCLUSION: Rosuvastatin treatment was associated with significant reductions in plasma concentrations of TC, LDL-C, and TG, urine and plasma oxidative stress markers, and plasma hs-CRP in these hypercholesterolemic patients. Rosuvastatin Calcium 12-24 C-reactive protein Homo sapiens 182-185 25159238-9 2014 After rosuvastatin therapy, serum total cholesterol, low-density lipoprotein cholesterol, and high-sensitivity C-reactive protein significantly decreased from 222 +- 18 to 142 +- 20 mg/dl, 148 +- 21 to 85 +- 18 mg/dl, and 1.7 +- 2.9 to 1.2 +- 3.1 mg/L, respectively (all p <0.01). Rosuvastatin Calcium 6-18 C-reactive protein Homo sapiens 111-129 20083077-10 2009 High-sensitive C-reactive protein was higher in the TCFA group (0.32 +/- 0.32 mg/dl vs. 0.17 +/- 0.16 mg/dl, p < 0.001). tcfa 52-56 C-reactive protein Homo sapiens 15-33 25087591-3 2014 The sum of n-6 EMFAs, without linoleic acid (LA), was positively associated with concentrations of CRP and IL-1Ra (r partial=0.139 and r partial=0.115, P<0.001). n-6 emfas 11-20 C-reactive protein Homo sapiens 99-102 20083077-15 2009 By stepwise regression, the ring-like enhancement, high-sensitive C-reactive protein, and diagnosis of acute events were associated with the presence of TCFA at the culprit site. tcfa 153-157 C-reactive protein Homo sapiens 66-84 25005327-7 2014 The treatment benefit of golimumab + MTX vs. MTX monotherapy was most pronounced within the subsets of patients with CRP >=3.0 mg/dL and SJC >= 20/TJC >= 12. Methotrexate 37-40 C-reactive protein Homo sapiens 117-120 19755356-1 2009 Rosuvastatin reduced venous thromboembolism in healthy older adults with elevated C-reactive protein levels. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 82-100 25005327-7 2014 The treatment benefit of golimumab + MTX vs. MTX monotherapy was most pronounced within the subsets of patients with CRP >=3.0 mg/dL and SJC >= 20/TJC >= 12. Methotrexate 45-48 C-reactive protein Homo sapiens 117-120 28839766-10 2014 In discriminating quiescent from active disease (FC>100 mug/g) the sensitivity and specificity of CRP were 0.48 (0.36-0.61) and 0.73 (0.6-0.85), and in mild from moderate or active disease (FC>250 mug/g), 0.60 (0.43-0.74) and (0.72 (0.60-0.82). fc> 49-54 C-reactive protein Homo sapiens 101-104 19726772-8 2009 Levels of total cholesterol, low-density lipoprotein cholesterol, interleukin-6, and C-reactive protein were significantly decreased in the fluvastatin group but were unchanged in the placebo group. Fluvastatin 140-151 C-reactive protein Homo sapiens 85-103 19410579-7 2009 Intraluminal administration of a pathophysiological level of CRP (7 microg/mL, 60 min) attenuated vasodilations to serotonin and AA but not to nitroprusside, exogenous PGI(2), or hydrogen peroxide (endothelium-dependent PGE(2) activator). Nitroprusside 143-156 C-reactive protein Homo sapiens 61-64 19410579-7 2009 Intraluminal administration of a pathophysiological level of CRP (7 microg/mL, 60 min) attenuated vasodilations to serotonin and AA but not to nitroprusside, exogenous PGI(2), or hydrogen peroxide (endothelium-dependent PGE(2) activator). Prostaglandins E 220-223 C-reactive protein Homo sapiens 61-64 28839766-10 2014 In discriminating quiescent from active disease (FC>100 mug/g) the sensitivity and specificity of CRP were 0.48 (0.36-0.61) and 0.73 (0.6-0.85), and in mild from moderate or active disease (FC>250 mug/g), 0.60 (0.43-0.74) and (0.72 (0.60-0.82). fc> 193-198 C-reactive protein Homo sapiens 101-104 19352723-1 2009 The aim of this study was to test our hypothesis that the urinary excretion of C-reactive protein (CRP), alpha 1-microglobulin (A1M), retinol-binding protein (RBP) and Clara cell protein (CC16) is increased in children with urinary tract infection (UTI) and relates to renal damage as measured by acute dimercaptosuccinic acid (DMSA) scintigraphy. Succimer 303-326 C-reactive protein Homo sapiens 79-97 24399680-0 2014 A new high-sensitive nephelometric method for assaying serum C-reactive protein based on phosphocholine interaction. Phosphorylcholine 89-103 C-reactive protein Homo sapiens 61-79 19352723-1 2009 The aim of this study was to test our hypothesis that the urinary excretion of C-reactive protein (CRP), alpha 1-microglobulin (A1M), retinol-binding protein (RBP) and Clara cell protein (CC16) is increased in children with urinary tract infection (UTI) and relates to renal damage as measured by acute dimercaptosuccinic acid (DMSA) scintigraphy. Succimer 328-332 C-reactive protein Homo sapiens 79-97 24399680-2 2014 Since CRP is able to bind phospholipids (mainly phosphocholine) in the presence of calcium ions, we explored the possibilities of developing a high-sensitive affordable nephelometric CRP assay based on diluted soy oil emulsions. Phosphorylcholine 48-62 C-reactive protein Homo sapiens 6-9 24410968-0 2014 Rosuvastatin can block pro-inflammatory actions of transgenic human C-reactive protein without reducing its circulating levels. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 68-86 19490202-4 2009 DISCUSSION: Thiazolidinediones attenuate circulating levels of pro-inflammatory mediators in patients with type 2 diabetes, including C-reactive protein, interleukin-6, CD40L, monocyte chemoattractant protein-1 and metalloproteinase-9. Thiazolidinediones 12-30 C-reactive protein Homo sapiens 134-152 24410968-3 2014 Here, we investigated whether rosuvastatin could block pro-inflammatory effects of human CRP without reducing circulating levels of human CRP. Rosuvastatin Calcium 30-42 C-reactive protein Homo sapiens 89-92 19226172-2 2009 When phosphocholine is appended to the protein-binding face this supramolecular assembly binds multivalently to the pentameric human C-reactive protein, a biomolecule implicated in inflammation and heart disease. Phosphorylcholine 5-19 C-reactive protein Homo sapiens 133-151 24410968-6 2014 In the CRP-transgenic strain, we found that rosuvastatin treatment decreased circulating levels of inflammatory response markers IL6 and TNFalpha without decreasing circulating levels of human CRP. Rosuvastatin Calcium 44-56 C-reactive protein Homo sapiens 7-10 24410968-8 2014 Rosuvastatin also reduced cardiac inflammation and oxidative tissue damage, reduced epididymal fat mass, and improved adipose tissue lipolysis much more in the CRP-transgenic strain than in the nontransgenic strain. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 160-163 19236874-2 2009 The present paper describes a robust and sensitive ELISA for CRP, based on the affinity of CRP for phosphocholine. Phosphorylcholine 99-113 C-reactive protein Homo sapiens 61-64 19236874-2 2009 The present paper describes a robust and sensitive ELISA for CRP, based on the affinity of CRP for phosphocholine. Phosphorylcholine 99-113 C-reactive protein Homo sapiens 91-94 19236874-4 2009 CRP present in a sample binds to the phosphocholine moiety presented at high density in the coating layer and is detectable by specific antibodies. Phosphorylcholine 37-51 C-reactive protein Homo sapiens 0-3 19306526-8 2009 The recently published JUPITER trial shows that patients with an elevated C-reactive protein benefit from treatment with a statin (rosuvastatin 20 mg) for primary prevention. Rosuvastatin Calcium 131-143 C-reactive protein Homo sapiens 74-92 24410968-9 2014 CONCLUSION: Rosuvastatin can protect against pro-inflammatory effects of human CRP in a manner that is not dependent on achieving a reduction in circulating levels of human CRP. Rosuvastatin Calcium 12-24 C-reactive protein Homo sapiens 79-82 24552299-2 2014 To enable the parallel detection of the differently abundant analytes, the low binding affinity between CRP and phosphocholine is exploited in a "low-sensitive" sandwich assay for CRP. Phosphorylcholine 112-126 C-reactive protein Homo sapiens 104-107 18481276-8 2009 The model was used to investigate how on-treatment CRP related to baseline CRP and estimated treatment effects with rosuvastatin. Rosuvastatin Calcium 116-128 C-reactive protein Homo sapiens 51-54 18481276-11 2009 There was also evidence of a dose-response relationship between CRP reductions from baseline and rosuvastatin. Rosuvastatin Calcium 97-109 C-reactive protein Homo sapiens 64-67 19271272-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 19271273-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 19271274-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 24552299-2 2014 To enable the parallel detection of the differently abundant analytes, the low binding affinity between CRP and phosphocholine is exploited in a "low-sensitive" sandwich assay for CRP. Phosphorylcholine 112-126 C-reactive protein Homo sapiens 180-183 23975559-6 2014 CRP and NIHSS were correlated with each other (r (2) = 0.39, P < 0.001) and were also independently associated with increased risk of mortality [odds ratios (95 % confidence interval) of 1.16 (1.05-1.28) and 1.20 (1.07-1.35) for CRP and NIHSS, respectively, P < 0.01]. nihss 8-13 C-reactive protein Homo sapiens 232-235 19271275-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 19271276-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 19271277-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 24429405-6 2014 Levels of suPAR significantly correlated in an inverse manner with eGFR (r=-0.36) and directly with C-reactive protein (r=0.20). supar 10-15 C-reactive protein Homo sapiens 100-118 19271278-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 19161294-7 2009 For the CRP assay, neutravidin-coated PQQ-doped PMMA nanospheres are used to bind with a biotinylated reporter antibody directed toward CRP. Polymethyl Methacrylate 48-52 C-reactive protein Homo sapiens 8-11 19161294-7 2009 For the CRP assay, neutravidin-coated PQQ-doped PMMA nanospheres are used to bind with a biotinylated reporter antibody directed toward CRP. Polymethyl Methacrylate 48-52 C-reactive protein Homo sapiens 136-139 24410000-7 2014 A peptide library constructed with D-amino acids was applied to screening against a clinically significant biomarker, C-reactive protein (CRP). d-amino acids 35-48 C-reactive protein Homo sapiens 118-136 19271446-0 2009 [Less vascular risk with rosuvastatin in elevated CRP]. Rosuvastatin Calcium 25-37 C-reactive protein Homo sapiens 50-53 24410000-7 2014 A peptide library constructed with D-amino acids was applied to screening against a clinically significant biomarker, C-reactive protein (CRP). d-amino acids 35-48 C-reactive protein Homo sapiens 138-141 25269199-13 2014 Slow dynamics of the number of swollen joints compared with CRP may be due to the low cumulative dose of methotrexate. Methotrexate 105-117 C-reactive protein Homo sapiens 60-63 19951408-10 2009 In the MTX group, ESR and CRP decreased. Methotrexate 7-10 C-reactive protein Homo sapiens 26-29 25138778-4 2014 CRP was analyzed as a categorical and continuous variable for the prediction of recurrence-free survival (RFS), disease-specific survival (DSS) and all-cause survival (ACS) using uni- and multivariate Cox regression analyses. dss 139-142 C-reactive protein Homo sapiens 0-3 19329405-10 2009 At 26-week, the MMS group also had significantly lower serum concentrations of CRP compared with that of baseline and the placebo group (p < 0.05). Methyl Methanesulfonate 16-19 C-reactive protein Homo sapiens 79-82 25138778-7 2014 In a multivariable Cox regression model adjusted for features significant in univariable analysis, categorized and continuous CRP levels were both independent predictors for RFS [hazard ratio (HR) 1.18, p = 0.050; HR 1.03, p = 0.012] and DSS (HR 1.61, p = 0.026; HR 1.06, p = 0.001). dss 238-241 C-reactive protein Homo sapiens 126-129 23754245-8 2013 Serum C-reactive protein (CRP), plasma IL-6, and DAS28 decreased significantly (p <0.001) after MTX treatment, but plasma TNF-alpha did not. Methotrexate 99-102 C-reactive protein Homo sapiens 6-24 21701608-3 2009 In healthy subjects with normal LDL cholesterol and elevated C-reactive protein, rosuvastatin treatment significantly decreased the incidence of cardiovascular events. Rosuvastatin Calcium 81-93 C-reactive protein Homo sapiens 61-79 19436657-7 2009 In addition, rosuvastatin has been found effective in reducing small-dense LDL, C-reactive protein and in increasing HDL cholesterol levels. Rosuvastatin Calcium 13-25 C-reactive protein Homo sapiens 80-98 23754245-8 2013 Serum C-reactive protein (CRP), plasma IL-6, and DAS28 decreased significantly (p <0.001) after MTX treatment, but plasma TNF-alpha did not. Methotrexate 99-102 C-reactive protein Homo sapiens 26-29 23913404-10 2013 Other observed effects of colesevelam in combination with other lipid-lowering drugs include reductions in apolipoprotein (apo) B (with statins, fibrates, ezetimibe, statin plus niacin, or statin plus ezetimibe) and high-sensitivity C-reactive protein (with statins), and increases in apo A-I (with statins, ezetimibe, or statins plus niacin). Colesevelam Hydrochloride 26-37 C-reactive protein Homo sapiens 233-251 18972590-6 2008 The median CRP (C-reactive protein) level was found to be significantly lower 1 week after administering the first dose of MTX (8.9mg/dL vs. 1.2mg/dL, p < 0.001). Methotrexate 123-126 C-reactive protein Homo sapiens 11-14 18972590-6 2008 The median CRP (C-reactive protein) level was found to be significantly lower 1 week after administering the first dose of MTX (8.9mg/dL vs. 1.2mg/dL, p < 0.001). Methotrexate 123-126 C-reactive protein Homo sapiens 16-34 17991470-7 2008 Endothelium-independent vasodilation evaluated by the invasive forearm technique with sodium nitroprusside was also found to be related to both CRP and e-selectin in an inverse way (p=0.005 and p=0.045, respectively). Nitroprusside 86-106 C-reactive protein Homo sapiens 144-147 23956442-4 2013 RESULTS: A sorafenib-induced Hand-Foot skin reaction in metastatic renal cell carcinoma patients was observed at a significantly higher rate in patients in the favorable-risk group in the Memorial Sloan-Kettering Cancer Center risk classification, and with Eastern Cooperative Oncology Group Performance Status of one or less, prior nephrectomy, higher hemoglobin, lower lactate dehydrogenase and lower C-reactive protein. Sorafenib 11-20 C-reactive protein Homo sapiens 403-421 18428198-12 2008 : Elevated plasma CRP concentrations appear to be a strong predictor of poor survival and lower probability of PSA response to treatment in patients with AIPC who are receiving docetaxel-based therapy. Docetaxel 177-186 C-reactive protein Homo sapiens 18-21 18356331-0 2008 Serum C-reactive protein concentrations are inversely associated with dietary flavonoid intake in U.S. adults. Flavonoids 78-87 C-reactive protein Homo sapiens 6-24 18356331-3 2008 We aimed to test the associations between dietary flavonoid intake and serum CRP concentrations among U.S. adults after adjusting for dietary, sociodemographic, and lifestyle factors. Flavonoids 50-59 C-reactive protein Homo sapiens 77-80 18356331-9 2008 Total flavonoid and also individual flavonol, anthocyanidin, and isoflavone intakes were inversely associated with serum CRP concentration after adjusting for the covariates (P < 0.05). 3-hydroxyflavone 36-44 C-reactive protein Homo sapiens 121-124 18356331-10 2008 Among the flavonoid compounds investigated, quercetin, kaempferol, malvidin, peonidin, daidzein, and genistein had inverse associations with serum CRP concentration (P < 0.05). Flavonoids 10-19 C-reactive protein Homo sapiens 147-150 18356331-10 2008 Among the flavonoid compounds investigated, quercetin, kaempferol, malvidin, peonidin, daidzein, and genistein had inverse associations with serum CRP concentration (P < 0.05). Quercetin 44-53 C-reactive protein Homo sapiens 147-150 18356331-12 2008 Our findings demonstrate that intake of dietary flavonoids is inversely associated with serum CRP concentrations in U.S. adults. Flavonoids 48-58 C-reactive protein Homo sapiens 94-97 17959861-7 2008 Additionally, within the group of salsalate-treated subjects, circulating levels of C-reactive protein were reduced by 34% (P < 0.05). salicylsalicylic acid 34-43 C-reactive protein Homo sapiens 84-102 23492986-9 2013 The Hosmer-Lemeshow test P-values of CRP at 48 h after hospital admission for SAP, PNec, and IM were 0.82, 0.47, and 0.24, respectively. BENSULIDE 78-81 C-reactive protein Homo sapiens 37-40 19017467-7 2008 Plasma CRP levels decreased from baseline 3.9 mg/l to 1.1 mg/l in the Pycnogenol group whereas the control group had initial values of 3.9 mg/l which decreased to 3.6 mg/l. pycnogenols 70-80 C-reactive protein Homo sapiens 7-10 17512573-3 2007 RESULTS: CRP was higher in ASV than RSV and HS, and negatively correlated with HDL-cholesterol and Apo-AI. Respiratory Syncytial Virus Vaccines 36-39 C-reactive protein Homo sapiens 9-12 23481452-1 2013 OBJECTIVE: The aim of this study is to compare two biologic parameters; C-reactive protein (CRP) and procalcitonin (PCT) in the detection of acute renal lesions assessed by DMSA scintigraphy in the urinary tract infection in child. Succimer 173-177 C-reactive protein Homo sapiens 72-90 17563829-13 2007 BP reduction with renin-angiotensin system blocker and hydrochlorothiazide therapy reduces LVH while lowering CRP level. Hydrochlorothiazide 55-74 C-reactive protein Homo sapiens 110-113 17535900-7 2007 In human neonates, the infectious marker C-reactive protein was correlated with elevated PGE(2) in the cerebrospinal fluid, and elevated central PGE(2) was associated with an increased apnea frequency. Prostaglandins E 89-92 C-reactive protein Homo sapiens 41-59 23481452-1 2013 OBJECTIVE: The aim of this study is to compare two biologic parameters; C-reactive protein (CRP) and procalcitonin (PCT) in the detection of acute renal lesions assessed by DMSA scintigraphy in the urinary tract infection in child. Succimer 173-177 C-reactive protein Homo sapiens 92-95 17207978-7 2007 Also, through antigen-antibody binding evaluation, the anti-C-reactive protein antibody immobilized on the PMBN surface worked well and it was confirmed that denaturation of the antibody on the PMBN layers was hardly occurred in spite of 60 days storage at 4 degrees C. The antibody conjugated phospholipid polymer layer with well-ordered phosphorylcholine group could be outstanding functional membrane for biomedical diagnostic devices without non-specific binding and reduction of immunologic activity of immobilized antibody. Phosphorylcholine 339-356 C-reactive protein Homo sapiens 60-78 23396741-9 2013 A statistically significant increase was observed in the AFI group with respect to MPV, C-reactive protein (CRP) and white blood cell (WBC) levels. AOQ 57-60 C-reactive protein Homo sapiens 88-106 17087780-6 2006 RESULTS: The free fatty acid (FFA) concentration at the 120-min time-point was associated with baseline alpha-1-acid glycoprotein (A1GP) (r = 0.57, P < 0.01), C-reactive protein (CRP) (r = 0.54, P < 0.02) and serum amyloid A (r = 0.53, P < 0.02); in total they accounted for 54% of the variation in FFA concentration at the 120-min time-point. Fatty Acids, Nonesterified 13-28 C-reactive protein Homo sapiens 162-180 17087780-6 2006 RESULTS: The free fatty acid (FFA) concentration at the 120-min time-point was associated with baseline alpha-1-acid glycoprotein (A1GP) (r = 0.57, P < 0.01), C-reactive protein (CRP) (r = 0.54, P < 0.02) and serum amyloid A (r = 0.53, P < 0.02); in total they accounted for 54% of the variation in FFA concentration at the 120-min time-point. Fatty Acids, Nonesterified 13-28 C-reactive protein Homo sapiens 182-185 17087780-6 2006 RESULTS: The free fatty acid (FFA) concentration at the 120-min time-point was associated with baseline alpha-1-acid glycoprotein (A1GP) (r = 0.57, P < 0.01), C-reactive protein (CRP) (r = 0.54, P < 0.02) and serum amyloid A (r = 0.53, P < 0.02); in total they accounted for 54% of the variation in FFA concentration at the 120-min time-point. Fatty Acids, Nonesterified 30-33 C-reactive protein Homo sapiens 162-180 23396741-9 2013 A statistically significant increase was observed in the AFI group with respect to MPV, C-reactive protein (CRP) and white blood cell (WBC) levels. AOQ 57-60 C-reactive protein Homo sapiens 108-111 17105880-6 2006 A significant decrease in NT-proBNP (p<0.01), high-sensitivity CRP (p<0.01) and plasma IL6 (p = 0.05) was also observed in the levosimendan group, whereas these markers remained unchanged in the placebo group; similar changes were observed after each drug infusion. Simendan 133-145 C-reactive protein Homo sapiens 66-69 23483125-0 2013 Impact of subcutaneous infiltration of 0.5% bupivacaine on post-operative C-reactive protein serum titer after craniotomy surgery. Bupivacaine 44-55 C-reactive protein Homo sapiens 74-92 22573476-8 2013 Intensified lipid-lowering therapy with RSV/EZT was associated with a greater decrease in low-density lipoprotein cholesterol levels compared with RSV (75.87 +- 31.64 vs 87.19 +- 31.7, P = .004), while no differential effect on triglyceride, high-density lipoprotein cholesterol or high-sensitivity C-reactive protein levels was noted between groups. Rosuvastatin Calcium 40-43 C-reactive protein Homo sapiens 299-317 16606653-8 2006 The decrease in beta-CTx was associated with the decrease in Disease Activity Score of 28 joints and C reactive protein during the 0-14 weeks interval. beta-ctx 16-24 C-reactive protein Homo sapiens 101-119 16962105-1 2006 C-reactive protein (CRP) is elevated in cardiovascular disease and binds to oxidized phosphatidylcholine (oxPtC) in the low-density lipoprotein (LDL) surface. oxptc 106-111 C-reactive protein Homo sapiens 0-18 16962105-1 2006 C-reactive protein (CRP) is elevated in cardiovascular disease and binds to oxidized phosphatidylcholine (oxPtC) in the low-density lipoprotein (LDL) surface. oxptc 106-111 C-reactive protein Homo sapiens 20-23 16962105-5 2006 Antioxidant activity of CRP was inhibited by phosphocholine (PC), indicating that the observed activity involves binding of CRP to oxPtC. Phosphorylcholine 45-59 C-reactive protein Homo sapiens 24-27 22520631-0 2012 Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. Docetaxel 146-155 C-reactive protein Homo sapiens 11-29 16962105-5 2006 Antioxidant activity of CRP was inhibited by phosphocholine (PC), indicating that the observed activity involves binding of CRP to oxPtC. Phosphorylcholine 45-59 C-reactive protein Homo sapiens 124-127 16962105-5 2006 Antioxidant activity of CRP was inhibited by phosphocholine (PC), indicating that the observed activity involves binding of CRP to oxPtC. Phosphorylcholine 61-63 C-reactive protein Homo sapiens 24-27 16962105-5 2006 Antioxidant activity of CRP was inhibited by phosphocholine (PC), indicating that the observed activity involves binding of CRP to oxPtC. Phosphorylcholine 61-63 C-reactive protein Homo sapiens 124-127 16552406-12 2006 The levels of CRP (P<0.05) and oxidized LDL (P<0.01) were significantly reduced in the MAO group after the 12-week weight loss, whereas these effects were not seen in the MHO group. 5'-DEOXY-5'-[N-METHYL-N-(2-AMINOOXYETHYL) AMINO]ADENOSINE 93-96 C-reactive protein Homo sapiens 14-17 16822291-6 2006 Anti-intercellular adhesion molecule-1 neutralising monoclonal antibody and nitric oxide donor, sodium nitroprusside, blocked the effect of CRP, reducing adhesion from 202% to 128% (P < 0.05) and 114% (P = 0.02) respectively. Nitroprusside 96-116 C-reactive protein Homo sapiens 140-143 22520631-4 2012 In the present study, a prospective trial was investigated retrospectively and a significant prognostic impact for C-reactive protein that was independent of multiple published prognostic models was identified in men receiving docetaxel-based chemotherapy for mCRPC. Docetaxel 227-236 C-reactive protein Homo sapiens 115-133 22267767-8 2012 CRP increased adhesion capacity, endothelin-1 and vWF secretion by CTEPH-ECs by 37%, 129% and 694%, respectively. cteph-ecs 67-76 C-reactive protein Homo sapiens 0-3 16881109-10 2006 MTX treatment decreased markers of RA activity such as the number of painful and swollen joints, erythrocyte sedimentation rate, Disease Activity Score, and C-reactive protein. Methotrexate 0-3 C-reactive protein Homo sapiens 157-175 16182316-10 2006 Fluvastatin suppressed the CRP-induced increases in 8-epi-prostaglandin F(2alpha) levels in the condition media. Fluvastatin 0-11 C-reactive protein Homo sapiens 27-30 16643876-5 2006 Competition experiments with different phosphatemonoesters revealed that CRP and SAP as well as part of the IgM bound to the phospholipids head groups, SAP mainly to phosphorylethanolamine, CRP to phosphorylcholine and phosphorylethanolamine and to a lesser extent to phosphorylserine, and IgM to phosphorylcholine and phosphorylserine. Phosphorylcholine 197-214 C-reactive protein Homo sapiens 73-76 23084719-7 2012 Positive DMSA findings significantly correlated with VUR (p<0.001) and higher C-reactive protein level (p<0.05). Succimer 9-13 C-reactive protein Homo sapiens 81-99 16643876-5 2006 Competition experiments with different phosphatemonoesters revealed that CRP and SAP as well as part of the IgM bound to the phospholipids head groups, SAP mainly to phosphorylethanolamine, CRP to phosphorylcholine and phosphorylethanolamine and to a lesser extent to phosphorylserine, and IgM to phosphorylcholine and phosphorylserine. Phosphorylcholine 197-214 C-reactive protein Homo sapiens 190-193 16643876-5 2006 Competition experiments with different phosphatemonoesters revealed that CRP and SAP as well as part of the IgM bound to the phospholipids head groups, SAP mainly to phosphorylethanolamine, CRP to phosphorylcholine and phosphorylethanolamine and to a lesser extent to phosphorylserine, and IgM to phosphorylcholine and phosphorylserine. Phosphorylcholine 297-314 C-reactive protein Homo sapiens 73-76 23084719-10 2012 Positive DMSA was well correlated with VUR and higher C-reactive protein level. Succimer 9-13 C-reactive protein Homo sapiens 54-72 16337748-5 2006 CRP is known to bind to phosphocholine in dead eukaryote and some live bacterial cell walls suggesting that CRP facilitates the phagocytosis of fragmented or intact dead cells and/or enhances host bacterial defenses. Phosphorylcholine 24-38 C-reactive protein Homo sapiens 0-3 22694671-10 2012 Waist circumference and hs-CRP (P < 0.001) were the main predictors of aortic and PAS. Aminosalicylic Acid 85-88 C-reactive protein Homo sapiens 27-30 16337748-5 2006 CRP is known to bind to phosphocholine in dead eukaryote and some live bacterial cell walls suggesting that CRP facilitates the phagocytosis of fragmented or intact dead cells and/or enhances host bacterial defenses. Phosphorylcholine 24-38 C-reactive protein Homo sapiens 108-111 25340109-0 2012 Association of CaxPO4 product with levels of serum C-reactive protein in regular hemodialysis patients. caxpo4 15-21 C-reactive protein Homo sapiens 51-69 16395099-8 2006 CONCLUSIONS: CRP levels of > or =40 mg/dL provide a better measure than chest radiographs to assess the effect of PCV in preventing pneumonia. penciclovir 117-120 C-reactive protein Homo sapiens 13-16 25340109-2 2012 In this study we sought to examine the association of the levels of serum C-reactive protein (CRP) with value of CaxPO4 product, in stable hemodialysis patients. caxpo4 113-119 C-reactive protein Homo sapiens 74-92 16123329-12 2005 Parthenolide, SN50, and BAY 11-7082 (NF-kappaB inhibitors) significantly blocked CRP-mediated PAI-1 expression. 3-(4-methylphenylsulfonyl)-2-propenenitrile 24-35 C-reactive protein Homo sapiens 81-84 22796447-0 2012 Expression and characterization of 15N-labeled human C-reactive protein in Escherichia coli and Pichia pastoris for use in isotope-dilution mass spectrometry. 15n 35-38 C-reactive protein Homo sapiens 53-71 16419648-7 2005 After adjustment for factors affecting CRP and hypertension, and additional adjustment for LTPA levels, the odds ratio (95% confidence interval) of hypertension by CRP was 2.21 (range: 1.33-3.72), 1.99 (1.17-3.42), and 2.38 (1.36-4.21) times higher in subjects in the second, third, and fourth quartiles of CRP, as compared to subjects in the first quartile, respectively. ltpa 91-95 C-reactive protein Homo sapiens 164-167 16419648-7 2005 After adjustment for factors affecting CRP and hypertension, and additional adjustment for LTPA levels, the odds ratio (95% confidence interval) of hypertension by CRP was 2.21 (range: 1.33-3.72), 1.99 (1.17-3.42), and 2.38 (1.36-4.21) times higher in subjects in the second, third, and fourth quartiles of CRP, as compared to subjects in the first quartile, respectively. ltpa 91-95 C-reactive protein Homo sapiens 164-167 22697388-4 2012 A pivotal trial was the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), which demonstrated significant reductions in cardiovascular morbidity and mortality in healthy individuals without elevated LDL cholesterol but with high levels of the inflammatory marker high-sensitivity C-reactive protein. Rosuvastatin Calcium 117-129 C-reactive protein Homo sapiens 346-364 15878871-12 2005 Single mutations at amino acid positions Lys(114), Asp(169), Thr(173), Tyr(175), and Leu(176) affected C1q binding to CRP. Leucine 85-88 C-reactive protein Homo sapiens 118-121 22121130-8 2012 In patients receiving placebo, the correlation with TGSS change was significant for baseline scores of the simplified disease activity index (SDAI; r=0.18, p=0.047) and swollen joint count 28 (r=0.22, p=0.019), with similar trends for C-reactive protein. tgss 52-56 C-reactive protein Homo sapiens 235-253 15976341-11 2005 CONCLUSIONS: The availability of CRP and WBC data during initial consultation greatly reduced prescription of amoxicillin, but had a lesser effect on newer, potent, broad spectrum antibiotics. Amoxicillin 110-121 C-reactive protein Homo sapiens 33-36 16027700-7 2005 The duration of fever and maximum serum C-reactive protein (CRP) levels also were significantly increased in the GT+TT group (P = .012 and .036, respectively), whereas plasma PAF-AH activity was significantly lower (P <.0001). gt+tt 113-118 C-reactive protein Homo sapiens 40-58 22555227-8 2012 There was a trend towards improvement in CRP in the rosuvastatin group (-3.23; SD, 18.18) compared with the placebo group (+17.43; SD, 38.03); P value, 0.161. Rosuvastatin Calcium 52-64 C-reactive protein Homo sapiens 41-44 16027700-7 2005 The duration of fever and maximum serum C-reactive protein (CRP) levels also were significantly increased in the GT+TT group (P = .012 and .036, respectively), whereas plasma PAF-AH activity was significantly lower (P <.0001). gt+tt 113-118 C-reactive protein Homo sapiens 60-63 22555227-10 2012 These data show that rosuvastatin with might decrease the CRP independent to IL-6 in patients with RA but does not improve the overall rheumatoid disease activity. Rosuvastatin Calcium 21-33 C-reactive protein Homo sapiens 58-61 15766555-7 2005 Finally, with the aid of anti-CRP monoclonal antibodies and by molecular modeling, we obtained evidence for involvement of the phosphorylcholine-binding site of CRP in cholesterol binding. Phosphorylcholine 127-144 C-reactive protein Homo sapiens 30-33 15766555-7 2005 Finally, with the aid of anti-CRP monoclonal antibodies and by molecular modeling, we obtained evidence for involvement of the phosphorylcholine-binding site of CRP in cholesterol binding. Phosphorylcholine 127-144 C-reactive protein Homo sapiens 161-164 15766555-8 2005 Thus, CRP can bind to cholesterol, and the interaction is mediated by the phosphorylcholine-binding site of CRP and the 3beta-hydroxyl group of cholesterol. Phosphorylcholine 74-91 C-reactive protein Homo sapiens 6-9 15766555-8 2005 Thus, CRP can bind to cholesterol, and the interaction is mediated by the phosphorylcholine-binding site of CRP and the 3beta-hydroxyl group of cholesterol. Phosphorylcholine 74-91 C-reactive protein Homo sapiens 108-111 15959408-6 2005 Thiazolidinediones decrease plasma levels of C reactive protein, possess antiinflammatory effects through a reduction of inflammatory cytokines production, decrease free fatty acids levels, antagonize angiotensin II effects, increase adiponectin expression and production, etc. Thiazolidinediones 0-18 C-reactive protein Homo sapiens 45-63 22230323-3 2012 METHODS AND RESULTS: We performed a study to evaluate potential genetic determinants of CRP response using genome-wide genetic data from a total of 6766 participants of European ancestry randomly allocated to 20 mg/d of rosuvastatin or placebo in the JUPITER trial. Rosuvastatin Calcium 220-232 C-reactive protein Homo sapiens 88-91 15790413-11 2005 The primary endpoint for the study is the influence of fluvastatin therapy on levels of inflammatory markers (CRP and interleukin-6) and on pregnancy associated plasma protein A (PAPP-A). Fluvastatin 55-66 C-reactive protein Homo sapiens 110-113 22230323-4 2012 Among 3386 rosuvastatin-allocated individuals, both CRP and LDL-C levels were reduced by 50% after 12 months of therapy (P<0.001 for both) and essentially uncorrelated (r(2)<0.03). Rosuvastatin Calcium 11-23 C-reactive protein Homo sapiens 52-55 22230323-9 2012 CONCLUSIONS: The genetic determinants of rosuvastatin-induced CRP reduction differ from, and are largely independent of, the major pharmacogenetic determinants of rosuvastatin-induced LDL-C reduction. Rosuvastatin Calcium 41-53 C-reactive protein Homo sapiens 62-65 22687786-12 2012 CONCLUSION: These results demonstrate that high dose rosuvastatin exerts greater effects on LDL-C, ROCK activity, and CRP than low dose rosuvastatin. Rosuvastatin Calcium 53-65 C-reactive protein Homo sapiens 118-121 15738628-7 2005 In patients receiving SASP and MTX, a high level of CRP and high ESR was seen 2 months prior to the occurrence of escape and remained unchanged after escape. Methotrexate 31-34 C-reactive protein Homo sapiens 52-55 22997483-7 2012 Additionally, nuclear factor- (NF-) kappaB inhibitor (BAY11-7082) potently inhibited both CRP and TNF-alpha stimulated PAPP-A mRNA and protein expression. 3-(4-methylphenylsulfonyl)-2-propenenitrile 54-64 C-reactive protein Homo sapiens 90-93 16403981-5 2005 An up to 6-fold increase of plasma F2-isoprostanes in HD patients is accompanied by an enhanced formation of indicators of inflammation (e.g. C-reactive protein) and decreases of endogenous antioxidants (e.g. ascorbate, alpha-tocopherol). F2-Isoprostanes 35-50 C-reactive protein Homo sapiens 142-160 21885491-9 2011 CONCLUSION: More MTX-naive patients with early RA who achieved radiographic nonprogression taking abatacept plus MTX also achieved DAS28 (CRP)-defined remission and LDAS compared with patients who received MTX alone, supporting the use of abatacept as a first-line biologic in combination with disease-modifying antirheumatic drugs. Methotrexate 17-20 C-reactive protein Homo sapiens 138-141 16103720-3 2005 For this reason we have evaluated in a cross-sectional and in an interventional study the possible correlation between CaxPO4 and CRP and the effect of the correction of a high CaxPO4 on CRP levels. caxpo4 177-183 C-reactive protein Homo sapiens 187-190 16103720-11 2005 A significant hyperbolic correlation between CaxPO4 and CRP was observed. caxpo4 45-51 C-reactive protein Homo sapiens 56-59 16103720-18 2005 CONCLUSIONS: Our data show that in chronic HD patients in steady clinical conditions with no clinical evidence of either infectious or inflammatory diseases, a high CaxPO4 is associated with high CRP concentrations. caxpo4 165-171 C-reactive protein Homo sapiens 196-199 22054387-0 2011 Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel. Docetaxel 140-149 C-reactive protein Homo sapiens 21-39 15466473-7 2004 Site-directed mutagenesis revealed that valine 34 and leucine 36 are critical for GPVI interaction with collagen and CRP. Leucine 54-61 C-reactive protein Homo sapiens 117-120 15550024-7 2004 Aspirin and clopidogrel were thus found to have similar effects on thrombotic variables and CRP in this patient population. Clopidogrel 12-23 C-reactive protein Homo sapiens 92-95 22054387-1 2011 OBJECTIVE: To verify the prognostic impact of C-reactive protein (CRP) for patients with castration-resistant prostate cancer (CRPC) treated with docetaxel in a single institution. Docetaxel 146-155 C-reactive protein Homo sapiens 46-64 22054387-1 2011 OBJECTIVE: To verify the prognostic impact of C-reactive protein (CRP) for patients with castration-resistant prostate cancer (CRPC) treated with docetaxel in a single institution. Docetaxel 146-155 C-reactive protein Homo sapiens 66-69 15474020-1 2004 Phosphorylcholine (PC) is a classical ligand of C-reactive protein (CRP), a clinically important acute phase protein. Phosphorylcholine 0-17 C-reactive protein Homo sapiens 48-66 22054387-10 2011 CONCLUSION: CRP is an independent prognostic factor for overall survival of patients with CRPC treated with docetaxel. Docetaxel 108-117 C-reactive protein Homo sapiens 12-15 15474020-1 2004 Phosphorylcholine (PC) is a classical ligand of C-reactive protein (CRP), a clinically important acute phase protein. Phosphorylcholine 0-17 C-reactive protein Homo sapiens 68-71 21817129-11 2011 In receiver operating characteristic analysis for inflammation, defined as an IL-6 level above 2.97 pg/ml (median), the discriminative power of SDMA (area under the curve [AUC]: 0.69 +- 0.05) directly followed that of C-reactive protein (AUC: 0.82 +- 0.04) and albumin (AUC: 0.72 +- 0.05; for all, P < 0.0001) and preceded that of ADMA (P = 0.002). symmetric dimethylarginine 144-148 C-reactive protein Homo sapiens 218-236 15474020-1 2004 Phosphorylcholine (PC) is a classical ligand of C-reactive protein (CRP), a clinically important acute phase protein. Phosphorylcholine 19-21 C-reactive protein Homo sapiens 48-66 15474020-1 2004 Phosphorylcholine (PC) is a classical ligand of C-reactive protein (CRP), a clinically important acute phase protein. Phosphorylcholine 19-21 C-reactive protein Homo sapiens 68-71 21440634-1 2011 With its homo-pentameric structure and calcium-dependent specificity for phosphocholine (PCh), human c-reactive protein (CRP) is produced by the liver and secreted in elevated quantities in response to inflammation. Phosphorylcholine 73-87 C-reactive protein Homo sapiens 101-119 21440634-1 2011 With its homo-pentameric structure and calcium-dependent specificity for phosphocholine (PCh), human c-reactive protein (CRP) is produced by the liver and secreted in elevated quantities in response to inflammation. Phosphorylcholine 73-87 C-reactive protein Homo sapiens 121-124 21440634-1 2011 With its homo-pentameric structure and calcium-dependent specificity for phosphocholine (PCh), human c-reactive protein (CRP) is produced by the liver and secreted in elevated quantities in response to inflammation. Phosphorylcholine 89-92 C-reactive protein Homo sapiens 101-119 15204760-5 2004 To investigate if the expression of CRP and Hsp70 was the result of free radical production, cells were treated with ufCB in the presence of antioxidants (NAL and Trolox). ufcb 117-121 C-reactive protein Homo sapiens 36-39 15050187-6 2004 A large-scale, randomized clinical trial-Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)-will test whether rosuvastatin therapy will reduce incident cardiovascular disease in subjects with elevated plasma hs-CRP concentrations who do not meet current criteria for initiation of lipid-lowering drug therapy. Rosuvastatin Calcium 175-187 C-reactive protein Homo sapiens 276-279 21440634-1 2011 With its homo-pentameric structure and calcium-dependent specificity for phosphocholine (PCh), human c-reactive protein (CRP) is produced by the liver and secreted in elevated quantities in response to inflammation. Phosphorylcholine 89-92 C-reactive protein Homo sapiens 121-124 21668975-11 2011 The CHO-P group showed a decrease in the both CRP elevation and CRP/albumin ratio (p < 0.05). cho-p 4-9 C-reactive protein Homo sapiens 46-49 14722642-8 2004 C-reactive protein increased over time, but compared to the other groups it was significantly lower in patients receiving metamizol after 4 h. Cytokine concentrations were not different among the three groups or over time, although interleukin 6 tended to decrease over time in the metamizol group. Dipyrone 122-131 C-reactive protein Homo sapiens 0-18 14742804-8 2004 Drugs including statins, fibrates, niacin, thiazolidinediones, and antiplatelet agents, as well as weight loss and exercise, have demonstrated efficacy in lowering CRP levels. Thiazolidinediones 43-61 C-reactive protein Homo sapiens 164-167 21668975-11 2011 The CHO-P group showed a decrease in the both CRP elevation and CRP/albumin ratio (p < 0.05). cho-p 4-9 C-reactive protein Homo sapiens 64-67 21668975-12 2011 The proportion of patients who showed CRP/albumin ratio considered normal was significantly greater (p < 0.05) in the CHO-P group (87.5%) than in the CO group (33.3%). cho-p 121-126 C-reactive protein Homo sapiens 38-41 21372222-0 2011 Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Lapatinib 154-163 C-reactive protein Homo sapiens 15-33 15540418-11 2004 With this, fosinopril was superior to captopril not only in its capacity of improving overall left ventricular contractile function, but it was characterized by a more pronounced effect on regression of the plasma pool of C-RP and TNF-alpha. Fosinopril 11-21 C-reactive protein Homo sapiens 222-226 15236798-3 2004 Strategies for decreasing elevated CRP include administration of statins, thiazolidinediones, and metformin; moderate alcohol consumption and appropriate weight loss are also helpful in this regard. Thiazolidinediones 74-92 C-reactive protein Homo sapiens 35-38 21492764-9 2011 CONCLUSIONS: Among adults with LDL-C <130 mg/dl and high-sensitivity C-reactive protein >=2 mg/l, rosuvastatin-allocated participants attaining LDL-C <50 mg/dl had a lower risk of cardiovascular events without a systematic increase in reported adverse events. Rosuvastatin Calcium 104-116 C-reactive protein Homo sapiens 72-90 14625121-7 2003 RESULTS: Median CRP concentrations were significantly higher in women receiving oral 17beta-E2 + NETA (P = 0.037) and CEE + MPA (P = 0.0001) for 3 months than in women taking the same types of HRT for 12 months and of those were not on HRT. 17beta-e2 85-94 C-reactive protein Homo sapiens 16-19 14636905-8 2003 High-sensitivity C-reactive protein median values were reduced by 33% to 34% in both the 80-mg rosuvastatin- and atorvastatin-treated groups. Rosuvastatin Calcium 95-107 C-reactive protein Homo sapiens 17-35 14636916-3 2003 Saturated fat consumption was modestly associated with elevated CRP (third quartile: OR 1.58, 95% CI 1.02 to 2.44; fourth quartile 1.44, 95% CI 0.80 to 2.58). saturated fat 0-13 C-reactive protein Homo sapiens 64-67 21393433-1 2011 AIMS: This study investigated the effect of clopidogrel treatment on inflammatory activity as evidenced by the change in high-sensitivity C-reactive protein (hsCRP) levels in a broad population of patients who are at high risk of atherothrombotic events. Clopidogrel 44-55 C-reactive protein Homo sapiens 138-156 12887727-2 2003 This study was undertaken to examine the changes of CRP levels during dextran-sulfate (DS) low-density lipoprotein (LDL) apheresis. Dextran Sulfate 70-85 C-reactive protein Homo sapiens 52-55 12887727-2 2003 This study was undertaken to examine the changes of CRP levels during dextran-sulfate (DS) low-density lipoprotein (LDL) apheresis. Dextran Sulfate 87-89 C-reactive protein Homo sapiens 52-55 12887727-4 2003 The efficiency in adsorption of CRP with DS column was evaluated by measuring CRP levels in both pre- and post-column plasma. Dextran Sulfate 41-43 C-reactive protein Homo sapiens 32-35 12887727-4 2003 The efficiency in adsorption of CRP with DS column was evaluated by measuring CRP levels in both pre- and post-column plasma. Dextran Sulfate 41-43 C-reactive protein Homo sapiens 78-81 20972810-8 2011 The pleural fluid DBL was positively correlated with serum C-reactive protein (p = 0.009), pleural fluid neutrophils (p < 0.001), and pleural fluid glucose (p < 0.001). disialyllactose 18-21 C-reactive protein Homo sapiens 59-77 12672736-13 2003 In multivariate models adjusting for Framingham Global Risk Score and CRP, upper quartiles of nitrotyrosine remained associated with CAD (odds ratio, 4.4; 95% confidence interval, 1.8-10.6; P<.001). 3-nitrotyrosine 94-107 C-reactive protein Homo sapiens 70-73 14650743-5 2003 CRP can bind phosphocholine largely present in bacterial membranes, cell membrane and lipoproteins, in addition CRP can recognize nuclear constituent in damaged cells. Phosphorylcholine 13-27 C-reactive protein Homo sapiens 0-3 21398452-1 2011 A turbidimetric method to determine serum C-reactive protein (CRP) concentration, based on soybean oil-phosphocholine interaction, was performed on horse serum samples to evaluate its potential diagnostic value in veterinary medicine. Phosphorylcholine 103-117 C-reactive protein Homo sapiens 62-65 14650743-5 2003 CRP can bind phosphocholine largely present in bacterial membranes, cell membrane and lipoproteins, in addition CRP can recognize nuclear constituent in damaged cells. Phosphorylcholine 13-27 C-reactive protein Homo sapiens 112-115 12480587-0 2002 [Effects of fluvastatin on the levels of C-reactive protein and lipids in patients with hyperlipidemia]. Fluvastatin 12-23 C-reactive protein Homo sapiens 41-59 21398452-3 2011 After 30 min of incubation at 37 C, the CRP-phosphocholine complexes were turbidimetrically, bichromatically (660 nm/700 nm) quantified on a commercial analyzer. Phosphorylcholine 45-59 C-reactive protein Homo sapiens 41-44 12480587-1 2002 OBJECTIVE: To observe the changes of C-reactive protein (CRP) level and its relationship with blood lipids, and the effects of fluvastatin on CRP and the lipids in patients with hyperlipidemia. Fluvastatin 127-138 C-reactive protein Homo sapiens 142-145 20696680-7 2011 Five days after the IV administration of 200 mg iron sucrose, a significant increase of RTC was observed, only in those patients with elevated baseline CRP levels who also showed an increase in CHr levels from <= 31.2 pg at baseline to >= 31.2 pg post-administration, supporting the presence of an independent positive correlation between CRP and RTC when iron is adequate. Ferric Oxide, Saccharated 48-60 C-reactive protein Homo sapiens 152-155 12480587-7 2002 Positive correlation of CRP, however, was observed after fluvastatin treatment with TC/HDL (r=0.62, P=0.041) and Lp(a) (r=0.320, P=0.011), while inverse relations were noted between CRP and HDL (r=-0.288, P=0.023). Fluvastatin 57-68 C-reactive protein Homo sapiens 24-27 12480587-9 2002 In addition to modulating blood lipid levels, fluvastatin also reduces CRP level, the latter possibly serving as an independent predictive factor for atherosclerotic cardiovascular diseases and also as an indicator for estimating the effectiveness of the treatment. Fluvastatin 46-57 C-reactive protein Homo sapiens 71-74 20696680-7 2011 Five days after the IV administration of 200 mg iron sucrose, a significant increase of RTC was observed, only in those patients with elevated baseline CRP levels who also showed an increase in CHr levels from <= 31.2 pg at baseline to >= 31.2 pg post-administration, supporting the presence of an independent positive correlation between CRP and RTC when iron is adequate. Ferric Oxide, Saccharated 48-60 C-reactive protein Homo sapiens 345-348 12607825-5 2002 Most importantly, alpha tocopherol therapy, especially at high doses, clearly shows a benefit with regards to LDL oxidation, isoprostanes and a decrease in inflammatory markers such as C-reactive protein, pro-inflammatory cytokines and PAI-1 levels. Tocopherols 24-34 C-reactive protein Homo sapiens 185-203 12468815-9 2002 The baseline acute-phase response was higher in patients treated with MTX (mean CRP 3.5 mg/dl) than in those treated with SSZ (CRP 2.4 mg/dl; P < 0.05) or AM (CRP 2.1 mg/dl; P < 0.05), suggesting that MTX was used preferentially in patients with high disease activity. Methotrexate 70-73 C-reactive protein Homo sapiens 80-83 21519150-10 2011 CRP/DM was associated with increased terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling positive cells and a higher ratio of Bax/Bcl-2 proteins compared with Wt/DM. deoxyuridine triphosphate 84-88 C-reactive protein Homo sapiens 0-3 12218140-1 2002 C-reactive protein (CRP), the major human acute-phase plasma protein, binds to phosphocholine (PCh) residues present in pneumococcal C-polysaccharide (PnC) of Streptococcus pneumoniae and to PCh exposed on damaged and apoptotic cells. Phosphorylcholine 79-93 C-reactive protein Homo sapiens 0-18 12218140-1 2002 C-reactive protein (CRP), the major human acute-phase plasma protein, binds to phosphocholine (PCh) residues present in pneumococcal C-polysaccharide (PnC) of Streptococcus pneumoniae and to PCh exposed on damaged and apoptotic cells. Phosphorylcholine 79-93 C-reactive protein Homo sapiens 20-23 12218140-1 2002 C-reactive protein (CRP), the major human acute-phase plasma protein, binds to phosphocholine (PCh) residues present in pneumococcal C-polysaccharide (PnC) of Streptococcus pneumoniae and to PCh exposed on damaged and apoptotic cells. Phosphorylcholine 95-98 C-reactive protein Homo sapiens 0-18 21135368-0 2010 Letter by Wells and Eisenberg regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials". Rosuvastatin Calcium 288-300 C-reactive protein Homo sapiens 150-168 12218140-1 2002 C-reactive protein (CRP), the major human acute-phase plasma protein, binds to phosphocholine (PCh) residues present in pneumococcal C-polysaccharide (PnC) of Streptococcus pneumoniae and to PCh exposed on damaged and apoptotic cells. Phosphorylcholine 95-98 C-reactive protein Homo sapiens 20-23 12218140-1 2002 C-reactive protein (CRP), the major human acute-phase plasma protein, binds to phosphocholine (PCh) residues present in pneumococcal C-polysaccharide (PnC) of Streptococcus pneumoniae and to PCh exposed on damaged and apoptotic cells. Phosphorylcholine 191-194 C-reactive protein Homo sapiens 0-18 12218140-1 2002 C-reactive protein (CRP), the major human acute-phase plasma protein, binds to phosphocholine (PCh) residues present in pneumococcal C-polysaccharide (PnC) of Streptococcus pneumoniae and to PCh exposed on damaged and apoptotic cells. Phosphorylcholine 191-194 C-reactive protein Homo sapiens 20-23 12218140-2 2002 CRP also binds, in a PCh-inhibitable manner, to ligands that do not contain PCh, such as fibronectin (Fn). Phosphorylcholine 21-24 C-reactive protein Homo sapiens 0-3 12037301-3 2002 The role of hCRP in host defence and the calcium-dependent ligand-binding specificity of hCRP for phosphocholine moieties have long been recognized. Phosphorylcholine 98-112 C-reactive protein Homo sapiens 89-93 21135369-0 2010 Letter by Vos et al regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials". Rosuvastatin Calcium 278-290 C-reactive protein Homo sapiens 140-158 11840366-7 2002 The behavior of CRP plasma levels resembled that of IL-6 PBMC release (23.3 +/- 4.7 in CU, 11.0 +/- 2.1 after 3 months in SMC, and 7.9 +/- 1.5 after 6 months in SMC, respectively). S-Methyl-L-cysteine 122-125 C-reactive protein Homo sapiens 16-19 21094359-0 2010 Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily). Rosuvastatin Calcium 156-168 C-reactive protein Homo sapiens 108-126 11684681-0 2002 Mapping the binding areas of human C-reactive protein for phosphorylcholine and polycationic compounds. Phosphorylcholine 58-75 C-reactive protein Homo sapiens 35-53 11684681-3 2002 Using this method, we compared the phosphorylcholine (PC)- and polycation-based binding activities of human CRP. Phosphorylcholine 35-52 C-reactive protein Homo sapiens 108-111 21094359-1 2010 Plasma levels of high-sensitivity C-reactive protein (hsCRP) are an important predictor of cardiovascular disease, and achievement of lower targets of hsCRP with rosuvastatin treatment was associated with improved cardiovascular outcomes. Rosuvastatin Calcium 162-174 C-reactive protein Homo sapiens 34-52 11684681-3 2002 Using this method, we compared the phosphorylcholine (PC)- and polycation-based binding activities of human CRP. Phosphorylcholine 54-56 C-reactive protein Homo sapiens 108-111 11684681-5 2002 The published crystallographic structures of CRP and the CRP.PC complex show it to be a ring-shaped pentamer with a single PC-binding site per subunit facing the same direction. Phosphorylcholine 61-63 C-reactive protein Homo sapiens 57-60 21094359-8 2010 In conclusion, central obesity, low HDL cholesterol, and CRP polymorphisms are major determinants of higher hsCRP levels in Chinese patients receiving treatment with rosuvastatin. Rosuvastatin Calcium 166-178 C-reactive protein Homo sapiens 57-60 20580035-14 2010 The addition of exercise training to rosuvastatin treatment further lowered CRP and reduced the size of the inflammatory monocyte population, suggesting an additive anti-inflammatory effect of exercise. Rosuvastatin Calcium 37-49 C-reactive protein Homo sapiens 76-79 11709513-9 2001 CRP <10 mg/l was achieved in 30% in the low LCT and 33% in the high LCT group (p=0.99). N-[5-(4-Nitrophenyl)-1,3,4-thiadiazol-2-yl]acetamide 47-50 C-reactive protein Homo sapiens 0-3 11709513-9 2001 CRP <10 mg/l was achieved in 30% in the low LCT and 33% in the high LCT group (p=0.99). N-[5-(4-Nitrophenyl)-1,3,4-thiadiazol-2-yl]acetamide 71-74 C-reactive protein Homo sapiens 0-3 20838744-9 2010 In conclusion, elevated levels of CRP, WBC count and fibrinogen were significantly associated with high platelet reactivity in patients under chronic clopidogrel treatment. Clopidogrel 150-161 C-reactive protein Homo sapiens 34-37 11594754-2 2001 Here we show that the human C-reactive protein is two-dimensionally crystallized upon specific adsorption on the phosphorylcholine ligand containing membranes by monolayer approach. Phosphorylcholine 113-130 C-reactive protein Homo sapiens 28-46 20843812-2 2010 At physiological pH, native pentameric CRP exhibits calcium-dependent binding specificity for phosphocholine. Phosphorylcholine 94-108 C-reactive protein Homo sapiens 39-42 10570224-6 2000 Synthetic oligosaccharides and phospho-oligosaccharides of various lengths and conformations were used to define the structural requirements for CRP recognition. inositol phosphate glycan 31-55 C-reactive protein Homo sapiens 145-148 20843812-7 2010 Some modifications in CRP were reversible at pH 7.0, for example, the phosphocholine-binding activity of CRP, which was reduced at acidic pH, was restored after pH neutralization. Phosphorylcholine 70-84 C-reactive protein Homo sapiens 22-25 20843812-7 2010 Some modifications in CRP were reversible at pH 7.0, for example, the phosphocholine-binding activity of CRP, which was reduced at acidic pH, was restored after pH neutralization. Phosphorylcholine 70-84 C-reactive protein Homo sapiens 105-108 10419867-13 1999 suPAR in RA was positively correlated to C reactive protein (CRP) (p<0.01) and erythrocyte sedimentation rate (p<0.05) and number of swollen joints (p<0.05). supar 0-5 C-reactive protein Homo sapiens 41-59 10419867-13 1999 suPAR in RA was positively correlated to C reactive protein (CRP) (p<0.01) and erythrocyte sedimentation rate (p<0.05) and number of swollen joints (p<0.05). supar 0-5 C-reactive protein Homo sapiens 61-64 10419867-17 1999 suPAR seems though not merely to be an acute phase reactant like CRP. supar 0-5 C-reactive protein Homo sapiens 65-68 10368284-0 1999 The physiological structure of human C-reactive protein and its complex with phosphocholine. Phosphorylcholine 77-91 C-reactive protein Homo sapiens 37-55 10368284-3 1999 However, CRP is likely to have important host defence, scavenging and metabolic functions through its capacity for calcium-dependent binding to exogenous and autologous molecules containing phosphocholine (PC) and then activating the classical complement pathway. Phosphorylcholine 190-204 C-reactive protein Homo sapiens 9-12 10368284-3 1999 However, CRP is likely to have important host defence, scavenging and metabolic functions through its capacity for calcium-dependent binding to exogenous and autologous molecules containing phosphocholine (PC) and then activating the classical complement pathway. Phosphorylcholine 206-208 C-reactive protein Homo sapiens 9-12 10368284-8 1999 CONCLUSIONS: The structure shows how large ligands containing PC may be bound by CRP via a phosphate oxygen that projects away from the surface of the protein. Phosphorylcholine 62-64 C-reactive protein Homo sapiens 81-84 20538278-11 2010 The further study indicated that losartan, NAC, PD98059, SP600125 significantly inhibited ERK1/2 and JNK phosphorylation, and PD98059, SP600125, PDTC completely antagonized AngII-induced CRP expression in HAECs. pyrazolanthrone 57-65 C-reactive protein Homo sapiens 187-190 10368284-11 1999 The hydrophobic pocket adjacent to bound PC invites the design of inhibitors of CRP binding that may have therapeutic relevance to the possible role of CRP in atherothrombotic events. Phosphorylcholine 41-43 C-reactive protein Homo sapiens 80-83 10368284-11 1999 The hydrophobic pocket adjacent to bound PC invites the design of inhibitors of CRP binding that may have therapeutic relevance to the possible role of CRP in atherothrombotic events. Phosphorylcholine 41-43 C-reactive protein Homo sapiens 152-155 20538278-11 2010 The further study indicated that losartan, NAC, PD98059, SP600125 significantly inhibited ERK1/2 and JNK phosphorylation, and PD98059, SP600125, PDTC completely antagonized AngII-induced CRP expression in HAECs. pyrazolanthrone 135-143 C-reactive protein Homo sapiens 187-190 20625281-4 2010 The Justification for the use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) demonstrated a significant benefit of rosuvastatin in low-risk patients with no apparent vascular disease, low-density lipoprotein levels of less than 3.4 mmol/l, and elevated high sensitivity C-reactive protein. Rosuvastatin Calcium 158-170 C-reactive protein Homo sapiens 313-331 9751087-8 1998 A 70-90% reduction in the swollen joint count, tender joint count, and C-reactive protein level was maintained for the entire 26 weeks in patients receiving 10 mg/kg of cA2 with MTX. Methotrexate 178-181 C-reactive protein Homo sapiens 71-89 20719717-3 2010 In addition, rosuvastatin reduces triglyceride and high-sensitivity C-reactive protein level and increases high-density lipoprotein (HDL) cholesterol, too. Rosuvastatin Calcium 13-25 C-reactive protein Homo sapiens 68-86 9614930-1 1998 C-reactive protein (CRP) is an acute phase serum protein that binds to phosphocholine (PC) and to components of damaged tissue. Phosphorylcholine 71-85 C-reactive protein Homo sapiens 0-18 9614930-1 1998 C-reactive protein (CRP) is an acute phase serum protein that binds to phosphocholine (PC) and to components of damaged tissue. Phosphorylcholine 71-85 C-reactive protein Homo sapiens 20-23 20805548-0 2010 Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein. Rosuvastatin Calcium 22-34 C-reactive protein Homo sapiens 144-162 9614930-1 1998 C-reactive protein (CRP) is an acute phase serum protein that binds to phosphocholine (PC) and to components of damaged tissue. Phosphorylcholine 87-89 C-reactive protein Homo sapiens 0-18 9614930-1 1998 C-reactive protein (CRP) is an acute phase serum protein that binds to phosphocholine (PC) and to components of damaged tissue. Phosphorylcholine 87-89 C-reactive protein Homo sapiens 20-23 9451003-0 1998 CRP interacts with promoter-bound sigma54 RNA polymerase and blocks transcriptional activation of the dctA promoter. CDTA 102-106 C-reactive protein Homo sapiens 0-3 9451003-2 1998 Analysis of the sigma54-dependent dctA promoter reveals a novel negative regulatory function for CRP. CDTA 34-38 C-reactive protein Homo sapiens 97-100 20805548-1 2010 CONTEXT: The Food and Drug Administration (FDA) recently approved rosuvastatin calcium for prevention of cardiovascular events in patients who have elevated levels of high-sensitivity C-reactive protein (hs-CRP) but not overt hyperlipidemia. Rosuvastatin Calcium 66-86 C-reactive protein Homo sapiens 184-202 9451003-3 1998 CRP can bind to two distant sites of the dctA promoter, sites which overlap the upstream activator sequences for the DctD activator. CDTA 41-45 C-reactive protein Homo sapiens 0-3 9451003-4 1998 CRP interacts with Esigma54 bound at the dctA promoter via DNA loop formation. CDTA 41-45 C-reactive protein Homo sapiens 0-3 20891039-3 2010 In parallel with CRP, the content of secretory phospholipase A, as a component of lipoproteins is on the rise; the enzyme hydrolyzes phosphatidylcholine in the surface monolayer of lipoproteins to form lysophosphatidylcholine that the CRP-pentamere displays a high affinity binding to. Lysophosphatidylcholines 202-225 C-reactive protein Homo sapiens 17-20 9451003-6 1998 CRP is able to repress activation of the dctA promoter, even in the absence of specific CRP-binding sites. CDTA 41-45 C-reactive protein Homo sapiens 0-3 20891039-6 2010 For this, lipoprotein-associated phospholipase A, hydrolyzes phosphatidylcholine to produce lysophosphatidylcholine that the CRP-pentamere binds to; it superimposes a physiological apoE/B-100-ligand, becomes itself a pathophysiological CRP/B-100-ligand, and directs a flow of the energy substrates towards the interstitial cells that exhibit pathophysiological CRB/B-100-receptors on the membrane. Lysophosphatidylcholines 92-115 C-reactive protein Homo sapiens 125-128 8906746-1 1996 C-reactive protein (CRP) is an acute phase serum protein that binds to phosphocholine (PC) on phospholipids and polysaccharides and to protein components of chromatin and small nuclear ribonucleoproteins. Phosphorylcholine 71-85 C-reactive protein Homo sapiens 0-18 8906746-1 1996 C-reactive protein (CRP) is an acute phase serum protein that binds to phosphocholine (PC) on phospholipids and polysaccharides and to protein components of chromatin and small nuclear ribonucleoproteins. Phosphorylcholine 71-85 C-reactive protein Homo sapiens 20-23 20891039-6 2010 For this, lipoprotein-associated phospholipase A, hydrolyzes phosphatidylcholine to produce lysophosphatidylcholine that the CRP-pentamere binds to; it superimposes a physiological apoE/B-100-ligand, becomes itself a pathophysiological CRP/B-100-ligand, and directs a flow of the energy substrates towards the interstitial cells that exhibit pathophysiological CRB/B-100-receptors on the membrane. Lysophosphatidylcholines 92-115 C-reactive protein Homo sapiens 236-239 8906746-1 1996 C-reactive protein (CRP) is an acute phase serum protein that binds to phosphocholine (PC) on phospholipids and polysaccharides and to protein components of chromatin and small nuclear ribonucleoproteins. Phosphorylcholine 87-89 C-reactive protein Homo sapiens 0-18 8906746-1 1996 C-reactive protein (CRP) is an acute phase serum protein that binds to phosphocholine (PC) on phospholipids and polysaccharides and to protein components of chromatin and small nuclear ribonucleoproteins. Phosphorylcholine 87-89 C-reactive protein Homo sapiens 20-23 8861742-7 1996 Serum levels of albumin remained stable, whereas serum CRP levels decreased both in the minocycline- and in the placebo-treated group. Minocycline 88-99 C-reactive protein Homo sapiens 55-58 8861742-8 1996 Serum levels of IL-6 decreased in the minocycline-treated group only and this decrease was positively correlated with the decrease in CRP levels. Minocycline 38-49 C-reactive protein Homo sapiens 134-137 20819623-12 2010 CONCLUSION: Salmeterol/fluticasone treatment reduced circulating C-reactive protein concentration in clinically stable moderate-to-severe chronic obstructive pulmonary disease patients after 6-month treatment. Salmeterol Xinafoate 12-22 C-reactive protein Homo sapiens 65-83 21547097-6 2010 Thus it appears that this pleiotropic effect of rosuvastatin may be responsible for part of its unusual effectiveness in reducing the risk of various cardiovascular endpoints found in JUPITER and calls into question the interpretation based only on LDL cholesterol and CRP changes. Rosuvastatin Calcium 48-60 C-reactive protein Homo sapiens 269-272 8573206-2 1995 Special attention is paid to the specific interaction of C-reactive protein with Ca(2+)-dependent and Ca(2+)-independent ligands: phosphorylcholine-containing compounds, lipoproteins, chromatin, galactans, polycations, etc. Phosphorylcholine 130-147 C-reactive protein Homo sapiens 57-75 20668802-10 2010 JUPITER represented a valid outcomes study but made a claim that rosuvastatin has special value in risk management because of decreased high sensitivity C-Reactive Protein. Rosuvastatin Calcium 65-77 C-reactive protein Homo sapiens 153-171 7780685-8 1995 Preincubation of CRP with phosphorylcholine led to a concentration-dependent loss of CRP-induced inhibition of substrate hydrolysis. Phosphorylcholine 26-43 C-reactive protein Homo sapiens 17-20 7780685-8 1995 Preincubation of CRP with phosphorylcholine led to a concentration-dependent loss of CRP-induced inhibition of substrate hydrolysis. Phosphorylcholine 26-43 C-reactive protein Homo sapiens 85-88 8189060-3 1994 Wild-type (wt) and all mutant rCRPs bound to phosphocholine-substituted BSA and also to pneumococcal C-polysaccharide with apparent avidities similar to native CRP, except for the R116L mutant which bound slightly less avidly. Phosphorylcholine 45-59 C-reactive protein Homo sapiens 31-34 8189060-9 1994 The data indicate that the negative charge of residue Asp-112 plays a major role in the formation of the C1q-binding site of CRP and that the positively-charged residue Lys-114 and to a lesser extent also Arg-116 play important but indirect roles in C1q-binding and activation of C by CRP complexes. Aspartic Acid 54-57 C-reactive protein Homo sapiens 125-128 20034371-11 2010 Current evidence suggests that inflammatory and metabolic factors associated with diabetes, such as high glucose, adipokines, modified lipoproteins and free fatty acids may trigger CRP production by endothelial cells, smooth muscle cells and monocytes/macrophages. Fatty Acids, Nonesterified 152-168 C-reactive protein Homo sapiens 181-184 8119992-0 1994 Effects of calcium, magnesium, and phosphorylcholine on secondary structures of human C-reactive protein and serum amyloid P component observed by infrared spectroscopy. Phosphorylcholine 35-52 C-reactive protein Homo sapiens 86-104 8119992-6 1994 Phosphorylcholine in the presence of calcium also affected the spectrum of CRP but not the spectrum of SAP. Phosphorylcholine 0-17 C-reactive protein Homo sapiens 75-78 20146674-13 2010 In ROS group CRP had tendency to decrease but same tendency took place in control. Rosuvastatin Calcium 3-6 C-reactive protein Homo sapiens 13-16 19640511-5 2009 In overall comparisons, quetiapine and olanzapine had the highest median levels for CRP, and olanzapine for E-selectin and ICAM-1. Quetiapine Fumarate 24-34 C-reactive protein Homo sapiens 84-87 8358980-0 1993 Better effect of methotrexate on C-reactive protein during daily compared to weekly treatment in rheumatoid arthritis. Methotrexate 17-29 C-reactive protein Homo sapiens 33-51 19853918-2 2009 Pull-down assays using an N-acetyl-D-glucosamine (GlcNAc)-agarose column demonstrated that CRP binds to the trimeric FBG domains, and that the GlcNAc-binding ability of the FBG domain is unaffected by CRP binding. Acetylglucosamine 26-48 C-reactive protein Homo sapiens 91-94 8097536-4 1993 In a trial comparing methotrexate with azathioprine significant differences could be found in favor of methotrexate by the variables of pain, DAS, ESR, C-reactive protein, hemoglobin and thrombocytes; not by Ritchie score, number of tender joints and number of swollen joints. Methotrexate 103-115 C-reactive protein Homo sapiens 152-170 8336521-3 1993 In Lineweaver- Burk analysis with phosphatidylcholine dispersed with Triton X-100, the apparent Km value of phospholipase D for phosphatidylcholine increased from 2.27 mg/ml to 3.72 mg/ml by addition of 7.5 micrograms/ml CRP whereas the Vmax value was not altered. Octoxynol 69-81 C-reactive protein Homo sapiens 221-224 19853918-2 2009 Pull-down assays using an N-acetyl-D-glucosamine (GlcNAc)-agarose column demonstrated that CRP binds to the trimeric FBG domains, and that the GlcNAc-binding ability of the FBG domain is unaffected by CRP binding. Acetylglucosamine 50-56 C-reactive protein Homo sapiens 91-94 19853918-2 2009 Pull-down assays using an N-acetyl-D-glucosamine (GlcNAc)-agarose column demonstrated that CRP binds to the trimeric FBG domains, and that the GlcNAc-binding ability of the FBG domain is unaffected by CRP binding. Acetylglucosamine 143-149 C-reactive protein Homo sapiens 201-204 8356407-5 1993 At onset (< or = 6 months) of RA only serum orosomucoid, but after three years morning stiffness, ESR, serum CRP and orosomucoid were significantly worse in patients whom later developed RSA. rabbit sperm membrane autoantigen 190-193 C-reactive protein Homo sapiens 112-115 20031900-0 2009 Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Rosuvastatin Calcium 28-40 C-reactive protein Homo sapiens 185-203 1460031-0 1992 Probing the phosphocholine-binding site of human C-reactive protein by site-directed mutagenesis. Phosphorylcholine 12-26 C-reactive protein Homo sapiens 49-67 1460031-2 1992 Most known CRP ligands bind to the phosphocholine (PCh)-binding site of the protein. Phosphorylcholine 35-49 C-reactive protein Homo sapiens 11-14 1460031-2 1992 Most known CRP ligands bind to the phosphocholine (PCh)-binding site of the protein. Phosphorylcholine 51-54 C-reactive protein Homo sapiens 11-14 1460031-3 1992 In the present study, we used oligonucleotide-directed site-specific mutagenesis to investigate structural determinants of the PCh-binding site of CRP. Phosphorylcholine 127-130 C-reactive protein Homo sapiens 147-150 1460031-10 1992 We conclude that the residues Lys-57, Arg-58, and Trp-67 contribute to the structure of the PCh-binding site of human CRP. Phosphorylcholine 92-95 C-reactive protein Homo sapiens 118-121 20031900-1 2009 BACKGROUND: As recently demonstrated, random allocation to rosuvastatin results in large relative risk reductions for first cardiovascular events among apparently healthy men and women with low levels of low-density lipoprotein cholesterol but elevated levels of high-sensitivity C-reactive protein. Rosuvastatin Calcium 59-71 C-reactive protein Homo sapiens 280-298 19455670-6 2009 Among ACS patients, plasma high sensitivity C-reactive protein (hs-CRP) levels were significantly higher in patients with VH-TCFA than in patients without VH-TCFA (7.9 +/- 2.6 mg/l versus 1.6 +/- 0.3 mg/l, p = 0.004). tcfa 125-129 C-reactive protein Homo sapiens 44-62 19455670-6 2009 Among ACS patients, plasma high sensitivity C-reactive protein (hs-CRP) levels were significantly higher in patients with VH-TCFA than in patients without VH-TCFA (7.9 +/- 2.6 mg/l versus 1.6 +/- 0.3 mg/l, p = 0.004). tcfa 158-162 C-reactive protein Homo sapiens 44-62 1364169-2 1992 Methotrexate was given as a single weekly dose of 7.5-10 mg. A correlation between serum concentration of CRP and proportion of CD8+ lymphocytes in peripheral blood was found in this group of patients. Methotrexate 0-12 C-reactive protein Homo sapiens 106-109 1375509-3 1992 CRP proteins are identified by their calcium-dependent interaction with phosphorylcholine. Phosphorylcholine 72-89 C-reactive protein Homo sapiens 0-3 1375509-5 1992 Thus, human CRP and SAP show high specificity that is complementary for the related compounds, phosphorylcholine and phosphorylethanolamine, respectively. Phosphorylcholine 95-112 C-reactive protein Homo sapiens 12-23 19545552-7 2009 In contrast, PEt inhibited the binding of both CRP and mCRP to pneumococcal C-polysaccharide, another phosphocholine-containing ligand to which CRP and mCRP were found to bind. Phosphorylcholine 102-116 C-reactive protein Homo sapiens 47-50 1859490-7 1991 Comparison between the 2 treatment groups at 24 weeks, by area-under-the-curve analysis, showed significantly more improvement in the MTX group in terms of the swollen joint count, pain score, erythrocyte sedimentation rate, C-reactive protein level, hemoglobin level, thrombocyte level, and disease activity score. Methotrexate 134-137 C-reactive protein Homo sapiens 225-243 19545552-7 2009 In contrast, PEt inhibited the binding of both CRP and mCRP to pneumococcal C-polysaccharide, another phosphocholine-containing ligand to which CRP and mCRP were found to bind. Phosphorylcholine 102-116 C-reactive protein Homo sapiens 56-59 19415724-5 2009 Subjects with vitamin D deficiency [25(OH)D level less than 50 nmol/L (20 ng/mL)] had higher mean values of serum C-reactive protein (CRP) (2.40 mg/L vs. 0.84 mg/L, P = 0.02) and creatinine (1.75 mg/dL vs. 1.24 mg/dL, P = 0.03) and lower serum albumin values (3.12 g/dL vs. 3.39 g/dL, P = 0.003) compared to subjects without vitamin D deficiency. Deuterium 22-23 C-reactive protein Homo sapiens 114-132 19415724-5 2009 Subjects with vitamin D deficiency [25(OH)D level less than 50 nmol/L (20 ng/mL)] had higher mean values of serum C-reactive protein (CRP) (2.40 mg/L vs. 0.84 mg/L, P = 0.02) and creatinine (1.75 mg/dL vs. 1.24 mg/dL, P = 0.03) and lower serum albumin values (3.12 g/dL vs. 3.39 g/dL, P = 0.003) compared to subjects without vitamin D deficiency. Deuterium 22-23 C-reactive protein Homo sapiens 134-137 1704398-0 1991 A synthetic peptide corresponding to the phosphorylcholine (PC)-binding region of human C-reactive protein possesses the TEPC-15 myeloma PC-idiotype. Phosphorylcholine 41-58 C-reactive protein Homo sapiens 88-106 19621776-0 2009 [A case of hypertrophic pachymeningitis treated successfully with antibiotics: the remarkable effect of minocycline hydrochloride in reducing the serum C-reactive protein value]. Minocycline 104-129 C-reactive protein Homo sapiens 152-170 1704398-0 1991 A synthetic peptide corresponding to the phosphorylcholine (PC)-binding region of human C-reactive protein possesses the TEPC-15 myeloma PC-idiotype. Phosphorylcholine 60-62 C-reactive protein Homo sapiens 88-106 1704398-2 1991 CRP molecules from all species display Ca2(+)-dependent binding to phosphorylcholine (PC). Phosphorylcholine 67-84 C-reactive protein Homo sapiens 0-3 1704398-2 1991 CRP molecules from all species display Ca2(+)-dependent binding to phosphorylcholine (PC). Phosphorylcholine 86-88 C-reactive protein Homo sapiens 0-3 1704398-3 1991 The conserved PC-binding region of CRP corresponds to amino acids 51-66 within the human CRP sequence. Phosphorylcholine 14-16 C-reactive protein Homo sapiens 35-38 1704398-3 1991 The conserved PC-binding region of CRP corresponds to amino acids 51-66 within the human CRP sequence. Phosphorylcholine 14-16 C-reactive protein Homo sapiens 89-92 1657391-0 1991 Involvements of fibronectin and lysophosphatidylcholine for selective binding of C-reactive protein. Lysophosphatidylcholines 32-55 C-reactive protein Homo sapiens 81-99 1657391-6 1991 On the other hand, CRP could aggregate liposome consisted of lyso-PC and phosphatidylcholine (PC), but not that consisted of PC alone. Lysophosphatidylcholines 61-68 C-reactive protein Homo sapiens 19-22 19621776-5 2009 Intravenous administration of some antibiotics (piperacillin sodium, ampicillin sodium/ sulbactam sodium, ampicillin sodium, cefozopran hydrochloride) was begun, but minocycline hydrochloride, which was subsequently administrated, proved remarkably effective in relieving symptoms and decreasing the serum C-reactive protein value, although other antibiotics showed little or no effect. Minocycline 166-191 C-reactive protein Homo sapiens 306-324 19656039-2 2009 : Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Rosuvastatin Calcium 2-14 C-reactive protein Homo sapiens 73-91 33813346-7 2021 RESULTS: In adjusted models we observed positive associations of monocarboxynonyl phthalate (MCNP) with CRP (beta = 0.092; 95% CI 0.026, 0.158) and IL-6 (beta = 0.108; 95% CI 0.013, 0.204). mcnp 93-97 C-reactive protein Homo sapiens 104-107 19118524-3 2009 In this study, we report that two synthetic FXR agonists, WAY-362450 and GW4064, suppressed interleukin-6-induced CRP expression in human Hep3B hepatoma cells. WAY-362450 58-68 C-reactive protein Homo sapiens 114-117 18801777-1 2009 OBJECTIVE: To assess the prognostic value of the baseline C-reactive protein (CRP) level in patients undergoing percutaneous coronary intervention (PCI) after pre-treatment with 600 mg of clopidogrel and whether there is an interaction between CRP level and abciximab in terms of outcome. Clopidogrel 188-199 C-reactive protein Homo sapiens 58-76 34863994-5 2022 According to the results, taking quercetin was significantly associated with partial earlier discharge and reduced serum levels of ALP, q-CRP, and LDH in the intervention group. Quercetin 33-42 C-reactive protein Homo sapiens 138-141 34863994-7 2022 Based on our observations, quercetin is safe and effective in lowering the serum levels of ALP, q-CRP, and LDH as critical markers involved in COVID-19 severity. Quercetin 27-36 C-reactive protein Homo sapiens 98-101 18801777-11 2009 CONCLUSION: In patients with CAD undergoing PCI after pretreatment with 600 mg of clopidogrel, baseline CRP level predicts one-year mortality and MACE. Clopidogrel 82-93 C-reactive protein Homo sapiens 104-107 34975846-4 2021 Cryo-electron microscopy was used to solve structures of CRP at pH 7.5 or pH 5 and in the presence or absence of the ligand phosphocholine (PCh), which yielded 7 new high-resolution structures of CRP, including pentameric and decameric complexes. Phosphorylcholine 124-138 C-reactive protein Homo sapiens 196-199 18775809-5 2009 RESULTS: Serum levels of [25(OH)D3] were low (21.6 +/- 12.2 ng/mL) and negatively correlated with age (r = -0.31, P < 0.001), diabetes mellitus (DM) (r = -0.20, P = 0.004), C-reactive protein (r = -0.25, P < 0.001), log(10) BNP (r = -0.22, P = 0.002), PP > 65 mmHg (r = -0.21, P = 0.003) and vascular calcifications (r = -0.26, P < 0.001). oh)d3 29-34 C-reactive protein Homo sapiens 176-194 34975846-4 2021 Cryo-electron microscopy was used to solve structures of CRP at pH 7.5 or pH 5 and in the presence or absence of the ligand phosphocholine (PCh), which yielded 7 new high-resolution structures of CRP, including pentameric and decameric complexes. Phosphorylcholine 140-143 C-reactive protein Homo sapiens 196-199 19778286-0 2009 A new turbidimetric method for assaying serum C-reactive protein based on phosphocholine interaction. Phosphorylcholine 74-88 C-reactive protein Homo sapiens 46-64 34416432-4 2021 In particular, the hydrogel contains phosphocholine moieties to specifically recognize C-Reactive protein (CRP). Phosphorylcholine 37-51 C-reactive protein Homo sapiens 87-105 19778286-1 2009 BACKGROUND: C-reactive protein (CRP) is able to bind phospholipids (mainly phosphocholine) in the presence of calcium ions. Phosphorylcholine 75-89 C-reactive protein Homo sapiens 12-30 34416432-4 2021 In particular, the hydrogel contains phosphocholine moieties to specifically recognize C-Reactive protein (CRP). Phosphorylcholine 37-51 C-reactive protein Homo sapiens 107-110 19778286-1 2009 BACKGROUND: C-reactive protein (CRP) is able to bind phospholipids (mainly phosphocholine) in the presence of calcium ions. Phosphorylcholine 75-89 C-reactive protein Homo sapiens 32-35 34869768-9 2021 dTAC correlated positively with Deltamonocyte 1 chemotactic protein (CCL-2) and DeltaC-reactive protein (CRP). dodecyltrimethylammonium 0-4 C-reactive protein Homo sapiens 105-108 19225250-7 2009 RESULTS: Fluvastatin treatment resulted in significant decreases in levels of total cholesterol, LDL cholesterol, triglyceride (p<0.005), and C-reactive protein (p<0.05). Fluvastatin 9-20 C-reactive protein Homo sapiens 145-163 34166564-4 2021 We examined the effect of five single nucleotide polymorphisms (SNPs) of Treg-related genes on the levels of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), alanine aminotransferase, and non-invasive hepatic fibrosis marker (Fibrosis-4 index) in a total of 138 participants with viral hepatitis. treg 73-77 C-reactive protein Homo sapiens 109-127 19120715-6 2008 HCTZ also increased plasma aldosterone and C-reactive protein levels. Hydrochlorothiazide 0-4 C-reactive protein Homo sapiens 43-61 34635132-9 2021 Although flaxseed oil supplementation had no such lowering-effect on lipid, meta-analysis revealed its lowering-effect on IL-6 (- 0.35 pg/ml, P = 0.033) and hs-CRP (- 1.54 mg/l, P = 0.004). Linseed Oil 9-21 C-reactive protein Homo sapiens 160-163 18997196-0 2008 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 71-89 34671655-3 2021 Aim: To investigate the association of inflammatory biomarkers such as leukocyte count and high-sensitivity C reactive proteins (hs-CRP) with platelet reactivity in PCI patients treated with clopidogrel. Clopidogrel 191-202 C-reactive protein Homo sapiens 132-135 34671655-10 2021 Conclusions: This was the first large real-world study reporting that both leukocyte count and hs-CRP were the independent factors for platelet reactivity in PCI populations treated with clopidogrel, among which higher leukocyte count was associated with more LTPR while higher hs-CRP was associated with more HTPR, providing new insights on individualized antiplatelet therapy. Clopidogrel 187-198 C-reactive protein Homo sapiens 98-101 34671655-10 2021 Conclusions: This was the first large real-world study reporting that both leukocyte count and hs-CRP were the independent factors for platelet reactivity in PCI populations treated with clopidogrel, among which higher leukocyte count was associated with more LTPR while higher hs-CRP was associated with more HTPR, providing new insights on individualized antiplatelet therapy. Clopidogrel 187-198 C-reactive protein Homo sapiens 281-284 18997196-9 2008 CONCLUSIONS: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. Rosuvastatin Calcium 142-154 C-reactive protein Homo sapiens 115-133 18929696-5 2008 High-sensitive C-reactive protein in the TCFA group was significantly higher than in the no-TCFA group (median 3.3 mg/L, interquartile 3.1, vs 1.7 mg/L, interquartile 2.2, p = 0.03). tcfa 41-45 C-reactive protein Homo sapiens 15-33 34244155-9 2021 Women randomized to omega-3-FA exhibiting >10% weight loss at 6 months showed greatest biomarker improvement including 6- and 12-month serum adiponectin, insulin, omentin and CRP, and 12-month tissue adiponectin. omega-3-fa 20-30 C-reactive protein Homo sapiens 175-178 18471410-9 2008 The plasma level of CRP in low-protein diet plus alpha-keto acid group was lower than that in the routine-protein diet group ( P<0.01). Keto Acids 55-64 C-reactive protein Homo sapiens 20-23 34203015-11 2021 Se biomarkers, most notably SELENOP, were inversely correlated with CRP (rs = -0.495), PCT (rs = -0.413), IL-6 (rs = -0.429), IL-1beta (rs = -0.440) and IL-10 (rs = -0.461). selenop 28-35 C-reactive protein Homo sapiens 68-71 35358776-4 2022 In an attempt to overcome these challenges, a multifunctional origami-paper-based device (ePADs) was developed to simultaneously detect CRP and PAB in whole blood. origami-paper-based device 62-88 C-reactive protein Homo sapiens 136-139 35509104-11 2022 Compared with the previous ICH risk scores, ICH-LR2S2 incorporates fasting blood glucose and C-reactive protein, improving its discriminative ability. lr2s2 48-53 C-reactive protein Homo sapiens 93-111 35397768-12 2022 Midazolam clearance was reduced by increased IL-6 and IL-6 explained more of the variability within our patients than CRP. Midazolam 0-9 C-reactive protein Homo sapiens 118-121 35448527-7 2022 CETP was positively related with triglycerides (R = 0.49), glucose (R = 0.54) and CRP (R = 0.64) before the treatment with methotrexate, which all disappeared afterwards. Methotrexate 123-135 C-reactive protein Homo sapiens 82-85 35054002-10 2022 The mean aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, and C-reactive protein levels were the highest in the MrMP group, along with higher incidences of extrapulmonary manifestations and atelectasis (during and post infection). mrmp 140-144 C-reactive protein Homo sapiens 90-108 35242650-0 2022 Efficacy of phentolamine combined with ambroxol aerosol inhalation in the treatment of pediatric severe pneumonia and its effect on serum IL-10 and CRP levels. Phentolamine 12-24 C-reactive protein Homo sapiens 148-151 35242650-1 2022 Background: The aim of the present study was to determine the therapeutic effect of phentolamine combined with Ambroxol aerosol inhalation on pediatric severe pneumonia and its effect on serum interleukin-10 (IL-10) and C-reactive protein (CRP) levels. Phentolamine 84-96 C-reactive protein Homo sapiens 220-238 35242650-1 2022 Background: The aim of the present study was to determine the therapeutic effect of phentolamine combined with Ambroxol aerosol inhalation on pediatric severe pneumonia and its effect on serum interleukin-10 (IL-10) and C-reactive protein (CRP) levels. Phentolamine 84-96 C-reactive protein Homo sapiens 240-243 18322245-4 2008 As reported previously, phosphocholine (PCh) inhibited CRP-E-LDL interaction, indicating the involvement of the PCh-binding site of CRP in binding to E-LDL. Phosphorylcholine 24-38 C-reactive protein Homo sapiens 55-58 18322245-4 2008 As reported previously, phosphocholine (PCh) inhibited CRP-E-LDL interaction, indicating the involvement of the PCh-binding site of CRP in binding to E-LDL. Phosphorylcholine 24-38 C-reactive protein Homo sapiens 132-135 18322245-4 2008 As reported previously, phosphocholine (PCh) inhibited CRP-E-LDL interaction, indicating the involvement of the PCh-binding site of CRP in binding to E-LDL. Phosphorylcholine 40-43 C-reactive protein Homo sapiens 55-58 18322245-4 2008 As reported previously, phosphocholine (PCh) inhibited CRP-E-LDL interaction, indicating the involvement of the PCh-binding site of CRP in binding to E-LDL. Phosphorylcholine 40-43 C-reactive protein Homo sapiens 132-135 18322245-4 2008 As reported previously, phosphocholine (PCh) inhibited CRP-E-LDL interaction, indicating the involvement of the PCh-binding site of CRP in binding to E-LDL. Phosphorylcholine 112-115 C-reactive protein Homo sapiens 55-58 18322245-4 2008 As reported previously, phosphocholine (PCh) inhibited CRP-E-LDL interaction, indicating the involvement of the PCh-binding site of CRP in binding to E-LDL. Phosphorylcholine 112-115 C-reactive protein Homo sapiens 132-135 18322245-5 2008 However, the amino acids Phe66 and Glu81 in CRP that participate in CRP-PCh interaction were not required for CRP-E-LDL interaction. Phosphorylcholine 72-75 C-reactive protein Homo sapiens 44-47 18322245-5 2008 However, the amino acids Phe66 and Glu81 in CRP that participate in CRP-PCh interaction were not required for CRP-E-LDL interaction. Phosphorylcholine 72-75 C-reactive protein Homo sapiens 68-71 18322245-5 2008 However, the amino acids Phe66 and Glu81 in CRP that participate in CRP-PCh interaction were not required for CRP-E-LDL interaction. Phosphorylcholine 72-75 C-reactive protein Homo sapiens 68-71 18322245-6 2008 Surprisingly, blocking of the PCh-binding site with phosphoethanolamine (PEt) dramatically increased the binding of CRP to E-LDL. Phosphorylcholine 30-33 C-reactive protein Homo sapiens 116-119 18322245-7 2008 The PEt-mediated enhancement in the binding of CRP to E-LDL was selective for E-LDL because PEt inhibited the binding of CRP to another PCh-binding site-ligand pneumococcal C-polysaccharide. Phosphorylcholine 136-139 C-reactive protein Homo sapiens 47-50 18322245-7 2008 The PEt-mediated enhancement in the binding of CRP to E-LDL was selective for E-LDL because PEt inhibited the binding of CRP to another PCh-binding site-ligand pneumococcal C-polysaccharide. Phosphorylcholine 136-139 C-reactive protein Homo sapiens 121-124 18292576-5 2008 SP600125 reduced the expression of the CRP gene induced by IL-1 plus IL-6. pyrazolanthrone 0-8 C-reactive protein Homo sapiens 39-42 18271807-7 2008 Finally, 10 days after starting the administration of methotrexate, the CRP value dramatically decreased from 7 mg/dL to 0.16 mg/dL, and thereafter the serum ferritin level started to decline, which thus enabled us to eventually taper the dose of oral prednisolone. Methotrexate 54-66 C-reactive protein Homo sapiens 72-75 19281089-9 2008 RESULTS: Multiple linear regression analysis indicated that ceHb, PaO2, and P50, were significant and independent predictors of CRP (R2 = 0.52, p < 0.0001). pao2 66-70 C-reactive protein Homo sapiens 128-131 17223112-6 2007 Rosuvastatin also produced superior dose-related decreases in median high-sensitivity C-reactive protein (22.9-38.5%). Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 86-104 17652082-9 2007 These results, confirmed in primary human hepatocytes and CASMC, demonstrate for the first time that IL-17 is a potent inducer of CRP expression via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation and suggest that IL-17 may mediate chronic inflammation, atherosclerosis, and thrombosis. casmc 58-63 C-reactive protein Homo sapiens 130-133 17963163-7 2007 MTX treatment was also followed by a decrease in the clinical markers of RA activity, such as the number of painful and swollen joints, erythrocyte sedimentation rate (ESR), disease activity score (DAS), and C-reactive protein (CRP) levels. Methotrexate 0-3 C-reactive protein Homo sapiens 208-226 17963163-7 2007 MTX treatment was also followed by a decrease in the clinical markers of RA activity, such as the number of painful and swollen joints, erythrocyte sedimentation rate (ESR), disease activity score (DAS), and C-reactive protein (CRP) levels. Methotrexate 0-3 C-reactive protein Homo sapiens 228-231 17595889-0 2007 Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 57-75 17595889-2 2007 In the present study we investigated the possibility that rosuvastatin directly affected CRP expression in stimulated human hepatocytes. Rosuvastatin Calcium 58-70 C-reactive protein Homo sapiens 89-92 3708910-1 1986 The uptake of C-reactive protein (CRP)-pneumococcal C-polysaccharide (CPS) complexes by neutrophils was studied. cps 70-73 C-reactive protein Homo sapiens 14-32 17595889-7 2007 Rosuvastatin reduced CRP expression by 32% and 46% in Hep3B and PHH, respectively. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 21-24 3708910-1 1986 The uptake of C-reactive protein (CRP)-pneumococcal C-polysaccharide (CPS) complexes by neutrophils was studied. cps 70-73 C-reactive protein Homo sapiens 34-37 17595889-9 2007 At 1 microM, rosuvastatin reduced CRP mRNA by 73% compared to IL-6-stimulated cells. Rosuvastatin Calcium 13-25 C-reactive protein Homo sapiens 34-37 3708910-3 1986 This promoted CPS (complexed to CRP) clearance which was further enhanced by additional complement activation. cps 14-17 C-reactive protein Homo sapiens 32-35 17595889-12 2007 CONCLUSIONS: Our results show a direct inhibitory effect of rosuvastatin on IL-6-induced expression of CRP in liver cells. Rosuvastatin Calcium 60-72 C-reactive protein Homo sapiens 103-106 17595889-14 2007 The effects of rosuvastatin in reducing the levels of CRP in plasma may have clinical utility in addition to its effects on atherogenic lipoproteins. Rosuvastatin Calcium 15-27 C-reactive protein Homo sapiens 54-57 17388968-4 2007 RESULTS: Among the wine phenolics tested, quercetin and resveratrol, in a dose-dependent manner, suppressed cytokine-induced CRP expression. Quercetin 42-51 C-reactive protein Homo sapiens 125-128 17184768-4 2007 Both flavonoids significantly inhibited mRNA level of iNOS, COX-2, and CRP. Flavonoids 5-15 C-reactive protein Homo sapiens 71-74 3723841-4 1986 CRP antigen is coupled to the carboxyfluorescein entrapped multilamellar liposomes by using N-hydroxysuccinimidyl 3-(2-pyridyldithio) propionate and dithiothreitol, and a specific lysis of liposomes is achieved upon the addition of anti-CRP antibody in the presence of complement. 6-carboxyfluorescein 30-48 C-reactive protein Homo sapiens 0-3 3723841-4 1986 CRP antigen is coupled to the carboxyfluorescein entrapped multilamellar liposomes by using N-hydroxysuccinimidyl 3-(2-pyridyldithio) propionate and dithiothreitol, and a specific lysis of liposomes is achieved upon the addition of anti-CRP antibody in the presence of complement. 6-carboxyfluorescein 30-48 C-reactive protein Homo sapiens 237-240 7056568-3 1982 It differed, however, from all other mammalian CRP"s characterised hitherto in being a glycoprotein bearing a single complex oligosaccharide on each polypeptide subunit. Oligosaccharides 125-140 C-reactive protein Homo sapiens 47-50 17184768-6 2007 The present study suggests that the modulation of iNOS, COX-2 and CRP by quercetin or kaempferol may contribute to the anti-inflammatory effects of these two structurally similar flavonoids in Chang Liver cells, via mechanisms likely to involve blockade of NF-kappaB activation and the resultant up-regulation of the pro-inflammatory genes. Quercetin 73-82 C-reactive protein Homo sapiens 66-69 17184768-6 2007 The present study suggests that the modulation of iNOS, COX-2 and CRP by quercetin or kaempferol may contribute to the anti-inflammatory effects of these two structurally similar flavonoids in Chang Liver cells, via mechanisms likely to involve blockade of NF-kappaB activation and the resultant up-regulation of the pro-inflammatory genes. Flavonoids 179-189 C-reactive protein Homo sapiens 66-69 17149558-0 2007 N-terminal brain natriuretic propeptide levels correlate with procalcitonin and C-reactive protein levels in septic patients. propeptide 29-39 C-reactive protein Homo sapiens 80-98 6796127-2 1981 The amino acid composition is given for a C-reactive protein isolated from the eggs of a marine teleost, Cyclopterus lumpus, by extraction with lecithin in the presence of Ca2+, followed by electrofocusing. Lecithins 144-152 C-reactive protein Homo sapiens 42-60 7462634-7 1981 CRP binding to liposomes was dependent on the presence of SA in the membrane and could occur with dimyristoyl phosphatidylethanolamine in place of DMPC. 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine 98-134 C-reactive protein Homo sapiens 0-3 16466728-0 2006 Soluble Fas, a mediator of apoptosis, C-reactive protein, and coronary and extracoronary atherosclerosis. ammonium ferrous sulfate 8-11 C-reactive protein Homo sapiens 38-56 915271-5 1977 Substrate-bound complexes of CPS-CRP selectively inhibited the uptake of IgG-coated E, EA(IgG); the inhibition was proportional to the concentration of CRP used to form the complex. cps 29-32 C-reactive protein Homo sapiens 33-36 17268399-1 2006 AIM: The aim of the paper was to elucidate whether and how, in end-stage renal disease (ESRD) patients on regular hemodialysis, the levels of C-reactive protein (CRP) correlate with CaxPO4 product; thus, a cross-sectional study was conducted on stable hemodialysis patients. caxpo4 182-188 C-reactive protein Homo sapiens 142-160 830761-6 1977 Similar C1 binding and C consumption in the presence of CRP were seen upon the interaction of multiple additional polyanions including DNA, ENA, hyaluronic acid, chondroitin sulfate, and dextran sulfate with the polycations protamine sulfate and poly-L-lysine. ENA 140-143 C-reactive protein Homo sapiens 56-59 830761-6 1977 Similar C1 binding and C consumption in the presence of CRP were seen upon the interaction of multiple additional polyanions including DNA, ENA, hyaluronic acid, chondroitin sulfate, and dextran sulfate with the polycations protamine sulfate and poly-L-lysine. Hyaluronic Acid 145-160 C-reactive protein Homo sapiens 56-59 33618152-4 2021 The use of cannabis plus cocaine leads to higher systemic levels of LPS, CRP, IL-6 and higher IL-6/IL-10 ratio, characterizing a proinflammatory profile. Cocaine 25-32 C-reactive protein Homo sapiens 73-76 33929089-1 2021 The aim was to analyze the relationship between peficitinib exposure and efficacy response according to American College of Rheumatology (ACR) 20 criteria and 28-joint disease activity score based on C-reactive protein (DAS28-CRP) in rheumatoid arthritis (RA) patients, and to identify relevant covariates by developing exposure-response models. peficitinib 48-59 C-reactive protein Homo sapiens 226-229 33929089-6 2021 The exposure-response models of effect of peficitinib on duration-dependent increase in ACR20 response rate and decrease in DAS28-CRP were adequately described by a continuous time Markov model and an indirect response model, respectively, with a sigmoidal Emax saturable of drug exposure in RA patients. peficitinib 42-53 C-reactive protein Homo sapiens 130-133 33929089-9 2021 Our exposure-response models of peficitinib in RA patients satisfactorily described duration-dependent improvements in ACR20 response rates and DAS28-CRP measurements, and provided consistent covariate effects. peficitinib 32-43 C-reactive protein Homo sapiens 150-153 17268399-1 2006 AIM: The aim of the paper was to elucidate whether and how, in end-stage renal disease (ESRD) patients on regular hemodialysis, the levels of C-reactive protein (CRP) correlate with CaxPO4 product; thus, a cross-sectional study was conducted on stable hemodialysis patients. caxpo4 182-188 C-reactive protein Homo sapiens 162-165 17268399-8 2006 Furthermore, significant positive correlation of logarithm of serum CRP with CaxPO4 product was found too. caxpo4 77-83 C-reactive protein Homo sapiens 68-71 17068712-5 2006 RESULTS: Peak CRP levels were reached on the second postoperative day in each group (medians: screws 8.7, DHS 12, PFN 14, HA 16, THA 16 mg/dL). (R)-Fenoprofen 114-117 C-reactive protein Homo sapiens 14-17 33571217-10 2021 In turn, multivariate regression analysis showed that bilirubin levels were negatively associated with high-sensitivity C-reactive protein levels and PDR, but positively correlated with urinary biopyrrin levels, oxidized metabolites of bilirubin. Bilirubin 54-63 C-reactive protein Homo sapiens 120-138 32453069-11 2021 CONCLUSION: Increased high-sensitivity C-reactive protein was associated with limited anatomic response to anti-vascular endothelial growth factor treatment and persistent DME. dme 172-175 C-reactive protein Homo sapiens 39-57 16751408-3 2006 C4BP bound to directly immobilized recombinant CRP as well as CRP attached to phosphorylcholine. Phosphorylcholine 78-95 C-reactive protein Homo sapiens 62-65 33479472-7 2021 We found that LncRNA NNT-AS1, CRP and PCT were all highly expressed in patients with RMPP. rmpp 85-89 C-reactive protein Homo sapiens 30-33 16026834-10 2006 RESULTS: The median (range) CRP level was significantly different between UA and UV [50.1 ng/ml (12.1-684.6) vs. 61 ng/ml (16.9-708.1)]. ulmoside A 74-76 C-reactive protein Homo sapiens 28-31 33479472-8 2021 LncRNA NNT-AS1 could positively correlate with the expressions of CRP and PCT, and jointly promote the occurrence of RMPP. rmpp 117-121 C-reactive protein Homo sapiens 66-69 33479472-9 2021 The combined diagnosis of LncRNA NNT-AS1, CRP and PCT could predict the occurrence of RMPP. rmpp 86-90 C-reactive protein Homo sapiens 42-45 16870092-6 2006 CRP levels remained significantly improved for more than 120 months with MTX. Methotrexate 73-76 C-reactive protein Homo sapiens 0-3 33521037-7 2020 Low density lipoprotein cholesterol (LDL-C) and high sensitivity C-reactive protein (hs-CRP) were significantly lower in the FRB group, compared to the RW group after 12 weeks of intervention. frb 125-128 C-reactive protein Homo sapiens 65-83 33521037-7 2020 Low density lipoprotein cholesterol (LDL-C) and high sensitivity C-reactive protein (hs-CRP) were significantly lower in the FRB group, compared to the RW group after 12 weeks of intervention. frb 125-128 C-reactive protein Homo sapiens 88-91 16500520-3 2006 We hypothesized that in essential hypertension (EH), oxidative stress, as measured by 8-iso-prostaglandin-F(2alpha) (8-iso-PGF(2alpha)), should be associated with increased CRP and endothelial activation, as evaluated by soluble intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion molecule-1 (VCAM-1) plasma levels. 8-iso-prostaglandin-f 86-107 C-reactive protein Homo sapiens 173-176 33438442-11 2022 More beneficial effects of EPA in survival were observed in men, pancreatic body-tail and low C-reactive protein patients. Eicosapentaenoic Acid 27-30 C-reactive protein Homo sapiens 94-112 16508926-9 2006 CONCLUSION: High CRP level, high ESR, or persistent disease activity was associated with greater radiographic progression in the group taking MTX alone, while little radiographic progression was seen in patients receiving both MTX and infliximab, regardless of the abnormal levels of these traditional predictors. Methotrexate 142-145 C-reactive protein Homo sapiens 17-20 33151775-6 2021 VitC increased superoxide dismutase (marker for endogenous antioxidant capacity) by 129% and mitigated C-reactive protein (marker for inflammation) in the plasma during exercise, but failed to alter the exercise-induced increase in lipid peroxidation (malondialdehyde) and free radicals (EPR-spectroscopy). Ascorbic Acid 0-4 C-reactive protein Homo sapiens 103-121 16520718-5 2006 In parallel assays, wells containing HUVECs and CRP were treated with tinzaparin at 1 mg/mL. Tinzaparin 70-80 C-reactive protein Homo sapiens 48-51 33254150-3 2021 Furthermore, we characterized the effect of the complexes of UA with ACBs on the expression of inflammatory biomarkers in human hepatoma HepG2 cell lines through C-reactive protein (CRP) western blot. Uric Acid 61-63 C-reactive protein Homo sapiens 162-180 16442368-7 2006 The median high-sensitivity C-reactive protein levels were significantly reduced statistically from baseline with rosuvastatin 20 mg and atorvastatin 20 mg among all patients and with rosuvastatin 10 and 20 mg and atorvastatin 20 mg in those patients with a baseline C-reactive protein level > 2.0 mg/L. Rosuvastatin Calcium 114-126 C-reactive protein Homo sapiens 28-46 33254150-3 2021 Furthermore, we characterized the effect of the complexes of UA with ACBs on the expression of inflammatory biomarkers in human hepatoma HepG2 cell lines through C-reactive protein (CRP) western blot. Uric Acid 61-63 C-reactive protein Homo sapiens 182-185 33254150-4 2021 The results showed UA molecules can be recognized by three ACBs with different binding constants, and ACBs successfully blocked the inflammatory stimulation of uric acid on HepG2 cell lines and inhibited the expression of the major inflammatory factor CRP by formations of complexes between UA and ACBs. Uric Acid 19-21 C-reactive protein Homo sapiens 252-255 33254150-4 2021 The results showed UA molecules can be recognized by three ACBs with different binding constants, and ACBs successfully blocked the inflammatory stimulation of uric acid on HepG2 cell lines and inhibited the expression of the major inflammatory factor CRP by formations of complexes between UA and ACBs. Uric Acid 291-293 C-reactive protein Homo sapiens 252-255 16442368-7 2006 The median high-sensitivity C-reactive protein levels were significantly reduced statistically from baseline with rosuvastatin 20 mg and atorvastatin 20 mg among all patients and with rosuvastatin 10 and 20 mg and atorvastatin 20 mg in those patients with a baseline C-reactive protein level > 2.0 mg/L. Rosuvastatin Calcium 184-196 C-reactive protein Homo sapiens 28-46 16858347-7 2006 Treatment of men with ischemic heart disease with rosuvastatin (10 mg for 3 months) led to achievement of target values of LDLCH in 77% of them, to significant lowering of concentrations of CRP and interleukin 6, and to improvement of endothelial function. Rosuvastatin Calcium 50-62 C-reactive protein Homo sapiens 190-193 33239071-14 2020 CONCLUSIONS: High levels of CRP, PLT, D-dimer, ASA, and >= 65 years of age increase the risk of preoperative DVTs in adult patients with closed DFFs. dffs 144-148 C-reactive protein Homo sapiens 28-31 33275095-10 2020 CONCLUSIONS: CRP serial measurements in the first week of TCZ therapy are useful in identifying patients developing poor outcomes. tioconazole 58-61 C-reactive protein Homo sapiens 13-16 16906379-1 2006 A 47-year-old man who had been taking minocycline for palmoplantar pustulosis developed fever, myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP). Minocycline 38-49 C-reactive protein Homo sapiens 156-174 32740676-10 2020 There was an increase in hs-CRP levels in both the treatment groups (olanzapine, p < 0.001; lurasidone, p < 0.001) with no significant difference between them (p = 0.467). Olanzapine 69-79 C-reactive protein Homo sapiens 28-31 33154657-7 2020 There was a positive correlation between alpha-tocopherol and hs-CRP in the nonsmoking and alcohol-drinking group. alpha-Tocopherol 41-57 C-reactive protein Homo sapiens 65-68 33154657-8 2020 There was a positive correlation between alpha-tocopherol and hs-CRP in the nonsmoking and alcohol-drinking female group. alpha-Tocopherol 41-57 C-reactive protein Homo sapiens 65-68 33154657-11 2020 Conclusion: There was a negative correlation between serum retinol and hs-CRP and positive correlation between alpha-tocopherol and hs-CRP. alpha-Tocopherol 111-127 C-reactive protein Homo sapiens 135-138 16906379-1 2006 A 47-year-old man who had been taking minocycline for palmoplantar pustulosis developed fever, myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP). Minocycline 38-49 C-reactive protein Homo sapiens 176-179 16906379-4 2006 Stopping minocycline led to amelioration of symptoms and normalization of CRP level. Minocycline 9-20 C-reactive protein Homo sapiens 74-77 33154724-10 2020 Furthermore, patients" C-reactive protein (CRP), albumin, and co-administration of PPI exhibited significant effects on the therapeutic window of patients receiving PCZ for prophylaxis. posaconazole 165-168 C-reactive protein Homo sapiens 23-41 16510377-0 2005 Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure. Fluvastatin 11-22 C-reactive protein Homo sapiens 51-69 33154724-10 2020 Furthermore, patients" C-reactive protein (CRP), albumin, and co-administration of PPI exhibited significant effects on the therapeutic window of patients receiving PCZ for prophylaxis. posaconazole 165-168 C-reactive protein Homo sapiens 43-46 32599147-9 2020 C-reactive protein (CRP) (Standardized Mean Difference (SMD): 0.49 CI 95% [0.37-0.61]) was significantly higher in the frail group whereas hemoglobin (SMD: -0.67[-0.90; -0.44]), albumin (SMD: -0.62[-0.84; -0.41]), 25-hydroxyvitamin D (25OHD) (SMD: -0.43 [-0.64; -0.21]) and, in men, free testosterone (SMD: -0.77 [-1.05; -0.49]) were significantly lower in the frail group. 25ohd 235-240 C-reactive protein Homo sapiens 0-18 32599147-9 2020 C-reactive protein (CRP) (Standardized Mean Difference (SMD): 0.49 CI 95% [0.37-0.61]) was significantly higher in the frail group whereas hemoglobin (SMD: -0.67[-0.90; -0.44]), albumin (SMD: -0.62[-0.84; -0.41]), 25-hydroxyvitamin D (25OHD) (SMD: -0.43 [-0.64; -0.21]) and, in men, free testosterone (SMD: -0.77 [-1.05; -0.49]) were significantly lower in the frail group. 25ohd 235-240 C-reactive protein Homo sapiens 20-23 33380704-6 2020 Results: : Both candesartan and atorvastatin treated groups showed significant decrease in serum levels IL-1beta and TNF-alpha, acute-phase reactants (CRP and ESR), number of swollen joint and patient global assessment. candesartan 16-27 C-reactive protein Homo sapiens 151-154 33088468-9 2020 Conclusions: The administration of acarbose in patients with MetS can decrease weight and abdominal obesity as well as the reduction of inflammatory and cardiovascular markers, including CRP, EFT, and IMT and also increases HDL. Acarbose 35-43 C-reactive protein Homo sapiens 187-190 32747455-9 2020 Tissue cholesterol, CRP levels and RAM 11 were significantly lower in simvastatin and ezetimibe rabbit groups compared with cholesterol diet alone. Simvastatin 70-81 C-reactive protein Homo sapiens 20-23 32731485-10 2020 Elevated CRP was found in 2/3 of people with low vitamin C and CRP was negatively correlated with vitamin C (p < 0.01). Ascorbic Acid 49-58 C-reactive protein Homo sapiens 9-12 32731485-10 2020 Elevated CRP was found in 2/3 of people with low vitamin C and CRP was negatively correlated with vitamin C (p < 0.01). Ascorbic Acid 98-107 C-reactive protein Homo sapiens 9-12 32731485-10 2020 Elevated CRP was found in 2/3 of people with low vitamin C and CRP was negatively correlated with vitamin C (p < 0.01). Ascorbic Acid 98-107 C-reactive protein Homo sapiens 63-66 32645105-8 2020 Fluoroquinolone-containing regimens were more likely selected for patients with cavitary lesions, diabetes mellitus, culture negativity, a low daily physical activity level, a decreased lymphocyte count and an increased CRP level. Fluoroquinolones 0-15 C-reactive protein Homo sapiens 220-223 32030452-9 2020 On multivariate logistic regression, C-reactive protein was positively associated with finding a true positive focus of fever on FDG-PET/CT (OR = 1.01 (95% CI 1.00-1.02) per mg/L increase in CRP), while leukocyte count was negatively associated with finding a true positive focus of fever (OR = 0.91 (95% CI 0.85-0.97) per 109 leukocytes/L increase). 4-fluoro-4-deoxyglucose 129-132 C-reactive protein Homo sapiens 37-55 32030452-9 2020 On multivariate logistic regression, C-reactive protein was positively associated with finding a true positive focus of fever on FDG-PET/CT (OR = 1.01 (95% CI 1.00-1.02) per mg/L increase in CRP), while leukocyte count was negatively associated with finding a true positive focus of fever (OR = 0.91 (95% CI 0.85-0.97) per 109 leukocytes/L increase). 4-fluoro-4-deoxyglucose 129-132 C-reactive protein Homo sapiens 191-194 32030452-12 2020 CRP and leukocyte count were significantly associated with FDG-PET/CT results, which may contribute to a priori assessment on the outcome of FDG-PET/CT. 4-fluoro-4-deoxyglucose 59-62 C-reactive protein Homo sapiens 0-3 32030452-12 2020 CRP and leukocyte count were significantly associated with FDG-PET/CT results, which may contribute to a priori assessment on the outcome of FDG-PET/CT. 4-fluoro-4-deoxyglucose 141-144 C-reactive protein Homo sapiens 0-3 32489296-0 2020 Effect of latanoprost on intraocular pressure, visual acuity and C-reactive protein. Latanoprost 10-21 C-reactive protein Homo sapiens 65-83 32489296-7 2020 Conclusion: Latanoprost can improve IOP, visual acuity, and CRP levels. Latanoprost 12-23 C-reactive protein Homo sapiens 60-63 31688897-12 2020 Moreover, we found significant associations between CDAD group and metabolic syndrome, prior use of antibiotic in the last 3 months, NAFLD and high serum levels of C-reactive protein. cdad 52-56 C-reactive protein Homo sapiens 164-182 32399331-0 2020 Elevated C-reactive Protein and Role of Steroids in Cocaine-associated Levamisole-induced Vasculitis. Cocaine 52-59 C-reactive protein Homo sapiens 9-27 32246038-0 2020 Associations of C-reactive Protein with 25-hydroxyvitamin D in 24 Specific Diseases: A Cross-sectional Study from NHANES. 25-hydroxyvitamin D 40-59 C-reactive protein Homo sapiens 16-34 32246038-2 2020 Thus, we examined the associations of one of the best markers for inflammation - C-reactive protein (CRP) with 25-hydroxyvitamin D [25(OH)D] in 24 specific diseases. 25-hydroxyvitamin D 111-130 C-reactive protein Homo sapiens 81-99 32246038-2 2020 Thus, we examined the associations of one of the best markers for inflammation - C-reactive protein (CRP) with 25-hydroxyvitamin D [25(OH)D] in 24 specific diseases. 25-hydroxyvitamin D 111-130 C-reactive protein Homo sapiens 101-104 32347005-6 2020 RESULTS: The CRP and IL-6 levels were lower in the TXA + DEX group than in the TXA group (all P < 0.001) at 24 h, 48 h, and 72 h postoperatively. Tranexamic Acid 51-54 C-reactive protein Homo sapiens 13-16 32229693-2 2020 Previous studies have reached mixed conclusions regarding the effect of vitamin C on reducing CRP or hs-CRP level. Ascorbic Acid 72-81 C-reactive protein Homo sapiens 94-97 32229693-2 2020 Previous studies have reached mixed conclusions regarding the effect of vitamin C on reducing CRP or hs-CRP level. Ascorbic Acid 72-81 C-reactive protein Homo sapiens 104-107 32229693-5 2020 Clinical trials which examined the effect of either vitamin C supplementation or vitamin C-enriched foods on CRP and hs-CRP levels were included. Ascorbic Acid 81-90 C-reactive protein Homo sapiens 109-112 32229693-7 2020 Results Overall, the pooled analysis revealed that vitamin C could decrease CRP level relative to placebo group (Weighted mean difference [WMD]=-0.73 mg/L: 95% CI: -1.30 to -0.15, p=0.013) with a considerable heterogeneity (I2=98%, p<0.001). Ascorbic Acid 51-60 C-reactive protein Homo sapiens 76-79 32229693-8 2020 Moreover, subgroup analyses revealed that the beneficial effect of vitamin C on CRP level alternation only was found in male (p=0.003), non-smoker (p=0.041), healthy (p=0.029) and younger participants (p=0.010). Ascorbic Acid 67-76 C-reactive protein Homo sapiens 80-83 32229693-9 2020 Vitamin C could improve CRP level only at doses of less than 500 mg/day (p=0.009). Ascorbic Acid 0-9 C-reactive protein Homo sapiens 24-27 32229693-11 2020 This finding was confirmed by all subgroup analyses expect for high quality articles in which hs-CRP level was elevated after vitamin C supplementation (p=0.026). Ascorbic Acid 126-135 C-reactive protein Homo sapiens 97-100 32229693-12 2020 Conclusion In conclusion, supplementation with vitamin C might have a significant effect only on CRP reduction. Ascorbic Acid 47-56 C-reactive protein Homo sapiens 97-100 31734364-9 2020 However, endocan and simvastatin combination treatment could suppress NO, ROS production and iNOS, CRP activation. Simvastatin 21-32 C-reactive protein Homo sapiens 99-102 32280080-1 2020 OBJECTIVE: This study aims to investigate the effect of nimodipine combined with betahistine on the levels of CRP and other inflammatory cytokines, as well as vascular endothelial function in patients with hypertensive cerebral vasospasm. Betahistine 81-92 C-reactive protein Homo sapiens 110-113 31889148-5 2019 Alum-adjuvanted hepatitis B vaccine elicited vital signs and inflammatory (CRP/innate cells) responses that were similar between primed/naive vaccinees, and low-level gene responses. alum-adjuvanted 0-15 C-reactive protein Homo sapiens 75-78 31237262-9 2019 The detection limit (LOD) of CRP in phosphate-buffered saline was 2.5 pg mL-1 with a sample volume of 0.25 muL. Phosphate-Buffered Saline 36-61 C-reactive protein Homo sapiens 29-32 31441836-9 2019 CONCLUSION: The combined administration of TXA + Dexa significantly reduced the level of postoperative CRP and IL-6, relieve postoperative pain, ameliorate the incidence of POVN, provide additional analgesic and antiemetic effects, reduce postoperative fatigue, and improve ROM, without increasing the risk of complications in primary TKA. Tranexamic Acid 43-46 C-reactive protein Homo sapiens 103-106 31208420-13 2019 CONCLUSIONS: DDP-4i effectively reduced serum CRP levels and showed no stronger effect than traditional oral antidiabetic agents. ddp-4i 13-19 C-reactive protein Homo sapiens 46-49 30892107-11 2019 CRP was associated with ME dose, with an estimated increase of 0.030 mg/kg (95% CI 0.024-0.035) in ME for a 50% increase in CRP level on the same day (p < .001). methionylglutamic acid 24-26 C-reactive protein Homo sapiens 0-3 30892107-11 2019 CRP was associated with ME dose, with an estimated increase of 0.030 mg/kg (95% CI 0.024-0.035) in ME for a 50% increase in CRP level on the same day (p < .001). methionylglutamic acid 24-26 C-reactive protein Homo sapiens 124-127 30682545-3 2019 The aim of this study was to investigate whether the serum concentrations of 25-hydroxyvitamin D (25[OH]D) within the first 48 h after ICU admission are associated with prognostic indicators (Acute Physiology and Chronic Health Evaluation [APACHE] II, Sequential Organ Failure Assessment [SOFA] score, Charlson comorbidity index [CCI]), clinical complications, serum C-reactive protein (CRP) concentrations, mechanical ventilation duration, and mortality. 25-hydroxyvitamin D 77-96 C-reactive protein Homo sapiens 367-385 30682545-3 2019 The aim of this study was to investigate whether the serum concentrations of 25-hydroxyvitamin D (25[OH]D) within the first 48 h after ICU admission are associated with prognostic indicators (Acute Physiology and Chronic Health Evaluation [APACHE] II, Sequential Organ Failure Assessment [SOFA] score, Charlson comorbidity index [CCI]), clinical complications, serum C-reactive protein (CRP) concentrations, mechanical ventilation duration, and mortality. 25-hydroxyvitamin D 77-96 C-reactive protein Homo sapiens 387-390 30800416-8 2019 Levels of 25-hydroxy-vitamin D were associated with self-perceived health (r = 0.18, P = 0.041, n = 130) and C-reactive protein (r = -0.13, P = 0.042) but not with the risk of side effects. 25-hydroxyvitamin D 10-30 C-reactive protein Homo sapiens 109-127 29993265-8 2019 Both EPA (-0.56 mg/L; 95%CI: -1.13, 0.00) and DHA (-0.5 mg/L; 95%CI: -1.0, -0.03) significantly reduced the concentrations of C-reactive protein (CRP), respectively, especially in subjects with dyslipidemia and higher baseline CRP concentrations. Eicosapentaenoic Acid 5-8 C-reactive protein Homo sapiens 126-144 29993265-8 2019 Both EPA (-0.56 mg/L; 95%CI: -1.13, 0.00) and DHA (-0.5 mg/L; 95%CI: -1.0, -0.03) significantly reduced the concentrations of C-reactive protein (CRP), respectively, especially in subjects with dyslipidemia and higher baseline CRP concentrations. Eicosapentaenoic Acid 5-8 C-reactive protein Homo sapiens 146-149 29993265-8 2019 Both EPA (-0.56 mg/L; 95%CI: -1.13, 0.00) and DHA (-0.5 mg/L; 95%CI: -1.0, -0.03) significantly reduced the concentrations of C-reactive protein (CRP), respectively, especially in subjects with dyslipidemia and higher baseline CRP concentrations. Eicosapentaenoic Acid 5-8 C-reactive protein Homo sapiens 227-230 29993265-10 2019 The present meta-analysis provides substantial evidence that EPA and DHA have independent (blood pressure) and shared (CRP concentration) effects on risk factors of chronic diseases, and high-quality RCTs with multi-center and large simple-size should be performed to confirm the present findings. Eicosapentaenoic Acid 61-64 C-reactive protein Homo sapiens 119-122 29623847-9 2019 The concentrations of tADA in patients with RF and CRP positive were significantly higher (Pv <0.05). azetidine-2,4-dicarboxylic acid 22-26 C-reactive protein Homo sapiens 51-54 30051214-9 2018 The serum IL-6 and CRP levels were inversely correlated with the plasma concentration ratios of N-desmethyltramadol to tramadol and of N,O-didesmethyltramadol to O-desmethyltramadol. N-demethyltramadol 96-115 C-reactive protein Homo sapiens 19-22 30278950-9 2018 CONCLUSIONS: Higher preoperative CRP levels have a robust prognostic impact on recurrence-free survival in DTC patients. dtc 107-110 C-reactive protein Homo sapiens 33-36 30126098-8 2018 Multiple linear regression, controlling for age and body mass index (BMI), demonstrated an inverse association between serum carotenoid concentrations and pro-inflammatory sTNFR-II (beta = 0.404, p = 0.005) and IL-6 concentrations (beta = -0.35, p = 0.001), but not IL-1ra or CRP. Carotenoids 125-135 C-reactive protein Homo sapiens 276-279 29669302-7 2018 Sodium ascorbate exerts anti-inflammatory activity by reducing the expression of NFkappaB, CRP, TNF-alpha, IL-1beta and IL-6 associated with enhanced expression of the anti-inflammatory cytokines, IL-4 and IL-10. Ascorbic Acid 0-16 C-reactive protein Homo sapiens 91-94 28847205-6 2018 The improvement in CRP observed in the MOD-C group was larger than the VIG-C group (p = .034). vig-c 71-76 C-reactive protein Homo sapiens 19-22 16510377-6 2005 A statistically significant reduction in C-reactive protein (CRP) over baseline values was observed in approximately 75% of patients treated with fluvastatin. Fluvastatin 146-157 C-reactive protein Homo sapiens 41-59 16510377-6 2005 A statistically significant reduction in C-reactive protein (CRP) over baseline values was observed in approximately 75% of patients treated with fluvastatin. Fluvastatin 146-157 C-reactive protein Homo sapiens 61-64 16510377-7 2005 Furthermore, mean values of CRP for the fluvastatin standard treatment groups, respectively, were 6.78 and 10.19 at 3 months and 4.47 and 11 at 6 months. Fluvastatin 40-51 C-reactive protein Homo sapiens 28-31 16253600-0 2005 Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Rosuvastatin Calcium 10-22 C-reactive protein Homo sapiens 26-44 29292430-3 2018 The developed GMR sensor can achieve a bulk sensitivity of 186 nm RIU-1, which supports a limit of detection of 3.2 ng mL-1 for recombinant CRP spiked in human serum. gmr 14-17 C-reactive protein Homo sapiens 140-143 29292430-5 2018 In addition, we demonstrate the efficacy of filtration of blood cells using microposts and simultaneous measurement of CRP concentration using a GMR sensor by using whole blood and plasma samples. gmr 145-148 C-reactive protein Homo sapiens 119-122 29159893-6 2018 RESULTS: CZP concentrations at weeks 2, 4 and 6 were higher in patients with clinical response, remission, CRP <= 5 mg/L or FC <= 250 mug/g at week 6 than without. Certolizumab Pegol 9-12 C-reactive protein Homo sapiens 107-110 29172154-2 2018 We have shown previously the calcium-independent adsorption of CRP toward 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and lysophosphatidylcholine (LPC) on supported phospholipid monolayers. 1-palmitoyl-2-oleoylphosphatidylcholine 74-122 C-reactive protein Homo sapiens 63-66 16265686-9 2005 After infliximab treatment (MTX + IFM Group) there was a significant decrease in DAS28 and modified Health Assessment Questionnaire scores and ESR and CRP levels. Methotrexate 28-31 C-reactive protein Homo sapiens 151-154 29172154-2 2018 We have shown previously the calcium-independent adsorption of CRP toward 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and lysophosphatidylcholine (LPC) on supported phospholipid monolayers. 1-palmitoyl-2-oleoylphosphatidylcholine 124-128 C-reactive protein Homo sapiens 63-66 29172154-7 2018 While, the addition of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE) or sphingomyelin to supported POPC monolayers blocked CRP adsorption. Sphingomyelins 87-100 C-reactive protein Homo sapiens 138-141 15961109-6 2005 NIHSS levels were positively correlated with CRP and fibrinogen at all time points. nihss 0-5 C-reactive protein Homo sapiens 45-48 30467439-7 2018 Bilirubin and albumin levels were lower in the serum of active CD patients than inactive CD patients and controls and negatively correlated with the CD activity index (r = -0328, p = 0.036, r = -0.518, p = 0.002) and CRP (r = -0.433, p = 0.002). Bilirubin 0-9 C-reactive protein Homo sapiens 217-220 16193198-6 2005 High-sensitivity C-reactive protein levels were significantly lowered by rosuvastatin therapy (median values, 3.1 vs 2.0 vs 1.9 mg/L, at 0, 8, and 20 weeks, respectively; p < 0.0001). Rosuvastatin Calcium 73-85 C-reactive protein Homo sapiens 17-35 28935270-6 2017 In univariate and multivariate analysis, CRP serum levels were independently associated with presence of BTO and EOC (HR 6.7 [5.2-8.5], p<0.001 and HR 2.2 [1.4-3.3], p<0.001). bto 105-108 C-reactive protein Homo sapiens 41-44 28582961-4 2017 The ZnSe/CdS/ZnS QDs are used as fluorescent labels to exploit their application in fluorescence-linked immunosorbent assay (FLISA) for the first time in the detection of C-reactive protein (CRP) with a limit of detection (LOD) of 0.85 ng/mL, which is more sensitive than that of CdSe/ZnS type-I QDs based FLISA (1.00 ng/mL). Selanylidenezinc 4-8 C-reactive protein Homo sapiens 171-189 28582961-4 2017 The ZnSe/CdS/ZnS QDs are used as fluorescent labels to exploit their application in fluorescence-linked immunosorbent assay (FLISA) for the first time in the detection of C-reactive protein (CRP) with a limit of detection (LOD) of 0.85 ng/mL, which is more sensitive than that of CdSe/ZnS type-I QDs based FLISA (1.00 ng/mL). Selanylidenezinc 4-8 C-reactive protein Homo sapiens 191-194 16175949-6 2005 After switching Aza to methotrexate (Mtx) treatment, his symptoms disappeared and CRP concentration returned to normal. Methotrexate 23-35 C-reactive protein Homo sapiens 82-85 28811499-7 2017 Stress-induction at the onset/progression of this disease is noticed as the high-level of lipid peroxides/low-level of free-thiols in association with increase of inflammatory-markers c-reactive protein and TNF-alpha. Lipid Peroxides 90-105 C-reactive protein Homo sapiens 184-202 16175949-6 2005 After switching Aza to methotrexate (Mtx) treatment, his symptoms disappeared and CRP concentration returned to normal. Methotrexate 37-40 C-reactive protein Homo sapiens 82-85 29113390-4 2017 Studying the correlation of serum bilirubin levels with iron, zinc, copper and high-sensitivity C-reactive protein, we found positive correlations for iron and zinc, and negative correlations for high-sensitivity C-reactive protein and copper in whole participants. Bilirubin 34-43 C-reactive protein Homo sapiens 96-114 29113390-4 2017 Studying the correlation of serum bilirubin levels with iron, zinc, copper and high-sensitivity C-reactive protein, we found positive correlations for iron and zinc, and negative correlations for high-sensitivity C-reactive protein and copper in whole participants. Bilirubin 34-43 C-reactive protein Homo sapiens 213-231 15985490-10 2005 CONCLUSIONS: We conclude that rosiglitazone: 1) causes a significant increase in GIR; 2) induces a decrease in inflammatory mediators, C-reactive protein, and serum amyloid A; 3) decreases the rise in FFAs and triglycerides after TG-Hep infusion; and 4) does not prevent FFA-induced IR. Fatty Acids, Nonesterified 201-204 C-reactive protein Homo sapiens 135-177 16002945-5 2005 MEASUREMENTS AND RESULTS: The mean peak C-reactive protein and lactate dehydrogenase levels were higher in SARS patients who were receiving ribavirin therapy than in SARS patients who were not receiving ribavirin therapy. Ribavirin 140-149 C-reactive protein Homo sapiens 40-58 28410854-4 2017 Serum bilirubin was found to be negatively correlated with C-reactive protein (CRP) concentration and erythrocyte sedimentation rate (ESR) (r=-0.165, P=0.030; r=-192, P=0.012) in patients with RA. Bilirubin 6-15 C-reactive protein Homo sapiens 59-77 28410854-4 2017 Serum bilirubin was found to be negatively correlated with C-reactive protein (CRP) concentration and erythrocyte sedimentation rate (ESR) (r=-0.165, P=0.030; r=-192, P=0.012) in patients with RA. Bilirubin 6-15 C-reactive protein Homo sapiens 79-82 15878871-7 2005 A previous study by our laboratory identified an amino acid position, Leu(176), critical for CRP binding to FcgammaRI and work by others (Agrawal, A., Shrive, A. K., Greenhough, T. J., and Volanakis, J. E. (2001) J. Immunol. Leucine 70-73 C-reactive protein Homo sapiens 93-96 15878871-12 2005 Single mutations at amino acid positions Lys(114), Asp(169), Thr(173), Tyr(175), and Leu(176) affected C1q binding to CRP. Aspartic Acid 51-54 C-reactive protein Homo sapiens 118-121 28044198-6 2017 In vivo, meloxicam significantly reduced serum C-reactive protein concentration, tooth movement velocity, orthodontically induced dentine root resorption (OIRR), osteoclast activity and the relative expression of inflammatory/osteoclast marker genes within the dental-periodontal tissue, while presenting good gastric tolerance. Meloxicam 9-18 C-reactive protein Homo sapiens 47-65 16012325-13 2005 Ara-C fever is common, and evaluation with inflammation markers is complicated by the fact that HDAC can induce a moderate release of both CRP and PCT. hdac 96-100 C-reactive protein Homo sapiens 139-142 16194025-3 2005 The aim of the study was: 1) to investigate the ability of the major tea polyphenols: (-)-epigallocatechin gallate (EGCG), theaflavins (TF) and gallic acid (GA) to protect in vitro human neutrophils from oxidative damage induced by phorbol myristate acetate (PMA), 2) estimation the level of reactive oxygen species (ROS) production in obese patient depending on the red tea Pu-Erh drinking, 3) estimation inflammatory marker: CRP. theaflavin 136-138 C-reactive protein Homo sapiens 427-430 28153283-1 2017 An immunosensor for fast and accurate determination of C-reactive protein (CRP) in human serum samples based on an array of all-silicon broad-band Mach-Zehnder interferometers (BB-MZIs) is demonstrated. bb-mzis 177-184 C-reactive protein Homo sapiens 55-73 15894122-6 2005 Serum CRP level did not change significantly over the course of observation: it was 3.25 mg/dl before, 2.36 mg/dl immediately after and 2.71 mg/dl 2h after exercise and unrelated to IL-6 level. Deuterium 147-149 C-reactive protein Homo sapiens 6-9 28153283-1 2017 An immunosensor for fast and accurate determination of C-reactive protein (CRP) in human serum samples based on an array of all-silicon broad-band Mach-Zehnder interferometers (BB-MZIs) is demonstrated. bb-mzis 177-184 C-reactive protein Homo sapiens 75-78 28153283-2 2017 The detection was based on monitoring the spectral shifts during the binding of CRP on the antibody molecules that have been immobilized on the sensing arms of the BB-MZIs. bb-mzis 164-171 C-reactive protein Homo sapiens 80-83 28105870-0 2017 Association of serum uric acid with high-sensitivity C-reactive protein in postmenopausal women. Uric Acid 21-30 C-reactive protein Homo sapiens 53-71 28105870-1 2017 OBJECTIVES: To explore the independent correlation between serum uric acid and low-grade inflammation (measured by high-sensitivity C-reactive protein, hs-CRP) in postmenopausal women. Uric Acid 65-74 C-reactive protein Homo sapiens 132-150 27928713-10 2017 At 10-day follow-up, improvement in redness, edema, and CRP levels from baseline was also greater in patients treated with Betesil compared with diclofenac (all p < 0.01). Diclofenac 145-155 C-reactive protein Homo sapiens 56-59 15701058-9 2005 Furthermore, specific MAPK inhibitors (PD98059, SB203580 and SP600125) inhibited the expression of IL-8 mRNA induced by CRP (50 microg/ml). pyrazolanthrone 61-69 C-reactive protein Homo sapiens 120-123 27815167-3 2017 Surprisingly, CRP binding to supported 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)/LPC monolayers was calcium-independent although CRP binding to supported POPC monolayers was calcium-dependent. 1-palmitoyl-2-oleoylphosphatidylcholine 39-87 C-reactive protein Homo sapiens 14-17 27815167-3 2017 Surprisingly, CRP binding to supported 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)/LPC monolayers was calcium-independent although CRP binding to supported POPC monolayers was calcium-dependent. 1-palmitoyl-2-oleoylphosphatidylcholine 89-93 C-reactive protein Homo sapiens 14-17 15718491-7 2005 Dihydroethidium staining showed that CRP produced SB203850- and TEMPOL-sensitive superoxide production in the arteriolar endothelium. sb203850 50-58 C-reactive protein Homo sapiens 37-40 15698590-0 2005 Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Fluvastatin 0-11 C-reactive protein Homo sapiens 148-166 27719651-3 2017 Hence, a systematic review and meta-analysis of available evidence was conducted in order to calculate the effect size of sibutramine therapy on C-reactive protein (CRP), leptin and adiponectin concentrations. sibutramine 122-133 C-reactive protein Homo sapiens 145-163 27719651-3 2017 Hence, a systematic review and meta-analysis of available evidence was conducted in order to calculate the effect size of sibutramine therapy on C-reactive protein (CRP), leptin and adiponectin concentrations. sibutramine 122-133 C-reactive protein Homo sapiens 165-168 27719651-6 2017 Subgroup analysis showed a greater CRP-lowering effect of sibutramine with doses <15 mg/day (WMD -17.26%, 95%CI: -31.02, -3.5, p=0.014) compared with doses .15 mg/day (WMD 6.01%, 95%CI: -43.38, 55.40, p=0.811). sibutramine 58-69 C-reactive protein Homo sapiens 35-38 27719651-8 2017 These results suggest a significant improvement of plasma CRP, leptin and adiponectin levels following treatment with sibutramine. sibutramine 118-129 C-reactive protein Homo sapiens 58-61 15698590-5 2005 We determined the effects of CRP in inducing inflammatory response and the effect of fluvastatin on CRP-dependent inflammatory activation in human cultured endothelial cells. Fluvastatin 85-96 C-reactive protein Homo sapiens 100-103 15698590-11 2005 The CRP also significantly induces the activation of NF-kappaB in endothelial cells, and those effects were apparently inhibited by 10 micromol/l of fluvastatin, but not complete. Fluvastatin 149-160 C-reactive protein Homo sapiens 4-7 15698590-12 2005 CONCLUSIONS: CRP stimulation result in induction of TNF-alpha and activation of NF-kappaB, and this effect could be significantly inhibited by fluvastatin, suggesting that CRP may play a direct role in atherogenesis by activating endothelial cells, and statins inhibit this response, which may provide an insight into the mechanisms of anti-inflammatory or anti-atherosclerotic actions of statins. Fluvastatin 143-154 C-reactive protein Homo sapiens 13-16 27274008-8 2016 Valine at position 11 showed the strongest association with the CRP level (P = 2.21 x 10-6 ), the SJC (P = 7.51 x 10-6 ), and the DAS28 (P = 0.002); it was marginally associated with the HAQ score (P = 0.044) but not with the TJC. Valine 0-6 C-reactive protein Homo sapiens 64-67 15698590-12 2005 CONCLUSIONS: CRP stimulation result in induction of TNF-alpha and activation of NF-kappaB, and this effect could be significantly inhibited by fluvastatin, suggesting that CRP may play a direct role in atherogenesis by activating endothelial cells, and statins inhibit this response, which may provide an insight into the mechanisms of anti-inflammatory or anti-atherosclerotic actions of statins. Fluvastatin 143-154 C-reactive protein Homo sapiens 172-175 15653029-11 2005 Also, LAS was associated with a significantly larger LA size, lower ejection fraction, and higher C-reactive protein levels. las 6-9 C-reactive protein Homo sapiens 98-116 26400051-5 2016 CONCLUSIONS: Increased serum levels of CRP and serum and aqueous levels of TNF-alpha in DME suggest that inflammation is involved in the pathogenesis of DME. dme 153-156 C-reactive protein Homo sapiens 39-42 16103720-3 2005 For this reason we have evaluated in a cross-sectional and in an interventional study the possible correlation between CaxPO4 and CRP and the effect of the correction of a high CaxPO4 on CRP levels. caxpo4 119-125 C-reactive protein Homo sapiens 130-133 15571366-2 2004 C-reactive protein determination at high amplification with [Ru(bpy)3]2+-containing microspheres. [ru(bpy)3]2+ 60-72 C-reactive protein Homo sapiens 0-18 27227519-8 2016 Multiple logistic regression analysis showed that the CRP>=16.5mg/L, LDH >=417IU/L and IL-6 >=14.75pg/ml were significant predictors regarding to RMPP. rmpp 155-159 C-reactive protein Homo sapiens 54-57 27227519-9 2016 CONCLUSIONS: CRP>=16.5mg/L, LDH >=417IU/L and IL-6 >=14.75pg/ml might be the significant predictors of RMPP in children, which can aid in early recognition of RMPP. rmpp 112-116 C-reactive protein Homo sapiens 13-16 27227519-9 2016 CONCLUSIONS: CRP>=16.5mg/L, LDH >=417IU/L and IL-6 >=14.75pg/ml might be the significant predictors of RMPP in children, which can aid in early recognition of RMPP. rmpp 168-172 C-reactive protein Homo sapiens 13-16 15572041-6 2004 CRP-induced the expression of tissue factor protein and the secretion of IL-6, IL-8, IL-1beta, TNFalpha and PGE(2). Prostaglandins E 108-111 C-reactive protein Homo sapiens 0-3 15459582-6 2004 TZDs decrease plasma insulin levels, improve endothelial function, decrease vascular inflammation, and decrease C-reactive protein levels, effects that are potentially beneficial in patients with heart failure. Thiazolidinediones 0-4 C-reactive protein Homo sapiens 112-130 27101096-8 2016 The fasting insulin (FINS) and C reactive protein (CRP) levels were significantly higher in obese patients complicated by mild increased TSH when compared to the obese patients with normal TSH (p<0.01). Thyrotropin 137-140 C-reactive protein Homo sapiens 31-49 27101096-8 2016 The fasting insulin (FINS) and C reactive protein (CRP) levels were significantly higher in obese patients complicated by mild increased TSH when compared to the obese patients with normal TSH (p<0.01). Thyrotropin 137-140 C-reactive protein Homo sapiens 51-54 15559367-1 2004 C-reactive protein (CRP) is a blood component comprised of five identical subunits with a combined molecular mass of 110 kDa; in the presence of Ca++ it binds phosphocholine (PC) with high affinity. Phosphorylcholine 159-173 C-reactive protein Homo sapiens 0-18 26926930-7 2016 White blood cell count, high-sensitivity C-reactive protein, and interleukin 6 were significantly higher in the PIS group during the postoperative period (P < .001). Monothiopyrophosphoric acid 112-115 C-reactive protein Homo sapiens 41-78 26847832-5 2016 The C-reactive protein (CRP) elevation and albumin decline of the AHCC group were significantly suppressed as compared to the control group during the GEM administration (P = 0.0012, P = 0.0007). 4-(N)-lauroylgemcitabine 151-154 C-reactive protein Homo sapiens 4-22 26847832-5 2016 The C-reactive protein (CRP) elevation and albumin decline of the AHCC group were significantly suppressed as compared to the control group during the GEM administration (P = 0.0012, P = 0.0007). 4-(N)-lauroylgemcitabine 151-154 C-reactive protein Homo sapiens 24-27 26602073-9 2015 In Cox multivariate analysis adjusted for age, gender, prednisolone treatment, smoking, baseline LDL cholesterol and high sensitivity C-reactive protein; simvastatin plus ezetimibe versus placebo was associated with 44% lower risk of cataract development (hazard ratio 0.56, 95% confidence interval 0.33 to 0.96, p = 0.034). Simvastatin 154-165 C-reactive protein Homo sapiens 134-152 26713054-8 2015 When PIS was constructed with combination of CRP and NLR, it was independently and significantly associated with both DFS and DSS (P=0.006, P=0.010). Monothiopyrophosphoric acid 5-8 C-reactive protein Homo sapiens 45-48 15559367-1 2004 C-reactive protein (CRP) is a blood component comprised of five identical subunits with a combined molecular mass of 110 kDa; in the presence of Ca++ it binds phosphocholine (PC) with high affinity. Phosphorylcholine 159-173 C-reactive protein Homo sapiens 20-23 26713054-10 2015 When PIS is constructed with combination of CRP and NLR, it is a potentially significant prognostic variable associated with poor survival regardless pathologic prognostic variables in patients with CRC after curative resection. Monothiopyrophosphoric acid 5-8 C-reactive protein Homo sapiens 44-47 15559367-1 2004 C-reactive protein (CRP) is a blood component comprised of five identical subunits with a combined molecular mass of 110 kDa; in the presence of Ca++ it binds phosphocholine (PC) with high affinity. Phosphorylcholine 175-177 C-reactive protein Homo sapiens 0-18 15559367-1 2004 C-reactive protein (CRP) is a blood component comprised of five identical subunits with a combined molecular mass of 110 kDa; in the presence of Ca++ it binds phosphocholine (PC) with high affinity. Phosphorylcholine 175-177 C-reactive protein Homo sapiens 20-23 15276105-0 2004 Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Clopidogrel 10-21 C-reactive protein Homo sapiens 61-79 26636527-7 2015 In ITP patients, serum UA and CRP levels significantly correlated with low platelet count (r = -0.362, p = 0.022; r = -0.383, p = 0.015, respectively); and UA levels significantly correlated with CRP levels (r = 0.436, p = 0.005). Uric Acid 23-25 C-reactive protein Homo sapiens 196-199 26032258-9 2015 Strong positive correlations between serum angiostatin level versus concentrations of TC, LDL-C, and C-RP were demonstrated before onset of the study (r = 0.48311, 0.6252, and 0.653, respectively) and after simvastatin therapy (r = 0.67752, 0.6485, and 0.8244, respectively). Simvastatin 207-218 C-reactive protein Homo sapiens 101-105 15276105-1 2004 This study sought to determine the effect of clopidogrel pretreatment on the increase in C-reactive protein (CRP) after percutaneous coronary intervention. Clopidogrel 45-56 C-reactive protein Homo sapiens 89-107 15276105-1 2004 This study sought to determine the effect of clopidogrel pretreatment on the increase in C-reactive protein (CRP) after percutaneous coronary intervention. Clopidogrel 45-56 C-reactive protein Homo sapiens 109-112 15276105-2 2004 Clopidogrel pretreatment attenuated the periprocedural increase in CRP by 65% and was independently associated with an attenuation in the CRP increase in a multivariate model. Clopidogrel 0-11 C-reactive protein Homo sapiens 67-70 15276105-2 2004 Clopidogrel pretreatment attenuated the periprocedural increase in CRP by 65% and was independently associated with an attenuation in the CRP increase in a multivariate model. Clopidogrel 0-11 C-reactive protein Homo sapiens 138-141 26276649-0 2015 Positive correlation between uric acid and C-reactive protein serum level in healthy individuals and patients with acute coronary syndromes. Uric Acid 29-38 C-reactive protein Homo sapiens 43-61 14970893-1 2004 OBJECTIVE: To observe the influence of different tocopherol isoforms on oxidized low density lipoprotein (oxLDL) or recombinant human C-reactive protein (rhCRP)-induced expression of intercellular adhesion molecule-1 (ICAM-1) in human umbilical vein endothelial cells (HUVECs) and to investigate the potential mechanisms and effects of different tocopherols on atherosclerosis. Tocopherols 49-59 C-reactive protein Homo sapiens 134-152 26276649-1 2015 AIM: To assess serum levels and correlation between uric acid (UA) and C-reactive protein (CRP) in acute coronary syndrome (ACS) and apparently healthy individuals. Uric Acid 52-61 C-reactive protein Homo sapiens 71-89 26276649-1 2015 AIM: To assess serum levels and correlation between uric acid (UA) and C-reactive protein (CRP) in acute coronary syndrome (ACS) and apparently healthy individuals. Uric Acid 52-61 C-reactive protein Homo sapiens 91-94 26276649-1 2015 AIM: To assess serum levels and correlation between uric acid (UA) and C-reactive protein (CRP) in acute coronary syndrome (ACS) and apparently healthy individuals. Uric Acid 63-65 C-reactive protein Homo sapiens 71-89 28839806-9 2015 IBDEX had a moderate but positive correlation with C reactive protein (r=0.51) and erythrocyte sedimentation rate (r=0.36) p values both <0.05. ibdex 0-5 C-reactive protein Homo sapiens 51-69 17143663-7 2004 The degree of improvement in CRP and ESR was significantly correlated with the length of time the MTX concentration-time curve remained above 0.02 microM in one week. Methotrexate 98-101 C-reactive protein Homo sapiens 29-32 25895432-1 2015 The aim of the present study was to examine the association between intake of five common antioxidative nutrients from supplements and medications (vitamin E, vitamin C, carotenoids, Se, and Zn) and levels of high-sensitivity C-reactive protein (hs-CRP) in the general population. Ascorbic Acid 159-168 C-reactive protein Homo sapiens 226-244 17143663-8 2004 Furthermore, the degree of improvement in CRP was also significantly correlated with the area under the concentration-time curve (AUC) for MTX. Methotrexate 139-142 C-reactive protein Homo sapiens 42-45 17143704-3 2004 The pleurisy developed concomitantly with MTX-induced leukocytopenia, and discontinuation of the MTX treatment partially improved the CRP level. Methotrexate 97-100 C-reactive protein Homo sapiens 134-137 12880690-3 2003 Insulin-sensitizing agents may have greater effects in reducing cardiovascular risk than secretagogues in the pre-diabetic state, and glitazones have been found to decrease CRP levels in patients with diabetes. Thiazolidinediones 134-144 C-reactive protein Homo sapiens 173-176 26798761-8 2015 The main features of PIS include fever, leukocytosis, elevated C-reactive protein levels, and coagulation disturbances. Monothiopyrophosphoric acid 21-24 C-reactive protein Homo sapiens 63-81 12667067-9 2003 In contrast, the L124V, L124A, and L124C forms of CRP exhibited both a decreased K(cAMP1)(app) and an increased K(cAMP2)(app) to produce 2.4-, 55-, and 204-fold reductions, respectively, in the difference between these two parameters compared to that observed for WT CRP. camp2 114-119 C-reactive protein Homo sapiens 50-53 25105909-7 2015 RESULT: In POCD group, the level of IL-6, IL-10, CRP, MMP-9 in serum and uTi /Ucr in urine was significantly higher than that in the group without POCD. pocd 11-15 C-reactive protein Homo sapiens 49-52 12667961-10 2003 Fluvastatin and cerivastatin also reduced the activation of NF-kappaB by CRP. Fluvastatin 0-11 C-reactive protein Homo sapiens 73-76 12535752-9 2003 CRP values were significantly increased in OH (P=0.016) and SCH (P=0.022) as compared to controls. sch 60-63 C-reactive protein Homo sapiens 0-3 25519029-5 2014 In the hyperlipidemic patients, the EPA administration significantly increased plasma adiponectin levels (p<0.05), accompanied by a decrease in insulin resistance designated by the HOMA-IR (homeostasis model assessment of insulin resistance) score (p<0.05) and Hs-CRP (high sensitivity C-reactive protein) value (p<0.05). Eicosapentaenoic Acid 36-39 C-reactive protein Homo sapiens 292-310 25393688-6 2014 Lipid intake modulated the pro-inflammatory effects of some SNPs, i.e., an increase in both saturated fatty acid and monounsaturated fatty acid intake in those homozygous for the polymorphic allele at rs2808630 was associated with a larger increase in CRP. Fatty Acids, Monounsaturated 117-143 C-reactive protein Homo sapiens 252-255 25088755-0 2014 Rapid flow through immunoassay for CRP determination based on polyethylene filters modified with omega-aminocellulose carbamate. Polyethylene 62-74 C-reactive protein Homo sapiens 35-38 12531203-0 2003 Quantitative detection of C-reactive protein using phosphocholine-labelled enzyme or microspheres. Phosphorylcholine 51-65 C-reactive protein Homo sapiens 26-44 25280405-7 2014 Additionally, vitamin C was inversely related to C-reactive protein, myeloperoxidase, and endotoxin (r = -0.46 to -0.55; P < 0.05), whereas endotoxin was positively correlated to C-reactive protein (r = 0.73; P < 0.05). Ascorbic Acid 14-23 C-reactive protein Homo sapiens 49-67 12531203-4 2003 Thus, generic systems for CRP detection, based solely on the interaction between CRP and phosphocholine (PC), have been developed. Phosphorylcholine 89-103 C-reactive protein Homo sapiens 26-29 12531203-4 2003 Thus, generic systems for CRP detection, based solely on the interaction between CRP and phosphocholine (PC), have been developed. Phosphorylcholine 105-107 C-reactive protein Homo sapiens 26-29 12714834-0 2002 Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. Clopidogrel 136-147 C-reactive protein Homo sapiens 45-63 25305703-1 2014 OBJECTIVE: We examined whether early loading of eicosapentaenoic acid (EPA) reduces clinical adverse events by 1 month, accompanied by a decrease in C-reactive protein (CRP) values in patients with acute myocardial infarction (MI). Eicosapentaenoic Acid 48-69 C-reactive protein Homo sapiens 149-167 25305703-1 2014 OBJECTIVE: We examined whether early loading of eicosapentaenoic acid (EPA) reduces clinical adverse events by 1 month, accompanied by a decrease in C-reactive protein (CRP) values in patients with acute myocardial infarction (MI). Eicosapentaenoic Acid 48-69 C-reactive protein Homo sapiens 169-172 25305703-1 2014 OBJECTIVE: We examined whether early loading of eicosapentaenoic acid (EPA) reduces clinical adverse events by 1 month, accompanied by a decrease in C-reactive protein (CRP) values in patients with acute myocardial infarction (MI). Eicosapentaenoic Acid 71-74 C-reactive protein Homo sapiens 149-167 12714834-2 2002 In this study, we showed that the combination regimen of clopidogrel with aspirin could downregulate the P-selectin expression on platelets and the plasma concentration of C-reactive protein (CRP) in acute stage of atherosclerotic ischemic stroke. Clopidogrel 57-68 C-reactive protein Homo sapiens 172-190 25305703-9 2014 Peak CRP values after PCI in the EPA group were significantly lower than those in the control group (median [interquartile range], 8.2 [5.6-10.2] mg/dl vs 9.7 [7.6-13.9] mg/dl, p<0.01). Eicosapentaenoic Acid 33-36 C-reactive protein Homo sapiens 5-8 25305703-11 2014 CONCLUSIONS: Early EPA treatment after PCI in the acute stage of MI reduces the incidence of ventricular arrhythmias, and lowers CRP values. Eicosapentaenoic Acid 19-22 C-reactive protein Homo sapiens 129-132 12714834-2 2002 In this study, we showed that the combination regimen of clopidogrel with aspirin could downregulate the P-selectin expression on platelets and the plasma concentration of C-reactive protein (CRP) in acute stage of atherosclerotic ischemic stroke. Clopidogrel 57-68 C-reactive protein Homo sapiens 192-195 12714834-5 2002 RESULTS: The combined regimen of clopidogrel and aspirin significantly reduced platelet P-selectin expression (93.6 +/- 16.6, p < 0.01) and plasma concentration of CRP (1.2 +/- 1.5 mg/dl, p < 0.01) after 7 days of stroke onset compared with the values (P-selectin; 115.5 +/- 20.7, CRP; 2.5 +/- 2.8 mg/dl) of initial 24 hr. Clopidogrel 33-44 C-reactive protein Homo sapiens 167-170 12714834-5 2002 RESULTS: The combined regimen of clopidogrel and aspirin significantly reduced platelet P-selectin expression (93.6 +/- 16.6, p < 0.01) and plasma concentration of CRP (1.2 +/- 1.5 mg/dl, p < 0.01) after 7 days of stroke onset compared with the values (P-selectin; 115.5 +/- 20.7, CRP; 2.5 +/- 2.8 mg/dl) of initial 24 hr. Clopidogrel 33-44 C-reactive protein Homo sapiens 287-290 12244213-0 2002 C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Phosphorylcholine 106-123 C-reactive protein Homo sapiens 0-18 24658166-11 2014 Carotid metabolism was directly correlated with monocytes" count and C-reactive protein concentration (P<0.02 and P<0.004, respectively). carotid 0-7 C-reactive protein Homo sapiens 69-87 12244213-1 2002 C-reactive protein (CRP) is an acute-phase protein that binds specifically to phosphorylcholine (PC) as a component of microbial capsular polysaccharide and participates in the innate immune response against microorganisms. Phosphorylcholine 97-99 C-reactive protein Homo sapiens 0-18 12244213-1 2002 C-reactive protein (CRP) is an acute-phase protein that binds specifically to phosphorylcholine (PC) as a component of microbial capsular polysaccharide and participates in the innate immune response against microorganisms. Phosphorylcholine 97-99 C-reactive protein Homo sapiens 20-23 23955082-8 2014 Coupling of S1P3 to heterotrimeric Galphaq triggered the expression of CRP, utilizing signaling pathways involving reactive oxygen species (ROS), Ca(2+) and extracellular signal-related kinases (ERKs). galphaq 35-42 C-reactive protein Homo sapiens 71-74 12244213-6 2002 We now report that CRP binds to oxidized LDL (OxLDL) and oxidized PtC (OxPtC), but does not bind to native, nonoxidized LDL nor to nonoxidized PtC, and its binding is mediated through the recognition of a PC moiety. Phosphorylcholine 205-207 C-reactive protein Homo sapiens 19-22 12244213-9 2002 These data suggest that CRP binds OxLDL and apoptotic cells by recognition of a PC moiety that becomes accessible as a result of oxidation of PtC molecule. Phosphorylcholine 80-82 C-reactive protein Homo sapiens 24-27 12208796-7 2002 C-reactive protein levels were reduced (P=0.03) in unstable angina patients receiving amoxicillin, and fibrinogen was reduced in both patient groups receiving antibiotics (P=0.06). Amoxicillin 86-97 C-reactive protein Homo sapiens 0-18 24525257-7 2014 3-Epi-25-OH-D3 was negatively associated with bilirubin and C-reactive protein but unrelated to gestational age, season, age after delivery, height and weight, and calcemia or renal function. 3-epi-25-oh-d3 0-14 C-reactive protein Homo sapiens 60-78 12208797-0 2002 Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Retinoids 86-94 C-reactive protein Homo sapiens 64-82 12147804-8 2002 However, the fluvastatin group had a significantly reduced PWV (from 1991+/-162 to 1709+/-134 cm/s), oxidized LDL-C serum levels (from 89.0+/-9.6 to 73.0+/-5.8 U/l) and CRP serum levels (from 0.97+/-0.32 to 0.26+/-0.16 mg/dl) compared with those in the placebo group. Fluvastatin 13-24 C-reactive protein Homo sapiens 169-172 24275204-8 2014 Independent predictive variables of CAF in CD were: CRP level >=5mg/dl (p=0.04), previous history of IBD surgery (p=0.037), Black race (p<0.01) and low body mass index (p<0.01). cafestol palmitate 36-39 C-reactive protein Homo sapiens 52-55 24275204-11 2014 Elevated CRP, low BMI, Black race and previous history of IBD surgery predicted CAF in CD but no variables were predictive of CAF in UC. cafestol palmitate 80-83 C-reactive protein Homo sapiens 9-12 12453315-8 2002 Patients on methotrexate (n = 14) experienced a reduction in CRP of 27 mg/l (6-83 mg/l), as compared with a decrease of 10 mg/l (3.4-13 mg/l; P = 0.04) in patients not on methotrexate. Methotrexate 12-24 C-reactive protein Homo sapiens 61-64 24440185-14 2014 On day +3, in the PIS group, median PCT was 0.22 ng/mL (95% confidence interval [CI]: 0.15-0.28), WBC 13.2 x 10(9)/L (11.4-15.6), and CRP 196 mg/L (149-243). Monothiopyrophosphoric acid 18-21 C-reactive protein Homo sapiens 134-137 24484547-11 2014 Ascorbic acid significantly reduced the proinflammatory biomarkers C-reactive protein and procalcitonin. Ascorbic Acid 0-13 C-reactive protein Homo sapiens 67-85 24229668-6 2013 RESULTS: In the multiple linear regression model, natural log-transformed CRP (lnCRP) and uric acid were independent predictors of natural log-transformed urinary albumin to creatinine ratio (lnACR) (beta = 0.18, 95% CI 0.10-0.27, P < 0.001 and beta = 0.18, 95% CI 0.09-0.27, P < 0.001). lnacr 192-197 C-reactive protein Homo sapiens 74-77 11801699-7 2002 RESULTS: Temperature, neutrophil count, and C-reactive protein value were significantly higher in patients with abnormal DMSA 1 findings than in those with abnormal DS 1 findings (P < 0.05). Succimer 121-125 C-reactive protein Homo sapiens 44-62 11711273-0 2001 Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein. Fluvastatin 26-37 C-reactive protein Homo sapiens 92-110 11549652-0 2001 Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. droloxifene 30-41 C-reactive protein Homo sapiens 45-63 11511988-2 2001 In children with a positive DMSA scan, mean C-reactive protein (CRP) was higher than in children with a normal DMSA scan (114+/-64 vs. 67+/-38 mg/dl, mean+/-SD, P=0.0002). Succimer 28-32 C-reactive protein Homo sapiens 44-62 11511988-2 2001 In children with a positive DMSA scan, mean C-reactive protein (CRP) was higher than in children with a normal DMSA scan (114+/-64 vs. 67+/-38 mg/dl, mean+/-SD, P=0.0002). Succimer 28-32 C-reactive protein Homo sapiens 64-67 11443197-9 2001 Reactive oxygen species generation by polymorphonuclear cells and MNC, p47(phox) subunit protein quantities, plasminogen activator inhibitor-1, and C-reactive protein levels decreased significantly after troglitazone intake. Troglitazone 204-216 C-reactive protein Homo sapiens 148-166 11238646-3 2001 We have previously reported that residue Asp(112) of CRP plays a major role in the formation of the C1q-binding site, while the neighboring Lys(114) hinders C1q binding. Aspartic Acid 41-44 C-reactive protein Homo sapiens 53-56 11238646-4 2001 The three-dimensional structure of CRP shows the presence of a deep, extended cleft in each protomer on the face of the pentamer opposite that containing the phosphocholine-binding sites. Phosphorylcholine 158-172 C-reactive protein Homo sapiens 35-38 11179352-3 2001 CRP binds to phosphorylcholine (ChoP), a constituent of eukaryotic membranes that is also found on the cell surface of major bacterial pathogens of the human respiratory tract, including Streptococcus pneumoniae and Haemophilus influenzae. Phosphorylcholine 13-30 C-reactive protein Homo sapiens 0-3 10793927-4 2000 CASE REPORT: A 4-year-old child was admitted for a right lower lobe pneumonia, with very high values of white blood cell count and CRP, worsening despite a treatment with high doses of amoxicillin, then with cefotaxime and vancomycin. Amoxicillin 185-196 C-reactive protein Homo sapiens 131-134 10811043-11 2000 Significantly more patients achieved normal CRP values when treated with penicillin (88%) as opposed to placebo (75%). Penicillins 73-83 C-reactive protein Homo sapiens 44-47 17657447-3 1999 Daily intake of rose-hip powder for four weeks by healthy volunteers and patients suffering from osteoarthritis, resulted in reduced serum C-reactive protein (CRP) levels and reduced chemotaxis of peripheral blood neutrophils. rose-hip powder 16-31 C-reactive protein Homo sapiens 139-157 17657447-3 1999 Daily intake of rose-hip powder for four weeks by healthy volunteers and patients suffering from osteoarthritis, resulted in reduced serum C-reactive protein (CRP) levels and reduced chemotaxis of peripheral blood neutrophils. rose-hip powder 16-31 C-reactive protein Homo sapiens 159-162 9613434-6 1998 The CRP levels in five acute-phase sera of turpentine oil-inoculated monkeys were 248-451 microg/ml (mean 371.2+/-73.8). Turpentine 43-57 C-reactive protein Homo sapiens 4-7 8702903-1 1996 Although cAMP binding to wild type cAMP receptor protein (CRP) induces specific DNA binding and activates transcription, cyclic nucleoside monophosphate (cNMP) binding to the CRP mutant Ser128 --> Ala does not, whereas the double CRP mutant Thr127 --> Leu/Ser128 --> Ala activates transcription even in the absence of cNMP. Leucine 258-261 C-reactive protein Homo sapiens 175-178 8702903-1 1996 Although cAMP binding to wild type cAMP receptor protein (CRP) induces specific DNA binding and activates transcription, cyclic nucleoside monophosphate (cNMP) binding to the CRP mutant Ser128 --> Ala does not, whereas the double CRP mutant Thr127 --> Leu/Ser128 --> Ala activates transcription even in the absence of cNMP. Leucine 258-261 C-reactive protein Homo sapiens 175-178 8740300-5 1996 C-reactive protein and grade of reflux correlated significantly with abnormal DMSA studies. Succimer 78-82 C-reactive protein Homo sapiens 0-18 8599761-1 1996 The structure of the classical acute phase reactant human C-reactive protein provides evidence that phosphocholine binding is mediated through calcium and a hydrophobic pocket centred on Phe 66. Phosphorylcholine 100-114 C-reactive protein Homo sapiens 58-76 8586887-5 1995 Thus minocyclin was given on the 7th hospital-day and this was effective for blood gas and C-reactive protein (CRP) levels. Minocycline 5-15 C-reactive protein Homo sapiens 91-109 8586887-5 1995 Thus minocyclin was given on the 7th hospital-day and this was effective for blood gas and C-reactive protein (CRP) levels. Minocycline 5-15 C-reactive protein Homo sapiens 111-114 7485521-6 1995 These data suggest that the potent inhibition of surfactant adsorption by CRP is primarily a result of a specific interaction between CRP and the phosphocholine headgroup of surfactant lipids in the subphase and that it can be reversed by the water-soluble CRP ligand, phosphocholine. Phosphorylcholine 269-283 C-reactive protein Homo sapiens 134-137 7485521-6 1995 These data suggest that the potent inhibition of surfactant adsorption by CRP is primarily a result of a specific interaction between CRP and the phosphocholine headgroup of surfactant lipids in the subphase and that it can be reversed by the water-soluble CRP ligand, phosphocholine. Phosphorylcholine 269-283 C-reactive protein Homo sapiens 134-137 7615279-7 1995 A significant correlation was also seen between the maximum blood lactulose concentrations and the C reactive protein concentrations. Lactulose 66-75 C-reactive protein Homo sapiens 99-117 8935189-8 1995 CRP level decreased only after MTX and CTX intravenous treatment. Methotrexate 31-34 C-reactive protein Homo sapiens 0-3 8144569-3 1994 Externally labeled SAP rapidly binds to two distinct forms of immobilized CRP (direct and phosphorylcholine captured) with a relatively high affinity (KD = 5 nM) at a molar ratio of specifically bound SAP/CRP = 0.3. Phosphorylcholine 90-107 C-reactive protein Homo sapiens 74-77 24523776-7 2013 (All p-values < 0.05) The results showed that treatment with dabigatran made greater changes in the serum level of CRP, D-dimer, F1 + 2. Dabigatran 64-74 C-reactive protein Homo sapiens 118-121 8144898-8 1994 Treatment of Raji cells with human serum led to calcium-dependent phosphocholine-inhibitable CRP binding. Phosphorylcholine 66-80 C-reactive protein Homo sapiens 93-96 24523776-8 2013 The pattern of changes in serum CRP levels D-dimer, F1 + 2 is much faster and with a greater slope in the dabigatran group. Dabigatran 106-116 C-reactive protein Homo sapiens 32-35 7508422-4 1993 As previously reported, FP shares the capacity of C-reactive protein (CRP) in other species to bind phosphocholine and we show here that it also resembles human CRP in binding only weakly to agarose, to human AA amyloid fibrils in vitro, and to mouse AA amyloid deposits in vivo. Phosphorylcholine 100-114 C-reactive protein Homo sapiens 50-68 22577128-6 2013 Significant (p < 0.001) elevation of ceruloplasmin (Cp) and C-reactive protein was associated with marked decreases in superoxide dismutase (p < 0.01), catalase (p < 0.001), and glutathione (p < 0.05) and significant (p < 0.001) increases in malondialdehyde (MDA) and uric acid when compared with control. Uric Acid 283-292 C-reactive protein Homo sapiens 63-81 23412713-9 2013 Furthermore, large effects indicated higher CK and CRP responses 16 h postmatch in SDEP than in CONT (P = .11-.87, d = 0.80-0.88). sdep 83-87 C-reactive protein Homo sapiens 51-54 23947403-9 2013 High inflammation or tumor burdens, as measured by CRP or tumor antigen levels, tend to lower peak plasma ascorbate levels after IVC. Ascorbic Acid 106-115 C-reactive protein Homo sapiens 51-54 7508422-4 1993 As previously reported, FP shares the capacity of C-reactive protein (CRP) in other species to bind phosphocholine and we show here that it also resembles human CRP in binding only weakly to agarose, to human AA amyloid fibrils in vitro, and to mouse AA amyloid deposits in vivo. Phosphorylcholine 100-114 C-reactive protein Homo sapiens 70-73 8228279-0 1993 A capillary electrophoresis-based assay for the binding of Ca2+ and phosphorylcholine to human C-reactive protein. Phosphorylcholine 68-85 C-reactive protein Homo sapiens 95-113 23874068-1 2013 UNLABELLED: The present study aimed to assess the effect of supplementation of omega-3 and/or vitamin C on serum interleukin-6 and high sensitivity C-reactive protein concentration and depression scores among shift workers in Shahid Tondgoyan oil refinery. Ascorbic Acid 94-103 C-reactive protein Homo sapiens 148-166 8228279-1 1993 Affinity capillary electrophoresis was performed to quantitate the binding of Ca2+ and phosphorylcholine to human C-reactive protein (CRP). Phosphorylcholine 87-104 C-reactive protein Homo sapiens 114-132 8228279-1 1993 Affinity capillary electrophoresis was performed to quantitate the binding of Ca2+ and phosphorylcholine to human C-reactive protein (CRP). Phosphorylcholine 87-104 C-reactive protein Homo sapiens 134-137 8336521-2 1993 Addition of 15 micrograms/ml CRP resulted in about 60% decrease in phospholipase D activity using phosphatidylcholine dispersed with Triton X-100 as substrate, and more using lipid suspension consisting of only phosphatidylcholine. Octoxynol 133-145 C-reactive protein Homo sapiens 29-32 23742939-8 2013 Plasma 25-hydroxyvitamin D was inversely associated with insulin, insulin resistance, triglycerides, total cholesterol, low-density lipoprotein cholesterol, and the ratio of total to high-density lipoprotein cholesterol but not with fasting glucose, apolipoprotein A1, apolipoprotein B, C-reactive protein, fibrinogen, or homocysteine. 25-hydroxyvitamin D 7-26 C-reactive protein Homo sapiens 287-305 1867921-5 1991 On admission the median levels of CRP: 74 mg/L, alpha-AT: 208 mg% and alpha-GA: 303 mg% were significantly higher (p less than 0.001) in patients with Ranson Index greater than or equal to 3 than in those with Ranson Index less than or equal to 2 (CRP: 166 mg/L, alpha-AT: 303 mg% and alpha-GA: 121 mg%). ranson 151-157 C-reactive protein Homo sapiens 34-37 23274196-2 2013 The LPD method could embed a monoclonal antibody of C-reactive protein (Anti-CRP), which is mixed with poly(l-lysine) (PL) as an organic binder, on/in titanium oxide thin layer deposited onto a surface plasmon resonance (SPR) sensing chip (F(Anti-CRP-PL)), allowing simple immobilization of anti-CRP capable of CRP detection. titanium dioxide 151-165 C-reactive protein Homo sapiens 52-70 23361365-10 2013 Taken together, our results demonstrate that DHA and EPA are able to reduce IL-6-induced CRP expression in HepG2 cells via an inhibition of STAT3 activation. Eicosapentaenoic Acid 53-56 C-reactive protein Homo sapiens 89-92 1867921-5 1991 On admission the median levels of CRP: 74 mg/L, alpha-AT: 208 mg% and alpha-GA: 303 mg% were significantly higher (p less than 0.001) in patients with Ranson Index greater than or equal to 3 than in those with Ranson Index less than or equal to 2 (CRP: 166 mg/L, alpha-AT: 303 mg% and alpha-GA: 121 mg%). ranson 151-157 C-reactive protein Homo sapiens 248-251 1867921-5 1991 On admission the median levels of CRP: 74 mg/L, alpha-AT: 208 mg% and alpha-GA: 303 mg% were significantly higher (p less than 0.001) in patients with Ranson Index greater than or equal to 3 than in those with Ranson Index less than or equal to 2 (CRP: 166 mg/L, alpha-AT: 303 mg% and alpha-GA: 121 mg%). ranson 210-216 C-reactive protein Homo sapiens 34-37 1991964-3 1991 CRP binding to several substrates, including phosphocholine, individual denatured histones, and chromatin, has been demonstrated. Phosphorylcholine 45-59 C-reactive protein Homo sapiens 0-3 23357670-2 2013 Sevelamer hydrochloride (Renagel ); a non-calcium phosphate binder reduces coronary artery and aortic calcification as compared to calcium containing phosphate binders and additionally effects inflammatory biomarkers such as C-reactive protein (CRP), and lowers LDL cholesterol in patients with CKD. Sevelamer 0-23 C-reactive protein Homo sapiens 225-243 23357670-2 2013 Sevelamer hydrochloride (Renagel ); a non-calcium phosphate binder reduces coronary artery and aortic calcification as compared to calcium containing phosphate binders and additionally effects inflammatory biomarkers such as C-reactive protein (CRP), and lowers LDL cholesterol in patients with CKD. Sevelamer 0-23 C-reactive protein Homo sapiens 245-248 23357670-2 2013 Sevelamer hydrochloride (Renagel ); a non-calcium phosphate binder reduces coronary artery and aortic calcification as compared to calcium containing phosphate binders and additionally effects inflammatory biomarkers such as C-reactive protein (CRP), and lowers LDL cholesterol in patients with CKD. Sevelamer 25-32 C-reactive protein Homo sapiens 225-243 4064588-3 1985 Comparison between the groups suggests that CRP correlates best with ESR in patients treated with penicillamine and in patients in clinical remission. Penicillamine 98-111 C-reactive protein Homo sapiens 44-47 23357670-2 2013 Sevelamer hydrochloride (Renagel ); a non-calcium phosphate binder reduces coronary artery and aortic calcification as compared to calcium containing phosphate binders and additionally effects inflammatory biomarkers such as C-reactive protein (CRP), and lowers LDL cholesterol in patients with CKD. Sevelamer 25-32 C-reactive protein Homo sapiens 245-248 1991964-6 1991 CRP binding to the H2A-H2B dimer and (H3-H4)2 tetramer was demonstrated and these reactions were inhibited by phosphocholine. Phosphorylcholine 110-124 C-reactive protein Homo sapiens 0-3 4038634-2 1985 The clearance rate of 125I-human CRP in mice and 125I-rat CRP in rats showed a T1/2 of approximately 4 h. The T1/2 was independent of circulating levels of CRP and was not affected by the presence of C-polysaccharide (CPS), a ligand to which CRP binds. cps 218-221 C-reactive protein Homo sapiens 33-36 2365997-1 1990 Human C-reactive protein (CRP) is known to activate the C system upon reaction with phosphocholine-containing or polycation-containing ligands. Phosphorylcholine 84-98 C-reactive protein Homo sapiens 6-24 6220082-1 1983 C-reactive protein (CRP), a trace serum protein that increases markedly in concentration during inflammatory reactions, was recently shown to bind to a subset of human IgG-FcR-bearing peripheral blood lymphocytes in the presence of a ligand such as pneumococcal C-polysaccharide (CPS). cps 280-283 C-reactive protein Homo sapiens 0-18 6220082-1 1983 C-reactive protein (CRP), a trace serum protein that increases markedly in concentration during inflammatory reactions, was recently shown to bind to a subset of human IgG-FcR-bearing peripheral blood lymphocytes in the presence of a ligand such as pneumococcal C-polysaccharide (CPS). cps 280-283 C-reactive protein Homo sapiens 20-23 23003113-2 2013 We tested the hypothesis of an independent relationship between serum concentrations of 25-hydroxyvitamin D [25(OH)D] and high-sensitivity C-reactive protein (CRP) in a cohort of HIV-positive people. 25-hydroxyvitamin D 88-107 C-reactive protein Homo sapiens 139-157 23003113-2 2013 We tested the hypothesis of an independent relationship between serum concentrations of 25-hydroxyvitamin D [25(OH)D] and high-sensitivity C-reactive protein (CRP) in a cohort of HIV-positive people. 25-hydroxyvitamin D 88-107 C-reactive protein Homo sapiens 159-162 22865000-8 2013 The higher CRP group was discriminated by the above variables in addition to lower VO(2max), serum metabolic syndrome components (triglycerides, glucose, and HDL cholesterol), higher insulin, homeostasis assessment of insulin resistance, uric acid, gamma-GT, and homocysteine. Uric Acid 238-247 C-reactive protein Homo sapiens 11-14 24490166-8 2013 In children with single episode of urticaria UAS correlated with CRP level. Phenindione 45-48 C-reactive protein Homo sapiens 65-68 6220082-3 1983 In the present study, we assessed the effects of CRP and CRP-CPS complexes on a variety of human lymphocyte functions in vitro. cps 61-64 C-reactive protein Homo sapiens 57-60 6877243-9 1983 Chondroitin sulfate was similar to heparin in its effects upon the CRP-poly-L-arginine (PLA) interaction, while hyaluronic acid enhanced CRP-PLA precipitation at all concentrations tested and DNA had neither augmenting nor solubilizing effects. polyarginine 71-86 C-reactive protein Homo sapiens 67-70 6877243-9 1983 Chondroitin sulfate was similar to heparin in its effects upon the CRP-poly-L-arginine (PLA) interaction, while hyaluronic acid enhanced CRP-PLA precipitation at all concentrations tested and DNA had neither augmenting nor solubilizing effects. Hyaluronic Acid 112-127 C-reactive protein Homo sapiens 137-140 7028874-9 1981 Reactivity of CRP with a multimeric form of phosphocholine (PC) (KLH-PC44) led to binding comparable to that observed with CPS, whereas monomeric PC inhibited the binding. cps 123-126 C-reactive protein Homo sapiens 14-17 7028875-3 1981 In the preceding paper we reported that C-reactive protein (CRP) in the presence of a multimeric binding specificity such as C-polysaccharide (CPS) binds to a small percentage of peripheral blood lymphocytes (PBL). cps 143-146 C-reactive protein Homo sapiens 40-58 7028875-3 1981 In the preceding paper we reported that C-reactive protein (CRP) in the presence of a multimeric binding specificity such as C-polysaccharide (CPS) binds to a small percentage of peripheral blood lymphocytes (PBL). cps 143-146 C-reactive protein Homo sapiens 60-63 7028875-5 1981 Heat-modified CRP and E-CPS-CRP each were found to bind to a similar percentage of PBL by microscopic visualization, and an identical degree of binding was observed by cytofluorimetric analysis. cps 24-27 C-reactive protein Homo sapiens 28-31 7028875-9 1981 CRP in the presence of CPS bound to cells of multiple human and murine cultured lines shown to have IgG FcR reactivity, but showed lesser or no binding to cell lines negative for FcR. cps 23-26 C-reactive protein Homo sapiens 0-3 471064-3 1979 CRP has a Ca2+-dependent binding specificity for phosphorylcholine, the polar head group of two widely distributed lipids, lecithin (phosphatidylcholine, PC) and sphingomyelin (SM). Lecithins 123-131 C-reactive protein Homo sapiens 0-3 2365997-1 1990 Human C-reactive protein (CRP) is known to activate the C system upon reaction with phosphocholine-containing or polycation-containing ligands. Phosphorylcholine 84-98 C-reactive protein Homo sapiens 26-29 471064-3 1979 CRP has a Ca2+-dependent binding specificity for phosphorylcholine, the polar head group of two widely distributed lipids, lecithin (phosphatidylcholine, PC) and sphingomyelin (SM). Sphingomyelins 162-175 C-reactive protein Homo sapiens 0-3 471064-3 1979 CRP has a Ca2+-dependent binding specificity for phosphorylcholine, the polar head group of two widely distributed lipids, lecithin (phosphatidylcholine, PC) and sphingomyelin (SM). Sphingomyelins 177-179 C-reactive protein Homo sapiens 0-3 24455278-14 2013 Deficiency of 25-hydroxyvitamin D was significantly associated with dyslipidemia (P = 0.0001), mean serum glucose (P = 0.0002) mean CRP (P = 0.04), and mean alkaline phosphatase (P = 0.01). 25-hydroxyvitamin D 14-33 C-reactive protein Homo sapiens 132-135 471064-5 1979 In addition, interaction of CRP with PC- and SM-containing lipid dispersions and with PC-containing liposomes can activate the complement system. Sphingomyelins 45-47 C-reactive protein Homo sapiens 28-31 33809417-10 2021 Low-dose garcinol did not affect cardiomyocyte viability but significantly reduced mitochondrial ROS, CRP, IL-1beta, IL-6, and TNF-alpha production in Lp(a)-stimulated cardiomyocytes (p < 0.05). garcinol 9-17 C-reactive protein Homo sapiens 102-105 22975466-0 2012 Relation of uric acid to serum levels of high-sensitivity C-reactive protein, triglycerides, and high-density lipoprotein cholesterol and to hepatic steatosis. Uric Acid 12-21 C-reactive protein Homo sapiens 58-76 15557765-8 2004 In a subgroup of patients with CRP, IL-6, sIL-6R, and ox-LDL baseline serum values > or = the median and IL-10 < or = the median, CRP was reduced on day 28 of fluvastatin treatment (p < 0.01), IL-6 and ox-LDL were reduced earlier, on day 14 (p = 0.05 and p < 0.05, respectively) while sIL-6R did not change significantly during the treatment period. Fluvastatin 165-176 C-reactive protein Homo sapiens 136-139 23107042-5 2012 Metformin, but not placebo, administered to simvastatin-treated IFG subjects reduced plasma levels of C-reactive protein, soluble intercellular adhesion molecule-1, as well as lymphocyte release of interleukin-2, interferon-gamma and tumor necrosis factor-alpha, which was accompanied by the improvement in insulin sensitivity and a reduction in free fatty acid levels. Simvastatin 44-55 C-reactive protein Homo sapiens 102-120 4151108-2 1974 Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. Lecithins 153-161 C-reactive protein Homo sapiens 64-82 4151108-2 1974 Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. Sphingomyelins 166-179 C-reactive protein Homo sapiens 64-82 34673277-4 2022 Here, we demonstrate that serum concentrations of TMAO were positively correlated with C-reactive protein (CRP) levels, and the appearance rate of dialysate IL-6 and PAI-1, in PD patients. trimethyloxamine 50-54 C-reactive protein Homo sapiens 87-105 4225405-0 1967 The nature of C-reactive protein in acute phase serum: evidence for an equilibrium form containing a mucopolysaccharide of serum. Glycosaminoglycans 101-119 C-reactive protein Homo sapiens 14-32 34673277-4 2022 Here, we demonstrate that serum concentrations of TMAO were positively correlated with C-reactive protein (CRP) levels, and the appearance rate of dialysate IL-6 and PAI-1, in PD patients. trimethyloxamine 50-54 C-reactive protein Homo sapiens 107-110 34941113-6 2021 RESULTS: The clinical efficacy and safety of leflunomide and methotrexate are evaluated by American College of Rheumatology (ACR)20/50/70, DAS28, total effective rate, adverse reaction rate, morning stiffness, swollen joint count, tender joint count, erythrocyte sedimentation rate, C-reactive protein, and rheumatoid factor. Methotrexate 61-73 C-reactive protein Homo sapiens 283-301 33550688-5 2021 All laboratory and clinical parameters were assessed before and within 24hr after tocilizumab administration RESULTS: After receiving TCZ, all patients showed significantly lower median IL 6, LDH, CRP, ferritin , TLC at p<0.001 and D-Dimer at p=0.223 than their baseline levels. tioconazole 134-137 C-reactive protein Homo sapiens 197-200 34047819-0 2021 Fluorescent hollow ZrO2@CdTe nanoparticles-based lateral flow assay for simultaneous detection of C-reactive protein and troponin T. Highly fluorescent hollow ZrO2@CdTe nanoparticles (NPs) were synthesized efficiently via the hydrothermal method. zirconium oxide 19-23 C-reactive protein Homo sapiens 98-116 34047819-0 2021 Fluorescent hollow ZrO2@CdTe nanoparticles-based lateral flow assay for simultaneous detection of C-reactive protein and troponin T. Highly fluorescent hollow ZrO2@CdTe nanoparticles (NPs) were synthesized efficiently via the hydrothermal method. cadmium telluride 24-28 C-reactive protein Homo sapiens 98-116 34751777-7 2021 LIPCAR plasma levels were significantly related to the two cardiac markers, N-terminal pro-B type natriuretic peptide and high-sensitivity cardiac troponin T, but not to inflammatory markers such as high sensitivity C-reactive protein and pentraxin-3, nor to patient reported outcomes such as depression and quality of life. lipcar 0-6 C-reactive protein Homo sapiens 216-234 34047819-0 2021 Fluorescent hollow ZrO2@CdTe nanoparticles-based lateral flow assay for simultaneous detection of C-reactive protein and troponin T. Highly fluorescent hollow ZrO2@CdTe nanoparticles (NPs) were synthesized efficiently via the hydrothermal method. zirconium oxide 159-163 C-reactive protein Homo sapiens 98-116 34047819-0 2021 Fluorescent hollow ZrO2@CdTe nanoparticles-based lateral flow assay for simultaneous detection of C-reactive protein and troponin T. Highly fluorescent hollow ZrO2@CdTe nanoparticles (NPs) were synthesized efficiently via the hydrothermal method. cadmium telluride 164-168 C-reactive protein Homo sapiens 98-116 33986298-3 2021 Here, we show that among 1,228 women attempting pregnancy, preconception 25-hydroxyvitamin D concentrations are positively associated with the live birth of a male infant, with notably stronger associations among women with elevated high sensitivity C-reactive protein, a marker of systemic low-grade inflammation. 25-hydroxyvitamin D 73-92 C-reactive protein Homo sapiens 250-268 33624897-0 2021 25-Hydroxyvitamin D serum levels inversely correlate to disease severity and serum C-reactive protein levels in patients with hidradenitis suppurativa. 25-hydroxyvitamin D 0-19 C-reactive protein Homo sapiens 83-101 33714740-6 2021 Here we demonstrate that photooxidation, or reaction with the biological oxidants HOCl and ONOOH, of the single disulfide present in the major human plasma inflammatory protein, C-reactive protein (CRP) can give rise to reversible disulfide bond formation with human serum albumin (HSA). onooh 91-96 C-reactive protein Homo sapiens 178-196 34869773-11 2021 Serum c-reactive protein, procalcitonin, and lipopolysaccharide were also upregulated with disease progression and positively correlated with Th17 abundance. th17 142-146 C-reactive protein Homo sapiens 6-24 33714740-6 2021 Here we demonstrate that photooxidation, or reaction with the biological oxidants HOCl and ONOOH, of the single disulfide present in the major human plasma inflammatory protein, C-reactive protein (CRP) can give rise to reversible disulfide bond formation with human serum albumin (HSA). onooh 91-96 C-reactive protein Homo sapiens 198-201 34651620-9 2021 Amine functionalized electrodes were conjugated to C-reactive protein (CRP) antibodies. Amines 0-5 C-reactive protein Homo sapiens 51-69 33833576-9 2021 Patients with resectable CRC with dMMR were more likely to have higher levels of neutrophil, monocyte, platelet, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), C-reactive protein to albumin ratio (CAR), Glasgow prognostic score (GPS) and C-reactive protein (CRP). dmmr 34-38 C-reactive protein Homo sapiens 217-235 33833576-9 2021 Patients with resectable CRC with dMMR were more likely to have higher levels of neutrophil, monocyte, platelet, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), C-reactive protein to albumin ratio (CAR), Glasgow prognostic score (GPS) and C-reactive protein (CRP). dmmr 34-38 C-reactive protein Homo sapiens 295-313 33833576-9 2021 Patients with resectable CRC with dMMR were more likely to have higher levels of neutrophil, monocyte, platelet, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), C-reactive protein to albumin ratio (CAR), Glasgow prognostic score (GPS) and C-reactive protein (CRP). dmmr 34-38 C-reactive protein Homo sapiens 315-318 34651620-9 2021 Amine functionalized electrodes were conjugated to C-reactive protein (CRP) antibodies. Amines 0-5 C-reactive protein Homo sapiens 71-74 33752670-8 2021 The logistic regression analysis showed that SF, D-dimer, and CRP are independent risk factors to predict RMPP. rmpp 106-110 C-reactive protein Homo sapiens 62-65 34651620-10 2021 Antibody-modified TPEs were applied for the sensitive detection of CRP, a biomarker of cardiovascular disease using electrochemical enzyme-linked immunosorbent assays (ELISA). tpes 18-22 C-reactive protein Homo sapiens 67-70 33752670-9 2021 CONCLUSION: SF, D-dimer, and CRP are statistically significant biomarkers to predict RMPP in Chinese children patients in the settings of pediatric emergency department. rmpp 85-89 C-reactive protein Homo sapiens 29-32 34420445-8 2021 RESULTS: An early post-ablation inflammatory response was observed in both groups with a significant increase of leukocytes, CRP and LDH within the first 20 h after HIFU. hifu 165-169 C-reactive protein Homo sapiens 125-128 34217687-7 2021 Ox-LDL induced NF-kappaB/NLRP3 pathway activation by inducing C-reactive protein expression, NLRP3 activation, caspase-1 activation, and IL-1beta secretion, which were inhibited by pretreatment with the combination of PAVA and RSV. Rosuvastatin Calcium 227-230 C-reactive protein Homo sapiens 62-80 33418065-10 2021 CONCLUSION: Current data suggest that the EPA to DHA ratio only correlates to the modulation of CRP by omega-3 supplementation of EPA and DHA, and SBP in studies that supplemented EPA and DHA in the range of 2 g to 6 g, shedding light on potential differential effects of EPA vs. DHA on inflammation and systolic blood pressure. Eicosapentaenoic Acid 130-133 C-reactive protein Homo sapiens 96-99 33418065-10 2021 CONCLUSION: Current data suggest that the EPA to DHA ratio only correlates to the modulation of CRP by omega-3 supplementation of EPA and DHA, and SBP in studies that supplemented EPA and DHA in the range of 2 g to 6 g, shedding light on potential differential effects of EPA vs. DHA on inflammation and systolic blood pressure. Eicosapentaenoic Acid 130-133 C-reactive protein Homo sapiens 96-99 33418065-10 2021 CONCLUSION: Current data suggest that the EPA to DHA ratio only correlates to the modulation of CRP by omega-3 supplementation of EPA and DHA, and SBP in studies that supplemented EPA and DHA in the range of 2 g to 6 g, shedding light on potential differential effects of EPA vs. DHA on inflammation and systolic blood pressure. Eicosapentaenoic Acid 130-133 C-reactive protein Homo sapiens 96-99 34372957-9 2021 Among patients whose DTAC was higher than the median intake, the levels of hs-CRP and PGF2alpha were significantly higher only in individuals with CC genotype. dodecyltrimethylammonium 21-25 C-reactive protein Homo sapiens 78-81 33655029-8 2021 The TTM LAMS placement led to a significant decrease in the serum levels of bilirubin, ALP, GGT, WBC and CRP. lams 8-12 C-reactive protein Homo sapiens 105-108 34464302-7 2021 DHS and PFN both increased hs-IL-6 (143.81 +- 89.12 and 94.13 +- 67.14, respectively), CRP (98.84 +- 31.81 and 104.4 +- 31.80, respectively), and CK (400.8 +- 31.81 and 250.7 +- 31.80, respectively) 24 hours postoperatively. (R)-Fenoprofen 8-11 C-reactive protein Homo sapiens 87-90 34157593-7 2021 Compared to other lipid emulsions, SMOFlipid was associated with a significant reduction in ALT, AST, gamma-glutamyltransferase, total bilirubin, TG, C-reactive protein and length of hospital stay. smoflipid 35-44 C-reactive protein Homo sapiens 150-168 33398528-8 2021 Based on a generalized estimating equations analysis model with time interaction considered, the only significant factor associated with changes in phenylalanine was changes in C-reactive protein concentrations from baseline to 12 months [B (coefficient) = 0.81, P < 0.001] after adjusting for methionine sulfoxide and total bilirubin levels. Bilirubin 325-334 C-reactive protein Homo sapiens 177-195 33479472-4 2021 The ROC curve was used to analyze the potential of LncRNA NNT-AS1, CRP and PCT as biomarkers for predicting RMPP. rmpp 108-112 C-reactive protein Homo sapiens 67-70 34385364-7 2021 Efficacy of FIL200 + MTX among these patients was comparable to the overall population, with higher rates of 20%/50%/70% improvement from baseline by American College of Rheumatology criteria, DAS28(CRP) <2.6, and remission; greater improvement in physical function and pain; and better inhibition of structural damage relative to MTX-mono. Methotrexate 21-24 C-reactive protein Homo sapiens 199-202 33318507-6 2020 Cox proportional hazards analysis of the multivariate model demonstrated that the highest tertile of DI-S had a significantly higher risk of all-cause mortality than the lowest two tertiles after adjustment for age, sex, smoking habit, body mass index, diabetes, prior cardiovascular disease, hemodialysis vintage, high sensitivity C-reactive protein, albumin, and number of remaining teeth (hazard ratio, 3.04; 95% confidence interval, 1.50-6.17; p = 0.002). di-s 101-105 C-reactive protein Homo sapiens 332-350 33224343-2 2020 However, the exact mechanism underlying the CRP-lowering effect of statins remains elusive. statins 67-74 C-reactive protein Homo sapiens 44-47 33224343-3 2020 Methods: In order to test the possibility of direct interaction, we performed an in silico study by testing the orientation of the respective ligands (statins) and phosphorylcholine (the standard ligand of CRP) in the CRP active site using Molecular Operating Environment (MOE) software. statins 151-158 C-reactive protein Homo sapiens 218-221 33224343-4 2020 Results: Docking experiments showed that all statins could directly interact with CRP. statins 45-52 C-reactive protein Homo sapiens 82-85 33224343-5 2020 Among statins, rosuvastatin had the strongest interaction with CRP (pKi = 16.14), followed by fluvastatin (pKi = 15.58), pitavastatin (pKi = 15.26), atorvastatin (pKi = 14.68), pravastatin (pKi = 13.95), simvastatin (pKi = 7.98) and lovastatin (pKi = 7.10). statins 6-13 C-reactive protein Homo sapiens 63-66 33224343-5 2020 Among statins, rosuvastatin had the strongest interaction with CRP (pKi = 16.14), followed by fluvastatin (pKi = 15.58), pitavastatin (pKi = 15.26), atorvastatin (pKi = 14.68), pravastatin (pKi = 13.95), simvastatin (pKi = 7.98) and lovastatin (pKi = 7.10). Simvastatin 204-215 C-reactive protein Homo sapiens 63-66 33224343-7 2020 Conclusions: This finding suggests a new mechanism of interaction between statins and CRP that could be independent of the putative cholesterol-lowering activity of statins. statins 74-81 C-reactive protein Homo sapiens 86-89 33224343-7 2020 Conclusions: This finding suggests a new mechanism of interaction between statins and CRP that could be independent of the putative cholesterol-lowering activity of statins. statins 165-172 C-reactive protein Homo sapiens 86-89 34182522-6 2021 The non-graded talc induced the highest changes in serum CRP levels, total white blood cell and neutrophil counts compared to other agents, while mitoxantrone induced the lowest. Talc 15-19 C-reactive protein Homo sapiens 57-60 29962216-4 2020 Our objective was to examine the relationship between dietary intake of antioxidants (carotenoids, vitamins A, C, E, and selenium) and serum CRP concentrations in mid-life and older AAs, while controlling for confounders. Carotenoids 86-97 C-reactive protein Homo sapiens 141-144 34182522-7 2021 Graded talc and bleomycin induced the same levels of changes in serum CRP levels and serum leukocyte counts. Talc 7-11 C-reactive protein Homo sapiens 70-73 34182522-7 2021 Graded talc and bleomycin induced the same levels of changes in serum CRP levels and serum leukocyte counts. Bleomycin 16-25 C-reactive protein Homo sapiens 70-73 35533613-8 2022 There was a significant difference between control and MMP and BMP (P > 0.0001) in terms of hs-CRP level. 2-tert-butyl-4-methylphenol 63-66 C-reactive protein Homo sapiens 95-98 32634728-9 2020 "Switched" patients to DOACs therapy showed an improved FMD (19.0 +- 6.6% vs 3.8 +- 1.3%, p < 0.0001); C-reactive protein (CRP) levels decreased in "switched" patients from 1.4 +- 0.5 to 1.0 +- 0.7 mg/dl (p < 0.05). doacs 23-28 C-reactive protein Homo sapiens 103-121 32634728-9 2020 "Switched" patients to DOACs therapy showed an improved FMD (19.0 +- 6.6% vs 3.8 +- 1.3%, p < 0.0001); C-reactive protein (CRP) levels decreased in "switched" patients from 1.4 +- 0.5 to 1.0 +- 0.7 mg/dl (p < 0.05). doacs 23-28 C-reactive protein Homo sapiens 123-126 35620202-9 2022 Compared with the general anesthesia group, the dosage of fentanyl in the radiomics-guided was lower, the VAS score at 6 h, 1 d, and 2 d after operation was smaller, and the levels of CRP and NSE were lower (all P < 0.05). Fentanyl 58-66 C-reactive protein Homo sapiens 184-187 33057114-10 2020 Considering different chemical forms of vitamin E, alpha-tocopherol, unlike other forms, had a reducing effect on serum levels of CRP and IL-6. alpha-Tocopherol 51-67 C-reactive protein Homo sapiens 130-133 35389096-0 2022 Epitope mapping of antibodies in C-reactive protein assay kits by hydrogen-deuterium exchange mass spectrometry explains differential results across kits. Deuterium 75-84 C-reactive protein Homo sapiens 33-51 35321185-13 2022 Logistic regression analysis showed that TIMI grade 3 and intraoperative use of tirofiban effectively reduced the risk of MACE (P < 0.05), while immediate stent implantation, increased WBC, hs-CRP and RDW on admission increased the risk of MACE (P < 0.05). Tirofiban 80-89 C-reactive protein Homo sapiens 193-196 31498074-10 2020 Predictors of poor certolizumab retention were: Current or ex-smoker [HR 1.11 (0.70-1.76), p=0.65], high CRP levels [HR 0.72 (0.45-1.16), p=0.18], biologic-naive [HR 0.81 (0.49-1.32), p=0.39] and good BASDAI50 response at first control visit [HR 0.54 (0.30-0.96), p=0.04]. Certolizumab Pegol 19-31 C-reactive protein Homo sapiens 105-108 35179770-11 2022 CONCLUSIONS: This clinical trial demonstrated the efficacy of PBW in minimizing the LHS, fever, and levels of ESR, CRP, and creatinine among hospitalized COVID-19 patients with moderate disease severity. (1~{S},4~{S},5~{R})-6-(hydroxymethyl)cyclohexane-1,2,3,4,5-pentol 62-65 C-reactive protein Homo sapiens 115-118 32802429-12 2020 Changes in CRP curve were less severe with the use of iodine when compared with the other two agents. Iodine 54-60 C-reactive protein Homo sapiens 11-14 32443740-8 2020 RESULTS: After adjusting for age, gender, C-reactive protein (CRP), and body mass index (BMI), a negative association was found between whole blood iron, ferritin, and TBI and incidence of reduced HDL-C (odds ratio (OR) = 0.63, 0.49, and 0.57, respectively). tbi 168-171 C-reactive protein Homo sapiens 42-60 32443740-8 2020 RESULTS: After adjusting for age, gender, C-reactive protein (CRP), and body mass index (BMI), a negative association was found between whole blood iron, ferritin, and TBI and incidence of reduced HDL-C (odds ratio (OR) = 0.63, 0.49, and 0.57, respectively). tbi 168-171 C-reactive protein Homo sapiens 62-65 35126375-9 2021 Most importantly, we proved that HZ-0408b treatment significantly ameliorated joint swelling after the onset of arthritis and dramatically reduced plasma C-reactive protein (CRP) levels in a monkey collagen-induced arthritis (CIA) model. hz-0408b 33-41 C-reactive protein Homo sapiens 154-172 32394193-7 2020 The reduction current of H202 at - 0.2 V catalysing by tag Pt/Ru/C as measured by a chronoamperometric method is proportional to the concentration of CRP. h202 25-29 C-reactive protein Homo sapiens 150-153 32189499-0 2020 Ultrasensitive Impedimetric Immunosensor for the Detection of C-Reactive Protein in Blood at Surface-Initiated-Reversible Addition-Fragmentation Chain Transfer Generated Poly(2-hydroxyethyl methacrylate) Brushes. HTR composite 170-203 C-reactive protein Homo sapiens 62-80 35126375-9 2021 Most importantly, we proved that HZ-0408b treatment significantly ameliorated joint swelling after the onset of arthritis and dramatically reduced plasma C-reactive protein (CRP) levels in a monkey collagen-induced arthritis (CIA) model. hz-0408b 33-41 C-reactive protein Homo sapiens 174-177 35173877-1 2022 OBJECTIVES: This prospective study aimed to explore the effects of various doses of rosuvastatin on the hemodynamic changes, highly sensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6) levels in elderly patients with unstable angina pectoris. Rosuvastatin Calcium 84-96 C-reactive protein Homo sapiens 142-160 32369295-7 2020 C-reactive protein (CRP) was statistically significantly lower in the diclofenac group than in the control group (33+-15 mg/L vs. 46+-22 mg/L, respectively, P<0.05). Diclofenac 70-80 C-reactive protein Homo sapiens 0-18 32369295-7 2020 C-reactive protein (CRP) was statistically significantly lower in the diclofenac group than in the control group (33+-15 mg/L vs. 46+-22 mg/L, respectively, P<0.05). Diclofenac 70-80 C-reactive protein Homo sapiens 20-23 32369295-10 2020 Lower CRP in the diclofenac group may indicate a reduced inflammatory response after CPB. Diclofenac 17-27 C-reactive protein Homo sapiens 6-9 32054445-8 2020 A moderate Spearman correlation occurred between SES-CD and CRP (r = 0.525), fCal (r = 0.450), and CDAI (r = 0.407), while a weak correlation was found with the platelet count (r = 0.257). ses-cd 49-55 C-reactive protein Homo sapiens 60-63 31955966-3 2020 This study systematically reviewed and summarized earlier findings from randomized clinical trials about the effects of statins on serum concentrations of C-reactive protein (CRP) and interleukin (IL)-6 in patients with abnormal glucose homeostasis. Simvastatin 120-127 C-reactive protein Homo sapiens 155-173 31955966-3 2020 This study systematically reviewed and summarized earlier findings from randomized clinical trials about the effects of statins on serum concentrations of C-reactive protein (CRP) and interleukin (IL)-6 in patients with abnormal glucose homeostasis. Simvastatin 120-127 C-reactive protein Homo sapiens 175-178 31955966-5 2020 RCTs were included if they compared the effects of statins on serum concentrations of CRP and IL-6 in adults with abnormal glucose homeostasis. Simvastatin 51-58 C-reactive protein Homo sapiens 86-89 31955966-11 2020 Pooling 6 effect sizes from 5 studies revealed a significantly reduced serum concentration of CRP after simvastatin therapy (WMD, -0.66; 95% CI, -0.79 to -0.54; I2 = 97.6%). Simvastatin 104-115 C-reactive protein Homo sapiens 94-97 31955966-12 2020 IMPLICATIONS: The administration of atorvastatin or simvastatin in patients with abnormal glucose hemostasis was associated with a reduced serum CRP concentration. Simvastatin 52-63 C-reactive protein Homo sapiens 145-148 22959763-5 2012 Women receiving 17-OHPC demonstrated significantly higher (P = .005) concentrations of CRP in epoch 1 than women receiving placebo but CRP values were similar in epoch 2 in both groups. 17 alpha-Hydroxyprogesterone Caproate 16-23 C-reactive protein Homo sapiens 87-90 22926451-5 2012 Plasma neopterin levels were positively correlated with urine fluoride levels (r = 0.67, p < 0.001) and serum hs-CRP levels were positively correlated with urine fluoride levels (r = 0.36, p < 0.001). Fluorides 165-173 C-reactive protein Homo sapiens 116-119 23203253-7 2012 Furthermore, urinary iodine is negatively correlated with waist, hips, SAD, glucose, insulin, HOMA-IR triglyceride, resistin, angiotensin II (Ang II), and CRP, while it was positively associated with TSH. Iodine 21-27 C-reactive protein Homo sapiens 155-158 35070979-8 2021 Further analysis of TAM subtypes revealed that serum CRP levels were associated with CD204+ and CD163+ Mphi densities (p < 0.0001 and p = 0.0003, respectively). tam 20-23 C-reactive protein Homo sapiens 53-56 22387034-6 2012 Low 25-OHD levels were negatively associated with C-reactive protein (inflammatory activation marker) and body mass index in multiple linear regression analysis. 25-ohd 4-10 C-reactive protein Homo sapiens 50-68 22387034-10 2012 Low 25-OHD levels are negatively associated with C-reactive protein, an inflammatory activation marker, and with obesity. 25-ohd 4-10 C-reactive protein Homo sapiens 49-67 31935793-6 2020 Statins reverted the increased levels of Lp-PLA2 and CRP. Simvastatin 0-7 C-reactive protein Homo sapiens 53-56 31955613-0 2020 Association Between Electronic Cigarette Use and Levels of High-Sensitivity C-Reactive Protein and Uric Acid. Uric Acid 99-108 C-reactive protein Homo sapiens 76-94 31955613-5 2020 After adjusting for confounding factors, electronic cigarette use was significantly associated with elevated serum high-sensitivity C-reactive protein levels (beta = 1.326, P = .002), uric acid levels (beta = 0.400, P = .042), and hyperuricemia (uric acid level of >7 mg/mL; odds ratio = 2.67, 95% confidence interval = 1.27-5.58). Uric Acid 246-255 C-reactive protein Homo sapiens 132-150 35095081-6 2022 Patients in the rhBNP group had significantly lower levels of white blood cell, C-reactive protein (CRP), D-dimers, troponin I, creatinine, and N-terminal (NT) -proBNP compared with those in the control group. rhbnp 16-21 C-reactive protein Homo sapiens 80-98 30913567-0 2020 Pathological Concentration of C-reactive Protein is Correlated to Increased Concentrations of Quetiapine, But Not of Risperidone, Olanzapine and Aripiprazole in a Naturalistic Setting. Olanzapine 130-140 C-reactive protein Homo sapiens 30-48 30913567-0 2020 Pathological Concentration of C-reactive Protein is Correlated to Increased Concentrations of Quetiapine, But Not of Risperidone, Olanzapine and Aripiprazole in a Naturalistic Setting. Aripiprazole 145-157 C-reactive protein Homo sapiens 30-48 30913567-8 2020 A trend for a positive correlation between CRP and serum concentration was found for olanzapine (n=24, Spearman"s Rho: r=0.385, p=0.063; linear regression: p=0.086). Olanzapine 85-95 C-reactive protein Homo sapiens 43-46 22798388-8 2012 In vitro experiments demonstrated that MPs were capable of converting pCRP to mCRP which could be inhibited by the anti-CRP compound 1,6 bis-phosphocholine. 1,6 bis-phosphocholine 133-155 C-reactive protein Homo sapiens 71-74 35095081-6 2022 Patients in the rhBNP group had significantly lower levels of white blood cell, C-reactive protein (CRP), D-dimers, troponin I, creatinine, and N-terminal (NT) -proBNP compared with those in the control group. rhbnp 16-21 C-reactive protein Homo sapiens 100-103 32646363-9 2020 Also, there was a positive correlation between serum urate levels and C-reactive protein and interleukin-1beta, as well as between Serum urate levels and hypertension severity. Uric Acid 53-58 C-reactive protein Homo sapiens 70-88 35095081-9 2022 On the basis of the multivariate regression analysis, CRP, creatinine, troponin I, and NT-proBNP were independent factors of all-cause mortality in 30 days.rhBNP is effective in the treatment of patients with RV dysfunction caused by acute PE who underwent CDT, which may be an alternative treatment option for improving clinical prognosis. rhbnp 156-161 C-reactive protein Homo sapiens 54-57 22486775-7 2012 RESULTS: Lower plasma levels of total and single carotenoids were associated with lower dietary intake of carotenoids, older age, male sex, lower physical activity, higher alcohol consumption, higher body mass index (BMI), higher systolic and diastolic blood pressures, lower levels of total cholesterol and HDL cholesterol and higher levels of CRP, IL-6 and MMP-9. Carotenoids 49-60 C-reactive protein Homo sapiens 345-348 2837757-3 1988 In the absence of cGMP, CRP*598 shows a more open conformation than CRP, as indicated by its sensitivity to proteolytic attack and 5,5"-dithiobis(2-nitrobenzoic acid)-mediated subunit crosslinking. 5,5"-dithiobis 131-145 C-reactive protein Homo sapiens 24-27 22486775-8 2012 After multivariate adjustments, plasma levels of total carotenoids and provitamin A carotenoids (beta-cryptoxanthine, alpha-carotene and beta-carotene) remained independently associated with sex, dietary intake of carotenoids, BMI, HDL cholesterol and MMP-9, whilst associations with CRP and IL-6 were not maintained. Carotenoids 55-66 C-reactive protein Homo sapiens 284-287 22349076-3 2012 Niacin also has beneficial effects on other cardiovascular risk factors, including lipoprotein(a), C-reactive protein, platelet-activating factor acetylhydrolase, plasminogen activator inhibitor 1 and fibrinogen. Niacin 0-6 C-reactive protein Homo sapiens 99-117 21889886-8 2012 Higher AA intake (a proinflammatory omega-6 fatty acid) was related to higher IL-6 (OR=1.96; P=.034) and CRP (OR=1.95; P=.039) concentrations. Fatty Acids, Omega-6 36-54 C-reactive protein Homo sapiens 105-108 22197455-8 2012 RESULTS: After six months of citrus-based juice consuming, there is significant differences at 95% confidence in oxidized LDL, C-Reactive Protein, and Homocysteine in Metabolic Syndrome patients who consume citrus-based juice. citrus-based juice 29-47 C-reactive protein Homo sapiens 127-145 22197455-8 2012 RESULTS: After six months of citrus-based juice consuming, there is significant differences at 95% confidence in oxidized LDL, C-Reactive Protein, and Homocysteine in Metabolic Syndrome patients who consume citrus-based juice. citrus-based juice 207-225 C-reactive protein Homo sapiens 127-145 22412148-9 2012 Higher intake of omega-6 relative to omega-3 PUFAs was associated with greater CRP (P = .01 after full adjustment) and greater odds of fatigue (odds ratio, 2.6 for the highest v lowest intake; P < .05). omega-6 17-24 C-reactive protein Homo sapiens 79-82 22237152-10 2012 Higher serum uric acid levels were found to correlate significantly with C-reactive protein (CRP) (r = 0.31, P = 0.002). Uric Acid 13-22 C-reactive protein Homo sapiens 73-91 22237152-10 2012 Higher serum uric acid levels were found to correlate significantly with C-reactive protein (CRP) (r = 0.31, P = 0.002). Uric Acid 13-22 C-reactive protein Homo sapiens 93-96 22634906-8 2012 RESULTS: Vitamin C treated group had a significant decrease in phosphorus (p=0.01), CRP level (p=0.01) and CaxP product (p=0.03). Ascorbic Acid 9-18 C-reactive protein Homo sapiens 84-87 22235107-9 2012 The C-reactive protein/albumin ratio was higher (P < .05) in controls than in CHO and GLN groups. CAV protocol 81-84 C-reactive protein Homo sapiens 4-22 22950641-5 2012 Simvastatin resulted in a significant decrease in CRP, which correlated with decreases in both total (r = 0.87, p < 0.05) and low-density lipoprotein cholesterol, IL-6, sICAM-1, sVCAM-1, oxLDL, and sFas at 6 months, compared to baseline. Simvastatin 0-11 C-reactive protein Homo sapiens 50-53 21868433-6 2011 Lipid hydroperoxides were correlated with CRP, whereas protein oxidation was associated with waist circumference and uric acid. Lipid Peroxides 0-20 C-reactive protein Homo sapiens 42-45 21970714-7 2011 A positive correlation between 24S-OH-Chol/TC ratio and plasma C reactive protein (CRP) levels was found in the whole sample, independent of possible confounders (multiple regression p: 0.04; r2: 0.10). 24s-oh- 31-38 C-reactive protein Homo sapiens 63-81 21970714-7 2011 A positive correlation between 24S-OH-Chol/TC ratio and plasma C reactive protein (CRP) levels was found in the whole sample, independent of possible confounders (multiple regression p: 0.04; r2: 0.10). 24s-oh- 31-38 C-reactive protein Homo sapiens 83-86 21970714-7 2011 A positive correlation between 24S-OH-Chol/TC ratio and plasma C reactive protein (CRP) levels was found in the whole sample, independent of possible confounders (multiple regression p: 0.04; r2: 0.10). chol 38-42 C-reactive protein Homo sapiens 63-81 21970714-7 2011 A positive correlation between 24S-OH-Chol/TC ratio and plasma C reactive protein (CRP) levels was found in the whole sample, independent of possible confounders (multiple regression p: 0.04; r2: 0.10). chol 38-42 C-reactive protein Homo sapiens 83-86 21550088-5 2011 Among the PCOS subjects, 25-hydroxyvitamin D concentrations were negatively correlated with body mass index (P = .033), C-reactive protein (P = .027), and free androgen index (P = .025) and positively correlated with quantitative insulin sensitivity check index (P = .035), high-density lipoprotein cholesterol (HDL-C) (P = .033), and sex hormone binding globulin (P = .038). 25-hydroxyvitamin D 25-44 C-reactive protein Homo sapiens 120-138 22745870-0 2011 Association of Serum Total Bilirubin with Serum High Sensitivity C-reactive Protein in Middle-aged Men. Bilirubin 27-36 C-reactive protein Homo sapiens 65-83 21658827-9 2011 In regression models adjusted for case-mix, dietary calorie and fat intake, body mass index, and history of hypertension, each 1-unit higher ratio of omega-6 to omega-3 intake was associated with a 0.55-mg/L increase in serum CRP level (P = 0.03). omega-6 150-157 C-reactive protein Homo sapiens 226-229 21477202-10 2011 Our preliminary findings showing a dose-related effect of simvastatin on levels of NOx, CRP and IL-6 suggest a potential therapeutic role for simvastatin in SCD. Simvastatin 58-69 C-reactive protein Homo sapiens 88-91 21671781-11 2011 CONCLUSIONS: Total bilirubin level appears to be inversely associated with the prevalence of MetS in rural Korean women >40 years of age in the KGRC, even after adjusting for risk factors of MetS, including body mass index (BMI), menopausal status, CRP levels, and homeostasis model assessment of insulin resistance (HOMA-IR). Bilirubin 19-28 C-reactive protein Homo sapiens 252-255 21276586-5 2011 Simvastatin and fenofibrate decreased monocyte release of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and monocyte chemoattractant protein-1 and lymphocyte release of interleukin-2, interferon-gamma, and tumor necrosis factor-alpha, which was accompanied by a decrease in plasma C-reactive protein levels. Simvastatin 0-11 C-reactive protein Homo sapiens 298-316 21211928-8 2011 Multivariate analysis indicated that the independent associating factors for TBI in HD patients were BKACS and C-reactive protein (CRP; r(2) = 0.358; P = .006). tbi 77-80 C-reactive protein Homo sapiens 111-129 21211928-8 2011 Multivariate analysis indicated that the independent associating factors for TBI in HD patients were BKACS and C-reactive protein (CRP; r(2) = 0.358; P = .006). tbi 77-80 C-reactive protein Homo sapiens 131-134 21211928-10 2011 Furthermore, arterial calcification of below-knee arteries and micro-inflammation represented as CRP were the independent associating factors for low TBI, which was the independent associating factor for PAD and CLI in HD patients. tbi 150-153 C-reactive protein Homo sapiens 97-100 22353651-2 2011 METHODS: Tacrolimus was administered if the effect of biologics was unsatisfactory for 24 weeks at least in terms of laboratory data or DAS28 level: ESR, CRP level and DAS28 level were not below 15 mm/h, 0.2 mg/dl or 2.6, respectively. Tacrolimus 9-19 C-reactive protein Homo sapiens 154-157 20890431-8 2010 For COPD patients, systolic Ppa correlated significantly with plasma CRP levels and plasma ET-1 levels. ppa 28-31 C-reactive protein Homo sapiens 69-72 19937362-9 2010 There was also significant reductions in serum C reactive protein levels in both sibutramine (P = 0.045, P = 0.02) and sibutramine plus metformin groups (P = 0.007, P = 0.001) after 3 and 12 months, respectively. sibutramine 81-92 C-reactive protein Homo sapiens 47-65 19937362-9 2010 There was also significant reductions in serum C reactive protein levels in both sibutramine (P = 0.045, P = 0.02) and sibutramine plus metformin groups (P = 0.007, P = 0.001) after 3 and 12 months, respectively. sibutramine 119-130 C-reactive protein Homo sapiens 47-65 20580206-3 2010 After 3 months and adjusting for differences in baseline CRP levels, baseline smoking and high baseline triglyceride levels, patients on haloperidol treatment had CRP levels that were 92.7% higher than those of patients on risperidone treatment (p=0.009). Haloperidol 137-148 C-reactive protein Homo sapiens 57-60 20580206-3 2010 After 3 months and adjusting for differences in baseline CRP levels, baseline smoking and high baseline triglyceride levels, patients on haloperidol treatment had CRP levels that were 92.7% higher than those of patients on risperidone treatment (p=0.009). Haloperidol 137-148 C-reactive protein Homo sapiens 163-166 20083320-0 2010 Inverse associations of serum bilirubin with high sensitivity C-reactive protein, glycated hemoglobin, and prevalence of type 2 diabetes in middle-aged and elderly Japanese men and women. Bilirubin 30-39 C-reactive protein Homo sapiens 62-80 20083320-1 2010 AIM: The aim of this study was to examine the association of serum bilirubin, an endogenous antioxidant, with serum high sensitivity C-reactive protein (hs-CRP) level, HbA(1c), and the prevalence of type 2 diabetes in middle-aged and elderly Japanese men and women (n=12,400). Bilirubin 67-76 C-reactive protein Homo sapiens 133-151 20450721-10 2010 After adjusting for age, duration of diabetes mellitus, smoking status, systolic blood pressure, body mass index, total cholesterol, triglyceride and C reactive protein, the serum UA levels in women was an independent risk factor associated with the prevalence of LEAD. Uric Acid 180-182 C-reactive protein Homo sapiens 150-168 20450721-12 2010 CONCLUSION: The increase of serum UA levels is associated with LEAD in women, in addition to age, duration of diabetes mellitus, smoking status, systolic blood pressure, body mass index, total cholesterol, triglyceride and C reactive protein. Uric Acid 34-36 C-reactive protein Homo sapiens 223-241 20142117-0 2010 Efficacy of simvastatin or ezetimibe on tissue factor, von Willebrand"s factor and C-reactive protein in patients with hypercholesterolaemia. Simvastatin 12-23 C-reactive protein Homo sapiens 83-101 19836015-1 2010 The association of 9 urinary monohydroxy polycyclic aromatic hydrocarbons (OH-PAHs) with serum C-reactive protein (CRP) was investigated using the National Health and Nutrition Examination Survey (NHANES) 2003-2004. oh-pahs 75-82 C-reactive protein Homo sapiens 95-113 19836015-1 2010 The association of 9 urinary monohydroxy polycyclic aromatic hydrocarbons (OH-PAHs) with serum C-reactive protein (CRP) was investigated using the National Health and Nutrition Examination Survey (NHANES) 2003-2004. oh-pahs 75-82 C-reactive protein Homo sapiens 115-118 19836015-3 2010 In adjusted logistic regressions, two OH-PAHs, 2-hydroxyphenanthrene and 9-hydroxyfluorene, were associated with elevated CRP (>3mg/l). oh-pahs 38-45 C-reactive protein Homo sapiens 122-125 19836015-12 2010 Given that inflammation (characterized here by CRP) is an important factor in the development of atherosclerosis and cardiovascular disease, these results suggest a role for OH-PAHs in the progression of atherosclerosis. oh-pahs 174-181 C-reactive protein Homo sapiens 47-50 20016119-8 2010 Likewise, the values for NT-proBNP were lower in CRP quartiles 1-3 than in quartile 4 (median 212.0 vs. 647.7 pg/ml; p < 0.01) in patients with heart disease after additional adjustment for the type of cardiac disorder. nt-probnp 25-34 C-reactive protein Homo sapiens 49-52 19640511-8 2009 The 18-month repeated measures CRP analysis confirmed the significantly higher values for olanzapine in those with low baseline CRP. Olanzapine 90-100 C-reactive protein Homo sapiens 31-34 19640511-8 2009 The 18-month repeated measures CRP analysis confirmed the significantly higher values for olanzapine in those with low baseline CRP. Olanzapine 90-100 C-reactive protein Homo sapiens 128-131 20099654-5 2009 Comparative analysis of the characteristics of the agents showed that paracetamol produced a more powerful antistress defense, as confirmed by the time course of changes in the levels of TNF-alpha and CRP. Acetaminophen 70-81 C-reactive protein Homo sapiens 201-204 19185299-4 2009 METHODS: Cross-sectional associations of C-reactive protein (CRP) and Interleukin-6 (Il-6) with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EHA) were evaluated in multivariable linear regression models adjusted for demographics, cardiovascular risk factors, medication use, exercise capacity, body-mass index, and waist-to-hip ratio. Eicosapentaenoic Acid 127-148 C-reactive protein Homo sapiens 41-59 19694216-8 2009 RESULTS: Simvastatin led to a significant decrease in total cholesterol, LDL cholesterol, triglycerides and C-reactive protein (CRP), while fibrinogen levels remained unaltered. Simvastatin 9-20 C-reactive protein Homo sapiens 128-131 19694216-10 2009 These changes were correlated with reduction in CRP following simvastatin. Simvastatin 62-73 C-reactive protein Homo sapiens 48-51 19694216-11 2009 Simvastatin-induced increase in clot permeability was associated only with age and decrease in CRP levels (R2 for the model = 0.61), while shortening of clot lysis time observed following simvastatin use was predicted only by reduction of triglycerides and CRP (R2 for the model = 0.62). Simvastatin 0-11 C-reactive protein Homo sapiens 95-98 19694216-11 2009 Simvastatin-induced increase in clot permeability was associated only with age and decrease in CRP levels (R2 for the model = 0.61), while shortening of clot lysis time observed following simvastatin use was predicted only by reduction of triglycerides and CRP (R2 for the model = 0.62). Simvastatin 0-11 C-reactive protein Homo sapiens 257-260 19296463-6 2009 RESULTS: In the epilepsy patients, switch from either phenytoin or carbamazepine produced significant declines in total cholesterol (-24.8 mg/dl), atherogenic (non-high-density lipoprotein) cholesterol (-19.9 mg/dl), triglycerides (-47.1mg/dl) (all p < 0.0001), and C-reactive protein (-31.4%; p = 0.027). Phenytoin 54-63 C-reactive protein Homo sapiens 269-287 19248856-8 2009 Serum C-reactive protein was significantly inversely associated with intakes of fruit (r=-0.19; P=0.004), vitamin C (r=-0.13, P=0.03), and folate (r=-0.18; P=0.004). Ascorbic Acid 106-115 C-reactive protein Homo sapiens 6-24 19575548-7 2009 Age, male gender, cigarette smoking, physical activity, body mass index, total cholesterol, high density lipoprotein cholesterol, gamma-glutamyltransferase, and uric acid were independently associated with CRP concentrations. Uric Acid 161-170 C-reactive protein Homo sapiens 206-209 20027140-2 2009 RESULTS: A term newborn delivered by caesarean section (birth weight 2550 g, birth length 47 cm, value of Apgar score 9/10) with good direct adaptation had on the first day of life increased levels of conjugated bilirubin (23 micromol/l), unconjugated bilirubin (55 micromol/l) and C-reactive protein 39.4 g/l. Bilirubin 212-221 C-reactive protein Homo sapiens 282-300 19180261-4 2008 Inflammatory markers such as C-reactive protein (CRP) also decrease after administration of certolizumab pegol. Certolizumab Pegol 92-110 C-reactive protein Homo sapiens 29-47 19180261-4 2008 Inflammatory markers such as C-reactive protein (CRP) also decrease after administration of certolizumab pegol. Certolizumab Pegol 92-110 C-reactive protein Homo sapiens 49-52 18855257-8 2008 Hydrophilic pravastatin increased the serum adiponectin level and decreased the CRP after switching from lipophilic simvastatin in the absence of any difference in the low-density lipoprotein cholesterol level and blood pressure. Simvastatin 116-127 C-reactive protein Homo sapiens 80-83 18785308-8 2008 Significant baseline correlations were noted between CRP and CTX-II (r=0.71), MMP-3 (r=0.45), and NTX (r=0.37) (p<or=0.001), as well as between CTX-II and NTX (r=0.49; p<0.0001). ctx-ii 61-67 C-reactive protein Homo sapiens 53-56 18785308-8 2008 Significant baseline correlations were noted between CRP and CTX-II (r=0.71), MMP-3 (r=0.45), and NTX (r=0.37) (p<or=0.001), as well as between CTX-II and NTX (r=0.49; p<0.0001). ctx-ii 147-153 C-reactive protein Homo sapiens 53-56 20209780-5 2008 In women with preeclampsia, CRP correlated positively and significantly with diastolic blood pressure, proteinuria and uric acid levels. Uric Acid 119-128 C-reactive protein Homo sapiens 28-31 18779292-8 2008 CONCLUSIONS: In middle-aged and older women free of CVD and cancer, plasma carotenoids were associated with smoking, obesity, LDL cholesterol, HDL cholesterol, Hb A(1c), and CRP. Carotenoids 75-86 C-reactive protein Homo sapiens 174-177 18565665-0 2008 Detection of C-reactive protein on a functional poly(thiophene) self-assembled monolayer using surface plasmon resonance. polythiophene 48-63 C-reactive protein Homo sapiens 13-31 18558298-10 2008 In addition, tHcy level was positively correlated with albumin and creatinine, and was negatively correlated with C-reactive protein, MIS, and comorbidity. thcy 13-17 C-reactive protein Homo sapiens 114-132 18436840-8 2008 RESULTS: Intraluminal treatment with a clinically relevant concentration of CRP (7 microg/mL, 60 minutes) significantly attenuated arteriolar dilation to endothelium-dependent NO-mediated agonists bradykinin and A23187 but not to endothelium-independent NO donor sodium nitroprusside. Calcimycin 212-218 C-reactive protein Homo sapiens 76-79 18379184-10 2008 Aztreonam and ciprofloxacin were then intravenously administered at doses of 4 g/day and 600 mg/day, respectively, resulting in the alleviation of fever in the patient as well as a decrease in CRP and disappearance of MDRP isolates from urine on day 67; that is, MDRP infection was consequently well controlled. Ciprofloxacin 14-27 C-reactive protein Homo sapiens 193-196 17436017-3 2008 A univariate analysis revealed that PNAC was significantly related to duration of fasting (p = 0.008) and parenteral nutrition (p < 0.0001), days of antibiotics use (p = 0.025), positive C-reactive protein (p = 0.018) or gastric culture (p = 0.018), and feeding intolerance (p < 0.0001). pnac 36-40 C-reactive protein Homo sapiens 190-208 19024002-2 2008 Administration of methacin in combination with albumin or C-reactive protein (but not with IgG) abolished the broncholytic effect of methacin. Oxyphenonium 133-141 C-reactive protein Homo sapiens 58-76 18057884-0 2008 Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Simvastatin 0-11 C-reactive protein Homo sapiens 21-39 18264935-6 2008 As expected, simvastatin caused significant reductions in total cholesterol, LDL cholesterol and triglycerides, as well as in C-reactive protein (CRP; -28%, p=0.001) and IL-6 (-20%, p=0.05) but failed to decrease plasma ADMA both in crude and adjusted analyses. Simvastatin 13-24 C-reactive protein Homo sapiens 126-144 18264935-6 2008 As expected, simvastatin caused significant reductions in total cholesterol, LDL cholesterol and triglycerides, as well as in C-reactive protein (CRP; -28%, p=0.001) and IL-6 (-20%, p=0.05) but failed to decrease plasma ADMA both in crude and adjusted analyses. Simvastatin 13-24 C-reactive protein Homo sapiens 146-149 17991651-8 2007 High-sensitivity CRP concentrations were significantly lowered with alpha-tocopherol supplementation than with placebo (32%; P < 0.001). alpha-Tocopherol 68-84 C-reactive protein Homo sapiens 17-20 17825696-14 2007 Peroxide levels correlated positively with CRP (P < 0.001) and LDL-cholesterol (LDL-C) (P = 0.003), and negatively with age (P = 0.002) and body mass index (P < 0.001). Peroxides 0-8 C-reactive protein Homo sapiens 43-46 17560879-0 2007 Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Simvastatin 35-46 C-reactive protein Homo sapiens 98-116 17560879-0 2007 Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Simvastatin 54-65 C-reactive protein Homo sapiens 98-116 17560879-3 2007 When averaged across doses, ezetimibe/simvastatin produced significantly greater reductions compared with simvastatin alone in LDL cholesterol (52.5% vs 38.0%, respectively) and CRP levels (31.0% vs 14.3%, respectively). Simvastatin 38-49 C-reactive protein Homo sapiens 178-181 17560879-6 2007 Reductions in CRP of similar magnitude were observed with ezetimibe/simvastatin and atorvastatin when averaged across doses and at each milligram-equivalent statin dose comparison. Simvastatin 68-79 C-reactive protein Homo sapiens 14-17 17499069-1 2007 Fluorescence intensity of N-isopropylacrylamide-glycidyl methacrylate (NIPAAm-GMA) copolymer conjugated with fluoreseinamine isomer1 was found to decrease considerably in the presence of NIPAAm-GMA copolymer containing O-phosphorylethanolamine (PEA), the specific ligand of C-reactive protein (CRP). nipaam-gma copolymer 187-207 C-reactive protein Homo sapiens 274-292 17499069-1 2007 Fluorescence intensity of N-isopropylacrylamide-glycidyl methacrylate (NIPAAm-GMA) copolymer conjugated with fluoreseinamine isomer1 was found to decrease considerably in the presence of NIPAAm-GMA copolymer containing O-phosphorylethanolamine (PEA), the specific ligand of C-reactive protein (CRP). nipaam-gma copolymer 187-207 C-reactive protein Homo sapiens 294-297 17498578-7 2007 The absolute risk reduction in the observed incidence of POCD was 20.6% for carriers of the CRP 1059C allele and 15.2% for carriers of the SELP 1087A allele. pocd 57-61 C-reactive protein Homo sapiens 92-95 17169549-7 2007 Then the CRP antigen was analyzed by competitive immunoassay with an MDMC. mdmc 69-73 C-reactive protein Homo sapiens 9-12 17351383-1 2007 OBJECTIVES: We evaluated whether the changes in the insulin sensitivity observed in hypertensive patients following treatment with an angiotensin II receptor blocker (candesartan) or calcium-channel antagonist (amlodipine) might be related to improvement of the endothelial function (END) and/or plasma level of high-sensitive C-reactive protein (CRP) following such treatment. candesartan 167-178 C-reactive protein Homo sapiens 327-345 17351383-1 2007 OBJECTIVES: We evaluated whether the changes in the insulin sensitivity observed in hypertensive patients following treatment with an angiotensin II receptor blocker (candesartan) or calcium-channel antagonist (amlodipine) might be related to improvement of the endothelial function (END) and/or plasma level of high-sensitive C-reactive protein (CRP) following such treatment. candesartan 167-178 C-reactive protein Homo sapiens 347-350 17351383-4 2007 While significant improvement of END was observed in patients receiving either drug, only candesartan, but not amlodipine, also reduced the plasma CRP and HOMA-IR index (2.13 +/- 1.92 --> 1.53 +/- 1.47, P < 0.05). candesartan 90-101 C-reactive protein Homo sapiens 147-150 17351383-5 2007 In the patients receiving treatment with candesartan, stepwise multivariate linear regression analysis revealed that the percent change in the HOMA-IR index was significantly and independently correlated with that in the plasma CRP (beta = 0.38, P < 0.05), but not with that in END: CONCLUSION: Improvement of the END alone by the antihypertensive medication might not entirely explain the improvement of the insulin sensitivity observed in these patients. candesartan 41-52 C-reactive protein Homo sapiens 228-231 16999946-0 2007 Reduction of C-reactive protein by a single 80 mg of simvastatin in patients with unstable angina. Simvastatin 53-64 C-reactive protein Homo sapiens 13-31 16999946-2 2007 Limited information has been available, however, with respect to evaluating a potential effect of a single high-dose simvastatin on CRP in patients with unstable angina (UA) within 48 h. We investigated whether a rapid CRP reduction can be achieved by a single 80 mg of simvastatin therapy in patients with UA given immediately on admission. Simvastatin 117-128 C-reactive protein Homo sapiens 132-135 16999946-2 2007 Limited information has been available, however, with respect to evaluating a potential effect of a single high-dose simvastatin on CRP in patients with unstable angina (UA) within 48 h. We investigated whether a rapid CRP reduction can be achieved by a single 80 mg of simvastatin therapy in patients with UA given immediately on admission. Simvastatin 117-128 C-reactive protein Homo sapiens 219-222 16999946-5 2007 RESULTS: We found that 80 mg of simvastatin induced significant reductions in serum median CRP concentrations and in mean CRP concentrations 48 h later following administration of simvastatin (25.4% and 32.7%, p<0.001, respectively). Simvastatin 32-43 C-reactive protein Homo sapiens 91-94 16999946-5 2007 RESULTS: We found that 80 mg of simvastatin induced significant reductions in serum median CRP concentrations and in mean CRP concentrations 48 h later following administration of simvastatin (25.4% and 32.7%, p<0.001, respectively). Simvastatin 32-43 C-reactive protein Homo sapiens 122-125 16999946-6 2007 CONCLUSIONS: A single high-dose simvastatin, given in the early time on admission, is an effective therapy for controlling inflammatory response in patients with UA, and the benefit to the vascular endothelium might occur quickly by reduction of CRP concentrations in this high-risk subgroup. Simvastatin 32-43 C-reactive protein Homo sapiens 246-249 16759717-5 2007 RESULTS: In unadjusted analyses, CRP was positively correlated with age, male gender, body mass index, blood pressure, smoking habit, creatinine, uric acid, triglycerides, an index of insulin resistance, and 8-isoprostane, and inversely correlated with high-density lipoprotein-cholesterol. Uric Acid 146-155 C-reactive protein Homo sapiens 33-36 17239709-10 2007 At 12 weeks, pioglitazone and simvastatin monotherapies significantly reduced hs-CRP (3.64 +/- 2.42 mg/l to 2.48 +/- 1.77 mg/l and 3.26 +/- 2.02 mg/l to 2.81 +/- 2.11 mg/l) and the combination regimen had an additive effect (from 3.49 +/- 1.97 mg/l to 2.06 +/- 1.42 mg/l, p < 0.001). Simvastatin 30-41 C-reactive protein Homo sapiens 81-84 17192349-0 2007 Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Eicosapentaenoic Acid 9-30 C-reactive protein Homo sapiens 91-109 18219956-0 2007 [The effects of early application of simvastatin on C-reactive protein level, blood lipids, and the clinical course of acute coronary syndrome]. Simvastatin 37-48 C-reactive protein Homo sapiens 52-70 18219956-6 2007 Mean CRP level decreased significantly within two weeks in the group of patients receiving simvastatin (from 14.9 +/- 9.7 to 7.6 +/- 6.0 mg/l; p = 0.02). Simvastatin 91-102 C-reactive protein Homo sapiens 5-8 17145229-0 2006 Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus. Simvastatin 49-60 C-reactive protein Homo sapiens 15-33 17145229-1 2006 The aim of this study was to investigate the time course of C-reactive protein (CRP) reduction with simvastatin in patients with type 2 diabetes mellitus. Simvastatin 100-111 C-reactive protein Homo sapiens 60-78 17145229-1 2006 The aim of this study was to investigate the time course of C-reactive protein (CRP) reduction with simvastatin in patients with type 2 diabetes mellitus. Simvastatin 100-111 C-reactive protein Homo sapiens 80-83 17145229-7 2006 After simvastatin administration, there was a significant reduction in levels of log(hs-CRP) (p = 0.001). Simvastatin 6-17 C-reactive protein Homo sapiens 88-91 17145229-8 2006 This effect of simvastatin was seen by day 7 (p = 0.008), with maximal reduction seen at day 14 (p = 0.004; hs-CRP in original units 3.1 +/- 0.5 mg/L with simvastatin and 4.1 +/- 0.6 mg/L with placebo). Simvastatin 15-26 C-reactive protein Homo sapiens 111-114 17145229-10 2006 By day 28 with simvastatin, hs-CRP had returned to near baseline levels. Simvastatin 15-26 C-reactive protein Homo sapiens 31-34 17145229-11 2006 In conclusion, in patients with type 2 diabetes mellitus, simvastatin reduced hs-CRP within 7 days. Simvastatin 58-69 C-reactive protein Homo sapiens 81-84 17165637-8 2006 Ezetimibe/ simvastatin, 10/20 mg/d, reduced high-sensitivity C-reactive protein and triglyceride levels significantly more than atorvastatin, 10 mg/d (P = .02), with comparable reductions at other doses. Simvastatin 11-22 C-reactive protein Homo sapiens 61-79 16950175-5 2006 Niacin decreased lipoprotein-associated phospholipase A2 and C-reactive protein levels (20% and 15%, respectively, p <0.05 for the 2 comparisons). Niacin 0-6 C-reactive protein Homo sapiens 61-79 16520354-7 2006 The LMW fluorescence predicted death both as a binary variable at the ROC cut-off, and as a continuous log-transformed variable when adjusted for age, albumin and C-reactive protein (CRP). 2-(4-Amino-N-ethylanilino)ethanol 4-7 C-reactive protein Homo sapiens 183-186 16611671-8 2006 In subjects with UA within the normal range, UA was significantly and independently associated with neutrophils count, C-reactive protein, IL-6, IL-1ra, IL-18, and TNF-alpha, whereas non-significant trends were observed for WBC (P=0.1) and sIL-6r (P=0.2). Uric Acid 45-47 C-reactive protein Homo sapiens 119-137 16642000-7 2006 Here we report the design, synthesis and efficacy of 1,6-bis(phosphocholine)-hexane as a specific small-molecule inhibitor of CRP. 1,6-bis(phosphocholine)-hexane 53-83 C-reactive protein Homo sapiens 126-129 16642000-9 2006 Administration of 1,6-bis(phosphocholine)-hexane to rats undergoing acute myocardial infarction abrogated the increase in infarct size and cardiac dysfunction produced by injection of human CRP. 1,6-bis(phosphocholine)-hexane 18-48 C-reactive protein Homo sapiens 190-193 16939632-14 2006 The data suggest that lipid lowering agents, ACE inhibitors, ARBs, antidiabetic agents, antiinflammatory and antiplatelet agents, vitamin E, and beta-adrenoreceptor antagonists lower serum or plasma levels of CRP, while vitamin C, oral estrogen and hydrochlorothiazide do not affect CRP levels. Ascorbic Acid 220-229 C-reactive protein Homo sapiens 209-212 16522902-5 2006 RESULTS: Plasma vitamin C, fruit intake, and dietary vitamin C intake were significantly and inversely associated with mean concentrations of C-reactive protein, an acute phase reactant, and tissue plasminogen activator (t-PA) antigen, a marker of endothelial dysfunction, even after adjustment for confounders. Ascorbic Acid 16-25 C-reactive protein Homo sapiens 142-160 16522902-5 2006 RESULTS: Plasma vitamin C, fruit intake, and dietary vitamin C intake were significantly and inversely associated with mean concentrations of C-reactive protein, an acute phase reactant, and tissue plasminogen activator (t-PA) antigen, a marker of endothelial dysfunction, even after adjustment for confounders. Ascorbic Acid 53-62 C-reactive protein Homo sapiens 142-160 16522902-7 2006 For plasma vitamin C (highest versus lowest quartile), the adjusted odds of elevated C-reactive protein and t-PA (highest tertile versus lowest tertile) were 0.56 (95% CI: 0.44, 0.71) and 0.79 (0.62, 1.00); for fruit intake, the corresponding odds ratios were 0.76 (0.60, 0.95) and 0.76 (0.61, 0.95). Ascorbic Acid 11-20 C-reactive protein Homo sapiens 85-103 16054696-5 2006 Here, we show that pravastatin and simvastatin prevent the induction of CRP expression in human hepatoma Hep3B cells exposed to proinflammatory cytokines IL-6 and IL-1beta The nitric oxide (NO) donor, sodium nitroprusside, also prevented the induction of CRP expression while the CRP inducers IL-6 and IL-1beta were present with the cells. Simvastatin 35-46 C-reactive protein Homo sapiens 72-75 16054696-5 2006 Here, we show that pravastatin and simvastatin prevent the induction of CRP expression in human hepatoma Hep3B cells exposed to proinflammatory cytokines IL-6 and IL-1beta The nitric oxide (NO) donor, sodium nitroprusside, also prevented the induction of CRP expression while the CRP inducers IL-6 and IL-1beta were present with the cells. Simvastatin 35-46 C-reactive protein Homo sapiens 255-258 16054696-5 2006 Here, we show that pravastatin and simvastatin prevent the induction of CRP expression in human hepatoma Hep3B cells exposed to proinflammatory cytokines IL-6 and IL-1beta The nitric oxide (NO) donor, sodium nitroprusside, also prevented the induction of CRP expression while the CRP inducers IL-6 and IL-1beta were present with the cells. Simvastatin 35-46 C-reactive protein Homo sapiens 255-258 16927536-4 2006 Chronic treatment with ascorbic acid markedly reduced systolic blood pressure and pulse pressure in ambulatory blood pressure monitoring in the elderly group (from 154.9 +/- 21.6 to 134.8 +/- 19.7 mmHg, p < 0.001; and from 79.1 +/- 22.1 to 63.4 +/- 18.7, p < 0.05; respectively), which was accompanied by an increase in the serum levels of ascorbic acid and decreases in the levels of C-reactive protein, 8-isoprostane, and malondialdehyde-modified low-density lipoproteins. Ascorbic Acid 23-36 C-reactive protein Homo sapiens 391-409 17208662-9 2006 Weight loss drugs, such as orlistat, a lipase inhibitor, and sibutramine, a serotonin and norepinephrine reuptake inhibitor, have both been shown to produce a decrease in C-reactive protein levels and an increase in serum adiponectin. sibutramine 61-72 C-reactive protein Homo sapiens 171-189 16332649-11 2005 Eicosapentaenoic acid in phospholipids (P = 0.06) and CEs (P < 0.05) and linolenic acid in CEs (P < 0.05) were inversely related to C-reactive protein. Eicosapentaenoic Acid 0-21 C-reactive protein Homo sapiens 138-156 16389569-8 2005 CRP also increased cytosolic peroxide levels; this effect was attenuated by antioxidants (ascorbate, alpha-tocopherol), expression of surface CD11b not being inhibited by antioxidants alone. Peroxides 29-37 C-reactive protein Homo sapiens 0-3 16389569-8 2005 CRP also increased cytosolic peroxide levels; this effect was attenuated by antioxidants (ascorbate, alpha-tocopherol), expression of surface CD11b not being inhibited by antioxidants alone. Ascorbic Acid 90-99 C-reactive protein Homo sapiens 0-3 16389569-8 2005 CRP also increased cytosolic peroxide levels; this effect was attenuated by antioxidants (ascorbate, alpha-tocopherol), expression of surface CD11b not being inhibited by antioxidants alone. alpha-Tocopherol 101-117 C-reactive protein Homo sapiens 0-3 16389569-9 2005 CONCLUSION: CRP induces CD11b expression in monocytes through a peroxide independent pathway involving both Syk phosphorylation and [Ca(2+)](i) release. Peroxides 64-72 C-reactive protein Homo sapiens 12-15 16280438-0 2005 A 4-wk intervention with high intake of carotenoid-rich vegetables and fruit reduces plasma C-reactive protein in healthy, nonsmoking men. Carotenoids 40-50 C-reactive protein Homo sapiens 92-110 16290959-8 2005 CONCLUSIONS: Estrogen and estrogen plus medroxyprogesterone significantly raise CRP levels in women with established coronary disease. Medroxyprogesterone 40-59 C-reactive protein Homo sapiens 80-83 16143120-6 2005 Patients with baseline C-reactive protein levels of 10 mg/L or greater (n = 119) showed clearer separation between active treatment and placebo (week 12 clinical response: certolizumab 400 mg, 53.1%; placebo, 17.9%; P = .005; post hoc analysis) owing to a lower placebo response rate than patients with C-reactive protein levels of less than 10 mg/L. Certolizumab Pegol 172-184 C-reactive protein Homo sapiens 23-41 16143120-9 2005 High placebo response rates in the large patient subgroup with low C-reactive protein levels may have obscured statistical separation between certolizumab and placebo. Certolizumab Pegol 142-154 C-reactive protein Homo sapiens 67-85 15057566-5 2005 C-reactive protein levels also correlated significantly in a negative manner with vitamin B12 and folate but positively with tHcy. thcy 125-129 C-reactive protein Homo sapiens 0-18 15982504-9 2005 In the vitamin C group CRP levels were lower on the seventh day (p<0.05). Ascorbic Acid 7-16 C-reactive protein Homo sapiens 23-26 15994744-13 2005 The CRP level of the group also decreased with Simvastatin but it did not reach significance (P = 0.057). Simvastatin 47-58 C-reactive protein Homo sapiens 4-7 15777554-1 2005 OBJECTIVE: This study assessed the effect of coadministration of ezetimibe and simvastatin on high sensitivity C-reactive protein (hs-CRP) in a large subject cohort (N=1089). Simvastatin 79-90 C-reactive protein Homo sapiens 111-129 15791030-4 2005 With adjustment for age, smoking status, and drinking status, the differences in CRP concentrations between those with the MS components of BMI, triglycerides, and uric acid and those without were greater in women than in men. Uric Acid 164-173 C-reactive protein Homo sapiens 81-84 15618128-13 2005 However, CRP was significantly associated with REE in HbSS (r = 0.8, P = 0.003) and an important predictor of REE/FFM. hbss 54-58 C-reactive protein Homo sapiens 9-12 16131811-8 2005 Calcium chelator, BAPTA-AM and anti-oxidants such as N-acetylcysteine and tiron suppressed CRP-induced NF-kappaB activation. 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester 18-26 C-reactive protein Homo sapiens 91-94 15660333-5 2005 Possible adverse effects of uric acid on the vasculature have been linked to increased chemokine and cytokine expression, induction of the renin-angiotensin system, and to increased vascular C-reactive protein (CRP) expression. Uric Acid 28-37 C-reactive protein Homo sapiens 191-209 15660333-5 2005 Possible adverse effects of uric acid on the vasculature have been linked to increased chemokine and cytokine expression, induction of the renin-angiotensin system, and to increased vascular C-reactive protein (CRP) expression. Uric Acid 28-37 C-reactive protein Homo sapiens 211-214 15622323-0 2004 C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. Indinavir 105-114 C-reactive protein Homo sapiens 0-18 15536598-5 2004 CRP was also increased in smokers (P = .023) and in subjects with a low vitamin C intake (P = .018). Ascorbic Acid 72-81 C-reactive protein Homo sapiens 0-3 15458276-7 2004 Supplementation with n-3 FA and a low n-6 FA intake decreased serum sTNF-R p55 and CRP levels in patients with RA. Fatty Acids, Omega-6 38-44 C-reactive protein Homo sapiens 83-86 15321699-6 2004 Co-infusion of the oxygen-derived free radical scavenger vitamin C significantly increased baseline FBF from 2.0 +/- 0.5 to 2.5 +/- 0.7 (mL/min/100 mL forearm tissue (P < 0.001)) and acetylcholine-stimulated FBF responses in patients with elevated CRP, but not in patients with low CRP serum levels. Ascorbic Acid 57-66 C-reactive protein Homo sapiens 251-254 15321699-6 2004 Co-infusion of the oxygen-derived free radical scavenger vitamin C significantly increased baseline FBF from 2.0 +/- 0.5 to 2.5 +/- 0.7 (mL/min/100 mL forearm tissue (P < 0.001)) and acetylcholine-stimulated FBF responses in patients with elevated CRP, but not in patients with low CRP serum levels. Ascorbic Acid 57-66 C-reactive protein Homo sapiens 285-288 15321699-7 2004 Vitamin C-induced increases in baseline FBF and in acetylcholine-stimulated FBF responses were significantly correlated with CRP serum levels. Ascorbic Acid 0-9 C-reactive protein Homo sapiens 125-128 15184351-7 2004 In study II ramipril alone did not significantly change lipoproteins and C-reactive protein levels, however, simvastatin combined with ramipril significantly changed lipoproteins and C-reactive protein levels more than ramipril alone (P<0.001 and P=0.048 by ANOVA, respectively). Simvastatin 109-120 C-reactive protein Homo sapiens 183-201 15257891-3 2004 The proteins were extracted from the cells after a 24-hour exposure of the cells to CRP of varied concentrations in the presence of CoCl(2), and Western blotting was performed for quantification of HIF-1alpha expression, the results were analyzed statistically with SPSS software. cobaltous chloride 132-139 C-reactive protein Homo sapiens 84-87 15047680-10 2004 RESULTS: Vitamin C supplementation yielded a 24.0% reduction (95% confidence interval, -38.9% to -5.5%, p = 0.036 compared to control) in plasma CRP, whereas the antioxidant mixture and placebo produced a nonsignificant 4.7% reduction (-23.9% to 19.3%) and 4.3% increase (-15.1% to 28.2%), respectively. Ascorbic Acid 9-18 C-reactive protein Homo sapiens 145-148 14671251-7 2004 Interestingly, vitamin C concentration was significantly inversely correlated with the levels of CRP and 8-epiPGF2alpha among stroke patients, and 8-epiPGF2alpha was significantly associated with the levels of CRP. Ascorbic Acid 15-24 C-reactive protein Homo sapiens 97-100 14504184-7 2003 Simvastatin, but not aspirin treatment, significantly lowered CRP levels (P<0.05). Simvastatin 0-11 C-reactive protein Homo sapiens 62-65 14572579-9 2003 Serum C-reactive protein levels correlated positively with biliary levels of 7-alpha-hydroxycholesterol (R = 0.948), 7-beta-hydroxycholesterol (R = 0.976), cholestan-3-beta,5-alpha,6-beta-triol (R = 0.823), 7-alpha-hydroxy-4-cholesten-3-one (R = 0.846,) and 7-ketocholesterol (R = 0.973). 7 alpha-hydroxy-4-cholesten-3-one 207-240 C-reactive protein Homo sapiens 6-24 14612213-5 2003 Both fenofibrate and simvastatin markedly reduced plasma levels of high-sensitivity CRP, IL-1 beta, and sCD40L, and improved endothelium-dependent FMD without mutual differences. Simvastatin 21-32 C-reactive protein Homo sapiens 84-87 12957441-8 2003 However, compared with placebo, candesartan significantly reduced plasma levels of malondialdehyde from 1.50 +/- 0.07 to 1.29 +/- 0.09 microM (p = 0.009); improved the percent flow-mediated dilator response to hyperemia from 5.17 +/- 0.24 to 6.22 +/- 0.26% (p < 0.001); and, furthermore, reduced plasma levels of monocyte chemoattractant protein (MCP-1) from 213 +/- 8 to 190 +/- 7 pg/ml (p = 0.003), tumor necrosis factor-alpha from 2.93 to 2.22 pg/ml (p = 0.026), and plasminogen activator inhibitor type 1 from 74 +/- 4 to 53 +/- 4 ng/ml (p < 0.001) but not C-reactive protein (CRP), matrix metalloproteinase protein, and fibrinogen. candesartan 32-43 C-reactive protein Homo sapiens 567-585 12957441-8 2003 However, compared with placebo, candesartan significantly reduced plasma levels of malondialdehyde from 1.50 +/- 0.07 to 1.29 +/- 0.09 microM (p = 0.009); improved the percent flow-mediated dilator response to hyperemia from 5.17 +/- 0.24 to 6.22 +/- 0.26% (p < 0.001); and, furthermore, reduced plasma levels of monocyte chemoattractant protein (MCP-1) from 213 +/- 8 to 190 +/- 7 pg/ml (p = 0.003), tumor necrosis factor-alpha from 2.93 to 2.22 pg/ml (p = 0.026), and plasminogen activator inhibitor type 1 from 74 +/- 4 to 53 +/- 4 ng/ml (p < 0.001) but not C-reactive protein (CRP), matrix metalloproteinase protein, and fibrinogen. candesartan 32-43 C-reactive protein Homo sapiens 587-590 12947436-1 2003 OBJECTIVE: To examine the relationships between circulating concentrations of C-reactive protein and concentrations of retinol, retinyl esters, vitamin C, vitamin E, carotenoids, and selenium. Ascorbic Acid 144-153 C-reactive protein Homo sapiens 78-96 12947436-1 2003 OBJECTIVE: To examine the relationships between circulating concentrations of C-reactive protein and concentrations of retinol, retinyl esters, vitamin C, vitamin E, carotenoids, and selenium. Carotenoids 166-177 C-reactive protein Homo sapiens 78-96 12947436-5 2003 RESULTS: C-reactive protein concentration (dichotomized at the sex-specific 85th percentile) was inversely and significantly associated with concentrations of retinol, retinyl esters, vitamin C, alpha-carotene, beta-carotene, cryptoxanthin, lutein/zeaxanthin, lycopene, and selenium after adjustment for age, sex, race or ethnicity, education, cotinine concentration, body mass index, leisure-time physical activity, and aspirin use. Ascorbic Acid 184-193 C-reactive protein Homo sapiens 9-27 14620923-5 2003 Candesartan reduced the levels of C-reactive protein (from 0.07 +/- 0.04 [median value +/- median absolute deviation] to 0.06 +/- 0.03 mg/dl, p < 0.0001), 8-epi-prostaglandin F2alpha (from 210 +/- 92 to 148 +/- 59 pg/mg creatinine, p < 0.0001), and 8-hydroxydeoxyguanosine (from 5.7 +/- 1.9 to 4.0 +/- 1.3 ng/mg creatinine, p < 0.0001), while the levels of these markers were not altered after the treatment with other antihypertensive agents. candesartan 0-11 C-reactive protein Homo sapiens 34-52 12892455-7 2003 RESULTS: Total lymphocyte count showed a significant early increase and serum c-reactive protein (CRP) was significantly decreased in the D(+)-EN group compared to the D(+)-PN group. d(+)-en 138-145 C-reactive protein Homo sapiens 78-96 12892455-7 2003 RESULTS: Total lymphocyte count showed a significant early increase and serum c-reactive protein (CRP) was significantly decreased in the D(+)-EN group compared to the D(+)-PN group. d(+)-en 138-145 C-reactive protein Homo sapiens 98-101 12716789-10 2003 Serum C-reactive protein was significantly associated with percent linoleic acid and eicosapentaenoic acid in nonsmoking men (P = 0.03 and P = 0.04, respectively) and with docosahexaenoic acid in nonsmoking women (r = -0.46, P < 0.0001). Eicosapentaenoic Acid 85-106 C-reactive protein Homo sapiens 6-24 14512726-4 2003 For both scoring methods, lower CDT scores were associated with age, poor education, increased serum C-reactive protein and history of cancer. cdt 32-35 C-reactive protein Homo sapiens 101-119 12398959-7 2002 Treatment with simvastatin 20, 40, and 80 mg led to significant reductions in CRP plasma levels versus placebo (p <0.05). Simvastatin 15-26 C-reactive protein Homo sapiens 78-81 12398959-10 2002 In summary, simvastatin significantly reduced CRP in patients with mixed hyperlipidemia and hypertriglyceridemia. Simvastatin 12-23 C-reactive protein Homo sapiens 46-49 12234946-0 2002 Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Simvastatin 0-11 C-reactive protein Homo sapiens 19-37 12234946-2 2002 The purpose of this study was to determine the rate at which highly sensitive C-reactive protein (hsCRP) levels change after initiation of simvastatin and whether this occurs independently of the change in LDL cholesterol. Simvastatin 139-150 C-reactive protein Homo sapiens 78-96 11835933-0 2002 Effects of simvastatin (40 and 80 mg) on highly sensitive C-reactive protein in patients with combined hyperlipidemia. Simvastatin 11-22 C-reactive protein Homo sapiens 58-76 12218258-6 2002 In the present study we investigated the association between plasma tHcy and C-reactive protein (CRP), a sensitive marker for inflammation, in psychogeriatric patients. thcy 68-72 C-reactive protein Homo sapiens 77-95 12218258-6 2002 In the present study we investigated the association between plasma tHcy and C-reactive protein (CRP), a sensitive marker for inflammation, in psychogeriatric patients. thcy 68-72 C-reactive protein Homo sapiens 97-100 12218258-10 2002 There was a significant correlation between plasma tHcy and serum CRP (rho = 0.19, p < 0.05). thcy 51-55 C-reactive protein Homo sapiens 66-69 11472751-3 2001 The aim of this study was to evaluate the effect of one year of simvastatin treatment on serum levels of CRP and to assess the influence of risk factors for CVD on CRP concentrations in patients with FH. Simvastatin 64-75 C-reactive protein Homo sapiens 105-108 11382718-7 2001 The effect of CRP on MCP-1 induction was not influenced by aspirin (at concentrations up to 1 mmol/L), but it was significantly inhibited by 5 micromol/L simvastatin. Simvastatin 154-165 C-reactive protein Homo sapiens 14-17 11128362-3 2000 RESULTS: There was a statistically significant positive crude correlation between C-reactive protein and TC (R = 0.19), TG (R = 0.29), BMI (R = 0.32), glucose (R = 0.11), and uric acid (R = 0.14) (all P < 0.0001). Uric Acid 175-184 C-reactive protein Homo sapiens 82-100 10201336-11 1999 However, a significant correlation was found between serum hyaluronan concentration and glomerular filtration rate (GFR) (r = -0.49, p< 0.005); GFR also tended to be correlated with serum TNFalpha (r = -0.31, p = 0.058) but not with serum IL-1beta and serum CRP. Hyaluronic Acid 59-69 C-reactive protein Homo sapiens 261-264 9359864-7 1997 The ability of C2 and C6 to potentiate the effects of cytokines suggests that the sphingomyelin-ceramide pathway participates in induction of CRP and SAA by IL-6+IL-1beta under these experimental conditions, most likely by transducing the effects of IL-1beta. Sphingomyelins 82-95 C-reactive protein Homo sapiens 142-145 9283073-4 1997 Binding of cAMP produced measurable differences in the susceptibility of CRP to the cleavage by Fe-EDTA. Fe(III)-EDTA 96-103 C-reactive protein Homo sapiens 73-76 9283073-8 1997 The F alpha-helix, which provides all base-specific contacts in the CRP-DNA complex, became hypersensitive to Fe-EDTA-mediated cleavage, whereas the solvent exposure of D and E alpha-helices was decreased upon binding of cAMP. Fe(III)-EDTA 110-117 C-reactive protein Homo sapiens 68-71 9028946-2 1997 We recently described a collagen-related triple-helical peptide (CRP) with the sequence GCP*(GPP*)GCP*G (single letter amino acid code: P* = hydroxyproline; Morton et al, Biochem J306:337, 1995). Hydroxyproline 141-155 C-reactive protein Homo sapiens 24-63 9028946-2 1997 We recently described a collagen-related triple-helical peptide (CRP) with the sequence GCP*(GPP*)GCP*G (single letter amino acid code: P* = hydroxyproline; Morton et al, Biochem J306:337, 1995). Hydroxyproline 141-155 C-reactive protein Homo sapiens 65-68 9059324-5 1997 Oral supplementation with eicosapentaenoic acid, in patients with cancer cachexia, resulted in a significant reduction in the serum concentration of the acute-phase protein C-reactive protein (11.0 +/- 4.8 mg/l before eicosapentaenoic acid compared with 0.8 +/- 0.8 mg/l after 4 weeks of eicosapentaenoic acid, P < 0.05), but no significant reduction in the serum concentration of the hepatocyte-stimulating cytokine interleukin-6. Eicosapentaenoic Acid 26-47 C-reactive protein Homo sapiens 173-191 9059324-5 1997 Oral supplementation with eicosapentaenoic acid, in patients with cancer cachexia, resulted in a significant reduction in the serum concentration of the acute-phase protein C-reactive protein (11.0 +/- 4.8 mg/l before eicosapentaenoic acid compared with 0.8 +/- 0.8 mg/l after 4 weeks of eicosapentaenoic acid, P < 0.05), but no significant reduction in the serum concentration of the hepatocyte-stimulating cytokine interleukin-6. Eicosapentaenoic Acid 218-239 C-reactive protein Homo sapiens 173-191 9059324-5 1997 Oral supplementation with eicosapentaenoic acid, in patients with cancer cachexia, resulted in a significant reduction in the serum concentration of the acute-phase protein C-reactive protein (11.0 +/- 4.8 mg/l before eicosapentaenoic acid compared with 0.8 +/- 0.8 mg/l after 4 weeks of eicosapentaenoic acid, P < 0.05), but no significant reduction in the serum concentration of the hepatocyte-stimulating cytokine interleukin-6. Eicosapentaenoic Acid 218-239 C-reactive protein Homo sapiens 173-191 9059324-6 1997 Production of interleukin-6 by peripheral blood mononuclear cells isolated from patients was significantly reduced after supplementation with eicosapentaenoic acid (interleukin-6 production by peripheral blood mononuclear cells exposed to 10 micrograms of lipopolysaccharide/ml: 10.2 +/- 2.1 ng/ml before supplementation with eicosapentaenoic acid compared with 3.5 +/- 1.7 ng/ml after supplementation, P < 0.05) and supernatants from these cells had reduced potential to stimulate C-reactive protein production by isolated human hepatocytes (hepatocyte C-reactive protein production in response to supernatants from peripheral blood mononuclear cell cultures exposed to 10 micrograms of lipopolysaccharide/ml: 150.4 +/- 18.6 ng/ml before eicosapentaenoic acid versus 118 +/- 14.9 ng/ml after 4 weeks of eicosapentaenoic acid, P < 0.05). Eicosapentaenoic Acid 142-163 C-reactive protein Homo sapiens 485-503 9059324-6 1997 Production of interleukin-6 by peripheral blood mononuclear cells isolated from patients was significantly reduced after supplementation with eicosapentaenoic acid (interleukin-6 production by peripheral blood mononuclear cells exposed to 10 micrograms of lipopolysaccharide/ml: 10.2 +/- 2.1 ng/ml before supplementation with eicosapentaenoic acid compared with 3.5 +/- 1.7 ng/ml after supplementation, P < 0.05) and supernatants from these cells had reduced potential to stimulate C-reactive protein production by isolated human hepatocytes (hepatocyte C-reactive protein production in response to supernatants from peripheral blood mononuclear cell cultures exposed to 10 micrograms of lipopolysaccharide/ml: 150.4 +/- 18.6 ng/ml before eicosapentaenoic acid versus 118 +/- 14.9 ng/ml after 4 weeks of eicosapentaenoic acid, P < 0.05). Eicosapentaenoic Acid 142-163 C-reactive protein Homo sapiens 557-575 7685225-4 1993 The DMARDs such as gold salts, D-penicillamine, sulphasalazine and azathioprine have been shown to reduce serum CRP concentrations significantly in patients with RA. gold salts 19-29 C-reactive protein Homo sapiens 112-115 7685225-4 1993 The DMARDs such as gold salts, D-penicillamine, sulphasalazine and azathioprine have been shown to reduce serum CRP concentrations significantly in patients with RA. Penicillamine 31-46 C-reactive protein Homo sapiens 112-115 1624792-7 1992 Comparing various mono-, di-, and trisaccharides as competitive inhibitors of the lectin binding activity of CRP, only beta-D-Gal-(1-3)-D-GalNAc, beta-D-Gal-(1-4)-D-GalNAc, and beta-D-Gal-(1-4)-beta-D-Gal-(1-4)-D-GlcNAc had significant inhibitory power at a concentration of 8 mmol/liter. mono-, di-, and trisaccharides 18-48 C-reactive protein Homo sapiens 109-112 1608680-6 1992 C-reactive protein decreased significantly faster in those with perforated appendix treated with imipenem than in those treated with tobramycin and metronidazole (58.2 mg/liter vs. 89.4 mg/liter, P less than 0.05 on the third postoperative day). Imipenem 97-105 C-reactive protein Homo sapiens 0-18 1701623-6 1990 Ascorbic acid concentrations tended to be lower in RA, however, and correlated inversely with those of haptoglobin, orosomucoid, and C reactive protein, indicating a relation between the ascorbic acid concentration and the degree of inflammation. Ascorbic Acid 0-13 C-reactive protein Homo sapiens 133-151 1701623-6 1990 Ascorbic acid concentrations tended to be lower in RA, however, and correlated inversely with those of haptoglobin, orosomucoid, and C reactive protein, indicating a relation between the ascorbic acid concentration and the degree of inflammation. Ascorbic Acid 187-200 C-reactive protein Homo sapiens 133-151 33233806-12 2020 The highest performance of CRP was observed in the second day with 89.4% sensitivity, 97.3% specificity, 94.5% PPV, and 98.3% NPV. DOP protocol 111-114 C-reactive protein Homo sapiens 27-30 34634403-8 2022 For a 10 mug/m3 increase in short-term exposure to O3, NO2, and SO2, there were significant increases of 1.05% (95%CI: 0.09%, 2.02%), 1.60% (95%CI: 0.49%, 2.72%), and 10.44% (95%CI: 4.20%, 17.05%) in CRP, respectively. Sulfur Dioxide 64-67 C-reactive protein Homo sapiens 200-203 34816729-11 2021 Both estimated glomerular filtration rate and hs-CRP (high-sensitivity C-reactive protein) had significant mediation effects on the association of trimethyllysine with cardiovascular death, with a mediation effect of 37.8% and 13.4%, respectively. trimethyllysine 147-162 C-reactive protein Homo sapiens 71-89 34834375-7 2021 In multivariate analysis, the log Cmin/dose of tacrolimus was significantly and positively associated with the hematocrit, ALAT, and CRP concentrations. Tacrolimus 47-57 C-reactive protein Homo sapiens 133-136 34834375-8 2021 CRP concentrations were higher (p = 0.003) for patients with tacrolimus overexposure (i.e., tacrolimus Cmin > 15 microg/L) (median CRP (10th-90th percentiles): 27 mg/L (3-149 mg/L), n = 91) than they were for patients with a tacrolimus Cmin <= 15 microg/L (13 mg/mL (3-95 mg/L), n = 1482)). Tacrolimus 61-71 C-reactive protein Homo sapiens 0-3 34834375-8 2021 CRP concentrations were higher (p = 0.003) for patients with tacrolimus overexposure (i.e., tacrolimus Cmin > 15 microg/L) (median CRP (10th-90th percentiles): 27 mg/L (3-149 mg/L), n = 91) than they were for patients with a tacrolimus Cmin <= 15 microg/L (13 mg/mL (3-95 mg/L), n = 1482)). Tacrolimus 92-102 C-reactive protein Homo sapiens 0-3 34834375-9 2021 CRP in the fourth quartile (49 to 334 mg/L) was associated with a 2.6-fold increased risk of tacrolimus Cmin overexposure. Tacrolimus 93-103 C-reactive protein Homo sapiens 0-3 34869089-7 2021 Meanwhile, the level of neutrophil, neutrophil/lymphocyte ratio (NLR), platelet count/lymphocyte ratio (PLR), mean platelet volume/lymphocyte ratio (MPVLR), C-reactive protein (CRP), lactic dehydrogenase (LDH), and interleukin (IL)-6 in the RMPP group was significantly higher (p < 0.01) than those in the NRMPP group. rmpp 241-245 C-reactive protein Homo sapiens 157-175 34869089-7 2021 Meanwhile, the level of neutrophil, neutrophil/lymphocyte ratio (NLR), platelet count/lymphocyte ratio (PLR), mean platelet volume/lymphocyte ratio (MPVLR), C-reactive protein (CRP), lactic dehydrogenase (LDH), and interleukin (IL)-6 in the RMPP group was significantly higher (p < 0.01) than those in the NRMPP group. rmpp 241-245 C-reactive protein Homo sapiens 177-180 34715908-2 2021 This analysis aims to identify whether any baseline characteristics or Week 12 clinical outcomes in nr-axSpA patients with elevated C-reactive protein (CRP) and/or sacroiliitis on magnetic resonance imaging (MRI) enrolled in the C-axSpAnd study are predictive of achieving clinical response after 1 year of certolizumab pegol (CZP). Certolizumab Pegol 307-325 C-reactive protein Homo sapiens 132-150 34715908-2 2021 This analysis aims to identify whether any baseline characteristics or Week 12 clinical outcomes in nr-axSpA patients with elevated C-reactive protein (CRP) and/or sacroiliitis on magnetic resonance imaging (MRI) enrolled in the C-axSpAnd study are predictive of achieving clinical response after 1 year of certolizumab pegol (CZP). Certolizumab Pegol 307-325 C-reactive protein Homo sapiens 152-155 34715908-2 2021 This analysis aims to identify whether any baseline characteristics or Week 12 clinical outcomes in nr-axSpA patients with elevated C-reactive protein (CRP) and/or sacroiliitis on magnetic resonance imaging (MRI) enrolled in the C-axSpAnd study are predictive of achieving clinical response after 1 year of certolizumab pegol (CZP). Certolizumab Pegol 327-330 C-reactive protein Homo sapiens 132-150 34715908-2 2021 This analysis aims to identify whether any baseline characteristics or Week 12 clinical outcomes in nr-axSpA patients with elevated C-reactive protein (CRP) and/or sacroiliitis on magnetic resonance imaging (MRI) enrolled in the C-axSpAnd study are predictive of achieving clinical response after 1 year of certolizumab pegol (CZP). Certolizumab Pegol 327-330 C-reactive protein Homo sapiens 152-155 34608242-7 2021 Correlation analyses revealed sphingomyelin (SM) and phosphatidylcholine (PC) positively correlate to tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP), and interleukin-6 (IL-6), while phosphatidylglycerol (PG), and phosphatidylinositol (PI) negatively correlate with them. Sphingomyelins 30-43 C-reactive protein Homo sapiens 143-161 34608242-7 2021 Correlation analyses revealed sphingomyelin (SM) and phosphatidylcholine (PC) positively correlate to tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP), and interleukin-6 (IL-6), while phosphatidylglycerol (PG), and phosphatidylinositol (PI) negatively correlate with them. Sphingomyelins 30-43 C-reactive protein Homo sapiens 163-166 34608242-7 2021 Correlation analyses revealed sphingomyelin (SM) and phosphatidylcholine (PC) positively correlate to tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP), and interleukin-6 (IL-6), while phosphatidylglycerol (PG), and phosphatidylinositol (PI) negatively correlate with them. Sphingomyelins 45-47 C-reactive protein Homo sapiens 143-161 34608242-7 2021 Correlation analyses revealed sphingomyelin (SM) and phosphatidylcholine (PC) positively correlate to tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP), and interleukin-6 (IL-6), while phosphatidylglycerol (PG), and phosphatidylinositol (PI) negatively correlate with them. Sphingomyelins 45-47 C-reactive protein Homo sapiens 163-166 34350496-0 2022 Fabrication of a surface-enhanced Raman spectroscopy-based analytical method consisting of multifunctional DNA three-way junction-conjugated porous gold nanoparticles and Au-Te nanoworm for C-reactive protein detection. au-te 171-176 C-reactive protein Homo sapiens 190-208 34345193-9 2021 In the change from Dall to DAA, hospital stay and CRP decreased, but bleeding volume increased. daa 27-30 C-reactive protein Homo sapiens 50-53 34203183-6 2021 In the PS-matched cohort (59 patients per group), the vitamin C protocol was associated with decreased values for vasopressor dosage, C-reactive protein concentration, and the Sequential Organ Failure Assessment score during the 4-day treatment period. Ascorbic Acid 54-63 C-reactive protein Homo sapiens 134-152 34172825-9 2021 In white women using the combination pill, only CRP contributed positively and independently to NT-proBNP. nt-probnp 96-105 C-reactive protein Homo sapiens 48-51 34406246-4 2021 RESULTS: Highly sensitive C-reactive protein levels differed significantly among the groups (p<0.001) and found to be highest in the low-density lipoprotein cholesterol tertile 1 and lowest in the low-density lipoprotein cholesterol tertile 3 (post-hoc p-values: tertile 1 vs. 2 <0.001; tertile 1 vs. 3 <0.001; tertile 2 vs. 3=0.019). -density lipoprotein cholesterol 200-232 C-reactive protein Homo sapiens 26-44 34406246-6 2021 There was also a negative correlation between highly sensitive C-reactive protein and high-density lipoprotein cholesterol, though the strength of this relationship was weak (r=-0.103, p=0.014). -density lipoprotein cholesterol 90-122 C-reactive protein Homo sapiens 63-81 35476639-8 2022 RESULTS: CRP had the greatest area under the curve (AUC) of 0.893 for diagnosing grade 2 DFU. 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone 89-92 C-reactive protein Homo sapiens 9-12 35476639-12 2022 CONCLUSION: CRP and PCT are the best markers for diagnosing grade 2 and grade 3 DFU respectively. 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone 80-83 C-reactive protein Homo sapiens 12-15 35399859-9 2022 After treatment, the inflammatory factor levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and high-sensitivity C-reactive protein (hs-CRP) in the diclofenac sodium group were observably higher compared with the celecoxib group (P < 0.05), and the inflammatory factor levels in the celecoxib group were remarkably higher compared with the iguratimod group (P < 0.05). Diclofenac 170-187 C-reactive protein Homo sapiens 135-153 35399859-9 2022 After treatment, the inflammatory factor levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and high-sensitivity C-reactive protein (hs-CRP) in the diclofenac sodium group were observably higher compared with the celecoxib group (P < 0.05), and the inflammatory factor levels in the celecoxib group were remarkably higher compared with the iguratimod group (P < 0.05). Diclofenac 170-187 C-reactive protein Homo sapiens 158-161 35267027-9 2022 Higher baseline CRP and/or prednisolone dose were associated with reduced peficitinib efficacy. peficitinib 74-85 C-reactive protein Homo sapiens 16-19 35268083-6 2022 Greater proportions of subjects with insufficient plasma vitamin C had lower high-density lipoprotein cholesterol levels and elevated levels of triglyceride, homocysteine and hs-CRP (all p < 0.001). Ascorbic Acid 57-66 C-reactive protein Homo sapiens 178-181 35131596-9 2022 Aripiprazole, as opposed to amisulpride and olanzapine, was associated with a reduced CRP level after one week, after which the CRP level caught up with the other drugs. Aripiprazole 0-12 C-reactive protein Homo sapiens 86-89 35131596-9 2022 Aripiprazole, as opposed to amisulpride and olanzapine, was associated with a reduced CRP level after one week, after which the CRP level caught up with the other drugs. Aripiprazole 0-12 C-reactive protein Homo sapiens 128-131 35131596-11 2022 CONCLUSION: Treatment with amisulpride, aripiprazole and olanzapine showed different effects on CRP levels in patients with schizophrenia spectrum disorders, modified by previous antipsychotics exposure status. Aripiprazole 40-52 C-reactive protein Homo sapiens 96-99 35131596-11 2022 CONCLUSION: Treatment with amisulpride, aripiprazole and olanzapine showed different effects on CRP levels in patients with schizophrenia spectrum disorders, modified by previous antipsychotics exposure status. Olanzapine 57-67 C-reactive protein Homo sapiens 96-99 35281240-11 2022 The RMPP group had higher neutrophil ratio (N%), C-reactive protein (CRP), interleukin-6 (IL-6), lactic dehydrogenase (LDH), and D-dimer than the GMPP group (P < 0.05). rmpp 4-8 C-reactive protein Homo sapiens 49-67 35281240-11 2022 The RMPP group had higher neutrophil ratio (N%), C-reactive protein (CRP), interleukin-6 (IL-6), lactic dehydrogenase (LDH), and D-dimer than the GMPP group (P < 0.05). rmpp 4-8 C-reactive protein Homo sapiens 69-72 35281240-15 2022 Conclusion: C-reactive protein, LDH, and D-dimer were predictive factors for RMPP. rmpp 77-81 C-reactive protein Homo sapiens 12-30 32622519-7 2020 Donors in the HALDN group had a longer procedure time (217 minutes, P < .0001), less estimated blood loss (51 mL, P < .0001), lower serum levels of C-reactive protein at postoperative day (POD) 1 (7.9 mg/dL, P < .0001) than those in the HARDN group. haldn 14-19 C-reactive protein Homo sapiens 148-166 31769434-0 2019 C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study. sunitinib 141-150 C-reactive protein Homo sapiens 0-18 31490211-10 2019 Cannabis-plus-cocaine use increased CRP, IL-8 and IL-6/IL-10 ratio, but decreased thiol content, and inflammatory and activated-classic monocyte percentages. Cocaine 14-21 C-reactive protein Homo sapiens 36-39 31350270-9 2019 Changes from baseline in DAS28-C-reactive protein/erythrocyte sedimentation rate and the ACR core set were significantly greater for both peficitinib doses versus placebo at week 12/ET (p<0.001). peficitinib 138-149 C-reactive protein Homo sapiens 31-49 31440156-12 2019 Furthermore, CRP and TNF-alpha levels of the POCD group were significantly higher at each postoperative time point (P < 0.05). pocd 45-49 C-reactive protein Homo sapiens 13-16 32292723-9 2019 Conclusion: Ezetimibe co-administered with simvastatin (10 mg) and high-dose statin monotherapy may show similar effects in reducing LDL-C, TG, and hs-CRP levels and in increasing HDL-C levels. Simvastatin 43-54 C-reactive protein Homo sapiens 151-154 31129912-4 2019 RESULTS: NECA, a bioactive adenosine analogue, partially inhibits aggregation and secretion to collagen or CRP in the absence or presence of the P2Y12 receptor antagonist, cangrelor and the cyclooxygenase inhibitor, indomethacin. Adenosine-5'-(N-ethylcarboxamide) 10-14 C-reactive protein Homo sapiens 108-111 31082330-15 2019 Subsequently, oral acetaminophen was initiated, and both her leukocyte count and C-reactive protein improved markedly. Acetaminophen 19-32 C-reactive protein Homo sapiens 81-99 30460516-9 2019 Additionally, olanzapine administration was found to induce both metabolic alterations (adiposity, lipogenesis, plasma free fatty acid, and acetate levels increase) (experiments = 3) and inflammation (experiments = 2) in rodents, whereas risperidone suppressed the resting metabolic rate in rodents (experiments = 5) and elevated fasting blood glucose, triglycerides, LDL, hs-CRP, antioxidant superoxide dismutase, and HOMA-IR in humans (experiment = 1). Olanzapine 14-24 C-reactive protein Homo sapiens 376-379 30959878-5 2019 The antibody capture of C-reactive protein (CRP) on the nano-surfaces was used to demonstrate the enhanced signal generated with increasing amounts of CuO in the nano-surface. cupric oxide 151-154 C-reactive protein Homo sapiens 24-42 30959878-5 2019 The antibody capture of C-reactive protein (CRP) on the nano-surfaces was used to demonstrate the enhanced signal generated with increasing amounts of CuO in the nano-surface. cupric oxide 151-154 C-reactive protein Homo sapiens 44-47 30632650-0 2019 C-reactive protein (CRP) rs3093059C predicts poor mizolastine response in chronic spontaneous urticaria patients with elevated serum CRP level. mizolastine 50-61 C-reactive protein Homo sapiens 0-18 30632650-0 2019 C-reactive protein (CRP) rs3093059C predicts poor mizolastine response in chronic spontaneous urticaria patients with elevated serum CRP level. mizolastine 50-61 C-reactive protein Homo sapiens 20-23 30632650-0 2019 C-reactive protein (CRP) rs3093059C predicts poor mizolastine response in chronic spontaneous urticaria patients with elevated serum CRP level. mizolastine 50-61 C-reactive protein Homo sapiens 133-136 30632650-11 2019 Our findings suggested that CSU patients carrying the rs3093059C allele may respond poorly to mizolastine with elevated serum CRP level. mizolastine 94-105 C-reactive protein Homo sapiens 126-129 30639628-7 2019 Longitudinal data analysis was performed to analyse the correlation between posaconazole serum trough concentrations and CRP values, corrected for potential factors that could influence the posaconazole concentration. posaconazole 76-88 C-reactive protein Homo sapiens 121-124 30538058-11 2019 Notably, Rivaroxaban use was also associated with a significant reduction in C reactive protein (CRP) (p < 0.001) during follow-up. Rivaroxaban 9-20 C-reactive protein Homo sapiens 77-95 30538058-11 2019 Notably, Rivaroxaban use was also associated with a significant reduction in C reactive protein (CRP) (p < 0.001) during follow-up. Rivaroxaban 9-20 C-reactive protein Homo sapiens 97-100 29926959-9 2019 RESULTS: Uric acid to creatinine ratio was significantly correlated with Crohn"s disease activity index (rho = 0.184, P = 0.002) and Harvey Bradshaw index (rho = 0.154, P = 0.010) and C-reactive protein (rho = 0.591, P < 0.001) in CD group. Uric Acid 9-18 C-reactive protein Homo sapiens 184-202 30637206-11 2018 Direct Bb was negatively correlated with CRP (P = 0.002). Bilirubin 7-9 C-reactive protein Homo sapiens 41-44 30182714-1 2018 In this work, we have designed an efficient and rapid surface-enhanced Raman spectroscopy (SERS) immunosensor for a supersensitive analysis of hypersensitive C-reactive protein (hs-CRP) with a label-free method by combining porous magnetic Ni@C nanospheres to aggregate together for simplifying the experiment operation and CaCO3 microcapsule to encapsulate rhodamine B as the Raman signal. rhodamine B 358-369 C-reactive protein Homo sapiens 158-176 30334413-9 2018 The negative correlation for the hs-CRP and fasting glucose and DIA were found in low hs-CRP (r= -0.619; p less than 0.05 and r= -0.580; p less than 0.05 respectively) and for the hs-CRP and uric acid (r=-0.850; p less than 0.05) in the moderate hs-CRP risk group. Uric Acid 191-200 C-reactive protein Homo sapiens 36-39 30334413-9 2018 The negative correlation for the hs-CRP and fasting glucose and DIA were found in low hs-CRP (r= -0.619; p less than 0.05 and r= -0.580; p less than 0.05 respectively) and for the hs-CRP and uric acid (r=-0.850; p less than 0.05) in the moderate hs-CRP risk group. Uric Acid 191-200 C-reactive protein Homo sapiens 89-92 30334413-9 2018 The negative correlation for the hs-CRP and fasting glucose and DIA were found in low hs-CRP (r= -0.619; p less than 0.05 and r= -0.580; p less than 0.05 respectively) and for the hs-CRP and uric acid (r=-0.850; p less than 0.05) in the moderate hs-CRP risk group. Uric Acid 191-200 C-reactive protein Homo sapiens 89-92 30334413-9 2018 The negative correlation for the hs-CRP and fasting glucose and DIA were found in low hs-CRP (r= -0.619; p less than 0.05 and r= -0.580; p less than 0.05 respectively) and for the hs-CRP and uric acid (r=-0.850; p less than 0.05) in the moderate hs-CRP risk group. Uric Acid 191-200 C-reactive protein Homo sapiens 89-92 29787958-12 2018 There was a positive correlation between QUIN and both CRP concentrations and whole blood IDO1 in MDD. Quinolinic Acid 41-45 C-reactive protein Homo sapiens 55-58 29527782-7 2018 Only in T1D boys serum UA was positively correlated with concentrations of subclinical inflammatory markers (CRP, IL-6, TNF-alpha), the indicators of renal function (albumin excretion rate, serum cystatin C level), blood pressure and negatively correlated with anti-inflammatory IL-10. Uric Acid 23-25 C-reactive protein Homo sapiens 109-112 29554535-2 2018 This study is the first to analyze blood levels of the pro-inflammatory biomarker C-reactive protein (CRP) in bipolar disorder patients treated with the cyclooxygenase-2 inhibitor, celecoxib (CBX). cbx 192-195 C-reactive protein Homo sapiens 82-100 29554535-2 2018 This study is the first to analyze blood levels of the pro-inflammatory biomarker C-reactive protein (CRP) in bipolar disorder patients treated with the cyclooxygenase-2 inhibitor, celecoxib (CBX). cbx 192-195 C-reactive protein Homo sapiens 102-105 29554535-9 2018 No significant differences in CRP levels were measured between CBX and placebo groups at baseline (P = 0.156), but by week 8 CRP was significantly decreased in the CBX group vs. placebo (P = 0.003). cbx 164-167 C-reactive protein Homo sapiens 125-128 29554535-10 2018 This indicates reduced inflammation in CBX-treated patients, and that CRP may be a useful biomarker for monitoring treatment response in BDD patients during SSRI + CBX combination treatment. cbx 164-167 C-reactive protein Homo sapiens 70-73 29554535-11 2018 CRP and IL-6 levels were positively correlated in the CBX group, and CRP levels were positively correlated with BMI. cbx 54-57 C-reactive protein Homo sapiens 0-3 29861487-5 2018 In study 1 (male: n = 242; 53%), plasma IL-6, TNFalpha and CRP were significantly higher (p < 0.05) in children with 25-hydroxyvitamin D (25(OH)D) >= 75 nmol/L compared to. 25-hydroxyvitamin D 120-139 C-reactive protein Homo sapiens 59-62 29713320-9 2018 1,6-bis(phosphocholine)-hexane (1,6-bisPC), which stabilizes CRP in its native pentameric form was used to validate CRP effects. 1,6-bis(phosphocholine)-hexane 0-30 C-reactive protein Homo sapiens 61-64 29713320-9 2018 1,6-bis(phosphocholine)-hexane (1,6-bisPC), which stabilizes CRP in its native pentameric form was used to validate CRP effects. 1,6-bis(phosphocholine)-hexane 0-30 C-reactive protein Homo sapiens 116-119 29713320-9 2018 1,6-bis(phosphocholine)-hexane (1,6-bisPC), which stabilizes CRP in its native pentameric form was used to validate CRP effects. 1,6-bis(phosphocholine)-hexane 32-41 C-reactive protein Homo sapiens 61-64 29713320-9 2018 1,6-bis(phosphocholine)-hexane (1,6-bisPC), which stabilizes CRP in its native pentameric form was used to validate CRP effects. 1,6-bis(phosphocholine)-hexane 32-41 C-reactive protein Homo sapiens 116-119 29713320-14 2018 1,6-bisPC reverses these effects via inhibition of the conformational change that leads to exposure of pro-inflammatory epitopes in CRP (pCRP* and mCRP). 1,6-bis(phosphocholine)-hexane 0-9 C-reactive protein Homo sapiens 132-135 29335342-6 2018 All TNFi were significantly better than placebo in reducing BASDAI and BASFI at 12 weeks and 24 weeks; all but certolizumab pegol (CZP) were statistically better than placebo in reducing CRP at 12 weeks; all but CZP and infliximab-dyyb (IFX biosimilar) were significantly better than placebo in reducing CRP at 24 weeks. Certolizumab Pegol 111-129 C-reactive protein Homo sapiens 187-190 29335342-6 2018 All TNFi were significantly better than placebo in reducing BASDAI and BASFI at 12 weeks and 24 weeks; all but certolizumab pegol (CZP) were statistically better than placebo in reducing CRP at 12 weeks; all but CZP and infliximab-dyyb (IFX biosimilar) were significantly better than placebo in reducing CRP at 24 weeks. Certolizumab Pegol 131-134 C-reactive protein Homo sapiens 187-190 29588485-7 2018 Study subjects in the highest tertile of serum uric acid level were older, more likely to be male, and had higher systolic blood pressure, body mass index, carotid artery intima-media thickness and serum triglyceride, high-sensitivity C-reactive protein, and low-density lipoprotein cholesterol levels and lower serum high-density lipoprotein cholesterol levels (all p < 0.05). Uric Acid 47-56 C-reactive protein Homo sapiens 235-253 29503075-10 2018 RESULTS: The ciprofloxacin group gave better results than the other 2 groups regarding total and differential leucocytic count and C-reactive protein level. Ciprofloxacin 13-26 C-reactive protein Homo sapiens 131-149 27984333-1 2018 BACKGROUND: Vitamin C is related to lower levels of high-sensitivity C-reactive protein (hsCRP), an inflammatory biomarker that predicts cardiovascular disease. Ascorbic Acid 12-21 C-reactive protein Homo sapiens 69-87 28220370-7 2017 RESULTS: The patients treated with candesartan had a significant lower value of PTX3 and hs-CRP, compared with those under treatment with other antihypertensive medication as follows: PTX3: 0.61 +- 0.49 vs 0.95 +- 1.04 ng/ml, P = 0.006 and hs-CRP: 0.19 +- 0.20 vs 0.20 +- 0.22 mg/dl, P = 0.54. candesartan 35-46 C-reactive protein Homo sapiens 92-95 28824047-7 2017 In multivariable analysis, lower levels of proteinuria and hemoglobin and higher levels of C-reactive protein were significantly associated with higher osteoglycin levels. osteoglycin 152-163 C-reactive protein Homo sapiens 91-109 28947985-6 2017 The PD patients with high urinary nickel concentrations demonstrated higher log serum levels of high sensitivity C-reactive protein (0.4+-0.5 versus 0.1+-0.5 mg/L, P=0.046) than patients with normal urinary nickel concentrations. Nickel 34-40 C-reactive protein Homo sapiens 113-131 28432842-10 2017 LAVI was related with CRP (beta=0.315, p<0.001), kynurenine (beta=0.256, p=0.005) and QUIN (beta=0.213, p=0.044). lavi 0-4 C-reactive protein Homo sapiens 22-25 28408375-4 2017 APPROACH AND RESULTS: Herein, we report a positive relationship between serum UA and acute-phase reactants, such as high-sensitivity C-reactive protein, fibrinogen, ferritin, complement C3, and erythrocyte sedimentation rate, in a cohort of 2731 nondiabetic adults. Uric Acid 78-80 C-reactive protein Homo sapiens 133-151 28408375-7 2017 We show that UA stimulates the expression of C-reactive protein, fibrinogen, ferritin, and complement C3 in a dose-dependent fashion. Uric Acid 13-15 C-reactive protein Homo sapiens 45-63 28453763-8 2017 Combining the HBI with PROp and PROc scores and then further adding CRP significantly improved the correlation with SES-CD [AUC = 0.78 and AUC = 0.88, respectively, p < 0.00001]. ses-cd 116-122 C-reactive protein Homo sapiens 68-71 28061321-12 2017 CONCLUSION: The subcutaneous application of sterile vitamin E acetate ointment leads to a reduction in the incisional SSI rate, lower post-operative pain, and decrease in C-reactive protein and white blood cell count. alpha-Tocopherol 52-69 C-reactive protein Homo sapiens 171-189 28231708-0 2017 Evaluating the Effect of Lidocaine on the Interactions of C-reactive Protein with Its Aptamer and Antibody by Dynamic Force Spectroscopy. Lidocaine 25-34 C-reactive protein Homo sapiens 58-76 28231708-2 2017 Herein, the effect of lidocaine on the interactions of C-reactive protein (CRP) with its aptamer and antibody under different temperature was investigated through dynamic force spectroscopy (DFS). Lidocaine 22-31 C-reactive protein Homo sapiens 55-73 28231708-2 2017 Herein, the effect of lidocaine on the interactions of C-reactive protein (CRP) with its aptamer and antibody under different temperature was investigated through dynamic force spectroscopy (DFS). Lidocaine 22-31 C-reactive protein Homo sapiens 75-78 28231708-3 2017 The results revealed that lidocaine could reduce the binding probabilities and binding affinities of the CRP-aptamer and the CRP-antibody. Lidocaine 26-35 C-reactive protein Homo sapiens 105-108 28231708-3 2017 The results revealed that lidocaine could reduce the binding probabilities and binding affinities of the CRP-aptamer and the CRP-antibody. Lidocaine 26-35 C-reactive protein Homo sapiens 125-128 28231708-4 2017 An interesting discovery was that lidocaine had differential influences on the dynamic force spectra of the CRP-aptamer and the CRP-antibody. Lidocaine 34-43 C-reactive protein Homo sapiens 108-111 28231708-4 2017 An interesting discovery was that lidocaine had differential influences on the dynamic force spectra of the CRP-aptamer and the CRP-antibody. Lidocaine 34-43 C-reactive protein Homo sapiens 128-131 28231708-5 2017 The energy landscape of the CRP-aptamer turned from two activation barriers to one after the treatment of lidocaine, while the one activation barrier in energy landscape of the CRP-antibody almost remained unchanged. Lidocaine 106-115 C-reactive protein Homo sapiens 28-31 28231708-6 2017 In addition, similar results were obtained for 25 and 37 C. In accordance with the result of molecular docking, the reduction of binding probabilities might be due to the binding of lidocaine on CRP. Lidocaine 183-192 C-reactive protein Homo sapiens 196-199 28231708-8 2017 Furthermore, differential effects of lidocaine on the interactions of CRP-aptamer and CRP-antibody might be attributed to the different dissociation processes and binding sites of the CRP-aptamer and the CRP-antibody and different structures of the aptamer and the antibody. Lidocaine 37-46 C-reactive protein Homo sapiens 70-73 28231708-8 2017 Furthermore, differential effects of lidocaine on the interactions of CRP-aptamer and CRP-antibody might be attributed to the different dissociation processes and binding sites of the CRP-aptamer and the CRP-antibody and different structures of the aptamer and the antibody. Lidocaine 37-46 C-reactive protein Homo sapiens 86-89 28231708-8 2017 Furthermore, differential effects of lidocaine on the interactions of CRP-aptamer and CRP-antibody might be attributed to the different dissociation processes and binding sites of the CRP-aptamer and the CRP-antibody and different structures of the aptamer and the antibody. Lidocaine 37-46 C-reactive protein Homo sapiens 86-89 28231708-8 2017 Furthermore, differential effects of lidocaine on the interactions of CRP-aptamer and CRP-antibody might be attributed to the different dissociation processes and binding sites of the CRP-aptamer and the CRP-antibody and different structures of the aptamer and the antibody. Lidocaine 37-46 C-reactive protein Homo sapiens 86-89 26783014-11 2017 CDI was positively associated with CRP by linear regression within racial groups. 1,1'-Carbonyldiimidazole 0-3 C-reactive protein Homo sapiens 35-38 28467580-9 2017 Mean CRP level was 14.2+-19 mg/L, 36.9+-59 mg/L, and 40.8+-66 mg/L in LH, NCAA, and CAA groups, respectively (p=0.008). ncaa 74-78 C-reactive protein Homo sapiens 5-8 28104989-5 2017 RESULTS: SES-CD correlated significantly with CD clinical activity and several standard biochemical parameters (albumin, leukocyte and platelet counts, C-reactive protein, erythrocyte sedimentation rate, fibrinogen). ses-cd 9-15 C-reactive protein Homo sapiens 152-170 28693022-0 2017 Temsirolimus Sensitive Stimulation of Platelet Activity, Apoptosis and Aggregation by Collagen Related Peptide. temsirolimus 0-12 C-reactive protein Homo sapiens 86-110 29099118-5 2017 Serum uric acid levels were statistically correlated with c-LDL, total bilirubin, albumin, GGT and CRP suggesting hyperuricemia could be associated with a dyslipidemic state, hepatic damage and increase in acute pro-inflammatory phase markers. Uric Acid 6-15 C-reactive protein Homo sapiens 99-102 27700539-10 2016 A serum TSH level below the mean in LT4-treated participants was associated with a higher serum free T4 but similar free and total T3; yet those with lower serum TSH levels exhibited higher serum high-density lipoprotein and lower serum low-density lipoprotein, triglycerides, and C-reactive protein. Thyrotropin 8-11 C-reactive protein Homo sapiens 281-299 28426854-0 2016 Elevated Baseline C-Reactive Protein as a Predictor of Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From the Simvastatin in Aneurysmal Subarachnoid Hemorrhage (STASH) Trial: Erratum. Simvastatin 119-130 C-reactive protein Homo sapiens 18-36 27827910-0 2016 The Effect of Serum 25-Hydroxyvitamin D Concentrations on Elevated Serum C-Reactive Protein Concentrations in Normal Weight, Overweight and Obese Participants of a Preventive Health Program. 25-hydroxyvitamin D 20-39 C-reactive protein Homo sapiens 73-91 27061381-8 2016 Meanwhile, the serum CRP was negatively correlated with serum TB levels but positively correlated with peripheral WBC and the Psoriasis Area and Severity Index (PASI). Bilirubin 62-64 C-reactive protein Homo sapiens 21-24 27428192-11 2016 No significant difference in the plasma CRP level was found between groups P and C. CONCLUSIONS: Parecoxib sodium decreases POCD incidence after total knee arthroplasty in elderly patients and may explain how this drug suppresses inflammation and acute postoperative pain caused by surgical trauma. parecoxib 97-113 C-reactive protein Homo sapiens 40-43 26032849-5 2016 The receiver-operating characteristic (ROC) analysis shows that CRP (area under the curve [AUC]: 0.59; 95% confidence interval [CI]: 0.53-0.66; P = .014) and TB (AUC: 0.58; 95% CI: 0.51-0.65; P = .019) are significantly associated with MACE but not UA (AUC: 0.61; 95% CI: 0.42-0.76; P = .083). Uric Acid 249-251 C-reactive protein Homo sapiens 64-67 27349017-0 2016 Low Serum Total Bilirubin Concentration was Associated with Increased High Sensitive C Reactive Protein Level in Patients with Impaired Glucose Tolerance and Type 2 Diabetes Mellitus Subjects. Bilirubin 16-25 C-reactive protein Homo sapiens 85-103 27213056-10 2016 Simvastatin treatment significantly increased FMD value, decreased CRP and TNF-alpha concentration. Simvastatin 0-11 C-reactive protein Homo sapiens 67-70 26566216-2 2016 METHODS: The prognostic CRP classification was constructed in the retrospective cohort, consisting of advanced PCa patients with first-line gemcitabine monotherapy (GEM). 4-(N)-lauroylgemcitabine 165-168 C-reactive protein Homo sapiens 24-27 27239922-9 2016 There were correlations between NT-proBNP levels and erythrocyte sedimentation rate, CRP, simplified disease activity index, and clinical disease activity index. nt-probnp 32-41 C-reactive protein Homo sapiens 85-88 26666588-5 2015 WBC (P = 0.001), ESR (P = 0.005), CRP (P < 0.001) and MPV levels (P = 0.011) were significantly higher in the APN group than those in the lower UTI group. apholate 113-116 C-reactive protein Homo sapiens 34-37 26549279-0 2015 Java project on periodontal diseases: effect of vitamin C/calcium threonate/citrus flavonoids supplementation on periodontal pathogens, CRP and HbA1c. Ascorbic Acid 48-57 C-reactive protein Homo sapiens 136-139 26569292-3 2015 We aimed to determine the relationship between cord blood 25-hydroxyvitamin D (25(OH)D) and C-reactive protein (CRP) in neonates. 25-hydroxyvitamin D 58-77 C-reactive protein Homo sapiens 92-110 26569292-3 2015 We aimed to determine the relationship between cord blood 25-hydroxyvitamin D (25(OH)D) and C-reactive protein (CRP) in neonates. 25-hydroxyvitamin D 58-77 C-reactive protein Homo sapiens 112-115 26370382-6 2015 In fully adjusted models, GMV was inversely associated with coronary artery CP (parameter estimate [beta] -0.47 [SE 0.15], P = 0.002; carotid artery CP (beta -1.92 [SE 0.62], P = 0.002; and aorta CP [beta -0.10 [SE 0.03] P = 0.002), whereas HbA1c and CRP did not associate with cerebral volumes. Guanosine-5'-Phosphovanadate 26-29 C-reactive protein Homo sapiens 251-254 25985199-0 2015 A simultaneous electrochemical multianalyte immunoassay of high sensitivity C-reactive protein and soluble CD40 ligand based on reduced graphene oxide-tetraethylene pentamine that directly adsorb metal ions as labels. tetraethylenepentamine 151-174 C-reactive protein Homo sapiens 76-94 25985199-1 2015 A simplified electrochemical multianalyte immunosensor for the simultaneous detection of high sensitivity C-reactive protein (hsCRP) and soluble CD40 ligand (sCD40L) that uses reduced graphene oxide-tetraethylene pentamine (rGO-TEPA) that directly adsorbs metal ions as labels is reported. tetraethylenepentamine 199-222 C-reactive protein Homo sapiens 106-124 25048713-2 2015 There is some evidence that there is a negative inverse relationship between plasma vitamin C concentration and the systemic inflammatory response as measured by C-reactive protein (CRP). Ascorbic Acid 84-93 C-reactive protein Homo sapiens 162-180 25048713-2 2015 There is some evidence that there is a negative inverse relationship between plasma vitamin C concentration and the systemic inflammatory response as measured by C-reactive protein (CRP). Ascorbic Acid 84-93 C-reactive protein Homo sapiens 182-185 26032258-7 2015 KEY FINDINGS: Simvastatin therapy improved the main parameters of lipid metabolism, including statistically significant (P < 0.05) reductions in TC (by 46%) and LDL-C (by 42%), and decreased inflammatory marker C-RP (by 32%), as compared with the baseline. Simvastatin 14-25 C-reactive protein Homo sapiens 214-218 26229324-4 2015 The aim of this study was to investigate whether oral administration of Vitamin C and E help in a reduction of the serum level of inflammatory mediator by serial measurement of high sensitivity C-reactive protein (hs-CRP) and by this reduction in the risk of renal damage. Ascorbic Acid 72-81 C-reactive protein Homo sapiens 194-212 25851564-5 2015 RESULTS: At diagnosis: PCDAI had poor correlation (r = 0.33); CRP (r = 0.54) and FC (r = 0.46) had moderate correlation with SES-CD. ses-cd 125-131 C-reactive protein Homo sapiens 62-65 25832424-8 2015 Pretreatment of the cells with the ROS scavenger N-acetyl-L-cysteine, ERK inhibitor PD98059 or NF-kappaB inhibitor PDTC blocked CRP-stimulated RAGE expression, but pretreatment with the NADPH oxidase inhibitor DPI, JNK inhibitor SP600125 or p38 MAPK inhibitor SB203580 did not significantly alter CRP-stimulated RAGE expression. 3-aminodiphenyleneiodium 210-213 C-reactive protein Homo sapiens 128-131 25150977-6 2015 Methods are illustrated in an applied example considering causal relationships between body mass index, C-reactive protein and uric acid. Uric Acid 127-136 C-reactive protein Homo sapiens 104-122 26005382-0 2015 Correlation Between C-reactive Protein and Non-enzymatic Antioxidants (Albumin, Ferritin, Uric Acid and Bilirubin) in Hemodialysis Patients. Bilirubin 104-113 C-reactive protein Homo sapiens 20-38 26005382-12 2015 Furthermore, the positive, linear correlation was determined between serum CRP and ferritin (r = 0.159, p = 0.114) and positive linear correlation between CRP and total serum bilirubin (r = 0.121, p = 0.230). Bilirubin 175-184 C-reactive protein Homo sapiens 155-158 25685360-1 2015 AIMS: To assess the prognostic importance of high-sensitive C reactive protein (hsCRP) in patients with mild to moderate aortic valve stenosis during placebo or simvastatin/ezetimibe treatment in Simvastatin and Ezetimibe in Aortic Stenosis (SEAS). Simvastatin 161-172 C-reactive protein Homo sapiens 60-78 25685360-1 2015 AIMS: To assess the prognostic importance of high-sensitive C reactive protein (hsCRP) in patients with mild to moderate aortic valve stenosis during placebo or simvastatin/ezetimibe treatment in Simvastatin and Ezetimibe in Aortic Stenosis (SEAS). Simvastatin 196-207 C-reactive protein Homo sapiens 60-78 24702708-3 2015 RESULTS: Male congenital heart disease patients with high serum uric acid concentrations (>7 mg/dl) showed significantly (p < 0.05) higher body mass index, serum creatinine, total cholesterol, low-density lipoprotein-cholesterol, triglycerides, and C-reactive protein concentrations than those male congenital heart disease patients with lower serum uric acid levels (<=7 mg/dl). Uric Acid 64-73 C-reactive protein Homo sapiens 255-273 24702708-4 2015 Meanwhile, female congenital heart disease patients with higher serum uric acid concentrations (>5.7 mg/dl) were significantly (p < 0.05) younger, more hypoxaemic, more obese, and with higher C-reactive protein and N-terminal-pro-B-type natriuretic peptide levels than those female congenital heart disease patients with lower serum uric acid concentrations (<=5.7 mg/dl). Uric Acid 70-79 C-reactive protein Homo sapiens 198-216 26089599-9 2015 In this respect, the development of clinically applicable derivatives of the palindromic compound 1,6-bis(phosphocholine)-hexane (1,6-bis PC) should be a major focus of future CRP research. 1,6-bis(phosphocholine)-hexane 98-128 C-reactive protein Homo sapiens 176-179 26089599-9 2015 In this respect, the development of clinically applicable derivatives of the palindromic compound 1,6-bis(phosphocholine)-hexane (1,6-bis PC) should be a major focus of future CRP research. 1,6-bis(phosphocholine)-hexane 130-140 C-reactive protein Homo sapiens 176-179 24879591-5 2014 A detail EIS study was conducted on the bioelectrode towards the quantitative detection of the target Ag-CRP in phosphate-buffered saline (PBS). Phosphate-Buffered Saline 112-137 C-reactive protein Homo sapiens 105-108 24879591-5 2014 A detail EIS study was conducted on the bioelectrode towards the quantitative detection of the target Ag-CRP in phosphate-buffered saline (PBS). pbs 139-142 C-reactive protein Homo sapiens 105-108 24879591-7 2014 The bioelectrode exhibited a linear response of CRP detection in the range of 10 ng mL(-1) to 10 mug mL(-1) with a sensitivity of 92.86 Omegacm(2) per decade CRP in pH 7.4 PBS. pbs 172-175 C-reactive protein Homo sapiens 48-51 24879591-7 2014 The bioelectrode exhibited a linear response of CRP detection in the range of 10 ng mL(-1) to 10 mug mL(-1) with a sensitivity of 92.86 Omegacm(2) per decade CRP in pH 7.4 PBS. pbs 172-175 C-reactive protein Homo sapiens 158-161 24894662-1 2014 An electrochemical impedance immunosensing method for the detection and quantification of C-reactive protein (alphaCRP) in phosphate buffered saline (PBS) is demonstrated. Phosphate-Buffered Saline 123-148 C-reactive protein Homo sapiens 90-108 25149995-6 2014 Apart from decreasing plasma total cholesterol, LDL cholesterol and apolipoprotein B-100 levels, simvastatin reduced plasma levels of FFA, leptin and TNF-alpha, as well as increased plasma levels of adiponectin, which was accompanied by a reduction in plasma CRP. Simvastatin 97-108 C-reactive protein Homo sapiens 259-262 24829443-10 2014 Several parameters were correlated with postoperative maximum CRP level: body temperature (P=0.001) and heart rate (P<0.001) at the end of surgery; intraoperative last lactate (P<0.001) and base excess (P<0.001); and red blood cell transfusion (P=0.019). excess 201-207 C-reactive protein Homo sapiens 62-65 24891317-10 2014 Post hoc analyses suggested a possible association between higher baseline C-reactive protein levels or MRI sacroiliac joint inflammation scores and higher rates of ASAS40 response to etanercept. asas40 165-171 C-reactive protein Homo sapiens 75-93 24447269-8 2014 The high-sensitivity C-reactive protein was decreased (tacrolimus group, 1 mo) and increased (cyclosporine group, 6 and 12 mo) after the kidney transplant. Tacrolimus 55-65 C-reactive protein Homo sapiens 21-39 24971305-10 2014 Among patients with elevated C-reactive protein concentrations, levels of both interleukin-6 (IL-6) and IL-10 decreased at 24 h of aminophylline therapy. Aminophylline 131-144 C-reactive protein Homo sapiens 29-47 24903748-11 2014 Unconjugated bilirubin correlated with haemoglobin, which was inversely correlated with CRP. Bilirubin 13-22 C-reactive protein Homo sapiens 88-91 24883106-6 2014 At week 12, CRP increased in the 500 mg AMH (p = 0.003) and placebo (p = 0.012) groups from their BL levels but not in the 1000 mg group. Tranexamic Acid 40-43 C-reactive protein Homo sapiens 12-15 24679039-0 2014 Serum uric acid can predict higher C-reactive protein levels in apparently healthy men. Uric Acid 6-15 C-reactive protein Homo sapiens 35-53 24645793-9 2014 AVA supplementation decreased DW-induced NRB at 24 h (P < 0.05) and CRP level 48 h (P < 0.05). avenanthramide-2C 0-3 C-reactive protein Homo sapiens 71-74 24627417-5 2014 For each 1-SD increase in serum urate, the serum CRP concentration was 20% higher in unadjusted linear regression models and 13% higher in multivariable linear regression models, after accounting for the effects of age, sex, race, socioeconomic and educational strata, renal function, lipids, smoking, and body mass index. Uric Acid 32-37 C-reactive protein Homo sapiens 49-52 24318630-9 2014 Serum uric acid level was positively and significantly associated with lumbar spine BMD independent of age, body mass index, smoking, drinking, physical activity, years after menopause, diabetes mellitus, hypertension, serum calcium, estimated glomerular filtration rate, plasma C-reactive protein, and serum alkaline phosphatase (standardized beta = 0.078, p = 0.049). Uric Acid 6-15 C-reactive protein Homo sapiens 279-329 23942869-11 2014 Multiple post hoc analyses demonstrated that CZP inhibited radiographic progression compared with placebo, particularly in patients with high baseline mTSS and C-reactive protein levels. Certolizumab Pegol 45-48 C-reactive protein Homo sapiens 160-178 25377123-3 2014 We investigated long-term associations between the antioxidant nutrient (vitamin C, alpha-tocopherol, beta-carotene) status and C-reactive protein (CRP) in a population-based cohort. Ascorbic Acid 73-82 C-reactive protein Homo sapiens 128-146 24375475-7 2014 Multivariate regression analysis showed that serum 25-hydroxyvitamin D level was independently associated with SYNTAX score (beta = -0.396, P < 0.001), hypertension (beta = -0.183, P = 0.003), high sensitive C-reactive protein (beta = -0.141, P = 0.014), and body mass index (beta = -0.135, P = 0.023) in patient group. 25-hydroxyvitamin D 51-70 C-reactive protein Homo sapiens 211-229 24719806-0 2014 Effect of Vitamin C Supplementation on C-reactive Protein Levels in Patients Undergoing Hemodialysis: A Randomized, Double Blind, Placebo-Controlled Study. Ascorbic Acid 10-19 C-reactive protein Homo sapiens 39-57 24719806-2 2014 OBJECTIVES: This study was performed to evaluate the effect of vitamin C supplementation on C-reactive protein levels in patients undergoing hemodialysis. Ascorbic Acid 63-72 C-reactive protein Homo sapiens 92-110 24719806-9 2014 After 2 months, median CRP reduced significantly in the vitamin C group to 10.7 (P = 0.04) vs. 22.6, and 30.6 mg/L in control groups. Ascorbic Acid 56-65 C-reactive protein Homo sapiens 23-26 24719806-10 2014 CONCLUSIONS: Our findings demonstrated that vitamin C supplementation modifies the levels of CRP in patients on hemodialysis. Ascorbic Acid 44-53 C-reactive protein Homo sapiens 93-96 24228847-2 2013 In this study, we aimed to elucidate the effect of oral vitamin C supplementation on inflammatory status in MHD patients with low vitamin C level and high hypersensitive C-reactive protein (hs-CRP) level. Ascorbic Acid 56-65 C-reactive protein Homo sapiens 170-188 23271170-4 2013 RESULTS: Univariate analysis showed that a baseline C-reactive protein (CRP) level of <1.5 mg/dL was the major determinant of TSS <0.5 at week 52 in the tacrolimus group. Tacrolimus 160-170 C-reactive protein Homo sapiens 52-70 23271170-4 2013 RESULTS: Univariate analysis showed that a baseline C-reactive protein (CRP) level of <1.5 mg/dL was the major determinant of TSS <0.5 at week 52 in the tacrolimus group. Tacrolimus 160-170 C-reactive protein Homo sapiens 72-75 23271170-8 2013 CONCLUSIONS: Adding tacrolimus to DMARDs significantly suppressed disease activity and joint destruction in patients with early rheumatoid arthritis, a disease duration <=3 years, a CRP <1.5 mg/dL, and a poor response to oral DMARDs. Tacrolimus 20-30 C-reactive protein Homo sapiens 185-188 24065415-7 2013 TREATMENT AND COURSE: Pragmatic treatment with antibiotics and diuretics as well as discontinuation of digitoxin led to normalization of leukocytes, CRP and digitoxin levels. Digitoxin 103-112 C-reactive protein Homo sapiens 149-152 24044608-6 2013 RESULTS: Observed results indicated that the CRP and SAA levels in HIV-positive subjects who are METH, cocaine and alcohol users were significantly higher when compared with either drugs of abuse or HIV-positive alone. Cocaine 103-110 C-reactive protein Homo sapiens 45-48 23677577-6 2013 HRs for retinol and carotenoids were attenuated somewhat after adjustment for CRP. Carotenoids 20-31 C-reactive protein Homo sapiens 78-81 22653321-6 2013 Bilirubin is inversely related to baPWV (R (2) = 0.0032, P = 0.003) and C-reactive protein (CRP) (correlation coefficient = -0.13, P < 0.001). Bilirubin 0-9 C-reactive protein Homo sapiens 72-90 22653321-6 2013 Bilirubin is inversely related to baPWV (R (2) = 0.0032, P = 0.003) and C-reactive protein (CRP) (correlation coefficient = -0.13, P < 0.001). Bilirubin 0-9 C-reactive protein Homo sapiens 92-95 22653321-9 2013 Additionally, reduced CRP may be one of mediators on the mechanisms how bilirubin reduces baPWV. Bilirubin 72-81 C-reactive protein Homo sapiens 22-25 23414908-7 2013 RESULTS: Serum bilirubin levels were lower in overweight healthy individuals of both sexes, and were negatively associated with abdominal obesity, insulin resistance, fasting glucose, fasting insulin, fasting triglycerides, total cholesterol, low-density lipoprotein cholesterol, and C-reactive protein levels but positively associated with aerobic body capabilities. Bilirubin 15-24 C-reactive protein Homo sapiens 284-302 23669654-7 2013 The decreasing trend of CRP levels is encouraging and may be related to the increase in total bilirubin levels. Bilirubin 94-103 C-reactive protein Homo sapiens 24-27 23361365-0 2013 Docosahexaenoic acid and eicosapentaenoic acid reduce C-reactive protein expression and STAT3 activation in IL-6-treated HepG2 cells. Eicosapentaenoic Acid 25-46 C-reactive protein Homo sapiens 54-72 23361365-4 2013 The aims of this study were to examine the effect of the n-3 PUFAs, docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA), on the modulation of IL-6-induced CRP expression and to explore its possible mechanisms. Eicosapentaenoic Acid 100-121 C-reactive protein Homo sapiens 163-166 23361365-5 2013 We demonstrated that DHA and EPA inhibited IL-6-induced CRP protein and mRNA expression, as well as reduced CRP promoter activity in HepG2 cells. Eicosapentaenoic Acid 29-32 C-reactive protein Homo sapiens 56-59 23361365-5 2013 We demonstrated that DHA and EPA inhibited IL-6-induced CRP protein and mRNA expression, as well as reduced CRP promoter activity in HepG2 cells. Eicosapentaenoic Acid 29-32 C-reactive protein Homo sapiens 108-111 23159435-4 2013 RESULTS: Simvastatin, but not placebo, reduced monocyte release of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta and monocyte chemoattractant protein-1, as well decreased plasma levels of C-reactive protein. Simvastatin 9-20 C-reactive protein Homo sapiens 204-222 23143351-5 2013 The GUCHD patients with serum TSH exceeding 5.6 mIU/L had a significantly higher level of serum NT-pro-BNP (195.1 [0.28; 5,280.3] vs 57.6 [0.00; 929.8]; p = 0.001) and CRP (0.30 [0.06; 1.87] vs 0.16 [0.00; 1.40]; p = 0.011] than those with a TSH level of 5.6 mIU/L or lower. Thyrotropin 30-33 C-reactive protein Homo sapiens 168-171 22898989-4 2013 The aim of this study is to determine the increase in SF and C-reactive protein (CRP) of PCa patients on ADT. adt 105-108 C-reactive protein Homo sapiens 61-79 23351824-6 2013 Baseline eicosapentaenoic acid (EPA) but not docosahexaenoic acid (DHA) was inversely related to C-reactive protein, pentraxin-3, adiponectin, natriuretic peptide, and troponin levels. Eicosapentaenoic Acid 9-30 C-reactive protein Homo sapiens 97-115 22809521-3 2013 A sensitive, label-free, non-amplified and reusable electrochemical impedimetric biosensor for the detection of CRP in blood serum was developed herein based on controlled and coverage optimised antibody immobilization on standard polycrystalline gold electrodes. polycrystalline gold 231-251 C-reactive protein Homo sapiens 112-115 23329452-3 2013 In this article a poly(dimethylsiloxane) (PDMS)-based immunosensor is presented for rapid detection of C-reactive protein. baysilon 18-40 C-reactive protein Homo sapiens 103-121 20593206-10 2012 Spearman"s correlation analysis showed that the Gensini"s score was significantly positively correlated with UAER, sex, age, BMI, SBP, the history of smoking and drinking, the duration of diabetes mellitus, HbA1c, FPG, PPG, LDL-C, Cre, C-reactive protein (CRP), uric acid (UA). Uric Acid 109-111 C-reactive protein Homo sapiens 236-254 20593206-10 2012 Spearman"s correlation analysis showed that the Gensini"s score was significantly positively correlated with UAER, sex, age, BMI, SBP, the history of smoking and drinking, the duration of diabetes mellitus, HbA1c, FPG, PPG, LDL-C, Cre, C-reactive protein (CRP), uric acid (UA). Uric Acid 109-111 C-reactive protein Homo sapiens 256-259 21913974-4 2012 Concomitantly, repeated administration of simvastatin, ramipril or simvastatin in combination with ramipril to these animals, increased nitric oxide (NO) production and decreased the elevated serum malondialdehyde (MDA) and high sensitivity C-reactive protein (hs-CRP) levels. Simvastatin 42-53 C-reactive protein Homo sapiens 241-259 21913974-4 2012 Concomitantly, repeated administration of simvastatin, ramipril or simvastatin in combination with ramipril to these animals, increased nitric oxide (NO) production and decreased the elevated serum malondialdehyde (MDA) and high sensitivity C-reactive protein (hs-CRP) levels. Simvastatin 67-78 C-reactive protein Homo sapiens 241-259 22488927-5 2012 RESULTS: Compared to healthy donors the average frequency of PBs among total peripheral blood lymphocytes is increased 30-fold during severe UC activity, and positively correlates with Pediatric Ulcerative Colitis Activity Index score, C-reactive protein level, and erythrocyte sedimentation rate. pbs 61-64 C-reactive protein Homo sapiens 236-254 23092643-7 2012 PIS was defined as the composite of a body temperature of >=38 C coinciding with CRP>10 mg/L. Monothiopyrophosphoric acid 0-3 C-reactive protein Homo sapiens 84-87 23268079-0 2012 [A case report of advanced gastric cancer with increased C-reactive protein(CRP) and decreased albumin levels: chemotherapy with nutritional supportive care using eicosapentaenoic acid (EPA)-enriched enteral nutrition agent]. Eicosapentaenoic Acid 163-184 C-reactive protein Homo sapiens 57-80 23268079-7 2012 Accordingly, nutritional supportive care using EN agent enriched with EPA during chemotherapy might be an effective treatment for patients with gastric cancer who show increased CRP and decreased albumin levels. Eicosapentaenoic Acid 70-73 C-reactive protein Homo sapiens 178-181 22617505-9 2012 CRP was higher in BiVAD than in LVAD patients throughout the study period (P = 0.003). bivad 18-23 C-reactive protein Homo sapiens 0-3 22810988-8 2012 Total carotenoids were also inversely related to HOMA-IR and CRP. Carotenoids 6-17 C-reactive protein Homo sapiens 49-64 22810988-12 2012 In conclusion, among U.S. adolescents, serum carotenoid concentrations were inversely associated with MetS status, HOMA-IR, and CRP, whereas serum vitamin C was inversely related to MetS status and serum uric acid. Carotenoids 45-55 C-reactive protein Homo sapiens 128-131 22451117-6 2012 C-reactive protein (CRP), ferritin and hemoglobin (Hgb) levels were correlated with serum 25-hydroxyvitamin D levels. 25-hydroxyvitamin D 90-109 C-reactive protein Homo sapiens 0-18 22572612-11 2012 Blood leukocytes and C-reactive protein (CRP) on the day of diagnosis were significantly higher in non-survivors compared to survivors in CDI (13.2 vs. 9.6 x 10(9)/l, p=0.009, and 106.0 vs. 79.4 mg/l, p<0.001, respectively). 1,1'-Carbonyldiimidazole 138-141 C-reactive protein Homo sapiens 41-44 22572612-14 2012 Leukocyte count and CRP are useful prognostic biomarkers in patients with CDI. 1,1'-Carbonyldiimidazole 74-77 C-reactive protein Homo sapiens 20-23 22462704-2 2012 The authors report a case of vasculopathy after ICB injection for a recurrent cystic CRP. indole-2-carboxylic acid 48-51 C-reactive protein Homo sapiens 85-88 22205356-6 2012 We found that 25-hydroxyvitamin D levels were positively associated with 1,25-dihydroxyvitamin D, the relationship being greatest in advanced disease (significant interaction), and inversely related to those of inflammatory markers C-reactive protein and IL-6. 25-hydroxyvitamin D 14-33 C-reactive protein Homo sapiens 232-250 22388612-5 2012 RESULTS: Regarding inflammation, 25-hydroxyvitamin D inversely correlated with both CRP and IL-6. 25-hydroxyvitamin D 33-52 C-reactive protein Homo sapiens 84-87 22119637-1 2012 PURPOSE: We previously demonstrated that converting patients from the enzyme-inducers phenytoin or carbamazepine to the non-inducers levetiracetam or lamotrigine reduces serum lipids and C-reactive protein (CRP). Phenytoin 86-95 C-reactive protein Homo sapiens 187-205 22119637-1 2012 PURPOSE: We previously demonstrated that converting patients from the enzyme-inducers phenytoin or carbamazepine to the non-inducers levetiracetam or lamotrigine reduces serum lipids and C-reactive protein (CRP). Phenytoin 86-95 C-reactive protein Homo sapiens 207-210 20678906-7 2012 Simvastatin use was associated with significant reductions in total cholesterol, LDL, ox-LDL and CRP. Simvastatin 0-11 C-reactive protein Homo sapiens 97-100 20678906-10 2012 Both crude and lipid-adjusted carotenoids were inversely correlated with CRP and IL-6 in plasma but the change in carotenoid status during simvastatin therapy was not specifically related to any changes in inflammatory markers. Carotenoids 30-41 C-reactive protein Homo sapiens 73-76 20678906-10 2012 Both crude and lipid-adjusted carotenoids were inversely correlated with CRP and IL-6 in plasma but the change in carotenoid status during simvastatin therapy was not specifically related to any changes in inflammatory markers. Carotenoids 30-40 C-reactive protein Homo sapiens 73-76 22104550-4 2011 Weight loss (-11.23 kg; 95% confidence interval, -11.54 to -10.92; P<0.001) reduced high-sensitivity C-reactive protein (-1.15 mg/L; 95% confidence interval, -1.30 to -0.41; P<0.001), low- and high-density lipoprotein cholesterol, triglycerides, and blood pressure. density lipoprotein cholesterol 204-235 C-reactive protein Homo sapiens 104-122 21301856-7 2011 CONCLUSIONS: Our findings suggest that erythrocyte PUFA, particularly LA and n-6 higher unsaturated fatty acids, are related to circulating CRP and adiponectin. n-6 higher unsaturated fatty acids 77-111 C-reactive protein Homo sapiens 140-143 21120595-6 2011 There is scarcity of literature on the role of monounsaturated fatty acids in inflammation, but results from this study suggested an association in healthy subjects between monounsaturated fatty acids and C-reactive protein, even at physiologically low levels. Fatty Acids, Monounsaturated 47-74 C-reactive protein Homo sapiens 205-223 21120595-6 2011 There is scarcity of literature on the role of monounsaturated fatty acids in inflammation, but results from this study suggested an association in healthy subjects between monounsaturated fatty acids and C-reactive protein, even at physiologically low levels. Fatty Acids, Monounsaturated 173-200 C-reactive protein Homo sapiens 205-223 21726166-0 2011 Relationship between bilirubin and C-reactive protein. Bilirubin 21-30 C-reactive protein Homo sapiens 35-53 21726166-2 2011 However, the number of studies which have focused on the relationship between bilirubin and C-reactive protein (CRP), which is a marker reflecting chronic vascular inflammation, are limited. Bilirubin 78-87 C-reactive protein Homo sapiens 92-110 21726166-2 2011 However, the number of studies which have focused on the relationship between bilirubin and C-reactive protein (CRP), which is a marker reflecting chronic vascular inflammation, are limited. Bilirubin 78-87 C-reactive protein Homo sapiens 112-115 21726166-4 2011 RESULT: CRP level showed a declining tendency as total bilirubin increased according to total bilirubin quartiles. Bilirubin 55-64 C-reactive protein Homo sapiens 8-11 21726166-4 2011 RESULT: CRP level showed a declining tendency as total bilirubin increased according to total bilirubin quartiles. Bilirubin 94-103 C-reactive protein Homo sapiens 8-11 21726166-5 2011 Negative relations of CRP with both total and direct bilirubin were found after adjustment of age, body mass index, hypertension, diabetes, hypercholesterolemia, cardiovascular disease, taking aspirin, smoking, alcohol drinking and regular exercise and total bilirubin or direct bilirubin. Bilirubin 53-62 C-reactive protein Homo sapiens 22-25 21726166-5 2011 Negative relations of CRP with both total and direct bilirubin were found after adjustment of age, body mass index, hypertension, diabetes, hypercholesterolemia, cardiovascular disease, taking aspirin, smoking, alcohol drinking and regular exercise and total bilirubin or direct bilirubin. Bilirubin 259-268 C-reactive protein Homo sapiens 22-25 21726166-5 2011 Negative relations of CRP with both total and direct bilirubin were found after adjustment of age, body mass index, hypertension, diabetes, hypercholesterolemia, cardiovascular disease, taking aspirin, smoking, alcohol drinking and regular exercise and total bilirubin or direct bilirubin. Bilirubin 259-268 C-reactive protein Homo sapiens 22-25 21726166-6 2011 CONCLUSIONS: This study found that elevation of the two types of bilirubin (total and direct) have a relationship with a low serum CRP level among apparently healthy Korean adults. Bilirubin 65-74 C-reactive protein Homo sapiens 131-134 21726166-7 2011 It is hypothesized that a low serum CRP level may be due to the antioxidant and anti-inflammatory effects of bilirubin metabolism. Bilirubin 109-118 C-reactive protein Homo sapiens 36-39 21729686-6 2011 RESULTS: Of the 27 patients assigned to AEG35156 in combination with high-dose cytarabine and idarubicin, 3 died during reinduction chemotherapy, 5 achieved complete remission (CR), and 6 achieved CR with incomplete platelet count recovery (CRp), for an overall response rate of 41%. AEG 35156 40-48 C-reactive protein Homo sapiens 177-179 21729686-6 2011 RESULTS: Of the 27 patients assigned to AEG35156 in combination with high-dose cytarabine and idarubicin, 3 died during reinduction chemotherapy, 5 achieved complete remission (CR), and 6 achieved CR with incomplete platelet count recovery (CRp), for an overall response rate of 41%. AEG 35156 40-48 C-reactive protein Homo sapiens 197-199 21729686-6 2011 RESULTS: Of the 27 patients assigned to AEG35156 in combination with high-dose cytarabine and idarubicin, 3 died during reinduction chemotherapy, 5 achieved complete remission (CR), and 6 achieved CR with incomplete platelet count recovery (CRp), for an overall response rate of 41%. AEG 35156 40-48 C-reactive protein Homo sapiens 241-244 22027793-4 2011 RESULTS: At the end of 12 months, the patients in simvastatin group showed significantly reduced total cholesterol, LDL-C, CRP, TNF-alpha, and (99)Tc(m)-MIBI uptake fraction. Simvastatin 50-61 C-reactive protein Homo sapiens 123-126 21816063-5 2011 RESULTS: Uric acid levels were negatively associated with duration of diabetes, fasting plasma glucose, glycohemoglobin, eGFR, HDL-cholesterol (all P < 0.001) and positively with BMI, CRP, waist circumference, triglycerides, systolic blood pressure, ACR, HOMA-IR and IMT (all P < 0.05). Uric Acid 9-18 C-reactive protein Homo sapiens 187-190 21447517-6 2011 The presence of intracytoplasmic C-reactive protein was assessed in formalin-fixed atrial specimens by immunohistochemistry. Formaldehyde 68-76 C-reactive protein Homo sapiens 33-51 21116816-15 2011 CRP levels increased from baseline to 72 h. CONCLUSIONS: Acetaminophen four times/day for 3 days significantly reduced the incidence and severity of post-dose symptoms following ZOL infusion. Acetaminophen 57-70 C-reactive protein Homo sapiens 0-3 21427737-7 2011 At high RBC EPA and RBC DHA, these predicted increases were 13.9+-8.1 mg/dl (23%) and 12.0+-12.3 mg/dl (18%), respectively, for triglycerides and 0.5+-0.5 mg/l (50%) and -0.5+-0.6 mg/l (-34%), respectively, for CRP. Eicosapentaenoic Acid 12-15 C-reactive protein Homo sapiens 211-214 21593678-8 2011 There was a positive correlation (R=0.516) between tADA activity and C-reactive protein levels in patients with CD. azetidine-2,4-dicarboxylic acid 51-55 C-reactive protein Homo sapiens 69-87 21765609-5 2011 Plasma C-reactive protein levels significantly correlated with dietary intakes of vitamin C (r = -0.30, p<0.005), beta-carotene (r = -0.23, p<0.05), and folate (r = -0.31, p<0.005). Ascorbic Acid 82-91 C-reactive protein Homo sapiens 7-25 21515122-12 2011 Participants" CRP and MPO were each inversely related (P<0.05) to FMD (r=-0.528 and -0.625) and plasma vitamin C (r=-0.646 and -0.701). Ascorbic Acid 106-115 C-reactive protein Homo sapiens 14-17 20960519-9 2011 Compared with historical IA, IA and tipifarnib showed a better CR duration (P = .04) and a trend toward a higher CR rate in patients with chromosome 5/7 abnormalities. tipifarnib 36-46 C-reactive protein Homo sapiens 63-65 20960519-9 2011 Compared with historical IA, IA and tipifarnib showed a better CR duration (P = .04) and a trend toward a higher CR rate in patients with chromosome 5/7 abnormalities. tipifarnib 36-46 C-reactive protein Homo sapiens 113-115 21456224-4 2011 Antibody of c-reactive protein (anti-CRP) was immobilized on the SiNW surface through polydimethylsiloxane (PDMS) microfluidic channel for detection of CRP. baysilon 86-106 C-reactive protein Homo sapiens 12-30 21456224-4 2011 Antibody of c-reactive protein (anti-CRP) was immobilized on the SiNW surface through polydimethylsiloxane (PDMS) microfluidic channel for detection of CRP. baysilon 86-106 C-reactive protein Homo sapiens 37-40 22009810-2 2011 There is a possible association between ventricular dysfunction following acute myocardial infarction and high Sensitivity C-reactive protein (HS-CRP) and uric acid. Uric Acid 155-164 C-reactive protein Homo sapiens 123-141 21519150-11 2011 The extent of cardiac fibrosis assessed by Sirius red staining and immunohistochemical staining for collagen type 1 was significantly increased in CRP/DM compared with Wt/DM. C.I. direct red 80 43-53 C-reactive protein Homo sapiens 147-150 20861740-2 2011 A recent study found CRP levels to be higher in individuals treated with certain antipsychotic medications such as olanzapine; however, it is not clear whether this is associated directly with drug intake or indirectly with drug-associated weight gain and insulin resistance. Olanzapine 115-125 C-reactive protein Homo sapiens 21-24 21218608-11 2011 Receiver operating characteristic curve analysis demonstrated cutoff values for NT-proBNP as 1800 pg/mL (sensitivity, 93.3%; specificity, 68.2%; positive predictive values, 66.7%; and negative predictive values, 93.8%) and for CRP as 48 mg/L (sensitivity, 72.7%; specificity, 61.9%; positive predictive values, 50.0%; and negative predictive values, 81.3%) to predict mortality in PE patients. nt-probnp 80-89 C-reactive protein Homo sapiens 227-230 20848462-7 2010 Weaker correlations were detected between the SES-CD and the CDAI (r = 0.473) or CRP (r = 0.525, both P < 0.0001). ses-cd 46-52 C-reactive protein Homo sapiens 81-84 21181364-14 2010 Simvastatin administration can significantly inhibit the DCs function and reduce the level of hs-CRP, indicating the suppression on inflammatory reaction may be one of the mechanisms by which simvastatin exerts its effect in treating RA. Simvastatin 0-11 C-reactive protein Homo sapiens 97-100 21181364-14 2010 Simvastatin administration can significantly inhibit the DCs function and reduce the level of hs-CRP, indicating the suppression on inflammatory reaction may be one of the mechanisms by which simvastatin exerts its effect in treating RA. Simvastatin 192-203 C-reactive protein Homo sapiens 97-100 20609575-4 2010 The CRP was attached to an aldehyde-functionalized DPI sensor chip at a concentration of 50 mug/ml, and attained 2.019 ng/mm2 to form a surface coverage with a 1.71x10(-14) mol/mm2 CRP monolayer. 3-aminodiphenyleneiodium 51-54 C-reactive protein Homo sapiens 4-7 20609575-6 2010 Moreover, the DPI biosensor signals directly reflected the considerable structural parameters and phenomena of conformational changes of CRP in a pH range of 2.0-10.0. 3-aminodiphenyleneiodium 14-17 C-reactive protein Homo sapiens 137-140 21336433-8 2010 CRP decreased more conspicuously in the treated group (P=0.028), and correlation between vitamin C input and CRP in supplemented participants was demonstrated (P=0.014). Ascorbic Acid 89-98 C-reactive protein Homo sapiens 109-112 20084446-2 2010 The present study aims to describe the profile of the simvastatin users and non-users in relation to FRS and high-sensitivity CRP (hs-CRP) levels. Simvastatin 54-65 C-reactive protein Homo sapiens 126-129 20084446-2 2010 The present study aims to describe the profile of the simvastatin users and non-users in relation to FRS and high-sensitivity CRP (hs-CRP) levels. Simvastatin 54-65 C-reactive protein Homo sapiens 134-137 20640997-9 2010 C-reactive protein blood levels were significantly lower in the HS group 75 mg/l vs. 96 mg/l at the third day (P<0.05) and 26 mg /l vs. 54 mg /l at the seventh day (P<0.01). hassio 64-66 C-reactive protein Homo sapiens 0-18 20676836-5 2010 In both groups studied, simvastatin significantly improved lipids, and reduced C-reactive protein and fibrinogen levels. Simvastatin 24-35 C-reactive protein Homo sapiens 79-97 20495302-8 2010 Serum bilirubin level was inversely related to insulin resistance using the homeostasis model assessment (HOMA-IR), serum insulin, and C-reactive protein (CRP) levels in multiple linear regression analyses. Bilirubin 6-15 C-reactive protein Homo sapiens 135-153 20495302-8 2010 Serum bilirubin level was inversely related to insulin resistance using the homeostasis model assessment (HOMA-IR), serum insulin, and C-reactive protein (CRP) levels in multiple linear regression analyses. Bilirubin 6-15 C-reactive protein Homo sapiens 155-158 20125012-3 2010 Specifically, phenytoin causes loss of bone mass in women, and both phenytoin and carbamazepine produce increases in serum lipids and C-reactive protein, as well as decreases in bioactive testosterone in men. Phenytoin 68-77 C-reactive protein Homo sapiens 134-152 20440247-8 2010 RESULTS: Five months of simvastatin treatment showed a decrease in lipid levels, concomitantly with reduction in PMNL priming, PMNL apoptosis, fibrinogen and CRP levels. Simvastatin 24-35 C-reactive protein Homo sapiens 158-161 21125811-9 2010 The levels of C-reactive protein, malondialdehyde-modified low-density lipoproteins, and 8-isoprostane were lower after chlortalidone therapy than after trichlormethiazide therapy. Chlorthalidone 120-133 C-reactive protein Homo sapiens 14-32 19800416-6 2010 Multivariate regression analysis demonstrated that age- and smoking-adjusted plasma CRP levels were associated negatively with HDL-C (beta=-0.224, P<0.001) and positively with LCAT activity (beta=0.119, P=0.034), as well as with the interaction between HDL-C and LCAT activity (beta=0.123, P=0.026). hdl-c 127-132 C-reactive protein Homo sapiens 84-87 19620133-12 2009 Western blotting for HS showed significant reduction in expression of HS, one of the main glycosaminoglycans in the glycocalyx, with C-reactive protein treatment. Heparitin Sulfate 21-23 C-reactive protein Homo sapiens 133-151 19620133-12 2009 Western blotting for HS showed significant reduction in expression of HS, one of the main glycosaminoglycans in the glycocalyx, with C-reactive protein treatment. Glycosaminoglycans 90-108 C-reactive protein Homo sapiens 133-151 19687237-14 2009 By use of a Cox regression model, a CRP concentration of < or = 15 mg/dl (odds ratio [OR], 3.57; 95% confidence interval [CI], 1.05 to 12.5; P = 0.043) and receipt of a fluoroquinolone (OR, 9.09; 95% CI, 1.96 to 50; P = 0.005) were independently associated with better outcomes. Fluoroquinolones 172-187 C-reactive protein Homo sapiens 36-39 19282159-7 2009 Compared to the control group, COPD was associated with higher tHcy concentrations also after adjusting for smoking, heart failure, renal function and C-reactive protein with logistic regression analysis (OR 1.36, 95% CI 1.06-1.72, p=0.01). thcy 63-67 C-reactive protein Homo sapiens 151-169 19886856-8 2009 Serum high sensitively C-reactive protein and uric acid increased significantly in chlorthalidone-treated patients compared to spironolactone treated patients. Chlorthalidone 83-97 C-reactive protein Homo sapiens 23-41 2837757-3 1988 In the absence of cGMP, CRP*598 shows a more open conformation than CRP, as indicated by its sensitivity to proteolytic attack and 5,5"-dithiobis(2-nitrobenzoic acid)-mediated subunit crosslinking. 5,5"-dithiobis 131-145 C-reactive protein Homo sapiens 68-71 3608194-0 1987 Affinity chromatography for C-reactive protein using p-nitrophenylphosphorylcholine as a ligand. O-(4-Nitrophenylphosphoryl)choline 53-83 C-reactive protein Homo sapiens 28-46 19555253-6 2009 Plasminogen activator inhibitor-1 (PAI-1) and high-sensitivity C reactive protein (hs-CRP) decreased after 12 months compared to baseline with simvastatin, and with fenofibrate + simvastatin even if the value obtained with fenofibrate-simvastatin was the lowest. Simvastatin 143-154 C-reactive protein Homo sapiens 63-81 19410579-7 2009 Intraluminal administration of a pathophysiological level of CRP (7 microg/mL, 60 min) attenuated vasodilations to serotonin and AA but not to nitroprusside, exogenous PGI(2), or hydrogen peroxide (endothelium-dependent PGE(2) activator). Prostaglandins I 168-171 C-reactive protein Homo sapiens 61-64 19461006-14 2009 CONCLUSIONS: The study demonstrates that consuming 960 mg/d of EPA and 600 mg/d of DHA can lower CRP. Eicosapentaenoic Acid 63-66 C-reactive protein Homo sapiens 97-100 3480076-0 1987 Measurement of C-reactive protein to compare ceftizoxime versus cefoxitin/doxycycline therapy for septic pelvis: a preliminary report. Ceftizoxime 45-56 C-reactive protein Homo sapiens 15-33 19324974-8 2009 MEASUREMENTS AND MAIN RESULTS: Pretreatment with simvastatin reduced LPS-induced BALF neutrophilia, myeloperoxidase, tumor necrosis factor-alpha, matrix metalloproteinases 7, 8, and 9, and C-reactive protein (CRP) as well as plasma CRP (all P < 0.05 vs. placebo). Simvastatin 49-60 C-reactive protein Homo sapiens 189-207 19324974-8 2009 MEASUREMENTS AND MAIN RESULTS: Pretreatment with simvastatin reduced LPS-induced BALF neutrophilia, myeloperoxidase, tumor necrosis factor-alpha, matrix metalloproteinases 7, 8, and 9, and C-reactive protein (CRP) as well as plasma CRP (all P < 0.05 vs. placebo). Simvastatin 49-60 C-reactive protein Homo sapiens 209-212 19324974-8 2009 MEASUREMENTS AND MAIN RESULTS: Pretreatment with simvastatin reduced LPS-induced BALF neutrophilia, myeloperoxidase, tumor necrosis factor-alpha, matrix metalloproteinases 7, 8, and 9, and C-reactive protein (CRP) as well as plasma CRP (all P < 0.05 vs. placebo). Simvastatin 49-60 C-reactive protein Homo sapiens 232-235 3480076-2 1987 In a study comparing ceftizoxime and cefoxitin/doxycycline in patients with septic pelvis, quantitative CRP levels were closely correlated with the responses and failures of therapy. Ceftizoxime 21-32 C-reactive protein Homo sapiens 104-107 19694216-8 2009 RESULTS: Simvastatin led to a significant decrease in total cholesterol, LDL cholesterol, triglycerides and C-reactive protein (CRP), while fibrinogen levels remained unaltered. Simvastatin 9-20 C-reactive protein Homo sapiens 108-126 3026463-1 1986 C-reactive protein (CRP), an acute-phase plasma protein of hepatic origin in man and rabbit, is a cyclic pentamer composed of five identical nonglycosylated Mr 22 500 subunits. cyclic pentamer 98-113 C-reactive protein Homo sapiens 0-18 19545696-7 2009 By Pearson"s correlation coefficient, UA was inversely correlated with estimated glomerular filtration rate (eGFR; R = -.39; P < .0001) and directly correlated with C-reactive protein (CRP; R = .10; P = .02). Uric Acid 38-40 C-reactive protein Homo sapiens 168-186 19545696-7 2009 By Pearson"s correlation coefficient, UA was inversely correlated with estimated glomerular filtration rate (eGFR; R = -.39; P < .0001) and directly correlated with C-reactive protein (CRP; R = .10; P = .02). Uric Acid 38-40 C-reactive protein Homo sapiens 188-191 3026463-1 1986 C-reactive protein (CRP), an acute-phase plasma protein of hepatic origin in man and rabbit, is a cyclic pentamer composed of five identical nonglycosylated Mr 22 500 subunits. cyclic pentamer 98-113 C-reactive protein Homo sapiens 20-23 18775100-0 2009 Effects of a flaxseed-derived lignan supplement on C-reactive protein, IL-6 and retinol-binding protein 4 in type 2 diabetic patients. derived lignan 22-36 C-reactive protein Homo sapiens 51-69 2859902-4 1985 We conclude that during treatment of rheumatoid arthritis with gold, penicillamine or sulphasalazine, SAA concentrations can be high when serum CRP and ESR are suppressed. Penicillamine 69-82 C-reactive protein Homo sapiens 144-147 19016317-13 2009 However, the plasma levels of IL-6 at 24 h and CRP at 72 h after stenting were higher in PES group compared with SES group (p < 0.05). polyether sulfone 89-92 C-reactive protein Homo sapiens 47-50 4084018-2 1985 CRP was purified using 4-step procedure including absorption on Sepharose 4B, phosphocholine-Sepharose, DE-52 ion exchange chromatography and gel filtration on Sephacryl S-200. sephacryl S 200 160-175 C-reactive protein Homo sapiens 0-3 6142705-2 1984 Polarographic determination (DPP and CRP) of triazolam in plasma and serum]. Triazolam 45-54 C-reactive protein Homo sapiens 37-40 19512978-9 2009 There was a decrease in C-reactive protein comparing aripiprazole treatment to placebo, although it did not reach significance (P = 0.087). Aripiprazole 53-65 C-reactive protein Homo sapiens 24-42 19222932-15 2009 Children with RSV/HMPV and raised CRP had higher a alpha-tocopherol concentrations. alpha-Tocopherol 51-67 C-reactive protein Homo sapiens 34-37 6887165-0 1983 Effect of IgG and C-reactive protein on complement depletion by monosodium urate crystals. Uric Acid 64-80 C-reactive protein Homo sapiens 18-36 19301201-7 2009 Simvastatin significantly reduced CRP by 26%, whereas IL-6 remained unchanged. Simvastatin 0-11 C-reactive protein Homo sapiens 34-37 6433926-2 1983 By addition of L-alpha-lecithin to the pleural effusion in the presence of calcium ions, a flocculence of the CRP-lecithin complex formed. Lecithins 23-31 C-reactive protein Homo sapiens 110-113 6433926-3 1983 Subsequent treatment of the CRP-lecithin complex with chloroform and sodium citrate buffer enabled extraction of the CRP in the buffer layer. Sodium Citrate 69-83 C-reactive protein Homo sapiens 28-31 6433926-3 1983 Subsequent treatment of the CRP-lecithin complex with chloroform and sodium citrate buffer enabled extraction of the CRP in the buffer layer. Sodium Citrate 69-83 C-reactive protein Homo sapiens 117-120 19101266-6 2009 However, LVA was associated with significantly less inflammatory response postoperatively compared with MECC, as indicated by a significant difference in interleukin-6 (p = 0.002), C-reactive protein (p = 0.002), monocyte percentage (p = 0.006), tumor necrosis factor-alpha (p = 0.002), and polymorphonuclear elastase (p = 0.001). mevinolinic acid 9-12 C-reactive protein Homo sapiens 181-199 7172508-5 1982 However in vitro addition of known ligands for CRP to acute phase serum resulted in lowering of the apparent CRP concentration in this assay and addition of as little as 1 microgram/l of free CPS or 1 mg/l of lecithin was demonstrable in this way. Lecithins 209-217 C-reactive protein Homo sapiens 47-50 18952164-0 2009 Vitamin C treatment reduces elevated C-reactive protein. Ascorbic Acid 0-9 C-reactive protein Homo sapiens 37-55 18952164-3 2009 We investigated whether vitamin C or E could reduce CRP. Ascorbic Acid 24-33 C-reactive protein Homo sapiens 52-55 18952164-8 2009 Among participants with CRP indicative of elevated cardiovascular risk (> or =1.0 mg/L), vitamin C reduced the median CRP by 25.3% vs placebo (p=0.02) (median reduction in the vitamin C group, 0.25 mg/L, 16.7%). Ascorbic Acid 92-101 C-reactive protein Homo sapiens 24-27 7073340-2 1982 Con-A binding correlated well with blood viscosity, C-reactive protein, and other individual acute phase reactants in patients with active RA. con 0-3 C-reactive protein Homo sapiens 52-70 18952164-8 2009 Among participants with CRP indicative of elevated cardiovascular risk (> or =1.0 mg/L), vitamin C reduced the median CRP by 25.3% vs placebo (p=0.02) (median reduction in the vitamin C group, 0.25 mg/L, 16.7%). Ascorbic Acid 92-101 C-reactive protein Homo sapiens 121-124 18952164-11 2009 In summary, treatment with vitamin C but not vitamin E significantly reduced CRP among individuals with CRP > or =1.0 mg/L. Ascorbic Acid 27-36 C-reactive protein Homo sapiens 77-80 18952164-11 2009 In summary, treatment with vitamin C but not vitamin E significantly reduced CRP among individuals with CRP > or =1.0 mg/L. Ascorbic Acid 27-36 C-reactive protein Homo sapiens 104-107 6166719-1 1981 Binding of human 125I-C-reactive protein (CRP) to sheep erythrocytes sensitized with pneumococcal C polysaccharide (E-PnC) was found to be Ca++ dependent and inhibitable by phosphocholine, CRP, and HOPC 8. e-pnc 116-121 C-reactive protein Homo sapiens 17-40 6166719-1 1981 Binding of human 125I-C-reactive protein (CRP) to sheep erythrocytes sensitized with pneumococcal C polysaccharide (E-PnC) was found to be Ca++ dependent and inhibitable by phosphocholine, CRP, and HOPC 8. e-pnc 116-121 C-reactive protein Homo sapiens 42-45 18845786-6 2008 The profile of changes in NT-proBNP correlated to changes in body temperature (P < 0.001), heart rate (P = 0.005), CRP (P < 0.001), and CT-proET-1 (P = 0.008), but not to blood pressure values. nt-probnp 26-35 C-reactive protein Homo sapiens 118-121 18585897-3 2008 RESULTS: Total serum carotenoids, smoking, overweight (body mass index 25-29.9 kg/m(2)), and obesity (body mass index > or = 30 mg/kg(2)) were significantly associated with the ox-LDL/LDL cholesterol ratio after adjusting for age, C-reactive protein, and chronic diseases. Carotenoids 21-32 C-reactive protein Homo sapiens 234-252 18178356-6 2008 The antibody binding of CRP was evaluated in two physiological buffers, phosphate buffered saline (PBS) and Dulbecco"s PBS (DPBS). Phosphate-Buffered Saline 72-97 C-reactive protein Homo sapiens 24-27 7436556-6 1980 ESR and C-reactive protein were shown to be the most suitable indices of disease improvement with penicillamine treatment. Penicillamine 98-111 C-reactive protein Homo sapiens 8-26 18761816-5 2008 The results showed that additional inhalation of budesonide and terbutaline could upregulate serum IL-2 levels, the percentages of CD3+ T and CD4+ T cells, and CD4/CD8 ratio, and decrease eosinophils and serum CRP level more efficiently than conventional treatment in patients with AECOPD. Terbutaline 64-75 C-reactive protein Homo sapiens 210-213 496450-4 1979 The relationship between CRP and ESR was, however, altered by treatment with gold, penicillamine, or high doses of prednisone. Penicillamine 83-96 C-reactive protein Homo sapiens 25-28 18600515-2 2008 We studied the associations between serum urate levels (determined in 503 subjects from a population of 1,344 subjects living in northern Madrid) and both the metabolic syndrome (MS) (defined by the Adult Treatment Panel III criteria) and C-reactive protein (CRP, determined in 382 subjects). Uric Acid 42-47 C-reactive protein Homo sapiens 239-257 18356331-10 2008 Among the flavonoid compounds investigated, quercetin, kaempferol, malvidin, peonidin, daidzein, and genistein had inverse associations with serum CRP concentration (P < 0.05). kaempferol 55-65 C-reactive protein Homo sapiens 147-150 18356331-10 2008 Among the flavonoid compounds investigated, quercetin, kaempferol, malvidin, peonidin, daidzein, and genistein had inverse associations with serum CRP concentration (P < 0.05). peonidin 77-85 C-reactive protein Homo sapiens 147-150 18356331-10 2008 Among the flavonoid compounds investigated, quercetin, kaempferol, malvidin, peonidin, daidzein, and genistein had inverse associations with serum CRP concentration (P < 0.05). daidzein 87-95 C-reactive protein Homo sapiens 147-150 18057884-2 2008 We tested the hypothesis that simvastatin inhibited CRP-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Simvastatin 30-41 C-reactive protein Homo sapiens 52-55 18057884-5 2008 RESULTS: Pre-treatment with simvastatin significantly attenuated the CRP-induced CD32 expression and NF-kappaB activation in human umbilical vein endothelial cells. Simvastatin 28-39 C-reactive protein Homo sapiens 69-72 18057884-6 2008 Simvastatin also decreased CRP-induced vascular cell adhesion molecule-1 expression and reduced monocyte adhesion on endothelial cells. Simvastatin 0-11 C-reactive protein Homo sapiens 27-30 1220346-6 1975 In comparison to the insignificant diagnostic relevancy of other acute-phase-reactions (BSR, CRP, number of leukozytes, blood protein fractions) from this results the conclusion that the determination of hydroxyproline may be used for the diagnostics of activity and also for the early diagnostics. Hydroxyproline 204-218 C-reactive protein Homo sapiens 93-96 18057884-10 2008 CONCLUSIONS: CRP-induced CD32 expression and NF-kappaB activation were attenuated by simvastatin. Simvastatin 85-96 C-reactive protein Homo sapiens 13-16 13634834-0 1959 [C-reactive protein in typhoid treated with combined chloramphenicol & phenylbutazone]. Phenylbutazone 75-89 C-reactive protein Homo sapiens 1-19 14803629-2 1951 The acute phase protein of the rabbit reacts with a special form of the pneumococcal somatic polysaccharide, designated Cx polysaccharide, in the same manner that the human C-reactive protein reacts with the classical C polysaccharide. cx polysaccharide 120-137 C-reactive protein Homo sapiens 173-191 19043252-4 2008 Moreover, candesartan treatment exhibited a tendency of reduction in inflammation markers such as high sensitive C-reactive protein (hsCRP) and interleukin-6 (IL-6). candesartan 10-21 C-reactive protein Homo sapiens 113-131 18087170-6 2008 In the IgAN group, hs-CRP showed positive correlations with IgA, uric acid, systolic blood pressure, BMI and age. Uric Acid 65-74 C-reactive protein Homo sapiens 22-25 34020736-5 2021 RESULTS: Compared with the common MPP group, the RMPP group had significantly higher incidence rates of fever, shortness of breath, lung consolidation, and pleural effusion (P < 0.05) and significantly higher serum levels of C-reactive protein and lactate dehydrogenase (P < 0.05). rmpp 49-53 C-reactive protein Homo sapiens 225-243 18284061-11 2007 CONCLUSION: The CRP concentration in EPS, with its significant role in the pathogenesis of CP, may serve as a basis for the diagnosis and classification of CP as well as an objective index for assessing the therapeutic effect on the disease. exophthalmos producing substance 37-40 C-reactive protein Homo sapiens 16-19 33745599-12 2021 CONCLUSIONS: The EPA and DHA levels were related to C-reactive protein (CRP) of inflammation maker, but non-significant associated with development allergic diseases. Eicosapentaenoic Acid 17-20 C-reactive protein Homo sapiens 52-70 17935553-6 2007 High sensitivity C-reactive protein decreased by 20% in the group treated with niacin for 52 weeks (p = 0.013). Niacin 79-85 C-reactive protein Homo sapiens 17-35 33745599-12 2021 CONCLUSIONS: The EPA and DHA levels were related to C-reactive protein (CRP) of inflammation maker, but non-significant associated with development allergic diseases. Eicosapentaenoic Acid 17-20 C-reactive protein Homo sapiens 72-75 33485635-10 2021 We found that blood pressure, cholesterol, C-reactive protein, alcohol and white blood cell count played important roles in the causal pathway from bilirubin to CVD. Bilirubin 148-157 C-reactive protein Homo sapiens 43-61 17196684-1 2007 BACKGROUND: We hypothesize that high-sensitivity C-reactive protein (hs-CRP) levels and cell adhesion molecules (CAMs) significantly reflect serial changes in patients with atherosclerotic-risk factors undergoing simvastatin therapy. Simvastatin 213-224 C-reactive protein Homo sapiens 72-75 17196684-2 2007 We further hypothesize that the site specificity of CRP on the expression of CAMs, which can be inhibited by simvastatin, is in the cytoplasm of endothelial cells (EC). Simvastatin 109-120 C-reactive protein Homo sapiens 52-55 33418065-7 2021 With all studies, the ratio of EPA to DHA was associated with C-reactive protein (CRP) (beta = -1.3121 (95% CI: -1.6610 to -0.9543), that is, the higher the EPA to DHA ratio, the greater the reduction. Eicosapentaenoic Acid 31-34 C-reactive protein Homo sapiens 62-80 17196684-9 2007 After simvastatin therapy was withdrawn, the hs-CRP level was once again significantly higher on day 270 than on day 180 (p<0.05), but VCAM-1 did not differ between day 180 and day 270. Simvastatin 6-17 C-reactive protein Homo sapiens 48-51 17196684-10 2007 25 micromol/L simvastatin markedly suppressed the CRP effect on VCAM-1 and intercellular CAM-1 expressions of EC. Simvastatin 14-25 C-reactive protein Homo sapiens 50-53 33418065-7 2021 With all studies, the ratio of EPA to DHA was associated with C-reactive protein (CRP) (beta = -1.3121 (95% CI: -1.6610 to -0.9543), that is, the higher the EPA to DHA ratio, the greater the reduction. Eicosapentaenoic Acid 31-34 C-reactive protein Homo sapiens 82-85 17196684-12 2007 However, pretreatment with simvastatin reduced the intensity of CRP in cytoplasm. Simvastatin 27-38 C-reactive protein Homo sapiens 64-67 33418065-7 2021 With all studies, the ratio of EPA to DHA was associated with C-reactive protein (CRP) (beta = -1.3121 (95% CI: -1.6610 to -0.9543), that is, the higher the EPA to DHA ratio, the greater the reduction. Eicosapentaenoic Acid 157-160 C-reactive protein Homo sapiens 62-80 17196684-13 2007 CONCLUSIONS: CRP-mediated inflammation is inhibited by simvastatin. Simvastatin 55-66 C-reactive protein Homo sapiens 13-16 17827864-7 2007 After adjustment for potential confounding factors, increased serum CRP concentrations of the 90th percentile (1.4 mg/L) or above were significantly associated with atmospheric concentration of suspended particulate matter (SPM) (odds ratio [OR] =1.49 for the range of observed concentrations, 95% confidence interval [CI]: 1.07-2.06) and sulfur dioxide (SO(2)) (OR =1.45, 95% CI: 1.04-2.03). Sulfur Dioxide 339-353 C-reactive protein Homo sapiens 68-71 33418065-7 2021 With all studies, the ratio of EPA to DHA was associated with C-reactive protein (CRP) (beta = -1.3121 (95% CI: -1.6610 to -0.9543), that is, the higher the EPA to DHA ratio, the greater the reduction. Eicosapentaenoic Acid 157-160 C-reactive protein Homo sapiens 82-85 33418065-8 2021 Using only studies that supplied EPA and DHA in the range of 2 g to 6 g, the ratio of EPA to DHA was also associated with CRP (beta = -2.10429 and 95% CI: -3.89963 to -0.30895); that is, an even more pronounced reduction in CRP with a higher EPA to DHA ratio. Eicosapentaenoic Acid 86-89 C-reactive protein Homo sapiens 122-125 33418065-8 2021 Using only studies that supplied EPA and DHA in the range of 2 g to 6 g, the ratio of EPA to DHA was also associated with CRP (beta = -2.10429 and 95% CI: -3.89963 to -0.30895); that is, an even more pronounced reduction in CRP with a higher EPA to DHA ratio. Eicosapentaenoic Acid 86-89 C-reactive protein Homo sapiens 224-227 17719471-6 2007 RESULTS: Both ezetimibe and simvastatin significantly reduced total cholesterol (-0.62 +/- 0.55 mmol/l and -1.28 +/- 0.49 mmol/l, respectively; p < 0.001), low-density lipoprotein cholesterol (-0.55 +/- 0.55 mmol/l and -1.28 +/- 0.49 mmol/l; p < 0.0001), and C-reactive protein (-5.35 +/- 9.25 mg/l and -5.05 +/- 6.30 mg/l; p < 0.001). Simvastatin 28-39 C-reactive protein Homo sapiens 265-283 33418065-8 2021 Using only studies that supplied EPA and DHA in the range of 2 g to 6 g, the ratio of EPA to DHA was also associated with CRP (beta = -2.10429 and 95% CI: -3.89963 to -0.30895); that is, an even more pronounced reduction in CRP with a higher EPA to DHA ratio. Eicosapentaenoic Acid 86-89 C-reactive protein Homo sapiens 122-125 33418065-8 2021 Using only studies that supplied EPA and DHA in the range of 2 g to 6 g, the ratio of EPA to DHA was also associated with CRP (beta = -2.10429 and 95% CI: -3.89963 to -0.30895); that is, an even more pronounced reduction in CRP with a higher EPA to DHA ratio. Eicosapentaenoic Acid 86-89 C-reactive protein Homo sapiens 224-227 33418065-10 2021 CONCLUSION: Current data suggest that the EPA to DHA ratio only correlates to the modulation of CRP by omega-3 supplementation of EPA and DHA, and SBP in studies that supplemented EPA and DHA in the range of 2 g to 6 g, shedding light on potential differential effects of EPA vs. DHA on inflammation and systolic blood pressure. Eicosapentaenoic Acid 42-45 C-reactive protein Homo sapiens 96-99 32951354-10 2021 Compared to controls with GCA, patients with TA-AAV were younger (median age 70 years versus 74 years), were more frequently men (48% versus 30%), and had high frequencies of atypical manifestations and higher C-reactive protein levels (median 10.8 mg/dl versus 7.0 mg/dl). ta-aav 45-51 C-reactive protein Homo sapiens 210-228 17580953-0 2007 Analysis of C-reactive protein on amide-linked N-hydroxysuccinimide-dextran arrays with a spectral surface plasmon resonance biosensor for serodiagnosis. n-hydroxysuccinimide-dextran 47-75 C-reactive protein Homo sapiens 12-30 33509121-8 2021 (4) In ROC curve analysis, CRP, LDH, FER, and neutrophils of leukocyte classification were independent related factors that could be used as valuable predictors of methylprednisolone pulse therapy for RMPP in children. rmpp 201-205 C-reactive protein Homo sapiens 27-30 17634458-5 2007 RESULTS: Among patients with a baseline CRP level of at least 10 mg per liter, 37% of patients in the certolizumab group had a response at week 6, as compared with 26% in the placebo group (P=0.04). Certolizumab Pegol 102-114 C-reactive protein Homo sapiens 40-43 33407216-5 2021 RESULTS: (1) Hospitalization time, preadmission fever duration, total fever duration, WBC, N %, CRP, LDH, ESR, ALT, AST, and D-D were significantly higher in the RMPP group than those in the GMPP group (all P < 0.05). rmpp 162-166 C-reactive protein Homo sapiens 96-99 17599452-0 2007 Usefulness of uric acid to predict changes in C-reactive protein and interleukin-6 in 3-year period in Italians aged 21 to 98 years. Uric Acid 14-23 C-reactive protein Homo sapiens 46-64 17599452-3 2007 Relations between baseline UA and changes in UA circulating levels with C-reactive protein (CRP) and interleukin-6 (IL-6) after 3 years of follow-up in a cohort of 892 Italian men and women aged 21 to 98 years was investigated. Uric Acid 27-29 C-reactive protein Homo sapiens 72-90 17599452-3 2007 Relations between baseline UA and changes in UA circulating levels with C-reactive protein (CRP) and interleukin-6 (IL-6) after 3 years of follow-up in a cohort of 892 Italian men and women aged 21 to 98 years was investigated. Uric Acid 27-29 C-reactive protein Homo sapiens 92-95 17599452-3 2007 Relations between baseline UA and changes in UA circulating levels with C-reactive protein (CRP) and interleukin-6 (IL-6) after 3 years of follow-up in a cohort of 892 Italian men and women aged 21 to 98 years was investigated. Uric Acid 45-47 C-reactive protein Homo sapiens 72-90 17599452-3 2007 Relations between baseline UA and changes in UA circulating levels with C-reactive protein (CRP) and interleukin-6 (IL-6) after 3 years of follow-up in a cohort of 892 Italian men and women aged 21 to 98 years was investigated. Uric Acid 45-47 C-reactive protein Homo sapiens 92-95 17599452-7 2007 The relation between UA and CRP persisted after adjustment for baseline IL-6. Uric Acid 21-23 C-reactive protein Homo sapiens 28-31 17599452-8 2007 Subjects with high UA at baseline had a progressively higher probability of developing clinically relevant increased IL-6 (>2.5 pg/ml) and CRP (>3 mg/L) during 3 years. Uric Acid 19-21 C-reactive protein Homo sapiens 142-145 32912236-5 2020 CdSe-QDs with sharp and tunable emission bands were used to simultaneously quantify CRP and IL-6 in a single test line, by using a single UV-light source and two suitable emission filters for readout through a widely available BioImager device. cdse-qds 0-8 C-reactive protein Homo sapiens 84-87 16860807-5 2007 The serum levels of C-reactive protein (CRP) were significantly reduced by simvastatin. Simvastatin 75-86 C-reactive protein Homo sapiens 20-38 16860807-5 2007 The serum levels of C-reactive protein (CRP) were significantly reduced by simvastatin. Simvastatin 75-86 C-reactive protein Homo sapiens 40-43 17633905-7 2007 Other lipid-lowering agents reported to reduce CRP include niacin, fibrates, and gemfibrozil. Niacin 59-65 C-reactive protein Homo sapiens 47-50 32512234-3 2020 We aimed to investigate the effect of O2-Suppl during exercise test (EET) on CRP level and muscle damage (CPK, LDH, lactate) in non-hypoxemic COPD patients. o2-suppl 38-46 C-reactive protein Homo sapiens 77-80 17545695-7 2007 A multiple regression analysis showed that, especially in the middle tertile of long-chain n-3 PUFAs (eicosapentaenoic acid and docosahexaenoic acid) intake, CRP was inversely related to the intake of oleic acid and linoleic acid in both sexes and to the intake of alpha-linolenic acid in women. Eicosapentaenoic Acid 102-123 C-reactive protein Homo sapiens 158-161 17696726-10 2007 High intakes of carotenoids and vitamin C, but not of vitamin E, seem to decrease the level of circulating hs-CRP. Carotenoids 16-27 C-reactive protein Homo sapiens 110-113 32512234-7 2020 The O2-Suppl protocol resulted in a lower increase in CRP (92.1 +- 112.4% vs. 400.1 +- 384.9%; p = 0.003). o2-suppl 4-12 C-reactive protein Homo sapiens 54-57 17696726-10 2007 High intakes of carotenoids and vitamin C, but not of vitamin E, seem to decrease the level of circulating hs-CRP. Ascorbic Acid 32-41 C-reactive protein Homo sapiens 110-113 17006702-10 2007 A significant correlation was found between C-RP levels and total and unconjugated bilirubin levels in FMF patients with attack (r = 0.43, P = 0.01; r = 0.40, P = 0.02, respectively). Bilirubin 83-92 C-reactive protein Homo sapiens 44-48 32719413-5 2020 Logistic regression analysis showed the male sex and higher C-reactive protein to be independent factors for response to anti-TNF agents and TAC, respectively. Tacrolimus 141-144 C-reactive protein Homo sapiens 60-78 17286233-6 2007 RESULTS: While a significant association be-tween macroalbuminuria and CRP could be observed (p<0,015), no associations were found between IL-6G(-174)C or IL1RA genotype and any stage of nephropathy. Polysorbates 44-49 C-reactive protein Homo sapiens 71-74 17409596-10 2007 Although there were no significant differences, the time to apyrexia, normalization of leukocytosis and a 50% decrease in C-reactive protein (CRP) occurred within a relatively shorter time frame in the CPFX group than in the EM group (3.5 versus 4 days, 4 versus 5.2 days, and 2.9 versus 10.3 days, respectively). Ciprofloxacin 202-206 C-reactive protein Homo sapiens 122-140 17409596-10 2007 Although there were no significant differences, the time to apyrexia, normalization of leukocytosis and a 50% decrease in C-reactive protein (CRP) occurred within a relatively shorter time frame in the CPFX group than in the EM group (3.5 versus 4 days, 4 versus 5.2 days, and 2.9 versus 10.3 days, respectively). Ciprofloxacin 202-206 C-reactive protein Homo sapiens 142-145 32599804-5 2020 Furthermore, a significant change in the electrochemical impedance from 45% to 70% (hs) and 38% to 60% (PBS) over the loading range of CRP was achieved. pbs 104-107 C-reactive protein Homo sapiens 135-138 17207028-11 2007 Moreover, maximum C-reactive protein values also appeared to be lower in the azithromycin group than in the no-treatment group and the cefcapene group. S 1006 135-144 C-reactive protein Homo sapiens 18-36 32599718-12 2020 There was a significant inverse correlation between C-reactive protein concentrations and vitamin C status (r = -0.424, p < 0.001). Ascorbic Acid 90-99 C-reactive protein Homo sapiens 52-70 16401615-5 2006 Plasma tHcy levels were positively correlated with disease duration and C-reactive protein CRP levels and negatively correlated with disease onset age. thcy 7-11 C-reactive protein Homo sapiens 91-94 16825699-7 2006 RESULTS: After adjustment for several predictors of inflammation, the odds ratio of high CRP (> or =1.0 mg/L) for increasing quartiles of total n-3 PUFA and eicosapentaenoic acid + docosahexaenoic acid were 1.0, 0.72, 0.57, and 0.44 (P for trend = 0.01) and 1.0, 0.91, 0.76, and 0.54 (P for trend = 0.03), respectively. Eicosapentaenoic Acid 160-181 C-reactive protein Homo sapiens 89-92 32599718-14 2020 Overall, the lowest mean vitamin C values (recorded at week two) corresponded with the highest mean C-reactive protein values and lowest mean neutrophil counts. Ascorbic Acid 25-34 C-reactive protein Homo sapiens 100-118 32615659-5 2020 Assessment of the C-reactive protein (CRP) level in serum showed a significant decrease in the krocinaTM group (p<0.05). krocinatm 95-104 C-reactive protein Homo sapiens 18-36 16728231-8 2006 In addition, sibutramine therapy was associated with significant C-reactive protein reduction compared with routine treatment (44% vs 9%, p = 0.035). sibutramine 13-24 C-reactive protein Homo sapiens 65-83 32615659-5 2020 Assessment of the C-reactive protein (CRP) level in serum showed a significant decrease in the krocinaTM group (p<0.05). krocinatm 95-104 C-reactive protein Homo sapiens 38-41 32503297-5 2020 In univariate analysis, C-reactive protein (CRP) (p = 0.002) and intake of only 125 mg of vitamin C (p = 0.001) were negatively associated with vitamin C levels, and duration of follow-up in our referral center (p = 0.009) was positively associated with vitamin C levels. Ascorbic Acid 144-153 C-reactive protein Homo sapiens 24-42 16796400-5 2006 Following the immunoreaction, the monoclonal anti-CRP conjugated nanocrystals were released by hydrolysis and dissolution instigated by the addition of a large volume of organic solvent-sodium hydroxide mixture. Sodium Hydroxide 186-202 C-reactive protein Homo sapiens 50-53 32503297-5 2020 In univariate analysis, C-reactive protein (CRP) (p = 0.002) and intake of only 125 mg of vitamin C (p = 0.001) were negatively associated with vitamin C levels, and duration of follow-up in our referral center (p = 0.009) was positively associated with vitamin C levels. Ascorbic Acid 144-153 C-reactive protein Homo sapiens 44-47 32503297-5 2020 In univariate analysis, C-reactive protein (CRP) (p = 0.002) and intake of only 125 mg of vitamin C (p = 0.001) were negatively associated with vitamin C levels, and duration of follow-up in our referral center (p = 0.009) was positively associated with vitamin C levels. Ascorbic Acid 144-153 C-reactive protein Homo sapiens 24-42 32503297-5 2020 In univariate analysis, C-reactive protein (CRP) (p = 0.002) and intake of only 125 mg of vitamin C (p = 0.001) were negatively associated with vitamin C levels, and duration of follow-up in our referral center (p = 0.009) was positively associated with vitamin C levels. Ascorbic Acid 144-153 C-reactive protein Homo sapiens 44-47 16713439-5 2006 Voglibose also decreased significantly the plasma levels of soluble intercellular adhesion molecule 1 and urinary excretion of 8-iso-prostaglandin F(2)alpha and 8-hydroxydeoxyguanosine (P<.01) and C-reactive protein (P<.05) relative to the control group. voglibose 0-9 C-reactive protein Homo sapiens 200-218 32503297-6 2020 In multivariate analysis, only CRP (p = 0.001) and intake of 125 mg of vitamin C (p < 0.0001) were independently associated with low plasma vitamin C concentration. Ascorbic Acid 140-149 C-reactive protein Homo sapiens 31-34 32578813-5 2020 Pre- and post-surgical CRP levels were significantly lower in the CHO group (p = 0.05 and p = 0.02, respectively). CAV protocol 66-69 C-reactive protein Homo sapiens 23-26 16564781-8 2006 Cox proportional hazards model showed that combination NT-proBNP-CRP was the strongest independent correlate of mortality (hazard ratio [HR] 4.3, 95% confidence interval [CI], 2.0-9.3; P <.001 for high NT-proBNP-high CRP vs low NT-proBNP-low CRP). nt-probnp 55-64 C-reactive protein Homo sapiens 65-68 16564781-8 2006 Cox proportional hazards model showed that combination NT-proBNP-CRP was the strongest independent correlate of mortality (hazard ratio [HR] 4.3, 95% confidence interval [CI], 2.0-9.3; P <.001 for high NT-proBNP-high CRP vs low NT-proBNP-low CRP). nt-probnp 55-64 C-reactive protein Homo sapiens 220-223 16564781-8 2006 Cox proportional hazards model showed that combination NT-proBNP-CRP was the strongest independent correlate of mortality (hazard ratio [HR] 4.3, 95% confidence interval [CI], 2.0-9.3; P <.001 for high NT-proBNP-high CRP vs low NT-proBNP-low CRP). nt-probnp 55-64 C-reactive protein Homo sapiens 220-223 32578813-6 2020 The preoperative CRP/albumin ratios in the CHO group were lower than in the fasting group (p = 0.03). CAV protocol 43-46 C-reactive protein Homo sapiens 17-20 31962161-2 2020 Toll-like receptor 4 (TLR4), mannose-binding lectin (MBL) and C-reactive protein (CRP) are molecules available for HCV PAMP recognition. PAMP protocol 119-123 C-reactive protein Homo sapiens 62-80 16549465-0 2006 Baseline plasma C-reactive protein concentrations influence lipid and lipoprotein responses to low-fat and high monounsaturated fatty acid diets in healthy men. Fatty Acids, Monounsaturated 112-138 C-reactive protein Homo sapiens 16-34 16314875-9 2006 In men, CRP was independently and positively associated to waist circumference, smoking, diastolic blood pressure, uric acid and triglycerides, and negatively associated to HDL-cholesterol. Uric Acid 115-124 C-reactive protein Homo sapiens 8-11 16182316-10 2006 Fluvastatin suppressed the CRP-induced increases in 8-epi-prostaglandin F(2alpha) levels in the condition media. 8-epi-prostaglandin f 52-73 C-reactive protein Homo sapiens 27-30 31962161-2 2020 Toll-like receptor 4 (TLR4), mannose-binding lectin (MBL) and C-reactive protein (CRP) are molecules available for HCV PAMP recognition. PAMP protocol 119-123 C-reactive protein Homo sapiens 82-85 15905085-4 2006 Binding of CRP to Fab"-fragment/polymer layers produced in phosphate buffered saline decreased with NaCl salt concentration. Phosphate-Buffered Saline 59-84 C-reactive protein Homo sapiens 11-14 31691260-6 2020 RESULTS: Uric acid was significantly and positively associated with blood pressure, BMI, waist circumference, insulin resistance, C-reactive protein and leptin (p < 0.01), while inversely with renal function (p = 0.01). Uric Acid 9-18 C-reactive protein Homo sapiens 130-148 16276071-9 2006 CONCLUSION: A postprandial monounsaturated fatty acid rich meal increases both plasma carotenoids and PON1 with a decrease in CRP levels, thus providing a novel potential explanation to the protective properties of a Mediterranean diet against atherogenesis. Fatty Acids, Monounsaturated 27-53 C-reactive protein Homo sapiens 126-129 16251237-0 2005 Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. Uric Acid 0-9 C-reactive protein Homo sapiens 18-36 16251237-4 2005 For investigating whether uric acid (UA)-induced inflammatory reaction and vascular remodeling is related to CRP, the UA-induced expression of CRP in human vascular smooth muscle cells (HVSMC) and human umbilical vein endothelial cells (HUVEC) was examined, as well as the pathogenetic role of CRP in vascular remodeling. Uric Acid 26-35 C-reactive protein Homo sapiens 109-112 32292750-1 2020 Studies assessing the effect of vitamin C and E co-supplementation on levels of circulating C-reactive protein (CRP) show contradictory results. Ascorbic Acid 32-41 C-reactive protein Homo sapiens 92-110 16251237-4 2005 For investigating whether uric acid (UA)-induced inflammatory reaction and vascular remodeling is related to CRP, the UA-induced expression of CRP in human vascular smooth muscle cells (HVSMC) and human umbilical vein endothelial cells (HUVEC) was examined, as well as the pathogenetic role of CRP in vascular remodeling. Uric Acid 37-39 C-reactive protein Homo sapiens 109-112 16251237-4 2005 For investigating whether uric acid (UA)-induced inflammatory reaction and vascular remodeling is related to CRP, the UA-induced expression of CRP in human vascular smooth muscle cells (HVSMC) and human umbilical vein endothelial cells (HUVEC) was examined, as well as the pathogenetic role of CRP in vascular remodeling. Uric Acid 37-39 C-reactive protein Homo sapiens 143-146 16251237-4 2005 For investigating whether uric acid (UA)-induced inflammatory reaction and vascular remodeling is related to CRP, the UA-induced expression of CRP in human vascular smooth muscle cells (HVSMC) and human umbilical vein endothelial cells (HUVEC) was examined, as well as the pathogenetic role of CRP in vascular remodeling. Uric Acid 37-39 C-reactive protein Homo sapiens 143-146 16251237-4 2005 For investigating whether uric acid (UA)-induced inflammatory reaction and vascular remodeling is related to CRP, the UA-induced expression of CRP in human vascular smooth muscle cells (HVSMC) and human umbilical vein endothelial cells (HUVEC) was examined, as well as the pathogenetic role of CRP in vascular remodeling. Uric Acid 118-120 C-reactive protein Homo sapiens 109-112 16251237-4 2005 For investigating whether uric acid (UA)-induced inflammatory reaction and vascular remodeling is related to CRP, the UA-induced expression of CRP in human vascular smooth muscle cells (HVSMC) and human umbilical vein endothelial cells (HUVEC) was examined, as well as the pathogenetic role of CRP in vascular remodeling. Uric Acid 118-120 C-reactive protein Homo sapiens 143-146 32292750-1 2020 Studies assessing the effect of vitamin C and E co-supplementation on levels of circulating C-reactive protein (CRP) show contradictory results. Ascorbic Acid 32-41 C-reactive protein Homo sapiens 112-115 16251237-4 2005 For investigating whether uric acid (UA)-induced inflammatory reaction and vascular remodeling is related to CRP, the UA-induced expression of CRP in human vascular smooth muscle cells (HVSMC) and human umbilical vein endothelial cells (HUVEC) was examined, as well as the pathogenetic role of CRP in vascular remodeling. Uric Acid 118-120 C-reactive protein Homo sapiens 143-146 16251237-7 2005 Inhibition of p38 or extracellular signal-regulated kinase 44/42 significantly suppressed UA-induced CRP expression, implicating these pathways in the response to UA. Uric Acid 90-92 C-reactive protein Homo sapiens 101-104 32292750-2 2020 We carried out a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the effect of vitamin C and E co-supplementation on CRP. Ascorbic Acid 116-125 C-reactive protein Homo sapiens 154-157 16251237-7 2005 Inhibition of p38 or extracellular signal-regulated kinase 44/42 significantly suppressed UA-induced CRP expression, implicating these pathways in the response to UA. Uric Acid 163-165 C-reactive protein Homo sapiens 101-104 16251237-8 2005 UA stimulated HVSMC proliferation whereas UA inhibited serum-induced proliferation of HUVEC assessed by 3H-thymidine uptake and cell counting, which was attenuated by co-incubation with probenecid, the organic anion transport inhibitor, suggesting that entry of UA into cells is responsible for CRP expression. Uric Acid 0-2 C-reactive protein Homo sapiens 295-298 32292750-7 2020 Subgroup analysis demonstrated that vitamin C and E co-supplementation significantly reduced serum CRP in participants >=30 years of age, but significantly increased serum CRP in participants <30 years of age. Ascorbic Acid 36-45 C-reactive protein Homo sapiens 99-102 16251237-8 2005 UA stimulated HVSMC proliferation whereas UA inhibited serum-induced proliferation of HUVEC assessed by 3H-thymidine uptake and cell counting, which was attenuated by co-incubation with probenecid, the organic anion transport inhibitor, suggesting that entry of UA into cells is responsible for CRP expression. Uric Acid 42-44 C-reactive protein Homo sapiens 295-298 16251237-8 2005 UA stimulated HVSMC proliferation whereas UA inhibited serum-induced proliferation of HUVEC assessed by 3H-thymidine uptake and cell counting, which was attenuated by co-incubation with probenecid, the organic anion transport inhibitor, suggesting that entry of UA into cells is responsible for CRP expression. Uric Acid 42-44 C-reactive protein Homo sapiens 295-298 16251237-11 2005 Treatment of vascular cells with anti-CRP antibody revealed a reversal of the effect of UA on cell proliferation and migration in HVSMC and NO release in HUVEC, which suggests that CRP expression may be responsible for UA-induced vascular remodeling. Uric Acid 88-90 C-reactive protein Homo sapiens 38-41 16251237-11 2005 Treatment of vascular cells with anti-CRP antibody revealed a reversal of the effect of UA on cell proliferation and migration in HVSMC and NO release in HUVEC, which suggests that CRP expression may be responsible for UA-induced vascular remodeling. Uric Acid 88-90 C-reactive protein Homo sapiens 181-184 32292750-7 2020 Subgroup analysis demonstrated that vitamin C and E co-supplementation significantly reduced serum CRP in participants >=30 years of age, but significantly increased serum CRP in participants <30 years of age. Ascorbic Acid 36-45 C-reactive protein Homo sapiens 172-175 16251237-13 2005 The observation that UA alters the proliferation/migration and NO release of human vascular cells, mediated by the expression of CRP, calls for careful reconsideration of the role of UA in hypertension and vascular disease. Uric Acid 21-23 C-reactive protein Homo sapiens 129-132 32724271-6 2020 We found a significant negative association between total bilirubin and CRP, TNF-alpha, visfatin and resistin values, and a significant positive association between total bilirubin and adiponectin values in both normal-weight and overweight groups. Bilirubin 58-67 C-reactive protein Homo sapiens 72-75 16263508-5 2005 Exposure to OE-UDP, OE-DEP, UDP, DEP, and 2,3,7,8-tetrachlorodibenzo-p-dioxin led to a greater increase of interleukin (IL)-8, tumor necrosis factor-alpha, and cyclooxygenase-2 mRNA expression than did the stripped particles, whereas sUDP, sDEP, UDP, and DEP led to a greater production of C-reactive protein and IL-6 mRNA. oe-udp 12-18 C-reactive protein Homo sapiens 290-308 16358230-6 2005 RESULTS: Patients with high CRP had significantly lower glomerular filtration rates and albumin, but increased LOOH and CD. Lipid Peroxides 111-115 C-reactive protein Homo sapiens 28-31 16113803-3 2005 Simvastatin, but not fenofibrate, lowered C-reactive protein (CRP) by 32% on day 3 (p<0.001), while both drugs reduced CRP significantly on day 28. Simvastatin 0-11 C-reactive protein Homo sapiens 42-60 16113803-3 2005 Simvastatin, but not fenofibrate, lowered C-reactive protein (CRP) by 32% on day 3 (p<0.001), while both drugs reduced CRP significantly on day 28. Simvastatin 0-11 C-reactive protein Homo sapiens 62-65 32724271-7 2020 Importantly, after adjusting for body mass index, we also found a significant negative association between total serum bilirubin levels and both visfatin and CRP serum levels. Bilirubin 119-128 C-reactive protein Homo sapiens 158-161 32724271-8 2020 Moreover, visfatin, resistin and CRP were predictors of the total serum bilirubin levels. Bilirubin 72-81 C-reactive protein Homo sapiens 33-36 15883229-9 2005 When compared with simvastatin or ramipril alone, combined therapy significantly reduced high-sensitivity C-reactive protein levels (P=0.004 by ANOVA). Simvastatin 19-30 C-reactive protein Homo sapiens 106-124 32366561-11 2020 TB was positively correlated with Hb and Alb, but negatively correlated with ESR and CRP (p<0.05). Bilirubin 0-2 C-reactive protein Homo sapiens 85-88 16218481-4 2005 First described as a component of the inflammatory pathway in acute coronary syndromes, CRP has been consistently found to be associated with the risk of future events in no-ST elevation acute coronary syndromes, independently of other risk factors, including troponine. troponine 260-269 C-reactive protein Homo sapiens 88-91 15690864-11 2005 Low dietary intake, low albumin, high platelet count, high CRP level and shorter survival were all significantly associated with low plasma vitamin C concentrations (<11 micromol/L). Ascorbic Acid 140-149 C-reactive protein Homo sapiens 59-62 15466473-7 2004 Site-directed mutagenesis revealed that valine 34 and leucine 36 are critical for GPVI interaction with collagen and CRP. Valine 40-46 C-reactive protein Homo sapiens 117-120 15753145-9 2004 In addition, alpha-tocopherol has been shown to decrease CRP levels in patients with CVD and having related risk factors for CVD (such as diabetes and smoking). alpha-Tocopherol 13-29 C-reactive protein Homo sapiens 57-60 15299098-4 2004 RESULTS: Univariate analysis yielded a significant correlation between vitamin C plasma levels and response to rHuEpo (n = 130, r = 0.25, P = 0.004), which still persisted after adjustment for transferrin saturation, C-reactive protein, malondialdehyde, parathyroid hormone, route of rHuEpo administration, residual renal function and diabetes mellitus (adjusted r = 0.23, P = 0.014). Ascorbic Acid 71-80 C-reactive protein Homo sapiens 217-235 15200442-8 2004 CONCLUSION: Data from a group consisting of patients with CRF, patients undergoing maintenance hemodialysis treatment, and renal transplant recipients provide evidence that conventional risk factors such as the presence of diabetes, ESRD, as well as elevated levels of the considered risk factor CRP, seem to play a more important role for cardiovascular outcome in patients with chronic kidney disease than elevated levels of AGEs, tHcy, and related metabolites. thcy 433-437 C-reactive protein Homo sapiens 296-299 15184288-9 2004 In stepwise multiple regression analysis, CAF, triglycerides, apolipoprotein B, and HRT use explained 46% of the variance in circulating CRP. cafestol palmitate 42-45 C-reactive protein Homo sapiens 137-140 15250255-1 2004 OBJECTIVE: To evaluate the effects of simvastatin combined with omega-3 fatty acids on high sensitive C-reactive protein (HsCRP), lipidemia, and fibrinolysis in coronary heart disease (CHD) and CHD risk equivalent patients with mixed dyslipidemia. Simvastatin 38-49 C-reactive protein Homo sapiens 102-120 15154943-8 2004 There was a positive correlation of CRP with body mass index (BMI), triglycerides, uric acid, fasting glucose, oral glucose tolerance test (OGTT) 1-h glucose, OGTT 2-h glucose, and a negative correlation with HDL cholesterol. Uric Acid 83-92 C-reactive protein Homo sapiens 36-39 14742804-8 2004 Drugs including statins, fibrates, niacin, thiazolidinediones, and antiplatelet agents, as well as weight loss and exercise, have demonstrated efficacy in lowering CRP levels. Niacin 35-41 C-reactive protein Homo sapiens 164-167 15334028-8 2004 The level of C-reactive protein increased on the second day after withdrawal of statin therapy (2,590.14 +/- 1,045.05 vs. 1,257.95 +/- 207.99 ng/ml); however, the total cholesterol and LDL-chol did not increase during the 3-day period after withdrawal of statin therapy. chol 169-173 C-reactive protein Homo sapiens 13-31 14706052-7 2004 There was a positive crude correlation between CRP and smoking, post-menopausal hormone use, body mass index, fasting glucose, triglycerides, hypertension, and uric acid (r = 0.11-0.36, P = 0.002-0.0001). Uric Acid 160-169 C-reactive protein Homo sapiens 47-50 15575349-9 2004 Vitamin C was inverse related to CRP (-0.01+/-0.005; p = 0.04) per 1 micromol/l, whereas alpha-tocopherol was positively related to CRP (0.03+/-0.01; p = 0.02) per 1 micro/l. Ascorbic Acid 0-9 C-reactive protein Homo sapiens 33-36 15575349-9 2004 Vitamin C was inverse related to CRP (-0.01+/-0.005; p = 0.04) per 1 micromol/l, whereas alpha-tocopherol was positively related to CRP (0.03+/-0.01; p = 0.02) per 1 micro/l. alpha-Tocopherol 89-105 C-reactive protein Homo sapiens 132-135 15575349-11 2004 CONCLUSION: The inverse relations between carotenoids, Vitamin C and sICAM-1, CRP and leukocytes may help to explain the possible protective effect of carotenoids and Vitamin C on atherosclerosis through an influence on inflammatory processes and endothelial function. Carotenoids 151-162 C-reactive protein Homo sapiens 78-81 15575349-11 2004 CONCLUSION: The inverse relations between carotenoids, Vitamin C and sICAM-1, CRP and leukocytes may help to explain the possible protective effect of carotenoids and Vitamin C on atherosclerosis through an influence on inflammatory processes and endothelial function. Ascorbic Acid 167-176 C-reactive protein Homo sapiens 78-81 15050096-6 2004 In our recent study, the results demonstrate that monocytes exhibit an enhanced production of interleukin-6 (IL-6) in response to CRP, and this response is significantly inhibited by simvastatin in a dose-dependent manner. Simvastatin 183-194 C-reactive protein Homo sapiens 130-133 15050096-10 2004 Our clinical investigation suggested that treatment with a single high-dose or a short-term common dose of simvastatin could rapidly reduce CRP level. Simvastatin 107-118 C-reactive protein Homo sapiens 140-143 14562390-6 2003 The LPO level was especially correlated with the concentration of serum CRP and CT severity index. Lipid Peroxides 4-7 C-reactive protein Homo sapiens 72-75 12826933-0 2003 Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Simvastatin 0-11 C-reactive protein Homo sapiens 76-94 12826933-5 2003 Also 10-8-10-6 mol/l simvastatin was coincubated with cells in the presence of CRP and LPS. Simvastatin 21-32 C-reactive protein Homo sapiens 79-82 12826933-11 2003 CONCLUSIONS: CRP and LPS could induce IL-6 release in human monocytes and simvastatin could inhibit this response in a dose-dependent manner, which may provide an insight into the mechanisms of anti-inflammatory or anti-atherosclerotic actions of simvastatin. Simvastatin 74-85 C-reactive protein Homo sapiens 13-16 12826933-11 2003 CONCLUSIONS: CRP and LPS could induce IL-6 release in human monocytes and simvastatin could inhibit this response in a dose-dependent manner, which may provide an insight into the mechanisms of anti-inflammatory or anti-atherosclerotic actions of simvastatin. Simvastatin 247-258 C-reactive protein Homo sapiens 13-16 12732400-7 2003 Serum uric acid concentrations were higher in hypertensives with PAD (404+/-101 vs. 347+/-80 micromol/l, P<0.001) independent of components of the metabolic syndrome (body mass index, triglycerides, insulin) and of age, gender, diabetes mellitus, pulse pressure, cholesterol, C-reactive protein, and treatment. Uric Acid 6-15 C-reactive protein Homo sapiens 279-297 12729319-5 2003 RESULTS: Metronidazole plus ciprofloxacin decreased the CRP in seven patients and the IOIBD score in six patients. Ciprofloxacin 28-41 C-reactive protein Homo sapiens 56-59 12426217-8 2002 Maximum relaxation response to CRP (79.5+/-10%) was attenuated by KCl (2.5+/-11.5%, P<0.001), BaCl (24.5+/-7.5%, P<0.001), and tetraethylammonium chloride (34.9+/-8.25%, P<0.01) but not by glibenclamide. bacl 97-101 C-reactive protein Homo sapiens 31-34 12477621-0 2002 Simvastatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with hyperlipidemia. Simvastatin 0-11 C-reactive protein Homo sapiens 61-79 12375804-5 2002 At a 4-month control, simvastatin reduced CRP levels (p = 0.009) while placebo did not (p = NS). Simvastatin 22-33 C-reactive protein Homo sapiens 42-45 12375804-8 2002 Simvastatin treatment reduces CRP levels, but without affecting the increased risk conferred by higher CRP levels at baseline. Simvastatin 0-11 C-reactive protein Homo sapiens 30-33 12046033-7 2002 In the treatment group, simvastatin administration for 8 weeks significantly reduced total cholesterol levels from 232 +/- 25 to 165 +/- 39 mg/dL (P < 0.001) and hs-CRP levels from a median of 0.23 mg/dL (range, 0.05 to 1.63 mg/dL) to 0.12 mg/dL (range, <0.006 to 1.45 mg/dL; P < 0.01), whereas it increased serum albumin levels from 3.4 +/- 0.3 to 3.6 +/- 0.4 g/dL (P < 0.001). Simvastatin 24-35 C-reactive protein Homo sapiens 168-171 12173196-11 2002 In contrast, IL-10 concentration at 6 h was higher in diclofenac-treated patients (P = 0.008), and this was associated with less pyrexia (P = 0.03), a lower leucocyte count (P = 0.0002) and a lower C-reactive protein concentration (P = 0.0039). Diclofenac 54-64 C-reactive protein Homo sapiens 198-216 12173196-13 2002 Cortisol concentration correlated with IL-6 concentration at 24 h. CONCLUSIONS: Administration of diclofenac was associated with lower IL-6 and higher IL-10 concentrations, and lower leucocyte count, C-reactive protein concentration and temperature. Diclofenac 98-108 C-reactive protein Homo sapiens 200-218 11988210-0 2002 Effect of cocaine usage on C-reactive protein, von Willebrand factor, and fibrinogen. Cocaine 10-17 C-reactive protein Homo sapiens 27-84 12324714-6 2002 RESULTS: In the heterogeneous study population, increased CRP concentrations significantly correlated with an increased cortisol:cortisone ratio (p < 0.001; r = 0.65, Spearman correlation coefficient). Cortisone 129-138 C-reactive protein Homo sapiens 58-61 12424566-10 2002 The biliary excretion of cysteinyl LTs was positively correlated with leukocyte concentration ( r = 0.68; P < 0.005) and C-reactive protein ( r = 0.73; P < 0.005) in blood. cysteinyl-leukotriene 25-38 C-reactive protein Homo sapiens 124-142 11844003-11 2001 CRP and IL-6 were important confounders in the relationship between serum uric acid and overall mortality. Uric Acid 74-83 C-reactive protein Homo sapiens 0-3 32147078-1 2020 OBJECTIVES: The present study was aimed to investigate the effect of alpha-tocopherol supplementation on biomarkers of endothelial function (Intercellular Adhesion Molecule 1 and Vascular Cell Adhesion Protein 1) and inflammatory markers (Interleukin 6 and high-sensitivity C-reactive protein) among the hemodialysis patients. alpha-Tocopherol 69-85 C-reactive protein Homo sapiens 274-292 11401933-10 2001 In a multiple logistic regression model adjusted for tHcy, the association of PLP with CRP remained highly significant (P=0.003). thcy 53-57 C-reactive protein Homo sapiens 87-90 31790083-11 2020 CONCLUSIONS: Anti-inflammatory effects of a diet should be assessed not only based on a high intake of omega-3 fatty acids but also balanced omega-6 / omega-3 ratio, which reduces PLR and CRP levels in patients with cardiovascular disease. omega-6 141-148 C-reactive protein Homo sapiens 188-191 11475149-6 2001 The intensity of Tc-99m MIBI scans correlated with disease activity as determined by lactate dehydrogenase (LDH) (p<0.05), C-reactive protein (CRP) (p<0.01), beta2-microglobulin (p<0.05), and serum ferritin (p<0.01). tc-99 17-22 C-reactive protein Homo sapiens 126-144 11475149-6 2001 The intensity of Tc-99m MIBI scans correlated with disease activity as determined by lactate dehydrogenase (LDH) (p<0.05), C-reactive protein (CRP) (p<0.01), beta2-microglobulin (p<0.05), and serum ferritin (p<0.01). tc-99 17-22 C-reactive protein Homo sapiens 146-149 11306519-5 2001 hs-CRP levels were significantly decreased after treatment with all 3 statins compared with baseline (median values: baseline, 2.6 mg/L; atorvastatin, 1.7 mg/L; simvastatin, 1.7 mg/L; and pravastatin, 1.9 mg/L; P<0.025). Simvastatin 161-172 C-reactive protein Homo sapiens 3-6 11306519-9 2001 CONCLUSIONS: Pravastatin, simvastatin, and atorvastatin significantly decreased levels of hs-CRP. Simvastatin 26-37 C-reactive protein Homo sapiens 93-96 32118713-6 2020 The HP&PHVHF group was superior to the CVVH group in CRP, APACHE II score (P < .01), and heart rate (HR), WBC, PCT, SOFA (P < .05). hp&phvhf 4-12 C-reactive protein Homo sapiens 53-56 11294804-6 2001 Serum C-reactive protein (CRP) concentrations were significantly higher in PAD patients (P<0.0001) and negatively correlated with L-ascorbic acid levels (r=-0.742, P<0.0001). Ascorbic Acid 133-148 C-reactive protein Homo sapiens 6-24 11294804-6 2001 Serum C-reactive protein (CRP) concentrations were significantly higher in PAD patients (P<0.0001) and negatively correlated with L-ascorbic acid levels (r=-0.742, P<0.0001). Ascorbic Acid 133-148 C-reactive protein Homo sapiens 26-29 11294804-7 2001 In stepwise multivariate analysis, low L-ascorbic acid concentration in PAD patients was associated with high CRP level (P=0.0001), smoking (P=0.0009), and shorter absolute claudication distance on a standardized graded treadmill test (P=0.029). Ascorbic Acid 39-54 C-reactive protein Homo sapiens 110-113 31591022-9 2020 Serum C-reactive protein (CRP) levels were significantly higher in the AFBN group than in the non-AFBN group (14.7 mg/dL versus 0.8 mg/dL, P = 0.009). afbn 71-75 C-reactive protein Homo sapiens 6-24 11294804-8 2001 CONCLUSIONS: Vitamin C concentrations are lower in intermittent claudicant patients in association with higher CRP levels and severity of PAD. Ascorbic Acid 13-22 C-reactive protein Homo sapiens 111-114 11182189-2 2001 The aim of the study was to assess the influence of simvastatin and aspirin on serum levels of C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in hypercholesterolemic subjects. Simvastatin 52-63 C-reactive protein Homo sapiens 95-113 11182189-7 2001 CONCLUSIONS: In men with hypercholesterolemia simvastatin treatment lowers serum levels of CRP and proinflammatory cytokines. Simvastatin 46-57 C-reactive protein Homo sapiens 91-94 31591022-9 2020 Serum C-reactive protein (CRP) levels were significantly higher in the AFBN group than in the non-AFBN group (14.7 mg/dL versus 0.8 mg/dL, P = 0.009). afbn 71-75 C-reactive protein Homo sapiens 26-29 31886224-11 2019 The TXA group also demonstrated a lower level of CRP on POD1 (p=0.02) and lower levels of CRP and serum D-dimer on POD3 (p=0.008 and p < 0.001). Tranexamic Acid 4-7 C-reactive protein Homo sapiens 49-52 11158409-7 2001 Interestingly, plasma C reactive protein (CRP) levels measured by highly sensitive CRP assay were correlated positively with plasma levels of thiobarbituric acid reactive substances (r=0.38, P<0.04) and negatively with plasma alpha-tocopherol levels (r=-0.46, P<0.01). alpha-Tocopherol 229-245 C-reactive protein Homo sapiens 22-40 11158409-7 2001 Interestingly, plasma C reactive protein (CRP) levels measured by highly sensitive CRP assay were correlated positively with plasma levels of thiobarbituric acid reactive substances (r=0.38, P<0.04) and negatively with plasma alpha-tocopherol levels (r=-0.46, P<0.01). alpha-Tocopherol 229-245 C-reactive protein Homo sapiens 42-45 31886224-11 2019 The TXA group also demonstrated a lower level of CRP on POD1 (p=0.02) and lower levels of CRP and serum D-dimer on POD3 (p=0.008 and p < 0.001). Tranexamic Acid 4-7 C-reactive protein Homo sapiens 90-93 11053781-0 2000 Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. alpha-Tocopherol 0-16 C-reactive protein Homo sapiens 49-67 10493968-6 1999 There was a significant negative correlation between PBMC-induced hepatocyte C-reactive protein production and survival (r=-0.45, p<0.01). PBMC 53-57 C-reactive protein Homo sapiens 77-95 10432314-5 1999 The formation of inositol phosphates and phosphatidic acid (PA), two markers of phospholipase C (PLC) activation, by CRP are inhibited by between 50 and 85% in the presence of wortmannin and LY294002. Inositol Phosphates 17-36 C-reactive protein Homo sapiens 117-120 10465182-2 1999 In a 6-month double-blind placebo controlled trial, a combination of transdermal oestradiol 80 microg with continuous oral norethisterone 1 mg significantly reduced C-reactive protein concentrations in postmenopausal women with type-2 diabetes. Norethindrone 123-137 C-reactive protein Homo sapiens 165-183 31228727-9 2019 Pooling 5 effect sizes from 2 studies, we found a significant reduction in serum concentrations of CRP following administration of Simvastatin (WMD: -0.29; 95% CI: -0.49, -0.10; I2 = 88.5%). Simvastatin 131-142 C-reactive protein Homo sapiens 99-102 10599348-2 1999 In patients with rheumatoid arthritis, significant positive correlations were found between urinary pyridinium crosslinks and C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and articular index. pyridine 100-110 C-reactive protein Homo sapiens 126-144 10599348-2 1999 In patients with rheumatoid arthritis, significant positive correlations were found between urinary pyridinium crosslinks and C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and articular index. pyridine 100-110 C-reactive protein Homo sapiens 146-149 31020672-1 2019 OBJECTIVES: The association of C-reactive protein (CRP) and serum 25-hydroxyvitamin D [25(OH)D] and cardiovascular disease (CVD) remains unknown. 25-hydroxyvitamin D 66-85 C-reactive protein Homo sapiens 31-49 9775136-11 1998 Cholesterolemia was reduced (P < 0.05) in all three pathologic groups when compared to the witness group; the difference existed when a low intensity inflammatory response was observed (mean CRP level 27.6 (10.5) mg/L in group 1). cholesterolemia 0-15 C-reactive protein Homo sapiens 194-197 31020672-1 2019 OBJECTIVES: The association of C-reactive protein (CRP) and serum 25-hydroxyvitamin D [25(OH)D] and cardiovascular disease (CVD) remains unknown. 25-hydroxyvitamin D 66-85 C-reactive protein Homo sapiens 51-54 9359864-0 1997 The sphingomyelin-ceramide pathway participates in cytokine regulation of C-reactive protein and serum amyloid A, but not alpha-fibrinogen. Sphingomyelins 4-17 C-reactive protein Homo sapiens 74-92 30783215-8 2019 Women receiving SPAZ had lower delivery AGP and CRP levels (p < 0.001). spaz 16-20 C-reactive protein Homo sapiens 48-51 30714949-6 2019 Low creatinine clearance correlated inversely (r = - 0.60) and plasma creatinine directly (r = 0.52) with the two-fold variability in heparan sulfate, which was the only shedding substance that also correlated with C-reactive protein (r = 0.51) and, therefore, showed higher concentrations after surgery. Heparitin Sulfate 134-149 C-reactive protein Homo sapiens 215-233 8766490-4 1996 Therefore, we investigated the impact of antenatal administration of 16-methylene-prednisolone (Decortilen solubile) on the maternal serum level of CRP and leukocyte count. prednylidene 69-94 C-reactive protein Homo sapiens 148-151 8181076-9 1994 Next, the effect of PMA, a PKC activator, and calcium ionophore, A23187, on anti-CRP-mediated inhibition of cytotoxicity were studied. Calcimycin 65-71 C-reactive protein Homo sapiens 81-84 31706905-7 2019 An uncontrolled clinical trial in 39 hypertriglyceridemic patients with steatosis showed reduction of liver fat by 47% and reductions in liver enzymes and C-reactive protein from the baseline when treated with niacin extended-release for 6 months These hypothesis-generating data indicate a novel repurposed use of niacin for NAFLD. Niacin 210-216 C-reactive protein Homo sapiens 155-173 8043897-4 1994 A positive correlation was found between C-reactive protein (CRP), an APR glycoprotein, and non-specific TBA reactivity as determined after borohydride reduction (BH4-resistant TBA, BR-TBA), both in non-diabetics (r = 0.61; P < 0.01) and diabetics (r = 0.68; P < 0.01). Borohydrides 140-151 C-reactive protein Homo sapiens 41-59 8043897-4 1994 A positive correlation was found between C-reactive protein (CRP), an APR glycoprotein, and non-specific TBA reactivity as determined after borohydride reduction (BH4-resistant TBA, BR-TBA), both in non-diabetics (r = 0.61; P < 0.01) and diabetics (r = 0.68; P < 0.01). Borohydrides 140-151 C-reactive protein Homo sapiens 61-64 8236991-1 1993 In a group of 18 patients with essential hyperlipidaemia the influence was studied of multivitamin CRP preparation given for 12 weeks, on lipid peroxides, cholesterol and triglycerides in the serum. Lipid Peroxides 138-153 C-reactive protein Homo sapiens 99-102 8312976-8 1993 Using a fluorescence polarization assay, it is also shown that 5-OH-Trp derivative of CRP interacts with RNAP as well as the native protein. 5-oh-trp 63-71 C-reactive protein Homo sapiens 86-89 30007118-10 2018 Treatment of platelets with Phox-I inhibited diverse CRP-induced responses, including: (i) ROS generation; (ii) release of P-selectin; (iii) secretion of ATP; (iv) platelet aggregation; and (v) phosphorylation of Akt. phox-i 28-34 C-reactive protein Homo sapiens 53-56 1328445-11 1992 These results indicate that although Agg-CRP enhances the intracellular generation of reactive oxygen intermediates by monocytes and neutrophils, extracellular release of those products is not influenced by cell interaction with Agg-CRP. reactive oxygen 86-101 C-reactive protein Homo sapiens 41-44 2120317-3 1990 CRP bound to the immunoaffinity column was eluted by 0.5 M acetate buffer, pH 5.0 containing 1.5 M NaCl. Acetates 59-66 C-reactive protein Homo sapiens 0-3 30210632-7 2018 Patients with dMMR status presented with increased neutrophil counts, and higher NLR and CRP levels in early stage CRC. dmmr 14-18 C-reactive protein Homo sapiens 89-92 29683202-4 2018 We confirmed that serum total cholesterol and uric acid were elevated in pre-eclamptic compared to healthy pregnancies and correlated positively to high sensitivity C-reactive protein (hsCRP) and the pre-eclampsia marker soluble fms-like tyrosine kinase-1 (sFlt-1). Uric Acid 46-55 C-reactive protein Homo sapiens 165-183 33972830-7 2021 Comparison of HCC patients with high (>2.5 mg/ dL) compared low serum CRP levels showed significant differences for blood levels of NLR, LMR, Hb, total bilirubin and liver transaminases, as well as Maximum Tumor Diameter (MTD) and percent of patients with Portal Vein Thrombosis (PVT). Bilirubin 152-161 C-reactive protein Homo sapiens 70-73 29631598-9 2018 Additionally, a univariate and multivariate logistic regression analysis demonstrated that the increased monocyte counts to high density lipoprotein cholesterol values were more sensitive than the other known risk factors (such as increased body mass index, homeostasis model assessment of insulin resistance and high sensitive C-reactive protein levels) in the prediction of the inflammation in patients with polycystic ovary syndrome. density lipoprotein cholesterol 129-160 C-reactive protein Homo sapiens 328-346 26640530-14 2015 Concentrations of IL-1beta, IL-6 and CRP were significantly higher in patients who developed POCD on day 1 following surgery than in the patients who did not develop POCD (P<0.05). pocd 93-97 C-reactive protein Homo sapiens 37-40 34536795-9 2021 CRP levels were lower in the paracetamol group during the early treatment. Acetaminophen 29-40 C-reactive protein Homo sapiens 0-3 34536795-12 2021 However, during early treatment, CRP levels were lower in the paracetamol group. Acetaminophen 62-73 C-reactive protein Homo sapiens 33-36 29892934-5 2018 MIE-PP was identified as a significant independent predictor of reduced CRP level on POD 1 (odds ratio 3.65, P = 0.042). mie-pp 0-6 C-reactive protein Homo sapiens 72-75 34641661-0 2021 En mann i 80-arene med gangvansker og hoy CRP-verdi. arene 13-18 C-reactive protein Homo sapiens 42-45 34532198-10 2021 The receiver operating characteristic (ROC) curve and Kaplan-Meier analysis results showed that UA and hs-CRP level had predictive value for three-year cardiovascular-related mortality in CAPD patients (uric acid: area under the curve (AUC)=0.822; hs-CRP: AUC=0.834, p < 0.001). Uric Acid 203-212 C-reactive protein Homo sapiens 106-109 34481517-5 2021 ASAS40 response rates in the CRP+/MRI+ subgroup was 52.3% (secukinumab) versus 21.8% (placebo; P < 0.0001) at week 16. asas40 0-6 C-reactive protein Homo sapiens 29-32 30332942-0 2018 A Meta-analysis of Randomized Control Trials: The Impact of Vitamin C Supplementation on Serum CRP and Serum hs-CRP Concentrations. Ascorbic Acid 60-69 C-reactive protein Homo sapiens 95-98 34276670-11 2021 TBIL was inversely proportional to CRP (rs=-0.328) and TNF(rs=-0.360), and positively proportional to C3 (rs=0.174) and C4 (rs=0.172). Bilirubin 0-4 C-reactive protein Homo sapiens 35-38 34183020-0 2021 Regular consumption of cod liver oil is associated with reduced basal and exercise-induced C-reactive protein levels; a prospective observational trial : A NEEDED (The North Sea Race Endurance Exercise Study) 2014 sub-study. Cod Liver Oil 23-36 C-reactive protein Homo sapiens 91-109 30332942-0 2018 A Meta-analysis of Randomized Control Trials: The Impact of Vitamin C Supplementation on Serum CRP and Serum hs-CRP Concentrations. Ascorbic Acid 60-69 C-reactive protein Homo sapiens 112-115 30332942-1 2018 OBJECTIVE: The present meta-analysis was designed to assess the effects of vitamin C supplementation on serum C-reactive Protein (CRP) levels. Ascorbic Acid 75-84 C-reactive protein Homo sapiens 110-128 30332942-1 2018 OBJECTIVE: The present meta-analysis was designed to assess the effects of vitamin C supplementation on serum C-reactive Protein (CRP) levels. Ascorbic Acid 75-84 C-reactive protein Homo sapiens 130-133 30332942-7 2018 The pooled effect size analysis showed a significant reducing effect of vitamin C supplementation on circulating CRP level (-0.23 mg/L, 95% CI, -0.44, -0.03, p=0.02), with a significant heterogeneity effect across the studies involved. Ascorbic Acid 72-81 C-reactive protein Homo sapiens 113-116 34126960-9 2021 25OHD levels inversely correlated with: i) IL-6 levels (rho - 0.284, p = 0.004); ii) the subsequent need of the ICU admission (relative risk, RR 0.99, 95% confidence interval (95%CI) 0.98-1.00, p = 0.011) regardless of age, gender, presence of at least 1 comorbidity among obesity, diabetes, arterial hypertension, creatinine, IL-6 and lactate dehydrogenase levels, neutrophil cells, lymphocytes and platelets count; iii) mortality (RR 0.97, 95%CI, 0.95-0.99, p = 0.011) regardless of age, gender, presence of diabetes, IL-6 and C-reactive protein and lactate dehydrogenase levels, neutrophil cells, lymphocytes and platelets count. 25ohd 0-5 C-reactive protein Homo sapiens 529-547 30332942-8 2018 Subgroup analyses showed that vitamin C supplementation significantly lowered CRP among trials. Ascorbic Acid 30-39 C-reactive protein Homo sapiens 78-81 30332942-10 2018 CONCLUSION: The present meta-analysis shows that vitamin C supplementation reduces serum CRP level, particularly in younger subjects, with higher CRP baseline level, at a lower dosage and intravenous administration. Ascorbic Acid 49-58 C-reactive protein Homo sapiens 89-92 30332942-10 2018 CONCLUSION: The present meta-analysis shows that vitamin C supplementation reduces serum CRP level, particularly in younger subjects, with higher CRP baseline level, at a lower dosage and intravenous administration. Ascorbic Acid 49-58 C-reactive protein Homo sapiens 146-149 28351163-12 2017 A significant correlation between CRP and UAS (r = 0.3; p = 0.011) was noted. Phenindione 42-45 C-reactive protein Homo sapiens 34-37 34223511-11 2021 Spearman"s correlation coefficient between CRP and pain NRS and that between CRP and pain IPOS were 0.15 (p < 0.001) and 0.16 (p < 0.001), respectively. ipos 90-94 C-reactive protein Homo sapiens 77-80 34126660-10 2021 In multivariate analysis, elevated C-reactive protein (CRP) before chemotherapy was an independent predictive factor for GEMAF (oddsratio 2.450, p=0.041). gemaf 121-126 C-reactive protein Homo sapiens 35-53 34126660-10 2021 In multivariate analysis, elevated C-reactive protein (CRP) before chemotherapy was an independent predictive factor for GEMAF (oddsratio 2.450, p=0.041). gemaf 121-126 C-reactive protein Homo sapiens 55-58 28550977-1 2017 AIMS: Evaluating the short-term influence of Ezetimibe and Simvastatin Combination Therapy on LDL-C, TG and hs-CRP expression level in patients with percutaneous coronary intervention. Simvastatin 59-70 C-reactive protein Homo sapiens 111-114 35304204-7 2022 We also found PFOA concentrations in serum were associated with the level of C-reactive protein (beta = 0.52, 95% CI: 0.40, 0.65). perfluorooctanoic acid 14-18 C-reactive protein Homo sapiens 77-95 28550977-10 2017 CONCLUSIONS: Combination therapy of Ezetimibe (10mg/day) and Simvastatin (40mg/day) was more effective than mono-therapy with Simvastatin (40mg/day) on reducing LDL-C, TG and hs-CRP level in percutaneous coronary intervention patients, leading to more significant anti-inflammatory effect. Simvastatin 61-72 C-reactive protein Homo sapiens 178-181 28220370-7 2017 RESULTS: The patients treated with candesartan had a significant lower value of PTX3 and hs-CRP, compared with those under treatment with other antihypertensive medication as follows: PTX3: 0.61 +- 0.49 vs 0.95 +- 1.04 ng/ml, P = 0.006 and hs-CRP: 0.19 +- 0.20 vs 0.20 +- 0.22 mg/dl, P = 0.54. candesartan 35-46 C-reactive protein Homo sapiens 243-246 35550621-8 2022 The trial aims to compare the effectiveness of a TB screening strategy based on CRP levels using a point-of-care (POC) assay on 2-year TB incidence and all-cause mortality (composite primary trial endpoint) and prevalent TB case detection and uptake of TPT (intermediate outcomes), relative to symptom-based TB screening (current practice). tpt 253-256 C-reactive protein Homo sapiens 80-83 35366569-10 2022 Thus, early on-treatment CRP kinetics is a promising low-cost and easy-to-implement biomarker to optimise therapy monitoring in patients with mUC treated with ICB. indole-2-carboxylic acid 159-162 C-reactive protein Homo sapiens 25-28 28220370-8 2017 CONCLUSIONS: Candesartan decreases PTX3 and hs-CRP plasma levels more powerful than other classes of antihypertensive drugs (beta blockers, calcium channel blockers, and diuretics), so we may assume that candesartan has a more potent action in reversing endothelial dysfunction and that it offers a higher vascular protection than other classes of antihypertensive drugs. candesartan 13-24 C-reactive protein Homo sapiens 47-50 35566611-10 2022 CONCLUSIONS: In patients with AE-ILD, PMX-DHP treatment was associated with an improved P/F ratio and lower WBC and CRP levels. 1,4-dihydropyridine 42-45 C-reactive protein Homo sapiens 116-119 28763896-0 2017 [Association between serum uric acid levels and high sensitive C-reactive protein in patients with type 2 diabetes]. Uric Acid 27-36 C-reactive protein Homo sapiens 63-81 28763896-1 2017 Objective: To investigate the relationship between serum uric acid (SUA) levels and high sensitive C-reactive protein (hs-CRP) in patients with type 2 diabetes mellitus (T2DM). Uric Acid 57-66 C-reactive protein Homo sapiens 99-117 28410341-9 2017 Median C-reactive protein and fecal calprotectin were higher (P < 0.05 at some visits) and plasma CZP concentrations were significantly lower (P < 0.0001 at all visits) in the persistent CZP-ADAb-positive group relative to the CZP-ADAb-negative group. czp-adab 193-201 C-reactive protein Homo sapiens 7-25 35066509-9 2022 There were lower levels of C-reactive protein at 12 and 24 h in the esmolol arm, as well as a statistically significant difference in trend over time between groups. esmolol 68-75 C-reactive protein Homo sapiens 27-45 35066509-13 2022 Esmolol was associated with decreased levels of C-reactive protein over 24 h. TRIAL REGISTRATION: www.clinicaltrials.gov. esmolol 0-7 C-reactive protein Homo sapiens 48-66 28410341-10 2017 Transient CZP-ADAb-positive and CZP-ADAb-negative patients had similar plasma CZP, C-reactive protein, and fecal calprotectin concentrations. czp-adab 10-18 C-reactive protein Homo sapiens 83-101 35300582-12 2022 Triglyceride, uric acid, CRP, vitamin B12, and homeostatic model assessment of insulin resistance were found to be affected by high uric acid levels. Uric Acid 132-141 C-reactive protein Homo sapiens 25-28 35268083-1 2022 BACKGROUND: to evaluate the prevalence and predictors of insufficient plasma vitamin C among adults in a subtropical region and its associations with cardiovascular disease risk factors including dyslipidemia and lipid-independent markers, namely homocysteine, high-sensitivity C-reactive protein (hs-CRP) and lipoprotein(a). Ascorbic Acid 77-86 C-reactive protein Homo sapiens 278-296 35268083-1 2022 BACKGROUND: to evaluate the prevalence and predictors of insufficient plasma vitamin C among adults in a subtropical region and its associations with cardiovascular disease risk factors including dyslipidemia and lipid-independent markers, namely homocysteine, high-sensitivity C-reactive protein (hs-CRP) and lipoprotein(a). Ascorbic Acid 77-86 C-reactive protein Homo sapiens 301-304 2593200-6 1989 As a result of this interaction, CRP inhibits the surface activity of a PG-DPPC mixture when tested with a Wilhelmy surfactometer or with the Enhorning pulsating bubble apparatus. pg-dppc 72-79 C-reactive protein Homo sapiens 33-36 28952295-8 2017 The improvement of white blood cells and CRP levels of the amoxicillin and clavulanate potassium group was more obvious than that of the ceftezole sodium group (P<0.05). Clavulanic Acid 75-96 C-reactive protein Homo sapiens 41-44 2803750-0 1989 Purification of human C-reactive protein by barium sulfate and preparative agarose electrophoresis. Sepharose 75-82 C-reactive protein Homo sapiens 22-40 2803750-2 1989 The methods described take advantage of the barium sulfate adsorption property of CRP and the unique biophysical property of CRP migration during electrophoresis in agarose gels containing Ca2+. Sepharose 165-172 C-reactive protein Homo sapiens 125-128 35296532-1 2022 BACKGROUND: 52-week results from C-axSpAnd demonstrated the safety and efficacy of certolizumab pegol (CZP) in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation (sacroiliitis on MRI and/or elevated C-reactive protein levels). Certolizumab Pegol 83-101 C-reactive protein Homo sapiens 257-275 29062328-7 2017 Plasma levels of CRP, ferritin and dopamine were higher in the group of smokers in the setting of lower levels of epinephrine, and leukocyte vitamin C, with CRP and vitamin C attaining statistical significance (P<0.04 and P<0.02 respectively). Ascorbic Acid 141-150 C-reactive protein Homo sapiens 17-20 35335925-9 2022 A negative correlation between C-Reactive Protein (CRP) and haloperidol clearance was observed, where clearance decreased significantly with increasing CRP up to a CRP concentration of 100 mg/L. Haloperidol 60-71 C-reactive protein Homo sapiens 51-54 35335925-9 2022 A negative correlation between C-Reactive Protein (CRP) and haloperidol clearance was observed, where clearance decreased significantly with increasing CRP up to a CRP concentration of 100 mg/L. Haloperidol 60-71 C-reactive protein Homo sapiens 152-155 35335925-9 2022 A negative correlation between C-Reactive Protein (CRP) and haloperidol clearance was observed, where clearance decreased significantly with increasing CRP up to a CRP concentration of 100 mg/L. Haloperidol 60-71 C-reactive protein Homo sapiens 164-167 35140620-9 2022 The results of BCA indicated that Gastrodin, Liquiritin, Hesperidin, Isoliquiritin, Hesperetin, and Isoliquiritigenin might be the active constituents to activate ROS and suppress hs-CRP as determined by spectrum-effect relationships. gastrodin 34-43 C-reactive protein Homo sapiens 183-186 3057546-1 1988 The influence of polyclonal and monoclonal antibodies, trypsin digestion and mercaptoethanol treatment of C-reactive protein (CRP) in the CRP binding to solid-phase phosphorylethanolamine (PE) has been investigated. Mercaptoethanol 77-92 C-reactive protein Homo sapiens 106-124 3057546-1 1988 The influence of polyclonal and monoclonal antibodies, trypsin digestion and mercaptoethanol treatment of C-reactive protein (CRP) in the CRP binding to solid-phase phosphorylethanolamine (PE) has been investigated. Mercaptoethanol 77-92 C-reactive protein Homo sapiens 126-129 3057546-1 1988 The influence of polyclonal and monoclonal antibodies, trypsin digestion and mercaptoethanol treatment of C-reactive protein (CRP) in the CRP binding to solid-phase phosphorylethanolamine (PE) has been investigated. Mercaptoethanol 77-92 C-reactive protein Homo sapiens 138-141 3057546-4 1988 On the other hand, binding of CRP to PE was abolished by mercaptoethanol treatment. Mercaptoethanol 57-72 C-reactive protein Homo sapiens 30-33 29062328-7 2017 Plasma levels of CRP, ferritin and dopamine were higher in the group of smokers in the setting of lower levels of epinephrine, and leukocyte vitamin C, with CRP and vitamin C attaining statistical significance (P<0.04 and P<0.02 respectively). Ascorbic Acid 165-174 C-reactive protein Homo sapiens 17-20 27748083-5 2017 Significant decreases from baseline in the Disease Activity Score in 28 joints using the C-reactive protein level were seen in the peficitinib 50 mg (P < 0.05) and 150 mg (P < 0.01) groups compared with placebo at week 12. peficitinib 131-142 C-reactive protein Homo sapiens 89-107 3696453-4 1987 In our study we evaluated two new laser nephelometric assays, both quantitative, based on the agglutination of polystyrene latex particles, able to show serum concentration of CRP and RF. Polystyrenes 111-122 C-reactive protein Homo sapiens 176-186 3723841-4 1986 CRP antigen is coupled to the carboxyfluorescein entrapped multilamellar liposomes by using N-hydroxysuccinimidyl 3-(2-pyridyldithio) propionate and dithiothreitol, and a specific lysis of liposomes is achieved upon the addition of anti-CRP antibody in the presence of complement. N-succinimidyl 3-(2-pyridyldithio)propionate 92-144 C-reactive protein Homo sapiens 0-3 3035044-8 1986 It is suggested that CRP may play a significant role in regulation of oxygen free radicals formed during acute and chronic inflammatory episides. oxygen free radicals 70-90 C-reactive protein Homo sapiens 21-24 28151820-13 2017 POCD was associated with elevated CRP on postoperative day 2 (median [interquartile range]; 175 [81-294] vs 112 [62-142] mg/L, P = .033); however, the maximum CRP value (OR [95% CI], 1.35 [0.97-1.87] for a 2-fold increase, P = .07) had no distinct effect on POCD. pocd 0-4 C-reactive protein Homo sapiens 34-37 4086983-1 1985 A new reagent for the rapid and reliable quantitative determination of C-reactive protein (CRP), using polystyrene particles coated with antibodies against CRP, is now available. Polystyrenes 103-114 C-reactive protein Homo sapiens 71-89 4086983-1 1985 A new reagent for the rapid and reliable quantitative determination of C-reactive protein (CRP), using polystyrene particles coated with antibodies against CRP, is now available. Polystyrenes 103-114 C-reactive protein Homo sapiens 91-94 28151820-13 2017 POCD was associated with elevated CRP on postoperative day 2 (median [interquartile range]; 175 [81-294] vs 112 [62-142] mg/L, P = .033); however, the maximum CRP value (OR [95% CI], 1.35 [0.97-1.87] for a 2-fold increase, P = .07) had no distinct effect on POCD. pocd 0-4 C-reactive protein Homo sapiens 159-162 27904146-0 2017 The correlation between high sensitivity C-reactive protein and erectile dysfunction patients with hypertension treated with vardenafil. Vardenafil Dihydrochloride 125-135 C-reactive protein Homo sapiens 41-59 6422757-6 1983 When EDTA is present, the electrophoretic mobility of CRP is altered to a beta mobility. Edetic Acid 5-9 C-reactive protein Homo sapiens 54-57 27904146-1 2017 We evaluate the correlation between the plasma level of C-reactive protein (CRP) in patients with erectile dysfunction (ED) and hypertension and to set up whether the CRP level affected by the treatment of vardenafil 10 mg orally once daily. Vardenafil Dihydrochloride 206-216 C-reactive protein Homo sapiens 167-170 27370977-7 2016 RESULTS: The multivariate-adjusted geometric mean of serum CRP concentrations was significantly decreased with an increasing B vitamins intake across quartiles of niacin (P for trend = .007), pyridoxine (P for trend = .042), and cobalamin (P for trend = .037) in men. Niacin 163-169 C-reactive protein Homo sapiens 59-62 6619042-0 1983 C-reactive protein measurement: a reliable method of diagnosing and monitoring the infected newborn for the assessment of a mezlocillin therapeutic trial. Mezlocillin 124-135 C-reactive protein Homo sapiens 0-18 6619042-1 1983 Clinical and bacteriological efficacy of mezlocillin was evaluated in 41 neonates (including 12 premature babies) with clinical and laboratory evidence of bacterial infection, as shown by elevated C-reactive protein serum concentrations. Mezlocillin 41-52 C-reactive protein Homo sapiens 197-215 6619042-6 1983 The efficacy of mezlocillin was documented by the decrease in C-reactive protein serum concentrations and by improvement in clinical condition. Mezlocillin 16-27 C-reactive protein Homo sapiens 62-80 6848619-4 1983 Fluorescent antibody studies in which biotin-avidin amplification was used confirm the presence of surface CRP (S-CRP) on a small percentage of nonphagocytic peripheral blood mononuclear cells. Biotin 38-44 C-reactive protein Homo sapiens 107-110 27370977-8 2016 In men, the mean serum CRP concentrations in the highest quartiles of niacin, pyridoxine, and cobalamin were 63%, 38%, and 58%, respectively, lower than that in the lowest quartile. Niacin 70-76 C-reactive protein Homo sapiens 23-26 7046573-0 1982 Binding of C-reactive protein to C-carbohydrate and PC-substituted protein. c-carbohydrate 33-47 C-reactive protein Homo sapiens 11-29 27370977-10 2016 CONCLUSION: High intake of niacin, pyridoxine, or cobalamin was independently associated with decreased serum CRP concentrations among HIV-infected men. Niacin 27-33 C-reactive protein Homo sapiens 110-113 7046573-4 1982 Phosphorylcholine is bound by CRP with much higher affinity than other phosphate monoesters speaking for a second binding site with specificity for the positively charged trimethylammonium group. Cetrimonium 171-188 C-reactive protein Homo sapiens 30-33 26996761-0 2016 Serum Bilirubin and Their Association With C-Reactive Protein in Patients With Migraine. Bilirubin 6-15 C-reactive protein Homo sapiens 43-61 7018409-2 1981 Significant improvement in 5 out of 7 clinical measurements and in erythrocyte sedimentation rate, viscosity, C-reactive protein was found in those patients taking dapsone. Dapsone 164-171 C-reactive protein Homo sapiens 110-128 7462634-8 1981 The binding was not inhibited by ethylenediaminetetraacetate (EDTA) but could be inhibited by CaCl2, whereas CRP binding to PC-Sepharose was inhibited by EDTA and required CaCl2. Edetic Acid 154-158 C-reactive protein Homo sapiens 109-112 26996761-2 2016 An inverse relationship between serum bilirubin and CRP has been observed in various diseases. Bilirubin 38-47 C-reactive protein Homo sapiens 52-55 27893692-3 2016 There were positive correlations of serum UA with creatinine (Cr), CRP, and CEA (r = 0.281, P = 0.023; r = 0.312, P = 0.001; r = 0.294, P = 0.017) in rectal cancer patients with metastasis. Uric Acid 42-44 C-reactive protein Homo sapiens 67-70 762075-3 1979 The NH2-terminal residue of CRP is pyrrolidonecarboxylic acid and the COOH terminus is proline. Proline 87-94 C-reactive protein Homo sapiens 28-31 70475-8 1977 By contrast, CRP did inhibit both thrombin-induced release of malondialdehyde, a prostaglandin endoperoxide nonprostanoate endproduct, and platelet aggregation induced by the prostaglandin endoperoxide precursor arachidonic acid. Prostaglandin Endoperoxides 81-107 C-reactive protein Homo sapiens 13-16 28344762-6 2016 We present a case of a 57-year-old male patient with an uncomplicated AAD-B who developed an "atypical" PIS post-TEVAR with severe refractory abdominal pains; leukocytosis and raised C-reactive protein. Monothiopyrophosphoric acid 104-107 C-reactive protein Homo sapiens 183-201 853247-3 1977 Precipitation of ascarid components by C-reactive protein resulted in false-positive reactions, but this precipitation was readily prevented by appropriate absorption of sera before testing. ascarid 17-24 C-reactive protein Homo sapiens 39-57 830761-8 1977 We suggest, therefore, C activation by polyanion-polycation interactions in the presence of CRP may be important to certain reactions of host defense and inflammation. polyanions 39-48 C-reactive protein Homo sapiens 92-95 809531-8 1975 The relative inhibitory capacity of phosphorylcholine and polycations in CPS- and polycations-CRP systems was consistent with the concept that phosphate esters and polycations react at the same or an overlapping combining site. phosphate esters 143-159 C-reactive protein Homo sapiens 94-97 26493023-5 2016 RESULTS: Uric acid was associated with several cardiovascular risk factors, namely higher HOMA-IR, CRP, TG, BMI, waist, SBP, preperitoneal fat and cIMT (all P < 0.001 to P < 0.0001). Uric Acid 9-18 C-reactive protein Homo sapiens 99-102 13836783-0 1960 [The C-reactive protein demonstrated by the polystyrene latex method]. Polystyrenes 44-55 C-reactive protein Homo sapiens 5-23 27604685-0 2016 Previous exposure to biologics and C-reactive protein are associated with the response to tacrolimus in inflammatory bowel disease. Tacrolimus 90-100 C-reactive protein Homo sapiens 35-53 33121297-4 2021 EVOO resulted in a significant reduction in plasma CRP (-0.40 +- 0.52 vs 0.007 +- 0.42 mg/L, p = .01 for EVOO and ROO respectively) and increased ex-vivo whole blood LPS-stimulated IL-10 production (12.13 +- 33.64 vs -17.47 +- 49.04 pg/mL, p = .035 for EVOO and ROO respectively). evoo 0-4 C-reactive protein Homo sapiens 51-54 27501379-14 2016 Daperno 2014 reported that the ICC for the CDEIS was 0.985 (95% CI 0.939-1.000) for average measures of video score and was 0.835 (95% CI 0.540-0.995) for single measures of video score.With respect to validity, correlation between the CDEIS and clinical measures, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), was also reported. cdeis 43-48 C-reactive protein Homo sapiens 275-293 33951210-8 2021 In third trimester, it was found that maternal selenium level positively correlated with monocyte (p:0.04,r:0.353) and negatively correlated with CRP level (p:0.03,r:-0.384). Selenium 47-55 C-reactive protein Homo sapiens 146-149 27501379-14 2016 Daperno 2014 reported that the ICC for the CDEIS was 0.985 (95% CI 0.939-1.000) for average measures of video score and was 0.835 (95% CI 0.540-0.995) for single measures of video score.With respect to validity, correlation between the CDEIS and clinical measures, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), was also reported. cdeis 43-48 C-reactive protein Homo sapiens 295-298 26778547-1 2016 OBJECTIVE: A direct, inverse correlation between 25-hydroxy vitamin D (25(OH) vitamin D) levels and C-reactive protein (CRP), a sensitive biomarker for inflammation, was found in some, but not all, studies. 25-hydroxyvitamin D 49-69 C-reactive protein Homo sapiens 100-118 33827267-2 2021 This systematic review and dose-response meta-analysis of randomized controlled trials was performed to summarize the effects of ALA supplementation on inflammatory markers such as C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in adults. Thioctic Acid 129-132 C-reactive protein Homo sapiens 181-199 33827267-10 2021 The findings of the meta-analysis showed that ALA supplementation significantly reduced CRP (WMD: -0.69 mg/L, 95% CI: -1.13, -0.26, P=0.002), IL-6 (WMD: -1.83 pg/ml, 95% CI: -2.90, -0.76, P=0.001), and TNF-alpha concentrations (WMD: -0.45 pg/ml, 95% CI: -0.85, -0.04, P=0.032). Thioctic Acid 46-49 C-reactive protein Homo sapiens 88-91 26778547-1 2016 OBJECTIVE: A direct, inverse correlation between 25-hydroxy vitamin D (25(OH) vitamin D) levels and C-reactive protein (CRP), a sensitive biomarker for inflammation, was found in some, but not all, studies. 25-hydroxyvitamin D 49-69 C-reactive protein Homo sapiens 120-123 27077879-5 2016 The ingestion of high amounts of OO PC, as contained in FVOO, tended to increase the proportions of IgA-coated bacteria and increased plasma levels of CRP. oo pc 33-38 C-reactive protein Homo sapiens 151-154 33513439-3 2021 In this study, we show that a pentraxin-like component (Ptx-like) with a C-terminal PTX domain, highly homologous to the short PTX of H. sapiens CRP, and a long N-terminal domain typical of long PTXs, is involved in the inflammatory response of Ciona robusta under LPS exposure in vivo. ptx 56-59 C-reactive protein Homo sapiens 145-148 33782413-9 2021 OC treatment was accompanied by a near-doubling of circulating GDF15 (on average, from 296 to 507 pg/mL) and CRP, so that the relative GDF15 levels remained low. oc 0-2 C-reactive protein Homo sapiens 109-112 33440261-12 2021 Malnutrition and elevated HS-CRP were associated with TB (AOR 2.2[1.23-3.90] and 6.8[3.75-12.60]). Terbium 54-56 C-reactive protein Homo sapiens 29-32 33440261-14 2021 No single factor was associated with mortality, only the combination of malnutrition and elevated HS-CRP was highly predictive of death (OR 9.8[1.88-50.95]); the association was stronger in TB- patients (33.3% vs 1.0%, OR 47.6 [7.03-322.23]). Terbium 190-192 C-reactive protein Homo sapiens 101-104 27022048-1 2016 and "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". Simvastatin 157-168 C-reactive protein Homo sapiens 82-100 32958697-8 2021 After adjustment for conventional confounding factors, patients with both elevated hs-CRP levels and MAIs were associated with approximately 4.7-fold of risk of ischaemic stroke within 1 year (16.7% vs 3.5%, HR 4.68, 95% CI 1.54 to 14.23, p=0.007), compared with those with non-elevated hs-CRP levels and NAI. nai 305-308 C-reactive protein Homo sapiens 86-89 27022050-0 2016 Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". Simvastatin 191-202 C-reactive protein Homo sapiens 116-134 26908433-8 2016 Higher CRP was also associated with smoking, hormone replacement therapy use, and gamma-tocopherol intake; lower CRP with physical activity, and intakes of dietary vitamin C and total fiber. Ascorbic Acid 164-173 C-reactive protein Homo sapiens 7-10 32892540-8 2021 The multivariable analysis showed that the count of lymphocytes, D-dimer, and CRP levels were significantly improved in the LMWH group, as compared to the control group (OR, (95% CI) 0.628 (0.248?0.965), p < 0.001), OR, (95% CI) 0.356 (0.089?0.674), p < 0.001, respectively). Heparin, Low-Molecular-Weight 124-128 C-reactive protein Homo sapiens 78-81 32892540-10 2021 CONCLUSION: LMWH treatment group demonstrated better laboratory findings, including a recovery in the lymphocyte count, CRP, and D-dimer results. Heparin, Low-Molecular-Weight 12-16 C-reactive protein Homo sapiens 120-123 26333345-1 2016 INTRODUCTION: Pentra MS CRP is an automated hematology analyzer capable of cytochemistry using Chlorazol black E, a lipid-staining agent, for white blood cell (WBC) differentials. chloramine-T 95-104 C-reactive protein Homo sapiens 24-27 26333345-2 2016 Pentra MS CRP displays a WBC scattergram according to the cell volume obtained using flow impedance and light absorbance reflecting the Chlorazol black E (CBE)-positive lipid content. direct black 3 136-153 C-reactive protein Homo sapiens 10-13 33568149-10 2021 Importantly, elevated levels of IgM anti-HPT78-108 HNE, IgM anti-IGKC2-19, and IgG anti-THRB328-345 were positively correlated with the disease activity score in 28 joints for C-reactive protein (DAS28-CRP). thrb328 88-95 C-reactive protein Homo sapiens 176-194 26758679-7 2016 Additionally, OH-PAHs were positively associated with activated leukocyte cell adhesion molecule (ALCAM) and C-reactive protein (CRP) (p < 0.05), and IQR increases in OH-PAHs were associated with >20% increases in CRP. oh-pahs 14-21 C-reactive protein Homo sapiens 109-127 33487271-9 2021 RESULTS: At the end of the two phases, the differences of changes in the probiotic + ALA group was significant in weight, WC, and CRP factors when compared to the other groups (P < 0.05). Thioctic Acid 85-88 C-reactive protein Homo sapiens 130-133 26758679-7 2016 Additionally, OH-PAHs were positively associated with activated leukocyte cell adhesion molecule (ALCAM) and C-reactive protein (CRP) (p < 0.05), and IQR increases in OH-PAHs were associated with >20% increases in CRP. oh-pahs 14-21 C-reactive protein Homo sapiens 129-132 26758679-7 2016 Additionally, OH-PAHs were positively associated with activated leukocyte cell adhesion molecule (ALCAM) and C-reactive protein (CRP) (p < 0.05), and IQR increases in OH-PAHs were associated with >20% increases in CRP. oh-pahs 170-177 C-reactive protein Homo sapiens 220-223 33321447-0 2021 Effect of chromium supplementation on hs-CRP, TNF-alpha and IL-6 as risk factor for cardiovascular diseases: A meta-analysis of randomized-controlled trials. Chromium 10-18 C-reactive protein Homo sapiens 41-44 26751969-8 2016 There existed a negative relationship between serum 25-hydroxyvitamin D (25OHD) level and disease activity index, e.g. 25OHD vs. Disease Activity Score in 28 joints (DAS28): r = -0.13, 95% CI -0.16 to -0.09; 25OHD vs. C-reactive protein: r = -0.12, 95% CI -0.23 to -0.00. 25-hydroxyvitamin D 52-71 C-reactive protein Homo sapiens 218-236 33321447-1 2021 BACKGROUND: The objective of this systematic review is to assess the relationship between chromium supplementation and inflammatory biomarkers levels (hs-CRP, TNF-alpha, IL-6) as risk factor for cardiovascular diseases. Chromium 90-98 C-reactive protein Homo sapiens 154-157 32897516-8 2021 Fluctuation of serum ICAM-1, CD40L, MMPs, FBG and hs-CRP can be ascribed to perturbation of immunological mechanisms stimulated by denosumab and zoledronic acid. Zoledronic Acid 145-160 C-reactive protein Homo sapiens 53-56 27511325-10 2016 The C-reactive protein concentration 48 h after trauma was significantly lower in the simvastatin group, but there was no significant difference according to the interleukin-6 level 48 h after trauma between the 2 groups. Simvastatin 86-97 C-reactive protein Homo sapiens 4-22 32846352-6 2020 Specifically, per 1 C increase in TV06 led to 2.241% (95%CI: 1.552%-2.935%) increase in hs-CRP. tv06 35-39 C-reactive protein Homo sapiens 92-95 27298824-5 2016 Baseline CRP correlated positively (r = 0.341, P = 0.002) with peroxide only in the diabetic group. Peroxides 63-71 C-reactive protein Homo sapiens 9-12 33299302-5 2020 Moreover, alpha lipoic acid 1200 mg/day reduced Hs-CRP levels compared to baseline and compared to 400 mg/day (p < 0.05 for both). Thioctic Acid 10-27 C-reactive protein Homo sapiens 51-54 26728928-7 2016 Whites had significant inverse trends between CRP and tertiles of total n-6 FAs (GM 1.20, 0.91 and 0.80; p=0.002) and marine-derived n-3 FAs (GM 1.22, 1.00 and 0.72; p<0.001) but a significant positive trend with TFAs (GM 0.80, 0.95 and 1.15; p=0.007). Fatty Acids, Omega-6 72-79 C-reactive protein Homo sapiens 46-49 32859477-10 2020 The inverse association of HCQ with inpatient mortality was particularly evident in patients having elevated C-reactive protein at entry. Hydroxychloroquine 27-30 C-reactive protein Homo sapiens 109-127 26728928-10 2016 CONCLUSIONS: With the exception of consistent inverse association of CRP with total n-6 FAs, there are considerable variations across the three populations in the associations of CRP with different FAs. Fatty Acids, Omega-6 84-91 C-reactive protein Homo sapiens 69-72 27197424-11 2016 The Q192R polymorphism was associated with simvastatin effectiveness on hs-CRP and FMD. Simvastatin 43-54 C-reactive protein Homo sapiens 75-78 32291175-9 2020 CONCLUSION: These results confirm that CR-POAP, defined as POD1 serum AMS >100 U/l and POD2 CRP >= 180 mg/l, is associated with an increased risk of CR-POPF. Chromium 39-41 C-reactive protein Homo sapiens 92-95 26137879-9 2015 Although compatible with no association, women in the highest tertile of erythrocyte eicosapentaenoic acid had a nonsignificant 32% (95% CI: -23 to 62%) reduced breast tissue CRP. Eicosapentaenoic Acid 85-106 C-reactive protein Homo sapiens 175-178 32732814-7 2020 tTG Ab correlated significantly with Systemic Lupus Erythematosus Disease Activity Index score (P < 0.001) and insignificantly with hemoglobin and C-reactive protein. Hydrotopotecan 0-3 C-reactive protein Homo sapiens 147-165 32782515-0 2020 Sodium valproate combined with levetiracetam in pediatric epilepsy and its influence on NSE, IL-6, hs-CRP and electroencephalogram improvement. Valproic Acid 0-16 C-reactive protein Homo sapiens 102-105 32782515-8 2020 In the treatment of pediatric epilepsy, sodium valproate combined with LEV produces better efficacy, fewer adverse reactions, significantly improves patients" QOL and notably lowers the content of NSE, IL-6 and hs-CRP with notable EEG improvement, so it is a safe and reliable treatment that is worth popularization. Valproic Acid 40-56 C-reactive protein Homo sapiens 214-217 32872320-9 2020 Further analyses showed a significant positive correlation of lnhs-CRP with lnZMPSTE24 (n = 110; r = 0.21; p = 0.01) and lnlamin A/C (n = 110; r = 0.24; p = 0.03). lnzmpste24 76-86 C-reactive protein Homo sapiens 67-70 26135139-6 2015 Measures of adiposity, low high-density lipoprotein cholesterol, high-sensitivity C-reactive protein, LVM and LVH were all significantly associated with elevated UA at baseline, but not with change over time. Uric Acid 162-164 C-reactive protein Homo sapiens 82-100 32842543-8 2020 In all studies, EEN treatment decreases inflammatory markers (i.e., hs-CRP and FCP). estradiol enanthate 16-19 C-reactive protein Homo sapiens 71-74 26280117-0 2015 Elevated Baseline C-Reactive Protein as a Predictor of Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From the Simvastatin in Aneurysmal Subarachnoid Hemorrhage (STASH) Trial. Simvastatin 119-130 C-reactive protein Homo sapiens 18-36 33132425-9 2020 Therefore, the number of concomitant DTADE and a small decrease in CRP on the 14th day of treatment were key factors for the appearance of LZD-associated thrombocytopenia in patients with long-term LZD therapy. Linezolid 139-142 C-reactive protein Homo sapiens 67-70 33132425-9 2020 Therefore, the number of concomitant DTADE and a small decrease in CRP on the 14th day of treatment were key factors for the appearance of LZD-associated thrombocytopenia in patients with long-term LZD therapy. Linezolid 198-201 C-reactive protein Homo sapiens 67-70 26330412-0 2015 Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Simvastatin 152-163 C-reactive protein Homo sapiens 77-95 32353822-12 2020 CONCLUSION: Sugammadex is rapid and effective in reversing rocuronium-induced neuromuscular block, and significantly reduces the extubation time and the release of postoperative CRP and PCT in children with congenital heart diseases. Sugammadex 12-22 C-reactive protein Homo sapiens 178-181 32303765-11 2020 RESULTS: Serum hs-CRP increased after 9-week use of EE+DNG (mean change+-SD 1.10+-2.11 mg/L) compared with EV+DNG (-0.06+-0.97 mg/L, p=0.001) or DNG only (0.13+-0.68 mg/L, p=0.021). dienogest 55-58 C-reactive protein Homo sapiens 18-21 25367868-7 2015 RESULTS: The WBC count, MPV and ESR values, and the serum concentration of CRP were higher in the APN group than in the lower UTI group (p < 0.05). apholate 98-101 C-reactive protein Homo sapiens 75-78 25669317-11 2015 The results of this meta-analysis suggest that supplementation with vitamin E in the form of either alpha-tocopherol or gamma-tocopherol would reduce serum CRP levels. alpha-Tocopherol 100-116 C-reactive protein Homo sapiens 156-159 32423040-8 2020 Plasma iTFA levels were inversely associated with serum triglycerides (p < 0.001), fasting plasma glucose (p < 0.001), body mass index (p < 0.001), systolic and diastolic blood pressure (p = 0.001 and p = 0.03) and C-reactive protein (p = 0.001). itfa 7-11 C-reactive protein Homo sapiens 215-233 31926627-9 2020 After multivariable adjustment, plasma copper was positively associated with serum CRP (FDR < 0.001), whereas selenium was negatively associated with serum CRP (FDR = 0.01). Selenium 113-121 C-reactive protein Homo sapiens 159-162 25916185-6 2015 In stratified analyses, the effect of As exposure on CRP was observed only in participants having EhGSH > median (uAs p(Wald) = 0.03; bAs p(Wald) = 0.05). Phenindione 117-120 C-reactive protein Homo sapiens 53-56 31926627-10 2020 Moreover, selenium and zinc attenuated the positive association between high plasma copper and CRP (P for interaction < 0.001). Selenium 10-18 C-reactive protein Homo sapiens 95-98 31926627-13 2020 CONCLUSIONS: Our results suggest that serum CRP is positively associated with plasma concentration of copper, and inversely associated with selenium. Selenium 140-148 C-reactive protein Homo sapiens 44-47 26193292-7 2015 Age, physical inactivity, abdominal obesity, a low LDL level, an elevated fasting glucose level, uric acid and urinary albumin to creatinine ratio (ACR) were correlated with log-CRP. Uric Acid 97-106 C-reactive protein Homo sapiens 178-181 31926627-14 2020 Plasma zinc, selenium and CRP genetic predisposition would modify the associations between plasma copper and serum CRP. Selenium 13-21 C-reactive protein Homo sapiens 115-118 26193292-10 2015 CONCLUSION: Age, physical inactivity, abdominal obesity, a low LDL level, an elevated fasting glucose level, uric acid and ACR are correlated with log-CRP. Uric Acid 109-118 C-reactive protein Homo sapiens 151-154 26159541-6 2015 METHODS: We applied an extended multilevel approach to a large cross-sectional study aimed to elucidate the hypothesized link between drinking water pollution from perfluoroctanoic acid (PFOA) and plasma levels of C-reactive protein (CRP) or lymphocyte counts. perfluorooctanoic acid 164-185 C-reactive protein Homo sapiens 214-232 31208925-7 2019 The CRP concentrations decreased more than 50% in all pediatric patients after the treatment with linezolid, however body temperatures at the end of treatment were higher than 37.5 C in 6 patients (42.9%). Linezolid 98-107 C-reactive protein Homo sapiens 4-7 26159541-6 2015 METHODS: We applied an extended multilevel approach to a large cross-sectional study aimed to elucidate the hypothesized link between drinking water pollution from perfluoroctanoic acid (PFOA) and plasma levels of C-reactive protein (CRP) or lymphocyte counts. perfluorooctanoic acid 164-185 C-reactive protein Homo sapiens 234-237 26159541-6 2015 METHODS: We applied an extended multilevel approach to a large cross-sectional study aimed to elucidate the hypothesized link between drinking water pollution from perfluoroctanoic acid (PFOA) and plasma levels of C-reactive protein (CRP) or lymphocyte counts. perfluorooctanoic acid 187-191 C-reactive protein Homo sapiens 214-232 26159541-6 2015 METHODS: We applied an extended multilevel approach to a large cross-sectional study aimed to elucidate the hypothesized link between drinking water pollution from perfluoroctanoic acid (PFOA) and plasma levels of C-reactive protein (CRP) or lymphocyte counts. perfluorooctanoic acid 187-191 C-reactive protein Homo sapiens 234-237 26159541-10 2015 In contrast, for CRP we found consistent between- and within-group effects, which corroborates the causal claim for the association between PFOA blood levels and CRP. perfluorooctanoic acid 140-144 C-reactive protein Homo sapiens 17-20 31572463-6 2019 Results: The 34 young healthy individuals who were assigned to the B-MeS group had lower fat-free mass, higher body mass index, waist-to-hip ratio, fat mass, and blood pressure, more visceral fat, they were less physically active, had higher C-reactive protein values and higher catalase activity. Sulfur 67-72 C-reactive protein Homo sapiens 242-260 30633345-8 2019 NAC, TTFA, DPI, inhibitors of ERK1/2, p38, and NF-kappaB all downregulated FPA-induced CRP expression. diphenyleneiodonium 11-14 C-reactive protein Homo sapiens 87-90 26159541-10 2015 In contrast, for CRP we found consistent between- and within-group effects, which corroborates the causal claim for the association between PFOA blood levels and CRP. perfluorooctanoic acid 140-144 C-reactive protein Homo sapiens 162-165 25770689-2 2015 Herein, we aimed to assess the relationship between serum total bilirubin level and severity of coronary artery disease (CAD) in association with the direct inflammatory marker such as C-reactive protein (CRP), the other indirect markers included in inflammation process such as neutrophil to lymphocyte ratio (NLR) and red cell distribution width (RDW) in patients with stable CAD. Bilirubin 64-73 C-reactive protein Homo sapiens 185-203 31059781-7 2019 Regression analysis showed that CRP and leptin levels explained ~25% and ~15% of the variance in central CO2 response, while 2-AG explained ~42% of the variance in peripheral response to hypoxia. Carbon Dioxide 105-108 C-reactive protein Homo sapiens 32-35 31060888-4 2019 At the molecular level, cirsiliol suppressed the expression of IL-6-induced inflammatory marker genes such as CRP, IL-1beta, ICAM-1 and SOCS3, IL-6-induced activation of Jak2, gp130, STAT3 and ERK and nuclear translocation of STAT3, as measured by PCR, immunofluorescence staining and western blot analysis. cirsiliol 24-33 C-reactive protein Homo sapiens 110-113 31248116-4 2019 The applicability of these electrode chips in bioaffinity assays was demonstrated by an immunoassay of human C-reactive protein (i) using Tb(III) chelate label displaying long-lived hot electron-induced electrochemiluminescence (HECL) and (ii) now for the first time fluorescein isothiocyanate (FITC) was utilized as an a low-cost organic label displaying a short-lived HECL in a real-world bioaffinity assay. Terbium 138-140 C-reactive protein Homo sapiens 109-127 25770689-2 2015 Herein, we aimed to assess the relationship between serum total bilirubin level and severity of coronary artery disease (CAD) in association with the direct inflammatory marker such as C-reactive protein (CRP), the other indirect markers included in inflammation process such as neutrophil to lymphocyte ratio (NLR) and red cell distribution width (RDW) in patients with stable CAD. Bilirubin 64-73 C-reactive protein Homo sapiens 205-208 25770689-8 2015 Futhermore, there was a moderate and significant inverse correlation between serum total bilirubin level and the severity of CAD (r=-0.173, p<0.001), CRP (r=-0.112, p<0.001), NLR (r=-0.070, p=0.026) and RDW (r=-0.074, p=0.027). Bilirubin 89-98 C-reactive protein Homo sapiens 153-156 25770689-10 2015 In addition, total bilirubin level was inversely correlated with CRP, NLR and RDW. Bilirubin 19-28 C-reactive protein Homo sapiens 65-68 24803523-10 2015 In addition, the CRP levels on postoperative day 1 were lower in the esmolol-treated groups, in a dose-dependent manner. esmolol 69-76 C-reactive protein Homo sapiens 17-20 30309781-10 2019 RESULTS: SAF was higher in malnourished participants and correlated negatively with serum albumin and cholesterol, HGS and energy, protein and fat intake and positively with C-reactive protein and chronological age; SAF did not correlate with dietary AGE intake. Safflower Oil 9-12 C-reactive protein Homo sapiens 174-192 29370415-8 2019 For AL responders, typical biomarker profiles were high initially but rapidly decreased for CRP and Hp post antifungal therapy, while low initial ANXA1 values were restored to normal levels after treatment. Aluminum 4-6 C-reactive protein Homo sapiens 92-102 24803523-12 2015 Treatment with esmolol decreased the inflammatory response and CRP production in a dose-dependent manner. esmolol 15-22 C-reactive protein Homo sapiens 63-66 30257125-1 2018 Exposures to occupationally relevant ultrafine, zinc- and copper-containing welding fumes cause inflammatory responses involving systemic IL-6, C-reactive protein (CRP) and serum amyloid A (SAA), all associated with elevated risk of cardiovascular events. ultrafine 37-46 C-reactive protein Homo sapiens 144-162 30257125-1 2018 Exposures to occupationally relevant ultrafine, zinc- and copper-containing welding fumes cause inflammatory responses involving systemic IL-6, C-reactive protein (CRP) and serum amyloid A (SAA), all associated with elevated risk of cardiovascular events. ultrafine 37-46 C-reactive protein Homo sapiens 164-167 26113950-12 2015 This study also reports a significant association between CRP and systolic blood pressure, diastolic blood pressure, uric acid AST and ALP (p. CONCLUSION: The inflammatory cytokines, IL6, TNF alpha and CRP are elevated in severe preeclampsia and may mediate some of the clinical manifestations of the disorder. Uric Acid 117-126 C-reactive protein Homo sapiens 58-61 30051214-9 2018 The serum IL-6 and CRP levels were inversely correlated with the plasma concentration ratios of N-desmethyltramadol to tramadol and of N,O-didesmethyltramadol to O-desmethyltramadol. O-demethyltramadol 162-181 C-reactive protein Homo sapiens 19-22 27122858-1 2015 BACKGROUND: In this study, we aimed to evaluate the effects of niacin on high sensitivity C reactive protein (hs-CRP) and cholesterol levels in non-ST elevated acute coronary syndrome (NSTE-ACS) patients. Niacin 63-69 C-reactive protein Homo sapiens 90-108 29803716-11 2018 For CRP, a significant small to medium effect was observed with probiotics (-0.43 mg/L), ARBs (-0.2 mg/L), omega-3 (-0.17 mg/L) and metformin (-0.16 mg/L). omega-3 107-114 C-reactive protein Homo sapiens 4-7 25864742-3 2015 The aim of this study was to (i) examine the influence of treadmill exercise test (TET) on serum C-reactive protein (CRP) and interleukin-6 (IL-6), and (ii) the influence of three-month trimetazidine therapy on serum CRP and IL-6 concentrations. tet 83-86 C-reactive protein Homo sapiens 97-115 29847333-8 2018 In another cohort of 749 patients presenting with at least one TB-related symptom and clinically evaluated, CRP had a sensitivity of 98.7% and specificity of 48.3%. Terbium 63-65 C-reactive protein Homo sapiens 108-111 29847333-10 2018 Use of CRP as a screening tool to exclude active TB could identify the same number of HIV-associated TB cases, but reduce the use of diagnostic sputum testing in TB-endemic regions. Terbium 49-51 C-reactive protein Homo sapiens 7-10 25864742-3 2015 The aim of this study was to (i) examine the influence of treadmill exercise test (TET) on serum C-reactive protein (CRP) and interleukin-6 (IL-6), and (ii) the influence of three-month trimetazidine therapy on serum CRP and IL-6 concentrations. tet 83-86 C-reactive protein Homo sapiens 117-120 25237581-1 2014 BACKGROUND: Multiple population-based human studies have established a strong association between increasing levels of serum C-reactive protein, uric acid and subsequent development of hypertension. Uric Acid 145-154 C-reactive protein Homo sapiens 125-143 29753588-0 2018 Effects of alpha-lipoic acid supplementation on C-reactive protein level: A systematic review and meta-analysis of randomized controlled clinical trials. Thioctic Acid 11-28 C-reactive protein Homo sapiens 48-66 29753588-1 2018 BACKGROUND AND AIM: The aim of this meta-analysis was to assess effects of alpha-lipoic acid supplementation on C-reactive protein (CRP) levels in clinical trial studies. Thioctic Acid 75-92 C-reactive protein Homo sapiens 112-130 29753588-1 2018 BACKGROUND AND AIM: The aim of this meta-analysis was to assess effects of alpha-lipoic acid supplementation on C-reactive protein (CRP) levels in clinical trial studies. Thioctic Acid 75-92 C-reactive protein Homo sapiens 132-135 24696418-0 2014 Bilirubin levels and their association with carotid intima media thickness and high-sensitivity C-reactive protein in patients with psoriasis vulgaris. Bilirubin 0-9 C-reactive protein Homo sapiens 96-114 29753588-4 2018 Estimated pooled random effects size analysis showed a significant reducing effect of alpha-lipoic acid supplementation on CRP level (-0.72 mg/l, 95% CI; -1.4, -0.04; P = 0.03) with a significant heterogeneity between the selected studies. Thioctic Acid 86-103 C-reactive protein Homo sapiens 123-126 29753588-5 2018 Sub-group analysis showed that alpha-lipoic acid supplementation could significantly reduce serum CRP level when the baseline CRP level was greater than 3 mg/l (-1.02 mg/l, 95% CI: -1.3, -0.73) and when trial duration was >8 weeks (-0.99 mg/l, 95% CI: -1.29, -0.70). Thioctic Acid 31-48 C-reactive protein Homo sapiens 98-101 29753588-5 2018 Sub-group analysis showed that alpha-lipoic acid supplementation could significantly reduce serum CRP level when the baseline CRP level was greater than 3 mg/l (-1.02 mg/l, 95% CI: -1.3, -0.73) and when trial duration was >8 weeks (-0.99 mg/l, 95% CI: -1.29, -0.70). Thioctic Acid 31-48 C-reactive protein Homo sapiens 126-129 29753588-6 2018 Results of subgroup analysis also showed that alpha lipoic acid supplementation could decrease CRP level only in non-diabetic patients (-1.02 mg/l, 95% CI: -1.31, -0.74). Thioctic Acid 46-63 C-reactive protein Homo sapiens 95-98 29753588-7 2018 CONCLUSIONS: Results of the current meta-analysis study showed that alpha-lipoic acid supplementation could significantly decrease CRP level in patients with elevated levels of this inflammatory marker. Thioctic Acid 68-85 C-reactive protein Homo sapiens 131-134 29659888-13 2018 Trends toward decreases in interleukin-6 (P = 0.10) and high-sensitivity C-reactive protein (P = 0.10) were also seen with eplerenone vs placebo. Eplerenone 123-133 C-reactive protein Homo sapiens 73-91 24442509-7 2014 CONCLUSIONS/INTERPRETATION: The minor rs1183910 A allele prompts a potential adverse metabolic profile with increased levels of non-fasting glucose, total cholesterol, LDL-cholesterol, ApoB, and alkaline phosphatase, but simultaneously has potential beneficial effects through decreased levels of CRP, gamma-glutamyltransferase and bilirubin. Bilirubin 332-341 C-reactive protein Homo sapiens 297-300 29554718-8 2018 Results: The taurolidine irrigation group had a significantly lower CRP (5.39 mg/dL vs. 7.55 mg/dL; p<0.001) and ESR (53.21 mm/hr vs. 58.74 mm/hr; p=0.003) on postoperative day 3 after TKA, as compared with the control group. taurolidine 13-24 C-reactive protein Homo sapiens 68-71 24184736-10 2014 There was a significant inverse relationship between plasma concentrations of CZP and baseline levels of C-reactive protein and body weight (P = .0014 and P = .0373, respectively). Certolizumab Pegol 78-81 C-reactive protein Homo sapiens 105-123 29435630-11 2018 Multivariate analysis showed correlations between AL and both local disease activity and serological findings such as serum C-reactive protein (CRP) and immunoglobulin (Ig) G. CONCLUSION: AL in patients with RA was correlated with local arthritis activity, as well as background characteristics and systemic disease activity. Aluminum 50-52 C-reactive protein Homo sapiens 124-142 29435630-11 2018 Multivariate analysis showed correlations between AL and both local disease activity and serological findings such as serum C-reactive protein (CRP) and immunoglobulin (Ig) G. CONCLUSION: AL in patients with RA was correlated with local arthritis activity, as well as background characteristics and systemic disease activity. Aluminum 50-52 C-reactive protein Homo sapiens 144-147 29435630-11 2018 Multivariate analysis showed correlations between AL and both local disease activity and serological findings such as serum C-reactive protein (CRP) and immunoglobulin (Ig) G. CONCLUSION: AL in patients with RA was correlated with local arthritis activity, as well as background characteristics and systemic disease activity. Aluminum 188-190 C-reactive protein Homo sapiens 124-142 29435630-11 2018 Multivariate analysis showed correlations between AL and both local disease activity and serological findings such as serum C-reactive protein (CRP) and immunoglobulin (Ig) G. CONCLUSION: AL in patients with RA was correlated with local arthritis activity, as well as background characteristics and systemic disease activity. Aluminum 188-190 C-reactive protein Homo sapiens 144-147 24131677-9 2013 Subjects with a history of smoking or coronary revascularization had significantly higher CRP levels, while subjects treated with sevelamer hydrochloride had significantly lower CRP. Sevelamer 130-153 C-reactive protein Homo sapiens 178-181 24131677-12 2013 Treatment with sevelamer hydrochloride is associated with lower CRP in HD patients. Sevelamer 15-38 C-reactive protein Homo sapiens 64-67 29772762-9 2018 In humans, chloroquine treatment did not affect viremia or clinical parameters during the acute stage of the disease (D1 to D14), but affected the levels of C-reactive Protein (CRP), IFNalpha, IL-6, and MCP1 over time (D1 to D16). Chloroquine 11-22 C-reactive protein Homo sapiens 157-175 29772762-9 2018 In humans, chloroquine treatment did not affect viremia or clinical parameters during the acute stage of the disease (D1 to D14), but affected the levels of C-reactive Protein (CRP), IFNalpha, IL-6, and MCP1 over time (D1 to D16). Chloroquine 11-22 C-reactive protein Homo sapiens 177-180 24369322-8 2013 C reactive protein (CRP) level was markedly reduced in the BehSpA group vs. the other SpA group (2.08 and 14.02 mg/L, respectively; p = 0.053). behspa 59-65 C-reactive protein Homo sapiens 0-18 29601504-4 2018 The measurement relies on the decrease of the oxidation current of the redox indicator Fe3+/Fe2+, resulting from the immunoreaction between CRP and anti-CRP. ferric sulfate 87-91 C-reactive protein Homo sapiens 140-143 29601504-4 2018 The measurement relies on the decrease of the oxidation current of the redox indicator Fe3+/Fe2+, resulting from the immunoreaction between CRP and anti-CRP. ferric sulfate 87-91 C-reactive protein Homo sapiens 153-156 29796304-1 2018 Aim: An electrochemical urine dipstick probe biosensor has been demonstrated using molybdenum electrodes on nanoporous polyamide substrate for the quantitative detection of two inflammatory protein biomarkers, CRP and IL-6. Nylons 119-128 C-reactive protein Homo sapiens 210-213 28462631-11 2018 KEY MESSAGES Serum high-sensitivity C-reactive protein (hsCRP) concentration is positively associated with sugar intake, and negatively with the consumption of minerals, vitamins and polyunsaturated fatty-acids (fruit and vegetables). Sugars 107-112 C-reactive protein Homo sapiens 36-54 24369322-8 2013 C reactive protein (CRP) level was markedly reduced in the BehSpA group vs. the other SpA group (2.08 and 14.02 mg/L, respectively; p = 0.053). behspa 59-65 C-reactive protein Homo sapiens 20-23 29172154-5 2018 CRP recognized 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-l-serine (POPS) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1"-rac-glycerol) (POPG) in the supported POPC monolayers without calcium at pH 7.4 and 5.5. 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1"-rac-glycerol) 77-136 C-reactive protein Homo sapiens 0-3 24209691-0 2013 High sensitive C-reactive protein and serum amyloid A are inversely related to serum bilirubin: effect-modification by metabolic syndrome. Bilirubin 85-94 C-reactive protein Homo sapiens 15-33 28556504-1 2017 AIM: To undertake a systematic review and meta-analysis of prospective studies to determine the effect of conjugated linoleic acids (CLAs) supplementation on serum C-reactive protein (CRP). Linoleic Acids 117-131 C-reactive protein Homo sapiens 164-182 28556504-1 2017 AIM: To undertake a systematic review and meta-analysis of prospective studies to determine the effect of conjugated linoleic acids (CLAs) supplementation on serum C-reactive protein (CRP). Linoleic Acids 117-131 C-reactive protein Homo sapiens 184-187 24209691-4 2013 We determined relationships of high sensitive C-reactive protein (hs-CRP) and SAA with bilirubin in subjects with and without metabolic syndrome (MetS). Bilirubin 87-96 C-reactive protein Homo sapiens 46-64 23722054-5 2013 In cross-sectional analyses, MR-proADM was independently related to current smoking, renal dysfunction, obesity, lower left-ventricular ejection fraction, and higher levels of N-terminal pro-B-type natriuretic peptide and C-reactive protein. mr-proadm 29-38 C-reactive protein Homo sapiens 222-240 29285227-10 2017 Results: Compared with the control group, the trimetazidine group had a lower frequency of patients with post-PCI serum CK-MB and cTnI levels higher than normal values; the trimetazidine group had also significantly lower serum hs-CRP and TNF-alpha levels, and higher IL-10 levels post-PCI. Trimetazidine 46-59 C-reactive protein Homo sapiens 231-234 29285227-10 2017 Results: Compared with the control group, the trimetazidine group had a lower frequency of patients with post-PCI serum CK-MB and cTnI levels higher than normal values; the trimetazidine group had also significantly lower serum hs-CRP and TNF-alpha levels, and higher IL-10 levels post-PCI. Trimetazidine 173-186 C-reactive protein Homo sapiens 231-234 23538053-8 2013 CRP also markedly improved risk stratification of patients with ADHF as a dual biomarker combination with MR-proADM (NRI 36.8% [p<0.001] for death at 30 days) or with sST2 (NRI 20.3%; [p<0.001] for one-year mortality). adhf 64-68 C-reactive protein Homo sapiens 0-3 27448501-6 2017 The assessment of predictive factors for response to tolvaptan showed that serum creatinine and C-reactive protein levels were important predictors of initial response, and that hepatic conditions, such as the Child-Pugh score or presence of hepatocellular carcinoma, as well as initial response, were significant predictors of long-term response. Tolvaptan 53-62 C-reactive protein Homo sapiens 96-114 27738972-4 2017 RESULTS: SES interacted with conscientiousness to predict levels of IL-6 (interaction b = .03, p = .002) and CRP (interaction b = .04, p = .014) and with neuroticism to predict IL-6 (interaction b = -.03, p = .004). Selenium 9-12 C-reactive protein Homo sapiens 109-112 23538053-8 2013 CRP also markedly improved risk stratification of patients with ADHF as a dual biomarker combination with MR-proADM (NRI 36.8% [p<0.001] for death at 30 days) or with sST2 (NRI 20.3%; [p<0.001] for one-year mortality). mr-proadm 106-115 C-reactive protein Homo sapiens 0-3 27444965-2 2017 We hypothesized that greater PA would buffer against the influence of perceived psychological stress (PPS) on systemic inflammation, operationalized as C-reactive protein (CRP, mg/L). Protactinium 29-31 C-reactive protein Homo sapiens 152-170 24325097-0 2013 [Oxidative mechanism of uric acid induced CRP expression in human umbilical vein endothelial cells]. Uric Acid 24-33 C-reactive protein Homo sapiens 42-45 27444965-2 2017 We hypothesized that greater PA would buffer against the influence of perceived psychological stress (PPS) on systemic inflammation, operationalized as C-reactive protein (CRP, mg/L). Protactinium 29-31 C-reactive protein Homo sapiens 172-175 27444965-3 2017 Specifically, we predicted that PA would moderate the relationship between PPS and CRP. Protactinium 32-34 C-reactive protein Homo sapiens 83-86 24325097-1 2013 OBJECTIVE: To explore the oxidative mechanism of uric acid (UA) induced CRP expression in human umbilical vein endothelial cells. Uric Acid 49-58 C-reactive protein Homo sapiens 72-75 27444965-6 2017 Using a moderated hierarchical regression analysis, PPS and PA significantly interacted to predict levels of CRP (p<0.05). Protactinium 60-62 C-reactive protein Homo sapiens 109-112 27444965-7 2017 Examination of the simple slopes revealed a disordinal interaction between PPS and PA, such that higher PA was protective against elevated CRP levels, but only when individuals also reported greater levels of PPS. Protactinium 83-85 C-reactive protein Homo sapiens 139-142 24325097-1 2013 OBJECTIVE: To explore the oxidative mechanism of uric acid (UA) induced CRP expression in human umbilical vein endothelial cells. Uric Acid 60-62 C-reactive protein Homo sapiens 72-75 27444965-7 2017 Examination of the simple slopes revealed a disordinal interaction between PPS and PA, such that higher PA was protective against elevated CRP levels, but only when individuals also reported greater levels of PPS. Protactinium 104-106 C-reactive protein Homo sapiens 139-142 27444965-9 2017 Findings also provide caution of future assumptions that relationships among PA, PPS, and physical health markers, such as CRP, are always positive (e.g., PA) or negative (e.g., PPS) in nature. Protactinium 77-79 C-reactive protein Homo sapiens 123-126 24325097-5 2013 The effects of N-acetyl cysteine (NAC) on UA-induced levels of ROS, mRNA and protein of CRP in HUVECs were also observed. Uric Acid 42-44 C-reactive protein Homo sapiens 88-91 24325097-6 2013 RESULTS: The results demonstrated that UA could significantly increase the mRNA and protein expression of CRP in HUVECs in time- and concentration-dependent manners. Uric Acid 39-41 C-reactive protein Homo sapiens 106-109 24325097-7 2013 HUVECs were stimulated with 12 mg/dL UA at 6 h, mRNA and protein levels of CRP significantly higher than that of control level (P<0.05), reached a peak at 12 h (P<0. Uric Acid 37-39 C-reactive protein Homo sapiens 75-78 24325097-9 2013 NAC reduced UA-induced levels of ROS, mRNA and protein of CRP in HUVECs compared with those of 12 mg/dL UA induced group(P<0. Uric Acid 12-14 C-reactive protein Homo sapiens 58-61 24325097-11 2013 CONCLUSION: Uric acid significantly increased mRNA and protein expression of CRP in HUVECs in time- and concentration-dependent manners. Uric Acid 12-21 C-reactive protein Homo sapiens 77-80 23924494-14 2013 The serum beta-amyloid protein and C-reactive protein concentrations were significantly increased at 24 hours after surgery in the POCD group. pocd 131-135 C-reactive protein Homo sapiens 35-53 27488221-4 2017 After ET administration, some decreasing trends were seen in biomarkers of oxidative damage and inflammation, including allantoin (urate oxidation), 8-hydroxy-2"-deoxyguanosine (DNA damage), 8-iso-PGF2alpha (lipid peroxidation), protein carbonylation, and C-reactive protein. Ergothioneine 6-8 C-reactive protein Homo sapiens 256-274 23053500-6 2013 The patient was initially treated with meropenem followed by fluoroquinolones for 3 weeks; however, her C-reactive protein level was high (10-20 mg/dL) even after the antimicrobial therapy. Fluoroquinolones 61-77 C-reactive protein Homo sapiens 104-122 27864148-0 2017 Three pentraxins C-reactive protein, serum amyloid p component and pentraxin 3 mediate complement activation using Collectin CL-P1. cl-p1 125-130 C-reactive protein Homo sapiens 17-35 27928713-10 2017 At 10-day follow-up, improvement in redness, edema, and CRP levels from baseline was also greater in patients treated with Betesil compared with diclofenac (all p < 0.01). betesil 123-130 C-reactive protein Homo sapiens 56-59 27815167-6 2017 Docking analysis predicted a new binding site for LPC in the absence of calcium ions, which is located on the opposite side of the known binding site for PC of cyclic pentameric CRP. pc 51-53 C-reactive protein Homo sapiens 178-181 23574727-7 2013 Amongst the EF and pro-inflammatory biomarkers, sevelamer carbonate decreased serum endothelin-1, plasminogen activator inhibitor-1, C-reactive protein and interleukin-6. Sevelamer 48-67 C-reactive protein Homo sapiens 133-151 28166841-10 2017 The overall associations between DII and ADII and long-term CRP were not statistically significant (P trend across tertiles=0 16 for DII and 0 10 for ADII). adii 41-45 C-reactive protein Homo sapiens 60-63 24082508-8 2013 ESR, Cp, and CRP increased significantly (P < 0.001) by 145, 28.7, and 42.5% in TUs and by 164, 50.5, and 74.3% in CPs, respectively, relative to control. cps 118-121 C-reactive protein Homo sapiens 13-16 27099336-7 2016 Comparison of trace elements between the four groups showed no difference in zinc and copper (both P > 0.05), whereas selenium and albumin were lower in the group with C-reactive protein > 40 mg/L ( P < 0.05). Selenium 121-129 C-reactive protein Homo sapiens 171-189 27099336-8 2016 Conclusion In patients on short-term parenteral nutrition, measurement of C-reactive protein is essential when interpreting zinc and selenium but not copper results. Selenium 133-141 C-reactive protein Homo sapiens 74-92 23380098-0 2013 Myeloperoxidase and C-reactive protein in patients with cocaine-associated chest pain. Cocaine 56-63 C-reactive protein Homo sapiens 20-38 27703393-8 2016 RESULTS: Elevation of CRP stress response was lower in the KET group and significantly different (P<=0.05) from that in the NS group. ket 59-62 C-reactive protein Homo sapiens 22-25 24695939-10 2013 CONCLUSION: Serum alanine aminotransferase, thioredoxin, and high-sensitivity C-reactive protein levels, and liver histology were clearly improved with vitamin C and E therapy. Ascorbic Acid 152-161 C-reactive protein Homo sapiens 78-96 26267328-8 2016 Additionally, patients who received selenium supplements had significantly decreased serum dehydroepiandrosterone (DHEA) levels (p=0.02), hirsutism (modified Ferriman-Gallwey scores) (p<0.001), serum high sensitivity C-reactive protein (hs-CRP) (p=0.02), and plasma malondialdehyde (MDA) levels (p=0.01) compared with placebo. Selenium 36-44 C-reactive protein Homo sapiens 220-238 23246421-9 2013 Multivariate analysis showed that CRP (odd ratio (OR)=3.0, 95% confidence interval (CI)=2.6-4.2, P=0.01 and serum vitamin D levels <30ng/ml OR=2.6, 95% CI=2.4-3.2, P=0.02 were associated with PFAPA. pfapa 195-200 C-reactive protein Homo sapiens 34-37 26199009-5 2016 RESULTS: Patients who had received PTX surgery were more likely to be older, have longer duration of dialysis, higher ultrafiltration rate, C-reactive protein (CRP), alkaline phosphatase (ALP), and lower albumin compared with those who had not receive PTX. ptx 35-38 C-reactive protein Homo sapiens 140-158 26199009-5 2016 RESULTS: Patients who had received PTX surgery were more likely to be older, have longer duration of dialysis, higher ultrafiltration rate, C-reactive protein (CRP), alkaline phosphatase (ALP), and lower albumin compared with those who had not receive PTX. ptx 35-38 C-reactive protein Homo sapiens 160-163 27904038-8 2016 Univariate and multiple logistic regression analyses identified the plasma C-reactive protein (CRP) level before the initial administration of linezolid and the concomitant use of a potassium-sparing diuretic as the independent variables associated with the development of hyponatremia. Linezolid 143-152 C-reactive protein Homo sapiens 75-93 27904038-8 2016 Univariate and multiple logistic regression analyses identified the plasma C-reactive protein (CRP) level before the initial administration of linezolid and the concomitant use of a potassium-sparing diuretic as the independent variables associated with the development of hyponatremia. Linezolid 143-152 C-reactive protein Homo sapiens 95-98 23351824-6 2013 Baseline eicosapentaenoic acid (EPA) but not docosahexaenoic acid (DHA) was inversely related to C-reactive protein, pentraxin-3, adiponectin, natriuretic peptide, and troponin levels. Eicosapentaenoic Acid 32-35 C-reactive protein Homo sapiens 97-115 26631004-0 2015 C-Reactive protein reactions to glucose-insulin-potassium infusion and relations to infarct size in patients with acute coronary syndromes. Potassium 48-57 C-reactive protein Homo sapiens 0-18 23013513-0 2013 Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein. Simvastatin 11-22 C-reactive protein Homo sapiens 75-93 27747720-4 2015 He was diagnosed with severe ILD; rituximab was discontinued, and treatment with fluticasone combined with salmeterol, methylprednisolone, and omeprazole was started, with an improvement of symptoms over 15 days with normalization in CRP at 30 days. Fluticasone 81-92 C-reactive protein Homo sapiens 234-237 26265215-0 2015 Nanomolar aluminum induces expression of the inflammatory systemic biomarker C-reactive protein (CRP) in human brain microvessel endothelial cells (hBMECs). Aluminum 10-18 C-reactive protein Homo sapiens 77-95 26265215-0 2015 Nanomolar aluminum induces expression of the inflammatory systemic biomarker C-reactive protein (CRP) in human brain microvessel endothelial cells (hBMECs). Aluminum 10-18 C-reactive protein Homo sapiens 97-100 23311699-17 2013 CONCLUSIONS: The main factors associated with UA increase were altered BMI (overweight and obesity), muscle hypotrophy (MMI), higher levels of urea, triglycerides, and CRP. Uric Acid 46-48 C-reactive protein Homo sapiens 168-171 26265215-6 2015 The three major findings in this short communication are: (i) that CRP is up-regulated in AD serum; (ii) that CRP serum levels increased in parallel with AD progression; and (iii) for the first time show that nanomolar aluminum potently up-regulates CRP expression in hBMECs to many times its "basal abundance". Aluminum 219-227 C-reactive protein Homo sapiens 67-70 26265215-6 2015 The three major findings in this short communication are: (i) that CRP is up-regulated in AD serum; (ii) that CRP serum levels increased in parallel with AD progression; and (iii) for the first time show that nanomolar aluminum potently up-regulates CRP expression in hBMECs to many times its "basal abundance". Aluminum 219-227 C-reactive protein Homo sapiens 110-113 26265215-6 2015 The three major findings in this short communication are: (i) that CRP is up-regulated in AD serum; (ii) that CRP serum levels increased in parallel with AD progression; and (iii) for the first time show that nanomolar aluminum potently up-regulates CRP expression in hBMECs to many times its "basal abundance". Aluminum 219-227 C-reactive protein Homo sapiens 110-113 26265215-7 2015 The results suggest that aluminum-induced CRP may in part contribute to a pathophysiological state associated with a chronic systemic inflammation of the human vasculature. Aluminum 25-33 C-reactive protein Homo sapiens 42-45 25895432-1 2015 The aim of the present study was to examine the association between intake of five common antioxidative nutrients from supplements and medications (vitamin E, vitamin C, carotenoids, Se, and Zn) and levels of high-sensitivity C-reactive protein (hs-CRP) in the general population. Selenium 183-185 C-reactive protein Homo sapiens 226-244 25899092-8 2015 Similarly, intake of n-6 PUFAs was inversely related to CRP (fourth quartile vs. first: beta = -0.09, 95% confidence interval: -0.16, -0.01). n-6 pufas 21-30 C-reactive protein Homo sapiens 56-59 23819120-5 2013 Patients who showed an increased silver concentration in the blood postoperatively presented a lower silver concentration in the wound fluids and a delayed decrease in C-reactive protein levels. Silver 33-39 C-reactive protein Homo sapiens 168-186 24167354-7 2013 C-Reactive Protein (CRP) was negatively correlated with lauric acid (P = 0.048), and both CRP and CRP/Albumin ratio were negatively correlated with margaric acid (P = 0.010, P = 0.008, resp.). margaric acid 148-161 C-reactive protein Homo sapiens 90-93 26125767-9 2015 We found a positive correlation between IL-6, TNF-alpha, YKL-40, and CRP levels 48 h after CBP treatment. 4,4'-Bis(N-carbazolyl)-1,1'-biphenyl 91-94 C-reactive protein Homo sapiens 69-72 24167354-7 2013 C-Reactive Protein (CRP) was negatively correlated with lauric acid (P = 0.048), and both CRP and CRP/Albumin ratio were negatively correlated with margaric acid (P = 0.010, P = 0.008, resp.). margaric acid 148-161 C-reactive protein Homo sapiens 90-93 24167365-2 2013 This study aimed to test two hypotheses: (1) serum 25-hydroxyvitamin D [25(OH)D] is inversely associated with type 2 diabetes mellitus (T2DM) and elevated hemoglobin A1c; (2) these associations are mediated by serum C-reactive protein (CRP). 25-hydroxyvitamin D 51-70 C-reactive protein Homo sapiens 216-234 25413674-8 2015 GBS induced a massive weight and fat mass loss, improved insulin sensitivity and lipid profile, decreased C-reactive protein, leptin, and CCL2 levels. gbs 0-3 C-reactive protein Homo sapiens 106-124 24167365-2 2013 This study aimed to test two hypotheses: (1) serum 25-hydroxyvitamin D [25(OH)D] is inversely associated with type 2 diabetes mellitus (T2DM) and elevated hemoglobin A1c; (2) these associations are mediated by serum C-reactive protein (CRP). 25-hydroxyvitamin D 51-70 C-reactive protein Homo sapiens 236-239 22573476-8 2013 Intensified lipid-lowering therapy with RSV/EZT was associated with a greater decrease in low-density lipoprotein cholesterol levels compared with RSV (75.87 +- 31.64 vs 87.19 +- 31.7, P = .004), while no differential effect on triglyceride, high-density lipoprotein cholesterol or high-sensitivity C-reactive protein levels was noted between groups. EZT 44-47 C-reactive protein Homo sapiens 299-317 23282120-7 2013 Serum high-sensitivity C-reactive protein levels were also significantly higher in the nondipper group than the other groups (P<.001) and significantly correlated with serum UA (r=0.358, P<.001). Uric Acid 177-179 C-reactive protein Homo sapiens 23-41 24408035-9 2015 Patients treated with parenteral omega-3 were associated with a significant reduction in new organ dysfunction (Delta-SOFA 2.2 +- 2.2 vs. 1.0 +- 1.5, P = .005 and maximum-SOFA 10.1 +- 4.2 vs. 8.1 +- 3.2, P = .041) and maximum CRP (186.7 +- 78 vs. 141.5 +- 62.6, P = .019). omega-3 33-40 C-reactive protein Homo sapiens 226-229 25451783-4 2015 To that purpose, we synthesized biotin-labeled peptides, corresponding to aggregation-determining sequences of the bacterial protein beta-galactosidase and two human disease biomarkers: C-reactive protein and prostate-specific antigen. Biotin 32-38 C-reactive protein Homo sapiens 186-204 23950601-4 2013 RESULTS: Ninety-day simvastatin treatment reduced lymphocyte release of TNF-alpha, interleukin-2 and interferon-gamma, which was accompanied by a decrease in plasma C-reactive protein. Simvastatin 20-31 C-reactive protein Homo sapiens 165-183 26652682-5 2015 We found that K2EDTA mean plasma concentrations of both IL-6 and CRP were not significantly different from concentrations in plasma processed immediately; this was observed for tubes stored up to 48 hours pre-processing at either temperature. k2edta 14-20 C-reactive protein Homo sapiens 65-68 23258737-4 2015 It investigated the possible relationship between inhalation exposure to Al fumes and levels of C-reactive protein (CRP) and alpha-1-antitrypsin (A1AT). Aluminum 73-75 C-reactive protein Homo sapiens 96-114 23258737-4 2015 It investigated the possible relationship between inhalation exposure to Al fumes and levels of C-reactive protein (CRP) and alpha-1-antitrypsin (A1AT). Aluminum 73-75 C-reactive protein Homo sapiens 116-119 23258737-17 2015 The study recommends the determination of CRP and A1AT in Al-exposed workers. Aluminum 58-60 C-reactive protein Homo sapiens 42-45 24261230-6 2013 RESULTS: The entire patient group showed a positive correlation between C-reactive protein (CRP) and serum uric acid (SUA) (r = 0.27; p < 0.01), suggesting that the nonspecific inflammatory processes were associated with uric acid levels in patients with HD. Uric Acid 107-116 C-reactive protein Homo sapiens 72-90 25401501-5 2014 In multivariable models, risk factors for serum selenium deficiency were country, previous tuberculosis, anemia, and elevated C-reactive protein. Selenium 48-56 C-reactive protein Homo sapiens 126-144 24261230-6 2013 RESULTS: The entire patient group showed a positive correlation between C-reactive protein (CRP) and serum uric acid (SUA) (r = 0.27; p < 0.01), suggesting that the nonspecific inflammatory processes were associated with uric acid levels in patients with HD. Uric Acid 107-116 C-reactive protein Homo sapiens 92-95 25280420-7 2014 Stearic acid was positively associated with CRP (35% increase; 95% CI, 2%-79%; P = 0.04). stearic acid 0-12 C-reactive protein Homo sapiens 44-47 23324149-9 2012 Independent risk factors for RMPP were febrile time, CRP, large consolidation area with high density in lungs with or without pleural effusion (OR = 1.586, P = 0.017; OR = 4.344, P = 0.001; OR = 2.660, P = 0.012), CT value 40 - 50 HU which were demonstrated by logistic regression analysis. rmpp 29-33 C-reactive protein Homo sapiens 53-56 25280420-10 2014 In particular, palmitic acid was associated with IL-6, and stearic acid was associated with CRP after multivariable adjustment. stearic acid 59-71 C-reactive protein Homo sapiens 92-95 24924751-7 2014 The uNGAL/Cr level was correlated with serum levels of white blood cells, C-reactive protein, CysC and with uKIM-1/Cr (P < 0.05). Chromium 10-12 C-reactive protein Homo sapiens 74-92 23324149-12 2012 CONCLUSION: The predictive factors for RMPP are febrile time (> 10 days), CRP (> 40 mg/L), large lobar consolidation with high density (> 2/3 pulmonary lobe, CT value > 40 HU with or without pleural effusion) for the purpose of treating earlier. rmpp 39-43 C-reactive protein Homo sapiens 77-80 23955082-0 2014 Inflammatory lipid sphingosine-1-phosphate upregulates C-reactive protein via C/EBPbeta and potentiates breast cancer progression. sphingosine 1-phosphate 19-42 C-reactive protein Homo sapiens 55-73 23091796-9 2012 Elevated CRP levels were associated with the highest risk for complicated appendicitis (hazard ratio [HR], 2.53; 95% confidence interval [CI], 1.38 to 4.65) followed by WBC (HR, 2.42; 95% CI, 1.07 to 5.46) and bilirubin (HR, 2.04; 95% CI, 1.09 to 3.82). Bilirubin 210-219 C-reactive protein Homo sapiens 9-12 22963460-2 2012 Inflammation and elevated C-reactive protein (CRP) are associated with poor prognosis and decreased survival in many types of cancer.Vitamin C has been suggested as having both a preventative and therapeutic role in a number of pathologies when administered at much higher-than-recommended dietary allowance levels.Since in vitro studies demonstrated inhibition of pro-inflammatory pathways by millimolar concentrations of vitamin C, we decided to analyze the effects of high dose IVC therapy in suppression of inflammation in cancer patients. Ascorbic Acid 133-142 C-reactive protein Homo sapiens 26-44 24732114-6 2014 Moreover, the results of the developed ELISA for the determination of CRP in the ethylenediaminetetraacetic acid plasma samples of patients are in good agreement with those obtained by the conventional ELISA. Edetic Acid 81-112 C-reactive protein Homo sapiens 70-73 22963460-2 2012 Inflammation and elevated C-reactive protein (CRP) are associated with poor prognosis and decreased survival in many types of cancer.Vitamin C has been suggested as having both a preventative and therapeutic role in a number of pathologies when administered at much higher-than-recommended dietary allowance levels.Since in vitro studies demonstrated inhibition of pro-inflammatory pathways by millimolar concentrations of vitamin C, we decided to analyze the effects of high dose IVC therapy in suppression of inflammation in cancer patients. Ascorbic Acid 133-142 C-reactive protein Homo sapiens 46-49 24886623-9 2014 RESULTS: Malnutrition and CRP were associated with low plasma selenium. Selenium 62-70 C-reactive protein Homo sapiens 26-29 22963460-7 2012 CONCLUSIONS: The high dose intravenous ascorbic acid therapy affects C-reactive protein levels and pro-inflammation cytokines in cancer patients. Ascorbic Acid 39-52 C-reactive protein Homo sapiens 69-87 24886623-11 2014 When CRP values were less than or equal to 40 mg/L, malnutrition was associated with low plasma selenium levels (odds ratio (OR) = 3.25, 95% confidence interval (CI) 1.39 to 7.63, P = 0.007; OR = 2.98, 95% CI 1.26 to 7.06, P = 0.013; OR = 2.49, 95% CI 1.01 to 6.17, P = 0.049, for CRP = 10, 20 and 40 mg/L, respectively). Selenium 96-104 C-reactive protein Homo sapiens 5-8 24886623-11 2014 When CRP values were less than or equal to 40 mg/L, malnutrition was associated with low plasma selenium levels (odds ratio (OR) = 3.25, 95% confidence interval (CI) 1.39 to 7.63, P = 0.007; OR = 2.98, 95% CI 1.26 to 7.06, P = 0.013; OR = 2.49, 95% CI 1.01 to 6.17, P = 0.049, for CRP = 10, 20 and 40 mg/L, respectively). Selenium 96-104 C-reactive protein Homo sapiens 281-284 22944235-12 2012 According to multivariate analyses, the predictors of CDAD included prior hospitalization (P < 0.01, OR = 0.002), CRP(P = 0.008, OR = 3.465), NSAID (P = 0.015, OR = 13.950) and WBC (P = 0.003, OR = 8.063). cdad 54-58 C-reactive protein Homo sapiens 117-120 24886623-13 2014 Similarly, the effect of CRP on low plasma selenium was significant for well-nourished patients (OR = 1.13; 95% CI 1.06 to 1.22, P <0.001) but not for the malnourished (OR = 1.03; 95% CI 0.99 to 1.08, P = 0.16). Selenium 43-51 C-reactive protein Homo sapiens 25-28 24797235-8 2014 CONCLUSIONS: TMZ treatment in CHF patients may improve clinical symptoms and cardiac function, reduce hospitalization for cardiac causes, and decrease serum levels of BNP and CRP. Trimetazidine 13-16 C-reactive protein Homo sapiens 175-178 22944235-13 2012 CONCLUSION: The administration of NSAID, elevated CRP and abnormal WBC are significantly associated with CDAD. cdad 105-109 C-reactive protein Homo sapiens 50-53 23798923-8 2012 CONCLUSIONS: Eight-week supplementation with quercein-vitamin C was effective in reducing oxidative stress and reducing inflammatory biomarkers including CRP and IL-6 with little effect on E-selectin in healthy subjects. quercein-vitamin c 45-63 C-reactive protein Homo sapiens 154-157 24087989-9 2014 The levels of plasma C-reactive protein, interleukin-6, and fibrinogen were significantly decreased in the LMWH group. Heparin, Low-Molecular-Weight 107-111 C-reactive protein Homo sapiens 21-39 22262261-9 2012 Bilirubin was inversely correlated with high-sensitivity C-reactive protein (hsCRP) (r = -0.117, P < 0.001). Bilirubin 0-9 C-reactive protein Homo sapiens 57-75 24603645-10 2014 Among participants aged >5 years, children in the highest tertile of CRP <1 mg/L at baseline, regarded as an indicator of low-grade inflammation, had a 0.04 z/y higher gain in BAZ (95% CI: 0.01, 0.09 z/y) during follow-up. BIS(5-AMIDINO-BENZIMIDAZOLYL)METHANE ZINC 182-185 C-reactive protein Homo sapiens 72-75 22712045-9 2012 RESULTS: The odds ratio for having metabolic syndrome in the highest versus lowest quartiles of serum uric acid levels was 2.67 (95% confidence interval [CI], 1.60 to 4.46) in males and 2.14 (95% CI, 1.50 to 3.05) in females after adjusting for age, smoking, alcohol intake, body mass index, total cholesterol, HbA1c, albumin, gamma-glutamyltransferase, blood urea nitrogen, and log C-reactive protein. Uric Acid 102-111 C-reactive protein Homo sapiens 383-401 24665572-5 2014 RESULTS: In the group of full-term neonates with PA significantly higher levels of cardiac tropon-inI (p = 0.000), CK-MB fraction (p = 0.000), brain natriuretic peptide (p = 0.003) and C-reactive protein (p = 0.017) were found, compared to the group of healthy full-term newborns. Protactinium 49-51 C-reactive protein Homo sapiens 185-203 24454896-13 2014 Patients with IPSS-V/S<1 and treated with tolterodine for 3 months had significant decrease of CRP levels after treatment. Tolterodine Tartrate 45-56 C-reactive protein Homo sapiens 98-101 24739831-4 2014 AIMS: Basal CRP levels were estimated in sera of patients with GBS and compared with adequate controls. gbs 63-66 C-reactive protein Homo sapiens 12-15 24739831-8 2014 RESULTS: CRP by LAT was positive in 24.4% GBS group, 34% NC group and 44% NNC group. gbs 42-45 C-reactive protein Homo sapiens 9-12 24739831-9 2014 The range of titer in CRP positive samples in the three patient groups (GBS, NC, NNC) was at concentration of 0.6 mg/dl to 19.2 mg/dl. gbs 72-75 C-reactive protein Homo sapiens 22-25 24739831-12 2014 High basal level of CRP was detected in patients with GBS. gbs 54-57 C-reactive protein Homo sapiens 20-23 24739831-13 2014 CONCLUSION: Autoimmune conditions like GBS can stimulate the production of a high level of inflammation resulting in an increase in the CRP production. gbs 39-42 C-reactive protein Homo sapiens 136-139 22260742-10 2012 Even after predonisolone and tacrolimus were tapered gradually and discontinued because of her good response, CRP and DAS-CRP became 0.0 mg/dL and 1.5, respectively. Tacrolimus 29-39 C-reactive protein Homo sapiens 110-113 24564598-6 2014 C-reactive protein (CRP), DAS28, and interleukin (IL)-6 negatively correlated with androstenedione response to ACTH 1-24. Androstenedione 83-98 C-reactive protein Homo sapiens 0-18 22260742-10 2012 Even after predonisolone and tacrolimus were tapered gradually and discontinued because of her good response, CRP and DAS-CRP became 0.0 mg/dL and 1.5, respectively. Tacrolimus 29-39 C-reactive protein Homo sapiens 122-125 24379064-5 2013 In tuberculosis sputum culture, the serum concentrations of IL-10 and ESR in TB positive group were 0.045+-0.013 mg/L and 62.50+-8.69 mm/1h, significantly higher than that of TB negative group (p < 0.05); whereas, the concentrations of serum PCT and CRP in TB positive and negative groups had no significant difference (p > 0.05). Terbium 77-79 C-reactive protein Homo sapiens 253-256 21996139-0 2012 Relation between serum 25-hydroxyvitamin D and C-reactive protein in asymptomatic adults (from the continuous National Health and Nutrition Examination Survey 2001 to 2006). 25-hydroxyvitamin D 23-42 C-reactive protein Homo sapiens 47-65 24095850-12 2013 In women, increased waist circumference and daily smoking are also associated with lower oxHDLlipid levels, and higher CRP levels and alcohol use are associated with higher oxHDLlipid levels. oxhdllipid 173-183 C-reactive protein Homo sapiens 119-122 24757857-5 2013 The study results permit to suppose that concentration of NO2+RNO in plasma is one of sensitive indicators of presence of inflammatory processes concomitant to premature discharge of amniotic fluid which by its sensitivity and specificity is superior to such indicators as number of leucocytes, ESR and concentration of C-reactive protein. Nitrogen Dioxide 58-61 C-reactive protein Homo sapiens 320-338 21996139-3 2012 We examined the relation between 25-hydroxyvitamin D [25(OH)D] and C-reactive protein (CRP) using the continuous National Health and Nutrition Examination Survey data from 2001 to 2006. 25-hydroxyvitamin D 33-52 C-reactive protein Homo sapiens 67-85 21996139-3 2012 We examined the relation between 25-hydroxyvitamin D [25(OH)D] and C-reactive protein (CRP) using the continuous National Health and Nutrition Examination Survey data from 2001 to 2006. 25-hydroxyvitamin D 33-52 C-reactive protein Homo sapiens 87-90 23383400-9 2012 Finally, sALS patients had significantly higher concentrations of IL6, sIL6R and C-reactive protein in the cerebrospinal fluid when compared to AD patients. sals 9-13 C-reactive protein Homo sapiens 81-99 24205495-6 2013 PCT and CRP concentrations were more accurate than WBC count for the diagnosis of CSHB-associated SBP. cshb 82-86 C-reactive protein Homo sapiens 8-11 24211751-3 2013 We undertook this study to compare the effect of pravastatin vs. placebo on the serum concentrations of C-reactive protein (CRP) in patients on CAPD. Pravastatin 49-60 C-reactive protein Homo sapiens 104-122 22907525-9 2012 CRP was highly correlated with direct bilirubin. Bilirubin 38-47 C-reactive protein Homo sapiens 0-3 24211751-3 2013 We undertook this study to compare the effect of pravastatin vs. placebo on the serum concentrations of C-reactive protein (CRP) in patients on CAPD. Pravastatin 49-60 C-reactive protein Homo sapiens 124-127 24211751-10 2013 CONCLUSIONS: Pravastatin significantly reduced serum levels of CRP and total and LDL-cholesterol compared to placebo. Pravastatin 13-24 C-reactive protein Homo sapiens 63-66 21865358-9 2011 Both simvastatin and metformin improved menstrual cyclicity and decreased hirsutism, acne, ovarian volume, body mass index, C-reactive protein, and soluble vascular cell adhesion molecule-1. Simvastatin 5-16 C-reactive protein Homo sapiens 124-142 24148690-6 2013 This was achieved by investigating the relationship between 14,15-DHETs and high-sensitivity C-reactive protein (hs-CRP) and blood lipoproteins. 14,15-dihydroxyeicosatrienoic acid 60-71 C-reactive protein Homo sapiens 93-111 21414247-8 2011 Intakes of vitamins C and E and carotene were inversely associated with the probability of having serum CRP concentrations >3 mg/l in multivariate logistic regression models. Carotenoids 32-40 C-reactive protein Homo sapiens 104-107 23751609-5 2013 Platelet counts and CRP were significantly elevated in GWVI+ compared to GWVI- patients without elevation in IPF or TPO. gwvi 55-59 C-reactive protein Homo sapiens 20-23 23751609-9 2013 Therefore, GWVI+ patients had elevated platelet counts, spontaneous aggregation, TRAP 6-induced secretion, and CRP, but no impairment of platelet function. gwvi 11-15 C-reactive protein Homo sapiens 111-114 23874068-1 2013 UNLABELLED: The present study aimed to assess the effect of supplementation of omega-3 and/or vitamin C on serum interleukin-6 and high sensitivity C-reactive protein concentration and depression scores among shift workers in Shahid Tondgoyan oil refinery. omega-3 79-86 C-reactive protein Homo sapiens 148-166 23874068-6 2013 Supplementation of omega-3 without vitamin C, is associated with a reduction in depression score (p<0.0001) and high sensitivity C-reactive protein concentration (p<0.01). omega-3 19-26 C-reactive protein Homo sapiens 132-150 23362728-5 2011 Ultra sensitive C reactive protein was significantly correlated with increased lipid risk factors of cardiovascular disease, thyroid stimulating hormone level and indices of oxidative stress in these patients. Thyrotropin 125-152 C-reactive protein Homo sapiens 16-34 23874068-7 2013 Therefore omega-3 supplementation showed a better effect on reducing depression score and high sensitivity C-reactive protein, but supplementation of vitamin C along with omega-3 did not have significant effect on change in C-reactive protein level compared to omega-3 alone. omega-3 10-17 C-reactive protein Homo sapiens 107-125 23558443-11 2013 O-DMA was the only isoflavonoid whose excretion was significantly associated with a decrease in both CRP (p-trend = 0.024) and WBC count (p-trend < 0.0001). O-desmethylangolensin 0-5 C-reactive protein Homo sapiens 101-104 23558443-12 2013 CONCLUSIONS: Though no clear pattern emerged, higher excretion of certain soy isoflavonoids was associated with decreased CRP concentration and WBC counts, suggesting a possible inverse association between soy intake and inflammation. isoflavonoids 78-91 C-reactive protein Homo sapiens 122-125 23274196-2 2013 The LPD method could embed a monoclonal antibody of C-reactive protein (Anti-CRP), which is mixed with poly(l-lysine) (PL) as an organic binder, on/in titanium oxide thin layer deposited onto a surface plasmon resonance (SPR) sensing chip (F(Anti-CRP-PL)), allowing simple immobilization of anti-CRP capable of CRP detection. pl 119-121 C-reactive protein Homo sapiens 52-70 22484413-11 2013 C reactive protein concentrations remained stable throughout the study in trimetazidine group at baseline and at the 6 month on follow up. Trimetazidine 74-87 C-reactive protein Homo sapiens 0-18 21642014-9 2011 There were significantly greater rates of clinical remission at week 6 for CZP in patients with increased concentrations of C-reactive protein (>=5 mg/L) at entry. Certolizumab Pegol 75-78 C-reactive protein Homo sapiens 124-142 22777489-6 2013 RESULTS: Comparing the PA and N-PA group, the first presented lower: total body mass (-13%), body mass index (-16%), fat mass (kg -39%, FM% -30%), CRP (-23%), serum insulin (-61%), homeostasis model assessment (HOMA, -35%) and serum leptin (-62%; P<0.05). Protactinium 23-25 C-reactive protein Homo sapiens 147-150 23853456-3 2013 AIM: To determine whether sub-antimicrobial dose-doxycycline (SDD) therapy can reduce systemic serum inflammatory biomarker C-reactive protein (CRP) in post-menopausal women who have chronic periodontitis. 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt 62-65 C-reactive protein Homo sapiens 124-142 21642014-12 2011 Significant differences between CZP and placebo were observed in patients who had increased concentrations of C-reactive protein when the study began. Certolizumab Pegol 32-35 C-reactive protein Homo sapiens 110-128 23853456-3 2013 AIM: To determine whether sub-antimicrobial dose-doxycycline (SDD) therapy can reduce systemic serum inflammatory biomarker C-reactive protein (CRP) in post-menopausal women who have chronic periodontitis. 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt 62-65 C-reactive protein Homo sapiens 144-147 20607595-4 2011 Simvastatin treatment significantly reduced C-reactive protein (CRP) levels while interleukin (IL)-6 levels remained unchanged. Simvastatin 0-11 C-reactive protein Homo sapiens 44-62 23545592-6 2013 When disease activity was compared between patients in which MTX-PG5 was detectable and undetectable, all indexes except the visual analog scale (VAS) and C-reactive protein (CRP) were found to be significantly lower in the former patients. mtx-pg5 61-68 C-reactive protein Homo sapiens 155-173 23545592-6 2013 When disease activity was compared between patients in which MTX-PG5 was detectable and undetectable, all indexes except the visual analog scale (VAS) and C-reactive protein (CRP) were found to be significantly lower in the former patients. mtx-pg5 61-68 C-reactive protein Homo sapiens 175-178 20607595-4 2011 Simvastatin treatment significantly reduced C-reactive protein (CRP) levels while interleukin (IL)-6 levels remained unchanged. Simvastatin 0-11 C-reactive protein Homo sapiens 64-67 21852972-12 2011 Increased C-reactive protein and gamma-glutamyl transferase levels were associated with decreased protein expression of both enzymes, and increased bilirubin levels, cholestasis, and presurgical exposure to omeprazole or pantoprazole were related to decreased PON3 protein. Bilirubin 148-157 C-reactive protein Homo sapiens 10-28 22884503-7 2012 Furthermore, mitoxantrone suppressed the expression of C-reactive protein (CRP). Mitoxantrone 13-25 C-reactive protein Homo sapiens 55-73 21548917-0 2011 Low levels of vitamin C in dialysis patients is associated with decreased prealbumin and increased C-reactive protein. Ascorbic Acid 14-23 C-reactive protein Homo sapiens 99-117 22884503-7 2012 Furthermore, mitoxantrone suppressed the expression of C-reactive protein (CRP). Mitoxantrone 13-25 C-reactive protein Homo sapiens 75-78 21167147-5 2011 Unconjugated bilirubin was negatively correlated with sd-LDL-C, ox-LDL and hs-CRP (r=-0.594, p<0.001; r=-0.249, p=0.016 and r=-0.373, p<0.001 respectively). Bilirubin 13-22 C-reactive protein Homo sapiens 78-81 22583484-8 2012 Systolic and diastolic blood pressure, serum albumin, LDL-C, HDL-C, Hb, Cr, and Ca were inversely associated with CRP. Chromium 72-74 C-reactive protein Homo sapiens 114-117 22029199-7 2011 A positive correlation was observed between adenosine deaminase and uric acid (r = 0.743, p < 0.001), adenosine deaminase and C-reactive protein (r = 0.648, p < 0.001) and also between C-reactive protein and uric acid (r = 0.712, p < 0.001). Uric Acid 214-223 C-reactive protein Homo sapiens 129-147 22056089-7 2011 Plasma selenium was correlated modestly with BMI (r=-0.138; p=0.096) and elevated CRP (>5.0 mg/L) (r=-0.143; p=0.084) in Malawi, and significantly with intake of cellular animal protein (g/d) (r=0.23; p=0.020) and serum zinc (r=0.13; p=0.044) in the Philippines. Selenium 7-15 C-reactive protein Homo sapiens 82-85 22212269-9 2011 Although TNF-alpha and CRP, except for IL-6, showed a tendency to increase in CG, all three tended to decrease in EG after 8 weeks. cysteinylglycine 78-80 C-reactive protein Homo sapiens 23-26 21653577-6 2011 However, dietary Zn and heme iron were positively associated with CRP [mean: 1.73, 1.75, 1.78, 1.88, and 1.96 mg/L across increasing quintiles of Zn and 1.72, 1.76, 1.83, 1.86, and 1.94 mg/L across increasing quintiles of heme iron (P-trend = 0.002 and 0.01, respectively). Heme 24-28 C-reactive protein Homo sapiens 66-69 21454703-5 2011 Exposure of C1q to heme significantly reduced the activation of the classical complement pathway, mediated by C-reactive protein (CRP) and IgG. Heme 19-23 C-reactive protein Homo sapiens 110-142 21454703-6 2011 Interaction analyses revealed that heme reduces the binding of C1q to CRP and IgG. Heme 35-39 C-reactive protein Homo sapiens 70-73 21454703-8 2011 Formation of complex of heme with C1q caused changes in the mechanism of recognition of IgG and CRP. Heme 24-28 C-reactive protein Homo sapiens 96-99 21067315-9 2011 The log(e)-transformed T/S ratio was inversely correlated with age (r= -0.345; p<0.001), PWV (r= -0.326; p<0.001) and C-reactive protein ( r= -0.133; p=0.027). Sulfur 25-26 C-reactive protein Homo sapiens 124-142 21149827-10 2011 CRP actions are prevented either by the inhibition of the intracellular aldosterone receptors using spironolactone (5 nmol/L) or by the inactivation of epithelial sodium channel using specific blockers. Spironolactone 100-114 C-reactive protein Homo sapiens 0-3 21701640-0 2011 Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression. Fluoxetine 11-21 C-reactive protein Homo sapiens 42-60 21701640-8 2011 In fluoxetine (20 mg/day) treatment group, there was a significant reduction in the levels of CRP (P = 0.046), ESR (P = 0.043) and WBC count (P = 0.021) after 2 months of treatment but no significant reduction in HRSD scale (P = 0.190). Fluoxetine 3-13 C-reactive protein Homo sapiens 94-97 20842069-14 2010 CONCLUSIONS: Most cases of childhood AHOM can be treated for 20 days, including a short period intravenously, with large doses of a well-absorbed antimicrobial such as clindamycin or a first-generation cephalosporin, provided the clinical response is good and C-reactive protein normalizes within 7 to 10 days. Clindamycin 168-179 C-reactive protein Homo sapiens 260-278 21224533-10 2010 Serum CRP levels at the time of 2W after CRT initiation (CRT2W) in CR group were low compared to those in non-CR group (p=0.071). Chromium 41-43 C-reactive protein Homo sapiens 6-9 21224533-12 2010 The prediction accuracies to discriminate CR from non-CR by CRP<=0.1 were 50%, 82%, and 75% in sensitivity, specificity and accuracy, respectively. Chromium 42-44 C-reactive protein Homo sapiens 60-63 21224533-12 2010 The prediction accuracies to discriminate CR from non-CR by CRP<=0.1 were 50%, 82%, and 75% in sensitivity, specificity and accuracy, respectively. Chromium 54-56 C-reactive protein Homo sapiens 60-63 20592333-10 2010 Multivariate regression analysis, including sex, age, body mass index, hypercholesterolaemia, smoking, hypertension diabetes, identified CG + CC genotype as the only independent predictor of preoperative CRP and IL-6 levels. cysteinylglycine 137-139 C-reactive protein Homo sapiens 204-207 20587876-6 2010 The mean of the hs-CRP levels was significantly higher in the DIH group compared with the normotensive group (12.9 +/- 12 vs. 7.2 +/- 5.2 mg/dL, respectively, P= 0.01). 1,3-Diiodo-5,5-dimethylhydantoin 62-65 C-reactive protein Homo sapiens 19-22 20415446-4 2010 Herein we describe how changing properties of substrate (phosphocholine, PC) self-assembly can affect both binding behavior and substrate affinity to a pentameric recognition protein (C-reactive protein, CRP). pc 73-75 C-reactive protein Homo sapiens 184-202 20415446-4 2010 Herein we describe how changing properties of substrate (phosphocholine, PC) self-assembly can affect both binding behavior and substrate affinity to a pentameric recognition protein (C-reactive protein, CRP). pc 73-75 C-reactive protein Homo sapiens 204-207 20047506-8 2010 In a previously conducted Phase IIa study, C-reactive protein levels decreased with DIO-902 treatment. ketoconazole 84-91 C-reactive protein Homo sapiens 43-61 19836015-3 2010 In adjusted logistic regressions, two OH-PAHs, 2-hydroxyphenanthrene and 9-hydroxyfluorene, were associated with elevated CRP (>3mg/l). fluoren-9-ol 73-90 C-reactive protein Homo sapiens 122-125 19836015-6 2010 Intermediate levels of 2-hydroxyphenanthrene (49-148ng/g creatinine), and 9-hydroxyfluorene (161-749ng/g creatinine) were also significantly associated with elevated CRP compared to the respective reference categories. fluoren-9-ol 74-91 C-reactive protein Homo sapiens 166-169 20587984-6 2010 However, after administration of linezolid (LZD) for 14 days, the infection had improved, and the white blood cell count and C-reactive protein values had normalized. Linezolid 33-42 C-reactive protein Homo sapiens 125-143 20587984-11 2010 After administration of LZD for 14 days intravenously and 14 days orally, the infection had improved, and the white blood cell count and C-reactive protein values had normalized. Linezolid 24-27 C-reactive protein Homo sapiens 137-155 19756031-5 2009 Plasma CRP levels were measured by a highly sensitive immunoassay that used monoclonal antibodies coated with polystyrene particles. Polystyrenes 110-121 C-reactive protein Homo sapiens 7-10 19153215-7 2009 Greater SDNN declines were observed among those with C-reactive protein (P(interaction) < 0.001) and augmentation index (P = 0.06) values at or above the 75th percentile and pulse pressure values below the 75th percentile (P < 0.001). sdnn 8-12 C-reactive protein Homo sapiens 53-71 19058981-9 2009 CRP was lower with HES200/0.62 (178 mg/mL) than gelatine (221 mg/mL) and HES130/0.4 (223 mg/mL) at 48 h (p=0.049 and p=0.009 respectively). hes200 19-25 C-reactive protein Homo sapiens 0-3 19143751-11 2009 Both dosages of pravastatin markedly inhibited the function of dendritic cells and lowered C-reactive protein, which is independent of plasma cholesterol lowering. Pravastatin 16-27 C-reactive protein Homo sapiens 91-109 18766955-5 2009 RESULTS: After treatment with spironolactone, flow-mediated vasodilation (FMD) improved from 3.18 +/- 0.46% to 3.95 +/- 0.49% (p < 0.001) whereas there was no significant change in endothelium-independent vasodilation with nitroglycerin and baseline diameter (18.4 +/- 1.15% vs. 18.3 +/- 1.13%, p = 0.046, and 3.5 +/- 0.1 vs. 3.52 +/- 0.1 mm, p = 0.952, respectively); serum nitrite concentration was reduced significantly from 6.9 +/- 0.34 to 6.8 +/- 0.33 micromol/L (p < 0.001), ESR from 59.90 +/- 4.86 to 51.22+/-4.26 mm in the first hour (p < 0.001), and CRP level from 15.2+/-3.8 to 9.4+/-2.6 mg/dL (p = 0.019). Spironolactone 30-44 C-reactive protein Homo sapiens 568-571 18664531-12 2008 The PA group had significantly lower serum CRP than the PI group. Protactinium 4-6 C-reactive protein Homo sapiens 43-46 18855257-8 2008 Hydrophilic pravastatin increased the serum adiponectin level and decreased the CRP after switching from lipophilic simvastatin in the absence of any difference in the low-density lipoprotein cholesterol level and blood pressure. Pravastatin 12-23 C-reactive protein Homo sapiens 80-83 18562112-6 2008 By use of an AFM tip, a pattern of ditch was engraved within the SAM of DSNHS, and anti-CRP was immobilized on the engraved SAM through replacement of N-hydroxysuccinimide group on the outside surface of DSNHS by the amine group of anti-CRP. N-hydroxysuccinimide 151-171 C-reactive protein Homo sapiens 88-91 18640464-18 2008 Mean levels of C-reactive protein were significantly reduced relative to placebo at all doses of DIO-902 (P=0.027); no reductions in either of these parameters were seen in the placebo group. ketoconazole 97-104 C-reactive protein Homo sapiens 15-33 22114593-1 2011 In this study, we investigate the effect of argan oil consumption on serum lipids, apolipoproteins (AI and B), CRP, and LDL susceptibility to oxidation in type 2 diabetic patients which are known to have a high level of cardiovascular risk due to lipid abnormalities and lipid peroxidation. argan oil 44-53 C-reactive protein Homo sapiens 111-114 18492832-7 2008 Twenty-four weeks of feeding a high-dairy eucaloric diet and hypocaloric diet resulted in an 11 (P < 0.03) and 29% (P < 0.01) decrease in CRP, respectively (post-test vs. pre-test), whereas there was no significant change in the low-dairy groups. dairy 36-41 C-reactive protein Homo sapiens 144-147 21819714-3 2011 CRP levels were statistically significantly lower on postoperative days 1 and 2 in patients in the DHS versus the GN group; no other differences were observed. gossypolone 114-116 C-reactive protein Homo sapiens 0-3 18547475-10 2008 In conclusion, the results of the present study support the notion that CRP and TC may be altered in patients with BP-I. bp-i 115-119 C-reactive protein Homo sapiens 72-75 17531242-2 2008 However, recent in vitro studies raised the possibility that the effects of CRP are caused by biologically active contaminants such as sodium azide and endotoxin. Sodium Azide 135-147 C-reactive protein Homo sapiens 76-79 21523662-10 2011 Multiple stepwise regression analysis showed that uric acid level was independently associated with WHR, GFR and CRP. Uric Acid 50-59 C-reactive protein Homo sapiens 113-116 18488422-8 2008 As well as the initial proof-of-principle studies, C-reactive protein binding was measured: electrical signals were changed in a linear fashion with the concentration (1 fM to 1 nM) in PBS containing 1.37 mM of salts. Lead 185-188 C-reactive protein Homo sapiens 51-69 18991814-8 2008 CONCLUSION: HMG-CoA-reductase inhibitor atorvastatin more effectively lowers concentration of CRP in blood plasma of patients with PA than with IHD what possibly is explained by higher initial level of this marker of inflammatory processes. Protactinium 131-133 C-reactive protein Homo sapiens 94-97 20018480-6 2010 An inverse relation was observed between plasma C-reactive protein and plasma vitamin C concentrations (P = 0.006). Ascorbic Acid 78-87 C-reactive protein Homo sapiens 48-66 17996517-0 2007 Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol. Pravastatin 24-35 C-reactive protein Homo sapiens 47-65 20831680-17 2010 High-sensitivity C reactive protein decreased in the pioglitazone group after full treatment compared to the end of titration period and to the acarbose group. Acarbose 144-152 C-reactive protein Homo sapiens 17-35 17996517-4 2007 We prospectively evaluated the effects of withdrawal from pravastatin (40 mg) treatment on CRP levels in 566 subjects who participated in a randomized, placebo-controlled trial. Pravastatin 58-69 C-reactive protein Homo sapiens 91-94 17996517-8 2007 Withdrawal from pravastatin led to a significant increase in both CRP and LDL cholesterol to approximately pretreatment levels (p <0.05 and <0.001, respectively). Pravastatin 16-27 C-reactive protein Homo sapiens 66-69 17996517-9 2007 Changes in CRP after withdrawal from pravastatin could not be predicted by the change in LDL cholesterol. Pravastatin 37-48 C-reactive protein Homo sapiens 11-14 20683528-0 2010 Electrogenerated chemiluminescence determination of C-reactive protein with carboxyl CdSe/ZnS core/shell quantum dots. carboxyl cdse 76-89 C-reactive protein Homo sapiens 52-70 20445760-9 2010 There was no overlap of lipids whose changes correlated with LDL-C or CRP responses to simvastatin suggesting that distinct metabolic pathways govern statin effects on these two biomarkers. Simvastatin 87-98 C-reactive protein Homo sapiens 70-73 17872451-7 2007 Whereas nateglinide treatment also reduced triglyceride, highly-sensitive C-reactive protein, and E-selectin, multiple regression analysis identified HbA1c as the only significant independent determinant of the change in carotid intima-media thickness. Nateglinide 8-19 C-reactive protein Homo sapiens 74-92 17389710-8 2007 These CR- and EX-induced energy deficits were accompanied by reductions in most of the major CHD risk factors, including plasma LDL-cholesterol, total cholesterol/HDL ratio, HOMA-IR index, and CRP concentrations that were similar in the two intervention groups. Chromium 6-8 C-reactive protein Homo sapiens 193-196 17401747-12 2007 C-reactive protein was higher in AMIMC than in non- AMIMC patients (p = 0.009). amimc 33-38 C-reactive protein Homo sapiens 0-18 17401747-12 2007 C-reactive protein was higher in AMIMC than in non- AMIMC patients (p = 0.009). amimc 52-57 C-reactive protein Homo sapiens 0-18 20379040-10 2010 Although the correlation index for this inverse association has been weak, both are independently associated with a higher prevalence of coronary artery disease, total bilirubin <or= 0.56 mg/dL (OR: 10.04; IC: 3.48-28.90; P < 0.001), and ultrasensitive C reactive protein > 3 mg/L (OR: 1.17; IC: 1.04-1.33; P = 0.009). Bilirubin 168-177 C-reactive protein Homo sapiens 259-277 19717151-1 2010 OBJECTIVE: To examine the association between concentrations of serum vitamin C, a contributive factor to prevention of cardiovascular disease and levels of hs-CRP, a risk factor for cardiovascular disease, in population-based samples of middle-aged men and women. Ascorbic Acid 70-79 C-reactive protein Homo sapiens 160-163 17446333-9 2007 NT-pro-BNP remained predictive of total and cardiovascular mortality after accounting for age, sex, diabetes mellitus, body mass index, smoking, hypertension, dyslipidemia, glomerular filtration rate, presence or absence of CAD on angiography, cardiovascular medication, revascularization at baseline, clinical signs of heart failure, LV systolic function, and C-reactive protein. pro-bnp 3-10 C-reactive protein Homo sapiens 361-379 17283264-0 2007 C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Pravastatin 115-126 C-reactive protein Homo sapiens 0-18 17283264-3 2007 METHODS AND RESULTS: Baseline CRP was related to risk over 3.2 years for primary a combined end point (definite or suspected death from coronary heart disease, nonfatal myocardial infarction, and fatal or nonfatal stroke; n=865 events) and secondary (coronary heart disease events or stroke alone) and tertiary (stroke plus transient ischemic attack) end points in the Prospective Study of Pravastatin in the Elderly at Risk (n=5804 men and women; age, 70 to 82 years). Pravastatin 390-401 C-reactive protein Homo sapiens 30-33 2521604-3 1989 The inhibition of cell attachment was dependent on the concentration of the CRP and involved the phosphorylcholine (PC) binding site of CRP since inhibition was prevented by allowing the CRP to react with either PC (or closely related monophosphate compounds) or a mAb specific for the PC-binding site of CRP. monophosphate 235-248 C-reactive protein Homo sapiens 76-79 2521604-3 1989 The inhibition of cell attachment was dependent on the concentration of the CRP and involved the phosphorylcholine (PC) binding site of CRP since inhibition was prevented by allowing the CRP to react with either PC (or closely related monophosphate compounds) or a mAb specific for the PC-binding site of CRP. monophosphate 235-248 C-reactive protein Homo sapiens 136-139 2521604-3 1989 The inhibition of cell attachment was dependent on the concentration of the CRP and involved the phosphorylcholine (PC) binding site of CRP since inhibition was prevented by allowing the CRP to react with either PC (or closely related monophosphate compounds) or a mAb specific for the PC-binding site of CRP. monophosphate 235-248 C-reactive protein Homo sapiens 136-139 2521604-3 1989 The inhibition of cell attachment was dependent on the concentration of the CRP and involved the phosphorylcholine (PC) binding site of CRP since inhibition was prevented by allowing the CRP to react with either PC (or closely related monophosphate compounds) or a mAb specific for the PC-binding site of CRP. monophosphate 235-248 C-reactive protein Homo sapiens 136-139 3198919-16 1988 By blotting and by ELISA all CRP reactions were blocked by PC and EDTA indicating binding through the calcium-dependent PC-binding site on CRP. Edetic Acid 66-70 C-reactive protein Homo sapiens 29-32 3198919-16 1988 By blotting and by ELISA all CRP reactions were blocked by PC and EDTA indicating binding through the calcium-dependent PC-binding site on CRP. Edetic Acid 66-70 C-reactive protein Homo sapiens 139-142 19717151-4 2010 Inverse associations between serum vitamin C concentrations and hs-CRP levels were established for both men and women. Ascorbic Acid 35-44 C-reactive protein Homo sapiens 67-70 19717151-5 2010 Multivariable-adjusted mean values of hs-CRP for the lowest to highest quintiles of vitamin C levels were 0.75, 0.65, 0.61, 0.61 and 0.47 mg/L (P for trend <0.001) for men, and 0.56, 0.51, 0.49, 0.41 and 0.41 mg/L (P for trend <0.001) for women. Ascorbic Acid 84-93 C-reactive protein Homo sapiens 41-44 19717151-6 2010 The inverse association between vitamin C and hs-CRP was stronger for non-smoking men and women, non-overweight women and postmenopausal women. Ascorbic Acid 32-41 C-reactive protein Homo sapiens 49-52 19717151-7 2010 CONCLUSIONS: Serum vitamin C concentrations were found to be inversely associated with hs-CRP levels in both men and women, primarily among non-smokers, non-overweight women and postmenopausal women. Ascorbic Acid 19-28 C-reactive protein Homo sapiens 90-93 20150839-12 2010 There was a nonsignificant reduction of CRP and IL-6 in the subgroup with FEV1 >50% during simvastatin treatment. Simvastatin 94-105 C-reactive protein Homo sapiens 40-43 3300834-4 1987 However, chloroquine had less impact on haemoglobin, ESR, rheumatoid factor levels and C-reactive protein than the other treatments. Chloroquine 9-20 C-reactive protein Homo sapiens 87-105 2443837-3 1987 Soluble native-CRP was found to express neo-CRP antigenicity upon treatment with acid; upon urea-chelation or heating in the absence of calcium; and upon adsorption onto uncoated polystyrene plates. Polystyrenes 179-190 C-reactive protein Homo sapiens 15-18 2443837-3 1987 Soluble native-CRP was found to express neo-CRP antigenicity upon treatment with acid; upon urea-chelation or heating in the absence of calcium; and upon adsorption onto uncoated polystyrene plates. Polystyrenes 179-190 C-reactive protein Homo sapiens 44-47 19640511-5 2009 In overall comparisons, quetiapine and olanzapine had the highest median levels for CRP, and olanzapine for E-selectin and ICAM-1. Olanzapine 39-49 C-reactive protein Homo sapiens 84-87 19640511-6 2009 Olanzapine was significantly different after baseline adjustment than perphenazine (p = .001) for E-selectin, and in those with low baseline CRP (<1 mg/L), olanzapine was significantly different than perphenazine (p < .001), risperidone (p < .001), and ziprasidone (p = .002) for CRP. Olanzapine 159-169 C-reactive protein Homo sapiens 141-144 19763135-6 2009 EPA treatment significantly reduced the levels of immunoreactive insulin, triglycerides, SAA-LDL, CRP, PWV and CAVI and increased the levels of adiponectin relative to the control group for 3 months (P<0.05). Eicosapentaenoic Acid 0-3 C-reactive protein Homo sapiens 98-101 2998916-5 1985 A negative correlation was found between serum selenium and C-reactive protein levels. Selenium 47-55 C-reactive protein Homo sapiens 60-78 6877243-2 1983 CRP binds with phosphocholine and phosphate esters; initiates reactions of agglutination, opsonization and complement consumption; and precipitates with protamine and synthetic polymers of lysine and arginine, and these reactivities are modulated by calcium and phosphocholine. phosphate esters 34-50 C-reactive protein Homo sapiens 0-3 6801137-1 1982 Rabbit CRP is similar to human CRP in structure, kinetics of appearance, and binding reactivities to phosphate esters and cationic polymers. phosphate esters 101-117 C-reactive protein Homo sapiens 7-10 6801137-1 1982 Rabbit CRP is similar to human CRP in structure, kinetics of appearance, and binding reactivities to phosphate esters and cationic polymers. phosphate esters 101-117 C-reactive protein Homo sapiens 31-34 7217669-4 1981 A weak interaction between CRP and agarose was observed, which was also CA++-dependent and could be inhibited by phosphocholine and galactose. Sepharose 35-42 C-reactive protein Homo sapiens 27-30 471064-3 1979 CRP has a Ca2+-dependent binding specificity for phosphorylcholine, the polar head group of two widely distributed lipids, lecithin (phosphatidylcholine, PC) and sphingomyelin (SM). pc 154-156 C-reactive protein Homo sapiens 0-3 471064-5 1979 In addition, interaction of CRP with PC- and SM-containing lipid dispersions and with PC-containing liposomes can activate the complement system. pc 37-39 C-reactive protein Homo sapiens 28-31 471064-5 1979 In addition, interaction of CRP with PC- and SM-containing lipid dispersions and with PC-containing liposomes can activate the complement system. pc 86-88 C-reactive protein Homo sapiens 28-31 471064-6 1979 We report here that binding of CRP to model membranes of PC requires the incorporation into the bilayer of lysophosphatidylcholine (LPC). pc 57-59 C-reactive protein Homo sapiens 31-34 19576345-5 2009 Primary end-point rates were directly related to increasing tertiles (from tertile 1 [T1] to tertile 3 [T3]) of UA (12.7%, 12.8%, and 17.6% respectively, p for trend <0.0001) and CRP (11.5%, 14.2%, and 17.3% respectively, p for trend <0.002). Uric Acid 112-114 C-reactive protein Homo sapiens 182-185 109055-4 1979 During treatment with gold and dapsone there were statistically significant gradual and progressive falls of similar magnitude in serum CRP and ESR. Dapsone 31-38 C-reactive protein Homo sapiens 136-139 271994-6 1977 Lesser, but significant, "background" glucose release independent of the presence of CRP also was observed with positively charged liposomes containing galactocerebroside, and this was associated with marked preferential consumption of the later-acting complement components (C3-C9). galactocerebroside 152-170 C-reactive protein Homo sapiens 85-88 19628101-7 2009 Mean serum CRP concentrations tended to decrease as the intake of eicosapentaenoic acid, docosahexaenoic acid, or their combination increased in men and women, although none of these relationships was statistically significant. Eicosapentaenoic Acid 66-87 C-reactive protein Homo sapiens 11-14 34058912-7 2021 Multivariable linear regression analysis was performed using variables that showed a significant correlation and p < 0.20 (serum creatinine, serum sodium, Ln-C-reactive protein, and dosage of erythropoiesis-stimulating agent) with the cerebral rSO2. rso2 244-248 C-reactive protein Homo sapiens 158-176 34047819-6 2021 The visual limits of detection of CRP and cTnT in mLFA were 10 mug/L and 0.1 mg/L, respectively. mlfa 50-54 C-reactive protein Homo sapiens 34-37 19151033-7 2009 RESULTS: Treatment with simvastatin or atorvastatin decreased CRP-induced release of CCL2, CCL3 and CCL4. Simvastatin 24-35 C-reactive protein Homo sapiens 62-65 19151033-9 2009 Treatments with 1 microM simvastatin or atorvastatin significantly inhibited monocyte migration in response to CRP. Simvastatin 25-36 C-reactive protein Homo sapiens 111-114 19195502-0 2009 Effect of beta blockers (metoprolol or propranolol) on effect of simvastatin in lowering C-reactive protein in acute myocardial infarction. Simvastatin 65-76 C-reactive protein Homo sapiens 89-107 34052657-7 2021 RESULTS: After GBS, HOMA-IR, CRP and IL-6 serum levels decreased. gbs 15-18 C-reactive protein Homo sapiens 29-32 19194541-4 2009 The patients in the high AoPWV group showed a significantly higher age and high-sensitivity C-reactive protein level, a greater prevalence of diabetes and statin use, left ventricular hypertrophy, average pulse pressure (PP), AoPWV and left ventricular mass index and a lower serum albumin level than those in the low AoPWV group (p<0.05). aopwv 25-30 C-reactive protein Homo sapiens 92-110 34049755-12 2022 The white blood cell count, neutrophil count, and CRP levels on postoperative day 7 significantly differed between the SSI and non-SSI cases in the PL group. pl 148-150 C-reactive protein Homo sapiens 50-53 34035894-0 2021 Associations between plasma levels of C-reactive protein and catecholamine metabolites in patients with major depression. Catecholamines 61-74 C-reactive protein Homo sapiens 38-56 18843258-7 2009 A dual-event Cox"s model confirmed 25-hydroxyvitamin D as an independent predictor of study outcomes when adjusted for age, heart failure, smoking, C-reactive protein, albumin, phosphate, use of converting enzyme inhibitors or angiotensin receptor blockers, and eGFR. 25-hydroxyvitamin D 35-54 C-reactive protein Homo sapiens 148-166 33847390-13 2021 Moreover, histological and ultrastructural improvements were seen in the rat population treated with BPA and Se, whereas ALT and AST levels were lowered and malondialdehyde (MDA), glutathione peroxidase (GPx), human C reactive protein (hCRP), and the serum levels of interleukin-6 (IL-6) were significantly modulated. Selenium 109-111 C-reactive protein Homo sapiens 216-234 33847390-13 2021 Moreover, histological and ultrastructural improvements were seen in the rat population treated with BPA and Se, whereas ALT and AST levels were lowered and malondialdehyde (MDA), glutathione peroxidase (GPx), human C reactive protein (hCRP), and the serum levels of interleukin-6 (IL-6) were significantly modulated. Selenium 109-111 C-reactive protein Homo sapiens 236-240 19444716-13 2009 RBC putrescine correlated with IL-6 and IL-10, and spermine correlated with CRP. Spermine 51-59 C-reactive protein Homo sapiens 76-79 32476589-5 2021 The overall failure rate of ceftriaxone mono-therapy was observed in 75.6% (11.7% in high-risk non-neutropenic fever with a mean C-reactive protein level of 21.1 (+-23.2) mmol/L and 63.9% in low-risk non-neutropenic fever with a mean C-reactive protein level of 17.6 (+-53.9) mmol/L). Ceftriaxone 28-39 C-reactive protein Homo sapiens 129-147 33185785-5 2021 The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006). Heparin, Low-Molecular-Weight 11-39 C-reactive protein Homo sapiens 159-177 33185785-5 2021 The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006). Heparin, Low-Molecular-Weight 11-39 C-reactive protein Homo sapiens 179-182 33185785-5 2021 The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006). Heparin, Low-Molecular-Weight 41-45 C-reactive protein Homo sapiens 159-177 33185785-5 2021 The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006). Heparin, Low-Molecular-Weight 41-45 C-reactive protein Homo sapiens 179-182 18760403-6 2008 Interestingly, bioclinical data analyses revealed significant correlation between GAG or ENV antigenemia (a protein causing dysimmune inflammatory effects) and C-reactive protein (CRP) levels (a systemic inflammation biomarker). Glycosaminoglycans 82-85 C-reactive protein Homo sapiens 160-178 33440046-9 2021 Patients on EEN had a shorter hospital stay [median (range) 10 (8-17) vs 13 (8-24) days; P = 0.04], higher day 7 albumin level (34 +- 4 vs 29 +- 3 g/L, P < 0.01), greater reduction in serum C-reactive protein and faecal calprotectin levels (both P = 0.04) and a lower composite outcome of colectomy/hospitalisation at 6 months (16% vs 39%; P = 0.045) compared to SOC. estradiol enanthate 12-15 C-reactive protein Homo sapiens 190-208 18760403-6 2008 Interestingly, bioclinical data analyses revealed significant correlation between GAG or ENV antigenemia (a protein causing dysimmune inflammatory effects) and C-reactive protein (CRP) levels (a systemic inflammation biomarker). Glycosaminoglycans 82-85 C-reactive protein Homo sapiens 180-183 33202082-6 2021 Replacing 10 min of sedentary time per day with VPA, regardless of how this was accumulated, was beneficially associated with CRP and both combined composite scores. Valproic Acid 48-51 C-reactive protein Homo sapiens 126-129 33677945-9 2021 25-OH-vitamin D deficiency was associated with increased CRP and dyspnea. 25-oh 0-5 C-reactive protein Homo sapiens 57-60 33224343-5 2020 Among statins, rosuvastatin had the strongest interaction with CRP (pKi = 16.14), followed by fluvastatin (pKi = 15.58), pitavastatin (pKi = 15.26), atorvastatin (pKi = 14.68), pravastatin (pKi = 13.95), simvastatin (pKi = 7.98) and lovastatin (pKi = 7.10). Pravastatin 177-188 C-reactive protein Homo sapiens 63-66 18971870-0 2008 Vitamin C-lipid metabolites: uptake and retention and effect on plasma C-reactive protein and oxidized LDL levels in healthy volunteers. Ascorbic Acid 0-9 C-reactive protein Homo sapiens 71-89 29962216-4 2020 Our objective was to examine the relationship between dietary intake of antioxidants (carotenoids, vitamins A, C, E, and selenium) and serum CRP concentrations in mid-life and older AAs, while controlling for confounders. Selenium 121-129 C-reactive protein Homo sapiens 141-144 18562112-1 2008 Atomic force microscope (AFM) was exploited to take picture of the molecular topology of C-reactive protein (CRP) in phosphate-buffered saline (PBS) solution. Phosphate-Buffered Saline 117-142 C-reactive protein Homo sapiens 89-107 33192498-8 2020 At the cellular and molecular level, the CD4, CD8, CD4/CD8, IL-6, TNF-alpha, and CRP levels were significantly improved when CM was complemented with XFG. 3-[(2~{S},3~{R},4~{R})-4-azanyl-2-carboxy-pyrrolidin-3-yl]propyl-$l^{3}-oxidanyl-bis(oxidanyl)boron 150-153 C-reactive protein Homo sapiens 81-84 18562112-1 2008 Atomic force microscope (AFM) was exploited to take picture of the molecular topology of C-reactive protein (CRP) in phosphate-buffered saline (PBS) solution. Phosphate-Buffered Saline 117-142 C-reactive protein Homo sapiens 109-112 18576337-9 2008 Young age at study entry and an elevated C-reactive protein concentration were the best predictors of achieving an ASAS40 response. asas40 115-121 C-reactive protein Homo sapiens 41-59 32603908-5 2020 We studied 10 postmenopausal women with IRDs treated with intravenous ZOL 5 mg. Five women experienced APR (APR+) associated with significant decreases in blood lymphocytes and increases in granulocytes and serum CRP. Zoledronic Acid 70-73 C-reactive protein Homo sapiens 213-216 18574092-10 2008 Low 25-hydroxyvitamin D levels were significantly correlated with variables of inflammation (C-reactive protein and interleukin 6 levels), oxidative burden (serum phospholipid and glutathione levels), and cell adhesion (vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 levels). 25-hydroxyvitamin D 4-23 C-reactive protein Homo sapiens 93-111 32923098-0 2020 C-reactive protein reduction with sacubitril-valsartan treatment in heart failure patients. sacubitril and valsartan sodium hydrate drug combination 34-44 C-reactive protein Homo sapiens 0-18 32923098-10 2020 After 6 months of Sacubitril-Valsartan therapy, 24 (69%) patients had an improvement in CRP values with a significantly reduction as compared to baseline (median 2.5 mg/L (Interquartile range (IQR) 1.3-5.0) vs. 2.2 mg/L (IQR 0.9-4.0), P=0.014 in the Wilcoxon test). sacubitril and valsartan sodium hydrate drug combination 18-28 C-reactive protein Homo sapiens 88-91 18356554-1 2008 OBJECTIVE: The purpose of this study was to assess whether increasing serum uric acid (UA) levels are related to cardiovascular disease (CVD) mortality, all-cause mortality, and incident (fatal and nonfatal) myocardial infarction (MI) in men from the general population taking into account C-reactive protein (CRP), a sensitive marker of systemic inflammation. Uric Acid 76-85 C-reactive protein Homo sapiens 290-308 32923098-11 2020 In the group of 17 (49%) patients with at least 25% improvement in CRP values with Sacubitril/Valsartan therapy, the benefit of several clinical, CPET and echocardiographic parameters were not significantly different from the benefit of patients with no improvement or an improvement inferior to 25% in CRP values. sacubitril and valsartan sodium hydrate drug combination 83-93 C-reactive protein Homo sapiens 67-70 32923098-12 2020 CONCLUSION: Sacubitril/Valsartan therapy was able to reduce CRP values in a chronic HF population. sacubitril and valsartan sodium hydrate drug combination 12-22 C-reactive protein Homo sapiens 60-63 31222631-7 2020 RESULTS: After covarying for age, gender, body mass index, chronic pain status, salivary flow rate, and NA, higher PA was associated with lower salivary CRP (beta = - 0.02, 95% CI (- 0.03, - 0.00) sr2 = .06, p = .01) but not IL-6; removing NA from this model did not change results. Protactinium 115-117 C-reactive protein Homo sapiens 153-156 31222631-10 2020 CONCLUSIONS: Findings suggest that higher PA may be associated with lower salivary CRP in young adults, even after accounting for NA and demographic characteristics. Protactinium 42-44 C-reactive protein Homo sapiens 83-86 32368640-5 2020 TCI633 could improve serum collagen type II C-telopeptide (sCTX-II) and serum C-reactive protein (sCRP) by 41.58% and 39.58%, respectively, after the study. tci633 0-6 C-reactive protein Homo sapiens 78-96 32265833-6 2020 In turn, TB+DM showed even higher levels of interferon gamma -IFN-gamma- and hGH (vs. TB), or IL-6, C reactive protein, cortisol and hGH (vs. DM). Terbium 9-11 C-reactive protein Homo sapiens 100-118 31826315-3 2020 Initially, backbone brushes of poly(2-isopropenyl-2-oxazoline) (PIPOx) were fabricated via surface initiated Cu0 plate-mediated controlled radical polymerization (SI-Cu0 CRP). poly(2-isopropenyl-2-oxazoline) 31-62 C-reactive protein Homo sapiens 170-173 31826315-3 2020 Initially, backbone brushes of poly(2-isopropenyl-2-oxazoline) (PIPOx) were fabricated via surface initiated Cu0 plate-mediated controlled radical polymerization (SI-Cu0 CRP). poly(2-isopropenyl-2-oxazoline) 64-69 C-reactive protein Homo sapiens 170-173 31323125-7 2020 CONCLUSIONS: The present findings suggest bodyweight, BUN, C-reactive protein, and hepatitis C as potential predictive factors of tolvaptan short-term response in patients with refractory ascites. Tolvaptan 130-139 C-reactive protein Homo sapiens 59-77 32021360-12 2020 The mediated proportions of CRP in associations of WC, WHR and WHtR with FEV1 were 7.96%, 9.59% and 5.76%, respectively. WC5 compound 51-53 C-reactive protein Homo sapiens 28-31 32021360-13 2020 The mediated proportions of CRP in associations of WC and WHR with FVC were 8.33% and 11.40%, respectively. WC5 compound 51-53 C-reactive protein Homo sapiens 28-31 32050883-15 2020 When all the patients (n= 125) were evaluated, a significant decrease in C-reactive protein, an increase in sodium, and a decrease in alanine aminotransferase were observed on the fourth day of micafungin treatment (p<0.05). Micafungin 194-204 C-reactive protein Homo sapiens 73-91 32561167-12 2020 Interestingly, V/S ratio showed significant positive correlation with high sensitivity C-reactive protein, a surrogate marker for systemic inflammation. Sulfur 17-18 C-reactive protein Homo sapiens 87-105 31520587-11 2020 Treatment of the patient with hydroxychloroquine conferred prolonged beneficial clinical effects, including stabilization of trismus and reduction of corticosteroid dose, C-reactive protein, and size of masses. Hydroxychloroquine 30-48 C-reactive protein Homo sapiens 171-189 30637662-8 2019 Overall, our study demonstrated that selenium supplementation for 4 weeks to patients undergoing for CABG surgery had beneficial effects on FPG, insulin, HOMA-IR, total-/HDL-cholesterol ratio, HDL-cholesterol, hs-CRP, GSH, and MDA levels, but did not affect other metabolic profiles. Selenium 37-45 C-reactive protein Homo sapiens 213-216 31432611-6 2019 In analysis of laboratory parameters and clinical scores, SAP patients receiving LMWH treatment had lower white blood cell counts, C-reactive protein level, Acute Physiology and Chronic Health Evaluation II score, and computed tomography severity index. Heparin, Low-Molecular-Weight 81-85 C-reactive protein Homo sapiens 131-149 31582860-0 2019 Effects of Conjugated Linoleic Acid Intake in the Form of Dietary Supplement or Enriched Food on C-Reactive Protein and Lipoprotein (a) Levels in Humans: A Literature Review and Meta-Analysis. Linoleic Acids 22-35 C-reactive protein Homo sapiens 97-115 31582860-2 2019 This study aimed to review the association between the intake of conjugated linoleic acid (CLA) in the form of dietary supplement or enriched food with different treatment durations and the levels of Lp(a) and CRP in human studies. Linoleic Acids 76-89 C-reactive protein Homo sapiens 210-213 30503868-9 2019 Strong correlations between V/S ratio and C-reactive protein (r=0.521, p=0.015) and high-density lipoprotein cholesterol (r=-0.576, p<0.001) were observed. Sulfur 0-1 C-reactive protein Homo sapiens 42-60 31307466-6 2019 A logistic regression model showed that serum C-reactive protein (CRP) was a predictor of AE-IP in the non-pulmonary surgery group (odds ratio 1.187, 95% confidence interval 1.073-1.344, P = 0.002). ae-ip 90-95 C-reactive protein Homo sapiens 46-64 31307466-6 2019 A logistic regression model showed that serum C-reactive protein (CRP) was a predictor of AE-IP in the non-pulmonary surgery group (odds ratio 1.187, 95% confidence interval 1.073-1.344, P = 0.002). ae-ip 90-95 C-reactive protein Homo sapiens 66-69 30672713-6 2019 Three hours after LPS infusion, animals were treated or not with CPFA for 6 h. Treatment with CPFA significantly reduced serum cytokines, C-reactive protein, procalcitonin, and endotoxin levels in patients with Gram-negative sepsis-induced AKI. cpfa 94-98 C-reactive protein Homo sapiens 138-156 30670105-5 2019 After adjustment for covariates, a significant positive association was observed between high DIL with fasting blood sugar (FBS) levels (OR: 7 52; 95 % CI 3 38, 16 75; P=0 0001) and high-sensitive C-reactive protein (hs-CRP) (OR: 3 03; 95 % CI 1 54, 5 94; P=0 001). Sugars 117-122 C-reactive protein Homo sapiens 220-223 30690246-5 2019 The most significant relationship with an increase of plasma CRP was found for myristic acid and, to a lesser extent, for oleic acid. Myristic Acid 79-92 C-reactive protein Homo sapiens 61-64 30690246-5 2019 The most significant relationship with an increase of plasma CRP was found for myristic acid and, to a lesser extent, for oleic acid. Oleic Acid 122-132 C-reactive protein Homo sapiens 61-64 30427060-4 2019 During longitudinal follow up, sCD14, CRP and sTF levels remained significantly increased in TB-DM compared with TB from baseline (pre-treatment), during treatment (2nd month) and at the completion (6th month) of anti-TB treatment (ATT), whereas sCD163 was significantly higher in TB-DM compared with TB only at baseline. Terbium 93-95 C-reactive protein Homo sapiens 38-41 30640654-8 2019 CRP was significantly lower in the levobupivacaine group 72 hours (p=0.03) and 120 hours (p=0.04) after surgery. Levobupivacaine 35-50 C-reactive protein Homo sapiens 0-3 30217538-2 2018 We examined how different indicators of NA and PA predicted concentrations of C-reactive protein (CRP) and seven peripheral inflammatory cytokines (IL-1beta, IL-6, TNF-alpha, IL-8, IL-4, IL-10, and IFN-gamma) that were examined in the form of an inflammatory composite. Protactinium 47-49 C-reactive protein Homo sapiens 78-96 30217538-2 2018 We examined how different indicators of NA and PA predicted concentrations of C-reactive protein (CRP) and seven peripheral inflammatory cytokines (IL-1beta, IL-6, TNF-alpha, IL-8, IL-4, IL-10, and IFN-gamma) that were examined in the form of an inflammatory composite. Protactinium 47-49 C-reactive protein Homo sapiens 98-101 17222008-4 2007 Polyclonal human CRP antibodies were introduced onto liposomes and magnetic beads through biotin-streptavidin interaction. Biotin 90-96 C-reactive protein Homo sapiens 17-20 16835597-6 2007 RESULTS: We observe a negative trend across quartiles of plasma beta-carotene for most biological variables clustering in the insulin resistance syndrome, as well as for traditional and new risk factors for type II diabetes and cardiovascular disease (CVD), including C-reactive protein and gamma-glutamyltranspeptidase (P<0.05). beta Carotene 64-77 C-reactive protein Homo sapiens 268-286 17912011-16 2007 A significant correlation was obtained between LLS and CRP (p < 0.001). lls 47-50 C-reactive protein Homo sapiens 55-58 17157900-7 2007 After coronary stenting, the rise in CRP levels was significantly higher in controls than those treated with naproxen (DeltaCRP=6.4 mg/L in the controls and 0.43 mg/L in the naproxen group, p<0.0001). Naproxen 109-117 C-reactive protein Homo sapiens 37-40 17157900-7 2007 After coronary stenting, the rise in CRP levels was significantly higher in controls than those treated with naproxen (DeltaCRP=6.4 mg/L in the controls and 0.43 mg/L in the naproxen group, p<0.0001). Naproxen 174-182 C-reactive protein Homo sapiens 37-40 17157900-10 2007 CONCLUSION: Our data show that naproxen pretreatment leads to significant suppression in PCI related CRP elevation. Naproxen 31-39 C-reactive protein Homo sapiens 101-104 16829029-10 2006 Selenium concentration correlated inversely with CRP in group 1. Selenium 0-8 C-reactive protein Homo sapiens 49-52 16546205-3 2006 We developed an ultra-sensitivity in-house immunometric assay on polystyrene beads for measuring CRP and studied its analytical and clinical performance. Polystyrenes 65-76 C-reactive protein Homo sapiens 97-100 16405521-1 2006 BACKGROUND: By site-directed mutagenesis of recombinant receptor fragments, we have previously identified residue lysine59 of the platelet collagen receptor glycoprotein VI (GPVI) as being critical for its interaction with the synthetic ligand collagen-related peptide (CRP) and the inhibitory phage antibody 10B12. lysine59 114-122 C-reactive protein Homo sapiens 270-273 16054696-5 2006 Here, we show that pravastatin and simvastatin prevent the induction of CRP expression in human hepatoma Hep3B cells exposed to proinflammatory cytokines IL-6 and IL-1beta The nitric oxide (NO) donor, sodium nitroprusside, also prevented the induction of CRP expression while the CRP inducers IL-6 and IL-1beta were present with the cells. Pravastatin 19-30 C-reactive protein Homo sapiens 72-75 16054696-5 2006 Here, we show that pravastatin and simvastatin prevent the induction of CRP expression in human hepatoma Hep3B cells exposed to proinflammatory cytokines IL-6 and IL-1beta The nitric oxide (NO) donor, sodium nitroprusside, also prevented the induction of CRP expression while the CRP inducers IL-6 and IL-1beta were present with the cells. Pravastatin 19-30 C-reactive protein Homo sapiens 255-258 16054696-5 2006 Here, we show that pravastatin and simvastatin prevent the induction of CRP expression in human hepatoma Hep3B cells exposed to proinflammatory cytokines IL-6 and IL-1beta The nitric oxide (NO) donor, sodium nitroprusside, also prevented the induction of CRP expression while the CRP inducers IL-6 and IL-1beta were present with the cells. Pravastatin 19-30 C-reactive protein Homo sapiens 255-258 15905085-8 2006 CRP could be detected in a concentration range of 1 ng/ml to 50 microg/ml from a standard solution in phosphate buffer and in a range of 4 ng/ml to 50 microg/ml from serum/PBS. Lead 172-175 C-reactive protein Homo sapiens 0-3 16637303-1 2006 BACKGROUND: We present the influence of monophasic combined oral contraceptive with 20 mmicrog ethinylestradiol /150 microg desogestrel upon some acute phase proteins: C- reactive protein, fibrinogen, haptoglobin and the connection between the proinflammatory effect of oestrogens METHODS: Forty clinically healthy young women between 18 and 35 years, using oral contraceptives in the duration of 12 months, are included in this study. Desogestrel 124-135 C-reactive protein Homo sapiens 168-187 16444450-0 2006 Time course of rapid C-reactive protein reduction by pravastatin in patients with stable angina. Pravastatin 53-64 C-reactive protein Homo sapiens 21-39 16444450-10 2006 These data suggested that a common daily dose of pravastatin resulted in rapid reduction of CRP within 24 hours and of lipid profile within 2 weeks, and the benefit to the vascular endothelium might occur quickly by reduction of CRP levels, which may be clinically important for patients in a high-risk subgroup, such as acute coronary artery disease. Pravastatin 49-60 C-reactive protein Homo sapiens 92-95 16444450-10 2006 These data suggested that a common daily dose of pravastatin resulted in rapid reduction of CRP within 24 hours and of lipid profile within 2 weeks, and the benefit to the vascular endothelium might occur quickly by reduction of CRP levels, which may be clinically important for patients in a high-risk subgroup, such as acute coronary artery disease. Pravastatin 49-60 C-reactive protein Homo sapiens 229-232 16526817-8 2006 Treating PPG with glinides improves IMT as well as interleukin-6 and C-reactive protein levels, while treating PPG with rapid-acting insulin analogues is also associated with improvements in endothelial dysfunction. ppg 9-12 C-reactive protein Homo sapiens 69-87 16423198-5 2006 RESULTS: Serum hs-CRP, TF, MCP-1 and Hsp-70 levels were significantly higher in OSAHS compared with control subjects. osahs 80-85 C-reactive protein Homo sapiens 18-21 16714254-9 2006 A significant decrease was observed in TC (14.7 %), LDLC (21.5 %), CRP (22.7 %), and VEGF (14.8 %) after 4 months of treatment with pravastatin. Pravastatin 132-143 C-reactive protein Homo sapiens 67-70 16714254-11 2006 In patients with hypercholesterolemia treated with pravastatin, a reduction in VEGF and CRP was seen in addition to lipid decreases. Pravastatin 51-62 C-reactive protein Homo sapiens 88-91 16332649-11 2005 Eicosapentaenoic acid in phospholipids (P = 0.06) and CEs (P < 0.05) and linolenic acid in CEs (P < 0.05) were inversely related to C-reactive protein. alpha-Linolenic Acid 76-90 C-reactive protein Homo sapiens 138-156 16389569-3 2005 METHODS: CRP-induced signalling events were examined in THP-1 and primary monocytes, measuring Syk phosphorylation by Western blotting, intracellular Ca(2+) ([Ca(2+)](i)) by Indo-1 fluorescence and surface expression of CD11b by flow cytometry. indo-1 174-180 C-reactive protein Homo sapiens 9-12 16372585-3 2005 Significant improvements in serum C-reactive protein levels, and significant decreases in peripheral eosinophil counts, serum eosinophil cationic protein (ECP) and sputum ECP were observed in the SPFX-treated group at day 21. sparfloxacin 196-200 C-reactive protein Homo sapiens 34-52 16236899-10 2005 Exhaled ethane concentrations were positively correlated with levels of lactate dehydrogenase (Spearman rank correlation coefficient [rs], 0.28, p = 0.026) and C-reactive protein (rs, 0.38, p = 0.025) and were inversely correlated with Pa(O2) (rs, - 0.40, p = 0.0026). Ethane 8-14 C-reactive protein Homo sapiens 160-178 16168192-11 2005 Serum selenium concentrations were predicted by serum total cholesterol (P<0.01), serum CRP concentrations (P<0.05) and dietary selenium (P<0.03). Selenium 6-14 C-reactive protein Homo sapiens 91-94 15970291-1 2005 OBJECTIVE: To compare the effects of raloxifene, estradiol valerate plus dienogest, and soy isoflavones (genistein) on serum concentrations of high-sensitive C-reactive protein in healthy postmenopausal women. Raloxifene Hydrochloride 37-47 C-reactive protein Homo sapiens 158-176 15976313-6 2005 We conclude that proapoptotic, antiproliferative, antimigratory, and antiangiogenic effects of this commercial CRP preparation on a number of endothelial cell phenotypes in culture may be explained by the presence of sodium azide in this preparation. Sodium Azide 217-229 C-reactive protein Homo sapiens 111-114 15801991-2 2005 The purpose of this study was to determine whether a more potent statin (cerivastatin) would further affect CRP, whether a relation ship between CRP and BChE existed, and if there were any relationships between CRP or BChE and lipids. cerivastatin 73-85 C-reactive protein Homo sapiens 108-111 15801991-8 2005 RESULTS: Median CRP levels at the pravastatin phase, 6 weeks of cerivastatin, and 12 weeks of cerivastatin, were 0.380 mg/dL, 0.403 mg/dL, and 0.364 mg/dL (p = 0.772), respectively. Pravastatin 34-45 C-reactive protein Homo sapiens 16-19 15801991-15 2005 CONCLUSION: Median CRP remained stable with pravastatin and cerivastatin use, although TC and LDL decreased. Pravastatin 44-55 C-reactive protein Homo sapiens 19-22 15801991-15 2005 CONCLUSION: Median CRP remained stable with pravastatin and cerivastatin use, although TC and LDL decreased. cerivastatin 60-72 C-reactive protein Homo sapiens 19-22 15678256-6 2005 In addition, ALA supplementation resulted in a significant decrease in the serum concentration of serum amyloid A (SAA) (p=0.014), C-reactive protein (CRP) (p=0.013), macrophage colony-stimulating factor (MCSF) (p<0.001), and interleukin (IL)-6 (p=0.028). alpha-Linolenic Acid 13-16 C-reactive protein Homo sapiens 131-149 15678256-6 2005 In addition, ALA supplementation resulted in a significant decrease in the serum concentration of serum amyloid A (SAA) (p=0.014), C-reactive protein (CRP) (p=0.013), macrophage colony-stimulating factor (MCSF) (p<0.001), and interleukin (IL)-6 (p=0.028). alpha-Linolenic Acid 13-16 C-reactive protein Homo sapiens 151-154 16331433-5 2005 Adjusted for age, race, and case-control status, mean CRP was 2-fold greater in the highest vs. lowest quartiles of estrone and androstenedione, and CRP was 2-fold less across quartiles of sex hormone binding globulin. Androstenedione 128-143 C-reactive protein Homo sapiens 54-57 16131811-8 2005 Calcium chelator, BAPTA-AM and anti-oxidants such as N-acetylcysteine and tiron suppressed CRP-induced NF-kappaB activation. 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt 74-79 C-reactive protein Homo sapiens 91-94 30142331-0 2018 Paper-based chemiluminescence enzyme-linked immunosorbent assay enhanced by biotin-streptavidin system for high-sensitivity C-reactive protein detection. Biotin 76-82 C-reactive protein Homo sapiens 124-142 29895378-9 2018 Changes in s-selenium were negatively related to changes in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), but there were no significant relationships to any other of the examined risk parameters for CVD including EF. Selenium 13-21 C-reactive protein Homo sapiens 60-78 29895378-9 2018 Changes in s-selenium were negatively related to changes in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), but there were no significant relationships to any other of the examined risk parameters for CVD including EF. Selenium 13-21 C-reactive protein Homo sapiens 80-83 30168206-1 2018 The transcriptional activator CooA belongs to the CRP/FNR (cAMP receptor protein/fumarate and nitrate reductase) superfamily of transcriptional regulators and uses heme to sense carbon monoxide (CO). Heme 164-168 C-reactive protein Homo sapiens 50-57 18356554-1 2008 OBJECTIVE: The purpose of this study was to assess whether increasing serum uric acid (UA) levels are related to cardiovascular disease (CVD) mortality, all-cause mortality, and incident (fatal and nonfatal) myocardial infarction (MI) in men from the general population taking into account C-reactive protein (CRP), a sensitive marker of systemic inflammation. Uric Acid 76-85 C-reactive protein Homo sapiens 310-313 15536598-8 2004 Stratified factor analyses in smoking subgroups, obese, and in under-reporters of energy, largely confirmed the results although in male never-smokers a combination of high fiber vitamin C/beta carotene intake was associated with low CRP levels. beta Carotene 189-202 C-reactive protein Homo sapiens 234-237 18356554-5 2008 In a Cox model, comparing extreme quartiles of the UA distribution, the hazard ratio for CVD mortality was 1.44 (95% confidence interval [CI] 1.04 to 2.0), and for all-cause mortality it was 1.40 (95% CI 1.13 to 1.74) after adjustment for conventional cardiovascular risk factors, CRP, and diuretic intake. Uric Acid 51-53 C-reactive protein Homo sapiens 281-284 19083425-10 2008 Vitamin C intake was independently inversely associated with elevated CRP, although the association was nonsignificant (P = .10). Ascorbic Acid 0-9 C-reactive protein Homo sapiens 70-73 29462102-7 2018 In contrast, reallocating a 30-min period in sedentary (beta = -0.70; P < 0.01) or LPA (beta = -0.71; P < 0.01) with MVPA was associated with a significant reduction in CRP level, whereas no impact on CRP was observed when a period of sedentary behavior was replaced with LPA. lpa 86-89 C-reactive protein Homo sapiens 175-178 29462102-7 2018 In contrast, reallocating a 30-min period in sedentary (beta = -0.70; P < 0.01) or LPA (beta = -0.71; P < 0.01) with MVPA was associated with a significant reduction in CRP level, whereas no impact on CRP was observed when a period of sedentary behavior was replaced with LPA. lpa 86-89 C-reactive protein Homo sapiens 207-210 29462102-7 2018 In contrast, reallocating a 30-min period in sedentary (beta = -0.70; P < 0.01) or LPA (beta = -0.71; P < 0.01) with MVPA was associated with a significant reduction in CRP level, whereas no impact on CRP was observed when a period of sedentary behavior was replaced with LPA. lpa 278-281 C-reactive protein Homo sapiens 175-178 29462102-7 2018 In contrast, reallocating a 30-min period in sedentary (beta = -0.70; P < 0.01) or LPA (beta = -0.71; P < 0.01) with MVPA was associated with a significant reduction in CRP level, whereas no impact on CRP was observed when a period of sedentary behavior was replaced with LPA. lpa 278-281 C-reactive protein Homo sapiens 207-210 15499954-17 2004 Initial leucopenia and a late (12-48 h) increase in CRP are valuable markers for invasive GBS. gbs 90-93 C-reactive protein Homo sapiens 52-55 15308231-1 2004 In this paper, we report the novel electrical measurement for the label-free detection of C-reactive protein (CRP) using resonant frequency shift in the monolithic thin film cantilever of micromachined Pb(Zr0.52Ti0.48)O3 (PZT) which was fabricated with the composition of SiO2/Ta/Pt/PZT/Pt/SiO2 on silicon nitride (SiNx) supporting layer for the dual purpose of electrical self-excitation and sensing. Lead 202-204 C-reactive protein Homo sapiens 90-108 15308231-1 2004 In this paper, we report the novel electrical measurement for the label-free detection of C-reactive protein (CRP) using resonant frequency shift in the monolithic thin film cantilever of micromachined Pb(Zr0.52Ti0.48)O3 (PZT) which was fabricated with the composition of SiO2/Ta/Pt/PZT/Pt/SiO2 on silicon nitride (SiNx) supporting layer for the dual purpose of electrical self-excitation and sensing. Lead 202-204 C-reactive protein Homo sapiens 110-113 15308231-1 2004 In this paper, we report the novel electrical measurement for the label-free detection of C-reactive protein (CRP) using resonant frequency shift in the monolithic thin film cantilever of micromachined Pb(Zr0.52Ti0.48)O3 (PZT) which was fabricated with the composition of SiO2/Ta/Pt/PZT/Pt/SiO2 on silicon nitride (SiNx) supporting layer for the dual purpose of electrical self-excitation and sensing. silicon nitride 298-313 C-reactive protein Homo sapiens 90-108 15308231-1 2004 In this paper, we report the novel electrical measurement for the label-free detection of C-reactive protein (CRP) using resonant frequency shift in the monolithic thin film cantilever of micromachined Pb(Zr0.52Ti0.48)O3 (PZT) which was fabricated with the composition of SiO2/Ta/Pt/PZT/Pt/SiO2 on silicon nitride (SiNx) supporting layer for the dual purpose of electrical self-excitation and sensing. silicon nitride 298-313 C-reactive protein Homo sapiens 110-113 29950204-12 2018 The high dose tigecycline can decrease the temperature, calcitonin and C-reactive protein levels, and can control infection without the hepatic and renal impairment, but it needs to be confimed by more prospective studies. Tigecycline 14-25 C-reactive protein Homo sapiens 71-89 17923463-1 2008 BACKGROUND: The Val-MARC trial showed that the angiotensin receptor blocker valsartan reduces high-sensitivity C reactive protein (hsCRP) levels, an effect that is independent of blood pressure, and seems to be neutralised by the addition of hydrochlorothiazide. Valine 16-19 C-reactive protein Homo sapiens 111-129 29306913-7 2018 To differentiate APA from HS, single variable of acetate, formate, white blood cell (WBC) and C-reactive protein (CRP) showed a high diagnostic value (area under the receiver operating characteristic [AUROC]<0.92), while they had a weak diagnostic value (AUROC<0.77) for identifying the APA and NAI. nai 301-304 C-reactive protein Homo sapiens 114-117 29306913-9 2018 A combination of five variables, i.e. leucine, lactate, betaine, WBC and CRP, showed a high diagnostic value (AUROC=0.973) for the APA discriminating from the NAI, and the sensitivity and specificity were 93.8% and 93.7%, respectively. nai 159-162 C-reactive protein Homo sapiens 73-76 15163463-12 2004 There was significant positive correlation between CRP and DIVCi (r=0.43, p <0.05) and IVCe (r=0.45, p <0.05) and between serum albumin and creatinine dialysate-to-plasma ratio (D/P Cr, r=0.57, p <0.01). Chromium 188-190 C-reactive protein Homo sapiens 51-54 18007271-3 2008 The objective was to determine the correlation of bacterial load, measured by quantitative tracheal aspirate (QTA), with serum C-reactive protein as an indicator of inflammatory response in episodes of ventilator-associated pneumonia and association of its variation with antibiotic appropriateness. 3-(phenylsulfonyl)benzene-1-sulfonamide 110-113 C-reactive protein Homo sapiens 127-145 14767534-10 2004 All these beneficial effects were parallel to a decrease in systemic inflammation (C-reactive protein, erythrocyte sedimentation rate) in cancer patients on indomethacin (p<0.0004). Indomethacin 157-169 C-reactive protein Homo sapiens 83-101 29362264-7 2018 RESULTS: In both sexes, greater CWh at 1 year was positively associated with BMI and WC, whereas greater CWh at most age periods in childhood and adolescence predicted higher CRP, TC, LDL-C, TGL, SBP, DBP, BMI and WC levels, as well as lower HDL-C level. [(2~{S},5~{R},8~{S},11~{S})-1-[(2~{R},3~{R},5~{R},6~{S})-3,5-dimethyl-6-oxidanyl-4-oxidanylidene-oxan-2-yl]-5,11-dimethyl-8-oxidanyl-13-[[(2~{S})-2-oxidanylpropanoyl]amino]tridecan-2-yl] ethanoate 105-108 C-reactive protein Homo sapiens 175-178 14504096-7 2004 The position of lysine59 on the apical surface of GPVI suggests a mode of CRP binding analogous to that used by the related killer cell Ig-like receptors to bind HLA. lysine59 16-24 C-reactive protein Homo sapiens 74-77 17311055-1 2008 OBJECTIVE: To examine the association between plasma concentrations of C-reactive protein (CRP) and the intake of vitamins and trace elements from supplements possibly related to inflammation such as vitamin C, vitamin E, carotenoids, selenium and zinc. Ascorbic Acid 200-209 C-reactive protein Homo sapiens 71-89 12947436-0 2003 C-reactive protein concentration and concentrations of blood vitamins, carotenoids, and selenium among United States adults. Selenium 88-96 C-reactive protein Homo sapiens 0-18 12947436-1 2003 OBJECTIVE: To examine the relationships between circulating concentrations of C-reactive protein and concentrations of retinol, retinyl esters, vitamin C, vitamin E, carotenoids, and selenium. Selenium 183-191 C-reactive protein Homo sapiens 78-96 12947436-5 2003 RESULTS: C-reactive protein concentration (dichotomized at the sex-specific 85th percentile) was inversely and significantly associated with concentrations of retinol, retinyl esters, vitamin C, alpha-carotene, beta-carotene, cryptoxanthin, lutein/zeaxanthin, lycopene, and selenium after adjustment for age, sex, race or ethnicity, education, cotinine concentration, body mass index, leisure-time physical activity, and aspirin use. beta Carotene 211-224 C-reactive protein Homo sapiens 9-27 28846105-9 2018 Treatment with an inflammatory lipid sphingosine-1-phosphate induced CRP, which may be secreted and exert an autocrine effect by binding to FcgammaRI and integrin alpha2. sphingosine 1-phosphate 37-60 C-reactive protein Homo sapiens 69-72 12741936-7 2003 There were significant inverse linear relationships between concentrations of CRP and plasma concentrations of the antioxidants lycopene, beta-carotene, cryptoxanthin and retinol. beta Carotene 138-151 C-reactive protein Homo sapiens 78-81 17311055-1 2008 OBJECTIVE: To examine the association between plasma concentrations of C-reactive protein (CRP) and the intake of vitamins and trace elements from supplements possibly related to inflammation such as vitamin C, vitamin E, carotenoids, selenium and zinc. Ascorbic Acid 200-209 C-reactive protein Homo sapiens 91-94 12667067-1 2003 A cyclic nucleotide-binding pocket of the CRP dimer is composed of amino acid residues contributed by both subunits. Nucleotides, Cyclic 2-19 C-reactive protein Homo sapiens 42-45 12667067-6 2003 Substitution of L124 with isoleucine (I), valine (V), cysteine (C), or alanine (A) generated a series of CRP variants that exhibited unique differences in apo-CRP resistance to protease, the mass of the core fragments generated in protease digestion reactions, cAMP-mediated allostery, and CRP-cAMP complex functionality. 2,6-DIISOPROPYLNAPHTHALENE 16-20 C-reactive protein Homo sapiens 105-108 29301121-0 2018 Association of Soluble Interleukin-2 Receptor and C-Reactive Protein with the Efficacy of Bendamustine Salvage Treatment for Indolent Lymphomas and Mantle Cell Lymphoma. Bendamustine Hydrochloride 90-102 C-reactive protein Homo sapiens 50-68 29301121-5 2018 The CR rate was significantly low in patients who had elevated levels of soluble interleukin-2 receptor (p = 0.024) and C-reactive protein (CRP; p = 0.004). Chromium 4-6 C-reactive protein Homo sapiens 120-138 29301121-5 2018 The CR rate was significantly low in patients who had elevated levels of soluble interleukin-2 receptor (p = 0.024) and C-reactive protein (CRP; p = 0.004). Chromium 4-6 C-reactive protein Homo sapiens 140-143 12818406-0 2003 Dietary alpha-linolenic acid decreases C-reactive protein, serum amyloid A and interleukin-6 in dyslipidaemic patients. alpha-Linolenic Acid 8-28 C-reactive protein Homo sapiens 39-57 17311055-6 2008 Especially vitamin E in combination with other vitamins like vitamin C, vitamin B(1), B(2), B(6), B(12), niacin, folic acid, pantothenic acid and selenium, was significantly associated with lower CRP levels. Niacin 105-111 C-reactive protein Homo sapiens 196-199 12818406-9 2003 RESULTS: Dietary supplementation with ALA decreased significantly CRP, SAA and IL-6 levels. alpha-Linolenic Acid 38-41 C-reactive protein Homo sapiens 66-69 12818406-13 2003 CONCLUSIONS: Dietary supplementation with ALA for 3 months decreases significantly CRP, SAA and IL-6 levels in dyslipidaemic patients. alpha-Linolenic Acid 42-45 C-reactive protein Homo sapiens 83-86 29466790-7 2018 The diagnostic accuracy for SB CD based on SBCE result was calculated for both FC and CRP. sb cd 28-33 C-reactive protein Homo sapiens 86-89 18023360-0 2007 Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin. Simvastatin 79-90 C-reactive protein Homo sapiens 10-28 28818242-4 2017 RESULTS: Women, blacks, Hispanics, and socioeconomically disadvantaged groups had higher risks of obesity and elevated C-reactive protein, with the SES gradients being more pronounced in female participants. Selenium 148-151 C-reactive protein Homo sapiens 119-137 12531220-1 2003 In a recent phase I study, a combination of gemcitabine at 10 mg/(m(2)min) for 12 h and mitoxantrone 12 mg/m(2) daily for 3 days, achieved a complete remission (CR) in 3 of 12 (25%) patients with refractory leukemia. Mitoxantrone 88-100 C-reactive protein Homo sapiens 161-163 18023360-5 2007 PURPOSE: The aim of the present study, therefore, was to assess the effects of both CRP on resistin expression and simvastatin on CRP-induced of resistin expression in cultured human PBMC. Simvastatin 115-126 C-reactive protein Homo sapiens 130-133 28832630-0 2017 Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D. BACKGROUND: The systemic inflammation is associated with clinical outcome and mortality in chronic obstructive pulmonary disease (COPD) patients. Formoterol Fumarate 36-46 C-reactive protein Homo sapiens 70-73 18023360-12 2007 Co-incubation with simvastatin significantly inhibited CRP-induced up-regulation of mRNA and protein expression of resistin. Simvastatin 19-30 C-reactive protein Homo sapiens 55-58 28832630-6 2017 CONCLUSIONS: A long-term treatment with Bud/Form alone or together with Tio can attenuate circulating CRP levels in COPD patients of group D, compared with Tio alone. Tiotropium Bromide 72-75 C-reactive protein Homo sapiens 102-105 12841342-0 2003 The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. cerivastatin 33-45 C-reactive protein Homo sapiens 68-86 12841342-1 2003 The aim of our study was to evaluate whether a single dose of cerivastatin at the time of admission of patients with unstable angina pectoris (UAP) or non-Q-wave myocardial infarction (NQMI) can influence the serum level of C-reactive protein (CRP), interleukin-6 (IL-6) and interleukin-8 (IL-8) 24 h later. cerivastatin 62-74 C-reactive protein Homo sapiens 224-242 18023360-14 2007 CONCLUSIONS: In the present study, the data showed that CRP could significantly increase resistin expression in cultured human PBMC, and this effect was inhibited by simvastatin, suggesting that CRP and resistin might be involved in the pathogenesis of atherosclerosis, and statin therapy might be beneficial for atherosclerotic disease by modifying CRP-induced resistin overexpression in PBMC. Simvastatin 166-177 C-reactive protein Homo sapiens 56-59 12841342-1 2003 The aim of our study was to evaluate whether a single dose of cerivastatin at the time of admission of patients with unstable angina pectoris (UAP) or non-Q-wave myocardial infarction (NQMI) can influence the serum level of C-reactive protein (CRP), interleukin-6 (IL-6) and interleukin-8 (IL-8) 24 h later. cerivastatin 62-74 C-reactive protein Homo sapiens 244-247 12841342-6 2003 In patients treated with cerivastatin (group C+, n = 13) we observed decrease in the CRP level (-6.73 +/- 3.93 mg/L); on the other hand, in group C- (n = 17) the CRP level increased (+7.92 +/- 2.77 mg/L, p = 0.004). cerivastatin 25-37 C-reactive protein Homo sapiens 85-88 18023360-14 2007 CONCLUSIONS: In the present study, the data showed that CRP could significantly increase resistin expression in cultured human PBMC, and this effect was inhibited by simvastatin, suggesting that CRP and resistin might be involved in the pathogenesis of atherosclerosis, and statin therapy might be beneficial for atherosclerotic disease by modifying CRP-induced resistin overexpression in PBMC. Simvastatin 166-177 C-reactive protein Homo sapiens 195-198 12841342-6 2003 In patients treated with cerivastatin (group C+, n = 13) we observed decrease in the CRP level (-6.73 +/- 3.93 mg/L); on the other hand, in group C- (n = 17) the CRP level increased (+7.92 +/- 2.77 mg/L, p = 0.004). cerivastatin 25-37 C-reactive protein Homo sapiens 162-165 12841342-9 2003 Our results suggest that early treatment with cerivastatin can decrease the serum level of CRP and IL-6 in patients with UAP/NQMI; this might positively influence their prognosis. cerivastatin 46-58 C-reactive protein Homo sapiens 91-94 28291838-9 2017 At multivariate analysis, age, female gender, HbA1c, BMI or waist circumference, and high-sensitivity C reactive protein (for LPA and SED-time only) were negatively associated with LPA and MPA and positively associated with SED-time in an independent manner. lpa 126-129 C-reactive protein Homo sapiens 102-120 18023360-14 2007 CONCLUSIONS: In the present study, the data showed that CRP could significantly increase resistin expression in cultured human PBMC, and this effect was inhibited by simvastatin, suggesting that CRP and resistin might be involved in the pathogenesis of atherosclerosis, and statin therapy might be beneficial for atherosclerotic disease by modifying CRP-induced resistin overexpression in PBMC. Simvastatin 166-177 C-reactive protein Homo sapiens 195-198 12595863-0 2003 Effect of atorvastatin and pravastatin on serum C-reactive protein. Pravastatin 27-38 C-reactive protein Homo sapiens 48-66 17929239-6 2007 Our experimental results demonstrate that betulin disulphate (B2S) and 9,9-bis(4"-hydroxyphenyl)fluorene disulphate (F2S) inhibit the interaction of C1q and its recombinant globular modules with target molecules IgG1, C-reactive protein (CRP) and long pentraxin 3 (PTX3). 11-[(2R)-butan-2-yl]-2-({2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]phenyl}amino)-5-methyl-5,11-dihydro-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one 117-120 C-reactive protein Homo sapiens 218-242 12595863-5 2003 A reduced or unchanged CRP level was seen in 67.2% of pravastatin-treated patients (45/67) and 73% of atorvastatin- treated patients (46/63) (P =.47). Pravastatin 54-65 C-reactive protein Homo sapiens 23-26 12595863-7 2003 However, whereas the reduction of CRP with pravastatin was unrelated to the degree of low-density lipoprotein reduction (r = -.05, P =.69), atorvastatin-induced CRP reductions correlated directly to the change in low-density lipoprotein-C (r =.33, P =.009). Pravastatin 43-54 C-reactive protein Homo sapiens 34-37 12595863-8 2003 CONCLUSIONS: High-dose atorvastatin and pravastatin both reduce CRP levels. Pravastatin 40-51 C-reactive protein Homo sapiens 64-67 12595863-9 2003 However, whereas pravastatin"s effect on CRP is independent of lipid-lowering efficacy, these data suggest that lipid-dependent mechanisms are, at least in part, active in atorvastatin-treated patients. Pravastatin 17-28 C-reactive protein Homo sapiens 41-44 12618085-7 2003 We genotyped representative SNPs in approximately 1300 Pima samples and found a single variant in the CRP promoter (SNP 133552) that was associated with T2DM (P=0.014), as well as a common haplotype (CGCG) that was associated with both T2DM (P=0.029) and corrected insulin response, a surrogate measure of insulin secretion in non-diabetic subjects (P=0.050). cgcg 200-204 C-reactive protein Homo sapiens 102-105 27834186-3 2016 OBJECTIVE: In this study, we assessed the impact of CLA supplementation on the levels of atherosclerosis markers - high-sensitivity C-reactive protein (hs-CRP) and asymmetrical dimethylarginine (ADMA). Linoleic Acids, Conjugated 52-55 C-reactive protein Homo sapiens 132-150 26922829-8 2016 RESULTS: Here, we demonstrated that CL-P1 bound CRP in a charge dependent manner and the interaction of CRP with CL-P1 mediated a classical complement activation pathway through C1q and additionally drove an amplification pathway using properdin. cl-p1 36-41 C-reactive protein Homo sapiens 48-51 26922829-8 2016 RESULTS: Here, we demonstrated that CL-P1 bound CRP in a charge dependent manner and the interaction of CRP with CL-P1 mediated a classical complement activation pathway through C1q and additionally drove an amplification pathway using properdin. cl-p1 36-41 C-reactive protein Homo sapiens 104-107 26922829-8 2016 RESULTS: Here, we demonstrated that CL-P1 bound CRP in a charge dependent manner and the interaction of CRP with CL-P1 mediated a classical complement activation pathway through C1q and additionally drove an amplification pathway using properdin. cl-p1 113-118 C-reactive protein Homo sapiens 104-107 12033985-4 2002 CRP molecules were aggregated in the presence of calcium and immobilized on the surface of polystyrene microtitre wells. Polystyrenes 91-102 C-reactive protein Homo sapiens 0-3 17761368-9 2007 tHcy showed significant correlations with hs-CRP (rs = 0.35; P = 0.003) and low-density lipoprotein-cholesterol (LDL-C; rs = 0.49; P = 0.005). thcy 0-4 C-reactive protein Homo sapiens 45-48 11577954-6 2001 METHODS: CRP serum levels were assessed using radial immunodiffusion assay in 174 subjects, 59 with moderate mean clinical attachment loss (AL) (2.39+/-0.29 mm) and 50 with high AL (3.79+/-0.86 mm) as compared to 65 periodontally healthy controls (AL, 1.74+/-0.18 mm). Aluminum 178-180 C-reactive protein Homo sapiens 9-12 11577954-17 2001 The percentage of subjects with elevated levels of CRP > or = 3 mm was significantly higher in the high clinical AL group (38%; 95% Cl: 26.7%, 49.3%) when compared to the control group (16.9%; 95% CI: 9.25%, 24.5%), P= 0.011. Aluminum 116-118 C-reactive protein Homo sapiens 51-54 11274243-4 2001 Patients with an elevated CRP (>6 mg/L; n = 29) had significantly reduced plasma prealbumin (0.36 +/- 0.02 versus 0.44 +/- 0.03 g/L; P: < 0.05), decreased total weekly creatinine clearance (C(Cr); 52.5 +/- 2.3 versus 63.1 +/- 3.2 L/1.73 m(2); P: < 0.01), and increased left ventricular thickness (1.24 +/- 0.05 versus 1.08 +/- 0.06 cm; P: < 0.05) at baseline compared with those who had a normal CRP (< or =6 mg/L; n = 21). Chromium 198-200 C-reactive protein Homo sapiens 26-29 26922829-9 2016 However, CRP also recruits complement factor H (CFH) on CL-P1 expressing cell surfaces, to inhibit the formation of a terminal complement complex in normal complement serum conditions. cl-p1 56-61 C-reactive protein Homo sapiens 9-12 26922829-10 2016 GENERAL SIGNIFICANCE: The interaction of collectin CL-P1 with CFH might be key for preventing attack on "self" as a result of complement activation induced by the CL-P1 and CRP interaction. cl-p1 51-56 C-reactive protein Homo sapiens 173-176 26303195-9 2016 A consumption of added sugars of >=10 % of the energy intake is associated with a more adverse plasma lipids profile and higher CRP than lower intake. Sugars 23-29 C-reactive protein Homo sapiens 131-134 26747436-8 2016 The effect size on plasma CRP concentrations was significant with lipophilic (atorvastatin) but not hydrophilic (pravastatin and rosuvastatin) statins. Pravastatin 113-124 C-reactive protein Homo sapiens 26-29 17761368-12 2007 These data support 4 main conclusions: (1) Elevation of hs-CRP and tHcy are common in CVD; (2) the significant relationship between tHcy and hs-CRP suggests that the association of tHcy with CVD risk may be dependent on inflammation-related mechanisms; (3) increased hs-CRP and tHcy show that patients with CVD may be at greater risk of subsequent coronary heart disease; and (4) admission hs-CRP could be used as an indicator of prognosis. thcy 132-136 C-reactive protein Homo sapiens 59-62 11305529-14 2001 In the secondary prevention model, hs-testing for CRP can reduce the cost-effectiveness of pravastatin from 16400 to 6830euro per quality adjusted life year gained. Pravastatin 91-102 C-reactive protein Homo sapiens 50-53 17761368-12 2007 These data support 4 main conclusions: (1) Elevation of hs-CRP and tHcy are common in CVD; (2) the significant relationship between tHcy and hs-CRP suggests that the association of tHcy with CVD risk may be dependent on inflammation-related mechanisms; (3) increased hs-CRP and tHcy show that patients with CVD may be at greater risk of subsequent coronary heart disease; and (4) admission hs-CRP could be used as an indicator of prognosis. thcy 132-136 C-reactive protein Homo sapiens 144-147 17761368-12 2007 These data support 4 main conclusions: (1) Elevation of hs-CRP and tHcy are common in CVD; (2) the significant relationship between tHcy and hs-CRP suggests that the association of tHcy with CVD risk may be dependent on inflammation-related mechanisms; (3) increased hs-CRP and tHcy show that patients with CVD may be at greater risk of subsequent coronary heart disease; and (4) admission hs-CRP could be used as an indicator of prognosis. thcy 132-136 C-reactive protein Homo sapiens 144-147 25753552-1 2016 BACKGROUND & AIM: The magnitude of systemic inflammatory response, as evidenced by C-reactive protein (CRP), is a major factor associated with lower zinc and selenium. Selenium 162-170 C-reactive protein Homo sapiens 87-105 25753552-1 2016 BACKGROUND & AIM: The magnitude of systemic inflammatory response, as evidenced by C-reactive protein (CRP), is a major factor associated with lower zinc and selenium. Selenium 162-170 C-reactive protein Homo sapiens 107-110 17761368-12 2007 These data support 4 main conclusions: (1) Elevation of hs-CRP and tHcy are common in CVD; (2) the significant relationship between tHcy and hs-CRP suggests that the association of tHcy with CVD risk may be dependent on inflammation-related mechanisms; (3) increased hs-CRP and tHcy show that patients with CVD may be at greater risk of subsequent coronary heart disease; and (4) admission hs-CRP could be used as an indicator of prognosis. thcy 132-136 C-reactive protein Homo sapiens 144-147 25753552-8 2016 Plasma selenium was significantly associated with CRP (rs = -0.489, p < 0.001) and albumin (rs = 0.600, p < 0.001). Selenium 7-15 C-reactive protein Homo sapiens 50-53 11059546-4 2000 RESULTS: Compared with each of the other variables, the Az for serum CRP (0.97 +/- 0.02) was found to be significantly greater (P < 0.01) for all except pABM (0.99 +/- 0.01; P > 0.05). pabm 156-160 C-reactive protein Homo sapiens 69-72 25753552-9 2016 With increasing CRP category (<=10, 11-80, >80 mg/l) the selenium/albumin ratio x100 was lower (2.3, 2.1 and 1.8 respectively, p < 0.001). Selenium 63-71 C-reactive protein Homo sapiens 16-19 25753552-13 2016 Plasma selenium was associated with both CRP and albumin. Selenium 7-15 C-reactive protein Homo sapiens 41-44 26865526-6 2016 Sensitivity of LAM increased significantly among participants with a lower Karnofsky Performance score, anemia, hypoalbuminemia, and higher C-reactive protein. lipoarabinomannan 15-18 C-reactive protein Homo sapiens 140-158 26865526-8 2016 The combination of LAM and AFB was significantly better than AFB alone among patients with Karnofsky Performance score <=90, hemoglobin <=10 g/dL, albumin <=25 g/L, C-reactive protein >=25 mg/L, or CD4 <200/mm(3). lipoarabinomannan 19-22 C-reactive protein Homo sapiens 174-192 26523504-4 2016 The impedance measurements were highly target specific, linear with logarithmic CRP concentrations in PBS and human serum across a 1 ng mL(-1) and 1000 ng mL(-1) range and associated with a detection limits of 0.06 and 0.08 ng mL(-1) respectively. Lead 102-105 C-reactive protein Homo sapiens 80-83 10886221-3 2000 A strong inhibition of IL-6 activity evaluated by quantification of C-reactive protein was observed in all patients and was correlated with the high CR rate achieved with this combination therapy. Chromium 149-151 C-reactive protein Homo sapiens 68-86 17761368-12 2007 These data support 4 main conclusions: (1) Elevation of hs-CRP and tHcy are common in CVD; (2) the significant relationship between tHcy and hs-CRP suggests that the association of tHcy with CVD risk may be dependent on inflammation-related mechanisms; (3) increased hs-CRP and tHcy show that patients with CVD may be at greater risk of subsequent coronary heart disease; and (4) admission hs-CRP could be used as an indicator of prognosis. thcy 132-136 C-reactive protein Homo sapiens 59-62 10411845-0 1999 Long-term effects of pravastatin on plasma concentration of C-reactive protein. Pravastatin 21-32 C-reactive protein Homo sapiens 60-78 26546248-7 2016 CRP levels also significantly correlated with an elevated ventilation/carbon dioxide production slope (R = +0.64, p = 0.008), a reduced oxygen uptake efficiency slope (R = -0.55, p = 0.026), and reduced end-tidal CO2 level at rest and with exercise (R = -0.759, p = 0.001 and R = -0.739, p = 0.001, respectively), reflecting impaired gas exchange. Carbon Dioxide 70-84 C-reactive protein Homo sapiens 0-3 26546248-7 2016 CRP levels also significantly correlated with an elevated ventilation/carbon dioxide production slope (R = +0.64, p = 0.008), a reduced oxygen uptake efficiency slope (R = -0.55, p = 0.026), and reduced end-tidal CO2 level at rest and with exercise (R = -0.759, p = 0.001 and R = -0.739, p = 0.001, respectively), reflecting impaired gas exchange. Carbon Dioxide 213-216 C-reactive protein Homo sapiens 0-3 10411845-8 1999 By contrast, median CRP levels and the mean change in CRP decreased over time among those allocated to pravastatin (median change, -17.4%; P=0.004 and mean change, -0.07 mg/dL; P=0.002). Pravastatin 103-114 C-reactive protein Homo sapiens 20-23 17761368-12 2007 These data support 4 main conclusions: (1) Elevation of hs-CRP and tHcy are common in CVD; (2) the significant relationship between tHcy and hs-CRP suggests that the association of tHcy with CVD risk may be dependent on inflammation-related mechanisms; (3) increased hs-CRP and tHcy show that patients with CVD may be at greater risk of subsequent coronary heart disease; and (4) admission hs-CRP could be used as an indicator of prognosis. thcy 132-136 C-reactive protein Homo sapiens 144-147 10411845-8 1999 By contrast, median CRP levels and the mean change in CRP decreased over time among those allocated to pravastatin (median change, -17.4%; P=0.004 and mean change, -0.07 mg/dL; P=0.002). Pravastatin 103-114 C-reactive protein Homo sapiens 54-57 17761368-12 2007 These data support 4 main conclusions: (1) Elevation of hs-CRP and tHcy are common in CVD; (2) the significant relationship between tHcy and hs-CRP suggests that the association of tHcy with CVD risk may be dependent on inflammation-related mechanisms; (3) increased hs-CRP and tHcy show that patients with CVD may be at greater risk of subsequent coronary heart disease; and (4) admission hs-CRP could be used as an indicator of prognosis. thcy 132-136 C-reactive protein Homo sapiens 144-147 10411845-9 1999 Thus, statistically significant differences were observed at 5 years between the pravastatin and placebo groups in terms of median CRP levels (difference, -21.6%; P=0.007), mean CRP levels (difference, -37.8%; P=0.002), and absolute mean change in CRP (difference, -0.137 mg/dL; P=0.003). Pravastatin 81-92 C-reactive protein Homo sapiens 131-134 10411845-9 1999 Thus, statistically significant differences were observed at 5 years between the pravastatin and placebo groups in terms of median CRP levels (difference, -21.6%; P=0.007), mean CRP levels (difference, -37.8%; P=0.002), and absolute mean change in CRP (difference, -0.137 mg/dL; P=0.003). Pravastatin 81-92 C-reactive protein Homo sapiens 178-181 17761368-12 2007 These data support 4 main conclusions: (1) Elevation of hs-CRP and tHcy are common in CVD; (2) the significant relationship between tHcy and hs-CRP suggests that the association of tHcy with CVD risk may be dependent on inflammation-related mechanisms; (3) increased hs-CRP and tHcy show that patients with CVD may be at greater risk of subsequent coronary heart disease; and (4) admission hs-CRP could be used as an indicator of prognosis. thcy 132-136 C-reactive protein Homo sapiens 144-147 10411845-9 1999 Thus, statistically significant differences were observed at 5 years between the pravastatin and placebo groups in terms of median CRP levels (difference, -21.6%; P=0.007), mean CRP levels (difference, -37.8%; P=0.002), and absolute mean change in CRP (difference, -0.137 mg/dL; P=0.003). Pravastatin 81-92 C-reactive protein Homo sapiens 178-181 26382010-7 2016 Women with gestational diabetes who received omega-3 had significantly lower serum C-reactive protein concentrations, low incidence of hyperbilirubinemia in newborns and decreased newborns" hospitalization rate. omega-3 45-52 C-reactive protein Homo sapiens 83-101 10066748-7 1999 Small angle neutron scattering measurements on the lacDNA.CRP(cAMP)2 complex in D2O/H2O mixtures show that the DNA is bent around the cAMP-ligated protein in solution. Deuterium Oxide 80-83 C-reactive protein Homo sapiens 58-61 17761368-12 2007 These data support 4 main conclusions: (1) Elevation of hs-CRP and tHcy are common in CVD; (2) the significant relationship between tHcy and hs-CRP suggests that the association of tHcy with CVD risk may be dependent on inflammation-related mechanisms; (3) increased hs-CRP and tHcy show that patients with CVD may be at greater risk of subsequent coronary heart disease; and (4) admission hs-CRP could be used as an indicator of prognosis. thcy 132-136 C-reactive protein Homo sapiens 59-62 17761368-12 2007 These data support 4 main conclusions: (1) Elevation of hs-CRP and tHcy are common in CVD; (2) the significant relationship between tHcy and hs-CRP suggests that the association of tHcy with CVD risk may be dependent on inflammation-related mechanisms; (3) increased hs-CRP and tHcy show that patients with CVD may be at greater risk of subsequent coronary heart disease; and (4) admission hs-CRP could be used as an indicator of prognosis. thcy 132-136 C-reactive protein Homo sapiens 144-147 17761368-12 2007 These data support 4 main conclusions: (1) Elevation of hs-CRP and tHcy are common in CVD; (2) the significant relationship between tHcy and hs-CRP suggests that the association of tHcy with CVD risk may be dependent on inflammation-related mechanisms; (3) increased hs-CRP and tHcy show that patients with CVD may be at greater risk of subsequent coronary heart disease; and (4) admission hs-CRP could be used as an indicator of prognosis. thcy 132-136 C-reactive protein Homo sapiens 144-147 17761368-12 2007 These data support 4 main conclusions: (1) Elevation of hs-CRP and tHcy are common in CVD; (2) the significant relationship between tHcy and hs-CRP suggests that the association of tHcy with CVD risk may be dependent on inflammation-related mechanisms; (3) increased hs-CRP and tHcy show that patients with CVD may be at greater risk of subsequent coronary heart disease; and (4) admission hs-CRP could be used as an indicator of prognosis. thcy 132-136 C-reactive protein Homo sapiens 144-147 9532638-8 1997 Plasma levels of C-reactive protein are all within normal limits, which may suggest that PA activity is restricted to a local inflammatory reaction in the airway mucosa. Protactinium 89-91 C-reactive protein Homo sapiens 17-35 9343841-8 1997 In the NSCLC patients there were significant negative correlations between concentrations of C-reactive protein and iron, transferrin, zinc, albumin, and selenium (p < 0.05). Selenium 154-162 C-reactive protein Homo sapiens 93-111 25989112-10 2016 Ks inversely correlated with fibrinogen, PF4 and C-reactive protein. Potassium 0-2 C-reactive protein Homo sapiens 49-67 26549279-0 2015 Java project on periodontal diseases: effect of vitamin C/calcium threonate/citrus flavonoids supplementation on periodontal pathogens, CRP and HbA1c. threonic acid 58-75 C-reactive protein Homo sapiens 136-139 17519643-10 2007 Glucose, insulin, the insulin resistance index and the CRP levels significantly increased after olanzapine. Olanzapine 96-106 C-reactive protein Homo sapiens 55-58 26708875-3 2015 RESULTS: The CRP and D-D levels in AL+DIC group were significantly higher than those in AL and control groups (P < 0.05); the CRP and D-D levels in AL group were significatly higher than those in control group (P < 0.05). Aluminum 35-37 C-reactive protein Homo sapiens 13-16 26708875-5 2015 After treatment of patients, the CRP and D-D levels in AL and AL+DIC groups were obviously reduced as compared with levels of these 2 groups before treatment (P <0.05); the CRP and D-D levels in AL+DIC after treatment were significantly higher than those in AL group (P <0.05). Aluminum 55-57 C-reactive protein Homo sapiens 33-36 26708875-5 2015 After treatment of patients, the CRP and D-D levels in AL and AL+DIC groups were obviously reduced as compared with levels of these 2 groups before treatment (P <0.05); the CRP and D-D levels in AL+DIC after treatment were significantly higher than those in AL group (P <0.05). Aluminum 55-57 C-reactive protein Homo sapiens 176-179 26708875-5 2015 After treatment of patients, the CRP and D-D levels in AL and AL+DIC groups were obviously reduced as compared with levels of these 2 groups before treatment (P <0.05); the CRP and D-D levels in AL+DIC after treatment were significantly higher than those in AL group (P <0.05). Aluminum 62-64 C-reactive protein Homo sapiens 33-36 26708875-5 2015 After treatment of patients, the CRP and D-D levels in AL and AL+DIC groups were obviously reduced as compared with levels of these 2 groups before treatment (P <0.05); the CRP and D-D levels in AL+DIC after treatment were significantly higher than those in AL group (P <0.05). Aluminum 62-64 C-reactive protein Homo sapiens 176-179 26708875-6 2015 CONCLUSION: The combined detection of CRP and D-D possesses a higher reference value for diagnosis and differentiation of AL and AL complicated with DIC, thus also has an important role in evaluation of therapeutic efficacy of AL. Aluminum 122-124 C-reactive protein Homo sapiens 38-41 8743104-0 1996 C-reactive protein: the difference between quantitation is serum and EDTA plasma. Edetic Acid 69-73 C-reactive protein Homo sapiens 0-18 8743104-1 1996 We report the differences between using either EDTA plasma or serum in a turbidimetric assay for quantitation of C-reactive protein (CRP). Edetic Acid 47-51 C-reactive protein Homo sapiens 113-131 8743104-1 1996 We report the differences between using either EDTA plasma or serum in a turbidimetric assay for quantitation of C-reactive protein (CRP). Edetic Acid 47-51 C-reactive protein Homo sapiens 133-136 8743104-8 1996 We discuss the role and function of EDTA in the CRP assay and suggest some hypothetical mechanisms. Edetic Acid 36-40 C-reactive protein Homo sapiens 48-51 26708875-6 2015 CONCLUSION: The combined detection of CRP and D-D possesses a higher reference value for diagnosis and differentiation of AL and AL complicated with DIC, thus also has an important role in evaluation of therapeutic efficacy of AL. Aluminum 129-131 C-reactive protein Homo sapiens 38-41 17351110-10 2007 Single-agent treatment with tipifarnib induced durable CR/CRp, which was associated with prolonged survival, in some patients with refractory or relapsed AML. tipifarnib 28-38 C-reactive protein Homo sapiens 55-57 26708875-6 2015 CONCLUSION: The combined detection of CRP and D-D possesses a higher reference value for diagnosis and differentiation of AL and AL complicated with DIC, thus also has an important role in evaluation of therapeutic efficacy of AL. Aluminum 129-131 C-reactive protein Homo sapiens 38-41 25893544-0 2015 Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome. icosapent ethyl (eicosapentaenoic acid ethyl ester) 0-51 C-reactive protein Homo sapiens 83-101 8603223-7 1996 The data show a correlation between the serum concentrations of TBAs with those of alanine aminotransferase (P=.03, Pearson"s correlation coefficient), total bilirubin (P<.001, Pearson"s correlation coefficient), and C-reactive protein (P=.01, Pearson"s correlation coefficient) measured during the acute phase. tbas 64-68 C-reactive protein Homo sapiens 220-238 17351110-10 2007 Single-agent treatment with tipifarnib induced durable CR/CRp, which was associated with prolonged survival, in some patients with refractory or relapsed AML. tipifarnib 28-38 C-reactive protein Homo sapiens 58-61 8196672-10 1994 The results suggest that the two distinct Ca(2+)-binding sites within each CRP subunit are composed of residues 134-148 and 152-176 and that these two nearly adjacent sites cooperate to exert an allosteric change in conformation allowing access to the PC-binding site. pc 252-254 C-reactive protein Homo sapiens 75-78 17299064-7 2007 RESULTS: PioFluMet reduced intima-media thickness more than FluMet and lowered glucose, IGF-I, and C-reactive protein more as well as the ratio of low-density lipoprotein to high-density lipoprotein cholesterol and the ratio of neutrophils to lymphocytes. flumet 12-18 C-reactive protein Homo sapiens 99-117 8203284-17 1994 Three other Cys-rich proteins, papilloma viral E7 and LIM motif-containing CRP and CRIP, isolated as Zn2+ proteins exhibit facile metal exchange in vitro with Cu1+. cuprous ion 159-163 C-reactive protein Homo sapiens 75-78 25963300-6 2015 It detected CRP spiked in diluted human whole blood, serum and plasma as well as the CRP levels in the ethylenediaminetetraacetic acid (EDTA) plasma samples of patients with the same precision as the clinically-accredited analyzer-based IA and conventional CRP sandwich ELISA. Edetic Acid 103-134 C-reactive protein Homo sapiens 85-88 25963300-6 2015 It detected CRP spiked in diluted human whole blood, serum and plasma as well as the CRP levels in the ethylenediaminetetraacetic acid (EDTA) plasma samples of patients with the same precision as the clinically-accredited analyzer-based IA and conventional CRP sandwich ELISA. Edetic Acid 103-134 C-reactive protein Homo sapiens 85-88 25963300-6 2015 It detected CRP spiked in diluted human whole blood, serum and plasma as well as the CRP levels in the ethylenediaminetetraacetic acid (EDTA) plasma samples of patients with the same precision as the clinically-accredited analyzer-based IA and conventional CRP sandwich ELISA. Edetic Acid 136-140 C-reactive protein Homo sapiens 85-88 25963300-6 2015 It detected CRP spiked in diluted human whole blood, serum and plasma as well as the CRP levels in the ethylenediaminetetraacetic acid (EDTA) plasma samples of patients with the same precision as the clinically-accredited analyzer-based IA and conventional CRP sandwich ELISA. Edetic Acid 136-140 C-reactive protein Homo sapiens 85-88 8215065-0 1993 Relationship of parotid saliva C-reactive protein to catecholamine release. Catecholamines 53-66 C-reactive protein Homo sapiens 31-49 17495273-6 2007 Compared with those with low CRP levels, subjects with high CRP levels (ie, >3.0 mg/L) were physically inactive (P = .01), were less likely to adopt the Mediterranean diet (P = .008), had higher glucose levels, had a higher prevalence of hypertension, had a lower high-density lipoprotein cholesterol, and had increased smoking habits and higher anthropometric indices (all P < .05). density lipoprotein cholesterol 272-303 C-reactive protein Homo sapiens 60-63 8329706-6 1993 Actinomycin D and cycloheximide blocked CRP-stimulated PCA, suggesting that de novo TF protein synthesis was required. Dactinomycin 0-13 C-reactive protein Homo sapiens 40-43 7685225-7 1993 Many studies have shown that serum CRP concentrations are not reduced by NSAIDs; however, one recent study has demonstrated that CRP concentration was reduced by the NSAIDs flurbiprofen and sustained-release ibuprofen in a subgroup of patients. Flurbiprofen 173-185 C-reactive protein Homo sapiens 129-132 7685226-6 1993 CRP concentrations in naproxen-treated and placebo patients were essentially unchanged. Naproxen 22-30 C-reactive protein Homo sapiens 0-3 25171681-15 2015 CONCLUSION: A logistic regression model incorporating temperature, ANC, and CRP correctly predicts methicillin resistance of S. aureus in 87% of cases. Methicillin 99-110 C-reactive protein Homo sapiens 76-79 26897954-6 2015 The mean CRP levels were 3.0 in the GDC group and 5.9 in the IDC group (p = 0.14). GDP-beta-L-galactose 36-39 C-reactive protein Homo sapiens 9-12 17379017-5 2007 C-reactive protein levels were decreased after 6 months of treatment with either pioglitazone or voglibose, with the former being more effective (-57%+/-8% vs -9%+/-18%; P<.05). voglibose 97-106 C-reactive protein Homo sapiens 0-18 25001295-8 2015 RESULTS: The levels of AHI and high sensitivity C-reactive protein (hsCRP) were significantly higher in the OSAHS group than in the control group. osahs 108-113 C-reactive protein Homo sapiens 48-66 8473487-6 1993 Approximately 90% of injected radioactivity was recovered in the urine after 7 d, and scintigraphic imaging studies with 123I-labeled CRP in 10 patients with different focal pathology showed no significant localization of tracer. Iodine-123 121-125 C-reactive protein Homo sapiens 134-137 1624792-4 1992 Using purified human CRP it could be shown that CRP immobilized onto polystyrene surfaces or onto latex beads binds distinct plasma glycoproteins including IgG, asialofetuin, asialo-beta 2-glycoprotein I and, likewise, synthetic glycoproteins as a lectin, exhibiting binding specificity for terminal galactosyl residues of the glycoprotein glycans. Polystyrenes 69-80 C-reactive protein Homo sapiens 48-51 17218153-4 2007 Further, significantly elevated levels of IFN-gamma, NO and CRP were observed in sodium antimony gluconate (SAG) unresponsive cases compared to responsive cases. Antimony Sodium Gluconate 81-106 C-reactive protein Homo sapiens 60-63 1834740-13 1991 The identity of this protein with Fc gamma RI was confirmed by the ability of both IgG-Sepharose and CRP-Sepharose to preclear the protein from cell lysates and by inhibition of binding to both IgG-Sepharose and CRP-Sepharose by anti-Fc gamma RI mAb 197. Sepharose 87-96 C-reactive protein Homo sapiens 212-215 1834740-13 1991 The identity of this protein with Fc gamma RI was confirmed by the ability of both IgG-Sepharose and CRP-Sepharose to preclear the protein from cell lysates and by inhibition of binding to both IgG-Sepharose and CRP-Sepharose by anti-Fc gamma RI mAb 197. Sepharose 105-114 C-reactive protein Homo sapiens 101-104 1834740-13 1991 The identity of this protein with Fc gamma RI was confirmed by the ability of both IgG-Sepharose and CRP-Sepharose to preclear the protein from cell lysates and by inhibition of binding to both IgG-Sepharose and CRP-Sepharose by anti-Fc gamma RI mAb 197. Sepharose 105-114 C-reactive protein Homo sapiens 101-104 25918522-7 2015 The CRP level in PA group was significantly higher than that in non-PA. Protactinium 17-19 C-reactive protein Homo sapiens 4-7 25918522-7 2015 The CRP level in PA group was significantly higher than that in non-PA. Protactinium 68-70 C-reactive protein Homo sapiens 4-7 1834740-13 1991 The identity of this protein with Fc gamma RI was confirmed by the ability of both IgG-Sepharose and CRP-Sepharose to preclear the protein from cell lysates and by inhibition of binding to both IgG-Sepharose and CRP-Sepharose by anti-Fc gamma RI mAb 197. Sepharose 105-114 C-reactive protein Homo sapiens 101-104 17218153-4 2007 Further, significantly elevated levels of IFN-gamma, NO and CRP were observed in sodium antimony gluconate (SAG) unresponsive cases compared to responsive cases. Antimony Sodium Gluconate 108-111 C-reactive protein Homo sapiens 60-63 1717553-4 1991 Three of the 5 mAb inhibited the Ca(2+)-dependent phosphorylcholine-(PC) binding activity of CRP, but did not bind to the PC-binding region itself. pc 69-71 C-reactive protein Homo sapiens 93-96 26020669-13 2015 CONCLUSIONS: Treatment with pravastatin plus ezetimibe decreases the CIMT with improvement in the concentration of total cholesterol, LDL-C and CRP levels with good toleration. Pravastatin 28-39 C-reactive protein Homo sapiens 144-147 17184768-3 2007 Kaempferol produced a significant concentration-dependent decrease of iNOS, COX-2 and CRP protein level at all concentrations, but the percentage of inhibition induced by quercetin was reduced at high concentrations. kaempferol 0-10 C-reactive protein Homo sapiens 86-89 24879591-3 2014 Ab-CRP was covalently immobilized on mercaptopropionic acid (MPA)-capped Pt nanoparticles that were covalently anchored over the graphene to form a bioelectrode. mpa 61-64 C-reactive protein Homo sapiens 3-6 2227796-1 1990 Healthy human serum reacted with C-reactive protein of human (hCRP) or rat (rCRP) immobilized on Sepharose 4B in the presence of Ca2+. Sepharose 97-109 C-reactive protein Homo sapiens 33-51 17184768-6 2007 The present study suggests that the modulation of iNOS, COX-2 and CRP by quercetin or kaempferol may contribute to the anti-inflammatory effects of these two structurally similar flavonoids in Chang Liver cells, via mechanisms likely to involve blockade of NF-kappaB activation and the resultant up-regulation of the pro-inflammatory genes. kaempferol 86-96 C-reactive protein Homo sapiens 66-69 17516714-3 2007 Subcutaneous certolizumab pegol 400mg once every 4 weeks (with an additional 400mg dose at week 2) was effective as induction and maintenance therapy in patients with moderate to severe Crohn"s disease in whom baseline serum C-reactive protein levels were >/=10 mg/L, according to data from two well designed, randomized phase III trials. Certolizumab Pegol 13-31 C-reactive protein Homo sapiens 225-243 34906743-7 2022 Compared with female patients without APRs, female patients with APRs had significantly higher levels of serum 25-dihydroxyvitamin D at baseline and serum C-reactive protein on the day ZA was administered (day 0). Zoledronic Acid 185-187 C-reactive protein Homo sapiens 155-173 34634403-8 2022 For a 10 mug/m3 increase in short-term exposure to O3, NO2, and SO2, there were significant increases of 1.05% (95%CI: 0.09%, 2.02%), 1.60% (95%CI: 0.49%, 2.72%), and 10.44% (95%CI: 4.20%, 17.05%) in CRP, respectively. Nitrogen Dioxide 55-58 C-reactive protein Homo sapiens 200-203 24558180-5 2014 An interquartile range (IQR) increase in NO2 exposure in lag 5 was associated with 51%, 10% and 9% increases in CRP, fibrinogen and HGF levels respectively. Nitrogen Dioxide 41-44 C-reactive protein Homo sapiens 112-115 24914983-0 2014 Structures of inactive CRP species reveal the atomic details of the allosteric transition that discriminates cyclic nucleotide second messengers. Nucleotides, Cyclic 109-126 C-reactive protein Homo sapiens 23-26 24914983-1 2014 The prokaryotic global transcription factor CRP has been considered to be an ideal model for in-depth study of both the allostery of the protein and the differential utilization of the homologous cyclic nucleotide second messengers cAMP and cGMP. Nucleotides, Cyclic 196-213 C-reactive protein Homo sapiens 44-47 17261959-7 2007 The effect of CRP on VCAM-1 expression in HUVECs and supernatant levels of MCP-1 and IL-6 were significantly suppressed by 25 micromol/L simvastatin with stepwise increased suppression as simvastatin dose increased to 50, 75, and 100 micromol/L (all P < 0.0001). Simvastatin 137-148 C-reactive protein Homo sapiens 14-17 24843385-10 2014 The levels of plasminogen activator inhibitor-1, high sensitivity C-reactive protein, and urinary 8-hydoroxydeoxyguanosine were reduced significantly by repaglinide treatment. repaglinide 153-164 C-reactive protein Homo sapiens 66-84 24388658-9 2014 Only plasma zinc and selenium were inversely associated with C-reactive protein (rs = -0.266, P = .004, rs = -0.322, P < .001, respectively). Selenium 21-29 C-reactive protein Homo sapiens 61-79 34798513-9 2022 Plasma selenium was positively associated with total serum protein, and negatively with CRP and ECW/TBW. Selenium 7-15 C-reactive protein Homo sapiens 88-91 34973877-6 2022 C-reactive protein (CRP) was identified as significant covariate affecting total meropenem clearance. Meropenem 81-90 C-reactive protein Homo sapiens 0-18 17261959-7 2007 The effect of CRP on VCAM-1 expression in HUVECs and supernatant levels of MCP-1 and IL-6 were significantly suppressed by 25 micromol/L simvastatin with stepwise increased suppression as simvastatin dose increased to 50, 75, and 100 micromol/L (all P < 0.0001). Simvastatin 188-199 C-reactive protein Homo sapiens 14-17 34973877-6 2022 C-reactive protein (CRP) was identified as significant covariate affecting total meropenem clearance. Meropenem 81-90 C-reactive protein Homo sapiens 20-23 34973877-9 2022 CONCLUSION: The findings of this study suggest that CRP might be helpful in managing meropenem dosing in critically ill patients. Meropenem 85-94 C-reactive protein Homo sapiens 52-55 25332991-5 2014 RESULTS: We found a significant increase in the production of lysozyme, CRP and calprotectin in glucan-treated children. Glucans 96-102 C-reactive protein Homo sapiens 72-75 17929126-8 2007 Of special interest was that the median levels of erythrocytes sedimentation rate, C-reactive protein, and rheumatoid factor were significantly decreased from 54.0 mm/h to 45.5 mm/h, from 1.50 mg/dl to 0.85 mg/dl, and from 57.0 IU/ml to 28.0 IU/ml, respectively, after administration of simvastatin. Simvastatin 287-298 C-reactive protein Homo sapiens 83-124 24881587-5 2014 The apnea hypopnea index was improved, and plasma BNP and high sensitive C-reactive protein levels were decreased in both groups with and without anemia by ASV therapy. ASV 156-159 C-reactive protein Homo sapiens 73-91 34797344-8 2021 RB was also associated with lower white blood cell count, C-reactive protein, and lactate levels. Rubidium 0-2 C-reactive protein Homo sapiens 58-76 17059995-8 2006 Moreover, uric acid levels correlated positively with levels of triglycerides, phosphate, C-reactive protein, and intracellular adhesion molecule 1 and negatively with levels of calcium, high-density lipoprotein cholesterol, and apolipoprotein A. Uric Acid 10-19 C-reactive protein Homo sapiens 90-147 34830542-8 2021 100% of children with CRP > 0.42 mg/L and PCT <= 6.92 ng/mL had confirmed sensitivity to cefuroxime. Cefuroxime 89-99 C-reactive protein Homo sapiens 22-25 24267260-7 2013 Treatment with Vytorin combination therapy modulated lipid profile and serum levels of the C-reactive protein more effectively, than treatment with Simvastatin monotherapy. Ezetimibe, Simvastatin Drug Combination 15-22 C-reactive protein Homo sapiens 91-109 34869089-7 2021 Meanwhile, the level of neutrophil, neutrophil/lymphocyte ratio (NLR), platelet count/lymphocyte ratio (PLR), mean platelet volume/lymphocyte ratio (MPVLR), C-reactive protein (CRP), lactic dehydrogenase (LDH), and interleukin (IL)-6 in the RMPP group was significantly higher (p < 0.01) than those in the NRMPP group. nrmpp 306-311 C-reactive protein Homo sapiens 157-175 17027827-6 2006 Logistic regression analysis of serum uric acid for MS disclosed for the top versus the bottom tertile an odds ratio (OR) of 1.89 (95% confidence interval [CI]: 1.45-2.46) in men and women combined, after adjustment for sex, age, TC, log CRP, log GGT, alcohol, and diuretic drug use, presence of diabetes/impaired fasting glucose, elevated BP, and smoking status. Uric Acid 38-47 C-reactive protein Homo sapiens 238-241 34869089-7 2021 Meanwhile, the level of neutrophil, neutrophil/lymphocyte ratio (NLR), platelet count/lymphocyte ratio (PLR), mean platelet volume/lymphocyte ratio (MPVLR), C-reactive protein (CRP), lactic dehydrogenase (LDH), and interleukin (IL)-6 in the RMPP group was significantly higher (p < 0.01) than those in the NRMPP group. nrmpp 306-311 C-reactive protein Homo sapiens 177-180 16925857-6 2006 Increasing ascorbic acid quartiles were associated with lower age, BMI, systolic and diastolic blood pressure, and CRP concentration, but with higher HDL-cholesterol concentration. Ascorbic Acid 11-24 C-reactive protein Homo sapiens 115-118 34559243-0 2021 Nets of biotin-derived gold nanoparticles as a label for the C-reactive protein immunoassay. Biotin 8-14 C-reactive protein Homo sapiens 61-79 34274954-5 2021 All three patients failing previous Venetoclax therapy and five out of seven patients with previous FLAG-Ida exposure achieved a CR/CRp after ACTIVE induction. flag-ida 100-108 C-reactive protein Homo sapiens 129-131 34274954-5 2021 All three patients failing previous Venetoclax therapy and five out of seven patients with previous FLAG-Ida exposure achieved a CR/CRp after ACTIVE induction. flag-ida 100-108 C-reactive protein Homo sapiens 132-135 24108112-12 2013 In patients with CD, Ks and lysis time were independently predicted by fibrinogen and C-reactive protein. Potassium 21-23 C-reactive protein Homo sapiens 86-104 23837738-6 2013 The most promising results were obtained with the nine-dentate chelate 6 and its Eu complex, which was conjugated to biotin and applied within the frame of a bioaffinity immunoassay of human C-reactive protein. Biotin 117-123 C-reactive protein Homo sapiens 191-209 16995340-15 2006 CONCLUSIONS: We demonstrated an activating effect of CRP on DTC in vitro. dtc 60-63 C-reactive protein Homo sapiens 53-56 23582088-6 2013 Six months of ASV therapy reduced levels of B-type natriuretic peptide, cystatin C, C-reactive protein, and noradrenaline and improved the glomerular filtration rate and ejection fraction (all P < .05). ASV 14-17 C-reactive protein Homo sapiens 84-102 34541293-9 2021 CRP level was significantly decreased in the lopinavir/ritonavir + atorvastatin group (P < 0.0001, Cohen"s d = 0.865) so that there was a significant difference in CRP level on the 6th day between the two groups (P = 0.01). lopinavir-ritonavir drug combination 45-64 C-reactive protein Homo sapiens 0-3 34541293-9 2021 CRP level was significantly decreased in the lopinavir/ritonavir + atorvastatin group (P < 0.0001, Cohen"s d = 0.865) so that there was a significant difference in CRP level on the 6th day between the two groups (P = 0.01). lopinavir-ritonavir drug combination 45-64 C-reactive protein Homo sapiens 164-167 16805747-8 2006 Univariate analysis showed that both homocysteine and CRP levels significantly correlated with free T4 and TSH level (p < 0.01 for both groups). Thyrotropin 107-110 C-reactive protein Homo sapiens 54-57 34482785-6 2022 high-sensitivity C-reactive protein, being a non-specific inflammatory marker could be an adjunct tool for TB prognosis. Terbium 107-109 C-reactive protein Homo sapiens 17-35 34479494-14 2021 CONCLUSION: Results suggest that increasing levels of Se and Zn were accompanied by a decrease in serum CRP level. Selenium 54-56 C-reactive protein Homo sapiens 104-107 34345193-10 2021 In the change from PL to OCM, operative time, CRP and CK decreased, but Hb also decreased. pl 19-21 C-reactive protein Homo sapiens 46-49 23616965-9 2013 Pairwise comparisons between the E only and E+B/PBT groups showed significantly lower FVC, FEV1 and FEV1/FVC values, and higher CRP levels and number of exacerbations compared with the B/PBT group. (E)-2-(pent-3-en-1-yn-1-yl)thiophene 48-51 C-reactive protein Homo sapiens 128-131 16569733-6 2006 RESULTS: Children with high CRP concentrations (highest tertile) had higher body mass index (BMI) sd scores, insulin, insulin resistance, uric acid, and adipocytokines and had more atherogenic lipoprotein profiles than other children. Uric Acid 138-147 C-reactive protein Homo sapiens 28-31 23249695-9 2013 Testosterone correlated with glucose-stimulated AP-1 activation, and androstenedione correlated with MMP9 and CRP levels and glucose-stimulated AP-1 activation. Androstenedione 69-84 C-reactive protein Homo sapiens 110-113 22847475-4 2012 In a proof of principle demonstration targeting the C-reactive protein, an ELISA carried out using an F-terminated diamond surface showed a signal-to-noise ratio of 3,900 which compares well to the signal-to-noise of 89 obtained in an antibody-based ELISA on a polystyrene microtiter plate, a standard test format used in most life science laboratories today. Polystyrenes 261-272 C-reactive protein Homo sapiens 52-70 34089882-6 2021 RESULTS: The plasma levels of fibrinogen, D-dimer, ESR, and CRP were significantly lower in the AL group, with an area under the curve of 0.848, 0.669, 0.865, and 0.841, respectively. Aluminum 96-98 C-reactive protein Homo sapiens 60-63 34249019-12 2021 Consuming orange juice daily for a period of weeks has been reported to reduce markers of inflammation, including C-reactive protein, as confirmed through a recent meta-analysis. orange juice 10-22 C-reactive protein Homo sapiens 114-132 35398417-4 2022 Here, we evaluated the associations between PM10, NO2 and O3 exposure (on the day of the blood sample collection and on the day before, and the mean annual residential level) and levels of the inflammatory biomarkers high-sensitivity C-reactive protein (hsCRP), interleukin (IL)-1beta, IL-6, IL-8, IL-10, IL-17A, IL-22, and tumor necrosis factor alpha. Nitrogen Dioxide 50-53 C-reactive protein Homo sapiens 234-252 16611716-5 2006 Serum creatinine, CRP, and maximal vasodilatory response to ACh were related to the UA (all P < 0.0001). Uric Acid 84-86 C-reactive protein Homo sapiens 18-21 35239329-4 2022 Nevertheless, 30 biomarkers were in association with at least one environmental factor; e.g., C-reactive protein levels were positively associated with NO (padj = 2.99 x 10-4), NO2 (padj = 4.15 x 10-4), and PM2.5 (padj = 1.92 x 10-6) even after multiple testing adjustment. Nitrogen Dioxide 177-180 C-reactive protein Homo sapiens 94-112 22159869-8 2012 The ratio of unconjugated alprazolam to 4-hydroxyalprazolam was correlated with CRP levels (r(s) = 0.49, P = 0.01). 4-hydroxyalprazolam 40-59 C-reactive protein Homo sapiens 80-83 20861716-8 2012 The naproxen-alone group showed significant elevations in CRP, alanine transaminase, and aspartate transaminase when compared with the other groups. Naproxen 4-12 C-reactive protein Homo sapiens 58-61 16611716-6 2006 In the multiple regression analysis, serum UA ranked as the third correlate of peak of forearm blood flow predictor, after homeostasis model assessment and CRP. Uric Acid 43-45 C-reactive protein Homo sapiens 156-159 16611716-7 2006 The data show an independent link between UA and endothelial function, also in a statistical model that included CRP. Uric Acid 42-44 C-reactive protein Homo sapiens 113-116 22153152-7 2012 RESULTS: Serum CRP concentration was positively associated with palmitic acid (P for trend=0.002) and inversely with alpha-linolenic acid (P for trend=0.01) in men, and positively with dihomo-gamma-linolenic acid (P for trend in men or women=0.01) and inversely with delta-5-desaturase (20:4n-6/20:3n-6) (P for trend in men and women=0.05 and 0.002, respectively) in men and women. alpha-Linolenic Acid 117-137 C-reactive protein Homo sapiens 15-18 22153152-7 2012 RESULTS: Serum CRP concentration was positively associated with palmitic acid (P for trend=0.002) and inversely with alpha-linolenic acid (P for trend=0.01) in men, and positively with dihomo-gamma-linolenic acid (P for trend in men or women=0.01) and inversely with delta-5-desaturase (20:4n-6/20:3n-6) (P for trend in men and women=0.05 and 0.002, respectively) in men and women. alpha-Linolenic Acid 122-137 C-reactive protein Homo sapiens 15-18 16340663-4 2006 Experimental studies suggest that uric acid induce its detrimental effects at the cellular level entering to vascular smooth muscle cells (VSMC) via an organic anion transport system, and followed by the activation of specific MAP kinases, nuclear transcription factors, with stimulation of COX-2, PDGF A and C chain, PDGF alpha receptor, and various inflammatory mediators, including C-reactive protein and monocyte chemoattractant protein-1. Uric Acid 34-43 C-reactive protein Homo sapiens 385-403 35534369-10 2022 The risk of primary and secondary outcomes with remdesivir differed by Ct and C-reactive protein (CRP) levels in patients receiving CIT: for 28 day mortality, the aHR was 0.48 (95% CI = 0.21-1.11) for Ct <25, 0.12 (95% CI = 0.02-0.66) for Ct <25 and <5 day symptom duration and 0.13 (95% CI = 0.03-0.50) for CRP <38 mg/L; for IMV and IMV/death, the aHR was 0.32 (95% CI = 0.13-0.77) and 0.33 (95% CI = 0.17-0.63), respectively, in patients with Ct <25. remdesivir 48-58 C-reactive protein Homo sapiens 78-96 35534369-10 2022 The risk of primary and secondary outcomes with remdesivir differed by Ct and C-reactive protein (CRP) levels in patients receiving CIT: for 28 day mortality, the aHR was 0.48 (95% CI = 0.21-1.11) for Ct <25, 0.12 (95% CI = 0.02-0.66) for Ct <25 and <5 day symptom duration and 0.13 (95% CI = 0.03-0.50) for CRP <38 mg/L; for IMV and IMV/death, the aHR was 0.32 (95% CI = 0.13-0.77) and 0.33 (95% CI = 0.17-0.63), respectively, in patients with Ct <25. remdesivir 48-58 C-reactive protein Homo sapiens 98-101 35631137-8 2022 High-sensitivity CRP and lipopolysaccharide-binding protein decreased following LOW-HIIT (-1.4 mg/L, p = 0.001 and -2.1 ng/mL, p = 0.004) and 3-RT (-0.6 mg/L, p = 0.044 and -2.0 ng/mL, p < 0.001). 3-rt 142-146 C-reactive protein Homo sapiens 17-20 22038585-1 2012 A complementary metal oxide semiconductor (CMOS) image sensor was utilized to detect the interaction of cardiovascular disease markers, troponin I and C-reactive protein. metal oxide 16-27 C-reactive protein Homo sapiens 151-169 16474305-4 2006 Efficacy of functional regeneration of the myocardium assessed 1 month after TABMC was related to blood plasma levels of CRP and neopterin before treatment. tabmc 77-82 C-reactive protein Homo sapiens 121-124 21301856-6 2011 In women, Pro12Ala appeared to interact with arachidonic acid on CRP (p = 0.04), as well as with docosatetraenoic acid on CRP (p = 0.08) and adiponectin (p = 0.02). Docosatetraenoic acid 97-118 C-reactive protein Homo sapiens 122-125 35477378-7 2022 The poisoning symptoms of TB were relieved in all patients, and ESR (42.09 +- 9.53 vs 8.04 +- 5.41, P < 0.05) and CRP (30.37 +- 16.02 vs 7.4 +- 2.68, P < 0.05) were decreased at the 3 postoperative months in the comparison of the preoperative. Terbium 26-28 C-reactive protein Homo sapiens 114-117 16474305-6 2006 Among patients with initially elevated levels of CRP and neopterin more positive changes of EF and SV occurred in those subjects in whom lowering of inflammation markers took place during 1 month after TABMC. tabmc 202-207 C-reactive protein Homo sapiens 49-52 21852104-4 2011 The agarose bead sensors used in the device are sensitized with anti-C-reactive protein (CRP) antibody, and a fluorescent sandwich-type immunoassay was run to characterize the performance of this device. Sepharose 4-11 C-reactive protein Homo sapiens 69-87 16858354-14 2006 CONCLUSION: Short term simvastatin use in patients with systolic heart failure due to CHD caused lowering of LDLCH and CRP however this was not associated with changes of left ventricular EF different from those in control group. Simvastatin 23-34 C-reactive protein Homo sapiens 119-122 21852104-4 2011 The agarose bead sensors used in the device are sensitized with anti-C-reactive protein (CRP) antibody, and a fluorescent sandwich-type immunoassay was run to characterize the performance of this device. Sepharose 4-11 C-reactive protein Homo sapiens 89-92 21116816-15 2011 CRP levels increased from baseline to 72 h. CONCLUSIONS: Acetaminophen four times/day for 3 days significantly reduced the incidence and severity of post-dose symptoms following ZOL infusion. Zoledronic Acid 178-181 C-reactive protein Homo sapiens 0-3 35487256-10 2022 LLoQ concentrations were established as 15 pg/mL, 100 pg/mL and 1 mg/L for TRAIL, IP-10 and CRP, respectively. lloq 0-4 C-reactive protein Homo sapiens 92-95 16615014-6 2006 The severity of pneumonia according to BTS criteria was correlated with the levels of CRP and leukocyte count (p= 0.037, p= 0.01, respectively). bts 39-42 C-reactive protein Homo sapiens 86-89 35080124-14 2022 CRP may be helpful in monitoring the radiologic disease activity in AxPsA. axpsa 68-73 C-reactive protein Homo sapiens 0-3 21047568-8 2011 Zoledronic acid administration triggered increased serum levels of TNFalpha, IFNgamma, IL-6 and CRP in >=70% of study volunteers, whilst characteristic APR symptoms were observed in >50% of participants. Zoledronic Acid 0-15 C-reactive protein Homo sapiens 96-99 21765609-5 2011 Plasma C-reactive protein levels significantly correlated with dietary intakes of vitamin C (r = -0.30, p<0.005), beta-carotene (r = -0.23, p<0.05), and folate (r = -0.31, p<0.005). beta Carotene 117-130 C-reactive protein Homo sapiens 7-25 16220077-5 2005 C-reactive protein could augment the production of reactive oxygen species (ROS) as measured by chemiluminescence and inhibitors of NAD(P)H oxidase (DPI and PAO) and ROS scavengers (superoxide dismutase, catalase, and 1% dimethyl sulphoxide) abolished C-reactive protein-induced IL-8 secretion. 3-aminodiphenyleneiodium 149-152 C-reactive protein Homo sapiens 0-18 20300755-11 2011 Serum 25-OH vitamin D levels were significantly negatively correlated with DAS28, CRP, and HAQ (respectively, r = -0.431, P = 0.000, r = -0.276, P = 0.026, and r = -0.267, P = 0.031). 25-oh 6-11 C-reactive protein Homo sapiens 82-85 16265685-5 2005 RESULTS: Simvastatin treatment significantly decreased serum CRP and TNF-a [from 14 +/- 6 to 7 +/- 3 mg/l (p = 0.025) and 30 +/- 5 to 16 +/- 4 pg/ml (p = 0.012), respectively], while quinapril had no significant changes in these 2 measures. Simvastatin 9-20 C-reactive protein Homo sapiens 61-64 21422984-3 2011 We examined the effect of pravastatin and rosuvastatin on CRP levels in 58 dyslipidemic HIV-infected patients. Pravastatin 26-37 C-reactive protein Homo sapiens 58-61 35392631-13 2022 Expression levels of other complement pathway-related proteins (HMGB1, S100A8, S100A9, CRP, C4) were decreased by DTMP, although not significantly affected by SNI. 2',3'-dideoxy-2',3'-didehydrothymidine monophosphate 114-118 C-reactive protein Homo sapiens 87-90 15761204-5 2005 RESULTS: CRP was elevated above control levels (0.54 [0.33 to 0.84] median, interquartile range mg/L) in patients with LAA (2.59 [0.56 to 3.99] mg/L; P<0.001) and with CAD (2.37 [0.57 to 4.78] mg/L; P=0.0013) but not in patients with cryptogenic etiology (0.74 [0.14 to 7.86] mg/L). laa 119-122 C-reactive protein Homo sapiens 9-12 35142908-4 2022 The filgotinib 200 mg + MTX and upadacitinib 15 mg + MTX groups showed a significantly higher DAS28-CRP < 2.6 than adalimumab 40 mg + MTX. upadacitinib 32-44 C-reactive protein Homo sapiens 100-103 35184484-0 2022 (Association of blood lead and blood selenium with serum high-sensitivity C-reactive protein among Chinese adults aged 19 to 79 years). Selenium 37-45 C-reactive protein Homo sapiens 74-92 35184484-1 2022 Objective: To investigate the association of blood lead and blood selenium with serum high-sensitivity C-reactive protein (hs-CRP) among Chinese adults aged 19 to 79 years. Selenium 66-74 C-reactive protein Homo sapiens 103-121 35184484-1 2022 Objective: To investigate the association of blood lead and blood selenium with serum high-sensitivity C-reactive protein (hs-CRP) among Chinese adults aged 19 to 79 years. Selenium 66-74 C-reactive protein Homo sapiens 126-129 35184484-7 2022 Generalized linear mixed models and restricted cubic spline models were used to analyze the association of blood lead and blood selenium with elevated hs-CRP. Selenium 128-136 C-reactive protein Homo sapiens 154-157 35184484-8 2022 Logistic regression models were used to analyze the multiplicative scale and additive scale interaction between blood lead and blood selenium on elevated hs-CRP. Selenium 133-141 C-reactive protein Homo sapiens 157-160 15803114-9 2005 CRP showed a positive correlation with BMI, insulin, homeostasis model assessment (HOMA), triglycerides, alanine aminotransferase (ALT), uric acid, PAI-1, fibrinogen and interleukin 6 (IL-6), and correlated negatively with apolipoprotein A-I and high-density lipoprotein cholesterol (HDL-C). Uric Acid 137-146 C-reactive protein Homo sapiens 0-3 35184484-12 2022 When compared with participants with the lowest quartile of blood selenium, the OR (95%CI) of elevated hs-CRP for participants with the second, third and highest quartiles were 0.86 (0.72-1.04), 0.91 (0.76-1.11), and 0.75 (0.61-0.92), respectively. Selenium 66-74 C-reactive protein Homo sapiens 106-109 35184484-14 2022 Conclusion: Blood concentration of lead was positively associated with elevated serum hs-CRP, and blood concentration of selenium was inversely related to elevated hs-CRP, while blood lead and selenium did not present interaction on elevated hs-CRP. Selenium 121-129 C-reactive protein Homo sapiens 167-170 16623120-3 2005 Moreover, statins may exhibit additional inhibitory effects on the atherogenesis, such as a modulation of the immune system as triggered by oxidatively modified LDL and a reduction of the inflammatory marker C-reactive protein (CRP). statins 10-17 C-reactive protein Homo sapiens 208-226 35197850-1 2021 Background: Given the limitations of three-step analgesic therapy and the extensive use of traditional Chinese medicine injections (TCMIs) for cancer-related pain (CRP), this network meta-analysis (NMA) aims to compare the efficacy and safety of different regimens of TCMIs for CRP. tcmis 268-273 C-reactive protein Homo sapiens 278-281 35197850-19 2021 Further, compared with analgesic treatment alone for patients with CRP, TCMIs + AN combination treatment strategies are significantly more effective. tcmis 72-77 C-reactive protein Homo sapiens 67-70 16623120-3 2005 Moreover, statins may exhibit additional inhibitory effects on the atherogenesis, such as a modulation of the immune system as triggered by oxidatively modified LDL and a reduction of the inflammatory marker C-reactive protein (CRP). statins 10-17 C-reactive protein Homo sapiens 228-231 16281491-8 2005 Only maximal dose simvastatin produced a significant reduction of C-reactive protein (CRP) to the disease day 14. Simvastatin 18-29 C-reactive protein Homo sapiens 66-84 35123474-8 2022 The CRP levels in the triamcinolone group were significantly lower than in the dexamethasone group at 7 days postoperatively (1.6 mg/dl vs. 3.0 mg/dl: p < 0.001). Triamcinolone 22-35 C-reactive protein Homo sapiens 4-7 16281491-8 2005 Only maximal dose simvastatin produced a significant reduction of C-reactive protein (CRP) to the disease day 14. Simvastatin 18-29 C-reactive protein Homo sapiens 86-89 16281491-10 2005 CONCLUSION: Use of simvastatin in ACS patients, initially normal level of LDLP cholesterol and elevated level of CRP produced a dose-dependent effect, alleviated inflammation and improved the disease course. Simvastatin 19-30 C-reactive protein Homo sapiens 113-116 35063243-8 2022 CONCLUSIONS: Selenium supplementation in diabetic HD patients had beneficial effects on markers of insulin metabolism, total-, LDL-, HDL-cholesterol, CRP and GSH levels. Selenium 13-21 C-reactive protein Homo sapiens 150-153 15556359-6 2004 In addition, when it was treated with 2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate, so-called MPC polymer, highly affinitive and selective immunosensing for CRP was achieved without non-specific binding from plasma proteins in human serum. 2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate 38-102 C-reactive protein Homo sapiens 177-180 15514264-6 2004 Changes in CRP and VCAM-1 were inversely associated with changes in serum eicosapentaenoic acid (EPA) (r = -0.496, P = 0.016; r = -0.418, P = 0.047), or EPA plus docosapentaenoic acid (r = -0.409, P = 0.053; r = -0.357, P = 0.091) after subjects consumed the ALA Diet. Eicosapentaenoic Acid 74-95 C-reactive protein Homo sapiens 11-14 34086854-12 2022 On the contrary, CRP was more frequently expressed compared with HNF-1beta in HCC and HCC component of cHCC-CCA (71 of 77, 92.21% versus 6 of 78, 7.69%; P < .001). chcc 103-107 C-reactive protein Homo sapiens 17-20 15514264-6 2004 Changes in CRP and VCAM-1 were inversely associated with changes in serum eicosapentaenoic acid (EPA) (r = -0.496, P = 0.016; r = -0.418, P = 0.047), or EPA plus docosapentaenoic acid (r = -0.409, P = 0.053; r = -0.357, P = 0.091) after subjects consumed the ALA Diet. Eicosapentaenoic Acid 97-100 C-reactive protein Homo sapiens 11-14 15514264-6 2004 Changes in CRP and VCAM-1 were inversely associated with changes in serum eicosapentaenoic acid (EPA) (r = -0.496, P = 0.016; r = -0.418, P = 0.047), or EPA plus docosapentaenoic acid (r = -0.409, P = 0.053; r = -0.357, P = 0.091) after subjects consumed the ALA Diet. Eicosapentaenoic Acid 153-156 C-reactive protein Homo sapiens 11-14 15332218-4 2004 RESULTS: Ninety-three patients (37%) with signs of inflammation (CRP > or = 1 mg/dL) had significantly lower levels of tHcy, tCys, and serum Alb than 157 noninflamed patients. thcy 122-126 C-reactive protein Homo sapiens 65-68 15332218-5 2004 tHcy and tCys levels correlated positively with serum Alb levels and negatively with CRP levels (rho = -0.24; P < 0.0001; rho = -0.15; P < 0.05, respectively) and other inflammation markers. thcy 0-4 C-reactive protein Homo sapiens 85-88 15332218-8 2004 Multivariate analysis showed that serum Alb, CRP, plasma folate, and vitamin B12 levels were independently associated with tHcy levels after adjustment for other variables. thcy 123-127 C-reactive protein Homo sapiens 45-48 15540478-9 2004 Researchers in the CURVES study found a significant reduction in CRP levels with pravastatin, simvastatin, and atorvastatin compared with baseline (p < 0.025). Simvastatin 94-105 C-reactive protein Homo sapiens 65-68 15193818-3 2004 RESULTS: Compared with diet alone, simvastatin significantly improved the percent flow-mediated dilator response to hyperemia and lowered plasma levels of tumor necrosis factor (TNF)-alpha, intercellular adhesion molecule type-1 (ICAM-1), serum levels of CRP, and fibrinogen (P<0.001, P<0.001, P=0.035, P<0.001 and P=0.014, respectively). Simvastatin 35-46 C-reactive protein Homo sapiens 255-258 15193818-5 2004 Further, we observed that patients with the highest pretreatment TNF-alpha, ICAM-1, and CRP levels showed the greatest extent of reductions on simvastatin. Simvastatin 143-154 C-reactive protein Homo sapiens 88-91 15036404-2 2004 However, the association between plasma tHcy and serum C-reactive protein (sCRP), taken as a marker of low-grade inflammation, is still uncertain. thcy 40-44 C-reactive protein Homo sapiens 55-73 15036404-5 2004 A positive association between plasma tHcy and serum CRP, independent of several confounders (socio-demographic status, known tHcy and sCRP determinants, inflammation markers, traditional vascular risk factors), was found for CVD+/comorbidity+ (p=0.001; not affected by dementia type) and dementia (p=0.001; not affected by dementia type), but not for CVD+/comorbidity- and controls. thcy 38-42 C-reactive protein Homo sapiens 53-56 15036404-5 2004 A positive association between plasma tHcy and serum CRP, independent of several confounders (socio-demographic status, known tHcy and sCRP determinants, inflammation markers, traditional vascular risk factors), was found for CVD+/comorbidity+ (p=0.001; not affected by dementia type) and dementia (p=0.001; not affected by dementia type), but not for CVD+/comorbidity- and controls. thcy 126-130 C-reactive protein Homo sapiens 53-56 14715352-0 2004 Effect of simvastatin on serum C-reactive protein during hormone replacement therapy. Simvastatin 10-21 C-reactive protein Homo sapiens 31-49 14579918-0 2003 Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia. Simvastatin 17-28 C-reactive protein Homo sapiens 50-68 14579918-3 2003 HYPOTHESIS: The study was undertaken to investigate whether a rapid LDL cholesterol and CRP reduction can be achieved by 2-week simvastatin therapy using a common lipid-lowering protocol in patients with hypercholesterolemia. Simvastatin 128-139 C-reactive protein Homo sapiens 88-91 14579918-10 2003 In addition, both doses of simvastatin induced significant reductions in mean CRP levels on Day 14 (22.3 and 23.1%) in a non dose-dependent manner (p < 0.001, respectively. Simvastatin 27-38 C-reactive protein Homo sapiens 78-81 14579918-11 2003 CONCLUSIONS: Our data suggest that a common daily dose of simvastatin, especially 40 mg, is an effective 2-week therapy for patients with hypercholesterolemia, and benefit to the vascular endothelium can be derived quickly by reduction of CRP levels. Simvastatin 58-69 C-reactive protein Homo sapiens 239-242 12821543-3 2003 After adjustment for other predictors of inflammation, intake of the n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) was inversely associated with plasma levels of sTNF-R1 and sTNF-R2 (P=0.03 and P<0.001, respectively) and somewhat less so for C-reactive protein (P=0.08). Eicosapentaenoic Acid 85-106 C-reactive protein Homo sapiens 274-292 12821543-3 2003 After adjustment for other predictors of inflammation, intake of the n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) was inversely associated with plasma levels of sTNF-R1 and sTNF-R2 (P=0.03 and P<0.001, respectively) and somewhat less so for C-reactive protein (P=0.08). Eicosapentaenoic Acid 108-111 C-reactive protein Homo sapiens 274-292 12964969-2 2003 This study was intended to determine whether CRP levels could differentiate between inflammatory and noninflammatory thyroid conditions, especially between type II inflammatory amiodarone-induced thyrotoxicosis (AIT) and type I iodine-induced AIT. Iodine 228-234 C-reactive protein Homo sapiens 45-48 21325466-9 2011 Treatment with drospirenone/EE was associated with elevations in total cholesterol, high-sensitivity C-reactive protein and leptin concentrations, whereas treatment with rosiglitazone led to lower triglycerides and higher adiponectin concentrations. drospirenone 15-27 C-reactive protein Homo sapiens 101-119 12714198-7 2003 CONCLUSIONS: Elevated serum CRP levels are associated with endothelial dysfunction, coronary artery calcification and cardiac diastolic dysfunction in chronic cocaine users. Cocaine 159-166 C-reactive protein Homo sapiens 28-31 21448308-9 2011 However, IL-6 and CRP were significantly lower in flurbiprofen group than in control group at the same day (p < 0.05). Flurbiprofen 50-62 C-reactive protein Homo sapiens 18-21 12603495-9 2003 The relative risk for death of all causes increased 1.43 (95% CI, 1.08-1.88) per tHcy quartile (P for trend = 0.01), and was only modestly reduced after adjustment for age, ejection fraction, total cholesterol, C-reactive protein, fibrinogen, smoking and hypertension to 1.37 (95% CI, 1.04-1.80) (P for trend = 0.03). thcy 81-85 C-reactive protein Homo sapiens 211-229 21448308-12 2011 CONCLUSIONS: Patients undergoing thoracotomy showed reduced postoperative pain, mean additional analgesic consumption, and serum IL-6 and CRP levels, when flurbiprofen was added to systemic analgesic therapy. Flurbiprofen 155-167 C-reactive protein Homo sapiens 138-141 21219690-10 2011 We found positive correlations between both PCT and CRP and TB score. Terbium 60-62 C-reactive protein Homo sapiens 52-55 12398959-0 2002 Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. Simvastatin 11-22 C-reactive protein Homo sapiens 26-44 12161055-8 2002 Partial correlation analyses of CRP and IL6 with other variables showed significant correlation of CRP with tHcy, and SA in patients with CHD only. thcy 108-112 C-reactive protein Homo sapiens 99-102 21677436-5 2011 RESULTS: At baseline there were no significant differences between groups in biomarkers of oxs, whereas high-sensitivity C-reactive protein and blood leukocytes were significantly elevated in group ARAS versus both healthy controls and group non-RAS. aras 198-202 C-reactive protein Homo sapiens 121-139 12015523-5 2002 HRT resulted in a significant increase in CRP concentrations in the women receiving the continuous combination of E2V plus norethindrone acetate and the continuous regimen of E2V plus local delivery of levonorgestrel. E2V 114-117 C-reactive protein Homo sapiens 42-45 21105857-6 2010 Furthermore, serum uric acid and high sensitivity C-reactive protein levels were decreased in dapagliflozin-treated patients. dapagliflozin 94-107 C-reactive protein Homo sapiens 50-68 12015523-5 2002 HRT resulted in a significant increase in CRP concentrations in the women receiving the continuous combination of E2V plus norethindrone acetate and the continuous regimen of E2V plus local delivery of levonorgestrel. E2V 175-178 C-reactive protein Homo sapiens 42-45 11927515-4 2002 CEEs increased median CRP levels from 0.27 to 0.46 mg/dL, simvastatin decreased CRP from 0.29 to 0.28 mg/dL, and the therapies combined increased CRP from 0.28 to 0.36 mg/dL (all P< or =0.02 versus respective baseline values). Simvastatin 58-69 C-reactive protein Homo sapiens 80-83 11927515-4 2002 CEEs increased median CRP levels from 0.27 to 0.46 mg/dL, simvastatin decreased CRP from 0.29 to 0.28 mg/dL, and the therapies combined increased CRP from 0.28 to 0.36 mg/dL (all P< or =0.02 versus respective baseline values). Simvastatin 58-69 C-reactive protein Homo sapiens 80-83 11927515-5 2002 Post hoc testing showed that the 29% increase in CRP on the combination of CEEs with simvastatin was significantly less than the 70% increase in CRP on CEEs alone (P<0.05). Simvastatin 85-96 C-reactive protein Homo sapiens 49-52 12056790-7 2002 In normal subjects and cancer patients, C-reactive protein concentrations were inversely correlated with circulating concentrations of retinol (r(2)=0.162), alpha-tocopherol (r(2)=0.297), lutein (r(2)=0.256), lycopene (r(2)=-0.171), alpha-(r(2)=0.140) and beta-carotene (r(2)=0.254): (all P<0.001). alpha-Tocopherol 157-173 C-reactive protein Homo sapiens 40-58 11382718-9 2001 CONCLUSIONS: These results further strengthen the role of CRP in the pathogenesis of vascular inflammation and, likely, atherosclerosis and provide a crucial insight into a novel mechanism of action of anti-atherosclerosis drugs such as simvastatin and fenofibrate. Simvastatin 237-248 C-reactive protein Homo sapiens 58-61 11117616-4 2000 Adjusted concentrations of all five carotenoids were significantly lower in those with C-reactive protein levels above 0.88 mg/dl (p = 0.001). Carotenoids 36-47 C-reactive protein Homo sapiens 87-105 11117616-8 2000 These cross-sectional data do not clarify the biologic relation between carotenoids and C-reactive protein but, to the extent that the carotenoids are associated with C-reactive protein levels, a carotenoid-heart disease association may be, in part, an inflammation-heart disease association. Carotenoids 135-146 C-reactive protein Homo sapiens 167-185 10982535-13 2000 CONCLUSIONS: In patients with angiographically defined CAD, tHCY is a significant predictor of mortality, independent of traditional risk factors, CRP, and MTHFR genotype. thcy 60-64 C-reactive protein Homo sapiens 147-150 10998075-2 2000 The aim of this study was firstly to examine whether tHcy is associated with endothelial dysfunction, increased adherence of leukocytes, and/or chronic low-grade inflammation, as estimated from plasma levels of von Willebrand factor (vWf), soluble vascular cell adhesion molecule 1 (sVCAM-1) and C-reactive protein (CRP), respectively. thcy 53-57 C-reactive protein Homo sapiens 296-314 10998075-2 2000 The aim of this study was firstly to examine whether tHcy is associated with endothelial dysfunction, increased adherence of leukocytes, and/or chronic low-grade inflammation, as estimated from plasma levels of von Willebrand factor (vWf), soluble vascular cell adhesion molecule 1 (sVCAM-1) and C-reactive protein (CRP), respectively. thcy 53-57 C-reactive protein Homo sapiens 316-319 10585318-7 1999 The levels of log hyaluronan correlated significantly to log CRP (R = 0.35; P < 0.001), serum albumin (R = -0.40; P < 0.0001), CVD (R = 0.36; P < 0.001), and age (R = 0.40; P < 0.0001), respectively. Hyaluronic Acid 18-28 C-reactive protein Homo sapiens 61-64 10585318-8 1999 Survival analysis by the Cox regression model showed that elevated hyaluronan levels were, independent of CVD, CRP, and age, significantly related to an increased mortality rate. Hyaluronic Acid 67-77 C-reactive protein Homo sapiens 111-114 9095612-6 1997 After the decrease in CRP, the decrease in total bilirubin concentration was delayed. Bilirubin 49-58 C-reactive protein Homo sapiens 22-25 9575343-3 1996 This pocket was found to be extremely sensitive towards modifications in the P1 position of CRP derived inhibitors, with valine being the preferred amino acid. Valine 121-127 C-reactive protein Homo sapiens 92-95 8280710-8 1993 Following L-MTP-PE infusion, induction of circulating TNF-alpha, IL-6, neopterin, and C-reactive protein was demonstrated. L-MTP-PE 10-18 C-reactive protein Homo sapiens 86-104 8388408-6 1993 A significant correlation (R2 = 0.4538, R = 0.6737, F = 7.617, p = 0.0000) was found between serum lipid peroxides and a set of indices of inflammation (ESR, total leucocyte count, C-reactive protein) and of hepatic function (aspartate aminotransferase (AST) or alkaline phosphatase (ALP) or bilirubin). Lipid Peroxides 99-114 C-reactive protein Homo sapiens 181-199 1650222-7 1991 Calcium phosphorylcholine (10 micrograms/ml) or sodium citrate (10 micrograms/ml) completely dissociated bound CRP. Sodium Citrate 48-62 C-reactive protein Homo sapiens 111-114 2338157-2 1990 The isolation was based on its calcium-dependent binding affinity for pneumococcal C-polysaccharide (CPS) according to the isolation procedure of human C-reactive protein. cps 101-104 C-reactive protein Homo sapiens 152-170 34719281-5 2022 RESULTS: Four adjacent cytosine and guanine nucleotides (CpG) sites were significantly differentially methylated and associated with C-reactive protein (CRP), 62 with waist circumference, and none to insulin resistance in models for both mothers and adolescents. cytosine and guanine nucleotides 23-55 C-reactive protein Homo sapiens 133-151 34719281-5 2022 RESULTS: Four adjacent cytosine and guanine nucleotides (CpG) sites were significantly differentially methylated and associated with C-reactive protein (CRP), 62 with waist circumference, and none to insulin resistance in models for both mothers and adolescents. cytosine and guanine nucleotides 23-55 C-reactive protein Homo sapiens 153-156 34432389-10 2022 High tumor burden, low albumin, and high CRP at baseline showed the greatest association with ADA development but not with subsequent NAb development. N-(2-acetamido)iminodiacetic acid 94-97 C-reactive protein Homo sapiens 41-44 34816729-11 2021 Both estimated glomerular filtration rate and hs-CRP (high-sensitivity C-reactive protein) had significant mediation effects on the association of trimethyllysine with cardiovascular death, with a mediation effect of 37.8% and 13.4%, respectively. trimethyllysine 147-162 C-reactive protein Homo sapiens 49-52 34273116-10 2021 Among the 25-OH-D deplete subgroup higher peak neutrophil counts, peak CRP, peak LDH, peak ferritin and lower trough lymphocyte counts were observed, without statistical significance. the 25- 6-13 C-reactive protein Homo sapiens 67-70 34221397-19 2021 The biological findings found average of white blood cells at 12256/12082 e/mm3, lymphocytes at 761/842 e/mm3, CRP at 181/199 mg/L, ferritin at 1747/528 mug/L, and fibrinogen at 6.92/6.27 g/L for the TCZ group versus NON TCZ group. tioconazole 200-203 C-reactive protein Homo sapiens 111-114 34167597-10 2021 Besides, the interaction of the SNP and DPI significantly affected hs-CRP and 8-isoprostane F2alpha (PGF2alpha) levels. 3-aminodiphenyleneiodium 40-43 C-reactive protein Homo sapiens 70-73 34243954-5 2021 Patients in the TCZ group had a more rapid normalization of C-reactive protein levels. tioconazole 16-19 C-reactive protein Homo sapiens 60-78 34063875-7 2021 Elevated CRP was observed using simple linear regressions in patients with type II diabetes, higher cumulative joint scores, increased number of affected joints, as well as elevated uric acid, erythrocyte sedimentation rate, and leukocyte count. Uric Acid 182-191 C-reactive protein Homo sapiens 9-12 35636449-8 2022 The present review suggests that TXA has an anti-inflammatory effect in patients undergoing orthopaedic surgery illustrated by decreased levels of C-reactive protein and interleukin-6 in patients receiving TXA compared with patients receiving no or lower doses of TXA. Tranexamic Acid 33-36 C-reactive protein Homo sapiens 147-165 35636449-8 2022 The present review suggests that TXA has an anti-inflammatory effect in patients undergoing orthopaedic surgery illustrated by decreased levels of C-reactive protein and interleukin-6 in patients receiving TXA compared with patients receiving no or lower doses of TXA. Tranexamic Acid 206-209 C-reactive protein Homo sapiens 147-165 20580698-5 2010 Serum alpha-carotene and beta-carotene concentrations were significantly associated with serum C-reactive protein (CRP) concentrations in men. beta Carotene 25-38 C-reactive protein Homo sapiens 95-113 20580698-5 2010 Serum alpha-carotene and beta-carotene concentrations were significantly associated with serum C-reactive protein (CRP) concentrations in men. beta Carotene 25-38 C-reactive protein Homo sapiens 115-118 20819623-0 2010 Salmeterol/fluticasone treatment reduces circulating C-reactive protein level in patients with stable chronic obstructive pulmonary disease. Fluticasone 11-22 C-reactive protein Homo sapiens 53-71 20819623-3 2010 We evaluated the effect of salmeterol/fluticasone propionate on circulating C-reactive protein level in stable chronic obstructive pulmonary disease patients. Fluticasone 38-60 C-reactive protein Homo sapiens 76-94 20819623-9 2010 Compared with ipratropium/albuterol, the combination of salmeterol/fluticasone significantly reduced circulating level of C-reactive protein (-1.73 vs. 0.08 mg/L, respectively, P < 0.05) after 6-month treatment. Fluticasone 67-78 C-reactive protein Homo sapiens 122-140 20819623-11 2010 Salmeterol/fluticasone treatment subjects who had a decrease of circulating C-reactive protein level had a significant improvement in FEV(1) and St George"s Respiratory Questionnaire total scores compared with those who did not (185 vs. 83 ml and -5.71 vs. -1.79 units, respectively, both P < 0.01). Fluticasone 11-22 C-reactive protein Homo sapiens 76-94 35636449-8 2022 The present review suggests that TXA has an anti-inflammatory effect in patients undergoing orthopaedic surgery illustrated by decreased levels of C-reactive protein and interleukin-6 in patients receiving TXA compared with patients receiving no or lower doses of TXA. Tranexamic Acid 264-267 C-reactive protein Homo sapiens 147-165 35517786-10 2022 Factors such as age, CRP, ALT and co-administration with proton pump inhibitors exhibited significant effects on PCZ C min. posaconazole 113-116 C-reactive protein Homo sapiens 21-24 20084527-12 2010 Furthermore, intracellular Glycer-AGEs increased the CRP mRNA concentration. tricaprin 27-33 C-reactive protein Homo sapiens 53-56 19415183-4 2010 The results showed that both the expression of Cx43 protein and gap junctional communication function post-48-h incubation were reduced and inhibited by the detoxified CRP, NaN(3), or detoxified dialyzed CRP plus NaN(3), but not by the detoxified dialyzed CRP or dialyzed NaN(3). Sodium Azide 213-219 C-reactive protein Homo sapiens 204-207 34986361-7 2022 RESULTS: NT-proBNP was significantly positively correlated with peak values of cardiac troponin I (cTnI) (r = 0.418), high-sensitivity C-reactive protein (hs-CRP) (r = 0.397) and left ventricular end-diastolic diameter (LVEDD) (r = 0.075) (P < 0.001). nt-probnp 9-18 C-reactive protein Homo sapiens 135-153 20394901-9 2010 Furthermore, the TBR in the stented lesions (in ACS and stable angina groups) correlated with C-reactive protein (r = 0.58, p = 0.04). tbr 17-20 C-reactive protein Homo sapiens 94-112 19782364-13 2010 There was significant positive correlation between MPV and CRP levels (p=0.002, r=0.482) in non-dipper hypertensives. dipper 96-102 C-reactive protein Homo sapiens 59-62 20097689-8 2010 In both groups, CRP levels decreased from 2.1 to 1.8 with ramipril and from 2.2 to 1.1 with the ramipril-Pycnogenol combination; the latter reached statistical significance. ramipril-pycnogenol 96-115 C-reactive protein Homo sapiens 16-19 19906811-6 2010 After multivariate adjustment for demographics, smoking, BMI, alcohol use, antioxidant vitamin status, intakes of protein and energy, and serum concentrations of creatinine and albumin, high vitamin B-6 intake was associated with protection against serum CRP concentrations >10 mg/L compared with < or =3 mg/L. Vitamin B 6 191-202 C-reactive protein Homo sapiens 255-258 19906811-8 2010 Among participants with vitamin B-6 intakes from 2 to 3 mg/d, the multivariate-adjusted prevalence of vitamin B-6 inadequacy was <10% in participants with serum CRP < or =3 mg/L but close to 50% in those with serum CRP > 10 mg/L (P < 0.001). Vitamin B 6 102-113 C-reactive protein Homo sapiens 164-167 19906811-8 2010 Among participants with vitamin B-6 intakes from 2 to 3 mg/d, the multivariate-adjusted prevalence of vitamin B-6 inadequacy was <10% in participants with serum CRP < or =3 mg/L but close to 50% in those with serum CRP > 10 mg/L (P < 0.001). Vitamin B 6 102-113 C-reactive protein Homo sapiens 221-224 19915887-7 2009 The phosphatidylethanolamine saturated to polyunsaturated fatty acid ratio showed highly significant positive correlations with the EDSS and CRP < 5 microg/ml. phosphatidylethanolamine 4-28 C-reactive protein Homo sapiens 141-144 19877087-11 2009 A combination of elevated CRP and SAA levels at baseline revealed the highest predictive value (81%) for ASAS response. asas 105-109 C-reactive protein Homo sapiens 26-29 19886856-8 2009 Serum high sensitively C-reactive protein and uric acid increased significantly in chlorthalidone-treated patients compared to spironolactone treated patients. Spironolactone 127-141 C-reactive protein Homo sapiens 23-41 19857103-7 2009 Additional experimentation was performed in which testing solutions were replaced with media after 1 h and the resulting supernatants quantified after 24 h. RESULTS: BAK induced significant amounts of interleukin (IL-) 1 and tumor necrosis factor (TNF), but only moderate amounts of C-reactive protein (CRP), IL- 10 and 12, and H(2)O(2). Benzalkonium Compounds 166-169 C-reactive protein Homo sapiens 283-301 19857103-7 2009 Additional experimentation was performed in which testing solutions were replaced with media after 1 h and the resulting supernatants quantified after 24 h. RESULTS: BAK induced significant amounts of interleukin (IL-) 1 and tumor necrosis factor (TNF), but only moderate amounts of C-reactive protein (CRP), IL- 10 and 12, and H(2)O(2). Benzalkonium Compounds 166-169 C-reactive protein Homo sapiens 303-306 19444092-10 2009 CONCLUSION: Ranolazine improves endothelial function, asymmetric dimethylarginine, and C-reactive protein levels in a group of patients with stable CAD. Ranolazine 12-22 C-reactive protein Homo sapiens 87-105 19721904-10 2009 Among the patients who presented lower concentrations of CRP it was found higher beta-carotene inadequacy (64.8%) and 50% of retinol inadequacy. beta Carotene 81-94 C-reactive protein Homo sapiens 57-60 19236874-0 2009 A robust quantitative solid phase immunoassay for the acute phase protein C-reactive protein (CRP) based on cytidine 5"-diphosphocholine coupled dendrimers. Cytidine Diphosphate Choline 108-136 C-reactive protein Homo sapiens 74-92 19236874-0 2009 A robust quantitative solid phase immunoassay for the acute phase protein C-reactive protein (CRP) based on cytidine 5"-diphosphocholine coupled dendrimers. Cytidine Diphosphate Choline 108-136 C-reactive protein Homo sapiens 94-97 19929286-10 2009 CRP concentration in the non-dipper group was higher than in the dipper (4.8 +/- 1.4 vs 3.6 +/- 1.6, p<0.01) and control (2.4 +/- 0.9, p<0.001) groups, and microalbuminuria was significantly higher in the non-dipper group compared with dipper (24.9 +/- 8.6 vs 13.4 +/- 8.8, p<0.001) and control (9.6 +/- 4.8, p<0.001) groups. dipper 29-35 C-reactive protein Homo sapiens 0-3 20157364-10 2008 CRP-stimulated production of IL-6, but not MCP-1, was modestly attenuated by short-term treatment with pravastatin. Pravastatin 103-114 C-reactive protein Homo sapiens 0-3 18501785-11 2008 RESULTS: CRP levels increased 10-fold on day 3 after MRI in 87% of MRI studies with Gd-DTPA (+59.3 +/- 57.9 mg/L [P < 0.001] versus -0.9 +/- 3.7 mg/L with gadobutrol versus -0.9 +/- 8.5 mg/L with 0.9% saline). Gadolinium DTPA 84-91 C-reactive protein Homo sapiens 9-12 18394014-0 2008 Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers. Raloxifene Hydrochloride 99-109 C-reactive protein Homo sapiens 113-131 18394014-2 2008 OBJECTIVES: To compare the impact of HT, tibolone, and raloxifene on C-reactive protein (CRP) and other inflammatory markers, and to investigate possible underlying mechanisms for changes in CRP and D-dimer. Raloxifene Hydrochloride 55-65 C-reactive protein Homo sapiens 69-87 18394014-2 2008 OBJECTIVES: To compare the impact of HT, tibolone, and raloxifene on C-reactive protein (CRP) and other inflammatory markers, and to investigate possible underlying mechanisms for changes in CRP and D-dimer. Raloxifene Hydrochloride 55-65 C-reactive protein Homo sapiens 89-92 18394014-6 2008 Also, tibolone was associated with an increase in CRP, in contrast to raloxifene, which reduced CRP. Raloxifene Hydrochloride 70-80 C-reactive protein Homo sapiens 96-99 18245817-7 2008 CRP also significantly increased intracellular cholesteryl ester accumulation compared with huSA. Cholesterol Esters 47-64 C-reactive protein Homo sapiens 0-3 18096828-6 2008 Reducing superoxide anion by antioxidant seleno-L-methionine or SOD mimetic (MnTBAP) effectively abolished the CRP-induced decrease in cholesterol efflux and the expression of ABCA1 and ABCG1. Selenomethionine 41-60 C-reactive protein Homo sapiens 111-114 17852073-6 2008 Plasma beta-carotene inversely correlated with IL-6 (r = -0.46, p=0.0002) and CRP (r = -0.41, p = 0.001). beta Carotene 7-20 C-reactive protein Homo sapiens 78-81 17960332-0 2008 Serum selenium concentrations correlate significantly with inflammatory biomarker high-sensitive CRP levels in Hungarian gestational diabetic and healthy pregnant women at mid-pregnancy. Selenium 6-14 C-reactive protein Homo sapiens 97-100 18057884-0 2008 Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Mevalonic Acid 108-118 C-reactive protein Homo sapiens 21-39 18057884-2 2008 We tested the hypothesis that simvastatin inhibited CRP-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Mevalonic Acid 124-134 C-reactive protein Homo sapiens 52-55 18605954-7 2008 A difference was found between the concentration of CRP in EDTA plasma and citrated plasma which also did not correspond to the dilution. Edetic Acid 59-63 C-reactive protein Homo sapiens 52-55 18097149-2 2008 In the last few years, several emerging risk factors have been proposed as predictors of ARAS, namely homocysteine, fibrinogen, C-reactive protein, lipoprotein(a) and creatinine. aras 89-93 C-reactive protein Homo sapiens 128-146 17719702-7 2007 CONCLUSIONS: A combination of low-fat margarine and milk enriched with plant sterols significantly reduced low-density lipoprotein cholesterol, apolipoprotein B and the ratio of apolipoprotein B to apolipoprotein A-I in mildly hypercholesterolemic subjects, but had no effect on C-reactive protein and lipoprotein (a) concentrations. Margarine 38-47 C-reactive protein Homo sapiens 279-297 17996517-10 2007 The difference between the pravastatin and placebo groups in terms of change in CRP by withdrawal was consistent and persisted in analysis corrected for body mass index, smoking status, blood pressure, and baseline levels of total cholesterol, LDL cholesterol, high-density lipoprotein cholesterol, or triglycerides. Pravastatin 27-38 C-reactive protein Homo sapiens 80-83 17996517-11 2007 In conclusion, withdrawal from pravastatin treatment resulted in an increase in CRP to approximately baseline levels, which is not related to the increase in LDL cholesterol. Pravastatin 31-42 C-reactive protein Homo sapiens 80-83 18039190-2 2007 CRP concentration was determined by laser nephelometry (BN II Analyzer) and CardioPhase high-sensitivity CRP (DADE BEHRING) was used as reagent which consists of polystyrene particles coated with mouse monoclonal antibodies to CRP. Polystyrenes 162-173 C-reactive protein Homo sapiens 105-108 18039190-2 2007 CRP concentration was determined by laser nephelometry (BN II Analyzer) and CardioPhase high-sensitivity CRP (DADE BEHRING) was used as reagent which consists of polystyrene particles coated with mouse monoclonal antibodies to CRP. Polystyrenes 162-173 C-reactive protein Homo sapiens 105-108 17112529-6 2007 Pravastatin treatment significantly decreased levels of total cholesterol (16%), low-density lipoprotein cholesterol (23%) and high-sensitivity C-reactive protein (37%) (p<0.01, respectively). Pravastatin 0-11 C-reactive protein Homo sapiens 144-162 17676666-2 2007 Using antibody-antigen interactions as a proof-of-concept system, the targeted plasma proteins, serum amyloid P (SAP), serum amyloid A (SAA), and C-reactive protein (CRP), could be selectively isolated and enriched from human plasma by antibody-immobilized PVDF membrane and directly identified by MALDI-TOF MS without additional elution step. polyvinylidene fluoride 257-261 C-reactive protein Homo sapiens 166-169 17635239-1 2007 BACKGROUND: In the light of an emerging role for early-mid treatment 18 F-deoxyfluoroglucose positron emission tomography (FDG-PET) as an important prognostic indicator in aggressive non-Hodgkin"s lymphoma (NHL) , we attempted to determine whether a simple parameter, such as the early-mid treatment CRP (C-reactive protein) level, could also be utilized as a significant prognostic factor in aggressive NHL. deoxyfluoroglucose 74-92 C-reactive protein Homo sapiens 300-303 17635239-1 2007 BACKGROUND: In the light of an emerging role for early-mid treatment 18 F-deoxyfluoroglucose positron emission tomography (FDG-PET) as an important prognostic indicator in aggressive non-Hodgkin"s lymphoma (NHL) , we attempted to determine whether a simple parameter, such as the early-mid treatment CRP (C-reactive protein) level, could also be utilized as a significant prognostic factor in aggressive NHL. deoxyfluoroglucose 74-92 C-reactive protein Homo sapiens 305-323 35327498-5 2022 Serum bilirubin levels are positively correlated with the levels of the antioxidative enzymes as superoxide dismutase, catalase, and glutathione peroxidase, while it is inversely correlated with C-reactive protein, TNF-alpha, interleukin (IL)-2, IL-6, and IL-10 release in diabetic kidney disease. Bilirubin 6-15 C-reactive protein Homo sapiens 195-213 17520506-5 2007 After changing the antibiotics to ceftriaxon and metronidazole, acute cholangitis being suspected, the fever subsided immediately and the CRP level decreased. Ceftriaxone 34-44 C-reactive protein Homo sapiens 138-141 17545695-6 2007 RESULTS: CRP was significantly and inversely related to the intakes of oleic acid (p=0.008) and alpha-linolenic acid (p=0.026) in women after adjustment for confounding factors. Oleic Acid 71-81 C-reactive protein Homo sapiens 9-12 17545695-6 2007 RESULTS: CRP was significantly and inversely related to the intakes of oleic acid (p=0.008) and alpha-linolenic acid (p=0.026) in women after adjustment for confounding factors. alpha-Linolenic Acid 96-116 C-reactive protein Homo sapiens 9-12 17545695-7 2007 A multiple regression analysis showed that, especially in the middle tertile of long-chain n-3 PUFAs (eicosapentaenoic acid and docosahexaenoic acid) intake, CRP was inversely related to the intake of oleic acid and linoleic acid in both sexes and to the intake of alpha-linolenic acid in women. Oleic Acid 201-211 C-reactive protein Homo sapiens 158-161 17545695-7 2007 A multiple regression analysis showed that, especially in the middle tertile of long-chain n-3 PUFAs (eicosapentaenoic acid and docosahexaenoic acid) intake, CRP was inversely related to the intake of oleic acid and linoleic acid in both sexes and to the intake of alpha-linolenic acid in women. alpha-Linolenic Acid 265-285 C-reactive protein Homo sapiens 158-161 17545695-8 2007 CONCLUSION: Intakes of oleic acid, linoleic acid, and alpha-linolenic acid would reduce serum CRP, especially when the intake of long-chain n-3 PUFAs is at a moderate level in Japanese. Oleic Acid 23-33 C-reactive protein Homo sapiens 94-97 17545695-8 2007 CONCLUSION: Intakes of oleic acid, linoleic acid, and alpha-linolenic acid would reduce serum CRP, especially when the intake of long-chain n-3 PUFAs is at a moderate level in Japanese. alpha-Linolenic Acid 54-74 C-reactive protein Homo sapiens 94-97 35296708-0 2022 Natural antibodies and CRP drive anaphylatoxin production by urate crystals. Uric Acid 61-66 C-reactive protein Homo sapiens 23-26 17237316-0 2007 Intake of fish oil, oleic acid, folic acid, and vitamins B-6 and E for 1 year decreases plasma C-reactive protein and reduces coronary heart disease risk factors in male patients in a cardiac rehabilitation program. Oleic Acid 20-30 C-reactive protein Homo sapiens 95-113 17329034-6 2007 Further, we have shown that atorvastain blocks the AGE-signaling to C-reactive protein (CRP) expression in human hepatoma cells in vitro via anti-oxidative properties. atorvastain 28-39 C-reactive protein Homo sapiens 68-86 17329034-6 2007 Further, we have shown that atorvastain blocks the AGE-signaling to C-reactive protein (CRP) expression in human hepatoma cells in vitro via anti-oxidative properties. atorvastain 28-39 C-reactive protein Homo sapiens 88-91 17329034-12 2007 Does the blockade by atorvastain of the AGE signaling pathway, in other words, the suppression of 8-hydroxydeoxyguanosine and CRP levels by atorvastatin treatment, contribute to its cardioprotective properties? atorvastain 21-32 C-reactive protein Homo sapiens 126-129 35296708-3 2022 We previously found that the soluble pattern recognition molecule C-reactive protein (CRP) recognizes MSU crystals, while enhancing complement activation. Uric Acid 102-105 C-reactive protein Homo sapiens 66-84 35296708-3 2022 We previously found that the soluble pattern recognition molecule C-reactive protein (CRP) recognizes MSU crystals, while enhancing complement activation. Uric Acid 102-105 C-reactive protein Homo sapiens 86-89 35296708-9 2022 We show that IgM and CRP both activate the classical complement pathway on MSU crystals. Uric Acid 75-78 C-reactive protein Homo sapiens 21-24 17274906-9 2006 Actinomycin D, the DNA-directed RNA polymerase inhibitor, completely blocked CRP and TNF-alpha induced PAPP-A expression. Dactinomycin 0-13 C-reactive protein Homo sapiens 77-80 35296708-11 2022 Notably, while CRP recognizes MSU crystals but not the related calcium pyrophosphate dihydrate (CPPD) crystals, natural IgM bound to both, suggesting common and distinct mechanisms of recognition of individual crystal types by complement activators. Uric Acid 30-33 C-reactive protein Homo sapiens 15-18 35232215-7 2022 EPA+DPA-FFA reduced least squares geometric mean high-sensitivity C-reactive protein by 5.8%; EPA-EE increased high-sensitivity C-reactive protein by 8.5% (P=0.034). Eicosapentaenoic Acid 0-3 C-reactive protein Homo sapiens 66-84 16796400-1 2006 A solid-phase sandwich fluorescence immunoassay using nanocrystals of a fluorogenic precursor, fluorescein diacetate (FDA), conjugated with monoclonal antibodies for the detection of C-reactive protein (CRP), is described. diacetylfluorescein 95-116 C-reactive protein Homo sapiens 203-206 16796400-1 2006 A solid-phase sandwich fluorescence immunoassay using nanocrystals of a fluorogenic precursor, fluorescein diacetate (FDA), conjugated with monoclonal antibodies for the detection of C-reactive protein (CRP), is described. diacetylfluorescein 118-121 C-reactive protein Homo sapiens 183-201 16796400-8 2006 The study demonstrates that the organic fluorogenic FDA nanocrystals can be applied for the detection of CRP, which is a clinically interesting plasma protein with a low limit of detection. diacetylfluorescein 52-55 C-reactive protein Homo sapiens 105-108 16564781-8 2006 Cox proportional hazards model showed that combination NT-proBNP-CRP was the strongest independent correlate of mortality (hazard ratio [HR] 4.3, 95% confidence interval [CI], 2.0-9.3; P <.001 for high NT-proBNP-high CRP vs low NT-proBNP-low CRP). -probnp 57-64 C-reactive protein Homo sapiens 65-68 16983929-16 2006 We conclude that elevated CRP is associated with lower RRF As a predictor of mortality, CRP may be better than RRF and D/P Cr. Chromium 123-125 C-reactive protein Homo sapiens 26-29 16244112-7 2006 Accordingly, CRP- and ox-LDL-induced MMP-1 production by monocytes was inhibited by anti-MCP-1 antibodies and indomethacin, respectively. Indomethacin 110-122 C-reactive protein Homo sapiens 13-16 35232215-12 2022 EPA+DPA-FFA also reduced triglycerides and high-sensitivity C-reactive protein without increasing low-density lipoprotein cholesterol. Eicosapentaenoic Acid 0-3 C-reactive protein Homo sapiens 60-78 35188180-5 2022 ASAS40 response was observed with CRP <=5 mg/l and SPARCC MRI spine score <2 with IXEQ4W (29%) and was significant with IXEQ2W (48%, p<0.05) vs PBO (13%). asas40 0-6 C-reactive protein Homo sapiens 34-37 15893181-3 2005 METHODS: We addressed the relative efficacy of pravastatin 40 mg and atorvastatin 80 mg daily to reduce LDL-C and CRP among 3,745 acute coronary syndrome patients. Pravastatin 47-58 C-reactive protein Homo sapiens 114-117 35079220-0 2022 Inverted J-Shaped Association of High-Sensitivity C-Reactive Protein with the Levels of Serum Uric Acid: Cross-Sectional and Longitudinal Analyses. Uric Acid 94-103 C-reactive protein Homo sapiens 50-68 15725942-0 2005 Evidence for sodium azide as an artifact mediating the modulation of inducible nitric oxide synthase by C-reactive protein. Sodium Azide 13-25 C-reactive protein Homo sapiens 104-122 15725942-7 2005 The inhibitory effects of commercial CRP or vehicle medium were lost on sodium azide removal by dialysis. Sodium Azide 72-84 C-reactive protein Homo sapiens 37-40 15725942-8 2005 In conclusion, sodium azide from the commercial CRP solution, but not CRP itself, mainly accounts for the inhibitory effect on IL-1beta-evoked iNOS induction and NO release. Sodium Azide 15-27 C-reactive protein Homo sapiens 48-51 15725942-9 2005 Care should be taken before attributing any biologic role to commercial CRP containing sodium azide. Sodium Azide 87-99 C-reactive protein Homo sapiens 72-75 15635109-3 2005 METHODS: We evaluated relationships between the LDL cholesterol and CRP levels achieved after treatment with 80 mg of atorvastatin or 40 mg of pravastatin per day and the risk of recurrent myocardial infarction or death from coronary causes among 3745 patients with acute coronary syndromes. Pravastatin 143-154 C-reactive protein Homo sapiens 68-71 15635109-7 2005 Although atorvastatin was more likely than pravastatin to result in low levels of LDL cholesterol and CRP, meeting these targets was more important in determining the outcomes than was the specific choice of therapy. Pravastatin 43-54 C-reactive protein Homo sapiens 102-105 34732318-0 2022 C-Reactive Protein, a Promising Approach for Acetaminophen Hepatotoxicity. Acetaminophen 45-58 C-reactive protein Homo sapiens 0-18 16277678-2 2005 Clinical indicators, including the disability score, the length of morning stiffness, and the degree of pain, and biochemical markers, including the erythrocyte sedimentation rate and C-reactive protein levels, were found to be inversely correlated with circulating vitamin B6 levels. Vitamin B 6 266-276 C-reactive protein Homo sapiens 184-202 34292266-5 2022 The proportion was calculated of (1) infants with CPS with, at 24 hours, a positive BC and/or CRP >=10 mg/L and/or clinical signs of infection and (2) infants without CPS with CRP <10 mg/L between 12 and 24 hours after OSEOS. cps 50-53 C-reactive protein Homo sapiens 94-97 16103725-7 2005 There was a negative correlation between serum CRP and CrCl (r = -0.370, p < 0.001). crcl 55-59 C-reactive protein Homo sapiens 47-50 15571826-13 2004 The activity of the mevalonate pathway in the liver may be related to the metabolism of CRP. Mevalonic Acid 20-30 C-reactive protein Homo sapiens 88-91 34292266-9 2022 CONCLUSION: A combination of BC, CRP, and clinical signs of infection can diagnose 98% (49/50) of infants with CPS 24 hours after OSEOS. cps 111-114 C-reactive protein Homo sapiens 33-36 2477447-8 1989 Binding to these bands was inhibited by both EDTA and PC indicating that CRP binds these proteins through the PC-binding site. Edetic Acid 45-49 C-reactive protein Homo sapiens 73-76 15340176-8 2004 Patients with dominant ER had higher levels of serum C-reactive protein (CRP) compared with levels in patients with dominant CR and patients with mixed remodeling (1.62 mg/dL +/- 2.05 [standard deviation] vs 0.19 mg/dL +/- 0.33 and 0.21 mg/dL +/- 0.39, respectively, P < .005). Chromium 73-75 C-reactive protein Homo sapiens 53-71 15229100-6 2004 Two weeks with inhaled fluticasone reduced CRP levels by 50% (95% CI, 9-73%); prednisone reduced it by 63% (95% CI, 29-81%). Fluticasone 23-34 C-reactive protein Homo sapiens 43-46 15229100-8 2004 An additional 8 weeks of fluticasone were associated with CRP levels that were lower than those at baseline (a 29% reduction; 95% CI, 7-46%). Fluticasone 25-36 C-reactive protein Homo sapiens 58-61 15265816-0 2004 Early effect of pravastatin on serum soluble CD40L, matrix metalloproteinase-9, and C-reactive protein in patients with acute myocardial infarction. Pravastatin 16-27 C-reactive protein Homo sapiens 84-102 15345737-6 2004 RESULTS: The serum beta-carotene concentration was inversely associated with C-reactive protein and interleukin-6 levels. beta Carotene 19-32 C-reactive protein Homo sapiens 77-95 15197140-9 2004 Interleukin-6 (P=0.04) and C-reactive protein (P=0.02) decreased more in the repaglinide group than in the glyburide group. repaglinide 77-88 C-reactive protein Homo sapiens 27-45 15226473-5 2004 The intake of alpha-linolenic acid was inversely related to plasma concentrations of CRP (beta = -0.55, P = 0.02), Il-6 (beta = -0.36, P = 0.01), and E-selectin (beta = -0.24, P = 0.008) after controlling for age, BMI, physical activity, smoking status, alcohol consumption, and intake of linoleic acid (n-6) and saturated fat. alpha-Linolenic Acid 14-34 C-reactive protein Homo sapiens 85-88 15250255-0 2004 Effects of simvastain combined with omega-3 fatty acids on high sensitive C-reactive protein, lipidemia, and fibrinolysis in patients with mixed dyslipidemia. simvastain 11-21 C-reactive protein Homo sapiens 74-92 15117211-0 2004 Evaluation of 2-methacryloyloxyethyl phosphorylcholine polymeric nanoparticle for immunoassay of C-reactive protein detection. 2-methacryloyloxyethyl phosphorylcholine 14-54 C-reactive protein Homo sapiens 97-115 15048997-0 2004 Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. 13c 145-148 C-reactive protein Homo sapiens 18-36 15575349-8 2004 beta-Carotene was inverse related to leukocytes (-0.23+/-0.07; p = 0.007) and CRP (-1.09+/-0.30; p = 0.0003) per 1 micromol/l. beta Carotene 0-13 C-reactive protein Homo sapiens 78-81 14743546-7 2003 Using a limit of 0.6 mg/L (75th percentile), significantly lower levels were observed for transthyretin, iron, retinol, and beta-carotene in the group with the higher CRP levels. beta Carotene 124-137 C-reactive protein Homo sapiens 167-170 12947436-5 2003 RESULTS: C-reactive protein concentration (dichotomized at the sex-specific 85th percentile) was inversely and significantly associated with concentrations of retinol, retinyl esters, vitamin C, alpha-carotene, beta-carotene, cryptoxanthin, lutein/zeaxanthin, lycopene, and selenium after adjustment for age, sex, race or ethnicity, education, cotinine concentration, body mass index, leisure-time physical activity, and aspirin use. Selenium 274-282 C-reactive protein Homo sapiens 9-27 12867288-1 2003 BACKGROUND: We reported a reciprocal relationship between reduced serum selenium (Se) and elevated serum C-reactive protein (CRP) in various pathological conditions in comparison with the levels in 141 healthy subjects. Selenium 72-80 C-reactive protein Homo sapiens 105-123 12867288-1 2003 BACKGROUND: We reported a reciprocal relationship between reduced serum selenium (Se) and elevated serum C-reactive protein (CRP) in various pathological conditions in comparison with the levels in 141 healthy subjects. Selenium 72-80 C-reactive protein Homo sapiens 125-128 12867288-1 2003 BACKGROUND: We reported a reciprocal relationship between reduced serum selenium (Se) and elevated serum C-reactive protein (CRP) in various pathological conditions in comparison with the levels in 141 healthy subjects. Selenium 82-84 C-reactive protein Homo sapiens 105-123 12867288-1 2003 BACKGROUND: We reported a reciprocal relationship between reduced serum selenium (Se) and elevated serum C-reactive protein (CRP) in various pathological conditions in comparison with the levels in 141 healthy subjects. Selenium 82-84 C-reactive protein Homo sapiens 125-128 12867288-8 2003 CONCLUSIONS: Selenium at physiological levels mediates inhibition of the activation of the transcription factor NF-kappaB which regulates genes that encode inflammatory cytokines, and that conversely, the reduction of selenium induces the synthesis of CRP by hepatocytes during the acute phase response. Selenium 13-21 C-reactive protein Homo sapiens 252-255 12934303-1 2003 Ineffectiveness of malaria treatment is in many cases explained by chloroquine resistance (CR) of plasmodia (CRP) which dominates in some regions of Africa and South-East Asia. Chloroquine 67-78 C-reactive protein Homo sapiens 109-112 12509980-1 2003 The complement regulatory protein (CRP) of Trypanosoma cruzi is a developmentally regulated glycosylphosphatidylinositol (GPI)-anchored membrane protein that protects the parasite from complement-mediated killing, and is an important virulence determinant of the microorganism. Glycosylphosphatidylinositols 92-120 C-reactive protein Homo sapiens 35-38 12509980-1 2003 The complement regulatory protein (CRP) of Trypanosoma cruzi is a developmentally regulated glycosylphosphatidylinositol (GPI)-anchored membrane protein that protects the parasite from complement-mediated killing, and is an important virulence determinant of the microorganism. Glycosylphosphatidylinositols 122-125 C-reactive protein Homo sapiens 35-38 11893365-1 2002 PURPOSE: C-reactive protein is an important risk factor for coronary artery disease, and plasma concentrations are lowered by treatment with pravastatin and aspirin. Pravastatin 141-152 C-reactive protein Homo sapiens 9-27 11589863-0 2001 Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Raloxifene Hydrochloride 104-114 C-reactive protein Homo sapiens 118-136 11426429-10 2001 The results of our studies demonstrated that although CRP-I and CRP-II could be bound directly to polystyrene, these directly immobilized CRPs failed to bind (125)I-FN . Polystyrenes 98-109 C-reactive protein Homo sapiens 54-57 11426429-10 2001 The results of our studies demonstrated that although CRP-I and CRP-II could be bound directly to polystyrene, these directly immobilized CRPs failed to bind (125)I-FN . Polystyrenes 98-109 C-reactive protein Homo sapiens 64-67 11426429-13 2001 (125)I-CRP-BSAs were all found to bind to equivalent levels on polystyrene (1.60-2.60 microg/cm2). Polystyrenes 63-74 C-reactive protein Homo sapiens 7-10 11426429-14 2001 When CRP-BSAs were immobilized on polystyrene, they all successfully bound (125)I-FN in a range of 34-72 ng/cm2 (mean). Polystyrenes 34-45 C-reactive protein Homo sapiens 5-8 11493133-7 2001 CONCLUSIONS: The strong and inverse association of serum beta-carotene level with C-reactive protein level and white blood cell count suggests that the relationship between serum beta-carotene concentration and disease risk might be confounded by inflammation. beta Carotene 57-70 C-reactive protein Homo sapiens 82-100 11493133-7 2001 CONCLUSIONS: The strong and inverse association of serum beta-carotene level with C-reactive protein level and white blood cell count suggests that the relationship between serum beta-carotene concentration and disease risk might be confounded by inflammation. beta Carotene 179-192 C-reactive protein Homo sapiens 82-100 11499569-10 2001 When patients were divided in two groups according to renal function, CRP resulted 7.4+/-6.3 mg/L in the group of patients with a C(Cr) lower than 20 mL/min (n=32) and 2.76+/-4.35 in the group of patients with a C(Cr) higher than 20 mL/min (n = 70) (p <0.0001). Chromium 132-134 C-reactive protein Homo sapiens 70-73 11306519-5 2001 hs-CRP levels were significantly decreased after treatment with all 3 statins compared with baseline (median values: baseline, 2.6 mg/L; atorvastatin, 1.7 mg/L; simvastatin, 1.7 mg/L; and pravastatin, 1.9 mg/L; P<0.025). Pravastatin 188-199 C-reactive protein Homo sapiens 3-6 11306519-9 2001 CONCLUSIONS: Pravastatin, simvastatin, and atorvastatin significantly decreased levels of hs-CRP. Pravastatin 13-24 C-reactive protein Homo sapiens 93-96 10548188-18 1999 PF did not influence mean concentrations of interleukin-6, granulocyte colony-stimulating factor, thromboxane B2, total white cell count, neutrophil count, or platelet count, but it was associated with significant reductions of alpha1-antitrypsin, haptoglobin, C-reactive protein, and complement fragment C3 in the first 6 hrs (p < .05). pf 0-2 C-reactive protein Homo sapiens 261-307 10524550-7 1999 It was concluded that a clinical response to chloroquine therapy in early RA patients can be predicted by a low CRP level at baseline. Chloroquine 45-56 C-reactive protein Homo sapiens 112-115 9924810-5 1998 The rate of dissociation of CRP protomers into individual subunits by treatment in 8 M urea-10 mM EDTA solution was rapid and complete in 2 min as assayed by an enzyme-linked immunofiltration assay using monoclonal antibodies specific to the mCRP. Edetic Acid 98-102 C-reactive protein Homo sapiens 28-31 7688075-3 1993 The selective removal of C-reactive protein from the plasma with phosphorylethanolamine-agarose inactivated hemolysis. Sepharose 88-95 C-reactive protein Homo sapiens 25-43 8339522-4 1993 Because no such correlation could be observed with apoSAA, results of this study suggest that the major mechanism of lowering the plasma levels of apoA-I and the plasma-cholesteryl content could be closely related to the appearance of large amounts of C-reactive protein in plasma or more likely to the process inducing the hepatic synthesis of this acute phase protein. cholesteryl 169-180 C-reactive protein Homo sapiens 252-270 1657391-4 1991 Addition of 5 mM EDTA allowed CRP to abolish this binding. Edetic Acid 17-21 C-reactive protein Homo sapiens 30-33 33972118-9 2021 After treatment with DAAs, an overall significant reduction of C-reactive protein (CRP) levels was found (p = 0.004). daas 21-25 C-reactive protein Homo sapiens 63-81 33972118-9 2021 After treatment with DAAs, an overall significant reduction of C-reactive protein (CRP) levels was found (p = 0.004). daas 21-25 C-reactive protein Homo sapiens 83-86 33972118-11 2021 CONCLUSIONS: Treatment of chronic hepatitis C with DAAs decrease carotid thickening, atheromatous plaques, and inflammatory markers like CRP. daas 51-55 C-reactive protein Homo sapiens 137-140 33809857-3 2021 Multilevel linear and logistic regression models were used to assess the associations of particulate matter (PM) and nitrogen dioxide (NO2) on log-transformed hs-CRP levels and odds ratios of CVD risk derived from CRP levels adjusted for confounders. Nitrogen Dioxide 135-138 C-reactive protein Homo sapiens 162-165 26640530-13 2015 In the DEX group compared with the control group, IL-1beta, IL-6 and CRP levels were markedly decreased at 6 h and 1 day after surgery (P<0.01). Dextromethorphan 7-10 C-reactive protein Homo sapiens 69-72 22353705-10 2012 Leflunomide showed partial superiority over methotrexate in the percentage of patients obtaining ACR50 and ACR70 response, doctor"s assessment of the disease activity, reduction in C-reactive protein (CRP) levels, and improvement of the quality of life (assessed with the modified health assessment questionnaire [HAQ]). Leflunomide 0-11 C-reactive protein Homo sapiens 181-199 22353705-10 2012 Leflunomide showed partial superiority over methotrexate in the percentage of patients obtaining ACR50 and ACR70 response, doctor"s assessment of the disease activity, reduction in C-reactive protein (CRP) levels, and improvement of the quality of life (assessed with the modified health assessment questionnaire [HAQ]). Leflunomide 0-11 C-reactive protein Homo sapiens 201-204 34799157-7 2022 It was found that blood Cr level showed significant dose-dependent relationships with increasing of MNF and urinary 8-OHdG, while negative association with CRP and C1q. Chromium 24-26 C-reactive protein Homo sapiens 156-159 34799157-9 2022 4.97% of the association between blood Cr level and the increased MNF was mediated by CRP. Chromium 39-41 C-reactive protein Homo sapiens 86-89 34931411-7 2022 Selenium levels associated positively with female sex, higher total cholesterol and glucose concentrations, and associated negatively with incidence of anemia, iron deficiency, current smoking, increasing C-reactive protein levels, and higher body mass index. Selenium 0-8 C-reactive protein Homo sapiens 205-223 34245388-0 2021 C-reactive protein predicts persistent bacteremia caused by community-acquired methicillin-resistant Staphylococcus aureus strain. Methicillin 79-90 C-reactive protein Homo sapiens 0-18 34798417-5 2021 3-(Dibutylamino)propylphosphonic acid (C10m) is a new substance that can suppress ischemic-reperfusion injury by targeting CRP in the complement cascade. 3-(dibutylamino)propylphosphonic acid 0-37 C-reactive protein Homo sapiens 123-126 34351640-6 2021 Remdesivir administration improved the levels of various biochemical parameters such as CRP, LDH, D-Dimer and ferritin both in diabetic and non-diabetic patients. remdesivir 0-10 C-reactive protein Homo sapiens 88-91 34882080-5 2021 Following the TMZ treatment, the leukocyte count in peripheral blood was decreased (5.3 %; r<0.01) and the serum concentration of high-sensitivity C-reactive protein was decreased (30.7 %; r<0.01) vs. increases of these indexes in the control group (17.9 %; r<0.05 and 17.8 %; r<0.05, respectively). Trimetazidine 14-17 C-reactive protein Homo sapiens 147-165 34867458-15 2021 Conclusion: Our findings showed that combination EX + CR intervention effectively decreased CRP, IL-6, and TNF-alpha in overweight and obese adults with active lifestyles, but not with sedentary lifestyle behavior. Chromium 54-56 C-reactive protein Homo sapiens 92-95 34331825-8 2021 Furthermore, an inverse association was observed between high dietary intake of vitamin B6 (OR vitaminB6 : 0.28; 95% CI: 0.08, 1.00; P=0.05) and vitamin B9 (OR vitaminB9 : 0.20; 95% CI: 0.06, 0.70; P=0.01) with hs-CRP level. Vitamin B 6 80-90 C-reactive protein Homo sapiens 214-217 34331825-10 2021 Similarly, high dietary intake of vitamin B6 and B9 was associated with lower odds of having a high hs-CRP level. Vitamin B 6 34-44 C-reactive protein Homo sapiens 103-106 34404175-5 2021 Result: Compared with AL group,AJI group had significantly higher levels of CRP,ESR,PC,PC/MPV and PCT(all P<0.05),but lower level of MPV (P<0.05).The AUCs for CRP,ESR,PC,PC/MPV and PCT were 0.820, 0.829, 0.689, 0.668 and 0.676,respectively. Aluminum 22-24 C-reactive protein Homo sapiens 76-79 34404175-5 2021 Result: Compared with AL group,AJI group had significantly higher levels of CRP,ESR,PC,PC/MPV and PCT(all P<0.05),but lower level of MPV (P<0.05).The AUCs for CRP,ESR,PC,PC/MPV and PCT were 0.820, 0.829, 0.689, 0.668 and 0.676,respectively. Aluminum 22-24 C-reactive protein Homo sapiens 159-162 34179035-9 2021 Patients receiving LPV/r or DRV/c were more likely younger, men, had higher C-reactive protein levels while less likely had hypertension, cardiovascular, pulmonary or kidney disease. lopinavir-ritonavir drug combination 19-24 C-reactive protein Homo sapiens 76-94 34916884-0 2021 Rising Plasma Beta-Carotene Is Associated With Diminishing C-Reactive Protein in Patients Consuming a Dark Green Leafy Vegetable-Rich, Low Inflammatory Foods Everyday (LIFE) Diet. beta Carotene 14-27 C-reactive protein Homo sapiens 59-77 34916884-2 2021 In this longitudinal retrospective chart review, we investigate whether patients intensively counseled to eat a specific diet high in dark green leafy vegetables, and thus high beta-carotene, have reductions in plasma high-sensitivity CRP (hsCRP). beta Carotene 177-190 C-reactive protein Homo sapiens 235-238 34916884-7 2021 The change in beta-carotene was inversely correlated with change in CRP (r = -0.68, P < .0001). beta Carotene 14-27 C-reactive protein Homo sapiens 68-71 35453148-10 2022 In addition, some tendencies were observed: serum HDL cholesterol tended to be inversely correlated with visceral adipose tissue cholesterol; high-sensitivity C-reactive protein tended to be correlated directly with subcutaneous adipose 24S-hydroxycholesterol and inversely with visceral 27-hydroxycholesterol. 24-hydroxycholesterol 237-259 C-reactive protein Homo sapiens 159-177 35463661-7 2022 Multivariate analysis showed that hemoglobin (Hb) and C-reactive protein (CRP) were predisposing factors of AL in children. Aluminum 108-110 C-reactive protein Homo sapiens 54-72 35463661-7 2022 Multivariate analysis showed that hemoglobin (Hb) and C-reactive protein (CRP) were predisposing factors of AL in children. Aluminum 108-110 C-reactive protein Homo sapiens 74-77 35442486-7 2022 After the intervention, as compared to the control group, ALA group showed significant reductions in serum levels of hs-CRP, TNF-alpha, 8-OHdG (p<0.001), urea, and BUN (p=0.029) with significant elevations in Hb concentration (p<0.001), serum iron (p=0.037) and transferrin saturation (p<0.001). Thioctic Acid 58-61 C-reactive protein Homo sapiens 120-123 35443454-13 2022 Severe patients were divided into 2 groups, who took injection Remdesivir along with antibiotics, LMWH, systemic steroids vs who didn"t, and CRP level were compared, but the difference was not significant (p = 0.06). remdesivir 63-73 C-reactive protein Homo sapiens 141-144 35443454-14 2022 Pre and post treatment CRP was also compared for Tocilizumab, Fevipiravir, Hydroxychloroquine, Doxycyline, but none of them were able to decrease CRP significantly (p > 0.05) in the severe or critical group but these drugs were effective in reducing CRP significantly (p<0.05) when given in mild-moderate group or if the treatment was started early. Hydroxychloroquine 75-93 C-reactive protein Homo sapiens 23-26 35453325-4 2022 Our objective was to describe the kinetics of four biomarkers related to pro-oxidative processes (nitrite/nitrate, malondialdehyde, 8-oxo-2"-deoxyguanosine, soluble endoglin) compared to four biomarkers of antioxidant processes (the ferric reducing ability of plasma, superoxide dismutase, asymmetric dimethylarginine, mid-regional pro-adrenomedullin) and four inflammatory biomarkers (CRP, IL-6, IL-10 and neopterin). Proline 73-76 C-reactive protein Homo sapiens 386-389 35230450-5 2022 High urinary N-Ag levels were associated with the absence of SARS-CoV-2 nucleocapsid antibodies, admission in intensive care units, high C-reactive protein levels, lymphopenia, eosinopenia, and high lactate dehydrogenase. n-ag 13-17 C-reactive protein Homo sapiens 137-155 35141743-5 2022 RESULTS: Over 12 weeks, the median NNT and the median CPR to achieve DAS28-CRP remission were 4.3 and JPY 1,799,696 (USD 16,361), respectively, for upadacitinib 15mg + csDMARD. upadacitinib 148-160 C-reactive protein Homo sapiens 75-78 35140620-9 2022 The results of BCA indicated that Gastrodin, Liquiritin, Hesperidin, Isoliquiritin, Hesperetin, and Isoliquiritigenin might be the active constituents to activate ROS and suppress hs-CRP as determined by spectrum-effect relationships. isoliquiritigenin 100-117 C-reactive protein Homo sapiens 183-186 35050355-16 2022 Plasma levels of several acylcarnitines, ceramides, and C-reactive protein were decreased by urolithin A, compared with placebo, at 4 months (baseline vs 4 mo: urolithin A, 2.14 (2.15) vs 2.07 (1.46); placebo, 2.17 (2.52) vs 2.65 (1.86)). 3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one 93-104 C-reactive protein Homo sapiens 56-74 2593200-5 1989 Our results show that CRP binds to liposomes containing DPPC and phosphatidylglycerol (PG). Phosphatidylglycerols 65-85 C-reactive protein Homo sapiens 22-25 2593200-5 1989 Our results show that CRP binds to liposomes containing DPPC and phosphatidylglycerol (PG). Phosphatidylglycerols 87-89 C-reactive protein Homo sapiens 22-25 2803750-0 1989 Purification of human C-reactive protein by barium sulfate and preparative agarose electrophoresis. Barium Sulfate 44-58 C-reactive protein Homo sapiens 22-40 2803750-2 1989 The methods described take advantage of the barium sulfate adsorption property of CRP and the unique biophysical property of CRP migration during electrophoresis in agarose gels containing Ca2+. Barium Sulfate 44-58 C-reactive protein Homo sapiens 82-85 2678976-9 1989 In the treatment with Norfloxacin, the count of leukocytes, erythrocyte sedimentation rate and CRP were obviously improved. Norfloxacin 22-33 C-reactive protein Homo sapiens 95-98 3285537-3 1988 Serum CRP concentration rose in response to operation in virtually all patients, regardless of immunosuppressive regimen, from mean baselines of 5.9 +/- 2.7 mcg/ml (AZA) and 6.8 +/- 6.5 mcg/ml (CsA) to mean peak levels of 43.8 +/- 33.4 mcg/ml and 65.1 +/- 39.5 mcg/ml, respectively. Azathioprine 165-168 C-reactive protein Homo sapiens 6-9 3285537-4 1988 CRP rose during 76% of acute rejection episodes in AZA patients by a mean of 29.7 +/- 37.4 mcg/ml. Azathioprine 51-54 C-reactive protein Homo sapiens 0-3 7462634-3 1981 We have previously presented a model for CRP-membrane interactions using liposomes composed of dimyristoyl phosphatidylcholine (DMPC), cholesterol (CHOL), stearylamine (SA), and galactosyl ceramide. Galactosylceramides 178-197 C-reactive protein Homo sapiens 41-44 7462634-8 1981 The binding was not inhibited by ethylenediaminetetraacetate (EDTA) but could be inhibited by CaCl2, whereas CRP binding to PC-Sepharose was inhibited by EDTA and required CaCl2. Calcium Chloride 172-177 C-reactive protein Homo sapiens 109-112 70475-8 1977 By contrast, CRP did inhibit both thrombin-induced release of malondialdehyde, a prostaglandin endoperoxide nonprostanoate endproduct, and platelet aggregation induced by the prostaglandin endoperoxide precursor arachidonic acid. prostaglandin endoperoxide nonprostanoate 81-122 C-reactive protein Homo sapiens 13-16 809531-2 1975 C-reactive protein-mediated consumption of complement by poly-L-lysine polymers and other polycations. poly-l-lysine polymers 57-79 C-reactive protein Homo sapiens 0-18 34030393-10 2021 AAMA (beta = 0.10), GAMA (beta = 0.16) and SigmaUAAM (beta = 0.12) were significantly (P < 0.05) related to increased CRP, which was significantly (P < 0.05) related to reduced FVC (beta = -55.3) and FEV1 (beta = -40.6). gama 20-24 C-reactive protein Homo sapiens 118-121 34030393-10 2021 AAMA (beta = 0.10), GAMA (beta = 0.16) and SigmaUAAM (beta = 0.12) were significantly (P < 0.05) related to increased CRP, which was significantly (P < 0.05) related to reduced FVC (beta = -55.3) and FEV1 (beta = -40.6). sigmauaam 43-52 C-reactive protein Homo sapiens 118-121 33997459-17 2021 Incentives such as a supply of foods approved according t the standards of the study, a sports program, individual feedback on study parameters reflecting health status, and group activities round off the MoKaRi concept.Low-density cholesterol is the primary outcome measure of the MoKaRi study, and the secondary endpoints comprise markers of nutrient status (e.g. fatty acid distribution in plasma and erythrocyte lipids), a metabolomic profiling, diabetes risk markers, clotting markers, and further cardiovascular risk factors, such as blood lipids, homocysteine and high-sensitive c-reactive protein.The MoKaRi study was registered before launch at ClinicalTrials.gov (identifier NCT02637778; https://clinicaltrials.gov/ct2/show/NCT02637778). low-density cholesterol 220-243 C-reactive protein Homo sapiens 586-604 33987139-2 2021 The current randomized controlled trial was carried out to evaluate the effect of zinc gluconate supplementation on migraine-related symptoms, serum level of high sensitivity C-reactive protein (hs-CRP) and lipid profile in migraineurs. gluconic acid 82-96 C-reactive protein Homo sapiens 175-193 33987044-11 2021 He was started on azathioprine and prednisone and showed a positive response, indicated by a decreasing erythrocyte sedimentation rate and C-reactive protein. Azathioprine 18-30 C-reactive protein Homo sapiens 139-157 32940751-6 2021 RESULTS: Following administration of methylprednisolone were significantly lower levels of CRP on all the four post-operative days; leukocytosis on the second day; the VAS/NRS score at rest after six, 12, and 18 hours post-operatively, diminished the dose of parenteral opioid preparations (oxycodone hydrochloride), the duration of analgesia by peripheral nerve block was significantly higher as compared with the placebo group (p < 0.000001). Methylprednisolone 37-55 C-reactive protein Homo sapiens 91-94 33285283-11 2021 Furthermore, C-reactive protein declined throughout the first 14 days after CCP transfusion. ccp 76-79 C-reactive protein Homo sapiens 13-31 33538550-0 2021 Initial Serum C-reactive Protein Level as a Predictor of Increasing Serum Vancomycin Concentration During Treatment. Vancomycin 74-84 C-reactive protein Homo sapiens 14-32 33538550-7 2021 Changes in vancomycin concentration/dose ratio were associated with C-reactive protein (CRP) and sodium (Na) levels on the initial day of TDM and with changes in white blood cell count, Na, and estimated glomerular filtration rates (eGFRs). Vancomycin 11-21 C-reactive protein Homo sapiens 68-86 33538550-7 2021 Changes in vancomycin concentration/dose ratio were associated with C-reactive protein (CRP) and sodium (Na) levels on the initial day of TDM and with changes in white blood cell count, Na, and estimated glomerular filtration rates (eGFRs). Vancomycin 11-21 C-reactive protein Homo sapiens 88-91 33538550-9 2021 CONCLUSION: A high serum CRP level on the initial day of TDM is an independent predictor of increasing vancomycin concentration/dose ratio in patients receiving intravenous vancomycin treatment, even if eGFR remains unchanged. Vancomycin 103-113 C-reactive protein Homo sapiens 25-28 33538550-9 2021 CONCLUSION: A high serum CRP level on the initial day of TDM is an independent predictor of increasing vancomycin concentration/dose ratio in patients receiving intravenous vancomycin treatment, even if eGFR remains unchanged. Vancomycin 173-183 C-reactive protein Homo sapiens 25-28 33197672-4 2021 RS2 might be able to reduce inflammatory mediators, therefore; our aim for this study was indicating RS2 effects on inflammatory mediators such as IL-6, TNF-a, and CRP among healthy and unhealthy subjects. n-hydroxy-2-[4-(4-phenoxy-benzenesulfonyl)-tetrahydro-pyran-4-yl]-acetamide 0-3 C-reactive protein Homo sapiens 164-167 33197672-4 2021 RS2 might be able to reduce inflammatory mediators, therefore; our aim for this study was indicating RS2 effects on inflammatory mediators such as IL-6, TNF-a, and CRP among healthy and unhealthy subjects. n-hydroxy-2-[4-(4-phenoxy-benzenesulfonyl)-tetrahydro-pyran-4-yl]-acetamide 101-104 C-reactive protein Homo sapiens 164-167 32095867-9 2020 Consistently, Mg intake was inversely associated with the levels of BMI, triceps skinfold, suprailiac skinfold, subscapular skinfold, fasting insulin, and C-reactive protein. Magnesium 14-16 C-reactive protein Homo sapiens 155-173 33266181-9 2020 Conclusion-The presented findings may contribute to a better understanding of the postoperative CRP course after SA. sa 113-115 C-reactive protein Homo sapiens 96-99 33240902-12 2020 Multivariate analysis revealed C-reactive protein >10 mg/L at disease relapse on AZA monotherapy [adjusted hazard ratio (HR), 4.72; 95% CI, 1.19-18.75, P = 0.027] and 6-thioguanine nucleotides level >=235 pmol/8 x 108 erythrocytes at AZA monotherapy (adjusted HR, 5.32; 95% CI, 1.40-20.14, P = 0.014) were associated with disease relapse on combination therapy. Azathioprine 81-84 C-reactive protein Homo sapiens 31-49 33240902-12 2020 Multivariate analysis revealed C-reactive protein >10 mg/L at disease relapse on AZA monotherapy [adjusted hazard ratio (HR), 4.72; 95% CI, 1.19-18.75, P = 0.027] and 6-thioguanine nucleotides level >=235 pmol/8 x 108 erythrocytes at AZA monotherapy (adjusted HR, 5.32; 95% CI, 1.40-20.14, P = 0.014) were associated with disease relapse on combination therapy. Azathioprine 234-237 C-reactive protein Homo sapiens 31-49 32892979-8 2020 HMP-O2 results in decreased markers of hepatocyte injury: ALT (p < 0.05) and LDH (p < 0.05), lower expression of CRP and higher expression of SOD1 vs SCS. hmp-o2 0-6 C-reactive protein Homo sapiens 113-116 32952647-0 2020 In vitro effects of azide-containing human CRP isoforms and oxLDL on U937-derived macrophage production of atherosclerosis-related cytokines. Azides 20-25 C-reactive protein Homo sapiens 43-46 32952647-3 2020 Azide, the commercial preservative of CRP, may influence its action in vitro. Azides 0-5 C-reactive protein Homo sapiens 38-41 32952647-4 2020 The present study aimed to determine the effects of both isoforms of azide-containing CRP (mCRP and pCRP) with and without oxLDL on cytokine production by U937-derived macrophages. Azides 69-74 C-reactive protein Homo sapiens 86-89 32657240-9 2020 Lower hemoglobin (Hgb), red blood cell count (RBC), higher C-reactive protein (CRP), pain scale score were found in CDS patients comparing with non-CDS group. cds 116-119 C-reactive protein Homo sapiens 59-77 32657240-9 2020 Lower hemoglobin (Hgb), red blood cell count (RBC), higher C-reactive protein (CRP), pain scale score were found in CDS patients comparing with non-CDS group. cds 116-119 C-reactive protein Homo sapiens 79-82 32657240-12 2020 Lower Hgb, RBC, higher CRP, pain scale score were found in CDS patients comparing with non-CDS. cds 59-62 C-reactive protein Homo sapiens 23-26 32740676-10 2020 There was an increase in hs-CRP levels in both the treatment groups (olanzapine, p < 0.001; lurasidone, p < 0.001) with no significant difference between them (p = 0.467). Lurasidone Hydrochloride 92-102 C-reactive protein Homo sapiens 28-31 32902234-4 2020 The relationship between serum miR-153-3p level and C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) was analyzed by Pearson"s correlation assay. mir-153-3p 31-41 C-reactive protein Homo sapiens 52-70 32902234-4 2020 The relationship between serum miR-153-3p level and C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) was analyzed by Pearson"s correlation assay. mir-153-3p 31-41 C-reactive protein Homo sapiens 72-75 32902234-7 2020 A positive correlation was found between the serum miR-153-3p level and ESR/CRP levels. mir-153-3p 51-61 C-reactive protein Homo sapiens 76-79 32908083-5 2020 Multivariable regression demonstrated rising odds of in-hospital death related with age (odds ratio (OR) = 1.055, p = 0.002), levels of C-reactive protein (CRP) (OR = 2.915, p < 0.001), creatinine (OR = 1.740, p = 0.023), lymphocyte count (OR = 0.999, p = 0.008), and magnesium level (OR = 0.032, p < 0.001) on admission. Magnesium 268-277 C-reactive protein Homo sapiens 136-154 32908083-5 2020 Multivariable regression demonstrated rising odds of in-hospital death related with age (odds ratio (OR) = 1.055, p = 0.002), levels of C-reactive protein (CRP) (OR = 2.915, p < 0.001), creatinine (OR = 1.740, p = 0.023), lymphocyte count (OR = 0.999, p = 0.008), and magnesium level (OR = 0.032, p < 0.001) on admission. Magnesium 268-277 C-reactive protein Homo sapiens 156-159 32872320-9 2020 Further analyses showed a significant positive correlation of lnhs-CRP with lnZMPSTE24 (n = 110; r = 0.21; p = 0.01) and lnlamin A/C (n = 110; r = 0.24; p = 0.03). lnlamin a 121-130 C-reactive protein Homo sapiens 67-70 32724758-3 2020 Prompt debridement, irrigation and drainage combined with empiric oral amoxicillin/clavulanic acid, resulted in clinical improvement and reduction of elevated inflammatory parameters specifically C-reactive protein. Amoxicillin-Potassium Clavulanate Combination 71-98 C-reactive protein Homo sapiens 196-214 32689936-5 2020 Our study aimed to investigate whether a leucine enriched BCAA dietary supplement (LEBDs) could quickly increase serum levels of albumin (Alb) or transthyretin (TTR) and decrease high-sensitivity C-reactive protein (CRP) in the development of severe malnutrition within a few days after stroke onset compared to standard BCAA dietary supplement (SBDs). Amino Acids, Branched-Chain 58-62 C-reactive protein Homo sapiens 196-214 32689936-5 2020 Our study aimed to investigate whether a leucine enriched BCAA dietary supplement (LEBDs) could quickly increase serum levels of albumin (Alb) or transthyretin (TTR) and decrease high-sensitivity C-reactive protein (CRP) in the development of severe malnutrition within a few days after stroke onset compared to standard BCAA dietary supplement (SBDs). Amino Acids, Branched-Chain 58-62 C-reactive protein Homo sapiens 216-219 32689936-17 2020 CONCLUSION: In acute stroke patients receiving leucine enriched BCAA dietary supplement, quick improvements in transthyretin and CRP were observed. Amino Acids, Branched-Chain 64-68 C-reactive protein Homo sapiens 129-132 33178875-5 2020 In addition, the levels of IMA, hs-CRP and FIB levels showed a strong link to BMI, WHR, TC, TG, LDL and glycated hemoglobin. Technetium 88-90 C-reactive protein Homo sapiens 35-38 32398008-12 2020 Both CRP and PCT values and white blood cell counts were positively correlated to the days needed from doxycycline treatment to defervescence. Doxycycline 103-114 C-reactive protein Homo sapiens 5-8 32398008-13 2020 CONCLUSION: CRP and PCT values might be useful in clinical investigations for patients with suspected rickettsioses and in predicting the response to doxycycline treatment for rickettsioses. Doxycycline 150-161 C-reactive protein Homo sapiens 12-15 32397609-8 2020 The anti-inflammatory effects of ProBeptigen in humans were also confirmed, with progressively declining high-sensitivity C-reactive protein (hs-CRP) levels. probeptigen 33-44 C-reactive protein Homo sapiens 123-141 32154703-4 2020 Anti-CRP functionalized micromotors (anti-CRP-rGO(reduced graphene oxide)/Ni/PtNPs (platinum nanoparticles))-based immunoassay coupled to thin layer Au-based electrochemical microfluidics operating at -0.20 V under controlled fluidic detection operations (30 muL min-1) allowed the sensitive (LOD = 0.54 mug/mL) and accurate CRP determination using very low volume preterm neonatal clinical samples (<10 muL) in just 8 min of total assay time. graphene oxide 58-72 C-reactive protein Homo sapiens 5-8 32373986-0 2020 Curative effects of vancomycin and cefotaxime combined with gamma globulin respectively in neonatal septicemia and their influences on PCT, CRP and hs-CRP. Vancomycin 20-30 C-reactive protein Homo sapiens 140-143 32373986-0 2020 Curative effects of vancomycin and cefotaxime combined with gamma globulin respectively in neonatal septicemia and their influences on PCT, CRP and hs-CRP. Vancomycin 20-30 C-reactive protein Homo sapiens 151-154 32373986-1 2020 OBJECTIVE: To explore the curative effects of vancomycin and cefotaxime combined with gamma globulin respectively in neonatal septicemia and their influences on PCT, CRP, and hs-CRP, so as to provide references for clinical treatment. Vancomycin 46-56 C-reactive protein Homo sapiens 166-169 32373986-1 2020 OBJECTIVE: To explore the curative effects of vancomycin and cefotaxime combined with gamma globulin respectively in neonatal septicemia and their influences on PCT, CRP, and hs-CRP, so as to provide references for clinical treatment. Vancomycin 46-56 C-reactive protein Homo sapiens 178-181 32061400-8 2020 Postoperative levels of C-reactive protein were less in the methylprednisolone group (P = .039). Methylprednisolone 60-78 C-reactive protein Homo sapiens 24-42 32157124-8 2020 Aminoadipic acid was found to be significantly correlated with CRP levels and 2-Hydroxy-3-methylbutyric acid and Palmitoleic acid with PCT levels. 2-Aminoadipic Acid 0-16 C-reactive protein Homo sapiens 63-66 32117266-1 2020 A monomeric form of C-reactive protein (CRP) which precipitates with cell wall pneumococcal C polysaccharide (CWPS) and retains the ability to reversibly bind to its ligand phosphocholine has been produced through urea-induced dissociation at an optimized concentration of 3 M urea over a 10 weeks period. cwps 110-114 C-reactive protein Homo sapiens 20-38 32117266-1 2020 A monomeric form of C-reactive protein (CRP) which precipitates with cell wall pneumococcal C polysaccharide (CWPS) and retains the ability to reversibly bind to its ligand phosphocholine has been produced through urea-induced dissociation at an optimized concentration of 3 M urea over a 10 weeks period. cwps 110-114 C-reactive protein Homo sapiens 40-43 31785343-1 2020 AIMS: C-reactive protein (CRP) is an important biomarker in systemic inflammation in COPD; reports have suggested inhaled corticosteroids (ICS) attenuate CRP levels. Iron-Sulfur-Molybdenum Cluster With Interstitial Carbon 139-142 C-reactive protein Homo sapiens 6-24 31785343-1 2020 AIMS: C-reactive protein (CRP) is an important biomarker in systemic inflammation in COPD; reports have suggested inhaled corticosteroids (ICS) attenuate CRP levels. Iron-Sulfur-Molybdenum Cluster With Interstitial Carbon 139-142 C-reactive protein Homo sapiens 154-157 31131461-7 2019 Compared with patients treated with pioglitazone plus sulfonylureas, the combination of sitagliptin and sulfonylureas was more effective in reducing LDL-C and in increasing HDL-C. High-sensitivity C-reactive protein was decreased by all pharmacological combinations. Sulfonylurea Compounds 54-67 C-reactive protein Homo sapiens 197-215 30565017-7 2019 Overall, magnesium and vitamin E co-supplementation for 12 weeks may benefit women with PCOS on hirsutism, serum hs-CRP, plasma NO, and TAC levels. Magnesium 9-18 C-reactive protein Homo sapiens 116-119 31687292-2 2019 We report a case of a 48-year-old woman on a prophylactic regimen of nitrofurantoin who exhibited classic signs of bacterial sepsis including elevated procalcitonin (PCL) and C-reactive protein (CRP) levels two days post-nephrolithotripsy. Nitrofurantoin 69-83 C-reactive protein Homo sapiens 175-193 31687292-2 2019 We report a case of a 48-year-old woman on a prophylactic regimen of nitrofurantoin who exhibited classic signs of bacterial sepsis including elevated procalcitonin (PCL) and C-reactive protein (CRP) levels two days post-nephrolithotripsy. Nitrofurantoin 69-83 C-reactive protein Homo sapiens 195-198 31687292-6 2019 A high index of suspicion for nitrofurantoin-associated pulmonary toxicity is warranted for patients on a regimen of nitrofurantoin who exhibit severe pulmonary symptoms and elevated PCL and CRP levels with no corresponding infection. Nitrofurantoin 30-44 C-reactive protein Homo sapiens 191-194 31687292-6 2019 A high index of suspicion for nitrofurantoin-associated pulmonary toxicity is warranted for patients on a regimen of nitrofurantoin who exhibit severe pulmonary symptoms and elevated PCL and CRP levels with no corresponding infection. Nitrofurantoin 117-131 C-reactive protein Homo sapiens 191-194 31243577-5 2019 If the CRP on the paper device is contacted with Ca (II) ions, the current (measured by using hexacyanoferrate as the electrochemical probe) decreases. hexacyanoferrate II 94-110 C-reactive protein Homo sapiens 7-10 31248116-4 2019 The applicability of these electrode chips in bioaffinity assays was demonstrated by an immunoassay of human C-reactive protein (i) using Tb(III) chelate label displaying long-lived hot electron-induced electrochemiluminescence (HECL) and (ii) now for the first time fluorescein isothiocyanate (FITC) was utilized as an a low-cost organic label displaying a short-lived HECL in a real-world bioaffinity assay. Fluorescein-5-isothiocyanate 267-293 C-reactive protein Homo sapiens 109-127 31248116-4 2019 The applicability of these electrode chips in bioaffinity assays was demonstrated by an immunoassay of human C-reactive protein (i) using Tb(III) chelate label displaying long-lived hot electron-induced electrochemiluminescence (HECL) and (ii) now for the first time fluorescein isothiocyanate (FITC) was utilized as an a low-cost organic label displaying a short-lived HECL in a real-world bioaffinity assay. Fluorescein-5-isothiocyanate 295-299 C-reactive protein Homo sapiens 109-127 31062578-7 2019 Both the SERS and SEM results showed that we completely eliminated the nonspecific binding of Au NPs onto the optimally anti-CRP-immobilized Au nanoplate. sers 9-13 C-reactive protein Homo sapiens 125-128 30795853-10 2019 DISCUSSION: CRP and neopterin levels are significantly increased in GIM and GA. Neopterin may be a useful biomarker and diagnostic test for detecting GIM and GA in clinical practice. Neopterin 80-89 C-reactive protein Homo sapiens 12-15 31249227-8 2019 Supplementation with high-dose Omega 3 resulted in a highly statistically significant decrease in total cholesterol, triglyceride, low-density lipoprotein, interleukin-6, C- reactive protein levels and a highly statistically significant increase in high-density lipoprotein (P <0.001). omega 3 31-38 C-reactive protein Homo sapiens 171-190 31143476-0 2019 Increased C-Reactive Protein in Brazilian Children: Association with Cardiometabolic Risk and Metabolic Syndrome Components (PASE Study). pase 125-129 C-reactive protein Homo sapiens 10-28 30626812-10 2019 In the SU-treated group, the proportion of patients with white blood cell and/or C-reactive protein elevation was higher in the cold season than in the warm season (p=0.04). Sulfonylurea Compounds 7-9 C-reactive protein Homo sapiens 81-99 30922146-7 2019 Significant reductions with bempedoic acid versus placebo were also observed in non-high-density lipoprotein cholesterol (-17.9%), total cholesterol (-14.8%), apolipoprotein B (-15.0%), and high-sensitivity C-reactive protein (-24.3%; P<0.001 for all comparisons). 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 28-42 C-reactive protein Homo sapiens 207-225 30908508-7 2019 RESULTS: At baseline, dietary Mg intake was inversely associated with serum hs-CRP even after adjustment for all the potential confounding factors. Magnesium 30-32 C-reactive protein Homo sapiens 79-82 30908508-10 2019 CONCLUSIONS: The results do not support the hypothesis that low dietary Mg intake contributes to the development of clinical knee OA, although Mg intake is inversely associated with serum hs-CRP level. Magnesium 143-145 C-reactive protein Homo sapiens 191-194 30308801-10 2019 Additionally, an interquartile range increase in 2,5-dichlorophenol (11.0 ng/mL) was associated with a 10% increase in C-reactive protein (95% CI: 1.92, 18.7). 2,5-dichlorophenol 49-67 C-reactive protein Homo sapiens 119-137 30762093-7 2019 Additionally, further analysis revealed that 8-OHdG was negatively correlated with FEV1, FEV1% predicted, and FEV1/FVC and positively correlated with C-reactive protein, procalcitonin, and neutrophil CD64. 8-ohdg 45-51 C-reactive protein Homo sapiens 150-168 30799917-9 2019 CRP levels were positively correlated with neopterin levels in acutely ill medical patients, explaining 28.4% of the variance in neopterin levels. Neopterin 43-52 C-reactive protein Homo sapiens 0-3 30799917-9 2019 CRP levels were positively correlated with neopterin levels in acutely ill medical patients, explaining 28.4% of the variance in neopterin levels. Neopterin 129-138 C-reactive protein Homo sapiens 0-3 29993265-8 2019 Both EPA (-0.56 mg/L; 95%CI: -1.13, 0.00) and DHA (-0.5 mg/L; 95%CI: -1.0, -0.03) significantly reduced the concentrations of C-reactive protein (CRP), respectively, especially in subjects with dyslipidemia and higher baseline CRP concentrations. Docosahexaenoic Acids 46-49 C-reactive protein Homo sapiens 126-144 29993265-8 2019 Both EPA (-0.56 mg/L; 95%CI: -1.13, 0.00) and DHA (-0.5 mg/L; 95%CI: -1.0, -0.03) significantly reduced the concentrations of C-reactive protein (CRP), respectively, especially in subjects with dyslipidemia and higher baseline CRP concentrations. Docosahexaenoic Acids 46-49 C-reactive protein Homo sapiens 146-149 29993265-8 2019 Both EPA (-0.56 mg/L; 95%CI: -1.13, 0.00) and DHA (-0.5 mg/L; 95%CI: -1.0, -0.03) significantly reduced the concentrations of C-reactive protein (CRP), respectively, especially in subjects with dyslipidemia and higher baseline CRP concentrations. Docosahexaenoic Acids 46-49 C-reactive protein Homo sapiens 227-230 29993265-10 2019 The present meta-analysis provides substantial evidence that EPA and DHA have independent (blood pressure) and shared (CRP concentration) effects on risk factors of chronic diseases, and high-quality RCTs with multi-center and large simple-size should be performed to confirm the present findings. Docosahexaenoic Acids 69-72 C-reactive protein Homo sapiens 119-122 29920123-8 2019 Significant changes in levels of CRP were observed in the beta-glucan-supplemented group; levels of SAA and IL-6 were not changed. beta-Glucans 58-69 C-reactive protein Homo sapiens 33-36 30051214-9 2018 The serum IL-6 and CRP levels were inversely correlated with the plasma concentration ratios of N-desmethyltramadol to tramadol and of N,O-didesmethyltramadol to O-desmethyltramadol. O,N-didesmethyltramadol 135-158 C-reactive protein Homo sapiens 19-22 30182714-0 2018 Combining Porous Magnetic Ni@C Nanospheres and CaCO3 Microcapsule as Surface-Enhanced Raman Spectroscopy Sensing Platform for Hypersensitive C-Reactive Protein Detection. Calcium Carbonate 47-52 C-reactive protein Homo sapiens 141-159 30182714-1 2018 In this work, we have designed an efficient and rapid surface-enhanced Raman spectroscopy (SERS) immunosensor for a supersensitive analysis of hypersensitive C-reactive protein (hs-CRP) with a label-free method by combining porous magnetic Ni@C nanospheres to aggregate together for simplifying the experiment operation and CaCO3 microcapsule to encapsulate rhodamine B as the Raman signal. sers 91-95 C-reactive protein Homo sapiens 158-176 30102967-2 2018 The objective of this study was to evaluate whether CRP might similarly predict antidepressant responses to lurasidone in patients with bipolar I depression. Lurasidone Hydrochloride 108-118 C-reactive protein Homo sapiens 52-55 30102967-9 2018 Increasing pre-treatment wr-CRP level predicted a larger overall antidepressant response to lurasidone, as well as an increased response for a number of individual depressive symptoms. Lurasidone Hydrochloride 92-102 C-reactive protein Homo sapiens 28-31 30102967-12 2018 Elevated CRP level prior to treatment was associated with an enhanced clinical response to lurasidone in patients with bipolar I depression. Lurasidone Hydrochloride 91-101 C-reactive protein Homo sapiens 9-12 30056003-1 2018 BACKGROUND: Several studies have shown that high level of plasma C-reactive protein (CRP) is associated with stroke outcomes and future vascular events, and a decrease in serum triiodothyronine (T3) was reported to be associated with stroke severity and poor prognosis. Triiodothyronine 195-197 C-reactive protein Homo sapiens 85-88 29654348-9 2018 The Pearson correlation coefficients showed that the DCE-MRI parameters correlated significantly with the level of CRP and ESR (P = 0.000, P = 0.014, P = 0.000; P = 0.000, P = 0.000, P = 0.013). ethylene dichloride 53-56 C-reactive protein Homo sapiens 115-118 29784344-2 2018 Indium Tin Oxide (ITO) disposable sheets were modified by using 11-cyanoundecyltrimethoxysilane (CUTMS) and PAMAM dendrimers (G:1 amino surfaces) for the first time to immobilize the anti-CRP antibody via covalent interactions. 11-CYANOUNDECYLTRIMETHOXYSILANE 64-95 C-reactive protein Homo sapiens 188-191 30154879-11 2018 After adjusted for CRP, although per 1-SD increase in TC level was still associated with an increment in 4 % in LVEF, it did not achieve achieve statistic significance. Technetium 54-56 C-reactive protein Homo sapiens 19-22 30180620-3 2018 The aim of the study was to describe the relationship between IBI and SBP of healthy subjects using CRP and diagonal analysis during baseline condition-supine position (SP)-and how the relationship changes during the physiological stress of active standing (AS). BI 6727 62-65 C-reactive protein Homo sapiens 100-103 30180620-8 2018 CRP analysis showed short diagonals indicating a very strong deterministic relationship between IBI and SBP with intermittent unlocking periods. BI 6727 96-99 C-reactive protein Homo sapiens 0-3 29561305-0 2018 Exploring the Use of C-Reactive Protein to Estimate the Pharmacodynamics of Vancomycin. Vancomycin 76-86 C-reactive protein Homo sapiens 21-39 29561305-2 2018 We investigated CRP PD linked to a vancomycin pharmacokinetic (PK) model using routinely collected data from noncritical care adults in secondary care. Vancomycin 35-45 C-reactive protein Homo sapiens 16-19 29561305-4 2018 A 2-compartment vancomycin PK model was linked to a previously described PD model describing CRP response. Vancomycin 16-26 C-reactive protein Homo sapiens 93-96 29561305-6 2018 Exposure-response relationships were explored with vancomycin area-under-the-concentration-time-curve (AUC) and EC50 (concentration of drug that causes a half maximal effect) using the index, AUC:EC50, fitted to CRP data using a sigmoidal Emax model. Vancomycin 51-61 C-reactive protein Homo sapiens 212-215 29558723-2 2018 Indium Tin Oxide (ITO) disposable sheets were modified by using 3-cyanopropyltrimethoxysilane (CPTMS) self-assembled monolayers (SAMs) for the first time for immobilizing the anti-CRP antibody via covalent interactions without the need for any cross-linking agent. cptms 95-100 C-reactive protein Homo sapiens 180-183 29793661-4 2018 Human studies have found that dietary Mg is inversely related to serum or plasma C-reactive protein (CRP). Magnesium 38-40 C-reactive protein Homo sapiens 81-99 29793661-4 2018 Human studies have found that dietary Mg is inversely related to serum or plasma C-reactive protein (CRP). Magnesium 38-40 C-reactive protein Homo sapiens 101-104 29793661-6 2018 In addition, elevated serum or plasma CRP in individuals with chronic disease is decreased by Mg supplementation, which suggests that Mg decreases the risk for chronic disease. Magnesium 94-96 C-reactive protein Homo sapiens 38-41 29793661-6 2018 In addition, elevated serum or plasma CRP in individuals with chronic disease is decreased by Mg supplementation, which suggests that Mg decreases the risk for chronic disease. Magnesium 134-136 C-reactive protein Homo sapiens 38-41 29604155-4 2018 High ADMA levels were seen in patients with higher weight, body mass index, waist circumference, triglycerides, uric acid, and high-sensitivity C-reactive protein, and lower levels of high-density lipoprotein cholesterol and in patients with type 2 DM. N,N-dimethylarginine 5-9 C-reactive protein Homo sapiens 144-162 29335723-0 2018 Review: In primary care, CRP testing, shared decision making, and procalcitonin reduce antibiotic prescribing for ARI. BAL-ARI8 114-117 C-reactive protein Homo sapiens 25-28 29440952-8 2018 The same antibiotics were used in Dr. Gavril Curteanu Clinical City Hospital of Oradea, where ampicillin in association with aminoglycoside was utilized in younger children (mean age 1.3 years), while ceftriaxone in older children (5.7 years) and children with high inflammation markers (ESR, CRP). Ampicillin 94-104 C-reactive protein Homo sapiens 293-296 29172154-5 2018 CRP recognized 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-l-serine (POPS) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1"-rac-glycerol) (POPG) in the supported POPC monolayers without calcium at pH 7.4 and 5.5. POPS 15-65 C-reactive protein Homo sapiens 0-3 29172154-5 2018 CRP recognized 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-l-serine (POPS) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1"-rac-glycerol) (POPG) in the supported POPC monolayers without calcium at pH 7.4 and 5.5. POPS 67-71 C-reactive protein Homo sapiens 0-3 28881893-3 2017 However, the role of CRP/Alb ratio for those with neoadjuvant chemotherapy (NAC) and the changes of CRP/Alb ratio around NAC have never been discussed. nac 121-124 C-reactive protein Homo sapiens 100-103 28881893-4 2017 The aim of this study is to evaluate the significance of CRP/Alb ratio around NAC for patients with cStage II/III esophageal squamous cell cancer (ESCC). nac 78-81 C-reactive protein Homo sapiens 57-60 28881893-6 2017 We retrospectively investigated the relation between pre-NAC and post-NAC CRP/Alb ratio and short and long outcomes. nac 70-73 C-reactive protein Homo sapiens 74-77 28881893-7 2017 The optimal cutoff level for pre-NAC and post-NAC CRP/Alb ratio was 0.030 and 0.048, respectively. nac 46-49 C-reactive protein Homo sapiens 50-53 28881893-9 2017 Post-NAC CRP/Alb ratio < 0.048 had a significantly higher overall survival rate than CRP/Alb ratio >=0.048 (P< 0.001). nac 5-8 C-reactive protein Homo sapiens 9-12 28881893-10 2017 Univariate analysis showed that cT, cN, pre-NAC CRP/Alb ratio < 0.030 and post-NAC CRP/Alb ratio < 0.048 was prognostic factors (P= 0.003, P= 0.022, P= 0.033, and P< 0.001, respectively). nac 44-47 C-reactive protein Homo sapiens 48-51 28881893-10 2017 Univariate analysis showed that cT, cN, pre-NAC CRP/Alb ratio < 0.030 and post-NAC CRP/Alb ratio < 0.048 was prognostic factors (P= 0.003, P= 0.022, P= 0.033, and P< 0.001, respectively). nac 82-85 C-reactive protein Homo sapiens 86-89 28881893-11 2017 Multivariate analysis showed that cT and post-NAC CRP/Alb ratio < 0.048 was independent prognostic factors (P= 0.030 and P< 0.001, respectively). nac 46-49 C-reactive protein Homo sapiens 50-53 28881893-12 2017 Post-NAC CRP/Alb ratio is an independent prognostic factor in patients with cStage II/III ESCC. nac 5-8 C-reactive protein Homo sapiens 9-12 28800269-7 2017 RESULTS: CRP levels and NLR were substantially higher in patients with SA than in subjects with NSA and healthy comparison subjects after adjusting the confounding factors. sa 71-73 C-reactive protein Homo sapiens 9-12 28744857-8 2017 Finally, methylprednisolone reduced the C-reactive protein response 24 h postoperatively; 31.1 (1.1) mg.l-1 vs. 68.4 (1.1) mg.l-1 , p < 0.001. Methylprednisolone 9-27 C-reactive protein Homo sapiens 40-58 28744857-9 2017 Pre-operative administration of methylprednisolone 125 mg reduced circulating markers of endothelial activation and damage, as well as the systemic inflammatory response (C-reactive protein) early after fast-track total knee arthroplasty. Methylprednisolone 32-50 C-reactive protein Homo sapiens 171-189 28534297-1 2017 A biofunctionalized reduced graphene oxide (rGO)-modified screen-printed carbon electrode (SPCE) was constructed as an immunosensor for C-reactive protein (CRP) detection, a biomarker released in early stage acute myocardial infarction. graphene oxide 28-42 C-reactive protein Homo sapiens 136-154 28534297-1 2017 A biofunctionalized reduced graphene oxide (rGO)-modified screen-printed carbon electrode (SPCE) was constructed as an immunosensor for C-reactive protein (CRP) detection, a biomarker released in early stage acute myocardial infarction. graphene oxide 28-42 C-reactive protein Homo sapiens 156-159 28760413-6 2017 Increased hydrogen sulfide and substance P levels in septic patients were associated with increased levels of inflammatory mediators - procalcitonin, C-reactive protein and interleukin-6. Hydrogen Sulfide 10-26 C-reactive protein Homo sapiens 150-168 28955060-7 2017 Vital signs, haematologic tables, peripheral blood smear left shift ratio, and blood-gas parameters did not differ significantly between the groups (p>0.05), but the C-reactive protein (mg/dl) values significantly decreased after pentoxifylline treatment (p<0.05). Pentoxifylline 233-247 C-reactive protein Homo sapiens 169-187 28955060-12 2017 CONCLUSIONS: Pentoxifylline treatment for nosocomial sepsis decreased C-reactive protein levels and heart rate more than pentaglobin therapy. Pentoxifylline 13-27 C-reactive protein Homo sapiens 70-88 28196391-4 2017 Results Following pentoxifylline therapy, the immature-to-total neutrophil ratio and C-reactive protein (CRP) levels were significantly decreased, while the blood pH and base excess were significantly increased (p < 0.05). Pentoxifylline 18-32 C-reactive protein Homo sapiens 85-103 28196391-4 2017 Results Following pentoxifylline therapy, the immature-to-total neutrophil ratio and C-reactive protein (CRP) levels were significantly decreased, while the blood pH and base excess were significantly increased (p < 0.05). Pentoxifylline 18-32 C-reactive protein Homo sapiens 105-108 28196391-8 2017 Conclusion The CRP levels and heart rate both decreased, while the pH and base excess parameters of the blood gas analysis changed positively after pentoxifylline treatment in VLBW preterm neonates with nosocomial sepsis. Pentoxifylline 148-162 C-reactive protein Homo sapiens 15-18 28036163-2 2017 We report herein the synthesis of immunosensors based on carboxylated cellulose nanofibrils (CNF) for CRP detection, as demonstrated by quartz crystal microgravimetry (QCM). carboxylated cellulose 57-79 C-reactive protein Homo sapiens 102-105 28036163-4 2017 Protein A was conjugated to the carboxylated CNF via N-(3-(Dimethylamino)propyl)-N"-ethylcarbodiimide hydrochloride/N-hydroxysuccinimide and used as a ligand for oriented immobilization of anti C-reactive protein (anti-CRP). n-(3-(dimethylamino)propyl)-n"-ethylcarbodiimide hydrochloride 53-115 C-reactive protein Homo sapiens 194-212 26754953-10 2016 Plasma and CSF CRP were also associated with CSI measures of basal ganglia glutamate and the glial marker myoinositol. Inositol 106-117 C-reactive protein Homo sapiens 15-18 25822238-7 2016 To detect IBI, the areas under the curve for the different tests were as follows: PCT, 0.77 (95% confidence interval [CI], 0.57-0.96); CRP, 0.54 (95% CI, 0.36-0.73); ANC, 0.53 (95% CI, 0.34-0.71); and WBC, 0.42 (0.24-0.61). BI 6727 10-13 C-reactive protein Homo sapiens 135-138 27703393-11 2016 CONCLUSION: Low-dose intravenous ketamine effectively attenuates the CRP stress response in patients undergoing emergency cesarean section with spinal anesthesia. Ketamine 33-41 C-reactive protein Homo sapiens 69-72 2477447-8 1989 Binding to these bands was inhibited by both EDTA and PC indicating that CRP binds these proteins through the PC-binding site. pc 54-56 C-reactive protein Homo sapiens 73-76 2477447-8 1989 Binding to these bands was inhibited by both EDTA and PC indicating that CRP binds these proteins through the PC-binding site. pc 110-112 C-reactive protein Homo sapiens 73-76 2471736-4 1989 The second group consisted of mAb that reacted with native CRP and also with CRP modified by direct immobilization on polystyrene plates, urea-chelation or SDS treatment in the absence of calcium, thus identifying a fifth native CRP epitope; these mAb displayed significantly greater reactivity with native than with modified CRP. Polystyrenes 118-129 C-reactive protein Homo sapiens 77-80 2471736-4 1989 The second group consisted of mAb that reacted with native CRP and also with CRP modified by direct immobilization on polystyrene plates, urea-chelation or SDS treatment in the absence of calcium, thus identifying a fifth native CRP epitope; these mAb displayed significantly greater reactivity with native than with modified CRP. Polystyrenes 118-129 C-reactive protein Homo sapiens 77-80 2471736-4 1989 The second group consisted of mAb that reacted with native CRP and also with CRP modified by direct immobilization on polystyrene plates, urea-chelation or SDS treatment in the absence of calcium, thus identifying a fifth native CRP epitope; these mAb displayed significantly greater reactivity with native than with modified CRP. Polystyrenes 118-129 C-reactive protein Homo sapiens 77-80 2837757-5 1988 CRP*598 can activate lacP+-directed abortive initiation in the presence of cAMP and less efficiently in the presence of cGMP or in the absence of cyclic nucleotide. Nucleotides, Cyclic 146-163 C-reactive protein Homo sapiens 0-3 3088865-0 1986 [Microprecipitation in agarose gel as a detection method for C-reactive protein in human serum]. Sepharose 23-30 C-reactive protein Homo sapiens 61-79 4084018-2 1985 CRP was purified using 4-step procedure including absorption on Sepharose 4B, phosphocholine-Sepharose, DE-52 ion exchange chromatography and gel filtration on Sephacryl S-200. Sepharose 64-76 C-reactive protein Homo sapiens 0-3 4084018-2 1985 CRP was purified using 4-step procedure including absorption on Sepharose 4B, phosphocholine-Sepharose, DE-52 ion exchange chromatography and gel filtration on Sephacryl S-200. Sepharose 64-73 C-reactive protein Homo sapiens 0-3 6693419-2 1984 We now report that CRP immobilized onto polystyrene surfaces binds soluble plasma fibronectin (Kd = 1.5 X 10(-8) M). Polystyrenes 40-51 C-reactive protein Homo sapiens 19-22 6429390-0 1984 [EDTA reduces avidity of anti-CRP sera]. Edetic Acid 1-5 C-reactive protein Homo sapiens 30-33 6433926-3 1983 Subsequent treatment of the CRP-lecithin complex with chloroform and sodium citrate buffer enabled extraction of the CRP in the buffer layer. Chloroform 54-64 C-reactive protein Homo sapiens 28-31 6433926-3 1983 Subsequent treatment of the CRP-lecithin complex with chloroform and sodium citrate buffer enabled extraction of the CRP in the buffer layer. Chloroform 54-64 C-reactive protein Homo sapiens 117-120 7061105-3 1982 Platelet activation induced by H-CRP was sensitive to the presence of EDTA and dibucaine, required metabolic energy and was inhibited by increased levels of cAMP. Edetic Acid 70-74 C-reactive protein Homo sapiens 31-36 7061105-3 1982 Platelet activation induced by H-CRP was sensitive to the presence of EDTA and dibucaine, required metabolic energy and was inhibited by increased levels of cAMP. Dibucaine 79-88 C-reactive protein Homo sapiens 31-36 7041546-4 1982 Studies of its binding specificities have indicated that CRP has reactivity with (a) phosphocholine and phosphate esters, and hence with lipids widely distributed in mammalian and microbial cells; and (b) with multiple widely distributed polycations, including those derived from leukocyte granules. phosphate esters 104-120 C-reactive protein Homo sapiens 57-60 7086148-2 1982 CRP was obtained from malignant ascitic and pleural fluids by calcium-dependent affinity chromatography on pneumococcal C-polysaccharide covalently coupled to cyanogen bromide-activated Sepharose. Sepharose 186-195 C-reactive protein Homo sapiens 0-3 7401063-5 1980 Therefore, the clinical relevance of CRP detected in RF positive sera by latex agglutination can be ascertained only following pretreatment of sera with 2-mercaptoethanol or by the use of radial immunodiffusion to circumvent interference by RF. Mercaptoethanol 153-170 C-reactive protein Homo sapiens 37-40 27364645-9 2016 Receiver operating characteristic analysis showed that the area under curve was 0.64 (confidence interval [CI], 0.513-0.737) for urinary 5-HIAA, which was lower than white blood cell count (0.69; CI, 0.574-0.797), neutrophil count (0.68; CI, 0.565-0.792), and C-reactive protein (0.76; CI, 0.657-0.857). Hydroxyindoleacetic Acid 137-143 C-reactive protein Homo sapiens 260-278 27825282-0 2016 Relationship between maternal c-reactive protein level and neonatal outcome in patients with preterm premature rupture of membranes treated with Ampicillin and Azithromycin. Ampicillin 145-155 C-reactive protein Homo sapiens 30-48 496400-6 1979 CDPC-AH Sepharose was used to purify the phosphorylcholine-binding myeloma protein HOPC8 and to separate C-reactive protein from the bulk of serum proteins. cdpc-ah sepharose 0-17 C-reactive protein Homo sapiens 105-123 33682538-10 2021 Markers of fibrosis and inflammation, including NIIINP, PICP, hs-CRP and TNF-alpha were also decreased after spironolactone therapy. Spironolactone 109-123 C-reactive protein Homo sapiens 65-68 27238921-8 2016 Patients with >90% adherence with doxycycline were 6.4 times more likely to experience reduction in tumor necrosis factor-alpha (P = 0.021) and 2.8 times more likely to experience reductions in high-sensitivity C-reactive protein (P = 0.133). Doxycycline 37-48 C-reactive protein Homo sapiens 214-232 27272805-6 2016 C-reactive protein (CRP) and interleukin-6 (IL-6) correlated with each other and exhibited positive correlation with age, body-mass index (BMI), leukocyte count, platelet count, kynurenine, kynurenine/tryptophan ratio and urinary neopterin and a negative correlation with vitamin D and retinol. Neopterin 230-239 C-reactive protein Homo sapiens 0-18 33497271-10 2021 The HCQ group showed greater reduction in the inflammatory indices erythrocyte sedimentation rate and C-reactive protein (CRP) level (p < .05), and a significantly lower incidence of angiographic progression than the non-HCQ group (19.0% vs. 51.7%, p = .035). Hydroxychloroquine 4-7 C-reactive protein Homo sapiens 102-120 26967918-6 2016 RESULTS: There was a significant interaction between C-reactive protein (CRP) and the BDNF Val66met polymorphism in predicting cognitive depressive symptoms (p=.004), such that higher CRP was related to more cognitive depressive symptoms among Met allele carriers, but not among Val/Val homozygotes. val66met 91-99 C-reactive protein Homo sapiens 184-187 33497271-10 2021 The HCQ group showed greater reduction in the inflammatory indices erythrocyte sedimentation rate and C-reactive protein (CRP) level (p < .05), and a significantly lower incidence of angiographic progression than the non-HCQ group (19.0% vs. 51.7%, p = .035). Hydroxychloroquine 4-7 C-reactive protein Homo sapiens 122-125 33497271-11 2021 After adjustment for age and usage of tocilizumab, angiographic progression was found to be independently associated with CRP (hazard ratio [95% confidence interval], HR [95% CI]: 1.102 [1.000-1.024], p = .046), and the usage of HCQ (HR [95% CI]: 0.266 [0.075-0.940], p = .040). Hydroxychloroquine 229-232 C-reactive protein Homo sapiens 122-125 27164124-8 2016 Thirty-eight percent of RIS patients had elevated CRP level and 91.5% of RIS patients had HHcy. Risedronic Acid 24-27 C-reactive protein Homo sapiens 50-53 33920813-8 2021 Serum Ca, Fe, Se, Zn correlated positively with SpO2, being inversely associated with fever, lung damage, and C-reactive protein concentrations. Selenium 0-2 C-reactive protein Homo sapiens 110-128 25941076-0 2016 Serum Levels of High-sensitivity C-Reactive Protein at Admission Are More Strongly Associated with Poststroke Depression in Acute Ischemic Stroke than Homocysteine Levels. Homocysteine 151-163 C-reactive protein Homo sapiens 33-51 33618966-8 2021 We also found that alpha-linolenic acid (ALA) and docosahexaenoic acid (DHA) enhanced the negative association between VO2max and CRP, suggesting that the anti-inflammatory response to VO2max capacity is associated with ALA and DHA levels. alpha-Linolenic Acid 19-39 C-reactive protein Homo sapiens 130-133 33618966-8 2021 We also found that alpha-linolenic acid (ALA) and docosahexaenoic acid (DHA) enhanced the negative association between VO2max and CRP, suggesting that the anti-inflammatory response to VO2max capacity is associated with ALA and DHA levels. alpha-Linolenic Acid 41-44 C-reactive protein Homo sapiens 130-133 26400456-0 2016 C-reactive protein: an early critical sign of clozapine-related myocarditis. Clozapine 46-55 C-reactive protein Homo sapiens 0-18 26400456-1 2016 OBJECTIVE: We present a case of clozapine-related myocarditis, with a rising C-reactive protein as the only initial evidence supporting the diagnosis. Clozapine 32-41 C-reactive protein Homo sapiens 77-95 26400456-6 2016 In keeping with the current clozapine monitoring guidelines, we demonstrate that a rise in C-reactive protein levels can be a critical early sign of myocarditis warranting close monitoring and serious consideration for cessation of clozapine. Clozapine 28-37 C-reactive protein Homo sapiens 91-109 26400456-6 2016 In keeping with the current clozapine monitoring guidelines, we demonstrate that a rise in C-reactive protein levels can be a critical early sign of myocarditis warranting close monitoring and serious consideration for cessation of clozapine. Clozapine 232-241 C-reactive protein Homo sapiens 91-109 30090398-6 2016 Interestingly, treatment with benzo[a]pyrene and naphthalene significantly up regulated the phosphorylation of the p65 subunit of NF-kappaB and increased the secretion of TNF-alpha and CRP compared to control. Benzo(a)pyrene 30-44 C-reactive protein Homo sapiens 185-188 33618966-8 2021 We also found that alpha-linolenic acid (ALA) and docosahexaenoic acid (DHA) enhanced the negative association between VO2max and CRP, suggesting that the anti-inflammatory response to VO2max capacity is associated with ALA and DHA levels. alpha-Linolenic Acid 220-223 C-reactive protein Homo sapiens 130-133 26089534-0 2016 Fever and elevated CRP-related to clozapine dose. Clozapine 34-43 C-reactive protein Homo sapiens 19-22 33618966-10 2021 CONCLUSIONS: This study suggests that omega-3 PUFAs are effect modifiers for VO2max and CRP and that the anti-inflammatory benefits of increasing cardiovascular fitness are associated with omega-3 PUFAs. omega-3 38-45 C-reactive protein Homo sapiens 88-91 33621131-9 2021 In addition, 13C-UBT and PASI scores were significantly positively correlated with CRP, platelet P-selectin, and percentage of lymphocytes. 13c-ubt 13-20 C-reactive protein Homo sapiens 83-86 30296044-7 2016 Six months of exenatide therapy resulted in normalization of glycemia, glycated hemoglobin and significant decrease of CRP level which suggested the improvement of the functional state of vascular endothelium due to reduction of chronic inflammation objectively reflected in the highly sensitive CRP level. Exenatide 14-23 C-reactive protein Homo sapiens 119-122 30296044-7 2016 Six months of exenatide therapy resulted in normalization of glycemia, glycated hemoglobin and significant decrease of CRP level which suggested the improvement of the functional state of vascular endothelium due to reduction of chronic inflammation objectively reflected in the highly sensitive CRP level. Exenatide 14-23 C-reactive protein Homo sapiens 296-299 32920994-8 2021 The results of TNF- alpha, IL-1 beta and CRP in the argon-helium cryoablation group was significantly better than that in the radiotherapy group(P < 0.001). Argon 52-57 C-reactive protein Homo sapiens 41-44 26588324-0 2015 Poly(3,4-ethylenedioxythiophene) Bearing Phosphorylcholine Groups for Metal-Free, Antibody-Free, and Low-Impedance Biosensors Specific for C-Reactive Protein. poly(3,4-ethylene dioxythiophene) 0-32 C-reactive protein Homo sapiens 139-157 26588324-6 2015 The specific interaction of CRP with phosphorylcholine in a calcium-containing buffer solution was determined by differential pulse voltammetry, which measures the altered redox reaction between the indicators ferricyanide/ferrocyanide as a result of the binding event. hexacyanoferrate II 223-235 C-reactive protein Homo sapiens 28-31 26602073-9 2015 In Cox multivariate analysis adjusted for age, gender, prednisolone treatment, smoking, baseline LDL cholesterol and high sensitivity C-reactive protein; simvastatin plus ezetimibe versus placebo was associated with 44% lower risk of cataract development (hazard ratio 0.56, 95% confidence interval 0.33 to 0.96, p = 0.034). Ezetimibe 171-180 C-reactive protein Homo sapiens 134-152 32971524-5 2021 The efficacy of silymarin was assessed by measuring serum C-reactive protein (CRP) (mg/dL), interleukin (IL)-6 (pg/mL), and IL-10 (pg/mL). Silymarin 16-25 C-reactive protein Homo sapiens 58-76 25986867-6 2015 RESULTS: Intraoperative blood loss and C-reactive protein levels at 3 and 7 days after surgery were significantly lower in LPG than in LTG (p = 0.018, 0.036, and 0.042, respectively). polyalanine 123-126 C-reactive protein Homo sapiens 39-57 32971524-5 2021 The efficacy of silymarin was assessed by measuring serum C-reactive protein (CRP) (mg/dL), interleukin (IL)-6 (pg/mL), and IL-10 (pg/mL). Silymarin 16-25 C-reactive protein Homo sapiens 78-81 32971524-7 2021 Data analysis showed that compared to the placebo, silymarin could decrease CRP, IL-6, and raise IL-10 significantly (the p values for all variables were <0.001). Silymarin 51-60 C-reactive protein Homo sapiens 76-79 26656519-6 2015 Anemia and high C-reactive protein levels retain their power in multivariate testing even in the era of the NCCN-IPI. diprotin A 113-116 C-reactive protein Homo sapiens 16-34 32986994-7 2020 CRP decreased significantly within the GBS and the ILI group, with this change significantly greater in the GBS group (between-group differences for deltas p < 0.001). gbs 39-42 C-reactive protein Homo sapiens 0-3 26371408-6 2015 In the whole group protein N-linked Hcy correlated only with C-reactive protein (CRP; r = 0.44, p < 0.0001). Homocysteine 36-39 C-reactive protein Homo sapiens 61-79 26371408-6 2015 In the whole group protein N-linked Hcy correlated only with C-reactive protein (CRP; r = 0.44, p < 0.0001). Homocysteine 36-39 C-reactive protein Homo sapiens 81-84 26371408-10 2015 Multiple regression adjusted for potential confounders showed that the only independent predictor of protein N-linked Hcy in the upper quartile was CRP > 3mg/L (odds ratio 3.04, 95% confidence interval 2.12-4.36, p < 0.0001). Homocysteine 118-121 C-reactive protein Homo sapiens 148-151 32986994-7 2020 CRP decreased significantly within the GBS and the ILI group, with this change significantly greater in the GBS group (between-group differences for deltas p < 0.001). gbs 108-111 C-reactive protein Homo sapiens 0-3 32734315-6 2020 After 8 weeks from diagnosis, we detected a significant improvement in CRP (p = 0.001) and albumin (p = 0.05), in EEN-induction group compared with the CS-induction group. estradiol enanthate 114-117 C-reactive protein Homo sapiens 71-74 26356577-4 2015 In this study we investigated the relation between SRBD and C-reactive protein (CRP) as a parameter of inflammation and the influence of SRBD treatment on CRP with additional regard to changes in metabolic and cardiovascular parameters. srbd 51-55 C-reactive protein Homo sapiens 60-78 26356577-4 2015 In this study we investigated the relation between SRBD and C-reactive protein (CRP) as a parameter of inflammation and the influence of SRBD treatment on CRP with additional regard to changes in metabolic and cardiovascular parameters. srbd 51-55 C-reactive protein Homo sapiens 80-83 26356577-4 2015 In this study we investigated the relation between SRBD and C-reactive protein (CRP) as a parameter of inflammation and the influence of SRBD treatment on CRP with additional regard to changes in metabolic and cardiovascular parameters. srbd 137-141 C-reactive protein Homo sapiens 155-158 3168329-1 1988 Hydrolysis of human C-reactive protein (CRP) at pH 4.5 and pH 7.4 with neutrophil-derived lysosomal enzymes yielded 10% trichloroacetic acid soluble peptides (Mr less than 14,000). Trichloroacetic Acid 120-140 C-reactive protein Homo sapiens 20-38 3168329-1 1988 Hydrolysis of human C-reactive protein (CRP) at pH 4.5 and pH 7.4 with neutrophil-derived lysosomal enzymes yielded 10% trichloroacetic acid soluble peptides (Mr less than 14,000). Trichloroacetic Acid 120-140 C-reactive protein Homo sapiens 40-43 3285537-1 1988 Acute or persistent elevations in serum C-reactive protein (CRP) concentration have been shown to be of value in diagnosing acute rejection episodes in azathioprine (AZA)-treated renal transplant recipients. Azathioprine 152-164 C-reactive protein Homo sapiens 40-58 3285537-1 1988 Acute or persistent elevations in serum C-reactive protein (CRP) concentration have been shown to be of value in diagnosing acute rejection episodes in azathioprine (AZA)-treated renal transplant recipients. Azathioprine 152-164 C-reactive protein Homo sapiens 60-63 3285537-1 1988 Acute or persistent elevations in serum C-reactive protein (CRP) concentration have been shown to be of value in diagnosing acute rejection episodes in azathioprine (AZA)-treated renal transplant recipients. Azathioprine 166-169 C-reactive protein Homo sapiens 40-58 3285537-1 1988 Acute or persistent elevations in serum C-reactive protein (CRP) concentration have been shown to be of value in diagnosing acute rejection episodes in azathioprine (AZA)-treated renal transplant recipients. Azathioprine 166-169 C-reactive protein Homo sapiens 60-63 26356577-8 2015 Severe SRBD was significantly associated with elevated levels of CRP (3.7 [1.8-7.0] mg/l, vs. moderate (p = 0.001), and mild SRBD (p<0.001), and higher prevalence of hypertension as compared to moderate and mild SRBD (p<0.001, respectively). srbd 7-11 C-reactive protein Homo sapiens 65-68 26356577-10 2015 If SRBD treatment was highly successful (AHI <5/h), CRP and quality of life improved significantly (p = 0.001 and p = 0.002), as did blood pressure (p<0.001 for systolic and diastolic values), although BMI increased (p<0.001). srbd 3-7 C-reactive protein Homo sapiens 55-58 26356577-15 2015 The SRBD therapy-induced CRP decrease was not associated with BMI changes or metabolic changes but rather with the magnitude of AHI improvement. srbd 4-8 C-reactive protein Homo sapiens 25-28 25893544-1 2015 BACKGROUND: The aim of this analysis was to examine the effects of icosapent ethyl (eicosapentaenoic acid ethyl ester, IPE) on high-sensitivity C-reactive protein (hsCRP) and lipid parameters in patients with metabolic syndrome, with and without stable statin therapy. eicosapentaenoic acid ethyl ester 84-117 C-reactive protein Homo sapiens 144-162 26320633-0 2015 Disposable integrated bismuth citrate-modified screen-printed immunosensor for ultrasensitive quantum dot-based electrochemical assay of C-reactive protein in human serum. bismuth tripotassium dicitrate 22-37 C-reactive protein Homo sapiens 137-155 3031632-0 1986 Synthetic peptides from C-reactive protein containing tuftsin-related sequences. Peptides 10-18 C-reactive protein Homo sapiens 24-42 3031632-1 1986 Peptides containing Lys-Pro-Arg or Thr-Lys-Arg segments corresponding to various regions of human C-reactive protein were synthesized. Peptides 0-8 C-reactive protein Homo sapiens 98-116 26320633-1 2015 A novel immunosensor based on graphite screen-printed electrodes (SPEs) modified with bismuth citrate was developed for the voltammetric determination of C-reactive protein (CRP) in human serum using quantum dots (QDs) labels. Graphite 30-38 C-reactive protein Homo sapiens 154-172 32696396-8 2020 The patients given Leflunomide also showed a significant reduction in C-reactive protein levels, indicating that immunopathological inflammation was well controlled. Leflunomide 19-30 C-reactive protein Homo sapiens 70-88 26320633-1 2015 A novel immunosensor based on graphite screen-printed electrodes (SPEs) modified with bismuth citrate was developed for the voltammetric determination of C-reactive protein (CRP) in human serum using quantum dots (QDs) labels. Graphite 30-38 C-reactive protein Homo sapiens 174-177 26320633-1 2015 A novel immunosensor based on graphite screen-printed electrodes (SPEs) modified with bismuth citrate was developed for the voltammetric determination of C-reactive protein (CRP) in human serum using quantum dots (QDs) labels. bismuth tripotassium dicitrate 86-101 C-reactive protein Homo sapiens 154-172 26320633-1 2015 A novel immunosensor based on graphite screen-printed electrodes (SPEs) modified with bismuth citrate was developed for the voltammetric determination of C-reactive protein (CRP) in human serum using quantum dots (QDs) labels. bismuth tripotassium dicitrate 86-101 C-reactive protein Homo sapiens 174-177 3919022-7 1985 These results suggest that CRP can stabilize membranes from the detergent-like effects of lysolipids and from potentially toxic materials such as platelet-activating factor. lysolipids 90-100 C-reactive protein Homo sapiens 27-30 6885107-5 1983 We have used Tb3+ as an isomorphous analogue to study Ca2+ binding to CRP. tb3+ 13-17 C-reactive protein Homo sapiens 70-73 6885107-8 1983 A 50-fold molar excess of Ca2+ is sufficient to displace the Tb3+ suggesting that Tb3+ is bound with greater affinity to CRP than the natural analogue Ca2+. tb3+ 82-86 C-reactive protein Homo sapiens 121-124 6885107-9 1983 We propose that Tb3+ (by inference Ca2+) binding takes place near the CRP subunit disulfide bond, where two histidine residues are present. tb3+ 16-20 C-reactive protein Homo sapiens 70-73 6885107-10 1983 The pH dependency of Tb3+ binding is best explained by the deprotonation of a histidine residue(s) in CRP. tb3+ 21-25 C-reactive protein Homo sapiens 102-105 25230323-5 2015 Compared with placebo, DHEA administration raised levels of testosterone, androstenedione, and DHEA-sulfate (DHEA-S), and increased the percent change from baseline in fasting IL-6 mRNA, IL-6 release, plasma IL-6, and CRP and MMP-2 protein. Dehydroepiandrosterone 23-27 C-reactive protein Homo sapiens 218-221 32738021-6 2020 Lathosterol and lanosterol were positively correlated with body mass index, fasting insulin and glucose, serum triglycerides, and C-reactive protein, and negatively correlated with HDL-cholesterol. lathosterol 0-11 C-reactive protein Homo sapiens 130-148 25461166-2 2015 The CRP detection has been carried out by monitoring the shift in Bragg wavelength (DeltalambdaB) of an etched FBG (eFBG) coated with an anti-CRP antibody (aCRP)-graphene oxide (GO) complex. graphene oxide 162-176 C-reactive protein Homo sapiens 4-7 25461166-2 2015 The CRP detection has been carried out by monitoring the shift in Bragg wavelength (DeltalambdaB) of an etched FBG (eFBG) coated with an anti-CRP antibody (aCRP)-graphene oxide (GO) complex. graphene oxide 162-176 C-reactive protein Homo sapiens 142-145 25461166-2 2015 The CRP detection has been carried out by monitoring the shift in Bragg wavelength (DeltalambdaB) of an etched FBG (eFBG) coated with an anti-CRP antibody (aCRP)-graphene oxide (GO) complex. graphene oxide 178-180 C-reactive protein Homo sapiens 4-7 7092339-4 1982 Changes in serum total sialic acid levels paralleled those in CRP and SAA in RA as well as in SLE. N-Acetylneuraminic Acid 23-34 C-reactive protein Homo sapiens 62-65 7217669-7 1981 Furthermore, CRP bound to galactocyl cerebroside-containing liposomes bound approximately twice as much C1q as the same amount of CRP bound to liposomes lacking the glycolipid. Glycolipids 165-175 C-reactive protein Homo sapiens 13-16 33053283-10 2020 CONCLUSIONS: In patients with rheumatoid arthritis refractory to biologic DMARDs, upadacitinib was superior to abatacept in the change from baseline in the DAS28-CRP and the achievement of remission at week 12 but was associated with more serious adverse events. upadacitinib 82-94 C-reactive protein Homo sapiens 162-165 4394061-5 1970 Groupings reactive with suitably linked N-acetylgalactosamine, therefore, appear to be located on the surfaces of molecules of human C-reactive protein. Acetylgalactosamine 40-61 C-reactive protein Homo sapiens 133-151 24962795-0 2015 Asymmetric dimethylarginine is associated with high-sensitivity C-reactive protein and early carotid atherosclerosis in women with previous gestational diabetes mellitus. dimethylarginine 11-27 C-reactive protein Homo sapiens 64-82 33019398-9 2020 Triglycerides and CRP were significantly lower post than pre n-3FA supplementation (160.64 +- 32.55 vs 169.35 +- 31.82) (P < .001) and (10.29 +- 4.39 vs 11.19 +- 4.83) (P = .006) respectively. n-3fa 61-66 C-reactive protein Homo sapiens 18-21 25331535-0 2015 Evaluation of high-sensitivity serum CRP levels compared to markers of airway inflammation and allergy as predictors of methacholine bronchial hyper-responsiveness in children. Methacholine Chloride 120-132 C-reactive protein Homo sapiens 37-40 25402372-1 2015 OBJECTIVE: To evaluate the effect of dipeptidyl-peptidase-4 (DPP-4) inhibitor vildagliptin on high sensitivity C-reactive protein (hsCRP) and arterial stiffness (AS) in patients with type 2 diabetes (T2DM). Vildagliptin 78-90 C-reactive protein Homo sapiens 111-129 26466690-8 2015 Using logistic regression models adjusted for the age, body mass index, smoking status, hypersensitive C-reactive protein levels, hypertension, hyperglycemia, and dyslipidemia, an increased baPWV (>1,400 cm/s) was significantly associated with moderate-to-severe AL compared with a normal pulmonary function (odds ratio=2.76; 95% confidence intervals, 1.37-5.55; p=0.004). bapwv 190-195 C-reactive protein Homo sapiens 103-121 13840007-0 1959 KENKEL H: Relationship of sialic acid and C-reactive protein levels in human serum. N-Acetylneuraminic Acid 26-37 C-reactive protein Homo sapiens 42-60 34038556-7 2021 In the NHANES, mean serum C-reactive protein significantly increased with increasing MDS (P-trend < 0.01) after adjusting for age and sex and other covariates, primarily among individuals with magnesium intake less than the Estimated Average Requirement (EAR; P-trend < 0.05). Magnesium 193-202 C-reactive protein Homo sapiens 26-44 34033648-20 2021 CONCLUSIONS: In this study, the treatment of severe Covid-19 Pneumonia with high-dose methylprednisolone for three days followed by oral prednisone for 14 days, compared with 6 mg dexamethasone for 7 to 10 days, statistically significantly decreased the recovery time, the need for transfer to intensive care and the severity markers C-reactive protein (CRP), D-dimer and LDH. Methylprednisolone 86-104 C-reactive protein Homo sapiens 334-352 34033648-20 2021 CONCLUSIONS: In this study, the treatment of severe Covid-19 Pneumonia with high-dose methylprednisolone for three days followed by oral prednisone for 14 days, compared with 6 mg dexamethasone for 7 to 10 days, statistically significantly decreased the recovery time, the need for transfer to intensive care and the severity markers C-reactive protein (CRP), D-dimer and LDH. Methylprednisolone 86-104 C-reactive protein Homo sapiens 354-357 32780727-8 2020 Receiver-operating-characteristics analyses using a 5-protein panel (CFHR5, LRG1, CRP, LBP and SAA1) exhibited discriminatory power in distinguishing between TB and ORD (AUC =0.81).ConclusionsWe report the most comprehensive TB plasma proteome to date, identifying numerous novel markers with verification in two independent cohorts, which led to a 5-protein biosignature with potential to improve TB diagnosis. Terbium 158-160 C-reactive protein Homo sapiens 82-85 34021415-5 2021 The optimal CRP cutoff value of Clavien-Dindo (CD) grade >= 3 for predicting severe complications for each group was determined. clavien-dindo 32-45 C-reactive protein Homo sapiens 12-15 25975878-0 2015 Correlation of magnesium deficiency with C-reactive protein in elective cardiac surgery with cardiopulmonary bypass for ischemic heart disease. Magnesium 15-24 C-reactive protein Homo sapiens 41-59 25975878-3 2015 We aimed to find a link between serum, erythrocyte, cardiac tissue magnesium concentration and C-reactive protein (CRP) as an inflammatory marker in patients undergoing elective cardiac surgery with CPB. Magnesium 67-76 C-reactive protein Homo sapiens 95-113 25975878-3 2015 We aimed to find a link between serum, erythrocyte, cardiac tissue magnesium concentration and C-reactive protein (CRP) as an inflammatory marker in patients undergoing elective cardiac surgery with CPB. Magnesium 67-76 C-reactive protein Homo sapiens 115-118 25204405-7 2014 These polyglutamates were further evaluated for their relationship with DAS28-3v (CRP). Polyglutamic Acid 6-20 C-reactive protein Homo sapiens 82-85 32639235-9 2020 DISCUSSION: RHB-102 was effective and safe in the treatment of men and women with IBS-D. Baseline C-reactive protein seemed to be predictive of response. Ondansetron hydrochloride dihydrate 12-19 C-reactive protein Homo sapiens 98-116 34016892-7 2021 CONCLUSIONS: Serum carcinoembryonic antigen and C-reactive protein to albumin ratio are associated with Evans I disease in patients with PDAC who receive NAC-GS. nac 154-157 C-reactive protein Homo sapiens 48-66 34016551-8 2021 CONCLUSIONS: The deterioration of thiol-disulfide homeostasis in favor of disulfide; correlations between ESR, CRP, and NT, TT support the use of thiol-disulfide variables in determining the disease activity level. thiol-disulfide 146-161 C-reactive protein Homo sapiens 111-114 32388479-4 2020 Quercetin and enzymatically-modified isoquercitrin (EMIQ - a food additive/nutraceutical that upon oral administration achieves far higher plasma concentrations of quercetin than quercetin per se) also have exerted a range of vascular-protective effects clinically and in rodents - improving endothelial function, warding off atherosclerosis, lowering blood pressure, decreasing C-reactive protein, aiding glycemic control, stabilizing platelets - that might also, at least in part, reflect CK2 inhibition. isoquercitrin 37-50 C-reactive protein Homo sapiens 379-397 25798379-2 2014 OBJECTIVES: This study is aimed to find anti-inflammatory aspects of high dose magnesium sulfate infusion during perioperative period of neurosurgical patients through checking the serial C-reactive protein (CRP) blood levels as a biomarker of inflammation. Magnesium Sulfate 79-96 C-reactive protein Homo sapiens 188-206 25798379-2 2014 OBJECTIVES: This study is aimed to find anti-inflammatory aspects of high dose magnesium sulfate infusion during perioperative period of neurosurgical patients through checking the serial C-reactive protein (CRP) blood levels as a biomarker of inflammation. Magnesium Sulfate 79-96 C-reactive protein Homo sapiens 208-211 32778146-9 2020 CRP and procalcitonin levels were lower in the DEX vs. non-DEX group during the 14-day treatment period [CRP-range, 5.6-20.3 vs. 8.3-21.1 mg/dL (P = 0.03); procalcitonin-range, 1.2-37.4 vs. 1.7-52.9 ng/mL (P = 0.04)]. Dextromethorphan 47-50 C-reactive protein Homo sapiens 0-3 33876782-11 2021 C-reactive protein levels less than 60mg/L by day 3 was seen in 17(74%) in methylprednisolone group and 2 (25%) in IVIG group (P=0.014). Methylprednisolone 75-93 C-reactive protein Homo sapiens 0-18 32778146-9 2020 CRP and procalcitonin levels were lower in the DEX vs. non-DEX group during the 14-day treatment period [CRP-range, 5.6-20.3 vs. 8.3-21.1 mg/dL (P = 0.03); procalcitonin-range, 1.2-37.4 vs. 1.7-52.9 ng/mL (P = 0.04)]. Dextromethorphan 47-50 C-reactive protein Homo sapiens 105-108 33735520-13 2021 CONCLUSION: In this retrospective study, theophylline and pentoxifylline was associated with an increase in ROX score and nominal decreases in CRP and mortality. Pentoxifylline 58-72 C-reactive protein Homo sapiens 143-146 32821285-5 2020 In cytokine-stimulated hepatocytes, apabetalone reduces the expression of C-reactive protein (CRP), alpha-2-macroglobulin, and serum amyloid P. The latter two are also reduced by apabetalone in the liver of endotoxemic mice. apabetalone 36-47 C-reactive protein Homo sapiens 74-92 33418065-10 2021 CONCLUSION: Current data suggest that the EPA to DHA ratio only correlates to the modulation of CRP by omega-3 supplementation of EPA and DHA, and SBP in studies that supplemented EPA and DHA in the range of 2 g to 6 g, shedding light on potential differential effects of EPA vs. DHA on inflammation and systolic blood pressure. Docosahexaenoic Acids 138-141 C-reactive protein Homo sapiens 96-99 33418065-10 2021 CONCLUSION: Current data suggest that the EPA to DHA ratio only correlates to the modulation of CRP by omega-3 supplementation of EPA and DHA, and SBP in studies that supplemented EPA and DHA in the range of 2 g to 6 g, shedding light on potential differential effects of EPA vs. DHA on inflammation and systolic blood pressure. Docosahexaenoic Acids 138-141 C-reactive protein Homo sapiens 96-99 33418065-10 2021 CONCLUSION: Current data suggest that the EPA to DHA ratio only correlates to the modulation of CRP by omega-3 supplementation of EPA and DHA, and SBP in studies that supplemented EPA and DHA in the range of 2 g to 6 g, shedding light on potential differential effects of EPA vs. DHA on inflammation and systolic blood pressure. Docosahexaenoic Acids 138-141 C-reactive protein Homo sapiens 96-99 33524773-8 2021 Within both patient groups, but not HC, we show a significant positive correlation of CRP with neopterin but not with biopterin. Neopterin 95-104 C-reactive protein Homo sapiens 86-89 33616345-9 2021 CRP was positively correlated with HOMA-IR, TC, and AHSG (r = 0.485, 0.331, 0.226, p < 0.05), negatively associated with 25-OH-VD (r = -0.443, p < 0.05), and had no correlation to TG and Hcy (r = 0.019, 0.058, p > 0.05). Technetium 44-46 C-reactive protein Homo sapiens 0-3 25337037-12 2014 Circulating markers (macrophage migration inhibitory factor, tumour necrosis factor-alpha, CRP, and vWF) were significantly associated with baPWV. bapwv 140-145 C-reactive protein Homo sapiens 91-94 23716069-4 2014 Our hypothesis was that there would be an inverse association between raised CRP levels and both TC and HDL-cholesterol levels. Technetium 97-99 C-reactive protein Homo sapiens 77-80 23716069-8 2014 We identified a significant (p<0.001) biphasic relationship between TC and CRP: TC increased within the healthy CRP range of less than 5 mg/l, but decreased with CRP levels above 10 mg/l. Technetium 71-73 C-reactive protein Homo sapiens 78-81 23716069-8 2014 We identified a significant (p<0.001) biphasic relationship between TC and CRP: TC increased within the healthy CRP range of less than 5 mg/l, but decreased with CRP levels above 10 mg/l. Technetium 71-73 C-reactive protein Homo sapiens 115-118 23716069-8 2014 We identified a significant (p<0.001) biphasic relationship between TC and CRP: TC increased within the healthy CRP range of less than 5 mg/l, but decreased with CRP levels above 10 mg/l. Technetium 71-73 C-reactive protein Homo sapiens 115-118 23716069-8 2014 We identified a significant (p<0.001) biphasic relationship between TC and CRP: TC increased within the healthy CRP range of less than 5 mg/l, but decreased with CRP levels above 10 mg/l. Technetium 83-85 C-reactive protein Homo sapiens 78-81 23716069-8 2014 We identified a significant (p<0.001) biphasic relationship between TC and CRP: TC increased within the healthy CRP range of less than 5 mg/l, but decreased with CRP levels above 10 mg/l. Technetium 83-85 C-reactive protein Homo sapiens 115-118 23716069-8 2014 We identified a significant (p<0.001) biphasic relationship between TC and CRP: TC increased within the healthy CRP range of less than 5 mg/l, but decreased with CRP levels above 10 mg/l. Technetium 83-85 C-reactive protein Homo sapiens 115-118 25078288-8 2014 Furthermore, patients whose Mg intake was low (87.3%) had significantly higher CRP than that of those who took adequate Mg (p = 0.025). Magnesium 28-30 C-reactive protein Homo sapiens 79-82 25078288-9 2014 The dietary Ca:Mg intake ratios were highly correlated with CRP, platelet counts, and red blood cell distribution (p < 0.05). Magnesium 15-17 C-reactive protein Homo sapiens 60-63 33616345-9 2021 CRP was positively correlated with HOMA-IR, TC, and AHSG (r = 0.485, 0.331, 0.226, p < 0.05), negatively associated with 25-OH-VD (r = -0.443, p < 0.05), and had no correlation to TG and Hcy (r = 0.019, 0.058, p > 0.05). Homocysteine 187-190 C-reactive protein Homo sapiens 0-3 32821285-5 2020 In cytokine-stimulated hepatocytes, apabetalone reduces the expression of C-reactive protein (CRP), alpha-2-macroglobulin, and serum amyloid P. The latter two are also reduced by apabetalone in the liver of endotoxemic mice. apabetalone 179-190 C-reactive protein Homo sapiens 74-92 25078288-10 2014 A dietary Ca:Mg intake ratio of 2.0-2.5 was significantly correlated to lower CRP levels (p = 0.013). Magnesium 13-15 C-reactive protein Homo sapiens 78-81 32821285-8 2020 In patients with stable coronary disease, plasma APR proteins CRP, IL-1 receptor antagonist, and fibrinogen gamma decrease after apabetalone treatment versus placebo, resulting in a predicted downregulation of the APR pathway and cytokine targets. apabetalone 129-140 C-reactive protein Homo sapiens 62-65 33517942-8 2021 In joint statistical tests, aflatoxin exposure was associated with serum biomarkers of inflammation (C-reactive protein, alpha-1-glycoprotein) and protein status (transthyretin, lysine, tryptophan), IGF-1, and linear growth (all p<0.01). Aflatoxins 28-37 C-reactive protein Homo sapiens 101-119 33185166-7 2021 Patients treated with MTX and doxycycline showed lower levels of DAS28, ESR, CRP, MMP-3 and MMP-9 and this was statistically significant. Doxycycline 30-41 C-reactive protein Homo sapiens 77-80 32631431-10 2020 A strong association was observed between CRP and MTV (rP = 0.66, p < 0.001) and a moderate to weak association between CRP and TLG (rP = 0.53, p < 0.001) and CRP and SUVpeak (rP = 0.45, p < 0.001). (5r)-3-Acetyl-4-Hydroxy-5-Methyl-5-[(1z)-2-Methylbuta-1,3-Dien-1-Yl]thiophen-2(5h)-One 129-132 C-reactive protein Homo sapiens 121-124 33254652-9 2020 In addition, urinary copper increased monotonically with plasma CRP elevation, which in turn, was positively associated with TC, TG, and LDL-C and negatively related to HDL-C (all P < 0.05). Technetium 125-127 C-reactive protein Homo sapiens 64-67 33254652-10 2020 Results from 3D mesh graphs demonstrated that increased levels of plasma CRP with higher urinary copper corresponded to higher TC, TG, LDL-C, and lower HDL-C concentrations. Technetium 127-129 C-reactive protein Homo sapiens 73-76 24939435-0 2014 Dietary magnesium intake is inversely associated with serum C-reactive protein levels: meta-analysis and systematic review. Magnesium 8-17 C-reactive protein Homo sapiens 60-78 24408146-12 2014 CONCLUSIONS: ADMA increased significantly after SAH, and the increase in ADMA started after the pro-inflammatory markers (CRP and IL-6) had peaked. N,N-dimethylarginine 73-77 C-reactive protein Homo sapiens 122-125 32631431-10 2020 A strong association was observed between CRP and MTV (rP = 0.66, p < 0.001) and a moderate to weak association between CRP and TLG (rP = 0.53, p < 0.001) and CRP and SUVpeak (rP = 0.45, p < 0.001). (5r)-3-Acetyl-4-Hydroxy-5-Methyl-5-[(1z)-2-Methylbuta-1,3-Dien-1-Yl]thiophen-2(5h)-One 129-132 C-reactive protein Homo sapiens 121-124 32329054-8 2020 ELISA analysis indicated that CRP expression in prostate adenocarcinoma subjects with TT + TC genotypes was statistically higher than in those with CC genotypes. Technetium 91-93 C-reactive protein Homo sapiens 30-33 32572032-0 2020 Author Correction: HIF1alpha inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis. Leflunomide 52-63 C-reactive protein Homo sapiens 68-71 31955550-8 2020 Compared to that in the control group, the OR (95% CI) of high baPWV in those with a borderline-high MCV was 3.68 (1.39-9.74) after adjusting for age, sex, body mass index, alcohol intake, smoking status, regular exercise, mean blood pressure, fasting plasma glucose, triglyceride, high-density lipoprotein cholesterol, C-reactive protein, gamma-glutamyltransferase, uric acid, hypertension medication, and diabetes medication. bapwv 63-68 C-reactive protein Homo sapiens 320-338 24814039-0 2014 Oral magnesium supplementation decreases C-reactive protein levels in subjects with prediabetes and hypomagnesemia: a clinical randomized double-blind placebo-controlled trial. Magnesium 5-14 C-reactive protein Homo sapiens 41-59 24814039-2 2014 We undertook this study to determine whether oral magnesium supplementation modifies serum levels of high-sensitivity C-reactive protein (hsCRP) in apparently healthy subjects with prediabetes and hypomagnesemia. Magnesium 50-59 C-reactive protein Homo sapiens 118-136 32572032-0 2020 Author Correction: HIF1alpha inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis. Leflunomide 52-63 C-reactive protein Homo sapiens 111-114 24346636-10 2014 CONCLUSIONS: POC-CRP testing increased more than 4-fold the proportion of HIV-infected adults immediately identified as IPT eligible and decreased the proportion of patients requiring referral for further tuberculosis diagnostic testing. isoprothiolane 120-123 C-reactive protein Homo sapiens 17-20 33073938-10 2020 CONCLUSIONS: Although pentoxifylline administration had caused significant reduction in CRP and TNF-alpha, as well as significant increase of albumin levels in the intervention group, but these changes were not significant in comparison with control group. Pentoxifylline 22-36 C-reactive protein Homo sapiens 88-91 32896775-0 2020 Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia. Lurasidone Hydrochloride 79-89 C-reactive protein Homo sapiens 15-33 32896775-6 2020 RESULTS: CRP combined with HDL, triglyceride-to-HDL (TG/HDL) ratio, or HOMA-IR at study baseline were significant moderators of the improvement in cognitive performance associated with lurasidone 160 mg/day (vs. placebo) treatment (p < .05). Lurasidone Hydrochloride 185-195 C-reactive protein Homo sapiens 9-12 32896775-7 2020 Greater placebo-corrected treatment effect size on the CogState composite score was observed for patients in the lurasidone 160 mg/day treatment group who had either low CRP and high HDL (d = 0.43), or low CRP and low HOMA-IR (d = 0.46). Lurasidone Hydrochloride 113-123 C-reactive protein Homo sapiens 170-173 32896775-7 2020 Greater placebo-corrected treatment effect size on the CogState composite score was observed for patients in the lurasidone 160 mg/day treatment group who had either low CRP and high HDL (d = 0.43), or low CRP and low HOMA-IR (d = 0.46). Lurasidone Hydrochloride 113-123 C-reactive protein Homo sapiens 206-209 32896775-10 2020 CONCLUSIONS: Findings of this post-hoc analysis based on a placebo-controlled trial in patients with schizophrenia suggest that baseline CRP level combined with measures of metabolic risk significantly moderated the improvement in cognitive performance associated with lurasidone 160 mg/day (vs. placebo) treatment. Lurasidone Hydrochloride 269-279 C-reactive protein Homo sapiens 137-140 24493300-13 2014 During intervention, the clonidine group had a lower number of steps per day (mean difference, -637 steps; P = .07), lower plasma norepinephrine level (mean difference, -42 pg/mL; P = .01), and lower serum C-reactive protein concentration (mean ratio, 0.69; P = .02) compared with the CFS placebo group. Clonidine 25-34 C-reactive protein Homo sapiens 206-224 32503662-2 2020 Furthermore, we hypothesize that early treatment with hydroxychloroquine sulphate is associated with more rapid resolve of clinical symptoms as assessed by the National Early Warning Score 2 (NEWS2), decreased admission rate to intensive care units and mortality, and improvement in protein biomarker profiles (C-reactive protein, markers of renal and hepatic injury, and established cardiac biomarkers like cardiac troponin and B-type natriuretic peptide). Hydroxychloroquine 54-81 C-reactive protein Homo sapiens 311-329 24716416-0 2014 Relationship between c-reactive protein and the asymmetric dimethylarginine-induced endothelial dysfunction pathway in vasospastic angina. dimethylarginine 59-75 C-reactive protein Homo sapiens 21-39 24716416-3 2014 We sought to demonstrate the relationship between high-sensitivity c-reactive protein (hs-CRP), a sensitive marker of inflammation, and the asymmetric dimethylarginine (ADMA)-induced endothelial dysfunction pathway in patients with VSA. dimethylarginine 151-167 C-reactive protein Homo sapiens 67-85 24716416-3 2014 We sought to demonstrate the relationship between high-sensitivity c-reactive protein (hs-CRP), a sensitive marker of inflammation, and the asymmetric dimethylarginine (ADMA)-induced endothelial dysfunction pathway in patients with VSA. dimethylarginine 151-167 C-reactive protein Homo sapiens 90-93 24716416-3 2014 We sought to demonstrate the relationship between high-sensitivity c-reactive protein (hs-CRP), a sensitive marker of inflammation, and the asymmetric dimethylarginine (ADMA)-induced endothelial dysfunction pathway in patients with VSA. N,N-dimethylarginine 169-173 C-reactive protein Homo sapiens 67-85 24716416-3 2014 We sought to demonstrate the relationship between high-sensitivity c-reactive protein (hs-CRP), a sensitive marker of inflammation, and the asymmetric dimethylarginine (ADMA)-induced endothelial dysfunction pathway in patients with VSA. N,N-dimethylarginine 169-173 C-reactive protein Homo sapiens 90-93 24716416-7 2014 Moreover, we found that CRP was directly related to ADMA (r = 0.69, P < 0.001) but inversely related to brachial FMD (r = -0.66, P < 0.001) in patients with VSA. N,N-dimethylarginine 52-56 C-reactive protein Homo sapiens 24-27 24716416-9 2014 These results indicate that there is a relationship between CRP and the ADMA-induced endothelial dysfunction pathway in patients with VSA. N,N-dimethylarginine 72-76 C-reactive protein Homo sapiens 60-63 32609313-15 2020 Decreases in non-high-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and high-sensitivity C-reactive protein levels were greater with bempedoic acid vs placebo. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 157-171 C-reactive protein Homo sapiens 113-131 32108382-17 2020 Xin Huang Pian treatment showed superior effects compared with Diclofenac Diethylamine Emulgel on decreasing levels of C-reactive protein and erythrocyte sedimentation rate. diclofenac diethylamine 63-86 C-reactive protein Homo sapiens 119-137 33061673-6 2020 Results: Serum T3, Ca, K, homocysteine, CRP, and Mg concentrations were significantly improved in Mg-treated groups compared to placebo groups. Magnesium 98-100 C-reactive protein Homo sapiens 40-43 33025951-4 2020 Bempedoic acid given at a dosage of 180 mg orally once daily produces a highly significant reduction in low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol, total cholesterol, apolipoprotein B and importantly also in high-sensitivity C-reactive protein. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 C-reactive protein Homo sapiens 268-286 24586854-10 2014 High sensitivity C-reactive protein (hsCRP) was positively correlated with traditional cardio-metabolic risk factors including waist circumference (r = 0.127, p = 0.05), triglycerides (r = 0.19, p = 0.003) and Total Cholesterol: High Density Lipoprotein ratio (TC:LDL) (r = 0.225, p<0.001). Technetium 261-263 C-reactive protein Homo sapiens 17-35 32286421-6 2020 Further, methionine, isoleucine, tryptophan, xanthurenic acid, and indole-3-carboxaldehyde were negatively associated with C-reactive protein (CRP), but 5-hydroxyindole-3-acetic acid was positively associated with CRP. xanthurenic acid 45-61 C-reactive protein Homo sapiens 123-141 24342929-6 2014 In linear regression analyses comprising age, smoking, triglyceride, HDL-cholesterol, C-reactive protein and waist circumference as well, creatinine was significantly and independently associated with ADMA, further in women glucose (inversely). N,N-dimethylarginine 201-205 C-reactive protein Homo sapiens 86-104 32757858-7 2020 In CD, significant correlations between DCE-MRI parameters and biomarkers (CRP, faecal calprotectin) were more frequent in unaffected segments than in affected segments. ethylene dichloride 40-43 C-reactive protein Homo sapiens 75-78 32286421-6 2020 Further, methionine, isoleucine, tryptophan, xanthurenic acid, and indole-3-carboxaldehyde were negatively associated with C-reactive protein (CRP), but 5-hydroxyindole-3-acetic acid was positively associated with CRP. xanthurenic acid 45-61 C-reactive protein Homo sapiens 143-146 32787053-7 2020 We demonstrate the fluorescence enhancement in detecting C-Reactive protein (CPR) antibody conjugated with fluorescein isothiocyanate (FITC) by means of near-field coupling between surface plasmons and fluorophores at spectral channels of emission. Fluorescein-5-isothiocyanate 135-139 C-reactive protein Homo sapiens 57-75 32535571-8 2020 Increased concentrations of catecholamines are associated with increased blood levels of proinflammatory cytokines such as IL-6 and TNF-b.the level of CRP may reflect the inflammatory process in the intima of blood vessels. Catecholamines 28-42 C-reactive protein Homo sapiens 151-154 32787053-7 2020 We demonstrate the fluorescence enhancement in detecting C-Reactive protein (CPR) antibody conjugated with fluorescein isothiocyanate (FITC) by means of near-field coupling between surface plasmons and fluorophores at spectral channels of emission. Fluorescein-5-isothiocyanate 135-139 C-reactive protein Homo sapiens 77-80 23974954-10 2014 CONCLUSIONS: Half the patients under azathioprine and/or infliximab in clinical remission have endoscopic and/or CRP evidence of residual active CD, whereas other patients with endoscopic and CRP normalisation have persistent clinical symptoms. Azathioprine 37-49 C-reactive protein Homo sapiens 113-116 23974954-10 2014 CONCLUSIONS: Half the patients under azathioprine and/or infliximab in clinical remission have endoscopic and/or CRP evidence of residual active CD, whereas other patients with endoscopic and CRP normalisation have persistent clinical symptoms. Azathioprine 37-49 C-reactive protein Homo sapiens 192-195 25159306-0 2014 Antioxidant response of osteoblasts to doxycycline in an inflammatory model induced by C-reactive protein and interleukin-6. Doxycycline 39-50 C-reactive protein Homo sapiens 87-105 23751609-5 2013 Platelet counts and CRP were significantly elevated in GWVI+ compared to GWVI- patients without elevation in IPF or TPO. gwvi+ 55-60 C-reactive protein Homo sapiens 20-23 32542640-4 2020 A total of 11 SNPs within the CRP gene were designated for exploration, by logistic regression analyses, of how they might interact with environmental factors to affect susceptibility to DFO. dfo 187-190 C-reactive protein Homo sapiens 30-33 32542640-9 2020 CONCLUSION: Genetic mutations within CRP functioned interactively with external factors to affect DFO risk. dfo 98-101 C-reactive protein Homo sapiens 37-40 23287846-0 2013 Supplementation with tocotrienol-rich fraction alters the plasma levels of Apolipoprotein A-I precursor, Apolipoprotein E precursor, and C-reactive protein precursor from young and old individuals. Tocotrienols 21-32 C-reactive protein Homo sapiens 137-155 33759155-12 2021 CONCLUSION: The duration of poisoning, coma degree, and serum levels of CK, LDH, CRP, and NSE were independent risk factors for DEACMP. deacmp 128-134 C-reactive protein Homo sapiens 81-84 30252104-6 2020 Results: We found that early-life SES exerted consistent protective effects for metabolic disorder across the life span, but waned with time for CRP. Selenium 34-37 C-reactive protein Homo sapiens 145-148 32684941-6 2020 Results: There was a significant non-linear relationship between lipid profile (TC, TG, HDL-C, LDL-C) and hs-CRP (P < 0.05). Technetium 80-82 C-reactive protein Homo sapiens 109-112 32684941-8 2020 Compared with medium levels of lipids group, pregnant women with higher levels of TC or TG have higher levels of hs-CRP, and pregnant women with lower levels of TC, HDL-C or LDL-C also have higher levels of hs-CRP in the vitamin D deficient group, and there was a significant correlation between low levels of TG and decreased hs-CRP (adjusted beta for TG: -0.063, 95%CI: - 0.120,-0.007) in the non-vitamin D deficient group. Technetium 82-84 C-reactive protein Homo sapiens 116-119 23522521-7 2013 In all patients" and non-survivors" samples the 16:0 DMA levels correlated negatively with plasma CRP values (RS=-0.48 and RS=-0.70, respectively; p<0.05), but not with APACHE II scores or other markers. N-myristoyl-alaninol 53-56 C-reactive protein Homo sapiens 98-101 32341698-7 2020 Analysis of the investigated parameters in the leading group after receiving alpha-lipoic acid for 4 months showed a significant decrease in the concentration of C-Reactive Protein, IL-6 and TNF-alpha. Thioctic Acid 77-94 C-reactive protein Homo sapiens 162-180 23558443-11 2013 O-DMA was the only isoflavonoid whose excretion was significantly associated with a decrease in both CRP (p-trend = 0.024) and WBC count (p-trend < 0.0001). isoflavonoid 19-31 C-reactive protein Homo sapiens 101-104 32275206-0 2020 On-the-fly rapid immunoassay for neonatal sepsis diagnosis: C-reactive protein accurate determination using magnetic graphene-based micromotors. Graphite 117-125 C-reactive protein Homo sapiens 60-78 32566124-0 2020 Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide. Temozolomide 133-145 C-reactive protein Homo sapiens 20-38 31494638-9 2019 IPTB demonstrated elevated CRP levels when compared to PTL (P = 0.019). iptb 0-4 C-reactive protein Homo sapiens 27-30 32428019-13 2020 Patients treated with Atrovastatin had significantly lower number of patients with hs-CRP (high-sensitivity C-reactive protein)/C-reactive protein (CRP) level beyond comparable safe limit and relatively better tolerated as opposed to Rosuvastatin-40mg.Thus given the lower price, Atorvastatin 80mg/day appeared to be more cost-effective. atrovastatin 22-34 C-reactive protein Homo sapiens 86-89 32428019-13 2020 Patients treated with Atrovastatin had significantly lower number of patients with hs-CRP (high-sensitivity C-reactive protein)/C-reactive protein (CRP) level beyond comparable safe limit and relatively better tolerated as opposed to Rosuvastatin-40mg.Thus given the lower price, Atorvastatin 80mg/day appeared to be more cost-effective. atrovastatin 22-34 C-reactive protein Homo sapiens 108-126 32428019-13 2020 Patients treated with Atrovastatin had significantly lower number of patients with hs-CRP (high-sensitivity C-reactive protein)/C-reactive protein (CRP) level beyond comparable safe limit and relatively better tolerated as opposed to Rosuvastatin-40mg.Thus given the lower price, Atorvastatin 80mg/day appeared to be more cost-effective. atrovastatin 22-34 C-reactive protein Homo sapiens 128-146 32428019-13 2020 Patients treated with Atrovastatin had significantly lower number of patients with hs-CRP (high-sensitivity C-reactive protein)/C-reactive protein (CRP) level beyond comparable safe limit and relatively better tolerated as opposed to Rosuvastatin-40mg.Thus given the lower price, Atorvastatin 80mg/day appeared to be more cost-effective. atrovastatin 22-34 C-reactive protein Homo sapiens 148-151 27122709-2 2013 However, several single polynucleotide polymorphisms (SNPs) in the CRP gene affect CRP levels. Polynucleotides 24-38 C-reactive protein Homo sapiens 67-70 27122709-2 2013 However, several single polynucleotide polymorphisms (SNPs) in the CRP gene affect CRP levels. Polynucleotides 24-38 C-reactive protein Homo sapiens 83-86 23361365-10 2013 Taken together, our results demonstrate that DHA and EPA are able to reduce IL-6-induced CRP expression in HepG2 cells via an inhibition of STAT3 activation. Docosahexaenoic Acids 45-48 C-reactive protein Homo sapiens 89-92 22865000-8 2013 The higher CRP group was discriminated by the above variables in addition to lower VO(2max), serum metabolic syndrome components (triglycerides, glucose, and HDL cholesterol), higher insulin, homeostasis assessment of insulin resistance, uric acid, gamma-GT, and homocysteine. Homocysteine 263-275 C-reactive protein Homo sapiens 11-14 23853456-3 2013 AIM: To determine whether sub-antimicrobial dose-doxycycline (SDD) therapy can reduce systemic serum inflammatory biomarker C-reactive protein (CRP) in post-menopausal women who have chronic periodontitis. Doxycycline 49-60 C-reactive protein Homo sapiens 144-147 32963724-12 2020 Homocysteine and physical activity can predict the inflammation status induced by CRP. Homocysteine 0-12 C-reactive protein Homo sapiens 82-85 31832494-10 2019 Higher CRP levels, penetrating disease, and a history of abdominal surgery were associated with an increased risk of PC retention (p = 0.007, p = 0.011, and p = 0.033, respectively). pc 117-119 C-reactive protein Homo sapiens 7-10 32001615-6 2020 Those with the homozygous variant had low hs-CRP levels (0.2-0.8 mg/L), and those tested demonstrated sensitivity to sulfonylurea given at a low dose, completely transitioning off insulin. Sulfonylurea Compounds 117-129 C-reactive protein Homo sapiens 45-48 23314142-1 2013 INTRODUCTION: There are associations between serum magnesium level and some risk factors of cardiovascular disease and atherosclerosis, such as lipid profile, serum albumin, C-reactive protein, serum phosphorus, parathyroid hormone, and diabetes mellitus in hemodialysis patients. Magnesium 51-60 C-reactive protein Homo sapiens 174-192 31832494-11 2019 On multivariate analysis, there was an independent association between small-bowel PC retention and CRP levels >5 mg/dL (OR = 15.5; p = 0.03). pc 83-85 C-reactive protein Homo sapiens 100-103 31286545-8 2019 Furthermore, SDNN was significantly lower in patients developing ACLF compared to those with only decompensation (median 10 (IQR9-12) vs 16 (11-24); P = 0.02), and correlated inversely with MELD and Child-Pugh scores, and C-reactive protein (all P < 0.0001) and white cell count (P < 0.001). sdnn 13-17 C-reactive protein Homo sapiens 222-240 23690656-4 2013 However, the correlations of CRP and SAA with SDAI were stronger (respective values of 0.63 and 0.54, P < 0.001 for both). sdai 46-50 C-reactive protein Homo sapiens 29-32 22989353-7 2012 Atrovastatin treatment showed a reduction in PMNL priming, PMNL apoptosis, fibrinogen and CRP levels concomitant with decreased lipid levels. atrovastatin 0-12 C-reactive protein Homo sapiens 90-93 22926451-4 2012 Plasma neopterin levels were significantly higher among patients with endemic fluorosis when compared with control group (2.40 +- 0.66 vs. 1.63 +- 0.27 ng/mL respectively; p < 0.001) and plasma hs-CRP levels were also significantly higher among patients with endemic fluorosis when compared with control group (2.41 +- 1.23 vs. 1.93 +- 0.64 mg/L respectively; p < 0.001). Neopterin 7-16 C-reactive protein Homo sapiens 200-203 32327953-2 2020 The aim of this article was to demonstrate the effects of grape polyphenols on the selected inflammatory mediators, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-a), and high-sensitivity C-reactive protein (hs-CRP). Polyphenols 64-75 C-reactive protein Homo sapiens 227-230 31826315-6 2020 The synthetic procedure of POx BBBs can be further simplified by using SI-Cu0 CRP with POx molecular brush as macromonomer (Mn =536 g mol-1 , PDI=1.10), which results in BBBs surface up to 60 nm with well-defined molecular structure. bbbs 31-35 C-reactive protein Homo sapiens 78-81 31575499-8 2020 Multivariable logistic regression analyses for vancomycin-treated populations revealed that abnormal white blood cell count (odds ratio [OR] 4.34, 95% confidence interval [CI] 1.31-14.39) was a risk factor for clinical failure and that no therapeutic drug monitoring (OR 3.10, 95% CI 1.35-7.12) and abnormally high C-reactive protein level (OR 3.54, 95% CI 1.26-9.92) were risk factors for mortality. Vancomycin 47-57 C-reactive protein Homo sapiens 315-333 30721699-3 2019 Our objective in this meta-analysis was to conduct a systematic review and meta-analysis on randomized controlled trials to indicate ALA effects on serum inflammatory mediators concentration such as tumor necrosis factor-alpha (TNF-alpha), c-reactive protein (CRP), and interleukin-6 (IL-6). Thioctic Acid 133-136 C-reactive protein Homo sapiens 240-258 31997860-13 2020 Temporary clozapine PM status may occur during severe systemic infections/inflammations with fever and C-reactive protein (CRP) elevations. Clozapine 10-19 C-reactive protein Homo sapiens 103-121 31997860-13 2020 Temporary clozapine PM status may occur during severe systemic infections/inflammations with fever and C-reactive protein (CRP) elevations. Clozapine 10-19 C-reactive protein Homo sapiens 123-126 31434637-4 2019 RESULTS: In the larger study (N=207), a greater number of prior DMARDs (>2 vs 0-1) was associated with smaller improvements in DAS28(CRP) (-1.8 vs -2.2), SDAI (-22.1 vs -26.9) and HAQ-DI (-0.43 vs -0.64) from baseline to week 24. sdai 157-161 C-reactive protein Homo sapiens 136-139 22703865-8 2012 Reductions in heart rate (p < 0.0001) and C-reactive protein (p = 0.02) were associated with reduced baPWV and accounted for the association between weight loss and reduced baPWV. bapwv 104-109 C-reactive protein Homo sapiens 45-63 22703865-8 2012 Reductions in heart rate (p < 0.0001) and C-reactive protein (p = 0.02) were associated with reduced baPWV and accounted for the association between weight loss and reduced baPWV. bapwv 176-181 C-reactive protein Homo sapiens 45-63 22248365-10 2012 Stepwise multiple regression analysis showed that the plasma level of dehydroepiandrosterone is significantly correlated with the plasma levels of the activated protein C-protein C inhibitor complex (F = 18.06) and high-sensitivity C-reactive protein (F = 4.94). Dehydroepiandrosterone 70-92 C-reactive protein Homo sapiens 232-250 30721699-3 2019 Our objective in this meta-analysis was to conduct a systematic review and meta-analysis on randomized controlled trials to indicate ALA effects on serum inflammatory mediators concentration such as tumor necrosis factor-alpha (TNF-alpha), c-reactive protein (CRP), and interleukin-6 (IL-6). Thioctic Acid 133-136 C-reactive protein Homo sapiens 260-263 22555281-3 2012 With Gly-Pro-Cys triplets appended to both of its termini, designated CRP(cys), chemical cross-linking using heterobifunctional reagents generates CRP(cys)-XL, a potent, widely used, polymeric agonist for platelet Glycoprotein VI, whereas non-cross-linked, monomeric CRP(cys) antagonizes Glycoprotein VI. Gly-Pro-Cys 5-16 C-reactive protein Homo sapiens 70-73 31416753-10 2019 The combination of CRP value with the number of positive risk factors in the IMDC model might predict prognosis in patients with IMDC intermediate-risk treated with first-line axitinib. Axitinib 176-184 C-reactive protein Homo sapiens 19-22 30893301-10 2019 For CRP, we found significant increases in NO2 at lag1-3 days after-Asian game period and significant increases in PM10 at lag1-2 days. Nitrogen Dioxide 43-46 C-reactive protein Homo sapiens 4-7 22555281-3 2012 With Gly-Pro-Cys triplets appended to both of its termini, designated CRP(cys), chemical cross-linking using heterobifunctional reagents generates CRP(cys)-XL, a potent, widely used, polymeric agonist for platelet Glycoprotein VI, whereas non-cross-linked, monomeric CRP(cys) antagonizes Glycoprotein VI. Gly-Pro-Cys 5-16 C-reactive protein Homo sapiens 147-150 22555281-3 2012 With Gly-Pro-Cys triplets appended to both of its termini, designated CRP(cys), chemical cross-linking using heterobifunctional reagents generates CRP(cys)-XL, a potent, widely used, polymeric agonist for platelet Glycoprotein VI, whereas non-cross-linked, monomeric CRP(cys) antagonizes Glycoprotein VI. Gly-Pro-Cys 5-16 C-reactive protein Homo sapiens 147-150 29728047-1 2019 In this study, poly[2-methacryloyloxyethyl phosphorylcholine (MPC)]-protected Fe3O4 nanoparticles were prepared and used for the label-free specific detection and collection of an acute inflammation marker, C-reactive protein (CRP), in a simulated body fluid. 2-methacryloyloxyethyl phosphorylcholine 62-65 C-reactive protein Homo sapiens 207-225 29728047-1 2019 In this study, poly[2-methacryloyloxyethyl phosphorylcholine (MPC)]-protected Fe3O4 nanoparticles were prepared and used for the label-free specific detection and collection of an acute inflammation marker, C-reactive protein (CRP), in a simulated body fluid. 2-methacryloyloxyethyl phosphorylcholine 62-65 C-reactive protein Homo sapiens 227-230 31411090-0 2019 Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis. Ezetimibe 136-145 C-reactive protein Homo sapiens 57-60 31336542-8 2019 However, positive correlation of CRP levels with BMI, FBS and PPBS was observed. Polybrominated Biphenyls 62-66 C-reactive protein Homo sapiens 33-36 30459011-6 2019 We examined the negative predictive value (NPV) of CRP and ESR for IBI. BI 6727 67-70 C-reactive protein Homo sapiens 51-54 30459011-11 2019 CONCLUSIONS: In our cross-sectional study of febrile children, IBI was unlikely with either a normal CRP or ESR. BI 6727 63-66 C-reactive protein Homo sapiens 101-104 22417160-3 2012 We designed a graphene-based CRET platform for homogeneous immunoassay of C-reactive protein (CRP), a key marker for human inflammation and cardiovascular diseases, using a luminol/hydrogen peroxide chemiluminescence (CL) reaction catalyzed by horseradish peroxidase. Graphite 14-22 C-reactive protein Homo sapiens 74-92 22417160-3 2012 We designed a graphene-based CRET platform for homogeneous immunoassay of C-reactive protein (CRP), a key marker for human inflammation and cardiovascular diseases, using a luminol/hydrogen peroxide chemiluminescence (CL) reaction catalyzed by horseradish peroxidase. Graphite 14-22 C-reactive protein Homo sapiens 94-97 22417160-4 2012 According to our results, anti-CRP antibody conjugated to graphene nanosheets enabled the capture of CRP at the concentration above 1.6 ng mL(-1). Graphite 58-66 C-reactive protein Homo sapiens 31-34 22417160-4 2012 According to our results, anti-CRP antibody conjugated to graphene nanosheets enabled the capture of CRP at the concentration above 1.6 ng mL(-1). Graphite 58-66 C-reactive protein Homo sapiens 101-104 22417160-6 2012 The graphene-based CRET platform was successfully applied to the detection of CRP in human serum samples in the range observed during acute inflammatory stress. Graphite 4-12 C-reactive protein Homo sapiens 78-81 22353440-0 2012 Effects of telmisartan on C-reactive protein levels: a meta-analysis of randomized controlled trials. Telmisartan 11-22 C-reactive protein Homo sapiens 26-44 22105230-9 2012 The initial corticosteroid dose, the number and frequency of apheresis sessions, or the previous failure of thiopurines and/or infliximab did not influence the initial remission rate, but a greater decrease in CRP levels was associated with a higher probability to obtain initial remission. thiopurines 108-119 C-reactive protein Homo sapiens 210-213 30599763-4 2019 Cases of clozapine-induced myocarditis were defined as having elevated C-reactive protein (CRP) or detectable troponin and at least 1 sign or symptom of myocarditis, in the absence of alternative plausible aetiologies. Clozapine 9-18 C-reactive protein Homo sapiens 71-89 30599763-4 2019 Cases of clozapine-induced myocarditis were defined as having elevated C-reactive protein (CRP) or detectable troponin and at least 1 sign or symptom of myocarditis, in the absence of alternative plausible aetiologies. Clozapine 9-18 C-reactive protein Homo sapiens 91-94 32292723-9 2019 Conclusion: Ezetimibe co-administered with simvastatin (10 mg) and high-dose statin monotherapy may show similar effects in reducing LDL-C, TG, and hs-CRP levels and in increasing HDL-C levels. Ezetimibe 12-21 C-reactive protein Homo sapiens 151-154 31180164-0 2019 Dynamics of neutrophil and C-reactive protein reflect the clinical course of pyrexia during combination therapy with dabrafenib and trametinib. dabrafenib 117-127 C-reactive protein Homo sapiens 27-45 30412376-3 2018 In this study, inspired by the highly specific interaction between CRP and the cell membrane, an excellent anti-biofouling compound 2-(methacryloyloxy)ethyl phosphorylcholine and a highly hydrophilic crosslinker N, N"-methylenebisacrylamide were employed to fabricate a novel cell membrane biomimetic polymer for selective capture of CRP in the presence of calcium ions. 2-methacryloyloxyethyl phosphorylcholine 132-174 C-reactive protein Homo sapiens 67-70 30412376-3 2018 In this study, inspired by the highly specific interaction between CRP and the cell membrane, an excellent anti-biofouling compound 2-(methacryloyloxy)ethyl phosphorylcholine and a highly hydrophilic crosslinker N, N"-methylenebisacrylamide were employed to fabricate a novel cell membrane biomimetic polymer for selective capture of CRP in the presence of calcium ions. 2-methacryloyloxyethyl phosphorylcholine 132-174 C-reactive protein Homo sapiens 334-337 22364157-2 2012 Low magnesium intakes and blood levels have been associated with type 2 diabetes, metabolic syndrome, elevated C-reactive protein, hypertension, atherosclerotic vascular disease, sudden cardiac death, osteoporosis, migraine headache, asthma, and colon cancer. Magnesium 4-13 C-reactive protein Homo sapiens 111-129 30603640-13 2018 Interestingly, monotherapy with HCQ for three months significantly reduced PCSK9 and CRP levels in inactive SLE patients. Hydroxychloroquine 32-35 C-reactive protein Homo sapiens 85-88 21710244-7 2012 Additionally, we found that sex, smoking status, age, and c-reactive protein were related to urinary excretion of 8-oxoGuo and 8-oxodG in colorectal cancer patients. 8-ohdg 127-134 C-reactive protein Homo sapiens 58-76 30917461-9 2019 While the CRP level at postoperative day 1 in the TLDG group were lower than that of LADG group, no statistical difference was observed (P=0.072). tldg 50-54 C-reactive protein Homo sapiens 10-13 30690246-6 2019 Trans octadecenoic acid, and to a lesser extent palmitooleic and nervonic fatty acids were found in inverse correlation with the CRP increase. nervonic fatty acids 65-85 C-reactive protein Homo sapiens 129-132 30546347-6 2018 Results: Chromium supplementation led to a significant reduction in serum high sensitivity C-reactive protein (hs-CRP) (-1.4 +- 1.5 vs. + 0.2 +- 2.2 mg/L, p = 0.01) compared with the placebo. Chromium 9-17 C-reactive protein Homo sapiens 91-109 31024716-10 2019 Magnesium intake was negatively correlated with IR, C-reactive protein, and testosterone, but positively correlated with HDL cholesterol. Magnesium 0-9 C-reactive protein Homo sapiens 52-70 23166441-10 2012 Triglycerides, very low-density lipoprotein cholesterol, and high sensitivity C-reactive protein were reduced with both the once-weekly and twice-daily exenatide regimens (P < 0.05). Exenatide 152-161 C-reactive protein Homo sapiens 78-96 21980169-10 2011 Pretreatment of HAECs with sepiapterin or diethylenetriamine NONOate, both of which preserve nitric oxide (NO), resulted in attenuation of CRP"s effects on CECs and EMPs. sepiapterin 27-38 C-reactive protein Homo sapiens 139-142 21970714-7 2011 A positive correlation between 24S-OH-Chol/TC ratio and plasma C reactive protein (CRP) levels was found in the whole sample, independent of possible confounders (multiple regression p: 0.04; r2: 0.10). Technetium 43-45 C-reactive protein Homo sapiens 63-81 30363704-8 2018 There was significantly increased SAF in patients with psoriasis with elevated levels of C-reactive protein (CRP) and increased erythrocyte sedimentation rate (ESR) compared to controls (p < 0.00001; p < 0.00001, respectively, after adjustment to age). Safflower Oil 34-37 C-reactive protein Homo sapiens 89-107 21970714-7 2011 A positive correlation between 24S-OH-Chol/TC ratio and plasma C reactive protein (CRP) levels was found in the whole sample, independent of possible confounders (multiple regression p: 0.04; r2: 0.10). Technetium 43-45 C-reactive protein Homo sapiens 83-86 30712159-0 2019 An origami paper-based electrochemical immunoassay for the C-reactive protein using a screen-printed carbon electrode modified with graphene and gold nanoparticles. origami paper 3-16 C-reactive protein Homo sapiens 59-77 30712159-0 2019 An origami paper-based electrochemical immunoassay for the C-reactive protein using a screen-printed carbon electrode modified with graphene and gold nanoparticles. Graphite 132-140 C-reactive protein Homo sapiens 59-77 30712159-1 2019 An origami paper-based electrochemical immunoassay for C-reactive protein (CRP) detection is described. origami paper 3-16 C-reactive protein Homo sapiens 55-73 30712159-1 2019 An origami paper-based electrochemical immunoassay for C-reactive protein (CRP) detection is described. origami paper 3-16 C-reactive protein Homo sapiens 75-78 30712159-6 2019 CRP was quantified by measuring the changes in the charge-transfer resistance of the electrode by using hexacyanoferrate as the redox probe. hexacyanoferrate II 104-120 C-reactive protein Homo sapiens 0-3 21645507-6 2011 Only exenatide gave a decrease of BMI, insulin resistance parameters such as fasting plasma insulin, HOMA-IR, and adiponectin and a decrease of inflammatory parameters such as tumor necrosis factor-alpha, and high sensitivity-C reactive protein. Exenatide 5-14 C-reactive protein Homo sapiens 226-244 30363704-8 2018 There was significantly increased SAF in patients with psoriasis with elevated levels of C-reactive protein (CRP) and increased erythrocyte sedimentation rate (ESR) compared to controls (p < 0.00001; p < 0.00001, respectively, after adjustment to age). Safflower Oil 34-37 C-reactive protein Homo sapiens 109-112 30212947-0 2018 Effect of linezolid on serum PCT, ESR, and CRP in patients with pulmonary tuberculosis and pneumonia. Linezolid 10-19 C-reactive protein Homo sapiens 43-46 30212947-12 2018 CONCLUSION: In the treatment of tuberculosis and pneumonia, linezolid can improve serum PCT, ESR, and CRP levels, and eradicate bacteria. Linezolid 60-69 C-reactive protein Homo sapiens 102-105 22577451-6 2011 RESULTS: Dietary intakes of "choline"/"choline and betaine" were not significantly associated with CVD risk; however, the higher intakes of choline and betaine were associated with higher serum concentrations of CRP, IL-6 and TNF-alpha. Betaine 152-159 C-reactive protein Homo sapiens 212-215 21306304-4 2011 The arginine/ADMA ratio decreased significantly across increasing tertiles of CRP and MPO. N,N-dimethylarginine 13-17 C-reactive protein Homo sapiens 78-81 21427737-0 2011 Associations of obesity with triglycerides and C-reactive protein are attenuated in adults with high red blood cell eicosapentaenoic and docosahexaenoic acids. Docosahexaenoic Acids 137-158 C-reactive protein Homo sapiens 47-65 30119141-8 2019 In the multivariate analyses, the N-stage, and CRP/Alb ratio >= 0.1 were identified as independent predictive factors for OS in patients with AEG and UGC (P = 0.0061 and P = 0.0439, respectively). N-(2-aminoethyl)glycine 145-148 C-reactive protein Homo sapiens 47-50 30119141-9 2019 CONCLUSIONS: The CRP/Alb ratio was strongly associated with poor prognosis in patients who underwent surgery for AEG and UGC. N-(2-aminoethyl)glycine 113-116 C-reactive protein Homo sapiens 17-20 30680541-1 2019 A portion of this article was previously published as part of an article titled "Human C-reactive protein and the metabolic syndrome" in the following journal: Curr Opin Lipidol. opin 165-169 C-reactive protein Homo sapiens 87-105 30662999-1 2019 A portion of this article was previously published as part of an article titled "Human C-reactive protein and the metabolic syndrome" in the following journal: Curr Opin Lipidol. opin 165-169 C-reactive protein Homo sapiens 87-105 30182714-1 2018 In this work, we have designed an efficient and rapid surface-enhanced Raman spectroscopy (SERS) immunosensor for a supersensitive analysis of hypersensitive C-reactive protein (hs-CRP) with a label-free method by combining porous magnetic Ni@C nanospheres to aggregate together for simplifying the experiment operation and CaCO3 microcapsule to encapsulate rhodamine B as the Raman signal. Calcium Carbonate 324-329 C-reactive protein Homo sapiens 158-176 21414625-9 2011 Increased CRP levels were an independent predictor of both abnormal FMD and IMT after adjusting for age, systolic and diastolic BP and total cholesterol. Benzo(a)pyrene 128-130 C-reactive protein Homo sapiens 10-13 30276144-0 2018 Impact of Omega-3 Supplementation on High Sensitive C-Reactive Protein Level and 30-Day Major Adverse Cardiac Events After the Implementation of Coronary Stent in Patients with Chronic Kidney Disease: A Randomized Clinical Study. omega-3 10-17 C-reactive protein Homo sapiens 52-70 30113354-0 2018 The Role of C-Reactive Protein in Early Detection of Myocarditis Associated With Clozapine. Clozapine 81-90 C-reactive protein Homo sapiens 12-30 29288248-4 2018 Therefore, the objective of this study was to perform a systematic review and meta-analysis on controlled clinical trials (RCT) assessing the effects of CLA supplementation on the circulating inflammatory markers, including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha). Linoleic Acids, Conjugated 153-156 C-reactive protein Homo sapiens 224-242 29548760-12 2018 For asymptomatic patients receiving clozapine, testing could include baseline electrocardiography, echocardiography as part of a cardiac consultation if patients have cardiac disease or risk factors, and monitoring of C-reactive protein and troponin as indicated. Clozapine 36-45 C-reactive protein Homo sapiens 218-236 29554535-2 2018 This study is the first to analyze blood levels of the pro-inflammatory biomarker C-reactive protein (CRP) in bipolar disorder patients treated with the cyclooxygenase-2 inhibitor, celecoxib (CBX). Celecoxib 181-190 C-reactive protein Homo sapiens 82-100 29554535-2 2018 This study is the first to analyze blood levels of the pro-inflammatory biomarker C-reactive protein (CRP) in bipolar disorder patients treated with the cyclooxygenase-2 inhibitor, celecoxib (CBX). Celecoxib 181-190 C-reactive protein Homo sapiens 102-105 20949557-7 2011 The CRP rs1205 AA genotype also was associated with an increased risk of CIMP+ rectal tumors (OR 2.5, 95%CI 1.2-5.3); conversely, the rs1417938 A allele was associated with a reduced risk of CIMP+ rectal tumors (OR 0.5, 95%CI 0.3-0.9). Cyclic IMP 73-77 C-reactive protein Homo sapiens 4-7 20841306-1 2011 OBJECTIVE: To determine (1) whether long-term treatment with exenatide is associated with reductions in C-reactive protein (CRP), systolic blood pressure (BP), and triglyceride concentrations in addition to reductions in body weight and hemoglobin A(1c) (A1C) levels and (2) whether these beneficial results persist without any loss of effect while exenatide is being used, and whether they reverse after its cessation. Exenatide 61-70 C-reactive protein Homo sapiens 104-122 20841306-1 2011 OBJECTIVE: To determine (1) whether long-term treatment with exenatide is associated with reductions in C-reactive protein (CRP), systolic blood pressure (BP), and triglyceride concentrations in addition to reductions in body weight and hemoglobin A(1c) (A1C) levels and (2) whether these beneficial results persist without any loss of effect while exenatide is being used, and whether they reverse after its cessation. Exenatide 61-70 C-reactive protein Homo sapiens 124-127 20841306-5 2011 Exenatide treatment reduced their mean weight by 7 kg, systolic BP by 8 mm Hg, triglycerides by 52 mg/dL, A1C by 1.3%, and CRP by 2.4 mg/L (P<.05 for all). Exenatide 0-9 C-reactive protein Homo sapiens 123-126 20841306-9 2011 CONCLUSION: Exenatide treatment in patients with type 2 diabetes has durable and persistent beneficial effects on A1C, weight, CRP, systolic BP, and triglyceride concentrations. Exenatide 12-21 C-reactive protein Homo sapiens 127-130 29288248-8 2018 Findings suggested that CLA supplementation increased blood levels of CRP by 0.89 mg/l (95% CI: 0.11, 1.68; P = 0.025) and TNF-alpha levels by 0.39 pg/ml (95% CI: 0.23, 0.55; P < 0.0001). Linoleic Acids, Conjugated 24-27 C-reactive protein Homo sapiens 70-73 20682616-5 2011 Cross-sectionally, higher C-reactive protein (CRP) levels correlated with lower levels of total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), and high-density lipoprotein-cholesterol ([HDL-C] P <= .015), whereas lipid ratios did not correlate with CRP. Technetium 109-111 C-reactive protein Homo sapiens 26-44 29288248-11 2018 CONCLUSIONS: This meta-analysis showed that CLA supplementation may increase inflammatory markers (CRP and TNF-alpha). Linoleic Acids, Conjugated 44-47 C-reactive protein Homo sapiens 99-102 20682616-5 2011 Cross-sectionally, higher C-reactive protein (CRP) levels correlated with lower levels of total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), and high-density lipoprotein-cholesterol ([HDL-C] P <= .015), whereas lipid ratios did not correlate with CRP. Technetium 109-111 C-reactive protein Homo sapiens 46-49 30002686-0 2018 Effect of magnesium supplements on serum C-reactive protein: a systematic review and meta-analysis. Magnesium 10-19 C-reactive protein Homo sapiens 41-59 29930690-8 2018 Conclusion: In summary, the current meta-analysis demonstrated the promising impact of ALA administration on decreasing inflammatory markers such as CRP, IL-6 and TNF-alpha among patients with MetS and related disorders. Thioctic Acid 87-90 C-reactive protein Homo sapiens 149-152 30002686-1 2018 Introduction: The aim of the study was to undertake a systematic review and meta-analysis of prospective studies to determine the effect of magnesium (Mg) supplementation on C-reactive protein (CRP). Magnesium 140-149 C-reactive protein Homo sapiens 174-192 30002686-1 2018 Introduction: The aim of the study was to undertake a systematic review and meta-analysis of prospective studies to determine the effect of magnesium (Mg) supplementation on C-reactive protein (CRP). Magnesium 140-149 C-reactive protein Homo sapiens 194-197 30002686-1 2018 Introduction: The aim of the study was to undertake a systematic review and meta-analysis of prospective studies to determine the effect of magnesium (Mg) supplementation on C-reactive protein (CRP). Magnesium 151-153 C-reactive protein Homo sapiens 174-192 30002686-1 2018 Introduction: The aim of the study was to undertake a systematic review and meta-analysis of prospective studies to determine the effect of magnesium (Mg) supplementation on C-reactive protein (CRP). Magnesium 151-153 C-reactive protein Homo sapiens 194-197 30002686-4 2018 Eligibility criteria: Randomized controlled trials evaluating the impact of Mg supplementation on CRP. Magnesium 76-78 C-reactive protein Homo sapiens 98-101 30002686-8 2018 Main outcome: Level of CRP after Mg supplementation. Magnesium 33-35 C-reactive protein Homo sapiens 23-26 30002686-14 2018 Conclusions: This meta-analysis suggests that Mg supplementation significantly reduces serum CRP level. Magnesium 46-48 C-reactive protein Homo sapiens 93-96 29573355-9 2018 CONCLUSIONS: Our findings indicate an association of plasma neopterin with risk of an inpatient hospital diagnosis of AF, which remains after adjustment for traditional risk factors as well as for CRP. Neopterin 60-69 C-reactive protein Homo sapiens 197-200 21242686-9 2011 A significant reduction in plasma CRP and IL-6 levels was observed in the Vit E PS group: CRP from 6.7 +- 4.8 to 4.8 +- 2.2 mg/l (p < 0.001) and IL-6 from 12.1 +- 1.4 to 7.5 +- 0.4 pg/ml (p < 0.05). vit 74-77 C-reactive protein Homo sapiens 34-37 21242686-9 2011 A significant reduction in plasma CRP and IL-6 levels was observed in the Vit E PS group: CRP from 6.7 +- 4.8 to 4.8 +- 2.2 mg/l (p < 0.001) and IL-6 from 12.1 +- 1.4 to 7.5 +- 0.4 pg/ml (p < 0.05). vit 74-77 C-reactive protein Homo sapiens 90-93 21325823-6 2011 AT(1) receptor blocker losartan blocked Ang II -induced CRP expression in mRNA and protein levels in U937 macrophages. Losartan 23-31 C-reactive protein Homo sapiens 56-59 19004529-6 2010 Only in the highest tertile of CRP, higher homocysteine was negatively associated with retention. Homocysteine 43-55 C-reactive protein Homo sapiens 31-34 19004529-8 2010 Both in the lower and middle tertile of CRP, higher homocysteine was associated with a faster rate of decline in information processing speed. Homocysteine 52-64 C-reactive protein Homo sapiens 40-43 29096935-16 2018 At 1st follow-up, CR (ITAS2010 = 0, CRP < 6mg/L and non-progressive disease on angiography) was observed in 173 (68.9%), partial response (PR) in 42 (16.7%) and no response was seen in only 36 (14%) patients. Chromium 18-20 C-reactive protein Homo sapiens 36-39 20395894-9 2010 ADMA levels were related to the total Sequential Organ Failure Assessment (SOFA) scores and arginine levels, and inversely related to IL-6 and CRP levels. N,N-dimethylarginine 0-4 C-reactive protein Homo sapiens 143-146 29618771-0 2018 Small molecule detection with aptamer based lateral flow assays: Applying aptamer-C-reactive protein cross-recognition for ampicillin detection. Ampicillin 123-133 C-reactive protein Homo sapiens 82-100 29618771-5 2018 We report the first cross-recognition of a small molecule (ampicillin) and a protein (C-reactive protein), predicted by in-silico analysis, then experimentally confirmed - using two different aptamers. Ampicillin 59-69 C-reactive protein Homo sapiens 86-104 29641780-10 2018 Increase and reduction of selenium occurred both in patients with high CRP and in those presenting normalization of this parameter. Selenium 26-34 C-reactive protein Homo sapiens 71-74 29707329-6 2018 Intraoperative blood loss, postoperative length of stay, and C-reactive protein value on postoperative day 1 were significantly more favorable in the MTXA group than the Sternotomy group (P<0.0001, P=0.0040 and P=0.0073, respectively). mtxa 150-154 C-reactive protein Homo sapiens 61-79 28984014-0 2018 Increased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis. Tolvaptan 110-119 C-reactive protein Homo sapiens 16-34 29362264-6 2018 PRIMARY OUTCOME MEASURES: C-reactive protein (CRP), total cholesterol (TC), LDL cholesterol (LDL-C), HDL-cholesterol (HDL-C), triglycerides (TGL), systolic and diastolic blood pressure (SBP and DBP), body mass index (BMI) and waist circumference (WC). Technetium 10-12 C-reactive protein Homo sapiens 26-44 29353502-9 2018 Statins and statin-ezetimibe combination, besides lipid modulation, have an anti-inflammatory effect proved by C-reactive protein level reduction. Ezetimibe 19-28 C-reactive protein Homo sapiens 111-129 20159819-6 2010 RESULTS: At least 94% of patients receiving cytarabine-based therapy and surviving for more than 3 or 5 years achieved a CR with either initial or salvage therapy; limited data suggest the same for patients receiving initial therapies that did not contain cytarabine. Cytarabine 44-54 C-reactive protein Homo sapiens 121-123 21516735-5 2010 RESULTS: The lornoxicam group exhibited a significant reduction in CRP and a decrease in IL-6. lornoxicam 13-23 C-reactive protein Homo sapiens 67-70 28984014-10 2018 On univariate analyses, serum C-reactive protein (CRP) level, the neutrophil-to-lymphocyte ratio, urinary blood urea nitrogen, and urinary AQP2 were predictors of the TVP response, with only serum CRP retained on multivariate analysis. Tolvaptan 167-170 C-reactive protein Homo sapiens 30-48 20364676-4 2010 It is concluded that elderly patients with CCI develop more pronounced inflammatory reaction manifest as elevated C-reactive protein level, activated cytokine system, and endothelial dysfunction due to a longer history of the disease, higher frequency of ischemic etiology of CCI, and impaired NO-production in endothelium. CCI 43-46 C-reactive protein Homo sapiens 114-132 28881893-3 2017 However, the role of CRP/Alb ratio for those with neoadjuvant chemotherapy (NAC) and the changes of CRP/Alb ratio around NAC have never been discussed. nac 76-79 C-reactive protein Homo sapiens 21-24 29558346-4 2018 The efficacy of RS was measured subjectively by the patient, physically by the physician and with the help of chosen scores (DAS28), questionnaires (HAQ), laboratory parameters [ESR, level of CRP, osteoprotegerin (OPG), serum amyloid A (SAA), hialuronic acid (HA)] and three-phase bone scintigraphy of affected knee joints. rs 16-18 C-reactive protein Homo sapiens 192-195 19581389-11 2009 Patients with a greater decrease in C-reactive protein (CRP) had higher average steady-state plasma A77 1726 concentrations: 49.7 +/- 39.0 mg/l in patients with DeltaCRP of more than 8.5 mg/l compared with 24.8 +/- 13.7 mg/l in patients with DeltaCRP of <or=8.5 mg/l (p = 0.015). deltacrp 161-169 C-reactive protein Homo sapiens 36-54 19581389-11 2009 Patients with a greater decrease in C-reactive protein (CRP) had higher average steady-state plasma A77 1726 concentrations: 49.7 +/- 39.0 mg/l in patients with DeltaCRP of more than 8.5 mg/l compared with 24.8 +/- 13.7 mg/l in patients with DeltaCRP of <or=8.5 mg/l (p = 0.015). deltacrp 161-169 C-reactive protein Homo sapiens 56-59 29212102-1 2017 A 24-year old woman with a history of Crohn"s disease developed bloody diarrhea and multiple abdominal abscesses, daily fever, leukocytosis, and elevated CRP several months after her immunosuppressive therapy with azathioprine was stopped. Azathioprine 214-226 C-reactive protein Homo sapiens 154-157 28965605-8 2017 Significant effects were observed for serum CRP (SMD=-0.48; 95% CI, -0.96 to 0; p=0.049) and GSH-PX (SMD=0.5; 95% CI, 0.36-0.64; p<0.001) after selenium supplementation. Selenium 147-155 C-reactive protein Homo sapiens 44-47 28986547-7 2017 Consistently, plasma magnesium was inversely correlated with plasma hs-CRP in our subsample analysis; the geometric mean hs-CRP concentration for ascending quartiles of plasma magnesium were 1.29 (1.06-1.57), 1.16 (0.95-1.41), 1.00 (0.81-1.22), and 0.71 (0.58-0.88) mg/l. Magnesium 21-30 C-reactive protein Homo sapiens 71-74 28986547-7 2017 Consistently, plasma magnesium was inversely correlated with plasma hs-CRP in our subsample analysis; the geometric mean hs-CRP concentration for ascending quartiles of plasma magnesium were 1.29 (1.06-1.57), 1.16 (0.95-1.41), 1.00 (0.81-1.22), and 0.71 (0.58-0.88) mg/l. Magnesium 21-30 C-reactive protein Homo sapiens 124-127 19852909-8 2009 More patients in the group ezetimibe plus statin achieved the combined target lipid control and CRP<3 mg/l (19% vs. 3%, p=0.002). Ezetimibe 27-36 C-reactive protein Homo sapiens 96-99 19852909-9 2009 DISCUSSION: Combination treatment of ezetimibe with statins on high coronary risk patients showed a better achievement of LDL-cholesterol goals with a reduction of CRP values. Ezetimibe 37-46 C-reactive protein Homo sapiens 164-167 19541503-13 2009 CONCLUSIONS: Unsaturated fat supplementation increased total dietary energy intake to recommended levels, had no adverse impact on blood lipids, improved nutritional status as assessed according to dry body weight, and reduced systemic inflammation as assessed according to C-reactive protein serum concentrations. Fats, Unsaturated 13-28 C-reactive protein Homo sapiens 274-292 19185299-4 2009 METHODS: Cross-sectional associations of C-reactive protein (CRP) and Interleukin-6 (Il-6) with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EHA) were evaluated in multivariable linear regression models adjusted for demographics, cardiovascular risk factors, medication use, exercise capacity, body-mass index, and waist-to-hip ratio. Docosahexaenoic Acids 96-116 C-reactive protein Homo sapiens 41-59 19185299-4 2009 METHODS: Cross-sectional associations of C-reactive protein (CRP) and Interleukin-6 (Il-6) with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EHA) were evaluated in multivariable linear regression models adjusted for demographics, cardiovascular risk factors, medication use, exercise capacity, body-mass index, and waist-to-hip ratio. Docosahexaenoic Acids 118-121 C-reactive protein Homo sapiens 41-59 19185299-4 2009 METHODS: Cross-sectional associations of C-reactive protein (CRP) and Interleukin-6 (Il-6) with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EHA) were evaluated in multivariable linear regression models adjusted for demographics, cardiovascular risk factors, medication use, exercise capacity, body-mass index, and waist-to-hip ratio. Docosahexaenoic Acids 118-121 C-reactive protein Homo sapiens 61-64 19185299-4 2009 METHODS: Cross-sectional associations of C-reactive protein (CRP) and Interleukin-6 (Il-6) with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EHA) were evaluated in multivariable linear regression models adjusted for demographics, cardiovascular risk factors, medication use, exercise capacity, body-mass index, and waist-to-hip ratio. eha 150-153 C-reactive protein Homo sapiens 41-59 19185299-4 2009 METHODS: Cross-sectional associations of C-reactive protein (CRP) and Interleukin-6 (Il-6) with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EHA) were evaluated in multivariable linear regression models adjusted for demographics, cardiovascular risk factors, medication use, exercise capacity, body-mass index, and waist-to-hip ratio. eha 150-153 C-reactive protein Homo sapiens 61-64 28986547-7 2017 Consistently, plasma magnesium was inversely correlated with plasma hs-CRP in our subsample analysis; the geometric mean hs-CRP concentration for ascending quartiles of plasma magnesium were 1.29 (1.06-1.57), 1.16 (0.95-1.41), 1.00 (0.81-1.22), and 0.71 (0.58-0.88) mg/l. Magnesium 176-185 C-reactive protein Homo sapiens 124-127 28868218-3 2017 This study aims to improve the secretion of recombinant CRP by Pichia pastoris via optimizing signal peptides, promoters and carbon sources. Peptides 101-109 C-reactive protein Homo sapiens 56-59 28868218-9 2017 The expression of CRP with the alpha-MF driven by the pGAP gave the highest yield of secreted CRP, about 3 mg/l of culture on the optimized culture conditions. pgap 54-58 C-reactive protein Homo sapiens 18-21 28868218-9 2017 The expression of CRP with the alpha-MF driven by the pGAP gave the highest yield of secreted CRP, about 3 mg/l of culture on the optimized culture conditions. pgap 54-58 C-reactive protein Homo sapiens 94-97 29202548-8 2017 A significant positive correlation was also revealed between TCA and CRP (r=0.324, P=0.030), but no significant association was found between other parameters. Trichloroacetic Acid 61-64 C-reactive protein Homo sapiens 69-72 19185299-5 2009 RESULTS: After multivariable adjustment, n-3 fatty acid levels (DHA+EPA) were inversely associated with CRP and IL-6. Docosahexaenoic Acids 64-67 C-reactive protein Homo sapiens 104-107 28965605-10 2017 CONCLUSION: Selenium supplementation decreased serum CRP and increased the GSH-PX level, suggesting a positive effect on reducing oxidative stress and inflammation in CHD. Selenium 12-20 C-reactive protein Homo sapiens 53-56 28646711-8 2017 In the high CRP (> 2322ng/mL) group, patients in the VPA + memantine arm had a significantly decreased in their CRP (p= 0.009), total cholesterol (p= 0.002), LDL (p= 0.002) levels, BMI (p= 0.001), and waist circumference (p< 0.001), compared to those in the VPA + placebo arm. Valproic Acid 56-59 C-reactive protein Homo sapiens 12-15 19387251-8 2009 CONCLUSION: The combination of elevated CRP and cTnI increased the risk of adverse cardiac events, demonstrating the additive impacts of active inflammation and myocardial injury on prognosis after SES implantation. ses 198-201 C-reactive protein Homo sapiens 40-43 28646711-8 2017 In the high CRP (> 2322ng/mL) group, patients in the VPA + memantine arm had a significantly decreased in their CRP (p= 0.009), total cholesterol (p= 0.002), LDL (p= 0.002) levels, BMI (p= 0.001), and waist circumference (p< 0.001), compared to those in the VPA + placebo arm. Valproic Acid 56-59 C-reactive protein Homo sapiens 115-118 19425005-5 2009 PC bound to CRP in the presence of metal ions Ca(2+) and Mg(2+). Magnesium 57-59 C-reactive protein Homo sapiens 12-15 28271327-8 2017 Above the hypoxia threshold (CT90 >= 10%) of CRP, MPV increased significantly and the presence of WMH increased twofold. 1-methyl-1H-1,2,3-triazole 101-104 C-reactive protein Homo sapiens 48-51 28302952-7 2017 RESULTS: In the pravastatin treatment group, Hs-CRP levels (median 711 microg/L, IQR 344-1500) significantly decreased 2 months later (median 592 microg/L, IQR 301-1390), and they remained significantly lower until the end of the study. Pravastatin 16-27 C-reactive protein Homo sapiens 48-51 28832630-0 2017 Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D. BACKGROUND: The systemic inflammation is associated with clinical outcome and mortality in chronic obstructive pulmonary disease (COPD) patients. Budesonide 25-35 C-reactive protein Homo sapiens 70-73 18401567-10 2009 There was no significant difference between CAD(+) and CAD(-) subjects in absolute frequencies for CRP -717A/G gene variant, but multivariate analysis showed that carriers of the rarer G allele had significantly higher CRP plasma concentrations in CAD(-) subjects (P = 0.031) and higher homocysteine concentrations in CAD(+) group (P < 0.001). Homocysteine 287-299 C-reactive protein Homo sapiens 219-222 28302952-9 2017 The reduction of Hs-CRP levels from the baseline to 2 months in the pravastatin group was statistically significant compared with the control (p=0.007). Pravastatin 68-79 C-reactive protein Homo sapiens 20-23 28302952-12 2017 CONCLUSION: In non-cardiogenic ischemic stroke, pravastatin treatment may reduce vascular inflammation as assessed by Hs-CRP, and higher Hs-CRP levels appeared to increase the risk of recurrent stroke and vascular events. Pravastatin 48-59 C-reactive protein Homo sapiens 121-124 28456849-8 2017 We found CRP >40 mg/L in 58% CA and 37% SA (p < 0.0001), and WBC >15 x 109/L in 58% CA and 43% SA (p < 0.0001). sa 43-45 C-reactive protein Homo sapiens 9-12 28431362-5 2017 RNA aptamers, which were specific recognized to CRP, were assembled on the surface of Au NPs modified electrode via gold-sulfur affinity. Sulfur 121-127 C-reactive protein Homo sapiens 48-51 18584186-0 2009 Short-term effect of tibolone on C-reactive protein in hypertensive postmenopausal women. tibolone 21-29 C-reactive protein Homo sapiens 33-51 18584186-1 2009 OBJECTIVE: To evaluate the effects of tibolone on the serum C-reactive protein (CRP) in hypertensive postmenopausal women. tibolone 38-46 C-reactive protein Homo sapiens 60-78 28846677-7 2017 Compared to the normal lung function group, patients with SAD and without AL had lower spirometric values, poorer quality of life and higher levels of C-reactive protein (CRP), as well as increased cardiovascular risk and more vascular age. Aluminum 74-76 C-reactive protein Homo sapiens 151-169 18584186-1 2009 OBJECTIVE: To evaluate the effects of tibolone on the serum C-reactive protein (CRP) in hypertensive postmenopausal women. tibolone 38-46 C-reactive protein Homo sapiens 80-83 18584186-9 2009 A significant increase in CRP values was observed in the tibolone group (p=0.001). tibolone 57-65 C-reactive protein Homo sapiens 26-29 18584186-10 2009 CONCLUSION: This trial demonstrated that tibolone treatment induced a significant increase in CRP and a significant decrease in total cholesterol in postmenopausal hypertensive women. tibolone 41-49 C-reactive protein Homo sapiens 94-97 19112166-7 2009 Rimonabant 20 mg produced significantly greater changes from baseline versus placebo in HDL-C (+7.4%) and TG levels (-18%; P<0.0001), as well as low-density lipoprotein (LDL) and HDL particle sizes, apolipoprotein A1 and B, HDL2, HDL3, C-reactive protein, and adiponectin levels (all P<0.05). Rimonabant 0-10 C-reactive protein Homo sapiens 239-257 19328934-6 2009 A correlation between plasma CRP concentration and BAL interleukin levels was present at discharge (IL-6 and IL-8) and at 6 months (IL-8) after LTx. Leukotriene C4 144-147 C-reactive protein Homo sapiens 29-32 27230223-9 2017 Patients with KSS had higher values of C-reactive protein (p = 0.005), lower hemoglobin levels (p = 0.003); more frequent hyponatremia (p = 0.004), hypoalbuminemia (p = 0.004), and coagulopathy (p = 0.003); and increase in cardiac troponins (p = 0.000). KSS 14-17 C-reactive protein Homo sapiens 39-57 27566957-2 2016 CRP outperformed the EB method in estimating collision frequencies in selected high collision concentration locations (HCCLs). hccls 119-124 C-reactive protein Homo sapiens 0-3 19035968-7 2009 Docosapentaenoic acid was the only polyunsaturated n-3 FA that was correlated to CRP in both groups. docosapentaenoic acid 0-21 C-reactive protein Homo sapiens 81-84 28846677-7 2017 Compared to the normal lung function group, patients with SAD and without AL had lower spirometric values, poorer quality of life and higher levels of C-reactive protein (CRP), as well as increased cardiovascular risk and more vascular age. Aluminum 74-76 C-reactive protein Homo sapiens 171-174 28702667-8 2017 Furthermore, MPTCs secreted higher levels of pro-inflammatory interleukin-6 (IL-6) cytokine and C-reactive protein (CRP) than MPCCs. mptcs 13-18 C-reactive protein Homo sapiens 96-114 19146796-6 2009 Blood pressure, cholesterol levels, C-reactive protein, and insulin resistance may improve in patients treated with exenatide. Exenatide 116-125 C-reactive protein Homo sapiens 36-54 28122441-2 2016 The IPI was calculatedas C-reactive protein x NLR (neutrophil/ lymphocyte ratio)/serum albumin. diprotin A 4-7 C-reactive protein Homo sapiens 25-43 28702667-8 2017 Furthermore, MPTCs secreted higher levels of pro-inflammatory interleukin-6 (IL-6) cytokine and C-reactive protein (CRP) than MPCCs. mptcs 13-18 C-reactive protein Homo sapiens 116-119 27289003-6 2016 RESULTS: After adjustment for age, C-reactive protein, and creatinine, high homocysteine levels were associated with cardiovascular events [hazard ratio (HR) 1.23 per standard deviation (SD); 95% confidence interval (CI): 1.03-1.47], MI (HR 1.38 per SD; 95% CI: 1.03-1.85), and all-cause mortality (HR 1.41 per SD; 95% CI: 1.19-1.68). Homocysteine 76-88 C-reactive protein Homo sapiens 35-53 27395328-10 2017 A plant-sourced pattern (beta-carotene, vitamin A, lutein and zeaxanthin) was inversely associated with CRP (p for trend across quartiles 0.005). beta Carotene 25-38 C-reactive protein Homo sapiens 104-107 28404545-5 2017 Doxepin was partially effective by impairment of CRP-dependent IP3 production. Inositol 1,4,5-Trisphosphate 63-66 C-reactive protein Homo sapiens 49-52 27512972-8 2016 Pentoxifylline treatment was associated with a significant reduction in plasma concentrations of TNF-alpha (WDF: -1.03 pg/ml, 95% CI: -1.54, -0.51; P < 0.001, 11 treatment arms) and CRP (WDF: -1.39 mg/l, 95% CI: -2.68, -0.10; P = 0.034, five treatment arms). Pentoxifylline 0-14 C-reactive protein Homo sapiens 185-188 27512972-11 2016 CONCLUSION: Pentoxifylline did not alter BP or plasma IL-6 concentration, but significantly reduced circulating TNF-alpha and CRP concentrations. Pentoxifylline 12-26 C-reactive protein Homo sapiens 126-129 27209579-7 2016 The SERS spectra showed distinct peaks for tags corresponding to three typical sepsis-specific biomarkers for diagnostics with the limit of detection values of 27 pM, 103 pM, and 78 pM for C-reactive protein (CRP), procalcitonin (PCT), and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), respectively. sers 4-8 C-reactive protein Homo sapiens 189-207 27209579-7 2016 The SERS spectra showed distinct peaks for tags corresponding to three typical sepsis-specific biomarkers for diagnostics with the limit of detection values of 27 pM, 103 pM, and 78 pM for C-reactive protein (CRP), procalcitonin (PCT), and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), respectively. sers 4-8 C-reactive protein Homo sapiens 209-212 28242268-8 2017 Circulating Gla17/tOCN levels correlated negatively with insulin sensitivity assessed by hyperinsulinemic-euglyceamic clamp (P=0.02) or insulin sensitivity index derived from oral glucose tolerance test (P=0.00003), and positively with insulin resistance assessed by HOMA-IR (P=0.0005) and with markers of subclinical inflammation and liver enzymes, including C-reactive protein (CRP; P=0.007) and aspartate aminotransferase (AST; P=0.009). gla17 12-17 C-reactive protein Homo sapiens 360-378 26857805-6 2016 The subjects with a serum hs-CRP >3 mg/dl had higher TC (P < 0.001), low-density lipoprotein cholesterol (LDL-C, P < 0.001), TG (P < 0.001), fat percentage (P < 0.001), and systolic and diastolic blood pressure (P < 0.001) compared with subjects with a serum hs-CRP <3 mg/dl. Technetium 56-58 C-reactive protein Homo sapiens 29-32 27007740-6 2016 Both the amide I and II bands, due to the polypeptide binder and CRP, were clearly observed in ATR-FTIR spectra. Amides 9-14 C-reactive protein Homo sapiens 65-68 27007740-7 2016 CRP amide I bands were extracted from difference spectra and yielded bands that agreed well with the reported amide I band of free (non-bonded) CRP in solution. Amides 4-9 C-reactive protein Homo sapiens 0-3 27007740-7 2016 CRP amide I bands were extracted from difference spectra and yielded bands that agreed well with the reported amide I band of free (non-bonded) CRP in solution. Amides 4-9 C-reactive protein Homo sapiens 144-147 27007740-7 2016 CRP amide I bands were extracted from difference spectra and yielded bands that agreed well with the reported amide I band of free (non-bonded) CRP in solution. Amides 110-115 C-reactive protein Homo sapiens 0-3 27007740-7 2016 CRP amide I bands were extracted from difference spectra and yielded bands that agreed well with the reported amide I band of free (non-bonded) CRP in solution. Amides 110-115 C-reactive protein Homo sapiens 144-147 27107066-9 2016 There was a significant inverse correlation between the individual values of the plasma hs-CRP and 8-OHdG in patients with benign disease and cancer (r=-0.40, p=0.02). 8-ohdg 99-105 C-reactive protein Homo sapiens 91-94 27107066-12 2016 A new finding with possible clinical relevance is a significant inverse correlation between the individual plasma values of the hs-CRP and 8-OHdG in patients with benign disease and cancer. 8-ohdg 139-145 C-reactive protein Homo sapiens 131-134 26032842-2 2016 OBJECTIVES: The aim of this study was to find out whether elevated serum levels (>=5 mg/l) of C-reactive protein (CRP), an established laboratory marker of infection and inflammation, are associated with increased serum concentrations of the atypical antipsychotic drugs clozapine, quetiapine, and risperidone. Clozapine 274-283 C-reactive protein Homo sapiens 97-115 26032842-2 2016 OBJECTIVES: The aim of this study was to find out whether elevated serum levels (>=5 mg/l) of C-reactive protein (CRP), an established laboratory marker of infection and inflammation, are associated with increased serum concentrations of the atypical antipsychotic drugs clozapine, quetiapine, and risperidone. Clozapine 274-283 C-reactive protein Homo sapiens 117-120 26032842-10 2016 CONCLUSIONS: In patients who exhibit signs of inflammation or infection with increased C-reactive protein values during psychopharmacological treatment, especially under clozapine and risperidone, therapeutic drug monitoring is recommendable in order to minimize the risk of intoxications due to elevated drug concentrations. Clozapine 170-179 C-reactive protein Homo sapiens 87-105 27965189-2 2016 This exploratory study examined whether, and to what extent, plasma magnesium is related to C-reactive protein (CRP) levels and cortisolaemia in MDD. Magnesium 68-77 C-reactive protein Homo sapiens 92-110 27965189-2 2016 This exploratory study examined whether, and to what extent, plasma magnesium is related to C-reactive protein (CRP) levels and cortisolaemia in MDD. Magnesium 68-77 C-reactive protein Homo sapiens 112-115 27965189-7 2016 A significant negative correlation was seen between magnesium and CRP in MDD (p<0.01), whereas no correlation was found in controls. Magnesium 52-61 C-reactive protein Homo sapiens 66-69 26523504-1 2016 For label-free and direct detection of C-reactive protein (CRP), an impedimetric sensor based on an indium tin oxide (ITO) electrode array functionalized with reduced graphene oxide-nanoparticle (rGO-NP) hybrid was fabricated and evaluated. graphene oxide 167-181 C-reactive protein Homo sapiens 59-62 26523504-3 2016 Impedimetric measurements in the presence of the redox couple [Fe(CN)6](3-/4-) showed significant changes in charge transfer resistance upon binding of CRP. fe(cn)6 63-70 C-reactive protein Homo sapiens 152-155 26919511-0 2016 Pre-Treatment Serum C-Reactive Protein Level Is An Independent Risk Factor for Development of Nephrotoxicity in Patients Receiving High-Dose Vancomycin. Vancomycin 141-151 C-reactive protein Homo sapiens 20-38 26919511-3 2016 In this study, we evaluated the pre-treatment serum CRP level as a risk factor of the development of nephrotoxicity in patients receiving high total daily doses (>2.5 g) of vancomycin. Vancomycin 176-186 C-reactive protein Homo sapiens 52-55 26919511-5 2016 Univariate analyses showed that patients who developed nephrotoxicity during vancomycin treatment had significantly higher median vancomycin serum concentration, duration of vancomycin treatment, and the serum CRP level within 24 h before vancomycin treatment than the non-nephrotoxicity group. Vancomycin 77-87 C-reactive protein Homo sapiens 210-213 26919511-6 2016 Multivariate logistic regression analysis showed that after adjustment for potential confounders, median vancomycin serum concentration, duration of treatment, serum CRP level within 24 h before vancomycin treatment, and nephrotoxic medication were found significantly associated with the development of nephrotoxicity. Vancomycin 195-205 C-reactive protein Homo sapiens 166-169 26919511-8 2016 In conclusion, this study provides the first evidence supporting the fact that the serum CRP level within 24 h before vancomycin treatment is an independent risk factor for the development of nephrotoxicity in patients receiving total daily doses of >2.5 g of vancomycin. Vancomycin 118-128 C-reactive protein Homo sapiens 89-92 26919511-8 2016 In conclusion, this study provides the first evidence supporting the fact that the serum CRP level within 24 h before vancomycin treatment is an independent risk factor for the development of nephrotoxicity in patients receiving total daily doses of >2.5 g of vancomycin. Vancomycin 263-273 C-reactive protein Homo sapiens 89-92 26919511-9 2016 Therefore, the serum CRP level within 24 h before vancomycin treatment could be a potential biomarker or prognostic factor for the development of vancomycin nephrotoxicity. Vancomycin 50-60 C-reactive protein Homo sapiens 21-24 26919511-9 2016 Therefore, the serum CRP level within 24 h before vancomycin treatment could be a potential biomarker or prognostic factor for the development of vancomycin nephrotoxicity. Vancomycin 146-156 C-reactive protein Homo sapiens 21-24 25982004-0 2015 Magnesium Status and Its Relationship with C-Reactive Protein in Obese Women. Magnesium 0-9 C-reactive protein Homo sapiens 43-61 25982004-1 2015 This study assessed the relationship between magnesium status and C-reactive protein concentration in obese and nonobese women. Magnesium 45-54 C-reactive protein Homo sapiens 66-84 25982004-10 2015 There was a positive correlation between urinary magnesium and serum C-reactive protein (p=0.015). Magnesium 49-58 C-reactive protein Homo sapiens 69-87 25982004-12 2015 The study shows a positive correlation between urinary magnesium concentrations and serum C-reactive protein, suggesting the influence of hypomagnesuria on this inflammatory protein in obese women. Magnesium 55-64 C-reactive protein Homo sapiens 90-108 25784709-7 2015 C-reactive protein values were lower in the benazepril group (0.38 versus 0.42 mg/dl, p = 0.020). benazepril 44-54 C-reactive protein Homo sapiens 0-18 25784709-10 2015 CONCLUSIONS: Hypertensive diabetic patients using benazepril had a greater reduction in C-reactive protein, and a slight improvement in FMD, than those taking losartan. benazepril 50-60 C-reactive protein Homo sapiens 88-106 26654738-11 2015 Although the CRP levels were reduced significantly within group comparisons in both groups (p<0.001), it was significantly lower after 12 days (p<0.05) in the PHMB group compared with the RLS group. polihexanide 165-169 C-reactive protein Homo sapiens 13-16 19275673-5 2009 Conversely, rimonabant, the first selective CB(1) receptor antagonist in clinical use, has been shown to reduce body weight, waist circumference, triglycerides, blood pressure, insulin resistance and C-reactive protein levels, and to increase HDL cholesterol and adiponectin concentrations in both non-diabetic and diabetic overweight/obese patients. Rimonabant 12-22 C-reactive protein Homo sapiens 200-218 19126823-0 2009 Increases in C-reactive protein may predict recurrence of clozapine-induced fever. Clozapine 58-67 C-reactive protein Homo sapiens 13-31 19126823-1 2009 OBJECTIVE: To report a case of recurrent clozapine-induced fever that was associated with a rise in C-reactive protein (CRP). Clozapine 41-50 C-reactive protein Homo sapiens 100-118 19126823-1 2009 OBJECTIVE: To report a case of recurrent clozapine-induced fever that was associated with a rise in C-reactive protein (CRP). Clozapine 41-50 C-reactive protein Homo sapiens 120-123 19126823-4 2009 On day 15 of clozapine therapy, he developed a benign fever (maximum 38.4 degrees C) that was associated with a rise in the CRP level (3.96 mg/dL). Clozapine 13-22 C-reactive protein Homo sapiens 124-127 19126823-6 2009 However, when the patient was rechallenged with clozapine, the CRP level became elevated (4.36 mg/dL) after 3 days of therapy, with a subsequent recurrence of fever (38.7 degrees C). Clozapine 48-57 C-reactive protein Homo sapiens 63-66 19126823-7 2009 DISCUSSION: We postulate that the elevation in CRP levels and the subsequent fever were caused by the effects of clozapine on the cytokine system via interleukin-6 and tumor necrosis factor-alpha, resulting in an inflammatory response with an acute phase reaction. Clozapine 113-122 C-reactive protein Homo sapiens 47-50 19126823-8 2009 This case is unique, as it is the first reported in the literature associating a recurrence of clozapine-induced fever with the known immunomodulatory effects of clozapine on cytokines and CRP level. Clozapine 95-104 C-reactive protein Homo sapiens 189-192 19126823-8 2009 This case is unique, as it is the first reported in the literature associating a recurrence of clozapine-induced fever with the known immunomodulatory effects of clozapine on cytokines and CRP level. Clozapine 162-171 C-reactive protein Homo sapiens 189-192 19126823-11 2009 Further research is needed to study whether CRP is a useful tool in predicting and managing clozapine fever. Clozapine 92-101 C-reactive protein Homo sapiens 44-47 18852383-6 2008 ADMA and NMMA (but not L-arginine) were significant predictors of carotid intima-media thickness, even after adjustment for cardiovascular risk factors, C-reactive protein, and renal function. N,N-dimethylarginine 0-4 C-reactive protein Homo sapiens 153-171 18785307-8 2008 There was a positive strong correlation between ADMA and CRP in patients with FMF. N,N-dimethylarginine 48-52 C-reactive protein Homo sapiens 57-60 18785307-9 2008 Stepwise linear regression analysis in patients with FMF revealed that age and CRP levels were independently associated with serum ADMA levels. N,N-dimethylarginine 131-135 C-reactive protein Homo sapiens 79-82 18635301-4 2008 In men, educational level was significantly associated with the baPWV value after adjustment for conventional risk factors, CRP and occupational stress (P for trend <0.0001). bapwv 64-69 C-reactive protein Homo sapiens 124-127 18633759-0 2008 Association between protein bound sialic acid and high sensitivity C-reactive protein in prehypertension: a possible indication of underlying cardiovascular risk. N-Acetylneuraminic Acid 34-45 C-reactive protein Homo sapiens 67-85 18389332-0 2008 Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Amlodipine 22-32 C-reactive protein Homo sapiens 102-120 18258634-6 2008 Similarly, participants who consumed >360 mg/d of betaine had, on average, 10% lower concentrations of homocysteine (P < 0.01), 19% lower concentrations of C-reactive protein (P < 0.1), and 12% lower concentrations of tumor necrosis factor-alpha (P < 0.05) than did those who consumed <260 mg/d. Betaine 53-60 C-reactive protein Homo sapiens 162-180 17196208-6 2008 Pentoxifylline treatment significantly reduced the adjusted levels of CRP and TNF-alpha compared to placebo after 6 months (P=0.04 and P<0.01, respectively). Pentoxifylline 0-14 C-reactive protein Homo sapiens 70-73 28242268-8 2017 Circulating Gla17/tOCN levels correlated negatively with insulin sensitivity assessed by hyperinsulinemic-euglyceamic clamp (P=0.02) or insulin sensitivity index derived from oral glucose tolerance test (P=0.00003), and positively with insulin resistance assessed by HOMA-IR (P=0.0005) and with markers of subclinical inflammation and liver enzymes, including C-reactive protein (CRP; P=0.007) and aspartate aminotransferase (AST; P=0.009). gla17 12-17 C-reactive protein Homo sapiens 380-383 18199130-10 2008 A decrease in endothelin-1 levels and an increase in nitrite/nitrate levels were found after chronic sildenafil; significant changes from baseline in C-reactive protein, interleukin 6, intercellular adhesion molecule and vascular adhesion molecule levels were also found. Sildenafil Citrate 101-111 C-reactive protein Homo sapiens 150-168 27605569-9 2017 Peak C-reactive protein (CRP) had a significant positive correlation with pleural effusion volume (P = 0.039) and was significantly greater in the non-ASV group (15.5 +- 6.3 vs 8.5 +- 6.1 mg/dl, P= 0.009). ASV 151-154 C-reactive protein Homo sapiens 25-28 18453780-6 2008 Serum ADMA levels showed significant and positive correlations with age, testosterone, and fibrinogen concentrations in men, and a borderline significance with triglyceride, C-reactive protein, and sex hormone-binding globulin in women. N,N-dimethylarginine 6-10 C-reactive protein Homo sapiens 174-192 27234357-4 2016 After 5 days of antibiotic therapy with cefuroxime, inflammatory parameters (CRP level and white blood cell count) remained highly elevated. Cefuroxime 40-50 C-reactive protein Homo sapiens 77-80 18035081-8 2007 After 2 years, CRP levels increased by 3.0% (from a mean level of 3.44 mg/L) in the bezafibrate group and by 3.7% (from 3.49 mg/L) in the placebo group. Bezafibrate 84-95 C-reactive protein Homo sapiens 15-18 27333994-6 2016 Following treatment with dapagliflozin, HbA1c levels significantly improved (7.44 +- 0.56 to 6.70 +- 0.0.57 %; p < 0.01), body weight significantly decreased (90.9 +- 16.5 to 87.1 +- 15.9 kg; p < 0.01), ketone bodies increased, adiponectin significantly increased, and high-sensitivity CRP tended to decrease. dapagliflozin 25-38 C-reactive protein Homo sapiens 292-295 18054734-4 2007 Rimonabant, the first selective CB(1) receptor blocker in clinical use, has been shown to reduce body weight, waist circumference, triglycerides, blood pressure, insulin resistance index and C-reactive protein levels, and to increase high-density lipoprotein (HDL) cholesterol and adiponectin concentrations in both non-diabetic and diabetic overweight/obese patients. Rimonabant 0-10 C-reactive protein Homo sapiens 191-209 27446307-7 2016 After treatment, the carvedilol and trimetazidine groups showed higher LVEF and CRP, longer walking distance in 6 min, as well as lower heart rate and blood pressure (both systolic and diastolic) compared to the control group. Trimetazidine 36-49 C-reactive protein Homo sapiens 80-83 17906106-9 2007 When patients were further categorized in relation to CRP (cut-off value, 1 mg/l), BA-FMD was significantly lower (3%, P < 0.01), whereas LDL-to-HDL ratio increased further (2.2, P < 0.001) in the subgroup of DQ2/8 and CRP > or = 1 patients compared with the remaining three subgroups. ba-fmd 83-89 C-reactive protein Homo sapiens 54-57 26011648-5 2016 Compared with HELP, DS led to significantly greater reductions in total cholesterol (-63.3% vs. -59.9%; P = 0.05), LDL-C (-70.5% vs. -63.0%; P = 0.02), CRP (-75.3% vs. -48.8%; P < 0.0001), and TNF-alpha (-23.7% vs. +14.7%; P = 0.003). ds 20-22 C-reactive protein Homo sapiens 152-155 18072818-12 2007 Krill omega-3 phospholipids demonstrated anti-inflammatory activity, lowering C-reactive protein (CRP) levels in a double-blind trial. krill omega-3 phospholipids 0-27 C-reactive protein Homo sapiens 78-96 18072818-12 2007 Krill omega-3 phospholipids demonstrated anti-inflammatory activity, lowering C-reactive protein (CRP) levels in a double-blind trial. krill omega-3 phospholipids 0-27 C-reactive protein Homo sapiens 98-101 27621861-8 2016 In addition, low serum selenium levels were associated with an increase in baseline C-reactive protein (CRP) (R(2)=0.059, P=0.041) and APACHE II scores (R(2)=0.209, P<0.001). Selenium 23-31 C-reactive protein Homo sapiens 84-102 17889151-11 2007 CONCLUSIONS: The anemia caused by everolimus--microcytosis, low serum iron, despite high ferritinemia, and elevated C-reactive protein levels--was consistent with the anemia of a chronic inflammatory state. Everolimus 34-44 C-reactive protein Homo sapiens 116-134 21291692-0 2007 Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia. Ezetimibe 101-110 C-reactive protein Homo sapiens 61-79 21291692-9 2007 CONCLUSIONS: The combination of rosuvastatin 40 mg and ezetimibe 10 mg offers the most effective LDL-C-lowering therapy yet reported, and is helpful in achieving lipid goals and reducing C-reactive protein levels in high-risk patients with severe hypercholesterolemia, including familial hypercholesterolemia. Ezetimibe 55-64 C-reactive protein Homo sapiens 187-205 27621861-8 2016 In addition, low serum selenium levels were associated with an increase in baseline C-reactive protein (CRP) (R(2)=0.059, P=0.041) and APACHE II scores (R(2)=0.209, P<0.001). Selenium 23-31 C-reactive protein Homo sapiens 104-107 27150702-7 2016 Furthermore, using the dual-functional random copolymer, CRP could be detected in a pooled blood serum diluted 100x with dramatic reduction of nonspecific adsorption. copolymer 46-55 C-reactive protein Homo sapiens 57-60 17613279-7 2007 RESULTS: At one-month follow-up, in the Pentoxifylline group, there was 20.9% decrease (p<0.001) in C-reactive protein, 18% reduction (p<0.001) in erythrocyte sedimentation rate, 11.1% reduction (p<0.001) in total leukocyte count and 5.8% increase (p=0.003) in serum albumin. Pentoxifylline 40-54 C-reactive protein Homo sapiens 103-121 26951717-13 2016 CONCLUSION: Our findings suggest that activation markers, particularly CRP, may have a role in identifying good response to TB therapy regardless of the strain of infection and could be further developed as point-of-care tests. Terbium 124-126 C-reactive protein Homo sapiens 71-74 17456842-8 2007 Assessing the joint effect of ADMA and CRP revealed that patients with either ADMA or CRP or both in the highest tertile had increased hazard ratios for cardiovascular events compared with patients with neither ADMA nor CRP in the highest tertile before and after adjustment for possible confounders (hazard ratio 4.59 [95% CI 2.07-10.15], P < 0.001). N,N-dimethylarginine 30-34 C-reactive protein Homo sapiens 86-89 17456842-8 2007 Assessing the joint effect of ADMA and CRP revealed that patients with either ADMA or CRP or both in the highest tertile had increased hazard ratios for cardiovascular events compared with patients with neither ADMA nor CRP in the highest tertile before and after adjustment for possible confounders (hazard ratio 4.59 [95% CI 2.07-10.15], P < 0.001). N,N-dimethylarginine 30-34 C-reactive protein Homo sapiens 86-89 17456842-9 2007 CONCLUSIONS: ADMA predicted cardiovascular events and enhanced the predictive role of CRP in patients with type 2 diabetes. N,N-dimethylarginine 13-17 C-reactive protein Homo sapiens 86-89 17560879-0 2007 Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Ezetimibe 25-34 C-reactive protein Homo sapiens 98-116 17560879-3 2007 When averaged across doses, ezetimibe/simvastatin produced significantly greater reductions compared with simvastatin alone in LDL cholesterol (52.5% vs 38.0%, respectively) and CRP levels (31.0% vs 14.3%, respectively). Ezetimibe 28-37 C-reactive protein Homo sapiens 178-181 17560879-4 2007 At each individual simvastatin dose, co-administration with ezetimibe produced significant further CRP reductions versus simvastatin alone. Ezetimibe 60-69 C-reactive protein Homo sapiens 99-102 17560879-6 2007 Reductions in CRP of similar magnitude were observed with ezetimibe/simvastatin and atorvastatin when averaged across doses and at each milligram-equivalent statin dose comparison. Ezetimibe 58-67 C-reactive protein Homo sapiens 14-17 17413107-6 2007 RESULTS: In age-adjusted linear regression analyses, magnesium intake was inversely associated with plasma concentrations of CRP (P for linear trend = 0.003), E-selectin (P = 0.001), and sICAM-1 (P = 0.03). Magnesium 53-62 C-reactive protein Homo sapiens 125-128 17413107-7 2007 After further adjustment for physical activity, smoking status, alcohol use, postmenopausal hormone use, and body mass index, dietary magnesium intake remained inversely associated with CRP and E-selectin. Magnesium 134-143 C-reactive protein Homo sapiens 186-189 17413107-8 2007 Multivariate-adjusted geometric means for women in the highest quintile of dietary magnesium intake were 24% lower for CRP (1.70 +/- 0.18 compared with 1.30 +/- 0.10 mg/dL; P for trend = 0.03) and 14% lower for E-selectin (48.5 +/- 1.84 compared with 41.9 +/- 1.58 ng/mL; P for trend = 0.01) than those for women in the lowest quintile. Magnesium 83-92 C-reactive protein Homo sapiens 119-122 17351383-1 2007 OBJECTIVES: We evaluated whether the changes in the insulin sensitivity observed in hypertensive patients following treatment with an angiotensin II receptor blocker (candesartan) or calcium-channel antagonist (amlodipine) might be related to improvement of the endothelial function (END) and/or plasma level of high-sensitive C-reactive protein (CRP) following such treatment. Amlodipine 211-221 C-reactive protein Homo sapiens 327-345 25976322-7 2016 CTQ+ patients also exhibited increased baseline expression of gene transcripts related to inflammatory signaling, and baseline inflammatory markers including c-reactive protein, interleukin (IL)-6, and IL-1 receptor antagonist were positively correlated with depression, fatigue, and stress scores in CTQ+ but not CTQ- patients. cysteine tryptophylquinone 0-3 C-reactive protein Homo sapiens 158-176 17351383-1 2007 OBJECTIVES: We evaluated whether the changes in the insulin sensitivity observed in hypertensive patients following treatment with an angiotensin II receptor blocker (candesartan) or calcium-channel antagonist (amlodipine) might be related to improvement of the endothelial function (END) and/or plasma level of high-sensitive C-reactive protein (CRP) following such treatment. Amlodipine 211-221 C-reactive protein Homo sapiens 347-350 26361646-5 2015 RESULTS: Pretreatment anemia, elevated pretreatment CRP levels, and higher risk NCCN-IPI groups were significantly associated with reduced PFS and OS (P = .001 and P = .003 for pretreatment anemia, P = .035 and P = .029 for elevated CRP, and P < .001 and P < .001 for higher risk NCCN-IPI groups). diprotin A 85-88 C-reactive protein Homo sapiens 233-236 26884762-9 2016 The carriers of the G allele (CG or GG) of rs9794 were also significantly associated with decreased level of CRP, regression coefficients was -0.219, and standard error was 0.114 (p = 0.012). cysteinylglycine 30-32 C-reactive protein Homo sapiens 109-112 26209292-9 2015 Levels of CRP and TNFalpha differentiated ketamine responders and non-responders. Ketamine 42-50 C-reactive protein Homo sapiens 10-13 25985199-0 2015 A simultaneous electrochemical multianalyte immunoassay of high sensitivity C-reactive protein and soluble CD40 ligand based on reduced graphene oxide-tetraethylene pentamine that directly adsorb metal ions as labels. graphene oxide 136-150 C-reactive protein Homo sapiens 76-94 25985199-1 2015 A simplified electrochemical multianalyte immunosensor for the simultaneous detection of high sensitivity C-reactive protein (hsCRP) and soluble CD40 ligand (sCD40L) that uses reduced graphene oxide-tetraethylene pentamine (rGO-TEPA) that directly adsorbs metal ions as labels is reported. graphene oxide 184-198 C-reactive protein Homo sapiens 106-124 17328057-4 2007 RESULTS: At baseline, an elevated C-reactive protein (CRP) level correlated positively with lipoprotein(a) (Lp[a]), intercellular adhesion molecule 1, interleukin-6, and homocysteine levels but was inversely correlated with concentrations of all other lipid moieties and sex hormone binding globulin (SHBG). Homocysteine 170-182 C-reactive protein Homo sapiens 34-52 17328057-4 2007 RESULTS: At baseline, an elevated C-reactive protein (CRP) level correlated positively with lipoprotein(a) (Lp[a]), intercellular adhesion molecule 1, interleukin-6, and homocysteine levels but was inversely correlated with concentrations of all other lipid moieties and sex hormone binding globulin (SHBG). Homocysteine 170-182 C-reactive protein Homo sapiens 54-57 17536486-1 2007 The objective of this study was to determine whether magnesium consumption is associated with inflammation (C-reactive protein [CRP]) in children. Magnesium 53-62 C-reactive protein Homo sapiens 108-126 17536486-1 2007 The objective of this study was to determine whether magnesium consumption is associated with inflammation (C-reactive protein [CRP]) in children. Magnesium 53-62 C-reactive protein Homo sapiens 128-131 27013809-6 2016 Both TSA and hs-CRP levels were found significantly correlated with fasting and postprandial blood sugar, hemoglobin A1c, and urine microalbumin levels in both DM and DN groups. Sugars 99-104 C-reactive protein Homo sapiens 16-19 17185364-4 2007 RESULTS: ADMA was correlated positively to age, female sex, diabetes mellitus, former and current smoking, and C-reactive protein and inversely to HDL cholesterol and triglycerides. N,N-dimethylarginine 9-13 C-reactive protein Homo sapiens 111-129 26329334-4 2015 Changes were most evident in patients with substantial reduction in inflammatory levels (TC +8.2% vs +1.6% and HDL-C +8.3% vs +2.2% in patients with C-reactive protein >= 10 mg/l normalizing upon treatment vs CRP < 10 mg/l throughout treatment period). Technetium 89-91 C-reactive protein Homo sapiens 149-167 26394632-4 2015 In clinical trials in patients with iMCD, siltuximab reduced levels of C-reactive protein (a biomarker for IL-6), and provided clinical responses. imcd 36-40 C-reactive protein Homo sapiens 71-89 26008686-5 2015 RESULTS: The two patients shared some common clinical features of acute attack of CDS, such as increased erythrocyte sedimentation rate, C-reactive protein, episode of fever, and increased white blood cells along with high blood glucose levels. cds 82-85 C-reactive protein Homo sapiens 137-155 26367537-9 2015 Combining our results with recent studies, we propose that C4, CRP, and IgM in serum are significantly associated with HCY concentration. Homocysteine 119-122 C-reactive protein Homo sapiens 63-66 17222729-0 2007 Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free C-reactive protein on human monocytes via nuclear factor kappa-B activation. Azides 189-194 C-reactive protein Homo sapiens 122-140 17243915-4 2007 The aim of this study was to investigate whether plasma concentrations of interleukin-6, interleukin-8, C-reactive protein, and monocyte chemoattractant protein-1 are increased with higher plasma homocysteine concentrations and whether decreasing homocysteine by vitamin supplementation decreases the concentration of these markers. Homocysteine 196-208 C-reactive protein Homo sapiens 104-122 17157900-7 2007 After coronary stenting, the rise in CRP levels was significantly higher in controls than those treated with naproxen (DeltaCRP=6.4 mg/L in the controls and 0.43 mg/L in the naproxen group, p<0.0001). deltacrp 119-127 C-reactive protein Homo sapiens 37-40 17004092-0 2006 Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Telmisartan 0-11 C-reactive protein Homo sapiens 33-51 26071592-11 2015 Ketamine compared with placebo group showed a significant reduction of pain scores (P = 0.01), C-reactive protein (P < 0.001) and morphine consumption (P < 0.001). Ketamine 0-8 C-reactive protein Homo sapiens 95-113 25893544-1 2015 BACKGROUND: The aim of this analysis was to examine the effects of icosapent ethyl (eicosapentaenoic acid ethyl ester, IPE) on high-sensitivity C-reactive protein (hsCRP) and lipid parameters in patients with metabolic syndrome, with and without stable statin therapy. eicosapentaenoic acid ethyl ester 67-82 C-reactive protein Homo sapiens 144-162 26436081-5 2015 The aim of this study is evaluation of effect of omega-3 supplementation on IL-6 and CRP level in chronic ambulatory peritoneal dialysis (CAPD) patients. omega-3 49-56 C-reactive protein Homo sapiens 85-88 17109677-6 2006 Rimonabant therapy is associated with an extra 8-10% increase in HDL-C and a 10-30% reduction in triglycerides and improvements in insulin resistance, glycaemic control in patients with diabetes and also adipokines and cytokines including C-reactive protein over hypocaloric diet therapy. Rimonabant 0-10 C-reactive protein Homo sapiens 239-257 17165637-8 2006 Ezetimibe/ simvastatin, 10/20 mg/d, reduced high-sensitivity C-reactive protein and triglyceride levels significantly more than atorvastatin, 10 mg/d (P = .02), with comparable reductions at other doses. Ezetimibe 0-9 C-reactive protein Homo sapiens 61-79 25187642-6 2015 RESULTS: Regression analysis revealed that baseline ESR in 2006 and the AAUC of ESR and CRP all had significant positive relationships with current ADMA (P = 0.004, P < 0.001 and P = 0.002, respectively). N,N-dimethylarginine 148-152 C-reactive protein Homo sapiens 88-91 26770145-8 2015 RESULTS: The extract attenuated the post-UBC increase in serum markers for muscle tissue damage: CK, LDH, and CRP. 1-(2-amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione 41-44 C-reactive protein Homo sapiens 110-113 25966642-5 2015 Treatment of cells with CRP (5, 10, 20 mug/ml) resulted in neurotoxicity and apoptosis, as was observed by MTT assay and Hoechst staining, respectively. hoechst 121-128 C-reactive protein Homo sapiens 24-27 17034359-1 2006 Does inflammation, as assessed by high sensitivity C-reactive protein (hs-CRP), in patients with end-stage renal disease (ESRD) tightly associate with increased serum levels of 8-oxo-7,8-dihydro-2"-deoxyguanosine (8- oxo-dG)? 8-ohdg 177-212 C-reactive protein Homo sapiens 51-69 17034359-1 2006 Does inflammation, as assessed by high sensitivity C-reactive protein (hs-CRP), in patients with end-stage renal disease (ESRD) tightly associate with increased serum levels of 8-oxo-7,8-dihydro-2"-deoxyguanosine (8- oxo-dG)? 8-ohdg 214-223 C-reactive protein Homo sapiens 51-69 26242117-9 2015 Scores for CM syndromes, BASDAI, night pain index, spinal pain index, PGA, CRP were improved in the BSG group (P < 0.05, P < 0.01). BSG 100-103 C-reactive protein Homo sapiens 75-78 16996837-8 2006 CONCLUSIONS: In patients with OSAS, UPPP appears to decrease levels of serum C-reactive protein. uppp 36-40 C-reactive protein Homo sapiens 77-95 16923447-9 2006 The same relation was present in the SES group, i.e., patients with a higher CRP level had a higher incidence of 12-month death or myocardial infarction compared with patients with a low CRP level (6.3% vs 1.0%, p = 0.005) and a higher 12-month mortality (5.2% vs 0%, p = 0.001). ses 37-40 C-reactive protein Homo sapiens 77-80 16923447-9 2006 The same relation was present in the SES group, i.e., patients with a higher CRP level had a higher incidence of 12-month death or myocardial infarction compared with patients with a low CRP level (6.3% vs 1.0%, p = 0.005) and a higher 12-month mortality (5.2% vs 0%, p = 0.001). ses 37-40 C-reactive protein Homo sapiens 187-190 16923447-11 2006 In conclusion, PCI in the SES era causes a smaller increase in CRP compared with the BMS era. ses 26-29 C-reactive protein Homo sapiens 63-66 26199924-0 2015 Inverse Correlation between Serum C-Reactive Protein and Magnesium Levels in Smokers and Nonsmokers. Magnesium 57-66 C-reactive protein Homo sapiens 34-52 26199924-2 2015 AIMS: To examine inverse correlation between CRP and magnesium levels in smokers and nonsmokers. Magnesium 53-62 C-reactive protein Homo sapiens 45-48 26199924-7 2015 A significant (P < 0.001) inverse relationship between serum CRP and magnesium concentrations were seen in smokers. Magnesium 72-81 C-reactive protein Homo sapiens 64-67 26199924-8 2015 CONCLUSION: This result shows that smoking increases serum CRP, an inflammatory marker parallel to decrease in serum magnesium levels in smokers having 20-40 years of age. Magnesium 117-126 C-reactive protein Homo sapiens 59-62 25530012-10 2015 Intake of cranberry polyphenols may play a role in promoting anti-inflammatory markers among CJC consumers, specifically lowering CRP levels. cranberry polyphenols 10-31 C-reactive protein Homo sapiens 130-133 25460898-0 2015 Graphene-based rapid and highly-sensitive immunoassay for C-reactive protein using a smartphone-based colorimetric reader. Graphite 0-8 C-reactive protein Homo sapiens 58-76 16970214-10 2006 Finally, the addition of ezetimibe reduced high-sensitivity C-reactive protein levels overall, and no significant interaction of treatment by race occurred (P = .83), Indicating a consistent effect across races. Ezetimibe 25-34 C-reactive protein Homo sapiens 60-78 16897175-0 2006 Carbohydrate ligands of human C-reactive protein: binding of neoglycoproteins containing galactose-6-phosphate and galactose-terminated disaccharide. galactose-6-phosphate 89-110 C-reactive protein Homo sapiens 30-48 16897175-1 2006 Binding of carbohydrate ligand by human C-reactive protein (CRP), in both native form and structurally deviated form (neoCRP or mCRP), was investigated using galactose-6-phosphate (Gal6P)- and Galbeta3GalNAc-containing bovine serum albumin (BSA) derivatives. galactose-6-phosphate 158-179 C-reactive protein Homo sapiens 40-58 16897175-1 2006 Binding of carbohydrate ligand by human C-reactive protein (CRP), in both native form and structurally deviated form (neoCRP or mCRP), was investigated using galactose-6-phosphate (Gal6P)- and Galbeta3GalNAc-containing bovine serum albumin (BSA) derivatives. galactose-6-phosphate 158-179 C-reactive protein Homo sapiens 60-63 25864742-0 2015 Effect of trimetazidine on serum interleukin-6 and C-reactive protein concentrations in patients with stable coronary artery disease. Trimetazidine 10-23 C-reactive protein Homo sapiens 51-69 25563735-0 2015 The effect of oral magnesium supplementation on serum C-reactive protein. Magnesium 19-28 C-reactive protein Homo sapiens 54-72 25563736-0 2015 Dietary magnesium intake is inversely associated with serum C-reactive protein levels: meta-analysis and systematic review. Magnesium 8-17 C-reactive protein Homo sapiens 60-78 25864742-14 2015 Moreover, it resulted in the reduction of CRP concentration The increase of IL-6 concentration after three-month trimetazidine treatment and the lack of changes of its concentration after TET is associated with yet another mechanism of trimetazidine. Trimetazidine 236-249 C-reactive protein Homo sapiens 42-45 25563738-1 2015 Dietary magnesium intake is inversely associated with serum C-reactive protein levels: meta-analysis and systematic review. Magnesium 8-17 C-reactive protein Homo sapiens 60-78 25563738-3 2015 The sentence should be: In addition, five Mg intervention studies (Table 2) reported on the association between Mg supplementation and serum CRP levels. Magnesium 42-44 C-reactive protein Homo sapiens 141-144 28834641-6 2015 A higher decrease of high-sensitivity C-reactive protein level was seen in the liothyronine group than in the placebo group (P = 0.009). Triiodothyronine 79-91 C-reactive protein Homo sapiens 38-56 16832152-5 2006 There were statistically significant associations between the CRP level and two CRP genotypes; the p value for the T allele of rs3091244 (CT + AT + TT vs. CC + CA + AA) was 0.002 (95% confidential interval [CI], 2.1-24), and the p value for the T allele of rs1130864 (TT + TC vs. CC) was 0.002 (95% CI, 2.1-24). Technetium 273-275 C-reactive protein Homo sapiens 62-65 16722027-13 2006 Median serum CRP decreased (p = 0.03), from 3.8 (1.6 - 8.5) mg/L on CAPD to 1.0 (0.4 - 4.4) mg/L on NIPD, but increased on CCPD [1.8 (1.3 - 21) mg/L] and at the end of the study [3.2 (0.3 - 8.2) mg/L]. nipd 100-104 C-reactive protein Homo sapiens 13-16 16722027-14 2006 Dialysate CRP decreased nonsignificantly, from 0.10 (0 - 0.5) mg/L on CAPD to 0 (0 - 0.03) mg/L on NIPD, to 0.01 (0 - 0.08) mg/L on CCPD, and to 0 (0 - 0) mg/L at final evaluation. nipd 99-103 C-reactive protein Homo sapiens 10-13 16369811-4 2006 RESULTS: After 3 months of treatment the median CRP levels increased by 29% in the CEE + MPA group and by 5% in the tibolone group. tibolone 116-124 C-reactive protein Homo sapiens 48-51 25151017-12 2014 High C-reactive protein values were consistently reported as an independent prognostic factor for mortality in invasive UBC. 1-(2-amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione 120-123 C-reactive protein Homo sapiens 5-23 16939632-6 2006 Angiotensin receptor blockers (ARBs) (valsartan, irbesartan, olmesartan, telmisartan) markedly reduce serum levels of CRP. Irbesartan 49-59 C-reactive protein Homo sapiens 118-121 16939632-6 2006 Angiotensin receptor blockers (ARBs) (valsartan, irbesartan, olmesartan, telmisartan) markedly reduce serum levels of CRP. olmesartan 61-71 C-reactive protein Homo sapiens 118-121 16939632-6 2006 Angiotensin receptor blockers (ARBs) (valsartan, irbesartan, olmesartan, telmisartan) markedly reduce serum levels of CRP. Telmisartan 73-84 C-reactive protein Homo sapiens 118-121 26449925-2 2015 We report about two patients who developed an up to threefold increase of dose-related serum concentrations of risperidone"s active moiety (risperidone plus 9-hydroxyrisperidone) during acute inflammation indicated by elevated C-reactive protein. Paliperidone Palmitate 157-177 C-reactive protein Homo sapiens 227-245 25975878-6 2015 RESULTS: There was a negative correlation between baseline serum magnesium and baseline CRP (P=0.009; r=-0.492), negative correlation between cardiac tissue magnesium at the time point 1 and baseline CRP (P=0.021; r=-0.443), and positive correlation between CRP at time point 3 and erythrocyte magnesium at time point 2 (P<0.001; r=0.637). Magnesium 65-74 C-reactive protein Homo sapiens 88-91 26020669-13 2015 CONCLUSIONS: Treatment with pravastatin plus ezetimibe decreases the CIMT with improvement in the concentration of total cholesterol, LDL-C and CRP levels with good toleration. Ezetimibe 45-54 C-reactive protein Homo sapiens 144-147 25380812-9 2014 Compared with placebo, BVA may more effectively improve joint pain, swollen joint counts, tender joint counts, ESR and CRP but was not shown to improve morning stiffness. Trihydroxy[(N-Hydroxybenzamidato)oxo]vanadate 23-26 C-reactive protein Homo sapiens 119-122 25023192-2 2014 RECENT FINDINGS: Both deficient magnesium intakes (<250 mg/day) and serum magnesium concentrations (<= 0.75 mmol/l) have been associated with elevated serum C-reactive protein concentration, a widely used indicator of inflammation. Magnesium 32-41 C-reactive protein Homo sapiens 163-181 25023192-2 2014 RECENT FINDINGS: Both deficient magnesium intakes (<250 mg/day) and serum magnesium concentrations (<= 0.75 mmol/l) have been associated with elevated serum C-reactive protein concentration, a widely used indicator of inflammation. Magnesium 77-86 C-reactive protein Homo sapiens 163-181 16616662-11 2006 CONCLUSION: Low-dose ketamine (0.5 mg/kg) attenuates increases in CRP, IL-6, and IL-10 while decreasing vasodilatation after CPB. Ketamine 21-29 C-reactive protein Homo sapiens 66-69 16401068-6 2006 The Forster resonance energy transfer method has been used to study the distance changes, induced by binding of cAMP, between Trp85 (fluorescence donor) and Cys178-AEDANS (fluorescence acceptor) in the CRP structure. 1,5-AEDANS 164-170 C-reactive protein Homo sapiens 202-205 25023192-3 2014 Achieving magnesium intakes or serum magnesium concentrations that indicate an adequate magnesium status generally attenuates elevated serum C-reactive protein to concentrations that are not indicative of chronic low-grade inflammation. Magnesium 10-19 C-reactive protein Homo sapiens 141-159 15905085-6 2006 In a 150 mM NaCl phosphate buffer, on the other hand, the fragments seem to be site-directly oriented and the response to CRP was fivefold. nacl phosphate 12-26 C-reactive protein Homo sapiens 122-125 25023192-3 2014 Achieving magnesium intakes or serum magnesium concentrations that indicate an adequate magnesium status generally attenuates elevated serum C-reactive protein to concentrations that are not indicative of chronic low-grade inflammation. Magnesium 37-46 C-reactive protein Homo sapiens 141-159 24744306-11 2014 Serum beta-carotene significantly moderated the associations between dietary beta-carotene and CRP (P-interaction < 0.05), and quartile 4 of dietary beta-carotene was associated with lower CRP concentrations only among participants with serum beta-carotene > 0.43 mumol/L. beta Carotene 6-19 C-reactive protein Homo sapiens 77-98 25023192-3 2014 Achieving magnesium intakes or serum magnesium concentrations that indicate an adequate magnesium status generally attenuates elevated serum C-reactive protein to concentrations that are not indicative of chronic low-grade inflammation. Magnesium 37-46 C-reactive protein Homo sapiens 141-159 24879591-1 2014 We report a protein antibody, Ab-CRP, functionalized Pt nanoparticle-decorated chemical vapor deposition (CVD)-grown graphene on glassy carbon electrode, as a bioelectrode, for the quantitative analysis of human C-reactive protein (CRP). Graphite 117-125 C-reactive protein Homo sapiens 33-36 24879591-1 2014 We report a protein antibody, Ab-CRP, functionalized Pt nanoparticle-decorated chemical vapor deposition (CVD)-grown graphene on glassy carbon electrode, as a bioelectrode, for the quantitative analysis of human C-reactive protein (CRP). Graphite 117-125 C-reactive protein Homo sapiens 212-230 24879591-1 2014 We report a protein antibody, Ab-CRP, functionalized Pt nanoparticle-decorated chemical vapor deposition (CVD)-grown graphene on glassy carbon electrode, as a bioelectrode, for the quantitative analysis of human C-reactive protein (CRP). Graphite 117-125 C-reactive protein Homo sapiens 232-235 24879591-3 2014 Ab-CRP was covalently immobilized on mercaptopropionic acid (MPA)-capped Pt nanoparticles that were covalently anchored over the graphene to form a bioelectrode. Graphite 129-137 C-reactive protein Homo sapiens 3-6 16424791-8 2006 Treatment with amlodipine, independently of blood pressure lowering, reduced atherosclerosis development in E3L/CRP mice. Amlodipine 15-25 C-reactive protein Homo sapiens 112-115 16123325-1 2005 OBJECTIVE: C-reactive protein (CRP) can promote atherothrombosis by decreasing endothelial nitric oxide synthase and prostacyclin, and by stimulating both plasminogen activator inhibitor-1 in endothelial cells and tissue factor in mononuclear cells. Epoprostenol 117-129 C-reactive protein Homo sapiens 11-29 16123325-1 2005 OBJECTIVE: C-reactive protein (CRP) can promote atherothrombosis by decreasing endothelial nitric oxide synthase and prostacyclin, and by stimulating both plasminogen activator inhibitor-1 in endothelial cells and tissue factor in mononuclear cells. Epoprostenol 117-129 C-reactive protein Homo sapiens 31-34 24744306-11 2014 Serum beta-carotene significantly moderated the associations between dietary beta-carotene and CRP (P-interaction < 0.05), and quartile 4 of dietary beta-carotene was associated with lower CRP concentrations only among participants with serum beta-carotene > 0.43 mumol/L. beta Carotene 6-19 C-reactive protein Homo sapiens 95-98 16145309-5 2005 In a minority of patients, estrogen-progestogen associations and tibolone increased IL-6 levels and induced unfavorable changes on inflammation markers (CRP: +93% +/- 8%, intracellular adhesion molecule: -3% +/- 2%, vascular cell adhesion molecule: -5% +/- 2%, E-selectin: +6% +/- 2%, s-thrombomodulin: +5% +/- 2%, IL-6: +12% +/- 4%; percent changes compared with baseline). tibolone 65-73 C-reactive protein Homo sapiens 153-156 15976313-7 2005 This study has implications for interpretation of in vitro studies using CRP preparations containing azide at equivalent or higher concentrations. Azides 101-106 C-reactive protein Homo sapiens 73-76 24865175-4 2014 In lithium-heparin tubes, statistically significant differences were observed in S-BIM values of all parameters, except urea nitrogen, CRP, and sodium, compared with S-NO-BIM. Lithium 3-10 C-reactive protein Homo sapiens 135-138 24874478-0 2014 C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. diprotin A 109-112 C-reactive protein Homo sapiens 0-18 24744306-11 2014 Serum beta-carotene significantly moderated the associations between dietary beta-carotene and CRP (P-interaction < 0.05), and quartile 4 of dietary beta-carotene was associated with lower CRP concentrations only among participants with serum beta-carotene > 0.43 mumol/L. beta Carotene 77-90 C-reactive protein Homo sapiens 95-98 24744306-11 2014 Serum beta-carotene significantly moderated the associations between dietary beta-carotene and CRP (P-interaction < 0.05), and quartile 4 of dietary beta-carotene was associated with lower CRP concentrations only among participants with serum beta-carotene > 0.43 mumol/L. beta Carotene 77-90 C-reactive protein Homo sapiens 95-98 15860734-11 2005 Most importantly, the increase in interleukin-8, intercellular adhesion molecule 1, and vascular cell adhesion molecule-1 and the decrease in eNOS and prostacyclin induced by CRP was abrogated with antibodies to CD32 and CD64. Epoprostenol 151-163 C-reactive protein Homo sapiens 175-178 24744306-13 2014 Serum beta-carotene was also a moderator of the dietary beta-carotene and CRP association. beta Carotene 6-19 C-reactive protein Homo sapiens 74-77 24744306-13 2014 Serum beta-carotene was also a moderator of the dietary beta-carotene and CRP association. beta Carotene 56-69 C-reactive protein Homo sapiens 74-77 24849439-11 2014 CRP, IL-6 and TNF-a levels in group A were increased at Tb and Tc (P<0.05 or P<0.01) and significantly higher than those in groups B and C (P<0.05 or P<0.01). Terbium 56-58 C-reactive protein Homo sapiens 0-3 16156319-10 2005 After PMX-F treatment, the patient"s temperature decreased to 36.8 degrees C; her WBC count and CRP level decreased to 9,200/microl and 3.8 mg/dl, respectively. pmx-f 6-11 C-reactive protein Homo sapiens 96-99 24619948-12 2014 C-reactive protein has also been investigated to relate clozapine toxicity to infection and/or inflammation. Clozapine 56-65 C-reactive protein Homo sapiens 0-18 24627603-9 2014 The changes in serum Alb level were inversely correlated with CRP changes; therefore, a possible involvement of the anti-inflammatory effect of BCAAs was inferred as a factor contributory to the suppression of decrease in serum Alb level. Amino Acids, Branched-Chain 144-149 C-reactive protein Homo sapiens 62-65 15996056-5 2005 An incremental positive correlation was observed between plasma CRP levels and TF induced by CRP or ss2-GPI. ss2-gpi 100-107 C-reactive protein Homo sapiens 64-67 25377123-3 2014 We investigated long-term associations between the antioxidant nutrient (vitamin C, alpha-tocopherol, beta-carotene) status and C-reactive protein (CRP) in a population-based cohort. beta Carotene 102-115 C-reactive protein Homo sapiens 128-146 24600548-6 2014 RESULTS: A significantly lower CRP level was detected in the epoprostenol group compared to the placebo group within 73-96 h (p = 0.04) and within 97-120 h (p = 0.008) after trauma. Epoprostenol 61-73 C-reactive protein Homo sapiens 31-34 25377123-8 2014 The beta-carotene status (n = 2,048) was inversely associated with elevated CRP [adjusted OR quintile 5 vs. 1: OR 0.61 (95% CI 0.38-0.98), p for trend = 0.01]. beta Carotene 4-17 C-reactive protein Homo sapiens 76-79 24600548-10 2014 CONCLUSIONS: Administration of the prostacyclin analogue epoprostenol significantly decreased CRP and, to some extent, IL-6 levels in patients with severe TBI compared to placebo. Epoprostenol 35-47 C-reactive protein Homo sapiens 94-97 24600548-10 2014 CONCLUSIONS: Administration of the prostacyclin analogue epoprostenol significantly decreased CRP and, to some extent, IL-6 levels in patients with severe TBI compared to placebo. Epoprostenol 57-69 C-reactive protein Homo sapiens 94-97 15904653-0 2005 Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus. Telmisartan 45-56 C-reactive protein Homo sapiens 102-120 24803739-4 2014 Blood CRP is synthesized primarily in the liver and the liver is an organ where antisense oligonucleotide (ASO) drugs accumulate. Oligonucleotides, Antisense 107-110 C-reactive protein Homo sapiens 6-9 15877999-0 2005 Effect of nifedipine on C-reactive protein levels in the coronary sinus and on coronary blood flow in response to acetylcholine in patients with stable angina pectoris having percutaneous coronary intervention. Nifedipine 10-20 C-reactive protein Homo sapiens 24-42 15877999-2 2005 Long-term treatment with nifedipine (nifedipine CR, 20 mg/day for 4 months) decreased levels of C-reactive protein in the coronary sinus (from 0.35 +/- 0.09 mg/dl to 0.07 +/- 0.01 mg/dl, mean +/- SEM, p <0.05) and enhanced acetylcholine-induced increases in coronary blood flow. Nifedipine 25-35 C-reactive protein Homo sapiens 96-114 25298714-8 2014 There was al so significant reduction in CRP level post operative days .There was side effect of honey was observed in our study, so it can be used as alternative for the management of dry socket. Aluminum 10-12 C-reactive protein Homo sapiens 41-44 24261602-9 2014 In the comparison of the laboratory parameters of the patients with or without the components of BDCAF, we found significantly higher levels of ESR and CRP in patients with erythema and arthralgia-arthritis versus without these involvements. bdcaf 97-102 C-reactive protein Homo sapiens 152-155 25159306-9 2014 The combination of IL-6 + CRP showed a 2-fold reduction in the yields of DHT, elevated to control values when combined with Dox (n=8; p<0.001). Doxycycline 124-127 C-reactive protein Homo sapiens 26-29 24097561-16 2013 These results suggest an involvement of the NF-kappaB pathway in mediating different effects of CRP on proximal CTEPH-PAEC. cteph-paec 112-122 C-reactive protein Homo sapiens 96-99 25228460-2 2014 Here we report a case of acute drug-induced fever with leukocytosis and a transient increase in CRP due to pantoprazole. Pantoprazole 107-119 C-reactive protein Homo sapiens 96-99 15823292-4 2005 Age, male gender, systolic blood pressure, heart rate, diabetes, and serum CRP levels increased with the quartiles divided by baPWV (all, p<0.01). bapwv 126-131 C-reactive protein Homo sapiens 75-78 15823292-6 2005 In conclusion, this cross sectional study has demonstrated in the general population that the arterial stiffness marker baPWV was independently correlated with serum CRP levels after adjustment for other established cardiovascular risks factors. bapwv 120-125 C-reactive protein Homo sapiens 166-169 24575132-8 2013 RESULTS: The hs-CRP level decreased significantly in both the omega-3 and CLA group (P < 0.05). Linoleic Acids, Conjugated 74-77 C-reactive protein Homo sapiens 16-19 15831660-0 2005 Irbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable angina. Irbesartan 0-10 C-reactive protein Homo sapiens 33-51 15338451-15 2005 A statistically significant positive correlation was observed between sE-selectin levels and CRP and ESR in patients with BD (r=0.78, p<0.001 and r=0.56, p<0.01, respectively). se-selectin 70-81 C-reactive protein Homo sapiens 93-96 25551930-6 2014 ADMA concentrations were positively correlated with mean age (P = 0.02, r = 0.360), LDL cholesterol levels (P = 0.006, r = 0.325), and CRP levels (P = 0.02, r = 0.268) and negatively correlated with serum albumin levels (P = 0.005, r = -0.331). N,N-dimethylarginine 0-4 C-reactive protein Homo sapiens 135-138 24149106-4 2014 RESULTS: As a continuous variable, lower serum TC level was found to be significantly associated with male sex, symptomatic tumor, advanced TNM stage, higher nuclear grade, microscopic venous invasion, poor Eastern Cooperative Oncology Group Performance Status, larger tumor size, elevated C-reactive protein level, and lower hemoglobin level. Technetium 47-49 C-reactive protein Homo sapiens 290-308 24633270-8 2013 Logistic regression showed significant association between sub-clinical hypothyroidism, total plasma homocysteine and high-sensitivity C-reactive protein in the study group. Homocysteine 101-113 C-reactive protein Homo sapiens 135-153 15667581-9 2005 The association between CRP levels and mortality was independent of potential confounding factors such as age, body-mass index, severity of HF, smoking habits, hypertension and TC levels. Technetium 177-179 C-reactive protein Homo sapiens 24-27 25332970-4 2013 RESULTS: We found a significant increase in production of changes in production of lysozyme and CRP in glucan-treated children. Glucans 103-109 C-reactive protein Homo sapiens 96-99 15667581-11 2005 Furthermore, patients with increased CRP and decreased TC (additive predictive effect) phenotype had 11.714-times higher risk (95% CI 2.619-52.385) of being nonsurvivors than patients with low CRP/high TC. Technetium 55-57 C-reactive protein Homo sapiens 193-196 15667581-11 2005 Furthermore, patients with increased CRP and decreased TC (additive predictive effect) phenotype had 11.714-times higher risk (95% CI 2.619-52.385) of being nonsurvivors than patients with low CRP/high TC. Technetium 202-204 C-reactive protein Homo sapiens 37-40 15616085-6 2005 PVAA inhibited the surgical stress response, as indicated by significantly less plasma glucose, cortisol, and C-reactive protein. pvaa 0-4 C-reactive protein Homo sapiens 110-128 24199788-0 2013 Clozapine-induced elevated C-reactive protein and fever mimic infection. Clozapine 0-9 C-reactive protein Homo sapiens 27-45 24199788-1 2013 Clozapine-induced fever has been reported frequently, but clozapine-induced elevated serum C-reactive protein (S-CRP) over 100 mg/L with early onset, without associated myocarditis, has not been reported in the literature. Clozapine 58-67 C-reactive protein Homo sapiens 91-109 23053500-6 2013 The patient was initially treated with meropenem followed by fluoroquinolones for 3 weeks; however, her C-reactive protein level was high (10-20 mg/dL) even after the antimicrobial therapy. Meropenem 39-48 C-reactive protein Homo sapiens 104-122 24082508-8 2013 ESR, Cp, and CRP increased significantly (P < 0.001) by 145, 28.7, and 42.5% in TUs and by 164, 50.5, and 74.3% in CPs, respectively, relative to control. TUS 83-86 C-reactive protein Homo sapiens 13-16 23228159-8 2013 CONCLUSIONS: There is a complex association between CRP and homocysteine with specific subcomponents of MetS in patients with bipolar disorder and schizophrenia. Homocysteine 60-72 C-reactive protein Homo sapiens 52-55 15668606-4 2005 RESULTS: C-reactive protein levels were increased by tibolone (76%; P < 0.001) and CEE+MPA (81%; P < 0.001). tibolone 53-61 C-reactive protein Homo sapiens 9-27 23827295-9 2013 CRP also showed the highest sensitivity (100%) and negative predictive value (100%) for PA. Protactinium 88-90 C-reactive protein Homo sapiens 0-3 15704253-0 2004 Homocysteine in relation to C-reactive protein and low-density lipoprotein cholesterol in assessment of cardiovascular risk. Homocysteine 0-12 C-reactive protein Homo sapiens 28-46 15704253-2 2004 We investigated the predictive value of homocysteine (Hcy) in relation to C-reactive protein (CRP) and low-density lipoprotein (LDL)-cholesterol in patients with confirmed coronary disease. Homocysteine 40-52 C-reactive protein Homo sapiens 74-92 15704253-2 2004 We investigated the predictive value of homocysteine (Hcy) in relation to C-reactive protein (CRP) and low-density lipoprotein (LDL)-cholesterol in patients with confirmed coronary disease. Homocysteine 40-52 C-reactive protein Homo sapiens 94-97 22653321-9 2013 Additionally, reduced CRP may be one of mediators on the mechanisms how bilirubin reduces baPWV. bapwv 90-95 C-reactive protein Homo sapiens 22-25 23361365-0 2013 Docosahexaenoic acid and eicosapentaenoic acid reduce C-reactive protein expression and STAT3 activation in IL-6-treated HepG2 cells. Docosahexaenoic Acids 0-20 C-reactive protein Homo sapiens 54-72 23361365-4 2013 The aims of this study were to examine the effect of the n-3 PUFAs, docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA), on the modulation of IL-6-induced CRP expression and to explore its possible mechanisms. Docosahexaenoic Acids 68-88 C-reactive protein Homo sapiens 163-166 23361365-5 2013 We demonstrated that DHA and EPA inhibited IL-6-induced CRP protein and mRNA expression, as well as reduced CRP promoter activity in HepG2 cells. Docosahexaenoic Acids 21-24 C-reactive protein Homo sapiens 56-59 23361365-5 2013 We demonstrated that DHA and EPA inhibited IL-6-induced CRP protein and mRNA expression, as well as reduced CRP promoter activity in HepG2 cells. Docosahexaenoic Acids 21-24 C-reactive protein Homo sapiens 108-111 15704253-2 2004 We investigated the predictive value of homocysteine (Hcy) in relation to C-reactive protein (CRP) and low-density lipoprotein (LDL)-cholesterol in patients with confirmed coronary disease. Homocysteine 54-57 C-reactive protein Homo sapiens 74-92 23827295-12 2013 CONCLUSIONS: CRP provides the highest diagnostic accuracy for PA. Protactinium 62-64 C-reactive protein Homo sapiens 13-16 15704253-9 2004 The results emphasize that detemination of Hcy may improve the predictive value of C-reactive protein and the LDL-cholesterol. Homocysteine 43-46 C-reactive protein Homo sapiens 83-101 22946790-7 2013 Subjects with elevated CRP values had a significant reduction in Standard Deviation of all normal RR intervals at rest (SDNN: p = 0.013), Total Power (TFA: p = 0.04) and Very Low Frequency band (VLF: p = 0.041). Trifluoroacetic Acid 151-154 C-reactive protein Homo sapiens 23-26 23826449-7 2013 Less than 24 h after methylprednisolone administration, the QRS width decreased significantly from 0.44 s to 0.18 s. In addition, CK and CRP levels declined sharply, which is associated with hemodynamic improvement. Methylprednisolone 21-39 C-reactive protein Homo sapiens 137-140 22945607-6 2013 RESULTS: At baseline, BAZ correlated with CRP (r=0.201, P<0.001) and CRP correlated with hepcidin (r=0.384, P<0.001). BIS(5-AMIDINO-BENZIMIDAZOLYL)METHANE ZINC 22-25 C-reactive protein Homo sapiens 42-45 23317933-2 2013 Previous studies assessing the effect of adenotonsillectomy (T&A) on CRP in children with OSAS have yielded conflicting results. t& 61-66 C-reactive protein Homo sapiens 73-76 23317933-3 2013 Therefore, the purpose of the current investigation was to perform a meta-analysis of the effect of T&A on CRP in children with OSAS and explore possible moderating factors. t& 100-105 C-reactive protein Homo sapiens 111-114 23317933-7 2013 RESULTS: Overall, T&A significantly reduced CRP (SMD=-0.79, 95% CI -1.33 to -0.25). t& 18-23 C-reactive protein Homo sapiens 48-51 23317933-10 2013 CONCLUSIONS: The results of the current study indicate that T&A significantly reduces CRP levels in children with OSAS. t& 60-65 C-reactive protein Homo sapiens 90-93 15097439-0 2004 Discordant erythrocyte sedimentation rate and C-reactive protein in children with inflammatory bowel disease taking azathioprine or 6-mercaptopurine. Azathioprine 116-128 C-reactive protein Homo sapiens 46-64 15097439-5 2004 The authors observed an unexplained discordance between ESR and CRP in children with asymptomatic IBD who were being treated with AZA or 6-MP. Azathioprine 130-133 C-reactive protein Homo sapiens 64-67 15097439-6 2004 OBJECTIVE: To characterize children with IBD in remission treated with 6-MP or AZA who have persistently elevated ESR but normal CRP. Azathioprine 79-82 C-reactive protein Homo sapiens 129-132 15097439-12 2004 Duration of AZA or 6-MP therapy was greater in the 11 children with asymptomatic disease and discordant ESR and CRP than in those with or without symptoms and with concordant ESR and CRP (58.1 +/- 16.4 months v 36.6 +/- 24.1 months, P = 0.0043). Azathioprine 12-15 C-reactive protein Homo sapiens 112-115 15097439-12 2004 Duration of AZA or 6-MP therapy was greater in the 11 children with asymptomatic disease and discordant ESR and CRP than in those with or without symptoms and with concordant ESR and CRP (58.1 +/- 16.4 months v 36.6 +/- 24.1 months, P = 0.0043). Azathioprine 12-15 C-reactive protein Homo sapiens 183-186 15097439-16 2004 CONCLUSIONS: The results suggest that among children treated with AZA or 6-MP, CRP may be a more reliable indirect indicator of inflammation than ESR. Azathioprine 66-69 C-reactive protein Homo sapiens 79-82 15097439-17 2004 This report alerts clinicians that some children taking AZA or 6-MP may have persistent elevation of the ESR with a normal CRP and have no clinical evidence of active disease. Azathioprine 56-59 C-reactive protein Homo sapiens 123-126 15086213-7 2004 Mean C-reactive protein of patients treated with octreotide 200 microg tid were 67.37 mg/L before and 48.51, 106.08 and 95.58 mg/L at 24, 48 and 72 hours after the start of therapy respectively. Octreotide 49-59 C-reactive protein Homo sapiens 5-23 23148500-2 2013 We aimed to investigate the effects of valsartan and amlodipine on the PTX3 and C-reactive protein (CRP) levels in patients with essential hypertension. Amlodipine 53-63 C-reactive protein Homo sapiens 80-98 23148500-2 2013 We aimed to investigate the effects of valsartan and amlodipine on the PTX3 and C-reactive protein (CRP) levels in patients with essential hypertension. Amlodipine 53-63 C-reactive protein Homo sapiens 100-103 23148500-7 2013 Although there was a significant decrease in the level of CRP after treatment in amlodipine group, there was no significant decrease in the levels of PTX3 and CRP after treatment in two groups. Amlodipine 81-91 C-reactive protein Homo sapiens 58-61 23629027-3 2012 We found that in CRPtg with established CIA, ASO-mediated lowering of blood human CRP levels improved the clinical signs of arthritis. Oligonucleotides, Antisense 45-48 C-reactive protein Homo sapiens 17-20 23170819-0 2013 The difference in C-reactive protein value between initial and 24 hours follow-up (D-CRP) data as a predictor of mortality in organophosphate poisoned patients. Organophosphates 126-141 C-reactive protein Homo sapiens 18-36 23170819-2 2013 The aim of this study was to evaluate the relationship between the serum C-reactive protein activity and clinical outcome in acute organophosphate-poisoned patients. Organophosphates 131-146 C-reactive protein Homo sapiens 73-91 23170819-11 2013 However, the difference in C-reactive protein value between initial and follow-up after 24 hours (D-CRP) was associated with mortality in the total population of patients with acute organophosphate poisoning. Organophosphates 182-197 C-reactive protein Homo sapiens 27-45 23113871-12 2012 Age-adjusted partial correlation test found a significant correlation between baPWV and CRP (r=0.462, p<0.001). bapwv 78-83 C-reactive protein Homo sapiens 88-91 14734128-11 2004 CONCLUSIONS: Changing immunosuppression from a standard AZA-based regimen to MMF resulted in a decrease in systemic inflammatory activity as indicated by levels of high-sensitive CRP. Azathioprine 56-59 C-reactive protein Homo sapiens 179-182 14734128-11 2004 CONCLUSIONS: Changing immunosuppression from a standard AZA-based regimen to MMF resulted in a decrease in systemic inflammatory activity as indicated by levels of high-sensitive CRP. Mycophenolic Acid 77-80 C-reactive protein Homo sapiens 179-182 23113871-13 2012 Multivariate regression analysis showed that baPWV was independently associated with age (p<0.001), serum albumin level (p=0.015), CRP (p=0.019) and residual renal CCr (p=0.045). bapwv 45-50 C-reactive protein Homo sapiens 134-137 23629027-4 2012 In addition, in healthy human volunteers the ASO was well tolerated and efficacious i.e., treatment achieved significant CRP lowering. Oligonucleotides, Antisense 45-48 C-reactive protein Homo sapiens 121-124 14656034-8 2003 The odds ratios were calculated continuously for homocysteine in dependence on C-reactive protein. Homocysteine 49-61 C-reactive protein Homo sapiens 79-97 23046186-4 2012 We identified an optimal buffer for the elution of CRP, which contained 0.05 M sodium phosphate and 2.0 M NaCl (pH 4.5). sodium phosphate 79-95 C-reactive protein Homo sapiens 51-54 14656034-11 2003 The continuously calculated odds ratio for homocysteine demonstrated a distinct influence of C-reactive protein. Homocysteine 43-55 C-reactive protein Homo sapiens 93-111 22833186-10 2012 However, the nonselective NSAID naproxen was associated with a significant decrease in the CRP level, whereas the cyclooxygenase 2-selective NSAID lumiracoxib was associated with a significant increase in the CRP level. Naproxen 32-40 C-reactive protein Homo sapiens 91-94 14656034-12 2003 In the group with high C-reactive protein levels, homocysteine levels above 9.6 micromol/l resulted in a markedly elevated risk (odds ratio 12), in the group with C-reactive protein levels below 5 mg/dl, a comparable risk increase was observed at a homocysteine level of 16.6 micromol/l. Homocysteine 50-62 C-reactive protein Homo sapiens 23-41 14656034-13 2003 This data strongly suggests that plasma homocysteine helps identify individuals at risk, especially among those with elevated C-reactive protein levels. Homocysteine 40-52 C-reactive protein Homo sapiens 126-144 22862963-8 2012 Adjustment for fasting glucose, insulin, and C-reactive protein further attenuated the association for DHEA but not for SHBG. Dehydroepiandrosterone 103-107 C-reactive protein Homo sapiens 45-63 22966033-9 2012 CRP was highest initially among patients with simultaneous ABO + ABA and among those with complicated outcomes, and was lower at the transition to oral therapy in the complicated outcome group (1.5 vs 2.1 mg/dL; P = .012). 6-amino-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine 59-62 C-reactive protein Homo sapiens 0-3 14504187-0 2003 C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Epoprostenol 29-41 C-reactive protein Homo sapiens 0-18 14504187-5 2003 Hence, the aim of this study was to examine the effect of CRP on PGI2 release from HAECs and human coronary artery endothelial cells (HCAECs). Epoprostenol 65-69 C-reactive protein Homo sapiens 58-61 22528165-12 2012 The mean (standard deviation) changes in CRP levels from baseline at 48 hr in Groups AA, PA, and PP were 141.0 (72.4), 153.5 (42.2), and 111.2 (84.6), respectively. Protactinium 89-91 C-reactive protein Homo sapiens 41-44 14504187-8 2003 CRP significantly decreased PGF-1alpha release from HAECs under basal (48% decrease, P<0.001; n=5) and stimulated (26% decrease, P<0.01; n=5) conditions. Prostaglandins F 28-31 C-reactive protein Homo sapiens 0-3 14504187-12 2003 CONCLUSIONS: Thus, CRP decreases PGI2 release from HAECs by inactivating PGIS via nitration, additionally contributing to its atherogenicity. Epoprostenol 33-37 C-reactive protein Homo sapiens 19-22 12947436-5 2003 RESULTS: C-reactive protein concentration (dichotomized at the sex-specific 85th percentile) was inversely and significantly associated with concentrations of retinol, retinyl esters, vitamin C, alpha-carotene, beta-carotene, cryptoxanthin, lutein/zeaxanthin, lycopene, and selenium after adjustment for age, sex, race or ethnicity, education, cotinine concentration, body mass index, leisure-time physical activity, and aspirin use. Cryptoxanthins 226-239 C-reactive protein Homo sapiens 9-27 12947436-5 2003 RESULTS: C-reactive protein concentration (dichotomized at the sex-specific 85th percentile) was inversely and significantly associated with concentrations of retinol, retinyl esters, vitamin C, alpha-carotene, beta-carotene, cryptoxanthin, lutein/zeaxanthin, lycopene, and selenium after adjustment for age, sex, race or ethnicity, education, cotinine concentration, body mass index, leisure-time physical activity, and aspirin use. Lutein 241-247 C-reactive protein Homo sapiens 9-27 14531304-8 2003 Intravenous panipenem/betamiprom was prescribed, and after 5 weeks, the patient recovered, was negative for C-reactive protein and had a negative venous blood culture. betamiprom 22-32 C-reactive protein Homo sapiens 108-126 22819907-8 2012 Multivariate analysis indicated that elevated CRP level was a significant risk factor for the positive findings of CTE (odds ratio 1.950; 95% CI (1.165-3.265), p=0.011). 1,1,1-trifluoro-2-chloroethane 115-118 C-reactive protein Homo sapiens 46-49 22819907-9 2012 CONCLUSIONS: The results of this study suggest that CTE could be helpful in patients suffering from unexplained gastrointestinal symptoms that cannot be explained by established examinations, especially those with elevated C-reactive protein levels. 1,1,1-trifluoro-2-chloroethane 52-55 C-reactive protein Homo sapiens 223-241 22081542-8 2012 Elevated hs-CRP at diagnosis was associated with disease location (P = 0.002), noninflammatory disease behavior (P = 0.058), and a subsequent need for later azathioprine/biological therapy (P < 0.001 and P = 0.024), respectively. Azathioprine 157-169 C-reactive protein Homo sapiens 12-15 22707608-8 2012 High C-reactive protein levels were associated with IFI, along with other factors such as high disease activity, mechanical ventilation, treatment with antibiotics, hemodialysis, high doses of glucocorticoids (GC), and treatment with mycophenolate mofetil. Mycophenolic Acid 234-255 C-reactive protein Homo sapiens 5-23 22412070-10 2012 Intake of sugar-sweetened but not artificially sweetened beverages was significantly associated with increased plasma triglycerides, C-reactive protein, interleukin-6, and tumor necrosis factor receptors 1 and 2 and decreased high-density lipoprotein, lipoprotein(a), and leptin (P<0.02). Sugars 10-15 C-reactive protein Homo sapiens 133-151 21968012-0 2012 Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial. Pentoxifylline 0-14 C-reactive protein Homo sapiens 88-106 21968012-6 2012 CONCLUSIONS: Pentoxifylline significantly decreased serum concentrations of TNF-alpha, IL-6 and CRP compared to placebo. Pentoxifylline 13-27 C-reactive protein Homo sapiens 96-99 12919896-6 2003 The levels of CRP was closely correlated with neopterin, TNF-alpha and IL-1beta(r=0.287, 0.314, 0.262, P<0.05, respectively), and SAA with neopterin (r=0.306, P<0.05). Neopterin 142-151 C-reactive protein Homo sapiens 14-17 22919212-0 2012 Effect of locally delivered tetracycline hydrochloride as an adjunct to scaling and root planing on Hba1c, C-reactive protein, and lipid profile in type 2 diabetes: A clinico-biochemical study. Tetracycline 28-54 C-reactive protein Homo sapiens 107-125 12926656-4 2003 The acute (as measured by C-reactive protein, CRP) and chronic (by erythrocyte sedimentation rate, ESR) phases of RF+ RA were suppressed by pulse intravenous (IV) combination of low dose methylprednisolone (MPS) + cyclophosphamide (CYC) for 3 consecutive days and weekly intravenous methotrexate (MTX) with simultaneous oral cyclosporine (CSA) + mycophenolate mofetil (MPM). Methylprednisolone 187-205 C-reactive protein Homo sapiens 26-44 12926656-4 2003 The acute (as measured by C-reactive protein, CRP) and chronic (by erythrocyte sedimentation rate, ESR) phases of RF+ RA were suppressed by pulse intravenous (IV) combination of low dose methylprednisolone (MPS) + cyclophosphamide (CYC) for 3 consecutive days and weekly intravenous methotrexate (MTX) with simultaneous oral cyclosporine (CSA) + mycophenolate mofetil (MPM). Methylprednisolone 187-205 C-reactive protein Homo sapiens 46-49 22349026-0 2012 The dual behavior of heat shock protein 70 and asymmetric dimethylarginine in relation to serum CRP levels in type 2 diabetes. dimethylarginine 58-74 C-reactive protein Homo sapiens 96-99 22349026-7 2012 Serum HSP70 and ADMA levels were significantly correlated in patients with high CRP levels (r=0.89, p<0.01), whereas there were no correlation in patients with low CRP (r=-0.37, p=0.07) and controls. N,N-dimethylarginine 16-20 C-reactive protein Homo sapiens 80-83 21889590-5 2012 We found that larger WMH volume was associated with advanced age, hypertension, and elevated levels of homocysteine and CRP but not with low-density lipoprotein levels. 1-methyl-1H-1,2,3-triazole 21-24 C-reactive protein Homo sapiens 120-123 21889590-6 2012 Homozygotes for IL-1beta-511T allele and carriers of CRP-286T allele that are associated with increased inflammatory response had larger WMH than the other allelic combinations. 1-methyl-1H-1,2,3-triazole 137-140 C-reactive protein Homo sapiens 53-56 15147103-6 2003 Homocysteine was associated with increased anger (anger-suppression and anger-experience), psychological parameters associated with cardiovascular disease and also mildly elevated CRP and homocysteine levels. Homocysteine 0-12 C-reactive protein Homo sapiens 180-183 23204899-10 2012 The area under the curve for cytokines and CRP for the silymarin group were significantly lower compared with preoperative levels, and were significantly lower compared with postoperative control group levels. Silymarin 55-64 C-reactive protein Homo sapiens 43-46 14696756-13 2003 SA was strongly correlated with CRP (r = 0.59, p < 0.0001), but not with patient age, any measure of blood pressure (BP), urea reduction ratio, plasma creatinine, lipid fractions or homocysteine. N-Acetylneuraminic Acid 0-2 C-reactive protein Homo sapiens 32-35 22509446-5 2012 RESULTS: Among the five subclasses of POPs, only organochlorine (OC) pesticides showed positive associations with CRP concentrations, while polychlorinated biphenyls (PCBs) showed inverse associations with CRP concentrations. POPS 38-42 C-reactive protein Homo sapiens 114-117 22997483-6 2012 Actinomycin D treatment completely prevented CRP and TNF-alpha induction of PAPP-A mRNA and protein expression. Dactinomycin 0-13 C-reactive protein Homo sapiens 45-48 14696756-14 2003 Levels of the chronic inflammation marker sialic acid correlate strongly with CRP and are increased in patients with cardiovascular disease, but show no relationship to hemodialysis session. N-Acetylneuraminic Acid 42-53 C-reactive protein Homo sapiens 78-81 12741936-7 2003 There were significant inverse linear relationships between concentrations of CRP and plasma concentrations of the antioxidants lycopene, beta-carotene, cryptoxanthin and retinol. Cryptoxanthins 153-166 C-reactive protein Homo sapiens 78-81 22189224-7 2011 NAF-chemotherapy for advanced esophageal cancer was very effective even when patients had malnutrition or high CRP levels. Sodium Fluoride 0-3 C-reactive protein Homo sapiens 111-114 12716789-10 2003 Serum C-reactive protein was significantly associated with percent linoleic acid and eicosapentaenoic acid in nonsmoking men (P = 0.03 and P = 0.04, respectively) and with docosahexaenoic acid in nonsmoking women (r = -0.46, P < 0.0001). Docosahexaenoic Acids 172-192 C-reactive protein Homo sapiens 6-24 12738395-13 2003 CRP was positively associated with body mass index (BMI), serum triglycerides, and sulfonylurea therapy and negatively associated with metformin therapy. Sulfonylurea Compounds 83-95 C-reactive protein Homo sapiens 0-3 22455741-8 2012 The level of CRP of (8.2 +- 14.9) mg/L before delivery in HCA group was significantly higher than (5.5 +- 7.2) mg/L in control group (P < 0.05). hca 58-61 C-reactive protein Homo sapiens 13-16 22934219-0 2012 The Value of Desmethylclozapine and Serum CRP in Clozapine Toxicity: A Case Report. Clozapine 49-58 C-reactive protein Homo sapiens 42-45 21784451-6 2011 BMIz was associated with elevated triglycerides (beta = 0.13), CRP (beta = 0.58), and interleukin-6 (beta= 0.14) and low high-density lipoprotein cholesterol (beta = -0.09; all P < .01). bmiz 0-4 C-reactive protein Homo sapiens 63-66 22057283-11 2012 CONCLUSIONS: Younger age (<30 years) and increased C-reactive protein level at remission were independent predictors of relapse in Crohn"s disease patients receiving thiopurines to maintain remission. thiopurines 169-180 C-reactive protein Homo sapiens 54-72 22121485-9 2012 In comparison to AVFs, the presence of a TC was associated with significantly higher levels of CRP (P = 0.03), IL-6 (P = 0.07), and IP-10 (P = 0.03). Technetium 41-43 C-reactive protein Homo sapiens 95-98 12660125-9 2003 Fifteen patients in the chlorhexidine-based group had a C-reactive protein (CRP) increase >50mg/L, compared with only eight patients in the control group [odds ratio: 3.13, confidence interval (CI) 0.82-12.39]. Chlorhexidine 24-37 C-reactive protein Homo sapiens 56-74 12660125-9 2003 Fifteen patients in the chlorhexidine-based group had a C-reactive protein (CRP) increase >50mg/L, compared with only eight patients in the control group [odds ratio: 3.13, confidence interval (CI) 0.82-12.39]. Chlorhexidine 24-37 C-reactive protein Homo sapiens 76-79 12660125-14 2003 Twelve of 15 patients in the chlorhexidine-based group had a CRP >50mg/L whereas only eight of 15 patients did so in the control group, which can be regarded as a slightly elevated risk for a CRP increase in the former group. Chlorhexidine 29-42 C-reactive protein Homo sapiens 61-64 12660125-14 2003 Twelve of 15 patients in the chlorhexidine-based group had a CRP >50mg/L whereas only eight of 15 patients did so in the control group, which can be regarded as a slightly elevated risk for a CRP increase in the former group. Chlorhexidine 29-42 C-reactive protein Homo sapiens 195-198 12660125-16 2003 These differences were not significant, but patients treated with chlorhexidine-based product seemed to have more problems with inflammation of the oral mucous membranes, resulting in an elevated mucositis score and a CRP increase. Chlorhexidine 66-79 C-reactive protein Homo sapiens 218-221 12641538-9 2003 CONCLUSIONS: Homocysteine-lowering vitamin treatment in healthy siblings of patients with premature atherosclerotic disease is associated with a decreased urinary albumin-to-creatinine ratio, but not with other markers of endothelial dysfunction, or in plasma C-reactive protein. Homocysteine 13-25 C-reactive protein Homo sapiens 260-278 20592101-8 2011 In addition, CRP was positively associated with TBARS and carbonyl levels, but was significantly inversely associated with Zn and Se levels. Selenium 130-132 C-reactive protein Homo sapiens 13-16 12198121-4 2002 By contrast, native pentameric CRP and CRP peptides 77-82, 174-185, and 201-206 failed to affect neutrophil apoptosis. Peptides 43-51 C-reactive protein Homo sapiens 39-42 12351557-6 2002 RESULTS: Both doses of tibolone and E(2) + NETA increased serum CRP by a similar extent as soon as 6 months with a sustained effect over the 24 month treatment period. tibolone 23-31 C-reactive protein Homo sapiens 64-67 21771657-3 2011 In this paper, we discuss the evidence that doxycycline and related non-antibiotic chemically modified tetracyclines (e.g., CMT-3) can effectively reduce cytokine (TNF-alpha, IL-6, and MCP-1) production by human mononuclear inflammatory cells when stimulated either by endotoxin (LPS) or by a complex of C-reactive protein/oxidized LDL cholesterol relevant to the pathogenesis of periodontal disease and ASCVD, respectively. Doxycycline 44-55 C-reactive protein Homo sapiens 304-322 24843534-9 2011 In contrast, the treatment with olmesartan/trichlormethiazide resulted in increased HbA1c, serum uric acid and worsening of estimated glomerular filtration rate, though there were no differences in other metabolic parameters including urine 8-hydroxy-2"-deoxyguanosine, C-reactive protein and adiponectin between the two treatments. olmesartan 32-42 C-reactive protein Homo sapiens 270-288 12351557-7 2002 For example, after 6 months of treatment, serum CRP increased by a median of +106% (P < 0.001), +89% (P < 0.05) and +139% (P < 0.001) for tibolone 1.25 mg/day, tibolone 2.5 mg/day and E(2) + NETA respectively. tibolone 147-155 C-reactive protein Homo sapiens 48-51 21648471-0 2011 Copper-glucosamine microcubes: synthesis, characterization, and C-reactive protein detection. copper-glucosamine 0-18 C-reactive protein Homo sapiens 64-82 12351557-7 2002 For example, after 6 months of treatment, serum CRP increased by a median of +106% (P < 0.001), +89% (P < 0.05) and +139% (P < 0.001) for tibolone 1.25 mg/day, tibolone 2.5 mg/day and E(2) + NETA respectively. tibolone 169-177 C-reactive protein Homo sapiens 48-51 12351557-8 2002 CONCLUSIONS: Tibolone and E(2) + NETA significantly increase serum CRP levels in healthy post-menopausal women to a comparable extent. tibolone 13-21 C-reactive protein Homo sapiens 67-70 21654459-15 2011 The factors that were characteristic of IPOM were: fever, limp, pain with rotation of the hip, elevated erythrocyte sedimentation rate, elevated C-reactive protein (CRP), and positive blood culture. ipom 40-44 C-reactive protein Homo sapiens 145-163 12351557-9 2002 Relationships between induced elevated CRP levels with tibolone and E(2) + NETA and cardiovascular events require further studies. tibolone 55-63 C-reactive protein Homo sapiens 39-42 22340226-7 2011 The erythrocytic H(2)S production was associated with increased systolic blood pressure (sBP), diastolic blood pressure (dBP), age, BMI, level of C-reactive protein (CRP), as well as triglycerides (TG) and high density lipoprotein cholesterol (HDL-C). Hydrogen Sulfide 17-22 C-reactive protein Homo sapiens 146-164 22340226-7 2011 The erythrocytic H(2)S production was associated with increased systolic blood pressure (sBP), diastolic blood pressure (dBP), age, BMI, level of C-reactive protein (CRP), as well as triglycerides (TG) and high density lipoprotein cholesterol (HDL-C). Hydrogen Sulfide 17-22 C-reactive protein Homo sapiens 166-169 21809148-1 2011 PURPOSE: We hypothesized that patients who received ketamine during thoracic surgery would benefit from suppression of the inflammatory cascade, represented by lower interleukin (IL)-6 and C-reactive protein (CRP) plasma levels. Ketamine 52-60 C-reactive protein Homo sapiens 189-207 24387072-3 2002 Methylprednisolone pulse therapy was effective in improving the serositis and normalizing CRP. Methylprednisolone 0-18 C-reactive protein Homo sapiens 90-93 21654459-15 2011 The factors that were characteristic of IPOM were: fever, limp, pain with rotation of the hip, elevated erythrocyte sedimentation rate, elevated C-reactive protein (CRP), and positive blood culture. ipom 40-44 C-reactive protein Homo sapiens 165-168 21809148-1 2011 PURPOSE: We hypothesized that patients who received ketamine during thoracic surgery would benefit from suppression of the inflammatory cascade, represented by lower interleukin (IL)-6 and C-reactive protein (CRP) plasma levels. Ketamine 52-60 C-reactive protein Homo sapiens 209-212 21505297-10 2011 CONCLUSION: Patients with unmasking TB-IRIS had higher pre-ART levels of plasma IFN-gamma and CRP, consistent with preexisting subclinical TB. Terbium 36-38 C-reactive protein Homo sapiens 94-97 21817894-9 2011 After the second PMX-F treatment, the patient"s temperature decreased to 37.0 C, and his WBC count, CRP levels, blood endotoxin, and PCT levels decreased. pmx-f 17-22 C-reactive protein Homo sapiens 100-103 21817894-12 2011 This case reflects association of PMX-F with decreased endotoxin, PCT, and CRP, suggesting the association of PMX-F with clinical improvement in mild-moderate sepsis in a young athlete. pmx-f 34-39 C-reactive protein Homo sapiens 75-78 21817894-12 2011 This case reflects association of PMX-F with decreased endotoxin, PCT, and CRP, suggesting the association of PMX-F with clinical improvement in mild-moderate sepsis in a young athlete. pmx-f 110-115 C-reactive protein Homo sapiens 75-78 21677600-6 2011 The levels of C-reactive protein and vascular cell adhesion molecule-1 declined significantly with AZA+everolimus, whereas MMF+everolimus patients demonstrated a significant increase in levels of C-reactive protein, vascular cell adhesion molecule-1, and von Willebrand factor. Azathioprine 99-102 C-reactive protein Homo sapiens 14-32 21677600-6 2011 The levels of C-reactive protein and vascular cell adhesion molecule-1 declined significantly with AZA+everolimus, whereas MMF+everolimus patients demonstrated a significant increase in levels of C-reactive protein, vascular cell adhesion molecule-1, and von Willebrand factor. Everolimus 103-113 C-reactive protein Homo sapiens 14-32 21677600-6 2011 The levels of C-reactive protein and vascular cell adhesion molecule-1 declined significantly with AZA+everolimus, whereas MMF+everolimus patients demonstrated a significant increase in levels of C-reactive protein, vascular cell adhesion molecule-1, and von Willebrand factor. Everolimus 127-137 C-reactive protein Homo sapiens 196-214 21733822-7 2011 Celecoxib significantly reduced plasma c-reactive protein and interleukin-6 mRNA and protein and increased 15(S)-hydroxy-eicosatetraenoic acid levels in bronchoalveolar lavage (BAL) samples. Celecoxib 0-9 C-reactive protein Homo sapiens 39-57 21870702-2 2011 MATERIAL AND METHODS: C-reactive protein measurement clinical value was examined by high sensitivity CRP method (hsCRP) and compared to clinical value of other heart attack risk factors: total cholesterol (TC) and cholesterol in HDL fraction (HDL-C), triglycerides (TG) and fibrinogen (FBG). Technetium 206-208 C-reactive protein Homo sapiens 22-40 21524186-9 2011 Cessation of clozapine is advised if troponin is more than twice the upper limit of normal or C-reactive protein is over 100 mg/L. Clozapine 13-22 C-reactive protein Homo sapiens 94-112 21422984-0 2011 High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. Ritonavir 105-114 C-reactive protein Homo sapiens 17-35 21441154-9 2011 However, with consideration of CAB, CAB (>=2 segments with >=50% stenosis) remained the only independent predictor for the highest quartile of C-reactive protein (OR, 8.69; 95% CI, 2.41-31.30) and homocysteine (OR, 11.44; 95% CI, 2.61-50.11). Homocysteine 203-215 C-reactive protein Homo sapiens 149-167 21117970-7 2011 TG and high-sensitivity C-reactive protein had greater reductions in the fenofibrate and fenofibrate plus ezetimibe groups than the ezetimibe alone group (P <= 0.05 for both) CONCLUSIONS: In this analysis of patients with mixed dyslipidemia, the lipid effects of ezetimibe plus fenofibrate were generally similar in metabolic syndrome patients versus those without metabolic syndrome. Ezetimibe 106-115 C-reactive protein Homo sapiens 24-42 21117970-7 2011 TG and high-sensitivity C-reactive protein had greater reductions in the fenofibrate and fenofibrate plus ezetimibe groups than the ezetimibe alone group (P <= 0.05 for both) CONCLUSIONS: In this analysis of patients with mixed dyslipidemia, the lipid effects of ezetimibe plus fenofibrate were generally similar in metabolic syndrome patients versus those without metabolic syndrome. Ezetimibe 132-141 C-reactive protein Homo sapiens 24-42 21117970-7 2011 TG and high-sensitivity C-reactive protein had greater reductions in the fenofibrate and fenofibrate plus ezetimibe groups than the ezetimibe alone group (P <= 0.05 for both) CONCLUSIONS: In this analysis of patients with mixed dyslipidemia, the lipid effects of ezetimibe plus fenofibrate were generally similar in metabolic syndrome patients versus those without metabolic syndrome. Ezetimibe 132-141 C-reactive protein Homo sapiens 24-42 21274876-11 2011 CRP and TNFalpha concentrations were independent predictors of abnormal PHES, ammonia and indole of abnormal EEG on multivariate analysis. Ammonia 78-85 C-reactive protein Homo sapiens 0-3 21325823-8 2011 The further study indicated that losartan, NAC, MEK1/2 inhibitor PD98059, p38MAPK inhibitor SB203580 obviously inhibited ERK1/2 and p38MAPK phosphorylation, and PD98059, SB203580 and NF-kappaB inhibitor PDTC reduced Ang II -induced mRNA and protein expression of CRP in U937 macrophages. Losartan 33-41 C-reactive protein Homo sapiens 263-266 21774782-5 2011 The CRP-lowering effects of tocotrienols are greater than tocopherol. Tocotrienols 28-40 C-reactive protein Homo sapiens 4-7 20714167-0 2011 C-reactive protein and mortality in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). dopps 110-115 C-reactive protein Homo sapiens 0-18 20434720-3 2010 In this study, we decided to evaluate the association between asymmetric dimethylarginine ([ADMA], an endogenous NO synthase inhibitor), high-sensitivity C-reactive protein ([hs-CRP]; a marker of chronic inflammation) and insulin resistance in early-stage type-2 diabetes. dimethylarginine 73-89 C-reactive protein Homo sapiens 154-172 20434720-3 2010 In this study, we decided to evaluate the association between asymmetric dimethylarginine ([ADMA], an endogenous NO synthase inhibitor), high-sensitivity C-reactive protein ([hs-CRP]; a marker of chronic inflammation) and insulin resistance in early-stage type-2 diabetes. dimethylarginine 73-89 C-reactive protein Homo sapiens 178-181 20434720-3 2010 In this study, we decided to evaluate the association between asymmetric dimethylarginine ([ADMA], an endogenous NO synthase inhibitor), high-sensitivity C-reactive protein ([hs-CRP]; a marker of chronic inflammation) and insulin resistance in early-stage type-2 diabetes. N,N-dimethylarginine 92-96 C-reactive protein Homo sapiens 154-172 20434720-11 2010 The association between ADMA and HOMA-IR in diabetic patients remained significant (r=0.255; p<0.05), after adjustment for BMI, waist circumference, serum lipids, and hs-CRP. N,N-dimethylarginine 24-28 C-reactive protein Homo sapiens 173-176 20716150-5 2010 RESULTS: C-reactive protein correlated negatively with TC (r = -0.184, p = 0.002), more so with HDLc (r = -0.327, p = 0.001) and therefore positively with TC:HDLc ratio (r = 0.204, p = 0.001). Technetium 55-57 C-reactive protein Homo sapiens 9-27 20716150-5 2010 RESULTS: C-reactive protein correlated negatively with TC (r = -0.184, p = 0.002), more so with HDLc (r = -0.327, p = 0.001) and therefore positively with TC:HDLc ratio (r = 0.204, p = 0.001). Technetium 155-157 C-reactive protein Homo sapiens 9-27 20716150-7 2010 Furthermore, the TC:HDLc ratio, but not TC, was positively related to event risk, again most marked in those with elevated CRP. Technetium 17-19 C-reactive protein Homo sapiens 123-126 20529243-7 2010 Both drugs induced reductions in C-reactive protein, reaching statistical significance after combining ezetimibe with the simvastatin therapy (baseline 0.59 +/- 0.14, simvastatin monotherapy 0.48 +/- 0.12 mg/dL and 0.35 +/- 0.12 mg/dL, p < 0.023). Ezetimibe 103-112 C-reactive protein Homo sapiens 33-51 20138492-7 2010 Multivariate linear regression analysis demonstrated a significant correlation between the change in the LF/HF ratio and that in the baPWV (beta=0.305, p=0.041), independent of the changes in the MBP, plasma CRP levels and heart rate. bapwv 133-138 C-reactive protein Homo sapiens 208-211 20234301-6 2010 The reduction of high-sensitive C-reactive protein (mg/L) and serum asymmetric dimethylarginine (micromol/L) was significantly greater in the AZ group than in the TCM group (between-group difference was 0.18 and 0.05; 95%CI: -0.01 to 0.36 and -0.01 to 0.11; P = 0.04 and 0.02, respectively). alizarin 142-144 C-reactive protein Homo sapiens 32-50 20229495-5 2010 RESULTS: : Higher values of body mass index (BMI), total cholesterol, LDL, cholesterol, TG, SDE, leucocytes, and CRP were calculated in children with PFH. N-n-Propyl-N-formylhydrazine 150-153 C-reactive protein Homo sapiens 113-116 21348392-13 2010 We observed an inverse correlation between serum magnesium and hs-CRP (r = -0.37, p = 0.02) in PD patients. Magnesium 49-58 C-reactive protein Homo sapiens 66-69 20001811-7 2009 The number of patients with elevated neopterin level was significantly correlated with stage, gastric wall involvement, the number of metastatic lymph nodes, and the level of serum CRP. Neopterin 37-46 C-reactive protein Homo sapiens 181-184 20001811-8 2009 The mean neopterin concentrations were significantly elevated in patients older than 60 years, in the presence of venous invasion and increased metastatic lymph node number, and in patients with elevated CRP levels. Neopterin 9-18 C-reactive protein Homo sapiens 204-207 19920794-5 2009 CRP revealed a negative correlation with DHEA (r = -0.248, P <0.05), although not with DHEA-S. Dehydroepiandrosterone 41-45 C-reactive protein Homo sapiens 0-3 19410579-8 2009 CRP also reduced basal NO production, caused tyrosine nitration of endothelial PGI(2)-S, and inhibited AA-stimulated PGI(2) release from arterioles. Epoprostenol 79-85 C-reactive protein Homo sapiens 0-3 19410579-11 2009 Collectively, our results suggest that CRP stimulates superoxide production and the subsequent formation of peroxynitrite from basal released NO compromises PGI(2) synthesis, and thus endothelium-dependent PGI(2)-mediated dilation, by inhibiting PGI(2)-S activity through tyrosine nitration. Epoprostenol 157-163 C-reactive protein Homo sapiens 39-42 19410579-11 2009 Collectively, our results suggest that CRP stimulates superoxide production and the subsequent formation of peroxynitrite from basal released NO compromises PGI(2) synthesis, and thus endothelium-dependent PGI(2)-mediated dilation, by inhibiting PGI(2)-S activity through tyrosine nitration. Epoprostenol 206-212 C-reactive protein Homo sapiens 39-42 19410579-11 2009 Collectively, our results suggest that CRP stimulates superoxide production and the subsequent formation of peroxynitrite from basal released NO compromises PGI(2) synthesis, and thus endothelium-dependent PGI(2)-mediated dilation, by inhibiting PGI(2)-S activity through tyrosine nitration. Epoprostenol 206-212 C-reactive protein Homo sapiens 39-42 19410579-12 2009 By impairing PGI(2)-S function, and thus PGI(2) release, CRP could promote endothelial dysfunction and participate in the development of coronary artery disease. Epoprostenol 13-19 C-reactive protein Homo sapiens 57-60 19410579-12 2009 By impairing PGI(2)-S function, and thus PGI(2) release, CRP could promote endothelial dysfunction and participate in the development of coronary artery disease. Epoprostenol 41-47 C-reactive protein Homo sapiens 57-60 19461006-14 2009 CONCLUSIONS: The study demonstrates that consuming 960 mg/d of EPA and 600 mg/d of DHA can lower CRP. Docosahexaenoic Acids 83-86 C-reactive protein Homo sapiens 97-100 19463506-3 2009 High-sensitivity C-reactive protein levels, similar in the 2 groups at baseline, were significantly more decreased by telmisartan than by ramipril at follow up (p = 0.013 for time-by-drug interaction). Telmisartan 118-129 C-reactive protein Homo sapiens 17-35 12087039-0 2002 Effect of losartan on plasma C-reactive protein in type 2 diabetic patients with microabluminuria. Losartan 10-18 C-reactive protein Homo sapiens 29-47 11996943-3 2002 The present study evaluated the effects of atorvastatin (10-40 mg) and bezafibrate (400 mg) on CRP concentrations after 6 and 12 months of treatment in 103 patients with combined (mixed) hyperlipidemia. Bezafibrate 71-82 C-reactive protein Homo sapiens 95-98 12075573-9 2002 Twenty-three (82.1%) of the subjects with low serum magnesium (five overweight and 18 obese) showed CRP concentration equal or more than 10 mg/l. Magnesium 52-61 C-reactive protein Homo sapiens 100-103 12075573-10 2002 There was a graded significant decrease between CRP concentration and serum magnesium levels (r = -0.39, P = 0.002). Magnesium 76-85 C-reactive protein Homo sapiens 48-51 12075573-12 2002 CONCLUSION: The results of this study show that low serum magnesium levels are independently related to elevated CRP concentration, in non-diabetic, non-hypertensive obese subjects. Magnesium 58-67 C-reactive protein Homo sapiens 113-116 11822785-5 2001 RESULTS: Serum osteocalcin and carboxyterminal propeptide of type I procollagen (markers of bone metabolism) were significantly decreased in the clodronate group at the end of the study, whereas the indices of disease activity including number of swollen joints, number of tender joints, patient"s and doctor"s estimation of condition (visual analogue scale), erythrocyte sedimentation rate and serum C-reactive protein level were not affected by clodronate treatment. Clodronic Acid 145-155 C-reactive protein Homo sapiens 401-419 11476244-4 2001 It was found that 2.5 mmol/L concentrations of the small cationic surfactant tetramethylammonium hydroxide (TMH), when present alone, substantially increased both reaction rates and sensitivity in the lower clinical ranges of CRP concentration when compared to normally used assay conditions containing PEG and the anionic detergent Gafac. tetramethylammonium 77-106 C-reactive protein Homo sapiens 226-229 11476244-4 2001 It was found that 2.5 mmol/L concentrations of the small cationic surfactant tetramethylammonium hydroxide (TMH), when present alone, substantially increased both reaction rates and sensitivity in the lower clinical ranges of CRP concentration when compared to normally used assay conditions containing PEG and the anionic detergent Gafac. tetramethylammonium 108-111 C-reactive protein Homo sapiens 226-229 11128362-3 2000 RESULTS: There was a statistically significant positive crude correlation between C-reactive protein and TC (R = 0.19), TG (R = 0.29), BMI (R = 0.32), glucose (R = 0.11), and uric acid (R = 0.14) (all P < 0.0001). Technetium 105-107 C-reactive protein Homo sapiens 82-100 10934201-2 2000 The cNMP-ligated CRP and mutants were cAMP, cGMP, and cIMP ligated with CRP, T127L CRP, S128A CRP, and T127L/S128A CRP. Cyclic IMP 54-58 C-reactive protein Homo sapiens 17-20 10934201-2 2000 The cNMP-ligated CRP and mutants were cAMP, cGMP, and cIMP ligated with CRP, T127L CRP, S128A CRP, and T127L/S128A CRP. Cyclic IMP 54-58 C-reactive protein Homo sapiens 72-75 10934201-2 2000 The cNMP-ligated CRP and mutants were cAMP, cGMP, and cIMP ligated with CRP, T127L CRP, S128A CRP, and T127L/S128A CRP. Cyclic IMP 54-58 C-reactive protein Homo sapiens 72-75 10934201-2 2000 The cNMP-ligated CRP and mutants were cAMP, cGMP, and cIMP ligated with CRP, T127L CRP, S128A CRP, and T127L/S128A CRP. Cyclic IMP 54-58 C-reactive protein Homo sapiens 72-75 10934201-2 2000 The cNMP-ligated CRP and mutants were cAMP, cGMP, and cIMP ligated with CRP, T127L CRP, S128A CRP, and T127L/S128A CRP. Cyclic IMP 54-58 C-reactive protein Homo sapiens 72-75 11040177-7 2000 C-reactive protein levels significantly decreased in the methylprednisolone group but not in the heparin group. Methylprednisolone 57-75 C-reactive protein Homo sapiens 0-18 10488951-10 1999 Plasma sialic acid concentration correlated with C-reactive protein (r = 0.58, P = 0.0001), serum triglyceride (r = 0.32, P = 0.002), and blood cholesterol concentration (r = 0.22, P = 0.04). N-Acetylneuraminic Acid 7-18 C-reactive protein Homo sapiens 49-67 9457607-8 1997 When only positive blood-cultures associated with a rise in C-reactive protein were considered, there were six episodes of CONS bacteraemia in the vancomycin group compared with 18 in the control group. Vancomycin 147-157 C-reactive protein Homo sapiens 60-78 9201433-2 1997 FAT is based on the property of CRP to agglutinate fat emulsions in the presence of CaCl2. Calcium Chloride 84-89 C-reactive protein Homo sapiens 32-35 8743104-5 1996 Addition of K3-EDTA to the reaction buffer improved the kinetics for sera with low concentrations of CRP, thus increasing the sensitivity of the assay. k3-edta 12-19 C-reactive protein Homo sapiens 101-104 7685225-4 1993 The DMARDs such as gold salts, D-penicillamine, sulphasalazine and azathioprine have been shown to reduce serum CRP concentrations significantly in patients with RA. Azathioprine 67-79 C-reactive protein Homo sapiens 112-115 2246517-10 1990 A synthetic peptide, RKSLKK, from the CRP sequence, when coupled to FITC-albumin, also mediated nuclear localization. Fluorescein-5-isothiocyanate 68-72 C-reactive protein Homo sapiens 38-41 2166760-4 1990 We report on the reverse phase HPLC separation of the small TCA-soluble peptides obtained when CRP is degraded with nonstimulated or PMA-stimulated neutrophils and purified neutrophil membranes. Trichloroacetic Acid 60-63 C-reactive protein Homo sapiens 95-98 2162197-6 1990 The amide I analyses indicated a structural distribution of 44% alpha-helix, 28% beta-strand, 18% turn, and 10% undefined for CRP in solution. Amides 4-9 C-reactive protein Homo sapiens 126-129 2162197-10 1990 Analysis of the amide I region of the CRP-cAMP cocrystal spectrum indicated a secondary structure distribution of 37% alpha-helix, 33% beta-strand, 17% turn, and 12% undefined. Amides 16-21 C-reactive protein Homo sapiens 38-41 33818688-6 2021 In clinical trials conducted in patients with or at risk for atherosclerotic cardiovascular disease or familial heterozygous hypercholesterolemia, bempedoic acid in combination with statins and/or ezetimibe significantly reduced LDL-C, apolipoprotein B, and high-sensitivity C-reactive protein compared with placebo. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 147-161 C-reactive protein Homo sapiens 275-293 33818688-6 2021 In clinical trials conducted in patients with or at risk for atherosclerotic cardiovascular disease or familial heterozygous hypercholesterolemia, bempedoic acid in combination with statins and/or ezetimibe significantly reduced LDL-C, apolipoprotein B, and high-sensitivity C-reactive protein compared with placebo. Ezetimibe 197-206 C-reactive protein Homo sapiens 275-293 32797224-7 2021 In addition, celecoxib has certain advantages in terms of better treatment effects and greater reductions in the ESR, CRP level, and complication rate. Celecoxib 13-22 C-reactive protein Homo sapiens 118-121 22549098-8 2012 Regression analysis models showed that CRP was the only independent predictor of 8-iso-PGF2alpha and ADMA levels in RA. N,N-dimethylarginine 101-105 C-reactive protein Homo sapiens 39-42 22549098-9 2012 CONCLUSIONS: Our study is the first to show positive associations between plasma ADMA levels and the production of 8-isoprostanes and CRP in RA. N,N-dimethylarginine 82-86 C-reactive protein Homo sapiens 135-138 34890370-8 2021 In obese women, the levels of CRP positively correlated with Zn, TNFalpha with Mg, IFNgamma with Cu and P. Magnesium 79-81 C-reactive protein Homo sapiens 30-33 34817840-5 2022 In addition, CCP transfusion caused a significant reduction in the overall inflammatory status of the patients regardless of the severity of disease or outcome, as evidenced by decreasing C-reactive protein, IL6 and ferritin levels. ccp 13-16 C-reactive protein Homo sapiens 188-206 34812265-2 2021 The study is designed to compare the glycolipid metabolism in patients with first-episode schizophrenia (FES) with sex- and age-matched healthy controls to investigate changes in serum levels of homocysteine (Hcy), macrophage migration inhibitory factor (MIF), and high-sensitive C-reactive protein (hs-CRP) and their relationships with the glycolipid metabolism in patients with FES. Glycolipids 37-47 C-reactive protein Homo sapiens 280-298 34812265-2 2021 The study is designed to compare the glycolipid metabolism in patients with first-episode schizophrenia (FES) with sex- and age-matched healthy controls to investigate changes in serum levels of homocysteine (Hcy), macrophage migration inhibitory factor (MIF), and high-sensitive C-reactive protein (hs-CRP) and their relationships with the glycolipid metabolism in patients with FES. Glycolipids 37-47 C-reactive protein Homo sapiens 303-306 34812265-2 2021 The study is designed to compare the glycolipid metabolism in patients with first-episode schizophrenia (FES) with sex- and age-matched healthy controls to investigate changes in serum levels of homocysteine (Hcy), macrophage migration inhibitory factor (MIF), and high-sensitive C-reactive protein (hs-CRP) and their relationships with the glycolipid metabolism in patients with FES. Glycolipids 341-351 C-reactive protein Homo sapiens 280-298 34812265-2 2021 The study is designed to compare the glycolipid metabolism in patients with first-episode schizophrenia (FES) with sex- and age-matched healthy controls to investigate changes in serum levels of homocysteine (Hcy), macrophage migration inhibitory factor (MIF), and high-sensitive C-reactive protein (hs-CRP) and their relationships with the glycolipid metabolism in patients with FES. Glycolipids 341-351 C-reactive protein Homo sapiens 303-306 34812265-15 2021 Conclusion: These findings suggest that increased concentrations of HCY, MIF, and hs-CRP may contribute to the abnormal glycolipid metabolism in the context of schizophrenia. Glycolipids 120-130 C-reactive protein Homo sapiens 85-88 34830542-6 2021 In children with CRP > 97.91 mg/L, there was a high percentage of sensitive cases to amoxicillin with clavulanic acid (87.5%). Amoxicillin-Potassium Clavulanate Combination 85-117 C-reactive protein Homo sapiens 17-20 34830542-9 2021 Concerning sensitivity to gentamicin, the most optimal cut-off point of WBC was >7.80 K/microL, while in the case of nitrofurantoin, it was CRP value > 0.11 mg/L (which was presented in 98.50% of children). Nitrofurantoin 117-131 C-reactive protein Homo sapiens 140-143 34871221-7 2021 All outcomes were measured after 10-day treatment.After treatment, patients who received AC exerted better improvements in erythrocyte sedimentation rate (P < .01), C-reactive protein (P < .01), serum lactate dehydrogenase (P < .01), interleukin 6 (P < .01), fever clearance time (P < .01), time of cough disappearance (P < .01), time of rale disappearance (P < .01), and time of signs disappeared by X-ray (P < .01), than those in patients who received EAS. Charcoal 89-91 C-reactive protein Homo sapiens 165-183 34551869-9 2021 By day 14 after infusion, adverse events (AEs) were reported in 2 individuals receiving CT-P59 20 mg/kg (headache and elevated C-reactive protein levels) and 1 receiving CT-P59 40 mg/kg (pyrexia) (all Common Terminology Criteria for Adverse Events grade 1). ct-p59 88-94 C-reactive protein Homo sapiens 127-145 34596129-2 2021 Incidence of composite ASCVD (myocardial infarction, ischemic stroke, and cardiovascular death) was compared between these 2 groups and factors contributing to the association of TC and ASCVD were evaluated.Patients in the high TC group were older and more likely to have diabetes and have higher C-reactive protein level. Technetium 228-230 C-reactive protein Homo sapiens 297-315 34462732-4 2021 Results indicate that icosapent ethyl (8g daily for 3 days followed by 4g daily for 11 days) significantly reduced high-sensitivity C-reactive protein (hs-CRP) and improved symptomatology compared with patients assigned to usual care. eicosapentaenoic acid ethyl ester 22-37 C-reactive protein Homo sapiens 132-150 34462732-4 2021 Results indicate that icosapent ethyl (8g daily for 3 days followed by 4g daily for 11 days) significantly reduced high-sensitivity C-reactive protein (hs-CRP) and improved symptomatology compared with patients assigned to usual care. eicosapentaenoic acid ethyl ester 22-37 C-reactive protein Homo sapiens 155-158 19383034-7 2009 Positive effects on the lipid profile and a reduction in C-reactive protein were also recorded with exenatide. Exenatide 100-109 C-reactive protein Homo sapiens 57-75 19381059-8 2009 With the treatment with antibiotics, 5-aminosalicylic acid, steroid, and azathioprine, as a whole, decreasing pattern and intermittent fine coordinated fluctuation of the levels of amylase and lipase along with the decrease of Crohn"s disease activity index (CDAI) and the CRP levels were observed. Azathioprine 73-85 C-reactive protein Homo sapiens 273-276 18401567-0 2009 C-reactive protein gene polymorphisms affect plasma CRP and homocysteine concentrations in subjects with and without angiographically confirmed coronary artery disease. Homocysteine 60-72 C-reactive protein Homo sapiens 0-18 19158225-0 2009 DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men. Docosahexaenoic Acids 0-3 C-reactive protein Homo sapiens 36-54 21166606-7 2011 The mean serum concentrations of IL-6 and CRP and the ESR had increased 1 year after PTX (p < 0.001, p < 0.01, and p < 0.001, respectively) in parallel with a decrease in cardiac function and an increase in circulating NT-proBNP. ptx 85-88 C-reactive protein Homo sapiens 42-45 19166691-2 2009 The effects of ezetimibe, alone or in combination with statins, on CRP and low-density lipoprotein (LDL) cholesterol were examined in 2 pooled analyses of randomized, placebo-controlled trials of ezetimibe 10 mg/day in patients with hypercholesterolemia: 6 12-week trials as monotherapy (n = 1,372) and 7 6- to 8-week trials as add-on to baseline statin therapy (n = 3,899). Ezetimibe 15-24 C-reactive protein Homo sapiens 67-70 19166691-5 2009 Reduction in CRP by ezetimibe monotherapy was numerically greater than with placebo (treatment difference 6%, p = 0.09). Ezetimibe 20-29 C-reactive protein Homo sapiens 13-16 19166691-6 2009 Added to statin therapy, ezetimibe was associated with a significant additional reduction in CRP (treatment difference 10%, p <0.001). Ezetimibe 25-34 C-reactive protein Homo sapiens 93-96 19166691-10 2009 In conclusion, the addition of ezetimibe to statin treatment provides significantly enhanced CRP reductions over and above those achieved with statin monotherapy. Ezetimibe 31-40 C-reactive protein Homo sapiens 93-96 19166691-11 2009 Correlations between changes in CRP and changes in LDL cholesterol were weakly positive and significant only when ezetimibe was added to statin treatment. Ezetimibe 114-123 C-reactive protein Homo sapiens 32-35 19283524-3 2009 In this study, we investigated the relationship between plasma homocysteine levels and single nucleotide polymorphism (SNP) of the gene coding for methylenetetrahydrofolate reductase (MTHFR), an enzyme involved in the biosynthesis of homocysteine, and the correlation between the plasma homocysteine levels and generally used inflammatory markers (C-reactive protein, erythrocyte sedimentation rate and matrix metalloproteinase-3) in 96 Japanese patients with RA. Homocysteine 63-75 C-reactive protein Homo sapiens 348-366 34610759-3 2021 Results: MiR-101-3p was increased in the NS patients and the dysregulation of miR-101-3p was associated with levels of procalcitonin, CRP, IL-8 and TNF-alpha. mir-101-3p 78-88 C-reactive protein Homo sapiens 134-137 34181278-4 2021 The IPI was calculated as neutrophil-to-lymphocyte ratio (NLR) x C-reactive protein to albumin ratio (CAR). diprotin A 4-7 C-reactive protein Homo sapiens 65-83 34297765-6 2021 A significant reduction in C-reactive protein levels (WMD: -0.52 mg/L, 95% CI: -0.73, -0.32, p < 0.001) following tocotrienols supplementation was observed, but this finding was attributed to a single study using delta-tocotrienols, not mixed tocotrienols. Tocotrienols 114-126 C-reactive protein Homo sapiens 27-45 34440064-8 2021 We found some little difference in the behaviour of the three treatments on some variables: olmesartan was the most effective in reducing fibrinogen, DBP, CRP, and AIx (-13.1%, -19.3%, -21.4%, and -56.8%, respectively). olmesartan 92-102 C-reactive protein Homo sapiens 155-158 19196363-6 2009 RESULTS: Serum aluminum, high sensitivity C-reactive protein (hsCRP), age, pulse pressure (PP), mean arterial pressure (MAP) and diabetes mellitus (DM) are important correlates of baPWV. bapwv 180-185 C-reactive protein Homo sapiens 42-60 20012308-0 2011 Randomized, controlled study of the effects of raloxifene on high sensitivity C-reactive protein and serum lipids. Raloxifene Hydrochloride 47-57 C-reactive protein Homo sapiens 78-96 18388037-0 2008 Association between protein-bound sialic acid and high-sensitivity C-reactive protein in essential hypertension: a possible indication of underlying cardiovascular risk. N-Acetylneuraminic Acid 34-45 C-reactive protein Homo sapiens 67-85 18388037-5 2008 Correlation analysis revealed a significant association between the protein-bound sialic acid with mean arterial pressure, C-reactive protein, and low-density lipoprotein-cholesterol. N-Acetylneuraminic Acid 82-93 C-reactive protein Homo sapiens 123-141 18388037-6 2008 The findings of the present study suggest that in essential hypertension there is an association between protein-bound sialic acid and C-reactive protein, which reflects the clustering of cardiovascular risk factors in these patients. N-Acetylneuraminic Acid 119-130 C-reactive protein Homo sapiens 135-153 34238597-10 2021 A joint effect was found between asymmetric dimethylarginine and C-reactive protein, explaining all-cause mortality (HR 15.21 CI 3.50-66.12 P=0.000). dimethylarginine 44-60 C-reactive protein Homo sapiens 65-83 34150059-8 2021 The serum levels of interleukin-6 (IL-6), C-reactive protein (CRP), tumor necrosis factor (TNF-alpha), malondialdehyde (MDA) and advanced oxidation protein products (AOPP) in the CG were lower than those in the MG after treatment, while the level of glutathione peroxidase (GSH-Px) was higher (P < 0.05). cg 179-181 C-reactive protein Homo sapiens 42-60 20012308-1 2011 OBJECTIVE: To investigate the effects of raloxifene, on serum lipids and high-sensitivity C-reactive protein (hs-CRP) in healthy postmenopausal women. Raloxifene Hydrochloride 41-51 C-reactive protein Homo sapiens 90-108 34150059-8 2021 The serum levels of interleukin-6 (IL-6), C-reactive protein (CRP), tumor necrosis factor (TNF-alpha), malondialdehyde (MDA) and advanced oxidation protein products (AOPP) in the CG were lower than those in the MG after treatment, while the level of glutathione peroxidase (GSH-Px) was higher (P < 0.05). cg 179-181 C-reactive protein Homo sapiens 62-65 23019501-12 2011 The percentage of subjects with elevated CRP leves of >5 mol/L was greater in the higher clinical AL group compared to the group with less attachment loss. Aluminum 101-103 C-reactive protein Homo sapiens 41-44 34150147-1 2021 OBJECTIVE: To explore the effect of pantoprazole and somatostatin combined with thrombin in the treatment of non-esophagogastric varicosity upper gastrointestinal bleeding (UGB) as well as its influence on serum hs-CRP and coagulation function. Pantoprazole 36-48 C-reactive protein Homo sapiens 215-218 19060982-7 2008 At all three test times, the medians for CRP and IL-6 were significantly more elevated in the CS and PS groups, while the medians for TNF-alpha were abnormal only in the CS group. ps 101-103 C-reactive protein Homo sapiens 41-44 18761816-5 2008 The results showed that additional inhalation of budesonide and terbutaline could upregulate serum IL-2 levels, the percentages of CD3+ T and CD4+ T cells, and CD4/CD8 ratio, and decrease eosinophils and serum CRP level more efficiently than conventional treatment in patients with AECOPD. Budesonide 49-59 C-reactive protein Homo sapiens 210-213 18328070-6 2008 Comparison of the two groups demonstrated that highly sensitive CRP, ferritin, 8-OHdG and 8-IsoPs were significantly reduced by taking BCAA granules. Amino Acids, Branched-Chain 135-139 C-reactive protein Homo sapiens 64-67 18328070-7 2008 The time-course analysis showed that ferritin and highly sensitive CRP seemed to decrease first, followed by a decrease of 8-OHdG and 8-IsoPs. 8-ohdg 123-129 C-reactive protein Homo sapiens 67-70 35595310-13 2022 CONCLUSIONS: There is a clinically modest effect of dietary polyphenols intervention in HbA1c, proteinuria, GFR, MDA, and C-reactive protein levels in patients with DN. Polyphenols 60-71 C-reactive protein Homo sapiens 122-140 20709501-4 2010 Multiple regression analysis showed that valproate (N=50) use was associated with 55% lower mean CRP concentrations and higher mean eGFR values; and phenytoin (N=32) use with 4% lower mean HbA1c values. Valproic Acid 41-50 C-reactive protein Homo sapiens 97-100 35584442-0 2022 C-reactive protein levels and prevalence of leukopenia in patients with inflammatory bowel disease treated with azathioprine and/or mesalazine: a real-life study. Azathioprine 112-124 C-reactive protein Homo sapiens 0-18 35584442-1 2022 OBJECTIVE: To examine serum C-reactive protein levels and the prevalence of leukopenia in patients with Crohn"s disease or ulcerative colitis undergoing treatment with azathioprine and/or mesalazine. Azathioprine 168-180 C-reactive protein Homo sapiens 28-46 18709001-4 2008 The aim of our study was to find out if there are any differences in the CRP levels between patients with normal myocardial perfusion and mild to moderate perfusion defects, detected with 99m-Tc sestamibi gated SPECT MPI. Technetium 188-194 C-reactive protein Homo sapiens 73-76 18501785-0 2008 C-reactive protein levels and clinical symptoms following gadolinium administration in hemodialysis patients. Gadolinium 58-68 C-reactive protein Homo sapiens 0-18 20891039-2 2010 Concurrently, sepharose column chromatography revealed an association of the bulk of plasma CRP with very low-density lipoproteins. Sepharose 14-23 C-reactive protein Homo sapiens 92-95 35380410-1 2022 OBJECTIVE: To investigate the effects of pentoxifylline (PTX) in combination with losartan compared to the high dose of losartan alone on serum markers of diabetic nephropathy such as HSP70, copeptin, CRP, and TNFalpha in patients with type 2 diabetes and nephropathy. Pentoxifylline 41-55 C-reactive protein Homo sapiens 201-204 20819623-12 2010 CONCLUSION: Salmeterol/fluticasone treatment reduced circulating C-reactive protein concentration in clinically stable moderate-to-severe chronic obstructive pulmonary disease patients after 6-month treatment. Fluticasone 23-34 C-reactive protein Homo sapiens 65-83 35459240-5 2022 Phenome-wide association study identified 27 clinical outcomes associated with genetically determined CRP and subsequent Mendelian randomisation analyses supported a causal association with schizophrenia, chronic airway obstruction and prostate cancer. phenome 0-7 C-reactive protein Homo sapiens 102-105 18635905-5 2008 Among the hyperlipidemic subjects treated with myo-inositol, compared to subjects without MetS, subjects with MetS had a significant increase in plasmalogens and a tendency towards reduced sdLDL, high sensitivity C-reactive protein (hsCRP), and blood glucose levels. Inositol 47-59 C-reactive protein Homo sapiens 213-231 18394014-0 2008 Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers. tibolone 86-94 C-reactive protein Homo sapiens 113-131 18394014-6 2008 Also, tibolone was associated with an increase in CRP, in contrast to raloxifene, which reduced CRP. tibolone 6-14 C-reactive protein Homo sapiens 50-53 18366986-7 2008 Lipid parameters, blood pressure, and C-reactive protein have been shown to improve favorably in patients treated with exenatide. Exenatide 119-128 C-reactive protein Homo sapiens 38-56 17942113-6 2007 Pretreatment with sepiapterin, a BH4 precursor, prevented CRP-mediated effects on BH(4) levels, superoxide production as well as eNOS activity. sepiapterin 18-29 C-reactive protein Homo sapiens 58-61 20364851-9 2010 This indicates that CRP binds to the PC membrane on the nanoparticle surface reversibly through a calcium bridging mechanism while changing the underlying membrane structure irreversibly as a result of binding. pc 37-39 C-reactive protein Homo sapiens 20-23 17872344-12 2007 CONCLUSION: Exenatide effectively treats obese patients with type 2 diabetes on insulin, leading to weight loss and reduction in levels of HbA1c, systolic blood pressure, triglycerides, and high-sensitivity CRP. Exenatide 12-21 C-reactive protein Homo sapiens 207-210 35440685-10 2022 The association of low serum magnesium levels with glycaemic control (HbA1c) and high-sensitivity C-reactive protein in individuals with type 1 diabetes is limited to subjects using a high insulin dose and suggests that insulin resistance, a type 2 diabetes feature, is a prerequisite for hypomagnesemia. Magnesium 29-38 C-reactive protein Homo sapiens 98-116 19415183-4 2010 The results showed that both the expression of Cx43 protein and gap junctional communication function post-48-h incubation were reduced and inhibited by the detoxified CRP, NaN(3), or detoxified dialyzed CRP plus NaN(3), but not by the detoxified dialyzed CRP or dialyzed NaN(3). Sodium Azide 213-219 C-reactive protein Homo sapiens 168-171 19415183-4 2010 The results showed that both the expression of Cx43 protein and gap junctional communication function post-48-h incubation were reduced and inhibited by the detoxified CRP, NaN(3), or detoxified dialyzed CRP plus NaN(3), but not by the detoxified dialyzed CRP or dialyzed NaN(3). Sodium Azide 213-219 C-reactive protein Homo sapiens 204-207 35492335-10 2022 C-reactive protein, D-dimer, and ferritin levels were lower in the nitazoxanide group than the placebo group on day 7. nitazoxanide 67-79 C-reactive protein Homo sapiens 0-18 19415183-4 2010 The results showed that both the expression of Cx43 protein and gap junctional communication function post-48-h incubation were reduced and inhibited by the detoxified CRP, NaN(3), or detoxified dialyzed CRP plus NaN(3), but not by the detoxified dialyzed CRP or dialyzed NaN(3). Sodium Azide 213-219 C-reactive protein Homo sapiens 204-207 17915148-0 2007 [Relationship between plasma C-reactive protein level and neointimal hyperplasia volume in patients with zotarolimus-eluting stents. zotarolimus 105-116 C-reactive protein Homo sapiens 29-47 19415183-4 2010 The results showed that both the expression of Cx43 protein and gap junctional communication function post-48-h incubation were reduced and inhibited by the detoxified CRP, NaN(3), or detoxified dialyzed CRP plus NaN(3), but not by the detoxified dialyzed CRP or dialyzed NaN(3). Sodium Azide 213-219 C-reactive protein Homo sapiens 168-171 17915148-4 2007 The objective of this study was to investigate the relationship between the basal CRP level and the neointimal hyperplasia volume measured by intracoronary ultrasound 4 months after implantation of a zotarolimus-eluting stent. zotarolimus 200-211 C-reactive protein Homo sapiens 82-85 19415183-4 2010 The results showed that both the expression of Cx43 protein and gap junctional communication function post-48-h incubation were reduced and inhibited by the detoxified CRP, NaN(3), or detoxified dialyzed CRP plus NaN(3), but not by the detoxified dialyzed CRP or dialyzed NaN(3). Sodium Azide 213-219 C-reactive protein Homo sapiens 204-207 17915148-15 2007 CONCLUSIONS: In this study, an independent correlation was observed between the CRP level before zotarolimus-eluting stent implantation and the neointimal hyperplasia volume at 4-month follow-up. zotarolimus 97-108 C-reactive protein Homo sapiens 80-83 20349300-6 2010 C-reactive protein levels were lower in the pravastatin group 72 h after surgery (nonstatin vs. pravastatin, P = 0.0180; atorvastatin vs. pravastatin, P = 0.0383). Pravastatin 44-55 C-reactive protein Homo sapiens 0-18 17719471-6 2007 RESULTS: Both ezetimibe and simvastatin significantly reduced total cholesterol (-0.62 +/- 0.55 mmol/l and -1.28 +/- 0.49 mmol/l, respectively; p < 0.001), low-density lipoprotein cholesterol (-0.55 +/- 0.55 mmol/l and -1.28 +/- 0.49 mmol/l; p < 0.0001), and C-reactive protein (-5.35 +/- 9.25 mg/l and -5.05 +/- 6.30 mg/l; p < 0.001). Ezetimibe 14-23 C-reactive protein Homo sapiens 265-283 17580953-0 2007 Analysis of C-reactive protein on amide-linked N-hydroxysuccinimide-dextran arrays with a spectral surface plasmon resonance biosensor for serodiagnosis. Amides 34-39 C-reactive protein Homo sapiens 12-30 17580953-1 2007 A new label-free array system using amide-linked (AL) NHS-dextran and a spectral SPR biosensor are presented for the high-throughput analysis of C-reactive protein (CRP) in human sera. Amides 36-41 C-reactive protein Homo sapiens 145-163 17580953-1 2007 A new label-free array system using amide-linked (AL) NHS-dextran and a spectral SPR biosensor are presented for the high-throughput analysis of C-reactive protein (CRP) in human sera. Amides 36-41 C-reactive protein Homo sapiens 165-168 17531211-4 2007 Confocal microscopic image analysis of H(2)DCFDA-labeled cells showed that CRP induced intracellular reactive oxygen species (ROS) generation by FcgammaRIIa(+) HEK293T cells. 2',7'-dichlorodihydrofluorescein diacetate 39-48 C-reactive protein Homo sapiens 75-78 35377160-10 2022 Icosapent ethyl reduced triglycerides (median reduction, 33.5 mg/dL, or 15.4%; P<0.0001) and hs-CRP (35.1%; P<0.0001) compared with placebo, similar to patients without HF (P-interaction>0.90). eicosapentaenoic acid ethyl ester 0-9 C-reactive protein Homo sapiens 96-99 35377160-12 2022 Conclusions In REDUCE-IT, icosapent ethyl provided similar improvements in triglyceride levels and hs-CRP as well as similar cardiovascular risk reduction in patients with and without HF. eicosapentaenoic acid ethyl ester 26-41 C-reactive protein Homo sapiens 102-105 35322409-15 2022 Increase in the C-reactive protein (CRP) level can signal inflammation rapidly and help to prevent clozapine intoxication following vaccination. Clozapine 99-108 C-reactive protein Homo sapiens 16-34 35322409-15 2022 Increase in the C-reactive protein (CRP) level can signal inflammation rapidly and help to prevent clozapine intoxication following vaccination. Clozapine 99-108 C-reactive protein Homo sapiens 36-39 17531211-8 2007 CONCLUSIONS: CRP-induced ROS generation by VSMCs, which requires functional activation of FcgammaRIIa and NADPH oxidase 4, orchestrates pro-inflammatory activities of VSMCs and may eventually promote atherogenesis and plaque rupture. vsmcs 43-48 C-reactive protein Homo sapiens 13-16 17531211-8 2007 CONCLUSIONS: CRP-induced ROS generation by VSMCs, which requires functional activation of FcgammaRIIa and NADPH oxidase 4, orchestrates pro-inflammatory activities of VSMCs and may eventually promote atherogenesis and plaque rupture. vsmcs 167-172 C-reactive protein Homo sapiens 13-16 17479208-1 2007 BACKGROUND: Little is known about the relationship between serum magnesium (Mg) and C-reactive protein (CRP) in heart failure (HF). Magnesium 65-74 C-reactive protein Homo sapiens 84-102 17479208-1 2007 BACKGROUND: Little is known about the relationship between serum magnesium (Mg) and C-reactive protein (CRP) in heart failure (HF). Magnesium 65-74 C-reactive protein Homo sapiens 104-107 35360574-11 2022 In boys, CRP (p = 0.03) and TGF-alpha (p < 0.01) showed significant associations with HSCL-10, that remained significant after adjustment. hscl-10 86-93 C-reactive protein Homo sapiens 9-12 35360574-13 2022 In boys, CRP was associated with HSCL-10 in those with high body fat and those being physical inactive, and the association between TWEAK and HSCL-10 was dependent upon sleep duration. hscl-10 142-149 C-reactive protein Homo sapiens 9-12 17479208-1 2007 BACKGROUND: Little is known about the relationship between serum magnesium (Mg) and C-reactive protein (CRP) in heart failure (HF). Magnesium 76-78 C-reactive protein Homo sapiens 84-102 20349300-6 2010 C-reactive protein levels were lower in the pravastatin group 72 h after surgery (nonstatin vs. pravastatin, P = 0.0180; atorvastatin vs. pravastatin, P = 0.0383). Pravastatin 96-107 C-reactive protein Homo sapiens 0-18 17479208-2 2007 AIM OF THE STUDY: To investigate the relationship, if any, between serum Mg and CRP in HF patients and, concomitantly, to test a hypothesis that Mg supplementation might affect serum CRP levels. Magnesium 73-75 C-reactive protein Homo sapiens 80-83 17479208-2 2007 AIM OF THE STUDY: To investigate the relationship, if any, between serum Mg and CRP in HF patients and, concomitantly, to test a hypothesis that Mg supplementation might affect serum CRP levels. Magnesium 145-147 C-reactive protein Homo sapiens 183-186 35065995-3 2022 We aimed to meta-analyze the effects of tibolone on anthropometric indicators of obesity, blood pressure (BP), and on C-reactive protein (CRP) levels in postmenopausal women. tibolone 40-48 C-reactive protein Homo sapiens 118-136 35065995-3 2022 We aimed to meta-analyze the effects of tibolone on anthropometric indicators of obesity, blood pressure (BP), and on C-reactive protein (CRP) levels in postmenopausal women. tibolone 40-48 C-reactive protein Homo sapiens 138-141 35065995-8 2022 Tibolone treatment administered in postmenopausal women increased BMI and CRP but did not change body weight, WC, and SBP. tibolone 0-8 C-reactive protein Homo sapiens 74-77 20349300-6 2010 C-reactive protein levels were lower in the pravastatin group 72 h after surgery (nonstatin vs. pravastatin, P = 0.0180; atorvastatin vs. pravastatin, P = 0.0383). Pravastatin 96-107 C-reactive protein Homo sapiens 0-18 17479208-11 2007 CONCLUSIONS: Oral Mg supplementation to HF patients significantly attenuates blood levels of CRP, a biomarker of inflammation. Magnesium 18-20 C-reactive protein Homo sapiens 93-96 20083961-7 2010 At baseline, CRP was positively correlated with IL-6 (r = 0.35), (TB-FM) (r = 0.36), and IA-FM (r = 0.31) and was inversely correlated with aerobic fitness measures (all r values > or = -0.24). Terbium 66-68 C-reactive protein Homo sapiens 13-16 17545695-7 2007 A multiple regression analysis showed that, especially in the middle tertile of long-chain n-3 PUFAs (eicosapentaenoic acid and docosahexaenoic acid) intake, CRP was inversely related to the intake of oleic acid and linoleic acid in both sexes and to the intake of alpha-linolenic acid in women. Docosahexaenoic Acids 128-148 C-reactive protein Homo sapiens 158-161 17561469-6 2007 RESULTS: The CC genotype was associated with lower plasma CRP concentration (GG, 6.5+/-5.8; GC, 3.3+/-4.4; CC, 2.3+/-3.1 mg/L; p=0.02). gallocatechol 92-94 C-reactive protein Homo sapiens 58-61 35160215-11 2022 Serum sulfatide levels were significantly correlated with albumin, cholesterol, C-reactive protein, and pentraxin 3. Sulfoglycosphingolipids 6-15 C-reactive protein Homo sapiens 80-98 35097067-9 2022 During the treatment, the lymphocyte count, ESR, IL-6, serum ferritin, LDH, CK-MB, hs-CRP and D-dimer levels all improved gradually, indicating that both Arbidol and methylprednisolone therapy were contributed to improving the condition of COVID-19 patients. Methylprednisolone 166-184 C-reactive protein Homo sapiens 86-89 19853918-2 2009 Pull-down assays using an N-acetyl-D-glucosamine (GlcNAc)-agarose column demonstrated that CRP binds to the trimeric FBG domains, and that the GlcNAc-binding ability of the FBG domain is unaffected by CRP binding. Sepharose 58-65 C-reactive protein Homo sapiens 91-94 17457796-7 2007 Patients with subepicardial DCE had: higher C-reactive protein (CRP) levels (38 +/- 32 vs. 14 +/- 24 mg/mL; P = 0.04), lower Framingham cardiovascular risk (3 +/- 3% vs. 9 +/- 5%; P < 0.001), lower incidence of perfusion SPECT defects (17% vs. 73%; P = 0.01), higher left ventricular (LV) end-diastolic volume (77 +/- 16 vs. 64 +/- 10 mL/m(2); P = 0.02), and higher regression of DCE areas at follow-up (-65 +/- 17% vs. -18 +/- 23%; P = 0.002). ethylene dichloride 28-31 C-reactive protein Homo sapiens 44-62 17457796-7 2007 Patients with subepicardial DCE had: higher C-reactive protein (CRP) levels (38 +/- 32 vs. 14 +/- 24 mg/mL; P = 0.04), lower Framingham cardiovascular risk (3 +/- 3% vs. 9 +/- 5%; P < 0.001), lower incidence of perfusion SPECT defects (17% vs. 73%; P = 0.01), higher left ventricular (LV) end-diastolic volume (77 +/- 16 vs. 64 +/- 10 mL/m(2); P = 0.02), and higher regression of DCE areas at follow-up (-65 +/- 17% vs. -18 +/- 23%; P = 0.002). ethylene dichloride 28-31 C-reactive protein Homo sapiens 64-67 19464010-6 2009 At the fifth day, the median CRP in the NN group was lower than in the SN group (p<0.0001), but higher than the NS and SS groups (p<0.0001). nn 40-42 C-reactive protein Homo sapiens 29-32 19454128-4 2009 The elongation product of 20 : 4n-6, 22 : 4n-6, was significantly decreased in membrane phosphatidylethanolamine and phosphatidylserine in multiple sclerosis patients (P = 0.01 and P = 0.03 respectively), and correlated inversely with severity of disease and C-reactive protein. phosphatidylethanolamine 88-112 C-reactive protein Homo sapiens 259-277 17185878-11 2007 Significant negative correlations were observed between the serum DHEA concentration and the serum concentration of fasting insulin, HOMA-R, leptin, and high-sensitivity C-reactive protein for all subjects. Dehydroepiandrosterone 66-70 C-reactive protein Homo sapiens 170-188 20031592-4 2009 The minor alleles of Ile27Leu (rs1169288) and Ser486Asn (rs2464196) were associated with 0.10 to 0.15 standard deviation units lower C-reactive protein and gamma-glutamyl transferase levels in EA. ile27leu 21-29 C-reactive protein Homo sapiens 133-151 17220790-9 2007 Mean CRP level was 5.18+/-5.7 mg/L in patients not taking MMF compared with 3.13+/-3.5 mg/L in those on 2000 mg per day (P=0.002). Mycophenolic Acid 58-61 C-reactive protein Homo sapiens 5-8 17006323-6 2006 Similarly, cardiac transplant patients yielded a significantly elevated C-reactive protein (CRP) (4.11+/-6.25 [transplant group (TX)] vs. 2.09+/-2.21 mg/L [control group (CTL)]; P=0.0195), and homocysteine (19.2+/-8.8 [TX] vs. 9.70+/-2.45 microM [CTL]; P<0.001). Homocysteine 193-205 C-reactive protein Homo sapiens 92-95 19628101-0 2009 Dietary intakes of alpha-linolenic and linoleic acids are inversely associated with serum C-reactive protein levels among Japanese men. alpha-linolenic 19-34 C-reactive protein Homo sapiens 90-108 19628101-0 2009 Dietary intakes of alpha-linolenic and linoleic acids are inversely associated with serum C-reactive protein levels among Japanese men. Linoleic Acids 39-53 C-reactive protein Homo sapiens 90-108 19151033-12 2009 Treatment with L-mevalonate or farnesylpyrophosphate, but not geranylgeranyl-pyrophosphate reversed the statin-induced effect on CRP-mediated functions and ERK 1/2 phosphorylation, confirming that statins blocked CRP-induced ERK 1/2 phosphorylation through the inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. l-mevalonate 15-27 C-reactive protein Homo sapiens 129-132 16829707-7 2006 However, the addition of losartan, but not enalapril, significantly decreased the urinary protein excretion level, plasma aldosterone, and hypersensitive-C-reactive protein at the end of the study. Losartan 25-33 C-reactive protein Homo sapiens 154-172 16825699-0 2006 Dietary long-chain n-3 fatty acids of marine origin and serum C-reactive protein concentrations are associated in a population with a diet rich in marine products. long-chain n-3 fatty acids 8-34 C-reactive protein Homo sapiens 62-80 16825699-7 2006 RESULTS: After adjustment for several predictors of inflammation, the odds ratio of high CRP (> or =1.0 mg/L) for increasing quartiles of total n-3 PUFA and eicosapentaenoic acid + docosahexaenoic acid were 1.0, 0.72, 0.57, and 0.44 (P for trend = 0.01) and 1.0, 0.91, 0.76, and 0.54 (P for trend = 0.03), respectively. Docosahexaenoic Acids 184-204 C-reactive protein Homo sapiens 89-92 16403905-10 2006 Clofarabine plus cytarabine has activity in adult AML, achieving a good CR rate. Cytarabine 17-27 C-reactive protein Homo sapiens 72-74 16897175-1 2006 Binding of carbohydrate ligand by human C-reactive protein (CRP), in both native form and structurally deviated form (neoCRP or mCRP), was investigated using galactose-6-phosphate (Gal6P)- and Galbeta3GalNAc-containing bovine serum albumin (BSA) derivatives. galactose-6-phosphate 181-186 C-reactive protein Homo sapiens 40-58 16897175-1 2006 Binding of carbohydrate ligand by human C-reactive protein (CRP), in both native form and structurally deviated form (neoCRP or mCRP), was investigated using galactose-6-phosphate (Gal6P)- and Galbeta3GalNAc-containing bovine serum albumin (BSA) derivatives. galactose-6-phosphate 181-186 C-reactive protein Homo sapiens 60-63 19151033-12 2009 Treatment with L-mevalonate or farnesylpyrophosphate, but not geranylgeranyl-pyrophosphate reversed the statin-induced effect on CRP-mediated functions and ERK 1/2 phosphorylation, confirming that statins blocked CRP-induced ERK 1/2 phosphorylation through the inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. l-mevalonate 15-27 C-reactive protein Homo sapiens 213-216 18789914-7 2008 A significantly higher percentage of circulating PL contained depolarised mitochondria (p=0.0003) which correlated with disease activity and C-reactive protein levels in patients. pl 49-51 C-reactive protein Homo sapiens 141-159 16875126-4 2006 The level of homocysteine is directly related to coronary heart disease (OR 9.2, 95% CI 2.3 to 21), stroke with major neurological deficit (OR 10.4, 95% CI 1.1 to 50), the level of creatinine (OR 4.6, 95 CI 1.1 to 10), and C-reactive protein (OR 3.2, 95% CI 0.9 to 15). Homocysteine 13-25 C-reactive protein Homo sapiens 223-241 20157364-0 2008 Effects of C-reactive Protein and Homocysteine on Cytokine Production: Modulation by Pravastatin. Pravastatin 85-96 C-reactive protein Homo sapiens 11-29 16046217-7 2006 Compared to these relatively weak associations with cardiovascular risk factors, ADMA levels showed strong associations with pulse pressure (p < 0.001), lack of smoking (p = 0.002) and lipoprotein (a) (p = 0.004) concentrations and weak associations with LDL-cholesterol (p = 0.02), and C-reactive protein levels (p = 0.04). N,N-dimethylarginine 81-85 C-reactive protein Homo sapiens 290-308 20157364-7 2008 Oral administration of pravastatin, 40mg daily for 2 days, decreased CRP-stimulated IL-6 production by approximately 20% (P = 0.02) 6 hours after incubation, but did not affect MCP-1 production (P = 0.69). Pravastatin 23-34 C-reactive protein Homo sapiens 69-72 18632424-0 2008 Pravastatin immunomodulates IL-6 and C-reactive protein, but not IL-1 and TNF-alpha, in cardio-pulmonary bypass. Pravastatin 0-11 C-reactive protein Homo sapiens 37-55 16607071-4 2006 The odds ratio for myocardial infarction increased progressively across the four quarters of the homocysteine distribution, after adjusting for only age and sex or for the full adjustment (age, sex, smoking, systolic blood pressure, total cholesterol, fibrinogen, C-reactive protein and interleukin-6). Homocysteine 97-109 C-reactive protein Homo sapiens 264-282 18632424-11 2008 CONCLUSIONS: Pravastatin induced a precocious modulation of IL-6 expression and a later reduction of plasma CRP levels. Pravastatin 13-24 C-reactive protein Homo sapiens 108-111 17311055-6 2008 Especially vitamin E in combination with other vitamins like vitamin C, vitamin B(1), B(2), B(6), B(12), niacin, folic acid, pantothenic acid and selenium, was significantly associated with lower CRP levels. Selenium 146-154 C-reactive protein Homo sapiens 196-199 16755160-12 2006 Stepwise regression analysis demonstrated that baseline homocysteine levels were related to folate (coefficient: -1.02; F: 64.5), creatinine (coefficient: 0.98; F: 11.3), and C reactive protein (coefficient: -0.64; F: 4.3). Homocysteine 56-68 C-reactive protein Homo sapiens 175-193 18024309-4 2007 RESULTS: Serum CRP level was comparable between the two groups before the treatment, but significantly reduced after vitamin B6 and folic acid treatment (7.56-/+2.94 mg/L vs 12.23-/+4.16 mg/L, P<0.05). Vitamin B 6 117-127 C-reactive protein Homo sapiens 15-18 18024309-5 2007 Additional vitamin B6 and folic acid treatment significantly lowered plasma HCA level (4.56-/+1.14 micromol/L vs 7.79-/+1.79 micromol/L, P<0.05), and correlation analysis demonstrated a positive correlation between plasma HCA and serum CRP levels (r=0.697, P<0.01). Vitamin B 6 11-21 C-reactive protein Homo sapiens 239-242 17827864-8 2007 In a two-pollutant model including SPM and nitrogen dioxide (NO(2)) concentrations, increased serum CRP concentrations were also associated with SPM (OR =1.94, 95% CI: 1.08-3.50), but no such association was found with NO(2) (OR =0.62, 95% CI: 0.26-1.48). Nitrogen Dioxide 43-59 C-reactive protein Homo sapiens 100-103 16143583-3 2006 The aim of this study was to evaluate IHD and smoking as potential causes of raised CRP levels in COPD and to test the association between inhaled corticosteroid (ICS) use and serum CRP levels. Iron-Sulfur-Molybdenum Cluster With Interstitial Carbon 163-166 C-reactive protein Homo sapiens 182-185 17598370-13 2007 Patients receiving treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor Type 1 antagonist (ARA-II) had significantly lower levels of CRP than those who were not under such treatment (n = 46, CRP = 8.7 (5.1-29.8) vs n = 44, CRP = 10.4 (6.1-37.2), p < 0.05) (Figure 1). ara-ii 127-133 C-reactive protein Homo sapiens 169-172 16543972-6 2006 In multivariable linear regression analysis, current smoking, high (versus moderate) alcohol consumption, ratio of total cholesterol/HDL-cholesterol (TC/HDL-C) and C-reactive protein (CRP) were significantly associated with elevated levels of sE-selectin and sICAM-1. se-selectin 243-254 C-reactive protein Homo sapiens 164-182 16543972-6 2006 In multivariable linear regression analysis, current smoking, high (versus moderate) alcohol consumption, ratio of total cholesterol/HDL-cholesterol (TC/HDL-C) and C-reactive protein (CRP) were significantly associated with elevated levels of sE-selectin and sICAM-1. se-selectin 243-254 C-reactive protein Homo sapiens 184-187 16899309-0 2007 Effect of spironolactone on C-reactive protein levels in patients with heart disease. Spironolactone 10-24 C-reactive protein Homo sapiens 28-46 16319543-10 2005 The association between C-reactive protein and disease was U-shaped and a graded association existed between homocysteine, cysteine, von Willebrand factor and disease. Homocysteine 109-121 C-reactive protein Homo sapiens 24-42 16899309-4 2007 We performed 4 separate studies to investigate whether spironolactone treatment would reduce levels of C-reactive protein (CRP), a marker of inflammation, in serum samples taken from patients suffering from different degrees of heart failure. Spironolactone 55-69 C-reactive protein Homo sapiens 103-121 16079884-6 2005 Significant progressive increases in baPWV were observed across the quartiles of CRP in male subjects and for UA in male and female subjects. bapwv 37-42 C-reactive protein Homo sapiens 81-84 16899309-4 2007 We performed 4 separate studies to investigate whether spironolactone treatment would reduce levels of C-reactive protein (CRP), a marker of inflammation, in serum samples taken from patients suffering from different degrees of heart failure. Spironolactone 55-69 C-reactive protein Homo sapiens 123-126 16079884-7 2005 In female subjects, the relationship of quartile CRP to baPWV had marginal significance (P = 0.055). bapwv 56-61 C-reactive protein Homo sapiens 49-52 16123329-10 2005 Pretreatment with TAT-C3 (a membrane-permeable RhoA inhibitor) and Y-27632 (Rho-kinase inhibitor) significantly inhibited CRP-induced PAI-1 expression. Y 27632 67-74 C-reactive protein Homo sapiens 122-125 15939816-6 2005 Egg feeding was associated with significant increases in both CRP and SAA in the LIS group (both P<0.01) but not in the LIR or OIR groups. lis 81-84 C-reactive protein Homo sapiens 62-65 17263297-0 2007 Role of the C-reactive protein for the diagnosis of TB among military personnel in South Korea. Terbium 52-54 C-reactive protein Homo sapiens 12-30 15802626-0 2005 C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Azides 89-94 C-reactive protein Homo sapiens 0-18 17211240-12 2007 Plasma CRP concentration in twins was predicted by polymorphisms at three loci in physiological series within the catecholamine biosynthetic/beta-adrenergic pathway: TH (tyrosine hydroxylase), ADRB1 (beta1-adrenergic receptor) and ADRB2 (beta2-adrenergic receptor). Catecholamines 114-127 C-reactive protein Homo sapiens 7-10 17366000-8 2007 The CRP level declined by postoperative day 3, but was significantly less in the OC group than in the LC group (p<0.001). oc 81-83 C-reactive protein Homo sapiens 4-7 15920065-3 2005 RESULTS: In age- and BMI-adjusted analyses, magnesium intake was inversely associated with plasma C-reactive protein (CRP) concentrations; CRP concentrations were 12% lower in the highest intake quintile than in the lowest (P for trend <0.0001). Magnesium 44-53 C-reactive protein Homo sapiens 98-116 15920065-3 2005 RESULTS: In age- and BMI-adjusted analyses, magnesium intake was inversely associated with plasma C-reactive protein (CRP) concentrations; CRP concentrations were 12% lower in the highest intake quintile than in the lowest (P for trend <0.0001). Magnesium 44-53 C-reactive protein Homo sapiens 118-121 15920065-4 2005 This association was not appreciably altered by further adjustment for other potential confounding variables including dietary factors; the mean CRP concentrations for ascending quintiles of magnesium intake were 1.50, 1.39, 1.35, 1.34, and 1.31 mg/l (P for trend = 0.0003). Magnesium 191-200 C-reactive protein Homo sapiens 145-148 17083384-8 2006 RESULTS: Patients with thrombocytosis and patients with elevated CRP levels had significantly higher pathological T stage, clinical stage, tumor size, histological grade, and percentage of microvascular invasion than did patients without THC and patients with CRP levels <1.0 mg/dL, respectively. Dronabinol 238-241 C-reactive protein Homo sapiens 65-68 15931619-6 2005 Elevated plasma Hcy levels correlated significantly with serum IL-6 ( r = 0.25, P < .001), C-peptide ( r = 0.22, P < .01), and the number of abnormal metabolic factors ( r = 0.20, P < .01), but not with C-reactive protein. Homocysteine 16-19 C-reactive protein Homo sapiens 212-230 15634723-7 2005 High-sensitivity C-reactive protein correlated with ADMA plasma concentrations (r = 0.29; P < 0.01). N,N-dimethylarginine 52-56 C-reactive protein Homo sapiens 17-35 16770616-6 2006 Ornidazole treatment was also associated with significant reductions in pain and duration of morning stiffness, significant improvement in the quality of life and both the physician"s and patient"s global assessments, and significant reductions in disease activity as assessed by objective laboratory measures (erythrocyte sedimentation rate and C-reactive protein level). Ornidazole 0-10 C-reactive protein Homo sapiens 346-364 15757598-5 2005 Plasma ADMA at baseline showed a significant positive correlation with serum C-reactive protein and plasma insulin and a significant negative correlation with serum levels of high-density lipoprotein and plasma alpha-tocopherol. N,N-dimethylarginine 7-11 C-reactive protein Homo sapiens 77-95 15757598-6 2005 During therapy, changes in plasma ADMA concentrations were significantly correlated with changes in the ratio of total cholesterol to high-density lipoprotein cholesterol and in serum C-reactive protein concentrations but not with changes in insulin levels. N,N-dimethylarginine 34-38 C-reactive protein Homo sapiens 184-202 16690736-3 2006 RESULTS: According to multiple linear regression analysis, C-reactive protein and interleukin-6 receptor were strongly and negatively associated with circulating vitamin B6 but not with folate concentrations, independent of age, sex, serum creatinine, serum albumin, total energy intake, smoking history, dietary nutrient intake, and circulating homocysteine and vitamin concentrations. Vitamin B 6 162-172 C-reactive protein Homo sapiens 59-77 27520409-15 2005 A statistically significant positive correlation was observed between sE-selectin levels and CRP and ESR in patients with BD (r = 0. se-selectin 70-81 C-reactive protein Homo sapiens 93-96 16343471-12 2006 CONCLUSIONS: 6 weeks after pravastatin therapy could significant modify the lipid profile and decrease the inflammatory markers including CRP and IL-6 in patients with hyperlididemia. Pravastatin 27-38 C-reactive protein Homo sapiens 138-141 15539624-11 2005 Importantly, IL-8 significantly induced CRP release in PHHs by 58.675+/-19.1-fold, which was blockable by LY333531. ruboxistaurin 106-114 C-reactive protein Homo sapiens 40-43 16520718-9 2006 LMWH effectively reversed the inhibitory effects of CRP on TFPI release from HUVECs. Heparin, Low-Molecular-Weight 0-4 C-reactive protein Homo sapiens 52-55 15527680-5 2004 Azathioprine and 6-mercaptopurine remain efficient beyond 4 years in patients with relapses and elevated C-reactive protein in spite of this therapy. Azathioprine 0-12 C-reactive protein Homo sapiens 105-123 16520718-10 2006 CONCLUSIONS: These findings support the hypothesis that CRP may play a direct role in promoting a hypercoagulable state by decreasing the release of the natural anticoagulant TFPI, which can be counteracted by LMWH. Heparin, Low-Molecular-Weight 210-214 C-reactive protein Homo sapiens 56-59 15770053-6 2004 There was a significant positive relation (r = 0.384, p < 0.001) between the levels of plasma Hcy and serum CRP in HD and CAPD patients. Homocysteine 97-100 C-reactive protein Homo sapiens 111-114 16498228-7 2006 Interestingly, in the TMZ group, CRP and nitrite levels were significantly lower than in the control group at each time point of the pre- and post-angioplasty periods, but the TNF-alpha levels were significantly decreased only in the post-angioplasty period. Trimetazidine 22-25 C-reactive protein Homo sapiens 33-36 15254884-9 2004 Sialic acid was the acute-phase response marker with the highest DR (3.16), and showed stronger correlations with other inflammatory markers, including C-reactive protein (CRP), than IL-6. N-Acetylneuraminic Acid 0-11 C-reactive protein Homo sapiens 152-170 15254884-9 2004 Sialic acid was the acute-phase response marker with the highest DR (3.16), and showed stronger correlations with other inflammatory markers, including C-reactive protein (CRP), than IL-6. N-Acetylneuraminic Acid 0-11 C-reactive protein Homo sapiens 172-175 16234304-6 2006 Lower alpha-linolenic acid was associated with higher C-reactive protein and IL-1ra, and lower eicosapentaenoic acid was associated with higher IL-6 and lower TGFbeta. alpha-Linolenic Acid 6-26 C-reactive protein Homo sapiens 54-72 16277783-4 2005 CLA supplementation increased levels of C-reactive protein (P=0.003) compared with the control group. Linoleic Acids, Conjugated 0-3 C-reactive protein Homo sapiens 40-58 15026269-6 2004 Levels of SAA and CRP were further inversely correlated with serum DHEA-s, but not with cortisol. Dehydroepiandrosterone 67-73 C-reactive protein Homo sapiens 18-21 16220077-5 2005 C-reactive protein could augment the production of reactive oxygen species (ROS) as measured by chemiluminescence and inhibitors of NAD(P)H oxidase (DPI and PAO) and ROS scavengers (superoxide dismutase, catalase, and 1% dimethyl sulphoxide) abolished C-reactive protein-induced IL-8 secretion. Dimethyl Sulfoxide 221-240 C-reactive protein Homo sapiens 0-18 14970111-9 2004 There were reductions in plasma concentrations of CRP, NT-pro BNP, TNF-alpha, and Fas/Apo-1 in the pentoxifylline compared with the placebo-treated group. Pentoxifylline 99-113 C-reactive protein Homo sapiens 50-53 16126025-8 2005 CRP decreased 5.2% with pravastatin and 36.4% with atorvastatin (p <0.0001). Pravastatin 24-35 C-reactive protein Homo sapiens 0-3 14718755-4 2004 Cord serum CRP correlated positively with amniotic fluid erythropoietin and umbilical artery pCO2. pco2 93-97 C-reactive protein Homo sapiens 11-14 16087988-7 2005 CONCLUSIONS: The study shows that in the present group of overweight subjects a high consumption of sugar-sweetened foods and drinks increased haptoglobin and transferrin but had, at best, only a limited influence on CRP. Sugars 100-105 C-reactive protein Homo sapiens 217-220 15954913-13 2005 Subjects with both CRP and sTNFrii in the highest tertile ("inflamed" status) appeared to derive more renal benefit from pravastatin than those without (P for interaction 0.047). Pravastatin 121-132 C-reactive protein Homo sapiens 19-22 14558211-4 2003 In an experimental study using patients with severe coronary disease, administration of celecoxib resulted in improved endothelial function together with reduced CRP levels. Celecoxib 88-97 C-reactive protein Homo sapiens 162-165 12921979-6 2003 CRP correlated significantly to other CHD risk factors like body mass index (BMI), systolic blood pressure, diastolic blood pressure, plasma fibrinogen, serum high-density lipoprotein cholesterol, plasma homocysteine, and serum triglycerides. Homocysteine 204-216 C-reactive protein Homo sapiens 0-3 16194025-3 2005 The aim of the study was: 1) to investigate the ability of the major tea polyphenols: (-)-epigallocatechin gallate (EGCG), theaflavins (TF) and gallic acid (GA) to protect in vitro human neutrophils from oxidative damage induced by phorbol myristate acetate (PMA), 2) estimation the level of reactive oxygen species (ROS) production in obese patient depending on the red tea Pu-Erh drinking, 3) estimation inflammatory marker: CRP. Gallic Acid 144-155 C-reactive protein Homo sapiens 427-430 16194025-3 2005 The aim of the study was: 1) to investigate the ability of the major tea polyphenols: (-)-epigallocatechin gallate (EGCG), theaflavins (TF) and gallic acid (GA) to protect in vitro human neutrophils from oxidative damage induced by phorbol myristate acetate (PMA), 2) estimation the level of reactive oxygen species (ROS) production in obese patient depending on the red tea Pu-Erh drinking, 3) estimation inflammatory marker: CRP. Gallic Acid 157-159 C-reactive protein Homo sapiens 427-430 15761204-5 2005 RESULTS: CRP was elevated above control levels (0.54 [0.33 to 0.84] median, interquartile range mg/L) in patients with LAA (2.59 [0.56 to 3.99] mg/L; P<0.001) and with CAD (2.37 [0.57 to 4.78] mg/L; P=0.0013) but not in patients with cryptogenic etiology (0.74 [0.14 to 7.86] mg/L). CyADIC regimen 171-174 C-reactive protein Homo sapiens 9-12 16277693-2 2005 Abnormal vitamin B6 status in rheumatoid arthritis has been associated with spontaneous tumor necrosis factor (TNF)-alpha production and markers of inflammation, including C-reactive protein and erythrocyte sedimentation rate. Vitamin B 6 9-19 C-reactive protein Homo sapiens 172-190 12829649-3 2003 Statistically significant hazard ratios of developing diabetes for those in the fourth (versus first) quartile of inflammation markers, adjusted for age, sex, ethnicity, study center, parental history of diabetes, and hypertension, ranged from 1.9 to 2.8 for sialic acid, orosomucoid, interleukin-6, and C-reactive protein. N-Acetylneuraminic Acid 259-270 C-reactive protein Homo sapiens 304-322 16113473-8 2005 We found that withdrawal of inhaled corticosteroids increased serum CRP levels, and that reintroduction of inhaled fluticasone could suppress CRP levels. Fluticasone 115-126 C-reactive protein Homo sapiens 142-145 12924621-9 2003 In the top quartile of CRP, the percentage of relative weight, systolic BP, diastolic BP, pulse pressure, and low density/high density lipoprotein-cholesterol (LDL-C/HDL-C) were significantly higher than in the bottom quartile. low density/high density lipoprotein-cholesterol 110-158 C-reactive protein Homo sapiens 23-26 15514264-4 2004 The ALA Diet decreased C-reactive protein (CRP, P < 0.01), whereas the LA Diet tended to decrease CRP (P = 0.08). alpha-Linolenic Acid 4-7 C-reactive protein Homo sapiens 23-41 15514264-4 2004 The ALA Diet decreased C-reactive protein (CRP, P < 0.01), whereas the LA Diet tended to decrease CRP (P = 0.08). alpha-Linolenic Acid 4-7 C-reactive protein Homo sapiens 43-46 15514264-6 2004 Changes in CRP and VCAM-1 were inversely associated with changes in serum eicosapentaenoic acid (EPA) (r = -0.496, P = 0.016; r = -0.418, P = 0.047), or EPA plus docosapentaenoic acid (r = -0.409, P = 0.053; r = -0.357, P = 0.091) after subjects consumed the ALA Diet. alpha-Linolenic Acid 259-262 C-reactive protein Homo sapiens 11-14 12788842-13 2003 Like oral estrogen, tibolone use is associated with a rise in CRP, with no change in homocysteine and consistent lowering of Lp(a). tibolone 20-28 C-reactive protein Homo sapiens 62-65 15543343-9 2004 Cerivastatin decreased serum CRP values by 49.5% (p = 0.001), and fenofibrate by 29.8% (p = 0.03). cerivastatin 0-12 C-reactive protein Homo sapiens 29-32 12667961-9 2003 The NF-kappaB activation caused by CRP was inhibited by 15-deoxy-12,14-prostaglandin J2 and the PPARgamma activators, rosiglitazone and pioglitazone. 15-deoxy-delta(12,14)-prostaglandin J2 56-87 C-reactive protein Homo sapiens 35-38 12721499-0 2003 Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. Sulfonylurea Compounds 24-36 C-reactive protein Homo sapiens 40-58 15543343-14 2004 Both cerivastatin and fenofibrate reduced CRP levels, the decrease being significantly greater after cerivastatin. cerivastatin 5-17 C-reactive protein Homo sapiens 42-45 12551863-7 2003 High-sensitivity C-reactive protein was significantly lower after celecoxib (1.3+/-0.4 mg/L) than after placebo (1.8+/-0.5 mg/L, P=0.019), as was oxidized LDL (43.6+/-2.4 versus 47.6+/-2.6 U/L, P=0.028), whereas prostaglandins did not change. Celecoxib 66-75 C-reactive protein Homo sapiens 17-35 15543343-14 2004 Both cerivastatin and fenofibrate reduced CRP levels, the decrease being significantly greater after cerivastatin. cerivastatin 101-113 C-reactive protein Homo sapiens 42-45 15469788-0 2004 [Effect of the early administration of pravastatin on C-reactive protein and interleukin-6 levels in the acute phase of myocardial infarction with ST segment elevation]. Pravastatin 39-50 C-reactive protein Homo sapiens 54-72 15058015-2 2003 The aim of the study was to assess the potential relationships between homocysteine and CRP levels and lipid coronary risk factors in men and women with diabetes. Homocysteine 71-83 C-reactive protein Homo sapiens 88-91 12480587-7 2002 Positive correlation of CRP, however, was observed after fluvastatin treatment with TC/HDL (r=0.62, P=0.041) and Lp(a) (r=0.320, P=0.011), while inverse relations were noted between CRP and HDL (r=-0.288, P=0.023). Technetium 84-86 C-reactive protein Homo sapiens 24-27 15469788-2 2004 The aim of this study was to evaluate the effect of early administration of pravastatin on plasma levels of CRP and IL-6 in patients with acute myocardial infarction and ST segment elevation. Pravastatin 76-87 C-reactive protein Homo sapiens 108-111 15469788-7 2004 After 7 days of treatment the administration of pravastatin was associated with a lower level of CRP (P=.002). Pravastatin 48-59 C-reactive protein Homo sapiens 97-100 15469788-8 2004 Mean and median CRP levels decreased from 48 hours to day 7 by 48.4% and 51.9% respectively in the pravastatin group, and by 32.5% and 15.9% respectively in the control group. Pravastatin 99-110 C-reactive protein Homo sapiens 16-19 15469788-11 2004 CONCLUSIONS: Early administration of pravastatin in the acute phase of myocardial infarction with ST segment elevation was associated with a lower level of CRP after 7 days of treatment, with no concomitant changes in IL-6 levels. Pravastatin 37-48 C-reactive protein Homo sapiens 156-159 12476646-7 2002 TCFAs are more common in patients with high serum total cholesterol (TC) and a high TC to high density cholesterol ratio, in women > 50 years, and in those patients with elevated levels of high sensitivity C-reactive protein. Technetium 0-2 C-reactive protein Homo sapiens 209-227 12009348-8 2002 Significantly higher high sensitivity C-reactive protein concentrations were found in women receiving conjugated equine E and tibolone than in women who were not taking any therapy. tibolone 126-134 C-reactive protein Homo sapiens 38-56 12009348-11 2002 CONCLUSION(S): Because high sensitivity C-reactive protein has recently emerged as an important predictor of cardiovascular disease, the higher high sensitivity C-reactive protein levels observed in women on conjugated equine estrogens and on tibolone have potential important clinical implications. tibolone 243-251 C-reactive protein Homo sapiens 161-179 12075573-0 2002 Relationship between serum magnesium levels and C-reactive protein concentration, in non-diabetic, non-hypertensive obese subjects. Magnesium 27-36 C-reactive protein Homo sapiens 48-66 12075573-1 2002 OBJECTIVE: To examine the association between serum magnesium levels and C-reactive protein (CRP) in non-diabetic, non-hypertensive obese subjects. Magnesium 52-61 C-reactive protein Homo sapiens 73-91 12075573-1 2002 OBJECTIVE: To examine the association between serum magnesium levels and C-reactive protein (CRP) in non-diabetic, non-hypertensive obese subjects. Magnesium 52-61 C-reactive protein Homo sapiens 93-96 15332218-4 2004 RESULTS: Ninety-three patients (37%) with signs of inflammation (CRP > or = 1 mg/dL) had significantly lower levels of tHcy, tCys, and serum Alb than 157 noninflamed patients. tcys 128-132 C-reactive protein Homo sapiens 65-68 15332218-5 2004 tHcy and tCys levels correlated positively with serum Alb levels and negatively with CRP levels (rho = -0.24; P < 0.0001; rho = -0.15; P < 0.05, respectively) and other inflammation markers. tcys 9-13 C-reactive protein Homo sapiens 85-88 15378141-13 2004 Antioxidants (superoxide dismutase, catalase, and dimethylthiourea) blocked CRP-induced oxygen radicals by WBCs. 1,3-dimethylthiourea 50-66 C-reactive protein Homo sapiens 76-79 11829199-10 2001 However, an infection-related increase in CRP may be associated with increased serum concentration of clozapine. Clozapine 102-111 C-reactive protein Homo sapiens 42-45 15540478-6 2004 The PRINCE trial evaluated the antiinflammatory effects of pravastatin and found a mean 16.9% reduction in CRP levels after 24 weeks of therapy. Pravastatin 59-70 C-reactive protein Homo sapiens 107-110 15540478-7 2004 AFCAPS/TexCAPS researchers found that lovastatin provded a 14.8% reduction in the median levels of CRP (p < 0.001). afcaps 0-6 C-reactive protein Homo sapiens 99-102 15540478-9 2004 Researchers in the CURVES study found a significant reduction in CRP levels with pravastatin, simvastatin, and atorvastatin compared with baseline (p < 0.025). Pravastatin 81-92 C-reactive protein Homo sapiens 65-68 15220952-0 2004 Increased alpha-linolenic acid intake lowers C-reactive protein, but has no effect on markers of atherosclerosis. alpha-Linolenic Acid 10-30 C-reactive protein Homo sapiens 45-63 11703959-8 2001 Subjects with CRP levels in the lower quartile had a significantly higher content of docosahexaenoic acid (DHA) in granulocytes than subjects with CRP levels in the upper quartile (p = 0.02), and in a multivariate linear regression analysis, DHA was independently correlated to CRP (R(2) = 0.179; p = 0.003). Docosahexaenoic Acids 85-105 C-reactive protein Homo sapiens 14-17 11703959-8 2001 Subjects with CRP levels in the lower quartile had a significantly higher content of docosahexaenoic acid (DHA) in granulocytes than subjects with CRP levels in the upper quartile (p = 0.02), and in a multivariate linear regression analysis, DHA was independently correlated to CRP (R(2) = 0.179; p = 0.003). Docosahexaenoic Acids 107-110 C-reactive protein Homo sapiens 14-17 11703959-8 2001 Subjects with CRP levels in the lower quartile had a significantly higher content of docosahexaenoic acid (DHA) in granulocytes than subjects with CRP levels in the upper quartile (p = 0.02), and in a multivariate linear regression analysis, DHA was independently correlated to CRP (R(2) = 0.179; p = 0.003). Docosahexaenoic Acids 242-245 C-reactive protein Homo sapiens 14-17 11703959-9 2001 The inverse correlation between CRP and DHA may reflect an anti-inflammatory effect of DHA in patients with stable coronary artery disease and suggest a novel mechanism by which fish consumption may decrease the risk of coronary artery disease. Docosahexaenoic Acids 40-43 C-reactive protein Homo sapiens 32-35 11703959-9 2001 The inverse correlation between CRP and DHA may reflect an anti-inflammatory effect of DHA in patients with stable coronary artery disease and suggest a novel mechanism by which fish consumption may decrease the risk of coronary artery disease. Docosahexaenoic Acids 87-90 C-reactive protein Homo sapiens 32-35 15220952-7 2004 After 1 and 2 y, ALA users had a lower CRP level than LA users (net differences -0.53 and -0.56 mg/l, respectively, P < 0.05). alpha-Linolenic Acid 17-20 C-reactive protein Homo sapiens 39-42 15220952-9 2004 CONCLUSIONS: A six-fold increased ALA intake lowers CRP, when compared to a control diet high in LA. alpha-Linolenic Acid 34-37 C-reactive protein Homo sapiens 52-55 15159228-1 2004 BACKGROUND: Low concentrations of pyridoxal-5"-phosphate (PLP), the active metabolite of vitamin B-6, are associated with high C-reactive protein (CRP) concentrations. Vitamin B 6 89-100 C-reactive protein Homo sapiens 127-145 11668312-11 2001 However, at 6-month follow-up, C-reactive protein levels in the doxycycline group were significantly lower than the baseline levels (P = .01). Doxycycline 64-75 C-reactive protein Homo sapiens 31-49 15159228-1 2004 BACKGROUND: Low concentrations of pyridoxal-5"-phosphate (PLP), the active metabolite of vitamin B-6, are associated with high C-reactive protein (CRP) concentrations. Vitamin B 6 89-100 C-reactive protein Homo sapiens 147-150 15204760-2 2004 In this study we have investigated the effects of environmental air pollution particles (PM10) and ultrafine carbon black (ufCB) on the expression of CRP and Hsp70 in the lung epithelial cell line, A549. ultrafine 99-108 C-reactive protein Homo sapiens 150-153 11383598-8 2001 Under azathioprine, gastroduodenal and intestinal permeability, CDAI, and C-reactive protein decreased. Azathioprine 6-18 C-reactive protein Homo sapiens 74-92 15204760-5 2004 To investigate if the expression of CRP and Hsp70 was the result of free radical production, cells were treated with ufCB in the presence of antioxidants (NAL and Trolox). Free Radicals 68-80 C-reactive protein Homo sapiens 36-39 14996776-10 2004 C-reactive protein decreased 5.2% with pravastatin and 36.4% with atorvastatin (P<.001). Pravastatin 39-50 C-reactive protein Homo sapiens 0-18 11250957-3 2001 OBJECTIVE: To examine variations in plasma homocysteine concentration in relation to C reactive protein (CRP) in patients presenting with acute coronary syndromes. Homocysteine 43-55 C-reactive protein Homo sapiens 85-103 11250957-3 2001 OBJECTIVE: To examine variations in plasma homocysteine concentration in relation to C reactive protein (CRP) in patients presenting with acute coronary syndromes. Homocysteine 43-55 C-reactive protein Homo sapiens 105-108 15133321-8 2004 There were significant negative correlations between CRP levels and serum beta-carotene and retinol concentrations. beta Carotene 74-87 C-reactive protein Homo sapiens 53-56 15133321-11 2004 The inverse correlations between CRP and beta-carotene or retinol indicate either decreased synthesis or increased utilization of these antioxidants. beta Carotene 41-54 C-reactive protein Homo sapiens 33-36 14638413-7 2003 The Crp-Fnr regulators stand out in responding to a broad spectrum of intracellular and exogenous signals such as cAMP, anoxia, the redox state, oxidative and nitrosative stress, nitric oxide, carbon monoxide, 2-oxoglutarate, or temperature. Ketoglutaric Acids 210-224 C-reactive protein Homo sapiens 4-7 11102253-7 2000 Forty-eight hours after randomization, mean C-reactive protein levels decreased by 2.6 mg. l(-1)in the methylprednisolone group, but increased by 1.6 mg. l(-1)in the placebo group (P=0.03). Methylprednisolone 103-121 C-reactive protein Homo sapiens 44-62 9610529-6 1998 For example, relative risks of future MI among those with high levels of both CRP and TC (RR=5.0, P=0.0001) were greater than the product of the individual risks associated with isolated elevations of either CRP (RR=1.5) or TC (RR=2.3). Technetium 224-226 C-reactive protein Homo sapiens 78-81 9610529-7 1998 In stratified analyses, baseline CRP level was predictive of risk for those with low as well as high levels of TC and the TC:HDL-C ratio. Technetium 111-113 C-reactive protein Homo sapiens 33-36 9610529-7 1998 In stratified analyses, baseline CRP level was predictive of risk for those with low as well as high levels of TC and the TC:HDL-C ratio. Technetium 122-124 C-reactive protein Homo sapiens 33-36 12667961-10 2003 Fluvastatin and cerivastatin also reduced the activation of NF-kappaB by CRP. cerivastatin 16-28 C-reactive protein Homo sapiens 73-76 12324296-9 2002 C-reactive protein concentrations were inversely related to beta-carotene (P < 0.001), lutein and zeaxanthin (P < 0.001), and lycopene (P = 0.023) concentrations. beta Carotene 60-73 C-reactive protein Homo sapiens 0-18 9589022-8 1998 On methylprednisolone (1 mg/kg daily) the eosinophil and platelet counts became normal within 5 days and erythrocyte sedimentation rate and the level of C-reactive protein fell. Methylprednisolone 3-21 C-reactive protein Homo sapiens 153-171 12056790-7 2002 In normal subjects and cancer patients, C-reactive protein concentrations were inversely correlated with circulating concentrations of retinol (r(2)=0.162), alpha-tocopherol (r(2)=0.297), lutein (r(2)=0.256), lycopene (r(2)=-0.171), alpha-(r(2)=0.140) and beta-carotene (r(2)=0.254): (all P<0.001). beta Carotene 256-269 C-reactive protein Homo sapiens 40-58 11781328-0 2002 Stoichiometry and structural effect of the cyclic nucleotide binding to cyclic AMP receptor protein. Nucleotides, Cyclic 43-60 C-reactive protein Homo sapiens 72-99 9574855-2 1998 CRP reductions have been reported to be greater in patients who later respond to lithium augmentation, and these patients also demonstrate higher CRP levels on the failed antidepressant, prior to the addition of lithium. Lithium 81-88 C-reactive protein Homo sapiens 0-3 9574855-5 1998 RESULTS: Patients on lithium monotherapy were significantly less likely to demonstrate elevated CRP, and a similar trend was noted in those patients taking lithium in combination with an antidepressant. Lithium 21-28 C-reactive protein Homo sapiens 96-99 11781328-3 2002 In this work, we performed a nuclear magnetic resonance study on CRP to investigate the stoichiometry of cyclic nucleotide binding to CRP. Nucleotides, Cyclic 105-122 C-reactive protein Homo sapiens 65-68 11781328-3 2002 In this work, we performed a nuclear magnetic resonance study on CRP to investigate the stoichiometry of cyclic nucleotide binding to CRP. Nucleotides, Cyclic 105-122 C-reactive protein Homo sapiens 134-137 12587783-7 2002 CRP levels were found to be significantly different between groups, higher in PG (6.2 +/- 0.86 mg/L) than those of CG (3.7 +/- 0.92 mg/L) and HG (0.854 +/- 0.2 mg/L) (p<0.05). cysteinylglycine 115-117 C-reactive protein Homo sapiens 0-3 9182890-5 1997 There were also significant correlations between sE-selectin levels and C-reactive protein (r = 0.80, P < 0.0001), and between sP-selectin levels and platelet counts (r = 0.57, P < 0.0001) in KD patients. se-selectin 49-60 C-reactive protein Homo sapiens 72-90 11434828-3 2001 OBJECTIVE: To test the hypothesis that pravastatin has anti-inflammatory effects as evidenced by CRP reduction. Pravastatin 39-50 C-reactive protein Homo sapiens 97-100 9562656-0 1997 Relationship between serum total sialic acid and C-reactive protein in silicosis. N-Acetylneuraminic Acid 33-44 C-reactive protein Homo sapiens 49-67 9562656-3 1997 The changes in serum total sialic acid levels were in parallel with those of CRP in silicosis. N-Acetylneuraminic Acid 27-38 C-reactive protein Homo sapiens 77-80 11434828-9 2001 RESULTS: In the primary prevention trial, compared with placebo, pravastatin reduced median CRP levels by 16.9% (P<.001) at 24 weeks, reflecting a decrease of 0.02 mg/dL in the pravastatin group while no change in CRP levels was observed in the placebo group. Pravastatin 65-76 C-reactive protein Homo sapiens 92-95 9562656-5 1997 Linear regression analysis revealed a close positive correlation between serum total sialic acid and CRP levels in silicosis (r = 0.86, p < 0.01). N-Acetylneuraminic Acid 85-96 C-reactive protein Homo sapiens 101-104 11434828-9 2001 RESULTS: In the primary prevention trial, compared with placebo, pravastatin reduced median CRP levels by 16.9% (P<.001) at 24 weeks, reflecting a decrease of 0.02 mg/dL in the pravastatin group while no change in CRP levels was observed in the placebo group. Pravastatin 65-76 C-reactive protein Homo sapiens 217-220 8616412-11 1996 C Reactive protein concentration was associated with raised serum fibrinogen, sialic acid, total cholesterol, triglyceride, glucose, and apolipoprotein B values. N-Acetylneuraminic Acid 78-89 C-reactive protein Homo sapiens 0-18 11434828-10 2001 This effect was seen as early as 12 weeks (median reduction in CRP with pravastatin, 14.7%; P<.001) and was present among all prespecified subgroups according to sex, age, smoking status, body mass index, baseline lipid levels, presence of diabetes, and use of aspirin or hormone replacement therapy. Pravastatin 72-83 C-reactive protein Homo sapiens 63-66 11434828-12 2001 In linear regression analyses, the only significant predictors of change in CRP on a log scale were randomized pravastatin allocation and baseline CRP levels (P<.001 for both). Pravastatin 111-122 C-reactive protein Homo sapiens 76-79 11434828-13 2001 Similar reductions in CRP levels were observed at 12 weeks (-14.3%) and 24 weeks (-13.1%) in the secondary prevention cohort treated with pravastatin (P<.005 for both). Pravastatin 138-149 C-reactive protein Homo sapiens 22-25 8579853-7 1996 But the CSF neopterin levels one day after admission were related to the period of positive serum C-reactive protein. Neopterin 12-21 C-reactive protein Homo sapiens 98-116 11434828-14 2001 CONCLUSIONS: In this prospective trial, pravastatin reduced CRP levels at both 12 and 24 weeks in a largely LDL-C-independent manner. Pravastatin 40-51 C-reactive protein Homo sapiens 60-63 11238259-0 2001 Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. cerivastatin 43-55 C-reactive protein Homo sapiens 19-37 8549944-8 1995 There were significantly greater decreases over the trial period in the median erythrocyte sedimentation rate, C reactive protein, and leucocyte count in the azathioprine group. Azathioprine 158-170 C-reactive protein Homo sapiens 111-129 11238259-4 2001 Overall, cerivastatin resulted in a 13.3% reduction in median CRP levels (P:<0.001) and a 24.5% reduction in mean CRP levels (P:<0.001). cerivastatin 9-21 C-reactive protein Homo sapiens 62-65 11238259-4 2001 Overall, cerivastatin resulted in a 13.3% reduction in median CRP levels (P:<0.001) and a 24.5% reduction in mean CRP levels (P:<0.001). cerivastatin 9-21 C-reactive protein Homo sapiens 117-120 11238259-8 2001 CONCLUSIONS: Among 785 patients with primary hypercholesterolemia, CRP levels were significantly reduced within 8 weeks of initiating cerivastatin therapy in a lipid-independent manner. cerivastatin 134-146 C-reactive protein Homo sapiens 67-70 7554564-2 1995 The neopterin concentrations significantly correlated with the Birmingham Vasculitis Activity Score as well as with the erythrocyte sedimentation rate and C-reactive protein. Neopterin 4-13 C-reactive protein Homo sapiens 155-173 11836849-0 2001 The effect of trimetazidine on C-reactive protein, cytokines and adhesion molecules in the course of acute myocardial infarction. Trimetazidine 14-27 C-reactive protein Homo sapiens 31-49 8119992-0 1994 Effects of calcium, magnesium, and phosphorylcholine on secondary structures of human C-reactive protein and serum amyloid P component observed by infrared spectroscopy. Magnesium 20-29 C-reactive protein Homo sapiens 86-104 8119992-4 1994 The CRP spectrum was also affected by magnesium, but the changes differed from those induced by calcium. Magnesium 38-47 C-reactive protein Homo sapiens 4-7 8097536-4 1993 In a trial comparing methotrexate with azathioprine significant differences could be found in favor of methotrexate by the variables of pain, DAS, ESR, C-reactive protein, hemoglobin and thrombocytes; not by Ritchie score, number of tender joints and number of swollen joints. Azathioprine 39-51 C-reactive protein Homo sapiens 152-170 1444626-3 1992 There were significant correlations between serum keratan sulphate concentrations in patients with RA and serum C reactive protein and the erythrocyte sedimentation rate. Keratan Sulfate 50-66 C-reactive protein Homo sapiens 112-130 1444626-4 1992 Serum keratan sulphate concentrations were also low in 29 men and women with ankylosing spondylitis and 29 patients with arthritis and high concentrations of C reactive protein. Keratan Sulfate 6-22 C-reactive protein Homo sapiens 158-176 1444626-5 1992 In 98 women undergoing an operation for benign breast disease there were decreases in serum keratan sulphate concentrations after the operation which correlated with doses in serum C reactive protein. Keratan Sulfate 92-108 C-reactive protein Homo sapiens 181-199 33813346-7 2021 RESULTS: In adjusted models we observed positive associations of monocarboxynonyl phthalate (MCNP) with CRP (beta = 0.092; 95% CI 0.026, 0.158) and IL-6 (beta = 0.108; 95% CI 0.013, 0.204). Mono(7-carboxy-2-methyloctyl) phthalate 65-91 C-reactive protein Homo sapiens 104-107 11836849-1 2001 The aim of this randomised, double-blind, placebo controlled, parallel group study was to assess the effect of trimetazidine (TMZ), a potent antiischaemic drug, on plasma C-reactive protein (C-RP), cytokine and adhesion molecule levels. Trimetazidine 111-124 C-reactive protein Homo sapiens 171-189 11836849-1 2001 The aim of this randomised, double-blind, placebo controlled, parallel group study was to assess the effect of trimetazidine (TMZ), a potent antiischaemic drug, on plasma C-reactive protein (C-RP), cytokine and adhesion molecule levels. Trimetazidine 126-129 C-reactive protein Homo sapiens 171-189 11836849-6 2001 Plasma C-RP level was significantly lower in TMZ group (39.5 mg/ml +/- 9.7 mg/ml) as compared to placebo (75.7 +/- 29.4 mg/ml, p < or = 0.001) and peaked 28 hours later in TMZ group. Trimetazidine 45-48 C-reactive protein Homo sapiens 7-11 11836849-6 2001 Plasma C-RP level was significantly lower in TMZ group (39.5 mg/ml +/- 9.7 mg/ml) as compared to placebo (75.7 +/- 29.4 mg/ml, p < or = 0.001) and peaked 28 hours later in TMZ group. Trimetazidine 175-178 C-reactive protein Homo sapiens 7-11 33801202-10 2021 We also demonstrated that the profile associated with the highest DCR was "less than 4.46 mg/dL of CRP levels and treatment with HAIC". dimethylamide-crotonin 66-69 C-reactive protein Homo sapiens 99-102 11836849-11 2001 The present study demonstrates a significant reduction of plasma C-reactive protein level in the course of acute myocardial infarction treated with streptokinase and intravenous trimetazidine infusion compared with the group of patients without trimetazidine treatment. Trimetazidine 178-191 C-reactive protein Homo sapiens 65-83 34799157-8 2022 Furthermore, a 1-unit increase in CRP was associated with decreases of - 0.765 to - 0.254 in MNF, - 0.400 to - 0.051 in urinary 8-OHdG. 8-ohdg 128-134 C-reactive protein Homo sapiens 34-37 11836849-11 2001 The present study demonstrates a significant reduction of plasma C-reactive protein level in the course of acute myocardial infarction treated with streptokinase and intravenous trimetazidine infusion compared with the group of patients without trimetazidine treatment. Trimetazidine 245-258 C-reactive protein Homo sapiens 65-83 11174913-6 2001 Moreover, potentially important associations have been established between elevated markers of inflammation, such as C-reactive protein and increased efficacy of established therapies; and, in particular, lipid-lowering therapy with the hepatic hydroxymethylglutaryl coenzyme A reductase inhibitor pravastatin. Pravastatin 298-309 C-reactive protein Homo sapiens 117-135 34974090-10 2022 Each one-unit increase in the log-transformed level 2-OHFlu (beta = 0.112, 95%CI = 0.018-0.206) and 2&3-OHPh (beta = 0.145, 95%CI = 0.037-0.253) were positively associated with C-reactive protein (CRP) among adolescents, but not among adults. 2&3-ohph 100-108 C-reactive protein Homo sapiens 177-195 34974090-10 2022 Each one-unit increase in the log-transformed level 2-OHFlu (beta = 0.112, 95%CI = 0.018-0.206) and 2&3-OHPh (beta = 0.145, 95%CI = 0.037-0.253) were positively associated with C-reactive protein (CRP) among adolescents, but not among adults. 2&3-ohph 100-108 C-reactive protein Homo sapiens 197-200 10879665-8 2000 CRP levels were lower when patients were dialyzed with polyamide (1.19 +/- 0.18 mg/dl) compared to the levels when the same patients were dialyzed with cuprophan (1.77 +/- 0.37 mg/dl, p = 0.02) or with polycarbonate (1.34 +/- 0.2 mg/dl, n.s). Nylons 55-64 C-reactive protein Homo sapiens 0-3 34704877-0 2022 Effectiveness of vitamin D2 supplementation on high-sensitivity C-reactive protein and other metabolic indices in menopausal Thai women: a randomized-controlled trial. Ergocalciferols 17-27 C-reactive protein Homo sapiens 64-82 34704877-1 2022 OBJECTIVE: To investigate the effectiveness of vitamin D2 supplementation with ergocalciferol on high-sensitivity C-reactive protein (hsCRP) level and other cardio-metabolic indices in menopausal Thai women. Ergocalciferols 47-57 C-reactive protein Homo sapiens 114-132 34704877-1 2022 OBJECTIVE: To investigate the effectiveness of vitamin D2 supplementation with ergocalciferol on high-sensitivity C-reactive protein (hsCRP) level and other cardio-metabolic indices in menopausal Thai women. Ergocalciferols 79-93 C-reactive protein Homo sapiens 114-132 10743792-9 2000 The levels of IgG anti-CII correlated with CRP (r = 0.270) and ESR (r = 0.253). N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide 23-26 C-reactive protein Homo sapiens 43-46 34911124-0 2022 An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Clozapine 44-53 C-reactive protein Homo sapiens 130-133 34798417-5 2021 3-(Dibutylamino)propylphosphonic acid (C10m) is a new substance that can suppress ischemic-reperfusion injury by targeting CRP in the complement cascade. c10m 39-43 C-reactive protein Homo sapiens 123-126 10743792-10 2000 CRP decreased significantly in patients (n = 13) who converted from IgG anti-CII positive to negative (p = 0.013). N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide 77-80 C-reactive protein Homo sapiens 0-3 10634389-2 2000 This study compared the effects of hormone replacement therapy (HRT) and raloxifene on serum C-reactive protein and homocysteine levels as markers of cardiovascular risk in healthy postmenopausal women. Raloxifene Hydrochloride 73-83 C-reactive protein Homo sapiens 93-111 34844579-7 2021 C-reactive protein and erythrocyte sedimentation rate in both groups were significantly lower than before treatment, but the improvement effect of vancomycin calcium sulfate implantation was better (p < 0.05). Vancomycin 147-157 C-reactive protein Homo sapiens 0-18 34844579-7 2021 C-reactive protein and erythrocyte sedimentation rate in both groups were significantly lower than before treatment, but the improvement effect of vancomycin calcium sulfate implantation was better (p < 0.05). Calcium Sulfate 158-173 C-reactive protein Homo sapiens 0-18 9770720-4 1998 When those patients who lost total body potassium were compared with those who had not, there was a significant increase in the baseline and 12-week C-reactive protein concentrations (p < 0.05). Potassium 40-49 C-reactive protein Homo sapiens 149-167 34733460-11 2021 For patients with PIH syndrome, Compound Danshen injection combined with magnesium sulfate can be used as a treatment plan, which can improve maternal and infant outcomes; control blood pressure; reduce 24 h urine protein and serum ET-1, Hcy, and CRP levels; and improve coagulation function. Magnesium Sulfate 73-90 C-reactive protein Homo sapiens 247-250 34675565-11 2021 Conclusion: The results of this study suggest that higher CRP might be one of the risk factors associated with lower VCM concentration in both normal and low renal function patients. Vancomycin 117-120 C-reactive protein Homo sapiens 58-61 34660338-11 2021 For example, after adjusting for age, sex, comorbidities, smoking, and drinking status, the C-reactive protein level was negatively associated with the TC lipid level (beta (SE) = -0.646 (0.219), p = 0.005). Technetium 152-154 C-reactive protein Homo sapiens 92-110 34515255-0 2021 What Is the Interaction between Urine C-Reactive Protein, Prostatic Inflammation, and Doxazosin Treatment in Patients with Benign Prostatic Hyperplasia? Doxazosin 86-95 C-reactive protein Homo sapiens 38-56 9770720-6 1998 There were significant correlations between the mean C-reactive protein concentration and the relative (r = -0.846, p < 0.001) and absolute (r = -0.806, p < 0.001) change in total body potassium over the follow-up period. Potassium 191-200 C-reactive protein Homo sapiens 53-71 9575343-1 1996 Analogs of the peptide Val-Thr-Val-Ala-Pro-Val-His-Ile, derived from the primary sequence of the acute phase reactant CRP, i.e. amino acid residues 89-96, were optimized to inhibit the enzymatic activities of human leukocyte elastase (hLE) and human leukocyte cathepsin G (hCG), which are associated with tissue damage occurring in the course of several chronic inflammatory conditions. val-thr-val-ala-pro-val-his 23-50 C-reactive protein Homo sapiens 118-121 8548035-0 1995 Immunohistochemical localization of C-reactive protein-binding sites in human atherosclerotic aortic lesions by a modified streptavidin-biotin-staining method. Biotin 136-142 C-reactive protein Homo sapiens 36-54 34142940-10 2021 Serum lipase and C-reactive protein levels at postoperative week 1 were higher in the histidinetryptophan-ketoglutarate group. alpha-ketoglutarate 106-119 C-reactive protein Homo sapiens 17-35 8548035-2 1995 In this report a more sensitive streptavidin-biotin technique was applied to detect the localization of CRP in human atherosclerotic lesions. Biotin 45-51 C-reactive protein Homo sapiens 104-107 34239907-7 2021 Similarly, 3rd tertiles of HDL and TC had lower levels of baseline inflammatory markers such as CRP, WBC, and NL ratio using linear regression analysis. Technetium 35-37 C-reactive protein Homo sapiens 96-99 8144569-6 1994 The ability of immobilized CRP to bind SAP was distinguished from CRP"s lectin-like binding reactivity since deglycosylated SAP retained its binding reactivity for CRP and sugars that inhibit CRP"s lectin-like binding activity failed to inhibit binding. Sugars 172-178 C-reactive protein Homo sapiens 27-30 8377450-9 1993 For persisting or increased fever or CRP elevation, 9 patients were treated with ceftriaxone and teicoplanin successfully. Ceftriaxone 81-92 C-reactive protein Homo sapiens 37-40 34189447-13 2021 Baseline absolute CRP serum levels were 5.53 +- 6.19 mg/dL (95% CI 6.91 to 4.15, n = 80) and 9.04 +- 7.69 (95% CI 9.04 to 10.82, n = 74) in the standard care and telmisartan added to standard care groups, respectively. Telmisartan 162-173 C-reactive protein Homo sapiens 18-21 34189447-15 2021 Day 8 CRP levels were 6.30 +- 8.19 mg/dL (95% CI 8.79-3.81, n = 44) and 2.37 +- 3.47 mg/dL (95% CI 3.44-1.30, n = 43, p = 0.0098) in the control and telmisartan groups, respectively (all values expressed as mean +- SD). Telmisartan 149-160 C-reactive protein Homo sapiens 6-9 1958695-6 1991 The lysosomotrophic agents (chloroquine, NH4Cl) greatly decreased the extent of CRP degradation without altering binding or internalization. Chloroquine 28-39 C-reactive protein Homo sapiens 80-83 34198765-3 2021 Herein, we proposed a lateral flow assay (LFA) strip based on surface-enhanced Raman scattering (SERS) nanotags (SERS-LFA strips) for the simultaneous and quantitative detection of dual infection biomarkers, serum amyloid A (SAA) and C-reactive protein (CRP), respectively. sers 113-117 C-reactive protein Homo sapiens 234-252 34198765-3 2021 Herein, we proposed a lateral flow assay (LFA) strip based on surface-enhanced Raman scattering (SERS) nanotags (SERS-LFA strips) for the simultaneous and quantitative detection of dual infection biomarkers, serum amyloid A (SAA) and C-reactive protein (CRP), respectively. sers 113-117 C-reactive protein Homo sapiens 254-257 1880430-5 1991 Also, adsorption of native CRP to the polystyrene surface in the ELISA system resulted in conformational changes of the adsorbed native CRP protein such that M-CRP reactive determinants were available for binding with anti-M-CRP MAbs, whereas native CRP adsorbed to the nitrocellulose membrane in the ELIFA system resulted in very limited conversion of CRP to M-CRP reactive epitopes. Polystyrenes 38-49 C-reactive protein Homo sapiens 27-30 34853573-10 2021 Olmesartan significantly decreased ASDAS, BASDAI, BASFI, ESR, CRP, IL-6, TNF-alpha, and SCORE as compared with placebo. olmesartan 0-10 C-reactive protein Homo sapiens 62-65 1880430-5 1991 Also, adsorption of native CRP to the polystyrene surface in the ELISA system resulted in conformational changes of the adsorbed native CRP protein such that M-CRP reactive determinants were available for binding with anti-M-CRP MAbs, whereas native CRP adsorbed to the nitrocellulose membrane in the ELIFA system resulted in very limited conversion of CRP to M-CRP reactive epitopes. Polystyrenes 38-49 C-reactive protein Homo sapiens 136-139 1880430-5 1991 Also, adsorption of native CRP to the polystyrene surface in the ELISA system resulted in conformational changes of the adsorbed native CRP protein such that M-CRP reactive determinants were available for binding with anti-M-CRP MAbs, whereas native CRP adsorbed to the nitrocellulose membrane in the ELIFA system resulted in very limited conversion of CRP to M-CRP reactive epitopes. Polystyrenes 38-49 C-reactive protein Homo sapiens 136-139 34092762-0 2021 Serum High-sensitivity C-reactive Protein Level and Corrected QT Interval in Agricultural Workers in Myanmar Exposed to Chronic Occupational Organophosphate Pesticides. Organophosphates 141-156 C-reactive protein Homo sapiens 23-41 1880430-5 1991 Also, adsorption of native CRP to the polystyrene surface in the ELISA system resulted in conformational changes of the adsorbed native CRP protein such that M-CRP reactive determinants were available for binding with anti-M-CRP MAbs, whereas native CRP adsorbed to the nitrocellulose membrane in the ELIFA system resulted in very limited conversion of CRP to M-CRP reactive epitopes. Polystyrenes 38-49 C-reactive protein Homo sapiens 136-139 1880430-5 1991 Also, adsorption of native CRP to the polystyrene surface in the ELISA system resulted in conformational changes of the adsorbed native CRP protein such that M-CRP reactive determinants were available for binding with anti-M-CRP MAbs, whereas native CRP adsorbed to the nitrocellulose membrane in the ELIFA system resulted in very limited conversion of CRP to M-CRP reactive epitopes. Polystyrenes 38-49 C-reactive protein Homo sapiens 136-139 35380410-1 2022 OBJECTIVE: To investigate the effects of pentoxifylline (PTX) in combination with losartan compared to the high dose of losartan alone on serum markers of diabetic nephropathy such as HSP70, copeptin, CRP, and TNFalpha in patients with type 2 diabetes and nephropathy. Losartan 82-90 C-reactive protein Homo sapiens 201-204 1880430-5 1991 Also, adsorption of native CRP to the polystyrene surface in the ELISA system resulted in conformational changes of the adsorbed native CRP protein such that M-CRP reactive determinants were available for binding with anti-M-CRP MAbs, whereas native CRP adsorbed to the nitrocellulose membrane in the ELIFA system resulted in very limited conversion of CRP to M-CRP reactive epitopes. Polystyrenes 38-49 C-reactive protein Homo sapiens 136-139 1880430-5 1991 Also, adsorption of native CRP to the polystyrene surface in the ELISA system resulted in conformational changes of the adsorbed native CRP protein such that M-CRP reactive determinants were available for binding with anti-M-CRP MAbs, whereas native CRP adsorbed to the nitrocellulose membrane in the ELIFA system resulted in very limited conversion of CRP to M-CRP reactive epitopes. Polystyrenes 38-49 C-reactive protein Homo sapiens 136-139 35245303-6 2022 In terms of efficacy, low/moderate-intensity statin plus ezetimibe reduced LDL-C (SE = 0.307; 95% CI 0.153-0.463), TC (SE = 0.217; 95% CI 0.098-0.337), triglyceride (SE = 0.307; 95% CI 0.153-0.463), and hs-CRP (SE = 0.190; 95% CI 0.018-0.362) significantly more than high-intensity statin therapy. Ezetimibe 57-66 C-reactive protein Homo sapiens 206-209 35229896-10 2022 TC, TG, LDL-C, ApoB and high-sensitivity C-reactive protein (hsCRP) at baseline had positive correlation with TC after treatment; ApoB at baseline had positive correlation, while HDL-C and free fat acid (FFA) at baseline had negative correlation with TG after treatment. Technetium 110-112 C-reactive protein Homo sapiens 41-59 35229896-10 2022 TC, TG, LDL-C, ApoB and high-sensitivity C-reactive protein (hsCRP) at baseline had positive correlation with TC after treatment; ApoB at baseline had positive correlation, while HDL-C and free fat acid (FFA) at baseline had negative correlation with TG after treatment. fat acid 194-202 C-reactive protein Homo sapiens 41-59 1650222-7 1991 Calcium phosphorylcholine (10 micrograms/ml) or sodium citrate (10 micrograms/ml) completely dissociated bound CRP. calcium phosphorylcholine 0-25 C-reactive protein Homo sapiens 111-114 1650222-10 1991 At concentrations of 100 micrograms/ml or greater, CRP also inhibited superoxide production in a cell-free xanthine oxidase-acetaldehyde system. Acetaldehyde 124-136 C-reactive protein Homo sapiens 51-54 34406670-6 2022 CRP levels decreased significantly after remdesivir administration in patients who remained non-intubated over the study period. remdesivir 41-51 C-reactive protein Homo sapiens 0-3 35052001-0 2022 Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Clozapine 56-65 C-reactive protein Homo sapiens 142-145 35277037-9 2022 In meta-analysis, Mg supplementation significantly decreased serum C reactive protein (CRP) and increased nitric oxide (NO) levels. Magnesium 18-20 C-reactive protein Homo sapiens 67-85 34967190-9 2021 RS supplementation significantly reduced blood C-reactive protein concentration in type 2 diabetes mellitus (T2DM) patients (SMD (95% CI): -0.35 (-0.65, -0.05), p=0.02). rs 0-2 C-reactive protein Homo sapiens 47-65 35277037-9 2022 In meta-analysis, Mg supplementation significantly decreased serum C reactive protein (CRP) and increased nitric oxide (NO) levels. Magnesium 18-20 C-reactive protein Homo sapiens 87-90 35277037-11 2022 In conclusion, Mg supplementation may significantly reduce different human inflammatory markers, in particular serum CRP and NO levels. Magnesium 15-17 C-reactive protein Homo sapiens 117-120 34967190-11 2021 CONCLUSIONS: RS supplementation may significantly reduce a few oxidative-stress and inflammation biomarkers such as malondialdehyde and C-reactive protein, particularly in T2DM patients. rs 13-15 C-reactive protein Homo sapiens 136-154 34659176-10 2021 In summary, we found that CRP directly activates the transcription of the aroX and NRPS operons and that the absence of CRP reduced cytotoxicity of K. oxytoca on HeLa cells, due to a significant reduction in TV production. tilivalline 208-210 C-reactive protein Homo sapiens 26-29 35204141-0 2022 Serum Lutein and Zeaxanthin Are Inversely Associated with High-Sensitivity C-Reactive Protein in Non-Smokers: The Mikkabi Study. Lutein 6-12 C-reactive protein Homo sapiens 75-93 34659176-10 2021 In summary, we found that CRP directly activates the transcription of the aroX and NRPS operons and that the absence of CRP reduced cytotoxicity of K. oxytoca on HeLa cells, due to a significant reduction in TV production. tilivalline 208-210 C-reactive protein Homo sapiens 120-123 35194371-4 2022 Conclusions: Treatment of severe COVID-19 pneumonia, Patients who were mechanically ventilated with methylprednisolone infusion 2 mg/kg/day for 10 days versus dexamethasone 6 mg for 10 days showed a statistically significant improvement in the MV days and length of stay in the intensive care unit, together with the overall mortality and severity inflammatory markers of cytokine storm c-reactive protein (CRP), D-dimer, ferritin, LDH, and N:L ratio. Methylprednisolone 100-118 C-reactive protein Homo sapiens 387-405 35194371-4 2022 Conclusions: Treatment of severe COVID-19 pneumonia, Patients who were mechanically ventilated with methylprednisolone infusion 2 mg/kg/day for 10 days versus dexamethasone 6 mg for 10 days showed a statistically significant improvement in the MV days and length of stay in the intensive care unit, together with the overall mortality and severity inflammatory markers of cytokine storm c-reactive protein (CRP), D-dimer, ferritin, LDH, and N:L ratio. Methylprednisolone 100-118 C-reactive protein Homo sapiens 407-410 34588979-7 2021 Similar trends favoring HCQ treatment were observed for uSFR (p = 0.05), CRP (p = 0.0008), ESR (p < 0.00001), IgM (p = 0.007) and IgA (p = 0.05). Hydroxychloroquine 24-27 C-reactive protein Homo sapiens 73-76 35005432-11 2022 Methylprednisolone treatment also reduced the C-reactive protein levels, compared to the standard care group on day 7. Methylprednisolone 0-18 C-reactive protein Homo sapiens 46-64 35307056-14 2022 Pearson correlation analysis showed that the blood magnesium level of sepsis patients was negatively correlated with PCT (r = -0.173, P < 0.05), and it was positively correlated with APACHE II score (r = 0.159, P < 0.05), but it had no correlation with CRP or SOFA score (r values were -0.029 and 0.091, both P > 0.05). Magnesium 51-60 C-reactive protein Homo sapiens 253-256 34588979-9 2021 Conclusion: HCQ treatment showed moderate efficacy to improve oral symptoms, uSFR, ESR, CRP, IgM and IgA. Hydroxychloroquine 12-15 C-reactive protein Homo sapiens 88-91 34394971-10 2021 Laboratory predictors of a LAM+ve status included renal dysfunction, P = 0.044, severe anaemia, P = 0.0116, and an elevated C-reactive protein, P = 0.0131. lipoarabinomannan 27-30 C-reactive protein Homo sapiens 124-142 34155310-1 2021 The purpose of the present study was to evaluate de influence of protein-sugar complexation on the stability and functionality of C-reactive protein, after exposure to constant high temperatures, in order to develop highly stable positive controls for in-vitro diagnostic tests. Sugars 73-78 C-reactive protein Homo sapiens 130-148 34177879-7 2021 The use of chloroquine did not significantly influence the patients" antibody titer but reduced C-reaction protein (CRP) level. Chloroquine 11-22 C-reactive protein Homo sapiens 116-119 34467691-5 2021 The results revealed that the main compounds of Euodiae Fructus, such as berberine and rutaecarpine, participated in the biological processes(such as neurotransmitter receptor activity) by regulating C-reactive protein(CRP), estrogen receptor 1(ESR1), 5-hydroxytryptamine(5-HT) receptor, and interleukin-6(IL-6) to exert sedative, anxiolytic, and antidepressant effects. rutecarpine 87-99 C-reactive protein Homo sapiens 219-222 35576800-11 2022 Mediation analysis showed that only miR-26a-5p significantly mediated air pollutant (PM2.5 and NO2)-induced effects on blood CRP and total cholesterol levels. Nitrogen Dioxide 95-98 C-reactive protein Homo sapiens 125-128 35576800-13 2022 Similarly, the proportions of indirect effects of miR-26a-5p on the association between NO2 exposure and CRP were 46.8% at lag2 (0.06 (0.02, 0.11), P = 0.003), 61.2% at lag3 (0.05 (0.00, 0.09), P = 0.04), and 30.8% at 5-day moving average (0.06 (0.02, 0.10), P = 0.01). Nitrogen Dioxide 88-91 C-reactive protein Homo sapiens 105-108 35534369-11 2022 CONCLUSIONS: The benefits of remdesivir administered with dexamethasone and tocilizumab in hospitalized COVID-19 patients differ depending on Ct and CRP. remdesivir 29-39 C-reactive protein Homo sapiens 149-152 35301057-8 2022 We decomposed the total effect of early-adult obesity on mid-life PF into direct and indirect (via CRP) effects, by employing a mediation analysis based on parametric g-computation. pf 66-68 C-reactive protein Homo sapiens 99-102 35309334-1 2022 Monomeric C-reactive protein (mCRP), once thought to be a figment of the imagination and whose biological activity was ascribed to its sodium azide preservative, has now pronounced itself as a critical molecule playing a direct role in mediating many of the acute and chronic aberrant pathological responses to inflammation. Sodium Azide 135-147 C-reactive protein Homo sapiens 10-28 35121786-8 2022 Notably, the magnitude of the associations between PCF/TAT and NAFLD/AO varied by the level of systemic inflammatory marker (hs-CRP level). PHENYL CHLOROFORMATE 51-54 C-reactive protein Homo sapiens 128-131 35192518-8 2022 C-reactive protein levels of the standard of care plus hydroxychloroquine group were significantly lower than that of the standard of care group at discharge (p = 0.034). Hydroxychloroquine 55-73 C-reactive protein Homo sapiens 0-18 35192518-11 2022 CONCLUSIONS: Hydroxychloroquine in addition to standard of care was associated with less intensive care unit admissions, early discharge and greater C-reactive protein reduction. Hydroxychloroquine 13-31 C-reactive protein Homo sapiens 149-167 35127179-9 2022 FeNO level was positively correlated with C-reactive protein in AECOPD patients while negatively correlated with brain natriuretic peptide in the AECOPD + PH group. feno 0-4 C-reactive protein Homo sapiens 42-60 35377256-6 2022 Furthermore, the genotypes of CRP polymorphisms and the interactions between polymorphisms of CRP and life event scale score had a significant influence on cognitive performance in BD patients after 12 weeks of VPA treatment. Valproic Acid 211-214 C-reactive protein Homo sapiens 30-33 35377256-6 2022 Furthermore, the genotypes of CRP polymorphisms and the interactions between polymorphisms of CRP and life event scale score had a significant influence on cognitive performance in BD patients after 12 weeks of VPA treatment. Valproic Acid 211-214 C-reactive protein Homo sapiens 94-97 3608191-1 1987 A slide test for detecting elevated levels of serum CRP using Intralipid and calcium chloride is described. Calcium Chloride 77-93 C-reactive protein Homo sapiens 52-55 2490853-3 1989 There were significant positive correlations between pyridinoline excretion and both C reactive protein and erythrocyte sedimentation rate, whereas there was an inverse relation with grip strength. pyridinoline 53-65 C-reactive protein Homo sapiens 85-103 3069247-6 1988 Seventeen of 36 patients treated with Cyclosporine A and prednisone had at least 1 acute rejection; only 8 of these patients experienced a significant rise in the CRP (mean increase 27 micrograms/ml) and in only 5 of these did the increase occur prior to or on the day of rejection diagnosis. Prednisone 57-67 C-reactive protein Homo sapiens 163-166 3385211-2 1988 We report here that human CRP acquired the ability to augment platelet reactivity when treated with an Fe2+ (Cu2+)-ascorbate system. fe2+ (cu2+)-ascorbate 103-124 C-reactive protein Homo sapiens 26-29 3471057-5 1986 The increase in the mitochondrial protein concentration of skeletal muscle that occurs with endurance training has a direct effect on improving work capacity by providing a greater potential for the CrP shuttle, produced by a greater surface area, increasing the number of transport sites for the exchange of substrates and products between the cytosol and the mitochondrial matrix, exerting a tighter control over the adenine nucleotides as they turnover during contractile and metabolic activity, and providing for a tighter control over the Embden-Meyerhof pathway to prevent excessive lactate production. Adenine Nucleotides 419-438 C-reactive protein Homo sapiens 199-202 3700607-9 1986 Mean CRP levels were inversely related to zymosan-induced complement activation in patients with complicated illness. Zymosan 42-49 C-reactive protein Homo sapiens 5-8 6477504-8 1984 In contrast, the much greater resemblance to human CRP confirms that the rat C-polysaccharide-binding/phosphocholine-binding protein is in fact rat CRP. Polysaccharides 79-93 C-reactive protein Homo sapiens 51-54 6363539-1 1984 C-reactive protein (CRP) is an acute phase serum protein in man that binds to the cell wall C-polysaccharide (PnC) of Streptococcus pneumoniae via phosphocholine (PC) determinants. c-polysaccharide 92-108 C-reactive protein Homo sapiens 0-18 6363539-1 1984 C-reactive protein (CRP) is an acute phase serum protein in man that binds to the cell wall C-polysaccharide (PnC) of Streptococcus pneumoniae via phosphocholine (PC) determinants. c-polysaccharide 92-108 C-reactive protein Homo sapiens 20-23 6300060-8 1983 Inhibition studies using purified C-polysaccharide-induced inhibition of the phosphate spin label-human C-reactive protein interaction showed competitive inhibition with a KI of 4.78 X 10(-5) M at 18 degrees C. The phosphate spin label did not bind to dogfish C-reactive protein. c-polysaccharide 34-50 C-reactive protein Homo sapiens 104-122 6300060-8 1983 Inhibition studies using purified C-polysaccharide-induced inhibition of the phosphate spin label-human C-reactive protein interaction showed competitive inhibition with a KI of 4.78 X 10(-5) M at 18 degrees C. The phosphate spin label did not bind to dogfish C-reactive protein. c-polysaccharide 34-50 C-reactive protein Homo sapiens 260-278 7092339-3 1982 The urinary excretion of sialyl lactose showed a positive correlation with the serum levels of SAA and CRP in RA (r = 0.45 and r = 0.45, respectively, p less than 0.01) but not in SLE (r = 0.05 and r = 0.10 respectively). Lactose 32-39 C-reactive protein Homo sapiens 103-106 7028875-3 1981 In the preceding paper we reported that C-reactive protein (CRP) in the presence of a multimeric binding specificity such as C-polysaccharide (CPS) binds to a small percentage of peripheral blood lymphocytes (PBL). c-polysaccharide 125-141 C-reactive protein Homo sapiens 40-58 7028875-3 1981 In the preceding paper we reported that C-reactive protein (CRP) in the presence of a multimeric binding specificity such as C-polysaccharide (CPS) binds to a small percentage of peripheral blood lymphocytes (PBL). c-polysaccharide 125-141 C-reactive protein Homo sapiens 60-63 7276568-4 1981 In the present report, calcium was shown to inhibit this reactivity in a dose-dependent manner, in direct contrast to the requirement for calcium for precipitation of CRP with C-polysaccharide. c-polysaccharide 176-192 C-reactive protein Homo sapiens 167-170 7217669-2 1981 Binding of CRP to multilamellar liposomes or unilamellar vesicles of egg-phosphatidylcholine required the presence of lysophosphatide in the bilayer. lysophosphatide 118-133 C-reactive protein Homo sapiens 11-14 6253923-1 1980 The cyclic AMP receptor protein (CRP) stimulates transcription of the lactose operon by binding to the lac promoter. Lactose 70-77 C-reactive protein Homo sapiens 4-31 6253923-1 1980 The cyclic AMP receptor protein (CRP) stimulates transcription of the lactose operon by binding to the lac promoter. Lactose 70-77 C-reactive protein Homo sapiens 33-36 109055-0 1979 Effects of gold, dapsone, and prednisone on serum C-reactive protein and haptoglobin and the erythrocyte sedimentation rate in rheumatoid arthritis. Prednisone 30-40 C-reactive protein Homo sapiens 50-68 109055-5 1979 During treatment with prednisone serum CRP and ESR fell abruptly by 28 days and thereafter altered little. Prednisone 22-32 C-reactive protein Homo sapiens 39-42 588590-0 1977 Purification of C-reactive protein on DEAE-cellulose by a simple two-step procedure utilizing the calcium-dependency of the protein. DEAE-Cellulose 38-52 C-reactive protein Homo sapiens 16-34 883788-3 1977 However, lower titers of alpha-antitoxin, lysine levels and C-reactive protein content were registered in the mastitis patients treated with cephaloridin. Cephaloridine 141-153 C-reactive protein Homo sapiens 60-78 403526-1 1977 Partial amino-acid sequence analyses of the amino terminus of rabbit C-reactive protein and of a peptide isolated from human C-reactive protein after cyanogen bromide cleavage show an extensive sequence homology between these proteins. Cyanogen Bromide 150-166 C-reactive protein Homo sapiens 125-143 13766142-0 1960 [Behavior of the C-reactive protein in relation to barbiturate anesthesia for minor gynecological operations]. barbituric acid 51-62 C-reactive protein Homo sapiens 17-35 13323365-0 1956 [Research on the behavior of the C-reactive protein in blood of patients with rheumatoid arthritis treated with prednisone]. Prednisone 112-122 C-reactive protein Homo sapiens 33-51 34031890-6 2021 Compared to placebo, use of prednisone was associated with reductions in levels of CRP on days 3, 5, and 7, (mean difference of 46%, p < 0.001 for each time point). Prednisone 28-38 C-reactive protein Homo sapiens 83-86 33856733-6 2021 Compared with placebo group, crocin reduced hs-CRP (-1.03 vs. 1.42, p = .007), TNF-alpha (-0.8 vs. 0.28, p = .009), and NF-kappaB (-0.39 vs. 0.01, p = .047) after 12 weeks intervention; these improvements were also significant in comparison with the baseline values. crocin 29-35 C-reactive protein Homo sapiens 47-50 33856733-9 2021 This study indicates that daily administration of 30 mg crocin supplement to patients with T2DM reduces the concentrations of hs-CRP, TNF-alpha, and NF-kappaB which are involved in the pathogenesis of complications of T2DM. crocin 56-62 C-reactive protein Homo sapiens 129-132 33827655-5 2021 Diagnostic performance was calculated and logistic regression analysis was performed to evaluate the association between FDG-PET/CT outcome and C-reactive protein level (CRP), leukocyte count, duration of antibiotic treatment, duration of ICU stay, quality of FDG-PET/CT, and dependency on mechanical ventilation. Fluorodeoxyglucose F18 121-124 C-reactive protein Homo sapiens 144-162 33760858-7 2021 The strong association between the use of colchicine and reduced mortality was further supported by the diverging linear trends of percent daily change in lymphocyte count (P = 0.018), neutrophil-to-lymphocyte ratio (P = 0.003), and in C-reactive protein levels (P = 0.009). Colchicine 42-52 C-reactive protein Homo sapiens 236-254 33691757-5 2021 RESULTS: In NAFLD patients, OMG significantly decreased levels of aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, homeostatic model assessment of insulin resistance (HOMA-IR), and high-sensitivity C-reactive protein (hsCRP), while no significant change was seen in hemoglobin A1c or body mass index. 2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine 28-31 C-reactive protein Homo sapiens 226-244 33398528-6 2021 Phenylalanine and tyrosine levels increased from normal through stages A, B and C. Cross-sectional analysis in patients at stage C showed that phenylalanine levels were related to total bilirubin, eGFR, valerylcarnitine, methionine sulfoxide, C-reactive protein, and male gender. Phenylalanine 143-156 C-reactive protein Homo sapiens 243-261 33398528-8 2021 Based on a generalized estimating equations analysis model with time interaction considered, the only significant factor associated with changes in phenylalanine was changes in C-reactive protein concentrations from baseline to 12 months [B (coefficient) = 0.81, P < 0.001] after adjusting for methionine sulfoxide and total bilirubin levels. Phenylalanine 148-161 C-reactive protein Homo sapiens 177-195 33290138-0 2021 Glucosamine and Chondroitin Use in Relation to C-Reactive Protein Concentration: Results by Supplement Form, Formulation, and Dose. Glucosamine 0-11 C-reactive protein Homo sapiens 47-65 33290138-1 2021 Objectives: Glucosamine and chondroitin supplements have been associated with reduced inflammation, as measured by C-reactive protein (CRP). Glucosamine 12-23 C-reactive protein Homo sapiens 115-133 33290138-1 2021 Objectives: Glucosamine and chondroitin supplements have been associated with reduced inflammation, as measured by C-reactive protein (CRP). Glucosamine 12-23 C-reactive protein Homo sapiens 135-138 33290138-14 2021 Conclusions: Although a significant inverse association was observed for glucosamine and chondroitin and CRP in early years, this association did not hold in later years. Glucosamine 73-84 C-reactive protein Homo sapiens 105-108 33430859-9 2021 The effective lipid-lowering drugs used were statin alone and statin in association with fenofibrate, which improved both the lipid profile values and the subclinical atherosclerosis markers (ankle-brachial index, carotid intima-media thickness and high-sensitivity C-reactive protein). Fenofibrate 89-100 C-reactive protein Homo sapiens 266-284 33423218-8 2021 Early increase in blood CRP appears to correlate with DCI after SAH, while increase in WBC correlates with poor functional outcome. dci 54-57 C-reactive protein Homo sapiens 24-27 33397249-8 2021 Curcumin and nano-curcumin supplementation also improved significant changes in plasma levels of total antioxidant capacity (TAC), malondialdehyde (MDA), Superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), high-sensitivity C-reactive protein (hs-CRP), Interleukin 1 beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) in comparison to the placebo (p<0.05). nano-curcumin 13-26 C-reactive protein Homo sapiens 232-250 33397249-8 2021 Curcumin and nano-curcumin supplementation also improved significant changes in plasma levels of total antioxidant capacity (TAC), malondialdehyde (MDA), Superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), high-sensitivity C-reactive protein (hs-CRP), Interleukin 1 beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) in comparison to the placebo (p<0.05). nano-curcumin 13-26 C-reactive protein Homo sapiens 255-258 33277455-13 2020 CONCLUSION: Significant differences between our groups showed that L-Carnitine could help hemodialysis patients with cardiopulmonary problems to suffer lower rate of inflammation and poor life quality as shown at least in comparison of the two factors including CRP and PETCO2 at rest. Carnitine 67-78 C-reactive protein Homo sapiens 262-265 33199442-8 2021 CONCLUSION: NSBB therapy seems to exert systemic anti-inflammatory activity as evidenced by reductions of WBC and CRP levels. nsbb 12-16 C-reactive protein Homo sapiens 114-117 33224343-5 2020 Among statins, rosuvastatin had the strongest interaction with CRP (pKi = 16.14), followed by fluvastatin (pKi = 15.58), pitavastatin (pKi = 15.26), atorvastatin (pKi = 14.68), pravastatin (pKi = 13.95), simvastatin (pKi = 7.98) and lovastatin (pKi = 7.10). Lovastatin 233-243 C-reactive protein Homo sapiens 63-66 32852338-7 2020 In addition, patients receiving famotidine displayed lower levels of serum markers for severe disease including lower median peak C-reactive protein levels (9.4 vs 12.7 mg/dL, P = 0.002), lower median procalcitonin levels (0.16 vs 0.30 ng/mL, P = 0.004), and a nonsignificant trend to lower median mean ferritin levels (797.5 vs 964.0 ng/mL, P = 0.076). Famotidine 32-42 C-reactive protein Homo sapiens 130-148 32173876-6 2020 25(OH)vitamin D levels were positively correlated with the number of teeth and negatively with C-reactive protein (CRP) and all periodontal parameters (P < .001). 25(oh)vitamin d 0-15 C-reactive protein Homo sapiens 95-113 32173876-6 2020 25(OH)vitamin D levels were positively correlated with the number of teeth and negatively with C-reactive protein (CRP) and all periodontal parameters (P < .001). 25(oh)vitamin d 0-15 C-reactive protein Homo sapiens 115-118 33520867-13 2020 Conclusions: L-carnitine supplementation was associated with lowering of CRP, IL-6, TNF-alpha, and MDA, and increasing SOD levels, but did not affect other inflammatory and oxidative stress biomarkers. Carnitine 13-24 C-reactive protein Homo sapiens 73-76 33439554-10 2020 C-reactive protein was significantly higher in patients with PMR activity on 18F-FDG PET/CT compared with those without 18F-FDG PET/CT activity (P value = 0.006). Fluorodeoxyglucose F18 77-84 C-reactive protein Homo sapiens 0-18 33439554-10 2020 C-reactive protein was significantly higher in patients with PMR activity on 18F-FDG PET/CT compared with those without 18F-FDG PET/CT activity (P value = 0.006). Fluorodeoxyglucose F18 120-127 C-reactive protein Homo sapiens 0-18 32461554-8 2020 Colchicine decreased concentrations of multiple inflammatory molecules, including C-reactive protein, interleukin 6, and resistin, in addition to vascular-related proteins (e.g., oxidized low-density lipoprotein receptor, phosphodiesterase 5A). Colchicine 0-10 C-reactive protein Homo sapiens 82-100 32676868-3 2020 The aim of this study was to assess the effect of colchicine as anti-inflammatory drug on the serum levels of the inflammatory markers (CRP) and (IL-6) in patients with chronic (RHD). Colchicine 50-60 C-reactive protein Homo sapiens 136-139 32676868-9 2020 Mean (CRP) was 6.09 +- 4.39 IU/ml before and became 3.34 +- 3.07I U/ml 1 month after colchicine therapy. Colchicine 85-95 C-reactive protein Homo sapiens 6-9 32676868-11 2020 CONCLUSION: In this pilot study, using colchicine as anti-inflammatory drug in patients with chronic (RHD) significantly reduced the serum inflammatory markers (CRP) and (IL-6), thus helping in ameliorating their chronic inflammatory state. Colchicine 39-49 C-reactive protein Homo sapiens 161-164 32394193-3 2020 Au nanoparticles were loaded on COF-LZUl to immobilise the CRP antibody (anti-CRP) on the surface of a glassy carbon electrode. Gold 0-2 C-reactive protein Homo sapiens 59-62 32394193-3 2020 Au nanoparticles were loaded on COF-LZUl to immobilise the CRP antibody (anti-CRP) on the surface of a glassy carbon electrode. Gold 0-2 C-reactive protein Homo sapiens 78-81 32304240-6 2020 CO2 e emissions for biochemical tests were 0.5 g/test CO2 e (95% CI, 0.4-0.6 g/test) for C-reactive protein (low because typically ordered with urea and electrolyte assessment), 49 g/test (95% CI, 45-53 g/test) for arterial blood gas assessment, and 99 g/test (95% CI, 84-113 g/test) for urea and electrolyte assessment. co2 e 0-5 C-reactive protein Homo sapiens 89-107 32304240-6 2020 CO2 e emissions for biochemical tests were 0.5 g/test CO2 e (95% CI, 0.4-0.6 g/test) for C-reactive protein (low because typically ordered with urea and electrolyte assessment), 49 g/test (95% CI, 45-53 g/test) for arterial blood gas assessment, and 99 g/test (95% CI, 84-113 g/test) for urea and electrolyte assessment. co2 e 54-59 C-reactive protein Homo sapiens 89-107 31875935-12 2020 The changes in P, Ca x P, LDL cholesterol, but not ACI and the changes in hs-CRP, were correlated with the change in TCPP levels. tetracarboxyphenylporphine 117-121 C-reactive protein Homo sapiens 77-80 2530919-0 1989 Electrochemical method for measuring C-reactive protein using crown ether--phosphate ester ionophores. crown ether--phosphate ester 62-90 C-reactive protein Homo sapiens 37-55 2803750-3 1989 The purified CRP had an apparant molecular weight of 28,000 as determined by migration of the reduced protein during SDS polyacrylamide gel electrophoresis. polyacrylamide 121-135 C-reactive protein Homo sapiens 13-16 3497902-3 1987 In about 50% of the cases, E-AT was found to be elevated to 2-3 times the normal concentrations, in relation to increasing serum content of C-reactive protein. e-at 27-31 C-reactive protein Homo sapiens 140-158 3098484-3 1986 Serum C-reactive protein levels in scleroderma patients before and after a seventy-two hour infusion of either PGE1 or placebo were measured in the present study. Alprostadil 111-115 C-reactive protein Homo sapiens 6-24 3098484-5 1986 Before the intravenous infusion, the PGE1-treated and placebo-treated groups had mean serum CRP concentrations of 14 +/- 9 and 10 +/- 9 mcg/ml, respectively. Alprostadil 37-41 C-reactive protein Homo sapiens 92-95 3086219-2 1986 We report here that the formerly observed interaction of CRP with snail galactans, as exemplified by Helix pomatia galactan, is not due to a lectin-like carbohydrate-binding reactivity, but, instead that CRP obviously binds to phosphate groups that are minor constituents of these polysaccharides. Polysaccharides 281-296 C-reactive protein Homo sapiens 57-60 3723841-4 1986 CRP antigen is coupled to the carboxyfluorescein entrapped multilamellar liposomes by using N-hydroxysuccinimidyl 3-(2-pyridyldithio) propionate and dithiothreitol, and a specific lysis of liposomes is achieved upon the addition of anti-CRP antibody in the presence of complement. Dithiothreitol 149-163 C-reactive protein Homo sapiens 0-3 6747291-2 1984 CRP reacts with the phosphocholine moiety of pneumococcal cell wall C-polysaccharide, and this reaction can lead to complement activation in vitro and protection against pneumococcal infection in vivo. c-polysaccharide 68-84 C-reactive protein Homo sapiens 0-3 6654860-2 1983 CRP was strongly adsorbed on a DEAE-cellulose column and was easily separated from other serum proteins. DEAE-Cellulose 31-45 C-reactive protein Homo sapiens 0-3 6656768-13 1983 The formation of F-CRP from native CRP resulted in a loss of capacity for calcium-dependent binding to the C-polysaccharide despite the persistence of calcium-independent binding reactivity for polycations. c-polysaccharide 107-123 C-reactive protein Homo sapiens 19-22 6656768-13 1983 The formation of F-CRP from native CRP resulted in a loss of capacity for calcium-dependent binding to the C-polysaccharide despite the persistence of calcium-independent binding reactivity for polycations. c-polysaccharide 107-123 C-reactive protein Homo sapiens 35-38 7046573-8 1982 In addition CRP has another binding site accounting for its ability to react with depyruvylated type 4 pneumococcal polysaccharide which does not contain phosphate or choline. Choline 167-174 C-reactive protein Homo sapiens 12-15 7462634-3 1981 We have previously presented a model for CRP-membrane interactions using liposomes composed of dimyristoyl phosphatidylcholine (DMPC), cholesterol (CHOL), stearylamine (SA), and galactosyl ceramide. Dimyristoylphosphatidylcholine 95-126 C-reactive protein Homo sapiens 41-44 7462634-3 1981 We have previously presented a model for CRP-membrane interactions using liposomes composed of dimyristoyl phosphatidylcholine (DMPC), cholesterol (CHOL), stearylamine (SA), and galactosyl ceramide. Dimyristoylphosphatidylcholine 128-132 C-reactive protein Homo sapiens 41-44 7462634-7 1981 CRP binding to liposomes was dependent on the presence of SA in the membrane and could occur with dimyristoyl phosphatidylethanolamine in place of DMPC. Dimyristoylphosphatidylcholine 147-151 C-reactive protein Homo sapiens 0-3 6792286-5 1981 Three bimolecular binding systems were studied: bovine serum albumin (BSA)-anti-BSA, ganglioside GM1-cholera toxin, and C-polysaccharide-C-reactive protein. c-polysaccharide 120-136 C-reactive protein Homo sapiens 137-155 762075-3 1979 The NH2-terminal residue of CRP is pyrrolidonecarboxylic acid and the COOH terminus is proline. Pyrrolidonecarboxylic Acid 35-61 C-reactive protein Homo sapiens 28-31 762075-6 1979 This value agrees well with the molecular weight of 21,500 established by gel filtration of CRP in 5.0 M guanidine Cl (Gotschlich, E.C., and Edelman, G.M. guanidine cl 105-117 C-reactive protein Homo sapiens 92-95 762075-26 1979 U.S.A. 74, 739--743) on the basis of sequence data on approximately 20 NH2-terminal residues of rabbit C-reactive protein, of Clt, and a cyanogen bromide fragment of human CRP. Cyanogen Bromide 137-153 C-reactive protein Homo sapiens 172-175 588590-2 1977 The method consists of two chromatographic separations on diethylaminoethyl (DEAE)-cellulose columns and utilized the difference between the binding of C-reactive protein to DEAE in the presence and absence of calcium. 2-diethylaminoethanol 77-81 C-reactive protein Homo sapiens 152-170 14211-6 1977 Since C-reactive protein binds specifically to the phosphorylcholine residue of pneumococcal C-polysaccharide, it is unlikely that pneumococcal cell walls must combine with C-reactive protein in order to activate the alternative pathway. c-polysaccharide 93-109 C-reactive protein Homo sapiens 6-24 265538-1 1977 Partial amino acid sequences of rabbit C-reactive protein, a peptide derived from human C-reactive protein by cyanogen bromide cleavage, and the C1t subcomponent of the human complement component C1 have been determined. Cyanogen Bromide 110-126 C-reactive protein Homo sapiens 88-106 4472155-5 1974 It was mediated by a heat-stable nondialyzable factor which separated with C-reactive protein (CRP) during fractionation and purification, correlated with serum CRP levels, and, like other known reactivities of CRP, was inhibited by phosphoryl choline. Choline 244-251 C-reactive protein Homo sapiens 75-93 4472155-5 1974 It was mediated by a heat-stable nondialyzable factor which separated with C-reactive protein (CRP) during fractionation and purification, correlated with serum CRP levels, and, like other known reactivities of CRP, was inhibited by phosphoryl choline. Choline 244-251 C-reactive protein Homo sapiens 95-98 4472155-5 1974 It was mediated by a heat-stable nondialyzable factor which separated with C-reactive protein (CRP) during fractionation and purification, correlated with serum CRP levels, and, like other known reactivities of CRP, was inhibited by phosphoryl choline. Choline 244-251 C-reactive protein Homo sapiens 161-164 4472155-5 1974 It was mediated by a heat-stable nondialyzable factor which separated with C-reactive protein (CRP) during fractionation and purification, correlated with serum CRP levels, and, like other known reactivities of CRP, was inhibited by phosphoryl choline. Choline 244-251 C-reactive protein Homo sapiens 161-164 5960999-0 1966 [Value of the method of passive hemagglutination with polysaccharide C in detecting C-reactive protein as compared to precipitation in capillaries and slide latex test with anti-CRP serum]. polysaccharide c 54-70 C-reactive protein Homo sapiens 84-102 34030393-11 2021 We further found that increased CRP significantly (P < 0.05) mediated 6.34-11.1% of the urinary acrylamide metabolites-associated lung function reductions. Acrylamide 96-106 C-reactive protein Homo sapiens 32-35 34030097-2 2021 Inspired by this, poly (diallyldimethylammonium chloride)-capped curcumin nanoparticles (PDDA@CUR NPs) with high loading capacity were synthesized as signal labels and further applied to dual-model colorimetric and fluorescence ELISA for the detection of C-reactive protein (CRP). poly-N,N-dimethyl-N,N-diallylammonium chloride 18-57 C-reactive protein Homo sapiens 255-273 34030097-2 2021 Inspired by this, poly (diallyldimethylammonium chloride)-capped curcumin nanoparticles (PDDA@CUR NPs) with high loading capacity were synthesized as signal labels and further applied to dual-model colorimetric and fluorescence ELISA for the detection of C-reactive protein (CRP). poly-N,N-dimethyl-N,N-diallylammonium chloride 18-57 C-reactive protein Homo sapiens 275-278 33903806-8 2021 In the case of serum, l-phenylalanine and p-hydroxyphenylacetic acid levels were positively correlated with CRP levels in both groups (all P < 0.05). Phenylalanine 22-37 C-reactive protein Homo sapiens 108-111 33876875-5 2021 L-citrulline supplementation decreased serum levels of insulin (p = .025), glucose (p = .032), HbA1c (p = .001), HOMA-IR (p = .037), TNF-alpha (p = .036), and hs-CRP (p = .027) significantly. Citrulline 0-12 C-reactive protein Homo sapiens 162-165 33987044-11 2021 He was started on azathioprine and prednisone and showed a positive response, indicated by a decreasing erythrocyte sedimentation rate and C-reactive protein. Prednisone 35-45 C-reactive protein Homo sapiens 139-157 32660331-7 2021 PCB exposure also associated with proportions of CD4T, NK, and granulocyte cell types, and with the neutrophil to lymphocyte ratio (NLR) (p < 0.05), and the estimated effect sizes of PCB on the epigenome were correlated with the effect sizes previously reported in an epigenome-wide study of C-reactive protein (r = 0.29; p = 2.22e-5), supporting previous studies on the association between PCB and immune dysfunction. Polychlorinated Biphenyls 0-3 C-reactive protein Homo sapiens 292-310 33387888-12 2021 The colchicine group was found to have a statistically significant lowering of CIMT and CRP compared to the non-colchicine group. Colchicine 4-14 C-reactive protein Homo sapiens 88-91 33734043-13 2021 In patients with COVID-19 treated with colchicine, the CRP levels decreased rapidly and normalized (from 99.4 to 4.2 mg/dL, p<0.001). Colchicine 39-49 C-reactive protein Homo sapiens 55-58 33734043-15 2021 The most informative criterion for inflammation lymphocyte-to-C-reactive protein ratio (LCR) increased in the colchicine group by 393 versus 54 in the control group (p = 0.003). Colchicine 110-120 C-reactive protein Homo sapiens 62-80 33596883-0 2021 The effect of L-Carnitine supplementation on clinical symptoms, C-reactive protein and malondialdehyde in obese women with knee osteoarthritis: a double blind randomized controlled trial. Carnitine 14-25 C-reactive protein Homo sapiens 64-82 33628506-14 2021 The administration of azithromycin to the Control group increased CRP and IL-6 levels, while reduced IL-10 and TNF-alpha on day 7 (p < 0.0001) compared with day 1. Azithromycin 22-34 C-reactive protein Homo sapiens 66-69 33557064-8 2021 The spearman"s correlation coefficients between BDG and ESR, and between BDG and CRP in patients without relapse or disseminated disease were 0.65 and 0.60, respectively. O(6)-n-butyldeoxyguanosine 73-76 C-reactive protein Homo sapiens 81-84 33708979-9 2021 Furthermore, the LPG-DT group has less blood loss, shorter flatus time, and lower postoperative-day-5 white blood cell (WBC) count and C-reactive protein (CRP) levels (P<0.05). lpg-dt 17-23 C-reactive protein Homo sapiens 135-153 33708979-9 2021 Furthermore, the LPG-DT group has less blood loss, shorter flatus time, and lower postoperative-day-5 white blood cell (WBC) count and C-reactive protein (CRP) levels (P<0.05). lpg-dt 17-23 C-reactive protein Homo sapiens 155-158 31787129-7 2021 Higher maternal choline levels partly mitigated the effect of CRP in male offspring. Choline 16-23 C-reactive protein Homo sapiens 62-65 32475360-7 2021 In conclusion, vitamin D3 intervention with a treatment dose of 50,000 IU per week for at least 2 months may help in lowering homocysteine and CRP levels and may improve liver function tests, which in turn might help in minimizing the risk of CVD and liver diseases among overweight women but negatively affect kidney function. Cholecalciferol 15-25 C-reactive protein Homo sapiens 143-146 33498799-4 2021 Logistic regression analysis was conducted to investigate the association between the omega3FA ratio and subclinical inflammation defined as CRP levels >=3 mg/dL. omega3fa 86-94 C-reactive protein Homo sapiens 141-144 33313124-15 2020 Conclusions: Elevated hs-CRP levels were associated with poor clinical outcomes in AIS patients receiving EVT. EVT 106-109 C-reactive protein Homo sapiens 25-28 33161498-6 2020 Colchicine resistance was defined as ongoing disease activity (>= 1 attack/month over 3 months or persistently elevated CRP) while taking the maximum tolerated dose of colchicine. Colchicine 0-10 C-reactive protein Homo sapiens 120-123 33133323-10 2020 Patients in the colchicine group also showed a more significant decrease in inflammatory markers for D-dimer (P = 0.037), CRP (P = 0.014), and ferritin (P = 0.012). Colchicine 16-26 C-reactive protein Homo sapiens 122-125 32758621-10 2020 Moreover, choline markedly enhanced the concentrations of inflammatory factors including LPS, CRP, IL-6, TNF-alpha, and CXCL1 in H. pylori-infected mice. Choline 10-17 C-reactive protein Homo sapiens 94-97 32866166-11 2020 CONCLUSION: In patients with chronic coronary artery disease and elevated hs-CRP, one-month exposure to colchicine 0.5 mg once daily was associated with a reduction of inflammatory markers. Colchicine 104-114 C-reactive protein Homo sapiens 77-80 32641296-10 2020 LPV plasma concentrations positively correlated with CRP values (r = 0.37, P < 0.001) and were significantly lower when tocilizumab was preadministered. Lopinavir 0-3 C-reactive protein Homo sapiens 53-56 32641296-14 2020 CRP values significantly correlated with LPV but not HCQ plasma concentrations, implying inhibition of cytochrome P450 3A4 (CYP3A4) metabolism by inflammation. Lopinavir 41-44 C-reactive protein Homo sapiens 0-3 31628482-3 2020 The objectives of this study were to determine whether treatment of patients with RA with lovastatin decreased CRP or reduced disease activity. Lovastatin 90-100 C-reactive protein Homo sapiens 111-114 31628482-4 2020 METHODS: We conducted a randomized double-blind placebo-controlled 12 week trial of lovastatin vs placebo in 64 RA patients with mild clinical disease activity but an elevated CRP. Lovastatin 84-94 C-reactive protein Homo sapiens 176-179 31628482-12 2020 A post hoc analysis of subjects not using biologic therapy demonstrated a significantly greater proportion achieving >=20% reduction in CRP from baseline in the lovastatin group compared with placebo (P-value = 0.007). Lovastatin 161-171 C-reactive protein Homo sapiens 136-139 31628482-16 2020 Lovastatin had a modest effect on CRP in subjects not using biologics, suggesting statins may be anti-inflammatory in selected patients. Lovastatin 0-10 C-reactive protein Homo sapiens 34-37 32278414-2 2020 In this work, we present a simple and fast colorimetric method for CRP detection that employs citrate-capped gold nanoparticles (AuNPs) and a CRP-binding aptamer as sensing elements. Citric Acid 94-101 C-reactive protein Homo sapiens 67-70 31255351-11 2020 Four of the ten were associated [glycine (inversely), caffeine, 1,7-dimethyluric acid, C52:3 triacylglycerol, (positively)], with C-reactive protein levels. Caffeine 54-62 C-reactive protein Homo sapiens 130-148 32154703-4 2020 Anti-CRP functionalized micromotors (anti-CRP-rGO(reduced graphene oxide)/Ni/PtNPs (platinum nanoparticles))-based immunoassay coupled to thin layer Au-based electrochemical microfluidics operating at -0.20 V under controlled fluidic detection operations (30 muL min-1) allowed the sensitive (LOD = 0.54 mug/mL) and accurate CRP determination using very low volume preterm neonatal clinical samples (<10 muL) in just 8 min of total assay time. Gold 149-151 C-reactive protein Homo sapiens 5-8 32248659-5 2021 The primary endpoint, prednisone-free remission, was defined as the absence of relapse through week 52 and normalization of the ESR and CRP. Prednisone 22-32 C-reactive protein Homo sapiens 136-139 32222830-3 2020 Herein, we have developed highly sensitive vertical flow immunokit (VFIK) for the detection of C-reactive protein (CRP), comprising an antibody/citrate conjugated gold nanoparticle in a fixed orientation surface. Citric Acid 144-151 C-reactive protein Homo sapiens 95-113 32222830-3 2020 Herein, we have developed highly sensitive vertical flow immunokit (VFIK) for the detection of C-reactive protein (CRP), comprising an antibody/citrate conjugated gold nanoparticle in a fixed orientation surface. Citric Acid 144-151 C-reactive protein Homo sapiens 115-118 31998900-3 2020 The CRP system was devised by stacking 9 films of the patterned polyimide to integrate micro-flow circuits, combining the functions of the even distribution of feeds, being completely mixed in less than a few milliseconds. polyimide 64-73 C-reactive protein Homo sapiens 4-7 31106659-4 2020 After 8 weeks of intervention, patients who received combined vitamin D3 and omega-3 fatty acids supplements compared with omega-3, vitamin D3, and placebo groups had significantly decreased CRP and TNF-alpha. Cholecalciferol 62-72 C-reactive protein Homo sapiens 191-194 31106659-4 2020 After 8 weeks of intervention, patients who received combined vitamin D3 and omega-3 fatty acids supplements compared with omega-3, vitamin D3, and placebo groups had significantly decreased CRP and TNF-alpha. Cholecalciferol 132-142 C-reactive protein Homo sapiens 191-194 32114587-12 2020 Multivariant analysis showed CRP and Hb levels to be independent prognostic parameters for CSS and OS. thiocysteine 91-94 C-reactive protein Homo sapiens 29-32 31522718-0 2019 Colchicine inhibits endothelial inflammation via NLRP3/CRP pathway. Colchicine 0-10 C-reactive protein Homo sapiens 55-58 31645635-10 2019 Age, body mass index, and C-reactive protein were significantly associated with arterial FDG uptake at both time points. Fluorodeoxyglucose F18 89-92 C-reactive protein Homo sapiens 26-44 31462374-0 2019 An Enzyme-Linked Immunosorbent Assay for C-Reactive Protein Based on Gold Nanoparticles@Metal Porphyrin Porous Compound. metal porphyrin 88-103 C-reactive protein Homo sapiens 41-59 31480610-7 2019 Serologically, there were significantly faster C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) normalization rates in the PEDD group (p < 0.001, p = 0.009, respectively). pedd 140-144 C-reactive protein Homo sapiens 47-65 31480610-7 2019 Serologically, there were significantly faster C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) normalization rates in the PEDD group (p < 0.001, p = 0.009, respectively). pedd 140-144 C-reactive protein Homo sapiens 67-70 30869182-6 2019 Compared with placebo, colchicine significantly reduced C-reactive protein (P <0.005), erythrocyte sedimentation rate (P <0.01), white blood cell count (P <0.005), and absolute neutrophil count (P <0.001). Colchicine 23-33 C-reactive protein Homo sapiens 56-74 31243577-0 2019 Disposable paper-based electrochemical sensor using thiol-terminated poly(2-methacryloyloxyethyl phosphorylcholine) for the label-free detection of C-reactive protein. poly(2-methacryloyloxyethyl-phosphorylcholine) 69-114 C-reactive protein Homo sapiens 148-166 31243577-11 2019 Graphical abstract Schematic presentation of highly sensitive and disposable paper-based electrochemical sensor using thiol-terminated poly(2-methacryloyloxyethyl phosphorylcholine) in the presence of Ca2+ for the label-free C-reactive protein detection. poly(2-methacryloyloxyethyl-phosphorylcholine) 135-180 C-reactive protein Homo sapiens 225-243 31237552-12 2019 The predictive accuracy of CRP for SXscore >0 and high CSS using receiver operator characteristic curves was set at the cut off point of 0.205 mg/dL and 0.145 mg/dL respectively, (sensitivity 70.9% and 98%, specialty 48% and 23.2%). thiocysteine 58-61 C-reactive protein Homo sapiens 27-30 31237552-13 2019 CONCLUSION: Serum CRP is correlated with SXscore and CSS, serum UA is independently associated with CSS. thiocysteine 53-56 C-reactive protein Homo sapiens 18-21 31237552-14 2019 CRP predicts high CSS at a lower level than it predicts SXscore. thiocysteine 18-21 C-reactive protein Homo sapiens 0-3 31237552-15 2019 Thus, serum CRP combined with serum UA may be useful to predict SXscore and CSS. thiocysteine 76-79 C-reactive protein Homo sapiens 12-15 31062578-6 2019 To confirm the binding of CRP onto the Au nanoplate, we assembled Au nanoparticles (NPs) onto the CRP-captured Au nanoplate by sandwich immunoreaction and obtained surface-enhanced Raman scattering (SERS) spectra and scanning electron microscopy (SEM) images. Gold 66-68 C-reactive protein Homo sapiens 26-29 31062578-7 2019 Both the SERS and SEM results showed that we completely eliminated the nonspecific binding of Au NPs onto the optimally anti-CRP-immobilized Au nanoplate. Gold 94-96 C-reactive protein Homo sapiens 125-128 31062578-7 2019 Both the SERS and SEM results showed that we completely eliminated the nonspecific binding of Au NPs onto the optimally anti-CRP-immobilized Au nanoplate. Gold 141-143 C-reactive protein Homo sapiens 125-128 31062578-8 2019 Compared with the anti-CRP-immobilized rough Au film and the randomly anti-CRP-attached Au nanoplate, the optimally anti-CRP-immobilized Au nanoplate provided a highly improved detection limit of 10-17 M. In this study, it was validated that ultraclean and ultraflat Au nanoplates can maximize the sensing capability of CRP. Gold 45-47 C-reactive protein Homo sapiens 23-26 31062578-8 2019 Compared with the anti-CRP-immobilized rough Au film and the randomly anti-CRP-attached Au nanoplate, the optimally anti-CRP-immobilized Au nanoplate provided a highly improved detection limit of 10-17 M. In this study, it was validated that ultraclean and ultraflat Au nanoplates can maximize the sensing capability of CRP. Gold 88-90 C-reactive protein Homo sapiens 75-78 31062578-8 2019 Compared with the anti-CRP-immobilized rough Au film and the randomly anti-CRP-attached Au nanoplate, the optimally anti-CRP-immobilized Au nanoplate provided a highly improved detection limit of 10-17 M. In this study, it was validated that ultraclean and ultraflat Au nanoplates can maximize the sensing capability of CRP. Gold 88-90 C-reactive protein Homo sapiens 75-78 31062578-8 2019 Compared with the anti-CRP-immobilized rough Au film and the randomly anti-CRP-attached Au nanoplate, the optimally anti-CRP-immobilized Au nanoplate provided a highly improved detection limit of 10-17 M. In this study, it was validated that ultraclean and ultraflat Au nanoplates can maximize the sensing capability of CRP. Gold 88-90 C-reactive protein Homo sapiens 75-78 31062578-8 2019 Compared with the anti-CRP-immobilized rough Au film and the randomly anti-CRP-attached Au nanoplate, the optimally anti-CRP-immobilized Au nanoplate provided a highly improved detection limit of 10-17 M. In this study, it was validated that ultraclean and ultraflat Au nanoplates can maximize the sensing capability of CRP. Gold 88-90 C-reactive protein Homo sapiens 75-78 31062578-8 2019 Compared with the anti-CRP-immobilized rough Au film and the randomly anti-CRP-attached Au nanoplate, the optimally anti-CRP-immobilized Au nanoplate provided a highly improved detection limit of 10-17 M. In this study, it was validated that ultraclean and ultraflat Au nanoplates can maximize the sensing capability of CRP. Gold 88-90 C-reactive protein Homo sapiens 75-78 31062578-8 2019 Compared with the anti-CRP-immobilized rough Au film and the randomly anti-CRP-attached Au nanoplate, the optimally anti-CRP-immobilized Au nanoplate provided a highly improved detection limit of 10-17 M. In this study, it was validated that ultraclean and ultraflat Au nanoplates can maximize the sensing capability of CRP. Gold 88-90 C-reactive protein Homo sapiens 75-78 31062578-8 2019 Compared with the anti-CRP-immobilized rough Au film and the randomly anti-CRP-attached Au nanoplate, the optimally anti-CRP-immobilized Au nanoplate provided a highly improved detection limit of 10-17 M. In this study, it was validated that ultraclean and ultraflat Au nanoplates can maximize the sensing capability of CRP. Gold 88-90 C-reactive protein Homo sapiens 75-78 31062578-8 2019 Compared with the anti-CRP-immobilized rough Au film and the randomly anti-CRP-attached Au nanoplate, the optimally anti-CRP-immobilized Au nanoplate provided a highly improved detection limit of 10-17 M. In this study, it was validated that ultraclean and ultraflat Au nanoplates can maximize the sensing capability of CRP. Gold 88-90 C-reactive protein Homo sapiens 75-78 31062578-8 2019 Compared with the anti-CRP-immobilized rough Au film and the randomly anti-CRP-attached Au nanoplate, the optimally anti-CRP-immobilized Au nanoplate provided a highly improved detection limit of 10-17 M. In this study, it was validated that ultraclean and ultraflat Au nanoplates can maximize the sensing capability of CRP. Gold 88-90 C-reactive protein Homo sapiens 75-78 31010106-11 2019 The levels of IL-8, C reactive protein (CRP), and cyclooxygenase (COX)-2 increased only after exposure to I-PM2.5. i-pm2 106-111 C-reactive protein Homo sapiens 20-38 31010106-11 2019 The levels of IL-8, C reactive protein (CRP), and cyclooxygenase (COX)-2 increased only after exposure to I-PM2.5. i-pm2 106-111 C-reactive protein Homo sapiens 40-43 30477283-4 2019 Vitamin D3 was administered in patients with either vitamin D deficiency or insufficiency and CRP serum vitamin D levels and PMS were re-examined at 6 months of administration. Cholecalciferol 0-10 C-reactive protein Homo sapiens 94-97 30682545-3 2019 The aim of this study was to investigate whether the serum concentrations of 25-hydroxyvitamin D (25[OH]D) within the first 48 h after ICU admission are associated with prognostic indicators (Acute Physiology and Chronic Health Evaluation [APACHE] II, Sequential Organ Failure Assessment [SOFA] score, Charlson comorbidity index [CCI]), clinical complications, serum C-reactive protein (CRP) concentrations, mechanical ventilation duration, and mortality. 25[oh]d 98-105 C-reactive protein Homo sapiens 367-385 30682545-3 2019 The aim of this study was to investigate whether the serum concentrations of 25-hydroxyvitamin D (25[OH]D) within the first 48 h after ICU admission are associated with prognostic indicators (Acute Physiology and Chronic Health Evaluation [APACHE] II, Sequential Organ Failure Assessment [SOFA] score, Charlson comorbidity index [CCI]), clinical complications, serum C-reactive protein (CRP) concentrations, mechanical ventilation duration, and mortality. 25[oh]d 98-105 C-reactive protein Homo sapiens 387-390 31086519-0 2019 Effect of sitagliptin and glimepiride on C-reactive protein (CRP) in overweight Type-2 diabetic patients. glimepiride 26-37 C-reactive protein Homo sapiens 61-64 31086519-1 2019 Objectives: To compare the anti-inflammatory effect of sitagliptin and glimepiride by measuring CRP in overweight Type-2 diabetic patients. glimepiride 71-82 C-reactive protein Homo sapiens 96-99 30847301-10 2019 Patients with continuously elevated CRP significantly had poor OS and DMFS (HR:2.610, 95%CI: 1.592-4.279, p < 0.001; HR:2.816, 95%CI: 1.486-5.302, p = 0.001, respectively). dmfs 70-74 C-reactive protein Homo sapiens 36-39 30308801-9 2019 An interquartile range increase in triclosan (55.2 ng/mL) was associated with a 12.5% (95% CI: 3.67, 22.0) increase in C-reactive protein, a 7.95% (95% CI: 1.95, 14.3) increase in interleukin 10, and a 7.93% (95% CI: 3.82, 12,2) increase in tumor necrosis factor-alpha. Triclosan 35-44 C-reactive protein Homo sapiens 119-137 30298971-2 2019 AIM: To determine whether the acute effects of fructose consumption on serum glucose, insulin, lipids and C-reactive protein differs according to body mass index (BMI) and/or ethnicity. Fructose 47-55 C-reactive protein Homo sapiens 106-124 29644527-5 2018 In TNF-alpha-stimulated primary human coronary artery endothelial cells, both CRP and IL-6 productions were reduced by 70% at 2 mM gemcabene concentration. gemcabene 131-140 C-reactive protein Homo sapiens 78-81 29644527-6 2018 To investigate the mechanism of gemcabene-mediated reduction of CRP, transfection studies were performed with human CRP regulatory sequences in luciferase/beta-gal system that showed 25-fold increase in IL-6- and IL-6 plus IL-1beta-stimulated CRP transcription. gemcabene 32-41 C-reactive protein Homo sapiens 64-67 29644527-6 2018 To investigate the mechanism of gemcabene-mediated reduction of CRP, transfection studies were performed with human CRP regulatory sequences in luciferase/beta-gal system that showed 25-fold increase in IL-6- and IL-6 plus IL-1beta-stimulated CRP transcription. gemcabene 32-41 C-reactive protein Homo sapiens 116-119 29644527-6 2018 To investigate the mechanism of gemcabene-mediated reduction of CRP, transfection studies were performed with human CRP regulatory sequences in luciferase/beta-gal system that showed 25-fold increase in IL-6- and IL-6 plus IL-1beta-stimulated CRP transcription. gemcabene 32-41 C-reactive protein Homo sapiens 116-119 29644527-7 2018 Luciferase activity was reduced by 50% by gemcabene, suggesting transcriptional down-regulation of CRP. gemcabene 42-51 C-reactive protein Homo sapiens 99-102 29644527-8 2018 Site-directed mutagenesis of human CRP promoter revealed that the overlapping downstream C/EBP and NF-kappaB binding sites are important for gemcabene-mediated CRP transcription. gemcabene 141-150 C-reactive protein Homo sapiens 35-38 29644527-8 2018 Site-directed mutagenesis of human CRP promoter revealed that the overlapping downstream C/EBP and NF-kappaB binding sites are important for gemcabene-mediated CRP transcription. gemcabene 141-150 C-reactive protein Homo sapiens 160-163 29644527-10 2018 In conclusion, gemcabene decreases CRP by C/EBP-delta and NF-kappaB-mediated transcriptional mechanism and suppresses IL-6 and IL-1beta-induced CRP production. gemcabene 15-24 C-reactive protein Homo sapiens 35-38 29644527-10 2018 In conclusion, gemcabene decreases CRP by C/EBP-delta and NF-kappaB-mediated transcriptional mechanism and suppresses IL-6 and IL-1beta-induced CRP production. gemcabene 15-24 C-reactive protein Homo sapiens 144-147 29802084-11 2018 CONCLUSIONS: D-dimer and CRP at the time of diagnosis are independent and significant predictors of outcome in CTEPH, available at the time of diagnosis. cteph 111-116 C-reactive protein Homo sapiens 25-28 30180620-6 2018 During SP, mean CRP showed high determinism (>=85%) and also brief but repeated events where both variables stay within a reduced space. sp 7-9 C-reactive protein Homo sapiens 16-19 29558723-2 2018 Indium Tin Oxide (ITO) disposable sheets were modified by using 3-cyanopropyltrimethoxysilane (CPTMS) self-assembled monolayers (SAMs) for the first time for immobilizing the anti-CRP antibody via covalent interactions without the need for any cross-linking agent. 3-CYANOPROPYLTRIMETHOXYSILANE 64-93 C-reactive protein Homo sapiens 180-183 28635516-0 2018 Concentration of UHCL1 in the Serum of Children with Acute Appendicitis, Before and After Surgery, and Its Correlation with CRP and Prealbumin. uhcl1 17-22 C-reactive protein Homo sapiens 124-127 29973023-17 2018 Serum procalcitonin and CRP of patients in citrate group after CBP treatment were significantly lower than those in heparin group (t=2.520, 2.710, P<0.05). Citric Acid 43-50 C-reactive protein Homo sapiens 24-27 29973023-18 2018 Decreased degree of serum procalcitonin and CRP of patients in citrate group after CBP treatment were (1.8+-0.6) ng/mL and (143+-69) mg/L, respectively, significantly higher than (0.9+-0.6) ng/mL and (95+-50) mg/L in heparin group (t=-4.033, -2.170, P<0.05 or P<0.01). Citric Acid 63-70 C-reactive protein Homo sapiens 44-47 29234038-0 2017 Sodium tanshinone IIA sulfate adjunct therapy reduces high-sensitivity C-reactive protein level in coronary artery disease patients: a randomized controlled trial. sodium tanshinone iia sulfate 0-29 C-reactive protein Homo sapiens 71-89 28922371-7 2017 High sensitivity C-reactive protein was the most elevated biomarker among current smokers when compared to never smokers [GM ratio = 1.39 (95% CI: 1.23, 1.57); p <0.001]. gm 122-124 C-reactive protein Homo sapiens 17-35 28499734-9 2017 Results of the multivariable analysis, after adjustment for factors such as pT stage, pN stage, tumor grade, presence of lymphovascular invasion, and C-reactive protein level, revealed that CONUT score was an independent predictor of CSS (hazard ratio [HR] = 5.44, P = 0.0016) and OS (HR = 2.90, P = 0.0214) and showed marginal significance for predicting RFS (HR = 2.26, P = 0.0581). thiocysteine 234-237 C-reactive protein Homo sapiens 150-168 28859644-0 2017 Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. Sunitinib 64-73 C-reactive protein Homo sapiens 20-38 28859644-13 2017 CONCLUSION: Baseline CRP was a significant predictive factor of sunitinib response and a prognostic factor of survival. Sunitinib 64-73 C-reactive protein Homo sapiens 21-24 28789684-0 2017 Blood lead, cadmium and mercury in relation to homocysteine and C-reactive protein in women of reproductive age: a panel study. Mercury 24-31 C-reactive protein Homo sapiens 64-82 28789684-1 2017 BACKGROUND: To examine the relationship between cadmium, lead, and mercury concentrations with high-sensitivity C-reactive protein (hs-CRP) and homocysteine in women. Mercury 67-74 C-reactive protein Homo sapiens 112-130 28529744-2 2017 The aim of the present study was to investigate the prognostic effect of pretreatment serum CRP level and CRP kinetics on patients with advanced RCC treated with sunitinib. Sunitinib 162-171 C-reactive protein Homo sapiens 106-109 28529744-9 2017 Therefore, CRP kinetics and normal pretreatment CRP level are prognostic indicators in patients with advanced RCC treated with sunitinib. Sunitinib 127-136 C-reactive protein Homo sapiens 11-14 28529744-9 2017 Therefore, CRP kinetics and normal pretreatment CRP level are prognostic indicators in patients with advanced RCC treated with sunitinib. Sunitinib 127-136 C-reactive protein Homo sapiens 48-51 28624829-5 2017 RESULTS: Besides the already established scoring systems like the MSKCC criteria, an elevated preoperative CRP level (>=0.5 mg/dL) was an independent predictor of CSS in our study group including the chosen postoperative adjuvant therapies (TKI vs. immunotherapy vs. others). thiocysteine 166-169 C-reactive protein Homo sapiens 107-110 27143795-4 2016 Abnormal CRP level was defined as >3mg/L. Aminoglutethimide 31-37 C-reactive protein Homo sapiens 9-12 27825282-0 2016 Relationship between maternal c-reactive protein level and neonatal outcome in patients with preterm premature rupture of membranes treated with Ampicillin and Azithromycin. Azithromycin 160-172 C-reactive protein Homo sapiens 30-48 26040439-5 2016 In addition, PCT and CRP levels were significantly higher in the WCH group than in the NT group. nt 87-89 C-reactive protein Homo sapiens 21-24 26152555-8 2016 The median C-reactive protein level of the ES group (99.0 mg/L; n = 13) was significantly higher than that of the non-ES group (13.9 mg/L; n = 38; P < 0.001). Einsteinium 43-45 C-reactive protein Homo sapiens 11-29 26783345-10 2016 RESULTS: Lower median CRP was significantly associated with MH 1.2mg/dl vs no MH 14.4mg/dl (p = 6.93x10(-6)). mh 60-62 C-reactive protein Homo sapiens 22-25 26783345-10 2016 RESULTS: Lower median CRP was significantly associated with MH 1.2mg/dl vs no MH 14.4mg/dl (p = 6.93x10(-6)). mh 78-80 C-reactive protein Homo sapiens 22-25 26883707-10 2016 Covariates such as age and interacting comedication ([es]omeprazole), also showed a significant correlation between VCZ and CRP concentrations (P < 0.05). Einsteinium 53-56 C-reactive protein Homo sapiens 124-127 26660887-2 2016 Poly(2-methacryloyloxyethyl-phosphorylcholine) was used as a CRP-specific polymer ligand layer and was grafted onto the plasmonic chip using surface-initiated controlled/living radical polymerization (limit of detection: ca. poly(2-methacryloyloxyethyl-phosphorylcholine) 0-46 C-reactive protein Homo sapiens 61-64 26844422-2 2016 The aptamers were then used for the construction of an Au nanoparticle enhanced surface plasmon resonance biosensor, which was introduced for the detection of CRP at concentrations ranging from 10 pM to 100 nM in diluted human serum. Gold 55-57 C-reactive protein Homo sapiens 159-162 26391378-8 2015 Multivariate analysis showed that three independent factors (age, initial values of CRP and use of fosfomycin) were significantly associated with the occurrence of HUS; of particular note, the adjusted odds ratio for use of fosfomycin was 0.15 (95% confidence interval 0.05-0.45). Fosfomycin 224-234 C-reactive protein Homo sapiens 84-87 26265215-5 2015 In the current pilot study we examined (i) CRP levels in human serum obtained from AD and age-matched control patients; and (ii) analyzed the effects of nanomolar aluminum sulfate on CRP expression in primary hBMECs. aluminum sulfate 163-179 C-reactive protein Homo sapiens 183-186 32256673-9 2020 The favorable associations between serum choline and LCSS and OS were only existed among patients with CRP >=3.0 mg/L. Choline 41-48 C-reactive protein Homo sapiens 103-106 32230908-3 2020 The microfluidic self-driving optical sensors were fabricated with transparent glass material and used for the enhanced surface plasmon resonance (SPR) optical detection of the model protein CRP using Au nanoparticles (AuNPs) and a sandwich immune reaction. Gold 201-203 C-reactive protein Homo sapiens 191-194 32182693-6 2020 An increased CRP level was significantly associated with shorter CSS (p < 0.001, log-rank test), as well as with shorter OS (p < 0.001, log-rank test) and loco-regional control (p = 0.001, log-rank test). thiocysteine 65-68 C-reactive protein Homo sapiens 13-16 32182693-7 2020 In addition, multivariate analysis identified CRP as an independent predictor for CSS (hazard ratio (HR) 1.59, 95% confidence interval (CI) 1.08-2.35; p = 0.020) as well as for OS (HR 1.62, 95%CI 1.17-2.24; p = 0.004) and LC (HR 1.50, 95%CI 1.06-2.14; p = 0.023). thiocysteine 82-85 C-reactive protein Homo sapiens 46-49 32182693-8 2020 In subgroup analysis, Kaplan Meier curves revealed that an elevated pre-treatment CRP level was a consistent prognostic factor for poor CSS (p = 0.003, log-rank test), OS (p = 0.001, log-rank test), and LC (p = 0.028, log-rank test) in patients treated with definitive (chemo-) radiotherapy, whereas a significant association in patients undergoing surgery and postoperative radiotherapy was not detected. thiocysteine 136-139 C-reactive protein Homo sapiens 82-85 32182693-9 2020 The pre-treatment CRP level seems to represent a prognostic factor for CSS, OS, and LC in patients with oral and oropharyngeal cancer, particularly in those treated with definitive (chemo-) radiotherapy. thiocysteine 71-74 C-reactive protein Homo sapiens 18-21 32104712-16 2020 Compared with control, additional diacerein also lowered body weight and CRP level in T2DM, but increased the rate of gastrointestinal syndromes. diacerein 34-43 C-reactive protein Homo sapiens 73-76 30934169-6 2020 The teicoplanin concentration producing 50% of the maximum inhibition of CRP production was estimated to be 2.66 mg/L. Teicoplanin 4-15 C-reactive protein Homo sapiens 73-76 30934169-9 2020 The population PKPD model of teicoplanin and CRP in this study should provide useful information for development of a dosing strategy including the sequential clinical benefit of teicoplanin. Teicoplanin 179-190 C-reactive protein Homo sapiens 45-48 32156842-11 2020 CONCLUSION: The current study indicates that nano-curcumin may show beneficial effects in lowering inflammation and hs-CRP levels, as well as adhesion molecules (ICAM-1, VCAM-1), in hemodialysis patients. nano-curcumin 45-58 C-reactive protein Homo sapiens 119-122 32208889-7 2020 WBC level on POD 1 was significantly higher in the PMDI group (p < 0.05), whereas the CRP levels on POD 1 (p < 0.01), 3 (p < 0.01), and 5 (p < 0.01) were significantly lower in the PMDI group than in the epidural catheter group. 4,4'-Diphenylmethane diisocyanate 181-185 C-reactive protein Homo sapiens 86-89 30913567-0 2020 Pathological Concentration of C-reactive Protein is Correlated to Increased Concentrations of Quetiapine, But Not of Risperidone, Olanzapine and Aripiprazole in a Naturalistic Setting. Risperidone 117-128 C-reactive protein Homo sapiens 30-48 31288869-6 2019 After adjustments, we found that individuals consuming more choline had worse lipid profile and glucose homeostasis, but lower CRP levels (p &lt; 0 001 for all comparisons) with no significant differences in anthropometric parameters and blood pressure. Choline 60-67 C-reactive protein Homo sapiens 127-130 32802107-8 2019 Administration of calcitriol in patients with non-ST-segment elevation acute coronary syndromes undergoing elective PCI can attenuate the increase in serum inflammatory biomarkers in the serum (hs-CRP and hs-IL-6) and thus decrease the inflammatory reaction caused by PCI. Calcitriol 18-28 C-reactive protein Homo sapiens 197-200 30661255-12 2019 At week 12, cilofexor-treated patients with a 25% or more relative reduction in ALP had greater reductions in serum alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, tissue inhibitor of metalloproteinase 1, C-reactive protein, and bile acids than nonresponders. Cilofexor 12-21 C-reactive protein Homo sapiens 239-257 31474035-16 2019 At PTH 24, the serum procalcitonin and C-reactive protein of patients in citric acid group were significantly lower than those in heparin group (t=2.635, 2.297, P<0.05). Citric Acid 73-84 C-reactive protein Homo sapiens 39-57 31428091-1 2019 The functions of pentraxins, like C-reactive protein (CRP), serum amyloid protein P (SAP) and pentraxin-3 (PTX3), are to coordinate spatially and temporally targeted clearance of injured tissue components, to protect against infections and to regulate related inflammation together with the complement system. pentraxins 17-27 C-reactive protein Homo sapiens 34-52 31428091-1 2019 The functions of pentraxins, like C-reactive protein (CRP), serum amyloid protein P (SAP) and pentraxin-3 (PTX3), are to coordinate spatially and temporally targeted clearance of injured tissue components, to protect against infections and to regulate related inflammation together with the complement system. pentraxins 17-27 C-reactive protein Homo sapiens 54-57 30915521-2 2019 Our aim in this meta-analysis was to determine the effect of L-carnitine on inflammatory mediators including C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6). Carnitine 61-72 C-reactive protein Homo sapiens 109-127 30915521-10 2019 The results of the meta-analysis indicated that L-carnitine supplementation was significantly associated with lower levels of CRP in comparison to controls (WMD = -1.23 mg/L; 95% CI: -1.73, -0.72 mg/dL; P < 0.0001). Carnitine 48-59 C-reactive protein Homo sapiens 126-129 31314839-4 2019 RESULTS: The plasma Cys-C, D-D and hs-CRP levels in the IPHI group were significantly higher than those in the control group (p < 0.01). iphi 56-60 C-reactive protein Homo sapiens 38-41 31314839-6 2019 In the IPHI patients, the plasma Cys-C, D-D and hs-CRP levels were positively correlated with each other (p < 0.001). iphi 7-11 C-reactive protein Homo sapiens 51-54 30893266-5 2019 RESULTS: We reported that the CRP resurge rate in the DHT group (0%) was significantly (p = 0.029) lower than that in the DHT group (16.1%) one day before the revision. Dihydrotestosterone 54-57 C-reactive protein Homo sapiens 30-33 30893266-7 2019 CONCLUSION: We found that disciplined use of DHT as a reimplantation criterion reduced CRP resurges before reimplantation and yielded a shorter LOS afterward. Dihydrotestosterone 45-48 C-reactive protein Homo sapiens 87-90 30460516-9 2019 Additionally, olanzapine administration was found to induce both metabolic alterations (adiposity, lipogenesis, plasma free fatty acid, and acetate levels increase) (experiments = 3) and inflammation (experiments = 2) in rodents, whereas risperidone suppressed the resting metabolic rate in rodents (experiments = 5) and elevated fasting blood glucose, triglycerides, LDL, hs-CRP, antioxidant superoxide dismutase, and HOMA-IR in humans (experiment = 1). Risperidone 238-249 C-reactive protein Homo sapiens 376-379 30690246-6 2019 Trans octadecenoic acid, and to a lesser extent palmitooleic and nervonic fatty acids were found in inverse correlation with the CRP increase. trans octadecenoic acid 0-23 C-reactive protein Homo sapiens 129-132 3480076-0 1987 Measurement of C-reactive protein to compare ceftizoxime versus cefoxitin/doxycycline therapy for septic pelvis: a preliminary report. Doxycycline 74-85 C-reactive protein Homo sapiens 15-33 30690246-6 2019 Trans octadecenoic acid, and to a lesser extent palmitooleic and nervonic fatty acids were found in inverse correlation with the CRP increase. palmitooleic and 48-64 C-reactive protein Homo sapiens 129-132 3480076-2 1987 In a study comparing ceftizoxime and cefoxitin/doxycycline in patients with septic pelvis, quantitative CRP levels were closely correlated with the responses and failures of therapy. Doxycycline 47-58 C-reactive protein Homo sapiens 104-107 885587-0 1977 Isolation of a peptido-polysaccharide from the dermatophyte Epidermophyton floccosum and a study of its reaction with human C-reactive protein and a mouse anti-phosphorylcholine myeloma serum. peptido-polysaccharide 15-37 C-reactive protein Homo sapiens 124-142 30838448-7 2019 The serum concentration of high sensitivity C-reactive protein and neutrophil-lymphocyte ratio were significantly decreased at 12 h, 24 h, and 48 h postoperatively in the RIPC group compared to those in the control group (P < 0.05). ripc 171-175 C-reactive protein Homo sapiens 44-62 885587-2 1977 Using immobilized Con A, a peptidopolysaccharide (PPS) has been isolated from Epidermophyton floccosum culture filtrate by affinity chromatography and shown to precipitate with Con A, human CRP sera and a mouse myeloma serum with specificity for phosphorylcholine (PC). peptidopolysaccharide 27-48 C-reactive protein Homo sapiens 190-193 32921322-0 2021 The Effect of Grape Products Containing Polyphenols on C-reactive protein Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Polyphenols 40-51 C-reactive protein Homo sapiens 55-73 31037275-7 2019 Results: TCJ significantly reduced sUA concentration by 19.2% (P < 0.05) and reduced by 19.4% (P = 0.09) and 6.3% (P = 0.08) proinflammatory high-sensitivity C-reactive protein and monocyte chemoattractant protein-1, respectively. tcj 9-12 C-reactive protein Homo sapiens 161-179 32921322-1 2021 Although grape polyphenols can decrease chronic inflammations, their effect on C-reactive protein (CRP) levels is still controversial. Polyphenols 15-26 C-reactive protein Homo sapiens 79-97 25982678-0 2015 The impact of thiamine supplementation on blood pressure, serum lipids and C-reactive protein in individuals with hyperglycemia: a randomised, double-blind cross-over trial. Thiamine 14-22 C-reactive protein Homo sapiens 75-93 32921322-1 2021 Although grape polyphenols can decrease chronic inflammations, their effect on C-reactive protein (CRP) levels is still controversial. Polyphenols 15-26 C-reactive protein Homo sapiens 99-102 30543573-9 2019 CONCLUSION: IBD patients on maintenance treatment with IFX show decreasing patterns of IFX-TLs over time associated with increasing patterns of CRP levels. Ifosfamide 55-58 C-reactive protein Homo sapiens 144-147 30680541-1 2019 A portion of this article was previously published as part of an article titled "Human C-reactive protein and the metabolic syndrome" in the following journal: Curr Opin Lipidol. curr 160-164 C-reactive protein Homo sapiens 87-105 32921322-2 2021 So, this meta-analysis was conducted to investigate the effect of grape products containing polyphenols on CRP concentrations. Polyphenols 92-103 C-reactive protein Homo sapiens 107-110 30662999-1 2019 A portion of this article was previously published as part of an article titled "Human C-reactive protein and the metabolic syndrome" in the following journal: Curr Opin Lipidol. curr 160-164 C-reactive protein Homo sapiens 87-105 30622255-5 2019 Glycan array data show that the neutral glycans are preferentially recognised by IgM in dog sera or by mannose binding lectin when antennal fucose and phosphorylcholine residues are removed; this pattern of reactivity is reversed for mammalian C-reactive protein, which can in turn be bound by the complement component C1q. Polysaccharides 0-6 C-reactive protein Homo sapiens 244-262 30622255-5 2019 Glycan array data show that the neutral glycans are preferentially recognised by IgM in dog sera or by mannose binding lectin when antennal fucose and phosphorylcholine residues are removed; this pattern of reactivity is reversed for mammalian C-reactive protein, which can in turn be bound by the complement component C1q. Polysaccharides 40-47 C-reactive protein Homo sapiens 244-262 26258408-8 2015 In MI patients, we found strong positive correlation between lipid metabolites related to the sphingolipid pathway, sphingomyelin, and ceramide and acute inflammatory markers (high-sensitivity C-reactive protein). Sphingolipids 94-106 C-reactive protein Homo sapiens 193-211 26235332-7 2015 Combined results of meta-analyses indicated that CRP was a prognostic factor in urological cancers (CSS: p < 0.01; OS: p < 0.01). thiocysteine 100-103 C-reactive protein Homo sapiens 49-52 26235332-9 2015 Specifically, prognostic impact of CRP was also noted in patients with localized RCC treated with nephrectomy (CSS: p < 0.01) and metastatic RCC treated with molecular-targeted therapy (OS: p < 0.01). thiocysteine 111-114 C-reactive protein Homo sapiens 35-38 32921322-7 2021 Based on the results, grape products containing polyphenol decreased the CRP levels significantly (SMD = -0.229; 95% CI: -0.41, -0.05; P = 0.013). Polyphenols 48-58 C-reactive protein Homo sapiens 73-76 32921322-9 2021 According to the subgroup analysis, higher doses of grape polyphenols ( 500 mg/d) and longer intervention periods (>= 12 wk) had significant effects on CRP levels. Polyphenols 58-69 C-reactive protein Homo sapiens 153-156 32921322-10 2021 Furthermore, grape polyphenols significantly reduced the CRP levels in patients with a clinical condition. Polyphenols 19-30 C-reactive protein Homo sapiens 57-60 29570259-11 2019 CONCLUSION: Our study suggests that dynamic changes in CRP can better predict survival in patients with mRCC who are treated with sunitinib. Sunitinib 130-139 C-reactive protein Homo sapiens 55-58 32921322-12 2021 According to the meta-regression results, the CRP level depends on the dose and duration of the grape polyphenols supplementation. Polyphenols 102-113 C-reactive protein Homo sapiens 46-49 26113681-7 2015 C-reactive protein (CRP), interleukin-10, monocyte chemotactic protein-1, macrophage inflammatory protein-1alpha and matrix metalloproteinase (MMP)-9 were significantly elevated in CTEPH patients. cteph 181-186 C-reactive protein Homo sapiens 0-18 32921322-13 2021 Based on the findings, grape products containing polyphenols had a significant effect on CRP levels. Polyphenols 49-60 C-reactive protein Homo sapiens 89-92 26113681-7 2015 C-reactive protein (CRP), interleukin-10, monocyte chemotactic protein-1, macrophage inflammatory protein-1alpha and matrix metalloproteinase (MMP)-9 were significantly elevated in CTEPH patients. cteph 181-186 C-reactive protein Homo sapiens 20-23 34027995-11 2021 CRP and IL-6 mediated the association between EAA and fatigue (CRP: 95% CI, 0.060-0.279; IL-6: 95% CI, 0.024-0.220). ethyl acetoacetate 46-49 C-reactive protein Homo sapiens 0-3 26113681-8 2015 Plasma CRP and MMP-9 levels correlated with neutrophil and macrophage accumulation, respectively.Enhanced systemic inflammation parallels local inflammatory cell infiltration in major pulmonary arteries at advanced stages of CTEPH. cteph 225-230 C-reactive protein Homo sapiens 7-10 26147588-4 2015 We studied the association between serum 25-hydroxyvitamin D and C-reactive protein through linear regression in 9,649 participants of the Rotterdam Study, an observational, prospective population-based cohort study. 25-hydroxyvitamin 41-58 C-reactive protein Homo sapiens 65-83 31168199-1 2018 - The aim was to examine whether the postprocedural change in C-reactive protein (CRP) and fibrinogen levels was associated with the extent of periprocedural arterial injury caused by endovascular treatment (EVT). EVT 208-211 C-reactive protein Homo sapiens 82-85 31168199-6 2018 There was significant increase in plasma CRP and fibrinogen levels 48 hours following EVT (p<0.001). EVT 86-89 C-reactive protein Homo sapiens 41-44 31168199-9 2018 Significant positive correlation was found between PTA treated segment length and CRP increase between 8 and 24 hours following EVT (r=0.313, p=0.02), balloon inflation time and CRP increase in the aforementioned time frame (r=0.270, p=0.03), as well as between CRP increase at 8 hours and stented segment length (r=0.535, p=0.01). EVT 128-131 C-reactive protein Homo sapiens 82-85 29644527-0 2018 Gemcabene, a first-in-class lipid-lowering agent in late-stage development, down-regulates acute-phase C-reactive protein via C/EBP-delta-mediated transcriptional mechanism. gemcabene 0-9 C-reactive protein Homo sapiens 103-121 29644527-2 2018 As a monotherapy and in combination with statins, gemcabene markedly reduced CRP in humans. gemcabene 50-59 C-reactive protein Homo sapiens 77-80 34027995-11 2021 CRP and IL-6 mediated the association between EAA and fatigue (CRP: 95% CI, 0.060-0.279; IL-6: 95% CI, 0.024-0.220). ethyl acetoacetate 46-49 C-reactive protein Homo sapiens 63-66 29644527-4 2018 In human hepatoma cells, gemcabene inhibited IL-6 plus IL-1beta-induced CRP production in a concentration-dependent manner, reaching 70% inhibition at 2 mM. gemcabene 25-34 C-reactive protein Homo sapiens 72-75 34055936-12 2021 Among patients with cardiac injury, patients with positive late gadolinium enhancement presented higher cardiac biomarker (high-sensitivity troponin I) and inflammatory factor (high-sensitivity C-reactive protein) on admission than the late gadolinium enhancement-negative subgroup. Gadolinium 64-74 C-reactive protein Homo sapiens 194-212 30522429-18 2018 Treatment of piperacillin/tazobactam and teicoplanin was started by discontinuing the current antibiotherapy of the patient who had no clinical response and elevated CRP level, 18 mg/dl. Teicoplanin 41-52 C-reactive protein Homo sapiens 166-169 30040854-10 2018 The levels of these two glycan features were correlated to C-reactive protein concentration, an inflammation marker and known prognostic indicator for bladder cancer, further strengthening the link between inflammation and abnormal plasma protein glycosylation. Polysaccharides 24-30 C-reactive protein Homo sapiens 59-77 25446285-5 2015 All studies in this field, except one, showed that L-carnitine could significantly reduce C-reactive protein and serum amyloid A, as two systemic inflammation markers, in HD patients. Carnitine 51-62 C-reactive protein Homo sapiens 90-108 25738560-1 2015 OBJECTIVES: The objective of this study was to determine the predictive value of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) to a positive fluorine-18 fluorodeoxyglucose ((18)F-FDG) PET/computed tomography (CT) result in patients with inflammation of unknown origin and fever of unknown origin. Fluorodeoxyglucose F18 161-191 C-reactive protein Homo sapiens 81-99 33601275-6 2021 Singlet oxygen (1O2)-mediated oxidation of multiple proteins (alpha-lactalbumin, lysozyme, beta-2-microglobulin, C-reactive protein), and subsequent incubation with the Cys-containing protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH), generates inter-protein cross-links as detected by SDS-PAGE, immunoblotting and mass spectrometry (MS). CHEBI:63768 16-19 C-reactive protein Homo sapiens 113-131 25738560-1 2015 OBJECTIVES: The objective of this study was to determine the predictive value of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) to a positive fluorine-18 fluorodeoxyglucose ((18)F-FDG) PET/computed tomography (CT) result in patients with inflammation of unknown origin and fever of unknown origin. Fluorodeoxyglucose F18 161-191 C-reactive protein Homo sapiens 101-104 29306913-7 2018 To differentiate APA from HS, single variable of acetate, formate, white blood cell (WBC) and C-reactive protein (CRP) showed a high diagnostic value (area under the receiver operating characteristic [AUROC]<0.92), while they had a weak diagnostic value (AUROC<0.77) for identifying the APA and NAI. apa 17-20 C-reactive protein Homo sapiens 94-112 29306913-7 2018 To differentiate APA from HS, single variable of acetate, formate, white blood cell (WBC) and C-reactive protein (CRP) showed a high diagnostic value (area under the receiver operating characteristic [AUROC]<0.92), while they had a weak diagnostic value (AUROC<0.77) for identifying the APA and NAI. apa 17-20 C-reactive protein Homo sapiens 114-117 29776344-10 2018 CONCLUSIONS: This study demonstrated that total circumferential lesion and CRP >=1.00 mg/dL are risk factors for esophageal fistula in T4b thoracic ESCC treated with dCRT. dcrt 169-173 C-reactive protein Homo sapiens 75-78 28529744-0 2017 Prognostic effect of serum C-reactive protein kinetics on advanced renal cell carcinoma treated with sunitinib. Sunitinib 101-110 C-reactive protein Homo sapiens 27-45 28529744-2 2017 The aim of the present study was to investigate the prognostic effect of pretreatment serum CRP level and CRP kinetics on patients with advanced RCC treated with sunitinib. Sunitinib 162-171 C-reactive protein Homo sapiens 92-95 27328763-5 2017 Colchicine resistance was defined as at least two attacks/month together with C-reactive protein and serum amyloid A levels above the normal range between attacks. Colchicine 0-10 C-reactive protein Homo sapiens 78-96 24595862-5 2015 RESULTS: Plasma concentrations of choline, but not betaine, were lower in smokers, and choline was positively associated with C-reactive protein and troponin T in nonsmokers, but not in smokers (p for interaction <0.03). Choline 87-94 C-reactive protein Homo sapiens 126-144 25389233-14 2015 Two putative mechanisms may contribute to the increased exposure of these glycans: (1) the canonical N-glycosylation site of the IgG-CH2 domain; (2) an IgG binding non-IgG molecule, like complement or C-reactive protein. Polysaccharides 74-81 C-reactive protein Homo sapiens 201-219 25618827-8 2015 An elevated CRP level was associated with decreased CSS in univariate (hazard ratio (HR) 3.36, 95% confidence interval (CI) 1.42-7.91; p=0.006) and multivariate analysis (HR 4.31, 95% CI 1.22-15.1; p=0.023). thiocysteine 52-55 C-reactive protein Homo sapiens 12-15 33895524-6 2021 Mean number of neutrophils, and mean serum CRP and D-dimer levels were higher in Etoricoxib-treated group (P < 0.05). Etoricoxib 81-91 C-reactive protein Homo sapiens 43-46 25618827-11 2015 CONCLUSIONS: In the present study, an elevated plasma CRP (>=8.6mgl(-1)) has been identified as a prognostic factor for poor CSS, OS and DFS in prostate cancer patients undergoing radiotherapy. thiocysteine 128-131 C-reactive protein Homo sapiens 54-57 27539098-0 2016 Hepatotoxic effects of fenofibrate in spontaneously hypertensive rats expressing human C-reactive protein. Fenofibrate 23-34 C-reactive protein Homo sapiens 87-105 33745599-12 2021 CONCLUSIONS: The EPA and DHA levels were related to C-reactive protein (CRP) of inflammation maker, but non-significant associated with development allergic diseases. Docosahexaenoic Acids 25-28 C-reactive protein Homo sapiens 52-70 27510844-7 2016 Serum C-reactive protein levels were significantly lower in the SLDG group than in the MLDG group on postoperative days 1, 3, and 7, and the 5-year overall survival rate was not significantly different between the two groups (93.7 vs. 87.6 %; p = 0.689). sldg 64-68 C-reactive protein Homo sapiens 6-24 26320436-8 2015 Six month disease control rate (complete response, partial response and stable disease) in response to sunitinib was significantly higher in patients with normal (<=0.5 mg/dl) than elevated baseline CRP (p<0.001). Sunitinib 103-112 C-reactive protein Homo sapiens 202-205 33745599-12 2021 CONCLUSIONS: The EPA and DHA levels were related to C-reactive protein (CRP) of inflammation maker, but non-significant associated with development allergic diseases. Docosahexaenoic Acids 25-28 C-reactive protein Homo sapiens 72-75 26320436-9 2015 CONCLUSIONS: CRP is a significant independent predictor of PFS for Japanese patients with mCCRCC treated with first-line sunitinib. Sunitinib 121-130 C-reactive protein Homo sapiens 13-16 33646351-8 2021 The HMEP group showed a higher C-reactive protein level (P = 0.001), erythrocyte sedimentation rate (P = 0.013), and blood platelet count (P = 0.005). hmep 4-8 C-reactive protein Homo sapiens 31-49 26320436-10 2015 Pretreatment CRP concentration may be a useful biomarker predicting response to sunitinib treatment. Sunitinib 80-89 C-reactive protein Homo sapiens 13-16 25470633-5 2015 RESULT: Significant difference in CRP was observed between groups A & B (p=0.000) and A & C (p=0.007). a & 66-72 C-reactive protein Homo sapiens 34-37 25237981-14 2016 C-reactive protein in the ibuprofen group increased by 60.1%, decreased by 47.1% in the AAB group, and decreased by 36% in the combination group. 4-Aminoazobenzene 88-91 C-reactive protein Homo sapiens 0-18 27543654-0 2016 Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy. Teicoplanin 52-63 C-reactive protein Homo sapiens 98-116 25204405-4 2014 RBC MTXGlu(n) concentrations that gave the highest inhibition activity across all three enzymes were linked with the disease activity score DAS28-3v (C-reactive protein [CRP]). mtxglu 4-10 C-reactive protein Homo sapiens 150-168 33418065-7 2021 With all studies, the ratio of EPA to DHA was associated with C-reactive protein (CRP) (beta = -1.3121 (95% CI: -1.6610 to -0.9543), that is, the higher the EPA to DHA ratio, the greater the reduction. Docosahexaenoic Acids 38-41 C-reactive protein Homo sapiens 62-80 25204405-4 2014 RBC MTXGlu(n) concentrations that gave the highest inhibition activity across all three enzymes were linked with the disease activity score DAS28-3v (C-reactive protein [CRP]). mtxglu 4-10 C-reactive protein Homo sapiens 170-173 25204405-7 2014 These polyglutamates were further evaluated for their relationship with DAS28-3v (CRP). das28-3v 72-80 C-reactive protein Homo sapiens 82-85 25204405-11 2014 CONCLUSIONS: The developed model describes a longitudinal relationship between RBC MTXGlu(3-5) concentrations and DAS28-3v (CRP) in patients with RA commencing MTX. mtxglu 83-89 C-reactive protein Homo sapiens 124-127 27424313-8 2016 When compared with placebo, both combination and fenofibrate significantly decreased apolipoprotein B and non-HDL cholesterol and improved flow-mediated dilation and reduced CRP and fibrinogen (all P<0.05 by ANOVA), however, there were no significant differences between combination and fenofibrate. Fenofibrate 49-60 C-reactive protein Homo sapiens 174-192 33418065-7 2021 With all studies, the ratio of EPA to DHA was associated with C-reactive protein (CRP) (beta = -1.3121 (95% CI: -1.6610 to -0.9543), that is, the higher the EPA to DHA ratio, the greater the reduction. Docosahexaenoic Acids 38-41 C-reactive protein Homo sapiens 82-85 27424313-12 2016 Otherwise, combination and fenofibrate significantly reduced apolipoprotein B and non-HDL cholesterol and improved flow-mediated dilation and reduced CRP and fibrinogen to a similar extent. Fenofibrate 27-38 C-reactive protein Homo sapiens 150-153 25088755-0 2014 Rapid flow through immunoassay for CRP determination based on polyethylene filters modified with omega-aminocellulose carbamate. omega-aminocellulose carbamate 97-127 C-reactive protein Homo sapiens 35-38 33418065-7 2021 With all studies, the ratio of EPA to DHA was associated with C-reactive protein (CRP) (beta = -1.3121 (95% CI: -1.6610 to -0.9543), that is, the higher the EPA to DHA ratio, the greater the reduction. Docosahexaenoic Acids 164-167 C-reactive protein Homo sapiens 82-85 33418065-8 2021 Using only studies that supplied EPA and DHA in the range of 2 g to 6 g, the ratio of EPA to DHA was also associated with CRP (beta = -2.10429 and 95% CI: -3.89963 to -0.30895); that is, an even more pronounced reduction in CRP with a higher EPA to DHA ratio. Docosahexaenoic Acids 41-44 C-reactive protein Homo sapiens 122-125 33418065-8 2021 Using only studies that supplied EPA and DHA in the range of 2 g to 6 g, the ratio of EPA to DHA was also associated with CRP (beta = -2.10429 and 95% CI: -3.89963 to -0.30895); that is, an even more pronounced reduction in CRP with a higher EPA to DHA ratio. Docosahexaenoic Acids 93-96 C-reactive protein Homo sapiens 122-125 25299074-2 2014 DESIGN AND METHODS: Five novel CRP-mfs, disctinct from the previously described native (nCRP) and modified (mCRP) C-reactive proteins, were separated from human plasma by polyacrylamide gel electrophoresis and immunodetected by western blot in subjects with or without increased BMI, cardiovascular disease (CVD), and diabetes (n = 1800). polyacrylamide 171-185 C-reactive protein Homo sapiens 31-34 27557504-4 2016 Patients with CRP/PNI ratio <=0.10 had a significantly better 5-year CSS compared to CRP/PNI ratio >0.10 (44.5% vs. 15.7%, P<0.001). thiocysteine 72-75 C-reactive protein Homo sapiens 14-17 27557504-5 2016 On multivariate analyses, we revealed that CRP/PNI ratio was a significant predictive factor of CSS (P=0.009). thiocysteine 96-99 C-reactive protein Homo sapiens 43-46 27557504-13 2016 CONCLUSION: The CRP/PNI ratio is a novel and useful prognostic score for CSS in patients with resectable ESCC. thiocysteine 73-76 C-reactive protein Homo sapiens 16-19 25240453-8 2014 Greater PAV regression in women versus men occurred with rosuvastatin (p = 0.004), those with diabetes (p = 0.01), stable coronary disease (p = 0.01), higher baseline LDL-C (p = 0.02), and higher CRP (p = 0.04) levels. EAP protocol 8-11 C-reactive protein Homo sapiens 196-199 33418065-8 2021 Using only studies that supplied EPA and DHA in the range of 2 g to 6 g, the ratio of EPA to DHA was also associated with CRP (beta = -2.10429 and 95% CI: -3.89963 to -0.30895); that is, an even more pronounced reduction in CRP with a higher EPA to DHA ratio. Docosahexaenoic Acids 93-96 C-reactive protein Homo sapiens 224-227 27471556-8 2016 In multivariate analysis of the entire cohort, the pretreatment CRP/Alb ratio was an independent prognostic factor for OS (HR, 1.394; 95% CI, 1.004-1.937; P = 0.048) and DMFS (HR, 1.545; 95% CI, 1.124-2.122; P = 0.007), but not for DFS (P = 0.083). dmfs 170-174 C-reactive protein Homo sapiens 64-67 33418065-8 2021 Using only studies that supplied EPA and DHA in the range of 2 g to 6 g, the ratio of EPA to DHA was also associated with CRP (beta = -2.10429 and 95% CI: -3.89963 to -0.30895); that is, an even more pronounced reduction in CRP with a higher EPA to DHA ratio. Docosahexaenoic Acids 93-96 C-reactive protein Homo sapiens 122-125 26032842-2 2016 OBJECTIVES: The aim of this study was to find out whether elevated serum levels (>=5 mg/l) of C-reactive protein (CRP), an established laboratory marker of infection and inflammation, are associated with increased serum concentrations of the atypical antipsychotic drugs clozapine, quetiapine, and risperidone. Risperidone 301-312 C-reactive protein Homo sapiens 97-115 33418065-8 2021 Using only studies that supplied EPA and DHA in the range of 2 g to 6 g, the ratio of EPA to DHA was also associated with CRP (beta = -2.10429 and 95% CI: -3.89963 to -0.30895); that is, an even more pronounced reduction in CRP with a higher EPA to DHA ratio. Docosahexaenoic Acids 93-96 C-reactive protein Homo sapiens 224-227 26032842-2 2016 OBJECTIVES: The aim of this study was to find out whether elevated serum levels (>=5 mg/l) of C-reactive protein (CRP), an established laboratory marker of infection and inflammation, are associated with increased serum concentrations of the atypical antipsychotic drugs clozapine, quetiapine, and risperidone. Risperidone 301-312 C-reactive protein Homo sapiens 117-120 26032842-10 2016 CONCLUSIONS: In patients who exhibit signs of inflammation or infection with increased C-reactive protein values during psychopharmacological treatment, especially under clozapine and risperidone, therapeutic drug monitoring is recommendable in order to minimize the risk of intoxications due to elevated drug concentrations. Risperidone 184-195 C-reactive protein Homo sapiens 87-105 33418065-10 2021 CONCLUSION: Current data suggest that the EPA to DHA ratio only correlates to the modulation of CRP by omega-3 supplementation of EPA and DHA, and SBP in studies that supplemented EPA and DHA in the range of 2 g to 6 g, shedding light on potential differential effects of EPA vs. DHA on inflammation and systolic blood pressure. Docosahexaenoic Acids 49-52 C-reactive protein Homo sapiens 96-99 33647767-8 2021 In agreement with the known anti-inflammatory action of testosterone, patients with long-polyQ and age >=60 years had increased levels of CRP (p = 0.018, not accounting for multiple testing). polyglutamine 89-94 C-reactive protein Homo sapiens 138-141 26376992-12 2016 In multivariate analysis, CRP and Hb levels were independent prognostic parameters regarding CSS/OS (CRP p = 0.016/p = 0.004; Hb p = 0.006/p = 0.004, respectively). thiocysteine 93-96 C-reactive protein Homo sapiens 26-29 33618966-8 2021 We also found that alpha-linolenic acid (ALA) and docosahexaenoic acid (DHA) enhanced the negative association between VO2max and CRP, suggesting that the anti-inflammatory response to VO2max capacity is associated with ALA and DHA levels. Docosahexaenoic Acids 50-70 C-reactive protein Homo sapiens 130-133 26376992-12 2016 In multivariate analysis, CRP and Hb levels were independent prognostic parameters regarding CSS/OS (CRP p = 0.016/p = 0.004; Hb p = 0.006/p = 0.004, respectively). thiocysteine 93-96 C-reactive protein Homo sapiens 101-104 33618966-8 2021 We also found that alpha-linolenic acid (ALA) and docosahexaenoic acid (DHA) enhanced the negative association between VO2max and CRP, suggesting that the anti-inflammatory response to VO2max capacity is associated with ALA and DHA levels. Docosahexaenoic Acids 72-75 C-reactive protein Homo sapiens 130-133 33618966-8 2021 We also found that alpha-linolenic acid (ALA) and docosahexaenoic acid (DHA) enhanced the negative association between VO2max and CRP, suggesting that the anti-inflammatory response to VO2max capacity is associated with ALA and DHA levels. Docosahexaenoic Acids 228-231 C-reactive protein Homo sapiens 130-133 26546831-12 2016 CRP was inversely associated with BA32 thickness (p<0.01) and KynA/3HK partially mediated the relationship between CRP and the thickness of right BA32 (p<0.05). L-Xyloside 34-38 C-reactive protein Homo sapiens 0-3 33409923-0 2021 Randomized Study of the Effects of Zinc, Vitamin A, and Magnesium Co-supplementation on Thyroid Function, Oxidative Stress, and hs-CRP in Patients with Hypothyroidism. Magnesium 56-65 C-reactive protein Homo sapiens 131-134 27311278-6 2016 Concerning CRP, the minimal detectable concentration revealed < 0.1 mg/dL, and prozone was observed in the sample containing > 30 mg/dL of CRP. prozone 82-89 C-reactive protein Homo sapiens 145-148 33389237-3 2021 Then, GOD and monoclonal anti-CRP antibody with a high molar ratio were covalently conjugated onto carboxylated dendrimers via typical carbodiimide coupling. Carbodiimides 135-147 C-reactive protein Homo sapiens 30-33 33861459-7 2021 Treatment with MgSO4 results in a significant reduction in serum levels of NGAL, Hb, T.Bill, IL-6, IL-8, SNSE, S100B, EGF, PAF, CRP and IgG. Magnesium Sulfate 15-20 C-reactive protein Homo sapiens 128-131 26735530-0 2016 Relationship Between 18F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level. Fluorodeoxyglucose F18 21-43 C-reactive protein Homo sapiens 173-191 33358258-13 2021 IMPLICATIONS: This study confirmed that the changes in bacterial counts and CRP levels were well described with mechanistic exposure-response modeling of vancomycin. Vancomycin 154-164 C-reactive protein Homo sapiens 76-79 26440923-9 2016 Compared with the control group, patients treated with vitamin D3 also had greater decreases in high sensitivity C-reactive protein and renin-angiotensin system activity (p < 0.05). Cholecalciferol 55-65 C-reactive protein Homo sapiens 113-131 33344594-9 2020 In case of deterioration, considering the hyperinflammatory state of the patients, methylprednisolone was intravenously administered at 0.75-1.5 mg/kg/d, usually for less than 14 d. Patient vital signs and oxygenation were closely monitored, in combination with imaging and routine blood tests such as C-reactive protein, biochemical indicators (liver and kidney function, myocardial enzymes, electrolytes, etc. Methylprednisolone 83-101 C-reactive protein Homo sapiens 302-320 26220267-10 2015 In patients with AAS, a pathological glucose uptake in aortic wall lesions by PET-CT was associated with high CRP levels and increased mortality and MAE at 3-year follow-up. aas 17-20 C-reactive protein Homo sapiens 110-113 26447154-7 2015 Percentages of d6-alpha-tocopherol AUC0- t final in both the chylomicron (r = -0.46 to -0.52) and VLDL (r = -0.49 to -0.68) fractions were inversely correlated with oxidized LDL, IL-10, IL-6, and C-reactive protein. d6-alpha-tocopherol 15-34 C-reactive protein Homo sapiens 196-214 26204331-9 2015 Patients in the olprinone group showed significantly lower BNP, WBC counts, and C-reactive protein levels after surgery. olprinone 16-25 C-reactive protein Homo sapiens 80-98 33208816-11 2020 Thus, patients with mRCC and spindle histology or poor IMDC risk scores had worse OS, and those with high CRP levels had shorter PFS in first-line axitinib treatment. Axitinib 147-155 C-reactive protein Homo sapiens 106-109 26334841-1 2015 The C-reactive protein (CRP), first described as a serum component capable of precipitating the C-polysaccharide of pneumococci, is one of the most important proteins because the serum concentration rises in the acute phase reaction. c-polysaccharide 96-112 C-reactive protein Homo sapiens 4-22 26334841-1 2015 The C-reactive protein (CRP), first described as a serum component capable of precipitating the C-polysaccharide of pneumococci, is one of the most important proteins because the serum concentration rises in the acute phase reaction. c-polysaccharide 96-112 C-reactive protein Homo sapiens 24-27 32738021-8 2020 Moreover, campesterol and beta-sitosterol were negatively correlated with body mass index, fasting insulin, and C-reactive protein and were positively correlated with HDL-cholesterol. gamma-sitosterol 26-41 C-reactive protein Homo sapiens 112-130 25537199-5 2015 A high CRP level was dichotomized as >3 mg/L. Aminoglutethimide 34-40 C-reactive protein Homo sapiens 7-10 32755653-11 2020 Multivariate analyses showed a reduction of unfavorable outcome in patients receiving AZI+-HCQ (hazard ratio [HR]=0.45, 95% confidence interval [CI: 0.21-0.97], P=0.04), particularly among an identified category of individuals (lymphocyte >=1000/mm3 or CRP >=100 mg/L). azi+-hcq 86-94 C-reactive protein Homo sapiens 253-256 26335759-2 2015 The objective of this study was to find out whether elevated serum levels of C-reactive protein (CRP) are associated with increased serum concentrations of the antidepressants citalopram and venlafaxine. Venlafaxine Hydrochloride 191-202 C-reactive protein Homo sapiens 77-95 26335759-2 2015 The objective of this study was to find out whether elevated serum levels of C-reactive protein (CRP) are associated with increased serum concentrations of the antidepressants citalopram and venlafaxine. Venlafaxine Hydrochloride 191-202 C-reactive protein Homo sapiens 97-100 25963300-3 2015 The Pr A/G functionalized Au SPR chip was then bound to anti-human CRP capture antibody (Ab), blocked with bovine serum albumin, and subsequently used for the detection of CRP. Gold 26-28 C-reactive protein Homo sapiens 67-70 25963300-3 2015 The Pr A/G functionalized Au SPR chip was then bound to anti-human CRP capture antibody (Ab), blocked with bovine serum albumin, and subsequently used for the detection of CRP. Gold 26-28 C-reactive protein Homo sapiens 172-175 32717709-7 2020 Our statistical results suggested that the concentrations of peripheral CRP may be significantly increased for suicidal PDDs, both compared with non-suicidal PDDs and HCs, respectively. Homocysteine 167-170 C-reactive protein Homo sapiens 72-75 25670405-6 2015 Low albumin and haemoglobin, and high C-reactive protein were significantly associated with CAA. caa 92-95 C-reactive protein Homo sapiens 38-56 32787939-9 2020 Bempedoic acid reduced LDL-C levels (MD - 22.91, 95% CI - 27.35 to - 18.47; I2 = 99%), and similarly reduced CRP levels (MD -24.70, 95% CI - 32.10 to - 17.30; I2 = 53%). 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 C-reactive protein Homo sapiens 109-112 25809368-11 2015 Reintervention before the first year after EVT was related to preprocedure CRP levels (HR 1.1, 95% CI 1.05 to 1.2; p<0.001). EVT 43-46 C-reactive protein Homo sapiens 75-78 25809368-13 2015 CONCLUSION: CRP values can be used as an independent marker of EVT outcome. EVT 63-66 C-reactive protein Homo sapiens 12-15 32680432-7 2020 Plasma CRP also showed a negative association with Hcys, and the ratio of saturated and polyunsaturated fatty acids intake showed a positive association with Hcys. Homocysteine 51-55 C-reactive protein Homo sapiens 7-10 28356827-0 2015 Effect of L-carnitine Supplementation on Circulating C-reactive Protein Levels: A Systematic Review and Meta-Analysis. Carnitine 10-21 C-reactive protein Homo sapiens 53-71 28356827-2 2015 There have been a number of clinical reports suggesting that supplementation with L-carnitine can modulate systemic inflammation and lower circulating CRP concentrations, but the results have not been consistent. Carnitine 82-93 C-reactive protein Homo sapiens 151-154 28356827-3 2015 METHODS: A comprehensive literature search in Medline, Scopus and Cochrane Central Register of Controlled Trials was performed in December 2012 to identify clinical trials investigating the impact of oral L-carnitine supplementation on serum/plasma CRP concentration. Carnitine 205-216 C-reactive protein Homo sapiens 249-252 32680432-8 2020 Regarding indirect effects, the results showed that the relationship between the presence of diabetes mellitus and Hcys is mediated by plasma CRP. Homocysteine 115-119 C-reactive protein Homo sapiens 142-145 28356827-6 2015 Meta-analysis of included trials revealed a significant reduction of circulating CRP concentrations in subjects under L-carnitine intervention compared to the control treatment. Carnitine 118-129 C-reactive protein Homo sapiens 81-84 28356827-9 2015 CONCLUSIONS: The overall findings of the present meta-analysis support the clinically relevant benefit of L-carnitine supplementation in lowering the circulating levels of CRP. Carnitine 106-117 C-reactive protein Homo sapiens 172-175 32680432-10 2020 Novelty In end-stage renal disease, CRP influences plasma Hcys directly and also indirectly through its mediating effect. Homocysteine 58-62 C-reactive protein Homo sapiens 36-39 33759155-9 2021 The levels of Lac, CK, CK-MB, LDH, CRP and NSE in the DEACMP group were higher than those in the non-DEACMP group. deacmp 54-60 C-reactive protein Homo sapiens 35-38 25719429-7 2015 RESULTS: Serum CRP concentrations were 23% lower after glucosamine and chondroitin compared to placebo (P = 0.048). Glucosamine 55-66 C-reactive protein Homo sapiens 15-18 33759155-11 2021 The duration of poisoning, coma degree, CK, LDH, NES, and CRP were closely associated with the occurrence of DEACMP. deacmp 109-115 C-reactive protein Homo sapiens 58-61 32706089-6 2020 Pentoxifylline, a non-specific phosphodiesterase inhibitor widely used to improve the rheological properties of blood, has beneficial anti-inflammatory properties and can significantly reduce the serum levels of pro-inflammatory cytokines such as interleukin (IL)-6, IL-1, tumour necrosis factor-alpha, C-reactive protein and other immunoregulators. Pentoxifylline 0-14 C-reactive protein Homo sapiens 303-321 25684985-9 2015 Multivariate analysis showed that crp was an independent prognostic indicator of css, with a hazard ratio of 3.04 (95% confidence interval: 1.22 to 7.55; p = 0.017). thiocysteine 81-84 C-reactive protein Homo sapiens 34-37 24740557-5 2015 RESULTS: In univariate analysis, clinical T stage classification and preoperative concentrations of hemoglobin, C-reactive protein, sodium, and albumin showed significant association with CSS. thiocysteine 188-191 C-reactive protein Homo sapiens 112-130 24231937-12 2014 Platelet counts on postoperative day (POD) 5, hemoglobin on POD 3, WBC counts, and CRP level on POD 2 were significantly higher in the DPS group than in the SPDP group and these differences continued to be significant for months after surgery. dps 135-138 C-reactive protein Homo sapiens 83-86 24622804-2 2014 OBJECTIVE: We compared 12 mo of vitamin D3 supplementation with placebo on weight, body composition, insulin, and C-reactive protein (CRP) in postmenopausal women in a weight-loss intervention. Cholecalciferol 32-42 C-reactive protein Homo sapiens 114-132 24589465-9 2014 For CSS, the pooled HR was 1.91 (95% CI, 1.36-2.69) with higher CRP expression in PCa, which strongly indicates poorer survival in PCa. thiocysteine 4-7 C-reactive protein Homo sapiens 64-67 26449925-2 2015 We report about two patients who developed an up to threefold increase of dose-related serum concentrations of risperidone"s active moiety (risperidone plus 9-hydroxyrisperidone) during acute inflammation indicated by elevated C-reactive protein. Risperidone 111-122 C-reactive protein Homo sapiens 227-245 26449925-2 2015 We report about two patients who developed an up to threefold increase of dose-related serum concentrations of risperidone"s active moiety (risperidone plus 9-hydroxyrisperidone) during acute inflammation indicated by elevated C-reactive protein. Risperidone 140-151 C-reactive protein Homo sapiens 227-245 26449925-6 2015 It is concluded that elevated C-reactive protein should be considered as an indication to control blood levels of risperidone and possibly dose adaption. Risperidone 114-125 C-reactive protein Homo sapiens 30-48 24879591-3 2014 Ab-CRP was covalently immobilized on mercaptopropionic acid (MPA)-capped Pt nanoparticles that were covalently anchored over the graphene to form a bioelectrode. 3-Mercaptopropionic Acid 37-59 C-reactive protein Homo sapiens 3-6 32569211-4 2020 Meanwhile, MIR103 and MIR107 were negatively correlated with acute pathologic and chronic health evaluation (APACHE) II score, sequential organ failure assessment (SOFA) score, serum creatinine, C-reactive protein, tumor necrosis factor, interleukin 1beta, interleukin 6 and interleukin 8, while positively correlated with albumin in sepsis patients. mir103 11-17 C-reactive protein Homo sapiens 195-213 24215209-0 2014 Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. Sunitinib 123-132 C-reactive protein Homo sapiens 36-54 24215209-1 2014 OBJECTIVE: To evaluate the impact of baseline serum C-reactive protein (CRP) level on outcome in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Sunitinib 163-172 C-reactive protein Homo sapiens 52-70 24215209-1 2014 OBJECTIVE: To evaluate the impact of baseline serum C-reactive protein (CRP) level on outcome in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Sunitinib 163-172 C-reactive protein Homo sapiens 72-75 24215209-12 2014 CONCLUSION: Baseline serum CRP level is a strong independent variable linked with RR, PFS and OS in patients with mRCC treated with sunitinib. Sunitinib 132-141 C-reactive protein Homo sapiens 27-30 24720919-9 2014 C-reactive protein and interleukin-6 were both significantly reduced in the colchicine group (-5.1 mg/l and -4.8 pg/ml, respectively; p < 0.001 for both, compared with the control group). Colchicine 76-86 C-reactive protein Homo sapiens 0-18 24327720-10 2014 Future studies of longer supplemental vitamin D3 duration are necessary to examine the complex influence of vitamin D3 on CRP and other chronic inflammatory cytokines for possible reduction of cancer health disparities in African Americans. Cholecalciferol 108-118 C-reactive protein Homo sapiens 122-125 32548142-18 2020 CONCLUSION: Our logistic regression analysis on differentiating factors of CA from SA showed that high CRP level was a strong dose-dependent predictor of CA. sa 83-85 C-reactive protein Homo sapiens 103-106 24967375-9 2014 The highest correlations were between DAPSA and SDAI (rho = 0.996) and between DAPSA and DAS28-CRP (rho = 0.957). dapsa 79-84 C-reactive protein Homo sapiens 95-98 24848523-8 2014 The best performances were obtained for polyhistidine-tagged standards with respect to limits of detection (CRP, 0.10 mug/mL; cystatin C, 0.003 mug/mL) and coefficients of variation (CRP, 2.4-7.0%; cystatin C, 3.0-8.9%). polyhistidine 40-53 C-reactive protein Homo sapiens 108-111 24848523-8 2014 The best performances were obtained for polyhistidine-tagged standards with respect to limits of detection (CRP, 0.10 mug/mL; cystatin C, 0.003 mug/mL) and coefficients of variation (CRP, 2.4-7.0%; cystatin C, 3.0-8.9%). polyhistidine 40-53 C-reactive protein Homo sapiens 183-186 24830565-0 2014 Localized surface plasmon resonance nanosensing of C-reactive protein with poly(2-methacryloyloxyethyl phosphorylcholine)-grafted gold nanoparticles prepared by surface-initiated atom transfer radical polymerization. poly(2-methacryloyloxyethyl-phosphorylcholine) 75-121 C-reactive protein Homo sapiens 51-69 32498466-7 2020 The data show that selection of acetic acid as the solvent in the silanization step generally yields a higher protein binding capacity for C-reactive protein (CRP) onto anti-CRP functionalized ring resonator sensors than using ethanol as the solvent. Acetic Acid 32-43 C-reactive protein Homo sapiens 139-157 24900154-9 2014 The CRP level (p < 0.001) and white blood cell count (p = 0.023) were significantly higher in the group of patients with diffuse splenic FDG uptake. Fluorodeoxyglucose F18 140-143 C-reactive protein Homo sapiens 4-7 24262327-3 2014 METHODS: Plasma CRP was measured within 6 hours of onset (median, 120 minutes) in 399 patients with primary or vitamin K antagonist-associated spontaneous intracerebral hemorrhage and without recent infection. Vitamin K 111-120 C-reactive protein Homo sapiens 16-19 24757857-5 2013 The study results permit to suppose that concentration of NO2+RNO in plasma is one of sensitive indicators of presence of inflammatory processes concomitant to premature discharge of amniotic fluid which by its sensitivity and specificity is superior to such indicators as number of leucocytes, ESR and concentration of C-reactive protein. (R)-2-(4-Nitrophenyl)oxirane 62-65 C-reactive protein Homo sapiens 320-338 32498466-7 2020 The data show that selection of acetic acid as the solvent in the silanization step generally yields a higher protein binding capacity for C-reactive protein (CRP) onto anti-CRP functionalized ring resonator sensors than using ethanol as the solvent. Acetic Acid 32-43 C-reactive protein Homo sapiens 159-162 23897106-6 2013 RESULTS: C-reactive protein (CRP) concentrations were positively correlated with the difference between ALBBCG and ALBmBCP in malnourished inpatients (r = 0.59, p < 0.001). albmbcp 115-122 C-reactive protein Homo sapiens 9-27 32498466-7 2020 The data show that selection of acetic acid as the solvent in the silanization step generally yields a higher protein binding capacity for C-reactive protein (CRP) onto anti-CRP functionalized ring resonator sensors than using ethanol as the solvent. Acetic Acid 32-43 C-reactive protein Homo sapiens 174-177 23897106-6 2013 RESULTS: C-reactive protein (CRP) concentrations were positively correlated with the difference between ALBBCG and ALBmBCP in malnourished inpatients (r = 0.59, p < 0.001). albmbcp 115-122 C-reactive protein Homo sapiens 29-32 32443042-11 2020 CONCLUSIONS: In this real-life prospective cohort using dose optimization, thiopurines were safe and effective in 21% of CD and 27% of UC patients, including normalization of C-reactive protein and erythrocyte sedimentation rate. thiopurines 75-86 C-reactive protein Homo sapiens 175-193 24034905-7 2013 Indirect EVT (in 307 CLI patients, 43%), was associated with MALE (p = .04, hazard ratio [95% confidence interval] 1.25 [1.01, 1.55]), and interacted with CRP >3 mg/dL (p < .004) but not with other baseline characteristics. EVT 9-12 C-reactive protein Homo sapiens 155-158 24194609-8 2014 Serum CRP was also negatively correlated with mature milk free choline (r = -0.278; P < .05), but no correlation was found between serum CRP and other choline compounds in mature milk. Choline 63-70 C-reactive protein Homo sapiens 6-9 24360391-10 2014 In both groups, citrulline was significantly inversely correlated with C-reactive protein (r(2) = 0.10, P < .01) on D0. Citrulline 16-26 C-reactive protein Homo sapiens 71-89 32466773-8 2020 CONCLUSIONS: In patients with T2DM and CHD, the 12-week intake of magnesium plus zinc had beneficial effects on FPG, HDL-cholesterol, CRP, insulin, total nitrite, TAC levels, and BDI and BAI score. Magnesium 66-75 C-reactive protein Homo sapiens 134-137 24360391-12 2014 CONCLUSIONS: At the onset of septic shock, plasma citrulline decreases and varies inversely with C-reactive protein and is lower when digestive bacterial translocation occurs. Citrulline 50-60 C-reactive protein Homo sapiens 97-115 24548331-8 2014 Among the laboratory factors, segmented neutrophil percentage, total bilirubin level, and C-reactive protein were significant in children with CAA (p = 0.014, p = 0.009, and p = 0.010). caa 143-146 C-reactive protein Homo sapiens 90-108 24034905-8 2013 Indirect EVT with CRP >3 mg/dL had higher MALE risk (HR 2.08), and interacted with diabetes mellitus (DM) presence. EVT 9-12 C-reactive protein Homo sapiens 18-21 24034905-9 2013 Indirect EVT with CRP >3 mg/dL and DM had higher MALE risk (HR 2.17). EVT 9-12 C-reactive protein Homo sapiens 18-21 22952245-3 2013 The objective of this study was to test whether concentrations of circulating inflammatory markers (C-reactive protein (CRP), interleukin-6 (IL-6) and interleukin 1 receptor antagonist (IL-1Ra)) were predictive for DCI following SAH. dci 215-218 C-reactive protein Homo sapiens 100-118 24084772-8 2013 In multivariate analysis, increased CRP levels were significantly associated with a poor outcome for CSS (HR=2.05; 95% CI=1.13-3.74; P=0.019) and DFS (HR=1.88; 95% CI=1.07-3.34; P=0.029). thiocysteine 101-104 C-reactive protein Homo sapiens 36-39 32286421-6 2020 Further, methionine, isoleucine, tryptophan, xanthurenic acid, and indole-3-carboxaldehyde were negatively associated with C-reactive protein (CRP), but 5-hydroxyindole-3-acetic acid was positively associated with CRP. indole-3-carbaldehyde 67-90 C-reactive protein Homo sapiens 123-141 32286421-6 2020 Further, methionine, isoleucine, tryptophan, xanthurenic acid, and indole-3-carboxaldehyde were negatively associated with C-reactive protein (CRP), but 5-hydroxyindole-3-acetic acid was positively associated with CRP. indole-3-carbaldehyde 67-90 C-reactive protein Homo sapiens 143-146 32286421-8 2020 Long-term overweight from childhood into late adolescence is associated with decreased urinary levels of gut bacteria-derived indole-3-acetic acid, and several urinary amino acids, including gut bacteria-derived indole-3-carboxaldehyde are associated with elevated CRP later on in life. indole-3-carbaldehyde 212-235 C-reactive protein Homo sapiens 265-268 23732776-8 2013 NTproCNP SDS was significantly inversely related to body temperature (r = -0.42, P < 0.01) and CRP (r = -0.56, P < 0.001). sds 9-12 C-reactive protein Homo sapiens 98-101 32999156-10 2020 The higher vancomycin concentration tended to be associated with the shorter time to 50% decline in CRP. Vancomycin 11-21 C-reactive protein Homo sapiens 100-103 24570490-8 2013 Landiolol also significantly reduced the postoperative peak C-reactive protein level compared to the control group (132 +- 55.4 vs. 161 +- 50.9 mgcL(-1), p = 0.004). landiolol 0-9 C-reactive protein Homo sapiens 60-78 33350327-10 2020 iSTAT was sensitive to CRP and hematocrit. istat 0-5 C-reactive protein Homo sapiens 23-26 23571148-7 2013 Higher-CRP (CRP >= 2.46 mg/L) predicted shorter overall survival, disease-free survival and DMFS than lower-CRP (CRP < 2.46 mg/L). dmfs 95-99 C-reactive protein Homo sapiens 7-10 23571148-7 2013 Higher-CRP (CRP >= 2.46 mg/L) predicted shorter overall survival, disease-free survival and DMFS than lower-CRP (CRP < 2.46 mg/L). dmfs 95-99 C-reactive protein Homo sapiens 12-15 23571148-7 2013 Higher-CRP (CRP >= 2.46 mg/L) predicted shorter overall survival, disease-free survival and DMFS than lower-CRP (CRP < 2.46 mg/L). dmfs 95-99 C-reactive protein Homo sapiens 12-15 32082496-5 2020 Late gadolinium enhancement extent was positively associated with cardiac troponin I serum levels and c-reactive protein and negatively with left ventricular ejection fraction at baseline study. Gadolinium 5-15 C-reactive protein Homo sapiens 102-120 23571148-7 2013 Higher-CRP (CRP >= 2.46 mg/L) predicted shorter overall survival, disease-free survival and DMFS than lower-CRP (CRP < 2.46 mg/L). dmfs 95-99 C-reactive protein Homo sapiens 12-15 32430154-9 2020 LDL-c and TC levels inversely correlated with C-reactive protein and interleukin-6, and positively correlated with the number of lymphocytes in patients. Technetium 10-12 C-reactive protein Homo sapiens 46-64 23457377-12 2013 ES for DAS28-CRP(4) was 1.2 +- 1.1 versus 1.1 +- 1.1 for DAS28-CRP(3) (p < 0.0001). Einsteinium 0-2 C-reactive protein Homo sapiens 13-16 23457377-12 2013 ES for DAS28-CRP(4) was 1.2 +- 1.1 versus 1.1 +- 1.1 for DAS28-CRP(3) (p < 0.0001). Einsteinium 0-2 C-reactive protein Homo sapiens 63-66 23497335-9 2013 Next to age and the presence of metastasis, multivariate analysis also identified CRP as a continuous variable as an independent prognosticator for CSS. thiocysteine 148-151 C-reactive protein Homo sapiens 82-85 23593612-8 2013 A Lipiodol dose exceeding 7 mL (HR=5.55, P=0.046) and the 10-month mortality (HR=7.693, P=0.004) were significantly associated with high serum CRP level in the group of patients with a tumor size of >=5 cm. Ethiodized Oil 2-10 C-reactive protein Homo sapiens 143-146 23268743-7 2013 In the RAW 264.7 macrophage-derived conditioned medium (RAW-CM)-induced 3T3-L1 adipocyte and 3T3-CM-induced RAW 264.7 macrophage models, pterostilbene significantly decreased IL-6 and TNF-alpha secretion and proinflammatory mRNA expression (COX-2, iNOS, IL-6, TNF-alpha, PAI-1, CRP, MCP-1, resistin, and leptin). pterostilbene 137-150 C-reactive protein Homo sapiens 278-281 22391858-0 2012 An investigation of the correlation between blood concentration of mizoribine and its efficacy in treatment of rheumatoid arthritis based on indices of drug survival and improvement in DAS28-CRP. mizoribine 67-77 C-reactive protein Homo sapiens 191-194 22391858-1 2012 OBJECTIVES: The efficacy of mizoribine (MZR) in treatment of rheumatoid arthritis (RA) was retrospectively investigated in terms of drug survival, improvement in Disease Activity Score-28 (DAS28)-C-reactive protein (CRP), and blood MZR concentration obtained 3 h after dosing (MZR-C3). mizoribine 28-38 C-reactive protein Homo sapiens 196-214 22391858-1 2012 OBJECTIVES: The efficacy of mizoribine (MZR) in treatment of rheumatoid arthritis (RA) was retrospectively investigated in terms of drug survival, improvement in Disease Activity Score-28 (DAS28)-C-reactive protein (CRP), and blood MZR concentration obtained 3 h after dosing (MZR-C3). mizoribine 28-38 C-reactive protein Homo sapiens 216-219 22958305-6 2012 Multivariate analysis identified CRP as an independent prognosticator for CSS as well as overall survival (p < 0.001). thiocysteine 74-77 C-reactive protein Homo sapiens 33-36 22564668-5 2012 RESULTS: More gain in weight for length SDS in the first 3 months of life was significantly associated with an increased number of MetS components [odds ratio (OR) = 1.34], prevalence of low high-density lipoprotein cholesterol (OR = 1.49), prevalence of MetS (OR = 2.51), increased C-reactive protein levels, and lower insulin sensitivity (P = 0.007) at the age of 21 yr. Low birth weight SDS was associated with lower insulin sensitivity (P = 0.036), but low birth weight SDS and adult IGF-I SDS were not significantly associated with any of the MetS components or MetS prevalence at 21 yr. sds 40-43 C-reactive protein Homo sapiens 283-301 22897994-7 2012 In OB individuals, DeltaMBF was inversely correlated with increase in endocannabinoid anandamide (r = -0.45, p = 0.044), but not with leptin (r = -0.02, p = 0.946) or with CRP (r = -0.33, p = 0.168). deltambf 19-27 C-reactive protein Homo sapiens 172-175 22113248-3 2012 We also examined whether exposure to mercury, an environmental contaminant in fish, which is also a major source of long-chain n-3 PUFA, was associated with CRP. Mercury 37-44 C-reactive protein Homo sapiens 157-160 22311704-4 2012 Elevated CRP was defined as >8 mg/L. Aminoglutethimide 25-31 C-reactive protein Homo sapiens 9-12 22311704-8 2012 Multivariate analysis showed that CRP and tumor site were independent prognostic indicators for CSS, with a hazard ratio of 2.66 (95% confidence interval (CI), 1.22-5.82; P = 0.014) and a hazard ratio of 1.67 (95% CI, 1.01-2.77; P = 0.045), respectively. thiocysteine 96-99 C-reactive protein Homo sapiens 34-37 22400913-6 2012 In the follow-up visit, we found a significant decrease in the frequency of patients with active TA (93% vs. 20%, p = 0.002), in the mean daily dose of prednisone (34.2 vs. 13.9 mg, p < 0.001) and in the median values of ESR (29.0 vs. 27.0 mm/h, p = 0.012) and CRP (10.3 vs. 5.3 mg/L, p = 0.012). Prednisone 152-162 C-reactive protein Homo sapiens 264-267 22142512-7 2012 Our results showed that CRP markedly activated c-Raf/MEK/ERK and JAK1/ERK signaling pathways but not JAK1/STAT3 signaling pathway by using the phosphor-specific antibodies against these pathways, and blockages of c-Raf/MEK/ERK and JAK1/ERK signaling pathways by the specific ERK1/2 inhibitor U0126 and JAK1 inhibitor piceatannol could significantly decrease CRP-induced MMP-10 expression. U 0126 292-297 C-reactive protein Homo sapiens 24-27 22037998-8 2012 After the initial bolus of intravenous corticosteroids, therapy transitions to oral prednisone administered at 1 mg/kg per day until the activity of the disease process attenuates, as demonstrated by improvement in systemic symptoms and normalization of both ESR and CRP. Prednisone 84-94 C-reactive protein Homo sapiens 267-270 22190023-7 2012 Significant linear upward trends across tertiles of fructose intake were observed for systolic blood pressure, fasting glucose, HOMA-IR, and C-reactive protein after adjusting for the same covariates (all P-trend < 0.04). Fructose 52-60 C-reactive protein Homo sapiens 141-159 21947022-3 2012 The aim of the study was to evaluate whether (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT can be used to detect inflammatory foci in neutropenic patients with elevated CRP and whether it helps to direct treatment. Fluorodeoxyglucose F18 71-74 C-reactive protein Homo sapiens 192-195 21918905-0 2012 Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. Colchicine 10-20 C-reactive protein Homo sapiens 63-81 21918905-3 2012 We performed a pilot randomized controlled trial comparing the effect of colchicine 1 mg per day with placebo on high sensitivity C-reactive protein (CRP) levels and platelet function in 80 patients with acute coronary syndrome or acute ischemic stroke who were followed for 30 days. Colchicine 73-83 C-reactive protein Homo sapiens 130-148 21918905-3 2012 We performed a pilot randomized controlled trial comparing the effect of colchicine 1 mg per day with placebo on high sensitivity C-reactive protein (CRP) levels and platelet function in 80 patients with acute coronary syndrome or acute ischemic stroke who were followed for 30 days. Colchicine 73-83 C-reactive protein Homo sapiens 150-153 21909023-8 2011 The fourth quartile of the hs-CRP at 24 h after percutaneous coronary intervention (PCI) had significantly larger volume of NIH than the first quartile (20.1+-25.1 vs. 2.7+-6.4 mm, P<0.05). 2-{[3,5-Bis(Trifluoromethyl)benzyl]amino}-N-Hydroxy-6-Oxo-1,6-Dihydropyrimidine-5-Carboxamide 124-127 C-reactive protein Homo sapiens 30-33 21939559-0 2011 Short-term effect of fenofibrate on C-reactive protein: A meta-analysis of randomized controlled trials. Fenofibrate 21-32 C-reactive protein Homo sapiens 36-54 21939559-2 2011 Some but not all randomized and non-randomized clinical trials found significant associations between fenofibrate therapy and CRP but the direction and magnitude of the association varied across studies. Fenofibrate 102-113 C-reactive protein Homo sapiens 126-129 21939559-4 2011 In this study we meta-analyzed randomized clinical trials to determine the short-term effect of fenofibrate on CRP. Fenofibrate 96-107 C-reactive protein Homo sapiens 111-114 21939559-9 2011 Inverse-variance weighted random effects meta-analysis revealed that short-term fenofibrate treatment significantly lowers CRP by 0.58 mg/L (95% CI: 0.36-0.80). Fenofibrate 80-91 C-reactive protein Homo sapiens 123-126 21939559-12 2011 CONCLUSION: Short-term treatment with fenofibrate significantly lowers CRP concentration. Fenofibrate 38-49 C-reactive protein Homo sapiens 71-74 21455669-7 2011 Logistic regression estimated the odds of elevated CRP (defined as >3.0 mg/l) across tertiles of dietary fiber intake. Aminoglutethimide 64-70 C-reactive protein Homo sapiens 51-54 21536287-4 2011 Adjusted values of the AS/WR-related parameters and serum CRP levels were higher in the subjects with serum O6FA levels in the highest tertile than in those with serum O6FA levels in the lowest tertile. o6fa 108-112 C-reactive protein Homo sapiens 58-61 21536287-4 2011 Adjusted values of the AS/WR-related parameters and serum CRP levels were higher in the subjects with serum O6FA levels in the highest tertile than in those with serum O6FA levels in the lowest tertile. o6fa 168-172 C-reactive protein Homo sapiens 58-61 21276586-5 2011 Simvastatin and fenofibrate decreased monocyte release of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and monocyte chemoattractant protein-1 and lymphocyte release of interleukin-2, interferon-gamma, and tumor necrosis factor-alpha, which was accompanied by a decrease in plasma C-reactive protein levels. Fenofibrate 16-27 C-reactive protein Homo sapiens 298-316 21558574-8 2011 After supplementation, SOD activity was significantly higher (p = .0037) in the supplemented group than the placebo group, and C-reactive protein was significantly (p = .00001) lower in athletes receiving GliSODin than those in the placebo group. glisodin 205-213 C-reactive protein Homo sapiens 127-145 21068344-7 2011 RESULTS: Low blood thiamine concentrations upon admission were detected in 57 patients (28.2%) and were shown to be independently associated with C-reactive protein concentrations >20 mg/dL (odds ratio: 2.17; 95% CI: 1.13, 4.17; P = 0.02) but not with malnutrition. Thiamine 19-27 C-reactive protein Homo sapiens 146-164 24368434-5 2014 l-Carnitine significantly decreased serum low-density lipoprotein (LDL) (mean difference: -5.82 mg/dL; 95% CI: -11.61, -0.04 mg/dL) and C-reactive protein (CRP) (-3.65 mg/L; -6.19, -1.12 mg/L). Carnitine 0-11 C-reactive protein Homo sapiens 136-154 24368434-5 2014 l-Carnitine significantly decreased serum low-density lipoprotein (LDL) (mean difference: -5.82 mg/dL; 95% CI: -11.61, -0.04 mg/dL) and C-reactive protein (CRP) (-3.65 mg/L; -6.19, -1.12 mg/L). Carnitine 0-11 C-reactive protein Homo sapiens 156-159 24368434-8 2014 CONCLUSIONS: This meta-analysis failed to confirm the previous findings regarding the effects of l-carnitine on hemoglobin and the erythropoietin dose but showed that l-carnitine significantly decreased serum LDL and CRP. Carnitine 167-178 C-reactive protein Homo sapiens 217-220 23932786-5 2014 RESULTS: Baseline CRP levels were higher in PNR compared with SR (26.2mg/L vs 9.6 mg/L, p=0.015) and RTA (26.2mg/L vs 7.6 mg/L, p=0.007). Strontium 62-64 C-reactive protein Homo sapiens 18-21 24201751-8 2014 In univariate analysis, we observed that a high plasma CRP level was a consistent factor for poor CSS in PC patients (hazard ratio (HR)=2.21; 95% confidence interval (CI)=1.68-2.92, P<0.001). thiocysteine 98-101 C-reactive protein Homo sapiens 55-58 25159306-8 2014 RESULTS: The yields of DHT from 14C-testosterone showed 2-fold and 1.8-fold- inhibition in response to IL-6 and CRP respectively and 28% stimulation in response to Dox, via the 5-alpha reductase pathway. Dihydrotestosterone 23-26 C-reactive protein Homo sapiens 112-115 25159306-9 2014 The combination of IL-6 + CRP showed a 2-fold reduction in the yields of DHT, elevated to control values when combined with Dox (n=8; p<0.001). Dihydrotestosterone 73-76 C-reactive protein Homo sapiens 26-29 25159306-11 2014 CONCLUSIONS: Inhibition of DHT synthesis in osteoblasts by IL-6 and CRP was overcome by doxycycline. Dihydrotestosterone 27-30 C-reactive protein Homo sapiens 68-71 21242686-10 2011 In the PS group, CRP varied from 6.2 +- 4.0 to 6.4 +- 3.7, and IL-6 from 10.6 +- 2.1 to 9.6 +- 3.5 (p = n.s.). polysulfone P 1700 7-9 C-reactive protein Homo sapiens 17-20 33086971-6 2020 Upon discontinuation of clozapine, her symptoms and elevated CRP level immediately improved and the steroid was successfully tapered and discontinued. Clozapine 24-33 C-reactive protein Homo sapiens 61-64 21957896-0 2011 The effect of quinapril treatment on insulin resistance, leptin and high sensitive C-reactive protein in hypertensive patients. Quinapril 14-23 C-reactive protein Homo sapiens 83-101 21188146-10 2010 AUC analysis revealed a strong correlation between citrulline and CRP (Pearson correlation r = 0.96). Citrulline 51-61 C-reactive protein Homo sapiens 66-69 24127651-8 2014 C-reactive protein increased more at discharge in the ticagrelor group (28.0 +- 38.0 vs. 26.1 +- 36.6 mg/l; p < 0.001) and interleukin-6 remained higher during the first month of treatment with ticagrelor. Ticagrelor 54-64 C-reactive protein Homo sapiens 0-18 24239465-8 2014 Specifically, in the patients with clear cell RCC, elevated CRP level was also associated with higher stage (RR 2.92, 95% CI 2.25-3.80, P<0.00001), poorer CSS (HR 2.60, 95% CI 2.32-2.88, P<0.00001), and poorer progression-free survival (HR 1.21, 95% CI 0.94-1.47, P<0.00001). thiocysteine 158-161 C-reactive protein Homo sapiens 60-63 24222149-0 2013 C-reactive protein is a negative independent factor in patients with stage IV colorectal cancer undergoing oxaliplatin-based chemotherapy. Oxaliplatin 107-118 C-reactive protein Homo sapiens 0-18 30856080-10 2019 These studies demonstrated that vitamin E, especially tocotrienol, was able to alleviate IL-1, IL-6, RANKL, iNOS and hs-CRP levels in relation to bone metabolism. Tocotrienols 54-65 C-reactive protein Homo sapiens 120-123 20638228-10 2010 Even after adjusting for other risk factors at baseline, preprocedural CRP levels were a significant predictive factor for RAO and any-cause death after EVT in a multivariable Cox analysis. EVT 153-156 C-reactive protein Homo sapiens 71-74 20638228-11 2010 CONCLUSIONS: Elevated preprocedural serum CRP levels were associated with RAO and any-cause death after EVT in hemodialysis patients with peripheral artery disease. EVT 104-107 C-reactive protein Homo sapiens 42-45 31673811-0 2019 Fluorescent fullerene nanoparticle-based lateral flow immunochromatographic assay for rapid quantitative detection of C-reactive protein. Fullerenes 12-21 C-reactive protein Homo sapiens 118-136 20204669-7 2010 Nitrite concentration reduced from 6.50 +/- 0.21 to 2.57 +/- 0.18 micromol/l (p < 0.001), ESR from 40.90 +/- 6.00 to 11.50 +/- 1.38 mm in the first hour (p < 0.001), and CRP level from 29.08 +/- 4.11 to 2.69 +/- 0.43 mg/dl (p < 0.001). Nitrites 0-7 C-reactive protein Homo sapiens 176-179 31673811-1 2019 A fluorescent fullerene nanoparticle (NP)-based lateral flow immunochromatographic assay (LFIA) was developed for the rapid and quantitative detection of C-reactive protein (CRP) in serum. Fullerenes 14-23 C-reactive protein Homo sapiens 154-172 31673811-1 2019 A fluorescent fullerene nanoparticle (NP)-based lateral flow immunochromatographic assay (LFIA) was developed for the rapid and quantitative detection of C-reactive protein (CRP) in serum. Fullerenes 14-23 C-reactive protein Homo sapiens 174-177 31673811-2 2019 The polyclonal CRP-antibody-conjugated fullerene NPs were simply prepared by 1-ethyl-3-(3-dimethyllaminopropyl)-carbodiimide hydrochloride coupling after carboxylation of fluorescent fullerene NPs. Fullerenes 39-48 C-reactive protein Homo sapiens 15-18 20143119-8 2010 Significant correlation was observed between VAS and CRP in the fenofibrate group (p < 0.05). Fenofibrate 64-75 C-reactive protein Homo sapiens 53-56 31673811-2 2019 The polyclonal CRP-antibody-conjugated fullerene NPs were simply prepared by 1-ethyl-3-(3-dimethyllaminopropyl)-carbodiimide hydrochloride coupling after carboxylation of fluorescent fullerene NPs. Carbodiimides 77-138 C-reactive protein Homo sapiens 15-18 31673811-2 2019 The polyclonal CRP-antibody-conjugated fullerene NPs were simply prepared by 1-ethyl-3-(3-dimethyllaminopropyl)-carbodiimide hydrochloride coupling after carboxylation of fluorescent fullerene NPs. Fullerenes 183-192 C-reactive protein Homo sapiens 15-18 20084502-9 2010 Low plasma citrulline at 24 h was associated with low plasma glutamine and arginine (p = 0.01 and 0.04), and high plasma CRP concentration, nosocomial infection rate, and 28-day mortality (p = 0.008, 0.03, and 0.02, respectively). Citrulline 11-21 C-reactive protein Homo sapiens 121-124 31673811-3 2019 By applying the CRP-antibody-conjugated fullerene NPs to a lateral flow test strip, quantitative analysis of CRP in serum was possible at a concentration range of 0.1-10 ng/ml within 15 min. Fullerenes 40-49 C-reactive protein Homo sapiens 16-19 31673811-3 2019 By applying the CRP-antibody-conjugated fullerene NPs to a lateral flow test strip, quantitative analysis of CRP in serum was possible at a concentration range of 0.1-10 ng/ml within 15 min. Fullerenes 40-49 C-reactive protein Homo sapiens 109-112 31222540-13 2019 Post-operative C-reactive protein level was significantly less in the methylprednisolone group (p < 0.001). Methylprednisolone 70-88 C-reactive protein Homo sapiens 15-33 20375501-6 2010 CRP increased during DCI and decreased in patients without DCI (difference 14 mg/l; 95% CI: -29 to 58). dci 21-24 C-reactive protein Homo sapiens 0-3 20375501-6 2010 CRP increased during DCI and decreased in patients without DCI (difference 14 mg/l; 95% CI: -29 to 58). dci 59-62 C-reactive protein Homo sapiens 0-3 31357161-6 2019 In five studies higher baseline interleukin-6 (IL-6) or C-reactive protein (CRP)/high-sensitivity-CRP (hsCRP) in blood predicted better response to medication with anti-inflammatory characteristics, such as ketamine and infliximab. Ketamine 207-215 C-reactive protein Homo sapiens 56-74 19696778-9 2009 Plasma levels of renin, angiotensin II and aldosterone were also increased with the thiazide period, whereas high-sensitivity C-reactive protein and oxidized low-density lipoprotein were decreased with azelnidipine. azelnidipine 202-214 C-reactive protein Homo sapiens 126-144 31253226-7 2019 Compared with pantoprazole alone, somatostatin combined with pantoprazole has a better therapeutic effect on SAP, and its mechanism may be related to reduction of serum CRP and ICAM-1. Pantoprazole 61-73 C-reactive protein Homo sapiens 169-172 31222137-1 2019 Pairwise and network meta-analyses on the relationship between the efficacy of the use of statins with or without ezetimibe and reductions in low-density lipoprotein cholesterol (LDLc) and C-reactive protein (CRP) in patients with chronic kidney disease (CKD) are presented. Ezetimibe 114-123 C-reactive protein Homo sapiens 189-207 19587086-7 2009 Citrulline correlated positively with albumin (P < 0.01) and BMI (P < 0.05) and negatively with C-reactive protein (P < 0.01). Citrulline 0-10 C-reactive protein Homo sapiens 102-120 19694217-7 2009 RESULTS: Patients with unstable anticoagulation on acenocoumarol had higher body mass index (p<0.01) and serum C-reactive protein levels (p<0.01) compared to stable counterparts. Acenocoumarol 51-64 C-reactive protein Homo sapiens 114-132 31222137-4 2019 The network meta-analysis for LDLc and CRP treatment objectives also showed that, regardless of eGFR and excluding dialysis patients, the number of MACEs decreased in patients with CKD, with reductions in both LDLc and CRP of less than 50% (surface under the cumulative ranking (SUCRA)/heterogeneity (vague)/n: 0.77/0.14/3). SACCHARIN SODIUM 279-284 C-reactive protein Homo sapiens 39-42 30709958-6 2019 Dichotomization of patients using receiver-operating characteristic curve analysis-based cutoffs for these biomarkers showed significantly higher proportions with LDA among patients with lower versus higher levels of CRP or leptin (40% vs 23%, p = 0.004, and 40% vs 25%, p = 0.011, respectively), as well as among those with higher versus lower levels of TNF-RI or VCAM-1 (43% vs 27%, p = 0.004, and 41% vs 25%, p = 0.004, respectively). lda 163-166 C-reactive protein Homo sapiens 217-220 18973929-6 2009 Current understanding of optimization of colchicine dosing is reviewed, as are recent findings on colchicine therapy of nonrheumatic cardiovascular, hepatic, and renal diseases (eg, lowering of C-reactive protein, and treatment of acute and recurrent pericarditis). Colchicine 98-108 C-reactive protein Homo sapiens 194-212 19035968-7 2009 Docosapentaenoic acid was the only polyunsaturated n-3 FA that was correlated to CRP in both groups. polyunsaturated n-3 fa 35-57 C-reactive protein Homo sapiens 81-84 18762766-5 2009 Statistical analysis showed a significant association over time between citrulline levels, to a lesser extent bacteraemia, but not neutropenia, and the inflammatory response measured by CRP. Citrulline 72-82 C-reactive protein Homo sapiens 186-189 30988752-0 2019 Effect of the drug combination of magnesium sulfate and phentolamine on homocysteine and C-reactive protein in the serum of patients with pregnancy-induced hypertension syndrome. Magnesium Sulfate 34-51 C-reactive protein Homo sapiens 89-107 18853090-8 2009 CONCLUSIONS: Azithromycin does not improve late angiographic outcomes but attenuates the elevation of C-reactive protein levels after stenting, indicating an anti-inflammatory effect. Azithromycin 13-25 C-reactive protein Homo sapiens 102-120 30988752-1 2019 Effect and clinical efficacy of magnesium sulfate combined with phentolamine on homocysteine and C-reactive protein in the serum of patients with pregnancy-induced hypertension syndrome were investigated. Magnesium Sulfate 32-49 C-reactive protein Homo sapiens 97-115 30988752-10 2019 In conclusion, the meliorative effect of magnesium sulphate combined with phentolamine on the level of MAP, the content of 24 h urine protein, SBP, DBP, Hcy and CRP in pregnant woman had a greater impact than that of the single use of the intravenous infusion of magnesium sulfate in the treatment of pregnancy-induced hypertension syndrome, and the clinical efficacy of magnesium sulphate combined with phentolamine was better, thus worthwhile to promote widely in clinic. Magnesium Sulfate 41-59 C-reactive protein Homo sapiens 161-164 30962499-1 2019 This study aimed to explore the effect of dietary magnesium intake on breast cancer risk both directly and indirectly via its effect on inflammatory markers C-reactive protein (CRP) and interleukin-6 (IL-6). Magnesium 50-59 C-reactive protein Homo sapiens 157-175 18469351-8 2008 The inflammatory marker high-sensitivity C-reactive protein decreased significantly only in the group receiving deferasirox (deferasirox -51%/year, deferoxamine +8.5%/year, p = 0.02). Deferasirox 112-123 C-reactive protein Homo sapiens 41-59 18799053-4 2008 RESULTS: In patients with clinical activity despite nearly normal erythrocyte sedimentation rate (ESR) and C reactive protein (CRP), disease activity could be shown by PET-CT. A long segmental, increased fluoro-deoxyglucose (FDG) uptake in the vessel wall served as confirmation of the vascular inflammation. Fluorodeoxyglucose F18 204-223 C-reactive protein Homo sapiens 107-125 18799053-4 2008 RESULTS: In patients with clinical activity despite nearly normal erythrocyte sedimentation rate (ESR) and C reactive protein (CRP), disease activity could be shown by PET-CT. A long segmental, increased fluoro-deoxyglucose (FDG) uptake in the vessel wall served as confirmation of the vascular inflammation. Fluorodeoxyglucose F18 204-223 C-reactive protein Homo sapiens 127-130 30962499-1 2019 This study aimed to explore the effect of dietary magnesium intake on breast cancer risk both directly and indirectly via its effect on inflammatory markers C-reactive protein (CRP) and interleukin-6 (IL-6). Magnesium 50-59 C-reactive protein Homo sapiens 177-180 30962499-8 2019 Path analysis revealed that dietary magnesium affected breast cancer risk both directly and indirectly by influencing the CRP level. Magnesium 36-45 C-reactive protein Homo sapiens 122-125 30962499-9 2019 The results indicate that a direct negative association and an indirect association through influencing the CRP level were observed between dietary magnesium intake and breast cancer risk. Magnesium 148-157 C-reactive protein Homo sapiens 108-111 18190628-4 2008 Elevated CRP was defined as > 0.5 mg/dL. Aminoglutethimide 25-31 C-reactive protein Homo sapiens 9-12 30273823-12 2019 CONCLUSIONS: A higher dietary intake of magnesium was associated with lower incident epilepsy, and this association was slightly mediated by CRP. Magnesium 40-49 C-reactive protein Homo sapiens 141-144 18190628-7 2008 Ten patients had a high CRP level before ChRT (> or = 0.5 mg/dL) and their CSS rate was significantly worse than that in the remaining patients (P = 0.003). thiocysteine 78-81 C-reactive protein Homo sapiens 24-27 18190628-8 2008 Multivariate analysis showed that CRP and cT stage were independent prognostic indicators for CSS, with a hazard ratio of 1.80 (95% confidence interval 1.01-2.97; P = 0.046). thiocysteine 94-97 C-reactive protein Homo sapiens 34-37 18258634-5 2008 RESULTS: Compared with the lowest tertile of choline intake (<250 mg/d), participants who consumed >310 mg/d had, on average, 22% lower concentrations of C-reactive protein (P < 0.05), 26% lower concentrations of interleukin-6 (P < 0.05), and 6% lower concentrations of tumor necrosis factor-alpha (P < 0.01). Choline 45-52 C-reactive protein Homo sapiens 160-178 29939848-5 2019 In addition, BA lowers levels of non-high-density lipoprotein cholesterol, C-reactive protein, and apolipoprotein B. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 13-15 C-reactive protein Homo sapiens 75-115 18225580-5 2007 The CRP isoforms were analyzed by native PAGE (polyacrylamide gel electrophoresis). polyacrylamide 47-61 C-reactive protein Homo sapiens 4-7 31202641-9 2019 Placebo-adjusted reductions from baseline with bempedoic acid also were significant for total cholesterol (-10%; P = .014), non-high-density lipoprotein cholesterol (-13%; P = .015), apolipoprotein B (-15%; P = .004), and high-sensitivity C-reactive protein (-44%; P = .002). 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 47-61 C-reactive protein Homo sapiens 239-257 17033807-3 2007 Compared with the CAA(-) group, the CAA(+) group had a longer duration of fever after intravenous gamma-globulin (IVGG) injection (2.4+/-2.9 vs. 1.5+/-1.2 days, p=0.008) and higher C-reactive protein (CRP)(12.3+/-7.8 vs. 8.7+/-7.1 mg/dL, p=0.038). caa 36-39 C-reactive protein Homo sapiens 181-199 17033807-3 2007 Compared with the CAA(-) group, the CAA(+) group had a longer duration of fever after intravenous gamma-globulin (IVGG) injection (2.4+/-2.9 vs. 1.5+/-1.2 days, p=0.008) and higher C-reactive protein (CRP)(12.3+/-7.8 vs. 8.7+/-7.1 mg/dL, p=0.038). caa 36-39 C-reactive protein Homo sapiens 201-204 24222149-1 2013 BACKGROUND/AIM: To determine the clinical significance of C-reactive protein (CRP) concentration in patients with stage IV colorectal cancer (CRC) undergoing oxaliplatin-based chemotherapy. Oxaliplatin 158-169 C-reactive protein Homo sapiens 58-76 24222149-1 2013 BACKGROUND/AIM: To determine the clinical significance of C-reactive protein (CRP) concentration in patients with stage IV colorectal cancer (CRC) undergoing oxaliplatin-based chemotherapy. Oxaliplatin 158-169 C-reactive protein Homo sapiens 78-81 23868086-11 2013 In a multivariate analysis, CRP and MMP-9 were associated with intima-media thickness, LTB4 and PGE2 with arterial stiffness, and lysozyme with hypertension. Leukotriene B4 87-91 C-reactive protein Homo sapiens 28-31 30047537-0 2018 A relation of serum homocysteine, uric acid and C-reactive protein level in patients with acute myocardial infarction. Homocysteine 20-32 C-reactive protein Homo sapiens 48-66 24377892-11 2013 (4) After adjusting for age, CRP, UA, partial correlation analysis showed that plasma TAS was negatively correlated with baPWV (r = -0.459, P < 0.05). tas 86-89 C-reactive protein Homo sapiens 29-32 17462553-1 2007 OBJECTIVE: The study evaluated the effect of a canned sardine supplement in C-reactive protein (CRP) in patients on hemodialysis (HD) and the compliance and adherence to this supplement. sardine 54-61 C-reactive protein Homo sapiens 96-99 17462553-12 2007 Although diabetic patients were excluded from the analysis (eight in the sardine supplementation group and seven in the control group) a significant CRP reduction was found (P = .034). sardine 73-80 C-reactive protein Homo sapiens 149-152 30047537-1 2018 Aim To determine the relationship of homocysteine (HCY), uric acid (UA) and C-reactive protein (CRP) in serum of patients with acute myocardial infarction (AMI) prior to application of percutaneous coronary intervention (PCI) and their level of correlation in serum of patients with normal and elevated CRP (predictor of worse cardiovascular outcomes). Homocysteine 37-49 C-reactive protein Homo sapiens 76-94 17522372-5 2007 Micronized fenofibrate also significantly decreased fibrinogen (421 +/- 152 vs 344 +/- 81 mg/dl, p <0.001), hs-CRP (3.3 +/- 3.3 vs 2.1 +/- 1.8 mg/L, p <0.01), and ESR (19.1 +/- 24.8 vs 9.7 +/- 8.7 mm/hr, p <0.01), but did not change proinsulin levels. Fenofibrate 11-22 C-reactive protein Homo sapiens 114-117 17522372-8 2007 In conclusion, after 12 wk, micronized fenofibrate therapy significantly decreased 3 inflammatory markers (hs-CRP, ESR, and fibrinogen) and improved the lipid profile by decreasing serum triglyceride, cholesterol, and non-HDL-cholesterol levels and increasing HDL-cholesterol; however, it did not change serum proinsulin level, a pancreatic stress marker. Fenofibrate 39-50 C-reactive protein Homo sapiens 110-113 17095576-7 2007 Piceatannol, an inhibitor of Syk tyrosine kinase, or infection of Syk small interference RNA blocked the recombinant CRP-induced RhoA activity and the phosphorylation of JNK and IRS-1. 3,3',4,5'-tetrahydroxystilbene 0-11 C-reactive protein Homo sapiens 117-120 17095576-8 2007 In addition, piceatannol also restrained CRP-induced endothelin-1 production. 3,3',4,5'-tetrahydroxystilbene 13-24 C-reactive protein Homo sapiens 41-44 23782971-11 2013 Plasma citrulline concentration less than or equal to 10 mumol/L at admission to the ICU was associated with higher intra-abdominal pressure, higher plasma C reactive protein concentration, and more frequent antibiotic use (all p<=0.005). Citrulline 7-17 C-reactive protein Homo sapiens 156-174 23343124-1 2013 BACKGROUND: Genetic variants of PPP1R3B, a gene encoding a critical protein involved in hepatic glycogen metabolism, were recently reported to be associated with plasma levels of lipids and C-reactive protein (CRP) among populations of mostly European descent. Glycogen 96-104 C-reactive protein Homo sapiens 190-208 23343124-1 2013 BACKGROUND: Genetic variants of PPP1R3B, a gene encoding a critical protein involved in hepatic glycogen metabolism, were recently reported to be associated with plasma levels of lipids and C-reactive protein (CRP) among populations of mostly European descent. Glycogen 96-104 C-reactive protein Homo sapiens 210-213 30047537-1 2018 Aim To determine the relationship of homocysteine (HCY), uric acid (UA) and C-reactive protein (CRP) in serum of patients with acute myocardial infarction (AMI) prior to application of percutaneous coronary intervention (PCI) and their level of correlation in serum of patients with normal and elevated CRP (predictor of worse cardiovascular outcomes). Homocysteine 37-49 C-reactive protein Homo sapiens 96-99 17209672-3 2007 Fenofibrate also has nonlipid (i.e. pleiotropic) effects (e.g. it reduces fibrinogen, C-reactive protein and uric acid levels and improves flow-mediated dilatation). Fenofibrate 0-11 C-reactive protein Homo sapiens 86-104 29645075-12 2018 Multivariate analysis identified the following as independent adverse factors for achievement of CR-CRp: platelets < 50 x 109 /L (P < .001), complex karyotype with >=3 chromosomal abnormalities (P = .02), regimens that did not include cytarabine or hypomethylating agents (P = .014), and no prior CR lasting >=12 months with frontline or salvage 1 therapies (P < .001). Cytarabine 244-254 C-reactive protein Homo sapiens 97-99 16945967-3 2006 Experiments with permeabilized myocytes revealed that with normal cytosolic energy reserves (mm: ATP 5, ADP 0.01, phosphocreatine (CrP) 10) fructose-1,6-bisphosphate (FBP; 1 mm) and fructose-6-phosphate (F6P; 1 mm) caused a transient increase of Ca(2+) spark frequency by 62 and 42%, respectively. Phosphocreatine 114-129 C-reactive protein Homo sapiens 131-134 23294924-9 2013 CONCLUSION: Lower albumin and elevated CRP levels could strongly predict MAE and MALE after EVT in hemodialysis patients. EVT 92-95 C-reactive protein Homo sapiens 39-42 29645075-12 2018 Multivariate analysis identified the following as independent adverse factors for achievement of CR-CRp: platelets < 50 x 109 /L (P < .001), complex karyotype with >=3 chromosomal abnormalities (P = .02), regimens that did not include cytarabine or hypomethylating agents (P = .014), and no prior CR lasting >=12 months with frontline or salvage 1 therapies (P < .001). Cytarabine 244-254 C-reactive protein Homo sapiens 100-103 22935083-4 2013 Compared with placebo, fenofibrate reduced lymphocyte release of interleukin-2, interferon-gamma and tumour necrosis factor-alpha, which was accompanied by a reduction in plasma C-reactive protein levels. Fenofibrate 23-34 C-reactive protein Homo sapiens 178-196 29645075-12 2018 Multivariate analysis identified the following as independent adverse factors for achievement of CR-CRp: platelets < 50 x 109 /L (P < .001), complex karyotype with >=3 chromosomal abnormalities (P = .02), regimens that did not include cytarabine or hypomethylating agents (P = .014), and no prior CR lasting >=12 months with frontline or salvage 1 therapies (P < .001). Cytarabine 244-254 C-reactive protein Homo sapiens 100-102 29567181-0 2018 Electrochemical detection of c-reactive protein based on anthraquinone-labeled antibody using a screen-printed graphene electrode. Graphite 111-119 C-reactive protein Homo sapiens 29-47 29567181-1 2018 In this present work, a novel electrochemical immunosensor employing a screen-printed graphene electrode (SPGE) for a simple and highly sensitive determination of C-reactive protein (CRP) in a sandwich-type format was proposed. Graphite 86-94 C-reactive protein Homo sapiens 163-181 16861734-6 2006 RESULTS: CRP levels were significantly decreased in carnitine group in contrast to the increase in the control group. Carnitine 52-61 C-reactive protein Homo sapiens 9-12 29567181-1 2018 In this present work, a novel electrochemical immunosensor employing a screen-printed graphene electrode (SPGE) for a simple and highly sensitive determination of C-reactive protein (CRP) in a sandwich-type format was proposed. Graphite 86-94 C-reactive protein Homo sapiens 183-186 16861734-8 2006 CONCLUSIONS: There was a significant benefit of L-carnitine on CRP, transferrin, total protein and albumin levels of the haemodialysis patients. Carnitine 48-59 C-reactive protein Homo sapiens 63-66 22738944-9 2012 CONCLUSIONS: Compared with weight measured concurrently, the rate of weight gain in risperidone-treated children accounts for an equal or larger share of the variance in certain cardiometabolic outcomes (eg, HDL cholesterol [DeltaR(2) = 8% vs DeltaR(2) = 11%] and high-sensitivity C-reactive protein [DeltaR(2) = 5% vs DeltaR(2) = 9%]) and may serve as a treatment target. Risperidone 84-95 C-reactive protein Homo sapiens 281-299 29471285-7 2018 High sensitivity C reactive protein (hsCRP) and arachidonic acid levels significantly decreased in the DHA group. Docosahexaenoic Acids 103-106 C-reactive protein Homo sapiens 17-35 29648566-0 2018 SERS-based lateral flow assay for quantitative detection of C-reactive protein as an early bio-indicator of a radiation-induced inflammatory response in nonhuman primates. sers 0-4 C-reactive protein Homo sapiens 60-78 23236325-0 2012 Fenofibrate reduces C-reactive protein levels in hypertriglyceridemic patients with high risks for cardiovascular diseases. Fenofibrate 0-11 C-reactive protein Homo sapiens 20-38 23236325-1 2012 BACKGROUND AND OBJECTIVES: The effects of fenofibrate on C-reactive protein (CRP) are under debate. Fenofibrate 42-53 C-reactive protein Homo sapiens 57-75 23236325-1 2012 BACKGROUND AND OBJECTIVES: The effects of fenofibrate on C-reactive protein (CRP) are under debate. Fenofibrate 42-53 C-reactive protein Homo sapiens 77-80 23236325-2 2012 We investigated the effect of fenofibrate on CRP levels and the variables determining changes. Fenofibrate 30-41 C-reactive protein Homo sapiens 45-48 23236325-5 2012 RESULTS: CRP levels decreased in both the fenofibrate (p=0.003) and comparison (p=0.048) groups. Fenofibrate 42-53 C-reactive protein Homo sapiens 9-12 23236325-7 2012 In patients with a baseline CRP level >=1 mg/L, CRP levels also decreased in both groups (p=0.000 and p=0.001 respectively), however, more in the fenofibrate group than in the comparison group (p=0.025). Fenofibrate 149-160 C-reactive protein Homo sapiens 28-31 23236325-7 2012 In patients with a baseline CRP level >=1 mg/L, CRP levels also decreased in both groups (p=0.000 and p=0.001 respectively), however, more in the fenofibrate group than in the comparison group (p=0.025). Fenofibrate 149-160 C-reactive protein Homo sapiens 51-54 23236325-8 2012 The reduction of CRP was associated with higher baseline CRP levels (r=-0.29, p=0.001), lower body mass index (BMI, r=0.23, p=0.007), and fenofibrate therapy (r=0.19, p=0.025). Fenofibrate 138-149 C-reactive protein Homo sapiens 17-20 23236325-9 2012 CRP levels decreased more in the fenofibrate group than in the comparison group in patients with a BMI <=26 kg/m(2) with borderline significance (-1.21+-1.82 mg/L vs. -0.89+-1.92 mg/L, p=0.097). Fenofibrate 33-44 C-reactive protein Homo sapiens 0-3 23236325-10 2012 In patients with a high density lipoprotein-cholesterol level <40 mg/dL, CRP levels were reduced only in the fenofibrate group (p=0.006). Fenofibrate 112-123 C-reactive protein Homo sapiens 76-79 23236325-11 2012 CONCLUSION: Fenofibrate reduced CRP levels in hypertriglyceridemic patients with high CRP and/or low high density lipoprotein-cholesterol levels and without severe overweight. Fenofibrate 12-23 C-reactive protein Homo sapiens 32-35 23236325-11 2012 CONCLUSION: Fenofibrate reduced CRP levels in hypertriglyceridemic patients with high CRP and/or low high density lipoprotein-cholesterol levels and without severe overweight. Fenofibrate 12-23 C-reactive protein Homo sapiens 86-89 16810076-0 2006 Effects of fenofibrate on C-reactive protein levels in hypertriglyceridemic patients. Fenofibrate 11-22 C-reactive protein Homo sapiens 26-44 16810076-1 2006 We investigated the effects of fenofibrate on C-reactive protein (CRP) levels in patients with hypertriglyceridemia. Fenofibrate 31-42 C-reactive protein Homo sapiens 46-64 16810076-1 2006 We investigated the effects of fenofibrate on C-reactive protein (CRP) levels in patients with hypertriglyceridemia. Fenofibrate 31-42 C-reactive protein Homo sapiens 66-69 16810076-8 2006 In patients with baseline CRP levels of >or=3 mg/dL, CRP levels were decreased in both the fenofibrate and control groups (P = 0.026 and 0.008, respectively). Fenofibrate 94-105 C-reactive protein Homo sapiens 26-29 16810076-8 2006 In patients with baseline CRP levels of >or=3 mg/dL, CRP levels were decreased in both the fenofibrate and control groups (P = 0.026 and 0.008, respectively). Fenofibrate 94-105 C-reactive protein Homo sapiens 56-59 16253380-5 2006 The treatment regimen consisting of rosiglitazone and glimepiride significantly lowered hs-CRP by -2.6 (3.9) mg/L (p<0.05) at week 12 in spite of no improvement in blood glucose. glimepiride 54-65 C-reactive protein Homo sapiens 91-94 16389569-5 2005 RESULTS: CRP induced phosphorylation of Syk and an increase in [Ca(2+)](i) both of which were inhibitable by the Syk specific antagonist, piceatannol. 3,3',4,5'-tetrahydroxystilbene 138-149 C-reactive protein Homo sapiens 9-12 16389569-6 2005 Piceatannol also inhibited the CRP-induced increase in surface CD11b. 3,3',4,5'-tetrahydroxystilbene 0-11 C-reactive protein Homo sapiens 31-34 15963746-6 2005 RESULTS: The peak C-reactive protein was significantly lower in the patients treated with HES than those treated with gelofusine [142 mg/L (113,196 mg/L) vs 246 mg/L (189,291 mg/L) mg/L, P < 0.01, Mann-Whitney test]. Helium 90-93 C-reactive protein Homo sapiens 18-36 29648566-2 2018 A surface-enhanced Raman scattering (SERS)-based lateral flow assay was developed for the quantitative detection of C-reactive protein (CRP) as an early bio-indicator of a radiation-induced inflammatory response in nonhuman primates. sers 37-41 C-reactive protein Homo sapiens 116-134 22918393-3 2012 RESULTS: CA9, OPN and CRP were univariately prognostic for overall survival (OS), cancer-specific survival (CSS) and disease-free survival (DFS) with CRP and CA9 being independently prognostic for OS/CSS and OS, respectively. thiocysteine 108-111 C-reactive protein Homo sapiens 22-25 29648566-2 2018 A surface-enhanced Raman scattering (SERS)-based lateral flow assay was developed for the quantitative detection of C-reactive protein (CRP) as an early bio-indicator of a radiation-induced inflammatory response in nonhuman primates. sers 37-41 C-reactive protein Homo sapiens 136-139 15591095-7 2005 Inhibition of ERK MAPK pathway using U0126 prevented CRP-induced IL-8 upregulation, and Western blot analysis revealed a rapid activation of ERK1/2 after CRP stimulation. U 0126 37-42 C-reactive protein Homo sapiens 53-56 29648566-3 2018 Raman reporter-embedded gold-core silver-shell nanoparticles with built-in hot spots were synthesized and conjugated with a CRP detection antibody to serve as SERS tags in the lateral flow assay. sers 159-163 C-reactive protein Homo sapiens 124-127 29648566-4 2018 The proposed SERS-based lateral flow assay can rapidly detect CRP with a limit of detection of 0.01 ng mL-1 and quantitative analysis ability. sers 13-17 C-reactive protein Homo sapiens 62-65 29178250-12 2018 However, PBR correlated significantly with inflammation markers (fibrinogen: r = .58; C-reactive protein: r = .42), platelet counts (r = .36) and inversely with measures of liver/renal function such as bilirubin (r = -.38) or estimated glomerular filtration rate (r = -.34) in CHF patients. pentabromophenol 9-12 C-reactive protein Homo sapiens 86-104 15827896-0 2005 L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients. Carnitine 0-11 C-reactive protein Homo sapiens 41-59 15827896-4 2005 The carnitine-treated group showed a statistically significant decrease in serum C-reactive protein and increase in serum albumin and transferrin, blood hemoglobin, and body mass index. Carnitine 4-13 C-reactive protein Homo sapiens 81-99 15827896-6 2005 These preliminary findings suggest that in MHD patients, L-carnitine therapy may suppress inflammation, particularly among those patients with C-reactive protein > or =3 mg/dL, and may improve protein-energy nutritional status. Carnitine 57-68 C-reactive protein Homo sapiens 143-161 15668660-6 2005 Bivariate analysis showed a significant inverse association between CRP and many nutrients (e.g., carbohydrates, proteins, lipids, thiamine, pyridoxine, tocopherol, and folate), but multiple-regression analysis indicated that only the effect of dietary folate intake was not dependent on other factors. Thiamine 131-139 C-reactive protein Homo sapiens 68-71 22863438-5 2012 RESULTS: CRP, Hcy, and IMA levels and lipid profiles were higher in patients with Oho than in euthyroid or Ohe subjects (p<0.05). Cyclohexylcarbamic Acid 82-85 C-reactive protein Homo sapiens 9-12 22863438-8 2012 In Oho patients, serum IMA levels were inversely correlated with free triiodothyronine (r=-0.555, p=0.001) and free thyroxine (r=-0.457, p=0.006) but positively correlated with anti-thyroid peroxidase antibody, C-reactive protein, and homocysteine levels (p<0.05). Cyclohexylcarbamic Acid 3-6 C-reactive protein Homo sapiens 211-229 22660810-12 2012 Colchicine users also had fewer deaths and lower CRP levels, although these did not achieve statistical significance. Colchicine 0-10 C-reactive protein Homo sapiens 49-52 22660810-14 2012 CONCLUSION: In this hypothesis-generating study, gout patients who took colchicine had a significantly lower prevalence of MI and exhibited trends toward reduced all-cause mortality and lower CRP level versus those who did not take colchicine. Colchicine 72-82 C-reactive protein Homo sapiens 192-195 22159869-8 2012 The ratio of unconjugated alprazolam to 4-hydroxyalprazolam was correlated with CRP levels (r(s) = 0.49, P = 0.01). Alprazolam 26-36 C-reactive protein Homo sapiens 80-83 29352395-7 2018 However, the CRP rs1130864 A allele carrier state was significantly more frequent: (i) in BD patients with thyroid disorders than in those without (pc = 0.046), especially among females (pc = 0.01) and independently of lithium treatment, (ii) in BD patients with rapid cycling than in those without (pc = 0.004). Lithium 219-226 C-reactive protein Homo sapiens 13-16 22159869-11 2012 CONCLUSIONS: The correlation between CYP3A4 activity (assessed by alprazolam 4-hydroxylation) and CRP level suggests that inflammation may downregulate CYP3A4 activity. Alprazolam 66-76 C-reactive protein Homo sapiens 98-101 22142512-7 2012 Our results showed that CRP markedly activated c-Raf/MEK/ERK and JAK1/ERK signaling pathways but not JAK1/STAT3 signaling pathway by using the phosphor-specific antibodies against these pathways, and blockages of c-Raf/MEK/ERK and JAK1/ERK signaling pathways by the specific ERK1/2 inhibitor U0126 and JAK1 inhibitor piceatannol could significantly decrease CRP-induced MMP-10 expression. 3,3',4,5'-tetrahydroxystilbene 317-328 C-reactive protein Homo sapiens 24-27 22509446-5 2012 RESULTS: Among the five subclasses of POPs, only organochlorine (OC) pesticides showed positive associations with CRP concentrations, while polychlorinated biphenyls (PCBs) showed inverse associations with CRP concentrations. Polychlorinated Biphenyls 140-165 C-reactive protein Homo sapiens 206-209 22509446-5 2012 RESULTS: Among the five subclasses of POPs, only organochlorine (OC) pesticides showed positive associations with CRP concentrations, while polychlorinated biphenyls (PCBs) showed inverse associations with CRP concentrations. Polychlorinated Biphenyls 167-171 C-reactive protein Homo sapiens 206-209 22509446-8 2012 CONCLUSIONS: In the current study, OC pesticides were associated with increased levels of CRP, a marker of inflammation, and both OC pesticides and PCBs may also modify the associations between CRP and insulin resistance. Polychlorinated Biphenyls 148-152 C-reactive protein Homo sapiens 194-197 22014622-3 2011 This work presents a sensitive sandwich immunoassay for the detection of CRP in human serum using zinc sulfide (ZnS) nanoparticles as novel fluorescence signal transducers. zinc sulfide 98-110 C-reactive protein Homo sapiens 73-76 15566918-3 2004 The changes in CFVR were negatively correlated with changes in high-sensitivity C-reactive protein levels in patients receiving azithromycin. Azithromycin 128-140 C-reactive protein Homo sapiens 80-98 15467191-0 2004 C-reactive protein-induced expression of CD40-CD40L and the effect of lovastatin and fenofibrate on it in human vascular endothelial cells. Fenofibrate 85-96 C-reactive protein Homo sapiens 0-18 15467191-9 2004 In conclusion, our data provide evidence to support the direct pro-inflammatory effects of CRP via CD40-CD40L signaling pathway involved in the pathogenesis of atherosclerosis, and lovastatin and fenofibrate possess anti-inflammatory effects independent of their lipid-lowering action. Fenofibrate 196-207 C-reactive protein Homo sapiens 91-94 15361500-13 2004 Post hoc analysis suggests both short and long term efficacy of CDP571 in patients with elevated baseline CRP (> or =10 mg/l). CDP 571 64-70 C-reactive protein Homo sapiens 106-109 22014622-3 2011 This work presents a sensitive sandwich immunoassay for the detection of CRP in human serum using zinc sulfide (ZnS) nanoparticles as novel fluorescence signal transducers. zinc sulfide 112-115 C-reactive protein Homo sapiens 73-76 29143878-12 2018 15d-PGJ2 correlated negatively with the inflammation marker C-reactive protein. 15-deoxy-delta(12,14)-prostaglandin J2 0-8 C-reactive protein Homo sapiens 60-78 22014622-5 2011 Quantification of CRP occurs when zinc ions released from ZnS nanoparticle labels are mixed with zinc-ion sensitive fluorescence indicator Fluozin-3 for fluorescence generation. zinc sulfide 58-61 C-reactive protein Homo sapiens 18-21 15308231-2 2004 The specific binding characteristics of CRP antigen to its antibody, which is immobilized with Calixcrown SAMs on Au surface deposited on microcantilever, is determined in high sensitivity to the nanogram level per milliliter by measuring the resonant frequency shift. Gold 114-116 C-reactive protein Homo sapiens 40-43 15490412-9 2004 Treatment with L-carnitine (20 mg/kg, given intravenously at the end of each dialysis session for 6 mo), significantly decreased serum C-reactive protein (CRP) levels, a proinflammatory cytokine known to inhibit erythropoiesis. Carnitine 15-26 C-reactive protein Homo sapiens 135-153 15490412-9 2004 Treatment with L-carnitine (20 mg/kg, given intravenously at the end of each dialysis session for 6 mo), significantly decreased serum C-reactive protein (CRP) levels, a proinflammatory cytokine known to inhibit erythropoiesis. Carnitine 15-26 C-reactive protein Homo sapiens 155-158 21507193-13 2011 RESULTS: The 3-year CSS was 74.0% in patients with normal and 44.0% with elevated CRP (P < 0.001). thiocysteine 22-25 C-reactive protein Homo sapiens 84-87 30720956-3 2018 The method for diagnosing SA was performed by determining the concentration in the blood of tumor necrosis factor alpha (TNF-alpha), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), alpha2-globulin and albumin. sa 26-28 C-reactive protein Homo sapiens 133-151 21507193-17 2011 CONCLUSIONS: This is the largest, contemporary series to date indicating that preoperative serum CRP is an independent risk factor for CSS. thiocysteine 137-140 C-reactive protein Homo sapiens 99-102 21779090-5 2011 Generalized linear regression analyses, adjusted for age, gender, race, tanner score, total energy intake and physical activity, revealed that PL dairy fatty acids were inversely associated with CRP, F2-iso and 15-keto in overweight, but not in normal weight adolescents (all P(interaction) < 0.05). dairy fatty acids 146-163 C-reactive protein Homo sapiens 195-198 15097439-0 2004 Discordant erythrocyte sedimentation rate and C-reactive protein in children with inflammatory bowel disease taking azathioprine or 6-mercaptopurine. Mercaptopurine 132-148 C-reactive protein Homo sapiens 46-64 15097439-5 2004 The authors observed an unexplained discordance between ESR and CRP in children with asymptomatic IBD who were being treated with AZA or 6-MP. Mercaptopurine 137-141 C-reactive protein Homo sapiens 64-67 15097439-6 2004 OBJECTIVE: To characterize children with IBD in remission treated with 6-MP or AZA who have persistently elevated ESR but normal CRP. Mercaptopurine 71-75 C-reactive protein Homo sapiens 129-132 15097439-12 2004 Duration of AZA or 6-MP therapy was greater in the 11 children with asymptomatic disease and discordant ESR and CRP than in those with or without symptoms and with concordant ESR and CRP (58.1 +/- 16.4 months v 36.6 +/- 24.1 months, P = 0.0043). Mercaptopurine 19-23 C-reactive protein Homo sapiens 112-115 15097439-12 2004 Duration of AZA or 6-MP therapy was greater in the 11 children with asymptomatic disease and discordant ESR and CRP than in those with or without symptoms and with concordant ESR and CRP (58.1 +/- 16.4 months v 36.6 +/- 24.1 months, P = 0.0043). Mercaptopurine 19-23 C-reactive protein Homo sapiens 183-186 15097439-16 2004 CONCLUSIONS: The results suggest that among children treated with AZA or 6-MP, CRP may be a more reliable indirect indicator of inflammation than ESR. Mercaptopurine 73-77 C-reactive protein Homo sapiens 79-82 15097439-17 2004 This report alerts clinicians that some children taking AZA or 6-MP may have persistent elevation of the ESR with a normal CRP and have no clinical evidence of active disease. Mercaptopurine 63-67 C-reactive protein Homo sapiens 123-126 30720956-3 2018 The method for diagnosing SA was performed by determining the concentration in the blood of tumor necrosis factor alpha (TNF-alpha), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), alpha2-globulin and albumin. sa 26-28 C-reactive protein Homo sapiens 153-156 30720956-6 2018 As independent variables or predictors - five laboratory parameters: TNF-alpha, CRP, ESR, alpha2-globulins and albumin, which had a high relationship with SA. sa 155-157 C-reactive protein Homo sapiens 80-83 14564337-10 2003 On the contrary, nitroglycerin significantly reduced plasma levels of C-reactive protein and sE-selectin and increased the levels of intraplatelet cGMP. Nitroglycerin 17-30 C-reactive protein Homo sapiens 70-88 21942979-3 2011 Fenofibrate also has nonlipid, pleiotropic effects (e.g. reducing levels of fibrinogen, C-reactive protein and various pro-inflammatory markers, and improving flow-mediated dilatation) that may contribute to its clinical efficacy, particularly in terms of improving microvascular outcomes. Fenofibrate 0-11 C-reactive protein Homo sapiens 88-106 21675801-2 2011 Fenofibrate also has a number of nonlipid, pleiotropic effects (e.g. reducing levels of fibrinogen, C-reactive protein, and various pro-inflammatory markers, and improving flow-mediated dilatation) that may contribute to its clinical efficacy, particularly in terms of improving microvascular outcomes. Fenofibrate 0-11 C-reactive protein Homo sapiens 100-118 21117970-7 2011 TG and high-sensitivity C-reactive protein had greater reductions in the fenofibrate and fenofibrate plus ezetimibe groups than the ezetimibe alone group (P <= 0.05 for both) CONCLUSIONS: In this analysis of patients with mixed dyslipidemia, the lipid effects of ezetimibe plus fenofibrate were generally similar in metabolic syndrome patients versus those without metabolic syndrome. Fenofibrate 73-84 C-reactive protein Homo sapiens 24-42 21117970-7 2011 TG and high-sensitivity C-reactive protein had greater reductions in the fenofibrate and fenofibrate plus ezetimibe groups than the ezetimibe alone group (P <= 0.05 for both) CONCLUSIONS: In this analysis of patients with mixed dyslipidemia, the lipid effects of ezetimibe plus fenofibrate were generally similar in metabolic syndrome patients versus those without metabolic syndrome. Fenofibrate 89-100 C-reactive protein Homo sapiens 24-42 14612213-5 2003 Both fenofibrate and simvastatin markedly reduced plasma levels of high-sensitivity CRP, IL-1 beta, and sCD40L, and improved endothelium-dependent FMD without mutual differences. Fenofibrate 5-16 C-reactive protein Homo sapiens 84-87 14557435-6 2003 In contrast, the treatment with ethinyl estradiol-cyproterone acetate increased serum CRP levels from 2.91 +/- 0.68 mg/liter to 4.58 +/- 0.84 mg/liter (P < 0.001). ethinyl estradiol-cyproterone acetate 32-69 C-reactive protein Homo sapiens 86-89 12947436-5 2003 RESULTS: C-reactive protein concentration (dichotomized at the sex-specific 85th percentile) was inversely and significantly associated with concentrations of retinol, retinyl esters, vitamin C, alpha-carotene, beta-carotene, cryptoxanthin, lutein/zeaxanthin, lycopene, and selenium after adjustment for age, sex, race or ethnicity, education, cotinine concentration, body mass index, leisure-time physical activity, and aspirin use. alpha-carotene 195-209 C-reactive protein Homo sapiens 9-27 14531304-8 2003 Intravenous panipenem/betamiprom was prescribed, and after 5 weeks, the patient recovered, was negative for C-reactive protein and had a negative venous blood culture. panipenem 12-21 C-reactive protein Homo sapiens 108-126 21117970-7 2011 TG and high-sensitivity C-reactive protein had greater reductions in the fenofibrate and fenofibrate plus ezetimibe groups than the ezetimibe alone group (P <= 0.05 for both) CONCLUSIONS: In this analysis of patients with mixed dyslipidemia, the lipid effects of ezetimibe plus fenofibrate were generally similar in metabolic syndrome patients versus those without metabolic syndrome. Fenofibrate 89-100 C-reactive protein Homo sapiens 24-42 29208852-10 2017 Therefore, methylprednisolone 500 mg/day for 3 days was started followed by prednisolone 30 mg/day and immunosuppressive agent (Cyclosporine 50 mg/day), which improved her general condition, elevated C-reactive protein levels, and extremely high serum ferritin levels. Methylprednisolone 11-29 C-reactive protein Homo sapiens 200-218 20884620-6 2011 Univariate Cox regression analysis followed by multivariate analysis showed that high-serum PCS levels were associated with renal progression and all-cause mortality independent of age, gender, diabetes status, albumin levels, serum IS, serum creatinine, Ca x P product, intact parathyroid hormone, haemoglobin or high-sensitivity C-reactive protein level. 4-cresol sulfate 92-95 C-reactive protein Homo sapiens 331-349 12792130-11 2003 The median time to reach the lowest maintenance dose of prednisone at which the ESR and CRP stayed low and stable was 48.7 months (95% CI: 34.6, 71.4 months), and the median lowest prednisone dose achieved was 7 mg/day (interquartile range of 1-16 mg/day). Prednisone 56-66 C-reactive protein Homo sapiens 88-91 12808486-11 2003 Furthermore, atenolol and nebivolol decreased serum high-sensitivity C-reactive protein levels by 14% (P=.05) and 15% (P=.05), respectively. Atenolol 13-21 C-reactive protein Homo sapiens 69-87 21350317-9 2011 Our results showed that calcitriol can effectively suppress iPTH secretion, reduce inflammatory markers (CRP and IL-6) and oxidative stress. Calcitriol 24-34 C-reactive protein Homo sapiens 105-108 28550977-1 2017 AIMS: Evaluating the short-term influence of Ezetimibe and Simvastatin Combination Therapy on LDL-C, TG and hs-CRP expression level in patients with percutaneous coronary intervention. Ezetimibe 45-54 C-reactive protein Homo sapiens 111-114 21274876-8 2011 Patients with abnormal PHES had higher CRP (17 +- 22 vs 7 +- 6, P < 0.01), IL6 (32 +- 54 vs 12 +- 13, P < 0.05) and TNFalpha (17 +- 8 vs 11 +- 7, P < 0.001) levels than those with normal PHES. Phenylalanine 23-27 C-reactive protein Homo sapiens 39-42 28550977-10 2017 CONCLUSIONS: Combination therapy of Ezetimibe (10mg/day) and Simvastatin (40mg/day) was more effective than mono-therapy with Simvastatin (40mg/day) on reducing LDL-C, TG and hs-CRP level in percutaneous coronary intervention patients, leading to more significant anti-inflammatory effect. Ezetimibe 36-45 C-reactive protein Homo sapiens 178-181 21274876-11 2011 CRP and TNFalpha concentrations were independent predictors of abnormal PHES, ammonia and indole of abnormal EEG on multivariate analysis. Phenylalanine 72-76 C-reactive protein Homo sapiens 0-3 21274876-11 2011 CRP and TNFalpha concentrations were independent predictors of abnormal PHES, ammonia and indole of abnormal EEG on multivariate analysis. indole 90-96 C-reactive protein Homo sapiens 0-3 12692010-0 2003 Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. Gemfibrozil 0-11 C-reactive protein Homo sapiens 27-45 27899322-10 2017 CONCLUSIONS: The prophylactic use of ampicillin and/or sulbactam in colorectal ESD is associated with reduced risk of PEECS, decreased CRP levels, and decreased abdominal pain. Ampicillin 37-47 C-reactive protein Homo sapiens 135-138 12351557-0 2002 Effects of tibolone and combined 17beta-estradiol and norethisterone acetate on serum C-reactive protein in healthy post-menopausal women: a randomized trial. Norethindrone Acetate 54-76 C-reactive protein Homo sapiens 86-104 12218140-3 2002 Crystallographic data on CRP-PCh complexes indicate that Phe(66) and Glu(81) contribute to the formation of the PCh binding site of CRP. Phenylalanine 57-60 C-reactive protein Homo sapiens 25-28 12218140-3 2002 Crystallographic data on CRP-PCh complexes indicate that Phe(66) and Glu(81) contribute to the formation of the PCh binding site of CRP. Phenylalanine 57-60 C-reactive protein Homo sapiens 132-135 12218140-4 2002 We used site-directed mutagenesis to analyze the contribution of Phe(66) and Glu(81) to the binding of CRP to PCh, and to generate a CRP mutant that does not bind to PCh-containing ligands. Phenylalanine 65-68 C-reactive protein Homo sapiens 103-106 12218140-10 2002 We conclude that Phe(66) is the major determinant of CRP-PCh interaction and is critical for binding of CRP to PnC. Phenylalanine 17-20 C-reactive protein Homo sapiens 53-56 12218140-10 2002 We conclude that Phe(66) is the major determinant of CRP-PCh interaction and is critical for binding of CRP to PnC. Phenylalanine 17-20 C-reactive protein Homo sapiens 104-107 20609575-4 2010 The CRP was attached to an aldehyde-functionalized DPI sensor chip at a concentration of 50 mug/ml, and attained 2.019 ng/mm2 to form a surface coverage with a 1.71x10(-14) mol/mm2 CRP monolayer. Aldehydes 27-35 C-reactive protein Homo sapiens 4-7 20609575-4 2010 The CRP was attached to an aldehyde-functionalized DPI sensor chip at a concentration of 50 mug/ml, and attained 2.019 ng/mm2 to form a surface coverage with a 1.71x10(-14) mol/mm2 CRP monolayer. Aldehydes 27-35 C-reactive protein Homo sapiens 181-184 20599914-10 2010 Pretreatment with L-165041 attenuated apoptosis induced by hypoxia with or without CRP in H9c2 cardiomyoblasts. 4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid 18-26 C-reactive protein Homo sapiens 83-86 20599914-12 2010 L-165041 attenuated CRP-induced pro-inflammatory signaling through p38MAPK and c-JNK in H9c2 cardiomyoblasts. 4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid 0-8 C-reactive protein Homo sapiens 20-23 20580698-5 2010 Serum alpha-carotene and beta-carotene concentrations were significantly associated with serum C-reactive protein (CRP) concentrations in men. alpha-carotene 6-20 C-reactive protein Homo sapiens 95-113 20580698-5 2010 Serum alpha-carotene and beta-carotene concentrations were significantly associated with serum C-reactive protein (CRP) concentrations in men. alpha-carotene 6-20 C-reactive protein Homo sapiens 115-118 11997273-10 2002 These proatherosclerotic effects of CRP were mediated, in part, via increased secretion of ET-1 and IL-6 (P<0.01) and were attenuated by both bosentan and IL-6 antagonism (P<0.01). Bosentan 145-153 C-reactive protein Homo sapiens 36-39 11997273-13 2002 Bosentan may be useful in decreasing CRP-mediated vascular disease. Bosentan 0-8 C-reactive protein Homo sapiens 37-40 28622279-14 2017 C- reactive protein levels were also significantly raised (p < 0.001) and mirrored the decrease in H2S levels. Hydrogen Sulfide 102-105 C-reactive protein Homo sapiens 0-19 11867823-11 2002 Median C reactive protein (CRP) levels declined in the AZM group from 10 to 5.4 mg/ml but remained constant in the placebo group (p<0.001). Azithromycin 55-58 C-reactive protein Homo sapiens 7-25 11867823-11 2002 Median C reactive protein (CRP) levels declined in the AZM group from 10 to 5.4 mg/ml but remained constant in the placebo group (p<0.001). Azithromycin 55-58 C-reactive protein Homo sapiens 27-30 11867823-13 2002 CONCLUSION: AZM in adults with CF significantly improved QOL, reduced CRP levels and the number of respiratory exacerbations, and reduced the rate of decline in lung function. Azithromycin 12-15 C-reactive protein Homo sapiens 70-73 19816045-8 2010 RESULTS: A significant decrease in red cell membrane thiobarbituric acid reacting substances and an increase in cytosolic superoxide dismutase (SOD) and plasma total antioxidant substances were observed in all patients after 6 months of treatment with BK-P and B-3 membranes except SOD and CRP in patients previously dialysed with triacetate cellulose membranes. bk-p 252-256 C-reactive protein Homo sapiens 290-293 19816045-11 2010 CONCLUSION: BK-P and B-3 HD membranes improved the OAB, beta2mu-globulin and CRP compared to PAN/AN69 and cellulose diacetate membranes. bk-p 12-16 C-reactive protein Homo sapiens 77-80 19631649-1 2009 It was found that C-reactive protein (CRP) could significantly increase the expression and activity of tissue factor (TF), but decrease that of tissue factor pathway inhibitor (TFPI) in human umbilical vein endothelial cells (HUVECs) in dose- and time-dependent manners, which could be antagonized by PDTC and U0126. U 0126 310-315 C-reactive protein Homo sapiens 18-36 11928041-6 2002 RESULTS: CRP levels were significantly higher 1 day after helium insufflation when compared with CO2 insufflation; however, no differences were observed 2 days after surgery. Helium 58-64 C-reactive protein Homo sapiens 9-12 19631649-1 2009 It was found that C-reactive protein (CRP) could significantly increase the expression and activity of tissue factor (TF), but decrease that of tissue factor pathway inhibitor (TFPI) in human umbilical vein endothelial cells (HUVECs) in dose- and time-dependent manners, which could be antagonized by PDTC and U0126. U 0126 310-315 C-reactive protein Homo sapiens 38-41 28242268-8 2017 Circulating Gla17/tOCN levels correlated negatively with insulin sensitivity assessed by hyperinsulinemic-euglyceamic clamp (P=0.02) or insulin sensitivity index derived from oral glucose tolerance test (P=0.00003), and positively with insulin resistance assessed by HOMA-IR (P=0.0005) and with markers of subclinical inflammation and liver enzymes, including C-reactive protein (CRP; P=0.007) and aspartate aminotransferase (AST; P=0.009). tocn 18-22 C-reactive protein Homo sapiens 360-378 28242268-8 2017 Circulating Gla17/tOCN levels correlated negatively with insulin sensitivity assessed by hyperinsulinemic-euglyceamic clamp (P=0.02) or insulin sensitivity index derived from oral glucose tolerance test (P=0.00003), and positively with insulin resistance assessed by HOMA-IR (P=0.0005) and with markers of subclinical inflammation and liver enzymes, including C-reactive protein (CRP; P=0.007) and aspartate aminotransferase (AST; P=0.009). tocn 18-22 C-reactive protein Homo sapiens 380-383 20449933-0 2009 Long-term results of immunosuppressive oral prednisone after coronary angioplasty in non-diabetic patients with elevated C-reactive protein levels. Prednisone 44-54 C-reactive protein Homo sapiens 123-141 11817593-10 2002 After adjustment for serum CRP, the relative risk slightly decreased, but remained significant, for Glc-Gal-PYD (2.6 [95% CI 1.1-6.3]). glc-gal-pyd 100-111 C-reactive protein Homo sapiens 27-30 27714653-14 2017 CONCLUSIONS: CRP and N/L ratio are potential predictors for advanced mCRC treated with FOLFIRI-bev. folfiri-bev 87-98 C-reactive protein Homo sapiens 13-16 11532280-4 2001 The wide distribution of PCh in polysaccharides of pathogens and in cellular membranes allows CRP to recognize a range of pathogenic targets as well as membranes of damaged and necrotic host cells. Polysaccharides 32-47 C-reactive protein Homo sapiens 94-97 11238291-8 2001 The Iatron, Olympus, and Wako methods demonstrated prozone effects at hs-CRP concentrations of 12, 206, and 117 mg/L, respectively. prozone 51-58 C-reactive protein Homo sapiens 73-76 19395785-0 2009 C-reactive protein level following treatment and withdrawal of lovastatin in diabetic nephropathy. Lovastatin 63-73 C-reactive protein Homo sapiens 0-18 19395785-1 2009 INTRODUCTION: We aimed to evaluate the high-sensitivity C-reactive protein (HS-CRP) level changes at the beginning and after withdrawal of lovastatin therapy in patients with diabetic nephropathy. Lovastatin 139-149 C-reactive protein Homo sapiens 56-74 19395785-1 2009 INTRODUCTION: We aimed to evaluate the high-sensitivity C-reactive protein (HS-CRP) level changes at the beginning and after withdrawal of lovastatin therapy in patients with diabetic nephropathy. Lovastatin 139-149 C-reactive protein Homo sapiens 79-82 19395785-8 2009 RESULTS: Serum level of HS-CRP was significantly reduced after 90 days of lovastatin therapy (P < .001). Lovastatin 74-84 C-reactive protein Homo sapiens 27-30 28513744-5 2017 The small organic molecule 2-oxo-1,2-dihydroquinoline-8-carboxylic acid (DQ) was designed based on the structural similarities between three hits from a set of compounds selected from a building block collection and evaluated with regards to affinity for CRP by NMR spectroscopy. 2-oxo-1,2-dihydroquinoline-8-carboxylic acid 27-71 C-reactive protein Homo sapiens 255-258 19395785-9 2009 Then, the HS-CRP reached the pretreatment baseline level on the 7th day after lovastatin withdrawal and maintained until the 30th day (P < .001). Lovastatin 78-88 C-reactive protein Homo sapiens 13-16 19395785-12 2009 CONCLUSIONS: Our findings suggest that lovastatin decreases serum CRP level in patients with diabetic nephropathy, and 7 days after lovastatin cessation, CRP level increases again. Lovastatin 39-49 C-reactive protein Homo sapiens 66-69 19395785-12 2009 CONCLUSIONS: Our findings suggest that lovastatin decreases serum CRP level in patients with diabetic nephropathy, and 7 days after lovastatin cessation, CRP level increases again. Lovastatin 39-49 C-reactive protein Homo sapiens 154-157 11260477-1 2001 Streptococcus pneumoniae is a major human pathogen and many interactions of this bacterium with its host appear to be mediated, directly or indirectly, by components of the bacterial cell wall, specifically by the phosphorylcholine residues which serve as anchors for surface-located choline-binding proteins and are also recognized by components of the host response, such as the human C-reactive protein, a class of myeloma proteins and PAF receptors. Choline 224-231 C-reactive protein Homo sapiens 387-405 27600660-0 2017 Serum levels of magnesium and their relationship with CRP in patients with OSA. Magnesium 16-25 C-reactive protein Homo sapiens 54-57 10914843-8 2000 Among the 824 patients, those taking prednisone were more likely to have had previous DMARD, and at study entry had higher radiographic scores for joint erosion and joint space narrowing and slightly higher swollen joint counts, C-reactive protein values, and rheumatoid factor titers than those not taking prednisone. Prednisone 37-47 C-reactive protein Homo sapiens 229-247 10066748-5 1999 The reduction of the binding constants with increase in KCl concentration indicated the formation of two ion pairs for the cAMP-ligated CRP and S128A complexes and four ion pairs for the cAMP-ligated T127L and CRP* complexes. Potassium Chloride 56-59 C-reactive protein Homo sapiens 136-139 10066748-5 1999 The reduction of the binding constants with increase in KCl concentration indicated the formation of two ion pairs for the cAMP-ligated CRP and S128A complexes and four ion pairs for the cAMP-ligated T127L and CRP* complexes. Potassium Chloride 56-59 C-reactive protein Homo sapiens 210-213 9359864-6 1997 D609, an inhibitor of ceramide production by acidic but not neutral sphingomyelinases, substantially inhibited induction of CRP and SAA by IL-6+IL-1beta. tricyclodecane-9-yl-xanthogenate 0-4 C-reactive protein Homo sapiens 124-127 19410976-3 2009 Therefore, we hypothesized that BDG consumption improves inflammatory markers and insulin sensitivity in overweight and obese subjects with moderately increased levels of C-reactive protein, indicating subclinical inflammation. O(6)-n-butyldeoxyguanosine 32-35 C-reactive protein Homo sapiens 171-189 19571581-9 2009 Lovastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, by modulating the RhoA activation, significantly reduced leptin-induced CRP production. Lovastatin 0-10 C-reactive protein Homo sapiens 140-143 18501785-11 2008 RESULTS: CRP levels increased 10-fold on day 3 after MRI in 87% of MRI studies with Gd-DTPA (+59.3 +/- 57.9 mg/L [P < 0.001] versus -0.9 +/- 3.7 mg/L with gadobutrol versus -0.9 +/- 8.5 mg/L with 0.9% saline). gadobutrol 158-168 C-reactive protein Homo sapiens 9-12 7636267-1 1995 C-Reactive protein (CRP) is an acute phase serum protein in man that binds to certain bacterial polysaccharides and to components exposed on damaged cells. Polysaccharides 96-111 C-reactive protein Homo sapiens 0-18 28540883-0 2017 The relationship between serum homocysteine and highly sensitive C- reactive protein levels in children on regular hemodialysis. Homocysteine 31-43 C-reactive protein Homo sapiens 65-84 7636267-1 1995 C-Reactive protein (CRP) is an acute phase serum protein in man that binds to certain bacterial polysaccharides and to components exposed on damaged cells. Polysaccharides 96-111 C-reactive protein Homo sapiens 20-23 18285551-0 2008 Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study. Fenofibrate 102-113 C-reactive protein Homo sapiens 22-40 18285551-0 2008 Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study. Fenofibrate 102-113 C-reactive protein Homo sapiens 42-45 18285551-5 2008 Moreover, among subjects with the metabolic syndrome, fenofibrate induced the greatest reduction in CRP levels for TT subjects of the i178T>A compared with TA and AA subjects (-30 for TT, -19 for TA, and -11% for AA; P = 0.004). Fenofibrate 54-65 C-reactive protein Homo sapiens 100-103 18285551-7 2008 CONCLUSIONS: Our results demonstrate that common genetic variants within the CRP gene affect baseline CRP levels and further modulate CRP response in subjects with the metabolic syndrome treated with fenofibrate. Fenofibrate 200-211 C-reactive protein Homo sapiens 77-80 18285551-7 2008 CONCLUSIONS: Our results demonstrate that common genetic variants within the CRP gene affect baseline CRP levels and further modulate CRP response in subjects with the metabolic syndrome treated with fenofibrate. Fenofibrate 200-211 C-reactive protein Homo sapiens 102-105 18285551-7 2008 CONCLUSIONS: Our results demonstrate that common genetic variants within the CRP gene affect baseline CRP levels and further modulate CRP response in subjects with the metabolic syndrome treated with fenofibrate. Fenofibrate 200-211 C-reactive protein Homo sapiens 102-105 7670778-4 1995 The nitrate serum levels correlated closely with CRP and ESR (r = 0.8, P < 0.001, each). Nitrates 4-11 C-reactive protein Homo sapiens 49-52 28540883-3 2017 The aim of this study was to assess the association between homocysteine (Hcy) and highly sensitive CRP (hsCRP) in cardiovascular risk prediction in children with chronic kidney disease (CKD) on HD. Homocysteine 60-72 C-reactive protein Homo sapiens 100-103 28540883-3 2017 The aim of this study was to assess the association between homocysteine (Hcy) and highly sensitive CRP (hsCRP) in cardiovascular risk prediction in children with chronic kidney disease (CKD) on HD. Homocysteine 74-77 C-reactive protein Homo sapiens 100-103 27524803-7 2017 We found an inverse relationship between 25-OH-D levels and BMI (P = 0.012), fat mass (P = 0.041), metabolic syndrome (P < 0.0001), fasting blood glucose (P = 0.023), homeostasis model assessment for insulin resistance (P = 0.008), waist circumference (P = 0.001), and fasting blood triglycerides (P = 0.002) and C-reactive protein (P = 0.005). 25-oh-d 41-48 C-reactive protein Homo sapiens 316-334 7674236-6 1995 As prednisone was reduced more placebo patients experienced an exacerbation of PMR symptoms, elevation of erythrocyte sedimentation rate and increased serum C-reactive protein. Prednisone 3-13 C-reactive protein Homo sapiens 157-175 18294004-4 2008 The CRP immunosensor was developed by covalently conjugating CRP antibodies with 3-mercaptopropionic acid (MPA) on the 3DOM gold film electrode. 3-Mercaptopropionic Acid 81-105 C-reactive protein Homo sapiens 4-7 18294004-4 2008 The CRP immunosensor was developed by covalently conjugating CRP antibodies with 3-mercaptopropionic acid (MPA) on the 3DOM gold film electrode. 3-Mercaptopropionic Acid 81-105 C-reactive protein Homo sapiens 61-64 18294004-4 2008 The CRP immunosensor was developed by covalently conjugating CRP antibodies with 3-mercaptopropionic acid (MPA) on the 3DOM gold film electrode. 3-Mercaptopropionic Acid 107-110 C-reactive protein Homo sapiens 4-7 7788147-5 1995 We found that CDP571 was well tolerated and caused reductions in markers of disease activity such as erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP): this was confirmed by a reduction in the disease activity score (DAS). CDP 571 14-20 C-reactive protein Homo sapiens 148-166 7788147-5 1995 We found that CDP571 was well tolerated and caused reductions in markers of disease activity such as erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP): this was confirmed by a reduction in the disease activity score (DAS). CDP 571 14-20 C-reactive protein Homo sapiens 168-171 28187400-9 2017 Higher baseline CRP levels were associated lower depression severity (correlation coefficient=-0.63) with bupropion-SSRI combination but not with SSRI monotherapy (correlation coefficient=0.40). Bupropion 106-115 C-reactive protein Homo sapiens 16-19 7788147-8 1995 The effects of 10 mg/kg CDP571 on ESR, CRP, tender joints, pain and symptom relief compared to placebo were statistically significant at weeks 1 or 2. CDP 571 24-30 C-reactive protein Homo sapiens 39-42 8295175-5 1993 In patients with RA the levels of urinary polyamines correlated significantly with the concentrations of serum C-reactive protein (CRP); there was also a statistically significant negative correlation between their urinary polyamine levels and average grip strength in either hand. Polyamines 42-52 C-reactive protein Homo sapiens 111-129 8295175-5 1993 In patients with RA the levels of urinary polyamines correlated significantly with the concentrations of serum C-reactive protein (CRP); there was also a statistically significant negative correlation between their urinary polyamine levels and average grip strength in either hand. Polyamines 42-52 C-reactive protein Homo sapiens 131-134 18176967-8 2008 In addition, the high CRP group showed more cumulative days of prednisone use per year (107 +/- 95 vs 58 +/- 48, P < 0.05), as well as a better response to infliximab (93 % vs 33 %, P = 0.06). Prednisone 63-73 C-reactive protein Homo sapiens 22-25 18605954-0 2008 Can both EDTA and citrate plasma samples be used in measurements of fibrinogen and C-reactive protein concentrations? Citric Acid 18-25 C-reactive protein Homo sapiens 83-101 17942113-12 2007 The pretreatment of cells with NO synthase inhibitor (N-nitro-l-arginine methyl ester [l-NAME]) also prevented CRP-mediated O(2)(-) production further strengthening CRP-mediated eNOS uncoupling. n-nitro-l-arginine methyl ester 54-85 C-reactive protein Homo sapiens 111-114 17942113-12 2007 The pretreatment of cells with NO synthase inhibitor (N-nitro-l-arginine methyl ester [l-NAME]) also prevented CRP-mediated O(2)(-) production further strengthening CRP-mediated eNOS uncoupling. n-nitro-l-arginine methyl ester 54-85 C-reactive protein Homo sapiens 165-168 8295175-5 1993 In patients with RA the levels of urinary polyamines correlated significantly with the concentrations of serum C-reactive protein (CRP); there was also a statistically significant negative correlation between their urinary polyamine levels and average grip strength in either hand. Polyamines 42-51 C-reactive protein Homo sapiens 111-129 8295175-5 1993 In patients with RA the levels of urinary polyamines correlated significantly with the concentrations of serum C-reactive protein (CRP); there was also a statistically significant negative correlation between their urinary polyamine levels and average grip strength in either hand. Polyamines 42-51 C-reactive protein Homo sapiens 131-134 8295175-7 1993 CONCLUSION: Our results confirm our previous report of an increase in the amount of free putrescine in synovial fluids and a significant correlation between the putrescine contents of synovial tissues and the serum CRP concentrations in patients with RA; they also suggest that urinary polyamine levels may be related to the activity and progression of RA, indicating that polyamine may play an important role in RA. Putrescine 161-171 C-reactive protein Homo sapiens 215-218 8295175-7 1993 CONCLUSION: Our results confirm our previous report of an increase in the amount of free putrescine in synovial fluids and a significant correlation between the putrescine contents of synovial tissues and the serum CRP concentrations in patients with RA; they also suggest that urinary polyamine levels may be related to the activity and progression of RA, indicating that polyamine may play an important role in RA. Polyamines 286-295 C-reactive protein Homo sapiens 215-218 8295175-7 1993 CONCLUSION: Our results confirm our previous report of an increase in the amount of free putrescine in synovial fluids and a significant correlation between the putrescine contents of synovial tissues and the serum CRP concentrations in patients with RA; they also suggest that urinary polyamine levels may be related to the activity and progression of RA, indicating that polyamine may play an important role in RA. Polyamines 373-382 C-reactive protein Homo sapiens 215-218 8329706-6 1993 Actinomycin D and cycloheximide blocked CRP-stimulated PCA, suggesting that de novo TF protein synthesis was required. Cycloheximide 18-31 C-reactive protein Homo sapiens 40-43 7685225-5 1993 CRP serum concentration is also reduced by the corticosteroids such as prednisone, but addition of pulse therapy with i.v. Prednisone 71-81 C-reactive protein Homo sapiens 0-3 28187400-11 2017 The estimated remission rate with CRP threshold based assignment (SSRI monotherapy for <1mg/L and Bupropion-SSRI for >=1mg/L) was 53.1%, with a number needed to treat of 8.6. Bupropion 101-110 C-reactive protein Homo sapiens 34-37 26953894-11 2017 In this study population, the trajectories of both ESR and CRP during 12 months follow-up suggest a predictive role of both inflammatory markers when monitoring treatment of DFO. dfo 174-177 C-reactive protein Homo sapiens 59-62 8368064-7 1993 The combination of two parameters, white blood cell count and C-reactive protein, can be applied to early identify Kawasaki patients at high or low risk of CAA. caa 156-159 C-reactive protein Homo sapiens 62-80 1624792-4 1992 Using purified human CRP it could be shown that CRP immobilized onto polystyrene surfaces or onto latex beads binds distinct plasma glycoproteins including IgG, asialofetuin, asialo-beta 2-glycoprotein I and, likewise, synthetic glycoproteins as a lectin, exhibiting binding specificity for terminal galactosyl residues of the glycoprotein glycans. Polysaccharides 340-347 C-reactive protein Homo sapiens 48-51 28545353-0 2017 Effect of Magnesium Supplementation on Plasma C-reactive Protein Concentrations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Magnesium 10-19 C-reactive protein Homo sapiens 46-64 34687739-11 2022 Lack of SCFA and L-isoleucine biosynthesis significantly correlated with disease severity and increased plasma concentrations of CXCL-10, NT-proBNP, C-reactive protein (CRP) (all P < .05). Isoleucine 17-29 C-reactive protein Homo sapiens 149-167 34687739-11 2022 Lack of SCFA and L-isoleucine biosynthesis significantly correlated with disease severity and increased plasma concentrations of CXCL-10, NT-proBNP, C-reactive protein (CRP) (all P < .05). Isoleucine 17-29 C-reactive protein Homo sapiens 169-172 34371361-7 2022 We found urinary CEMA+3-HPMA ( acrolein) was significantly associated with higher levels of serum triglycerides (TG), hs-CRP, and lower levels of high-density lipoprotein cholesterol (HDL-C). Acrolein 31-39 C-reactive protein Homo sapiens 121-124 34371361-11 2022 In conclusion, acrolein exposure is associated with the levels of serum TG, HDL-C, and hs-CRP. Acrolein 15-23 C-reactive protein Homo sapiens 90-93 34371361-12 2022 Hs-CRP may mediate acrolein-associated alterations of blood lipids. Acrolein 19-27 C-reactive protein Homo sapiens 3-6 28545353-2 2017 OBJECTIVE: A systematic review and meta-analysis of randomized controlled trials (RCTs) were performed to evaluating the effect of oral magnesium supplementation on plasma C-reactive protein (CRP) concentrations. Magnesium 136-145 C-reactive protein Homo sapiens 172-190 28545353-2 2017 OBJECTIVE: A systematic review and meta-analysis of randomized controlled trials (RCTs) were performed to evaluating the effect of oral magnesium supplementation on plasma C-reactive protein (CRP) concentrations. Magnesium 136-145 C-reactive protein Homo sapiens 192-195 28545353-3 2017 METHOD: PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases were searched (from inception to August 09, 2016) to identify RCTs, evaluating the effect of magnesium on CRP levels. Magnesium 169-178 C-reactive protein Homo sapiens 182-185 28545353-6 2017 RESULTS: Overall, the impact of magnesium supplementation on plasma concentrations of CRP was assessed in 11 studies. Magnesium 32-41 C-reactive protein Homo sapiens 86-89 34889102-7 2021 Prior ACEi/ARB use was associated with lower levels of soluble urokinase plasminogen activator receptor and C-reactive protein. acei 6-10 C-reactive protein Homo sapiens 108-126 28545353-10 2017 CONCLUSION: Results of the present meta-analysis indicated that magnesium supplementation reduces CRP levels among individuals with inflammation (CRP levels > 3 mg/dL). Magnesium 64-73 C-reactive protein Homo sapiens 98-101 28545353-10 2017 CONCLUSION: Results of the present meta-analysis indicated that magnesium supplementation reduces CRP levels among individuals with inflammation (CRP levels > 3 mg/dL). Magnesium 64-73 C-reactive protein Homo sapiens 146-149 29056769-10 2017 At baseline higher levels of CRP and ESR were observed in patients with relapse of the disease at the end of treatment and with LDA shorter than 6 months. lda 128-131 C-reactive protein Homo sapiens 29-40 34363189-7 2021 Clarithromycin use was associated with decreases in circulating C-reactive protein, tumour necrosis factor-alpha and interleukin (IL)-6; by increase of production of interferon-gamma and decrease of production of interleukin-6 by mononuclear cells; and by suppression of SARS-CoV-2 viral load. Clarithromycin 0-14 C-reactive protein Homo sapiens 64-82 27760401-8 2016 Multivariable logistic regression analysis including age, sex, vascular risk factors, serum C-reactive protein, estimated glomerular filtration rate and homocysteine tertile disclosed that the highest serum homocysteine tertile was an independent predictor of advanced cerebral artery calcification (odds ratio = 1.45, confidence interval = 1.02-2.05) and advanced cerebral atherosclerosis (odds ratio = 1.42, confidence interval = 1.01-1.99) compared to the lowest group. Homocysteine 207-219 C-reactive protein Homo sapiens 92-110 34708886-7 2021 RESULTS: In total, six studies were included, of which four reported c-reactive protein (CRP) standardized mean reductions in the colchicine group (N = 165) as opposed to the control (N = 252; SMD = -0.49, p < 0.001). Colchicine 130-140 C-reactive protein Homo sapiens 69-87 34708886-7 2021 RESULTS: In total, six studies were included, of which four reported c-reactive protein (CRP) standardized mean reductions in the colchicine group (N = 165) as opposed to the control (N = 252; SMD = -0.49, p < 0.001). Colchicine 130-140 C-reactive protein Homo sapiens 89-92 34912764-8 2021 In comparison to the FMF patients according to colchicine response, colchicine resistance patients had a significantly higher median (IQR) endocan levels than colchicine responsive patients (36.98 ng/ml (97.41) vs. 13.57 ng/ml (27.87), p = 0.007), but there were no differences between in terms of median ESR and CRP levels. Colchicine 68-78 C-reactive protein Homo sapiens 313-316 28243294-0 2016 Randomized Trial of the Effect of Magnesium Sulfate Continuous Infusion on IL-6 and CRP Serum Levels Following Abdominal Aortic Aneurysm Surgery. Magnesium Sulfate 34-51 C-reactive protein Homo sapiens 84-87 34825958-9 2022 Age and phosphate were directly, while BMI, plasma lipid concentrations, and CRP were inversely associated with circulating boron. Boron 124-129 C-reactive protein Homo sapiens 77-80 27721228-0 2016 A Randomized Clinical Trial of the Effect of Pentoxifylline on C-Reactive Protein Level and Dialysis Adequacy in End-stage Renal Disease Patients on Maintenance Hemodialysis. Pentoxifylline 45-59 C-reactive protein Homo sapiens 63-81 34684536-14 2021 The number of circulating leukocytes and neutrophils, and the level of hs-C-Reactive Protein also decreased after 3 months of the meat-, lactose-, and gluten-free diet. Lactose 137-144 C-reactive protein Homo sapiens 74-92 27721228-3 2016 This study evaluated the effect of pentoxifylline on serum CRP level and KT/V in end-stage renal disease patients on maintenance hemodialysis. Pentoxifylline 35-49 C-reactive protein Homo sapiens 59-62 27721228-4 2016 MATERIAL AND METHODS: This 1-month randomized, double-blind, placebo-controlled clinical trial involving 73 patients with end-stage renal disease on maintenance hemodialysis assessed the effectiveness of 400 mg/d of pentoxifylline on serum CRP level decrease and improvement of dialysis adequacy. Pentoxifylline 216-230 C-reactive protein Homo sapiens 240-243 27721228-5 2016 RESULTS: The difference in mean serum CRP levels of the pentoxifylline and placebo groups was not significant before study. Pentoxifylline 56-70 C-reactive protein Homo sapiens 38-41 34629871-8 2021 The values of some markers of inflammation (CRP and fibrinogen) were significantly lower in SCZ patients. SCZ 92-95 C-reactive protein Homo sapiens 44-47 27721228-8 2016 CONCLUSIONS: Among patients on maintenance hemodialysis, a 1-month trial of pentoxifylline was associated with a substantial improvement of adequacy of dialysis and a significant prevention from serum CRP level increase, but not a significant reduction in the mean serum CRP level. Pentoxifylline 76-90 C-reactive protein Homo sapiens 201-204 27721228-8 2016 CONCLUSIONS: Among patients on maintenance hemodialysis, a 1-month trial of pentoxifylline was associated with a substantial improvement of adequacy of dialysis and a significant prevention from serum CRP level increase, but not a significant reduction in the mean serum CRP level. Pentoxifylline 76-90 C-reactive protein Homo sapiens 271-274 27703781-5 2016 Physical symptoms and CRP elevation resolved shortly after clozapine cessation. Clozapine 59-68 C-reactive protein Homo sapiens 22-25 34302591-8 2021 Venlafaxine also significantly declined the rheumatoid factor (p < 0.01) and C-reactive protein (p < 0.05) levels and increased the RBC count (p < 0.01) and Hb value (p < 0.001). Venlafaxine Hydrochloride 0-11 C-reactive protein Homo sapiens 77-95 27022050-0 2016 Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". Ezetimibe 178-187 C-reactive protein Homo sapiens 116-134 27020868-2 2016 The aim of the study was to investigate serum neopterin and PCT levels with WBC (white blood cell) and CRP (C-reactive protein) levels in patient group (PG) and healthy control group (HCG) and to investigate the relationship of these markers with burn wound infections (BWI). Neopterin 46-55 C-reactive protein Homo sapiens 103-106 22477298-7 2007 A positive correlation between 11-dehydro-TXB(2) and CRP was found in the study population (r(s)=0.63, P<0.001). 11-dehydro-txb 31-45 C-reactive protein Homo sapiens 53-56 22477298-8 2007 Using logistic regression analysis, CRP was the only independent correlate of 11-dehydro-TXB(2) (beta(CRP)=11.9, P<0.01), whereas only the presence of PAOD was an independent predictor of high PMA levels (beta(PAOD)=13.7, P=0.001). 11-dehydro-txb 78-92 C-reactive protein Homo sapiens 36-39 22477298-8 2007 Using logistic regression analysis, CRP was the only independent correlate of 11-dehydro-TXB(2) (beta(CRP)=11.9, P<0.01), whereas only the presence of PAOD was an independent predictor of high PMA levels (beta(PAOD)=13.7, P=0.001). 11-dehydro-txb 78-92 C-reactive protein Homo sapiens 102-105 17580953-1 2007 A new label-free array system using amide-linked (AL) NHS-dextran and a spectral SPR biosensor are presented for the high-throughput analysis of C-reactive protein (CRP) in human sera. (al) nhs-dextran 49-65 C-reactive protein Homo sapiens 145-163 17580953-1 2007 A new label-free array system using amide-linked (AL) NHS-dextran and a spectral SPR biosensor are presented for the high-throughput analysis of C-reactive protein (CRP) in human sera. (al) nhs-dextran 49-65 C-reactive protein Homo sapiens 165-168 17488302-3 2007 An elevated CRP was defined as >0.5 mg/dL. Aminoglutethimide 28-34 C-reactive protein Homo sapiens 12-15 17633905-7 2007 Other lipid-lowering agents reported to reduce CRP include niacin, fibrates, and gemfibrozil. Gemfibrozil 81-92 C-reactive protein Homo sapiens 47-50 17603261-2 2007 Laboratory examination revealed a high level of C-reactive protein and an elevated erythrocyte sedimentation rate, as well as hypergammaglobulinemia, and 18F-FDG-PET revealed an accumulation of 18 fluorodeoxyglucose in the great vessels. Fluorodeoxyglucose F18 197-215 C-reactive protein Homo sapiens 48-66 17518172-0 2007 [Stress response under continuous infusion of remifentanil compared to bolus doses of fentanyl assessed by levels of cytokines, C-reactive protein, and cortisol during and after abdominal hysterectomy]. Remifentanil 46-58 C-reactive protein Homo sapiens 128-146 17207028-11 2007 Moreover, maximum C-reactive protein values also appeared to be lower in the azithromycin group than in the no-treatment group and the cefcapene group. Azithromycin 77-89 C-reactive protein Homo sapiens 18-36 16990410-4 2006 RESULTS: Patients receiving micronized fenofibrate for 24 months in addition to antihypertensive treatment had decreased concentrations of total cholesterol, LDL-cholesterol, triglyceride, apolipoprotein B100, oxidized LDL, high-sensitivity C-reactive protein, P-selectin, and cytokines. Fenofibrate 39-50 C-reactive protein Homo sapiens 241-259 34420187-0 2021 Colchicine effectively attenuates inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) in patients with non-ST-segment elevation myocardial infarction: a randomised, double-blind, placebo-controlled clinical trial. Colchicine 0-10 C-reactive protein Homo sapiens 74-92 27020868-2 2016 The aim of the study was to investigate serum neopterin and PCT levels with WBC (white blood cell) and CRP (C-reactive protein) levels in patient group (PG) and healthy control group (HCG) and to investigate the relationship of these markers with burn wound infections (BWI). Neopterin 46-55 C-reactive protein Homo sapiens 108-126 34420187-0 2021 Colchicine effectively attenuates inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) in patients with non-ST-segment elevation myocardial infarction: a randomised, double-blind, placebo-controlled clinical trial. Colchicine 0-10 C-reactive protein Homo sapiens 97-100 34420187-4 2021 The present study aimed to evaluate the effects of colchicine, as an anti-inflammatory drug, on hs-CRP levels in NSTEMI patients. Colchicine 51-61 C-reactive protein Homo sapiens 99-102 34420187-8 2021 Our results revealed that, in both colchicine and placebo groups, hs-CRP levels were significantly mitigated in NSTEMI patients compared to baseline (P < 0.001). Colchicine 35-45 C-reactive protein Homo sapiens 69-72 34420187-9 2021 However, the decreasing properties of colchicine on hs-CRP levels were remarkably stronger than placebo following the 30 days of treatment (P < 0.001). Colchicine 38-48 C-reactive protein Homo sapiens 55-58 34650548-8 2021 These findings suggest increased glycolysis, perturbation in the citrate cycle, oxidative stress, protein catabolism and increased urea cycle activity are key characteristics of newly presenting RA patients with elevated CRP. Citric Acid 65-72 C-reactive protein Homo sapiens 221-224 16622651-11 2006 DISCUSSION: In contrast to the non-survivors, we observed a significant decrease in the C-reactive protein levels shortly after initiation of the GTX treatment in the surviving patients. hexylglutathione 146-149 C-reactive protein Homo sapiens 88-106 16837886-12 2006 Oral E(2) (P = 0.04) and E(2) with NETA (P < 0.01) increased C-reactive protein (CRP). Norethindrone Acetate 35-39 C-reactive protein Homo sapiens 64-82 16837886-12 2006 Oral E(2) (P = 0.04) and E(2) with NETA (P < 0.01) increased C-reactive protein (CRP). Norethindrone Acetate 35-39 C-reactive protein Homo sapiens 84-87 16837886-14 2006 The addition of NETA influenced the change in CRP, as the increase in CRP was more pronounced after E(2) without NETA (P = 0.005). Norethindrone Acetate 16-20 C-reactive protein Homo sapiens 46-49 34712084-2 2021 In this study, we aimed to investigate the relationship of EFTT with CRP and NLR in patients with MS over 65 years. eftt 59-63 C-reactive protein Homo sapiens 69-72 16837886-14 2006 The addition of NETA influenced the change in CRP, as the increase in CRP was more pronounced after E(2) without NETA (P = 0.005). Norethindrone Acetate 16-20 C-reactive protein Homo sapiens 70-73 26523504-0 2016 Label-free and direct detection of C-reactive protein using reduced graphene oxide-nanoparticle hybrid impedimetric sensor. graphene oxide 68-82 C-reactive protein Homo sapiens 35-53 34302132-6 2021 RESULTS: Median C-reactive protein level was 10.8 mg/dL in the vitamin D3 group and 10.6 mg/dL in the control group (p = 0.465). Cholecalciferol 63-73 C-reactive protein Homo sapiens 16-34 26288012-0 2016 Dietary Magnesium Is Positively Associated With Skeletal Muscle Power and Indices of Muscle Mass and May Attenuate the Association Between Circulating C-Reactive Protein and Muscle Mass in Women. Magnesium 8-17 C-reactive protein Homo sapiens 151-169 34174557-11 2021 For males, higher maternal choline competed with the negative association of maternal CRP on Processing Speed. Choline 27-34 C-reactive protein Homo sapiens 86-89 34350496-2 2022 In this study, we constructed a surface-enhanced Raman spectroscopy (SERS) biosensor composed of a multifunctional DNA three-way junction (DNA 3WJ), porous gold nanoplates (pAuNPs), and an Au-Te nanoworm structure for detection of CRP. Gold 189-191 C-reactive protein Homo sapiens 231-234 16875159-7 2006 The micronized fenofibrate caused a significant decrease in serum total cholesterol (by 15%), TG (by 38%), CRP (by 35%), fibrinogen (by 26%) and TBARS (by 33%) concentrations associated with a increase in CAT (by 35%), GSH-Px (by 63%), SOD (by 31%) activities. Fenofibrate 15-26 C-reactive protein Homo sapiens 107-110 16635056-2 2006 Polyarthralgia improved with a reduction in serum C-reactive protein concentration soon after the start of edaravone administration. Edaravone 107-116 C-reactive protein Homo sapiens 50-68 26288012-10 2016 We also found that higher hs-CRP was negatively associated with skeletal muscle mass and, in statistical modeling, that a higher dietary Mg attenuated this negative relationship by 6.5%, with greater attenuation in women older than 50 years. Magnesium 137-139 C-reactive protein Homo sapiens 29-32 25976322-7 2016 CTQ+ patients also exhibited increased baseline expression of gene transcripts related to inflammatory signaling, and baseline inflammatory markers including c-reactive protein, interleukin (IL)-6, and IL-1 receptor antagonist were positively correlated with depression, fatigue, and stress scores in CTQ+ but not CTQ- patients. ctq+ 0-4 C-reactive protein Homo sapiens 158-176 15905085-4 2006 Binding of CRP to Fab"-fragment/polymer layers produced in phosphate buffered saline decreased with NaCl salt concentration. nacl salt 100-109 C-reactive protein Homo sapiens 11-14 34344464-9 2021 RESULTS: We found that the plasma of patients with very high risk, aggressive PCa and high level of C-reactive protein have a peculiar metabolic phenotype (metabotype) characterized by extremely high levels of GlycA and GlycB. glycb 220-225 C-reactive protein Homo sapiens 100-118 26458724-8 2015 Although CRP elevation (P = 0.001) and postoperative complication occurrence (P = 0.045) was each significantly associated with RFS in the univariate analysis, multivariate analysis identified CRP elevation (P = 0.017) but not complication occurrence (P = 0.682) as an independent prognostic factor. Br-paroxetine 128-131 C-reactive protein Homo sapiens 9-12 34126229-10 2021 Summarizing earlier studies, we demonstrated that circulating concentrations of inflammatory cytokines such as CRP, TNF-alpha, and IL-6 might be decreased following vitamin D supplementation among individuals with AGH. agh 214-217 C-reactive protein Homo sapiens 111-114 16856769-1 2006 Effects of coffee and caffeine on cholesterol, fibrinogen and C-reactive protein. Caffeine 22-30 C-reactive protein Homo sapiens 62-80 16856769-7 2006 The literature indicates a strong relationship between boiled, unfiltered coffee consumption and elevated cholesterol levels; however, there is a critical gap in the literature regarding the effects of coffee or caffeine consumption on fibrinogen or CRP, which is an independent predictor of CVD risk. Caffeine 212-220 C-reactive protein Homo sapiens 250-253 26436683-7 2015 RESULTS: In comparison with the SIA, the reductions in CRP (P=0.003) and leptin (p<0.001) were larger in the DCIA at 6 weeks. DCIA 112-116 C-reactive protein Homo sapiens 55-58 16092057-14 2005 C-reactive protein was significantly reduced in all treatment groups, with the atorvastatin and combination groups having the greatest reduction (65% and 68%, respectively, P < .01 vs the fenofibrate group, 44%). Fenofibrate 191-202 C-reactive protein Homo sapiens 0-18 34326122-3 2021 Experimental use of colchicine resulted in an 85% decrease in C reactive protein levels 3 days after treatment initiation and a 182.6% decrease in interleukin-6 levels 8 days after treatment initiation. Colchicine 20-30 C-reactive protein Homo sapiens 62-80 26092924-4 2015 PBP cases had either WHO defined radiographically confirmed pneumonia or "other infiltrate" on chest radiograph with C-reactive protein >= 40 mg/L. Monobenzone 0-3 C-reactive protein Homo sapiens 117-135 34922399-11 2021 Univariate analysis showed that the age of onset of symptoms, age of diagnosis, chronic arthritis, myalgia and diarrhea during attacks, and the number of attacks, high ISSF and Pras score, high C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) values under colchicine treatment were risk factors for colchicine-resistant FMF. Colchicine 316-326 C-reactive protein Homo sapiens 214-217 16092057-18 2005 Atorvastatin and combination treatment were more effective than fenofibrate alone in reducing CRP levels. Fenofibrate 64-75 C-reactive protein Homo sapiens 94-97 15829266-2 2005 These altered phospholipids include lysophosphotidylcholine (LPC) that is a ligand for CRP and is also antigenic for natural IgM antibodies. lpc 61-64 C-reactive protein Homo sapiens 87-90 15648000-6 2005 In a pilot study, we provided preliminary evidence that treatment with L-carnitine, 20 mg/kg 3 times weekly at the end of each hemodialysis treatment, was associated with a reduction in serum CRP levels and improvement in anabolic status. Carnitine 71-82 C-reactive protein Homo sapiens 192-195 15527680-5 2004 Azathioprine and 6-mercaptopurine remain efficient beyond 4 years in patients with relapses and elevated C-reactive protein in spite of this therapy. Mercaptopurine 17-33 C-reactive protein Homo sapiens 105-123 15333733-3 2004 In a fully adjusted, multiple linear regression model, lower serum lutein + zeaxanthin was significantly associated with smoking, heavy drinking, being white, female, or not being physically active, having lower dietary lutein + zeaxanthin, higher fat-free mass, a higher percentage of fat mass, a higher waist-hip ratio, lower serum cholesterol, a higher white blood cell count, and high levels of C-reactive protein (P < 0.05). Zeaxanthins 76-86 C-reactive protein Homo sapiens 399-417 34245511-8 2021 The factors that make a statistically significant contribution to the development of AU in patients with COPD were the frequency of exacerbations over the previous 12 months, ICP, fibrinogen and CRP levels, FEV1; in BA patients - WHR, ICP. Gold 85-87 C-reactive protein Homo sapiens 195-198 34104331-9 2021 A higher DCI was significantly associated with the higher hs-CRP levels (odds ratio (OR) = 1.36, 95% confidence interval (CI) = (0.9-1.8)). dci 9-12 C-reactive protein Homo sapiens 61-64 34104331-12 2021 The chronotype diminished the hs-CRP predicted by the DCI. dci 54-57 C-reactive protein Homo sapiens 33-36 26690891-11 2015 CONCLUSIONS: Results from this study suggested that Hcy concentration was increased in RA patients and associated with RA-related immunological-inflammatory and metabolic laboratory markers, including folate, vitamin B12, CRP, CysC, C3, C4. Homocysteine 52-55 C-reactive protein Homo sapiens 222-225 34527114-11 2020 Plasma level of C-reactive protein (CRP) was significantly decreased in AZT group as well. Azithromycin 72-75 C-reactive protein Homo sapiens 16-34 34527114-11 2020 Plasma level of C-reactive protein (CRP) was significantly decreased in AZT group as well. Azithromycin 72-75 C-reactive protein Homo sapiens 36-39 15142951-7 2004 Collagen or CRP-stimulated 12-H(P)ETE generation was inhibited by staurosporine, PP2, wortmannin, BAPTA/AM, EGTA, and L-655238, implicating src-tyrosine kinases, PI3-kinase, Ca2+ mobilization, and p12-LOX translocation. 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid 98-103 C-reactive protein Homo sapiens 12-15 26256914-2 2015 The study aims to evaluate amylase concentration of drainage fluid (d-AMY) and serum C-reactive protein (CRP) as the predictive factors related to PF amounting to Clavien-Dindo (CD) grade III. clavien-dindo 163-176 C-reactive protein Homo sapiens 105-108 35623869-11 2022 l-Carnitine supplementation significantly reduced the levels of CRP (mean change +- SE: -34.9 +- 6.5) and IL-6 (mean change +- SE: -10.64 +- 2.16) compared to the baseline, which is both statistically significant compared with the control group (p < 0.05). Carnitine 0-11 C-reactive protein Homo sapiens 64-67 15187573-7 2004 The percent magnitude of change in CRP concentrations favored quinapril at all time points, starting 12 h after treatment initiation. Quinapril 62-71 C-reactive protein Homo sapiens 35-38 25970116-8 2015 PTX therapy was associated with significant reduction of serum tumor necrosis factor-alpha and C-reactive protein concentrations. Pentoxifylline 0-3 C-reactive protein Homo sapiens 95-113 15187573-8 2004 When characterizing CRP production during treatments, the time courses were significantly different and demonstrated lower CRP concentrations with quinapril (p = 0.0107). Quinapril 147-156 C-reactive protein Homo sapiens 20-23 15187573-8 2004 When characterizing CRP production during treatments, the time courses were significantly different and demonstrated lower CRP concentrations with quinapril (p = 0.0107). Quinapril 147-156 C-reactive protein Homo sapiens 123-126 14718755-5 2004 A negative correlation existed between cord serum CRP and umbilical artery pH and pO2. PO-2 82-85 C-reactive protein Homo sapiens 50-53 14625121-7 2003 RESULTS: Median CRP concentrations were significantly higher in women receiving oral 17beta-E2 + NETA (P = 0.037) and CEE + MPA (P = 0.0001) for 3 months than in women taking the same types of HRT for 12 months and of those were not on HRT. Norethindrone Acetate 97-101 C-reactive protein Homo sapiens 16-19 35618852-3 2022 The objective of this study was to investigate the relationship between easily assessable findings (hyperventilation, fever, white blood cell count (WBC), and C-reactive protein (CRP)) and the occurrence of DCI and unfavorable neurological outcome at discharge in aSAH patients. dci 207-210 C-reactive protein Homo sapiens 159-177 35618852-3 2022 The objective of this study was to investigate the relationship between easily assessable findings (hyperventilation, fever, white blood cell count (WBC), and C-reactive protein (CRP)) and the occurrence of DCI and unfavorable neurological outcome at discharge in aSAH patients. dci 207-210 C-reactive protein Homo sapiens 179-182 35175945-3 2022 In this case, a 65-year-old man with BNT162b2 mRNA COVID-19 vaccination underwent 18F-FDG PET/CT to evaluate prolonged fever and elevated serum C-reactive protein. Fluorodeoxyglucose F18 82-89 C-reactive protein Homo sapiens 144-162 25636121-10 2015 Elevated CRP at diagnosis was associated with a higher risk of progression to surgery in patients with CD (P < 0.0001) and the need for azathioprine in the overall PIBD cohort (P = 0.002). Azathioprine 139-151 C-reactive protein Homo sapiens 9-12 35152124-5 2022 RESULTS: In the algorithm we created, the most important parameter in the distinction between CAA and NCAA is CRP. caa 94-97 C-reactive protein Homo sapiens 110-113 14602060-7 2003 CDP571 is not effective in unselected patients with active Crohn"s disease, but it may be effective in patients with elevated C-reactive protein. CDP 571 0-6 C-reactive protein Homo sapiens 126-144 25904961-7 2015 Before adjusting for age and BMI, CRP was correlated with LDL (r= 0.16, p= 0.03), total cholesterol (TC) (r= 0.17, p= 0. Technetium 101-103 C-reactive protein Homo sapiens 34-37 12927682-10 2003 CONCLUSIONS: In acute inflammation and poorly controlled diabetes, CRP is suggested to be inversely associated with serum HDL-C, independent of PG and TP. pg 144-146 C-reactive protein Homo sapiens 67-70 12947436-5 2003 RESULTS: C-reactive protein concentration (dichotomized at the sex-specific 85th percentile) was inversely and significantly associated with concentrations of retinol, retinyl esters, vitamin C, alpha-carotene, beta-carotene, cryptoxanthin, lutein/zeaxanthin, lycopene, and selenium after adjustment for age, sex, race or ethnicity, education, cotinine concentration, body mass index, leisure-time physical activity, and aspirin use. Zeaxanthins 248-258 C-reactive protein Homo sapiens 9-27 35381435-5 2022 I-CRP-treated human NK cells exhibited an increased degranulation activity against K562 target cells, as shown by CD107a assay, and this correlates with cytotoxicity against K562 cells observed in calcein release assay. fluorexon 197-204 C-reactive protein Homo sapiens 2-5 25263526-5 2015 During the 5 days preceding delivery, median CRP, WBC, and IL-6 levels were significantly higher in the HCA than in no-HCA group (P < 0.001). hca 104-107 C-reactive protein Homo sapiens 45-48 34597384-11 2022 FMDBA correlated with serum testosterone (r=0.45, p<0.001), IL-6 (r=-0.41, P=0.002), and CRP (r=-0.28, P=0.041). fmdba 0-5 C-reactive protein Homo sapiens 89-92 12667961-7 2003 CRP alone was a weak inducer of NO production in VSMC as measured by determining nitrite levels, and interferon-gamma alone was totally ineffective, whereas CRP plus interferon-gamma was a powerful stimulus. Nitrites 81-88 C-reactive protein Homo sapiens 0-3 12524412-4 2003 NO derived nitrite excretion determined from a 24 hour sterile urine collection was correlated with intestinal macromolecular permeability (polyethylene glycol excretion ratio), markers of systemic endotoxin exposure (IgG:IgM endotoxin core antibody (EndoCAb) ratio), disease severity, and the magnitude of systemic inflammation (peak C reactive protein (CRP) and Acute Physiology and Chronic Health Evaluation score II (APACHE-II)). Nitrites 11-18 C-reactive protein Homo sapiens 335-353 12524412-4 2003 NO derived nitrite excretion determined from a 24 hour sterile urine collection was correlated with intestinal macromolecular permeability (polyethylene glycol excretion ratio), markers of systemic endotoxin exposure (IgG:IgM endotoxin core antibody (EndoCAb) ratio), disease severity, and the magnitude of systemic inflammation (peak C reactive protein (CRP) and Acute Physiology and Chronic Health Evaluation score II (APACHE-II)). Nitrites 11-18 C-reactive protein Homo sapiens 355-358 12476646-7 2002 TCFAs are more common in patients with high serum total cholesterol (TC) and a high TC to high density cholesterol ratio, in women > 50 years, and in those patients with elevated levels of high sensitivity C-reactive protein. tcfas 0-5 C-reactive protein Homo sapiens 209-227 12426217-8 2002 Maximum relaxation response to CRP (79.5+/-10%) was attenuated by KCl (2.5+/-11.5%, P<0.001), BaCl (24.5+/-7.5%, P<0.001), and tetraethylammonium chloride (34.9+/-8.25%, P<0.01) but not by glibenclamide. Potassium Chloride 66-69 C-reactive protein Homo sapiens 31-34 25831676-6 2015 However, reverse was true for serum magnesium levels which were significantly higher (p<0.001) in the controls (2.52+-0.18mg/L) as against the cases (1.09+-0.38mg/dl).Serum C-reactive protein-to-magnesium ratio was significantly higher (p<0.001) in smokers than in the non-smokers. Magnesium 36-45 C-reactive protein Homo sapiens 176-194 12426217-8 2002 Maximum relaxation response to CRP (79.5+/-10%) was attenuated by KCl (2.5+/-11.5%, P<0.001), BaCl (24.5+/-7.5%, P<0.001), and tetraethylammonium chloride (34.9+/-8.25%, P<0.01) but not by glibenclamide. Tetraethylammonium 133-160 C-reactive protein Homo sapiens 31-34 16737144-6 2002 The CRP concentration was in the SR group, as compared with the AF group, increased (4.67 mg/l vs. 3.65 mg/l, p = 0.043), similarly as the concentration of IL-8 (12.53 ng/l vs. 8.1 ng/l, p = 0.039). Strontium 33-35 C-reactive protein Homo sapiens 4-7 12566669-6 2002 Plasma 8-iso-PGF(2alpha) concentration was linearly correlated with serum haptoglobin, C-reactive protein (CRP) and plasma MDA (r = 0.58, p = 0.003; r = 0.29, p < 0.05 and r = 0.38, p < 0.05 respectively). 8-iso-pgf 7-16 C-reactive protein Homo sapiens 87-105 12566669-6 2002 Plasma 8-iso-PGF(2alpha) concentration was linearly correlated with serum haptoglobin, C-reactive protein (CRP) and plasma MDA (r = 0.58, p = 0.003; r = 0.29, p < 0.05 and r = 0.38, p < 0.05 respectively). 8-iso-pgf 7-16 C-reactive protein Homo sapiens 107-110 12566669-9 2002 We also found that plasma 8-iso-PGF(2alpha) was casually related to some acute phase reactant proteins such as serum CRP, albumin and haptoglobin. 8-iso-pgf 26-35 C-reactive protein Homo sapiens 117-120 11430324-4 2001 METHODS: The level of C-reactive protein was measured at base line and after one year in 5742 participants in a five-year randomized trial of lovastatin for the primary prevention of acute coronary events. Lovastatin 142-152 C-reactive protein Homo sapiens 22-40 11430324-6 2001 Lovastatin therapy reduced the C-reactive protein level by 14.8 percent (P<0.001), an effect not explained by lovastatin-induced changes in the lipid profile. Lovastatin 0-10 C-reactive protein Homo sapiens 31-49 11430324-8 2001 However, lovastatin was also effective among those with a ratio of total to HDL cholesterol that was lower than the median and a C-reactive protein level higher than the median (number needed to treat, 43; P=0.02). Lovastatin 9-19 C-reactive protein Homo sapiens 129-147 11158409-7 2001 Interestingly, plasma C reactive protein (CRP) levels measured by highly sensitive CRP assay were correlated positively with plasma levels of thiobarbituric acid reactive substances (r=0.38, P<0.04) and negatively with plasma alpha-tocopherol levels (r=-0.46, P<0.01). Thiobarbituric Acid Reactive Substances 142-181 C-reactive protein Homo sapiens 22-40 11158409-7 2001 Interestingly, plasma C reactive protein (CRP) levels measured by highly sensitive CRP assay were correlated positively with plasma levels of thiobarbituric acid reactive substances (r=0.38, P<0.04) and negatively with plasma alpha-tocopherol levels (r=-0.46, P<0.01). Thiobarbituric Acid Reactive Substances 142-181 C-reactive protein Homo sapiens 42-45 11158409-7 2001 Interestingly, plasma C reactive protein (CRP) levels measured by highly sensitive CRP assay were correlated positively with plasma levels of thiobarbituric acid reactive substances (r=0.38, P<0.04) and negatively with plasma alpha-tocopherol levels (r=-0.46, P<0.01). Thiobarbituric Acid Reactive Substances 142-181 C-reactive protein Homo sapiens 83-86 10570224-6 2000 Synthetic oligosaccharides and phospho-oligosaccharides of various lengths and conformations were used to define the structural requirements for CRP recognition. synthetic oligosaccharides 0-26 C-reactive protein Homo sapiens 145-148 10769429-7 2000 The demonstrated drop in 1,25(OH)2D3 (D-hormone) levels in patients with RA in correlation with C-reactive protein (CRP) is of significance in the pathogenesis of RA-induced osteoporosis and could further promote the process of inflammation. Calcitriol 25-36 C-reactive protein Homo sapiens 96-114 10769429-7 2000 The demonstrated drop in 1,25(OH)2D3 (D-hormone) levels in patients with RA in correlation with C-reactive protein (CRP) is of significance in the pathogenesis of RA-induced osteoporosis and could further promote the process of inflammation. Calcitriol 25-36 C-reactive protein Homo sapiens 116-119 10769432-4 2000 The treatment with 1 alpha-hydroxycholecalciferol resulted in an insignificant decrease in the number of swollen and tender joints, morning stiffness, CRP and ESR. alpha-hydroxycholecalciferol 21-49 C-reactive protein Homo sapiens 151-154 24824633-9 2014 Adiponectin levels were higher (P = 0.035) and high-sensitivity C-reactive protein levels were lower (P = 0.038) with vildagliptin vs glimepiride. Vildagliptin 118-130 C-reactive protein Homo sapiens 64-82 24948355-6 2014 Baseline plasma neopterin, KTR and C-reactive protein (CRP) were significantly associated with an increased risk of overall cancer in models adjusted for covariates (P for trend across quartiles = .006 for neopterin, .022 for KTR, and .005 for CRP). Neopterin 206-215 C-reactive protein Homo sapiens 55-58 25443702-10 2014 The association between DHEA and CHD risk remained significant after adjustment for traditional cardiovascular risk factors, serum total testosterone and estradiol, C-reactive protein, and renal function, and remained unchanged after exclusion of the first 2.6 years of follow-up to reduce reverse causality. Dehydroepiandrosterone 24-28 C-reactive protein Homo sapiens 165-183 24375982-7 2014 In postmenopausal women receiving MHT, CRP was positively associated with femoral neck BMD (beta = 0.011, P = 0.04). 4-METHYL-5-THIAZOLEETHANOL 34-37 C-reactive protein Homo sapiens 39-42 10555884-6 1999 A significant decrease of ESR and CRP was observed after 90 days in the AL group, but with no significant variation after 30 days in the AL group, and after both 30 and 90 days in the placebo group. Alendronate 72-74 C-reactive protein Homo sapiens 34-37 10432314-5 1999 The formation of inositol phosphates and phosphatidic acid (PA), two markers of phospholipase C (PLC) activation, by CRP are inhibited by between 50 and 85% in the presence of wortmannin and LY294002. Phosphatidic Acids 41-58 C-reactive protein Homo sapiens 117-120 25035450-8 2014 Stool frequency, C reactive protein and albumin normalised within 48 h of starting oral valgancyclovir. valgancyclovir 88-102 C-reactive protein Homo sapiens 17-35 10432314-5 1999 The formation of inositol phosphates and phosphatidic acid (PA), two markers of phospholipase C (PLC) activation, by CRP are inhibited by between 50 and 85% in the presence of wortmannin and LY294002. Phosphatidic Acids 60-62 C-reactive protein Homo sapiens 117-120 24517733-4 2014 EXPERIMENTAL APPROACH: Effects of CRP on transcytosis of FITC-labelled LDL were examined with human umbilical vein endothelial cells and venous rings in vitro and, in vivo, ApoE(-/-) mice. Fluorescein-5-isothiocyanate 57-61 C-reactive protein Homo sapiens 34-37 9676757-9 1998 Mean urinary pyridinoline and deoxypyridinoline levels correlated strongly with BMD change at all sites, were increased in patients with active disease (p < 0.005), and correlated closely with mean C-reactive protein (CRP) (p < 0.005, r > 0.41 for both). pyridinoline 13-25 C-reactive protein Homo sapiens 201-219 9676757-9 1998 Mean urinary pyridinoline and deoxypyridinoline levels correlated strongly with BMD change at all sites, were increased in patients with active disease (p < 0.005), and correlated closely with mean C-reactive protein (CRP) (p < 0.005, r > 0.41 for both). pyridinoline 13-25 C-reactive protein Homo sapiens 221-224 9380601-4 1997 During haemodialysis using polysulfone membranes CRP from the initial value of 4819.4 +/- 4328.2 ng/ml decreased to 3316.9 +/- 3882.7 ng/ml just after haemodialysis (p < 0.01) and increased to 5086.9 +/- 4193.0 ng/ml 22 hours after haemodialysis (p < 0.05). polysulfone P 1700 27-38 C-reactive protein Homo sapiens 49-52 8906746-1 1996 C-reactive protein (CRP) is an acute phase serum protein that binds to phosphocholine (PC) on phospholipids and polysaccharides and to protein components of chromatin and small nuclear ribonucleoproteins. Polysaccharides 112-127 C-reactive protein Homo sapiens 0-18 8906746-1 1996 C-reactive protein (CRP) is an acute phase serum protein that binds to phosphocholine (PC) on phospholipids and polysaccharides and to protein components of chromatin and small nuclear ribonucleoproteins. Polysaccharides 112-127 C-reactive protein Homo sapiens 20-23 8733437-6 1996 The prednisone dose was decreased as soon as clinical symptoms disappeared and erythrocyte sedimentation rate, C reactive protein level, or both, had normalised. Prednisone 4-14 C-reactive protein Homo sapiens 111-129 24849439-11 2014 CRP, IL-6 and TNF-a levels in group A were increased at Tb and Tc (P<0.05 or P<0.01) and significantly higher than those in groups B and C (P<0.05 or P<0.01). Technetium 63-65 C-reactive protein Homo sapiens 0-3 11854810-22 1995 The data demonstrate that oral prednisone is effective in reducing proteinuria and improving the biological markers of disease activity (i.e., ESR, CRP, C3, C4, and anti-dsDNA) following short-term treatment of active lupus nephritis. Prednisone 31-41 C-reactive protein Homo sapiens 148-151 24518747-0 2014 Dietary magnesium intake is inversely associated with serum C-reactive protein levels: meta-analysis and systematic review. Magnesium 8-17 C-reactive protein Homo sapiens 60-78 7812211-3 1994 Among various clinical and laboratory parameters, PCAP was significantly related to the percentage of bone marrow plasma cells, the neoplastic growth fraction, as determined by Ki67 monoclonal antibody, and to serum levels of C-reactive protein. pcap 50-54 C-reactive protein Homo sapiens 226-244 24518747-1 2014 BACKGROUND/OBJECTIVES: The aim of this study was to quantitatively summarize the association of dietary magnesium (Mg) intake with serum C-reactive protein (CRP) levels in the general population. Magnesium 104-113 C-reactive protein Homo sapiens 137-155 8043897-4 1994 A positive correlation was found between C-reactive protein (CRP), an APR glycoprotein, and non-specific TBA reactivity as determined after borohydride reduction (BH4-resistant TBA, BR-TBA), both in non-diabetics (r = 0.61; P < 0.01) and diabetics (r = 0.68; P < 0.01). br-tba 182-188 C-reactive protein Homo sapiens 61-64 24518747-1 2014 BACKGROUND/OBJECTIVES: The aim of this study was to quantitatively summarize the association of dietary magnesium (Mg) intake with serum C-reactive protein (CRP) levels in the general population. Magnesium 104-113 C-reactive protein Homo sapiens 157-160 1328445-0 1992 C-reactive protein selectively enhances the intracellular generation of reactive oxygen products by IgG-stimulated monocytes and neutrophils. reactive oxygen products 72-96 C-reactive protein Homo sapiens 0-18 24518747-1 2014 BACKGROUND/OBJECTIVES: The aim of this study was to quantitatively summarize the association of dietary magnesium (Mg) intake with serum C-reactive protein (CRP) levels in the general population. Magnesium 115-117 C-reactive protein Homo sapiens 137-155 1328445-12 1992 It is tempting to speculate that CRP can selectively boost the microbicidal activities of monocytes and neutrophils within an inflammatory site by amplifying the intracellular generation of reactive oxygen products without increasing damage to surrounding normal tissues. reactive oxygen products 190-214 C-reactive protein Homo sapiens 33-36 24518747-1 2014 BACKGROUND/OBJECTIVES: The aim of this study was to quantitatively summarize the association of dietary magnesium (Mg) intake with serum C-reactive protein (CRP) levels in the general population. Magnesium 115-117 C-reactive protein Homo sapiens 157-160 24518747-5 2014 Meta-regression was used to determine the linear association of dietary Mg intake and adjusted geometric means of CRP levels. Magnesium 72-74 C-reactive protein Homo sapiens 114-117 24518747-8 2014 A weighted inverse association between Mg intake and serum CRP levels was observed (beta-coefficient: -0.0028; 95% confidence interval (CI), -0.0043 to -0.0013; P(trend) = 0.001) from four cross-sectional studies. Magnesium 39-41 C-reactive protein Homo sapiens 59-62 24518747-10 2014 Qualitative assessment among five intervention studies also showed a potential beneficial effect of Mg intake on serum CRP levels. Magnesium 100-102 C-reactive protein Homo sapiens 119-122 24518747-11 2014 CONCLUSIONS: This meta-analysis and systematic review indicates that dietary Mg intake is significantly and inversely associated with serum CRP levels. Magnesium 77-79 C-reactive protein Homo sapiens 140-143 1613696-2 1992 Putrescine levels in the synovial tissues correlated with serum C reactive protein concentration in patients with RA. Putrescine 0-10 C-reactive protein Homo sapiens 64-82 24959459-8 2014 Fatigue (p = 0.002) and changes in CRP (p=0.001) were significantly lower in MP group. Methylprednisolone 77-79 C-reactive protein Homo sapiens 35-38 1568518-4 1992 In the pefloxacin treatment group all indices except C-reactive protein and severity of pain determined using a visual analogue scale were significantly improved 12 months after treatment. Pefloxacin 7-17 C-reactive protein Homo sapiens 53-71 24587064-11 2014 Serum CRP levels correlated negatively with HDL-C (r = -0.352, P = 0.006) and TC (r = -0.262, P = 0.043). Technetium 78-80 C-reactive protein Homo sapiens 6-9 33813346-9 2021 In contrast, we observed inverse associations of monoethyl phthalate (MEP) (beta = -0.019; 95% CI -0.036, -0.001) and monobenzyl phthalate (MBzP) (beta = -0.034; 95% CI -0.058, -0.010) with CRP levels only after adjustment for BMI. monoethyl phthalate 49-68 C-reactive protein Homo sapiens 190-193 33813346-9 2021 In contrast, we observed inverse associations of monoethyl phthalate (MEP) (beta = -0.019; 95% CI -0.036, -0.001) and monobenzyl phthalate (MBzP) (beta = -0.034; 95% CI -0.058, -0.010) with CRP levels only after adjustment for BMI. monoethyl phthalate 70-73 C-reactive protein Homo sapiens 190-193 34974090-10 2022 Each one-unit increase in the log-transformed level 2-OHFlu (beta = 0.112, 95%CI = 0.018-0.206) and 2&3-OHPh (beta = 0.145, 95%CI = 0.037-0.253) were positively associated with C-reactive protein (CRP) among adolescents, but not among adults. 2-ohflu 52-59 C-reactive protein Homo sapiens 177-195 34974090-10 2022 Each one-unit increase in the log-transformed level 2-OHFlu (beta = 0.112, 95%CI = 0.018-0.206) and 2&3-OHPh (beta = 0.145, 95%CI = 0.037-0.253) were positively associated with C-reactive protein (CRP) among adolescents, but not among adults. 2-ohflu 52-59 C-reactive protein Homo sapiens 197-200 24141169-5 2014 Intraluminal treatment of pressurized arterioles with a pathophysiological level of CRP (7 microg/mL; 60 minutes) attenuated endothelium-dependent nitric oxide-mediated and prostacyclin-mediated dilations to serotonin and arachidonic acid, respectively. Epoprostenol 173-185 C-reactive protein Homo sapiens 84-87 24141169-11 2014 CONCLUSIONS: CRP elicits endothelium-dependent oxidative stress and compromises nitric oxide-mediated and prostacyclin-mediated vasomotor function via LOX-1 activation. Epoprostenol 106-118 C-reactive protein Homo sapiens 13-16 34839601-13 2021 Urea nitrogen level, creatinine level, and CRP value of patients in citrate group were significantly lower than those in heparin group (P<0.05). Citric Acid 68-75 C-reactive protein Homo sapiens 43-46 34607230-8 2021 Besides, in patients, receiving lovastatin the CRP, IL-6, IL-8 levels were significantly decreased from T1 to T3 than to the control group. Lovastatin 32-42 C-reactive protein Homo sapiens 47-50 24238772-11 2014 Although there was no correlation between CRP and baPWV in patients with stable asthma, CRP was positively correlated with baPWV in patients with severe asthma (r = 0.229, p = 0.039). bapwv 123-128 C-reactive protein Homo sapiens 88-91 34740538-10 2022 RESULTS: Although oral L-carnitine supplementation led to the decreased high-sensitivity C-reactive protein, this change was not significant compared with the placebo. Carnitine 23-34 C-reactive protein Homo sapiens 89-107 24231099-11 2013 In Study 2, PQQ supplementation resulted in significant decreases in the levels of plasma C-reactive protein, IL-6 and urinary methylated amines such as trimethylamine N-oxide, and changes in urinary metabolites consistent with enhanced mitochondria-related functions. PQQ Cofactor 12-15 C-reactive protein Homo sapiens 90-108 34460893-7 2021 The downregulation of miR-181b showed a significant association with the white blood cell count, absolute neutrophils, and the C-reactive protein of patients. mir-181b 22-30 C-reactive protein Homo sapiens 127-145 23735372-1 2013 BACKGROUND: We investigated the relationship between C-reactive protein (CRP) and homocysteine on follow-up and subsequent mortality in young ischemic stroke patients in a population-based study. Homocysteine 82-94 C-reactive protein Homo sapiens 53-71 34132891-8 2021 There were positive significant correlations between levels of vitamin D3 and acute-phase reactants in serum, such as C-reactive protein (P = 0.0292). Cholecalciferol 63-73 C-reactive protein Homo sapiens 118-136 23735372-1 2013 BACKGROUND: We investigated the relationship between C-reactive protein (CRP) and homocysteine on follow-up and subsequent mortality in young ischemic stroke patients in a population-based study. Homocysteine 82-94 C-reactive protein Homo sapiens 73-76 23735372-12 2013 CONCLUSIONS: There is an independent association between CRP and homocysteine levels obtained several years after ischemic stroke in young adults and subsequent mortality, even when adjusting for traditional risk factors. Homocysteine 65-77 C-reactive protein Homo sapiens 57-60 23978069-7 2013 Patients over 55 years exhibited a positive correlation between CRP and myo-inositol peak area in the left hippocampus (P < 0.05), while there was no relationship between RAGE and any metabolite (P > 0.05). Inositol 72-84 C-reactive protein Homo sapiens 64-67 34261033-8 2021 In the strongest multiple regression model, CXCL10/IP-10, VEGFA, IFN-gamma, CRP and Factor D/Adipsin explained 52% of the variation in overall maximal FDG uptake. Fluorodeoxyglucose F18 151-154 C-reactive protein Homo sapiens 76-92 23786284-12 2013 Change ( ) in BMI z-score correlated with CRP (r = 0.47, P = 0.012) and exhaled nitric oxide (eNO) (r = 0.46, P = 0.034), and ACQ was associated with CRP (r = 0.43, P = 0.029). acenaphthenequinone 129-132 C-reactive protein Homo sapiens 154-157 34117263-4 2021 We then used linear models to identify DMPs associated with CRP concentrations. Unithiol 39-43 C-reactive protein Homo sapiens 60-63 34117263-8 2021 We subsequently identified 14 novel DMPs associated with CRP. Unithiol 36-40 C-reactive protein Homo sapiens 57-60 23445482-6 2013 METHODS: Human CRP was labeled with fluorescein isothiocyanate (FITC) and human serum albumin (HuSA) was labeled with phycoerythrin (PE) and used for screening. Fluorescein-5-isothiocyanate 64-68 C-reactive protein Homo sapiens 15-18 35018669-7 2022 In multivariate analysis, only CRP minimum level (>=50mg/l) was associated with the contributory status of 18 F-FDG-PET/CT. Fluorodeoxyglucose F18 107-115 C-reactive protein Homo sapiens 31-34 23507424-7 2013 Atorvastatin alone or combined with ezetimibe reduced both LDL-cholesterol and CRP (P<0.002 vs. baseline; Wilcoxon); ezetimibe did not modify CRP. Ezetimibe 36-45 C-reactive protein Homo sapiens 59-82 23507424-7 2013 Atorvastatin alone or combined with ezetimibe reduced both LDL-cholesterol and CRP (P<0.002 vs. baseline; Wilcoxon); ezetimibe did not modify CRP. Ezetimibe 36-45 C-reactive protein Homo sapiens 79-82 23013513-0 2013 Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein. Ezetimibe 27-36 C-reactive protein Homo sapiens 75-93 35495414-6 2022 The results of our study revealed that colchicine has a marginally significant effect on hs-CRP attenuation. Colchicine 39-49 C-reactive protein Homo sapiens 92-95 24021937-9 2013 Losartan reduced Ang II- induced CRP expression in hepatocytes. Losartan 0-8 C-reactive protein Homo sapiens 33-36 23853456-0 2013 The effect of sub-antimicrobial dose-doxycycline periodontal therapy on serum inflammatory biomarker C-reactive protein levels in post-menopausal Women: A 2-year, double-blinded, randomized clinical trial. Doxycycline 37-48 C-reactive protein Homo sapiens 101-119 35381033-10 2022 Colchicine was observed to significantly reduce COVID-19 severity (OR: 0.41, 95% CI (0.22, 0.76); p = 0.005), and CRP levels (WMD: -19.99, 95% CI (-32.09, -7.89); p = 0.001). Colchicine 0-10 C-reactive protein Homo sapiens 114-117 35381033-12 2022 CONCLUSION: Colchicine treatment decreased CRP levels and COVID-19 severity, with dimer levels, all-cause mortality and mechanical ventilation remaining seemingly unaffected. Colchicine 12-22 C-reactive protein Homo sapiens 43-46 23853456-3 2013 AIM: To determine whether sub-antimicrobial dose-doxycycline (SDD) therapy can reduce systemic serum inflammatory biomarker C-reactive protein (CRP) in post-menopausal women who have chronic periodontitis. Doxycycline 49-60 C-reactive protein Homo sapiens 124-142 23197238-9 2012 Plasma CRP values were positively correlated with BMI, AHI, DSI and% of time <90% Sa02 (p<0.05). sa02 85-89 C-reactive protein Homo sapiens 7-10 35357665-0 2022 Amelioration of C-Reactive Protein and Lectin Like Oxidized Low Density Lipoprotein Receptor Complex Induced Endothelial Dysfunction by Oligomeric Proanthocyanidins. Proanthocyanidins 147-164 C-reactive protein Homo sapiens 16-34 35204141-0 2022 Serum Lutein and Zeaxanthin Are Inversely Associated with High-Sensitivity C-Reactive Protein in Non-Smokers: The Mikkabi Study. Zeaxanthins 17-27 C-reactive protein Homo sapiens 75-93 35140620-9 2022 The results of BCA indicated that Gastrodin, Liquiritin, Hesperidin, Isoliquiritin, Hesperetin, and Isoliquiritigenin might be the active constituents to activate ROS and suppress hs-CRP as determined by spectrum-effect relationships. neoisoliquiritin 69-82 C-reactive protein Homo sapiens 183-186 23046186-5 2012 Purified CRP was digested with trypsin and subjected to high-performance LC with an optimal mobile phase of acetonitrile-water containing 0.1% formic acid (50:50, v/v) and an optimal mobile phase flow rate of 0.2 mL/min. acetonitrile 108-120 C-reactive protein Homo sapiens 9-12 22820438-9 2012 CONCLUSION: ADMA levels do not change significantly during anti-TNF therapy, despite the fact that they associate with CRP and DAS28, which are significantly reduced during such treatment in patients with rheumatoid arthritis. N,N-dimethylarginine 12-16 C-reactive protein Homo sapiens 119-122 22966033-9 2012 CRP was highest initially among patients with simultaneous ABO + ABA and among those with complicated outcomes, and was lower at the transition to oral therapy in the complicated outcome group (1.5 vs 2.1 mg/dL; P = .012). alisol B 23-acetate 65-68 C-reactive protein Homo sapiens 0-3 22345157-3 2012 This pilot study tested the hypothesis that TNF-alpha blockade with pentoxifylline lowers PAI-1 and high-sensitivity CRP (hsCRP) in obese individuals. Pentoxifylline 68-82 C-reactive protein Homo sapiens 117-120 22345157-5 2012 A proportional odds model was used to compare the change in PAI-1 and CRP in the pentoxifylline and placebo groups. Pentoxifylline 81-95 C-reactive protein Homo sapiens 70-73 23798918-1 2012 BACKGROUND: This study aimed to investigate whether magnesium supplementation might affect serum magnesium, high sensitive C-reactive protein (hs-CRP), plasma fibrinogen, and interleukin 6 (IL-6) levels in healthy middle-aged overweight women. Magnesium 52-61 C-reactive protein Homo sapiens 123-141 22962225-3 2012 We aimed to compare plasma cortisol (a stress marker) and C-reactive protein (an inflammation marker) as statistical predictors of plasma betaine concentrations. Betaine 138-145 C-reactive protein Homo sapiens 58-76 22371409-5 2012 BP reduction was associated with a decrease in CRP concentration. Benzo(a)pyrene 0-2 C-reactive protein Homo sapiens 47-50 21970819-7 2012 LOD for 3-NT, T4, and CRP were 0.5mug/mL, 23nM, and 5mug/mL, respectively thus demonstrating the ability of the CTI to detect proteins and small molecules within clinical reference ranges. titanium carbide 112-115 C-reactive protein Homo sapiens 22-25 22907037-9 2012 Potentially promising avenues include the combination of magnesium with a statin to reduce cholesterol, C-reactive protein and CIMT, and its early use to reduce stroke morbidity and mortality. Magnesium 57-66 C-reactive protein Homo sapiens 104-122 22461977-0 2012 Elevated serum C-reactive protein relates to increased cerebral myoinositol levels in middle-aged adults. Inositol 64-75 C-reactive protein Homo sapiens 15-33 22461977-5 2012 Independent of age, sex and education, serum CRP was significantly related to higher cerebral myo-inositol/creatine ratio (F(4,31) = 4.74, P = 0.004), a relationship which remained unchanged after adjustment for cardiovascular risk (F(5,30) = 4.356, CRP beta = 0.322, P = 0.045). Inositol 94-106 C-reactive protein Homo sapiens 45-48 21977068-9 2011 At 4 weeks, the pulmonary functions significantly improved in doxycycline group and the mean reduction in baseline serum CRP was significantly greater in doxycycline group as compared with reference group. Doxycycline 154-165 C-reactive protein Homo sapiens 121-124 21640381-5 2011 In HepG2 cells, ER stress triggered by tunicamycin, thapsigargin and homocysteine markedly induced CRP expression and the activation of protein kinase R-like endoplasmic reticulum kinase (PERK), inositol-requiring transmembrane kinase/endonuclease 1alpha (IRE1alpha), activating transcription factor 6 (ATF6), and hepatocyte-specific cyclic AMP response element binding protein H (CREBH). Homocysteine 69-81 C-reactive protein Homo sapiens 99-102 21852972-12 2011 Increased C-reactive protein and gamma-glutamyl transferase levels were associated with decreased protein expression of both enzymes, and increased bilirubin levels, cholestasis, and presurgical exposure to omeprazole or pantoprazole were related to decreased PON3 protein. Pantoprazole 221-233 C-reactive protein Homo sapiens 10-28 21212164-8 2011 RESULTS: Lower serum magnesium was independently associated with PWV (P = 0.018) in addition to age, CRP, HR, diabetes and mean arterial pressure (model R(2) = 0.45; P < 0.001). Magnesium 21-30 C-reactive protein Homo sapiens 101-104 35058315-6 2022 The SAA and CRP levels at T1 to T3 in patients with stroke receiving EVT were higher compared with those in controls (all p<0.001), and their levels at T3 were significantly higher than those at T1 (both p<0.0001) while similar to those in patients with non-EVT stroke. EVT 69-72 C-reactive protein Homo sapiens 12-15 35058315-6 2022 The SAA and CRP levels at T1 to T3 in patients with stroke receiving EVT were higher compared with those in controls (all p<0.001), and their levels at T3 were significantly higher than those at T1 (both p<0.0001) while similar to those in patients with non-EVT stroke. EVT 258-261 C-reactive protein Homo sapiens 12-15 21731566-0 2011 Effects of ezetimibe added to ongoing statin therapy on C-reactive protein levels in hypercholesterolemic patients. Ezetimibe 11-20 C-reactive protein Homo sapiens 56-74 21731566-3 2011 We investigated the effect of ezetimibe on CRP levels in patients taking statins. Ezetimibe 30-39 C-reactive protein Homo sapiens 43-46 21406101-11 2011 Interleukin (IL)-6 and C-reactive protein (CRP) showed a significantly quicker decrease after 24 h of treatment among patients treated with MPDN. Methylprednisolone 140-144 C-reactive protein Homo sapiens 23-41 21406101-11 2011 Interleukin (IL)-6 and C-reactive protein (CRP) showed a significantly quicker decrease after 24 h of treatment among patients treated with MPDN. Methylprednisolone 140-144 C-reactive protein Homo sapiens 43-46 21245772-8 2011 In the multivariate analysis, the predictors of improvement of HOMA-IR in response to telmisartan treatment were low levels of cytokines, whereas systolic and diastolic blood pressure and the elevation of high-sensitivity C-reactive protein had a negative effect. Telmisartan 86-97 C-reactive protein Homo sapiens 222-240 21046182-5 2011 RESULTS: Plasma homocysteine levels were positively associated with microalbuminuria in men but not in women (p-interaction <0.0001) after adjusting for age, race/ethnicity, smoking, drinking, body mass index, physical activity, glomerular filtration rate, blood pressure, high-density lipoprotein cholesterol, glycated hemoglobin, serum folate, serum vitamin B(12), and C-reactive protein. Homocysteine 16-28 C-reactive protein Homo sapiens 374-392 21519150-9 2011 Nuclear staining of 8-hydroxydeoxyguanosine was also increased in CRP/DM compared with Wt/DM. 8-ohdg 20-43 C-reactive protein Homo sapiens 66-69 21044014-10 2011 However, the effect of ezetimibe monotherapy on CRP reduction has not been well defined. Ezetimibe 23-32 C-reactive protein Homo sapiens 48-51 21199787-14 2010 Magnesium supplementation vs placebo decreased plasma CRP in participants with baseline values > 3.0 mg/L. Magnesium 0-9 C-reactive protein Homo sapiens 54-57 20538278-9 2010 Losartan reduced AngII-induced CRP expression in mRNA and protein levels in HAECs. Losartan 0-8 C-reactive protein Homo sapiens 31-34 20538278-11 2010 The further study indicated that losartan, NAC, PD98059, SP600125 significantly inhibited ERK1/2 and JNK phosphorylation, and PD98059, SP600125, PDTC completely antagonized AngII-induced CRP expression in HAECs. Losartan 33-41 C-reactive protein Homo sapiens 187-190 20653803-0 2010 Relationship of serum homocysteine and high sensitivity C-reactive protein in elderly people with essential hypertension. Homocysteine 22-34 C-reactive protein Homo sapiens 56-74 20659228-4 2010 Evaluated TC was accompanied by decreased C-reactive protein (CRP). Technetium 10-12 C-reactive protein Homo sapiens 42-60 20659228-4 2010 Evaluated TC was accompanied by decreased C-reactive protein (CRP). Technetium 10-12 C-reactive protein Homo sapiens 62-65 20929499-9 2010 The magnitude of decrease in CRP correlated with that of BMI, WC, fat mass, TG, TC and LDL-C. Technetium 80-82 C-reactive protein Homo sapiens 29-32 27046088-19 2010 PS-treated patients showed significantly (P <= 0.05) higher values for leucocytes, thrombocytes, ferritin, and CRP and lower values for haemoglobin, transferrin, creatinine, uric acid, creatine kinase (CK), and sodium than PMMA-treated patients. ps 0-2 C-reactive protein Homo sapiens 114-117 20094057-9 2010 Moreover, the regression coefficient of CRP levels with age was significantly steeper in subjects with the CC genotype than in those with the TC or TT genotype (P=0.028). Technetium 142-144 C-reactive protein Homo sapiens 40-43 20101184-0 2010 Clozapine therapy raises serum concentrations of high sensitive C-reactive protein in schizophrenic patients. Clozapine 0-9 C-reactive protein Homo sapiens 64-82 20101184-2 2010 The aim was to find whether clozapine, the prototype of atypical antipsychotic drugs, altered their serum concentrations of high sensitive C-reactive protein (hsCRP), an inflammatory marker of high clinical importance. Clozapine 28-37 C-reactive protein Homo sapiens 139-157 19716563-6 2010 On multivariate logistic analyses after adjustment for traditional atherosclerotic risk factors, multi-vessel coronary disease and high sensitivity C-reactive protein, neopterin levels were independently associated with the presence of complex carotid plaques (adjusted OR 2.21 per SD increase, 95%CI 1.13-4.33, P=0.02). Neopterin 168-177 C-reactive protein Homo sapiens 148-166 20078877-9 2010 CONCLUSION: The significant associations between certain gene variants with concentration variations in serum C-reactive protein and homocysteine among adult women need to be confirmed in further genetic association studies. Homocysteine 133-145 C-reactive protein Homo sapiens 110-128 20144072-4 2010 Serum ADMA was related directly to C-reactive protein and reversely to FMD. N,N-dimethylarginine 6-10 C-reactive protein Homo sapiens 35-53 21591350-11 2010 We observed a positive correlation between increased concentrations of neopterin in serum and increased levels of TNF-alpha and CRP, increasing the number of leukocytes and platelets count and the degree of disease activity in patients with both UC and CD, but was no statistically significant differences between the two groups of patients. Neopterin 71-80 C-reactive protein Homo sapiens 128-131 20595787-9 2010 3) High-sensitive c-reactive protein in serum and heart rate variability (HRV) were useful biomarkers of not only exposure to ultrafine particles but disorder of cardiovascular disease, 8-hydroxydeoxyguanosine in urine is a biomarker of acute lung injury by welder fume, and VEGF and CA15-3 are highly sensitive and specific biomarkers of pulmonary fibrosis. 8-ohdg 186-209 C-reactive protein Homo sapiens 18-36 19809863-3 2009 The aim of the study was to investigate serum Hcy concentration in patients with probable AD with age-matched controls and to determine whether there was an association between serum Hcy and C-reactive protein concentration in patients with probable AD. Homocysteine 183-186 C-reactive protein Homo sapiens 191-209 19231245-9 2009 Postoperative C-reactive protein concentration was also lower (p < 0.05) in the ketamine-treated patients compared with the placebo-treated patients. Ketamine 83-91 C-reactive protein Homo sapiens 14-32 19263143-9 2009 Furthermore, the C-reactive protein level on postoperative day 7 was lower in the TLDG group than in the LADG group (p < 0.05). tldg 82-86 C-reactive protein Homo sapiens 17-35 19960974-1 2009 OBJECTIVE: To observe the effect of combined therapy with Bailing Capsule (BC) and benazepril on the levels of urinary albumin excretion rate (UAER) and C-reactive protein (CRP) for exploring its protective effect on early diabetic nephropathy. benazepril 83-93 C-reactive protein Homo sapiens 153-171 19960974-1 2009 OBJECTIVE: To observe the effect of combined therapy with Bailing Capsule (BC) and benazepril on the levels of urinary albumin excretion rate (UAER) and C-reactive protein (CRP) for exploring its protective effect on early diabetic nephropathy. benazepril 83-93 C-reactive protein Homo sapiens 173-176 19960974-5 2009 CONCLUSION: Combined use of BC and benazepril could significantly lower the UAER and CRP levels in patients with early diabetic nephropathy to alleviate the renal impairment, showing an effect better than that of using benazepril alone. benazepril 35-45 C-reactive protein Homo sapiens 85-88 19422355-14 2009 The post-operative CRP concentration was significantly (P<0.01, Mann-Whitney U-test) lower in the ketamine-treated than in the placebo-treated group. Ketamine 101-109 C-reactive protein Homo sapiens 19-22 19632576-3 2009 We hypothesized that baseline plasma or bronchoalveolar lavage (BAL) CRP might be prognostic for the long-term outcome after LTx. Leukotriene C4 125-128 C-reactive protein Homo sapiens 69-72 19659653-10 2009 Serum H2S levels were inversely correlated with serum CRP levels (r = -0.337, P < 0.01). Hydrogen Sulfide 6-9 C-reactive protein Homo sapiens 54-57 19852292-5 2009 The 24 h CRP (mg/L) in both QYD and octreotide group (11.05 +/- 3.57 and 12.48 +/- 3.80) was also lower than that in the control group (17.70 +/- 4.93, P < 0.05), while the 24 h IL-10 (ng/L) in the QYD group (105.00 +/- 31.85) was higher than that in the octreotide group (77.98 +/- 33.13) and the control group (75.98 +/- 30.99) respectively. Octreotide 36-46 C-reactive protein Homo sapiens 9-12 19852292-5 2009 The 24 h CRP (mg/L) in both QYD and octreotide group (11.05 +/- 3.57 and 12.48 +/- 3.80) was also lower than that in the control group (17.70 +/- 4.93, P < 0.05), while the 24 h IL-10 (ng/L) in the QYD group (105.00 +/- 31.85) was higher than that in the octreotide group (77.98 +/- 33.13) and the control group (75.98 +/- 30.99) respectively. Octreotide 258-268 C-reactive protein Homo sapiens 9-12 19658273-3 2009 Recent findings from epidemiologic studies support that magnesium intake is inversely associated with C-reactive protein concentration, an important marker of inflammation strongly associated with cardiovascular disease risk. Magnesium 56-65 C-reactive protein Homo sapiens 102-120 19628101-7 2009 Mean serum CRP concentrations tended to decrease as the intake of eicosapentaenoic acid, docosahexaenoic acid, or their combination increased in men and women, although none of these relationships was statistically significant. Docosahexaenoic Acids 89-109 C-reactive protein Homo sapiens 11-14 19245380-8 2009 At 24 hours, the mean plasma CRP concentration in the SES group was 20.21 mg/dL versus 8.95 mg/dL in the BMS group (P = 0.15). ses 54-57 C-reactive protein Homo sapiens 29-32 19161294-7 2009 For the CRP assay, neutravidin-coated PQQ-doped PMMA nanospheres are used to bind with a biotinylated reporter antibody directed toward CRP. PQQ Cofactor 38-41 C-reactive protein Homo sapiens 8-11 19161294-7 2009 For the CRP assay, neutravidin-coated PQQ-doped PMMA nanospheres are used to bind with a biotinylated reporter antibody directed toward CRP. PQQ Cofactor 38-41 C-reactive protein Homo sapiens 136-139 19161209-8 2009 RESULTS: Mean Gadolinium-concentrations were higher in bowel loops of patients with more active disease, as defined by endoscopic and histopathological examination, CRP, and HBI. Gadolinium 14-24 C-reactive protein Homo sapiens 165-168 19479127-4 2009 C-reactive protein followed the neopterin curve with a delay of 4 days. Neopterin 32-41 C-reactive protein Homo sapiens 0-18 19199981-6 2009 Randomized trials of rimonabant in patients with overweight or obesity and/or type 2 diabetes have demonstrated marked and significant improvements in body weight, waist circumference, glycemic control (in patients with type 2 diabetes), features of atherogenic dyslipidemia, insulin resistance, adipose tissue-derived cytokines (leptin and adiponectin) and C-reactive protein (a marker of systemic inflammation). Rimonabant 21-31 C-reactive protein Homo sapiens 358-376 18433756-5 2008 Human CRP was undetectable in the sera of wild-type mice and present at only low levels (1.41 +/- 0.2 microg/ml) in vehicle-treated CRPtg mice (n=6-8 mice/group). crptg 132-137 C-reactive protein Homo sapiens 6-9 21291777-0 2008 Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein. Ezetimibe 0-9 C-reactive protein Homo sapiens 248-266 18388031-5 2008 Cilostazol increased high-density lipoprotein-cholesterol level, maximal walking distance, and FBF(h), whereas pentoxifylline reduced C-reactive protein level and increased maximal walking distance in total and nonsmoking groups. Pentoxifylline 111-125 C-reactive protein Homo sapiens 134-152 19083473-6 2008 Also, there is an inverse relationship between serum magnesium levels and high-sensitivity C-reactive protein. Magnesium 53-62 C-reactive protein Homo sapiens 91-109 19009820-0 2008 Magnesium and its relationship to C-reactive protein among hemodialysis patients. Magnesium 0-9 C-reactive protein Homo sapiens 34-52 19009820-2 2008 Recently, a possible correlation between serum magnesium (Mg) and C-reactive protein (CRP) has been stressed. Magnesium 47-56 C-reactive protein Homo sapiens 66-84 19009820-2 2008 Recently, a possible correlation between serum magnesium (Mg) and C-reactive protein (CRP) has been stressed. Magnesium 47-56 C-reactive protein Homo sapiens 86-89 19009820-4 2008 In this study we aimed to determine the relationship between serum Mg and hs-CRP levels in patients undergoing HD. Magnesium 67-69 C-reactive protein Homo sapiens 77-80 19009820-11 2008 There was a significant negative correlation between serum Mg and serum hs-CRP (p < 0.04). Magnesium 59-61 C-reactive protein Homo sapiens 75-78 17641003-1 2008 OBJECTIVE: To assess the hypothesis that magnesium deficiency is associated with elevated high-sensitivity C-reactive protein (hsCRP) levels. Magnesium 41-50 C-reactive protein Homo sapiens 107-125 18634144-7 2008 The patients in the LS group were younger than those in the SR group (41 +/- 9 vs 48 +/- 13 yrs; p < 0.006) and were more likely to have oligoarthritis involving ankles (58% vs 32%; p = 0.04) and high C-reactive protein concentrations (63% vs 33%; p < 0.005). leucylserine 20-22 C-reactive protein Homo sapiens 204-222 20157362-5 2008 The hypothesis was that etoricoxib would be non-inferior or superior to placebo in effect on C-reactive protein (CRP), LDL-cholesterol, homocysteine, and fibrinogen. Etoricoxib 24-34 C-reactive protein Homo sapiens 93-111 20157362-5 2008 The hypothesis was that etoricoxib would be non-inferior or superior to placebo in effect on C-reactive protein (CRP), LDL-cholesterol, homocysteine, and fibrinogen. Etoricoxib 24-34 C-reactive protein Homo sapiens 113-116 20157364-6 2008 RESULTS: Both human recombinant CRP and LPS significantly increased the production of IL-6 and MCP-1 in whole blood samples more than 4-fold (P < 0.001) but homocysteine did not. Homocysteine 160-172 C-reactive protein Homo sapiens 32-35 18426513-2 2008 Rimonabant 20 mg daily consistently reduced body weight, waist circumference, triglycerides, blood pressure, insulin resistance and C-reactive protein levels, and increased HDL cholesterol concentrations in both non-diabetic and type-2 diabetic overweight/obese patients. Rimonabant 0-10 C-reactive protein Homo sapiens 132-150 18203326-16 2008 Lipoprotein(a) [Lp(a)] also correlated with rheumatoid factor (RF) and C-reactive protein (CRP); homocysteine (HCy) correlated with CRP and correlated inversely with folate and vitamin B12 production. Homocysteine 97-109 C-reactive protein Homo sapiens 132-135 18203326-16 2008 Lipoprotein(a) [Lp(a)] also correlated with rheumatoid factor (RF) and C-reactive protein (CRP); homocysteine (HCy) correlated with CRP and correlated inversely with folate and vitamin B12 production. Homocysteine 111-114 C-reactive protein Homo sapiens 132-135 18724811-10 2008 CONCLUSIONS: The results of our investigation show that plasma layer stratification might occur in primary lithium-heparin tubes for a limited number of routine clinical chemistry tests, introducing a statistically significant bias in the measurement of GGT, LDH, triglycerides and CRP in the upper vs. the bottom section. Lithium 107-114 C-reactive protein Homo sapiens 282-285 18303686-3 2008 Clinical trials showed that, compared to placebo, rimonabant 20 mg/ day consistently increases weight loss, reduces waist circumference, improves atherogenic dyslipidaemia (low HDL cholesterol, high triglycerides, high small dense LDL), diminishes insulin resistance, reduces HbA1c levels, and contributes to lower blood pressure and C-reactive protein levels. Rimonabant 50-60 C-reactive protein Homo sapiens 334-352 18154742-8 2007 In addition, rimonabant was associated with favorable changes in several other cardiometabolic risk factors, including significant increases in serum levels of high-density lipoprotein cholesterol and adiponectin, as well as reductions in serum levels of triglycerides, small, dense low-density lipoprotein particles, C-reactive protein, insulin resistance, and glycosylated hemoglobin. Rimonabant 13-23 C-reactive protein Homo sapiens 318-336 18030179-7 2007 RESULTS: PMX-F treatment significantly increased systolic and diastolic blood pressures (P = 0.0004 for both) and significantly reduced heart rate (P < 0.0001), the blood endotoxin level (P = 0.0011), blood IL-6 level (P = 0.039), C-reactive protein level (P < 0.0001), and white blood cell count (P < 0.0001). pmx-f 9-14 C-reactive protein Homo sapiens 234-252 17588396-8 2007 Methylprednisolone attenuated postoperative tumor necrosis factor-alpha, interleukin 6, interleukin 8, and C-reactive protein levels while increasing interleukin 10 release. Methylprednisolone 0-18 C-reactive protein Homo sapiens 107-125 17548728-6 2007 Neopterin levels > or = 12.11 nmol/L at 4 months remained a predictor of death alone and of death or acute coronary events after multivariable adjustment that included adjustment for month 4 low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and statin regimen (hazard ratio, 2.39 [95% CI, 1.43 to 3.99], P=0.001; and hazard ratio, 1.60 [95% CI, 1.21 to 2.11], P=0.001). Neopterin 0-9 C-reactive protein Homo sapiens 248-266 17392496-3 2007 Treatment with rimonabant was also associated with other favorable changes, including better glycemic control in type 2 diabetes mellitus, improved lipid profile, reduced blood pressure, increased adiponectin levels, fall in high-sensitivity C-reactive protein concentrations, and an overall decrease in the prevalence of the metabolic syndrome. Rimonabant 15-25 C-reactive protein Homo sapiens 242-260 17477740-1 2007 Application of a fiber optic biosensor (FOB) to the real-time investigation of the interaction kinetics between FITC-conjugated monoclonal sheep anti-human C-reactive protein (CRP) antibody and CRP isoforms on the surface of optical fiber is described. Fluorescein-5-isothiocyanate 112-116 C-reactive protein Homo sapiens 156-174 17477740-1 2007 Application of a fiber optic biosensor (FOB) to the real-time investigation of the interaction kinetics between FITC-conjugated monoclonal sheep anti-human C-reactive protein (CRP) antibody and CRP isoforms on the surface of optical fiber is described. Fluorescein-5-isothiocyanate 112-116 C-reactive protein Homo sapiens 176-179 17477740-1 2007 Application of a fiber optic biosensor (FOB) to the real-time investigation of the interaction kinetics between FITC-conjugated monoclonal sheep anti-human C-reactive protein (CRP) antibody and CRP isoforms on the surface of optical fiber is described. Fluorescein-5-isothiocyanate 112-116 C-reactive protein Homo sapiens 194-197 17477740-5 2007 Specifically, the association and dissociation rate constants of the reaction between FITC-conjugated monoclonal sheep anti-human CRP antibody and the pCRP and mCRP are determined. Fluorescein-5-isothiocyanate 86-90 C-reactive protein Homo sapiens 130-133 18229569-9 2007 CONCLUSIONS: Plasma homocysteine is significantly elevated in COPD patients relative to age and sex-matched controls and is related to serum CRP and COPD severity. Homocysteine 20-32 C-reactive protein Homo sapiens 141-144 17379997-11 2007 Steroid therapy including methylprednisolone pulse therapy (500 mg/day, 3 days) and 2 courses of plasma exchange were effective in reducing the fever, anti-GBM antibody titer and C-reactive protein level. Methylprednisolone 26-44 C-reactive protein Homo sapiens 179-197 17261959-10 2007 Compared with simvastatin, losartan had less effect on suppression of CRP-mediated inflammation. Losartan 27-35 C-reactive protein Homo sapiens 70-73 17004092-10 2006 Furthermore, telmisartan dose-dependently inhibited AGE-induced ROS generation and subsequent CRP gene and protein induction in Hep3B cells. Telmisartan 13-24 C-reactive protein Homo sapiens 94-97 17051744-4 2006 RESULTS: The level of homocysteine showed statistically significant negative linear correlation with HDL-cholesterol and the anti-atherogenic ApoAI, and showed a positive correlation with CRP and FXIII activities in the entire patient population. Homocysteine 22-34 C-reactive protein Homo sapiens 188-191 16690736-3 2006 RESULTS: According to multiple linear regression analysis, C-reactive protein and interleukin-6 receptor were strongly and negatively associated with circulating vitamin B6 but not with folate concentrations, independent of age, sex, serum creatinine, serum albumin, total energy intake, smoking history, dietary nutrient intake, and circulating homocysteine and vitamin concentrations. Homocysteine 346-358 C-reactive protein Homo sapiens 59-77 16740374-0 2006 Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: a pilot study. Ezetimibe 98-107 C-reactive protein Homo sapiens 36-54 16680063-0 2006 Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension. Doxazosin 10-19 C-reactive protein Homo sapiens 23-41 16464786-5 2006 The aim of this study was to investigate whether individuals with increased plasma homocysteine concentrations have altered levels of serum CRP and IL-6. Homocysteine 83-95 C-reactive protein Homo sapiens 140-143 16390766-11 2005 Selective estrogen receptor agonists (SERMs) did not demonstrate an effect on CRP levels, although tibolone did increase CRP in one reviewed trial. tibolone 99-107 C-reactive protein Homo sapiens 121-124 16175949-6 2005 After switching Aza to methotrexate (Mtx) treatment, his symptoms disappeared and CRP concentration returned to normal. Azathioprine 16-19 C-reactive protein Homo sapiens 82-85 16282749-6 2005 CONCLUSIONS: It was contemplated that together with serum CRP and ESR, neopterin could be a useful laboratory parameter in patients in whom disease activation could not be determined. Neopterin 71-80 C-reactive protein Homo sapiens 58-61 18370716-1 2005 BACKGROUND: The aim of this study was to assess the effect of celecoxib, a cyclooxygenase- 2-specific inhibitor, on insulin sensitivity, C-reactive protein, homocysteine, and metabolic profile in overweight or obese subjects. Celecoxib 62-71 C-reactive protein Homo sapiens 137-155 15988120-3 2005 The mean ratio of serum pilsicainide concentration to dose per body weight (C/D) increased with increases in the C-reactive protein (CRP) concentration in Study 1. pilsicainide 24-36 C-reactive protein Homo sapiens 113-131 15988120-3 2005 The mean ratio of serum pilsicainide concentration to dose per body weight (C/D) increased with increases in the C-reactive protein (CRP) concentration in Study 1. pilsicainide 24-36 C-reactive protein Homo sapiens 133-136 15988120-6 2005 These results suggest C/D is increased in patients with high CRP levels because of binding of pilsicainide to protein, resulting decreased clearance. pilsicainide 94-106 C-reactive protein Homo sapiens 61-64 15930481-3 2005 The objective of this study was to determine whether dietary magnesium consumption is associated with C-reactive protein (CRP), a marker of inflammation, in a nationally representative sample. Magnesium 61-70 C-reactive protein Homo sapiens 102-120 15930481-3 2005 The objective of this study was to determine whether dietary magnesium consumption is associated with C-reactive protein (CRP), a marker of inflammation, in a nationally representative sample. Magnesium 61-70 C-reactive protein Homo sapiens 122-125 15930481-7 2005 After controlling for demographic and cardiovascular risk factors, adults who consumed <RDA of magnesium were 1.48-1.75 times more likely to have elevated CRP than adults who consumed > or =RDA (Odds Ratio [OR] for intake <50% RDA = 1.75, 95% Confidence Interval [CI] 1.08-2.87). Magnesium 98-107 C-reactive protein Homo sapiens 158-161 15930481-8 2005 Adults who were over age 40 with a BMI >25 and who consumed <50% RDA for magnesium were 2.24 times more likely to have elevated CRP (95% CI 1.13-4.46) than adults > or =RDA. Magnesium 79-88 C-reactive protein Homo sapiens 134-137 15723869-4 2005 Two months after treatment, both SPT and IPT resulted in significant reductions in serum CRP compared with the untreated control (0.5 +/- 0.2 mg/L for SPT, P = 0.030 and 0.8 +/- 0.2 mg/L for IPT, P = 0.001). isoprothiolane 41-44 C-reactive protein Homo sapiens 89-92 2593200-5 1989 Our results show that CRP binds to liposomes containing DPPC and phosphatidylglycerol (PG). 1,2-Dipalmitoylphosphatidylcholine 56-60 C-reactive protein Homo sapiens 22-25 2530919-2 1989 We have synthesized new crown ether-phosphate ester ionophores having high affinity for CRP. crown ether-phosphate ester 24-51 C-reactive protein Homo sapiens 88-91 2530919-4 1989 The incorporation of these crown ether-phosphate ester ionophores into poly(vinyl chloride) membrane electrodes yields a CRP-sensitive electrode with sensitivity in the microgram per milliliter range. crown ether-phosphate ester 27-54 C-reactive protein Homo sapiens 121-124 3057546-1 1988 The influence of polyclonal and monoclonal antibodies, trypsin digestion and mercaptoethanol treatment of C-reactive protein (CRP) in the CRP binding to solid-phase phosphorylethanolamine (PE) has been investigated. phosphorylethanolamine 165-187 C-reactive protein Homo sapiens 106-124 3057546-1 1988 The influence of polyclonal and monoclonal antibodies, trypsin digestion and mercaptoethanol treatment of C-reactive protein (CRP) in the CRP binding to solid-phase phosphorylethanolamine (PE) has been investigated. phosphorylethanolamine 165-187 C-reactive protein Homo sapiens 126-129 15514264-6 2004 Changes in CRP and VCAM-1 were inversely associated with changes in serum eicosapentaenoic acid (EPA) (r = -0.496, P = 0.016; r = -0.418, P = 0.047), or EPA plus docosapentaenoic acid (r = -0.409, P = 0.053; r = -0.357, P = 0.091) after subjects consumed the ALA Diet. docosapentaenoic acid 162-183 C-reactive protein Homo sapiens 11-14 3057546-1 1988 The influence of polyclonal and monoclonal antibodies, trypsin digestion and mercaptoethanol treatment of C-reactive protein (CRP) in the CRP binding to solid-phase phosphorylethanolamine (PE) has been investigated. phosphorylethanolamine 165-187 C-reactive protein Homo sapiens 138-141 3057546-1 1988 The influence of polyclonal and monoclonal antibodies, trypsin digestion and mercaptoethanol treatment of C-reactive protein (CRP) in the CRP binding to solid-phase phosphorylethanolamine (PE) has been investigated. phosphorylethanolamine 189-191 C-reactive protein Homo sapiens 106-124 3057546-1 1988 The influence of polyclonal and monoclonal antibodies, trypsin digestion and mercaptoethanol treatment of C-reactive protein (CRP) in the CRP binding to solid-phase phosphorylethanolamine (PE) has been investigated. phosphorylethanolamine 189-191 C-reactive protein Homo sapiens 126-129 15542408-0 2004 C-reactive protein predicts response to pentoxifylline in patients with idiopathic dilated cardiomyopathy. Pentoxifylline 40-54 C-reactive protein Homo sapiens 0-18 15540478-7 2004 AFCAPS/TexCAPS researchers found that lovastatin provded a 14.8% reduction in the median levels of CRP (p < 0.001). texcaps 7-14 C-reactive protein Homo sapiens 99-102 3341221-6 1988 The erythrocyte sedimentation rate and C-reactive protein level were both higher in patients with Ga-67 uptake compared with those with a negative scan result (p less than 0.01 in both). Gallium 98-100 C-reactive protein Homo sapiens 39-57 15148294-7 2004 The proinflammatory, proatherogenic effects of CRP that have been documented in endothelial cells include the following: decreased nitric oxide and prostacyclin and increased endothelin-1, cell adhesion molecules, monocyte chemoattractant protein-1 and interleukin-8, and increased plasminogen activator inhibitor-1. Epoprostenol 148-160 C-reactive protein Homo sapiens 47-50 15080376-4 2004 The relation of baPWV with serum alpha-tocopherol and CRP levels was cross-sectionally analyzed after adjusting for other cardiovascular risk factors. bapwv 16-21 C-reactive protein Homo sapiens 54-57 3034878-3 1987 Close examination of the primary structure of human C-reactive protein revealed three regions evenly distributed throughout the protein each of which contain peptide sequences closely resembling the amino acid sequence of the immunomodulator peptide tuftsin, Thr-Lys-Pro-Arg. prolylarginine 267-274 C-reactive protein Homo sapiens 52-70 3708910-1 1986 The uptake of C-reactive protein (CRP)-pneumococcal C-polysaccharide (CPS) complexes by neutrophils was studied. polysaccharide C-substance (Streptococcus) 39-68 C-reactive protein Homo sapiens 14-32 3708910-1 1986 The uptake of C-reactive protein (CRP)-pneumococcal C-polysaccharide (CPS) complexes by neutrophils was studied. polysaccharide C-substance (Streptococcus) 39-68 C-reactive protein Homo sapiens 34-37 15080376-6 2004 Multiple linear regression analysis indicated that serum CRP levels were associated with an elevation of baPWV, in addition to age, systolic blood pressure and heart rate. bapwv 105-110 C-reactive protein Homo sapiens 57-60 15080376-8 2004 Multivariate-adjusted means of baPWV according to serum CRP quartile were 1,431, 1,436, 1,507 and 1,508 cm/s (p = 0.033). bapwv 31-36 C-reactive protein Homo sapiens 56-59 3518282-3 1986 For the diagnostic ascertainment of the rejection crises as well as for the estimation of the effectiveness of the antirejection therapy with high doses of prednisolone the daily CRP serum control is a valuable contrivance. Prednisolone 156-168 C-reactive protein Homo sapiens 179-182 6142008-12 1984 After salazopyrine treatment, all the above mentioned abnormalities corrected except that 5" nucleotidase activity remained slightly lower than normal, alkaline phosphatase levels remained slightly higher than normal, and C-reactive protein levels remained very high, though lower than those during intense disease activity. Salazopyrine 6-18 C-reactive protein Homo sapiens 222-240 6654860-5 1983 The fluorescence of the complex of CRP and 8-anilino-1-naphthalene sulfonate (ANS) changed with change of the pH, suggesting that CRP may show pH-dependent conformational change. 8-anilino-1-naphthalenesulfonic acid 43-76 C-reactive protein Homo sapiens 35-38 6654860-5 1983 The fluorescence of the complex of CRP and 8-anilino-1-naphthalene sulfonate (ANS) changed with change of the pH, suggesting that CRP may show pH-dependent conformational change. 8-anilino-1-naphthalenesulfonic acid 43-76 C-reactive protein Homo sapiens 130-133 6654860-5 1983 The fluorescence of the complex of CRP and 8-anilino-1-naphthalene sulfonate (ANS) changed with change of the pH, suggesting that CRP may show pH-dependent conformational change. 8-anilino-1-naphthalenesulfonic acid 78-81 C-reactive protein Homo sapiens 35-38 6654860-5 1983 The fluorescence of the complex of CRP and 8-anilino-1-naphthalene sulfonate (ANS) changed with change of the pH, suggesting that CRP may show pH-dependent conformational change. 8-anilino-1-naphthalenesulfonic acid 78-81 C-reactive protein Homo sapiens 130-133 6654860-7 1983 Ca2+-dependent change of the fluorescence of the complex of CRP and ANS was also detected. 8-anilino-1-naphthalenesulfonic acid 68-71 C-reactive protein Homo sapiens 60-63 15332580-5 2004 A statistically significant correlation exists between homocysteine serum levels and acute phase proteins (C-reactive protein, fibrinogen) in patients with unstable angina. Homocysteine 55-67 C-reactive protein Homo sapiens 107-125 6656768-11 1983 F-CRP chromatographed through Sephadex G-150 in the presence or absence of 6M urea as a protein of apparent mol. sephadex 30-44 C-reactive protein Homo sapiens 2-5 7046573-6 1982 Protein that has been coupled with phosphorylcholine or phosphorylethanolamine is able to precipitate with CRP. phosphorylethanolamine 56-78 C-reactive protein Homo sapiens 107-110 12919896-6 2003 The levels of CRP was closely correlated with neopterin, TNF-alpha and IL-1beta(r=0.287, 0.314, 0.262, P<0.05, respectively), and SAA with neopterin (r=0.306, P<0.05). Neopterin 46-55 C-reactive protein Homo sapiens 14-17 7462634-8 1981 The binding was not inhibited by ethylenediaminetetraacetate (EDTA) but could be inhibited by CaCl2, whereas CRP binding to PC-Sepharose was inhibited by EDTA and required CaCl2. pc-sepharose 124-136 C-reactive protein Homo sapiens 109-112 588590-2 1977 The method consists of two chromatographic separations on diethylaminoethyl (DEAE)-cellulose columns and utilized the difference between the binding of C-reactive protein to DEAE in the presence and absence of calcium. Cellulose 83-92 C-reactive protein Homo sapiens 152-170 12821543-3 2003 After adjustment for other predictors of inflammation, intake of the n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) was inversely associated with plasma levels of sTNF-R1 and sTNF-R2 (P=0.03 and P<0.001, respectively) and somewhat less so for C-reactive protein (P=0.08). Docosahexaenoic Acids 117-137 C-reactive protein Homo sapiens 274-292 70475-5 1977 In the present investigation, CRP was found by direct assay to inhibit the release of endogenous ADP and/or serotonin concomitant with inhibition of platelet aggregation stimulated by ADP, epinephrine, thrombin, and AHGG. Epinephrine 189-200 C-reactive protein Homo sapiens 30-33 12821543-3 2003 After adjustment for other predictors of inflammation, intake of the n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) was inversely associated with plasma levels of sTNF-R1 and sTNF-R2 (P=0.03 and P<0.001, respectively) and somewhat less so for C-reactive protein (P=0.08). Docosahexaenoic Acids 139-142 C-reactive protein Homo sapiens 274-292 830761-6 1977 Similar C1 binding and C consumption in the presence of CRP were seen upon the interaction of multiple additional polyanions including DNA, ENA, hyaluronic acid, chondroitin sulfate, and dextran sulfate with the polycations protamine sulfate and poly-L-lysine. Chondroitin Sulfates 162-181 C-reactive protein Homo sapiens 56-59 977942-2 1976 Inhibition by CRP of platelet reactivities stimulated by poly-L-lysine, ADP, epinephrine, and collagen. Epinephrine 77-88 C-reactive protein Homo sapiens 14-17 12244213-10 2002 We propose that, analogous to EO6 and scavenger receptors, CRP is a part of the innate immune response to oxidized PC-bearing phospholipids within OxLDL and on the plasma membranes of apoptotic cells. eo6 30-33 C-reactive protein Homo sapiens 59-62 977942-4 1976 In the present experiments, CRP was found also to inhibit the ability of washed human platelets to aggregate in response to poly-L-lysine (PLL); in these experiments, the magnitude of the inhibitory effect was dependent upon the m.w. N-(3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl)-N-(3-oxo-3-phenyl-2-methylpropyl)piperazine 139-142 C-reactive protein Homo sapiens 28-31 977942-7 1976 CRP similarly inhibited ADP- and epinephrine-stimulated platelet aggregation in platelet-rich plasma (PRP), and this was characterized by relatively minimal suppression of the primary wave of aggregation. Epinephrine 33-44 C-reactive protein Homo sapiens 0-3 12241010-8 2002 On the first postoperative day CRP and PCT were elevated and their levels correlated with neopterin (Pearson"s correlation coefficient r=0.51 and r=0.76, respectively). Neopterin 90-99 C-reactive protein Homo sapiens 31-34 33024987-7 2021 In patients receiving ivosidenib (n = 60) or enasidenib (n = 91), end-of-induction complete remission (CR) rates were 55% and 47%, respectively, and CR/CR with incomplete neutrophil or platelet recovery (CR/CRi/CRp) rates were 72% and 63%, respectively. ivosidenib 22-32 C-reactive protein Homo sapiens 103-105 33024987-7 2021 In patients receiving ivosidenib (n = 60) or enasidenib (n = 91), end-of-induction complete remission (CR) rates were 55% and 47%, respectively, and CR/CR with incomplete neutrophil or platelet recovery (CR/CRi/CRp) rates were 72% and 63%, respectively. ivosidenib 22-32 C-reactive protein Homo sapiens 149-151 33024987-7 2021 In patients receiving ivosidenib (n = 60) or enasidenib (n = 91), end-of-induction complete remission (CR) rates were 55% and 47%, respectively, and CR/CR with incomplete neutrophil or platelet recovery (CR/CRi/CRp) rates were 72% and 63%, respectively. ivosidenib 22-32 C-reactive protein Homo sapiens 149-151 33024987-7 2021 In patients receiving ivosidenib (n = 60) or enasidenib (n = 91), end-of-induction complete remission (CR) rates were 55% and 47%, respectively, and CR/CR with incomplete neutrophil or platelet recovery (CR/CRi/CRp) rates were 72% and 63%, respectively. ivosidenib 22-32 C-reactive protein Homo sapiens 149-151 33024987-7 2021 In patients receiving ivosidenib (n = 60) or enasidenib (n = 91), end-of-induction complete remission (CR) rates were 55% and 47%, respectively, and CR/CR with incomplete neutrophil or platelet recovery (CR/CRi/CRp) rates were 72% and 63%, respectively. ivosidenib 22-32 C-reactive protein Homo sapiens 211-214 12166247-3 2002 Despite removal of the central venous catheter and administration of vancomycin, fever and increased C-reactive protein level persisted. Vancomycin 69-79 C-reactive protein Homo sapiens 101-119 33024987-8 2021 In patients with a best overall response of CR/CRi/CRp, 16/41 (39%) receiving ivosidenib had IDH1 mutation clearance and 15/64 (23%) receiving enasidenib had IDH2 mutation clearance by digital polymerase chain reaction; furthermore, 16/20 (80%) and 10/16 (63%), respectively, became negative for measurable residual disease by multiparameter flow cytometry. ivosidenib 78-88 C-reactive protein Homo sapiens 44-46 33024987-8 2021 In patients with a best overall response of CR/CRi/CRp, 16/41 (39%) receiving ivosidenib had IDH1 mutation clearance and 15/64 (23%) receiving enasidenib had IDH2 mutation clearance by digital polymerase chain reaction; furthermore, 16/20 (80%) and 10/16 (63%), respectively, became negative for measurable residual disease by multiparameter flow cytometry. ivosidenib 78-88 C-reactive protein Homo sapiens 51-54 32402726-3 2021 Oral prednisolone was administered on day 33 then fever subsided with dramatically clinical improvement (decreased CRP and resolution of lung consolidation). Prednisolone 5-17 C-reactive protein Homo sapiens 115-118 33599556-8 2021 VPA was inversely associated with hs-CRP, leptin, and IL-6 in children with higher BF% (beta=-0.344 to -0.181, 95% CI=-0.477 to -0.033) but not among children with lower BF% (beta=-0.007 to 0.033, 95% CI=-0.183 to 0.184). VALPROIC ACID 0-3 C-reactive protein Homo sapiens 37-40 11749774-12 2001 After administration of methylprednisolone or aprotinin, leukocyte CD11b expression, plasma IL-6, IL-8, C-reactive protein levels, and MPO activity decreased by different extent. Methylprednisolone 24-42 C-reactive protein Homo sapiens 104-122 32858120-0 2021 Meta-analysis of astaxanthin supplementation on obesity, blood pressure, CRP, glycemic biomarkers, and lipid profile: Reanalysis is needed. astaxanthine 17-28 C-reactive protein Homo sapiens 73-76 11383794-8 2001 Increase in CRP and PMN-elastase was significantly higher in the untreated control than in the PTX patients. Pentoxifylline 95-98 C-reactive protein Homo sapiens 12-15 33228249-2 2020 Piezoelectric lithium niobate (LiNbO3) substrates were used to study their frequency response characteristics in a SAW sensor with a CRP sensing area. lithium niobate 14-29 C-reactive protein Homo sapiens 133-136 33228249-2 2020 Piezoelectric lithium niobate (LiNbO3) substrates were used to study their frequency response characteristics in a SAW sensor with a CRP sensing area. lithium niobate 31-37 C-reactive protein Homo sapiens 133-136 11342801-1 2001 In the past year, evidence from epidemiological studies in patients with renal disease has confirmed associations between both elevated plasma total homocysteine concentrations and the inflammatory marker C-reactive protein with an increased risk of arteriosclerotic vascular disease. Homocysteine 149-161 C-reactive protein Homo sapiens 205-223 32755613-0 2020 The effects of astaxanthin supplementation on obesity, blood pressure, CRP, glycemic biomarkers, and lipid profile: A meta-analysis of randomized controlled trials. astaxanthine 15-26 C-reactive protein Homo sapiens 71-74 11076538-5 2000 The secondary structure of apo-CRP was determined by analyses of the NOE connectivities, the amide proton exchange rates, and the (1)H-(15)N steady-state NOE values. Amides 93-98 C-reactive protein Homo sapiens 31-34 32987917-8 2020 Finally, Hs-CRP was reduced after 3 months of ABA consumption. Abscisic Acid 46-49 C-reactive protein Homo sapiens 12-15 11007832-6 2000 RESULTS: Significant correlations were observed between Log high-sensitivity CRP (hsCRP) and sVCAM-1 (R=0.39; P<0.01) and sICAM-1 (R=0.47; P:<0.001) levels but not between Log hsCRP and sE-selectin levels in 60 patients examined with a hsCRP assay. se-selectin 192-203 C-reactive protein Homo sapiens 77-80 10982535-0 2000 Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Homocysteine 7-19 C-reactive protein Homo sapiens 85-103 31677282-11 2020 In multivariable analyses, higher bioavailable 25OHD levels were significantly associated with better survival, independent of nonclinical and clinical prognostic factors including serum C-reactive protein, Barcelona Clinic Liver Cancer (BCLC) stage, and cancer treatment. 1,25,26-trihydroxyvitamin D3 47-52 C-reactive protein Homo sapiens 187-205 10569656-4 1999 There were significant positive associations between CRP levels and age, number of cigarettes smoked per day, body mass index, systolic and diastolic blood pressure, total cholesterol, triglycerides, lipoprotein(a), apolipoprotein B, tissue-type plasminogen activator antigen, D-dimers, total homocysteine, and fibrinogen (all p values <0.05). Homocysteine 293-305 C-reactive protein Homo sapiens 53-56 32541643-12 2020 CONCLUSIONS Valsartan inhibited the increase in hs-CRP and IL-6 levels, improved clinical efficacies, increased ABI, and decreased the restenosis rate after the interventional therapy in patients with arteriosclerosis obliterans of the lower extremities. Valsartan 12-21 C-reactive protein Homo sapiens 51-54 10569656-6 1999 In multivariate analysis, age, smoking status, and serum levels of tissue-type plasminogen activator antigen, fibrinogen, lipoprotein(a), and total homocysteine were independent correlates of CRP levels. Homocysteine 148-160 C-reactive protein Homo sapiens 192-195 10096789-8 1999 In the Type I diabetic group, log(C-reactive protein) correlated significantly with von Willebrand factor (r = 0.439, p<0.005) and vascular cell adhesion molecule-1 (r = 0.384, p<0.02), but not with sE-selectin (r = 0.008, p = 0.96). se-selectin 205-216 C-reactive protein Homo sapiens 34-52 32415945-0 2020 Efficacy of cefotaxime combined with gamma globulins on C-reactive protein and procalcitonin in neonatal sepsis. Cefotaxime 12-22 C-reactive protein Homo sapiens 56-74 9481022-13 1998 In part 2 (DTaP was substituted for DTwP), there were no elevations of IL-6 or CRP, thus indicating that whole-cell pertussis component of DTwP was responsible for IL-6 and CRP elevations. dtwp 139-143 C-reactive protein Homo sapiens 173-176 32398645-9 2020 Longitudinal structural equation modelling was used to investigate the mediating role of CRP in the relationship between DS-PGS and cognitive-affective versus somatic symptoms. diphenylguanidine 121-127 C-reactive protein Homo sapiens 89-92 32398645-11 2020 Mediation analyses revealed that CRP mediated the relationship between DS-PGS and somatic symptoms, but not the association between DS-PGS and cognitive-affective symptoms. diphenylguanidine 71-77 C-reactive protein Homo sapiens 33-36 32399331-0 2020 Elevated C-reactive Protein and Role of Steroids in Cocaine-associated Levamisole-induced Vasculitis. Levamisole 71-81 C-reactive protein Homo sapiens 9-27 32373986-0 2020 Curative effects of vancomycin and cefotaxime combined with gamma globulin respectively in neonatal septicemia and their influences on PCT, CRP and hs-CRP. Cefotaxime 35-45 C-reactive protein Homo sapiens 140-143 8956080-2 1996 The octapeptide Val89-Thr-Val-Ala-Pro-Val-His-Ile96 (CRP 89-96) is shown to inhibit hLE and hCG to a larger extent than peptides of similar chain lengths corresponding to the active sites of their natural inhibitors, alpha 1-protease inhibitor and alpha-antichymotrypsin, respectively. val-ala-pro-val-his 26-45 C-reactive protein Homo sapiens 53-56 32373986-0 2020 Curative effects of vancomycin and cefotaxime combined with gamma globulin respectively in neonatal septicemia and their influences on PCT, CRP and hs-CRP. Cefotaxime 35-45 C-reactive protein Homo sapiens 151-154 32373986-1 2020 OBJECTIVE: To explore the curative effects of vancomycin and cefotaxime combined with gamma globulin respectively in neonatal septicemia and their influences on PCT, CRP, and hs-CRP, so as to provide references for clinical treatment. Cefotaxime 61-71 C-reactive protein Homo sapiens 166-169 32373986-1 2020 OBJECTIVE: To explore the curative effects of vancomycin and cefotaxime combined with gamma globulin respectively in neonatal septicemia and their influences on PCT, CRP, and hs-CRP, so as to provide references for clinical treatment. Cefotaxime 61-71 C-reactive protein Homo sapiens 178-181 32373986-6 2020 CONCLUSIONS: Cefotaxime combined with gamma globulin in the treatment of patients with neonatal septicemia has short improvement time in clinical symptoms, high total effective rate of drugs, low mortality, fewer adverse reactions and complications, and can significantly reduce levels of serum CRP, PCT, and hs-CRP, which is worthy of further promotion and application in clinical practice. Cefotaxime 13-23 C-reactive protein Homo sapiens 295-298 32373986-6 2020 CONCLUSIONS: Cefotaxime combined with gamma globulin in the treatment of patients with neonatal septicemia has short improvement time in clinical symptoms, high total effective rate of drugs, low mortality, fewer adverse reactions and complications, and can significantly reduce levels of serum CRP, PCT, and hs-CRP, which is worthy of further promotion and application in clinical practice. Cefotaxime 13-23 C-reactive protein Homo sapiens 312-315 32523491-12 2020 Our conclusions are that the administration of ceftazidime as an empirical antibiotic lowers CRP level, although not significantly, while there is no decrease in several inflammatory markers. Ceftazidime 47-58 C-reactive protein Homo sapiens 93-96 32396523-9 2020 Compared with patients who used prednisolone and had low CRP levels, high CRP predicted increased mortality both in patients who used prednisolone (HR 3.09, 95% CI 1.25 to 7.65) and those who did not (HR 2.35, 95% CI 0.94 to 5.87). Prednisolone 134-146 C-reactive protein Homo sapiens 74-77 8699873-15 1995 In the PTX group the following variables were improved compared with the placebo group: CD11b expression on PMNs, elastase released from PMNs, fibrinogen, CRP, TNF-alpha, and IL6 in plasma. Pentoxifylline 7-10 C-reactive protein Homo sapiens 155-158 31654094-0 2020 Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes. ruxolitinib 81-92 C-reactive protein Homo sapiens 21-39 7988727-0 1994 Interleukin-10 and pentoxifylline inhibit C-reactive protein-induced tissue factor gene expression in peripheral human blood monocytes. Pentoxifylline 19-33 C-reactive protein Homo sapiens 42-60 31654094-0 2020 Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes. ruxolitinib 81-92 C-reactive protein Homo sapiens 41-44 31654094-1 2020 OBJECTIVE AND DESIGN: To determine whether inflammatory hepatocytes may constitute primary targets for ruxolitinib, a Janus kinase (JAK) inhibitor, its effects towards expression of hepatic acute-phase proteins, especially C-reactive protein (CRP), were assessed. ruxolitinib 103-114 C-reactive protein Homo sapiens 223-241 31654094-3 2020 RESULTS: Ruxolitinib was found to fully inhibit lipopolysaccharide (LPS)-induced CRP secretion and mRNA expression, at concentrations (IC50 = 12.9 nM) achievable in human blood. ruxolitinib 9-20 C-reactive protein Homo sapiens 81-84 31654094-5 2020 Ruxolitinib was additionally found to block the activation of the IL6/JAK/signal transducer and activator of transcription (STAT) pathway triggered by LPS and whose inhibition by the neutralizing anti-IL6 receptor antibody tocilizumab prevented CRP induction. ruxolitinib 0-11 C-reactive protein Homo sapiens 245-248 31654094-6 2020 CONCLUSION: Ruxolitinib can potently repress induction of CRP in inflammatory human hepatocytes, most likely through targeting the IL6/JAK/STAT signalling cascade. ruxolitinib 12-23 C-reactive protein Homo sapiens 58-61 7988727-3 1994 We report the inhibitory effect of interleukin 10 (IL-10) and that of pentoxifylline, a methyl xanthine derivative, on monocyte expression of TF activity, TF protein and TF mRNA in response to CRP. Pentoxifylline 70-84 C-reactive protein Homo sapiens 193-196 7988727-3 1994 We report the inhibitory effect of interleukin 10 (IL-10) and that of pentoxifylline, a methyl xanthine derivative, on monocyte expression of TF activity, TF protein and TF mRNA in response to CRP. methylxanthine 88-103 C-reactive protein Homo sapiens 193-196 7929814-3 1994 After intravenous injection into mice and rabbits of human C-reactive protein, human SAP, and mouse SAP, each labeled with 125I-TC, most of the radioactivity remaining in the body at 24 h was located in hepatocytes. 125i-tc 123-130 C-reactive protein Homo sapiens 59-77 31794588-5 2019 MF59 induced negligible mucosal antibodies to V2 and an inflammatory profile with blood C-reactive Protein (CRP) levels correlating with neutralizing antibody titers. MF59 oil emulsion 0-4 C-reactive protein Homo sapiens 88-106 30565017-7 2019 Overall, magnesium and vitamin E co-supplementation for 12 weeks may benefit women with PCOS on hirsutism, serum hs-CRP, plasma NO, and TAC levels. Vitamin E 23-32 C-reactive protein Homo sapiens 116-119 7996715-5 1994 Increases of serum sialic acid highly accompanied with increases of CRP, alpha 1 or alpha 2 fraction of serum protein and elevation of erythrocyte sedimentation rate (ESR), indicating that serum sialic acid levels reflected more strictly inflammatory status than ESR. N-Acetylneuraminic Acid 19-30 C-reactive protein Homo sapiens 68-91 31178729-13 2019 TGP + IS can improve the clinical symptoms, such as lacrimal and salivary gland secretion function (Schirmer"s test, salivary flow rate), inflammatory indices (ESR, CRP, and RF) and immunoglobulins (gamma-globulin, IgG, IgA, and IgM) on the basis of IS monotherapy. tgp + 0-5 C-reactive protein Homo sapiens 165-168 1374844-0 1992 Localization of sequence-determined neoepitopes and neutrophil digestion fragments of C-reactive protein utilizing monoclonal antibodies and synthetic peptides. Peptides 151-159 C-reactive protein Homo sapiens 86-104 29670279-9 2019 An IV injection of F-652 induced dose-dependent increases in serum marker serum amyloid A, C-reactive protein, and FIB, and decreased serum triglycerides. f-652 19-24 C-reactive protein Homo sapiens 91-109 31035488-6 2019 The association between calcidiol/paricalcitol treatment and elevated mortality remained significant after adjusting for age, sex, diabetes, C-reactive protein, and hemodialysis vintage. Calcifediol 24-33 C-reactive protein Homo sapiens 141-159 1958695-5 1991 U-937 cells degraded about 25% of the internalized [125I]CRP into TCA-soluble radiolabeled products. Trichloroacetic Acid 66-69 C-reactive protein Homo sapiens 57-60 2165398-1 1990 Induction of C-reactive protein (CRP) by conditioned medium from lipopolysaccharide-stimulated human monocytes in two human hepatoma-cell lines, Hep 3B and NPLC/PRF/5, was potentiated 3-6-fold by the methylxanthine caffeine. methylxanthine 200-214 C-reactive protein Homo sapiens 13-31 30850240-10 2019 Blood levels of C-reactive protein (CRP), bilirubin, leukocyte, monocyte and neutrophil counts increased rapidly and transiently after AS01B but not after Alum or placebo. as01b 135-140 C-reactive protein Homo sapiens 16-34 30850240-12 2019 Modelling revealed associations between systemic symptoms and increased levels of CRP and IL-6 after the first HBsAg-AS01B or HBsAg-Alum immunization. as01b 117-122 C-reactive protein Homo sapiens 82-85 2165398-1 1990 Induction of C-reactive protein (CRP) by conditioned medium from lipopolysaccharide-stimulated human monocytes in two human hepatoma-cell lines, Hep 3B and NPLC/PRF/5, was potentiated 3-6-fold by the methylxanthine caffeine. methylxanthine 200-214 C-reactive protein Homo sapiens 33-36 33783450-4 2021 Furthermore, bempedoic acid has also been associated with the improvement of other biomarkers, including reduced apolipoprotein B and high-sensitivity C-reactive protein, effects that can increase the clinical benefits of this treatment. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 13-27 C-reactive protein Homo sapiens 151-169 30793124-7 2019 High levels of CRP were significantly correlated (p < 0.05), with a greater BOP (r = 0.360) and PPD (r = 0.321). bop 79-82 C-reactive protein Homo sapiens 15-18 33236293-8 2021 Also, increased serum magnesium level may play a role in decreased white blood cell, neutrophil, lymphocyte cell count and increased CRP levels in the third trimester. Magnesium 22-31 C-reactive protein Homo sapiens 133-136 30793124-12 2019 Pregnancy showed an increased in the level of CRP, which was positively correlated with BOP and PPD. bop 88-91 C-reactive protein Homo sapiens 46-49 34273116-9 2021 The "no dexamethasone" cohort 25-OH-D deplete subgroup recorded significantly higher peak D-Dimer levels (1874ugFEU/L vs 1233ugFEU/L) (p value = 0.0309), CRP (177 vs 107.5) (p=0.0055) and ventilatory support requirement (25.5% vs 6.67%) (p value = 0.007) compared to the replete subgroup. ort 25- 26-33 C-reactive protein Homo sapiens 150-153 30406638-26 2018 The mean CRP in the cannabidiol group was 9.428 mg/L compared to 7.638 mg/L in the placebo group (MD 1.79, 95% CI -5.67 to 9.25; moderate certainty evidence). Cannabidiol 20-31 C-reactive protein Homo sapiens 9-12 29439591-7 2018 CT-P13 treatment significantly improved DAS28-CRP scores at 12 and 24 weeks (p = .0001 vs baseline for both timepoints) in patients with RA and BASDAI scores at 12 and 24 weeks (p = .0001 vs baseline for both timepoints) in patients with AS. CT-P13 0-6 C-reactive protein Homo sapiens 46-49 30214547-11 2018 The OPEP group also exhibited a greater decrease in white blood cell count, neutrophil percentage and CRP levels, compared with the MP group. opep 4-8 C-reactive protein Homo sapiens 102-105 34901050-10 2021 Increase in C-reactive protein was found in the group of patients treated with calcium carbonate. Calcium Carbonate 79-96 C-reactive protein Homo sapiens 12-30 29127503-9 2018 The probability of having an undetectable CRP was associated with a lower body mass index (p < 0.0001) and no cyamemazine add-on antipsychotic therapy (p = 0.001). cyamemazine 113-124 C-reactive protein Homo sapiens 42-45 34675565-7 2021 Elderly age, short stature, and higher C-reactive protein (CRP) level were significantly more common in the lower VCM concentration group compared with appropriate VCM concentration group. Vancomycin 114-117 C-reactive protein Homo sapiens 39-57 34675565-7 2021 Elderly age, short stature, and higher C-reactive protein (CRP) level were significantly more common in the lower VCM concentration group compared with appropriate VCM concentration group. Vancomycin 114-117 C-reactive protein Homo sapiens 59-62 34570274-10 2021 Hcy level was negatively correlated with folate (p = 0.009) and vitamin B12 level (p = 0.02) and positively with age (p = 0.01), C-reactive protein (CRP; p = 0.05), and Simplified Disease Activity Index (SDAI; p = 0.03). Homocysteine 0-3 C-reactive protein Homo sapiens 129-147 29852208-9 2018 Escitalopram significantly decreased CRP and IL-6 levels (both P < 0.05). Citalopram 0-12 C-reactive protein Homo sapiens 37-40 34570274-10 2021 Hcy level was negatively correlated with folate (p = 0.009) and vitamin B12 level (p = 0.02) and positively with age (p = 0.01), C-reactive protein (CRP; p = 0.05), and Simplified Disease Activity Index (SDAI; p = 0.03). Homocysteine 0-3 C-reactive protein Homo sapiens 149-152 29540200-10 2018 Treatment with sulfasalazine resulted in significantly reduced IgG hypogalactosylation (p = 0.003) even after adjusting for age, sex, and CRP (p = 0.009). Sulfasalazine 15-28 C-reactive protein Homo sapiens 138-141 34372961-8 2021 Both dietary and serum omega-3 PUFAs, mainly EPA and DPA, were negatively correlated with PCOS-related parameters, such as BMI, fasting insulin, total testosterone and high-sensitivity C-reactive protein (hs-CRP), but positively correlated with follicle-stimulating hormone (FSH) and sex hormone-binding globulin (SHBG). docosapentaenoic acid 53-56 C-reactive protein Homo sapiens 185-203 34372961-8 2021 Both dietary and serum omega-3 PUFAs, mainly EPA and DPA, were negatively correlated with PCOS-related parameters, such as BMI, fasting insulin, total testosterone and high-sensitivity C-reactive protein (hs-CRP), but positively correlated with follicle-stimulating hormone (FSH) and sex hormone-binding globulin (SHBG). docosapentaenoic acid 53-56 C-reactive protein Homo sapiens 208-211 29122443-7 2018 Correlation analyses revealed significant and positive relationships of saturated LPC, BCAA, AAA, and Glu with blood pressure, glucose, triglycerides, apolipoprotein B, and high-sensitivity C-reactive protein, while unsaturated LPC, Gln, Gln/Glu, and 25-hydroxyvitamin D exhibited an opposite trend. saturated 72-81 C-reactive protein Homo sapiens 190-208 34315463-8 2021 RESULTS: Individuals with higher succinate levels had higher levels of visceral adipose tissue (VAT) mass (+ 42.5%), triglycerides (+ 63.9%), C-reactive protein (+ 124.2%), diastolic blood pressure (+ 5.5%), and pro-inflammatory omega-6 oxylipins than individuals with lower succinate levels. Succinic Acid 33-42 C-reactive protein Homo sapiens 142-160 29768263-12 2018 FPA activated ERK1/2 and p38 phosphorylation, and PD98059 and SB203580 reduced FPA-induced CRP expression. SB 203580 62-70 C-reactive protein Homo sapiens 91-94 29121681-5 2018 We found inflammatory behavior for the CTBFR group with a significant difference in serum concentration of C-reactive protein between pre- and post-moment (0.96+-0.37 to 1.71+-1.45, p=0.049), with no difference between groups, and a time effect in interleukin-6 (pre=0.86+-0.43; post=1.02+-0.46, p=0.016). ctbfr 39-44 C-reactive protein Homo sapiens 107-125 34172394-9 2021 Compared with placebo, bempedoic acid significantly lowered apolipoprotein B, non-high-density lipoprotein cholesterol, and total cholesterol (nominal P < .001 for all), and high-sensitivity C-reactive protein (P = .029). 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 23-37 C-reactive protein Homo sapiens 191-209 28582961-4 2017 The ZnSe/CdS/ZnS QDs are used as fluorescent labels to exploit their application in fluorescence-linked immunosorbent assay (FLISA) for the first time in the detection of C-reactive protein (CRP) with a limit of detection (LOD) of 0.85 ng/mL, which is more sensitive than that of CdSe/ZnS type-I QDs based FLISA (1.00 ng/mL). cdse 280-284 C-reactive protein Homo sapiens 171-189 28582961-4 2017 The ZnSe/CdS/ZnS QDs are used as fluorescent labels to exploit their application in fluorescence-linked immunosorbent assay (FLISA) for the first time in the detection of C-reactive protein (CRP) with a limit of detection (LOD) of 0.85 ng/mL, which is more sensitive than that of CdSe/ZnS type-I QDs based FLISA (1.00 ng/mL). cdse 280-284 C-reactive protein Homo sapiens 191-194 28778482-9 2017 In addition, wild-type mice treated with purified human CRP showed significant decreases in the insulin secretion index (HOMA-beta cells) and the insulin stimulation index in isolated islets that were reversed by the addition of L-NAME, aminoguanidine or NAC. NG-Nitroarginine Methyl Ester 229-235 C-reactive protein Homo sapiens 56-59 34134125-13 2021 Concordance values between SDAI remission and the optimal cutoff points of DAS28-ESR, DAS28-CRP, and CDAI were 3.06, 2.37, and 3.20, respectively. sdai 27-31 C-reactive protein Homo sapiens 92-95 28219664-4 2017 Insulin sensitivity increased 31% (p <0.001) among pioglitazone-treated subjects, associated with a decrease in C-reactive protein concentration (p <=0.001), a decrease in plasma triglyceride, and increase in high-density lipoprotein cholesterol concentrations (p <=0.001), accompanied by significant changes in apolipoprotein A1 and B concentrations and lipoprotein subclasses known to decrease CVD risk. Pioglitazone 54-66 C-reactive protein Homo sapiens 115-133 28153283-0 2017 Fast label-free detection of C-reactive protein using broad-band Mach-Zehnder interferometers integrated on silicon chips. Silicon 108-121 C-reactive protein Homo sapiens 29-47 34143369-1 2022 This is a comprehensive systematic review and dose-response meta-analysis evaluating the effects of oral magnesium supplementation on inflammatory biomarkers including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) among adults. Magnesium 105-114 C-reactive protein Homo sapiens 168-186 28036163-0 2017 Immunosensors for C-Reactive Protein Based on Ultrathin Films of Carboxylated Cellulose Nanofibrils. Cellulose 78-87 C-reactive protein Homo sapiens 18-36 34143369-1 2022 This is a comprehensive systematic review and dose-response meta-analysis evaluating the effects of oral magnesium supplementation on inflammatory biomarkers including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) among adults. Magnesium 105-114 C-reactive protein Homo sapiens 188-191 35576800-11 2022 Mediation analysis showed that only miR-26a-5p significantly mediated air pollutant (PM2.5 and NO2)-induced effects on blood CRP and total cholesterol levels. mir-26a-5p 36-46 C-reactive protein Homo sapiens 125-128 35576800-12 2022 For example, 34.1% of PM2.5-associated changes in CRP were significantly mediated by miR-26a-5p at lag4 (indirect effects, 0.06 (0.02, 0.10), P = 0.005). mir-26a-5p 85-95 C-reactive protein Homo sapiens 50-53 28068560-9 2017 Serum C-reactive protein levels and homeostasis model assessment of insulin resistance tended to decrease in the SPG + ASA group, but they were not altered in the ASA group. spirogermanium 113-116 C-reactive protein Homo sapiens 6-24 27756037-9 2016 Changes in SAA-LDL level were significantly and positively correlated with those in CRP in both the RSV (r=0.549, p=0.003) and PTV (r=0.576, p=0.004) groups. pitavastatin 127-130 C-reactive protein Homo sapiens 84-87 27597810-0 2016 Prasugrel Results in Higher Decrease in High-Sensitivity C-Reactive Protein Level in Patients Undergoing Percutaneous Coronary Intervention Comparing to Clopidogrel. Prasugrel Hydrochloride 0-9 C-reactive protein Homo sapiens 57-75 27597810-2 2016 In the present study, we compared the effects of clopidogrel and prasugrel on high-sensitivity C-reactive protein (hs-CRP) in patients undergoing percutaneous coronary intervention (PCI). Prasugrel Hydrochloride 65-74 C-reactive protein Homo sapiens 95-113 35634398-8 2022 Patients at the highest tertile of dietary magnesium intake had lower serum levels of inflammatory biomarkers, including CRP (11.8 +- 2.2 vs. 29.5 +- 2.1 mg/L, p < 0.001) and ESR (15.8 +- 2.4 vs. 34.7 +- 2.4 mm/hr, p < 0.001), than those at the lowest tertile. Magnesium 43-52 C-reactive protein Homo sapiens 121-124 26222760-12 2016 IVIG rescue monotherapy (aOR, 3.05; 95%CI: 1.05-8.84) also predicted non-response after adjusting for fever pattern and post-IVIG CRP. ivig 0-4 C-reactive protein Homo sapiens 130-133 26588324-2 2015 We developed a new 3,4-ethylenedioxythiophene (EDOT) derivative bearing a zwitterionic phosphorylcholine group via a facile synthesis through the Michael-type addition thiol-ene "click" reaction for the detection of an acute-phase biomarker human C-reactive protein (CRP). 3,4-ethylenedioxythiophene 19-45 C-reactive protein Homo sapiens 247-265 26588324-2 2015 We developed a new 3,4-ethylenedioxythiophene (EDOT) derivative bearing a zwitterionic phosphorylcholine group via a facile synthesis through the Michael-type addition thiol-ene "click" reaction for the detection of an acute-phase biomarker human C-reactive protein (CRP). 3,4-ethylenedioxythiophene 19-45 C-reactive protein Homo sapiens 267-270 26588324-2 2015 We developed a new 3,4-ethylenedioxythiophene (EDOT) derivative bearing a zwitterionic phosphorylcholine group via a facile synthesis through the Michael-type addition thiol-ene "click" reaction for the detection of an acute-phase biomarker human C-reactive protein (CRP). 3,4-ethylenedioxythiophene 47-51 C-reactive protein Homo sapiens 247-265 26588324-2 2015 We developed a new 3,4-ethylenedioxythiophene (EDOT) derivative bearing a zwitterionic phosphorylcholine group via a facile synthesis through the Michael-type addition thiol-ene "click" reaction for the detection of an acute-phase biomarker human C-reactive protein (CRP). 3,4-ethylenedioxythiophene 47-51 C-reactive protein Homo sapiens 267-270 35548441-6 2022 N-MID and PINP levels were inversely associated with fasting blood glucose, HOMA-IR, CRP, eGFR, and triglycerides (all P < 0.05), whereas beta-CTX levels were negatively associated with triglycerides (P < 0.05). n-mid 0-5 C-reactive protein Homo sapiens 85-88 26088452-0 2015 High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib. Erlotinib Hydrochloride 123-132 C-reactive protein Homo sapiens 20-38 26088452-4 2015 The aim of our retrospective study was to evaluate the association of baseline serum levels of C-reactive protein (CRP) with outcomes in patients with advanced-stage NSCLC treated with erlotinib. Erlotinib Hydrochloride 185-194 C-reactive protein Homo sapiens 95-113 26088452-4 2015 The aim of our retrospective study was to evaluate the association of baseline serum levels of C-reactive protein (CRP) with outcomes in patients with advanced-stage NSCLC treated with erlotinib. Erlotinib Hydrochloride 185-194 C-reactive protein Homo sapiens 115-118 26088452-10 2015 In conclusion, the results of the conducted retrospective study suggest that high baseline level of CRP was independently associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib. Erlotinib Hydrochloride 203-212 C-reactive protein Homo sapiens 100-103 35232215-7 2022 EPA+DPA-FFA reduced least squares geometric mean high-sensitivity C-reactive protein by 5.8%; EPA-EE increased high-sensitivity C-reactive protein by 8.5% (P=0.034). docosapentaenoic acid 4-7 C-reactive protein Homo sapiens 66-84 35232215-12 2022 EPA+DPA-FFA also reduced triglycerides and high-sensitivity C-reactive protein without increasing low-density lipoprotein cholesterol. docosapentaenoic acid 4-7 C-reactive protein Homo sapiens 60-78 35121786-8 2022 Notably, the magnitude of the associations between PCF/TAT and NAFLD/AO varied by the level of systemic inflammatory marker (hs-CRP level). Triethylenemelamine 55-58 C-reactive protein Homo sapiens 128-131 35077066-13 2022 Increased CRP was associated with elevated hs-CRP in 3 months after discharge and elevated homocysteine levels in both groups, indicating the persistence of prolonged inflammatory vascular reaction in patients after SARS-CoV-2 associated pneumonia, more pronounced in group 2 patients. Homocysteine 91-103 C-reactive protein Homo sapiens 10-13 25802967-6 2015 TAB-positive patients were more likely to be older (age 75.2 +- 7.8 vs 69.7 +- 11.0 years, P = 0.0002), complain of jaw claudication (relative-risk = 3.26, P = 0.0014), and have thrombocytosis (relative-risk = 3.3, P = 0.0072) and elevated CRP (relative-risk = 1.8, P = 0.037). tab 0-3 C-reactive protein Homo sapiens 240-243 25895432-0 2015 Vitamin E supplementation is associated with lower levels of C-reactive protein only in higher dosages and combined with other antioxidants: The Cooperative Health Research in the Region of Augsburg (KORA) F4 study. Vitamin E 0-9 C-reactive protein Homo sapiens 61-79 25895432-1 2015 The aim of the present study was to examine the association between intake of five common antioxidative nutrients from supplements and medications (vitamin E, vitamin C, carotenoids, Se, and Zn) and levels of high-sensitivity C-reactive protein (hs-CRP) in the general population. Vitamin E 148-157 C-reactive protein Homo sapiens 226-244 34991572-10 2022 Although there were no statistically significant differences in clinical markers between groups, however, utra-sensitive C-reactive protein (us-CRP), parathyroid hormone (PTH), body mass index (BMI) and the bone markers U-PYD and PYD/CR were higher in vitamin D deficient older subjects aged >=50 years and female subjects younger than 50 years respectively compared to those with insufficiency or optimal concentrations (p value < 0.05. utra 106-110 C-reactive protein Homo sapiens 121-139 25695403-11 2015 Plasma C-reactive protein and fibrinogen increased with MK-7123 treatment. 2-hydroxy-N,N-dimethyl-3-(2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-enylamino)benzamide 56-63 C-reactive protein Homo sapiens 7-25 3521858-4 1986 Imidazole.2-hydroxybenzoate was more effective than sulindac on Ritchie"s articular index, left hand proximal interphalangeal joint circumference, erythrocyte sedimentation rate, and C-reactive protein. Salicylic Acid 10-27 C-reactive protein Homo sapiens 183-201 25607338-3 2015 In this study, the authors aimed to compare the anti-inflammatory properties of pioglitazone and metformin, with respect to their effect on serum concentrations of highly sensitive C-reactive protein (hsCRP), osteoprotegerin (OPG), intercellular adhesion molecule-1 (ICAM-1) and adiponectin. Pioglitazone 80-92 C-reactive protein Homo sapiens 181-199 25636208-8 2015 After surgical resection of PDAC lesions, CRP and TNFSF13 levels significantly decreased (p < 0.01). pdac 28-32 C-reactive protein Homo sapiens 42-45 26419097-1 2015 BACKGROUND: The present study was designed to evaluate the postoperative values such as body temperature (BT), white blood cells (WBC), P/F ratio and C-reactive protein (CRP) associated with propofol or sevoflurane in patients undergoing thoracic surgery with one-lung ventilation. Propofol 191-199 C-reactive protein Homo sapiens 150-168 26419097-1 2015 BACKGROUND: The present study was designed to evaluate the postoperative values such as body temperature (BT), white blood cells (WBC), P/F ratio and C-reactive protein (CRP) associated with propofol or sevoflurane in patients undergoing thoracic surgery with one-lung ventilation. Propofol 191-199 C-reactive protein Homo sapiens 170-173 26419097-7 2015 CONCLUSIONS: Propofol and sevoflurane had similar effect on BT, WBC, P/F ratio and CRP in patients undergoing thoracic surgery with one-lung ventilation. Propofol 13-21 C-reactive protein Homo sapiens 83-86 26510263-6 2015 After 24 hours, compared to the isoflurane group, the propofol group had significantly lower levels of CRP (P < 0.001), IL-6 (P < 0.001) and IL-8 (P < 0.001), with higher levels CD11 (P = 0.009) and CD18 (P = 0.002) expression. Propofol 54-62 C-reactive protein Homo sapiens 103-106 25746074-6 2015 Treatment with oral prednisolone (1 mg/kg/day) improved her limb claudication and normalized serum C-reactive protein level. Prednisolone 20-32 C-reactive protein Homo sapiens 99-117 25017001-2 2014 The authors tested the hypothesis that C-reactive protein (CRP), a commonly available marker of systemic inflammation, predicts differential response to escitalopram (a serotonin reuptake inhibitor) and nortriptyline (a norepinephrine reuptake inhibitor). Citalopram 153-165 C-reactive protein Homo sapiens 39-57 25017001-2 2014 The authors tested the hypothesis that C-reactive protein (CRP), a commonly available marker of systemic inflammation, predicts differential response to escitalopram (a serotonin reuptake inhibitor) and nortriptyline (a norepinephrine reuptake inhibitor). Citalopram 153-165 C-reactive protein Homo sapiens 59-62 25017001-4 2014 CRP was measured with a high-sensitivity method in serum samples from 241 adult men and women with major depressive disorder randomly allocated to 12-week treatment with escitalopram (N=115) or nortriptyline (N=126). Citalopram 170-182 C-reactive protein Homo sapiens 0-3 25017001-7 2014 For patients with low levels of CRP (<1 mg/L), improvement on the MADRS score was 3 points higher with escitalopram than with nortriptyline. Citalopram 106-118 C-reactive protein Homo sapiens 32-35 25025992-9 2014 The levels of total white blood cell count and high-sensitivity C-reactive protein decreased significantly (P<0.001 and P<0.001, respectively) in the pioglitazone group, whereas these levels did not differ in the control group (P=0.15 and 0.39, respectively) after the treatment. Pioglitazone 156-168 C-reactive protein Homo sapiens 64-82 25559834-9 2014 Preoperative CRP levels did not differ between the groups (P=0.351) and in all patients they were lower than 20 mg/L, but postoperative CRP was significantly higher in propofol group (31+-6 vs 15+-7 ng/L; P=0.035); Pre- and postoperative procalcitonin was within the reference range (<0.04 microg/L) in both groups. Propofol 168-176 C-reactive protein Homo sapiens 136-139 25454789-7 2014 CRP and total:HDL cholesterol increased, and HDL cholesterol decreased, with increasing cotinine concentration across nonsmokers and smokers (all p < .001). Cotinine 88-96 C-reactive protein Homo sapiens 0-3 25474434-0 2014 Environmental carbon monoxide level is associated with the level of high-sensitivity C-reactive protein in peritoneal dialysis patients. Carbon Monoxide 14-29 C-reactive protein Homo sapiens 85-103 24859042-3 2014 Depressive symptoms were assessed by the Patient Health Questionnaire-9, and high-sensitivity serum CRP was quantified by latex-enhanced nephelometry. Latex 122-127 C-reactive protein Homo sapiens 100-103 25194409-6 2014 In addition, erythrocyte sedimentation rate, C-reactive protein, and high-sensitivity C-reactive protein values were significantly lower in the pioglitazone group (P = .03, P < .001, and P = .01). Pioglitazone 144-156 C-reactive protein Homo sapiens 45-63 25194409-6 2014 In addition, erythrocyte sedimentation rate, C-reactive protein, and high-sensitivity C-reactive protein values were significantly lower in the pioglitazone group (P = .03, P < .001, and P = .01). Pioglitazone 144-156 C-reactive protein Homo sapiens 86-104 25192300-9 2014 After three months of infliximab and prednisolone treatment, CRP and disease activity score (DAS 28) values decreased in both groups (p < 0.05), and Duke activity status index (DASI) increased (p < 0.05). Prednisolone 37-49 C-reactive protein Homo sapiens 61-64 24953430-13 2014 In particular, the inflammation biomarkers C-reactive protein, IL-6, and IL-1alpha could indicate the prognostic benefit of gemcitabine chemotherapy and should now be tested in prospective patient-controlled trials. gemcitabine 124-135 C-reactive protein Homo sapiens 43-61 24065043-10 2014 CONCLUSIONS: Eight weeks of taurine supplementation associated with nutritional counseling is able to increase adiponectin levels and to decrease markers of inflammation (high-sensitivity C-reactive protein) and lipid peroxidation (TBARS) in obese women. Taurine 28-35 C-reactive protein Homo sapiens 188-206 24872812-5 2014 Free thyroxine (FT4) levels were negatively associated with body mass index, waist circumference, triglyceride, c-reactive protein, and HOMA-IR and positively with high-density lipoprotein cholesterol in both genders. Thyroxine 5-14 C-reactive protein Homo sapiens 112-130 24499591-11 2013 After 3-months, CRP was higher in the sucrose-added than in the sucrose-free group (p = 0.04), but no further differences were found between the groups, including the insulin requirements, anthropometric variables, body composition, and glycemic control. Sucrose 38-45 C-reactive protein Homo sapiens 16-19 24499591-14 2013 However, although the sucrose intakes increase CRP levels, the amount of sugar in the diet was not associated with this inflammatory marker. Sucrose 22-29 C-reactive protein Homo sapiens 47-50 24027184-10 2013 Stratification on vitamin E intakes showed that inverse associations between dietary n-3 and n-6 PUFA intakes and elevated CRP were substantial only in individuals with low intakes of vitamin E. Vitamin E 18-27 C-reactive protein Homo sapiens 123-126 23524525-9 2013 A significant decrease in leptin (-3.1 ng/ml) and interleukin-6 (-0.4 pg/ml) was found only with pioglitazone; a similar trend (-2.5 ng/ml and -0.3 pg/ml, respectively) was maintained after the addition of rosuvastatin.Rosuvastatin+pioglitazone decreased tumor necrosis factor-alpha (-0.3 ng/ml) and were superior to glibenclamide+rosuvastatin in reducing high-sensitivity C-reactive protein (-0.4 mg/l).Pioglitazone decreased ultrasound parameters, and the addition of rosuvastatin further decreased them both compared with randomization and glibenclamide. Pioglitazone 97-109 C-reactive protein Homo sapiens 373-391 24325121-1 2013 OBJECTIVE: To analyze the expression of Gaq in peripheral blood T lymphocytes of the patients with polymyositis (PM) and its correlation with disease activity evaluated by the clinical markers [manual muscle test (MMT),myositis disease activity assessment (MDAA),creatine phosphokinase (CK), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)]. SCHEMBL8057315 40-43 C-reactive protein Homo sapiens 330-355 23761297-9 2013 Among the circulating molecules tested in this study, HDL, Ox-LDL, and CRP showed dose-response relationships with arsenic exposure. Arsenic 115-122 C-reactive protein Homo sapiens 71-74 23302662-7 2013 Associations between CRP measurements >3 mg/l and extracted DP were then examined with logistic regression models providing OR and 95% CI. dp 63-65 C-reactive protein Homo sapiens 21-24 23302662-9 2013 Of the four extracted DP, a DP with high loading values of vegetables and vegetable oils, leading to high intakes of antioxidant micronutrients and essential fatty acids, was significantly and negatively associated with risk of elevated CRP (OR 0 88; 95% CI 0 78, 0 98). dp 22-24 C-reactive protein Homo sapiens 237-240 23302662-9 2013 Of the four extracted DP, a DP with high loading values of vegetables and vegetable oils, leading to high intakes of antioxidant micronutrients and essential fatty acids, was significantly and negatively associated with risk of elevated CRP (OR 0 88; 95% CI 0 78, 0 98). dp 28-30 C-reactive protein Homo sapiens 237-240 23302662-10 2013 Conversely, a DP reflecting a high n-6:n-3 fatty acid intake ratio was positively and significantly associated with elevated CRP (adjusted OR 1 15; 95% CI 1 00, 1 32). dp 14-16 C-reactive protein Homo sapiens 125-128 23547047-9 2013 Six months posttreatment, the PioFluMet-treated girls had a lower glucose-induced insulinemia, a lower C-reactive protein level, and a thinner intima media than the EE-CA-treated girls, and they were viscerally less adipose, had a higher lean mass, and were more likely to have regular cycles. pioflumet 30-39 C-reactive protein Homo sapiens 103-121 22865000-8 2013 The higher CRP group was discriminated by the above variables in addition to lower VO(2max), serum metabolic syndrome components (triglycerides, glucose, and HDL cholesterol), higher insulin, homeostasis assessment of insulin resistance, uric acid, gamma-GT, and homocysteine. glutaurine 249-257 C-reactive protein Homo sapiens 11-14 24229459-5 2013 Other variables that improved with pioglitazone were the CRP, IL-6, and patient-reported assessment of global health. Pioglitazone 35-47 C-reactive protein Homo sapiens 57-60 23114023-8 2012 The presence of CRP inhibited the association of Dil-labelled oxLDL to human macrophages. dil-labelled oxldl 49-67 C-reactive protein Homo sapiens 16-19 22771801-6 2012 Pharmacological inhibition of phosphatidylinositol (PI)-3 kinase by wortmannin partially reversed the effects of CRP on adiponectin, TNF-alpha and leptin genes expression. Wortmannin 68-78 C-reactive protein Homo sapiens 113-116 22944158-0 2012 [Effect and risk factors of pitavastatin on high sensitivity C-reactive protein in patients with hypercholesterolemia: a multilevel models analysis]. pitavastatin 28-40 C-reactive protein Homo sapiens 61-79 22944158-1 2012 OBJECTIVE: To evaluate the effect of pitavastatin on high sensitivity C-reactive protein (hsCRP) in patients with hypercholesterolemia, and determine risk factors for the effect. pitavastatin 37-49 C-reactive protein Homo sapiens 70-88 22460050-5 2012 CRP levels were quantified by latex-enhanced nephelometry. Latex 30-35 C-reactive protein Homo sapiens 0-3 22560282-7 2012 The feasibility of the present sensing system was demonstrated on the detection of CRP, where the silicon-based inexpensive chips and the simple optical setup were employed. Silicon 98-105 C-reactive protein Homo sapiens 83-86 21993383-5 2012 C-reactive protein (70.9%) and serum amyloid A (34.9%) were also significantly reduced with the pioglitazone use, whereas the HDL particle size was increased (8.80 nm vs. 8.95 nm; p = 0.044) by changes in the distribution of HDL(2b), HDL(3b), and HDL(3c) subclasses. Pioglitazone 96-108 C-reactive protein Homo sapiens 0-18 21980169-10 2011 Pretreatment of HAECs with sepiapterin or diethylenetriamine NONOate, both of which preserve nitric oxide (NO), resulted in attenuation of CRP"s effects on CECs and EMPs. 2,2'-(hydroxynitrosohydrazono)bis-ethanamine 42-68 C-reactive protein Homo sapiens 139-142 21999871-11 2011 High-sensitivity C-reactive protein was decreased by pioglitazone, whereas it was increased by glimepiride. Pioglitazone 53-65 C-reactive protein Homo sapiens 17-35 21410593-7 2011 On the other hand, the KDG showed high CRP (89.7 +- 55.6 mg/l) and high IL-6 (242.2 +- 243.5 pg/ml), and CRP (r = 0.60, P < 0.0001) and IL-6 (r = 0.78, P < 0.0001) significantly correlated with log (BNP). 2-keto-3-deoxygluconate 23-26 C-reactive protein Homo sapiens 39-42 21640381-0 2011 Carbon monoxide, a reaction product of heme oxygenase-1, suppresses the expression of C-reactive protein by endoplasmic reticulum stress through modulation of the unfolded protein response. Carbon Monoxide 0-15 C-reactive protein Homo sapiens 86-104 24049588-7 2011 Prednisolone was administered, her fever subsided and ESR, CRP and hemoglobin were normalized. Prednisolone 0-12 C-reactive protein Homo sapiens 59-62 21349512-6 2011 There were CRP elevations of 6.0% (95% confidence interval (CI) 1.7-10.8%) and 8.3% (95% CI 2.9-14.0%) in relation to interquartile range (IQR) increases in urinary MBzP and MiBP, respectively. mono-benzyl phthalate 165-169 C-reactive protein Homo sapiens 11-14 21349512-9 2011 CRP and GGT were also inversely related to several phthalate metabolites, primarily oxidized metabolites. phthalic acid 51-60 C-reactive protein Homo sapiens 0-3 21482278-2 2011 The CL intensity in the presence of CRP and its ligand, O-phosphorylethanolamine (PEA), was greatly enhanced due to the aggregation of GNPs after the addition of 0.5M NaCl. phosphorylethanolamine 56-80 C-reactive protein Homo sapiens 36-39 21482278-2 2011 The CL intensity in the presence of CRP and its ligand, O-phosphorylethanolamine (PEA), was greatly enhanced due to the aggregation of GNPs after the addition of 0.5M NaCl. phosphorylethanolamine 82-85 C-reactive protein Homo sapiens 36-39 21255215-9 2011 Participants assigned to pioglitazone gained more weight and experienced greater improvements in some coronary risk measures [high-density lipoprotein (HDL)-cholesterol, triglycerides, adiponectin and C-reactive protein (CRP)] than did those assigned to metformin. Pioglitazone 25-37 C-reactive protein Homo sapiens 201-219 21255215-9 2011 Participants assigned to pioglitazone gained more weight and experienced greater improvements in some coronary risk measures [high-density lipoprotein (HDL)-cholesterol, triglycerides, adiponectin and C-reactive protein (CRP)] than did those assigned to metformin. Pioglitazone 25-37 C-reactive protein Homo sapiens 221-224 20727556-5 2011 Induction of CRP protein was mimicked by ceramide, whereas bromopalmitate and other common free fatty acids such as oleate or linoleate were ineffective. Ceramides 41-49 C-reactive protein Homo sapiens 13-16 21360619-3 2011 Both proteins bind to phosphoethanolamine and we show here that, under physiological conditions, phosphoethanolamine is bound with higher affinity by human SAP than by human CRP. phosphorylethanolamine 22-41 C-reactive protein Homo sapiens 174-177 21360619-3 2011 Both proteins bind to phosphoethanolamine and we show here that, under physiological conditions, phosphoethanolamine is bound with higher affinity by human SAP than by human CRP. phosphorylethanolamine 97-116 C-reactive protein Homo sapiens 174-177 21360619-5 2011 Docking simulations show many more low energy positions for phosphoethanolamine bound by CRP than by SAP and are consistent with the crystallographic and functional binding results. phosphorylethanolamine 60-79 C-reactive protein Homo sapiens 89-92 21281508-10 2011 NT-proCNP was strongly associated with inflammatory parameters (i.e. C-reactive protein, procalcitonin and TNF-alpha), biomarkers of organ dysfunction and clinical composite scores (APACHE-II, SOFA, SAPS2). nt-procnp 0-9 C-reactive protein Homo sapiens 69-87 20961967-11 2011 The adiponectin concentration was increased (P<0.05), and OPG and CRP levels were decreased in the pioglitazone group (P<0.05), but were unchanged in the metformin group. Pioglitazone 102-114 C-reactive protein Homo sapiens 69-72 21701640-0 2011 Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression. Citalopram 26-38 C-reactive protein Homo sapiens 42-60 21701640-9 2011 Similarly, in escitalopram treatment group, there was a significant reduction in CRP (P = 0.041), ESR (P = 0.030) and WBC count (P = 0.017) after 2 months of treatment but no significant reduction in HRSD scale (P = 0.169). Citalopram 14-26 C-reactive protein Homo sapiens 81-84 19847435-8 2011 However, the patient"s proteinuria, cylinduria, and elevated C-reactive protein persisted; these findings eventually resolved after treatment with 30 mg of prednisolone daily. Prednisolone 156-168 C-reactive protein Homo sapiens 61-79 20926154-2 2010 Here we present an updated meta-analysis of the respective effects of rosiglitazone and pioglitazone on the levels of C-reactive protein (CRP), a biomarker and predictor of CAD risks. Pioglitazone 88-100 C-reactive protein Homo sapiens 118-136 20926154-2 2010 Here we present an updated meta-analysis of the respective effects of rosiglitazone and pioglitazone on the levels of C-reactive protein (CRP), a biomarker and predictor of CAD risks. Pioglitazone 88-100 C-reactive protein Homo sapiens 138-141 20926154-10 2010 CONCLUSIONS: Our meta-analysis suggested that both rosiglitazone and pioglitazone significantly decrease serum CRP levels. Pioglitazone 69-81 C-reactive protein Homo sapiens 111-114 21122063-9 2010 Reductions in high-sensitivity C-reactive protein were greater in the FDC and pioglitazone groups. Pioglitazone 78-90 C-reactive protein Homo sapiens 31-49 20881254-6 2010 Like Dex, both CpdA and IL-6 increase the positive APPs, serum amyloid A and C-reactive protein, and decrease the negative APP, corticosteroid binding globulin. CPDA 15-19 C-reactive protein Homo sapiens 77-95 20462979-10 2010 Multivariate analysis identified the post-S-1 group (hazard ratio, 0.43; P = 0.001), gender, performance status, liver metastasis, and lactate dehydrogenase and C-reactive protein levels at progressive disease for gemcitabine to be prognostic factors for residual survival. gemcitabine 214-225 C-reactive protein Homo sapiens 161-179 20362753-7 2010 RESULTS: On univariate analyses, low 25-hydroxyvitamin D(3) levels were inversely correlated with asymmetric dimethylarginine concentrations, high-sensitivity C-reactive protein levels, and body mass index. Calcifediol 37-59 C-reactive protein Homo sapiens 159-177 20074254-4 2010 In a preliminary study, the human PASMCs were stimulated by a variety of concentrations of CRP (5-200 microg/mL) at different time points (0, 3, 6, 9, 12, 18 and 24 h) for the purpose of determining the dose- and time-dependent effects of CRP on inflammatory response of the cells. pasmcs 34-40 C-reactive protein Homo sapiens 91-94 20074254-12 2010 The present study demonstrated that inhibiting effect of atorvastatin on CRP-induced inflammatory response in cultured PASMCs was associated with NF-kappaB pathway. pasmcs 119-125 C-reactive protein Homo sapiens 73-76 20171318-2 2010 The affinity towards CRP is imparted to GNP by tethering O-phosphorylethanolamine (PEA) onto their surface. phosphorylethanolamine 57-81 C-reactive protein Homo sapiens 21-24 19446654-6 2010 FROM THE CLINICAL EDITOR: In this study, silicon nanowire field effect transistors were fabricated to be responsive to C-reactive protein. Silicon 41-48 C-reactive protein Homo sapiens 119-137 20920173-12 2010 SAE related to AGE accumulation (r = -0.370, P < 0.05), CRP (r = -0.429, P < 0.05) and creatinine clearance (r = 0.440, P < 0.05), but not to IMT and endothelial activation markers. SELENAZOLE-4-CARBOXYAMIDE-ADENINE DINUCLEOTIDE 0-3 C-reactive protein Homo sapiens 59-62 20068292-10 2010 CONCLUSION: CLS with heparin/gentamicin tended to decrease CRI compared to citrate 46% and heparin and frankly improved the CRP course after catheter insertion. Gentamicins 29-39 C-reactive protein Homo sapiens 124-127 21028996-0 2010 Pitavastatin further decreases serum high-sensitive C-reactive protein levels in hypertensive patients with hypercholesterolemia treated with angiotensin II, type-1 receptor antagonists. pitavastatin 0-12 C-reactive protein Homo sapiens 52-70 21028996-3 2010 We determined the effect of pitavastatin on serum levels of highly sensitive CRP (hs-CRP) in 30 patients with hypercholesterolemia undergoing treatment with anti-hypertensive medication including ARBs. pitavastatin 28-40 C-reactive protein Homo sapiens 77-80 21028996-3 2010 We determined the effect of pitavastatin on serum levels of highly sensitive CRP (hs-CRP) in 30 patients with hypercholesterolemia undergoing treatment with anti-hypertensive medication including ARBs. pitavastatin 28-40 C-reactive protein Homo sapiens 85-88 21028996-13 2010 In conclusion, pitavastatin was found to have powerful anti-inflammatory, add-on effects over the similar effects of ARB as assessed by hs-CRP. pitavastatin 15-27 C-reactive protein Homo sapiens 139-142 19716812-0 2009 The binding of C-reactive protein, in the presence of phosphoethanolamine, to low-density lipoproteins is due to phosphoethanolamine-generated acidic pH. phosphorylethanolamine 54-73 C-reactive protein Homo sapiens 15-33 19716812-0 2009 The binding of C-reactive protein, in the presence of phosphoethanolamine, to low-density lipoproteins is due to phosphoethanolamine-generated acidic pH. phosphorylethanolamine 113-132 C-reactive protein Homo sapiens 15-33 19268941-8 2009 CRP treatment also resulted in increased dihydroethidium staining for superoxide in aortic endothelium and membrane translocation of p47phox, a regulatory subunit of NADPH oxidase. dihydroethidium 41-56 C-reactive protein Homo sapiens 0-3 19584979-5 2009 The main outcome measure was the change in CRP levels from baseline to 12 weeks in the ramipril- versus placebo treated patients. Ramipril 87-95 C-reactive protein Homo sapiens 43-46 19096190-5 2009 After 6 months, patients in the pioglitazone group had significantly improved blood sugar, high-sensitivity C-reactive protein, and plasma adiponectin levels. Pioglitazone 32-44 C-reactive protein Homo sapiens 108-126 19082523-7 2009 Smoking-related CRP elevations only occurred in cotinine-based comparisons (p <or= 0.03), and not when smoking was self-reported. Cotinine 48-56 C-reactive protein Homo sapiens 16-19 19203554-5 2009 Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained. Sulfasalazine 22-36 C-reactive protein Homo sapiens 113-131 19911855-9 2009 Consistent with its angiotensin receptor-blocking effects, valsartan also reduces circulating levels of biochemical markers that are associated with angiotensin II-mediated endothelial dysfunction and CV risk (e.g. high-sensitivity C-reactive protein or oxidized low-density lipoprotein). Valsartan 59-68 C-reactive protein Homo sapiens 232-250 19075492-1 2008 AIM: The effect of pitavastatin on high-sensitivity C-reactive protein (hs-CRP) has not been reported, yet, in humans. pitavastatin 19-31 C-reactive protein Homo sapiens 75-78 19075492-9 2008 The administration of pitavastatin reduced serum hs-CRP levels by 34.8%. pitavastatin 22-34 C-reactive protein Homo sapiens 52-55 18844762-5 2008 In the RAH group, serum C3 (183.9+/-47.5 mg/dL) and hs-CRP (6.9+/-5.8 mg/L) were higher than in the CAH group (C3, 123.1+/-42.3 mg/dL; P < .001, hs-CRP, 4.2+/-4.8; P = .021, respectively). [(2~{S},3~{S},4~{S},5~{R})-3,4,5-tris(oxidanyl)-5-(phosphonooxymethyl)oxolan-2-yl]methanesulfonic acid 7-10 C-reactive protein Homo sapiens 55-58 18844762-5 2008 In the RAH group, serum C3 (183.9+/-47.5 mg/dL) and hs-CRP (6.9+/-5.8 mg/L) were higher than in the CAH group (C3, 123.1+/-42.3 mg/dL; P < .001, hs-CRP, 4.2+/-4.8; P = .021, respectively). [(2~{S},3~{S},4~{S},5~{R})-3,4,5-tris(oxidanyl)-5-(phosphonooxymethyl)oxolan-2-yl]methanesulfonic acid 7-10 C-reactive protein Homo sapiens 151-154 18562112-4 2008 Bis(N-succinimido)-11,11"-dithiobis (undecyl succinate) (DSNHS) was synthesized for use as a linker for immobilizing anti-CRP antibody (anti-CRP) onto the gold surface of a surface plasmon resonance (SPR) sensor chip. bis(n-succinimido)-11,11"-dithiobis (undecyl succinate) 0-55 C-reactive protein Homo sapiens 122-125 18562112-4 2008 Bis(N-succinimido)-11,11"-dithiobis (undecyl succinate) (DSNHS) was synthesized for use as a linker for immobilizing anti-CRP antibody (anti-CRP) onto the gold surface of a surface plasmon resonance (SPR) sensor chip. bis(n-succinimido)-11,11"-dithiobis (undecyl succinate) 0-55 C-reactive protein Homo sapiens 141-144 18486609-4 2008 METHODS: We investigated the interaction of CRP with native LDL using sucrose density gradient ultracentrifugation. Sucrose 70-77 C-reactive protein Homo sapiens 44-47 18486609-5 2008 RESULTS: We found that the blocking of the phosphocholine-binding sites of CRP with phosphoethanolamine (PEt) converted CRP into a potent molecule for binding to native LDL. phosphorylethanolamine 84-103 C-reactive protein Homo sapiens 75-78 18486609-5 2008 RESULTS: We found that the blocking of the phosphocholine-binding sites of CRP with phosphoethanolamine (PEt) converted CRP into a potent molecule for binding to native LDL. phosphorylethanolamine 84-103 C-reactive protein Homo sapiens 120-123 18628422-6 2008 CRP levels were measured by high-sensitivity latex-enhanced nephelometry. Latex 45-50 C-reactive protein Homo sapiens 0-3 18577834-3 2008 Pioglitazone significantly improved insulin resistance, reduced high-sensitivity C-reactive protein, increased high-molecular-weight adiponectin and high-density lipoprotein cholesterol levels. Pioglitazone 0-12 C-reactive protein Homo sapiens 81-99 18799820-8 2008 Perindopril significantly reduced plasma levels of oxidized LDLs, CRP, MCP-1, fibrinogen and PAI-1, and increased interleukin-10. Perindopril 0-11 C-reactive protein Homo sapiens 66-69 18436840-10 2008 DHE staining showed that CRP produced TEMPOL-sensitive superoxide production in the arteriolar endothelium. dihydroethidium 0-3 C-reactive protein Homo sapiens 25-28 18488422-0 2008 Quantitative measurements of C-reactive protein using silicon nanowire arrays. Silicon 54-61 C-reactive protein Homo sapiens 29-47 18396656-7 2007 Data from the logistic regression analysis showed that: when hs-CRP (> or =3 mg/L), the OR of BMI, TG, high blood pressure, HDL-C, cigarett smoking, blood glucose all appeared statistical significance whereas hs-CRP between 1-2.99 mg/L, the OR of trational CHD risk factors did not show statistical significance but 60.98% of the males and 59.02% of the females would have high hs-CRP incriminate traditional CHD risk factors. Blood Glucose 152-165 C-reactive protein Homo sapiens 64-67 17499069-0 2007 Use of chemically modified thermoresponsive copolymers for the detection of C-reactive protein. copolymers 44-54 C-reactive protein Homo sapiens 76-94 17499069-1 2007 Fluorescence intensity of N-isopropylacrylamide-glycidyl methacrylate (NIPAAm-GMA) copolymer conjugated with fluoreseinamine isomer1 was found to decrease considerably in the presence of NIPAAm-GMA copolymer containing O-phosphorylethanolamine (PEA), the specific ligand of C-reactive protein (CRP). n-isopropylacrylamide-glycidyl methacrylate 26-69 C-reactive protein Homo sapiens 274-292 17499069-1 2007 Fluorescence intensity of N-isopropylacrylamide-glycidyl methacrylate (NIPAAm-GMA) copolymer conjugated with fluoreseinamine isomer1 was found to decrease considerably in the presence of NIPAAm-GMA copolymer containing O-phosphorylethanolamine (PEA), the specific ligand of C-reactive protein (CRP). n-isopropylacrylamide-glycidyl methacrylate 26-69 C-reactive protein Homo sapiens 294-297 17499069-1 2007 Fluorescence intensity of N-isopropylacrylamide-glycidyl methacrylate (NIPAAm-GMA) copolymer conjugated with fluoreseinamine isomer1 was found to decrease considerably in the presence of NIPAAm-GMA copolymer containing O-phosphorylethanolamine (PEA), the specific ligand of C-reactive protein (CRP). phosphorylethanolamine 219-243 C-reactive protein Homo sapiens 274-292 17499069-1 2007 Fluorescence intensity of N-isopropylacrylamide-glycidyl methacrylate (NIPAAm-GMA) copolymer conjugated with fluoreseinamine isomer1 was found to decrease considerably in the presence of NIPAAm-GMA copolymer containing O-phosphorylethanolamine (PEA), the specific ligand of C-reactive protein (CRP). phosphorylethanolamine 219-243 C-reactive protein Homo sapiens 294-297 17499069-1 2007 Fluorescence intensity of N-isopropylacrylamide-glycidyl methacrylate (NIPAAm-GMA) copolymer conjugated with fluoreseinamine isomer1 was found to decrease considerably in the presence of NIPAAm-GMA copolymer containing O-phosphorylethanolamine (PEA), the specific ligand of C-reactive protein (CRP). phosphorylethanolamine 245-248 C-reactive protein Homo sapiens 274-292 17499069-1 2007 Fluorescence intensity of N-isopropylacrylamide-glycidyl methacrylate (NIPAAm-GMA) copolymer conjugated with fluoreseinamine isomer1 was found to decrease considerably in the presence of NIPAAm-GMA copolymer containing O-phosphorylethanolamine (PEA), the specific ligand of C-reactive protein (CRP). phosphorylethanolamine 245-248 C-reactive protein Homo sapiens 294-297 17650792-6 2007 After treatment, the general condition of patients was improved, the recovery time of intestinal tract function was shortened and the concentrations of C3, CRP and IL-6 significantly decreased in CTG, with the effects better than those in RTG respectively (P < 0.01 or P < 0.05). ctg 196-199 C-reactive protein Homo sapiens 156-159 17379017-4 2007 Pioglitazone, but not voglibose, reduced CRP levels within 1 month (-51%+/-7%, mean+/-SEM; P<.001). Pioglitazone 0-12 C-reactive protein Homo sapiens 41-44 17239709-1 2007 OBJECTIVES: The purpose of this study was to test the safety and efficacy of pioglitazone and simvastatin in combination versus each drug individually in non-diabetic subjects with cardiovascular disease (CVD) and elevated high-sensitivity C-reactive protein (hs-CRP) levels. Pioglitazone 77-89 C-reactive protein Homo sapiens 240-258 17239709-1 2007 OBJECTIVES: The purpose of this study was to test the safety and efficacy of pioglitazone and simvastatin in combination versus each drug individually in non-diabetic subjects with cardiovascular disease (CVD) and elevated high-sensitivity C-reactive protein (hs-CRP) levels. Pioglitazone 77-89 C-reactive protein Homo sapiens 263-266 17239709-10 2007 At 12 weeks, pioglitazone and simvastatin monotherapies significantly reduced hs-CRP (3.64 +/- 2.42 mg/l to 2.48 +/- 1.77 mg/l and 3.26 +/- 2.02 mg/l to 2.81 +/- 2.11 mg/l) and the combination regimen had an additive effect (from 3.49 +/- 1.97 mg/l to 2.06 +/- 1.42 mg/l, p < 0.001). Pioglitazone 13-25 C-reactive protein Homo sapiens 81-84 17239709-12 2007 Homeostasis model assessment decreased in those receiving pioglitazone, and the correlation between changes in HOMA and hs-CRP was significant (r = 0.43; p < 0.05). Pioglitazone 58-70 C-reactive protein Homo sapiens 123-126 17239709-15 2007 CONCLUSIONS: Pioglitazone, probably by reducing insulin resistance, has additive anti-inflammatory effects to simvastatin in non-diabetic subjects with CVD and high hs-CRP. Pioglitazone 13-25 C-reactive protein Homo sapiens 168-171 17634717-2 2007 When the dose of prednisolone was reduced, she experienced chest pain with elevated CRP and D-dimer, resulting in admission to our hospital with marked cardiomegaly and pleural effusion. Prednisolone 17-29 C-reactive protein Homo sapiens 84-87 17351328-0 2007 C-Reactive protein-induced endothelial microparticle generation in HUVECs is related to BH4-dependent NO formation. sapropterin 88-91 C-reactive protein Homo sapiens 0-18 17351328-7 2007 CONCLUSIONS: This study demonstrates that CRP induces EMP generation in HUVECs and this effect is, at least in part, related to impaired BH(4)-dependent NO production. sapropterin 137-142 C-reactive protein Homo sapiens 42-45 17161243-6 2006 A marked reduction in platelet aggregation and active GP IIb/IIIa expression (p < or = 0.001) with clopidogrel + eptifibatide was associated with a decrease in CRP and TNF-alpha release (p < or = 0.001). Eptifibatide 116-128 C-reactive protein Homo sapiens 163-166 16552402-7 2006 Improvement in SAE was accompanied by improvement of arterial BP, glucose and lipid metabolism, and reduction of CRP values. SELENAZOLE-4-CARBOXYAMIDE-ADENINE DINUCLEOTIDE 15-18 C-reactive protein Homo sapiens 113-116 16978370-6 2006 Statistically significant differences in favour of RSGMET relative to MET were seen for homeostatic model assessment (HOMA)-derived estimates of insulin sensitivity and pancreatic B-cell function, C-reactive protein (CRP), and systolic blood pressure. rsgmet 51-57 C-reactive protein Homo sapiens 197-215 16897175-0 2006 Carbohydrate ligands of human C-reactive protein: binding of neoglycoproteins containing galactose-6-phosphate and galactose-terminated disaccharide. Disaccharides 136-148 C-reactive protein Homo sapiens 30-48 16939632-6 2006 Angiotensin receptor blockers (ARBs) (valsartan, irbesartan, olmesartan, telmisartan) markedly reduce serum levels of CRP. Valsartan 38-47 C-reactive protein Homo sapiens 118-121 16939632-8 2006 Antidiabetic agents (rosiglitazone and pioglitazone) reduce CRP levels, while insulin is ineffective. Pioglitazone 39-51 C-reactive protein Homo sapiens 60-63 16939632-14 2006 The data suggest that lipid lowering agents, ACE inhibitors, ARBs, antidiabetic agents, antiinflammatory and antiplatelet agents, vitamin E, and beta-adrenoreceptor antagonists lower serum or plasma levels of CRP, while vitamin C, oral estrogen and hydrochlorothiazide do not affect CRP levels. Vitamin E 130-139 C-reactive protein Homo sapiens 209-212 16939632-14 2006 The data suggest that lipid lowering agents, ACE inhibitors, ARBs, antidiabetic agents, antiinflammatory and antiplatelet agents, vitamin E, and beta-adrenoreceptor antagonists lower serum or plasma levels of CRP, while vitamin C, oral estrogen and hydrochlorothiazide do not affect CRP levels. Vitamin E 130-139 C-reactive protein Homo sapiens 283-286 16596028-0 2006 The effect of extended-release metoprolol succinate on C-reactive protein levels in persons with hypertension. Metoprolol 31-51 C-reactive protein Homo sapiens 55-73 16596028-1 2006 The objective of this study was to determine whether 3 months of treatment with extended-release metoprolol succinate would reduce C-reactive protein (CRP) levels. Metoprolol 97-117 C-reactive protein Homo sapiens 131-149 16596028-1 2006 The objective of this study was to determine whether 3 months of treatment with extended-release metoprolol succinate would reduce C-reactive protein (CRP) levels. Metoprolol 97-117 C-reactive protein Homo sapiens 151-154 16596028-5 2006 The 13 patients who received 200 mg of extended-release metoprolol had a 32% decline in CRP from 7.0+/-9.0 mg/L to 4.8+/-6.6 mg/L (-2.2 mg/L) (p=0.005) over the 3-month period, whereas lower doses did not reduce CRP (p>0.05). Metoprolol 56-66 C-reactive protein Homo sapiens 88-91 16596028-5 2006 The 13 patients who received 200 mg of extended-release metoprolol had a 32% decline in CRP from 7.0+/-9.0 mg/L to 4.8+/-6.6 mg/L (-2.2 mg/L) (p=0.005) over the 3-month period, whereas lower doses did not reduce CRP (p>0.05). Metoprolol 56-66 C-reactive protein Homo sapiens 212-215 16596028-7 2006 If CRP evolves into a confirmed modifiable risk factor, a beta blocker such as metoprolol may be a useful addition to pharmacotherapy options. Metoprolol 79-89 C-reactive protein Homo sapiens 3-6 16500336-12 2006 CONCLUSION(S): Vitamin E attenuated C-reactive protein increases in postmenopausal women treated with estrogen replacement therapy but not with HT. Vitamin E 15-24 C-reactive protein Homo sapiens 36-54 16461819-9 2006 Treatment with pioglitazone significantly lowered plasma insulin (-22.9%; P<0.001), improved QUICKI insulin sensitivity index (3.7%; P<0.001), increased HDL cholesterol (8.2%; P<0.001), and reduced triglycerides (-15.1%; P=0.003), free fatty acids (-14%; P=0.005), and C-reactive protein (-28.6%; P=0.001). Pioglitazone 15-27 C-reactive protein Homo sapiens 278-296 16461819-12 2006 CONCLUSIONS: In nondiabetic patients with cardiovascular risk factors, pioglitazone treatment enhances insulin sensitivity, decreases C-reactive protein, and improves endothelial vasodilator function. Pioglitazone 71-83 C-reactive protein Homo sapiens 134-152 16596001-4 2006 The therapeutic efficacy of infliximab was markedly demonstrated; the patient"s C-reactive protein (CRP) value returned to almost normal range with subsequent tapering of the dosage of oral prednisolone in the absence of further relapse. Prednisolone 190-202 C-reactive protein Homo sapiens 80-98 16596001-4 2006 The therapeutic efficacy of infliximab was markedly demonstrated; the patient"s C-reactive protein (CRP) value returned to almost normal range with subsequent tapering of the dosage of oral prednisolone in the absence of further relapse. Prednisolone 190-202 C-reactive protein Homo sapiens 100-103 15580352-6 2005 RESULTS: Serum levels of pentosidine were on average significantly higher in RA patients than in healthy subjects and correlated significantly to ESR, CRP, and serum levels of IL-6. pentosidine 25-36 C-reactive protein Homo sapiens 151-154 16324176-4 2005 Temporal arteritis was suspected and prednisolone started with prompt resolution of the headache, chin hypoesthesia, ESR, and CRP. Prednisolone 37-49 C-reactive protein Homo sapiens 126-129 16220077-7 2005 The inhibitors of ERK 1/2 (PD98059), p38 (SB203580) MAPK, and NF-kappaB (PDTC and MG132) significantly decreased C-reactive protein-induced IL-8 secretion in human monocytes. SB 203580 42-50 C-reactive protein Homo sapiens 113-131 16220077-7 2005 The inhibitors of ERK 1/2 (PD98059), p38 (SB203580) MAPK, and NF-kappaB (PDTC and MG132) significantly decreased C-reactive protein-induced IL-8 secretion in human monocytes. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 82-87 C-reactive protein Homo sapiens 113-131 16123332-0 2005 Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils. Peroxynitrous Acid 90-103 C-reactive protein Homo sapiens 31-49 16129801-0 2005 C-reactive protein in heart failure: prognostic value and the effect of valsartan. Valsartan 72-81 C-reactive protein Homo sapiens 0-18 16129801-2 2005 We assessed the prognostic value of CRP in patients randomized in Val-HeFT (Valsartan Heart Failure Trial) and studied changes in CRP that were associated with valsartan. Valsartan 160-169 C-reactive protein Homo sapiens 130-133 16129801-5 2005 Interactions were tested to determine whether differences in CRP changes from baseline to 4 and 12 months between groups randomly assigned to valsartan or placebo depended on baseline ACE inhibitor use. Valsartan 142-151 C-reactive protein Homo sapiens 61-64 16129801-11 2005 CRP did not change significantly over time in the placebo group; however, after 12 months, valsartan was associated with a decrease in CRP in patients not receiving ACE inhibitors but not in those receiving ACE inhibitors at 12 months. Valsartan 91-100 C-reactive protein Homo sapiens 135-138 16146609-7 2005 CONCLUSION: DFPP can remarkably reduce the level of RF, CRP, ESR of blood. dfpp 12-16 C-reactive protein Homo sapiens 56-59 15956115-7 2005 Perindopril-indapamide combination therapy is more effective than beta-blockade in lowering elevated CRP in hypertensive subjects. Perindopril 0-11 C-reactive protein Homo sapiens 101-104 15956115-7 2005 Perindopril-indapamide combination therapy is more effective than beta-blockade in lowering elevated CRP in hypertensive subjects. Indapamide 12-22 C-reactive protein Homo sapiens 101-104 15956010-6 2005 In the first year, C-reactive protein, a marker of inflammation, was strongly correlated with hand bone loss in placebo-treated patients but not in prednisolone-treated patients, suggesting that prednisolone breaks the link between bone loss and inflammation. Prednisolone 195-207 C-reactive protein Homo sapiens 19-37 15904653-0 2005 Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus. Ramipril 29-37 C-reactive protein Homo sapiens 102-120 16020877-0 2005 Association between C-reactive protein and insulin resistance in a Japanese population: the Minoh Study. minoh 92-97 C-reactive protein Homo sapiens 20-38 15791030-0 2005 C-reactive protein concentration is more strongly related to metabolic syndrome in women than in men: the Minoh Study. minoh 106-111 C-reactive protein Homo sapiens 0-18 15795363-6 2005 CRP did not alter endothelial NO synthase protein expression but increased protein expression of GTP cyclohydrolase-1, the rate-limiting enzyme in the synthesis of tetrahydrobiopterin, the NO synthase cofactor. sapropterin 164-183 C-reactive protein Homo sapiens 0-3 15668660-6 2005 Bivariate analysis showed a significant inverse association between CRP and many nutrients (e.g., carbohydrates, proteins, lipids, thiamine, pyridoxine, tocopherol, and folate), but multiple-regression analysis indicated that only the effect of dietary folate intake was not dependent on other factors. Pyridoxine 141-151 C-reactive protein Homo sapiens 68-71 15750984-0 2004 [Cystatin C, beta2-microglobulin and C-reactive protein in hemodiafiltration and on-line endogenous liquid reinfusion and in low flux polysulphone bicarbonate conventional hemodialysis]. polysulphone bicarbonate 134-158 C-reactive protein Homo sapiens 37-55 15663536-10 2004 It was suggested that the case presented here was quite rare, having an extremely high level of CRP which was successfully managed by DFPP. dfpp 134-138 C-reactive protein Homo sapiens 96-99 15184351-7 2004 In study II ramipril alone did not significantly change lipoproteins and C-reactive protein levels, however, simvastatin combined with ramipril significantly changed lipoproteins and C-reactive protein levels more than ramipril alone (P<0.001 and P=0.048 by ANOVA, respectively). Ramipril 135-143 C-reactive protein Homo sapiens 183-201 15184351-7 2004 In study II ramipril alone did not significantly change lipoproteins and C-reactive protein levels, however, simvastatin combined with ramipril significantly changed lipoproteins and C-reactive protein levels more than ramipril alone (P<0.001 and P=0.048 by ANOVA, respectively). Ramipril 135-143 C-reactive protein Homo sapiens 183-201 15615187-8 2004 Standard immunosuppressive therapy with cyclosporine A and prednisolone significantly suppresses the acute phase CRP reaction both in operation itself and acute rejection, but not in infection. Prednisolone 59-71 C-reactive protein Homo sapiens 113-116 15059636-0 2004 Vitamin E modulation of C-reactive protein in smokers with acute coronary syndromes. Vitamin E 0-9 C-reactive protein Homo sapiens 24-42 15059636-9 2004 CRP levels fell in both the vitamin E group and the placebo group over the treatment period (from 17.2 +/- 2.9 to 6.1 +/- 0.8 mg/l and from 21.5 +/- 4.9 to 5.9 +/- 0.9 mg/l, p = NS for the difference between active and placebo groups). Vitamin E 28-37 C-reactive protein Homo sapiens 0-3 15059636-10 2004 However, vitamin E treatment was associated with significantly lower 6 month CRP levels in smokers versus smokers on placebo (4.7 +/- 0.71 mg/l vs. 8.26 +/- 1.5 mg/l, p =.02). Vitamin E 9-18 C-reactive protein Homo sapiens 77-80 15059636-11 2004 Vitamin E reduces CRP levels in smokers with acute coronary syndromes for up to 6 months after hospitalization. Vitamin E 0-9 C-reactive protein Homo sapiens 18-21 14709351-0 2004 Relationship of circulating C-reactive protein levels to thyroid status and cardiovascular risk in hyperlipidemic euthyroid subjects: low free thyroxine is associated with elevated hsCRP. Thyroxine 143-152 C-reactive protein Homo sapiens 28-46 14642813-5 2003 We investigated the applicability of the complement regulatory protein (CRP), Crry, to cytomedicine. cytomedicine 87-99 C-reactive protein Homo sapiens 72-75 14633951-9 2003 The higher PegIFN dose was associated with a significant decrease in levels of C reactive protein (p=0.003, day 0 v 85). pegifn 11-17 C-reactive protein Homo sapiens 79-97 14504187-10 2003 By increasing both superoxide and inducible NO synthase, CRP resulted in increased nitration of PGIS by peroxynitrite. Peroxynitrous Acid 104-117 C-reactive protein Homo sapiens 57-60 14504187-11 2003 The increased nitration and decreased activity of PGIS by CRP was reversed with peroxynitrite scavengers. Peroxynitrous Acid 80-93 C-reactive protein Homo sapiens 58-61 14572579-9 2003 Serum C-reactive protein levels correlated positively with biliary levels of 7-alpha-hydroxycholesterol (R = 0.948), 7-beta-hydroxycholesterol (R = 0.976), cholestan-3-beta,5-alpha,6-beta-triol (R = 0.823), 7-alpha-hydroxy-4-cholesten-3-one (R = 0.846,) and 7-ketocholesterol (R = 0.973). cholestan-3-beta,5-alpha,6-beta-triol 156-193 C-reactive protein Homo sapiens 6-24 12955709-9 2003 Intravenous steroid pulse therapy followed by oral prednisolone (PSL) was effective for reducing the fever, eosinophilia, anti-GBM antibody titer, and C-reactive protein level, but did not improve renal function because renal tissue already was irreversibly damaged. Prednisolone 65-68 C-reactive protein Homo sapiens 151-169 12947436-1 2003 OBJECTIVE: To examine the relationships between circulating concentrations of C-reactive protein and concentrations of retinol, retinyl esters, vitamin C, vitamin E, carotenoids, and selenium. retinyl esters 128-142 C-reactive protein Homo sapiens 78-96 12947436-1 2003 OBJECTIVE: To examine the relationships between circulating concentrations of C-reactive protein and concentrations of retinol, retinyl esters, vitamin C, vitamin E, carotenoids, and selenium. Vitamin E 155-164 C-reactive protein Homo sapiens 78-96 12947436-5 2003 RESULTS: C-reactive protein concentration (dichotomized at the sex-specific 85th percentile) was inversely and significantly associated with concentrations of retinol, retinyl esters, vitamin C, alpha-carotene, beta-carotene, cryptoxanthin, lutein/zeaxanthin, lycopene, and selenium after adjustment for age, sex, race or ethnicity, education, cotinine concentration, body mass index, leisure-time physical activity, and aspirin use. retinyl esters 168-182 C-reactive protein Homo sapiens 9-27 12741936-7 2003 There were significant inverse linear relationships between concentrations of CRP and plasma concentrations of the antioxidants lycopene, beta-carotene, cryptoxanthin and retinol. Lycopene 128-136 C-reactive protein Homo sapiens 78-81 12716789-6 2003 Saturated-to-omega-3 and saturated-to-omega-6 FA ratios were significantly and positively associated with C-reactive protein (P < 0.0001) and IL-6 (P < 0.001), respectively. saturated 0-9 C-reactive protein Homo sapiens 106-124 12716789-6 2003 Saturated-to-omega-3 and saturated-to-omega-6 FA ratios were significantly and positively associated with C-reactive protein (P < 0.0001) and IL-6 (P < 0.001), respectively. saturated 25-34 C-reactive protein Homo sapiens 106-124 12531220-1 2003 In a recent phase I study, a combination of gemcitabine at 10 mg/(m(2)min) for 12 h and mitoxantrone 12 mg/m(2) daily for 3 days, achieved a complete remission (CR) in 3 of 12 (25%) patients with refractory leukemia. gemcitabine 44-55 C-reactive protein Homo sapiens 161-163 12934959-4 2003 However, in our study, when the clinical significance of CRP and L-Homocystine was compared, we found that CRP often was not increased when there was extensive infection of Mycobacterium Tuberculosis as well as asymptomatic infection by Cytomegalovirus, Herpes Simplex Virus Type I, Human Herpes Virus Type 6, Borrelia Burgdorferi, or Chlamydia Trachomatis in the heart (and other parts of the body), particularly when there was liver cell dysfunction such as an increase in ALT. Homocystine 65-78 C-reactive protein Homo sapiens 107-110 12589119-6 2003 Using multivariate logistic regression, the following score was identified to have excellent prognostic significance for MC: CRP (mg/l) - 10 x Lyc (%). Methylcholanthrene 121-123 C-reactive protein Homo sapiens 125-128 12589119-8 2003 Combined use of CRP levels and relative lymphocyte counts may be helpful in accurately predicting an MC after AMI and should therefore be routinely assessed. Methylcholanthrene 101-103 C-reactive protein Homo sapiens 16-19 12398959-8 2002 Although CRP change was weakly correlated with changes in LDL cholesterol, TGs, and HDL cholesterol, results of regression analyses showed that only baseline CRP and treatment allocation were significant predictors of CRP response after 6 weeks of study drug administration. trichlorosucrose 75-78 C-reactive protein Homo sapiens 9-12 12413502-6 2002 hs-CRP was determined using latex-enhanced immunonephelometric assays on a BN II analyzer (Behring). Latex 28-33 C-reactive protein Homo sapiens 3-6 12351557-6 2002 RESULTS: Both doses of tibolone and E(2) + NETA increased serum CRP by a similar extent as soon as 6 months with a sustained effect over the 24 month treatment period. e(2) + neta 36-47 C-reactive protein Homo sapiens 64-67 12351557-7 2002 For example, after 6 months of treatment, serum CRP increased by a median of +106% (P < 0.001), +89% (P < 0.05) and +139% (P < 0.001) for tibolone 1.25 mg/day, tibolone 2.5 mg/day and E(2) + NETA respectively. neta 200-204 C-reactive protein Homo sapiens 48-51 12351557-8 2002 CONCLUSIONS: Tibolone and E(2) + NETA significantly increase serum CRP levels in healthy post-menopausal women to a comparable extent. e(2) + neta 26-37 C-reactive protein Homo sapiens 67-70 12351557-9 2002 Relationships between induced elevated CRP levels with tibolone and E(2) + NETA and cardiovascular events require further studies. e(2) + neta 68-79 C-reactive protein Homo sapiens 39-42 12177794-7 2002 Cancer patients with an acute phase response (C-reactive protein >10 mg x l(-1), n=26) had reduced metabolism as measured with the erythromycin breath test 1/T(MAX) (Kruskal-Wallis Anova, P=0.0062) as compared to controls (C-reactive protein < or =10 mg x l(-1), n=14) Indeed, metabolism was significantly associated with C-reactive protein over the whole concentration range of this acute-phase marker (r=-0.64, Spearman Rank Correlation, P<0.00001). Erythromycin 134-146 C-reactive protein Homo sapiens 46-64 12197410-11 2002 Also asprine, as an antiinflammation agent, changing the CRP levels, would be of benefit for patients with vascular disease because its antiaggregation and antiinflammatory effects. asprine 5-12 C-reactive protein Homo sapiens 57-60 11728484-3 2001 C-reactive protein was measured by latex-enhanced immunoturbidimetric assay, serum tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) by high sensitivity ELISA. Latex 35-40 C-reactive protein Homo sapiens 0-18 24383779-7 2001 We treated the patient with prednisolone and warfarin, which resulted in an improvement in CRP levels and no thrombosis-related complications. Prednisolone 28-40 C-reactive protein Homo sapiens 91-94 11977347-0 2001 C-reactive protein (CRP) as a response to postoperative stress in laparoscopic cholecystectomy using the abdominal wall lift, with performed pneumoperitoneum (CO2), and in open cholecystectomy. N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide 159-162 C-reactive protein Homo sapiens 0-18 10840987-6 2000 Plasma C-RP levels decreased significantly (-49%, P = 0.004) in patients who received vitamin E. Vitamin E 86-95 C-reactive protein Homo sapiens 7-11 10840987-8 2000 CONCLUSIONS: This study indicates that consumption of commercial tomato juice increases plasma lycopene levels and the intrinsic resistance of LDL to oxidation almost as effectively as supplementation with a high dose of vitamin E, which also decreases plasma levels of C-RP, a risk factor for myocardial infarction, in patients with diabetes. Vitamin E 221-230 C-reactive protein Homo sapiens 270-274 10521363-7 1999 Binding of CRP to E-LDL was demonstrated by sucrose flotation experiments. Sucrose 44-51 C-reactive protein Homo sapiens 11-14 9927522-8 1999 The metalloprotease inhibitor TAPI had only a marginal effect on CRP-mediated sIL-6R release, suggesting that shedding occurs via a mechanism distinct from that previously reported. sil-6r 78-84 C-reactive protein Homo sapiens 65-68 11185689-5 1999 She was diagnosed as RP and treatment with 30 mg/day of prednisolone dramatically improved all symptoms and signs, accompanied by a fall in ESR, CRP and autoantibodies. Prednisolone 56-68 C-reactive protein Homo sapiens 145-148 9858442-8 1998 There was a significant correlation between pentosidine and C-reactive protein (CRP), erythrocyte sedimentation rate, and Lansbury Index (p < 0.01). pentosidine 44-55 C-reactive protein Homo sapiens 60-78 9858442-8 1998 There was a significant correlation between pentosidine and C-reactive protein (CRP), erythrocyte sedimentation rate, and Lansbury Index (p < 0.01). pentosidine 44-55 C-reactive protein Homo sapiens 80-83 9858442-10 1998 Pentosidine was significantly higher in the high activity group (CRP > or = 2.0 mg/dl and Lansbury Index > or = 50%) than in the low activity group (CRP < 2.0 and/or Lansbury Index < 50) (100.9 +/- 42.8 vs 58.5 +/- 39.6 nmol/; p = 0.0013). pentosidine 0-11 C-reactive protein Homo sapiens 65-68 9858442-10 1998 Pentosidine was significantly higher in the high activity group (CRP > or = 2.0 mg/dl and Lansbury Index > or = 50%) than in the low activity group (CRP < 2.0 and/or Lansbury Index < 50) (100.9 +/- 42.8 vs 58.5 +/- 39.6 nmol/; p = 0.0013). pentosidine 0-11 C-reactive protein Homo sapiens 155-158 9851262-12 1998 CONCLUSION: Early "aggressive" drug treatment, using sulphasalazine and/or methotrexate, aimed at reduction of the CRP level, significantly reduces the (rate of) radiographic progression in RA. Sulfasalazine 53-67 C-reactive protein Homo sapiens 115-118 9805917-3 1998 Her symptoms were alleviated and erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels returned to normal following the administration of prednisolone (40 mg/day). Prednisolone 157-169 C-reactive protein Homo sapiens 74-92 9805917-3 1998 Her symptoms were alleviated and erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels returned to normal following the administration of prednisolone (40 mg/day). Prednisolone 157-169 C-reactive protein Homo sapiens 94-97 9805917-8 1998 We propose that the pulmonary thromboembolism observed in this case was related to the initial pulmonary involvement of Takayasu arteritis, since the patient"s symptoms, ESR and CRP levels all improved markedly following the administration of prednisolone. Prednisolone 243-255 C-reactive protein Homo sapiens 178-181 9359864-4 1997 The cell-permeable ceramide analogues C2 and C6 each greatly potentiated induction of both CRP and SAA mRNA by IL-6+IL-1beta but did not affect the responses of alpha-fibrinogen to IL-6 or to IL-6+IL-1beta. Ceramides 19-27 C-reactive protein Homo sapiens 91-94 9359864-6 1997 D609, an inhibitor of ceramide production by acidic but not neutral sphingomyelinases, substantially inhibited induction of CRP and SAA by IL-6+IL-1beta. Ceramides 22-30 C-reactive protein Homo sapiens 124-127 9359864-7 1997 The ability of C2 and C6 to potentiate the effects of cytokines suggests that the sphingomyelin-ceramide pathway participates in induction of CRP and SAA by IL-6+IL-1beta under these experimental conditions, most likely by transducing the effects of IL-1beta. Ceramides 96-104 C-reactive protein Homo sapiens 142-145 9291856-4 1997 Oral prednisolone, starting dose 7.5 or 20 mg daily, was used as a rescue drug in patients with intolerable joint pain and stiffness and with C-reactive protein (CRP) > or = 20 mg/l, and was tapered down according to protocol guidelines. Prednisolone 5-17 C-reactive protein Homo sapiens 142-160 9291856-4 1997 Oral prednisolone, starting dose 7.5 or 20 mg daily, was used as a rescue drug in patients with intolerable joint pain and stiffness and with C-reactive protein (CRP) > or = 20 mg/l, and was tapered down according to protocol guidelines. Prednisolone 5-17 C-reactive protein Homo sapiens 162-165 9181655-7 1997 Tobramycin seemed to enhance the resolution of inflammation by a more rapid decline in C-reactive protein levels. Tobramycin 0-10 C-reactive protein Homo sapiens 87-105 8648114-8 1996 Using mAb to LPG with known ligand specificities, we define a novel ligand for CRP as the repeating phosphorylated disaccharide units that form the backbone of LPG. Disaccharides 115-127 C-reactive protein Homo sapiens 79-82 8636270-4 1996 The treatment with prednisolone rapidly and progressively decreased serum levels of thyroglobulin, T4, and C-reactive protein and the erythrocyte sedimentation rate. Prednisolone 19-31 C-reactive protein Homo sapiens 107-125 7485521-5 1995 The inhibition of surfactant adsorption by CRP was effectively eliminated by the addition of phosphocholine at a molar ratio of 300:1 (phosphocholine:CRP), but it was not diminished by the addition of identical molar ratios of o-phosphoethanolamine or DL-alpha-glycerophosphate at the same molar ratios. phosphorylethanolamine 227-248 C-reactive protein Homo sapiens 43-46 7830359-2 1994 On out patient clinic, the CRP had been kept from 0.5 to 1.5 mg/dl in dose of 10 mg of prednisolone. Prednisolone 87-99 C-reactive protein Homo sapiens 27-30 7979374-6 1994 Both SAP and CRP displayed a similar binding preference for PC vs phosphoethanolamine (PE). phosphorylethanolamine 66-85 C-reactive protein Homo sapiens 13-16 7979374-6 1994 Both SAP and CRP displayed a similar binding preference for PC vs phosphoethanolamine (PE). phosphorylethanolamine 87-89 C-reactive protein Homo sapiens 13-16 7685225-4 1993 The DMARDs such as gold salts, D-penicillamine, sulphasalazine and azathioprine have been shown to reduce serum CRP concentrations significantly in patients with RA. Sulfasalazine 48-62 C-reactive protein Homo sapiens 112-115 8507933-2 1993 The IL-6 and CRP levels, which were extremely high before treatment, declined rapidly with corticosteroid and cyclophosphamide. Cyclophosphamide 110-126 C-reactive protein Homo sapiens 13-16 1424289-5 1992 The MOCM from prednisolone-treated monocytes induced less SAA and CRP production by HepG2 cells; (ii) IL-1 alpha and IL-1 beta both induced CRP and SAA synthesis by HepG2 cells, but only in the presence of IL-6. Prednisolone 14-26 C-reactive protein Homo sapiens 66-69 1424289-5 1992 The MOCM from prednisolone-treated monocytes induced less SAA and CRP production by HepG2 cells; (ii) IL-1 alpha and IL-1 beta both induced CRP and SAA synthesis by HepG2 cells, but only in the presence of IL-6. Prednisolone 14-26 C-reactive protein Homo sapiens 140-143 1608680-6 1992 C-reactive protein decreased significantly faster in those with perforated appendix treated with imipenem than in those treated with tobramycin and metronidazole (58.2 mg/liter vs. 89.4 mg/liter, P less than 0.05 on the third postoperative day). Tobramycin 133-143 C-reactive protein Homo sapiens 0-18 1968353-4 1990 Significant improvements were observed in chest expansion, number of active joints, ESR and CRP which deteriorated after withdrawal of sulphasalazine. Sulfasalazine 135-149 C-reactive protein Homo sapiens 92-95 33775207-0 2021 C-reactive protein and ground-glass opacity as predictors for intractable interstitial lung disease in patients with systemic sclerosis under cyclophosphamide treatment regardless of concomitant glucocorticoids. Cyclophosphamide 142-158 C-reactive protein Homo sapiens 0-18 33775207-11 2021 CONCLUSIONS: High CRP levels with non-widespread GGO predicted progressive ILD in patients with SSc treated with CYC. Cyclophosphamide 113-116 C-reactive protein Homo sapiens 18-21 33776003-3 2021 Her ANCA titers remained stable; however, her C-reactive protein increased on 5 mg/day prednisolone before admission. Prednisolone 87-99 C-reactive protein Homo sapiens 46-64 34850657-0 2021 Does C-reactive protein predict time to recovery and benefit from oseltamivir treatment in primary care patients with influenza-like illness? Oseltamivir 66-77 C-reactive protein Homo sapiens 5-23 34850657-4 2021 This study aimed to investigate whether a C-reactive protein (CRP) concentration of >=30 mg/L can predict (1) ILI disease duration, and (2) which patients are most likely to benefit from oseltamivir treatment. Oseltamivir 187-198 C-reactive protein Homo sapiens 42-60 34850657-4 2021 This study aimed to investigate whether a C-reactive protein (CRP) concentration of >=30 mg/L can predict (1) ILI disease duration, and (2) which patients are most likely to benefit from oseltamivir treatment. Oseltamivir 187-198 C-reactive protein Homo sapiens 62-65 34918136-8 2021 Young age, bloody sputum, low serum creatinine, and high C-reactive protein levels were independently associated with CY use in MPA. Cyclophosphamide 118-120 C-reactive protein Homo sapiens 57-75 34542654-7 2022 On multivariate regression analysis of collected data infection of retropharyngeal, pretracheal and carotid space, C-reactive protein and procalcitonine values were statistically significant predictors for DNM development. 1-DEOXYNOJIRIMYCIN 206-209 C-reactive protein Homo sapiens 115-133 34344464-9 2021 RESULTS: We found that the plasma of patients with very high risk, aggressive PCa and high level of C-reactive protein have a peculiar metabolic phenotype (metabotype) characterized by extremely high levels of GlycA and GlycB. glyca 210-215 C-reactive protein Homo sapiens 100-118 34922405-0 2021 C-reactive protein and ground-glass opacity as predictors for intractable interstitial lung disease in patients with systemic sclerosis under cyclophosphamide treatment regardless of concomitant glucocorticoids. Cyclophosphamide 142-158 C-reactive protein Homo sapiens 0-18 35271871-0 2022 The association of C-reactive protein with responses to escitalopram antidepressant treatment in patients with major depressive disorder. Citalopram 56-68 C-reactive protein Homo sapiens 19-37 35271871-3 2022 We hypothesized that in adults with major depressive disorder, the peripheral biomarker, CRP, was associated with the response to escitalopram (SSRI). Citalopram 130-142 C-reactive protein Homo sapiens 89-92 35271871-14 2022 CONCLUSIONS: We observed a predictive role of CRP for remission and symptomatic improvement after escitalopram treatment of MDD patients based on continuous or categorical CRP levels. Citalopram 98-110 C-reactive protein Homo sapiens 172-175 35429740-17 2022 And ApoB, CRP and BDNF could be as potential peripheral candidates in cognitive evaluation to distinguish UD and BD. UD 106-108 C-reactive protein Homo sapiens 10-13 35594016-9 2022 28-joint Disease Activity Score, Simplified Disease Activity Index and Maastricht Ankylosing Spondylitis Enthesitis score were also significantly worse in the nADAb-positive patients (p < 0.04, adjusted analyses), as were serum calprotectin, C-reactive protein and numbers of circulating peripheral leukocytes (p <= 0.001). nadab 159-164 C-reactive protein Homo sapiens 242-260 35575465-10 2022 Sarcopenia (HR 2.08) and C-reactive protein > 6.5 mg/L (HR 2.57) were determined as independent poor prognostic factors for PFS of erlotinib therapy. Erlotinib Hydrochloride 131-140 C-reactive protein Homo sapiens 25-43 35312849-9 2022 The significant increase in area value of alpha-linoleic and eicosadienoic acids were positively correlated with the elevated level of C-reactive protein at postoperative day 2 (Spearman"s rho = 0.843, P < 0.001; Spearman"s rho = 0.785, P = 0.001). eicosadienoic acids 61-80 C-reactive protein Homo sapiens 135-153 35142908-4 2022 The filgotinib 200 mg + MTX and upadacitinib 15 mg + MTX groups showed a significantly higher DAS28-CRP < 2.6 than adalimumab 40 mg + MTX. GLPG0634 4-14 C-reactive protein Homo sapiens 100-103 35116046-10 2022 The patient"s arthralgia and high CRP level persisted after we increased her oral prednisolone dose and added oral methotrexate, but her symptoms eventually improved with the addition of intravenous tocilizumab. Prednisolone 82-94 C-reactive protein Homo sapiens 34-37 3385211-7 1988 The modification of the CRP structure was confirmed by the change in the fluorescence spectrum of 8-anilino-1-naphthalene sulfonate complexed with CRP, the increased susceptibility of CRP to proteolytic enzymes and the altered reactivity to anti-CRP mAb. 8-anilino-1-naphthalenesulfonic acid 98-131 C-reactive protein Homo sapiens 24-27 3385211-7 1988 The modification of the CRP structure was confirmed by the change in the fluorescence spectrum of 8-anilino-1-naphthalene sulfonate complexed with CRP, the increased susceptibility of CRP to proteolytic enzymes and the altered reactivity to anti-CRP mAb. 8-anilino-1-naphthalenesulfonic acid 98-131 C-reactive protein Homo sapiens 147-150 3385211-7 1988 The modification of the CRP structure was confirmed by the change in the fluorescence spectrum of 8-anilino-1-naphthalene sulfonate complexed with CRP, the increased susceptibility of CRP to proteolytic enzymes and the altered reactivity to anti-CRP mAb. 8-anilino-1-naphthalenesulfonic acid 98-131 C-reactive protein Homo sapiens 147-150 3385211-7 1988 The modification of the CRP structure was confirmed by the change in the fluorescence spectrum of 8-anilino-1-naphthalene sulfonate complexed with CRP, the increased susceptibility of CRP to proteolytic enzymes and the altered reactivity to anti-CRP mAb. 8-anilino-1-naphthalenesulfonic acid 98-131 C-reactive protein Homo sapiens 147-150 3660286-1 1987 In a prospective study serum C-reactive protein concentrations were measured in nine patients with "active" pulmonary sarcoidosis (as assessed by bronchoalveolar lavage lymphocyte counts, gallium-67 lung scanning, and serial pulmonary function testing), and in five patients with "inactive" disease. Gallium 188-195 C-reactive protein Homo sapiens 29-47 3919022-6 1985 Hydrolysis of multilamellar dipalmitoylphosphatidylcholine liposomes by purified phospholipase A2, was also inhibited by CRP. 1,2-Dipalmitoylphosphatidylcholine 28-58 C-reactive protein Homo sapiens 121-124 7333010-1 1981 Two new, rapid and sensitive radioimmunoassays for human C-reactive protein (CRP) have been established using antiserum coupled to magnetizable cellulose particles, which facilitate phase separation. Cellulose 144-153 C-reactive protein Homo sapiens 57-75 7333010-1 1981 Two new, rapid and sensitive radioimmunoassays for human C-reactive protein (CRP) have been established using antiserum coupled to magnetizable cellulose particles, which facilitate phase separation. Cellulose 144-153 C-reactive protein Homo sapiens 77-80 271994-9 1977 We conclude that (i) CRP can sensitize appropriate liposomes for complement-dependent damage via the primary complement pathway starting at the level of C1q; (ii) of those studied, liposomes that are most susceptible to membrane damage contain phosphatidylcholine, have a positive charge, and contain a ceramide glycolipid; and (iii) such liposomes also are sensitive, although to a much lesser degree, to complement-dependent lysis initiated in the absence of CRP and involving consumption of terminal in excess of early acting complement components. ceramide glycolipid 303-322 C-reactive protein Homo sapiens 21-24 921822-3 1977 Cultures of rheumatoid synovium in 14C-labeled amino acids produced radioactive IgG, IgM, IgA, and C3; but not CRP, indicating the synovial-bound CRP was not of local origin. Carbon-14 35-38 C-reactive protein Homo sapiens 146-149 13163339-4 1954 Crystalline C-reactive protein has its isoelectric point at pH 4.82 as determined by free electrophoresis in McIlvaine"s buffer. mcilvaine"s buffer 109-127 C-reactive protein Homo sapiens 12-30 33230526-13 2021 The least-squares mean change (decrease) from baseline (standard error) in DAS28-CRP at W22 was 2.21 (0.22) for CT-P13 s.c. (n = 162) and 1.94 (0.21) for CT-P13 i.v. CT-P13 112-118 C-reactive protein Homo sapiens 81-84 33853292-5 2021 Among previously untreated patients, composite response (CRc) was achieved in 13/15 (87%, 8 CR, 4 Cri, 1 CRp) treated with quizartinib/AZA and 14/19 (74%, 1 CR, 8 CRi, 5 CRp) in quizartinib/LDAC. quizartinib 123-134 C-reactive protein Homo sapiens 57-59 33898494-7 2021 The associations between E-DII quartiles and hs-CRP concentration were assessed using regression models adjusted for age, body mass index, smoking status, and amount of physical activity. e-dii 25-30 C-reactive protein Homo sapiens 48-51 33898494-11 2021 The odds ratio (95% confidence interval) of having an elevated hs-CRP concentration (>3 mg/L) was 1.72 (1.10-2.67) in the highest E-DII quartile (P trend = 0.03) in men. e-dii 130-135 C-reactive protein Homo sapiens 66-69 33684473-3 2021 Therefore, we performed a systematic review and meta-analysis of data from the literature to determine the association between CRP and post-procedure ALE in PAD patients. Epinephrine 150-153 C-reactive protein Homo sapiens 127-130 33684473-4 2021 METHODS: Studies investigating the association between CRP and post-procedure ALE (target vessel revascularization, amputation, restenosis, disease progression, and the composite endpoint of any of these adverse limb events) were identified in the Medline, EMBASE, and Cochrane databases. Epinephrine 78-81 C-reactive protein Homo sapiens 55-58 33398528-8 2021 Based on a generalized estimating equations analysis model with time interaction considered, the only significant factor associated with changes in phenylalanine was changes in C-reactive protein concentrations from baseline to 12 months [B (coefficient) = 0.81, P < 0.001] after adjusting for methionine sulfoxide and total bilirubin levels. methionine sulfoxide 294-314 C-reactive protein Homo sapiens 177-195 33290138-0 2021 Glucosamine and Chondroitin Use in Relation to C-Reactive Protein Concentration: Results by Supplement Form, Formulation, and Dose. Chondroitin 16-27 C-reactive protein Homo sapiens 47-65 33290138-1 2021 Objectives: Glucosamine and chondroitin supplements have been associated with reduced inflammation, as measured by C-reactive protein (CRP). Chondroitin 28-39 C-reactive protein Homo sapiens 115-133 33290138-1 2021 Objectives: Glucosamine and chondroitin supplements have been associated with reduced inflammation, as measured by C-reactive protein (CRP). Chondroitin 28-39 C-reactive protein Homo sapiens 135-138 33290138-14 2021 Conclusions: Although a significant inverse association was observed for glucosamine and chondroitin and CRP in early years, this association did not hold in later years. Chondroitin 89-100 C-reactive protein Homo sapiens 105-108 33636418-6 2021 Differences across treatments showed that the group receiving both fish oil and cranberry experienced reductions (P < 0.05) in erythrocyte sedimentation rate and C-reactive protein compared to the control group and the group treated with fish oil alone, and a reduction in DAS28-CRP was verified when the fish oil and cranberry group was compared to the control group. Fish Oils 67-75 C-reactive protein Homo sapiens 162-180 33636418-6 2021 Differences across treatments showed that the group receiving both fish oil and cranberry experienced reductions (P < 0.05) in erythrocyte sedimentation rate and C-reactive protein compared to the control group and the group treated with fish oil alone, and a reduction in DAS28-CRP was verified when the fish oil and cranberry group was compared to the control group. Fish Oils 67-75 C-reactive protein Homo sapiens 279-282 33370348-9 2020 The most consistent findings were for cysteamine 450mg twice daily that had effects additional to that observed with placebo, with improved symptoms, CRISS additional 9.85 points (95% CI 0.02, 19.7) p = 0.05, reduced blood leukocyte count by 2.46x109 /l (95% CI 0.11, 4.80), p = 0.041 and reduced CRP by geometric mean 2.57 nmol/l (95% CI 0.15, 0.99), p = 0.049. Cysteamine 38-48 C-reactive protein Homo sapiens 297-300 33224343-6 2020 According to the above-mentioned results, rosuvastatin, fluvastatin, pitavastatin and atorvastatin were found to have stronger binding to CRP compared with the standard ligand phosphocholine (pKi = 14.55). pitavastatin 69-81 C-reactive protein Homo sapiens 138-141 31747058-8 2020 CONCLUSIONS: We identified age >=55, NLR >=13, and CRP >=30 before DNI treatment as clinical predictors of a DNM complication. 1-DEOXYNOJIRIMYCIN 109-112 C-reactive protein Homo sapiens 51-54 32755613-8 2020 As for the levels of CRP, only when astaxanthin was administered (i) for relatively long periods (>= 12 weeks) (WMD: -0.528 mg/l, 95 % CI: -0.990 to -0.066), and (ii) at high dose (> 12 mg/day) (WMD: -0.389 mg/dl, 95 % CI: -0.596 to -0.183), the levels of CRP would decrease. astaxanthine 36-47 C-reactive protein Homo sapiens 21-24 32755613-8 2020 As for the levels of CRP, only when astaxanthin was administered (i) for relatively long periods (>= 12 weeks) (WMD: -0.528 mg/l, 95 % CI: -0.990 to -0.066), and (ii) at high dose (> 12 mg/day) (WMD: -0.389 mg/dl, 95 % CI: -0.596 to -0.183), the levels of CRP would decrease. astaxanthine 36-47 C-reactive protein Homo sapiens 256-259 32755613-9 2020 CONCLUSION: In summary, our systematic review and meta-analysis revealed that astaxanthin consumption was associated with increase in HDL-C and decrease in CRP. astaxanthine 78-89 C-reactive protein Homo sapiens 156-159 33057114-1 2020 The previous meta-analysis of clinical trials revealed a beneficial effect of vitamin E supplementation on serum C-reactive protein (CRP) concentrations; however, it is unknown whether this vitamin has the same influence on other inflammatory biomarkers. Vitamin E 78-87 C-reactive protein Homo sapiens 113-131 33057114-1 2020 The previous meta-analysis of clinical trials revealed a beneficial effect of vitamin E supplementation on serum C-reactive protein (CRP) concentrations; however, it is unknown whether this vitamin has the same influence on other inflammatory biomarkers. Vitamin E 78-87 C-reactive protein Homo sapiens 133-136 33057114-7 2020 Based on 36 effect sizes from 26 RCTs on serum concentrations of CRP, we found a significant reduction following supplementation with vitamin E (- 0.52, 95% CI - 0.80, - 0.23 mg/L, P < 0.001). Vitamin E 134-143 C-reactive protein Homo sapiens 65-68 32921364-2 2020 We tested the hypothesis that parenteral omega-3 FA from a lipid emulsion that includes fish oil could be beneficial in patients with predicted SAP by reducing C-reactive protein (CRP) concentration (primary outcome), and modulating the inflammatory response and improving clinical outcome (secondary outcomes). Fish Oils 88-96 C-reactive protein Homo sapiens 160-178 32921364-2 2020 We tested the hypothesis that parenteral omega-3 FA from a lipid emulsion that includes fish oil could be beneficial in patients with predicted SAP by reducing C-reactive protein (CRP) concentration (primary outcome), and modulating the inflammatory response and improving clinical outcome (secondary outcomes). Fish Oils 88-96 C-reactive protein Homo sapiens 180-183 32921364-5 2020 Administration of fish oil resulted in lower total blood leukocyte number (P = 0.04), CRP (P = 0.013), interleukin-8 (P = 0.05) and intercellular adhesion molecule 1 (P = 0.01) concentrations, multiple organ dysfunction score, sequential organ failure assessment score (P = 0.004), early warning score (P = 0.01), and systemic inflammatory response syndrome (P = 0.03) compared to the control group. Fish Oils 18-26 C-reactive protein Homo sapiens 86-89 32645631-8 2020 Baricitinib decreased the systemic inflammation by lowering expression of IL-6 and CRP and reducing ESR and serum concentrations of adiponectin. baricitinib 0-11 C-reactive protein Homo sapiens 83-86 32923098-0 2020 C-reactive protein reduction with sacubitril-valsartan treatment in heart failure patients. Valsartan 45-54 C-reactive protein Homo sapiens 0-18 32923098-10 2020 After 6 months of Sacubitril-Valsartan therapy, 24 (69%) patients had an improvement in CRP values with a significantly reduction as compared to baseline (median 2.5 mg/L (Interquartile range (IQR) 1.3-5.0) vs. 2.2 mg/L (IQR 0.9-4.0), P=0.014 in the Wilcoxon test). Valsartan 29-38 C-reactive protein Homo sapiens 88-91 32923098-12 2020 CONCLUSION: Sacubitril/Valsartan therapy was able to reduce CRP values in a chronic HF population. Valsartan 23-32 C-reactive protein Homo sapiens 60-63 32599804-3 2020 Here, we report the fabrication of an interdigitated sensing device integrated with polyvinyl alcohol (PVA) nanofibers and carbon nanotubes (CNT) for the detection of an inflammatory biomarker, C-reactive protein (CRP). Polyvinyl Alcohol 84-101 C-reactive protein Homo sapiens 194-212 32599804-3 2020 Here, we report the fabrication of an interdigitated sensing device integrated with polyvinyl alcohol (PVA) nanofibers and carbon nanotubes (CNT) for the detection of an inflammatory biomarker, C-reactive protein (CRP). Polyvinyl Alcohol 84-101 C-reactive protein Homo sapiens 214-217 32599804-3 2020 Here, we report the fabrication of an interdigitated sensing device integrated with polyvinyl alcohol (PVA) nanofibers and carbon nanotubes (CNT) for the detection of an inflammatory biomarker, C-reactive protein (CRP). Polyvinyl Alcohol 103-106 C-reactive protein Homo sapiens 194-212 32132385-10 2020 NH with a higher initial TCB level was related to an increased chance of elevated CRP (4.7% vs. 1.5%, odds ratio: 3.29, p = 0.024) and pyuria (20.6% vs. 12.6%, odds ratio: 1.79, p < 0.001). tcb 25-28 C-reactive protein Homo sapiens 82-85 32132385-13 2020 CONCLUSION: In well-appearing neonates below 7 days old, NH with a higher initial TCB is associated with an increased rate in pyuria and abnormal CRP. tcb 82-85 C-reactive protein Homo sapiens 146-149 32234180-4 2020 hs-CRP was determined by latex enhanced immunoturbidimetry. Latex 25-30 C-reactive protein Homo sapiens 3-6 32046485-3 2020 Herein, we expand this scope by utilizing phytic acid-doped polyaniline as a novel redox-charging polymer support enabling the reagentless assaying of C-reactive protein in serum with good sensitivity. Phytic Acid 42-53 C-reactive protein Homo sapiens 151-169 31734899-10 2020 CT-P13 demonstrated comparable improvements in DAS28-ESR, DAS28-CRP and ACR responses to reference infliximab. CT-P13 0-6 C-reactive protein Homo sapiens 64-67 31287400-7 2020 High sensitivity C-reactive protein value (OR 1.06; 95% CI 1.00-1.13, p=0.026) at baseline also was a predictive factor of mMDA achievement at 6 months in the laboratory-enhanced prediction model. MMDA 123-127 C-reactive protein Homo sapiens 17-35 32223493-8 2020 Furthermore, osteophyte size in the MC was negatively correlated with the inflammatory markers C-reactive protein (r = -0.492, p = 0.0027) and erythrocyte sedimentation rate (r = -0.529, p = 0.0016), whereas that in the LC was negatively correlated with disease activity (r = -0.589, p = 0.0023). Methylcholanthrene 36-38 C-reactive protein Homo sapiens 95-113 31998000-10 2019 In psoriatic patients with normal body weight, nervonic ceramide (C24:1) correlated with PASI (r = 0.38; p = 0.042) and CRP (C-reactive protein) (r = 0.42; p = 0.023). Ceramides 56-64 C-reactive protein Homo sapiens 120-123 31998000-10 2019 In psoriatic patients with normal body weight, nervonic ceramide (C24:1) correlated with PASI (r = 0.38; p = 0.042) and CRP (C-reactive protein) (r = 0.42; p = 0.023). Ceramides 56-64 C-reactive protein Homo sapiens 125-143 31998000-11 2019 In overweight patients, the concentration of lignoceric ceramide (C24:0) correlated inversely with the severity of the disease (r = -0.41; p = 0.022) and CRP (r = -0.6; p = 0.0004). Ceramides 56-64 C-reactive protein Homo sapiens 154-157 31613870-8 2019 The most intense (grade 3) alcian blue staining was significantly correlated with diabetes as well as higher levels of Ca x Pi product, hs-CRP, fibrinogen, SDF-1alpha, PAI-1, and sTM. Alcian Blue 27-38 C-reactive protein Homo sapiens 139-142 31180164-0 2019 Dynamics of neutrophil and C-reactive protein reflect the clinical course of pyrexia during combination therapy with dabrafenib and trametinib. trametinib 132-142 C-reactive protein Homo sapiens 27-45 32754703-8 2020 When taking the magnitude of surgery into account, TIVA using propofol was significantly associated with a reduction in particular C-reactive protein (P = .04). Propofol 62-70 C-reactive protein Homo sapiens 131-149 30761717-8 2019 Increases in HDL cholesterol, decreases in triglycerides, liver enzyme and high-sensitivity C-reactive protein levels, and reductions in abdominal visceral fat area and insulin resistance were observed only in the CTZ group. Cilostazol 214-217 C-reactive protein Homo sapiens 92-110 30537058-5 2019 The results demonstrated that, compared with placebo and enalapril, ramipril had a better effect on reducing systolic blood pressure after short-term usage of drugs (<12 months), while perindopril had better effects on reducing diastolic blood pressure and C-reactive protein expression. Ramipril 68-76 C-reactive protein Homo sapiens 260-278 30090974-12 2019 A chronic inflammation pattern characterized by decreased albumin and increased C-reactive protein and alpha-1-acid glycoprotein levels led to high lurbinectedin exposure. PM 01183 148-161 C-reactive protein Homo sapiens 80-98 29675557-11 2019 In this same sample, the E-DII also was associated with CRP >= 3 mg/l (ORDIIcontinuous = 1.12; 95% CI 1.05, 1.19). e-dii 25-30 C-reactive protein Homo sapiens 56-59 30788348-9 2019 The AUC of serum CRP in diagnosing PPE was 0.79. ppe 35-38 C-reactive protein Homo sapiens 17-20 30557399-9 2018 In female patients, lower HCT, higher creatinine, higher CRP concentrations and higher telomerase activity were also achieved by higher EDIP scores (P < 0.05). edip 136-140 C-reactive protein Homo sapiens 57-60 30375293-1 2018 As the results of clinical trials are inconsistent, we conducted this research to assess the effect of purified anthocyanins or anthocyanin-rich extract supplementation on C-reactive protein (CRP) levels. Anthocyanins 112-123 C-reactive protein Homo sapiens 172-190 30375293-1 2018 As the results of clinical trials are inconsistent, we conducted this research to assess the effect of purified anthocyanins or anthocyanin-rich extract supplementation on C-reactive protein (CRP) levels. Anthocyanins 112-123 C-reactive protein Homo sapiens 192-195 30375293-10 2018 Although changes in CRP concentrations had no association with trial duration, a significant relationship was found between anthocyanin dosage and CRP level. Anthocyanins 124-135 C-reactive protein Homo sapiens 147-150 30278529-13 2018 Serum levels of IL-8, TNF-alpha, IL-17A, LTB4 and CRP decreased significantly after YFN treatment compared to the placebo group (P < 0.05). yfn 84-87 C-reactive protein Homo sapiens 50-53 30168206-1 2018 The transcriptional activator CooA belongs to the CRP/FNR (cAMP receptor protein/fumarate and nitrate reductase) superfamily of transcriptional regulators and uses heme to sense carbon monoxide (CO). Carbon Monoxide 178-193 C-reactive protein Homo sapiens 50-57 30168206-1 2018 The transcriptional activator CooA belongs to the CRP/FNR (cAMP receptor protein/fumarate and nitrate reductase) superfamily of transcriptional regulators and uses heme to sense carbon monoxide (CO). Carbon Monoxide 195-197 C-reactive protein Homo sapiens 50-57 29508247-1 2018 Background Ruxolitinib, a Janus kinase 1 (JAK1)/JAK2 inhibitor, plus capecitabine improved overall survival (OS) vs capecitabine in a subgroup analysis of patients with metastatic pancreatic cancer and systemic inflammation (C-reactive protein [CRP] >13 mg/dL) in the randomized phase II RECAP study. ruxolitinib 11-22 C-reactive protein Homo sapiens 225-243 30221147-8 2018 In a linear regression model adjusted for age, gender, and BMI, a significant inverse association of C-reactive protein (CRP) (p = 0.031) and faecal calprotectin (FC) (p = 0.025) with 25-OH-D3 levels was observed for CD patients. Calcifediol 184-192 C-reactive protein Homo sapiens 101-119 30221147-8 2018 In a linear regression model adjusted for age, gender, and BMI, a significant inverse association of C-reactive protein (CRP) (p = 0.031) and faecal calprotectin (FC) (p = 0.025) with 25-OH-D3 levels was observed for CD patients. Calcifediol 184-192 C-reactive protein Homo sapiens 121-124 29784018-9 2018 The dose of prednisolone was successfully tapered, and the elevated levels of C-reactive protein were normalized. Prednisolone 12-24 C-reactive protein Homo sapiens 78-96 29774220-6 2018 One week after prednisolone treatment initiation, CRP decreased to negative, and joint pain was almost completely resolved. Prednisolone 15-27 C-reactive protein Homo sapiens 50-53 29148260-11 2018 A significant positive correlations were found between CRP levels and BOP (P = .0148) and PD (P = .0425); and significant negative correlation was found for MBL in group 3, respectively (P = .0212). bop 70-73 C-reactive protein Homo sapiens 55-58 29439678-7 2018 In addition, interaction between polymorphism of MTHFR (rs1801133, known as C677T) and CRP was significant (P for interaction = 0.046); the global methylation level was significantly increased by 0.61% per quartile category for CRP in the CT/TT group (those with the minor allele T, P for trend = 0.001), whereas no association was observed in the CC group (wild type). Carbon Tetrachloride 239-241 C-reactive protein Homo sapiens 87-90 29756965-6 2018 RESULTS: the increase in percentage of fat, uric acid concentration and ultra-sensitive C reactive protein in the blood was positively associated with VAI in males. vai 151-154 C-reactive protein Homo sapiens 88-106 28983603-6 2017 Serum IL-6, TNF-alpha and CRP in patients with CIH were increased, while NO and NOS were decreased. cih 47-50 C-reactive protein Homo sapiens 26-29 28983603-12 2017 In conclusion, age, male gender, BMI, smoking and T2DM history, serum IL-6, TNF-alpha and CRP were positively correlated with CIH combined with hypertension, while NO and NOS were negatively correlated with CIH. cih 126-129 C-reactive protein Homo sapiens 90-93 28422153-5 2017 Gemcitabine/cisplatin model was based on training group of 71 patients and included CRP, histological type, performance status, RRM1 rs1042927, ERCC2 rs13181, ERCC1 rs3212986, and XRCC1 rs25487. gemcitabine 0-11 C-reactive protein Homo sapiens 84-87 28260186-5 2017 In the ZODIAC study a larger reduction in high sensitivity C reactive protein (hs-CRP) was observed under zofenopril (-0.52 vs. +0.97 mg/dL under irbesartan, p = 0.001), suggesting a potential protective effect against the development of atherosclerosis. zofenopril 106-116 C-reactive protein Homo sapiens 59-77 28185715-8 2017 Multivariable analysis showed that the liver/spleen ratio was strongly correlated with high-sensitivity C-reactive protein concentration in the pioglitazone group (F = 9.973; P < 0.01) and abdominal visceral fat volume in the metformin group (F = 6.049; P < 0.05). Pioglitazone 144-156 C-reactive protein Homo sapiens 104-122 27909869-9 2017 omega3-polyunsaturated fatty intake also decreased the serum concentrations of interleukin-6 and C-reactive protein (p < 0.05). omega3-polyunsaturated fatty 0-28 C-reactive protein Homo sapiens 97-115 28207527-8 2017 CT-1 and high sensitivity-C reactive protein (hs-CRP) levels were significantly decreased in the ZA10 group after 4 and 8 weeks (4 weeks: -73% and 96%; 8 weeks: -89% and -98%; all P < 0.01), without differences among the 3 groups (P > 0.05). za10 97-101 C-reactive protein Homo sapiens 49-52 28089080-8 2017 C-reactive protein was reduced by 1.1 +- 0.5 mg/L (39 +- 17%) on Salba-chia, compared to 0.2 +- 0.4 mg/L (7 +- 20%) on control (P = 0.045). salba-chia 65-75 C-reactive protein Homo sapiens 0-18 28214863-7 2017 RESULTS: A 48h CRP treatment significantly increased the percentage of annexin-V-binding cells (>=5microg/ml), [Ca2+]i (>=5microg/ml), ceramide (20microg/ml) and caspase-activity (20microg/ml). Ceramides 141-149 C-reactive protein Homo sapiens 15-18 28214863-11 2017 CONCLUSION: C-reactive protein triggers eryptosis, an effect at least partially due to increase of [Ca2+]i, increase of ceramide abundance and caspase activation. Ceramides 120-128 C-reactive protein Homo sapiens 12-30 28042411-0 2017 Clomiphene Citrate Treatment Cycle Outcomes of Polycystic Ovary Syndrome Patients Based on Basal High Sensitive C-Reactive Protein Levels: A Cross-Sectional Study. Clomiphene 0-18 C-reactive protein Homo sapiens 112-130 27701058-11 2016 Furthermore, high sensitivity C-reactive protein was found to be negatively correlated with palmitic acid levels. Palmitic Acid 92-105 C-reactive protein Homo sapiens 30-48 27752903-6 2016 SLE patients with PBI, particularly those with bacterial isolates, had significantly higher levels of serum PCT and CRP than those without PBI. pbi 18-21 C-reactive protein Homo sapiens 116-119 27752903-7 2016 Serum PCT and CRP were not associated with SLE disease activity, but positively with the values of PSI in active SLE patients with PBI. pbi 131-134 C-reactive protein Homo sapiens 14-17 27139906-10 2016 RESULTS: Serum gamma-tocopherol was associated with increasing concentrations of hs-CRP, SAA and E-selectin (P-trend all <0.0001), while alpha-tocopherol was associated with decreasing concentrations of IL-6 and hs-CRP (P-trend all <0.001). gamma-Tocopherol 15-31 C-reactive protein Homo sapiens 84-87 26494833-11 2016 In summary, roxadustat was well tolerated and corrected anemia in incident HD and PD patients, regardless of baseline iron repletion status or C-reactive protein level and with oral or IV iron supplementation; it also reduced serum hepcidin levels. roxadustat 12-22 C-reactive protein Homo sapiens 143-161 26861200-8 2016 Antiparkinson drugs did not affect O&NS biomarkers, but levodopa+carbidopa significantly increased CRP. Levodopa 56-64 C-reactive protein Homo sapiens 99-102 27725465-9 2016 With the concomitant use of prednisolone, the fever and elevation of CRP levels eventually improved, and the patient was discharged. Prednisolone 28-40 C-reactive protein Homo sapiens 69-72 26566216-2 2016 METHODS: The prognostic CRP classification was constructed in the retrospective cohort, consisting of advanced PCa patients with first-line gemcitabine monotherapy (GEM). gemcitabine 140-151 C-reactive protein Homo sapiens 24-27 26351344-7 2015 In a prespecified subgroup analysis of patients with inflammation, defined by serum C-reactive protein levels greater than the study population median (ie, 13 mg/L), OS was significantly greater with ruxolitinib than with placebo (hazard ratio, 0.47; 95% CI, 0.26 to 0.85; P = .011). ruxolitinib 200-211 C-reactive protein Homo sapiens 84-102 25791914-6 2015 C-reactive protein (CRP) was quantified by latex-enhanced nephelometry. Latex 43-48 C-reactive protein Homo sapiens 0-18 25791914-6 2015 C-reactive protein (CRP) was quantified by latex-enhanced nephelometry. Latex 43-48 C-reactive protein Homo sapiens 20-23 26688994-9 2015 Propofol anesthesia and postoperative propofol sedation resulted in a reduced peak postoperative BT and lower CRP levels on POD 2 after esophagectomy than sevoflurane anesthesia followed by midazolam sedation. Propofol 0-8 C-reactive protein Homo sapiens 110-113 26688994-9 2015 Propofol anesthesia and postoperative propofol sedation resulted in a reduced peak postoperative BT and lower CRP levels on POD 2 after esophagectomy than sevoflurane anesthesia followed by midazolam sedation. Propofol 38-46 C-reactive protein Homo sapiens 110-113 26335759-2 2015 The objective of this study was to find out whether elevated serum levels of C-reactive protein (CRP) are associated with increased serum concentrations of the antidepressants citalopram and venlafaxine. Citalopram 176-186 C-reactive protein Homo sapiens 77-95 26335759-2 2015 The objective of this study was to find out whether elevated serum levels of C-reactive protein (CRP) are associated with increased serum concentrations of the antidepressants citalopram and venlafaxine. Citalopram 176-186 C-reactive protein Homo sapiens 97-100 26308525-9 2015 The regression coefficients of baseline CRP for the two periods were 1.41 (95% confidence interval [CI] 0.21-2.61) and 2.62 (95% CI 0.25-4.98), respectively, after adjusting for sex, age, baseline UPDRS-III score, dementia, and incremental L-dopa equivalent dose. Levodopa 240-246 C-reactive protein Homo sapiens 40-43 26557375-6 2015 However, some differences have been observed: the male:female ratio, the proportion of patients with objective signs of inflammation such as bone marrow oedema as detected by MRI, and the proportion of patients with increased levels of C reactive protein were higher in patients with AS. Arsenic 284-286 C-reactive protein Homo sapiens 236-254 25966642-5 2015 Treatment of cells with CRP (5, 10, 20 mug/ml) resulted in neurotoxicity and apoptosis, as was observed by MTT assay and Hoechst staining, respectively. monooxyethylene trimethylolpropane tristearate 107-110 C-reactive protein Homo sapiens 24-27 25832424-8 2015 Pretreatment of the cells with the ROS scavenger N-acetyl-L-cysteine, ERK inhibitor PD98059 or NF-kappaB inhibitor PDTC blocked CRP-stimulated RAGE expression, but pretreatment with the NADPH oxidase inhibitor DPI, JNK inhibitor SP600125 or p38 MAPK inhibitor SB203580 did not significantly alter CRP-stimulated RAGE expression. SB 203580 260-268 C-reactive protein Homo sapiens 128-131 25234663-14 2015 Newly developed AAU was associated with an elevated time-varying CRP [HR 1.02 (95% CI 1.01, 1.04)]. aau 16-19 C-reactive protein Homo sapiens 65-68 25616705-7 2015 RESULTS: Methylglyoxal-derived hydroimidazolone-1 was significantly increased in the diabetes group compared with controls, 155.3 (standard deviation (SD) = 41.0) versus 143.0 (SD = 35.1) U/mL, p = 0.003, as was C-reactive protein, median 0.51 (0.27, 1.83) versus 0.31 (0.19, 0.67) mg/L, p < 0.001. methylglyoxal-derived hydroimidazolone 9-47 C-reactive protein Homo sapiens 212-230 25719429-7 2015 RESULTS: Serum CRP concentrations were 23% lower after glucosamine and chondroitin compared to placebo (P = 0.048). Chondroitin 71-82 C-reactive protein Homo sapiens 15-18 25597988-11 2015 CONCLUSION: Early CRP values can perhaps be used as a prognostic factor for long-term neurological outcome prediction after endovascular treatment of aSAH. asah 150-154 C-reactive protein Homo sapiens 18-21 28255396-10 2015 Moreover, the hs-CRP had significant inverse relationships with serum albumin (P=0.0001) and vitamin E and C intakes but was not significant. Vitamin E 93-102 C-reactive protein Homo sapiens 17-20 28255396-12 2015 Conclusion:Our findings indicated hs-CRP levels of hemodialysis patients to have significant inverse relationships with serum albumin and vitamin E and C intakes but was not significant. Vitamin E 138-147 C-reactive protein Homo sapiens 37-40 26155615-14 2015 Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) proved to be also significantly higher in the patients with DD than in those without DD. dd 126-128 C-reactive protein Homo sapiens 41-59 26155615-14 2015 Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) proved to be also significantly higher in the patients with DD than in those without DD. dd 126-128 C-reactive protein Homo sapiens 61-64 25454789-5 2014 Uni- and multivariate regression models were used to examine the relationships between the concentration of cotinine and C-reactive protein (CRP), high-density lipoprotein (HDL) cholesterol, and fibrinogen concentrations, as well as total:HDL cholesterol ratios. Cotinine 108-116 C-reactive protein Homo sapiens 121-139 25454789-5 2014 Uni- and multivariate regression models were used to examine the relationships between the concentration of cotinine and C-reactive protein (CRP), high-density lipoprotein (HDL) cholesterol, and fibrinogen concentrations, as well as total:HDL cholesterol ratios. Cotinine 108-116 C-reactive protein Homo sapiens 141-144 25242580-0 2014 Palmitic acid exerts pro-inflammatory effects on vascular smooth muscle cells by inducing the expression of C-reactive protein, inducible nitric oxide synthase and tumor necrosis factor-alpha. Palmitic Acid 0-13 C-reactive protein Homo sapiens 108-126 25242580-5 2014 The purpose of the present study was to observe the effect of palmitic acid on the expression of C-reactive protein (CRP), tumor necrosis factor alpha (TNF-alpha) and inducible nitric oxide synthase (iNOS) in VSMCs. Palmitic Acid 62-75 C-reactive protein Homo sapiens 97-115 25242580-5 2014 The purpose of the present study was to observe the effect of palmitic acid on the expression of C-reactive protein (CRP), tumor necrosis factor alpha (TNF-alpha) and inducible nitric oxide synthase (iNOS) in VSMCs. Palmitic Acid 62-75 C-reactive protein Homo sapiens 117-120 25242580-8 2014 The results showed that palmitic acid significantly stimulated mRNA and protein expression of CRP, TNF-alpha and iNOS in VSMCs in time- and concentration-dependent manners, and therefore, palmitic acid is able to exert a pro-inflammatory effect on VSMCs via stimulating CRP, TNF-alpha and iNOS expression. Palmitic Acid 24-37 C-reactive protein Homo sapiens 94-97 25242580-8 2014 The results showed that palmitic acid significantly stimulated mRNA and protein expression of CRP, TNF-alpha and iNOS in VSMCs in time- and concentration-dependent manners, and therefore, palmitic acid is able to exert a pro-inflammatory effect on VSMCs via stimulating CRP, TNF-alpha and iNOS expression. Palmitic Acid 24-37 C-reactive protein Homo sapiens 270-273 25242580-8 2014 The results showed that palmitic acid significantly stimulated mRNA and protein expression of CRP, TNF-alpha and iNOS in VSMCs in time- and concentration-dependent manners, and therefore, palmitic acid is able to exert a pro-inflammatory effect on VSMCs via stimulating CRP, TNF-alpha and iNOS expression. Palmitic Acid 188-201 C-reactive protein Homo sapiens 94-97 25242580-8 2014 The results showed that palmitic acid significantly stimulated mRNA and protein expression of CRP, TNF-alpha and iNOS in VSMCs in time- and concentration-dependent manners, and therefore, palmitic acid is able to exert a pro-inflammatory effect on VSMCs via stimulating CRP, TNF-alpha and iNOS expression. Palmitic Acid 188-201 C-reactive protein Homo sapiens 270-273 25034026-0 2014 Synthesis of water-soluble CdSe quantum dots with various fluorescent properties and their application in immunoassay for determination of C-reactive protein. cdse 27-31 C-reactive protein Homo sapiens 139-157 24575826-7 2014 CONCLUSIONS: Vitamin E-coated dialyzer can reduce the oxidative stress and inflammation status reflected by the decreasing of serum TBARS, oxLDL, CRP, and IL-6 levels, and this new dialyzer does not affect the dialysis adequacy. Vitamin E 13-22 C-reactive protein Homo sapiens 146-149 24847348-8 2014 The C-reactive protein level normalized 7 days after the prednisolone therapy. Prednisolone 57-69 C-reactive protein Homo sapiens 4-22 24065043-9 2014 Different from placebo, taurine-supplemented group showed significant increase in plasma taurine (97%) and adiponectin (12%) and significant reduction in the inflammatory marker hs-C-reactive protein (29%) and in the lipid peroxidation marker thiobarbituric acid reactive substances (TBARS) (20%). Taurine 24-31 C-reactive protein Homo sapiens 181-199 23932312-6 2014 RESULTS: At week 52, CRP was inhibited to 4% and 40% of baseline by TCZ8 and TCZ4, respectively. tcz4 77-81 C-reactive protein Homo sapiens 21-24 25247259-6 2014 Additionally, LMM CS was able to significantly decrease GGT activity by approximately 31% and plasmatic CRP levels by about 9%. Chondroitin Sulfates 18-20 C-reactive protein Homo sapiens 104-107 24303898-8 2013 Prednisolone was administrated in a significantly greater percentage of patients with elevated CRP compared to patients with normal CRP. Prednisolone 0-12 C-reactive protein Homo sapiens 95-98 24252844-8 2013 Further, pioglitazone significantly reduced RA disease activity (P=0.02) and CRP levels (P=0.001), while improving lipid profiles. Pioglitazone 9-21 C-reactive protein Homo sapiens 77-80 23807528-5 2013 Pioglitazone was associated with a significant decrease in high-sensitive C-reactive protein (hs-CRP), but sitagliptin did not. Pioglitazone 0-12 C-reactive protein Homo sapiens 74-92 24027184-10 2013 Stratification on vitamin E intakes showed that inverse associations between dietary n-3 and n-6 PUFA intakes and elevated CRP were substantial only in individuals with low intakes of vitamin E. Vitamin E 184-193 C-reactive protein Homo sapiens 123-126 23564918-8 2013 NT-proBN P values >91 pg/mL conferred HRs of 2.05 (95% CI 1.47-2.86) for all-cause and 4.47 (2.38-8.39) for CV mortality, independently of CV risk factors, including CRP and albumin excretion rate (AER). -probn 2-8 C-reactive protein Homo sapiens 169-172 22906565-4 2013 Anthocyanin consumption significantly decreased the levels of serum high sensitivity C-reactive protein (hsCRP) (-21.6% vs. -2.5%, P = 0.001), soluble vascular cell adhesion molecule-1 (sVCAM-1) (-12.3% vs. 0.4%, P = 0.005) and plasma IL-1beta (-12.8% vs. -1.3%, P = 0.019) compared to the placebo. Anthocyanins 0-11 C-reactive protein Homo sapiens 85-103 23275373-6 2013 Moreover, urinary nicotinuric acid level was positively correlated with body mass index, blood pressure, total cholesterol, low-density lipoprotein cholesterol, triacylglycerol and high sensitivity C-reactive protein, but negatively correlated with high-density lipoprotein cholesterol. nicotinuric acid 18-34 C-reactive protein Homo sapiens 198-216 23789212-0 2013 Perilla oil and exercise decrease expressions of tumor necrosis factor-alpha, plasminogen activator inhibitor-1 and highly sensitive C-reactive protein in patients with hyperlipidemia. perilla seed oil 0-11 C-reactive protein Homo sapiens 133-151 23767277-5 2013 RESULTS: Serum CRP level was positively associated with serum ferritin and zinc protoporphyrin levels (r = 0.16 and r = 0.15; p = .0168 and p = .0290, respectively). zinc protoporphyrin 75-94 C-reactive protein Homo sapiens 15-18 23767277-12 2013 CRP level was positively associated with: serum ferritin and zinc protoporphyrin levels. zinc protoporphyrin 61-80 C-reactive protein Homo sapiens 0-3 23148500-2 2013 We aimed to investigate the effects of valsartan and amlodipine on the PTX3 and C-reactive protein (CRP) levels in patients with essential hypertension. Valsartan 39-48 C-reactive protein Homo sapiens 80-98 23148500-2 2013 We aimed to investigate the effects of valsartan and amlodipine on the PTX3 and C-reactive protein (CRP) levels in patients with essential hypertension. Valsartan 39-48 C-reactive protein Homo sapiens 100-103 21913974-4 2012 Concomitantly, repeated administration of simvastatin, ramipril or simvastatin in combination with ramipril to these animals, increased nitric oxide (NO) production and decreased the elevated serum malondialdehyde (MDA) and high sensitivity C-reactive protein (hs-CRP) levels. Ramipril 55-63 C-reactive protein Homo sapiens 241-259 21913974-4 2012 Concomitantly, repeated administration of simvastatin, ramipril or simvastatin in combination with ramipril to these animals, increased nitric oxide (NO) production and decreased the elevated serum malondialdehyde (MDA) and high sensitivity C-reactive protein (hs-CRP) levels. Ramipril 99-107 C-reactive protein Homo sapiens 241-259 22459541-6 2012 This effect was most pronounced in patients with baseline syndesmophytes plus elevated CRP: mean mSASSS progression was 4.36+-4.53 in patients with low NSAIDs intake versus 0.14+-1.80 with high intake, p=0.02. msasss 97-103 C-reactive protein Homo sapiens 87-90 21782401-9 2012 Reduction in LDL levels positively associated with increased levels of MCP-1 (P < 0.008) among placebo group, and also decreased hCRP levels strongly correlated with the increases in VO2 (P < 0.0004) among the placebo, and vitamin E subjects (P < 0.01). Vitamin E 229-238 C-reactive protein Homo sapiens 132-136 22617505-10 2012 CRP positively correlated with the doses of the epinephrine and norepinephrine and the monocyte counts, and negatively correlated with the lymphocyte count. Epinephrine 48-59 C-reactive protein Homo sapiens 0-3 22810988-10 2012 Retinol+retinyl esters exhibited an inverse relationship with CRP and a positive relationship with uric acid and HOMA-IR as well as MetS binary outcome. retinyl esters 8-22 C-reactive protein Homo sapiens 62-65 22873489-5 2012 RESULTS: Circulating concentrations of CRP and SAA were associated with increased adiposity as measured by DEXA after adjustment for age at 24-months, race/ethnicity, dietary energy intake, weight change, and NSAID use. Dexa-BEAM protocol 107-111 C-reactive protein Homo sapiens 39-42 24688920-0 2012 Impact of Vitamin E Supplementation on Blood Pressure and Hs-CRP in Type 2 Diabetic Patients doi: 10.5681/hpp.2012.009. Vitamin E 10-19 C-reactive protein Homo sapiens 61-64 22483930-1 2012 A fluorescence chemical sensor for C-reactive protein (CRP) was developed based on the selective interaction with CdSe and ZnSe quantum dots (QDs) coated with O-phosphorylethanolamine (PEA). cdse 114-118 C-reactive protein Homo sapiens 55-58 22483930-1 2012 A fluorescence chemical sensor for C-reactive protein (CRP) was developed based on the selective interaction with CdSe and ZnSe quantum dots (QDs) coated with O-phosphorylethanolamine (PEA). phosphorylethanolamine 159-183 C-reactive protein Homo sapiens 35-53 22483930-1 2012 A fluorescence chemical sensor for C-reactive protein (CRP) was developed based on the selective interaction with CdSe and ZnSe quantum dots (QDs) coated with O-phosphorylethanolamine (PEA). phosphorylethanolamine 159-183 C-reactive protein Homo sapiens 55-58 22533665-8 2012 Both high-CRP and high-leptin were associated with high blood glucose, waist circumference and serum triglyceride. Blood Glucose 56-69 C-reactive protein Homo sapiens 10-13 21953589-10 2012 Treatment with prednisolone at both dosages reduced CRP levels significantly. Prednisolone 15-27 C-reactive protein Homo sapiens 52-55 21950726-8 2012 Compared with the control group, serum high-sensitivity C-reactive protein and plasma endothelin-1 levels were significantly lower and adiponectin level significantly higher in patients in the pioglitazone group. Pioglitazone 193-205 C-reactive protein Homo sapiens 56-74 22509446-5 2012 RESULTS: Among the five subclasses of POPs, only organochlorine (OC) pesticides showed positive associations with CRP concentrations, while polychlorinated biphenyls (PCBs) showed inverse associations with CRP concentrations. Hydrocarbons, Chlorinated 49-63 C-reactive protein Homo sapiens 114-117 22509446-5 2012 RESULTS: Among the five subclasses of POPs, only organochlorine (OC) pesticides showed positive associations with CRP concentrations, while polychlorinated biphenyls (PCBs) showed inverse associations with CRP concentrations. Hydrocarbons, Chlorinated 65-67 C-reactive protein Homo sapiens 114-117 22153152-7 2012 RESULTS: Serum CRP concentration was positively associated with palmitic acid (P for trend=0.002) and inversely with alpha-linolenic acid (P for trend=0.01) in men, and positively with dihomo-gamma-linolenic acid (P for trend in men or women=0.01) and inversely with delta-5-desaturase (20:4n-6/20:3n-6) (P for trend in men and women=0.05 and 0.002, respectively) in men and women. Palmitic Acid 64-77 C-reactive protein Homo sapiens 15-18 21995428-16 2012 Moreover, when used in combination with classical biomarkers, CRP levels may be a useful adjunct for decision-making in relation to treatment of patients with non-purulent PPE. ppe 172-175 C-reactive protein Homo sapiens 62-65 22870491-9 2012 However, elevated levels of serum CRP and synovial fluid IL-6 (r = 0.034; p < 0.05) were decreased insignificantly (p < 0.1) after vitamin E supplementation in knee OA patients. Vitamin E 137-146 C-reactive protein Homo sapiens 34-37 24578930-0 2012 Serum C-reactive protein level is a significant prognostic indicator in patients with advanced urothelial cancer treated with gemcitabine-cisplatin or carboplatin - preliminary results. gemcitabine 126-137 C-reactive protein Homo sapiens 6-24 24578930-0 2012 Serum C-reactive protein level is a significant prognostic indicator in patients with advanced urothelial cancer treated with gemcitabine-cisplatin or carboplatin - preliminary results. Carboplatin 151-162 C-reactive protein Homo sapiens 6-24 22090467-5 2012 All participants had decreases in body weight (BW), BMI, and waist circumference during the 2-mo treatment (P < 0.0001); however, only the DP group had decreases in serum TG, C-reactive protein (CRP), and AUC for insulin and GI after a glucose tolerance test. dp 142-144 C-reactive protein Homo sapiens 178-196 22223149-12 2012 SB203580 (5 muM) and PDTC (50 muM) efficiently suppressed those effects of CRP in HK-2 cells. SB 203580 0-8 C-reactive protein Homo sapiens 75-78 21771657-3 2011 In this paper, we discuss the evidence that doxycycline and related non-antibiotic chemically modified tetracyclines (e.g., CMT-3) can effectively reduce cytokine (TNF-alpha, IL-6, and MCP-1) production by human mononuclear inflammatory cells when stimulated either by endotoxin (LPS) or by a complex of C-reactive protein/oxidized LDL cholesterol relevant to the pathogenesis of periodontal disease and ASCVD, respectively. Tetracyclines 103-116 C-reactive protein Homo sapiens 304-322 24843534-9 2011 In contrast, the treatment with olmesartan/trichlormethiazide resulted in increased HbA1c, serum uric acid and worsening of estimated glomerular filtration rate, though there were no differences in other metabolic parameters including urine 8-hydroxy-2"-deoxyguanosine, C-reactive protein and adiponectin between the two treatments. Trichlormethiazide 43-61 C-reactive protein Homo sapiens 270-288 22250462-3 2011 Empirical chemotherapy was started with intravenous ampicillin, gentamicin, and cefotaxime based on laboratory data on CSF cells (84/microL) and serum CRP (13.8mg/dL) data. Cefotaxime 80-90 C-reactive protein Homo sapiens 151-154 21689722-7 2011 By site-directed mutagenesis, we determined H284 in the N-acetylglucosamine (GlcNAc)-binding pocket of the FBG, to be the critical CRP-binding residue. L-Pyroglutamic acid ethyl ester 44-48 C-reactive protein Homo sapiens 131-134 21689722-8 2011 This conformational switch involving H284, explains how the pathophysiologically-driven FBG:CRP interaction diverts the M-ficolin away from GlcNAc/pathogen-recognition to host protein-protein interaction, thus enabling the host to regain homeostatic control. L-Pyroglutamic acid ethyl ester 37-41 C-reactive protein Homo sapiens 92-95 21410593-7 2011 On the other hand, the KDG showed high CRP (89.7 +- 55.6 mg/l) and high IL-6 (242.2 +- 243.5 pg/ml), and CRP (r = 0.60, P < 0.0001) and IL-6 (r = 0.78, P < 0.0001) significantly correlated with log (BNP). 2-keto-3-deoxygluconate 23-26 C-reactive protein Homo sapiens 105-108 20664555-9 2011 A positive correlation between the reduction in OPN and the log natural (ln) C-reactive protein (CRP) was seen in the valsartan-treated group. Valsartan 118-127 C-reactive protein Homo sapiens 77-95 20664555-9 2011 A positive correlation between the reduction in OPN and the log natural (ln) C-reactive protein (CRP) was seen in the valsartan-treated group. Valsartan 118-127 C-reactive protein Homo sapiens 97-100 21456224-0 2011 In-situ detection of C-reactive protein using silicon nanowire field effect transistor. Silicon 46-53 C-reactive protein Homo sapiens 21-39 21456224-1 2011 Label-free, sensitive, and real-time c-reactive protein (CRP) sensor was fabricated using p-type silicon nanowire (SiNW) based structures configured as field effect transistors (FET) using the conventional "top-down" semiconductor processes. Silicon 97-104 C-reactive protein Homo sapiens 37-55 21456224-1 2011 Label-free, sensitive, and real-time c-reactive protein (CRP) sensor was fabricated using p-type silicon nanowire (SiNW) based structures configured as field effect transistors (FET) using the conventional "top-down" semiconductor processes. Silicon 97-104 C-reactive protein Homo sapiens 57-60 21325823-8 2011 The further study indicated that losartan, NAC, MEK1/2 inhibitor PD98059, p38MAPK inhibitor SB203580 obviously inhibited ERK1/2 and p38MAPK phosphorylation, and PD98059, SB203580 and NF-kappaB inhibitor PDTC reduced Ang II -induced mRNA and protein expression of CRP in U937 macrophages. SB 203580 92-100 C-reactive protein Homo sapiens 263-266 21370577-4 2011 Intravenous methylprednisolone sodium succinate (500 mg/day for three days)therapy and oral prednisolone (40 mg/day) improved her fever, hematuria, serum CRP and MPO-ANCA titer. Prednisolone 18-30 C-reactive protein Homo sapiens 154-157 21915224-3 2011 We tested the hypothesis that high sensitivity C-reactive protein (hs-CRP), a biomarker of inflammation, is associated with DD in asymptomatic AAs. dd 124-126 C-reactive protein Homo sapiens 47-65 19787290-6 2010 CRP levels decreased significantly at follow-up in the pioglitazone group (3.2 +- 1.97 vs. 2.37 +- 1.56 mg/l) but not in the control group (3.0 +- 1.92 vs. 3.93 +- 2.14 mg/l; P = 0.003). Pioglitazone 55-67 C-reactive protein Homo sapiens 0-3 20607580-7 2010 After treatment with oral prednisolone at initial dose of 40 mg (1 mg/kg body weight), urinary findings rapidly became normal with mild elevation of serum creatinine to 1.5 mg/dl and trace level of serum C-reactive protein in 1 month. Prednisolone 26-38 C-reactive protein Homo sapiens 204-222 20670183-4 2010 Beyond these effects on glucose metabolism, pioglitazone has positive effects on lipid metabolism, blood pressure, endothelial function, adiponectin and C-reactive protein levels. Pioglitazone 44-56 C-reactive protein Homo sapiens 153-171 20133929-9 2010 Patients on prednisolone had faster defervescence and faster decline in serum C-reactive protein levels compared with placebo. Prednisolone 12-24 C-reactive protein Homo sapiens 78-96 20429644-12 2010 CONCLUSION: These results suggest that the disease activity of RA correlated with serum levels of IL-6, TNF-alpha, and CRP, and it might influence BOP in the patients with moderate to high disease activity. bop 147-150 C-reactive protein Homo sapiens 119-122 20097689-8 2010 In both groups, CRP levels decreased from 2.1 to 1.8 with ramipril and from 2.2 to 1.1 with the ramipril-Pycnogenol combination; the latter reached statistical significance. Ramipril 58-66 C-reactive protein Homo sapiens 16-19 19683568-5 2010 RESULTS: Longitudinal mixed linear regression models adjusting for age, race, site, time between exams, and outcome variable at year X showed that higher CES-D scores predicted higher subsequent CRP levels and vice versa over a 7-year period. Cerium 154-157 C-reactive protein Homo sapiens 195-198 19567495-9 2009 Desmosine levels were positively associated with plasma C-reactive protein (rho = 0.59; p = 0.03), sputum interleukin-8 (rho = 0.86; p < 0.01), and sputum neutrophil elastase (rho = 0.78; p < 0.01). Desmosine 0-9 C-reactive protein Homo sapiens 56-74 19781372-8 2009 In addition, preincubation of EPCs with SB203580, an inhibitor of p38 mitogen-activated protein kinase (MAPK) decreased CRP inhibition of IL-8 mRNA expression at 12 hours in EPCs. SB 203580 40-48 C-reactive protein Homo sapiens 120-123 19672401-7 2009 Cotinine levels indicated that all samples came from non-smokers and that CRP levels were higher in African Americans than in Caucasians and higher in females than in males. Cotinine 0-8 C-reactive protein Homo sapiens 74-77 19410579-0 2009 C-reactive protein impairs coronary arteriolar dilation to prostacyclin synthase activation: role of peroxynitrite. Peroxynitrous Acid 101-114 C-reactive protein Homo sapiens 0-18 19410579-11 2009 Collectively, our results suggest that CRP stimulates superoxide production and the subsequent formation of peroxynitrite from basal released NO compromises PGI(2) synthesis, and thus endothelium-dependent PGI(2)-mediated dilation, by inhibiting PGI(2)-S activity through tyrosine nitration. Peroxynitrous Acid 108-121 C-reactive protein Homo sapiens 39-42 19463506-0 2009 Comparison of the effects of ramipril versus telmisartan on high-sensitivity C-reactive protein and endothelial progenitor cells after acute coronary syndrome. Ramipril 29-37 C-reactive protein Homo sapiens 77-95 19463506-3 2009 High-sensitivity C-reactive protein levels, similar in the 2 groups at baseline, were significantly more decreased by telmisartan than by ramipril at follow up (p = 0.013 for time-by-drug interaction). Ramipril 138-146 C-reactive protein Homo sapiens 17-35 18758684-3 2009 There was significant reduction of CRP level in pioglitazone and rosiglitazone group. Pioglitazone 48-60 C-reactive protein Homo sapiens 35-38 19164258-8 2009 beta-Cryptoxanthin concentrations were also inversely related to CRP concentrations. Beta-Cryptoxanthin 0-18 C-reactive protein Homo sapiens 65-68 18826856-5 2008 After adjusting for independent variables including age, diabetic status and plasma levels of C-reactive protein, phosphorus and albumin significant predictors of iPTH were race (p < 0.01), gender (p < 0.05), serum calcium (p < 0.05), BSAP (p < 0.0001) and doses of vitamin D analogs (p < 0.001). ipth 163-167 C-reactive protein Homo sapiens 94-112 18813885-7 2008 RESULTS: Patients discharged with triple therapy including OAC seemed to be at higher risk: patients in group 3 had decreased left ventricular ejection fraction and increased inflammatory state as measured by plasma fibrinogen and C-reactive protein. SDZ 33-243 59-62 C-reactive protein Homo sapiens 231-249 18451774-5 2008 There was a trend for a differential effect between groups for CRP as it decreased 32% in the AS group but increased 50% for P (P=0.076). Arsenic 94-96 C-reactive protein Homo sapiens 63-66 18565400-8 2008 We found that TpP correlated only weakly with cardiac troponin I, B-type natriuretic peptide, and high-sensitivity C-reactive protein ( r <0.15 for each). tpp 14-17 C-reactive protein Homo sapiens 115-133 18285551-6 2008 Similarly, for the m301G>A>T, major allele carriers displayed maximal reduction of CRP over noncarriers (-20 for GG, -15 for GA and GT, and -0.3% for TA and AA; P = 0.020). Gallium 131-133 C-reactive protein Homo sapiens 89-92 18672762-1 2008 OBJECTIVE: To evaluate the clinical therapeutic effect of Compound Paeonol Dripping Pill (CPDP) and its effect on the levels of plasma inflammatory mediators, including C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and monocyte chemotactic protein-1 (MCP-1). cpdp 90-94 C-reactive protein Homo sapiens 169-187 18427279-5 2008 Levels of CRP, VEGF, and TNFalpha at 1 month were significantly lower in pitavastatin than placebo group. pitavastatin 73-85 C-reactive protein Homo sapiens 10-13 18356331-9 2008 Total flavonoid and also individual flavonol, anthocyanidin, and isoflavone intakes were inversely associated with serum CRP concentration after adjusting for the covariates (P < 0.05). Anthocyanins 46-59 C-reactive protein Homo sapiens 121-124 17716746-11 2008 Mildly elevated plasma levels of CRP (above 3.2 mg/L) were associated with higher CES-D scores, but not after correction for the confounding effect of age and chronic diseases. Cerium 82-85 C-reactive protein Homo sapiens 33-36 18789149-12 2008 Interestingly, anti-chondroitin sulphate C IgM antibody levels showed inverse correlation both with the Disease Activity Score (DAS) 28 scores and C-reactive protein (CRP) levels in rheumatoid arthritis. Chondroitin Sulfates 20-40 C-reactive protein Homo sapiens 147-165 18789149-12 2008 Interestingly, anti-chondroitin sulphate C IgM antibody levels showed inverse correlation both with the Disease Activity Score (DAS) 28 scores and C-reactive protein (CRP) levels in rheumatoid arthritis. Chondroitin Sulfates 20-40 C-reactive protein Homo sapiens 167-170 17942113-5 2007 CRP treatment significantly decreased levels of BH4 thereby promoting eNOS uncoupling. sapropterin 48-51 C-reactive protein Homo sapiens 0-3 17942113-6 2007 Pretreatment with sepiapterin, a BH4 precursor, prevented CRP-mediated effects on BH(4) levels, superoxide production as well as eNOS activity. sapropterin 33-36 C-reactive protein Homo sapiens 58-61 17942113-6 2007 Pretreatment with sepiapterin, a BH4 precursor, prevented CRP-mediated effects on BH(4) levels, superoxide production as well as eNOS activity. sapropterin 82-87 C-reactive protein Homo sapiens 58-61 17942113-12 2007 The pretreatment of cells with NO synthase inhibitor (N-nitro-l-arginine methyl ester [l-NAME]) also prevented CRP-mediated O(2)(-) production further strengthening CRP-mediated eNOS uncoupling. NG-Nitroarginine Methyl Ester 87-93 C-reactive protein Homo sapiens 111-114 17942113-12 2007 The pretreatment of cells with NO synthase inhibitor (N-nitro-l-arginine methyl ester [l-NAME]) also prevented CRP-mediated O(2)(-) production further strengthening CRP-mediated eNOS uncoupling. NG-Nitroarginine Methyl Ester 87-93 C-reactive protein Homo sapiens 165-168 17382928-6 2007 The presence of the TCCG haplotype was associated with greater CRP concentrations in Caucasian women (p=0.0004) and this relationship was maintained after adjustment for age, BMI, smoking, diabetes, and cholesterol-lowering therapy (p=0.003). tccg 20-24 C-reactive protein Homo sapiens 63-66 17556865-13 2007 CR P was also more reduced in the pioglitazone group at 20 weeks of treatment (p<0.05). Pioglitazone 34-46 C-reactive protein Homo sapiens 0-4 17296856-4 2007 Compared with subjects with no detectable cotinine, those with detectable but low-level cotinine (range, 0.05 to 0.215 ng/mL) had significantly higher levels of both fibrinogen (adjusted mean difference, 8.9 mg/dL; 95% CI, 0.9 to 17.0; P=0.03) and homocysteine (0.8 micromol/L; 95% CI, 0.4 to 1.1; P<0.001) but not C-reactive protein or white blood cell count. Cotinine 88-96 C-reactive protein Homo sapiens 318-336 17353582-1 2007 OBJECTIVES: a) To evaluate the effect of Neptune Krill Oil (NKO) on C-reactive protein (CRP) on patients with chronic inflammation and b) to evaluate the effectiveness of NKO on arthritic symptoms. neptune krill oil 41-58 C-reactive protein Homo sapiens 68-86 17353582-1 2007 OBJECTIVES: a) To evaluate the effect of Neptune Krill Oil (NKO) on C-reactive protein (CRP) on patients with chronic inflammation and b) to evaluate the effectiveness of NKO on arthritic symptoms. neptune krill oil 41-58 C-reactive protein Homo sapiens 88-91 17365762-2 2007 The association between serum cotinine and serum CRP was analyzed using multiple linear regression, with adjustment for other study variables. Cotinine 30-38 C-reactive protein Homo sapiens 49-52 17365762-4 2007 Multiple regression analysis indicated that a change in serum cotinine of 0.5 ng/ml was associated with a 0.96 mg/dl change in CRP (95% CI=0.93-1.00), even after adjustment for age, white blood cell count, and body mass index percentile. Cotinine 62-70 C-reactive protein Homo sapiens 127-130 17365762-5 2007 We found a significant association between secondhand smoke exposure, assessed by serum cotinine, and elevated serum CRP among nonsmoking youth. Cotinine 88-96 C-reactive protein Homo sapiens 117-120 17551260-9 2007 MSX, which had a prevalence of 31%, was significantly associated with elevated CRP levels. msx 0-3 C-reactive protein Homo sapiens 79-82 17551260-10 2007 Among MSX components, the strongest positive association with the highest quartile of CRP was with waist circumference in males as well as in females (age-adjusted odds ratio OR 3.06 and 95% confidence interval CI 1.82-5.14; OR 7.04 and 95% CI 4.79-10.34, respectively). msx 6-9 C-reactive protein Homo sapiens 86-89 17551260-16 2007 CONCLUSIONS: Abdominal adiposity adds to the variance in plasma CRP levels in elderly patients with MSX. msx 100-103 C-reactive protein Homo sapiens 64-67 18332612-4 2007 The level of C-reactive protein was higher in the high beta-D-glucan group (>5 pg/ml) than in the low beta-D-glucan group. maltotriose 55-68 C-reactive protein Homo sapiens 13-31 18332612-4 2007 The level of C-reactive protein was higher in the high beta-D-glucan group (>5 pg/ml) than in the low beta-D-glucan group. maltotriose 105-118 C-reactive protein Homo sapiens 13-31 16611705-7 2006 CRP levels were quantified by using latex-enhanced nephelometry. Latex 36-41 C-reactive protein Homo sapiens 0-3 4032729-4 1985 In 1 patient treated with AC-1370 for postoperative infection, clinical findings, WBC and CRP improved: the drug was evaluated as effective. cefpimizole 26-33 C-reactive protein Homo sapiens 90-93 16430914-9 2006 SB203580, a P38 inhibitor, significantly attenuated the CRP-induced responses while SP600125 (c-jun kinase inhibitor) did not. SB 203580 0-8 C-reactive protein Homo sapiens 56-59 16643876-5 2006 Competition experiments with different phosphatemonoesters revealed that CRP and SAP as well as part of the IgM bound to the phospholipids head groups, SAP mainly to phosphorylethanolamine, CRP to phosphorylcholine and phosphorylethanolamine and to a lesser extent to phosphorylserine, and IgM to phosphorylcholine and phosphorylserine. phosphorylethanolamine 166-188 C-reactive protein Homo sapiens 73-76 16643876-5 2006 Competition experiments with different phosphatemonoesters revealed that CRP and SAP as well as part of the IgM bound to the phospholipids head groups, SAP mainly to phosphorylethanolamine, CRP to phosphorylcholine and phosphorylethanolamine and to a lesser extent to phosphorylserine, and IgM to phosphorylcholine and phosphorylserine. phosphorylethanolamine 219-241 C-reactive protein Homo sapiens 73-76 16251237-8 2005 UA stimulated HVSMC proliferation whereas UA inhibited serum-induced proliferation of HUVEC assessed by 3H-thymidine uptake and cell counting, which was attenuated by co-incubation with probenecid, the organic anion transport inhibitor, suggesting that entry of UA into cells is responsible for CRP expression. Probenecid 186-196 C-reactive protein Homo sapiens 295-298 16205450-1 2005 AIMS: To evaluate the hypothesis that angiotensin-converting enzyme inhibitor therapy with ramipril reduces baseline levels of C-reactive protein in patients at high cardiovascular risk. Ramipril 91-99 C-reactive protein Homo sapiens 127-145 16205450-8 2005 CONCLUSION: Highly sensitive C-reactive protein levels were reduced after a 6-month ramipril therapy in secondary prevention patients, suggesting an anti-inflammatory effect of angiotensin-converting enzyme inhibitors. Ramipril 84-92 C-reactive protein Homo sapiens 29-47 6396081-1 1984 The structure of complexes formed between cAMP receptor protein (CRP) and various restriction fragments from the promoter region of the lactose operon has been analysed by measurements of electrodichroism. Lactose 136-143 C-reactive protein Homo sapiens 42-63 15790934-3 2005 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) reductase inhibitors, or statins, significantly reduce cardiovascular events and mortality in patients with or without coronary artery disease and reduce plasma CRP levels in humans. 3-hydroxy-3-methylglutaryl 0-26 C-reactive protein Homo sapiens 211-214 6396081-1 1984 The structure of complexes formed between cAMP receptor protein (CRP) and various restriction fragments from the promoter region of the lactose operon has been analysed by measurements of electrodichroism. Lactose 136-143 C-reactive protein Homo sapiens 65-68 15701058-3 2005 In the present study, we examined the effect of pitavastatin (NK-104), a synthetic statin (3-hydroxy-3-methylglutaryl CoA reductase inhibitor), on IL-8 production induced by CRP in human AoEC (aortic endothelial cells). pitavastatin 48-60 C-reactive protein Homo sapiens 174-177 15701058-3 2005 In the present study, we examined the effect of pitavastatin (NK-104), a synthetic statin (3-hydroxy-3-methylglutaryl CoA reductase inhibitor), on IL-8 production induced by CRP in human AoEC (aortic endothelial cells). pitavastatin 62-68 C-reactive protein Homo sapiens 174-177 6430016-1 1984 Passive haemagglutination technique for C-reactive protein measurement using a commercially available C-polysaccharide and single radial immunodiffusion showed a close correlation. c-polysaccharide 102-118 C-reactive protein Homo sapiens 40-58 15701058-7 2005 The production of IL-8 induced by CRP (10 microg/ml) was enhanced significantly and was inhibited by pitavastatin. pitavastatin 101-113 C-reactive protein Homo sapiens 34-37 15701058-8 2005 The expression of IL-8 mRNA was increased in a dose-dependent manner after stimulation with CRP (1-100 microg/ml), whereas expression of IL-8 mRNA induced by CRP (50 microg/ml) was significantly diminished by 5 microM pitavastatin. pitavastatin 218-230 C-reactive protein Homo sapiens 92-95 15883229-9 2005 When compared with simvastatin or ramipril alone, combined therapy significantly reduced high-sensitivity C-reactive protein levels (P=0.004 by ANOVA). Ramipril 34-42 C-reactive protein Homo sapiens 106-124 15829266-2 2005 These altered phospholipids include lysophosphotidylcholine (LPC) that is a ligand for CRP and is also antigenic for natural IgM antibodies. lysophosphotidylcholine 36-59 C-reactive protein Homo sapiens 87-90 6433926-4 1983 This extracted CRP was further purified by sequential treatment on column chromatography of DEAE cellulose (DE52) and gel filtration using Sephacryl S-300. DEAE-Cellulose 92-106 C-reactive protein Homo sapiens 15-18 7086148-2 1982 CRP was obtained from malignant ascitic and pleural fluids by calcium-dependent affinity chromatography on pneumococcal C-polysaccharide covalently coupled to cyanogen bromide-activated Sepharose. Cyanogen Bromide 159-175 C-reactive protein Homo sapiens 0-3 15619396-0 2005 Effect of antispastic agents (calcium antagonists and/or isosorbide dinitrate) on high-sensitivity C-reactive protein in patients with coronary vasospastic angina pectoris and no hemodynamically significant coronary artery disease. Isosorbide Dinitrate 57-77 C-reactive protein Homo sapiens 99-117 7402294-7 1980 In addition, colchicine, currently used for the treatment of amyloidosis, blocks the secretion of SAA from the hepatocyte, as has been shown for another acute phase reactan, C-reactive protein. Colchicine 13-23 C-reactive protein Homo sapiens 174-192 15829165-8 2005 We found that the AHI(CO2) correlated significantly with the apnea-hypopnea index measured with conventional CRP (AHI(CRP)) (r = 0.94; p < 0.001). N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide 22-25 C-reactive protein Homo sapiens 109-112 15829165-8 2005 We found that the AHI(CO2) correlated significantly with the apnea-hypopnea index measured with conventional CRP (AHI(CRP)) (r = 0.94; p < 0.001). N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide 22-25 C-reactive protein Homo sapiens 114-122 15829165-9 2005 An AHI(CO2) > 5 turned out to be highly predictive of an AHI(CRP) > 10. N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide 7-10 C-reactive protein Homo sapiens 60-68 15142951-7 2004 Collagen or CRP-stimulated 12-H(P)ETE generation was inhibited by staurosporine, PP2, wortmannin, BAPTA/AM, EGTA, and L-655238, implicating src-tyrosine kinases, PI3-kinase, Ca2+ mobilization, and p12-LOX translocation. Wortmannin 86-96 C-reactive protein Homo sapiens 12-15 496450-4 1979 The relationship between CRP and ESR was, however, altered by treatment with gold, penicillamine, or high doses of prednisone. Prednisone 115-125 C-reactive protein Homo sapiens 25-28 448084-11 1979 Complement damage in the presence of CRP was enhanced by certain sphingolipids and also by digalactosyl diglyceride, but not by sphingomyelin. Sphingolipids 65-78 C-reactive protein Homo sapiens 37-40 14709450-3 2004 CRP was measured with a high-sensitivity latex-enhanced turbidimetric assay. Latex 41-46 C-reactive protein Homo sapiens 0-3 425611-1 1979 The human serum proteins C-reactive protein (CRP), the 9.5 Salpha1-glycoprotein and C1q show, when tested in the agar gel diffusion under certain buffer conditions, strong precipitin reactions with polysaccharides of the galactan type, indicating that they may have lectin-like recognition sites. Polysaccharides 198-213 C-reactive protein Homo sapiens 25-43 14520627-6 2003 The MIS and serum concentrations of high-sensitivity C-reactive protein, interleukin 6 (IL-6), tumor necrosis factor-alpha, and lactate dehydrogenase had positive correlation with required EPO dose and EPO responsiveness index (EPO divided by hemoglobin), whereas serum total iron binding capacity (TIBC), prealbumin and total cholesterol, as well as blood lymphocyte count had statistically significant but negative correlations with indices of refractory anemia. tibc 299-303 C-reactive protein Homo sapiens 53-71 12947436-5 2003 RESULTS: C-reactive protein concentration (dichotomized at the sex-specific 85th percentile) was inversely and significantly associated with concentrations of retinol, retinyl esters, vitamin C, alpha-carotene, beta-carotene, cryptoxanthin, lutein/zeaxanthin, lycopene, and selenium after adjustment for age, sex, race or ethnicity, education, cotinine concentration, body mass index, leisure-time physical activity, and aspirin use. Lycopene 260-268 C-reactive protein Homo sapiens 9-27 425611-1 1979 The human serum proteins C-reactive protein (CRP), the 9.5 Salpha1-glycoprotein and C1q show, when tested in the agar gel diffusion under certain buffer conditions, strong precipitin reactions with polysaccharides of the galactan type, indicating that they may have lectin-like recognition sites. Polysaccharides 198-213 C-reactive protein Homo sapiens 45-48 12947436-5 2003 RESULTS: C-reactive protein concentration (dichotomized at the sex-specific 85th percentile) was inversely and significantly associated with concentrations of retinol, retinyl esters, vitamin C, alpha-carotene, beta-carotene, cryptoxanthin, lutein/zeaxanthin, lycopene, and selenium after adjustment for age, sex, race or ethnicity, education, cotinine concentration, body mass index, leisure-time physical activity, and aspirin use. Cotinine 344-352 C-reactive protein Homo sapiens 9-27 15537271-0 2003 [Effect of bethametasone on blood cell count and C-reactive protein in patients with threatened preterm delivery]. bethametasone 11-24 C-reactive protein Homo sapiens 49-67 4454851-2 1974 Highly purified C-reactive protein extracted by chromatography on DEAE-cellulose]. DEAE-Cellulose 66-80 C-reactive protein Homo sapiens 16-34 12730556-9 2003 Mean C-reactive protein concentration declined from 0.30 to 0.20 mg/L among patients assigned to pioglitazone and increased from 0.41 to 0.45 mg/L among patients assigned to placebo (P=0.06 for comparison of mean change). Pioglitazone 97-109 C-reactive protein Homo sapiens 5-23 5873592-0 1965 [Relationship between the general and specific immunological reconstruction of the body and the production of C-reactive protein in polyvaccine immunization]. polyvaccine 132-143 C-reactive protein Homo sapiens 110-128 12584627-11 2003 CONCLUSION: Following uncomplicated UFE, a steep increase in CRP occurs with no or only a mild increase in the WBC count, which does not indicate an infected fibroid. Fe(Iii) Uroporphyrin 36-39 C-reactive protein Homo sapiens 61-64 12468815-9 2002 The baseline acute-phase response was higher in patients treated with MTX (mean CRP 3.5 mg/dl) than in those treated with SSZ (CRP 2.4 mg/dl; P < 0.05) or AM (CRP 2.1 mg/dl; P < 0.05), suggesting that MTX was used preferentially in patients with high disease activity. Sulfasalazine 122-125 C-reactive protein Homo sapiens 127-130 12468815-9 2002 The baseline acute-phase response was higher in patients treated with MTX (mean CRP 3.5 mg/dl) than in those treated with SSZ (CRP 2.4 mg/dl; P < 0.05) or AM (CRP 2.1 mg/dl; P < 0.05), suggesting that MTX was used preferentially in patients with high disease activity. Sulfasalazine 122-125 C-reactive protein Homo sapiens 127-130 14803629-2 1951 The acute phase protein of the rabbit reacts with a special form of the pneumococcal somatic polysaccharide, designated Cx polysaccharide, in the same manner that the human C-reactive protein reacts with the classical C polysaccharide. Polysaccharides 93-107 C-reactive protein Homo sapiens 173-191 12218140-1 2002 C-reactive protein (CRP), the major human acute-phase plasma protein, binds to phosphocholine (PCh) residues present in pneumococcal C-polysaccharide (PnC) of Streptococcus pneumoniae and to PCh exposed on damaged and apoptotic cells. polysaccharide C-substance (Streptococcus) 151-154 C-reactive protein Homo sapiens 0-18 12218140-1 2002 C-reactive protein (CRP), the major human acute-phase plasma protein, binds to phosphocholine (PCh) residues present in pneumococcal C-polysaccharide (PnC) of Streptococcus pneumoniae and to PCh exposed on damaged and apoptotic cells. polysaccharide C-substance (Streptococcus) 151-154 C-reactive protein Homo sapiens 20-23 14803629-2 1951 The acute phase protein of the rabbit reacts with a special form of the pneumococcal somatic polysaccharide, designated Cx polysaccharide, in the same manner that the human C-reactive protein reacts with the classical C polysaccharide. Polysaccharides 123-137 C-reactive protein Homo sapiens 173-191 33861260-5 2021 After an annealing step, the MF-DNA-4WJ assembly configuration and selective binding of CRP were confirmed through native TBM-PAGE (Tris-borate-magnesium chloride-polyacrylamide gel electrophoresis). polyacrylamide 163-177 C-reactive protein Homo sapiens 88-91 12616983-1 2002 The effects of two third-generation monophasic combined oral contraceptives (COC) and a postmenopausal hormone replacement therapy (HRT) consisting of 2 mg 17 beta-oestradiol on the plasma level of the acute-phase indicator C-reactive protein (CRP) and other acute-phase reactants were analysed. beta-oestradiol 159-174 C-reactive protein Homo sapiens 224-242 33251579-7 2021 Furthermore, colchicine tended to reduce the hs-CRP increase (standardized mean difference=-0.31, 95% CI -0.72 to 0.1, P=0.133) compared with placebo. Colchicine 13-23 C-reactive protein Homo sapiens 48-51 11852009-0 2002 [Eptifibatide blocks the increase in C-reactive protein concentration after coronary angioplasty]. Eptifibatide 1-13 C-reactive protein Homo sapiens 37-55 11852009-1 2002 We measured C-reactive protein concentrations in 31 patients with interventional procedures after blocking thrombosis in 17 of them by the administration of a 12 hour long infusion of eptifibatide in order to evaluate the role of arterial thrombosis. Eptifibatide 184-196 C-reactive protein Homo sapiens 12-30 33251579-8 2021 CONCLUSIONS: Colchicine therapy near halves the risk of cardiovascular events in CCS compared with placebo, and is associated with a non-significant 23% risk reduction in ACS, together with a trend toward a greater reduction of hs-CRP. Colchicine 13-23 C-reactive protein Homo sapiens 231-234 11852009-4 2002 There was a decrease in C reactive protein 24 hours after angioplasty in eptifibatide group (0.24 0.27 vs 1.34 0.89 mg/dl; p < 0.001), but it increased again 48 hours after the procedure although to a lesser extent than in the control group (0.57 0.55 vs 2.18 2.1 mg/dl; p < 0.05). Eptifibatide 73-85 C-reactive protein Homo sapiens 24-42 11852009-5 2002 Eptifibatide, a synthetic peptide which is a selective blocker of the platelet GP IIb/IIIa receptor significantly reduced C-reactive protein concentration after angioplasty. Eptifibatide 0-12 C-reactive protein Homo sapiens 122-140 33660924-8 2021 Compared with placebo, colchicine modestly lowered levels of NRCI parameters (P values <0.05 for hs-CRP, WBCC, NC and NLR), while the changes of UACR and estimated glomerular filtration rate (eGFR) were similar between the two groups. Colchicine 23-33 C-reactive protein Homo sapiens 100-103 12235715-1 2002 OBJECTIVE: To study the effect of betamethasone therapy on maternal white blood cell count, C-reactive protein and erythrocyte sedimentation rate in women at high risk for preterm delivery. Betamethasone 34-47 C-reactive protein Homo sapiens 92-110 11401933-0 2001 Low circulating vitamin B(6) is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. Niacinamide 16-25 C-reactive protein Homo sapiens 85-103 33618966-4 2021 APPROACH AND RESULTS: In this cross-sectional study using data from 435 participants in NHANES and linear regression models with CRP as the outcome, we observed significant negative interactions between VO2max and omega-3 polyunsaturated fatty acids (PUFAs) but not saturated, monounsaturated, or omega-6 PUFAs. vo2max 203-209 C-reactive protein Homo sapiens 129-132 11401933-5 2001 We hypothesized a relationship between pyridoxal 5"-phosphate (PLP), the active form of vitamin B(6), and the marker of inflammation C-reactive protein (CRP). Niacinamide 88-97 C-reactive protein Homo sapiens 153-156 33618966-5 2021 When stratified by omega-3 PUFA tertiles, participants in the medium tertile, but not low tertile, show an enhanced negative association between VO2max and CRP, with a -32.0% difference (95% CI: -44.95, -15.9%) per 10 mL/kg/min of VO2max. vo2max 145-151 C-reactive protein Homo sapiens 156-159 33618966-8 2021 We also found that alpha-linolenic acid (ALA) and docosahexaenoic acid (DHA) enhanced the negative association between VO2max and CRP, suggesting that the anti-inflammatory response to VO2max capacity is associated with ALA and DHA levels. vo2max 119-125 C-reactive protein Homo sapiens 130-133 33552084-7 2020 In this model, the combination of E-CRP and clarithromycin drastically reduced bacteremia and increased survival of mice when compared to the protective effects of either E-CRP or clarithromycin alone. Clarithromycin 180-194 C-reactive protein Homo sapiens 36-39 11069205-6 2000 In diabetic patients, multiple regression showed, at each time, that TBARS and IL-6 were independently correlated with CRP, considering CRP as the dependent variable. tbars 69-74 C-reactive protein Homo sapiens 119-122 10585345-3 1999 METHODS: We compared the clinical efficacy of an automated and commercially available latex-enhanced assay (Latex) for hs-CRP (Dade Behring) to a validated in-house ELISA, previously shown to predict future peripheral arterial disease (PAD) in asymptomatic populations. Latex 86-91 C-reactive protein Homo sapiens 119-125 10432314-5 1999 The formation of inositol phosphates and phosphatidic acid (PA), two markers of phospholipase C (PLC) activation, by CRP are inhibited by between 50 and 85% in the presence of wortmannin and LY294002. Wortmannin 176-186 C-reactive protein Homo sapiens 117-120 33403775-9 2021 In parallel with CRP, PO2/FiO2 ratio increased progressively during the three steps from 183+-95 to 361+-144 mmHg (p < 0.001). PO-2 22-25 C-reactive protein Homo sapiens 17-20 10074595-3 1998 After treatment with prednisolone (PSL, 40 mg/day), the levels of C-reactive protein (CRP) and serum amyloid A decreased to within normal limits for 2 weeks. Prednisolone 21-33 C-reactive protein Homo sapiens 66-84 10074595-3 1998 After treatment with prednisolone (PSL, 40 mg/day), the levels of C-reactive protein (CRP) and serum amyloid A decreased to within normal limits for 2 weeks. Prednisolone 21-33 C-reactive protein Homo sapiens 86-89 10074595-3 1998 After treatment with prednisolone (PSL, 40 mg/day), the levels of C-reactive protein (CRP) and serum amyloid A decreased to within normal limits for 2 weeks. Prednisolone 35-38 C-reactive protein Homo sapiens 66-84 10074595-3 1998 After treatment with prednisolone (PSL, 40 mg/day), the levels of C-reactive protein (CRP) and serum amyloid A decreased to within normal limits for 2 weeks. Prednisolone 35-38 C-reactive protein Homo sapiens 86-89 32920994-8 2021 The results of TNF- alpha, IL-1 beta and CRP in the argon-helium cryoablation group was significantly better than that in the radiotherapy group(P < 0.001). Helium 58-64 C-reactive protein Homo sapiens 41-44 33155402-11 2021 CRP was negatively correlated with same-day citrulline (P < .03 for all) and ANC (P < .04 for all). Citrulline 44-54 C-reactive protein Homo sapiens 0-3 9514872-9 1998 Among markers of inflammation and matrix destruction, pentosidine levels in plasma from RA patients were correlated with the levels of C-reactive protein (CRP), erythrocyte sedimentation rate, white blood cell count, and platelet count. pentosidine 54-65 C-reactive protein Homo sapiens 135-153 9514872-9 1998 Among markers of inflammation and matrix destruction, pentosidine levels in plasma from RA patients were correlated with the levels of C-reactive protein (CRP), erythrocyte sedimentation rate, white blood cell count, and platelet count. pentosidine 54-65 C-reactive protein Homo sapiens 155-158 9514872-10 1998 Multiple stepwise regression analysis reveals an independent influence of CRP on plasma pentosidine levels. pentosidine 88-99 C-reactive protein Homo sapiens 74-77 33315350-9 2020 According to the paired samples analyses of the comparison between hospitalization and discharge, CRP levels significantly drops in the Alum Group (from 54.09 to 27, P = 0.001) but not in the Control Group. aluminum sulfate 136-140 C-reactive protein Homo sapiens 98-101 9751471-4 1998 The mean (+/-SEM) C-reactive protein (CRP) and sP-selectin levels were significantly reduced from 3.9(0.89) to 2.01(0.53) mg/dl and from 332.8 (48.2) to 116.2 (11.1) respectively, after 3 months of SSZ. Sulfasalazine 198-201 C-reactive protein Homo sapiens 18-36 9751471-4 1998 The mean (+/-SEM) C-reactive protein (CRP) and sP-selectin levels were significantly reduced from 3.9(0.89) to 2.01(0.53) mg/dl and from 332.8 (48.2) to 116.2 (11.1) respectively, after 3 months of SSZ. Sulfasalazine 198-201 C-reactive protein Homo sapiens 38-41 9359864-0 1997 The sphingomyelin-ceramide pathway participates in cytokine regulation of C-reactive protein and serum amyloid A, but not alpha-fibrinogen. Ceramides 18-26 C-reactive protein Homo sapiens 74-92 32425120-10 2020 CONCLUSIONS: Patients at high risk of recurrent cardiovascular disease events with an hs-CRP of 2 mg/L or greater can reduce the occurrence of ASCVD events with canakinumab or colchicine therapy. Colchicine 176-186 C-reactive protein Homo sapiens 89-92 9210690-9 1997 Postoperative serum levels of the C-reactive protein on days 2 and 7 were lower in cefodizime-treated patients (19 +/- 6 and 4 +/- 2 mg/liter versus 23 +/- 6 and 11 +/- 5 mg/liter; P < 0.05 for both). cefodizime 83-93 C-reactive protein Homo sapiens 34-52 8859218-5 1996 By incubating purified native CRP supplemented with normal human serum as a source of C we detected the C components Clq, Clr, Cls, C4 and C3 in the same speckled immunofluorescent pattern on HEp-2 cell nuclei as described characteristically for CRP binding. (R)-chloroquine 117-120 C-reactive protein Homo sapiens 30-33 32618142-16 2020 Higher phenylalanine levels were correlated with higher APACHE II and SOFA scores, higher C-reactive protein levels and incidence of using inotropic agents, and changes in cytokines suggestive of immunosuppression, but lower levels of pre-albumin and transferrin. Phenylalanine 7-20 C-reactive protein Homo sapiens 90-108 8666316-5 1996 Elevations of both serum C-reactive protein (CRP) levels and body temperature after GM-suppressed IFN-alpha injection suggest that the administration of GM by suppressing IL-6 production, may attenuate the IL-6-related responses induced by IFN-alpha injection. Gabexate 153-155 C-reactive protein Homo sapiens 25-43 8666316-5 1996 Elevations of both serum C-reactive protein (CRP) levels and body temperature after GM-suppressed IFN-alpha injection suggest that the administration of GM by suppressing IL-6 production, may attenuate the IL-6-related responses induced by IFN-alpha injection. Gabexate 153-155 C-reactive protein Homo sapiens 45-48 32618142-17 2020 Further multivariable analysis showed that phenylalanine >= 112 muM predicted death over 1 year independently of age, APACHE II and SOFA scores, atrial fibrillation, C-reactive protein, cholesterol, pre-albumin, transferrin, and interleukin-8 and interleukin-10. Phenylalanine 43-56 C-reactive protein Homo sapiens 166-184 32929124-7 2020 Thu Baseline levels of PCT and CRP have been addressed as independent predictors of mortality in patients with COVID-19. thu 0-3 C-reactive protein Homo sapiens 31-34 7492221-4 1995 After prednisolone it decreased significantly, by 28%, at which time inflammatory activity (as indicated by C reactive protein, erythrocyte sedimentation rate, joint count, and early morning stiffness) was also reduced considerably. Prednisolone 6-18 C-reactive protein Homo sapiens 108-126 32756464-7 2020 Statistical regression analysis showed that caffeine intake was a negative predictor of C-reactive protein (CRP) (p = 0.001). Caffeine 44-52 C-reactive protein Homo sapiens 88-106 8043897-4 1994 A positive correlation was found between C-reactive protein (CRP), an APR glycoprotein, and non-specific TBA reactivity as determined after borohydride reduction (BH4-resistant TBA, BR-TBA), both in non-diabetics (r = 0.61; P < 0.01) and diabetics (r = 0.68; P < 0.01). sapropterin 163-166 C-reactive protein Homo sapiens 41-59 8043897-4 1994 A positive correlation was found between C-reactive protein (CRP), an APR glycoprotein, and non-specific TBA reactivity as determined after borohydride reduction (BH4-resistant TBA, BR-TBA), both in non-diabetics (r = 0.61; P < 0.01) and diabetics (r = 0.68; P < 0.01). sapropterin 163-166 C-reactive protein Homo sapiens 61-64 7688075-3 1993 The selective removal of C-reactive protein from the plasma with phosphorylethanolamine-agarose inactivated hemolysis. phosphorylethanolamine 65-87 C-reactive protein Homo sapiens 25-43 32756464-7 2020 Statistical regression analysis showed that caffeine intake was a negative predictor of C-reactive protein (CRP) (p = 0.001). Caffeine 44-52 C-reactive protein Homo sapiens 108-111 32722956-4 2022 RESULTS: Thiamin supplementation significantly decreased serum high-sensitivity C-reactive protein (hs-CRP) (beta - 0.98 mg/L; 95% CI, -1.54, -0.42; p = .001) and plasma malondialdehyde (MDA) levels (beta - 0.86 micromol/L; 95% CI, -1.15, -0.57; p < .001) when compared with the placebo. Thiamine 9-16 C-reactive protein Homo sapiens 80-98 1350713-2 1992 The IL-6 and C-reactive protein (CRP) levels, which were extremely high before treatment, declined rapidly with administration of prednisolone. Prednisolone 130-142 C-reactive protein Homo sapiens 13-31 1350713-2 1992 The IL-6 and C-reactive protein (CRP) levels, which were extremely high before treatment, declined rapidly with administration of prednisolone. Prednisolone 130-142 C-reactive protein Homo sapiens 33-36 1375509-5 1992 Thus, human CRP and SAP show high specificity that is complementary for the related compounds, phosphorylcholine and phosphorylethanolamine, respectively. phosphorylethanolamine 117-139 C-reactive protein Homo sapiens 12-23 34055047-0 2021 Virgin coconut oil is effective in lowering C-reactive protein levels among suspect and probable cases of COVID-19. virgin coconut oil 0-18 C-reactive protein Homo sapiens 44-62 33813346-9 2021 In contrast, we observed inverse associations of monoethyl phthalate (MEP) (beta = -0.019; 95% CI -0.036, -0.001) and monobenzyl phthalate (MBzP) (beta = -0.034; 95% CI -0.058, -0.010) with CRP levels only after adjustment for BMI. mono-benzyl phthalate 140-144 C-reactive protein Homo sapiens 190-193 32722956-7 2022 CONCLUSION: Overall, thiamin supplementation for 6 weeks to patients with GDM significantly reduced hs-CRP and MDA levels, and gene expression of TNF-alpha, but did not affect other biomarkers of inflammation and oxidative stress. Thiamine 21-28 C-reactive protein Homo sapiens 103-106 32286421-6 2020 Further, methionine, isoleucine, tryptophan, xanthurenic acid, and indole-3-carboxaldehyde were negatively associated with C-reactive protein (CRP), but 5-hydroxyindole-3-acetic acid was positively associated with CRP. Isoleucine 21-31 C-reactive protein Homo sapiens 143-146 32091040-4 2020 Free PAG binding to the functionalised anti-CRP surface shows that only 47 +- 3% of CRP capture antibodies are correctly presenting Fab regions for antigen capture. pag 5-8 C-reactive protein Homo sapiens 44-47 33814982-9 2021 The leucocyte count, NLR, and C-reactive protein (CRP) level increased with increasing BG level. Blood Glucose 87-89 C-reactive protein Homo sapiens 30-48 33814982-9 2021 The leucocyte count, NLR, and C-reactive protein (CRP) level increased with increasing BG level. Blood Glucose 87-89 C-reactive protein Homo sapiens 50-53 26463833-3 2015 Ruxolitinib increased median survival from 1.8 to 2.7 months in patients with pancreatic cancer who had high levels of the inflammation marker C-reactive protein in their blood. ruxolitinib 0-11 C-reactive protein Homo sapiens 143-161 32295417-8 2020 High-sensitivity C-reactive protein concentration also increased less after 24 hours in the colchicine versus placebo groups (11% [-14 to 80] versus 66% [1 to 172], P=0.001). Colchicine 92-102 C-reactive protein Homo sapiens 17-35 32295417-9 2020 CONCLUSIONS: Acute preprocedural administration of colchicine attenuated the increase in interleukin-6 and high-sensitivity C-reactive protein concentrations after PCI when compared with placebo but did not lower the risk of PCI-related myocardial injury. Colchicine 51-61 C-reactive protein Homo sapiens 124-142 32144909-14 2020 Compared with the FTS group, the level of CRP on 3 d and the levels of N, CRP, IL-6 on 6 d in the FTS+LEAS group were significantly decreased (P<0.05). leas 102-106 C-reactive protein Homo sapiens 74-77 20368375-9 2009 HDL and C-reactive protein (CRP) levels improved gradually with increasing dietary phylloquinone intake (p < 0.05 for trend). Vitamin K 1 83-96 C-reactive protein Homo sapiens 8-26 20368375-9 2009 HDL and C-reactive protein (CRP) levels improved gradually with increasing dietary phylloquinone intake (p < 0.05 for trend). Vitamin K 1 83-96 C-reactive protein Homo sapiens 28-31 34933225-6 2022 The 10.5 nm CdSe/ZnS QDs incorporated DMSNs-QDs for C-reactive protein (CRP) detection achieved a limit of detection of 5 pg mL-1 (equivalent to 4.2 x 10-14 M) with naked eye, which is lower than literature reports and commercial LFIA products. cdse 12-16 C-reactive protein Homo sapiens 52-70 32559734-9 2020 Statistical analysis showed that low-fructose diet compared to control group significantly declined fasting blood glucose (FBG), Hemoglobin A1c (HbA1c), Triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C) and high-sensitivity C-reactive protein (hs-CRP) (P = 0.015, P = 0.001, P=<0.0001, P= <0.0001 and P= <0.0001 respectively). Fructose 37-45 C-reactive protein Homo sapiens 238-256 34933225-6 2022 The 10.5 nm CdSe/ZnS QDs incorporated DMSNs-QDs for C-reactive protein (CRP) detection achieved a limit of detection of 5 pg mL-1 (equivalent to 4.2 x 10-14 M) with naked eye, which is lower than literature reports and commercial LFIA products. cdse 12-16 C-reactive protein Homo sapiens 72-75 34459522-8 2022 The pooled results showed that fish oil supplementation caused a significant reduction of the CRP(C-reactive protein) level (random model: WMD, -3.36, 95%CI: -5.46 to -1.26, P = .002), especially in patients with baseline CRP >= 5 mg/L (random model: WMD, -4.43, 95%CI: -6.10 to -2.76, P = .00001, I2 = 41%). Fish Oils 31-39 C-reactive protein Homo sapiens 222-225 34459522-12 2022 CONCLUSIONS: Fish oil supplementation could reduce the level of CRP in hemodialysis patients, especially in patients with CRP >= 5 mg/L, but had no effects on IL-6 and TNF-alpha. Fish Oils 13-21 C-reactive protein Homo sapiens 64-67 32559734-9 2020 Statistical analysis showed that low-fructose diet compared to control group significantly declined fasting blood glucose (FBG), Hemoglobin A1c (HbA1c), Triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C) and high-sensitivity C-reactive protein (hs-CRP) (P = 0.015, P = 0.001, P=<0.0001, P= <0.0001 and P= <0.0001 respectively). Fructose 37-45 C-reactive protein Homo sapiens 261-264 34459522-12 2022 CONCLUSIONS: Fish oil supplementation could reduce the level of CRP in hemodialysis patients, especially in patients with CRP >= 5 mg/L, but had no effects on IL-6 and TNF-alpha. Fish Oils 13-21 C-reactive protein Homo sapiens 122-125 32559734-10 2020 CONCLUSION: Our results showed that eight weeks of low-fructose diet results in a significant improvement in FBG, HbA1c, TG, HDL-C and hs-CRP in patients with type 2 diabetes. Fructose 55-63 C-reactive protein Homo sapiens 138-141 31692333-8 2019 We estimated the concentration of immobilized antibody that is specific to human C-reactive protein (anti-hCRP) by measuring the localized surface plasmon resonance (LSPR) shifts after exposing the surface of Au nanostructures to the antibody. Gold 209-211 C-reactive protein Homo sapiens 81-99 31692333-8 2019 We estimated the concentration of immobilized antibody that is specific to human C-reactive protein (anti-hCRP) by measuring the localized surface plasmon resonance (LSPR) shifts after exposing the surface of Au nanostructures to the antibody. Gold 209-211 C-reactive protein Homo sapiens 106-110 34917038-10 2021 Baseline SUVmax (64Cu)Cu-DOTATATE uptake values showed a weak positive correlation with the inflammatory biomarker high-sensitivity c-reactive protein (tau =0.26, p=0.045). cu-dotatate 22-33 C-reactive protein Homo sapiens 132-150 31777551-7 2019 The alveolar M2 TAM density was also significantly associated with the CRP level (P=0.0309), invasive size (P<0.0001), tumor differentiation (P=0.0192), tumor status (P=0.0108) and pathological stage (P=0.0110). TAM protocol 16-19 C-reactive protein Homo sapiens 71-74 34815694-8 2021 AIU group had substantially higher baseline C-reactive protein and NT-proBNP levels, and increased neutrophil percent. aiu 0-3 C-reactive protein Homo sapiens 44-62 31141297-7 2019 Increased DCA and GDCA concentrations were significantly associated with decreased HbA1c or fasting blood glucose and CRP levels, whereas increased GDCA and GUDCA concentrations were associated with decreased waist circumference in the OW/OB group during treatment. Deoxycholic Acid 10-13 C-reactive protein Homo sapiens 118-121 34655117-8 2021 Multivariate logistic regression showed that WBC and sUA had significance for protective effects between non-MPP and SMPP, but CRP did not have significance between the two groups, N and PLT had significance for risk factors; WBC and sUA did not have significance for the protective effects between non-MPP and MMPP, CRP had significance between the two groups, N and PLT had significance for the risk effects. smpp 117-121 C-reactive protein Homo sapiens 317-320 34357446-6 2021 RESULTS: The maximum post-operative CRP level was significantly elevated in the 4DF group (87 vs. 29%; p < 0.001), whereas leukocyte concentration and body temperature did not differ between groups. 5-Chloro-N~2~-(1,1-Dioxido-2,3-Dihydro-1,2-Benzothiazol-6-Yl)-N~4~-Ethyl-N~4~-(1h-Indazol-4-Yl)pyrimidine-2,4-Diamine 80-83 C-reactive protein Homo sapiens 36-39 31284074-3 2019 The current study tested the ability of low dose colchicine to reduce CRP levels at 30 days after an acute MI, a key marker of future outcome, and its safety and tolerability in this setting. Colchicine 49-59 C-reactive protein Homo sapiens 70-73 31284074-6 2019 RESULTS: At 30-day follow-up, 44% of patients treated with colchicine had a CRP level >=2 mg/L compared to 50% of those randomized to placebo (P = .35) and the median CRP in patients randomized to colchicine was 1.6 mg/L (interquartile range [IQR] 0.7-3.5) compared to 2.0 mg/L (IQR 0.9-4.0) in patients randomized to placebo (P = .11). Colchicine 59-69 C-reactive protein Homo sapiens 76-79 34529909-10 2022 The area under the receiver operating curve of C-DII in predicting hs-CRP was found to be quite high (0.864, 95% CI: 0.795-0.933). c-dii 47-52 C-reactive protein Homo sapiens 70-73 31284074-6 2019 RESULTS: At 30-day follow-up, 44% of patients treated with colchicine had a CRP level >=2 mg/L compared to 50% of those randomized to placebo (P = .35) and the median CRP in patients randomized to colchicine was 1.6 mg/L (interquartile range [IQR] 0.7-3.5) compared to 2.0 mg/L (IQR 0.9-4.0) in patients randomized to placebo (P = .11). Colchicine 59-69 C-reactive protein Homo sapiens 170-173 34420546-9 2022 Also, a positive association between E-DII and C-reactive protein (CRP) was observed (BE-DII = 1.37, 95% CI: 0.72, 2.02), such that with each unit increase in E-E-DII, the CRP levels were increased by 1.37 units. e-dii 37-42 C-reactive protein Homo sapiens 47-65 31284074-7 2019 The median absolute reduction in CRP levels was -4.3 mg/L (IQR -1.1 to -14.1) among colchicine treated patients and -3.3 mg/L (IQR -0.9 to -14.4, P = .44) in placebo treated patients. Colchicine 84-94 C-reactive protein Homo sapiens 33-36 34420546-9 2022 Also, a positive association between E-DII and C-reactive protein (CRP) was observed (BE-DII = 1.37, 95% CI: 0.72, 2.02), such that with each unit increase in E-E-DII, the CRP levels were increased by 1.37 units. e-dii 37-42 C-reactive protein Homo sapiens 67-70 34420546-9 2022 Also, a positive association between E-DII and C-reactive protein (CRP) was observed (BE-DII = 1.37, 95% CI: 0.72, 2.02), such that with each unit increase in E-E-DII, the CRP levels were increased by 1.37 units. e-dii 37-42 C-reactive protein Homo sapiens 172-175 31327803-9 2019 The patient was diagnosed with vasculo-Behcet"s disease and treated with corticosteroids, colchicine, and infliximab, which led to obvious improvement of the MRI findings and reduction in CRP. Colchicine 90-100 C-reactive protein Homo sapiens 188-191 34136969-6 2021 Compared to treatment with tocilizumab, baricitinib showed a similar improvement in tender and swollen joint count and serum CRP levels, and a significantly greater improvement in PGA at 24 weeks. baricitinib 40-51 C-reactive protein Homo sapiens 125-128 34142940-10 2021 Serum lipase and C-reactive protein levels at postoperative week 1 were higher in the histidinetryptophan-ketoglutarate group. histidinetryptophan 86-105 C-reactive protein Homo sapiens 17-35 31469126-6 2019 RESULTS The median value of CRP levels in maternal blood was 47.5 mg/dl in the IUGR group and 15.255 mg/dl in the AGA group (p=0.001). aga 114-117 C-reactive protein Homo sapiens 28-31 34080237-6 2021 Compared with baseline, serum levels of IL-6, TNF-alpha, MCP-1 and CRP were significantly reduced in patients receiving curcuminoids (p < .05) without any significant changes in placebo group; however, changes in the activities of GPx and SOD in serum were not significant between two groups. Diarylheptanoids 120-132 C-reactive protein Homo sapiens 67-70 31375659-9 2019 In the venlafaxine study, a correlation was observed only between CRP level at randomisation and response, suggesting differences between the two active treatments and the two studies. Venlafaxine Hydrochloride 7-18 C-reactive protein Homo sapiens 66-69 34405148-0 2021 Effect of Collagen Hydrolysate and Fish Oil on High-Sensitivity C-Reactive Protein and Glucose Homeostasis in Patients with severe Burn; a Randomized Clinical Trial. Fish Oils 35-43 C-reactive protein Homo sapiens 64-82 33715687-0 2021 C-Reactive Protein Sensor Based on Porous Silicon Bragg Stack Interferometers. Silicon 42-49 C-reactive protein Homo sapiens 0-18 31337804-7 2019 Citrate dialysis increased HD efficacy and reduced plasma levels of CRP, fibrinogen, IL6 and chemerin. Citric Acid 0-7 C-reactive protein Homo sapiens 68-71 34204618-5 2021 The results revealed statistically significant differences in subjects treated with the polyphenolic extract compared to the placebo: A decrease in homocysteine, oxidized low-density lipoprotein (OxLDL), TNF-alpha, sTNFR1, and C-reactive protein (CRP). polyphenolic extract 88-108 C-reactive protein Homo sapiens 227-245 34204618-5 2021 The results revealed statistically significant differences in subjects treated with the polyphenolic extract compared to the placebo: A decrease in homocysteine, oxidized low-density lipoprotein (OxLDL), TNF-alpha, sTNFR1, and C-reactive protein (CRP). polyphenolic extract 88-108 C-reactive protein Homo sapiens 247-250 31062578-2 2019 Here, we report both highly specific and supersensitive detection of C-reactive protein (CRP) by employing atomically flat Au nanoplates. Gold 123-125 C-reactive protein Homo sapiens 69-87 34064175-11 2021 Patients who received calcifediol after admission were more likely than those not receiving treatment to have comorbidity and a lower rate of CURB-65 score for pneumonia severity >= 3 (one point for each of confusion, urea > 7 mmol/L, respiratory rate >= 30/min, systolic blood pressure < 90 mm Hg or diastolic blood pressure <= 60 mm Hg, and age >= 65 years), acute respiratory distress syndrome (moderate or severe), c-reactive protein, chronic kidney disease, and blood urea nitrogen. Calcifediol 22-33 C-reactive protein Homo sapiens 419-437 31062578-2 2019 Here, we report both highly specific and supersensitive detection of C-reactive protein (CRP) by employing atomically flat Au nanoplates. Gold 123-125 C-reactive protein Homo sapiens 89-92 31062578-4 2019 To maximize the binding capacity for CRP, we carefully optimized the Au nanoplate-Cys3-protein G-anti-CRP structure by observing atomic force microscopy (AFM) images. Gold 69-71 C-reactive protein Homo sapiens 37-40 35453148-10 2022 In addition, some tendencies were observed: serum HDL cholesterol tended to be inversely correlated with visceral adipose tissue cholesterol; high-sensitivity C-reactive protein tended to be correlated directly with subcutaneous adipose 24S-hydroxycholesterol and inversely with visceral 27-hydroxycholesterol. 27-hydroxycholesterol 288-309 C-reactive protein Homo sapiens 159-177 31062578-4 2019 To maximize the binding capacity for CRP, we carefully optimized the Au nanoplate-Cys3-protein G-anti-CRP structure by observing atomic force microscopy (AFM) images. Gold 69-71 C-reactive protein Homo sapiens 102-105 31062578-5 2019 The optimally anti-CRP-immobilized Au nanoplates allowed extremely specific detection of CRP at the attomolar level. Gold 35-37 C-reactive protein Homo sapiens 19-22 35498793-16 2022 Conclusion: The N%, PLT, CRP, LDH and D-dimer were risk factors for SMPP. smpp 68-72 C-reactive protein Homo sapiens 25-28 31062578-5 2019 The optimally anti-CRP-immobilized Au nanoplates allowed extremely specific detection of CRP at the attomolar level. Gold 35-37 C-reactive protein Homo sapiens 89-92 31062578-6 2019 To confirm the binding of CRP onto the Au nanoplate, we assembled Au nanoparticles (NPs) onto the CRP-captured Au nanoplate by sandwich immunoreaction and obtained surface-enhanced Raman scattering (SERS) spectra and scanning electron microscopy (SEM) images. Gold 39-41 C-reactive protein Homo sapiens 26-29 35267027-7 2022 Baseline C-reactive protein (CRP) and prednisolone dose were identified as clinically significant negative predictive factors: treatment effect decreased as CRP or prednisolone dose increased, for both peficitinib doses. Prednisolone 38-50 C-reactive protein Homo sapiens 157-160 35140620-9 2022 The results of BCA indicated that Gastrodin, Liquiritin, Hesperidin, Isoliquiritin, Hesperetin, and Isoliquiritigenin might be the active constituents to activate ROS and suppress hs-CRP as determined by spectrum-effect relationships. liquiritin 45-55 C-reactive protein Homo sapiens 183-186 35140620-9 2022 The results of BCA indicated that Gastrodin, Liquiritin, Hesperidin, Isoliquiritin, Hesperetin, and Isoliquiritigenin might be the active constituents to activate ROS and suppress hs-CRP as determined by spectrum-effect relationships. hesperetin 84-94 C-reactive protein Homo sapiens 183-186 31062578-6 2019 To confirm the binding of CRP onto the Au nanoplate, we assembled Au nanoparticles (NPs) onto the CRP-captured Au nanoplate by sandwich immunoreaction and obtained surface-enhanced Raman scattering (SERS) spectra and scanning electron microscopy (SEM) images. Gold 66-68 C-reactive protein Homo sapiens 26-29 30500627-9 2019 The adjusted hazard ratios of EVT versus F-P bypass for restenosis were 0.77 (P = 0.46) in cases with a low BMI (<=18 kg/m2) or an elevated CRP level (>=1 mg/dL) and 3.35 (P < 0.01) in other cases. EVT 30-33 C-reactive protein Homo sapiens 143-146 30089532-5 2019 We found higher body temperature, neutrophil percentage, and C-Reactive protein (CRP) values and a lower hemoglobin level in the IBIs group. ibis 129-133 C-reactive protein Homo sapiens 81-84 30767788-3 2019 RESULTS: At the end of study, serum high sensitive C-reactive protein (hs-CRP) and activity of nuclear factor kappa B (NF-kappaB) were reduced in Cit group significantly more than placebo group (P-value = 0.02 and < 0.01 respectively). Citrulline 146-149 C-reactive protein Homo sapiens 51-69 30755272-4 2019 A recent rifampicin exposure 1 week earlier had resulted in a massive rise of CRP levels without organ manifestations. Rifampin 9-19 C-reactive protein Homo sapiens 78-81 29728047-1 2019 In this study, poly[2-methacryloyloxyethyl phosphorylcholine (MPC)]-protected Fe3O4 nanoparticles were prepared and used for the label-free specific detection and collection of an acute inflammation marker, C-reactive protein (CRP), in a simulated body fluid. poly(2-methacryloyloxyethyl-phosphorylcholine) 15-60 C-reactive protein Homo sapiens 207-225 29728047-1 2019 In this study, poly[2-methacryloyloxyethyl phosphorylcholine (MPC)]-protected Fe3O4 nanoparticles were prepared and used for the label-free specific detection and collection of an acute inflammation marker, C-reactive protein (CRP), in a simulated body fluid. poly(2-methacryloyloxyethyl-phosphorylcholine) 15-60 C-reactive protein Homo sapiens 227-230 31434498-6 2019 The beneficial effect of fisetin was likely attributable to reduced levels of MMP-2, MMP-9, and CRP in the serum, as evidenced by strong linear correlations between serum levels of such markers with the NIHSS scores in all enrolled patients. fisetin 25-32 C-reactive protein Homo sapiens 96-99 28967799-6 2019 None of the five studies assessing the effects of coffee found changes in C-reactive protein (CPR), but one out of three trials found decreased CPR levels in response to caffeine. Caffeine 170-178 C-reactive protein Homo sapiens 144-147 31740368-9 2019 RESULTS: Compared with placebo, colchicine reduced markers of inflammation, including C-reactive protein, erythrocyte sedimentation rate, and GlycA (P < .01). Colchicine 32-42 C-reactive protein Homo sapiens 86-104 31168199-1 2018 - The aim was to examine whether the postprocedural change in C-reactive protein (CRP) and fibrinogen levels was associated with the extent of periprocedural arterial injury caused by endovascular treatment (EVT). EVT 208-211 C-reactive protein Homo sapiens 62-80 30352836-6 2018 Pooled results showed that high CRP/Alb ratio was associated with poor overall survival (OS) (HR = 1.51, 95% CI: 1.30-1.75, P<0.001) and poor distant metastasis-free survival (DMFS) (HR = 1.23, 95% CI: 1.07-1.43, P=0.005). dmfs 179-183 C-reactive protein Homo sapiens 32-35 30205424-6 2018 Pearson correlation analysis showed significant correlations between plasma hs-CRP and alpha-carotene and retinol concentrations. alpha-carotene 87-101 C-reactive protein Homo sapiens 79-82 30122937-7 2018 Results: The markers of pain and disease activity, C-reactive protein and erythrocyte sedimentation rate were significantly improved when Azil was used, as an adjuvant with Etan, compared with the use of Etan and placebo. azilsartan 138-142 C-reactive protein Homo sapiens 51-69 29660401-6 2018 RESULTS: 54 patients received 128 courses of IV fosfomycin in combination with a second antibiotic, resulting in improved FEV1 (0.94 L vs 1.24 L, p < 0.01) and reduced CRP (65 mg/L vs 19.3 mg/L, p < 0.01). Fosfomycin 48-58 C-reactive protein Homo sapiens 171-174 29567181-3 2018 The Anti-1 Ab was first covalently anchored onto an L-cysteine/gold-modified disposable SPGE (L-Cys/Au/SPGE) to create the anti-CRP surface. Gold 100-102 C-reactive protein Homo sapiens 128-131 29849779-6 2018 The correlation analyses of serum inflammatory factor and BDNF levels with depression showed that CRP and TNF-alpha were positively correlated with SDS score, while BDNF level was negatively correlated with SDS score. sds 148-151 C-reactive protein Homo sapiens 98-101 29469010-5 2018 RESULTS: Thiamine deficiency was detected in 61 patients within the first 10 d of ICU stay, 57 cases being diagnosed on admission and 4 new cases on the 5th d. C-reactive protein concentration during ICU stay was independently associated with decreased blood thiamine concentrations (P = 0.003). Thiamine 9-17 C-reactive protein Homo sapiens 160-178 29469010-5 2018 RESULTS: Thiamine deficiency was detected in 61 patients within the first 10 d of ICU stay, 57 cases being diagnosed on admission and 4 new cases on the 5th d. C-reactive protein concentration during ICU stay was independently associated with decreased blood thiamine concentrations (P = 0.003). Thiamine 259-267 C-reactive protein Homo sapiens 160-178 28982550-12 2018 Inflammation as measured by CRP was also reduced in the carnitine group, compared with the control group. Carnitine 56-65 C-reactive protein Homo sapiens 28-31 28351163-14 2017 CONCLUSIONS: Desloratadine exerted anti-inflammatory and antioxidant effects on CSU patients revealed by CRP. desloratadine 13-26 C-reactive protein Homo sapiens 105-108 28834922-7 2017 The route of VRCZ administration, C-reactive protein concentration determined on the same day as VRCZ plasma concentration measurement, CYP2C19 extensive metabolizer, and patient age were independent factors influencing the VRCZ/N-oxide ratio (R = 0.489, standardized regression coefficient = 0.385, 0.380, -0.231, and 0.231; P = 0.001, 0.001, 0.032, and 0.036, respectively). Oxides 231-236 C-reactive protein Homo sapiens 34-52 28431362-5 2017 RNA aptamers, which were specific recognized to CRP, were assembled on the surface of Au NPs modified electrode via gold-sulfur affinity. Gold 86-88 C-reactive protein Homo sapiens 48-51 28804234-15 2017 Significant positive correlation was observed between nitrite and CRP ( r = 0.46, p < 0.05), TNF-alpha ( r = 0.53, p < 0.05), and inverse correlation with FMD ( r =0.62, p < 0.05). Nitrites 54-61 C-reactive protein Homo sapiens 66-69 27395328-10 2017 A plant-sourced pattern (beta-carotene, vitamin A, lutein and zeaxanthin) was inversely associated with CRP (p for trend across quartiles 0.005). Zeaxanthins 62-72 C-reactive protein Homo sapiens 104-107 28404545-4 2017 As shown in the present study, doxepin significantly diminished the stimulatory effect of GPVI agonist collagen-related peptide (CRP) on intracellular Ca2+ release as well as subsequent extracellular Ca2+ influx. Doxepin 31-38 C-reactive protein Homo sapiens 103-127 28404545-4 2017 As shown in the present study, doxepin significantly diminished the stimulatory effect of GPVI agonist collagen-related peptide (CRP) on intracellular Ca2+ release as well as subsequent extracellular Ca2+ influx. Doxepin 31-38 C-reactive protein Homo sapiens 129-132 28404545-5 2017 Doxepin was partially effective by impairment of CRP-dependent IP3 production. Doxepin 0-7 C-reactive protein Homo sapiens 49-52 28404545-6 2017 Moreover, doxepin abrogated CRP-induced platelet degranulation and integrin alphaIIbbeta3 activation and aggregation. Doxepin 10-17 C-reactive protein Homo sapiens 28-31 28791854-1 2017 BACKGROUND: L-carnitine has been used for several years as an adjuvant therapy in oxidative stress, blood sugar, high-sensitivity C-reactive protein (CRP), anemia, etc. Carnitine 12-23 C-reactive protein Homo sapiens 130-148 28791854-1 2017 BACKGROUND: L-carnitine has been used for several years as an adjuvant therapy in oxidative stress, blood sugar, high-sensitivity C-reactive protein (CRP), anemia, etc. Carnitine 12-23 C-reactive protein Homo sapiens 150-153 28031420-0 2017 Novel Protein Glycan-Derived Markers of Systemic Inflammation and C-Reactive Protein in Relation to Glycemia, Insulin Resistance, and Insulin Secretion. Polysaccharides 14-20 C-reactive protein Homo sapiens 66-84 28031420-5 2017 RESULTS: GlycA and GlycB had a strong correlation with CRP (r = 0.60 [P < 0.001] and r = 0.46 [P < 0.001], respectively). glycb 19-24 C-reactive protein Homo sapiens 55-58 28114138-13 2017 CONCLUSIONS: Even though pGSN was inversely correlated with age, CRP and IL-6, suggesting that inflammation may influence pGSN, lower pGSN levels were not associated with hospitalization, all-cause and cardio-vascular mortality in this patient population. pgsn 25-29 C-reactive protein Homo sapiens 65-68 27161894-11 2016 Serum concentration of IL-6 and CRP decreased from 8.1 +- 6.6 pg/mL to 4.6 +- 4.1 pg/mL (p < 0.05) and from 0.50 (0.10-1.27) mg/dL to 0.28 (0.09-0.62) mg/dL (p < 0.05), respectively only in the cholecalciferol group. Cholecalciferol 200-215 C-reactive protein Homo sapiens 32-35 26865084-7 2016 CRP levels in plasma were positively correlated with the body mass index (BMI), insulin and glucose levels, HOMA-IR, HOMA-beta, WBC and neutrophil counts, and the NLR, and were negatively correlated with TAS and total thiol levels in the overall studied population. tas 204-207 C-reactive protein Homo sapiens 0-3 27678439-8 2016 The median percent change in CRP was -26.1% (P = .196) and -53.9% (P < .001) for gemcabene 300 mg and 900 mg, respectively, vs -11.1% for placebo. gemcabene 84-93 C-reactive protein Homo sapiens 29-32 27678439-10 2016 CONCLUSIONS: Gemcabene as add-on to stable statin therapy demonstrated additional dose-dependent and statistically significant reductions in LDL-C of >20% and CRP >40% compared to placebo. gemcabene 13-22 C-reactive protein Homo sapiens 162-165 26667361-2 2016 Tissue factor (TF), C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha) and monocyte chemoattractant protein 1 (MCP-1) may play critical roles in the process of CTEPH thrombosis and pulmonary vascular remodeling. cteph 175-180 C-reactive protein Homo sapiens 20-38 26667361-9 2016 In CTEPH patients, the expression of CRP, TNF-alpha, and MCP-1 was significantly higher than that in controls (P < 0.05). cteph 3-8 C-reactive protein Homo sapiens 37-40 26667361-11 2016 In CTEPH patients, levels of CRP, MCP-1, and TNF-alpha significantly correlated with the level of TF antigen in plasma. cteph 3-8 C-reactive protein Homo sapiens 29-32 27253137-5 2016 The assay was 257-fold more sensitive than that with a conventional Au-based lateral flow test strip for CRP detection. Gold 68-70 C-reactive protein Homo sapiens 105-108 25891993-7 2016 The overall survival of patients who achieve CR/CRp/CRi showed significantly prolonged survival compared with patients who did not in C-FLAG (P < 0.001) and was a favorable predictor of longer survival by multivariate analysis (P = 0.009). c-flag 134-140 C-reactive protein Homo sapiens 45-47 25891993-7 2016 The overall survival of patients who achieve CR/CRp/CRi showed significantly prolonged survival compared with patients who did not in C-FLAG (P < 0.001) and was a favorable predictor of longer survival by multivariate analysis (P = 0.009). c-flag 134-140 C-reactive protein Homo sapiens 48-51 26456189-1 2016 OBJECTIVE: To assess the interaction of three single nucleotide polymorphisms in the C-reactive protein (CRP) gene and plasma fatty acid (FA) levels in modulating inflammatory profile. plasma fatty acid 119-136 C-reactive protein Homo sapiens 85-103 27508369-3 2016 The release characteristics of CRP in distilled water and the reaction between CRP and phenol were studied and fitted using MATLAB software. Phenol 87-93 C-reactive protein Homo sapiens 31-34 27508369-5 2016 KMnO4 released from CRP can effectively degrade phenol-contaminated water with different concentrations. Phenol 48-54 C-reactive protein Homo sapiens 20-23 27508369-8 2016 The results indicate phenol can be effectively removed by CRP and smaller dosage of KMnO4 was required compared with literature values. Phenol 21-27 C-reactive protein Homo sapiens 58-61 26147939-7 2015 According to Pearson"s analysis, alpha 1-acid levels are significantly positively correlated with erythrocyte sedimentation rate, C-reactive protein, and skin lesions and arthritis of BDCAF scores. alpha 1-acid 33-45 C-reactive protein Homo sapiens 130-148 26001859-6 2015 Colchicine resistance was defined as at least one attack per month for three consecutive months and elevated erythrocyte sedimentation rate or C-reactive protein or serum amyloid A in-between attacks despite taking adequate dose of colchicine. Colchicine 0-10 C-reactive protein Homo sapiens 143-161 26171208-9 2015 Our meta-analysis results revealed that RFS and CSS were significantly different between patients with elevated CRP levels and those with low CRP levels (P<0.0001 and P<0.00001, respectively); however, that was not the case for OS (P=0.22) in the multivariate or the univariate model. thiocysteine 48-51 C-reactive protein Homo sapiens 112-115 26171208-9 2015 Our meta-analysis results revealed that RFS and CSS were significantly different between patients with elevated CRP levels and those with low CRP levels (P<0.0001 and P<0.00001, respectively); however, that was not the case for OS (P=0.22) in the multivariate or the univariate model. thiocysteine 48-51 C-reactive protein Homo sapiens 142-145 25128285-5 2014 High CRP level was dichotomized as >3 mg/L. Aminoglutethimide 32-38 C-reactive protein Homo sapiens 5-8 24932476-6 2014 Compared to patients without MH, CRP values at follow-up colonoscopy were significantly lower in patients with MH (TNF1 group: p = 8.35x10-5; TNF2 group: p = 0.002). mh 111-113 C-reactive protein Homo sapiens 33-36 24932476-9 2014 CONCLUSIONS: We identified low serum CRP level at follow-up colonoscopy as predictor for MH, while MH was an excellent negative predictor for the need for surgery. mh 89-91 C-reactive protein Homo sapiens 37-40 24612599-3 2014 This study aimed to assess the association between initial tumor size, involved organs, pre-treatment C-reactive protein (CRP) levels, and reduction in tumor size in patients with clear cell RCC (CCRCC) treated with sunitinib. Sunitinib 216-225 C-reactive protein Homo sapiens 102-120 24612599-3 2014 This study aimed to assess the association between initial tumor size, involved organs, pre-treatment C-reactive protein (CRP) levels, and reduction in tumor size in patients with clear cell RCC (CCRCC) treated with sunitinib. Sunitinib 216-225 C-reactive protein Homo sapiens 122-125 24612599-11 2014 CONCLUSIONS: Patients with CCRCC with smaller lung metastatic lesions and lower CRP levels may achieve greater percent reductions in tumor size with sunitinib therapy than patients with extra-pulmonary lesions, large lung lesions, and/or higher CRP levels. Sunitinib 149-158 C-reactive protein Homo sapiens 80-83 24345579-12 2014 Surrogate markers of general health status (temperature, C-reactive protein and haemoglobin levels at diagnosis) were significantly correlated with AMH SDS. sds 152-155 C-reactive protein Homo sapiens 57-75 24578648-7 2014 The serum levels of CRP and TNF-alpha negative correlate with ALA, DHA, and DGLA. Dihydroalprenolol 67-70 C-reactive protein Homo sapiens 20-23 24578648-7 2014 The serum levels of CRP and TNF-alpha negative correlate with ALA, DHA, and DGLA. 8,11,14-Eicosatrienoic Acid 76-80 C-reactive protein Homo sapiens 20-23 24870724-8 2014 For CSS the pooled HR (HR: 1.33, 95%CI: 1.28-1.39) for higher CRP expression could strongly predict poorer survival in urological cancers. thiocysteine 4-7 C-reactive protein Homo sapiens 62-65 24097561-8 2013 The effects of pyrrolidine-dithio-carbamate ammonium (PDTC), an inhibitor of the NF-kappaB pathway, were investigated on CRP-induced adhesion of monocytes to PAEC, adhesion molecule expression, endothelin-1 (ET-1), interleukin-6 (IL-6), and von Willebrand factor (vWF) secretion. prolinedithiocarbamate 54-58 C-reactive protein Homo sapiens 121-124 23763486-4 2013 This was confirmed in cell culture systems - acrolein stimulated the production of IL-6 in mouse neuroblastoma Neuro-2a cells, mouse macrophage-like J774.1 cells, and human umbilical vein endothelial cells (HUVEC), and IL-6 in turn stimulated the production of CRP in human hepatocarcinoma cells. Acrolein 45-53 C-reactive protein Homo sapiens 261-264 24047226-9 2013 Multivariable logistic regression analysis showed that prior administration of carbapenems (odds ratio (OR) 7.04, 95% confidence interval (CI) 1.43-34.77) or corticosteroids (OR 6.67, 95% CI 1.19-37.44), and C-reactive protein >= 40 mg/l (OR 18.11, 95% CI 2.22-148.07) were positive predictive factors. Carbapenems 79-90 C-reactive protein Homo sapiens 208-226 23752073-7 2013 RESULTS: The plasma citrulline levels correlated negatively with CRP (r = -0.332, P = 0.008), ESR (r = -0.290, P = 0.022), and PCDAI (r = -0.424, P = 0.001) in patients with CD. Citrulline 20-30 C-reactive protein Homo sapiens 65-68 23752073-9 2013 In subgroup analysis, patients with CD with jejunal involvement showed significantly negative correlations of plasma citrulline levels with CRP (r = -0.628, P = 0.016) and PCDAI (r = -0.632, P = 0.015); however, patients with CD without jejunal involvement revealed no correlations of plasma citrulline levels with CRP and PCDAI. Citrulline 117-127 C-reactive protein Homo sapiens 140-143 23752073-9 2013 In subgroup analysis, patients with CD with jejunal involvement showed significantly negative correlations of plasma citrulline levels with CRP (r = -0.628, P = 0.016) and PCDAI (r = -0.632, P = 0.015); however, patients with CD without jejunal involvement revealed no correlations of plasma citrulline levels with CRP and PCDAI. Citrulline 117-127 C-reactive protein Homo sapiens 315-318 23752073-12 2013 CONCLUSIONS: Plasma citrulline levels correlated with disease severity as measured by PCDAI, CRP, and ESR in pediatric patients with CD with jejunal involvement. Citrulline 20-30 C-reactive protein Homo sapiens 93-96 23607532-9 2013 Ten weeks after IFX infusion, CD activity index, ESR, CRP and intestinal mucosal healing were improved markedly in CD patients, and IL-21 expression and Th17 cell infiltration were decreased significantly compared with those before IFX therapy. Ifosfamide 16-19 C-reactive protein Homo sapiens 54-57 24532615-8 2013 C-reactive protein and creatine kinase levels 7 days after surgery were significantly lower in the landiolol group. landiolol 99-108 C-reactive protein Homo sapiens 0-18 23711057-20 2013 In the course of the two-month treatment, the accumulation of fl uorodeoxyglucose during the PET-CT imaging has normalized; the originally pathologically enlarged nodes have become smaller, the originally elevated CRP level has normalized and the originally signifi cantly lower haemoglobin level has risen. Fluorodeoxyglucose F18 62-81 C-reactive protein Homo sapiens 214-217 23484158-5 2013 After three months of mulberry leaf consumption, serum triglyceride and low-density lipoprotein (LDL) level were significantly reduced and more than half of all patients" CRP levels decreased every month as well as the mean CRP level but no statistically significant difference was found. mulberry leaf 22-35 C-reactive protein Homo sapiens 171-174 23484158-5 2013 After three months of mulberry leaf consumption, serum triglyceride and low-density lipoprotein (LDL) level were significantly reduced and more than half of all patients" CRP levels decreased every month as well as the mean CRP level but no statistically significant difference was found. mulberry leaf 22-35 C-reactive protein Homo sapiens 224-227 23484158-7 2013 It can be concluded that mulberry leaf powder exhibited antioxidant activity and mulberry leaf powder has potential to decrease serum triglyceride, LDL, and CRP levels in mild dyslipidemia patients without causing severe adverse reactions. mulberry leaf 81-94 C-reactive protein Homo sapiens 157-160 23807991-13 2013 The evaluation of dependence of sensitivity and specificity for procalciotonine test and C-reactive protein the area under curve of procalcitonine test was larger in patients with rheumatic diseases (0.85 against 0.79) and in patients of cardio-therapeutic profile (0.92 against 0.90). procalcitonine 132-146 C-reactive protein Homo sapiens 89-107 23516493-4 2013 NT-proBNP was significantly associated with both CRP (r = 0.38; p = 0.001) and suPAR (r = 0.42; p<0.001) in black men only. probnp 3-9 C-reactive protein Homo sapiens 49-52 22267767-9 2012 CRP-induced adhesion of CTEPH-ECs to monocytes was mediated by ICAM-1. cteph 24-29 C-reactive protein Homo sapiens 0-3 22267767-12 2012 CRP may contribute to persistent obstruction of proximal pulmonary arteries in CTEPH by promoting vascular remodelling, endothelial dysfunction and in situ thrombosis. cteph 79-84 C-reactive protein Homo sapiens 0-3 22671963-0 2012 C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib. Sunitinib 89-98 C-reactive protein Homo sapiens 0-18 22671963-1 2012 OBJECTIVES: To investigate the prognostic role of C-reactive protein in patients with advanced renal cell carcinoma treated with sunitinib. Sunitinib 129-138 C-reactive protein Homo sapiens 50-68 22671963-8 2012 CONCLUSIONS: C-reactive protein is an independent prognostic indicator for patients with advanced renal cell carcinoma treated with sunitinib. Sunitinib 132-141 C-reactive protein Homo sapiens 13-31 22454490-0 2012 Interleukin-6 and C-reactive protein levels after 3 years of treatment with darunavir/ritonavir monotherapy or darunavir/ritonavir + two nucleoside reverse transcriptase inhibitors in the MONET trial. Darunavir 111-120 C-reactive protein Homo sapiens 18-36 22371409-3 2012 MATERIAL/METHODS: The aim of this study was to evaluate the effects of antihypertensive therapy (perindopril, bisoprolol and combined therapy) on plasma CRP concentration in 67 subjects with mild or moderate hypertension who have been treatment-naive and otherwise healthy. Bisoprolol 110-120 C-reactive protein Homo sapiens 153-156 22330622-3 2012 RESULTS: The levels of CRP, IL-6 and TNF-alpha increased immediately after CAS (P<0.05 or <0.01). cas 75-78 C-reactive protein Homo sapiens 23-26 22330622-6 2012 CONCLUSION: CAS was associated with a significant increase in plasma CRP, IL-6 and TNF-alpha. cas 12-15 C-reactive protein Homo sapiens 69-72 21613382-11 2012 The low-fructose diet also decreased high sensitivity C-reactive protein (hsCRP) (4.3 +- 4.9 versus 3.3 +- 4.5 mg/L; P < 0.01) and soluble intercellular adhesion molecule (sICAM) (250.9 +- 59.4 versus 227 +- 50.5 ng/mL; P < 0.05). Fructose 8-16 C-reactive protein Homo sapiens 54-72 22687800-2 2012 Subsequently she received four weeks of oral levofloxacin and eight weeks of oral clarithromycin due to persistent elevation of C-reactive protein. Clarithromycin 82-96 C-reactive protein Homo sapiens 128-146 23091854-9 2012 There was a positive correlation between CRP and MG levels (r = 0.45; p = 0.01). Pyruvaldehyde 49-51 C-reactive protein Homo sapiens 41-44 21125400-6 2011 Presence of PPT was correlated with the presence of renal abscess, extension of renal hypoperfusion areas as well with levels of CRP, leukocytosis, and urine leukocytes using the Fisher"s exact Test and the Wilcoxon Test. 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol 12-15 C-reactive protein Homo sapiens 129-132 21125400-8 2011 Twenty-nine patients (11%) showed PPT which was significantly associated with the extension of the wedge-shaped renal hypoperfusion areas (P < 0.001), the presence of a renal abscess (P < 0.01), as well as the level of CRP (P < 0.001) and urine leukocytes (P < 0.01). 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol 34-37 C-reactive protein Homo sapiens 225-228 21472493-9 2011 Circulating 1,25(OH)(2)D was directly related to circulating 25(OH)D levels and kidney function (P < 0.001), and inversely associated with C-reactive protein (P = 0.020). 1,25(oh 12-19 C-reactive protein Homo sapiens 142-160 20592101-8 2011 In addition, CRP was positively associated with TBARS and carbonyl levels, but was significantly inversely associated with Zn and Se levels. Thiobarbituric Acid Reactive Substances 48-53 C-reactive protein Homo sapiens 13-16 21648471-2 2011 Although bulk microstructures and the nanostructure of metallic copper exhibit distinct applications, the amino sugar surface-functionalized copper is almost biocompatible and exhibits advanced features such as more crystallinity, high thermal stability, and electrochemical feasibility toward biomolecule (C-reactive protein, CRP) detection. Amino Sugars 106-117 C-reactive protein Homo sapiens 307-325 21648471-2 2011 Although bulk microstructures and the nanostructure of metallic copper exhibit distinct applications, the amino sugar surface-functionalized copper is almost biocompatible and exhibits advanced features such as more crystallinity, high thermal stability, and electrochemical feasibility toward biomolecule (C-reactive protein, CRP) detection. Amino Sugars 106-117 C-reactive protein Homo sapiens 327-330 21648471-4 2011 The combination of a biointerface membrane, from glucosamine functionalization, and electroactive sites of metallic copper provides a very efficient electrochemical response against various concentration of CRP. Glucosamine 49-60 C-reactive protein Homo sapiens 207-210 21531233-2 2011 BACKGROUND: Prednisone at immunosuppressive doses after stenting has shown remarkable efficacy in reducing ischemic recurrences in nondiabetic patients with high post-procedural levels of C-reactive protein; the study aim was to compare the clinical outcome obtained in a control group of patients treated with bare metal stents versus 2 other study groups--bare metal stent plus oral prednisone or drug eluting stents--assuming similar optimal adjunctive medical treatment. Prednisone 12-22 C-reactive protein Homo sapiens 188-206 20601378-5 2011 SP was significantly correlated with SF in ST, IBD and ESR for IBD and CRP for ST and hemoglobin for ST. sp 0-2 C-reactive protein Homo sapiens 71-74 20562124-9 2011 Patients receiving azithromycin demonstrated better FEV1 (p = 0.028), and lower airway neutrophilia (p = 0.015) and systemic C-reactive protein levels (p = 0.050) over time. Azithromycin 19-31 C-reactive protein Homo sapiens 125-143 20967757-9 2011 Finally, we observed in primary cultured rat hepatocytes that U0126 (a selective inhibitor of MAPK/ERK kinase1/2) corrected hCRP-induced impairment of insulin signaling. U 0126 62-67 C-reactive protein Homo sapiens 124-128 20337818-12 2010 For PUVA, we observed a significant reduction in TNF-alpha, IL-6 and CRP, and a significant increase in adiponectin. puva 4-8 C-reactive protein Homo sapiens 69-72 21063409-7 2010 On multivariate analysis, CRP remained highly significant for CSS (chi(2)=17.3, P<0.0001) and OS (chi(2)=9.8, P<0.002), in addition to other pre-operative variables including log of neutrophil/lymphocyte ratio, red blood cell count and white cell count. thiocysteine 62-65 C-reactive protein Homo sapiens 26-29 21063409-8 2010 C-reactive protein was significant in addition to the pre-operative nomogram score (chi(2)=12.5, P=0.0004 for OS, chi(2)=16.2, P=0.0001 for CSS and chi(2)=8.6, P=0.003 for DFS) and was still significant when other pre-operative variables were included. thiocysteine 140-143 C-reactive protein Homo sapiens 0-18 20838282-8 2010 Under multiple regression analysis, the Hb level and the C-reactive protein level were the significant predictors for diffuse splenic FDG uptake. Fluorodeoxyglucose F18 134-137 C-reactive protein Homo sapiens 57-75 20683528-9 2010 Much stronger ECL responses were observed from the Au/CD electrode, at which a dynamic range of 1.0-10.0 microg mL(-1) CRP and a limit of detection of 1.0 microg mL(-1) CRP were obtained, respectively. Gold 51-53 C-reactive protein Homo sapiens 119-122 20683528-9 2010 Much stronger ECL responses were observed from the Au/CD electrode, at which a dynamic range of 1.0-10.0 microg mL(-1) CRP and a limit of detection of 1.0 microg mL(-1) CRP were obtained, respectively. Gold 51-53 C-reactive protein Homo sapiens 169-172 20463585-5 2010 RESULTS: CRP levels significantly increased in the SP group (P < 0.0001) but not in the RP group or the LTNP group. sp 51-53 C-reactive protein Homo sapiens 9-12 20068559-8 2010 CONCLUSIONS: L-carnitine supplementation to diet is useful for reducing TNF-alpha and CRP, and for improving liver function, glucose plasma level, lipid profile, HOMA-IR, and histological manifestations of NASH. Carnitine 13-24 C-reactive protein Homo sapiens 86-89 20863217-9 2010 CONCLUSION: l-Carnitine supplement reduces serum CRP, a marker of systemic inflammation, and plasma fibrinogen, an inflammation-related coagulation factor, in hemodialysis patients. Carnitine 12-23 C-reactive protein Homo sapiens 49-52 19159953-6 2009 The CAA (+) cases of the older group had a longer duration of total fever (14.1 +/- 10.4 vs 6.5 +/- 1.9 days, p = 0.045), especially with respect to post-intravenous gamma globulin (IVGG) fever (7.9 +/- 9.6 vs 1.1 +/- 0.8 days, p = 0.052), and had higher total white blood cell counts, erythrocyte sedimentation rates, C-reactive protein levels, total bilirubin levels, and Harada scores and lower serum albumin and sodium levels than the CAA (-) cases. caa 4-7 C-reactive protein Homo sapiens 319-337 19341863-1 2009 OBJECTIVES: Our aim was to investigate in a prospective study a potential role of C-reactive protein (CRP) in predicting the outcome in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). cteph 225-230 C-reactive protein Homo sapiens 102-105 19341863-3 2009 METHODS: Plasma levels of CRP have been measured in consecutive patients diagnosed with PAH and CTEPH, at the time of right heart catheterization. cteph 96-101 C-reactive protein Homo sapiens 26-29 19341863-4 2009 RESULTS: Circulating CRP levels were increased in CTEPH and PAH patients compared with those in control subjects (4.9 mg l(-1), 95% confidence interval [CI]: 3.9 to 6.2 mg l(-1); 4.4 mg l(-1), 95% CI: 3.5 to 5.4 mg l(-1); and 2.3 mg l(-1), 95% CI: 1.9 to 2.7 mg l(-1), respectively; p < 0.0001). cteph 50-55 C-reactive protein Homo sapiens 21-24 19341863-7 2009 In CTEPH patients, circulating CRP levels significantly decreased 12 months after pulmonary endarterectomy (n = 23, 4.0 mg l(-1), 95% CI: 2.8 to 5.8 mg l(-1), to 1.6 mg l(-1), 95% CI: 2.2 to 3.0 mg l(-1); p = 0.004). cteph 3-8 C-reactive protein Homo sapiens 31-34 19074515-6 2009 Moreover, we discuss the impact of CRP genetic polymorphisms on hsCRP changes in response to 3-week fenofibrate treatment in the genetic intervention of the Genetics of Lipid Lowering Drugs and Diet Network study. Fenofibrate 100-111 C-reactive protein Homo sapiens 35-38 19074515-8 2009 CRP genetic variants further influence differing plasma hsCRP response after 3-week fenofibrate treatment in patients with metabolic syndrome. Fenofibrate 84-95 C-reactive protein Homo sapiens 0-3 20027156-13 2009 Nitrite levels correlated positively with C-reactive protein, total white blood cells, and triglycerides. Nitrites 0-7 C-reactive protein Homo sapiens 42-60 18799080-10 2008 In SSc CRP basal level was significantly higher than in controls (4.70+/-2.01 mg/dl vs. 1.40+/-1.79 mg/dl, p<0.005) and reduced significantly after PGE1 (3.39+/-2.06 mg/dl, p<0.05). Alprostadil 151-155 C-reactive protein Homo sapiens 7-10 18332893-8 2008 Platelet production of thromboxane B2 (TXB(2)) was also reduced by C1q both in the presence and absence of CRP, whereas CRP alone had no effect on TXB(2) production. Thromboxane B2 23-37 C-reactive protein Homo sapiens 107-110 18285417-10 2008 Finally, change in the PYR/Cr ratio was positively associated baseline IL-6, hs-CRP, and their changes (all P < 0.05) in women, but not men. pyridinoline 23-26 C-reactive protein Homo sapiens 80-83 18048424-8 2008 Guanidinosuccinate concentrations did not change, but correlated inversely with CRP (r = -0.736; P = 0.001), PINI-score (r = -0.716; P = 0.002) and correlated positively with plasma urea concentration (r = 0.54; P = 0.02). guanidinosuccinic acid 0-18 C-reactive protein Homo sapiens 80-83 17531588-8 2007 Smoking appeared to modify the associations of ICA-IMT with CRP (p = 0.009) and with IL-6 (p = 0.006); the association was more pronounced in current (vs former or never) smokers. isocyanic acid 47-50 C-reactive protein Homo sapiens 60-63 17699419-5 2007 Multivariable logistic regression was used to determine the association of periodontitis with low serum albumin, defined as < 3.5 mg/dl, and with high CRP, defined as > 3.0 mg/dl. Aminoglutethimide 167-173 C-reactive protein Homo sapiens 154-157 17115196-1 2007 The aim of this study was to assess the serum concentration of high-sensitivity C-reactive protein (hs-CRP) in children with nephrotic syndrome (NS) treated with prednisone and cyclosporine A (CyA). Prednisone 162-172 C-reactive protein Homo sapiens 80-98 17378768-4 2006 CRP, which was originally identified as a protein that could precipitate the C-polysaccharide of pneumococcal cell walls, has been widely used as a clinical marker of the state of inflammation, since its production by hepatocytes increases during the acute phase of the inflammatory response. c-polysaccharide 77-93 C-reactive protein Homo sapiens 0-3 17003600-8 2006 In the female group, however, log hs-CRP was significantly correlated (P < .05) with total cholesterol (r = 0.30), low-density lipoprotein (r = 0.27), tryglycerides (r = 0.51), and body mass index (r = 0.36). tryglycerides 154-167 C-reactive protein Homo sapiens 37-40 16383313-0 2006 Rapid electrochemiluminoimmunoassay of human C-reactive protein at planar disposable oxide-coated silicon electrodes. Oxides 85-90 C-reactive protein Homo sapiens 45-63 16330177-12 2006 Concerning the membranes, the highest levels of CRP were observed in patients dialyzed with Cuprophane with a significant increase from 15.1 +/- 3.6 to 21.2 +/- 3.1 mg/l after 6 months (P < 0.05); a significant reduction of CRP levels was observed in patients dialyzed with polysulfone in the same follow-up period (from 13.5 +/- 2.9 to 8.1 +/- 2.4 mg/l; P < 0.05). polysulfone P 1700 277-288 C-reactive protein Homo sapiens 48-51 16157235-5 2005 Levels of alpha- and beta-carotene in patients with stroke were negatively associated with hs-CRP level (R = -0.29 and -0.41, respectively, P < 0.01) and with neurologic deficits (R = -0.28 and -0.27, respectively, P < 0.05). alpha- and beta-carotene 10-34 C-reactive protein Homo sapiens 94-97 16157235-8 2005 CONCLUSION: Plasma concentrations of alpha- and beta-carotene are lower in patients with acute ischemic stroke than in healthy controls and are negatively correlated with hs-CRP level and neurologic deficits. alpha- and beta-carotene 37-61 C-reactive protein Homo sapiens 174-177 16157235-9 2005 The negative association between neurologic deficits and combined plasma alpha- and beta-carotene levels is confounded by hs-CRP. alpha- and beta-carotene 73-97 C-reactive protein Homo sapiens 125-128 16141529-0 2005 Lovastatin reduces nuclear factor kappaB activation induced by C-reactive protein in human vascular endothelial cells. Lovastatin 0-10 C-reactive protein Homo sapiens 63-81 16141529-6 2005 By using an electrophoretic mobility shift assays (EMSA), we found that CRP (50 microg/ml) increased activation of NF-kappaB and degradation of inhibitory kappa B (IkappaB) in HUVECs, reaching a maximal effect after the incubation with CRP for 1 h. Lovastatin (10(-5) mol/l) diminished NF-kappaB activation induced by CRP. Lovastatin 249-259 C-reactive protein Homo sapiens 72-75 16141529-8 2005 Preincubation of HUVECs with pyrrolidinethiocarbamate (PDTC, NF-kappaB inhibitor) diminished CD40 expression induced by CRP with flow cytometry. prolinedithiocarbamate 55-59 C-reactive protein Homo sapiens 120-123 15718491-7 2005 Dihydroethidium staining showed that CRP produced SB203850- and TEMPOL-sensitive superoxide production in the arteriolar endothelium. tempol 64-70 C-reactive protein Homo sapiens 37-40 15853856-0 2005 The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients. Fenofibrate 14-25 C-reactive protein Homo sapiens 60-78 15696567-8 2005 After 4 weeks of prednisone therapy, ESR was elevated in 13.2% patients, CRP in 41.9%, and serum IL-6 in 37.2%. Prednisone 17-27 C-reactive protein Homo sapiens 73-76 15694950-0 2005 Lovastatin compromises C-reactive protein induced endothelial dysfunction including altered expression of cell adhesion molecules and increased monocyte recruitment. Lovastatin 0-10 C-reactive protein Homo sapiens 23-41 16103720-0 2005 A high calcium-phosphate product is associated with high C-reactive protein concentrations in hemodialysis patients. calcium phosphate 7-24 C-reactive protein Homo sapiens 57-75 15543343-14 2004 Both cerivastatin and fenofibrate reduced CRP levels, the decrease being significantly greater after cerivastatin. Fenofibrate 22-33 C-reactive protein Homo sapiens 42-45 15540478-7 2004 AFCAPS/TexCAPS researchers found that lovastatin provded a 14.8% reduction in the median levels of CRP (p < 0.001). Lovastatin 38-48 C-reactive protein Homo sapiens 99-102 15554350-0 2004 The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic obese patients. Fenofibrate 14-25 C-reactive protein Homo sapiens 60-78 15554350-3 2004 Our objective was to evaluate the effect of fenofibrate on the levels of high-sensitivity C-reactive protein in dyslipidemic obese patients. Fenofibrate 44-55 C-reactive protein Homo sapiens 90-108 15554350-9 2004 Levels of high-sensitivity C-reactive protein decreased significantly (approximately 74.1%) after fenofibrate treatment from a mean of 0.58+/-0.3 mg/dL to 0.15+/-0.2 mg/dL, P < 0.01. Fenofibrate 98-109 C-reactive protein Homo sapiens 27-45 14764586-7 2004 A similar global effect of fenofibrate on acute phase protein expression is observed in hyperlipidemic patients chronically treated with fenofibrate, which displayed decreased plasma concentrations of the positive APR proteins fibrinogen, C-reactive protein, serum amyloid A, plasminogen, and alpha2-macroglobulin and increased plasma concentrations of the negative APR albumin, underlining the clinical significance of our findings. Fenofibrate 27-38 C-reactive protein Homo sapiens 239-257 14764586-7 2004 A similar global effect of fenofibrate on acute phase protein expression is observed in hyperlipidemic patients chronically treated with fenofibrate, which displayed decreased plasma concentrations of the positive APR proteins fibrinogen, C-reactive protein, serum amyloid A, plasminogen, and alpha2-macroglobulin and increased plasma concentrations of the negative APR albumin, underlining the clinical significance of our findings. Fenofibrate 137-148 C-reactive protein Homo sapiens 239-257 14512033-5 2003 RESULTS: In the critically-ill group circulating concentrations of C-reactive protein and malondialdehyde were significantly higher (P<0.05) and cholesterol, triglyceride, alpha-tocopherol, lutein, lycopene, alpha- and beta-carotene were all significantly lower (P<0.01) compared with the control group. alpha- and beta-carotene 211-235 C-reactive protein Homo sapiens 67-85 12941708-8 2003 ANCOVA revealed that treatment with pioglitazone was associated with a low CRP and PWV, independent of the changes in parameters related to glucose metabolism. ancova 0-6 C-reactive protein Homo sapiens 75-78 12475452-8 2002 CONCLUSIONS: In patients with persistently high CRP levels after successful coronary artery stent implantation, oral immunosuppressive therapy with prednisone results in a striking reduction of clinical events and angiographic restenosis rate. Prednisone 148-158 C-reactive protein Homo sapiens 48-51 12324296-9 2002 C-reactive protein concentrations were inversely related to beta-carotene (P < 0.001), lutein and zeaxanthin (P < 0.001), and lycopene (P = 0.023) concentrations. Zeaxanthins 101-111 C-reactive protein Homo sapiens 0-18 12244213-1 2002 C-reactive protein (CRP) is an acute-phase protein that binds specifically to phosphorylcholine (PC) as a component of microbial capsular polysaccharide and participates in the innate immune response against microorganisms. Polysaccharides 138-152 C-reactive protein Homo sapiens 0-18 12244213-1 2002 C-reactive protein (CRP) is an acute-phase protein that binds specifically to phosphorylcholine (PC) as a component of microbial capsular polysaccharide and participates in the innate immune response against microorganisms. Polysaccharides 138-152 C-reactive protein Homo sapiens 20-23 12008177-0 2002 Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Lovastatin 99-109 C-reactive protein Homo sapiens 113-131 12015523-5 2002 HRT resulted in a significant increase in CRP concentrations in the women receiving the continuous combination of E2V plus norethindrone acetate and the continuous regimen of E2V plus local delivery of levonorgestrel. Norethindrone Acetate 123-144 C-reactive protein Homo sapiens 42-45 12025914-0 2002 Effect of ciprofibrate on C-reactive protein and fibrinogen levels. ciprofibrate 10-22 C-reactive protein Homo sapiens 26-44 11571238-5 2001 MLD of patients with elevated CRP levels exhibited a greater reduction during CPT and a greater increase after NTG than of patients with normal CRP levels (-15+/-12% versus -7+/-14%, P=0.037, and 31+/-23% versus 13+/-25%, P=0.011, respectively). Nitroglycerin 111-114 C-reactive protein Homo sapiens 30-33 11359830-10 2001 Both SAP and CRP bound to zymosan and enhanced its uptake by PMN. Zymosan 26-33 C-reactive protein Homo sapiens 13-16 11382718-9 2001 CONCLUSIONS: These results further strengthen the role of CRP in the pathogenesis of vascular inflammation and, likely, atherosclerosis and provide a crucial insight into a novel mechanism of action of anti-atherosclerosis drugs such as simvastatin and fenofibrate. Fenofibrate 253-264 C-reactive protein Homo sapiens 58-61 11330538-10 2001 During this period there was an increasing negative correlation between peak-CRP and tissue pO2 which was highly significant at 60 min after reperfusion (r=-0.70, P<0.002). PO-2 92-95 C-reactive protein Homo sapiens 77-80 10839761-4 2000 Azithromycin reduced a global rank sum score of 4 inflammatory markers (C-reactive protein [CRP], interleukin [IL]-1, IL-6, tumor necrosis factor-alpha; P=.011) and a global rank sum change score (+/-SD) (from 535+/-201 to 587+/-190; P=.027) at 6 (but not 3) months. Azithromycin 0-12 C-reactive protein Homo sapiens 72-90 10839761-4 2000 Azithromycin reduced a global rank sum score of 4 inflammatory markers (C-reactive protein [CRP], interleukin [IL]-1, IL-6, tumor necrosis factor-alpha; P=.011) and a global rank sum change score (+/-SD) (from 535+/-201 to 587+/-190; P=.027) at 6 (but not 3) months. Azithromycin 0-12 C-reactive protein Homo sapiens 92-95 10503839-8 1999 Nitrate levels were positively correlated with blood and 24 h urinary neopterin (e.g. plasma nitrate and blood neopterin: r = 0.54, P<0.0001), and in some cases, to C-reactive protein. Nitrates 0-7 C-reactive protein Homo sapiens 168-186 10515645-3 1999 1,25(OH)2D3 (P < 0.01) and iPTH (P < 0.01) were negatively related to CRP, whereas the urinary excretion of pyridinoline (P < 0.01) and deoxypyridinoline (P < 0.01)-collagen cross-links showed a positive correlation with CRP. Calcitriol 0-11 C-reactive protein Homo sapiens 76-79 9788654-10 1998 Nitrate+nitrite levels returned to normal within 24 h. CRP generation increased during 12 h following trauma and was most marked in severest trauma (ISS >50). Nitrates 0-7 C-reactive protein Homo sapiens 55-58 9788654-10 1998 Nitrate+nitrite levels returned to normal within 24 h. CRP generation increased during 12 h following trauma and was most marked in severest trauma (ISS >50). Nitrites 8-15 C-reactive protein Homo sapiens 55-58 9655393-8 1998 In hyperlipidaemic patients, fenofibrate treatment decreases the plasma concentrations of interleukin-6, fibrinogen and C-reactive protein. Fenofibrate 29-40 C-reactive protein Homo sapiens 120-138 9437833-1 1997 C-reactive protein (C-RP) was purified from harbor seal (Phoca vitulina) serum by calcium dependant phosphoryl-choline and protein A affinity chromatography. Choline 111-118 C-reactive protein Homo sapiens 20-24 8599761-1 1996 The structure of the classical acute phase reactant human C-reactive protein provides evidence that phosphocholine binding is mediated through calcium and a hydrophobic pocket centred on Phe 66. Phenylalanine 187-190 C-reactive protein Homo sapiens 58-76 9575343-1 1996 Analogs of the peptide Val-Thr-Val-Ala-Pro-Val-His-Ile, derived from the primary sequence of the acute phase reactant CRP, i.e. amino acid residues 89-96, were optimized to inhibit the enzymatic activities of human leukocyte elastase (hLE) and human leukocyte cathepsin G (hCG), which are associated with tissue damage occurring in the course of several chronic inflammatory conditions. Isoleucine 51-54 C-reactive protein Homo sapiens 118-121 7627386-0 1995 Ranitidine reduces postoperative interleukin-6 induced C-reactive protein synthesis. Ranitidine 0-10 C-reactive protein Homo sapiens 55-73 7627386-9 1995 C-reactive protein levels were also significantly increased in all patients after 24, 48, and 120 hours, respectively; however, at 48 hours, CRP was significantly reduced in ranitidine-treated patients compared with non-ranitidine-treated patients (p = 0.02). Ranitidine 174-184 C-reactive protein Homo sapiens 141-144 7627386-11 1995 However, the reduced CRP level in ranitidine-treated patients suggests that H2RAs modulate IL-6 signal transduction in hepatic cells. Ranitidine 34-44 C-reactive protein Homo sapiens 21-24 8377450-9 1993 For persisting or increased fever or CRP elevation, 9 patients were treated with ceftriaxone and teicoplanin successfully. Teicoplanin 97-108 C-reactive protein Homo sapiens 37-40 8514726-3 1993 The decrease in phosphocreatine (CrP) determined by NMR was 20, 33, and 71% for 28%-, 64%-, and 90%-CON, respectively. Phosphocreatine 16-31 C-reactive protein Homo sapiens 33-36 1909052-0 1991 Erythromycin and phenoxymethylpenicillin (penicillin V) in the treatment of respiratory tract infections as related to microbiological findings and serum C-reactive protein. Penicillin V 17-40 C-reactive protein Homo sapiens 154-172 1909052-0 1991 Erythromycin and phenoxymethylpenicillin (penicillin V) in the treatment of respiratory tract infections as related to microbiological findings and serum C-reactive protein. Penicillin V 42-54 C-reactive protein Homo sapiens 154-172 2170518-8 1990 This enhanced CRP response was sensitive to cycloheximide. Cycloheximide 44-57 C-reactive protein Homo sapiens 14-17 2165398-0 1990 Induction of C-reactive protein by cytokines in human hepatoma cell lines is potentiated by caffeine. Caffeine 92-100 C-reactive protein Homo sapiens 13-31 2165398-1 1990 Induction of C-reactive protein (CRP) by conditioned medium from lipopolysaccharide-stimulated human monocytes in two human hepatoma-cell lines, Hep 3B and NPLC/PRF/5, was potentiated 3-6-fold by the methylxanthine caffeine. Caffeine 215-223 C-reactive protein Homo sapiens 13-31 2165398-1 1990 Induction of C-reactive protein (CRP) by conditioned medium from lipopolysaccharide-stimulated human monocytes in two human hepatoma-cell lines, Hep 3B and NPLC/PRF/5, was potentiated 3-6-fold by the methylxanthine caffeine. Caffeine 215-223 C-reactive protein Homo sapiens 33-36 2165398-11 1990 Caffeine similarly potentiated induction of CRP by these defined cytokine signals in these two cell lines. Caffeine 0-8 C-reactive protein Homo sapiens 44-47 2165398-13 1990 Thus these results indicate that the mechanism by which caffeine potentiates CRP induction by cytokines appears to be independent of increases in intracellular concentrations of the two second messengers, cyclic AMP and Ca2+; the precise nature of this mechanism is unclear at the present time. Caffeine 56-64 C-reactive protein Homo sapiens 77-80 2165398-15 1990 The differential response of CRP and SAA to caffeine is of particular interest, since induction of both of these two major acute-phase proteins can be accomplished by identical extracellular signals. Caffeine 44-52 C-reactive protein Homo sapiens 29-32 33806226-6 2021 The secondary outcomes were comparison of copeptin with C-reactive protein (CRP) in predicting DCI. dci 95-98 C-reactive protein Homo sapiens 76-79 34946329-9 2021 C-reactive protein (CRP) increased significantly in the No-AA group throughout all time intervals, and from the first 24 h to the 25-72 h in the NAA and CAA groups. caa 153-156 C-reactive protein Homo sapiens 0-18 34946329-11 2021 CRP was significantly higher in the first 24 h in the CAA than in the No-AA group, and in the 24-48 h in the CAA group than in the No-AA and NAA groups. caa 54-57 C-reactive protein Homo sapiens 0-3 34946329-11 2021 CRP was significantly higher in the first 24 h in the CAA than in the No-AA group, and in the 24-48 h in the CAA group than in the No-AA and NAA groups. caa 109-112 C-reactive protein Homo sapiens 0-3 34935703-5 2022 Out of 17 studies included for the qualitative analysis, 11 studies reported that inflammatory markers like C-reactive protein and cytokines were reduced in the colchicine group, suggesting an anti-inflammatory role of colchicine in coronary artery disease. Colchicine 161-171 C-reactive protein Homo sapiens 108-126 34691435-0 2021 The role of C-Reactive protein as an inflammatory marker to predict prolonged QTc interval in rifampicin-resistant tuberculosis patients: A case-control study. Rifampin 94-104 C-reactive protein Homo sapiens 12-30 34691435-1 2021 Background: long-term use of anti-tuberculosis drugs (ATD) increases the risk of QTc prolongation, while C-reactive protein (CRP) can be used as an inflammatory marker of Mycobacterium tuberculosis infection.Objective: correlation of CRP on the QTc interval in Rifampicin-resistant tuberculosis (RR-TB) patients with the short regimen. Rifampin 261-271 C-reactive protein Homo sapiens 105-123 34691435-1 2021 Background: long-term use of anti-tuberculosis drugs (ATD) increases the risk of QTc prolongation, while C-reactive protein (CRP) can be used as an inflammatory marker of Mycobacterium tuberculosis infection.Objective: correlation of CRP on the QTc interval in Rifampicin-resistant tuberculosis (RR-TB) patients with the short regimen. Rifampin 261-271 C-reactive protein Homo sapiens 125-128 34691435-1 2021 Background: long-term use of anti-tuberculosis drugs (ATD) increases the risk of QTc prolongation, while C-reactive protein (CRP) can be used as an inflammatory marker of Mycobacterium tuberculosis infection.Objective: correlation of CRP on the QTc interval in Rifampicin-resistant tuberculosis (RR-TB) patients with the short regimen. Rifampin 261-271 C-reactive protein Homo sapiens 234-237 34901963-6 2021 RESULTS: White blood cell counts (P=0.0176) and C-reactive protein (P=0.0036) were higher in patients with splenic 18F-FDG uptake exceeding hepatic 18F-FDG uptake. Fluorodeoxyglucose F18 115-122 C-reactive protein Homo sapiens 48-66 34901963-6 2021 RESULTS: White blood cell counts (P=0.0176) and C-reactive protein (P=0.0036) were higher in patients with splenic 18F-FDG uptake exceeding hepatic 18F-FDG uptake. Fluorodeoxyglucose F18 148-155 C-reactive protein Homo sapiens 48-66 34453188-7 2021 The selected Au@Ag-Pt NPs were conjugated with monoclonal antibodies and used as the colorimetric and catalytic labels in lateral flow immunoassay of the inflammation biomarker: C-reactive protein (CRP). Gold 13-15 C-reactive protein Homo sapiens 178-196 34453188-7 2021 The selected Au@Ag-Pt NPs were conjugated with monoclonal antibodies and used as the colorimetric and catalytic labels in lateral flow immunoassay of the inflammation biomarker: C-reactive protein (CRP). Gold 13-15 C-reactive protein Homo sapiens 198-201 34453188-9 2021 The use of Au@Ag-Pt NPs as the catalytic label produces a 65-fold lower limit of CRP detection in serum (15 pg mL-1) compared with Au NPs and ensures the lowest limit of detection for equipment-free lateral flow immunoassays. Gold 11-13 C-reactive protein Homo sapiens 81-84 34409634-10 2022 Colchicine significantly reduced hs-CRP (-4.25, p=0.001) compared to controls but did not significantly affect IL-beta1 and IL-18 levels. Colchicine 0-10 C-reactive protein Homo sapiens 36-39 34409634-11 2022 CONCLUSIONS: Colchicine reduced cardiovascular events and inflammatory markers, hs-CRP and IL-6, in patients with coronary disease compared to controls. Colchicine 13-23 C-reactive protein Homo sapiens 83-86 34264887-2 2021 STUDY QUESTION: Can colchicine reduce inflammation (high-sensitivity C-reactive protein (hs-CRP)) in CAD? Colchicine 20-30 C-reactive protein Homo sapiens 69-87 34264887-2 2021 STUDY QUESTION: Can colchicine reduce inflammation (high-sensitivity C-reactive protein (hs-CRP)) in CAD? Colchicine 20-30 C-reactive protein Homo sapiens 92-95 34264887-7 2021 RESULTS: The meta-analysis revealed a mean reduction of 0.36 mg/L in hs-CRP levels (95% confidence interval (CI): -0.51 to -0.20) with add-on colchicine. Colchicine 142-152 C-reactive protein Homo sapiens 72-75 34628456-8 2021 The mean age, disease duration, DAS28-CRP, and the rate of corticosteroids usage were significantly higher in the DIP-positive than in the DIP-negative group (p = 0.0031, 0.0062, 0.0342, and 0.0011, respectively). dip 114-117 C-reactive protein Homo sapiens 38-41 35486963-7 2022 Furthermore, 8-OHdG, 8-iso-PGF2alpha, MPV, CRP, and TGF-beta1 were found to significantly mediate 8.06-48.92% of the ACR metabolites-associated 10-year CVD risk increment. Acrylamide 117-120 C-reactive protein Homo sapiens 43-46 35243815-9 2022 Both hs-CRP and NT-proBNP were independently associated with the composite endpoint in the overall cohort (hs-CRP: adjusted HR 1.07, 95% CI 1.00-1.15, P = 0.036; NT-proBNP: adjusted HR 1.11, 95% CI 1.02-1.22, P = 0.019). probnp 165-171 C-reactive protein Homo sapiens 8-11 35399435-4 2022 Different trials statistically proved colchicine"s role in ACS by lowering the levels of high c-reactive protein, decreasing low attenuation plaque volume, and stabilizing plaque. Colchicine 38-48 C-reactive protein Homo sapiens 94-112 35265308-0 2022 Effect of Edaravone Combined with Anticoagulant Therapy on the Serum hs-CRP, IL-6, and TNF-alpha Levels and Activity of Daily Living in Patients with Acute Cerebral Infarction. Edaravone 10-19 C-reactive protein Homo sapiens 72-75 35265308-1 2022 Objective: To explore the effect of edaravone combined with anticoagulant therapy on the serum hs-CRP, IL-6, and TNF-alpha levels and the activity of daily living (ADL) in patients with acute cerebral infarction (ACI). Edaravone 36-45 C-reactive protein Homo sapiens 98-101 35178353-7 2022 We showed a pro-inflammatory/pro-oxidative milieu increasing along treatment with nilotinib compared with imatinib or dasatinib, as demonstrated by higher hs-CRP and oxLDL levels and increased IL6/IL10 and TNFalpha/IL10 ratios only in nilotinib cohort. nilotinib 82-91 C-reactive protein Homo sapiens 158-161 34979555-12 2022 BD patients who were stratified into the high MCN group had a higher VPA response rate, better WCST performance, lower CRP level, and less MetS. mcn 46-49 C-reactive protein Homo sapiens 119-122 2477447-5 1989 CRP immunoprecipitated the U1 RNA species from [32P]labeled HeLa cells and the protein bands of the Sm/RNP complex from [35S]-methionine-labeled HeLa cells. Phosphorus-32 48-51 C-reactive protein Homo sapiens 0-3 2837757-3 1988 In the absence of cGMP, CRP*598 shows a more open conformation than CRP, as indicated by its sensitivity to proteolytic attack and 5,5"-dithiobis(2-nitrobenzoic acid)-mediated subunit crosslinking. 2-NITROBENZOIC ACID 146-165 C-reactive protein Homo sapiens 24-27 2837757-3 1988 In the absence of cGMP, CRP*598 shows a more open conformation than CRP, as indicated by its sensitivity to proteolytic attack and 5,5"-dithiobis(2-nitrobenzoic acid)-mediated subunit crosslinking. 2-NITROBENZOIC ACID 146-165 C-reactive protein Homo sapiens 68-71 3337932-3 1988 Clinical deterioration after initiation of thyroxine replacement was followed by delayed improvement with reduction in initially elevated ESR and CRP. Thyroxine 43-52 C-reactive protein Homo sapiens 146-149 3480076-0 1987 Measurement of C-reactive protein to compare ceftizoxime versus cefoxitin/doxycycline therapy for septic pelvis: a preliminary report. Cefoxitin 64-73 C-reactive protein Homo sapiens 15-33 3480076-2 1987 In a study comparing ceftizoxime and cefoxitin/doxycycline in patients with septic pelvis, quantitative CRP levels were closely correlated with the responses and failures of therapy. Cefoxitin 37-46 C-reactive protein Homo sapiens 104-107 2946790-3 1986 Binding of CRP to PMNL was examined by flow cytometry after cell incubation with fluorescein-labeled heat-aggregated CRP (Agg-CRP) or Agg-CRP and fluorescein-conjugated F(ab")2 anti-CRP antibodies. Fluorescein 81-92 C-reactive protein Homo sapiens 11-14 2946790-3 1986 Binding of CRP to PMNL was examined by flow cytometry after cell incubation with fluorescein-labeled heat-aggregated CRP (Agg-CRP) or Agg-CRP and fluorescein-conjugated F(ab")2 anti-CRP antibodies. Fluorescein 81-92 C-reactive protein Homo sapiens 117-120 2946790-3 1986 Binding of CRP to PMNL was examined by flow cytometry after cell incubation with fluorescein-labeled heat-aggregated CRP (Agg-CRP) or Agg-CRP and fluorescein-conjugated F(ab")2 anti-CRP antibodies. Fluorescein 81-92 C-reactive protein Homo sapiens 117-120 2946790-3 1986 Binding of CRP to PMNL was examined by flow cytometry after cell incubation with fluorescein-labeled heat-aggregated CRP (Agg-CRP) or Agg-CRP and fluorescein-conjugated F(ab")2 anti-CRP antibodies. Fluorescein 81-92 C-reactive protein Homo sapiens 117-120 2946790-3 1986 Binding of CRP to PMNL was examined by flow cytometry after cell incubation with fluorescein-labeled heat-aggregated CRP (Agg-CRP) or Agg-CRP and fluorescein-conjugated F(ab")2 anti-CRP antibodies. Fluorescein 81-92 C-reactive protein Homo sapiens 117-120 2946790-3 1986 Binding of CRP to PMNL was examined by flow cytometry after cell incubation with fluorescein-labeled heat-aggregated CRP (Agg-CRP) or Agg-CRP and fluorescein-conjugated F(ab")2 anti-CRP antibodies. Fluorescein 146-157 C-reactive protein Homo sapiens 11-14 2859902-4 1985 We conclude that during treatment of rheumatoid arthritis with gold, penicillamine or sulphasalazine, SAA concentrations can be high when serum CRP and ESR are suppressed. Sulfasalazine 86-100 C-reactive protein Homo sapiens 144-147 6427351-1 1984 Two simple rapid and precise fluorescence assays for determining serum levels of C-reactive protein (CRP) are described which employ sheep antibodies to CRP covalently linked to magnetisable cellulose/iron oxide particles. Cellulose 191-200 C-reactive protein Homo sapiens 81-99 6427351-1 1984 Two simple rapid and precise fluorescence assays for determining serum levels of C-reactive protein (CRP) are described which employ sheep antibodies to CRP covalently linked to magnetisable cellulose/iron oxide particles. Cellulose 191-200 C-reactive protein Homo sapiens 101-104 6427351-1 1984 Two simple rapid and precise fluorescence assays for determining serum levels of C-reactive protein (CRP) are described which employ sheep antibodies to CRP covalently linked to magnetisable cellulose/iron oxide particles. Cellulose 191-200 C-reactive protein Homo sapiens 153-156 6427351-2 1984 The first (a fluoroimmunoassay) is based on competitive binding of CRP in the sample or standard with fluorescein-labelled CRP, a 30 min incubation time, simple separation with a magnet followed by elution of the bound fraction into alkaline methanol and fluorescence quantitation. Fluorescein 102-113 C-reactive protein Homo sapiens 67-70 6427351-2 1984 The first (a fluoroimmunoassay) is based on competitive binding of CRP in the sample or standard with fluorescein-labelled CRP, a 30 min incubation time, simple separation with a magnet followed by elution of the bound fraction into alkaline methanol and fluorescence quantitation. Fluorescein 102-113 C-reactive protein Homo sapiens 123-126 6427351-3 1984 In the second (a "sandwich" immunofluorometric assay) an excess of solid-phase linked antiserum is incubated with sample and fluorescein-labelled purified sheep anti-CRP immunoglobulin followed by separation, elution and quantitation of the bound fraction. Fluorescein 125-136 C-reactive protein Homo sapiens 166-169 6152529-5 1984 After 12 months of therapy with sulphasalazine the immunoglobulins and CRP returned to the level found in the inactive colitis. Sulfasalazine 32-46 C-reactive protein Homo sapiens 71-74 7172508-2 1982 A radiometric ligand binding assay for human C-reactive protein (CRP) was established using pneumococcal C polysaccharide (CPS) coupled to magnetizable cellulose particles as the solid phase ligand. Cellulose 152-161 C-reactive protein Homo sapiens 45-63 7172508-2 1982 A radiometric ligand binding assay for human C-reactive protein (CRP) was established using pneumococcal C polysaccharide (CPS) coupled to magnetizable cellulose particles as the solid phase ligand. Cellulose 152-161 C-reactive protein Homo sapiens 65-68 659600-4 1978 Double-labeling experiments indicated that 60-80% of CRP-binding lymphocytes also showed Fc receptors reacting with fluorescein-conjugated IgG aggregates. Fluorescein 116-127 C-reactive protein Homo sapiens 53-56 659600-8 1978 A 12-15-h incubation of lymphocytes at 37 degrees C in 5% CO2-air showed persistence of CRP binding in substantial proportions of cells particularly in acute rheumatic fever. N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide 58-61 C-reactive protein Homo sapiens 88-91 13662372-2 1959 Behavior of lysozyme power and of C reactive protein in animals treated with meprobamate]. Meprobamate 77-88 C-reactive protein Homo sapiens 34-52 33740541-6 2021 As a proof of concept, the proposed PTB7-Th/H2O2 system was successfully applied in the construction of a label-free PEC aptasensor for sensitive analysis of CRP, which performed a wide detection range from 1 pM to 1000 nM with a low detection limit of 0.33 pM. Thorium 41-43 C-reactive protein Homo sapiens 158-161 33655591-8 2021 FT3 level showed a negative correlation with length of hospital stay and C-reactive protein level (rho: -0.216, p: 0.001; rho: - 0.383, p < 0.0001). CHEMBL240806 0-3 C-reactive protein Homo sapiens 73-91 34055821-11 2021 Correlation analyses showed that changes in oxylipins were positively correlated with serum levels of IL-6 and C-reactive protein. Oxylipins 44-53 C-reactive protein Homo sapiens 111-129 33861260-5 2021 After an annealing step, the MF-DNA-4WJ assembly configuration and selective binding of CRP were confirmed through native TBM-PAGE (Tris-borate-magnesium chloride-polyacrylamide gel electrophoresis). Tobramycin 122-125 C-reactive protein Homo sapiens 88-91 33861260-5 2021 After an annealing step, the MF-DNA-4WJ assembly configuration and selective binding of CRP were confirmed through native TBM-PAGE (Tris-borate-magnesium chloride-polyacrylamide gel electrophoresis). tris-borate 132-143 C-reactive protein Homo sapiens 88-91 33861260-5 2021 After an annealing step, the MF-DNA-4WJ assembly configuration and selective binding of CRP were confirmed through native TBM-PAGE (Tris-borate-magnesium chloride-polyacrylamide gel electrophoresis). Magnesium Chloride 144-162 C-reactive protein Homo sapiens 88-91 33071012-9 2021 C-reactive protein was lower 4 h postprandially in the anthocyanins (1.80 mg/L, IQR 0.90) vs control arm (2.30 mg/L, IQR 1.95) (P = 0.026), accompanied by a trend for lower concentrations of interleukin-6 (P = 0.075). Anthocyanins 55-67 C-reactive protein Homo sapiens 0-18 33636044-8 2021 CONCLUSION: Postoperative CRP values and DFA output may facilitate appropriate postoperative management after DP. dp 110-112 C-reactive protein Homo sapiens 26-29 33605405-7 2021 180 patients initiated GC compared with 294 who did not.At baseline, the increased CRP is the main factor that favors the initiation of GC followed by smoking, absence of ACPA, prescription of methotrexate as a monotherapy and age.5 years follow-up of DAS28-CRP, HAQ or VAS pain values did not differ between the two groups.We also analysed a subgroup of 139 patients who received >1 g of prednisolone during the 5 years period. Prednisolone 389-401 C-reactive protein Homo sapiens 83-86 33403775-8 2021 In the 31 patients who received ruxolitinib symptoms improved (dyspnea scale) at day 7 in 25 out of 31 patients (80.6%); C-reactive protein decreased progressively from baseline (79.1+-73.4 mg/dl) to day15 (18.6+-33.2, p=0.022). ruxolitinib 32-43 C-reactive protein Homo sapiens 121-139 33389237-3 2021 Then, GOD and monoclonal anti-CRP antibody with a high molar ratio were covalently conjugated onto carboxylated dendrimers via typical carbodiimide coupling. carboxylated dendrimers 99-122 C-reactive protein Homo sapiens 30-33 33094728-6 2021 Pro-inflammatory cytokines; C-reactive protein, TNF-alpha, and interleukin-6 showed significant reduction after treatment with EMPA, compared to baseline levels. empagliflozin 127-131 C-reactive protein Homo sapiens 28-46 32860944-0 2021 Reply to "Meta-analysis of astaxanthin supplementation on obesity, blood pressure, CRP, glycemic biomarkers, and lipid profile: Reanalysis is needed". astaxanthine 27-38 C-reactive protein Homo sapiens 83-86 33292329-16 2020 CONCLUSIONS: The external application of CQBG combined with Western-medicine-basic treatment in patients with AGA improved arthralgia and swelling, shortened the period of taking NSAIDs, and reduced the levels of CRP and serum UA. polyethylene glycol-glutaminase-asparaginase 110-113 C-reactive protein Homo sapiens 213-216 32996694-7 2020 CONCLUSION: The normalization of CRP within 1 month from baseline predicted GC-free remission in PMR patients treated with PSL, and resulted in a lower cumulative PSL dose. Prednisolone 123-126 C-reactive protein Homo sapiens 33-36 32996694-7 2020 CONCLUSION: The normalization of CRP within 1 month from baseline predicted GC-free remission in PMR patients treated with PSL, and resulted in a lower cumulative PSL dose. Prednisolone 163-166 C-reactive protein Homo sapiens 33-36 32856532-7 2020 Results: In the TIRA-1 cohort, anti-CCP-positive patients had significantly higher 28-joint Disease Activity Score, swollen joint count, C-reactive protein level, and erythrocyte sedimentation rate during follow-up compared with anti-CCP-negative patients. cyclic citrullinated peptide 36-39 C-reactive protein Homo sapiens 137-155 33015730-0 2020 Molybdenum disulfide-gold nanoparticle nanocomposite in field-effect transistor back-gate for enhanced C-reactive protein detection. molybdenum disulfide 0-20 C-reactive protein Homo sapiens 103-121 32305772-10 2020 Increased CRP significantly mediated 5.39% and 5.87% of the AMCC-associated FVC and FEV1 reductions, respectively. N-acetyl-S-(N-methylcarbamoyl)cysteine 60-64 C-reactive protein Homo sapiens 10-13 32531990-6 2020 Increasing itaconate correlated with improved DAS44 score and decreasing levels of C-reactive protein (CRP). itaconic acid 11-20 C-reactive protein Homo sapiens 83-101 32531990-6 2020 Increasing itaconate correlated with improved DAS44 score and decreasing levels of C-reactive protein (CRP). itaconic acid 11-20 C-reactive protein Homo sapiens 103-106 31965076-8 2020 Deficiency of serum 25-hydroxyvitamin D in hypertensive subjects was significantly associated with CRP positivity, low levels of mean serum calcium, low levels of mean serum phosphorous, high levels of mean alkaline phosphatase (p < 0.0001), and abnormal alanine transaminase (ALT) (p = 0.0015) compared with the same parameters in the normotensive subjects. Calcifediol 20-39 C-reactive protein Homo sapiens 99-102 32233700-1 2022 The aim of this prospective study (Clinical Trials Identifier: NCT02993744) was to detect the effect of fetal lung maturation with betamethasone on the maternal inflammatory parameters C-reactive protein (CRP) and leukocytes. Betamethasone 131-144 C-reactive protein Homo sapiens 185-203 32233700-1 2022 The aim of this prospective study (Clinical Trials Identifier: NCT02993744) was to detect the effect of fetal lung maturation with betamethasone on the maternal inflammatory parameters C-reactive protein (CRP) and leukocytes. Betamethasone 131-144 C-reactive protein Homo sapiens 205-208 31270281-12 2020 In patients with TAK without immunosuppressive therapy, ba-PWV significantly correlated with CRP (r=0.419, P=0.008) but not ESR (P>0.05). ba-pwv 56-62 C-reactive protein Homo sapiens 93-96 31669599-5 2020 Subgroup analyses showed that administration of higher doses of anthocyanins (>300 mg/day) significantly decreased levels of CRP, IL-6, TNF-alpha, and VCAM-1. Anthocyanins 64-76 C-reactive protein Homo sapiens 125-128 31558056-7 2020 Analysis of the area under the curve according to multiple receiver operating characteristics showed that DNI had a higher capability to predict sepsis than other parameters (0.815 for DNI, 0.700 for procalcitonin, 0.681 for C-reactive protein, and 0.741 for white blood cell). DNI 106-109 C-reactive protein Homo sapiens 225-243 30856080-10 2019 These studies demonstrated that vitamin E, especially tocotrienol, was able to alleviate IL-1, IL-6, RANKL, iNOS and hs-CRP levels in relation to bone metabolism. Vitamin E 32-41 C-reactive protein Homo sapiens 120-123 31577714-3 2019 PATIENT CONCERNS: A 39-year-old man with a recurrent episode of gouty arthritis presented prednisolone-resistant polyarthritis with high level of C-reactive protein (CRP). Prednisolone 90-102 C-reactive protein Homo sapiens 146-164 31577714-3 2019 PATIENT CONCERNS: A 39-year-old man with a recurrent episode of gouty arthritis presented prednisolone-resistant polyarthritis with high level of C-reactive protein (CRP). Prednisolone 90-102 C-reactive protein Homo sapiens 166-169 30341727-8 2019 Low CRP (<1 mg/L) in patients with MDD predicts better response to escitalopram while higher levels are associated with better response to noradrenergic/dopaminergic antidepressants. Citalopram 70-82 C-reactive protein Homo sapiens 4-7 30574207-2 2018 Methods: We investigated whether empagliflozin (EMPA) exerts anti-inflammatory effects that are reflected in decreased high-sensitivity C-reactive protein (hsCRP) values. empagliflozin 33-46 C-reactive protein Homo sapiens 136-154 30574207-2 2018 Methods: We investigated whether empagliflozin (EMPA) exerts anti-inflammatory effects that are reflected in decreased high-sensitivity C-reactive protein (hsCRP) values. empagliflozin 48-52 C-reactive protein Homo sapiens 136-154 30412376-3 2018 In this study, inspired by the highly specific interaction between CRP and the cell membrane, an excellent anti-biofouling compound 2-(methacryloyloxy)ethyl phosphorylcholine and a highly hydrophilic crosslinker N, N"-methylenebisacrylamide were employed to fabricate a novel cell membrane biomimetic polymer for selective capture of CRP in the presence of calcium ions. N,N'-methylenebisacrylamide 212-240 C-reactive protein Homo sapiens 67-70 30375293-0 2018 Effect of purified anthocyanins or anthocyanin-rich extracts on C-reactive protein levels: a systematic review and meta-analysis of randomised clinical trials. Anthocyanins 19-31 C-reactive protein Homo sapiens 64-82 30375293-0 2018 Effect of purified anthocyanins or anthocyanin-rich extracts on C-reactive protein levels: a systematic review and meta-analysis of randomised clinical trials. Anthocyanins 19-30 C-reactive protein Homo sapiens 64-82 30375293-1 2018 As the results of clinical trials are inconsistent, we conducted this research to assess the effect of purified anthocyanins or anthocyanin-rich extract supplementation on C-reactive protein (CRP) levels. Anthocyanins 112-124 C-reactive protein Homo sapiens 172-190 30375293-1 2018 As the results of clinical trials are inconsistent, we conducted this research to assess the effect of purified anthocyanins or anthocyanin-rich extract supplementation on C-reactive protein (CRP) levels. Anthocyanins 112-124 C-reactive protein Homo sapiens 192-195 29996169-13 2018 Only the cumulative number of days with CRP > 50 mg/L significantly correlated with the number of follow-up endoscopic sessions and DEN. Diethylnitrosamine 135-138 C-reactive protein Homo sapiens 40-43 31158931-0 2018 The relationship between intoxication severity and blood interleukin 6, interleukin 10 and CRP levels in carbon monoxide-poisoned patients. Carbon Monoxide 105-120 C-reactive protein Homo sapiens 91-94 30130674-2 2018 A previous study found that increased C-reactive protein (CRP), a marker of systemic inflammation, is associated with worse response to the serotonergic antidepressant escitalopram and better response to the noradrenergic antidepressant nortriptyline. Citalopram 168-180 C-reactive protein Homo sapiens 38-56 30130674-2 2018 A previous study found that increased C-reactive protein (CRP), a marker of systemic inflammation, is associated with worse response to the serotonergic antidepressant escitalopram and better response to the noradrenergic antidepressant nortriptyline. Citalopram 168-180 C-reactive protein Homo sapiens 58-61 30130674-6 2018 RESULTS: A higher polygenic risk score for CRP was associated with slightly better response to escitalopram and slightly worse response to nortriptyline, reflected in a statistically significant interaction between polygenic risk score and drug (beta = 1.07, 95% CI = 0.26-1.87, p = 0.0093). Citalopram 95-107 C-reactive protein Homo sapiens 43-46 29675680-0 2018 A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. ruxolitinib 45-56 C-reactive protein Homo sapiens 168-186 29680881-8 2018 At weeks 12 and 24, baricitinib-treated patients had larger responses compared to placebo-treated patients for multiple efficacy outcomes: American College of Rheumatology 20/50/70 response, low disease activity, remission, Disease Activity Score 28-C-reactive protein, and Health Assessment Questionnaire-Disability Index. baricitinib 20-31 C-reactive protein Homo sapiens 250-268 29805261-4 2018 Results: In GBS-A patients, the mean CRP and NLR levels at admission/discharge and third-month control were significantly higher, and the mean albumin level was significantly lower in the Hughes disability scale (HDS)>=3 group. gbs-a 12-17 C-reactive protein Homo sapiens 37-40 29805261-7 2018 Both GBS-A and GBS-P patients had higher mean NLR, PLR, and CRP levels and lower mean albumin values than healthy controls. gbs-a 5-10 C-reactive protein Homo sapiens 60-63 29563947-3 2018 Although intravenous cefotaxime and tobramycin were administered, her fever persisted and her C-reactive protein level increased to 307 mg/L. Cefotaxime 21-31 C-reactive protein Homo sapiens 94-112 29563947-3 2018 Although intravenous cefotaxime and tobramycin were administered, her fever persisted and her C-reactive protein level increased to 307 mg/L. Tobramycin 36-46 C-reactive protein Homo sapiens 94-112 29435151-4 2018 Firstly, we found that serum arsenic was positively associated with blood pressure, cholesterol, glucose and C-reactive protein. Arsenic 29-36 C-reactive protein Homo sapiens 109-127 28013285-6 2017 Serum high-sensitivity C-reactive protein (CRP) was measured on admission by latex-enhanced immunophelometric assay. Latex 77-82 C-reactive protein Homo sapiens 23-41 28013285-6 2017 Serum high-sensitivity C-reactive protein (CRP) was measured on admission by latex-enhanced immunophelometric assay. Latex 77-82 C-reactive protein Homo sapiens 43-46 28978343-8 2017 Among the total population, after adjustment for age, sex, race, C-reactive protein, smoking, and physical activity, glucose homeostasis factors, visceral adiposity index and lipid accumulation product improved across the quarters of the first and third DP; and a reverse pattern with the second DP. dp 254-256 C-reactive protein Homo sapiens 65-83 28784116-5 2017 RESULTS: Prednisolone normalized erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in PMR patients. Prednisolone 9-21 C-reactive protein Homo sapiens 94-97 28580833-6 2017 RESULTS: Our results indicate that inflammatory indices [C-reactive protein (CRP), platelets] decreased in the taurine group in pre-exercise, post-supplementation and post-exercise, post-supplementation as compared with pre-exercise, pre-supplementation ( p < 0.05) whereas these indices increased in pre-exercise, post-supplementation and post-exercise, post-supplementation as compared with pre-exercise, pre-supplementation in the placebo group ( p < 0.05). Taurine 111-118 C-reactive protein Homo sapiens 57-75 28580833-6 2017 RESULTS: Our results indicate that inflammatory indices [C-reactive protein (CRP), platelets] decreased in the taurine group in pre-exercise, post-supplementation and post-exercise, post-supplementation as compared with pre-exercise, pre-supplementation ( p < 0.05) whereas these indices increased in pre-exercise, post-supplementation and post-exercise, post-supplementation as compared with pre-exercise, pre-supplementation in the placebo group ( p < 0.05). Taurine 111-118 C-reactive protein Homo sapiens 77-80 28603799-4 2017 Ag NPs were conjugated to antibodies with specific recognition for the corresponding target antigenic molecule, CRP, and the Ag NPs were used to catalyse the oxidation of TMB by H2O2. 3,3',5,5'-tetramethylbenzidine 171-174 C-reactive protein Homo sapiens 112-115 29062328-7 2017 Plasma levels of CRP, ferritin and dopamine were higher in the group of smokers in the setting of lower levels of epinephrine, and leukocyte vitamin C, with CRP and vitamin C attaining statistical significance (P<0.04 and P<0.02 respectively). Epinephrine 114-125 C-reactive protein Homo sapiens 17-20 27797973-5 2017 Patients with low glycerophospholipids presented with more systemic inflammation (C-reactive protein and fibrinogen negatively and albumin positively correlated) but less adaptive immune cell tumor infiltration (lower tumor and immune cell PD-L1 expression), less oxygenic respiration and increased triglyceride biosynthesis in tumor cells, and lower histone expressions, correlating with higher numbers of expressed genes and more transcriptional noise, a putative neo-pluripotent tumor cell phenotype.Conclusions: Low serum phospholipids and essential amino acids are correlated with worse outcome in ovarian cancer, accompanied by a specific tumor cell phenotype. Glycerophospholipids 18-38 C-reactive protein Homo sapiens 82-100 28031420-5 2017 RESULTS: GlycA and GlycB had a strong correlation with CRP (r = 0.60 [P < 0.001] and r = 0.46 [P < 0.001], respectively). glyca 9-14 C-reactive protein Homo sapiens 55-58 27653088-12 2017 As D9D expression increases with higher intake of saturated FA and carbohydrates, dietary changes may influence D9D activity and thus CRP. saturated 50-59 C-reactive protein Homo sapiens 134-137 27370977-7 2016 RESULTS: The multivariate-adjusted geometric mean of serum CRP concentrations was significantly decreased with an increasing B vitamins intake across quartiles of niacin (P for trend = .007), pyridoxine (P for trend = .042), and cobalamin (P for trend = .037) in men. Pyridoxine 192-202 C-reactive protein Homo sapiens 59-62 27370977-8 2016 In men, the mean serum CRP concentrations in the highest quartiles of niacin, pyridoxine, and cobalamin were 63%, 38%, and 58%, respectively, lower than that in the lowest quartile. Pyridoxine 78-88 C-reactive protein Homo sapiens 23-26 27370977-9 2016 In women, the mean serum CRP concentrations in the highest quartiles of riboflavin (P for trend = .084) and pyridoxine (P for trend = .093) were 37% and 47%, respectively, lower than that in the lowest quartile. Pyridoxine 108-118 C-reactive protein Homo sapiens 25-28 27370977-10 2016 CONCLUSION: High intake of niacin, pyridoxine, or cobalamin was independently associated with decreased serum CRP concentrations among HIV-infected men. Pyridoxine 35-45 C-reactive protein Homo sapiens 110-113 27620205-4 2016 NHANES latex-enhanced nephelometry quantified serum CRP levels. Latex 7-12 C-reactive protein Homo sapiens 52-55 27540251-17 2016 Therefore the new gentamicin prescription chart is safer as toxic levels are identified sooner, which reduces the risk of babies suffering adverse effects.Since the introduction of the new gentamicin prescription chart 31% of babies received more than the necessary number of gentamicin doses, as dictated by the CRP results and blood culture result at 36 hrs. Gentamicins 18-28 C-reactive protein Homo sapiens 313-316 27540251-17 2016 Therefore the new gentamicin prescription chart is safer as toxic levels are identified sooner, which reduces the risk of babies suffering adverse effects.Since the introduction of the new gentamicin prescription chart 31% of babies received more than the necessary number of gentamicin doses, as dictated by the CRP results and blood culture result at 36 hrs. Gentamicins 189-199 C-reactive protein Homo sapiens 313-316 27540251-17 2016 Therefore the new gentamicin prescription chart is safer as toxic levels are identified sooner, which reduces the risk of babies suffering adverse effects.Since the introduction of the new gentamicin prescription chart 31% of babies received more than the necessary number of gentamicin doses, as dictated by the CRP results and blood culture result at 36 hrs. Gentamicins 189-199 C-reactive protein Homo sapiens 313-316 27597810-9 2016 Prasugrel administration also resulted in a significant reduction in hs-CRP level (P < 0.001). Prasugrel Hydrochloride 0-9 C-reactive protein Homo sapiens 72-75 27597810-10 2016 A significant 73% overall reduction in the hs-CRP level was seen with prasugrel compared with 39% overall reduction in hs-CRP level with clopidogrel (P = 0.002). Prasugrel Hydrochloride 70-79 C-reactive protein Homo sapiens 46-49 27482309-7 2016 C-reactive protein was higher in the volatile group than in the propofol group (8.4 +- 5.6 vs. 7.1 +- 5.3 mg/dl, P = 0.001), and postoperative white blood cells count was higher in the volatile group than in the propofol group (9.2 +- 3.2 x 10(3)/microl vs. 8.6 +- 3.4 x 10(3)/microl, P = 0.041). Propofol 64-72 C-reactive protein Homo sapiens 0-18 27455959-10 2016 In patients, prednisolone abolished symptoms, normalized C-reactive protein, and reduced melatonin, IL-6, IL-8, and TNF-alpha concentrations (2P < 0.05), while IL-10 increased between 10:00 and 14:00. Prednisolone 13-25 C-reactive protein Homo sapiens 57-75 26908433-8 2016 Higher CRP was also associated with smoking, hormone replacement therapy use, and gamma-tocopherol intake; lower CRP with physical activity, and intakes of dietary vitamin C and total fiber. gamma-Tocopherol 82-98 C-reactive protein Homo sapiens 7-10 26758677-8 2016 The patients in the MC group had higher elevation of the CRP mean values post-operatively (p = 0.01). Methylcholanthrene 20-22 C-reactive protein Homo sapiens 57-60 27508369-1 2016 Controlled-release KMnO4 (CRP) technology has been recently developed as an improved, highly efficient technique in wastewater treatment. Potassium Permanganate 19-24 C-reactive protein Homo sapiens 26-29 27508369-5 2016 KMnO4 released from CRP can effectively degrade phenol-contaminated water with different concentrations. Potassium Permanganate 0-5 C-reactive protein Homo sapiens 20-23 26038004-9 2015 The CRP level tended to be lower in the rTM group than in the GM group. Gabexate 62-64 C-reactive protein Homo sapiens 4-7 25669317-0 2015 Effect of vitamin E supplementation on serum C-reactive protein level: a meta-analysis of randomized controlled trials. Vitamin E 10-19 C-reactive protein Homo sapiens 45-63 25669317-4 2015 The aim of this study was to systematically review randomized controlled trials (RCTs) that report on the effects of vitamin E supplementation (alpha- and gamma-tocopherols) on CRP levels. Vitamin E 117-126 C-reactive protein Homo sapiens 177-180 25669317-9 2015 Pooled analysis showed a significant reduction in CRP levels of 0.62 mg/l (95% confidence interval = -0.92, -0.31; P < 0.001) in vitamin E-treated individuals, with the evidence of heterogeneity across studies. Vitamin E 132-141 C-reactive protein Homo sapiens 50-53 25669317-11 2015 The results of this meta-analysis suggest that supplementation with vitamin E in the form of either alpha-tocopherol or gamma-tocopherol would reduce serum CRP levels. Vitamin E 68-77 C-reactive protein Homo sapiens 156-159 25669317-11 2015 The results of this meta-analysis suggest that supplementation with vitamin E in the form of either alpha-tocopherol or gamma-tocopherol would reduce serum CRP levels. gamma-Tocopherol 120-136 C-reactive protein Homo sapiens 156-159 24651682-12 2015 CONCLUSIONS: These findings suggest that the antioxidants in a 30-day intervention of V8 juice affect CRP levels in a sample of female patients with HF. v8 juice 86-94 C-reactive protein Homo sapiens 102-105 24997614-8 2015 In addition, the C-reactive protein level was significantly lower in the CT group than in the AT group, whereas interleukin-6, tumor necrosis factor-alpha, and total cholesterol levels were significantly lower in both groups (p < 0.05). ct 73-75 C-reactive protein Homo sapiens 17-35 25964889-0 2015 Effect of pioglitazone therapy on high sensitive C-reactive protein and lipid profile in diabetic patients with renal transplantation; a randomize clinical trial. Pioglitazone 10-22 C-reactive protein Homo sapiens 49-67 25964889-2 2015 OBJECTIVES: This study designed for evaluating the efficacy of pioglitazone on C-reactive protein and lipid profile in diabetic kidney transplant receivers. Pioglitazone 63-75 C-reactive protein Homo sapiens 79-97 25775471-7 2015 Furthermore, CTP patients with cardiovascular involvement were significantly older, had higher systolic and diastolic pressures, C-reactive protein, glucose, and uric acid, higher rates of diabetes, hypertension, and use of moderate- to high-dose glucocorticoids, and longer disease duration compared to patients without involvement (all p < 0.05). Cytidine Triphosphate 13-16 C-reactive protein Homo sapiens 129-147 25441108-10 2015 One patient with multiple relapses after 7 lines of therapy had a CRp at a ruxolitinib dose of 200 mg b.i.d. ruxolitinib 75-86 C-reactive protein Homo sapiens 66-69 25441108-11 2015 CONCLUSION: In this cohort of heavily pretreated patients with relapsed or refractory acute leukemias, ruxolitinib was overall reasonably well tolerated, with 1 patient achieving CRp. ruxolitinib 103-114 C-reactive protein Homo sapiens 179-182 26089929-11 2015 C-reactive protein was also decreased insignificant after receive pioglitazone (P = 0.333). Pioglitazone 66-78 C-reactive protein Homo sapiens 0-18 25017001-8 2014 For patients with higher CRP levels, improvement on the MADRS score was 3 points higher with nortriptyline than with escitalopram. Citalopram 117-129 C-reactive protein Homo sapiens 25-28 24946826-5 2014 RESULTS: Unadjusted linear regression showed significant associations between periodontal and systemic parameters; the strongest association (r = 0.629; p < 0.001) was found between BOP and CRP levels, the periodontal and systemic inflammation marker, respectively. bop 185-188 C-reactive protein Homo sapiens 193-196 24946826-6 2014 Stepwise regression analysis models revealed that BOP was a predictor of systemic CRP levels (p < 0.0001). bop 50-53 C-reactive protein Homo sapiens 82-85 24946826-7 2014 BOP was the only periodontal parameter significantly associated with each systemic parameter (CRP, FIB, and WBC). bop 0-3 C-reactive protein Homo sapiens 94-97 24946826-8 2014 CONCLUSION: In coronary heart disease patients with periodontitis, BOP is strongly associated with systemic CRP levels; this association possibly reflects the potential significance of the local periodontal inflammatory burden for systemic inflammation. bop 67-70 C-reactive protein Homo sapiens 108-111 25352195-6 2014 Compared with the CS group, the FTS group had significantly shorter duration to first flatus, time to regular diet, postoperative hospital days and hospital expense, less complications, lower white blood count (WBC) and serum of C-reactive protein (CRP) on postoperative day 5 and 7. fts 32-35 C-reactive protein Homo sapiens 229-247 25352195-6 2014 Compared with the CS group, the FTS group had significantly shorter duration to first flatus, time to regular diet, postoperative hospital days and hospital expense, less complications, lower white blood count (WBC) and serum of C-reactive protein (CRP) on postoperative day 5 and 7. fts 32-35 C-reactive protein Homo sapiens 249-252 25190488-9 2014 In the 137 untreated patients, dp-ucMGP levels were significantly (p < 0.05) associated both in the uni- and multivariate analysis with age, body mass index, plasma levels of albumin, C-reactive protein, and FGF-23, and the vascular calcification score. dp 31-33 C-reactive protein Homo sapiens 187-205 24769306-5 2014 RESULTS: Pioglitazone lowered plasma insulin (P < 0.001), improved insulin sensitivity (P < 0.001), increased HDL (P < 0.001), and reduced triglycerides (P = 0.003), free fatty acids (P = 0.005), and C-reactive protein (P = 0.001). Pioglitazone 9-21 C-reactive protein Homo sapiens 209-227 24752806-0 2014 Label-free detection of C-reactive protein using highly dispersible gold nanoparticles synthesized by reducible biomimetic block copolymers. copolymers 129-139 C-reactive protein Homo sapiens 24-42 24662652-8 2014 In a multivariate analysis, CRP was the only independent predictor for the outcome of F-FDG PET/CT. f-fdg 86-91 C-reactive protein Homo sapiens 28-31 24578648-7 2014 The serum levels of CRP and TNF-alpha negative correlate with ALA, DHA, and DGLA. ala 62-65 C-reactive protein Homo sapiens 20-23 25185422-8 2014 Moreover, CRP resulted in the activation of NF-kappaB significantly, which was diminished by PI3K inhibitor wortmannin. Wortmannin 108-118 C-reactive protein Homo sapiens 10-13 24603289-9 2014 Inclusion of CRP in multivariate analyses significantly reduced the strength of association between some co-variables such as radiological contrast and gentamicin administration but not others. Gentamicins 152-162 C-reactive protein Homo sapiens 13-16 23787477-11 2013 Plasma CRP increased on MG2 and MG4, while IL-6 only increased on MG2 (P < 0.001). mg4 32-35 C-reactive protein Homo sapiens 7-10 23017687-7 2013 This report is the first description of the detection of CRP in human serum using a silicon-based biosensor. Silicon 84-91 C-reactive protein Homo sapiens 57-60 23359066-3 2013 METHODS AND RESULTS: The primary objective of this study was to evaluate the effect on C-reactive protein (CRP) after a 16-week treatment period with either pioglitazone or metformin. Pioglitazone 157-169 C-reactive protein Homo sapiens 87-105 23359066-3 2013 METHODS AND RESULTS: The primary objective of this study was to evaluate the effect on C-reactive protein (CRP) after a 16-week treatment period with either pioglitazone or metformin. Pioglitazone 157-169 C-reactive protein Homo sapiens 107-110 24167354-7 2013 C-Reactive Protein (CRP) was negatively correlated with lauric acid (P = 0.048), and both CRP and CRP/Albumin ratio were negatively correlated with margaric acid (P = 0.010, P = 0.008, resp.). lauric acid 56-67 C-reactive protein Homo sapiens 0-18 24167354-7 2013 C-Reactive Protein (CRP) was negatively correlated with lauric acid (P = 0.048), and both CRP and CRP/Albumin ratio were negatively correlated with margaric acid (P = 0.010, P = 0.008, resp.). lauric acid 56-67 C-reactive protein Homo sapiens 20-23 24240788-9 2013 In the CY group, the hazard ratio after adjusting for age, sex, Birmingham vasculitis activity score values, serum albumin levels and C-reactive protein (CRP) levels was 0.657 (95% CI, 0.254-1.699; p=0.386). Cyclophosphamide 7-9 C-reactive protein Homo sapiens 134-152 24240788-9 2013 In the CY group, the hazard ratio after adjusting for age, sex, Birmingham vasculitis activity score values, serum albumin levels and C-reactive protein (CRP) levels was 0.657 (95% CI, 0.254-1.699; p=0.386). Cyclophosphamide 7-9 C-reactive protein Homo sapiens 154-157 23952947-6 2013 We demonstrated ability of perindopril to affect proinflammatory status: to suppress factors of subclinical inflammation (interleukin-6 and C-reactive protein) and to elevate level of anti-inflammatory interleukin-10. Perindopril 27-38 C-reactive protein Homo sapiens 140-158 23710164-4 2013 Pioglitazone significantly improved C-reactive protein level irrespective of changes in insulin sensitivity. Pioglitazone 0-12 C-reactive protein Homo sapiens 36-54 22520732-0 2012 Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin. gemcitabine 138-149 C-reactive protein Homo sapiens 10-28 22658699-0 2012 Effect of pitavastatin treatment on changes of plaque volume and composition according to the reduction of high-sensitivity C-reactive protein levels. pitavastatin 10-22 C-reactive protein Homo sapiens 124-142 22791755-4 2012 RESULTS: EE-CA and low-dose PioFluMet reduced androgen excess comparably, but had divergent effects on C-reactive protein, high molecular weight adiponectin, lipids, carotid intima media thickness, lean mass, abdominal and visceral fat, and on the expression of CD163, leptin, TNF-like weak inducer of apoptosis receptor, and angiopoietin-like protein 4, respectively, related to macrophage activation, fat accretion, inflammation, and lipoprotein metabolism in adipose tissue. pioflumet 28-37 C-reactive protein Homo sapiens 103-121 22689805-7 2012 The CR rate plus CRp was 17.8% with decitabine versus 7.8% with TC (odds ratio, 2.5; 95% CI, 1.4 to 4.8; P = .001). Decitabine 36-46 C-reactive protein Homo sapiens 4-6 22689805-7 2012 The CR rate plus CRp was 17.8% with decitabine versus 7.8% with TC (odds ratio, 2.5; 95% CI, 1.4 to 4.8; P = .001). Decitabine 36-46 C-reactive protein Homo sapiens 17-20 22483930-0 2012 CdSe and ZnSe quantum dots capped with PEA for screening C-reactive protein in human serum. cdse 0-4 C-reactive protein Homo sapiens 57-75 22483930-1 2012 A fluorescence chemical sensor for C-reactive protein (CRP) was developed based on the selective interaction with CdSe and ZnSe quantum dots (QDs) coated with O-phosphorylethanolamine (PEA). cdse 114-118 C-reactive protein Homo sapiens 35-53 21499712-10 2012 Multivariate analysis identified the CT+TT genotype as an independent predictor of pre- and postoperative CRP levels. Carbon Tetrachloride 37-40 C-reactive protein Homo sapiens 106-109 22168310-7 2012 Postoperative CRP positively correlated with epinephrine dosage and CPB duration. Epinephrine 45-56 C-reactive protein Homo sapiens 14-17 22371409-3 2012 MATERIAL/METHODS: The aim of this study was to evaluate the effects of antihypertensive therapy (perindopril, bisoprolol and combined therapy) on plasma CRP concentration in 67 subjects with mild or moderate hypertension who have been treatment-naive and otherwise healthy. Perindopril 97-108 C-reactive protein Homo sapiens 153-156 22371409-6 2012 The CRP-lowering effect of perindopril and bisoprolol was comparable and the degree of reduction might reflect their similar influence on blood pressure. Perindopril 27-38 C-reactive protein Homo sapiens 4-7 22340737-13 2012 The CRP levels were significantly inversely correlated with free thyroxine levels (r = -0.547; p = 0.01). Thyroxine 65-74 C-reactive protein Homo sapiens 4-7 22035573-5 2012 In a multiple stepwise regression including all subjects, subcutaneous adipose tissue thickness of upper back, cholesterol and ultrasensitive C-reactive protein were the best predictors for ETP. Ethionamide 190-193 C-reactive protein Homo sapiens 142-160 22530144-9 2012 The mean of morning stiffness, fatigue scores, CRP and CDAI decreased statistically when prednisolone was administrated at 10 p.m. Prednisolone 89-101 C-reactive protein Homo sapiens 47-50 21496483-8 2011 In the subset of persistent fatigued and never-fatigued individuals the CRP SNP (rs3091244) was associated with hsCRP level (p=0.02). hscrp 112-117 C-reactive protein Homo sapiens 72-75 22029000-2 2011 Beyond these effects on glucose metabolism, pioglitazone has positive effects on lipid metabolism, blood pressure, endothelial function, adiponectin, and C-reactive protein levels. Pioglitazone 44-56 C-reactive protein Homo sapiens 154-172 21349512-3 2011 The aim of this study was to explore the relationship between urinary phthalate metabolite concentrations and serum markers of inflammation and oxidative stress (C-reactive protein (CRP) and gamma glutamyltransferase (GGT), respectively). phthalic acid 70-79 C-reactive protein Homo sapiens 162-180 21349512-3 2011 The aim of this study was to explore the relationship between urinary phthalate metabolite concentrations and serum markers of inflammation and oxidative stress (C-reactive protein (CRP) and gamma glutamyltransferase (GGT), respectively). phthalic acid 70-79 C-reactive protein Homo sapiens 182-185 21349512-5 2011 In multivariable linear regression models, we observed significant positive associations between CRP and mono-benzyl phthalate (MBzP) and mono-isobutyl phthalate (MiBP). mono-benzyl phthalate 105-126 C-reactive protein Homo sapiens 97-100 21349512-5 2011 In multivariable linear regression models, we observed significant positive associations between CRP and mono-benzyl phthalate (MBzP) and mono-isobutyl phthalate (MiBP). mono-benzyl phthalate 128-132 C-reactive protein Homo sapiens 97-100 20838325-0 2011 Amifostine-related fever-rash during fractionated radiotherapy: diagnostic and predictive role of C-reactive protein. Amifostine 0-10 C-reactive protein Homo sapiens 98-116 20838325-2 2011 Here, we focus on the role of C-reactive protein (CRP) as a putative marker linked with amifostine fever/rash. Amifostine 88-98 C-reactive protein Homo sapiens 30-48 20838325-2 2011 Here, we focus on the role of C-reactive protein (CRP) as a putative marker linked with amifostine fever/rash. Amifostine 88-98 C-reactive protein Homo sapiens 50-53 20838325-10 2011 This sharp CRP rise was specific for amifostine-related fever/rash. Amifostine 37-47 C-reactive protein Homo sapiens 11-14 20838325-13 2011 CONCLUSIONS: Sharp rise of CRP levels on the day after the fever/rash development suggest amifostine-related etiology of fever/rash. Amifostine 90-100 C-reactive protein Homo sapiens 27-30 21339857-9 2011 Clinically, the pioglitazone treated group showed significant improvement in DAS28 (P = 0.001) and C-reactive protein (P < 0.0001) compared to placebo group. Pioglitazone 16-28 C-reactive protein Homo sapiens 99-117 21211686-7 2011 RESULTS: Pioglitazone-treated patients demonstrated greater increases in high-density lipoprotein cholesterol (HDL-C) and reductions in glycated hemoglobin, triglycerides, and C-reactive protein. Pioglitazone 9-21 C-reactive protein Homo sapiens 176-194 21519150-6 2011 Echocardiography and hemodynamic measurements 6 weeks after injection showed lower fractional shortening and left ventricular (LV) dP/dt max in CRP/DM compared with Wt/DM. dp 131-133 C-reactive protein Homo sapiens 144-147 22004661-13 2011 The highest tobramycin serum concentration was significantly associated with vasopressor support, renal and hepatic dysfunction, and C-reactive protein. Tobramycin 12-22 C-reactive protein Homo sapiens 133-151 20940516-1 2011 AIM: Pitavastatin significantly improved lipid profiles and reduced serum high-sensitivity C-reactive protein (hs-CRP) levels in a multi-center and prospective study. pitavastatin 5-17 C-reactive protein Homo sapiens 91-109 22247668-4 2011 The detection principle is demonstrated with a time-resolved fluorescence immunoassay for the detection of C-reactive protein (CRP) using CdSe-ZnS nanoparticles and green light excitation. cdse 138-142 C-reactive protein Homo sapiens 107-125 22247668-4 2011 The detection principle is demonstrated with a time-resolved fluorescence immunoassay for the detection of C-reactive protein (CRP) using CdSe-ZnS nanoparticles and green light excitation. cdse 138-142 C-reactive protein Homo sapiens 127-130 20337818-5 2010 CRP and IL-6 correlated with PASI. pasi 29-33 C-reactive protein Homo sapiens 0-3 20831680-17 2010 High-sensitivity C reactive protein decreased in the pioglitazone group after full treatment compared to the end of titration period and to the acarbose group. Pioglitazone 53-65 C-reactive protein Homo sapiens 17-35 20855282-0 2010 [Response to metoprolol succinate sustained-release tablets in correlation to pulse pressure, serum vascular endothelial growth factor and C-reactive protein in elderly hypertensive patients with chronic heart failure]. Metoprolol 13-33 C-reactive protein Homo sapiens 139-157 20657531-9 2010 C-reactive protein (CRP) levels decreased marginally with Ramipril, but significantly with Pycnogenol from 2.17 to 1.62 mg/dL. Ramipril 58-66 C-reactive protein Homo sapiens 0-18 20657531-9 2010 C-reactive protein (CRP) levels decreased marginally with Ramipril, but significantly with Pycnogenol from 2.17 to 1.62 mg/dL. Ramipril 58-66 C-reactive protein Homo sapiens 20-23 20205737-8 2010 Plasma C-reactive protein concentration was lower (P < 0.05) on wk 8 in subjects given 2 mg astaxanthin. astaxanthine 95-106 C-reactive protein Homo sapiens 7-25 19700161-7 2010 Among non-smokers, serum cotinine levels were independently positively associated with CRP, fibrinogen, factor VIII, VWF and t-PA and inversely associated with albumin, after adjustment for age, gender, social and behavioural factors. Cotinine 25-33 C-reactive protein Homo sapiens 87-90 19700161-8 2010 The differences in CRP, fibrinogen and albumin between cotinine < or =0.05 and >0.7 ng/ml were one-third to one half the size of differences between cotinine < or =0.05 ng/ml and current smokers, but were of similar magnitude for VWF and t-PA. Cotinine 55-63 C-reactive protein Homo sapiens 19-22 19700161-8 2010 The differences in CRP, fibrinogen and albumin between cotinine < or =0.05 and >0.7 ng/ml were one-third to one half the size of differences between cotinine < or =0.05 ng/ml and current smokers, but were of similar magnitude for VWF and t-PA. Cotinine 155-163 C-reactive protein Homo sapiens 19-22 21212585-8 2010 After treatment with oral prednisolone (40 mg/day), her headache disappeared and her serum CRP level returned to normal. Prednisolone 26-38 C-reactive protein Homo sapiens 91-94 19638294-4 2009 A significant increase in C-reactive protein (CRP), serum amyloid A (SAA) and haptoglobin (HP) levels after MPTP treatment. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 108-112 C-reactive protein Homo sapiens 26-44 19545552-0 2009 Binding of the monomeric form of C-reactive protein to enzymatically-modified low-density lipoprotein: effects of phosphoethanolamine. phosphorylethanolamine 114-133 C-reactive protein Homo sapiens 33-51 19545552-6 2009 In the presence of the small-molecule compound phosphoethanolamine (PEt), at 37 degrees C, the binding of mCRP to E-LDL was enhanced <2-fold, while the binding of CRP to E-LDL was enhanced >10-fold. phosphorylethanolamine 47-66 C-reactive protein Homo sapiens 107-110 19497445-10 2009 Patients with DM + MC were more insulin resistant than DM patients and had an elevated whole blood viscosity that correlated with plasma glucose (p = 0.001) and C-reactive protein (p = 0.003). Methylcholanthrene 19-21 C-reactive protein Homo sapiens 161-179 19109317-4 2009 RESULTS: Systemic signs/symptoms were significantly less frequent (P = 0.004) and ESR and C-reactive protein (CRP) values at diagnosis were significantly lower (P = 0.03 and P = 0.04, respectively) in patients with CIEs. cies 215-219 C-reactive protein Homo sapiens 90-108 19151033-12 2009 Treatment with L-mevalonate or farnesylpyrophosphate, but not geranylgeranyl-pyrophosphate reversed the statin-induced effect on CRP-mediated functions and ERK 1/2 phosphorylation, confirming that statins blocked CRP-induced ERK 1/2 phosphorylation through the inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. farnesyl pyrophosphate 31-52 C-reactive protein Homo sapiens 129-132 19151033-12 2009 Treatment with L-mevalonate or farnesylpyrophosphate, but not geranylgeranyl-pyrophosphate reversed the statin-induced effect on CRP-mediated functions and ERK 1/2 phosphorylation, confirming that statins blocked CRP-induced ERK 1/2 phosphorylation through the inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. farnesyl pyrophosphate 31-52 C-reactive protein Homo sapiens 213-216 19195502-0 2009 Effect of beta blockers (metoprolol or propranolol) on effect of simvastatin in lowering C-reactive protein in acute myocardial infarction. Propranolol 39-50 C-reactive protein Homo sapiens 89-107 19070303-6 2008 The concentration of C-reactive protein was significantly higher (CTL: 0.028 +/- 0.005 mg x dl(-1); CMS: 0.025 +/-0.003 mg x dl(-1)), and that of adrenaline was significantly lower in CTL compared to CMS (CTL: 46.8 +/- 7.5 pg x ml(-1); CMS: 71 +/- 22.5 pg x ml(-1)). Epinephrine 146-156 C-reactive protein Homo sapiens 21-39 18597411-8 2008 RESULTS: OxLDL-ab were positively correlated with CRP (r = 0.33, p < 0.001) and negatively correlated with HDL cholesterol (r = -0.28, p = 0.001). oxldl-ab 9-17 C-reactive protein Homo sapiens 50-53 18413496-4 2008 Pioglitazone treatment led to improvement in levels of multiple cardiovascular risk markers, including high-sensitivity C-reactive protein, apolipoprotein B, apolipoprotein A1, high-density lipoprotein (HDL) cholesterol, triglyceride, insulin, and free fatty acid. Pioglitazone 0-12 C-reactive protein Homo sapiens 120-138 18322245-6 2008 Surprisingly, blocking of the PCh-binding site with phosphoethanolamine (PEt) dramatically increased the binding of CRP to E-LDL. phosphorylethanolamine 52-71 C-reactive protein Homo sapiens 116-119 17768592-5 2008 Pioglitazone ameliorated lipid profile and lowered liver enzymes and C-reactive protein. Pioglitazone 0-12 C-reactive protein Homo sapiens 69-87 17923463-1 2008 BACKGROUND: The Val-MARC trial showed that the angiotensin receptor blocker valsartan reduces high-sensitivity C reactive protein (hsCRP) levels, an effect that is independent of blood pressure, and seems to be neutralised by the addition of hydrochlorothiazide. Valsartan 76-85 C-reactive protein Homo sapiens 111-129 18292576-8 2008 SB203580 inhibited the phosphorylation of c-Fos enhanced by IL-1 plus IL-6, and diminished expression of the CRP gene. SB 203580 0-8 C-reactive protein Homo sapiens 109-112 18271807-4 2008 The fever, rashes and arthralgia disappeared after medication of medium-dose oral prednisolone, however, the CRP value persisted at high levels, and the serum ferritin level nevertheless increased by 5200 ng/mL. Prednisolone 82-94 C-reactive protein Homo sapiens 109-112 18271807-7 2008 Finally, 10 days after starting the administration of methotrexate, the CRP value dramatically decreased from 7 mg/dL to 0.16 mg/dL, and thereafter the serum ferritin level started to decline, which thus enabled us to eventually taper the dose of oral prednisolone. Prednisolone 252-264 C-reactive protein Homo sapiens 72-75 17311055-1 2008 OBJECTIVE: To examine the association between plasma concentrations of C-reactive protein (CRP) and the intake of vitamins and trace elements from supplements possibly related to inflammation such as vitamin C, vitamin E, carotenoids, selenium and zinc. Vitamin E 211-220 C-reactive protein Homo sapiens 71-89 17311055-6 2008 Especially vitamin E in combination with other vitamins like vitamin C, vitamin B(1), B(2), B(6), B(12), niacin, folic acid, pantothenic acid and selenium, was significantly associated with lower CRP levels. Vitamin E 11-20 C-reactive protein Homo sapiens 196-199 17311055-7 2008 Odds ratios for elevated CRP levels (>3.0 mg/l) after multivariable adjustment were 0.57 (95% confidence interval (CI): 0.37, 0.89) for the intake of vitamin E and 0.57 (95% CI: 0.35, 0.91) for the intake of multivitamins, defined as taking three or more different vitamins. Vitamin E 153-162 C-reactive protein Homo sapiens 25-28 17652082-8 2007 IL-17 stimulated p38 MAPK and ERK1/2 activation, and SB203580 and PD98059 blunted IL-17-mediated NF-kappaB and C/EBP activation and CRP transcription. SB 203580 53-61 C-reactive protein Homo sapiens 132-135 17614367-10 2007 The immunoassay with the LFDA for 10 min (total assay time of approximately 23 min) with a CRP sample volume of 0.5 microL yielded an LOD of 0.15 pM, which is equivalent to 75 zmol. lfda 25-29 C-reactive protein Homo sapiens 91-94 17605895-0 2007 Effects of folic acid and vitamin B complex on serum C-reactive protein and albumin levels in stable hemodialysis patients. Niacinamide 26-35 C-reactive protein Homo sapiens 53-71 17299064-7 2007 RESULTS: PioFluMet reduced intima-media thickness more than FluMet and lowered glucose, IGF-I, and C-reactive protein more as well as the ratio of low-density lipoprotein to high-density lipoprotein cholesterol and the ratio of neutrophils to lymphocytes. pioflumet 9-18 C-reactive protein Homo sapiens 99-117 17379017-5 2007 C-reactive protein levels were decreased after 6 months of treatment with either pioglitazone or voglibose, with the former being more effective (-57%+/-8% vs -9%+/-18%; P<.05). Pioglitazone 81-93 C-reactive protein Homo sapiens 0-18 17307426-7 2007 High-sensitivity C-reactive protein levels decreased by an average of 68% in the rosiglitazone group (5.99 +/- 0.88 to 1.91 +/- 0.28 mg/L, P < .001), compared with a nonsignificant 4% reduction in hsCRP with metformin (5.69 +/- 0.83 to 5.46 +/- 0.92 mg/L; P = nonsignificant). hscrp 200-205 C-reactive protein Homo sapiens 17-35 16678922-6 2007 Levels of CRP were quantified by utilizing latex-enhanced nephelometry. Latex 43-48 C-reactive protein Homo sapiens 10-13 17045826-12 2007 The LPS-induced CRP acute-phase protein of inflammation (0.58+/-0.13 and 3.52+/-0.41 mg/dL, before and after LPS, respectively) was significantly inhibited by a pre-treatment with prednisolone (1.39+/-0.32 mg/dL, p<0.01) and attenuated (2.65+/-0.30 mg/dL, p=0.09) with cilomilast. Prednisolone 180-192 C-reactive protein Homo sapiens 16-19 16995340-8 2006 Cytotoxic effects of CRP were determined by a commercially available Live/Dead assay and MTT assay. monooxyethylene trimethylolpropane tristearate 89-92 C-reactive protein Homo sapiens 21-24 16159895-7 2006 Pioglitazone therapy in men with advanced diabetic nephropathy reduced WBC count by 1,125/mul (P < 0.001), CRP by 41% (P = 0.042), IL-6 by 38% (P = 0.009), and MMP-9 by 29% (P = 0.016). Pioglitazone 0-12 C-reactive protein Homo sapiens 110-113 16383313-0 2006 Rapid electrochemiluminoimmunoassay of human C-reactive protein at planar disposable oxide-coated silicon electrodes. Silicon 98-105 C-reactive protein Homo sapiens 45-63 16306801-5 2005 We studied the effect of 4 weeks of pioglitazone treatment on endothelial function, metabolic changes, and C-reactive protein in patients with type 2 diabetes. Pioglitazone 36-48 C-reactive protein Homo sapiens 107-125 16306801-10 2005 Pioglitazone treatment reduced insulin, FFA, and C-reactive protein concentrations compared with placebo (18.3 +/- 2.4 versus 14.8 +/- 2.1 mU/L, P = 0.03; 641 +/- 46 versus 542 +/- 33 mumol/L, P = 0.04; and 3.5 +/- 0.6 mg/L versus 2.6 +/- 0.5 mg/L, P = 0.01; respectively). Pioglitazone 0-12 C-reactive protein Homo sapiens 49-67 16123332-7 2005 Native CRP had no detectable effect at 4 hours, whereas it enhanced IL-8 release after a 24-hour incubation that was blocked by L-NAME. NG-Nitroarginine Methyl Ester 128-134 C-reactive protein Homo sapiens 7-10 16123332-9 2005 These results suggest that loss of the pentameric symmetry in CRP, resulting in formation of mCRP, leads to IL-8 release from human neutrophils via peroxynitrite-mediated activation of nuclear factor-kappaB and activator protein-1. Peroxynitrous Acid 148-161 C-reactive protein Homo sapiens 62-65 16087988-2 2005 OBJECTIVE: We investigated the effect of a diet with a high content of sucrose or artificial sweeteners on the inflammatory markers CRP, haptoglobin, and transferrin in overweight subjects. Sucrose 71-78 C-reactive protein Homo sapiens 132-135 15701058-8 2005 The expression of IL-8 mRNA was increased in a dose-dependent manner after stimulation with CRP (1-100 microg/ml), whereas expression of IL-8 mRNA induced by CRP (50 microg/ml) was significantly diminished by 5 microM pitavastatin. pitavastatin 218-230 C-reactive protein Homo sapiens 158-161 15701058-9 2005 Furthermore, specific MAPK inhibitors (PD98059, SB203580 and SP600125) inhibited the expression of IL-8 mRNA induced by CRP (50 microg/ml). SB 203580 48-56 C-reactive protein Homo sapiens 120-123 15701058-10 2005 The phosphorylation of all three MAPKs [ERK (extracellular-signal-regulated kinase), p38 MAPK and JNK (c-Jun N-terminal kinase)] induced by CRP (10 microg/ml) was also significantly inhibited by pitavastatin. pitavastatin 195-207 C-reactive protein Homo sapiens 140-143 15799714-4 2005 Kibayashi and co-workers in this issue of Clinical Science confirm that CRP induces IL-8 production in human aortic endothelial cells in vitro, via the activation of MAPKs (mitogen-activated protein kinases), an effect that can be inhibited by pitavastatin. pitavastatin 244-256 C-reactive protein Homo sapiens 72-75 15718491-7 2005 Dihydroethidium staining showed that CRP produced SB203850- and TEMPOL-sensitive superoxide production in the arteriolar endothelium. dihydroethidium 0-15 C-reactive protein Homo sapiens 37-40 15674405-3 2005 In 463 participants, we measured serum C-reactive protein concentration using a high-sensitivity immunonephelometric latex-enhanced assay. Latex 117-122 C-reactive protein Homo sapiens 39-57 16642663-10 2005 The positive correlation of high serum iPTH with inflammation implies further need to control hyperphosphatemia and secondary hyperparathyroidism in HD patients, also inverse correlation of serum CRP with cholesterol and triglyceride further support the malnutrition-inflammation complex syndrome (MICS) which frequently seen in hemodialysis patients (Tab. ipth 39-43 C-reactive protein Homo sapiens 196-199 15616030-8 2005 In addition C-reactive protein levels decreased marginally in the vitamin E compared with the placebo group (P = 0.05). Vitamin E 66-75 C-reactive protein Homo sapiens 12-30 15569851-8 2005 NT-proBNP and CRP predicted CHF in subjects receiving perindopril-based therapy. Perindopril 54-65 C-reactive protein Homo sapiens 14-17 15774170-10 2005 CONCLUSIONS: Tight control of blood glucose by intensive insulin therapy expedited healing of human sepsis, and increased the HLA-DR expression of peripheral and suppressed the elevated serum CRP. Blood Glucose 30-43 C-reactive protein Homo sapiens 192-195 15172423-13 2004 Valsartan but not amlodipine reduced CRP levels. Valsartan 0-9 C-reactive protein Homo sapiens 37-40 15172423-15 2004 CONCLUSIONS: The ARB valsartan has BP-independent effects on LVH, ROS formation by monocytes, and CRP in hypertensive patients with LVH. Valsartan 21-30 C-reactive protein Homo sapiens 98-101 15072729-6 2004 RESULTS: Among nondiabetic women, current PHT users had lower mean fibrinogen, PAI1, and low-density lipoprotein cholesterol (LDLC) levels than those in never users (38.4 mg/dl, 8.68 ng/ml, and 14.16 mg/dl lower, respectively) but higher CRP and triglyceride levels (1.53 mg/l and 31.43 mg/dl higher, respectively). pht 42-45 C-reactive protein Homo sapiens 238-241 14747180-9 2004 CONCLUSIONS: The significant increase in serum CRP levels during COH, especially after HCG administration, suggests that COH potentiates a state of systemic inflammation. coh 65-68 C-reactive protein Homo sapiens 47-50 14747180-9 2004 CONCLUSIONS: The significant increase in serum CRP levels during COH, especially after HCG administration, suggests that COH potentiates a state of systemic inflammation. coh 121-124 C-reactive protein Homo sapiens 47-50 14709365-8 2004 CONCLUSIONS: These results extend previous findings of an inverse relationship between Vitamin B(6) and CRP. Niacinamide 87-96 C-reactive protein Homo sapiens 104-107 14638413-7 2003 The Crp-Fnr regulators stand out in responding to a broad spectrum of intracellular and exogenous signals such as cAMP, anoxia, the redox state, oxidative and nitrosative stress, nitric oxide, carbon monoxide, 2-oxoglutarate, or temperature. Carbon Monoxide 193-208 C-reactive protein Homo sapiens 4-7 14572579-9 2003 Serum C-reactive protein levels correlated positively with biliary levels of 7-alpha-hydroxycholesterol (R = 0.948), 7-beta-hydroxycholesterol (R = 0.976), cholestan-3-beta,5-alpha,6-beta-triol (R = 0.823), 7-alpha-hydroxy-4-cholesten-3-one (R = 0.846,) and 7-ketocholesterol (R = 0.973). 7-ketocholesterol 258-275 C-reactive protein Homo sapiens 6-24 14512033-5 2003 RESULTS: In the critically-ill group circulating concentrations of C-reactive protein and malondialdehyde were significantly higher (P<0.05) and cholesterol, triglyceride, alpha-tocopherol, lutein, lycopene, alpha- and beta-carotene were all significantly lower (P<0.01) compared with the control group. Lycopene 201-209 C-reactive protein Homo sapiens 67-85 12941708-8 2003 ANCOVA revealed that treatment with pioglitazone was associated with a low CRP and PWV, independent of the changes in parameters related to glucose metabolism. Pioglitazone 36-48 C-reactive protein Homo sapiens 75-78 12960503-5 2003 RESULTS: Prednisolone was effective in the short term but resulted in an increase in C-reactive protein (CRP), peripheral leukocytes, and serum total bilirubin. Prednisolone 9-21 C-reactive protein Homo sapiens 85-103 12960503-5 2003 RESULTS: Prednisolone was effective in the short term but resulted in an increase in C-reactive protein (CRP), peripheral leukocytes, and serum total bilirubin. Prednisolone 9-21 C-reactive protein Homo sapiens 105-108 12667961-9 2003 The NF-kappaB activation caused by CRP was inhibited by 15-deoxy-12,14-prostaglandin J2 and the PPARgamma activators, rosiglitazone and pioglitazone. Pioglitazone 136-148 C-reactive protein Homo sapiens 35-38 12526945-10 2003 Low vitamin B(6) levels were significantly correlated with serum concentrations of C-reactive protein (r = -0.36, 95% CI = -0.59 to -0.09, p < 0.01) and alpha(1)-acid-glycoprotein (r = -0.37, 95% CI = -0.59 to -0.10, p < 0.01). Niacinamide 4-13 C-reactive protein Homo sapiens 83-101 12631257-6 2003 RESULTS: In both groups, the combination of chemotherapy with either pamidronate or ibandronate produced a reduction in bone resorption and tumour burden as measured by NTX, IL-6, paraprotein, CRP, and beta 2-microglobulin from the second month of treatment, having no effect on bone formation. Ibandronic Acid 84-95 C-reactive protein Homo sapiens 193-196 12324296-9 2002 C-reactive protein concentrations were inversely related to beta-carotene (P < 0.001), lutein and zeaxanthin (P < 0.001), and lycopene (P = 0.023) concentrations. Lycopene 132-140 C-reactive protein Homo sapiens 0-18 12031599-7 2002 Serum CRP was measured by latex-enhanced assay. Latex 26-31 C-reactive protein Homo sapiens 6-9 12056790-7 2002 In normal subjects and cancer patients, C-reactive protein concentrations were inversely correlated with circulating concentrations of retinol (r(2)=0.162), alpha-tocopherol (r(2)=0.297), lutein (r(2)=0.256), lycopene (r(2)=-0.171), alpha-(r(2)=0.140) and beta-carotene (r(2)=0.254): (all P<0.001). Lycopene 209-217 C-reactive protein Homo sapiens 40-58 11754740-8 2002 When the synchronous system was applied to a sandwich-type EIA for human C-reactive protein, the protein was detected with a sensitivity of 50 attomole per well of a micro-titer plate (0.1 ml) in a 1-h reaction. attomole 143-151 C-reactive protein Homo sapiens 73-91 11377237-9 2001 However, about 2 weeks after the start of steroid administration, a fever and a further elevation of CRP were observed with an increase of beta-D-glucan in serum. maltotriose 139-152 C-reactive protein Homo sapiens 101-104 9613434-4 1998 The purity of monkey CRP prepared by chromatography procedures was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). polyacrylamide gels 103-121 C-reactive protein Homo sapiens 21-24 9194208-3 1997 Bucillamine was at least as effective ad D-penicillamine in terms of improvement in the swollen joint count, tenderness score, morning stiffness, modified health assessment questionnaire, and Westergren erythrocyte sedimentation rate (ESR), and more effective in terms of improvement in the tender joint count, grip strength, C-reactive protein (CRP), and rheumatoid factor (RF) titer. bucillamine 0-11 C-reactive protein Homo sapiens 326-344 9194208-3 1997 Bucillamine was at least as effective ad D-penicillamine in terms of improvement in the swollen joint count, tenderness score, morning stiffness, modified health assessment questionnaire, and Westergren erythrocyte sedimentation rate (ESR), and more effective in terms of improvement in the tender joint count, grip strength, C-reactive protein (CRP), and rheumatoid factor (RF) titer. bucillamine 0-11 C-reactive protein Homo sapiens 346-349 8956080-2 1996 The octapeptide Val89-Thr-Val-Ala-Pro-Val-His-Ile96 (CRP 89-96) is shown to inhibit hLE and hCG to a larger extent than peptides of similar chain lengths corresponding to the active sites of their natural inhibitors, alpha 1-protease inhibitor and alpha-antichymotrypsin, respectively. DELTA-(L-ALPHA-AMINOADIPOYL)-L-CYSTEINYL-GLYCINE 92-95 C-reactive protein Homo sapiens 53-56 8833207-12 1996 Only one patient treated with ibandronate showed an increase in IL-6 and CRP levels. Ibandronic Acid 30-41 C-reactive protein Homo sapiens 73-76 9575343-1 1996 Analogs of the peptide Val-Thr-Val-Ala-Pro-Val-His-Ile, derived from the primary sequence of the acute phase reactant CRP, i.e. amino acid residues 89-96, were optimized to inhibit the enzymatic activities of human leukocyte elastase (hLE) and human leukocyte cathepsin G (hCG), which are associated with tissue damage occurring in the course of several chronic inflammatory conditions. DELTA-(L-ALPHA-AMINOADIPOYL)-L-CYSTEINYL-GLYCINE 273-276 C-reactive protein Homo sapiens 118-121 8548035-1 1995 One-step fluorescein-conjugated polyclonal antibody technique has shown that C-reactive protein (CRP) was located only extracellularly in human atherosclerotic lesions. Fluorescein 9-20 C-reactive protein Homo sapiens 77-95 8548035-1 1995 One-step fluorescein-conjugated polyclonal antibody technique has shown that C-reactive protein (CRP) was located only extracellularly in human atherosclerotic lesions. Fluorescein 9-20 C-reactive protein Homo sapiens 97-100 8069038-5 1994 In regionally stunned porcine myocardium, pyruvate infusion increased recovery of regional ventricular function from 33% +/- 4% of preischemic systolic wall thickening to 81% +/- 4% and increased the (CrP)/(Cr) x (P(i)) ratio fivefold from 0.21 +/- 0.04 to 1.05 +/- 0.08. Pyruvic Acid 42-50 C-reactive protein Homo sapiens 201-204 1362778-5 1992 The sulfasalazine group also demonstrated a significant fall in serum hyaluronic acid, IgM rheumatoid factor and C-reactive protein concentration. Sulfasalazine 4-17 C-reactive protein Homo sapiens 113-131 1350192-3 1992 At 12 weeks, the group treated with sulphasalazine had a lower platelet count (Mann-Whitney U test), erythrocyte sedimentation rate, and articular index, with a greater decrease in erythrocyte sedimentation rate (Students t test) and C reactive protein between 0 and 12 weeks. Sulfasalazine 36-50 C-reactive protein Homo sapiens 234-252 1928036-9 1991 In the patients with Crohn"s disease, recovery of 51Cr-EDTA to 6 h was significantly correlated with some nonspecific laboratory indicators of inflammatory activity, namely, erythrocyte sedimentation rate, platelet count, white blood cell count, serum albumin, and C-reactive protein, but not with hemoglobin. 51cr-edta 50-59 C-reactive protein Homo sapiens 265-283 1909052-0 1991 Erythromycin and phenoxymethylpenicillin (penicillin V) in the treatment of respiratory tract infections as related to microbiological findings and serum C-reactive protein. Erythromycin 0-12 C-reactive protein Homo sapiens 154-172 34979348-0 2022 Doping of MXenes enhances the electrochemical response of peptide-imprinted conductive polymers for the recognition of C-Reactive protein. mxenes 10-16 C-reactive protein Homo sapiens 119-137 34405275-6 2022 RESULTS: After adjustment for age, sex, educational level, illness duration, antidepressant use, chlorpromazine equivalent dose, tobacco smoking and obesity, a negative correlation was found between hs-CRP level and the perfusion of 4 brain areas: the right inferior frontal gyrus, the right middle/superior temporal gyrus, the left superior parietal lobe, and the right postcentral/transverse temporal gyrus (p-voxel < 0.001, k > 80, uncorrected). Chlorpromazine 97-111 C-reactive protein Homo sapiens 202-205 34946329-9 2021 C-reactive protein (CRP) increased significantly in the No-AA group throughout all time intervals, and from the first 24 h to the 25-72 h in the NAA and CAA groups. 1-naphthaleneacetic acid 145-148 C-reactive protein Homo sapiens 0-18 34946329-11 2021 CRP was significantly higher in the first 24 h in the CAA than in the No-AA group, and in the 24-48 h in the CAA group than in the No-AA and NAA groups. 1-naphthaleneacetic acid 141-144 C-reactive protein Homo sapiens 0-3 34977111-6 2021 Purified anthocyanins also markedly decreased circulating tumor necrosis factor alpha (WMD: -1.62 pg/mL, 95% CI: -2.76, -0.48 pg/mL; p = 0.005) and C-reactive protein (WMD: -0.028 mg/dL, 95% CI: -0.050, -0.005 mg/dL; p = 0.014). Anthocyanins 9-21 C-reactive protein Homo sapiens 148-166 34977111-7 2021 Besides, administration of anthocyanin-rich berries could significantly lower blood total cholesterol (WMD: -4.48 mg/dL, 95% CI: -8.94, -0.02 mg/dL; p = 0.049) and C-reactive protein (WMD: -0.046 mg/dL, 95% CI: -0.070, -0.022 mg/dL; p < 0.001). Anthocyanins 27-38 C-reactive protein Homo sapiens 164-182 34926619-9 2021 Furthermore, the level of hs-CRP had a good ability to discriminate between patients with FGCM and FLM (AUC = 0.94, 95% confidence interval: 0.4213-0.9964). fgcm 90-94 C-reactive protein Homo sapiens 29-32 34926619-9 2021 Furthermore, the level of hs-CRP had a good ability to discriminate between patients with FGCM and FLM (AUC = 0.94, 95% confidence interval: 0.4213-0.9964). flumequine 99-102 C-reactive protein Homo sapiens 29-32 34608769-5 2021 Further covariate modeling with this combined dataset showed that in addition to AAG; age, bodyweight, albumin, CRP and ICU admission were predictive of total imatinib oral clearance. Imatinib Mesylate 159-167 C-reactive protein Homo sapiens 112-115 34217687-7 2021 Ox-LDL induced NF-kappaB/NLRP3 pathway activation by inducing C-reactive protein expression, NLRP3 activation, caspase-1 activation, and IL-1beta secretion, which were inhibited by pretreatment with the combination of PAVA and RSV. pelargonic acid vanillylamide 218-222 C-reactive protein Homo sapiens 62-80 34210318-8 2021 RESULTS: There was a significant interaction between CAV-1 rs3807992 and healthy DP on high-density cholesterol (HDL) (P-interaction = 0.03), TC/HDL (P-interaction = 0.03) and high sensitivity C-reactive protein (hs-CRP) (P-interaction = 0.04); in A-allele carriers, higher following a healthy DP was related to a higher level of HDL and lower TC/HDL and hs-CRP. dp 81-83 C-reactive protein Homo sapiens 193-211 34210318-8 2021 RESULTS: There was a significant interaction between CAV-1 rs3807992 and healthy DP on high-density cholesterol (HDL) (P-interaction = 0.03), TC/HDL (P-interaction = 0.03) and high sensitivity C-reactive protein (hs-CRP) (P-interaction = 0.04); in A-allele carriers, higher following a healthy DP was related to a higher level of HDL and lower TC/HDL and hs-CRP. dp 294-296 C-reactive protein Homo sapiens 193-211 34194240-8 2021 Concerning blood parameters, the add on therapy with QP, reduced LDH (-35.5%), Ferritin (-40%), CRP (-54.8%) and D-dimer (-11.9%). SCHEMBL5970696 53-55 C-reactive protein Homo sapiens 96-99 34922405-11 2021 CONCLUSION: High CRP levels with non-widespread GGO predicted progressive ILD in patients with SSc treated with CYC. Cyclophosphamide 112-115 C-reactive protein Homo sapiens 17-20 34267439-11 2021 There was a positive correlation between CDK-1 gene expression and CRP before and after RO-3306 addition. RO 3306 88-95 C-reactive protein Homo sapiens 67-70 34981467-10 2021 A significant change in CRP (p = 0.002) and ESR (p = 0.0001) was observed in patients supplemented with curcuminoids at the end of 8 weeks compared to placebo. Diarylheptanoids 104-116 C-reactive protein Homo sapiens 24-27 34981467-13 2021 CONCLUSIONS: The results showed that curcuminoids supplementation for a period of 8 weeks (500 mg/day) can improve ESR and serum levels of CRP in stage-3 CRC subjects and improve the global quality of life and functional scales compared to placebo. Diarylheptanoids 37-49 C-reactive protein Homo sapiens 139-142 35588947-8 2022 For BD patients, the plasma 7-KC level was negatively correlated with the BD activity index (BDAI) while 27-OHC was positively correlated with high-sensitivity C-reactive protein (hs-CRP) in patients with active course of the disease. 27-hydroxycholesterol 105-111 C-reactive protein Homo sapiens 160-178 35620570-3 2022 Results: The empagliflozin-metformin combination increased levels of the antioxidants (TAS, SOD, and GPx up to 1.1-fold; P < 0.01), decreased the levels of prooxidants (AOPP and isoprostanes up to 1.2-fold, P < 0.01; AGE up to 1.5-fold, P < 0.01), and decreased inflammatory parameters (up to 1.5-fold, CRP P < 0.01; IL-6 P < 0.001). empagliflozin 13-26 C-reactive protein Homo sapiens 303-306 35232215-7 2022 EPA+DPA-FFA reduced least squares geometric mean high-sensitivity C-reactive protein by 5.8%; EPA-EE increased high-sensitivity C-reactive protein by 8.5% (P=0.034). epa-ee 94-100 C-reactive protein Homo sapiens 128-146 35091276-11 2022 The effects of astaxanthin on blood C-reactive protein and tumor necrosis factor-alpha concentrations were not significant. astaxanthine 15-26 C-reactive protein Homo sapiens 36-54 35115918-0 2021 Intermediate Effects of Body Mass Index and C-Reactive Protein on the Serum Cotinine- Leukocyte Telomere Length Association. Cotinine 76-84 C-reactive protein Homo sapiens 44-62 35115918-3 2021 In the combined sample, after adjusting for age, race, sex, physical activity, and alcohol use, the total effect of serum cotinine on LTL was significant (standardized regression coefficient, beta = -0.049, p = 0.001) without BMI and CRP included in the model. Cotinine 122-130 C-reactive protein Homo sapiens 234-237 35115918-4 2021 With inclusion of BMI but without CRP in the model, the direct effect of cotinine on LTL in its absolute value increased to beta = -0.053 (p < 0.001), and the suppression effect of BMI was estimated at 8.8%. Cotinine 73-81 C-reactive protein Homo sapiens 34-37 35115918-5 2021 With inclusion of CRP but without BMI in the model, the direct effect of cotinine on LTL in its absolute value decreased to beta = -0.040 (p = 0.008), and the mediation effect of CRP was estimated at 16.9%. Cotinine 73-81 C-reactive protein Homo sapiens 18-21 35115918-6 2021 With inclusion of both BMI and CRP in the model, BMI and CRP still had significant suppression and mediation effects, respectively, on the cotinine-LTL association. Cotinine 139-147 C-reactive protein Homo sapiens 31-34 35115918-6 2021 With inclusion of both BMI and CRP in the model, BMI and CRP still had significant suppression and mediation effects, respectively, on the cotinine-LTL association. Cotinine 139-147 C-reactive protein Homo sapiens 57-60